Variance evaluation
ERM
2024-02-05
Last updated: 2024-02-05
Checks: 7 0
Knit directory: Cardiotoxicity/
This reproducible R Markdown analysis was created with workflowr (version 1.7.1). The Checks tab describes the reproducibility checks that were applied when the results were created. The Past versions tab lists the development history.
Great! Since the R Markdown file has been committed to the Git repository, you know the exact version of the code that produced these results.
Great job! The global environment was empty. Objects defined in the global environment can affect the analysis in your R Markdown file in unknown ways. For reproduciblity it’s best to always run the code in an empty environment.
The command set.seed(20230109) was run prior to running
the code in the R Markdown file. Setting a seed ensures that any results
that rely on randomness, e.g. subsampling or permutations, are
reproducible.
Great job! Recording the operating system, R version, and package versions is critical for reproducibility.
Nice! There were no cached chunks for this analysis, so you can be confident that you successfully produced the results during this run.
Great job! Using relative paths to the files within your workflowr project makes it easier to run your code on other machines.
Great! You are using Git for version control. Tracking code development and connecting the code version to the results is critical for reproducibility.
The results in this page were generated with repository version df08393. See the Past versions tab to see a history of the changes made to the R Markdown and HTML files.
Note that you need to be careful to ensure that all relevant files for
the analysis have been committed to Git prior to generating the results
(you can use wflow_publish or
wflow_git_commit). workflowr only checks the R Markdown
file, but you know if there are other scripts or data files that it
depends on. Below is the status of the Git repository when the results
were generated:
Ignored files:
Ignored: .RData
Ignored: .Rhistory
Ignored: .Rproj.user/
Ignored: analysis/variance_values by gene.png
Ignored: data/41588_2018_171_MOESM3_ESMeQTL_ST2_for paper.csv
Ignored: data/Arr_GWAS.txt
Ignored: data/Arr_geneset.RDS
Ignored: data/BC_cell_lines.csv
Ignored: data/BurridgeDOXTOX.RDS
Ignored: data/CADGWASgene_table.csv
Ignored: data/CAD_geneset.RDS
Ignored: data/CALIMA_Data/
Ignored: data/CMD04_75DRCviability.csv
Ignored: data/CMD04_87DRCviability.csv
Ignored: data/CMD05_75DRCviability.csv
Ignored: data/CMD05_87DRCviability.csv
Ignored: data/Clamp_Summary.csv
Ignored: data/Cormotif_24_k1-5_raw.RDS
Ignored: data/Counts_RNA_ERMatthews.txt
Ignored: data/DAgostres24.RDS
Ignored: data/DAtable1.csv
Ignored: data/DDEMresp_list.csv
Ignored: data/DDE_reQTL.txt
Ignored: data/DDEresp_list.csv
Ignored: data/DEG-GO/
Ignored: data/DEG_cormotif.RDS
Ignored: data/DF_Plate_Peak.csv
Ignored: data/DRC48hoursdata.csv
Ignored: data/Da24counts.txt
Ignored: data/Dx24counts.txt
Ignored: data/Dx_reQTL_specific.txt
Ignored: data/EPIstorelist24.RDS
Ignored: data/Ep24counts.txt
Ignored: data/FC_necela.RDS
Ignored: data/FC_necela_names.RDS
Ignored: data/Full_LD_rep.csv
Ignored: data/GOIsig.csv
Ignored: data/GOplots.R
Ignored: data/GTEX_setsimple.csv
Ignored: data/GTEX_sig24.RDS
Ignored: data/GTEx_gene_list.csv
Ignored: data/HFGWASgene_table.csv
Ignored: data/HF_geneset.RDS
Ignored: data/Heart_Left_Ventricle.v8.egenes.txt
Ignored: data/Heatmap_mat.RDS
Ignored: data/Heatmap_sig.RDS
Ignored: data/Hf_GWAS.txt
Ignored: data/K_cluster
Ignored: data/K_cluster_kisthree.csv
Ignored: data/K_cluster_kistwo.csv
Ignored: data/Knowles_log2cpm_real.RDS
Ignored: data/Knowles_variation_data.RDS
Ignored: data/Knowles_variation_data_conc.RDS
Ignored: data/Knowlesvarlist.RDS
Ignored: data/LD50_05via.csv
Ignored: data/LDH48hoursdata.csv
Ignored: data/Mt24counts.txt
Ignored: data/NoRespDEG_final.csv
Ignored: data/RINsamplelist.txt
Ignored: data/RNA_seq_trial.RDS
Ignored: data/Schneider_GWAS.txt
Ignored: data/Seonane2019supp1.txt
Ignored: data/Sup_replicate_values.csv
Ignored: data/TMMnormed_x.RDS
Ignored: data/TOP2Bi-24hoursGO_analysis.csv
Ignored: data/TR24counts.txt
Ignored: data/TableS10.csv
Ignored: data/TableS11.csv
Ignored: data/TableS9.csv
Ignored: data/Top2_expression.RDS
Ignored: data/Top2biresp_cluster24h.csv
Ignored: data/Var_test_list.RDS
Ignored: data/Var_test_list24.RDS
Ignored: data/Var_test_list24alt.RDS
Ignored: data/Var_test_list3.RDS
Ignored: data/Vargenes.RDS
Ignored: data/Viabilitylistfull.csv
Ignored: data/allexpressedgenes.txt
Ignored: data/allfinal3hour.RDS
Ignored: data/allgenes.txt
Ignored: data/allmatrix.RDS
Ignored: data/allmymatrix.RDS
Ignored: data/annotation_data_frame.RDS
Ignored: data/averageviabilitytable.RDS
Ignored: data/averageviabilitytable.csv
Ignored: data/avgLD50.RDS
Ignored: data/avg_LD50.RDS
Ignored: data/avg_via_table.csv
Ignored: data/backGL.txt
Ignored: data/burr_genes.RDS
Ignored: data/calcium_data.RDS
Ignored: data/clamp_summary.RDS
Ignored: data/cormotif_3hk1-8.RDS
Ignored: data/cormotif_initalK5.RDS
Ignored: data/cormotif_initialK5.RDS
Ignored: data/cormotif_initialall.RDS
Ignored: data/cormotifprobs.csv
Ignored: data/counts24hours.RDS
Ignored: data/cpmcount.RDS
Ignored: data/cpmnorm_counts.csv
Ignored: data/crispr_genes.csv
Ignored: data/ctnnt_results.txt
Ignored: data/cvd_GWAS.txt
Ignored: data/dat_cpm.RDS
Ignored: data/data_outline.txt
Ignored: data/drug_noveh1.csv
Ignored: data/efit2.RDS
Ignored: data/efit2_final.RDS
Ignored: data/efit2results.RDS
Ignored: data/ensembl_backup.RDS
Ignored: data/ensgtotal.txt
Ignored: data/filcpm_counts.RDS
Ignored: data/filenameonly.txt
Ignored: data/filtered_cpm_counts.csv
Ignored: data/filtered_raw_counts.csv
Ignored: data/filtermatrix_x.RDS
Ignored: data/folder_05top/
Ignored: data/framefun24.RDS
Ignored: data/geneDoxonlyQTL.csv
Ignored: data/gene_corr_df.RDS
Ignored: data/gene_corr_frame.RDS
Ignored: data/gene_prob_tran3h.RDS
Ignored: data/gene_probabilityk5.RDS
Ignored: data/geneset_24.RDS
Ignored: data/gostresTop2bi_ER.RDS
Ignored: data/gostresTop2bi_LR
Ignored: data/gostresTop2bi_LR.RDS
Ignored: data/gostresTop2bi_TI.RDS
Ignored: data/gostrescoNR
Ignored: data/gtex/
Ignored: data/heartgenes.csv
Ignored: data/highly_var_genelist.RDS
Ignored: data/hsa_kegg_anno.RDS
Ignored: data/individualDRCfile.RDS
Ignored: data/individual_DRC48.RDS
Ignored: data/individual_LDH48.RDS
Ignored: data/indv_noveh1.csv
Ignored: data/kegglistDEG.RDS
Ignored: data/kegglistDEG24.RDS
Ignored: data/kegglistDEG3.RDS
Ignored: data/knowfig4.csv
Ignored: data/knowfig5.csv
Ignored: data/label_list.RDS
Ignored: data/ld50_table.csv
Ignored: data/mean_vardrug1.csv
Ignored: data/mean_varframe.csv
Ignored: data/mymatrix.RDS
Ignored: data/new_ld50avg.RDS
Ignored: data/nonresponse_cluster24h.csv
Ignored: data/norm_LDH.csv
Ignored: data/norm_counts.csv
Ignored: data/old_sets/
Ignored: data/organized_drugframe.csv
Ignored: data/pca_all_anno.csv
Ignored: data/plan2plot.png
Ignored: data/plot_intv_list.RDS
Ignored: data/plot_list_DRC.RDS
Ignored: data/qval24hr.RDS
Ignored: data/qval3hr.RDS
Ignored: data/qvalueEPItemp.RDS
Ignored: data/raw_counts.csv
Ignored: data/response_cluster24h.csv
Ignored: data/sampsettrz.RDS
Ignored: data/schneider_closest_output.RDS
Ignored: data/sigVDA24.txt
Ignored: data/sigVDA3.txt
Ignored: data/sigVDX24.txt
Ignored: data/sigVDX3.txt
Ignored: data/sigVEP24.txt
Ignored: data/sigVEP3.txt
Ignored: data/sigVMT24.txt
Ignored: data/sigVMT3.txt
Ignored: data/sigVTR24.txt
Ignored: data/sigVTR3.txt
Ignored: data/siglist.RDS
Ignored: data/siglist_final.RDS
Ignored: data/siglist_old.RDS
Ignored: data/slope_table.csv
Ignored: data/supp10_24hlist.RDS
Ignored: data/supp10_3hlist.RDS
Ignored: data/supp_normLDH48.RDS
Ignored: data/supp_pca_all_anno.RDS
Ignored: data/supp_viadata.csv
Ignored: data/table3a.omar
Ignored: data/test_run_sample_list.txt
Ignored: data/testlist.txt
Ignored: data/toplistall.RDS
Ignored: data/trtonly_24h_genes.RDS
Ignored: data/trtonly_3h_genes.RDS
Ignored: data/tvl24hour.txt
Ignored: data/tvl24hourw.txt
Ignored: data/venn_code.R
Ignored: data/viability.RDS
Untracked files:
Untracked: .RDataTmp
Untracked: .RDataTmp1
Untracked: .RDataTmp2
Untracked: .RDataTmp3
Untracked: 3hr all.pdf
Untracked: Code_files_list.csv
Untracked: Data_files_list.csv
Untracked: Doxorubicin_vehicle_3_24.csv
Untracked: Doxtoplist.csv
Untracked: EPIqvalue_analysis.Rmd
Untracked: Final.sup.pdf
Untracked: GWAS_list_of_interest.xlsx
Untracked: KEGGpathwaylist.R
Untracked: NA
Untracked: OmicNavigator_learn.R
Untracked: SNP_egenes_allfiles.RDS
Untracked: SNP_frame_pdf
Untracked: SNP_frame_pdf.pdf
Untracked: SigDoxtoplist.csv
Untracked: analysis/DRC_viability_check.Rmd
Untracked: analysis/New_code_dec-23.R
Untracked: analysis/cellcycle_kegg_genes.R
Untracked: analysis/ciFIT.R
Untracked: analysis/export_to_excel.R
Untracked: analysis/featureCountsPLAY.R
Untracked: cleanupfiles_script.R
Untracked: code/biomart_gene_names.R
Untracked: code/constantcode.R
Untracked: code/corMotifcustom.R
Untracked: code/cpm_boxplot.R
Untracked: code/extracting_ggplot_data.R
Untracked: code/movingfilesto_ppl.R
Untracked: code/pearson_extract_func.R
Untracked: code/pearson_tox_extract.R
Untracked: code/plot1C.fun.R
Untracked: code/spearman_extract_func.R
Untracked: code/venndiagramcolor_control.R
Untracked: cormotif_p.post.list_4.csv
Untracked: figS1024h.pdf
Untracked: final.pdf
Untracked: individual-legenddark2.png
Untracked: installed_old.rda
Untracked: listoftranscripts
Untracked: motif_ER.txt
Untracked: motif_LR.txt
Untracked: motif_NR.txt
Untracked: motif_TI.txt
Untracked: output/ABHD8_dif_values.RDS
Untracked: output/C3orf18_dif_values.RDS
Untracked: output/Cardiotox_dif_values.RDS
Untracked: output/DNR_DEGlist.csv
Untracked: output/DNRvenn.RDS
Untracked: output/DOX_DEGlist.csv
Untracked: output/DOX_de_goi.csv
Untracked: output/DOXvenn.RDS
Untracked: output/EEF1B2_dif_values.RDS
Untracked: output/EEIG1_dif_values.RDS
Untracked: output/EPI_DEGlist.csv
Untracked: output/EPIvenn.RDS
Untracked: output/ESGN_rds.RDS
Untracked: output/FC_necela.RDS
Untracked: output/FC_necela_names.RDS
Untracked: output/FRS2_dif_values.RDS
Untracked: output/Figures/
Untracked: output/GTEXv8_gene_median_tpm.RDS
Untracked: output/GTEXv8_gene_tpm_heart_left_ventricle.RDS
Untracked: output/HDDC2_dif_values.RDS
Untracked: output/HER2_gene.RDS
Untracked: output/KEGGcellcyclegenes.RDS
Untracked: output/Knowles_S13.csv
Untracked: output/Knowles_log2cpm.csv
Untracked: output/Knowles_supp13.csv
Untracked: output/LD50tox_table.RDS
Untracked: output/MTX_DEGlist.csv
Untracked: output/MTXvenn.RDS
Untracked: output/PEX16_dif_values.RDS
Untracked: output/RASIP1_dif_values.RDS
Untracked: output/RMI1_dif_values.RDS
Untracked: output/RSID_QTL_list_full.txt
Untracked: output/SETA_analysis_reyes.RDS
Untracked: output/SGWAS_top50_order.csv
Untracked: output/SLC27A1_dif_values.RDS
Untracked: output/SLC28A3_dif_values.RDS
Untracked: output/SNP_egenes_allfiles.RDS
Untracked: output/SNP_list_ID.RDS
Untracked: output/SNP_list_full.txt
Untracked: output/SNP_supp.RDS
Untracked: output/TGFBR3L_dif_values.RDS
Untracked: output/TNS2_dif_values.RDS
Untracked: output/TOP_50SNPreffile.csv
Untracked: output/TRZ_DEGlist.csv
Untracked: output/TableS8.csv
Untracked: output/Volcanoplot_10
Untracked: output/Volcanoplot_10.RDS
Untracked: output/ZNF740_dif_values.RDS
Untracked: output/allfinal_sup10.RDS
Untracked: output/counts_v8_heart_left_ventricle_gct.RDS
Untracked: output/crisprfoldchange.RDS
Untracked: output/endocytosisgenes.csv
Untracked: output/expre7k.csv
Untracked: output/expressed_egenes_by_RSID.csv
Untracked: output/gene_corr_fig9.RDS
Untracked: output/genes.RDS
Untracked: output/legend_b.RDS
Untracked: output/motif_ERrep.RDS
Untracked: output/motif_LRrep.RDS
Untracked: output/motif_NRrep.RDS
Untracked: output/motif_TI_rep.RDS
Untracked: output/near_genes_SNP1.RDS
Untracked: output/necela_list_test.RDS
Untracked: output/necela_val_genes.RDS
Untracked: output/output-old/
Untracked: output/rank24genes.csv
Untracked: output/rank3genes.csv
Untracked: output/sequencinginformationforsupp.csv
Untracked: output/sequencinginformationforsupp.prn
Untracked: output/sigVDA24.txt
Untracked: output/sigVDA3.txt
Untracked: output/sigVDX24.txt
Untracked: output/sigVDX3.txt
Untracked: output/sigVEP24.txt
Untracked: output/sigVEP3.txt
Untracked: output/sigVMT24.txt
Untracked: output/sigVMT3.txt
Untracked: output/sigVTR24.txt
Untracked: output/sigVTR3.txt
Untracked: output/supplementary_motif_list_GO.RDS
Untracked: output/test_biomart_run.RDS
Untracked: output/toptablebydrug.RDS
Untracked: output/trop_knowles_fun.csv
Untracked: output/tvl24hour.txt
Untracked: output/x_counts.RDS
Untracked: reneebasecode.R
Unstaged changes:
Modified: analysis/DRC_analysis.Rmd
Modified: analysis/GOI_plots.Rmd
Modified: analysis/GTEx_genes.Rmd
Deleted: analysis/Knowles2019.Rmd
Modified: output/daplot.RDS
Modified: output/dxplot.RDS
Modified: output/epplot.RDS
Modified: output/mtplot.RDS
Modified: output/plan2plot.png
Modified: output/trplot.RDS
Modified: output/veplot.RDS
Note that any generated files, e.g. HTML, png, CSS, etc., are not included in this status report because it is ok for generated content to have uncommitted changes.
These are the previous versions of the repository in which changes were
made to the R Markdown (analysis/variance_scrip.Rmd) and
HTML (docs/variance_scrip.html) files. If you’ve configured
a remote Git repository (see ?wflow_git_remote), click on
the hyperlinks in the table below to view the files as they were in that
past version.
| File | Version | Author | Date | Message |
|---|---|---|---|---|
| Rmd | df08393 | reneeisnowhere | 2024-02-05 | updates to scripts |
| html | 3622a69 | reneeisnowhere | 2023-09-28 | Build site. |
| Rmd | 33ba27d | reneeisnowhere | 2023-09-28 | updated code and CSS |
| html | e55bbd2 | reneeisnowhere | 2023-08-08 | Build site. |
| Rmd | b80c66f | reneeisnowhere | 2023-08-08 | adding svglite |
| html | c6714dc | reneeisnowhere | 2023-07-28 | Build site. |
| Rmd | 822464b | reneeisnowhere | 2023-07-28 | new figures update |
| Rmd | 62286c3 | reneeisnowhere | 2023-07-28 | Updateing figure code |
| Rmd | 06800c9 | reneeisnowhere | 2023-07-26 | Commits to small changes and edits |
| html | e365e38 | reneeisnowhere | 2023-07-25 | Build site. |
| Rmd | 2f233ea | reneeisnowhere | 2023-07-25 | updates to table and padjust |
| html | 80bc58e | reneeisnowhere | 2023-07-25 | Build site. |
| Rmd | 73acb47 | reneeisnowhere | 2023-07-25 | new BH correction plus shiny |
| html | fd6ed5c | reneeisnowhere | 2023-07-24 | Build site. |
| Rmd | 4ef2f8a | reneeisnowhere | 2023-07-24 | adding adj p value |
| html | f916c7e | reneeisnowhere | 2023-07-20 | Build site. |
| Rmd | 4dadb9f | reneeisnowhere | 2023-07-20 | adding in an alternate hypothesis for var.test |
| html | 8a1d460 | reneeisnowhere | 2023-07-20 | Build site. |
| Rmd | a26bff7 | reneeisnowhere | 2023-07-20 | adding in GO analysis |
| html | f47a934 | reneeisnowhere | 2023-07-20 | Build site. |
| Rmd | 3ea3f28 | reneeisnowhere | 2023-07-20 | adding new analysis |
| html | e48b9f5 | reneeisnowhere | 2023-07-14 | Build site. |
| Rmd | fcc6805 | reneeisnowhere | 2023-07-14 | adding link to variance scrip for Michelle |
library(tidyverse)
library(ggpubr)
library(ggsignif)
library(gprofiler2)
library(paletteer)
library(ggVennDiagram)
library(gridtext)
library(scales)
library(kableExtra)
library(qvalue)
library(data.table)
library(ComplexHeatmap)variance of genes across treatment
This contains the wrangling of the data frame and analysis code, and is how the analysis was processed.
filcpm_counts <- read.csv("data/filtered_cpm_counts.csv", row.names = 1)
mean_vardrug <- filcpm_counts %>%
select(c(starts_with("Da")&ends_with("24h")),
c(starts_with("Do")&ends_with("24h")),
c(starts_with("Ep")&ends_with("24h")),
c(starts_with("Mi")&ends_with("24h")),
c(starts_with("Tr")&ends_with("24h")),
c(starts_with("Ve")&ends_with("24h")),
c(starts_with("Da")&ends_with("3h")),
c(starts_with("Do")&ends_with("3h")),
c(starts_with("Ep")&ends_with("3h")),
c(starts_with("Mi")&ends_with("3h")),
c(starts_with("Tr")&ends_with("3h")),
c(starts_with("Ve")&ends_with("3h")))
rownames(mean_vardrug) <- rownames(filcpm_counts)
write.csv(mean_vardrug, "data/organized_drugframe.csv")
mean_vardrug1 <- mean_vardrug %>%
rowwise() %>%
mutate(mean.Da.3=mean(c_across(Da.1.3h:Da.6.3h)),
var.Da.3=var(c_across(Da.1.3h:Da.6.3h)),
mean.Do.3=mean(c_across(Do.1.3h:Do.6.3h)),
var.Do.3=var(c_across(Do.1.3h:Do.6.3h)),
mean.Ep.3=mean(c_across(Ep.1.3h:Ep.6.3h)),
var.Ep.3=var(c_across(Ep.1.3h:Ep.6.3h)),
mean.Mi.3=mean(c_across(Mi.1.3h:Mi.6.3h)),
var.Mi.3=var(c_across(Mi.1.3h:Mi.6.3h)),
mean.Tr.3=mean(c_across(Tr.1.3h:Tr.6.3h)),
var.Tr.3=var(c_across(Tr.1.3h:Tr.6.3h)),
mean.Ve.3=mean(c_across(Ve.1.3h:Ve.6.3h)),
var.Ve.3=var(c_across(Ve.1.3h:Ve.6.3h)),
mean.Da.24=mean(c_across(Da.1.24h:Da.6.24h)),
var.Da.24=var(c_across(Da.1.24h:Da.6.24h)),
mean.Do.24=mean(c_across(Do.1.24h:Do.6.24h)),
var.Do.24=var(c_across(Do.1.24h:Do.6.24h)),
mean.Ep.24=mean(c_across(Ep.1.24h:Ep.6.24h)),
var.Ep.24=var(c_across(Ep.1.24h:Ep.6.24h)),
mean.Mi.24=mean(c_across(Mi.1.24h:Mi.6.24h)),
var.Mi.24=var(c_across(Mi.1.24h:Mi.6.24h)),
mean.Tr.24=mean(c_across(Tr.1.24h:Tr.6.24h)),
var.Tr.24=var(c_across(Tr.1.24h:Tr.6.24h)),
mean.Ve.24=mean(c_across(Ve.1.24h:Ve.6.24h)),
var.Ve.24=var(c_across(Ve.1.24h:Ve.6.24h))) %>%
select(mean.Da.3:var.Ve.24)
rownames(mean_vardrug1) <- rownames(filcpm_counts)
write.csv(mean_vardrug1,"data/mean_vardrug1.csv")plotting of data
mean_vardrug1 <- read.csv("data/mean_vardrug1.csv", row.names = 1)
drug_frame <- mean_vardrug1 %>%
rownames_to_column(var = "entrezid") %>%
pivot_longer(cols = mean.Da.3:var.Ve.24,
names_to = "short",
values_to = "values") %>%
separate(short, into = c("calc", "treatment", "time")) %>%
mutate(treatment = factor(
treatment,
levels = c("Do", "Ep", "Da", "Mi", "Tr", "Ve"),
labels = c("DOX", "EPI", "DNR", "MTX", "TRZ", "VEH")
)) %>%
mutate(time = factor(
time,
levels = c("3", "24"),
labels = c("3 hours", "24 hours")
)) %>%
group_by(treatment, time, calc) %>%
as.data.frame
drug_pal_fact <-
c("#8B006D",
"#DF707E",
"#F1B72B",
"#3386DD",
"#707031",
"#41B333")
drug_frame %>%
filter(calc != "mean") %>%
ggplot(., aes(x = treatment, y = values, fill = treatment)) +
# geom_violin(outlier.shape = NA) +
geom_boxplot(outlier.shape= NA)+
geom_signif(
comparisons = list(
c("DOX", "VEH"),
c("EPI", "VEH"),
c("DNR", "VEH"),
c("MTX", "VEH"),
c("TRZ", "VEH")
),
test = "t.test",
tip_length = 0.01,
map_signif_level = FALSE,
textsize = 4,
# y_position = 0.5,
step_increase = 0.1
) +
facet_wrap( ~ time) +
ggtitle("Variance") +
coord_cartesian(ylim = c(0, 1)) +
# ylim(0,2)+
scale_fill_manual(values = drug_pal_fact) +
theme_bw() +
xlab(" ") +
ylab(expression("variance of log "[2] ~ " cpm ")) +
theme(
strip.background = element_rect(
fill = "white",
linetype = 1,
linewidth = 0.5
),
plot.title = element_text(size = 12, hjust = 0.5, face = "bold"),
axis.title = element_text(size = 10, color = "black"),
axis.ticks = element_line(linewidth = 1.0),
panel.background = element_rect(colour = "black", size = 1),
axis.text.x = element_blank(),
strip.text.x = element_text(margin = margin(2, 0, 2, 0, "mm"), face = "bold")
)
drug_frame %>%
filter(calc!="mean") %>%
ggplot(., aes(x= treatment, y=values))+
geom_violin(outlier.shape=NA)+
geom_signif(comparisons =list(c("DOX","VEH"),
c("EPI","VEH"),
c("DNR","VEH"),
c("MTX","VEH"),
c("TRZ","VEH")),
test= "var.test",
map_signif_level=FALSE,
textsize =4,
y_position=(.3),
step_increase = 0.1)+
facet_wrap(~time)+
ggtitle("var statistics")+
ylim(0,0.5)
# drug_frame %>%
# filter(calc!="mean") %>%
# as.matrix() %>%
# Heatmap()
drug_frame %>%
filter(calc != "var") %>%
ggplot(., aes(x = treatment, y = values, fill = treatment)) +
geom_violin(outlier.shape = NA) +
# geom_boxplot(outlier.shape= NA)+
geom_signif(
comparisons = list(
c("TRZ", "VEH"),
c("MTX", "VEH"),
c("DNR", "VEH"),
c("EPI", "VEH"),
c("DOX", "VEH")
),
test = "t.test",
tip_length = 0.01,
map_signif_level = FALSE,
textsize = 4,
y_position = 11,
step_increase = 0.05
) +
facet_wrap(. ~ time) +
ggtitle("Means") +
ylim(0, 18) +
scale_fill_manual(values = drug_pal_fact) +
theme_bw() +
xlab(" ") +
ylab(expression("counts log"[2] ~ "cpm ")) +
theme(
strip.background = element_rect(
fill = "white",
linetype = 1,
linewidth = 0.5
),
plot.title = element_text(size = 12, hjust = 0.5, face = "bold"),
axis.title = element_text(size = 10, color = "black"),
axis.ticks = element_line(linewidth = 1.0),
panel.background = element_rect(colour = "black", size = 1),
axis.text.x = element_blank(),
strip.text.x = element_text(margin = margin(2, 0, 2, 0, "mm"), face = "bold")
)
Finding where the variance may exist
This is initial analysis to see if DOX response eGenes are increased in variance within my data.
mean_vardrug1 <- read.csv("data/mean_vardrug1.csv",row.names = 1)
my_exp_genes <- read.csv("data/backGL.txt")
GTEx_genes <- read.csv("data/GTEx_gene_list.csv",row.names = 1)
GTEx <- intersect(GTEx_genes$entrezgene_id,my_exp_genes$ENTREZID)
knowles5 <-readRDS("output/knowles5.RDS")
drug_frame2<- mean_vardrug1 %>%
rownames_to_column(var = "entrezid") %>%
filter(entrezid %in%knowles5$entrezgene_id) %>%
pivot_longer(cols = mean.Da.3:var.Ve.24, names_to = "short", values_to = "values") %>%
separate(short, into=c("calc","treatment","time")) %>%
mutate(treatment= factor(treatment, levels = c("Do","Ep","Da","Mi","Tr","Ve"),labels = c("DOX","EPI","DNR","MTX","TRZ","VEH"))) %>%
mutate(time= factor(time, levels = c("3","24"), labels= c("3 hours","24 hours"))) %>%
group_by(treatment, time, calc) %>%
as.data.frame
ggplot(drug_frame2, aes(x= treatment, y=values))+
geom_violin()+
geom_signif(comparisons =list(c("DOX","VEH"),
c("EPI","VEH"),
c("DNR","VEH"),
c("MTX","VEH"),
c("TRZ","VEH")),
test= "t.test",
map_signif_level=TRUE,
textsize =4,
step_increase = 0.1)+
ggtitle(" Dox eGenes")+
# stat_compare_means(method= "anova", label.y=15, label.x =2)+
facet_wrap(time~calc, scales = "free_y")
drug_frame2 %>%
filter(calc!="mean") %>%
ggplot(., aes(x= treatment, y=values))+
geom_boxplot()+
geom_signif(comparisons =list(c("DOX","VEH"),
c("EPI","VEH"),
c("DNR","VEH"),
c("MTX","VEH"),
c("TRZ","VEH")),
test= "t.test",
map_signif_level=TRUE,
textsize =4,
step_increase = 0.1)+
facet_wrap(~time)+
ggtitle("var using response eGenes")+
ylim(0,5.0)
drug_frame2 %>%
filter(calc!="var") %>%
ggplot(., aes(x= treatment, y=values))+
geom_violin()+
geom_signif(comparisons =list(c("TRZ","VEH"),
c("MTX","VEH"),
c("DNR","VEH"),
c("EPI","VEH"),
c("DOX","VEH")),
test= "t.test",
map_signif_level=TRUE,
textsize =4,
step_increase = 0.05)+
facet_wrap(.~time)+
ggtitle("Means using response eGenes")+
ylim(0,18)
We found significant differences to the vehicle in the EPI 24 hour variance. This was based on a smaller set of genes,
This was a different way of wrangling the values with var.test as the function across all genes.
organized_drugframe <- read.csv("data/organized_drugframe.csv",
row.names = 1)
DNR.VEH.24 <- organized_drugframe %>%
select(c(starts_with("Da")&ends_with("24h")),
c(starts_with("Ve")&ends_with("24h"))) %>%
rowwise() %>%
mutate(data=list(var.test(c_across(starts_with("Da")),c_across(starts_with("Ve")))))
DOX.VEH.24 <- organized_drugframe %>%
select(c(starts_with("Do")&ends_with("24h")),
c(starts_with("Ve")&ends_with("24h"))) %>%
rowwise() %>%
mutate(data=list(var.test(c_across(starts_with("Do")),c_across(starts_with("Ve")))))
EPI.VEH.24 <- organized_drugframe %>%
select(c(starts_with("Ep")&ends_with("24h")),
c(starts_with("Ve")&ends_with("24h"))) %>%
rowwise() %>%
mutate(data=list(var.test(c_across(starts_with("Ep")),c_across(starts_with("Ve")))))
MTX.VEH.24 <- organized_drugframe %>%
select(c(starts_with("Mi")&ends_with("24h")),
c(starts_with("Ve")&ends_with("24h"))) %>%
rowwise() %>%
mutate(data=list(var.test(c_across(starts_with("Mi")),c_across(starts_with("Ve")))))
TRZ.VEH.24 <- organized_drugframe %>%
select(c(starts_with("Tr")&ends_with("24h")),
c(starts_with("Ve")&ends_with("24h"))) %>%
rowwise() %>%
mutate(data=list(var.test(c_across(starts_with("Tr")),c_across(starts_with("Ve")))))
DNR.VEH.3 <- organized_drugframe %>%
select(c(starts_with("Da")&ends_with("3h")),
c(starts_with("Ve")&ends_with("3h"))) %>%
rowwise() %>%
mutate(data=list(var.test(c_across(starts_with("Da")),c_across(starts_with("Ve")))))
DOX.VEH.3 <- organized_drugframe %>%
select(c(starts_with("Do")&ends_with("3h")),
c(starts_with("Ve")&ends_with("3h"))) %>%
rowwise() %>%
mutate(data=list(var.test(c_across(starts_with("Do")),c_across(starts_with("Ve")))))
EPI.VEH.3 <- organized_drugframe %>%
select(c(starts_with("Ep")&ends_with("3h")),
c(starts_with("Ve")&ends_with("3h"))) %>%
rowwise() %>%
mutate(data=list(var.test(c_across(starts_with("Ep")),c_across(starts_with("Ve")))))
MTX.VEH.3 <- organized_drugframe %>%
select(c(starts_with("Mi")&ends_with("3h")),
c(starts_with("Ve")&ends_with("3h"))) %>%
rowwise() %>%
mutate(data=list(var.test(c_across(starts_with("Mi")),c_across(starts_with("Ve")))))
TRZ.VEH.3 <- organized_drugframe %>%
rownames_to_column(.id = "gene") %>%
rowwise() %>%
select(c(starts_with("Tr")&ends_with("3h")),
c(starts_with("Ve")&ends_with("3h"))) %>%
mutate(data=list(var.test(c_across(starts_with("Tr")),c_across(starts_with("Ve")))))
Var_test_list24 <- list(DNR.VEH.24,DOX.VEH.24,EPI.VEH.24,MTX.VEH.24,TRZ.VEH.24)
names(Var_test_list24) <- c('DNR.VEH.24','DOX.VEH.24','EPI.VEH.24','MTX.VEH.24','TRZ.VEH.24')
saveRDS(Var_test_list24,"data/Var_test_list24.RDS")
Var_test_list3 <- list(DNR.VEH.3,DOX.VEH.3,EPI.VEH.3,MTX.VEH.3,TRZ.VEH.3)
names(Var_test_list3) <- c('DNR.VEH.3','DOX.VEH.3','EPI.VEH.3','MTX.VEH.3','TRZ.VEH.3')
saveRDS(Var_test_list3,"data/Var_test_list3.RDS") Watch for the caption to tell which data set is plotted! #### 3 hour
organized_drugframe <- read.csv("data/organized_drugframe.csv",
row.names = 1)
Var_test_list3 <- readRDS("data/Var_test_list3.RDS")
#Is the data normally distributed?
set3 <- names(Var_test_list3)
shorterlist <- Var_test_list3[[1]][[13]]
names(shorterlist) <- rownames(organized_drugframe)
framefun3 <- data.frame(ENTREZID=rownames(organized_drugframe))
for (i in 1:length(set3)){
a <- set3[i]
s_list<- Var_test_list3[[i]][[13]]
names(s_list) <- rownames(organized_drugframe)
hold<- map_df(s_list, ~as.data.frame(.x$p.value), .id="ENTREZID")
framefun3[paste0(a)] <- hold$`.x$p.value`
}
est3pDNR <- qvalue(p=framefun3$DNR.VEH.3)
est3pDOX <- qvalue(p=framefun3$DOX.VEH.3)
est3pEPI <- qvalue(p=framefun3$EPI.VEH.3)
est3pMTX <- qvalue(p=framefun3$MTX.VEH.3)
est3pTRZ <- qvalue(p=framefun3$TRZ.VEH.3)
summary(est3pDNR)
Call:
qvalue(p = framefun3$DNR.VEH.3)
pi0: 1
Cumulative number of significant calls:
<1e-04 <0.001 <0.01 <0.025 <0.05 <0.1 <1
p-value 1 8 72 192 385 806 14084
q-value 0 0 0 0 0 0 14084
local FDR 0 0 0 0 0 0 1summary(est3pDOX)
Call:
qvalue(p = framefun3$DOX.VEH.3)
pi0: 1
Cumulative number of significant calls:
<1e-04 <0.001 <0.01 <0.025 <0.05 <0.1 <1
p-value 1 8 66 167 346 746 14084
q-value 0 0 0 0 0 0 14084
local FDR 0 0 0 0 0 0 1summary(est3pEPI)
Call:
qvalue(p = framefun3$EPI.VEH.3)
pi0: 1
Cumulative number of significant calls:
<1e-04 <0.001 <0.01 <0.025 <0.05 <0.1 <1
p-value 1 6 50 139 332 667 14084
q-value 0 0 0 0 0 0 14084
local FDR 0 0 0 0 0 0 2summary(est3pMTX)
Call:
qvalue(p = framefun3$MTX.VEH.3)
pi0: 1
Cumulative number of significant calls:
<1e-04 <0.001 <0.01 <0.025 <0.05 <0.1 <1
p-value 2 9 57 138 277 608 14084
q-value 0 0 0 0 0 0 14084
local FDR 0 0 0 0 0 0 4summary(est3pTRZ)
Call:
qvalue(p = framefun3$TRZ.VEH.3)
pi0: 1
Cumulative number of significant calls:
<1e-04 <0.001 <0.01 <0.025 <0.05 <0.1 <1
p-value 0 2 41 116 262 561 14084
q-value 0 0 0 0 0 0 14084
local FDR 0 0 0 0 0 0 0EPIq3 <- data.table(pvalues=est3pEPI$pvalues,EPIqvalues=est3pEPI$qvalues)
EPI3_genelist <- framefun3 %>% dplyr::select(ENTREZID,EPI.VEH.3)
EPIstorelist3 <- EPI3_genelist %>%
full_join(.,EPIq3, by=c("EPI.VEH.3"="pvalues")) #%>%
# dplyr::filter(qvalues<.1) %>%
# mutate(ENTREZID=as.integer(ENTREZID))
# saveRDS(storeEPI,"data/qvalueEPItemp.RDS")
DNRq3<- data.table(pvalues=est3pDNR$pvalues,DNRqvalues=est3pDNR$qvalues)
DNR3_genelist <- framefun3 %>% dplyr::select(ENTREZID,DNR.VEH.3)
DNRstorelist3 <-DNR3_genelist %>%
full_join(.,DNRq3, by=c("DNR.VEH.3"="pvalues")) #%>%
# dplyr::filter(qvalues<.2)
DOXq3 <- data.table(pvalues=est3pDOX$pvalues,DOXqvalues=est3pDOX$qvalues)
DOX3_genelist <- framefun3 %>% dplyr::select(ENTREZID,DOX.VEH.3)
DOXstorelist3 <-DOX3_genelist %>%
full_join(.,DOXq3, by=c("DOX.VEH.3"="pvalues")) #%>%
# dplyr::filter(qvalues<.2)
MTXq3 <- data.table(pvalues=est3pMTX$pvalues,MTXqvalues=est3pMTX$qvalues)
MTX3_genelist <- framefun3 %>% dplyr::select(ENTREZID,MTX.VEH.3)
MTXstorelist3 <-MTX3_genelist %>%
full_join(.,MTXq3, by=c("MTX.VEH.3"="pvalues"))# %>%
# dplyr::filter(qvalues<.2)
TRZq3 <- data.table(pvalues=est3pTRZ$pvalues,TRZqvalues=est3pTRZ$qvalues)
TRZ3_genelist <- framefun3 %>% dplyr::select(ENTREZID,TRZ.VEH.3)
TRZstorelist3 <- TRZ3_genelist %>%
full_join(.,TRZq3, by=c("TRZ.VEH.3"="pvalues")) #%>%
# dplyr::filter(qvalues<.2)
#
# DOXstorelist3$DOXqvalues,EPIstorelist3$EPIqvalues,MTXstorelist3$MTXqvalues]
qval3hr <- DOXstorelist3 %>%
full_join(.,EPIstorelist3, by="ENTREZID") %>%
full_join(.,DNRstorelist3, by="ENTREZID") %>%
full_join(.,MTXstorelist3, by="ENTREZID") %>%
full_join(.,TRZstorelist3, by="ENTREZID") %>%
select(ENTREZID, ends_with("qvalues"))
# saveRDS(qval3hr,"data/qval3hr.RDS")We ended up using the qvalue package to find genes that are more than likely highly variable genes.
24 hour
organized_drugframe <- read.csv("data/organized_drugframe.csv",
row.names = 1)
Var_test_list24 <- readRDS("data/Var_test_list24.RDS")
set24 <- names(Var_test_list24)
framefun24 <- data.frame(ENTREZID=rownames(organized_drugframe))
for (i in 1:length(set24)){
a <- set24[i]
s_list<- Var_test_list24[[i]][[13]]
names(s_list) <- rownames(organized_drugframe)
hold<- map_df(s_list, ~as.data.frame(.x$p.value), .id="ENTREZID")
framefun24[paste0(a)] <- hold$`.x$p.value`
}
est24pDNR <- qvalue(p=framefun24$DNR.VEH.24)
est24pDOX <- qvalue(p=framefun24$DOX.VEH.24)
est24pEPI <- qvalue(p=framefun24$EPI.VEH.24)
est24pMTX <- qvalue(p=framefun24$MTX.VEH.24)
est24pTRZ <- qvalue(p=framefun24$TRZ.VEH.24)
summary(est24pDNR)
Call:
qvalue(p = framefun24$DNR.VEH.24)
pi0: 0.9026405
Cumulative number of significant calls:
<1e-04 <0.001 <0.01 <0.025 <0.05 <0.1 <1
p-value 6 26 231 515 928 1787 14084
q-value 0 0 0 0 0 0 14084
local FDR 0 0 0 0 0 0 14084summary(est24pDOX)
Call:
qvalue(p = framefun24$DOX.VEH.24)
pi0: 0.915478
Cumulative number of significant calls:
<1e-04 <0.001 <0.01 <0.025 <0.05 <0.1 <1
p-value 3 39 313 646 1089 1966 14084
q-value 0 0 0 0 0 0 14084
local FDR 0 0 0 0 0 0 11385summary(est24pEPI)
Call:
qvalue(p = framefun24$EPI.VEH.24)
pi0: 0.7730889
Cumulative number of significant calls:
<1e-04 <0.001 <0.01 <0.025 <0.05 <0.1 <1
p-value 23 165 824 1479 2211 3361 14084
q-value 0 0 3 4 56 508 14084
local FDR 0 0 1 3 55 256 9612summary(est24pMTX)
Call:
qvalue(p = framefun24$MTX.VEH.24)
pi0: 1
Cumulative number of significant calls:
<1e-04 <0.001 <0.01 <0.025 <0.05 <0.1 <1
p-value 0 6 47 117 269 609 14084
q-value 0 0 0 0 0 0 14084
local FDR 0 0 0 0 0 0 0summary(est24pTRZ)
Call:
qvalue(p = framefun24$TRZ.VEH.24)
pi0: 1
Cumulative number of significant calls:
<1e-04 <0.001 <0.01 <0.025 <0.05 <0.1 <1
p-value 1 3 24 63 157 384 14084
q-value 0 0 0 0 0 0 14084
local FDR 0 0 0 0 0 0 0EPIq24 <- data.table(pvalues=est24pEPI$pvalues,EPIqvalues=est24pEPI$qvalues)
EPI24_genelist <- framefun24 %>% dplyr::select(ENTREZID,EPI.VEH.24)
EPIstorelist24 <- EPI24_genelist %>%
full_join(.,EPIq24, by=c("EPI.VEH.24"="pvalues")) #%>%
# dplyr::filter(qvalues<.1) %>%
# mutate(ENTREZID=as.integer(ENTREZID))
# saveRDS(storeEPI,"data/qvalueEPItemp.RDS")
DNRq24 <- data.table(pvalues=est24pDNR$pvalues,DNRqvalues=est24pDNR$qvalues)
DNR24_genelist <- framefun24 %>% dplyr::select(ENTREZID,DNR.VEH.24)
DNRstorelist24 <-DNR24_genelist %>%
full_join(.,DNRq24, by=c("DNR.VEH.24"="pvalues")) #%>%
# dplyr::filter(qvalues<.2)
DOXq24 <- data.table(pvalues=est24pDOX$pvalues,DOXqvalues=est24pDOX$qvalues)
DOX24_genelist <- framefun24 %>% dplyr::select(ENTREZID,DOX.VEH.24)
DOXstorelist24 <-DOX24_genelist %>%
full_join(.,DOXq24, by=c("DOX.VEH.24"="pvalues")) #%>%
# dplyr::filter(qvalues<.2)
#
MTXq24 <- data.table(pvalues=est24pMTX$pvalues,MTXqvalues=est24pMTX$qvalues)
MTX24_genelist <- framefun24 %>% dplyr::select(ENTREZID,MTX.VEH.24)
MTXstorelist24 <-MTX24_genelist %>%
full_join(.,MTXq24, by=c("MTX.VEH.24"="pvalues"))# %>%
# dplyr::filter(qvalues<.2)
TRZq24 <- data.table(pvalues=est24pTRZ$pvalues,TRZqvalues=est24pTRZ$qvalues)
TRZ24_genelist <- framefun24 %>% dplyr::select(ENTREZID,TRZ.VEH.24)
TRZstorelist24 <- TRZ24_genelist %>%
full_join(.,TRZq24, by=c("TRZ.VEH.24"="pvalues")) #%>%
# dplyr::filter(qvalues<.2)
qval24hr <- DOXstorelist24 %>%
full_join(.,EPIstorelist24, by="ENTREZID") %>%
full_join(.,DNRstorelist24, by="ENTREZID") %>%
full_join(.,MTXstorelist24, by="ENTREZID") %>%
full_join(.,TRZstorelist24, by="ENTREZID") %>%
select(ENTREZID, ends_with("qvalues"), ends_with("24"))
# saveRDS(qval24hr,"data/qval24hr.RDS") evaluation of F statistic using correlation
organized_drugframe <- read.csv("data/organized_drugframe.csv",
row.names = 1)
Var_test_list3 <- readRDS("data/Var_test_list3.RDS")
#Is the data normally distributed?
set3 <- names(Var_test_list3)
shorterlist <- Var_test_list3[[1]][[13]]
names(shorterlist) <- rownames(organized_drugframe)
statfun3 <- data.frame(ENTREZID=rownames(organized_drugframe))
for (i in 1:length(set3)){
a <- set3[i]
s_list<- Var_test_list3[[i]][[13]]
names(s_list) <- rownames(organized_drugframe)
hold<- map_df(s_list, ~as.data.frame(.x$statistic), .id="ENTREZID")
statfun3[paste0(a)] <- hold$`.x$statistic`
}
Var_test_list24 <- readRDS("data/Var_test_list24.RDS")
set24 <- names(Var_test_list24)
statfun24 <- data.frame(ENTREZID=rownames(organized_drugframe))
for (i in 1:length(set24)){
a <- set24[i]
s_list<- Var_test_list24[[i]][[13]]
names(s_list) <- rownames(organized_drugframe)
hold<- map_df(s_list, ~as.data.frame(.x$statistic), .id="ENTREZID")
statfun24[paste0(a)] <- hold$`.x$statistic`
}
col_fun <- circlize::colorRamp2(c(-1,0, 1), c("blue","white", "red"))
# to combine with 3 hr
matstat24 <- statfun24 %>%
column_to_rownames('ENTREZID') %>%
as.matrix(.) #%>%
# rowwise() %>%
# 24 hour spearman correlation
statfun24 %>%
column_to_rownames('ENTREZID') %>%
# as.matrix(.) #%>%
cor(.,method="spearman", use="pairwise") %>%
Heatmap(., column_title = "24 hour F stat corr", col=col_fun)
# to combine with 24 hr
matstat3 <-
statfun3 %>%
column_to_rownames('ENTREZID') %>%
as.matrix(.)
statfun3 %>%
column_to_rownames('ENTREZID') %>%
# as.matrix(.) %>%
# rowwise() %>%
cor(.) %>%
Heatmap(., column_title = "3 hour F stat corr", col=col_fun)
matstatall <- statfun24 %>%
full_join(., statfun3, by="ENTREZID") %>%
column_to_rownames('ENTREZID') %>%
as.matrix(.)
statfun24 %>%
full_join(., statfun3, by="ENTREZID") %>%
column_to_rownames('ENTREZID') %>%
# as.matrix(.) %>%
# rowwise() %>%
cor(., method="spearman") %>%
Heatmap(., column_title = "3 & 24 hr F stat corr",
col=col_fun,
cell_fun = function(j, i, x, y, width, height, fill) {
grid.text(sprintf("%.2f", .[i, j]), x, y, gp = gpar(fontsize = 10))})
matframeall <-framefun24 %>%
full_join(., framefun3, by="ENTREZID") %>%
column_to_rownames('ENTREZID') %>%
as.matrix(.)
framefun3 %>%
column_to_rownames('ENTREZID') %>%
# as.matrix(.) %>%
# rowwise() %>%
cor(., method="spearman",use="pairwise") %>%
Heatmap(., column_title = "3 hour pval corr", col=col_fun)
matframe24 <- framefun24 %>%
# full_join(., framefun, by="ENTREZID") %>%
column_to_rownames('ENTREZID') %>%
as.matrix(.)# %>%
framefun24 %>%
full_join(., framefun3, by="ENTREZID") %>%
column_to_rownames('ENTREZID') %>%
# as.matrix(.) %>%
# rowwise() %>%
cor(.,method="spearman") %>%
Heatmap(., column_title = "24 and 3 hour p val correlation", col=col_fun,
cell_fun = function(j, i, x, y, width, height, fill) {
grid.text(sprintf("%.2f", .[i, j]), x, y, gp = gpar(fontsize = 10))})
q stat plots using Spearman correlation
# sum(qvalue24hr$EPIqvalues<0.1)
qvalue3hr <- readRDS("data/qval3hr.RDS")
qvalue3hr %>%
column_to_rownames('ENTREZID') %>%
select(!TRZqvalues) %>%
as.matrix(.) %>%
# rowwise() %>%
cor(., method="spearman") %>%
Heatmap(., column_title = "3 hour q value corr (Spearman)", col=col_fun,
)
| Version | Author | Date |
|---|---|---|
| 3622a69 | reneeisnowhere | 2023-09-28 |
qvalue24hr <- readRDS("data/qval24hr.RDS")
qvalue24hr %>%
column_to_rownames('ENTREZID') %>%
select(!MTXqvalues) %>%
select(ends_with("qvalues")) %>%
as.matrix(.) %>%
# rowwise() %>%
cor(.,method="spearman", use="pairwise")%>%
Heatmap(., column_title = "24 hour q value corr", col=col_fun,na_col = "tan",
cell_fun = function(j, i, x, y, width, height, fill) {
grid.text(sprintf("%.2f", .[i, j]), x, y, gp = gpar(fontsize = 10))})
| Version | Author | Date |
|---|---|---|
| 3622a69 | reneeisnowhere | 2023-09-28 |
3 and 24 hour histogram of var using un-adjusted and adjust p.values
framefun3 %>%
pivot_longer(col=!ENTREZID,names_to= "combo", values_to = "p.value") %>%
separate(combo, into= c("drug", NA,"time")) %>%
mutate(drug = factor(drug, levels = c("DOX", "EPI", "DNR","MTX", "TRZ"))) %>%
ggplot(.,aes(x=p.value,col=drug,fill=drug))+
geom_histogram()+
facet_wrap(~drug)+
ggtitle("3 hour var.test un-adjusted p.value ")
hist(est3pDNR)+labs(caption= "DNR 3")
hist(est3pDOX)+labs(caption= "DOX 3")
hist(est3pEPI)+labs(caption= "EPI 3")
hist(est3pMTX)+labs(caption= "MTX 3")
hist(est3pTRZ)+labs(caption= "TRZ 3")
plot(est3pDNR)
plot(est3pDOX)
plot(est3pEPI)
plot(est3pMTX)
plot(est3pTRZ)
framefun24 %>%
dplyr::filter(ENTREZID %in% EPIstorelist24$ENTREZID) %>%
pivot_longer(col=!ENTREZID,names_to= "combo", values_to = "p.value") %>%
separate(combo, into= c("drug", NA,"time")) %>%
mutate(drug = factor(drug, levels = c("DOX", "EPI", "DNR","MTX", "TRZ"))) %>%
ggplot(.,aes(x=p.value,col=drug,fill=drug))+
geom_histogram()+
facet_wrap(~drug)+
ggtitle("24 hour var.test un-adjusted p.value")
hist(est24pDNR)+labs(caption= "DNR 24")
hist(est24pDOX)+labs(caption= "DOX 24")
hist(est24pEPI)+labs(caption= "EPI 24")
hist(est24pMTX)+labs(caption= "MTX 24")
hist(est24pTRZ)+labs(caption= "TRZ 24")
plot(est24pDNR, caption =paste("DNR"))
print("DNR")[1] "DNR"plot(est24pDOX)
print("DOX")[1] "DOX"plot(est24pEPI)
print("EPI")[1] "EPI"plot(est24pMTX)
print("MTX")[1] "MTX"plot(est24pTRZ)
print("TRZ")[1] "TRZ"backGL <-read_csv("data/backGL.txt",
col_types = cols(...1 = col_skip()))
var3 <- list <- framefun3 %>%
pivot_longer(col=!ENTREZID,names_to= "combo", values_to = "p.value") %>%
separate(combo, into= c("drug", NA,"time")) %>%
mutate(drug = factor(drug, levels = c("DOX", "EPI", "DNR","MTX", "TRZ"))) %>%
filter(p.value<0.05)
var24 <- list <- framefun24 %>%
pivot_longer(col=!ENTREZID,names_to= "combo", values_to = "p.value") %>%
separate(combo, into= c("drug", NA,"time")) %>%
mutate(drug = factor(drug, levels = c("DOX", "EPI", "DNR","MTX", "TRZ"))) %>%
filter(p.value<0.05)
DOX_24_var <- var24 %>% filter(drug=="DOX") %>% select(ENTREZID)#1089
EPI_24_var <- var24 %>% filter(drug=="EPI")%>% select(ENTREZID)#2211
DNR_24_var <- var24 %>% filter(drug=="DNR")%>% select(ENTREZID)#928
MTX_24_var <- var24 %>% filter(drug=="MTX")%>% select(ENTREZID)#269
TRZ_24_var <- var24 %>% filter(drug=="TRZ")%>% select(ENTREZID)#157
geneset_24 <- list(DOX_24_var$ENTREZID, EPI_24_var$ENTREZID, DNR_24_var$ENTREZID, MTX_24_var$ENTREZID, TRZ_24_var$ENTREZID)
names(geneset_24) <- c("DOX_24_var","EPI_24_var","DNR_24_var" ,"MTX_24_var","TRZ_24_var")
DOX_3_var <- var3 %>% filter(drug=="DOX")%>% select(ENTREZID)#346
EPI_3_var <- var3 %>% filter(drug=="EPI")%>% select(ENTREZID)#332
DNR_3_var <- var3 %>% filter(drug=="DNR")%>% select(ENTREZID)#385
MTX_3_var <- var3 %>% filter(drug=="MTX")%>% select(ENTREZID)#277
TRZ_3_var <- var3 %>% filter(drug=="TRZ")%>% select(ENTREZID)#262
geneset_3 <- list(DOX_3_var$ENTREZID,EPI_3_var$ENTREZID,DNR_3_var$ENTREZID ,MTX_3_var$ENTREZID,TRZ_3_var$ENTREZID)
names(geneset_3) <- c("DOX_3_var","EPI_3_var","DNR_3_var" ,"MTX_3_var","TRZ_3_var")
# saveRDS(geneset_24,"data/geneset_24.RDS")Venn of highly variable genes
based on nominal pvalues <0.05
geneset_24 <- readRDS("data/geneset_24.RDS")
ggVennDiagram::ggVennDiagram(geneset_24,
category.names = c("DOX\nn = 1089 ",
"EPI\nn = 2211\n",
"DNR\nn = 928",
"MTX\nn = 269",
"TRZ\nn = 157"),
show_intersect = FALSE,
set_color = "black",
category_size = c(6,6,6,6),
label = "count",
label_percent_digit = 1,
label_size = 4,
label_alpha = 0,
label_color = "black",
edge_lty = "solid", set_size = 4.5)+
scale_x_continuous(expand = expansion(mult = .3))+
scale_y_continuous(expand = expansion(mult = .2))+
scale_color_paletteer_d(palette = "fishualize::Bodianus_pulchellus")+
scale_fill_distiller(palette="Spectral", direction = -1)+
labs(title = "24 hour var genes p. value <0.05",
caption = paste("n =", length(unique(var24$ENTREZID)),"genes"))+
theme(plot.title = element_text(size = rel(1.6), hjust = 0.5, vjust =1))
24 hour DOX highly variable genes
based on nominal pvalues <0.05
# DOX_var24gost <- gost(query = DOX_24_var$ENTREZID,
# organism = "hsapiens",
# significant = FALSE,
# ordered_query = TRUE,
# domain_scope = "custom",
# measure_underrepresentation = FALSE,
# evcodes = FALSE,
# numeric_ns="ENTREZGENE",
# user_threshold = 0.05,
# correction_method = "fdr",
# custom_bg = backGL$ENTREZID,
# sources=c("GO:BP","KEGG"))
# saveRDS(DOX_var24gost,"data/DEG-GO/var/DOX_var24gost.RDS")
DOX_var24gost <- readRDS("data/DEG-GO/var/DOX_var24gost.RDS")
DOX_var24p <- gostplot(DOX_var24gost, capped = FALSE, interactive = TRUE)
DOX_var24pDOX_var24_table <- DOX_var24gost$result %>%
dplyr::select(c(source, term_id, term_name,intersection_size, term_size, p_value))
DOX_var24_table %>%
dplyr::filter(source=="GO:BP") %>%
dplyr::select(p_value,term_name,intersection_size) %>%
slice_min(., n=10 ,order_by=p_value) %>%
mutate(log_val = -log10(p_value)) %>%
# slice_max(., n=10,order_by = p_value) %>%
ggplot(., aes(x = log_val, y =reorder(term_name,p_value), col= intersection_size)) +
geom_point(aes(size = intersection_size)) +
geom_vline(xintercept = (-log10(0.05)), col="red")+
scale_y_discrete(labels = label_wrap(30))+
guides(col="none", size=guide_legend(title = "# of intersected \n terms"))+
ggtitle('DOX24 hour top 10 GO:BP terms') +
xlab(expression(" -"~log[10]~("adj. p-value")))+
ylab("GO: BP term")+
theme_bw()+
theme(plot.title = element_text(size = rel(1.5), hjust = 0.5),
axis.title = element_text(size = 15, color = "black"),
axis.ticks = element_line(linewidth = 1.5),
axis.line = element_line(linewidth = 1.5),
axis.text = element_text(size = 10, color = "black", angle = 0),
strip.text.x = element_text(size = 15, color = "black", face = "bold")) 
DOX_var24_table %>%
mutate_at(.vars = 6, .funs= scientific_format()) %>%
kable(.,caption = "DOX 24 enrichment terms of highly var genes") %>%
kable_paper("striped", full_width = FALSE) %>%
kable_styling(full_width = FALSE, position = "left",bootstrap_options = c("striped","hover")) %>%
scroll_box(width = "100%", height = "400px")| source | term_id | term_name | intersection_size | term_size | p_value |
|---|---|---|---|---|---|
| GO:BP | GO:0070932 | histone H3 deacetylation | 6 | 12 | 4.92e-02 |
| GO:BP | GO:0006625 | protein targeting to peroxisome | 2 | 19 | 1.47e-01 |
| GO:BP | GO:0043545 | molybdopterin cofactor metabolic process | 4 | 6 | 1.47e-01 |
| GO:BP | GO:1905515 | non-motile cilium assembly | 13 | 58 | 1.47e-01 |
| GO:BP | GO:0051189 | prosthetic group metabolic process | 4 | 6 | 1.47e-01 |
| GO:BP | GO:0140252 | regulation protein catabolic process at postsynapse | 1 | 3 | 1.47e-01 |
| GO:BP | GO:0006777 | Mo-molybdopterin cofactor biosynthetic process | 4 | 6 | 1.47e-01 |
| GO:BP | GO:0019720 | Mo-molybdopterin cofactor metabolic process | 4 | 6 | 1.47e-01 |
| GO:BP | GO:0032324 | molybdopterin cofactor biosynthetic process | 4 | 6 | 1.47e-01 |
| GO:BP | GO:0072662 | protein localization to peroxisome | 2 | 19 | 1.47e-01 |
| GO:BP | GO:0043124 | negative regulation of I-kappaB kinase/NF-kappaB signaling | 9 | 36 | 1.47e-01 |
| GO:BP | GO:0016558 | protein import into peroxisome matrix | 2 | 14 | 1.47e-01 |
| GO:BP | GO:0072663 | establishment of protein localization to peroxisome | 2 | 19 | 1.47e-01 |
| GO:BP | GO:0015919 | peroxisomal membrane transport | 2 | 20 | 1.64e-01 |
| GO:BP | GO:0140250 | regulation protein catabolic process at synapse | 1 | 5 | 1.70e-01 |
| GO:BP | GO:0043574 | peroxisomal transport | 2 | 22 | 1.70e-01 |
| GO:BP | GO:0060856 | establishment of blood-brain barrier | 2 | 9 | 1.72e-01 |
| GO:BP | GO:0072014 | proximal tubule development | 3 | 7 | 1.83e-01 |
| GO:BP | GO:0010506 | regulation of autophagy | 27 | 313 | 1.83e-01 |
| GO:BP | GO:0031333 | negative regulation of protein-containing complex assembly | 3 | 130 | 1.83e-01 |
| GO:BP | GO:2000654 | regulation of cellular response to testosterone stimulus | 2 | 2 | 1.83e-01 |
| GO:BP | GO:1900038 | negative regulation of cellular response to hypoxia | 2 | 8 | 1.83e-01 |
| GO:BP | GO:0140467 | integrated stress response signaling | 8 | 35 | 1.83e-01 |
| GO:BP | GO:0035845 | photoreceptor cell outer segment organization | 2 | 10 | 1.96e-01 |
| GO:BP | GO:0060857 | establishment of glial blood-brain barrier | 1 | 2 | 1.96e-01 |
| GO:BP | GO:0002941 | synoviocyte proliferation | 2 | 3 | 1.96e-01 |
| GO:BP | GO:1901645 | regulation of synoviocyte proliferation | 2 | 3 | 1.96e-01 |
| GO:BP | GO:0150011 | regulation of neuron projection arborization | 2 | 14 | 1.96e-01 |
| GO:BP | GO:0044743 | protein transmembrane import into intracellular organelle | 2 | 36 | 1.96e-01 |
| GO:BP | GO:0007031 | peroxisome organization | 2 | 34 | 1.96e-01 |
| GO:BP | GO:0016241 | regulation of macroautophagy | 15 | 151 | 1.96e-01 |
| GO:BP | GO:0046499 | S-adenosylmethioninamine metabolic process | 1 | 1 | 1.96e-01 |
| GO:BP | GO:0090521 | podocyte cell migration | 4 | 7 | 1.96e-01 |
| GO:BP | GO:1901647 | positive regulation of synoviocyte proliferation | 2 | 3 | 1.96e-01 |
| GO:BP | GO:0031468 | nuclear membrane reassembly | 6 | 24 | 2.00e-01 |
| GO:BP | GO:0010226 | response to lithium ion | 7 | 16 | 2.00e-01 |
| GO:BP | GO:0030111 | regulation of Wnt signaling pathway | 6 | 273 | 2.00e-01 |
| GO:BP | GO:0043508 | negative regulation of JUN kinase activity | 3 | 13 | 2.00e-01 |
| GO:BP | GO:0036250 | peroxisome transport along microtubule | 1 | 1 | 2.01e-01 |
| GO:BP | GO:0016242 | negative regulation of macroautophagy | 6 | 34 | 2.01e-01 |
| GO:BP | GO:0042770 | signal transduction in response to DNA damage | 9 | 178 | 2.01e-01 |
| GO:BP | GO:0008286 | insulin receptor signaling pathway | 13 | 105 | 2.01e-01 |
| GO:BP | GO:0031119 | tRNA pseudouridine synthesis | 1 | 6 | 2.14e-01 |
| GO:BP | GO:0033274 | response to vitamin B2 | 1 | 1 | 2.14e-01 |
| GO:BP | GO:0006481 | C-terminal protein methylation | 1 | 2 | 2.16e-01 |
| GO:BP | GO:1900037 | regulation of cellular response to hypoxia | 2 | 13 | 2.16e-01 |
| GO:BP | GO:0098815 | modulation of excitatory postsynaptic potential | 10 | 40 | 2.16e-01 |
| GO:BP | GO:0061956 | penetration of cumulus oophorus | 1 | 1 | 2.16e-01 |
| GO:BP | GO:0071285 | cellular response to lithium ion | 4 | 8 | 2.16e-01 |
| GO:BP | GO:0006346 | DNA methylation-dependent heterochromatin formation | 3 | 22 | 2.16e-01 |
| GO:BP | GO:0008594 | photoreceptor cell morphogenesis | 2 | 4 | 2.16e-01 |
| GO:BP | GO:0032825 | positive regulation of natural killer cell differentiation | 3 | 7 | 2.16e-01 |
| GO:BP | GO:0072092 | ureteric bud invasion | 2 | 3 | 2.16e-01 |
| GO:BP | GO:0046329 | negative regulation of JNK cascade | 4 | 36 | 2.16e-01 |
| GO:BP | GO:0042063 | gliogenesis | 9 | 235 | 2.16e-01 |
| GO:BP | GO:0000301 | retrograde transport, vesicle recycling within Golgi | 3 | 9 | 2.16e-01 |
| GO:BP | GO:0046498 | S-adenosylhomocysteine metabolic process | 1 | 2 | 2.16e-01 |
| GO:BP | GO:2000777 | positive regulation of proteasomal ubiquitin-dependent protein catabolic process involved in cellular response to hypoxia | 2 | 2 | 2.16e-01 |
| GO:BP | GO:1902902 | negative regulation of autophagosome assembly | 5 | 14 | 2.20e-01 |
| GO:BP | GO:0065002 | intracellular protein transmembrane transport | 2 | 52 | 2.20e-01 |
| GO:BP | GO:0140354 | lipid import into cell | 6 | 15 | 2.26e-01 |
| GO:BP | GO:0044773 | mitotic DNA damage checkpoint signaling | 12 | 81 | 2.28e-01 |
| GO:BP | GO:0051891 | positive regulation of cardioblast differentiation | 2 | 4 | 2.28e-01 |
| GO:BP | GO:1902389 | ceramide 1-phosphate transport | 1 | 7 | 2.29e-01 |
| GO:BP | GO:1990637 | response to prolactin | 2 | 3 | 2.30e-01 |
| GO:BP | GO:0031641 | regulation of myelination | 7 | 36 | 2.30e-01 |
| GO:BP | GO:1905209 | positive regulation of cardiocyte differentiation | 3 | 11 | 2.30e-01 |
| GO:BP | GO:0044091 | membrane biogenesis | 10 | 58 | 2.30e-01 |
| GO:BP | GO:0080135 | regulation of cellular response to stress | 33 | 616 | 2.30e-01 |
| GO:BP | GO:0044721 | protein import into peroxisome matrix, substrate release | 1 | 2 | 2.34e-01 |
| GO:BP | GO:0101024 | mitotic nuclear membrane organization | 4 | 9 | 2.34e-01 |
| GO:BP | GO:0007084 | mitotic nuclear membrane reassembly | 4 | 9 | 2.34e-01 |
| GO:BP | GO:1903050 | regulation of proteolysis involved in protein catabolic process | 19 | 214 | 2.36e-01 |
| GO:BP | GO:0140245 | regulation of translation at postsynapse | 3 | 6 | 2.36e-01 |
| GO:BP | GO:0048144 | fibroblast proliferation | 10 | 92 | 2.36e-01 |
| GO:BP | GO:0021595 | rhombomere structural organization | 1 | 1 | 2.36e-01 |
| GO:BP | GO:0001825 | blastocyst formation | 8 | 37 | 2.36e-01 |
| GO:BP | GO:0140329 | lysophospholipid translocation | 1 | 1 | 2.36e-01 |
| GO:BP | GO:1903599 | positive regulation of autophagy of mitochondrion | 2 | 13 | 2.36e-01 |
| GO:BP | GO:0021659 | rhombomere 3 structural organization | 1 | 1 | 2.36e-01 |
| GO:BP | GO:0021660 | rhombomere 3 formation | 1 | 1 | 2.36e-01 |
| GO:BP | GO:0021664 | rhombomere 5 morphogenesis | 1 | 1 | 2.36e-01 |
| GO:BP | GO:0021665 | rhombomere 5 structural organization | 1 | 1 | 2.36e-01 |
| GO:BP | GO:0016562 | protein import into peroxisome matrix, receptor recycling | 1 | 7 | 2.36e-01 |
| GO:BP | GO:0016561 | protein import into peroxisome matrix, translocation | 1 | 3 | 2.36e-01 |
| GO:BP | GO:0016560 | protein import into peroxisome matrix, docking | 1 | 3 | 2.36e-01 |
| GO:BP | GO:0021666 | rhombomere 5 formation | 1 | 1 | 2.36e-01 |
| GO:BP | GO:0017015 | regulation of transforming growth factor beta receptor signaling pathway | 18 | 128 | 2.36e-01 |
| GO:BP | GO:0048388 | endosomal lumen acidification | 3 | 13 | 2.36e-01 |
| GO:BP | GO:0021571 | rhombomere 5 development | 2 | 2 | 2.36e-01 |
| GO:BP | GO:0140243 | regulation of translation at synapse | 3 | 6 | 2.36e-01 |
| GO:BP | GO:0048264 | determination of ventral identity | 1 | 1 | 2.36e-01 |
| GO:BP | GO:0061136 | regulation of proteasomal protein catabolic process | 18 | 183 | 2.36e-01 |
| GO:BP | GO:0071709 | membrane assembly | 11 | 53 | 2.36e-01 |
| GO:BP | GO:0045687 | positive regulation of glial cell differentiation | 3 | 28 | 2.36e-01 |
| GO:BP | GO:1903348 | positive regulation of bicellular tight junction assembly | 1 | 5 | 2.36e-01 |
| GO:BP | GO:0045685 | regulation of glial cell differentiation | 4 | 47 | 2.36e-01 |
| GO:BP | GO:0019262 | N-acetylneuraminate catabolic process | 3 | 6 | 2.36e-01 |
| GO:BP | GO:0071806 | protein transmembrane transport | 2 | 62 | 2.36e-01 |
| GO:BP | GO:0045736 | negative regulation of cyclin-dependent protein serine/threonine kinase activity | 5 | 27 | 2.36e-01 |
| GO:BP | GO:0021594 | rhombomere formation | 1 | 1 | 2.36e-01 |
| GO:BP | GO:2000143 | negative regulation of DNA-templated transcription initiation | 1 | 6 | 2.36e-01 |
| GO:BP | GO:0006054 | N-acetylneuraminate metabolic process | 4 | 11 | 2.36e-01 |
| GO:BP | GO:0106057 | negative regulation of calcineurin-mediated signaling | 4 | 14 | 2.36e-01 |
| GO:BP | GO:0048193 | Golgi vesicle transport | 22 | 285 | 2.36e-01 |
| GO:BP | GO:0061198 | fungiform papilla formation | 1 | 3 | 2.36e-01 |
| GO:BP | GO:0140058 | neuron projection arborization | 2 | 29 | 2.36e-01 |
| GO:BP | GO:1903298 | negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway | 1 | 6 | 2.36e-01 |
| GO:BP | GO:0071901 | negative regulation of protein serine/threonine kinase activity | 12 | 101 | 2.36e-01 |
| GO:BP | GO:1903297 | regulation of hypoxia-induced intrinsic apoptotic signaling pathway | 1 | 6 | 2.36e-01 |
| GO:BP | GO:0051797 | regulation of hair follicle development | 2 | 16 | 2.36e-01 |
| GO:BP | GO:0061044 | negative regulation of vascular wound healing | 3 | 4 | 2.36e-01 |
| GO:BP | GO:1903426 | regulation of reactive oxygen species biosynthetic process | 5 | 29 | 2.36e-01 |
| GO:BP | GO:0016049 | cell growth | 23 | 418 | 2.36e-01 |
| GO:BP | GO:0034983 | peptidyl-lysine deacetylation | 3 | 8 | 2.36e-01 |
| GO:BP | GO:0070885 | negative regulation of calcineurin-NFAT signaling cascade | 4 | 14 | 2.36e-01 |
| GO:BP | GO:0014044 | Schwann cell development | 7 | 28 | 2.36e-01 |
| GO:BP | GO:0014037 | Schwann cell differentiation | 8 | 34 | 2.36e-01 |
| GO:BP | GO:0070159 | mitochondrial threonyl-tRNA aminoacylation | 1 | 1 | 2.36e-01 |
| GO:BP | GO:0051890 | regulation of cardioblast differentiation | 2 | 5 | 2.36e-01 |
| GO:BP | GO:0035873 | lactate transmembrane transport | 2 | 5 | 2.36e-01 |
| GO:BP | GO:0010507 | negative regulation of autophagy | 7 | 74 | 2.36e-01 |
| GO:BP | GO:0002528 | regulation of vascular permeability involved in acute inflammatory response | 1 | 2 | 2.36e-01 |
| GO:BP | GO:0002543 | activation of blood coagulation via clotting cascade | 1 | 2 | 2.36e-01 |
| GO:BP | GO:0046604 | positive regulation of mitotic centrosome separation | 2 | 3 | 2.36e-01 |
| GO:BP | GO:0002829 | negative regulation of type 2 immune response | 4 | 7 | 2.36e-01 |
| GO:BP | GO:1901526 | positive regulation of mitophagy | 1 | 6 | 2.36e-01 |
| GO:BP | GO:1901534 | positive regulation of hematopoietic progenitor cell differentiation | 2 | 6 | 2.36e-01 |
| GO:BP | GO:0070828 | heterochromatin organization | 4 | 77 | 2.36e-01 |
| GO:BP | GO:0035745 | T-helper 2 cell cytokine production | 1 | 3 | 2.36e-01 |
| GO:BP | GO:0070303 | negative regulation of stress-activated protein kinase signaling cascade | 4 | 46 | 2.36e-01 |
| GO:BP | GO:1902068 | regulation of sphingolipid mediated signaling pathway | 1 | 1 | 2.36e-01 |
| GO:BP | GO:2000655 | negative regulation of cellular response to testosterone stimulus | 1 | 1 | 2.36e-01 |
| GO:BP | GO:0010827 | regulation of glucose transmembrane transport | 9 | 55 | 2.36e-01 |
| GO:BP | GO:1901985 | positive regulation of protein acetylation | 7 | 41 | 2.36e-01 |
| GO:BP | GO:2000463 | positive regulation of excitatory postsynaptic potential | 7 | 28 | 2.36e-01 |
| GO:BP | GO:0036124 | histone H3-K9 trimethylation | 2 | 9 | 2.36e-01 |
| GO:BP | GO:0070662 | mast cell proliferation | 2 | 6 | 2.36e-01 |
| GO:BP | GO:0070666 | regulation of mast cell proliferation | 2 | 6 | 2.36e-01 |
| GO:BP | GO:2000551 | regulation of T-helper 2 cell cytokine production | 1 | 3 | 2.36e-01 |
| GO:BP | GO:2000553 | positive regulation of T-helper 2 cell cytokine production | 1 | 3 | 2.36e-01 |
| GO:BP | GO:0051835 | positive regulation of synapse structural plasticity | 2 | 2 | 2.36e-01 |
| GO:BP | GO:0036294 | cellular response to decreased oxygen levels | 6 | 131 | 2.36e-01 |
| GO:BP | GO:0010756 | positive regulation of plasminogen activation | 1 | 7 | 2.36e-01 |
| GO:BP | GO:0036257 | multivesicular body organization | 5 | 33 | 2.36e-01 |
| GO:BP | GO:0035999 | tetrahydrofolate interconversion | 3 | 9 | 2.36e-01 |
| GO:BP | GO:0042176 | regulation of protein catabolic process | 41 | 331 | 2.36e-01 |
| GO:BP | GO:0003007 | heart morphogenesis | 26 | 216 | 2.36e-01 |
| GO:BP | GO:0070933 | histone H4 deacetylation | 3 | 7 | 2.36e-01 |
| GO:BP | GO:0071456 | cellular response to hypoxia | 6 | 123 | 2.36e-01 |
| GO:BP | GO:0003279 | cardiac septum development | 11 | 101 | 2.36e-01 |
| GO:BP | GO:0071453 | cellular response to oxygen levels | 6 | 144 | 2.36e-01 |
| GO:BP | GO:0140718 | facultative heterochromatin formation | 3 | 35 | 2.36e-01 |
| GO:BP | GO:0009157 | deoxyribonucleoside monophosphate biosynthetic process | 3 | 9 | 2.36e-01 |
| GO:BP | GO:0009177 | pyrimidine deoxyribonucleoside monophosphate biosynthetic process | 2 | 4 | 2.36e-01 |
| GO:BP | GO:0042659 | regulation of cell fate specification | 2 | 23 | 2.36e-01 |
| GO:BP | GO:0071375 | cellular response to peptide hormone stimulus | 20 | 241 | 2.36e-01 |
| GO:BP | GO:0150175 | regulation of phosphatidylethanolamine metabolic process | 1 | 1 | 2.36e-01 |
| GO:BP | GO:0150178 | regulation of phosphatidylserine metabolic process | 1 | 1 | 2.36e-01 |
| GO:BP | GO:0198738 | cell-cell signaling by wnt | 6 | 376 | 2.36e-01 |
| GO:BP | GO:0035284 | brain segmentation | 2 | 2 | 2.36e-01 |
| GO:BP | GO:2001243 | negative regulation of intrinsic apoptotic signaling pathway | 5 | 89 | 2.36e-01 |
| GO:BP | GO:0016072 | rRNA metabolic process | 30 | 258 | 2.36e-01 |
| GO:BP | GO:0016055 | Wnt signaling pathway | 6 | 375 | 2.36e-01 |
| GO:BP | GO:0051490 | negative regulation of filopodium assembly | 2 | 6 | 2.36e-01 |
| GO:BP | GO:0042543 | protein N-linked glycosylation via arginine | 1 | 1 | 2.36e-01 |
| GO:BP | GO:0035627 | ceramide transport | 1 | 15 | 2.36e-01 |
| GO:BP | GO:0010001 | glial cell differentiation | 8 | 170 | 2.36e-01 |
| GO:BP | GO:0042254 | ribosome biogenesis | 34 | 301 | 2.36e-01 |
| GO:BP | GO:0045926 | negative regulation of growth | 14 | 206 | 2.36e-01 |
| GO:BP | GO:0009894 | regulation of catabolic process | 54 | 875 | 2.36e-01 |
| GO:BP | GO:2000233 | negative regulation of rRNA processing | 2 | 3 | 2.36e-01 |
| GO:BP | GO:0003283 | atrial septum development | 3 | 23 | 2.36e-01 |
| GO:BP | GO:0015727 | lactate transport | 2 | 5 | 2.36e-01 |
| GO:BP | GO:0051977 | lysophospholipid transport | 1 | 2 | 2.36e-01 |
| GO:BP | GO:0015793 | glycerol transmembrane transport | 2 | 4 | 2.36e-01 |
| GO:BP | GO:1900226 | negative regulation of NLRP3 inflammasome complex assembly | 1 | 6 | 2.36e-01 |
| GO:BP | GO:1900113 | negative regulation of histone H3-K9 trimethylation | 2 | 3 | 2.36e-01 |
| GO:BP | GO:0003184 | pulmonary valve morphogenesis | 2 | 19 | 2.36e-01 |
| GO:BP | GO:1902856 | negative regulation of non-motile cilium assembly | 2 | 2 | 2.36e-01 |
| GO:BP | GO:0051561 | positive regulation of mitochondrial calcium ion concentration | 2 | 11 | 2.36e-01 |
| GO:BP | GO:0033484 | intracellular nitric oxide homeostasis | 2 | 3 | 2.36e-01 |
| GO:BP | GO:1901753 | leukotriene A4 biosynthetic process | 1 | 1 | 2.36e-01 |
| GO:BP | GO:0031999 | negative regulation of fatty acid beta-oxidation | 2 | 5 | 2.36e-01 |
| GO:BP | GO:0072384 | organelle transport along microtubule | 2 | 84 | 2.36e-01 |
| GO:BP | GO:1904491 | protein localization to ciliary transition zone | 1 | 7 | 2.36e-01 |
| GO:BP | GO:0006364 | rRNA processing | 27 | 221 | 2.36e-01 |
| GO:BP | GO:0032736 | positive regulation of interleukin-13 production | 1 | 7 | 2.36e-01 |
| GO:BP | GO:0032754 | positive regulation of interleukin-5 production | 1 | 6 | 2.36e-01 |
| GO:BP | GO:1990144 | intrinsic apoptotic signaling pathway in response to hypoxia | 2 | 9 | 2.36e-01 |
| GO:BP | GO:0001173 | DNA-templated transcriptional start site selection | 2 | 2 | 2.36e-01 |
| GO:BP | GO:0001174 | transcriptional start site selection at RNA polymerase II promoter | 2 | 2 | 2.36e-01 |
| GO:BP | GO:0007032 | endosome organization | 10 | 92 | 2.36e-01 |
| GO:BP | GO:0060296 | regulation of cilium beat frequency involved in ciliary motility | 2 | 6 | 2.36e-01 |
| GO:BP | GO:0097167 | circadian regulation of translation | 2 | 4 | 2.36e-01 |
| GO:BP | GO:0006575 | cellular modified amino acid metabolic process | 3 | 96 | 2.36e-01 |
| GO:BP | GO:0043618 | regulation of transcription from RNA polymerase II promoter in response to stress | 6 | 36 | 2.36e-01 |
| GO:BP | GO:0032823 | regulation of natural killer cell differentiation | 3 | 8 | 2.36e-01 |
| GO:BP | GO:0030512 | negative regulation of transforming growth factor beta receptor signaling pathway | 14 | 86 | 2.36e-01 |
| GO:BP | GO:0060766 | negative regulation of androgen receptor signaling pathway | 2 | 12 | 2.36e-01 |
| GO:BP | GO:0001522 | pseudouridine synthesis | 1 | 18 | 2.36e-01 |
| GO:BP | GO:0000077 | DNA damage checkpoint signaling | 6 | 121 | 2.36e-01 |
| GO:BP | GO:0032869 | cellular response to insulin stimulus | 16 | 174 | 2.36e-01 |
| GO:BP | GO:0032091 | negative regulation of protein binding | 2 | 77 | 2.36e-01 |
| GO:BP | GO:0032873 | negative regulation of stress-activated MAPK cascade | 4 | 46 | 2.36e-01 |
| GO:BP | GO:0030308 | negative regulation of cell growth | 12 | 160 | 2.36e-01 |
| GO:BP | GO:0072201 | negative regulation of mesenchymal cell proliferation | 1 | 7 | 2.36e-01 |
| GO:BP | GO:0060828 | regulation of canonical Wnt signaling pathway | 4 | 213 | 2.36e-01 |
| GO:BP | GO:0032055 | negative regulation of translation in response to stress | 2 | 4 | 2.36e-01 |
| GO:BP | GO:1990116 | ribosome-associated ubiquitin-dependent protein catabolic process | 3 | 5 | 2.36e-01 |
| GO:BP | GO:0032700 | negative regulation of interleukin-17 production | 4 | 9 | 2.36e-01 |
| GO:BP | GO:0032691 | negative regulation of interleukin-1 beta production | 1 | 13 | 2.36e-01 |
| GO:BP | GO:1905114 | cell surface receptor signaling pathway involved in cell-cell signaling | 7 | 448 | 2.36e-01 |
| GO:BP | GO:0031573 | mitotic intra-S DNA damage checkpoint signaling | 5 | 15 | 2.36e-01 |
| GO:BP | GO:0031571 | mitotic G1 DNA damage checkpoint signaling | 6 | 30 | 2.36e-01 |
| GO:BP | GO:0000291 | nuclear-transcribed mRNA catabolic process, exonucleolytic | 3 | 19 | 2.36e-01 |
| GO:BP | GO:0031503 | protein-containing complex localization | 25 | 168 | 2.36e-01 |
| GO:BP | GO:0044539 | long-chain fatty acid import into cell | 5 | 14 | 2.36e-01 |
| GO:BP | GO:0032510 | endosome to lysosome transport via multivesicular body sorting pathway | 4 | 17 | 2.36e-01 |
| GO:BP | GO:0006890 | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 6 | 52 | 2.36e-01 |
| GO:BP | GO:0006892 | post-Golgi vesicle-mediated transport | 7 | 103 | 2.36e-01 |
| GO:BP | GO:0044088 | regulation of vacuole organization | 9 | 50 | 2.36e-01 |
| GO:BP | GO:0045053 | protein retention in Golgi apparatus | 1 | 5 | 2.36e-01 |
| GO:BP | GO:1904716 | positive regulation of chaperone-mediated autophagy | 1 | 1 | 2.36e-01 |
| GO:BP | GO:0048814 | regulation of dendrite morphogenesis | 7 | 58 | 2.36e-01 |
| GO:BP | GO:0006913 | nucleocytoplasmic transport | 18 | 295 | 2.36e-01 |
| GO:BP | GO:0031329 | regulation of cellular catabolic process | 38 | 555 | 2.36e-01 |
| GO:BP | GO:0006565 | L-serine catabolic process | 2 | 4 | 2.36e-01 |
| GO:BP | GO:1905897 | regulation of response to endoplasmic reticulum stress | 6 | 76 | 2.36e-01 |
| GO:BP | GO:0060633 | negative regulation of transcription initiation by RNA polymerase II | 1 | 6 | 2.36e-01 |
| GO:BP | GO:0060413 | atrial septum morphogenesis | 3 | 15 | 2.36e-01 |
| GO:BP | GO:0048713 | regulation of oligodendrocyte differentiation | 3 | 25 | 2.36e-01 |
| GO:BP | GO:1903701 | substantia propria of cornea development | 1 | 1 | 2.36e-01 |
| GO:BP | GO:0006399 | tRNA metabolic process | 5 | 186 | 2.36e-01 |
| GO:BP | GO:0048709 | oligodendrocyte differentiation | 5 | 68 | 2.36e-01 |
| GO:BP | GO:0031643 | positive regulation of myelination | 3 | 12 | 2.36e-01 |
| GO:BP | GO:1990114 | RNA polymerase II core complex assembly | 1 | 1 | 2.36e-01 |
| GO:BP | GO:0030178 | negative regulation of Wnt signaling pathway | 3 | 140 | 2.36e-01 |
| GO:BP | GO:0007179 | transforming growth factor beta receptor signaling pathway | 23 | 179 | 2.36e-01 |
| GO:BP | GO:0031584 | activation of phospholipase D activity | 1 | 4 | 2.36e-01 |
| GO:BP | GO:0045628 | regulation of T-helper 2 cell differentiation | 1 | 7 | 2.36e-01 |
| GO:BP | GO:0043506 | regulation of JUN kinase activity | 4 | 49 | 2.36e-01 |
| GO:BP | GO:0006231 | dTMP biosynthetic process | 2 | 4 | 2.36e-01 |
| GO:BP | GO:0007264 | small GTPase mediated signal transduction | 16 | 421 | 2.36e-01 |
| GO:BP | GO:0001779 | natural killer cell differentiation | 4 | 18 | 2.36e-01 |
| GO:BP | GO:1904030 | negative regulation of cyclin-dependent protein kinase activity | 5 | 27 | 2.36e-01 |
| GO:BP | GO:0072093 | metanephric renal vesicle formation | 2 | 4 | 2.36e-01 |
| GO:BP | GO:0021782 | glial cell development | 12 | 84 | 2.36e-01 |
| GO:BP | GO:0051122 | hepoxilin biosynthetic process | 2 | 5 | 2.36e-01 |
| GO:BP | GO:1990755 | mitotic spindle microtubule depolymerization | 1 | 1 | 2.36e-01 |
| GO:BP | GO:0099072 | regulation of postsynaptic membrane neurotransmitter receptor levels | 10 | 70 | 2.36e-01 |
| GO:BP | GO:0044774 | mitotic DNA integrity checkpoint signaling | 12 | 85 | 2.36e-01 |
| GO:BP | GO:0060081 | membrane hyperpolarization | 1 | 7 | 2.36e-01 |
| GO:BP | GO:0051121 | hepoxilin metabolic process | 2 | 5 | 2.36e-01 |
| GO:BP | GO:0006611 | protein export from nucleus | 9 | 55 | 2.36e-01 |
| GO:BP | GO:0090090 | negative regulation of canonical Wnt signaling pathway | 3 | 114 | 2.36e-01 |
| GO:BP | GO:0006605 | protein targeting | 4 | 307 | 2.36e-01 |
| GO:BP | GO:0045630 | positive regulation of T-helper 2 cell differentiation | 1 | 4 | 2.36e-01 |
| GO:BP | GO:0022011 | myelination in peripheral nervous system | 5 | 25 | 2.36e-01 |
| GO:BP | GO:0051169 | nuclear transport | 18 | 295 | 2.36e-01 |
| GO:BP | GO:1903844 | regulation of cellular response to transforming growth factor beta stimulus | 18 | 129 | 2.36e-01 |
| GO:BP | GO:0060070 | canonical Wnt signaling pathway | 5 | 251 | 2.36e-01 |
| GO:BP | GO:0032292 | peripheral nervous system axon ensheathment | 5 | 25 | 2.36e-01 |
| GO:BP | GO:0021915 | neural tube development | 18 | 146 | 2.36e-01 |
| GO:BP | GO:0044819 | mitotic G1/S transition checkpoint signaling | 6 | 30 | 2.36e-01 |
| GO:BP | GO:0098696 | regulation of neurotransmitter receptor localization to postsynaptic specialization membrane | 1 | 11 | 2.36e-01 |
| GO:BP | GO:0003162 | atrioventricular node development | 2 | 8 | 2.37e-01 |
| GO:BP | GO:0048145 | regulation of fibroblast proliferation | 8 | 77 | 2.37e-01 |
| GO:BP | GO:0031345 | negative regulation of cell projection organization | 19 | 156 | 2.37e-01 |
| GO:BP | GO:0060371 | regulation of atrial cardiac muscle cell membrane depolarization | 2 | 7 | 2.37e-01 |
| GO:BP | GO:0014912 | negative regulation of smooth muscle cell migration | 6 | 25 | 2.37e-01 |
| GO:BP | GO:0002830 | positive regulation of type 2 immune response | 1 | 7 | 2.37e-01 |
| GO:BP | GO:0045064 | T-helper 2 cell differentiation | 1 | 10 | 2.37e-01 |
| GO:BP | GO:1900225 | regulation of NLRP3 inflammasome complex assembly | 1 | 23 | 2.37e-01 |
| GO:BP | GO:1902766 | skeletal muscle satellite cell migration | 1 | 2 | 2.37e-01 |
| GO:BP | GO:0008643 | carbohydrate transport | 16 | 111 | 2.37e-01 |
| GO:BP | GO:0051168 | nuclear export | 11 | 150 | 2.37e-01 |
| GO:BP | GO:0036500 | ATF6-mediated unfolded protein response | 2 | 9 | 2.40e-01 |
| GO:BP | GO:1901800 | positive regulation of proteasomal protein catabolic process | 16 | 111 | 2.40e-01 |
| GO:BP | GO:0002182 | cytoplasmic translational elongation | 4 | 12 | 2.40e-01 |
| GO:BP | GO:0001666 | response to hypoxia | 8 | 237 | 2.40e-01 |
| GO:BP | GO:0051129 | negative regulation of cellular component organization | 41 | 604 | 2.40e-01 |
| GO:BP | GO:0007113 | endomitotic cell cycle | 1 | 3 | 2.40e-01 |
| GO:BP | GO:0007616 | long-term memory | 7 | 31 | 2.40e-01 |
| GO:BP | GO:0035743 | CD4-positive, alpha-beta T cell cytokine production | 1 | 5 | 2.40e-01 |
| GO:BP | GO:0070291 | N-acylethanolamine metabolic process | 2 | 4 | 2.40e-01 |
| GO:BP | GO:0061009 | common bile duct development | 2 | 4 | 2.40e-01 |
| GO:BP | GO:0002552 | serotonin secretion by mast cell | 1 | 1 | 2.40e-01 |
| GO:BP | GO:0016236 | macroautophagy | 21 | 308 | 2.40e-01 |
| GO:BP | GO:0000056 | ribosomal small subunit export from nucleus | 3 | 8 | 2.40e-01 |
| GO:BP | GO:0035622 | intrahepatic bile duct development | 1 | 2 | 2.40e-01 |
| GO:BP | GO:0021816 | extension of a leading process involved in cell motility in cerebral cortex radial glia guided migration | 1 | 2 | 2.40e-01 |
| GO:BP | GO:0015791 | polyol transmembrane transport | 2 | 6 | 2.40e-01 |
| GO:BP | GO:0097193 | intrinsic apoptotic signaling pathway | 15 | 262 | 2.40e-01 |
| GO:BP | GO:0099123 | somato-dendritic dopamine secretion | 1 | 1 | 2.40e-01 |
| GO:BP | GO:0044546 | NLRP3 inflammasome complex assembly | 1 | 23 | 2.40e-01 |
| GO:BP | GO:0008033 | tRNA processing | 4 | 128 | 2.40e-01 |
| GO:BP | GO:0042137 | sequestering of neurotransmitter | 1 | 1 | 2.40e-01 |
| GO:BP | GO:0032692 | negative regulation of interleukin-1 production | 1 | 15 | 2.42e-01 |
| GO:BP | GO:0043254 | regulation of protein-containing complex assembly | 3 | 348 | 2.42e-01 |
| GO:BP | GO:0031570 | DNA integrity checkpoint signaling | 6 | 129 | 2.42e-01 |
| GO:BP | GO:0017148 | negative regulation of translation | 13 | 165 | 2.43e-01 |
| GO:BP | GO:0046653 | tetrahydrofolate metabolic process | 3 | 14 | 2.44e-01 |
| GO:BP | GO:0048384 | retinoic acid receptor signaling pathway | 5 | 26 | 2.44e-01 |
| GO:BP | GO:0060020 | Bergmann glial cell differentiation | 3 | 9 | 2.45e-01 |
| GO:BP | GO:0042461 | photoreceptor cell development | 2 | 30 | 2.45e-01 |
| GO:BP | GO:0032634 | interleukin-5 production | 1 | 8 | 2.45e-01 |
| GO:BP | GO:0032674 | regulation of interleukin-5 production | 1 | 8 | 2.45e-01 |
| GO:BP | GO:0046328 | regulation of JNK cascade | 10 | 114 | 2.45e-01 |
| GO:BP | GO:0032872 | regulation of stress-activated MAPK cascade | 13 | 154 | 2.45e-01 |
| GO:BP | GO:0140632 | canonical inflammasome complex assembly | 1 | 23 | 2.45e-01 |
| GO:BP | GO:0046324 | regulation of glucose import | 7 | 41 | 2.45e-01 |
| GO:BP | GO:0045624 | positive regulation of T-helper cell differentiation | 1 | 11 | 2.45e-01 |
| GO:BP | GO:0002051 | osteoblast fate commitment | 2 | 2 | 2.46e-01 |
| GO:BP | GO:0003177 | pulmonary valve development | 2 | 22 | 2.46e-01 |
| GO:BP | GO:0045657 | positive regulation of monocyte differentiation | 1 | 7 | 2.46e-01 |
| GO:BP | GO:0039702 | viral budding via host ESCRT complex | 4 | 22 | 2.46e-01 |
| GO:BP | GO:0009411 | response to UV | 13 | 141 | 2.46e-01 |
| GO:BP | GO:1901524 | regulation of mitophagy | 3 | 13 | 2.47e-01 |
| GO:BP | GO:0032616 | interleukin-13 production | 1 | 10 | 2.49e-01 |
| GO:BP | GO:2000677 | regulation of transcription regulatory region DNA binding | 4 | 43 | 2.49e-01 |
| GO:BP | GO:0032656 | regulation of interleukin-13 production | 1 | 10 | 2.49e-01 |
| GO:BP | GO:0061197 | fungiform papilla morphogenesis | 1 | 4 | 2.50e-01 |
| GO:BP | GO:0043620 | regulation of DNA-templated transcription in response to stress | 6 | 41 | 2.50e-01 |
| GO:BP | GO:0009838 | abscission | 2 | 6 | 2.50e-01 |
| GO:BP | GO:0140374 | antiviral innate immune response | 1 | 17 | 2.50e-01 |
| GO:BP | GO:1902473 | regulation of protein localization to synapse | 1 | 22 | 2.51e-01 |
| GO:BP | GO:0010508 | positive regulation of autophagy | 6 | 133 | 2.51e-01 |
| GO:BP | GO:0034249 | negative regulation of amide metabolic process | 14 | 186 | 2.51e-01 |
| GO:BP | GO:1902683 | regulation of receptor localization to synapse | 1 | 21 | 2.51e-01 |
| GO:BP | GO:0048262 | determination of dorsal/ventral asymmetry | 2 | 6 | 2.51e-01 |
| GO:BP | GO:0010046 | response to mycotoxin | 2 | 3 | 2.51e-01 |
| GO:BP | GO:0010453 | regulation of cell fate commitment | 2 | 26 | 2.51e-01 |
| GO:BP | GO:0002540 | leukotriene production involved in inflammatory response | 2 | 2 | 2.56e-01 |
| GO:BP | GO:0062044 | negative regulation of cardiac epithelial to mesenchymal transition | 1 | 2 | 2.56e-01 |
| GO:BP | GO:0002538 | arachidonic acid metabolite production involved in inflammatory response | 2 | 2 | 2.56e-01 |
| GO:BP | GO:0060211 | regulation of nuclear-transcribed mRNA poly(A) tail shortening | 3 | 15 | 2.56e-01 |
| GO:BP | GO:0046628 | positive regulation of insulin receptor signaling pathway | 1 | 20 | 2.56e-01 |
| GO:BP | GO:1902116 | negative regulation of organelle assembly | 8 | 40 | 2.56e-01 |
| GO:BP | GO:0045639 | positive regulation of myeloid cell differentiation | 3 | 67 | 2.56e-01 |
| GO:BP | GO:0072578 | neurotransmitter-gated ion channel clustering | 4 | 12 | 2.56e-01 |
| GO:BP | GO:0035732 | nitric oxide storage | 1 | 1 | 2.56e-01 |
| GO:BP | GO:0042060 | wound healing | 9 | 320 | 2.56e-01 |
| GO:BP | GO:0036293 | response to decreased oxygen levels | 8 | 249 | 2.56e-01 |
| GO:BP | GO:0002726 | positive regulation of T cell cytokine production | 1 | 14 | 2.56e-01 |
| GO:BP | GO:0043407 | negative regulation of MAP kinase activity | 4 | 50 | 2.56e-01 |
| GO:BP | GO:1905006 | negative regulation of epithelial to mesenchymal transition involved in endocardial cushion formation | 1 | 2 | 2.56e-01 |
| GO:BP | GO:1900425 | negative regulation of defense response to bacterium | 2 | 4 | 2.56e-01 |
| GO:BP | GO:0071559 | response to transforming growth factor beta | 19 | 227 | 2.56e-01 |
| GO:BP | GO:0014909 | smooth muscle cell migration | 11 | 65 | 2.56e-01 |
| GO:BP | GO:0051452 | intracellular pH reduction | 5 | 45 | 2.56e-01 |
| GO:BP | GO:0006914 | autophagy | 33 | 513 | 2.56e-01 |
| GO:BP | GO:0032753 | positive regulation of interleukin-4 production | 1 | 8 | 2.56e-01 |
| GO:BP | GO:0002541 | activation of plasma proteins involved in acute inflammatory response | 1 | 2 | 2.56e-01 |
| GO:BP | GO:0002192 | IRES-dependent translational initiation of linear mRNA | 1 | 1 | 2.56e-01 |
| GO:BP | GO:0042704 | uterine wall breakdown | 1 | 2 | 2.56e-01 |
| GO:BP | GO:0034219 | carbohydrate transmembrane transport | 12 | 92 | 2.56e-01 |
| GO:BP | GO:0060789 | hair follicle placode formation | 1 | 5 | 2.56e-01 |
| GO:BP | GO:0030330 | DNA damage response, signal transduction by p53 class mediator | 6 | 69 | 2.56e-01 |
| GO:BP | GO:0050678 | regulation of epithelial cell proliferation | 18 | 276 | 2.56e-01 |
| GO:BP | GO:0061196 | fungiform papilla development | 1 | 5 | 2.56e-01 |
| GO:BP | GO:1903146 | regulation of autophagy of mitochondrion | 5 | 37 | 2.56e-01 |
| GO:BP | GO:0097352 | autophagosome maturation | 8 | 55 | 2.56e-01 |
| GO:BP | GO:0030037 | actin filament reorganization involved in cell cycle | 1 | 1 | 2.56e-01 |
| GO:BP | GO:0018410 | C-terminal protein amino acid modification | 1 | 10 | 2.56e-01 |
| GO:BP | GO:0007018 | microtubule-based movement | 3 | 300 | 2.56e-01 |
| GO:BP | GO:0035283 | central nervous system segmentation | 2 | 2 | 2.56e-01 |
| GO:BP | GO:0120033 | negative regulation of plasma membrane bounded cell projection assembly | 7 | 28 | 2.56e-01 |
| GO:BP | GO:0006383 | transcription by RNA polymerase III | 7 | 54 | 2.56e-01 |
| GO:BP | GO:0001841 | neural tube formation | 10 | 101 | 2.56e-01 |
| GO:BP | GO:0046761 | viral budding from plasma membrane | 3 | 13 | 2.56e-01 |
| GO:BP | GO:0046456 | icosanoid biosynthetic process | 3 | 29 | 2.56e-01 |
| GO:BP | GO:0010907 | positive regulation of glucose metabolic process | 5 | 36 | 2.56e-01 |
| GO:BP | GO:0061919 | process utilizing autophagic mechanism | 33 | 513 | 2.56e-01 |
| GO:BP | GO:1904627 | response to phorbol 13-acetate 12-myristate | 2 | 4 | 2.56e-01 |
| GO:BP | GO:0006446 | regulation of translational initiation | 9 | 73 | 2.56e-01 |
| GO:BP | GO:0035364 | thymine transport | 1 | 1 | 2.56e-01 |
| GO:BP | GO:0070302 | regulation of stress-activated protein kinase signaling cascade | 13 | 157 | 2.56e-01 |
| GO:BP | GO:0110017 | cap-independent translational initiation of linear mRNA | 1 | 1 | 2.56e-01 |
| GO:BP | GO:0010867 | positive regulation of triglyceride biosynthetic process | 2 | 14 | 2.56e-01 |
| GO:BP | GO:1904628 | cellular response to phorbol 13-acetate 12-myristate | 2 | 4 | 2.56e-01 |
| GO:BP | GO:0045922 | negative regulation of fatty acid metabolic process | 4 | 25 | 2.56e-01 |
| GO:BP | GO:0086050 | membrane repolarization during bundle of His cell action potential | 1 | 1 | 2.58e-01 |
| GO:BP | GO:1901983 | regulation of protein acetylation | 9 | 69 | 2.58e-01 |
| GO:BP | GO:0086052 | membrane repolarization during SA node cell action potential | 1 | 1 | 2.58e-01 |
| GO:BP | GO:0032287 | peripheral nervous system myelin maintenance | 3 | 8 | 2.58e-01 |
| GO:BP | GO:0032148 | activation of protein kinase B activity | 1 | 23 | 2.58e-01 |
| GO:BP | GO:0032071 | regulation of endodeoxyribonuclease activity | 2 | 7 | 2.58e-01 |
| GO:BP | GO:0070849 | response to epidermal growth factor | 5 | 44 | 2.58e-01 |
| GO:BP | GO:2000736 | regulation of stem cell differentiation | 5 | 71 | 2.58e-01 |
| GO:BP | GO:1905207 | regulation of cardiocyte differentiation | 3 | 22 | 2.58e-01 |
| GO:BP | GO:2000377 | regulation of reactive oxygen species metabolic process | 13 | 108 | 2.58e-01 |
| GO:BP | GO:0050773 | regulation of dendrite development | 8 | 90 | 2.58e-01 |
| GO:BP | GO:0032436 | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 13 | 89 | 2.58e-01 |
| GO:BP | GO:0099633 | protein localization to postsynaptic specialization membrane | 1 | 19 | 2.58e-01 |
| GO:BP | GO:2000785 | regulation of autophagosome assembly | 4 | 44 | 2.58e-01 |
| GO:BP | GO:0003358 | noradrenergic neuron development | 1 | 2 | 2.58e-01 |
| GO:BP | GO:0019043 | establishment of viral latency | 2 | 3 | 2.58e-01 |
| GO:BP | GO:1904292 | regulation of ERAD pathway | 4 | 22 | 2.58e-01 |
| GO:BP | GO:1990442 | intrinsic apoptotic signaling pathway in response to nitrosative stress | 2 | 3 | 2.58e-01 |
| GO:BP | GO:0016575 | histone deacetylation | 10 | 87 | 2.58e-01 |
| GO:BP | GO:0051090 | regulation of DNA-binding transcription factor activity | 3 | 335 | 2.58e-01 |
| GO:BP | GO:0003281 | ventricular septum development | 8 | 69 | 2.58e-01 |
| GO:BP | GO:0045732 | positive regulation of protein catabolic process | 23 | 192 | 2.58e-01 |
| GO:BP | GO:0061469 | regulation of type B pancreatic cell proliferation | 3 | 14 | 2.58e-01 |
| GO:BP | GO:0051101 | regulation of DNA binding | 3 | 104 | 2.58e-01 |
| GO:BP | GO:0097113 | AMPA glutamate receptor clustering | 3 | 7 | 2.58e-01 |
| GO:BP | GO:0045725 | positive regulation of glycogen biosynthetic process | 3 | 12 | 2.58e-01 |
| GO:BP | GO:0120009 | intermembrane lipid transfer | 1 | 43 | 2.58e-01 |
| GO:BP | GO:0072033 | renal vesicle formation | 2 | 8 | 2.58e-01 |
| GO:BP | GO:0097688 | glutamate receptor clustering | 3 | 7 | 2.58e-01 |
| GO:BP | GO:0001830 | trophectodermal cell fate commitment | 1 | 1 | 2.58e-01 |
| GO:BP | GO:1903580 | positive regulation of ATP metabolic process | 1 | 11 | 2.58e-01 |
| GO:BP | GO:1902237 | positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway | 2 | 10 | 2.58e-01 |
| GO:BP | GO:0050849 | negative regulation of calcium-mediated signaling | 4 | 15 | 2.58e-01 |
| GO:BP | GO:0051593 | response to folic acid | 1 | 9 | 2.58e-01 |
| GO:BP | GO:0060191 | regulation of lipase activity | 4 | 52 | 2.58e-01 |
| GO:BP | GO:1902455 | negative regulation of stem cell population maintenance | 3 | 21 | 2.58e-01 |
| GO:BP | GO:0031269 | pseudopodium assembly | 3 | 14 | 2.58e-01 |
| GO:BP | GO:0099645 | neurotransmitter receptor localization to postsynaptic specialization membrane | 1 | 19 | 2.58e-01 |
| GO:BP | GO:0046753 | non-lytic viral release | 3 | 14 | 2.58e-01 |
| GO:BP | GO:0051567 | histone H3-K9 methylation | 2 | 18 | 2.58e-01 |
| GO:BP | GO:0006435 | threonyl-tRNA aminoacylation | 1 | 3 | 2.58e-01 |
| GO:BP | GO:1900078 | positive regulation of cellular response to insulin stimulus | 1 | 23 | 2.58e-01 |
| GO:BP | GO:2001171 | positive regulation of ATP biosynthetic process | 1 | 10 | 2.58e-01 |
| GO:BP | GO:0051100 | negative regulation of binding | 2 | 135 | 2.58e-01 |
| GO:BP | GO:0043114 | regulation of vascular permeability | 2 | 35 | 2.58e-01 |
| GO:BP | GO:0043372 | positive regulation of CD4-positive, alpha-beta T cell differentiation | 1 | 16 | 2.58e-01 |
| GO:BP | GO:1903708 | positive regulation of hemopoiesis | 2 | 118 | 2.58e-01 |
| GO:BP | GO:0043414 | macromolecule methylation | 8 | 272 | 2.58e-01 |
| GO:BP | GO:0006735 | NADH regeneration | 1 | 15 | 2.58e-01 |
| GO:BP | GO:0009086 | methionine biosynthetic process | 1 | 10 | 2.58e-01 |
| GO:BP | GO:1904999 | positive regulation of leukocyte adhesion to arterial endothelial cell | 1 | 1 | 2.58e-01 |
| GO:BP | GO:0060765 | regulation of androgen receptor signaling pathway | 3 | 24 | 2.58e-01 |
| GO:BP | GO:1990379 | lipid transport across blood-brain barrier | 1 | 6 | 2.58e-01 |
| GO:BP | GO:0042634 | regulation of hair cycle | 2 | 22 | 2.58e-01 |
| GO:BP | GO:0061621 | canonical glycolysis | 1 | 15 | 2.58e-01 |
| GO:BP | GO:0042595 | behavioral response to starvation | 1 | 1 | 2.58e-01 |
| GO:BP | GO:0045429 | positive regulation of nitric oxide biosynthetic process | 5 | 26 | 2.58e-01 |
| GO:BP | GO:1902107 | positive regulation of leukocyte differentiation | 2 | 118 | 2.58e-01 |
| GO:BP | GO:0003209 | cardiac atrium morphogenesis | 3 | 26 | 2.58e-01 |
| GO:BP | GO:0002828 | regulation of type 2 immune response | 1 | 15 | 2.58e-01 |
| GO:BP | GO:0060173 | limb development | 20 | 142 | 2.58e-01 |
| GO:BP | GO:1902459 | positive regulation of stem cell population maintenance | 4 | 44 | 2.58e-01 |
| GO:BP | GO:0003406 | retinal pigment epithelium development | 1 | 4 | 2.58e-01 |
| GO:BP | GO:0061718 | glucose catabolic process to pyruvate | 1 | 15 | 2.58e-01 |
| GO:BP | GO:0090071 | negative regulation of ribosome biogenesis | 2 | 4 | 2.58e-01 |
| GO:BP | GO:0046530 | photoreceptor cell differentiation | 2 | 40 | 2.58e-01 |
| GO:BP | GO:0010970 | transport along microtubule | 2 | 162 | 2.58e-01 |
| GO:BP | GO:0098884 | postsynaptic neurotransmitter receptor internalization | 4 | 17 | 2.58e-01 |
| GO:BP | GO:0090649 | response to oxygen-glucose deprivation | 2 | 7 | 2.58e-01 |
| GO:BP | GO:0014040 | positive regulation of Schwann cell differentiation | 1 | 2 | 2.58e-01 |
| GO:BP | GO:2000810 | regulation of bicellular tight junction assembly | 1 | 15 | 2.58e-01 |
| GO:BP | GO:0021658 | rhombomere 3 morphogenesis | 1 | 1 | 2.58e-01 |
| GO:BP | GO:0021593 | rhombomere morphogenesis | 1 | 1 | 2.58e-01 |
| GO:BP | GO:0032673 | regulation of interleukin-4 production | 1 | 14 | 2.58e-01 |
| GO:BP | GO:0048736 | appendage development | 20 | 142 | 2.58e-01 |
| GO:BP | GO:0032868 | response to insulin | 17 | 215 | 2.58e-01 |
| GO:BP | GO:0032633 | interleukin-4 production | 1 | 14 | 2.58e-01 |
| GO:BP | GO:0031393 | negative regulation of prostaglandin biosynthetic process | 1 | 2 | 2.58e-01 |
| GO:BP | GO:0072656 | maintenance of protein location in mitochondrion | 2 | 5 | 2.58e-01 |
| GO:BP | GO:0031268 | pseudopodium organization | 3 | 14 | 2.58e-01 |
| GO:BP | GO:0106230 | protein depropionylation | 1 | 2 | 2.58e-01 |
| GO:BP | GO:0014812 | muscle cell migration | 12 | 76 | 2.58e-01 |
| GO:BP | GO:0140239 | postsynaptic endocytosis | 4 | 17 | 2.58e-01 |
| GO:BP | GO:1901751 | leukotriene A4 metabolic process | 1 | 2 | 2.58e-01 |
| GO:BP | GO:2001224 | positive regulation of neuron migration | 3 | 19 | 2.58e-01 |
| GO:BP | GO:0050667 | homocysteine metabolic process | 1 | 11 | 2.58e-01 |
| GO:BP | GO:0014910 | regulation of smooth muscle cell migration | 10 | 58 | 2.58e-01 |
| GO:BP | GO:0014860 | neurotransmitter secretion involved in regulation of skeletal muscle contraction | 1 | 1 | 2.58e-01 |
| GO:BP | GO:0043587 | tongue morphogenesis | 3 | 7 | 2.59e-01 |
| GO:BP | GO:0071763 | nuclear membrane organization | 6 | 42 | 2.59e-01 |
| GO:BP | GO:0060612 | adipose tissue development | 4 | 41 | 2.59e-01 |
| GO:BP | GO:0061029 | eyelid development in camera-type eye | 3 | 12 | 2.59e-01 |
| GO:BP | GO:0072344 | rescue of stalled ribosome | 3 | 9 | 2.61e-01 |
| GO:BP | GO:0007341 | penetration of zona pellucida | 1 | 4 | 2.62e-01 |
| GO:BP | GO:0070875 | positive regulation of glycogen metabolic process | 3 | 13 | 2.62e-01 |
| GO:BP | GO:0033026 | negative regulation of mast cell apoptotic process | 1 | 1 | 2.63e-01 |
| GO:BP | GO:0006687 | glycosphingolipid metabolic process | 1 | 48 | 2.63e-01 |
| GO:BP | GO:1903008 | organelle disassembly | 12 | 137 | 2.63e-01 |
| GO:BP | GO:0043433 | negative regulation of DNA-binding transcription factor activity | 2 | 138 | 2.63e-01 |
| GO:BP | GO:0070528 | protein kinase C signaling | 1 | 24 | 2.63e-01 |
| GO:BP | GO:0006046 | N-acetylglucosamine catabolic process | 2 | 3 | 2.63e-01 |
| GO:BP | GO:0046627 | negative regulation of insulin receptor signaling pathway | 1 | 29 | 2.63e-01 |
| GO:BP | GO:0051045 | negative regulation of membrane protein ectodomain proteolysis | 3 | 7 | 2.63e-01 |
| GO:BP | GO:0001558 | regulation of cell growth | 19 | 357 | 2.63e-01 |
| GO:BP | GO:0006891 | intra-Golgi vesicle-mediated transport | 4 | 33 | 2.64e-01 |
| GO:BP | GO:1903313 | positive regulation of mRNA metabolic process | 10 | 121 | 2.64e-01 |
| GO:BP | GO:0061620 | glycolytic process through glucose-6-phosphate | 1 | 17 | 2.64e-01 |
| GO:BP | GO:0014015 | positive regulation of gliogenesis | 3 | 45 | 2.64e-01 |
| GO:BP | GO:0044601 | protein denucleotidylation | 1 | 1 | 2.64e-01 |
| GO:BP | GO:0001510 | RNA methylation | 3 | 87 | 2.64e-01 |
| GO:BP | GO:0010755 | regulation of plasminogen activation | 1 | 16 | 2.64e-01 |
| GO:BP | GO:0044602 | protein deadenylylation | 1 | 1 | 2.64e-01 |
| GO:BP | GO:0060677 | ureteric bud elongation | 2 | 7 | 2.64e-01 |
| GO:BP | GO:0060980 | cell migration involved in coronary vasculogenesis | 1 | 1 | 2.66e-01 |
| GO:BP | GO:1903781 | positive regulation of cardiac conduction | 1 | 1 | 2.66e-01 |
| GO:BP | GO:2000036 | regulation of stem cell population maintenance | 5 | 62 | 2.67e-01 |
| GO:BP | GO:0044087 | regulation of cellular component biogenesis | 4 | 809 | 2.67e-01 |
| GO:BP | GO:0061326 | renal tubule development | 7 | 77 | 2.67e-01 |
| GO:BP | GO:1900077 | negative regulation of cellular response to insulin stimulus | 1 | 31 | 2.68e-01 |
| GO:BP | GO:0046755 | viral budding | 4 | 26 | 2.68e-01 |
| GO:BP | GO:0018210 | peptidyl-threonine modification | 10 | 104 | 2.68e-01 |
| GO:BP | GO:0046579 | positive regulation of Ras protein signal transduction | 5 | 45 | 2.68e-01 |
| GO:BP | GO:0046457 | prostanoid biosynthetic process | 1 | 19 | 2.68e-01 |
| GO:BP | GO:0009065 | glutamine family amino acid catabolic process | 3 | 20 | 2.68e-01 |
| GO:BP | GO:0042439 | ethanolamine-containing compound metabolic process | 2 | 5 | 2.68e-01 |
| GO:BP | GO:0090141 | positive regulation of mitochondrial fission | 2 | 21 | 2.68e-01 |
| GO:BP | GO:0071228 | cellular response to tumor cell | 1 | 4 | 2.68e-01 |
| GO:BP | GO:0061615 | glycolytic process through fructose-6-phosphate | 1 | 17 | 2.68e-01 |
| GO:BP | GO:0002369 | T cell cytokine production | 1 | 18 | 2.68e-01 |
| GO:BP | GO:0061073 | ciliary body morphogenesis | 1 | 3 | 2.68e-01 |
| GO:BP | GO:0002724 | regulation of T cell cytokine production | 1 | 18 | 2.68e-01 |
| GO:BP | GO:0062009 | secondary palate development | 4 | 20 | 2.68e-01 |
| GO:BP | GO:0001516 | prostaglandin biosynthetic process | 1 | 19 | 2.68e-01 |
| GO:BP | GO:1902809 | regulation of skeletal muscle fiber differentiation | 2 | 4 | 2.68e-01 |
| GO:BP | GO:0046128 | purine ribonucleoside metabolic process | 1 | 16 | 2.68e-01 |
| GO:BP | GO:0006527 | arginine catabolic process | 2 | 7 | 2.68e-01 |
| GO:BP | GO:0045654 | positive regulation of megakaryocyte differentiation | 1 | 9 | 2.68e-01 |
| GO:BP | GO:0051103 | DNA ligation involved in DNA repair | 2 | 5 | 2.68e-01 |
| GO:BP | GO:0046500 | S-adenosylmethionine metabolic process | 1 | 13 | 2.68e-01 |
| GO:BP | GO:0048698 | negative regulation of collateral sprouting in absence of injury | 1 | 1 | 2.68e-01 |
| GO:BP | GO:0048714 | positive regulation of oligodendrocyte differentiation | 2 | 13 | 2.68e-01 |
| GO:BP | GO:1901796 | regulation of signal transduction by p53 class mediator | 7 | 101 | 2.69e-01 |
| GO:BP | GO:0003356 | regulation of cilium beat frequency | 2 | 10 | 2.70e-01 |
| GO:BP | GO:0018026 | peptidyl-lysine monomethylation | 2 | 11 | 2.70e-01 |
| GO:BP | GO:0045655 | regulation of monocyte differentiation | 1 | 13 | 2.70e-01 |
| GO:BP | GO:0051102 | DNA ligation involved in DNA recombination | 1 | 1 | 2.70e-01 |
| GO:BP | GO:0032733 | positive regulation of interleukin-10 production | 1 | 16 | 2.70e-01 |
| GO:BP | GO:0030810 | positive regulation of nucleotide biosynthetic process | 1 | 12 | 2.70e-01 |
| GO:BP | GO:1904407 | positive regulation of nitric oxide metabolic process | 5 | 27 | 2.70e-01 |
| GO:BP | GO:0003275 | apoptotic process involved in outflow tract morphogenesis | 1 | 3 | 2.70e-01 |
| GO:BP | GO:0045622 | regulation of T-helper cell differentiation | 1 | 20 | 2.70e-01 |
| GO:BP | GO:0006400 | tRNA modification | 3 | 90 | 2.70e-01 |
| GO:BP | GO:0090520 | sphingolipid mediated signaling pathway | 3 | 11 | 2.70e-01 |
| GO:BP | GO:0000097 | sulfur amino acid biosynthetic process | 1 | 14 | 2.70e-01 |
| GO:BP | GO:0019083 | viral transcription | 2 | 48 | 2.70e-01 |
| GO:BP | GO:0045726 | positive regulation of integrin biosynthetic process | 1 | 2 | 2.70e-01 |
| GO:BP | GO:0043923 | positive regulation by host of viral transcription | 4 | 18 | 2.70e-01 |
| GO:BP | GO:0120035 | regulation of plasma membrane bounded cell projection organization | 50 | 529 | 2.70e-01 |
| GO:BP | GO:0075713 | establishment of integrated proviral latency | 1 | 1 | 2.70e-01 |
| GO:BP | GO:0061014 | positive regulation of mRNA catabolic process | 8 | 93 | 2.70e-01 |
| GO:BP | GO:0006555 | methionine metabolic process | 1 | 13 | 2.70e-01 |
| GO:BP | GO:1904375 | regulation of protein localization to cell periphery | 17 | 113 | 2.70e-01 |
| GO:BP | GO:0033173 | calcineurin-NFAT signaling cascade | 6 | 37 | 2.70e-01 |
| GO:BP | GO:0006790 | sulfur compound metabolic process | 3 | 248 | 2.70e-01 |
| GO:BP | GO:0051795 | positive regulation of timing of catagen | 1 | 3 | 2.70e-01 |
| GO:BP | GO:0070482 | response to oxygen levels | 8 | 272 | 2.70e-01 |
| GO:BP | GO:1900373 | positive regulation of purine nucleotide biosynthetic process | 1 | 12 | 2.70e-01 |
| GO:BP | GO:0042092 | type 2 immune response | 1 | 19 | 2.70e-01 |
| GO:BP | GO:1902109 | negative regulation of mitochondrial membrane permeability involved in apoptotic process | 1 | 2 | 2.70e-01 |
| GO:BP | GO:0010693 | negative regulation of alkaline phosphatase activity | 1 | 2 | 2.70e-01 |
| GO:BP | GO:1902256 | regulation of apoptotic process involved in outflow tract morphogenesis | 1 | 3 | 2.70e-01 |
| GO:BP | GO:2000156 | regulation of retrograde vesicle-mediated transport, Golgi to ER | 1 | 2 | 2.70e-01 |
| GO:BP | GO:0009221 | pyrimidine deoxyribonucleotide biosynthetic process | 2 | 7 | 2.71e-01 |
| GO:BP | GO:0046073 | dTMP metabolic process | 2 | 7 | 2.71e-01 |
| GO:BP | GO:2001169 | regulation of ATP biosynthetic process | 1 | 17 | 2.71e-01 |
| GO:BP | GO:0071606 | chemokine (C-C motif) ligand 4 production | 1 | 1 | 2.71e-01 |
| GO:BP | GO:0032070 | regulation of deoxyribonuclease activity | 2 | 9 | 2.71e-01 |
| GO:BP | GO:0010641 | positive regulation of platelet-derived growth factor receptor signaling pathway | 1 | 4 | 2.71e-01 |
| GO:BP | GO:2000174 | regulation of pro-T cell differentiation | 1 | 1 | 2.71e-01 |
| GO:BP | GO:0010962 | regulation of glucan biosynthetic process | 4 | 25 | 2.71e-01 |
| GO:BP | GO:1990550 | mitochondrial alpha-ketoglutarate transmembrane transport | 1 | 1 | 2.71e-01 |
| GO:BP | GO:0140708 | CAT tailing | 1 | 1 | 2.71e-01 |
| GO:BP | GO:0042040 | metal incorporation into metallo-molybdopterin complex | 1 | 1 | 2.71e-01 |
| GO:BP | GO:0062025 | regulation of SCF-dependent proteasomal ubiquitin-dependent protein catabolic process | 1 | 1 | 2.71e-01 |
| GO:BP | GO:0018315 | molybdenum incorporation into molybdenum-molybdopterin complex | 1 | 1 | 2.71e-01 |
| GO:BP | GO:0005979 | regulation of glycogen biosynthetic process | 4 | 25 | 2.71e-01 |
| GO:BP | GO:0062026 | negative regulation of SCF-dependent proteasomal ubiquitin-dependent catabolic process | 1 | 1 | 2.71e-01 |
| GO:BP | GO:0071644 | negative regulation of chemokine (C-C motif) ligand 4 production | 1 | 1 | 2.71e-01 |
| GO:BP | GO:0071643 | regulation of chemokine (C-C motif) ligand 4 production | 1 | 1 | 2.71e-01 |
| GO:BP | GO:0036123 | histone H3-K9 dimethylation | 2 | 3 | 2.71e-01 |
| GO:BP | GO:0060674 | placenta blood vessel development | 4 | 26 | 2.71e-01 |
| GO:BP | GO:2000176 | positive regulation of pro-T cell differentiation | 1 | 1 | 2.71e-01 |
| GO:BP | GO:0060428 | lung epithelium development | 6 | 30 | 2.71e-01 |
| GO:BP | GO:0009896 | positive regulation of catabolic process | 30 | 464 | 2.71e-01 |
| GO:BP | GO:0072579 | glycine receptor clustering | 1 | 1 | 2.71e-01 |
| GO:BP | GO:0035092 | sperm DNA condensation | 2 | 7 | 2.71e-01 |
| GO:BP | GO:0010800 | positive regulation of peptidyl-threonine phosphorylation | 4 | 23 | 2.71e-01 |
| GO:BP | GO:0090166 | Golgi disassembly | 1 | 6 | 2.71e-01 |
| GO:BP | GO:0016239 | positive regulation of macroautophagy | 7 | 70 | 2.71e-01 |
| GO:BP | GO:2000516 | positive regulation of CD4-positive, alpha-beta T cell activation | 1 | 20 | 2.71e-01 |
| GO:BP | GO:0007265 | Ras protein signal transduction | 12 | 294 | 2.76e-01 |
| GO:BP | GO:0035970 | peptidyl-threonine dephosphorylation | 4 | 17 | 2.76e-01 |
| GO:BP | GO:2000045 | regulation of G1/S transition of mitotic cell cycle | 10 | 149 | 2.77e-01 |
| GO:BP | GO:0031331 | positive regulation of cellular catabolic process | 20 | 277 | 2.77e-01 |
| GO:BP | GO:0060411 | cardiac septum morphogenesis | 7 | 67 | 2.77e-01 |
| GO:BP | GO:0045786 | negative regulation of cell cycle | 20 | 338 | 2.77e-01 |
| GO:BP | GO:0047496 | vesicle transport along microtubule | 1 | 41 | 2.77e-01 |
| GO:BP | GO:0043393 | regulation of protein binding | 2 | 172 | 2.77e-01 |
| GO:BP | GO:0050732 | negative regulation of peptidyl-tyrosine phosphorylation | 1 | 46 | 2.77e-01 |
| GO:BP | GO:0010799 | regulation of peptidyl-threonine phosphorylation | 5 | 35 | 2.77e-01 |
| GO:BP | GO:0007224 | smoothened signaling pathway | 18 | 124 | 2.77e-01 |
| GO:BP | GO:0071939 | vitamin A import into cell | 1 | 1 | 2.77e-01 |
| GO:BP | GO:0007258 | JUN phosphorylation | 1 | 2 | 2.77e-01 |
| GO:BP | GO:0070670 | response to interleukin-4 | 4 | 22 | 2.77e-01 |
| GO:BP | GO:2000774 | positive regulation of cellular senescence | 2 | 9 | 2.77e-01 |
| GO:BP | GO:0033365 | protein localization to organelle | 5 | 859 | 2.77e-01 |
| GO:BP | GO:0006211 | 5-methylcytosine catabolic process | 1 | 3 | 2.77e-01 |
| GO:BP | GO:0006414 | translational elongation | 6 | 65 | 2.77e-01 |
| GO:BP | GO:0031639 | plasminogen activation | 1 | 19 | 2.77e-01 |
| GO:BP | GO:0099111 | microtubule-based transport | 2 | 191 | 2.77e-01 |
| GO:BP | GO:0099149 | regulation of postsynaptic neurotransmitter receptor internalization | 4 | 11 | 2.77e-01 |
| GO:BP | GO:0072001 | renal system development | 29 | 251 | 2.77e-01 |
| GO:BP | GO:0050673 | epithelial cell proliferation | 31 | 323 | 2.77e-01 |
| GO:BP | GO:0071938 | vitamin A transport | 1 | 1 | 2.77e-01 |
| GO:BP | GO:0045981 | positive regulation of nucleotide metabolic process | 1 | 16 | 2.77e-01 |
| GO:BP | GO:0032507 | maintenance of protein location in cell | 2 | 58 | 2.77e-01 |
| GO:BP | GO:0014038 | regulation of Schwann cell differentiation | 1 | 3 | 2.77e-01 |
| GO:BP | GO:0046638 | positive regulation of alpha-beta T cell differentiation | 1 | 27 | 2.77e-01 |
| GO:BP | GO:0001826 | inner cell mass cell differentiation | 2 | 5 | 2.77e-01 |
| GO:BP | GO:0021815 | modulation of microtubule cytoskeleton involved in cerebral cortex radial glia guided migration | 1 | 5 | 2.77e-01 |
| GO:BP | GO:0021766 | hippocampus development | 2 | 62 | 2.77e-01 |
| GO:BP | GO:0009451 | RNA modification | 4 | 162 | 2.77e-01 |
| GO:BP | GO:0010866 | regulation of triglyceride biosynthetic process | 2 | 19 | 2.77e-01 |
| GO:BP | GO:0010954 | positive regulation of protein processing | 1 | 18 | 2.77e-01 |
| GO:BP | GO:0072283 | metanephric renal vesicle morphogenesis | 3 | 11 | 2.77e-01 |
| GO:BP | GO:0072287 | metanephric distal tubule morphogenesis | 1 | 1 | 2.77e-01 |
| GO:BP | GO:0030705 | cytoskeleton-dependent intracellular transport | 2 | 194 | 2.77e-01 |
| GO:BP | GO:0097114 | NMDA glutamate receptor clustering | 2 | 5 | 2.77e-01 |
| GO:BP | GO:0050775 | positive regulation of dendrite morphogenesis | 4 | 36 | 2.77e-01 |
| GO:BP | GO:0010518 | positive regulation of phospholipase activity | 1 | 27 | 2.77e-01 |
| GO:BP | GO:0043630 | ncRNA polyadenylation involved in polyadenylation-dependent ncRNA catabolic process | 1 | 1 | 2.77e-01 |
| GO:BP | GO:0000288 | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 6 | 64 | 2.77e-01 |
| GO:BP | GO:0000289 | nuclear-transcribed mRNA poly(A) tail shortening | 4 | 33 | 2.77e-01 |
| GO:BP | GO:0010923 | negative regulation of phosphatase activity | 2 | 30 | 2.77e-01 |
| GO:BP | GO:1990134 | epithelial cell apoptotic process involved in palatal shelf morphogenesis | 1 | 1 | 2.77e-01 |
| GO:BP | GO:0006386 | termination of RNA polymerase III transcription | 1 | 1 | 2.77e-01 |
| GO:BP | GO:0006388 | tRNA splicing, via endonucleolytic cleavage and ligation | 3 | 13 | 2.77e-01 |
| GO:BP | GO:0035914 | skeletal muscle cell differentiation | 8 | 52 | 2.77e-01 |
| GO:BP | GO:0035910 | ascending aorta morphogenesis | 1 | 4 | 2.77e-01 |
| GO:BP | GO:2000656 | regulation of apolipoprotein binding | 1 | 1 | 2.77e-01 |
| GO:BP | GO:0072273 | metanephric nephron morphogenesis | 4 | 19 | 2.77e-01 |
| GO:BP | GO:2000657 | negative regulation of apolipoprotein binding | 1 | 1 | 2.77e-01 |
| GO:BP | GO:0043928 | exonucleolytic catabolism of deadenylated mRNA | 3 | 13 | 2.77e-01 |
| GO:BP | GO:0010498 | proteasomal protein catabolic process | 50 | 486 | 2.77e-01 |
| GO:BP | GO:1990705 | cholangiocyte proliferation | 1 | 3 | 2.77e-01 |
| GO:BP | GO:0097720 | calcineurin-mediated signaling | 6 | 38 | 2.77e-01 |
| GO:BP | GO:0033002 | muscle cell proliferation | 10 | 157 | 2.77e-01 |
| GO:BP | GO:0097499 | protein localization to non-motile cilium | 3 | 10 | 2.77e-01 |
| GO:BP | GO:0043370 | regulation of CD4-positive, alpha-beta T cell differentiation | 1 | 27 | 2.77e-01 |
| GO:BP | GO:0002553 | histamine secretion by mast cell | 3 | 8 | 2.77e-01 |
| GO:BP | GO:0043556 | regulation of translation in response to oxidative stress | 1 | 1 | 2.77e-01 |
| GO:BP | GO:0030326 | embryonic limb morphogenesis | 6 | 89 | 2.77e-01 |
| GO:BP | GO:0032486 | Rap protein signal transduction | 2 | 13 | 2.77e-01 |
| GO:BP | GO:0032870 | cellular response to hormone stimulus | 32 | 457 | 2.77e-01 |
| GO:BP | GO:0030488 | tRNA methylation | 2 | 42 | 2.77e-01 |
| GO:BP | GO:0007093 | mitotic cell cycle checkpoint signaling | 9 | 139 | 2.77e-01 |
| GO:BP | GO:0046626 | regulation of insulin receptor signaling pathway | 4 | 53 | 2.77e-01 |
| GO:BP | GO:1990416 | cellular response to brain-derived neurotrophic factor stimulus | 2 | 8 | 2.77e-01 |
| GO:BP | GO:0032922 | circadian regulation of gene expression | 6 | 63 | 2.77e-01 |
| GO:BP | GO:0032938 | negative regulation of translation in response to oxidative stress | 1 | 1 | 2.77e-01 |
| GO:BP | GO:0021569 | rhombomere 3 development | 1 | 2 | 2.77e-01 |
| GO:BP | GO:0002940 | tRNA N2-guanine methylation | 1 | 4 | 2.77e-01 |
| GO:BP | GO:0061952 | midbody abscission | 3 | 17 | 2.77e-01 |
| GO:BP | GO:0071394 | cellular response to testosterone stimulus | 2 | 11 | 2.77e-01 |
| GO:BP | GO:0071454 | cellular response to anoxia | 1 | 1 | 2.77e-01 |
| GO:BP | GO:0051794 | regulation of timing of catagen | 1 | 4 | 2.77e-01 |
| GO:BP | GO:1903048 | regulation of acetylcholine-gated cation channel activity | 1 | 1 | 2.77e-01 |
| GO:BP | GO:1903049 | negative regulation of acetylcholine-gated cation channel activity | 1 | 1 | 2.77e-01 |
| GO:BP | GO:0051560 | mitochondrial calcium ion homeostasis | 2 | 23 | 2.77e-01 |
| GO:BP | GO:0018027 | peptidyl-lysine dimethylation | 2 | 22 | 2.77e-01 |
| GO:BP | GO:0009067 | aspartate family amino acid biosynthetic process | 1 | 18 | 2.77e-01 |
| GO:BP | GO:0015770 | sucrose transport | 1 | 4 | 2.77e-01 |
| GO:BP | GO:0006479 | protein methylation | 2 | 160 | 2.77e-01 |
| GO:BP | GO:0006692 | prostanoid metabolic process | 3 | 32 | 2.77e-01 |
| GO:BP | GO:0050679 | positive regulation of epithelial cell proliferation | 7 | 155 | 2.77e-01 |
| GO:BP | GO:0008631 | intrinsic apoptotic signaling pathway in response to oxidative stress | 4 | 41 | 2.77e-01 |
| GO:BP | GO:0002349 | histamine production involved in inflammatory response | 3 | 8 | 2.77e-01 |
| GO:BP | GO:0015772 | oligosaccharide transport | 1 | 4 | 2.77e-01 |
| GO:BP | GO:1904714 | regulation of chaperone-mediated autophagy | 1 | 8 | 2.77e-01 |
| GO:BP | GO:0032611 | interleukin-1 beta production | 1 | 48 | 2.77e-01 |
| GO:BP | GO:0035113 | embryonic appendage morphogenesis | 6 | 89 | 2.77e-01 |
| GO:BP | GO:0015854 | guanine transport | 1 | 2 | 2.77e-01 |
| GO:BP | GO:0090069 | regulation of ribosome biogenesis | 2 | 5 | 2.77e-01 |
| GO:BP | GO:0035344 | hypoxanthine transport | 1 | 2 | 2.77e-01 |
| GO:BP | GO:0045900 | negative regulation of translational elongation | 2 | 5 | 2.77e-01 |
| GO:BP | GO:0009301 | snRNA transcription | 3 | 18 | 2.77e-01 |
| GO:BP | GO:0009265 | 2’-deoxyribonucleotide biosynthetic process | 3 | 14 | 2.77e-01 |
| GO:BP | GO:0009263 | deoxyribonucleotide biosynthetic process | 3 | 14 | 2.77e-01 |
| GO:BP | GO:0018107 | peptidyl-threonine phosphorylation | 9 | 97 | 2.77e-01 |
| GO:BP | GO:0060382 | regulation of DNA strand elongation | 4 | 16 | 2.77e-01 |
| GO:BP | GO:0061647 | histone H3-K9 modification | 2 | 23 | 2.77e-01 |
| GO:BP | GO:1900034 | regulation of cellular response to heat | 4 | 16 | 2.77e-01 |
| GO:BP | GO:2001242 | regulation of intrinsic apoptotic signaling pathway | 7 | 147 | 2.77e-01 |
| GO:BP | GO:0015811 | L-cystine transport | 2 | 3 | 2.77e-01 |
| GO:BP | GO:0003230 | cardiac atrium development | 2 | 34 | 2.77e-01 |
| GO:BP | GO:0150172 | regulation of phosphatidylcholine metabolic process | 1 | 10 | 2.77e-01 |
| GO:BP | GO:0042637 | catagen | 1 | 4 | 2.77e-01 |
| GO:BP | GO:0009250 | glucan biosynthetic process | 5 | 39 | 2.77e-01 |
| GO:BP | GO:0006580 | ethanolamine metabolic process | 1 | 1 | 2.77e-01 |
| GO:BP | GO:0140238 | presynaptic endocytosis | 11 | 65 | 2.77e-01 |
| GO:BP | GO:0060606 | tube closure | 3 | 91 | 2.77e-01 |
| GO:BP | GO:0008045 | motor neuron axon guidance | 2 | 25 | 2.77e-01 |
| GO:BP | GO:0071050 | sno(s)RNA polyadenylation | 1 | 1 | 2.77e-01 |
| GO:BP | GO:1904798 | positive regulation of core promoter binding | 1 | 4 | 2.77e-01 |
| GO:BP | GO:1900544 | positive regulation of purine nucleotide metabolic process | 1 | 16 | 2.77e-01 |
| GO:BP | GO:0019857 | 5-methylcytosine metabolic process | 1 | 3 | 2.77e-01 |
| GO:BP | GO:0060044 | negative regulation of cardiac muscle cell proliferation | 2 | 9 | 2.77e-01 |
| GO:BP | GO:0062237 | protein localization to postsynapse | 1 | 39 | 2.77e-01 |
| GO:BP | GO:0080170 | hydrogen peroxide transmembrane transport | 1 | 1 | 2.77e-01 |
| GO:BP | GO:0060709 | glycogen cell differentiation involved in embryonic placenta development | 1 | 1 | 2.77e-01 |
| GO:BP | GO:1903539 | protein localization to postsynaptic membrane | 1 | 38 | 2.77e-01 |
| GO:BP | GO:0002441 | histamine secretion involved in inflammatory response | 3 | 8 | 2.77e-01 |
| GO:BP | GO:1905898 | positive regulation of response to endoplasmic reticulum stress | 5 | 34 | 2.77e-01 |
| GO:BP | GO:0001843 | neural tube closure | 3 | 90 | 2.77e-01 |
| GO:BP | GO:0035720 | intraciliary anterograde transport | 4 | 17 | 2.77e-01 |
| GO:BP | GO:0070914 | UV-damage excision repair | 3 | 13 | 2.77e-01 |
| GO:BP | GO:1903578 | regulation of ATP metabolic process | 1 | 22 | 2.77e-01 |
| GO:BP | GO:0001881 | receptor recycling | 1 | 38 | 2.77e-01 |
| GO:BP | GO:0002711 | positive regulation of T cell mediated immunity | 1 | 29 | 2.77e-01 |
| GO:BP | GO:1903435 | positive regulation of constitutive secretory pathway | 1 | 1 | 2.77e-01 |
| GO:BP | GO:2000111 | positive regulation of macrophage apoptotic process | 1 | 2 | 2.77e-01 |
| GO:BP | GO:0006693 | prostaglandin metabolic process | 3 | 32 | 2.77e-01 |
| GO:BP | GO:0045197 | establishment or maintenance of epithelial cell apical/basal polarity | 1 | 47 | 2.77e-01 |
| GO:BP | GO:0006469 | negative regulation of protein kinase activity | 14 | 179 | 2.77e-01 |
| GO:BP | GO:1903319 | positive regulation of protein maturation | 1 | 19 | 2.77e-01 |
| GO:BP | GO:0046385 | deoxyribose phosphate biosynthetic process | 3 | 14 | 2.77e-01 |
| GO:BP | GO:0001954 | positive regulation of cell-matrix adhesion | 1 | 44 | 2.77e-01 |
| GO:BP | GO:0015766 | disaccharide transport | 1 | 4 | 2.77e-01 |
| GO:BP | GO:0001942 | hair follicle development | 3 | 67 | 2.77e-01 |
| GO:BP | GO:0005978 | glycogen biosynthetic process | 5 | 39 | 2.77e-01 |
| GO:BP | GO:0032202 | telomere assembly | 2 | 4 | 2.77e-01 |
| GO:BP | GO:0061143 | alveolar primary septum development | 1 | 1 | 2.77e-01 |
| GO:BP | GO:1903409 | reactive oxygen species biosynthetic process | 5 | 36 | 2.77e-01 |
| GO:BP | GO:0042278 | purine nucleoside metabolic process | 1 | 20 | 2.77e-01 |
| GO:BP | GO:0006007 | glucose catabolic process | 1 | 22 | 2.77e-01 |
| GO:BP | GO:0008213 | protein alkylation | 2 | 160 | 2.77e-01 |
| GO:BP | GO:0032651 | regulation of interleukin-1 beta production | 1 | 48 | 2.77e-01 |
| GO:BP | GO:0003149 | membranous septum morphogenesis | 2 | 8 | 2.77e-01 |
| GO:BP | GO:0006997 | nucleus organization | 10 | 126 | 2.77e-01 |
| GO:BP | GO:0000012 | single strand break repair | 2 | 10 | 2.78e-01 |
| GO:BP | GO:0036213 | contractile ring contraction | 1 | 1 | 2.78e-01 |
| GO:BP | GO:0000916 | actomyosin contractile ring contraction | 1 | 1 | 2.78e-01 |
| GO:BP | GO:0072104 | glomerular capillary formation | 1 | 5 | 2.78e-01 |
| GO:BP | GO:0072103 | glomerulus vasculature morphogenesis | 1 | 5 | 2.78e-01 |
| GO:BP | GO:0031344 | regulation of cell projection organization | 50 | 541 | 2.78e-01 |
| GO:BP | GO:1904796 | regulation of core promoter binding | 1 | 5 | 2.78e-01 |
| GO:BP | GO:0000302 | response to reactive oxygen species | 15 | 160 | 2.78e-01 |
| GO:BP | GO:1903818 | positive regulation of voltage-gated potassium channel activity | 1 | 11 | 2.78e-01 |
| GO:BP | GO:0019042 | viral latency | 2 | 4 | 2.79e-01 |
| GO:BP | GO:0051603 | proteolysis involved in protein catabolic process | 42 | 706 | 2.79e-01 |
| GO:BP | GO:0060788 | ectodermal placode formation | 1 | 10 | 2.79e-01 |
| GO:BP | GO:0071697 | ectodermal placode morphogenesis | 1 | 10 | 2.79e-01 |
| GO:BP | GO:0010720 | positive regulation of cell development | 4 | 317 | 2.80e-01 |
| GO:BP | GO:0035088 | establishment or maintenance of apical/basal cell polarity | 1 | 50 | 2.81e-01 |
| GO:BP | GO:0061245 | establishment or maintenance of bipolar cell polarity | 1 | 50 | 2.81e-01 |
| GO:BP | GO:0036258 | multivesicular body assembly | 4 | 32 | 2.81e-01 |
| GO:BP | GO:0002351 | serotonin production involved in inflammatory response | 1 | 2 | 2.82e-01 |
| GO:BP | GO:0048146 | positive regulation of fibroblast proliferation | 5 | 45 | 2.82e-01 |
| GO:BP | GO:0036245 | cellular response to menadione | 1 | 2 | 2.82e-01 |
| GO:BP | GO:0051057 | positive regulation of small GTPase mediated signal transduction | 5 | 51 | 2.82e-01 |
| GO:BP | GO:0002442 | serotonin secretion involved in inflammatory response | 1 | 2 | 2.82e-01 |
| GO:BP | GO:0043247 | telomere maintenance in response to DNA damage | 5 | 29 | 2.82e-01 |
| GO:BP | GO:0006642 | triglyceride mobilization | 1 | 3 | 2.82e-01 |
| GO:BP | GO:0072714 | response to selenite ion | 1 | 1 | 2.82e-01 |
| GO:BP | GO:1905364 | regulation of endosomal vesicle fusion | 1 | 1 | 2.82e-01 |
| GO:BP | GO:1905007 | positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation | 1 | 5 | 2.82e-01 |
| GO:BP | GO:0072595 | maintenance of protein localization in organelle | 4 | 39 | 2.82e-01 |
| GO:BP | GO:1904738 | vascular associated smooth muscle cell migration | 4 | 25 | 2.82e-01 |
| GO:BP | GO:0006664 | glycolipid metabolic process | 1 | 88 | 2.82e-01 |
| GO:BP | GO:0044272 | sulfur compound biosynthetic process | 2 | 122 | 2.82e-01 |
| GO:BP | GO:1904895 | ESCRT complex assembly | 1 | 1 | 2.82e-01 |
| GO:BP | GO:1904997 | regulation of leukocyte adhesion to arterial endothelial cell | 1 | 3 | 2.82e-01 |
| GO:BP | GO:0010770 | positive regulation of cell morphogenesis involved in differentiation | 4 | 37 | 2.82e-01 |
| GO:BP | GO:0031646 | positive regulation of nervous system process | 3 | 21 | 2.82e-01 |
| GO:BP | GO:0086069 | bundle of His cell to Purkinje myocyte communication | 2 | 14 | 2.82e-01 |
| GO:BP | GO:0032203 | telomere formation via telomerase | 1 | 1 | 2.82e-01 |
| GO:BP | GO:0010769 | regulation of cell morphogenesis involved in differentiation | 4 | 37 | 2.82e-01 |
| GO:BP | GO:1904902 | ESCRT III complex assembly | 1 | 1 | 2.82e-01 |
| GO:BP | GO:0006760 | folic acid-containing compound metabolic process | 1 | 22 | 2.82e-01 |
| GO:BP | GO:0072715 | cellular response to selenite ion | 1 | 1 | 2.82e-01 |
| GO:BP | GO:1900112 | regulation of histone H3-K9 trimethylation | 2 | 5 | 2.82e-01 |
| GO:BP | GO:0032612 | interleukin-1 production | 1 | 56 | 2.82e-01 |
| GO:BP | GO:0071985 | multivesicular body sorting pathway | 5 | 48 | 2.82e-01 |
| GO:BP | GO:1903595 | positive regulation of histamine secretion by mast cell | 2 | 4 | 2.82e-01 |
| GO:BP | GO:1903593 | regulation of histamine secretion by mast cell | 2 | 4 | 2.82e-01 |
| GO:BP | GO:0014852 | regulation of skeletal muscle contraction by neural stimulation via neuromuscular junction | 1 | 2 | 2.82e-01 |
| GO:BP | GO:1900449 | regulation of glutamate receptor signaling pathway | 2 | 5 | 2.82e-01 |
| GO:BP | GO:1903509 | liposaccharide metabolic process | 1 | 88 | 2.82e-01 |
| GO:BP | GO:0019752 | carboxylic acid metabolic process | 4 | 681 | 2.82e-01 |
| GO:BP | GO:0034058 | endosomal vesicle fusion | 3 | 10 | 2.82e-01 |
| GO:BP | GO:0120032 | regulation of plasma membrane bounded cell projection assembly | 22 | 165 | 2.82e-01 |
| GO:BP | GO:0071696 | ectodermal placode development | 1 | 11 | 2.82e-01 |
| GO:BP | GO:1903744 | positive regulation of anterograde synaptic vesicle transport | 1 | 2 | 2.82e-01 |
| GO:BP | GO:0034337 | RNA folding | 1 | 1 | 2.82e-01 |
| GO:BP | GO:0034453 | microtubule anchoring | 1 | 25 | 2.82e-01 |
| GO:BP | GO:0034660 | ncRNA metabolic process | 56 | 561 | 2.82e-01 |
| GO:BP | GO:0008645 | hexose transmembrane transport | 10 | 84 | 2.82e-01 |
| GO:BP | GO:0032259 | methylation | 9 | 313 | 2.82e-01 |
| GO:BP | GO:0009119 | ribonucleoside metabolic process | 1 | 23 | 2.82e-01 |
| GO:BP | GO:0071472 | cellular response to salt stress | 2 | 11 | 2.82e-01 |
| GO:BP | GO:1900247 | regulation of cytoplasmic translational elongation | 3 | 10 | 2.82e-01 |
| GO:BP | GO:1902805 | positive regulation of synaptic vesicle transport | 1 | 2 | 2.82e-01 |
| GO:BP | GO:0015914 | phospholipid transport | 1 | 75 | 2.82e-01 |
| GO:BP | GO:1900138 | negative regulation of phospholipase A2 activity | 1 | 4 | 2.82e-01 |
| GO:BP | GO:0034379 | very-low-density lipoprotein particle assembly | 1 | 8 | 2.82e-01 |
| GO:BP | GO:0022404 | molting cycle process | 3 | 69 | 2.82e-01 |
| GO:BP | GO:0014020 | primary neural tube formation | 3 | 94 | 2.82e-01 |
| GO:BP | GO:0022405 | hair cycle process | 3 | 69 | 2.82e-01 |
| GO:BP | GO:0060561 | apoptotic process involved in morphogenesis | 3 | 21 | 2.82e-01 |
| GO:BP | GO:0032613 | interleukin-10 production | 1 | 24 | 2.82e-01 |
| GO:BP | GO:0032652 | regulation of interleukin-1 production | 1 | 56 | 2.82e-01 |
| GO:BP | GO:0010824 | regulation of centrosome duplication | 3 | 44 | 2.82e-01 |
| GO:BP | GO:1904574 | negative regulation of selenocysteine insertion sequence binding | 1 | 1 | 2.82e-01 |
| GO:BP | GO:1904573 | regulation of selenocysteine insertion sequence binding | 1 | 1 | 2.82e-01 |
| GO:BP | GO:0032653 | regulation of interleukin-10 production | 1 | 24 | 2.82e-01 |
| GO:BP | GO:0043968 | histone H2A acetylation | 2 | 22 | 2.82e-01 |
| GO:BP | GO:1904572 | negative regulation of mRNA binding | 1 | 1 | 2.82e-01 |
| GO:BP | GO:1904570 | negative regulation of selenocysteine incorporation | 1 | 1 | 2.82e-01 |
| GO:BP | GO:1904569 | regulation of selenocysteine incorporation | 1 | 1 | 2.82e-01 |
| GO:BP | GO:0043922 | negative regulation by host of viral transcription | 1 | 11 | 2.82e-01 |
| GO:BP | GO:0006636 | unsaturated fatty acid biosynthetic process | 1 | 34 | 2.82e-01 |
| GO:BP | GO:1901605 | alpha-amino acid metabolic process | 2 | 151 | 2.82e-01 |
| GO:BP | GO:0043651 | linoleic acid metabolic process | 2 | 12 | 2.82e-01 |
| GO:BP | GO:1904482 | cellular response to tetrahydrofolate | 1 | 1 | 2.82e-01 |
| GO:BP | GO:0030865 | cortical cytoskeleton organization | 9 | 55 | 2.82e-01 |
| GO:BP | GO:1904481 | response to tetrahydrofolate | 1 | 1 | 2.82e-01 |
| GO:BP | GO:0035905 | ascending aorta development | 1 | 5 | 2.82e-01 |
| GO:BP | GO:0032808 | lacrimal gland development | 1 | 5 | 2.82e-01 |
| GO:BP | GO:0010517 | regulation of phospholipase activity | 1 | 37 | 2.82e-01 |
| GO:BP | GO:1904294 | positive regulation of ERAD pathway | 3 | 16 | 2.82e-01 |
| GO:BP | GO:0007254 | JNK cascade | 6 | 138 | 2.82e-01 |
| GO:BP | GO:1901653 | cellular response to peptide | 22 | 287 | 2.82e-01 |
| GO:BP | GO:0014003 | oligodendrocyte development | 5 | 27 | 2.82e-01 |
| GO:BP | GO:1903076 | regulation of protein localization to plasma membrane | 12 | 90 | 2.82e-01 |
| GO:BP | GO:0001955 | blood vessel maturation | 2 | 6 | 2.82e-01 |
| GO:BP | GO:0002763 | positive regulation of myeloid leukocyte differentiation | 2 | 34 | 2.82e-01 |
| GO:BP | GO:2000481 | positive regulation of cAMP-dependent protein kinase activity | 2 | 5 | 2.82e-01 |
| GO:BP | GO:0001822 | kidney development | 28 | 244 | 2.82e-01 |
| GO:BP | GO:2000016 | negative regulation of determination of dorsal identity | 1 | 1 | 2.82e-01 |
| GO:BP | GO:0000394 | RNA splicing, via endonucleolytic cleavage and ligation | 3 | 14 | 2.82e-01 |
| GO:BP | GO:0048818 | positive regulation of hair follicle maturation | 1 | 5 | 2.82e-01 |
| GO:BP | GO:0002011 | morphogenesis of an epithelial sheet | 2 | 52 | 2.82e-01 |
| GO:BP | GO:0000455 | enzyme-directed rRNA pseudouridine synthesis | 2 | 6 | 2.82e-01 |
| GO:BP | GO:0003266 | regulation of secondary heart field cardioblast proliferation | 2 | 8 | 2.82e-01 |
| GO:BP | GO:0003271 | smoothened signaling pathway involved in regulation of secondary heart field cardioblast proliferation | 1 | 1 | 2.82e-01 |
| GO:BP | GO:0003274 | endocardial cushion fusion | 1 | 5 | 2.82e-01 |
| GO:BP | GO:2000679 | positive regulation of transcription regulatory region DNA binding | 2 | 18 | 2.82e-01 |
| GO:BP | GO:0003284 | septum primum development | 1 | 5 | 2.82e-01 |
| GO:BP | GO:0000720 | pyrimidine dimer repair by nucleotide-excision repair | 1 | 4 | 2.82e-01 |
| GO:BP | GO:0003289 | atrial septum primum morphogenesis | 1 | 5 | 2.82e-01 |
| GO:BP | GO:2001301 | lipoxin biosynthetic process | 1 | 2 | 2.82e-01 |
| GO:BP | GO:0045113 | regulation of integrin biosynthetic process | 1 | 2 | 2.82e-01 |
| GO:BP | GO:0046898 | response to cycloheximide | 2 | 4 | 2.82e-01 |
| GO:BP | GO:0060193 | positive regulation of lipase activity | 1 | 34 | 2.82e-01 |
| GO:BP | GO:0003338 | metanephros morphogenesis | 5 | 22 | 2.82e-01 |
| GO:BP | GO:2000821 | regulation of grooming behavior | 2 | 3 | 2.82e-01 |
| GO:BP | GO:0051573 | negative regulation of histone H3-K9 methylation | 2 | 5 | 2.82e-01 |
| GO:BP | GO:0003357 | noradrenergic neuron differentiation | 1 | 7 | 2.82e-01 |
| GO:BP | GO:0006417 | regulation of translation | 22 | 370 | 2.82e-01 |
| GO:BP | GO:0006392 | transcription elongation by mitochondrial RNA polymerase | 1 | 1 | 2.82e-01 |
| GO:BP | GO:0045911 | positive regulation of DNA recombination | 4 | 57 | 2.82e-01 |
| GO:BP | GO:0001838 | embryonic epithelial tube formation | 12 | 116 | 2.82e-01 |
| GO:BP | GO:0046521 | sphingoid catabolic process | 1 | 1 | 2.82e-01 |
| GO:BP | GO:0006621 | protein retention in ER lumen | 1 | 8 | 2.82e-01 |
| GO:BP | GO:0001936 | regulation of endothelial cell proliferation | 8 | 102 | 2.82e-01 |
| GO:BP | GO:0000052 | citrulline metabolic process | 1 | 7 | 2.82e-01 |
| GO:BP | GO:0097190 | apoptotic signaling pathway | 18 | 494 | 2.83e-01 |
| GO:BP | GO:0099628 | neurotransmitter receptor diffusion trapping | 2 | 4 | 2.83e-01 |
| GO:BP | GO:0006121 | mitochondrial electron transport, succinate to ubiquinone | 1 | 5 | 2.83e-01 |
| GO:BP | GO:0090310 | negative regulation of DNA methylation-dependent heterochromatin formation | 1 | 2 | 2.83e-01 |
| GO:BP | GO:2000249 | regulation of actin cytoskeleton reorganization | 3 | 32 | 2.83e-01 |
| GO:BP | GO:0098970 | postsynaptic neurotransmitter receptor diffusion trapping | 2 | 4 | 2.83e-01 |
| GO:BP | GO:0006591 | ornithine metabolic process | 3 | 6 | 2.83e-01 |
| GO:BP | GO:0000050 | urea cycle | 3 | 7 | 2.83e-01 |
| GO:BP | GO:0090208 | positive regulation of triglyceride metabolic process | 2 | 18 | 2.83e-01 |
| GO:BP | GO:0051348 | negative regulation of transferase activity | 18 | 234 | 2.83e-01 |
| GO:BP | GO:1900076 | regulation of cellular response to insulin stimulus | 1 | 56 | 2.83e-01 |
| GO:BP | GO:0098953 | receptor diffusion trapping | 2 | 4 | 2.83e-01 |
| GO:BP | GO:0000973 | post-transcriptional tethering of RNA polymerase II gene DNA at nuclear periphery | 1 | 2 | 2.83e-01 |
| GO:BP | GO:0010464 | regulation of mesenchymal cell proliferation | 1 | 25 | 2.83e-01 |
| GO:BP | GO:1902866 | regulation of retina development in camera-type eye | 1 | 1 | 2.83e-01 |
| GO:BP | GO:0042093 | T-helper cell differentiation | 1 | 40 | 2.84e-01 |
| GO:BP | GO:0097711 | ciliary basal body-plasma membrane docking | 1 | 2 | 2.84e-01 |
| GO:BP | GO:0097120 | receptor localization to synapse | 1 | 55 | 2.84e-01 |
| GO:BP | GO:1903706 | regulation of hemopoiesis | 3 | 279 | 2.84e-01 |
| GO:BP | GO:0045494 | photoreceptor cell maintenance | 1 | 27 | 2.84e-01 |
| GO:BP | GO:0003205 | cardiac chamber development | 13 | 149 | 2.85e-01 |
| GO:BP | GO:0046635 | positive regulation of alpha-beta T cell activation | 1 | 36 | 2.85e-01 |
| GO:BP | GO:0099518 | vesicle cytoskeletal trafficking | 1 | 60 | 2.85e-01 |
| GO:BP | GO:1901000 | regulation of response to salt stress | 1 | 4 | 2.85e-01 |
| GO:BP | GO:1900069 | regulation of cellular hyperosmotic salinity response | 1 | 4 | 2.85e-01 |
| GO:BP | GO:0031507 | heterochromatin formation | 3 | 69 | 2.85e-01 |
| GO:BP | GO:0033037 | polysaccharide localization | 1 | 1 | 2.86e-01 |
| GO:BP | GO:0060491 | regulation of cell projection assembly | 22 | 167 | 2.86e-01 |
| GO:BP | GO:0018175 | protein nucleotidylation | 1 | 2 | 2.86e-01 |
| GO:BP | GO:0001947 | heart looping | 8 | 50 | 2.86e-01 |
| GO:BP | GO:0018117 | protein adenylylation | 1 | 2 | 2.86e-01 |
| GO:BP | GO:0061043 | regulation of vascular wound healing | 3 | 9 | 2.86e-01 |
| GO:BP | GO:0002294 | CD4-positive, alpha-beta T cell differentiation involved in immune response | 1 | 40 | 2.86e-01 |
| GO:BP | GO:0071479 | cellular response to ionizing radiation | 5 | 68 | 2.86e-01 |
| GO:BP | GO:0071245 | cellular response to carbon monoxide | 1 | 1 | 2.86e-01 |
| GO:BP | GO:1903078 | positive regulation of protein localization to plasma membrane | 8 | 50 | 2.86e-01 |
| GO:BP | GO:0015749 | monosaccharide transmembrane transport | 10 | 85 | 2.86e-01 |
| GO:BP | GO:0033630 | positive regulation of cell adhesion mediated by integrin | 3 | 14 | 2.86e-01 |
| GO:BP | GO:0071560 | cellular response to transforming growth factor beta stimulus | 17 | 222 | 2.86e-01 |
| GO:BP | GO:0043436 | oxoacid metabolic process | 4 | 696 | 2.86e-01 |
| GO:BP | GO:1903052 | positive regulation of proteolysis involved in protein catabolic process | 16 | 127 | 2.86e-01 |
| GO:BP | GO:0002293 | alpha-beta T cell differentiation involved in immune response | 1 | 40 | 2.86e-01 |
| GO:BP | GO:0070106 | interleukin-27-mediated signaling pathway | 2 | 4 | 2.86e-01 |
| GO:BP | GO:0007017 | microtubule-based process | 35 | 760 | 2.86e-01 |
| GO:BP | GO:0086054 | bundle of His cell to Purkinje myocyte communication by electrical coupling | 1 | 2 | 2.86e-01 |
| GO:BP | GO:0045814 | negative regulation of gene expression, epigenetic | 8 | 79 | 2.86e-01 |
| GO:BP | GO:0006082 | organic acid metabolic process | 4 | 700 | 2.86e-01 |
| GO:BP | GO:0060929 | atrioventricular node cell fate commitment | 1 | 2 | 2.86e-01 |
| GO:BP | GO:0000479 | endonucleolytic cleavage of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 2 | 17 | 2.86e-01 |
| GO:BP | GO:0046637 | regulation of alpha-beta T cell differentiation | 1 | 38 | 2.86e-01 |
| GO:BP | GO:0002287 | alpha-beta T cell activation involved in immune response | 1 | 40 | 2.86e-01 |
| GO:BP | GO:0051492 | regulation of stress fiber assembly | 7 | 81 | 2.86e-01 |
| GO:BP | GO:0071897 | DNA biosynthetic process | 13 | 175 | 2.86e-01 |
| GO:BP | GO:0000478 | endonucleolytic cleavage involved in rRNA processing | 2 | 17 | 2.86e-01 |
| GO:BP | GO:0003218 | cardiac left ventricle formation | 1 | 2 | 2.86e-01 |
| GO:BP | GO:1901846 | positive regulation of cell communication by electrical coupling involved in cardiac conduction | 1 | 2 | 2.86e-01 |
| GO:BP | GO:0061888 | regulation of astrocyte activation | 2 | 3 | 2.86e-01 |
| GO:BP | GO:2000408 | negative regulation of T cell extravasation | 1 | 1 | 2.86e-01 |
| GO:BP | GO:0032886 | regulation of microtubule-based process | 18 | 217 | 2.86e-01 |
| GO:BP | GO:0090394 | negative regulation of excitatory postsynaptic potential | 2 | 8 | 2.86e-01 |
| GO:BP | GO:0072721 | cellular response to dithiothreitol | 1 | 1 | 2.87e-01 |
| GO:BP | GO:0036146 | cellular response to mycotoxin | 1 | 1 | 2.87e-01 |
| GO:BP | GO:0000082 | G1/S transition of mitotic cell cycle | 14 | 207 | 2.87e-01 |
| GO:BP | GO:0070446 | negative regulation of oligodendrocyte progenitor proliferation | 1 | 1 | 2.88e-01 |
| GO:BP | GO:0009215 | purine deoxyribonucleoside triphosphate metabolic process | 2 | 6 | 2.88e-01 |
| GO:BP | GO:0042631 | cellular response to water deprivation | 1 | 1 | 2.88e-01 |
| GO:BP | GO:0034248 | regulation of amide metabolic process | 31 | 424 | 2.88e-01 |
| GO:BP | GO:0035272 | exocrine system development | 2 | 34 | 2.88e-01 |
| GO:BP | GO:0032660 | regulation of interleukin-17 production | 5 | 20 | 2.88e-01 |
| GO:BP | GO:0033144 | negative regulation of intracellular steroid hormone receptor signaling pathway | 2 | 31 | 2.88e-01 |
| GO:BP | GO:0071879 | positive regulation of adenylate cyclase-activating adrenergic receptor signaling pathway | 1 | 1 | 2.88e-01 |
| GO:BP | GO:0000154 | rRNA modification | 6 | 35 | 2.88e-01 |
| GO:BP | GO:2001234 | negative regulation of apoptotic signaling pathway | 7 | 194 | 2.88e-01 |
| GO:BP | GO:0030031 | cell projection assembly | 55 | 469 | 2.88e-01 |
| GO:BP | GO:0071241 | cellular response to inorganic substance | 22 | 164 | 2.88e-01 |
| GO:BP | GO:0072080 | nephron tubule development | 3 | 73 | 2.88e-01 |
| GO:BP | GO:1900371 | regulation of purine nucleotide biosynthetic process | 1 | 25 | 2.88e-01 |
| GO:BP | GO:0044027 | negative regulation of gene expression via CpG island methylation | 1 | 1 | 2.88e-01 |
| GO:BP | GO:0090140 | regulation of mitochondrial fission | 2 | 28 | 2.88e-01 |
| GO:BP | GO:0035281 | pre-miRNA export from nucleus | 1 | 2 | 2.88e-01 |
| GO:BP | GO:0061433 | cellular response to caloric restriction | 1 | 1 | 2.88e-01 |
| GO:BP | GO:0090527 | actin filament reorganization | 2 | 10 | 2.88e-01 |
| GO:BP | GO:0061439 | kidney vasculature morphogenesis | 1 | 7 | 2.88e-01 |
| GO:BP | GO:1901522 | positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus | 4 | 16 | 2.88e-01 |
| GO:BP | GO:0061438 | renal system vasculature morphogenesis | 1 | 7 | 2.88e-01 |
| GO:BP | GO:0010904 | regulation of UDP-glucose catabolic process | 1 | 1 | 2.88e-01 |
| GO:BP | GO:0010905 | negative regulation of UDP-glucose catabolic process | 1 | 1 | 2.88e-01 |
| GO:BP | GO:1904226 | regulation of glycogen synthase activity, transferring glucose-1-phosphate | 1 | 1 | 2.88e-01 |
| GO:BP | GO:0061015 | snRNA import into nucleus | 1 | 2 | 2.88e-01 |
| GO:BP | GO:0010934 | macrophage cytokine production | 2 | 27 | 2.88e-01 |
| GO:BP | GO:0003170 | heart valve development | 6 | 65 | 2.88e-01 |
| GO:BP | GO:0010935 | regulation of macrophage cytokine production | 2 | 27 | 2.88e-01 |
| GO:BP | GO:0046323 | glucose import | 7 | 53 | 2.88e-01 |
| GO:BP | GO:0060397 | growth hormone receptor signaling pathway via JAK-STAT | 2 | 9 | 2.88e-01 |
| GO:BP | GO:1904227 | negative regulation of glycogen synthase activity, transferring glucose-1-phosphate | 1 | 1 | 2.88e-01 |
| GO:BP | GO:0032620 | interleukin-17 production | 5 | 20 | 2.88e-01 |
| GO:BP | GO:0030808 | regulation of nucleotide biosynthetic process | 1 | 25 | 2.88e-01 |
| GO:BP | GO:1904058 | positive regulation of sensory perception of pain | 2 | 3 | 2.88e-01 |
| GO:BP | GO:1903847 | regulation of aorta morphogenesis | 1 | 2 | 2.88e-01 |
| GO:BP | GO:0002292 | T cell differentiation involved in immune response | 1 | 42 | 2.88e-01 |
| GO:BP | GO:0035264 | multicellular organism growth | 3 | 123 | 2.88e-01 |
| GO:BP | GO:0045444 | fat cell differentiation | 15 | 187 | 2.88e-01 |
| GO:BP | GO:0015842 | aminergic neurotransmitter loading into synaptic vesicle | 1 | 1 | 2.88e-01 |
| GO:BP | GO:0035418 | protein localization to synapse | 1 | 68 | 2.88e-01 |
| GO:BP | GO:0104004 | cellular response to environmental stimulus | 14 | 268 | 2.88e-01 |
| GO:BP | GO:0021814 | cell motility involved in cerebral cortex radial glia guided migration | 1 | 7 | 2.88e-01 |
| GO:BP | GO:0034260 | negative regulation of GTPase activity | 3 | 29 | 2.88e-01 |
| GO:BP | GO:0033262 | regulation of nuclear cell cycle DNA replication | 2 | 11 | 2.88e-01 |
| GO:BP | GO:0021546 | rhombomere development | 2 | 4 | 2.88e-01 |
| GO:BP | GO:0060999 | positive regulation of dendritic spine development | 6 | 33 | 2.88e-01 |
| GO:BP | GO:1990739 | granulosa cell proliferation | 1 | 1 | 2.88e-01 |
| GO:BP | GO:0060022 | hard palate development | 2 | 5 | 2.88e-01 |
| GO:BP | GO:0043525 | positive regulation of neuron apoptotic process | 6 | 41 | 2.88e-01 |
| GO:BP | GO:0120031 | plasma membrane bounded cell projection assembly | 54 | 461 | 2.88e-01 |
| GO:BP | GO:0021761 | limbic system development | 2 | 81 | 2.88e-01 |
| GO:BP | GO:0106074 | aminoacyl-tRNA metabolism involved in translational fidelity | 2 | 11 | 2.88e-01 |
| GO:BP | GO:0043516 | regulation of DNA damage response, signal transduction by p53 class mediator | 3 | 35 | 2.88e-01 |
| GO:BP | GO:0019068 | virion assembly | 5 | 35 | 2.88e-01 |
| GO:BP | GO:0099590 | neurotransmitter receptor internalization | 4 | 19 | 2.88e-01 |
| GO:BP | GO:0071279 | cellular response to cobalt ion | 1 | 4 | 2.88e-01 |
| GO:BP | GO:0106014 | regulation of inflammatory response to wounding | 1 | 4 | 2.88e-01 |
| GO:BP | GO:1904197 | positive regulation of granulosa cell proliferation | 1 | 1 | 2.88e-01 |
| GO:BP | GO:1903432 | regulation of TORC1 signaling | 6 | 48 | 2.88e-01 |
| GO:BP | GO:0051128 | regulation of cellular component organization | 6 | 2011 | 2.88e-01 |
| GO:BP | GO:1904262 | negative regulation of TORC1 signaling | 4 | 24 | 2.88e-01 |
| GO:BP | GO:1904195 | regulation of granulosa cell proliferation | 1 | 1 | 2.88e-01 |
| GO:BP | GO:0051615 | histamine uptake | 1 | 3 | 2.88e-01 |
| GO:BP | GO:1903849 | positive regulation of aorta morphogenesis | 1 | 2 | 2.88e-01 |
| GO:BP | GO:0042558 | pteridine-containing compound metabolic process | 1 | 28 | 2.88e-01 |
| GO:BP | GO:0002720 | positive regulation of cytokine production involved in immune response | 1 | 49 | 2.88e-01 |
| GO:BP | GO:0055093 | response to hyperoxia | 2 | 18 | 2.88e-01 |
| GO:BP | GO:0002718 | regulation of cytokine production involved in immune response | 4 | 70 | 2.88e-01 |
| GO:BP | GO:0097176 | epoxide metabolic process | 1 | 4 | 2.88e-01 |
| GO:BP | GO:0070873 | regulation of glycogen metabolic process | 4 | 28 | 2.88e-01 |
| GO:BP | GO:1905005 | regulation of epithelial to mesenchymal transition involved in endocardial cushion formation | 1 | 6 | 2.88e-01 |
| GO:BP | GO:0048660 | regulation of smooth muscle cell proliferation | 2 | 106 | 2.88e-01 |
| GO:BP | GO:0045112 | integrin biosynthetic process | 1 | 3 | 2.88e-01 |
| GO:BP | GO:0051771 | negative regulation of nitric-oxide synthase biosynthetic process | 1 | 3 | 2.88e-01 |
| GO:BP | GO:0003263 | cardioblast proliferation | 2 | 9 | 2.88e-01 |
| GO:BP | GO:1904748 | regulation of apoptotic process involved in development | 2 | 9 | 2.88e-01 |
| GO:BP | GO:0003264 | regulation of cardioblast proliferation | 2 | 9 | 2.88e-01 |
| GO:BP | GO:0010918 | positive regulation of mitochondrial membrane potential | 2 | 9 | 2.88e-01 |
| GO:BP | GO:0043112 | receptor metabolic process | 1 | 62 | 2.88e-01 |
| GO:BP | GO:0060271 | cilium assembly | 37 | 292 | 2.88e-01 |
| GO:BP | GO:0010839 | negative regulation of keratinocyte proliferation | 4 | 19 | 2.88e-01 |
| GO:BP | GO:0061343 | cell adhesion involved in heart morphogenesis | 1 | 6 | 2.88e-01 |
| GO:BP | GO:0030334 | regulation of cell migration | 9 | 706 | 2.88e-01 |
| GO:BP | GO:0042552 | myelination | 11 | 111 | 2.88e-01 |
| GO:BP | GO:2000514 | regulation of CD4-positive, alpha-beta T cell activation | 1 | 39 | 2.88e-01 |
| GO:BP | GO:1900221 | regulation of amyloid-beta clearance | 1 | 13 | 2.88e-01 |
| GO:BP | GO:1904550 | response to arachidonic acid | 1 | 1 | 2.88e-01 |
| GO:BP | GO:0009855 | determination of bilateral symmetry | 14 | 102 | 2.88e-01 |
| GO:BP | GO:0032238 | adenosine transport | 1 | 2 | 2.88e-01 |
| GO:BP | GO:1902337 | regulation of apoptotic process involved in morphogenesis | 2 | 9 | 2.88e-01 |
| GO:BP | GO:0000055 | ribosomal large subunit export from nucleus | 2 | 8 | 2.88e-01 |
| GO:BP | GO:0009628 | response to abiotic stimulus | 42 | 868 | 2.88e-01 |
| GO:BP | GO:0002367 | cytokine production involved in immune response | 4 | 70 | 2.88e-01 |
| GO:BP | GO:0003278 | apoptotic process involved in heart morphogenesis | 1 | 6 | 2.88e-01 |
| GO:BP | GO:0071214 | cellular response to abiotic stimulus | 14 | 268 | 2.88e-01 |
| GO:BP | GO:0006413 | translational initiation | 11 | 116 | 2.88e-01 |
| GO:BP | GO:0030224 | monocyte differentiation | 1 | 26 | 2.88e-01 |
| GO:BP | GO:1902774 | late endosome to lysosome transport | 3 | 20 | 2.88e-01 |
| GO:BP | GO:0051899 | membrane depolarization | 1 | 60 | 2.88e-01 |
| GO:BP | GO:0000096 | sulfur amino acid metabolic process | 1 | 27 | 2.88e-01 |
| GO:BP | GO:0046322 | negative regulation of fatty acid oxidation | 1 | 12 | 2.88e-01 |
| GO:BP | GO:0032434 | regulation of proteasomal ubiquitin-dependent protein catabolic process | 17 | 133 | 2.88e-01 |
| GO:BP | GO:0061757 | leukocyte adhesion to arterial endothelial cell | 1 | 4 | 2.88e-01 |
| GO:BP | GO:0070986 | left/right axis specification | 3 | 13 | 2.88e-01 |
| GO:BP | GO:0031122 | cytoplasmic microtubule organization | 6 | 60 | 2.88e-01 |
| GO:BP | GO:0031324 | negative regulation of cellular metabolic process | 39 | 1735 | 2.88e-01 |
| GO:BP | GO:2000378 | negative regulation of reactive oxygen species metabolic process | 5 | 34 | 2.89e-01 |
| GO:BP | GO:1905314 | semi-lunar valve development | 2 | 41 | 2.89e-01 |
| GO:BP | GO:0051097 | negative regulation of helicase activity | 1 | 5 | 2.89e-01 |
| GO:BP | GO:0034589 | hydroxyproline transport | 1 | 1 | 2.89e-01 |
| GO:BP | GO:0015826 | threonine transport | 1 | 1 | 2.89e-01 |
| GO:BP | GO:0010825 | positive regulation of centrosome duplication | 1 | 3 | 2.89e-01 |
| GO:BP | GO:0007632 | visual behavior | 1 | 41 | 2.89e-01 |
| GO:BP | GO:0019320 | hexose catabolic process | 1 | 32 | 2.89e-01 |
| GO:BP | GO:0006972 | hyperosmotic response | 5 | 19 | 2.89e-01 |
| GO:BP | GO:0008617 | guanosine metabolic process | 1 | 1 | 2.89e-01 |
| GO:BP | GO:0010822 | positive regulation of mitochondrion organization | 3 | 68 | 2.89e-01 |
| GO:BP | GO:0048661 | positive regulation of smooth muscle cell proliferation | 8 | 63 | 2.89e-01 |
| GO:BP | GO:1901068 | guanosine-containing compound metabolic process | 1 | 1 | 2.89e-01 |
| GO:BP | GO:0060562 | epithelial tube morphogenesis | 6 | 278 | 2.89e-01 |
| GO:BP | GO:0051403 | stress-activated MAPK cascade | 7 | 190 | 2.90e-01 |
| GO:BP | GO:0070884 | regulation of calcineurin-NFAT signaling cascade | 5 | 32 | 2.90e-01 |
| GO:BP | GO:0046605 | regulation of centrosome cycle | 3 | 51 | 2.90e-01 |
| GO:BP | GO:0007529 | establishment of synaptic specificity at neuromuscular junction | 1 | 2 | 2.90e-01 |
| GO:BP | GO:0015748 | organophosphate ester transport | 1 | 106 | 2.90e-01 |
| GO:BP | GO:0008366 | axon ensheathment | 11 | 113 | 2.90e-01 |
| GO:BP | GO:0007272 | ensheathment of neurons | 11 | 113 | 2.90e-01 |
| GO:BP | GO:1990849 | vacuolar localization | 6 | 62 | 2.90e-01 |
| GO:BP | GO:1903788 | positive regulation of glutathione biosynthetic process | 1 | 1 | 2.90e-01 |
| GO:BP | GO:0048280 | vesicle fusion with Golgi apparatus | 1 | 8 | 2.90e-01 |
| GO:BP | GO:0009953 | dorsal/ventral pattern formation | 10 | 55 | 2.90e-01 |
| GO:BP | GO:0019547 | arginine catabolic process to ornithine | 1 | 1 | 2.90e-01 |
| GO:BP | GO:0002315 | marginal zone B cell differentiation | 1 | 6 | 2.90e-01 |
| GO:BP | GO:0009912 | auditory receptor cell fate commitment | 2 | 4 | 2.90e-01 |
| GO:BP | GO:0034067 | protein localization to Golgi apparatus | 1 | 27 | 2.90e-01 |
| GO:BP | GO:0061157 | mRNA destabilization | 7 | 89 | 2.90e-01 |
| GO:BP | GO:0009968 | negative regulation of signal transduction | 4 | 1006 | 2.90e-01 |
| GO:BP | GO:0071364 | cellular response to epidermal growth factor stimulus | 4 | 41 | 2.90e-01 |
| GO:BP | GO:0001938 | positive regulation of endothelial cell proliferation | 6 | 74 | 2.90e-01 |
| GO:BP | GO:1902806 | regulation of cell cycle G1/S phase transition | 12 | 169 | 2.90e-01 |
| GO:BP | GO:0010746 | regulation of long-chain fatty acid import across plasma membrane | 2 | 5 | 2.90e-01 |
| GO:BP | GO:0071329 | cellular response to sucrose stimulus | 1 | 1 | 2.90e-01 |
| GO:BP | GO:0035305 | negative regulation of dephosphorylation | 2 | 39 | 2.90e-01 |
| GO:BP | GO:0001952 | regulation of cell-matrix adhesion | 2 | 97 | 2.90e-01 |
| GO:BP | GO:0019217 | regulation of fatty acid metabolic process | 3 | 66 | 2.90e-01 |
| GO:BP | GO:0040007 | growth | 6 | 742 | 2.90e-01 |
| GO:BP | GO:1901018 | positive regulation of potassium ion transmembrane transporter activity | 1 | 20 | 2.90e-01 |
| GO:BP | GO:0046684 | response to pyrethroid | 1 | 1 | 2.90e-01 |
| GO:BP | GO:0018023 | peptidyl-lysine trimethylation | 2 | 33 | 2.90e-01 |
| GO:BP | GO:0010837 | regulation of keratinocyte proliferation | 6 | 33 | 2.90e-01 |
| GO:BP | GO:0002709 | regulation of T cell mediated immunity | 1 | 39 | 2.90e-01 |
| GO:BP | GO:0070857 | regulation of bile acid biosynthetic process | 2 | 7 | 2.90e-01 |
| GO:BP | GO:0042073 | intraciliary transport | 7 | 46 | 2.90e-01 |
| GO:BP | GO:2000074 | regulation of type B pancreatic cell development | 2 | 8 | 2.90e-01 |
| GO:BP | GO:0071324 | cellular response to disaccharide stimulus | 1 | 1 | 2.90e-01 |
| GO:BP | GO:0046578 | regulation of Ras protein signal transduction | 5 | 166 | 2.90e-01 |
| GO:BP | GO:0009799 | specification of symmetry | 14 | 103 | 2.90e-01 |
| GO:BP | GO:0072102 | glomerulus morphogenesis | 1 | 7 | 2.90e-01 |
| GO:BP | GO:1905403 | negative regulation of activated CD8-positive, alpha-beta T cell apoptotic process | 1 | 2 | 2.90e-01 |
| GO:BP | GO:0086013 | membrane repolarization during cardiac muscle cell action potential | 2 | 18 | 2.90e-01 |
| GO:BP | GO:0006525 | arginine metabolic process | 4 | 13 | 2.90e-01 |
| GO:BP | GO:0006833 | water transport | 2 | 10 | 2.90e-01 |
| GO:BP | GO:0021681 | cerebellar granular layer development | 2 | 11 | 2.90e-01 |
| GO:BP | GO:0072073 | kidney epithelium development | 8 | 112 | 2.90e-01 |
| GO:BP | GO:1990646 | cellular response to prolactin | 1 | 2 | 2.90e-01 |
| GO:BP | GO:0060120 | inner ear receptor cell fate commitment | 2 | 4 | 2.90e-01 |
| GO:BP | GO:0031330 | negative regulation of cellular catabolic process | 13 | 165 | 2.90e-01 |
| GO:BP | GO:0099562 | maintenance of postsynaptic density structure | 2 | 6 | 2.90e-01 |
| GO:BP | GO:0072308 | negative regulation of metanephric nephron tubule epithelial cell differentiation | 1 | 1 | 2.90e-01 |
| GO:BP | GO:0032418 | lysosome localization | 6 | 62 | 2.90e-01 |
| GO:BP | GO:0030641 | regulation of cellular pH | 6 | 70 | 2.90e-01 |
| GO:BP | GO:1904717 | regulation of AMPA glutamate receptor clustering | 2 | 4 | 2.90e-01 |
| GO:BP | GO:0048659 | smooth muscle cell proliferation | 2 | 110 | 2.90e-01 |
| GO:BP | GO:0006476 | protein deacetylation | 10 | 106 | 2.90e-01 |
| GO:BP | GO:1905382 | positive regulation of snRNA transcription by RNA polymerase II | 1 | 3 | 2.90e-01 |
| GO:BP | GO:0043586 | tongue development | 1 | 15 | 2.90e-01 |
| GO:BP | GO:1905949 | negative regulation of calcium ion import across plasma membrane | 2 | 4 | 2.90e-01 |
| GO:BP | GO:0006537 | glutamate biosynthetic process | 1 | 5 | 2.90e-01 |
| GO:BP | GO:0032885 | regulation of polysaccharide biosynthetic process | 4 | 31 | 2.90e-01 |
| GO:BP | GO:0021520 | spinal cord motor neuron cell fate specification | 1 | 5 | 2.90e-01 |
| GO:BP | GO:0044843 | cell cycle G1/S phase transition | 14 | 229 | 2.90e-01 |
| GO:BP | GO:0000183 | rDNA heterochromatin formation | 2 | 9 | 2.90e-01 |
| GO:BP | GO:0106104 | regulation of glutamate receptor clustering | 2 | 4 | 2.90e-01 |
| GO:BP | GO:0072077 | renal vesicle morphogenesis | 3 | 14 | 2.90e-01 |
| GO:BP | GO:0051823 | regulation of synapse structural plasticity | 2 | 5 | 2.90e-01 |
| GO:BP | GO:0043367 | CD4-positive, alpha-beta T cell differentiation | 1 | 50 | 2.91e-01 |
| GO:BP | GO:0070127 | tRNA aminoacylation for mitochondrial protein translation | 1 | 8 | 2.91e-01 |
| GO:BP | GO:0006633 | fatty acid biosynthetic process | 4 | 104 | 2.91e-01 |
| GO:BP | GO:0001715 | ectodermal cell fate specification | 1 | 1 | 2.91e-01 |
| GO:BP | GO:0042665 | regulation of ectodermal cell fate specification | 1 | 1 | 2.91e-01 |
| GO:BP | GO:0042666 | negative regulation of ectodermal cell fate specification | 1 | 1 | 2.91e-01 |
| GO:BP | GO:1904205 | negative regulation of skeletal muscle hypertrophy | 1 | 1 | 2.93e-01 |
| GO:BP | GO:0051495 | positive regulation of cytoskeleton organization | 8 | 165 | 2.94e-01 |
| GO:BP | GO:0009611 | response to wounding | 11 | 415 | 2.94e-01 |
| GO:BP | GO:0032790 | ribosome disassembly | 3 | 11 | 2.94e-01 |
| GO:BP | GO:1904507 | positive regulation of telomere maintenance in response to DNA damage | 3 | 14 | 2.95e-01 |
| GO:BP | GO:0043297 | apical junction assembly | 2 | 51 | 2.95e-01 |
| GO:BP | GO:0032816 | positive regulation of natural killer cell activation | 3 | 16 | 2.95e-01 |
| GO:BP | GO:0042795 | snRNA transcription by RNA polymerase II | 2 | 15 | 2.95e-01 |
| GO:BP | GO:0071353 | cellular response to interleukin-4 | 3 | 21 | 2.95e-01 |
| GO:BP | GO:0006665 | sphingolipid metabolic process | 1 | 131 | 2.95e-01 |
| GO:BP | GO:0002066 | columnar/cuboidal epithelial cell development | 5 | 38 | 2.95e-01 |
| GO:BP | GO:0000075 | cell cycle checkpoint signaling | 6 | 183 | 2.95e-01 |
| GO:BP | GO:1900029 | positive regulation of ruffle assembly | 3 | 12 | 2.95e-01 |
| GO:BP | GO:0045933 | positive regulation of muscle contraction | 1 | 32 | 2.95e-01 |
| GO:BP | GO:0071499 | cellular response to laminar fluid shear stress | 2 | 8 | 2.95e-01 |
| GO:BP | GO:2000145 | regulation of cell motility | 14 | 742 | 2.95e-01 |
| GO:BP | GO:1904996 | positive regulation of leukocyte adhesion to vascular endothelial cell | 2 | 13 | 2.95e-01 |
| GO:BP | GO:0021591 | ventricular system development | 3 | 29 | 2.95e-01 |
| GO:BP | GO:1903742 | regulation of anterograde synaptic vesicle transport | 1 | 3 | 2.95e-01 |
| GO:BP | GO:0021598 | abducens nerve morphogenesis | 1 | 1 | 2.95e-01 |
| GO:BP | GO:0045324 | late endosome to vacuole transport | 4 | 36 | 2.95e-01 |
| GO:BP | GO:0032007 | negative regulation of TOR signaling | 6 | 47 | 2.95e-01 |
| GO:BP | GO:0021599 | abducens nerve formation | 1 | 1 | 2.95e-01 |
| GO:BP | GO:2001204 | regulation of osteoclast development | 1 | 4 | 2.95e-01 |
| GO:BP | GO:0071918 | urea transmembrane transport | 1 | 2 | 2.95e-01 |
| GO:BP | GO:0043405 | regulation of MAP kinase activity | 7 | 141 | 2.95e-01 |
| GO:BP | GO:0021560 | abducens nerve development | 1 | 1 | 2.95e-01 |
| GO:BP | GO:0001821 | histamine secretion | 3 | 9 | 2.95e-01 |
| GO:BP | GO:0044342 | type B pancreatic cell proliferation | 4 | 26 | 2.95e-01 |
| GO:BP | GO:0106056 | regulation of calcineurin-mediated signaling | 5 | 32 | 2.95e-01 |
| GO:BP | GO:1902105 | regulation of leukocyte differentiation | 2 | 199 | 2.95e-01 |
| GO:BP | GO:1901655 | cellular response to ketone | 6 | 86 | 2.95e-01 |
| GO:BP | GO:0021572 | rhombomere 6 development | 1 | 1 | 2.95e-01 |
| GO:BP | GO:0000423 | mitophagy | 4 | 37 | 2.95e-01 |
| GO:BP | GO:2001300 | lipoxin metabolic process | 1 | 3 | 2.95e-01 |
| GO:BP | GO:0061726 | mitochondrion disassembly | 8 | 92 | 2.95e-01 |
| GO:BP | GO:0090084 | negative regulation of inclusion body assembly | 3 | 10 | 2.95e-01 |
| GO:BP | GO:0000422 | autophagy of mitochondrion | 8 | 92 | 2.95e-01 |
| GO:BP | GO:0061041 | regulation of wound healing | 5 | 95 | 2.95e-01 |
| GO:BP | GO:0010002 | cardioblast differentiation | 2 | 15 | 2.95e-01 |
| GO:BP | GO:0048488 | synaptic vesicle endocytosis | 10 | 63 | 2.95e-01 |
| GO:BP | GO:0021527 | spinal cord association neuron differentiation | 1 | 3 | 2.97e-01 |
| GO:BP | GO:1904527 | negative regulation of microtubule binding | 1 | 2 | 2.98e-01 |
| GO:BP | GO:0043555 | regulation of translation in response to stress | 3 | 23 | 2.98e-01 |
| GO:BP | GO:0021935 | cerebellar granule cell precursor tangential migration | 1 | 2 | 2.98e-01 |
| GO:BP | GO:0010463 | mesenchymal cell proliferation | 1 | 35 | 2.98e-01 |
| GO:BP | GO:0035437 | maintenance of protein localization in endoplasmic reticulum | 1 | 11 | 2.98e-01 |
| GO:BP | GO:0002090 | regulation of receptor internalization | 6 | 49 | 2.98e-01 |
| GO:BP | GO:1903433 | regulation of constitutive secretory pathway | 1 | 2 | 2.99e-01 |
| GO:BP | GO:0036120 | cellular response to platelet-derived growth factor stimulus | 1 | 21 | 2.99e-01 |
| GO:BP | GO:0006303 | double-strand break repair via nonhomologous end joining | 9 | 61 | 2.99e-01 |
| GO:BP | GO:0006809 | nitric oxide biosynthetic process | 6 | 51 | 2.99e-01 |
| GO:BP | GO:0009116 | nucleoside metabolic process | 1 | 42 | 2.99e-01 |
| GO:BP | GO:1901673 | regulation of mitotic spindle assembly | 3 | 23 | 2.99e-01 |
| GO:BP | GO:0006730 | one-carbon metabolic process | 1 | 29 | 2.99e-01 |
| GO:BP | GO:0033152 | immunoglobulin V(D)J recombination | 2 | 8 | 2.99e-01 |
| GO:BP | GO:1902410 | mitotic cytokinetic process | 3 | 23 | 2.99e-01 |
| GO:BP | GO:0031098 | stress-activated protein kinase signaling cascade | 7 | 196 | 2.99e-01 |
| GO:BP | GO:0003430 | growth plate cartilage chondrocyte growth | 1 | 3 | 2.99e-01 |
| GO:BP | GO:0061684 | chaperone-mediated autophagy | 1 | 16 | 2.99e-01 |
| GO:BP | GO:0048313 | Golgi inheritance | 1 | 15 | 2.99e-01 |
| GO:BP | GO:0048308 | organelle inheritance | 1 | 15 | 2.99e-01 |
| GO:BP | GO:0007289 | spermatid nucleus differentiation | 2 | 16 | 2.99e-01 |
| GO:BP | GO:0098528 | skeletal muscle fiber differentiation | 2 | 5 | 2.99e-01 |
| GO:BP | GO:0006354 | DNA-templated transcription elongation | 8 | 122 | 3.00e-01 |
| GO:BP | GO:0042304 | regulation of fatty acid biosynthetic process | 2 | 30 | 3.00e-01 |
| GO:BP | GO:0061763 | multivesicular body-lysosome fusion | 2 | 11 | 3.01e-01 |
| GO:BP | GO:0051469 | vesicle fusion with vacuole | 2 | 11 | 3.01e-01 |
| GO:BP | GO:0006563 | L-serine metabolic process | 2 | 10 | 3.01e-01 |
| GO:BP | GO:1902176 | negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway | 3 | 18 | 3.01e-01 |
| GO:BP | GO:0034976 | response to endoplasmic reticulum stress | 12 | 234 | 3.01e-01 |
| GO:BP | GO:0036003 | positive regulation of transcription from RNA polymerase II promoter in response to stress | 3 | 18 | 3.01e-01 |
| GO:BP | GO:0033143 | regulation of intracellular steroid hormone receptor signaling pathway | 6 | 61 | 3.01e-01 |
| GO:BP | GO:0042303 | molting cycle | 3 | 78 | 3.01e-01 |
| GO:BP | GO:0042633 | hair cycle | 3 | 78 | 3.01e-01 |
| GO:BP | GO:0042542 | response to hydrogen peroxide | 10 | 103 | 3.01e-01 |
| GO:BP | GO:0060448 | dichotomous subdivision of terminal units involved in lung branching | 1 | 2 | 3.01e-01 |
| GO:BP | GO:0046365 | monosaccharide catabolic process | 1 | 38 | 3.01e-01 |
| GO:BP | GO:0072429 | response to intra-S DNA damage checkpoint signaling | 1 | 4 | 3.01e-01 |
| GO:BP | GO:0009068 | aspartate family amino acid catabolic process | 2 | 12 | 3.01e-01 |
| GO:BP | GO:0033673 | negative regulation of kinase activity | 14 | 197 | 3.02e-01 |
| GO:BP | GO:1905268 | negative regulation of chromatin organization | 1 | 4 | 3.02e-01 |
| GO:BP | GO:0031452 | negative regulation of heterochromatin formation | 1 | 4 | 3.02e-01 |
| GO:BP | GO:0045778 | positive regulation of ossification | 7 | 40 | 3.02e-01 |
| GO:BP | GO:0120262 | negative regulation of heterochromatin organization | 1 | 4 | 3.02e-01 |
| GO:BP | GO:0090383 | phagosome acidification | 2 | 5 | 3.02e-01 |
| GO:BP | GO:0009416 | response to light stimulus | 20 | 246 | 3.03e-01 |
| GO:BP | GO:0001816 | cytokine production | 2 | 451 | 3.03e-01 |
| GO:BP | GO:2000060 | positive regulation of ubiquitin-dependent protein catabolic process | 13 | 103 | 3.03e-01 |
| GO:BP | GO:0034661 | ncRNA catabolic process | 6 | 41 | 3.03e-01 |
| GO:BP | GO:0072087 | renal vesicle development | 3 | 15 | 3.03e-01 |
| GO:BP | GO:0060479 | lung cell differentiation | 4 | 18 | 3.03e-01 |
| GO:BP | GO:0001817 | regulation of cytokine production | 2 | 447 | 3.03e-01 |
| GO:BP | GO:0002190 | cap-independent translational initiation | 1 | 4 | 3.03e-01 |
| GO:BP | GO:0007346 | regulation of mitotic cell cycle | 25 | 441 | 3.03e-01 |
| GO:BP | GO:0043434 | response to peptide hormone | 22 | 321 | 3.03e-01 |
| GO:BP | GO:0009408 | response to heat | 8 | 84 | 3.03e-01 |
| GO:BP | GO:0061744 | motor behavior | 1 | 17 | 3.03e-01 |
| GO:BP | GO:0060291 | long-term synaptic potentiation | 1 | 64 | 3.03e-01 |
| GO:BP | GO:0021514 | ventral spinal cord interneuron differentiation | 1 | 5 | 3.03e-01 |
| GO:BP | GO:2000562 | negative regulation of CD4-positive, alpha-beta T cell proliferation | 3 | 7 | 3.03e-01 |
| GO:BP | GO:0060487 | lung epithelial cell differentiation | 4 | 18 | 3.03e-01 |
| GO:BP | GO:0045185 | maintenance of protein location | 2 | 83 | 3.03e-01 |
| GO:BP | GO:0045647 | negative regulation of erythrocyte differentiation | 2 | 7 | 3.03e-01 |
| GO:BP | GO:0015724 | formate transport | 1 | 1 | 3.03e-01 |
| GO:BP | GO:1900542 | regulation of purine nucleotide metabolic process | 1 | 40 | 3.03e-01 |
| GO:BP | GO:1901223 | negative regulation of NIK/NF-kappaB signaling | 4 | 21 | 3.03e-01 |
| GO:BP | GO:0043162 | ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway | 4 | 35 | 3.03e-01 |
| GO:BP | GO:0097324 | melanocyte migration | 1 | 3 | 3.03e-01 |
| GO:BP | GO:0033024 | mast cell apoptotic process | 1 | 3 | 3.03e-01 |
| GO:BP | GO:0033025 | regulation of mast cell apoptotic process | 1 | 3 | 3.03e-01 |
| GO:BP | GO:0032060 | bleb assembly | 2 | 9 | 3.03e-01 |
| GO:BP | GO:0015797 | mannitol transmembrane transport | 1 | 1 | 3.03e-01 |
| GO:BP | GO:0061314 | Notch signaling involved in heart development | 1 | 9 | 3.03e-01 |
| GO:BP | GO:0090101 | negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 15 | 124 | 3.03e-01 |
| GO:BP | GO:0002383 | immune response in brain or nervous system | 1 | 1 | 3.03e-01 |
| GO:BP | GO:0015860 | purine nucleoside transmembrane transport | 1 | 3 | 3.03e-01 |
| GO:BP | GO:0015840 | urea transport | 1 | 2 | 3.03e-01 |
| GO:BP | GO:0097281 | immune complex formation | 1 | 1 | 3.03e-01 |
| GO:BP | GO:0006750 | glutathione biosynthetic process | 3 | 13 | 3.04e-01 |
| GO:BP | GO:0034614 | cellular response to reactive oxygen species | 11 | 121 | 3.04e-01 |
| GO:BP | GO:0060560 | developmental growth involved in morphogenesis | 11 | 204 | 3.04e-01 |
| GO:BP | GO:0050779 | RNA destabilization | 7 | 92 | 3.04e-01 |
| GO:BP | GO:0070830 | bicellular tight junction assembly | 1 | 43 | 3.04e-01 |
| GO:BP | GO:0000226 | microtubule cytoskeleton organization | 25 | 552 | 3.04e-01 |
| GO:BP | GO:1901687 | glutathione derivative biosynthetic process | 1 | 3 | 3.04e-01 |
| GO:BP | GO:1901685 | glutathione derivative metabolic process | 1 | 3 | 3.04e-01 |
| GO:BP | GO:1902231 | positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage | 2 | 7 | 3.04e-01 |
| GO:BP | GO:0045637 | regulation of myeloid cell differentiation | 2 | 152 | 3.04e-01 |
| GO:BP | GO:2000807 | regulation of synaptic vesicle clustering | 2 | 7 | 3.04e-01 |
| GO:BP | GO:0006140 | regulation of nucleotide metabolic process | 1 | 40 | 3.04e-01 |
| GO:BP | GO:0036119 | response to platelet-derived growth factor | 1 | 23 | 3.04e-01 |
| GO:BP | GO:0048048 | embryonic eye morphogenesis | 4 | 25 | 3.04e-01 |
| GO:BP | GO:0061013 | regulation of mRNA catabolic process | 11 | 161 | 3.04e-01 |
| GO:BP | GO:0060927 | cardiac pacemaker cell fate commitment | 1 | 3 | 3.05e-01 |
| GO:BP | GO:0032147 | activation of protein kinase activity | 1 | 82 | 3.05e-01 |
| GO:BP | GO:0061512 | protein localization to cilium | 9 | 61 | 3.05e-01 |
| GO:BP | GO:0043632 | modification-dependent macromolecule catabolic process | 63 | 637 | 3.05e-01 |
| GO:BP | GO:0003214 | cardiac left ventricle morphogenesis | 3 | 12 | 3.05e-01 |
| GO:BP | GO:0002824 | positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 1 | 62 | 3.05e-01 |
| GO:BP | GO:0060121 | vestibular receptor cell stereocilium organization | 1 | 1 | 3.05e-01 |
| GO:BP | GO:0031998 | regulation of fatty acid beta-oxidation | 1 | 16 | 3.05e-01 |
| GO:BP | GO:0043392 | negative regulation of DNA binding | 1 | 46 | 3.05e-01 |
| GO:BP | GO:0030036 | actin cytoskeleton organization | 1 | 612 | 3.05e-01 |
| GO:BP | GO:1990700 | nucleolar chromatin organization | 2 | 10 | 3.05e-01 |
| GO:BP | GO:0019287 | isopentenyl diphosphate biosynthetic process, mevalonate pathway | 1 | 3 | 3.05e-01 |
| GO:BP | GO:0007417 | central nervous system development | 2 | 792 | 3.05e-01 |
| GO:BP | GO:0019627 | urea metabolic process | 3 | 7 | 3.05e-01 |
| GO:BP | GO:0051127 | positive regulation of actin nucleation | 2 | 14 | 3.05e-01 |
| GO:BP | GO:0036260 | RNA capping | 2 | 20 | 3.05e-01 |
| GO:BP | GO:0010650 | positive regulation of cell communication by electrical coupling | 1 | 3 | 3.05e-01 |
| GO:BP | GO:0042759 | long-chain fatty acid biosynthetic process | 2 | 14 | 3.05e-01 |
| GO:BP | GO:0035862 | dITP metabolic process | 1 | 1 | 3.05e-01 |
| GO:BP | GO:0016331 | morphogenesis of embryonic epithelium | 13 | 132 | 3.05e-01 |
| GO:BP | GO:0035863 | dITP catabolic process | 1 | 1 | 3.05e-01 |
| GO:BP | GO:0071941 | nitrogen cycle metabolic process | 3 | 7 | 3.05e-01 |
| GO:BP | GO:0002456 | T cell mediated immunity | 1 | 53 | 3.05e-01 |
| GO:BP | GO:0003167 | atrioventricular bundle cell differentiation | 1 | 3 | 3.05e-01 |
| GO:BP | GO:0003179 | heart valve morphogenesis | 5 | 55 | 3.05e-01 |
| GO:BP | GO:0042791 | 5S class rRNA transcription by RNA polymerase III | 2 | 6 | 3.05e-01 |
| GO:BP | GO:0002068 | glandular epithelial cell development | 4 | 28 | 3.05e-01 |
| GO:BP | GO:1902415 | regulation of mRNA binding | 2 | 10 | 3.05e-01 |
| GO:BP | GO:0000079 | regulation of cyclin-dependent protein serine/threonine kinase activity | 9 | 85 | 3.05e-01 |
| GO:BP | GO:1904816 | positive regulation of protein localization to chromosome, telomeric region | 3 | 13 | 3.05e-01 |
| GO:BP | GO:0097201 | negative regulation of transcription from RNA polymerase II promoter in response to stress | 2 | 10 | 3.05e-01 |
| GO:BP | GO:0009097 | isoleucine biosynthetic process | 1 | 2 | 3.05e-01 |
| GO:BP | GO:0072513 | positive regulation of secondary heart field cardioblast proliferation | 1 | 2 | 3.05e-01 |
| GO:BP | GO:0051496 | positive regulation of stress fiber assembly | 3 | 47 | 3.05e-01 |
| GO:BP | GO:0042981 | regulation of apoptotic process | 4 | 1088 | 3.05e-01 |
| GO:BP | GO:0002700 | regulation of production of molecular mediator of immune response | 5 | 108 | 3.05e-01 |
| GO:BP | GO:1905380 | regulation of snRNA transcription by RNA polymerase II | 1 | 4 | 3.05e-01 |
| GO:BP | GO:0001887 | selenium compound metabolic process | 1 | 2 | 3.05e-01 |
| GO:BP | GO:0097115 | neurexin clustering involved in presynaptic membrane assembly | 1 | 1 | 3.05e-01 |
| GO:BP | GO:0110020 | regulation of actomyosin structure organization | 7 | 90 | 3.05e-01 |
| GO:BP | GO:0023057 | negative regulation of signaling | 4 | 1076 | 3.05e-01 |
| GO:BP | GO:0048789 | cytoskeletal matrix organization at active zone | 1 | 1 | 3.05e-01 |
| GO:BP | GO:0016260 | selenocysteine biosynthetic process | 1 | 2 | 3.05e-01 |
| GO:BP | GO:0098869 | cellular oxidant detoxification | 2 | 65 | 3.05e-01 |
| GO:BP | GO:0010648 | negative regulation of cell communication | 4 | 1074 | 3.05e-01 |
| GO:BP | GO:0034644 | cellular response to UV | 7 | 86 | 3.05e-01 |
| GO:BP | GO:0014013 | regulation of gliogenesis | 3 | 68 | 3.05e-01 |
| GO:BP | GO:1902414 | protein localization to cell junction | 1 | 93 | 3.05e-01 |
| GO:BP | GO:0061371 | determination of heart left/right asymmetry | 8 | 52 | 3.05e-01 |
| GO:BP | GO:0043629 | ncRNA polyadenylation | 1 | 2 | 3.05e-01 |
| GO:BP | GO:0003143 | embryonic heart tube morphogenesis | 8 | 56 | 3.05e-01 |
| GO:BP | GO:0007035 | vacuolar acidification | 3 | 30 | 3.05e-01 |
| GO:BP | GO:0034470 | ncRNA processing | 42 | 400 | 3.05e-01 |
| GO:BP | GO:0006782 | protoporphyrinogen IX biosynthetic process | 1 | 9 | 3.05e-01 |
| GO:BP | GO:1905671 | regulation of lysosome organization | 2 | 6 | 3.07e-01 |
| GO:BP | GO:2000629 | negative regulation of miRNA metabolic process | 4 | 20 | 3.07e-01 |
| GO:BP | GO:1901216 | positive regulation of neuron death | 5 | 70 | 3.07e-01 |
| GO:BP | GO:0097009 | energy homeostasis | 2 | 39 | 3.07e-01 |
| GO:BP | GO:1900004 | negative regulation of serine-type endopeptidase activity | 1 | 4 | 3.07e-01 |
| GO:BP | GO:0046634 | regulation of alpha-beta T cell activation | 1 | 58 | 3.07e-01 |
| GO:BP | GO:0009636 | response to toxic substance | 7 | 158 | 3.07e-01 |
| GO:BP | GO:0072015 | podocyte development | 1 | 9 | 3.07e-01 |
| GO:BP | GO:0120192 | tight junction assembly | 1 | 47 | 3.07e-01 |
| GO:BP | GO:1902572 | negative regulation of serine-type peptidase activity | 1 | 4 | 3.07e-01 |
| GO:BP | GO:0043153 | entrainment of circadian clock by photoperiod | 3 | 27 | 3.07e-01 |
| GO:BP | GO:0061764 | late endosome to lysosome transport via multivesicular body sorting pathway | 1 | 2 | 3.07e-01 |
| GO:BP | GO:0007030 | Golgi organization | 10 | 137 | 3.07e-01 |
| GO:BP | GO:0070070 | proton-transporting V-type ATPase complex assembly | 1 | 7 | 3.07e-01 |
| GO:BP | GO:2000279 | negative regulation of DNA biosynthetic process | 6 | 34 | 3.07e-01 |
| GO:BP | GO:0051974 | negative regulation of telomerase activity | 3 | 11 | 3.07e-01 |
| GO:BP | GO:1904659 | glucose transmembrane transport | 9 | 81 | 3.07e-01 |
| GO:BP | GO:0007422 | peripheral nervous system development | 7 | 67 | 3.07e-01 |
| GO:BP | GO:0002821 | positive regulation of adaptive immune response | 1 | 66 | 3.07e-01 |
| GO:BP | GO:0061117 | negative regulation of heart growth | 3 | 19 | 3.07e-01 |
| GO:BP | GO:0072319 | vesicle uncoating | 2 | 9 | 3.07e-01 |
| GO:BP | GO:0048696 | regulation of collateral sprouting in absence of injury | 1 | 2 | 3.07e-01 |
| GO:BP | GO:0060087 | relaxation of vascular associated smooth muscle | 1 | 7 | 3.07e-01 |
| GO:BP | GO:0055022 | negative regulation of cardiac muscle tissue growth | 3 | 19 | 3.07e-01 |
| GO:BP | GO:2000738 | positive regulation of stem cell differentiation | 2 | 17 | 3.07e-01 |
| GO:BP | GO:0002702 | positive regulation of production of molecular mediator of immune response | 4 | 77 | 3.07e-01 |
| GO:BP | GO:0034486 | vacuolar transmembrane transport | 1 | 3 | 3.07e-01 |
| GO:BP | GO:0016570 | histone modification | 8 | 433 | 3.07e-01 |
| GO:BP | GO:0045582 | positive regulation of T cell differentiation | 1 | 74 | 3.08e-01 |
| GO:BP | GO:0043066 | negative regulation of apoptotic process | 6 | 660 | 3.08e-01 |
| GO:BP | GO:0021828 | gonadotrophin-releasing hormone neuronal migration to the hypothalamus | 2 | 6 | 3.08e-01 |
| GO:BP | GO:0048016 | inositol phosphate-mediated signaling | 6 | 45 | 3.08e-01 |
| GO:BP | GO:0021856 | hypothalamic tangential migration using cell-axon interactions | 2 | 6 | 3.08e-01 |
| GO:BP | GO:0021522 | spinal cord motor neuron differentiation | 2 | 18 | 3.08e-01 |
| GO:BP | GO:0035356 | intracellular triglyceride homeostasis | 1 | 5 | 3.08e-01 |
| GO:BP | GO:0046015 | regulation of transcription by glucose | 1 | 6 | 3.08e-01 |
| GO:BP | GO:0072175 | epithelial tube formation | 12 | 127 | 3.08e-01 |
| GO:BP | GO:0006448 | regulation of translational elongation | 4 | 19 | 3.08e-01 |
| GO:BP | GO:0045428 | regulation of nitric oxide biosynthetic process | 5 | 38 | 3.08e-01 |
| GO:BP | GO:1901532 | regulation of hematopoietic progenitor cell differentiation | 3 | 34 | 3.08e-01 |
| GO:BP | GO:0006511 | ubiquitin-dependent protein catabolic process | 61 | 615 | 3.08e-01 |
| GO:BP | GO:0048662 | negative regulation of smooth muscle cell proliferation | 1 | 42 | 3.08e-01 |
| GO:BP | GO:0072307 | regulation of metanephric nephron tubule epithelial cell differentiation | 2 | 5 | 3.08e-01 |
| GO:BP | GO:1901606 | alpha-amino acid catabolic process | 5 | 63 | 3.08e-01 |
| GO:BP | GO:0072257 | metanephric nephron tubule epithelial cell differentiation | 2 | 5 | 3.08e-01 |
| GO:BP | GO:0002708 | positive regulation of lymphocyte mediated immunity | 1 | 58 | 3.08e-01 |
| GO:BP | GO:2000208 | positive regulation of ribosomal small subunit export from nucleus | 1 | 1 | 3.09e-01 |
| GO:BP | GO:0019264 | glycine biosynthetic process from serine | 1 | 2 | 3.09e-01 |
| GO:BP | GO:0031668 | cellular response to extracellular stimulus | 16 | 219 | 3.09e-01 |
| GO:BP | GO:0001933 | negative regulation of protein phosphorylation | 22 | 277 | 3.09e-01 |
| GO:BP | GO:0062043 | positive regulation of cardiac epithelial to mesenchymal transition | 1 | 9 | 3.09e-01 |
| GO:BP | GO:0033631 | cell-cell adhesion mediated by integrin | 1 | 12 | 3.09e-01 |
| GO:BP | GO:0048819 | regulation of hair follicle maturation | 1 | 9 | 3.09e-01 |
| GO:BP | GO:0120012 | intermembrane sphingolipid transfer | 1 | 1 | 3.09e-01 |
| GO:BP | GO:0140235 | RNA polyadenylation at postsynapse | 1 | 1 | 3.09e-01 |
| GO:BP | GO:0072009 | nephron epithelium development | 3 | 86 | 3.09e-01 |
| GO:BP | GO:0071900 | regulation of protein serine/threonine kinase activity | 15 | 282 | 3.09e-01 |
| GO:BP | GO:2000626 | negative regulation of miRNA catabolic process | 1 | 1 | 3.09e-01 |
| GO:BP | GO:0032909 | regulation of transforming growth factor beta2 production | 1 | 9 | 3.09e-01 |
| GO:BP | GO:0032906 | transforming growth factor beta2 production | 1 | 9 | 3.09e-01 |
| GO:BP | GO:0035107 | appendage morphogenesis | 15 | 114 | 3.09e-01 |
| GO:BP | GO:0035108 | limb morphogenesis | 15 | 114 | 3.09e-01 |
| GO:BP | GO:0071307 | cellular response to vitamin K | 1 | 4 | 3.09e-01 |
| GO:BP | GO:0002286 | T cell activation involved in immune response | 1 | 55 | 3.09e-01 |
| GO:BP | GO:0098773 | skin epidermis development | 3 | 87 | 3.09e-01 |
| GO:BP | GO:0030029 | actin filament-based process | 1 | 687 | 3.09e-01 |
| GO:BP | GO:0010692 | regulation of alkaline phosphatase activity | 1 | 8 | 3.09e-01 |
| GO:BP | GO:0046686 | response to cadmium ion | 6 | 41 | 3.09e-01 |
| GO:BP | GO:0097576 | vacuole fusion | 2 | 12 | 3.09e-01 |
| GO:BP | GO:0035710 | CD4-positive, alpha-beta T cell activation | 1 | 64 | 3.09e-01 |
| GO:BP | GO:0035694 | mitochondrial protein catabolic process | 1 | 6 | 3.09e-01 |
| GO:BP | GO:1901628 | positive regulation of postsynaptic membrane organization | 1 | 2 | 3.09e-01 |
| GO:BP | GO:0044848 | biological phase | 1 | 9 | 3.09e-01 |
| GO:BP | GO:0046632 | alpha-beta T cell differentiation | 1 | 67 | 3.09e-01 |
| GO:BP | GO:0009066 | aspartate family amino acid metabolic process | 1 | 39 | 3.09e-01 |
| GO:BP | GO:0007420 | brain development | 1 | 591 | 3.09e-01 |
| GO:BP | GO:0045056 | transcytosis | 1 | 17 | 3.09e-01 |
| GO:BP | GO:0060338 | regulation of type I interferon-mediated signaling pathway | 5 | 35 | 3.09e-01 |
| GO:BP | GO:2000200 | regulation of ribosomal subunit export from nucleus | 1 | 1 | 3.09e-01 |
| GO:BP | GO:1904719 | positive regulation of AMPA glutamate receptor clustering | 1 | 2 | 3.09e-01 |
| GO:BP | GO:0043634 | polyadenylation-dependent ncRNA catabolic process | 2 | 8 | 3.09e-01 |
| GO:BP | GO:1903671 | negative regulation of sprouting angiogenesis | 2 | 11 | 3.09e-01 |
| GO:BP | GO:0009176 | pyrimidine deoxyribonucleoside monophosphate metabolic process | 2 | 9 | 3.09e-01 |
| GO:BP | GO:2000202 | positive regulation of ribosomal subunit export from nucleus | 1 | 1 | 3.09e-01 |
| GO:BP | GO:0043687 | post-translational protein modification | 1 | 64 | 3.09e-01 |
| GO:BP | GO:0060509 | type I pneumocyte differentiation | 2 | 8 | 3.09e-01 |
| GO:BP | GO:0044851 | hair cycle phase | 1 | 9 | 3.09e-01 |
| GO:BP | GO:1905664 | regulation of calcium ion import across plasma membrane | 3 | 8 | 3.09e-01 |
| GO:BP | GO:2000206 | regulation of ribosomal small subunit export from nucleus | 1 | 1 | 3.09e-01 |
| GO:BP | GO:0003211 | cardiac ventricle formation | 2 | 10 | 3.09e-01 |
| GO:BP | GO:1903894 | regulation of IRE1-mediated unfolded protein response | 2 | 14 | 3.09e-01 |
| GO:BP | GO:0043067 | regulation of programmed cell death | 4 | 1111 | 3.09e-01 |
| GO:BP | GO:0006520 | amino acid metabolic process | 2 | 222 | 3.09e-01 |
| GO:BP | GO:2000199 | positive regulation of ribonucleoprotein complex localization | 1 | 1 | 3.09e-01 |
| GO:BP | GO:0006643 | membrane lipid metabolic process | 1 | 173 | 3.09e-01 |
| GO:BP | GO:0015012 | heparan sulfate proteoglycan biosynthetic process | 1 | 27 | 3.09e-01 |
| GO:BP | GO:1905867 | epididymis development | 1 | 2 | 3.09e-01 |
| GO:BP | GO:0045795 | positive regulation of cell volume | 1 | 1 | 3.09e-01 |
| GO:BP | GO:0030521 | androgen receptor signaling pathway | 2 | 39 | 3.09e-01 |
| GO:BP | GO:0097345 | mitochondrial outer membrane permeabilization | 2 | 35 | 3.09e-01 |
| GO:BP | GO:0042492 | gamma-delta T cell differentiation | 2 | 7 | 3.09e-01 |
| GO:BP | GO:0016567 | protein ubiquitination | 1 | 717 | 3.09e-01 |
| GO:BP | GO:0051177 | meiotic sister chromatid cohesion | 1 | 12 | 3.09e-01 |
| GO:BP | GO:0071475 | cellular hyperosmotic salinity response | 1 | 6 | 3.09e-01 |
| GO:BP | GO:0006368 | transcription elongation by RNA polymerase II | 7 | 106 | 3.09e-01 |
| GO:BP | GO:1901988 | negative regulation of cell cycle phase transition | 7 | 235 | 3.09e-01 |
| GO:BP | GO:0000731 | DNA synthesis involved in DNA repair | 3 | 36 | 3.09e-01 |
| GO:BP | GO:0072310 | glomerular epithelial cell development | 1 | 9 | 3.09e-01 |
| GO:BP | GO:0120193 | tight junction organization | 1 | 52 | 3.09e-01 |
| GO:BP | GO:0006977 | DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest | 1 | 18 | 3.09e-01 |
| GO:BP | GO:0043069 | negative regulation of programmed cell death | 3 | 678 | 3.10e-01 |
| GO:BP | GO:0001935 | endothelial cell proliferation | 8 | 116 | 3.10e-01 |
| GO:BP | GO:0046544 | development of secondary male sexual characteristics | 1 | 1 | 3.10e-01 |
| GO:BP | GO:1904029 | regulation of cyclin-dependent protein kinase activity | 9 | 88 | 3.10e-01 |
| GO:BP | GO:1901610 | positive regulation of vesicle transport along microtubule | 1 | 3 | 3.10e-01 |
| GO:BP | GO:0098693 | regulation of synaptic vesicle cycle | 3 | 13 | 3.10e-01 |
| GO:BP | GO:0044557 | relaxation of smooth muscle | 2 | 9 | 3.10e-01 |
| GO:BP | GO:0097091 | synaptic vesicle clustering | 3 | 16 | 3.10e-01 |
| GO:BP | GO:0051574 | positive regulation of histone H3-K9 methylation | 1 | 5 | 3.10e-01 |
| GO:BP | GO:0061626 | pharyngeal arch artery morphogenesis | 1 | 10 | 3.10e-01 |
| GO:BP | GO:2001034 | positive regulation of double-strand break repair via nonhomologous end joining | 2 | 12 | 3.10e-01 |
| GO:BP | GO:0090400 | stress-induced premature senescence | 1 | 7 | 3.10e-01 |
| GO:BP | GO:1904637 | cellular response to ionomycin | 1 | 3 | 3.10e-01 |
| GO:BP | GO:0070997 | neuron death | 15 | 286 | 3.10e-01 |
| GO:BP | GO:0010811 | positive regulation of cell-substrate adhesion | 1 | 100 | 3.10e-01 |
| GO:BP | GO:0031274 | positive regulation of pseudopodium assembly | 2 | 11 | 3.10e-01 |
| GO:BP | GO:1904636 | response to ionomycin | 1 | 3 | 3.10e-01 |
| GO:BP | GO:0045204 | MAPK export from nucleus | 1 | 3 | 3.10e-01 |
| GO:BP | GO:0045214 | sarcomere organization | 2 | 43 | 3.10e-01 |
| GO:BP | GO:0031272 | regulation of pseudopodium assembly | 2 | 11 | 3.10e-01 |
| GO:BP | GO:0030336 | negative regulation of cell migration | 12 | 227 | 3.10e-01 |
| GO:BP | GO:0009200 | deoxyribonucleoside triphosphate metabolic process | 2 | 8 | 3.10e-01 |
| GO:BP | GO:1901381 | positive regulation of potassium ion transmembrane transport | 1 | 30 | 3.10e-01 |
| GO:BP | GO:0002572 | pro-T cell differentiation | 1 | 1 | 3.10e-01 |
| GO:BP | GO:0000956 | nuclear-transcribed mRNA catabolic process | 8 | 120 | 3.10e-01 |
| GO:BP | GO:0035883 | enteroendocrine cell differentiation | 4 | 24 | 3.10e-01 |
| GO:BP | GO:0032713 | negative regulation of interleukin-4 production | 2 | 5 | 3.10e-01 |
| GO:BP | GO:1901607 | alpha-amino acid biosynthetic process | 5 | 59 | 3.10e-01 |
| GO:BP | GO:0010838 | positive regulation of keratinocyte proliferation | 1 | 9 | 3.10e-01 |
| GO:BP | GO:0060236 | regulation of mitotic spindle organization | 4 | 42 | 3.10e-01 |
| GO:BP | GO:1905397 | activated CD8-positive, alpha-beta T cell apoptotic process | 1 | 3 | 3.10e-01 |
| GO:BP | GO:0031076 | embryonic camera-type eye development | 4 | 28 | 3.10e-01 |
| GO:BP | GO:0001178 | regulation of transcriptional start site selection at RNA polymerase II promoter | 1 | 1 | 3.10e-01 |
| GO:BP | GO:2000766 | negative regulation of cytoplasmic translation | 2 | 7 | 3.10e-01 |
| GO:BP | GO:0010835 | regulation of protein ADP-ribosylation | 2 | 9 | 3.10e-01 |
| GO:BP | GO:0046501 | protoporphyrinogen IX metabolic process | 1 | 11 | 3.10e-01 |
| GO:BP | GO:0006623 | protein targeting to vacuole | 1 | 42 | 3.10e-01 |
| GO:BP | GO:0060213 | positive regulation of nuclear-transcribed mRNA poly(A) tail shortening | 3 | 13 | 3.10e-01 |
| GO:BP | GO:0048640 | negative regulation of developmental growth | 6 | 95 | 3.10e-01 |
| GO:BP | GO:0060632 | regulation of microtubule-based movement | 3 | 31 | 3.10e-01 |
| GO:BP | GO:0060600 | dichotomous subdivision of an epithelial terminal unit | 2 | 8 | 3.10e-01 |
| GO:BP | GO:0035458 | cellular response to interferon-beta | 4 | 15 | 3.10e-01 |
| GO:BP | GO:0021849 | neuroblast division in subventricular zone | 1 | 3 | 3.10e-01 |
| GO:BP | GO:2000015 | regulation of determination of dorsal identity | 1 | 3 | 3.10e-01 |
| GO:BP | GO:0034405 | response to fluid shear stress | 4 | 31 | 3.10e-01 |
| GO:BP | GO:0048203 | vesicle targeting, trans-Golgi to endosome | 1 | 2 | 3.10e-01 |
| GO:BP | GO:0019080 | viral gene expression | 2 | 96 | 3.10e-01 |
| GO:BP | GO:1904377 | positive regulation of protein localization to cell periphery | 8 | 57 | 3.10e-01 |
| GO:BP | GO:0062042 | regulation of cardiac epithelial to mesenchymal transition | 1 | 10 | 3.10e-01 |
| GO:BP | GO:0071641 | negative regulation of macrophage inflammatory protein 1 alpha production | 1 | 2 | 3.10e-01 |
| GO:BP | GO:0045591 | positive regulation of regulatory T cell differentiation | 4 | 14 | 3.10e-01 |
| GO:BP | GO:0048207 | vesicle targeting, rough ER to cis-Golgi | 1 | 24 | 3.10e-01 |
| GO:BP | GO:0034242 | negative regulation of syncytium formation by plasma membrane fusion | 1 | 3 | 3.10e-01 |
| GO:BP | GO:0048208 | COPII vesicle coating | 1 | 24 | 3.10e-01 |
| GO:BP | GO:0071500 | cellular response to nitrosative stress | 2 | 6 | 3.10e-01 |
| GO:BP | GO:0099565 | chemical synaptic transmission, postsynaptic | 1 | 75 | 3.10e-01 |
| GO:BP | GO:0045621 | positive regulation of lymphocyte differentiation | 1 | 86 | 3.10e-01 |
| GO:BP | GO:0048293 | regulation of isotype switching to IgE isotypes | 2 | 5 | 3.10e-01 |
| GO:BP | GO:0048295 | positive regulation of isotype switching to IgE isotypes | 1 | 3 | 3.10e-01 |
| GO:BP | GO:0001895 | retina homeostasis | 1 | 44 | 3.10e-01 |
| GO:BP | GO:0001824 | blastocyst development | 11 | 94 | 3.10e-01 |
| GO:BP | GO:0033554 | cellular response to stress | 65 | 1681 | 3.10e-01 |
| GO:BP | GO:0021612 | facial nerve structural organization | 1 | 7 | 3.10e-01 |
| GO:BP | GO:1905402 | regulation of activated CD8-positive, alpha-beta T cell apoptotic process | 1 | 3 | 3.10e-01 |
| GO:BP | GO:1904179 | positive regulation of adipose tissue development | 1 | 6 | 3.10e-01 |
| GO:BP | GO:0060079 | excitatory postsynaptic potential | 1 | 70 | 3.10e-01 |
| GO:BP | GO:0021543 | pallium development | 3 | 139 | 3.10e-01 |
| GO:BP | GO:0006290 | pyrimidine dimer repair | 1 | 8 | 3.10e-01 |
| GO:BP | GO:0048289 | isotype switching to IgE isotypes | 2 | 5 | 3.10e-01 |
| GO:BP | GO:0051570 | regulation of histone H3-K9 methylation | 3 | 11 | 3.10e-01 |
| GO:BP | GO:0043401 | steroid hormone mediated signaling pathway | 9 | 112 | 3.10e-01 |
| GO:BP | GO:0043616 | keratinocyte proliferation | 7 | 38 | 3.10e-01 |
| GO:BP | GO:0015782 | CMP-N-acetylneuraminate transmembrane transport | 1 | 1 | 3.10e-01 |
| GO:BP | GO:0008347 | glial cell migration | 2 | 47 | 3.10e-01 |
| GO:BP | GO:1900244 | positive regulation of synaptic vesicle endocytosis | 2 | 4 | 3.10e-01 |
| GO:BP | GO:0072176 | nephric duct development | 2 | 12 | 3.10e-01 |
| GO:BP | GO:0002296 | T-helper 1 cell lineage commitment | 1 | 3 | 3.10e-01 |
| GO:BP | GO:0005977 | glycogen metabolic process | 6 | 64 | 3.10e-01 |
| GO:BP | GO:0015853 | adenine transport | 1 | 5 | 3.10e-01 |
| GO:BP | GO:0030194 | positive regulation of blood coagulation | 2 | 21 | 3.10e-01 |
| GO:BP | GO:0015855 | pyrimidine nucleobase transport | 1 | 3 | 3.10e-01 |
| GO:BP | GO:0015864 | pyrimidine nucleoside transport | 1 | 4 | 3.10e-01 |
| GO:BP | GO:0030177 | positive regulation of Wnt signaling pathway | 3 | 120 | 3.10e-01 |
| GO:BP | GO:0051489 | regulation of filopodium assembly | 3 | 44 | 3.10e-01 |
| GO:BP | GO:0007507 | heart development | 46 | 506 | 3.10e-01 |
| GO:BP | GO:1900048 | positive regulation of hemostasis | 2 | 21 | 3.10e-01 |
| GO:BP | GO:0001658 | branching involved in ureteric bud morphogenesis | 1 | 43 | 3.10e-01 |
| GO:BP | GO:0061082 | myeloid leukocyte cytokine production | 2 | 38 | 3.10e-01 |
| GO:BP | GO:0045717 | negative regulation of fatty acid biosynthetic process | 2 | 14 | 3.10e-01 |
| GO:BP | GO:1900027 | regulation of ruffle assembly | 5 | 23 | 3.10e-01 |
| GO:BP | GO:0002232 | leukocyte chemotaxis involved in inflammatory response | 1 | 4 | 3.10e-01 |
| GO:BP | GO:0098792 | xenophagy | 2 | 12 | 3.10e-01 |
| GO:BP | GO:0001661 | conditioned taste aversion | 1 | 2 | 3.10e-01 |
| GO:BP | GO:0016358 | dendrite development | 12 | 202 | 3.10e-01 |
| GO:BP | GO:0007613 | memory | 1 | 92 | 3.10e-01 |
| GO:BP | GO:0022409 | positive regulation of cell-cell adhesion | 13 | 189 | 3.10e-01 |
| GO:BP | GO:0045652 | regulation of megakaryocyte differentiation | 1 | 33 | 3.10e-01 |
| GO:BP | GO:0061000 | negative regulation of dendritic spine development | 1 | 10 | 3.10e-01 |
| GO:BP | GO:0033028 | myeloid cell apoptotic process | 4 | 25 | 3.10e-01 |
| GO:BP | GO:0015862 | uridine transport | 1 | 4 | 3.10e-01 |
| GO:BP | GO:0033559 | unsaturated fatty acid metabolic process | 4 | 66 | 3.10e-01 |
| GO:BP | GO:0040012 | regulation of locomotion | 14 | 763 | 3.10e-01 |
| GO:BP | GO:0086011 | membrane repolarization during action potential | 2 | 22 | 3.10e-01 |
| GO:BP | GO:0031638 | zymogen activation | 1 | 45 | 3.10e-01 |
| GO:BP | GO:0000266 | mitochondrial fission | 2 | 38 | 3.10e-01 |
| GO:BP | GO:0040029 | epigenetic regulation of gene expression | 16 | 153 | 3.10e-01 |
| GO:BP | GO:0061890 | positive regulation of astrocyte activation | 1 | 1 | 3.10e-01 |
| GO:BP | GO:0070384 | Harderian gland development | 1 | 4 | 3.10e-01 |
| GO:BP | GO:0090222 | centrosome-templated microtubule nucleation | 1 | 2 | 3.10e-01 |
| GO:BP | GO:0060322 | head development | 1 | 633 | 3.10e-01 |
| GO:BP | GO:0009615 | response to virus | 2 | 275 | 3.10e-01 |
| GO:BP | GO:0032446 | protein modification by small protein conjugation | 1 | 787 | 3.10e-01 |
| GO:BP | GO:0046394 | carboxylic acid biosynthetic process | 2 | 223 | 3.10e-01 |
| GO:BP | GO:0032231 | regulation of actin filament bundle assembly | 7 | 91 | 3.10e-01 |
| GO:BP | GO:0010424 | DNA methylation on cytosine within a CG sequence | 1 | 1 | 3.10e-01 |
| GO:BP | GO:0010519 | negative regulation of phospholipase activity | 1 | 7 | 3.10e-01 |
| GO:BP | GO:1905458 | positive regulation of lymphoid progenitor cell differentiation | 1 | 3 | 3.10e-01 |
| GO:BP | GO:0051987 | positive regulation of attachment of spindle microtubules to kinetochore | 2 | 11 | 3.10e-01 |
| GO:BP | GO:0010569 | regulation of double-strand break repair via homologous recombination | 3 | 63 | 3.10e-01 |
| GO:BP | GO:2000297 | negative regulation of synapse maturation | 1 | 1 | 3.10e-01 |
| GO:BP | GO:0031929 | TOR signaling | 11 | 115 | 3.10e-01 |
| GO:BP | GO:0090303 | positive regulation of wound healing | 3 | 45 | 3.10e-01 |
| GO:BP | GO:0032509 | endosome transport via multivesicular body sorting pathway | 4 | 41 | 3.10e-01 |
| GO:BP | GO:0060295 | regulation of cilium movement involved in cell motility | 2 | 12 | 3.10e-01 |
| GO:BP | GO:1905215 | negative regulation of RNA binding | 1 | 2 | 3.10e-01 |
| GO:BP | GO:1902019 | regulation of cilium-dependent cell motility | 2 | 12 | 3.10e-01 |
| GO:BP | GO:0070613 | regulation of protein processing | 1 | 47 | 3.10e-01 |
| GO:BP | GO:0048560 | establishment of anatomical structure orientation | 1 | 2 | 3.10e-01 |
| GO:BP | GO:0000076 | DNA replication checkpoint signaling | 2 | 15 | 3.10e-01 |
| GO:BP | GO:0110061 | regulation of angiotensin-activated signaling pathway | 1 | 2 | 3.10e-01 |
| GO:BP | GO:0006998 | nuclear envelope organization | 6 | 57 | 3.11e-01 |
| GO:BP | GO:0006885 | regulation of pH | 6 | 74 | 3.11e-01 |
| GO:BP | GO:0034250 | positive regulation of amide metabolic process | 15 | 149 | 3.11e-01 |
| GO:BP | GO:0006658 | phosphatidylserine metabolic process | 1 | 21 | 3.11e-01 |
| GO:BP | GO:0046209 | nitric oxide metabolic process | 6 | 55 | 3.11e-01 |
| GO:BP | GO:0002705 | positive regulation of leukocyte mediated immunity | 1 | 68 | 3.11e-01 |
| GO:BP | GO:0060996 | dendritic spine development | 11 | 80 | 3.11e-01 |
| GO:BP | GO:0071264 | positive regulation of translational initiation in response to starvation | 1 | 2 | 3.11e-01 |
| GO:BP | GO:0071262 | regulation of translational initiation in response to starvation | 1 | 2 | 3.11e-01 |
| GO:BP | GO:0002279 | mast cell activation involved in immune response | 4 | 31 | 3.11e-01 |
| GO:BP | GO:0001572 | lactosylceramide biosynthetic process | 1 | 2 | 3.12e-01 |
| GO:BP | GO:0046478 | lactosylceramide metabolic process | 1 | 2 | 3.12e-01 |
| GO:BP | GO:0016053 | organic acid biosynthetic process | 2 | 224 | 3.12e-01 |
| GO:BP | GO:0046320 | regulation of fatty acid oxidation | 3 | 31 | 3.13e-01 |
| GO:BP | GO:2000058 | regulation of ubiquitin-dependent protein catabolic process | 18 | 160 | 3.13e-01 |
| GO:BP | GO:0035490 | regulation of leukotriene production involved in inflammatory response | 1 | 1 | 3.13e-01 |
| GO:BP | GO:1901331 | positive regulation of odontoblast differentiation | 1 | 1 | 3.13e-01 |
| GO:BP | GO:0046602 | regulation of mitotic centrosome separation | 2 | 8 | 3.13e-01 |
| GO:BP | GO:0033023 | mast cell homeostasis | 1 | 4 | 3.13e-01 |
| GO:BP | GO:0051098 | regulation of binding | 2 | 317 | 3.13e-01 |
| GO:BP | GO:1903724 | positive regulation of centriole elongation | 1 | 5 | 3.13e-01 |
| GO:BP | GO:0036296 | response to increased oxygen levels | 2 | 25 | 3.13e-01 |
| GO:BP | GO:0033750 | ribosome localization | 3 | 15 | 3.13e-01 |
| GO:BP | GO:0070668 | positive regulation of mast cell proliferation | 1 | 4 | 3.13e-01 |
| GO:BP | GO:0001560 | regulation of cell growth by extracellular stimulus | 1 | 3 | 3.13e-01 |
| GO:BP | GO:0000054 | ribosomal subunit export from nucleus | 3 | 15 | 3.13e-01 |
| GO:BP | GO:1901657 | glycosyl compound metabolic process | 1 | 62 | 3.13e-01 |
| GO:BP | GO:2000232 | regulation of rRNA processing | 3 | 16 | 3.13e-01 |
| GO:BP | GO:0035491 | positive regulation of leukotriene production involved in inflammatory response | 1 | 1 | 3.13e-01 |
| GO:BP | GO:1904251 | regulation of bile acid metabolic process | 2 | 9 | 3.13e-01 |
| GO:BP | GO:0032831 | positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation | 2 | 2 | 3.13e-01 |
| GO:BP | GO:0032829 | regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation | 2 | 2 | 3.13e-01 |
| GO:BP | GO:1990418 | response to insulin-like growth factor stimulus | 1 | 2 | 3.13e-01 |
| GO:BP | GO:1902110 | positive regulation of mitochondrial membrane permeability involved in apoptotic process | 2 | 38 | 3.13e-01 |
| GO:BP | GO:0008635 | activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c | 2 | 7 | 3.13e-01 |
| GO:BP | GO:0060537 | muscle tissue development | 33 | 343 | 3.13e-01 |
| GO:BP | GO:0051453 | regulation of intracellular pH | 10 | 65 | 3.13e-01 |
| GO:BP | GO:0080164 | regulation of nitric oxide metabolic process | 5 | 40 | 3.13e-01 |
| GO:BP | GO:0060383 | positive regulation of DNA strand elongation | 1 | 1 | 3.13e-01 |
| GO:BP | GO:1903526 | negative regulation of membrane tubulation | 1 | 2 | 3.14e-01 |
| GO:BP | GO:0140507 | granzyme-mediated programmed cell death signaling pathway | 1 | 3 | 3.14e-01 |
| GO:BP | GO:0045727 | positive regulation of translation | 13 | 126 | 3.14e-01 |
| GO:BP | GO:0051726 | regulation of cell cycle | 26 | 956 | 3.14e-01 |
| GO:BP | GO:0032020 | ISG15-protein conjugation | 1 | 6 | 3.14e-01 |
| GO:BP | GO:0044042 | glucan metabolic process | 6 | 64 | 3.14e-01 |
| GO:BP | GO:0034377 | plasma lipoprotein particle assembly | 1 | 19 | 3.14e-01 |
| GO:BP | GO:0045589 | regulation of regulatory T cell differentiation | 5 | 21 | 3.14e-01 |
| GO:BP | GO:0050995 | negative regulation of lipid catabolic process | 1 | 14 | 3.14e-01 |
| GO:BP | GO:0070563 | negative regulation of vitamin D receptor signaling pathway | 1 | 2 | 3.14e-01 |
| GO:BP | GO:0099533 | positive regulation of presynaptic cytosolic calcium concentration | 1 | 1 | 3.14e-01 |
| GO:BP | GO:0042539 | hypotonic salinity response | 1 | 2 | 3.14e-01 |
| GO:BP | GO:1990748 | cellular detoxification | 1 | 76 | 3.14e-01 |
| GO:BP | GO:0071477 | cellular hypotonic salinity response | 1 | 2 | 3.14e-01 |
| GO:BP | GO:0051225 | spindle assembly | 3 | 120 | 3.14e-01 |
| GO:BP | GO:0003323 | type B pancreatic cell development | 3 | 19 | 3.14e-01 |
| GO:BP | GO:0060900 | embryonic camera-type eye formation | 2 | 8 | 3.14e-01 |
| GO:BP | GO:0006406 | mRNA export from nucleus | 5 | 59 | 3.14e-01 |
| GO:BP | GO:0032720 | negative regulation of tumor necrosis factor production | 5 | 32 | 3.14e-01 |
| GO:BP | GO:1903317 | regulation of protein maturation | 1 | 50 | 3.14e-01 |
| GO:BP | GO:0071383 | cellular response to steroid hormone stimulus | 13 | 166 | 3.14e-01 |
| GO:BP | GO:0030163 | protein catabolic process | 87 | 901 | 3.15e-01 |
| GO:BP | GO:0090305 | nucleic acid phosphodiester bond hydrolysis | 9 | 211 | 3.15e-01 |
| GO:BP | GO:2001057 | reactive nitrogen species metabolic process | 6 | 56 | 3.15e-01 |
| GO:BP | GO:0006538 | glutamate catabolic process | 1 | 7 | 3.15e-01 |
| GO:BP | GO:0009314 | response to radiation | 17 | 352 | 3.15e-01 |
| GO:BP | GO:0030038 | contractile actin filament bundle assembly | 7 | 94 | 3.15e-01 |
| GO:BP | GO:0043149 | stress fiber assembly | 7 | 94 | 3.15e-01 |
| GO:BP | GO:0010212 | response to ionizing radiation | 7 | 130 | 3.15e-01 |
| GO:BP | GO:0051091 | positive regulation of DNA-binding transcription factor activity | 3 | 199 | 3.16e-01 |
| GO:BP | GO:0032874 | positive regulation of stress-activated MAPK cascade | 4 | 96 | 3.16e-01 |
| GO:BP | GO:0043111 | replication fork arrest | 1 | 2 | 3.16e-01 |
| GO:BP | GO:0035601 | protein deacylation | 10 | 116 | 3.16e-01 |
| GO:BP | GO:0097533 | cellular stress response to acid chemical | 1 | 2 | 3.16e-01 |
| GO:BP | GO:0097532 | stress response to acid chemical | 1 | 2 | 3.16e-01 |
| GO:BP | GO:0043116 | negative regulation of vascular permeability | 1 | 16 | 3.16e-01 |
| GO:BP | GO:0032881 | regulation of polysaccharide metabolic process | 4 | 34 | 3.16e-01 |
| GO:BP | GO:0035441 | cell migration involved in vasculogenesis | 1 | 4 | 3.16e-01 |
| GO:BP | GO:0035457 | cellular response to interferon-alpha | 1 | 7 | 3.16e-01 |
| GO:BP | GO:0010563 | negative regulation of phosphorus metabolic process | 22 | 345 | 3.16e-01 |
| GO:BP | GO:0072720 | response to dithiothreitol | 1 | 2 | 3.16e-01 |
| GO:BP | GO:0006450 | regulation of translational fidelity | 2 | 16 | 3.16e-01 |
| GO:BP | GO:0006567 | threonine catabolic process | 1 | 3 | 3.16e-01 |
| GO:BP | GO:0014855 | striated muscle cell proliferation | 4 | 57 | 3.16e-01 |
| GO:BP | GO:0055111 | ingression involved in gastrulation with mouth forming second | 1 | 1 | 3.16e-01 |
| GO:BP | GO:0043010 | camera-type eye development | 3 | 236 | 3.16e-01 |
| GO:BP | GO:1902034 | negative regulation of hematopoietic stem cell proliferation | 1 | 2 | 3.16e-01 |
| GO:BP | GO:0060057 | apoptotic process involved in mammary gland involution | 1 | 3 | 3.16e-01 |
| GO:BP | GO:0043585 | nose morphogenesis | 1 | 3 | 3.16e-01 |
| GO:BP | GO:0090625 | siRNA-mediated gene silencing by mRNA destabilization | 1 | 1 | 3.16e-01 |
| GO:BP | GO:1904814 | regulation of protein localization to chromosome, telomeric region | 2 | 15 | 3.16e-01 |
| GO:BP | GO:0046381 | CMP-N-acetylneuraminate metabolic process | 1 | 1 | 3.16e-01 |
| GO:BP | GO:0019075 | virus maturation | 1 | 2 | 3.16e-01 |
| GO:BP | GO:0019184 | nonribosomal peptide biosynthetic process | 3 | 15 | 3.16e-01 |
| GO:BP | GO:0062002 | regulation of all-trans-retinyl-ester hydrolase, 11-cis retinol forming activity | 1 | 1 | 3.16e-01 |
| GO:BP | GO:0062003 | negative regulation of all-trans-retinyl-ester hydrolase, 11-cis retinol forming activity | 1 | 1 | 3.16e-01 |
| GO:BP | GO:0060675 | ureteric bud morphogenesis | 1 | 49 | 3.16e-01 |
| GO:BP | GO:0019432 | triglyceride biosynthetic process | 5 | 31 | 3.16e-01 |
| GO:BP | GO:0060928 | atrioventricular node cell development | 1 | 4 | 3.16e-01 |
| GO:BP | GO:0060058 | positive regulation of apoptotic process involved in mammary gland involution | 1 | 3 | 3.16e-01 |
| GO:BP | GO:0090308 | regulation of DNA methylation-dependent heterochromatin formation | 3 | 16 | 3.16e-01 |
| GO:BP | GO:0006670 | sphingosine metabolic process | 1 | 18 | 3.16e-01 |
| GO:BP | GO:0060284 | regulation of cell development | 5 | 605 | 3.16e-01 |
| GO:BP | GO:0060078 | regulation of postsynaptic membrane potential | 1 | 82 | 3.16e-01 |
| GO:BP | GO:0072594 | establishment of protein localization to organelle | 3 | 422 | 3.16e-01 |
| GO:BP | GO:0019941 | modification-dependent protein catabolic process | 61 | 625 | 3.16e-01 |
| GO:BP | GO:0060922 | atrioventricular node cell differentiation | 1 | 4 | 3.16e-01 |
| GO:BP | GO:0060932 | His-Purkinje system cell differentiation | 1 | 4 | 3.16e-01 |
| GO:BP | GO:1902571 | regulation of serine-type peptidase activity | 1 | 4 | 3.16e-01 |
| GO:BP | GO:0034633 | retinol transport | 1 | 1 | 3.16e-01 |
| GO:BP | GO:0042669 | regulation of inner ear auditory receptor cell fate specification | 1 | 1 | 3.16e-01 |
| GO:BP | GO:2000109 | regulation of macrophage apoptotic process | 1 | 6 | 3.16e-01 |
| GO:BP | GO:0010936 | negative regulation of macrophage cytokine production | 1 | 7 | 3.16e-01 |
| GO:BP | GO:0006884 | cell volume homeostasis | 5 | 24 | 3.16e-01 |
| GO:BP | GO:0003292 | cardiac septum cell differentiation | 1 | 4 | 3.16e-01 |
| GO:BP | GO:0042797 | tRNA transcription by RNA polymerase III | 2 | 7 | 3.16e-01 |
| GO:BP | GO:0002244 | hematopoietic progenitor cell differentiation | 7 | 109 | 3.16e-01 |
| GO:BP | GO:1900003 | regulation of serine-type endopeptidase activity | 1 | 4 | 3.16e-01 |
| GO:BP | GO:0045669 | positive regulation of osteoblast differentiation | 1 | 54 | 3.16e-01 |
| GO:BP | GO:0050872 | white fat cell differentiation | 3 | 15 | 3.16e-01 |
| GO:BP | GO:0046901 | tetrahydrofolylpolyglutamate biosynthetic process | 1 | 1 | 3.16e-01 |
| GO:BP | GO:0001542 | ovulation from ovarian follicle | 1 | 8 | 3.16e-01 |
| GO:BP | GO:0140766 | siRNA-mediated gene silencing | 1 | 1 | 3.16e-01 |
| GO:BP | GO:0022602 | ovulation cycle process | 2 | 37 | 3.16e-01 |
| GO:BP | GO:0031060 | regulation of histone methylation | 1 | 47 | 3.16e-01 |
| GO:BP | GO:0071409 | cellular response to cycloheximide | 1 | 2 | 3.16e-01 |
| GO:BP | GO:0060056 | mammary gland involution | 2 | 8 | 3.16e-01 |
| GO:BP | GO:0006367 | transcription initiation at RNA polymerase II promoter | 5 | 93 | 3.16e-01 |
| GO:BP | GO:0071462 | cellular response to water stimulus | 1 | 4 | 3.16e-01 |
| GO:BP | GO:0060979 | vasculogenesis involved in coronary vascular morphogenesis | 1 | 4 | 3.16e-01 |
| GO:BP | GO:0006055 | CMP-N-acetylneuraminate biosynthetic process | 1 | 1 | 3.16e-01 |
| GO:BP | GO:0045598 | regulation of fat cell differentiation | 9 | 102 | 3.16e-01 |
| GO:BP | GO:0006404 | RNA import into nucleus | 1 | 4 | 3.16e-01 |
| GO:BP | GO:0140861 | DNA repair-dependent chromatin remodeling | 1 | 6 | 3.16e-01 |
| GO:BP | GO:0021904 | dorsal/ventral neural tube patterning | 1 | 21 | 3.16e-01 |
| GO:BP | GO:0072171 | mesonephric tubule morphogenesis | 1 | 50 | 3.16e-01 |
| GO:BP | GO:0006886 | intracellular protein transport | 4 | 803 | 3.16e-01 |
| GO:BP | GO:0045830 | positive regulation of isotype switching | 2 | 19 | 3.16e-01 |
| GO:BP | GO:0006405 | RNA export from nucleus | 6 | 78 | 3.16e-01 |
| GO:BP | GO:0043633 | polyadenylation-dependent RNA catabolic process | 2 | 9 | 3.16e-01 |
| GO:BP | GO:0099022 | vesicle tethering | 1 | 31 | 3.16e-01 |
| GO:BP | GO:1902043 | positive regulation of extrinsic apoptotic signaling pathway via death domain receptors | 3 | 11 | 3.16e-01 |
| GO:BP | GO:0000086 | G2/M transition of mitotic cell cycle | 2 | 134 | 3.17e-01 |
| GO:BP | GO:0007219 | Notch signaling pathway | 12 | 146 | 3.17e-01 |
| GO:BP | GO:2001014 | regulation of skeletal muscle cell differentiation | 3 | 16 | 3.17e-01 |
| GO:BP | GO:1902686 | mitochondrial outer membrane permeabilization involved in programmed cell death | 2 | 40 | 3.17e-01 |
| GO:BP | GO:0070059 | intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | 4 | 56 | 3.17e-01 |
| GO:BP | GO:0009394 | 2’-deoxyribonucleotide metabolic process | 5 | 35 | 3.17e-01 |
| GO:BP | GO:0010387 | COP9 signalosome assembly | 1 | 3 | 3.17e-01 |
| GO:BP | GO:0031644 | regulation of nervous system process | 1 | 90 | 3.17e-01 |
| GO:BP | GO:0050820 | positive regulation of coagulation | 2 | 23 | 3.17e-01 |
| GO:BP | GO:1904994 | regulation of leukocyte adhesion to vascular endothelial cell | 2 | 16 | 3.17e-01 |
| GO:BP | GO:0043268 | positive regulation of potassium ion transport | 1 | 36 | 3.18e-01 |
| GO:BP | GO:2000077 | negative regulation of type B pancreatic cell development | 1 | 2 | 3.18e-01 |
| GO:BP | GO:1900273 | positive regulation of long-term synaptic potentiation | 4 | 19 | 3.18e-01 |
| GO:BP | GO:0006258 | UDP-glucose catabolic process | 1 | 2 | 3.18e-01 |
| GO:BP | GO:0097237 | cellular response to toxic substance | 1 | 82 | 3.19e-01 |
| GO:BP | GO:0060370 | susceptibility to T cell mediated cytotoxicity | 1 | 2 | 3.19e-01 |
| GO:BP | GO:0006607 | NLS-bearing protein import into nucleus | 3 | 18 | 3.19e-01 |
| GO:BP | GO:0000122 | negative regulation of transcription by RNA polymerase II | 13 | 740 | 3.19e-01 |
| GO:BP | GO:0042779 | tRNA 3’-trailer cleavage | 1 | 3 | 3.19e-01 |
| GO:BP | GO:0034244 | negative regulation of transcription elongation by RNA polymerase II | 3 | 17 | 3.19e-01 |
| GO:BP | GO:0060260 | regulation of transcription initiation by RNA polymerase II | 1 | 69 | 3.19e-01 |
| GO:BP | GO:0048320 | axial mesoderm formation | 1 | 2 | 3.19e-01 |
| GO:BP | GO:1901608 | regulation of vesicle transport along microtubule | 1 | 4 | 3.19e-01 |
| GO:BP | GO:2000622 | regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 2 | 12 | 3.19e-01 |
| GO:BP | GO:0072237 | metanephric proximal tubule development | 1 | 3 | 3.19e-01 |
| GO:BP | GO:0072156 | distal tubule morphogenesis | 1 | 3 | 3.19e-01 |
| GO:BP | GO:0032511 | late endosome to vacuole transport via multivesicular body sorting pathway | 3 | 27 | 3.19e-01 |
| GO:BP | GO:0009648 | photoperiodism | 3 | 28 | 3.21e-01 |
| GO:BP | GO:0070304 | positive regulation of stress-activated protein kinase signaling cascade | 4 | 98 | 3.21e-01 |
| GO:BP | GO:0140212 | regulation of long-chain fatty acid import into cell | 2 | 7 | 3.21e-01 |
| GO:BP | GO:0060041 | retina development in camera-type eye | 2 | 109 | 3.21e-01 |
| GO:BP | GO:0042044 | fluid transport | 2 | 17 | 3.21e-01 |
| GO:BP | GO:0045892 | negative regulation of DNA-templated transcription | 23 | 1015 | 3.21e-01 |
| GO:BP | GO:0070647 | protein modification by small protein conjugation or removal | 1 | 898 | 3.21e-01 |
| GO:BP | GO:0033032 | regulation of myeloid cell apoptotic process | 3 | 20 | 3.21e-01 |
| GO:BP | GO:0071276 | cellular response to cadmium ion | 3 | 24 | 3.21e-01 |
| GO:BP | GO:0021508 | floor plate formation | 1 | 3 | 3.21e-01 |
| GO:BP | GO:0098700 | neurotransmitter loading into synaptic vesicle | 1 | 1 | 3.21e-01 |
| GO:BP | GO:0030010 | establishment of cell polarity | 1 | 134 | 3.21e-01 |
| GO:BP | GO:0060538 | skeletal muscle organ development | 15 | 139 | 3.21e-01 |
| GO:BP | GO:0006690 | icosanoid metabolic process | 1 | 60 | 3.21e-01 |
| GO:BP | GO:0051092 | positive regulation of NF-kappaB transcription factor activity | 1 | 116 | 3.21e-01 |
| GO:BP | GO:0046337 | phosphatidylethanolamine metabolic process | 1 | 19 | 3.21e-01 |
| GO:BP | GO:0065005 | protein-lipid complex assembly | 1 | 21 | 3.21e-01 |
| GO:BP | GO:0021855 | hypothalamus cell migration | 2 | 6 | 3.21e-01 |
| GO:BP | GO:0022008 | neurogenesis | 13 | 1294 | 3.21e-01 |
| GO:BP | GO:0071684 | organism emergence from protective structure | 1 | 23 | 3.21e-01 |
| GO:BP | GO:0045597 | positive regulation of cell differentiation | 5 | 620 | 3.21e-01 |
| GO:BP | GO:0035188 | hatching | 1 | 23 | 3.21e-01 |
| GO:BP | GO:0003181 | atrioventricular valve morphogenesis | 2 | 25 | 3.21e-01 |
| GO:BP | GO:0001835 | blastocyst hatching | 1 | 23 | 3.21e-01 |
| GO:BP | GO:0071638 | negative regulation of monocyte chemotactic protein-1 production | 1 | 3 | 3.22e-01 |
| GO:BP | GO:1903507 | negative regulation of nucleic acid-templated transcription | 23 | 1017 | 3.22e-01 |
| GO:BP | GO:0097531 | mast cell migration | 2 | 12 | 3.22e-01 |
| GO:BP | GO:0010948 | negative regulation of cell cycle process | 8 | 273 | 3.22e-01 |
| GO:BP | GO:0060548 | negative regulation of cell death | 3 | 756 | 3.22e-01 |
| GO:BP | GO:0043161 | proteasome-mediated ubiquitin-dependent protein catabolic process | 41 | 427 | 3.22e-01 |
| GO:BP | GO:0010941 | regulation of cell death | 4 | 1219 | 3.22e-01 |
| GO:BP | GO:0072348 | sulfur compound transport | 6 | 39 | 3.22e-01 |
| GO:BP | GO:0097166 | lens epithelial cell proliferation | 1 | 1 | 3.22e-01 |
| GO:BP | GO:0042326 | negative regulation of phosphorylation | 23 | 300 | 3.22e-01 |
| GO:BP | GO:0046519 | sphingoid metabolic process | 1 | 19 | 3.22e-01 |
| GO:BP | GO:0090224 | regulation of spindle organization | 4 | 45 | 3.22e-01 |
| GO:BP | GO:0021516 | dorsal spinal cord development | 1 | 7 | 3.22e-01 |
| GO:BP | GO:0030307 | positive regulation of cell growth | 2 | 135 | 3.22e-01 |
| GO:BP | GO:0010637 | negative regulation of mitochondrial fusion | 1 | 8 | 3.22e-01 |
| GO:BP | GO:0048102 | autophagic cell death | 1 | 6 | 3.22e-01 |
| GO:BP | GO:1903556 | negative regulation of tumor necrosis factor superfamily cytokine production | 5 | 33 | 3.22e-01 |
| GO:BP | GO:0036035 | osteoclast development | 1 | 10 | 3.22e-01 |
| GO:BP | GO:0006610 | ribosomal protein import into nucleus | 1 | 4 | 3.22e-01 |
| GO:BP | GO:1905281 | positive regulation of retrograde transport, endosome to Golgi | 1 | 2 | 3.22e-01 |
| GO:BP | GO:0051798 | positive regulation of hair follicle development | 1 | 9 | 3.22e-01 |
| GO:BP | GO:0034059 | response to anoxia | 1 | 3 | 3.22e-01 |
| GO:BP | GO:0042416 | dopamine biosynthetic process | 1 | 8 | 3.22e-01 |
| GO:BP | GO:2000010 | positive regulation of protein localization to cell surface | 2 | 16 | 3.22e-01 |
| GO:BP | GO:0048103 | somatic stem cell division | 1 | 10 | 3.22e-01 |
| GO:BP | GO:2001111 | positive regulation of lens epithelial cell proliferation | 1 | 1 | 3.22e-01 |
| GO:BP | GO:0061386 | closure of optic fissure | 1 | 2 | 3.22e-01 |
| GO:BP | GO:2001109 | regulation of lens epithelial cell proliferation | 1 | 1 | 3.22e-01 |
| GO:BP | GO:0048199 | vesicle targeting, to, from or within Golgi | 1 | 31 | 3.22e-01 |
| GO:BP | GO:0071376 | cellular response to corticotropin-releasing hormone stimulus | 1 | 3 | 3.23e-01 |
| GO:BP | GO:0043435 | response to corticotropin-releasing hormone | 1 | 3 | 3.23e-01 |
| GO:BP | GO:1904155 | DN2 thymocyte differentiation | 1 | 1 | 3.23e-01 |
| GO:BP | GO:0031669 | cellular response to nutrient levels | 14 | 194 | 3.23e-01 |
| GO:BP | GO:0019303 | D-ribose catabolic process | 1 | 2 | 3.23e-01 |
| GO:BP | GO:0003431 | growth plate cartilage chondrocyte development | 1 | 5 | 3.23e-01 |
| GO:BP | GO:2001244 | positive regulation of intrinsic apoptotic signaling pathway | 3 | 52 | 3.23e-01 |
| GO:BP | GO:1901798 | positive regulation of signal transduction by p53 class mediator | 3 | 28 | 3.23e-01 |
| GO:BP | GO:0006656 | phosphatidylcholine biosynthetic process | 1 | 25 | 3.23e-01 |
| GO:BP | GO:0001818 | negative regulation of cytokine production | 1 | 165 | 3.24e-01 |
| GO:BP | GO:0045838 | positive regulation of membrane potential | 2 | 12 | 3.24e-01 |
| GO:BP | GO:0045986 | negative regulation of smooth muscle contraction | 3 | 12 | 3.24e-01 |
| GO:BP | GO:0097242 | amyloid-beta clearance | 1 | 27 | 3.24e-01 |
| GO:BP | GO:0009262 | deoxyribonucleotide metabolic process | 5 | 36 | 3.24e-01 |
| GO:BP | GO:0021610 | facial nerve morphogenesis | 1 | 8 | 3.24e-01 |
| GO:BP | GO:0035735 | intraciliary transport involved in cilium assembly | 2 | 7 | 3.24e-01 |
| GO:BP | GO:1902108 | regulation of mitochondrial membrane permeability involved in apoptotic process | 2 | 42 | 3.24e-01 |
| GO:BP | GO:0040011 | locomotion | 17 | 954 | 3.24e-01 |
| GO:BP | GO:1904293 | negative regulation of ERAD pathway | 1 | 6 | 3.24e-01 |
| GO:BP | GO:0021561 | facial nerve development | 1 | 8 | 3.24e-01 |
| GO:BP | GO:0019692 | deoxyribose phosphate metabolic process | 5 | 36 | 3.24e-01 |
| GO:BP | GO:0021684 | cerebellar granular layer formation | 1 | 6 | 3.24e-01 |
| GO:BP | GO:0021707 | cerebellar granule cell differentiation | 1 | 6 | 3.24e-01 |
| GO:BP | GO:0045932 | negative regulation of muscle contraction | 4 | 20 | 3.24e-01 |
| GO:BP | GO:0051493 | regulation of cytoskeleton organization | 25 | 459 | 3.24e-01 |
| GO:BP | GO:0060416 | response to growth hormone | 5 | 25 | 3.24e-01 |
| GO:BP | GO:0097479 | synaptic vesicle localization | 6 | 50 | 3.24e-01 |
| GO:BP | GO:0060998 | regulation of dendritic spine development | 6 | 48 | 3.24e-01 |
| GO:BP | GO:0060152 | microtubule-based peroxisome localization | 1 | 2 | 3.24e-01 |
| GO:BP | GO:0060151 | peroxisome localization | 1 | 2 | 3.24e-01 |
| GO:BP | GO:0016259 | selenocysteine metabolic process | 1 | 2 | 3.25e-01 |
| GO:BP | GO:0033034 | positive regulation of myeloid cell apoptotic process | 1 | 6 | 3.25e-01 |
| GO:BP | GO:0031392 | regulation of prostaglandin biosynthetic process | 1 | 6 | 3.25e-01 |
| GO:BP | GO:0010586 | miRNA metabolic process | 11 | 81 | 3.25e-01 |
| GO:BP | GO:0002091 | negative regulation of receptor internalization | 2 | 14 | 3.25e-01 |
| GO:BP | GO:0060212 | negative regulation of nuclear-transcribed mRNA poly(A) tail shortening | 1 | 3 | 3.26e-01 |
| GO:BP | GO:0030575 | nuclear body organization | 2 | 14 | 3.26e-01 |
| GO:BP | GO:2001037 | positive regulation of tongue muscle cell differentiation | 1 | 1 | 3.26e-01 |
| GO:BP | GO:0001708 | cell fate specification | 2 | 56 | 3.26e-01 |
| GO:BP | GO:0035981 | tongue muscle cell differentiation | 1 | 1 | 3.26e-01 |
| GO:BP | GO:2001035 | regulation of tongue muscle cell differentiation | 1 | 1 | 3.26e-01 |
| GO:BP | GO:0030540 | female genitalia development | 2 | 14 | 3.26e-01 |
| GO:BP | GO:0072078 | nephron tubule morphogenesis | 1 | 57 | 3.26e-01 |
| GO:BP | GO:0042147 | retrograde transport, endosome to Golgi | 7 | 88 | 3.26e-01 |
| GO:BP | GO:0032233 | positive regulation of actin filament bundle assembly | 3 | 54 | 3.26e-01 |
| GO:BP | GO:0038202 | TORC1 signaling | 6 | 58 | 3.26e-01 |
| GO:BP | GO:0009649 | entrainment of circadian clock | 3 | 31 | 3.26e-01 |
| GO:BP | GO:0019076 | viral release from host cell | 3 | 28 | 3.26e-01 |
| GO:BP | GO:0035891 | exit from host cell | 3 | 28 | 3.26e-01 |
| GO:BP | GO:0072331 | signal transduction by p53 class mediator | 8 | 161 | 3.26e-01 |
| GO:BP | GO:0060412 | ventricular septum morphogenesis | 4 | 40 | 3.26e-01 |
| GO:BP | GO:1901890 | positive regulation of cell junction assembly | 1 | 82 | 3.26e-01 |
| GO:BP | GO:0070141 | response to UV-A | 3 | 11 | 3.26e-01 |
| GO:BP | GO:0090204 | protein localization to nuclear pore | 1 | 3 | 3.26e-01 |
| GO:BP | GO:0061418 | regulation of transcription from RNA polymerase II promoter in response to hypoxia | 2 | 11 | 3.27e-01 |
| GO:BP | GO:0007519 | skeletal muscle tissue development | 14 | 129 | 3.27e-01 |
| GO:BP | GO:1903774 | positive regulation of viral budding via host ESCRT complex | 1 | 3 | 3.27e-01 |
| GO:BP | GO:0061738 | late endosomal microautophagy | 1 | 3 | 3.27e-01 |
| GO:BP | GO:1902174 | positive regulation of keratinocyte apoptotic process | 1 | 3 | 3.27e-01 |
| GO:BP | GO:0050806 | positive regulation of synaptic transmission | 1 | 106 | 3.27e-01 |
| GO:BP | GO:0001188 | RNA polymerase I preinitiation complex assembly | 2 | 9 | 3.27e-01 |
| GO:BP | GO:0043217 | myelin maintenance | 3 | 15 | 3.28e-01 |
| GO:BP | GO:1990138 | neuron projection extension | 2 | 148 | 3.28e-01 |
| GO:BP | GO:0035794 | positive regulation of mitochondrial membrane permeability | 2 | 43 | 3.28e-01 |
| GO:BP | GO:0051650 | establishment of vesicle localization | 2 | 175 | 3.28e-01 |
| GO:BP | GO:0031167 | rRNA methylation | 1 | 24 | 3.28e-01 |
| GO:BP | GO:0010972 | negative regulation of G2/M transition of mitotic cell cycle | 1 | 60 | 3.28e-01 |
| GO:BP | GO:0072088 | nephron epithelium morphogenesis | 1 | 59 | 3.29e-01 |
| GO:BP | GO:2000142 | regulation of DNA-templated transcription initiation | 1 | 76 | 3.29e-01 |
| GO:BP | GO:1904505 | regulation of telomere maintenance in response to DNA damage | 3 | 17 | 3.29e-01 |
| GO:BP | GO:1902742 | apoptotic process involved in development | 3 | 30 | 3.29e-01 |
| GO:BP | GO:0051298 | centrosome duplication | 6 | 68 | 3.29e-01 |
| GO:BP | GO:0071248 | cellular response to metal ion | 18 | 139 | 3.29e-01 |
| GO:BP | GO:0098732 | macromolecule deacylation | 10 | 119 | 3.29e-01 |
| GO:BP | GO:0006096 | glycolytic process | 1 | 70 | 3.29e-01 |
| GO:BP | GO:1905691 | lipid droplet disassembly | 1 | 7 | 3.30e-01 |
| GO:BP | GO:2000146 | negative regulation of cell motility | 12 | 236 | 3.30e-01 |
| GO:BP | GO:0043387 | mycotoxin catabolic process | 1 | 2 | 3.30e-01 |
| GO:BP | GO:0035278 | miRNA-mediated gene silencing by inhibition of translation | 2 | 15 | 3.30e-01 |
| GO:BP | GO:0046725 | negative regulation by virus of viral protein levels in host cell | 1 | 2 | 3.30e-01 |
| GO:BP | GO:0032688 | negative regulation of interferon-beta production | 2 | 10 | 3.30e-01 |
| GO:BP | GO:0032429 | regulation of phospholipase A2 activity | 1 | 8 | 3.30e-01 |
| GO:BP | GO:1900028 | negative regulation of ruffle assembly | 2 | 4 | 3.30e-01 |
| GO:BP | GO:0060021 | roof of mouth development | 9 | 71 | 3.30e-01 |
| GO:BP | GO:0034471 | ncRNA 5’-end processing | 1 | 5 | 3.30e-01 |
| GO:BP | GO:0072183 | negative regulation of nephron tubule epithelial cell differentiation | 1 | 2 | 3.30e-01 |
| GO:BP | GO:0000967 | rRNA 5’-end processing | 1 | 5 | 3.30e-01 |
| GO:BP | GO:1905214 | regulation of RNA binding | 2 | 13 | 3.30e-01 |
| GO:BP | GO:1902750 | negative regulation of cell cycle G2/M phase transition | 1 | 62 | 3.30e-01 |
| GO:BP | GO:1901377 | organic heteropentacyclic compound catabolic process | 1 | 2 | 3.30e-01 |
| GO:BP | GO:0046223 | aflatoxin catabolic process | 1 | 2 | 3.30e-01 |
| GO:BP | GO:0031532 | actin cytoskeleton reorganization | 5 | 96 | 3.30e-01 |
| GO:BP | GO:0000472 | endonucleolytic cleavage to generate mature 5’-end of SSU-rRNA from (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 1 | 5 | 3.30e-01 |
| GO:BP | GO:0019372 | lipoxygenase pathway | 1 | 5 | 3.30e-01 |
| GO:BP | GO:0001820 | serotonin secretion | 1 | 5 | 3.30e-01 |
| GO:BP | GO:0045636 | positive regulation of melanocyte differentiation | 1 | 4 | 3.30e-01 |
| GO:BP | GO:0002822 | regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 1 | 97 | 3.30e-01 |
| GO:BP | GO:0045954 | positive regulation of natural killer cell mediated cytotoxicity | 3 | 10 | 3.30e-01 |
| GO:BP | GO:0009407 | toxin catabolic process | 1 | 2 | 3.30e-01 |
| GO:BP | GO:0072666 | establishment of protein localization to vacuole | 1 | 55 | 3.30e-01 |
| GO:BP | GO:0046631 | alpha-beta T cell activation | 1 | 89 | 3.30e-01 |
| GO:BP | GO:0019085 | early viral transcription | 1 | 2 | 3.30e-01 |
| GO:BP | GO:0045739 | positive regulation of DNA repair | 4 | 120 | 3.30e-01 |
| GO:BP | GO:1903786 | regulation of glutathione biosynthetic process | 1 | 2 | 3.30e-01 |
| GO:BP | GO:0002706 | regulation of lymphocyte mediated immunity | 1 | 83 | 3.30e-01 |
| GO:BP | GO:0008206 | bile acid metabolic process | 4 | 34 | 3.30e-01 |
| GO:BP | GO:0048012 | hepatocyte growth factor receptor signaling pathway | 2 | 10 | 3.30e-01 |
| GO:BP | GO:1901987 | regulation of cell cycle phase transition | 18 | 391 | 3.30e-01 |
| GO:BP | GO:0060179 | male mating behavior | 2 | 5 | 3.30e-01 |
| GO:BP | GO:1901214 | regulation of neuron death | 13 | 246 | 3.30e-01 |
| GO:BP | GO:1901998 | toxin transport | 3 | 37 | 3.30e-01 |
| GO:BP | GO:0106217 | tRNA C3-cytosine methylation | 1 | 2 | 3.30e-01 |
| GO:BP | GO:1901165 | positive regulation of trophoblast cell migration | 2 | 6 | 3.30e-01 |
| GO:BP | GO:0003376 | sphingosine-1-phosphate receptor signaling pathway | 2 | 10 | 3.30e-01 |
| GO:BP | GO:0010730 | negative regulation of hydrogen peroxide biosynthetic process | 1 | 2 | 3.30e-01 |
| GO:BP | GO:1990743 | protein sialylation | 1 | 5 | 3.30e-01 |
| GO:BP | GO:1901626 | regulation of postsynaptic membrane organization | 1 | 2 | 3.30e-01 |
| GO:BP | GO:0048147 | negative regulation of fibroblast proliferation | 3 | 31 | 3.30e-01 |
| GO:BP | GO:1903999 | negative regulation of eating behavior | 1 | 1 | 3.30e-01 |
| GO:BP | GO:0009162 | deoxyribonucleoside monophosphate metabolic process | 3 | 18 | 3.30e-01 |
| GO:BP | GO:0061333 | renal tubule morphogenesis | 1 | 61 | 3.30e-01 |
| GO:BP | GO:0072028 | nephron morphogenesis | 1 | 62 | 3.30e-01 |
| GO:BP | GO:1905799 | regulation of intraciliary retrograde transport | 1 | 2 | 3.30e-01 |
| GO:BP | GO:0003340 | negative regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis | 1 | 2 | 3.30e-01 |
| GO:BP | GO:0098754 | detoxification | 1 | 91 | 3.30e-01 |
| GO:BP | GO:0071468 | cellular response to acidic pH | 1 | 10 | 3.30e-01 |
| GO:BP | GO:0070664 | negative regulation of leukocyte proliferation | 10 | 51 | 3.30e-01 |
| GO:BP | GO:0097212 | lysosomal membrane organization | 2 | 13 | 3.30e-01 |
| GO:BP | GO:0062033 | positive regulation of mitotic sister chromatid segregation | 1 | 6 | 3.30e-01 |
| GO:BP | GO:0007625 | grooming behavior | 3 | 10 | 3.30e-01 |
| GO:BP | GO:1902679 | negative regulation of RNA biosynthetic process | 23 | 1026 | 3.30e-01 |
| GO:BP | GO:0031118 | rRNA pseudouridine synthesis | 2 | 10 | 3.30e-01 |
| GO:BP | GO:0051608 | histamine transport | 3 | 11 | 3.30e-01 |
| GO:BP | GO:1901642 | nucleoside transmembrane transport | 1 | 6 | 3.30e-01 |
| GO:BP | GO:0003018 | vascular process in circulatory system | 3 | 198 | 3.30e-01 |
| GO:BP | GO:0050893 | sensory processing | 1 | 4 | 3.30e-01 |
| GO:BP | GO:1901135 | carbohydrate derivative metabolic process | 3 | 843 | 3.30e-01 |
| GO:BP | GO:0019827 | stem cell population maintenance | 7 | 149 | 3.30e-01 |
| GO:BP | GO:0006566 | threonine metabolic process | 1 | 4 | 3.30e-01 |
| GO:BP | GO:0001778 | plasma membrane repair | 3 | 28 | 3.30e-01 |
| GO:BP | GO:0009082 | branched-chain amino acid biosynthetic process | 1 | 4 | 3.30e-01 |
| GO:BP | GO:1904204 | regulation of skeletal muscle hypertrophy | 1 | 1 | 3.30e-01 |
| GO:BP | GO:1905168 | positive regulation of double-strand break repair via homologous recombination | 2 | 35 | 3.30e-01 |
| GO:BP | GO:1902115 | regulation of organelle assembly | 19 | 186 | 3.30e-01 |
| GO:BP | GO:0002712 | regulation of B cell mediated immunity | 3 | 39 | 3.30e-01 |
| GO:BP | GO:0031295 | T cell costimulation | 3 | 22 | 3.30e-01 |
| GO:BP | GO:0044839 | cell cycle G2/M phase transition | 2 | 149 | 3.30e-01 |
| GO:BP | GO:0034122 | negative regulation of toll-like receptor signaling pathway | 2 | 13 | 3.30e-01 |
| GO:BP | GO:0003206 | cardiac chamber morphogenesis | 9 | 109 | 3.30e-01 |
| GO:BP | GO:0021604 | cranial nerve structural organization | 1 | 8 | 3.30e-01 |
| GO:BP | GO:0009240 | isopentenyl diphosphate biosynthetic process | 1 | 5 | 3.30e-01 |
| GO:BP | GO:0014911 | positive regulation of smooth muscle cell migration | 4 | 30 | 3.30e-01 |
| GO:BP | GO:0010977 | negative regulation of neuron projection development | 15 | 117 | 3.30e-01 |
| GO:BP | GO:0030193 | regulation of blood coagulation | 3 | 50 | 3.30e-01 |
| GO:BP | GO:1903039 | positive regulation of leukocyte cell-cell adhesion | 11 | 157 | 3.30e-01 |
| GO:BP | GO:0046490 | isopentenyl diphosphate metabolic process | 1 | 5 | 3.30e-01 |
| GO:BP | GO:0045947 | negative regulation of translational initiation | 2 | 18 | 3.30e-01 |
| GO:BP | GO:0006048 | UDP-N-acetylglucosamine biosynthetic process | 2 | 9 | 3.30e-01 |
| GO:BP | GO:0098914 | membrane repolarization during atrial cardiac muscle cell action potential | 1 | 6 | 3.30e-01 |
| GO:BP | GO:0033210 | leptin-mediated signaling pathway | 1 | 10 | 3.30e-01 |
| GO:BP | GO:0061912 | selective autophagy | 11 | 90 | 3.30e-01 |
| GO:BP | GO:1990182 | exosomal secretion | 3 | 18 | 3.30e-01 |
| GO:BP | GO:0051152 | positive regulation of smooth muscle cell differentiation | 1 | 10 | 3.30e-01 |
| GO:BP | GO:0045580 | regulation of T cell differentiation | 1 | 110 | 3.30e-01 |
| GO:BP | GO:0071374 | cellular response to parathyroid hormone stimulus | 2 | 7 | 3.30e-01 |
| GO:BP | GO:0002889 | regulation of immunoglobulin mediated immune response | 3 | 39 | 3.30e-01 |
| GO:BP | GO:0035904 | aorta development | 2 | 50 | 3.30e-01 |
| GO:BP | GO:1903427 | negative regulation of reactive oxygen species biosynthetic process | 2 | 12 | 3.30e-01 |
| GO:BP | GO:0009130 | pyrimidine nucleoside monophosphate biosynthetic process | 2 | 13 | 3.30e-01 |
| GO:BP | GO:0048596 | embryonic camera-type eye morphogenesis | 3 | 18 | 3.30e-01 |
| GO:BP | GO:0001712 | ectodermal cell fate commitment | 1 | 2 | 3.30e-01 |
| GO:BP | GO:0010631 | epithelial cell migration | 16 | 252 | 3.30e-01 |
| GO:BP | GO:1905475 | regulation of protein localization to membrane | 1 | 150 | 3.30e-01 |
| GO:BP | GO:0090148 | membrane fission | 4 | 44 | 3.30e-01 |
| GO:BP | GO:0031061 | negative regulation of histone methylation | 1 | 9 | 3.30e-01 |
| GO:BP | GO:1902437 | positive regulation of male mating behavior | 1 | 2 | 3.31e-01 |
| GO:BP | GO:2000402 | negative regulation of lymphocyte migration | 2 | 10 | 3.31e-01 |
| GO:BP | GO:1902435 | regulation of male mating behavior | 1 | 2 | 3.31e-01 |
| GO:BP | GO:1904862 | inhibitory synapse assembly | 1 | 13 | 3.31e-01 |
| GO:BP | GO:1904780 | negative regulation of protein localization to centrosome | 1 | 2 | 3.31e-01 |
| GO:BP | GO:1904253 | positive regulation of bile acid metabolic process | 1 | 3 | 3.31e-01 |
| GO:BP | GO:0032079 | positive regulation of endodeoxyribonuclease activity | 1 | 4 | 3.31e-01 |
| GO:BP | GO:0070859 | positive regulation of bile acid biosynthetic process | 1 | 3 | 3.31e-01 |
| GO:BP | GO:0009267 | cellular response to starvation | 11 | 152 | 3.31e-01 |
| GO:BP | GO:0035994 | response to muscle stretch | 3 | 26 | 3.31e-01 |
| GO:BP | GO:0060086 | circadian temperature homeostasis | 1 | 3 | 3.31e-01 |
| GO:BP | GO:0045948 | positive regulation of translational initiation | 3 | 23 | 3.31e-01 |
| GO:BP | GO:0140213 | negative regulation of long-chain fatty acid import into cell | 1 | 4 | 3.31e-01 |
| GO:BP | GO:0061889 | negative regulation of astrocyte activation | 1 | 2 | 3.31e-01 |
| GO:BP | GO:0010748 | negative regulation of long-chain fatty acid import across plasma membrane | 1 | 4 | 3.31e-01 |
| GO:BP | GO:0048311 | mitochondrion distribution | 1 | 14 | 3.31e-01 |
| GO:BP | GO:1990535 | neuron projection maintenance | 2 | 9 | 3.31e-01 |
| GO:BP | GO:0000271 | polysaccharide biosynthetic process | 5 | 53 | 3.31e-01 |
| GO:BP | GO:0090092 | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 5 | 230 | 3.31e-01 |
| GO:BP | GO:0017182 | peptidyl-diphthamide metabolic process | 2 | 7 | 3.31e-01 |
| GO:BP | GO:1904752 | regulation of vascular associated smooth muscle cell migration | 4 | 23 | 3.31e-01 |
| GO:BP | GO:1902803 | regulation of synaptic vesicle transport | 1 | 5 | 3.31e-01 |
| GO:BP | GO:0072521 | purine-containing compound metabolic process | 2 | 390 | 3.31e-01 |
| GO:BP | GO:0071888 | macrophage apoptotic process | 2 | 9 | 3.31e-01 |
| GO:BP | GO:0017183 | peptidyl-diphthamide biosynthetic process from peptidyl-histidine | 2 | 7 | 3.31e-01 |
| GO:BP | GO:1901652 | response to peptide | 31 | 377 | 3.32e-01 |
| GO:BP | GO:0032682 | negative regulation of chemokine production | 2 | 12 | 3.32e-01 |
| GO:BP | GO:0061001 | regulation of dendritic spine morphogenesis | 6 | 39 | 3.32e-01 |
| GO:BP | GO:0042149 | cellular response to glucose starvation | 5 | 51 | 3.32e-01 |
| GO:BP | GO:0036473 | cell death in response to oxidative stress | 5 | 75 | 3.33e-01 |
| GO:BP | GO:0140157 | ammonium import across plasma membrane | 1 | 3 | 3.33e-01 |
| GO:BP | GO:0003222 | ventricular trabecula myocardium morphogenesis | 1 | 12 | 3.33e-01 |
| GO:BP | GO:0090207 | regulation of triglyceride metabolic process | 2 | 29 | 3.33e-01 |
| GO:BP | GO:0002526 | acute inflammatory response | 2 | 49 | 3.33e-01 |
| GO:BP | GO:0072210 | metanephric nephron development | 3 | 29 | 3.33e-01 |
| GO:BP | GO:0001702 | gastrulation with mouth forming second | 1 | 21 | 3.33e-01 |
| GO:BP | GO:1901016 | regulation of potassium ion transmembrane transporter activity | 1 | 45 | 3.33e-01 |
| GO:BP | GO:1903036 | positive regulation of response to wounding | 3 | 55 | 3.33e-01 |
| GO:BP | GO:1903241 | U2-type prespliceosome assembly | 3 | 24 | 3.33e-01 |
| GO:BP | GO:0033077 | T cell differentiation in thymus | 8 | 56 | 3.33e-01 |
| GO:BP | GO:1905049 | negative regulation of metallopeptidase activity | 2 | 7 | 3.33e-01 |
| GO:BP | GO:0009304 | tRNA transcription | 2 | 8 | 3.33e-01 |
| GO:BP | GO:0071392 | cellular response to estradiol stimulus | 2 | 26 | 3.33e-01 |
| GO:BP | GO:0045066 | regulatory T cell differentiation | 5 | 22 | 3.33e-01 |
| GO:BP | GO:0045930 | negative regulation of mitotic cell cycle | 6 | 211 | 3.33e-01 |
| GO:BP | GO:1901503 | ether biosynthetic process | 1 | 11 | 3.33e-01 |
| GO:BP | GO:2000134 | negative regulation of G1/S transition of mitotic cell cycle | 7 | 64 | 3.33e-01 |
| GO:BP | GO:0070301 | cellular response to hydrogen peroxide | 7 | 73 | 3.33e-01 |
| GO:BP | GO:0043001 | Golgi to plasma membrane protein transport | 2 | 37 | 3.33e-01 |
| GO:BP | GO:0006901 | vesicle coating | 1 | 36 | 3.33e-01 |
| GO:BP | GO:0048585 | negative regulation of response to stimulus | 4 | 1248 | 3.33e-01 |
| GO:BP | GO:0048669 | collateral sprouting in absence of injury | 1 | 4 | 3.33e-01 |
| GO:BP | GO:0007010 | cytoskeleton organization | 4 | 1226 | 3.33e-01 |
| GO:BP | GO:0032069 | regulation of nuclease activity | 2 | 17 | 3.33e-01 |
| GO:BP | GO:0032364 | intracellular oxygen homeostasis | 1 | 6 | 3.33e-01 |
| GO:BP | GO:0014846 | esophagus smooth muscle contraction | 1 | 2 | 3.33e-01 |
| GO:BP | GO:0035633 | maintenance of blood-brain barrier | 1 | 26 | 3.33e-01 |
| GO:BP | GO:0002440 | production of molecular mediator of immune response | 5 | 135 | 3.33e-01 |
| GO:BP | GO:0009992 | intracellular water homeostasis | 1 | 3 | 3.33e-01 |
| GO:BP | GO:0035148 | tube formation | 3 | 138 | 3.33e-01 |
| GO:BP | GO:0009071 | serine family amino acid catabolic process | 2 | 10 | 3.33e-01 |
| GO:BP | GO:0008652 | amino acid biosynthetic process | 5 | 64 | 3.33e-01 |
| GO:BP | GO:0060038 | cardiac muscle cell proliferation | 3 | 44 | 3.33e-01 |
| GO:BP | GO:0000045 | autophagosome assembly | 12 | 103 | 3.33e-01 |
| GO:BP | GO:0045348 | positive regulation of MHC class II biosynthetic process | 2 | 8 | 3.34e-01 |
| GO:BP | GO:0007610 | behavior | 2 | 436 | 3.34e-01 |
| GO:BP | GO:0014878 | response to electrical stimulus involved in regulation of muscle adaptation | 1 | 2 | 3.34e-01 |
| GO:BP | GO:0031848 | protection from non-homologous end joining at telomere | 1 | 10 | 3.34e-01 |
| GO:BP | GO:0051095 | regulation of helicase activity | 1 | 12 | 3.34e-01 |
| GO:BP | GO:1901163 | regulation of trophoblast cell migration | 3 | 12 | 3.34e-01 |
| GO:BP | GO:0045773 | positive regulation of axon extension | 1 | 33 | 3.34e-01 |
| GO:BP | GO:0051591 | response to cAMP | 8 | 66 | 3.34e-01 |
| GO:BP | GO:1903131 | mononuclear cell differentiation | 2 | 294 | 3.34e-01 |
| GO:BP | GO:0046642 | negative regulation of alpha-beta T cell proliferation | 3 | 9 | 3.34e-01 |
| GO:BP | GO:2000781 | positive regulation of double-strand break repair | 3 | 79 | 3.34e-01 |
| GO:BP | GO:0010994 | free ubiquitin chain polymerization | 1 | 8 | 3.34e-01 |
| GO:BP | GO:0032792 | negative regulation of CREB transcription factor activity | 1 | 4 | 3.34e-01 |
| GO:BP | GO:1905710 | positive regulation of membrane permeability | 2 | 45 | 3.34e-01 |
| GO:BP | GO:0097117 | guanylate kinase-associated protein clustering | 1 | 2 | 3.34e-01 |
| GO:BP | GO:0051648 | vesicle localization | 2 | 192 | 3.34e-01 |
| GO:BP | GO:0002568 | somatic diversification of T cell receptor genes | 1 | 4 | 3.34e-01 |
| GO:BP | GO:0014065 | phosphatidylinositol 3-kinase signaling | 7 | 100 | 3.34e-01 |
| GO:BP | GO:0043011 | myeloid dendritic cell differentiation | 1 | 10 | 3.34e-01 |
| GO:BP | GO:0071034 | CUT catabolic process | 1 | 5 | 3.34e-01 |
| GO:BP | GO:0045190 | isotype switching | 3 | 39 | 3.34e-01 |
| GO:BP | GO:0007614 | short-term memory | 2 | 9 | 3.34e-01 |
| GO:BP | GO:2001279 | regulation of unsaturated fatty acid biosynthetic process | 1 | 7 | 3.34e-01 |
| GO:BP | GO:0002183 | cytoplasmic translational initiation | 2 | 38 | 3.34e-01 |
| GO:BP | GO:0002204 | somatic recombination of immunoglobulin genes involved in immune response | 3 | 39 | 3.34e-01 |
| GO:BP | GO:0002208 | somatic diversification of immunoglobulins involved in immune response | 3 | 39 | 3.34e-01 |
| GO:BP | GO:2001259 | positive regulation of cation channel activity | 1 | 49 | 3.34e-01 |
| GO:BP | GO:0046889 | positive regulation of lipid biosynthetic process | 3 | 63 | 3.34e-01 |
| GO:BP | GO:0098727 | maintenance of cell number | 7 | 151 | 3.34e-01 |
| GO:BP | GO:2001235 | positive regulation of apoptotic signaling pathway | 7 | 108 | 3.34e-01 |
| GO:BP | GO:0043653 | mitochondrial fragmentation involved in apoptotic process | 1 | 9 | 3.34e-01 |
| GO:BP | GO:1900046 | regulation of hemostasis | 3 | 50 | 3.34e-01 |
| GO:BP | GO:1900110 | negative regulation of histone H3-K9 dimethylation | 1 | 2 | 3.34e-01 |
| GO:BP | GO:0003415 | chondrocyte hypertrophy | 1 | 6 | 3.34e-01 |
| GO:BP | GO:0002320 | lymphoid progenitor cell differentiation | 2 | 17 | 3.34e-01 |
| GO:BP | GO:0061205 | paramesonephric duct development | 1 | 4 | 3.34e-01 |
| GO:BP | GO:0045765 | regulation of angiogenesis | 5 | 203 | 3.34e-01 |
| GO:BP | GO:0071043 | CUT metabolic process | 1 | 5 | 3.34e-01 |
| GO:BP | GO:1900451 | positive regulation of glutamate receptor signaling pathway | 1 | 2 | 3.34e-01 |
| GO:BP | GO:1901475 | pyruvate transmembrane transport | 1 | 5 | 3.34e-01 |
| GO:BP | GO:0010917 | negative regulation of mitochondrial membrane potential | 1 | 9 | 3.34e-01 |
| GO:BP | GO:1904753 | negative regulation of vascular associated smooth muscle cell migration | 1 | 11 | 3.34e-01 |
| GO:BP | GO:1905651 | regulation of artery morphogenesis | 1 | 5 | 3.34e-01 |
| GO:BP | GO:0010638 | positive regulation of organelle organization | 27 | 439 | 3.34e-01 |
| GO:BP | GO:1902033 | regulation of hematopoietic stem cell proliferation | 2 | 12 | 3.34e-01 |
| GO:BP | GO:0040008 | regulation of growth | 4 | 501 | 3.34e-01 |
| GO:BP | GO:0009414 | response to water deprivation | 1 | 4 | 3.34e-01 |
| GO:BP | GO:1905205 | positive regulation of connective tissue replacement | 1 | 3 | 3.34e-01 |
| GO:BP | GO:0009439 | cyanate metabolic process | 1 | 2 | 3.34e-01 |
| GO:BP | GO:0009440 | cyanate catabolic process | 1 | 2 | 3.34e-01 |
| GO:BP | GO:0050771 | negative regulation of axonogenesis | 4 | 58 | 3.34e-01 |
| GO:BP | GO:1902170 | cellular response to reactive nitrogen species | 3 | 16 | 3.34e-01 |
| GO:BP | GO:1902229 | regulation of intrinsic apoptotic signaling pathway in response to DNA damage | 2 | 37 | 3.34e-01 |
| GO:BP | GO:0003171 | atrioventricular valve development | 2 | 27 | 3.34e-01 |
| GO:BP | GO:0032025 | response to cobalt ion | 1 | 10 | 3.34e-01 |
| GO:BP | GO:1902423 | regulation of attachment of mitotic spindle microtubules to kinetochore | 1 | 8 | 3.34e-01 |
| GO:BP | GO:0044782 | cilium organization | 37 | 313 | 3.34e-01 |
| GO:BP | GO:1902425 | positive regulation of attachment of mitotic spindle microtubules to kinetochore | 1 | 8 | 3.34e-01 |
| GO:BP | GO:0009895 | negative regulation of catabolic process | 1 | 280 | 3.34e-01 |
| GO:BP | GO:2000209 | regulation of anoikis | 1 | 23 | 3.34e-01 |
| GO:BP | GO:0090132 | epithelium migration | 16 | 252 | 3.34e-01 |
| GO:BP | GO:0010640 | regulation of platelet-derived growth factor receptor signaling pathway | 1 | 19 | 3.34e-01 |
| GO:BP | GO:0032775 | DNA methylation on adenine | 1 | 2 | 3.34e-01 |
| GO:BP | GO:0002819 | regulation of adaptive immune response | 1 | 106 | 3.34e-01 |
| GO:BP | GO:1905653 | positive regulation of artery morphogenesis | 1 | 5 | 3.34e-01 |
| GO:BP | GO:1903034 | regulation of response to wounding | 4 | 121 | 3.34e-01 |
| GO:BP | GO:1901525 | negative regulation of mitophagy | 1 | 6 | 3.34e-01 |
| GO:BP | GO:0051656 | establishment of organelle localization | 2 | 378 | 3.34e-01 |
| GO:BP | GO:1903026 | negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding | 1 | 6 | 3.34e-01 |
| GO:BP | GO:0002681 | somatic recombination of T cell receptor gene segments | 1 | 4 | 3.34e-01 |
| GO:BP | GO:0072396 | response to cell cycle checkpoint signaling | 1 | 8 | 3.34e-01 |
| GO:BP | GO:0072402 | response to DNA integrity checkpoint signaling | 1 | 8 | 3.34e-01 |
| GO:BP | GO:0072423 | response to DNA damage checkpoint signaling | 1 | 8 | 3.34e-01 |
| GO:BP | GO:0010813 | neuropeptide catabolic process | 1 | 4 | 3.34e-01 |
| GO:BP | GO:0045837 | negative regulation of membrane potential | 1 | 9 | 3.34e-01 |
| GO:BP | GO:0006848 | pyruvate transport | 1 | 5 | 3.34e-01 |
| GO:BP | GO:0000469 | cleavage involved in rRNA processing | 2 | 29 | 3.34e-01 |
| GO:BP | GO:0009247 | glycolipid biosynthetic process | 3 | 61 | 3.34e-01 |
| GO:BP | GO:0090402 | oncogene-induced cell senescence | 1 | 3 | 3.34e-01 |
| GO:BP | GO:0060438 | trachea development | 2 | 13 | 3.34e-01 |
| GO:BP | GO:0031294 | lymphocyte costimulation | 3 | 23 | 3.34e-01 |
| GO:BP | GO:0090331 | negative regulation of platelet aggregation | 1 | 11 | 3.34e-01 |
| GO:BP | GO:0036342 | post-anal tail morphogenesis | 2 | 13 | 3.34e-01 |
| GO:BP | GO:2000480 | negative regulation of cAMP-dependent protein kinase activity | 1 | 10 | 3.34e-01 |
| GO:BP | GO:0048820 | hair follicle maturation | 1 | 15 | 3.34e-01 |
| GO:BP | GO:0043316 | cytotoxic T cell degranulation | 1 | 2 | 3.34e-01 |
| GO:BP | GO:0018872 | arsonoacetate metabolic process | 1 | 1 | 3.34e-01 |
| GO:BP | GO:0001975 | response to amphetamine | 2 | 22 | 3.34e-01 |
| GO:BP | GO:0099578 | regulation of translation at postsynapse, modulating synaptic transmission | 1 | 3 | 3.34e-01 |
| GO:BP | GO:0006297 | nucleotide-excision repair, DNA gap filling | 1 | 5 | 3.34e-01 |
| GO:BP | GO:0019860 | uracil metabolic process | 1 | 2 | 3.34e-01 |
| GO:BP | GO:0033153 | T cell receptor V(D)J recombination | 1 | 4 | 3.34e-01 |
| GO:BP | GO:0099547 | regulation of translation at synapse, modulating synaptic transmission | 1 | 3 | 3.34e-01 |
| GO:BP | GO:0002009 | morphogenesis of an epithelium | 38 | 418 | 3.34e-01 |
| GO:BP | GO:0019694 | alkanesulfonate metabolic process | 2 | 6 | 3.34e-01 |
| GO:BP | GO:1903722 | regulation of centriole elongation | 1 | 7 | 3.34e-01 |
| GO:BP | GO:1904425 | negative regulation of GTP binding | 1 | 3 | 3.34e-01 |
| GO:BP | GO:0006338 | chromatin remodeling | 8 | 378 | 3.34e-01 |
| GO:BP | GO:1903725 | regulation of phospholipid metabolic process | 1 | 29 | 3.34e-01 |
| GO:BP | GO:0007368 | determination of left/right symmetry | 12 | 97 | 3.34e-01 |
| GO:BP | GO:0071478 | cellular response to radiation | 8 | 156 | 3.34e-01 |
| GO:BP | GO:0019530 | taurine metabolic process | 2 | 6 | 3.34e-01 |
| GO:BP | GO:0033209 | tumor necrosis factor-mediated signaling pathway | 1 | 76 | 3.34e-01 |
| GO:BP | GO:0071496 | cellular response to external stimulus | 22 | 270 | 3.34e-01 |
| GO:BP | GO:0017085 | response to insecticide | 1 | 4 | 3.34e-01 |
| GO:BP | GO:1904177 | regulation of adipose tissue development | 1 | 8 | 3.34e-01 |
| GO:BP | GO:0021603 | cranial nerve formation | 2 | 4 | 3.34e-01 |
| GO:BP | GO:0021886 | hypothalamus gonadotrophin-releasing hormone neuron differentiation | 2 | 7 | 3.35e-01 |
| GO:BP | GO:0021888 | hypothalamus gonadotrophin-releasing hormone neuron development | 2 | 7 | 3.35e-01 |
| GO:BP | GO:0007023 | post-chaperonin tubulin folding pathway | 1 | 6 | 3.35e-01 |
| GO:BP | GO:0008050 | female courtship behavior | 1 | 2 | 3.35e-01 |
| GO:BP | GO:0097474 | retinal cone cell apoptotic process | 1 | 1 | 3.35e-01 |
| GO:BP | GO:0048319 | axial mesoderm morphogenesis | 1 | 3 | 3.35e-01 |
| GO:BP | GO:0006893 | Golgi to plasma membrane transport | 3 | 60 | 3.35e-01 |
| GO:BP | GO:2000564 | regulation of CD8-positive, alpha-beta T cell proliferation | 1 | 7 | 3.35e-01 |
| GO:BP | GO:1904161 | DNA synthesis involved in UV-damage excision repair | 1 | 2 | 3.35e-01 |
| GO:BP | GO:0003016 | respiratory system process | 1 | 30 | 3.35e-01 |
| GO:BP | GO:0021683 | cerebellar granular layer morphogenesis | 1 | 8 | 3.35e-01 |
| GO:BP | GO:0000972 | transcription-dependent tethering of RNA polymerase II gene DNA at nuclear periphery | 1 | 6 | 3.35e-01 |
| GO:BP | GO:2001150 | positive regulation of dipeptide transmembrane transport | 1 | 2 | 3.35e-01 |
| GO:BP | GO:0140469 | GCN2-mediated signaling | 1 | 3 | 3.35e-01 |
| GO:BP | GO:0097734 | extracellular exosome biogenesis | 3 | 18 | 3.35e-01 |
| GO:BP | GO:0042886 | amide transport | 1 | 235 | 3.35e-01 |
| GO:BP | GO:0051012 | microtubule sliding | 1 | 2 | 3.35e-01 |
| GO:BP | GO:0120034 | positive regulation of plasma membrane bounded cell projection assembly | 10 | 94 | 3.35e-01 |
| GO:BP | GO:2000273 | positive regulation of signaling receptor activity | 1 | 33 | 3.35e-01 |
| GO:BP | GO:0090088 | regulation of oligopeptide transport | 1 | 2 | 3.35e-01 |
| GO:BP | GO:0090089 | regulation of dipeptide transport | 1 | 2 | 3.35e-01 |
| GO:BP | GO:0098885 | modification of postsynaptic actin cytoskeleton | 2 | 10 | 3.35e-01 |
| GO:BP | GO:0035740 | CD8-positive, alpha-beta T cell proliferation | 1 | 7 | 3.35e-01 |
| GO:BP | GO:0032571 | response to vitamin K | 1 | 5 | 3.35e-01 |
| GO:BP | GO:2001148 | regulation of dipeptide transmembrane transport | 1 | 2 | 3.35e-01 |
| GO:BP | GO:0030321 | transepithelial chloride transport | 2 | 7 | 3.35e-01 |
| GO:BP | GO:0072218 | metanephric ascending thin limb development | 1 | 2 | 3.35e-01 |
| GO:BP | GO:2000878 | positive regulation of oligopeptide transport | 1 | 2 | 3.35e-01 |
| GO:BP | GO:0046724 | oxalic acid secretion | 1 | 1 | 3.35e-01 |
| GO:BP | GO:0010565 | regulation of cellular ketone metabolic process | 3 | 98 | 3.35e-01 |
| GO:BP | GO:0007161 | calcium-independent cell-matrix adhesion | 1 | 3 | 3.35e-01 |
| GO:BP | GO:0098781 | ncRNA transcription | 6 | 61 | 3.35e-01 |
| GO:BP | GO:0072021 | ascending thin limb development | 1 | 2 | 3.35e-01 |
| GO:BP | GO:2000880 | positive regulation of dipeptide transport | 1 | 2 | 3.35e-01 |
| GO:BP | GO:0090114 | COPII-coated vesicle budding | 1 | 40 | 3.35e-01 |
| GO:BP | GO:0000101 | sulfur amino acid transport | 2 | 10 | 3.36e-01 |
| GO:BP | GO:0050728 | negative regulation of inflammatory response | 14 | 87 | 3.36e-01 |
| GO:BP | GO:0061318 | renal filtration cell differentiation | 1 | 17 | 3.36e-01 |
| GO:BP | GO:0072112 | podocyte differentiation | 1 | 17 | 3.36e-01 |
| GO:BP | GO:0022604 | regulation of cell morphogenesis | 13 | 220 | 3.36e-01 |
| GO:BP | GO:0002285 | lymphocyte activation involved in immune response | 1 | 111 | 3.37e-01 |
| GO:BP | GO:0045936 | negative regulation of phosphate metabolic process | 9 | 344 | 3.37e-01 |
| GO:BP | GO:0070085 | glycosylation | 9 | 202 | 3.37e-01 |
| GO:BP | GO:0036444 | calcium import into the mitochondrion | 1 | 12 | 3.37e-01 |
| GO:BP | GO:0097156 | fasciculation of motor neuron axon | 1 | 2 | 3.37e-01 |
| GO:BP | GO:1901862 | negative regulation of muscle tissue development | 2 | 9 | 3.37e-01 |
| GO:BP | GO:1900376 | regulation of secondary metabolite biosynthetic process | 2 | 12 | 3.37e-01 |
| GO:BP | GO:0051043 | regulation of membrane protein ectodomain proteolysis | 4 | 18 | 3.37e-01 |
| GO:BP | GO:0043455 | regulation of secondary metabolic process | 2 | 12 | 3.37e-01 |
| GO:BP | GO:0033505 | floor plate morphogenesis | 1 | 3 | 3.37e-01 |
| GO:BP | GO:0000493 | box H/ACA snoRNP assembly | 1 | 2 | 3.37e-01 |
| GO:BP | GO:0045634 | regulation of melanocyte differentiation | 1 | 5 | 3.37e-01 |
| GO:BP | GO:0001654 | eye development | 3 | 272 | 3.37e-01 |
| GO:BP | GO:0048021 | regulation of melanin biosynthetic process | 2 | 12 | 3.37e-01 |
| GO:BP | GO:0035329 | hippo signaling | 6 | 41 | 3.37e-01 |
| GO:BP | GO:0036465 | synaptic vesicle recycling | 10 | 73 | 3.37e-01 |
| GO:BP | GO:0048167 | regulation of synaptic plasticity | 1 | 141 | 3.37e-01 |
| GO:BP | GO:0048668 | collateral sprouting | 2 | 25 | 3.37e-01 |
| GO:BP | GO:0035726 | common myeloid progenitor cell proliferation | 1 | 5 | 3.38e-01 |
| GO:BP | GO:0060372 | regulation of atrial cardiac muscle cell membrane repolarization | 1 | 6 | 3.38e-01 |
| GO:BP | GO:0086028 | bundle of His cell to Purkinje myocyte signaling | 1 | 6 | 3.38e-01 |
| GO:BP | GO:0043009 | chordate embryonic development | 46 | 534 | 3.38e-01 |
| GO:BP | GO:0086043 | bundle of His cell action potential | 1 | 6 | 3.38e-01 |
| GO:BP | GO:1903408 | positive regulation of P-type sodium:potassium-exchanging transporter activity | 1 | 2 | 3.38e-01 |
| GO:BP | GO:0009266 | response to temperature stimulus | 8 | 133 | 3.38e-01 |
| GO:BP | GO:1903406 | regulation of P-type sodium:potassium-exchanging transporter activity | 1 | 2 | 3.38e-01 |
| GO:BP | GO:0018195 | peptidyl-arginine modification | 1 | 18 | 3.38e-01 |
| GO:BP | GO:0098880 | maintenance of postsynaptic specialization structure | 2 | 9 | 3.38e-01 |
| GO:BP | GO:0046348 | amino sugar catabolic process | 3 | 9 | 3.38e-01 |
| GO:BP | GO:1901342 | regulation of vasculature development | 5 | 206 | 3.38e-01 |
| GO:BP | GO:0042754 | negative regulation of circadian rhythm | 1 | 10 | 3.38e-01 |
| GO:BP | GO:0006754 | ATP biosynthetic process | 1 | 87 | 3.38e-01 |
| GO:BP | GO:0007399 | nervous system development | 6 | 1904 | 3.39e-01 |
| GO:BP | GO:0043558 | regulation of translational initiation in response to stress | 2 | 16 | 3.39e-01 |
| GO:BP | GO:0045619 | regulation of lymphocyte differentiation | 1 | 132 | 3.39e-01 |
| GO:BP | GO:0045913 | positive regulation of carbohydrate metabolic process | 4 | 60 | 3.39e-01 |
| GO:BP | GO:0006895 | Golgi to endosome transport | 2 | 17 | 3.39e-01 |
| GO:BP | GO:0070071 | proton-transporting two-sector ATPase complex assembly | 1 | 15 | 3.39e-01 |
| GO:BP | GO:1904979 | negative regulation of endosome organization | 1 | 2 | 3.39e-01 |
| GO:BP | GO:0021628 | olfactory nerve formation | 1 | 2 | 3.39e-01 |
| GO:BP | GO:0070374 | positive regulation of ERK1 and ERK2 cascade | 1 | 121 | 3.39e-01 |
| GO:BP | GO:0007174 | epidermal growth factor catabolic process | 1 | 2 | 3.39e-01 |
| GO:BP | GO:0150063 | visual system development | 3 | 273 | 3.39e-01 |
| GO:BP | GO:0001657 | ureteric bud development | 1 | 75 | 3.39e-01 |
| GO:BP | GO:0060993 | kidney morphogenesis | 1 | 73 | 3.39e-01 |
| GO:BP | GO:0035521 | monoubiquitinated histone deubiquitination | 1 | 30 | 3.39e-01 |
| GO:BP | GO:1905366 | negative regulation of intralumenal vesicle formation | 1 | 2 | 3.39e-01 |
| GO:BP | GO:1905365 | regulation of intralumenal vesicle formation | 1 | 2 | 3.39e-01 |
| GO:BP | GO:0035522 | monoubiquitinated histone H2A deubiquitination | 1 | 30 | 3.39e-01 |
| GO:BP | GO:0055008 | cardiac muscle tissue morphogenesis | 2 | 54 | 3.40e-01 |
| GO:BP | GO:0007042 | lysosomal lumen acidification | 2 | 21 | 3.40e-01 |
| GO:BP | GO:0050818 | regulation of coagulation | 3 | 55 | 3.40e-01 |
| GO:BP | GO:0060116 | vestibular receptor cell morphogenesis | 1 | 1 | 3.40e-01 |
| GO:BP | GO:0071650 | negative regulation of chemokine (C-C motif) ligand 5 production | 1 | 3 | 3.40e-01 |
| GO:BP | GO:0072163 | mesonephric epithelium development | 1 | 76 | 3.40e-01 |
| GO:BP | GO:0097178 | ruffle assembly | 6 | 37 | 3.40e-01 |
| GO:BP | GO:0050427 | 3’-phosphoadenosine 5’-phosphosulfate metabolic process | 1 | 10 | 3.40e-01 |
| GO:BP | GO:1903423 | positive regulation of synaptic vesicle recycling | 2 | 6 | 3.40e-01 |
| GO:BP | GO:0034311 | diol metabolic process | 1 | 26 | 3.40e-01 |
| GO:BP | GO:0007263 | nitric oxide mediated signal transduction | 1 | 20 | 3.40e-01 |
| GO:BP | GO:0072164 | mesonephric tubule development | 1 | 76 | 3.40e-01 |
| GO:BP | GO:0097112 | gamma-aminobutyric acid receptor clustering | 1 | 3 | 3.40e-01 |
| GO:BP | GO:0071705 | nitrogen compound transport | 6 | 1684 | 3.40e-01 |
| GO:BP | GO:0034035 | purine ribonucleoside bisphosphate metabolic process | 1 | 10 | 3.40e-01 |
| GO:BP | GO:0072311 | glomerular epithelial cell differentiation | 1 | 17 | 3.40e-01 |
| GO:BP | GO:1902235 | regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway | 2 | 29 | 3.40e-01 |
| GO:BP | GO:0097722 | sperm motility | 1 | 61 | 3.40e-01 |
| GO:BP | GO:0003352 | regulation of cilium movement | 2 | 17 | 3.40e-01 |
| GO:BP | GO:0006699 | bile acid biosynthetic process | 3 | 25 | 3.40e-01 |
| GO:BP | GO:0061484 | hematopoietic stem cell homeostasis | 4 | 20 | 3.40e-01 |
| GO:BP | GO:0030317 | flagellated sperm motility | 1 | 61 | 3.40e-01 |
| GO:BP | GO:0003231 | cardiac ventricle development | 9 | 114 | 3.40e-01 |
| GO:BP | GO:0010810 | regulation of cell-substrate adhesion | 1 | 172 | 3.40e-01 |
| GO:BP | GO:0090398 | cellular senescence | 5 | 83 | 3.40e-01 |
| GO:BP | GO:0099622 | cardiac muscle cell membrane repolarization | 2 | 31 | 3.40e-01 |
| GO:BP | GO:0061061 | muscle structure development | 41 | 546 | 3.40e-01 |
| GO:BP | GO:0010649 | regulation of cell communication by electrical coupling | 3 | 17 | 3.40e-01 |
| GO:BP | GO:1901072 | glucosamine-containing compound catabolic process | 2 | 5 | 3.40e-01 |
| GO:BP | GO:0090170 | regulation of Golgi inheritance | 1 | 4 | 3.40e-01 |
| GO:BP | GO:0003166 | bundle of His development | 1 | 6 | 3.40e-01 |
| GO:BP | GO:0015876 | acetyl-CoA transport | 1 | 1 | 3.40e-01 |
| GO:BP | GO:0040013 | negative regulation of locomotion | 13 | 265 | 3.40e-01 |
| GO:BP | GO:1903978 | regulation of microglial cell activation | 3 | 9 | 3.40e-01 |
| GO:BP | GO:0050927 | positive regulation of positive chemotaxis | 1 | 20 | 3.41e-01 |
| GO:BP | GO:0006606 | protein import into nucleus | 8 | 147 | 3.41e-01 |
| GO:BP | GO:0048169 | regulation of long-term neuronal synaptic plasticity | 3 | 20 | 3.41e-01 |
| GO:BP | GO:0090130 | tissue migration | 16 | 256 | 3.41e-01 |
| GO:BP | GO:0046330 | positive regulation of JNK cascade | 5 | 72 | 3.41e-01 |
| GO:BP | GO:0034243 | regulation of transcription elongation by RNA polymerase II | 9 | 85 | 3.41e-01 |
| GO:BP | GO:0090125 | cell-cell adhesion involved in synapse maturation | 1 | 2 | 3.41e-01 |
| GO:BP | GO:0042994 | cytoplasmic sequestering of transcription factor | 3 | 15 | 3.41e-01 |
| GO:BP | GO:1902017 | regulation of cilium assembly | 8 | 57 | 3.42e-01 |
| GO:BP | GO:2000779 | regulation of double-strand break repair | 7 | 121 | 3.42e-01 |
| GO:BP | GO:0033033 | negative regulation of myeloid cell apoptotic process | 2 | 10 | 3.42e-01 |
| GO:BP | GO:0060689 | cell differentiation involved in salivary gland development | 1 | 2 | 3.42e-01 |
| GO:BP | GO:0061511 | centriole elongation | 1 | 8 | 3.42e-01 |
| GO:BP | GO:0003207 | cardiac chamber formation | 2 | 14 | 3.43e-01 |
| GO:BP | GO:0048880 | sensory system development | 3 | 275 | 3.43e-01 |
| GO:BP | GO:1903421 | regulation of synaptic vesicle recycling | 4 | 23 | 3.43e-01 |
| GO:BP | GO:0048589 | developmental growth | 4 | 522 | 3.43e-01 |
| GO:BP | GO:0044092 | negative regulation of molecular function | 3 | 755 | 3.43e-01 |
| GO:BP | GO:0060819 | inactivation of X chromosome by genomic imprinting | 1 | 2 | 3.43e-01 |
| GO:BP | GO:0030219 | megakaryocyte differentiation | 1 | 54 | 3.43e-01 |
| GO:BP | GO:0042908 | xenobiotic transport | 2 | 30 | 3.43e-01 |
| GO:BP | GO:2000628 | regulation of miRNA metabolic process | 4 | 67 | 3.44e-01 |
| GO:BP | GO:0106027 | neuron projection organization | 10 | 76 | 3.44e-01 |
| GO:BP | GO:0036498 | IRE1-mediated unfolded protein response | 2 | 19 | 3.44e-01 |
| GO:BP | GO:0002312 | B cell activation involved in immune response | 4 | 57 | 3.44e-01 |
| GO:BP | GO:0034612 | response to tumor necrosis factor | 16 | 172 | 3.44e-01 |
| GO:BP | GO:1900248 | negative regulation of cytoplasmic translational elongation | 1 | 2 | 3.44e-01 |
| GO:BP | GO:0051030 | snRNA transport | 1 | 6 | 3.44e-01 |
| GO:BP | GO:0072006 | nephron development | 3 | 117 | 3.44e-01 |
| GO:BP | GO:0030968 | endoplasmic reticulum unfolded protein response | 9 | 70 | 3.44e-01 |
| GO:BP | GO:0016032 | viral process | 29 | 344 | 3.44e-01 |
| GO:BP | GO:0050672 | negative regulation of lymphocyte proliferation | 9 | 46 | 3.44e-01 |
| GO:BP | GO:0001823 | mesonephros development | 1 | 77 | 3.45e-01 |
| GO:BP | GO:0051450 | myoblast proliferation | 2 | 17 | 3.45e-01 |
| GO:BP | GO:0044878 | mitotic cytokinesis checkpoint signaling | 1 | 4 | 3.45e-01 |
| GO:BP | GO:0090169 | regulation of spindle assembly | 3 | 32 | 3.45e-01 |
| GO:BP | GO:0072575 | epithelial cell proliferation involved in liver morphogenesis | 1 | 18 | 3.45e-01 |
| GO:BP | GO:0007249 | I-kappaB kinase/NF-kappaB signaling | 18 | 227 | 3.45e-01 |
| GO:BP | GO:0072574 | hepatocyte proliferation | 1 | 18 | 3.45e-01 |
| GO:BP | GO:1903772 | regulation of viral budding via host ESCRT complex | 1 | 4 | 3.45e-01 |
| GO:BP | GO:0050873 | brown fat cell differentiation | 2 | 41 | 3.45e-01 |
| GO:BP | GO:0006043 | glucosamine catabolic process | 1 | 2 | 3.45e-01 |
| GO:BP | GO:0032785 | negative regulation of DNA-templated transcription, elongation | 3 | 20 | 3.45e-01 |
| GO:BP | GO:0070200 | establishment of protein localization to telomere | 3 | 16 | 3.45e-01 |
| GO:BP | GO:0042538 | hyperosmotic salinity response | 1 | 8 | 3.45e-01 |
| GO:BP | GO:0106049 | regulation of cellular response to osmotic stress | 1 | 10 | 3.45e-01 |
| GO:BP | GO:0060840 | artery development | 5 | 83 | 3.45e-01 |
| GO:BP | GO:0060534 | trachea cartilage development | 1 | 4 | 3.45e-01 |
| GO:BP | GO:0061771 | response to caloric restriction | 1 | 3 | 3.45e-01 |
| GO:BP | GO:0030309 | poly-N-acetyllactosamine metabolic process | 1 | 6 | 3.45e-01 |
| GO:BP | GO:1900195 | positive regulation of oocyte maturation | 1 | 3 | 3.45e-01 |
| GO:BP | GO:0050926 | regulation of positive chemotaxis | 1 | 20 | 3.45e-01 |
| GO:BP | GO:2000271 | positive regulation of fibroblast apoptotic process | 1 | 9 | 3.45e-01 |
| GO:BP | GO:0000462 | maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 3 | 38 | 3.46e-01 |
| GO:BP | GO:0034111 | negative regulation of homotypic cell-cell adhesion | 1 | 13 | 3.46e-01 |
| GO:BP | GO:1903147 | negative regulation of autophagy of mitochondrion | 1 | 7 | 3.46e-01 |
| GO:BP | GO:1903748 | negative regulation of establishment of protein localization to mitochondrion | 2 | 5 | 3.46e-01 |
| GO:BP | GO:0006090 | pyruvate metabolic process | 1 | 93 | 3.46e-01 |
| GO:BP | GO:0003198 | epithelial to mesenchymal transition involved in endocardial cushion formation | 1 | 14 | 3.46e-01 |
| GO:BP | GO:0009227 | nucleotide-sugar catabolic process | 1 | 3 | 3.46e-01 |
| GO:BP | GO:0035771 | interleukin-4-mediated signaling pathway | 1 | 4 | 3.46e-01 |
| GO:BP | GO:0035617 | stress granule disassembly | 1 | 5 | 3.46e-01 |
| GO:BP | GO:2000466 | negative regulation of glycogen (starch) synthase activity | 1 | 3 | 3.46e-01 |
| GO:BP | GO:0006863 | purine nucleobase transport | 1 | 7 | 3.46e-01 |
| GO:BP | GO:0015858 | nucleoside transport | 1 | 8 | 3.46e-01 |
| GO:BP | GO:0032715 | negative regulation of interleukin-6 production | 4 | 24 | 3.46e-01 |
| GO:BP | GO:1901991 | negative regulation of mitotic cell cycle phase transition | 2 | 166 | 3.46e-01 |
| GO:BP | GO:0009890 | negative regulation of biosynthetic process | 76 | 1280 | 3.46e-01 |
| GO:BP | GO:0072330 | monocarboxylic acid biosynthetic process | 4 | 145 | 3.46e-01 |
| GO:BP | GO:0048588 | developmental cell growth | 1 | 192 | 3.46e-01 |
| GO:BP | GO:0042271 | susceptibility to natural killer cell mediated cytotoxicity | 1 | 3 | 3.46e-01 |
| GO:BP | GO:0032077 | positive regulation of deoxyribonuclease activity | 1 | 5 | 3.46e-01 |
| GO:BP | GO:0016571 | histone methylation | 3 | 117 | 3.46e-01 |
| GO:BP | GO:0051877 | pigment granule aggregation in cell center | 1 | 2 | 3.46e-01 |
| GO:BP | GO:1903929 | primary palate development | 1 | 2 | 3.46e-01 |
| GO:BP | GO:0072665 | protein localization to vacuole | 1 | 72 | 3.47e-01 |
| GO:BP | GO:0033273 | response to vitamin | 1 | 61 | 3.47e-01 |
| GO:BP | GO:1990961 | xenobiotic detoxification by transmembrane export across the plasma membrane | 1 | 7 | 3.47e-01 |
| GO:BP | GO:2000136 | regulation of cell proliferation involved in heart morphogenesis | 2 | 17 | 3.48e-01 |
| GO:BP | GO:0009070 | serine family amino acid biosynthetic process | 2 | 16 | 3.48e-01 |
| GO:BP | GO:0035358 | regulation of peroxisome proliferator activated receptor signaling pathway | 1 | 11 | 3.48e-01 |
| GO:BP | GO:0009063 | amino acid catabolic process | 5 | 78 | 3.48e-01 |
| GO:BP | GO:0031623 | receptor internalization | 9 | 95 | 3.48e-01 |
| GO:BP | GO:0002381 | immunoglobulin production involved in immunoglobulin-mediated immune response | 3 | 41 | 3.49e-01 |
| GO:BP | GO:0099555 | trans-synaptic signaling by nitric oxide, modulating synaptic transmission | 1 | 2 | 3.49e-01 |
| GO:BP | GO:0007062 | sister chromatid cohesion | 2 | 52 | 3.49e-01 |
| GO:BP | GO:0099554 | trans-synaptic signaling by soluble gas, modulating synaptic transmission | 1 | 2 | 3.49e-01 |
| GO:BP | GO:0009206 | purine ribonucleoside triphosphate biosynthetic process | 1 | 96 | 3.49e-01 |
| GO:BP | GO:0007043 | cell-cell junction assembly | 1 | 105 | 3.50e-01 |
| GO:BP | GO:0090176 | microtubule cytoskeleton organization involved in establishment of planar polarity | 1 | 3 | 3.50e-01 |
| GO:BP | GO:0030166 | proteoglycan biosynthetic process | 1 | 51 | 3.50e-01 |
| GO:BP | GO:0060294 | cilium movement involved in cell motility | 1 | 69 | 3.50e-01 |
| GO:BP | GO:0021517 | ventral spinal cord development | 2 | 25 | 3.50e-01 |
| GO:BP | GO:0051972 | regulation of telomerase activity | 4 | 45 | 3.50e-01 |
| GO:BP | GO:0010747 | positive regulation of long-chain fatty acid import across plasma membrane | 1 | 1 | 3.50e-01 |
| GO:BP | GO:0061450 | trophoblast cell migration | 3 | 13 | 3.50e-01 |
| GO:BP | GO:1901888 | regulation of cell junction assembly | 2 | 168 | 3.50e-01 |
| GO:BP | GO:0072576 | liver morphogenesis | 1 | 19 | 3.50e-01 |
| GO:BP | GO:0002703 | regulation of leukocyte mediated immunity | 1 | 118 | 3.50e-01 |
| GO:BP | GO:0030091 | protein repair | 1 | 7 | 3.50e-01 |
| GO:BP | GO:0009145 | purine nucleoside triphosphate biosynthetic process | 1 | 97 | 3.50e-01 |
| GO:BP | GO:0015911 | long-chain fatty acid import across plasma membrane | 2 | 9 | 3.50e-01 |
| GO:BP | GO:0030576 | Cajal body organization | 1 | 4 | 3.51e-01 |
| GO:BP | GO:1903573 | negative regulation of response to endoplasmic reticulum stress | 3 | 41 | 3.51e-01 |
| GO:BP | GO:0032945 | negative regulation of mononuclear cell proliferation | 9 | 46 | 3.51e-01 |
| GO:BP | GO:0006361 | transcription initiation at RNA polymerase I promoter | 2 | 11 | 3.51e-01 |
| GO:BP | GO:0042771 | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 3 | 43 | 3.52e-01 |
| GO:BP | GO:0019236 | response to pheromone | 1 | 1 | 3.52e-01 |
| GO:BP | GO:1901990 | regulation of mitotic cell cycle phase transition | 24 | 308 | 3.52e-01 |
| GO:BP | GO:0044057 | regulation of system process | 2 | 405 | 3.52e-01 |
| GO:BP | GO:0051351 | positive regulation of ligase activity | 2 | 9 | 3.52e-01 |
| GO:BP | GO:0010558 | negative regulation of macromolecule biosynthetic process | 72 | 1214 | 3.53e-01 |
| GO:BP | GO:0007160 | cell-matrix adhesion | 1 | 179 | 3.53e-01 |
| GO:BP | GO:0015031 | protein transport | 5 | 1361 | 3.53e-01 |
| GO:BP | GO:0010921 | regulation of phosphatase activity | 2 | 65 | 3.53e-01 |
| GO:BP | GO:0001504 | neurotransmitter uptake | 2 | 29 | 3.53e-01 |
| GO:BP | GO:0002761 | regulation of myeloid leukocyte differentiation | 2 | 77 | 3.53e-01 |
| GO:BP | GO:0008361 | regulation of cell size | 8 | 159 | 3.53e-01 |
| GO:BP | GO:1902816 | regulation of protein localization to microtubule | 1 | 5 | 3.53e-01 |
| GO:BP | GO:0060972 | left/right pattern formation | 12 | 101 | 3.53e-01 |
| GO:BP | GO:1902817 | negative regulation of protein localization to microtubule | 1 | 5 | 3.53e-01 |
| GO:BP | GO:0033387 | putrescine biosynthetic process from ornithine | 1 | 3 | 3.53e-01 |
| GO:BP | GO:0009629 | response to gravity | 2 | 5 | 3.53e-01 |
| GO:BP | GO:0046460 | neutral lipid biosynthetic process | 2 | 36 | 3.53e-01 |
| GO:BP | GO:0045672 | positive regulation of osteoclast differentiation | 2 | 11 | 3.53e-01 |
| GO:BP | GO:0046463 | acylglycerol biosynthetic process | 2 | 36 | 3.53e-01 |
| GO:BP | GO:0021934 | hindbrain tangential cell migration | 1 | 3 | 3.53e-01 |
| GO:BP | GO:0010635 | regulation of mitochondrial fusion | 1 | 11 | 3.53e-01 |
| GO:BP | GO:0000460 | maturation of 5.8S rRNA | 5 | 36 | 3.53e-01 |
| GO:BP | GO:0097061 | dendritic spine organization | 9 | 67 | 3.53e-01 |
| GO:BP | GO:0032211 | negative regulation of telomere maintenance via telomerase | 2 | 19 | 3.54e-01 |
| GO:BP | GO:0061528 | aspartate secretion | 1 | 2 | 3.54e-01 |
| GO:BP | GO:0002065 | columnar/cuboidal epithelial cell differentiation | 8 | 80 | 3.54e-01 |
| GO:BP | GO:0006014 | D-ribose metabolic process | 1 | 3 | 3.54e-01 |
| GO:BP | GO:1902807 | negative regulation of cell cycle G1/S phase transition | 2 | 70 | 3.54e-01 |
| GO:BP | GO:1904448 | regulation of aspartate secretion | 1 | 2 | 3.54e-01 |
| GO:BP | GO:0007033 | vacuole organization | 11 | 197 | 3.54e-01 |
| GO:BP | GO:2000969 | positive regulation of AMPA receptor activity | 2 | 4 | 3.54e-01 |
| GO:BP | GO:0007155 | cell adhesion | 3 | 1012 | 3.54e-01 |
| GO:BP | GO:1905477 | positive regulation of protein localization to membrane | 9 | 84 | 3.54e-01 |
| GO:BP | GO:0098658 | inorganic anion import across plasma membrane | 1 | 1 | 3.54e-01 |
| GO:BP | GO:1904450 | positive regulation of aspartate secretion | 1 | 2 | 3.54e-01 |
| GO:BP | GO:0010975 | regulation of neuron projection development | 31 | 372 | 3.54e-01 |
| GO:BP | GO:0050942 | positive regulation of pigment cell differentiation | 1 | 5 | 3.54e-01 |
| GO:BP | GO:0071827 | plasma lipoprotein particle organization | 1 | 27 | 3.54e-01 |
| GO:BP | GO:0035795 | negative regulation of mitochondrial membrane permeability | 3 | 17 | 3.54e-01 |
| GO:BP | GO:0097680 | double-strand break repair via classical nonhomologous end joining | 1 | 6 | 3.54e-01 |
| GO:BP | GO:0033189 | response to vitamin A | 3 | 12 | 3.54e-01 |
| GO:BP | GO:0007163 | establishment or maintenance of cell polarity | 1 | 206 | 3.54e-01 |
| GO:BP | GO:0048286 | lung alveolus development | 1 | 39 | 3.54e-01 |
| GO:BP | GO:0072010 | glomerular epithelium development | 1 | 18 | 3.54e-01 |
| GO:BP | GO:0072234 | metanephric nephron tubule development | 3 | 14 | 3.54e-01 |
| GO:BP | GO:0046890 | regulation of lipid biosynthetic process | 9 | 134 | 3.54e-01 |
| GO:BP | GO:0060997 | dendritic spine morphogenesis | 7 | 50 | 3.54e-01 |
| GO:BP | GO:1901660 | calcium ion export | 1 | 3 | 3.55e-01 |
| GO:BP | GO:1902045 | negative regulation of Fas signaling pathway | 1 | 2 | 3.55e-01 |
| GO:BP | GO:0051446 | positive regulation of meiotic cell cycle | 3 | 16 | 3.55e-01 |
| GO:BP | GO:0021532 | neural tube patterning | 1 | 31 | 3.55e-01 |
| GO:BP | GO:0010765 | positive regulation of sodium ion transport | 3 | 30 | 3.55e-01 |
| GO:BP | GO:0009201 | ribonucleoside triphosphate biosynthetic process | 1 | 102 | 3.55e-01 |
| GO:BP | GO:1904018 | positive regulation of vasculature development | 11 | 115 | 3.55e-01 |
| GO:BP | GO:0045766 | positive regulation of angiogenesis | 11 | 115 | 3.55e-01 |
| GO:BP | GO:0050795 | regulation of behavior | 7 | 39 | 3.55e-01 |
| GO:BP | GO:1904263 | positive regulation of TORC1 signaling | 3 | 24 | 3.55e-01 |
| GO:BP | GO:0062196 | regulation of lysosome size | 1 | 8 | 3.55e-01 |
| GO:BP | GO:0045576 | mast cell activation | 4 | 35 | 3.55e-01 |
| GO:BP | GO:0042297 | vocal learning | 1 | 4 | 3.55e-01 |
| GO:BP | GO:0032057 | negative regulation of translational initiation in response to stress | 1 | 5 | 3.55e-01 |
| GO:BP | GO:1903812 | L-serine import across plasma membrane | 1 | 2 | 3.55e-01 |
| GO:BP | GO:0043518 | negative regulation of DNA damage response, signal transduction by p53 class mediator | 1 | 13 | 3.55e-01 |
| GO:BP | GO:0046902 | regulation of mitochondrial membrane permeability | 2 | 54 | 3.55e-01 |
| GO:BP | GO:1901215 | negative regulation of neuron death | 9 | 167 | 3.55e-01 |
| GO:BP | GO:0002063 | chondrocyte development | 2 | 24 | 3.55e-01 |
| GO:BP | GO:0050870 | positive regulation of T cell activation | 1 | 144 | 3.55e-01 |
| GO:BP | GO:2000757 | negative regulation of peptidyl-lysine acetylation | 1 | 13 | 3.55e-01 |
| GO:BP | GO:0006112 | energy reserve metabolic process | 6 | 73 | 3.55e-01 |
| GO:BP | GO:0060426 | lung vasculature development | 1 | 3 | 3.55e-01 |
| GO:BP | GO:0097070 | ductus arteriosus closure | 1 | 2 | 3.55e-01 |
| GO:BP | GO:0046865 | terpenoid transport | 1 | 3 | 3.55e-01 |
| GO:BP | GO:0046601 | positive regulation of centriole replication | 1 | 9 | 3.55e-01 |
| GO:BP | GO:0046864 | isoprenoid transport | 1 | 3 | 3.55e-01 |
| GO:BP | GO:0098596 | imitative learning | 1 | 4 | 3.55e-01 |
| GO:BP | GO:0015711 | organic anion transport | 1 | 264 | 3.55e-01 |
| GO:BP | GO:0098718 | serine import across plasma membrane | 1 | 2 | 3.55e-01 |
| GO:BP | GO:0009792 | embryo development ending in birth or egg hatching | 6 | 551 | 3.56e-01 |
| GO:BP | GO:0006869 | lipid transport | 3 | 272 | 3.56e-01 |
| GO:BP | GO:0072350 | tricarboxylic acid metabolic process | 1 | 13 | 3.56e-01 |
| GO:BP | GO:0003150 | muscular septum morphogenesis | 1 | 4 | 3.56e-01 |
| GO:BP | GO:0006915 | apoptotic process | 4 | 1443 | 3.56e-01 |
| GO:BP | GO:0043650 | dicarboxylic acid biosynthetic process | 1 | 9 | 3.56e-01 |
| GO:BP | GO:0051170 | import into nucleus | 8 | 152 | 3.56e-01 |
| GO:BP | GO:0051222 | positive regulation of protein transport | 6 | 242 | 3.56e-01 |
| GO:BP | GO:0043470 | regulation of carbohydrate catabolic process | 7 | 47 | 3.56e-01 |
| GO:BP | GO:0070342 | brown fat cell proliferation | 1 | 1 | 3.56e-01 |
| GO:BP | GO:1903358 | regulation of Golgi organization | 2 | 17 | 3.56e-01 |
| GO:BP | GO:0062013 | positive regulation of small molecule metabolic process | 3 | 104 | 3.56e-01 |
| GO:BP | GO:1902811 | positive regulation of skeletal muscle fiber differentiation | 1 | 2 | 3.56e-01 |
| GO:BP | GO:0090594 | inflammatory response to wounding | 1 | 12 | 3.56e-01 |
| GO:BP | GO:0106383 | dAMP salvage | 1 | 3 | 3.56e-01 |
| GO:BP | GO:0009171 | purine deoxyribonucleoside monophosphate biosynthetic process | 1 | 3 | 3.56e-01 |
| GO:BP | GO:0106381 | purine deoxyribonucleotide salvage | 1 | 3 | 3.56e-01 |
| GO:BP | GO:0046070 | dGTP metabolic process | 1 | 3 | 3.56e-01 |
| GO:BP | GO:0006170 | dAMP biosynthetic process | 1 | 3 | 3.56e-01 |
| GO:BP | GO:0046907 | intracellular transport | 5 | 1453 | 3.56e-01 |
| GO:BP | GO:0015742 | alpha-ketoglutarate transport | 1 | 3 | 3.56e-01 |
| GO:BP | GO:0006289 | nucleotide-excision repair | 4 | 79 | 3.56e-01 |
| GO:BP | GO:0050730 | regulation of peptidyl-tyrosine phosphorylation | 1 | 166 | 3.57e-01 |
| GO:BP | GO:0030517 | negative regulation of axon extension | 3 | 41 | 3.57e-01 |
| GO:BP | GO:0006549 | isoleucine metabolic process | 1 | 6 | 3.58e-01 |
| GO:BP | GO:0003164 | His-Purkinje system development | 1 | 7 | 3.58e-01 |
| GO:BP | GO:0003215 | cardiac right ventricle morphogenesis | 1 | 17 | 3.58e-01 |
| GO:BP | GO:0051610 | serotonin uptake | 1 | 8 | 3.58e-01 |
| GO:BP | GO:0045661 | regulation of myoblast differentiation | 4 | 61 | 3.58e-01 |
| GO:BP | GO:0015851 | nucleobase transport | 1 | 7 | 3.58e-01 |
| GO:BP | GO:0060065 | uterus development | 2 | 13 | 3.58e-01 |
| GO:BP | GO:0061323 | cell proliferation involved in heart morphogenesis | 2 | 18 | 3.58e-01 |
| GO:BP | GO:0002699 | positive regulation of immune effector process | 1 | 130 | 3.58e-01 |
| GO:BP | GO:0010828 | positive regulation of glucose transmembrane transport | 4 | 31 | 3.58e-01 |
| GO:BP | GO:0006749 | glutathione metabolic process | 6 | 41 | 3.58e-01 |
| GO:BP | GO:1902018 | negative regulation of cilium assembly | 3 | 15 | 3.58e-01 |
| GO:BP | GO:1903598 | positive regulation of gap junction assembly | 1 | 7 | 3.58e-01 |
| GO:BP | GO:0043122 | regulation of I-kappaB kinase/NF-kappaB signaling | 16 | 203 | 3.58e-01 |
| GO:BP | GO:0002469 | myeloid dendritic cell antigen processing and presentation | 1 | 1 | 3.59e-01 |
| GO:BP | GO:0002491 | antigen processing and presentation of endogenous peptide antigen via MHC class II | 1 | 1 | 3.59e-01 |
| GO:BP | GO:0002352 | B cell negative selection | 1 | 2 | 3.59e-01 |
| GO:BP | GO:0055014 | atrial cardiac muscle cell development | 1 | 3 | 3.59e-01 |
| GO:BP | GO:0055011 | atrial cardiac muscle cell differentiation | 1 | 3 | 3.59e-01 |
| GO:BP | GO:0035520 | monoubiquitinated protein deubiquitination | 1 | 36 | 3.59e-01 |
| GO:BP | GO:0035721 | intraciliary retrograde transport | 2 | 14 | 3.59e-01 |
| GO:BP | GO:0006473 | protein acetylation | 6 | 190 | 3.59e-01 |
| GO:BP | GO:0060285 | cilium-dependent cell motility | 1 | 74 | 3.59e-01 |
| GO:BP | GO:0042048 | olfactory behavior | 1 | 7 | 3.59e-01 |
| GO:BP | GO:0140112 | extracellular vesicle biogenesis | 3 | 20 | 3.59e-01 |
| GO:BP | GO:0001539 | cilium or flagellum-dependent cell motility | 1 | 74 | 3.59e-01 |
| GO:BP | GO:0035050 | embryonic heart tube development | 8 | 69 | 3.59e-01 |
| GO:BP | GO:0099003 | vesicle-mediated transport in synapse | 21 | 180 | 3.59e-01 |
| GO:BP | GO:1902855 | regulation of non-motile cilium assembly | 2 | 10 | 3.59e-01 |
| GO:BP | GO:0061045 | negative regulation of wound healing | 2 | 51 | 3.60e-01 |
| GO:BP | GO:0048168 | regulation of neuronal synaptic plasticity | 2 | 42 | 3.60e-01 |
| GO:BP | GO:0060192 | negative regulation of lipase activity | 1 | 13 | 3.60e-01 |
| GO:BP | GO:0046621 | negative regulation of organ growth | 3 | 27 | 3.60e-01 |
| GO:BP | GO:0003433 | chondrocyte development involved in endochondral bone morphogenesis | 1 | 6 | 3.61e-01 |
| GO:BP | GO:0060425 | lung morphogenesis | 1 | 38 | 3.61e-01 |
| GO:BP | GO:0046349 | amino sugar biosynthetic process | 2 | 11 | 3.61e-01 |
| GO:BP | GO:0021510 | spinal cord development | 9 | 59 | 3.61e-01 |
| GO:BP | GO:0071640 | regulation of macrophage inflammatory protein 1 alpha production | 1 | 3 | 3.61e-01 |
| GO:BP | GO:0051481 | negative regulation of cytosolic calcium ion concentration | 2 | 9 | 3.61e-01 |
| GO:BP | GO:0033627 | cell adhesion mediated by integrin | 2 | 63 | 3.61e-01 |
| GO:BP | GO:0010663 | positive regulation of striated muscle cell apoptotic process | 1 | 12 | 3.61e-01 |
| GO:BP | GO:0071608 | macrophage inflammatory protein-1 alpha production | 1 | 3 | 3.61e-01 |
| GO:BP | GO:0010666 | positive regulation of cardiac muscle cell apoptotic process | 1 | 12 | 3.61e-01 |
| GO:BP | GO:0060706 | cell differentiation involved in embryonic placenta development | 4 | 20 | 3.61e-01 |
| GO:BP | GO:0071825 | protein-lipid complex subunit organization | 1 | 29 | 3.61e-01 |
| GO:BP | GO:1903202 | negative regulation of oxidative stress-induced cell death | 3 | 40 | 3.61e-01 |
| GO:BP | GO:0006631 | fatty acid metabolic process | 6 | 276 | 3.61e-01 |
| GO:BP | GO:0071474 | cellular hyperosmotic response | 1 | 13 | 3.62e-01 |
| GO:BP | GO:0055086 | nucleobase-containing small molecule metabolic process | 2 | 487 | 3.62e-01 |
| GO:BP | GO:0034616 | response to laminar fluid shear stress | 2 | 14 | 3.62e-01 |
| GO:BP | GO:0090263 | positive regulation of canonical Wnt signaling pathway | 9 | 91 | 3.62e-01 |
| GO:BP | GO:0002717 | positive regulation of natural killer cell mediated immunity | 3 | 11 | 3.62e-01 |
| GO:BP | GO:0006597 | spermine biosynthetic process | 1 | 2 | 3.62e-01 |
| GO:BP | GO:0016477 | cell migration | 11 | 1081 | 3.62e-01 |
| GO:BP | GO:0043413 | macromolecule glycosylation | 3 | 187 | 3.62e-01 |
| GO:BP | GO:0140546 | defense response to symbiont | 1 | 202 | 3.62e-01 |
| GO:BP | GO:1903895 | negative regulation of IRE1-mediated unfolded protein response | 1 | 5 | 3.62e-01 |
| GO:BP | GO:0090309 | positive regulation of DNA methylation-dependent heterochromatin formation | 2 | 12 | 3.62e-01 |
| GO:BP | GO:0045191 | regulation of isotype switching | 2 | 27 | 3.62e-01 |
| GO:BP | GO:0051607 | defense response to virus | 1 | 202 | 3.62e-01 |
| GO:BP | GO:0072012 | glomerulus vasculature development | 1 | 22 | 3.62e-01 |
| GO:BP | GO:0006235 | dTTP biosynthetic process | 1 | 4 | 3.62e-01 |
| GO:BP | GO:0009212 | pyrimidine deoxyribonucleoside triphosphate biosynthetic process | 1 | 4 | 3.62e-01 |
| GO:BP | GO:0043409 | negative regulation of MAPK cascade | 5 | 145 | 3.62e-01 |
| GO:BP | GO:0046075 | dTTP metabolic process | 1 | 4 | 3.62e-01 |
| GO:BP | GO:0021783 | preganglionic parasympathetic fiber development | 1 | 11 | 3.62e-01 |
| GO:BP | GO:0007080 | mitotic metaphase plate congression | 4 | 55 | 3.62e-01 |
| GO:BP | GO:0006325 | chromatin organization | 10 | 551 | 3.62e-01 |
| GO:BP | GO:0006486 | protein glycosylation | 3 | 187 | 3.62e-01 |
| GO:BP | GO:0010499 | proteasomal ubiquitin-independent protein catabolic process | 1 | 3 | 3.62e-01 |
| GO:BP | GO:0030318 | melanocyte differentiation | 2 | 16 | 3.62e-01 |
| GO:BP | GO:0055089 | fatty acid homeostasis | 1 | 12 | 3.62e-01 |
| GO:BP | GO:0071362 | cellular response to ether | 1 | 5 | 3.62e-01 |
| GO:BP | GO:1902166 | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 1 | 15 | 3.62e-01 |
| GO:BP | GO:0051865 | protein autoubiquitination | 5 | 75 | 3.63e-01 |
| GO:BP | GO:0010469 | regulation of signaling receptor activity | 2 | 107 | 3.63e-01 |
| GO:BP | GO:2001233 | regulation of apoptotic signaling pathway | 8 | 307 | 3.63e-01 |
| GO:BP | GO:2000630 | positive regulation of miRNA metabolic process | 2 | 48 | 3.63e-01 |
| GO:BP | GO:0010823 | negative regulation of mitochondrion organization | 3 | 46 | 3.63e-01 |
| GO:BP | GO:0098751 | bone cell development | 2 | 26 | 3.63e-01 |
| GO:BP | GO:0043388 | positive regulation of DNA binding | 2 | 44 | 3.63e-01 |
| GO:BP | GO:0043276 | anoikis | 1 | 32 | 3.63e-01 |
| GO:BP | GO:0014068 | positive regulation of phosphatidylinositol 3-kinase signaling | 3 | 55 | 3.63e-01 |
| GO:BP | GO:0033036 | macromolecule localization | 5 | 2450 | 3.63e-01 |
| GO:BP | GO:0072136 | metanephric mesenchymal cell proliferation involved in metanephros development | 1 | 2 | 3.63e-01 |
| GO:BP | GO:0009069 | serine family amino acid metabolic process | 3 | 30 | 3.63e-01 |
| GO:BP | GO:0000459 | exonucleolytic trimming involved in rRNA processing | 2 | 9 | 3.63e-01 |
| GO:BP | GO:0000467 | exonucleolytic trimming to generate mature 3’-end of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 2 | 9 | 3.63e-01 |
| GO:BP | GO:0072135 | kidney mesenchymal cell proliferation | 1 | 2 | 3.63e-01 |
| GO:BP | GO:0046824 | positive regulation of nucleocytoplasmic transport | 3 | 51 | 3.63e-01 |
| GO:BP | GO:0050890 | cognition | 21 | 227 | 3.63e-01 |
| GO:BP | GO:0010632 | regulation of epithelial cell migration | 4 | 195 | 3.63e-01 |
| GO:BP | GO:0009142 | nucleoside triphosphate biosynthetic process | 1 | 111 | 3.64e-01 |
| GO:BP | GO:0010389 | regulation of G2/M transition of mitotic cell cycle | 1 | 92 | 3.64e-01 |
| GO:BP | GO:0090083 | regulation of inclusion body assembly | 3 | 16 | 3.64e-01 |
| GO:BP | GO:0070169 | positive regulation of biomineral tissue development | 6 | 39 | 3.64e-01 |
| GO:BP | GO:1903347 | negative regulation of bicellular tight junction assembly | 1 | 3 | 3.64e-01 |
| GO:BP | GO:0003383 | apical constriction | 1 | 4 | 3.64e-01 |
| GO:BP | GO:0042733 | embryonic digit morphogenesis | 1 | 51 | 3.65e-01 |
| GO:BP | GO:1901379 | regulation of potassium ion transmembrane transport | 1 | 64 | 3.65e-01 |
| GO:BP | GO:0046847 | filopodium assembly | 3 | 56 | 3.65e-01 |
| GO:BP | GO:0035455 | response to interferon-alpha | 1 | 16 | 3.65e-01 |
| GO:BP | GO:0001705 | ectoderm formation | 1 | 3 | 3.65e-01 |
| GO:BP | GO:0032058 | positive regulation of translational initiation in response to stress | 1 | 4 | 3.66e-01 |
| GO:BP | GO:0031065 | positive regulation of histone deacetylation | 2 | 22 | 3.66e-01 |
| GO:BP | GO:0045667 | regulation of osteoblast differentiation | 1 | 99 | 3.66e-01 |
| GO:BP | GO:0002361 | CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation | 2 | 3 | 3.66e-01 |
| GO:BP | GO:0044778 | meiotic DNA integrity checkpoint signaling | 1 | 1 | 3.66e-01 |
| GO:BP | GO:0021801 | cerebral cortex radial glia-guided migration | 1 | 22 | 3.66e-01 |
| GO:BP | GO:1905037 | autophagosome organization | 12 | 110 | 3.66e-01 |
| GO:BP | GO:0014734 | skeletal muscle hypertrophy | 1 | 1 | 3.66e-01 |
| GO:BP | GO:0022030 | telencephalon glial cell migration | 1 | 22 | 3.66e-01 |
| GO:BP | GO:0016973 | poly(A)+ mRNA export from nucleus | 2 | 15 | 3.66e-01 |
| GO:BP | GO:0007339 | binding of sperm to zona pellucida | 2 | 20 | 3.66e-01 |
| GO:BP | GO:0060068 | vagina development | 2 | 8 | 3.66e-01 |
| GO:BP | GO:1901387 | positive regulation of voltage-gated calcium channel activity | 3 | 13 | 3.66e-01 |
| GO:BP | GO:0048806 | genitalia development | 3 | 28 | 3.66e-01 |
| GO:BP | GO:0012501 | programmed cell death | 4 | 1479 | 3.66e-01 |
| GO:BP | GO:0045723 | positive regulation of fatty acid biosynthetic process | 1 | 12 | 3.66e-01 |
| GO:BP | GO:0032402 | melanosome transport | 3 | 19 | 3.66e-01 |
| GO:BP | GO:0018022 | peptidyl-lysine methylation | 3 | 104 | 3.66e-01 |
| GO:BP | GO:0016447 | somatic recombination of immunoglobulin gene segments | 3 | 47 | 3.66e-01 |
| GO:BP | GO:0086091 | regulation of heart rate by cardiac conduction | 2 | 36 | 3.66e-01 |
| GO:BP | GO:0150173 | positive regulation of phosphatidylcholine metabolic process | 1 | 3 | 3.66e-01 |
| GO:BP | GO:2001247 | positive regulation of phosphatidylcholine biosynthetic process | 1 | 3 | 3.66e-01 |
| GO:BP | GO:0001893 | maternal placenta development | 3 | 28 | 3.66e-01 |
| GO:BP | GO:0051960 | regulation of nervous system development | 19 | 357 | 3.67e-01 |
| GO:BP | GO:1902905 | positive regulation of supramolecular fiber organization | 7 | 151 | 3.67e-01 |
| GO:BP | GO:0030239 | myofibril assembly | 2 | 66 | 3.67e-01 |
| GO:BP | GO:0050769 | positive regulation of neurogenesis | 2 | 189 | 3.68e-01 |
| GO:BP | GO:0016266 | O-glycan processing | 1 | 30 | 3.68e-01 |
| GO:BP | GO:0003309 | type B pancreatic cell differentiation | 3 | 22 | 3.68e-01 |
| GO:BP | GO:0010634 | positive regulation of epithelial cell migration | 3 | 132 | 3.68e-01 |
| GO:BP | GO:1905870 | positive regulation of 3’-UTR-mediated mRNA stabilization | 1 | 4 | 3.68e-01 |
| GO:BP | GO:0002042 | cell migration involved in sprouting angiogenesis | 3 | 45 | 3.68e-01 |
| GO:BP | GO:0021515 | cell differentiation in spinal cord | 2 | 24 | 3.68e-01 |
| GO:BP | GO:0071076 | RNA 3’ uridylation | 1 | 4 | 3.68e-01 |
| GO:BP | GO:0030518 | intracellular steroid hormone receptor signaling pathway | 7 | 95 | 3.68e-01 |
| GO:BP | GO:0043243 | positive regulation of protein-containing complex disassembly | 3 | 30 | 3.68e-01 |
| GO:BP | GO:0050932 | regulation of pigment cell differentiation | 1 | 6 | 3.68e-01 |
| GO:BP | GO:2000727 | positive regulation of cardiac muscle cell differentiation | 1 | 6 | 3.68e-01 |
| GO:BP | GO:0045722 | positive regulation of gluconeogenesis | 1 | 16 | 3.68e-01 |
| GO:BP | GO:0061440 | kidney vasculature development | 1 | 24 | 3.68e-01 |
| GO:BP | GO:0080134 | regulation of response to stress | 55 | 1075 | 3.68e-01 |
| GO:BP | GO:0014874 | response to stimulus involved in regulation of muscle adaptation | 2 | 12 | 3.68e-01 |
| GO:BP | GO:0061437 | renal system vasculature development | 1 | 24 | 3.68e-01 |
| GO:BP | GO:1900101 | regulation of endoplasmic reticulum unfolded protein response | 4 | 29 | 3.68e-01 |
| GO:BP | GO:0051056 | regulation of small GTPase mediated signal transduction | 7 | 257 | 3.68e-01 |
| GO:BP | GO:0000480 | endonucleolytic cleavage in 5’-ETS of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 1 | 8 | 3.68e-01 |
| GO:BP | GO:1903513 | endoplasmic reticulum to cytosol transport | 2 | 28 | 3.68e-01 |
| GO:BP | GO:2000098 | negative regulation of smooth muscle cell-matrix adhesion | 1 | 1 | 3.68e-01 |
| GO:BP | GO:0048593 | camera-type eye morphogenesis | 2 | 91 | 3.68e-01 |
| GO:BP | GO:0042423 | catecholamine biosynthetic process | 1 | 11 | 3.68e-01 |
| GO:BP | GO:0032787 | monocarboxylic acid metabolic process | 2 | 433 | 3.68e-01 |
| GO:BP | GO:0090685 | RNA localization to nucleus | 3 | 19 | 3.68e-01 |
| GO:BP | GO:0009713 | catechol-containing compound biosynthetic process | 1 | 11 | 3.68e-01 |
| GO:BP | GO:0090671 | telomerase RNA localization to Cajal body | 3 | 19 | 3.68e-01 |
| GO:BP | GO:1902913 | positive regulation of neuroepithelial cell differentiation | 1 | 2 | 3.68e-01 |
| GO:BP | GO:0090670 | RNA localization to Cajal body | 3 | 19 | 3.68e-01 |
| GO:BP | GO:0031063 | regulation of histone deacetylation | 3 | 36 | 3.68e-01 |
| GO:BP | GO:0046034 | ATP metabolic process | 1 | 116 | 3.68e-01 |
| GO:BP | GO:0034352 | positive regulation of glial cell apoptotic process | 1 | 2 | 3.68e-01 |
| GO:BP | GO:0090611 | ubiquitin-independent protein catabolic process via the multivesicular body sorting pathway | 1 | 5 | 3.68e-01 |
| GO:BP | GO:0007000 | nucleolus organization | 1 | 17 | 3.68e-01 |
| GO:BP | GO:0010992 | ubiquitin recycling | 1 | 12 | 3.68e-01 |
| GO:BP | GO:0055002 | striated muscle cell development | 2 | 67 | 3.68e-01 |
| GO:BP | GO:0034389 | lipid droplet organization | 2 | 30 | 3.68e-01 |
| GO:BP | GO:0010876 | lipid localization | 1 | 310 | 3.68e-01 |
| GO:BP | GO:0034465 | response to carbon monoxide | 1 | 3 | 3.68e-01 |
| GO:BP | GO:0048532 | anatomical structure arrangement | 1 | 13 | 3.68e-01 |
| GO:BP | GO:1902938 | regulation of intracellular calcium activated chloride channel activity | 1 | 1 | 3.68e-01 |
| GO:BP | GO:0090672 | telomerase RNA localization | 3 | 19 | 3.68e-01 |
| GO:BP | GO:0031327 | negative regulation of cellular biosynthetic process | 73 | 1239 | 3.68e-01 |
| GO:BP | GO:0110032 | positive regulation of G2/MI transition of meiotic cell cycle | 1 | 3 | 3.68e-01 |
| GO:BP | GO:0071467 | cellular response to pH | 1 | 16 | 3.68e-01 |
| GO:BP | GO:0048665 | neuron fate specification | 1 | 14 | 3.68e-01 |
| GO:BP | GO:0051084 | ‘de novo’ post-translational protein folding | 1 | 35 | 3.68e-01 |
| GO:BP | GO:0007611 | learning or memory | 1 | 202 | 3.68e-01 |
| GO:BP | GO:0042698 | ovulation cycle | 2 | 54 | 3.68e-01 |
| GO:BP | GO:0001773 | myeloid dendritic cell activation | 1 | 12 | 3.68e-01 |
| GO:BP | GO:0046370 | fructose biosynthetic process | 1 | 2 | 3.68e-01 |
| GO:BP | GO:0047484 | regulation of response to osmotic stress | 1 | 12 | 3.68e-01 |
| GO:BP | GO:0051083 | ‘de novo’ cotranslational protein folding | 1 | 2 | 3.68e-01 |
| GO:BP | GO:1902951 | negative regulation of dendritic spine maintenance | 1 | 2 | 3.68e-01 |
| GO:BP | GO:0036261 | 7-methylguanosine cap hypermethylation | 1 | 8 | 3.68e-01 |
| GO:BP | GO:0030970 | retrograde protein transport, ER to cytosol | 2 | 28 | 3.68e-01 |
| GO:BP | GO:1903311 | regulation of mRNA metabolic process | 16 | 267 | 3.69e-01 |
| GO:BP | GO:0006352 | DNA-templated transcription initiation | 2 | 130 | 3.69e-01 |
| GO:BP | GO:0006996 | organelle organization | 4 | 3000 | 3.69e-01 |
| GO:BP | GO:0050767 | regulation of neurogenesis | 16 | 301 | 3.69e-01 |
| GO:BP | GO:0035295 | tube development | 35 | 821 | 3.69e-01 |
| GO:BP | GO:0050999 | regulation of nitric-oxide synthase activity | 1 | 25 | 3.70e-01 |
| GO:BP | GO:0001701 | in utero embryonic development | 20 | 344 | 3.70e-01 |
| GO:BP | GO:0051457 | maintenance of protein location in nucleus | 2 | 22 | 3.70e-01 |
| GO:BP | GO:0009219 | pyrimidine deoxyribonucleotide metabolic process | 3 | 21 | 3.70e-01 |
| GO:BP | GO:1902175 | regulation of oxidative stress-induced intrinsic apoptotic signaling pathway | 3 | 25 | 3.70e-01 |
| GO:BP | GO:2000678 | negative regulation of transcription regulatory region DNA binding | 3 | 17 | 3.71e-01 |
| GO:BP | GO:0010571 | positive regulation of nuclear cell cycle DNA replication | 1 | 6 | 3.71e-01 |
| GO:BP | GO:0086019 | cell-cell signaling involved in cardiac conduction | 2 | 33 | 3.71e-01 |
| GO:BP | GO:0010719 | negative regulation of epithelial to mesenchymal transition | 2 | 29 | 3.71e-01 |
| GO:BP | GO:0098964 | anterograde dendritic transport of messenger ribonucleoprotein complex | 1 | 2 | 3.71e-01 |
| GO:BP | GO:0045332 | phospholipid translocation | 1 | 33 | 3.72e-01 |
| GO:BP | GO:0072659 | protein localization to plasma membrane | 1 | 249 | 3.72e-01 |
| GO:BP | GO:1904951 | positive regulation of establishment of protein localization | 10 | 258 | 3.72e-01 |
| GO:BP | GO:0042667 | auditory receptor cell fate specification | 1 | 1 | 3.73e-01 |
| GO:BP | GO:0060415 | muscle tissue morphogenesis | 2 | 60 | 3.73e-01 |
| GO:BP | GO:0032458 | slow endocytic recycling | 1 | 2 | 3.73e-01 |
| GO:BP | GO:0008630 | intrinsic apoptotic signaling pathway in response to DNA damage | 5 | 94 | 3.73e-01 |
| GO:BP | GO:0110111 | negative regulation of animal organ morphogenesis | 1 | 1 | 3.73e-01 |
| GO:BP | GO:0042483 | negative regulation of odontogenesis | 1 | 1 | 3.73e-01 |
| GO:BP | GO:0031547 | brain-derived neurotrophic factor receptor signaling pathway | 1 | 6 | 3.73e-01 |
| GO:BP | GO:0042489 | negative regulation of odontogenesis of dentin-containing tooth | 1 | 1 | 3.73e-01 |
| GO:BP | GO:0016050 | vesicle organization | 18 | 320 | 3.73e-01 |
| GO:BP | GO:0048870 | cell motility | 12 | 1182 | 3.73e-01 |
| GO:BP | GO:0007021 | tubulin complex assembly | 1 | 9 | 3.73e-01 |
| GO:BP | GO:0048015 | phosphatidylinositol-mediated signaling | 10 | 123 | 3.73e-01 |
| GO:BP | GO:0031445 | regulation of heterochromatin formation | 3 | 22 | 3.73e-01 |
| GO:BP | GO:0071044 | histone mRNA catabolic process | 2 | 11 | 3.73e-01 |
| GO:BP | GO:0120261 | regulation of heterochromatin organization | 3 | 22 | 3.73e-01 |
| GO:BP | GO:0060429 | epithelium development | 9 | 850 | 3.74e-01 |
| GO:BP | GO:2000393 | negative regulation of lamellipodium morphogenesis | 1 | 2 | 3.74e-01 |
| GO:BP | GO:0061311 | cell surface receptor signaling pathway involved in heart development | 1 | 25 | 3.74e-01 |
| GO:BP | GO:0002028 | regulation of sodium ion transport | 6 | 72 | 3.75e-01 |
| GO:BP | GO:1905259 | negative regulation of nitrosative stress-induced intrinsic apoptotic signaling pathway | 1 | 2 | 3.75e-01 |
| GO:BP | GO:1902661 | positive regulation of glucose mediated signaling pathway | 1 | 3 | 3.75e-01 |
| GO:BP | GO:1902659 | regulation of glucose mediated signaling pathway | 1 | 3 | 3.75e-01 |
| GO:BP | GO:1905258 | regulation of nitrosative stress-induced intrinsic apoptotic signaling pathway | 1 | 2 | 3.75e-01 |
| GO:BP | GO:0010763 | positive regulation of fibroblast migration | 2 | 15 | 3.75e-01 |
| GO:BP | GO:0035456 | response to interferon-beta | 4 | 22 | 3.75e-01 |
| GO:BP | GO:0010971 | positive regulation of G2/M transition of mitotic cell cycle | 3 | 27 | 3.75e-01 |
| GO:BP | GO:0044255 | cellular lipid metabolic process | 2 | 740 | 3.75e-01 |
| GO:BP | GO:0000290 | deadenylation-dependent decapping of nuclear-transcribed mRNA | 1 | 9 | 3.75e-01 |
| GO:BP | GO:0006554 | lysine catabolic process | 1 | 6 | 3.75e-01 |
| GO:BP | GO:0033617 | mitochondrial cytochrome c oxidase assembly | 3 | 25 | 3.75e-01 |
| GO:BP | GO:0019046 | release from viral latency | 1 | 2 | 3.75e-01 |
| GO:BP | GO:0019045 | latent virus replication | 1 | 2 | 3.75e-01 |
| GO:BP | GO:0006990 | positive regulation of transcription from RNA polymerase II promoter involved in unfolded protein response | 1 | 2 | 3.75e-01 |
| GO:BP | GO:0045815 | transcription initiation-coupled chromatin remodeling | 1 | 26 | 3.75e-01 |
| GO:BP | GO:0046618 | xenobiotic export from cell | 1 | 8 | 3.75e-01 |
| GO:BP | GO:0045184 | establishment of protein localization | 5 | 1462 | 3.75e-01 |
| GO:BP | GO:0030182 | neuron differentiation | 7 | 1061 | 3.75e-01 |
| GO:BP | GO:0048486 | parasympathetic nervous system development | 1 | 12 | 3.76e-01 |
| GO:BP | GO:0097283 | keratinocyte apoptotic process | 1 | 5 | 3.76e-01 |
| GO:BP | GO:1903984 | positive regulation of TRAIL-activated apoptotic signaling pathway | 1 | 3 | 3.76e-01 |
| GO:BP | GO:1902172 | regulation of keratinocyte apoptotic process | 1 | 5 | 3.76e-01 |
| GO:BP | GO:0090666 | scaRNA localization to Cajal body | 1 | 5 | 3.76e-01 |
| GO:BP | GO:0048263 | determination of dorsal identity | 1 | 5 | 3.76e-01 |
| GO:BP | GO:1904747 | positive regulation of apoptotic process involved in development | 1 | 5 | 3.76e-01 |
| GO:BP | GO:0032570 | response to progesterone | 3 | 27 | 3.76e-01 |
| GO:BP | GO:0071902 | positive regulation of protein serine/threonine kinase activity | 8 | 135 | 3.76e-01 |
| GO:BP | GO:0032515 | negative regulation of phosphoprotein phosphatase activity | 1 | 21 | 3.76e-01 |
| GO:BP | GO:0046039 | GTP metabolic process | 2 | 21 | 3.76e-01 |
| GO:BP | GO:0022616 | DNA strand elongation | 5 | 35 | 3.76e-01 |
| GO:BP | GO:0030578 | PML body organization | 1 | 6 | 3.76e-01 |
| GO:BP | GO:0003017 | lymph circulation | 1 | 2 | 3.76e-01 |
| GO:BP | GO:0006641 | triglyceride metabolic process | 3 | 68 | 3.76e-01 |
| GO:BP | GO:1902339 | positive regulation of apoptotic process involved in morphogenesis | 1 | 5 | 3.76e-01 |
| GO:BP | GO:0007182 | common-partner SMAD protein phosphorylation | 1 | 6 | 3.76e-01 |
| GO:BP | GO:0001579 | medium-chain fatty acid transport | 1 | 2 | 3.76e-01 |
| GO:BP | GO:0098597 | observational learning | 1 | 5 | 3.76e-01 |
| GO:BP | GO:0044320 | cellular response to leptin stimulus | 1 | 15 | 3.76e-01 |
| GO:BP | GO:0019370 | leukotriene biosynthetic process | 1 | 7 | 3.76e-01 |
| GO:BP | GO:0061038 | uterus morphogenesis | 1 | 5 | 3.76e-01 |
| GO:BP | GO:0120161 | regulation of cold-induced thermogenesis | 5 | 112 | 3.76e-01 |
| GO:BP | GO:0006888 | endoplasmic reticulum to Golgi vesicle-mediated transport | 2 | 119 | 3.76e-01 |
| GO:BP | GO:1902165 | regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 1 | 17 | 3.76e-01 |
| GO:BP | GO:0046900 | tetrahydrofolylpolyglutamate metabolic process | 1 | 2 | 3.76e-01 |
| GO:BP | GO:0032984 | protein-containing complex disassembly | 15 | 222 | 3.76e-01 |
| GO:BP | GO:0002067 | glandular epithelial cell differentiation | 4 | 50 | 3.76e-01 |
| GO:BP | GO:0044314 | protein K27-linked ubiquitination | 1 | 8 | 3.77e-01 |
| GO:BP | GO:0002521 | leukocyte differentiation | 2 | 382 | 3.77e-01 |
| GO:BP | GO:0032528 | microvillus organization | 3 | 19 | 3.77e-01 |
| GO:BP | GO:0032814 | regulation of natural killer cell activation | 3 | 20 | 3.77e-01 |
| GO:BP | GO:0097320 | plasma membrane tubulation | 3 | 18 | 3.77e-01 |
| GO:BP | GO:0002366 | leukocyte activation involved in immune response | 1 | 154 | 3.77e-01 |
| GO:BP | GO:0042594 | response to starvation | 12 | 178 | 3.77e-01 |
| GO:BP | GO:0000727 | double-strand break repair via break-induced replication | 1 | 11 | 3.77e-01 |
| GO:BP | GO:0042256 | cytosolic ribosome assembly | 1 | 5 | 3.77e-01 |
| GO:BP | GO:0048813 | dendrite morphogenesis | 7 | 120 | 3.77e-01 |
| GO:BP | GO:0003161 | cardiac conduction system development | 2 | 33 | 3.77e-01 |
| GO:BP | GO:0099624 | atrial cardiac muscle cell membrane repolarization | 1 | 9 | 3.77e-01 |
| GO:BP | GO:1902749 | regulation of cell cycle G2/M phase transition | 1 | 103 | 3.77e-01 |
| GO:BP | GO:0002313 | mature B cell differentiation involved in immune response | 1 | 17 | 3.77e-01 |
| GO:BP | GO:0061428 | negative regulation of transcription from RNA polymerase II promoter in response to hypoxia | 1 | 4 | 3.77e-01 |
| GO:BP | GO:2000642 | negative regulation of early endosome to late endosome transport | 1 | 2 | 3.77e-01 |
| GO:BP | GO:0051149 | positive regulation of muscle cell differentiation | 3 | 53 | 3.77e-01 |
| GO:BP | GO:0007619 | courtship behavior | 1 | 3 | 3.77e-01 |
| GO:BP | GO:0000379 | tRNA-type intron splice site recognition and cleavage | 1 | 3 | 3.77e-01 |
| GO:BP | GO:0002263 | cell activation involved in immune response | 1 | 157 | 3.77e-01 |
| GO:BP | GO:1904851 | positive regulation of establishment of protein localization to telomere | 2 | 10 | 3.77e-01 |
| GO:BP | GO:0099041 | vesicle tethering to Golgi | 1 | 5 | 3.77e-01 |
| GO:BP | GO:0006493 | protein O-linked glycosylation | 4 | 69 | 3.77e-01 |
| GO:BP | GO:0009651 | response to salt stress | 2 | 18 | 3.77e-01 |
| GO:BP | GO:0033007 | negative regulation of mast cell activation involved in immune response | 1 | 4 | 3.77e-01 |
| GO:BP | GO:2000479 | regulation of cAMP-dependent protein kinase activity | 3 | 16 | 3.77e-01 |
| GO:BP | GO:0006465 | signal peptide processing | 2 | 13 | 3.77e-01 |
| GO:BP | GO:0048385 | regulation of retinoic acid receptor signaling pathway | 2 | 13 | 3.77e-01 |
| GO:BP | GO:0001941 | postsynaptic membrane organization | 5 | 29 | 3.77e-01 |
| GO:BP | GO:0070989 | oxidative demethylation | 1 | 10 | 3.77e-01 |
| GO:BP | GO:0050931 | pigment cell differentiation | 3 | 26 | 3.77e-01 |
| GO:BP | GO:0051904 | pigment granule transport | 3 | 19 | 3.77e-01 |
| GO:BP | GO:0032401 | establishment of melanosome localization | 3 | 20 | 3.77e-01 |
| GO:BP | GO:0002157 | positive regulation of thyroid hormone mediated signaling pathway | 1 | 3 | 3.77e-01 |
| GO:BP | GO:0070372 | regulation of ERK1 and ERK2 cascade | 1 | 191 | 3.77e-01 |
| GO:BP | GO:0032696 | negative regulation of interleukin-13 production | 1 | 3 | 3.77e-01 |
| GO:BP | GO:0030217 | T cell differentiation | 1 | 185 | 3.77e-01 |
| GO:BP | GO:0097191 | extrinsic apoptotic signaling pathway | 9 | 179 | 3.78e-01 |
| GO:BP | GO:0106106 | cold-induced thermogenesis | 5 | 113 | 3.78e-01 |
| GO:BP | GO:0106071 | positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway | 1 | 3 | 3.78e-01 |
| GO:BP | GO:0034473 | U1 snRNA 3’-end processing | 1 | 3 | 3.78e-01 |
| GO:BP | GO:0034476 | U5 snRNA 3’-end processing | 1 | 3 | 3.78e-01 |
| GO:BP | GO:0043113 | receptor clustering | 7 | 45 | 3.78e-01 |
| GO:BP | GO:0030501 | positive regulation of bone mineralization | 5 | 34 | 3.79e-01 |
| GO:BP | GO:0043628 | regulatory ncRNA 3’-end processing | 3 | 19 | 3.79e-01 |
| GO:BP | GO:0051292 | nuclear pore complex assembly | 1 | 9 | 3.79e-01 |
| GO:BP | GO:1990830 | cellular response to leukemia inhibitory factor | 10 | 84 | 3.79e-01 |
| GO:BP | GO:0007020 | microtubule nucleation | 3 | 39 | 3.79e-01 |
| GO:BP | GO:0033572 | transferrin transport | 2 | 8 | 3.79e-01 |
| GO:BP | GO:0035781 | CD86 biosynthetic process | 1 | 2 | 3.79e-01 |
| GO:BP | GO:0035909 | aorta morphogenesis | 2 | 26 | 3.79e-01 |
| GO:BP | GO:2000725 | regulation of cardiac muscle cell differentiation | 2 | 14 | 3.79e-01 |
| GO:BP | GO:0070507 | regulation of microtubule cytoskeleton organization | 9 | 146 | 3.79e-01 |
| GO:BP | GO:0072236 | metanephric loop of Henle development | 1 | 3 | 3.79e-01 |
| GO:BP | GO:0071332 | cellular response to fructose stimulus | 1 | 2 | 3.79e-01 |
| GO:BP | GO:1902513 | regulation of organelle transport along microtubule | 1 | 9 | 3.79e-01 |
| GO:BP | GO:1900242 | regulation of synaptic vesicle endocytosis | 3 | 16 | 3.80e-01 |
| GO:BP | GO:0006050 | mannosamine metabolic process | 1 | 2 | 3.80e-01 |
| GO:BP | GO:0048566 | embryonic digestive tract development | 3 | 20 | 3.80e-01 |
| GO:BP | GO:0048009 | insulin-like growth factor receptor signaling pathway | 3 | 42 | 3.80e-01 |
| GO:BP | GO:0090128 | regulation of synapse maturation | 2 | 15 | 3.80e-01 |
| GO:BP | GO:1905709 | negative regulation of membrane permeability | 3 | 19 | 3.80e-01 |
| GO:BP | GO:0006051 | N-acetylmannosamine metabolic process | 1 | 2 | 3.80e-01 |
| GO:BP | GO:1902083 | negative regulation of peptidyl-cysteine S-nitrosylation | 1 | 6 | 3.80e-01 |
| GO:BP | GO:0010564 | regulation of cell cycle process | 47 | 626 | 3.80e-01 |
| GO:BP | GO:0010544 | negative regulation of platelet activation | 1 | 17 | 3.80e-01 |
| GO:BP | GO:0051640 | organelle localization | 2 | 503 | 3.80e-01 |
| GO:BP | GO:0007100 | mitotic centrosome separation | 2 | 13 | 3.80e-01 |
| GO:BP | GO:0010660 | regulation of muscle cell apoptotic process | 2 | 56 | 3.80e-01 |
| GO:BP | GO:0042267 | natural killer cell mediated cytotoxicity | 5 | 34 | 3.80e-01 |
| GO:BP | GO:0097355 | protein localization to heterochromatin | 1 | 3 | 3.80e-01 |
| GO:BP | GO:0060809 | mesodermal to mesenchymal transition involved in gastrulation | 1 | 2 | 3.80e-01 |
| GO:BP | GO:0010447 | response to acidic pH | 1 | 16 | 3.81e-01 |
| GO:BP | GO:0048087 | positive regulation of developmental pigmentation | 1 | 7 | 3.81e-01 |
| GO:BP | GO:0048863 | stem cell differentiation | 10 | 197 | 3.81e-01 |
| GO:BP | GO:0032480 | negative regulation of type I interferon production | 4 | 23 | 3.81e-01 |
| GO:BP | GO:0044321 | response to leptin | 2 | 19 | 3.81e-01 |
| GO:BP | GO:1902035 | positive regulation of hematopoietic stem cell proliferation | 1 | 7 | 3.81e-01 |
| GO:BP | GO:0001829 | trophectodermal cell differentiation | 2 | 15 | 3.81e-01 |
| GO:BP | GO:0060716 | labyrinthine layer blood vessel development | 2 | 16 | 3.81e-01 |
| GO:BP | GO:0043266 | regulation of potassium ion transport | 1 | 73 | 3.81e-01 |
| GO:BP | GO:0018105 | peptidyl-serine phosphorylation | 1 | 247 | 3.81e-01 |
| GO:BP | GO:0046839 | phospholipid dephosphorylation | 1 | 39 | 3.81e-01 |
| GO:BP | GO:0009725 | response to hormone | 38 | 642 | 3.81e-01 |
| GO:BP | GO:0032687 | negative regulation of interferon-alpha production | 1 | 2 | 3.81e-01 |
| GO:BP | GO:0097155 | fasciculation of sensory neuron axon | 1 | 3 | 3.81e-01 |
| GO:BP | GO:0002714 | positive regulation of B cell mediated immunity | 2 | 26 | 3.81e-01 |
| GO:BP | GO:0021943 | formation of radial glial scaffolds | 1 | 3 | 3.81e-01 |
| GO:BP | GO:0006851 | mitochondrial calcium ion transmembrane transport | 1 | 17 | 3.81e-01 |
| GO:BP | GO:0007418 | ventral midline development | 1 | 4 | 3.81e-01 |
| GO:BP | GO:0046629 | gamma-delta T cell activation | 2 | 9 | 3.81e-01 |
| GO:BP | GO:0045346 | regulation of MHC class II biosynthetic process | 1 | 11 | 3.81e-01 |
| GO:BP | GO:0061042 | vascular wound healing | 1 | 17 | 3.81e-01 |
| GO:BP | GO:0002891 | positive regulation of immunoglobulin mediated immune response | 2 | 26 | 3.81e-01 |
| GO:BP | GO:0035729 | cellular response to hepatocyte growth factor stimulus | 2 | 13 | 3.81e-01 |
| GO:BP | GO:0006458 | ‘de novo’ protein folding | 1 | 39 | 3.81e-01 |
| GO:BP | GO:0062197 | cellular response to chemical stress | 13 | 293 | 3.81e-01 |
| GO:BP | GO:0003341 | cilium movement | 1 | 97 | 3.81e-01 |
| GO:BP | GO:0034498 | early endosome to Golgi transport | 1 | 9 | 3.81e-01 |
| GO:BP | GO:0006903 | vesicle targeting | 1 | 61 | 3.81e-01 |
| GO:BP | GO:0007051 | spindle organization | 10 | 188 | 3.81e-01 |
| GO:BP | GO:0071107 | response to parathyroid hormone | 2 | 9 | 3.81e-01 |
| GO:BP | GO:1905562 | regulation of vascular endothelial cell proliferation | 2 | 21 | 3.81e-01 |
| GO:BP | GO:0101023 | vascular endothelial cell proliferation | 2 | 21 | 3.81e-01 |
| GO:BP | GO:0002674 | negative regulation of acute inflammatory response | 1 | 5 | 3.81e-01 |
| GO:BP | GO:0016052 | carbohydrate catabolic process | 1 | 120 | 3.81e-01 |
| GO:BP | GO:0031348 | negative regulation of defense response | 20 | 159 | 3.82e-01 |
| GO:BP | GO:0022603 | regulation of anatomical structure morphogenesis | 36 | 691 | 3.82e-01 |
| GO:BP | GO:0046660 | female sex differentiation | 7 | 91 | 3.82e-01 |
| GO:BP | GO:0051094 | positive regulation of developmental process | 41 | 957 | 3.83e-01 |
| GO:BP | GO:0016482 | cytosolic transport | 10 | 161 | 3.83e-01 |
| GO:BP | GO:0045599 | negative regulation of fat cell differentiation | 4 | 43 | 3.83e-01 |
| GO:BP | GO:0043200 | response to amino acid | 1 | 95 | 3.83e-01 |
| GO:BP | GO:0031032 | actomyosin structure organization | 10 | 186 | 3.83e-01 |
| GO:BP | GO:0034204 | lipid translocation | 1 | 38 | 3.84e-01 |
| GO:BP | GO:0010940 | positive regulation of necrotic cell death | 1 | 13 | 3.84e-01 |
| GO:BP | GO:0021627 | olfactory nerve morphogenesis | 1 | 3 | 3.84e-01 |
| GO:BP | GO:0046640 | regulation of alpha-beta T cell proliferation | 5 | 23 | 3.84e-01 |
| GO:BP | GO:0051253 | negative regulation of RNA metabolic process | 18 | 1119 | 3.85e-01 |
| GO:BP | GO:0043649 | dicarboxylic acid catabolic process | 1 | 14 | 3.85e-01 |
| GO:BP | GO:0120163 | negative regulation of cold-induced thermogenesis | 1 | 40 | 3.85e-01 |
| GO:BP | GO:0003418 | growth plate cartilage chondrocyte differentiation | 1 | 8 | 3.85e-01 |
| GO:BP | GO:1900060 | negative regulation of ceramide biosynthetic process | 1 | 5 | 3.85e-01 |
| GO:BP | GO:0071320 | cellular response to cAMP | 5 | 41 | 3.85e-01 |
| GO:BP | GO:0050714 | positive regulation of protein secretion | 3 | 100 | 3.85e-01 |
| GO:BP | GO:0060114 | vestibular receptor cell differentiation | 1 | 1 | 3.85e-01 |
| GO:BP | GO:0006110 | regulation of glycolytic process | 6 | 40 | 3.85e-01 |
| GO:BP | GO:0090235 | regulation of metaphase plate congression | 1 | 13 | 3.85e-01 |
| GO:BP | GO:0016077 | sno(s)RNA catabolic process | 1 | 3 | 3.85e-01 |
| GO:BP | GO:0045216 | cell-cell junction organization | 1 | 153 | 3.85e-01 |
| GO:BP | GO:0060118 | vestibular receptor cell development | 1 | 1 | 3.85e-01 |
| GO:BP | GO:1990823 | response to leukemia inhibitory factor | 10 | 85 | 3.85e-01 |
| GO:BP | GO:0010906 | regulation of glucose metabolic process | 7 | 86 | 3.85e-01 |
| GO:BP | GO:1902896 | terminal web assembly | 1 | 2 | 3.85e-01 |
| GO:BP | GO:0090505 | epiboly involved in wound healing | 1 | 30 | 3.85e-01 |
| GO:BP | GO:0110155 | NAD-cap decapping | 1 | 3 | 3.85e-01 |
| GO:BP | GO:0030259 | lipid glycosylation | 1 | 6 | 3.85e-01 |
| GO:BP | GO:0032075 | positive regulation of nuclease activity | 1 | 7 | 3.85e-01 |
| GO:BP | GO:1903670 | regulation of sprouting angiogenesis | 3 | 28 | 3.85e-01 |
| GO:BP | GO:0071676 | negative regulation of mononuclear cell migration | 3 | 16 | 3.85e-01 |
| GO:BP | GO:0044319 | wound healing, spreading of cells | 1 | 30 | 3.85e-01 |
| GO:BP | GO:0006906 | vesicle fusion | 8 | 104 | 3.85e-01 |
| GO:BP | GO:0031125 | rRNA 3’-end processing | 2 | 10 | 3.85e-01 |
| GO:BP | GO:0048017 | inositol lipid-mediated signaling | 10 | 126 | 3.85e-01 |
| GO:BP | GO:1903721 | positive regulation of I-kappaB phosphorylation | 1 | 5 | 3.85e-01 |
| GO:BP | GO:0019323 | pentose catabolic process | 1 | 2 | 3.85e-01 |
| GO:BP | GO:1900407 | regulation of cellular response to oxidative stress | 2 | 67 | 3.86e-01 |
| GO:BP | GO:0007623 | circadian rhythm | 5 | 165 | 3.86e-01 |
| GO:BP | GO:0051775 | response to redox state | 2 | 12 | 3.86e-01 |
| GO:BP | GO:0048538 | thymus development | 3 | 35 | 3.86e-01 |
| GO:BP | GO:0000278 | mitotic cell cycle | 39 | 827 | 3.86e-01 |
| GO:BP | GO:0051881 | regulation of mitochondrial membrane potential | 4 | 60 | 3.86e-01 |
| GO:BP | GO:0051147 | regulation of muscle cell differentiation | 10 | 118 | 3.86e-01 |
| GO:BP | GO:0120041 | positive regulation of macrophage proliferation | 1 | 4 | 3.86e-01 |
| GO:BP | GO:0070371 | ERK1 and ERK2 cascade | 1 | 211 | 3.86e-01 |
| GO:BP | GO:0061951 | establishment of protein localization to plasma membrane | 1 | 59 | 3.86e-01 |
| GO:BP | GO:0032506 | cytokinetic process | 3 | 39 | 3.86e-01 |
| GO:BP | GO:0060926 | cardiac pacemaker cell development | 1 | 8 | 3.86e-01 |
| GO:BP | GO:0015916 | fatty-acyl-CoA transport | 1 | 2 | 3.86e-01 |
| GO:BP | GO:1901337 | thioester transport | 1 | 2 | 3.86e-01 |
| GO:BP | GO:0055064 | chloride ion homeostasis | 3 | 13 | 3.87e-01 |
| GO:BP | GO:0016578 | histone deubiquitination | 1 | 46 | 3.87e-01 |
| GO:BP | GO:0006499 | N-terminal protein myristoylation | 1 | 4 | 3.87e-01 |
| GO:BP | GO:0018377 | protein myristoylation | 1 | 4 | 3.87e-01 |
| GO:BP | GO:0050860 | negative regulation of T cell receptor signaling pathway | 3 | 17 | 3.87e-01 |
| GO:BP | GO:2000809 | positive regulation of synaptic vesicle clustering | 1 | 3 | 3.87e-01 |
| GO:BP | GO:0010841 | positive regulation of circadian sleep/wake cycle, wakefulness | 1 | 1 | 3.87e-01 |
| GO:BP | GO:0032543 | mitochondrial translation | 2 | 130 | 3.87e-01 |
| GO:BP | GO:2001222 | regulation of neuron migration | 3 | 38 | 3.87e-01 |
| GO:BP | GO:0051409 | response to nitrosative stress | 1 | 10 | 3.87e-01 |
| GO:BP | GO:2000302 | positive regulation of synaptic vesicle exocytosis | 1 | 3 | 3.87e-01 |
| GO:BP | GO:1900073 | regulation of neuromuscular synaptic transmission | 1 | 2 | 3.87e-01 |
| GO:BP | GO:1900075 | positive regulation of neuromuscular synaptic transmission | 1 | 2 | 3.87e-01 |
| GO:BP | GO:0002523 | leukocyte migration involved in inflammatory response | 1 | 9 | 3.87e-01 |
| GO:BP | GO:1904861 | excitatory synapse assembly | 1 | 26 | 3.87e-01 |
| GO:BP | GO:2001252 | positive regulation of chromosome organization | 11 | 103 | 3.87e-01 |
| GO:BP | GO:0030242 | autophagy of peroxisome | 2 | 10 | 3.87e-01 |
| GO:BP | GO:0046341 | CDP-diacylglycerol metabolic process | 2 | 13 | 3.87e-01 |
| GO:BP | GO:0060574 | intestinal epithelial cell maturation | 1 | 3 | 3.87e-01 |
| GO:BP | GO:0006919 | activation of cysteine-type endopeptidase activity involved in apoptotic process | 4 | 65 | 3.87e-01 |
| GO:BP | GO:0051340 | regulation of ligase activity | 2 | 11 | 3.87e-01 |
| GO:BP | GO:0021537 | telencephalon development | 3 | 201 | 3.87e-01 |
| GO:BP | GO:0045342 | MHC class II biosynthetic process | 1 | 12 | 3.87e-01 |
| GO:BP | GO:0051898 | negative regulation of protein kinase B signaling | 2 | 36 | 3.87e-01 |
| GO:BP | GO:1901984 | negative regulation of protein acetylation | 1 | 16 | 3.87e-01 |
| GO:BP | GO:1904273 | L-alanine import across plasma membrane | 1 | 4 | 3.87e-01 |
| GO:BP | GO:1905868 | regulation of 3’-UTR-mediated mRNA stabilization | 1 | 5 | 3.88e-01 |
| GO:BP | GO:0090504 | epiboly | 1 | 31 | 3.88e-01 |
| GO:BP | GO:0000338 | protein deneddylation | 1 | 11 | 3.88e-01 |
| GO:BP | GO:0051346 | negative regulation of hydrolase activity | 1 | 220 | 3.88e-01 |
| GO:BP | GO:0009205 | purine ribonucleoside triphosphate metabolic process | 1 | 137 | 3.88e-01 |
| GO:BP | GO:0018209 | peptidyl-serine modification | 1 | 259 | 3.88e-01 |
| GO:BP | GO:2000352 | negative regulation of endothelial cell apoptotic process | 3 | 22 | 3.88e-01 |
| GO:BP | GO:0032530 | regulation of microvillus organization | 2 | 10 | 3.89e-01 |
| GO:BP | GO:0051418 | microtubule nucleation by microtubule organizing center | 1 | 5 | 3.89e-01 |
| GO:BP | GO:0045165 | cell fate commitment | 3 | 155 | 3.89e-01 |
| GO:BP | GO:0006553 | lysine metabolic process | 1 | 7 | 3.89e-01 |
| GO:BP | GO:0072170 | metanephric tubule development | 3 | 15 | 3.89e-01 |
| GO:BP | GO:0003148 | outflow tract septum morphogenesis | 1 | 23 | 3.89e-01 |
| GO:BP | GO:0030866 | cortical actin cytoskeleton organization | 5 | 35 | 3.89e-01 |
| GO:BP | GO:0022614 | membrane to membrane docking | 1 | 5 | 3.89e-01 |
| GO:BP | GO:0030278 | regulation of ossification | 11 | 84 | 3.89e-01 |
| GO:BP | GO:0072243 | metanephric nephron epithelium development | 3 | 15 | 3.89e-01 |
| GO:BP | GO:0043536 | positive regulation of blood vessel endothelial cell migration | 3 | 47 | 3.89e-01 |
| GO:BP | GO:0006937 | regulation of muscle contraction | 1 | 133 | 3.89e-01 |
| GO:BP | GO:0048754 | branching morphogenesis of an epithelial tube | 1 | 121 | 3.89e-01 |
| GO:BP | GO:0032527 | protein exit from endoplasmic reticulum | 5 | 43 | 3.89e-01 |
| GO:BP | GO:0051905 | establishment of pigment granule localization | 3 | 20 | 3.89e-01 |
| GO:BP | GO:1903012 | positive regulation of bone development | 1 | 1 | 3.89e-01 |
| GO:BP | GO:0071356 | cellular response to tumor necrosis factor | 14 | 155 | 3.89e-01 |
| GO:BP | GO:0061756 | leukocyte adhesion to vascular endothelial cell | 2 | 27 | 3.89e-01 |
| GO:BP | GO:0035509 | negative regulation of myosin-light-chain-phosphatase activity | 1 | 3 | 3.89e-01 |
| GO:BP | GO:0085020 | protein K6-linked ubiquitination | 1 | 9 | 3.90e-01 |
| GO:BP | GO:0010232 | vascular transport | 8 | 72 | 3.90e-01 |
| GO:BP | GO:0009226 | nucleotide-sugar biosynthetic process | 3 | 19 | 3.90e-01 |
| GO:BP | GO:0150104 | transport across blood-brain barrier | 8 | 72 | 3.90e-01 |
| GO:BP | GO:0006041 | glucosamine metabolic process | 1 | 3 | 3.90e-01 |
| GO:BP | GO:0051893 | regulation of focal adhesion assembly | 1 | 59 | 3.90e-01 |
| GO:BP | GO:0090109 | regulation of cell-substrate junction assembly | 1 | 59 | 3.90e-01 |
| GO:BP | GO:0030324 | lung development | 12 | 146 | 3.90e-01 |
| GO:BP | GO:1903902 | positive regulation of viral life cycle | 2 | 19 | 3.90e-01 |
| GO:BP | GO:0016445 | somatic diversification of immunoglobulins | 3 | 53 | 3.90e-01 |
| GO:BP | GO:0072657 | protein localization to membrane | 2 | 523 | 3.90e-01 |
| GO:BP | GO:0032474 | otolith morphogenesis | 1 | 3 | 3.90e-01 |
| GO:BP | GO:0071494 | cellular response to UV-C | 1 | 4 | 3.90e-01 |
| GO:BP | GO:0032607 | interferon-alpha production | 3 | 19 | 3.90e-01 |
| GO:BP | GO:0032647 | regulation of interferon-alpha production | 3 | 19 | 3.90e-01 |
| GO:BP | GO:0045648 | positive regulation of erythrocyte differentiation | 3 | 27 | 3.90e-01 |
| GO:BP | GO:0010587 | miRNA catabolic process | 2 | 10 | 3.90e-01 |
| GO:BP | GO:0090596 | sensory organ morphogenesis | 3 | 178 | 3.91e-01 |
| GO:BP | GO:0035967 | cellular response to topologically incorrect protein | 12 | 111 | 3.91e-01 |
| GO:BP | GO:0007517 | muscle organ development | 24 | 277 | 3.91e-01 |
| GO:BP | GO:0019284 | L-methionine salvage from S-adenosylmethionine | 1 | 3 | 3.91e-01 |
| GO:BP | GO:0045054 | constitutive secretory pathway | 1 | 7 | 3.91e-01 |
| GO:BP | GO:0048644 | muscle organ morphogenesis | 2 | 63 | 3.91e-01 |
| GO:BP | GO:0014888 | striated muscle adaptation | 4 | 40 | 3.91e-01 |
| GO:BP | GO:0050994 | regulation of lipid catabolic process | 1 | 38 | 3.91e-01 |
| GO:BP | GO:2000042 | negative regulation of double-strand break repair via homologous recombination | 1 | 16 | 3.91e-01 |
| GO:BP | GO:0070555 | response to interleukin-1 | 1 | 83 | 3.91e-01 |
| GO:BP | GO:0009144 | purine nucleoside triphosphate metabolic process | 1 | 142 | 3.92e-01 |
| GO:BP | GO:0042796 | snRNA transcription by RNA polymerase III | 1 | 8 | 3.92e-01 |
| GO:BP | GO:0044093 | positive regulation of molecular function | 10 | 1149 | 3.92e-01 |
| GO:BP | GO:0033574 | response to testosterone | 3 | 29 | 3.92e-01 |
| GO:BP | GO:0010826 | negative regulation of centrosome duplication | 1 | 12 | 3.92e-01 |
| GO:BP | GO:0046606 | negative regulation of centrosome cycle | 1 | 12 | 3.92e-01 |
| GO:BP | GO:0008285 | negative regulation of cell population proliferation | 20 | 513 | 3.92e-01 |
| GO:BP | GO:0042551 | neuron maturation | 4 | 33 | 3.92e-01 |
| GO:BP | GO:0090174 | organelle membrane fusion | 8 | 106 | 3.93e-01 |
| GO:BP | GO:0019086 | late viral transcription | 1 | 4 | 3.93e-01 |
| GO:BP | GO:0001667 | ameboidal-type cell migration | 20 | 358 | 3.93e-01 |
| GO:BP | GO:0051988 | regulation of attachment of spindle microtubules to kinetochore | 2 | 18 | 3.93e-01 |
| GO:BP | GO:0043517 | positive regulation of DNA damage response, signal transduction by p53 class mediator | 1 | 16 | 3.93e-01 |
| GO:BP | GO:0043412 | macromolecule modification | 4 | 3090 | 3.93e-01 |
| GO:BP | GO:1900424 | regulation of defense response to bacterium | 2 | 12 | 3.93e-01 |
| GO:BP | GO:1903365 | regulation of fear response | 2 | 8 | 3.93e-01 |
| GO:BP | GO:0048843 | negative regulation of axon extension involved in axon guidance | 2 | 26 | 3.93e-01 |
| GO:BP | GO:0086009 | membrane repolarization | 2 | 41 | 3.93e-01 |
| GO:BP | GO:0045927 | positive regulation of growth | 2 | 199 | 3.93e-01 |
| GO:BP | GO:1902894 | negative regulation of miRNA transcription | 3 | 19 | 3.93e-01 |
| GO:BP | GO:0009199 | ribonucleoside triphosphate metabolic process | 1 | 144 | 3.93e-01 |
| GO:BP | GO:0045646 | regulation of erythrocyte differentiation | 4 | 39 | 3.93e-01 |
| GO:BP | GO:0097035 | regulation of membrane lipid distribution | 1 | 43 | 3.93e-01 |
| GO:BP | GO:0032414 | positive regulation of ion transmembrane transporter activity | 1 | 85 | 3.93e-01 |
| GO:BP | GO:0061156 | pulmonary artery morphogenesis | 1 | 7 | 3.93e-01 |
| GO:BP | GO:0030728 | ovulation | 1 | 14 | 3.93e-01 |
| GO:BP | GO:0001574 | ganglioside biosynthetic process | 2 | 14 | 3.93e-01 |
| GO:BP | GO:0060122 | inner ear receptor cell stereocilium organization | 4 | 23 | 3.93e-01 |
| GO:BP | GO:0008219 | cell death | 4 | 1596 | 3.93e-01 |
| GO:BP | GO:0022612 | gland morphogenesis | 4 | 98 | 3.94e-01 |
| GO:BP | GO:0009101 | glycoprotein biosynthetic process | 10 | 252 | 3.94e-01 |
| GO:BP | GO:1903830 | magnesium ion transmembrane transport | 2 | 16 | 3.94e-01 |
| GO:BP | GO:0022411 | cellular component disassembly | 2 | 427 | 3.94e-01 |
| GO:BP | GO:2000370 | positive regulation of clathrin-dependent endocytosis | 1 | 5 | 3.95e-01 |
| GO:BP | GO:0099543 | trans-synaptic signaling by soluble gas | 1 | 2 | 3.95e-01 |
| GO:BP | GO:0099548 | trans-synaptic signaling by nitric oxide | 1 | 2 | 3.95e-01 |
| GO:BP | GO:0010657 | muscle cell apoptotic process | 2 | 60 | 3.95e-01 |
| GO:BP | GO:0051299 | centrosome separation | 2 | 14 | 3.95e-01 |
| GO:BP | GO:0010815 | bradykinin catabolic process | 1 | 6 | 3.95e-01 |
| GO:BP | GO:0015886 | heme transport | 1 | 9 | 3.95e-01 |
| GO:BP | GO:0006029 | proteoglycan metabolic process | 1 | 77 | 3.95e-01 |
| GO:BP | GO:0090559 | regulation of membrane permeability | 2 | 64 | 3.95e-01 |
| GO:BP | GO:0006266 | DNA ligation | 2 | 16 | 3.95e-01 |
| GO:BP | GO:0000447 | endonucleolytic cleavage in ITS1 to separate SSU-rRNA from 5.8S rRNA and LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 1 | 10 | 3.95e-01 |
| GO:BP | GO:0007004 | telomere maintenance via telomerase | 4 | 63 | 3.95e-01 |
| GO:BP | GO:0061025 | membrane fusion | 12 | 137 | 3.95e-01 |
| GO:BP | GO:0061387 | regulation of extent of cell growth | 5 | 97 | 3.95e-01 |
| GO:BP | GO:0070198 | protein localization to chromosome, telomeric region | 4 | 30 | 3.95e-01 |
| GO:BP | GO:0060042 | retina morphogenesis in camera-type eye | 1 | 40 | 3.95e-01 |
| GO:BP | GO:0034551 | mitochondrial respiratory chain complex III assembly | 1 | 10 | 3.96e-01 |
| GO:BP | GO:1990778 | protein localization to cell periphery | 1 | 300 | 3.96e-01 |
| GO:BP | GO:0017062 | respiratory chain complex III assembly | 1 | 10 | 3.96e-01 |
| GO:BP | GO:0002228 | natural killer cell mediated immunity | 5 | 34 | 3.96e-01 |
| GO:BP | GO:0140214 | positive regulation of long-chain fatty acid import into cell | 1 | 2 | 3.96e-01 |
| GO:BP | GO:1903238 | positive regulation of leukocyte tethering or rolling | 1 | 5 | 3.96e-01 |
| GO:BP | GO:0048703 | embryonic viscerocranium morphogenesis | 1 | 8 | 3.97e-01 |
| GO:BP | GO:1990408 | calcitonin gene-related peptide receptor signaling pathway | 1 | 2 | 3.97e-01 |
| GO:BP | GO:0007175 | negative regulation of epidermal growth factor-activated receptor activity | 2 | 13 | 3.97e-01 |
| GO:BP | GO:0045934 | negative regulation of nucleobase-containing compound metabolic process | 19 | 1209 | 3.97e-01 |
| GO:BP | GO:0009056 | catabolic process | 2 | 2088 | 3.97e-01 |
| GO:BP | GO:0002449 | lymphocyte mediated immunity | 1 | 142 | 3.97e-01 |
| GO:BP | GO:1905271 | regulation of proton-transporting ATP synthase activity, rotational mechanism | 1 | 3 | 3.97e-01 |
| GO:BP | GO:0009129 | pyrimidine nucleoside monophosphate metabolic process | 2 | 18 | 3.97e-01 |
| GO:BP | GO:2000697 | negative regulation of epithelial cell differentiation involved in kidney development | 1 | 3 | 3.97e-01 |
| GO:BP | GO:0030099 | myeloid cell differentiation | 2 | 310 | 3.97e-01 |
| GO:BP | GO:1905273 | positive regulation of proton-transporting ATP synthase activity, rotational mechanism | 1 | 3 | 3.97e-01 |
| GO:BP | GO:1905706 | regulation of mitochondrial ATP synthesis coupled proton transport | 1 | 3 | 3.97e-01 |
| GO:BP | GO:0030258 | lipid modification | 2 | 162 | 3.97e-01 |
| GO:BP | GO:0010332 | response to gamma radiation | 3 | 50 | 3.97e-01 |
| GO:BP | GO:0006855 | xenobiotic transmembrane transport | 1 | 11 | 3.97e-01 |
| GO:BP | GO:2000323 | negative regulation of glucocorticoid receptor signaling pathway | 1 | 6 | 3.97e-01 |
| GO:BP | GO:0009084 | glutamine family amino acid biosynthetic process | 1 | 16 | 3.97e-01 |
| GO:BP | GO:0002347 | response to tumor cell | 1 | 22 | 3.98e-01 |
| GO:BP | GO:2000407 | regulation of T cell extravasation | 1 | 3 | 3.98e-01 |
| GO:BP | GO:0021799 | cerebral cortex radially oriented cell migration | 1 | 28 | 3.99e-01 |
| GO:BP | GO:0048489 | synaptic vesicle transport | 3 | 36 | 3.99e-01 |
| GO:BP | GO:0070203 | regulation of establishment of protein localization to telomere | 2 | 11 | 3.99e-01 |
| GO:BP | GO:1990603 | dark adaptation | 1 | 3 | 3.99e-01 |
| GO:BP | GO:0071485 | cellular response to absence of light | 1 | 3 | 3.99e-01 |
| GO:BP | GO:0071625 | vocalization behavior | 3 | 13 | 3.99e-01 |
| GO:BP | GO:0086015 | SA node cell action potential | 1 | 12 | 3.99e-01 |
| GO:BP | GO:2000288 | positive regulation of myoblast proliferation | 1 | 9 | 3.99e-01 |
| GO:BP | GO:0009646 | response to absence of light | 1 | 3 | 3.99e-01 |
| GO:BP | GO:0048699 | generation of neurons | 7 | 1119 | 3.99e-01 |
| GO:BP | GO:1904153 | negative regulation of retrograde protein transport, ER to cytosol | 1 | 9 | 3.99e-01 |
| GO:BP | GO:0072235 | metanephric distal tubule development | 1 | 2 | 3.99e-01 |
| GO:BP | GO:0001101 | response to acid chemical | 1 | 105 | 3.99e-01 |
| GO:BP | GO:0035621 | ER to Golgi ceramide transport | 1 | 3 | 3.99e-01 |
| GO:BP | GO:0086018 | SA node cell to atrial cardiac muscle cell signaling | 1 | 12 | 3.99e-01 |
| GO:BP | GO:0016073 | snRNA metabolic process | 3 | 54 | 3.99e-01 |
| GO:BP | GO:0048845 | venous blood vessel morphogenesis | 1 | 9 | 4.00e-01 |
| GO:BP | GO:0009064 | glutamine family amino acid metabolic process | 2 | 60 | 4.00e-01 |
| GO:BP | GO:0060920 | cardiac pacemaker cell differentiation | 1 | 9 | 4.00e-01 |
| GO:BP | GO:0061635 | regulation of protein complex stability | 2 | 11 | 4.00e-01 |
| GO:BP | GO:0002460 | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 1 | 161 | 4.00e-01 |
| GO:BP | GO:0045879 | negative regulation of smoothened signaling pathway | 3 | 30 | 4.00e-01 |
| GO:BP | GO:1903596 | regulation of gap junction assembly | 1 | 8 | 4.00e-01 |
| GO:BP | GO:0060923 | cardiac muscle cell fate commitment | 1 | 7 | 4.00e-01 |
| GO:BP | GO:0048386 | positive regulation of retinoic acid receptor signaling pathway | 1 | 5 | 4.00e-01 |
| GO:BP | GO:1903035 | negative regulation of response to wounding | 2 | 64 | 4.00e-01 |
| GO:BP | GO:0040014 | regulation of multicellular organism growth | 1 | 53 | 4.00e-01 |
| GO:BP | GO:0001894 | tissue homeostasis | 2 | 170 | 4.00e-01 |
| GO:BP | GO:0060249 | anatomical structure homeostasis | 2 | 170 | 4.00e-01 |
| GO:BP | GO:0002924 | negative regulation of humoral immune response mediated by circulating immunoglobulin | 1 | 5 | 4.00e-01 |
| GO:BP | GO:0150116 | regulation of cell-substrate junction organization | 1 | 64 | 4.00e-01 |
| GO:BP | GO:0070634 | transepithelial ammonium transport | 1 | 1 | 4.00e-01 |
| GO:BP | GO:0048812 | neuron projection morphogenesis | 28 | 512 | 4.00e-01 |
| GO:BP | GO:0060119 | inner ear receptor cell development | 5 | 33 | 4.00e-01 |
| GO:BP | GO:0035751 | regulation of lysosomal lumen pH | 1 | 26 | 4.00e-01 |
| GO:BP | GO:0032780 | negative regulation of ATP-dependent activity | 1 | 18 | 4.00e-01 |
| GO:BP | GO:0072182 | regulation of nephron tubule epithelial cell differentiation | 2 | 10 | 4.00e-01 |
| GO:BP | GO:0006278 | RNA-templated DNA biosynthetic process | 4 | 64 | 4.00e-01 |
| GO:BP | GO:0009991 | response to extracellular stimulus | 28 | 377 | 4.00e-01 |
| GO:BP | GO:0032988 | ribonucleoprotein complex disassembly | 1 | 8 | 4.00e-01 |
| GO:BP | GO:0031056 | regulation of histone modification | 1 | 125 | 4.00e-01 |
| GO:BP | GO:0090385 | phagosome-lysosome fusion | 2 | 12 | 4.00e-01 |
| GO:BP | GO:0042752 | regulation of circadian rhythm | 6 | 97 | 4.00e-01 |
| GO:BP | GO:0097105 | presynaptic membrane assembly | 2 | 8 | 4.00e-01 |
| GO:BP | GO:0097104 | postsynaptic membrane assembly | 2 | 8 | 4.00e-01 |
| GO:BP | GO:0014066 | regulation of phosphatidylinositol 3-kinase signaling | 5 | 78 | 4.00e-01 |
| GO:BP | GO:0045860 | positive regulation of protein kinase activity | 1 | 260 | 4.00e-01 |
| GO:BP | GO:0051851 | modulation by host of symbiont process | 1 | 68 | 4.00e-01 |
| GO:BP | GO:0060965 | negative regulation of miRNA-mediated gene silencing | 1 | 10 | 4.00e-01 |
| GO:BP | GO:0002335 | mature B cell differentiation | 1 | 21 | 4.00e-01 |
| GO:BP | GO:0030513 | positive regulation of BMP signaling pathway | 1 | 34 | 4.00e-01 |
| GO:BP | GO:1903037 | regulation of leukocyte cell-cell adhesion | 1 | 211 | 4.00e-01 |
| GO:BP | GO:0006783 | heme biosynthetic process | 1 | 30 | 4.00e-01 |
| GO:BP | GO:0005976 | polysaccharide metabolic process | 6 | 80 | 4.01e-01 |
| GO:BP | GO:0044772 | mitotic cell cycle phase transition | 3 | 418 | 4.01e-01 |
| GO:BP | GO:1903719 | regulation of I-kappaB phosphorylation | 1 | 6 | 4.01e-01 |
| GO:BP | GO:2000192 | negative regulation of fatty acid transport | 1 | 7 | 4.01e-01 |
| GO:BP | GO:0050680 | negative regulation of epithelial cell proliferation | 6 | 111 | 4.01e-01 |
| GO:BP | GO:0015909 | long-chain fatty acid transport | 1 | 38 | 4.01e-01 |
| GO:BP | GO:0032400 | melanosome localization | 3 | 22 | 4.01e-01 |
| GO:BP | GO:0034143 | regulation of toll-like receptor 4 signaling pathway | 2 | 15 | 4.01e-01 |
| GO:BP | GO:0048294 | negative regulation of isotype switching to IgE isotypes | 1 | 2 | 4.01e-01 |
| GO:BP | GO:0009409 | response to cold | 1 | 41 | 4.01e-01 |
| GO:BP | GO:0110030 | regulation of G2/MI transition of meiotic cell cycle | 1 | 3 | 4.01e-01 |
| GO:BP | GO:1901995 | positive regulation of meiotic cell cycle phase transition | 1 | 3 | 4.01e-01 |
| GO:BP | GO:1902036 | regulation of hematopoietic stem cell differentiation | 2 | 15 | 4.01e-01 |
| GO:BP | GO:0031589 | cell-substrate adhesion | 1 | 281 | 4.01e-01 |
| GO:BP | GO:0009415 | response to water | 1 | 9 | 4.02e-01 |
| GO:BP | GO:1902751 | positive regulation of cell cycle G2/M phase transition | 3 | 30 | 4.02e-01 |
| GO:BP | GO:0006420 | arginyl-tRNA aminoacylation | 1 | 3 | 4.03e-01 |
| GO:BP | GO:0050774 | negative regulation of dendrite morphogenesis | 1 | 7 | 4.03e-01 |
| GO:BP | GO:0035562 | negative regulation of chromatin binding | 1 | 8 | 4.03e-01 |
| GO:BP | GO:0006006 | glucose metabolic process | 1 | 151 | 4.03e-01 |
| GO:BP | GO:0044283 | small molecule biosynthetic process | 2 | 425 | 4.04e-01 |
| GO:BP | GO:0042059 | negative regulation of epidermal growth factor receptor signaling pathway | 3 | 26 | 4.04e-01 |
| GO:BP | GO:0050863 | regulation of T cell activation | 1 | 216 | 4.04e-01 |
| GO:BP | GO:0003272 | endocardial cushion formation | 1 | 24 | 4.04e-01 |
| GO:BP | GO:0048667 | cell morphogenesis involved in neuron differentiation | 22 | 463 | 4.04e-01 |
| GO:BP | GO:0061833 | protein localization to tricellular tight junction | 1 | 2 | 4.04e-01 |
| GO:BP | GO:0007271 | synaptic transmission, cholinergic | 2 | 15 | 4.04e-01 |
| GO:BP | GO:0006044 | N-acetylglucosamine metabolic process | 3 | 16 | 4.04e-01 |
| GO:BP | GO:2000601 | positive regulation of Arp2/3 complex-mediated actin nucleation | 1 | 9 | 4.04e-01 |
| GO:BP | GO:0098609 | cell-cell adhesion | 2 | 609 | 4.04e-01 |
| GO:BP | GO:0007492 | endoderm development | 1 | 65 | 4.04e-01 |
| GO:BP | GO:0018108 | peptidyl-tyrosine phosphorylation | 1 | 256 | 4.04e-01 |
| GO:BP | GO:0072205 | metanephric collecting duct development | 2 | 5 | 4.04e-01 |
| GO:BP | GO:1901483 | regulation of transcription factor catabolic process | 1 | 3 | 4.04e-01 |
| GO:BP | GO:1901485 | positive regulation of transcription factor catabolic process | 1 | 3 | 4.04e-01 |
| GO:BP | GO:0002697 | regulation of immune effector process | 1 | 190 | 4.04e-01 |
| GO:BP | GO:0033628 | regulation of cell adhesion mediated by integrin | 2 | 36 | 4.05e-01 |
| GO:BP | GO:0035728 | response to hepatocyte growth factor | 2 | 15 | 4.05e-01 |
| GO:BP | GO:0033006 | regulation of mast cell activation involved in immune response | 3 | 21 | 4.05e-01 |
| GO:BP | GO:0030323 | respiratory tube development | 12 | 150 | 4.05e-01 |
| GO:BP | GO:0018212 | peptidyl-tyrosine modification | 1 | 258 | 4.05e-01 |
| GO:BP | GO:0051402 | neuron apoptotic process | 8 | 200 | 4.05e-01 |
| GO:BP | GO:0000018 | regulation of DNA recombination | 4 | 101 | 4.06e-01 |
| GO:BP | GO:0007585 | respiratory gaseous exchange by respiratory system | 1 | 49 | 4.06e-01 |
| GO:BP | GO:0034599 | cellular response to oxidative stress | 16 | 240 | 4.06e-01 |
| GO:BP | GO:1902254 | negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 1 | 22 | 4.06e-01 |
| GO:BP | GO:0032447 | protein urmylation | 1 | 4 | 4.06e-01 |
| GO:BP | GO:0042473 | outer ear morphogenesis | 1 | 5 | 4.06e-01 |
| GO:BP | GO:2000467 | positive regulation of glycogen (starch) synthase activity | 1 | 4 | 4.06e-01 |
| GO:BP | GO:0060304 | regulation of phosphatidylinositol dephosphorylation | 1 | 5 | 4.06e-01 |
| GO:BP | GO:0043967 | histone H4 acetylation | 2 | 57 | 4.06e-01 |
| GO:BP | GO:0034391 | regulation of smooth muscle cell apoptotic process | 1 | 15 | 4.06e-01 |
| GO:BP | GO:0060440 | trachea formation | 1 | 7 | 4.06e-01 |
| GO:BP | GO:0034390 | smooth muscle cell apoptotic process | 1 | 15 | 4.06e-01 |
| GO:BP | GO:0035357 | peroxisome proliferator activated receptor signaling pathway | 1 | 19 | 4.06e-01 |
| GO:BP | GO:0009141 | nucleoside triphosphate metabolic process | 1 | 159 | 4.06e-01 |
| GO:BP | GO:0120040 | regulation of macrophage proliferation | 1 | 4 | 4.06e-01 |
| GO:BP | GO:0032411 | positive regulation of transporter activity | 1 | 93 | 4.06e-01 |
| GO:BP | GO:0002143 | tRNA wobble position uridine thiolation | 1 | 4 | 4.06e-01 |
| GO:BP | GO:0072531 | pyrimidine-containing compound transmembrane transport | 1 | 9 | 4.07e-01 |
| GO:BP | GO:0048633 | positive regulation of skeletal muscle tissue growth | 1 | 6 | 4.07e-01 |
| GO:BP | GO:0010256 | endomembrane system organization | 28 | 496 | 4.07e-01 |
| GO:BP | GO:0035556 | intracellular signal transduction | 43 | 2065 | 4.07e-01 |
| GO:BP | GO:0006099 | tricarboxylic acid cycle | 1 | 30 | 4.07e-01 |
| GO:BP | GO:0018364 | peptidyl-glutamine methylation | 1 | 4 | 4.08e-01 |
| GO:BP | GO:0086002 | cardiac muscle cell action potential involved in contraction | 2 | 45 | 4.08e-01 |
| GO:BP | GO:0097006 | regulation of plasma lipoprotein particle levels | 1 | 45 | 4.08e-01 |
| GO:BP | GO:0071260 | cellular response to mechanical stimulus | 2 | 59 | 4.08e-01 |
| GO:BP | GO:0048598 | embryonic morphogenesis | 5 | 440 | 4.08e-01 |
| GO:BP | GO:0032768 | regulation of monooxygenase activity | 1 | 34 | 4.08e-01 |
| GO:BP | GO:0009755 | hormone-mediated signaling pathway | 10 | 139 | 4.08e-01 |
| GO:BP | GO:0051962 | positive regulation of nervous system development | 2 | 221 | 4.08e-01 |
| GO:BP | GO:0015693 | magnesium ion transport | 2 | 17 | 4.08e-01 |
| GO:BP | GO:1905665 | positive regulation of calcium ion import across plasma membrane | 2 | 6 | 4.09e-01 |
| GO:BP | GO:0016444 | somatic cell DNA recombination | 3 | 55 | 4.09e-01 |
| GO:BP | GO:0006984 | ER-nucleus signaling pathway | 2 | 45 | 4.09e-01 |
| GO:BP | GO:0002562 | somatic diversification of immune receptors via germline recombination within a single locus | 3 | 55 | 4.09e-01 |
| GO:BP | GO:0000724 | double-strand break repair via homologous recombination | 4 | 149 | 4.09e-01 |
| GO:BP | GO:0035308 | negative regulation of protein dephosphorylation | 1 | 28 | 4.10e-01 |
| GO:BP | GO:0034329 | cell junction assembly | 4 | 344 | 4.10e-01 |
| GO:BP | GO:0006900 | vesicle budding from membrane | 1 | 76 | 4.10e-01 |
| GO:BP | GO:0036462 | TRAIL-activated apoptotic signaling pathway | 2 | 10 | 4.10e-01 |
| GO:BP | GO:0090155 | negative regulation of sphingolipid biosynthetic process | 1 | 6 | 4.10e-01 |
| GO:BP | GO:1902882 | regulation of response to oxidative stress | 2 | 76 | 4.10e-01 |
| GO:BP | GO:0060324 | face development | 3 | 45 | 4.10e-01 |
| GO:BP | GO:0035739 | CD4-positive, alpha-beta T cell proliferation | 3 | 12 | 4.10e-01 |
| GO:BP | GO:0060037 | pharyngeal system development | 1 | 23 | 4.10e-01 |
| GO:BP | GO:2000561 | regulation of CD4-positive, alpha-beta T cell proliferation | 3 | 12 | 4.10e-01 |
| GO:BP | GO:0060113 | inner ear receptor cell differentiation | 4 | 47 | 4.10e-01 |
| GO:BP | GO:0120263 | positive regulation of heterochromatin organization | 2 | 15 | 4.11e-01 |
| GO:BP | GO:1900109 | regulation of histone H3-K9 dimethylation | 1 | 2 | 4.11e-01 |
| GO:BP | GO:0031453 | positive regulation of heterochromatin formation | 2 | 15 | 4.11e-01 |
| GO:BP | GO:0032006 | regulation of TOR signaling | 8 | 96 | 4.11e-01 |
| GO:BP | GO:0090234 | regulation of kinetochore assembly | 1 | 3 | 4.11e-01 |
| GO:BP | GO:0006837 | serotonin transport | 1 | 11 | 4.11e-01 |
| GO:BP | GO:0009644 | response to high light intensity | 1 | 2 | 4.11e-01 |
| GO:BP | GO:0060967 | negative regulation of gene silencing by RNA | 1 | 11 | 4.11e-01 |
| GO:BP | GO:1900369 | negative regulation of post-transcriptional gene silencing by RNA | 1 | 11 | 4.11e-01 |
| GO:BP | GO:0060149 | negative regulation of post-transcriptional gene silencing | 1 | 11 | 4.11e-01 |
| GO:BP | GO:1903059 | regulation of protein lipidation | 2 | 11 | 4.11e-01 |
| GO:BP | GO:0043406 | positive regulation of MAP kinase activity | 5 | 82 | 4.11e-01 |
| GO:BP | GO:0018904 | ether metabolic process | 1 | 20 | 4.11e-01 |
| GO:BP | GO:0006970 | response to osmotic stress | 2 | 67 | 4.11e-01 |
| GO:BP | GO:0007052 | mitotic spindle organization | 7 | 129 | 4.11e-01 |
| GO:BP | GO:0046633 | alpha-beta T cell proliferation | 5 | 24 | 4.11e-01 |
| GO:BP | GO:0002230 | positive regulation of defense response to virus by host | 3 | 23 | 4.11e-01 |
| GO:BP | GO:1903577 | cellular response to L-arginine | 1 | 3 | 4.11e-01 |
| GO:BP | GO:0030162 | regulation of proteolysis | 4 | 535 | 4.11e-01 |
| GO:BP | GO:0043299 | leukocyte degranulation | 4 | 41 | 4.11e-01 |
| GO:BP | GO:1904684 | negative regulation of metalloendopeptidase activity | 1 | 4 | 4.11e-01 |
| GO:BP | GO:1990440 | positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress | 1 | 11 | 4.11e-01 |
| GO:BP | GO:0006983 | ER overload response | 1 | 12 | 4.11e-01 |
| GO:BP | GO:1903121 | regulation of TRAIL-activated apoptotic signaling pathway | 1 | 4 | 4.11e-01 |
| GO:BP | GO:1900363 | regulation of mRNA polyadenylation | 2 | 11 | 4.12e-01 |
| GO:BP | GO:0070814 | hydrogen sulfide biosynthetic process | 1 | 4 | 4.12e-01 |
| GO:BP | GO:2000104 | negative regulation of DNA-templated DNA replication | 1 | 7 | 4.12e-01 |
| GO:BP | GO:0032466 | negative regulation of cytokinesis | 1 | 7 | 4.12e-01 |
| GO:BP | GO:0044837 | actomyosin contractile ring organization | 1 | 7 | 4.12e-01 |
| GO:BP | GO:2000278 | regulation of DNA biosynthetic process | 7 | 111 | 4.12e-01 |
| GO:BP | GO:0000296 | spermine transport | 1 | 3 | 4.12e-01 |
| GO:BP | GO:0009211 | pyrimidine deoxyribonucleoside triphosphate metabolic process | 1 | 6 | 4.13e-01 |
| GO:BP | GO:0006925 | inflammatory cell apoptotic process | 1 | 15 | 4.13e-01 |
| GO:BP | GO:0060539 | diaphragm development | 1 | 5 | 4.13e-01 |
| GO:BP | GO:0035865 | cellular response to potassium ion | 2 | 9 | 4.13e-01 |
| GO:BP | GO:0060541 | respiratory system development | 13 | 163 | 4.13e-01 |
| GO:BP | GO:0090335 | regulation of brown fat cell differentiation | 1 | 17 | 4.13e-01 |
| GO:BP | GO:0060907 | positive regulation of macrophage cytokine production | 1 | 18 | 4.13e-01 |
| GO:BP | GO:0098598 | learned vocalization behavior or vocal learning | 1 | 4 | 4.13e-01 |
| GO:BP | GO:0072488 | ammonium transmembrane transport | 2 | 6 | 4.13e-01 |
| GO:BP | GO:1990845 | adaptive thermogenesis | 5 | 121 | 4.13e-01 |
| GO:BP | GO:0043303 | mast cell degranulation | 3 | 30 | 4.13e-01 |
| GO:BP | GO:0006047 | UDP-N-acetylglucosamine metabolic process | 2 | 13 | 4.13e-01 |
| GO:BP | GO:0042088 | T-helper 1 type immune response | 2 | 26 | 4.13e-01 |
| GO:BP | GO:0060988 | lipid tube assembly | 1 | 2 | 4.13e-01 |
| GO:BP | GO:0035928 | rRNA import into mitochondrion | 1 | 3 | 4.13e-01 |
| GO:BP | GO:0060340 | positive regulation of type I interferon-mediated signaling pathway | 2 | 17 | 4.13e-01 |
| GO:BP | GO:0098915 | membrane repolarization during ventricular cardiac muscle cell action potential | 1 | 10 | 4.13e-01 |
| GO:BP | GO:0120127 | response to zinc ion starvation | 1 | 6 | 4.13e-01 |
| GO:BP | GO:0060023 | soft palate development | 1 | 3 | 4.13e-01 |
| GO:BP | GO:0034224 | cellular response to zinc ion starvation | 1 | 6 | 4.13e-01 |
| GO:BP | GO:0048259 | regulation of receptor-mediated endocytosis | 7 | 87 | 4.13e-01 |
| GO:BP | GO:0021773 | striatal medium spiny neuron differentiation | 1 | 3 | 4.13e-01 |
| GO:BP | GO:0009446 | putrescine biosynthetic process | 1 | 4 | 4.13e-01 |
| GO:BP | GO:0051036 | regulation of endosome size | 1 | 13 | 4.13e-01 |
| GO:BP | GO:0070862 | negative regulation of protein exit from endoplasmic reticulum | 1 | 10 | 4.13e-01 |
| GO:BP | GO:0016267 | O-glycan processing, core 1 | 1 | 2 | 4.14e-01 |
| GO:BP | GO:0010595 | positive regulation of endothelial cell migration | 5 | 94 | 4.14e-01 |
| GO:BP | GO:1990791 | dorsal root ganglion development | 1 | 6 | 4.14e-01 |
| GO:BP | GO:0035878 | nail development | 1 | 8 | 4.15e-01 |
| GO:BP | GO:0051251 | positive regulation of lymphocyte activation | 1 | 199 | 4.15e-01 |
| GO:BP | GO:0014075 | response to amine | 2 | 34 | 4.15e-01 |
| GO:BP | GO:0034620 | cellular response to unfolded protein | 10 | 91 | 4.15e-01 |
| GO:BP | GO:1905203 | regulation of connective tissue replacement | 1 | 5 | 4.15e-01 |
| GO:BP | GO:1903251 | multi-ciliated epithelial cell differentiation | 1 | 6 | 4.15e-01 |
| GO:BP | GO:0061138 | morphogenesis of a branching epithelium | 1 | 143 | 4.15e-01 |
| GO:BP | GO:0051875 | pigment granule localization | 3 | 22 | 4.15e-01 |
| GO:BP | GO:0009790 | embryo development | 8 | 875 | 4.15e-01 |
| GO:BP | GO:0000281 | mitotic cytokinesis | 5 | 81 | 4.16e-01 |
| GO:BP | GO:0007621 | negative regulation of female receptivity | 1 | 1 | 4.16e-01 |
| GO:BP | GO:0007159 | leukocyte cell-cell adhesion | 1 | 234 | 4.16e-01 |
| GO:BP | GO:0007005 | mitochondrion organization | 2 | 500 | 4.17e-01 |
| GO:BP | GO:2000756 | regulation of peptidyl-lysine acetylation | 5 | 57 | 4.17e-01 |
| GO:BP | GO:0036499 | PERK-mediated unfolded protein response | 2 | 17 | 4.18e-01 |
| GO:BP | GO:0071047 | polyadenylation-dependent mRNA catabolic process | 1 | 4 | 4.18e-01 |
| GO:BP | GO:0071042 | nuclear polyadenylation-dependent mRNA catabolic process | 1 | 4 | 4.18e-01 |
| GO:BP | GO:0010727 | negative regulation of hydrogen peroxide metabolic process | 1 | 4 | 4.18e-01 |
| GO:BP | GO:0042780 | tRNA 3’-end processing | 1 | 7 | 4.18e-01 |
| GO:BP | GO:0098735 | positive regulation of the force of heart contraction | 1 | 4 | 4.18e-01 |
| GO:BP | GO:0010706 | ganglioside biosynthetic process via lactosylceramide | 1 | 5 | 4.18e-01 |
| GO:BP | GO:0003254 | regulation of membrane depolarization | 2 | 37 | 4.18e-01 |
| GO:BP | GO:0044282 | small molecule catabolic process | 3 | 271 | 4.18e-01 |
| GO:BP | GO:0042450 | arginine biosynthetic process via ornithine | 1 | 1 | 4.18e-01 |
| GO:BP | GO:0007584 | response to nutrient | 1 | 109 | 4.18e-01 |
| GO:BP | GO:0051668 | localization within membrane | 2 | 605 | 4.18e-01 |
| GO:BP | GO:0019676 | ammonia assimilation cycle | 1 | 2 | 4.18e-01 |
| GO:BP | GO:0055081 | monoatomic anion homeostasis | 3 | 14 | 4.18e-01 |
| GO:BP | GO:0043534 | blood vessel endothelial cell migration | 5 | 97 | 4.18e-01 |
| GO:BP | GO:0035640 | exploration behavior | 3 | 21 | 4.18e-01 |
| GO:BP | GO:1903429 | regulation of cell maturation | 2 | 13 | 4.18e-01 |
| GO:BP | GO:0006779 | porphyrin-containing compound biosynthetic process | 1 | 33 | 4.18e-01 |
| GO:BP | GO:0006878 | intracellular copper ion homeostasis | 2 | 15 | 4.18e-01 |
| GO:BP | GO:0072282 | metanephric nephron tubule morphogenesis | 1 | 5 | 4.18e-01 |
| GO:BP | GO:1903909 | regulation of receptor clustering | 2 | 12 | 4.18e-01 |
| GO:BP | GO:1903215 | negative regulation of protein targeting to mitochondrion | 1 | 3 | 4.18e-01 |
| GO:BP | GO:0006974 | DNA damage response | 29 | 785 | 4.18e-01 |
| GO:BP | GO:0000725 | recombinational repair | 4 | 153 | 4.18e-01 |
| GO:BP | GO:0035641 | locomotory exploration behavior | 2 | 11 | 4.18e-01 |
| GO:BP | GO:0033014 | tetrapyrrole biosynthetic process | 1 | 33 | 4.18e-01 |
| GO:BP | GO:0042475 | odontogenesis of dentin-containing tooth | 1 | 55 | 4.18e-01 |
| GO:BP | GO:0006635 | fatty acid beta-oxidation | 1 | 68 | 4.18e-01 |
| GO:BP | GO:0071526 | semaphorin-plexin signaling pathway | 5 | 44 | 4.18e-01 |
| GO:BP | GO:1903543 | positive regulation of exosomal secretion | 2 | 13 | 4.18e-01 |
| GO:BP | GO:1903911 | positive regulation of receptor clustering | 1 | 6 | 4.19e-01 |
| GO:BP | GO:0046822 | regulation of nucleocytoplasmic transport | 4 | 97 | 4.19e-01 |
| GO:BP | GO:2000773 | negative regulation of cellular senescence | 1 | 19 | 4.19e-01 |
| GO:BP | GO:0006403 | RNA localization | 18 | 182 | 4.19e-01 |
| GO:BP | GO:0071351 | cellular response to interleukin-18 | 1 | 3 | 4.19e-01 |
| GO:BP | GO:0035655 | interleukin-18-mediated signaling pathway | 1 | 3 | 4.19e-01 |
| GO:BP | GO:0031328 | positive regulation of cellular biosynthetic process | 102 | 1564 | 4.19e-01 |
| GO:BP | GO:1902532 | negative regulation of intracellular signal transduction | 12 | 438 | 4.19e-01 |
| GO:BP | GO:1904557 | L-alanine transmembrane transport | 1 | 4 | 4.19e-01 |
| GO:BP | GO:0060628 | regulation of ER to Golgi vesicle-mediated transport | 1 | 9 | 4.19e-01 |
| GO:BP | GO:0046467 | membrane lipid biosynthetic process | 4 | 124 | 4.19e-01 |
| GO:BP | GO:2000322 | regulation of glucocorticoid receptor signaling pathway | 1 | 7 | 4.19e-01 |
| GO:BP | GO:0007435 | salivary gland morphogenesis | 1 | 25 | 4.19e-01 |
| GO:BP | GO:1901329 | regulation of odontoblast differentiation | 1 | 2 | 4.19e-01 |
| GO:BP | GO:0000389 | mRNA 3’-splice site recognition | 1 | 6 | 4.19e-01 |
| GO:BP | GO:0031069 | hair follicle morphogenesis | 1 | 18 | 4.19e-01 |
| GO:BP | GO:0090312 | positive regulation of protein deacetylation | 2 | 28 | 4.19e-01 |
| GO:BP | GO:0045945 | positive regulation of transcription by RNA polymerase III | 1 | 19 | 4.19e-01 |
| GO:BP | GO:0030101 | natural killer cell activation | 5 | 42 | 4.19e-01 |
| GO:BP | GO:0007286 | spermatid development | 2 | 105 | 4.19e-01 |
| GO:BP | GO:1904694 | negative regulation of vascular associated smooth muscle contraction | 1 | 3 | 4.20e-01 |
| GO:BP | GO:2000251 | positive regulation of actin cytoskeleton reorganization | 1 | 14 | 4.20e-01 |
| GO:BP | GO:0031952 | regulation of protein autophosphorylation | 3 | 39 | 4.20e-01 |
| GO:BP | GO:0070848 | response to growth factor | 34 | 572 | 4.20e-01 |
| GO:BP | GO:0016103 | diterpenoid catabolic process | 1 | 1 | 4.20e-01 |
| GO:BP | GO:0034653 | retinoic acid catabolic process | 1 | 1 | 4.20e-01 |
| GO:BP | GO:0048671 | negative regulation of collateral sprouting | 1 | 9 | 4.20e-01 |
| GO:BP | GO:1904867 | protein localization to Cajal body | 2 | 12 | 4.20e-01 |
| GO:BP | GO:1905776 | positive regulation of DNA helicase activity | 1 | 3 | 4.20e-01 |
| GO:BP | GO:0046122 | purine deoxyribonucleoside metabolic process | 1 | 3 | 4.20e-01 |
| GO:BP | GO:1905464 | positive regulation of DNA duplex unwinding | 1 | 3 | 4.20e-01 |
| GO:BP | GO:1990090 | cellular response to nerve growth factor stimulus | 3 | 41 | 4.20e-01 |
| GO:BP | GO:1903405 | protein localization to nuclear body | 2 | 12 | 4.20e-01 |
| GO:BP | GO:0009153 | purine deoxyribonucleotide biosynthetic process | 1 | 4 | 4.20e-01 |
| GO:BP | GO:0070202 | regulation of establishment of protein localization to chromosome | 2 | 12 | 4.20e-01 |
| GO:BP | GO:0006545 | glycine biosynthetic process | 1 | 4 | 4.20e-01 |
| GO:BP | GO:2001032 | regulation of double-strand break repair via nonhomologous end joining | 2 | 25 | 4.20e-01 |
| GO:BP | GO:0001945 | lymph vessel development | 2 | 22 | 4.20e-01 |
| GO:BP | GO:1901336 | lactone biosynthetic process | 1 | 3 | 4.20e-01 |
| GO:BP | GO:0019853 | L-ascorbic acid biosynthetic process | 1 | 3 | 4.20e-01 |
| GO:BP | GO:0071482 | cellular response to light stimulus | 7 | 99 | 4.20e-01 |
| GO:BP | GO:1903525 | regulation of membrane tubulation | 1 | 5 | 4.20e-01 |
| GO:BP | GO:0038083 | peptidyl-tyrosine autophosphorylation | 2 | 18 | 4.20e-01 |
| GO:BP | GO:0032210 | regulation of telomere maintenance via telomerase | 3 | 49 | 4.20e-01 |
| GO:BP | GO:0048729 | tissue morphogenesis | 5 | 504 | 4.20e-01 |
| GO:BP | GO:0086070 | SA node cell to atrial cardiac muscle cell communication | 1 | 14 | 4.20e-01 |
| GO:BP | GO:0048592 | eye morphogenesis | 2 | 113 | 4.21e-01 |
| GO:BP | GO:0042307 | positive regulation of protein import into nucleus | 2 | 32 | 4.21e-01 |
| GO:BP | GO:0001709 | cell fate determination | 1 | 25 | 4.21e-01 |
| GO:BP | GO:0034109 | homotypic cell-cell adhesion | 3 | 70 | 4.21e-01 |
| GO:BP | GO:1901844 | regulation of cell communication by electrical coupling involved in cardiac conduction | 2 | 12 | 4.21e-01 |
| GO:BP | GO:0018202 | peptidyl-histidine modification | 2 | 11 | 4.21e-01 |
| GO:BP | GO:0050772 | positive regulation of axonogenesis | 1 | 72 | 4.21e-01 |
| GO:BP | GO:0046470 | phosphatidylcholine metabolic process | 1 | 53 | 4.21e-01 |
| GO:BP | GO:0031914 | negative regulation of synaptic plasticity | 1 | 2 | 4.21e-01 |
| GO:BP | GO:1904706 | negative regulation of vascular associated smooth muscle cell proliferation | 1 | 24 | 4.21e-01 |
| GO:BP | GO:0008104 | protein localization | 6 | 2129 | 4.21e-01 |
| GO:BP | GO:0090100 | positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 2 | 100 | 4.21e-01 |
| GO:BP | GO:2000379 | positive regulation of reactive oxygen species metabolic process | 5 | 46 | 4.21e-01 |
| GO:BP | GO:1904357 | negative regulation of telomere maintenance via telomere lengthening | 2 | 26 | 4.21e-01 |
| GO:BP | GO:0060715 | syncytiotrophoblast cell differentiation involved in labyrinthine layer development | 1 | 3 | 4.21e-01 |
| GO:BP | GO:0007178 | transmembrane receptor protein serine/threonine kinase signaling pathway | 19 | 303 | 4.21e-01 |
| GO:BP | GO:0001755 | neural crest cell migration | 3 | 49 | 4.22e-01 |
| GO:BP | GO:0033004 | negative regulation of mast cell activation | 1 | 4 | 4.22e-01 |
| GO:BP | GO:2001268 | negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway | 1 | 5 | 4.23e-01 |
| GO:BP | GO:0009404 | toxin metabolic process | 2 | 7 | 4.23e-01 |
| GO:BP | GO:0060043 | regulation of cardiac muscle cell proliferation | 2 | 32 | 4.23e-01 |
| GO:BP | GO:0051028 | mRNA transport | 8 | 117 | 4.23e-01 |
| GO:BP | GO:0060666 | dichotomous subdivision of terminal units involved in salivary gland branching | 1 | 4 | 4.23e-01 |
| GO:BP | GO:0070727 | cellular macromolecule localization | 6 | 2138 | 4.23e-01 |
| GO:BP | GO:0060337 | type I interferon-mediated signaling pathway | 6 | 51 | 4.23e-01 |
| GO:BP | GO:0046543 | development of secondary female sexual characteristics | 1 | 7 | 4.23e-01 |
| GO:BP | GO:0070676 | intralumenal vesicle formation | 1 | 4 | 4.23e-01 |
| GO:BP | GO:0034121 | regulation of toll-like receptor signaling pathway | 2 | 19 | 4.23e-01 |
| GO:BP | GO:2000647 | negative regulation of stem cell proliferation | 2 | 18 | 4.23e-01 |
| GO:BP | GO:0048520 | positive regulation of behavior | 3 | 13 | 4.23e-01 |
| GO:BP | GO:2000405 | negative regulation of T cell migration | 1 | 4 | 4.23e-01 |
| GO:BP | GO:0033133 | positive regulation of glucokinase activity | 1 | 4 | 4.23e-01 |
| GO:BP | GO:0009217 | purine deoxyribonucleoside triphosphate catabolic process | 1 | 4 | 4.23e-01 |
| GO:BP | GO:0035036 | sperm-egg recognition | 2 | 22 | 4.23e-01 |
| GO:BP | GO:0017145 | stem cell division | 1 | 26 | 4.23e-01 |
| GO:BP | GO:0006418 | tRNA aminoacylation for protein translation | 1 | 40 | 4.23e-01 |
| GO:BP | GO:0044849 | estrous cycle | 2 | 13 | 4.23e-01 |
| GO:BP | GO:0045588 | positive regulation of gamma-delta T cell differentiation | 1 | 4 | 4.23e-01 |
| GO:BP | GO:1990481 | mRNA pseudouridine synthesis | 1 | 9 | 4.23e-01 |
| GO:BP | GO:0006282 | regulation of DNA repair | 9 | 198 | 4.23e-01 |
| GO:BP | GO:1903542 | negative regulation of exosomal secretion | 1 | 4 | 4.23e-01 |
| GO:BP | GO:0045472 | response to ether | 1 | 7 | 4.23e-01 |
| GO:BP | GO:0033151 | V(D)J recombination | 2 | 16 | 4.23e-01 |
| GO:BP | GO:2001257 | regulation of cation channel activity | 1 | 100 | 4.23e-01 |
| GO:BP | GO:0000902 | cell morphogenesis | 40 | 761 | 4.23e-01 |
| GO:BP | GO:0097709 | connective tissue replacement | 2 | 8 | 4.23e-01 |
| GO:BP | GO:0071492 | cellular response to UV-A | 2 | 8 | 4.23e-01 |
| GO:BP | GO:1900271 | regulation of long-term synaptic potentiation | 5 | 34 | 4.23e-01 |
| GO:BP | GO:0010821 | regulation of mitochondrion organization | 1 | 135 | 4.23e-01 |
| GO:BP | GO:0002520 | immune system development | 10 | 144 | 4.23e-01 |
| GO:BP | GO:0061370 | testosterone biosynthetic process | 1 | 3 | 4.23e-01 |
| GO:BP | GO:0010875 | positive regulation of cholesterol efflux | 1 | 23 | 4.23e-01 |
| GO:BP | GO:0001951 | intestinal D-glucose absorption | 1 | 3 | 4.23e-01 |
| GO:BP | GO:2000819 | regulation of nucleotide-excision repair | 3 | 27 | 4.23e-01 |
| GO:BP | GO:0014032 | neural crest cell development | 4 | 71 | 4.23e-01 |
| GO:BP | GO:0002532 | production of molecular mediator involved in inflammatory response | 2 | 49 | 4.23e-01 |
| GO:BP | GO:0030098 | lymphocyte differentiation | 1 | 260 | 4.23e-01 |
| GO:BP | GO:2000269 | regulation of fibroblast apoptotic process | 1 | 17 | 4.23e-01 |
| GO:BP | GO:0090630 | activation of GTPase activity | 3 | 99 | 4.23e-01 |
| GO:BP | GO:0097090 | presynaptic membrane organization | 2 | 8 | 4.23e-01 |
| GO:BP | GO:0046825 | regulation of protein export from nucleus | 4 | 30 | 4.23e-01 |
| GO:BP | GO:1901030 | positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway | 2 | 12 | 4.23e-01 |
| GO:BP | GO:0097028 | dendritic cell differentiation | 1 | 23 | 4.23e-01 |
| GO:BP | GO:1902893 | regulation of miRNA transcription | 3 | 56 | 4.23e-01 |
| GO:BP | GO:1903428 | positive regulation of reactive oxygen species biosynthetic process | 2 | 12 | 4.23e-01 |
| GO:BP | GO:0034341 | response to type II interferon | 7 | 83 | 4.23e-01 |
| GO:BP | GO:0070341 | fat cell proliferation | 2 | 10 | 4.23e-01 |
| GO:BP | GO:2001185 | regulation of CD8-positive, alpha-beta T cell activation | 1 | 13 | 4.24e-01 |
| GO:BP | GO:1904417 | positive regulation of xenophagy | 1 | 7 | 4.24e-01 |
| GO:BP | GO:0001763 | morphogenesis of a branching structure | 1 | 154 | 4.24e-01 |
| GO:BP | GO:0031667 | response to nutrient levels | 26 | 353 | 4.24e-01 |
| GO:BP | GO:0035279 | miRNA-mediated gene silencing by mRNA destabilization | 1 | 3 | 4.24e-01 |
| GO:BP | GO:0003163 | sinoatrial node development | 1 | 10 | 4.24e-01 |
| GO:BP | GO:0018242 | protein O-linked glycosylation via serine | 1 | 7 | 4.24e-01 |
| GO:BP | GO:0018243 | protein O-linked glycosylation via threonine | 1 | 7 | 4.24e-01 |
| GO:BP | GO:1904415 | regulation of xenophagy | 1 | 7 | 4.24e-01 |
| GO:BP | GO:0042391 | regulation of membrane potential | 1 | 293 | 4.24e-01 |
| GO:BP | GO:0007157 | heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules | 5 | 29 | 4.24e-01 |
| GO:BP | GO:1905269 | positive regulation of chromatin organization | 2 | 15 | 4.24e-01 |
| GO:BP | GO:0000070 | mitotic sister chromatid segregation | 9 | 179 | 4.24e-01 |
| GO:BP | GO:0016525 | negative regulation of angiogenesis | 2 | 72 | 4.25e-01 |
| GO:BP | GO:0032990 | cell part morphogenesis | 29 | 551 | 4.25e-01 |
| GO:BP | GO:0009152 | purine ribonucleotide biosynthetic process | 1 | 179 | 4.25e-01 |
| GO:BP | GO:0042746 | circadian sleep/wake cycle, wakefulness | 1 | 1 | 4.25e-01 |
| GO:BP | GO:0008535 | respiratory chain complex IV assembly | 3 | 29 | 4.25e-01 |
| GO:BP | GO:1901098 | positive regulation of autophagosome maturation | 1 | 6 | 4.25e-01 |
| GO:BP | GO:0010840 | regulation of circadian sleep/wake cycle, wakefulness | 1 | 1 | 4.25e-01 |
| GO:BP | GO:1901160 | primary amino compound metabolic process | 2 | 8 | 4.25e-01 |
| GO:BP | GO:0010665 | regulation of cardiac muscle cell apoptotic process | 3 | 33 | 4.25e-01 |
| GO:BP | GO:0045862 | positive regulation of proteolysis | 3 | 295 | 4.25e-01 |
| GO:BP | GO:1901264 | carbohydrate derivative transport | 1 | 63 | 4.25e-01 |
| GO:BP | GO:0016080 | synaptic vesicle targeting | 1 | 3 | 4.25e-01 |
| GO:BP | GO:1903047 | mitotic cell cycle process | 32 | 694 | 4.25e-01 |
| GO:BP | GO:0110156 | methylguanosine-cap decapping | 1 | 14 | 4.25e-01 |
| GO:BP | GO:0061419 | positive regulation of transcription from RNA polymerase II promoter in response to hypoxia | 1 | 5 | 4.25e-01 |
| GO:BP | GO:1902037 | negative regulation of hematopoietic stem cell differentiation | 1 | 4 | 4.25e-01 |
| GO:BP | GO:0007088 | regulation of mitotic nuclear division | 1 | 100 | 4.25e-01 |
| GO:BP | GO:0035137 | hindlimb morphogenesis | 2 | 20 | 4.25e-01 |
| GO:BP | GO:0048515 | spermatid differentiation | 2 | 111 | 4.25e-01 |
| GO:BP | GO:0031648 | protein destabilization | 3 | 45 | 4.25e-01 |
| GO:BP | GO:0032989 | cellular component morphogenesis | 33 | 639 | 4.25e-01 |
| GO:BP | GO:0032232 | negative regulation of actin filament bundle assembly | 3 | 26 | 4.26e-01 |
| GO:BP | GO:0060317 | cardiac epithelial to mesenchymal transition | 1 | 28 | 4.26e-01 |
| GO:BP | GO:0007431 | salivary gland development | 1 | 26 | 4.26e-01 |
| GO:BP | GO:0002719 | negative regulation of cytokine production involved in immune response | 1 | 16 | 4.26e-01 |
| GO:BP | GO:0060575 | intestinal epithelial cell differentiation | 2 | 17 | 4.26e-01 |
| GO:BP | GO:0061384 | heart trabecula morphogenesis | 1 | 29 | 4.26e-01 |
| GO:BP | GO:0045931 | positive regulation of mitotic cell cycle | 8 | 113 | 4.26e-01 |
| GO:BP | GO:0007164 | establishment of tissue polarity | 8 | 70 | 4.26e-01 |
| GO:BP | GO:0001736 | establishment of planar polarity | 8 | 70 | 4.26e-01 |
| GO:BP | GO:1990410 | adrenomedullin receptor signaling pathway | 1 | 3 | 4.26e-01 |
| GO:BP | GO:0072162 | metanephric mesenchymal cell differentiation | 1 | 3 | 4.26e-01 |
| GO:BP | GO:0090185 | negative regulation of kidney development | 1 | 3 | 4.26e-01 |
| GO:BP | GO:1902430 | negative regulation of amyloid-beta formation | 2 | 17 | 4.26e-01 |
| GO:BP | GO:0055075 | potassium ion homeostasis | 2 | 22 | 4.26e-01 |
| GO:BP | GO:0035239 | tube morphogenesis | 10 | 663 | 4.26e-01 |
| GO:BP | GO:2000181 | negative regulation of blood vessel morphogenesis | 2 | 73 | 4.26e-01 |
| GO:BP | GO:0030522 | intracellular receptor signaling pathway | 19 | 227 | 4.27e-01 |
| GO:BP | GO:1901678 | iron coordination entity transport | 1 | 11 | 4.27e-01 |
| GO:BP | GO:0120039 | plasma membrane bounded cell projection morphogenesis | 28 | 527 | 4.27e-01 |
| GO:BP | GO:0033674 | positive regulation of kinase activity | 1 | 317 | 4.27e-01 |
| GO:BP | GO:0014732 | skeletal muscle atrophy | 1 | 5 | 4.27e-01 |
| GO:BP | GO:0043491 | protein kinase B signaling | 7 | 146 | 4.27e-01 |
| GO:BP | GO:0002448 | mast cell mediated immunity | 3 | 33 | 4.27e-01 |
| GO:BP | GO:0060430 | lung saccule development | 1 | 7 | 4.27e-01 |
| GO:BP | GO:0048646 | anatomical structure formation involved in morphogenesis | 14 | 870 | 4.27e-01 |
| GO:BP | GO:0042753 | positive regulation of circadian rhythm | 1 | 10 | 4.27e-01 |
| GO:BP | GO:0071378 | cellular response to growth hormone stimulus | 2 | 18 | 4.27e-01 |
| GO:BP | GO:0060396 | growth hormone receptor signaling pathway | 2 | 18 | 4.27e-01 |
| GO:BP | GO:0061614 | miRNA transcription | 3 | 57 | 4.27e-01 |
| GO:BP | GO:0051754 | meiotic sister chromatid cohesion, centromeric | 1 | 4 | 4.27e-01 |
| GO:BP | GO:0090481 | pyrimidine nucleotide-sugar transmembrane transport | 2 | 12 | 4.27e-01 |
| GO:BP | GO:0048284 | organelle fusion | 8 | 135 | 4.29e-01 |
| GO:BP | GO:0009996 | negative regulation of cell fate specification | 1 | 4 | 4.29e-01 |
| GO:BP | GO:0045944 | positive regulation of transcription by RNA polymerase II | 71 | 937 | 4.29e-01 |
| GO:BP | GO:0000712 | resolution of meiotic recombination intermediates | 1 | 13 | 4.29e-01 |
| GO:BP | GO:0014834 | skeletal muscle satellite cell maintenance involved in skeletal muscle regeneration | 1 | 4 | 4.29e-01 |
| GO:BP | GO:0002696 | positive regulation of leukocyte activation | 1 | 222 | 4.29e-01 |
| GO:BP | GO:1902747 | negative regulation of lens fiber cell differentiation | 1 | 5 | 4.29e-01 |
| GO:BP | GO:0048254 | snoRNA localization | 1 | 5 | 4.29e-01 |
| GO:BP | GO:0050848 | regulation of calcium-mediated signaling | 6 | 52 | 4.29e-01 |
| GO:BP | GO:1901343 | negative regulation of vasculature development | 2 | 73 | 4.29e-01 |
| GO:BP | GO:0009057 | macromolecule catabolic process | 108 | 1199 | 4.30e-01 |
| GO:BP | GO:0051153 | regulation of striated muscle cell differentiation | 6 | 67 | 4.30e-01 |
| GO:BP | GO:0048738 | cardiac muscle tissue development | 7 | 198 | 4.30e-01 |
| GO:BP | GO:0048041 | focal adhesion assembly | 1 | 81 | 4.30e-01 |
| GO:BP | GO:0000723 | telomere maintenance | 7 | 142 | 4.30e-01 |
| GO:BP | GO:0051965 | positive regulation of synapse assembly | 7 | 44 | 4.30e-01 |
| GO:BP | GO:0033875 | ribonucleoside bisphosphate metabolic process | 2 | 92 | 4.31e-01 |
| GO:BP | GO:0034032 | purine nucleoside bisphosphate metabolic process | 2 | 92 | 4.31e-01 |
| GO:BP | GO:0033865 | nucleoside bisphosphate metabolic process | 2 | 92 | 4.31e-01 |
| GO:BP | GO:0060055 | angiogenesis involved in wound healing | 1 | 25 | 4.31e-01 |
| GO:BP | GO:0062014 | negative regulation of small molecule metabolic process | 2 | 71 | 4.31e-01 |
| GO:BP | GO:1903650 | negative regulation of cytoplasmic transport | 1 | 3 | 4.31e-01 |
| GO:BP | GO:2001245 | regulation of phosphatidylcholine biosynthetic process | 1 | 5 | 4.31e-01 |
| GO:BP | GO:0060024 | rhythmic synaptic transmission | 1 | 3 | 4.31e-01 |
| GO:BP | GO:0070925 | organelle assembly | 62 | 817 | 4.32e-01 |
| GO:BP | GO:0002437 | inflammatory response to antigenic stimulus | 2 | 36 | 4.32e-01 |
| GO:BP | GO:0006011 | UDP-glucose metabolic process | 1 | 6 | 4.32e-01 |
| GO:BP | GO:0090497 | mesenchymal cell migration | 3 | 51 | 4.32e-01 |
| GO:BP | GO:0048666 | neuron development | 8 | 877 | 4.32e-01 |
| GO:BP | GO:0046827 | positive regulation of protein export from nucleus | 2 | 15 | 4.32e-01 |
| GO:BP | GO:0035051 | cardiocyte differentiation | 9 | 129 | 4.32e-01 |
| GO:BP | GO:1900151 | regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 2 | 24 | 4.32e-01 |
| GO:BP | GO:0002443 | leukocyte mediated immunity | 1 | 194 | 4.32e-01 |
| GO:BP | GO:1901876 | regulation of calcium ion binding | 1 | 2 | 4.32e-01 |
| GO:BP | GO:0019318 | hexose metabolic process | 1 | 185 | 4.32e-01 |
| GO:BP | GO:0071407 | cellular response to organic cyclic compound | 27 | 414 | 4.32e-01 |
| GO:BP | GO:0002860 | positive regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 1 | 3 | 4.32e-01 |
| GO:BP | GO:0006402 | mRNA catabolic process | 11 | 216 | 4.32e-01 |
| GO:BP | GO:0070131 | positive regulation of mitochondrial translation | 2 | 17 | 4.32e-01 |
| GO:BP | GO:1901877 | negative regulation of calcium ion binding | 1 | 2 | 4.32e-01 |
| GO:BP | GO:1990089 | response to nerve growth factor | 3 | 41 | 4.32e-01 |
| GO:BP | GO:0006924 | activation-induced cell death of T cells | 1 | 8 | 4.32e-01 |
| GO:BP | GO:0048701 | embryonic cranial skeleton morphogenesis | 3 | 31 | 4.32e-01 |
| GO:BP | GO:0035850 | epithelial cell differentiation involved in kidney development | 1 | 35 | 4.32e-01 |
| GO:BP | GO:0048318 | axial mesoderm development | 1 | 6 | 4.32e-01 |
| GO:BP | GO:0021894 | cerebral cortex GABAergic interneuron development | 1 | 3 | 4.32e-01 |
| GO:BP | GO:0072137 | condensed mesenchymal cell proliferation | 1 | 2 | 4.32e-01 |
| GO:BP | GO:1904064 | positive regulation of cation transmembrane transport | 1 | 99 | 4.33e-01 |
| GO:BP | GO:0072177 | mesonephric duct development | 1 | 7 | 4.33e-01 |
| GO:BP | GO:0048302 | regulation of isotype switching to IgG isotypes | 2 | 7 | 4.33e-01 |
| GO:BP | GO:0002275 | myeloid cell activation involved in immune response | 5 | 48 | 4.33e-01 |
| GO:BP | GO:0034605 | cellular response to heat | 2 | 51 | 4.33e-01 |
| GO:BP | GO:2000169 | regulation of peptidyl-cysteine S-nitrosylation | 1 | 9 | 4.34e-01 |
| GO:BP | GO:0051385 | response to mineralocorticoid | 2 | 25 | 4.34e-01 |
| GO:BP | GO:0009151 | purine deoxyribonucleotide metabolic process | 2 | 12 | 4.34e-01 |
| GO:BP | GO:0032206 | positive regulation of telomere maintenance | 7 | 64 | 4.34e-01 |
| GO:BP | GO:0007596 | blood coagulation | 8 | 150 | 4.34e-01 |
| GO:BP | GO:0042274 | ribosomal small subunit biogenesis | 7 | 79 | 4.34e-01 |
| GO:BP | GO:0051254 | positive regulation of RNA metabolic process | 103 | 1441 | 4.35e-01 |
| GO:BP | GO:0000381 | regulation of alternative mRNA splicing, via spliceosome | 5 | 53 | 4.35e-01 |
| GO:BP | GO:0072160 | nephron tubule epithelial cell differentiation | 2 | 12 | 4.35e-01 |
| GO:BP | GO:0050867 | positive regulation of cell activation | 1 | 229 | 4.35e-01 |
| GO:BP | GO:0009260 | ribonucleotide biosynthetic process | 1 | 191 | 4.35e-01 |
| GO:BP | GO:0010728 | regulation of hydrogen peroxide biosynthetic process | 1 | 5 | 4.35e-01 |
| GO:BP | GO:0090503 | RNA phosphodiester bond hydrolysis, exonucleolytic | 2 | 41 | 4.35e-01 |
| GO:BP | GO:0038060 | nitric oxide-cGMP-mediated signaling pathway | 1 | 2 | 4.35e-01 |
| GO:BP | GO:0099163 | synaptic signaling by nitric oxide | 1 | 3 | 4.35e-01 |
| GO:BP | GO:0016311 | dephosphorylation | 4 | 284 | 4.35e-01 |
| GO:BP | GO:0043039 | tRNA aminoacylation | 1 | 43 | 4.35e-01 |
| GO:BP | GO:0090316 | positive regulation of intracellular protein transport | 5 | 133 | 4.35e-01 |
| GO:BP | GO:0046326 | positive regulation of glucose import | 3 | 26 | 4.35e-01 |
| GO:BP | GO:0045050 | protein insertion into ER membrane by stop-transfer membrane-anchor sequence | 1 | 10 | 4.35e-01 |
| GO:BP | GO:0071357 | cellular response to type I interferon | 6 | 52 | 4.35e-01 |
| GO:BP | GO:0033366 | protein localization to secretory granule | 1 | 1 | 4.35e-01 |
| GO:BP | GO:0042490 | mechanoreceptor differentiation | 4 | 49 | 4.35e-01 |
| GO:BP | GO:0048730 | epidermis morphogenesis | 1 | 20 | 4.35e-01 |
| GO:BP | GO:0090257 | regulation of muscle system process | 1 | 184 | 4.35e-01 |
| GO:BP | GO:0043280 | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 5 | 96 | 4.35e-01 |
| GO:BP | GO:0086012 | membrane depolarization during cardiac muscle cell action potential | 2 | 21 | 4.35e-01 |
| GO:BP | GO:0060218 | hematopoietic stem cell differentiation | 3 | 30 | 4.35e-01 |
| GO:BP | GO:0071476 | cellular hypotonic response | 1 | 8 | 4.36e-01 |
| GO:BP | GO:0035507 | regulation of myosin-light-chain-phosphatase activity | 1 | 5 | 4.36e-01 |
| GO:BP | GO:0090502 | RNA phosphodiester bond hydrolysis, endonucleolytic | 3 | 72 | 4.36e-01 |
| GO:BP | GO:0007034 | vacuolar transport | 1 | 149 | 4.36e-01 |
| GO:BP | GO:0018146 | keratan sulfate biosynthetic process | 1 | 13 | 4.36e-01 |
| GO:BP | GO:0002639 | positive regulation of immunoglobulin production | 2 | 30 | 4.36e-01 |
| GO:BP | GO:0150012 | positive regulation of neuron projection arborization | 1 | 8 | 4.36e-01 |
| GO:BP | GO:0021602 | cranial nerve morphogenesis | 3 | 16 | 4.37e-01 |
| GO:BP | GO:0006978 | DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator | 1 | 18 | 4.37e-01 |
| GO:BP | GO:0048858 | cell projection morphogenesis | 28 | 531 | 4.37e-01 |
| GO:BP | GO:0140053 | mitochondrial gene expression | 2 | 162 | 4.37e-01 |
| GO:BP | GO:0032930 | positive regulation of superoxide anion generation | 1 | 10 | 4.37e-01 |
| GO:BP | GO:0019082 | viral protein processing | 3 | 31 | 4.37e-01 |
| GO:BP | GO:0031953 | negative regulation of protein autophosphorylation | 2 | 9 | 4.37e-01 |
| GO:BP | GO:0050691 | regulation of defense response to virus by host | 5 | 30 | 4.37e-01 |
| GO:BP | GO:0021795 | cerebral cortex cell migration | 1 | 37 | 4.37e-01 |
| GO:BP | GO:0045104 | intermediate filament cytoskeleton organization | 1 | 39 | 4.37e-01 |
| GO:BP | GO:0030316 | osteoclast differentiation | 10 | 66 | 4.37e-01 |
| GO:BP | GO:2000026 | regulation of multicellular organismal development | 15 | 1014 | 4.37e-01 |
| GO:BP | GO:0034227 | tRNA thio-modification | 1 | 5 | 4.37e-01 |
| GO:BP | GO:0043488 | regulation of mRNA stability | 8 | 147 | 4.38e-01 |
| GO:BP | GO:0042438 | melanin biosynthetic process | 2 | 17 | 4.38e-01 |
| GO:BP | GO:0002200 | somatic diversification of immune receptors | 3 | 62 | 4.38e-01 |
| GO:BP | GO:0071346 | cellular response to type II interferon | 6 | 69 | 4.38e-01 |
| GO:BP | GO:0032784 | regulation of DNA-templated transcription elongation | 9 | 99 | 4.38e-01 |
| GO:BP | GO:1902358 | sulfate transmembrane transport | 2 | 11 | 4.39e-01 |
| GO:BP | GO:0006999 | nuclear pore organization | 1 | 14 | 4.39e-01 |
| GO:BP | GO:0048025 | negative regulation of mRNA splicing, via spliceosome | 2 | 23 | 4.39e-01 |
| GO:BP | GO:0022407 | regulation of cell-cell adhesion | 1 | 295 | 4.39e-01 |
| GO:BP | GO:0045937 | positive regulation of phosphate metabolic process | 2 | 597 | 4.39e-01 |
| GO:BP | GO:1904526 | regulation of microtubule binding | 1 | 10 | 4.39e-01 |
| GO:BP | GO:0051651 | maintenance of location in cell | 2 | 170 | 4.39e-01 |
| GO:BP | GO:0006541 | glutamine metabolic process | 1 | 24 | 4.39e-01 |
| GO:BP | GO:0045103 | intermediate filament-based process | 1 | 40 | 4.39e-01 |
| GO:BP | GO:0016197 | endosomal transport | 13 | 231 | 4.39e-01 |
| GO:BP | GO:0046835 | carbohydrate phosphorylation | 3 | 21 | 4.39e-01 |
| GO:BP | GO:0006954 | inflammatory response | 2 | 429 | 4.39e-01 |
| GO:BP | GO:0048841 | regulation of axon extension involved in axon guidance | 2 | 31 | 4.39e-01 |
| GO:BP | GO:0009268 | response to pH | 1 | 26 | 4.39e-01 |
| GO:BP | GO:0046549 | retinal cone cell development | 2 | 5 | 4.39e-01 |
| GO:BP | GO:0010562 | positive regulation of phosphorus metabolic process | 2 | 597 | 4.39e-01 |
| GO:BP | GO:0014706 | striated muscle tissue development | 18 | 210 | 4.39e-01 |
| GO:BP | GO:1903829 | positive regulation of protein localization | 1 | 386 | 4.39e-01 |
| GO:BP | GO:0072178 | nephric duct morphogenesis | 1 | 8 | 4.39e-01 |
| GO:BP | GO:0030033 | microvillus assembly | 2 | 15 | 4.39e-01 |
| GO:BP | GO:0043038 | amino acid activation | 1 | 44 | 4.39e-01 |
| GO:BP | GO:0043029 | T cell homeostasis | 3 | 27 | 4.39e-01 |
| GO:BP | GO:0072207 | metanephric epithelium development | 3 | 16 | 4.39e-01 |
| GO:BP | GO:0090042 | tubulin deacetylation | 2 | 23 | 4.39e-01 |
| GO:BP | GO:0046390 | ribose phosphate biosynthetic process | 1 | 197 | 4.39e-01 |
| GO:BP | GO:0055017 | cardiac muscle tissue growth | 3 | 65 | 4.39e-01 |
| GO:BP | GO:0002735 | positive regulation of myeloid dendritic cell cytokine production | 1 | 6 | 4.39e-01 |
| GO:BP | GO:0002372 | myeloid dendritic cell cytokine production | 1 | 6 | 4.39e-01 |
| GO:BP | GO:2000291 | regulation of myoblast proliferation | 1 | 11 | 4.39e-01 |
| GO:BP | GO:0002733 | regulation of myeloid dendritic cell cytokine production | 1 | 6 | 4.39e-01 |
| GO:BP | GO:0045785 | positive regulation of cell adhesion | 1 | 320 | 4.39e-01 |
| GO:BP | GO:1902850 | microtubule cytoskeleton organization involved in mitosis | 8 | 157 | 4.39e-01 |
| GO:BP | GO:0002573 | myeloid leukocyte differentiation | 1 | 151 | 4.39e-01 |
| GO:BP | GO:0009952 | anterior/posterior pattern specification | 1 | 127 | 4.39e-01 |
| GO:BP | GO:0035634 | response to stilbenoid | 1 | 2 | 4.40e-01 |
| GO:BP | GO:0002328 | pro-B cell differentiation | 1 | 10 | 4.40e-01 |
| GO:BP | GO:0071389 | cellular response to mineralocorticoid stimulus | 1 | 9 | 4.40e-01 |
| GO:BP | GO:0021979 | hypothalamus cell differentiation | 2 | 8 | 4.40e-01 |
| GO:BP | GO:0006513 | protein monoubiquitination | 1 | 80 | 4.40e-01 |
| GO:BP | GO:0043543 | protein acylation | 6 | 228 | 4.41e-01 |
| GO:BP | GO:0045833 | negative regulation of lipid metabolic process | 2 | 72 | 4.41e-01 |
| GO:BP | GO:0035583 | sequestering of TGFbeta in extracellular matrix | 1 | 3 | 4.41e-01 |
| GO:BP | GO:0051894 | positive regulation of focal adhesion assembly | 2 | 24 | 4.41e-01 |
| GO:BP | GO:0048008 | platelet-derived growth factor receptor signaling pathway | 1 | 52 | 4.41e-01 |
| GO:BP | GO:0001819 | positive regulation of cytokine production | 1 | 276 | 4.41e-01 |
| GO:BP | GO:0034124 | regulation of MyD88-dependent toll-like receptor signaling pathway | 1 | 2 | 4.41e-01 |
| GO:BP | GO:0000910 | cytokinesis | 2 | 164 | 4.41e-01 |
| GO:BP | GO:0032388 | positive regulation of intracellular transport | 6 | 170 | 4.41e-01 |
| GO:BP | GO:2000194 | regulation of female gonad development | 1 | 4 | 4.41e-01 |
| GO:BP | GO:0009303 | rRNA transcription | 4 | 37 | 4.41e-01 |
| GO:BP | GO:0031400 | negative regulation of protein modification process | 1 | 418 | 4.41e-01 |
| GO:BP | GO:0031017 | exocrine pancreas development | 1 | 4 | 4.41e-01 |
| GO:BP | GO:0071498 | cellular response to fluid shear stress | 2 | 19 | 4.41e-01 |
| GO:BP | GO:0043410 | positive regulation of MAPK cascade | 1 | 317 | 4.41e-01 |
| GO:BP | GO:0003400 | regulation of COPII vesicle coating | 1 | 3 | 4.41e-01 |
| GO:BP | GO:0045664 | regulation of neuron differentiation | 1 | 137 | 4.41e-01 |
| GO:BP | GO:1903979 | negative regulation of microglial cell activation | 1 | 5 | 4.41e-01 |
| GO:BP | GO:0001649 | osteoblast differentiation | 1 | 179 | 4.42e-01 |
| GO:BP | GO:0033500 | carbohydrate homeostasis | 12 | 169 | 4.42e-01 |
| GO:BP | GO:0002839 | positive regulation of immune response to tumor cell | 2 | 7 | 4.42e-01 |
| GO:BP | GO:1903025 | regulation of RNA polymerase II regulatory region sequence-specific DNA binding | 1 | 15 | 4.42e-01 |
| GO:BP | GO:0070672 | response to interleukin-15 | 1 | 3 | 4.42e-01 |
| GO:BP | GO:0010225 | response to UV-C | 2 | 13 | 4.42e-01 |
| GO:BP | GO:1902044 | regulation of Fas signaling pathway | 1 | 4 | 4.42e-01 |
| GO:BP | GO:0070669 | response to interleukin-2 | 1 | 3 | 4.42e-01 |
| GO:BP | GO:0002836 | positive regulation of response to tumor cell | 2 | 7 | 4.42e-01 |
| GO:BP | GO:0046645 | positive regulation of gamma-delta T cell activation | 1 | 4 | 4.42e-01 |
| GO:BP | GO:1903576 | response to L-arginine | 1 | 3 | 4.42e-01 |
| GO:BP | GO:0021533 | cell differentiation in hindbrain | 1 | 18 | 4.42e-01 |
| GO:BP | GO:0001880 | Mullerian duct regression | 1 | 4 | 4.42e-01 |
| GO:BP | GO:0034198 | cellular response to amino acid starvation | 4 | 48 | 4.42e-01 |
| GO:BP | GO:0090162 | establishment of epithelial cell polarity | 2 | 29 | 4.42e-01 |
| GO:BP | GO:0021535 | cell migration in hindbrain | 2 | 12 | 4.42e-01 |
| GO:BP | GO:0070813 | hydrogen sulfide metabolic process | 1 | 5 | 4.42e-01 |
| GO:BP | GO:0009092 | homoserine metabolic process | 1 | 5 | 4.42e-01 |
| GO:BP | GO:0031016 | pancreas development | 5 | 53 | 4.42e-01 |
| GO:BP | GO:0019346 | transsulfuration | 1 | 5 | 4.42e-01 |
| GO:BP | GO:0045923 | positive regulation of fatty acid metabolic process | 1 | 26 | 4.42e-01 |
| GO:BP | GO:0034968 | histone lysine methylation | 2 | 89 | 4.42e-01 |
| GO:BP | GO:0051310 | metaphase plate congression | 4 | 69 | 4.42e-01 |
| GO:BP | GO:0030335 | positive regulation of cell migration | 21 | 407 | 4.43e-01 |
| GO:BP | GO:1905809 | negative regulation of synapse organization | 1 | 8 | 4.43e-01 |
| GO:BP | GO:0050804 | modulation of chemical synaptic transmission | 1 | 341 | 4.43e-01 |
| GO:BP | GO:0097084 | vascular associated smooth muscle cell development | 1 | 11 | 4.43e-01 |
| GO:BP | GO:0140009 | L-aspartate import across plasma membrane | 1 | 5 | 4.43e-01 |
| GO:BP | GO:0044281 | small molecule metabolic process | 4 | 1389 | 4.43e-01 |
| GO:BP | GO:1904754 | positive regulation of vascular associated smooth muscle cell migration | 2 | 12 | 4.43e-01 |
| GO:BP | GO:0051150 | regulation of smooth muscle cell differentiation | 1 | 28 | 4.43e-01 |
| GO:BP | GO:0099177 | regulation of trans-synaptic signaling | 1 | 342 | 4.43e-01 |
| GO:BP | GO:0042772 | DNA damage response, signal transduction resulting in transcription | 1 | 19 | 4.44e-01 |
| GO:BP | GO:0060136 | embryonic process involved in female pregnancy | 1 | 6 | 4.44e-01 |
| GO:BP | GO:0002070 | epithelial cell maturation | 2 | 16 | 4.44e-01 |
| GO:BP | GO:0062012 | regulation of small molecule metabolic process | 2 | 246 | 4.44e-01 |
| GO:BP | GO:0035902 | response to immobilization stress | 3 | 16 | 4.44e-01 |
| GO:BP | GO:0097503 | sialylation | 2 | 18 | 4.44e-01 |
| GO:BP | GO:0010661 | positive regulation of muscle cell apoptotic process | 1 | 20 | 4.44e-01 |
| GO:BP | GO:0048638 | regulation of developmental growth | 2 | 258 | 4.44e-01 |
| GO:BP | GO:0045794 | negative regulation of cell volume | 1 | 4 | 4.44e-01 |
| GO:BP | GO:0048261 | negative regulation of receptor-mediated endocytosis | 2 | 25 | 4.44e-01 |
| GO:BP | GO:0001656 | metanephros development | 4 | 64 | 4.45e-01 |
| GO:BP | GO:1901096 | regulation of autophagosome maturation | 2 | 16 | 4.45e-01 |
| GO:BP | GO:2001016 | positive regulation of skeletal muscle cell differentiation | 1 | 5 | 4.45e-01 |
| GO:BP | GO:1903236 | regulation of leukocyte tethering or rolling | 1 | 6 | 4.45e-01 |
| GO:BP | GO:0008360 | regulation of cell shape | 5 | 126 | 4.45e-01 |
| GO:BP | GO:0099558 | maintenance of synapse structure | 3 | 25 | 4.45e-01 |
| GO:BP | GO:0016485 | protein processing | 1 | 183 | 4.45e-01 |
| GO:BP | GO:0048511 | rhythmic process | 6 | 237 | 4.45e-01 |
| GO:BP | GO:0090501 | RNA phosphodiester bond hydrolysis | 5 | 136 | 4.45e-01 |
| GO:BP | GO:1903051 | negative regulation of proteolysis involved in protein catabolic process | 4 | 61 | 4.45e-01 |
| GO:BP | GO:0051238 | sequestering of metal ion | 2 | 17 | 4.45e-01 |
| GO:BP | GO:0090330 | regulation of platelet aggregation | 1 | 21 | 4.46e-01 |
| GO:BP | GO:0048513 | animal organ development | 1 | 2189 | 4.47e-01 |
| GO:BP | GO:0097011 | cellular response to granulocyte macrophage colony-stimulating factor stimulus | 1 | 6 | 4.47e-01 |
| GO:BP | GO:0097012 | response to granulocyte macrophage colony-stimulating factor | 1 | 6 | 4.47e-01 |
| GO:BP | GO:0045880 | positive regulation of smoothened signaling pathway | 4 | 31 | 4.47e-01 |
| GO:BP | GO:0070673 | response to interleukin-18 | 1 | 5 | 4.47e-01 |
| GO:BP | GO:0140052 | cellular response to oxidised low-density lipoprotein particle stimulus | 1 | 7 | 4.47e-01 |
| GO:BP | GO:0051939 | gamma-aminobutyric acid import | 1 | 3 | 4.47e-01 |
| GO:BP | GO:0030097 | hemopoiesis | 3 | 656 | 4.47e-01 |
| GO:BP | GO:0050817 | coagulation | 8 | 153 | 4.47e-01 |
| GO:BP | GO:0006261 | DNA-templated DNA replication | 6 | 148 | 4.47e-01 |
| GO:BP | GO:0036376 | sodium ion export across plasma membrane | 2 | 12 | 4.47e-01 |
| GO:BP | GO:0007044 | cell-substrate junction assembly | 1 | 91 | 4.47e-01 |
| GO:BP | GO:0051154 | negative regulation of striated muscle cell differentiation | 3 | 31 | 4.47e-01 |
| GO:BP | GO:0071216 | cellular response to biotic stimulus | 8 | 138 | 4.47e-01 |
| GO:BP | GO:0090329 | regulation of DNA-templated DNA replication | 3 | 47 | 4.47e-01 |
| GO:BP | GO:0060231 | mesenchymal to epithelial transition | 2 | 12 | 4.47e-01 |
| GO:BP | GO:0030490 | maturation of SSU-rRNA | 5 | 54 | 4.47e-01 |
| GO:BP | GO:0010035 | response to inorganic substance | 31 | 414 | 4.47e-01 |
| GO:BP | GO:0015780 | nucleotide-sugar transmembrane transport | 2 | 13 | 4.47e-01 |
| GO:BP | GO:0000959 | mitochondrial RNA metabolic process | 1 | 50 | 4.48e-01 |
| GO:BP | GO:0048631 | regulation of skeletal muscle tissue growth | 1 | 7 | 4.48e-01 |
| GO:BP | GO:0006582 | melanin metabolic process | 2 | 18 | 4.48e-01 |
| GO:BP | GO:0042401 | biogenic amine biosynthetic process | 1 | 24 | 4.48e-01 |
| GO:BP | GO:0035303 | regulation of dephosphorylation | 2 | 105 | 4.48e-01 |
| GO:BP | GO:0048026 | positive regulation of mRNA splicing, via spliceosome | 2 | 21 | 4.48e-01 |
| GO:BP | GO:0060992 | response to fungicide | 1 | 4 | 4.48e-01 |
| GO:BP | GO:0006639 | acylglycerol metabolic process | 3 | 92 | 4.48e-01 |
| GO:BP | GO:0048597 | post-embryonic camera-type eye morphogenesis | 1 | 4 | 4.48e-01 |
| GO:BP | GO:0002339 | B cell selection | 1 | 4 | 4.48e-01 |
| GO:BP | GO:1903541 | regulation of exosomal secretion | 2 | 15 | 4.48e-01 |
| GO:BP | GO:0070841 | inclusion body assembly | 2 | 22 | 4.48e-01 |
| GO:BP | GO:0031529 | ruffle organization | 6 | 45 | 4.48e-01 |
| GO:BP | GO:0070346 | positive regulation of fat cell proliferation | 1 | 3 | 4.48e-01 |
| GO:BP | GO:0007635 | chemosensory behavior | 1 | 10 | 4.48e-01 |
| GO:BP | GO:0055013 | cardiac muscle cell development | 5 | 71 | 4.48e-01 |
| GO:BP | GO:0030516 | regulation of axon extension | 1 | 84 | 4.48e-01 |
| GO:BP | GO:0006596 | polyamine biosynthetic process | 2 | 13 | 4.48e-01 |
| GO:BP | GO:0032197 | retrotransposition | 1 | 4 | 4.48e-01 |
| GO:BP | GO:2000108 | positive regulation of leukocyte apoptotic process | 1 | 18 | 4.48e-01 |
| GO:BP | GO:1902230 | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage | 1 | 29 | 4.48e-01 |
| GO:BP | GO:1901654 | response to ketone | 7 | 147 | 4.49e-01 |
| GO:BP | GO:1903301 | positive regulation of hexokinase activity | 1 | 5 | 4.49e-01 |
| GO:BP | GO:0007599 | hemostasis | 8 | 153 | 4.49e-01 |
| GO:BP | GO:0016074 | sno(s)RNA metabolic process | 2 | 16 | 4.49e-01 |
| GO:BP | GO:0097067 | cellular response to thyroid hormone stimulus | 2 | 14 | 4.49e-01 |
| GO:BP | GO:0014819 | regulation of skeletal muscle contraction | 1 | 14 | 4.49e-01 |
| GO:BP | GO:0002890 | negative regulation of immunoglobulin mediated immune response | 1 | 9 | 4.50e-01 |
| GO:BP | GO:0002713 | negative regulation of B cell mediated immunity | 1 | 9 | 4.50e-01 |
| GO:BP | GO:0005996 | monosaccharide metabolic process | 1 | 209 | 4.50e-01 |
| GO:BP | GO:0043320 | natural killer cell degranulation | 2 | 6 | 4.50e-01 |
| GO:BP | GO:0050708 | regulation of protein secretion | 4 | 185 | 4.50e-01 |
| GO:BP | GO:0042713 | sperm ejaculation | 1 | 3 | 4.50e-01 |
| GO:BP | GO:0048864 | stem cell development | 4 | 76 | 4.50e-01 |
| GO:BP | GO:0060011 | Sertoli cell proliferation | 1 | 4 | 4.50e-01 |
| GO:BP | GO:0006638 | neutral lipid metabolic process | 3 | 93 | 4.50e-01 |
| GO:BP | GO:0000028 | ribosomal small subunit assembly | 2 | 18 | 4.50e-01 |
| GO:BP | GO:0006691 | leukotriene metabolic process | 1 | 12 | 4.50e-01 |
| GO:BP | GO:0033089 | positive regulation of T cell differentiation in thymus | 1 | 5 | 4.50e-01 |
| GO:BP | GO:0003413 | chondrocyte differentiation involved in endochondral bone morphogenesis | 1 | 12 | 4.50e-01 |
| GO:BP | GO:0007423 | sensory organ development | 3 | 396 | 4.50e-01 |
| GO:BP | GO:1905456 | regulation of lymphoid progenitor cell differentiation | 1 | 10 | 4.50e-01 |
| GO:BP | GO:1901566 | organonitrogen compound biosynthetic process | 13 | 1484 | 4.50e-01 |
| GO:BP | GO:0044770 | cell cycle phase transition | 27 | 504 | 4.50e-01 |
| GO:BP | GO:1904152 | regulation of retrograde protein transport, ER to cytosol | 1 | 13 | 4.50e-01 |
| GO:BP | GO:0048291 | isotype switching to IgG isotypes | 2 | 8 | 4.50e-01 |
| GO:BP | GO:0071649 | regulation of chemokine (C-C motif) ligand 5 production | 1 | 6 | 4.50e-01 |
| GO:BP | GO:0090230 | regulation of centromere complex assembly | 1 | 4 | 4.50e-01 |
| GO:BP | GO:0071609 | chemokine (C-C motif) ligand 5 production | 1 | 6 | 4.50e-01 |
| GO:BP | GO:0120305 | regulation of pigmentation | 1 | 11 | 4.50e-01 |
| GO:BP | GO:0048070 | regulation of developmental pigmentation | 1 | 11 | 4.50e-01 |
| GO:BP | GO:0072593 | reactive oxygen species metabolic process | 9 | 156 | 4.51e-01 |
| GO:BP | GO:0071634 | regulation of transforming growth factor beta production | 1 | 31 | 4.51e-01 |
| GO:BP | GO:1902003 | regulation of amyloid-beta formation | 3 | 33 | 4.51e-01 |
| GO:BP | GO:2000252 | negative regulation of feeding behavior | 1 | 2 | 4.51e-01 |
| GO:BP | GO:0072334 | UDP-galactose transmembrane transport | 1 | 4 | 4.51e-01 |
| GO:BP | GO:0097500 | receptor localization to non-motile cilium | 1 | 4 | 4.51e-01 |
| GO:BP | GO:0009309 | amine biosynthetic process | 1 | 25 | 4.51e-01 |
| GO:BP | GO:0051223 | regulation of protein transport | 1 | 404 | 4.51e-01 |
| GO:BP | GO:0051315 | attachment of mitotic spindle microtubules to kinetochore | 1 | 21 | 4.51e-01 |
| GO:BP | GO:0045823 | positive regulation of heart contraction | 1 | 32 | 4.51e-01 |
| GO:BP | GO:0045663 | positive regulation of myoblast differentiation | 4 | 37 | 4.51e-01 |
| GO:BP | GO:0008295 | spermidine biosynthetic process | 1 | 3 | 4.51e-01 |
| GO:BP | GO:0001568 | blood vessel development | 36 | 534 | 4.52e-01 |
| GO:BP | GO:0140747 | regulation of ncRNA transcription | 1 | 23 | 4.52e-01 |
| GO:BP | GO:0002913 | positive regulation of lymphocyte anergy | 1 | 2 | 4.52e-01 |
| GO:BP | GO:2000583 | regulation of platelet-derived growth factor receptor-alpha signaling pathway | 1 | 4 | 4.52e-01 |
| GO:BP | GO:0002669 | positive regulation of T cell anergy | 1 | 2 | 4.52e-01 |
| GO:BP | GO:0051702 | biological process involved in interaction with symbiont | 1 | 78 | 4.52e-01 |
| GO:BP | GO:2000121 | regulation of removal of superoxide radicals | 1 | 6 | 4.52e-01 |
| GO:BP | GO:0031509 | subtelomeric heterochromatin formation | 1 | 7 | 4.52e-01 |
| GO:BP | GO:0014041 | regulation of neuron maturation | 1 | 6 | 4.52e-01 |
| GO:BP | GO:0008272 | sulfate transport | 2 | 12 | 4.52e-01 |
| GO:BP | GO:1903431 | positive regulation of cell maturation | 1 | 6 | 4.52e-01 |
| GO:BP | GO:0061024 | membrane organization | 1 | 671 | 4.52e-01 |
| GO:BP | GO:0006952 | defense response | 2 | 944 | 4.52e-01 |
| GO:BP | GO:0070262 | peptidyl-serine dephosphorylation | 2 | 14 | 4.52e-01 |
| GO:BP | GO:0071637 | regulation of monocyte chemotactic protein-1 production | 1 | 7 | 4.52e-01 |
| GO:BP | GO:0070444 | oligodendrocyte progenitor proliferation | 1 | 5 | 4.52e-01 |
| GO:BP | GO:0002040 | sprouting angiogenesis | 5 | 98 | 4.52e-01 |
| GO:BP | GO:0070445 | regulation of oligodendrocyte progenitor proliferation | 1 | 5 | 4.52e-01 |
| GO:BP | GO:1900193 | regulation of oocyte maturation | 1 | 5 | 4.52e-01 |
| GO:BP | GO:1901097 | negative regulation of autophagosome maturation | 1 | 5 | 4.52e-01 |
| GO:BP | GO:0010662 | regulation of striated muscle cell apoptotic process | 3 | 36 | 4.52e-01 |
| GO:BP | GO:0110154 | RNA decapping | 1 | 17 | 4.52e-01 |
| GO:BP | GO:0071605 | monocyte chemotactic protein-1 production | 1 | 7 | 4.52e-01 |
| GO:BP | GO:0042180 | cellular ketone metabolic process | 9 | 158 | 4.53e-01 |
| GO:BP | GO:0006629 | lipid metabolic process | 2 | 994 | 4.53e-01 |
| GO:BP | GO:0006391 | transcription initiation at mitochondrial promoter | 1 | 4 | 4.53e-01 |
| GO:BP | GO:0006337 | nucleosome disassembly | 2 | 16 | 4.53e-01 |
| GO:BP | GO:0048496 | maintenance of animal organ identity | 1 | 4 | 4.53e-01 |
| GO:BP | GO:0021670 | lateral ventricle development | 1 | 11 | 4.53e-01 |
| GO:BP | GO:0097062 | dendritic spine maintenance | 2 | 15 | 4.53e-01 |
| GO:BP | GO:0042339 | keratan sulfate metabolic process | 1 | 15 | 4.53e-01 |
| GO:BP | GO:0034767 | positive regulation of monoatomic ion transmembrane transport | 1 | 114 | 4.53e-01 |
| GO:BP | GO:0110053 | regulation of actin filament organization | 12 | 228 | 4.54e-01 |
| GO:BP | GO:0036016 | cellular response to interleukin-3 | 1 | 6 | 4.54e-01 |
| GO:BP | GO:0036015 | response to interleukin-3 | 1 | 6 | 4.54e-01 |
| GO:BP | GO:0045719 | negative regulation of glycogen biosynthetic process | 1 | 7 | 4.54e-01 |
| GO:BP | GO:0021987 | cerebral cortex development | 3 | 101 | 4.54e-01 |
| GO:BP | GO:0036336 | dendritic cell migration | 1 | 15 | 4.54e-01 |
| GO:BP | GO:0042168 | heme metabolic process | 1 | 40 | 4.54e-01 |
| GO:BP | GO:0014014 | negative regulation of gliogenesis | 3 | 26 | 4.54e-01 |
| GO:BP | GO:0043523 | regulation of neuron apoptotic process | 13 | 167 | 4.54e-01 |
| GO:BP | GO:1904978 | regulation of endosome organization | 1 | 5 | 4.54e-01 |
| GO:BP | GO:0022615 | protein to membrane docking | 1 | 5 | 4.54e-01 |
| GO:BP | GO:0006470 | protein dephosphorylation | 22 | 214 | 4.55e-01 |
| GO:BP | GO:0097278 | complement-dependent cytotoxicity | 1 | 4 | 4.55e-01 |
| GO:BP | GO:0006164 | purine nucleotide biosynthetic process | 1 | 209 | 4.55e-01 |
| GO:BP | GO:0002857 | positive regulation of natural killer cell mediated immune response to tumor cell | 1 | 3 | 4.55e-01 |
| GO:BP | GO:1903524 | positive regulation of blood circulation | 1 | 32 | 4.55e-01 |
| GO:BP | GO:1900223 | positive regulation of amyloid-beta clearance | 1 | 5 | 4.55e-01 |
| GO:BP | GO:0009204 | deoxyribonucleoside triphosphate catabolic process | 1 | 5 | 4.55e-01 |
| GO:BP | GO:0021756 | striatum development | 1 | 17 | 4.55e-01 |
| GO:BP | GO:0051769 | regulation of nitric-oxide synthase biosynthetic process | 2 | 13 | 4.55e-01 |
| GO:BP | GO:0051767 | nitric-oxide synthase biosynthetic process | 2 | 13 | 4.55e-01 |
| GO:BP | GO:0009146 | purine nucleoside triphosphate catabolic process | 1 | 5 | 4.55e-01 |
| GO:BP | GO:1900025 | negative regulation of substrate adhesion-dependent cell spreading | 2 | 11 | 4.55e-01 |
| GO:BP | GO:0055007 | cardiac muscle cell differentiation | 7 | 103 | 4.55e-01 |
| GO:BP | GO:0032757 | positive regulation of interleukin-8 production | 1 | 31 | 4.55e-01 |
| GO:BP | GO:0008284 | positive regulation of cell population proliferation | 21 | 631 | 4.56e-01 |
| GO:BP | GO:0086014 | atrial cardiac muscle cell action potential | 1 | 17 | 4.56e-01 |
| GO:BP | GO:0051594 | detection of glucose | 1 | 1 | 4.56e-01 |
| GO:BP | GO:0042832 | defense response to protozoan | 1 | 10 | 4.56e-01 |
| GO:BP | GO:0086026 | atrial cardiac muscle cell to AV node cell signaling | 1 | 17 | 4.56e-01 |
| GO:BP | GO:0042476 | odontogenesis | 2 | 86 | 4.56e-01 |
| GO:BP | GO:0106001 | intestinal hexose absorption | 1 | 3 | 4.56e-01 |
| GO:BP | GO:0051783 | regulation of nuclear division | 1 | 116 | 4.56e-01 |
| GO:BP | GO:0086066 | atrial cardiac muscle cell to AV node cell communication | 1 | 17 | 4.56e-01 |
| GO:BP | GO:0034287 | detection of monosaccharide stimulus | 1 | 1 | 4.56e-01 |
| GO:BP | GO:0097623 | potassium ion export across plasma membrane | 1 | 10 | 4.56e-01 |
| GO:BP | GO:0090200 | positive regulation of release of cytochrome c from mitochondria | 1 | 23 | 4.56e-01 |
| GO:BP | GO:0009730 | detection of carbohydrate stimulus | 1 | 1 | 4.56e-01 |
| GO:BP | GO:0003208 | cardiac ventricle morphogenesis | 6 | 62 | 4.56e-01 |
| GO:BP | GO:0010668 | ectodermal cell differentiation | 1 | 5 | 4.56e-01 |
| GO:BP | GO:0009732 | detection of hexose stimulus | 1 | 1 | 4.56e-01 |
| GO:BP | GO:0038031 | non-canonical Wnt signaling pathway via JNK cascade | 1 | 4 | 4.56e-01 |
| GO:BP | GO:0051347 | positive regulation of transferase activity | 1 | 400 | 4.56e-01 |
| GO:BP | GO:0032056 | positive regulation of translation in response to stress | 1 | 8 | 4.56e-01 |
| GO:BP | GO:0043255 | regulation of carbohydrate biosynthetic process | 6 | 77 | 4.56e-01 |
| GO:BP | GO:0046683 | response to organophosphorus | 9 | 96 | 4.56e-01 |
| GO:BP | GO:0033043 | regulation of organelle organization | 51 | 1028 | 4.56e-01 |
| GO:BP | GO:0150115 | cell-substrate junction organization | 1 | 98 | 4.56e-01 |
| GO:BP | GO:0044550 | secondary metabolite biosynthetic process | 2 | 18 | 4.57e-01 |
| GO:BP | GO:0006349 | regulation of gene expression by genomic imprinting | 2 | 14 | 4.57e-01 |
| GO:BP | GO:0046189 | phenol-containing compound biosynthetic process | 3 | 28 | 4.57e-01 |
| GO:BP | GO:0051497 | negative regulation of stress fiber assembly | 2 | 23 | 4.57e-01 |
| GO:BP | GO:0001659 | temperature homeostasis | 5 | 132 | 4.57e-01 |
| GO:BP | GO:0031223 | auditory behavior | 1 | 6 | 4.57e-01 |
| GO:BP | GO:1990173 | protein localization to nucleoplasm | 2 | 14 | 4.57e-01 |
| GO:BP | GO:0002921 | negative regulation of humoral immune response | 1 | 10 | 4.57e-01 |
| GO:BP | GO:0042998 | positive regulation of Golgi to plasma membrane protein transport | 1 | 5 | 4.58e-01 |
| GO:BP | GO:0071363 | cellular response to growth factor stimulus | 30 | 551 | 4.58e-01 |
| GO:BP | GO:0070201 | regulation of establishment of protein localization | 1 | 428 | 4.58e-01 |
| GO:BP | GO:0006509 | membrane protein ectodomain proteolysis | 5 | 34 | 4.58e-01 |
| GO:BP | GO:1901185 | negative regulation of ERBB signaling pathway | 3 | 30 | 4.58e-01 |
| GO:BP | GO:0034440 | lipid oxidation | 2 | 94 | 4.58e-01 |
| GO:BP | GO:0045943 | positive regulation of transcription by RNA polymerase I | 3 | 34 | 4.58e-01 |
| GO:BP | GO:2000758 | positive regulation of peptidyl-lysine acetylation | 3 | 31 | 4.58e-01 |
| GO:BP | GO:0010833 | telomere maintenance via telomere lengthening | 4 | 73 | 4.58e-01 |
| GO:BP | GO:0042417 | dopamine metabolic process | 1 | 23 | 4.58e-01 |
| GO:BP | GO:0003203 | endocardial cushion morphogenesis | 1 | 36 | 4.58e-01 |
| GO:BP | GO:0050686 | negative regulation of mRNA processing | 2 | 25 | 4.58e-01 |
| GO:BP | GO:0035136 | forelimb morphogenesis | 2 | 21 | 4.58e-01 |
| GO:BP | GO:0055070 | copper ion homeostasis | 2 | 18 | 4.59e-01 |
| GO:BP | GO:1990403 | embryonic brain development | 2 | 13 | 4.59e-01 |
| GO:BP | GO:0021697 | cerebellar cortex formation | 1 | 22 | 4.59e-01 |
| GO:BP | GO:0090425 | acinar cell differentiation | 1 | 5 | 4.59e-01 |
| GO:BP | GO:0033260 | nuclear DNA replication | 2 | 35 | 4.59e-01 |
| GO:BP | GO:0045586 | regulation of gamma-delta T cell differentiation | 1 | 6 | 4.59e-01 |
| GO:BP | GO:2000097 | regulation of smooth muscle cell-matrix adhesion | 1 | 3 | 4.59e-01 |
| GO:BP | GO:0042670 | retinal cone cell differentiation | 2 | 6 | 4.59e-01 |
| GO:BP | GO:0048541 | Peyer’s patch development | 1 | 6 | 4.59e-01 |
| GO:BP | GO:0032928 | regulation of superoxide anion generation | 1 | 11 | 4.59e-01 |
| GO:BP | GO:0051646 | mitochondrion localization | 1 | 47 | 4.59e-01 |
| GO:BP | GO:0048537 | mucosa-associated lymphoid tissue development | 1 | 6 | 4.59e-01 |
| GO:BP | GO:0036503 | ERAD pathway | 4 | 106 | 4.60e-01 |
| GO:BP | GO:0008315 | G2/MI transition of meiotic cell cycle | 1 | 5 | 4.60e-01 |
| GO:BP | GO:0009798 | axis specification | 4 | 63 | 4.60e-01 |
| GO:BP | GO:0072522 | purine-containing compound biosynthetic process | 1 | 218 | 4.60e-01 |
| GO:BP | GO:0042110 | T cell activation | 1 | 313 | 4.60e-01 |
| GO:BP | GO:0061005 | cell differentiation involved in kidney development | 1 | 42 | 4.60e-01 |
| GO:BP | GO:0050918 | positive chemotaxis | 1 | 40 | 4.60e-01 |
| GO:BP | GO:0045595 | regulation of cell differentiation | 6 | 1137 | 4.60e-01 |
| GO:BP | GO:0001892 | embryonic placenta development | 5 | 71 | 4.60e-01 |
| GO:BP | GO:0048268 | clathrin coat assembly | 2 | 13 | 4.60e-01 |
| GO:BP | GO:0035624 | receptor transactivation | 1 | 3 | 4.61e-01 |
| GO:BP | GO:0071404 | cellular response to low-density lipoprotein particle stimulus | 2 | 19 | 4.61e-01 |
| GO:BP | GO:0010700 | negative regulation of norepinephrine secretion | 1 | 2 | 4.61e-01 |
| GO:BP | GO:0032811 | negative regulation of epinephrine secretion | 1 | 2 | 4.61e-01 |
| GO:BP | GO:1905279 | regulation of retrograde transport, endosome to Golgi | 1 | 6 | 4.61e-01 |
| GO:BP | GO:0010659 | cardiac muscle cell apoptotic process | 3 | 36 | 4.61e-01 |
| GO:BP | GO:0002072 | optic cup morphogenesis involved in camera-type eye development | 1 | 4 | 4.61e-01 |
| GO:BP | GO:0048663 | neuron fate commitment | 1 | 29 | 4.61e-01 |
| GO:BP | GO:0042407 | cristae formation | 2 | 18 | 4.61e-01 |
| GO:BP | GO:0050688 | regulation of defense response to virus | 8 | 63 | 4.61e-01 |
| GO:BP | GO:0009891 | positive regulation of biosynthetic process | 103 | 1604 | 4.61e-01 |
| GO:BP | GO:0003197 | endocardial cushion development | 2 | 46 | 4.62e-01 |
| GO:BP | GO:1903608 | protein localization to cytoplasmic stress granule | 1 | 7 | 4.62e-01 |
| GO:BP | GO:0019755 | one-carbon compound transport | 1 | 23 | 4.62e-01 |
| GO:BP | GO:1903575 | cornified envelope assembly | 1 | 6 | 4.62e-01 |
| GO:BP | GO:0071702 | organic substance transport | 3 | 2116 | 4.62e-01 |
| GO:BP | GO:0030838 | positive regulation of actin filament polymerization | 3 | 39 | 4.62e-01 |
| GO:BP | GO:1904896 | ESCRT complex disassembly | 1 | 10 | 4.62e-01 |
| GO:BP | GO:0009950 | dorsal/ventral axis specification | 1 | 9 | 4.62e-01 |
| GO:BP | GO:1901797 | negative regulation of signal transduction by p53 class mediator | 1 | 32 | 4.62e-01 |
| GO:BP | GO:0045995 | regulation of embryonic development | 6 | 80 | 4.62e-01 |
| GO:BP | GO:1904903 | ESCRT III complex disassembly | 1 | 10 | 4.62e-01 |
| GO:BP | GO:0061081 | positive regulation of myeloid leukocyte cytokine production involved in immune response | 1 | 26 | 4.62e-01 |
| GO:BP | GO:0071604 | transforming growth factor beta production | 1 | 32 | 4.62e-01 |
| GO:BP | GO:0048545 | response to steroid hormone | 16 | 245 | 4.62e-01 |
| GO:BP | GO:0006979 | response to oxidative stress | 24 | 352 | 4.62e-01 |
| GO:BP | GO:0050768 | negative regulation of neurogenesis | 8 | 113 | 4.62e-01 |
| GO:BP | GO:1902253 | regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 1 | 32 | 4.62e-01 |
| GO:BP | GO:0032328 | alanine transport | 2 | 14 | 4.62e-01 |
| GO:BP | GO:0006971 | hypotonic response | 1 | 10 | 4.62e-01 |
| GO:BP | GO:0050858 | negative regulation of antigen receptor-mediated signaling pathway | 3 | 20 | 4.62e-01 |
| GO:BP | GO:0072173 | metanephric tubule morphogenesis | 1 | 6 | 4.63e-01 |
| GO:BP | GO:0070175 | positive regulation of enamel mineralization | 1 | 2 | 4.63e-01 |
| GO:BP | GO:0032252 | secretory granule localization | 1 | 9 | 4.63e-01 |
| GO:BP | GO:0099170 | postsynaptic modulation of chemical synaptic transmission | 3 | 23 | 4.63e-01 |
| GO:BP | GO:0086100 | endothelin receptor signaling pathway | 1 | 9 | 4.63e-01 |
| GO:BP | GO:0055123 | digestive system development | 8 | 100 | 4.63e-01 |
| GO:BP | GO:0010557 | positive regulation of macromolecule biosynthetic process | 106 | 1507 | 4.64e-01 |
| GO:BP | GO:0001913 | T cell mediated cytotoxicity | 3 | 22 | 4.64e-01 |
| GO:BP | GO:0044346 | fibroblast apoptotic process | 1 | 23 | 4.64e-01 |
| GO:BP | GO:0042269 | regulation of natural killer cell mediated cytotoxicity | 3 | 18 | 4.64e-01 |
| GO:BP | GO:0019509 | L-methionine salvage from methylthioadenosine | 1 | 5 | 4.64e-01 |
| GO:BP | GO:0051123 | RNA polymerase II preinitiation complex assembly | 1 | 54 | 4.64e-01 |
| GO:BP | GO:0090075 | relaxation of muscle | 1 | 29 | 4.64e-01 |
| GO:BP | GO:0019934 | cGMP-mediated signaling | 1 | 22 | 4.64e-01 |
| GO:BP | GO:0051220 | cytoplasmic sequestering of protein | 3 | 23 | 4.65e-01 |
| GO:BP | GO:0019216 | regulation of lipid metabolic process | 2 | 250 | 4.66e-01 |
| GO:BP | GO:0060339 | negative regulation of type I interferon-mediated signaling pathway | 2 | 15 | 4.66e-01 |
| GO:BP | GO:0002634 | regulation of germinal center formation | 1 | 6 | 4.66e-01 |
| GO:BP | GO:0006498 | N-terminal protein lipidation | 1 | 7 | 4.66e-01 |
| GO:BP | GO:0014891 | striated muscle atrophy | 1 | 6 | 4.66e-01 |
| GO:BP | GO:0048731 | system development | 7 | 2901 | 4.66e-01 |
| GO:BP | GO:0033504 | floor plate development | 1 | 8 | 4.66e-01 |
| GO:BP | GO:0080111 | DNA demethylation | 1 | 23 | 4.66e-01 |
| GO:BP | GO:0051125 | regulation of actin nucleation | 2 | 31 | 4.66e-01 |
| GO:BP | GO:0002692 | negative regulation of cellular extravasation | 1 | 5 | 4.66e-01 |
| GO:BP | GO:0061723 | glycophagy | 1 | 4 | 4.66e-01 |
| GO:BP | GO:1904888 | cranial skeletal system development | 4 | 51 | 4.66e-01 |
| GO:BP | GO:2000737 | negative regulation of stem cell differentiation | 1 | 24 | 4.66e-01 |
| GO:BP | GO:0010667 | negative regulation of cardiac muscle cell apoptotic process | 2 | 21 | 4.66e-01 |
| GO:BP | GO:0002534 | cytokine production involved in inflammatory response | 3 | 33 | 4.66e-01 |
| GO:BP | GO:0098963 | dendritic transport of messenger ribonucleoprotein complex | 1 | 4 | 4.66e-01 |
| GO:BP | GO:0098961 | dendritic transport of ribonucleoprotein complex | 1 | 4 | 4.66e-01 |
| GO:BP | GO:0038007 | netrin-activated signaling pathway | 1 | 8 | 4.66e-01 |
| GO:BP | GO:0007338 | single fertilization | 1 | 70 | 4.66e-01 |
| GO:BP | GO:1900015 | regulation of cytokine production involved in inflammatory response | 3 | 33 | 4.66e-01 |
| GO:BP | GO:1990928 | response to amino acid starvation | 4 | 51 | 4.66e-01 |
| GO:BP | GO:0001561 | fatty acid alpha-oxidation | 1 | 5 | 4.66e-01 |
| GO:BP | GO:0042104 | positive regulation of activated T cell proliferation | 2 | 13 | 4.66e-01 |
| GO:BP | GO:0009150 | purine ribonucleotide metabolic process | 4 | 295 | 4.66e-01 |
| GO:BP | GO:0002087 | regulation of respiratory gaseous exchange by nervous system process | 2 | 8 | 4.66e-01 |
| GO:BP | GO:0051345 | positive regulation of hydrolase activity | 1 | 422 | 4.66e-01 |
| GO:BP | GO:1902992 | negative regulation of amyloid precursor protein catabolic process | 2 | 20 | 4.66e-01 |
| GO:BP | GO:0032465 | regulation of cytokinesis | 1 | 79 | 4.66e-01 |
| GO:BP | GO:0000466 | maturation of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 3 | 25 | 4.66e-01 |
| GO:BP | GO:0002923 | regulation of humoral immune response mediated by circulating immunoglobulin | 1 | 6 | 4.66e-01 |
| GO:BP | GO:0006659 | phosphatidylserine biosynthetic process | 1 | 4 | 4.66e-01 |
| GO:BP | GO:2000696 | regulation of epithelial cell differentiation involved in kidney development | 2 | 12 | 4.66e-01 |
| GO:BP | GO:0099010 | modification of postsynaptic structure | 2 | 17 | 4.66e-01 |
| GO:BP | GO:0060800 | regulation of cell differentiation involved in embryonic placenta development | 1 | 2 | 4.66e-01 |
| GO:BP | GO:0006335 | DNA replication-dependent chromatin assembly | 1 | 6 | 4.66e-01 |
| GO:BP | GO:0051782 | negative regulation of cell division | 2 | 15 | 4.66e-01 |
| GO:BP | GO:0048846 | axon extension involved in axon guidance | 2 | 35 | 4.66e-01 |
| GO:BP | GO:1902284 | neuron projection extension involved in neuron projection guidance | 2 | 35 | 4.66e-01 |
| GO:BP | GO:0048148 | behavioral response to cocaine | 2 | 9 | 4.66e-01 |
| GO:BP | GO:0000904 | cell morphogenesis involved in differentiation | 27 | 516 | 4.66e-01 |
| GO:BP | GO:0072359 | circulatory system development | 56 | 884 | 4.66e-01 |
| GO:BP | GO:0051249 | regulation of lymphocyte activation | 1 | 296 | 4.66e-01 |
| GO:BP | GO:0060911 | cardiac cell fate commitment | 1 | 11 | 4.66e-01 |
| GO:BP | GO:0080171 | lytic vacuole organization | 5 | 88 | 4.66e-01 |
| GO:BP | GO:0051017 | actin filament bundle assembly | 4 | 138 | 4.66e-01 |
| GO:BP | GO:0007040 | lysosome organization | 5 | 88 | 4.66e-01 |
| GO:BP | GO:0009062 | fatty acid catabolic process | 1 | 89 | 4.66e-01 |
| GO:BP | GO:0008053 | mitochondrial fusion | 1 | 28 | 4.66e-01 |
| GO:BP | GO:0071577 | zinc ion transmembrane transport | 2 | 21 | 4.66e-01 |
| GO:BP | GO:2000008 | regulation of protein localization to cell surface | 2 | 37 | 4.66e-01 |
| GO:BP | GO:0060009 | Sertoli cell development | 1 | 10 | 4.66e-01 |
| GO:BP | GO:0048568 | embryonic organ development | 22 | 316 | 4.67e-01 |
| GO:BP | GO:0048490 | anterograde synaptic vesicle transport | 1 | 16 | 4.68e-01 |
| GO:BP | GO:0030325 | adrenal gland development | 2 | 22 | 4.68e-01 |
| GO:BP | GO:0010182 | sugar mediated signaling pathway | 1 | 5 | 4.68e-01 |
| GO:BP | GO:0001562 | response to protozoan | 1 | 11 | 4.68e-01 |
| GO:BP | GO:0099514 | synaptic vesicle cytoskeletal transport | 1 | 16 | 4.68e-01 |
| GO:BP | GO:0099517 | synaptic vesicle transport along microtubule | 1 | 16 | 4.68e-01 |
| GO:BP | GO:0090307 | mitotic spindle assembly | 4 | 70 | 4.68e-01 |
| GO:BP | GO:0010255 | glucose mediated signaling pathway | 1 | 5 | 4.68e-01 |
| GO:BP | GO:0090240 | positive regulation of histone H4 acetylation | 1 | 6 | 4.68e-01 |
| GO:BP | GO:0097494 | regulation of vesicle size | 1 | 19 | 4.68e-01 |
| GO:BP | GO:0009757 | hexose mediated signaling | 1 | 5 | 4.68e-01 |
| GO:BP | GO:0046053 | dAMP metabolic process | 1 | 5 | 4.68e-01 |
| GO:BP | GO:0032957 | inositol trisphosphate metabolic process | 1 | 10 | 4.68e-01 |
| GO:BP | GO:0043281 | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 7 | 155 | 4.69e-01 |
| GO:BP | GO:0086064 | cell communication by electrical coupling involved in cardiac conduction | 3 | 26 | 4.69e-01 |
| GO:BP | GO:0002295 | T-helper cell lineage commitment | 1 | 7 | 4.69e-01 |
| GO:BP | GO:0098703 | calcium ion import across plasma membrane | 3 | 23 | 4.69e-01 |
| GO:BP | GO:0034201 | response to oleic acid | 1 | 5 | 4.69e-01 |
| GO:BP | GO:1904356 | regulation of telomere maintenance via telomere lengthening | 3 | 56 | 4.69e-01 |
| GO:BP | GO:1900102 | negative regulation of endoplasmic reticulum unfolded protein response | 2 | 16 | 4.70e-01 |
| GO:BP | GO:0071732 | cellular response to nitric oxide | 2 | 14 | 4.70e-01 |
| GO:BP | GO:0055094 | response to lipoprotein particle | 2 | 20 | 4.70e-01 |
| GO:BP | GO:0048014 | Tie signaling pathway | 1 | 3 | 4.71e-01 |
| GO:BP | GO:0016240 | autophagosome membrane docking | 1 | 7 | 4.71e-01 |
| GO:BP | GO:0006955 | immune response | 2 | 882 | 4.71e-01 |
| GO:BP | GO:0014028 | notochord formation | 1 | 3 | 4.71e-01 |
| GO:BP | GO:2000780 | negative regulation of double-strand break repair | 1 | 30 | 4.72e-01 |
| GO:BP | GO:1900452 | regulation of long-term synaptic depression | 2 | 10 | 4.72e-01 |
| GO:BP | GO:0048708 | astrocyte differentiation | 1 | 58 | 4.72e-01 |
| GO:BP | GO:0060576 | intestinal epithelial cell development | 2 | 11 | 4.72e-01 |
| GO:BP | GO:0002862 | negative regulation of inflammatory response to antigenic stimulus | 3 | 16 | 4.72e-01 |
| GO:BP | GO:0061337 | cardiac conduction | 3 | 88 | 4.72e-01 |
| GO:BP | GO:0008306 | associative learning | 5 | 65 | 4.72e-01 |
| GO:BP | GO:0032469 | endoplasmic reticulum calcium ion homeostasis | 3 | 26 | 4.73e-01 |
| GO:BP | GO:0036211 | protein modification process | 1 | 2901 | 4.73e-01 |
| GO:BP | GO:0035025 | positive regulation of Rho protein signal transduction | 1 | 22 | 4.73e-01 |
| GO:BP | GO:0016076 | snRNA catabolic process | 1 | 5 | 4.73e-01 |
| GO:BP | GO:0000819 | sister chromatid segregation | 10 | 217 | 4.73e-01 |
| GO:BP | GO:0072584 | caveolin-mediated endocytosis | 1 | 9 | 4.73e-01 |
| GO:BP | GO:0060439 | trachea morphogenesis | 1 | 7 | 4.73e-01 |
| GO:BP | GO:0051649 | establishment of localization in cell | 5 | 1836 | 4.73e-01 |
| GO:BP | GO:0061517 | macrophage proliferation | 1 | 7 | 4.73e-01 |
| GO:BP | GO:0007595 | lactation | 3 | 32 | 4.73e-01 |
| GO:BP | GO:0009113 | purine nucleobase biosynthetic process | 1 | 10 | 4.73e-01 |
| GO:BP | GO:0048170 | positive regulation of long-term neuronal synaptic plasticity | 1 | 5 | 4.73e-01 |
| GO:BP | GO:0034340 | response to type I interferon | 6 | 57 | 4.74e-01 |
| GO:BP | GO:0032482 | Rab protein signal transduction | 1 | 19 | 4.74e-01 |
| GO:BP | GO:1902416 | positive regulation of mRNA binding | 1 | 8 | 4.75e-01 |
| GO:BP | GO:0048066 | developmental pigmentation | 3 | 36 | 4.75e-01 |
| GO:BP | GO:0045843 | negative regulation of striated muscle tissue development | 1 | 5 | 4.75e-01 |
| GO:BP | GO:0002701 | negative regulation of production of molecular mediator of immune response | 1 | 21 | 4.75e-01 |
| GO:BP | GO:0048844 | artery morphogenesis | 3 | 58 | 4.75e-01 |
| GO:BP | GO:0009165 | nucleotide biosynthetic process | 1 | 240 | 4.75e-01 |
| GO:BP | GO:0090314 | positive regulation of protein targeting to membrane | 1 | 22 | 4.75e-01 |
| GO:BP | GO:0016054 | organic acid catabolic process | 2 | 187 | 4.75e-01 |
| GO:BP | GO:0006273 | lagging strand elongation | 1 | 4 | 4.75e-01 |
| GO:BP | GO:0006272 | leading strand elongation | 1 | 4 | 4.75e-01 |
| GO:BP | GO:2000434 | regulation of protein neddylation | 1 | 19 | 4.75e-01 |
| GO:BP | GO:0046622 | positive regulation of organ growth | 2 | 33 | 4.75e-01 |
| GO:BP | GO:0071480 | cellular response to gamma radiation | 1 | 29 | 4.75e-01 |
| GO:BP | GO:0046395 | carboxylic acid catabolic process | 2 | 187 | 4.75e-01 |
| GO:BP | GO:0006536 | glutamate metabolic process | 1 | 25 | 4.76e-01 |
| GO:BP | GO:0019395 | fatty acid oxidation | 1 | 93 | 4.76e-01 |
| GO:BP | GO:0006612 | protein targeting to membrane | 1 | 118 | 4.76e-01 |
| GO:BP | GO:1990009 | retinal cell apoptotic process | 1 | 5 | 4.76e-01 |
| GO:BP | GO:0002155 | regulation of thyroid hormone mediated signaling pathway | 1 | 5 | 4.76e-01 |
| GO:BP | GO:0061572 | actin filament bundle organization | 4 | 140 | 4.77e-01 |
| GO:BP | GO:0016925 | protein sumoylation | 6 | 59 | 4.77e-01 |
| GO:BP | GO:0045834 | positive regulation of lipid metabolic process | 2 | 108 | 4.77e-01 |
| GO:BP | GO:0045590 | negative regulation of regulatory T cell differentiation | 1 | 3 | 4.77e-01 |
| GO:BP | GO:0070874 | negative regulation of glycogen metabolic process | 1 | 7 | 4.77e-01 |
| GO:BP | GO:2000171 | negative regulation of dendrite development | 1 | 7 | 4.77e-01 |
| GO:BP | GO:0021798 | forebrain dorsal/ventral pattern formation | 1 | 2 | 4.77e-01 |
| GO:BP | GO:0006778 | porphyrin-containing compound metabolic process | 1 | 44 | 4.77e-01 |
| GO:BP | GO:0036337 | Fas signaling pathway | 1 | 5 | 4.77e-01 |
| GO:BP | GO:0071514 | genomic imprinting | 1 | 9 | 4.77e-01 |
| GO:BP | GO:0032640 | tumor necrosis factor production | 6 | 91 | 4.77e-01 |
| GO:BP | GO:0051055 | negative regulation of lipid biosynthetic process | 3 | 46 | 4.77e-01 |
| GO:BP | GO:0043043 | peptide biosynthetic process | 56 | 666 | 4.77e-01 |
| GO:BP | GO:0044528 | regulation of mitochondrial mRNA stability | 1 | 7 | 4.77e-01 |
| GO:BP | GO:0070527 | platelet aggregation | 3 | 52 | 4.77e-01 |
| GO:BP | GO:1904874 | positive regulation of telomerase RNA localization to Cajal body | 2 | 15 | 4.77e-01 |
| GO:BP | GO:0032956 | regulation of actin cytoskeleton organization | 15 | 299 | 4.77e-01 |
| GO:BP | GO:0032680 | regulation of tumor necrosis factor production | 6 | 91 | 4.77e-01 |
| GO:BP | GO:1901293 | nucleoside phosphate biosynthetic process | 1 | 241 | 4.77e-01 |
| GO:BP | GO:0006622 | protein targeting to lysosome | 3 | 28 | 4.77e-01 |
| GO:BP | GO:0032819 | positive regulation of natural killer cell proliferation | 1 | 4 | 4.77e-01 |
| GO:BP | GO:0016191 | synaptic vesicle uncoating | 1 | 7 | 4.77e-01 |
| GO:BP | GO:0002457 | T cell antigen processing and presentation | 1 | 4 | 4.77e-01 |
| GO:BP | GO:0046643 | regulation of gamma-delta T cell activation | 1 | 6 | 4.77e-01 |
| GO:BP | GO:0050658 | RNA transport | 9 | 144 | 4.77e-01 |
| GO:BP | GO:0051289 | protein homotetramerization | 1 | 42 | 4.77e-01 |
| GO:BP | GO:0050657 | nucleic acid transport | 9 | 144 | 4.77e-01 |
| GO:BP | GO:0022029 | telencephalon cell migration | 1 | 44 | 4.77e-01 |
| GO:BP | GO:0055090 | acylglycerol homeostasis | 1 | 17 | 4.77e-01 |
| GO:BP | GO:0009225 | nucleotide-sugar metabolic process | 4 | 35 | 4.77e-01 |
| GO:BP | GO:0070328 | triglyceride homeostasis | 1 | 17 | 4.77e-01 |
| GO:BP | GO:0045136 | development of secondary sexual characteristics | 1 | 9 | 4.77e-01 |
| GO:BP | GO:0002858 | regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 1 | 4 | 4.77e-01 |
| GO:BP | GO:0009566 | fertilization | 6 | 93 | 4.77e-01 |
| GO:BP | GO:0034144 | negative regulation of toll-like receptor 4 signaling pathway | 1 | 6 | 4.77e-01 |
| GO:BP | GO:0010874 | regulation of cholesterol efflux | 1 | 31 | 4.77e-01 |
| GO:BP | GO:0060419 | heart growth | 3 | 72 | 4.77e-01 |
| GO:BP | GO:0072017 | distal tubule development | 1 | 6 | 4.77e-01 |
| GO:BP | GO:0045829 | negative regulation of isotype switching | 1 | 4 | 4.77e-01 |
| GO:BP | GO:1901376 | organic heteropentacyclic compound metabolic process | 1 | 2 | 4.77e-01 |
| GO:BP | GO:0072070 | loop of Henle development | 1 | 8 | 4.77e-01 |
| GO:BP | GO:0001845 | phagolysosome assembly | 2 | 14 | 4.77e-01 |
| GO:BP | GO:0046222 | aflatoxin metabolic process | 1 | 2 | 4.77e-01 |
| GO:BP | GO:0043385 | mycotoxin metabolic process | 1 | 2 | 4.77e-01 |
| GO:BP | GO:0003229 | ventricular cardiac muscle tissue development | 2 | 52 | 4.77e-01 |
| GO:BP | GO:0045747 | positive regulation of Notch signaling pathway | 1 | 37 | 4.77e-01 |
| GO:BP | GO:0055010 | ventricular cardiac muscle tissue morphogenesis | 1 | 43 | 4.77e-01 |
| GO:BP | GO:0051973 | positive regulation of telomerase activity | 2 | 31 | 4.77e-01 |
| GO:BP | GO:0051235 | maintenance of location | 12 | 260 | 4.77e-01 |
| GO:BP | GO:0035773 | insulin secretion involved in cellular response to glucose stimulus | 6 | 49 | 4.78e-01 |
| GO:BP | GO:0034110 | regulation of homotypic cell-cell adhesion | 1 | 26 | 4.78e-01 |
| GO:BP | GO:2000105 | positive regulation of DNA-templated DNA replication | 1 | 13 | 4.78e-01 |
| GO:BP | GO:0061180 | mammary gland epithelium development | 3 | 57 | 4.78e-01 |
| GO:BP | GO:0099504 | synaptic vesicle cycle | 17 | 163 | 4.78e-01 |
| GO:BP | GO:0055057 | neuroblast division | 1 | 12 | 4.78e-01 |
| GO:BP | GO:0034285 | response to disaccharide | 1 | 4 | 4.78e-01 |
| GO:BP | GO:1903715 | regulation of aerobic respiration | 1 | 28 | 4.78e-01 |
| GO:BP | GO:0009744 | response to sucrose | 1 | 4 | 4.78e-01 |
| GO:BP | GO:0009124 | nucleoside monophosphate biosynthetic process | 3 | 37 | 4.78e-01 |
| GO:BP | GO:0003339 | regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis | 1 | 4 | 4.78e-01 |
| GO:BP | GO:0009311 | oligosaccharide metabolic process | 2 | 43 | 4.79e-01 |
| GO:BP | GO:0035666 | TRIF-dependent toll-like receptor signaling pathway | 1 | 4 | 4.80e-01 |
| GO:BP | GO:0090068 | positive regulation of cell cycle process | 15 | 209 | 4.80e-01 |
| GO:BP | GO:0002260 | lymphocyte homeostasis | 4 | 45 | 4.80e-01 |
| GO:BP | GO:0035234 | ectopic germ cell programmed cell death | 1 | 11 | 4.80e-01 |
| GO:BP | GO:0007612 | learning | 8 | 115 | 4.80e-01 |
| GO:BP | GO:0051258 | protein polymerization | 12 | 241 | 4.80e-01 |
| GO:BP | GO:0036369 | transcription factor catabolic process | 1 | 5 | 4.80e-01 |
| GO:BP | GO:0044000 | movement in host | 10 | 138 | 4.80e-01 |
| GO:BP | GO:0002281 | macrophage activation involved in immune response | 2 | 8 | 4.80e-01 |
| GO:BP | GO:0032986 | protein-DNA complex disassembly | 2 | 18 | 4.81e-01 |
| GO:BP | GO:1903779 | regulation of cardiac conduction | 2 | 23 | 4.81e-01 |
| GO:BP | GO:0140115 | export across plasma membrane | 2 | 46 | 4.81e-01 |
| GO:BP | GO:0045859 | regulation of protein kinase activity | 1 | 479 | 4.81e-01 |
| GO:BP | GO:1900087 | positive regulation of G1/S transition of mitotic cell cycle | 2 | 42 | 4.81e-01 |
| GO:BP | GO:0060267 | positive regulation of respiratory burst | 1 | 3 | 4.81e-01 |
| GO:BP | GO:0051301 | cell division | 22 | 570 | 4.81e-01 |
| GO:BP | GO:0014033 | neural crest cell differentiation | 4 | 80 | 4.81e-01 |
| GO:BP | GO:0032376 | positive regulation of cholesterol transport | 1 | 30 | 4.81e-01 |
| GO:BP | GO:0032373 | positive regulation of sterol transport | 1 | 30 | 4.81e-01 |
| GO:BP | GO:0043562 | cellular response to nitrogen levels | 1 | 9 | 4.81e-01 |
| GO:BP | GO:0090311 | regulation of protein deacetylation | 3 | 53 | 4.81e-01 |
| GO:BP | GO:0006995 | cellular response to nitrogen starvation | 1 | 9 | 4.81e-01 |
| GO:BP | GO:0045738 | negative regulation of DNA repair | 1 | 32 | 4.81e-01 |
| GO:BP | GO:0046655 | folic acid metabolic process | 2 | 14 | 4.81e-01 |
| GO:BP | GO:0140014 | mitotic nuclear division | 13 | 251 | 4.81e-01 |
| GO:BP | GO:0038030 | non-canonical Wnt signaling pathway via MAPK cascade | 1 | 5 | 4.81e-01 |
| GO:BP | GO:0120162 | positive regulation of cold-induced thermogenesis | 3 | 69 | 4.82e-01 |
| GO:BP | GO:1902570 | protein localization to nucleolus | 1 | 15 | 4.83e-01 |
| GO:BP | GO:0043487 | regulation of RNA stability | 8 | 159 | 4.83e-01 |
| GO:BP | GO:0043569 | negative regulation of insulin-like growth factor receptor signaling pathway | 1 | 6 | 4.83e-01 |
| GO:BP | GO:0046599 | regulation of centriole replication | 1 | 21 | 4.84e-01 |
| GO:BP | GO:2000772 | regulation of cellular senescence | 2 | 38 | 4.84e-01 |
| GO:BP | GO:0030206 | chondroitin sulfate biosynthetic process | 1 | 17 | 4.84e-01 |
| GO:BP | GO:0097186 | amelogenesis | 3 | 14 | 4.84e-01 |
| GO:BP | GO:0039692 | single stranded viral RNA replication via double stranded DNA intermediate | 2 | 16 | 4.84e-01 |
| GO:BP | GO:0032205 | negative regulation of telomere maintenance | 2 | 33 | 4.84e-01 |
| GO:BP | GO:2001137 | positive regulation of endocytic recycling | 1 | 7 | 4.84e-01 |
| GO:BP | GO:0002832 | negative regulation of response to biotic stimulus | 8 | 88 | 4.85e-01 |
| GO:BP | GO:0002842 | positive regulation of T cell mediated immune response to tumor cell | 1 | 3 | 4.85e-01 |
| GO:BP | GO:1902262 | apoptotic process involved in blood vessel morphogenesis | 1 | 4 | 4.85e-01 |
| GO:BP | GO:0015908 | fatty acid transport | 1 | 58 | 4.85e-01 |
| GO:BP | GO:0021885 | forebrain cell migration | 1 | 46 | 4.85e-01 |
| GO:BP | GO:0009445 | putrescine metabolic process | 1 | 6 | 4.85e-01 |
| GO:BP | GO:0032835 | glomerulus development | 1 | 54 | 4.85e-01 |
| GO:BP | GO:0009612 | response to mechanical stimulus | 9 | 158 | 4.85e-01 |
| GO:BP | GO:0072529 | pyrimidine-containing compound catabolic process | 1 | 29 | 4.85e-01 |
| GO:BP | GO:0036037 | CD8-positive, alpha-beta T cell activation | 1 | 15 | 4.85e-01 |
| GO:BP | GO:0055006 | cardiac cell development | 5 | 77 | 4.85e-01 |
| GO:BP | GO:1901020 | negative regulation of calcium ion transmembrane transporter activity | 4 | 27 | 4.86e-01 |
| GO:BP | GO:0043604 | amide biosynthetic process | 67 | 775 | 4.86e-01 |
| GO:BP | GO:0045737 | positive regulation of cyclin-dependent protein serine/threonine kinase activity | 2 | 23 | 4.86e-01 |
| GO:BP | GO:0060841 | venous blood vessel development | 1 | 13 | 4.86e-01 |
| GO:BP | GO:0007169 | transmembrane receptor protein tyrosine kinase signaling pathway | 1 | 484 | 4.86e-01 |
| GO:BP | GO:0061383 | trabecula morphogenesis | 1 | 43 | 4.86e-01 |
| GO:BP | GO:0060712 | spongiotrophoblast layer development | 1 | 11 | 4.86e-01 |
| GO:BP | GO:0007638 | mechanosensory behavior | 1 | 8 | 4.87e-01 |
| GO:BP | GO:0035966 | response to topologically incorrect protein | 14 | 150 | 4.87e-01 |
| GO:BP | GO:0061525 | hindgut development | 1 | 5 | 4.87e-01 |
| GO:BP | GO:2000095 | regulation of Wnt signaling pathway, planar cell polarity pathway | 2 | 15 | 4.87e-01 |
| GO:BP | GO:0071805 | potassium ion transmembrane transport | 1 | 129 | 4.87e-01 |
| GO:BP | GO:1900378 | positive regulation of secondary metabolite biosynthetic process | 1 | 7 | 4.87e-01 |
| GO:BP | GO:0048023 | positive regulation of melanin biosynthetic process | 1 | 7 | 4.87e-01 |
| GO:BP | GO:0030238 | male sex determination | 2 | 8 | 4.88e-01 |
| GO:BP | GO:0003417 | growth plate cartilage development | 1 | 15 | 4.88e-01 |
| GO:BP | GO:0033619 | membrane protein proteolysis | 6 | 45 | 4.88e-01 |
| GO:BP | GO:0002931 | response to ischemia | 5 | 46 | 4.88e-01 |
| GO:BP | GO:0007267 | cell-cell signaling | 3 | 1138 | 4.88e-01 |
| GO:BP | GO:0045670 | regulation of osteoclast differentiation | 1 | 38 | 4.88e-01 |
| GO:BP | GO:0008333 | endosome to lysosome transport | 4 | 63 | 4.89e-01 |
| GO:BP | GO:1901799 | negative regulation of proteasomal protein catabolic process | 3 | 47 | 4.89e-01 |
| GO:BP | GO:0006637 | acyl-CoA metabolic process | 1 | 71 | 4.89e-01 |
| GO:BP | GO:0035383 | thioester metabolic process | 1 | 71 | 4.89e-01 |
| GO:BP | GO:0006829 | zinc ion transport | 2 | 23 | 4.89e-01 |
| GO:BP | GO:0150117 | positive regulation of cell-substrate junction organization | 2 | 29 | 4.90e-01 |
| GO:BP | GO:0016264 | gap junction assembly | 1 | 14 | 4.90e-01 |
| GO:BP | GO:0060977 | coronary vasculature morphogenesis | 1 | 17 | 4.90e-01 |
| GO:BP | GO:0008585 | female gonad development | 3 | 77 | 4.90e-01 |
| GO:BP | GO:0051961 | negative regulation of nervous system development | 8 | 118 | 4.90e-01 |
| GO:BP | GO:0032386 | regulation of intracellular transport | 9 | 292 | 4.90e-01 |
| GO:BP | GO:0048534 | hematopoietic or lymphoid organ development | 5 | 70 | 4.90e-01 |
| GO:BP | GO:0014898 | cardiac muscle hypertrophy in response to stress | 2 | 23 | 4.90e-01 |
| GO:BP | GO:0008215 | spermine metabolic process | 1 | 5 | 4.90e-01 |
| GO:BP | GO:0003299 | muscle hypertrophy in response to stress | 2 | 23 | 4.90e-01 |
| GO:BP | GO:0014887 | cardiac muscle adaptation | 2 | 23 | 4.90e-01 |
| GO:BP | GO:1903201 | regulation of oxidative stress-induced cell death | 3 | 56 | 4.90e-01 |
| GO:BP | GO:0043086 | negative regulation of catalytic activity | 1 | 478 | 4.90e-01 |
| GO:BP | GO:0010658 | striated muscle cell apoptotic process | 3 | 39 | 4.90e-01 |
| GO:BP | GO:0051241 | negative regulation of multicellular organismal process | 1 | 748 | 4.90e-01 |
| GO:BP | GO:0051240 | positive regulation of multicellular organismal process | 3 | 1101 | 4.90e-01 |
| GO:BP | GO:0072553 | terminal button organization | 1 | 5 | 4.90e-01 |
| GO:BP | GO:0045577 | regulation of B cell differentiation | 2 | 20 | 4.90e-01 |
| GO:BP | GO:0046148 | pigment biosynthetic process | 1 | 48 | 4.90e-01 |
| GO:BP | GO:0035510 | DNA dealkylation | 1 | 28 | 4.90e-01 |
| GO:BP | GO:0015848 | spermidine transport | 1 | 3 | 4.90e-01 |
| GO:BP | GO:0010804 | negative regulation of tumor necrosis factor-mediated signaling pathway | 1 | 18 | 4.90e-01 |
| GO:BP | GO:0032534 | regulation of microvillus assembly | 1 | 6 | 4.90e-01 |
| GO:BP | GO:0009259 | ribonucleotide metabolic process | 4 | 311 | 4.90e-01 |
| GO:BP | GO:0010862 | positive regulation of pathway-restricted SMAD protein phosphorylation | 1 | 37 | 4.90e-01 |
| GO:BP | GO:0006620 | post-translational protein targeting to endoplasmic reticulum membrane | 1 | 15 | 4.91e-01 |
| GO:BP | GO:0051236 | establishment of RNA localization | 9 | 147 | 4.91e-01 |
| GO:BP | GO:0060074 | synapse maturation | 3 | 25 | 4.91e-01 |
| GO:BP | GO:0032367 | intracellular cholesterol transport | 2 | 28 | 4.91e-01 |
| GO:BP | GO:0046475 | glycerophospholipid catabolic process | 2 | 21 | 4.91e-01 |
| GO:BP | GO:0043666 | regulation of phosphoprotein phosphatase activity | 1 | 47 | 4.92e-01 |
| GO:BP | GO:1900152 | negative regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 1 | 12 | 4.93e-01 |
| GO:BP | GO:0031126 | sno(s)RNA 3’-end processing | 1 | 12 | 4.93e-01 |
| GO:BP | GO:0035927 | RNA import into mitochondrion | 1 | 4 | 4.93e-01 |
| GO:BP | GO:0051029 | rRNA transport | 1 | 5 | 4.93e-01 |
| GO:BP | GO:0033119 | negative regulation of RNA splicing | 2 | 28 | 4.93e-01 |
| GO:BP | GO:0051984 | positive regulation of chromosome segregation | 2 | 27 | 4.93e-01 |
| GO:BP | GO:0006412 | translation | 29 | 646 | 4.94e-01 |
| GO:BP | GO:0043542 | endothelial cell migration | 8 | 182 | 4.94e-01 |
| GO:BP | GO:0070268 | cornification | 1 | 2 | 4.94e-01 |
| GO:BP | GO:0030220 | platelet formation | 1 | 17 | 4.94e-01 |
| GO:BP | GO:0002637 | regulation of immunoglobulin production | 4 | 43 | 4.95e-01 |
| GO:BP | GO:0051054 | positive regulation of DNA metabolic process | 12 | 265 | 4.96e-01 |
| GO:BP | GO:0001944 | vasculature development | 8 | 559 | 4.96e-01 |
| GO:BP | GO:0051146 | striated muscle cell differentiation | 16 | 233 | 4.96e-01 |
| GO:BP | GO:0048675 | axon extension | 1 | 110 | 4.96e-01 |
| GO:BP | GO:0061795 | Golgi lumen acidification | 1 | 13 | 4.96e-01 |
| GO:BP | GO:0032703 | negative regulation of interleukin-2 production | 1 | 10 | 4.96e-01 |
| GO:BP | GO:0016075 | rRNA catabolic process | 2 | 19 | 4.96e-01 |
| GO:BP | GO:0097306 | cellular response to alcohol | 5 | 70 | 4.96e-01 |
| GO:BP | GO:0006302 | double-strand break repair | 18 | 271 | 4.96e-01 |
| GO:BP | GO:0002694 | regulation of leukocyte activation | 1 | 348 | 4.97e-01 |
| GO:BP | GO:0090287 | regulation of cellular response to growth factor stimulus | 4 | 265 | 4.97e-01 |
| GO:BP | GO:0071417 | cellular response to organonitrogen compound | 1 | 485 | 4.97e-01 |
| GO:BP | GO:1902808 | positive regulation of cell cycle G1/S phase transition | 3 | 52 | 4.97e-01 |
| GO:BP | GO:0051156 | glucose 6-phosphate metabolic process | 3 | 25 | 4.97e-01 |
| GO:BP | GO:1903555 | regulation of tumor necrosis factor superfamily cytokine production | 6 | 94 | 4.97e-01 |
| GO:BP | GO:0001937 | negative regulation of endothelial cell proliferation | 1 | 32 | 4.97e-01 |
| GO:BP | GO:0071706 | tumor necrosis factor superfamily cytokine production | 6 | 94 | 4.97e-01 |
| GO:BP | GO:0036265 | RNA (guanine-N7)-methylation | 1 | 6 | 4.97e-01 |
| GO:BP | GO:0044786 | cell cycle DNA replication | 2 | 40 | 4.97e-01 |
| GO:BP | GO:0006359 | regulation of transcription by RNA polymerase III | 1 | 30 | 4.97e-01 |
| GO:BP | GO:2000059 | negative regulation of ubiquitin-dependent protein catabolic process | 3 | 47 | 4.97e-01 |
| GO:BP | GO:0048840 | otolith development | 1 | 6 | 4.97e-01 |
| GO:BP | GO:0006506 | GPI anchor biosynthetic process | 1 | 30 | 4.97e-01 |
| GO:BP | GO:1905216 | positive regulation of RNA binding | 1 | 9 | 4.97e-01 |
| GO:BP | GO:0050684 | regulation of mRNA processing | 13 | 127 | 4.97e-01 |
| GO:BP | GO:0032801 | receptor catabolic process | 3 | 24 | 4.97e-01 |
| GO:BP | GO:0006703 | estrogen biosynthetic process | 1 | 6 | 4.97e-01 |
| GO:BP | GO:1902746 | regulation of lens fiber cell differentiation | 1 | 8 | 4.97e-01 |
| GO:BP | GO:2000147 | positive regulation of cell motility | 21 | 421 | 4.97e-01 |
| GO:BP | GO:0036305 | ameloblast differentiation | 1 | 5 | 4.97e-01 |
| GO:BP | GO:1900119 | positive regulation of execution phase of apoptosis | 1 | 7 | 4.97e-01 |
| GO:BP | GO:0048635 | negative regulation of muscle organ development | 1 | 6 | 4.97e-01 |
| GO:BP | GO:0035019 | somatic stem cell population maintenance | 1 | 50 | 4.97e-01 |
| GO:BP | GO:0008340 | determination of adult lifespan | 2 | 16 | 4.97e-01 |
| GO:BP | GO:0043087 | regulation of GTPase activity | 11 | 302 | 4.98e-01 |
| GO:BP | GO:0006518 | peptide metabolic process | 64 | 771 | 4.98e-01 |
| GO:BP | GO:1900153 | positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 2 | 13 | 4.98e-01 |
| GO:BP | GO:0019740 | nitrogen utilization | 1 | 4 | 4.98e-01 |
| GO:BP | GO:0002715 | regulation of natural killer cell mediated immunity | 3 | 18 | 4.98e-01 |
| GO:BP | GO:0046931 | pore complex assembly | 1 | 19 | 4.98e-01 |
| GO:BP | GO:0051604 | protein maturation | 1 | 259 | 4.99e-01 |
| GO:BP | GO:0046321 | positive regulation of fatty acid oxidation | 2 | 15 | 4.99e-01 |
| GO:BP | GO:1902895 | positive regulation of miRNA transcription | 1 | 42 | 4.99e-01 |
| GO:BP | GO:0006880 | intracellular sequestering of iron ion | 1 | 3 | 4.99e-01 |
| GO:BP | GO:0070897 | transcription preinitiation complex assembly | 1 | 67 | 4.99e-01 |
| GO:BP | GO:0008637 | apoptotic mitochondrial changes | 2 | 90 | 4.99e-01 |
| GO:BP | GO:0043373 | CD4-positive, alpha-beta T cell lineage commitment | 1 | 9 | 4.99e-01 |
| GO:BP | GO:1903649 | regulation of cytoplasmic transport | 2 | 25 | 4.99e-01 |
| GO:BP | GO:2000465 | regulation of glycogen (starch) synthase activity | 1 | 8 | 4.99e-01 |
| GO:BP | GO:0098810 | neurotransmitter reuptake | 1 | 21 | 4.99e-01 |
| GO:BP | GO:0001525 | angiogenesis | 6 | 390 | 4.99e-01 |
| GO:BP | GO:0140694 | non-membrane-bounded organelle assembly | 5 | 357 | 4.99e-01 |
| GO:BP | GO:0070453 | regulation of heme biosynthetic process | 1 | 7 | 4.99e-01 |
| GO:BP | GO:0055118 | negative regulation of cardiac muscle contraction | 1 | 4 | 4.99e-01 |
| GO:BP | GO:0043408 | regulation of MAPK cascade | 1 | 475 | 4.99e-01 |
| GO:BP | GO:1901463 | regulation of tetrapyrrole biosynthetic process | 1 | 7 | 4.99e-01 |
| GO:BP | GO:0031053 | primary miRNA processing | 2 | 16 | 4.99e-01 |
| GO:BP | GO:0006936 | muscle contraction | 1 | 267 | 4.99e-01 |
| GO:BP | GO:1990874 | vascular associated smooth muscle cell proliferation | 2 | 55 | 4.99e-01 |
| GO:BP | GO:0048484 | enteric nervous system development | 1 | 7 | 4.99e-01 |
| GO:BP | GO:0002855 | regulation of natural killer cell mediated immune response to tumor cell | 1 | 4 | 5.00e-01 |
| GO:BP | GO:1901895 | negative regulation of ATPase-coupled calcium transmembrane transporter activity | 1 | 3 | 5.00e-01 |
| GO:BP | GO:0007617 | mating behavior | 4 | 21 | 5.00e-01 |
| GO:BP | GO:0002377 | immunoglobulin production | 7 | 70 | 5.00e-01 |
| GO:BP | GO:1904683 | regulation of metalloendopeptidase activity | 1 | 6 | 5.00e-01 |
| GO:BP | GO:0060914 | heart formation | 2 | 29 | 5.00e-01 |
| GO:BP | GO:0060039 | pericardium development | 1 | 17 | 5.00e-01 |
| GO:BP | GO:0002420 | natural killer cell mediated cytotoxicity directed against tumor cell target | 1 | 4 | 5.00e-01 |
| GO:BP | GO:0042693 | muscle cell fate commitment | 1 | 11 | 5.00e-01 |
| GO:BP | GO:0043507 | positive regulation of JUN kinase activity | 2 | 34 | 5.00e-01 |
| GO:BP | GO:0021544 | subpallium development | 1 | 18 | 5.00e-01 |
| GO:BP | GO:0052548 | regulation of endopeptidase activity | 4 | 232 | 5.00e-01 |
| GO:BP | GO:0032927 | positive regulation of activin receptor signaling pathway | 1 | 7 | 5.00e-01 |
| GO:BP | GO:0035864 | response to potassium ion | 2 | 12 | 5.00e-01 |
| GO:BP | GO:1903508 | positive regulation of nucleic acid-templated transcription | 93 | 1315 | 5.00e-01 |
| GO:BP | GO:0007019 | microtubule depolymerization | 1 | 43 | 5.00e-01 |
| GO:BP | GO:0043502 | regulation of muscle adaptation | 5 | 69 | 5.00e-01 |
| GO:BP | GO:0045893 | positive regulation of DNA-templated transcription | 93 | 1315 | 5.00e-01 |
| GO:BP | GO:0051172 | negative regulation of nitrogen compound metabolic process | 4 | 1849 | 5.00e-01 |
| GO:BP | GO:0055001 | muscle cell development | 11 | 165 | 5.01e-01 |
| GO:BP | GO:2001056 | positive regulation of cysteine-type endopeptidase activity | 5 | 107 | 5.01e-01 |
| GO:BP | GO:0071402 | cellular response to lipoprotein particle stimulus | 2 | 23 | 5.01e-01 |
| GO:BP | GO:0043501 | skeletal muscle adaptation | 2 | 19 | 5.01e-01 |
| GO:BP | GO:0070887 | cellular response to chemical stimulus | 4 | 1869 | 5.01e-01 |
| GO:BP | GO:1903998 | regulation of eating behavior | 1 | 1 | 5.01e-01 |
| GO:BP | GO:0045048 | protein insertion into ER membrane | 3 | 23 | 5.01e-01 |
| GO:BP | GO:0031062 | positive regulation of histone methylation | 1 | 36 | 5.01e-01 |
| GO:BP | GO:1905774 | regulation of DNA helicase activity | 1 | 5 | 5.02e-01 |
| GO:BP | GO:0019693 | ribose phosphate metabolic process | 4 | 319 | 5.02e-01 |
| GO:BP | GO:0046580 | negative regulation of Ras protein signal transduction | 1 | 47 | 5.02e-01 |
| GO:BP | GO:0006505 | GPI anchor metabolic process | 1 | 31 | 5.02e-01 |
| GO:BP | GO:0072318 | clathrin coat disassembly | 1 | 8 | 5.02e-01 |
| GO:BP | GO:0035855 | megakaryocyte development | 1 | 16 | 5.02e-01 |
| GO:BP | GO:0030509 | BMP signaling pathway | 2 | 123 | 5.02e-01 |
| GO:BP | GO:0042749 | regulation of circadian sleep/wake cycle | 2 | 9 | 5.02e-01 |
| GO:BP | GO:0090199 | regulation of release of cytochrome c from mitochondria | 2 | 39 | 5.02e-01 |
| GO:BP | GO:0033003 | regulation of mast cell activation | 3 | 25 | 5.02e-01 |
| GO:BP | GO:0044351 | macropinocytosis | 1 | 8 | 5.02e-01 |
| GO:BP | GO:0048630 | skeletal muscle tissue growth | 1 | 8 | 5.02e-01 |
| GO:BP | GO:0043065 | positive regulation of apoptotic process | 13 | 393 | 5.03e-01 |
| GO:BP | GO:0046777 | protein autophosphorylation | 10 | 188 | 5.03e-01 |
| GO:BP | GO:0065009 | regulation of molecular function | 14 | 1939 | 5.03e-01 |
| GO:BP | GO:0006221 | pyrimidine nucleotide biosynthetic process | 2 | 28 | 5.03e-01 |
| GO:BP | GO:0070562 | regulation of vitamin D receptor signaling pathway | 1 | 9 | 5.03e-01 |
| GO:BP | GO:0007076 | mitotic chromosome condensation | 1 | 19 | 5.03e-01 |
| GO:BP | GO:1903071 | positive regulation of ER-associated ubiquitin-dependent protein catabolic process | 1 | 8 | 5.04e-01 |
| GO:BP | GO:0086003 | cardiac muscle cell contraction | 2 | 67 | 5.04e-01 |
| GO:BP | GO:0006040 | amino sugar metabolic process | 2 | 33 | 5.04e-01 |
| GO:BP | GO:0016233 | telomere capping | 2 | 36 | 5.04e-01 |
| GO:BP | GO:0032725 | positive regulation of granulocyte macrophage colony-stimulating factor production | 1 | 5 | 5.05e-01 |
| GO:BP | GO:0051896 | regulation of protein kinase B signaling | 4 | 123 | 5.05e-01 |
| GO:BP | GO:0002252 | immune effector process | 1 | 318 | 5.05e-01 |
| GO:BP | GO:0043270 | positive regulation of monoatomic ion transport | 1 | 154 | 5.05e-01 |
| GO:BP | GO:0046545 | development of primary female sexual characteristics | 3 | 79 | 5.05e-01 |
| GO:BP | GO:0042918 | alkanesulfonate transport | 1 | 6 | 5.05e-01 |
| GO:BP | GO:0015734 | taurine transport | 1 | 6 | 5.05e-01 |
| GO:BP | GO:0060180 | female mating behavior | 1 | 2 | 5.05e-01 |
| GO:BP | GO:0045924 | regulation of female receptivity | 1 | 2 | 5.05e-01 |
| GO:BP | GO:0002154 | thyroid hormone mediated signaling pathway | 1 | 6 | 5.05e-01 |
| GO:BP | GO:0010664 | negative regulation of striated muscle cell apoptotic process | 2 | 24 | 5.05e-01 |
| GO:BP | GO:2001012 | mesenchymal cell differentiation involved in renal system development | 1 | 5 | 5.05e-01 |
| GO:BP | GO:0072161 | mesenchymal cell differentiation involved in kidney development | 1 | 5 | 5.05e-01 |
| GO:BP | GO:0086065 | cell communication involved in cardiac conduction | 2 | 58 | 5.05e-01 |
| GO:BP | GO:0034764 | positive regulation of transmembrane transport | 1 | 158 | 5.05e-01 |
| GO:BP | GO:0046719 | regulation by virus of viral protein levels in host cell | 1 | 8 | 5.05e-01 |
| GO:BP | GO:0048483 | autonomic nervous system development | 3 | 28 | 5.06e-01 |
| GO:BP | GO:0033013 | tetrapyrrole metabolic process | 1 | 52 | 5.06e-01 |
| GO:BP | GO:0071038 | nuclear polyadenylation-dependent tRNA catabolic process | 1 | 7 | 5.06e-01 |
| GO:BP | GO:0071035 | nuclear polyadenylation-dependent rRNA catabolic process | 1 | 7 | 5.06e-01 |
| GO:BP | GO:0072530 | purine-containing compound transmembrane transport | 1 | 20 | 5.06e-01 |
| GO:BP | GO:0071046 | nuclear polyadenylation-dependent ncRNA catabolic process | 1 | 7 | 5.06e-01 |
| GO:BP | GO:0106354 | tRNA surveillance | 1 | 7 | 5.06e-01 |
| GO:BP | GO:0071029 | nuclear ncRNA surveillance | 1 | 7 | 5.06e-01 |
| GO:BP | GO:0061448 | connective tissue development | 7 | 208 | 5.06e-01 |
| GO:BP | GO:0072044 | collecting duct development | 2 | 6 | 5.06e-01 |
| GO:BP | GO:0003002 | regionalization | 5 | 273 | 5.06e-01 |
| GO:BP | GO:0150077 | regulation of neuroinflammatory response | 2 | 13 | 5.06e-01 |
| GO:BP | GO:0006451 | translational readthrough | 1 | 10 | 5.06e-01 |
| GO:BP | GO:0001514 | selenocysteine incorporation | 1 | 10 | 5.06e-01 |
| GO:BP | GO:0070199 | establishment of protein localization to chromosome | 3 | 25 | 5.06e-01 |
| GO:BP | GO:0045445 | myoblast differentiation | 4 | 90 | 5.06e-01 |
| GO:BP | GO:0032677 | regulation of interleukin-8 production | 1 | 43 | 5.06e-01 |
| GO:BP | GO:0032637 | interleukin-8 production | 1 | 43 | 5.06e-01 |
| GO:BP | GO:0009750 | response to fructose | 1 | 3 | 5.07e-01 |
| GO:BP | GO:0045063 | T-helper 1 cell differentiation | 1 | 14 | 5.07e-01 |
| GO:BP | GO:0035442 | dipeptide transmembrane transport | 1 | 4 | 5.07e-01 |
| GO:BP | GO:1901699 | cellular response to nitrogen compound | 1 | 517 | 5.07e-01 |
| GO:BP | GO:0006552 | leucine catabolic process | 1 | 6 | 5.07e-01 |
| GO:BP | GO:0032727 | positive regulation of interferon-alpha production | 2 | 17 | 5.07e-01 |
| GO:BP | GO:0042938 | dipeptide transport | 1 | 4 | 5.07e-01 |
| GO:BP | GO:0035332 | positive regulation of hippo signaling | 1 | 6 | 5.07e-01 |
| GO:BP | GO:0048523 | negative regulation of cellular process | 7 | 3625 | 5.07e-01 |
| GO:BP | GO:0061178 | regulation of insulin secretion involved in cellular response to glucose stimulus | 5 | 40 | 5.07e-01 |
| GO:BP | GO:0110104 | mRNA alternative polyadenylation | 1 | 5 | 5.07e-01 |
| GO:BP | GO:0035338 | long-chain fatty-acyl-CoA biosynthetic process | 2 | 14 | 5.08e-01 |
| GO:BP | GO:0071484 | cellular response to light intensity | 1 | 4 | 5.08e-01 |
| GO:BP | GO:2000625 | regulation of miRNA catabolic process | 1 | 5 | 5.08e-01 |
| GO:BP | GO:2000726 | negative regulation of cardiac muscle cell differentiation | 1 | 8 | 5.08e-01 |
| GO:BP | GO:0006986 | response to unfolded protein | 12 | 128 | 5.08e-01 |
| GO:BP | GO:0021854 | hypothalamus development | 3 | 15 | 5.08e-01 |
| GO:BP | GO:0090168 | Golgi reassembly | 1 | 5 | 5.08e-01 |
| GO:BP | GO:0035646 | endosome to melanosome transport | 1 | 9 | 5.08e-01 |
| GO:BP | GO:2000197 | regulation of ribonucleoprotein complex localization | 1 | 6 | 5.08e-01 |
| GO:BP | GO:0043485 | endosome to pigment granule transport | 1 | 9 | 5.08e-01 |
| GO:BP | GO:1904031 | positive regulation of cyclin-dependent protein kinase activity | 2 | 26 | 5.08e-01 |
| GO:BP | GO:0048757 | pigment granule maturation | 1 | 9 | 5.08e-01 |
| GO:BP | GO:2000316 | regulation of T-helper 17 type immune response | 2 | 16 | 5.08e-01 |
| GO:BP | GO:0050901 | leukocyte tethering or rolling | 2 | 16 | 5.08e-01 |
| GO:BP | GO:0021892 | cerebral cortex GABAergic interneuron differentiation | 1 | 3 | 5.08e-01 |
| GO:BP | GO:0010718 | positive regulation of epithelial to mesenchymal transition | 1 | 48 | 5.08e-01 |
| GO:BP | GO:0006813 | potassium ion transport | 1 | 147 | 5.08e-01 |
| GO:BP | GO:0042130 | negative regulation of T cell proliferation | 6 | 38 | 5.08e-01 |
| GO:BP | GO:0043547 | positive regulation of GTPase activity | 6 | 222 | 5.08e-01 |
| GO:BP | GO:0060973 | cell migration involved in heart development | 1 | 20 | 5.08e-01 |
| GO:BP | GO:0030900 | forebrain development | 2 | 281 | 5.09e-01 |
| GO:BP | GO:0051336 | regulation of hydrolase activity | 10 | 701 | 5.09e-01 |
| GO:BP | GO:0001934 | positive regulation of protein phosphorylation | 1 | 496 | 5.09e-01 |
| GO:BP | GO:0072329 | monocarboxylic acid catabolic process | 1 | 105 | 5.09e-01 |
| GO:BP | GO:0006771 | riboflavin metabolic process | 1 | 3 | 5.09e-01 |
| GO:BP | GO:1904464 | regulation of matrix metallopeptidase secretion | 1 | 5 | 5.09e-01 |
| GO:BP | GO:1905048 | regulation of metallopeptidase activity | 2 | 14 | 5.09e-01 |
| GO:BP | GO:0150003 | regulation of spontaneous synaptic transmission | 1 | 6 | 5.09e-01 |
| GO:BP | GO:1902991 | regulation of amyloid precursor protein catabolic process | 3 | 39 | 5.09e-01 |
| GO:BP | GO:0036344 | platelet morphogenesis | 1 | 19 | 5.09e-01 |
| GO:BP | GO:1990773 | matrix metallopeptidase secretion | 1 | 5 | 5.09e-01 |
| GO:BP | GO:0051303 | establishment of chromosome localization | 4 | 75 | 5.09e-01 |
| GO:BP | GO:2000311 | regulation of AMPA receptor activity | 3 | 15 | 5.09e-01 |
| GO:BP | GO:0090313 | regulation of protein targeting to membrane | 1 | 27 | 5.10e-01 |
| GO:BP | GO:0007628 | adult walking behavior | 2 | 23 | 5.10e-01 |
| GO:BP | GO:0050865 | regulation of cell activation | 1 | 384 | 5.10e-01 |
| GO:BP | GO:0040018 | positive regulation of multicellular organism growth | 3 | 22 | 5.10e-01 |
| GO:BP | GO:0042026 | protein refolding | 3 | 26 | 5.10e-01 |
| GO:BP | GO:0048565 | digestive tract development | 7 | 92 | 5.10e-01 |
| GO:BP | GO:0031018 | endocrine pancreas development | 3 | 32 | 5.10e-01 |
| GO:BP | GO:0003228 | atrial cardiac muscle tissue development | 2 | 18 | 5.10e-01 |
| GO:BP | GO:1902680 | positive regulation of RNA biosynthetic process | 93 | 1322 | 5.10e-01 |
| GO:BP | GO:0010165 | response to X-ray | 2 | 29 | 5.10e-01 |
| GO:BP | GO:0009988 | cell-cell recognition | 2 | 32 | 5.10e-01 |
| GO:BP | GO:0006672 | ceramide metabolic process | 1 | 80 | 5.11e-01 |
| GO:BP | GO:0035790 | platelet-derived growth factor receptor-alpha signaling pathway | 1 | 6 | 5.11e-01 |
| GO:BP | GO:0032968 | positive regulation of transcription elongation by RNA polymerase II | 5 | 49 | 5.12e-01 |
| GO:BP | GO:0086001 | cardiac muscle cell action potential | 2 | 68 | 5.12e-01 |
| GO:BP | GO:0009112 | nucleobase metabolic process | 2 | 27 | 5.12e-01 |
| GO:BP | GO:0032817 | regulation of natural killer cell proliferation | 1 | 4 | 5.12e-01 |
| GO:BP | GO:0001553 | luteinization | 1 | 10 | 5.12e-01 |
| GO:BP | GO:0032648 | regulation of interferon-beta production | 5 | 43 | 5.12e-01 |
| GO:BP | GO:0043549 | regulation of kinase activity | 1 | 560 | 5.12e-01 |
| GO:BP | GO:0071295 | cellular response to vitamin | 2 | 22 | 5.12e-01 |
| GO:BP | GO:0071695 | anatomical structure maturation | 2 | 48 | 5.12e-01 |
| GO:BP | GO:0032608 | interferon-beta production | 5 | 43 | 5.12e-01 |
| GO:BP | GO:2000672 | negative regulation of motor neuron apoptotic process | 1 | 10 | 5.12e-01 |
| GO:BP | GO:0034105 | positive regulation of tissue remodeling | 1 | 4 | 5.12e-01 |
| GO:BP | GO:0099625 | ventricular cardiac muscle cell membrane repolarization | 1 | 21 | 5.13e-01 |
| GO:BP | GO:0034145 | positive regulation of toll-like receptor 4 signaling pathway | 1 | 7 | 5.13e-01 |
| GO:BP | GO:0002250 | adaptive immune response | 1 | 218 | 5.13e-01 |
| GO:BP | GO:0044706 | multi-multicellular organism process | 1 | 135 | 5.13e-01 |
| GO:BP | GO:0060402 | calcium ion transport into cytosol | 3 | 18 | 5.13e-01 |
| GO:BP | GO:0045921 | positive regulation of exocytosis | 6 | 62 | 5.13e-01 |
| GO:BP | GO:0014046 | dopamine secretion | 1 | 23 | 5.14e-01 |
| GO:BP | GO:0033138 | positive regulation of peptidyl-serine phosphorylation | 4 | 70 | 5.14e-01 |
| GO:BP | GO:0009642 | response to light intensity | 2 | 11 | 5.14e-01 |
| GO:BP | GO:0090027 | negative regulation of monocyte chemotaxis | 1 | 4 | 5.14e-01 |
| GO:BP | GO:0043584 | nose development | 1 | 10 | 5.14e-01 |
| GO:BP | GO:0044381 | glucose import in response to insulin stimulus | 1 | 4 | 5.14e-01 |
| GO:BP | GO:0008589 | regulation of smoothened signaling pathway | 7 | 73 | 5.14e-01 |
| GO:BP | GO:0039529 | RIG-I signaling pathway | 1 | 22 | 5.14e-01 |
| GO:BP | GO:0043588 | skin development | 2 | 175 | 5.14e-01 |
| GO:BP | GO:0015825 | L-serine transport | 1 | 7 | 5.14e-01 |
| GO:BP | GO:0050778 | positive regulation of immune response | 1 | 369 | 5.14e-01 |
| GO:BP | GO:0097116 | gephyrin clustering involved in postsynaptic density assembly | 1 | 3 | 5.14e-01 |
| GO:BP | GO:0090179 | planar cell polarity pathway involved in neural tube closure | 1 | 12 | 5.14e-01 |
| GO:BP | GO:0080009 | mRNA methylation | 2 | 16 | 5.14e-01 |
| GO:BP | GO:0045662 | negative regulation of myoblast differentiation | 3 | 19 | 5.14e-01 |
| GO:BP | GO:0061724 | lipophagy | 1 | 7 | 5.15e-01 |
| GO:BP | GO:0000425 | pexophagy | 1 | 6 | 5.15e-01 |
| GO:BP | GO:0034332 | adherens junction organization | 2 | 41 | 5.15e-01 |
| GO:BP | GO:0016115 | terpenoid catabolic process | 1 | 4 | 5.15e-01 |
| GO:BP | GO:0048387 | negative regulation of retinoic acid receptor signaling pathway | 1 | 6 | 5.15e-01 |
| GO:BP | GO:0002363 | alpha-beta T cell lineage commitment | 1 | 11 | 5.16e-01 |
| GO:BP | GO:0099623 | regulation of cardiac muscle cell membrane repolarization | 1 | 20 | 5.16e-01 |
| GO:BP | GO:0010927 | cellular component assembly involved in morphogenesis | 2 | 106 | 5.16e-01 |
| GO:BP | GO:0051412 | response to corticosterone | 1 | 10 | 5.17e-01 |
| GO:BP | GO:1902315 | nuclear cell cycle DNA replication initiation | 1 | 5 | 5.17e-01 |
| GO:BP | GO:0040017 | positive regulation of locomotion | 4 | 429 | 5.17e-01 |
| GO:BP | GO:0034087 | establishment of mitotic sister chromatid cohesion | 1 | 7 | 5.17e-01 |
| GO:BP | GO:1902975 | mitotic DNA replication initiation | 1 | 5 | 5.17e-01 |
| GO:BP | GO:1902292 | cell cycle DNA replication initiation | 1 | 5 | 5.17e-01 |
| GO:BP | GO:0071887 | leukocyte apoptotic process | 4 | 81 | 5.17e-01 |
| GO:BP | GO:1901071 | glucosamine-containing compound metabolic process | 3 | 19 | 5.17e-01 |
| GO:BP | GO:0043306 | positive regulation of mast cell degranulation | 2 | 10 | 5.17e-01 |
| GO:BP | GO:0032532 | regulation of microvillus length | 1 | 4 | 5.17e-01 |
| GO:BP | GO:0033008 | positive regulation of mast cell activation involved in immune response | 2 | 10 | 5.17e-01 |
| GO:BP | GO:0021696 | cerebellar cortex morphogenesis | 1 | 30 | 5.17e-01 |
| GO:BP | GO:0097211 | cellular response to gonadotropin-releasing hormone | 1 | 3 | 5.17e-01 |
| GO:BP | GO:0001573 | ganglioside metabolic process | 2 | 22 | 5.18e-01 |
| GO:BP | GO:1901620 | regulation of smoothened signaling pathway involved in dorsal/ventral neural tube patterning | 1 | 12 | 5.18e-01 |
| GO:BP | GO:0034499 | late endosome to Golgi transport | 1 | 5 | 5.18e-01 |
| GO:BP | GO:0060143 | positive regulation of syncytium formation by plasma membrane fusion | 1 | 12 | 5.18e-01 |
| GO:BP | GO:0045198 | establishment of epithelial cell apical/basal polarity | 1 | 14 | 5.19e-01 |
| GO:BP | GO:0061087 | positive regulation of histone H3-K27 methylation | 1 | 4 | 5.19e-01 |
| GO:BP | GO:0042593 | glucose homeostasis | 11 | 168 | 5.19e-01 |
| GO:BP | GO:0043524 | negative regulation of neuron apoptotic process | 5 | 120 | 5.19e-01 |
| GO:BP | GO:1901565 | organonitrogen compound catabolic process | 57 | 1145 | 5.19e-01 |
| GO:BP | GO:0055021 | regulation of cardiac muscle tissue growth | 2 | 45 | 5.19e-01 |
| GO:BP | GO:0051341 | regulation of oxidoreductase activity | 1 | 68 | 5.19e-01 |
| GO:BP | GO:0090322 | regulation of superoxide metabolic process | 1 | 19 | 5.19e-01 |
| GO:BP | GO:0002064 | epithelial cell development | 10 | 156 | 5.19e-01 |
| GO:BP | GO:1903307 | positive regulation of regulated secretory pathway | 5 | 32 | 5.19e-01 |
| GO:BP | GO:0014889 | muscle atrophy | 1 | 9 | 5.19e-01 |
| GO:BP | GO:0006584 | catecholamine metabolic process | 1 | 30 | 5.19e-01 |
| GO:BP | GO:0032776 | DNA methylation on cytosine | 1 | 4 | 5.19e-01 |
| GO:BP | GO:0009712 | catechol-containing compound metabolic process | 1 | 30 | 5.19e-01 |
| GO:BP | GO:0017004 | cytochrome complex assembly | 3 | 38 | 5.20e-01 |
| GO:BP | GO:0002423 | natural killer cell mediated immune response to tumor cell | 1 | 4 | 5.20e-01 |
| GO:BP | GO:1903846 | positive regulation of cellular response to transforming growth factor beta stimulus | 2 | 30 | 5.20e-01 |
| GO:BP | GO:0007098 | centrosome cycle | 3 | 127 | 5.20e-01 |
| GO:BP | GO:0030511 | positive regulation of transforming growth factor beta receptor signaling pathway | 2 | 30 | 5.20e-01 |
| GO:BP | GO:0042776 | proton motive force-driven mitochondrial ATP synthesis | 1 | 57 | 5.20e-01 |
| GO:BP | GO:0032366 | intracellular sterol transport | 2 | 30 | 5.20e-01 |
| GO:BP | GO:0061002 | negative regulation of dendritic spine morphogenesis | 1 | 6 | 5.20e-01 |
| GO:BP | GO:0043415 | positive regulation of skeletal muscle tissue regeneration | 1 | 4 | 5.20e-01 |
| GO:BP | GO:0098916 | anterograde trans-synaptic signaling | 1 | 490 | 5.20e-01 |
| GO:BP | GO:0007268 | chemical synaptic transmission | 1 | 490 | 5.20e-01 |
| GO:BP | GO:0060613 | fat pad development | 1 | 6 | 5.20e-01 |
| GO:BP | GO:0019751 | polyol metabolic process | 1 | 82 | 5.20e-01 |
| GO:BP | GO:0010830 | regulation of myotube differentiation | 3 | 31 | 5.21e-01 |
| GO:BP | GO:0051290 | protein heterotetramerization | 1 | 12 | 5.21e-01 |
| GO:BP | GO:0003073 | regulation of systemic arterial blood pressure | 1 | 62 | 5.21e-01 |
| GO:BP | GO:0007622 | rhythmic behavior | 1 | 32 | 5.21e-01 |
| GO:BP | GO:0046685 | response to arsenic-containing substance | 1 | 30 | 5.21e-01 |
| GO:BP | GO:0018119 | peptidyl-cysteine S-nitrosylation | 1 | 11 | 5.21e-01 |
| GO:BP | GO:0042921 | glucocorticoid receptor signaling pathway | 1 | 13 | 5.21e-01 |
| GO:BP | GO:0017014 | protein nitrosylation | 1 | 11 | 5.21e-01 |
| GO:BP | GO:0042127 | regulation of cell population proliferation | 34 | 1147 | 5.22e-01 |
| GO:BP | GO:0043144 | sno(s)RNA processing | 1 | 13 | 5.22e-01 |
| GO:BP | GO:0071470 | cellular response to osmotic stress | 2 | 42 | 5.22e-01 |
| GO:BP | GO:0033157 | regulation of intracellular protein transport | 6 | 197 | 5.22e-01 |
| GO:BP | GO:0039536 | negative regulation of RIG-I signaling pathway | 1 | 7 | 5.22e-01 |
| GO:BP | GO:0099537 | trans-synaptic signaling | 1 | 495 | 5.22e-01 |
| GO:BP | GO:2000303 | regulation of ceramide biosynthetic process | 1 | 11 | 5.22e-01 |
| GO:BP | GO:0030148 | sphingolipid biosynthetic process | 1 | 88 | 5.22e-01 |
| GO:BP | GO:0071773 | cellular response to BMP stimulus | 2 | 131 | 5.23e-01 |
| GO:BP | GO:0071772 | response to BMP | 2 | 131 | 5.23e-01 |
| GO:BP | GO:0072132 | mesenchyme morphogenesis | 1 | 50 | 5.23e-01 |
| GO:BP | GO:0019748 | secondary metabolic process | 4 | 34 | 5.23e-01 |
| GO:BP | GO:0002684 | positive regulation of immune system process | 2 | 581 | 5.23e-01 |
| GO:BP | GO:0048242 | epinephrine secretion | 1 | 2 | 5.23e-01 |
| GO:BP | GO:0014060 | regulation of epinephrine secretion | 1 | 2 | 5.23e-01 |
| GO:BP | GO:2000617 | positive regulation of histone H3-K9 acetylation | 1 | 6 | 5.23e-01 |
| GO:BP | GO:0009756 | carbohydrate mediated signaling | 1 | 6 | 5.23e-01 |
| GO:BP | GO:0006595 | polyamine metabolic process | 2 | 16 | 5.24e-01 |
| GO:BP | GO:0043330 | response to exogenous dsRNA | 3 | 27 | 5.24e-01 |
| GO:BP | GO:0071380 | cellular response to prostaglandin E stimulus | 1 | 14 | 5.24e-01 |
| GO:BP | GO:0061515 | myeloid cell development | 1 | 57 | 5.24e-01 |
| GO:BP | GO:1901401 | regulation of tetrapyrrole metabolic process | 1 | 8 | 5.24e-01 |
| GO:BP | GO:0006487 | protein N-linked glycosylation | 1 | 65 | 5.24e-01 |
| GO:BP | GO:0002158 | osteoclast proliferation | 1 | 7 | 5.24e-01 |
| GO:BP | GO:0060964 | regulation of miRNA-mediated gene silencing | 1 | 25 | 5.24e-01 |
| GO:BP | GO:0043369 | CD4-positive or CD8-positive, alpha-beta T cell lineage commitment | 1 | 11 | 5.24e-01 |
| GO:BP | GO:1902001 | fatty acid transmembrane transport | 2 | 15 | 5.24e-01 |
| GO:BP | GO:0036297 | interstrand cross-link repair | 1 | 37 | 5.24e-01 |
| GO:BP | GO:0090435 | protein localization to nuclear envelope | 1 | 14 | 5.24e-01 |
| GO:BP | GO:1901570 | fatty acid derivative biosynthetic process | 1 | 33 | 5.25e-01 |
| GO:BP | GO:0015931 | nucleobase-containing compound transport | 17 | 194 | 5.26e-01 |
| GO:BP | GO:0000165 | MAPK cascade | 1 | 556 | 5.27e-01 |
| GO:BP | GO:0046513 | ceramide biosynthetic process | 4 | 53 | 5.27e-01 |
| GO:BP | GO:0021772 | olfactory bulb development | 2 | 19 | 5.27e-01 |
| GO:BP | GO:0051058 | negative regulation of small GTPase mediated signal transduction | 1 | 53 | 5.27e-01 |
| GO:BP | GO:0045910 | negative regulation of DNA recombination | 1 | 31 | 5.27e-01 |
| GO:BP | GO:0070173 | regulation of enamel mineralization | 1 | 2 | 5.27e-01 |
| GO:BP | GO:0033687 | osteoblast proliferation | 2 | 27 | 5.27e-01 |
| GO:BP | GO:0032230 | positive regulation of synaptic transmission, GABAergic | 2 | 10 | 5.27e-01 |
| GO:BP | GO:0070316 | regulation of G0 to G1 transition | 3 | 34 | 5.28e-01 |
| GO:BP | GO:0071800 | podosome assembly | 2 | 13 | 5.28e-01 |
| GO:BP | GO:0032412 | regulation of monoatomic ion transmembrane transporter activity | 1 | 190 | 5.28e-01 |
| GO:BP | GO:0033353 | S-adenosylmethionine cycle | 1 | 7 | 5.28e-01 |
| GO:BP | GO:0043102 | amino acid salvage | 1 | 5 | 5.28e-01 |
| GO:BP | GO:0006390 | mitochondrial transcription | 2 | 18 | 5.28e-01 |
| GO:BP | GO:0090025 | regulation of monocyte chemotaxis | 3 | 12 | 5.28e-01 |
| GO:BP | GO:0071267 | L-methionine salvage | 1 | 5 | 5.28e-01 |
| GO:BP | GO:0071265 | L-methionine biosynthetic process | 1 | 5 | 5.28e-01 |
| GO:BP | GO:0030100 | regulation of endocytosis | 14 | 211 | 5.28e-01 |
| GO:BP | GO:0030155 | regulation of cell adhesion | 1 | 539 | 5.28e-01 |
| GO:BP | GO:0014897 | striated muscle hypertrophy | 5 | 73 | 5.28e-01 |
| GO:BP | GO:1904424 | regulation of GTP binding | 2 | 16 | 5.29e-01 |
| GO:BP | GO:0045821 | positive regulation of glycolytic process | 2 | 15 | 5.29e-01 |
| GO:BP | GO:0042311 | vasodilation | 1 | 39 | 5.29e-01 |
| GO:BP | GO:0048670 | regulation of collateral sprouting | 1 | 18 | 5.29e-01 |
| GO:BP | GO:0010942 | positive regulation of cell death | 17 | 441 | 5.29e-01 |
| GO:BP | GO:0099536 | synaptic signaling | 1 | 511 | 5.29e-01 |
| GO:BP | GO:0035774 | positive regulation of insulin secretion involved in cellular response to glucose stimulus | 3 | 18 | 5.29e-01 |
| GO:BP | GO:0010882 | regulation of cardiac muscle contraction by calcium ion signaling | 2 | 25 | 5.29e-01 |
| GO:BP | GO:0042327 | positive regulation of phosphorylation | 1 | 547 | 5.29e-01 |
| GO:BP | GO:0034205 | amyloid-beta formation | 3 | 41 | 5.30e-01 |
| GO:BP | GO:0098876 | vesicle-mediated transport to the plasma membrane | 1 | 143 | 5.30e-01 |
| GO:BP | GO:0090659 | walking behavior | 2 | 25 | 5.30e-01 |
| GO:BP | GO:0070663 | regulation of leukocyte proliferation | 6 | 141 | 5.30e-01 |
| GO:BP | GO:1901137 | carbohydrate derivative biosynthetic process | 5 | 544 | 5.30e-01 |
| GO:BP | GO:1904385 | cellular response to angiotensin | 2 | 23 | 5.30e-01 |
| GO:BP | GO:0046006 | regulation of activated T cell proliferation | 3 | 21 | 5.30e-01 |
| GO:BP | GO:0010628 | positive regulation of gene expression | 2 | 783 | 5.30e-01 |
| GO:BP | GO:0032049 | cardiolipin biosynthetic process | 1 | 7 | 5.31e-01 |
| GO:BP | GO:0043068 | positive regulation of programmed cell death | 13 | 399 | 5.31e-01 |
| GO:BP | GO:0045058 | T cell selection | 2 | 22 | 5.31e-01 |
| GO:BP | GO:2000106 | regulation of leukocyte apoptotic process | 3 | 57 | 5.31e-01 |
| GO:BP | GO:0007411 | axon guidance | 2 | 185 | 5.31e-01 |
| GO:BP | GO:0043473 | pigmentation | 1 | 92 | 5.31e-01 |
| GO:BP | GO:0000966 | RNA 5’-end processing | 1 | 22 | 5.31e-01 |
| GO:BP | GO:0090178 | regulation of establishment of planar polarity involved in neural tube closure | 1 | 13 | 5.32e-01 |
| GO:BP | GO:0018205 | peptidyl-lysine modification | 5 | 336 | 5.32e-01 |
| GO:BP | GO:0032331 | negative regulation of chondrocyte differentiation | 1 | 18 | 5.32e-01 |
| GO:BP | GO:0007275 | multicellular organism development | 1 | 3386 | 5.32e-01 |
| GO:BP | GO:0044089 | positive regulation of cellular component biogenesis | 1 | 420 | 5.32e-01 |
| GO:BP | GO:0097485 | neuron projection guidance | 2 | 186 | 5.33e-01 |
| GO:BP | GO:0007006 | mitochondrial membrane organization | 2 | 114 | 5.33e-01 |
| GO:BP | GO:0035265 | organ growth | 5 | 131 | 5.33e-01 |
| GO:BP | GO:1902531 | regulation of intracellular signal transduction | 26 | 1345 | 5.33e-01 |
| GO:BP | GO:0060443 | mammary gland morphogenesis | 2 | 39 | 5.33e-01 |
| GO:BP | GO:0030195 | negative regulation of blood coagulation | 1 | 34 | 5.33e-01 |
| GO:BP | GO:0034475 | U4 snRNA 3’-end processing | 1 | 8 | 5.33e-01 |
| GO:BP | GO:0061308 | cardiac neural crest cell development involved in heart development | 1 | 15 | 5.33e-01 |
| GO:BP | GO:0042177 | negative regulation of protein catabolic process | 10 | 100 | 5.33e-01 |
| GO:BP | GO:0061307 | cardiac neural crest cell differentiation involved in heart development | 1 | 15 | 5.33e-01 |
| GO:BP | GO:0035924 | cellular response to vascular endothelial growth factor stimulus | 3 | 54 | 5.33e-01 |
| GO:BP | GO:0044065 | regulation of respiratory system process | 2 | 11 | 5.33e-01 |
| GO:BP | GO:0014745 | negative regulation of muscle adaptation | 1 | 9 | 5.33e-01 |
| GO:BP | GO:0050650 | chondroitin sulfate proteoglycan biosynthetic process | 1 | 20 | 5.33e-01 |
| GO:BP | GO:0015850 | organic hydroxy compound transport | 6 | 174 | 5.33e-01 |
| GO:BP | GO:0007158 | neuron cell-cell adhesion | 2 | 13 | 5.33e-01 |
| GO:BP | GO:0001776 | leukocyte homeostasis | 5 | 69 | 5.33e-01 |
| GO:BP | GO:0001678 | intracellular glucose homeostasis | 3 | 110 | 5.33e-01 |
| GO:BP | GO:0032204 | regulation of telomere maintenance | 4 | 96 | 5.33e-01 |
| GO:BP | GO:0048468 | cell development | 13 | 1963 | 5.34e-01 |
| GO:BP | GO:0006526 | arginine biosynthetic process | 1 | 4 | 5.34e-01 |
| GO:BP | GO:0034504 | protein localization to nucleus | 11 | 276 | 5.34e-01 |
| GO:BP | GO:0071280 | cellular response to copper ion | 2 | 18 | 5.34e-01 |
| GO:BP | GO:0050919 | negative chemotaxis | 2 | 42 | 5.34e-01 |
| GO:BP | GO:0002837 | regulation of immune response to tumor cell | 2 | 10 | 5.34e-01 |
| GO:BP | GO:0010939 | regulation of necrotic cell death | 1 | 38 | 5.34e-01 |
| GO:BP | GO:0034097 | response to cytokine | 2 | 607 | 5.34e-01 |
| GO:BP | GO:0031346 | positive regulation of cell projection organization | 22 | 303 | 5.34e-01 |
| GO:BP | GO:2000107 | negative regulation of leukocyte apoptotic process | 2 | 33 | 5.34e-01 |
| GO:BP | GO:0014894 | response to denervation involved in regulation of muscle adaptation | 1 | 8 | 5.34e-01 |
| GO:BP | GO:0021762 | substantia nigra development | 1 | 41 | 5.34e-01 |
| GO:BP | GO:0051454 | intracellular pH elevation | 1 | 4 | 5.34e-01 |
| GO:BP | GO:0014877 | response to muscle inactivity involved in regulation of muscle adaptation | 1 | 8 | 5.34e-01 |
| GO:BP | GO:0097577 | sequestering of iron ion | 1 | 3 | 5.35e-01 |
| GO:BP | GO:0097106 | postsynaptic density organization | 4 | 30 | 5.35e-01 |
| GO:BP | GO:0033211 | adiponectin-activated signaling pathway | 1 | 7 | 5.36e-01 |
| GO:BP | GO:0007229 | integrin-mediated signaling pathway | 1 | 89 | 5.36e-01 |
| GO:BP | GO:0007409 | axonogenesis | 5 | 359 | 5.36e-01 |
| GO:BP | GO:1900264 | positive regulation of DNA-directed DNA polymerase activity | 1 | 13 | 5.36e-01 |
| GO:BP | GO:1904872 | regulation of telomerase RNA localization to Cajal body | 2 | 18 | 5.36e-01 |
| GO:BP | GO:0051491 | positive regulation of filopodium assembly | 1 | 25 | 5.36e-01 |
| GO:BP | GO:1901993 | regulation of meiotic cell cycle phase transition | 1 | 5 | 5.36e-01 |
| GO:BP | GO:1900182 | positive regulation of protein localization to nucleus | 3 | 75 | 5.36e-01 |
| GO:BP | GO:1903672 | positive regulation of sprouting angiogenesis | 2 | 14 | 5.36e-01 |
| GO:BP | GO:0006264 | mitochondrial DNA replication | 1 | 13 | 5.36e-01 |
| GO:BP | GO:1900262 | regulation of DNA-directed DNA polymerase activity | 1 | 13 | 5.36e-01 |
| GO:BP | GO:0000209 | protein polyubiquitination | 6 | 226 | 5.36e-01 |
| GO:BP | GO:0050685 | positive regulation of mRNA processing | 2 | 30 | 5.36e-01 |
| GO:BP | GO:1900368 | regulation of post-transcriptional gene silencing by RNA | 1 | 27 | 5.36e-01 |
| GO:BP | GO:0010883 | regulation of lipid storage | 1 | 39 | 5.36e-01 |
| GO:BP | GO:0046620 | regulation of organ growth | 3 | 71 | 5.36e-01 |
| GO:BP | GO:0006111 | regulation of gluconeogenesis | 1 | 42 | 5.36e-01 |
| GO:BP | GO:0070306 | lens fiber cell differentiation | 3 | 30 | 5.36e-01 |
| GO:BP | GO:0140719 | constitutive heterochromatin formation | 1 | 10 | 5.36e-01 |
| GO:BP | GO:0045787 | positive regulation of cell cycle | 19 | 274 | 5.36e-01 |
| GO:BP | GO:1900047 | negative regulation of hemostasis | 1 | 34 | 5.36e-01 |
| GO:BP | GO:0006868 | glutamine transport | 1 | 8 | 5.36e-01 |
| GO:BP | GO:0061302 | smooth muscle cell-matrix adhesion | 1 | 5 | 5.36e-01 |
| GO:BP | GO:0022898 | regulation of transmembrane transporter activity | 1 | 199 | 5.36e-01 |
| GO:BP | GO:0060644 | mammary gland epithelial cell differentiation | 1 | 14 | 5.36e-01 |
| GO:BP | GO:0031958 | corticosteroid receptor signaling pathway | 1 | 14 | 5.36e-01 |
| GO:BP | GO:0060393 | regulation of pathway-restricted SMAD protein phosphorylation | 1 | 50 | 5.36e-01 |
| GO:BP | GO:0035162 | embryonic hemopoiesis | 1 | 19 | 5.36e-01 |
| GO:BP | GO:0010863 | positive regulation of phospholipase C activity | 1 | 18 | 5.37e-01 |
| GO:BP | GO:0060045 | positive regulation of cardiac muscle cell proliferation | 1 | 21 | 5.37e-01 |
| GO:BP | GO:0071396 | cellular response to lipid | 26 | 398 | 5.38e-01 |
| GO:BP | GO:0021843 | substrate-independent telencephalic tangential interneuron migration | 1 | 3 | 5.38e-01 |
| GO:BP | GO:0021826 | substrate-independent telencephalic tangential migration | 1 | 3 | 5.38e-01 |
| GO:BP | GO:0021830 | interneuron migration from the subpallium to the cortex | 1 | 3 | 5.38e-01 |
| GO:BP | GO:0032535 | regulation of cellular component size | 15 | 305 | 5.38e-01 |
| GO:BP | GO:0009170 | purine deoxyribonucleoside monophosphate metabolic process | 1 | 7 | 5.38e-01 |
| GO:BP | GO:0061052 | negative regulation of cell growth involved in cardiac muscle cell development | 1 | 10 | 5.38e-01 |
| GO:BP | GO:0014067 | negative regulation of phosphatidylinositol 3-kinase signaling | 1 | 12 | 5.38e-01 |
| GO:BP | GO:0090153 | regulation of sphingolipid biosynthetic process | 1 | 12 | 5.39e-01 |
| GO:BP | GO:0002870 | T cell anergy | 1 | 4 | 5.39e-01 |
| GO:BP | GO:0002667 | regulation of T cell anergy | 1 | 4 | 5.39e-01 |
| GO:BP | GO:0050770 | regulation of axonogenesis | 1 | 139 | 5.39e-01 |
| GO:BP | GO:1905038 | regulation of membrane lipid metabolic process | 1 | 12 | 5.39e-01 |
| GO:BP | GO:0001890 | placenta development | 7 | 117 | 5.39e-01 |
| GO:BP | GO:1905198 | manchette assembly | 1 | 4 | 5.39e-01 |
| GO:BP | GO:0044790 | suppression of viral release by host | 1 | 16 | 5.39e-01 |
| GO:BP | GO:0002911 | regulation of lymphocyte anergy | 1 | 4 | 5.39e-01 |
| GO:BP | GO:0002249 | lymphocyte anergy | 1 | 4 | 5.39e-01 |
| GO:BP | GO:0010594 | regulation of endothelial cell migration | 6 | 143 | 5.39e-01 |
| GO:BP | GO:0071425 | hematopoietic stem cell proliferation | 2 | 29 | 5.39e-01 |
| GO:BP | GO:0071816 | tail-anchored membrane protein insertion into ER membrane | 1 | 17 | 5.39e-01 |
| GO:BP | GO:0071166 | ribonucleoprotein complex localization | 1 | 7 | 5.39e-01 |
| GO:BP | GO:0070561 | vitamin D receptor signaling pathway | 1 | 10 | 5.39e-01 |
| GO:BP | GO:0051382 | kinetochore assembly | 2 | 18 | 5.39e-01 |
| GO:BP | GO:0009887 | animal organ morphogenesis | 4 | 742 | 5.40e-01 |
| GO:BP | GO:0032200 | telomere organization | 7 | 166 | 5.40e-01 |
| GO:BP | GO:0046826 | negative regulation of protein export from nucleus | 1 | 6 | 5.40e-01 |
| GO:BP | GO:0007009 | plasma membrane organization | 8 | 116 | 5.40e-01 |
| GO:BP | GO:0045116 | protein neddylation | 1 | 26 | 5.40e-01 |
| GO:BP | GO:0010605 | negative regulation of macromolecule metabolic process | 5 | 2135 | 5.40e-01 |
| GO:BP | GO:0042306 | regulation of protein import into nucleus | 2 | 51 | 5.41e-01 |
| GO:BP | GO:0032604 | granulocyte macrophage colony-stimulating factor production | 1 | 5 | 5.41e-01 |
| GO:BP | GO:0032645 | regulation of granulocyte macrophage colony-stimulating factor production | 1 | 5 | 5.41e-01 |
| GO:BP | GO:0043129 | surfactant homeostasis | 1 | 12 | 5.41e-01 |
| GO:BP | GO:0050793 | regulation of developmental process | 14 | 1835 | 5.41e-01 |
| GO:BP | GO:0071694 | maintenance of protein location in extracellular region | 1 | 4 | 5.41e-01 |
| GO:BP | GO:0014896 | muscle hypertrophy | 5 | 74 | 5.41e-01 |
| GO:BP | GO:0050852 | T cell receptor signaling pathway | 3 | 84 | 5.41e-01 |
| GO:BP | GO:0060008 | Sertoli cell differentiation | 1 | 15 | 5.42e-01 |
| GO:BP | GO:0043500 | muscle adaptation | 6 | 90 | 5.42e-01 |
| GO:BP | GO:0021553 | olfactory nerve development | 1 | 5 | 5.42e-01 |
| GO:BP | GO:0045008 | depyrimidination | 1 | 8 | 5.42e-01 |
| GO:BP | GO:0070935 | 3’-UTR-mediated mRNA stabilization | 2 | 19 | 5.42e-01 |
| GO:BP | GO:0033131 | regulation of glucokinase activity | 1 | 7 | 5.42e-01 |
| GO:BP | GO:0040016 | embryonic cleavage | 1 | 7 | 5.42e-01 |
| GO:BP | GO:0009312 | oligosaccharide biosynthetic process | 1 | 15 | 5.42e-01 |
| GO:BP | GO:0098974 | postsynaptic actin cytoskeleton organization | 1 | 11 | 5.42e-01 |
| GO:BP | GO:0039530 | MDA-5 signaling pathway | 1 | 8 | 5.42e-01 |
| GO:BP | GO:0072332 | intrinsic apoptotic signaling pathway by p53 class mediator | 3 | 77 | 5.42e-01 |
| GO:BP | GO:0032273 | positive regulation of protein polymerization | 4 | 76 | 5.42e-01 |
| GO:BP | GO:0150079 | negative regulation of neuroinflammatory response | 1 | 6 | 5.42e-01 |
| GO:BP | GO:0090150 | establishment of protein localization to membrane | 1 | 250 | 5.42e-01 |
| GO:BP | GO:0060147 | regulation of post-transcriptional gene silencing | 1 | 28 | 5.42e-01 |
| GO:BP | GO:0048712 | negative regulation of astrocyte differentiation | 1 | 9 | 5.42e-01 |
| GO:BP | GO:0048639 | positive regulation of developmental growth | 1 | 124 | 5.42e-01 |
| GO:BP | GO:0055015 | ventricular cardiac muscle cell development | 1 | 10 | 5.42e-01 |
| GO:BP | GO:0070509 | calcium ion import | 1 | 37 | 5.42e-01 |
| GO:BP | GO:0046849 | bone remodeling | 1 | 59 | 5.42e-01 |
| GO:BP | GO:0070166 | enamel mineralization | 2 | 11 | 5.42e-01 |
| GO:BP | GO:0030199 | collagen fibril organization | 1 | 56 | 5.42e-01 |
| GO:BP | GO:0045022 | early endosome to late endosome transport | 4 | 40 | 5.42e-01 |
| GO:BP | GO:0051260 | protein homooligomerization | 4 | 136 | 5.42e-01 |
| GO:BP | GO:2000317 | negative regulation of T-helper 17 type immune response | 1 | 7 | 5.42e-01 |
| GO:BP | GO:0072683 | T cell extravasation | 1 | 8 | 5.42e-01 |
| GO:BP | GO:0002069 | columnar/cuboidal epithelial cell maturation | 1 | 9 | 5.42e-01 |
| GO:BP | GO:0007049 | cell cycle | 41 | 1529 | 5.42e-01 |
| GO:BP | GO:0042255 | ribosome assembly | 4 | 56 | 5.42e-01 |
| GO:BP | GO:0003012 | muscle system process | 1 | 334 | 5.42e-01 |
| GO:BP | GO:1900454 | positive regulation of long-term synaptic depression | 1 | 3 | 5.42e-01 |
| GO:BP | GO:0034142 | toll-like receptor 4 signaling pathway | 2 | 24 | 5.43e-01 |
| GO:BP | GO:0097202 | activation of cysteine-type endopeptidase activity | 2 | 16 | 5.43e-01 |
| GO:BP | GO:0032479 | regulation of type I interferon production | 9 | 76 | 5.43e-01 |
| GO:BP | GO:0010543 | regulation of platelet activation | 1 | 32 | 5.43e-01 |
| GO:BP | GO:0043467 | regulation of generation of precursor metabolites and energy | 5 | 89 | 5.43e-01 |
| GO:BP | GO:0032606 | type I interferon production | 9 | 76 | 5.43e-01 |
| GO:BP | GO:0009100 | glycoprotein metabolic process | 3 | 316 | 5.45e-01 |
| GO:BP | GO:0021988 | olfactory lobe development | 2 | 21 | 5.45e-01 |
| GO:BP | GO:0043476 | pigment accumulation | 1 | 11 | 5.45e-01 |
| GO:BP | GO:0043482 | cellular pigment accumulation | 1 | 11 | 5.45e-01 |
| GO:BP | GO:1903753 | negative regulation of p38MAPK cascade | 1 | 5 | 5.45e-01 |
| GO:BP | GO:1901992 | positive regulation of mitotic cell cycle phase transition | 3 | 86 | 5.45e-01 |
| GO:BP | GO:0046649 | lymphocyte activation | 1 | 465 | 5.45e-01 |
| GO:BP | GO:0031398 | positive regulation of protein ubiquitination | 9 | 108 | 5.46e-01 |
| GO:BP | GO:0090177 | establishment of planar polarity involved in neural tube closure | 1 | 14 | 5.46e-01 |
| GO:BP | GO:0051451 | myoblast migration | 1 | 11 | 5.47e-01 |
| GO:BP | GO:0048266 | behavioral response to pain | 1 | 11 | 5.47e-01 |
| GO:BP | GO:0038166 | angiotensin-activated signaling pathway | 1 | 10 | 5.47e-01 |
| GO:BP | GO:0042726 | flavin-containing compound metabolic process | 1 | 4 | 5.47e-01 |
| GO:BP | GO:0032218 | riboflavin transport | 1 | 2 | 5.47e-01 |
| GO:BP | GO:0060740 | prostate gland epithelium morphogenesis | 1 | 20 | 5.47e-01 |
| GO:BP | GO:1902744 | negative regulation of lamellipodium organization | 1 | 4 | 5.47e-01 |
| GO:BP | GO:0070584 | mitochondrion morphogenesis | 2 | 21 | 5.47e-01 |
| GO:BP | GO:1900274 | regulation of phospholipase C activity | 1 | 20 | 5.48e-01 |
| GO:BP | GO:0042745 | circadian sleep/wake cycle | 2 | 11 | 5.48e-01 |
| GO:BP | GO:0097119 | postsynaptic density protein 95 clustering | 1 | 7 | 5.48e-01 |
| GO:BP | GO:0071539 | protein localization to centrosome | 3 | 31 | 5.48e-01 |
| GO:BP | GO:2000615 | regulation of histone H3-K9 acetylation | 1 | 7 | 5.48e-01 |
| GO:BP | GO:2000310 | regulation of NMDA receptor activity | 2 | 19 | 5.48e-01 |
| GO:BP | GO:0031109 | microtubule polymerization or depolymerization | 6 | 119 | 5.48e-01 |
| GO:BP | GO:0015074 | DNA integration | 1 | 9 | 5.48e-01 |
| GO:BP | GO:0060174 | limb bud formation | 1 | 10 | 5.48e-01 |
| GO:BP | GO:0050819 | negative regulation of coagulation | 1 | 38 | 5.48e-01 |
| GO:BP | GO:0015986 | proton motive force-driven ATP synthesis | 1 | 66 | 5.48e-01 |
| GO:BP | GO:0032409 | regulation of transporter activity | 1 | 211 | 5.48e-01 |
| GO:BP | GO:0060966 | regulation of gene silencing by RNA | 1 | 29 | 5.48e-01 |
| GO:BP | GO:1903069 | regulation of ER-associated ubiquitin-dependent protein catabolic process | 1 | 10 | 5.48e-01 |
| GO:BP | GO:0045087 | innate immune response | 1 | 488 | 5.48e-01 |
| GO:BP | GO:0072528 | pyrimidine-containing compound biosynthetic process | 2 | 33 | 5.48e-01 |
| GO:BP | GO:0032347 | regulation of aldosterone biosynthetic process | 1 | 8 | 5.48e-01 |
| GO:BP | GO:1901861 | regulation of muscle tissue development | 3 | 35 | 5.48e-01 |
| GO:BP | GO:0051338 | regulation of transferase activity | 1 | 679 | 5.48e-01 |
| GO:BP | GO:0032344 | regulation of aldosterone metabolic process | 1 | 8 | 5.48e-01 |
| GO:BP | GO:0002732 | positive regulation of dendritic cell cytokine production | 1 | 8 | 5.48e-01 |
| GO:BP | GO:1990253 | cellular response to leucine starvation | 1 | 13 | 5.48e-01 |
| GO:BP | GO:0051053 | negative regulation of DNA metabolic process | 5 | 112 | 5.49e-01 |
| GO:BP | GO:0045023 | G0 to G1 transition | 3 | 35 | 5.49e-01 |
| GO:BP | GO:0050000 | chromosome localization | 4 | 82 | 5.49e-01 |
| GO:BP | GO:0032781 | positive regulation of ATP-dependent activity | 4 | 40 | 5.49e-01 |
| GO:BP | GO:0060831 | smoothened signaling pathway involved in dorsal/ventral neural tube patterning | 1 | 14 | 5.49e-01 |
| GO:BP | GO:0097646 | calcitonin family receptor signaling pathway | 1 | 4 | 5.49e-01 |
| GO:BP | GO:0000098 | sulfur amino acid catabolic process | 1 | 7 | 5.50e-01 |
| GO:BP | GO:0072203 | cell proliferation involved in metanephros development | 1 | 8 | 5.50e-01 |
| GO:BP | GO:0014856 | skeletal muscle cell proliferation | 1 | 14 | 5.50e-01 |
| GO:BP | GO:0090091 | positive regulation of extracellular matrix disassembly | 1 | 6 | 5.50e-01 |
| GO:BP | GO:0036353 | histone H2A-K119 monoubiquitination | 1 | 8 | 5.50e-01 |
| GO:BP | GO:0002834 | regulation of response to tumor cell | 2 | 11 | 5.50e-01 |
| GO:BP | GO:0010522 | regulation of calcium ion transport into cytosol | 2 | 10 | 5.51e-01 |
| GO:BP | GO:0048732 | gland development | 3 | 318 | 5.51e-01 |
| GO:BP | GO:0036166 | phenotypic switching | 1 | 7 | 5.51e-01 |
| GO:BP | GO:0060135 | maternal process involved in female pregnancy | 3 | 41 | 5.52e-01 |
| GO:BP | GO:0010038 | response to metal ion | 16 | 264 | 5.52e-01 |
| GO:BP | GO:0019369 | arachidonic acid metabolic process | 1 | 26 | 5.52e-01 |
| GO:BP | GO:0046854 | phosphatidylinositol phosphate biosynthetic process | 1 | 59 | 5.52e-01 |
| GO:BP | GO:0042692 | muscle cell differentiation | 25 | 324 | 5.52e-01 |
| GO:BP | GO:0000132 | establishment of mitotic spindle orientation | 1 | 31 | 5.52e-01 |
| GO:BP | GO:0009438 | methylglyoxal metabolic process | 1 | 7 | 5.52e-01 |
| GO:BP | GO:0071313 | cellular response to caffeine | 1 | 10 | 5.52e-01 |
| GO:BP | GO:0032880 | regulation of protein localization | 1 | 710 | 5.52e-01 |
| GO:BP | GO:0001503 | ossification | 1 | 313 | 5.52e-01 |
| GO:BP | GO:0051145 | smooth muscle cell differentiation | 2 | 54 | 5.52e-01 |
| GO:BP | GO:0006490 | oligosaccharide-lipid intermediate biosynthetic process | 1 | 21 | 5.52e-01 |
| GO:BP | GO:0051661 | maintenance of centrosome location | 1 | 6 | 5.52e-01 |
| GO:BP | GO:0099566 | regulation of postsynaptic cytosolic calcium ion concentration | 1 | 6 | 5.52e-01 |
| GO:BP | GO:2000641 | regulation of early endosome to late endosome transport | 2 | 17 | 5.53e-01 |
| GO:BP | GO:0021587 | cerebellum morphogenesis | 1 | 36 | 5.53e-01 |
| GO:BP | GO:0060389 | pathway-restricted SMAD protein phosphorylation | 1 | 55 | 5.53e-01 |
| GO:BP | GO:1905098 | negative regulation of guanyl-nucleotide exchange factor activity | 1 | 6 | 5.53e-01 |
| GO:BP | GO:0050746 | regulation of lipoprotein metabolic process | 2 | 15 | 5.53e-01 |
| GO:BP | GO:0061003 | positive regulation of dendritic spine morphogenesis | 2 | 17 | 5.53e-01 |
| GO:BP | GO:0001912 | positive regulation of leukocyte mediated cytotoxicity | 3 | 20 | 5.53e-01 |
| GO:BP | GO:0043030 | regulation of macrophage activation | 3 | 31 | 5.53e-01 |
| GO:BP | GO:0060054 | positive regulation of epithelial cell proliferation involved in wound healing | 1 | 5 | 5.53e-01 |
| GO:BP | GO:0071731 | response to nitric oxide | 2 | 16 | 5.53e-01 |
| GO:BP | GO:0010623 | programmed cell death involved in cell development | 1 | 13 | 5.53e-01 |
| GO:BP | GO:0007173 | epidermal growth factor receptor signaling pathway | 7 | 93 | 5.53e-01 |
| GO:BP | GO:0035767 | endothelial cell chemotaxis | 1 | 23 | 5.53e-01 |
| GO:BP | GO:0048562 | embryonic organ morphogenesis | 16 | 187 | 5.53e-01 |
| GO:BP | GO:0001909 | leukocyte mediated cytotoxicity | 5 | 54 | 5.53e-01 |
| GO:BP | GO:0071393 | cellular response to progesterone stimulus | 1 | 5 | 5.53e-01 |
| GO:BP | GO:0007096 | regulation of exit from mitosis | 2 | 17 | 5.54e-01 |
| GO:BP | GO:1905939 | regulation of gonad development | 1 | 8 | 5.54e-01 |
| GO:BP | GO:0070172 | positive regulation of tooth mineralization | 1 | 2 | 5.54e-01 |
| GO:BP | GO:0019221 | cytokine-mediated signaling pathway | 1 | 274 | 5.54e-01 |
| GO:BP | GO:0071872 | cellular response to epinephrine stimulus | 1 | 10 | 5.54e-01 |
| GO:BP | GO:0006744 | ubiquinone biosynthetic process | 1 | 17 | 5.54e-01 |
| GO:BP | GO:1901663 | quinone biosynthetic process | 1 | 17 | 5.54e-01 |
| GO:BP | GO:0035116 | embryonic hindlimb morphogenesis | 1 | 17 | 5.54e-01 |
| GO:BP | GO:0002248 | connective tissue replacement involved in inflammatory response wound healing | 1 | 4 | 5.54e-01 |
| GO:BP | GO:1901164 | negative regulation of trophoblast cell migration | 1 | 4 | 5.54e-01 |
| GO:BP | GO:0031175 | neuron projection development | 6 | 780 | 5.54e-01 |
| GO:BP | GO:0097210 | response to gonadotropin-releasing hormone | 1 | 4 | 5.54e-01 |
| GO:BP | GO:0035524 | proline transmembrane transport | 1 | 8 | 5.55e-01 |
| GO:BP | GO:0042996 | regulation of Golgi to plasma membrane protein transport | 1 | 9 | 5.55e-01 |
| GO:BP | GO:0033344 | cholesterol efflux | 1 | 40 | 5.55e-01 |
| GO:BP | GO:0071481 | cellular response to X-ray | 1 | 10 | 5.55e-01 |
| GO:BP | GO:0048251 | elastic fiber assembly | 1 | 12 | 5.55e-01 |
| GO:BP | GO:0051963 | regulation of synapse assembly | 10 | 83 | 5.55e-01 |
| GO:BP | GO:0044248 | cellular catabolic process | 1 | 1229 | 5.55e-01 |
| GO:BP | GO:0030225 | macrophage differentiation | 1 | 35 | 5.55e-01 |
| GO:BP | GO:0090317 | negative regulation of intracellular protein transport | 4 | 37 | 5.55e-01 |
| GO:BP | GO:0035372 | protein localization to microtubule | 1 | 18 | 5.55e-01 |
| GO:BP | GO:0014870 | response to muscle inactivity | 1 | 9 | 5.55e-01 |
| GO:BP | GO:0042440 | pigment metabolic process | 1 | 60 | 5.55e-01 |
| GO:BP | GO:0021700 | developmental maturation | 17 | 211 | 5.55e-01 |
| GO:BP | GO:0006024 | glycosaminoglycan biosynthetic process | 2 | 60 | 5.55e-01 |
| GO:BP | GO:0033598 | mammary gland epithelial cell proliferation | 1 | 23 | 5.55e-01 |
| GO:BP | GO:1901617 | organic hydroxy compound biosynthetic process | 10 | 172 | 5.55e-01 |
| GO:BP | GO:0099068 | postsynapse assembly | 4 | 32 | 5.55e-01 |
| GO:BP | GO:1903318 | negative regulation of protein maturation | 3 | 19 | 5.56e-01 |
| GO:BP | GO:0010955 | negative regulation of protein processing | 3 | 19 | 5.56e-01 |
| GO:BP | GO:0060142 | regulation of syncytium formation by plasma membrane fusion | 1 | 15 | 5.56e-01 |
| GO:BP | GO:0006616 | SRP-dependent cotranslational protein targeting to membrane, translocation | 1 | 8 | 5.56e-01 |
| GO:BP | GO:1904779 | regulation of protein localization to centrosome | 1 | 10 | 5.57e-01 |
| GO:BP | GO:0007252 | I-kappaB phosphorylation | 1 | 14 | 5.57e-01 |
| GO:BP | GO:0070265 | necrotic cell death | 4 | 53 | 5.57e-01 |
| GO:BP | GO:0051302 | regulation of cell division | 2 | 145 | 5.57e-01 |
| GO:BP | GO:0032261 | purine nucleotide salvage | 1 | 10 | 5.57e-01 |
| GO:BP | GO:0009120 | deoxyribonucleoside metabolic process | 1 | 9 | 5.57e-01 |
| GO:BP | GO:0001787 | natural killer cell proliferation | 1 | 6 | 5.57e-01 |
| GO:BP | GO:0031023 | microtubule organizing center organization | 3 | 137 | 5.57e-01 |
| GO:BP | GO:0003091 | renal water homeostasis | 1 | 13 | 5.58e-01 |
| GO:BP | GO:0035672 | oligopeptide transmembrane transport | 1 | 5 | 5.58e-01 |
| GO:BP | GO:0006857 | oligopeptide transport | 1 | 5 | 5.58e-01 |
| GO:BP | GO:0030073 | insulin secretion | 4 | 141 | 5.58e-01 |
| GO:BP | GO:0050777 | negative regulation of immune response | 6 | 111 | 5.58e-01 |
| GO:BP | GO:0043277 | apoptotic cell clearance | 2 | 35 | 5.58e-01 |
| GO:BP | GO:0048514 | blood vessel morphogenesis | 18 | 462 | 5.58e-01 |
| GO:BP | GO:1904355 | positive regulation of telomere capping | 1 | 14 | 5.58e-01 |
| GO:BP | GO:0060420 | regulation of heart growth | 2 | 50 | 5.58e-01 |
| GO:BP | GO:1902275 | regulation of chromatin organization | 1 | 49 | 5.58e-01 |
| GO:BP | GO:1901385 | regulation of voltage-gated calcium channel activity | 4 | 29 | 5.58e-01 |
| GO:BP | GO:1902075 | cellular response to salt | 9 | 142 | 5.58e-01 |
| GO:BP | GO:0001836 | release of cytochrome c from mitochondria | 2 | 47 | 5.58e-01 |
| GO:BP | GO:0006002 | fructose 6-phosphate metabolic process | 1 | 8 | 5.58e-01 |
| GO:BP | GO:0010359 | regulation of anion channel activity | 1 | 5 | 5.58e-01 |
| GO:BP | GO:0070129 | regulation of mitochondrial translation | 2 | 26 | 5.58e-01 |
| GO:BP | GO:0036089 | cleavage furrow formation | 1 | 7 | 5.58e-01 |
| GO:BP | GO:0018394 | peptidyl-lysine acetylation | 3 | 160 | 5.58e-01 |
| GO:BP | GO:0043308 | eosinophil degranulation | 1 | 4 | 5.59e-01 |
| GO:BP | GO:0002278 | eosinophil activation involved in immune response | 1 | 4 | 5.59e-01 |
| GO:BP | GO:1903367 | positive regulation of fear response | 1 | 4 | 5.59e-01 |
| GO:BP | GO:0098780 | response to mitochondrial depolarisation | 2 | 21 | 5.59e-01 |
| GO:BP | GO:0051294 | establishment of spindle orientation | 3 | 36 | 5.60e-01 |
| GO:BP | GO:2001237 | negative regulation of extrinsic apoptotic signaling pathway | 2 | 78 | 5.60e-01 |
| GO:BP | GO:0061049 | cell growth involved in cardiac muscle cell development | 2 | 19 | 5.60e-01 |
| GO:BP | GO:0003298 | physiological muscle hypertrophy | 2 | 19 | 5.60e-01 |
| GO:BP | GO:0003301 | physiological cardiac muscle hypertrophy | 2 | 19 | 5.60e-01 |
| GO:BP | GO:1905564 | positive regulation of vascular endothelial cell proliferation | 1 | 15 | 5.60e-01 |
| GO:BP | GO:0021695 | cerebellar cortex development | 2 | 44 | 5.60e-01 |
| GO:BP | GO:0060219 | camera-type eye photoreceptor cell differentiation | 3 | 18 | 5.61e-01 |
| GO:BP | GO:0048645 | animal organ formation | 3 | 51 | 5.61e-01 |
| GO:BP | GO:0071397 | cellular response to cholesterol | 1 | 11 | 5.61e-01 |
| GO:BP | GO:0061640 | cytoskeleton-dependent cytokinesis | 5 | 104 | 5.61e-01 |
| GO:BP | GO:0003416 | endochondral bone growth | 1 | 23 | 5.61e-01 |
| GO:BP | GO:2000116 | regulation of cysteine-type endopeptidase activity | 7 | 169 | 5.61e-01 |
| GO:BP | GO:0007389 | pattern specification process | 5 | 306 | 5.61e-01 |
| GO:BP | GO:0060512 | prostate gland morphogenesis | 1 | 21 | 5.61e-01 |
| GO:BP | GO:0038034 | signal transduction in absence of ligand | 4 | 52 | 5.61e-01 |
| GO:BP | GO:0097192 | extrinsic apoptotic signaling pathway in absence of ligand | 4 | 52 | 5.61e-01 |
| GO:BP | GO:0050776 | regulation of immune response | 1 | 484 | 5.61e-01 |
| GO:BP | GO:0044691 | tooth eruption | 1 | 5 | 5.61e-01 |
| GO:BP | GO:0086005 | ventricular cardiac muscle cell action potential | 1 | 29 | 5.61e-01 |
| GO:BP | GO:2000515 | negative regulation of CD4-positive, alpha-beta T cell activation | 3 | 21 | 5.61e-01 |
| GO:BP | GO:0021932 | hindbrain radial glia guided cell migration | 1 | 8 | 5.61e-01 |
| GO:BP | GO:1903299 | regulation of hexokinase activity | 1 | 8 | 5.61e-01 |
| GO:BP | GO:2000351 | regulation of endothelial cell apoptotic process | 3 | 35 | 5.62e-01 |
| GO:BP | GO:0051897 | positive regulation of protein kinase B signaling | 1 | 79 | 5.62e-01 |
| GO:BP | GO:0007281 | germ cell development | 2 | 187 | 5.62e-01 |
| GO:BP | GO:0016556 | mRNA modification | 3 | 29 | 5.62e-01 |
| GO:BP | GO:0002666 | positive regulation of T cell tolerance induction | 1 | 4 | 5.62e-01 |
| GO:BP | GO:0043462 | regulation of ATP-dependent activity | 6 | 63 | 5.62e-01 |
| GO:BP | GO:0035860 | glial cell-derived neurotrophic factor receptor signaling pathway | 1 | 6 | 5.62e-01 |
| GO:BP | GO:0010629 | negative regulation of gene expression | 1 | 785 | 5.63e-01 |
| GO:BP | GO:0051050 | positive regulation of transport | 1 | 667 | 5.63e-01 |
| GO:BP | GO:0008610 | lipid biosynthetic process | 15 | 560 | 5.63e-01 |
| GO:BP | GO:0051262 | protein tetramerization | 1 | 64 | 5.63e-01 |
| GO:BP | GO:0006163 | purine nucleotide metabolic process | 1 | 371 | 5.63e-01 |
| GO:BP | GO:0010761 | fibroblast migration | 3 | 52 | 5.63e-01 |
| GO:BP | GO:0098698 | postsynaptic specialization assembly | 3 | 23 | 5.63e-01 |
| GO:BP | GO:0043084 | penile erection | 1 | 6 | 5.64e-01 |
| GO:BP | GO:0043954 | cellular component maintenance | 5 | 59 | 5.64e-01 |
| GO:BP | GO:0035561 | regulation of chromatin binding | 1 | 20 | 5.64e-01 |
| GO:BP | GO:0002861 | regulation of inflammatory response to antigenic stimulus | 1 | 24 | 5.64e-01 |
| GO:BP | GO:0043201 | response to leucine | 1 | 13 | 5.65e-01 |
| GO:BP | GO:1903651 | positive regulation of cytoplasmic transport | 1 | 11 | 5.66e-01 |
| GO:BP | GO:0006551 | leucine metabolic process | 1 | 8 | 5.66e-01 |
| GO:BP | GO:0061303 | cornea development in camera-type eye | 1 | 4 | 5.66e-01 |
| GO:BP | GO:0008593 | regulation of Notch signaling pathway | 3 | 78 | 5.67e-01 |
| GO:BP | GO:0050798 | activated T cell proliferation | 3 | 25 | 5.67e-01 |
| GO:BP | GO:0045730 | respiratory burst | 2 | 21 | 5.67e-01 |
| GO:BP | GO:0021575 | hindbrain morphogenesis | 1 | 38 | 5.67e-01 |
| GO:BP | GO:0090201 | negative regulation of release of cytochrome c from mitochondria | 2 | 18 | 5.69e-01 |
| GO:BP | GO:1900744 | regulation of p38MAPK cascade | 2 | 32 | 5.69e-01 |
| GO:BP | GO:0051000 | positive regulation of nitric-oxide synthase activity | 1 | 14 | 5.69e-01 |
| GO:BP | GO:0015718 | monocarboxylic acid transport | 1 | 90 | 5.70e-01 |
| GO:BP | GO:0071895 | odontoblast differentiation | 1 | 5 | 5.70e-01 |
| GO:BP | GO:0097187 | dentinogenesis | 1 | 4 | 5.70e-01 |
| GO:BP | GO:1901386 | negative regulation of voltage-gated calcium channel activity | 2 | 13 | 5.70e-01 |
| GO:BP | GO:0046512 | sphingosine biosynthetic process | 1 | 13 | 5.70e-01 |
| GO:BP | GO:0046520 | sphingoid biosynthetic process | 1 | 13 | 5.70e-01 |
| GO:BP | GO:0019321 | pentose metabolic process | 1 | 9 | 5.70e-01 |
| GO:BP | GO:0035335 | peptidyl-tyrosine dephosphorylation | 1 | 26 | 5.71e-01 |
| GO:BP | GO:0021953 | central nervous system neuron differentiation | 3 | 108 | 5.71e-01 |
| GO:BP | GO:0051639 | actin filament network formation | 1 | 7 | 5.71e-01 |
| GO:BP | GO:1901838 | positive regulation of transcription of nucleolar large rRNA by RNA polymerase I | 1 | 10 | 5.72e-01 |
| GO:BP | GO:1905462 | regulation of DNA duplex unwinding | 1 | 7 | 5.72e-01 |
| GO:BP | GO:0090239 | regulation of histone H4 acetylation | 1 | 10 | 5.72e-01 |
| GO:BP | GO:0043970 | histone H3-K9 acetylation | 1 | 8 | 5.72e-01 |
| GO:BP | GO:0061548 | ganglion development | 1 | 12 | 5.72e-01 |
| GO:BP | GO:0051096 | positive regulation of helicase activity | 1 | 7 | 5.72e-01 |
| GO:BP | GO:0045005 | DNA-templated DNA replication maintenance of fidelity | 2 | 48 | 5.72e-01 |
| GO:BP | GO:0006356 | regulation of transcription by RNA polymerase I | 3 | 45 | 5.72e-01 |
| GO:BP | GO:0031663 | lipopolysaccharide-mediated signaling pathway | 4 | 36 | 5.72e-01 |
| GO:BP | GO:0099563 | modification of synaptic structure | 1 | 24 | 5.72e-01 |
| GO:BP | GO:1903322 | positive regulation of protein modification by small protein conjugation or removal | 10 | 126 | 5.72e-01 |
| GO:BP | GO:0051085 | chaperone cofactor-dependent protein refolding | 3 | 30 | 5.72e-01 |
| GO:BP | GO:0043457 | regulation of cellular respiration | 1 | 42 | 5.73e-01 |
| GO:BP | GO:0002360 | T cell lineage commitment | 1 | 15 | 5.73e-01 |
| GO:BP | GO:0048762 | mesenchymal cell differentiation | 15 | 204 | 5.73e-01 |
| GO:BP | GO:0044804 | autophagy of nucleus | 2 | 18 | 5.73e-01 |
| GO:BP | GO:0055091 | phospholipid homeostasis | 1 | 12 | 5.73e-01 |
| GO:BP | GO:0033147 | negative regulation of intracellular estrogen receptor signaling pathway | 1 | 11 | 5.74e-01 |
| GO:BP | GO:0007166 | cell surface receptor signaling pathway | 4 | 1898 | 5.74e-01 |
| GO:BP | GO:0021545 | cranial nerve development | 1 | 31 | 5.74e-01 |
| GO:BP | GO:0035089 | establishment of apical/basal cell polarity | 1 | 18 | 5.75e-01 |
| GO:BP | GO:0001967 | suckling behavior | 1 | 10 | 5.75e-01 |
| GO:BP | GO:1905806 | regulation of synapse pruning | 1 | 5 | 5.75e-01 |
| GO:BP | GO:0023041 | neuronal signal transduction | 1 | 6 | 5.75e-01 |
| GO:BP | GO:0019538 | protein metabolic process | 1 | 4241 | 5.75e-01 |
| GO:BP | GO:0000380 | alternative mRNA splicing, via spliceosome | 5 | 70 | 5.75e-01 |
| GO:BP | GO:0070498 | interleukin-1-mediated signaling pathway | 2 | 20 | 5.75e-01 |
| GO:BP | GO:0033120 | positive regulation of RNA splicing | 2 | 34 | 5.75e-01 |
| GO:BP | GO:0045017 | glycerolipid biosynthetic process | 4 | 218 | 5.75e-01 |
| GO:BP | GO:0046325 | negative regulation of glucose import | 1 | 10 | 5.75e-01 |
| GO:BP | GO:0030510 | regulation of BMP signaling pathway | 1 | 84 | 5.75e-01 |
| GO:BP | GO:0006206 | pyrimidine nucleobase metabolic process | 1 | 13 | 5.75e-01 |
| GO:BP | GO:0007566 | embryo implantation | 5 | 39 | 5.75e-01 |
| GO:BP | GO:0060710 | chorio-allantoic fusion | 1 | 6 | 5.75e-01 |
| GO:BP | GO:0043304 | regulation of mast cell degranulation | 2 | 20 | 5.75e-01 |
| GO:BP | GO:0038061 | NIK/NF-kappaB signaling | 5 | 86 | 5.75e-01 |
| GO:BP | GO:0015808 | L-alanine transport | 1 | 9 | 5.75e-01 |
| GO:BP | GO:0050665 | hydrogen peroxide biosynthetic process | 1 | 11 | 5.75e-01 |
| GO:BP | GO:0060306 | regulation of membrane repolarization | 1 | 28 | 5.75e-01 |
| GO:BP | GO:0070778 | L-aspartate transmembrane transport | 1 | 11 | 5.75e-01 |
| GO:BP | GO:0006940 | regulation of smooth muscle contraction | 1 | 42 | 5.75e-01 |
| GO:BP | GO:0032329 | serine transport | 1 | 10 | 5.75e-01 |
| GO:BP | GO:1902074 | response to salt | 1 | 271 | 5.75e-01 |
| GO:BP | GO:0050892 | intestinal absorption | 3 | 22 | 5.76e-01 |
| GO:BP | GO:0042249 | establishment of planar polarity of embryonic epithelium | 1 | 15 | 5.76e-01 |
| GO:BP | GO:2000243 | positive regulation of reproductive process | 5 | 54 | 5.76e-01 |
| GO:BP | GO:1905508 | protein localization to microtubule organizing center | 3 | 33 | 5.76e-01 |
| GO:BP | GO:0006023 | aminoglycan biosynthetic process | 2 | 63 | 5.76e-01 |
| GO:BP | GO:0048524 | positive regulation of viral process | 5 | 55 | 5.76e-01 |
| GO:BP | GO:0014741 | negative regulation of muscle hypertrophy | 2 | 27 | 5.76e-01 |
| GO:BP | GO:0032897 | negative regulation of viral transcription | 1 | 15 | 5.76e-01 |
| GO:BP | GO:0086010 | membrane depolarization during action potential | 1 | 28 | 5.76e-01 |
| GO:BP | GO:0031401 | positive regulation of protein modification process | 1 | 719 | 5.76e-01 |
| GO:BP | GO:0048854 | brain morphogenesis | 1 | 28 | 5.76e-01 |
| GO:BP | GO:2000822 | regulation of behavioral fear response | 1 | 7 | 5.77e-01 |
| GO:BP | GO:0036010 | protein localization to endosome | 1 | 26 | 5.77e-01 |
| GO:BP | GO:0008300 | isoprenoid catabolic process | 1 | 5 | 5.77e-01 |
| GO:BP | GO:0070861 | regulation of protein exit from endoplasmic reticulum | 1 | 22 | 5.77e-01 |
| GO:BP | GO:1990776 | response to angiotensin | 2 | 24 | 5.77e-01 |
| GO:BP | GO:0071073 | positive regulation of phospholipid biosynthetic process | 1 | 7 | 5.77e-01 |
| GO:BP | GO:0060325 | face morphogenesis | 3 | 28 | 5.78e-01 |
| GO:BP | GO:0051174 | regulation of phosphorus metabolic process | 2 | 994 | 5.78e-01 |
| GO:BP | GO:0019220 | regulation of phosphate metabolic process | 2 | 993 | 5.78e-01 |
| GO:BP | GO:0061037 | negative regulation of cartilage development | 1 | 23 | 5.78e-01 |
| GO:BP | GO:0051641 | cellular localization | 4 | 2810 | 5.78e-01 |
| GO:BP | GO:0002467 | germinal center formation | 1 | 10 | 5.78e-01 |
| GO:BP | GO:1904062 | regulation of monoatomic cation transmembrane transport | 1 | 230 | 5.78e-01 |
| GO:BP | GO:0002181 | cytoplasmic translation | 1 | 156 | 5.78e-01 |
| GO:BP | GO:0019098 | reproductive behavior | 3 | 26 | 5.78e-01 |
| GO:BP | GO:0006655 | phosphatidylglycerol biosynthetic process | 1 | 9 | 5.78e-01 |
| GO:BP | GO:0010592 | positive regulation of lamellipodium assembly | 2 | 25 | 5.78e-01 |
| GO:BP | GO:2000671 | regulation of motor neuron apoptotic process | 1 | 12 | 5.78e-01 |
| GO:BP | GO:0016126 | sterol biosynthetic process | 2 | 52 | 5.78e-01 |
| GO:BP | GO:0032435 | negative regulation of proteasomal ubiquitin-dependent protein catabolic process | 2 | 35 | 5.78e-01 |
| GO:BP | GO:1903010 | regulation of bone development | 1 | 6 | 5.78e-01 |
| GO:BP | GO:0050727 | regulation of inflammatory response | 26 | 212 | 5.79e-01 |
| GO:BP | GO:0060341 | regulation of cellular localization | 1 | 798 | 5.79e-01 |
| GO:BP | GO:0120255 | olefinic compound biosynthetic process | 2 | 17 | 5.79e-01 |
| GO:BP | GO:0071379 | cellular response to prostaglandin stimulus | 1 | 16 | 5.79e-01 |
| GO:BP | GO:0006743 | ubiquinone metabolic process | 1 | 19 | 5.79e-01 |
| GO:BP | GO:0009081 | branched-chain amino acid metabolic process | 1 | 26 | 5.79e-01 |
| GO:BP | GO:0036438 | maintenance of lens transparency | 1 | 6 | 5.79e-01 |
| GO:BP | GO:0062207 | regulation of pattern recognition receptor signaling pathway | 4 | 68 | 5.79e-01 |
| GO:BP | GO:0008334 | histone mRNA metabolic process | 2 | 21 | 5.80e-01 |
| GO:BP | GO:0042985 | negative regulation of amyloid precursor protein biosynthetic process | 1 | 7 | 5.80e-01 |
| GO:BP | GO:0055023 | positive regulation of cardiac muscle tissue growth | 1 | 24 | 5.80e-01 |
| GO:BP | GO:0044771 | meiotic cell cycle phase transition | 1 | 7 | 5.80e-01 |
| GO:BP | GO:0071028 | nuclear mRNA surveillance | 1 | 10 | 5.81e-01 |
| GO:BP | GO:0045671 | negative regulation of osteoclast differentiation | 3 | 20 | 5.81e-01 |
| GO:BP | GO:1900272 | negative regulation of long-term synaptic potentiation | 1 | 8 | 5.81e-01 |
| GO:BP | GO:0045061 | thymic T cell selection | 1 | 10 | 5.81e-01 |
| GO:BP | GO:0015872 | dopamine transport | 1 | 29 | 5.81e-01 |
| GO:BP | GO:1902950 | regulation of dendritic spine maintenance | 1 | 7 | 5.81e-01 |
| GO:BP | GO:1903959 | regulation of monoatomic anion transmembrane transport | 1 | 6 | 5.81e-01 |
| GO:BP | GO:0071314 | cellular response to cocaine | 1 | 7 | 5.81e-01 |
| GO:BP | GO:0007167 | enzyme-linked receptor protein signaling pathway | 1 | 763 | 5.81e-01 |
| GO:BP | GO:0002840 | regulation of T cell mediated immune response to tumor cell | 1 | 5 | 5.81e-01 |
| GO:BP | GO:0010960 | magnesium ion homeostasis | 1 | 9 | 5.81e-01 |
| GO:BP | GO:0043331 | response to dsRNA | 3 | 33 | 5.81e-01 |
| GO:BP | GO:0031077 | post-embryonic camera-type eye development | 1 | 7 | 5.81e-01 |
| GO:BP | GO:0046596 | regulation of viral entry into host cell | 1 | 32 | 5.81e-01 |
| GO:BP | GO:1903896 | positive regulation of IRE1-mediated unfolded protein response | 1 | 7 | 5.81e-01 |
| GO:BP | GO:0048050 | post-embryonic eye morphogenesis | 1 | 7 | 5.81e-01 |
| GO:BP | GO:0006776 | vitamin A metabolic process | 1 | 3 | 5.81e-01 |
| GO:BP | GO:0098962 | regulation of postsynaptic neurotransmitter receptor activity | 1 | 12 | 5.82e-01 |
| GO:BP | GO:0098927 | vesicle-mediated transport between endosomal compartments | 4 | 42 | 5.82e-01 |
| GO:BP | GO:1904705 | regulation of vascular associated smooth muscle cell proliferation | 1 | 53 | 5.82e-01 |
| GO:BP | GO:0019532 | oxalate transport | 1 | 5 | 5.82e-01 |
| GO:BP | GO:0009892 | negative regulation of metabolic process | 5 | 2293 | 5.83e-01 |
| GO:BP | GO:0046474 | glycerophospholipid biosynthetic process | 3 | 189 | 5.83e-01 |
| GO:BP | GO:1902533 | positive regulation of intracellular signal transduction | 1 | 726 | 5.83e-01 |
| GO:BP | GO:0006883 | intracellular sodium ion homeostasis | 2 | 13 | 5.83e-01 |
| GO:BP | GO:0033540 | fatty acid beta-oxidation using acyl-CoA oxidase | 1 | 12 | 5.83e-01 |
| GO:BP | GO:0098719 | sodium ion import across plasma membrane | 2 | 14 | 5.83e-01 |
| GO:BP | GO:0051701 | biological process involved in interaction with host | 10 | 154 | 5.83e-01 |
| GO:BP | GO:0001569 | branching involved in blood vessel morphogenesis | 3 | 29 | 5.83e-01 |
| GO:BP | GO:0010644 | cell communication by electrical coupling | 2 | 31 | 5.83e-01 |
| GO:BP | GO:2001258 | negative regulation of cation channel activity | 4 | 30 | 5.84e-01 |
| GO:BP | GO:1903980 | positive regulation of microglial cell activation | 1 | 2 | 5.84e-01 |
| GO:BP | GO:0019935 | cyclic-nucleotide-mediated signaling | 2 | 55 | 5.84e-01 |
| GO:BP | GO:2001267 | regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway | 1 | 13 | 5.84e-01 |
| GO:BP | GO:0010759 | positive regulation of macrophage chemotaxis | 1 | 9 | 5.84e-01 |
| GO:BP | GO:0046834 | lipid phosphorylation | 1 | 16 | 5.84e-01 |
| GO:BP | GO:0010243 | response to organonitrogen compound | 2 | 782 | 5.84e-01 |
| GO:BP | GO:0042181 | ketone biosynthetic process | 2 | 37 | 5.84e-01 |
| GO:BP | GO:0051248 | negative regulation of protein metabolic process | 1 | 816 | 5.84e-01 |
| GO:BP | GO:0098868 | bone growth | 1 | 24 | 5.84e-01 |
| GO:BP | GO:0019646 | aerobic electron transport chain | 1 | 74 | 5.84e-01 |
| GO:BP | GO:0051785 | positive regulation of nuclear division | 3 | 38 | 5.84e-01 |
| GO:BP | GO:0030851 | granulocyte differentiation | 1 | 27 | 5.84e-01 |
| GO:BP | GO:0008544 | epidermis development | 2 | 210 | 5.84e-01 |
| GO:BP | GO:0002831 | regulation of response to biotic stimulus | 25 | 293 | 5.84e-01 |
| GO:BP | GO:0006644 | phospholipid metabolic process | 2 | 316 | 5.85e-01 |
| GO:BP | GO:0032836 | glomerular basement membrane development | 1 | 9 | 5.85e-01 |
| GO:BP | GO:0048608 | reproductive structure development | 9 | 212 | 5.85e-01 |
| GO:BP | GO:0006022 | aminoglycan metabolic process | 3 | 93 | 5.85e-01 |
| GO:BP | GO:0009396 | folic acid-containing compound biosynthetic process | 1 | 7 | 5.85e-01 |
| GO:BP | GO:0001764 | neuron migration | 3 | 133 | 5.85e-01 |
| GO:BP | GO:0031145 | anaphase-promoting complex-dependent catabolic process | 2 | 23 | 5.85e-01 |
| GO:BP | GO:1990504 | dense core granule exocytosis | 1 | 7 | 5.85e-01 |
| GO:BP | GO:0042760 | very long-chain fatty acid catabolic process | 1 | 5 | 5.85e-01 |
| GO:BP | GO:0048521 | negative regulation of behavior | 1 | 5 | 5.86e-01 |
| GO:BP | GO:0010950 | positive regulation of endopeptidase activity | 2 | 126 | 5.86e-01 |
| GO:BP | GO:0031115 | negative regulation of microtubule polymerization | 1 | 13 | 5.86e-01 |
| GO:BP | GO:0045321 | leukocyte activation | 1 | 554 | 5.86e-01 |
| GO:BP | GO:0040001 | establishment of mitotic spindle localization | 1 | 36 | 5.86e-01 |
| GO:BP | GO:0045579 | positive regulation of B cell differentiation | 1 | 10 | 5.86e-01 |
| GO:BP | GO:0042448 | progesterone metabolic process | 1 | 13 | 5.86e-01 |
| GO:BP | GO:0008344 | adult locomotory behavior | 4 | 60 | 5.86e-01 |
| GO:BP | GO:0008216 | spermidine metabolic process | 1 | 7 | 5.86e-01 |
| GO:BP | GO:0016486 | peptide hormone processing | 1 | 27 | 5.87e-01 |
| GO:BP | GO:0035304 | regulation of protein dephosphorylation | 1 | 75 | 5.87e-01 |
| GO:BP | GO:1900180 | regulation of protein localization to nucleus | 4 | 117 | 5.87e-01 |
| GO:BP | GO:0003009 | skeletal muscle contraction | 2 | 31 | 5.88e-01 |
| GO:BP | GO:0006401 | RNA catabolic process | 11 | 256 | 5.88e-01 |
| GO:BP | GO:0099188 | postsynaptic cytoskeleton organization | 1 | 14 | 5.88e-01 |
| GO:BP | GO:0032008 | positive regulation of TOR signaling | 2 | 43 | 5.88e-01 |
| GO:BP | GO:0030070 | insulin processing | 1 | 6 | 5.88e-01 |
| GO:BP | GO:0048143 | astrocyte activation | 2 | 12 | 5.89e-01 |
| GO:BP | GO:0002376 | immune system process | 2 | 1447 | 5.89e-01 |
| GO:BP | GO:0009190 | cyclic nucleotide biosynthetic process | 2 | 14 | 5.89e-01 |
| GO:BP | GO:0032891 | negative regulation of organic acid transport | 1 | 17 | 5.89e-01 |
| GO:BP | GO:0003151 | outflow tract morphogenesis | 1 | 68 | 5.89e-01 |
| GO:BP | GO:0006939 | smooth muscle contraction | 7 | 75 | 5.89e-01 |
| GO:BP | GO:0032374 | regulation of cholesterol transport | 1 | 45 | 5.89e-01 |
| GO:BP | GO:0032371 | regulation of sterol transport | 1 | 45 | 5.89e-01 |
| GO:BP | GO:0035066 | positive regulation of histone acetylation | 2 | 25 | 5.89e-01 |
| GO:BP | GO:0031987 | locomotion involved in locomotory behavior | 1 | 9 | 5.89e-01 |
| GO:BP | GO:0007099 | centriole replication | 2 | 38 | 5.89e-01 |
| GO:BP | GO:0070231 | T cell apoptotic process | 2 | 39 | 5.89e-01 |
| GO:BP | GO:0010639 | negative regulation of organelle organization | 15 | 318 | 5.89e-01 |
| GO:BP | GO:0043535 | regulation of blood vessel endothelial cell migration | 3 | 75 | 5.89e-01 |
| GO:BP | GO:0021846 | cell proliferation in forebrain | 1 | 14 | 5.90e-01 |
| GO:BP | GO:0048469 | cell maturation | 11 | 108 | 5.90e-01 |
| GO:BP | GO:0006378 | mRNA polyadenylation | 4 | 39 | 5.90e-01 |
| GO:BP | GO:0098656 | monoatomic anion transmembrane transport | 9 | 71 | 5.90e-01 |
| GO:BP | GO:0001959 | regulation of cytokine-mediated signaling pathway | 3 | 117 | 5.90e-01 |
| GO:BP | GO:0003337 | mesenchymal to epithelial transition involved in metanephros morphogenesis | 1 | 8 | 5.90e-01 |
| GO:BP | GO:0061085 | regulation of histone H3-K27 methylation | 1 | 4 | 5.91e-01 |
| GO:BP | GO:0106070 | regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway | 1 | 11 | 5.91e-01 |
| GO:BP | GO:0010762 | regulation of fibroblast migration | 3 | 37 | 5.91e-01 |
| GO:BP | GO:0032970 | regulation of actin filament-based process | 15 | 340 | 5.92e-01 |
| GO:BP | GO:0032212 | positive regulation of telomere maintenance via telomerase | 3 | 31 | 5.92e-01 |
| GO:BP | GO:0009117 | nucleotide metabolic process | 1 | 423 | 5.92e-01 |
| GO:BP | GO:0006661 | phosphatidylinositol biosynthetic process | 2 | 119 | 5.92e-01 |
| GO:BP | GO:0070601 | centromeric sister chromatid cohesion | 1 | 11 | 5.93e-01 |
| GO:BP | GO:0060711 | labyrinthine layer development | 4 | 35 | 5.93e-01 |
| GO:BP | GO:0006260 | DNA replication | 8 | 255 | 5.93e-01 |
| GO:BP | GO:0009155 | purine deoxyribonucleotide catabolic process | 1 | 7 | 5.93e-01 |
| GO:BP | GO:0006544 | glycine metabolic process | 1 | 10 | 5.93e-01 |
| GO:BP | GO:0015824 | proline transport | 1 | 11 | 5.93e-01 |
| GO:BP | GO:0019985 | translesion synthesis | 1 | 24 | 5.93e-01 |
| GO:BP | GO:0061162 | establishment of monopolar cell polarity | 1 | 20 | 5.93e-01 |
| GO:BP | GO:0032088 | negative regulation of NF-kappaB transcription factor activity | 3 | 66 | 5.93e-01 |
| GO:BP | GO:0046112 | nucleobase biosynthetic process | 1 | 18 | 5.93e-01 |
| GO:BP | GO:0030859 | polarized epithelial cell differentiation | 1 | 19 | 5.93e-01 |
| GO:BP | GO:0003013 | circulatory system process | 3 | 447 | 5.93e-01 |
| GO:BP | GO:0046784 | viral mRNA export from host cell nucleus | 1 | 6 | 5.93e-01 |
| GO:BP | GO:0098761 | cellular response to interleukin-7 | 1 | 12 | 5.93e-01 |
| GO:BP | GO:0098760 | response to interleukin-7 | 1 | 12 | 5.93e-01 |
| GO:BP | GO:0001502 | cartilage condensation | 1 | 12 | 5.93e-01 |
| GO:BP | GO:0042554 | superoxide anion generation | 1 | 20 | 5.93e-01 |
| GO:BP | GO:0001556 | oocyte maturation | 2 | 22 | 5.93e-01 |
| GO:BP | GO:0002224 | toll-like receptor signaling pathway | 5 | 43 | 5.93e-01 |
| GO:BP | GO:0051665 | membrane raft localization | 1 | 4 | 5.94e-01 |
| GO:BP | GO:1905208 | negative regulation of cardiocyte differentiation | 1 | 11 | 5.94e-01 |
| GO:BP | GO:0050856 | regulation of T cell receptor signaling pathway | 3 | 30 | 5.94e-01 |
| GO:BP | GO:0140962 | multicellular organismal-level chemical homeostasis | 2 | 34 | 5.94e-01 |
| GO:BP | GO:0042363 | fat-soluble vitamin catabolic process | 1 | 1 | 5.94e-01 |
| GO:BP | GO:0010831 | positive regulation of myotube differentiation | 1 | 10 | 5.94e-01 |
| GO:BP | GO:0048706 | embryonic skeletal system development | 7 | 78 | 5.94e-01 |
| GO:BP | GO:0043154 | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 3 | 59 | 5.94e-01 |
| GO:BP | GO:0009913 | epidermal cell differentiation | 1 | 116 | 5.94e-01 |
| GO:BP | GO:1903204 | negative regulation of oxidative stress-induced neuron death | 1 | 19 | 5.94e-01 |
| GO:BP | GO:0070233 | negative regulation of T cell apoptotic process | 1 | 14 | 5.94e-01 |
| GO:BP | GO:0043307 | eosinophil activation | 1 | 4 | 5.94e-01 |
| GO:BP | GO:0072202 | cell differentiation involved in metanephros development | 2 | 16 | 5.94e-01 |
| GO:BP | GO:0002447 | eosinophil mediated immunity | 1 | 5 | 5.94e-01 |
| GO:BP | GO:0046785 | microtubule polymerization | 4 | 84 | 5.94e-01 |
| GO:BP | GO:0000184 | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 2 | 39 | 5.94e-01 |
| GO:BP | GO:0033313 | meiotic cell cycle checkpoint signaling | 1 | 6 | 5.94e-01 |
| GO:BP | GO:0002691 | regulation of cellular extravasation | 2 | 24 | 5.94e-01 |
| GO:BP | GO:0009966 | regulation of signal transduction | 4 | 2285 | 5.95e-01 |
| GO:BP | GO:0014733 | regulation of skeletal muscle adaptation | 1 | 11 | 5.95e-01 |
| GO:BP | GO:0051602 | response to electrical stimulus | 2 | 26 | 5.95e-01 |
| GO:BP | GO:0061458 | reproductive system development | 9 | 215 | 5.95e-01 |
| GO:BP | GO:0002756 | MyD88-independent toll-like receptor signaling pathway | 1 | 8 | 5.95e-01 |
| GO:BP | GO:0035461 | vitamin transmembrane transport | 1 | 14 | 5.96e-01 |
| GO:BP | GO:0019722 | calcium-mediated signaling | 11 | 122 | 5.96e-01 |
| GO:BP | GO:0061564 | axon development | 5 | 398 | 5.96e-01 |
| GO:BP | GO:0045780 | positive regulation of bone resorption | 1 | 12 | 5.96e-01 |
| GO:BP | GO:0006753 | nucleoside phosphate metabolic process | 1 | 429 | 5.96e-01 |
| GO:BP | GO:0008608 | attachment of spindle microtubules to kinetochore | 1 | 42 | 5.96e-01 |
| GO:BP | GO:0045988 | negative regulation of striated muscle contraction | 1 | 7 | 5.97e-01 |
| GO:BP | GO:0006688 | glycosphingolipid biosynthetic process | 2 | 25 | 5.97e-01 |
| GO:BP | GO:0050878 | regulation of body fluid levels | 10 | 236 | 5.97e-01 |
| GO:BP | GO:0140888 | interferon-mediated signaling pathway | 6 | 67 | 5.97e-01 |
| GO:BP | GO:0048856 | anatomical structure development | 1 | 4128 | 5.97e-01 |
| GO:BP | GO:0005975 | carbohydrate metabolic process | 2 | 433 | 5.97e-01 |
| GO:BP | GO:0043171 | peptide catabolic process | 1 | 16 | 5.97e-01 |
| GO:BP | GO:0051131 | chaperone-mediated protein complex assembly | 1 | 21 | 5.97e-01 |
| GO:BP | GO:0070254 | mucus secretion | 1 | 8 | 5.97e-01 |
| GO:BP | GO:0043031 | negative regulation of macrophage activation | 1 | 9 | 5.97e-01 |
| GO:BP | GO:0035196 | miRNA processing | 4 | 41 | 5.97e-01 |
| GO:BP | GO:0003407 | neural retina development | 1 | 48 | 5.97e-01 |
| GO:BP | GO:0006497 | protein lipidation | 8 | 89 | 5.99e-01 |
| GO:BP | GO:0051239 | regulation of multicellular organismal process | 4 | 2035 | 5.99e-01 |
| GO:BP | GO:0010757 | negative regulation of plasminogen activation | 1 | 7 | 5.99e-01 |
| GO:BP | GO:1903077 | negative regulation of protein localization to plasma membrane | 1 | 21 | 5.99e-01 |
| GO:BP | GO:0045935 | positive regulation of nucleobase-containing compound metabolic process | 97 | 1602 | 5.99e-01 |
| GO:BP | GO:0006700 | C21-steroid hormone biosynthetic process | 2 | 17 | 6.00e-01 |
| GO:BP | GO:0010310 | regulation of hydrogen peroxide metabolic process | 1 | 14 | 6.00e-01 |
| GO:BP | GO:0001932 | regulation of protein phosphorylation | 1 | 796 | 6.00e-01 |
| GO:BP | GO:0098542 | defense response to other organism | 1 | 608 | 6.00e-01 |
| GO:BP | GO:0060071 | Wnt signaling pathway, planar cell polarity pathway | 3 | 51 | 6.00e-01 |
| GO:BP | GO:0008299 | isoprenoid biosynthetic process | 1 | 26 | 6.00e-01 |
| GO:BP | GO:0045906 | negative regulation of vasoconstriction | 1 | 6 | 6.00e-01 |
| GO:BP | GO:1905150 | regulation of voltage-gated sodium channel activity | 1 | 6 | 6.00e-01 |
| GO:BP | GO:0002418 | immune response to tumor cell | 2 | 12 | 6.00e-01 |
| GO:BP | GO:0031954 | positive regulation of protein autophosphorylation | 1 | 26 | 6.00e-01 |
| GO:BP | GO:0055085 | transmembrane transport | 3 | 998 | 6.01e-01 |
| GO:BP | GO:0045010 | actin nucleation | 2 | 50 | 6.01e-01 |
| GO:BP | GO:0008015 | blood circulation | 1 | 374 | 6.01e-01 |
| GO:BP | GO:0048241 | epinephrine transport | 1 | 4 | 6.01e-01 |
| GO:BP | GO:0042364 | water-soluble vitamin biosynthetic process | 1 | 8 | 6.02e-01 |
| GO:BP | GO:0098840 | protein transport along microtubule | 1 | 14 | 6.02e-01 |
| GO:BP | GO:0061339 | establishment or maintenance of monopolar cell polarity | 1 | 20 | 6.02e-01 |
| GO:BP | GO:0097421 | liver regeneration | 2 | 23 | 6.02e-01 |
| GO:BP | GO:0034427 | nuclear-transcribed mRNA catabolic process, exonucleolytic, 3’-5’ | 1 | 11 | 6.02e-01 |
| GO:BP | GO:0002031 | G protein-coupled receptor internalization | 1 | 10 | 6.02e-01 |
| GO:BP | GO:0099118 | microtubule-based protein transport | 1 | 14 | 6.02e-01 |
| GO:BP | GO:0097154 | GABAergic neuron differentiation | 1 | 5 | 6.02e-01 |
| GO:BP | GO:0031146 | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process | 2 | 47 | 6.02e-01 |
| GO:BP | GO:0035336 | long-chain fatty-acyl-CoA metabolic process | 2 | 19 | 6.02e-01 |
| GO:BP | GO:0007320 | insemination | 1 | 5 | 6.03e-01 |
| GO:BP | GO:0035973 | aggrephagy | 1 | 8 | 6.03e-01 |
| GO:BP | GO:1905719 | protein localization to perinuclear region of cytoplasm | 1 | 8 | 6.03e-01 |
| GO:BP | GO:0030879 | mammary gland development | 5 | 106 | 6.03e-01 |
| GO:BP | GO:0050435 | amyloid-beta metabolic process | 3 | 48 | 6.04e-01 |
| GO:BP | GO:1902903 | regulation of supramolecular fiber organization | 14 | 326 | 6.04e-01 |
| GO:BP | GO:0042045 | epithelial fluid transport | 1 | 7 | 6.04e-01 |
| GO:BP | GO:1903506 | regulation of nucleic acid-templated transcription | 5 | 2576 | 6.04e-01 |
| GO:BP | GO:0072711 | cellular response to hydroxyurea | 1 | 10 | 6.04e-01 |
| GO:BP | GO:0042773 | ATP synthesis coupled electron transport | 1 | 82 | 6.04e-01 |
| GO:BP | GO:0009410 | response to xenobiotic stimulus | 1 | 279 | 6.04e-01 |
| GO:BP | GO:0042775 | mitochondrial ATP synthesis coupled electron transport | 1 | 82 | 6.04e-01 |
| GO:BP | GO:0006355 | regulation of DNA-templated transcription | 5 | 2574 | 6.04e-01 |
| GO:BP | GO:0021702 | cerebellar Purkinje cell differentiation | 1 | 10 | 6.04e-01 |
| GO:BP | GO:0071871 | response to epinephrine | 1 | 12 | 6.04e-01 |
| GO:BP | GO:2000573 | positive regulation of DNA biosynthetic process | 3 | 67 | 6.05e-01 |
| GO:BP | GO:0007059 | chromosome segregation | 13 | 369 | 6.05e-01 |
| GO:BP | GO:0060351 | cartilage development involved in endochondral bone morphogenesis | 1 | 26 | 6.05e-01 |
| GO:BP | GO:0140448 | signaling receptor ligand precursor processing | 1 | 29 | 6.05e-01 |
| GO:BP | GO:0014831 | gastro-intestinal system smooth muscle contraction | 1 | 5 | 6.05e-01 |
| GO:BP | GO:0001676 | long-chain fatty acid metabolic process | 2 | 65 | 6.05e-01 |
| GO:BP | GO:0070886 | positive regulation of calcineurin-NFAT signaling cascade | 2 | 16 | 6.05e-01 |
| GO:BP | GO:0010812 | negative regulation of cell-substrate adhesion | 5 | 44 | 6.05e-01 |
| GO:BP | GO:0106058 | positive regulation of calcineurin-mediated signaling | 2 | 16 | 6.05e-01 |
| GO:BP | GO:0006935 | chemotaxis | 6 | 389 | 6.05e-01 |
| GO:BP | GO:0009306 | protein secretion | 4 | 262 | 6.06e-01 |
| GO:BP | GO:0060444 | branching involved in mammary gland duct morphogenesis | 1 | 20 | 6.06e-01 |
| GO:BP | GO:1901184 | regulation of ERBB signaling pathway | 6 | 66 | 6.06e-01 |
| GO:BP | GO:0099171 | presynaptic modulation of chemical synaptic transmission | 3 | 26 | 6.06e-01 |
| GO:BP | GO:0072577 | endothelial cell apoptotic process | 3 | 40 | 6.07e-01 |
| GO:BP | GO:1903140 | regulation of establishment of endothelial barrier | 1 | 12 | 6.07e-01 |
| GO:BP | GO:1901550 | regulation of endothelial cell development | 1 | 12 | 6.07e-01 |
| GO:BP | GO:0071415 | cellular response to purine-containing compound | 1 | 11 | 6.07e-01 |
| GO:BP | GO:0010952 | positive regulation of peptidase activity | 2 | 135 | 6.07e-01 |
| GO:BP | GO:0072089 | stem cell proliferation | 3 | 84 | 6.07e-01 |
| GO:BP | GO:0035592 | establishment of protein localization to extracellular region | 4 | 262 | 6.07e-01 |
| GO:BP | GO:0042330 | taxis | 6 | 389 | 6.08e-01 |
| GO:BP | GO:0099175 | regulation of postsynapse organization | 8 | 83 | 6.08e-01 |
| GO:BP | GO:0002424 | T cell mediated immune response to tumor cell | 1 | 6 | 6.08e-01 |
| GO:BP | GO:0043382 | positive regulation of memory T cell differentiation | 1 | 3 | 6.08e-01 |
| GO:BP | GO:0032471 | negative regulation of endoplasmic reticulum calcium ion concentration | 1 | 9 | 6.09e-01 |
| GO:BP | GO:2001141 | regulation of RNA biosynthetic process | 5 | 2593 | 6.09e-01 |
| GO:BP | GO:0043416 | regulation of skeletal muscle tissue regeneration | 1 | 5 | 6.09e-01 |
| GO:BP | GO:0051247 | positive regulation of protein metabolic process | 2 | 1123 | 6.09e-01 |
| GO:BP | GO:0034497 | protein localization to phagophore assembly site | 1 | 17 | 6.10e-01 |
| GO:BP | GO:0060395 | SMAD protein signal transduction | 1 | 65 | 6.10e-01 |
| GO:BP | GO:0050432 | catecholamine secretion | 1 | 31 | 6.10e-01 |
| GO:BP | GO:0001774 | microglial cell activation | 2 | 19 | 6.10e-01 |
| GO:BP | GO:1901698 | response to nitrogen compound | 2 | 830 | 6.10e-01 |
| GO:BP | GO:0099084 | postsynaptic specialization organization | 4 | 36 | 6.10e-01 |
| GO:BP | GO:1901989 | positive regulation of cell cycle phase transition | 6 | 103 | 6.10e-01 |
| GO:BP | GO:0043085 | positive regulation of catalytic activity | 1 | 834 | 6.10e-01 |
| GO:BP | GO:0071398 | cellular response to fatty acid | 1 | 25 | 6.10e-01 |
| GO:BP | GO:0071333 | cellular response to glucose stimulus | 5 | 93 | 6.10e-01 |
| GO:BP | GO:0010739 | positive regulation of protein kinase A signaling | 1 | 6 | 6.11e-01 |
| GO:BP | GO:0050847 | progesterone receptor signaling pathway | 1 | 9 | 6.11e-01 |
| GO:BP | GO:0060421 | positive regulation of heart growth | 1 | 27 | 6.11e-01 |
| GO:BP | GO:0035115 | embryonic forelimb morphogenesis | 1 | 17 | 6.11e-01 |
| GO:BP | GO:0030422 | siRNA processing | 1 | 7 | 6.11e-01 |
| GO:BP | GO:0050810 | regulation of steroid biosynthetic process | 1 | 51 | 6.11e-01 |
| GO:BP | GO:0046386 | deoxyribose phosphate catabolic process | 2 | 22 | 6.11e-01 |
| GO:BP | GO:0009264 | deoxyribonucleotide catabolic process | 2 | 22 | 6.11e-01 |
| GO:BP | GO:0009749 | response to glucose | 7 | 137 | 6.11e-01 |
| GO:BP | GO:0071712 | ER-associated misfolded protein catabolic process | 1 | 12 | 6.11e-01 |
| GO:BP | GO:0034315 | regulation of Arp2/3 complex-mediated actin nucleation | 1 | 25 | 6.12e-01 |
| GO:BP | GO:1900016 | negative regulation of cytokine production involved in inflammatory response | 2 | 13 | 6.12e-01 |
| GO:BP | GO:0001738 | morphogenesis of a polarized epithelium | 8 | 88 | 6.12e-01 |
| GO:BP | GO:0043328 | protein transport to vacuole involved in ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway | 1 | 16 | 6.12e-01 |
| GO:BP | GO:0006957 | complement activation, alternative pathway | 1 | 5 | 6.12e-01 |
| GO:BP | GO:0030204 | chondroitin sulfate metabolic process | 1 | 28 | 6.12e-01 |
| GO:BP | GO:0006351 | DNA-templated transcription | 7 | 2683 | 6.12e-01 |
| GO:BP | GO:0097659 | nucleic acid-templated transcription | 7 | 2684 | 6.13e-01 |
| GO:BP | GO:0052372 | modulation by symbiont of entry into host | 1 | 38 | 6.13e-01 |
| GO:BP | GO:0045071 | negative regulation of viral genome replication | 1 | 37 | 6.13e-01 |
| GO:BP | GO:0010454 | negative regulation of cell fate commitment | 1 | 6 | 6.13e-01 |
| GO:BP | GO:0000041 | transition metal ion transport | 4 | 71 | 6.13e-01 |
| GO:BP | GO:0050905 | neuromuscular process | 6 | 107 | 6.14e-01 |
| GO:BP | GO:0006307 | DNA dealkylation involved in DNA repair | 1 | 9 | 6.14e-01 |
| GO:BP | GO:0043631 | RNA polyadenylation | 4 | 41 | 6.14e-01 |
| GO:BP | GO:0031297 | replication fork processing | 1 | 42 | 6.14e-01 |
| GO:BP | GO:0043568 | positive regulation of insulin-like growth factor receptor signaling pathway | 1 | 8 | 6.15e-01 |
| GO:BP | GO:0097484 | dendrite extension | 1 | 27 | 6.15e-01 |
| GO:BP | GO:1904925 | positive regulation of autophagy of mitochondrion in response to mitochondrial depolarization | 1 | 14 | 6.15e-01 |
| GO:BP | GO:0036303 | lymph vessel morphogenesis | 1 | 17 | 6.15e-01 |
| GO:BP | GO:0097066 | response to thyroid hormone | 2 | 23 | 6.15e-01 |
| GO:BP | GO:0052547 | regulation of peptidase activity | 4 | 271 | 6.15e-01 |
| GO:BP | GO:2000096 | positive regulation of Wnt signaling pathway, planar cell polarity pathway | 1 | 9 | 6.15e-01 |
| GO:BP | GO:0002755 | MyD88-dependent toll-like receptor signaling pathway | 2 | 14 | 6.15e-01 |
| GO:BP | GO:0031670 | cellular response to nutrient | 2 | 31 | 6.15e-01 |
| GO:BP | GO:0006084 | acetyl-CoA metabolic process | 1 | 28 | 6.15e-01 |
| GO:BP | GO:0006534 | cysteine metabolic process | 1 | 11 | 6.15e-01 |
| GO:BP | GO:0008156 | negative regulation of DNA replication | 1 | 19 | 6.16e-01 |
| GO:BP | GO:0034085 | establishment of sister chromatid cohesion | 1 | 11 | 6.16e-01 |
| GO:BP | GO:0006109 | regulation of carbohydrate metabolic process | 2 | 144 | 6.16e-01 |
| GO:BP | GO:1902041 | regulation of extrinsic apoptotic signaling pathway via death domain receptors | 4 | 40 | 6.16e-01 |
| GO:BP | GO:0048742 | regulation of skeletal muscle fiber development | 1 | 8 | 6.16e-01 |
| GO:BP | GO:0070252 | actin-mediated cell contraction | 2 | 89 | 6.16e-01 |
| GO:BP | GO:0014854 | response to inactivity | 1 | 11 | 6.16e-01 |
| GO:BP | GO:0033235 | positive regulation of protein sumoylation | 1 | 12 | 6.16e-01 |
| GO:BP | GO:0140895 | cell surface toll-like receptor signaling pathway | 2 | 27 | 6.16e-01 |
| GO:BP | GO:0016579 | protein deubiquitination | 1 | 129 | 6.16e-01 |
| GO:BP | GO:0034330 | cell junction organization | 1 | 575 | 6.16e-01 |
| GO:BP | GO:2000651 | positive regulation of sodium ion transmembrane transporter activity | 1 | 14 | 6.16e-01 |
| GO:BP | GO:0048745 | smooth muscle tissue development | 1 | 19 | 6.17e-01 |
| GO:BP | GO:1904376 | negative regulation of protein localization to cell periphery | 1 | 23 | 6.18e-01 |
| GO:BP | GO:0034695 | response to prostaglandin E | 1 | 17 | 6.18e-01 |
| GO:BP | GO:0048857 | neural nucleus development | 1 | 50 | 6.18e-01 |
| GO:BP | GO:0090026 | positive regulation of monocyte chemotaxis | 2 | 7 | 6.18e-01 |
| GO:BP | GO:0050796 | regulation of insulin secretion | 2 | 116 | 6.18e-01 |
| GO:BP | GO:0071692 | protein localization to extracellular region | 4 | 266 | 6.18e-01 |
| GO:BP | GO:0006144 | purine nucleobase metabolic process | 1 | 15 | 6.18e-01 |
| GO:BP | GO:0072698 | protein localization to microtubule cytoskeleton | 3 | 52 | 6.18e-01 |
| GO:BP | GO:0031647 | regulation of protein stability | 11 | 290 | 6.18e-01 |
| GO:BP | GO:0035886 | vascular associated smooth muscle cell differentiation | 1 | 27 | 6.19e-01 |
| GO:BP | GO:0071384 | cellular response to corticosteroid stimulus | 3 | 47 | 6.19e-01 |
| GO:BP | GO:0007144 | female meiosis I | 1 | 9 | 6.19e-01 |
| GO:BP | GO:0001775 | cell activation | 1 | 655 | 6.19e-01 |
| GO:BP | GO:0045600 | positive regulation of fat cell differentiation | 3 | 50 | 6.20e-01 |
| GO:BP | GO:0071331 | cellular response to hexose stimulus | 5 | 94 | 6.20e-01 |
| GO:BP | GO:2000234 | positive regulation of rRNA processing | 1 | 10 | 6.20e-01 |
| GO:BP | GO:0034472 | snRNA 3’-end processing | 1 | 21 | 6.20e-01 |
| GO:BP | GO:1900024 | regulation of substrate adhesion-dependent cell spreading | 5 | 54 | 6.21e-01 |
| GO:BP | GO:0006269 | DNA replication, synthesis of RNA primer | 1 | 7 | 6.21e-01 |
| GO:BP | GO:0010764 | negative regulation of fibroblast migration | 1 | 9 | 6.21e-01 |
| GO:BP | GO:0002246 | wound healing involved in inflammatory response | 1 | 6 | 6.21e-01 |
| GO:BP | GO:0061008 | hepaticobiliary system development | 8 | 112 | 6.21e-01 |
| GO:BP | GO:1901568 | fatty acid derivative metabolic process | 1 | 48 | 6.21e-01 |
| GO:BP | GO:0035493 | SNARE complex assembly | 2 | 22 | 6.22e-01 |
| GO:BP | GO:0072091 | regulation of stem cell proliferation | 2 | 58 | 6.22e-01 |
| GO:BP | GO:0060713 | labyrinthine layer morphogenesis | 2 | 17 | 6.22e-01 |
| GO:BP | GO:0032774 | RNA biosynthetic process | 7 | 2714 | 6.22e-01 |
| GO:BP | GO:0031343 | positive regulation of cell killing | 3 | 23 | 6.22e-01 |
| GO:BP | GO:0032342 | aldosterone biosynthetic process | 1 | 9 | 6.22e-01 |
| GO:BP | GO:0090382 | phagosome maturation | 1 | 24 | 6.22e-01 |
| GO:BP | GO:0050921 | positive regulation of chemotaxis | 1 | 85 | 6.22e-01 |
| GO:BP | GO:0060346 | bone trabecula formation | 1 | 9 | 6.22e-01 |
| GO:BP | GO:0035581 | sequestering of extracellular ligand from receptor | 1 | 7 | 6.22e-01 |
| GO:BP | GO:0032786 | positive regulation of DNA-templated transcription, elongation | 5 | 58 | 6.23e-01 |
| GO:BP | GO:2000786 | positive regulation of autophagosome assembly | 1 | 19 | 6.23e-01 |
| GO:BP | GO:1900026 | positive regulation of substrate adhesion-dependent cell spreading | 2 | 39 | 6.23e-01 |
| GO:BP | GO:0045089 | positive regulation of innate immune response | 10 | 182 | 6.23e-01 |
| GO:BP | GO:0061050 | regulation of cell growth involved in cardiac muscle cell development | 1 | 13 | 6.23e-01 |
| GO:BP | GO:0060759 | regulation of response to cytokine stimulus | 3 | 126 | 6.23e-01 |
| GO:BP | GO:0098534 | centriole assembly | 2 | 41 | 6.23e-01 |
| GO:BP | GO:0032355 | response to estradiol | 2 | 83 | 6.23e-01 |
| GO:BP | GO:0051148 | negative regulation of muscle cell differentiation | 4 | 52 | 6.23e-01 |
| GO:BP | GO:0051383 | kinetochore organization | 2 | 23 | 6.24e-01 |
| GO:BP | GO:0031000 | response to caffeine | 1 | 13 | 6.24e-01 |
| GO:BP | GO:0062125 | regulation of mitochondrial gene expression | 2 | 31 | 6.24e-01 |
| GO:BP | GO:0003351 | epithelial cilium movement involved in extracellular fluid movement | 1 | 29 | 6.25e-01 |
| GO:BP | GO:0048871 | multicellular organismal-level homeostasis | 1 | 532 | 6.25e-01 |
| GO:BP | GO:0042325 | regulation of phosphorylation | 1 | 881 | 6.25e-01 |
| GO:BP | GO:0044417 | translocation of molecules into host | 1 | 7 | 6.25e-01 |
| GO:BP | GO:0072710 | response to hydroxyurea | 1 | 11 | 6.25e-01 |
| GO:BP | GO:0043249 | erythrocyte maturation | 1 | 12 | 6.26e-01 |
| GO:BP | GO:1901533 | negative regulation of hematopoietic progenitor cell differentiation | 1 | 11 | 6.26e-01 |
| GO:BP | GO:0010959 | regulation of metal ion transport | 1 | 275 | 6.26e-01 |
| GO:BP | GO:0001961 | positive regulation of cytokine-mediated signaling pathway | 1 | 44 | 6.27e-01 |
| GO:BP | GO:1900222 | negative regulation of amyloid-beta clearance | 1 | 7 | 6.27e-01 |
| GO:BP | GO:0003008 | system process | 3 | 1189 | 6.27e-01 |
| GO:BP | GO:0051250 | negative regulation of lymphocyte activation | 11 | 90 | 6.27e-01 |
| GO:BP | GO:0002673 | regulation of acute inflammatory response | 1 | 21 | 6.27e-01 |
| GO:BP | GO:0090407 | organophosphate biosynthetic process | 1 | 506 | 6.27e-01 |
| GO:BP | GO:1901564 | organonitrogen compound metabolic process | 1 | 4955 | 6.27e-01 |
| GO:BP | GO:0045724 | positive regulation of cilium assembly | 2 | 25 | 6.28e-01 |
| GO:BP | GO:0002027 | regulation of heart rate | 2 | 86 | 6.28e-01 |
| GO:BP | GO:0030500 | regulation of bone mineralization | 1 | 53 | 6.28e-01 |
| GO:BP | GO:0043368 | positive T cell selection | 1 | 16 | 6.28e-01 |
| GO:BP | GO:0031440 | regulation of mRNA 3’-end processing | 2 | 22 | 6.30e-01 |
| GO:BP | GO:0044242 | cellular lipid catabolic process | 1 | 170 | 6.30e-01 |
| GO:BP | GO:0046782 | regulation of viral transcription | 1 | 19 | 6.30e-01 |
| GO:BP | GO:0035065 | regulation of histone acetylation | 3 | 47 | 6.30e-01 |
| GO:BP | GO:0070988 | demethylation | 1 | 52 | 6.30e-01 |
| GO:BP | GO:0051781 | positive regulation of cell division | 1 | 64 | 6.30e-01 |
| GO:BP | GO:0071326 | cellular response to monosaccharide stimulus | 5 | 95 | 6.30e-01 |
| GO:BP | GO:0000491 | small nucleolar ribonucleoprotein complex assembly | 1 | 12 | 6.30e-01 |
| GO:BP | GO:0050982 | detection of mechanical stimulus | 2 | 32 | 6.30e-01 |
| GO:BP | GO:0003056 | regulation of vascular associated smooth muscle contraction | 1 | 8 | 6.30e-01 |
| GO:BP | GO:0036315 | cellular response to sterol | 1 | 14 | 6.30e-01 |
| GO:BP | GO:0007176 | regulation of epidermal growth factor-activated receptor activity | 2 | 24 | 6.30e-01 |
| GO:BP | GO:0001768 | establishment of T cell polarity | 1 | 10 | 6.30e-01 |
| GO:BP | GO:0009111 | vitamin catabolic process | 1 | 3 | 6.30e-01 |
| GO:BP | GO:0060343 | trabecula formation | 2 | 23 | 6.30e-01 |
| GO:BP | GO:0071803 | positive regulation of podosome assembly | 1 | 6 | 6.30e-01 |
| GO:BP | GO:0045840 | positive regulation of mitotic nuclear division | 2 | 29 | 6.30e-01 |
| GO:BP | GO:0032502 | developmental process | 1 | 4494 | 6.30e-01 |
| GO:BP | GO:0060263 | regulation of respiratory burst | 1 | 10 | 6.30e-01 |
| GO:BP | GO:0009148 | pyrimidine nucleoside triphosphate biosynthetic process | 1 | 17 | 6.30e-01 |
| GO:BP | GO:0061820 | telomeric D-loop disassembly | 1 | 8 | 6.30e-01 |
| GO:BP | GO:1903441 | protein localization to ciliary membrane | 1 | 11 | 6.30e-01 |
| GO:BP | GO:0043101 | purine-containing compound salvage | 1 | 14 | 6.30e-01 |
| GO:BP | GO:0007196 | adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathway | 1 | 1 | 6.30e-01 |
| GO:BP | GO:0002886 | regulation of myeloid leukocyte mediated immunity | 3 | 34 | 6.30e-01 |
| GO:BP | GO:1903170 | negative regulation of calcium ion transmembrane transport | 4 | 35 | 6.30e-01 |
| GO:BP | GO:0046718 | viral entry into host cell | 7 | 107 | 6.31e-01 |
| GO:BP | GO:0044597 | daunorubicin metabolic process | 1 | 7 | 6.31e-01 |
| GO:BP | GO:0009746 | response to hexose | 7 | 138 | 6.31e-01 |
| GO:BP | GO:0035270 | endocrine system development | 6 | 86 | 6.31e-01 |
| GO:BP | GO:0070585 | protein localization to mitochondrion | 7 | 123 | 6.31e-01 |
| GO:BP | GO:0002645 | positive regulation of tolerance induction | 1 | 6 | 6.31e-01 |
| GO:BP | GO:0072538 | T-helper 17 type immune response | 2 | 24 | 6.31e-01 |
| GO:BP | GO:0032387 | negative regulation of intracellular transport | 5 | 49 | 6.32e-01 |
| GO:BP | GO:0031116 | positive regulation of microtubule polymerization | 1 | 31 | 6.32e-01 |
| GO:BP | GO:1904923 | regulation of autophagy of mitochondrion in response to mitochondrial depolarization | 1 | 15 | 6.32e-01 |
| GO:BP | GO:0070167 | regulation of biomineral tissue development | 7 | 67 | 6.32e-01 |
| GO:BP | GO:0006694 | steroid biosynthetic process | 6 | 121 | 6.32e-01 |
| GO:BP | GO:0071322 | cellular response to carbohydrate stimulus | 11 | 105 | 6.32e-01 |
| GO:BP | GO:0051571 | positive regulation of histone H3-K4 methylation | 2 | 20 | 6.32e-01 |
| GO:BP | GO:0046949 | fatty-acyl-CoA biosynthetic process | 2 | 20 | 6.32e-01 |
| GO:BP | GO:0018193 | peptidyl-amino acid modification | 1 | 963 | 6.32e-01 |
| GO:BP | GO:0050922 | negative regulation of chemotaxis | 2 | 44 | 6.32e-01 |
| GO:BP | GO:1904358 | positive regulation of telomere maintenance via telomere lengthening | 3 | 33 | 6.32e-01 |
| GO:BP | GO:0048024 | regulation of mRNA splicing, via spliceosome | 6 | 96 | 6.32e-01 |
| GO:BP | GO:0050731 | positive regulation of peptidyl-tyrosine phosphorylation | 1 | 105 | 6.32e-01 |
| GO:BP | GO:0050891 | multicellular organismal-level water homeostasis | 1 | 16 | 6.32e-01 |
| GO:BP | GO:0019637 | organophosphate metabolic process | 4 | 784 | 6.32e-01 |
| GO:BP | GO:0031325 | positive regulation of cellular metabolic process | 154 | 2270 | 6.32e-01 |
| GO:BP | GO:0060717 | chorion development | 1 | 8 | 6.33e-01 |
| GO:BP | GO:0038127 | ERBB signaling pathway | 9 | 107 | 6.33e-01 |
| GO:BP | GO:0048681 | negative regulation of axon regeneration | 1 | 11 | 6.33e-01 |
| GO:BP | GO:0046697 | decidualization | 2 | 19 | 6.33e-01 |
| GO:BP | GO:0002269 | leukocyte activation involved in inflammatory response | 2 | 21 | 6.34e-01 |
| GO:BP | GO:0010832 | negative regulation of myotube differentiation | 1 | 10 | 6.34e-01 |
| GO:BP | GO:0060253 | negative regulation of glial cell proliferation | 1 | 13 | 6.34e-01 |
| GO:BP | GO:0045836 | positive regulation of meiotic nuclear division | 1 | 9 | 6.35e-01 |
| GO:BP | GO:0060347 | heart trabecula formation | 1 | 13 | 6.35e-01 |
| GO:BP | GO:0002730 | regulation of dendritic cell cytokine production | 1 | 10 | 6.35e-01 |
| GO:BP | GO:0090043 | regulation of tubulin deacetylation | 1 | 21 | 6.35e-01 |
| GO:BP | GO:0090175 | regulation of establishment of planar polarity | 3 | 54 | 6.35e-01 |
| GO:BP | GO:0016202 | regulation of striated muscle tissue development | 1 | 13 | 6.35e-01 |
| GO:BP | GO:1900117 | regulation of execution phase of apoptosis | 1 | 13 | 6.35e-01 |
| GO:BP | GO:0055012 | ventricular cardiac muscle cell differentiation | 1 | 15 | 6.35e-01 |
| GO:BP | GO:0010887 | negative regulation of cholesterol storage | 1 | 9 | 6.35e-01 |
| GO:BP | GO:0016322 | neuron remodeling | 1 | 11 | 6.35e-01 |
| GO:BP | GO:0002371 | dendritic cell cytokine production | 1 | 10 | 6.35e-01 |
| GO:BP | GO:0071300 | cellular response to retinoic acid | 4 | 49 | 6.35e-01 |
| GO:BP | GO:0098743 | cell aggregation | 1 | 12 | 6.35e-01 |
| GO:BP | GO:0010893 | positive regulation of steroid biosynthetic process | 1 | 15 | 6.35e-01 |
| GO:BP | GO:0006182 | cGMP biosynthetic process | 1 | 6 | 6.35e-01 |
| GO:BP | GO:0030299 | intestinal cholesterol absorption | 1 | 8 | 6.35e-01 |
| GO:BP | GO:0006285 | base-excision repair, AP site formation | 1 | 12 | 6.35e-01 |
| GO:BP | GO:0039694 | viral RNA genome replication | 2 | 27 | 6.35e-01 |
| GO:BP | GO:0031282 | regulation of guanylate cyclase activity | 1 | 3 | 6.35e-01 |
| GO:BP | GO:0099601 | regulation of neurotransmitter receptor activity | 4 | 40 | 6.35e-01 |
| GO:BP | GO:0007548 | sex differentiation | 8 | 191 | 6.35e-01 |
| GO:BP | GO:0030431 | sleep | 1 | 13 | 6.35e-01 |
| GO:BP | GO:0002827 | positive regulation of T-helper 1 type immune response | 1 | 5 | 6.35e-01 |
| GO:BP | GO:0034727 | piecemeal microautophagy of the nucleus | 1 | 9 | 6.35e-01 |
| GO:BP | GO:0009143 | nucleoside triphosphate catabolic process | 1 | 10 | 6.35e-01 |
| GO:BP | GO:0000463 | maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 1 | 15 | 6.35e-01 |
| GO:BP | GO:0098937 | anterograde dendritic transport | 1 | 9 | 6.35e-01 |
| GO:BP | GO:0060976 | coronary vasculature development | 2 | 44 | 6.36e-01 |
| GO:BP | GO:0030889 | negative regulation of B cell proliferation | 1 | 9 | 6.36e-01 |
| GO:BP | GO:0046823 | negative regulation of nucleocytoplasmic transport | 2 | 21 | 6.37e-01 |
| GO:BP | GO:0070307 | lens fiber cell development | 1 | 11 | 6.37e-01 |
| GO:BP | GO:0014743 | regulation of muscle hypertrophy | 3 | 49 | 6.37e-01 |
| GO:BP | GO:0097194 | execution phase of apoptosis | 4 | 53 | 6.37e-01 |
| GO:BP | GO:0033005 | positive regulation of mast cell activation | 2 | 13 | 6.37e-01 |
| GO:BP | GO:0003300 | cardiac muscle hypertrophy | 5 | 72 | 6.37e-01 |
| GO:BP | GO:0031111 | negative regulation of microtubule polymerization or depolymerization | 2 | 39 | 6.37e-01 |
| GO:BP | GO:0060215 | primitive hemopoiesis | 1 | 7 | 6.37e-01 |
| GO:BP | GO:0016926 | protein desumoylation | 1 | 9 | 6.38e-01 |
| GO:BP | GO:0008406 | gonad development | 5 | 158 | 6.38e-01 |
| GO:BP | GO:2001238 | positive regulation of extrinsic apoptotic signaling pathway | 4 | 40 | 6.38e-01 |
| GO:BP | GO:0015695 | organic cation transport | 1 | 34 | 6.38e-01 |
| GO:BP | GO:0021694 | cerebellar Purkinje cell layer formation | 1 | 12 | 6.39e-01 |
| GO:BP | GO:0070922 | RISC complex assembly | 1 | 9 | 6.39e-01 |
| GO:BP | GO:0010501 | RNA secondary structure unwinding | 1 | 8 | 6.39e-01 |
| GO:BP | GO:0042987 | amyloid precursor protein catabolic process | 3 | 53 | 6.39e-01 |
| GO:BP | GO:1901099 | negative regulation of signal transduction in absence of ligand | 2 | 25 | 6.40e-01 |
| GO:BP | GO:0016024 | CDP-diacylglycerol biosynthetic process | 1 | 12 | 6.40e-01 |
| GO:BP | GO:2001240 | negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 2 | 25 | 6.40e-01 |
| GO:BP | GO:0042158 | lipoprotein biosynthetic process | 8 | 92 | 6.40e-01 |
| GO:BP | GO:1904036 | negative regulation of epithelial cell apoptotic process | 3 | 43 | 6.40e-01 |
| GO:BP | GO:0034394 | protein localization to cell surface | 2 | 61 | 6.40e-01 |
| GO:BP | GO:0071222 | cellular response to lipopolysaccharide | 7 | 110 | 6.40e-01 |
| GO:BP | GO:0042428 | serotonin metabolic process | 1 | 6 | 6.41e-01 |
| GO:BP | GO:0006858 | extracellular transport | 1 | 32 | 6.41e-01 |
| GO:BP | GO:0061099 | negative regulation of protein tyrosine kinase activity | 2 | 27 | 6.41e-01 |
| GO:BP | GO:0010717 | regulation of epithelial to mesenchymal transition | 1 | 86 | 6.41e-01 |
| GO:BP | GO:0034284 | response to monosaccharide | 1 | 142 | 6.41e-01 |
| GO:BP | GO:0014074 | response to purine-containing compound | 8 | 108 | 6.41e-01 |
| GO:BP | GO:0002934 | desmosome organization | 1 | 9 | 6.42e-01 |
| GO:BP | GO:0033081 | regulation of T cell differentiation in thymus | 1 | 16 | 6.42e-01 |
| GO:BP | GO:0007215 | glutamate receptor signaling pathway | 4 | 29 | 6.42e-01 |
| GO:BP | GO:0043903 | regulation of biological process involved in symbiotic interaction | 1 | 40 | 6.42e-01 |
| GO:BP | GO:0032365 | intracellular lipid transport | 2 | 42 | 6.42e-01 |
| GO:BP | GO:0046856 | phosphatidylinositol dephosphorylation | 2 | 29 | 6.42e-01 |
| GO:BP | GO:0006705 | mineralocorticoid biosynthetic process | 1 | 9 | 6.42e-01 |
| GO:BP | GO:0070646 | protein modification by small protein removal | 1 | 147 | 6.42e-01 |
| GO:BP | GO:0051707 | response to other organism | 2 | 820 | 6.43e-01 |
| GO:BP | GO:0070102 | interleukin-6-mediated signaling pathway | 1 | 14 | 6.44e-01 |
| GO:BP | GO:0045088 | regulation of innate immune response | 12 | 232 | 6.44e-01 |
| GO:BP | GO:0043603 | amide metabolic process | 80 | 993 | 6.44e-01 |
| GO:BP | GO:0015701 | bicarbonate transport | 2 | 19 | 6.44e-01 |
| GO:BP | GO:0072075 | metanephric mesenchyme development | 1 | 10 | 6.44e-01 |
| GO:BP | GO:1903729 | regulation of plasma membrane organization | 1 | 15 | 6.44e-01 |
| GO:BP | GO:2000369 | regulation of clathrin-dependent endocytosis | 1 | 18 | 6.44e-01 |
| GO:BP | GO:0071218 | cellular response to misfolded protein | 2 | 23 | 6.44e-01 |
| GO:BP | GO:0043207 | response to external biotic stimulus | 2 | 820 | 6.44e-01 |
| GO:BP | GO:0006576 | biogenic amine metabolic process | 1 | 57 | 6.44e-01 |
| GO:BP | GO:0051130 | positive regulation of cellular component organization | 2 | 906 | 6.44e-01 |
| GO:BP | GO:0032369 | negative regulation of lipid transport | 1 | 20 | 6.44e-01 |
| GO:BP | GO:0001767 | establishment of lymphocyte polarity | 1 | 11 | 6.44e-01 |
| GO:BP | GO:0030644 | intracellular chloride ion homeostasis | 1 | 7 | 6.45e-01 |
| GO:BP | GO:0030002 | intracellular monoatomic anion homeostasis | 1 | 7 | 6.45e-01 |
| GO:BP | GO:0033762 | response to glucagon | 1 | 13 | 6.45e-01 |
| GO:BP | GO:0048643 | positive regulation of skeletal muscle tissue development | 1 | 14 | 6.45e-01 |
| GO:BP | GO:1903214 | regulation of protein targeting to mitochondrion | 2 | 39 | 6.45e-01 |
| GO:BP | GO:1903533 | regulation of protein targeting | 4 | 66 | 6.45e-01 |
| GO:BP | GO:0051968 | positive regulation of synaptic transmission, glutamatergic | 3 | 20 | 6.46e-01 |
| GO:BP | GO:1901701 | cellular response to oxygen-containing compound | 1 | 893 | 6.46e-01 |
| GO:BP | GO:0007530 | sex determination | 2 | 12 | 6.46e-01 |
| GO:BP | GO:0008207 | C21-steroid hormone metabolic process | 3 | 28 | 6.46e-01 |
| GO:BP | GO:0044090 | positive regulation of vacuole organization | 1 | 21 | 6.47e-01 |
| GO:BP | GO:0050654 | chondroitin sulfate proteoglycan metabolic process | 1 | 31 | 6.47e-01 |
| GO:BP | GO:0007369 | gastrulation | 1 | 146 | 6.47e-01 |
| GO:BP | GO:0032011 | ARF protein signal transduction | 2 | 18 | 6.48e-01 |
| GO:BP | GO:0032012 | regulation of ARF protein signal transduction | 2 | 18 | 6.48e-01 |
| GO:BP | GO:0061028 | establishment of endothelial barrier | 2 | 38 | 6.48e-01 |
| GO:BP | GO:0006171 | cAMP biosynthetic process | 1 | 8 | 6.49e-01 |
| GO:BP | GO:0002682 | regulation of immune system process | 3 | 877 | 6.49e-01 |
| GO:BP | GO:0010801 | negative regulation of peptidyl-threonine phosphorylation | 1 | 15 | 6.49e-01 |
| GO:BP | GO:0014072 | response to isoquinoline alkaloid | 2 | 16 | 6.49e-01 |
| GO:BP | GO:0043278 | response to morphine | 2 | 16 | 6.49e-01 |
| GO:BP | GO:0070170 | regulation of tooth mineralization | 1 | 4 | 6.49e-01 |
| GO:BP | GO:0048557 | embryonic digestive tract morphogenesis | 1 | 8 | 6.49e-01 |
| GO:BP | GO:0033314 | mitotic DNA replication checkpoint signaling | 1 | 9 | 6.49e-01 |
| GO:BP | GO:0035020 | regulation of Rac protein signal transduction | 2 | 21 | 6.50e-01 |
| GO:BP | GO:0070661 | leukocyte proliferation | 13 | 188 | 6.50e-01 |
| GO:BP | GO:0070475 | rRNA base methylation | 1 | 8 | 6.51e-01 |
| GO:BP | GO:0002664 | regulation of T cell tolerance induction | 1 | 6 | 6.51e-01 |
| GO:BP | GO:0030902 | hindbrain development | 2 | 114 | 6.51e-01 |
| GO:BP | GO:0097502 | mannosylation | 1 | 32 | 6.51e-01 |
| GO:BP | GO:1903727 | positive regulation of phospholipid metabolic process | 1 | 9 | 6.52e-01 |
| GO:BP | GO:0032102 | negative regulation of response to external stimulus | 26 | 269 | 6.52e-01 |
| GO:BP | GO:0070571 | negative regulation of neuron projection regeneration | 1 | 12 | 6.52e-01 |
| GO:BP | GO:0033047 | regulation of mitotic sister chromatid segregation | 1 | 52 | 6.52e-01 |
| GO:BP | GO:0032288 | myelin assembly | 1 | 19 | 6.52e-01 |
| GO:BP | GO:0045820 | negative regulation of glycolytic process | 1 | 13 | 6.52e-01 |
| GO:BP | GO:0010829 | negative regulation of glucose transmembrane transport | 1 | 14 | 6.52e-01 |
| GO:BP | GO:0045123 | cellular extravasation | 3 | 44 | 6.52e-01 |
| GO:BP | GO:0045137 | development of primary sexual characteristics | 5 | 161 | 6.53e-01 |
| GO:BP | GO:1903232 | melanosome assembly | 1 | 19 | 6.53e-01 |
| GO:BP | GO:0019915 | lipid storage | 1 | 66 | 6.53e-01 |
| GO:BP | GO:0044380 | protein localization to cytoskeleton | 3 | 55 | 6.53e-01 |
| GO:BP | GO:0007041 | lysosomal transport | 9 | 115 | 6.53e-01 |
| GO:BP | GO:0016051 | carbohydrate biosynthetic process | 4 | 155 | 6.53e-01 |
| GO:BP | GO:0001889 | liver development | 1 | 110 | 6.53e-01 |
| GO:BP | GO:0022904 | respiratory electron transport chain | 1 | 104 | 6.53e-01 |
| GO:BP | GO:0009607 | response to biotic stimulus | 2 | 850 | 6.53e-01 |
| GO:BP | GO:0045454 | cell redox homeostasis | 1 | 38 | 6.53e-01 |
| GO:BP | GO:2000272 | negative regulation of signaling receptor activity | 2 | 33 | 6.53e-01 |
| GO:BP | GO:1904707 | positive regulation of vascular associated smooth muscle cell proliferation | 2 | 29 | 6.54e-01 |
| GO:BP | GO:0033059 | cellular pigmentation | 4 | 58 | 6.55e-01 |
| GO:BP | GO:0009791 | post-embryonic development | 2 | 74 | 6.55e-01 |
| GO:BP | GO:0060760 | positive regulation of response to cytokine stimulus | 1 | 49 | 6.55e-01 |
| GO:BP | GO:0033135 | regulation of peptidyl-serine phosphorylation | 4 | 100 | 6.55e-01 |
| GO:BP | GO:0051291 | protein heterooligomerization | 1 | 21 | 6.55e-01 |
| GO:BP | GO:0034331 | cell junction maintenance | 3 | 40 | 6.56e-01 |
| GO:BP | GO:0046007 | negative regulation of activated T cell proliferation | 1 | 8 | 6.56e-01 |
| GO:BP | GO:0010996 | response to auditory stimulus | 1 | 16 | 6.56e-01 |
| GO:BP | GO:0071219 | cellular response to molecule of bacterial origin | 9 | 114 | 6.56e-01 |
| GO:BP | GO:0032271 | regulation of protein polymerization | 8 | 168 | 6.56e-01 |
| GO:BP | GO:0006094 | gluconeogenesis | 1 | 67 | 6.56e-01 |
| GO:BP | GO:0043583 | ear development | 9 | 153 | 6.57e-01 |
| GO:BP | GO:0044598 | doxorubicin metabolic process | 1 | 8 | 6.57e-01 |
| GO:BP | GO:0002920 | regulation of humoral immune response | 1 | 18 | 6.57e-01 |
| GO:BP | GO:0010803 | regulation of tumor necrosis factor-mediated signaling pathway | 1 | 41 | 6.57e-01 |
| GO:BP | GO:0007183 | SMAD protein complex assembly | 1 | 12 | 6.57e-01 |
| GO:BP | GO:0030647 | aminoglycoside antibiotic metabolic process | 1 | 7 | 6.57e-01 |
| GO:BP | GO:0019852 | L-ascorbic acid metabolic process | 1 | 9 | 6.57e-01 |
| GO:BP | GO:1901334 | lactone metabolic process | 1 | 9 | 6.57e-01 |
| GO:BP | GO:0030638 | polyketide metabolic process | 1 | 8 | 6.57e-01 |
| GO:BP | GO:0016180 | snRNA processing | 1 | 26 | 6.57e-01 |
| GO:BP | GO:0072527 | pyrimidine-containing compound metabolic process | 1 | 67 | 6.57e-01 |
| GO:BP | GO:0035024 | negative regulation of Rho protein signal transduction | 2 | 21 | 6.58e-01 |
| GO:BP | GO:0032536 | regulation of cell projection size | 1 | 8 | 6.58e-01 |
| GO:BP | GO:0050687 | negative regulation of defense response to virus | 2 | 30 | 6.58e-01 |
| GO:BP | GO:0010248 | establishment or maintenance of transmembrane electrochemical gradient | 1 | 7 | 6.59e-01 |
| GO:BP | GO:0014009 | glial cell proliferation | 3 | 40 | 6.59e-01 |
| GO:BP | GO:0070344 | regulation of fat cell proliferation | 1 | 9 | 6.59e-01 |
| GO:BP | GO:0032042 | mitochondrial DNA metabolic process | 1 | 22 | 6.59e-01 |
| GO:BP | GO:0032966 | negative regulation of collagen biosynthetic process | 1 | 7 | 6.59e-01 |
| GO:BP | GO:0060333 | type II interferon-mediated signaling pathway | 2 | 21 | 6.59e-01 |
| GO:BP | GO:2000050 | regulation of non-canonical Wnt signaling pathway | 2 | 23 | 6.59e-01 |
| GO:BP | GO:0021884 | forebrain neuron development | 2 | 16 | 6.59e-01 |
| GO:BP | GO:0042574 | retinal metabolic process | 1 | 11 | 6.59e-01 |
| GO:BP | GO:1903532 | positive regulation of secretion by cell | 3 | 199 | 6.59e-01 |
| GO:BP | GO:0043094 | cellular metabolic compound salvage | 2 | 25 | 6.59e-01 |
| GO:BP | GO:0097049 | motor neuron apoptotic process | 1 | 18 | 6.59e-01 |
| GO:BP | GO:0032689 | negative regulation of type II interferon production | 1 | 16 | 6.59e-01 |
| GO:BP | GO:0090066 | regulation of anatomical structure size | 19 | 395 | 6.59e-01 |
| GO:BP | GO:0008283 | cell population proliferation | 51 | 1378 | 6.59e-01 |
| GO:BP | GO:0044403 | biological process involved in symbiotic interaction | 1 | 223 | 6.59e-01 |
| GO:BP | GO:0097107 | postsynaptic density assembly | 2 | 16 | 6.59e-01 |
| GO:BP | GO:0060323 | head morphogenesis | 3 | 33 | 6.59e-01 |
| GO:BP | GO:0032496 | response to lipopolysaccharide | 11 | 178 | 6.59e-01 |
| GO:BP | GO:0048011 | neurotrophin TRK receptor signaling pathway | 1 | 23 | 6.59e-01 |
| GO:BP | GO:1904353 | regulation of telomere capping | 1 | 23 | 6.59e-01 |
| GO:BP | GO:0007168 | receptor guanylyl cyclase signaling pathway | 1 | 5 | 6.59e-01 |
| GO:BP | GO:0034765 | regulation of monoatomic ion transmembrane transport | 1 | 295 | 6.60e-01 |
| GO:BP | GO:0030201 | heparan sulfate proteoglycan metabolic process | 1 | 11 | 6.60e-01 |
| GO:BP | GO:0048013 | ephrin receptor signaling pathway | 3 | 41 | 6.60e-01 |
| GO:BP | GO:0031112 | positive regulation of microtubule polymerization or depolymerization | 1 | 35 | 6.60e-01 |
| GO:BP | GO:0007266 | Rho protein signal transduction | 2 | 114 | 6.60e-01 |
| GO:BP | GO:0008654 | phospholipid biosynthetic process | 1 | 234 | 6.61e-01 |
| GO:BP | GO:0034312 | diol biosynthetic process | 1 | 20 | 6.61e-01 |
| GO:BP | GO:0030593 | neutrophil chemotaxis | 1 | 39 | 6.61e-01 |
| GO:BP | GO:0007565 | female pregnancy | 7 | 122 | 6.61e-01 |
| GO:BP | GO:0016078 | tRNA catabolic process | 1 | 14 | 6.61e-01 |
| GO:BP | GO:0032770 | positive regulation of monooxygenase activity | 1 | 20 | 6.61e-01 |
| GO:BP | GO:0071027 | nuclear RNA surveillance | 1 | 14 | 6.61e-01 |
| GO:BP | GO:0030520 | intracellular estrogen receptor signaling pathway | 3 | 41 | 6.62e-01 |
| GO:BP | GO:0001783 | B cell apoptotic process | 2 | 21 | 6.62e-01 |
| GO:BP | GO:0006353 | DNA-templated transcription termination | 1 | 22 | 6.62e-01 |
| GO:BP | GO:0051259 | protein complex oligomerization | 8 | 185 | 6.63e-01 |
| GO:BP | GO:0032341 | aldosterone metabolic process | 1 | 10 | 6.63e-01 |
| GO:BP | GO:0061900 | glial cell activation | 2 | 23 | 6.64e-01 |
| GO:BP | GO:0038066 | p38MAPK cascade | 2 | 43 | 6.64e-01 |
| GO:BP | GO:0046488 | phosphatidylinositol metabolic process | 2 | 140 | 6.64e-01 |
| GO:BP | GO:0050821 | protein stabilization | 7 | 191 | 6.64e-01 |
| GO:BP | GO:0030072 | peptide hormone secretion | 4 | 166 | 6.64e-01 |
| GO:BP | GO:0045631 | regulation of mechanoreceptor differentiation | 1 | 8 | 6.64e-01 |
| GO:BP | GO:2000980 | regulation of inner ear receptor cell differentiation | 1 | 8 | 6.64e-01 |
| GO:BP | GO:0044344 | cellular response to fibroblast growth factor stimulus | 2 | 81 | 6.64e-01 |
| GO:BP | GO:0045607 | regulation of inner ear auditory receptor cell differentiation | 1 | 8 | 6.64e-01 |
| GO:BP | GO:0007026 | negative regulation of microtubule depolymerization | 1 | 27 | 6.64e-01 |
| GO:BP | GO:0032370 | positive regulation of lipid transport | 1 | 58 | 6.64e-01 |
| GO:BP | GO:0019319 | hexose biosynthetic process | 1 | 70 | 6.64e-01 |
| GO:BP | GO:0042632 | cholesterol homeostasis | 1 | 58 | 6.64e-01 |
| GO:BP | GO:0044409 | entry into host | 7 | 113 | 6.64e-01 |
| GO:BP | GO:0032729 | positive regulation of type II interferon production | 3 | 36 | 6.64e-01 |
| GO:BP | GO:0051293 | establishment of spindle localization | 1 | 48 | 6.64e-01 |
| GO:BP | GO:0021675 | nerve development | 1 | 57 | 6.65e-01 |
| GO:BP | GO:1905039 | carboxylic acid transmembrane transport | 4 | 118 | 6.65e-01 |
| GO:BP | GO:1902004 | positive regulation of amyloid-beta formation | 1 | 17 | 6.65e-01 |
| GO:BP | GO:0060441 | epithelial tube branching involved in lung morphogenesis | 1 | 20 | 6.65e-01 |
| GO:BP | GO:0033604 | negative regulation of catecholamine secretion | 1 | 6 | 6.65e-01 |
| GO:BP | GO:0015800 | acidic amino acid transport | 4 | 39 | 6.65e-01 |
| GO:BP | GO:0051937 | catecholamine transport | 1 | 38 | 6.65e-01 |
| GO:BP | GO:1903510 | mucopolysaccharide metabolic process | 2 | 74 | 6.66e-01 |
| GO:BP | GO:0051099 | positive regulation of binding | 1 | 150 | 6.66e-01 |
| GO:BP | GO:0140527 | reciprocal homologous recombination | 1 | 36 | 6.66e-01 |
| GO:BP | GO:0007131 | reciprocal meiotic recombination | 1 | 36 | 6.66e-01 |
| GO:BP | GO:0043032 | positive regulation of macrophage activation | 2 | 12 | 6.66e-01 |
| GO:BP | GO:1902745 | positive regulation of lamellipodium organization | 2 | 32 | 6.66e-01 |
| GO:BP | GO:0043931 | ossification involved in bone maturation | 2 | 17 | 6.66e-01 |
| GO:BP | GO:0046879 | hormone secretion | 5 | 210 | 6.67e-01 |
| GO:BP | GO:1900116 | extracellular negative regulation of signal transduction | 1 | 9 | 6.67e-01 |
| GO:BP | GO:1900115 | extracellular regulation of signal transduction | 1 | 9 | 6.67e-01 |
| GO:BP | GO:0002752 | cell surface pattern recognition receptor signaling pathway | 2 | 27 | 6.67e-01 |
| GO:BP | GO:0055092 | sterol homeostasis | 1 | 59 | 6.67e-01 |
| GO:BP | GO:0000027 | ribosomal large subunit assembly | 1 | 23 | 6.67e-01 |
| GO:BP | GO:0051252 | regulation of RNA metabolic process | 5 | 2845 | 6.67e-01 |
| GO:BP | GO:0065003 | protein-containing complex assembly | 2 | 1335 | 6.67e-01 |
| GO:BP | GO:1901836 | regulation of transcription of nucleolar large rRNA by RNA polymerase I | 1 | 15 | 6.68e-01 |
| GO:BP | GO:0030833 | regulation of actin filament polymerization | 5 | 110 | 6.68e-01 |
| GO:BP | GO:1903825 | organic acid transmembrane transport | 4 | 119 | 6.68e-01 |
| GO:BP | GO:0030041 | actin filament polymerization | 6 | 134 | 6.69e-01 |
| GO:BP | GO:2000117 | negative regulation of cysteine-type endopeptidase activity | 3 | 64 | 6.69e-01 |
| GO:BP | GO:1902307 | positive regulation of sodium ion transmembrane transport | 1 | 17 | 6.69e-01 |
| GO:BP | GO:0055119 | relaxation of cardiac muscle | 1 | 17 | 6.69e-01 |
| GO:BP | GO:1905523 | positive regulation of macrophage migration | 1 | 13 | 6.69e-01 |
| GO:BP | GO:0032272 | negative regulation of protein polymerization | 1 | 71 | 6.69e-01 |
| GO:BP | GO:0007589 | body fluid secretion | 4 | 60 | 6.70e-01 |
| GO:BP | GO:0022038 | corpus callosum development | 2 | 20 | 6.70e-01 |
| GO:BP | GO:0098813 | nuclear chromosome segregation | 8 | 273 | 6.70e-01 |
| GO:BP | GO:0071868 | cellular response to monoamine stimulus | 5 | 60 | 6.71e-01 |
| GO:BP | GO:0071870 | cellular response to catecholamine stimulus | 5 | 60 | 6.71e-01 |
| GO:BP | GO:0051155 | positive regulation of striated muscle cell differentiation | 2 | 31 | 6.71e-01 |
| GO:BP | GO:0009395 | phospholipid catabolic process | 2 | 37 | 6.71e-01 |
| GO:BP | GO:0071360 | cellular response to exogenous dsRNA | 1 | 14 | 6.71e-01 |
| GO:BP | GO:2000649 | regulation of sodium ion transmembrane transporter activity | 1 | 44 | 6.71e-01 |
| GO:BP | GO:0030183 | B cell differentiation | 1 | 94 | 6.71e-01 |
| GO:BP | GO:0002444 | myeloid leukocyte mediated immunity | 5 | 60 | 6.71e-01 |
| GO:BP | GO:0008016 | regulation of heart contraction | 4 | 173 | 6.71e-01 |
| GO:BP | GO:0045824 | negative regulation of innate immune response | 4 | 53 | 6.72e-01 |
| GO:BP | GO:0002686 | negative regulation of leukocyte migration | 2 | 30 | 6.72e-01 |
| GO:BP | GO:0044241 | lipid digestion | 1 | 10 | 6.72e-01 |
| GO:BP | GO:0002274 | myeloid leukocyte activation | 8 | 123 | 6.72e-01 |
| GO:BP | GO:0045040 | protein insertion into mitochondrial outer membrane | 1 | 15 | 6.72e-01 |
| GO:BP | GO:0007008 | outer mitochondrial membrane organization | 1 | 15 | 6.72e-01 |
| GO:BP | GO:0010656 | negative regulation of muscle cell apoptotic process | 2 | 35 | 6.72e-01 |
| GO:BP | GO:0009743 | response to carbohydrate | 1 | 161 | 6.72e-01 |
| GO:BP | GO:0044458 | motile cilium assembly | 4 | 45 | 6.73e-01 |
| GO:BP | GO:0008217 | regulation of blood pressure | 1 | 115 | 6.73e-01 |
| GO:BP | GO:1901894 | regulation of ATPase-coupled calcium transmembrane transporter activity | 1 | 9 | 6.73e-01 |
| GO:BP | GO:1902287 | semaphorin-plexin signaling pathway involved in axon guidance | 1 | 14 | 6.73e-01 |
| GO:BP | GO:0001754 | eye photoreceptor cell differentiation | 3 | 30 | 6.73e-01 |
| GO:BP | GO:2000319 | regulation of T-helper 17 cell differentiation | 1 | 10 | 6.73e-01 |
| GO:BP | GO:0045807 | positive regulation of endocytosis | 6 | 104 | 6.73e-01 |
| GO:BP | GO:1901032 | negative regulation of response to reactive oxygen species | 1 | 13 | 6.73e-01 |
| GO:BP | GO:1903206 | negative regulation of hydrogen peroxide-induced cell death | 1 | 13 | 6.73e-01 |
| GO:BP | GO:1904871 | positive regulation of protein localization to Cajal body | 1 | 11 | 6.73e-01 |
| GO:BP | GO:1904869 | regulation of protein localization to Cajal body | 1 | 11 | 6.73e-01 |
| GO:BP | GO:0060216 | definitive hemopoiesis | 1 | 18 | 6.73e-01 |
| GO:BP | GO:1905097 | regulation of guanyl-nucleotide exchange factor activity | 1 | 10 | 6.73e-01 |
| GO:BP | GO:0070723 | response to cholesterol | 1 | 16 | 6.73e-01 |
| GO:BP | GO:0019222 | regulation of metabolic process | 1 | 5017 | 6.73e-01 |
| GO:BP | GO:0019058 | viral life cycle | 17 | 244 | 6.74e-01 |
| GO:BP | GO:2000811 | negative regulation of anoikis | 1 | 17 | 6.74e-01 |
| GO:BP | GO:0032024 | positive regulation of insulin secretion | 1 | 56 | 6.74e-01 |
| GO:BP | GO:0048704 | embryonic skeletal system morphogenesis | 4 | 55 | 6.74e-01 |
| GO:BP | GO:0055088 | lipid homeostasis | 7 | 115 | 6.74e-01 |
| GO:BP | GO:0002790 | peptide secretion | 4 | 170 | 6.74e-01 |
| GO:BP | GO:0043173 | nucleotide salvage | 1 | 15 | 6.74e-01 |
| GO:BP | GO:0010459 | negative regulation of heart rate | 1 | 7 | 6.74e-01 |
| GO:BP | GO:0006301 | postreplication repair | 1 | 34 | 6.74e-01 |
| GO:BP | GO:0090110 | COPII-coated vesicle cargo loading | 1 | 15 | 6.74e-01 |
| GO:BP | GO:1905476 | negative regulation of protein localization to membrane | 1 | 29 | 6.74e-01 |
| GO:BP | GO:0050885 | neuromuscular process controlling balance | 3 | 35 | 6.74e-01 |
| GO:BP | GO:0042058 | regulation of epidermal growth factor receptor signaling pathway | 5 | 60 | 6.74e-01 |
| GO:BP | GO:0018231 | peptidyl-S-diacylglycerol-L-cysteine biosynthetic process from peptidyl-cysteine | 2 | 21 | 6.74e-01 |
| GO:BP | GO:0060315 | negative regulation of ryanodine-sensitive calcium-release channel activity | 1 | 10 | 6.74e-01 |
| GO:BP | GO:0018230 | peptidyl-L-cysteine S-palmitoylation | 2 | 21 | 6.74e-01 |
| GO:BP | GO:0023051 | regulation of signaling | 4 | 2565 | 6.74e-01 |
| GO:BP | GO:0032410 | negative regulation of transporter activity | 6 | 58 | 6.74e-01 |
| GO:BP | GO:0001916 | positive regulation of T cell mediated cytotoxicity | 2 | 13 | 6.74e-01 |
| GO:BP | GO:0071875 | adrenergic receptor signaling pathway | 2 | 24 | 6.75e-01 |
| GO:BP | GO:1901028 | regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway | 2 | 25 | 6.75e-01 |
| GO:BP | GO:0051788 | response to misfolded protein | 2 | 25 | 6.75e-01 |
| GO:BP | GO:0006826 | iron ion transport | 4 | 40 | 6.75e-01 |
| GO:BP | GO:2001135 | regulation of endocytic recycling | 1 | 17 | 6.75e-01 |
| GO:BP | GO:0072583 | clathrin-dependent endocytosis | 3 | 43 | 6.76e-01 |
| GO:BP | GO:0099550 | trans-synaptic signaling, modulating synaptic transmission | 1 | 10 | 6.76e-01 |
| GO:BP | GO:0018958 | phenol-containing compound metabolic process | 1 | 61 | 6.76e-01 |
| GO:BP | GO:0032649 | regulation of type II interferon production | 3 | 52 | 6.76e-01 |
| GO:BP | GO:0006281 | DNA repair | 8 | 534 | 6.76e-01 |
| GO:BP | GO:0010646 | regulation of cell communication | 4 | 2573 | 6.76e-01 |
| GO:BP | GO:0022412 | cellular process involved in reproduction in multicellular organism | 2 | 252 | 6.76e-01 |
| GO:BP | GO:0035589 | G protein-coupled purinergic nucleotide receptor signaling pathway | 1 | 4 | 6.76e-01 |
| GO:BP | GO:0050866 | negative regulation of cell activation | 2 | 124 | 6.77e-01 |
| GO:BP | GO:0051276 | chromosome organization | 19 | 543 | 6.77e-01 |
| GO:BP | GO:0006220 | pyrimidine nucleotide metabolic process | 2 | 46 | 6.77e-01 |
| GO:BP | GO:0046636 | negative regulation of alpha-beta T cell activation | 3 | 25 | 6.78e-01 |
| GO:BP | GO:0014829 | vascular associated smooth muscle contraction | 2 | 20 | 6.78e-01 |
| GO:BP | GO:0002088 | lens development in camera-type eye | 5 | 57 | 6.78e-01 |
| GO:BP | GO:0043380 | regulation of memory T cell differentiation | 1 | 4 | 6.78e-01 |
| GO:BP | GO:0048563 | post-embryonic animal organ morphogenesis | 1 | 8 | 6.78e-01 |
| GO:BP | GO:0060394 | negative regulation of pathway-restricted SMAD protein phosphorylation | 1 | 13 | 6.78e-01 |
| GO:BP | GO:0090657 | telomeric loop disassembly | 1 | 9 | 6.78e-01 |
| GO:BP | GO:0097300 | programmed necrotic cell death | 2 | 39 | 6.78e-01 |
| GO:BP | GO:0018198 | peptidyl-cysteine modification | 2 | 41 | 6.78e-01 |
| GO:BP | GO:0014842 | regulation of skeletal muscle satellite cell proliferation | 1 | 8 | 6.78e-01 |
| GO:BP | GO:2000765 | regulation of cytoplasmic translation | 2 | 27 | 6.78e-01 |
| GO:BP | GO:0010713 | negative regulation of collagen metabolic process | 1 | 8 | 6.78e-01 |
| GO:BP | GO:0006098 | pentose-phosphate shunt | 1 | 19 | 6.79e-01 |
| GO:BP | GO:0002029 | desensitization of G protein-coupled receptor signaling pathway | 1 | 14 | 6.79e-01 |
| GO:BP | GO:0006907 | pinocytosis | 1 | 18 | 6.79e-01 |
| GO:BP | GO:2001236 | regulation of extrinsic apoptotic signaling pathway | 4 | 123 | 6.79e-01 |
| GO:BP | GO:0008089 | anterograde axonal transport | 1 | 45 | 6.79e-01 |
| GO:BP | GO:0008543 | fibroblast growth factor receptor signaling pathway | 1 | 60 | 6.79e-01 |
| GO:BP | GO:0032609 | type II interferon production | 3 | 53 | 6.80e-01 |
| GO:BP | GO:0008212 | mineralocorticoid metabolic process | 1 | 10 | 6.80e-01 |
| GO:BP | GO:0071495 | cellular response to endogenous stimulus | 1 | 1107 | 6.80e-01 |
| GO:BP | GO:0034309 | primary alcohol biosynthetic process | 1 | 12 | 6.80e-01 |
| GO:BP | GO:0034505 | tooth mineralization | 2 | 17 | 6.80e-01 |
| GO:BP | GO:0071305 | cellular response to vitamin D | 1 | 14 | 6.80e-01 |
| GO:BP | GO:0035023 | regulation of Rho protein signal transduction | 1 | 71 | 6.80e-01 |
| GO:BP | GO:0032526 | response to retinoic acid | 6 | 85 | 6.80e-01 |
| GO:BP | GO:0090276 | regulation of peptide hormone secretion | 2 | 132 | 6.80e-01 |
| GO:BP | GO:0071229 | cellular response to acid chemical | 2 | 71 | 6.81e-01 |
| GO:BP | GO:0071347 | cellular response to interleukin-1 | 4 | 64 | 6.81e-01 |
| GO:BP | GO:0034350 | regulation of glial cell apoptotic process | 1 | 10 | 6.81e-01 |
| GO:BP | GO:0042415 | norepinephrine metabolic process | 1 | 7 | 6.81e-01 |
| GO:BP | GO:0031338 | regulation of vesicle fusion | 1 | 17 | 6.81e-01 |
| GO:BP | GO:0010715 | regulation of extracellular matrix disassembly | 1 | 11 | 6.81e-01 |
| GO:BP | GO:0090103 | cochlea morphogenesis | 1 | 15 | 6.81e-01 |
| GO:BP | GO:0098856 | intestinal lipid absorption | 1 | 10 | 6.81e-01 |
| GO:BP | GO:0015740 | C4-dicarboxylate transport | 2 | 24 | 6.82e-01 |
| GO:BP | GO:0033623 | regulation of integrin activation | 1 | 11 | 6.82e-01 |
| GO:BP | GO:0019218 | regulation of steroid metabolic process | 1 | 69 | 6.82e-01 |
| GO:BP | GO:0070365 | hepatocyte differentiation | 1 | 12 | 6.82e-01 |
| GO:BP | GO:0048243 | norepinephrine secretion | 1 | 5 | 6.82e-01 |
| GO:BP | GO:0014061 | regulation of norepinephrine secretion | 1 | 5 | 6.82e-01 |
| GO:BP | GO:0044419 | biological process involved in interspecies interaction between organisms | 2 | 963 | 6.83e-01 |
| GO:BP | GO:0048265 | response to pain | 1 | 17 | 6.83e-01 |
| GO:BP | GO:2000191 | regulation of fatty acid transport | 1 | 19 | 6.83e-01 |
| GO:BP | GO:0016573 | histone acetylation | 1 | 143 | 6.83e-01 |
| GO:BP | GO:0034694 | response to prostaglandin | 1 | 21 | 6.83e-01 |
| GO:BP | GO:0050881 | musculoskeletal movement | 2 | 41 | 6.83e-01 |
| GO:BP | GO:0032623 | interleukin-2 production | 1 | 31 | 6.83e-01 |
| GO:BP | GO:0032663 | regulation of interleukin-2 production | 1 | 31 | 6.83e-01 |
| GO:BP | GO:0051653 | spindle localization | 1 | 52 | 6.83e-01 |
| GO:BP | GO:0008584 | male gonad development | 3 | 99 | 6.84e-01 |
| GO:BP | GO:0031399 | regulation of protein modification process | 1 | 1173 | 6.84e-01 |
| GO:BP | GO:0071345 | cellular response to cytokine stimulus | 1 | 540 | 6.84e-01 |
| GO:BP | GO:0016237 | lysosomal microautophagy | 1 | 11 | 6.84e-01 |
| GO:BP | GO:0045793 | positive regulation of cell size | 1 | 11 | 6.84e-01 |
| GO:BP | GO:0002517 | T cell tolerance induction | 1 | 6 | 6.85e-01 |
| GO:BP | GO:0008625 | extrinsic apoptotic signaling pathway via death domain receptors | 6 | 72 | 6.85e-01 |
| GO:BP | GO:0010758 | regulation of macrophage chemotaxis | 1 | 14 | 6.85e-01 |
| GO:BP | GO:1902047 | polyamine transmembrane transport | 1 | 10 | 6.85e-01 |
| GO:BP | GO:0061430 | bone trabecula morphogenesis | 1 | 12 | 6.85e-01 |
| GO:BP | GO:0060627 | regulation of vesicle-mediated transport | 29 | 403 | 6.85e-01 |
| GO:BP | GO:0048546 | digestive tract morphogenesis | 3 | 31 | 6.86e-01 |
| GO:BP | GO:0070936 | protein K48-linked ubiquitination | 2 | 66 | 6.86e-01 |
| GO:BP | GO:0002791 | regulation of peptide secretion | 2 | 134 | 6.86e-01 |
| GO:BP | GO:0071277 | cellular response to calcium ion | 5 | 67 | 6.86e-01 |
| GO:BP | GO:0009147 | pyrimidine nucleoside triphosphate metabolic process | 1 | 22 | 6.86e-01 |
| GO:BP | GO:0010737 | protein kinase A signaling | 2 | 23 | 6.86e-01 |
| GO:BP | GO:0042487 | regulation of odontogenesis of dentin-containing tooth | 1 | 6 | 6.86e-01 |
| GO:BP | GO:0006941 | striated muscle contraction | 4 | 152 | 6.86e-01 |
| GO:BP | GO:1901863 | positive regulation of muscle tissue development | 1 | 18 | 6.86e-01 |
| GO:BP | GO:0016188 | synaptic vesicle maturation | 1 | 22 | 6.86e-01 |
| GO:BP | GO:0045686 | negative regulation of glial cell differentiation | 1 | 15 | 6.86e-01 |
| GO:BP | GO:0002698 | negative regulation of immune effector process | 2 | 59 | 6.86e-01 |
| GO:BP | GO:0009914 | hormone transport | 5 | 215 | 6.86e-01 |
| GO:BP | GO:0045940 | positive regulation of steroid metabolic process | 1 | 20 | 6.86e-01 |
| GO:BP | GO:0071867 | response to monoamine | 5 | 62 | 6.86e-01 |
| GO:BP | GO:0046364 | monosaccharide biosynthetic process | 1 | 79 | 6.86e-01 |
| GO:BP | GO:0071869 | response to catecholamine | 5 | 62 | 6.86e-01 |
| GO:BP | GO:0070863 | positive regulation of protein exit from endoplasmic reticulum | 1 | 10 | 6.86e-01 |
| GO:BP | GO:0019886 | antigen processing and presentation of exogenous peptide antigen via MHC class II | 2 | 15 | 6.86e-01 |
| GO:BP | GO:0030850 | prostate gland development | 1 | 35 | 6.86e-01 |
| GO:BP | GO:0046546 | development of primary male sexual characteristics | 3 | 100 | 6.86e-01 |
| GO:BP | GO:0071774 | response to fibroblast growth factor | 2 | 84 | 6.86e-01 |
| GO:BP | GO:1903203 | regulation of oxidative stress-induced neuron death | 1 | 25 | 6.87e-01 |
| GO:BP | GO:0051770 | positive regulation of nitric-oxide synthase biosynthetic process | 1 | 10 | 6.87e-01 |
| GO:BP | GO:0050851 | antigen receptor-mediated signaling pathway | 1 | 106 | 6.87e-01 |
| GO:BP | GO:0002638 | negative regulation of immunoglobulin production | 1 | 5 | 6.88e-01 |
| GO:BP | GO:0009308 | amine metabolic process | 1 | 68 | 6.88e-01 |
| GO:BP | GO:0031347 | regulation of defense response | 37 | 448 | 6.88e-01 |
| GO:BP | GO:2000392 | regulation of lamellipodium morphogenesis | 1 | 10 | 6.88e-01 |
| GO:BP | GO:0002888 | positive regulation of myeloid leukocyte mediated immunity | 1 | 12 | 6.88e-01 |
| GO:BP | GO:0050877 | nervous system process | 1 | 634 | 6.89e-01 |
| GO:BP | GO:0090087 | regulation of peptide transport | 2 | 136 | 6.89e-01 |
| GO:BP | GO:2000345 | regulation of hepatocyte proliferation | 1 | 13 | 6.89e-01 |
| GO:BP | GO:0046688 | response to copper ion | 2 | 29 | 6.89e-01 |
| GO:BP | GO:0050879 | multicellular organismal movement | 2 | 41 | 6.89e-01 |
| GO:BP | GO:0043933 | protein-containing complex organization | 2 | 1496 | 6.89e-01 |
| GO:BP | GO:0022401 | negative adaptation of signaling pathway | 1 | 15 | 6.89e-01 |
| GO:BP | GO:0032048 | cardiolipin metabolic process | 1 | 13 | 6.89e-01 |
| GO:BP | GO:0002098 | tRNA wobble uridine modification | 1 | 16 | 6.90e-01 |
| GO:BP | GO:0019932 | second-messenger-mediated signaling | 15 | 191 | 6.90e-01 |
| GO:BP | GO:0048771 | tissue remodeling | 1 | 114 | 6.90e-01 |
| GO:BP | GO:0002833 | positive regulation of response to biotic stimulus | 10 | 192 | 6.91e-01 |
| GO:BP | GO:0022406 | membrane docking | 5 | 84 | 6.91e-01 |
| GO:BP | GO:0032501 | multicellular organismal process | 1 | 4794 | 6.91e-01 |
| GO:BP | GO:0120036 | plasma membrane bounded cell projection organization | 1 | 1201 | 6.91e-01 |
| GO:BP | GO:0042116 | macrophage activation | 4 | 57 | 6.91e-01 |
| GO:BP | GO:0009967 | positive regulation of signal transduction | 1 | 1133 | 6.91e-01 |
| GO:BP | GO:0034508 | centromere complex assembly | 1 | 28 | 6.91e-01 |
| GO:BP | GO:0031579 | membrane raft organization | 1 | 19 | 6.91e-01 |
| GO:BP | GO:0071025 | RNA surveillance | 1 | 16 | 6.92e-01 |
| GO:BP | GO:0071801 | regulation of podosome assembly | 1 | 8 | 6.92e-01 |
| GO:BP | GO:0048570 | notochord morphogenesis | 1 | 9 | 6.92e-01 |
| GO:BP | GO:0045199 | maintenance of epithelial cell apical/basal polarity | 1 | 10 | 6.92e-01 |
| GO:BP | GO:0035825 | homologous recombination | 1 | 43 | 6.92e-01 |
| GO:BP | GO:0051445 | regulation of meiotic cell cycle | 4 | 45 | 6.92e-01 |
| GO:BP | GO:0009653 | anatomical structure morphogenesis | 13 | 1974 | 6.92e-01 |
| GO:BP | GO:0035090 | maintenance of apical/basal cell polarity | 1 | 10 | 6.92e-01 |
| GO:BP | GO:1903747 | regulation of establishment of protein localization to mitochondrion | 2 | 44 | 6.92e-01 |
| GO:BP | GO:0030878 | thyroid gland development | 1 | 17 | 6.92e-01 |
| GO:BP | GO:0060603 | mammary gland duct morphogenesis | 1 | 28 | 6.92e-01 |
| GO:BP | GO:0006468 | protein phosphorylation | 1 | 1167 | 6.92e-01 |
| GO:BP | GO:0022010 | central nervous system myelination | 1 | 12 | 6.92e-01 |
| GO:BP | GO:0032291 | axon ensheathment in central nervous system | 1 | 12 | 6.92e-01 |
| GO:BP | GO:0031114 | regulation of microtubule depolymerization | 1 | 31 | 6.92e-01 |
| GO:BP | GO:0018393 | internal peptidyl-lysine acetylation | 1 | 148 | 6.93e-01 |
| GO:BP | GO:0002707 | negative regulation of lymphocyte mediated immunity | 1 | 24 | 6.94e-01 |
| GO:BP | GO:0098586 | cellular response to virus | 1 | 40 | 6.94e-01 |
| GO:BP | GO:0051657 | maintenance of organelle location | 1 | 11 | 6.94e-01 |
| GO:BP | GO:1901222 | regulation of NIK/NF-kappaB signaling | 5 | 65 | 6.94e-01 |
| GO:BP | GO:0002076 | osteoblast development | 1 | 12 | 6.94e-01 |
| GO:BP | GO:2000114 | regulation of establishment of cell polarity | 2 | 22 | 6.95e-01 |
| GO:BP | GO:0001956 | positive regulation of neurotransmitter secretion | 1 | 12 | 6.95e-01 |
| GO:BP | GO:0001501 | skeletal system development | 19 | 377 | 6.95e-01 |
| GO:BP | GO:0070229 | negative regulation of lymphocyte apoptotic process | 1 | 23 | 6.95e-01 |
| GO:BP | GO:0043576 | regulation of respiratory gaseous exchange | 2 | 15 | 6.96e-01 |
| GO:BP | GO:0007416 | synapse assembly | 15 | 152 | 6.96e-01 |
| GO:BP | GO:0000280 | nuclear division | 1 | 344 | 6.96e-01 |
| GO:BP | GO:0021692 | cerebellar Purkinje cell layer morphogenesis | 1 | 16 | 6.96e-01 |
| GO:BP | GO:0006396 | RNA processing | 1 | 929 | 6.96e-01 |
| GO:BP | GO:0006475 | internal protein amino acid acetylation | 1 | 150 | 6.96e-01 |
| GO:BP | GO:0015810 | aspartate transmembrane transport | 1 | 16 | 6.96e-01 |
| GO:BP | GO:0033044 | regulation of chromosome organization | 7 | 236 | 6.96e-01 |
| GO:BP | GO:0045869 | negative regulation of single stranded viral RNA replication via double stranded DNA intermediate | 1 | 12 | 6.96e-01 |
| GO:BP | GO:0033629 | negative regulation of cell adhesion mediated by integrin | 1 | 10 | 6.97e-01 |
| GO:BP | GO:0043379 | memory T cell differentiation | 1 | 5 | 6.97e-01 |
| GO:BP | GO:0048634 | regulation of muscle organ development | 1 | 14 | 6.97e-01 |
| GO:BP | GO:0030030 | cell projection organization | 1 | 1233 | 6.97e-01 |
| GO:BP | GO:0006119 | oxidative phosphorylation | 1 | 122 | 6.97e-01 |
| GO:BP | GO:0030901 | midbrain development | 1 | 69 | 6.97e-01 |
| GO:BP | GO:0060669 | embryonic placenta morphogenesis | 2 | 22 | 6.97e-01 |
| GO:BP | GO:0048678 | response to axon injury | 1 | 64 | 6.97e-01 |
| GO:BP | GO:0046486 | glycerolipid metabolic process | 5 | 311 | 6.97e-01 |
| GO:BP | GO:0048260 | positive regulation of receptor-mediated endocytosis | 2 | 42 | 6.97e-01 |
| GO:BP | GO:0015844 | monoamine transport | 1 | 45 | 6.97e-01 |
| GO:BP | GO:0030261 | chromosome condensation | 1 | 33 | 6.97e-01 |
| GO:BP | GO:2001223 | negative regulation of neuron migration | 1 | 8 | 6.97e-01 |
| GO:BP | GO:0042129 | regulation of T cell proliferation | 4 | 95 | 6.98e-01 |
| GO:BP | GO:0019430 | removal of superoxide radicals | 1 | 17 | 6.99e-01 |
| GO:BP | GO:0006810 | transport | 3 | 3298 | 6.99e-01 |
| GO:BP | GO:0030218 | erythrocyte differentiation | 6 | 107 | 6.99e-01 |
| GO:BP | GO:0010556 | regulation of macromolecule biosynthetic process | 5 | 3012 | 6.99e-01 |
| GO:BP | GO:0033108 | mitochondrial respiratory chain complex assembly | 5 | 94 | 7.00e-01 |
| GO:BP | GO:0048711 | positive regulation of astrocyte differentiation | 1 | 11 | 7.00e-01 |
| GO:BP | GO:0043648 | dicarboxylic acid metabolic process | 1 | 74 | 7.00e-01 |
| GO:BP | GO:0030595 | leukocyte chemotaxis | 2 | 115 | 7.00e-01 |
| GO:BP | GO:1902117 | positive regulation of organelle assembly | 5 | 73 | 7.00e-01 |
| GO:BP | GO:0140029 | exocytic process | 1 | 69 | 7.01e-01 |
| GO:BP | GO:0051047 | positive regulation of secretion | 3 | 215 | 7.01e-01 |
| GO:BP | GO:0060795 | cell fate commitment involved in formation of primary germ layer | 2 | 18 | 7.01e-01 |
| GO:BP | GO:0061036 | positive regulation of cartilage development | 2 | 25 | 7.01e-01 |
| GO:BP | GO:0072074 | kidney mesenchyme development | 1 | 13 | 7.01e-01 |
| GO:BP | GO:0075522 | IRES-dependent viral translational initiation | 1 | 11 | 7.01e-01 |
| GO:BP | GO:0015980 | energy derivation by oxidation of organic compounds | 1 | 288 | 7.02e-01 |
| GO:BP | GO:0010288 | response to lead ion | 1 | 18 | 7.02e-01 |
| GO:BP | GO:0010591 | regulation of lamellipodium assembly | 2 | 33 | 7.02e-01 |
| GO:BP | GO:0006650 | glycerophospholipid metabolic process | 1 | 252 | 7.02e-01 |
| GO:BP | GO:1903867 | extraembryonic membrane development | 1 | 11 | 7.03e-01 |
| GO:BP | GO:0097396 | response to interleukin-17 | 1 | 13 | 7.03e-01 |
| GO:BP | GO:0098814 | spontaneous synaptic transmission | 1 | 10 | 7.03e-01 |
| GO:BP | GO:0002823 | negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 1 | 26 | 7.04e-01 |
| GO:BP | GO:0015804 | neutral amino acid transport | 3 | 43 | 7.04e-01 |
| GO:BP | GO:0040037 | negative regulation of fibroblast growth factor receptor signaling pathway | 1 | 16 | 7.04e-01 |
| GO:BP | GO:0010633 | negative regulation of epithelial cell migration | 4 | 53 | 7.04e-01 |
| GO:BP | GO:1902285 | semaphorin-plexin signaling pathway involved in neuron projection guidance | 1 | 16 | 7.04e-01 |
| GO:BP | GO:0048710 | regulation of astrocyte differentiation | 2 | 21 | 7.04e-01 |
| GO:BP | GO:0002323 | natural killer cell activation involved in immune response | 1 | 6 | 7.04e-01 |
| GO:BP | GO:0060670 | branching involved in labyrinthine layer morphogenesis | 1 | 10 | 7.05e-01 |
| GO:BP | GO:0042098 | T cell proliferation | 5 | 120 | 7.05e-01 |
| GO:BP | GO:0061077 | chaperone-mediated protein folding | 5 | 65 | 7.05e-01 |
| GO:BP | GO:0099638 | endosome to plasma membrane protein transport | 1 | 15 | 7.05e-01 |
| GO:BP | GO:0002683 | negative regulation of immune system process | 24 | 289 | 7.05e-01 |
| GO:BP | GO:0010881 | regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion | 1 | 20 | 7.06e-01 |
| GO:BP | GO:0031326 | regulation of cellular biosynthetic process | 17 | 3080 | 7.06e-01 |
| GO:BP | GO:0070977 | bone maturation | 2 | 19 | 7.06e-01 |
| GO:BP | GO:0048641 | regulation of skeletal muscle tissue development | 1 | 20 | 7.06e-01 |
| GO:BP | GO:0008298 | intracellular mRNA localization | 1 | 11 | 7.06e-01 |
| GO:BP | GO:0043123 | positive regulation of I-kappaB kinase/NF-kappaB signaling | 1 | 153 | 7.07e-01 |
| GO:BP | GO:0002237 | response to molecule of bacterial origin | 8 | 187 | 7.07e-01 |
| GO:BP | GO:0016043 | cellular component organization | 5 | 5076 | 7.08e-01 |
| GO:BP | GO:0048519 | negative regulation of biological process | 7 | 4045 | 7.08e-01 |
| GO:BP | GO:0099173 | postsynapse organization | 14 | 155 | 7.09e-01 |
| GO:BP | GO:0071071 | regulation of phospholipid biosynthetic process | 1 | 15 | 7.09e-01 |
| GO:BP | GO:1904037 | positive regulation of epithelial cell apoptotic process | 1 | 26 | 7.09e-01 |
| GO:BP | GO:0003157 | endocardium development | 1 | 9 | 7.09e-01 |
| GO:BP | GO:0042462 | eye photoreceptor cell development | 3 | 19 | 7.09e-01 |
| GO:BP | GO:0006457 | protein folding | 1 | 192 | 7.09e-01 |
| GO:BP | GO:0060155 | platelet dense granule organization | 1 | 23 | 7.09e-01 |
| GO:BP | GO:1902305 | regulation of sodium ion transmembrane transport | 1 | 51 | 7.10e-01 |
| GO:BP | GO:0010561 | negative regulation of glycoprotein biosynthetic process | 1 | 10 | 7.10e-01 |
| GO:BP | GO:1903351 | cellular response to dopamine | 4 | 47 | 7.10e-01 |
| GO:BP | GO:0019933 | cAMP-mediated signaling | 1 | 35 | 7.10e-01 |
| GO:BP | GO:0015833 | peptide transport | 4 | 179 | 7.10e-01 |
| GO:BP | GO:0072655 | establishment of protein localization to mitochondrion | 6 | 118 | 7.11e-01 |
| GO:BP | GO:0010613 | positive regulation of cardiac muscle hypertrophy | 1 | 22 | 7.11e-01 |
| GO:BP | GO:0032740 | positive regulation of interleukin-17 production | 1 | 12 | 7.11e-01 |
| GO:BP | GO:0007218 | neuropeptide signaling pathway | 1 | 36 | 7.11e-01 |
| GO:BP | GO:0030048 | actin filament-based movement | 2 | 112 | 7.11e-01 |
| GO:BP | GO:0035630 | bone mineralization involved in bone maturation | 1 | 6 | 7.11e-01 |
| GO:BP | GO:0032330 | regulation of chondrocyte differentiation | 1 | 37 | 7.11e-01 |
| GO:BP | GO:0071310 | cellular response to organic substance | 2 | 1399 | 7.11e-01 |
| GO:BP | GO:0023058 | adaptation of signaling pathway | 1 | 16 | 7.11e-01 |
| GO:BP | GO:0045746 | negative regulation of Notch signaling pathway | 1 | 31 | 7.11e-01 |
| GO:BP | GO:0000963 | mitochondrial RNA processing | 1 | 20 | 7.11e-01 |
| GO:BP | GO:0051179 | localization | 5 | 3969 | 7.11e-01 |
| GO:BP | GO:0007007 | inner mitochondrial membrane organization | 3 | 40 | 7.11e-01 |
| GO:BP | GO:0036475 | neuron death in response to oxidative stress | 1 | 28 | 7.11e-01 |
| GO:BP | GO:0035542 | regulation of SNARE complex assembly | 1 | 13 | 7.11e-01 |
| GO:BP | GO:0051261 | protein depolymerization | 1 | 105 | 7.12e-01 |
| GO:BP | GO:0002089 | lens morphogenesis in camera-type eye | 1 | 18 | 7.12e-01 |
| GO:BP | GO:0048485 | sympathetic nervous system development | 1 | 14 | 7.12e-01 |
| GO:BP | GO:1901142 | insulin metabolic process | 1 | 11 | 7.12e-01 |
| GO:BP | GO:0070227 | lymphocyte apoptotic process | 2 | 56 | 7.12e-01 |
| GO:BP | GO:0070266 | necroptotic process | 1 | 32 | 7.12e-01 |
| GO:BP | GO:0046184 | aldehyde biosynthetic process | 1 | 14 | 7.12e-01 |
| GO:BP | GO:0090030 | regulation of steroid hormone biosynthetic process | 1 | 15 | 7.12e-01 |
| GO:BP | GO:0045806 | negative regulation of endocytosis | 1 | 56 | 7.12e-01 |
| GO:BP | GO:0002695 | negative regulation of leukocyte activation | 12 | 105 | 7.12e-01 |
| GO:BP | GO:0071621 | granulocyte chemotaxis | 1 | 53 | 7.12e-01 |
| GO:BP | GO:1990266 | neutrophil migration | 1 | 52 | 7.12e-01 |
| GO:BP | GO:0032467 | positive regulation of cytokinesis | 3 | 33 | 7.12e-01 |
| GO:BP | GO:0048741 | skeletal muscle fiber development | 2 | 30 | 7.12e-01 |
| GO:BP | GO:0042596 | fear response | 3 | 32 | 7.12e-01 |
| GO:BP | GO:0006801 | superoxide metabolic process | 1 | 42 | 7.12e-01 |
| GO:BP | GO:0044249 | cellular biosynthetic process | 10 | 4245 | 7.13e-01 |
| GO:BP | GO:0010880 | regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | 2 | 27 | 7.13e-01 |
| GO:BP | GO:0048285 | organelle fission | 6 | 388 | 7.14e-01 |
| GO:BP | GO:0016226 | iron-sulfur cluster assembly | 1 | 29 | 7.15e-01 |
| GO:BP | GO:0006740 | NADPH regeneration | 1 | 22 | 7.15e-01 |
| GO:BP | GO:0021895 | cerebral cortex neuron differentiation | 1 | 14 | 7.15e-01 |
| GO:BP | GO:0031163 | metallo-sulfur cluster assembly | 1 | 29 | 7.15e-01 |
| GO:BP | GO:0009060 | aerobic respiration | 2 | 168 | 7.15e-01 |
| GO:BP | GO:0051280 | negative regulation of release of sequestered calcium ion into cytosol | 1 | 11 | 7.15e-01 |
| GO:BP | GO:0042976 | activation of Janus kinase activity | 1 | 7 | 7.15e-01 |
| GO:BP | GO:0021879 | forebrain neuron differentiation | 3 | 23 | 7.15e-01 |
| GO:BP | GO:1901841 | regulation of high voltage-gated calcium channel activity | 1 | 12 | 7.15e-01 |
| GO:BP | GO:0071549 | cellular response to dexamethasone stimulus | 1 | 24 | 7.15e-01 |
| GO:BP | GO:0042559 | pteridine-containing compound biosynthetic process | 1 | 12 | 7.15e-01 |
| GO:BP | GO:0002399 | MHC class II protein complex assembly | 1 | 4 | 7.15e-01 |
| GO:BP | GO:0002503 | peptide antigen assembly with MHC class II protein complex | 1 | 4 | 7.15e-01 |
| GO:BP | GO:1903350 | response to dopamine | 4 | 48 | 7.15e-01 |
| GO:BP | GO:0090715 | immunological memory formation process | 1 | 6 | 7.15e-01 |
| GO:BP | GO:0002468 | dendritic cell antigen processing and presentation | 1 | 6 | 7.15e-01 |
| GO:BP | GO:0010524 | positive regulation of calcium ion transport into cytosol | 1 | 7 | 7.16e-01 |
| GO:BP | GO:1900103 | positive regulation of endoplasmic reticulum unfolded protein response | 1 | 13 | 7.16e-01 |
| GO:BP | GO:0006882 | intracellular zinc ion homeostasis | 1 | 28 | 7.16e-01 |
| GO:BP | GO:0034654 | nucleobase-containing compound biosynthetic process | 7 | 3070 | 7.16e-01 |
| GO:BP | GO:0014841 | skeletal muscle satellite cell proliferation | 1 | 10 | 7.16e-01 |
| GO:BP | GO:0001682 | tRNA 5’-leader removal | 1 | 13 | 7.16e-01 |
| GO:BP | GO:0051443 | positive regulation of ubiquitin-protein transferase activity | 1 | 31 | 7.16e-01 |
| GO:BP | GO:0042398 | cellular modified amino acid biosynthetic process | 2 | 26 | 7.16e-01 |
| GO:BP | GO:0035567 | non-canonical Wnt signaling pathway | 3 | 62 | 7.16e-01 |
| GO:BP | GO:0032094 | response to food | 1 | 22 | 7.16e-01 |
| GO:BP | GO:0014047 | glutamate secretion | 1 | 14 | 7.16e-01 |
| GO:BP | GO:0006515 | protein quality control for misfolded or incompletely synthesized proteins | 2 | 28 | 7.16e-01 |
| GO:BP | GO:0051918 | negative regulation of fibrinolysis | 1 | 8 | 7.16e-01 |
| GO:BP | GO:0001662 | behavioral fear response | 2 | 29 | 7.17e-01 |
| GO:BP | GO:0006360 | transcription by RNA polymerase I | 3 | 62 | 7.17e-01 |
| GO:BP | GO:0051494 | negative regulation of cytoskeleton organization | 6 | 140 | 7.17e-01 |
| GO:BP | GO:0043302 | positive regulation of leukocyte degranulation | 2 | 15 | 7.17e-01 |
| GO:BP | GO:0007398 | ectoderm development | 1 | 15 | 7.17e-01 |
| GO:BP | GO:0019219 | regulation of nucleobase-containing compound metabolic process | 5 | 3080 | 7.17e-01 |
| GO:BP | GO:0031334 | positive regulation of protein-containing complex assembly | 1 | 161 | 7.17e-01 |
| GO:BP | GO:0034314 | Arp2/3 complex-mediated actin nucleation | 1 | 40 | 7.17e-01 |
| GO:BP | GO:0034762 | regulation of transmembrane transport | 1 | 391 | 7.17e-01 |
| GO:BP | GO:0051234 | establishment of localization | 3 | 3433 | 7.17e-01 |
| GO:BP | GO:0016064 | immunoglobulin mediated immune response | 4 | 76 | 7.17e-01 |
| GO:BP | GO:0006366 | transcription by RNA polymerase II | 11 | 1995 | 7.17e-01 |
| GO:BP | GO:0030301 | cholesterol transport | 1 | 80 | 7.17e-01 |
| GO:BP | GO:1905954 | positive regulation of lipid localization | 1 | 75 | 7.17e-01 |
| GO:BP | GO:0045069 | regulation of viral genome replication | 1 | 64 | 7.18e-01 |
| GO:BP | GO:0044703 | multi-organism reproductive process | 9 | 131 | 7.18e-01 |
| GO:BP | GO:1900745 | positive regulation of p38MAPK cascade | 1 | 22 | 7.18e-01 |
| GO:BP | GO:0043269 | regulation of monoatomic ion transport | 1 | 373 | 7.18e-01 |
| GO:BP | GO:0036314 | response to sterol | 1 | 19 | 7.18e-01 |
| GO:BP | GO:2000178 | negative regulation of neural precursor cell proliferation | 1 | 21 | 7.18e-01 |
| GO:BP | GO:0033327 | Leydig cell differentiation | 1 | 9 | 7.18e-01 |
| GO:BP | GO:0014742 | positive regulation of muscle hypertrophy | 1 | 22 | 7.18e-01 |
| GO:BP | GO:0031397 | negative regulation of protein ubiquitination | 6 | 76 | 7.18e-01 |
| GO:BP | GO:0006310 | DNA recombination | 4 | 257 | 7.19e-01 |
| GO:BP | GO:0015812 | gamma-aminobutyric acid transport | 1 | 11 | 7.19e-01 |
| GO:BP | GO:0045653 | negative regulation of megakaryocyte differentiation | 1 | 17 | 7.19e-01 |
| GO:BP | GO:0030007 | intracellular potassium ion homeostasis | 1 | 11 | 7.19e-01 |
| GO:BP | GO:0009719 | response to endogenous stimulus | 1 | 1278 | 7.20e-01 |
| GO:BP | GO:1902993 | positive regulation of amyloid precursor protein catabolic process | 1 | 22 | 7.20e-01 |
| GO:BP | GO:0009059 | macromolecule biosynthetic process | 20 | 3730 | 7.21e-01 |
| GO:BP | GO:0071840 | cellular component organization or biogenesis | 1 | 5274 | 7.22e-01 |
| GO:BP | GO:0001731 | formation of translation preinitiation complex | 1 | 11 | 7.23e-01 |
| GO:BP | GO:0015846 | polyamine transport | 1 | 12 | 7.23e-01 |
| GO:BP | GO:0009127 | purine nucleoside monophosphate biosynthetic process | 1 | 21 | 7.23e-01 |
| GO:BP | GO:0035282 | segmentation | 1 | 75 | 7.23e-01 |
| GO:BP | GO:0015918 | sterol transport | 4 | 92 | 7.24e-01 |
| GO:BP | GO:0006839 | mitochondrial transport | 2 | 185 | 7.24e-01 |
| GO:BP | GO:0072337 | modified amino acid transport | 2 | 35 | 7.24e-01 |
| GO:BP | GO:0071451 | cellular response to superoxide | 1 | 19 | 7.24e-01 |
| GO:BP | GO:0071450 | cellular response to oxygen radical | 1 | 19 | 7.24e-01 |
| GO:BP | GO:0050670 | regulation of lymphocyte proliferation | 5 | 126 | 7.24e-01 |
| GO:BP | GO:0023056 | positive regulation of signaling | 1 | 1256 | 7.24e-01 |
| GO:BP | GO:0044070 | regulation of monoatomic anion transport | 1 | 12 | 7.24e-01 |
| GO:BP | GO:0002820 | negative regulation of adaptive immune response | 1 | 27 | 7.24e-01 |
| GO:BP | GO:0010647 | positive regulation of cell communication | 1 | 1255 | 7.24e-01 |
| GO:BP | GO:0120178 | steroid hormone biosynthetic process | 3 | 29 | 7.25e-01 |
| GO:BP | GO:0045740 | positive regulation of DNA replication | 1 | 35 | 7.25e-01 |
| GO:BP | GO:0001837 | epithelial to mesenchymal transition | 8 | 138 | 7.25e-01 |
| GO:BP | GO:0043312 | neutrophil degranulation | 1 | 5 | 7.25e-01 |
| GO:BP | GO:0098935 | dendritic transport | 1 | 13 | 7.26e-01 |
| GO:BP | GO:0043248 | proteasome assembly | 1 | 13 | 7.26e-01 |
| GO:BP | GO:0072111 | cell proliferation involved in kidney development | 1 | 17 | 7.26e-01 |
| GO:BP | GO:0019724 | B cell mediated immunity | 4 | 77 | 7.26e-01 |
| GO:BP | GO:0019229 | regulation of vasoconstriction | 1 | 38 | 7.26e-01 |
| GO:BP | GO:0070232 | regulation of T cell apoptotic process | 1 | 24 | 7.26e-01 |
| GO:BP | GO:0002209 | behavioral defense response | 2 | 30 | 7.26e-01 |
| GO:BP | GO:0046068 | cGMP metabolic process | 1 | 11 | 7.26e-01 |
| GO:BP | GO:0071359 | cellular response to dsRNA | 1 | 18 | 7.27e-01 |
| GO:BP | GO:0010566 | regulation of ketone biosynthetic process | 1 | 16 | 7.27e-01 |
| GO:BP | GO:2000648 | positive regulation of stem cell proliferation | 1 | 31 | 7.27e-01 |
| GO:BP | GO:0032642 | regulation of chemokine production | 2 | 46 | 7.27e-01 |
| GO:BP | GO:0032602 | chemokine production | 2 | 46 | 7.27e-01 |
| GO:BP | GO:0070633 | transepithelial transport | 2 | 24 | 7.28e-01 |
| GO:BP | GO:0002092 | positive regulation of receptor internalization | 1 | 21 | 7.28e-01 |
| GO:BP | GO:0070168 | negative regulation of biomineral tissue development | 1 | 19 | 7.28e-01 |
| GO:BP | GO:0032413 | negative regulation of ion transmembrane transporter activity | 5 | 51 | 7.28e-01 |
| GO:BP | GO:0031113 | regulation of microtubule polymerization | 2 | 52 | 7.28e-01 |
| GO:BP | GO:0051049 | regulation of transport | 1 | 1267 | 7.29e-01 |
| GO:BP | GO:0010611 | regulation of cardiac muscle hypertrophy | 2 | 48 | 7.29e-01 |
| GO:BP | GO:0016601 | Rac protein signal transduction | 2 | 42 | 7.29e-01 |
| GO:BP | GO:0060048 | cardiac muscle contraction | 2 | 123 | 7.29e-01 |
| GO:BP | GO:0018130 | heterocycle biosynthetic process | 5 | 3132 | 7.29e-01 |
| GO:BP | GO:0016042 | lipid catabolic process | 1 | 225 | 7.30e-01 |
| GO:BP | GO:0030168 | platelet activation | 2 | 91 | 7.30e-01 |
| GO:BP | GO:0050920 | regulation of chemotaxis | 1 | 142 | 7.30e-01 |
| GO:BP | GO:0002097 | tRNA wobble base modification | 1 | 19 | 7.30e-01 |
| GO:BP | GO:2001239 | regulation of extrinsic apoptotic signaling pathway in absence of ligand | 2 | 35 | 7.30e-01 |
| GO:BP | GO:1904321 | response to forskolin | 1 | 11 | 7.31e-01 |
| GO:BP | GO:1904322 | cellular response to forskolin | 1 | 11 | 7.31e-01 |
| GO:BP | GO:0007620 | copulation | 1 | 10 | 7.31e-01 |
| GO:BP | GO:0007626 | locomotory behavior | 10 | 138 | 7.31e-01 |
| GO:BP | GO:0016310 | phosphorylation | 1 | 1372 | 7.31e-01 |
| GO:BP | GO:0022402 | cell cycle process | 19 | 1086 | 7.31e-01 |
| GO:BP | GO:0019438 | aromatic compound biosynthetic process | 5 | 3133 | 7.31e-01 |
| GO:BP | GO:0050807 | regulation of synapse organization | 13 | 184 | 7.32e-01 |
| GO:BP | GO:0061097 | regulation of protein tyrosine kinase activity | 4 | 65 | 7.32e-01 |
| GO:BP | GO:0098657 | import into cell | 11 | 166 | 7.33e-01 |
| GO:BP | GO:0061462 | protein localization to lysosome | 3 | 46 | 7.33e-01 |
| GO:BP | GO:0051052 | regulation of DNA metabolic process | 15 | 452 | 7.33e-01 |
| GO:BP | GO:0075294 | positive regulation by symbiont of entry into host | 1 | 11 | 7.33e-01 |
| GO:BP | GO:1901700 | response to oxygen-containing compound | 1 | 1223 | 7.33e-01 |
| GO:BP | GO:0046598 | positive regulation of viral entry into host cell | 1 | 11 | 7.33e-01 |
| GO:BP | GO:1901029 | negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway | 1 | 13 | 7.33e-01 |
| GO:BP | GO:0000002 | mitochondrial genome maintenance | 1 | 29 | 7.33e-01 |
| GO:BP | GO:0061098 | positive regulation of protein tyrosine kinase activity | 2 | 33 | 7.33e-01 |
| GO:BP | GO:1901077 | regulation of relaxation of muscle | 1 | 8 | 7.33e-01 |
| GO:BP | GO:0014857 | regulation of skeletal muscle cell proliferation | 1 | 10 | 7.33e-01 |
| GO:BP | GO:0030282 | bone mineralization | 1 | 82 | 7.33e-01 |
| GO:BP | GO:0070373 | negative regulation of ERK1 and ERK2 cascade | 1 | 59 | 7.34e-01 |
| GO:BP | GO:0032944 | regulation of mononuclear cell proliferation | 5 | 129 | 7.34e-01 |
| GO:BP | GO:0009223 | pyrimidine deoxyribonucleotide catabolic process | 1 | 15 | 7.34e-01 |
| GO:BP | GO:0001910 | regulation of leukocyte mediated cytotoxicity | 3 | 30 | 7.35e-01 |
| GO:BP | GO:0006820 | monoatomic anion transport | 9 | 83 | 7.35e-01 |
| GO:BP | GO:0035082 | axoneme assembly | 1 | 52 | 7.35e-01 |
| GO:BP | GO:0006767 | water-soluble vitamin metabolic process | 4 | 49 | 7.35e-01 |
| GO:BP | GO:0002495 | antigen processing and presentation of peptide antigen via MHC class II | 2 | 17 | 7.35e-01 |
| GO:BP | GO:0006695 | cholesterol biosynthetic process | 1 | 46 | 7.35e-01 |
| GO:BP | GO:1902883 | negative regulation of response to oxidative stress | 1 | 18 | 7.35e-01 |
| GO:BP | GO:0150078 | positive regulation of neuroinflammatory response | 1 | 4 | 7.35e-01 |
| GO:BP | GO:1902653 | secondary alcohol biosynthetic process | 1 | 46 | 7.35e-01 |
| GO:BP | GO:0001782 | B cell homeostasis | 2 | 24 | 7.35e-01 |
| GO:BP | GO:0071385 | cellular response to glucocorticoid stimulus | 2 | 40 | 7.35e-01 |
| GO:BP | GO:0039532 | negative regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway | 1 | 17 | 7.35e-01 |
| GO:BP | GO:0051209 | release of sequestered calcium ion into cytosol | 2 | 82 | 7.35e-01 |
| GO:BP | GO:0045987 | positive regulation of smooth muscle contraction | 1 | 17 | 7.36e-01 |
| GO:BP | GO:0006706 | steroid catabolic process | 1 | 13 | 7.36e-01 |
| GO:BP | GO:1903038 | negative regulation of leukocyte cell-cell adhesion | 3 | 74 | 7.36e-01 |
| GO:BP | GO:0060088 | auditory receptor cell stereocilium organization | 1 | 9 | 7.36e-01 |
| GO:BP | GO:0060348 | bone development | 15 | 170 | 7.36e-01 |
| GO:BP | GO:0042308 | negative regulation of protein import into nucleus | 1 | 13 | 7.36e-01 |
| GO:BP | GO:0050854 | regulation of antigen receptor-mediated signaling pathway | 1 | 40 | 7.36e-01 |
| GO:BP | GO:0030203 | glycosaminoglycan metabolic process | 2 | 87 | 7.36e-01 |
| GO:BP | GO:0046942 | carboxylic acid transport | 1 | 216 | 7.36e-01 |
| GO:BP | GO:0090277 | positive regulation of peptide hormone secretion | 1 | 69 | 7.36e-01 |
| GO:BP | GO:0001960 | negative regulation of cytokine-mediated signaling pathway | 1 | 53 | 7.36e-01 |
| GO:BP | GO:0043374 | CD8-positive, alpha-beta T cell differentiation | 1 | 8 | 7.36e-01 |
| GO:BP | GO:0015849 | organic acid transport | 1 | 217 | 7.37e-01 |
| GO:BP | GO:0009889 | regulation of biosynthetic process | 5 | 3169 | 7.37e-01 |
| GO:BP | GO:0120254 | olefinic compound metabolic process | 2 | 84 | 7.37e-01 |
| GO:BP | GO:0006000 | fructose metabolic process | 1 | 10 | 7.37e-01 |
| GO:BP | GO:0010669 | epithelial structure maintenance | 1 | 15 | 7.38e-01 |
| GO:BP | GO:0043300 | regulation of leukocyte degranulation | 2 | 27 | 7.38e-01 |
| GO:BP | GO:0021513 | spinal cord dorsal/ventral patterning | 1 | 7 | 7.38e-01 |
| GO:BP | GO:0048525 | negative regulation of viral process | 1 | 64 | 7.38e-01 |
| GO:BP | GO:0051283 | negative regulation of sequestering of calcium ion | 2 | 83 | 7.38e-01 |
| GO:BP | GO:0050790 | regulation of catalytic activity | 1 | 1380 | 7.38e-01 |
| GO:BP | GO:0014070 | response to organic cyclic compound | 2 | 640 | 7.38e-01 |
| GO:BP | GO:0045091 | regulation of single stranded viral RNA replication via double stranded DNA intermediate | 1 | 15 | 7.38e-01 |
| GO:BP | GO:0009948 | anterior/posterior axis specification | 1 | 32 | 7.39e-01 |
| GO:BP | GO:0002062 | chondrocyte differentiation | 2 | 90 | 7.39e-01 |
| GO:BP | GO:2000052 | positive regulation of non-canonical Wnt signaling pathway | 1 | 14 | 7.39e-01 |
| GO:BP | GO:0007379 | segment specification | 1 | 14 | 7.39e-01 |
| GO:BP | GO:0060350 | endochondral bone morphogenesis | 1 | 47 | 7.40e-01 |
| GO:BP | GO:1900095 | regulation of dosage compensation by inactivation of X chromosome | 1 | 13 | 7.41e-01 |
| GO:BP | GO:0051447 | negative regulation of meiotic cell cycle | 1 | 9 | 7.41e-01 |
| GO:BP | GO:0002793 | positive regulation of peptide secretion | 1 | 70 | 7.42e-01 |
| GO:BP | GO:0045039 | protein insertion into mitochondrial inner membrane | 1 | 13 | 7.42e-01 |
| GO:BP | GO:0046503 | glycerolipid catabolic process | 2 | 42 | 7.42e-01 |
| GO:BP | GO:1901021 | positive regulation of calcium ion transmembrane transporter activity | 3 | 39 | 7.42e-01 |
| GO:BP | GO:0046466 | membrane lipid catabolic process | 2 | 30 | 7.42e-01 |
| GO:BP | GO:0008064 | regulation of actin polymerization or depolymerization | 5 | 126 | 7.42e-01 |
| GO:BP | GO:0022900 | electron transport chain | 1 | 142 | 7.42e-01 |
| GO:BP | GO:0006304 | DNA modification | 1 | 89 | 7.42e-01 |
| GO:BP | GO:0033045 | regulation of sister chromatid segregation | 6 | 99 | 7.42e-01 |
| GO:BP | GO:0000768 | syncytium formation by plasma membrane fusion | 1 | 37 | 7.43e-01 |
| GO:BP | GO:0035330 | regulation of hippo signaling | 1 | 21 | 7.43e-01 |
| GO:BP | GO:0140253 | cell-cell fusion | 1 | 37 | 7.43e-01 |
| GO:BP | GO:1901224 | positive regulation of NIK/NF-kappaB signaling | 2 | 40 | 7.43e-01 |
| GO:BP | GO:0050869 | negative regulation of B cell activation | 2 | 19 | 7.44e-01 |
| GO:BP | GO:0098930 | axonal transport | 1 | 60 | 7.44e-01 |
| GO:BP | GO:0034101 | erythrocyte homeostasis | 6 | 114 | 7.44e-01 |
| GO:BP | GO:0002704 | negative regulation of leukocyte mediated immunity | 1 | 28 | 7.44e-01 |
| GO:BP | GO:0051282 | regulation of sequestering of calcium ion | 2 | 85 | 7.44e-01 |
| GO:BP | GO:0031110 | regulation of microtubule polymerization or depolymerization | 2 | 82 | 7.44e-01 |
| GO:BP | GO:0099054 | presynapse assembly | 1 | 39 | 7.45e-01 |
| GO:BP | GO:0071243 | cellular response to arsenic-containing substance | 1 | 18 | 7.45e-01 |
| GO:BP | GO:0001541 | ovarian follicle development | 1 | 41 | 7.45e-01 |
| GO:BP | GO:0006357 | regulation of transcription by RNA polymerase II | 3 | 1914 | 7.45e-01 |
| GO:BP | GO:0032878 | regulation of establishment or maintenance of cell polarity | 1 | 26 | 7.45e-01 |
| GO:BP | GO:0051205 | protein insertion into membrane | 5 | 62 | 7.45e-01 |
| GO:BP | GO:0043484 | regulation of RNA splicing | 13 | 164 | 7.46e-01 |
| GO:BP | GO:0006836 | neurotransmitter transport | 3 | 138 | 7.47e-01 |
| GO:BP | GO:0065004 | protein-DNA complex assembly | 1 | 185 | 7.47e-01 |
| GO:BP | GO:0010458 | exit from mitosis | 2 | 30 | 7.47e-01 |
| GO:BP | GO:0010738 | regulation of protein kinase A signaling | 1 | 13 | 7.47e-01 |
| GO:BP | GO:0043647 | inositol phosphate metabolic process | 1 | 35 | 7.47e-01 |
| GO:BP | GO:0042984 | regulation of amyloid precursor protein biosynthetic process | 1 | 14 | 7.47e-01 |
| GO:BP | GO:0042983 | amyloid precursor protein biosynthetic process | 1 | 14 | 7.47e-01 |
| GO:BP | GO:0031396 | regulation of protein ubiquitination | 15 | 191 | 7.47e-01 |
| GO:BP | GO:0035296 | regulation of tube diameter | 2 | 99 | 7.47e-01 |
| GO:BP | GO:0097746 | blood vessel diameter maintenance | 2 | 99 | 7.47e-01 |
| GO:BP | GO:0010842 | retina layer formation | 1 | 16 | 7.47e-01 |
| GO:BP | GO:0039535 | regulation of RIG-I signaling pathway | 1 | 17 | 7.48e-01 |
| GO:BP | GO:0032104 | regulation of response to extracellular stimulus | 1 | 19 | 7.48e-01 |
| GO:BP | GO:0006950 | response to stress | 5 | 2780 | 7.48e-01 |
| GO:BP | GO:0032107 | regulation of response to nutrient levels | 1 | 19 | 7.48e-01 |
| GO:BP | GO:0035584 | calcium-mediated signaling using intracellular calcium source | 1 | 14 | 7.48e-01 |
| GO:BP | GO:0042220 | response to cocaine | 3 | 28 | 7.48e-01 |
| GO:BP | GO:0030857 | negative regulation of epithelial cell differentiation | 2 | 31 | 7.48e-01 |
| GO:BP | GO:0042790 | nucleolar large rRNA transcription by RNA polymerase I | 1 | 21 | 7.49e-01 |
| GO:BP | GO:0042221 | response to chemical | 4 | 2559 | 7.50e-01 |
| GO:BP | GO:0060761 | negative regulation of response to cytokine stimulus | 1 | 57 | 7.50e-01 |
| GO:BP | GO:0035150 | regulation of tube size | 2 | 99 | 7.50e-01 |
| GO:BP | GO:0048839 | inner ear development | 7 | 132 | 7.50e-01 |
| GO:BP | GO:0051284 | positive regulation of sequestering of calcium ion | 1 | 13 | 7.50e-01 |
| GO:BP | GO:0045745 | positive regulation of G protein-coupled receptor signaling pathway | 1 | 13 | 7.50e-01 |
| GO:BP | GO:0001508 | action potential | 2 | 105 | 7.50e-01 |
| GO:BP | GO:0009888 | tissue development | 9 | 1425 | 7.50e-01 |
| GO:BP | GO:0045668 | negative regulation of osteoblast differentiation | 2 | 36 | 7.52e-01 |
| GO:BP | GO:0031123 | RNA 3’-end processing | 8 | 100 | 7.52e-01 |
| GO:BP | GO:0009123 | nucleoside monophosphate metabolic process | 3 | 64 | 7.52e-01 |
| GO:BP | GO:0051279 | regulation of release of sequestered calcium ion into cytosol | 2 | 60 | 7.52e-01 |
| GO:BP | GO:0051569 | regulation of histone H3-K4 methylation | 2 | 26 | 7.52e-01 |
| GO:BP | GO:0042789 | mRNA transcription by RNA polymerase II | 1 | 45 | 7.52e-01 |
| GO:BP | GO:0030149 | sphingolipid catabolic process | 1 | 26 | 7.52e-01 |
| GO:BP | GO:0050792 | regulation of viral process | 8 | 122 | 7.52e-01 |
| GO:BP | GO:0042953 | lipoprotein transport | 1 | 14 | 7.53e-01 |
| GO:BP | GO:0030832 | regulation of actin filament length | 5 | 127 | 7.53e-01 |
| GO:BP | GO:0046661 | male sex differentiation | 3 | 114 | 7.54e-01 |
| GO:BP | GO:1901889 | negative regulation of cell junction assembly | 1 | 24 | 7.54e-01 |
| GO:BP | GO:0048799 | animal organ maturation | 2 | 20 | 7.54e-01 |
| GO:BP | GO:0060033 | anatomical structure regression | 1 | 11 | 7.54e-01 |
| GO:BP | GO:0043567 | regulation of insulin-like growth factor receptor signaling pathway | 1 | 17 | 7.54e-01 |
| GO:BP | GO:0070542 | response to fatty acid | 1 | 43 | 7.54e-01 |
| GO:BP | GO:0021871 | forebrain regionalization | 1 | 8 | 7.54e-01 |
| GO:BP | GO:0007216 | G protein-coupled glutamate receptor signaling pathway | 1 | 5 | 7.55e-01 |
| GO:BP | GO:0001710 | mesodermal cell fate commitment | 1 | 9 | 7.55e-01 |
| GO:BP | GO:0014904 | myotube cell development | 2 | 34 | 7.55e-01 |
| GO:BP | GO:0022408 | negative regulation of cell-cell adhesion | 4 | 116 | 7.55e-01 |
| GO:BP | GO:0048705 | skeletal system morphogenesis | 9 | 155 | 7.55e-01 |
| GO:BP | GO:0030534 | adult behavior | 5 | 92 | 7.55e-01 |
| GO:BP | GO:0002643 | regulation of tolerance induction | 1 | 10 | 7.55e-01 |
| GO:BP | GO:0060047 | heart contraction | 4 | 205 | 7.55e-01 |
| GO:BP | GO:0015837 | amine transport | 1 | 56 | 7.55e-01 |
| GO:BP | GO:0051208 | sequestering of calcium ion | 2 | 89 | 7.55e-01 |
| GO:BP | GO:0050803 | regulation of synapse structure or activity | 13 | 187 | 7.55e-01 |
| GO:BP | GO:1901362 | organic cyclic compound biosynthetic process | 5 | 3237 | 7.55e-01 |
| GO:BP | GO:0048873 | homeostasis of number of cells within a tissue | 1 | 24 | 7.57e-01 |
| GO:BP | GO:1904427 | positive regulation of calcium ion transmembrane transport | 6 | 60 | 7.57e-01 |
| GO:BP | GO:0000303 | response to superoxide | 1 | 21 | 7.57e-01 |
| GO:BP | GO:1903205 | regulation of hydrogen peroxide-induced cell death | 1 | 20 | 7.57e-01 |
| GO:BP | GO:0035518 | histone H2A monoubiquitination | 1 | 19 | 7.57e-01 |
| GO:BP | GO:0006968 | cellular defense response | 3 | 15 | 7.57e-01 |
| GO:BP | GO:1902969 | mitotic DNA replication | 1 | 14 | 7.57e-01 |
| GO:BP | GO:0098883 | synapse pruning | 1 | 8 | 7.57e-01 |
| GO:BP | GO:0021819 | layer formation in cerebral cortex | 1 | 12 | 7.57e-01 |
| GO:BP | GO:0007283 | spermatogenesis | 1 | 330 | 7.57e-01 |
| GO:BP | GO:1905953 | negative regulation of lipid localization | 1 | 32 | 7.57e-01 |
| GO:BP | GO:0051044 | positive regulation of membrane protein ectodomain proteolysis | 1 | 11 | 7.58e-01 |
| GO:BP | GO:0051246 | regulation of protein metabolic process | 4 | 1974 | 7.58e-01 |
| GO:BP | GO:0006949 | syncytium formation | 1 | 39 | 7.58e-01 |
| GO:BP | GO:0002026 | regulation of the force of heart contraction | 1 | 23 | 7.58e-01 |
| GO:BP | GO:0001885 | endothelial cell development | 1 | 53 | 7.58e-01 |
| GO:BP | GO:0010614 | negative regulation of cardiac muscle hypertrophy | 1 | 26 | 7.60e-01 |
| GO:BP | GO:0043984 | histone H4-K16 acetylation | 1 | 14 | 7.60e-01 |
| GO:BP | GO:1901661 | quinone metabolic process | 1 | 32 | 7.60e-01 |
| GO:BP | GO:0072539 | T-helper 17 cell differentiation | 1 | 14 | 7.60e-01 |
| GO:BP | GO:0090077 | foam cell differentiation | 2 | 22 | 7.60e-01 |
| GO:BP | GO:0010742 | macrophage derived foam cell differentiation | 2 | 22 | 7.60e-01 |
| GO:BP | GO:0030154 | cell differentiation | 5 | 2958 | 7.61e-01 |
| GO:BP | GO:0030032 | lamellipodium assembly | 3 | 61 | 7.61e-01 |
| GO:BP | GO:0014808 | release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | 2 | 28 | 7.61e-01 |
| GO:BP | GO:0042982 | amyloid precursor protein metabolic process | 3 | 69 | 7.62e-01 |
| GO:BP | GO:0002825 | regulation of T-helper 1 type immune response | 1 | 10 | 7.62e-01 |
| GO:BP | GO:0055082 | intracellular chemical homeostasis | 18 | 486 | 7.62e-01 |
| GO:BP | GO:0032743 | positive regulation of interleukin-2 production | 1 | 20 | 7.62e-01 |
| GO:BP | GO:0015936 | coenzyme A metabolic process | 1 | 18 | 7.62e-01 |
| GO:BP | GO:0038179 | neurotrophin signaling pathway | 1 | 35 | 7.62e-01 |
| GO:BP | GO:0097530 | granulocyte migration | 1 | 67 | 7.62e-01 |
| GO:BP | GO:0032925 | regulation of activin receptor signaling pathway | 1 | 20 | 7.63e-01 |
| GO:BP | GO:0002093 | auditory receptor cell morphogenesis | 1 | 10 | 7.63e-01 |
| GO:BP | GO:0007528 | neuromuscular junction development | 1 | 39 | 7.63e-01 |
| GO:BP | GO:0090713 | immunological memory process | 1 | 7 | 7.64e-01 |
| GO:BP | GO:0016045 | detection of bacterium | 1 | 8 | 7.64e-01 |
| GO:BP | GO:0050864 | regulation of B cell activation | 3 | 77 | 7.64e-01 |
| GO:BP | GO:0099172 | presynapse organization | 1 | 42 | 7.64e-01 |
| GO:BP | GO:0009886 | post-embryonic animal morphogenesis | 1 | 10 | 7.64e-01 |
| GO:BP | GO:0001655 | urogenital system development | 1 | 49 | 7.64e-01 |
| GO:BP | GO:0010885 | regulation of cholesterol storage | 1 | 14 | 7.65e-01 |
| GO:BP | GO:1903019 | negative regulation of glycoprotein metabolic process | 1 | 12 | 7.65e-01 |
| GO:BP | GO:0030071 | regulation of mitotic metaphase/anaphase transition | 5 | 88 | 7.65e-01 |
| GO:BP | GO:0031054 | pre-miRNA processing | 1 | 14 | 7.65e-01 |
| GO:BP | GO:0048869 | cellular developmental process | 5 | 2984 | 7.65e-01 |
| GO:BP | GO:0048232 | male gamete generation | 1 | 343 | 7.66e-01 |
| GO:BP | GO:0060292 | long-term synaptic depression | 2 | 21 | 7.67e-01 |
| GO:BP | GO:0021549 | cerebellum development | 1 | 78 | 7.67e-01 |
| GO:BP | GO:0021511 | spinal cord patterning | 1 | 9 | 7.67e-01 |
| GO:BP | GO:0007413 | axonal fasciculation | 1 | 18 | 7.67e-01 |
| GO:BP | GO:0106030 | neuron projection fasciculation | 1 | 18 | 7.67e-01 |
| GO:BP | GO:0071312 | cellular response to alkaloid | 2 | 29 | 7.67e-01 |
| GO:BP | GO:0030003 | intracellular monoatomic cation homeostasis | 13 | 357 | 7.68e-01 |
| GO:BP | GO:0044872 | lipoprotein localization | 1 | 15 | 7.68e-01 |
| GO:BP | GO:0033993 | response to lipid | 34 | 592 | 7.68e-01 |
| GO:BP | GO:0055080 | monoatomic cation homeostasis | 15 | 401 | 7.68e-01 |
| GO:BP | GO:0000305 | response to oxygen radical | 1 | 22 | 7.68e-01 |
| GO:BP | GO:0071824 | protein-DNA complex subunit organization | 1 | 204 | 7.68e-01 |
| GO:BP | GO:0050930 | induction of positive chemotaxis | 1 | 12 | 7.68e-01 |
| GO:BP | GO:0099116 | tRNA 5’-end processing | 1 | 16 | 7.68e-01 |
| GO:BP | GO:0042491 | inner ear auditory receptor cell differentiation | 3 | 29 | 7.68e-01 |
| GO:BP | GO:0030514 | negative regulation of BMP signaling pathway | 1 | 45 | 7.68e-01 |
| GO:BP | GO:0090399 | replicative senescence | 1 | 13 | 7.69e-01 |
| GO:BP | GO:0070972 | protein localization to endoplasmic reticulum | 1 | 78 | 7.69e-01 |
| GO:BP | GO:0032092 | positive regulation of protein binding | 2 | 78 | 7.69e-01 |
| GO:BP | GO:0046883 | regulation of hormone secretion | 2 | 168 | 7.70e-01 |
| GO:BP | GO:0002053 | positive regulation of mesenchymal cell proliferation | 1 | 18 | 7.70e-01 |
| GO:BP | GO:0071466 | cellular response to xenobiotic stimulus | 11 | 105 | 7.70e-01 |
| GO:BP | GO:0150076 | neuroinflammatory response | 2 | 33 | 7.70e-01 |
| GO:BP | GO:1903312 | negative regulation of mRNA metabolic process | 4 | 81 | 7.71e-01 |
| GO:BP | GO:0002429 | immune response-activating cell surface receptor signaling pathway | 1 | 151 | 7.71e-01 |
| GO:BP | GO:0001505 | regulation of neurotransmitter levels | 3 | 149 | 7.71e-01 |
| GO:BP | GO:0051281 | positive regulation of release of sequestered calcium ion into cytosol | 1 | 27 | 7.72e-01 |
| GO:BP | GO:0006835 | dicarboxylic acid transport | 5 | 62 | 7.72e-01 |
| GO:BP | GO:0060445 | branching involved in salivary gland morphogenesis | 1 | 17 | 7.73e-01 |
| GO:BP | GO:1903514 | release of sequestered calcium ion into cytosol by endoplasmic reticulum | 2 | 28 | 7.73e-01 |
| GO:BP | GO:0043244 | regulation of protein-containing complex disassembly | 4 | 113 | 7.73e-01 |
| GO:BP | GO:0008154 | actin polymerization or depolymerization | 6 | 160 | 7.74e-01 |
| GO:BP | GO:0019882 | antigen processing and presentation | 6 | 69 | 7.74e-01 |
| GO:BP | GO:0010744 | positive regulation of macrophage derived foam cell differentiation | 1 | 8 | 7.74e-01 |
| GO:BP | GO:0048583 | regulation of response to stimulus | 4 | 2890 | 7.74e-01 |
| GO:BP | GO:0043489 | RNA stabilization | 4 | 59 | 7.74e-01 |
| GO:BP | GO:0006796 | phosphate-containing compound metabolic process | 9 | 2139 | 7.74e-01 |
| GO:BP | GO:0034349 | glial cell apoptotic process | 1 | 15 | 7.75e-01 |
| GO:BP | GO:0001756 | somitogenesis | 2 | 48 | 7.75e-01 |
| GO:BP | GO:0022607 | cellular component assembly | 5 | 2466 | 7.75e-01 |
| GO:BP | GO:0007015 | actin filament organization | 14 | 373 | 7.76e-01 |
| GO:BP | GO:0006271 | DNA strand elongation involved in DNA replication | 1 | 15 | 7.76e-01 |
| GO:BP | GO:0010721 | negative regulation of cell development | 10 | 191 | 7.76e-01 |
| GO:BP | GO:0061644 | protein localization to CENP-A containing chromatin | 1 | 17 | 7.76e-01 |
| GO:BP | GO:0006091 | generation of precursor metabolites and energy | 1 | 369 | 7.76e-01 |
| GO:BP | GO:0045638 | negative regulation of myeloid cell differentiation | 4 | 69 | 7.76e-01 |
| GO:BP | GO:0060563 | neuroepithelial cell differentiation | 2 | 22 | 7.76e-01 |
| GO:BP | GO:0032368 | regulation of lipid transport | 1 | 92 | 7.77e-01 |
| GO:BP | GO:1900006 | positive regulation of dendrite development | 1 | 14 | 7.77e-01 |
| GO:BP | GO:0008595 | anterior/posterior axis specification, embryo | 1 | 10 | 7.77e-01 |
| GO:BP | GO:0007351 | tripartite regional subdivision | 1 | 10 | 7.77e-01 |
| GO:BP | GO:0045912 | negative regulation of carbohydrate metabolic process | 3 | 38 | 7.78e-01 |
| GO:BP | GO:0048246 | macrophage chemotaxis | 1 | 21 | 7.78e-01 |
| GO:BP | GO:0035337 | fatty-acyl-CoA metabolic process | 2 | 31 | 7.78e-01 |
| GO:BP | GO:0003382 | epithelial cell morphogenesis | 1 | 24 | 7.78e-01 |
| GO:BP | GO:0007194 | negative regulation of adenylate cyclase activity | 1 | 13 | 7.78e-01 |
| GO:BP | GO:1904035 | regulation of epithelial cell apoptotic process | 4 | 71 | 7.78e-01 |
| GO:BP | GO:0032879 | regulation of localization | 1 | 1555 | 7.78e-01 |
| GO:BP | GO:0070734 | histone H3-K27 methylation | 1 | 9 | 7.78e-01 |
| GO:BP | GO:0034656 | nucleobase-containing small molecule catabolic process | 1 | 20 | 7.78e-01 |
| GO:BP | GO:0002504 | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II | 2 | 19 | 7.78e-01 |
| GO:BP | GO:0005980 | glycogen catabolic process | 1 | 14 | 7.78e-01 |
| GO:BP | GO:0050729 | positive regulation of inflammatory response | 9 | 75 | 7.78e-01 |
| GO:BP | GO:0002220 | innate immune response activating cell surface receptor signaling pathway | 2 | 37 | 7.78e-01 |
| GO:BP | GO:0002396 | MHC protein complex assembly | 1 | 8 | 7.78e-01 |
| GO:BP | GO:0002501 | peptide antigen assembly with MHC protein complex | 1 | 8 | 7.78e-01 |
| GO:BP | GO:0051590 | positive regulation of neurotransmitter transport | 1 | 16 | 7.79e-01 |
| GO:BP | GO:0022410 | circadian sleep/wake cycle process | 1 | 10 | 7.79e-01 |
| GO:BP | GO:0140056 | organelle localization by membrane tethering | 3 | 74 | 7.79e-01 |
| GO:BP | GO:0045721 | negative regulation of gluconeogenesis | 1 | 12 | 7.79e-01 |
| GO:BP | GO:1903522 | regulation of blood circulation | 4 | 198 | 7.79e-01 |
| GO:BP | GO:1990573 | potassium ion import across plasma membrane | 1 | 31 | 7.79e-01 |
| GO:BP | GO:0043279 | response to alkaloid | 6 | 68 | 7.79e-01 |
| GO:BP | GO:0061053 | somite development | 3 | 63 | 7.80e-01 |
| GO:BP | GO:0051926 | negative regulation of calcium ion transport | 4 | 45 | 7.80e-01 |
| GO:BP | GO:0009058 | biosynthetic process | 24 | 4590 | 7.80e-01 |
| GO:BP | GO:0051216 | cartilage development | 5 | 151 | 7.80e-01 |
| GO:BP | GO:0003015 | heart process | 4 | 216 | 7.81e-01 |
| GO:BP | GO:1904019 | epithelial cell apoptotic process | 3 | 98 | 7.81e-01 |
| GO:BP | GO:0050868 | negative regulation of T cell activation | 8 | 67 | 7.81e-01 |
| GO:BP | GO:0006793 | phosphorus metabolic process | 9 | 2161 | 7.81e-01 |
| GO:BP | GO:0009299 | mRNA transcription | 1 | 50 | 7.82e-01 |
| GO:BP | GO:0002221 | pattern recognition receptor signaling pathway | 5 | 115 | 7.82e-01 |
| GO:BP | GO:0010951 | negative regulation of endopeptidase activity | 3 | 102 | 7.84e-01 |
| GO:BP | GO:0050764 | regulation of phagocytosis | 3 | 57 | 7.84e-01 |
| GO:BP | GO:0006873 | intracellular monoatomic ion homeostasis | 13 | 362 | 7.84e-01 |
| GO:BP | GO:0007091 | metaphase/anaphase transition of mitotic cell cycle | 5 | 91 | 7.84e-01 |
| GO:BP | GO:1901576 | organic substance biosynthetic process | 10 | 4539 | 7.84e-01 |
| GO:BP | GO:1902099 | regulation of metaphase/anaphase transition of cell cycle | 5 | 89 | 7.84e-01 |
| GO:BP | GO:0060259 | regulation of feeding behavior | 1 | 9 | 7.84e-01 |
| GO:BP | GO:0032760 | positive regulation of tumor necrosis factor production | 2 | 55 | 7.85e-01 |
| GO:BP | GO:0006244 | pyrimidine nucleotide catabolic process | 1 | 19 | 7.86e-01 |
| GO:BP | GO:0010171 | body morphogenesis | 3 | 45 | 7.86e-01 |
| GO:BP | GO:1903955 | positive regulation of protein targeting to mitochondrion | 1 | 30 | 7.86e-01 |
| GO:BP | GO:0061035 | regulation of cartilage development | 1 | 54 | 7.87e-01 |
| GO:BP | GO:0007631 | feeding behavior | 4 | 52 | 7.87e-01 |
| GO:BP | GO:0050801 | monoatomic ion homeostasis | 15 | 408 | 7.87e-01 |
| GO:BP | GO:0051983 | regulation of chromosome segregation | 7 | 121 | 7.87e-01 |
| GO:BP | GO:2000300 | regulation of synaptic vesicle exocytosis | 2 | 35 | 7.87e-01 |
| GO:BP | GO:0042074 | cell migration involved in gastrulation | 1 | 10 | 7.87e-01 |
| GO:BP | GO:0033233 | regulation of protein sumoylation | 1 | 22 | 7.87e-01 |
| GO:BP | GO:0001914 | regulation of T cell mediated cytotoxicity | 2 | 17 | 7.88e-01 |
| GO:BP | GO:0033622 | integrin activation | 1 | 18 | 7.88e-01 |
| GO:BP | GO:0031349 | positive regulation of defense response | 12 | 251 | 7.89e-01 |
| GO:BP | GO:0009048 | dosage compensation by inactivation of X chromosome | 2 | 27 | 7.90e-01 |
| GO:BP | GO:0002762 | negative regulation of myeloid leukocyte differentiation | 3 | 33 | 7.90e-01 |
| GO:BP | GO:0001906 | cell killing | 5 | 69 | 7.90e-01 |
| GO:BP | GO:0022037 | metencephalon development | 1 | 84 | 7.90e-01 |
| GO:BP | GO:0031281 | positive regulation of cyclase activity | 1 | 23 | 7.90e-01 |
| GO:BP | GO:1905521 | regulation of macrophage migration | 1 | 24 | 7.90e-01 |
| GO:BP | GO:0045956 | positive regulation of calcium ion-dependent exocytosis | 1 | 11 | 7.90e-01 |
| GO:BP | GO:0099509 | regulation of presynaptic cytosolic calcium ion concentration | 1 | 10 | 7.90e-01 |
| GO:BP | GO:0032728 | positive regulation of interferon-beta production | 2 | 29 | 7.90e-01 |
| GO:BP | GO:0008088 | axo-dendritic transport | 1 | 73 | 7.91e-01 |
| GO:BP | GO:0008210 | estrogen metabolic process | 1 | 16 | 7.91e-01 |
| GO:BP | GO:0034446 | substrate adhesion-dependent cell spreading | 7 | 97 | 7.91e-01 |
| GO:BP | GO:0002768 | immune response-regulating cell surface receptor signaling pathway | 1 | 162 | 7.91e-01 |
| GO:BP | GO:2000401 | regulation of lymphocyte migration | 2 | 41 | 7.92e-01 |
| GO:BP | GO:0001696 | gastric acid secretion | 1 | 10 | 7.92e-01 |
| GO:BP | GO:0010922 | positive regulation of phosphatase activity | 1 | 26 | 7.92e-01 |
| GO:BP | GO:0045601 | regulation of endothelial cell differentiation | 1 | 27 | 7.92e-01 |
| GO:BP | GO:0002262 | myeloid cell homeostasis | 7 | 140 | 7.93e-01 |
| GO:BP | GO:0002483 | antigen processing and presentation of endogenous peptide antigen | 1 | 16 | 7.93e-01 |
| GO:BP | GO:0018345 | protein palmitoylation | 2 | 30 | 7.93e-01 |
| GO:BP | GO:0051931 | regulation of sensory perception | 2 | 13 | 7.93e-01 |
| GO:BP | GO:0051930 | regulation of sensory perception of pain | 2 | 13 | 7.93e-01 |
| GO:BP | GO:0061842 | microtubule organizing center localization | 2 | 31 | 7.93e-01 |
| GO:BP | GO:0009251 | glucan catabolic process | 1 | 14 | 7.93e-01 |
| GO:BP | GO:0010878 | cholesterol storage | 1 | 16 | 7.93e-01 |
| GO:BP | GO:0061709 | reticulophagy | 1 | 17 | 7.93e-01 |
| GO:BP | GO:0060080 | inhibitory postsynaptic potential | 1 | 8 | 7.93e-01 |
| GO:BP | GO:0051180 | vitamin transport | 1 | 28 | 7.93e-01 |
| GO:BP | GO:0051642 | centrosome localization | 2 | 31 | 7.93e-01 |
| GO:BP | GO:0006120 | mitochondrial electron transport, NADH to ubiquinone | 1 | 42 | 7.94e-01 |
| GO:BP | GO:0043982 | histone H4-K8 acetylation | 1 | 16 | 7.94e-01 |
| GO:BP | GO:0043981 | histone H4-K5 acetylation | 1 | 16 | 7.94e-01 |
| GO:BP | GO:0042310 | vasoconstriction | 1 | 51 | 7.94e-01 |
| GO:BP | GO:0030433 | ubiquitin-dependent ERAD pathway | 5 | 83 | 7.94e-01 |
| GO:BP | GO:0006259 | DNA metabolic process | 27 | 884 | 7.94e-01 |
| GO:BP | GO:0048512 | circadian behavior | 2 | 30 | 7.95e-01 |
| GO:BP | GO:1902743 | regulation of lamellipodium organization | 2 | 44 | 7.95e-01 |
| GO:BP | GO:0045333 | cellular respiration | 2 | 211 | 7.95e-01 |
| GO:BP | GO:0097553 | calcium ion transmembrane import into cytosol | 4 | 115 | 7.96e-01 |
| GO:BP | GO:0045779 | negative regulation of bone resorption | 1 | 7 | 7.96e-01 |
| GO:BP | GO:0097094 | craniofacial suture morphogenesis | 1 | 15 | 7.96e-01 |
| GO:BP | GO:0031365 | N-terminal protein amino acid modification | 1 | 28 | 7.96e-01 |
| GO:BP | GO:0036474 | cell death in response to hydrogen peroxide | 1 | 23 | 7.97e-01 |
| GO:BP | GO:0001953 | negative regulation of cell-matrix adhesion | 2 | 26 | 7.97e-01 |
| GO:BP | GO:0002478 | antigen processing and presentation of exogenous peptide antigen | 2 | 24 | 7.97e-01 |
| GO:BP | GO:0007029 | endoplasmic reticulum organization | 6 | 83 | 7.97e-01 |
| GO:BP | GO:0045453 | bone resorption | 4 | 40 | 7.98e-01 |
| GO:BP | GO:1902476 | chloride transmembrane transport | 6 | 51 | 7.98e-01 |
| GO:BP | GO:0002689 | negative regulation of leukocyte chemotaxis | 1 | 10 | 7.98e-01 |
| GO:BP | GO:0048584 | positive regulation of response to stimulus | 1 | 1555 | 7.99e-01 |
| GO:BP | GO:0021872 | forebrain generation of neurons | 3 | 29 | 7.99e-01 |
| GO:BP | GO:1903557 | positive regulation of tumor necrosis factor superfamily cytokine production | 2 | 57 | 7.99e-01 |
| GO:BP | GO:0051966 | regulation of synaptic transmission, glutamatergic | 5 | 46 | 7.99e-01 |
| GO:BP | GO:0015813 | L-glutamate transmembrane transport | 1 | 19 | 7.99e-01 |
| GO:BP | GO:0051917 | regulation of fibrinolysis | 1 | 10 | 7.99e-01 |
| GO:BP | GO:0040020 | regulation of meiotic nuclear division | 1 | 19 | 7.99e-01 |
| GO:BP | GO:0000470 | maturation of LSU-rRNA | 1 | 28 | 7.99e-01 |
| GO:BP | GO:0031280 | negative regulation of cyclase activity | 1 | 13 | 8.01e-01 |
| GO:BP | GO:0046887 | positive regulation of hormone secretion | 1 | 90 | 8.01e-01 |
| GO:BP | GO:0014002 | astrocyte development | 1 | 27 | 8.01e-01 |
| GO:BP | GO:0015807 | L-amino acid transport | 3 | 65 | 8.02e-01 |
| GO:BP | GO:0071354 | cellular response to interleukin-6 | 1 | 23 | 8.02e-01 |
| GO:BP | GO:0022414 | reproductive process | 1 | 927 | 8.02e-01 |
| GO:BP | GO:0010470 | regulation of gastrulation | 1 | 13 | 8.03e-01 |
| GO:BP | GO:0021680 | cerebellar Purkinje cell layer development | 1 | 24 | 8.03e-01 |
| GO:BP | GO:0044784 | metaphase/anaphase transition of cell cycle | 5 | 92 | 8.03e-01 |
| GO:BP | GO:0031124 | mRNA 3’-end processing | 4 | 58 | 8.03e-01 |
| GO:BP | GO:0019725 | cellular homeostasis | 20 | 569 | 8.04e-01 |
| GO:BP | GO:0033146 | regulation of intracellular estrogen receptor signaling pathway | 1 | 28 | 8.04e-01 |
| GO:BP | GO:0045124 | regulation of bone resorption | 1 | 24 | 8.04e-01 |
| GO:BP | GO:0000003 | reproduction | 1 | 934 | 8.04e-01 |
| GO:BP | GO:0050766 | positive regulation of phagocytosis | 2 | 38 | 8.05e-01 |
| GO:BP | GO:0034103 | regulation of tissue remodeling | 2 | 45 | 8.05e-01 |
| GO:BP | GO:0060326 | cell chemotaxis | 2 | 162 | 8.05e-01 |
| GO:BP | GO:1905146 | lysosomal protein catabolic process | 1 | 19 | 8.05e-01 |
| GO:BP | GO:0048679 | regulation of axon regeneration | 1 | 23 | 8.05e-01 |
| GO:BP | GO:0098662 | inorganic cation transmembrane transport | 1 | 517 | 8.05e-01 |
| GO:BP | GO:0045616 | regulation of keratinocyte differentiation | 1 | 25 | 8.05e-01 |
| GO:BP | GO:0071108 | protein K48-linked deubiquitination | 1 | 24 | 8.05e-01 |
| GO:BP | GO:0060384 | innervation | 1 | 22 | 8.05e-01 |
| GO:BP | GO:0098543 | detection of other organism | 1 | 9 | 8.05e-01 |
| GO:BP | GO:0003180 | aortic valve morphogenesis | 1 | 33 | 8.05e-01 |
| GO:BP | GO:0021954 | central nervous system neuron development | 5 | 61 | 8.05e-01 |
| GO:BP | GO:0044030 | regulation of DNA methylation | 1 | 16 | 8.05e-01 |
| GO:BP | GO:0048569 | post-embryonic animal organ development | 1 | 15 | 8.06e-01 |
| GO:BP | GO:0051546 | keratinocyte migration | 1 | 15 | 8.06e-01 |
| GO:BP | GO:0045132 | meiotic chromosome segregation | 1 | 64 | 8.06e-01 |
| GO:BP | GO:0001578 | microtubule bundle formation | 1 | 79 | 8.06e-01 |
| GO:BP | GO:0006308 | DNA catabolic process | 1 | 19 | 8.06e-01 |
| GO:BP | GO:0044271 | cellular nitrogen compound biosynthetic process | 19 | 3750 | 8.06e-01 |
| GO:BP | GO:0015874 | norepinephrine transport | 1 | 9 | 8.06e-01 |
| GO:BP | GO:0042102 | positive regulation of T cell proliferation | 3 | 47 | 8.06e-01 |
| GO:BP | GO:0048599 | oocyte development | 3 | 38 | 8.07e-01 |
| GO:BP | GO:0032793 | positive regulation of CREB transcription factor activity | 1 | 15 | 8.08e-01 |
| GO:BP | GO:1903320 | regulation of protein modification by small protein conjugation or removal | 14 | 232 | 8.08e-01 |
| GO:BP | GO:0002753 | cytosolic pattern recognition receptor signaling pathway | 1 | 68 | 8.09e-01 |
| GO:BP | GO:0021955 | central nervous system neuron axonogenesis | 1 | 31 | 8.09e-01 |
| GO:BP | GO:0010596 | negative regulation of endothelial cell migration | 1 | 40 | 8.09e-01 |
| GO:BP | GO:1904950 | negative regulation of establishment of protein localization | 8 | 95 | 8.09e-01 |
| GO:BP | GO:0010817 | regulation of hormone levels | 7 | 336 | 8.09e-01 |
| GO:BP | GO:0002218 | activation of innate immune response | 6 | 142 | 8.10e-01 |
| GO:BP | GO:0097284 | hepatocyte apoptotic process | 1 | 17 | 8.10e-01 |
| GO:BP | GO:0006959 | humoral immune response | 2 | 80 | 8.10e-01 |
| GO:BP | GO:0090266 | regulation of mitotic cell cycle spindle assembly checkpoint | 1 | 19 | 8.10e-01 |
| GO:BP | GO:0033280 | response to vitamin D | 1 | 24 | 8.10e-01 |
| GO:BP | GO:0042481 | regulation of odontogenesis | 1 | 10 | 8.10e-01 |
| GO:BP | GO:0090231 | regulation of spindle checkpoint | 1 | 19 | 8.10e-01 |
| GO:BP | GO:1903504 | regulation of mitotic spindle checkpoint | 1 | 19 | 8.10e-01 |
| GO:BP | GO:0007549 | dosage compensation | 2 | 29 | 8.10e-01 |
| GO:BP | GO:0045446 | endothelial cell differentiation | 3 | 90 | 8.11e-01 |
| GO:BP | GO:0072673 | lamellipodium morphogenesis | 1 | 17 | 8.12e-01 |
| GO:BP | GO:0150105 | protein localization to cell-cell junction | 1 | 17 | 8.13e-01 |
| GO:BP | GO:0009083 | branched-chain amino acid catabolic process | 1 | 21 | 8.13e-01 |
| GO:BP | GO:0000038 | very long-chain fatty acid metabolic process | 2 | 27 | 8.14e-01 |
| GO:BP | GO:0006066 | alcohol metabolic process | 1 | 265 | 8.14e-01 |
| GO:BP | GO:0035315 | hair cell differentiation | 1 | 34 | 8.14e-01 |
| GO:BP | GO:0098655 | monoatomic cation transmembrane transport | 1 | 540 | 8.14e-01 |
| GO:BP | GO:1903321 | negative regulation of protein modification by small protein conjugation or removal | 6 | 86 | 8.14e-01 |
| GO:BP | GO:0044085 | cellular component biogenesis | 5 | 2724 | 8.14e-01 |
| GO:BP | GO:0010575 | positive regulation of vascular endothelial growth factor production | 1 | 18 | 8.15e-01 |
| GO:BP | GO:0010468 | regulation of gene expression | 6 | 3580 | 8.15e-01 |
| GO:BP | GO:0048536 | spleen development | 1 | 28 | 8.15e-01 |
| GO:BP | GO:0031323 | regulation of cellular metabolic process | 6 | 4174 | 8.15e-01 |
| GO:BP | GO:0010976 | positive regulation of neuron projection development | 7 | 131 | 8.16e-01 |
| GO:BP | GO:1903749 | positive regulation of establishment of protein localization to mitochondrion | 1 | 33 | 8.17e-01 |
| GO:BP | GO:0043403 | skeletal muscle tissue regeneration | 2 | 31 | 8.17e-01 |
| GO:BP | GO:0061436 | establishment of skin barrier | 1 | 18 | 8.17e-01 |
| GO:BP | GO:0050871 | positive regulation of B cell activation | 2 | 53 | 8.17e-01 |
| GO:BP | GO:0042113 | B cell activation | 11 | 170 | 8.17e-01 |
| GO:BP | GO:0032481 | positive regulation of type I interferon production | 3 | 45 | 8.17e-01 |
| GO:BP | GO:0019233 | sensory perception of pain | 6 | 48 | 8.17e-01 |
| GO:BP | GO:0070242 | thymocyte apoptotic process | 1 | 17 | 8.18e-01 |
| GO:BP | GO:0010033 | response to organic substance | 3 | 1957 | 8.18e-01 |
| GO:BP | GO:0089718 | amino acid import across plasma membrane | 2 | 39 | 8.18e-01 |
| GO:BP | GO:0010888 | negative regulation of lipid storage | 1 | 16 | 8.18e-01 |
| GO:BP | GO:0019079 | viral genome replication | 1 | 101 | 8.19e-01 |
| GO:BP | GO:0031341 | regulation of cell killing | 3 | 36 | 8.19e-01 |
| GO:BP | GO:0031100 | animal organ regeneration | 4 | 47 | 8.19e-01 |
| GO:BP | GO:0006874 | intracellular calcium ion homeostasis | 4 | 200 | 8.19e-01 |
| GO:BP | GO:0033198 | response to ATP | 1 | 24 | 8.19e-01 |
| GO:BP | GO:0071786 | endoplasmic reticulum tubular network organization | 1 | 19 | 8.19e-01 |
| GO:BP | GO:0043652 | engulfment of apoptotic cell | 1 | 11 | 8.20e-01 |
| GO:BP | GO:0046651 | lymphocyte proliferation | 6 | 162 | 8.21e-01 |
| GO:BP | GO:0051353 | positive regulation of oxidoreductase activity | 1 | 43 | 8.21e-01 |
| GO:BP | GO:0030262 | apoptotic nuclear changes | 1 | 20 | 8.22e-01 |
| GO:BP | GO:0051350 | negative regulation of lyase activity | 1 | 15 | 8.22e-01 |
| GO:BP | GO:0000272 | polysaccharide catabolic process | 1 | 14 | 8.22e-01 |
| GO:BP | GO:0006814 | sodium ion transport | 9 | 160 | 8.22e-01 |
| GO:BP | GO:0007292 | female gamete generation | 1 | 103 | 8.22e-01 |
| GO:BP | GO:0051204 | protein insertion into mitochondrial membrane | 2 | 34 | 8.23e-01 |
| GO:BP | GO:0070228 | regulation of lymphocyte apoptotic process | 1 | 37 | 8.23e-01 |
| GO:BP | GO:0070741 | response to interleukin-6 | 1 | 23 | 8.23e-01 |
| GO:BP | GO:0003094 | glomerular filtration | 1 | 21 | 8.23e-01 |
| GO:BP | GO:1905952 | regulation of lipid localization | 1 | 112 | 8.23e-01 |
| GO:BP | GO:0007095 | mitotic G2 DNA damage checkpoint signaling | 1 | 35 | 8.23e-01 |
| GO:BP | GO:1904646 | cellular response to amyloid-beta | 2 | 29 | 8.23e-01 |
| GO:BP | GO:0000413 | protein peptidyl-prolyl isomerization | 1 | 26 | 8.23e-01 |
| GO:BP | GO:0031214 | biomineral tissue development | 1 | 111 | 8.23e-01 |
| GO:BP | GO:0007276 | gamete generation | 1 | 461 | 8.24e-01 |
| GO:BP | GO:0046851 | negative regulation of bone remodeling | 1 | 9 | 8.24e-01 |
| GO:BP | GO:0032026 | response to magnesium ion | 1 | 10 | 8.24e-01 |
| GO:BP | GO:0097164 | ammonium ion metabolic process | 1 | 14 | 8.24e-01 |
| GO:BP | GO:0032228 | regulation of synaptic transmission, GABAergic | 2 | 23 | 8.24e-01 |
| GO:BP | GO:0046885 | regulation of hormone biosynthetic process | 1 | 21 | 8.24e-01 |
| GO:BP | GO:0019081 | viral translation | 1 | 18 | 8.25e-01 |
| GO:BP | GO:0060485 | mesenchyme development | 14 | 249 | 8.25e-01 |
| GO:BP | GO:0030001 | metal ion transport | 1 | 562 | 8.26e-01 |
| GO:BP | GO:0009605 | response to external stimulus | 1 | 1719 | 8.26e-01 |
| GO:BP | GO:2001251 | negative regulation of chromosome organization | 2 | 90 | 8.27e-01 |
| GO:BP | GO:0042592 | homeostatic process | 1 | 1159 | 8.28e-01 |
| GO:BP | GO:0035176 | social behavior | 2 | 34 | 8.28e-01 |
| GO:BP | GO:0060251 | regulation of glial cell proliferation | 1 | 26 | 8.28e-01 |
| GO:BP | GO:0016137 | glycoside metabolic process | 1 | 16 | 8.28e-01 |
| GO:BP | GO:0052652 | cyclic purine nucleotide metabolic process | 2 | 30 | 8.28e-01 |
| GO:BP | GO:0071548 | response to dexamethasone | 1 | 36 | 8.29e-01 |
| GO:BP | GO:0008542 | visual learning | 1 | 37 | 8.29e-01 |
| GO:BP | GO:0060117 | auditory receptor cell development | 1 | 14 | 8.30e-01 |
| GO:BP | GO:0030011 | maintenance of cell polarity | 1 | 16 | 8.30e-01 |
| GO:BP | GO:1901031 | regulation of response to reactive oxygen species | 1 | 28 | 8.30e-01 |
| GO:BP | GO:0032438 | melanosome organization | 1 | 36 | 8.31e-01 |
| GO:BP | GO:0007259 | receptor signaling pathway via JAK-STAT | 6 | 86 | 8.31e-01 |
| GO:BP | GO:0048821 | erythrocyte development | 1 | 30 | 8.31e-01 |
| GO:BP | GO:1902904 | negative regulation of supramolecular fiber organization | 5 | 140 | 8.32e-01 |
| GO:BP | GO:0071622 | regulation of granulocyte chemotaxis | 1 | 27 | 8.32e-01 |
| GO:BP | GO:0042573 | retinoic acid metabolic process | 1 | 12 | 8.32e-01 |
| GO:BP | GO:0070296 | sarcoplasmic reticulum calcium ion transport | 2 | 31 | 8.32e-01 |
| GO:BP | GO:0070570 | regulation of neuron projection regeneration | 1 | 25 | 8.32e-01 |
| GO:BP | GO:0062208 | positive regulation of pattern recognition receptor signaling pathway | 1 | 27 | 8.32e-01 |
| GO:BP | GO:0010155 | regulation of proton transport | 1 | 18 | 8.32e-01 |
| GO:BP | GO:0098660 | inorganic ion transmembrane transport | 1 | 563 | 8.33e-01 |
| GO:BP | GO:0032456 | endocytic recycling | 5 | 80 | 8.33e-01 |
| GO:BP | GO:0032943 | mononuclear cell proliferation | 6 | 168 | 8.35e-01 |
| GO:BP | GO:0042430 | indole-containing compound metabolic process | 1 | 8 | 8.35e-01 |
| GO:BP | GO:0002758 | innate immune response-activating signaling pathway | 5 | 122 | 8.35e-01 |
| GO:BP | GO:0050805 | negative regulation of synaptic transmission | 3 | 35 | 8.36e-01 |
| GO:BP | GO:0016192 | vesicle-mediated transport | 58 | 1238 | 8.36e-01 |
| GO:BP | GO:1904063 | negative regulation of cation transmembrane transport | 5 | 64 | 8.36e-01 |
| GO:BP | GO:0098661 | inorganic anion transmembrane transport | 7 | 66 | 8.36e-01 |
| GO:BP | GO:0035384 | thioester biosynthetic process | 2 | 38 | 8.36e-01 |
| GO:BP | GO:0070918 | regulatory ncRNA processing | 4 | 47 | 8.36e-01 |
| GO:BP | GO:1903900 | regulation of viral life cycle | 3 | 101 | 8.36e-01 |
| GO:BP | GO:0071616 | acyl-CoA biosynthetic process | 2 | 38 | 8.36e-01 |
| GO:BP | GO:0009994 | oocyte differentiation | 3 | 39 | 8.36e-01 |
| GO:BP | GO:0003176 | aortic valve development | 1 | 37 | 8.37e-01 |
| GO:BP | GO:0048002 | antigen processing and presentation of peptide antigen | 3 | 41 | 8.37e-01 |
| GO:BP | GO:0048753 | pigment granule organization | 1 | 37 | 8.37e-01 |
| GO:BP | GO:1903169 | regulation of calcium ion transmembrane transport | 11 | 122 | 8.37e-01 |
| GO:BP | GO:0009187 | cyclic nucleotide metabolic process | 2 | 31 | 8.37e-01 |
| GO:BP | GO:1903530 | regulation of secretion by cell | 4 | 382 | 8.38e-01 |
| GO:BP | GO:0007162 | negative regulation of cell adhesion | 18 | 192 | 8.38e-01 |
| GO:BP | GO:0006921 | cellular component disassembly involved in execution phase of apoptosis | 1 | 22 | 8.38e-01 |
| GO:BP | GO:0048255 | mRNA stabilization | 3 | 50 | 8.38e-01 |
| GO:BP | GO:0031960 | response to corticosteroid | 5 | 109 | 8.38e-01 |
| GO:BP | GO:0032981 | mitochondrial respiratory chain complex I assembly | 1 | 55 | 8.38e-01 |
| GO:BP | GO:0010257 | NADH dehydrogenase complex assembly | 1 | 55 | 8.38e-01 |
| GO:BP | GO:0046427 | positive regulation of receptor signaling pathway via JAK-STAT | 2 | 21 | 8.39e-01 |
| GO:BP | GO:0009954 | proximal/distal pattern formation | 1 | 15 | 8.39e-01 |
| GO:BP | GO:0097205 | renal filtration | 1 | 23 | 8.40e-01 |
| GO:BP | GO:0009110 | vitamin biosynthetic process | 1 | 14 | 8.40e-01 |
| GO:BP | GO:0035809 | regulation of urine volume | 1 | 14 | 8.40e-01 |
| GO:BP | GO:0007130 | synaptonemal complex assembly | 1 | 10 | 8.40e-01 |
| GO:BP | GO:0046850 | regulation of bone remodeling | 1 | 30 | 8.40e-01 |
| GO:BP | GO:1902236 | negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway | 1 | 17 | 8.40e-01 |
| GO:BP | GO:0051703 | biological process involved in intraspecies interaction between organisms | 2 | 34 | 8.40e-01 |
| GO:BP | GO:0017157 | regulation of exocytosis | 9 | 147 | 8.40e-01 |
| GO:BP | GO:0010043 | response to zinc ion | 1 | 31 | 8.40e-01 |
| GO:BP | GO:0015868 | purine ribonucleotide transport | 1 | 19 | 8.40e-01 |
| GO:BP | GO:0002283 | neutrophil activation involved in immune response | 1 | 7 | 8.40e-01 |
| GO:BP | GO:2000193 | positive regulation of fatty acid transport | 1 | 11 | 8.40e-01 |
| GO:BP | GO:0042178 | xenobiotic catabolic process | 1 | 12 | 8.40e-01 |
| GO:BP | GO:0097435 | supramolecular fiber organization | 6 | 665 | 8.42e-01 |
| GO:BP | GO:0007274 | neuromuscular synaptic transmission | 1 | 14 | 8.42e-01 |
| GO:BP | GO:0001974 | blood vessel remodeling | 2 | 32 | 8.42e-01 |
| GO:BP | GO:0042157 | lipoprotein metabolic process | 1 | 116 | 8.42e-01 |
| GO:BP | GO:0048872 | homeostasis of number of cells | 12 | 228 | 8.42e-01 |
| GO:BP | GO:0016125 | sterol metabolic process | 5 | 111 | 8.42e-01 |
| GO:BP | GO:0007212 | dopamine receptor signaling pathway | 1 | 27 | 8.42e-01 |
| GO:BP | GO:0006305 | DNA alkylation | 1 | 46 | 8.43e-01 |
| GO:BP | GO:0006306 | DNA methylation | 1 | 46 | 8.43e-01 |
| GO:BP | GO:0008277 | regulation of G protein-coupled receptor signaling pathway | 4 | 94 | 8.43e-01 |
| GO:BP | GO:0051173 | positive regulation of nitrogen compound metabolic process | 3 | 2412 | 8.43e-01 |
| GO:BP | GO:0051093 | negative regulation of developmental process | 21 | 665 | 8.43e-01 |
| GO:BP | GO:0050850 | positive regulation of calcium-mediated signaling | 2 | 22 | 8.43e-01 |
| GO:BP | GO:0002757 | immune response-activating signaling pathway | 1 | 230 | 8.44e-01 |
| GO:BP | GO:1903055 | positive regulation of extracellular matrix organization | 1 | 24 | 8.44e-01 |
| GO:BP | GO:0038095 | Fc-epsilon receptor signaling pathway | 1 | 17 | 8.45e-01 |
| GO:BP | GO:0051953 | negative regulation of amine transport | 1 | 15 | 8.45e-01 |
| GO:BP | GO:0071880 | adenylate cyclase-activating adrenergic receptor signaling pathway | 1 | 19 | 8.45e-01 |
| GO:BP | GO:0001570 | vasculogenesis | 1 | 67 | 8.46e-01 |
| GO:BP | GO:0006508 | proteolysis | 3 | 1318 | 8.46e-01 |
| GO:BP | GO:0090183 | regulation of kidney development | 1 | 22 | 8.46e-01 |
| GO:BP | GO:0006270 | DNA replication initiation | 2 | 35 | 8.46e-01 |
| GO:BP | GO:0007568 | aging | 9 | 115 | 8.46e-01 |
| GO:BP | GO:0010574 | regulation of vascular endothelial growth factor production | 1 | 20 | 8.46e-01 |
| GO:BP | GO:0040036 | regulation of fibroblast growth factor receptor signaling pathway | 1 | 25 | 8.46e-01 |
| GO:BP | GO:0034763 | negative regulation of transmembrane transport | 4 | 96 | 8.47e-01 |
| GO:BP | GO:0051957 | positive regulation of amino acid transport | 1 | 16 | 8.47e-01 |
| GO:BP | GO:0006898 | receptor-mediated endocytosis | 15 | 196 | 8.50e-01 |
| GO:BP | GO:0097696 | receptor signaling pathway via STAT | 4 | 88 | 8.50e-01 |
| GO:BP | GO:0070050 | neuron cellular homeostasis | 1 | 46 | 8.50e-01 |
| GO:BP | GO:0006942 | regulation of striated muscle contraction | 1 | 85 | 8.50e-01 |
| GO:BP | GO:0051938 | L-glutamate import | 1 | 25 | 8.50e-01 |
| GO:BP | GO:0070534 | protein K63-linked ubiquitination | 1 | 52 | 8.50e-01 |
| GO:BP | GO:0006275 | regulation of DNA replication | 3 | 116 | 8.50e-01 |
| GO:BP | GO:1902644 | tertiary alcohol metabolic process | 1 | 17 | 8.51e-01 |
| GO:BP | GO:0007039 | protein catabolic process in the vacuole | 1 | 22 | 8.51e-01 |
| GO:BP | GO:0042743 | hydrogen peroxide metabolic process | 1 | 29 | 8.53e-01 |
| GO:BP | GO:0000083 | regulation of transcription involved in G1/S transition of mitotic cell cycle | 1 | 20 | 8.53e-01 |
| GO:BP | GO:0045292 | mRNA cis splicing, via spliceosome | 1 | 26 | 8.53e-01 |
| GO:BP | GO:0033522 | histone H2A ubiquitination | 1 | 28 | 8.54e-01 |
| GO:BP | GO:0030903 | notochord development | 1 | 17 | 8.54e-01 |
| GO:BP | GO:0035235 | ionotropic glutamate receptor signaling pathway | 1 | 14 | 8.54e-01 |
| GO:BP | GO:0070536 | protein K63-linked deubiquitination | 1 | 33 | 8.54e-01 |
| GO:BP | GO:0048010 | vascular endothelial growth factor receptor signaling pathway | 1 | 48 | 8.54e-01 |
| GO:BP | GO:0051438 | regulation of ubiquitin-protein transferase activity | 1 | 55 | 8.55e-01 |
| GO:BP | GO:0055074 | calcium ion homeostasis | 4 | 214 | 8.56e-01 |
| GO:BP | GO:0007143 | female meiotic nuclear division | 1 | 25 | 8.56e-01 |
| GO:BP | GO:0008202 | steroid metabolic process | 11 | 204 | 8.56e-01 |
| GO:BP | GO:0097581 | lamellipodium organization | 3 | 78 | 8.57e-01 |
| GO:BP | GO:0033555 | multicellular organismal response to stress | 2 | 57 | 8.57e-01 |
| GO:BP | GO:0045822 | negative regulation of heart contraction | 1 | 17 | 8.57e-01 |
| GO:BP | GO:0016338 | calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules | 1 | 10 | 8.57e-01 |
| GO:BP | GO:0014823 | response to activity | 1 | 46 | 8.57e-01 |
| GO:BP | GO:1902369 | negative regulation of RNA catabolic process | 4 | 69 | 8.58e-01 |
| GO:BP | GO:0034728 | nucleosome organization | 7 | 98 | 8.59e-01 |
| GO:BP | GO:0071674 | mononuclear cell migration | 1 | 102 | 8.59e-01 |
| GO:BP | GO:0090102 | cochlea development | 1 | 35 | 8.59e-01 |
| GO:BP | GO:2001044 | regulation of integrin-mediated signaling pathway | 1 | 20 | 8.59e-01 |
| GO:BP | GO:0032196 | transposition | 1 | 17 | 8.59e-01 |
| GO:BP | GO:0002764 | immune response-regulating signaling pathway | 1 | 242 | 8.59e-01 |
| GO:BP | GO:0048609 | multicellular organismal reproductive process | 1 | 538 | 8.59e-01 |
| GO:BP | GO:0023061 | signal release | 6 | 321 | 8.59e-01 |
| GO:BP | GO:0090151 | establishment of protein localization to mitochondrial membrane | 2 | 38 | 8.59e-01 |
| GO:BP | GO:1904894 | positive regulation of receptor signaling pathway via STAT | 2 | 22 | 8.59e-01 |
| GO:BP | GO:0034308 | primary alcohol metabolic process | 3 | 61 | 8.59e-01 |
| GO:BP | GO:0034220 | monoatomic ion transmembrane transport | 1 | 632 | 8.59e-01 |
| GO:BP | GO:0032892 | positive regulation of organic acid transport | 2 | 27 | 8.59e-01 |
| GO:BP | GO:0045471 | response to ethanol | 3 | 73 | 8.59e-01 |
| GO:BP | GO:0006739 | NADP metabolic process | 2 | 40 | 8.59e-01 |
| GO:BP | GO:0098581 | detection of external biotic stimulus | 1 | 11 | 8.59e-01 |
| GO:BP | GO:0051384 | response to glucocorticoid | 4 | 93 | 8.59e-01 |
| GO:BP | GO:0032508 | DNA duplex unwinding | 4 | 74 | 8.60e-01 |
| GO:BP | GO:0007350 | blastoderm segmentation | 1 | 17 | 8.60e-01 |
| GO:BP | GO:0007605 | sensory perception of sound | 3 | 98 | 8.60e-01 |
| GO:BP | GO:0007064 | mitotic sister chromatid cohesion | 1 | 30 | 8.62e-01 |
| GO:BP | GO:0007405 | neuroblast proliferation | 1 | 51 | 8.63e-01 |
| GO:BP | GO:0006775 | fat-soluble vitamin metabolic process | 2 | 20 | 8.63e-01 |
| GO:BP | GO:0046058 | cAMP metabolic process | 1 | 19 | 8.65e-01 |
| GO:BP | GO:0097529 | myeloid leukocyte migration | 1 | 120 | 8.65e-01 |
| GO:BP | GO:0030855 | epithelial cell differentiation | 1 | 442 | 8.65e-01 |
| GO:BP | GO:0035249 | synaptic transmission, glutamatergic | 6 | 64 | 8.65e-01 |
| GO:BP | GO:0006805 | xenobiotic metabolic process | 1 | 56 | 8.65e-01 |
| GO:BP | GO:0051932 | synaptic transmission, GABAergic | 3 | 36 | 8.65e-01 |
| GO:BP | GO:0015698 | inorganic anion transport | 1 | 104 | 8.65e-01 |
| GO:BP | GO:0043966 | histone H3 acetylation | 2 | 59 | 8.66e-01 |
| GO:BP | GO:0071230 | cellular response to amino acid stimulus | 1 | 65 | 8.66e-01 |
| GO:BP | GO:0010818 | T cell chemotaxis | 1 | 12 | 8.66e-01 |
| GO:BP | GO:0048240 | sperm capacitation | 1 | 7 | 8.66e-01 |
| GO:BP | GO:1903523 | negative regulation of blood circulation | 1 | 18 | 8.66e-01 |
| GO:BP | GO:0099560 | synaptic membrane adhesion | 1 | 22 | 8.66e-01 |
| GO:BP | GO:0051224 | negative regulation of protein transport | 7 | 91 | 8.67e-01 |
| GO:BP | GO:0006812 | monoatomic cation transport | 1 | 669 | 8.67e-01 |
| GO:BP | GO:0098659 | inorganic cation import across plasma membrane | 4 | 73 | 8.67e-01 |
| GO:BP | GO:0099587 | inorganic ion import across plasma membrane | 4 | 73 | 8.67e-01 |
| GO:BP | GO:0032635 | interleukin-6 production | 4 | 86 | 8.68e-01 |
| GO:BP | GO:0032675 | regulation of interleukin-6 production | 4 | 86 | 8.68e-01 |
| GO:BP | GO:0070193 | synaptonemal complex organization | 1 | 13 | 8.68e-01 |
| GO:BP | GO:0035459 | vesicle cargo loading | 1 | 27 | 8.68e-01 |
| GO:BP | GO:0019883 | antigen processing and presentation of endogenous antigen | 1 | 19 | 8.68e-01 |
| GO:BP | GO:0065008 | regulation of biological quality | 1 | 2102 | 8.68e-01 |
| GO:BP | GO:0019884 | antigen processing and presentation of exogenous antigen | 2 | 28 | 8.68e-01 |
| GO:BP | GO:1905517 | macrophage migration | 1 | 34 | 8.68e-01 |
| GO:BP | GO:0045861 | negative regulation of proteolysis | 6 | 211 | 8.69e-01 |
| GO:BP | GO:0007127 | meiosis I | 1 | 77 | 8.69e-01 |
| GO:BP | GO:0060349 | bone morphogenesis | 1 | 74 | 8.70e-01 |
| GO:BP | GO:0032504 | multicellular organism reproduction | 1 | 556 | 8.70e-01 |
| GO:BP | GO:0002507 | tolerance induction | 1 | 15 | 8.71e-01 |
| GO:BP | GO:0071675 | regulation of mononuclear cell migration | 3 | 71 | 8.72e-01 |
| GO:BP | GO:0045070 | positive regulation of viral genome replication | 1 | 28 | 8.73e-01 |
| GO:BP | GO:0071294 | cellular response to zinc ion | 1 | 15 | 8.73e-01 |
| GO:BP | GO:0042471 | ear morphogenesis | 3 | 73 | 8.73e-01 |
| GO:BP | GO:1901019 | regulation of calcium ion transmembrane transporter activity | 5 | 71 | 8.73e-01 |
| GO:BP | GO:0006766 | vitamin metabolic process | 6 | 73 | 8.73e-01 |
| GO:BP | GO:1902600 | proton transmembrane transport | 1 | 111 | 8.73e-01 |
| GO:BP | GO:0007214 | gamma-aminobutyric acid signaling pathway | 1 | 12 | 8.74e-01 |
| GO:BP | GO:0010573 | vascular endothelial growth factor production | 1 | 23 | 8.74e-01 |
| GO:BP | GO:0046677 | response to antibiotic | 2 | 43 | 8.75e-01 |
| GO:BP | GO:0051171 | regulation of nitrogen compound metabolic process | 6 | 4292 | 8.75e-01 |
| GO:BP | GO:0003158 | endothelium development | 3 | 104 | 8.75e-01 |
| GO:BP | GO:0031279 | regulation of cyclase activity | 3 | 37 | 8.76e-01 |
| GO:BP | GO:0048878 | chemical homeostasis | 24 | 676 | 8.76e-01 |
| GO:BP | GO:2000404 | regulation of T cell migration | 1 | 28 | 8.76e-01 |
| GO:BP | GO:0097305 | response to alcohol | 7 | 159 | 8.76e-01 |
| GO:BP | GO:0048522 | positive regulation of cellular process | 7 | 4099 | 8.77e-01 |
| GO:BP | GO:0006821 | chloride transport | 6 | 58 | 8.77e-01 |
| GO:BP | GO:0010390 | histone monoubiquitination | 1 | 31 | 8.77e-01 |
| GO:BP | GO:0034766 | negative regulation of monoatomic ion transmembrane transport | 5 | 70 | 8.78e-01 |
| GO:BP | GO:0003006 | developmental process involved in reproduction | 1 | 598 | 8.78e-01 |
| GO:BP | GO:0046717 | acid secretion | 2 | 25 | 8.78e-01 |
| GO:BP | GO:0050900 | leukocyte migration | 2 | 209 | 8.78e-01 |
| GO:BP | GO:0034104 | negative regulation of tissue remodeling | 1 | 13 | 8.78e-01 |
| GO:BP | GO:0032941 | secretion by tissue | 1 | 25 | 8.78e-01 |
| GO:BP | GO:0002253 | activation of immune response | 1 | 272 | 8.78e-01 |
| GO:BP | GO:0042755 | eating behavior | 1 | 16 | 8.79e-01 |
| GO:BP | GO:0051503 | adenine nucleotide transport | 1 | 23 | 8.79e-01 |
| GO:BP | GO:0006298 | mismatch repair | 1 | 29 | 8.79e-01 |
| GO:BP | GO:0061982 | meiosis I cell cycle process | 1 | 81 | 8.79e-01 |
| GO:BP | GO:0006081 | cellular aldehyde metabolic process | 3 | 52 | 8.79e-01 |
| GO:BP | GO:0046471 | phosphatidylglycerol metabolic process | 1 | 23 | 8.82e-01 |
| GO:BP | GO:0034502 | protein localization to chromosome | 6 | 110 | 8.82e-01 |
| GO:BP | GO:0051046 | regulation of secretion | 4 | 418 | 8.82e-01 |
| GO:BP | GO:1902475 | L-alpha-amino acid transmembrane transport | 2 | 55 | 8.82e-01 |
| GO:BP | GO:0002474 | antigen processing and presentation of peptide antigen via MHC class I | 1 | 25 | 8.83e-01 |
| GO:BP | GO:0044273 | sulfur compound catabolic process | 1 | 31 | 8.84e-01 |
| GO:BP | GO:0042273 | ribosomal large subunit biogenesis | 2 | 73 | 8.86e-01 |
| GO:BP | GO:0042531 | positive regulation of tyrosine phosphorylation of STAT protein | 1 | 23 | 8.88e-01 |
| GO:BP | GO:0042472 | inner ear morphogenesis | 4 | 59 | 8.88e-01 |
| GO:BP | GO:0006654 | phosphatidic acid biosynthetic process | 1 | 30 | 8.88e-01 |
| GO:BP | GO:0045109 | intermediate filament organization | 2 | 21 | 8.89e-01 |
| GO:BP | GO:0010894 | negative regulation of steroid biosynthetic process | 1 | 18 | 8.89e-01 |
| GO:BP | GO:0010466 | negative regulation of peptidase activity | 1 | 131 | 8.90e-01 |
| GO:BP | GO:0044270 | cellular nitrogen compound catabolic process | 8 | 378 | 8.91e-01 |
| GO:BP | GO:0009893 | positive regulation of metabolic process | 5 | 2880 | 8.93e-01 |
| GO:BP | GO:0032890 | regulation of organic acid transport | 1 | 49 | 8.93e-01 |
| GO:BP | GO:0032392 | DNA geometric change | 4 | 80 | 8.93e-01 |
| GO:BP | GO:0042742 | defense response to bacterium | 1 | 95 | 8.94e-01 |
| GO:BP | GO:1904645 | response to amyloid-beta | 2 | 32 | 8.94e-01 |
| GO:BP | GO:0035590 | purinergic nucleotide receptor signaling pathway | 1 | 16 | 8.94e-01 |
| GO:BP | GO:0046700 | heterocycle catabolic process | 8 | 381 | 8.94e-01 |
| GO:BP | GO:0060314 | regulation of ryanodine-sensitive calcium-release channel activity | 1 | 23 | 8.94e-01 |
| GO:BP | GO:0015865 | purine nucleotide transport | 1 | 23 | 8.94e-01 |
| GO:BP | GO:0033137 | negative regulation of peptidyl-serine phosphorylation | 1 | 26 | 8.94e-01 |
| GO:BP | GO:0051928 | positive regulation of calcium ion transport | 7 | 82 | 8.94e-01 |
| GO:BP | GO:0034655 | nucleobase-containing compound catabolic process | 11 | 358 | 8.94e-01 |
| GO:BP | GO:0085029 | extracellular matrix assembly | 1 | 41 | 8.95e-01 |
| GO:BP | GO:0030279 | negative regulation of ossification | 1 | 25 | 8.95e-01 |
| GO:BP | GO:0045596 | negative regulation of cell differentiation | 32 | 482 | 8.95e-01 |
| GO:BP | GO:0002021 | response to dietary excess | 1 | 22 | 8.95e-01 |
| GO:BP | GO:0042730 | fibrinolysis | 1 | 15 | 8.95e-01 |
| GO:BP | GO:0070665 | positive regulation of leukocyte proliferation | 4 | 83 | 8.96e-01 |
| GO:BP | GO:0080090 | regulation of primary metabolic process | 6 | 4417 | 8.96e-01 |
| GO:BP | GO:0001707 | mesoderm formation | 1 | 53 | 8.96e-01 |
| GO:BP | GO:1901880 | negative regulation of protein depolymerization | 1 | 64 | 8.96e-01 |
| GO:BP | GO:0019953 | sexual reproduction | 1 | 631 | 8.96e-01 |
| GO:BP | GO:1902373 | negative regulation of mRNA catabolic process | 3 | 57 | 8.96e-01 |
| GO:BP | GO:0010604 | positive regulation of macromolecule metabolic process | 3 | 2646 | 8.97e-01 |
| GO:BP | GO:0009126 | purine nucleoside monophosphate metabolic process | 1 | 39 | 8.97e-01 |
| GO:BP | GO:0002455 | humoral immune response mediated by circulating immunoglobulin | 1 | 22 | 8.97e-01 |
| GO:BP | GO:0007204 | positive regulation of cytosolic calcium ion concentration | 4 | 90 | 8.97e-01 |
| GO:BP | GO:0045744 | negative regulation of G protein-coupled receptor signaling pathway | 1 | 38 | 8.98e-01 |
| GO:BP | GO:0098739 | import across plasma membrane | 9 | 133 | 8.98e-01 |
| GO:BP | GO:0001523 | retinoid metabolic process | 4 | 40 | 8.98e-01 |
| GO:BP | GO:0001963 | synaptic transmission, dopaminergic | 1 | 16 | 8.99e-01 |
| GO:BP | GO:0060544 | regulation of necroptotic process | 1 | 23 | 8.99e-01 |
| GO:BP | GO:0045682 | regulation of epidermis development | 3 | 45 | 9.01e-01 |
| GO:BP | GO:0042446 | hormone biosynthetic process | 3 | 40 | 9.01e-01 |
| GO:BP | GO:0048333 | mesodermal cell differentiation | 1 | 22 | 9.01e-01 |
| GO:BP | GO:0055078 | sodium ion homeostasis | 2 | 26 | 9.01e-01 |
| GO:BP | GO:0048332 | mesoderm morphogenesis | 1 | 55 | 9.01e-01 |
| GO:BP | GO:0071168 | protein localization to chromatin | 2 | 48 | 9.01e-01 |
| GO:BP | GO:0098742 | cell-cell adhesion via plasma-membrane adhesion molecules | 1 | 168 | 9.01e-01 |
| GO:BP | GO:1903305 | regulation of regulated secretory pathway | 5 | 89 | 9.02e-01 |
| GO:BP | GO:0033866 | nucleoside bisphosphate biosynthetic process | 2 | 49 | 9.02e-01 |
| GO:BP | GO:0034030 | ribonucleoside bisphosphate biosynthetic process | 2 | 49 | 9.02e-01 |
| GO:BP | GO:0034033 | purine nucleoside bisphosphate biosynthetic process | 2 | 49 | 9.02e-01 |
| GO:BP | GO:1901575 | organic substance catabolic process | 143 | 1712 | 9.02e-01 |
| GO:BP | GO:0010743 | regulation of macrophage derived foam cell differentiation | 1 | 18 | 9.03e-01 |
| GO:BP | GO:0006865 | amino acid transport | 4 | 102 | 9.03e-01 |
| GO:BP | GO:1901615 | organic hydroxy compound metabolic process | 3 | 376 | 9.04e-01 |
| GO:BP | GO:0001675 | acrosome assembly | 1 | 16 | 9.04e-01 |
| GO:BP | GO:0044818 | mitotic G2/M transition checkpoint | 2 | 50 | 9.06e-01 |
| GO:BP | GO:0007165 | signal transduction | 5 | 3818 | 9.06e-01 |
| GO:BP | GO:0045055 | regulated exocytosis | 4 | 155 | 9.06e-01 |
| GO:BP | GO:0150146 | cell junction disassembly | 1 | 20 | 9.06e-01 |
| GO:BP | GO:0042501 | serine phosphorylation of STAT protein | 1 | 9 | 9.06e-01 |
| GO:BP | GO:0014902 | myotube differentiation | 4 | 88 | 9.07e-01 |
| GO:BP | GO:0090288 | negative regulation of cellular response to growth factor stimulus | 1 | 81 | 9.07e-01 |
| GO:BP | GO:0045604 | regulation of epidermal cell differentiation | 1 | 39 | 9.07e-01 |
| GO:BP | GO:0055117 | regulation of cardiac muscle contraction | 2 | 70 | 9.07e-01 |
| GO:BP | GO:0009880 | embryonic pattern specification | 3 | 50 | 9.07e-01 |
| GO:BP | GO:0006811 | monoatomic ion transport | 1 | 775 | 9.08e-01 |
| GO:BP | GO:0050954 | sensory perception of mechanical stimulus | 3 | 112 | 9.08e-01 |
| GO:BP | GO:0042445 | hormone metabolic process | 2 | 133 | 9.08e-01 |
| GO:BP | GO:0008037 | cell recognition | 2 | 87 | 9.09e-01 |
| GO:BP | GO:0061351 | neural precursor cell proliferation | 2 | 114 | 9.09e-01 |
| GO:BP | GO:1903828 | negative regulation of protein localization | 3 | 160 | 9.09e-01 |
| GO:BP | GO:1902042 | negative regulation of extrinsic apoptotic signaling pathway via death domain receptors | 1 | 24 | 9.09e-01 |
| GO:BP | GO:0070588 | calcium ion transmembrane transport | 7 | 213 | 9.09e-01 |
| GO:BP | GO:0016101 | diterpenoid metabolic process | 4 | 43 | 9.11e-01 |
| GO:BP | GO:0046473 | phosphatidic acid metabolic process | 1 | 32 | 9.12e-01 |
| GO:BP | GO:0032924 | activin receptor signaling pathway | 1 | 34 | 9.12e-01 |
| GO:BP | GO:0045920 | negative regulation of exocytosis | 1 | 26 | 9.12e-01 |
| GO:BP | GO:0019439 | aromatic compound catabolic process | 8 | 387 | 9.12e-01 |
| GO:BP | GO:0046173 | polyol biosynthetic process | 1 | 47 | 9.13e-01 |
| GO:BP | GO:0045939 | negative regulation of steroid metabolic process | 1 | 19 | 9.13e-01 |
| GO:BP | GO:0030837 | negative regulation of actin filament polymerization | 1 | 57 | 9.13e-01 |
| GO:BP | GO:0045684 | positive regulation of epidermis development | 1 | 20 | 9.13e-01 |
| GO:BP | GO:0002685 | regulation of leukocyte migration | 4 | 131 | 9.15e-01 |
| GO:BP | GO:0060255 | regulation of macromolecule metabolic process | 7 | 4617 | 9.17e-01 |
| GO:BP | GO:0016070 | RNA metabolic process | 1 | 3600 | 9.18e-01 |
| GO:BP | GO:0050853 | B cell receptor signaling pathway | 1 | 32 | 9.18e-01 |
| GO:BP | GO:0010467 | gene expression | 2 | 4587 | 9.19e-01 |
| GO:BP | GO:0051568 | histone H3-K4 methylation | 3 | 57 | 9.19e-01 |
| GO:BP | GO:0006482 | protein demethylation | 1 | 27 | 9.19e-01 |
| GO:BP | GO:0008214 | protein dealkylation | 1 | 27 | 9.19e-01 |
| GO:BP | GO:0007187 | G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger | 2 | 18 | 9.19e-01 |
| GO:BP | GO:0043242 | negative regulation of protein-containing complex disassembly | 1 | 72 | 9.20e-01 |
| GO:BP | GO:1990806 | ligand-gated ion channel signaling pathway | 1 | 20 | 9.20e-01 |
| GO:BP | GO:0035306 | positive regulation of dephosphorylation | 1 | 47 | 9.20e-01 |
| GO:BP | GO:0002548 | monocyte chemotaxis | 3 | 22 | 9.21e-01 |
| GO:BP | GO:0062098 | regulation of programmed necrotic cell death | 1 | 26 | 9.22e-01 |
| GO:BP | GO:0042509 | regulation of tyrosine phosphorylation of STAT protein | 1 | 34 | 9.22e-01 |
| GO:BP | GO:2000144 | positive regulation of DNA-templated transcription initiation | 3 | 65 | 9.23e-01 |
| GO:BP | GO:0007269 | neurotransmitter secretion | 5 | 104 | 9.23e-01 |
| GO:BP | GO:0099643 | signal release from synapse | 5 | 104 | 9.23e-01 |
| GO:BP | GO:0045666 | positive regulation of neuron differentiation | 2 | 63 | 9.23e-01 |
| GO:BP | GO:0042572 | retinol metabolic process | 1 | 24 | 9.23e-01 |
| GO:BP | GO:0070979 | protein K11-linked ubiquitination | 1 | 29 | 9.23e-01 |
| GO:BP | GO:0017156 | calcium-ion regulated exocytosis | 3 | 46 | 9.24e-01 |
| GO:BP | GO:0006807 | nitrogen compound metabolic process | 1 | 7441 | 9.25e-01 |
| GO:BP | GO:0006862 | nucleotide transport | 1 | 28 | 9.26e-01 |
| GO:BP | GO:0008203 | cholesterol metabolic process | 3 | 101 | 9.26e-01 |
| GO:BP | GO:0071103 | DNA conformation change | 4 | 87 | 9.26e-01 |
| GO:BP | GO:0018208 | peptidyl-proline modification | 1 | 43 | 9.26e-01 |
| GO:BP | GO:0030198 | extracellular matrix organization | 1 | 233 | 9.27e-01 |
| GO:BP | GO:0043062 | extracellular structure organization | 1 | 234 | 9.28e-01 |
| GO:BP | GO:0002251 | organ or tissue specific immune response | 1 | 13 | 9.28e-01 |
| GO:BP | GO:0032350 | regulation of hormone metabolic process | 1 | 30 | 9.28e-01 |
| GO:BP | GO:0003333 | amino acid transmembrane transport | 3 | 71 | 9.28e-01 |
| GO:BP | GO:0007140 | male meiotic nuclear division | 1 | 27 | 9.28e-01 |
| GO:BP | GO:0045229 | external encapsulating structure organization | 1 | 234 | 9.28e-01 |
| GO:BP | GO:0007260 | tyrosine phosphorylation of STAT protein | 1 | 36 | 9.29e-01 |
| GO:BP | GO:0042100 | B cell proliferation | 2 | 45 | 9.29e-01 |
| GO:BP | GO:0043627 | response to estrogen | 1 | 52 | 9.31e-01 |
| GO:BP | GO:0050671 | positive regulation of lymphocyte proliferation | 3 | 72 | 9.31e-01 |
| GO:BP | GO:0006626 | protein targeting to mitochondrion | 3 | 100 | 9.31e-01 |
| GO:BP | GO:1901879 | regulation of protein depolymerization | 1 | 78 | 9.33e-01 |
| GO:BP | GO:0000578 | embryonic axis specification | 1 | 26 | 9.34e-01 |
| GO:BP | GO:0033363 | secretory granule organization | 1 | 50 | 9.34e-01 |
| GO:BP | GO:0043170 | macromolecule metabolic process | 1 | 7069 | 9.36e-01 |
| GO:BP | GO:0016079 | synaptic vesicle exocytosis | 3 | 74 | 9.38e-01 |
| GO:BP | GO:0032946 | positive regulation of mononuclear cell proliferation | 3 | 75 | 9.38e-01 |
| GO:BP | GO:0045665 | negative regulation of neuron differentiation | 2 | 43 | 9.38e-01 |
| GO:BP | GO:0048278 | vesicle docking | 1 | 57 | 9.38e-01 |
| GO:BP | GO:0086004 | regulation of cardiac muscle cell contraction | 1 | 34 | 9.38e-01 |
| GO:BP | GO:0050808 | synapse organization | 1 | 365 | 9.38e-01 |
| GO:BP | GO:0046434 | organophosphate catabolic process | 5 | 113 | 9.38e-01 |
| GO:BP | GO:1900181 | negative regulation of protein localization to nucleus | 1 | 28 | 9.38e-01 |
| GO:BP | GO:1903707 | negative regulation of hemopoiesis | 5 | 69 | 9.38e-01 |
| GO:BP | GO:0090304 | nucleic acid metabolic process | 1 | 4048 | 9.38e-01 |
| GO:BP | GO:0009595 | detection of biotic stimulus | 1 | 20 | 9.40e-01 |
| GO:BP | GO:0032965 | regulation of collagen biosynthetic process | 1 | 30 | 9.41e-01 |
| GO:BP | GO:0051592 | response to calcium ion | 3 | 113 | 9.41e-01 |
| GO:BP | GO:1901361 | organic cyclic compound catabolic process | 8 | 406 | 9.42e-01 |
| GO:BP | GO:0032103 | positive regulation of response to external stimulus | 13 | 337 | 9.42e-01 |
| GO:BP | GO:0001704 | formation of primary germ layer | 6 | 96 | 9.43e-01 |
| GO:BP | GO:0031103 | axon regeneration | 1 | 42 | 9.43e-01 |
| GO:BP | GO:0030856 | regulation of epithelial cell differentiation | 4 | 101 | 9.43e-01 |
| GO:BP | GO:0030888 | regulation of B cell proliferation | 1 | 35 | 9.43e-01 |
| GO:BP | GO:0023052 | signaling | 5 | 4141 | 9.43e-01 |
| GO:BP | GO:0016339 | calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules | 1 | 28 | 9.44e-01 |
| GO:BP | GO:0140013 | meiotic nuclear division | 1 | 120 | 9.44e-01 |
| GO:BP | GO:0050789 | regulation of biological process | 1 | 8061 | 9.44e-01 |
| GO:BP | GO:0032101 | regulation of response to external stimulus | 26 | 662 | 9.44e-01 |
| GO:BP | GO:1902652 | secondary alcohol metabolic process | 3 | 108 | 9.46e-01 |
| GO:BP | GO:0140352 | export from cell | 6 | 611 | 9.47e-01 |
| GO:BP | GO:0006284 | base-excision repair | 1 | 44 | 9.47e-01 |
| GO:BP | GO:0032940 | secretion by cell | 5 | 569 | 9.47e-01 |
| GO:BP | GO:0003014 | renal system process | 1 | 78 | 9.47e-01 |
| GO:BP | GO:0035725 | sodium ion transmembrane transport | 7 | 113 | 9.48e-01 |
| GO:BP | GO:0006720 | isoprenoid metabolic process | 1 | 85 | 9.48e-01 |
| GO:BP | GO:0046165 | alcohol biosynthetic process | 1 | 110 | 9.48e-01 |
| GO:BP | GO:0002687 | positive regulation of leukocyte migration | 2 | 84 | 9.48e-01 |
| GO:BP | GO:0045742 | positive regulation of epidermal growth factor receptor signaling pathway | 1 | 26 | 9.49e-01 |
| GO:BP | GO:0006721 | terpenoid metabolic process | 4 | 50 | 9.49e-01 |
| GO:BP | GO:0009166 | nucleotide catabolic process | 2 | 69 | 9.50e-01 |
| GO:BP | GO:0007154 | cell communication | 5 | 4226 | 9.50e-01 |
| GO:BP | GO:0051716 | cellular response to stimulus | 6 | 4953 | 9.50e-01 |
| GO:BP | GO:2000027 | regulation of animal organ morphogenesis | 2 | 101 | 9.51e-01 |
| GO:BP | GO:0051480 | regulation of cytosolic calcium ion concentration | 1 | 40 | 9.51e-01 |
| GO:BP | GO:0009581 | detection of external stimulus | 2 | 67 | 9.51e-01 |
| GO:BP | GO:0072678 | T cell migration | 1 | 38 | 9.51e-01 |
| GO:BP | GO:0048518 | positive regulation of biological process | 7 | 4579 | 9.52e-01 |
| GO:BP | GO:0008038 | neuron recognition | 1 | 39 | 9.52e-01 |
| GO:BP | GO:0045143 | homologous chromosome segregation | 2 | 34 | 9.53e-01 |
| GO:BP | GO:0046928 | regulation of neurotransmitter secretion | 2 | 57 | 9.54e-01 |
| GO:BP | GO:0006139 | nucleobase-containing compound metabolic process | 1 | 4455 | 9.54e-01 |
| GO:BP | GO:0009582 | detection of abiotic stimulus | 2 | 68 | 9.55e-01 |
| GO:BP | GO:0051954 | positive regulation of amine transport | 1 | 26 | 9.55e-01 |
| GO:BP | GO:0016574 | histone ubiquitination | 1 | 46 | 9.55e-01 |
| GO:BP | GO:0039531 | regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway | 1 | 40 | 9.56e-01 |
| GO:BP | GO:0032735 | positive regulation of interleukin-12 production | 1 | 19 | 9.56e-01 |
| GO:BP | GO:1901186 | positive regulation of ERBB signaling pathway | 1 | 28 | 9.56e-01 |
| GO:BP | GO:0022600 | digestive system process | 4 | 54 | 9.56e-01 |
| GO:BP | GO:0001706 | endoderm formation | 2 | 46 | 9.57e-01 |
| GO:BP | GO:0002690 | positive regulation of leukocyte chemotaxis | 1 | 51 | 9.57e-01 |
| GO:BP | GO:1902930 | regulation of alcohol biosynthetic process | 1 | 33 | 9.57e-01 |
| GO:BP | GO:1903046 | meiotic cell cycle process | 1 | 135 | 9.57e-01 |
| GO:BP | GO:0044238 | primary metabolic process | 1 | 7806 | 9.57e-01 |
| GO:BP | GO:0051955 | regulation of amino acid transport | 1 | 28 | 9.58e-01 |
| GO:BP | GO:0072676 | lymphocyte migration | 2 | 59 | 9.59e-01 |
| GO:BP | GO:0046483 | heterocycle metabolic process | 1 | 4570 | 9.59e-01 |
| GO:BP | GO:0010712 | regulation of collagen metabolic process | 1 | 34 | 9.59e-01 |
| GO:BP | GO:0006725 | cellular aromatic compound metabolic process | 1 | 4596 | 9.60e-01 |
| GO:BP | GO:0006879 | intracellular iron ion homeostasis | 2 | 52 | 9.60e-01 |
| GO:BP | GO:0021536 | diencephalon development | 3 | 41 | 9.60e-01 |
| GO:BP | GO:0071459 | protein localization to chromosome, centromeric region | 1 | 42 | 9.60e-01 |
| GO:BP | GO:0007156 | homophilic cell adhesion via plasma membrane adhesion molecules | 2 | 104 | 9.60e-01 |
| GO:BP | GO:0031102 | neuron projection regeneration | 1 | 47 | 9.61e-01 |
| GO:BP | GO:1903115 | regulation of actin filament-based movement | 1 | 39 | 9.61e-01 |
| GO:BP | GO:0007601 | visual perception | 11 | 96 | 9.61e-01 |
| GO:BP | GO:0006887 | exocytosis | 6 | 256 | 9.66e-01 |
| GO:BP | GO:0006195 | purine nucleotide catabolic process | 1 | 48 | 9.66e-01 |
| GO:BP | GO:0098771 | inorganic ion homeostasis | 9 | 351 | 9.66e-01 |
| GO:BP | GO:0050953 | sensory perception of light stimulus | 11 | 97 | 9.66e-01 |
| GO:BP | GO:1901360 | organic cyclic compound metabolic process | 1 | 4747 | 9.66e-01 |
| GO:BP | GO:0007094 | mitotic spindle assembly checkpoint signaling | 1 | 44 | 9.66e-01 |
| GO:BP | GO:0071173 | spindle assembly checkpoint signaling | 1 | 44 | 9.66e-01 |
| GO:BP | GO:0071174 | mitotic spindle checkpoint signaling | 1 | 44 | 9.66e-01 |
| GO:BP | GO:0065007 | biological regulation | 1 | 8320 | 9.67e-01 |
| GO:BP | GO:0002446 | neutrophil mediated immunity | 1 | 17 | 9.67e-01 |
| GO:BP | GO:0060261 | positive regulation of transcription initiation by RNA polymerase II | 2 | 59 | 9.69e-01 |
| GO:BP | GO:0031577 | spindle checkpoint signaling | 1 | 45 | 9.69e-01 |
| GO:BP | GO:0051339 | regulation of lyase activity | 2 | 39 | 9.69e-01 |
| GO:BP | GO:0034641 | cellular nitrogen compound metabolic process | 1 | 4946 | 9.70e-01 |
| GO:BP | GO:1901292 | nucleoside phosphate catabolic process | 2 | 74 | 9.71e-01 |
| GO:BP | GO:0017158 | regulation of calcium ion-dependent exocytosis | 1 | 29 | 9.71e-01 |
| GO:BP | GO:0045841 | negative regulation of mitotic metaphase/anaphase transition | 1 | 46 | 9.71e-01 |
| GO:BP | GO:0045581 | negative regulation of T cell differentiation | 1 | 27 | 9.72e-01 |
| GO:BP | GO:0010324 | membrane invagination | 1 | 49 | 9.72e-01 |
| GO:BP | GO:0042246 | tissue regeneration | 2 | 54 | 9.72e-01 |
| GO:BP | GO:1902106 | negative regulation of leukocyte differentiation | 4 | 65 | 9.72e-01 |
| GO:BP | GO:0032964 | collagen biosynthetic process | 1 | 39 | 9.72e-01 |
| GO:BP | GO:0006334 | nucleosome assembly | 4 | 80 | 9.72e-01 |
| GO:BP | GO:1901976 | regulation of cell cycle checkpoint | 1 | 45 | 9.73e-01 |
| GO:BP | GO:0043271 | negative regulation of monoatomic ion transport | 1 | 90 | 9.73e-01 |
| GO:BP | GO:2000816 | negative regulation of mitotic sister chromatid separation | 1 | 47 | 9.75e-01 |
| GO:BP | GO:0033046 | negative regulation of sister chromatid segregation | 1 | 47 | 9.75e-01 |
| GO:BP | GO:1902100 | negative regulation of metaphase/anaphase transition of cell cycle | 1 | 47 | 9.75e-01 |
| GO:BP | GO:0033048 | negative regulation of mitotic sister chromatid segregation | 1 | 47 | 9.75e-01 |
| GO:BP | GO:1903053 | regulation of extracellular matrix organization | 1 | 46 | 9.76e-01 |
| GO:BP | GO:0072523 | purine-containing compound catabolic process | 1 | 53 | 9.76e-01 |
| GO:BP | GO:0010559 | regulation of glycoprotein biosynthetic process | 1 | 32 | 9.76e-01 |
| GO:BP | GO:0048477 | oogenesis | 2 | 64 | 9.76e-01 |
| GO:BP | GO:0045761 | regulation of adenylate cyclase activity | 1 | 32 | 9.77e-01 |
| GO:BP | GO:0009617 | response to bacterium | 12 | 321 | 9.77e-01 |
| GO:BP | GO:0050433 | regulation of catecholamine secretion | 1 | 29 | 9.77e-01 |
| GO:BP | GO:1905819 | negative regulation of chromosome separation | 1 | 48 | 9.79e-01 |
| GO:BP | GO:0051985 | negative regulation of chromosome segregation | 1 | 48 | 9.79e-01 |
| GO:BP | GO:0006909 | phagocytosis | 4 | 148 | 9.79e-01 |
| GO:BP | GO:0021983 | pituitary gland development | 1 | 22 | 9.80e-01 |
| GO:BP | GO:0042119 | neutrophil activation | 1 | 16 | 9.80e-01 |
| GO:BP | GO:0046496 | nicotinamide nucleotide metabolic process | 1 | 66 | 9.80e-01 |
| GO:BP | GO:0019362 | pyridine nucleotide metabolic process | 1 | 66 | 9.80e-01 |
| GO:BP | GO:0030216 | keratinocyte differentiation | 4 | 75 | 9.81e-01 |
| GO:BP | GO:0046903 | secretion | 5 | 645 | 9.81e-01 |
| GO:BP | GO:2000241 | regulation of reproductive process | 5 | 128 | 9.82e-01 |
| GO:BP | GO:0051588 | regulation of neurotransmitter transport | 2 | 70 | 9.82e-01 |
| GO:BP | GO:1901136 | carbohydrate derivative catabolic process | 5 | 137 | 9.83e-01 |
| GO:BP | GO:0022617 | extracellular matrix disassembly | 1 | 36 | 9.83e-01 |
| GO:BP | GO:0050896 | response to stimulus | 7 | 5770 | 9.83e-01 |
| GO:BP | GO:0002688 | regulation of leukocyte chemotaxis | 1 | 68 | 9.83e-01 |
| GO:BP | GO:0035307 | positive regulation of protein dephosphorylation | 1 | 36 | 9.84e-01 |
| GO:BP | GO:0007129 | homologous chromosome pairing at meiosis | 1 | 24 | 9.84e-01 |
| GO:BP | GO:0007498 | mesoderm development | 1 | 89 | 9.85e-01 |
| GO:BP | GO:0031424 | keratinization | 1 | 13 | 9.85e-01 |
| GO:BP | GO:0045839 | negative regulation of mitotic nuclear division | 1 | 54 | 9.85e-01 |
| GO:BP | GO:1903018 | regulation of glycoprotein metabolic process | 1 | 36 | 9.85e-01 |
| GO:BP | GO:0000377 | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 1 | 289 | 9.85e-01 |
| GO:BP | GO:0072524 | pyridine-containing compound metabolic process | 1 | 72 | 9.85e-01 |
| GO:BP | GO:2000177 | regulation of neural precursor cell proliferation | 1 | 64 | 9.85e-01 |
| GO:BP | GO:0000398 | mRNA splicing, via spliceosome | 1 | 289 | 9.85e-01 |
| GO:BP | GO:0051924 | regulation of calcium ion transport | 3 | 172 | 9.85e-01 |
| GO:BP | GO:0006816 | calcium ion transport | 7 | 269 | 9.85e-01 |
| GO:BP | GO:0000375 | RNA splicing, via transesterification reactions | 1 | 293 | 9.85e-01 |
| GO:BP | GO:0045047 | protein targeting to ER | 1 | 49 | 9.86e-01 |
| GO:BP | GO:0038093 | Fc receptor signaling pathway | 1 | 36 | 9.86e-01 |
| GO:BP | GO:0071677 | positive regulation of mononuclear cell migration | 2 | 39 | 9.86e-01 |
| GO:BP | GO:0051321 | meiotic cell cycle | 1 | 188 | 9.86e-01 |
| GO:BP | GO:0045620 | negative regulation of lymphocyte differentiation | 1 | 33 | 9.86e-01 |
| GO:BP | GO:0007193 | adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway | 2 | 37 | 9.86e-01 |
| GO:BP | GO:0072599 | establishment of protein localization to endoplasmic reticulum | 1 | 53 | 9.86e-01 |
| GO:BP | GO:0035987 | endodermal cell differentiation | 1 | 38 | 9.86e-01 |
| GO:BP | GO:0046425 | regulation of receptor signaling pathway via JAK-STAT | 3 | 52 | 9.88e-01 |
| GO:BP | GO:0036230 | granulocyte activation | 1 | 19 | 9.88e-01 |
| GO:BP | GO:2000242 | negative regulation of reproductive process | 2 | 42 | 9.88e-01 |
| GO:BP | GO:0010608 | post-transcriptional regulation of gene expression | 1 | 468 | 9.88e-01 |
| GO:BP | GO:0006897 | endocytosis | 19 | 527 | 9.88e-01 |
| GO:BP | GO:0010965 | regulation of mitotic sister chromatid separation | 1 | 58 | 9.89e-01 |
| GO:BP | GO:0032615 | interleukin-12 production | 1 | 29 | 9.89e-01 |
| GO:BP | GO:0032655 | regulation of interleukin-12 production | 1 | 29 | 9.89e-01 |
| GO:BP | GO:0048247 | lymphocyte chemotaxis | 1 | 24 | 9.89e-01 |
| GO:BP | GO:0008380 | RNA splicing | 1 | 419 | 9.89e-01 |
| GO:BP | GO:0007586 | digestion | 5 | 60 | 9.90e-01 |
| GO:BP | GO:0051784 | negative regulation of nuclear division | 1 | 57 | 9.91e-01 |
| GO:BP | GO:0006397 | mRNA processing | 1 | 450 | 9.91e-01 |
| GO:BP | GO:0034113 | heterotypic cell-cell adhesion | 1 | 37 | 9.91e-01 |
| GO:BP | GO:0051306 | mitotic sister chromatid separation | 1 | 61 | 9.91e-01 |
| GO:BP | GO:1904892 | regulation of receptor signaling pathway via STAT | 3 | 54 | 9.92e-01 |
| GO:BP | GO:0051952 | regulation of amine transport | 2 | 55 | 9.92e-01 |
| GO:BP | GO:0031099 | regeneration | 6 | 142 | 9.93e-01 |
| GO:BP | GO:0070192 | chromosome organization involved in meiotic cell cycle | 1 | 35 | 9.93e-01 |
| GO:BP | GO:0044237 | cellular metabolic process | 2 | 6996 | 9.94e-01 |
| GO:BP | GO:1990869 | cellular response to chemokine | 2 | 37 | 9.94e-01 |
| GO:BP | GO:1990868 | response to chemokine | 2 | 37 | 9.94e-01 |
| GO:BP | GO:0030858 | positive regulation of epithelial cell differentiation | 1 | 37 | 9.94e-01 |
| GO:BP | GO:0050830 | defense response to Gram-positive bacterium | 1 | 33 | 9.95e-01 |
| GO:BP | GO:1903531 | negative regulation of secretion by cell | 3 | 99 | 9.96e-01 |
| GO:BP | GO:0016071 | mRNA metabolic process | 1 | 665 | 9.96e-01 |
| GO:BP | GO:0009620 | response to fungus | 1 | 22 | 9.96e-01 |
| GO:BP | GO:0050709 | negative regulation of protein secretion | 1 | 44 | 9.97e-01 |
| GO:BP | GO:0006956 | complement activation | 1 | 23 | 9.97e-01 |
| GO:BP | GO:1905818 | regulation of chromosome separation | 1 | 71 | 9.98e-01 |
| GO:BP | GO:0051051 | negative regulation of transport | 4 | 318 | 9.99e-01 |
| GO:BP | GO:0007189 | adenylate cyclase-activating G protein-coupled receptor signaling pathway | 2 | 78 | 9.99e-01 |
| GO:BP | GO:0051304 | chromosome separation | 1 | 76 | 1.00e+00 |
| GO:BP | GO:0032963 | collagen metabolic process | 1 | 74 | 1.00e+00 |
| GO:BP | GO:0006614 | SRP-dependent cotranslational protein targeting to membrane | 1 | 30 | 1.00e+00 |
| GO:BP | GO:0022618 | ribonucleoprotein complex assembly | 1 | 203 | 1.00e+00 |
| GO:BP | GO:0007608 | sensory perception of smell | 1 | 16 | 1.00e+00 |
| GO:BP | GO:0050794 | regulation of cellular process | 3 | 7552 | 1.00e+00 |
| GO:BP | GO:0016441 | post-transcriptional gene silencing | 2 | 65 | 1.00e+00 |
| GO:BP | GO:0007606 | sensory perception of chemical stimulus | 1 | 31 | 1.00e+00 |
| GO:BP | GO:0007600 | sensory perception | 1 | 269 | 1.00e+00 |
| GO:BP | GO:0009593 | detection of chemical stimulus | 1 | 27 | 1.00e+00 |
| GO:BP | GO:0045291 | mRNA trans splicing, SL addition | 1 | 6 | 1.00e+00 |
| GO:BP | GO:0051606 | detection of stimulus | 2 | 110 | 1.00e+00 |
| GO:BP | GO:0006617 | SRP-dependent cotranslational protein targeting to membrane, signal sequence recognition | 1 | 17 | 1.00e+00 |
| GO:BP | GO:0006911 | phagocytosis, engulfment | 2 | 33 | 1.00e+00 |
| GO:BP | GO:0008152 | metabolic process | 1 | 8518 | 1.00e+00 |
| GO:BP | GO:0009987 | cellular process | 1 | 11336 | 1.00e+00 |
| GO:BP | GO:0006376 | mRNA splice site selection | 2 | 31 | 1.00e+00 |
| GO:BP | GO:0035194 | ncRNA-mediated post-transcriptional gene silencing | 2 | 60 | 1.00e+00 |
| GO:BP | GO:0000395 | mRNA 5’-splice site recognition | 1 | 8 | 1.00e+00 |
| GO:BP | GO:0035195 | miRNA-mediated gene silencing | 2 | 55 | 1.00e+00 |
| GO:BP | GO:0099024 | plasma membrane invagination | 3 | 42 | 1.00e+00 |
| GO:BP | GO:0000387 | spliceosomal snRNP assembly | 1 | 45 | 1.00e+00 |
| GO:BP | GO:0051048 | negative regulation of secretion | 3 | 111 | 1.00e+00 |
| GO:BP | GO:0007186 | G protein-coupled receptor signaling pathway | 1 | 389 | 1.00e+00 |
| GO:BP | GO:0006613 | cotranslational protein targeting to membrane | 1 | 35 | 1.00e+00 |
| GO:BP | GO:0008150 | biological_process | 1 | 12070 | 1.00e+00 |
| GO:BP | GO:0000353 | formation of quadruple SL/U4/U5/U6 snRNP | 1 | 6 | 1.00e+00 |
| GO:BP | GO:0007188 | adenylate cyclase-modulating G protein-coupled receptor signaling pathway | 6 | 118 | 1.00e+00 |
| GO:BP | GO:0071704 | organic substance metabolic process | 1 | 8169 | 1.00e+00 |
| GO:BP | GO:0031047 | RNA-mediated gene silencing | 2 | 103 | 1.00e+00 |
| GO:BP | GO:0000245 | spliceosomal complex assembly | 1 | 73 | 1.00e+00 |
| GO:BP | GO:0000244 | spliceosomal tri-snRNP complex assembly | 1 | 20 | 1.00e+00 |
| GO:BP | GO:0050829 | defense response to Gram-negative bacterium | 1 | 20 | 1.00e+00 |
| GO:BP | GO:0071826 | ribonucleoprotein complex subunit organization | 1 | 211 | 1.00e+00 |
| GO:BP | GO:0000365 | mRNA trans splicing, via spliceosome | 1 | 6 | 1.00e+00 |
| GO:BP | GO:0022613 | ribonucleoprotein complex biogenesis | 1 | 453 | 1.00e+00 |
| KEGG | KEGG:03250 | Viral life cycle - HIV-1 | 11 | 56 | 2.34e-01 |
| KEGG | KEGG:04213 | Longevity regulating pathway - multiple species | 8 | 55 | 2.34e-01 |
| KEGG | KEGG:05166 | Human T-cell leukemia virus 1 infection | 11 | 180 | 2.93e-01 |
| KEGG | KEGG:05212 | Pancreatic cancer | 12 | 75 | 2.93e-01 |
| KEGG | KEGG:04146 | Peroxisome | 2 | 68 | 2.93e-01 |
| KEGG | KEGG:05210 | Colorectal cancer | 8 | 84 | 2.93e-01 |
| KEGG | KEGG:04933 | AGE-RAGE signaling pathway in diabetic complications | 8 | 91 | 2.93e-01 |
| KEGG | KEGG:05231 | Choline metabolism in cancer | 9 | 84 | 2.93e-01 |
| KEGG | KEGG:04068 | FoxO signaling pathway | 11 | 109 | 2.93e-01 |
| KEGG | KEGG:05221 | Acute myeloid leukemia | 7 | 56 | 2.93e-01 |
| KEGG | KEGG:05220 | Chronic myeloid leukemia | 7 | 75 | 2.93e-01 |
| KEGG | KEGG:01522 | Endocrine resistance | 8 | 85 | 2.93e-01 |
| KEGG | KEGG:04660 | T cell receptor signaling pathway | 8 | 70 | 2.93e-01 |
| KEGG | KEGG:04218 | Cellular senescence | 9 | 145 | 2.93e-01 |
| KEGG | KEGG:05223 | Non-small cell lung cancer | 7 | 67 | 2.93e-01 |
| KEGG | KEGG:04071 | Sphingolipid signaling pathway | 10 | 107 | 2.93e-01 |
| KEGG | KEGG:04658 | Th1 and Th2 cell differentiation | 9 | 53 | 2.95e-01 |
| KEGG | KEGG:00670 | One carbon pool by folate | 1 | 18 | 2.95e-01 |
| KEGG | KEGG:05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 9 | 69 | 2.95e-01 |
| KEGG | KEGG:04664 | Fc epsilon RI signaling pathway | 6 | 46 | 2.95e-01 |
| KEGG | KEGG:04150 | mTOR signaling pathway | 14 | 135 | 2.95e-01 |
| KEGG | KEGG:04010 | MAPK signaling pathway | 20 | 240 | 2.95e-01 |
| KEGG | KEGG:05213 | Endometrial cancer | 5 | 57 | 2.95e-01 |
| KEGG | KEGG:04930 | Type II diabetes mellitus | 1 | 35 | 2.95e-01 |
| KEGG | KEGG:03013 | Nucleocytoplasmic transport | 10 | 99 | 2.95e-01 |
| KEGG | KEGG:04360 | Axon guidance | 14 | 162 | 2.95e-01 |
| KEGG | KEGG:00900 | Terpenoid backbone biosynthesis | 1 | 21 | 2.95e-01 |
| KEGG | KEGG:05224 | Breast cancer | 10 | 117 | 2.95e-01 |
| KEGG | KEGG:00520 | Amino sugar and nucleotide sugar metabolism | 8 | 46 | 3.10e-01 |
| KEGG | KEGG:04330 | Notch signaling pathway | 2 | 51 | 3.10e-01 |
| KEGG | KEGG:05161 | Hepatitis B | 13 | 136 | 3.10e-01 |
| KEGG | KEGG:04216 | Ferroptosis | 6 | 33 | 3.10e-01 |
| KEGG | KEGG:05031 | Amphetamine addiction | 3 | 49 | 3.10e-01 |
| KEGG | KEGG:04210 | Apoptosis | 8 | 118 | 3.24e-01 |
| KEGG | KEGG:01523 | Antifolate resistance | 1 | 24 | 3.24e-01 |
| KEGG | KEGG:00524 | Neomycin, kanamycin and gentamicin biosynthesis | 2 | 4 | 3.24e-01 |
| KEGG | KEGG:00590 | Arachidonic acid metabolism | 1 | 26 | 3.24e-01 |
| KEGG | KEGG:04370 | VEGF signaling pathway | 6 | 49 | 3.24e-01 |
| KEGG | KEGG:00790 | Folate biosynthesis | 5 | 18 | 3.24e-01 |
| KEGG | KEGG:05225 | Hepatocellular carcinoma | 10 | 145 | 3.25e-01 |
| KEGG | KEGG:04710 | Circadian rhythm | 4 | 30 | 3.25e-01 |
| KEGG | KEGG:00534 | Glycosaminoglycan biosynthesis - heparan sulfate / heparin | 1 | 20 | 3.25e-01 |
| KEGG | KEGG:04140 | Autophagy - animal | 9 | 133 | 3.25e-01 |
| KEGG | KEGG:03018 | RNA degradation | 9 | 74 | 3.25e-01 |
| KEGG | KEGG:04917 | Prolactin signaling pathway | 9 | 56 | 3.25e-01 |
| KEGG | KEGG:04130 | SNARE interactions in vesicular transport | 2 | 32 | 3.26e-01 |
| KEGG | KEGG:03450 | Non-homologous end-joining | 3 | 12 | 3.28e-01 |
| KEGG | KEGG:04066 | HIF-1 signaling pathway | 2 | 89 | 3.28e-01 |
| KEGG | KEGG:04666 | Fc gamma R-mediated phagocytosis | 7 | 75 | 3.28e-01 |
| KEGG | KEGG:04662 | B cell receptor signaling pathway | 7 | 56 | 3.28e-01 |
| KEGG | KEGG:04931 | Insulin resistance | 1 | 95 | 3.28e-01 |
| KEGG | KEGG:04392 | Hippo signaling pathway - multiple species | 5 | 25 | 3.28e-01 |
| KEGG | KEGG:04910 | Insulin signaling pathway | 9 | 121 | 3.28e-01 |
| KEGG | KEGG:04122 | Sulfur relay system | 2 | 8 | 3.32e-01 |
| KEGG | KEGG:04625 | C-type lectin receptor signaling pathway | 11 | 76 | 3.50e-01 |
| KEGG | KEGG:04611 | Platelet activation | 1 | 89 | 3.50e-01 |
| KEGG | KEGG:00010 | Glycolysis / Gluconeogenesis | 1 | 44 | 3.56e-01 |
| KEGG | KEGG:00920 | Sulfur metabolism | 1 | 10 | 3.56e-01 |
| KEGG | KEGG:04152 | AMPK signaling pathway | 8 | 103 | 3.56e-01 |
| KEGG | KEGG:04926 | Relaxin signaling pathway | 1 | 104 | 3.56e-01 |
| KEGG | KEGG:05418 | Fluid shear stress and atherosclerosis | 1 | 114 | 3.56e-01 |
| KEGG | KEGG:00290 | Valine, leucine and isoleucine biosynthesis | 1 | 3 | 3.57e-01 |
| KEGG | KEGG:04015 | Rap1 signaling pathway | 12 | 164 | 3.57e-01 |
| KEGG | KEGG:01230 | Biosynthesis of amino acids | 1 | 60 | 3.57e-01 |
| KEGG | KEGG:00515 | Mannose type O-glycan biosynthesis | 1 | 19 | 3.57e-01 |
| KEGG | KEGG:04390 | Hippo signaling pathway | 1 | 134 | 3.73e-01 |
| KEGG | KEGG:04072 | Phospholipase D signaling pathway | 9 | 110 | 3.75e-01 |
| KEGG | KEGG:00220 | Arginine biosynthesis | 2 | 16 | 3.88e-01 |
| KEGG | KEGG:04530 | Tight junction | 1 | 137 | 3.88e-01 |
| KEGG | KEGG:01200 | Carbon metabolism | 3 | 98 | 4.03e-01 |
| KEGG | KEGG:04062 | Chemokine signaling pathway | 1 | 113 | 4.13e-01 |
| KEGG | KEGG:03264 | Virion - Flavivirus | 1 | 1 | 4.13e-01 |
| KEGG | KEGG:04211 | Longevity regulating pathway | 6 | 78 | 4.15e-01 |
| KEGG | KEGG:04520 | Adherens junction | 5 | 67 | 4.22e-01 |
| KEGG | KEGG:05415 | Diabetic cardiomyopathy | 1 | 169 | 4.22e-01 |
| KEGG | KEGG:05017 | Spinocerebellar ataxia | 4 | 124 | 4.22e-01 |
| KEGG | KEGG:05016 | Huntington disease | 7 | 256 | 4.22e-01 |
| KEGG | KEGG:04726 | Serotonergic synapse | 4 | 63 | 4.22e-01 |
| KEGG | KEGG:04371 | Apelin signaling pathway | 10 | 106 | 4.22e-01 |
| KEGG | KEGG:05219 | Bladder cancer | 3 | 37 | 4.22e-01 |
| KEGG | KEGG:04012 | ErbB signaling pathway | 6 | 78 | 4.22e-01 |
| KEGG | KEGG:03440 | Homologous recombination | 2 | 39 | 4.22e-01 |
| KEGG | KEGG:05206 | MicroRNAs in cancer | 6 | 149 | 4.35e-01 |
| KEGG | KEGG:05134 | Legionellosis | 2 | 39 | 4.35e-01 |
| KEGG | KEGG:04919 | Thyroid hormone signaling pathway | 2 | 112 | 4.35e-01 |
| KEGG | KEGG:05211 | Renal cell carcinoma | 5 | 65 | 4.39e-01 |
| KEGG | KEGG:04144 | Endocytosis | 1 | 232 | 4.41e-01 |
| KEGG | KEGG:05215 | Prostate cancer | 5 | 86 | 4.49e-01 |
| KEGG | KEGG:01250 | Biosynthesis of nucleotide sugars | 5 | 35 | 4.49e-01 |
| KEGG | KEGG:00910 | Nitrogen metabolism | 1 | 10 | 4.49e-01 |
| KEGG | KEGG:00600 | Sphingolipid metabolism | 4 | 44 | 4.49e-01 |
| KEGG | KEGG:04730 | Long-term depression | 2 | 42 | 4.49e-01 |
| KEGG | KEGG:04350 | TGF-beta signaling pathway | 10 | 84 | 4.49e-01 |
| KEGG | KEGG:05218 | Melanoma | 4 | 58 | 4.49e-01 |
| KEGG | KEGG:04935 | Growth hormone synthesis, secretion and action | 7 | 98 | 4.49e-01 |
| KEGG | KEGG:04960 | Aldosterone-regulated sodium reabsorption | 3 | 26 | 4.49e-01 |
| KEGG | KEGG:04975 | Fat digestion and absorption | 1 | 19 | 4.49e-01 |
| KEGG | KEGG:05012 | Parkinson disease | 6 | 226 | 4.49e-01 |
| KEGG | KEGG:05202 | Transcriptional misregulation in cancer | 3 | 128 | 4.49e-01 |
| KEGG | KEGG:03015 | mRNA surveillance pathway | 6 | 86 | 4.49e-01 |
| KEGG | KEGG:05140 | Leishmaniasis | 4 | 42 | 4.49e-01 |
| KEGG | KEGG:01524 | Platinum drug resistance | 4 | 65 | 4.49e-01 |
| KEGG | KEGG:05214 | Glioma | 4 | 67 | 4.77e-01 |
| KEGG | KEGG:05165 | Human papillomavirus infection | 1 | 272 | 4.80e-01 |
| KEGG | KEGG:00020 | Citrate cycle (TCA cycle) | 1 | 28 | 4.82e-01 |
| KEGG | KEGG:03022 | Basal transcription factors | 1 | 40 | 4.83e-01 |
| KEGG | KEGG:00565 | Ether lipid metabolism | 1 | 28 | 4.83e-01 |
| KEGG | KEGG:04137 | Mitophagy - animal | 7 | 70 | 4.83e-01 |
| KEGG | KEGG:05203 | Viral carcinogenesis | 4 | 172 | 4.87e-01 |
| KEGG | KEGG:05135 | Yersinia infection | 8 | 112 | 4.89e-01 |
| KEGG | KEGG:04310 | Wnt signaling pathway | 1 | 138 | 4.89e-01 |
| KEGG | KEGG:00604 | Glycosphingolipid biosynthesis - ganglio series | 2 | 12 | 4.99e-01 |
| KEGG | KEGG:00513 | Various types of N-glycan biosynthesis | 2 | 36 | 5.11e-01 |
| KEGG | KEGG:05145 | Toxoplasmosis | 5 | 82 | 5.13e-01 |
| KEGG | KEGG:04929 | GnRH secretion | 4 | 53 | 5.13e-01 |
| KEGG | KEGG:04380 | Osteoclast differentiation | 12 | 87 | 5.17e-01 |
| KEGG | KEGG:04659 | Th17 cell differentiation | 7 | 64 | 5.17e-01 |
| KEGG | KEGG:04964 | Proximal tubule bicarbonate reclamation | 1 | 20 | 5.17e-01 |
| KEGG | KEGG:00561 | Glycerolipid metabolism | 1 | 49 | 5.28e-01 |
| KEGG | KEGG:05200 | Pathways in cancer | 22 | 409 | 5.28e-01 |
| KEGG | KEGG:00970 | Aminoacyl-tRNA biosynthesis | 1 | 44 | 5.30e-01 |
| KEGG | KEGG:05226 | Gastric cancer | 7 | 117 | 5.32e-01 |
| KEGG | KEGG:04217 | Necroptosis | 13 | 106 | 5.37e-01 |
| KEGG | KEGG:00270 | Cysteine and methionine metabolism | 5 | 38 | 5.52e-01 |
| KEGG | KEGG:00860 | Porphyrin metabolism | 1 | 22 | 5.53e-01 |
| KEGG | KEGG:05034 | Alcoholism | 4 | 122 | 5.54e-01 |
| KEGG | KEGG:03020 | RNA polymerase | 2 | 34 | 5.54e-01 |
| KEGG | KEGG:05164 | Influenza A | 10 | 103 | 5.54e-01 |
| KEGG | KEGG:05152 | Tuberculosis | 14 | 106 | 5.65e-01 |
| KEGG | KEGG:00480 | Glutathione metabolism | 5 | 44 | 5.78e-01 |
| KEGG | KEGG:05132 | Salmonella infection | 20 | 214 | 5.78e-01 |
| KEGG | KEGG:04932 | Non-alcoholic fatty liver disease | 8 | 131 | 5.78e-01 |
| KEGG | KEGG:04060 | Cytokine-cytokine receptor interaction | 1 | 98 | 5.78e-01 |
| KEGG | KEGG:04141 | Protein processing in endoplasmic reticulum | 15 | 161 | 5.78e-01 |
| KEGG | KEGG:04540 | Gap junction | 2 | 73 | 5.78e-01 |
| KEGG | KEGG:04921 | Oxytocin signaling pathway | 10 | 115 | 5.82e-01 |
| KEGG | KEGG:04913 | Ovarian steroidogenesis | 3 | 28 | 5.82e-01 |
| KEGG | KEGG:04014 | Ras signaling pathway | 11 | 171 | 5.82e-01 |
| KEGG | KEGG:05321 | Inflammatory bowel disease | 2 | 22 | 5.82e-01 |
| KEGG | KEGG:04022 | cGMP-PKG signaling pathway | 9 | 133 | 5.82e-01 |
| KEGG | KEGG:00250 | Alanine, aspartate and glutamate metabolism | 1 | 29 | 5.82e-01 |
| KEGG | KEGG:05216 | Thyroid cancer | 2 | 35 | 5.82e-01 |
| KEGG | KEGG:05144 | Malaria | 1 | 20 | 5.82e-01 |
| KEGG | KEGG:04670 | Leukocyte transendothelial migration | 3 | 79 | 5.82e-01 |
| KEGG | KEGG:05205 | Proteoglycans in cancer | 9 | 170 | 5.82e-01 |
| KEGG | KEGG:04720 | Long-term potentiation | 3 | 55 | 5.82e-01 |
| KEGG | KEGG:01521 | EGFR tyrosine kinase inhibitor resistance | 4 | 74 | 5.82e-01 |
| KEGG | KEGG:00760 | Nicotinate and nicotinamide metabolism | 1 | 28 | 5.82e-01 |
| KEGG | KEGG:03040 | Spliceosome | 1 | 132 | 5.82e-01 |
| KEGG | KEGG:00061 | Fatty acid biosynthesis | 2 | 12 | 5.82e-01 |
| KEGG | KEGG:03060 | Protein export | 1 | 23 | 5.82e-01 |
| KEGG | KEGG:05230 | Central carbon metabolism in cancer | 5 | 62 | 5.82e-01 |
| KEGG | KEGG:05170 | Human immunodeficiency virus 1 infection | 11 | 165 | 5.82e-01 |
| KEGG | KEGG:00130 | Ubiquinone and other terpenoid-quinone biosynthesis | 1 | 9 | 5.82e-01 |
| KEGG | KEGG:04550 | Signaling pathways regulating pluripotency of stem cells | 11 | 104 | 5.82e-01 |
| KEGG | KEGG:05010 | Alzheimer disease | 16 | 315 | 5.82e-01 |
| KEGG | KEGG:03430 | Mismatch repair | 1 | 22 | 5.82e-01 |
| KEGG | KEGG:04110 | Cell cycle | 2 | 151 | 5.91e-01 |
| KEGG | KEGG:00564 | Glycerophospholipid metabolism | 1 | 76 | 5.97e-01 |
| KEGG | KEGG:05030 | Cocaine addiction | 5 | 35 | 5.97e-01 |
| KEGG | KEGG:05142 | Chagas disease | 4 | 75 | 6.02e-01 |
| KEGG | KEGG:01100 | Metabolic pathways | 4 | 1146 | 6.02e-01 |
| KEGG | KEGG:04610 | Complement and coagulation cascades | 1 | 40 | 6.05e-01 |
| KEGG | KEGG:05217 | Basal cell carcinoma | 3 | 49 | 6.13e-01 |
| KEGG | KEGG:00532 | Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 1 | 21 | 6.13e-01 |
| KEGG | KEGG:03008 | Ribosome biogenesis in eukaryotes | 8 | 75 | 6.13e-01 |
| KEGG | KEGG:00310 | Lysine degradation | 2 | 59 | 6.15e-01 |
| KEGG | KEGG:04713 | Circadian entrainment | 4 | 69 | 6.15e-01 |
| KEGG | KEGG:04215 | Apoptosis - multiple species | 3 | 30 | 6.15e-01 |
| KEGG | KEGG:00601 | Glycosphingolipid biosynthesis - lacto and neolacto series | 1 | 14 | 6.15e-01 |
| KEGG | KEGG:05167 | Kaposi sarcoma-associated herpesvirus infection | 7 | 145 | 6.15e-01 |
| KEGG | KEGG:00260 | Glycine, serine and threonine metabolism | 2 | 31 | 6.15e-01 |
| KEGG | KEGG:05163 | Human cytomegalovirus infection | 11 | 176 | 6.15e-01 |
| KEGG | KEGG:04923 | Regulation of lipolysis in adipocytes | 3 | 41 | 6.15e-01 |
| KEGG | KEGG:04922 | Glucagon signaling pathway | 4 | 84 | 6.22e-01 |
| KEGG | KEGG:04613 | Neutrophil extracellular trap formation | 1 | 110 | 6.26e-01 |
| KEGG | KEGG:05131 | Shigellosis | 13 | 210 | 6.27e-01 |
| KEGG | KEGG:04142 | Lysosome | 6 | 118 | 6.29e-01 |
| KEGG | KEGG:00232 | Caffeine metabolism | 1 | 1 | 6.29e-01 |
| KEGG | KEGG:03410 | Base excision repair | 1 | 33 | 6.29e-01 |
| KEGG | KEGG:04721 | Synaptic vesicle cycle | 4 | 51 | 6.31e-01 |
| KEGG | KEGG:05169 | Epstein-Barr virus infection | 1 | 153 | 6.31e-01 |
| KEGG | KEGG:00450 | Selenocompound metabolism | 1 | 14 | 6.31e-01 |
| KEGG | KEGG:00052 | Galactose metabolism | 3 | 22 | 6.34e-01 |
| KEGG | KEGG:04728 | Dopaminergic synapse | 4 | 103 | 6.36e-01 |
| KEGG | KEGG:04961 | Endocrine and other factor-regulated calcium reabsorption | 3 | 41 | 6.36e-01 |
| KEGG | KEGG:04979 | Cholesterol metabolism | 1 | 33 | 6.36e-01 |
| KEGG | KEGG:03030 | DNA replication | 1 | 35 | 6.43e-01 |
| KEGG | KEGG:04725 | Cholinergic synapse | 4 | 83 | 6.43e-01 |
| KEGG | KEGG:04916 | Melanogenesis | 4 | 77 | 6.62e-01 |
| KEGG | KEGG:05323 | Rheumatoid arthritis | 3 | 43 | 6.73e-01 |
| KEGG | KEGG:03050 | Proteasome | 1 | 42 | 6.73e-01 |
| KEGG | KEGG:00051 | Fructose and mannose metabolism | 3 | 27 | 6.73e-01 |
| KEGG | KEGG:00562 | Inositol phosphate metabolism | 3 | 66 | 6.76e-01 |
| KEGG | KEGG:05208 | Chemical carcinogenesis - reactive oxygen species | 7 | 186 | 6.76e-01 |
| KEGG | KEGG:04722 | Neurotrophin signaling pathway | 4 | 110 | 6.76e-01 |
| KEGG | KEGG:05022 | Pathways of neurodegeneration - multiple diseases | 7 | 385 | 6.76e-01 |
| KEGG | KEGG:04915 | Estrogen signaling pathway | 5 | 97 | 6.81e-01 |
| KEGG | KEGG:04920 | Adipocytokine signaling pathway | 5 | 51 | 6.95e-01 |
| KEGG | KEGG:05014 | Amyotrophic lateral sclerosis | 7 | 303 | 7.08e-01 |
| KEGG | KEGG:03420 | Nucleotide excision repair | 1 | 43 | 7.11e-01 |
| KEGG | KEGG:04714 | Thermogenesis | 3 | 195 | 7.11e-01 |
| KEGG | KEGG:05410 | Hypertrophic cardiomyopathy | 1 | 73 | 7.23e-01 |
| KEGG | KEGG:05416 | Viral myocarditis | 1 | 40 | 7.23e-01 |
| KEGG | KEGG:04630 | JAK-STAT signaling pathway | 8 | 88 | 7.23e-01 |
| KEGG | KEGG:04120 | Ubiquitin mediated proteolysis | 3 | 134 | 7.23e-01 |
| KEGG | KEGG:05020 | Prion disease | 4 | 220 | 7.23e-01 |
| KEGG | KEGG:05414 | Dilated cardiomyopathy | 1 | 78 | 7.31e-01 |
| KEGG | KEGG:05417 | Lipid and atherosclerosis | 10 | 153 | 7.31e-01 |
| KEGG | KEGG:04620 | Toll-like receptor signaling pathway | 5 | 60 | 7.31e-01 |
| KEGG | KEGG:05168 | Herpes simplex virus 1 infection | 2 | 415 | 7.32e-01 |
| KEGG | KEGG:03460 | Fanconi anemia pathway | 1 | 48 | 7.39e-01 |
| KEGG | KEGG:05146 | Amoebiasis | 1 | 64 | 7.47e-01 |
| KEGG | KEGG:04966 | Collecting duct acid secretion | 2 | 19 | 7.49e-01 |
| KEGG | KEGG:04510 | Focal adhesion | 8 | 177 | 7.56e-01 |
| KEGG | KEGG:04145 | Phagosome | 1 | 99 | 7.56e-01 |
| KEGG | KEGG:05133 | Pertussis | 5 | 45 | 7.58e-01 |
| KEGG | KEGG:04914 | Progesterone-mediated oocyte maturation | 7 | 86 | 7.58e-01 |
| KEGG | KEGG:05207 | Chemical carcinogenesis - receptor activation | 7 | 142 | 7.59e-01 |
| KEGG | KEGG:05162 | Measles | 9 | 98 | 7.59e-01 |
| KEGG | KEGG:04970 | Salivary secretion | 1 | 55 | 7.59e-01 |
| KEGG | KEGG:04934 | Cushing syndrome | 5 | 121 | 7.59e-01 |
| KEGG | KEGG:04064 | NF-kappa B signaling pathway | 1 | 71 | 7.59e-01 |
| KEGG | KEGG:00190 | Oxidative phosphorylation | 1 | 106 | 7.65e-01 |
| KEGG | KEGG:00512 | Mucin type O-glycan biosynthesis | 1 | 22 | 7.78e-01 |
| KEGG | KEGG:03010 | Ribosome | 1 | 127 | 7.78e-01 |
| KEGG | KEGG:05322 | Systemic lupus erythematosus | 1 | 61 | 7.82e-01 |
| KEGG | KEGG:04724 | Glutamatergic synapse | 8 | 74 | 7.83e-01 |
| KEGG | KEGG:04668 | TNF signaling pathway | 7 | 87 | 7.85e-01 |
| KEGG | KEGG:04950 | Maturity onset diabetes of the young | 2 | 4 | 7.85e-01 |
| KEGG | KEGG:04650 | Natural killer cell mediated cytotoxicity | 2 | 63 | 7.90e-01 |
| KEGG | KEGG:01240 | Biosynthesis of cofactors | 1 | 115 | 7.94e-01 |
| KEGG | KEGG:00330 | Arginine and proline metabolism | 2 | 38 | 7.94e-01 |
| KEGG | KEGG:04973 | Carbohydrate digestion and absorption | 2 | 31 | 7.96e-01 |
| KEGG | KEGG:05204 | Chemical carcinogenesis - DNA adducts | 1 | 23 | 8.04e-01 |
| KEGG | KEGG:00630 | Glyoxylate and dicarboxylate metabolism | 1 | 25 | 8.05e-01 |
| KEGG | KEGG:04070 | Phosphatidylinositol signaling system | 3 | 91 | 8.05e-01 |
| KEGG | KEGG:05110 | Vibrio cholerae infection | 3 | 43 | 8.05e-01 |
| KEGG | KEGG:00982 | Drug metabolism - cytochrome P450 | 1 | 21 | 8.05e-01 |
| KEGG | KEGG:04261 | Adrenergic signaling in cardiomyocytes | 4 | 128 | 8.20e-01 |
| KEGG | KEGG:00980 | Metabolism of xenobiotics by cytochrome P450 | 1 | 26 | 8.22e-01 |
| KEGG | KEGG:05160 | Hepatitis C | 4 | 115 | 8.22e-01 |
| KEGG | KEGG:04151 | PI3K-Akt signaling pathway | 12 | 254 | 8.22e-01 |
| KEGG | KEGG:00510 | N-Glycan biosynthesis | 1 | 48 | 8.22e-01 |
| KEGG | KEGG:04912 | GnRH signaling pathway | 1 | 76 | 8.22e-01 |
| KEGG | KEGG:05222 | Small cell lung cancer | 2 | 87 | 8.22e-01 |
| KEGG | KEGG:04136 | Autophagy - other | 1 | 31 | 8.22e-01 |
| KEGG | KEGG:04927 | Cortisol synthesis and secretion | 1 | 48 | 8.22e-01 |
| KEGG | KEGG:04978 | Mineral absorption | 3 | 42 | 8.22e-01 |
| KEGG | KEGG:04810 | Regulation of actin cytoskeleton | 8 | 179 | 8.22e-01 |
| KEGG | KEGG:04936 | Alcoholic liver disease | 3 | 97 | 8.22e-01 |
| KEGG | KEGG:00514 | Other types of O-glycan biosynthesis | 1 | 37 | 8.22e-01 |
| KEGG | KEGG:03320 | PPAR signaling pathway | 5 | 50 | 8.22e-01 |
| KEGG | KEGG:05130 | Pathogenic Escherichia coli infection | 6 | 150 | 8.22e-01 |
| KEGG | KEGG:00983 | Drug metabolism - other enzymes | 1 | 44 | 8.22e-01 |
| KEGG | KEGG:05100 | Bacterial invasion of epithelial cells | 4 | 74 | 8.22e-01 |
| KEGG | KEGG:04270 | Vascular smooth muscle contraction | 1 | 94 | 8.32e-01 |
| KEGG | KEGG:00500 | Starch and sucrose metabolism | 2 | 23 | 8.51e-01 |
| KEGG | KEGG:04114 | Oocyte meiosis | 8 | 108 | 8.57e-01 |
| KEGG | KEGG:04115 | p53 signaling pathway | 1 | 65 | 8.64e-01 |
| KEGG | KEGG:00030 | Pentose phosphate pathway | 1 | 24 | 8.64e-01 |
| KEGG | KEGG:04657 | IL-17 signaling pathway | 2 | 56 | 8.71e-01 |
| KEGG | KEGG:00071 | Fatty acid degradation | 2 | 32 | 8.77e-01 |
| KEGG | KEGG:04940 | Type I diabetes mellitus | 2 | 15 | 8.78e-01 |
| KEGG | KEGG:04623 | Cytosolic DNA-sensing pathway | 3 | 42 | 8.85e-01 |
| KEGG | KEGG:05340 | Primary immunodeficiency | 1 | 12 | 8.95e-01 |
| KEGG | KEGG:00100 | Steroid biosynthesis | 1 | 17 | 8.96e-01 |
| KEGG | KEGG:04340 | Hedgehog signaling pathway | 1 | 49 | 9.06e-01 |
| KEGG | KEGG:00563 | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 1 | 25 | 9.09e-01 |
| KEGG | KEGG:04024 | cAMP signaling pathway | 6 | 151 | 9.10e-01 |
| KEGG | KEGG:04928 | Parathyroid hormone synthesis, secretion and action | 6 | 82 | 9.16e-01 |
| KEGG | KEGG:00830 | Retinol metabolism | 2 | 16 | 9.16e-01 |
| KEGG | KEGG:04925 | Aldosterone synthesis and secretion | 1 | 77 | 9.31e-01 |
| KEGG | KEGG:05150 | Staphylococcus aureus infection | 2 | 18 | 9.32e-01 |
| KEGG | KEGG:04621 | NOD-like receptor signaling pathway | 1 | 117 | 9.32e-01 |
| KEGG | KEGG:04640 | Hematopoietic cell lineage | 1 | 31 | 9.36e-01 |
| KEGG | KEGG:05120 | Epithelial cell signaling in Helicobacter pylori infection | 3 | 58 | 9.38e-01 |
| KEGG | KEGG:05310 | Asthma | 1 | 3 | 9.40e-01 |
| KEGG | KEGG:04622 | RIG-I-like receptor signaling pathway | 3 | 49 | 9.40e-01 |
| KEGG | KEGG:04962 | Vasopressin-regulated water reabsorption | 2 | 38 | 9.49e-01 |
| KEGG | KEGG:01232 | Nucleotide metabolism | 3 | 69 | 9.49e-01 |
| KEGG | KEGG:04727 | GABAergic synapse | 1 | 55 | 9.49e-01 |
| KEGG | KEGG:00240 | Pyrimidine metabolism | 1 | 46 | 9.49e-01 |
| KEGG | KEGG:01212 | Fatty acid metabolism | 2 | 50 | 9.49e-01 |
| KEGG | KEGG:00140 | Steroid hormone biosynthesis | 1 | 19 | 9.49e-01 |
| KEGG | KEGG:04744 | Phototransduction | 1 | 12 | 9.49e-01 |
| KEGG | KEGG:00000 | KEGG root term | 8 | 5558 | 9.49e-01 |
| KEGG | KEGG:04924 | Renin secretion | 3 | 50 | 9.59e-01 |
| KEGG | KEGG:04020 | Calcium signaling pathway | 1 | 157 | 9.71e-01 |
| KEGG | KEGG:05330 | Allograft rejection | 1 | 10 | 9.72e-01 |
| KEGG | KEGG:05332 | Graft-versus-host disease | 1 | 10 | 9.89e-01 |
| KEGG | KEGG:00040 | Pentose and glucuronate interconversions | 1 | 12 | 9.90e-01 |
| KEGG | KEGG:04918 | Thyroid hormone synthesis | 3 | 55 | 9.90e-01 |
| KEGG | KEGG:04612 | Antigen processing and presentation | 1 | 41 | 9.94e-01 |
| KEGG | KEGG:04971 | Gastric acid secretion | 1 | 52 | 9.99e-01 |
| KEGG | KEGG:05320 | Autoimmune thyroid disease | 1 | 11 | 9.99e-01 |
| KEGG | KEGG:04080 | Neuroactive ligand-receptor interaction | 1 | 108 | 9.99e-01 |
| KEGG | KEGG:04972 | Pancreatic secretion | 3 | 58 | 9.99e-01 |
| KEGG | KEGG:04260 | Cardiac muscle contraction | 1 | 67 | 9.99e-01 |
| KEGG | KEGG:04061 | Viral protein interaction with cytokine and cytokine receptor | 1 | 20 | 9.99e-01 |
| KEGG | KEGG:05171 | Coronavirus disease - COVID-19 | 5 | 162 | 9.99e-01 |
| KEGG | KEGG:04740 | Olfactory transduction | 1 | 25 | 9.99e-01 |
| KEGG | KEGG:00230 | Purine metabolism | 4 | 97 | 9.99e-01 |
| KEGG | KEGG:04974 | Protein digestion and absorption | 2 | 61 | 9.99e-01 |
| KEGG | KEGG:04750 | Inflammatory mediator regulation of TRP channels | 2 | 72 | 9.99e-01 |
| KEGG | KEGG:00620 | Pyruvate metabolism | 1 | 33 | 9.99e-01 |
| KEGG | KEGG:00280 | Valine, leucine and isoleucine degradation | 1 | 43 | 9.99e-01 |
| KEGG | KEGG:05032 | Morphine addiction | 1 | 56 | 9.99e-01 |
| KEGG | KEGG:04976 | Bile secretion | 2 | 42 | 9.99e-01 |
| KEGG | KEGG:05412 | Arrhythmogenic right ventricular cardiomyopathy | 1 | 63 | 9.99e-01 |
| KEGG | KEGG:04723 | Retrograde endocannabinoid signaling | 1 | 99 | 9.99e-01 |
| KEGG | KEGG:04672 | Intestinal immune network for IgA production | 1 | 12 | 9.99e-01 |
| KEGG | KEGG:04514 | Cell adhesion molecules | 3 | 83 | 9.99e-01 |
| KEGG | KEGG:04512 | ECM-receptor interaction | 1 | 69 | 9.99e-01 |
| KEGG | KEGG:04911 | Insulin secretion | 3 | 64 | 9.99e-01 |
24 hour EPI highly variable genes
based on nominal pvalues <0.05
# EPI_var24gost <- gost(query = EPI_24_var$ENTREZID,
# organism = "hsapiens",
# significant = FALSE,
# ordered_query = TRUE,
# domain_scope = "custom",
# measure_underrepresentation = FALSE,
# evcodes = FALSE,
# numeric_ns="ENTREZGENE",
# user_threshold = 0.05,
# correction_method = "fdr",
# custom_bg = backGL$ENTREZID,
# sources=c("GO:BP","KEGG"))
#
# saveRDS(EPI_var24gost,"data/DEG-GO/var/EPI_var24gost.RDS")
EPI_var24gost <- readRDS("data/DEG-GO/var/EPI_var24gost.RDS")
# EPI_var24p <- gostplot(EPI_var24gost, capped = FALSE, interactive = TRUE)
# EPI_var24p
EPI_var24_table <- EPI_var24gost$result %>%
dplyr::select(c(source, term_id, term_name,intersection_size, term_size, p_value))
EPI_var24_table %>%
dplyr::filter(source=="GO:BP") %>%
dplyr::select(p_value,term_name,intersection_size) %>%
slice_min(., n=3 ,order_by=p_value) %>%
mutate(log_val = -log10(p_value)) %>%
# slice_max(., n=10,order_by = p_value) %>%
ggplot(., aes(x = log_val, y =reorder(term_name,p_value), col= intersection_size)) +
geom_point(aes(size = intersection_size)) +
geom_vline(xintercept = (-log10(0.05)), col="red")+
scale_y_discrete(labels = label_wrap(30))+
guides(col="none", size=guide_legend(title = "# of intersected \n terms"))+
ggtitle('EPI24 hour top 10 GO:BP terms') +
xlab(expression(" -"~log[10]~("adj. p-value")))+
ylab("GO: BP term")+
theme_bw()+
theme(plot.title = element_text(size = rel(1.5), hjust = 0.5),
axis.title = element_text(size = 15, color = "black"),
axis.ticks = element_line(linewidth = 1.5),
axis.line = element_line(linewidth = 1.5),
axis.text = element_text(size = 10, color = "black", angle = 0),
strip.text.x = element_text(size = 15, color = "black", face = "bold")) 
| Version | Author | Date |
|---|---|---|
| 3622a69 | reneeisnowhere | 2023-09-28 |
EPI_var24_table %>%
mutate_at(.vars = 6, .funs= scientific_format()) %>%
kable(.,caption = "EPI 24 enrichment terms of highly var genes") %>%
kable_paper("striped", full_width = FALSE) %>%
kable_styling(full_width = FALSE, position = "left",bootstrap_options = c("striped","hover")) %>%
scroll_box(width = "100%", height = "400px")| source | term_id | term_name | intersection_size | term_size | p_value |
|---|---|---|---|---|---|
| GO:BP | GO:0007032 | endosome organization | 20 | 92 | 1.12e-01 |
| GO:BP | GO:0006977 | DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest | 6 | 18 | 1.42e-01 |
| GO:BP | GO:0090174 | organelle membrane fusion | 23 | 106 | 1.42e-01 |
| GO:BP | GO:0031571 | mitotic G1 DNA damage checkpoint signaling | 8 | 30 | 1.42e-01 |
| GO:BP | GO:0010498 | proteasomal protein catabolic process | 112 | 486 | 1.42e-01 |
| GO:BP | GO:0090148 | membrane fission | 12 | 44 | 1.42e-01 |
| GO:BP | GO:0046499 | S-adenosylmethioninamine metabolic process | 1 | 1 | 1.42e-01 |
| GO:BP | GO:0009301 | snRNA transcription | 7 | 18 | 1.42e-01 |
| GO:BP | GO:0048193 | Golgi vesicle transport | 66 | 285 | 1.42e-01 |
| GO:BP | GO:0006974 | DNA damage response | 75 | 785 | 1.42e-01 |
| GO:BP | GO:0042754 | negative regulation of circadian rhythm | 5 | 10 | 1.42e-01 |
| GO:BP | GO:0090201 | negative regulation of release of cytochrome c from mitochondria | 10 | 18 | 1.42e-01 |
| GO:BP | GO:0048284 | organelle fusion | 25 | 135 | 1.42e-01 |
| GO:BP | GO:0016050 | vesicle organization | 46 | 320 | 1.42e-01 |
| GO:BP | GO:0016189 | synaptic vesicle to endosome fusion | 2 | 3 | 1.42e-01 |
| GO:BP | GO:0016236 | macroautophagy | 43 | 308 | 1.42e-01 |
| GO:BP | GO:0051640 | organelle localization | 6 | 503 | 1.42e-01 |
| GO:BP | GO:1902440 | protein localization to mitotic spindle pole body | 1 | 1 | 1.42e-01 |
| GO:BP | GO:0060340 | positive regulation of type I interferon-mediated signaling pathway | 10 | 17 | 1.42e-01 |
| GO:BP | GO:0032509 | endosome transport via multivesicular body sorting pathway | 10 | 41 | 1.42e-01 |
| GO:BP | GO:0007093 | mitotic cell cycle checkpoint signaling | 23 | 139 | 1.42e-01 |
| GO:BP | GO:0017182 | peptidyl-diphthamide metabolic process | 4 | 7 | 1.42e-01 |
| GO:BP | GO:1903527 | positive regulation of membrane tubulation | 2 | 3 | 1.42e-01 |
| GO:BP | GO:0031032 | actomyosin structure organization | 23 | 186 | 1.42e-01 |
| GO:BP | GO:0017183 | peptidyl-diphthamide biosynthetic process from peptidyl-histidine | 4 | 7 | 1.42e-01 |
| GO:BP | GO:0036257 | multivesicular body organization | 9 | 33 | 1.42e-01 |
| GO:BP | GO:0006906 | vesicle fusion | 23 | 104 | 1.42e-01 |
| GO:BP | GO:0000075 | cell cycle checkpoint signaling | 26 | 183 | 1.42e-01 |
| GO:BP | GO:0043632 | modification-dependent macromolecule catabolic process | 145 | 637 | 1.42e-01 |
| GO:BP | GO:0044819 | mitotic G1/S transition checkpoint signaling | 8 | 30 | 1.42e-01 |
| GO:BP | GO:0043247 | telomere maintenance in response to DNA damage | 8 | 29 | 1.42e-01 |
| GO:BP | GO:0006448 | regulation of translational elongation | 7 | 19 | 1.42e-01 |
| GO:BP | GO:0043149 | stress fiber assembly | 15 | 94 | 1.42e-01 |
| GO:BP | GO:0030038 | contractile actin filament bundle assembly | 15 | 94 | 1.42e-01 |
| GO:BP | GO:0043161 | proteasome-mediated ubiquitin-dependent protein catabolic process | 98 | 427 | 1.42e-01 |
| GO:BP | GO:0042771 | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 10 | 43 | 1.42e-01 |
| GO:BP | GO:0036258 | multivesicular body assembly | 9 | 32 | 1.42e-01 |
| GO:BP | GO:0030433 | ubiquitin-dependent ERAD pathway | 3 | 83 | 1.42e-01 |
| GO:BP | GO:0030330 | DNA damage response, signal transduction by p53 class mediator | 12 | 69 | 1.42e-01 |
| GO:BP | GO:0002182 | cytoplasmic translational elongation | 5 | 12 | 1.42e-01 |
| GO:BP | GO:0042770 | signal transduction in response to DNA damage | 18 | 178 | 1.42e-01 |
| GO:BP | GO:0035344 | hypoxanthine transport | 2 | 2 | 1.52e-01 |
| GO:BP | GO:0015854 | guanine transport | 2 | 2 | 1.52e-01 |
| GO:BP | GO:1903525 | regulation of membrane tubulation | 2 | 5 | 1.54e-01 |
| GO:BP | GO:0009157 | deoxyribonucleoside monophosphate biosynthetic process | 5 | 9 | 1.55e-01 |
| GO:BP | GO:0110020 | regulation of actomyosin structure organization | 14 | 90 | 1.55e-01 |
| GO:BP | GO:0051492 | regulation of stress fiber assembly | 13 | 81 | 1.55e-01 |
| GO:BP | GO:0008630 | intrinsic apoptotic signaling pathway in response to DNA damage | 15 | 94 | 1.55e-01 |
| GO:BP | GO:0071988 | protein localization to spindle pole body | 2 | 2 | 1.55e-01 |
| GO:BP | GO:1903566 | positive regulation of protein localization to cilium | 2 | 7 | 1.55e-01 |
| GO:BP | GO:0036250 | peroxisome transport along microtubule | 1 | 1 | 1.55e-01 |
| GO:BP | GO:0060011 | Sertoli cell proliferation | 4 | 4 | 1.55e-01 |
| GO:BP | GO:0045324 | late endosome to vacuole transport | 9 | 36 | 1.55e-01 |
| GO:BP | GO:0070932 | histone H3 deacetylation | 2 | 12 | 1.57e-01 |
| GO:BP | GO:0060338 | regulation of type I interferon-mediated signaling pathway | 14 | 35 | 1.57e-01 |
| GO:BP | GO:0010640 | regulation of platelet-derived growth factor receptor signaling pathway | 7 | 19 | 1.57e-01 |
| GO:BP | GO:0000070 | mitotic sister chromatid segregation | 26 | 179 | 1.57e-01 |
| GO:BP | GO:0046498 | S-adenosylhomocysteine metabolic process | 1 | 2 | 1.57e-01 |
| GO:BP | GO:0006511 | ubiquitin-dependent protein catabolic process | 139 | 615 | 1.57e-01 |
| GO:BP | GO:0006481 | C-terminal protein methylation | 1 | 2 | 1.57e-01 |
| GO:BP | GO:0045724 | positive regulation of cilium assembly | 2 | 25 | 1.57e-01 |
| GO:BP | GO:1990683 | DNA double-strand break attachment to nuclear envelope | 2 | 2 | 1.57e-01 |
| GO:BP | GO:1901800 | positive regulation of proteasomal protein catabolic process | 32 | 111 | 1.61e-01 |
| GO:BP | GO:0018345 | protein palmitoylation | 5 | 30 | 1.68e-01 |
| GO:BP | GO:0060056 | mammary gland involution | 5 | 8 | 1.68e-01 |
| GO:BP | GO:0000301 | retrograde transport, vesicle recycling within Golgi | 4 | 9 | 1.69e-01 |
| GO:BP | GO:0036503 | ERAD pathway | 3 | 106 | 1.73e-01 |
| GO:BP | GO:0006914 | autophagy | 65 | 513 | 1.73e-01 |
| GO:BP | GO:0045930 | negative regulation of mitotic cell cycle | 29 | 211 | 1.73e-01 |
| GO:BP | GO:0061919 | process utilizing autophagic mechanism | 65 | 513 | 1.73e-01 |
| GO:BP | GO:0007346 | regulation of mitotic cell cycle | 53 | 441 | 1.73e-01 |
| GO:BP | GO:0019941 | modification-dependent protein catabolic process | 140 | 625 | 1.74e-01 |
| GO:BP | GO:1900247 | regulation of cytoplasmic translational elongation | 3 | 10 | 1.74e-01 |
| GO:BP | GO:0044773 | mitotic DNA damage checkpoint signaling | 12 | 81 | 1.80e-01 |
| GO:BP | GO:1902511 | negative regulation of apoptotic DNA fragmentation | 1 | 2 | 1.80e-01 |
| GO:BP | GO:0044774 | mitotic DNA integrity checkpoint signaling | 14 | 85 | 1.80e-01 |
| GO:BP | GO:0006498 | N-terminal protein lipidation | 4 | 7 | 1.80e-01 |
| GO:BP | GO:0071985 | multivesicular body sorting pathway | 10 | 48 | 1.80e-01 |
| GO:BP | GO:0032076 | negative regulation of deoxyribonuclease activity | 1 | 1 | 1.80e-01 |
| GO:BP | GO:1905818 | regulation of chromosome separation | 13 | 71 | 1.82e-01 |
| GO:BP | GO:0061136 | regulation of proteasomal protein catabolic process | 47 | 183 | 1.82e-01 |
| GO:BP | GO:0044721 | protein import into peroxisome matrix, substrate release | 1 | 2 | 1.86e-01 |
| GO:BP | GO:0031584 | activation of phospholipase D activity | 1 | 4 | 1.86e-01 |
| GO:BP | GO:1903050 | regulation of proteolysis involved in protein catabolic process | 54 | 214 | 1.87e-01 |
| GO:BP | GO:0018202 | peptidyl-histidine modification | 3 | 11 | 1.88e-01 |
| GO:BP | GO:0018342 | protein prenylation | 4 | 10 | 1.88e-01 |
| GO:BP | GO:0006890 | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 7 | 52 | 1.88e-01 |
| GO:BP | GO:0006399 | tRNA metabolic process | 36 | 186 | 1.88e-01 |
| GO:BP | GO:0016241 | regulation of macroautophagy | 19 | 151 | 1.88e-01 |
| GO:BP | GO:0097354 | prenylation | 4 | 10 | 1.88e-01 |
| GO:BP | GO:0009215 | purine deoxyribonucleoside triphosphate metabolic process | 4 | 6 | 1.88e-01 |
| GO:BP | GO:0003274 | endocardial cushion fusion | 2 | 5 | 1.88e-01 |
| GO:BP | GO:0098781 | ncRNA transcription | 15 | 61 | 1.88e-01 |
| GO:BP | GO:0098876 | vesicle-mediated transport to the plasma membrane | 8 | 143 | 1.88e-01 |
| GO:BP | GO:0016925 | protein sumoylation | 18 | 59 | 1.88e-01 |
| GO:BP | GO:0045630 | positive regulation of T-helper 2 cell differentiation | 1 | 4 | 1.88e-01 |
| GO:BP | GO:0032436 | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 26 | 89 | 1.88e-01 |
| GO:BP | GO:0031848 | protection from non-homologous end joining at telomere | 4 | 10 | 1.88e-01 |
| GO:BP | GO:1903625 | negative regulation of DNA catabolic process | 1 | 3 | 1.91e-01 |
| GO:BP | GO:0034315 | regulation of Arp2/3 complex-mediated actin nucleation | 6 | 25 | 1.91e-01 |
| GO:BP | GO:0061956 | penetration of cumulus oophorus | 1 | 1 | 1.91e-01 |
| GO:BP | GO:1903955 | positive regulation of protein targeting to mitochondrion | 1 | 30 | 1.91e-01 |
| GO:BP | GO:1903564 | regulation of protein localization to cilium | 2 | 11 | 1.91e-01 |
| GO:BP | GO:0010965 | regulation of mitotic sister chromatid separation | 11 | 58 | 1.91e-01 |
| GO:BP | GO:0018377 | protein myristoylation | 3 | 4 | 1.91e-01 |
| GO:BP | GO:0042704 | uterine wall breakdown | 2 | 2 | 1.91e-01 |
| GO:BP | GO:0032231 | regulation of actin filament bundle assembly | 5 | 91 | 1.91e-01 |
| GO:BP | GO:0006499 | N-terminal protein myristoylation | 3 | 4 | 1.91e-01 |
| GO:BP | GO:0034243 | regulation of transcription elongation by RNA polymerase II | 24 | 85 | 1.91e-01 |
| GO:BP | GO:1901990 | regulation of mitotic cell cycle phase transition | 38 | 308 | 1.91e-01 |
| GO:BP | GO:0061025 | membrane fusion | 26 | 137 | 1.91e-01 |
| GO:BP | GO:0032511 | late endosome to vacuole transport via multivesicular body sorting pathway | 8 | 27 | 1.91e-01 |
| GO:BP | GO:0009200 | deoxyribonucleoside triphosphate metabolic process | 5 | 8 | 1.92e-01 |
| GO:BP | GO:0016561 | protein import into peroxisome matrix, translocation | 1 | 3 | 1.96e-01 |
| GO:BP | GO:2000058 | regulation of ubiquitin-dependent protein catabolic process | 42 | 160 | 1.96e-01 |
| GO:BP | GO:1903749 | positive regulation of establishment of protein localization to mitochondrion | 1 | 33 | 1.96e-01 |
| GO:BP | GO:2000553 | positive regulation of T-helper 2 cell cytokine production | 1 | 3 | 1.96e-01 |
| GO:BP | GO:0090385 | phagosome-lysosome fusion | 6 | 12 | 1.96e-01 |
| GO:BP | GO:0072384 | organelle transport along microtubule | 2 | 84 | 1.96e-01 |
| GO:BP | GO:0018344 | protein geranylgeranylation | 3 | 6 | 1.96e-01 |
| GO:BP | GO:0061343 | cell adhesion involved in heart morphogenesis | 2 | 6 | 2.00e-01 |
| GO:BP | GO:0061015 | snRNA import into nucleus | 2 | 2 | 2.00e-01 |
| GO:BP | GO:0000077 | DNA damage checkpoint signaling | 15 | 121 | 2.00e-01 |
| GO:BP | GO:0000209 | protein polyubiquitination | 29 | 226 | 2.00e-01 |
| GO:BP | GO:0043982 | histone H4-K8 acetylation | 6 | 16 | 2.00e-01 |
| GO:BP | GO:0070889 | platelet alpha granule organization | 2 | 2 | 2.00e-01 |
| GO:BP | GO:0043981 | histone H4-K5 acetylation | 6 | 16 | 2.00e-01 |
| GO:BP | GO:0019262 | N-acetylneuraminate catabolic process | 4 | 6 | 2.00e-01 |
| GO:BP | GO:0036514 | dopaminergic neuron axon guidance | 3 | 3 | 2.00e-01 |
| GO:BP | GO:1904938 | planar cell polarity pathway involved in axon guidance | 3 | 3 | 2.00e-01 |
| GO:BP | GO:0006996 | organelle organization | 15 | 3000 | 2.04e-01 |
| GO:BP | GO:0032434 | regulation of proteasomal ubiquitin-dependent protein catabolic process | 35 | 133 | 2.04e-01 |
| GO:BP | GO:1903214 | regulation of protein targeting to mitochondrion | 1 | 39 | 2.04e-01 |
| GO:BP | GO:0007005 | mitochondrion organization | 4 | 500 | 2.04e-01 |
| GO:BP | GO:0060081 | membrane hyperpolarization | 1 | 7 | 2.04e-01 |
| GO:BP | GO:0034498 | early endosome to Golgi transport | 5 | 9 | 2.04e-01 |
| GO:BP | GO:1904951 | positive regulation of establishment of protein localization | 2 | 258 | 2.04e-01 |
| GO:BP | GO:0061912 | selective autophagy | 14 | 90 | 2.04e-01 |
| GO:BP | GO:0006605 | protein targeting | 4 | 307 | 2.04e-01 |
| GO:BP | GO:0033047 | regulation of mitotic sister chromatid segregation | 10 | 52 | 2.04e-01 |
| GO:BP | GO:0044154 | histone H3-K14 acetylation | 2 | 12 | 2.04e-01 |
| GO:BP | GO:0032754 | positive regulation of interleukin-5 production | 1 | 6 | 2.04e-01 |
| GO:BP | GO:0098696 | regulation of neurotransmitter receptor localization to postsynaptic specialization membrane | 1 | 11 | 2.04e-01 |
| GO:BP | GO:0016073 | snRNA metabolic process | 12 | 54 | 2.04e-01 |
| GO:BP | GO:0051304 | chromosome separation | 13 | 76 | 2.04e-01 |
| GO:BP | GO:0051222 | positive regulation of protein transport | 2 | 242 | 2.04e-01 |
| GO:BP | GO:0045628 | regulation of T-helper 2 cell differentiation | 1 | 7 | 2.04e-01 |
| GO:BP | GO:0051603 | proteolysis involved in protein catabolic process | 77 | 706 | 2.04e-01 |
| GO:BP | GO:0070127 | tRNA aminoacylation for mitochondrial protein translation | 2 | 8 | 2.04e-01 |
| GO:BP | GO:1902857 | positive regulation of non-motile cilium assembly | 1 | 7 | 2.04e-01 |
| GO:BP | GO:0051125 | regulation of actin nucleation | 7 | 31 | 2.04e-01 |
| GO:BP | GO:0016560 | protein import into peroxisome matrix, docking | 1 | 3 | 2.04e-01 |
| GO:BP | GO:1903747 | regulation of establishment of protein localization to mitochondrion | 1 | 44 | 2.05e-01 |
| GO:BP | GO:0051306 | mitotic sister chromatid separation | 11 | 61 | 2.05e-01 |
| GO:BP | GO:0043517 | positive regulation of DNA damage response, signal transduction by p53 class mediator | 4 | 16 | 2.06e-01 |
| GO:BP | GO:0099576 | regulation of protein catabolic process at postsynapse, modulating synaptic transmission | 1 | 4 | 2.06e-01 |
| GO:BP | GO:0035745 | T-helper 2 cell cytokine production | 1 | 3 | 2.06e-01 |
| GO:BP | GO:0009838 | abscission | 3 | 6 | 2.06e-01 |
| GO:BP | GO:0045900 | negative regulation of translational elongation | 3 | 5 | 2.06e-01 |
| GO:BP | GO:0030540 | female genitalia development | 8 | 14 | 2.06e-01 |
| GO:BP | GO:1902774 | late endosome to lysosome transport | 9 | 20 | 2.06e-01 |
| GO:BP | GO:2000551 | regulation of T-helper 2 cell cytokine production | 1 | 3 | 2.06e-01 |
| GO:BP | GO:0031577 | spindle checkpoint signaling | 9 | 45 | 2.08e-01 |
| GO:BP | GO:0000045 | autophagosome assembly | 5 | 103 | 2.10e-01 |
| GO:BP | GO:0099532 | synaptic vesicle endosomal processing | 2 | 7 | 2.10e-01 |
| GO:BP | GO:0007030 | Golgi organization | 32 | 137 | 2.11e-01 |
| GO:BP | GO:0002941 | synoviocyte proliferation | 2 | 3 | 2.11e-01 |
| GO:BP | GO:0051030 | snRNA transport | 3 | 6 | 2.11e-01 |
| GO:BP | GO:0120034 | positive regulation of plasma membrane bounded cell projection assembly | 3 | 94 | 2.11e-01 |
| GO:BP | GO:1901647 | positive regulation of synoviocyte proliferation | 2 | 3 | 2.11e-01 |
| GO:BP | GO:1901645 | regulation of synoviocyte proliferation | 2 | 3 | 2.11e-01 |
| GO:BP | GO:1902117 | positive regulation of organelle assembly | 4 | 73 | 2.13e-01 |
| GO:BP | GO:0031643 | positive regulation of myelination | 3 | 12 | 2.14e-01 |
| GO:BP | GO:1903546 | protein localization to photoreceptor outer segment | 3 | 5 | 2.14e-01 |
| GO:BP | GO:0006368 | transcription elongation by RNA polymerase II | 17 | 106 | 2.14e-01 |
| GO:BP | GO:0043162 | ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway | 8 | 35 | 2.15e-01 |
| GO:BP | GO:0051661 | maintenance of centrosome location | 4 | 6 | 2.15e-01 |
| GO:BP | GO:0043619 | regulation of transcription from RNA polymerase II promoter in response to oxidative stress | 3 | 7 | 2.15e-01 |
| GO:BP | GO:0032736 | positive regulation of interleukin-13 production | 1 | 7 | 2.15e-01 |
| GO:BP | GO:2001243 | negative regulation of intrinsic apoptotic signaling pathway | 12 | 89 | 2.17e-01 |
| GO:BP | GO:1903052 | positive regulation of proteolysis involved in protein catabolic process | 34 | 127 | 2.19e-01 |
| GO:BP | GO:1905037 | autophagosome organization | 26 | 110 | 2.19e-01 |
| GO:BP | GO:0043516 | regulation of DNA damage response, signal transduction by p53 class mediator | 6 | 35 | 2.19e-01 |
| GO:BP | GO:0035305 | negative regulation of dephosphorylation | 4 | 39 | 2.24e-01 |
| GO:BP | GO:0016197 | endosomal transport | 53 | 231 | 2.24e-01 |
| GO:BP | GO:0072331 | signal transduction by p53 class mediator | 19 | 161 | 2.24e-01 |
| GO:BP | GO:0032364 | intracellular oxygen homeostasis | 3 | 6 | 2.25e-01 |
| GO:BP | GO:0034486 | vacuolar transmembrane transport | 2 | 3 | 2.25e-01 |
| GO:BP | GO:0000226 | microtubule cytoskeleton organization | 5 | 552 | 2.32e-01 |
| GO:BP | GO:1901987 | regulation of cell cycle phase transition | 44 | 391 | 2.33e-01 |
| GO:BP | GO:1901798 | positive regulation of signal transduction by p53 class mediator | 7 | 28 | 2.33e-01 |
| GO:BP | GO:0002830 | positive regulation of type 2 immune response | 1 | 7 | 2.33e-01 |
| GO:BP | GO:1902855 | regulation of non-motile cilium assembly | 1 | 10 | 2.33e-01 |
| GO:BP | GO:1901988 | negative regulation of cell cycle phase transition | 28 | 235 | 2.33e-01 |
| GO:BP | GO:0045064 | T-helper 2 cell differentiation | 1 | 10 | 2.33e-01 |
| GO:BP | GO:0016180 | snRNA processing | 1 | 26 | 2.33e-01 |
| GO:BP | GO:0031570 | DNA integrity checkpoint signaling | 15 | 129 | 2.33e-01 |
| GO:BP | GO:0019043 | establishment of viral latency | 2 | 3 | 2.33e-01 |
| GO:BP | GO:1903047 | mitotic cell cycle process | 74 | 694 | 2.33e-01 |
| GO:BP | GO:1903358 | regulation of Golgi organization | 7 | 17 | 2.34e-01 |
| GO:BP | GO:0033211 | adiponectin-activated signaling pathway | 4 | 7 | 2.35e-01 |
| GO:BP | GO:0006670 | sphingosine metabolic process | 3 | 18 | 2.36e-01 |
| GO:BP | GO:0042795 | snRNA transcription by RNA polymerase II | 5 | 15 | 2.36e-01 |
| GO:BP | GO:1901991 | negative regulation of mitotic cell cycle phase transition | 22 | 166 | 2.37e-01 |
| GO:BP | GO:0050688 | regulation of defense response to virus | 20 | 63 | 2.37e-01 |
| GO:BP | GO:0032074 | negative regulation of nuclease activity | 1 | 6 | 2.37e-01 |
| GO:BP | GO:0034314 | Arp2/3 complex-mediated actin nucleation | 7 | 40 | 2.37e-01 |
| GO:BP | GO:1903241 | U2-type prespliceosome assembly | 2 | 24 | 2.37e-01 |
| GO:BP | GO:0035743 | CD4-positive, alpha-beta T cell cytokine production | 1 | 5 | 2.37e-01 |
| GO:BP | GO:0035720 | intraciliary anterograde transport | 7 | 17 | 2.38e-01 |
| GO:BP | GO:0140374 | antiviral innate immune response | 1 | 17 | 2.38e-01 |
| GO:BP | GO:1903533 | regulation of protein targeting | 1 | 66 | 2.38e-01 |
| GO:BP | GO:0032634 | interleukin-5 production | 1 | 8 | 2.42e-01 |
| GO:BP | GO:1905515 | non-motile cilium assembly | 16 | 58 | 2.42e-01 |
| GO:BP | GO:0045624 | positive regulation of T-helper cell differentiation | 1 | 11 | 2.42e-01 |
| GO:BP | GO:0060271 | cilium assembly | 4 | 292 | 2.42e-01 |
| GO:BP | GO:1902100 | negative regulation of metaphase/anaphase transition of cell cycle | 9 | 47 | 2.42e-01 |
| GO:BP | GO:1902017 | regulation of cilium assembly | 2 | 57 | 2.42e-01 |
| GO:BP | GO:0032968 | positive regulation of transcription elongation by RNA polymerase II | 15 | 49 | 2.42e-01 |
| GO:BP | GO:0098967 | exocytic insertion of neurotransmitter receptor to postsynaptic membrane | 2 | 5 | 2.42e-01 |
| GO:BP | GO:0032674 | regulation of interleukin-5 production | 1 | 8 | 2.42e-01 |
| GO:BP | GO:0030488 | tRNA methylation | 13 | 42 | 2.42e-01 |
| GO:BP | GO:0140014 | mitotic nuclear division | 32 | 251 | 2.42e-01 |
| GO:BP | GO:0010867 | positive regulation of triglyceride biosynthetic process | 3 | 14 | 2.43e-01 |
| GO:BP | GO:0061734 | parkin-mediated stimulation of mitophagy in response to mitochondrial depolarization | 1 | 6 | 2.43e-01 |
| GO:BP | GO:0042796 | snRNA transcription by RNA polymerase III | 3 | 8 | 2.43e-01 |
| GO:BP | GO:1902473 | regulation of protein localization to synapse | 1 | 22 | 2.43e-01 |
| GO:BP | GO:0006626 | protein targeting to mitochondrion | 2 | 100 | 2.43e-01 |
| GO:BP | GO:1902683 | regulation of receptor localization to synapse | 1 | 21 | 2.43e-01 |
| GO:BP | GO:0051169 | nuclear transport | 37 | 295 | 2.43e-01 |
| GO:BP | GO:0006913 | nucleocytoplasmic transport | 37 | 295 | 2.43e-01 |
| GO:BP | GO:1904333 | positive regulation of error-prone translesion synthesis | 1 | 1 | 2.43e-01 |
| GO:BP | GO:1904331 | regulation of error-prone translesion synthesis | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0008631 | intrinsic apoptotic signaling pathway in response to oxidative stress | 8 | 41 | 2.43e-01 |
| GO:BP | GO:0061386 | closure of optic fissure | 1 | 2 | 2.43e-01 |
| GO:BP | GO:0007031 | peroxisome organization | 3 | 34 | 2.43e-01 |
| GO:BP | GO:0062232 | prostanoid catabolic process | 1 | 2 | 2.43e-01 |
| GO:BP | GO:0046519 | sphingoid metabolic process | 3 | 19 | 2.43e-01 |
| GO:BP | GO:0046834 | lipid phosphorylation | 6 | 16 | 2.43e-01 |
| GO:BP | GO:1901796 | regulation of signal transduction by p53 class mediator | 15 | 101 | 2.43e-01 |
| GO:BP | GO:0048278 | vesicle docking | 6 | 57 | 2.43e-01 |
| GO:BP | GO:1903569 | positive regulation of protein localization to ciliary membrane | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0043928 | exonucleolytic catabolism of deadenylated mRNA | 6 | 13 | 2.43e-01 |
| GO:BP | GO:1903829 | positive regulation of protein localization | 2 | 386 | 2.43e-01 |
| GO:BP | GO:0043967 | histone H4 acetylation | 14 | 57 | 2.43e-01 |
| GO:BP | GO:0032906 | transforming growth factor beta2 production | 3 | 9 | 2.43e-01 |
| GO:BP | GO:0000278 | mitotic cell cycle | 86 | 827 | 2.43e-01 |
| GO:BP | GO:1905344 | prostaglandin catabolic process | 1 | 2 | 2.43e-01 |
| GO:BP | GO:0016242 | negative regulation of macroautophagy | 6 | 34 | 2.43e-01 |
| GO:BP | GO:0035308 | negative regulation of protein dephosphorylation | 3 | 28 | 2.43e-01 |
| GO:BP | GO:0032656 | regulation of interleukin-13 production | 1 | 10 | 2.43e-01 |
| GO:BP | GO:0006046 | N-acetylglucosamine catabolic process | 3 | 3 | 2.43e-01 |
| GO:BP | GO:2000060 | positive regulation of ubiquitin-dependent protein catabolic process | 27 | 103 | 2.43e-01 |
| GO:BP | GO:0032616 | interleukin-13 production | 1 | 10 | 2.43e-01 |
| GO:BP | GO:0032909 | regulation of transforming growth factor beta2 production | 3 | 9 | 2.43e-01 |
| GO:BP | GO:0015853 | adenine transport | 2 | 5 | 2.43e-01 |
| GO:BP | GO:1900118 | negative regulation of execution phase of apoptosis | 1 | 6 | 2.44e-01 |
| GO:BP | GO:0018410 | C-terminal protein amino acid modification | 1 | 10 | 2.44e-01 |
| GO:BP | GO:1905135 | biotin import across plasma membrane | 2 | 2 | 2.44e-01 |
| GO:BP | GO:0071140 | resolution of mitotic recombination intermediates | 2 | 2 | 2.44e-01 |
| GO:BP | GO:0006054 | N-acetylneuraminate metabolic process | 5 | 11 | 2.44e-01 |
| GO:BP | GO:0033044 | regulation of chromosome organization | 28 | 236 | 2.44e-01 |
| GO:BP | GO:1903778 | protein localization to vacuolar membrane | 1 | 1 | 2.44e-01 |
| GO:BP | GO:0046628 | positive regulation of insulin receptor signaling pathway | 1 | 20 | 2.44e-01 |
| GO:BP | GO:0006892 | post-Golgi vesicle-mediated transport | 22 | 103 | 2.44e-01 |
| GO:BP | GO:0003093 | regulation of glomerular filtration | 2 | 9 | 2.44e-01 |
| GO:BP | GO:0033235 | positive regulation of protein sumoylation | 2 | 12 | 2.47e-01 |
| GO:BP | GO:1990114 | RNA polymerase II core complex assembly | 1 | 1 | 2.47e-01 |
| GO:BP | GO:0002726 | positive regulation of T cell cytokine production | 1 | 14 | 2.47e-01 |
| GO:BP | GO:0032753 | positive regulation of interleukin-4 production | 1 | 8 | 2.47e-01 |
| GO:BP | GO:1905819 | negative regulation of chromosome separation | 9 | 48 | 2.49e-01 |
| GO:BP | GO:0051985 | negative regulation of chromosome segregation | 9 | 48 | 2.49e-01 |
| GO:BP | GO:0044782 | cilium organization | 4 | 313 | 2.49e-01 |
| GO:BP | GO:0048597 | post-embryonic camera-type eye morphogenesis | 3 | 4 | 2.49e-01 |
| GO:BP | GO:0016049 | cell growth | 2 | 418 | 2.49e-01 |
| GO:BP | GO:0043508 | negative regulation of JUN kinase activity | 3 | 13 | 2.49e-01 |
| GO:BP | GO:0016094 | polyprenol biosynthetic process | 1 | 3 | 2.50e-01 |
| GO:BP | GO:0007006 | mitochondrial membrane organization | 2 | 114 | 2.51e-01 |
| GO:BP | GO:0000819 | sister chromatid segregation | 27 | 217 | 2.51e-01 |
| GO:BP | GO:0032070 | regulation of deoxyribonuclease activity | 1 | 9 | 2.51e-01 |
| GO:BP | GO:0072332 | intrinsic apoptotic signaling pathway by p53 class mediator | 14 | 77 | 2.51e-01 |
| GO:BP | GO:0032784 | regulation of DNA-templated transcription elongation | 26 | 99 | 2.51e-01 |
| GO:BP | GO:1904417 | positive regulation of xenophagy | 3 | 7 | 2.51e-01 |
| GO:BP | GO:1900078 | positive regulation of cellular response to insulin stimulus | 1 | 23 | 2.51e-01 |
| GO:BP | GO:0061024 | membrane organization | 5 | 671 | 2.51e-01 |
| GO:BP | GO:0006354 | DNA-templated transcription elongation | 18 | 122 | 2.51e-01 |
| GO:BP | GO:1904415 | regulation of xenophagy | 3 | 7 | 2.51e-01 |
| GO:BP | GO:0099633 | protein localization to postsynaptic specialization membrane | 1 | 19 | 2.51e-01 |
| GO:BP | GO:0051223 | regulation of protein transport | 2 | 404 | 2.51e-01 |
| GO:BP | GO:1905461 | positive regulation of vascular associated smooth muscle cell apoptotic process | 1 | 7 | 2.51e-01 |
| GO:BP | GO:1903729 | regulation of plasma membrane organization | 2 | 15 | 2.51e-01 |
| GO:BP | GO:1902166 | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 6 | 15 | 2.51e-01 |
| GO:BP | GO:0099645 | neurotransmitter receptor localization to postsynaptic specialization membrane | 1 | 19 | 2.51e-01 |
| GO:BP | GO:0002339 | B cell selection | 3 | 4 | 2.51e-01 |
| GO:BP | GO:0003245 | cardiac muscle tissue growth involved in heart morphogenesis | 1 | 1 | 2.51e-01 |
| GO:BP | GO:0032148 | activation of protein kinase B activity | 1 | 23 | 2.51e-01 |
| GO:BP | GO:0006388 | tRNA splicing, via endonucleolytic cleavage and ligation | 5 | 13 | 2.52e-01 |
| GO:BP | GO:1902228 | positive regulation of macrophage colony-stimulating factor signaling pathway | 1 | 1 | 2.52e-01 |
| GO:BP | GO:0060611 | mammary gland fat development | 1 | 1 | 2.52e-01 |
| GO:BP | GO:0044772 | mitotic cell cycle phase transition | 46 | 418 | 2.52e-01 |
| GO:BP | GO:0032053 | ciliary basal body organization | 1 | 4 | 2.52e-01 |
| GO:BP | GO:2000785 | regulation of autophagosome assembly | 3 | 44 | 2.52e-01 |
| GO:BP | GO:1902510 | regulation of apoptotic DNA fragmentation | 1 | 8 | 2.52e-01 |
| GO:BP | GO:0061952 | midbody abscission | 5 | 17 | 2.52e-01 |
| GO:BP | GO:0006893 | Golgi to plasma membrane transport | 13 | 60 | 2.52e-01 |
| GO:BP | GO:0001921 | positive regulation of receptor recycling | 1 | 11 | 2.52e-01 |
| GO:BP | GO:1902455 | negative regulation of stem cell population maintenance | 5 | 21 | 2.52e-01 |
| GO:BP | GO:0098792 | xenophagy | 4 | 12 | 2.52e-01 |
| GO:BP | GO:0051017 | actin filament bundle assembly | 16 | 138 | 2.53e-01 |
| GO:BP | GO:1902339 | positive regulation of apoptotic process involved in morphogenesis | 3 | 5 | 2.53e-01 |
| GO:BP | GO:0070201 | regulation of establishment of protein localization | 2 | 428 | 2.53e-01 |
| GO:BP | GO:0033365 | protein localization to organelle | 5 | 859 | 2.53e-01 |
| GO:BP | GO:0072655 | establishment of protein localization to mitochondrion | 2 | 118 | 2.53e-01 |
| GO:BP | GO:2000463 | positive regulation of excitatory postsynaptic potential | 1 | 28 | 2.53e-01 |
| GO:BP | GO:0001844 | protein insertion into mitochondrial membrane involved in apoptotic signaling pathway | 3 | 5 | 2.53e-01 |
| GO:BP | GO:1904747 | positive regulation of apoptotic process involved in development | 3 | 5 | 2.53e-01 |
| GO:BP | GO:0097320 | plasma membrane tubulation | 2 | 18 | 2.53e-01 |
| GO:BP | GO:0051040 | regulation of calcium-independent cell-cell adhesion | 2 | 2 | 2.55e-01 |
| GO:BP | GO:0070183 | mitochondrial tryptophanyl-tRNA aminoacylation | 1 | 1 | 2.56e-01 |
| GO:BP | GO:0032673 | regulation of interleukin-4 production | 1 | 14 | 2.57e-01 |
| GO:BP | GO:0015786 | UDP-glucose transmembrane transport | 2 | 2 | 2.57e-01 |
| GO:BP | GO:0010652 | positive regulation of cell communication by chemical coupling | 1 | 1 | 2.57e-01 |
| GO:BP | GO:0070256 | negative regulation of mucus secretion | 2 | 2 | 2.57e-01 |
| GO:BP | GO:1990116 | ribosome-associated ubiquitin-dependent protein catabolic process | 3 | 5 | 2.57e-01 |
| GO:BP | GO:0070585 | protein localization to mitochondrion | 1 | 123 | 2.57e-01 |
| GO:BP | GO:2001045 | negative regulation of integrin-mediated signaling pathway | 1 | 3 | 2.57e-01 |
| GO:BP | GO:0010970 | transport along microtubule | 2 | 162 | 2.57e-01 |
| GO:BP | GO:0043372 | positive regulation of CD4-positive, alpha-beta T cell differentiation | 1 | 16 | 2.57e-01 |
| GO:BP | GO:0032633 | interleukin-4 production | 1 | 14 | 2.57e-01 |
| GO:BP | GO:0002828 | regulation of type 2 immune response | 1 | 15 | 2.57e-01 |
| GO:BP | GO:0086044 | atrial cardiac muscle cell to AV node cell communication by electrical coupling | 1 | 1 | 2.57e-01 |
| GO:BP | GO:1990029 | vasomotion | 1 | 1 | 2.57e-01 |
| GO:BP | GO:0010645 | regulation of cell communication by chemical coupling | 1 | 1 | 2.57e-01 |
| GO:BP | GO:0098906 | regulation of Purkinje myocyte action potential | 1 | 1 | 2.57e-01 |
| GO:BP | GO:0097193 | intrinsic apoptotic signaling pathway | 27 | 262 | 2.57e-01 |
| GO:BP | GO:0086055 | Purkinje myocyte to ventricular cardiac muscle cell communication by electrical coupling | 1 | 1 | 2.57e-01 |
| GO:BP | GO:0090520 | sphingolipid mediated signaling pathway | 2 | 11 | 2.57e-01 |
| GO:BP | GO:2000786 | positive regulation of autophagosome assembly | 2 | 19 | 2.57e-01 |
| GO:BP | GO:0006986 | response to unfolded protein | 1 | 128 | 2.57e-01 |
| GO:BP | GO:0062196 | regulation of lysosome size | 2 | 8 | 2.57e-01 |
| GO:BP | GO:0046627 | negative regulation of insulin receptor signaling pathway | 1 | 29 | 2.57e-01 |
| GO:BP | GO:0070159 | mitochondrial threonyl-tRNA aminoacylation | 1 | 1 | 2.57e-01 |
| GO:BP | GO:0070727 | cellular macromolecule localization | 9 | 2138 | 2.57e-01 |
| GO:BP | GO:0070925 | organelle assembly | 6 | 817 | 2.57e-01 |
| GO:BP | GO:0043001 | Golgi to plasma membrane protein transport | 3 | 37 | 2.57e-01 |
| GO:BP | GO:0042823 | pyridoxal phosphate biosynthetic process | 2 | 2 | 2.57e-01 |
| GO:BP | GO:0070528 | protein kinase C signaling | 1 | 24 | 2.57e-01 |
| GO:BP | GO:0019042 | viral latency | 2 | 4 | 2.57e-01 |
| GO:BP | GO:0006891 | intra-Golgi vesicle-mediated transport | 7 | 33 | 2.57e-01 |
| GO:BP | GO:0008104 | protein localization | 9 | 2129 | 2.57e-01 |
| GO:BP | GO:0098801 | regulation of renal system process | 3 | 21 | 2.57e-01 |
| GO:BP | GO:0051571 | positive regulation of histone H3-K4 methylation | 8 | 20 | 2.58e-01 |
| GO:BP | GO:1903624 | regulation of DNA catabolic process | 1 | 10 | 2.60e-01 |
| GO:BP | GO:0006497 | protein lipidation | 7 | 89 | 2.60e-01 |
| GO:BP | GO:0007616 | long-term memory | 1 | 31 | 2.60e-01 |
| GO:BP | GO:0036124 | histone H3-K9 trimethylation | 2 | 9 | 2.60e-01 |
| GO:BP | GO:0001516 | prostaglandin biosynthetic process | 1 | 19 | 2.61e-01 |
| GO:BP | GO:0098779 | positive regulation of mitophagy in response to mitochondrial depolarization | 1 | 10 | 2.61e-01 |
| GO:BP | GO:0033233 | regulation of protein sumoylation | 3 | 22 | 2.61e-01 |
| GO:BP | GO:1900239 | regulation of phenotypic switching | 2 | 3 | 2.61e-01 |
| GO:BP | GO:0033499 | galactose catabolic process via UDP-galactose | 1 | 4 | 2.61e-01 |
| GO:BP | GO:0001560 | regulation of cell growth by extracellular stimulus | 2 | 3 | 2.61e-01 |
| GO:BP | GO:0033045 | regulation of sister chromatid segregation | 14 | 99 | 2.61e-01 |
| GO:BP | GO:1900077 | negative regulation of cellular response to insulin stimulus | 1 | 31 | 2.61e-01 |
| GO:BP | GO:0051225 | spindle assembly | 18 | 120 | 2.61e-01 |
| GO:BP | GO:0001510 | RNA methylation | 22 | 87 | 2.61e-01 |
| GO:BP | GO:1903432 | regulation of TORC1 signaling | 8 | 48 | 2.61e-01 |
| GO:BP | GO:0002724 | regulation of T cell cytokine production | 1 | 18 | 2.61e-01 |
| GO:BP | GO:1903512 | phytanic acid metabolic process | 2 | 2 | 2.61e-01 |
| GO:BP | GO:1903301 | positive regulation of hexokinase activity | 3 | 5 | 2.61e-01 |
| GO:BP | GO:0061572 | actin filament bundle organization | 16 | 140 | 2.61e-01 |
| GO:BP | GO:0009057 | macromolecule catabolic process | 8 | 1199 | 2.61e-01 |
| GO:BP | GO:0035966 | response to topologically incorrect protein | 1 | 150 | 2.61e-01 |
| GO:BP | GO:0090316 | positive regulation of intracellular protein transport | 1 | 133 | 2.61e-01 |
| GO:BP | GO:0036260 | RNA capping | 6 | 20 | 2.61e-01 |
| GO:BP | GO:0045010 | actin nucleation | 8 | 50 | 2.61e-01 |
| GO:BP | GO:1905459 | regulation of vascular associated smooth muscle cell apoptotic process | 1 | 9 | 2.61e-01 |
| GO:BP | GO:0042407 | cristae formation | 1 | 18 | 2.61e-01 |
| GO:BP | GO:0042157 | lipoprotein metabolic process | 10 | 116 | 2.61e-01 |
| GO:BP | GO:0061198 | fungiform papilla formation | 1 | 3 | 2.61e-01 |
| GO:BP | GO:0001961 | positive regulation of cytokine-mediated signaling pathway | 16 | 44 | 2.61e-01 |
| GO:BP | GO:0042543 | protein N-linked glycosylation via arginine | 1 | 1 | 2.61e-01 |
| GO:BP | GO:0043328 | protein transport to vacuole involved in ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway | 5 | 16 | 2.61e-01 |
| GO:BP | GO:0010642 | negative regulation of platelet-derived growth factor receptor signaling pathway | 4 | 10 | 2.61e-01 |
| GO:BP | GO:1901985 | positive regulation of protein acetylation | 11 | 41 | 2.61e-01 |
| GO:BP | GO:1905288 | vascular associated smooth muscle cell apoptotic process | 1 | 9 | 2.61e-01 |
| GO:BP | GO:0046128 | purine ribonucleoside metabolic process | 1 | 16 | 2.61e-01 |
| GO:BP | GO:1902229 | regulation of intrinsic apoptotic signaling pathway in response to DNA damage | 9 | 37 | 2.61e-01 |
| GO:BP | GO:0015031 | protein transport | 7 | 1361 | 2.61e-01 |
| GO:BP | GO:0006661 | phosphatidylinositol biosynthetic process | 28 | 119 | 2.61e-01 |
| GO:BP | GO:0007094 | mitotic spindle assembly checkpoint signaling | 8 | 44 | 2.61e-01 |
| GO:BP | GO:0046457 | prostanoid biosynthetic process | 1 | 19 | 2.61e-01 |
| GO:BP | GO:0071173 | spindle assembly checkpoint signaling | 8 | 44 | 2.61e-01 |
| GO:BP | GO:1902172 | regulation of keratinocyte apoptotic process | 3 | 5 | 2.61e-01 |
| GO:BP | GO:0002369 | T cell cytokine production | 1 | 18 | 2.61e-01 |
| GO:BP | GO:0071174 | mitotic spindle checkpoint signaling | 8 | 44 | 2.61e-01 |
| GO:BP | GO:0097283 | keratinocyte apoptotic process | 3 | 5 | 2.61e-01 |
| GO:BP | GO:0032733 | positive regulation of interleukin-10 production | 1 | 16 | 2.62e-01 |
| GO:BP | GO:0045622 | regulation of T-helper cell differentiation | 1 | 20 | 2.62e-01 |
| GO:BP | GO:0042659 | regulation of cell fate specification | 3 | 23 | 2.62e-01 |
| GO:BP | GO:0006182 | cGMP biosynthetic process | 1 | 6 | 2.62e-01 |
| GO:BP | GO:0042092 | type 2 immune response | 1 | 19 | 2.62e-01 |
| GO:BP | GO:0007168 | receptor guanylyl cyclase signaling pathway | 1 | 5 | 2.62e-01 |
| GO:BP | GO:0000394 | RNA splicing, via endonucleolytic cleavage and ligation | 5 | 14 | 2.63e-01 |
| GO:BP | GO:0032899 | regulation of neurotrophin production | 2 | 2 | 2.63e-01 |
| GO:BP | GO:0000722 | telomere maintenance via recombination | 4 | 14 | 2.63e-01 |
| GO:BP | GO:0086053 | AV node cell to bundle of His cell communication by electrical coupling | 2 | 3 | 2.63e-01 |
| GO:BP | GO:0042158 | lipoprotein biosynthetic process | 21 | 92 | 2.63e-01 |
| GO:BP | GO:0044090 | positive regulation of vacuole organization | 2 | 21 | 2.63e-01 |
| GO:BP | GO:2000516 | positive regulation of CD4-positive, alpha-beta T cell activation | 1 | 20 | 2.63e-01 |
| GO:BP | GO:0015910 | long-chain fatty acid import into peroxisome | 2 | 3 | 2.63e-01 |
| GO:BP | GO:0044088 | regulation of vacuole organization | 3 | 50 | 2.65e-01 |
| GO:BP | GO:0036518 | chemorepulsion of dopaminergic neuron axon | 2 | 2 | 2.66e-01 |
| GO:BP | GO:1902254 | negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 8 | 22 | 2.66e-01 |
| GO:BP | GO:0045769 | negative regulation of asymmetric cell division | 1 | 1 | 2.66e-01 |
| GO:BP | GO:0034660 | ncRNA metabolic process | 88 | 561 | 2.66e-01 |
| GO:BP | GO:0140354 | lipid import into cell | 5 | 15 | 2.66e-01 |
| GO:BP | GO:1902176 | negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway | 6 | 18 | 2.66e-01 |
| GO:BP | GO:0010936 | negative regulation of macrophage cytokine production | 3 | 7 | 2.67e-01 |
| GO:BP | GO:0042323 | negative regulation of circadian sleep/wake cycle, non-REM sleep | 1 | 1 | 2.67e-01 |
| GO:BP | GO:0098815 | modulation of excitatory postsynaptic potential | 1 | 40 | 2.67e-01 |
| GO:BP | GO:1902068 | regulation of sphingolipid mediated signaling pathway | 1 | 1 | 2.67e-01 |
| GO:BP | GO:0043543 | protein acylation | 41 | 228 | 2.67e-01 |
| GO:BP | GO:0008033 | tRNA processing | 24 | 128 | 2.67e-01 |
| GO:BP | GO:0090129 | positive regulation of synapse maturation | 2 | 8 | 2.67e-01 |
| GO:BP | GO:0007059 | chromosome segregation | 46 | 369 | 2.67e-01 |
| GO:BP | GO:0038166 | angiotensin-activated signaling pathway | 1 | 10 | 2.67e-01 |
| GO:BP | GO:1990849 | vacuolar localization | 12 | 62 | 2.67e-01 |
| GO:BP | GO:0046465 | dolichyl diphosphate metabolic process | 1 | 5 | 2.67e-01 |
| GO:BP | GO:0006488 | dolichol-linked oligosaccharide biosynthetic process | 2 | 20 | 2.67e-01 |
| GO:BP | GO:0032418 | lysosome localization | 12 | 62 | 2.67e-01 |
| GO:BP | GO:0035810 | positive regulation of urine volume | 1 | 10 | 2.67e-01 |
| GO:BP | GO:0035601 | protein deacylation | 4 | 116 | 2.67e-01 |
| GO:BP | GO:0006489 | dolichyl diphosphate biosynthetic process | 1 | 5 | 2.67e-01 |
| GO:BP | GO:0032900 | negative regulation of neurotrophin production | 1 | 1 | 2.67e-01 |
| GO:BP | GO:0032244 | positive regulation of nucleoside transport | 1 | 1 | 2.67e-01 |
| GO:BP | GO:0090502 | RNA phosphodiester bond hydrolysis, endonucleolytic | 1 | 72 | 2.67e-01 |
| GO:BP | GO:0016558 | protein import into peroxisome matrix | 1 | 14 | 2.67e-01 |
| GO:BP | GO:0047496 | vesicle transport along microtubule | 1 | 41 | 2.67e-01 |
| GO:BP | GO:0072319 | vesicle uncoating | 4 | 9 | 2.68e-01 |
| GO:BP | GO:0070242 | thymocyte apoptotic process | 7 | 17 | 2.68e-01 |
| GO:BP | GO:0045003 | double-strand break repair via synthesis-dependent strand annealing | 3 | 7 | 2.68e-01 |
| GO:BP | GO:1903567 | regulation of protein localization to ciliary membrane | 1 | 2 | 2.68e-01 |
| GO:BP | GO:1903320 | regulation of protein modification by small protein conjugation or removal | 29 | 232 | 2.69e-01 |
| GO:BP | GO:0015919 | peroxisomal membrane transport | 2 | 20 | 2.69e-01 |
| GO:BP | GO:1900117 | regulation of execution phase of apoptosis | 1 | 13 | 2.69e-01 |
| GO:BP | GO:1903539 | protein localization to postsynaptic membrane | 1 | 38 | 2.69e-01 |
| GO:BP | GO:0042278 | purine nucleoside metabolic process | 1 | 20 | 2.70e-01 |
| GO:BP | GO:2001251 | negative regulation of chromosome organization | 13 | 90 | 2.70e-01 |
| GO:BP | GO:0030705 | cytoskeleton-dependent intracellular transport | 2 | 194 | 2.70e-01 |
| GO:BP | GO:0061626 | pharyngeal arch artery morphogenesis | 2 | 10 | 2.70e-01 |
| GO:BP | GO:0062237 | protein localization to postsynapse | 1 | 39 | 2.70e-01 |
| GO:BP | GO:0045736 | negative regulation of cyclin-dependent protein serine/threonine kinase activity | 9 | 27 | 2.70e-01 |
| GO:BP | GO:1904030 | negative regulation of cyclin-dependent protein kinase activity | 9 | 27 | 2.70e-01 |
| GO:BP | GO:0019388 | galactose catabolic process | 1 | 5 | 2.70e-01 |
| GO:BP | GO:0034393 | positive regulation of smooth muscle cell apoptotic process | 1 | 8 | 2.70e-01 |
| GO:BP | GO:0046886 | positive regulation of hormone biosynthetic process | 3 | 9 | 2.70e-01 |
| GO:BP | GO:0043248 | proteasome assembly | 6 | 13 | 2.70e-01 |
| GO:BP | GO:0006490 | oligosaccharide-lipid intermediate biosynthetic process | 2 | 21 | 2.70e-01 |
| GO:BP | GO:1903701 | substantia propria of cornea development | 1 | 1 | 2.70e-01 |
| GO:BP | GO:0035815 | positive regulation of renal sodium excretion | 1 | 7 | 2.71e-01 |
| GO:BP | GO:0099111 | microtubule-based transport | 2 | 191 | 2.71e-01 |
| GO:BP | GO:0046907 | intracellular transport | 6 | 1453 | 2.71e-01 |
| GO:BP | GO:0046385 | deoxyribose phosphate biosynthetic process | 6 | 14 | 2.71e-01 |
| GO:BP | GO:0009265 | 2’-deoxyribonucleotide biosynthetic process | 6 | 14 | 2.71e-01 |
| GO:BP | GO:0034976 | response to endoplasmic reticulum stress | 3 | 234 | 2.71e-01 |
| GO:BP | GO:0009263 | deoxyribonucleotide biosynthetic process | 6 | 14 | 2.71e-01 |
| GO:BP | GO:0098914 | membrane repolarization during atrial cardiac muscle cell action potential | 2 | 6 | 2.71e-01 |
| GO:BP | GO:0048264 | determination of ventral identity | 1 | 1 | 2.71e-01 |
| GO:BP | GO:2001234 | negative regulation of apoptotic signaling pathway | 25 | 194 | 2.72e-01 |
| GO:BP | GO:0003171 | atrioventricular valve development | 3 | 27 | 2.72e-01 |
| GO:BP | GO:0001845 | phagolysosome assembly | 6 | 14 | 2.72e-01 |
| GO:BP | GO:0032388 | positive regulation of intracellular transport | 1 | 170 | 2.72e-01 |
| GO:BP | GO:0045841 | negative regulation of mitotic metaphase/anaphase transition | 8 | 46 | 2.72e-01 |
| GO:BP | GO:0098732 | macromolecule deacylation | 4 | 119 | 2.72e-01 |
| GO:BP | GO:0006839 | mitochondrial transport | 1 | 185 | 2.72e-01 |
| GO:BP | GO:1900029 | positive regulation of ruffle assembly | 4 | 12 | 2.72e-01 |
| GO:BP | GO:1905508 | protein localization to microtubule organizing center | 1 | 33 | 2.72e-01 |
| GO:BP | GO:0030219 | megakaryocyte differentiation | 2 | 54 | 2.72e-01 |
| GO:BP | GO:0046638 | positive regulation of alpha-beta T cell differentiation | 1 | 27 | 2.72e-01 |
| GO:BP | GO:1990755 | mitotic spindle microtubule depolymerization | 1 | 1 | 2.73e-01 |
| GO:BP | GO:0001173 | DNA-templated transcriptional start site selection | 1 | 2 | 2.73e-01 |
| GO:BP | GO:0001174 | transcriptional start site selection at RNA polymerase II promoter | 1 | 2 | 2.73e-01 |
| GO:BP | GO:0045197 | establishment or maintenance of epithelial cell apical/basal polarity | 1 | 47 | 2.75e-01 |
| GO:BP | GO:1902165 | regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 6 | 17 | 2.75e-01 |
| GO:BP | GO:1904505 | regulation of telomere maintenance in response to DNA damage | 6 | 17 | 2.75e-01 |
| GO:BP | GO:0006404 | RNA import into nucleus | 2 | 4 | 2.75e-01 |
| GO:BP | GO:0000291 | nuclear-transcribed mRNA catabolic process, exonucleolytic | 7 | 19 | 2.75e-01 |
| GO:BP | GO:1905786 | positive regulation of anaphase-promoting complex-dependent catabolic process | 2 | 2 | 2.75e-01 |
| GO:BP | GO:0006309 | apoptotic DNA fragmentation | 1 | 13 | 2.75e-01 |
| GO:BP | GO:0062033 | positive regulation of mitotic sister chromatid segregation | 2 | 6 | 2.75e-01 |
| GO:BP | GO:0006303 | double-strand break repair via nonhomologous end joining | 13 | 61 | 2.75e-01 |
| GO:BP | GO:0050732 | negative regulation of peptidyl-tyrosine phosphorylation | 1 | 46 | 2.75e-01 |
| GO:BP | GO:0032055 | negative regulation of translation in response to stress | 2 | 4 | 2.75e-01 |
| GO:BP | GO:0006043 | glucosamine catabolic process | 2 | 2 | 2.75e-01 |
| GO:BP | GO:0050893 | sensory processing | 2 | 4 | 2.75e-01 |
| GO:BP | GO:0019348 | dolichol metabolic process | 2 | 22 | 2.75e-01 |
| GO:BP | GO:0051890 | regulation of cardioblast differentiation | 2 | 5 | 2.75e-01 |
| GO:BP | GO:0032786 | positive regulation of DNA-templated transcription, elongation | 16 | 58 | 2.75e-01 |
| GO:BP | GO:0002543 | activation of blood coagulation via clotting cascade | 1 | 2 | 2.75e-01 |
| GO:BP | GO:0043370 | regulation of CD4-positive, alpha-beta T cell differentiation | 1 | 27 | 2.76e-01 |
| GO:BP | GO:1905143 | eukaryotic translation initiation factor 2 complex assembly | 1 | 1 | 2.77e-01 |
| GO:BP | GO:0010518 | positive regulation of phospholipase activity | 1 | 27 | 2.78e-01 |
| GO:BP | GO:0045184 | establishment of protein localization | 7 | 1462 | 2.78e-01 |
| GO:BP | GO:0001919 | regulation of receptor recycling | 1 | 19 | 2.78e-01 |
| GO:BP | GO:0043574 | peroxisomal transport | 2 | 22 | 2.78e-01 |
| GO:BP | GO:2000134 | negative regulation of G1/S transition of mitotic cell cycle | 9 | 64 | 2.79e-01 |
| GO:BP | GO:0034311 | diol metabolic process | 3 | 26 | 2.79e-01 |
| GO:BP | GO:0043153 | entrainment of circadian clock by photoperiod | 5 | 27 | 2.79e-01 |
| GO:BP | GO:0098813 | nuclear chromosome segregation | 34 | 273 | 2.79e-01 |
| GO:BP | GO:1904925 | positive regulation of autophagy of mitochondrion in response to mitochondrial depolarization | 1 | 14 | 2.79e-01 |
| GO:BP | GO:0046328 | regulation of JNK cascade | 16 | 114 | 2.79e-01 |
| GO:BP | GO:0002711 | positive regulation of T cell mediated immunity | 1 | 29 | 2.79e-01 |
| GO:BP | GO:1904262 | negative regulation of TORC1 signaling | 7 | 24 | 2.79e-01 |
| GO:BP | GO:0001954 | positive regulation of cell-matrix adhesion | 1 | 44 | 2.79e-01 |
| GO:BP | GO:0006693 | prostaglandin metabolic process | 1 | 32 | 2.79e-01 |
| GO:BP | GO:0006692 | prostanoid metabolic process | 1 | 32 | 2.79e-01 |
| GO:BP | GO:0021595 | rhombomere structural organization | 1 | 1 | 2.79e-01 |
| GO:BP | GO:0021594 | rhombomere formation | 1 | 1 | 2.79e-01 |
| GO:BP | GO:1901525 | negative regulation of mitophagy | 2 | 6 | 2.79e-01 |
| GO:BP | GO:0021659 | rhombomere 3 structural organization | 1 | 1 | 2.79e-01 |
| GO:BP | GO:0021660 | rhombomere 3 formation | 1 | 1 | 2.79e-01 |
| GO:BP | GO:0021998 | neural plate mediolateral regionalization | 1 | 1 | 2.79e-01 |
| GO:BP | GO:1901620 | regulation of smoothened signaling pathway involved in dorsal/ventral neural tube patterning | 1 | 12 | 2.79e-01 |
| GO:BP | GO:0032446 | protein modification by small protein conjugation | 64 | 787 | 2.79e-01 |
| GO:BP | GO:0021664 | rhombomere 5 morphogenesis | 1 | 1 | 2.79e-01 |
| GO:BP | GO:0021665 | rhombomere 5 structural organization | 1 | 1 | 2.79e-01 |
| GO:BP | GO:0031453 | positive regulation of heterochromatin formation | 5 | 15 | 2.79e-01 |
| GO:BP | GO:0031627 | telomeric loop formation | 1 | 2 | 2.79e-01 |
| GO:BP | GO:0032069 | regulation of nuclease activity | 1 | 17 | 2.79e-01 |
| GO:BP | GO:0021666 | rhombomere 5 formation | 1 | 1 | 2.79e-01 |
| GO:BP | GO:1905285 | fibrous ring of heart morphogenesis | 1 | 1 | 2.79e-01 |
| GO:BP | GO:0048338 | mesoderm structural organization | 1 | 1 | 2.79e-01 |
| GO:BP | GO:0048372 | lateral mesodermal cell fate commitment | 1 | 1 | 2.79e-01 |
| GO:BP | GO:0120263 | positive regulation of heterochromatin organization | 5 | 15 | 2.79e-01 |
| GO:BP | GO:1905179 | negative regulation of cardiac muscle tissue regeneration | 2 | 2 | 2.79e-01 |
| GO:BP | GO:1903322 | positive regulation of protein modification by small protein conjugation or removal | 18 | 126 | 2.79e-01 |
| GO:BP | GO:0006175 | dATP biosynthetic process | 1 | 1 | 2.79e-01 |
| GO:BP | GO:0009202 | deoxyribonucleoside triphosphate biosynthetic process | 1 | 1 | 2.79e-01 |
| GO:BP | GO:0048352 | paraxial mesoderm structural organization | 1 | 1 | 2.79e-01 |
| GO:BP | GO:0032613 | interleukin-10 production | 1 | 24 | 2.79e-01 |
| GO:BP | GO:1904923 | regulation of autophagy of mitochondrion in response to mitochondrial depolarization | 1 | 15 | 2.79e-01 |
| GO:BP | GO:0009216 | purine deoxyribonucleoside triphosphate biosynthetic process | 1 | 1 | 2.79e-01 |
| GO:BP | GO:0046761 | viral budding from plasma membrane | 4 | 13 | 2.79e-01 |
| GO:BP | GO:0035088 | establishment or maintenance of apical/basal cell polarity | 1 | 50 | 2.79e-01 |
| GO:BP | GO:1990822 | basic amino acid transmembrane transport | 4 | 14 | 2.79e-01 |
| GO:BP | GO:0002352 | B cell negative selection | 2 | 2 | 2.79e-01 |
| GO:BP | GO:1904748 | regulation of apoptotic process involved in development | 4 | 9 | 2.79e-01 |
| GO:BP | GO:0046068 | cGMP metabolic process | 1 | 11 | 2.79e-01 |
| GO:BP | GO:0035493 | SNARE complex assembly | 1 | 22 | 2.79e-01 |
| GO:BP | GO:0045732 | positive regulation of protein catabolic process | 44 | 192 | 2.79e-01 |
| GO:BP | GO:1990079 | cartilage homeostasis | 1 | 2 | 2.79e-01 |
| GO:BP | GO:0010389 | regulation of G2/M transition of mitotic cell cycle | 23 | 92 | 2.79e-01 |
| GO:BP | GO:1904668 | positive regulation of ubiquitin protein ligase activity | 4 | 13 | 2.79e-01 |
| GO:BP | GO:0010506 | regulation of autophagy | 39 | 313 | 2.79e-01 |
| GO:BP | GO:1904412 | regulation of cardiac ventricle development | 1 | 1 | 2.79e-01 |
| GO:BP | GO:1904414 | positive regulation of cardiac ventricle development | 1 | 1 | 2.79e-01 |
| GO:BP | GO:0006436 | tryptophanyl-tRNA aminoacylation | 1 | 2 | 2.79e-01 |
| GO:BP | GO:0044770 | cell cycle phase transition | 53 | 504 | 2.79e-01 |
| GO:BP | GO:0048378 | regulation of lateral mesodermal cell fate specification | 1 | 1 | 2.79e-01 |
| GO:BP | GO:0048377 | lateral mesodermal cell fate specification | 1 | 1 | 2.79e-01 |
| GO:BP | GO:0009119 | ribonucleoside metabolic process | 1 | 23 | 2.79e-01 |
| GO:BP | GO:0000723 | telomere maintenance | 17 | 142 | 2.79e-01 |
| GO:BP | GO:0061245 | establishment or maintenance of bipolar cell polarity | 1 | 50 | 2.79e-01 |
| GO:BP | GO:0061197 | fungiform papilla morphogenesis | 1 | 4 | 2.79e-01 |
| GO:BP | GO:0032653 | regulation of interleukin-10 production | 1 | 24 | 2.79e-01 |
| GO:BP | GO:0072659 | protein localization to plasma membrane | 2 | 249 | 2.79e-01 |
| GO:BP | GO:0006636 | unsaturated fatty acid biosynthetic process | 1 | 34 | 2.79e-01 |
| GO:BP | GO:0072662 | protein localization to peroxisome | 1 | 19 | 2.79e-01 |
| GO:BP | GO:0072663 | establishment of protein localization to peroxisome | 1 | 19 | 2.79e-01 |
| GO:BP | GO:0006625 | protein targeting to peroxisome | 1 | 19 | 2.79e-01 |
| GO:BP | GO:1905178 | regulation of cardiac muscle tissue regeneration | 2 | 2 | 2.79e-01 |
| GO:BP | GO:0033157 | regulation of intracellular protein transport | 1 | 197 | 2.79e-01 |
| GO:BP | GO:1902337 | regulation of apoptotic process involved in morphogenesis | 4 | 9 | 2.79e-01 |
| GO:BP | GO:0060296 | regulation of cilium beat frequency involved in ciliary motility | 3 | 6 | 2.79e-01 |
| GO:BP | GO:0010638 | positive regulation of organelle organization | 49 | 439 | 2.79e-01 |
| GO:BP | GO:0051797 | regulation of hair follicle development | 3 | 16 | 2.79e-01 |
| GO:BP | GO:0033048 | negative regulation of mitotic sister chromatid segregation | 8 | 47 | 2.79e-01 |
| GO:BP | GO:0001977 | renal system process involved in regulation of blood volume | 2 | 9 | 2.79e-01 |
| GO:BP | GO:1902766 | skeletal muscle satellite cell migration | 1 | 2 | 2.79e-01 |
| GO:BP | GO:0033046 | negative regulation of sister chromatid segregation | 8 | 47 | 2.79e-01 |
| GO:BP | GO:0016093 | polyprenol metabolic process | 2 | 23 | 2.79e-01 |
| GO:BP | GO:2000816 | negative regulation of mitotic sister chromatid separation | 8 | 47 | 2.79e-01 |
| GO:BP | GO:0042488 | positive regulation of odontogenesis of dentin-containing tooth | 1 | 2 | 2.79e-01 |
| GO:BP | GO:0008217 | regulation of blood pressure | 2 | 115 | 2.79e-01 |
| GO:BP | GO:0007033 | vacuole organization | 45 | 197 | 2.79e-01 |
| GO:BP | GO:0140438 | protein stearoylation | 1 | 1 | 2.80e-01 |
| GO:BP | GO:0097120 | receptor localization to synapse | 1 | 55 | 2.80e-01 |
| GO:BP | GO:0140056 | organelle localization by membrane tethering | 6 | 74 | 2.80e-01 |
| GO:BP | GO:0003376 | sphingosine-1-phosphate receptor signaling pathway | 5 | 10 | 2.80e-01 |
| GO:BP | GO:0140157 | ammonium import across plasma membrane | 2 | 3 | 2.80e-01 |
| GO:BP | GO:0097240 | chromosome attachment to the nuclear envelope | 2 | 3 | 2.80e-01 |
| GO:BP | GO:0072657 | protein localization to membrane | 3 | 523 | 2.80e-01 |
| GO:BP | GO:0120032 | regulation of plasma membrane bounded cell projection assembly | 3 | 165 | 2.80e-01 |
| GO:BP | GO:0090176 | microtubule cytoskeleton organization involved in establishment of planar polarity | 2 | 3 | 2.80e-01 |
| GO:BP | GO:0099518 | vesicle cytoskeletal trafficking | 1 | 60 | 2.80e-01 |
| GO:BP | GO:1900076 | regulation of cellular response to insulin stimulus | 1 | 56 | 2.80e-01 |
| GO:BP | GO:0086066 | atrial cardiac muscle cell to AV node cell communication | 3 | 17 | 2.80e-01 |
| GO:BP | GO:0086054 | bundle of His cell to Purkinje myocyte communication by electrical coupling | 1 | 2 | 2.80e-01 |
| GO:BP | GO:0086043 | bundle of His cell action potential | 2 | 6 | 2.80e-01 |
| GO:BP | GO:0086028 | bundle of His cell to Purkinje myocyte signaling | 2 | 6 | 2.80e-01 |
| GO:BP | GO:0086026 | atrial cardiac muscle cell to AV node cell signaling | 3 | 17 | 2.80e-01 |
| GO:BP | GO:0086021 | SA node cell to atrial cardiac muscle cell communication by electrical coupling | 1 | 2 | 2.80e-01 |
| GO:BP | GO:0086014 | atrial cardiac muscle cell action potential | 3 | 17 | 2.80e-01 |
| GO:BP | GO:0098905 | regulation of bundle of His cell action potential | 1 | 2 | 2.80e-01 |
| GO:BP | GO:0006308 | DNA catabolic process | 1 | 19 | 2.80e-01 |
| GO:BP | GO:0045786 | negative regulation of cell cycle | 38 | 338 | 2.80e-01 |
| GO:BP | GO:0099123 | somato-dendritic dopamine secretion | 1 | 1 | 2.80e-01 |
| GO:BP | GO:0003193 | pulmonary valve formation | 1 | 2 | 2.80e-01 |
| GO:BP | GO:0032471 | negative regulation of endoplasmic reticulum calcium ion concentration | 4 | 9 | 2.80e-01 |
| GO:BP | GO:0002552 | serotonin secretion by mast cell | 1 | 1 | 2.80e-01 |
| GO:BP | GO:0046753 | non-lytic viral release | 6 | 14 | 2.80e-01 |
| GO:BP | GO:0046635 | positive regulation of alpha-beta T cell activation | 1 | 36 | 2.80e-01 |
| GO:BP | GO:0046626 | regulation of insulin receptor signaling pathway | 1 | 53 | 2.80e-01 |
| GO:BP | GO:0046514 | ceramide catabolic process | 3 | 16 | 2.80e-01 |
| GO:BP | GO:0046456 | icosanoid biosynthetic process | 1 | 29 | 2.80e-01 |
| GO:BP | GO:0002294 | CD4-positive, alpha-beta T cell differentiation involved in immune response | 1 | 40 | 2.80e-01 |
| GO:BP | GO:0015878 | biotin transport | 2 | 3 | 2.80e-01 |
| GO:BP | GO:0010243 | response to organonitrogen compound | 4 | 782 | 2.80e-01 |
| GO:BP | GO:0010517 | regulation of phospholipase activity | 1 | 37 | 2.80e-01 |
| GO:BP | GO:0032456 | endocytic recycling | 4 | 80 | 2.80e-01 |
| GO:BP | GO:0036515 | serotonergic neuron axon guidance | 2 | 2 | 2.80e-01 |
| GO:BP | GO:0043968 | histone H2A acetylation | 3 | 22 | 2.80e-01 |
| GO:BP | GO:0043634 | polyadenylation-dependent ncRNA catabolic process | 4 | 8 | 2.80e-01 |
| GO:BP | GO:0033140 | negative regulation of peptidyl-serine phosphorylation of STAT protein | 1 | 3 | 2.80e-01 |
| GO:BP | GO:0032790 | ribosome disassembly | 4 | 11 | 2.80e-01 |
| GO:BP | GO:1904896 | ESCRT complex disassembly | 3 | 10 | 2.80e-01 |
| GO:BP | GO:1904903 | ESCRT III complex disassembly | 3 | 10 | 2.80e-01 |
| GO:BP | GO:0043201 | response to leucine | 4 | 13 | 2.80e-01 |
| GO:BP | GO:0043124 | negative regulation of I-kappaB kinase/NF-kappaB signaling | 8 | 36 | 2.80e-01 |
| GO:BP | GO:0042093 | T-helper cell differentiation | 1 | 40 | 2.80e-01 |
| GO:BP | GO:0010866 | regulation of triglyceride biosynthetic process | 3 | 19 | 2.80e-01 |
| GO:BP | GO:0042752 | regulation of circadian rhythm | 8 | 97 | 2.80e-01 |
| GO:BP | GO:0010643 | cell communication by chemical coupling | 1 | 2 | 2.80e-01 |
| GO:BP | GO:0050927 | positive regulation of positive chemotaxis | 2 | 20 | 2.80e-01 |
| GO:BP | GO:0042137 | sequestering of neurotransmitter | 1 | 1 | 2.80e-01 |
| GO:BP | GO:0014810 | positive regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion | 1 | 1 | 2.80e-01 |
| GO:BP | GO:0033609 | oxalate metabolic process | 1 | 1 | 2.80e-01 |
| GO:BP | GO:0060612 | adipose tissue development | 7 | 41 | 2.80e-01 |
| GO:BP | GO:0060193 | positive regulation of lipase activity | 1 | 34 | 2.80e-01 |
| GO:BP | GO:0060831 | smoothened signaling pathway involved in dorsal/ventral neural tube patterning | 1 | 14 | 2.80e-01 |
| GO:BP | GO:0022411 | cellular component disassembly | 3 | 427 | 2.80e-01 |
| GO:BP | GO:0007010 | cytoskeleton organization | 10 | 1226 | 2.80e-01 |
| GO:BP | GO:0060058 | positive regulation of apoptotic process involved in mammary gland involution | 2 | 3 | 2.80e-01 |
| GO:BP | GO:0060057 | apoptotic process involved in mammary gland involution | 2 | 3 | 2.80e-01 |
| GO:BP | GO:1902749 | regulation of cell cycle G2/M phase transition | 25 | 103 | 2.80e-01 |
| GO:BP | GO:0003174 | mitral valve development | 2 | 12 | 2.80e-01 |
| GO:BP | GO:0032007 | negative regulation of TOR signaling | 11 | 47 | 2.80e-01 |
| GO:BP | GO:0070255 | regulation of mucus secretion | 2 | 6 | 2.80e-01 |
| GO:BP | GO:0060491 | regulation of cell projection assembly | 3 | 167 | 2.80e-01 |
| GO:BP | GO:0002293 | alpha-beta T cell differentiation involved in immune response | 1 | 40 | 2.80e-01 |
| GO:BP | GO:0000076 | DNA replication checkpoint signaling | 4 | 15 | 2.80e-01 |
| GO:BP | GO:0002287 | alpha-beta T cell activation involved in immune response | 1 | 40 | 2.80e-01 |
| GO:BP | GO:0046637 | regulation of alpha-beta T cell differentiation | 1 | 38 | 2.80e-01 |
| GO:BP | GO:0016575 | histone deacetylation | 19 | 87 | 2.80e-01 |
| GO:BP | GO:0034497 | protein localization to phagophore assembly site | 1 | 17 | 2.80e-01 |
| GO:BP | GO:0016570 | histone modification | 23 | 433 | 2.81e-01 |
| GO:BP | GO:0070254 | mucus secretion | 5 | 8 | 2.82e-01 |
| GO:BP | GO:0048280 | vesicle fusion with Golgi apparatus | 2 | 8 | 2.82e-01 |
| GO:BP | GO:1904507 | positive regulation of telomere maintenance in response to DNA damage | 5 | 14 | 2.82e-01 |
| GO:BP | GO:0046329 | negative regulation of JNK cascade | 4 | 36 | 2.84e-01 |
| GO:BP | GO:0050926 | regulation of positive chemotaxis | 2 | 20 | 2.84e-01 |
| GO:BP | GO:1901304 | regulation of spermidine biosynthetic process | 1 | 1 | 2.84e-01 |
| GO:BP | GO:2000679 | positive regulation of transcription regulatory region DNA binding | 3 | 18 | 2.84e-01 |
| GO:BP | GO:1901307 | positive regulation of spermidine biosynthetic process | 1 | 1 | 2.84e-01 |
| GO:BP | GO:0002072 | optic cup morphogenesis involved in camera-type eye development | 1 | 4 | 2.84e-01 |
| GO:BP | GO:0043629 | ncRNA polyadenylation | 2 | 2 | 2.84e-01 |
| GO:BP | GO:0072656 | maintenance of protein location in mitochondrion | 2 | 5 | 2.84e-01 |
| GO:BP | GO:0010948 | negative regulation of cell cycle process | 29 | 273 | 2.84e-01 |
| GO:BP | GO:2001252 | positive regulation of chromosome organization | 24 | 103 | 2.84e-01 |
| GO:BP | GO:0061196 | fungiform papilla development | 1 | 5 | 2.84e-01 |
| GO:BP | GO:0060789 | hair follicle placode formation | 1 | 5 | 2.84e-01 |
| GO:BP | GO:0007341 | penetration of zona pellucida | 1 | 4 | 2.84e-01 |
| GO:BP | GO:1903896 | positive regulation of IRE1-mediated unfolded protein response | 4 | 7 | 2.84e-01 |
| GO:BP | GO:0035813 | regulation of renal sodium excretion | 1 | 10 | 2.84e-01 |
| GO:BP | GO:0045070 | positive regulation of viral genome replication | 3 | 28 | 2.84e-01 |
| GO:BP | GO:0006170 | dAMP biosynthetic process | 2 | 3 | 2.85e-01 |
| GO:BP | GO:0106381 | purine deoxyribonucleotide salvage | 2 | 3 | 2.85e-01 |
| GO:BP | GO:0009171 | purine deoxyribonucleoside monophosphate biosynthetic process | 2 | 3 | 2.85e-01 |
| GO:BP | GO:0051301 | cell division | 56 | 570 | 2.85e-01 |
| GO:BP | GO:0106383 | dAMP salvage | 2 | 3 | 2.85e-01 |
| GO:BP | GO:2000514 | regulation of CD4-positive, alpha-beta T cell activation | 1 | 39 | 2.85e-01 |
| GO:BP | GO:0045931 | positive regulation of mitotic cell cycle | 15 | 113 | 2.85e-01 |
| GO:BP | GO:0002084 | protein depalmitoylation | 1 | 10 | 2.85e-01 |
| GO:BP | GO:1904628 | cellular response to phorbol 13-acetate 12-myristate | 3 | 4 | 2.85e-01 |
| GO:BP | GO:1904627 | response to phorbol 13-acetate 12-myristate | 3 | 4 | 2.85e-01 |
| GO:BP | GO:0045687 | positive regulation of glial cell differentiation | 4 | 28 | 2.85e-01 |
| GO:BP | GO:0032205 | negative regulation of telomere maintenance | 6 | 33 | 2.85e-01 |
| GO:BP | GO:0007017 | microtubule-based process | 5 | 760 | 2.85e-01 |
| GO:BP | GO:1901523 | icosanoid catabolic process | 1 | 2 | 2.85e-01 |
| GO:BP | GO:1901255 | nucleotide-excision repair involved in interstrand cross-link repair | 2 | 2 | 2.85e-01 |
| GO:BP | GO:0042981 | regulation of apoptotic process | 5 | 1088 | 2.85e-01 |
| GO:BP | GO:0032880 | regulation of protein localization | 2 | 710 | 2.86e-01 |
| GO:BP | GO:0030262 | apoptotic nuclear changes | 1 | 20 | 2.87e-01 |
| GO:BP | GO:0015858 | nucleoside transport | 2 | 8 | 2.87e-01 |
| GO:BP | GO:0034453 | microtubule anchoring | 1 | 25 | 2.87e-01 |
| GO:BP | GO:0015727 | lactate transport | 2 | 5 | 2.87e-01 |
| GO:BP | GO:0090501 | RNA phosphodiester bond hydrolysis | 1 | 136 | 2.87e-01 |
| GO:BP | GO:1990390 | protein K33-linked ubiquitination | 1 | 2 | 2.87e-01 |
| GO:BP | GO:0006863 | purine nucleobase transport | 2 | 7 | 2.87e-01 |
| GO:BP | GO:0061517 | macrophage proliferation | 3 | 7 | 2.87e-01 |
| GO:BP | GO:0060382 | regulation of DNA strand elongation | 6 | 16 | 2.87e-01 |
| GO:BP | GO:0072698 | protein localization to microtubule cytoskeleton | 1 | 52 | 2.87e-01 |
| GO:BP | GO:0002720 | positive regulation of cytokine production involved in immune response | 1 | 49 | 2.87e-01 |
| GO:BP | GO:0051497 | negative regulation of stress fiber assembly | 2 | 23 | 2.87e-01 |
| GO:BP | GO:1903147 | negative regulation of autophagy of mitochondrion | 2 | 7 | 2.87e-01 |
| GO:BP | GO:0009190 | cyclic nucleotide biosynthetic process | 1 | 14 | 2.87e-01 |
| GO:BP | GO:0002541 | activation of plasma proteins involved in acute inflammatory response | 1 | 2 | 2.87e-01 |
| GO:BP | GO:0002292 | T cell differentiation involved in immune response | 1 | 42 | 2.87e-01 |
| GO:BP | GO:0006418 | tRNA aminoacylation for protein translation | 3 | 40 | 2.87e-01 |
| GO:BP | GO:0071044 | histone mRNA catabolic process | 3 | 11 | 2.87e-01 |
| GO:BP | GO:0043587 | tongue morphogenesis | 4 | 7 | 2.87e-01 |
| GO:BP | GO:0043066 | negative regulation of apoptotic process | 2 | 660 | 2.87e-01 |
| GO:BP | GO:0039702 | viral budding via host ESCRT complex | 5 | 22 | 2.87e-01 |
| GO:BP | GO:0038202 | TORC1 signaling | 9 | 58 | 2.87e-01 |
| GO:BP | GO:0036245 | cellular response to menadione | 2 | 2 | 2.87e-01 |
| GO:BP | GO:0035873 | lactate transmembrane transport | 2 | 5 | 2.87e-01 |
| GO:BP | GO:0006002 | fructose 6-phosphate metabolic process | 2 | 8 | 2.87e-01 |
| GO:BP | GO:0120031 | plasma membrane bounded cell projection assembly | 5 | 461 | 2.87e-01 |
| GO:BP | GO:0035809 | regulation of urine volume | 1 | 14 | 2.87e-01 |
| GO:BP | GO:0097400 | interleukin-17-mediated signaling pathway | 2 | 8 | 2.87e-01 |
| GO:BP | GO:0006012 | galactose metabolic process | 1 | 9 | 2.87e-01 |
| GO:BP | GO:0035418 | protein localization to synapse | 1 | 68 | 2.87e-01 |
| GO:BP | GO:0061384 | heart trabecula morphogenesis | 3 | 29 | 2.87e-01 |
| GO:BP | GO:0006457 | protein folding | 2 | 192 | 2.88e-01 |
| GO:BP | GO:0030949 | positive regulation of vascular endothelial growth factor receptor signaling pathway | 3 | 13 | 2.88e-01 |
| GO:BP | GO:0051899 | membrane depolarization | 1 | 60 | 2.88e-01 |
| GO:BP | GO:0035812 | renal sodium excretion | 1 | 11 | 2.88e-01 |
| GO:BP | GO:0007096 | regulation of exit from mitosis | 3 | 17 | 2.88e-01 |
| GO:BP | GO:0045654 | positive regulation of megakaryocyte differentiation | 1 | 9 | 2.88e-01 |
| GO:BP | GO:0035520 | monoubiquitinated protein deubiquitination | 2 | 36 | 2.89e-01 |
| GO:BP | GO:0070647 | protein modification by small protein conjugation or removal | 87 | 898 | 2.89e-01 |
| GO:BP | GO:0043069 | negative regulation of programmed cell death | 2 | 678 | 2.90e-01 |
| GO:BP | GO:0044062 | regulation of excretion | 1 | 12 | 2.91e-01 |
| GO:BP | GO:0090341 | negative regulation of secretion of lysosomal enzymes | 1 | 1 | 2.91e-01 |
| GO:BP | GO:0003085 | negative regulation of systemic arterial blood pressure | 1 | 14 | 2.91e-01 |
| GO:BP | GO:0010332 | response to gamma radiation | 13 | 50 | 2.91e-01 |
| GO:BP | GO:0090110 | COPII-coated vesicle cargo loading | 5 | 15 | 2.91e-01 |
| GO:BP | GO:0043067 | regulation of programmed cell death | 5 | 1111 | 2.91e-01 |
| GO:BP | GO:1901698 | response to nitrogen compound | 4 | 830 | 2.91e-01 |
| GO:BP | GO:0031468 | nuclear membrane reassembly | 8 | 24 | 2.91e-01 |
| GO:BP | GO:1905269 | positive regulation of chromatin organization | 5 | 15 | 2.91e-01 |
| GO:BP | GO:1903716 | guanine transmembrane transport | 1 | 1 | 2.91e-01 |
| GO:BP | GO:0006921 | cellular component disassembly involved in execution phase of apoptosis | 1 | 22 | 2.91e-01 |
| GO:BP | GO:0098780 | response to mitochondrial depolarisation | 1 | 21 | 2.91e-01 |
| GO:BP | GO:0051782 | negative regulation of cell division | 4 | 15 | 2.91e-01 |
| GO:BP | GO:0032386 | regulation of intracellular transport | 1 | 292 | 2.91e-01 |
| GO:BP | GO:0002709 | regulation of T cell mediated immunity | 1 | 39 | 2.91e-01 |
| GO:BP | GO:0051050 | positive regulation of transport | 2 | 667 | 2.91e-01 |
| GO:BP | GO:0032482 | Rab protein signal transduction | 4 | 19 | 2.91e-01 |
| GO:BP | GO:0046053 | dAMP metabolic process | 3 | 5 | 2.91e-01 |
| GO:BP | GO:0048636 | positive regulation of muscle organ development | 2 | 3 | 2.91e-01 |
| GO:BP | GO:1902099 | regulation of metaphase/anaphase transition of cell cycle | 12 | 89 | 2.91e-01 |
| GO:BP | GO:0045844 | positive regulation of striated muscle tissue development | 2 | 3 | 2.91e-01 |
| GO:BP | GO:0034402 | recruitment of 3’-end processing factors to RNA polymerase II holoenzyme complex | 1 | 2 | 2.91e-01 |
| GO:BP | GO:0048144 | fibroblast proliferation | 24 | 92 | 2.91e-01 |
| GO:BP | GO:0030031 | cell projection assembly | 5 | 469 | 2.92e-01 |
| GO:BP | GO:0044380 | protein localization to cytoskeleton | 1 | 55 | 2.92e-01 |
| GO:BP | GO:0032933 | SREBP signaling pathway | 1 | 14 | 2.92e-01 |
| GO:BP | GO:0080135 | regulation of cellular response to stress | 64 | 616 | 2.92e-01 |
| GO:BP | GO:0090199 | regulation of release of cytochrome c from mitochondria | 13 | 39 | 2.92e-01 |
| GO:BP | GO:0051668 | localization within membrane | 3 | 605 | 2.92e-01 |
| GO:BP | GO:0070933 | histone H4 deacetylation | 1 | 7 | 2.92e-01 |
| GO:BP | GO:0060191 | regulation of lipase activity | 1 | 52 | 2.92e-01 |
| GO:BP | GO:0042147 | retrograde transport, endosome to Golgi | 20 | 88 | 2.92e-01 |
| GO:BP | GO:0036297 | interstrand cross-link repair | 6 | 37 | 2.92e-01 |
| GO:BP | GO:0072396 | response to cell cycle checkpoint signaling | 2 | 8 | 2.92e-01 |
| GO:BP | GO:0072423 | response to DNA damage checkpoint signaling | 2 | 8 | 2.92e-01 |
| GO:BP | GO:0072402 | response to DNA integrity checkpoint signaling | 2 | 8 | 2.92e-01 |
| GO:BP | GO:0006228 | UTP biosynthetic process | 3 | 8 | 2.92e-01 |
| GO:BP | GO:0055008 | cardiac muscle tissue morphogenesis | 4 | 54 | 2.92e-01 |
| GO:BP | GO:2000601 | positive regulation of Arp2/3 complex-mediated actin nucleation | 1 | 9 | 2.92e-01 |
| GO:BP | GO:1902846 | positive regulation of mitotic spindle elongation | 1 | 1 | 2.92e-01 |
| GO:BP | GO:2000045 | regulation of G1/S transition of mitotic cell cycle | 15 | 149 | 2.92e-01 |
| GO:BP | GO:0018009 | N-terminal peptidyl-L-cysteine N-palmitoylation | 1 | 2 | 2.92e-01 |
| GO:BP | GO:0051346 | negative regulation of hydrolase activity | 2 | 220 | 2.92e-01 |
| GO:BP | GO:0051084 | ‘de novo’ post-translational protein folding | 3 | 35 | 2.92e-01 |
| GO:BP | GO:0032510 | endosome to lysosome transport via multivesicular body sorting pathway | 4 | 17 | 2.92e-01 |
| GO:BP | GO:0034391 | regulation of smooth muscle cell apoptotic process | 1 | 15 | 2.92e-01 |
| GO:BP | GO:0015802 | basic amino acid transport | 4 | 17 | 2.92e-01 |
| GO:BP | GO:1902363 | regulation of protein localization to spindle pole body | 1 | 1 | 2.92e-01 |
| GO:BP | GO:0055048 | anastral spindle assembly | 1 | 1 | 2.92e-01 |
| GO:BP | GO:0034390 | smooth muscle cell apoptotic process | 1 | 15 | 2.92e-01 |
| GO:BP | GO:1902410 | mitotic cytokinetic process | 5 | 23 | 2.92e-01 |
| GO:BP | GO:2001242 | regulation of intrinsic apoptotic signaling pathway | 28 | 147 | 2.92e-01 |
| GO:BP | GO:0032887 | regulation of spindle elongation | 1 | 1 | 2.92e-01 |
| GO:BP | GO:1902365 | positive regulation of protein localization to spindle pole body | 1 | 1 | 2.92e-01 |
| GO:BP | GO:0033484 | intracellular nitric oxide homeostasis | 2 | 3 | 2.92e-01 |
| GO:BP | GO:0033262 | regulation of nuclear cell cycle DNA replication | 3 | 11 | 2.92e-01 |
| GO:BP | GO:0032888 | regulation of mitotic spindle elongation | 1 | 1 | 2.92e-01 |
| GO:BP | GO:0016233 | telomere capping | 7 | 36 | 2.92e-01 |
| GO:BP | GO:2000587 | negative regulation of platelet-derived growth factor receptor-beta signaling pathway | 2 | 4 | 2.92e-01 |
| GO:BP | GO:0033036 | macromolecule localization | 9 | 2450 | 2.92e-01 |
| GO:BP | GO:0046520 | sphingoid biosynthetic process | 2 | 13 | 2.92e-01 |
| GO:BP | GO:0051036 | regulation of endosome size | 2 | 13 | 2.92e-01 |
| GO:BP | GO:0003222 | ventricular trabecula myocardium morphogenesis | 2 | 12 | 2.92e-01 |
| GO:BP | GO:1904385 | cellular response to angiotensin | 1 | 23 | 2.92e-01 |
| GO:BP | GO:1902226 | regulation of macrophage colony-stimulating factor signaling pathway | 2 | 2 | 2.92e-01 |
| GO:BP | GO:0007007 | inner mitochondrial membrane organization | 1 | 40 | 2.92e-01 |
| GO:BP | GO:0062044 | negative regulation of cardiac epithelial to mesenchymal transition | 1 | 2 | 2.92e-01 |
| GO:BP | GO:0009177 | pyrimidine deoxyribonucleoside monophosphate biosynthetic process | 2 | 4 | 2.92e-01 |
| GO:BP | GO:0010457 | centriole-centriole cohesion | 1 | 14 | 2.92e-01 |
| GO:BP | GO:1901668 | regulation of superoxide dismutase activity | 1 | 4 | 2.92e-01 |
| GO:BP | GO:0045741 | positive regulation of epidermal growth factor-activated receptor activity | 2 | 8 | 2.92e-01 |
| GO:BP | GO:0046039 | GTP metabolic process | 5 | 21 | 2.92e-01 |
| GO:BP | GO:0046060 | dATP metabolic process | 2 | 3 | 2.92e-01 |
| GO:BP | GO:0061519 | macrophage homeostasis | 1 | 3 | 2.92e-01 |
| GO:BP | GO:0009648 | photoperiodism | 5 | 28 | 2.92e-01 |
| GO:BP | GO:0046488 | phosphatidylinositol metabolic process | 31 | 140 | 2.92e-01 |
| GO:BP | GO:0046512 | sphingosine biosynthetic process | 2 | 13 | 2.92e-01 |
| GO:BP | GO:0048102 | autophagic cell death | 2 | 6 | 2.92e-01 |
| GO:BP | GO:0002192 | IRES-dependent translational initiation of linear mRNA | 1 | 1 | 2.92e-01 |
| GO:BP | GO:0044565 | dendritic cell proliferation | 2 | 3 | 2.92e-01 |
| GO:BP | GO:0048548 | regulation of pinocytosis | 3 | 11 | 2.92e-01 |
| GO:BP | GO:0035284 | brain segmentation | 2 | 2 | 2.92e-01 |
| GO:BP | GO:1990778 | protein localization to cell periphery | 2 | 300 | 2.92e-01 |
| GO:BP | GO:0035364 | thymine transport | 1 | 1 | 2.92e-01 |
| GO:BP | GO:0035702 | monocyte homeostasis | 1 | 2 | 2.92e-01 |
| GO:BP | GO:0035732 | nitric oxide storage | 1 | 1 | 2.92e-01 |
| GO:BP | GO:0071501 | cellular response to sterol depletion | 1 | 14 | 2.92e-01 |
| GO:BP | GO:1905784 | regulation of anaphase-promoting complex-dependent catabolic process | 1 | 4 | 2.92e-01 |
| GO:BP | GO:0071076 | RNA 3’ uridylation | 3 | 4 | 2.92e-01 |
| GO:BP | GO:0042159 | lipoprotein catabolic process | 3 | 14 | 2.92e-01 |
| GO:BP | GO:0042311 | vasodilation | 3 | 39 | 2.92e-01 |
| GO:BP | GO:0060341 | regulation of cellular localization | 2 | 798 | 2.92e-01 |
| GO:BP | GO:1902230 | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage | 7 | 29 | 2.92e-01 |
| GO:BP | GO:1905006 | negative regulation of epithelial to mesenchymal transition involved in endocardial cushion formation | 1 | 2 | 2.92e-01 |
| GO:BP | GO:0043367 | CD4-positive, alpha-beta T cell differentiation | 1 | 50 | 2.92e-01 |
| GO:BP | GO:0043506 | regulation of JUN kinase activity | 5 | 49 | 2.92e-01 |
| GO:BP | GO:1902902 | negative regulation of autophagosome assembly | 3 | 14 | 2.92e-01 |
| GO:BP | GO:0099170 | postsynaptic modulation of chemical synaptic transmission | 1 | 23 | 2.92e-01 |
| GO:BP | GO:0040007 | growth | 2 | 742 | 2.92e-01 |
| GO:BP | GO:0006231 | dTMP biosynthetic process | 2 | 4 | 2.92e-01 |
| GO:BP | GO:0031641 | regulation of myelination | 6 | 36 | 2.92e-01 |
| GO:BP | GO:0097190 | apoptotic signaling pathway | 54 | 494 | 2.92e-01 |
| GO:BP | GO:0031589 | cell-substrate adhesion | 2 | 281 | 2.92e-01 |
| GO:BP | GO:0097352 | autophagosome maturation | 9 | 55 | 2.92e-01 |
| GO:BP | GO:0090208 | positive regulation of triglyceride metabolic process | 3 | 18 | 2.92e-01 |
| GO:BP | GO:0097499 | protein localization to non-motile cilium | 3 | 10 | 2.92e-01 |
| GO:BP | GO:0000389 | mRNA 3’-splice site recognition | 1 | 6 | 2.92e-01 |
| GO:BP | GO:0030163 | protein catabolic process | 6 | 901 | 2.92e-01 |
| GO:BP | GO:0110017 | cap-independent translational initiation of linear mRNA | 1 | 1 | 2.92e-01 |
| GO:BP | GO:0006414 | translational elongation | 10 | 65 | 2.92e-01 |
| GO:BP | GO:0032232 | negative regulation of actin filament bundle assembly | 2 | 26 | 2.92e-01 |
| GO:BP | GO:0032242 | regulation of nucleoside transport | 1 | 2 | 2.92e-01 |
| GO:BP | GO:0006424 | glutamyl-tRNA aminoacylation | 1 | 2 | 2.92e-01 |
| GO:BP | GO:0021540 | corpus callosum morphogenesis | 1 | 5 | 2.92e-01 |
| GO:BP | GO:0006433 | prolyl-tRNA aminoacylation | 1 | 2 | 2.92e-01 |
| GO:BP | GO:0031646 | positive regulation of nervous system process | 3 | 21 | 2.92e-01 |
| GO:BP | GO:0099072 | regulation of postsynaptic membrane neurotransmitter receptor levels | 1 | 70 | 2.92e-01 |
| GO:BP | GO:0098904 | regulation of AV node cell action potential | 2 | 3 | 2.92e-01 |
| GO:BP | GO:0021571 | rhombomere 5 development | 2 | 2 | 2.92e-01 |
| GO:BP | GO:0030037 | actin filament reorganization involved in cell cycle | 1 | 1 | 2.93e-01 |
| GO:BP | GO:0016567 | protein ubiquitination | 60 | 717 | 2.93e-01 |
| GO:BP | GO:0045214 | sarcomere organization | 6 | 43 | 2.93e-01 |
| GO:BP | GO:0101024 | mitotic nuclear membrane organization | 1 | 9 | 2.94e-01 |
| GO:BP | GO:0007084 | mitotic nuclear membrane reassembly | 1 | 9 | 2.94e-01 |
| GO:BP | GO:0042819 | vitamin B6 biosynthetic process | 2 | 3 | 2.94e-01 |
| GO:BP | GO:0034316 | negative regulation of Arp2/3 complex-mediated actin nucleation | 3 | 5 | 2.94e-01 |
| GO:BP | GO:1902177 | positive regulation of oxidative stress-induced intrinsic apoptotic signaling pathway | 1 | 5 | 2.94e-01 |
| GO:BP | GO:0003161 | cardiac conduction system development | 3 | 33 | 2.94e-01 |
| GO:BP | GO:0044375 | regulation of peroxisome size | 1 | 3 | 2.94e-01 |
| GO:BP | GO:0009116 | nucleoside metabolic process | 1 | 42 | 2.94e-01 |
| GO:BP | GO:0010661 | positive regulation of muscle cell apoptotic process | 1 | 20 | 2.94e-01 |
| GO:BP | GO:0015851 | nucleobase transport | 2 | 7 | 2.94e-01 |
| GO:BP | GO:0043039 | tRNA aminoacylation | 3 | 43 | 2.95e-01 |
| GO:BP | GO:2000382 | positive regulation of mesoderm development | 1 | 1 | 2.95e-01 |
| GO:BP | GO:0046604 | positive regulation of mitotic centrosome separation | 2 | 3 | 2.95e-01 |
| GO:BP | GO:1902807 | negative regulation of cell cycle G1/S phase transition | 9 | 70 | 2.95e-01 |
| GO:BP | GO:0046854 | phosphatidylinositol phosphate biosynthetic process | 15 | 59 | 2.95e-01 |
| GO:BP | GO:0003184 | pulmonary valve morphogenesis | 2 | 19 | 2.95e-01 |
| GO:BP | GO:0007088 | regulation of mitotic nuclear division | 17 | 100 | 2.97e-01 |
| GO:BP | GO:0060548 | negative regulation of cell death | 2 | 756 | 2.97e-01 |
| GO:BP | GO:0006435 | threonyl-tRNA aminoacylation | 1 | 3 | 2.97e-01 |
| GO:BP | GO:0042267 | natural killer cell mediated cytotoxicity | 2 | 34 | 2.99e-01 |
| GO:BP | GO:1902174 | positive regulation of keratinocyte apoptotic process | 2 | 3 | 2.99e-01 |
| GO:BP | GO:0003177 | pulmonary valve development | 4 | 22 | 3.00e-01 |
| GO:BP | GO:0033690 | positive regulation of osteoblast proliferation | 4 | 10 | 3.01e-01 |
| GO:BP | GO:0060291 | long-term synaptic potentiation | 1 | 64 | 3.01e-01 |
| GO:BP | GO:0045776 | negative regulation of blood pressure | 3 | 30 | 3.02e-01 |
| GO:BP | GO:0043983 | histone H4-K12 acetylation | 1 | 7 | 3.03e-01 |
| GO:BP | GO:1905843 | regulation of cellular response to gamma radiation | 1 | 1 | 3.04e-01 |
| GO:BP | GO:2001228 | regulation of response to gamma radiation | 1 | 1 | 3.04e-01 |
| GO:BP | GO:0009649 | entrainment of circadian clock | 5 | 31 | 3.04e-01 |
| GO:BP | GO:0097089 | methyl-branched fatty acid metabolic process | 1 | 3 | 3.04e-01 |
| GO:BP | GO:0006991 | response to sterol depletion | 1 | 16 | 3.04e-01 |
| GO:BP | GO:0006516 | glycoprotein catabolic process | 1 | 29 | 3.05e-01 |
| GO:BP | GO:1990776 | response to angiotensin | 1 | 24 | 3.05e-01 |
| GO:BP | GO:0032147 | activation of protein kinase activity | 1 | 82 | 3.05e-01 |
| GO:BP | GO:0043038 | amino acid activation | 3 | 44 | 3.05e-01 |
| GO:BP | GO:0050687 | negative regulation of defense response to virus | 9 | 30 | 3.05e-01 |
| GO:BP | GO:0007589 | body fluid secretion | 7 | 60 | 3.05e-01 |
| GO:BP | GO:0010033 | response to organic substance | 7 | 1957 | 3.05e-01 |
| GO:BP | GO:0009162 | deoxyribonucleoside monophosphate metabolic process | 6 | 18 | 3.05e-01 |
| GO:BP | GO:0044784 | metaphase/anaphase transition of cell cycle | 12 | 92 | 3.05e-01 |
| GO:BP | GO:1900095 | regulation of dosage compensation by inactivation of X chromosome | 4 | 13 | 3.05e-01 |
| GO:BP | GO:0002824 | positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 1 | 62 | 3.05e-01 |
| GO:BP | GO:0060068 | vagina development | 4 | 8 | 3.05e-01 |
| GO:BP | GO:0051835 | positive regulation of synapse structural plasticity | 2 | 2 | 3.05e-01 |
| GO:BP | GO:0042176 | regulation of protein catabolic process | 59 | 331 | 3.05e-01 |
| GO:BP | GO:0098734 | macromolecule depalmitoylation | 1 | 13 | 3.05e-01 |
| GO:BP | GO:0001881 | receptor recycling | 1 | 38 | 3.05e-01 |
| GO:BP | GO:0090306 | meiotic spindle assembly | 4 | 8 | 3.05e-01 |
| GO:BP | GO:0071499 | cellular response to laminar fluid shear stress | 3 | 8 | 3.05e-01 |
| GO:BP | GO:0002456 | T cell mediated immunity | 1 | 53 | 3.05e-01 |
| GO:BP | GO:0051083 | ‘de novo’ cotranslational protein folding | 1 | 2 | 3.06e-01 |
| GO:BP | GO:0000724 | double-strand break repair via homologous recombination | 17 | 149 | 3.06e-01 |
| GO:BP | GO:0051452 | intracellular pH reduction | 7 | 45 | 3.06e-01 |
| GO:BP | GO:0009304 | tRNA transcription | 3 | 8 | 3.06e-01 |
| GO:BP | GO:0006904 | vesicle docking involved in exocytosis | 1 | 37 | 3.07e-01 |
| GO:BP | GO:1902414 | protein localization to cell junction | 1 | 93 | 3.07e-01 |
| GO:BP | GO:0022406 | membrane docking | 2 | 84 | 3.07e-01 |
| GO:BP | GO:0043545 | molybdopterin cofactor metabolic process | 3 | 6 | 3.07e-01 |
| GO:BP | GO:0001830 | trophectodermal cell fate commitment | 1 | 1 | 3.07e-01 |
| GO:BP | GO:0010639 | negative regulation of organelle organization | 33 | 318 | 3.07e-01 |
| GO:BP | GO:0006777 | Mo-molybdopterin cofactor biosynthetic process | 3 | 6 | 3.07e-01 |
| GO:BP | GO:0044818 | mitotic G2/M transition checkpoint | 13 | 50 | 3.07e-01 |
| GO:BP | GO:0086050 | membrane repolarization during bundle of His cell action potential | 1 | 1 | 3.07e-01 |
| GO:BP | GO:0043633 | polyadenylation-dependent RNA catabolic process | 4 | 9 | 3.07e-01 |
| GO:BP | GO:0019720 | Mo-molybdopterin cofactor metabolic process | 3 | 6 | 3.07e-01 |
| GO:BP | GO:0051189 | prosthetic group metabolic process | 3 | 6 | 3.07e-01 |
| GO:BP | GO:1902151 | regulation of response to DNA integrity checkpoint signaling | 1 | 1 | 3.07e-01 |
| GO:BP | GO:0032324 | molybdopterin cofactor biosynthetic process | 3 | 6 | 3.07e-01 |
| GO:BP | GO:0086052 | membrane repolarization during SA node cell action potential | 1 | 1 | 3.07e-01 |
| GO:BP | GO:1902145 | regulation of response to cell cycle checkpoint signaling | 1 | 1 | 3.07e-01 |
| GO:BP | GO:1902175 | regulation of oxidative stress-induced intrinsic apoptotic signaling pathway | 7 | 25 | 3.07e-01 |
| GO:BP | GO:0002228 | natural killer cell mediated immunity | 2 | 34 | 3.07e-01 |
| GO:BP | GO:1902153 | regulation of response to DNA damage checkpoint signaling | 1 | 1 | 3.07e-01 |
| GO:BP | GO:0097254 | renal tubular secretion | 1 | 15 | 3.07e-01 |
| GO:BP | GO:1900114 | positive regulation of histone H3-K9 trimethylation | 1 | 2 | 3.08e-01 |
| GO:BP | GO:0046634 | regulation of alpha-beta T cell activation | 1 | 58 | 3.09e-01 |
| GO:BP | GO:0006383 | transcription by RNA polymerase III | 10 | 54 | 3.09e-01 |
| GO:BP | GO:0044743 | protein transmembrane import into intracellular organelle | 1 | 36 | 3.10e-01 |
| GO:BP | GO:1903978 | regulation of microglial cell activation | 4 | 9 | 3.10e-01 |
| GO:BP | GO:0090307 | mitotic spindle assembly | 1 | 70 | 3.10e-01 |
| GO:BP | GO:0002821 | positive regulation of adaptive immune response | 1 | 66 | 3.10e-01 |
| GO:BP | GO:1901659 | glycosyl compound biosynthetic process | 5 | 19 | 3.10e-01 |
| GO:BP | GO:1905070 | anterior visceral endoderm cell migration | 1 | 1 | 3.11e-01 |
| GO:BP | GO:0002718 | regulation of cytokine production involved in immune response | 1 | 70 | 3.11e-01 |
| GO:BP | GO:0008053 | mitochondrial fusion | 1 | 28 | 3.11e-01 |
| GO:BP | GO:0035710 | CD4-positive, alpha-beta T cell activation | 1 | 64 | 3.11e-01 |
| GO:BP | GO:0061865 | polarized secretion of basement membrane proteins in epithelium | 1 | 1 | 3.11e-01 |
| GO:BP | GO:0061029 | eyelid development in camera-type eye | 3 | 12 | 3.11e-01 |
| GO:BP | GO:0060760 | positive regulation of response to cytokine stimulus | 16 | 49 | 3.11e-01 |
| GO:BP | GO:0002367 | cytokine production involved in immune response | 1 | 70 | 3.11e-01 |
| GO:BP | GO:0006183 | GTP biosynthetic process | 3 | 9 | 3.11e-01 |
| GO:BP | GO:0033260 | nuclear DNA replication | 6 | 35 | 3.11e-01 |
| GO:BP | GO:0045725 | positive regulation of glycogen biosynthetic process | 3 | 12 | 3.11e-01 |
| GO:BP | GO:0003241 | growth involved in heart morphogenesis | 1 | 4 | 3.11e-01 |
| GO:BP | GO:0072595 | maintenance of protein localization in organelle | 6 | 39 | 3.11e-01 |
| GO:BP | GO:0036261 | 7-methylguanosine cap hypermethylation | 3 | 8 | 3.11e-01 |
| GO:BP | GO:2000690 | regulation of cardiac muscle cell myoblast differentiation | 1 | 1 | 3.11e-01 |
| GO:BP | GO:0046322 | negative regulation of fatty acid oxidation | 3 | 12 | 3.11e-01 |
| GO:BP | GO:0061864 | basement membrane constituent secretion | 1 | 1 | 3.11e-01 |
| GO:BP | GO:2000691 | negative regulation of cardiac muscle cell myoblast differentiation | 1 | 1 | 3.11e-01 |
| GO:BP | GO:0060809 | mesodermal to mesenchymal transition involved in gastrulation | 2 | 2 | 3.11e-01 |
| GO:BP | GO:0002708 | positive regulation of lymphocyte mediated immunity | 1 | 58 | 3.11e-01 |
| GO:BP | GO:0045582 | positive regulation of T cell differentiation | 1 | 74 | 3.11e-01 |
| GO:BP | GO:0098869 | cellular oxidant detoxification | 1 | 65 | 3.11e-01 |
| GO:BP | GO:0021593 | rhombomere morphogenesis | 1 | 1 | 3.12e-01 |
| GO:BP | GO:0046632 | alpha-beta T cell differentiation | 1 | 67 | 3.12e-01 |
| GO:BP | GO:0035970 | peptidyl-threonine dephosphorylation | 6 | 17 | 3.12e-01 |
| GO:BP | GO:0090309 | positive regulation of DNA methylation-dependent heterochromatin formation | 4 | 12 | 3.12e-01 |
| GO:BP | GO:0060900 | embryonic camera-type eye formation | 1 | 8 | 3.12e-01 |
| GO:BP | GO:0090383 | phagosome acidification | 3 | 5 | 3.12e-01 |
| GO:BP | GO:0014040 | positive regulation of Schwann cell differentiation | 1 | 2 | 3.12e-01 |
| GO:BP | GO:0021658 | rhombomere 3 morphogenesis | 1 | 1 | 3.12e-01 |
| GO:BP | GO:0034616 | response to laminar fluid shear stress | 4 | 14 | 3.12e-01 |
| GO:BP | GO:0060763 | mammary duct terminal end bud growth | 1 | 3 | 3.12e-01 |
| GO:BP | GO:0045839 | negative regulation of mitotic nuclear division | 8 | 54 | 3.12e-01 |
| GO:BP | GO:0061951 | establishment of protein localization to plasma membrane | 3 | 59 | 3.12e-01 |
| GO:BP | GO:0031338 | regulation of vesicle fusion | 1 | 17 | 3.12e-01 |
| GO:BP | GO:0035304 | regulation of protein dephosphorylation | 4 | 75 | 3.12e-01 |
| GO:BP | GO:0097070 | ductus arteriosus closure | 2 | 2 | 3.12e-01 |
| GO:BP | GO:0015689 | molybdate ion transport | 1 | 1 | 3.12e-01 |
| GO:BP | GO:2001015 | negative regulation of skeletal muscle cell differentiation | 2 | 3 | 3.12e-01 |
| GO:BP | GO:0002286 | T cell activation involved in immune response | 1 | 55 | 3.12e-01 |
| GO:BP | GO:0043589 | skin morphogenesis | 1 | 10 | 3.12e-01 |
| GO:BP | GO:1903259 | exon-exon junction complex disassembly | 1 | 1 | 3.13e-01 |
| GO:BP | GO:2000233 | negative regulation of rRNA processing | 2 | 3 | 3.13e-01 |
| GO:BP | GO:0001952 | regulation of cell-matrix adhesion | 1 | 97 | 3.13e-01 |
| GO:BP | GO:0010941 | regulation of cell death | 4 | 1219 | 3.14e-01 |
| GO:BP | GO:0006565 | L-serine catabolic process | 2 | 4 | 3.14e-01 |
| GO:BP | GO:0006900 | vesicle budding from membrane | 16 | 76 | 3.14e-01 |
| GO:BP | GO:0048661 | positive regulation of smooth muscle cell proliferation | 3 | 63 | 3.14e-01 |
| GO:BP | GO:0043687 | post-translational protein modification | 1 | 64 | 3.14e-01 |
| GO:BP | GO:0010453 | regulation of cell fate commitment | 2 | 26 | 3.14e-01 |
| GO:BP | GO:0045299 | otolith mineralization | 2 | 2 | 3.14e-01 |
| GO:BP | GO:0007052 | mitotic spindle organization | 3 | 129 | 3.14e-01 |
| GO:BP | GO:0006458 | ‘de novo’ protein folding | 3 | 39 | 3.14e-01 |
| GO:BP | GO:0140467 | integrated stress response signaling | 9 | 35 | 3.15e-01 |
| GO:BP | GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway | 2 | 3 | 3.15e-01 |
| GO:BP | GO:1900739 | regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway | 2 | 3 | 3.15e-01 |
| GO:BP | GO:0061077 | chaperone-mediated protein folding | 5 | 65 | 3.15e-01 |
| GO:BP | GO:1902459 | positive regulation of stem cell population maintenance | 6 | 44 | 3.15e-01 |
| GO:BP | GO:0060079 | excitatory postsynaptic potential | 1 | 70 | 3.15e-01 |
| GO:BP | GO:0031860 | telomeric 3’ overhang formation | 1 | 4 | 3.15e-01 |
| GO:BP | GO:0051168 | nuclear export | 19 | 150 | 3.15e-01 |
| GO:BP | GO:0007613 | memory | 1 | 92 | 3.15e-01 |
| GO:BP | GO:0006886 | intracellular protein transport | 4 | 803 | 3.16e-01 |
| GO:BP | GO:0021904 | dorsal/ventral neural tube patterning | 1 | 21 | 3.16e-01 |
| GO:BP | GO:0048227 | plasma membrane to endosome transport | 2 | 8 | 3.16e-01 |
| GO:BP | GO:0010811 | positive regulation of cell-substrate adhesion | 1 | 100 | 3.18e-01 |
| GO:BP | GO:0008286 | insulin receptor signaling pathway | 1 | 105 | 3.18e-01 |
| GO:BP | GO:2000671 | regulation of motor neuron apoptotic process | 4 | 12 | 3.18e-01 |
| GO:BP | GO:0031398 | positive regulation of protein ubiquitination | 15 | 108 | 3.18e-01 |
| GO:BP | GO:0007035 | vacuolar acidification | 5 | 30 | 3.18e-01 |
| GO:BP | GO:0098974 | postsynaptic actin cytoskeleton organization | 1 | 11 | 3.18e-01 |
| GO:BP | GO:0090305 | nucleic acid phosphodiester bond hydrolysis | 1 | 211 | 3.19e-01 |
| GO:BP | GO:0035508 | positive regulation of myosin-light-chain-phosphatase activity | 1 | 1 | 3.19e-01 |
| GO:BP | GO:0009451 | RNA modification | 29 | 162 | 3.19e-01 |
| GO:BP | GO:0048672 | positive regulation of collateral sprouting | 4 | 10 | 3.20e-01 |
| GO:BP | GO:0016191 | synaptic vesicle uncoating | 3 | 7 | 3.20e-01 |
| GO:BP | GO:0016482 | cytosolic transport | 32 | 161 | 3.21e-01 |
| GO:BP | GO:0032898 | neurotrophin production | 2 | 4 | 3.21e-01 |
| GO:BP | GO:0110053 | regulation of actin filament organization | 6 | 228 | 3.21e-01 |
| GO:BP | GO:0061763 | multivesicular body-lysosome fusion | 3 | 11 | 3.21e-01 |
| GO:BP | GO:0046449 | creatinine metabolic process | 1 | 2 | 3.21e-01 |
| GO:BP | GO:0019060 | intracellular transport of viral protein in host cell | 1 | 2 | 3.21e-01 |
| GO:BP | GO:0051469 | vesicle fusion with vacuole | 3 | 11 | 3.21e-01 |
| GO:BP | GO:0044539 | long-chain fatty acid import into cell | 4 | 14 | 3.21e-01 |
| GO:BP | GO:0030581 | symbiont intracellular protein transport in host | 1 | 2 | 3.21e-01 |
| GO:BP | GO:0033314 | mitotic DNA replication checkpoint signaling | 4 | 9 | 3.22e-01 |
| GO:BP | GO:0140591 | nuclear envelope budding | 1 | 1 | 3.22e-01 |
| GO:BP | GO:0071705 | nitrogen compound transport | 5 | 1684 | 3.22e-01 |
| GO:BP | GO:0099565 | chemical synaptic transmission, postsynaptic | 1 | 75 | 3.22e-01 |
| GO:BP | GO:0003010 | voluntary skeletal muscle contraction | 2 | 5 | 3.22e-01 |
| GO:BP | GO:2000232 | regulation of rRNA processing | 5 | 16 | 3.22e-01 |
| GO:BP | GO:0062009 | secondary palate development | 5 | 20 | 3.22e-01 |
| GO:BP | GO:1904375 | regulation of protein localization to cell periphery | 1 | 113 | 3.22e-01 |
| GO:BP | GO:0019934 | cGMP-mediated signaling | 1 | 22 | 3.22e-01 |
| GO:BP | GO:0014721 | twitch skeletal muscle contraction | 2 | 5 | 3.22e-01 |
| GO:BP | GO:0045621 | positive regulation of lymphocyte differentiation | 1 | 86 | 3.22e-01 |
| GO:BP | GO:0048388 | endosomal lumen acidification | 3 | 13 | 3.22e-01 |
| GO:BP | GO:0051496 | positive regulation of stress fiber assembly | 6 | 47 | 3.23e-01 |
| GO:BP | GO:0000725 | recombinational repair | 17 | 153 | 3.23e-01 |
| GO:BP | GO:0002702 | positive regulation of production of molecular mediator of immune response | 1 | 77 | 3.23e-01 |
| GO:BP | GO:0099578 | regulation of translation at postsynapse, modulating synaptic transmission | 2 | 3 | 3.23e-01 |
| GO:BP | GO:0099547 | regulation of translation at synapse, modulating synaptic transmission | 2 | 3 | 3.23e-01 |
| GO:BP | GO:0006400 | tRNA modification | 16 | 90 | 3.25e-01 |
| GO:BP | GO:0098910 | regulation of atrial cardiac muscle cell action potential | 1 | 4 | 3.25e-01 |
| GO:BP | GO:0008298 | intracellular mRNA localization | 3 | 11 | 3.25e-01 |
| GO:BP | GO:0003105 | negative regulation of glomerular filtration | 1 | 3 | 3.25e-01 |
| GO:BP | GO:0010641 | positive regulation of platelet-derived growth factor receptor signaling pathway | 1 | 4 | 3.25e-01 |
| GO:BP | GO:0086017 | Purkinje myocyte action potential | 1 | 4 | 3.25e-01 |
| GO:BP | GO:0060840 | artery development | 5 | 83 | 3.25e-01 |
| GO:BP | GO:1904263 | positive regulation of TORC1 signaling | 4 | 24 | 3.26e-01 |
| GO:BP | GO:0048532 | anatomical structure arrangement | 2 | 13 | 3.26e-01 |
| GO:BP | GO:0071375 | cellular response to peptide hormone stimulus | 2 | 241 | 3.27e-01 |
| GO:BP | GO:1900453 | negative regulation of long-term synaptic depression | 1 | 3 | 3.28e-01 |
| GO:BP | GO:0002705 | positive regulation of leukocyte mediated immunity | 1 | 68 | 3.28e-01 |
| GO:BP | GO:0042760 | very long-chain fatty acid catabolic process | 2 | 5 | 3.28e-01 |
| GO:BP | GO:0010800 | positive regulation of peptidyl-threonine phosphorylation | 8 | 23 | 3.29e-01 |
| GO:BP | GO:0060212 | negative regulation of nuclear-transcribed mRNA poly(A) tail shortening | 2 | 3 | 3.29e-01 |
| GO:BP | GO:0032974 | amino acid transmembrane export from vacuole | 1 | 1 | 3.29e-01 |
| GO:BP | GO:0035303 | regulation of dephosphorylation | 5 | 105 | 3.29e-01 |
| GO:BP | GO:0010972 | negative regulation of G2/M transition of mitotic cell cycle | 15 | 60 | 3.29e-01 |
| GO:BP | GO:0070070 | proton-transporting V-type ATPase complex assembly | 4 | 7 | 3.29e-01 |
| GO:BP | GO:0039536 | negative regulation of RIG-I signaling pathway | 3 | 7 | 3.29e-01 |
| GO:BP | GO:0032462 | regulation of protein homooligomerization | 2 | 4 | 3.29e-01 |
| GO:BP | GO:0010476 | gibberellin mediated signaling pathway | 1 | 1 | 3.29e-01 |
| GO:BP | GO:0031145 | anaphase-promoting complex-dependent catabolic process | 5 | 23 | 3.29e-01 |
| GO:BP | GO:0045039 | protein insertion into mitochondrial inner membrane | 5 | 13 | 3.29e-01 |
| GO:BP | GO:0009739 | response to gibberellin | 1 | 1 | 3.29e-01 |
| GO:BP | GO:0009740 | gibberellic acid mediated signaling pathway | 1 | 1 | 3.29e-01 |
| GO:BP | GO:0006513 | protein monoubiquitination | 10 | 80 | 3.29e-01 |
| GO:BP | GO:0030239 | myofibril assembly | 4 | 66 | 3.29e-01 |
| GO:BP | GO:1990748 | cellular detoxification | 1 | 76 | 3.29e-01 |
| GO:BP | GO:0003203 | endocardial cushion morphogenesis | 3 | 36 | 3.29e-01 |
| GO:BP | GO:0070291 | N-acylethanolamine metabolic process | 2 | 4 | 3.29e-01 |
| GO:BP | GO:0070875 | positive regulation of glycogen metabolic process | 3 | 13 | 3.29e-01 |
| GO:BP | GO:0089708 | L-histidine transmembrane export from vacuole | 1 | 1 | 3.29e-01 |
| GO:BP | GO:0071370 | cellular response to gibberellin stimulus | 1 | 1 | 3.29e-01 |
| GO:BP | GO:0010390 | histone monoubiquitination | 3 | 31 | 3.29e-01 |
| GO:BP | GO:0099624 | atrial cardiac muscle cell membrane repolarization | 2 | 9 | 3.29e-01 |
| GO:BP | GO:0000423 | mitophagy | 4 | 37 | 3.29e-01 |
| GO:BP | GO:0033559 | unsaturated fatty acid metabolic process | 1 | 66 | 3.29e-01 |
| GO:BP | GO:1904377 | positive regulation of protein localization to cell periphery | 8 | 57 | 3.30e-01 |
| GO:BP | GO:0043984 | histone H4-K16 acetylation | 4 | 14 | 3.30e-01 |
| GO:BP | GO:0048698 | negative regulation of collateral sprouting in absence of injury | 1 | 1 | 3.31e-01 |
| GO:BP | GO:1901657 | glycosyl compound metabolic process | 1 | 62 | 3.32e-01 |
| GO:BP | GO:0061026 | cardiac muscle tissue regeneration | 3 | 6 | 3.32e-01 |
| GO:BP | GO:0006500 | N-terminal protein palmitoylation | 1 | 3 | 3.32e-01 |
| GO:BP | GO:0051127 | positive regulation of actin nucleation | 3 | 14 | 3.33e-01 |
| GO:BP | GO:0016554 | cytidine to uridine editing | 4 | 6 | 3.35e-01 |
| GO:BP | GO:0110155 | NAD-cap decapping | 2 | 3 | 3.35e-01 |
| GO:BP | GO:0003275 | apoptotic process involved in outflow tract morphogenesis | 1 | 3 | 3.36e-01 |
| GO:BP | GO:0051795 | positive regulation of timing of catagen | 1 | 3 | 3.36e-01 |
| GO:BP | GO:2000156 | regulation of retrograde vesicle-mediated transport, Golgi to ER | 1 | 2 | 3.36e-01 |
| GO:BP | GO:0046051 | UTP metabolic process | 3 | 10 | 3.36e-01 |
| GO:BP | GO:0045726 | positive regulation of integrin biosynthetic process | 1 | 2 | 3.36e-01 |
| GO:BP | GO:0097698 | telomere maintenance via base-excision repair | 1 | 1 | 3.36e-01 |
| GO:BP | GO:0034127 | regulation of MyD88-independent toll-like receptor signaling pathway | 1 | 2 | 3.36e-01 |
| GO:BP | GO:0051656 | establishment of organelle localization | 3 | 378 | 3.36e-01 |
| GO:BP | GO:0051443 | positive regulation of ubiquitin-protein transferase activity | 6 | 31 | 3.36e-01 |
| GO:BP | GO:0002674 | negative regulation of acute inflammatory response | 2 | 5 | 3.36e-01 |
| GO:BP | GO:0055002 | striated muscle cell development | 4 | 67 | 3.36e-01 |
| GO:BP | GO:0046203 | spermidine catabolic process | 1 | 2 | 3.36e-01 |
| GO:BP | GO:0006041 | glucosamine metabolic process | 2 | 3 | 3.36e-01 |
| GO:BP | GO:0009148 | pyrimidine nucleoside triphosphate biosynthetic process | 4 | 17 | 3.36e-01 |
| GO:BP | GO:0072594 | establishment of protein localization to organelle | 3 | 422 | 3.36e-01 |
| GO:BP | GO:0060078 | regulation of postsynaptic membrane potential | 1 | 82 | 3.36e-01 |
| GO:BP | GO:0032469 | endoplasmic reticulum calcium ion homeostasis | 8 | 26 | 3.36e-01 |
| GO:BP | GO:0003283 | atrial septum development | 2 | 23 | 3.36e-01 |
| GO:BP | GO:0032465 | regulation of cytokinesis | 3 | 79 | 3.36e-01 |
| GO:BP | GO:1902389 | ceramide 1-phosphate transport | 3 | 7 | 3.36e-01 |
| GO:BP | GO:0051102 | DNA ligation involved in DNA recombination | 1 | 1 | 3.36e-01 |
| GO:BP | GO:0046185 | aldehyde catabolic process | 2 | 12 | 3.36e-01 |
| GO:BP | GO:0008356 | asymmetric cell division | 2 | 14 | 3.36e-01 |
| GO:BP | GO:0009447 | putrescine catabolic process | 1 | 2 | 3.36e-01 |
| GO:BP | GO:1902256 | regulation of apoptotic process involved in outflow tract morphogenesis | 1 | 3 | 3.36e-01 |
| GO:BP | GO:0033043 | regulation of organelle organization | 101 | 1028 | 3.36e-01 |
| GO:BP | GO:0048844 | artery morphogenesis | 4 | 58 | 3.36e-01 |
| GO:BP | GO:0075713 | establishment of integrated proviral latency | 1 | 1 | 3.36e-01 |
| GO:BP | GO:0022616 | DNA strand elongation | 10 | 35 | 3.36e-01 |
| GO:BP | GO:0007588 | excretion | 1 | 18 | 3.36e-01 |
| GO:BP | GO:0052652 | cyclic purine nucleotide metabolic process | 1 | 30 | 3.36e-01 |
| GO:BP | GO:0046208 | spermine catabolic process | 1 | 2 | 3.36e-01 |
| GO:BP | GO:0046755 | viral budding | 5 | 26 | 3.36e-01 |
| GO:BP | GO:1905898 | positive regulation of response to endoplasmic reticulum stress | 9 | 34 | 3.36e-01 |
| GO:BP | GO:0051664 | nuclear pore localization | 1 | 4 | 3.36e-01 |
| GO:BP | GO:0030579 | ubiquitin-dependent SMAD protein catabolic process | 2 | 5 | 3.36e-01 |
| GO:BP | GO:1904707 | positive regulation of vascular associated smooth muscle cell proliferation | 1 | 29 | 3.36e-01 |
| GO:BP | GO:0010693 | negative regulation of alkaline phosphatase activity | 1 | 2 | 3.36e-01 |
| GO:BP | GO:1901569 | fatty acid derivative catabolic process | 1 | 10 | 3.36e-01 |
| GO:BP | GO:0031116 | positive regulation of microtubule polymerization | 4 | 31 | 3.36e-01 |
| GO:BP | GO:0003071 | renal system process involved in regulation of systemic arterial blood pressure | 2 | 14 | 3.36e-01 |
| GO:BP | GO:0031396 | regulation of protein ubiquitination | 23 | 191 | 3.36e-01 |
| GO:BP | GO:0120041 | positive regulation of macrophage proliferation | 2 | 4 | 3.36e-01 |
| GO:BP | GO:0030951 | establishment or maintenance of microtubule cytoskeleton polarity | 1 | 4 | 3.36e-01 |
| GO:BP | GO:0042759 | long-chain fatty acid biosynthetic process | 3 | 14 | 3.36e-01 |
| GO:BP | GO:0010823 | negative regulation of mitochondrion organization | 6 | 46 | 3.36e-01 |
| GO:BP | GO:0097237 | cellular response to toxic substance | 1 | 82 | 3.36e-01 |
| GO:BP | GO:0010907 | positive regulation of glucose metabolic process | 5 | 36 | 3.36e-01 |
| GO:BP | GO:0010967 | regulation of polyamine biosynthetic process | 1 | 2 | 3.36e-01 |
| GO:BP | GO:0140245 | regulation of translation at postsynapse | 3 | 6 | 3.36e-01 |
| GO:BP | GO:0140243 | regulation of translation at synapse | 3 | 6 | 3.36e-01 |
| GO:BP | GO:0031644 | regulation of nervous system process | 1 | 90 | 3.36e-01 |
| GO:BP | GO:0032352 | positive regulation of hormone metabolic process | 3 | 11 | 3.36e-01 |
| GO:BP | GO:0060415 | muscle tissue morphogenesis | 4 | 60 | 3.37e-01 |
| GO:BP | GO:0031333 | negative regulation of protein-containing complex assembly | 1 | 130 | 3.37e-01 |
| GO:BP | GO:0030071 | regulation of mitotic metaphase/anaphase transition | 11 | 88 | 3.37e-01 |
| GO:BP | GO:0060574 | intestinal epithelial cell maturation | 2 | 3 | 3.37e-01 |
| GO:BP | GO:0060613 | fat pad development | 3 | 6 | 3.37e-01 |
| GO:BP | GO:0045017 | glycerolipid biosynthetic process | 40 | 218 | 3.37e-01 |
| GO:BP | GO:0006690 | icosanoid metabolic process | 1 | 60 | 3.37e-01 |
| GO:BP | GO:1905209 | positive regulation of cardiocyte differentiation | 3 | 11 | 3.37e-01 |
| GO:BP | GO:0032872 | regulation of stress-activated MAPK cascade | 10 | 154 | 3.37e-01 |
| GO:BP | GO:0051798 | positive regulation of hair follicle development | 2 | 9 | 3.37e-01 |
| GO:BP | GO:0009187 | cyclic nucleotide metabolic process | 1 | 31 | 3.37e-01 |
| GO:BP | GO:0051649 | establishment of localization in cell | 5 | 1836 | 3.37e-01 |
| GO:BP | GO:0090382 | phagosome maturation | 7 | 24 | 3.37e-01 |
| GO:BP | GO:0006884 | cell volume homeostasis | 5 | 24 | 3.38e-01 |
| GO:BP | GO:1990550 | mitochondrial alpha-ketoglutarate transmembrane transport | 1 | 1 | 3.38e-01 |
| GO:BP | GO:1904798 | positive regulation of core promoter binding | 1 | 4 | 3.38e-01 |
| GO:BP | GO:0097355 | protein localization to heterochromatin | 2 | 3 | 3.39e-01 |
| GO:BP | GO:0051276 | chromosome organization | 57 | 543 | 3.39e-01 |
| GO:BP | GO:0140708 | CAT tailing | 1 | 1 | 3.39e-01 |
| GO:BP | GO:0000027 | ribosomal large subunit assembly | 1 | 23 | 3.39e-01 |
| GO:BP | GO:0032049 | cardiolipin biosynthetic process | 3 | 7 | 3.39e-01 |
| GO:BP | GO:0099188 | postsynaptic cytoskeleton organization | 1 | 14 | 3.39e-01 |
| GO:BP | GO:0005979 | regulation of glycogen biosynthetic process | 4 | 25 | 3.39e-01 |
| GO:BP | GO:0051045 | negative regulation of membrane protein ectodomain proteolysis | 3 | 7 | 3.39e-01 |
| GO:BP | GO:0010962 | regulation of glucan biosynthetic process | 4 | 25 | 3.39e-01 |
| GO:BP | GO:0062025 | regulation of SCF-dependent proteasomal ubiquitin-dependent protein catabolic process | 1 | 1 | 3.39e-01 |
| GO:BP | GO:0062026 | negative regulation of SCF-dependent proteasomal ubiquitin-dependent catabolic process | 1 | 1 | 3.39e-01 |
| GO:BP | GO:0048484 | enteric nervous system development | 3 | 7 | 3.39e-01 |
| GO:BP | GO:0051092 | positive regulation of NF-kappaB transcription factor activity | 1 | 116 | 3.40e-01 |
| GO:BP | GO:0030010 | establishment of cell polarity | 1 | 134 | 3.40e-01 |
| GO:BP | GO:0048208 | COPII vesicle coating | 2 | 24 | 3.41e-01 |
| GO:BP | GO:0048207 | vesicle targeting, rough ER to cis-Golgi | 2 | 24 | 3.41e-01 |
| GO:BP | GO:0031591 | wybutosine biosynthetic process | 2 | 4 | 3.42e-01 |
| GO:BP | GO:0042273 | ribosomal large subunit biogenesis | 2 | 73 | 3.42e-01 |
| GO:BP | GO:0072579 | glycine receptor clustering | 1 | 1 | 3.42e-01 |
| GO:BP | GO:2000174 | regulation of pro-T cell differentiation | 1 | 1 | 3.42e-01 |
| GO:BP | GO:0031590 | wybutosine metabolic process | 2 | 4 | 3.42e-01 |
| GO:BP | GO:0042040 | metal incorporation into metallo-molybdopterin complex | 1 | 1 | 3.42e-01 |
| GO:BP | GO:2000176 | positive regulation of pro-T cell differentiation | 1 | 1 | 3.42e-01 |
| GO:BP | GO:0018315 | molybdenum incorporation into molybdenum-molybdopterin complex | 1 | 1 | 3.42e-01 |
| GO:BP | GO:1990743 | protein sialylation | 2 | 5 | 3.42e-01 |
| GO:BP | GO:0034242 | negative regulation of syncytium formation by plasma membrane fusion | 2 | 3 | 3.43e-01 |
| GO:BP | GO:1900242 | regulation of synaptic vesicle endocytosis | 2 | 16 | 3.43e-01 |
| GO:BP | GO:0071139 | resolution of recombination intermediates | 3 | 6 | 3.44e-01 |
| GO:BP | GO:0071697 | ectodermal placode morphogenesis | 1 | 10 | 3.44e-01 |
| GO:BP | GO:1990961 | xenobiotic detoxification by transmembrane export across the plasma membrane | 1 | 7 | 3.44e-01 |
| GO:BP | GO:0071596 | ubiquitin-dependent protein catabolic process via the N-end rule pathway | 2 | 3 | 3.44e-01 |
| GO:BP | GO:0060788 | ectodermal placode formation | 1 | 10 | 3.44e-01 |
| GO:BP | GO:0031915 | positive regulation of synaptic plasticity | 1 | 6 | 3.44e-01 |
| GO:BP | GO:0006378 | mRNA polyadenylation | 4 | 39 | 3.44e-01 |
| GO:BP | GO:0071691 | cardiac muscle thin filament assembly | 1 | 3 | 3.45e-01 |
| GO:BP | GO:0006857 | oligopeptide transport | 2 | 5 | 3.45e-01 |
| GO:BP | GO:0000086 | G2/M transition of mitotic cell cycle | 29 | 134 | 3.45e-01 |
| GO:BP | GO:0090398 | cellular senescence | 7 | 83 | 3.45e-01 |
| GO:BP | GO:0071847 | TNFSF11-mediated signaling pathway | 1 | 3 | 3.45e-01 |
| GO:BP | GO:0017156 | calcium-ion regulated exocytosis | 1 | 46 | 3.45e-01 |
| GO:BP | GO:0033554 | cellular response to stress | 128 | 1681 | 3.45e-01 |
| GO:BP | GO:0045607 | regulation of inner ear auditory receptor cell differentiation | 1 | 8 | 3.45e-01 |
| GO:BP | GO:0060755 | negative regulation of mast cell chemotaxis | 1 | 1 | 3.45e-01 |
| GO:BP | GO:0097576 | vacuole fusion | 3 | 12 | 3.45e-01 |
| GO:BP | GO:0043618 | regulation of transcription from RNA polymerase II promoter in response to stress | 6 | 36 | 3.45e-01 |
| GO:BP | GO:0031146 | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process | 1 | 47 | 3.45e-01 |
| GO:BP | GO:0031550 | positive regulation of brain-derived neurotrophic factor receptor signaling pathway | 1 | 2 | 3.45e-01 |
| GO:BP | GO:0045631 | regulation of mechanoreceptor differentiation | 1 | 8 | 3.45e-01 |
| GO:BP | GO:0035672 | oligopeptide transmembrane transport | 2 | 5 | 3.45e-01 |
| GO:BP | GO:0006487 | protein N-linked glycosylation | 3 | 65 | 3.45e-01 |
| GO:BP | GO:1903299 | regulation of hexokinase activity | 2 | 8 | 3.45e-01 |
| GO:BP | GO:1903621 | protein localization to photoreceptor connecting cilium | 1 | 1 | 3.45e-01 |
| GO:BP | GO:0065002 | intracellular protein transmembrane transport | 1 | 52 | 3.45e-01 |
| GO:BP | GO:2000980 | regulation of inner ear receptor cell differentiation | 1 | 8 | 3.45e-01 |
| GO:BP | GO:1900103 | positive regulation of endoplasmic reticulum unfolded protein response | 5 | 13 | 3.45e-01 |
| GO:BP | GO:0003281 | ventricular septum development | 4 | 69 | 3.45e-01 |
| GO:BP | GO:0051567 | histone H3-K9 methylation | 2 | 18 | 3.46e-01 |
| GO:BP | GO:0007258 | JUN phosphorylation | 1 | 2 | 3.46e-01 |
| GO:BP | GO:0003215 | cardiac right ventricle morphogenesis | 2 | 17 | 3.46e-01 |
| GO:BP | GO:0046836 | glycolipid transport | 3 | 7 | 3.46e-01 |
| GO:BP | GO:0060113 | inner ear receptor cell differentiation | 9 | 47 | 3.47e-01 |
| GO:BP | GO:0070231 | T cell apoptotic process | 1 | 39 | 3.47e-01 |
| GO:BP | GO:0070302 | regulation of stress-activated protein kinase signaling cascade | 10 | 157 | 3.47e-01 |
| GO:BP | GO:1990134 | epithelial cell apoptotic process involved in palatal shelf morphogenesis | 1 | 1 | 3.48e-01 |
| GO:BP | GO:1905161 | protein localization to phagocytic vesicle | 1 | 2 | 3.48e-01 |
| GO:BP | GO:0090182 | regulation of secretion of lysosomal enzymes | 1 | 2 | 3.48e-01 |
| GO:BP | GO:0090150 | establishment of protein localization to membrane | 2 | 250 | 3.48e-01 |
| GO:BP | GO:1903008 | organelle disassembly | 26 | 137 | 3.48e-01 |
| GO:BP | GO:0050806 | positive regulation of synaptic transmission | 1 | 106 | 3.48e-01 |
| GO:BP | GO:1903049 | negative regulation of acetylcholine-gated cation channel activity | 1 | 1 | 3.48e-01 |
| GO:BP | GO:0140650 | radial glia-guided pyramidal neuron migration | 2 | 4 | 3.48e-01 |
| GO:BP | GO:0042634 | regulation of hair cycle | 3 | 22 | 3.48e-01 |
| GO:BP | GO:1905171 | positive regulation of protein localization to phagocytic vesicle | 1 | 2 | 3.48e-01 |
| GO:BP | GO:1905169 | regulation of protein localization to phagocytic vesicle | 1 | 2 | 3.48e-01 |
| GO:BP | GO:1903048 | regulation of acetylcholine-gated cation channel activity | 1 | 1 | 3.48e-01 |
| GO:BP | GO:0031086 | nuclear-transcribed mRNA catabolic process, deadenylation-independent decay | 2 | 7 | 3.48e-01 |
| GO:BP | GO:0098754 | detoxification | 1 | 91 | 3.48e-01 |
| GO:BP | GO:0071932 | replication fork reversal | 2 | 5 | 3.48e-01 |
| GO:BP | GO:0060709 | glycogen cell differentiation involved in embryonic placenta development | 1 | 1 | 3.48e-01 |
| GO:BP | GO:0070303 | negative regulation of stress-activated protein kinase signaling cascade | 4 | 46 | 3.48e-01 |
| GO:BP | GO:1902115 | regulation of organelle assembly | 5 | 186 | 3.48e-01 |
| GO:BP | GO:0032873 | negative regulation of stress-activated MAPK cascade | 4 | 46 | 3.48e-01 |
| GO:BP | GO:0034470 | ncRNA processing | 82 | 400 | 3.48e-01 |
| GO:BP | GO:0032941 | secretion by tissue | 4 | 25 | 3.48e-01 |
| GO:BP | GO:1903826 | L-arginine transmembrane transport | 3 | 12 | 3.49e-01 |
| GO:BP | GO:0034198 | cellular response to amino acid starvation | 2 | 48 | 3.49e-01 |
| GO:BP | GO:0043112 | receptor metabolic process | 1 | 62 | 3.49e-01 |
| GO:BP | GO:0048382 | mesendoderm development | 2 | 5 | 3.49e-01 |
| GO:BP | GO:0006611 | protein export from nucleus | 11 | 55 | 3.50e-01 |
| GO:BP | GO:0002706 | regulation of lymphocyte mediated immunity | 1 | 83 | 3.51e-01 |
| GO:BP | GO:0018205 | peptidyl-lysine modification | 61 | 336 | 3.52e-01 |
| GO:BP | GO:0032570 | response to progesterone | 7 | 27 | 3.52e-01 |
| GO:BP | GO:0071696 | ectodermal placode development | 1 | 11 | 3.52e-01 |
| GO:BP | GO:0060561 | apoptotic process involved in morphogenesis | 4 | 21 | 3.52e-01 |
| GO:BP | GO:0035283 | central nervous system segmentation | 2 | 2 | 3.53e-01 |
| GO:BP | GO:0050000 | chromosome localization | 12 | 82 | 3.53e-01 |
| GO:BP | GO:0046631 | alpha-beta T cell activation | 1 | 89 | 3.53e-01 |
| GO:BP | GO:0072528 | pyrimidine-containing compound biosynthetic process | 6 | 33 | 3.53e-01 |
| GO:BP | GO:0002822 | regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 1 | 97 | 3.53e-01 |
| GO:BP | GO:0008635 | activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c | 3 | 7 | 3.53e-01 |
| GO:BP | GO:0036166 | phenotypic switching | 3 | 7 | 3.53e-01 |
| GO:BP | GO:0060211 | regulation of nuclear-transcribed mRNA poly(A) tail shortening | 5 | 15 | 3.53e-01 |
| GO:BP | GO:0003418 | growth plate cartilage chondrocyte differentiation | 4 | 8 | 3.53e-01 |
| GO:BP | GO:0072673 | lamellipodium morphogenesis | 1 | 17 | 3.53e-01 |
| GO:BP | GO:0051170 | import into nucleus | 16 | 152 | 3.53e-01 |
| GO:BP | GO:0044381 | glucose import in response to insulin stimulus | 2 | 4 | 3.53e-01 |
| GO:BP | GO:2001014 | regulation of skeletal muscle cell differentiation | 5 | 16 | 3.53e-01 |
| GO:BP | GO:0042149 | cellular response to glucose starvation | 10 | 51 | 3.54e-01 |
| GO:BP | GO:0090235 | regulation of metaphase plate congression | 2 | 13 | 3.54e-01 |
| GO:BP | GO:1902750 | negative regulation of cell cycle G2/M phase transition | 15 | 62 | 3.54e-01 |
| GO:BP | GO:0006476 | protein deacetylation | 3 | 106 | 3.54e-01 |
| GO:BP | GO:1903972 | regulation of cellular response to macrophage colony-stimulating factor stimulus | 1 | 3 | 3.54e-01 |
| GO:BP | GO:0042482 | positive regulation of odontogenesis | 1 | 5 | 3.54e-01 |
| GO:BP | GO:1903969 | regulation of response to macrophage colony-stimulating factor | 1 | 3 | 3.54e-01 |
| GO:BP | GO:1990138 | neuron projection extension | 1 | 148 | 3.54e-01 |
| GO:BP | GO:0007018 | microtubule-based movement | 2 | 300 | 3.54e-01 |
| GO:BP | GO:0014038 | regulation of Schwann cell differentiation | 1 | 3 | 3.54e-01 |
| GO:BP | GO:0019988 | charged-tRNA amino acid modification | 1 | 1 | 3.54e-01 |
| GO:BP | GO:0043114 | regulation of vascular permeability | 1 | 35 | 3.54e-01 |
| GO:BP | GO:0002143 | tRNA wobble position uridine thiolation | 2 | 4 | 3.54e-01 |
| GO:BP | GO:1904796 | regulation of core promoter binding | 1 | 5 | 3.54e-01 |
| GO:BP | GO:0032447 | protein urmylation | 2 | 4 | 3.54e-01 |
| GO:BP | GO:1901983 | regulation of protein acetylation | 14 | 69 | 3.54e-01 |
| GO:BP | GO:0045580 | regulation of T cell differentiation | 1 | 110 | 3.54e-01 |
| GO:BP | GO:0071951 | conversion of methionyl-tRNA to N-formyl-methionyl-tRNA | 1 | 1 | 3.54e-01 |
| GO:BP | GO:0021569 | rhombomere 3 development | 1 | 2 | 3.54e-01 |
| GO:BP | GO:0009235 | cobalamin metabolic process | 1 | 8 | 3.54e-01 |
| GO:BP | GO:0019076 | viral release from host cell | 7 | 28 | 3.54e-01 |
| GO:BP | GO:0035891 | exit from host cell | 7 | 28 | 3.54e-01 |
| GO:BP | GO:0043556 | regulation of translation in response to oxidative stress | 1 | 1 | 3.55e-01 |
| GO:BP | GO:1905475 | regulation of protein localization to membrane | 1 | 150 | 3.55e-01 |
| GO:BP | GO:0007179 | transforming growth factor beta receptor signaling pathway | 18 | 179 | 3.55e-01 |
| GO:BP | GO:0071938 | vitamin A transport | 1 | 1 | 3.55e-01 |
| GO:BP | GO:0042321 | negative regulation of circadian sleep/wake cycle, sleep | 1 | 2 | 3.55e-01 |
| GO:BP | GO:0061143 | alveolar primary septum development | 1 | 1 | 3.55e-01 |
| GO:BP | GO:0035814 | negative regulation of renal sodium excretion | 1 | 2 | 3.55e-01 |
| GO:BP | GO:0044087 | regulation of cellular component biogenesis | 5 | 809 | 3.55e-01 |
| GO:BP | GO:0032938 | negative regulation of translation in response to oxidative stress | 1 | 1 | 3.55e-01 |
| GO:BP | GO:0071939 | vitamin A import into cell | 1 | 1 | 3.55e-01 |
| GO:BP | GO:0039532 | negative regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway | 5 | 17 | 3.55e-01 |
| GO:BP | GO:0032204 | regulation of telomere maintenance | 11 | 96 | 3.55e-01 |
| GO:BP | GO:0046474 | glycerophospholipid biosynthetic process | 33 | 189 | 3.55e-01 |
| GO:BP | GO:0001825 | blastocyst formation | 1 | 37 | 3.55e-01 |
| GO:BP | GO:1903708 | positive regulation of hemopoiesis | 1 | 118 | 3.55e-01 |
| GO:BP | GO:0071218 | cellular response to misfolded protein | 7 | 23 | 3.55e-01 |
| GO:BP | GO:1902107 | positive regulation of leukocyte differentiation | 1 | 118 | 3.55e-01 |
| GO:BP | GO:0071901 | negative regulation of protein serine/threonine kinase activity | 22 | 101 | 3.56e-01 |
| GO:BP | GO:0060766 | negative regulation of androgen receptor signaling pathway | 1 | 12 | 3.56e-01 |
| GO:BP | GO:1904193 | negative regulation of cholangiocyte apoptotic process | 1 | 1 | 3.56e-01 |
| GO:BP | GO:0002700 | regulation of production of molecular mediator of immune response | 1 | 108 | 3.56e-01 |
| GO:BP | GO:0051302 | regulation of cell division | 6 | 145 | 3.56e-01 |
| GO:BP | GO:1905776 | positive regulation of DNA helicase activity | 2 | 3 | 3.56e-01 |
| GO:BP | GO:0006470 | protein dephosphorylation | 7 | 214 | 3.56e-01 |
| GO:BP | GO:1902488 | cholangiocyte apoptotic process | 1 | 1 | 3.56e-01 |
| GO:BP | GO:1904192 | regulation of cholangiocyte apoptotic process | 1 | 1 | 3.56e-01 |
| GO:BP | GO:0044092 | negative regulation of molecular function | 3 | 755 | 3.56e-01 |
| GO:BP | GO:1901860 | positive regulation of mitochondrial DNA metabolic process | 2 | 3 | 3.56e-01 |
| GO:BP | GO:0042822 | pyridoxal phosphate metabolic process | 2 | 4 | 3.56e-01 |
| GO:BP | GO:0048145 | regulation of fibroblast proliferation | 18 | 77 | 3.56e-01 |
| GO:BP | GO:0032467 | positive regulation of cytokinesis | 2 | 33 | 3.56e-01 |
| GO:BP | GO:0006098 | pentose-phosphate shunt | 4 | 19 | 3.56e-01 |
| GO:BP | GO:0010669 | epithelial structure maintenance | 1 | 15 | 3.56e-01 |
| GO:BP | GO:0006089 | lactate metabolic process | 3 | 16 | 3.56e-01 |
| GO:BP | GO:0000281 | mitotic cytokinesis | 11 | 81 | 3.56e-01 |
| GO:BP | GO:0080009 | mRNA methylation | 4 | 16 | 3.56e-01 |
| GO:BP | GO:0007091 | metaphase/anaphase transition of mitotic cell cycle | 11 | 91 | 3.56e-01 |
| GO:BP | GO:0043631 | RNA polyadenylation | 4 | 41 | 3.56e-01 |
| GO:BP | GO:0043922 | negative regulation by host of viral transcription | 1 | 11 | 3.56e-01 |
| GO:BP | GO:0060219 | camera-type eye photoreceptor cell differentiation | 5 | 18 | 3.56e-01 |
| GO:BP | GO:1905464 | positive regulation of DNA duplex unwinding | 2 | 3 | 3.56e-01 |
| GO:BP | GO:0048008 | platelet-derived growth factor receptor signaling pathway | 8 | 52 | 3.56e-01 |
| GO:BP | GO:1901992 | positive regulation of mitotic cell cycle phase transition | 11 | 86 | 3.57e-01 |
| GO:BP | GO:0045600 | positive regulation of fat cell differentiation | 11 | 50 | 3.57e-01 |
| GO:BP | GO:0072318 | clathrin coat disassembly | 3 | 8 | 3.57e-01 |
| GO:BP | GO:0034067 | protein localization to Golgi apparatus | 7 | 27 | 3.57e-01 |
| GO:BP | GO:1901653 | cellular response to peptide | 2 | 287 | 3.57e-01 |
| GO:BP | GO:0021852 | pyramidal neuron migration to cerebral cortex | 1 | 1 | 3.57e-01 |
| GO:BP | GO:0097494 | regulation of vesicle size | 2 | 19 | 3.57e-01 |
| GO:BP | GO:0022402 | cell cycle process | 108 | 1086 | 3.57e-01 |
| GO:BP | GO:0051657 | maintenance of organelle location | 4 | 11 | 3.57e-01 |
| GO:BP | GO:0140212 | regulation of long-chain fatty acid import into cell | 2 | 7 | 3.57e-01 |
| GO:BP | GO:0045739 | positive regulation of DNA repair | 9 | 120 | 3.58e-01 |
| GO:BP | GO:0009221 | pyrimidine deoxyribonucleotide biosynthetic process | 3 | 7 | 3.58e-01 |
| GO:BP | GO:0045655 | regulation of monocyte differentiation | 3 | 13 | 3.58e-01 |
| GO:BP | GO:0035054 | embryonic heart tube anterior/posterior pattern specification | 2 | 2 | 3.58e-01 |
| GO:BP | GO:0032915 | positive regulation of transforming growth factor beta2 production | 1 | 3 | 3.58e-01 |
| GO:BP | GO:0048371 | lateral mesodermal cell differentiation | 1 | 2 | 3.58e-01 |
| GO:BP | GO:0000956 | nuclear-transcribed mRNA catabolic process | 27 | 120 | 3.58e-01 |
| GO:BP | GO:1990928 | response to amino acid starvation | 2 | 51 | 3.58e-01 |
| GO:BP | GO:0031573 | mitotic intra-S DNA damage checkpoint signaling | 3 | 15 | 3.59e-01 |
| GO:BP | GO:0045005 | DNA-templated DNA replication maintenance of fidelity | 10 | 48 | 3.59e-01 |
| GO:BP | GO:0034312 | diol biosynthetic process | 2 | 20 | 3.59e-01 |
| GO:BP | GO:0035845 | photoreceptor cell outer segment organization | 3 | 10 | 3.59e-01 |
| GO:BP | GO:0033133 | positive regulation of glucokinase activity | 1 | 4 | 3.59e-01 |
| GO:BP | GO:0031503 | protein-containing complex localization | 1 | 168 | 3.59e-01 |
| GO:BP | GO:0006312 | mitotic recombination | 5 | 22 | 3.59e-01 |
| GO:BP | GO:0042637 | catagen | 1 | 4 | 3.59e-01 |
| GO:BP | GO:0002819 | regulation of adaptive immune response | 1 | 106 | 3.59e-01 |
| GO:BP | GO:0051794 | regulation of timing of catagen | 1 | 4 | 3.59e-01 |
| GO:BP | GO:0048549 | positive regulation of pinocytosis | 2 | 7 | 3.59e-01 |
| GO:BP | GO:0097398 | cellular response to interleukin-17 | 2 | 12 | 3.59e-01 |
| GO:BP | GO:0036496 | regulation of translational initiation by eIF2 alpha dephosphorylation | 1 | 2 | 3.59e-01 |
| GO:BP | GO:0051891 | positive regulation of cardioblast differentiation | 1 | 4 | 3.59e-01 |
| GO:BP | GO:0035790 | platelet-derived growth factor receptor-alpha signaling pathway | 3 | 6 | 3.59e-01 |
| GO:BP | GO:0072338 | lactam metabolic process | 1 | 2 | 3.59e-01 |
| GO:BP | GO:0009992 | intracellular water homeostasis | 2 | 3 | 3.59e-01 |
| GO:BP | GO:0035910 | ascending aorta morphogenesis | 1 | 4 | 3.59e-01 |
| GO:BP | GO:0051650 | establishment of vesicle localization | 1 | 175 | 3.59e-01 |
| GO:BP | GO:0097191 | extrinsic apoptotic signaling pathway | 22 | 179 | 3.59e-01 |
| GO:BP | GO:0000289 | nuclear-transcribed mRNA poly(A) tail shortening | 9 | 33 | 3.59e-01 |
| GO:BP | GO:1901575 | organic substance catabolic process | 9 | 1712 | 3.59e-01 |
| GO:BP | GO:1900079 | regulation of arginine biosynthetic process | 1 | 1 | 3.59e-01 |
| GO:BP | GO:0006915 | apoptotic process | 4 | 1443 | 3.59e-01 |
| GO:BP | GO:0006580 | ethanolamine metabolic process | 1 | 1 | 3.59e-01 |
| GO:BP | GO:0009082 | branched-chain amino acid biosynthetic process | 2 | 4 | 3.59e-01 |
| GO:BP | GO:1905051 | regulation of base-excision repair | 1 | 2 | 3.59e-01 |
| GO:BP | GO:1905053 | positive regulation of base-excision repair | 1 | 2 | 3.59e-01 |
| GO:BP | GO:0090384 | phagosome-lysosome docking | 1 | 1 | 3.59e-01 |
| GO:BP | GO:0051865 | protein autoubiquitination | 7 | 75 | 3.59e-01 |
| GO:BP | GO:0120040 | regulation of macrophage proliferation | 2 | 4 | 3.59e-01 |
| GO:BP | GO:0071806 | protein transmembrane transport | 1 | 62 | 3.59e-01 |
| GO:BP | GO:0003094 | glomerular filtration | 2 | 21 | 3.59e-01 |
| GO:BP | GO:1905767 | regulation of double-stranded telomeric DNA binding | 1 | 1 | 3.59e-01 |
| GO:BP | GO:0051090 | regulation of DNA-binding transcription factor activity | 2 | 335 | 3.59e-01 |
| GO:BP | GO:0032825 | positive regulation of natural killer cell differentiation | 2 | 7 | 3.59e-01 |
| GO:BP | GO:1905768 | negative regulation of double-stranded telomeric DNA binding | 1 | 1 | 3.59e-01 |
| GO:BP | GO:0006633 | fatty acid biosynthetic process | 1 | 104 | 3.59e-01 |
| GO:BP | GO:0031297 | replication fork processing | 9 | 42 | 3.59e-01 |
| GO:BP | GO:0044786 | cell cycle DNA replication | 6 | 40 | 3.59e-01 |
| GO:BP | GO:0007176 | regulation of epidermal growth factor-activated receptor activity | 7 | 24 | 3.59e-01 |
| GO:BP | GO:0032988 | ribonucleoprotein complex disassembly | 2 | 8 | 3.60e-01 |
| GO:BP | GO:0044089 | positive regulation of cellular component biogenesis | 4 | 420 | 3.60e-01 |
| GO:BP | GO:0016311 | dephosphorylation | 9 | 284 | 3.60e-01 |
| GO:BP | GO:2000657 | negative regulation of apolipoprotein binding | 1 | 1 | 3.60e-01 |
| GO:BP | GO:2000656 | regulation of apolipoprotein binding | 1 | 1 | 3.60e-01 |
| GO:BP | GO:0060373 | regulation of ventricular cardiac muscle cell membrane depolarization | 1 | 6 | 3.61e-01 |
| GO:BP | GO:0019827 | stem cell population maintenance | 13 | 149 | 3.61e-01 |
| GO:BP | GO:0009436 | glyoxylate catabolic process | 1 | 1 | 3.61e-01 |
| GO:BP | GO:0086068 | Purkinje myocyte to ventricular cardiac muscle cell communication | 1 | 6 | 3.61e-01 |
| GO:BP | GO:0080170 | hydrogen peroxide transmembrane transport | 1 | 1 | 3.61e-01 |
| GO:BP | GO:2000369 | regulation of clathrin-dependent endocytosis | 5 | 18 | 3.61e-01 |
| GO:BP | GO:0072344 | rescue of stalled ribosome | 3 | 9 | 3.61e-01 |
| GO:BP | GO:0086029 | Purkinje myocyte to ventricular cardiac muscle cell signaling | 1 | 6 | 3.61e-01 |
| GO:BP | GO:0048147 | negative regulation of fibroblast proliferation | 7 | 31 | 3.62e-01 |
| GO:BP | GO:0045905 | positive regulation of translational termination | 1 | 4 | 3.62e-01 |
| GO:BP | GO:0051983 | regulation of chromosome segregation | 14 | 121 | 3.62e-01 |
| GO:BP | GO:0045815 | transcription initiation-coupled chromatin remodeling | 2 | 26 | 3.62e-01 |
| GO:BP | GO:0006346 | DNA methylation-dependent heterochromatin formation | 6 | 22 | 3.62e-01 |
| GO:BP | GO:1900450 | negative regulation of glutamate receptor signaling pathway | 1 | 1 | 3.62e-01 |
| GO:BP | GO:0045054 | constitutive secretory pathway | 1 | 7 | 3.62e-01 |
| GO:BP | GO:0051646 | mitochondrion localization | 1 | 47 | 3.62e-01 |
| GO:BP | GO:0043630 | ncRNA polyadenylation involved in polyadenylation-dependent ncRNA catabolic process | 1 | 1 | 3.62e-01 |
| GO:BP | GO:0071050 | sno(s)RNA polyadenylation | 1 | 1 | 3.62e-01 |
| GO:BP | GO:0051041 | positive regulation of calcium-independent cell-cell adhesion | 1 | 1 | 3.62e-01 |
| GO:BP | GO:0007254 | JNK cascade | 9 | 138 | 3.62e-01 |
| GO:BP | GO:0000082 | G1/S transition of mitotic cell cycle | 18 | 207 | 3.62e-01 |
| GO:BP | GO:0048644 | muscle organ morphogenesis | 4 | 63 | 3.63e-01 |
| GO:BP | GO:0021532 | neural tube patterning | 1 | 31 | 3.63e-01 |
| GO:BP | GO:0046092 | deoxycytidine metabolic process | 1 | 1 | 3.64e-01 |
| GO:BP | GO:1903721 | positive regulation of I-kappaB phosphorylation | 2 | 5 | 3.64e-01 |
| GO:BP | GO:1904141 | positive regulation of microglial cell migration | 2 | 3 | 3.64e-01 |
| GO:BP | GO:0051123 | RNA polymerase II preinitiation complex assembly | 5 | 54 | 3.64e-01 |
| GO:BP | GO:0046618 | xenobiotic export from cell | 1 | 8 | 3.65e-01 |
| GO:BP | GO:0016077 | sno(s)RNA catabolic process | 2 | 3 | 3.65e-01 |
| GO:BP | GO:1901989 | positive regulation of cell cycle phase transition | 13 | 103 | 3.66e-01 |
| GO:BP | GO:0010256 | endomembrane system organization | 57 | 496 | 3.66e-01 |
| GO:BP | GO:0038145 | macrophage colony-stimulating factor signaling pathway | 1 | 3 | 3.66e-01 |
| GO:BP | GO:0055078 | sodium ion homeostasis | 1 | 26 | 3.66e-01 |
| GO:BP | GO:0048167 | regulation of synaptic plasticity | 1 | 141 | 3.66e-01 |
| GO:BP | GO:1902850 | microtubule cytoskeleton organization involved in mitosis | 3 | 157 | 3.66e-01 |
| GO:BP | GO:0039692 | single stranded viral RNA replication via double stranded DNA intermediate | 5 | 16 | 3.66e-01 |
| GO:BP | GO:0032869 | cellular response to insulin stimulus | 1 | 174 | 3.66e-01 |
| GO:BP | GO:0036213 | contractile ring contraction | 1 | 1 | 3.66e-01 |
| GO:BP | GO:0031929 | TOR signaling | 15 | 115 | 3.66e-01 |
| GO:BP | GO:0051495 | positive regulation of cytoskeleton organization | 15 | 165 | 3.66e-01 |
| GO:BP | GO:1904884 | positive regulation of telomerase catalytic core complex assembly | 1 | 2 | 3.66e-01 |
| GO:BP | GO:0010636 | positive regulation of mitochondrial fusion | 1 | 2 | 3.66e-01 |
| GO:BP | GO:0098969 | neurotransmitter receptor transport to postsynaptic membrane | 2 | 16 | 3.66e-01 |
| GO:BP | GO:0009446 | putrescine biosynthetic process | 2 | 4 | 3.66e-01 |
| GO:BP | GO:0070383 | DNA cytosine deamination | 3 | 5 | 3.66e-01 |
| GO:BP | GO:0046745 | viral capsid secondary envelopment | 1 | 1 | 3.66e-01 |
| GO:BP | GO:0003181 | atrioventricular valve morphogenesis | 3 | 25 | 3.66e-01 |
| GO:BP | GO:0033209 | tumor necrosis factor-mediated signaling pathway | 1 | 76 | 3.66e-01 |
| GO:BP | GO:0046580 | negative regulation of Ras protein signal transduction | 1 | 47 | 3.66e-01 |
| GO:BP | GO:0097310 | cap2 mRNA methylation | 1 | 1 | 3.66e-01 |
| GO:BP | GO:1904868 | telomerase catalytic core complex assembly | 1 | 2 | 3.66e-01 |
| GO:BP | GO:0010707 | globoside biosynthetic process via lactosylceramide | 1 | 1 | 3.66e-01 |
| GO:BP | GO:1904882 | regulation of telomerase catalytic core complex assembly | 1 | 2 | 3.66e-01 |
| GO:BP | GO:0097194 | execution phase of apoptosis | 1 | 53 | 3.66e-01 |
| GO:BP | GO:0061383 | trabecula morphogenesis | 3 | 43 | 3.66e-01 |
| GO:BP | GO:0021508 | floor plate formation | 2 | 3 | 3.66e-01 |
| GO:BP | GO:0000916 | actomyosin contractile ring contraction | 1 | 1 | 3.66e-01 |
| GO:BP | GO:0002285 | lymphocyte activation involved in immune response | 1 | 111 | 3.66e-01 |
| GO:BP | GO:0006621 | protein retention in ER lumen | 1 | 8 | 3.66e-01 |
| GO:BP | GO:0051641 | cellular localization | 9 | 2810 | 3.66e-01 |
| GO:BP | GO:0051156 | glucose 6-phosphate metabolic process | 5 | 25 | 3.66e-01 |
| GO:BP | GO:0051648 | vesicle localization | 1 | 192 | 3.66e-01 |
| GO:BP | GO:0002442 | serotonin secretion involved in inflammatory response | 1 | 2 | 3.66e-01 |
| GO:BP | GO:0045619 | regulation of lymphocyte differentiation | 1 | 132 | 3.66e-01 |
| GO:BP | GO:0018126 | protein hydroxylation | 4 | 26 | 3.66e-01 |
| GO:BP | GO:0070374 | positive regulation of ERK1 and ERK2 cascade | 1 | 121 | 3.66e-01 |
| GO:BP | GO:0090128 | regulation of synapse maturation | 2 | 15 | 3.66e-01 |
| GO:BP | GO:0006260 | DNA replication | 53 | 255 | 3.66e-01 |
| GO:BP | GO:0019083 | viral transcription | 2 | 48 | 3.66e-01 |
| GO:BP | GO:0002351 | serotonin production involved in inflammatory response | 1 | 2 | 3.66e-01 |
| GO:BP | GO:0051046 | regulation of secretion | 3 | 418 | 3.66e-01 |
| GO:BP | GO:0060119 | inner ear receptor cell development | 7 | 33 | 3.66e-01 |
| GO:BP | GO:0043456 | regulation of pentose-phosphate shunt | 2 | 6 | 3.67e-01 |
| GO:BP | GO:0006352 | DNA-templated transcription initiation | 31 | 130 | 3.67e-01 |
| GO:BP | GO:0140029 | exocytic process | 1 | 69 | 3.67e-01 |
| GO:BP | GO:0006631 | fatty acid metabolic process | 3 | 276 | 3.67e-01 |
| GO:BP | GO:0009786 | regulation of asymmetric cell division | 1 | 1 | 3.67e-01 |
| GO:BP | GO:0006384 | transcription initiation at RNA polymerase III promoter | 2 | 8 | 3.67e-01 |
| GO:BP | GO:0061909 | autophagosome-lysosome fusion | 3 | 8 | 3.67e-01 |
| GO:BP | GO:0048662 | negative regulation of smooth muscle cell proliferation | 1 | 42 | 3.67e-01 |
| GO:BP | GO:0021873 | forebrain neuroblast division | 1 | 3 | 3.67e-01 |
| GO:BP | GO:0062176 | R-loop processing | 2 | 6 | 3.67e-01 |
| GO:BP | GO:0140861 | DNA repair-dependent chromatin remodeling | 2 | 6 | 3.67e-01 |
| GO:BP | GO:0012501 | programmed cell death | 4 | 1479 | 3.67e-01 |
| GO:BP | GO:0060157 | urinary bladder development | 2 | 2 | 3.68e-01 |
| GO:BP | GO:0010810 | regulation of cell-substrate adhesion | 1 | 172 | 3.68e-01 |
| GO:BP | GO:0097396 | response to interleukin-17 | 2 | 13 | 3.68e-01 |
| GO:BP | GO:0051784 | negative regulation of nuclear division | 8 | 57 | 3.68e-01 |
| GO:BP | GO:0031112 | positive regulation of microtubule polymerization or depolymerization | 4 | 35 | 3.70e-01 |
| GO:BP | GO:0016239 | positive regulation of macroautophagy | 9 | 70 | 3.70e-01 |
| GO:BP | GO:0002440 | production of molecular mediator of immune response | 1 | 135 | 3.71e-01 |
| GO:BP | GO:0048738 | cardiac muscle tissue development | 8 | 198 | 3.71e-01 |
| GO:BP | GO:1903894 | regulation of IRE1-mediated unfolded protein response | 5 | 14 | 3.72e-01 |
| GO:BP | GO:0006575 | cellular modified amino acid metabolic process | 1 | 96 | 3.72e-01 |
| GO:BP | GO:0002230 | positive regulation of defense response to virus by host | 8 | 23 | 3.72e-01 |
| GO:BP | GO:1904482 | cellular response to tetrahydrofolate | 1 | 1 | 3.72e-01 |
| GO:BP | GO:1904481 | response to tetrahydrofolate | 1 | 1 | 3.72e-01 |
| GO:BP | GO:1902001 | fatty acid transmembrane transport | 4 | 15 | 3.72e-01 |
| GO:BP | GO:1905168 | positive regulation of double-strand break repair via homologous recombination | 2 | 35 | 3.72e-01 |
| GO:BP | GO:0043414 | macromolecule methylation | 43 | 272 | 3.73e-01 |
| GO:BP | GO:0097205 | renal filtration | 2 | 23 | 3.74e-01 |
| GO:BP | GO:1901797 | negative regulation of signal transduction by p53 class mediator | 5 | 32 | 3.74e-01 |
| GO:BP | GO:0030149 | sphingolipid catabolic process | 3 | 26 | 3.74e-01 |
| GO:BP | GO:1902253 | regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 5 | 32 | 3.74e-01 |
| GO:BP | GO:0006241 | CTP biosynthetic process | 3 | 12 | 3.74e-01 |
| GO:BP | GO:0035855 | megakaryocyte development | 1 | 16 | 3.74e-01 |
| GO:BP | GO:0070584 | mitochondrion morphogenesis | 6 | 21 | 3.75e-01 |
| GO:BP | GO:1900221 | regulation of amyloid-beta clearance | 1 | 13 | 3.75e-01 |
| GO:BP | GO:0006392 | transcription elongation by mitochondrial RNA polymerase | 1 | 1 | 3.75e-01 |
| GO:BP | GO:2001044 | regulation of integrin-mediated signaling pathway | 1 | 20 | 3.75e-01 |
| GO:BP | GO:1900112 | regulation of histone H3-K9 trimethylation | 1 | 5 | 3.75e-01 |
| GO:BP | GO:0010706 | ganglioside biosynthetic process via lactosylceramide | 2 | 5 | 3.76e-01 |
| GO:BP | GO:0017126 | nucleologenesis | 1 | 2 | 3.77e-01 |
| GO:BP | GO:0009217 | purine deoxyribonucleoside triphosphate catabolic process | 2 | 4 | 3.77e-01 |
| GO:BP | GO:0014050 | negative regulation of glutamate secretion | 1 | 2 | 3.77e-01 |
| GO:BP | GO:0090071 | negative regulation of ribosome biogenesis | 2 | 4 | 3.77e-01 |
| GO:BP | GO:0016578 | histone deubiquitination | 3 | 46 | 3.77e-01 |
| GO:BP | GO:0021529 | spinal cord oligodendrocyte cell differentiation | 1 | 2 | 3.77e-01 |
| GO:BP | GO:1903780 | negative regulation of cardiac conduction | 1 | 1 | 3.77e-01 |
| GO:BP | GO:0003415 | chondrocyte hypertrophy | 2 | 6 | 3.77e-01 |
| GO:BP | GO:0002190 | cap-independent translational initiation | 2 | 4 | 3.77e-01 |
| GO:BP | GO:1901845 | negative regulation of cell communication by electrical coupling involved in cardiac conduction | 1 | 1 | 3.77e-01 |
| GO:BP | GO:0051128 | regulation of cellular component organization | 9 | 2011 | 3.77e-01 |
| GO:BP | GO:0048593 | camera-type eye morphogenesis | 2 | 91 | 3.77e-01 |
| GO:BP | GO:0010651 | negative regulation of cell communication by electrical coupling | 1 | 1 | 3.77e-01 |
| GO:BP | GO:0032901 | positive regulation of neurotrophin production | 1 | 1 | 3.77e-01 |
| GO:BP | GO:0010774 | meiotic strand invasion involved in reciprocal meiotic recombination | 1 | 1 | 3.77e-01 |
| GO:BP | GO:0000708 | meiotic strand invasion | 1 | 1 | 3.77e-01 |
| GO:BP | GO:0000709 | meiotic joint molecule formation | 1 | 1 | 3.77e-01 |
| GO:BP | GO:0009153 | purine deoxyribonucleotide biosynthetic process | 2 | 4 | 3.77e-01 |
| GO:BP | GO:0001955 | blood vessel maturation | 1 | 6 | 3.77e-01 |
| GO:BP | GO:0048588 | developmental cell growth | 1 | 192 | 3.77e-01 |
| GO:BP | GO:0044839 | cell cycle G2/M phase transition | 31 | 149 | 3.77e-01 |
| GO:BP | GO:0035878 | nail development | 2 | 8 | 3.77e-01 |
| GO:BP | GO:2000273 | positive regulation of signaling receptor activity | 3 | 33 | 3.78e-01 |
| GO:BP | GO:0051607 | defense response to virus | 1 | 202 | 3.78e-01 |
| GO:BP | GO:0140546 | defense response to symbiont | 1 | 202 | 3.78e-01 |
| GO:BP | GO:1904354 | negative regulation of telomere capping | 3 | 8 | 3.78e-01 |
| GO:BP | GO:0055001 | muscle cell development | 7 | 165 | 3.78e-01 |
| GO:BP | GO:0160007 | glutathione import into mitochondrion | 1 | 1 | 3.78e-01 |
| GO:BP | GO:0098877 | neurotransmitter receptor transport to plasma membrane | 2 | 17 | 3.78e-01 |
| GO:BP | GO:0098727 | maintenance of cell number | 13 | 151 | 3.78e-01 |
| GO:BP | GO:1903540 | establishment of protein localization to postsynaptic membrane | 2 | 16 | 3.78e-01 |
| GO:BP | GO:0007051 | spindle organization | 4 | 188 | 3.79e-01 |
| GO:BP | GO:0070227 | lymphocyte apoptotic process | 1 | 56 | 3.80e-01 |
| GO:BP | GO:0061159 | establishment of bipolar cell polarity involved in cell morphogenesis | 1 | 1 | 3.80e-01 |
| GO:BP | GO:0051892 | negative regulation of cardioblast differentiation | 1 | 1 | 3.80e-01 |
| GO:BP | GO:0072033 | renal vesicle formation | 2 | 8 | 3.82e-01 |
| GO:BP | GO:2000727 | positive regulation of cardiac muscle cell differentiation | 2 | 6 | 3.82e-01 |
| GO:BP | GO:0000354 | cis assembly of pre-catalytic spliceosome | 1 | 2 | 3.82e-01 |
| GO:BP | GO:0071560 | cellular response to transforming growth factor beta stimulus | 23 | 222 | 3.82e-01 |
| GO:BP | GO:0051058 | negative regulation of small GTPase mediated signal transduction | 1 | 53 | 3.82e-01 |
| GO:BP | GO:0032879 | regulation of localization | 7 | 1555 | 3.82e-01 |
| GO:BP | GO:0002703 | regulation of leukocyte mediated immunity | 1 | 118 | 3.82e-01 |
| GO:BP | GO:0032056 | positive regulation of translation in response to stress | 3 | 8 | 3.82e-01 |
| GO:BP | GO:0070979 | protein K11-linked ubiquitination | 5 | 29 | 3.82e-01 |
| GO:BP | GO:1904139 | regulation of microglial cell migration | 1 | 3 | 3.82e-01 |
| GO:BP | GO:0042354 | L-fucose metabolic process | 1 | 4 | 3.82e-01 |
| GO:BP | GO:0007066 | female meiosis sister chromatid cohesion | 1 | 1 | 3.82e-01 |
| GO:BP | GO:1904124 | microglial cell migration | 1 | 3 | 3.82e-01 |
| GO:BP | GO:0061518 | microglial cell proliferation | 1 | 4 | 3.82e-01 |
| GO:BP | GO:0003271 | smoothened signaling pathway involved in regulation of secondary heart field cardioblast proliferation | 1 | 1 | 3.82e-01 |
| GO:BP | GO:1903321 | negative regulation of protein modification by small protein conjugation or removal | 9 | 86 | 3.82e-01 |
| GO:BP | GO:0043063 | intercellular bridge organization | 1 | 1 | 3.82e-01 |
| GO:BP | GO:0000707 | meiotic DNA recombinase assembly | 1 | 1 | 3.82e-01 |
| GO:BP | GO:0009170 | purine deoxyribonucleoside monophosphate metabolic process | 3 | 7 | 3.82e-01 |
| GO:BP | GO:0007160 | cell-matrix adhesion | 1 | 179 | 3.83e-01 |
| GO:BP | GO:0045113 | regulation of integrin biosynthetic process | 1 | 2 | 3.86e-01 |
| GO:BP | GO:0048818 | positive regulation of hair follicle maturation | 1 | 5 | 3.86e-01 |
| GO:BP | GO:0035905 | ascending aorta development | 1 | 5 | 3.86e-01 |
| GO:BP | GO:1905007 | positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation | 1 | 5 | 3.86e-01 |
| GO:BP | GO:0003289 | atrial septum primum morphogenesis | 1 | 5 | 3.86e-01 |
| GO:BP | GO:1905207 | regulation of cardiocyte differentiation | 4 | 22 | 3.86e-01 |
| GO:BP | GO:0003284 | septum primum development | 1 | 5 | 3.86e-01 |
| GO:BP | GO:0006275 | regulation of DNA replication | 25 | 116 | 3.86e-01 |
| GO:BP | GO:1904572 | negative regulation of mRNA binding | 1 | 1 | 3.86e-01 |
| GO:BP | GO:1904569 | regulation of selenocysteine incorporation | 1 | 1 | 3.86e-01 |
| GO:BP | GO:0051126 | negative regulation of actin nucleation | 1 | 6 | 3.86e-01 |
| GO:BP | GO:0048199 | vesicle targeting, to, from or within Golgi | 2 | 31 | 3.86e-01 |
| GO:BP | GO:2001239 | regulation of extrinsic apoptotic signaling pathway in absence of ligand | 6 | 35 | 3.86e-01 |
| GO:BP | GO:1904570 | negative regulation of selenocysteine incorporation | 1 | 1 | 3.86e-01 |
| GO:BP | GO:1904574 | negative regulation of selenocysteine insertion sequence binding | 1 | 1 | 3.86e-01 |
| GO:BP | GO:1904573 | regulation of selenocysteine insertion sequence binding | 1 | 1 | 3.86e-01 |
| GO:BP | GO:0060560 | developmental growth involved in morphogenesis | 1 | 204 | 3.86e-01 |
| GO:BP | GO:0043555 | regulation of translation in response to stress | 6 | 23 | 3.86e-01 |
| GO:BP | GO:0043434 | response to peptide hormone | 2 | 321 | 3.86e-01 |
| GO:BP | GO:0097291 | renal phosphate ion absorption | 1 | 1 | 3.86e-01 |
| GO:BP | GO:0042490 | mechanoreceptor differentiation | 9 | 49 | 3.86e-01 |
| GO:BP | GO:0007062 | sister chromatid cohesion | 2 | 52 | 3.86e-01 |
| GO:BP | GO:0090114 | COPII-coated vesicle budding | 9 | 40 | 3.86e-01 |
| GO:BP | GO:0060677 | ureteric bud elongation | 2 | 7 | 3.86e-01 |
| GO:BP | GO:0009056 | catabolic process | 10 | 2088 | 3.86e-01 |
| GO:BP | GO:1905364 | regulation of endosomal vesicle fusion | 1 | 1 | 3.86e-01 |
| GO:BP | GO:0007163 | establishment or maintenance of cell polarity | 1 | 206 | 3.86e-01 |
| GO:BP | GO:0072714 | response to selenite ion | 1 | 1 | 3.86e-01 |
| GO:BP | GO:0072715 | cellular response to selenite ion | 1 | 1 | 3.86e-01 |
| GO:BP | GO:0051569 | regulation of histone H3-K4 methylation | 8 | 26 | 3.86e-01 |
| GO:BP | GO:2000641 | regulation of early endosome to late endosome transport | 3 | 17 | 3.86e-01 |
| GO:BP | GO:0031548 | regulation of brain-derived neurotrophic factor receptor signaling pathway | 1 | 2 | 3.86e-01 |
| GO:BP | GO:0060020 | Bergmann glial cell differentiation | 1 | 9 | 3.86e-01 |
| GO:BP | GO:0097167 | circadian regulation of translation | 2 | 4 | 3.86e-01 |
| GO:BP | GO:0046521 | sphingoid catabolic process | 1 | 1 | 3.86e-01 |
| GO:BP | GO:0035553 | oxidative single-stranded RNA demethylation | 1 | 3 | 3.86e-01 |
| GO:BP | GO:1904895 | ESCRT complex assembly | 1 | 1 | 3.86e-01 |
| GO:BP | GO:1904902 | ESCRT III complex assembly | 1 | 1 | 3.86e-01 |
| GO:BP | GO:1904292 | regulation of ERAD pathway | 5 | 22 | 3.86e-01 |
| GO:BP | GO:2000630 | positive regulation of miRNA metabolic process | 7 | 48 | 3.86e-01 |
| GO:BP | GO:0007072 | positive regulation of transcription involved in exit from mitosis | 1 | 1 | 3.86e-01 |
| GO:BP | GO:0000729 | DNA double-strand break processing | 6 | 18 | 3.86e-01 |
| GO:BP | GO:0050870 | positive regulation of T cell activation | 1 | 144 | 3.86e-01 |
| GO:BP | GO:0034727 | piecemeal microautophagy of the nucleus | 1 | 9 | 3.86e-01 |
| GO:BP | GO:0035552 | oxidative single-stranded DNA demethylation | 1 | 3 | 3.86e-01 |
| GO:BP | GO:0071732 | cellular response to nitric oxide | 5 | 14 | 3.86e-01 |
| GO:BP | GO:2000010 | positive regulation of protein localization to cell surface | 3 | 16 | 3.86e-01 |
| GO:BP | GO:0018022 | peptidyl-lysine methylation | 22 | 104 | 3.86e-01 |
| GO:BP | GO:1902751 | positive regulation of cell cycle G2/M phase transition | 8 | 30 | 3.86e-01 |
| GO:BP | GO:0061419 | positive regulation of transcription from RNA polymerase II promoter in response to hypoxia | 2 | 5 | 3.86e-01 |
| GO:BP | GO:2000622 | regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 3 | 12 | 3.86e-01 |
| GO:BP | GO:0043586 | tongue development | 1 | 15 | 3.86e-01 |
| GO:BP | GO:0006978 | DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator | 3 | 18 | 3.86e-01 |
| GO:BP | GO:1902206 | negative regulation of interleukin-2-mediated signaling pathway | 1 | 1 | 3.86e-01 |
| GO:BP | GO:0106354 | tRNA surveillance | 3 | 7 | 3.86e-01 |
| GO:BP | GO:1902233 | negative regulation of positive thymic T cell selection | 1 | 1 | 3.86e-01 |
| GO:BP | GO:1902205 | regulation of interleukin-2-mediated signaling pathway | 1 | 1 | 3.86e-01 |
| GO:BP | GO:0097711 | ciliary basal body-plasma membrane docking | 1 | 2 | 3.86e-01 |
| GO:BP | GO:0000280 | nuclear division | 40 | 344 | 3.86e-01 |
| GO:BP | GO:0050730 | regulation of peptidyl-tyrosine phosphorylation | 1 | 166 | 3.86e-01 |
| GO:BP | GO:1904705 | regulation of vascular associated smooth muscle cell proliferation | 1 | 53 | 3.86e-01 |
| GO:BP | GO:1900193 | regulation of oocyte maturation | 3 | 5 | 3.86e-01 |
| GO:BP | GO:0071029 | nuclear ncRNA surveillance | 3 | 7 | 3.86e-01 |
| GO:BP | GO:0007296 | vitellogenesis | 1 | 4 | 3.86e-01 |
| GO:BP | GO:0032200 | telomere organization | 17 | 166 | 3.86e-01 |
| GO:BP | GO:0042276 | error-prone translesion synthesis | 1 | 11 | 3.86e-01 |
| GO:BP | GO:0071035 | nuclear polyadenylation-dependent rRNA catabolic process | 3 | 7 | 3.86e-01 |
| GO:BP | GO:0071038 | nuclear polyadenylation-dependent tRNA catabolic process | 3 | 7 | 3.86e-01 |
| GO:BP | GO:0045210 | FasL biosynthetic process | 1 | 1 | 3.86e-01 |
| GO:BP | GO:0071046 | nuclear polyadenylation-dependent ncRNA catabolic process | 3 | 7 | 3.86e-01 |
| GO:BP | GO:0071897 | DNA biosynthetic process | 21 | 175 | 3.86e-01 |
| GO:BP | GO:1902215 | negative regulation of interleukin-4-mediated signaling pathway | 1 | 1 | 3.86e-01 |
| GO:BP | GO:0048370 | lateral mesoderm formation | 1 | 3 | 3.87e-01 |
| GO:BP | GO:0043966 | histone H3 acetylation | 2 | 59 | 3.87e-01 |
| GO:BP | GO:0006261 | DNA-templated DNA replication | 32 | 148 | 3.87e-01 |
| GO:BP | GO:0033687 | osteoblast proliferation | 7 | 27 | 3.87e-01 |
| GO:BP | GO:0048369 | lateral mesoderm morphogenesis | 1 | 3 | 3.87e-01 |
| GO:BP | GO:0003292 | cardiac septum cell differentiation | 1 | 4 | 3.87e-01 |
| GO:BP | GO:0060922 | atrioventricular node cell differentiation | 1 | 4 | 3.87e-01 |
| GO:BP | GO:0001880 | Mullerian duct regression | 1 | 4 | 3.87e-01 |
| GO:BP | GO:0003197 | endocardial cushion development | 3 | 46 | 3.87e-01 |
| GO:BP | GO:0060928 | atrioventricular node cell development | 1 | 4 | 3.87e-01 |
| GO:BP | GO:0048714 | positive regulation of oligodendrocyte differentiation | 2 | 13 | 3.87e-01 |
| GO:BP | GO:0002699 | positive regulation of immune effector process | 1 | 130 | 3.87e-01 |
| GO:BP | GO:0018027 | peptidyl-lysine dimethylation | 3 | 22 | 3.88e-01 |
| GO:BP | GO:0006606 | protein import into nucleus | 15 | 147 | 3.89e-01 |
| GO:BP | GO:0048050 | post-embryonic eye morphogenesis | 3 | 7 | 3.90e-01 |
| GO:BP | GO:0071480 | cellular response to gamma radiation | 7 | 29 | 3.90e-01 |
| GO:BP | GO:0032233 | positive regulation of actin filament bundle assembly | 7 | 54 | 3.90e-01 |
| GO:BP | GO:0031077 | post-embryonic camera-type eye development | 3 | 7 | 3.90e-01 |
| GO:BP | GO:0070243 | regulation of thymocyte apoptotic process | 4 | 11 | 3.90e-01 |
| GO:BP | GO:0015881 | creatine transmembrane transport | 1 | 4 | 3.90e-01 |
| GO:BP | GO:0032717 | negative regulation of interleukin-8 production | 3 | 12 | 3.90e-01 |
| GO:BP | GO:0048025 | negative regulation of mRNA splicing, via spliceosome | 1 | 23 | 3.90e-01 |
| GO:BP | GO:0007507 | heart development | 17 | 506 | 3.90e-01 |
| GO:BP | GO:0003254 | regulation of membrane depolarization | 2 | 37 | 3.90e-01 |
| GO:BP | GO:0071348 | cellular response to interleukin-11 | 1 | 1 | 3.90e-01 |
| GO:BP | GO:0042063 | gliogenesis | 10 | 235 | 3.90e-01 |
| GO:BP | GO:0045842 | positive regulation of mitotic metaphase/anaphase transition | 3 | 14 | 3.90e-01 |
| GO:BP | GO:0051103 | DNA ligation involved in DNA repair | 2 | 5 | 3.90e-01 |
| GO:BP | GO:1990874 | vascular associated smooth muscle cell proliferation | 1 | 55 | 3.90e-01 |
| GO:BP | GO:0003356 | regulation of cilium beat frequency | 3 | 10 | 3.90e-01 |
| GO:BP | GO:0007492 | endoderm development | 4 | 65 | 3.90e-01 |
| GO:BP | GO:1905303 | positive regulation of macropinocytosis | 1 | 2 | 3.90e-01 |
| GO:BP | GO:0075523 | viral translational frameshifting | 1 | 1 | 3.90e-01 |
| GO:BP | GO:0051642 | centrosome localization | 7 | 31 | 3.90e-01 |
| GO:BP | GO:0010616 | negative regulation of cardiac muscle adaptation | 1 | 7 | 3.90e-01 |
| GO:BP | GO:0009785 | blue light signaling pathway | 1 | 2 | 3.90e-01 |
| GO:BP | GO:2001125 | negative regulation of translational frameshifting | 1 | 1 | 3.90e-01 |
| GO:BP | GO:0006654 | phosphatidic acid biosynthetic process | 7 | 30 | 3.90e-01 |
| GO:BP | GO:1902275 | regulation of chromatin organization | 10 | 49 | 3.90e-01 |
| GO:BP | GO:0045494 | photoreceptor cell maintenance | 1 | 27 | 3.90e-01 |
| GO:BP | GO:2001124 | regulation of translational frameshifting | 1 | 1 | 3.90e-01 |
| GO:BP | GO:0045657 | positive regulation of monocyte differentiation | 2 | 7 | 3.90e-01 |
| GO:BP | GO:0032483 | regulation of Rab protein signal transduction | 3 | 7 | 3.90e-01 |
| GO:BP | GO:0072201 | negative regulation of mesenchymal cell proliferation | 1 | 7 | 3.90e-01 |
| GO:BP | GO:0086004 | regulation of cardiac muscle cell contraction | 2 | 34 | 3.90e-01 |
| GO:BP | GO:0086070 | SA node cell to atrial cardiac muscle cell communication | 2 | 14 | 3.90e-01 |
| GO:BP | GO:0061842 | microtubule organizing center localization | 7 | 31 | 3.90e-01 |
| GO:BP | GO:1903243 | negative regulation of cardiac muscle hypertrophy in response to stress | 1 | 7 | 3.90e-01 |
| GO:BP | GO:0002091 | negative regulation of receptor internalization | 3 | 14 | 3.90e-01 |
| GO:BP | GO:1901524 | regulation of mitophagy | 2 | 13 | 3.90e-01 |
| GO:BP | GO:0007264 | small GTPase mediated signal transduction | 4 | 421 | 3.90e-01 |
| GO:BP | GO:0006144 | purine nucleobase metabolic process | 5 | 15 | 3.90e-01 |
| GO:BP | GO:0010660 | regulation of muscle cell apoptotic process | 1 | 56 | 3.90e-01 |
| GO:BP | GO:0071483 | cellular response to blue light | 1 | 2 | 3.90e-01 |
| GO:BP | GO:0030952 | establishment or maintenance of cytoskeleton polarity | 1 | 7 | 3.90e-01 |
| GO:BP | GO:1901099 | negative regulation of signal transduction in absence of ligand | 5 | 25 | 3.90e-01 |
| GO:BP | GO:2001240 | negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 5 | 25 | 3.90e-01 |
| GO:BP | GO:0071245 | cellular response to carbon monoxide | 1 | 1 | 3.90e-01 |
| GO:BP | GO:0010649 | regulation of cell communication by electrical coupling | 5 | 17 | 3.90e-01 |
| GO:BP | GO:0008608 | attachment of spindle microtubules to kinetochore | 6 | 42 | 3.90e-01 |
| GO:BP | GO:1903719 | regulation of I-kappaB phosphorylation | 2 | 6 | 3.91e-01 |
| GO:BP | GO:0071559 | response to transforming growth factor beta | 28 | 227 | 3.91e-01 |
| GO:BP | GO:0006290 | pyrimidine dimer repair | 3 | 8 | 3.91e-01 |
| GO:BP | GO:0032077 | positive regulation of deoxyribonuclease activity | 2 | 5 | 3.92e-01 |
| GO:BP | GO:0019470 | 4-hydroxyproline catabolic process | 1 | 4 | 3.92e-01 |
| GO:BP | GO:0019471 | 4-hydroxyproline metabolic process | 1 | 4 | 3.92e-01 |
| GO:BP | GO:0009209 | pyrimidine ribonucleoside triphosphate biosynthetic process | 3 | 13 | 3.92e-01 |
| GO:BP | GO:0042866 | pyruvate biosynthetic process | 1 | 2 | 3.92e-01 |
| GO:BP | GO:0014020 | primary neural tube formation | 11 | 94 | 3.92e-01 |
| GO:BP | GO:0060371 | regulation of atrial cardiac muscle cell membrane depolarization | 1 | 7 | 3.92e-01 |
| GO:BP | GO:1905381 | negative regulation of snRNA transcription by RNA polymerase II | 1 | 1 | 3.92e-01 |
| GO:BP | GO:0045913 | positive regulation of carbohydrate metabolic process | 7 | 60 | 3.93e-01 |
| GO:BP | GO:0000712 | resolution of meiotic recombination intermediates | 3 | 13 | 3.93e-01 |
| GO:BP | GO:0072330 | monocarboxylic acid biosynthetic process | 1 | 145 | 3.93e-01 |
| GO:BP | GO:0051091 | positive regulation of DNA-binding transcription factor activity | 1 | 199 | 3.93e-01 |
| GO:BP | GO:1904294 | positive regulation of ERAD pathway | 4 | 16 | 3.93e-01 |
| GO:BP | GO:0007249 | I-kappaB kinase/NF-kappaB signaling | 28 | 227 | 3.93e-01 |
| GO:BP | GO:0032466 | negative regulation of cytokinesis | 2 | 7 | 3.94e-01 |
| GO:BP | GO:0055089 | fatty acid homeostasis | 2 | 12 | 3.94e-01 |
| GO:BP | GO:1903039 | positive regulation of leukocyte cell-cell adhesion | 1 | 157 | 3.94e-01 |
| GO:BP | GO:1901030 | positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway | 4 | 12 | 3.94e-01 |
| GO:BP | GO:0071549 | cellular response to dexamethasone stimulus | 7 | 24 | 3.94e-01 |
| GO:BP | GO:0032241 | positive regulation of nucleobase-containing compound transport | 1 | 6 | 3.94e-01 |
| GO:BP | GO:0045188 | regulation of circadian sleep/wake cycle, non-REM sleep | 1 | 2 | 3.94e-01 |
| GO:BP | GO:0006887 | exocytosis | 3 | 256 | 3.94e-01 |
| GO:BP | GO:0032229 | negative regulation of synaptic transmission, GABAergic | 1 | 3 | 3.94e-01 |
| GO:BP | GO:0032868 | response to insulin | 1 | 215 | 3.94e-01 |
| GO:BP | GO:0042439 | ethanolamine-containing compound metabolic process | 2 | 5 | 3.94e-01 |
| GO:BP | GO:1902231 | positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage | 3 | 7 | 3.94e-01 |
| GO:BP | GO:0034124 | regulation of MyD88-dependent toll-like receptor signaling pathway | 2 | 2 | 3.95e-01 |
| GO:BP | GO:0036123 | histone H3-K9 dimethylation | 1 | 3 | 3.95e-01 |
| GO:BP | GO:0050804 | modulation of chemical synaptic transmission | 2 | 341 | 3.95e-01 |
| GO:BP | GO:0003400 | regulation of COPII vesicle coating | 2 | 3 | 3.95e-01 |
| GO:BP | GO:0036120 | cellular response to platelet-derived growth factor stimulus | 1 | 21 | 3.96e-01 |
| GO:BP | GO:0003148 | outflow tract septum morphogenesis | 2 | 23 | 3.96e-01 |
| GO:BP | GO:1903441 | protein localization to ciliary membrane | 1 | 11 | 3.96e-01 |
| GO:BP | GO:1902044 | regulation of Fas signaling pathway | 2 | 4 | 3.96e-01 |
| GO:BP | GO:0099177 | regulation of trans-synaptic signaling | 2 | 342 | 3.96e-01 |
| GO:BP | GO:0035518 | histone H2A monoubiquitination | 2 | 19 | 3.96e-01 |
| GO:BP | GO:0061647 | histone H3-K9 modification | 2 | 23 | 3.96e-01 |
| GO:BP | GO:0071236 | cellular response to antibiotic | 2 | 11 | 3.96e-01 |
| GO:BP | GO:0007611 | learning or memory | 1 | 202 | 3.97e-01 |
| GO:BP | GO:0000959 | mitochondrial RNA metabolic process | 3 | 50 | 3.97e-01 |
| GO:BP | GO:1900240 | negative regulation of phenotypic switching | 1 | 2 | 3.97e-01 |
| GO:BP | GO:0035281 | pre-miRNA export from nucleus | 1 | 2 | 3.97e-01 |
| GO:BP | GO:0006907 | pinocytosis | 4 | 18 | 3.97e-01 |
| GO:BP | GO:0045652 | regulation of megakaryocyte differentiation | 1 | 33 | 3.97e-01 |
| GO:BP | GO:0042221 | response to chemical | 8 | 2559 | 3.97e-01 |
| GO:BP | GO:0048596 | embryonic camera-type eye morphogenesis | 1 | 18 | 3.97e-01 |
| GO:BP | GO:0034446 | substrate adhesion-dependent cell spreading | 1 | 97 | 3.97e-01 |
| GO:BP | GO:0021520 | spinal cord motor neuron cell fate specification | 1 | 5 | 3.97e-01 |
| GO:BP | GO:0044779 | meiotic spindle checkpoint signaling | 1 | 2 | 3.97e-01 |
| GO:BP | GO:0032263 | GMP salvage | 2 | 4 | 3.97e-01 |
| GO:BP | GO:0018026 | peptidyl-lysine monomethylation | 2 | 11 | 3.97e-01 |
| GO:BP | GO:1905931 | negative regulation of vascular associated smooth muscle cell differentiation involved in phenotypic switching | 1 | 2 | 3.97e-01 |
| GO:BP | GO:0046122 | purine deoxyribonucleoside metabolic process | 2 | 3 | 3.97e-01 |
| GO:BP | GO:0006364 | rRNA processing | 44 | 221 | 3.97e-01 |
| GO:BP | GO:0014809 | regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion | 1 | 4 | 3.97e-01 |
| GO:BP | GO:0051788 | response to misfolded protein | 7 | 25 | 3.97e-01 |
| GO:BP | GO:1905916 | negative regulation of cell differentiation involved in phenotypic switching | 1 | 2 | 3.97e-01 |
| GO:BP | GO:0044209 | AMP salvage | 2 | 5 | 3.97e-01 |
| GO:BP | GO:0008219 | cell death | 4 | 1596 | 3.97e-01 |
| GO:BP | GO:0008299 | isoprenoid biosynthetic process | 1 | 26 | 3.97e-01 |
| GO:BP | GO:0010564 | regulation of cell cycle process | 63 | 626 | 3.97e-01 |
| GO:BP | GO:0050686 | negative regulation of mRNA processing | 1 | 25 | 3.97e-01 |
| GO:BP | GO:0001556 | oocyte maturation | 8 | 22 | 3.98e-01 |
| GO:BP | GO:2000036 | regulation of stem cell population maintenance | 7 | 62 | 3.98e-01 |
| GO:BP | GO:0032238 | adenosine transport | 1 | 2 | 3.98e-01 |
| GO:BP | GO:0000056 | ribosomal small subunit export from nucleus | 3 | 8 | 3.98e-01 |
| GO:BP | GO:0071479 | cellular response to ionizing radiation | 7 | 68 | 3.98e-01 |
| GO:BP | GO:1903209 | positive regulation of oxidative stress-induced cell death | 1 | 13 | 3.98e-01 |
| GO:BP | GO:0051615 | histamine uptake | 1 | 3 | 3.98e-01 |
| GO:BP | GO:2000279 | negative regulation of DNA biosynthetic process | 5 | 34 | 3.98e-01 |
| GO:BP | GO:0051901 | positive regulation of mitochondrial depolarization | 1 | 6 | 3.98e-01 |
| GO:BP | GO:0051438 | regulation of ubiquitin-protein transferase activity | 8 | 55 | 3.98e-01 |
| GO:BP | GO:0060324 | face development | 6 | 45 | 3.98e-01 |
| GO:BP | GO:0007097 | nuclear migration | 4 | 23 | 3.98e-01 |
| GO:BP | GO:0030859 | polarized epithelial cell differentiation | 4 | 19 | 3.98e-01 |
| GO:BP | GO:0015842 | aminergic neurotransmitter loading into synaptic vesicle | 1 | 1 | 3.98e-01 |
| GO:BP | GO:0001558 | regulation of cell growth | 2 | 357 | 3.98e-01 |
| GO:BP | GO:0042772 | DNA damage response, signal transduction resulting in transcription | 3 | 19 | 3.98e-01 |
| GO:BP | GO:0010657 | muscle cell apoptotic process | 1 | 60 | 3.98e-01 |
| GO:BP | GO:0009303 | rRNA transcription | 7 | 37 | 3.98e-01 |
| GO:BP | GO:1903626 | positive regulation of DNA catabolic process | 2 | 5 | 3.98e-01 |
| GO:BP | GO:0006950 | response to stress | 3 | 2780 | 3.98e-01 |
| GO:BP | GO:0034227 | tRNA thio-modification | 2 | 5 | 3.98e-01 |
| GO:BP | GO:0032091 | negative regulation of protein binding | 1 | 77 | 3.98e-01 |
| GO:BP | GO:0031346 | positive regulation of cell projection organization | 3 | 303 | 3.98e-01 |
| GO:BP | GO:1903421 | regulation of synaptic vesicle recycling | 2 | 23 | 3.98e-01 |
| GO:BP | GO:0071586 | CAAX-box protein processing | 1 | 2 | 3.98e-01 |
| GO:BP | GO:0017185 | peptidyl-lysine hydroxylation | 2 | 9 | 3.99e-01 |
| GO:BP | GO:0019752 | carboxylic acid metabolic process | 2 | 681 | 3.99e-01 |
| GO:BP | GO:0034224 | cellular response to zinc ion starvation | 2 | 6 | 3.99e-01 |
| GO:BP | GO:0120127 | response to zinc ion starvation | 2 | 6 | 3.99e-01 |
| GO:BP | GO:0006984 | ER-nucleus signaling pathway | 1 | 45 | 3.99e-01 |
| GO:BP | GO:0061512 | protein localization to cilium | 2 | 61 | 3.99e-01 |
| GO:BP | GO:1902065 | response to L-glutamate | 4 | 11 | 3.99e-01 |
| GO:BP | GO:0070873 | regulation of glycogen metabolic process | 4 | 28 | 3.99e-01 |
| GO:BP | GO:0043122 | regulation of I-kappaB kinase/NF-kappaB signaling | 26 | 203 | 3.99e-01 |
| GO:BP | GO:0006669 | sphinganine-1-phosphate biosynthetic process | 1 | 1 | 3.99e-01 |
| GO:BP | GO:0070897 | transcription preinitiation complex assembly | 18 | 67 | 3.99e-01 |
| GO:BP | GO:0043977 | histone H2A-K5 acetylation | 1 | 1 | 3.99e-01 |
| GO:BP | GO:0043980 | histone H2B-K12 acetylation | 1 | 1 | 3.99e-01 |
| GO:BP | GO:0072132 | mesenchyme morphogenesis | 1 | 50 | 4.00e-01 |
| GO:BP | GO:0003278 | apoptotic process involved in heart morphogenesis | 1 | 6 | 4.00e-01 |
| GO:BP | GO:1905005 | regulation of epithelial to mesenchymal transition involved in endocardial cushion formation | 1 | 6 | 4.00e-01 |
| GO:BP | GO:0006655 | phosphatidylglycerol biosynthetic process | 3 | 9 | 4.00e-01 |
| GO:BP | GO:0051771 | negative regulation of nitric-oxide synthase biosynthetic process | 1 | 3 | 4.00e-01 |
| GO:BP | GO:0045112 | integrin biosynthetic process | 1 | 3 | 4.00e-01 |
| GO:BP | GO:0032976 | release of matrix enzymes from mitochondria | 1 | 1 | 4.00e-01 |
| GO:BP | GO:0010212 | response to ionizing radiation | 12 | 130 | 4.00e-01 |
| GO:BP | GO:0006221 | pyrimidine nucleotide biosynthetic process | 5 | 28 | 4.00e-01 |
| GO:BP | GO:1902806 | regulation of cell cycle G1/S phase transition | 15 | 169 | 4.00e-01 |
| GO:BP | GO:0010592 | positive regulation of lamellipodium assembly | 1 | 25 | 4.01e-01 |
| GO:BP | GO:0006473 | protein acetylation | 31 | 190 | 4.01e-01 |
| GO:BP | GO:0032048 | cardiolipin metabolic process | 4 | 13 | 4.02e-01 |
| GO:BP | GO:0045639 | positive regulation of myeloid cell differentiation | 3 | 67 | 4.02e-01 |
| GO:BP | GO:0035092 | sperm DNA condensation | 2 | 7 | 4.02e-01 |
| GO:BP | GO:1903849 | positive regulation of aorta morphogenesis | 1 | 2 | 4.02e-01 |
| GO:BP | GO:1903847 | regulation of aorta morphogenesis | 1 | 2 | 4.02e-01 |
| GO:BP | GO:0009636 | response to toxic substance | 1 | 158 | 4.02e-01 |
| GO:BP | GO:0001909 | leukocyte mediated cytotoxicity | 2 | 54 | 4.02e-01 |
| GO:BP | GO:0010835 | regulation of protein ADP-ribosylation | 3 | 9 | 4.02e-01 |
| GO:BP | GO:0046073 | dTMP metabolic process | 2 | 7 | 4.03e-01 |
| GO:BP | GO:0002447 | eosinophil mediated immunity | 3 | 5 | 4.03e-01 |
| GO:BP | GO:0086069 | bundle of His cell to Purkinje myocyte communication | 2 | 14 | 4.03e-01 |
| GO:BP | GO:0006598 | polyamine catabolic process | 1 | 4 | 4.03e-01 |
| GO:BP | GO:0008295 | spermidine biosynthetic process | 1 | 3 | 4.03e-01 |
| GO:BP | GO:0045050 | protein insertion into ER membrane by stop-transfer membrane-anchor sequence | 2 | 10 | 4.03e-01 |
| GO:BP | GO:0006423 | cysteinyl-tRNA aminoacylation | 1 | 2 | 4.03e-01 |
| GO:BP | GO:0014015 | positive regulation of gliogenesis | 4 | 45 | 4.03e-01 |
| GO:BP | GO:0046785 | microtubule polymerization | 7 | 84 | 4.03e-01 |
| GO:BP | GO:0015012 | heparan sulfate proteoglycan biosynthetic process | 1 | 27 | 4.03e-01 |
| GO:BP | GO:0060992 | response to fungicide | 2 | 4 | 4.03e-01 |
| GO:BP | GO:0097212 | lysosomal membrane organization | 3 | 13 | 4.03e-01 |
| GO:BP | GO:0042816 | vitamin B6 metabolic process | 2 | 5 | 4.03e-01 |
| GO:BP | GO:0006370 | 7-methylguanosine mRNA capping | 2 | 7 | 4.03e-01 |
| GO:BP | GO:0051444 | negative regulation of ubiquitin-protein transferase activity | 2 | 21 | 4.03e-01 |
| GO:BP | GO:0048384 | retinoic acid receptor signaling pathway | 4 | 26 | 4.03e-01 |
| GO:BP | GO:1903977 | positive regulation of glial cell migration | 1 | 5 | 4.03e-01 |
| GO:BP | GO:0051204 | protein insertion into mitochondrial membrane | 9 | 34 | 4.03e-01 |
| GO:BP | GO:0140238 | presynaptic endocytosis | 13 | 65 | 4.03e-01 |
| GO:BP | GO:0071400 | cellular response to oleic acid | 1 | 3 | 4.03e-01 |
| GO:BP | GO:0043436 | oxoacid metabolic process | 2 | 696 | 4.03e-01 |
| GO:BP | GO:1900101 | regulation of endoplasmic reticulum unfolded protein response | 8 | 29 | 4.03e-01 |
| GO:BP | GO:0007020 | microtubule nucleation | 4 | 39 | 4.04e-01 |
| GO:BP | GO:0036119 | response to platelet-derived growth factor | 1 | 23 | 4.04e-01 |
| GO:BP | GO:0006740 | NADPH regeneration | 4 | 22 | 4.04e-01 |
| GO:BP | GO:0048524 | positive regulation of viral process | 2 | 55 | 4.04e-01 |
| GO:BP | GO:0046889 | positive regulation of lipid biosynthetic process | 11 | 63 | 4.04e-01 |
| GO:BP | GO:0035507 | regulation of myosin-light-chain-phosphatase activity | 2 | 5 | 4.04e-01 |
| GO:BP | GO:0007144 | female meiosis I | 4 | 9 | 4.04e-01 |
| GO:BP | GO:0015887 | pantothenate transmembrane transport | 1 | 1 | 4.04e-01 |
| GO:BP | GO:0031449 | regulation of slow-twitch skeletal muscle fiber contraction | 1 | 1 | 4.04e-01 |
| GO:BP | GO:0009267 | cellular response to starvation | 18 | 152 | 4.04e-01 |
| GO:BP | GO:2000380 | regulation of mesoderm development | 1 | 3 | 4.04e-01 |
| GO:BP | GO:0016237 | lysosomal microautophagy | 1 | 11 | 4.04e-01 |
| GO:BP | GO:0021527 | spinal cord association neuron differentiation | 1 | 3 | 4.04e-01 |
| GO:BP | GO:0006082 | organic acid metabolic process | 2 | 700 | 4.04e-01 |
| GO:BP | GO:1904357 | negative regulation of telomere maintenance via telomere lengthening | 4 | 26 | 4.04e-01 |
| GO:BP | GO:0002366 | leukocyte activation involved in immune response | 1 | 154 | 4.04e-01 |
| GO:BP | GO:0051049 | regulation of transport | 2 | 1267 | 4.04e-01 |
| GO:BP | GO:0150077 | regulation of neuroinflammatory response | 5 | 13 | 4.04e-01 |
| GO:BP | GO:0070372 | regulation of ERK1 and ERK2 cascade | 1 | 191 | 4.04e-01 |
| GO:BP | GO:0006421 | asparaginyl-tRNA aminoacylation | 1 | 3 | 4.04e-01 |
| GO:BP | GO:0009100 | glycoprotein metabolic process | 3 | 316 | 4.04e-01 |
| GO:BP | GO:0072350 | tricarboxylic acid metabolic process | 2 | 13 | 4.04e-01 |
| GO:BP | GO:0051574 | positive regulation of histone H3-K9 methylation | 1 | 5 | 4.04e-01 |
| GO:BP | GO:0002263 | cell activation involved in immune response | 1 | 157 | 4.04e-01 |
| GO:BP | GO:0014706 | striated muscle tissue development | 8 | 210 | 4.04e-01 |
| GO:BP | GO:0019243 | methylglyoxal catabolic process to D-lactate via S-lactoyl-glutathione | 1 | 4 | 4.04e-01 |
| GO:BP | GO:0019249 | lactate biosynthetic process | 1 | 3 | 4.04e-01 |
| GO:BP | GO:0030217 | T cell differentiation | 1 | 185 | 4.04e-01 |
| GO:BP | GO:0009120 | deoxyribonucleoside metabolic process | 3 | 9 | 4.04e-01 |
| GO:BP | GO:0002449 | lymphocyte mediated immunity | 2 | 142 | 4.04e-01 |
| GO:BP | GO:0019918 | peptidyl-arginine methylation, to symmetrical-dimethyl arginine | 1 | 1 | 4.04e-01 |
| GO:BP | GO:0035437 | maintenance of protein localization in endoplasmic reticulum | 1 | 11 | 4.04e-01 |
| GO:BP | GO:0031397 | negative regulation of protein ubiquitination | 18 | 76 | 4.04e-01 |
| GO:BP | GO:0051457 | maintenance of protein location in nucleus | 5 | 22 | 4.04e-01 |
| GO:BP | GO:0032261 | purine nucleotide salvage | 3 | 10 | 4.04e-01 |
| GO:BP | GO:0009615 | response to virus | 1 | 275 | 4.04e-01 |
| GO:BP | GO:0090162 | establishment of epithelial cell polarity | 5 | 29 | 4.04e-01 |
| GO:BP | GO:0060576 | intestinal epithelial cell development | 3 | 11 | 4.04e-01 |
| GO:BP | GO:1902101 | positive regulation of metaphase/anaphase transition of cell cycle | 3 | 14 | 4.04e-01 |
| GO:BP | GO:0044849 | estrous cycle | 4 | 13 | 4.04e-01 |
| GO:BP | GO:1904195 | regulation of granulosa cell proliferation | 1 | 1 | 4.04e-01 |
| GO:BP | GO:1904197 | positive regulation of granulosa cell proliferation | 1 | 1 | 4.04e-01 |
| GO:BP | GO:1990739 | granulosa cell proliferation | 1 | 1 | 4.04e-01 |
| GO:BP | GO:0043620 | regulation of DNA-templated transcription in response to stress | 6 | 41 | 4.04e-01 |
| GO:BP | GO:0071346 | cellular response to type II interferon | 1 | 69 | 4.05e-01 |
| GO:BP | GO:2000173 | negative regulation of branching morphogenesis of a nerve | 1 | 1 | 4.05e-01 |
| GO:BP | GO:1904799 | regulation of neuron remodeling | 1 | 1 | 4.05e-01 |
| GO:BP | GO:0032956 | regulation of actin cytoskeleton organization | 3 | 299 | 4.05e-01 |
| GO:BP | GO:0010825 | positive regulation of centrosome duplication | 1 | 3 | 4.05e-01 |
| GO:BP | GO:1904800 | negative regulation of neuron remodeling | 1 | 1 | 4.05e-01 |
| GO:BP | GO:2000008 | regulation of protein localization to cell surface | 3 | 37 | 4.05e-01 |
| GO:BP | GO:0009147 | pyrimidine nucleoside triphosphate metabolic process | 4 | 22 | 4.05e-01 |
| GO:BP | GO:0046461 | neutral lipid catabolic process | 1 | 25 | 4.05e-01 |
| GO:BP | GO:0046464 | acylglycerol catabolic process | 1 | 25 | 4.05e-01 |
| GO:BP | GO:0097719 | neural tissue regeneration | 1 | 1 | 4.05e-01 |
| GO:BP | GO:0046037 | GMP metabolic process | 2 | 23 | 4.06e-01 |
| GO:BP | GO:0032206 | positive regulation of telomere maintenance | 13 | 64 | 4.06e-01 |
| GO:BP | GO:0090596 | sensory organ morphogenesis | 3 | 178 | 4.06e-01 |
| GO:BP | GO:1905949 | negative regulation of calcium ion import across plasma membrane | 1 | 4 | 4.06e-01 |
| GO:BP | GO:0014912 | negative regulation of smooth muscle cell migration | 7 | 25 | 4.06e-01 |
| GO:BP | GO:0010719 | negative regulation of epithelial to mesenchymal transition | 2 | 29 | 4.06e-01 |
| GO:BP | GO:0046075 | dTTP metabolic process | 2 | 4 | 4.07e-01 |
| GO:BP | GO:0032875 | regulation of DNA endoreduplication | 2 | 4 | 4.07e-01 |
| GO:BP | GO:1905320 | regulation of mesenchymal stem cell migration | 2 | 4 | 4.07e-01 |
| GO:BP | GO:0002331 | pre-B cell allelic exclusion | 1 | 2 | 4.07e-01 |
| GO:BP | GO:0022409 | positive regulation of cell-cell adhesion | 1 | 189 | 4.07e-01 |
| GO:BP | GO:1901565 | organonitrogen compound catabolic process | 6 | 1145 | 4.07e-01 |
| GO:BP | GO:0097695 | establishment of protein-containing complex localization to telomere | 1 | 3 | 4.07e-01 |
| GO:BP | GO:1905477 | positive regulation of protein localization to membrane | 11 | 84 | 4.07e-01 |
| GO:BP | GO:0008617 | guanosine metabolic process | 1 | 1 | 4.07e-01 |
| GO:BP | GO:0007057 | spindle assembly involved in female meiosis I | 2 | 4 | 4.07e-01 |
| GO:BP | GO:0060087 | relaxation of vascular associated smooth muscle | 1 | 7 | 4.07e-01 |
| GO:BP | GO:1901068 | guanosine-containing compound metabolic process | 1 | 1 | 4.07e-01 |
| GO:BP | GO:0060391 | positive regulation of SMAD protein signal transduction | 3 | 17 | 4.07e-01 |
| GO:BP | GO:0010458 | exit from mitosis | 3 | 30 | 4.07e-01 |
| GO:BP | GO:0070278 | extracellular matrix constituent secretion | 2 | 12 | 4.07e-01 |
| GO:BP | GO:0032922 | circadian regulation of gene expression | 8 | 63 | 4.07e-01 |
| GO:BP | GO:0048169 | regulation of long-term neuronal synaptic plasticity | 5 | 20 | 4.07e-01 |
| GO:BP | GO:0045869 | negative regulation of single stranded viral RNA replication via double stranded DNA intermediate | 4 | 12 | 4.07e-01 |
| GO:BP | GO:0045588 | positive regulation of gamma-delta T cell differentiation | 1 | 4 | 4.07e-01 |
| GO:BP | GO:0071846 | actin filament debranching | 1 | 1 | 4.07e-01 |
| GO:BP | GO:1905322 | positive regulation of mesenchymal stem cell migration | 2 | 4 | 4.07e-01 |
| GO:BP | GO:0045742 | positive regulation of epidermal growth factor receptor signaling pathway | 3 | 26 | 4.07e-01 |
| GO:BP | GO:0006235 | dTTP biosynthetic process | 2 | 4 | 4.07e-01 |
| GO:BP | GO:0097694 | establishment of RNA localization to telomere | 1 | 3 | 4.07e-01 |
| GO:BP | GO:0046466 | membrane lipid catabolic process | 3 | 30 | 4.07e-01 |
| GO:BP | GO:0009212 | pyrimidine deoxyribonucleoside triphosphate biosynthetic process | 2 | 4 | 4.07e-01 |
| GO:BP | GO:0032459 | regulation of protein oligomerization | 2 | 6 | 4.07e-01 |
| GO:BP | GO:0042748 | circadian sleep/wake cycle, non-REM sleep | 1 | 3 | 4.07e-01 |
| GO:BP | GO:0003343 | septum transversum development | 1 | 2 | 4.07e-01 |
| GO:BP | GO:0032885 | regulation of polysaccharide biosynthetic process | 4 | 31 | 4.07e-01 |
| GO:BP | GO:1905319 | mesenchymal stem cell migration | 2 | 4 | 4.07e-01 |
| GO:BP | GO:0006537 | glutamate biosynthetic process | 1 | 5 | 4.07e-01 |
| GO:BP | GO:0003186 | tricuspid valve morphogenesis | 1 | 5 | 4.07e-01 |
| GO:BP | GO:0018105 | peptidyl-serine phosphorylation | 1 | 247 | 4.07e-01 |
| GO:BP | GO:1902105 | regulation of leukocyte differentiation | 1 | 199 | 4.07e-01 |
| GO:BP | GO:0042661 | regulation of mesodermal cell fate specification | 1 | 4 | 4.07e-01 |
| GO:BP | GO:0007529 | establishment of synaptic specificity at neuromuscular junction | 1 | 2 | 4.07e-01 |
| GO:BP | GO:0046036 | CTP metabolic process | 3 | 14 | 4.07e-01 |
| GO:BP | GO:1901545 | response to raffinose | 1 | 1 | 4.07e-01 |
| GO:BP | GO:0001836 | release of cytochrome c from mitochondria | 13 | 47 | 4.07e-01 |
| GO:BP | GO:0097403 | cellular response to raffinose | 1 | 1 | 4.07e-01 |
| GO:BP | GO:0033119 | negative regulation of RNA splicing | 1 | 28 | 4.07e-01 |
| GO:BP | GO:0003342 | proepicardium development | 1 | 2 | 4.07e-01 |
| GO:BP | GO:0006952 | defense response | 2 | 944 | 4.07e-01 |
| GO:BP | GO:0050890 | cognition | 1 | 227 | 4.09e-01 |
| GO:BP | GO:2000654 | regulation of cellular response to testosterone stimulus | 1 | 2 | 4.09e-01 |
| GO:BP | GO:0051097 | negative regulation of helicase activity | 1 | 5 | 4.09e-01 |
| GO:BP | GO:0071285 | cellular response to lithium ion | 3 | 8 | 4.10e-01 |
| GO:BP | GO:1901327 | response to tacrolimus | 1 | 1 | 4.10e-01 |
| GO:BP | GO:1903979 | negative regulation of microglial cell activation | 2 | 5 | 4.10e-01 |
| GO:BP | GO:0070328 | triglyceride homeostasis | 3 | 17 | 4.10e-01 |
| GO:BP | GO:0055090 | acylglycerol homeostasis | 3 | 17 | 4.10e-01 |
| GO:BP | GO:0006479 | protein methylation | 1 | 160 | 4.10e-01 |
| GO:BP | GO:1902905 | positive regulation of supramolecular fiber organization | 2 | 151 | 4.10e-01 |
| GO:BP | GO:0043401 | steroid hormone mediated signaling pathway | 2 | 112 | 4.10e-01 |
| GO:BP | GO:0001933 | negative regulation of protein phosphorylation | 1 | 277 | 4.10e-01 |
| GO:BP | GO:0051783 | regulation of nuclear division | 18 | 116 | 4.10e-01 |
| GO:BP | GO:0008213 | protein alkylation | 1 | 160 | 4.10e-01 |
| GO:BP | GO:0019935 | cyclic-nucleotide-mediated signaling | 1 | 55 | 4.11e-01 |
| GO:BP | GO:1990646 | cellular response to prolactin | 1 | 2 | 4.11e-01 |
| GO:BP | GO:0006048 | UDP-N-acetylglucosamine biosynthetic process | 3 | 9 | 4.11e-01 |
| GO:BP | GO:0006903 | vesicle targeting | 4 | 61 | 4.11e-01 |
| GO:BP | GO:0070483 | detection of hypoxia | 1 | 2 | 4.11e-01 |
| GO:BP | GO:0042487 | regulation of odontogenesis of dentin-containing tooth | 1 | 6 | 4.11e-01 |
| GO:BP | GO:0000910 | cytokinesis | 4 | 164 | 4.11e-01 |
| GO:BP | GO:0002158 | osteoclast proliferation | 1 | 7 | 4.11e-01 |
| GO:BP | GO:0071374 | cellular response to parathyroid hormone stimulus | 2 | 7 | 4.11e-01 |
| GO:BP | GO:0010906 | regulation of glucose metabolic process | 7 | 86 | 4.11e-01 |
| GO:BP | GO:0070371 | ERK1 and ERK2 cascade | 1 | 211 | 4.11e-01 |
| GO:BP | GO:0021514 | ventral spinal cord interneuron differentiation | 1 | 5 | 4.12e-01 |
| GO:BP | GO:0048819 | regulation of hair follicle maturation | 3 | 9 | 4.12e-01 |
| GO:BP | GO:1903788 | positive regulation of glutathione biosynthetic process | 1 | 1 | 4.12e-01 |
| GO:BP | GO:0042274 | ribosomal small subunit biogenesis | 10 | 79 | 4.12e-01 |
| GO:BP | GO:0044851 | hair cycle phase | 3 | 9 | 4.12e-01 |
| GO:BP | GO:0044848 | biological phase | 3 | 9 | 4.12e-01 |
| GO:BP | GO:0071329 | cellular response to sucrose stimulus | 1 | 1 | 4.12e-01 |
| GO:BP | GO:0071324 | cellular response to disaccharide stimulus | 1 | 1 | 4.12e-01 |
| GO:BP | GO:0006901 | vesicle coating | 2 | 36 | 4.12e-01 |
| GO:BP | GO:1903846 | positive regulation of cellular response to transforming growth factor beta stimulus | 5 | 30 | 4.12e-01 |
| GO:BP | GO:0085017 | entry into host cell by a symbiont-containing vacuole | 1 | 1 | 4.12e-01 |
| GO:BP | GO:0043086 | negative regulation of catalytic activity | 2 | 478 | 4.12e-01 |
| GO:BP | GO:0030511 | positive regulation of transforming growth factor beta receptor signaling pathway | 5 | 30 | 4.12e-01 |
| GO:BP | GO:0016559 | peroxisome fission | 1 | 9 | 4.12e-01 |
| GO:BP | GO:1902903 | regulation of supramolecular fiber organization | 27 | 326 | 4.14e-01 |
| GO:BP | GO:1904205 | negative regulation of skeletal muscle hypertrophy | 1 | 1 | 4.14e-01 |
| GO:BP | GO:0003149 | membranous septum morphogenesis | 2 | 8 | 4.14e-01 |
| GO:BP | GO:0018209 | peptidyl-serine modification | 1 | 259 | 4.14e-01 |
| GO:BP | GO:1901652 | response to peptide | 2 | 377 | 4.14e-01 |
| GO:BP | GO:0007172 | signal complex assembly | 3 | 7 | 4.14e-01 |
| GO:BP | GO:0061083 | regulation of protein refolding | 1 | 2 | 4.14e-01 |
| GO:BP | GO:0061084 | negative regulation of protein refolding | 1 | 2 | 4.14e-01 |
| GO:BP | GO:0019320 | hexose catabolic process | 1 | 32 | 4.14e-01 |
| GO:BP | GO:0003336 | corneocyte desquamation | 1 | 1 | 4.14e-01 |
| GO:BP | GO:1904353 | regulation of telomere capping | 6 | 23 | 4.14e-01 |
| GO:BP | GO:0071763 | nuclear membrane organization | 6 | 42 | 4.14e-01 |
| GO:BP | GO:0086027 | AV node cell to bundle of His cell signaling | 1 | 9 | 4.14e-01 |
| GO:BP | GO:1904024 | negative regulation of glucose catabolic process to lactate via pyruvate | 1 | 3 | 4.14e-01 |
| GO:BP | GO:0046165 | alcohol biosynthetic process | 5 | 110 | 4.14e-01 |
| GO:BP | GO:0086016 | AV node cell action potential | 1 | 9 | 4.14e-01 |
| GO:BP | GO:0071887 | leukocyte apoptotic process | 1 | 81 | 4.14e-01 |
| GO:BP | GO:0043174 | nucleoside salvage | 2 | 9 | 4.15e-01 |
| GO:BP | GO:0033278 | cell proliferation in midbrain | 3 | 4 | 4.15e-01 |
| GO:BP | GO:0097688 | glutamate receptor clustering | 3 | 7 | 4.15e-01 |
| GO:BP | GO:0090188 | negative regulation of pancreatic juice secretion | 1 | 4 | 4.15e-01 |
| GO:BP | GO:0097113 | AMPA glutamate receptor clustering | 3 | 7 | 4.15e-01 |
| GO:BP | GO:0006302 | double-strand break repair | 23 | 271 | 4.15e-01 |
| GO:BP | GO:0003272 | endocardial cushion formation | 2 | 24 | 4.15e-01 |
| GO:BP | GO:1901673 | regulation of mitotic spindle assembly | 4 | 23 | 4.15e-01 |
| GO:BP | GO:0014745 | negative regulation of muscle adaptation | 1 | 9 | 4.15e-01 |
| GO:BP | GO:0046710 | GDP metabolic process | 1 | 10 | 4.15e-01 |
| GO:BP | GO:0031173 | otolith mineralization completed early in development | 1 | 1 | 4.16e-01 |
| GO:BP | GO:0008347 | glial cell migration | 3 | 47 | 4.16e-01 |
| GO:BP | GO:0098795 | global gene silencing by mRNA cleavage | 1 | 4 | 4.16e-01 |
| GO:BP | GO:0140694 | non-membrane-bounded organelle assembly | 32 | 357 | 4.16e-01 |
| GO:BP | GO:0044242 | cellular lipid catabolic process | 2 | 170 | 4.16e-01 |
| GO:BP | GO:1903251 | multi-ciliated epithelial cell differentiation | 2 | 6 | 4.16e-01 |
| GO:BP | GO:0048709 | oligodendrocyte differentiation | 4 | 68 | 4.16e-01 |
| GO:BP | GO:0016574 | histone ubiquitination | 4 | 46 | 4.16e-01 |
| GO:BP | GO:0070245 | positive regulation of thymocyte apoptotic process | 2 | 5 | 4.17e-01 |
| GO:BP | GO:0048660 | regulation of smooth muscle cell proliferation | 2 | 106 | 4.17e-01 |
| GO:BP | GO:0060804 | positive regulation of Wnt signaling pathway by BMP signaling pathway | 1 | 1 | 4.18e-01 |
| GO:BP | GO:0051042 | negative regulation of calcium-independent cell-cell adhesion | 1 | 1 | 4.18e-01 |
| GO:BP | GO:0009151 | purine deoxyribonucleotide metabolic process | 4 | 12 | 4.18e-01 |
| GO:BP | GO:0090169 | regulation of spindle assembly | 5 | 32 | 4.18e-01 |
| GO:BP | GO:0030512 | negative regulation of transforming growth factor beta receptor signaling pathway | 9 | 86 | 4.18e-01 |
| GO:BP | GO:2000583 | regulation of platelet-derived growth factor receptor-alpha signaling pathway | 2 | 4 | 4.18e-01 |
| GO:BP | GO:0021572 | rhombomere 6 development | 1 | 1 | 4.18e-01 |
| GO:BP | GO:0019432 | triglyceride biosynthetic process | 3 | 31 | 4.18e-01 |
| GO:BP | GO:0005980 | glycogen catabolic process | 2 | 14 | 4.18e-01 |
| GO:BP | GO:0090239 | regulation of histone H4 acetylation | 3 | 10 | 4.18e-01 |
| GO:BP | GO:0021599 | abducens nerve formation | 1 | 1 | 4.18e-01 |
| GO:BP | GO:0021935 | cerebellar granule cell precursor tangential migration | 1 | 2 | 4.18e-01 |
| GO:BP | GO:0021598 | abducens nerve morphogenesis | 1 | 1 | 4.18e-01 |
| GO:BP | GO:0000132 | establishment of mitotic spindle orientation | 3 | 31 | 4.18e-01 |
| GO:BP | GO:0032006 | regulation of TOR signaling | 18 | 96 | 4.18e-01 |
| GO:BP | GO:0140527 | reciprocal homologous recombination | 7 | 36 | 4.18e-01 |
| GO:BP | GO:0006367 | transcription initiation at RNA polymerase II promoter | 8 | 93 | 4.18e-01 |
| GO:BP | GO:0019068 | virion assembly | 9 | 35 | 4.18e-01 |
| GO:BP | GO:0021560 | abducens nerve development | 1 | 1 | 4.18e-01 |
| GO:BP | GO:0045903 | positive regulation of translational fidelity | 1 | 1 | 4.18e-01 |
| GO:BP | GO:0034501 | protein localization to kinetochore | 3 | 18 | 4.18e-01 |
| GO:BP | GO:0014722 | regulation of skeletal muscle contraction by calcium ion signaling | 1 | 5 | 4.18e-01 |
| GO:BP | GO:0070075 | tear secretion | 1 | 2 | 4.18e-01 |
| GO:BP | GO:0060169 | negative regulation of adenosine receptor signaling pathway | 1 | 1 | 4.18e-01 |
| GO:BP | GO:1904527 | negative regulation of microtubule binding | 1 | 2 | 4.18e-01 |
| GO:BP | GO:0060407 | negative regulation of penile erection | 1 | 1 | 4.18e-01 |
| GO:BP | GO:1904015 | cellular response to serotonin | 1 | 1 | 4.18e-01 |
| GO:BP | GO:0003230 | cardiac atrium development | 2 | 34 | 4.18e-01 |
| GO:BP | GO:1904014 | response to serotonin | 1 | 1 | 4.18e-01 |
| GO:BP | GO:0043558 | regulation of translational initiation in response to stress | 4 | 16 | 4.18e-01 |
| GO:BP | GO:1903083 | protein localization to condensed chromosome | 3 | 18 | 4.18e-01 |
| GO:BP | GO:0035904 | aorta development | 3 | 50 | 4.18e-01 |
| GO:BP | GO:0046111 | xanthine biosynthetic process | 1 | 1 | 4.18e-01 |
| GO:BP | GO:1902480 | protein localization to mitotic spindle | 1 | 1 | 4.18e-01 |
| GO:BP | GO:0002183 | cytoplasmic translational initiation | 3 | 38 | 4.18e-01 |
| GO:BP | GO:0046173 | polyol biosynthetic process | 3 | 47 | 4.18e-01 |
| GO:BP | GO:0046340 | diacylglycerol catabolic process | 1 | 3 | 4.18e-01 |
| GO:BP | GO:0002011 | morphogenesis of an epithelial sheet | 2 | 52 | 4.18e-01 |
| GO:BP | GO:0061171 | establishment of bipolar cell polarity | 1 | 1 | 4.18e-01 |
| GO:BP | GO:0039535 | regulation of RIG-I signaling pathway | 5 | 17 | 4.18e-01 |
| GO:BP | GO:1990403 | embryonic brain development | 5 | 13 | 4.18e-01 |
| GO:BP | GO:0048194 | Golgi vesicle budding | 1 | 10 | 4.18e-01 |
| GO:BP | GO:0060575 | intestinal epithelial cell differentiation | 4 | 17 | 4.18e-01 |
| GO:BP | GO:0007131 | reciprocal meiotic recombination | 7 | 36 | 4.18e-01 |
| GO:BP | GO:0060765 | regulation of androgen receptor signaling pathway | 1 | 24 | 4.18e-01 |
| GO:BP | GO:0007265 | Ras protein signal transduction | 3 | 294 | 4.18e-01 |
| GO:BP | GO:0048146 | positive regulation of fibroblast proliferation | 11 | 45 | 4.19e-01 |
| GO:BP | GO:0048592 | eye morphogenesis | 2 | 113 | 4.19e-01 |
| GO:BP | GO:0021915 | neural tube development | 2 | 146 | 4.19e-01 |
| GO:BP | GO:1904181 | positive regulation of membrane depolarization | 1 | 8 | 4.19e-01 |
| GO:BP | GO:0016340 | calcium-dependent cell-matrix adhesion | 1 | 2 | 4.19e-01 |
| GO:BP | GO:1903115 | regulation of actin filament-based movement | 2 | 39 | 4.19e-01 |
| GO:BP | GO:0002098 | tRNA wobble uridine modification | 5 | 16 | 4.20e-01 |
| GO:BP | GO:0042326 | negative regulation of phosphorylation | 1 | 300 | 4.20e-01 |
| GO:BP | GO:1902895 | positive regulation of miRNA transcription | 6 | 42 | 4.21e-01 |
| GO:BP | GO:0070911 | global genome nucleotide-excision repair | 1 | 2 | 4.22e-01 |
| GO:BP | GO:0010225 | response to UV-C | 4 | 13 | 4.22e-01 |
| GO:BP | GO:0016579 | protein deubiquitination | 3 | 129 | 4.22e-01 |
| GO:BP | GO:0090069 | regulation of ribosome biogenesis | 2 | 5 | 4.22e-01 |
| GO:BP | GO:0009204 | deoxyribonucleoside triphosphate catabolic process | 2 | 5 | 4.22e-01 |
| GO:BP | GO:0009146 | purine nucleoside triphosphate catabolic process | 2 | 5 | 4.22e-01 |
| GO:BP | GO:0061614 | miRNA transcription | 8 | 57 | 4.22e-01 |
| GO:BP | GO:0010923 | negative regulation of phosphatase activity | 2 | 30 | 4.23e-01 |
| GO:BP | GO:0071294 | cellular response to zinc ion | 1 | 15 | 4.23e-01 |
| GO:BP | GO:0086072 | AV node cell-bundle of His cell adhesion involved in cell communication | 1 | 1 | 4.23e-01 |
| GO:BP | GO:1901666 | positive regulation of NAD+ ADP-ribosyltransferase activity | 1 | 1 | 4.23e-01 |
| GO:BP | GO:0006895 | Golgi to endosome transport | 5 | 17 | 4.23e-01 |
| GO:BP | GO:0002066 | columnar/cuboidal epithelial cell development | 5 | 38 | 4.23e-01 |
| GO:BP | GO:0010609 | mRNA localization resulting in post-transcriptional regulation of gene expression | 1 | 2 | 4.23e-01 |
| GO:BP | GO:0006955 | immune response | 2 | 882 | 4.23e-01 |
| GO:BP | GO:1901664 | regulation of NAD+ ADP-ribosyltransferase activity | 1 | 1 | 4.23e-01 |
| GO:BP | GO:0003430 | growth plate cartilage chondrocyte growth | 1 | 3 | 4.23e-01 |
| GO:BP | GO:0031365 | N-terminal protein amino acid modification | 6 | 28 | 4.23e-01 |
| GO:BP | GO:0110154 | RNA decapping | 5 | 17 | 4.23e-01 |
| GO:BP | GO:1903423 | positive regulation of synaptic vesicle recycling | 3 | 6 | 4.23e-01 |
| GO:BP | GO:0048659 | smooth muscle cell proliferation | 2 | 110 | 4.23e-01 |
| GO:BP | GO:0042791 | 5S class rRNA transcription by RNA polymerase III | 2 | 6 | 4.23e-01 |
| GO:BP | GO:0071357 | cellular response to type I interferon | 4 | 52 | 4.23e-01 |
| GO:BP | GO:0003179 | heart valve morphogenesis | 3 | 55 | 4.23e-01 |
| GO:BP | GO:0080129 | proteasome core complex assembly | 1 | 1 | 4.23e-01 |
| GO:BP | GO:0033169 | histone H3-K9 demethylation | 1 | 5 | 4.23e-01 |
| GO:BP | GO:0034454 | microtubule anchoring at centrosome | 4 | 12 | 4.23e-01 |
| GO:BP | GO:0060037 | pharyngeal system development | 2 | 23 | 4.23e-01 |
| GO:BP | GO:0033234 | negative regulation of protein sumoylation | 1 | 8 | 4.23e-01 |
| GO:BP | GO:0009443 | pyridoxal 5’-phosphate salvage | 1 | 1 | 4.23e-01 |
| GO:BP | GO:0010971 | positive regulation of G2/M transition of mitotic cell cycle | 7 | 27 | 4.23e-01 |
| GO:BP | GO:0009113 | purine nucleobase biosynthetic process | 3 | 10 | 4.23e-01 |
| GO:BP | GO:1901186 | positive regulation of ERBB signaling pathway | 3 | 28 | 4.23e-01 |
| GO:BP | GO:0034341 | response to type II interferon | 1 | 83 | 4.23e-01 |
| GO:BP | GO:0002460 | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 1 | 161 | 4.23e-01 |
| GO:BP | GO:0097114 | NMDA glutamate receptor clustering | 2 | 5 | 4.23e-01 |
| GO:BP | GO:1903944 | negative regulation of hepatocyte apoptotic process | 2 | 6 | 4.24e-01 |
| GO:BP | GO:1904888 | cranial skeletal system development | 1 | 51 | 4.24e-01 |
| GO:BP | GO:0046645 | positive regulation of gamma-delta T cell activation | 1 | 4 | 4.24e-01 |
| GO:BP | GO:0140754 | reorganization of cellular membranes to establish viral sites of replication | 1 | 1 | 4.25e-01 |
| GO:BP | GO:1903706 | regulation of hemopoiesis | 9 | 279 | 4.25e-01 |
| GO:BP | GO:1903430 | negative regulation of cell maturation | 3 | 4 | 4.25e-01 |
| GO:BP | GO:1903531 | negative regulation of secretion by cell | 1 | 99 | 4.25e-01 |
| GO:BP | GO:0008045 | motor neuron axon guidance | 2 | 25 | 4.25e-01 |
| GO:BP | GO:0051595 | response to methylglyoxal | 1 | 2 | 4.25e-01 |
| GO:BP | GO:0045860 | positive regulation of protein kinase activity | 1 | 260 | 4.25e-01 |
| GO:BP | GO:0001838 | embryonic epithelial tube formation | 13 | 116 | 4.25e-01 |
| GO:BP | GO:1903037 | regulation of leukocyte cell-cell adhesion | 1 | 211 | 4.25e-01 |
| GO:BP | GO:0070131 | positive regulation of mitochondrial translation | 5 | 17 | 4.25e-01 |
| GO:BP | GO:0008654 | phospholipid biosynthetic process | 43 | 234 | 4.25e-01 |
| GO:BP | GO:0072521 | purine-containing compound metabolic process | 2 | 390 | 4.25e-01 |
| GO:BP | GO:1901605 | alpha-amino acid metabolic process | 1 | 151 | 4.26e-01 |
| GO:BP | GO:0042364 | water-soluble vitamin biosynthetic process | 3 | 8 | 4.26e-01 |
| GO:BP | GO:0009452 | 7-methylguanosine RNA capping | 2 | 8 | 4.26e-01 |
| GO:BP | GO:0072429 | response to intra-S DNA damage checkpoint signaling | 1 | 4 | 4.26e-01 |
| GO:BP | GO:1902745 | positive regulation of lamellipodium organization | 1 | 32 | 4.26e-01 |
| GO:BP | GO:0008215 | spermine metabolic process | 1 | 5 | 4.26e-01 |
| GO:BP | GO:0006013 | mannose metabolic process | 2 | 9 | 4.26e-01 |
| GO:BP | GO:1900864 | mitochondrial RNA modification | 3 | 9 | 4.26e-01 |
| GO:BP | GO:0070900 | mitochondrial tRNA modification | 3 | 9 | 4.26e-01 |
| GO:BP | GO:0002068 | glandular epithelial cell development | 4 | 28 | 4.27e-01 |
| GO:BP | GO:0043562 | cellular response to nitrogen levels | 3 | 9 | 4.27e-01 |
| GO:BP | GO:0001843 | neural tube closure | 10 | 90 | 4.27e-01 |
| GO:BP | GO:0006995 | cellular response to nitrogen starvation | 3 | 9 | 4.27e-01 |
| GO:BP | GO:0086019 | cell-cell signaling involved in cardiac conduction | 3 | 33 | 4.27e-01 |
| GO:BP | GO:0010612 | regulation of cardiac muscle adaptation | 1 | 10 | 4.28e-01 |
| GO:BP | GO:0000422 | autophagy of mitochondrion | 1 | 92 | 4.28e-01 |
| GO:BP | GO:0046339 | diacylglycerol metabolic process | 4 | 23 | 4.28e-01 |
| GO:BP | GO:0048048 | embryonic eye morphogenesis | 1 | 25 | 4.28e-01 |
| GO:BP | GO:1905938 | positive regulation of germ cell proliferation | 1 | 2 | 4.28e-01 |
| GO:BP | GO:0061726 | mitochondrion disassembly | 1 | 92 | 4.28e-01 |
| GO:BP | GO:2000256 | positive regulation of male germ cell proliferation | 1 | 2 | 4.28e-01 |
| GO:BP | GO:0050863 | regulation of T cell activation | 1 | 216 | 4.28e-01 |
| GO:BP | GO:1903242 | regulation of cardiac muscle hypertrophy in response to stress | 1 | 10 | 4.28e-01 |
| GO:BP | GO:0015860 | purine nucleoside transmembrane transport | 1 | 3 | 4.28e-01 |
| GO:BP | GO:0048286 | lung alveolus development | 8 | 39 | 4.28e-01 |
| GO:BP | GO:0055015 | ventricular cardiac muscle cell development | 1 | 10 | 4.28e-01 |
| GO:BP | GO:0048670 | regulation of collateral sprouting | 4 | 18 | 4.28e-01 |
| GO:BP | GO:0018108 | peptidyl-tyrosine phosphorylation | 1 | 256 | 4.28e-01 |
| GO:BP | GO:0003073 | regulation of systemic arterial blood pressure | 1 | 62 | 4.28e-01 |
| GO:BP | GO:0031424 | keratinization | 1 | 13 | 4.28e-01 |
| GO:BP | GO:2000110 | negative regulation of macrophage apoptotic process | 1 | 3 | 4.28e-01 |
| GO:BP | GO:0009048 | dosage compensation by inactivation of X chromosome | 7 | 27 | 4.28e-01 |
| GO:BP | GO:0002697 | regulation of immune effector process | 1 | 190 | 4.28e-01 |
| GO:BP | GO:0071702 | organic substance transport | 5 | 2116 | 4.28e-01 |
| GO:BP | GO:0018212 | peptidyl-tyrosine modification | 1 | 258 | 4.29e-01 |
| GO:BP | GO:0097049 | motor neuron apoptotic process | 4 | 18 | 4.29e-01 |
| GO:BP | GO:1902170 | cellular response to reactive nitrogen species | 5 | 16 | 4.29e-01 |
| GO:BP | GO:2000145 | regulation of cell motility | 13 | 742 | 4.29e-01 |
| GO:BP | GO:0033631 | cell-cell adhesion mediated by integrin | 1 | 12 | 4.29e-01 |
| GO:BP | GO:0033131 | regulation of glucokinase activity | 1 | 7 | 4.29e-01 |
| GO:BP | GO:0046330 | positive regulation of JNK cascade | 5 | 72 | 4.29e-01 |
| GO:BP | GO:0051310 | metaphase plate congression | 9 | 69 | 4.29e-01 |
| GO:BP | GO:0098693 | regulation of synaptic vesicle cycle | 4 | 13 | 4.29e-01 |
| GO:BP | GO:2000586 | regulation of platelet-derived growth factor receptor-beta signaling pathway | 2 | 8 | 4.29e-01 |
| GO:BP | GO:1900194 | negative regulation of oocyte maturation | 2 | 2 | 4.29e-01 |
| GO:BP | GO:0002747 | antigen processing and presentation following phagocytosis | 1 | 1 | 4.29e-01 |
| GO:BP | GO:0060336 | negative regulation of type II interferon-mediated signaling pathway | 2 | 6 | 4.29e-01 |
| GO:BP | GO:0061354 | planar cell polarity pathway involved in pericardium morphogenesis | 1 | 1 | 4.29e-01 |
| GO:BP | GO:0008015 | blood circulation | 2 | 374 | 4.29e-01 |
| GO:BP | GO:0015911 | long-chain fatty acid import across plasma membrane | 3 | 9 | 4.29e-01 |
| GO:BP | GO:0060606 | tube closure | 10 | 91 | 4.29e-01 |
| GO:BP | GO:0030865 | cortical cytoskeleton organization | 2 | 55 | 4.29e-01 |
| GO:BP | GO:0006281 | DNA repair | 39 | 534 | 4.29e-01 |
| GO:BP | GO:0007252 | I-kappaB phosphorylation | 3 | 14 | 4.29e-01 |
| GO:BP | GO:0051596 | methylglyoxal catabolic process | 1 | 5 | 4.29e-01 |
| GO:BP | GO:0002505 | antigen processing and presentation of polysaccharide antigen via MHC class II | 1 | 1 | 4.29e-01 |
| GO:BP | GO:0006264 | mitochondrial DNA replication | 4 | 13 | 4.29e-01 |
| GO:BP | GO:0060897 | neural plate regionalization | 1 | 6 | 4.29e-01 |
| GO:BP | GO:0006004 | fucose metabolic process | 1 | 10 | 4.29e-01 |
| GO:BP | GO:0009251 | glucan catabolic process | 2 | 14 | 4.29e-01 |
| GO:BP | GO:0048820 | hair follicle maturation | 4 | 15 | 4.29e-01 |
| GO:BP | GO:0001659 | temperature homeostasis | 5 | 132 | 4.29e-01 |
| GO:BP | GO:0046754 | viral exocytosis | 1 | 1 | 4.29e-01 |
| GO:BP | GO:0019287 | isopentenyl diphosphate biosynthetic process, mevalonate pathway | 1 | 3 | 4.29e-01 |
| GO:BP | GO:2000181 | negative regulation of blood vessel morphogenesis | 1 | 73 | 4.29e-01 |
| GO:BP | GO:0097281 | immune complex formation | 1 | 1 | 4.29e-01 |
| GO:BP | GO:0061341 | non-canonical Wnt signaling pathway involved in heart development | 1 | 1 | 4.29e-01 |
| GO:BP | GO:0002383 | immune response in brain or nervous system | 1 | 1 | 4.29e-01 |
| GO:BP | GO:0061346 | planar cell polarity pathway involved in heart morphogenesis | 1 | 1 | 4.29e-01 |
| GO:BP | GO:0061347 | planar cell polarity pathway involved in outflow tract morphogenesis | 1 | 1 | 4.29e-01 |
| GO:BP | GO:0120162 | positive regulation of cold-induced thermogenesis | 1 | 69 | 4.29e-01 |
| GO:BP | GO:0061348 | planar cell polarity pathway involved in ventricular septum morphogenesis | 1 | 1 | 4.29e-01 |
| GO:BP | GO:0009631 | cold acclimation | 1 | 2 | 4.29e-01 |
| GO:BP | GO:0061349 | planar cell polarity pathway involved in cardiac right atrium morphogenesis | 1 | 1 | 4.29e-01 |
| GO:BP | GO:0061350 | planar cell polarity pathway involved in cardiac muscle tissue morphogenesis | 1 | 1 | 4.29e-01 |
| GO:BP | GO:0046348 | amino sugar catabolic process | 4 | 9 | 4.29e-01 |
| GO:BP | GO:0061727 | methylglyoxal catabolic process to lactate | 1 | 5 | 4.29e-01 |
| GO:BP | GO:0043588 | skin development | 3 | 175 | 4.29e-01 |
| GO:BP | GO:0045727 | positive regulation of translation | 28 | 126 | 4.29e-01 |
| GO:BP | GO:1901135 | carbohydrate derivative metabolic process | 3 | 843 | 4.29e-01 |
| GO:BP | GO:0042255 | ribosome assembly | 1 | 56 | 4.29e-01 |
| GO:BP | GO:0050918 | positive chemotaxis | 2 | 40 | 4.29e-01 |
| GO:BP | GO:0032970 | regulation of actin filament-based process | 7 | 340 | 4.29e-01 |
| GO:BP | GO:1904743 | negative regulation of telomeric DNA binding | 1 | 2 | 4.29e-01 |
| GO:BP | GO:0035456 | response to interferon-beta | 7 | 22 | 4.29e-01 |
| GO:BP | GO:1904886 | beta-catenin destruction complex disassembly | 1 | 4 | 4.29e-01 |
| GO:BP | GO:1904934 | negative regulation of cell proliferation in midbrain | 1 | 1 | 4.29e-01 |
| GO:BP | GO:0051177 | meiotic sister chromatid cohesion | 1 | 12 | 4.29e-01 |
| GO:BP | GO:0051053 | negative regulation of DNA metabolic process | 1 | 112 | 4.29e-01 |
| GO:BP | GO:0036006 | cellular response to macrophage colony-stimulating factor stimulus | 1 | 6 | 4.29e-01 |
| GO:BP | GO:1904959 | regulation of cytochrome-c oxidase activity | 2 | 7 | 4.29e-01 |
| GO:BP | GO:0060331 | negative regulation of response to type II interferon | 2 | 6 | 4.29e-01 |
| GO:BP | GO:0098751 | bone cell development | 1 | 26 | 4.29e-01 |
| GO:BP | GO:1905301 | regulation of macropinocytosis | 1 | 3 | 4.29e-01 |
| GO:BP | GO:1901343 | negative regulation of vasculature development | 1 | 73 | 4.29e-01 |
| GO:BP | GO:0003175 | tricuspid valve development | 1 | 6 | 4.29e-01 |
| GO:BP | GO:0043031 | negative regulation of macrophage activation | 3 | 9 | 4.29e-01 |
| GO:BP | GO:1904955 | planar cell polarity pathway involved in midbrain dopaminergic neuron differentiation | 1 | 1 | 4.29e-01 |
| GO:BP | GO:0016525 | negative regulation of angiogenesis | 1 | 72 | 4.29e-01 |
| GO:BP | GO:0015724 | formate transport | 1 | 1 | 4.29e-01 |
| GO:BP | GO:0051056 | regulation of small GTPase mediated signal transduction | 2 | 257 | 4.29e-01 |
| GO:BP | GO:0045670 | regulation of osteoclast differentiation | 4 | 38 | 4.29e-01 |
| GO:BP | GO:0007049 | cell cycle | 145 | 1529 | 4.29e-01 |
| GO:BP | GO:0036293 | response to decreased oxygen levels | 22 | 249 | 4.29e-01 |
| GO:BP | GO:0006549 | isoleucine metabolic process | 2 | 6 | 4.29e-01 |
| GO:BP | GO:0033505 | floor plate morphogenesis | 2 | 3 | 4.29e-01 |
| GO:BP | GO:0045198 | establishment of epithelial cell apical/basal polarity | 4 | 14 | 4.29e-01 |
| GO:BP | GO:1901687 | glutathione derivative biosynthetic process | 1 | 3 | 4.29e-01 |
| GO:BP | GO:1905396 | cellular response to flavonoid | 1 | 1 | 4.29e-01 |
| GO:BP | GO:1901685 | glutathione derivative metabolic process | 1 | 3 | 4.29e-01 |
| GO:BP | GO:0006788 | heme oxidation | 1 | 2 | 4.29e-01 |
| GO:BP | GO:0071397 | cellular response to cholesterol | 3 | 11 | 4.29e-01 |
| GO:BP | GO:0036517 | chemoattraction of serotonergic neuron axon | 1 | 1 | 4.29e-01 |
| GO:BP | GO:0051085 | chaperone cofactor-dependent protein refolding | 2 | 30 | 4.29e-01 |
| GO:BP | GO:0080120 | CAAX-box protein maturation | 1 | 3 | 4.29e-01 |
| GO:BP | GO:1901096 | regulation of autophagosome maturation | 5 | 16 | 4.29e-01 |
| GO:BP | GO:0090207 | regulation of triglyceride metabolic process | 3 | 29 | 4.29e-01 |
| GO:BP | GO:0015797 | mannitol transmembrane transport | 1 | 1 | 4.29e-01 |
| GO:BP | GO:0006782 | protoporphyrinogen IX biosynthetic process | 1 | 9 | 4.29e-01 |
| GO:BP | GO:1902607 | negative regulation of large conductance calcium-activated potassium channel activity | 1 | 1 | 4.29e-01 |
| GO:BP | GO:0031400 | negative regulation of protein modification process | 12 | 418 | 4.29e-01 |
| GO:BP | GO:0033210 | leptin-mediated signaling pathway | 2 | 10 | 4.29e-01 |
| GO:BP | GO:0036359 | renal potassium excretion | 1 | 2 | 4.29e-01 |
| GO:BP | GO:0016243 | regulation of autophagosome size | 1 | 2 | 4.29e-01 |
| GO:BP | GO:0006272 | leading strand elongation | 2 | 4 | 4.29e-01 |
| GO:BP | GO:2001233 | regulation of apoptotic signaling pathway | 33 | 307 | 4.29e-01 |
| GO:BP | GO:0090161 | Golgi ribbon formation | 1 | 9 | 4.30e-01 |
| GO:BP | GO:0060122 | inner ear receptor cell stereocilium organization | 5 | 23 | 4.30e-01 |
| GO:BP | GO:1900186 | negative regulation of clathrin-dependent endocytosis | 1 | 4 | 4.30e-01 |
| GO:BP | GO:0048681 | negative regulation of axon regeneration | 1 | 11 | 4.30e-01 |
| GO:BP | GO:0031076 | embryonic camera-type eye development | 1 | 28 | 4.30e-01 |
| GO:BP | GO:0099622 | cardiac muscle cell membrane repolarization | 3 | 31 | 4.31e-01 |
| GO:BP | GO:0009097 | isoleucine biosynthetic process | 1 | 2 | 4.32e-01 |
| GO:BP | GO:0046365 | monosaccharide catabolic process | 1 | 38 | 4.32e-01 |
| GO:BP | GO:0007080 | mitotic metaphase plate congression | 7 | 55 | 4.33e-01 |
| GO:BP | GO:0042249 | establishment of planar polarity of embryonic epithelium | 4 | 15 | 4.33e-01 |
| GO:BP | GO:0060260 | regulation of transcription initiation by RNA polymerase II | 5 | 69 | 4.34e-01 |
| GO:BP | GO:0010992 | ubiquitin recycling | 4 | 12 | 4.34e-01 |
| GO:BP | GO:0086067 | AV node cell to bundle of His cell communication | 1 | 11 | 4.34e-01 |
| GO:BP | GO:1903676 | positive regulation of cap-dependent translational initiation | 1 | 1 | 4.34e-01 |
| GO:BP | GO:0000963 | mitochondrial RNA processing | 5 | 20 | 4.34e-01 |
| GO:BP | GO:0035862 | dITP metabolic process | 1 | 1 | 4.34e-01 |
| GO:BP | GO:0035863 | dITP catabolic process | 1 | 1 | 4.34e-01 |
| GO:BP | GO:0060395 | SMAD protein signal transduction | 7 | 65 | 4.34e-01 |
| GO:BP | GO:1903674 | regulation of cap-dependent translational initiation | 1 | 1 | 4.34e-01 |
| GO:BP | GO:0051251 | positive regulation of lymphocyte activation | 1 | 199 | 4.34e-01 |
| GO:BP | GO:0016331 | morphogenesis of embryonic epithelium | 15 | 132 | 4.35e-01 |
| GO:BP | GO:0097752 | regulation of DNA stability | 1 | 3 | 4.35e-01 |
| GO:BP | GO:0007042 | lysosomal lumen acidification | 3 | 21 | 4.35e-01 |
| GO:BP | GO:0042908 | xenobiotic transport | 3 | 30 | 4.35e-01 |
| GO:BP | GO:0034201 | response to oleic acid | 2 | 5 | 4.35e-01 |
| GO:BP | GO:0007159 | leukocyte cell-cell adhesion | 1 | 234 | 4.35e-01 |
| GO:BP | GO:1905870 | positive regulation of 3’-UTR-mediated mRNA stabilization | 2 | 4 | 4.35e-01 |
| GO:BP | GO:0097115 | neurexin clustering involved in presynaptic membrane assembly | 1 | 1 | 4.35e-01 |
| GO:BP | GO:0048789 | cytoskeletal matrix organization at active zone | 1 | 1 | 4.35e-01 |
| GO:BP | GO:0050902 | leukocyte adhesive activation | 1 | 2 | 4.35e-01 |
| GO:BP | GO:0032690 | negative regulation of interleukin-1 alpha production | 1 | 1 | 4.35e-01 |
| GO:BP | GO:0046394 | carboxylic acid biosynthetic process | 1 | 223 | 4.35e-01 |
| GO:BP | GO:0046579 | positive regulation of Ras protein signal transduction | 4 | 45 | 4.36e-01 |
| GO:BP | GO:0010002 | cardioblast differentiation | 3 | 15 | 4.36e-01 |
| GO:BP | GO:0010591 | regulation of lamellipodium assembly | 1 | 33 | 4.36e-01 |
| GO:BP | GO:0071307 | cellular response to vitamin K | 2 | 4 | 4.37e-01 |
| GO:BP | GO:0045006 | DNA deamination | 4 | 9 | 4.37e-01 |
| GO:BP | GO:0002931 | response to ischemia | 6 | 46 | 4.37e-01 |
| GO:BP | GO:0043097 | pyrimidine nucleoside salvage | 1 | 2 | 4.37e-01 |
| GO:BP | GO:0045586 | regulation of gamma-delta T cell differentiation | 1 | 6 | 4.37e-01 |
| GO:BP | GO:0016053 | organic acid biosynthetic process | 1 | 224 | 4.37e-01 |
| GO:BP | GO:0097712 | vesicle targeting, trans-Golgi to periciliary membrane compartment | 1 | 1 | 4.37e-01 |
| GO:BP | GO:0045936 | negative regulation of phosphate metabolic process | 1 | 344 | 4.37e-01 |
| GO:BP | GO:0060386 | synapse assembly involved in innervation | 1 | 1 | 4.37e-01 |
| GO:BP | GO:2000234 | positive regulation of rRNA processing | 3 | 10 | 4.37e-01 |
| GO:BP | GO:0048845 | venous blood vessel morphogenesis | 3 | 9 | 4.38e-01 |
| GO:BP | GO:0048261 | negative regulation of receptor-mediated endocytosis | 4 | 25 | 4.38e-01 |
| GO:BP | GO:0007218 | neuropeptide signaling pathway | 1 | 36 | 4.38e-01 |
| GO:BP | GO:0010563 | negative regulation of phosphorus metabolic process | 1 | 345 | 4.38e-01 |
| GO:BP | GO:0001841 | neural tube formation | 11 | 101 | 4.38e-01 |
| GO:BP | GO:1902178 | fibroblast growth factor receptor apoptotic signaling pathway | 1 | 1 | 4.38e-01 |
| GO:BP | GO:0034161 | positive regulation of toll-like receptor 8 signaling pathway | 1 | 2 | 4.38e-01 |
| GO:BP | GO:0035513 | oxidative RNA demethylation | 1 | 5 | 4.38e-01 |
| GO:BP | GO:0034159 | regulation of toll-like receptor 8 signaling pathway | 1 | 2 | 4.38e-01 |
| GO:BP | GO:0070430 | positive regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway | 1 | 2 | 4.38e-01 |
| GO:BP | GO:0015835 | peptidoglycan transport | 1 | 1 | 4.38e-01 |
| GO:BP | GO:0006624 | vacuolar protein processing | 1 | 2 | 4.38e-01 |
| GO:BP | GO:0009913 | epidermal cell differentiation | 3 | 116 | 4.38e-01 |
| GO:BP | GO:0060261 | positive regulation of transcription initiation by RNA polymerase II | 4 | 59 | 4.38e-01 |
| GO:BP | GO:0048170 | positive regulation of long-term neuronal synaptic plasticity | 1 | 5 | 4.38e-01 |
| GO:BP | GO:0036159 | inner dynein arm assembly | 1 | 8 | 4.39e-01 |
| GO:BP | GO:1902103 | negative regulation of metaphase/anaphase transition of meiotic cell cycle | 1 | 2 | 4.39e-01 |
| GO:BP | GO:0071472 | cellular response to salt stress | 2 | 11 | 4.39e-01 |
| GO:BP | GO:1905133 | negative regulation of meiotic chromosome separation | 1 | 2 | 4.39e-01 |
| GO:BP | GO:0006297 | nucleotide-excision repair, DNA gap filling | 2 | 5 | 4.39e-01 |
| GO:BP | GO:0042117 | monocyte activation | 1 | 8 | 4.39e-01 |
| GO:BP | GO:0032480 | negative regulation of type I interferon production | 7 | 23 | 4.39e-01 |
| GO:BP | GO:0061764 | late endosome to lysosome transport via multivesicular body sorting pathway | 1 | 2 | 4.40e-01 |
| GO:BP | GO:0021546 | rhombomere development | 1 | 4 | 4.40e-01 |
| GO:BP | GO:1905930 | regulation of vascular associated smooth muscle cell differentiation involved in phenotypic switching | 1 | 3 | 4.40e-01 |
| GO:BP | GO:1905915 | regulation of cell differentiation involved in phenotypic switching | 1 | 3 | 4.40e-01 |
| GO:BP | GO:0036451 | cap mRNA methylation | 1 | 2 | 4.40e-01 |
| GO:BP | GO:0070997 | neuron death | 24 | 286 | 4.40e-01 |
| GO:BP | GO:0001576 | globoside biosynthetic process | 1 | 2 | 4.40e-01 |
| GO:BP | GO:0097309 | cap1 mRNA methylation | 1 | 2 | 4.40e-01 |
| GO:BP | GO:0030036 | actin cytoskeleton organization | 10 | 612 | 4.40e-01 |
| GO:BP | GO:0090679 | cell differentiation involved in phenotypic switching | 1 | 3 | 4.40e-01 |
| GO:BP | GO:1905420 | vascular associated smooth muscle cell differentiation involved in phenotypic switching | 1 | 3 | 4.40e-01 |
| GO:BP | GO:0001575 | globoside metabolic process | 1 | 2 | 4.40e-01 |
| GO:BP | GO:0072665 | protein localization to vacuole | 2 | 72 | 4.40e-01 |
| GO:BP | GO:0072695 | regulation of DNA recombination at telomere | 1 | 2 | 4.40e-01 |
| GO:BP | GO:1900027 | regulation of ruffle assembly | 6 | 23 | 4.40e-01 |
| GO:BP | GO:0039694 | viral RNA genome replication | 6 | 27 | 4.40e-01 |
| GO:BP | GO:0070914 | UV-damage excision repair | 4 | 13 | 4.40e-01 |
| GO:BP | GO:0048550 | negative regulation of pinocytosis | 1 | 4 | 4.40e-01 |
| GO:BP | GO:0051048 | negative regulation of secretion | 1 | 111 | 4.40e-01 |
| GO:BP | GO:1904823 | purine nucleobase transmembrane transport | 1 | 3 | 4.40e-01 |
| GO:BP | GO:1904586 | cellular response to putrescine | 1 | 1 | 4.40e-01 |
| GO:BP | GO:1904585 | response to putrescine | 1 | 1 | 4.40e-01 |
| GO:BP | GO:0048696 | regulation of collateral sprouting in absence of injury | 1 | 2 | 4.40e-01 |
| GO:BP | GO:0048239 | negative regulation of DNA recombination at telomere | 1 | 2 | 4.40e-01 |
| GO:BP | GO:1990828 | hepatocyte dedifferentiation | 1 | 1 | 4.40e-01 |
| GO:BP | GO:2000278 | regulation of DNA biosynthetic process | 11 | 111 | 4.40e-01 |
| GO:BP | GO:0045722 | positive regulation of gluconeogenesis | 3 | 16 | 4.40e-01 |
| GO:BP | GO:0009208 | pyrimidine ribonucleoside triphosphate metabolic process | 3 | 16 | 4.40e-01 |
| GO:BP | GO:0009950 | dorsal/ventral axis specification | 2 | 9 | 4.40e-01 |
| GO:BP | GO:0010586 | miRNA metabolic process | 10 | 81 | 4.40e-01 |
| GO:BP | GO:1902237 | positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway | 3 | 10 | 4.40e-01 |
| GO:BP | GO:0099022 | vesicle tethering | 2 | 31 | 4.41e-01 |
| GO:BP | GO:0043065 | positive regulation of apoptotic process | 2 | 393 | 4.41e-01 |
| GO:BP | GO:0010839 | negative regulation of keratinocyte proliferation | 6 | 19 | 4.41e-01 |
| GO:BP | GO:0070682 | proteasome regulatory particle assembly | 2 | 3 | 4.41e-01 |
| GO:BP | GO:0038029 | epidermal growth factor receptor signaling pathway via MAPK cascade | 1 | 1 | 4.41e-01 |
| GO:BP | GO:0072578 | neurotransmitter-gated ion channel clustering | 4 | 12 | 4.41e-01 |
| GO:BP | GO:1990575 | mitochondrial L-ornithine transmembrane transport | 1 | 2 | 4.41e-01 |
| GO:BP | GO:0043254 | regulation of protein-containing complex assembly | 1 | 348 | 4.41e-01 |
| GO:BP | GO:0070571 | negative regulation of neuron projection regeneration | 1 | 12 | 4.41e-01 |
| GO:BP | GO:0009609 | response to symbiotic bacterium | 2 | 2 | 4.41e-01 |
| GO:BP | GO:0009608 | response to symbiont | 2 | 2 | 4.41e-01 |
| GO:BP | GO:0031442 | positive regulation of mRNA 3’-end processing | 1 | 10 | 4.41e-01 |
| GO:BP | GO:0033523 | histone H2B ubiquitination | 1 | 10 | 4.41e-01 |
| GO:BP | GO:0010464 | regulation of mesenchymal cell proliferation | 2 | 25 | 4.41e-01 |
| GO:BP | GO:0032874 | positive regulation of stress-activated MAPK cascade | 6 | 96 | 4.41e-01 |
| GO:BP | GO:0045685 | regulation of glial cell differentiation | 4 | 47 | 4.42e-01 |
| GO:BP | GO:0051303 | establishment of chromosome localization | 10 | 75 | 4.42e-01 |
| GO:BP | GO:0071393 | cellular response to progesterone stimulus | 2 | 5 | 4.42e-01 |
| GO:BP | GO:0036337 | Fas signaling pathway | 2 | 5 | 4.42e-01 |
| GO:BP | GO:1901072 | glucosamine-containing compound catabolic process | 3 | 5 | 4.42e-01 |
| GO:BP | GO:1903593 | regulation of histamine secretion by mast cell | 2 | 4 | 4.42e-01 |
| GO:BP | GO:0051012 | microtubule sliding | 1 | 2 | 4.42e-01 |
| GO:BP | GO:1903595 | positive regulation of histamine secretion by mast cell | 2 | 4 | 4.42e-01 |
| GO:BP | GO:0033564 | anterior/posterior axon guidance | 1 | 4 | 4.42e-01 |
| GO:BP | GO:0060644 | mammary gland epithelial cell differentiation | 5 | 14 | 4.43e-01 |
| GO:BP | GO:0090240 | positive regulation of histone H4 acetylation | 2 | 6 | 4.43e-01 |
| GO:BP | GO:0031629 | synaptic vesicle fusion to presynaptic active zone membrane | 2 | 19 | 4.43e-01 |
| GO:BP | GO:0098920 | retrograde trans-synaptic signaling by lipid | 1 | 4 | 4.43e-01 |
| GO:BP | GO:0030098 | lymphocyte differentiation | 1 | 260 | 4.43e-01 |
| GO:BP | GO:0098921 | retrograde trans-synaptic signaling by endocannabinoid | 1 | 4 | 4.43e-01 |
| GO:BP | GO:0071345 | cellular response to cytokine stimulus | 2 | 540 | 4.43e-01 |
| GO:BP | GO:0006216 | cytidine catabolic process | 3 | 6 | 4.43e-01 |
| GO:BP | GO:0010692 | regulation of alkaline phosphatase activity | 1 | 8 | 4.43e-01 |
| GO:BP | GO:0120012 | intermembrane sphingolipid transfer | 1 | 1 | 4.43e-01 |
| GO:BP | GO:0062043 | positive regulation of cardiac epithelial to mesenchymal transition | 1 | 9 | 4.43e-01 |
| GO:BP | GO:0046087 | cytidine metabolic process | 3 | 6 | 4.43e-01 |
| GO:BP | GO:0006402 | mRNA catabolic process | 39 | 216 | 4.43e-01 |
| GO:BP | GO:0051884 | regulation of timing of anagen | 2 | 5 | 4.43e-01 |
| GO:BP | GO:0045911 | positive regulation of DNA recombination | 4 | 57 | 4.43e-01 |
| GO:BP | GO:1905770 | regulation of mesodermal cell differentiation | 1 | 6 | 4.43e-01 |
| GO:BP | GO:0045672 | positive regulation of osteoclast differentiation | 3 | 11 | 4.43e-01 |
| GO:BP | GO:1904023 | regulation of glucose catabolic process to lactate via pyruvate | 1 | 4 | 4.43e-01 |
| GO:BP | GO:0009972 | cytidine deamination | 3 | 6 | 4.43e-01 |
| GO:BP | GO:0010001 | glial cell differentiation | 7 | 170 | 4.43e-01 |
| GO:BP | GO:0006166 | purine ribonucleoside salvage | 1 | 7 | 4.43e-01 |
| GO:BP | GO:0009894 | regulation of catabolic process | 147 | 875 | 4.43e-01 |
| GO:BP | GO:0046473 | phosphatidic acid metabolic process | 7 | 32 | 4.43e-01 |
| GO:BP | GO:0051660 | establishment of centrosome localization | 2 | 8 | 4.43e-01 |
| GO:BP | GO:2000199 | positive regulation of ribonucleoprotein complex localization | 1 | 1 | 4.43e-01 |
| GO:BP | GO:0070887 | cellular response to chemical stimulus | 4 | 1869 | 4.43e-01 |
| GO:BP | GO:0070898 | RNA polymerase III preinitiation complex assembly | 1 | 1 | 4.43e-01 |
| GO:BP | GO:0071107 | response to parathyroid hormone | 1 | 9 | 4.43e-01 |
| GO:BP | GO:0071279 | cellular response to cobalt ion | 1 | 4 | 4.43e-01 |
| GO:BP | GO:0030576 | Cajal body organization | 1 | 4 | 4.43e-01 |
| GO:BP | GO:0071712 | ER-associated misfolded protein catabolic process | 3 | 12 | 4.43e-01 |
| GO:BP | GO:0019661 | glucose catabolic process to lactate via pyruvate | 1 | 4 | 4.43e-01 |
| GO:BP | GO:0019660 | glycolytic fermentation | 1 | 4 | 4.43e-01 |
| GO:BP | GO:0019659 | glucose catabolic process to lactate | 1 | 4 | 4.43e-01 |
| GO:BP | GO:0034340 | response to type I interferon | 4 | 57 | 4.43e-01 |
| GO:BP | GO:0031651 | negative regulation of heat generation | 1 | 1 | 4.43e-01 |
| GO:BP | GO:2000626 | negative regulation of miRNA catabolic process | 1 | 1 | 4.43e-01 |
| GO:BP | GO:2000564 | regulation of CD8-positive, alpha-beta T cell proliferation | 3 | 7 | 4.43e-01 |
| GO:BP | GO:0046850 | regulation of bone remodeling | 2 | 30 | 4.43e-01 |
| GO:BP | GO:0090160 | Golgi to lysosome transport | 3 | 10 | 4.43e-01 |
| GO:BP | GO:0006486 | protein glycosylation | 2 | 187 | 4.43e-01 |
| GO:BP | GO:0019264 | glycine biosynthetic process from serine | 1 | 2 | 4.43e-01 |
| GO:BP | GO:2000208 | positive regulation of ribosomal small subunit export from nucleus | 1 | 1 | 4.43e-01 |
| GO:BP | GO:2000206 | regulation of ribosomal small subunit export from nucleus | 1 | 1 | 4.43e-01 |
| GO:BP | GO:0010720 | positive regulation of cell development | 1 | 317 | 4.43e-01 |
| GO:BP | GO:2000202 | positive regulation of ribosomal subunit export from nucleus | 1 | 1 | 4.43e-01 |
| GO:BP | GO:2000200 | regulation of ribosomal subunit export from nucleus | 1 | 1 | 4.43e-01 |
| GO:BP | GO:0048285 | organelle fission | 42 | 388 | 4.43e-01 |
| GO:BP | GO:0016601 | Rac protein signal transduction | 1 | 42 | 4.43e-01 |
| GO:BP | GO:0008589 | regulation of smoothened signaling pathway | 1 | 73 | 4.43e-01 |
| GO:BP | GO:0140235 | RNA polyadenylation at postsynapse | 1 | 1 | 4.43e-01 |
| GO:BP | GO:1903608 | protein localization to cytoplasmic stress granule | 2 | 7 | 4.43e-01 |
| GO:BP | GO:1900262 | regulation of DNA-directed DNA polymerase activity | 3 | 13 | 4.43e-01 |
| GO:BP | GO:1900264 | positive regulation of DNA-directed DNA polymerase activity | 3 | 13 | 4.43e-01 |
| GO:BP | GO:0035627 | ceramide transport | 4 | 15 | 4.43e-01 |
| GO:BP | GO:1900425 | negative regulation of defense response to bacterium | 2 | 4 | 4.43e-01 |
| GO:BP | GO:1901003 | negative regulation of fermentation | 1 | 4 | 4.43e-01 |
| GO:BP | GO:0042640 | anagen | 2 | 5 | 4.43e-01 |
| GO:BP | GO:0035740 | CD8-positive, alpha-beta T cell proliferation | 3 | 7 | 4.43e-01 |
| GO:BP | GO:0042391 | regulation of membrane potential | 1 | 293 | 4.43e-01 |
| GO:BP | GO:1901628 | positive regulation of postsynaptic membrane organization | 1 | 2 | 4.43e-01 |
| GO:BP | GO:0033674 | positive regulation of kinase activity | 1 | 317 | 4.43e-01 |
| GO:BP | GO:0061312 | BMP signaling pathway involved in heart development | 1 | 7 | 4.43e-01 |
| GO:BP | GO:0003007 | heart morphogenesis | 8 | 216 | 4.43e-01 |
| GO:BP | GO:0036372 | opsin transport | 1 | 2 | 4.43e-01 |
| GO:BP | GO:1904719 | positive regulation of AMPA glutamate receptor clustering | 1 | 2 | 4.43e-01 |
| GO:BP | GO:0002755 | MyD88-dependent toll-like receptor signaling pathway | 2 | 14 | 4.43e-01 |
| GO:BP | GO:0043413 | macromolecule glycosylation | 2 | 187 | 4.43e-01 |
| GO:BP | GO:0035522 | monoubiquitinated histone H2A deubiquitination | 2 | 30 | 4.43e-01 |
| GO:BP | GO:0035521 | monoubiquitinated histone deubiquitination | 2 | 30 | 4.43e-01 |
| GO:BP | GO:0060731 | positive regulation of intestinal epithelial structure maintenance | 1 | 1 | 4.44e-01 |
| GO:BP | GO:0070715 | sodium-dependent organic cation transport | 1 | 1 | 4.44e-01 |
| GO:BP | GO:0030242 | autophagy of peroxisome | 3 | 10 | 4.44e-01 |
| GO:BP | GO:0043068 | positive regulation of programmed cell death | 2 | 399 | 4.44e-01 |
| GO:BP | GO:0031109 | microtubule polymerization or depolymerization | 14 | 119 | 4.44e-01 |
| GO:BP | GO:0003332 | negative regulation of extracellular matrix constituent secretion | 1 | 2 | 4.44e-01 |
| GO:BP | GO:0090618 | DNA clamp unloading | 1 | 2 | 4.44e-01 |
| GO:BP | GO:0032365 | intracellular lipid transport | 9 | 42 | 4.44e-01 |
| GO:BP | GO:0003170 | heart valve development | 5 | 65 | 4.44e-01 |
| GO:BP | GO:1901617 | organic hydroxy compound biosynthetic process | 7 | 172 | 4.44e-01 |
| GO:BP | GO:0060795 | cell fate commitment involved in formation of primary germ layer | 2 | 18 | 4.44e-01 |
| GO:BP | GO:0033144 | negative regulation of intracellular steroid hormone receptor signaling pathway | 1 | 31 | 4.44e-01 |
| GO:BP | GO:2000736 | regulation of stem cell differentiation | 5 | 71 | 4.44e-01 |
| GO:BP | GO:0043402 | glucocorticoid mediated signaling pathway | 1 | 1 | 4.44e-01 |
| GO:BP | GO:0031444 | slow-twitch skeletal muscle fiber contraction | 1 | 2 | 4.44e-01 |
| GO:BP | GO:0021718 | superior olivary nucleus development | 1 | 1 | 4.44e-01 |
| GO:BP | GO:0002787 | negative regulation of antibacterial peptide production | 1 | 1 | 4.44e-01 |
| GO:BP | GO:0014728 | regulation of the force of skeletal muscle contraction | 1 | 3 | 4.44e-01 |
| GO:BP | GO:1905430 | cellular response to glycine | 1 | 2 | 4.44e-01 |
| GO:BP | GO:0035909 | aorta morphogenesis | 2 | 26 | 4.44e-01 |
| GO:BP | GO:0051967 | negative regulation of synaptic transmission, glutamatergic | 1 | 7 | 4.44e-01 |
| GO:BP | GO:0002785 | negative regulation of antimicrobial peptide production | 1 | 1 | 4.44e-01 |
| GO:BP | GO:0048302 | regulation of isotype switching to IgG isotypes | 4 | 7 | 4.44e-01 |
| GO:BP | GO:0021722 | superior olivary nucleus maturation | 1 | 1 | 4.44e-01 |
| GO:BP | GO:0051568 | histone H3-K4 methylation | 12 | 57 | 4.44e-01 |
| GO:BP | GO:0014862 | regulation of skeletal muscle contraction by chemo-mechanical energy conversion | 1 | 3 | 4.44e-01 |
| GO:BP | GO:0071356 | cellular response to tumor necrosis factor | 1 | 155 | 4.44e-01 |
| GO:BP | GO:0021586 | pons maturation | 1 | 1 | 4.44e-01 |
| GO:BP | GO:0002696 | positive regulation of leukocyte activation | 1 | 222 | 4.44e-01 |
| GO:BP | GO:0034635 | glutathione transport | 2 | 9 | 4.44e-01 |
| GO:BP | GO:0044557 | relaxation of smooth muscle | 1 | 9 | 4.44e-01 |
| GO:BP | GO:0008348 | negative regulation of antimicrobial humoral response | 1 | 1 | 4.44e-01 |
| GO:BP | GO:0098953 | receptor diffusion trapping | 2 | 4 | 4.44e-01 |
| GO:BP | GO:0098970 | postsynaptic neurotransmitter receptor diffusion trapping | 2 | 4 | 4.44e-01 |
| GO:BP | GO:2000321 | positive regulation of T-helper 17 cell differentiation | 2 | 3 | 4.44e-01 |
| GO:BP | GO:0070304 | positive regulation of stress-activated protein kinase signaling cascade | 6 | 98 | 4.44e-01 |
| GO:BP | GO:0019682 | glyceraldehyde-3-phosphate metabolic process | 1 | 5 | 4.44e-01 |
| GO:BP | GO:0032957 | inositol trisphosphate metabolic process | 2 | 10 | 4.44e-01 |
| GO:BP | GO:0061723 | glycophagy | 1 | 4 | 4.44e-01 |
| GO:BP | GO:0099628 | neurotransmitter receptor diffusion trapping | 2 | 4 | 4.44e-01 |
| GO:BP | GO:0009052 | pentose-phosphate shunt, non-oxidative branch | 1 | 6 | 4.44e-01 |
| GO:BP | GO:0019751 | polyol metabolic process | 4 | 82 | 4.44e-01 |
| GO:BP | GO:0046643 | regulation of gamma-delta T cell activation | 1 | 6 | 4.45e-01 |
| GO:BP | GO:1900449 | regulation of glutamate receptor signaling pathway | 2 | 5 | 4.45e-01 |
| GO:BP | GO:0046501 | protoporphyrinogen IX metabolic process | 1 | 11 | 4.45e-01 |
| GO:BP | GO:2000821 | regulation of grooming behavior | 2 | 3 | 4.45e-01 |
| GO:BP | GO:0043163 | cell envelope organization | 1 | 1 | 4.45e-01 |
| GO:BP | GO:1990758 | mitotic sister chromatid biorientation | 1 | 1 | 4.46e-01 |
| GO:BP | GO:0030336 | negative regulation of cell migration | 20 | 227 | 4.46e-01 |
| GO:BP | GO:0034115 | negative regulation of heterotypic cell-cell adhesion | 2 | 6 | 4.46e-01 |
| GO:BP | GO:0035880 | embryonic nail plate morphogenesis | 1 | 4 | 4.46e-01 |
| GO:BP | GO:0008614 | pyridoxine metabolic process | 1 | 2 | 4.46e-01 |
| GO:BP | GO:0030334 | regulation of cell migration | 12 | 706 | 4.46e-01 |
| GO:BP | GO:0015864 | pyrimidine nucleoside transport | 1 | 4 | 4.46e-01 |
| GO:BP | GO:0050867 | positive regulation of cell activation | 1 | 229 | 4.46e-01 |
| GO:BP | GO:0008615 | pyridoxine biosynthetic process | 1 | 2 | 4.46e-01 |
| GO:BP | GO:1904273 | L-alanine import across plasma membrane | 1 | 4 | 4.46e-01 |
| GO:BP | GO:1902682 | protein localization to pericentric heterochromatin | 1 | 1 | 4.46e-01 |
| GO:BP | GO:1901970 | positive regulation of mitotic sister chromatid separation | 3 | 18 | 4.46e-01 |
| GO:BP | GO:0019532 | oxalate transport | 1 | 5 | 4.46e-01 |
| GO:BP | GO:0017062 | respiratory chain complex III assembly | 2 | 10 | 4.46e-01 |
| GO:BP | GO:0044342 | type B pancreatic cell proliferation | 4 | 26 | 4.46e-01 |
| GO:BP | GO:0018008 | N-terminal peptidyl-glycine N-myristoylation | 1 | 2 | 4.46e-01 |
| GO:BP | GO:0018023 | peptidyl-lysine trimethylation | 2 | 33 | 4.46e-01 |
| GO:BP | GO:0099500 | vesicle fusion to plasma membrane | 2 | 19 | 4.46e-01 |
| GO:BP | GO:0099187 | presynaptic cytoskeleton organization | 1 | 1 | 4.46e-01 |
| GO:BP | GO:0099140 | presynaptic actin cytoskeleton organization | 1 | 1 | 4.46e-01 |
| GO:BP | GO:0045069 | regulation of viral genome replication | 4 | 64 | 4.46e-01 |
| GO:BP | GO:0015855 | pyrimidine nucleobase transport | 1 | 3 | 4.46e-01 |
| GO:BP | GO:0002443 | leukocyte mediated immunity | 1 | 194 | 4.46e-01 |
| GO:BP | GO:0010799 | regulation of peptidyl-threonine phosphorylation | 8 | 35 | 4.46e-01 |
| GO:BP | GO:0001779 | natural killer cell differentiation | 3 | 18 | 4.46e-01 |
| GO:BP | GO:0010424 | DNA methylation on cytosine within a CG sequence | 1 | 1 | 4.46e-01 |
| GO:BP | GO:0045637 | regulation of myeloid cell differentiation | 5 | 152 | 4.46e-01 |
| GO:BP | GO:0072584 | caveolin-mediated endocytosis | 2 | 9 | 4.46e-01 |
| GO:BP | GO:0032870 | cellular response to hormone stimulus | 2 | 457 | 4.46e-01 |
| GO:BP | GO:0097192 | extrinsic apoptotic signaling pathway in absence of ligand | 10 | 52 | 4.46e-01 |
| GO:BP | GO:0009953 | dorsal/ventral pattern formation | 1 | 55 | 4.46e-01 |
| GO:BP | GO:0045879 | negative regulation of smoothened signaling pathway | 4 | 30 | 4.46e-01 |
| GO:BP | GO:0045948 | positive regulation of translational initiation | 6 | 23 | 4.46e-01 |
| GO:BP | GO:0010888 | negative regulation of lipid storage | 5 | 16 | 4.46e-01 |
| GO:BP | GO:2000146 | negative regulation of cell motility | 21 | 236 | 4.46e-01 |
| GO:BP | GO:0016072 | rRNA metabolic process | 49 | 258 | 4.46e-01 |
| GO:BP | GO:1902031 | regulation of NADP metabolic process | 2 | 8 | 4.46e-01 |
| GO:BP | GO:0038034 | signal transduction in absence of ligand | 10 | 52 | 4.46e-01 |
| GO:BP | GO:1902116 | negative regulation of organelle assembly | 4 | 40 | 4.46e-01 |
| GO:BP | GO:0034968 | histone lysine methylation | 18 | 89 | 4.46e-01 |
| GO:BP | GO:0048168 | regulation of neuronal synaptic plasticity | 3 | 42 | 4.46e-01 |
| GO:BP | GO:1902262 | apoptotic process involved in blood vessel morphogenesis | 2 | 4 | 4.46e-01 |
| GO:BP | GO:0034551 | mitochondrial respiratory chain complex III assembly | 2 | 10 | 4.46e-01 |
| GO:BP | GO:0097242 | amyloid-beta clearance | 1 | 27 | 4.46e-01 |
| GO:BP | GO:0015862 | uridine transport | 1 | 4 | 4.46e-01 |
| GO:BP | GO:0009896 | positive regulation of catabolic process | 35 | 464 | 4.46e-01 |
| GO:BP | GO:0060537 | muscle tissue development | 12 | 343 | 4.46e-01 |
| GO:BP | GO:0000469 | cleavage involved in rRNA processing | 7 | 29 | 4.46e-01 |
| GO:BP | GO:0070646 | protein modification by small protein removal | 3 | 147 | 4.46e-01 |
| GO:BP | GO:0070587 | regulation of cell-cell adhesion involved in gastrulation | 2 | 6 | 4.46e-01 |
| GO:BP | GO:0051653 | spindle localization | 4 | 52 | 4.46e-01 |
| GO:BP | GO:0000288 | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 14 | 64 | 4.46e-01 |
| GO:BP | GO:0061709 | reticulophagy | 1 | 17 | 4.46e-01 |
| GO:BP | GO:0060443 | mammary gland morphogenesis | 2 | 39 | 4.46e-01 |
| GO:BP | GO:0000272 | polysaccharide catabolic process | 2 | 14 | 4.46e-01 |
| GO:BP | GO:0022038 | corpus callosum development | 1 | 20 | 4.46e-01 |
| GO:BP | GO:0045204 | MAPK export from nucleus | 1 | 3 | 4.46e-01 |
| GO:BP | GO:0030032 | lamellipodium assembly | 2 | 61 | 4.46e-01 |
| GO:BP | GO:1905516 | positive regulation of fertilization | 1 | 3 | 4.47e-01 |
| GO:BP | GO:0120036 | plasma membrane bounded cell projection organization | 6 | 1201 | 4.47e-01 |
| GO:BP | GO:0001824 | blastocyst development | 1 | 94 | 4.47e-01 |
| GO:BP | GO:0044057 | regulation of system process | 2 | 405 | 4.47e-01 |
| GO:BP | GO:0043297 | apical junction assembly | 3 | 51 | 4.47e-01 |
| GO:BP | GO:1903078 | positive regulation of protein localization to plasma membrane | 6 | 50 | 4.47e-01 |
| GO:BP | GO:2000677 | regulation of transcription regulatory region DNA binding | 3 | 43 | 4.47e-01 |
| GO:BP | GO:0042492 | gamma-delta T cell differentiation | 2 | 7 | 4.47e-01 |
| GO:BP | GO:0021502 | neural fold elevation formation | 1 | 3 | 4.47e-01 |
| GO:BP | GO:0035999 | tetrahydrofolate interconversion | 2 | 9 | 4.47e-01 |
| GO:BP | GO:0070101 | positive regulation of chemokine-mediated signaling pathway | 1 | 2 | 4.47e-01 |
| GO:BP | GO:2001237 | negative regulation of extrinsic apoptotic signaling pathway | 10 | 78 | 4.47e-01 |
| GO:BP | GO:0045651 | positive regulation of macrophage differentiation | 1 | 12 | 4.47e-01 |
| GO:BP | GO:0071494 | cellular response to UV-C | 2 | 4 | 4.47e-01 |
| GO:BP | GO:0000479 | endonucleolytic cleavage of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 3 | 17 | 4.47e-01 |
| GO:BP | GO:0035082 | axoneme assembly | 1 | 52 | 4.47e-01 |
| GO:BP | GO:0030910 | olfactory placode formation | 1 | 2 | 4.47e-01 |
| GO:BP | GO:0000478 | endonucleolytic cleavage involved in rRNA processing | 3 | 17 | 4.47e-01 |
| GO:BP | GO:0071699 | olfactory placode morphogenesis | 1 | 2 | 4.47e-01 |
| GO:BP | GO:0071698 | olfactory placode development | 1 | 2 | 4.47e-01 |
| GO:BP | GO:2000628 | regulation of miRNA metabolic process | 8 | 67 | 4.47e-01 |
| GO:BP | GO:0061890 | positive regulation of astrocyte activation | 1 | 1 | 4.47e-01 |
| GO:BP | GO:0061888 | regulation of astrocyte activation | 2 | 3 | 4.47e-01 |
| GO:BP | GO:0001942 | hair follicle development | 2 | 67 | 4.47e-01 |
| GO:BP | GO:0006508 | proteolysis | 1 | 1318 | 4.47e-01 |
| GO:BP | GO:0032259 | methylation | 47 | 313 | 4.47e-01 |
| GO:BP | GO:0070899 | mitochondrial tRNA wobble uridine modification | 1 | 1 | 4.48e-01 |
| GO:BP | GO:0002572 | pro-T cell differentiation | 1 | 1 | 4.48e-01 |
| GO:BP | GO:1905458 | positive regulation of lymphoid progenitor cell differentiation | 1 | 3 | 4.48e-01 |
| GO:BP | GO:0070384 | Harderian gland development | 1 | 4 | 4.48e-01 |
| GO:BP | GO:0043094 | cellular metabolic compound salvage | 6 | 25 | 4.48e-01 |
| GO:BP | GO:0003014 | renal system process | 1 | 78 | 4.48e-01 |
| GO:BP | GO:0001895 | retina homeostasis | 1 | 44 | 4.48e-01 |
| GO:BP | GO:0050691 | regulation of defense response to virus by host | 9 | 30 | 4.48e-01 |
| GO:BP | GO:1904582 | positive regulation of intracellular mRNA localization | 1 | 3 | 4.48e-01 |
| GO:BP | GO:0031445 | regulation of heterochromatin formation | 5 | 22 | 4.48e-01 |
| GO:BP | GO:0021612 | facial nerve structural organization | 1 | 7 | 4.48e-01 |
| GO:BP | GO:0050921 | positive regulation of chemotaxis | 3 | 85 | 4.48e-01 |
| GO:BP | GO:0120261 | regulation of heterochromatin organization | 5 | 22 | 4.48e-01 |
| GO:BP | GO:0045747 | positive regulation of Notch signaling pathway | 8 | 37 | 4.48e-01 |
| GO:BP | GO:0030238 | male sex determination | 2 | 8 | 4.48e-01 |
| GO:BP | GO:0022407 | regulation of cell-cell adhesion | 1 | 295 | 4.49e-01 |
| GO:BP | GO:0040008 | regulation of growth | 1 | 501 | 4.49e-01 |
| GO:BP | GO:0110012 | protein localization to P-body | 1 | 1 | 4.49e-01 |
| GO:BP | GO:0005981 | regulation of glycogen catabolic process | 1 | 4 | 4.49e-01 |
| GO:BP | GO:0038173 | interleukin-17A-mediated signaling pathway | 1 | 1 | 4.49e-01 |
| GO:BP | GO:0010569 | regulation of double-strand break repair via homologous recombination | 4 | 63 | 4.49e-01 |
| GO:BP | GO:0002334 | transitional two stage B cell differentiation | 1 | 1 | 4.49e-01 |
| GO:BP | GO:0045669 | positive regulation of osteoblast differentiation | 3 | 54 | 4.49e-01 |
| GO:BP | GO:0045785 | positive regulation of cell adhesion | 1 | 320 | 4.49e-01 |
| GO:BP | GO:0062042 | regulation of cardiac epithelial to mesenchymal transition | 1 | 10 | 4.49e-01 |
| GO:BP | GO:0051100 | negative regulation of binding | 1 | 135 | 4.49e-01 |
| GO:BP | GO:0090151 | establishment of protein localization to mitochondrial membrane | 7 | 38 | 4.49e-01 |
| GO:BP | GO:0042797 | tRNA transcription by RNA polymerase III | 2 | 7 | 4.49e-01 |
| GO:BP | GO:0072020 | proximal straight tubule development | 1 | 1 | 4.50e-01 |
| GO:BP | GO:1905215 | negative regulation of RNA binding | 1 | 2 | 4.50e-01 |
| GO:BP | GO:0010833 | telomere maintenance via telomere lengthening | 8 | 73 | 4.50e-01 |
| GO:BP | GO:0040012 | regulation of locomotion | 13 | 763 | 4.50e-01 |
| GO:BP | GO:0042023 | DNA endoreduplication | 2 | 5 | 4.50e-01 |
| GO:BP | GO:0072022 | descending thin limb development | 1 | 1 | 4.50e-01 |
| GO:BP | GO:1905073 | regulation of tight junction disassembly | 1 | 2 | 4.50e-01 |
| GO:BP | GO:0048560 | establishment of anatomical structure orientation | 1 | 2 | 4.50e-01 |
| GO:BP | GO:1905075 | positive regulation of tight junction disassembly | 1 | 2 | 4.50e-01 |
| GO:BP | GO:0042254 | ribosome biogenesis | 54 | 301 | 4.50e-01 |
| GO:BP | GO:0072232 | metanephric proximal convoluted tubule segment 2 development | 1 | 1 | 4.50e-01 |
| GO:BP | GO:0072230 | metanephric proximal straight tubule development | 1 | 1 | 4.50e-01 |
| GO:BP | GO:0032823 | regulation of natural killer cell differentiation | 2 | 8 | 4.50e-01 |
| GO:BP | GO:0072220 | metanephric descending thin limb development | 1 | 1 | 4.50e-01 |
| GO:BP | GO:0032876 | negative regulation of DNA endoreduplication | 1 | 1 | 4.50e-01 |
| GO:BP | GO:0070257 | positive regulation of mucus secretion | 1 | 4 | 4.50e-01 |
| GO:BP | GO:1905071 | tight junction disassembly | 1 | 2 | 4.50e-01 |
| GO:BP | GO:0007549 | dosage compensation | 7 | 29 | 4.50e-01 |
| GO:BP | GO:0072032 | proximal convoluted tubule segment 2 development | 1 | 1 | 4.50e-01 |
| GO:BP | GO:0070266 | necroptotic process | 4 | 32 | 4.50e-01 |
| GO:BP | GO:1904637 | cellular response to ionomycin | 1 | 3 | 4.50e-01 |
| GO:BP | GO:0051450 | myoblast proliferation | 3 | 17 | 4.50e-01 |
| GO:BP | GO:0061698 | protein deglutarylation | 1 | 2 | 4.50e-01 |
| GO:BP | GO:0016926 | protein desumoylation | 3 | 9 | 4.50e-01 |
| GO:BP | GO:0014732 | skeletal muscle atrophy | 2 | 5 | 4.50e-01 |
| GO:BP | GO:0010508 | positive regulation of autophagy | 12 | 133 | 4.50e-01 |
| GO:BP | GO:1902893 | regulation of miRNA transcription | 7 | 56 | 4.50e-01 |
| GO:BP | GO:0046323 | glucose import | 10 | 53 | 4.50e-01 |
| GO:BP | GO:0090068 | positive regulation of cell cycle process | 32 | 209 | 4.50e-01 |
| GO:BP | GO:1903131 | mononuclear cell differentiation | 1 | 294 | 4.50e-01 |
| GO:BP | GO:0001819 | positive regulation of cytokine production | 1 | 276 | 4.50e-01 |
| GO:BP | GO:1903402 | regulation of renal phosphate excretion | 1 | 2 | 4.50e-01 |
| GO:BP | GO:0032416 | negative regulation of sodium:proton antiporter activity | 1 | 1 | 4.50e-01 |
| GO:BP | GO:0106230 | protein depropionylation | 1 | 2 | 4.50e-01 |
| GO:BP | GO:0030223 | neutrophil differentiation | 1 | 8 | 4.50e-01 |
| GO:BP | GO:0044722 | renal phosphate excretion | 1 | 2 | 4.50e-01 |
| GO:BP | GO:1903943 | regulation of hepatocyte apoptotic process | 2 | 7 | 4.50e-01 |
| GO:BP | GO:0001661 | conditioned taste aversion | 1 | 2 | 4.50e-01 |
| GO:BP | GO:0060683 | regulation of branching involved in salivary gland morphogenesis by epithelial-mesenchymal signaling | 1 | 1 | 4.50e-01 |
| GO:BP | GO:0071394 | cellular response to testosterone stimulus | 2 | 11 | 4.50e-01 |
| GO:BP | GO:0036179 | osteoclast maturation | 1 | 1 | 4.50e-01 |
| GO:BP | GO:0043410 | positive regulation of MAPK cascade | 1 | 317 | 4.50e-01 |
| GO:BP | GO:0039530 | MDA-5 signaling pathway | 3 | 8 | 4.50e-01 |
| GO:BP | GO:0048262 | determination of dorsal/ventral asymmetry | 1 | 6 | 4.50e-01 |
| GO:BP | GO:0051403 | stress-activated MAPK cascade | 10 | 190 | 4.50e-01 |
| GO:BP | GO:1904732 | regulation of electron transfer activity | 2 | 8 | 4.50e-01 |
| GO:BP | GO:1904636 | response to ionomycin | 1 | 3 | 4.50e-01 |
| GO:BP | GO:0070358 | actin polymerization-dependent cell motility | 2 | 6 | 4.50e-01 |
| GO:BP | GO:0036092 | phosphatidylinositol-3-phosphate biosynthetic process | 2 | 19 | 4.50e-01 |
| GO:BP | GO:1990637 | response to prolactin | 1 | 3 | 4.50e-01 |
| GO:BP | GO:0036049 | peptidyl-lysine desuccinylation | 1 | 2 | 4.50e-01 |
| GO:BP | GO:0036048 | protein desuccinylation | 1 | 2 | 4.50e-01 |
| GO:BP | GO:0140718 | facultative heterochromatin formation | 1 | 35 | 4.50e-01 |
| GO:BP | GO:0003402 | planar cell polarity pathway involved in axis elongation | 2 | 6 | 4.50e-01 |
| GO:BP | GO:1990678 | histone H4-K16 deacetylation | 1 | 1 | 4.50e-01 |
| GO:BP | GO:0034612 | response to tumor necrosis factor | 1 | 172 | 4.50e-01 |
| GO:BP | GO:1905820 | positive regulation of chromosome separation | 4 | 28 | 4.50e-01 |
| GO:BP | GO:0060712 | spongiotrophoblast layer development | 4 | 11 | 4.50e-01 |
| GO:BP | GO:1900272 | negative regulation of long-term synaptic potentiation | 1 | 8 | 4.51e-01 |
| GO:BP | GO:0072717 | cellular response to actinomycin D | 1 | 4 | 4.51e-01 |
| GO:BP | GO:1904058 | positive regulation of sensory perception of pain | 2 | 3 | 4.51e-01 |
| GO:BP | GO:0007089 | traversing start control point of mitotic cell cycle | 1 | 4 | 4.51e-01 |
| GO:BP | GO:0099637 | neurotransmitter receptor transport | 2 | 21 | 4.51e-01 |
| GO:BP | GO:0022404 | molting cycle process | 2 | 69 | 4.52e-01 |
| GO:BP | GO:0022405 | hair cycle process | 2 | 69 | 4.52e-01 |
| GO:BP | GO:0032881 | regulation of polysaccharide metabolic process | 4 | 34 | 4.52e-01 |
| GO:BP | GO:0010226 | response to lithium ion | 6 | 16 | 4.52e-01 |
| GO:BP | GO:0014886 | transition between slow and fast fiber | 1 | 1 | 4.52e-01 |
| GO:BP | GO:0106380 | purine ribonucleotide salvage | 1 | 7 | 4.53e-01 |
| GO:BP | GO:0070104 | negative regulation of interleukin-6-mediated signaling pathway | 1 | 2 | 4.53e-01 |
| GO:BP | GO:0071539 | protein localization to centrosome | 6 | 31 | 4.53e-01 |
| GO:BP | GO:0036005 | response to macrophage colony-stimulating factor | 1 | 8 | 4.53e-01 |
| GO:BP | GO:0006449 | regulation of translational termination | 1 | 10 | 4.53e-01 |
| GO:BP | GO:0003279 | cardiac septum development | 4 | 101 | 4.53e-01 |
| GO:BP | GO:1990786 | cellular response to dsDNA | 1 | 2 | 4.53e-01 |
| GO:BP | GO:1990784 | response to dsDNA | 1 | 2 | 4.53e-01 |
| GO:BP | GO:0021516 | dorsal spinal cord development | 1 | 7 | 4.53e-01 |
| GO:BP | GO:0071264 | positive regulation of translational initiation in response to starvation | 1 | 2 | 4.53e-01 |
| GO:BP | GO:0070085 | glycosylation | 2 | 202 | 4.53e-01 |
| GO:BP | GO:0110061 | regulation of angiotensin-activated signaling pathway | 1 | 2 | 4.53e-01 |
| GO:BP | GO:0043010 | camera-type eye development | 3 | 236 | 4.53e-01 |
| GO:BP | GO:0071262 | regulation of translational initiation in response to starvation | 1 | 2 | 4.53e-01 |
| GO:BP | GO:0044843 | cell cycle G1/S phase transition | 18 | 229 | 4.53e-01 |
| GO:BP | GO:0030259 | lipid glycosylation | 2 | 6 | 4.53e-01 |
| GO:BP | GO:0090222 | centrosome-templated microtubule nucleation | 1 | 2 | 4.53e-01 |
| GO:BP | GO:0034655 | nucleobase-containing compound catabolic process | 3 | 358 | 4.53e-01 |
| GO:BP | GO:1990418 | response to insulin-like growth factor stimulus | 1 | 2 | 4.53e-01 |
| GO:BP | GO:0040001 | establishment of mitotic spindle localization | 3 | 36 | 4.53e-01 |
| GO:BP | GO:0061643 | chemorepulsion of axon | 2 | 6 | 4.53e-01 |
| GO:BP | GO:0035912 | dorsal aorta morphogenesis | 1 | 6 | 4.53e-01 |
| GO:BP | GO:0001572 | lactosylceramide biosynthetic process | 1 | 2 | 4.53e-01 |
| GO:BP | GO:0060896 | neural plate pattern specification | 1 | 8 | 4.53e-01 |
| GO:BP | GO:0046478 | lactosylceramide metabolic process | 1 | 2 | 4.53e-01 |
| GO:BP | GO:0003013 | circulatory system process | 2 | 447 | 4.53e-01 |
| GO:BP | GO:0003223 | ventricular compact myocardium morphogenesis | 1 | 7 | 4.53e-01 |
| GO:BP | GO:0003162 | atrioventricular node development | 1 | 8 | 4.53e-01 |
| GO:BP | GO:0090043 | regulation of tubulin deacetylation | 1 | 21 | 4.54e-01 |
| GO:BP | GO:0007015 | actin filament organization | 3 | 373 | 4.54e-01 |
| GO:BP | GO:0106074 | aminoacyl-tRNA metabolism involved in translational fidelity | 1 | 11 | 4.54e-01 |
| GO:BP | GO:0006538 | glutamate catabolic process | 1 | 7 | 4.54e-01 |
| GO:BP | GO:0090527 | actin filament reorganization | 2 | 10 | 4.54e-01 |
| GO:BP | GO:0051726 | regulation of cell cycle | 89 | 956 | 4.54e-01 |
| GO:BP | GO:0006450 | regulation of translational fidelity | 4 | 16 | 4.54e-01 |
| GO:BP | GO:0060383 | positive regulation of DNA strand elongation | 1 | 1 | 4.54e-01 |
| GO:BP | GO:0032075 | positive regulation of nuclease activity | 2 | 7 | 4.55e-01 |
| GO:BP | GO:0072092 | ureteric bud invasion | 1 | 3 | 4.55e-01 |
| GO:BP | GO:0043569 | negative regulation of insulin-like growth factor receptor signaling pathway | 2 | 6 | 4.55e-01 |
| GO:BP | GO:0031529 | ruffle organization | 3 | 45 | 4.55e-01 |
| GO:BP | GO:0042539 | hypotonic salinity response | 1 | 2 | 4.55e-01 |
| GO:BP | GO:1901492 | positive regulation of lymphangiogenesis | 1 | 2 | 4.55e-01 |
| GO:BP | GO:0071477 | cellular hypotonic salinity response | 1 | 2 | 4.55e-01 |
| GO:BP | GO:1903724 | positive regulation of centriole elongation | 1 | 5 | 4.55e-01 |
| GO:BP | GO:0046719 | regulation by virus of viral protein levels in host cell | 1 | 8 | 4.55e-01 |
| GO:BP | GO:0048483 | autonomic nervous system development | 1 | 28 | 4.56e-01 |
| GO:BP | GO:0075522 | IRES-dependent viral translational initiation | 1 | 11 | 4.56e-01 |
| GO:BP | GO:0051445 | regulation of meiotic cell cycle | 5 | 45 | 4.56e-01 |
| GO:BP | GO:0055013 | cardiac muscle cell development | 5 | 71 | 4.56e-01 |
| GO:BP | GO:0071105 | response to interleukin-11 | 1 | 1 | 4.56e-01 |
| GO:BP | GO:0030030 | cell projection organization | 6 | 1233 | 4.56e-01 |
| GO:BP | GO:0055086 | nucleobase-containing small molecule metabolic process | 2 | 487 | 4.58e-01 |
| GO:BP | GO:0046503 | glycerolipid catabolic process | 1 | 42 | 4.58e-01 |
| GO:BP | GO:0000390 | spliceosomal complex disassembly | 1 | 3 | 4.58e-01 |
| GO:BP | GO:0050714 | positive regulation of protein secretion | 5 | 100 | 4.58e-01 |
| GO:BP | GO:0044804 | autophagy of nucleus | 1 | 18 | 4.58e-01 |
| GO:BP | GO:0090529 | cell septum assembly | 1 | 1 | 4.58e-01 |
| GO:BP | GO:0019080 | viral gene expression | 4 | 96 | 4.58e-01 |
| GO:BP | GO:0009445 | putrescine metabolic process | 2 | 6 | 4.58e-01 |
| GO:BP | GO:0060887 | limb epidermis development | 1 | 1 | 4.58e-01 |
| GO:BP | GO:0071926 | endocannabinoid signaling pathway | 1 | 5 | 4.58e-01 |
| GO:BP | GO:0000917 | division septum assembly | 1 | 1 | 4.58e-01 |
| GO:BP | GO:0031124 | mRNA 3’-end processing | 4 | 58 | 4.58e-01 |
| GO:BP | GO:0071310 | cellular response to organic substance | 4 | 1399 | 4.58e-01 |
| GO:BP | GO:0000023 | maltose metabolic process | 1 | 2 | 4.58e-01 |
| GO:BP | GO:2000832 | negative regulation of steroid hormone secretion | 1 | 4 | 4.58e-01 |
| GO:BP | GO:1904666 | regulation of ubiquitin protein ligase activity | 1 | 26 | 4.58e-01 |
| GO:BP | GO:2000847 | negative regulation of corticosteroid hormone secretion | 1 | 4 | 4.58e-01 |
| GO:BP | GO:1905451 | positive regulation of Fc-gamma receptor signaling pathway involved in phagocytosis | 1 | 3 | 4.58e-01 |
| GO:BP | GO:2000850 | negative regulation of glucocorticoid secretion | 1 | 4 | 4.58e-01 |
| GO:BP | GO:0043157 | response to cation stress | 1 | 1 | 4.58e-01 |
| GO:BP | GO:0034097 | response to cytokine | 2 | 607 | 4.58e-01 |
| GO:BP | GO:0017015 | regulation of transforming growth factor beta receptor signaling pathway | 15 | 128 | 4.58e-01 |
| GO:BP | GO:0014037 | Schwann cell differentiation | 2 | 34 | 4.58e-01 |
| GO:BP | GO:1905314 | semi-lunar valve development | 2 | 41 | 4.58e-01 |
| GO:BP | GO:0045838 | positive regulation of membrane potential | 1 | 12 | 4.58e-01 |
| GO:BP | GO:1902532 | negative regulation of intracellular signal transduction | 40 | 438 | 4.58e-01 |
| GO:BP | GO:0006998 | nuclear envelope organization | 7 | 57 | 4.59e-01 |
| GO:BP | GO:0008593 | regulation of Notch signaling pathway | 8 | 78 | 4.59e-01 |
| GO:BP | GO:0090435 | protein localization to nuclear envelope | 1 | 14 | 4.59e-01 |
| GO:BP | GO:0003226 | right ventricular compact myocardium morphogenesis | 1 | 1 | 4.59e-01 |
| GO:BP | GO:0009226 | nucleotide-sugar biosynthetic process | 5 | 19 | 4.59e-01 |
| GO:BP | GO:1902743 | regulation of lamellipodium organization | 1 | 44 | 4.59e-01 |
| GO:BP | GO:0070482 | response to oxygen levels | 23 | 272 | 4.59e-01 |
| GO:BP | GO:0042275 | error-free postreplication DNA repair | 1 | 1 | 4.59e-01 |
| GO:BP | GO:0006520 | amino acid metabolic process | 1 | 222 | 4.59e-01 |
| GO:BP | GO:0002329 | pre-B cell differentiation | 1 | 4 | 4.59e-01 |
| GO:BP | GO:0043433 | negative regulation of DNA-binding transcription factor activity | 1 | 138 | 4.60e-01 |
| GO:BP | GO:0031062 | positive regulation of histone methylation | 5 | 36 | 4.60e-01 |
| GO:BP | GO:1903526 | negative regulation of membrane tubulation | 1 | 2 | 4.60e-01 |
| GO:BP | GO:0042669 | regulation of inner ear auditory receptor cell fate specification | 1 | 1 | 4.60e-01 |
| GO:BP | GO:0045840 | positive regulation of mitotic nuclear division | 9 | 29 | 4.61e-01 |
| GO:BP | GO:1905380 | regulation of snRNA transcription by RNA polymerase II | 2 | 4 | 4.61e-01 |
| GO:BP | GO:0045945 | positive regulation of transcription by RNA polymerase III | 3 | 19 | 4.61e-01 |
| GO:BP | GO:0009438 | methylglyoxal metabolic process | 1 | 7 | 4.61e-01 |
| GO:BP | GO:0006567 | threonine catabolic process | 1 | 3 | 4.61e-01 |
| GO:BP | GO:0051130 | positive regulation of cellular component organization | 4 | 906 | 4.61e-01 |
| GO:BP | GO:0055012 | ventricular cardiac muscle cell differentiation | 3 | 15 | 4.62e-01 |
| GO:BP | GO:0048538 | thymus development | 5 | 35 | 4.62e-01 |
| GO:BP | GO:0046487 | glyoxylate metabolic process | 1 | 5 | 4.62e-01 |
| GO:BP | GO:0051974 | negative regulation of telomerase activity | 2 | 11 | 4.62e-01 |
| GO:BP | GO:0042481 | regulation of odontogenesis | 1 | 10 | 4.62e-01 |
| GO:BP | GO:0035296 | regulation of tube diameter | 1 | 99 | 4.62e-01 |
| GO:BP | GO:0035356 | intracellular triglyceride homeostasis | 2 | 5 | 4.62e-01 |
| GO:BP | GO:0010744 | positive regulation of macrophage derived foam cell differentiation | 1 | 8 | 4.62e-01 |
| GO:BP | GO:0051294 | establishment of spindle orientation | 3 | 36 | 4.62e-01 |
| GO:BP | GO:0046578 | regulation of Ras protein signal transduction | 7 | 166 | 4.62e-01 |
| GO:BP | GO:0070885 | negative regulation of calcineurin-NFAT signaling cascade | 3 | 14 | 4.62e-01 |
| GO:BP | GO:0061640 | cytoskeleton-dependent cytokinesis | 12 | 104 | 4.62e-01 |
| GO:BP | GO:0071417 | cellular response to organonitrogen compound | 2 | 485 | 4.62e-01 |
| GO:BP | GO:0106057 | negative regulation of calcineurin-mediated signaling | 3 | 14 | 4.62e-01 |
| GO:BP | GO:0021952 | central nervous system projection neuron axonogenesis | 1 | 23 | 4.62e-01 |
| GO:BP | GO:1903975 | regulation of glial cell migration | 1 | 12 | 4.62e-01 |
| GO:BP | GO:0051781 | positive regulation of cell division | 3 | 64 | 4.62e-01 |
| GO:BP | GO:0097746 | blood vessel diameter maintenance | 1 | 99 | 4.62e-01 |
| GO:BP | GO:0003188 | heart valve formation | 1 | 16 | 4.62e-01 |
| GO:BP | GO:0008334 | histone mRNA metabolic process | 3 | 21 | 4.62e-01 |
| GO:BP | GO:0009411 | response to UV | 26 | 141 | 4.62e-01 |
| GO:BP | GO:2000271 | positive regulation of fibroblast apoptotic process | 3 | 9 | 4.62e-01 |
| GO:BP | GO:1902570 | protein localization to nucleolus | 2 | 15 | 4.62e-01 |
| GO:BP | GO:0031167 | rRNA methylation | 1 | 24 | 4.62e-01 |
| GO:BP | GO:2000144 | positive regulation of DNA-templated transcription initiation | 4 | 65 | 4.62e-01 |
| GO:BP | GO:0007064 | mitotic sister chromatid cohesion | 1 | 30 | 4.62e-01 |
| GO:BP | GO:0009394 | 2’-deoxyribonucleotide metabolic process | 9 | 35 | 4.63e-01 |
| GO:BP | GO:0046463 | acylglycerol biosynthetic process | 3 | 36 | 4.63e-01 |
| GO:BP | GO:0046460 | neutral lipid biosynthetic process | 3 | 36 | 4.63e-01 |
| GO:BP | GO:0035150 | regulation of tube size | 1 | 99 | 4.63e-01 |
| GO:BP | GO:0043111 | replication fork arrest | 1 | 2 | 4.63e-01 |
| GO:BP | GO:0045091 | regulation of single stranded viral RNA replication via double stranded DNA intermediate | 4 | 15 | 4.63e-01 |
| GO:BP | GO:1905774 | regulation of DNA helicase activity | 2 | 5 | 4.63e-01 |
| GO:BP | GO:0021647 | vestibulocochlear nerve maturation | 1 | 1 | 4.63e-01 |
| GO:BP | GO:0090308 | regulation of DNA methylation-dependent heterochromatin formation | 4 | 16 | 4.63e-01 |
| GO:BP | GO:0071031 | nuclear mRNA surveillance of mRNA 3’-end processing | 1 | 1 | 4.63e-01 |
| GO:BP | GO:0051347 | positive regulation of transferase activity | 1 | 400 | 4.63e-01 |
| GO:BP | GO:0001579 | medium-chain fatty acid transport | 1 | 2 | 4.63e-01 |
| GO:BP | GO:0052648 | ribitol phosphate metabolic process | 1 | 1 | 4.64e-01 |
| GO:BP | GO:0009231 | riboflavin biosynthetic process | 1 | 1 | 4.64e-01 |
| GO:BP | GO:0009398 | FMN biosynthetic process | 1 | 1 | 4.64e-01 |
| GO:BP | GO:0010722 | regulation of ferrochelatase activity | 1 | 1 | 4.64e-01 |
| GO:BP | GO:0046324 | regulation of glucose import | 8 | 41 | 4.64e-01 |
| GO:BP | GO:0046444 | FMN metabolic process | 1 | 1 | 4.64e-01 |
| GO:BP | GO:0048521 | negative regulation of behavior | 1 | 5 | 4.64e-01 |
| GO:BP | GO:0052647 | pentitol phosphate metabolic process | 1 | 1 | 4.64e-01 |
| GO:BP | GO:0021515 | cell differentiation in spinal cord | 2 | 24 | 4.64e-01 |
| GO:BP | GO:0016268 | O-glycan processing, core 2 | 1 | 1 | 4.64e-01 |
| GO:BP | GO:0031330 | negative regulation of cellular catabolic process | 1 | 165 | 4.64e-01 |
| GO:BP | GO:0034633 | retinol transport | 1 | 1 | 4.64e-01 |
| GO:BP | GO:0043585 | nose morphogenesis | 1 | 3 | 4.64e-01 |
| GO:BP | GO:1901663 | quinone biosynthetic process | 3 | 17 | 4.64e-01 |
| GO:BP | GO:0014041 | regulation of neuron maturation | 2 | 6 | 4.64e-01 |
| GO:BP | GO:0036353 | histone H2A-K119 monoubiquitination | 1 | 8 | 4.64e-01 |
| GO:BP | GO:0006055 | CMP-N-acetylneuraminate biosynthetic process | 1 | 1 | 4.64e-01 |
| GO:BP | GO:0000715 | nucleotide-excision repair, DNA damage recognition | 1 | 1 | 4.64e-01 |
| GO:BP | GO:0007623 | circadian rhythm | 9 | 165 | 4.64e-01 |
| GO:BP | GO:0046381 | CMP-N-acetylneuraminate metabolic process | 1 | 1 | 4.64e-01 |
| GO:BP | GO:0046885 | regulation of hormone biosynthetic process | 3 | 21 | 4.64e-01 |
| GO:BP | GO:0006744 | ubiquinone biosynthetic process | 3 | 17 | 4.64e-01 |
| GO:BP | GO:0048713 | regulation of oligodendrocyte differentiation | 1 | 25 | 4.64e-01 |
| GO:BP | GO:2000171 | negative regulation of dendrite development | 2 | 7 | 4.64e-01 |
| GO:BP | GO:0046599 | regulation of centriole replication | 2 | 21 | 4.65e-01 |
| GO:BP | GO:0046349 | amino sugar biosynthetic process | 3 | 11 | 4.65e-01 |
| GO:BP | GO:0033522 | histone H2A ubiquitination | 2 | 28 | 4.65e-01 |
| GO:BP | GO:0048736 | appendage development | 2 | 142 | 4.65e-01 |
| GO:BP | GO:0060074 | synapse maturation | 2 | 25 | 4.65e-01 |
| GO:BP | GO:0000413 | protein peptidyl-prolyl isomerization | 1 | 26 | 4.65e-01 |
| GO:BP | GO:0033023 | mast cell homeostasis | 1 | 4 | 4.65e-01 |
| GO:BP | GO:1902034 | negative regulation of hematopoietic stem cell proliferation | 1 | 2 | 4.65e-01 |
| GO:BP | GO:1902311 | regulation of copper ion transmembrane transport | 1 | 1 | 4.65e-01 |
| GO:BP | GO:0015817 | histidine transport | 1 | 4 | 4.65e-01 |
| GO:BP | GO:0060173 | limb development | 2 | 142 | 4.65e-01 |
| GO:BP | GO:0070428 | regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway | 1 | 3 | 4.65e-01 |
| GO:BP | GO:1902024 | L-histidine transport | 1 | 4 | 4.65e-01 |
| GO:BP | GO:0042454 | ribonucleoside catabolic process | 4 | 12 | 4.65e-01 |
| GO:BP | GO:0006888 | endoplasmic reticulum to Golgi vesicle-mediated transport | 9 | 119 | 4.65e-01 |
| GO:BP | GO:0051647 | nucleus localization | 4 | 28 | 4.65e-01 |
| GO:BP | GO:0006003 | fructose 2,6-bisphosphate metabolic process | 1 | 4 | 4.65e-01 |
| GO:BP | GO:1905132 | regulation of meiotic chromosome separation | 1 | 2 | 4.65e-01 |
| GO:BP | GO:0035825 | homologous recombination | 7 | 43 | 4.65e-01 |
| GO:BP | GO:1901994 | negative regulation of meiotic cell cycle phase transition | 1 | 2 | 4.65e-01 |
| GO:BP | GO:0010942 | positive regulation of cell death | 2 | 441 | 4.65e-01 |
| GO:BP | GO:0042110 | T cell activation | 1 | 313 | 4.65e-01 |
| GO:BP | GO:0070586 | cell-cell adhesion involved in gastrulation | 2 | 7 | 4.65e-01 |
| GO:BP | GO:0034389 | lipid droplet organization | 3 | 30 | 4.65e-01 |
| GO:BP | GO:0043465 | regulation of fermentation | 1 | 5 | 4.65e-01 |
| GO:BP | GO:0002181 | cytoplasmic translation | 3 | 156 | 4.65e-01 |
| GO:BP | GO:0006113 | fermentation | 1 | 5 | 4.65e-01 |
| GO:BP | GO:1902102 | regulation of metaphase/anaphase transition of meiotic cell cycle | 1 | 2 | 4.65e-01 |
| GO:BP | GO:0044785 | metaphase/anaphase transition of meiotic cell cycle | 1 | 2 | 4.65e-01 |
| GO:BP | GO:1903839 | positive regulation of mRNA 3’-UTR binding | 1 | 1 | 4.65e-01 |
| GO:BP | GO:1903837 | regulation of mRNA 3’-UTR binding | 1 | 1 | 4.65e-01 |
| GO:BP | GO:0033139 | regulation of peptidyl-serine phosphorylation of STAT protein | 1 | 6 | 4.65e-01 |
| GO:BP | GO:0090042 | tubulin deacetylation | 1 | 23 | 4.65e-01 |
| GO:BP | GO:0048291 | isotype switching to IgG isotypes | 4 | 8 | 4.65e-01 |
| GO:BP | GO:0016556 | mRNA modification | 5 | 29 | 4.67e-01 |
| GO:BP | GO:0120161 | regulation of cold-induced thermogenesis | 4 | 112 | 4.67e-01 |
| GO:BP | GO:0030913 | paranodal junction assembly | 2 | 6 | 4.67e-01 |
| GO:BP | GO:0007113 | endomitotic cell cycle | 1 | 3 | 4.67e-01 |
| GO:BP | GO:0006622 | protein targeting to lysosome | 6 | 28 | 4.67e-01 |
| GO:BP | GO:0001915 | negative regulation of T cell mediated cytotoxicity | 1 | 3 | 4.67e-01 |
| GO:BP | GO:1901136 | carbohydrate derivative catabolic process | 1 | 137 | 4.67e-01 |
| GO:BP | GO:1900477 | negative regulation of G1/S transition of mitotic cell cycle by negative regulation of transcription from RNA polymerase II promoter | 1 | 1 | 4.67e-01 |
| GO:BP | GO:0014819 | regulation of skeletal muscle contraction | 2 | 14 | 4.67e-01 |
| GO:BP | GO:0071389 | cellular response to mineralocorticoid stimulus | 2 | 9 | 4.67e-01 |
| GO:BP | GO:0098528 | skeletal muscle fiber differentiation | 2 | 5 | 4.67e-01 |
| GO:BP | GO:0033344 | cholesterol efflux | 1 | 40 | 4.67e-01 |
| GO:BP | GO:0001731 | formation of translation preinitiation complex | 1 | 11 | 4.67e-01 |
| GO:BP | GO:0031443 | fast-twitch skeletal muscle fiber contraction | 1 | 3 | 4.67e-01 |
| GO:BP | GO:0051570 | regulation of histone H3-K9 methylation | 1 | 11 | 4.67e-01 |
| GO:BP | GO:1990166 | protein localization to site of double-strand break | 1 | 5 | 4.67e-01 |
| GO:BP | GO:0071478 | cellular response to radiation | 20 | 156 | 4.68e-01 |
| GO:BP | GO:1990466 | protein autosumoylation | 1 | 1 | 4.68e-01 |
| GO:BP | GO:0010759 | positive regulation of macrophage chemotaxis | 1 | 9 | 4.68e-01 |
| GO:BP | GO:0048320 | axial mesoderm formation | 1 | 2 | 4.68e-01 |
| GO:BP | GO:0110156 | methylguanosine-cap decapping | 4 | 14 | 4.68e-01 |
| GO:BP | GO:0046331 | lateral inhibition | 1 | 3 | 4.68e-01 |
| GO:BP | GO:0036295 | cellular response to increased oxygen levels | 3 | 12 | 4.68e-01 |
| GO:BP | GO:0090083 | regulation of inclusion body assembly | 3 | 16 | 4.68e-01 |
| GO:BP | GO:2000142 | regulation of DNA-templated transcription initiation | 5 | 76 | 4.68e-01 |
| GO:BP | GO:0060628 | regulation of ER to Golgi vesicle-mediated transport | 3 | 9 | 4.68e-01 |
| GO:BP | GO:0045168 | cell-cell signaling involved in cell fate commitment | 1 | 3 | 4.68e-01 |
| GO:BP | GO:0006790 | sulfur compound metabolic process | 1 | 248 | 4.68e-01 |
| GO:BP | GO:0019985 | translesion synthesis | 1 | 24 | 4.69e-01 |
| GO:BP | GO:0046341 | CDP-diacylglycerol metabolic process | 4 | 13 | 4.69e-01 |
| GO:BP | GO:0098700 | neurotransmitter loading into synaptic vesicle | 1 | 1 | 4.69e-01 |
| GO:BP | GO:0051057 | positive regulation of small GTPase mediated signal transduction | 4 | 51 | 4.69e-01 |
| GO:BP | GO:1900151 | regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 6 | 24 | 4.69e-01 |
| GO:BP | GO:0031098 | stress-activated protein kinase signaling cascade | 10 | 196 | 4.69e-01 |
| GO:BP | GO:0035617 | stress granule disassembly | 2 | 5 | 4.69e-01 |
| GO:BP | GO:0072034 | renal vesicle induction | 1 | 3 | 4.69e-01 |
| GO:BP | GO:0009250 | glucan biosynthetic process | 5 | 39 | 4.69e-01 |
| GO:BP | GO:0106106 | cold-induced thermogenesis | 4 | 113 | 4.69e-01 |
| GO:BP | GO:0060926 | cardiac pacemaker cell development | 1 | 8 | 4.69e-01 |
| GO:BP | GO:0005978 | glycogen biosynthetic process | 5 | 39 | 4.69e-01 |
| GO:BP | GO:0060120 | inner ear receptor cell fate commitment | 2 | 4 | 4.69e-01 |
| GO:BP | GO:0031547 | brain-derived neurotrophic factor receptor signaling pathway | 1 | 6 | 4.69e-01 |
| GO:BP | GO:0009912 | auditory receptor cell fate commitment | 2 | 4 | 4.69e-01 |
| GO:BP | GO:1902746 | regulation of lens fiber cell differentiation | 2 | 8 | 4.70e-01 |
| GO:BP | GO:0010746 | regulation of long-chain fatty acid import across plasma membrane | 2 | 5 | 4.70e-01 |
| GO:BP | GO:0071498 | cellular response to fluid shear stress | 5 | 19 | 4.71e-01 |
| GO:BP | GO:1905868 | regulation of 3’-UTR-mediated mRNA stabilization | 2 | 5 | 4.71e-01 |
| GO:BP | GO:0032464 | positive regulation of protein homooligomerization | 1 | 2 | 4.71e-01 |
| GO:BP | GO:0030166 | proteoglycan biosynthetic process | 1 | 51 | 4.71e-01 |
| GO:BP | GO:0030947 | regulation of vascular endothelial growth factor receptor signaling pathway | 3 | 27 | 4.71e-01 |
| GO:BP | GO:0150066 | negative regulation of deacetylase activity | 1 | 2 | 4.71e-01 |
| GO:BP | GO:1901726 | negative regulation of histone deacetylase activity | 1 | 2 | 4.71e-01 |
| GO:BP | GO:0006668 | sphinganine-1-phosphate metabolic process | 1 | 2 | 4.71e-01 |
| GO:BP | GO:2000042 | negative regulation of double-strand break repair via homologous recombination | 2 | 16 | 4.71e-01 |
| GO:BP | GO:0042416 | dopamine biosynthetic process | 1 | 8 | 4.71e-01 |
| GO:BP | GO:0002358 | B cell homeostatic proliferation | 1 | 1 | 4.71e-01 |
| GO:BP | GO:0051249 | regulation of lymphocyte activation | 1 | 296 | 4.71e-01 |
| GO:BP | GO:0051345 | positive regulation of hydrolase activity | 1 | 422 | 4.71e-01 |
| GO:BP | GO:0002441 | histamine secretion involved in inflammatory response | 3 | 8 | 4.71e-01 |
| GO:BP | GO:0070498 | interleukin-1-mediated signaling pathway | 2 | 20 | 4.71e-01 |
| GO:BP | GO:1990117 | B cell receptor apoptotic signaling pathway | 1 | 2 | 4.71e-01 |
| GO:BP | GO:0048103 | somatic stem cell division | 1 | 10 | 4.71e-01 |
| GO:BP | GO:2000209 | regulation of anoikis | 2 | 23 | 4.71e-01 |
| GO:BP | GO:0071638 | negative regulation of monocyte chemotactic protein-1 production | 1 | 3 | 4.71e-01 |
| GO:BP | GO:0061795 | Golgi lumen acidification | 2 | 13 | 4.71e-01 |
| GO:BP | GO:2000673 | positive regulation of motor neuron apoptotic process | 1 | 1 | 4.71e-01 |
| GO:BP | GO:0032287 | peripheral nervous system myelin maintenance | 2 | 8 | 4.71e-01 |
| GO:BP | GO:0060244 | negative regulation of cell proliferation involved in contact inhibition | 1 | 3 | 4.71e-01 |
| GO:BP | GO:0009098 | leucine biosynthetic process | 1 | 2 | 4.71e-01 |
| GO:BP | GO:0002553 | histamine secretion by mast cell | 3 | 8 | 4.71e-01 |
| GO:BP | GO:0002349 | histamine production involved in inflammatory response | 3 | 8 | 4.71e-01 |
| GO:BP | GO:0001906 | cell killing | 2 | 69 | 4.72e-01 |
| GO:BP | GO:0035987 | endodermal cell differentiation | 2 | 38 | 4.72e-01 |
| GO:BP | GO:0045087 | innate immune response | 3 | 488 | 4.72e-01 |
| GO:BP | GO:1904557 | L-alanine transmembrane transport | 1 | 4 | 4.72e-01 |
| GO:BP | GO:0070262 | peptidyl-serine dephosphorylation | 4 | 14 | 4.72e-01 |
| GO:BP | GO:1905765 | negative regulation of protection from non-homologous end joining at telomere | 1 | 3 | 4.72e-01 |
| GO:BP | GO:0045055 | regulated exocytosis | 1 | 155 | 4.72e-01 |
| GO:BP | GO:0061819 | telomeric DNA-containing double minutes formation | 1 | 3 | 4.72e-01 |
| GO:BP | GO:1905764 | regulation of protection from non-homologous end joining at telomere | 1 | 3 | 4.72e-01 |
| GO:BP | GO:0043388 | positive regulation of DNA binding | 3 | 44 | 4.72e-01 |
| GO:BP | GO:0034472 | snRNA 3’-end processing | 4 | 21 | 4.72e-01 |
| GO:BP | GO:0006413 | translational initiation | 17 | 116 | 4.72e-01 |
| GO:BP | GO:0030309 | poly-N-acetyllactosamine metabolic process | 2 | 6 | 4.72e-01 |
| GO:BP | GO:0072393 | microtubule anchoring at microtubule organizing center | 4 | 14 | 4.72e-01 |
| GO:BP | GO:1904155 | DN2 thymocyte differentiation | 1 | 1 | 4.72e-01 |
| GO:BP | GO:0098916 | anterograde trans-synaptic signaling | 2 | 490 | 4.72e-01 |
| GO:BP | GO:0007268 | chemical synaptic transmission | 2 | 490 | 4.72e-01 |
| GO:BP | GO:1902808 | positive regulation of cell cycle G1/S phase transition | 5 | 52 | 4.72e-01 |
| GO:BP | GO:0032506 | cytokinetic process | 5 | 39 | 4.72e-01 |
| GO:BP | GO:0086013 | membrane repolarization during cardiac muscle cell action potential | 2 | 18 | 4.72e-01 |
| GO:BP | GO:0090522 | vesicle tethering involved in exocytosis | 1 | 9 | 4.72e-01 |
| GO:BP | GO:1904778 | positive regulation of protein localization to cell cortex | 1 | 6 | 4.72e-01 |
| GO:BP | GO:1904356 | regulation of telomere maintenance via telomere lengthening | 6 | 56 | 4.72e-01 |
| GO:BP | GO:0032984 | protein-containing complex disassembly | 24 | 222 | 4.72e-01 |
| GO:BP | GO:0030521 | androgen receptor signaling pathway | 1 | 39 | 4.72e-01 |
| GO:BP | GO:1905114 | cell surface receptor signaling pathway involved in cell-cell signaling | 1 | 448 | 4.73e-01 |
| GO:BP | GO:0002087 | regulation of respiratory gaseous exchange by nervous system process | 1 | 8 | 4.73e-01 |
| GO:BP | GO:0035588 | G protein-coupled purinergic receptor signaling pathway | 1 | 8 | 4.73e-01 |
| GO:BP | GO:0001973 | G protein-coupled adenosine receptor signaling pathway | 1 | 8 | 4.73e-01 |
| GO:BP | GO:0008216 | spermidine metabolic process | 1 | 7 | 4.73e-01 |
| GO:BP | GO:2000282 | regulation of cellular amino acid biosynthetic process | 1 | 3 | 4.73e-01 |
| GO:BP | GO:2001288 | positive regulation of caveolin-mediated endocytosis | 1 | 3 | 4.73e-01 |
| GO:BP | GO:0032801 | receptor catabolic process | 2 | 24 | 4.73e-01 |
| GO:BP | GO:1905162 | regulation of phagosome maturation | 1 | 2 | 4.73e-01 |
| GO:BP | GO:0000821 | regulation of arginine metabolic process | 1 | 3 | 4.73e-01 |
| GO:BP | GO:0033299 | secretion of lysosomal enzymes | 1 | 7 | 4.73e-01 |
| GO:BP | GO:0033013 | tetrapyrrole metabolic process | 2 | 52 | 4.73e-01 |
| GO:BP | GO:0090186 | regulation of pancreatic juice secretion | 1 | 6 | 4.73e-01 |
| GO:BP | GO:1904751 | positive regulation of protein localization to nucleolus | 1 | 3 | 4.74e-01 |
| GO:BP | GO:0032927 | positive regulation of activin receptor signaling pathway | 2 | 7 | 4.74e-01 |
| GO:BP | GO:0045814 | negative regulation of gene expression, epigenetic | 8 | 79 | 4.74e-01 |
| GO:BP | GO:0040020 | regulation of meiotic nuclear division | 1 | 19 | 4.74e-01 |
| GO:BP | GO:1901699 | cellular response to nitrogen compound | 2 | 517 | 4.75e-01 |
| GO:BP | GO:1901568 | fatty acid derivative metabolic process | 1 | 48 | 4.75e-01 |
| GO:BP | GO:0071043 | CUT metabolic process | 2 | 5 | 4.75e-01 |
| GO:BP | GO:0071034 | CUT catabolic process | 2 | 5 | 4.75e-01 |
| GO:BP | GO:0030641 | regulation of cellular pH | 8 | 70 | 4.76e-01 |
| GO:BP | GO:0099537 | trans-synaptic signaling | 2 | 495 | 4.76e-01 |
| GO:BP | GO:0003431 | growth plate cartilage chondrocyte development | 1 | 5 | 4.76e-01 |
| GO:BP | GO:1905281 | positive regulation of retrograde transport, endosome to Golgi | 1 | 2 | 4.76e-01 |
| GO:BP | GO:1903844 | regulation of cellular response to transforming growth factor beta stimulus | 15 | 129 | 4.76e-01 |
| GO:BP | GO:0046903 | secretion | 3 | 645 | 4.76e-01 |
| GO:BP | GO:0009755 | hormone-mediated signaling pathway | 2 | 139 | 4.76e-01 |
| GO:BP | GO:0045022 | early endosome to late endosome transport | 5 | 40 | 4.76e-01 |
| GO:BP | GO:0051220 | cytoplasmic sequestering of protein | 6 | 23 | 4.76e-01 |
| GO:BP | GO:0021561 | facial nerve development | 1 | 8 | 4.76e-01 |
| GO:BP | GO:0021610 | facial nerve morphogenesis | 1 | 8 | 4.76e-01 |
| GO:BP | GO:0006506 | GPI anchor biosynthetic process | 2 | 30 | 4.76e-01 |
| GO:BP | GO:0001702 | gastrulation with mouth forming second | 1 | 21 | 4.76e-01 |
| GO:BP | GO:1904293 | negative regulation of ERAD pathway | 1 | 6 | 4.76e-01 |
| GO:BP | GO:1902164 | positive regulation of DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator | 1 | 4 | 4.76e-01 |
| GO:BP | GO:0036342 | post-anal tail morphogenesis | 5 | 13 | 4.76e-01 |
| GO:BP | GO:0055057 | neuroblast division | 1 | 12 | 4.77e-01 |
| GO:BP | GO:0032197 | retrotransposition | 2 | 4 | 4.77e-01 |
| GO:BP | GO:0048499 | synaptic vesicle membrane organization | 2 | 23 | 4.77e-01 |
| GO:BP | GO:0035801 | adrenal cortex development | 1 | 2 | 4.77e-01 |
| GO:BP | GO:0016264 | gap junction assembly | 1 | 14 | 4.77e-01 |
| GO:BP | GO:1905429 | response to glycine | 1 | 2 | 4.77e-01 |
| GO:BP | GO:1904200 | iodide transmembrane transport | 1 | 1 | 4.77e-01 |
| GO:BP | GO:0055017 | cardiac muscle tissue growth | 3 | 65 | 4.77e-01 |
| GO:BP | GO:0071634 | regulation of transforming growth factor beta production | 2 | 31 | 4.77e-01 |
| GO:BP | GO:0001778 | plasma membrane repair | 7 | 28 | 4.77e-01 |
| GO:BP | GO:0014724 | regulation of twitch skeletal muscle contraction | 1 | 3 | 4.77e-01 |
| GO:BP | GO:0009262 | deoxyribonucleotide metabolic process | 9 | 36 | 4.78e-01 |
| GO:BP | GO:0019692 | deoxyribose phosphate metabolic process | 9 | 36 | 4.78e-01 |
| GO:BP | GO:0034214 | protein hexamerization | 1 | 9 | 4.78e-01 |
| GO:BP | GO:1904717 | regulation of AMPA glutamate receptor clustering | 2 | 4 | 4.78e-01 |
| GO:BP | GO:0071233 | cellular response to leucine | 3 | 10 | 4.78e-01 |
| GO:BP | GO:0006515 | protein quality control for misfolded or incompletely synthesized proteins | 1 | 28 | 4.78e-01 |
| GO:BP | GO:0043393 | regulation of protein binding | 1 | 172 | 4.78e-01 |
| GO:BP | GO:0009084 | glutamine family amino acid biosynthetic process | 3 | 16 | 4.78e-01 |
| GO:BP | GO:0106104 | regulation of glutamate receptor clustering | 2 | 4 | 4.78e-01 |
| GO:BP | GO:0099562 | maintenance of postsynaptic density structure | 2 | 6 | 4.78e-01 |
| GO:BP | GO:0046605 | regulation of centrosome cycle | 8 | 51 | 4.78e-01 |
| GO:BP | GO:0006101 | citrate metabolic process | 1 | 5 | 4.78e-01 |
| GO:BP | GO:0035278 | miRNA-mediated gene silencing by inhibition of translation | 3 | 15 | 4.79e-01 |
| GO:BP | GO:0010507 | negative regulation of autophagy | 9 | 74 | 4.79e-01 |
| GO:BP | GO:1900087 | positive regulation of G1/S transition of mitotic cell cycle | 4 | 42 | 4.79e-01 |
| GO:BP | GO:0051493 | regulation of cytoskeleton organization | 41 | 459 | 4.79e-01 |
| GO:BP | GO:0033137 | negative regulation of peptidyl-serine phosphorylation | 6 | 26 | 4.79e-01 |
| GO:BP | GO:0072583 | clathrin-dependent endocytosis | 8 | 43 | 4.79e-01 |
| GO:BP | GO:1902742 | apoptotic process involved in development | 4 | 30 | 4.79e-01 |
| GO:BP | GO:1904996 | positive regulation of leukocyte adhesion to vascular endothelial cell | 2 | 13 | 4.79e-01 |
| GO:BP | GO:0032369 | negative regulation of lipid transport | 3 | 20 | 4.79e-01 |
| GO:BP | GO:0051823 | regulation of synapse structural plasticity | 2 | 5 | 4.79e-01 |
| GO:BP | GO:0007100 | mitotic centrosome separation | 3 | 13 | 4.80e-01 |
| GO:BP | GO:0043030 | regulation of macrophage activation | 7 | 31 | 4.80e-01 |
| GO:BP | GO:0051494 | negative regulation of cytoskeleton organization | 3 | 140 | 4.80e-01 |
| GO:BP | GO:0038007 | netrin-activated signaling pathway | 1 | 8 | 4.80e-01 |
| GO:BP | GO:0070124 | mitochondrial translational initiation | 1 | 2 | 4.81e-01 |
| GO:BP | GO:0070071 | proton-transporting two-sector ATPase complex assembly | 2 | 15 | 4.81e-01 |
| GO:BP | GO:0032463 | negative regulation of protein homooligomerization | 1 | 2 | 4.81e-01 |
| GO:BP | GO:0060151 | peroxisome localization | 1 | 2 | 4.81e-01 |
| GO:BP | GO:0060152 | microtubule-based peroxisome localization | 1 | 2 | 4.81e-01 |
| GO:BP | GO:0032460 | negative regulation of protein oligomerization | 1 | 2 | 4.81e-01 |
| GO:BP | GO:0034405 | response to fluid shear stress | 4 | 31 | 4.81e-01 |
| GO:BP | GO:0090166 | Golgi disassembly | 1 | 6 | 4.82e-01 |
| GO:BP | GO:0032543 | mitochondrial translation | 3 | 130 | 4.82e-01 |
| GO:BP | GO:0035128 | post-embryonic forelimb morphogenesis | 1 | 2 | 4.82e-01 |
| GO:BP | GO:0035120 | post-embryonic appendage morphogenesis | 1 | 2 | 4.82e-01 |
| GO:BP | GO:0035127 | post-embryonic limb morphogenesis | 1 | 2 | 4.82e-01 |
| GO:BP | GO:0044270 | cellular nitrogen compound catabolic process | 3 | 378 | 4.82e-01 |
| GO:BP | GO:0071392 | cellular response to estradiol stimulus | 4 | 26 | 4.82e-01 |
| GO:BP | GO:0001561 | fatty acid alpha-oxidation | 2 | 5 | 4.82e-01 |
| GO:BP | GO:0002521 | leukocyte differentiation | 1 | 382 | 4.82e-01 |
| GO:BP | GO:0006612 | protein targeting to membrane | 1 | 118 | 4.82e-01 |
| GO:BP | GO:1900152 | negative regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 3 | 12 | 4.82e-01 |
| GO:BP | GO:0090204 | protein localization to nuclear pore | 1 | 3 | 4.83e-01 |
| GO:BP | GO:0036369 | transcription factor catabolic process | 1 | 5 | 4.83e-01 |
| GO:BP | GO:0072716 | response to actinomycin D | 1 | 5 | 4.83e-01 |
| GO:BP | GO:0044321 | response to leptin | 3 | 19 | 4.83e-01 |
| GO:BP | GO:0035981 | tongue muscle cell differentiation | 1 | 1 | 4.83e-01 |
| GO:BP | GO:0060316 | positive regulation of ryanodine-sensitive calcium-release channel activity | 1 | 9 | 4.83e-01 |
| GO:BP | GO:2001037 | positive regulation of tongue muscle cell differentiation | 1 | 1 | 4.83e-01 |
| GO:BP | GO:2001035 | regulation of tongue muscle cell differentiation | 1 | 1 | 4.83e-01 |
| GO:BP | GO:0006050 | mannosamine metabolic process | 1 | 2 | 4.83e-01 |
| GO:BP | GO:0014887 | cardiac muscle adaptation | 3 | 23 | 4.83e-01 |
| GO:BP | GO:0090107 | regulation of high-density lipoprotein particle assembly | 1 | 3 | 4.83e-01 |
| GO:BP | GO:0006051 | N-acetylmannosamine metabolic process | 1 | 2 | 4.83e-01 |
| GO:BP | GO:0003299 | muscle hypertrophy in response to stress | 3 | 23 | 4.83e-01 |
| GO:BP | GO:0046700 | heterocycle catabolic process | 3 | 381 | 4.83e-01 |
| GO:BP | GO:0014898 | cardiac muscle hypertrophy in response to stress | 3 | 23 | 4.83e-01 |
| GO:BP | GO:0002097 | tRNA wobble base modification | 5 | 19 | 4.83e-01 |
| GO:BP | GO:0061551 | trigeminal ganglion development | 1 | 3 | 4.83e-01 |
| GO:BP | GO:0003084 | positive regulation of systemic arterial blood pressure | 1 | 7 | 4.83e-01 |
| GO:BP | GO:0000425 | pexophagy | 1 | 6 | 4.83e-01 |
| GO:BP | GO:0072107 | positive regulation of ureteric bud formation | 1 | 2 | 4.83e-01 |
| GO:BP | GO:0071500 | cellular response to nitrosative stress | 1 | 6 | 4.83e-01 |
| GO:BP | GO:0072175 | epithelial tube formation | 11 | 127 | 4.83e-01 |
| GO:BP | GO:0060920 | cardiac pacemaker cell differentiation | 1 | 9 | 4.83e-01 |
| GO:BP | GO:0099536 | synaptic signaling | 2 | 511 | 4.83e-01 |
| GO:BP | GO:1902415 | regulation of mRNA binding | 2 | 10 | 4.83e-01 |
| GO:BP | GO:0016553 | base conversion or substitution editing | 4 | 10 | 4.83e-01 |
| GO:BP | GO:2000725 | regulation of cardiac muscle cell differentiation | 3 | 14 | 4.83e-01 |
| GO:BP | GO:1902904 | negative regulation of supramolecular fiber organization | 3 | 140 | 4.83e-01 |
| GO:BP | GO:0001755 | neural crest cell migration | 1 | 49 | 4.83e-01 |
| GO:BP | GO:0072095 | regulation of branch elongation involved in ureteric bud branching | 1 | 2 | 4.83e-01 |
| GO:BP | GO:1903774 | positive regulation of viral budding via host ESCRT complex | 1 | 3 | 4.83e-01 |
| GO:BP | GO:0072106 | regulation of ureteric bud formation | 1 | 2 | 4.83e-01 |
| GO:BP | GO:0035442 | dipeptide transmembrane transport | 2 | 4 | 4.83e-01 |
| GO:BP | GO:0051489 | regulation of filopodium assembly | 5 | 44 | 4.83e-01 |
| GO:BP | GO:0061055 | myotome development | 1 | 2 | 4.83e-01 |
| GO:BP | GO:0032196 | transposition | 7 | 17 | 4.83e-01 |
| GO:BP | GO:0042026 | protein refolding | 3 | 26 | 4.83e-01 |
| GO:BP | GO:0042938 | dipeptide transport | 2 | 4 | 4.83e-01 |
| GO:BP | GO:0061030 | epithelial cell differentiation involved in mammary gland alveolus development | 1 | 2 | 4.83e-01 |
| GO:BP | GO:0061738 | late endosomal microautophagy | 1 | 3 | 4.83e-01 |
| GO:BP | GO:0045859 | regulation of protein kinase activity | 1 | 479 | 4.83e-01 |
| GO:BP | GO:0001922 | B-1 B cell homeostasis | 1 | 4 | 4.83e-01 |
| GO:BP | GO:0044351 | macropinocytosis | 2 | 8 | 4.83e-01 |
| GO:BP | GO:0006505 | GPI anchor metabolic process | 2 | 31 | 4.83e-01 |
| GO:BP | GO:0032787 | monocarboxylic acid metabolic process | 3 | 433 | 4.83e-01 |
| GO:BP | GO:0001666 | response to hypoxia | 20 | 237 | 4.83e-01 |
| GO:BP | GO:1900452 | regulation of long-term synaptic depression | 1 | 10 | 4.83e-01 |
| GO:BP | GO:0001578 | microtubule bundle formation | 1 | 79 | 4.83e-01 |
| GO:BP | GO:1902725 | negative regulation of satellite cell differentiation | 1 | 2 | 4.83e-01 |
| GO:BP | GO:0035907 | dorsal aorta development | 1 | 8 | 4.83e-01 |
| GO:BP | GO:0009886 | post-embryonic animal morphogenesis | 4 | 10 | 4.83e-01 |
| GO:BP | GO:0033152 | immunoglobulin V(D)J recombination | 2 | 8 | 4.83e-01 |
| GO:BP | GO:0071731 | response to nitric oxide | 5 | 16 | 4.83e-01 |
| GO:BP | GO:1905323 | telomerase holoenzyme complex assembly | 1 | 6 | 4.83e-01 |
| GO:BP | GO:0150106 | regulation of protein localization to cell-cell junction | 1 | 2 | 4.84e-01 |
| GO:BP | GO:0071709 | membrane assembly | 1 | 53 | 4.84e-01 |
| GO:BP | GO:0043473 | pigmentation | 2 | 92 | 4.85e-01 |
| GO:BP | GO:0097345 | mitochondrial outer membrane permeabilization | 6 | 35 | 4.85e-01 |
| GO:BP | GO:0048386 | positive regulation of retinoic acid receptor signaling pathway | 1 | 5 | 4.85e-01 |
| GO:BP | GO:0001820 | serotonin secretion | 1 | 5 | 4.85e-01 |
| GO:BP | GO:0060379 | cardiac muscle cell myoblast differentiation | 2 | 11 | 4.85e-01 |
| GO:BP | GO:0003417 | growth plate cartilage development | 5 | 15 | 4.85e-01 |
| GO:BP | GO:0090329 | regulation of DNA-templated DNA replication | 10 | 47 | 4.85e-01 |
| GO:BP | GO:1904580 | regulation of intracellular mRNA localization | 1 | 4 | 4.85e-01 |
| GO:BP | GO:0007289 | spermatid nucleus differentiation | 2 | 16 | 4.86e-01 |
| GO:BP | GO:0001711 | endodermal cell fate commitment | 1 | 9 | 4.86e-01 |
| GO:BP | GO:0007169 | transmembrane receptor protein tyrosine kinase signaling pathway | 1 | 484 | 4.87e-01 |
| GO:BP | GO:1905691 | lipid droplet disassembly | 1 | 7 | 4.87e-01 |
| GO:BP | GO:2000448 | positive regulation of macrophage migration inhibitory factor signaling pathway | 1 | 2 | 4.87e-01 |
| GO:BP | GO:0014003 | oligodendrocyte development | 2 | 27 | 4.87e-01 |
| GO:BP | GO:0009135 | purine nucleoside diphosphate metabolic process | 1 | 17 | 4.87e-01 |
| GO:BP | GO:1990845 | adaptive thermogenesis | 1 | 121 | 4.87e-01 |
| GO:BP | GO:0006563 | L-serine metabolic process | 2 | 10 | 4.87e-01 |
| GO:BP | GO:0009179 | purine ribonucleoside diphosphate metabolic process | 1 | 17 | 4.87e-01 |
| GO:BP | GO:1990478 | response to ultrasound | 1 | 2 | 4.87e-01 |
| GO:BP | GO:0033002 | muscle cell proliferation | 2 | 157 | 4.87e-01 |
| GO:BP | GO:0003308 | negative regulation of Wnt signaling pathway involved in heart development | 2 | 6 | 4.88e-01 |
| GO:BP | GO:0009068 | aspartate family amino acid catabolic process | 2 | 12 | 4.89e-01 |
| GO:BP | GO:1905524 | negative regulation of protein autoubiquitination | 1 | 2 | 4.89e-01 |
| GO:BP | GO:0042501 | serine phosphorylation of STAT protein | 1 | 9 | 4.90e-01 |
| GO:BP | GO:1900745 | positive regulation of p38MAPK cascade | 1 | 22 | 4.90e-01 |
| GO:BP | GO:0046131 | pyrimidine ribonucleoside metabolic process | 3 | 7 | 4.90e-01 |
| GO:BP | GO:0046133 | pyrimidine ribonucleoside catabolic process | 3 | 7 | 4.90e-01 |
| GO:BP | GO:0001736 | establishment of planar polarity | 12 | 70 | 4.90e-01 |
| GO:BP | GO:0046223 | aflatoxin catabolic process | 1 | 2 | 4.90e-01 |
| GO:BP | GO:0007040 | lysosome organization | 9 | 88 | 4.90e-01 |
| GO:BP | GO:0060221 | retinal rod cell differentiation | 2 | 9 | 4.90e-01 |
| GO:BP | GO:0060364 | frontal suture morphogenesis | 1 | 4 | 4.90e-01 |
| GO:BP | GO:2000210 | positive regulation of anoikis | 1 | 6 | 4.90e-01 |
| GO:BP | GO:1904690 | positive regulation of cytoplasmic translational initiation | 2 | 5 | 4.90e-01 |
| GO:BP | GO:1903786 | regulation of glutathione biosynthetic process | 1 | 2 | 4.90e-01 |
| GO:BP | GO:0007517 | muscle organ development | 10 | 277 | 4.90e-01 |
| GO:BP | GO:0051129 | negative regulation of cellular component organization | 45 | 604 | 4.90e-01 |
| GO:BP | GO:0046490 | isopentenyl diphosphate metabolic process | 1 | 5 | 4.90e-01 |
| GO:BP | GO:0001780 | neutrophil homeostasis | 1 | 16 | 4.90e-01 |
| GO:BP | GO:0090497 | mesenchymal cell migration | 1 | 51 | 4.90e-01 |
| GO:BP | GO:1901642 | nucleoside transmembrane transport | 1 | 6 | 4.90e-01 |
| GO:BP | GO:0106217 | tRNA C3-cytosine methylation | 1 | 2 | 4.90e-01 |
| GO:BP | GO:1901377 | organic heteropentacyclic compound catabolic process | 1 | 2 | 4.90e-01 |
| GO:BP | GO:0009407 | toxin catabolic process | 1 | 2 | 4.90e-01 |
| GO:BP | GO:0009240 | isopentenyl diphosphate biosynthetic process | 1 | 5 | 4.90e-01 |
| GO:BP | GO:0080171 | lytic vacuole organization | 9 | 88 | 4.90e-01 |
| GO:BP | GO:1900122 | positive regulation of receptor binding | 1 | 7 | 4.90e-01 |
| GO:BP | GO:0043387 | mycotoxin catabolic process | 1 | 2 | 4.90e-01 |
| GO:BP | GO:0007164 | establishment of tissue polarity | 12 | 70 | 4.90e-01 |
| GO:BP | GO:1901626 | regulation of postsynaptic membrane organization | 1 | 2 | 4.90e-01 |
| GO:BP | GO:0031119 | tRNA pseudouridine synthesis | 1 | 6 | 4.90e-01 |
| GO:BP | GO:0055006 | cardiac cell development | 5 | 77 | 4.90e-01 |
| GO:BP | GO:0034058 | endosomal vesicle fusion | 2 | 10 | 4.90e-01 |
| GO:BP | GO:0071453 | cellular response to oxygen levels | 11 | 144 | 4.90e-01 |
| GO:BP | GO:0033151 | V(D)J recombination | 2 | 16 | 4.90e-01 |
| GO:BP | GO:0006465 | signal peptide processing | 3 | 13 | 4.90e-01 |
| GO:BP | GO:0060412 | ventricular septum morphogenesis | 2 | 40 | 4.90e-01 |
| GO:BP | GO:0010743 | regulation of macrophage derived foam cell differentiation | 2 | 18 | 4.90e-01 |
| GO:BP | GO:2000536 | negative regulation of entry of bacterium into host cell | 1 | 1 | 4.90e-01 |
| GO:BP | GO:0021604 | cranial nerve structural organization | 1 | 8 | 4.90e-01 |
| GO:BP | GO:0046600 | negative regulation of centriole replication | 1 | 7 | 4.91e-01 |
| GO:BP | GO:1901522 | positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus | 4 | 16 | 4.91e-01 |
| GO:BP | GO:0007610 | behavior | 1 | 436 | 4.91e-01 |
| GO:BP | GO:0072530 | purine-containing compound transmembrane transport | 2 | 20 | 4.91e-01 |
| GO:BP | GO:0048812 | neuron projection morphogenesis | 1 | 512 | 4.92e-01 |
| GO:BP | GO:0001959 | regulation of cytokine-mediated signaling pathway | 8 | 117 | 4.92e-01 |
| GO:BP | GO:0009163 | nucleoside biosynthetic process | 3 | 15 | 4.92e-01 |
| GO:BP | GO:0034404 | nucleobase-containing small molecule biosynthetic process | 3 | 15 | 4.92e-01 |
| GO:BP | GO:0043101 | purine-containing compound salvage | 3 | 14 | 4.92e-01 |
| GO:BP | GO:0006566 | threonine metabolic process | 1 | 4 | 4.92e-01 |
| GO:BP | GO:1905897 | regulation of response to endoplasmic reticulum stress | 16 | 76 | 4.92e-01 |
| GO:BP | GO:0033240 | positive regulation of amine metabolic process | 1 | 7 | 4.92e-01 |
| GO:BP | GO:0061099 | negative regulation of protein tyrosine kinase activity | 4 | 27 | 4.93e-01 |
| GO:BP | GO:0042059 | negative regulation of epidermal growth factor receptor signaling pathway | 5 | 26 | 4.93e-01 |
| GO:BP | GO:0032608 | interferon-beta production | 11 | 43 | 4.93e-01 |
| GO:BP | GO:0055025 | positive regulation of cardiac muscle tissue development | 1 | 2 | 4.93e-01 |
| GO:BP | GO:0032648 | regulation of interferon-beta production | 11 | 43 | 4.93e-01 |
| GO:BP | GO:0048589 | developmental growth | 1 | 522 | 4.93e-01 |
| GO:BP | GO:0051491 | positive regulation of filopodium assembly | 3 | 25 | 4.93e-01 |
| GO:BP | GO:0003335 | corneocyte development | 1 | 2 | 4.94e-01 |
| GO:BP | GO:0051900 | regulation of mitochondrial depolarization | 1 | 15 | 4.94e-01 |
| GO:BP | GO:0002376 | immune system process | 2 | 1447 | 4.94e-01 |
| GO:BP | GO:1904204 | regulation of skeletal muscle hypertrophy | 1 | 1 | 4.94e-01 |
| GO:BP | GO:1903333 | negative regulation of protein folding | 1 | 4 | 4.94e-01 |
| GO:BP | GO:1901020 | negative regulation of calcium ion transmembrane transporter activity | 2 | 27 | 4.94e-01 |
| GO:BP | GO:0072488 | ammonium transmembrane transport | 2 | 6 | 4.94e-01 |
| GO:BP | GO:0006282 | regulation of DNA repair | 11 | 198 | 4.94e-01 |
| GO:BP | GO:0014029 | neural crest formation | 1 | 13 | 4.94e-01 |
| GO:BP | GO:0045821 | positive regulation of glycolytic process | 3 | 15 | 4.94e-01 |
| GO:BP | GO:0061724 | lipophagy | 2 | 7 | 4.95e-01 |
| GO:BP | GO:0031507 | heterochromatin formation | 7 | 69 | 4.95e-01 |
| GO:BP | GO:0010748 | negative regulation of long-chain fatty acid import across plasma membrane | 1 | 4 | 4.95e-01 |
| GO:BP | GO:0002694 | regulation of leukocyte activation | 1 | 348 | 4.95e-01 |
| GO:BP | GO:0044248 | cellular catabolic process | 7 | 1229 | 4.95e-01 |
| GO:BP | GO:0032079 | positive regulation of endodeoxyribonuclease activity | 1 | 4 | 4.95e-01 |
| GO:BP | GO:0015791 | polyol transmembrane transport | 3 | 6 | 4.95e-01 |
| GO:BP | GO:0007229 | integrin-mediated signaling pathway | 2 | 89 | 4.95e-01 |
| GO:BP | GO:0046827 | positive regulation of protein export from nucleus | 2 | 15 | 4.95e-01 |
| GO:BP | GO:0140213 | negative regulation of long-chain fatty acid import into cell | 1 | 4 | 4.95e-01 |
| GO:BP | GO:0034644 | cellular response to UV | 16 | 86 | 4.95e-01 |
| GO:BP | GO:2000109 | regulation of macrophage apoptotic process | 1 | 6 | 4.95e-01 |
| GO:BP | GO:0006007 | glucose catabolic process | 2 | 22 | 4.95e-01 |
| GO:BP | GO:0048162 | multi-layer follicle stage | 1 | 2 | 4.95e-01 |
| GO:BP | GO:0001546 | preantral ovarian follicle growth | 1 | 2 | 4.95e-01 |
| GO:BP | GO:0045647 | negative regulation of erythrocyte differentiation | 2 | 7 | 4.95e-01 |
| GO:BP | GO:0003151 | outflow tract morphogenesis | 3 | 68 | 4.96e-01 |
| GO:BP | GO:1904780 | negative regulation of protein localization to centrosome | 1 | 2 | 4.96e-01 |
| GO:BP | GO:0120039 | plasma membrane bounded cell projection morphogenesis | 1 | 527 | 4.96e-01 |
| GO:BP | GO:0032239 | regulation of nucleobase-containing compound transport | 1 | 15 | 4.96e-01 |
| GO:BP | GO:0045986 | negative regulation of smooth muscle contraction | 1 | 12 | 4.96e-01 |
| GO:BP | GO:0019439 | aromatic compound catabolic process | 3 | 387 | 4.96e-01 |
| GO:BP | GO:0005996 | monosaccharide metabolic process | 13 | 209 | 4.96e-01 |
| GO:BP | GO:0051956 | negative regulation of amino acid transport | 1 | 10 | 4.96e-01 |
| GO:BP | GO:0044091 | membrane biogenesis | 12 | 58 | 4.96e-01 |
| GO:BP | GO:0060086 | circadian temperature homeostasis | 1 | 3 | 4.96e-01 |
| GO:BP | GO:0070859 | positive regulation of bile acid biosynthetic process | 1 | 3 | 4.96e-01 |
| GO:BP | GO:0061889 | negative regulation of astrocyte activation | 1 | 2 | 4.96e-01 |
| GO:BP | GO:0030029 | actin filament-based process | 11 | 687 | 4.96e-01 |
| GO:BP | GO:0051336 | regulation of hydrolase activity | 2 | 701 | 4.96e-01 |
| GO:BP | GO:1904253 | positive regulation of bile acid metabolic process | 1 | 3 | 4.96e-01 |
| GO:BP | GO:0072093 | metanephric renal vesicle formation | 1 | 4 | 4.96e-01 |
| GO:BP | GO:0097581 | lamellipodium organization | 2 | 78 | 4.96e-01 |
| GO:BP | GO:0030111 | regulation of Wnt signaling pathway | 8 | 273 | 4.96e-01 |
| GO:BP | GO:0031987 | locomotion involved in locomotory behavior | 1 | 9 | 4.96e-01 |
| GO:BP | GO:0035196 | miRNA processing | 1 | 41 | 4.96e-01 |
| GO:BP | GO:0060444 | branching involved in mammary gland duct morphogenesis | 1 | 20 | 4.96e-01 |
| GO:BP | GO:0045649 | regulation of macrophage differentiation | 1 | 17 | 4.96e-01 |
| GO:BP | GO:0031122 | cytoplasmic microtubule organization | 6 | 60 | 4.96e-01 |
| GO:BP | GO:0048858 | cell projection morphogenesis | 1 | 531 | 4.96e-01 |
| GO:BP | GO:0003210 | cardiac atrium formation | 1 | 2 | 4.96e-01 |
| GO:BP | GO:0048013 | ephrin receptor signaling pathway | 9 | 41 | 4.96e-01 |
| GO:BP | GO:1905665 | positive regulation of calcium ion import across plasma membrane | 1 | 6 | 4.96e-01 |
| GO:BP | GO:0043408 | regulation of MAPK cascade | 1 | 475 | 4.96e-01 |
| GO:BP | GO:0019050 | suppression by virus of host apoptotic process | 1 | 2 | 4.96e-01 |
| GO:BP | GO:0071604 | transforming growth factor beta production | 2 | 32 | 4.96e-01 |
| GO:BP | GO:0042451 | purine nucleoside biosynthetic process | 1 | 11 | 4.96e-01 |
| GO:BP | GO:0043584 | nose development | 2 | 10 | 4.96e-01 |
| GO:BP | GO:0035914 | skeletal muscle cell differentiation | 9 | 52 | 4.96e-01 |
| GO:BP | GO:0000212 | meiotic spindle organization | 1 | 14 | 4.96e-01 |
| GO:BP | GO:0097709 | connective tissue replacement | 2 | 8 | 4.96e-01 |
| GO:BP | GO:0042455 | ribonucleoside biosynthetic process | 1 | 11 | 4.96e-01 |
| GO:BP | GO:0034158 | toll-like receptor 8 signaling pathway | 1 | 3 | 4.96e-01 |
| GO:BP | GO:0070434 | positive regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway | 1 | 4 | 4.96e-01 |
| GO:BP | GO:2000807 | regulation of synaptic vesicle clustering | 2 | 7 | 4.96e-01 |
| GO:BP | GO:0060770 | negative regulation of epithelial cell proliferation involved in prostate gland development | 1 | 6 | 4.96e-01 |
| GO:BP | GO:0140205 | oligopeptide import across plasma membrane | 1 | 2 | 4.96e-01 |
| GO:BP | GO:0071383 | cellular response to steroid hormone stimulus | 2 | 166 | 4.96e-01 |
| GO:BP | GO:0052041 | suppression by symbiont of host programmed cell death | 1 | 2 | 4.96e-01 |
| GO:BP | GO:0007043 | cell-cell junction assembly | 3 | 105 | 4.96e-01 |
| GO:BP | GO:0033668 | suppression by symbiont of host apoptotic process | 1 | 2 | 4.96e-01 |
| GO:BP | GO:0035600 | tRNA methylthiolation | 1 | 2 | 4.96e-01 |
| GO:BP | GO:0140206 | dipeptide import across plasma membrane | 1 | 2 | 4.96e-01 |
| GO:BP | GO:0046129 | purine ribonucleoside biosynthetic process | 1 | 11 | 4.96e-01 |
| GO:BP | GO:0099541 | trans-synaptic signaling by lipid | 1 | 6 | 4.97e-01 |
| GO:BP | GO:0036294 | cellular response to decreased oxygen levels | 10 | 131 | 4.97e-01 |
| GO:BP | GO:1905064 | negative regulation of vascular associated smooth muscle cell differentiation | 2 | 8 | 4.97e-01 |
| GO:BP | GO:0001654 | eye development | 3 | 272 | 4.97e-01 |
| GO:BP | GO:0009211 | pyrimidine deoxyribonucleoside triphosphate metabolic process | 2 | 6 | 4.97e-01 |
| GO:BP | GO:0030278 | regulation of ossification | 4 | 84 | 4.97e-01 |
| GO:BP | GO:1901334 | lactone metabolic process | 1 | 9 | 4.97e-01 |
| GO:BP | GO:0019852 | L-ascorbic acid metabolic process | 1 | 9 | 4.97e-01 |
| GO:BP | GO:0099542 | trans-synaptic signaling by endocannabinoid | 1 | 6 | 4.97e-01 |
| GO:BP | GO:0006689 | ganglioside catabolic process | 1 | 5 | 4.97e-01 |
| GO:BP | GO:0043501 | skeletal muscle adaptation | 4 | 19 | 4.98e-01 |
| GO:BP | GO:0006640 | monoacylglycerol biosynthetic process | 1 | 2 | 4.98e-01 |
| GO:BP | GO:0016042 | lipid catabolic process | 2 | 225 | 4.98e-01 |
| GO:BP | GO:0018277 | protein deamination | 1 | 2 | 4.98e-01 |
| GO:BP | GO:0009167 | purine ribonucleoside monophosphate metabolic process | 2 | 37 | 4.99e-01 |
| GO:BP | GO:0046061 | dATP catabolic process | 1 | 2 | 4.99e-01 |
| GO:BP | GO:0006749 | glutathione metabolic process | 3 | 41 | 4.99e-01 |
| GO:BP | GO:0010994 | free ubiquitin chain polymerization | 1 | 8 | 4.99e-01 |
| GO:BP | GO:0042475 | odontogenesis of dentin-containing tooth | 4 | 55 | 4.99e-01 |
| GO:BP | GO:0048340 | paraxial mesoderm morphogenesis | 1 | 9 | 4.99e-01 |
| GO:BP | GO:0030224 | monocyte differentiation | 2 | 26 | 4.99e-01 |
| GO:BP | GO:0034250 | positive regulation of amide metabolic process | 29 | 149 | 4.99e-01 |
| GO:BP | GO:0021955 | central nervous system neuron axonogenesis | 1 | 31 | 4.99e-01 |
| GO:BP | GO:0007056 | spindle assembly involved in female meiosis | 2 | 5 | 4.99e-01 |
| GO:BP | GO:0090677 | reversible differentiation | 1 | 5 | 4.99e-01 |
| GO:BP | GO:0006417 | regulation of translation | 59 | 370 | 4.99e-01 |
| GO:BP | GO:0071072 | negative regulation of phospholipid biosynthetic process | 2 | 6 | 4.99e-01 |
| GO:BP | GO:0072014 | proximal tubule development | 1 | 7 | 4.99e-01 |
| GO:BP | GO:0046110 | xanthine metabolic process | 1 | 1 | 4.99e-01 |
| GO:BP | GO:0003183 | mitral valve morphogenesis | 1 | 11 | 4.99e-01 |
| GO:BP | GO:0060337 | type I interferon-mediated signaling pathway | 14 | 51 | 4.99e-01 |
| GO:BP | GO:0002636 | positive regulation of germinal center formation | 1 | 1 | 4.99e-01 |
| GO:BP | GO:1903051 | negative regulation of proteolysis involved in protein catabolic process | 9 | 61 | 4.99e-01 |
| GO:BP | GO:0043103 | hypoxanthine salvage | 1 | 2 | 4.99e-01 |
| GO:BP | GO:0014046 | dopamine secretion | 2 | 23 | 4.99e-01 |
| GO:BP | GO:0060038 | cardiac muscle cell proliferation | 4 | 44 | 4.99e-01 |
| GO:BP | GO:0060307 | regulation of ventricular cardiac muscle cell membrane repolarization | 1 | 16 | 4.99e-01 |
| GO:BP | GO:0043470 | regulation of carbohydrate catabolic process | 6 | 47 | 4.99e-01 |
| GO:BP | GO:0032990 | cell part morphogenesis | 1 | 551 | 5.00e-01 |
| GO:BP | GO:1901533 | negative regulation of hematopoietic progenitor cell differentiation | 1 | 11 | 5.00e-01 |
| GO:BP | GO:0048669 | collateral sprouting in absence of injury | 1 | 4 | 5.00e-01 |
| GO:BP | GO:0042633 | hair cycle | 2 | 78 | 5.00e-01 |
| GO:BP | GO:0042303 | molting cycle | 2 | 78 | 5.00e-01 |
| GO:BP | GO:0002252 | immune effector process | 1 | 318 | 5.01e-01 |
| GO:BP | GO:0051984 | positive regulation of chromosome segregation | 2 | 27 | 5.01e-01 |
| GO:BP | GO:0150063 | visual system development | 3 | 273 | 5.01e-01 |
| GO:BP | GO:0060065 | uterus development | 3 | 13 | 5.03e-01 |
| GO:BP | GO:0060142 | regulation of syncytium formation by plasma membrane fusion | 5 | 15 | 5.03e-01 |
| GO:BP | GO:0006743 | ubiquinone metabolic process | 3 | 19 | 5.03e-01 |
| GO:BP | GO:0045922 | negative regulation of fatty acid metabolic process | 4 | 25 | 5.03e-01 |
| GO:BP | GO:0060044 | negative regulation of cardiac muscle cell proliferation | 3 | 9 | 5.04e-01 |
| GO:BP | GO:0016477 | cell migration | 17 | 1081 | 5.04e-01 |
| GO:BP | GO:1903649 | regulation of cytoplasmic transport | 4 | 25 | 5.04e-01 |
| GO:BP | GO:0014878 | response to electrical stimulus involved in regulation of muscle adaptation | 1 | 2 | 5.05e-01 |
| GO:BP | GO:0018872 | arsonoacetate metabolic process | 1 | 1 | 5.05e-01 |
| GO:BP | GO:1903429 | regulation of cell maturation | 5 | 13 | 5.05e-01 |
| GO:BP | GO:0051351 | positive regulation of ligase activity | 3 | 9 | 5.05e-01 |
| GO:BP | GO:0032775 | DNA methylation on adenine | 1 | 2 | 5.05e-01 |
| GO:BP | GO:1903722 | regulation of centriole elongation | 1 | 7 | 5.06e-01 |
| GO:BP | GO:0030308 | negative regulation of cell growth | 1 | 160 | 5.07e-01 |
| GO:BP | GO:1902162 | regulation of DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator | 1 | 5 | 5.07e-01 |
| GO:BP | GO:0006469 | negative regulation of protein kinase activity | 36 | 179 | 5.07e-01 |
| GO:BP | GO:0051299 | centrosome separation | 3 | 14 | 5.08e-01 |
| GO:BP | GO:0090178 | regulation of establishment of planar polarity involved in neural tube closure | 3 | 13 | 5.08e-01 |
| GO:BP | GO:0031023 | microtubule organizing center organization | 19 | 137 | 5.08e-01 |
| GO:BP | GO:2000342 | negative regulation of chemokine (C-X-C motif) ligand 2 production | 1 | 2 | 5.08e-01 |
| GO:BP | GO:0070129 | regulation of mitochondrial translation | 6 | 26 | 5.08e-01 |
| GO:BP | GO:0044065 | regulation of respiratory system process | 1 | 11 | 5.08e-01 |
| GO:BP | GO:0045187 | regulation of circadian sleep/wake cycle, sleep | 1 | 7 | 5.08e-01 |
| GO:BP | GO:0060413 | atrial septum morphogenesis | 1 | 15 | 5.08e-01 |
| GO:BP | GO:0035089 | establishment of apical/basal cell polarity | 3 | 18 | 5.08e-01 |
| GO:BP | GO:0038108 | negative regulation of appetite by leptin-mediated signaling pathway | 1 | 3 | 5.08e-01 |
| GO:BP | GO:0001934 | positive regulation of protein phosphorylation | 1 | 496 | 5.09e-01 |
| GO:BP | GO:0042058 | regulation of epidermal growth factor receptor signaling pathway | 14 | 60 | 5.09e-01 |
| GO:BP | GO:0090402 | oncogene-induced cell senescence | 1 | 3 | 5.09e-01 |
| GO:BP | GO:0061205 | paramesonephric duct development | 1 | 4 | 5.09e-01 |
| GO:BP | GO:0001707 | mesoderm formation | 1 | 53 | 5.09e-01 |
| GO:BP | GO:0090336 | positive regulation of brown fat cell differentiation | 1 | 11 | 5.09e-01 |
| GO:BP | GO:0036473 | cell death in response to oxidative stress | 9 | 75 | 5.09e-01 |
| GO:BP | GO:0035458 | cellular response to interferon-beta | 5 | 15 | 5.10e-01 |
| GO:BP | GO:0051043 | regulation of membrane protein ectodomain proteolysis | 1 | 18 | 5.10e-01 |
| GO:BP | GO:0045787 | positive regulation of cell cycle | 29 | 274 | 5.10e-01 |
| GO:BP | GO:0044283 | small molecule biosynthetic process | 1 | 425 | 5.10e-01 |
| GO:BP | GO:0099623 | regulation of cardiac muscle cell membrane repolarization | 2 | 20 | 5.10e-01 |
| GO:BP | GO:0050865 | regulation of cell activation | 1 | 384 | 5.10e-01 |
| GO:BP | GO:0048880 | sensory system development | 3 | 275 | 5.10e-01 |
| GO:BP | GO:1905653 | positive regulation of artery morphogenesis | 1 | 5 | 5.10e-01 |
| GO:BP | GO:1905651 | regulation of artery morphogenesis | 1 | 5 | 5.10e-01 |
| GO:BP | GO:0032507 | maintenance of protein location in cell | 6 | 58 | 5.10e-01 |
| GO:BP | GO:0002681 | somatic recombination of T cell receptor gene segments | 1 | 4 | 5.10e-01 |
| GO:BP | GO:1901214 | regulation of neuron death | 20 | 246 | 5.10e-01 |
| GO:BP | GO:0033153 | T cell receptor V(D)J recombination | 1 | 4 | 5.10e-01 |
| GO:BP | GO:1901475 | pyruvate transmembrane transport | 1 | 5 | 5.10e-01 |
| GO:BP | GO:0006848 | pyruvate transport | 1 | 5 | 5.10e-01 |
| GO:BP | GO:0002568 | somatic diversification of T cell receptor genes | 1 | 4 | 5.10e-01 |
| GO:BP | GO:1900110 | negative regulation of histone H3-K9 dimethylation | 1 | 2 | 5.10e-01 |
| GO:BP | GO:1902425 | positive regulation of attachment of mitotic spindle microtubules to kinetochore | 1 | 8 | 5.10e-01 |
| GO:BP | GO:1902423 | regulation of attachment of mitotic spindle microtubules to kinetochore | 1 | 8 | 5.10e-01 |
| GO:BP | GO:2000617 | positive regulation of histone H3-K9 acetylation | 2 | 6 | 5.11e-01 |
| GO:BP | GO:0014032 | neural crest cell development | 7 | 71 | 5.11e-01 |
| GO:BP | GO:0086009 | membrane repolarization | 3 | 41 | 5.11e-01 |
| GO:BP | GO:1904562 | phosphatidylinositol 5-phosphate metabolic process | 1 | 2 | 5.11e-01 |
| GO:BP | GO:0030490 | maturation of SSU-rRNA | 7 | 54 | 5.11e-01 |
| GO:BP | GO:0043549 | regulation of kinase activity | 1 | 560 | 5.11e-01 |
| GO:BP | GO:1905857 | positive regulation of pentose-phosphate shunt | 1 | 3 | 5.11e-01 |
| GO:BP | GO:0048563 | post-embryonic animal organ morphogenesis | 3 | 8 | 5.12e-01 |
| GO:BP | GO:0051882 | mitochondrial depolarization | 1 | 17 | 5.12e-01 |
| GO:BP | GO:0007175 | negative regulation of epidermal growth factor-activated receptor activity | 3 | 13 | 5.12e-01 |
| GO:BP | GO:0061156 | pulmonary artery morphogenesis | 2 | 7 | 5.12e-01 |
| GO:BP | GO:0002250 | adaptive immune response | 1 | 218 | 5.12e-01 |
| GO:BP | GO:0010571 | positive regulation of nuclear cell cycle DNA replication | 2 | 6 | 5.12e-01 |
| GO:BP | GO:0043217 | myelin maintenance | 3 | 15 | 5.12e-01 |
| GO:BP | GO:0009439 | cyanate metabolic process | 1 | 2 | 5.12e-01 |
| GO:BP | GO:0009440 | cyanate catabolic process | 1 | 2 | 5.12e-01 |
| GO:BP | GO:0006307 | DNA dealkylation involved in DNA repair | 1 | 9 | 5.13e-01 |
| GO:BP | GO:0032458 | slow endocytic recycling | 1 | 2 | 5.13e-01 |
| GO:BP | GO:0018195 | peptidyl-arginine modification | 1 | 18 | 5.13e-01 |
| GO:BP | GO:0050778 | positive regulation of immune response | 1 | 369 | 5.14e-01 |
| GO:BP | GO:0042401 | biogenic amine biosynthetic process | 2 | 24 | 5.14e-01 |
| GO:BP | GO:0031113 | regulation of microtubule polymerization | 4 | 52 | 5.14e-01 |
| GO:BP | GO:0000463 | maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 3 | 15 | 5.14e-01 |
| GO:BP | GO:0009062 | fatty acid catabolic process | 1 | 89 | 5.14e-01 |
| GO:BP | GO:1900048 | positive regulation of hemostasis | 1 | 21 | 5.14e-01 |
| GO:BP | GO:0030194 | positive regulation of blood coagulation | 1 | 21 | 5.14e-01 |
| GO:BP | GO:0061298 | retina vasculature development in camera-type eye | 2 | 14 | 5.14e-01 |
| GO:BP | GO:0048332 | mesoderm morphogenesis | 1 | 55 | 5.14e-01 |
| GO:BP | GO:2000291 | regulation of myoblast proliferation | 2 | 11 | 5.14e-01 |
| GO:BP | GO:0009112 | nucleobase metabolic process | 6 | 27 | 5.14e-01 |
| GO:BP | GO:0019860 | uracil metabolic process | 1 | 2 | 5.14e-01 |
| GO:BP | GO:0051490 | negative regulation of filopodium assembly | 1 | 6 | 5.15e-01 |
| GO:BP | GO:0007224 | smoothened signaling pathway | 1 | 124 | 5.15e-01 |
| GO:BP | GO:1903530 | regulation of secretion by cell | 2 | 382 | 5.15e-01 |
| GO:BP | GO:0046685 | response to arsenic-containing substance | 2 | 30 | 5.15e-01 |
| GO:BP | GO:1902232 | regulation of positive thymic T cell selection | 1 | 2 | 5.15e-01 |
| GO:BP | GO:0007281 | germ cell development | 2 | 187 | 5.15e-01 |
| GO:BP | GO:0055117 | regulation of cardiac muscle contraction | 3 | 70 | 5.15e-01 |
| GO:BP | GO:0010822 | positive regulation of mitochondrion organization | 3 | 68 | 5.15e-01 |
| GO:BP | GO:0007622 | rhythmic behavior | 2 | 32 | 5.15e-01 |
| GO:BP | GO:0007023 | post-chaperonin tubulin folding pathway | 1 | 6 | 5.15e-01 |
| GO:BP | GO:0098927 | vesicle-mediated transport between endosomal compartments | 5 | 42 | 5.15e-01 |
| GO:BP | GO:1902227 | negative regulation of macrophage colony-stimulating factor signaling pathway | 1 | 1 | 5.15e-01 |
| GO:BP | GO:1905205 | positive regulation of connective tissue replacement | 1 | 3 | 5.15e-01 |
| GO:BP | GO:0021860 | pyramidal neuron development | 1 | 8 | 5.15e-01 |
| GO:BP | GO:2000781 | positive regulation of double-strand break repair | 4 | 79 | 5.15e-01 |
| GO:BP | GO:0009220 | pyrimidine ribonucleotide biosynthetic process | 3 | 18 | 5.15e-01 |
| GO:BP | GO:0009126 | purine nucleoside monophosphate metabolic process | 2 | 39 | 5.15e-01 |
| GO:BP | GO:0001817 | regulation of cytokine production | 1 | 447 | 5.15e-01 |
| GO:BP | GO:0009124 | nucleoside monophosphate biosynthetic process | 9 | 37 | 5.15e-01 |
| GO:BP | GO:2000672 | negative regulation of motor neuron apoptotic process | 3 | 10 | 5.15e-01 |
| GO:BP | GO:1902214 | regulation of interleukin-4-mediated signaling pathway | 1 | 2 | 5.15e-01 |
| GO:BP | GO:0048319 | axial mesoderm morphogenesis | 1 | 3 | 5.15e-01 |
| GO:BP | GO:0033089 | positive regulation of T cell differentiation in thymus | 3 | 5 | 5.15e-01 |
| GO:BP | GO:1900451 | positive regulation of glutamate receptor signaling pathway | 1 | 2 | 5.15e-01 |
| GO:BP | GO:0097117 | guanylate kinase-associated protein clustering | 1 | 2 | 5.15e-01 |
| GO:BP | GO:0039533 | regulation of MDA-5 signaling pathway | 2 | 5 | 5.15e-01 |
| GO:BP | GO:0060018 | astrocyte fate commitment | 1 | 2 | 5.15e-01 |
| GO:BP | GO:0036498 | IRE1-mediated unfolded protein response | 5 | 19 | 5.15e-01 |
| GO:BP | GO:0051006 | positive regulation of lipoprotein lipase activity | 1 | 4 | 5.15e-01 |
| GO:BP | GO:0090117 | endosome to lysosome transport of low-density lipoprotein particle | 1 | 2 | 5.15e-01 |
| GO:BP | GO:0099625 | ventricular cardiac muscle cell membrane repolarization | 2 | 21 | 5.15e-01 |
| GO:BP | GO:0045661 | regulation of myoblast differentiation | 7 | 61 | 5.15e-01 |
| GO:BP | GO:0072289 | metanephric nephron tubule formation | 1 | 2 | 5.15e-01 |
| GO:BP | GO:0021522 | spinal cord motor neuron differentiation | 2 | 18 | 5.15e-01 |
| GO:BP | GO:0140469 | GCN2-mediated signaling | 1 | 3 | 5.15e-01 |
| GO:BP | GO:0009101 | glycoprotein biosynthetic process | 2 | 252 | 5.16e-01 |
| GO:BP | GO:0010821 | regulation of mitochondrion organization | 10 | 135 | 5.16e-01 |
| GO:BP | GO:0042733 | embryonic digit morphogenesis | 1 | 51 | 5.16e-01 |
| GO:BP | GO:0001816 | cytokine production | 1 | 451 | 5.16e-01 |
| GO:BP | GO:0072666 | establishment of protein localization to vacuole | 8 | 55 | 5.16e-01 |
| GO:BP | GO:0060315 | negative regulation of ryanodine-sensitive calcium-release channel activity | 1 | 10 | 5.16e-01 |
| GO:BP | GO:0033630 | positive regulation of cell adhesion mediated by integrin | 3 | 14 | 5.16e-01 |
| GO:BP | GO:0070922 | RISC complex assembly | 1 | 9 | 5.16e-01 |
| GO:BP | GO:0044528 | regulation of mitochondrial mRNA stability | 2 | 7 | 5.16e-01 |
| GO:BP | GO:0090646 | mitochondrial tRNA processing | 3 | 12 | 5.16e-01 |
| GO:BP | GO:0030150 | protein import into mitochondrial matrix | 1 | 19 | 5.16e-01 |
| GO:BP | GO:0032571 | response to vitamin K | 1 | 5 | 5.16e-01 |
| GO:BP | GO:0034394 | protein localization to cell surface | 11 | 61 | 5.16e-01 |
| GO:BP | GO:0046467 | membrane lipid biosynthetic process | 7 | 124 | 5.16e-01 |
| GO:BP | GO:0034143 | regulation of toll-like receptor 4 signaling pathway | 3 | 15 | 5.16e-01 |
| GO:BP | GO:0062207 | regulation of pattern recognition receptor signaling pathway | 16 | 68 | 5.16e-01 |
| GO:BP | GO:0000154 | rRNA modification | 1 | 35 | 5.16e-01 |
| GO:BP | GO:0033182 | regulation of histone ubiquitination | 1 | 6 | 5.16e-01 |
| GO:BP | GO:0097474 | retinal cone cell apoptotic process | 1 | 1 | 5.16e-01 |
| GO:BP | GO:0008050 | female courtship behavior | 1 | 2 | 5.16e-01 |
| GO:BP | GO:2000059 | negative regulation of ubiquitin-dependent protein catabolic process | 6 | 47 | 5.16e-01 |
| GO:BP | GO:1905523 | positive regulation of macrophage migration | 3 | 13 | 5.16e-01 |
| GO:BP | GO:0003408 | optic cup formation involved in camera-type eye development | 1 | 1 | 5.16e-01 |
| GO:BP | GO:0060599 | lateral sprouting involved in mammary gland duct morphogenesis | 1 | 2 | 5.16e-01 |
| GO:BP | GO:0030216 | keratinocyte differentiation | 1 | 75 | 5.16e-01 |
| GO:BP | GO:0010529 | negative regulation of transposition | 6 | 14 | 5.16e-01 |
| GO:BP | GO:0010528 | regulation of transposition | 6 | 14 | 5.16e-01 |
| GO:BP | GO:0099509 | regulation of presynaptic cytosolic calcium ion concentration | 1 | 10 | 5.16e-01 |
| GO:BP | GO:1902527 | positive regulation of protein monoubiquitination | 1 | 5 | 5.16e-01 |
| GO:BP | GO:0006081 | cellular aldehyde metabolic process | 3 | 52 | 5.16e-01 |
| GO:BP | GO:0010463 | mesenchymal cell proliferation | 2 | 35 | 5.16e-01 |
| GO:BP | GO:1904506 | negative regulation of telomere maintenance in response to DNA damage | 1 | 3 | 5.16e-01 |
| GO:BP | GO:0060067 | cervix development | 1 | 2 | 5.16e-01 |
| GO:BP | GO:0018002 | N-terminal peptidyl-glutamic acid acetylation | 1 | 2 | 5.16e-01 |
| GO:BP | GO:0017190 | N-terminal peptidyl-aspartic acid acetylation | 1 | 2 | 5.16e-01 |
| GO:BP | GO:0035726 | common myeloid progenitor cell proliferation | 1 | 5 | 5.16e-01 |
| GO:BP | GO:0002719 | negative regulation of cytokine production involved in immune response | 3 | 16 | 5.16e-01 |
| GO:BP | GO:0060775 | planar cell polarity pathway involved in gastrula mediolateral intercalation | 1 | 2 | 5.16e-01 |
| GO:BP | GO:0006044 | N-acetylglucosamine metabolic process | 4 | 16 | 5.16e-01 |
| GO:BP | GO:0030177 | positive regulation of Wnt signaling pathway | 4 | 120 | 5.16e-01 |
| GO:BP | GO:1905832 | positive regulation of spindle assembly | 1 | 7 | 5.16e-01 |
| GO:BP | GO:0006997 | nucleus organization | 12 | 126 | 5.16e-01 |
| GO:BP | GO:0006310 | DNA recombination | 20 | 257 | 5.16e-01 |
| GO:BP | GO:0120009 | intermembrane lipid transfer | 7 | 43 | 5.16e-01 |
| GO:BP | GO:0097300 | programmed necrotic cell death | 4 | 39 | 5.16e-01 |
| GO:BP | GO:0051095 | regulation of helicase activity | 1 | 12 | 5.16e-01 |
| GO:BP | GO:0060031 | mediolateral intercalation | 1 | 2 | 5.16e-01 |
| GO:BP | GO:0034035 | purine ribonucleoside bisphosphate metabolic process | 1 | 10 | 5.16e-01 |
| GO:BP | GO:0014891 | striated muscle atrophy | 2 | 6 | 5.16e-01 |
| GO:BP | GO:0045671 | negative regulation of osteoclast differentiation | 2 | 20 | 5.16e-01 |
| GO:BP | GO:0001821 | histamine secretion | 1 | 9 | 5.16e-01 |
| GO:BP | GO:0036315 | cellular response to sterol | 3 | 14 | 5.16e-01 |
| GO:BP | GO:1904161 | DNA synthesis involved in UV-damage excision repair | 1 | 2 | 5.16e-01 |
| GO:BP | GO:0060372 | regulation of atrial cardiac muscle cell membrane repolarization | 1 | 6 | 5.16e-01 |
| GO:BP | GO:0090100 | positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 12 | 100 | 5.16e-01 |
| GO:BP | GO:0043123 | positive regulation of I-kappaB kinase/NF-kappaB signaling | 18 | 153 | 5.16e-01 |
| GO:BP | GO:0090089 | regulation of dipeptide transport | 1 | 2 | 5.16e-01 |
| GO:BP | GO:0090088 | regulation of oligopeptide transport | 1 | 2 | 5.16e-01 |
| GO:BP | GO:0046724 | oxalic acid secretion | 1 | 1 | 5.16e-01 |
| GO:BP | GO:0034627 | ‘de novo’ NAD biosynthetic process | 1 | 2 | 5.16e-01 |
| GO:BP | GO:0061642 | chemoattraction of axon | 1 | 2 | 5.16e-01 |
| GO:BP | GO:1900244 | positive regulation of synaptic vesicle endocytosis | 2 | 4 | 5.16e-01 |
| GO:BP | GO:2001150 | positive regulation of dipeptide transmembrane transport | 1 | 2 | 5.16e-01 |
| GO:BP | GO:2001148 | regulation of dipeptide transmembrane transport | 1 | 2 | 5.16e-01 |
| GO:BP | GO:0032042 | mitochondrial DNA metabolic process | 5 | 22 | 5.16e-01 |
| GO:BP | GO:0010824 | regulation of centrosome duplication | 6 | 44 | 5.16e-01 |
| GO:BP | GO:0086003 | cardiac muscle cell contraction | 4 | 67 | 5.16e-01 |
| GO:BP | GO:0009247 | glycolipid biosynthetic process | 4 | 61 | 5.16e-01 |
| GO:BP | GO:2000323 | negative regulation of glucocorticoid receptor signaling pathway | 1 | 6 | 5.16e-01 |
| GO:BP | GO:0034203 | glycolipid translocation | 1 | 1 | 5.16e-01 |
| GO:BP | GO:0009309 | amine biosynthetic process | 2 | 25 | 5.16e-01 |
| GO:BP | GO:0060369 | positive regulation of Fc receptor mediated stimulatory signaling pathway | 1 | 5 | 5.16e-01 |
| GO:BP | GO:0030575 | nuclear body organization | 2 | 14 | 5.16e-01 |
| GO:BP | GO:0051885 | positive regulation of timing of anagen | 1 | 2 | 5.16e-01 |
| GO:BP | GO:0009298 | GDP-mannose biosynthetic process | 1 | 4 | 5.16e-01 |
| GO:BP | GO:0060430 | lung saccule development | 2 | 7 | 5.16e-01 |
| GO:BP | GO:0001676 | long-chain fatty acid metabolic process | 5 | 65 | 5.16e-01 |
| GO:BP | GO:1904752 | regulation of vascular associated smooth muscle cell migration | 4 | 23 | 5.16e-01 |
| GO:BP | GO:0001706 | endoderm formation | 2 | 46 | 5.16e-01 |
| GO:BP | GO:1904742 | regulation of telomeric DNA binding | 1 | 4 | 5.16e-01 |
| GO:BP | GO:1905449 | regulation of Fc-gamma receptor signaling pathway involved in phagocytosis | 1 | 5 | 5.16e-01 |
| GO:BP | GO:0006446 | regulation of translational initiation | 11 | 73 | 5.16e-01 |
| GO:BP | GO:1905438 | non-canonical Wnt signaling pathway involved in midbrain dopaminergic neuron differentiation | 1 | 1 | 5.16e-01 |
| GO:BP | GO:0046426 | negative regulation of receptor signaling pathway via JAK-STAT | 3 | 20 | 5.16e-01 |
| GO:BP | GO:1905395 | response to flavonoid | 1 | 2 | 5.16e-01 |
| GO:BP | GO:0009637 | response to blue light | 1 | 3 | 5.16e-01 |
| GO:BP | GO:0060419 | heart growth | 3 | 72 | 5.16e-01 |
| GO:BP | GO:1904933 | regulation of cell proliferation in midbrain | 1 | 1 | 5.16e-01 |
| GO:BP | GO:0001704 | formation of primary germ layer | 4 | 96 | 5.16e-01 |
| GO:BP | GO:0050427 | 3’-phosphoadenosine 5’-phosphosulfate metabolic process | 1 | 10 | 5.16e-01 |
| GO:BP | GO:1901361 | organic cyclic compound catabolic process | 3 | 406 | 5.16e-01 |
| GO:BP | GO:2000878 | positive regulation of oligopeptide transport | 1 | 2 | 5.16e-01 |
| GO:BP | GO:2000880 | positive regulation of dipeptide transport | 1 | 2 | 5.16e-01 |
| GO:BP | GO:0042594 | response to starvation | 19 | 178 | 5.17e-01 |
| GO:BP | GO:0097156 | fasciculation of motor neuron axon | 1 | 2 | 5.17e-01 |
| GO:BP | GO:0010991 | negative regulation of SMAD protein complex assembly | 1 | 5 | 5.17e-01 |
| GO:BP | GO:0000165 | MAPK cascade | 1 | 556 | 5.17e-01 |
| GO:BP | GO:0060681 | branch elongation involved in ureteric bud branching | 1 | 3 | 5.17e-01 |
| GO:BP | GO:0043537 | negative regulation of blood vessel endothelial cell migration | 1 | 25 | 5.17e-01 |
| GO:BP | GO:0061550 | cranial ganglion development | 1 | 4 | 5.17e-01 |
| GO:BP | GO:0060236 | regulation of mitotic spindle organization | 5 | 42 | 5.17e-01 |
| GO:BP | GO:0060249 | anatomical structure homeostasis | 4 | 170 | 5.17e-01 |
| GO:BP | GO:0035752 | lysosomal lumen pH elevation | 1 | 3 | 5.17e-01 |
| GO:BP | GO:0098773 | skin epidermis development | 2 | 87 | 5.17e-01 |
| GO:BP | GO:0061178 | regulation of insulin secretion involved in cellular response to glucose stimulus | 10 | 40 | 5.17e-01 |
| GO:BP | GO:0000493 | box H/ACA snoRNP assembly | 1 | 2 | 5.17e-01 |
| GO:BP | GO:0061217 | regulation of mesonephros development | 1 | 2 | 5.17e-01 |
| GO:BP | GO:0003231 | cardiac ventricle development | 4 | 114 | 5.17e-01 |
| GO:BP | GO:0042491 | inner ear auditory receptor cell differentiation | 1 | 29 | 5.17e-01 |
| GO:BP | GO:0060509 | type I pneumocyte differentiation | 2 | 8 | 5.17e-01 |
| GO:BP | GO:0006452 | translational frameshifting | 1 | 3 | 5.17e-01 |
| GO:BP | GO:1902358 | sulfate transmembrane transport | 1 | 11 | 5.17e-01 |
| GO:BP | GO:0001894 | tissue homeostasis | 4 | 170 | 5.17e-01 |
| GO:BP | GO:0009176 | pyrimidine deoxyribonucleoside monophosphate metabolic process | 2 | 9 | 5.17e-01 |
| GO:BP | GO:0048679 | regulation of axon regeneration | 1 | 23 | 5.17e-01 |
| GO:BP | GO:0097411 | hypoxia-inducible factor-1alpha signaling pathway | 1 | 4 | 5.17e-01 |
| GO:BP | GO:1903377 | negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway | 1 | 5 | 5.17e-01 |
| GO:BP | GO:0046326 | positive regulation of glucose import | 6 | 26 | 5.17e-01 |
| GO:BP | GO:1902856 | negative regulation of non-motile cilium assembly | 1 | 2 | 5.17e-01 |
| GO:BP | GO:1903408 | positive regulation of P-type sodium:potassium-exchanging transporter activity | 1 | 2 | 5.17e-01 |
| GO:BP | GO:1903406 | regulation of P-type sodium:potassium-exchanging transporter activity | 1 | 2 | 5.17e-01 |
| GO:BP | GO:0006919 | activation of cysteine-type endopeptidase activity involved in apoptotic process | 11 | 65 | 5.17e-01 |
| GO:BP | GO:0006301 | postreplication repair | 1 | 34 | 5.18e-01 |
| GO:BP | GO:0010927 | cellular component assembly involved in morphogenesis | 4 | 106 | 5.18e-01 |
| GO:BP | GO:0090170 | regulation of Golgi inheritance | 1 | 4 | 5.18e-01 |
| GO:BP | GO:0030155 | regulation of cell adhesion | 1 | 539 | 5.18e-01 |
| GO:BP | GO:1905793 | protein localization to pericentriolar material | 1 | 2 | 5.19e-01 |
| GO:BP | GO:0097112 | gamma-aminobutyric acid receptor clustering | 1 | 3 | 5.19e-01 |
| GO:BP | GO:0006501 | C-terminal protein lipidation | 2 | 6 | 5.19e-01 |
| GO:BP | GO:0050820 | positive regulation of coagulation | 1 | 23 | 5.19e-01 |
| GO:BP | GO:0060729 | intestinal epithelial structure maintenance | 2 | 4 | 5.19e-01 |
| GO:BP | GO:0002761 | regulation of myeloid leukocyte differentiation | 5 | 77 | 5.19e-01 |
| GO:BP | GO:1905366 | negative regulation of intralumenal vesicle formation | 1 | 2 | 5.19e-01 |
| GO:BP | GO:0055010 | ventricular cardiac muscle tissue morphogenesis | 2 | 43 | 5.19e-01 |
| GO:BP | GO:1905365 | regulation of intralumenal vesicle formation | 1 | 2 | 5.19e-01 |
| GO:BP | GO:0042327 | positive regulation of phosphorylation | 1 | 547 | 5.19e-01 |
| GO:BP | GO:0070427 | nucleotide-binding oligomerization domain containing 1 signaling pathway | 2 | 5 | 5.19e-01 |
| GO:BP | GO:0015793 | glycerol transmembrane transport | 1 | 4 | 5.19e-01 |
| GO:BP | GO:1904979 | negative regulation of endosome organization | 1 | 2 | 5.19e-01 |
| GO:BP | GO:0007174 | epidermal growth factor catabolic process | 1 | 2 | 5.19e-01 |
| GO:BP | GO:0040013 | negative regulation of locomotion | 22 | 265 | 5.19e-01 |
| GO:BP | GO:0051205 | protein insertion into membrane | 14 | 62 | 5.19e-01 |
| GO:BP | GO:1901993 | regulation of meiotic cell cycle phase transition | 2 | 5 | 5.19e-01 |
| GO:BP | GO:0006664 | glycolipid metabolic process | 6 | 88 | 5.19e-01 |
| GO:BP | GO:0000050 | urea cycle | 2 | 7 | 5.19e-01 |
| GO:BP | GO:0051454 | intracellular pH elevation | 2 | 4 | 5.20e-01 |
| GO:BP | GO:0042074 | cell migration involved in gastrulation | 1 | 10 | 5.20e-01 |
| GO:BP | GO:0045667 | regulation of osteoblast differentiation | 4 | 99 | 5.20e-01 |
| GO:BP | GO:2000758 | positive regulation of peptidyl-lysine acetylation | 6 | 31 | 5.20e-01 |
| GO:BP | GO:0048523 | negative regulation of cellular process | 8 | 3625 | 5.20e-01 |
| GO:BP | GO:0003413 | chondrocyte differentiation involved in endochondral bone morphogenesis | 4 | 12 | 5.21e-01 |
| GO:BP | GO:0061515 | myeloid cell development | 1 | 57 | 5.21e-01 |
| GO:BP | GO:0048488 | synaptic vesicle endocytosis | 11 | 63 | 5.21e-01 |
| GO:BP | GO:0042996 | regulation of Golgi to plasma membrane protein transport | 2 | 9 | 5.21e-01 |
| GO:BP | GO:1905664 | regulation of calcium ion import across plasma membrane | 1 | 8 | 5.21e-01 |
| GO:BP | GO:0001708 | cell fate specification | 2 | 56 | 5.22e-01 |
| GO:BP | GO:0044648 | histone H3-K4 dimethylation | 1 | 6 | 5.22e-01 |
| GO:BP | GO:0044320 | cellular response to leptin stimulus | 1 | 15 | 5.22e-01 |
| GO:BP | GO:0090232 | positive regulation of spindle checkpoint | 3 | 12 | 5.23e-01 |
| GO:BP | GO:0090267 | positive regulation of mitotic cell cycle spindle assembly checkpoint | 3 | 12 | 5.23e-01 |
| GO:BP | GO:0090125 | cell-cell adhesion involved in synapse maturation | 1 | 2 | 5.23e-01 |
| GO:BP | GO:0110091 | negative regulation of hippocampal neuron apoptotic process | 1 | 2 | 5.23e-01 |
| GO:BP | GO:0032989 | cellular component morphogenesis | 1 | 639 | 5.24e-01 |
| GO:BP | GO:0050802 | circadian sleep/wake cycle, sleep | 1 | 9 | 5.24e-01 |
| GO:BP | GO:0032728 | positive regulation of interferon-beta production | 8 | 29 | 5.24e-01 |
| GO:BP | GO:0022605 | mammalian oogenesis stage | 3 | 6 | 5.24e-01 |
| GO:BP | GO:0007266 | Rho protein signal transduction | 6 | 114 | 5.24e-01 |
| GO:BP | GO:0010043 | response to zinc ion | 1 | 31 | 5.24e-01 |
| GO:BP | GO:0060400 | negative regulation of growth hormone receptor signaling pathway | 1 | 3 | 5.24e-01 |
| GO:BP | GO:0003032 | detection of oxygen | 1 | 5 | 5.24e-01 |
| GO:BP | GO:0150147 | cell-cell junction disassembly | 1 | 4 | 5.24e-01 |
| GO:BP | GO:0060999 | positive regulation of dendritic spine development | 7 | 33 | 5.24e-01 |
| GO:BP | GO:0060819 | inactivation of X chromosome by genomic imprinting | 1 | 2 | 5.24e-01 |
| GO:BP | GO:0090481 | pyrimidine nucleotide-sugar transmembrane transport | 3 | 12 | 5.24e-01 |
| GO:BP | GO:0150012 | positive regulation of neuron projection arborization | 2 | 8 | 5.24e-01 |
| GO:BP | GO:0046134 | pyrimidine nucleoside biosynthetic process | 1 | 4 | 5.24e-01 |
| GO:BP | GO:0006954 | inflammatory response | 1 | 429 | 5.24e-01 |
| GO:BP | GO:0071456 | cellular response to hypoxia | 9 | 123 | 5.24e-01 |
| GO:BP | GO:0006896 | Golgi to vacuole transport | 4 | 19 | 5.24e-01 |
| GO:BP | GO:0050678 | regulation of epithelial cell proliferation | 22 | 276 | 5.24e-01 |
| GO:BP | GO:0061525 | hindgut development | 2 | 5 | 5.24e-01 |
| GO:BP | GO:0061511 | centriole elongation | 1 | 8 | 5.24e-01 |
| GO:BP | GO:0003198 | epithelial to mesenchymal transition involved in endocardial cushion formation | 1 | 14 | 5.24e-01 |
| GO:BP | GO:0060384 | innervation | 1 | 22 | 5.24e-01 |
| GO:BP | GO:1903900 | regulation of viral life cycle | 5 | 101 | 5.24e-01 |
| GO:BP | GO:0007098 | centrosome cycle | 1 | 127 | 5.24e-01 |
| GO:BP | GO:0046849 | bone remodeling | 4 | 59 | 5.24e-01 |
| GO:BP | GO:0009152 | purine ribonucleotide biosynthetic process | 1 | 179 | 5.25e-01 |
| GO:BP | GO:0071816 | tail-anchored membrane protein insertion into ER membrane | 4 | 17 | 5.25e-01 |
| GO:BP | GO:0090241 | negative regulation of histone H4 acetylation | 1 | 2 | 5.25e-01 |
| GO:BP | GO:0007501 | mesodermal cell fate specification | 1 | 5 | 5.25e-01 |
| GO:BP | GO:0031063 | regulation of histone deacetylation | 7 | 36 | 5.25e-01 |
| GO:BP | GO:0031666 | positive regulation of lipopolysaccharide-mediated signaling pathway | 1 | 4 | 5.25e-01 |
| GO:BP | GO:0120316 | sperm flagellum assembly | 2 | 26 | 5.25e-01 |
| GO:BP | GO:0034157 | positive regulation of toll-like receptor 7 signaling pathway | 1 | 2 | 5.25e-01 |
| GO:BP | GO:0044281 | small molecule metabolic process | 7 | 1389 | 5.25e-01 |
| GO:BP | GO:1900025 | negative regulation of substrate adhesion-dependent cell spreading | 3 | 11 | 5.25e-01 |
| GO:BP | GO:0007026 | negative regulation of microtubule depolymerization | 3 | 27 | 5.25e-01 |
| GO:BP | GO:0071353 | cellular response to interleukin-4 | 4 | 21 | 5.25e-01 |
| GO:BP | GO:0034165 | positive regulation of toll-like receptor 9 signaling pathway | 1 | 3 | 5.25e-01 |
| GO:BP | GO:0089709 | L-histidine transmembrane transport | 1 | 5 | 5.25e-01 |
| GO:BP | GO:0070426 | positive regulation of nucleotide-binding oligomerization domain containing signaling pathway | 1 | 4 | 5.25e-01 |
| GO:BP | GO:0007009 | plasma membrane organization | 1 | 116 | 5.25e-01 |
| GO:BP | GO:0016032 | viral process | 5 | 344 | 5.25e-01 |
| GO:BP | GO:0046184 | aldehyde biosynthetic process | 3 | 14 | 5.25e-01 |
| GO:BP | GO:1903509 | liposaccharide metabolic process | 6 | 88 | 5.25e-01 |
| GO:BP | GO:0009725 | response to hormone | 5 | 642 | 5.25e-01 |
| GO:BP | GO:1902110 | positive regulation of mitochondrial membrane permeability involved in apoptotic process | 6 | 38 | 5.27e-01 |
| GO:BP | GO:0006177 | GMP biosynthetic process | 3 | 13 | 5.27e-01 |
| GO:BP | GO:0086011 | membrane repolarization during action potential | 2 | 22 | 5.27e-01 |
| GO:BP | GO:0044790 | suppression of viral release by host | 4 | 16 | 5.27e-01 |
| GO:BP | GO:0006167 | AMP biosynthetic process | 3 | 14 | 5.27e-01 |
| GO:BP | GO:0008272 | sulfate transport | 1 | 12 | 5.27e-01 |
| GO:BP | GO:2001244 | positive regulation of intrinsic apoptotic signaling pathway | 7 | 52 | 5.27e-01 |
| GO:BP | GO:0050685 | positive regulation of mRNA processing | 2 | 30 | 5.27e-01 |
| GO:BP | GO:1903772 | regulation of viral budding via host ESCRT complex | 1 | 4 | 5.27e-01 |
| GO:BP | GO:0044878 | mitotic cytokinesis checkpoint signaling | 1 | 4 | 5.27e-01 |
| GO:BP | GO:0060534 | trachea cartilage development | 1 | 4 | 5.27e-01 |
| GO:BP | GO:0010832 | negative regulation of myotube differentiation | 2 | 10 | 5.27e-01 |
| GO:BP | GO:0010717 | regulation of epithelial to mesenchymal transition | 3 | 86 | 5.27e-01 |
| GO:BP | GO:1903779 | regulation of cardiac conduction | 1 | 23 | 5.27e-01 |
| GO:BP | GO:0090503 | RNA phosphodiester bond hydrolysis, exonucleolytic | 1 | 41 | 5.27e-01 |
| GO:BP | GO:0007034 | vacuolar transport | 15 | 149 | 5.27e-01 |
| GO:BP | GO:1990090 | cellular response to nerve growth factor stimulus | 5 | 41 | 5.28e-01 |
| GO:BP | GO:0048160 | primary follicle stage | 1 | 1 | 5.28e-01 |
| GO:BP | GO:0002314 | germinal center B cell differentiation | 2 | 3 | 5.28e-01 |
| GO:BP | GO:0001667 | ameboidal-type cell migration | 5 | 358 | 5.28e-01 |
| GO:BP | GO:0010635 | regulation of mitochondrial fusion | 1 | 11 | 5.28e-01 |
| GO:BP | GO:0035510 | DNA dealkylation | 6 | 28 | 5.28e-01 |
| GO:BP | GO:0009650 | UV protection | 3 | 11 | 5.28e-01 |
| GO:BP | GO:0010887 | negative regulation of cholesterol storage | 1 | 9 | 5.28e-01 |
| GO:BP | GO:0071679 | commissural neuron axon guidance | 3 | 11 | 5.28e-01 |
| GO:BP | GO:0034103 | regulation of tissue remodeling | 2 | 45 | 5.28e-01 |
| GO:BP | GO:1905663 | positive regulation of telomerase RNA reverse transcriptase activity | 1 | 2 | 5.28e-01 |
| GO:BP | GO:0016573 | histone acetylation | 3 | 143 | 5.28e-01 |
| GO:BP | GO:0019081 | viral translation | 1 | 18 | 5.28e-01 |
| GO:BP | GO:0061365 | positive regulation of triglyceride lipase activity | 1 | 4 | 5.28e-01 |
| GO:BP | GO:0048566 | embryonic digestive tract development | 5 | 20 | 5.29e-01 |
| GO:BP | GO:0043276 | anoikis | 1 | 32 | 5.29e-01 |
| GO:BP | GO:0002023 | reduction of food intake in response to dietary excess | 2 | 2 | 5.29e-01 |
| GO:BP | GO:0086002 | cardiac muscle cell action potential involved in contraction | 3 | 45 | 5.30e-01 |
| GO:BP | GO:0007418 | ventral midline development | 2 | 4 | 5.30e-01 |
| GO:BP | GO:0015721 | bile acid and bile salt transport | 1 | 11 | 5.30e-01 |
| GO:BP | GO:0061002 | negative regulation of dendritic spine morphogenesis | 2 | 6 | 5.30e-01 |
| GO:BP | GO:0010742 | macrophage derived foam cell differentiation | 2 | 22 | 5.30e-01 |
| GO:BP | GO:0090077 | foam cell differentiation | 2 | 22 | 5.30e-01 |
| GO:BP | GO:0010633 | negative regulation of epithelial cell migration | 2 | 53 | 5.31e-01 |
| GO:BP | GO:1901301 | regulation of cargo loading into COPII-coated vesicle | 1 | 2 | 5.31e-01 |
| GO:BP | GO:0048203 | vesicle targeting, trans-Golgi to endosome | 1 | 2 | 5.31e-01 |
| GO:BP | GO:0150146 | cell junction disassembly | 3 | 20 | 5.31e-01 |
| GO:BP | GO:1903352 | L-ornithine transmembrane transport | 1 | 4 | 5.31e-01 |
| GO:BP | GO:1904706 | negative regulation of vascular associated smooth muscle cell proliferation | 3 | 24 | 5.31e-01 |
| GO:BP | GO:0036309 | protein localization to M-band | 1 | 2 | 5.31e-01 |
| GO:BP | GO:0036371 | protein localization to T-tubule | 1 | 2 | 5.31e-01 |
| GO:BP | GO:0014733 | regulation of skeletal muscle adaptation | 3 | 11 | 5.32e-01 |
| GO:BP | GO:0051877 | pigment granule aggregation in cell center | 1 | 2 | 5.32e-01 |
| GO:BP | GO:0010718 | positive regulation of epithelial to mesenchymal transition | 2 | 48 | 5.32e-01 |
| GO:BP | GO:1903929 | primary palate development | 1 | 2 | 5.32e-01 |
| GO:BP | GO:1901264 | carbohydrate derivative transport | 5 | 63 | 5.32e-01 |
| GO:BP | GO:0006029 | proteoglycan metabolic process | 1 | 77 | 5.32e-01 |
| GO:BP | GO:0060284 | regulation of cell development | 1 | 605 | 5.32e-01 |
| GO:BP | GO:0031648 | protein destabilization | 5 | 45 | 5.32e-01 |
| GO:BP | GO:0043407 | negative regulation of MAP kinase activity | 3 | 50 | 5.32e-01 |
| GO:BP | GO:0044282 | small molecule catabolic process | 2 | 271 | 5.32e-01 |
| GO:BP | GO:0048668 | collateral sprouting | 4 | 25 | 5.32e-01 |
| GO:BP | GO:0032727 | positive regulation of interferon-alpha production | 2 | 17 | 5.33e-01 |
| GO:BP | GO:0099555 | trans-synaptic signaling by nitric oxide, modulating synaptic transmission | 1 | 2 | 5.33e-01 |
| GO:BP | GO:0099554 | trans-synaptic signaling by soluble gas, modulating synaptic transmission | 1 | 2 | 5.33e-01 |
| GO:BP | GO:0040016 | embryonic cleavage | 2 | 7 | 5.33e-01 |
| GO:BP | GO:0014048 | regulation of glutamate secretion | 1 | 8 | 5.33e-01 |
| GO:BP | GO:0090177 | establishment of planar polarity involved in neural tube closure | 3 | 14 | 5.33e-01 |
| GO:BP | GO:0050965 | detection of temperature stimulus involved in sensory perception of pain | 1 | 10 | 5.33e-01 |
| GO:BP | GO:0006415 | translational termination | 1 | 17 | 5.33e-01 |
| GO:BP | GO:0035751 | regulation of lysosomal lumen pH | 3 | 26 | 5.33e-01 |
| GO:BP | GO:0002904 | positive regulation of B cell apoptotic process | 1 | 2 | 5.33e-01 |
| GO:BP | GO:0038171 | cannabinoid signaling pathway | 1 | 5 | 5.33e-01 |
| GO:BP | GO:1902445 | regulation of mitochondrial membrane permeability involved in programmed necrotic cell death | 1 | 3 | 5.33e-01 |
| GO:BP | GO:0098917 | retrograde trans-synaptic signaling | 1 | 7 | 5.33e-01 |
| GO:BP | GO:0030091 | protein repair | 1 | 7 | 5.33e-01 |
| GO:BP | GO:0097296 | activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway | 1 | 3 | 5.33e-01 |
| GO:BP | GO:0043622 | cortical microtubule organization | 1 | 4 | 5.33e-01 |
| GO:BP | GO:0006408 | snRNA export from nucleus | 1 | 4 | 5.33e-01 |
| GO:BP | GO:1901844 | regulation of cell communication by electrical coupling involved in cardiac conduction | 3 | 12 | 5.33e-01 |
| GO:BP | GO:0010747 | positive regulation of long-chain fatty acid import across plasma membrane | 1 | 1 | 5.33e-01 |
| GO:BP | GO:0009099 | valine biosynthetic process | 1 | 3 | 5.33e-01 |
| GO:BP | GO:2000319 | regulation of T-helper 17 cell differentiation | 3 | 10 | 5.33e-01 |
| GO:BP | GO:0043969 | histone H2B acetylation | 1 | 3 | 5.33e-01 |
| GO:BP | GO:0006808 | regulation of nitrogen utilization | 1 | 2 | 5.33e-01 |
| GO:BP | GO:0014855 | striated muscle cell proliferation | 5 | 57 | 5.33e-01 |
| GO:BP | GO:0006109 | regulation of carbohydrate metabolic process | 16 | 144 | 5.33e-01 |
| GO:BP | GO:0061097 | regulation of protein tyrosine kinase activity | 3 | 65 | 5.33e-01 |
| GO:BP | GO:0010758 | regulation of macrophage chemotaxis | 1 | 14 | 5.33e-01 |
| GO:BP | GO:1902263 | apoptotic process involved in embryonic digit morphogenesis | 1 | 3 | 5.33e-01 |
| GO:BP | GO:0006359 | regulation of transcription by RNA polymerase III | 4 | 30 | 5.34e-01 |
| GO:BP | GO:0051121 | hepoxilin metabolic process | 1 | 5 | 5.34e-01 |
| GO:BP | GO:0046649 | lymphocyte activation | 1 | 465 | 5.34e-01 |
| GO:BP | GO:0051122 | hepoxilin biosynthetic process | 1 | 5 | 5.34e-01 |
| GO:BP | GO:1902816 | regulation of protein localization to microtubule | 1 | 5 | 5.34e-01 |
| GO:BP | GO:0086064 | cell communication by electrical coupling involved in cardiac conduction | 1 | 26 | 5.34e-01 |
| GO:BP | GO:0021934 | hindbrain tangential cell migration | 1 | 3 | 5.34e-01 |
| GO:BP | GO:1902817 | negative regulation of protein localization to microtubule | 1 | 5 | 5.34e-01 |
| GO:BP | GO:0045597 | positive regulation of cell differentiation | 1 | 620 | 5.34e-01 |
| GO:BP | GO:0035020 | regulation of Rac protein signal transduction | 3 | 21 | 5.35e-01 |
| GO:BP | GO:0010501 | RNA secondary structure unwinding | 1 | 8 | 5.35e-01 |
| GO:BP | GO:0032958 | inositol phosphate biosynthetic process | 6 | 19 | 5.36e-01 |
| GO:BP | GO:0009260 | ribonucleotide biosynthetic process | 1 | 191 | 5.37e-01 |
| GO:BP | GO:0060759 | regulation of response to cytokine stimulus | 8 | 126 | 5.37e-01 |
| GO:BP | GO:2000643 | positive regulation of early endosome to late endosome transport | 1 | 7 | 5.37e-01 |
| GO:BP | GO:0018208 | peptidyl-proline modification | 1 | 43 | 5.37e-01 |
| GO:BP | GO:0090521 | podocyte cell migration | 2 | 7 | 5.37e-01 |
| GO:BP | GO:0006401 | RNA catabolic process | 2 | 256 | 5.37e-01 |
| GO:BP | GO:1904776 | regulation of protein localization to cell cortex | 1 | 8 | 5.37e-01 |
| GO:BP | GO:0048863 | stem cell differentiation | 2 | 197 | 5.37e-01 |
| GO:BP | GO:0097680 | double-strand break repair via classical nonhomologous end joining | 1 | 6 | 5.38e-01 |
| GO:BP | GO:0060213 | positive regulation of nuclear-transcribed mRNA poly(A) tail shortening | 2 | 13 | 5.38e-01 |
| GO:BP | GO:0010961 | intracellular magnesium ion homeostasis | 1 | 4 | 5.38e-01 |
| GO:BP | GO:0090327 | negative regulation of locomotion involved in locomotory behavior | 1 | 1 | 5.38e-01 |
| GO:BP | GO:0001738 | morphogenesis of a polarized epithelium | 9 | 88 | 5.38e-01 |
| GO:BP | GO:0150079 | negative regulation of neuroinflammatory response | 2 | 6 | 5.38e-01 |
| GO:BP | GO:0010562 | positive regulation of phosphorus metabolic process | 1 | 597 | 5.38e-01 |
| GO:BP | GO:0048665 | neuron fate specification | 1 | 14 | 5.38e-01 |
| GO:BP | GO:0070570 | regulation of neuron projection regeneration | 1 | 25 | 5.38e-01 |
| GO:BP | GO:0051338 | regulation of transferase activity | 1 | 679 | 5.38e-01 |
| GO:BP | GO:0048864 | stem cell development | 3 | 76 | 5.38e-01 |
| GO:BP | GO:0061162 | establishment of monopolar cell polarity | 3 | 20 | 5.38e-01 |
| GO:BP | GO:0045937 | positive regulation of phosphate metabolic process | 1 | 597 | 5.38e-01 |
| GO:BP | GO:0030199 | collagen fibril organization | 2 | 56 | 5.38e-01 |
| GO:BP | GO:0035455 | response to interferon-alpha | 1 | 16 | 5.39e-01 |
| GO:BP | GO:0061098 | positive regulation of protein tyrosine kinase activity | 2 | 33 | 5.39e-01 |
| GO:BP | GO:0051453 | regulation of intracellular pH | 7 | 65 | 5.39e-01 |
| GO:BP | GO:0010889 | regulation of sequestering of triglyceride | 3 | 12 | 5.39e-01 |
| GO:BP | GO:0098542 | defense response to other organism | 2 | 608 | 5.39e-01 |
| GO:BP | GO:0046135 | pyrimidine nucleoside catabolic process | 3 | 8 | 5.39e-01 |
| GO:BP | GO:0048313 | Golgi inheritance | 2 | 15 | 5.39e-01 |
| GO:BP | GO:0051482 | positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway | 1 | 12 | 5.39e-01 |
| GO:BP | GO:0010614 | negative regulation of cardiac muscle hypertrophy | 2 | 26 | 5.39e-01 |
| GO:BP | GO:0006643 | membrane lipid metabolic process | 9 | 173 | 5.39e-01 |
| GO:BP | GO:0010862 | positive regulation of pathway-restricted SMAD protein phosphorylation | 2 | 37 | 5.39e-01 |
| GO:BP | GO:0055007 | cardiac muscle cell differentiation | 16 | 103 | 5.39e-01 |
| GO:BP | GO:0048308 | organelle inheritance | 2 | 15 | 5.39e-01 |
| GO:BP | GO:0043650 | dicarboxylic acid biosynthetic process | 1 | 9 | 5.40e-01 |
| GO:BP | GO:1902523 | positive regulation of protein K63-linked ubiquitination | 1 | 5 | 5.40e-01 |
| GO:BP | GO:0098534 | centriole assembly | 5 | 41 | 5.40e-01 |
| GO:BP | GO:0060730 | regulation of intestinal epithelial structure maintenance | 1 | 1 | 5.40e-01 |
| GO:BP | GO:0090084 | negative regulation of inclusion body assembly | 2 | 10 | 5.40e-01 |
| GO:BP | GO:1903543 | positive regulation of exosomal secretion | 3 | 13 | 5.40e-01 |
| GO:BP | GO:2000737 | negative regulation of stem cell differentiation | 2 | 24 | 5.40e-01 |
| GO:BP | GO:0006651 | diacylglycerol biosynthetic process | 1 | 7 | 5.40e-01 |
| GO:BP | GO:0046602 | regulation of mitotic centrosome separation | 2 | 8 | 5.40e-01 |
| GO:BP | GO:2001034 | positive regulation of double-strand break repair via nonhomologous end joining | 1 | 12 | 5.41e-01 |
| GO:BP | GO:0010881 | regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion | 4 | 20 | 5.41e-01 |
| GO:BP | GO:1902045 | negative regulation of Fas signaling pathway | 1 | 2 | 5.41e-01 |
| GO:BP | GO:0033387 | putrescine biosynthetic process from ornithine | 1 | 3 | 5.41e-01 |
| GO:BP | GO:0031440 | regulation of mRNA 3’-end processing | 5 | 22 | 5.41e-01 |
| GO:BP | GO:0010880 | regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | 6 | 27 | 5.41e-01 |
| GO:BP | GO:0048477 | oogenesis | 1 | 64 | 5.42e-01 |
| GO:BP | GO:0070525 | tRNA threonylcarbamoyladenosine metabolic process | 4 | 16 | 5.42e-01 |
| GO:BP | GO:0051280 | negative regulation of release of sequestered calcium ion into cytosol | 1 | 11 | 5.42e-01 |
| GO:BP | GO:0006427 | histidyl-tRNA aminoacylation | 1 | 2 | 5.43e-01 |
| GO:BP | GO:0046390 | ribose phosphate biosynthetic process | 1 | 197 | 5.43e-01 |
| GO:BP | GO:0060325 | face morphogenesis | 3 | 28 | 5.43e-01 |
| GO:BP | GO:0070375 | ERK5 cascade | 1 | 3 | 5.44e-01 |
| GO:BP | GO:0042749 | regulation of circadian sleep/wake cycle | 1 | 9 | 5.44e-01 |
| GO:BP | GO:2000615 | regulation of histone H3-K9 acetylation | 2 | 7 | 5.45e-01 |
| GO:BP | GO:0035616 | histone H2B conserved C-terminal lysine deubiquitination | 1 | 4 | 5.45e-01 |
| GO:BP | GO:0006885 | regulation of pH | 8 | 74 | 5.45e-01 |
| GO:BP | GO:0032057 | negative regulation of translational initiation in response to stress | 1 | 5 | 5.45e-01 |
| GO:BP | GO:0097039 | protein linear polyubiquitination | 1 | 5 | 5.45e-01 |
| GO:BP | GO:0098596 | imitative learning | 1 | 4 | 5.45e-01 |
| GO:BP | GO:0002069 | columnar/cuboidal epithelial cell maturation | 2 | 9 | 5.45e-01 |
| GO:BP | GO:0046865 | terpenoid transport | 1 | 3 | 5.45e-01 |
| GO:BP | GO:0046864 | isoprenoid transport | 1 | 3 | 5.45e-01 |
| GO:BP | GO:0042297 | vocal learning | 1 | 4 | 5.45e-01 |
| GO:BP | GO:0060426 | lung vasculature development | 1 | 3 | 5.45e-01 |
| GO:BP | GO:0033143 | regulation of intracellular steroid hormone receptor signaling pathway | 1 | 61 | 5.45e-01 |
| GO:BP | GO:0042476 | odontogenesis | 5 | 86 | 5.45e-01 |
| GO:BP | GO:0035729 | cellular response to hepatocyte growth factor stimulus | 3 | 13 | 5.45e-01 |
| GO:BP | GO:0048711 | positive regulation of astrocyte differentiation | 3 | 11 | 5.45e-01 |
| GO:BP | GO:1901160 | primary amino compound metabolic process | 3 | 8 | 5.45e-01 |
| GO:BP | GO:0031587 | positive regulation of inositol 1,4,5-trisphosphate-sensitive calcium-release channel activity | 1 | 3 | 5.45e-01 |
| GO:BP | GO:2000322 | regulation of glucocorticoid receptor signaling pathway | 1 | 7 | 5.45e-01 |
| GO:BP | GO:0035641 | locomotory exploration behavior | 3 | 11 | 5.46e-01 |
| GO:BP | GO:1903202 | negative regulation of oxidative stress-induced cell death | 5 | 40 | 5.46e-01 |
| GO:BP | GO:0016074 | sno(s)RNA metabolic process | 4 | 16 | 5.47e-01 |
| GO:BP | GO:0048012 | hepatocyte growth factor receptor signaling pathway | 2 | 10 | 5.47e-01 |
| GO:BP | GO:0070342 | brown fat cell proliferation | 1 | 1 | 5.47e-01 |
| GO:BP | GO:1904688 | regulation of cytoplasmic translational initiation | 2 | 6 | 5.47e-01 |
| GO:BP | GO:1901660 | calcium ion export | 1 | 3 | 5.47e-01 |
| GO:BP | GO:0042307 | positive regulation of protein import into nucleus | 1 | 32 | 5.47e-01 |
| GO:BP | GO:1900748 | positive regulation of vascular endothelial growth factor signaling pathway | 2 | 7 | 5.47e-01 |
| GO:BP | GO:1902558 | 5’-adenylyl sulfate transmembrane transport | 1 | 2 | 5.47e-01 |
| GO:BP | GO:0002052 | positive regulation of neuroblast proliferation | 3 | 19 | 5.47e-01 |
| GO:BP | GO:0032691 | negative regulation of interleukin-1 beta production | 3 | 13 | 5.47e-01 |
| GO:BP | GO:0046963 | 3’-phosphoadenosine 5’-phosphosulfate transport | 1 | 2 | 5.47e-01 |
| GO:BP | GO:1902559 | 3’-phospho-5’-adenylyl sulfate transmembrane transport | 1 | 2 | 5.47e-01 |
| GO:BP | GO:0051451 | myoblast migration | 2 | 11 | 5.47e-01 |
| GO:BP | GO:0036500 | ATF6-mediated unfolded protein response | 1 | 9 | 5.47e-01 |
| GO:BP | GO:0060045 | positive regulation of cardiac muscle cell proliferation | 2 | 21 | 5.47e-01 |
| GO:BP | GO:0034504 | protein localization to nucleus | 22 | 276 | 5.47e-01 |
| GO:BP | GO:0045048 | protein insertion into ER membrane | 5 | 23 | 5.47e-01 |
| GO:BP | GO:0039529 | RIG-I signaling pathway | 5 | 22 | 5.47e-01 |
| GO:BP | GO:0009895 | negative regulation of catabolic process | 1 | 280 | 5.47e-01 |
| GO:BP | GO:0000038 | very long-chain fatty acid metabolic process | 1 | 27 | 5.47e-01 |
| GO:BP | GO:0046686 | response to cadmium ion | 1 | 41 | 5.47e-01 |
| GO:BP | GO:0015742 | alpha-ketoglutarate transport | 1 | 3 | 5.47e-01 |
| GO:BP | GO:1903860 | negative regulation of dendrite extension | 1 | 2 | 5.47e-01 |
| GO:BP | GO:0051610 | serotonin uptake | 1 | 8 | 5.47e-01 |
| GO:BP | GO:0018201 | peptidyl-glycine modification | 1 | 4 | 5.47e-01 |
| GO:BP | GO:0061646 | positive regulation of glutamate neurotransmitter secretion in response to membrane depolarization | 1 | 2 | 5.47e-01 |
| GO:BP | GO:0070537 | histone H2A K63-linked deubiquitination | 2 | 8 | 5.47e-01 |
| GO:BP | GO:2001258 | negative regulation of cation channel activity | 2 | 30 | 5.47e-01 |
| GO:BP | GO:0006213 | pyrimidine nucleoside metabolic process | 4 | 16 | 5.47e-01 |
| GO:BP | GO:1903146 | regulation of autophagy of mitochondrion | 3 | 37 | 5.47e-01 |
| GO:BP | GO:0014043 | negative regulation of neuron maturation | 1 | 2 | 5.47e-01 |
| GO:BP | GO:0008610 | lipid biosynthetic process | 1 | 560 | 5.47e-01 |
| GO:BP | GO:0046601 | positive regulation of centriole replication | 1 | 9 | 5.47e-01 |
| GO:BP | GO:0000731 | DNA synthesis involved in DNA repair | 8 | 36 | 5.47e-01 |
| GO:BP | GO:1901021 | positive regulation of calcium ion transmembrane transporter activity | 2 | 39 | 5.47e-01 |
| GO:BP | GO:0003150 | muscular septum morphogenesis | 1 | 4 | 5.47e-01 |
| GO:BP | GO:1903726 | negative regulation of phospholipid metabolic process | 2 | 7 | 5.47e-01 |
| GO:BP | GO:0018393 | internal peptidyl-lysine acetylation | 3 | 148 | 5.47e-01 |
| GO:BP | GO:1990253 | cellular response to leucine starvation | 2 | 13 | 5.48e-01 |
| GO:BP | GO:0070507 | regulation of microtubule cytoskeleton organization | 15 | 146 | 5.48e-01 |
| GO:BP | GO:0060828 | regulation of canonical Wnt signaling pathway | 6 | 213 | 5.48e-01 |
| GO:BP | GO:0060304 | regulation of phosphatidylinositol dephosphorylation | 2 | 5 | 5.48e-01 |
| GO:BP | GO:0120181 | focal adhesion disassembly | 1 | 8 | 5.48e-01 |
| GO:BP | GO:1902525 | regulation of protein monoubiquitination | 1 | 6 | 5.48e-01 |
| GO:BP | GO:0120180 | cell-substrate junction disassembly | 1 | 8 | 5.48e-01 |
| GO:BP | GO:0038163 | thrombopoietin-mediated signaling pathway | 1 | 3 | 5.49e-01 |
| GO:BP | GO:0010935 | regulation of macrophage cytokine production | 3 | 27 | 5.49e-01 |
| GO:BP | GO:0010934 | macrophage cytokine production | 3 | 27 | 5.49e-01 |
| GO:BP | GO:0002278 | eosinophil activation involved in immune response | 2 | 4 | 5.49e-01 |
| GO:BP | GO:0043308 | eosinophil degranulation | 2 | 4 | 5.49e-01 |
| GO:BP | GO:1905953 | negative regulation of lipid localization | 8 | 32 | 5.49e-01 |
| GO:BP | GO:0009404 | toxin metabolic process | 3 | 7 | 5.49e-01 |
| GO:BP | GO:0090031 | positive regulation of steroid hormone biosynthetic process | 1 | 5 | 5.49e-01 |
| GO:BP | GO:1902811 | positive regulation of skeletal muscle fiber differentiation | 1 | 2 | 5.50e-01 |
| GO:BP | GO:0072329 | monocarboxylic acid catabolic process | 1 | 105 | 5.50e-01 |
| GO:BP | GO:0060070 | canonical Wnt signaling pathway | 7 | 251 | 5.50e-01 |
| GO:BP | GO:0050776 | regulation of immune response | 1 | 484 | 5.50e-01 |
| GO:BP | GO:0035315 | hair cell differentiation | 1 | 34 | 5.50e-01 |
| GO:BP | GO:0046070 | dGTP metabolic process | 1 | 3 | 5.50e-01 |
| GO:BP | GO:0072334 | UDP-galactose transmembrane transport | 1 | 4 | 5.50e-01 |
| GO:BP | GO:0038134 | ERBB2-EGFR signaling pathway | 2 | 6 | 5.50e-01 |
| GO:BP | GO:0045926 | negative regulation of growth | 1 | 206 | 5.50e-01 |
| GO:BP | GO:0140888 | interferon-mediated signaling pathway | 4 | 67 | 5.52e-01 |
| GO:BP | GO:0070076 | histone lysine demethylation | 3 | 20 | 5.52e-01 |
| GO:BP | GO:0021859 | pyramidal neuron differentiation | 1 | 11 | 5.52e-01 |
| GO:BP | GO:0045820 | negative regulation of glycolytic process | 2 | 13 | 5.52e-01 |
| GO:BP | GO:0019079 | viral genome replication | 2 | 101 | 5.52e-01 |
| GO:BP | GO:0060043 | regulation of cardiac muscle cell proliferation | 3 | 32 | 5.53e-01 |
| GO:BP | GO:0071548 | response to dexamethasone | 8 | 36 | 5.53e-01 |
| GO:BP | GO:0010990 | regulation of SMAD protein complex assembly | 1 | 6 | 5.53e-01 |
| GO:BP | GO:0036289 | peptidyl-serine autophosphorylation | 1 | 8 | 5.53e-01 |
| GO:BP | GO:0000967 | rRNA 5’-end processing | 1 | 5 | 5.53e-01 |
| GO:BP | GO:0031669 | cellular response to nutrient levels | 20 | 194 | 5.53e-01 |
| GO:BP | GO:1900744 | regulation of p38MAPK cascade | 1 | 32 | 5.53e-01 |
| GO:BP | GO:0022410 | circadian sleep/wake cycle process | 1 | 10 | 5.53e-01 |
| GO:BP | GO:0000730 | DNA recombinase assembly | 1 | 3 | 5.53e-01 |
| GO:BP | GO:0048368 | lateral mesoderm development | 1 | 10 | 5.53e-01 |
| GO:BP | GO:0002248 | connective tissue replacement involved in inflammatory response wound healing | 1 | 4 | 5.53e-01 |
| GO:BP | GO:0034471 | ncRNA 5’-end processing | 1 | 5 | 5.53e-01 |
| GO:BP | GO:0008582 | regulation of synaptic assembly at neuromuscular junction | 1 | 4 | 5.53e-01 |
| GO:BP | GO:0090735 | DNA repair complex assembly | 1 | 3 | 5.53e-01 |
| GO:BP | GO:0090200 | positive regulation of release of cytochrome c from mitochondria | 1 | 23 | 5.53e-01 |
| GO:BP | GO:0048873 | homeostasis of number of cells within a tissue | 1 | 24 | 5.53e-01 |
| GO:BP | GO:0000472 | endonucleolytic cleavage to generate mature 5’-end of SSU-rRNA from (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 1 | 5 | 5.53e-01 |
| GO:BP | GO:0006699 | bile acid biosynthetic process | 1 | 25 | 5.53e-01 |
| GO:BP | GO:0006475 | internal protein amino acid acetylation | 3 | 150 | 5.53e-01 |
| GO:BP | GO:0009185 | ribonucleoside diphosphate metabolic process | 1 | 27 | 5.53e-01 |
| GO:BP | GO:0055011 | atrial cardiac muscle cell differentiation | 1 | 3 | 5.53e-01 |
| GO:BP | GO:1901534 | positive regulation of hematopoietic progenitor cell differentiation | 1 | 6 | 5.53e-01 |
| GO:BP | GO:0010762 | regulation of fibroblast migration | 5 | 37 | 5.53e-01 |
| GO:BP | GO:0055014 | atrial cardiac muscle cell development | 1 | 3 | 5.53e-01 |
| GO:BP | GO:1990089 | response to nerve growth factor | 5 | 41 | 5.53e-01 |
| GO:BP | GO:0003433 | chondrocyte development involved in endochondral bone morphogenesis | 1 | 6 | 5.53e-01 |
| GO:BP | GO:0006623 | protein targeting to vacuole | 8 | 42 | 5.53e-01 |
| GO:BP | GO:0015074 | DNA integration | 2 | 9 | 5.53e-01 |
| GO:BP | GO:0035137 | hindlimb morphogenesis | 3 | 20 | 5.53e-01 |
| GO:BP | GO:0030048 | actin filament-based movement | 3 | 112 | 5.53e-01 |
| GO:BP | GO:0090119 | vesicle-mediated cholesterol transport | 2 | 9 | 5.53e-01 |
| GO:BP | GO:0032008 | positive regulation of TOR signaling | 5 | 43 | 5.53e-01 |
| GO:BP | GO:0006110 | regulation of glycolytic process | 5 | 40 | 5.53e-01 |
| GO:BP | GO:1904779 | regulation of protein localization to centrosome | 2 | 10 | 5.54e-01 |
| GO:BP | GO:0021783 | preganglionic parasympathetic fiber development | 1 | 11 | 5.54e-01 |
| GO:BP | GO:0032011 | ARF protein signal transduction | 5 | 18 | 5.54e-01 |
| GO:BP | GO:0032012 | regulation of ARF protein signal transduction | 5 | 18 | 5.54e-01 |
| GO:BP | GO:0035148 | tube formation | 11 | 138 | 5.54e-01 |
| GO:BP | GO:1904994 | regulation of leukocyte adhesion to vascular endothelial cell | 2 | 16 | 5.54e-01 |
| GO:BP | GO:0070884 | regulation of calcineurin-NFAT signaling cascade | 4 | 32 | 5.54e-01 |
| GO:BP | GO:1904738 | vascular associated smooth muscle cell migration | 4 | 25 | 5.54e-01 |
| GO:BP | GO:0010729 | positive regulation of hydrogen peroxide biosynthetic process | 1 | 3 | 5.54e-01 |
| GO:BP | GO:0034260 | negative regulation of GTPase activity | 3 | 29 | 5.54e-01 |
| GO:BP | GO:0002344 | B cell affinity maturation | 1 | 2 | 5.54e-01 |
| GO:BP | GO:0006597 | spermine biosynthetic process | 1 | 2 | 5.54e-01 |
| GO:BP | GO:0060143 | positive regulation of syncytium formation by plasma membrane fusion | 4 | 12 | 5.54e-01 |
| GO:BP | GO:0002332 | transitional stage B cell differentiation | 1 | 2 | 5.54e-01 |
| GO:BP | GO:2001241 | positive regulation of extrinsic apoptotic signaling pathway in absence of ligand | 1 | 10 | 5.54e-01 |
| GO:BP | GO:0048671 | negative regulation of collateral sprouting | 2 | 9 | 5.54e-01 |
| GO:BP | GO:1905719 | protein localization to perinuclear region of cytoplasm | 1 | 8 | 5.54e-01 |
| GO:BP | GO:0002343 | peripheral B cell selection | 1 | 2 | 5.54e-01 |
| GO:BP | GO:0007519 | skeletal muscle tissue development | 22 | 129 | 5.54e-01 |
| GO:BP | GO:0018394 | peptidyl-lysine acetylation | 8 | 160 | 5.54e-01 |
| GO:BP | GO:1904219 | positive regulation of CDP-diacylglycerol-serine O-phosphatidyltransferase activity | 1 | 2 | 5.54e-01 |
| GO:BP | GO:1904217 | regulation of CDP-diacylglycerol-serine O-phosphatidyltransferase activity | 1 | 2 | 5.54e-01 |
| GO:BP | GO:1904222 | positive regulation of serine C-palmitoyltransferase activity | 1 | 2 | 5.54e-01 |
| GO:BP | GO:0034155 | regulation of toll-like receptor 7 signaling pathway | 1 | 2 | 5.54e-01 |
| GO:BP | GO:2000446 | regulation of macrophage migration inhibitory factor signaling pathway | 1 | 3 | 5.54e-01 |
| GO:BP | GO:0035691 | macrophage migration inhibitory factor signaling pathway | 1 | 3 | 5.54e-01 |
| GO:BP | GO:0006406 | mRNA export from nucleus | 11 | 59 | 5.54e-01 |
| GO:BP | GO:0061339 | establishment or maintenance of monopolar cell polarity | 3 | 20 | 5.55e-01 |
| GO:BP | GO:0045989 | positive regulation of striated muscle contraction | 1 | 12 | 5.55e-01 |
| GO:BP | GO:0010575 | positive regulation of vascular endothelial growth factor production | 1 | 18 | 5.55e-01 |
| GO:BP | GO:0061718 | glucose catabolic process to pyruvate | 1 | 15 | 5.55e-01 |
| GO:BP | GO:0098930 | axonal transport | 6 | 60 | 5.55e-01 |
| GO:BP | GO:0008361 | regulation of cell size | 16 | 159 | 5.55e-01 |
| GO:BP | GO:0030097 | hemopoiesis | 1 | 656 | 5.55e-01 |
| GO:BP | GO:0045604 | regulation of epidermal cell differentiation | 1 | 39 | 5.55e-01 |
| GO:BP | GO:0035023 | regulation of Rho protein signal transduction | 4 | 71 | 5.55e-01 |
| GO:BP | GO:0045598 | regulation of fat cell differentiation | 13 | 102 | 5.55e-01 |
| GO:BP | GO:0061621 | canonical glycolysis | 1 | 15 | 5.55e-01 |
| GO:BP | GO:0090263 | positive regulation of canonical Wnt signaling pathway | 3 | 91 | 5.55e-01 |
| GO:BP | GO:0018146 | keratan sulfate biosynthetic process | 2 | 13 | 5.55e-01 |
| GO:BP | GO:0035329 | hippo signaling | 8 | 41 | 5.55e-01 |
| GO:BP | GO:0009127 | purine nucleoside monophosphate biosynthetic process | 4 | 21 | 5.55e-01 |
| GO:BP | GO:0006735 | NADH regeneration | 1 | 15 | 5.55e-01 |
| GO:BP | GO:0003330 | regulation of extracellular matrix constituent secretion | 2 | 7 | 5.55e-01 |
| GO:BP | GO:0048630 | skeletal muscle tissue growth | 2 | 8 | 5.55e-01 |
| GO:BP | GO:1990481 | mRNA pseudouridine synthesis | 1 | 9 | 5.55e-01 |
| GO:BP | GO:0018210 | peptidyl-threonine modification | 11 | 104 | 5.55e-01 |
| GO:BP | GO:0071695 | anatomical structure maturation | 2 | 48 | 5.55e-01 |
| GO:BP | GO:0008544 | epidermis development | 4 | 210 | 5.55e-01 |
| GO:BP | GO:1990401 | embryonic lung development | 1 | 1 | 5.55e-01 |
| GO:BP | GO:0098609 | cell-cell adhesion | 1 | 609 | 5.55e-01 |
| GO:BP | GO:0010512 | negative regulation of phosphatidylinositol biosynthetic process | 1 | 2 | 5.55e-01 |
| GO:BP | GO:1902686 | mitochondrial outer membrane permeabilization involved in programmed cell death | 6 | 40 | 5.55e-01 |
| GO:BP | GO:0070286 | axonemal dynein complex assembly | 1 | 20 | 5.55e-01 |
| GO:BP | GO:0006047 | UDP-N-acetylglucosamine metabolic process | 3 | 13 | 5.55e-01 |
| GO:BP | GO:0061462 | protein localization to lysosome | 1 | 46 | 5.55e-01 |
| GO:BP | GO:0019221 | cytokine-mediated signaling pathway | 1 | 274 | 5.55e-01 |
| GO:BP | GO:0038180 | nerve growth factor signaling pathway | 1 | 10 | 5.55e-01 |
| GO:BP | GO:0014888 | striated muscle adaptation | 7 | 40 | 5.55e-01 |
| GO:BP | GO:0071362 | cellular response to ether | 1 | 5 | 5.55e-01 |
| GO:BP | GO:0015780 | nucleotide-sugar transmembrane transport | 3 | 13 | 5.55e-01 |
| GO:BP | GO:0097284 | hepatocyte apoptotic process | 3 | 17 | 5.55e-01 |
| GO:BP | GO:0071888 | macrophage apoptotic process | 1 | 9 | 5.55e-01 |
| GO:BP | GO:0021819 | layer formation in cerebral cortex | 2 | 12 | 5.55e-01 |
| GO:BP | GO:0040018 | positive regulation of multicellular organism growth | 1 | 22 | 5.56e-01 |
| GO:BP | GO:0060603 | mammary gland duct morphogenesis | 1 | 28 | 5.56e-01 |
| GO:BP | GO:0120035 | regulation of plasma membrane bounded cell projection organization | 1 | 529 | 5.56e-01 |
| GO:BP | GO:2001236 | regulation of extrinsic apoptotic signaling pathway | 13 | 123 | 5.56e-01 |
| GO:BP | GO:0019318 | hexose metabolic process | 11 | 185 | 5.56e-01 |
| GO:BP | GO:0070544 | histone H3-K36 demethylation | 1 | 5 | 5.56e-01 |
| GO:BP | GO:0008284 | positive regulation of cell population proliferation | 1 | 631 | 5.56e-01 |
| GO:BP | GO:0010499 | proteasomal ubiquitin-independent protein catabolic process | 1 | 3 | 5.57e-01 |
| GO:BP | GO:0140115 | export across plasma membrane | 1 | 46 | 5.57e-01 |
| GO:BP | GO:0015909 | long-chain fatty acid transport | 2 | 38 | 5.57e-01 |
| GO:BP | GO:0014013 | regulation of gliogenesis | 4 | 68 | 5.58e-01 |
| GO:BP | GO:0040029 | epigenetic regulation of gene expression | 4 | 153 | 5.58e-01 |
| GO:BP | GO:0072229 | metanephric proximal convoluted tubule development | 1 | 2 | 5.58e-01 |
| GO:BP | GO:0072019 | proximal convoluted tubule development | 1 | 2 | 5.58e-01 |
| GO:BP | GO:0097150 | neuronal stem cell population maintenance | 1 | 21 | 5.58e-01 |
| GO:BP | GO:0070828 | heterochromatin organization | 7 | 77 | 5.58e-01 |
| GO:BP | GO:0035590 | purinergic nucleotide receptor signaling pathway | 2 | 16 | 5.58e-01 |
| GO:BP | GO:0007173 | epidermal growth factor receptor signaling pathway | 10 | 93 | 5.58e-01 |
| GO:BP | GO:0140053 | mitochondrial gene expression | 3 | 162 | 5.59e-01 |
| GO:BP | GO:0015822 | ornithine transport | 1 | 5 | 5.60e-01 |
| GO:BP | GO:0036003 | positive regulation of transcription from RNA polymerase II promoter in response to stress | 3 | 18 | 5.60e-01 |
| GO:BP | GO:1901137 | carbohydrate derivative biosynthetic process | 3 | 544 | 5.60e-01 |
| GO:BP | GO:0051608 | histamine transport | 1 | 11 | 5.60e-01 |
| GO:BP | GO:0045728 | respiratory burst after phagocytosis | 1 | 2 | 5.60e-01 |
| GO:BP | GO:1901740 | negative regulation of myoblast fusion | 1 | 2 | 5.60e-01 |
| GO:BP | GO:0003018 | vascular process in circulatory system | 1 | 198 | 5.60e-01 |
| GO:BP | GO:0014741 | negative regulation of muscle hypertrophy | 2 | 27 | 5.61e-01 |
| GO:BP | GO:0044778 | meiotic DNA integrity checkpoint signaling | 1 | 1 | 5.61e-01 |
| GO:BP | GO:0031401 | positive regulation of protein modification process | 1 | 719 | 5.61e-01 |
| GO:BP | GO:0071481 | cellular response to X-ray | 2 | 10 | 5.61e-01 |
| GO:BP | GO:0046839 | phospholipid dephosphorylation | 1 | 39 | 5.61e-01 |
| GO:BP | GO:0045453 | bone resorption | 3 | 40 | 5.61e-01 |
| GO:BP | GO:2000303 | regulation of ceramide biosynthetic process | 2 | 11 | 5.61e-01 |
| GO:BP | GO:0031344 | regulation of cell projection organization | 1 | 541 | 5.61e-01 |
| GO:BP | GO:0017157 | regulation of exocytosis | 1 | 147 | 5.61e-01 |
| GO:BP | GO:0046629 | gamma-delta T cell activation | 1 | 9 | 5.61e-01 |
| GO:BP | GO:0014856 | skeletal muscle cell proliferation | 4 | 14 | 5.61e-01 |
| GO:BP | GO:0051096 | positive regulation of helicase activity | 2 | 7 | 5.61e-01 |
| GO:BP | GO:0006164 | purine nucleotide biosynthetic process | 1 | 209 | 5.61e-01 |
| GO:BP | GO:0098901 | regulation of cardiac muscle cell action potential | 1 | 30 | 5.61e-01 |
| GO:BP | GO:1903347 | negative regulation of bicellular tight junction assembly | 1 | 3 | 5.61e-01 |
| GO:BP | GO:0014734 | skeletal muscle hypertrophy | 1 | 1 | 5.61e-01 |
| GO:BP | GO:1905214 | regulation of RNA binding | 2 | 13 | 5.61e-01 |
| GO:BP | GO:1903899 | positive regulation of PERK-mediated unfolded protein response | 1 | 3 | 5.61e-01 |
| GO:BP | GO:0008089 | anterograde axonal transport | 2 | 45 | 5.61e-01 |
| GO:BP | GO:1905462 | regulation of DNA duplex unwinding | 2 | 7 | 5.61e-01 |
| GO:BP | GO:0038020 | insulin receptor recycling | 1 | 4 | 5.61e-01 |
| GO:BP | GO:1902202 | regulation of hepatocyte growth factor receptor signaling pathway | 1 | 3 | 5.61e-01 |
| GO:BP | GO:0003383 | apical constriction | 1 | 4 | 5.61e-01 |
| GO:BP | GO:0060485 | mesenchyme development | 2 | 249 | 5.61e-01 |
| GO:BP | GO:0031056 | regulation of histone modification | 20 | 125 | 5.61e-01 |
| GO:BP | GO:0032515 | negative regulation of phosphoprotein phosphatase activity | 1 | 21 | 5.61e-01 |
| GO:BP | GO:0007028 | cytoplasm organization | 1 | 8 | 5.61e-01 |
| GO:BP | GO:0070244 | negative regulation of thymocyte apoptotic process | 2 | 6 | 5.61e-01 |
| GO:BP | GO:0006639 | acylglycerol metabolic process | 1 | 92 | 5.61e-01 |
| GO:BP | GO:0000902 | cell morphogenesis | 1 | 761 | 5.61e-01 |
| GO:BP | GO:0072077 | renal vesicle morphogenesis | 2 | 14 | 5.61e-01 |
| GO:BP | GO:0035025 | positive regulation of Rho protein signal transduction | 2 | 22 | 5.61e-01 |
| GO:BP | GO:0018198 | peptidyl-cysteine modification | 2 | 41 | 5.61e-01 |
| GO:BP | GO:0031999 | negative regulation of fatty acid beta-oxidation | 1 | 5 | 5.61e-01 |
| GO:BP | GO:0039534 | negative regulation of MDA-5 signaling pathway | 1 | 3 | 5.61e-01 |
| GO:BP | GO:0032058 | positive regulation of translational initiation in response to stress | 1 | 4 | 5.61e-01 |
| GO:BP | GO:1903201 | regulation of oxidative stress-induced cell death | 1 | 56 | 5.61e-01 |
| GO:BP | GO:0048599 | oocyte development | 11 | 38 | 5.61e-01 |
| GO:BP | GO:0034145 | positive regulation of toll-like receptor 4 signaling pathway | 1 | 7 | 5.61e-01 |
| GO:BP | GO:0043173 | nucleotide salvage | 3 | 15 | 5.61e-01 |
| GO:BP | GO:0003307 | regulation of Wnt signaling pathway involved in heart development | 2 | 7 | 5.61e-01 |
| GO:BP | GO:0045778 | positive regulation of ossification | 9 | 40 | 5.61e-01 |
| GO:BP | GO:0051987 | positive regulation of attachment of spindle microtubules to kinetochore | 1 | 11 | 5.61e-01 |
| GO:BP | GO:2000676 | positive regulation of type B pancreatic cell apoptotic process | 1 | 2 | 5.62e-01 |
| GO:BP | GO:0006638 | neutral lipid metabolic process | 1 | 93 | 5.62e-01 |
| GO:BP | GO:0042423 | catecholamine biosynthetic process | 1 | 11 | 5.62e-01 |
| GO:BP | GO:0009713 | catechol-containing compound biosynthetic process | 1 | 11 | 5.62e-01 |
| GO:BP | GO:2000738 | positive regulation of stem cell differentiation | 1 | 17 | 5.62e-01 |
| GO:BP | GO:0061013 | regulation of mRNA catabolic process | 28 | 161 | 5.62e-01 |
| GO:BP | GO:1905039 | carboxylic acid transmembrane transport | 10 | 118 | 5.62e-01 |
| GO:BP | GO:0140889 | DNA replication-dependent chromatin disassembly | 1 | 3 | 5.62e-01 |
| GO:BP | GO:0048646 | anatomical structure formation involved in morphogenesis | 6 | 870 | 5.62e-01 |
| GO:BP | GO:0097178 | ruffle assembly | 2 | 37 | 5.62e-01 |
| GO:BP | GO:0090297 | positive regulation of mitochondrial DNA replication | 1 | 2 | 5.62e-01 |
| GO:BP | GO:0046104 | thymidine metabolic process | 1 | 5 | 5.62e-01 |
| GO:BP | GO:1903934 | positive regulation of DNA primase activity | 1 | 5 | 5.62e-01 |
| GO:BP | GO:0072138 | mesenchymal cell proliferation involved in ureteric bud development | 1 | 3 | 5.62e-01 |
| GO:BP | GO:0110032 | positive regulation of G2/MI transition of meiotic cell cycle | 1 | 3 | 5.62e-01 |
| GO:BP | GO:0003130 | BMP signaling pathway involved in heart induction | 1 | 2 | 5.62e-01 |
| GO:BP | GO:0001938 | positive regulation of endothelial cell proliferation | 2 | 74 | 5.62e-01 |
| GO:BP | GO:0003134 | endodermal-mesodermal cell signaling involved in heart induction | 1 | 2 | 5.62e-01 |
| GO:BP | GO:0003133 | endodermal-mesodermal cell signaling | 1 | 2 | 5.62e-01 |
| GO:BP | GO:0016082 | synaptic vesicle priming | 1 | 16 | 5.62e-01 |
| GO:BP | GO:1902292 | cell cycle DNA replication initiation | 1 | 5 | 5.62e-01 |
| GO:BP | GO:0090224 | regulation of spindle organization | 5 | 45 | 5.62e-01 |
| GO:BP | GO:1905072 | cardiac jelly development | 1 | 3 | 5.62e-01 |
| GO:BP | GO:1903932 | regulation of DNA primase activity | 1 | 5 | 5.62e-01 |
| GO:BP | GO:0019626 | short-chain fatty acid catabolic process | 1 | 6 | 5.62e-01 |
| GO:BP | GO:1902990 | mitotic telomere maintenance via semi-conservative replication | 1 | 2 | 5.62e-01 |
| GO:BP | GO:0060128 | corticotropin hormone secreting cell differentiation | 1 | 2 | 5.62e-01 |
| GO:BP | GO:1902975 | mitotic DNA replication initiation | 1 | 5 | 5.62e-01 |
| GO:BP | GO:0060710 | chorio-allantoic fusion | 2 | 6 | 5.62e-01 |
| GO:BP | GO:0007167 | enzyme-linked receptor protein signaling pathway | 1 | 763 | 5.62e-01 |
| GO:BP | GO:1900159 | positive regulation of bone mineralization involved in bone maturation | 1 | 2 | 5.62e-01 |
| GO:BP | GO:0010801 | negative regulation of peptidyl-threonine phosphorylation | 1 | 15 | 5.62e-01 |
| GO:BP | GO:0031175 | neuron projection development | 1 | 780 | 5.62e-01 |
| GO:BP | GO:1904977 | lymphatic endothelial cell migration | 1 | 3 | 5.62e-01 |
| GO:BP | GO:0106056 | regulation of calcineurin-mediated signaling | 4 | 32 | 5.62e-01 |
| GO:BP | GO:0045216 | cell-cell junction organization | 5 | 153 | 5.62e-01 |
| GO:BP | GO:0046125 | pyrimidine deoxyribonucleoside metabolic process | 1 | 5 | 5.62e-01 |
| GO:BP | GO:1902315 | nuclear cell cycle DNA replication initiation | 1 | 5 | 5.62e-01 |
| GO:BP | GO:0032703 | negative regulation of interleukin-2 production | 2 | 10 | 5.62e-01 |
| GO:BP | GO:0043009 | chordate embryonic development | 2 | 534 | 5.62e-01 |
| GO:BP | GO:0060294 | cilium movement involved in cell motility | 5 | 69 | 5.63e-01 |
| GO:BP | GO:2000565 | negative regulation of CD8-positive, alpha-beta T cell proliferation | 1 | 2 | 5.63e-01 |
| GO:BP | GO:1902533 | positive regulation of intracellular signal transduction | 1 | 726 | 5.63e-01 |
| GO:BP | GO:1904029 | regulation of cyclin-dependent protein kinase activity | 18 | 88 | 5.64e-01 |
| GO:BP | GO:0014033 | neural crest cell differentiation | 1 | 80 | 5.64e-01 |
| GO:BP | GO:0021872 | forebrain generation of neurons | 2 | 29 | 5.64e-01 |
| GO:BP | GO:0052150 | modulation by symbiont of host apoptotic process | 1 | 3 | 5.64e-01 |
| GO:BP | GO:0039526 | modulation by virus of host apoptotic process | 1 | 3 | 5.64e-01 |
| GO:BP | GO:0120163 | negative regulation of cold-induced thermogenesis | 1 | 40 | 5.64e-01 |
| GO:BP | GO:0046653 | tetrahydrofolate metabolic process | 2 | 14 | 5.64e-01 |
| GO:BP | GO:0009164 | nucleoside catabolic process | 4 | 15 | 5.64e-01 |
| GO:BP | GO:0052040 | modulation by symbiont of host programmed cell death | 1 | 3 | 5.64e-01 |
| GO:BP | GO:0006596 | polyamine biosynthetic process | 1 | 13 | 5.64e-01 |
| GO:BP | GO:0003290 | atrial septum secundum morphogenesis | 1 | 2 | 5.65e-01 |
| GO:BP | GO:0099638 | endosome to plasma membrane protein transport | 3 | 15 | 5.65e-01 |
| GO:BP | GO:0051851 | modulation by host of symbiont process | 1 | 68 | 5.65e-01 |
| GO:BP | GO:0051248 | negative regulation of protein metabolic process | 1 | 816 | 5.65e-01 |
| GO:BP | GO:0016577 | histone demethylation | 3 | 21 | 5.65e-01 |
| GO:BP | GO:0051284 | positive regulation of sequestering of calcium ion | 1 | 13 | 5.65e-01 |
| GO:BP | GO:0014004 | microglia differentiation | 2 | 6 | 5.65e-01 |
| GO:BP | GO:0072522 | purine-containing compound biosynthetic process | 1 | 218 | 5.65e-01 |
| GO:BP | GO:0051293 | establishment of spindle localization | 3 | 48 | 5.65e-01 |
| GO:BP | GO:0032967 | positive regulation of collagen biosynthetic process | 1 | 23 | 5.65e-01 |
| GO:BP | GO:0051666 | actin cortical patch localization | 1 | 2 | 5.65e-01 |
| GO:BP | GO:0030316 | osteoclast differentiation | 2 | 66 | 5.65e-01 |
| GO:BP | GO:0045907 | positive regulation of vasoconstriction | 1 | 15 | 5.65e-01 |
| GO:BP | GO:1904893 | negative regulation of receptor signaling pathway via STAT | 3 | 21 | 5.65e-01 |
| GO:BP | GO:0045822 | negative regulation of heart contraction | 1 | 17 | 5.66e-01 |
| GO:BP | GO:0032891 | negative regulation of organic acid transport | 1 | 17 | 5.66e-01 |
| GO:BP | GO:0042745 | circadian sleep/wake cycle | 1 | 11 | 5.66e-01 |
| GO:BP | GO:0050961 | detection of temperature stimulus involved in sensory perception | 1 | 12 | 5.66e-01 |
| GO:BP | GO:0090611 | ubiquitin-independent protein catabolic process via the multivesicular body sorting pathway | 1 | 5 | 5.66e-01 |
| GO:BP | GO:0045321 | leukocyte activation | 1 | 554 | 5.66e-01 |
| GO:BP | GO:1903825 | organic acid transmembrane transport | 10 | 119 | 5.66e-01 |
| GO:BP | GO:0070988 | demethylation | 3 | 52 | 5.66e-01 |
| GO:BP | GO:0036211 | protein modification process | 1 | 2901 | 5.66e-01 |
| GO:BP | GO:2000537 | regulation of B cell chemotaxis | 1 | 1 | 5.66e-01 |
| GO:BP | GO:0050849 | negative regulation of calcium-mediated signaling | 3 | 15 | 5.66e-01 |
| GO:BP | GO:0003416 | endochondral bone growth | 6 | 23 | 5.66e-01 |
| GO:BP | GO:0010890 | positive regulation of sequestering of triglyceride | 2 | 7 | 5.66e-01 |
| GO:BP | GO:2000538 | positive regulation of B cell chemotaxis | 1 | 1 | 5.66e-01 |
| GO:BP | GO:1903937 | response to acrylamide | 1 | 1 | 5.66e-01 |
| GO:BP | GO:0045976 | negative regulation of mitotic cell cycle, embryonic | 1 | 2 | 5.66e-01 |
| GO:BP | GO:0007530 | sex determination | 2 | 12 | 5.66e-01 |
| GO:BP | GO:0055003 | cardiac myofibril assembly | 1 | 19 | 5.66e-01 |
| GO:BP | GO:0031114 | regulation of microtubule depolymerization | 4 | 31 | 5.66e-01 |
| GO:BP | GO:0043096 | purine nucleobase salvage | 1 | 3 | 5.66e-01 |
| GO:BP | GO:0046090 | deoxyadenosine metabolic process | 1 | 2 | 5.66e-01 |
| GO:BP | GO:0006157 | deoxyadenosine catabolic process | 1 | 2 | 5.66e-01 |
| GO:BP | GO:0046101 | hypoxanthine biosynthetic process | 1 | 3 | 5.66e-01 |
| GO:BP | GO:0046103 | inosine biosynthetic process | 1 | 3 | 5.66e-01 |
| GO:BP | GO:0031060 | regulation of histone methylation | 11 | 47 | 5.66e-01 |
| GO:BP | GO:0033617 | mitochondrial cytochrome c oxidase assembly | 5 | 25 | 5.66e-01 |
| GO:BP | GO:0080182 | histone H3-K4 trimethylation | 2 | 16 | 5.67e-01 |
| GO:BP | GO:0045141 | meiotic telomere clustering | 1 | 5 | 5.67e-01 |
| GO:BP | GO:0070670 | response to interleukin-4 | 4 | 22 | 5.67e-01 |
| GO:BP | GO:0051409 | response to nitrosative stress | 1 | 10 | 5.67e-01 |
| GO:BP | GO:0002756 | MyD88-independent toll-like receptor signaling pathway | 1 | 8 | 5.67e-01 |
| GO:BP | GO:0046320 | regulation of fatty acid oxidation | 3 | 31 | 5.68e-01 |
| GO:BP | GO:0001525 | angiogenesis | 7 | 390 | 5.68e-01 |
| GO:BP | GO:0001682 | tRNA 5’-leader removal | 3 | 13 | 5.68e-01 |
| GO:BP | GO:0014883 | transition between fast and slow fiber | 1 | 7 | 5.68e-01 |
| GO:BP | GO:0021801 | cerebral cortex radial glia-guided migration | 3 | 22 | 5.68e-01 |
| GO:BP | GO:0042667 | auditory receptor cell fate specification | 1 | 1 | 5.68e-01 |
| GO:BP | GO:0035773 | insulin secretion involved in cellular response to glucose stimulus | 11 | 49 | 5.68e-01 |
| GO:BP | GO:0001946 | lymphangiogenesis | 1 | 12 | 5.68e-01 |
| GO:BP | GO:0022030 | telencephalon glial cell migration | 3 | 22 | 5.68e-01 |
| GO:BP | GO:1903506 | regulation of nucleic acid-templated transcription | 2 | 2576 | 5.68e-01 |
| GO:BP | GO:0006355 | regulation of DNA-templated transcription | 2 | 2574 | 5.68e-01 |
| GO:BP | GO:0007178 | transmembrane receptor protein serine/threonine kinase signaling pathway | 25 | 303 | 5.68e-01 |
| GO:BP | GO:0002053 | positive regulation of mesenchymal cell proliferation | 2 | 18 | 5.68e-01 |
| GO:BP | GO:0034465 | response to carbon monoxide | 1 | 3 | 5.68e-01 |
| GO:BP | GO:0007019 | microtubule depolymerization | 4 | 43 | 5.68e-01 |
| GO:BP | GO:1903651 | positive regulation of cytoplasmic transport | 2 | 11 | 5.68e-01 |
| GO:BP | GO:0017196 | N-terminal peptidyl-methionine acetylation | 1 | 8 | 5.68e-01 |
| GO:BP | GO:1903170 | negative regulation of calcium ion transmembrane transport | 2 | 35 | 5.68e-01 |
| GO:BP | GO:0022612 | gland morphogenesis | 3 | 98 | 5.68e-01 |
| GO:BP | GO:0006278 | RNA-templated DNA biosynthetic process | 6 | 64 | 5.68e-01 |
| GO:BP | GO:0016052 | carbohydrate catabolic process | 7 | 120 | 5.68e-01 |
| GO:BP | GO:0097210 | response to gonadotropin-releasing hormone | 1 | 4 | 5.68e-01 |
| GO:BP | GO:1900195 | positive regulation of oocyte maturation | 1 | 3 | 5.68e-01 |
| GO:BP | GO:0071786 | endoplasmic reticulum tubular network organization | 1 | 19 | 5.68e-01 |
| GO:BP | GO:0014841 | skeletal muscle satellite cell proliferation | 3 | 10 | 5.68e-01 |
| GO:BP | GO:0006432 | phenylalanyl-tRNA aminoacylation | 1 | 4 | 5.68e-01 |
| GO:BP | GO:0070918 | regulatory ncRNA processing | 1 | 47 | 5.68e-01 |
| GO:BP | GO:0045645 | positive regulation of eosinophil differentiation | 1 | 1 | 5.68e-01 |
| GO:BP | GO:0045643 | regulation of eosinophil differentiation | 1 | 1 | 5.68e-01 |
| GO:BP | GO:0046825 | regulation of protein export from nucleus | 5 | 30 | 5.68e-01 |
| GO:BP | GO:0098884 | postsynaptic neurotransmitter receptor internalization | 2 | 17 | 5.68e-01 |
| GO:BP | GO:0050673 | epithelial cell proliferation | 24 | 323 | 5.68e-01 |
| GO:BP | GO:0000079 | regulation of cyclin-dependent protein serine/threonine kinase activity | 11 | 85 | 5.68e-01 |
| GO:BP | GO:0045659 | negative regulation of neutrophil differentiation | 1 | 2 | 5.68e-01 |
| GO:BP | GO:0031668 | cellular response to extracellular stimulus | 22 | 219 | 5.68e-01 |
| GO:BP | GO:0061418 | regulation of transcription from RNA polymerase II promoter in response to hypoxia | 2 | 11 | 5.68e-01 |
| GO:BP | GO:0019627 | urea metabolic process | 2 | 7 | 5.68e-01 |
| GO:BP | GO:0034248 | regulation of amide metabolic process | 65 | 424 | 5.68e-01 |
| GO:BP | GO:1904749 | regulation of protein localization to nucleolus | 1 | 7 | 5.68e-01 |
| GO:BP | GO:0140239 | postsynaptic endocytosis | 2 | 17 | 5.68e-01 |
| GO:BP | GO:0071941 | nitrogen cycle metabolic process | 2 | 7 | 5.68e-01 |
| GO:BP | GO:0110110 | positive regulation of animal organ morphogenesis | 1 | 26 | 5.69e-01 |
| GO:BP | GO:2001141 | regulation of RNA biosynthetic process | 2 | 2593 | 5.70e-01 |
| GO:BP | GO:0030953 | astral microtubule organization | 1 | 11 | 5.70e-01 |
| GO:BP | GO:0072697 | protein localization to cell cortex | 1 | 10 | 5.70e-01 |
| GO:BP | GO:1902019 | regulation of cilium-dependent cell motility | 3 | 12 | 5.70e-01 |
| GO:BP | GO:0060295 | regulation of cilium movement involved in cell motility | 3 | 12 | 5.70e-01 |
| GO:BP | GO:0060390 | regulation of SMAD protein signal transduction | 3 | 27 | 5.70e-01 |
| GO:BP | GO:0071036 | nuclear polyadenylation-dependent snoRNA catabolic process | 1 | 2 | 5.70e-01 |
| GO:BP | GO:0048210 | Golgi vesicle fusion to target membrane | 1 | 4 | 5.70e-01 |
| GO:BP | GO:0032781 | positive regulation of ATP-dependent activity | 8 | 40 | 5.70e-01 |
| GO:BP | GO:0060033 | anatomical structure regression | 1 | 11 | 5.70e-01 |
| GO:BP | GO:1903312 | negative regulation of mRNA metabolic process | 1 | 81 | 5.70e-01 |
| GO:BP | GO:2000105 | positive regulation of DNA-templated DNA replication | 3 | 13 | 5.70e-01 |
| GO:BP | GO:0061939 | c-di-GMP signaling | 1 | 1 | 5.70e-01 |
| GO:BP | GO:0007021 | tubulin complex assembly | 1 | 9 | 5.70e-01 |
| GO:BP | GO:0006006 | glucose metabolic process | 9 | 151 | 5.70e-01 |
| GO:BP | GO:0051000 | positive regulation of nitric-oxide synthase activity | 2 | 14 | 5.70e-01 |
| GO:BP | GO:0071037 | nuclear polyadenylation-dependent snRNA catabolic process | 1 | 2 | 5.70e-01 |
| GO:BP | GO:0009792 | embryo development ending in birth or egg hatching | 2 | 551 | 5.70e-01 |
| GO:BP | GO:0001549 | cumulus cell differentiation | 1 | 1 | 5.70e-01 |
| GO:BP | GO:0048486 | parasympathetic nervous system development | 1 | 12 | 5.70e-01 |
| GO:BP | GO:1905259 | negative regulation of nitrosative stress-induced intrinsic apoptotic signaling pathway | 1 | 2 | 5.70e-01 |
| GO:BP | GO:0060466 | activation of meiosis involved in egg activation | 1 | 2 | 5.70e-01 |
| GO:BP | GO:0003229 | ventricular cardiac muscle tissue development | 2 | 52 | 5.70e-01 |
| GO:BP | GO:0045765 | regulation of angiogenesis | 1 | 203 | 5.70e-01 |
| GO:BP | GO:0071039 | nuclear polyadenylation-dependent CUT catabolic process | 1 | 2 | 5.70e-01 |
| GO:BP | GO:0097692 | histone H3-K4 monomethylation | 1 | 8 | 5.70e-01 |
| GO:BP | GO:1905258 | regulation of nitrosative stress-induced intrinsic apoptotic signaling pathway | 1 | 2 | 5.70e-01 |
| GO:BP | GO:0045648 | positive regulation of erythrocyte differentiation | 1 | 27 | 5.70e-01 |
| GO:BP | GO:0006554 | lysine catabolic process | 1 | 6 | 5.70e-01 |
| GO:BP | GO:0010714 | positive regulation of collagen metabolic process | 1 | 24 | 5.70e-01 |
| GO:BP | GO:0006672 | ceramide metabolic process | 3 | 80 | 5.71e-01 |
| GO:BP | GO:0009051 | pentose-phosphate shunt, oxidative branch | 1 | 4 | 5.71e-01 |
| GO:BP | GO:0006659 | phosphatidylserine biosynthetic process | 1 | 4 | 5.71e-01 |
| GO:BP | GO:0018107 | peptidyl-threonine phosphorylation | 10 | 97 | 5.71e-01 |
| GO:BP | GO:0043970 | histone H3-K9 acetylation | 2 | 8 | 5.71e-01 |
| GO:BP | GO:0018282 | metal incorporation into metallo-sulfur cluster | 1 | 2 | 5.71e-01 |
| GO:BP | GO:0090505 | epiboly involved in wound healing | 1 | 30 | 5.71e-01 |
| GO:BP | GO:0045682 | regulation of epidermis development | 1 | 45 | 5.71e-01 |
| GO:BP | GO:0017148 | negative regulation of translation | 26 | 165 | 5.71e-01 |
| GO:BP | GO:0018283 | iron incorporation into metallo-sulfur cluster | 1 | 2 | 5.71e-01 |
| GO:BP | GO:0001837 | epithelial to mesenchymal transition | 4 | 138 | 5.71e-01 |
| GO:BP | GO:1903523 | negative regulation of blood circulation | 1 | 18 | 5.71e-01 |
| GO:BP | GO:0044319 | wound healing, spreading of cells | 1 | 30 | 5.71e-01 |
| GO:BP | GO:0042727 | flavin-containing compound biosynthetic process | 1 | 2 | 5.71e-01 |
| GO:BP | GO:0021766 | hippocampus development | 1 | 62 | 5.71e-01 |
| GO:BP | GO:0045932 | negative regulation of muscle contraction | 1 | 20 | 5.71e-01 |
| GO:BP | GO:0032897 | negative regulation of viral transcription | 1 | 15 | 5.71e-01 |
| GO:BP | GO:0001188 | RNA polymerase I preinitiation complex assembly | 2 | 9 | 5.71e-01 |
| GO:BP | GO:0031329 | regulation of cellular catabolic process | 51 | 555 | 5.71e-01 |
| GO:BP | GO:0007182 | common-partner SMAD protein phosphorylation | 1 | 6 | 5.71e-01 |
| GO:BP | GO:0030578 | PML body organization | 1 | 6 | 5.71e-01 |
| GO:BP | GO:0000290 | deadenylation-dependent decapping of nuclear-transcribed mRNA | 1 | 9 | 5.71e-01 |
| GO:BP | GO:0097264 | self proteolysis | 1 | 7 | 5.71e-01 |
| GO:BP | GO:0061038 | uterus morphogenesis | 1 | 5 | 5.71e-01 |
| GO:BP | GO:0098597 | observational learning | 1 | 5 | 5.71e-01 |
| GO:BP | GO:0061620 | glycolytic process through glucose-6-phosphate | 1 | 17 | 5.71e-01 |
| GO:BP | GO:0031087 | deadenylation-independent decapping of nuclear-transcribed mRNA | 1 | 6 | 5.72e-01 |
| GO:BP | GO:0090335 | regulation of brown fat cell differentiation | 1 | 17 | 5.72e-01 |
| GO:BP | GO:0021997 | neural plate axis specification | 1 | 2 | 5.72e-01 |
| GO:BP | GO:0005977 | glycogen metabolic process | 4 | 64 | 5.72e-01 |
| GO:BP | GO:0010745 | negative regulation of macrophage derived foam cell differentiation | 1 | 10 | 5.72e-01 |
| GO:BP | GO:0000184 | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 5 | 39 | 5.72e-01 |
| GO:BP | GO:0010944 | negative regulation of transcription by competitive promoter binding | 2 | 8 | 5.72e-01 |
| GO:BP | GO:1901342 | regulation of vasculature development | 1 | 206 | 5.72e-01 |
| GO:BP | GO:0030157 | pancreatic juice secretion | 1 | 11 | 5.72e-01 |
| GO:BP | GO:0071314 | cellular response to cocaine | 2 | 7 | 5.73e-01 |
| GO:BP | GO:1902659 | regulation of glucose mediated signaling pathway | 1 | 3 | 5.73e-01 |
| GO:BP | GO:0051051 | negative regulation of transport | 1 | 318 | 5.73e-01 |
| GO:BP | GO:1902661 | positive regulation of glucose mediated signaling pathway | 1 | 3 | 5.73e-01 |
| GO:BP | GO:1900113 | negative regulation of histone H3-K9 trimethylation | 1 | 3 | 5.73e-01 |
| GO:BP | GO:0051298 | centrosome duplication | 8 | 68 | 5.73e-01 |
| GO:BP | GO:0090387 | phagolysosome assembly involved in apoptotic cell clearance | 1 | 2 | 5.73e-01 |
| GO:BP | GO:0070432 | regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway | 1 | 6 | 5.73e-01 |
| GO:BP | GO:0090190 | positive regulation of branching involved in ureteric bud morphogenesis | 2 | 13 | 5.73e-01 |
| GO:BP | GO:0044255 | cellular lipid metabolic process | 4 | 740 | 5.73e-01 |
| GO:BP | GO:0072087 | renal vesicle development | 2 | 15 | 5.73e-01 |
| GO:BP | GO:0007193 | adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway | 2 | 37 | 5.73e-01 |
| GO:BP | GO:0090386 | phagosome maturation involved in apoptotic cell clearance | 1 | 2 | 5.73e-01 |
| GO:BP | GO:1901532 | regulation of hematopoietic progenitor cell differentiation | 3 | 34 | 5.73e-01 |
| GO:BP | GO:0099179 | regulation of synaptic membrane adhesion | 1 | 4 | 5.73e-01 |
| GO:BP | GO:0033313 | meiotic cell cycle checkpoint signaling | 1 | 6 | 5.73e-01 |
| GO:BP | GO:0000055 | ribosomal large subunit export from nucleus | 1 | 8 | 5.73e-01 |
| GO:BP | GO:0000727 | double-strand break repair via break-induced replication | 1 | 11 | 5.73e-01 |
| GO:BP | GO:0060676 | ureteric bud formation | 1 | 5 | 5.73e-01 |
| GO:BP | GO:0043525 | positive regulation of neuron apoptotic process | 6 | 41 | 5.73e-01 |
| GO:BP | GO:0001842 | neural fold formation | 1 | 5 | 5.73e-01 |
| GO:BP | GO:0062208 | positive regulation of pattern recognition receptor signaling pathway | 3 | 27 | 5.73e-01 |
| GO:BP | GO:0042256 | cytosolic ribosome assembly | 1 | 5 | 5.73e-01 |
| GO:BP | GO:0002684 | positive regulation of immune system process | 1 | 581 | 5.73e-01 |
| GO:BP | GO:0051307 | meiotic chromosome separation | 1 | 5 | 5.73e-01 |
| GO:BP | GO:0051340 | regulation of ligase activity | 3 | 11 | 5.73e-01 |
| GO:BP | GO:1904491 | protein localization to ciliary transition zone | 2 | 7 | 5.73e-01 |
| GO:BP | GO:0032688 | negative regulation of interferon-beta production | 2 | 10 | 5.73e-01 |
| GO:BP | GO:0060306 | regulation of membrane repolarization | 1 | 28 | 5.73e-01 |
| GO:BP | GO:0001932 | regulation of protein phosphorylation | 1 | 796 | 5.73e-01 |
| GO:BP | GO:0031123 | RNA 3’-end processing | 9 | 100 | 5.73e-01 |
| GO:BP | GO:0019075 | virus maturation | 1 | 2 | 5.73e-01 |
| GO:BP | GO:0033189 | response to vitamin A | 4 | 12 | 5.74e-01 |
| GO:BP | GO:0032025 | response to cobalt ion | 1 | 10 | 5.74e-01 |
| GO:BP | GO:0030388 | fructose 1,6-bisphosphate metabolic process | 1 | 6 | 5.74e-01 |
| GO:BP | GO:0071459 | protein localization to chromosome, centromeric region | 4 | 42 | 5.74e-01 |
| GO:BP | GO:0010574 | regulation of vascular endothelial growth factor production | 1 | 20 | 5.74e-01 |
| GO:BP | GO:0035051 | cardiocyte differentiation | 4 | 129 | 5.74e-01 |
| GO:BP | GO:0070849 | response to epidermal growth factor | 4 | 44 | 5.74e-01 |
| GO:BP | GO:0060339 | negative regulation of type I interferon-mediated signaling pathway | 4 | 15 | 5.75e-01 |
| GO:BP | GO:0033688 | regulation of osteoblast proliferation | 4 | 23 | 5.75e-01 |
| GO:BP | GO:0030301 | cholesterol transport | 1 | 80 | 5.75e-01 |
| GO:BP | GO:0051179 | localization | 10 | 3969 | 5.75e-01 |
| GO:BP | GO:0060484 | lung-associated mesenchyme development | 1 | 5 | 5.75e-01 |
| GO:BP | GO:2000254 | regulation of male germ cell proliferation | 1 | 4 | 5.75e-01 |
| GO:BP | GO:0090504 | epiboly | 1 | 31 | 5.75e-01 |
| GO:BP | GO:0045947 | negative regulation of translational initiation | 2 | 18 | 5.75e-01 |
| GO:BP | GO:0010884 | positive regulation of lipid storage | 1 | 18 | 5.75e-01 |
| GO:BP | GO:1901387 | positive regulation of voltage-gated calcium channel activity | 1 | 13 | 5.75e-01 |
| GO:BP | GO:0080111 | DNA demethylation | 5 | 23 | 5.75e-01 |
| GO:BP | GO:0045746 | negative regulation of Notch signaling pathway | 3 | 31 | 5.75e-01 |
| GO:BP | GO:0001967 | suckling behavior | 2 | 10 | 5.75e-01 |
| GO:BP | GO:0051098 | regulation of binding | 1 | 317 | 5.75e-01 |
| GO:BP | GO:1903054 | negative regulation of extracellular matrix organization | 1 | 6 | 5.75e-01 |
| GO:BP | GO:0022604 | regulation of cell morphogenesis | 4 | 220 | 5.75e-01 |
| GO:BP | GO:0043412 | macromolecule modification | 1 | 3090 | 5.75e-01 |
| GO:BP | GO:1900153 | positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 2 | 13 | 5.76e-01 |
| GO:BP | GO:1902367 | negative regulation of Notch signaling pathway involved in somitogenesis | 1 | 2 | 5.76e-01 |
| GO:BP | GO:1902366 | regulation of Notch signaling pathway involved in somitogenesis | 1 | 2 | 5.76e-01 |
| GO:BP | GO:1902359 | Notch signaling pathway involved in somitogenesis | 1 | 2 | 5.76e-01 |
| GO:BP | GO:0010804 | negative regulation of tumor necrosis factor-mediated signaling pathway | 3 | 18 | 5.76e-01 |
| GO:BP | GO:0042136 | neurotransmitter biosynthetic process | 1 | 5 | 5.76e-01 |
| GO:BP | GO:0021578 | hindbrain maturation | 1 | 4 | 5.76e-01 |
| GO:BP | GO:0010837 | regulation of keratinocyte proliferation | 7 | 33 | 5.77e-01 |
| GO:BP | GO:2000344 | positive regulation of acrosome reaction | 1 | 6 | 5.77e-01 |
| GO:BP | GO:0061387 | regulation of extent of cell growth | 18 | 97 | 5.77e-01 |
| GO:BP | GO:0070475 | rRNA base methylation | 1 | 8 | 5.77e-01 |
| GO:BP | GO:0010826 | negative regulation of centrosome duplication | 1 | 12 | 5.78e-01 |
| GO:BP | GO:0046606 | negative regulation of centrosome cycle | 1 | 12 | 5.78e-01 |
| GO:BP | GO:0016571 | histone methylation | 17 | 117 | 5.78e-01 |
| GO:BP | GO:0043576 | regulation of respiratory gaseous exchange | 1 | 15 | 5.78e-01 |
| GO:BP | GO:0014047 | glutamate secretion | 1 | 14 | 5.78e-01 |
| GO:BP | GO:0097659 | nucleic acid-templated transcription | 2 | 2684 | 5.78e-01 |
| GO:BP | GO:0015937 | coenzyme A biosynthetic process | 2 | 11 | 5.78e-01 |
| GO:BP | GO:0044042 | glucan metabolic process | 4 | 64 | 5.78e-01 |
| GO:BP | GO:2000756 | regulation of peptidyl-lysine acetylation | 9 | 57 | 5.78e-01 |
| GO:BP | GO:1902022 | L-lysine transport | 1 | 6 | 5.78e-01 |
| GO:BP | GO:0009165 | nucleotide biosynthetic process | 1 | 240 | 5.78e-01 |
| GO:BP | GO:0046533 | negative regulation of photoreceptor cell differentiation | 1 | 3 | 5.78e-01 |
| GO:BP | GO:0010644 | cell communication by electrical coupling | 1 | 31 | 5.78e-01 |
| GO:BP | GO:1901185 | negative regulation of ERBB signaling pathway | 5 | 30 | 5.78e-01 |
| GO:BP | GO:0072174 | metanephric tubule formation | 1 | 3 | 5.78e-01 |
| GO:BP | GO:1902108 | regulation of mitochondrial membrane permeability involved in apoptotic process | 6 | 42 | 5.78e-01 |
| GO:BP | GO:0006351 | DNA-templated transcription | 2 | 2683 | 5.78e-01 |
| GO:BP | GO:1903401 | L-lysine transmembrane transport | 1 | 6 | 5.78e-01 |
| GO:BP | GO:0051146 | striated muscle cell differentiation | 7 | 233 | 5.78e-01 |
| GO:BP | GO:1902606 | regulation of large conductance calcium-activated potassium channel activity | 1 | 3 | 5.78e-01 |
| GO:BP | GO:1901028 | regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway | 4 | 25 | 5.78e-01 |
| GO:BP | GO:0021762 | substantia nigra development | 3 | 41 | 5.78e-01 |
| GO:BP | GO:0044771 | meiotic cell cycle phase transition | 2 | 7 | 5.78e-01 |
| GO:BP | GO:1990927 | calcium ion regulated lysosome exocytosis | 1 | 3 | 5.78e-01 |
| GO:BP | GO:0031585 | regulation of inositol 1,4,5-trisphosphate-sensitive calcium-release channel activity | 1 | 4 | 5.79e-01 |
| GO:BP | GO:0036302 | atrioventricular canal development | 3 | 12 | 5.79e-01 |
| GO:BP | GO:0001829 | trophectodermal cell differentiation | 3 | 15 | 5.79e-01 |
| GO:BP | GO:0051785 | positive regulation of nuclear division | 11 | 38 | 5.79e-01 |
| GO:BP | GO:2000642 | negative regulation of early endosome to late endosome transport | 1 | 2 | 5.79e-01 |
| GO:BP | GO:0001710 | mesodermal cell fate commitment | 1 | 9 | 5.79e-01 |
| GO:BP | GO:0035967 | cellular response to topologically incorrect protein | 21 | 111 | 5.79e-01 |
| GO:BP | GO:0090314 | positive regulation of protein targeting to membrane | 3 | 22 | 5.79e-01 |
| GO:BP | GO:0033173 | calcineurin-NFAT signaling cascade | 6 | 37 | 5.79e-01 |
| GO:BP | GO:0000379 | tRNA-type intron splice site recognition and cleavage | 1 | 3 | 5.79e-01 |
| GO:BP | GO:0007369 | gastrulation | 5 | 146 | 5.79e-01 |
| GO:BP | GO:1901215 | negative regulation of neuron death | 15 | 167 | 5.79e-01 |
| GO:BP | GO:0060768 | regulation of epithelial cell proliferation involved in prostate gland development | 1 | 9 | 5.79e-01 |
| GO:BP | GO:1902033 | regulation of hematopoietic stem cell proliferation | 3 | 12 | 5.79e-01 |
| GO:BP | GO:0090153 | regulation of sphingolipid biosynthetic process | 2 | 12 | 5.79e-01 |
| GO:BP | GO:0035461 | vitamin transmembrane transport | 3 | 14 | 5.79e-01 |
| GO:BP | GO:1905038 | regulation of membrane lipid metabolic process | 2 | 12 | 5.79e-01 |
| GO:BP | GO:1901293 | nucleoside phosphate biosynthetic process | 1 | 241 | 5.79e-01 |
| GO:BP | GO:0043649 | dicarboxylic acid catabolic process | 1 | 14 | 5.79e-01 |
| GO:BP | GO:0007619 | courtship behavior | 1 | 3 | 5.80e-01 |
| GO:BP | GO:0002157 | positive regulation of thyroid hormone mediated signaling pathway | 1 | 3 | 5.80e-01 |
| GO:BP | GO:0032461 | positive regulation of protein oligomerization | 1 | 4 | 5.80e-01 |
| GO:BP | GO:0035728 | response to hepatocyte growth factor | 3 | 15 | 5.80e-01 |
| GO:BP | GO:1905278 | positive regulation of epithelial tube formation | 2 | 7 | 5.80e-01 |
| GO:BP | GO:0043524 | negative regulation of neuron apoptotic process | 11 | 120 | 5.80e-01 |
| GO:BP | GO:0061615 | glycolytic process through fructose-6-phosphate | 1 | 17 | 5.80e-01 |
| GO:BP | GO:0031064 | negative regulation of histone deacetylation | 1 | 2 | 5.80e-01 |
| GO:BP | GO:0010726 | positive regulation of hydrogen peroxide metabolic process | 1 | 4 | 5.80e-01 |
| GO:BP | GO:0060538 | skeletal muscle organ development | 23 | 139 | 5.80e-01 |
| GO:BP | GO:0001777 | T cell homeostatic proliferation | 1 | 1 | 5.80e-01 |
| GO:BP | GO:1905276 | regulation of epithelial tube formation | 2 | 7 | 5.80e-01 |
| GO:BP | GO:0034476 | U5 snRNA 3’-end processing | 1 | 3 | 5.80e-01 |
| GO:BP | GO:0034473 | U1 snRNA 3’-end processing | 1 | 3 | 5.80e-01 |
| GO:BP | GO:0006550 | isoleucine catabolic process | 1 | 4 | 5.80e-01 |
| GO:BP | GO:0002070 | epithelial cell maturation | 3 | 16 | 5.80e-01 |
| GO:BP | GO:0032774 | RNA biosynthetic process | 2 | 2714 | 5.81e-01 |
| GO:BP | GO:0043085 | positive regulation of catalytic activity | 1 | 834 | 5.81e-01 |
| GO:BP | GO:0034397 | telomere localization | 1 | 5 | 5.81e-01 |
| GO:BP | GO:0008655 | pyrimidine-containing compound salvage | 2 | 5 | 5.81e-01 |
| GO:BP | GO:0090220 | chromosome localization to nuclear envelope involved in homologous chromosome segregation | 1 | 5 | 5.81e-01 |
| GO:BP | GO:1901725 | regulation of histone deacetylase activity | 2 | 8 | 5.81e-01 |
| GO:BP | GO:0045943 | positive regulation of transcription by RNA polymerase I | 5 | 34 | 5.81e-01 |
| GO:BP | GO:0006767 | water-soluble vitamin metabolic process | 1 | 49 | 5.81e-01 |
| GO:BP | GO:0070723 | response to cholesterol | 3 | 16 | 5.81e-01 |
| GO:BP | GO:0009130 | pyrimidine nucleoside monophosphate biosynthetic process | 2 | 13 | 5.81e-01 |
| GO:BP | GO:0035781 | CD86 biosynthetic process | 1 | 2 | 5.81e-01 |
| GO:BP | GO:0021517 | ventral spinal cord development | 1 | 25 | 5.81e-01 |
| GO:BP | GO:0099639 | neurotransmitter receptor transport, endosome to plasma membrane | 2 | 10 | 5.81e-01 |
| GO:BP | GO:0006086 | acetyl-CoA biosynthetic process from pyruvate | 1 | 10 | 5.81e-01 |
| GO:BP | GO:0098887 | neurotransmitter receptor transport, endosome to postsynaptic membrane | 2 | 10 | 5.81e-01 |
| GO:BP | GO:0071332 | cellular response to fructose stimulus | 1 | 2 | 5.81e-01 |
| GO:BP | GO:0032366 | intracellular sterol transport | 5 | 30 | 5.82e-01 |
| GO:BP | GO:0001826 | inner cell mass cell differentiation | 2 | 5 | 5.83e-01 |
| GO:BP | GO:1900407 | regulation of cellular response to oxidative stress | 1 | 67 | 5.83e-01 |
| GO:BP | GO:0002763 | positive regulation of myeloid leukocyte differentiation | 4 | 34 | 5.83e-01 |
| GO:BP | GO:0006259 | DNA metabolic process | 66 | 884 | 5.83e-01 |
| GO:BP | GO:2000104 | negative regulation of DNA-templated DNA replication | 2 | 7 | 5.83e-01 |
| GO:BP | GO:0035791 | platelet-derived growth factor receptor-beta signaling pathway | 2 | 15 | 5.83e-01 |
| GO:BP | GO:0010977 | negative regulation of neuron projection development | 19 | 117 | 5.84e-01 |
| GO:BP | GO:0000022 | mitotic spindle elongation | 1 | 10 | 5.84e-01 |
| GO:BP | GO:0018193 | peptidyl-amino acid modification | 36 | 963 | 5.84e-01 |
| GO:BP | GO:0006001 | fructose catabolic process | 1 | 2 | 5.84e-01 |
| GO:BP | GO:0061624 | fructose catabolic process to hydroxyacetone phosphate and glyceraldehyde-3-phosphate | 1 | 2 | 5.84e-01 |
| GO:BP | GO:0009071 | serine family amino acid catabolic process | 2 | 10 | 5.84e-01 |
| GO:BP | GO:0045132 | meiotic chromosome segregation | 9 | 64 | 5.84e-01 |
| GO:BP | GO:0048009 | insulin-like growth factor receptor signaling pathway | 4 | 42 | 5.85e-01 |
| GO:BP | GO:0003138 | primary heart field specification | 1 | 3 | 5.85e-01 |
| GO:BP | GO:0048850 | hypophysis morphogenesis | 1 | 2 | 5.85e-01 |
| GO:BP | GO:0003213 | cardiac right atrium morphogenesis | 1 | 2 | 5.85e-01 |
| GO:BP | GO:0050995 | negative regulation of lipid catabolic process | 1 | 14 | 5.85e-01 |
| GO:BP | GO:2001286 | regulation of caveolin-mediated endocytosis | 1 | 5 | 5.86e-01 |
| GO:BP | GO:0043507 | positive regulation of JUN kinase activity | 8 | 34 | 5.86e-01 |
| GO:BP | GO:0000380 | alternative mRNA splicing, via spliceosome | 1 | 70 | 5.86e-01 |
| GO:BP | GO:0006526 | arginine biosynthetic process | 1 | 4 | 5.86e-01 |
| GO:BP | GO:0036151 | phosphatidylcholine acyl-chain remodeling | 1 | 12 | 5.86e-01 |
| GO:BP | GO:0015872 | dopamine transport | 2 | 29 | 5.86e-01 |
| GO:BP | GO:0042998 | positive regulation of Golgi to plasma membrane protein transport | 1 | 5 | 5.86e-01 |
| GO:BP | GO:1901386 | negative regulation of voltage-gated calcium channel activity | 1 | 13 | 5.86e-01 |
| GO:BP | GO:0035883 | enteroendocrine cell differentiation | 3 | 24 | 5.86e-01 |
| GO:BP | GO:0042339 | keratan sulfate metabolic process | 2 | 15 | 5.86e-01 |
| GO:BP | GO:0019932 | second-messenger-mediated signaling | 1 | 191 | 5.86e-01 |
| GO:BP | GO:0050999 | regulation of nitric-oxide synthase activity | 7 | 25 | 5.87e-01 |
| GO:BP | GO:1903541 | regulation of exosomal secretion | 3 | 15 | 5.87e-01 |
| GO:BP | GO:1904591 | positive regulation of protein import | 1 | 2 | 5.87e-01 |
| GO:BP | GO:0043084 | penile erection | 2 | 6 | 5.87e-01 |
| GO:BP | GO:0009409 | response to cold | 1 | 41 | 5.87e-01 |
| GO:BP | GO:0061009 | common bile duct development | 1 | 4 | 5.87e-01 |
| GO:BP | GO:0097155 | fasciculation of sensory neuron axon | 1 | 3 | 5.87e-01 |
| GO:BP | GO:0048666 | neuron development | 1 | 877 | 5.87e-01 |
| GO:BP | GO:0009299 | mRNA transcription | 8 | 50 | 5.87e-01 |
| GO:BP | GO:0046596 | regulation of viral entry into host cell | 2 | 32 | 5.87e-01 |
| GO:BP | GO:0018230 | peptidyl-L-cysteine S-palmitoylation | 5 | 21 | 5.87e-01 |
| GO:BP | GO:0060438 | trachea development | 2 | 13 | 5.87e-01 |
| GO:BP | GO:0018231 | peptidyl-S-diacylglycerol-L-cysteine biosynthetic process from peptidyl-cysteine | 5 | 21 | 5.87e-01 |
| GO:BP | GO:0010596 | negative regulation of endothelial cell migration | 4 | 40 | 5.87e-01 |
| GO:BP | GO:0002074 | extraocular skeletal muscle development | 1 | 2 | 5.87e-01 |
| GO:BP | GO:0038183 | bile acid signaling pathway | 1 | 3 | 5.88e-01 |
| GO:BP | GO:0070841 | inclusion body assembly | 3 | 22 | 5.89e-01 |
| GO:BP | GO:0030258 | lipid modification | 4 | 162 | 5.89e-01 |
| GO:BP | GO:0009132 | nucleoside diphosphate metabolic process | 1 | 32 | 5.90e-01 |
| GO:BP | GO:0046504 | glycerol ether biosynthetic process | 2 | 10 | 5.90e-01 |
| GO:BP | GO:0008611 | ether lipid biosynthetic process | 2 | 10 | 5.90e-01 |
| GO:BP | GO:0097384 | cellular lipid biosynthetic process | 2 | 10 | 5.90e-01 |
| GO:BP | GO:0090303 | positive regulation of wound healing | 3 | 45 | 5.90e-01 |
| GO:BP | GO:0021895 | cerebral cortex neuron differentiation | 3 | 14 | 5.90e-01 |
| GO:BP | GO:0001775 | cell activation | 1 | 655 | 5.90e-01 |
| GO:BP | GO:0072079 | nephron tubule formation | 2 | 12 | 5.90e-01 |
| GO:BP | GO:0048762 | mesenchymal cell differentiation | 6 | 204 | 5.90e-01 |
| GO:BP | GO:0006720 | isoprenoid metabolic process | 2 | 85 | 5.91e-01 |
| GO:BP | GO:1904322 | cellular response to forskolin | 3 | 11 | 5.91e-01 |
| GO:BP | GO:1904321 | response to forskolin | 3 | 11 | 5.91e-01 |
| GO:BP | GO:0048339 | paraxial mesoderm development | 1 | 15 | 5.91e-01 |
| GO:BP | GO:0043523 | regulation of neuron apoptotic process | 15 | 167 | 5.92e-01 |
| GO:BP | GO:1903679 | positive regulation of cap-independent translational initiation | 1 | 3 | 5.92e-01 |
| GO:BP | GO:1903677 | regulation of cap-independent translational initiation | 1 | 3 | 5.92e-01 |
| GO:BP | GO:1903427 | negative regulation of reactive oxygen species biosynthetic process | 1 | 12 | 5.92e-01 |
| GO:BP | GO:0070901 | mitochondrial tRNA methylation | 1 | 4 | 5.92e-01 |
| GO:BP | GO:0010628 | positive regulation of gene expression | 1 | 783 | 5.92e-01 |
| GO:BP | GO:0072337 | modified amino acid transport | 4 | 35 | 5.92e-01 |
| GO:BP | GO:0006390 | mitochondrial transcription | 1 | 18 | 5.92e-01 |
| GO:BP | GO:0045136 | development of secondary sexual characteristics | 2 | 9 | 5.92e-01 |
| GO:BP | GO:0090037 | positive regulation of protein kinase C signaling | 2 | 7 | 5.92e-01 |
| GO:BP | GO:0051939 | gamma-aminobutyric acid import | 1 | 3 | 5.93e-01 |
| GO:BP | GO:0042182 | ketone catabolic process | 1 | 9 | 5.93e-01 |
| GO:BP | GO:0051047 | positive regulation of secretion | 1 | 215 | 5.93e-01 |
| GO:BP | GO:0010841 | positive regulation of circadian sleep/wake cycle, wakefulness | 1 | 1 | 5.93e-01 |
| GO:BP | GO:0071470 | cellular response to osmotic stress | 5 | 42 | 5.93e-01 |
| GO:BP | GO:2000809 | positive regulation of synaptic vesicle clustering | 1 | 3 | 5.93e-01 |
| GO:BP | GO:1990809 | endoplasmic reticulum tubular network membrane organization | 1 | 4 | 5.93e-01 |
| GO:BP | GO:0035247 | peptidyl-arginine omega-N-methylation | 1 | 3 | 5.93e-01 |
| GO:BP | GO:0035794 | positive regulation of mitochondrial membrane permeability | 6 | 43 | 5.93e-01 |
| GO:BP | GO:1900075 | positive regulation of neuromuscular synaptic transmission | 1 | 2 | 5.93e-01 |
| GO:BP | GO:2000302 | positive regulation of synaptic vesicle exocytosis | 1 | 3 | 5.93e-01 |
| GO:BP | GO:0001754 | eye photoreceptor cell differentiation | 6 | 30 | 5.93e-01 |
| GO:BP | GO:0048771 | tissue remodeling | 6 | 114 | 5.93e-01 |
| GO:BP | GO:0007595 | lactation | 3 | 32 | 5.93e-01 |
| GO:BP | GO:0002320 | lymphoid progenitor cell differentiation | 2 | 17 | 5.93e-01 |
| GO:BP | GO:1900073 | regulation of neuromuscular synaptic transmission | 1 | 2 | 5.93e-01 |
| GO:BP | GO:0071360 | cellular response to exogenous dsRNA | 1 | 14 | 5.94e-01 |
| GO:BP | GO:0030148 | sphingolipid biosynthetic process | 3 | 88 | 5.94e-01 |
| GO:BP | GO:0061014 | positive regulation of mRNA catabolic process | 17 | 93 | 5.94e-01 |
| GO:BP | GO:1900060 | negative regulation of ceramide biosynthetic process | 1 | 5 | 5.94e-01 |
| GO:BP | GO:0051953 | negative regulation of amine transport | 1 | 15 | 5.94e-01 |
| GO:BP | GO:0032479 | regulation of type I interferon production | 17 | 76 | 5.94e-01 |
| GO:BP | GO:0070072 | vacuolar proton-transporting V-type ATPase complex assembly | 2 | 5 | 5.94e-01 |
| GO:BP | GO:1901998 | toxin transport | 5 | 37 | 5.94e-01 |
| GO:BP | GO:0031324 | negative regulation of cellular metabolic process | 3 | 1735 | 5.94e-01 |
| GO:BP | GO:2001256 | regulation of store-operated calcium entry | 1 | 11 | 5.94e-01 |
| GO:BP | GO:0014065 | phosphatidylinositol 3-kinase signaling | 4 | 100 | 5.94e-01 |
| GO:BP | GO:0032606 | type I interferon production | 17 | 76 | 5.94e-01 |
| GO:BP | GO:0061469 | regulation of type B pancreatic cell proliferation | 2 | 14 | 5.94e-01 |
| GO:BP | GO:0046824 | positive regulation of nucleocytoplasmic transport | 4 | 51 | 5.94e-01 |
| GO:BP | GO:0006942 | regulation of striated muscle contraction | 3 | 85 | 5.94e-01 |
| GO:BP | GO:0042325 | regulation of phosphorylation | 1 | 881 | 5.94e-01 |
| GO:BP | GO:0032647 | regulation of interferon-alpha production | 2 | 19 | 5.94e-01 |
| GO:BP | GO:0032607 | interferon-alpha production | 2 | 19 | 5.94e-01 |
| GO:BP | GO:0051684 | maintenance of Golgi location | 1 | 3 | 5.94e-01 |
| GO:BP | GO:0030866 | cortical actin cytoskeleton organization | 1 | 35 | 5.94e-01 |
| GO:BP | GO:0043307 | eosinophil activation | 2 | 4 | 5.94e-01 |
| GO:BP | GO:0030879 | mammary gland development | 9 | 106 | 5.95e-01 |
| GO:BP | GO:0038066 | p38MAPK cascade | 1 | 43 | 5.95e-01 |
| GO:BP | GO:1901184 | regulation of ERBB signaling pathway | 14 | 66 | 5.95e-01 |
| GO:BP | GO:1905232 | cellular response to L-glutamate | 1 | 4 | 5.95e-01 |
| GO:BP | GO:0006553 | lysine metabolic process | 1 | 7 | 5.96e-01 |
| GO:BP | GO:0043255 | regulation of carbohydrate biosynthetic process | 5 | 77 | 5.97e-01 |
| GO:BP | GO:1904753 | negative regulation of vascular associated smooth muscle cell migration | 2 | 11 | 5.97e-01 |
| GO:BP | GO:0032886 | regulation of microtubule-based process | 21 | 217 | 5.97e-01 |
| GO:BP | GO:1903076 | regulation of protein localization to plasma membrane | 8 | 90 | 5.97e-01 |
| GO:BP | GO:0036296 | response to increased oxygen levels | 2 | 25 | 5.97e-01 |
| GO:BP | GO:0040015 | negative regulation of multicellular organism growth | 3 | 13 | 5.97e-01 |
| GO:BP | GO:0098909 | regulation of cardiac muscle cell action potential involved in regulation of contraction | 2 | 8 | 5.97e-01 |
| GO:BP | GO:0071243 | cellular response to arsenic-containing substance | 1 | 18 | 6.00e-01 |
| GO:BP | GO:0045737 | positive regulation of cyclin-dependent protein serine/threonine kinase activity | 3 | 23 | 6.00e-01 |
| GO:BP | GO:0048024 | regulation of mRNA splicing, via spliceosome | 1 | 96 | 6.00e-01 |
| GO:BP | GO:0048246 | macrophage chemotaxis | 1 | 21 | 6.00e-01 |
| GO:BP | GO:0009218 | pyrimidine ribonucleotide metabolic process | 1 | 25 | 6.00e-01 |
| GO:BP | GO:0051252 | regulation of RNA metabolic process | 2 | 2845 | 6.00e-01 |
| GO:BP | GO:0022412 | cellular process involved in reproduction in multicellular organism | 2 | 252 | 6.00e-01 |
| GO:BP | GO:0097091 | synaptic vesicle clustering | 3 | 16 | 6.00e-01 |
| GO:BP | GO:0009161 | ribonucleoside monophosphate metabolic process | 2 | 50 | 6.00e-01 |
| GO:BP | GO:0010573 | vascular endothelial growth factor production | 1 | 23 | 6.00e-01 |
| GO:BP | GO:0086065 | cell communication involved in cardiac conduction | 3 | 58 | 6.00e-01 |
| GO:BP | GO:0051707 | response to other organism | 1 | 820 | 6.00e-01 |
| GO:BP | GO:0006090 | pyruvate metabolic process | 5 | 93 | 6.00e-01 |
| GO:BP | GO:0016485 | protein processing | 1 | 183 | 6.01e-01 |
| GO:BP | GO:0006783 | heme biosynthetic process | 1 | 30 | 6.01e-01 |
| GO:BP | GO:0007338 | single fertilization | 1 | 70 | 6.01e-01 |
| GO:BP | GO:0009168 | purine ribonucleoside monophosphate biosynthetic process | 1 | 19 | 6.01e-01 |
| GO:BP | GO:0043207 | response to external biotic stimulus | 1 | 820 | 6.01e-01 |
| GO:BP | GO:0070103 | regulation of interleukin-6-mediated signaling pathway | 1 | 4 | 6.01e-01 |
| GO:BP | GO:0001573 | ganglioside metabolic process | 3 | 22 | 6.01e-01 |
| GO:BP | GO:0050792 | regulation of viral process | 5 | 122 | 6.01e-01 |
| GO:BP | GO:0022614 | membrane to membrane docking | 1 | 5 | 6.01e-01 |
| GO:BP | GO:0035509 | negative regulation of myosin-light-chain-phosphatase activity | 1 | 3 | 6.01e-01 |
| GO:BP | GO:0007422 | peripheral nervous system development | 3 | 67 | 6.01e-01 |
| GO:BP | GO:0051418 | microtubule nucleation by microtubule organizing center | 1 | 5 | 6.01e-01 |
| GO:BP | GO:1990044 | protein localization to lipid droplet | 1 | 4 | 6.01e-01 |
| GO:BP | GO:0002067 | glandular epithelial cell differentiation | 5 | 50 | 6.01e-01 |
| GO:BP | GO:0045862 | positive regulation of proteolysis | 4 | 295 | 6.01e-01 |
| GO:BP | GO:0015918 | sterol transport | 1 | 92 | 6.01e-01 |
| GO:BP | GO:0010469 | regulation of signaling receptor activity | 2 | 107 | 6.01e-01 |
| GO:BP | GO:0060767 | epithelial cell proliferation involved in prostate gland development | 1 | 10 | 6.01e-01 |
| GO:BP | GO:1901223 | negative regulation of NIK/NF-kappaB signaling | 1 | 21 | 6.01e-01 |
| GO:BP | GO:0006556 | S-adenosylmethionine biosynthetic process | 1 | 3 | 6.01e-01 |
| GO:BP | GO:0014889 | muscle atrophy | 2 | 9 | 6.01e-01 |
| GO:BP | GO:0071322 | cellular response to carbohydrate stimulus | 10 | 105 | 6.01e-01 |
| GO:BP | GO:0009155 | purine deoxyribonucleotide catabolic process | 2 | 7 | 6.01e-01 |
| GO:BP | GO:0002246 | wound healing involved in inflammatory response | 1 | 6 | 6.01e-01 |
| GO:BP | GO:0097201 | negative regulation of transcription from RNA polymerase II promoter in response to stress | 2 | 10 | 6.01e-01 |
| GO:BP | GO:0045806 | negative regulation of endocytosis | 3 | 56 | 6.01e-01 |
| GO:BP | GO:0106058 | positive regulation of calcineurin-mediated signaling | 2 | 16 | 6.01e-01 |
| GO:BP | GO:0051541 | elastin metabolic process | 1 | 5 | 6.01e-01 |
| GO:BP | GO:0010155 | regulation of proton transport | 3 | 18 | 6.01e-01 |
| GO:BP | GO:0045124 | regulation of bone resorption | 1 | 24 | 6.01e-01 |
| GO:BP | GO:0007155 | cell adhesion | 2 | 1012 | 6.01e-01 |
| GO:BP | GO:0019284 | L-methionine salvage from S-adenosylmethionine | 1 | 3 | 6.01e-01 |
| GO:BP | GO:0051315 | attachment of mitotic spindle microtubules to kinetochore | 4 | 21 | 6.01e-01 |
| GO:BP | GO:0050920 | regulation of chemotaxis | 3 | 142 | 6.01e-01 |
| GO:BP | GO:0070886 | positive regulation of calcineurin-NFAT signaling cascade | 2 | 16 | 6.01e-01 |
| GO:BP | GO:1905661 | regulation of telomerase RNA reverse transcriptase activity | 1 | 3 | 6.01e-01 |
| GO:BP | GO:1904396 | regulation of neuromuscular junction development | 1 | 5 | 6.01e-01 |
| GO:BP | GO:0051124 | synaptic assembly at neuromuscular junction | 1 | 6 | 6.01e-01 |
| GO:BP | GO:0062149 | detection of stimulus involved in sensory perception of pain | 1 | 15 | 6.01e-01 |
| GO:BP | GO:0050996 | positive regulation of lipid catabolic process | 1 | 16 | 6.01e-01 |
| GO:BP | GO:0007398 | ectoderm development | 1 | 15 | 6.02e-01 |
| GO:BP | GO:1901858 | regulation of mitochondrial DNA metabolic process | 2 | 8 | 6.02e-01 |
| GO:BP | GO:0098885 | modification of postsynaptic actin cytoskeleton | 2 | 10 | 6.02e-01 |
| GO:BP | GO:0031946 | regulation of glucocorticoid biosynthetic process | 2 | 9 | 6.02e-01 |
| GO:BP | GO:0048490 | anterograde synaptic vesicle transport | 1 | 16 | 6.02e-01 |
| GO:BP | GO:0099514 | synaptic vesicle cytoskeletal transport | 1 | 16 | 6.02e-01 |
| GO:BP | GO:0099517 | synaptic vesicle transport along microtubule | 1 | 16 | 6.02e-01 |
| GO:BP | GO:0042088 | T-helper 1 type immune response | 2 | 26 | 6.02e-01 |
| GO:BP | GO:0003205 | cardiac chamber development | 14 | 149 | 6.02e-01 |
| GO:BP | GO:0021747 | cochlear nucleus development | 1 | 3 | 6.03e-01 |
| GO:BP | GO:0055023 | positive regulation of cardiac muscle tissue growth | 2 | 24 | 6.03e-01 |
| GO:BP | GO:0006650 | glycerophospholipid metabolic process | 39 | 252 | 6.03e-01 |
| GO:BP | GO:0048840 | otolith development | 2 | 6 | 6.04e-01 |
| GO:BP | GO:0001923 | B-1 B cell differentiation | 1 | 3 | 6.04e-01 |
| GO:BP | GO:0090009 | primitive streak formation | 1 | 5 | 6.04e-01 |
| GO:BP | GO:1901490 | regulation of lymphangiogenesis | 1 | 5 | 6.04e-01 |
| GO:BP | GO:0033762 | response to glucagon | 3 | 13 | 6.04e-01 |
| GO:BP | GO:0062125 | regulation of mitochondrial gene expression | 5 | 31 | 6.05e-01 |
| GO:BP | GO:0060023 | soft palate development | 1 | 3 | 6.05e-01 |
| GO:BP | GO:1904816 | positive regulation of protein localization to chromosome, telomeric region | 2 | 13 | 6.05e-01 |
| GO:BP | GO:0007076 | mitotic chromosome condensation | 4 | 19 | 6.05e-01 |
| GO:BP | GO:0046479 | glycosphingolipid catabolic process | 1 | 10 | 6.05e-01 |
| GO:BP | GO:0032890 | regulation of organic acid transport | 2 | 49 | 6.05e-01 |
| GO:BP | GO:0009607 | response to biotic stimulus | 1 | 850 | 6.05e-01 |
| GO:BP | GO:0010594 | regulation of endothelial cell migration | 2 | 143 | 6.06e-01 |
| GO:BP | GO:0038160 | CXCL12-activated CXCR4 signaling pathway | 1 | 3 | 6.06e-01 |
| GO:BP | GO:0099543 | trans-synaptic signaling by soluble gas | 1 | 2 | 6.06e-01 |
| GO:BP | GO:0099548 | trans-synaptic signaling by nitric oxide | 1 | 2 | 6.06e-01 |
| GO:BP | GO:0006662 | glycerol ether metabolic process | 3 | 16 | 6.07e-01 |
| GO:BP | GO:0039531 | regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway | 8 | 40 | 6.07e-01 |
| GO:BP | GO:0046485 | ether lipid metabolic process | 3 | 16 | 6.07e-01 |
| GO:BP | GO:0009314 | response to radiation | 27 | 352 | 6.07e-01 |
| GO:BP | GO:0015886 | heme transport | 1 | 9 | 6.07e-01 |
| GO:BP | GO:0035019 | somatic stem cell population maintenance | 4 | 50 | 6.07e-01 |
| GO:BP | GO:0000492 | box C/D snoRNP assembly | 1 | 10 | 6.07e-01 |
| GO:BP | GO:0001539 | cilium or flagellum-dependent cell motility | 5 | 74 | 6.07e-01 |
| GO:BP | GO:1903513 | endoplasmic reticulum to cytosol transport | 4 | 28 | 6.07e-01 |
| GO:BP | GO:0086023 | adenylate cyclase-activating adrenergic receptor signaling pathway involved in heart process | 1 | 6 | 6.07e-01 |
| GO:BP | GO:0030970 | retrograde protein transport, ER to cytosol | 4 | 28 | 6.07e-01 |
| GO:BP | GO:0060334 | regulation of type II interferon-mediated signaling pathway | 2 | 12 | 6.07e-01 |
| GO:BP | GO:0071333 | cellular response to glucose stimulus | 9 | 93 | 6.07e-01 |
| GO:BP | GO:0060330 | regulation of response to type II interferon | 2 | 12 | 6.07e-01 |
| GO:BP | GO:0006739 | NADP metabolic process | 5 | 40 | 6.07e-01 |
| GO:BP | GO:0048133 | male germ-line stem cell asymmetric division | 1 | 1 | 6.07e-01 |
| GO:BP | GO:0060285 | cilium-dependent cell motility | 5 | 74 | 6.07e-01 |
| GO:BP | GO:0007216 | G protein-coupled glutamate receptor signaling pathway | 1 | 5 | 6.07e-01 |
| GO:BP | GO:0060242 | contact inhibition | 1 | 8 | 6.07e-01 |
| GO:BP | GO:1902882 | regulation of response to oxidative stress | 1 | 76 | 6.07e-01 |
| GO:BP | GO:0044241 | lipid digestion | 1 | 10 | 6.07e-01 |
| GO:BP | GO:0000462 | maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 4 | 38 | 6.07e-01 |
| GO:BP | GO:0035973 | aggrephagy | 2 | 8 | 6.07e-01 |
| GO:BP | GO:1905706 | regulation of mitochondrial ATP synthesis coupled proton transport | 1 | 3 | 6.07e-01 |
| GO:BP | GO:1905271 | regulation of proton-transporting ATP synthase activity, rotational mechanism | 1 | 3 | 6.07e-01 |
| GO:BP | GO:1905273 | positive regulation of proton-transporting ATP synthase activity, rotational mechanism | 1 | 3 | 6.07e-01 |
| GO:BP | GO:0010761 | fibroblast migration | 5 | 52 | 6.07e-01 |
| GO:BP | GO:0140214 | positive regulation of long-chain fatty acid import into cell | 1 | 2 | 6.07e-01 |
| GO:BP | GO:0016024 | CDP-diacylglycerol biosynthetic process | 3 | 12 | 6.07e-01 |
| GO:BP | GO:0008206 | bile acid metabolic process | 1 | 34 | 6.07e-01 |
| GO:BP | GO:0060297 | regulation of sarcomere organization | 1 | 7 | 6.07e-01 |
| GO:BP | GO:2000849 | regulation of glucocorticoid secretion | 1 | 5 | 6.07e-01 |
| GO:BP | GO:0046952 | ketone body catabolic process | 1 | 2 | 6.07e-01 |
| GO:BP | GO:0009968 | negative regulation of signal transduction | 1 | 1006 | 6.07e-01 |
| GO:BP | GO:0010883 | regulation of lipid storage | 8 | 39 | 6.07e-01 |
| GO:BP | GO:0046500 | S-adenosylmethionine metabolic process | 3 | 13 | 6.08e-01 |
| GO:BP | GO:1905936 | regulation of germ cell proliferation | 1 | 5 | 6.08e-01 |
| GO:BP | GO:1905521 | regulation of macrophage migration | 1 | 24 | 6.08e-01 |
| GO:BP | GO:1904355 | positive regulation of telomere capping | 3 | 14 | 6.08e-01 |
| GO:BP | GO:0060393 | regulation of pathway-restricted SMAD protein phosphorylation | 2 | 50 | 6.08e-01 |
| GO:BP | GO:0060323 | head morphogenesis | 3 | 33 | 6.08e-01 |
| GO:BP | GO:0048702 | embryonic neurocranium morphogenesis | 1 | 7 | 6.08e-01 |
| GO:BP | GO:1903238 | positive regulation of leukocyte tethering or rolling | 1 | 5 | 6.08e-01 |
| GO:BP | GO:1904153 | negative regulation of retrograde protein transport, ER to cytosol | 1 | 9 | 6.08e-01 |
| GO:BP | GO:0072709 | cellular response to sorbitol | 1 | 5 | 6.08e-01 |
| GO:BP | GO:0006855 | xenobiotic transmembrane transport | 1 | 11 | 6.08e-01 |
| GO:BP | GO:0006810 | transport | 7 | 3298 | 6.09e-01 |
| GO:BP | GO:0016048 | detection of temperature stimulus | 1 | 13 | 6.09e-01 |
| GO:BP | GO:1904257 | zinc ion import into Golgi lumen | 1 | 3 | 6.09e-01 |
| GO:BP | GO:0030431 | sleep | 1 | 13 | 6.09e-01 |
| GO:BP | GO:1901799 | negative regulation of proteasomal protein catabolic process | 6 | 47 | 6.10e-01 |
| GO:BP | GO:0060354 | negative regulation of cell adhesion molecule production | 1 | 5 | 6.10e-01 |
| GO:BP | GO:1990408 | calcitonin gene-related peptide receptor signaling pathway | 1 | 2 | 6.10e-01 |
| GO:BP | GO:1990603 | dark adaptation | 1 | 3 | 6.10e-01 |
| GO:BP | GO:0035621 | ER to Golgi ceramide transport | 1 | 3 | 6.10e-01 |
| GO:BP | GO:0042073 | intraciliary transport | 7 | 46 | 6.10e-01 |
| GO:BP | GO:0071485 | cellular response to absence of light | 1 | 3 | 6.10e-01 |
| GO:BP | GO:0009646 | response to absence of light | 1 | 3 | 6.10e-01 |
| GO:BP | GO:1905208 | negative regulation of cardiocyte differentiation | 2 | 11 | 6.10e-01 |
| GO:BP | GO:0060753 | regulation of mast cell chemotaxis | 1 | 7 | 6.10e-01 |
| GO:BP | GO:2000370 | positive regulation of clathrin-dependent endocytosis | 1 | 5 | 6.10e-01 |
| GO:BP | GO:0050746 | regulation of lipoprotein metabolic process | 3 | 15 | 6.10e-01 |
| GO:BP | GO:0090030 | regulation of steroid hormone biosynthetic process | 3 | 15 | 6.11e-01 |
| GO:BP | GO:0051240 | positive regulation of multicellular organismal process | 3 | 1101 | 6.11e-01 |
| GO:BP | GO:0009225 | nucleotide-sugar metabolic process | 3 | 35 | 6.11e-01 |
| GO:BP | GO:0072197 | ureter morphogenesis | 1 | 5 | 6.12e-01 |
| GO:BP | GO:0051344 | negative regulation of cyclic-nucleotide phosphodiesterase activity | 1 | 6 | 6.12e-01 |
| GO:BP | GO:0042402 | cellular biogenic amine catabolic process | 1 | 13 | 6.12e-01 |
| GO:BP | GO:1903845 | negative regulation of cellular response to transforming growth factor beta stimulus | 1 | 2 | 6.12e-01 |
| GO:BP | GO:0006742 | NADP catabolic process | 1 | 3 | 6.12e-01 |
| GO:BP | GO:0019677 | NAD catabolic process | 1 | 3 | 6.12e-01 |
| GO:BP | GO:0006595 | polyamine metabolic process | 1 | 16 | 6.12e-01 |
| GO:BP | GO:0051728 | cell cycle switching, mitotic to meiotic cell cycle | 1 | 2 | 6.12e-01 |
| GO:BP | GO:0051729 | germline cell cycle switching, mitotic to meiotic cell cycle | 1 | 2 | 6.12e-01 |
| GO:BP | GO:0060184 | cell cycle switching | 1 | 2 | 6.12e-01 |
| GO:BP | GO:0071636 | positive regulation of transforming growth factor beta production | 1 | 16 | 6.12e-01 |
| GO:BP | GO:1901863 | positive regulation of muscle tissue development | 4 | 18 | 6.12e-01 |
| GO:BP | GO:0072527 | pyrimidine-containing compound metabolic process | 11 | 67 | 6.12e-01 |
| GO:BP | GO:0030730 | sequestering of triglyceride | 3 | 13 | 6.12e-01 |
| GO:BP | GO:1904971 | regulation of viral translation | 1 | 3 | 6.13e-01 |
| GO:BP | GO:1904973 | positive regulation of viral translation | 1 | 3 | 6.13e-01 |
| GO:BP | GO:0048729 | tissue morphogenesis | 3 | 504 | 6.13e-01 |
| GO:BP | GO:0034163 | regulation of toll-like receptor 9 signaling pathway | 2 | 6 | 6.13e-01 |
| GO:BP | GO:1900749 | (R)-carnitine transport | 1 | 1 | 6.13e-01 |
| GO:BP | GO:0086018 | SA node cell to atrial cardiac muscle cell signaling | 1 | 12 | 6.13e-01 |
| GO:BP | GO:0086015 | SA node cell action potential | 1 | 12 | 6.13e-01 |
| GO:BP | GO:0045646 | regulation of erythrocyte differentiation | 6 | 39 | 6.13e-01 |
| GO:BP | GO:1902270 | (R)-carnitine transmembrane transport | 1 | 1 | 6.13e-01 |
| GO:BP | GO:1903332 | regulation of protein folding | 1 | 8 | 6.13e-01 |
| GO:BP | GO:0008637 | apoptotic mitochondrial changes | 2 | 90 | 6.13e-01 |
| GO:BP | GO:0045638 | negative regulation of myeloid cell differentiation | 2 | 69 | 6.13e-01 |
| GO:BP | GO:0044272 | sulfur compound biosynthetic process | 1 | 122 | 6.13e-01 |
| GO:BP | GO:2000288 | positive regulation of myoblast proliferation | 1 | 9 | 6.13e-01 |
| GO:BP | GO:0006509 | membrane protein ectodomain proteolysis | 1 | 34 | 6.13e-01 |
| GO:BP | GO:0015701 | bicarbonate transport | 1 | 19 | 6.13e-01 |
| GO:BP | GO:0098880 | maintenance of postsynaptic specialization structure | 2 | 9 | 6.13e-01 |
| GO:BP | GO:0044249 | cellular biosynthetic process | 3 | 4245 | 6.13e-01 |
| GO:BP | GO:1901701 | cellular response to oxygen-containing compound | 1 | 893 | 6.13e-01 |
| GO:BP | GO:0000480 | endonucleolytic cleavage in 5’-ETS of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 2 | 8 | 6.14e-01 |
| GO:BP | GO:0002051 | osteoblast fate commitment | 1 | 2 | 6.14e-01 |
| GO:BP | GO:0060841 | venous blood vessel development | 2 | 13 | 6.14e-01 |
| GO:BP | GO:1901216 | positive regulation of neuron death | 9 | 70 | 6.14e-01 |
| GO:BP | GO:2000192 | negative regulation of fatty acid transport | 1 | 7 | 6.15e-01 |
| GO:BP | GO:0032071 | regulation of endodeoxyribonuclease activity | 1 | 7 | 6.15e-01 |
| GO:BP | GO:0007498 | mesoderm development | 1 | 89 | 6.15e-01 |
| GO:BP | GO:0021782 | glial cell development | 3 | 84 | 6.15e-01 |
| GO:BP | GO:0070315 | G1 to G0 transition involved in cell differentiation | 1 | 4 | 6.15e-01 |
| GO:BP | GO:0032435 | negative regulation of proteasomal ubiquitin-dependent protein catabolic process | 4 | 35 | 6.15e-01 |
| GO:BP | GO:0018216 | peptidyl-arginine methylation | 3 | 15 | 6.15e-01 |
| GO:BP | GO:0019673 | GDP-mannose metabolic process | 1 | 7 | 6.15e-01 |
| GO:BP | GO:0046902 | regulation of mitochondrial membrane permeability | 7 | 54 | 6.15e-01 |
| GO:BP | GO:0042789 | mRNA transcription by RNA polymerase II | 7 | 45 | 6.15e-01 |
| GO:BP | GO:0036499 | PERK-mediated unfolded protein response | 3 | 17 | 6.15e-01 |
| GO:BP | GO:0033033 | negative regulation of myeloid cell apoptotic process | 1 | 10 | 6.15e-01 |
| GO:BP | GO:0070292 | N-acylphosphatidylethanolamine metabolic process | 1 | 5 | 6.15e-01 |
| GO:BP | GO:0048294 | negative regulation of isotype switching to IgE isotypes | 1 | 2 | 6.15e-01 |
| GO:BP | GO:0070169 | positive regulation of biomineral tissue development | 9 | 39 | 6.15e-01 |
| GO:BP | GO:0002042 | cell migration involved in sprouting angiogenesis | 4 | 45 | 6.15e-01 |
| GO:BP | GO:0019896 | axonal transport of mitochondrion | 2 | 17 | 6.15e-01 |
| GO:BP | GO:0046782 | regulation of viral transcription | 1 | 19 | 6.17e-01 |
| GO:BP | GO:0006289 | nucleotide-excision repair | 6 | 79 | 6.17e-01 |
| GO:BP | GO:0030220 | platelet formation | 2 | 17 | 6.17e-01 |
| GO:BP | GO:1905222 | atrioventricular canal morphogenesis | 1 | 4 | 6.17e-01 |
| GO:BP | GO:0110030 | regulation of G2/MI transition of meiotic cell cycle | 1 | 3 | 6.17e-01 |
| GO:BP | GO:0009081 | branched-chain amino acid metabolic process | 2 | 26 | 6.17e-01 |
| GO:BP | GO:0015939 | pantothenate metabolic process | 1 | 2 | 6.17e-01 |
| GO:BP | GO:1901995 | positive regulation of meiotic cell cycle phase transition | 1 | 3 | 6.17e-01 |
| GO:BP | GO:0051231 | spindle elongation | 1 | 12 | 6.17e-01 |
| GO:BP | GO:2000065 | negative regulation of cortisol biosynthetic process | 1 | 4 | 6.17e-01 |
| GO:BP | GO:0010556 | regulation of macromolecule biosynthetic process | 2 | 3012 | 6.17e-01 |
| GO:BP | GO:0061209 | cell proliferation involved in mesonephros development | 1 | 3 | 6.17e-01 |
| GO:BP | GO:0032348 | negative regulation of aldosterone biosynthetic process | 1 | 4 | 6.17e-01 |
| GO:BP | GO:2001224 | positive regulation of neuron migration | 4 | 19 | 6.17e-01 |
| GO:BP | GO:0051094 | positive regulation of developmental process | 1 | 957 | 6.17e-01 |
| GO:BP | GO:0090141 | positive regulation of mitochondrial fission | 1 | 21 | 6.17e-01 |
| GO:BP | GO:0032345 | negative regulation of aldosterone metabolic process | 1 | 4 | 6.17e-01 |
| GO:BP | GO:0002327 | immature B cell differentiation | 1 | 11 | 6.17e-01 |
| GO:BP | GO:0032210 | regulation of telomere maintenance via telomerase | 6 | 49 | 6.17e-01 |
| GO:BP | GO:0098957 | anterograde axonal transport of mitochondrion | 1 | 5 | 6.17e-01 |
| GO:BP | GO:0006420 | arginyl-tRNA aminoacylation | 1 | 3 | 6.18e-01 |
| GO:BP | GO:0042148 | strand invasion | 1 | 5 | 6.18e-01 |
| GO:BP | GO:1903830 | magnesium ion transmembrane transport | 1 | 16 | 6.18e-01 |
| GO:BP | GO:0035589 | G protein-coupled purinergic nucleotide receptor signaling pathway | 1 | 4 | 6.18e-01 |
| GO:BP | GO:0031134 | sister chromatid biorientation | 1 | 3 | 6.18e-01 |
| GO:BP | GO:0007423 | sensory organ development | 4 | 396 | 6.18e-01 |
| GO:BP | GO:0060965 | negative regulation of miRNA-mediated gene silencing | 1 | 10 | 6.18e-01 |
| GO:BP | GO:2000772 | regulation of cellular senescence | 8 | 38 | 6.19e-01 |
| GO:BP | GO:0051382 | kinetochore assembly | 2 | 18 | 6.19e-01 |
| GO:BP | GO:0000820 | regulation of glutamine family amino acid metabolic process | 1 | 5 | 6.20e-01 |
| GO:BP | GO:0070966 | nuclear-transcribed mRNA catabolic process, no-go decay | 1 | 3 | 6.20e-01 |
| GO:BP | GO:0009994 | oocyte differentiation | 11 | 39 | 6.20e-01 |
| GO:BP | GO:0071331 | cellular response to hexose stimulus | 9 | 94 | 6.20e-01 |
| GO:BP | GO:0032692 | negative regulation of interleukin-1 production | 3 | 15 | 6.20e-01 |
| GO:BP | GO:0090101 | negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 10 | 124 | 6.20e-01 |
| GO:BP | GO:0007041 | lysosomal transport | 11 | 115 | 6.21e-01 |
| GO:BP | GO:0050878 | regulation of body fluid levels | 1 | 236 | 6.22e-01 |
| GO:BP | GO:0051385 | response to mineralocorticoid | 3 | 25 | 6.22e-01 |
| GO:BP | GO:0032273 | positive regulation of protein polymerization | 15 | 76 | 6.22e-01 |
| GO:BP | GO:1901503 | ether biosynthetic process | 2 | 11 | 6.22e-01 |
| GO:BP | GO:0046100 | hypoxanthine metabolic process | 1 | 3 | 6.22e-01 |
| GO:BP | GO:0006154 | adenosine catabolic process | 1 | 3 | 6.22e-01 |
| GO:BP | GO:0006779 | porphyrin-containing compound biosynthetic process | 1 | 33 | 6.22e-01 |
| GO:BP | GO:0061303 | cornea development in camera-type eye | 1 | 4 | 6.22e-01 |
| GO:BP | GO:0003209 | cardiac atrium morphogenesis | 1 | 26 | 6.22e-01 |
| GO:BP | GO:0002905 | regulation of mature B cell apoptotic process | 1 | 3 | 6.22e-01 |
| GO:BP | GO:0042306 | regulation of protein import into nucleus | 1 | 51 | 6.22e-01 |
| GO:BP | GO:0034475 | U4 snRNA 3’-end processing | 2 | 8 | 6.22e-01 |
| GO:BP | GO:0034244 | negative regulation of transcription elongation by RNA polymerase II | 2 | 17 | 6.22e-01 |
| GO:BP | GO:0032350 | regulation of hormone metabolic process | 1 | 30 | 6.22e-01 |
| GO:BP | GO:0030099 | myeloid cell differentiation | 2 | 310 | 6.22e-01 |
| GO:BP | GO:0033138 | positive regulation of peptidyl-serine phosphorylation | 8 | 70 | 6.22e-01 |
| GO:BP | GO:0014808 | release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | 6 | 28 | 6.22e-01 |
| GO:BP | GO:0010667 | negative regulation of cardiac muscle cell apoptotic process | 3 | 21 | 6.22e-01 |
| GO:BP | GO:0046124 | purine deoxyribonucleoside catabolic process | 1 | 2 | 6.22e-01 |
| GO:BP | GO:0071276 | cellular response to cadmium ion | 3 | 24 | 6.22e-01 |
| GO:BP | GO:0009150 | purine ribonucleotide metabolic process | 1 | 295 | 6.22e-01 |
| GO:BP | GO:0072531 | pyrimidine-containing compound transmembrane transport | 1 | 9 | 6.22e-01 |
| GO:BP | GO:0060167 | regulation of adenosine receptor signaling pathway | 1 | 2 | 6.22e-01 |
| GO:BP | GO:0033197 | response to vitamin E | 2 | 9 | 6.22e-01 |
| GO:BP | GO:0045603 | positive regulation of endothelial cell differentiation | 1 | 8 | 6.22e-01 |
| GO:BP | GO:0032682 | negative regulation of chemokine production | 2 | 12 | 6.22e-01 |
| GO:BP | GO:0072711 | cellular response to hydroxyurea | 2 | 10 | 6.22e-01 |
| GO:BP | GO:0090189 | regulation of branching involved in ureteric bud morphogenesis | 2 | 14 | 6.22e-01 |
| GO:BP | GO:0033014 | tetrapyrrole biosynthetic process | 1 | 33 | 6.22e-01 |
| GO:BP | GO:0010921 | regulation of phosphatase activity | 2 | 65 | 6.22e-01 |
| GO:BP | GO:0002901 | mature B cell apoptotic process | 1 | 3 | 6.22e-01 |
| GO:BP | GO:0042473 | outer ear morphogenesis | 1 | 5 | 6.22e-01 |
| GO:BP | GO:0051174 | regulation of phosphorus metabolic process | 1 | 994 | 6.22e-01 |
| GO:BP | GO:0006220 | pyrimidine nucleotide metabolic process | 5 | 46 | 6.22e-01 |
| GO:BP | GO:0010046 | response to mycotoxin | 1 | 3 | 6.22e-01 |
| GO:BP | GO:0051593 | response to folic acid | 2 | 9 | 6.22e-01 |
| GO:BP | GO:0019220 | regulation of phosphate metabolic process | 1 | 993 | 6.22e-01 |
| GO:BP | GO:0055022 | negative regulation of cardiac muscle tissue growth | 4 | 19 | 6.22e-01 |
| GO:BP | GO:0001678 | intracellular glucose homeostasis | 10 | 110 | 6.22e-01 |
| GO:BP | GO:0046462 | monoacylglycerol metabolic process | 1 | 8 | 6.22e-01 |
| GO:BP | GO:0060440 | trachea formation | 1 | 7 | 6.22e-01 |
| GO:BP | GO:0050951 | sensory perception of temperature stimulus | 1 | 13 | 6.22e-01 |
| GO:BP | GO:0046059 | dAMP catabolic process | 1 | 2 | 6.22e-01 |
| GO:BP | GO:0015808 | L-alanine transport | 1 | 9 | 6.22e-01 |
| GO:BP | GO:0060411 | cardiac septum morphogenesis | 6 | 67 | 6.22e-01 |
| GO:BP | GO:0006099 | tricarboxylic acid cycle | 2 | 30 | 6.22e-01 |
| GO:BP | GO:2000378 | negative regulation of reactive oxygen species metabolic process | 3 | 34 | 6.22e-01 |
| GO:BP | GO:0061117 | negative regulation of heart growth | 4 | 19 | 6.22e-01 |
| GO:BP | GO:0007292 | female gamete generation | 1 | 103 | 6.22e-01 |
| GO:BP | GO:0009310 | amine catabolic process | 1 | 14 | 6.22e-01 |
| GO:BP | GO:0002906 | negative regulation of mature B cell apoptotic process | 1 | 3 | 6.22e-01 |
| GO:BP | GO:0044419 | biological process involved in interspecies interaction between organisms | 1 | 963 | 6.22e-01 |
| GO:BP | GO:0061157 | mRNA destabilization | 16 | 89 | 6.22e-01 |
| GO:BP | GO:0055064 | chloride ion homeostasis | 2 | 13 | 6.22e-01 |
| GO:BP | GO:0009266 | response to temperature stimulus | 2 | 133 | 6.22e-01 |
| GO:BP | GO:0040011 | locomotion | 14 | 954 | 6.22e-01 |
| GO:BP | GO:0097720 | calcineurin-mediated signaling | 6 | 38 | 6.23e-01 |
| GO:BP | GO:0032780 | negative regulation of ATP-dependent activity | 1 | 18 | 6.24e-01 |
| GO:BP | GO:0002031 | G protein-coupled receptor internalization | 2 | 10 | 6.24e-01 |
| GO:BP | GO:0032940 | secretion by cell | 2 | 569 | 6.25e-01 |
| GO:BP | GO:0051402 | neuron apoptotic process | 17 | 200 | 6.25e-01 |
| GO:BP | GO:0099566 | regulation of postsynaptic cytosolic calcium ion concentration | 2 | 6 | 6.25e-01 |
| GO:BP | GO:0006837 | serotonin transport | 1 | 11 | 6.25e-01 |
| GO:BP | GO:0010648 | negative regulation of cell communication | 1 | 1074 | 6.25e-01 |
| GO:BP | GO:0110089 | regulation of hippocampal neuron apoptotic process | 1 | 2 | 6.25e-01 |
| GO:BP | GO:0023057 | negative regulation of signaling | 1 | 1076 | 6.25e-01 |
| GO:BP | GO:0002793 | positive regulation of peptide secretion | 3 | 70 | 6.25e-01 |
| GO:BP | GO:0003129 | heart induction | 2 | 9 | 6.25e-01 |
| GO:BP | GO:0110088 | hippocampal neuron apoptotic process | 1 | 2 | 6.25e-01 |
| GO:BP | GO:0006369 | termination of RNA polymerase II transcription | 1 | 8 | 6.25e-01 |
| GO:BP | GO:2000638 | regulation of SREBP signaling pathway | 1 | 7 | 6.25e-01 |
| GO:BP | GO:0032914 | positive regulation of transforming growth factor beta1 production | 1 | 6 | 6.25e-01 |
| GO:BP | GO:0035425 | autocrine signaling | 1 | 3 | 6.25e-01 |
| GO:BP | GO:0016055 | Wnt signaling pathway | 9 | 375 | 6.25e-01 |
| GO:BP | GO:1900222 | negative regulation of amyloid-beta clearance | 2 | 7 | 6.25e-01 |
| GO:BP | GO:0090649 | response to oxygen-glucose deprivation | 1 | 7 | 6.25e-01 |
| GO:BP | GO:0014816 | skeletal muscle satellite cell differentiation | 1 | 6 | 6.25e-01 |
| GO:BP | GO:0002071 | glandular epithelial cell maturation | 1 | 7 | 6.25e-01 |
| GO:BP | GO:0061072 | iris morphogenesis | 1 | 5 | 6.25e-01 |
| GO:BP | GO:1903376 | regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway | 1 | 8 | 6.25e-01 |
| GO:BP | GO:0036480 | neuron intrinsic apoptotic signaling pathway in response to oxidative stress | 1 | 8 | 6.25e-01 |
| GO:BP | GO:0003323 | type B pancreatic cell development | 2 | 19 | 6.25e-01 |
| GO:BP | GO:0010885 | regulation of cholesterol storage | 1 | 14 | 6.25e-01 |
| GO:BP | GO:0031110 | regulation of microtubule polymerization or depolymerization | 6 | 82 | 6.25e-01 |
| GO:BP | GO:1902035 | positive regulation of hematopoietic stem cell proliferation | 2 | 7 | 6.25e-01 |
| GO:BP | GO:0090311 | regulation of protein deacetylation | 1 | 53 | 6.25e-01 |
| GO:BP | GO:0090234 | regulation of kinetochore assembly | 1 | 3 | 6.25e-01 |
| GO:BP | GO:0036303 | lymph vessel morphogenesis | 1 | 17 | 6.25e-01 |
| GO:BP | GO:0001911 | negative regulation of leukocyte mediated cytotoxicity | 1 | 11 | 6.25e-01 |
| GO:BP | GO:0120317 | sperm mitochondrial sheath assembly | 1 | 2 | 6.25e-01 |
| GO:BP | GO:2000049 | positive regulation of cell-cell adhesion mediated by cadherin | 2 | 8 | 6.25e-01 |
| GO:BP | GO:0098742 | cell-cell adhesion via plasma-membrane adhesion molecules | 1 | 168 | 6.25e-01 |
| GO:BP | GO:2001222 | regulation of neuron migration | 1 | 38 | 6.25e-01 |
| GO:BP | GO:0034654 | nucleobase-containing compound biosynthetic process | 2 | 3070 | 6.25e-01 |
| GO:BP | GO:0016078 | tRNA catabolic process | 3 | 14 | 6.25e-01 |
| GO:BP | GO:0048633 | positive regulation of skeletal muscle tissue growth | 1 | 6 | 6.25e-01 |
| GO:BP | GO:0071027 | nuclear RNA surveillance | 3 | 14 | 6.25e-01 |
| GO:BP | GO:0032400 | melanosome localization | 4 | 22 | 6.25e-01 |
| GO:BP | GO:0060457 | negative regulation of digestive system process | 1 | 7 | 6.25e-01 |
| GO:BP | GO:0060368 | regulation of Fc receptor mediated stimulatory signaling pathway | 1 | 10 | 6.25e-01 |
| GO:BP | GO:0018364 | peptidyl-glutamine methylation | 1 | 4 | 6.26e-01 |
| GO:BP | GO:0032212 | positive regulation of telomere maintenance via telomerase | 4 | 31 | 6.26e-01 |
| GO:BP | GO:0019219 | regulation of nucleobase-containing compound metabolic process | 2 | 3080 | 6.26e-01 |
| GO:BP | GO:0045901 | positive regulation of translational elongation | 1 | 4 | 6.26e-01 |
| GO:BP | GO:0048525 | negative regulation of viral process | 3 | 64 | 6.26e-01 |
| GO:BP | GO:0031326 | regulation of cellular biosynthetic process | 2 | 3080 | 6.26e-01 |
| GO:BP | GO:0048010 | vascular endothelial growth factor receptor signaling pathway | 5 | 48 | 6.26e-01 |
| GO:BP | GO:0040034 | regulation of development, heterochronic | 2 | 8 | 6.26e-01 |
| GO:BP | GO:1901739 | regulation of myoblast fusion | 3 | 12 | 6.27e-01 |
| GO:BP | GO:1903140 | regulation of establishment of endothelial barrier | 2 | 12 | 6.27e-01 |
| GO:BP | GO:0032211 | negative regulation of telomere maintenance via telomerase | 2 | 19 | 6.27e-01 |
| GO:BP | GO:0010666 | positive regulation of cardiac muscle cell apoptotic process | 1 | 12 | 6.27e-01 |
| GO:BP | GO:0000720 | pyrimidine dimer repair by nucleotide-excision repair | 1 | 4 | 6.27e-01 |
| GO:BP | GO:0010663 | positive regulation of striated muscle cell apoptotic process | 1 | 12 | 6.27e-01 |
| GO:BP | GO:0060245 | detection of cell density | 1 | 9 | 6.27e-01 |
| GO:BP | GO:1902512 | positive regulation of apoptotic DNA fragmentation | 1 | 4 | 6.27e-01 |
| GO:BP | GO:0034643 | establishment of mitochondrion localization, microtubule-mediated | 3 | 26 | 6.27e-01 |
| GO:BP | GO:0198738 | cell-cell signaling by wnt | 9 | 376 | 6.27e-01 |
| GO:BP | GO:0070230 | positive regulation of lymphocyte apoptotic process | 3 | 10 | 6.27e-01 |
| GO:BP | GO:0019740 | nitrogen utilization | 1 | 4 | 6.27e-01 |
| GO:BP | GO:1901550 | regulation of endothelial cell development | 2 | 12 | 6.27e-01 |
| GO:BP | GO:0047497 | mitochondrion transport along microtubule | 3 | 26 | 6.27e-01 |
| GO:BP | GO:0016322 | neuron remodeling | 2 | 11 | 6.27e-01 |
| GO:BP | GO:1990959 | eosinophil homeostasis | 1 | 2 | 6.27e-01 |
| GO:BP | GO:0010828 | positive regulation of glucose transmembrane transport | 6 | 31 | 6.27e-01 |
| GO:BP | GO:0010875 | positive regulation of cholesterol efflux | 5 | 23 | 6.27e-01 |
| GO:BP | GO:0050432 | catecholamine secretion | 2 | 31 | 6.27e-01 |
| GO:BP | GO:0055075 | potassium ion homeostasis | 3 | 22 | 6.27e-01 |
| GO:BP | GO:0035994 | response to muscle stretch | 2 | 26 | 6.27e-01 |
| GO:BP | GO:0021510 | spinal cord development | 4 | 59 | 6.27e-01 |
| GO:BP | GO:1904754 | positive regulation of vascular associated smooth muscle cell migration | 2 | 12 | 6.27e-01 |
| GO:BP | GO:0009644 | response to high light intensity | 1 | 2 | 6.27e-01 |
| GO:BP | GO:0072359 | circulatory system development | 24 | 884 | 6.27e-01 |
| GO:BP | GO:0071326 | cellular response to monosaccharide stimulus | 9 | 95 | 6.27e-01 |
| GO:BP | GO:0098598 | learned vocalization behavior or vocal learning | 1 | 4 | 6.27e-01 |
| GO:BP | GO:0035459 | vesicle cargo loading | 5 | 27 | 6.27e-01 |
| GO:BP | GO:0035239 | tube morphogenesis | 10 | 663 | 6.27e-01 |
| GO:BP | GO:0021761 | limbic system development | 1 | 81 | 6.27e-01 |
| GO:BP | GO:0044837 | actomyosin contractile ring organization | 1 | 7 | 6.27e-01 |
| GO:BP | GO:0035793 | positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway | 1 | 3 | 6.27e-01 |
| GO:BP | GO:0033135 | regulation of peptidyl-serine phosphorylation | 24 | 100 | 6.27e-01 |
| GO:BP | GO:0046622 | positive regulation of organ growth | 3 | 33 | 6.27e-01 |
| GO:BP | GO:0046835 | carbohydrate phosphorylation | 1 | 21 | 6.27e-01 |
| GO:BP | GO:0098868 | bone growth | 6 | 24 | 6.27e-01 |
| GO:BP | GO:0060149 | negative regulation of post-transcriptional gene silencing | 1 | 11 | 6.27e-01 |
| GO:BP | GO:0051172 | negative regulation of nitrogen compound metabolic process | 3 | 1849 | 6.27e-01 |
| GO:BP | GO:0015693 | magnesium ion transport | 1 | 17 | 6.27e-01 |
| GO:BP | GO:0071364 | cellular response to epidermal growth factor stimulus | 3 | 41 | 6.27e-01 |
| GO:BP | GO:0060539 | diaphragm development | 1 | 5 | 6.27e-01 |
| GO:BP | GO:0033962 | P-body assembly | 4 | 20 | 6.27e-01 |
| GO:BP | GO:0030518 | intracellular steroid hormone receptor signaling pathway | 1 | 95 | 6.27e-01 |
| GO:BP | GO:0001504 | neurotransmitter uptake | 2 | 29 | 6.27e-01 |
| GO:BP | GO:0021675 | nerve development | 3 | 57 | 6.27e-01 |
| GO:BP | GO:0001827 | inner cell mass cell fate commitment | 1 | 2 | 6.27e-01 |
| GO:BP | GO:0001828 | inner cell mass cellular morphogenesis | 1 | 2 | 6.27e-01 |
| GO:BP | GO:0097062 | dendritic spine maintenance | 3 | 15 | 6.27e-01 |
| GO:BP | GO:1904031 | positive regulation of cyclin-dependent protein kinase activity | 3 | 26 | 6.27e-01 |
| GO:BP | GO:1900369 | negative regulation of post-transcriptional gene silencing by RNA | 1 | 11 | 6.27e-01 |
| GO:BP | GO:1900238 | regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway | 1 | 3 | 6.27e-01 |
| GO:BP | GO:0015889 | cobalamin transport | 1 | 6 | 6.27e-01 |
| GO:BP | GO:0046112 | nucleobase biosynthetic process | 3 | 18 | 6.27e-01 |
| GO:BP | GO:0060967 | negative regulation of gene silencing by RNA | 1 | 11 | 6.27e-01 |
| GO:BP | GO:2000591 | positive regulation of metanephric mesenchymal cell migration | 1 | 3 | 6.27e-01 |
| GO:BP | GO:0001574 | ganglioside biosynthetic process | 2 | 14 | 6.27e-01 |
| GO:BP | GO:0060292 | long-term synaptic depression | 1 | 21 | 6.27e-01 |
| GO:BP | GO:0070862 | negative regulation of protein exit from endoplasmic reticulum | 1 | 10 | 6.27e-01 |
| GO:BP | GO:0000296 | spermine transport | 1 | 3 | 6.27e-01 |
| GO:BP | GO:0036506 | maintenance of unfolded protein | 1 | 3 | 6.27e-01 |
| GO:BP | GO:1904378 | maintenance of unfolded protein involved in ERAD pathway | 1 | 3 | 6.27e-01 |
| GO:BP | GO:2000780 | negative regulation of double-strand break repair | 2 | 30 | 6.27e-01 |
| GO:BP | GO:1900109 | regulation of histone H3-K9 dimethylation | 1 | 2 | 6.28e-01 |
| GO:BP | GO:0051052 | regulation of DNA metabolic process | 1 | 452 | 6.28e-01 |
| GO:BP | GO:0042219 | cellular modified amino acid catabolic process | 1 | 16 | 6.28e-01 |
| GO:BP | GO:0071320 | cellular response to cAMP | 9 | 41 | 6.28e-01 |
| GO:BP | GO:0090155 | negative regulation of sphingolipid biosynthetic process | 1 | 6 | 6.28e-01 |
| GO:BP | GO:0010764 | negative regulation of fibroblast migration | 2 | 9 | 6.28e-01 |
| GO:BP | GO:0003009 | skeletal muscle contraction | 4 | 31 | 6.28e-01 |
| GO:BP | GO:0009259 | ribonucleotide metabolic process | 1 | 311 | 6.28e-01 |
| GO:BP | GO:0030182 | neuron differentiation | 1 | 1061 | 6.29e-01 |
| GO:BP | GO:0030501 | positive regulation of bone mineralization | 7 | 34 | 6.29e-01 |
| GO:BP | GO:0071398 | cellular response to fatty acid | 2 | 25 | 6.29e-01 |
| GO:BP | GO:0007250 | activation of NF-kappaB-inducing kinase activity | 1 | 13 | 6.29e-01 |
| GO:BP | GO:0070814 | hydrogen sulfide biosynthetic process | 1 | 4 | 6.29e-01 |
| GO:BP | GO:0060363 | cranial suture morphogenesis | 1 | 8 | 6.29e-01 |
| GO:BP | GO:0071288 | cellular response to mercury ion | 1 | 2 | 6.29e-01 |
| GO:BP | GO:0060389 | pathway-restricted SMAD protein phosphorylation | 2 | 55 | 6.29e-01 |
| GO:BP | GO:0052372 | modulation by symbiont of entry into host | 2 | 38 | 6.29e-01 |
| GO:BP | GO:0007099 | centriole replication | 4 | 38 | 6.29e-01 |
| GO:BP | GO:1903897 | regulation of PERK-mediated unfolded protein response | 2 | 10 | 6.29e-01 |
| GO:BP | GO:0006361 | transcription initiation at RNA polymerase I promoter | 2 | 11 | 6.29e-01 |
| GO:BP | GO:0016267 | O-glycan processing, core 1 | 1 | 2 | 6.29e-01 |
| GO:BP | GO:1901655 | cellular response to ketone | 17 | 86 | 6.29e-01 |
| GO:BP | GO:1903577 | cellular response to L-arginine | 1 | 3 | 6.29e-01 |
| GO:BP | GO:0019377 | glycolipid catabolic process | 1 | 12 | 6.29e-01 |
| GO:BP | GO:0006268 | DNA unwinding involved in DNA replication | 1 | 22 | 6.29e-01 |
| GO:BP | GO:0014850 | response to muscle activity | 4 | 17 | 6.29e-01 |
| GO:BP | GO:0032965 | regulation of collagen biosynthetic process | 1 | 30 | 6.29e-01 |
| GO:BP | GO:0006366 | transcription by RNA polymerase II | 1 | 1995 | 6.29e-01 |
| GO:BP | GO:0002090 | regulation of receptor internalization | 4 | 49 | 6.29e-01 |
| GO:BP | GO:0034249 | negative regulation of amide metabolic process | 28 | 186 | 6.29e-01 |
| GO:BP | GO:2000026 | regulation of multicellular organismal development | 1 | 1014 | 6.29e-01 |
| GO:BP | GO:0018130 | heterocycle biosynthetic process | 2 | 3132 | 6.29e-01 |
| GO:BP | GO:0033326 | cerebrospinal fluid secretion | 1 | 3 | 6.29e-01 |
| GO:BP | GO:0014066 | regulation of phosphatidylinositol 3-kinase signaling | 3 | 78 | 6.29e-01 |
| GO:BP | GO:0046878 | positive regulation of saliva secretion | 1 | 2 | 6.29e-01 |
| GO:BP | GO:0030950 | establishment or maintenance of actin cytoskeleton polarity | 1 | 3 | 6.29e-01 |
| GO:BP | GO:0016476 | regulation of embryonic cell shape | 1 | 3 | 6.29e-01 |
| GO:BP | GO:0035378 | carbon dioxide transmembrane transport | 1 | 1 | 6.29e-01 |
| GO:BP | GO:0045071 | negative regulation of viral genome replication | 2 | 37 | 6.29e-01 |
| GO:BP | GO:0033363 | secretory granule organization | 10 | 50 | 6.29e-01 |
| GO:BP | GO:0044829 | positive regulation by host of viral genome replication | 2 | 10 | 6.29e-01 |
| GO:BP | GO:0072237 | metanephric proximal tubule development | 1 | 3 | 6.29e-01 |
| GO:BP | GO:0045880 | positive regulation of smoothened signaling pathway | 3 | 31 | 6.29e-01 |
| GO:BP | GO:1903671 | negative regulation of sprouting angiogenesis | 2 | 11 | 6.29e-01 |
| GO:BP | GO:0051702 | biological process involved in interaction with symbiont | 1 | 78 | 6.29e-01 |
| GO:BP | GO:0019438 | aromatic compound biosynthetic process | 2 | 3133 | 6.29e-01 |
| GO:BP | GO:1900102 | negative regulation of endoplasmic reticulum unfolded protein response | 3 | 16 | 6.30e-01 |
| GO:BP | GO:0070989 | oxidative demethylation | 1 | 10 | 6.30e-01 |
| GO:BP | GO:0006607 | NLS-bearing protein import into nucleus | 3 | 18 | 6.30e-01 |
| GO:BP | GO:0000271 | polysaccharide biosynthetic process | 4 | 53 | 6.30e-01 |
| GO:BP | GO:2000251 | positive regulation of actin cytoskeleton reorganization | 1 | 14 | 6.30e-01 |
| GO:BP | GO:0016444 | somatic cell DNA recombination | 4 | 55 | 6.30e-01 |
| GO:BP | GO:0002562 | somatic diversification of immune receptors via germline recombination within a single locus | 4 | 55 | 6.30e-01 |
| GO:BP | GO:0031103 | axon regeneration | 1 | 42 | 6.30e-01 |
| GO:BP | GO:0046597 | negative regulation of viral entry into host cell | 1 | 14 | 6.31e-01 |
| GO:BP | GO:0031069 | hair follicle morphogenesis | 1 | 18 | 6.31e-01 |
| GO:BP | GO:0007435 | salivary gland morphogenesis | 1 | 25 | 6.31e-01 |
| GO:BP | GO:1904045 | cellular response to aldosterone | 1 | 5 | 6.31e-01 |
| GO:BP | GO:0010803 | regulation of tumor necrosis factor-mediated signaling pathway | 5 | 41 | 6.32e-01 |
| GO:BP | GO:0097010 | eukaryotic translation initiation factor 4F complex assembly | 1 | 3 | 6.32e-01 |
| GO:BP | GO:0006084 | acetyl-CoA metabolic process | 2 | 28 | 6.32e-01 |
| GO:BP | GO:0002701 | negative regulation of production of molecular mediator of immune response | 3 | 21 | 6.32e-01 |
| GO:BP | GO:0007286 | spermatid development | 1 | 105 | 6.32e-01 |
| GO:BP | GO:0060046 | regulation of acrosome reaction | 1 | 8 | 6.32e-01 |
| GO:BP | GO:0051234 | establishment of localization | 7 | 3433 | 6.32e-01 |
| GO:BP | GO:0048545 | response to steroid hormone | 2 | 245 | 6.32e-01 |
| GO:BP | GO:0071352 | cellular response to interleukin-2 | 1 | 2 | 6.33e-01 |
| GO:BP | GO:0019693 | ribose phosphate metabolic process | 1 | 319 | 6.33e-01 |
| GO:BP | GO:0038110 | interleukin-2-mediated signaling pathway | 1 | 2 | 6.33e-01 |
| GO:BP | GO:0009749 | response to glucose | 15 | 137 | 6.33e-01 |
| GO:BP | GO:0034164 | negative regulation of toll-like receptor 9 signaling pathway | 1 | 3 | 6.33e-01 |
| GO:BP | GO:1905203 | regulation of connective tissue replacement | 1 | 5 | 6.33e-01 |
| GO:BP | GO:0048870 | cell motility | 17 | 1182 | 6.33e-01 |
| GO:BP | GO:0021773 | striatal medium spiny neuron differentiation | 1 | 3 | 6.34e-01 |
| GO:BP | GO:0033627 | cell adhesion mediated by integrin | 2 | 63 | 6.34e-01 |
| GO:BP | GO:0050769 | positive regulation of neurogenesis | 17 | 189 | 6.34e-01 |
| GO:BP | GO:0009889 | regulation of biosynthetic process | 2 | 3169 | 6.34e-01 |
| GO:BP | GO:0036149 | phosphatidylinositol acyl-chain remodeling | 1 | 3 | 6.34e-01 |
| GO:BP | GO:0097676 | histone H3-K36 dimethylation | 1 | 4 | 6.34e-01 |
| GO:BP | GO:2000318 | positive regulation of T-helper 17 type immune response | 2 | 7 | 6.34e-01 |
| GO:BP | GO:0071351 | cellular response to interleukin-18 | 1 | 3 | 6.34e-01 |
| GO:BP | GO:0035655 | interleukin-18-mediated signaling pathway | 1 | 3 | 6.34e-01 |
| GO:BP | GO:0051004 | regulation of lipoprotein lipase activity | 1 | 11 | 6.34e-01 |
| GO:BP | GO:2000074 | regulation of type B pancreatic cell development | 1 | 8 | 6.34e-01 |
| GO:BP | GO:0002940 | tRNA N2-guanine methylation | 1 | 4 | 6.34e-01 |
| GO:BP | GO:0072282 | metanephric nephron tubule morphogenesis | 1 | 5 | 6.34e-01 |
| GO:BP | GO:0035246 | peptidyl-arginine N-methylation | 1 | 4 | 6.35e-01 |
| GO:BP | GO:0009887 | animal organ morphogenesis | 5 | 742 | 6.35e-01 |
| GO:BP | GO:0002115 | store-operated calcium entry | 2 | 15 | 6.35e-01 |
| GO:BP | GO:0097503 | sialylation | 2 | 18 | 6.35e-01 |
| GO:BP | GO:0045779 | negative regulation of bone resorption | 1 | 7 | 6.35e-01 |
| GO:BP | GO:0035562 | negative regulation of chromatin binding | 2 | 8 | 6.35e-01 |
| GO:BP | GO:0051247 | positive regulation of protein metabolic process | 1 | 1123 | 6.36e-01 |
| GO:BP | GO:0032486 | Rap protein signal transduction | 1 | 13 | 6.36e-01 |
| GO:BP | GO:0045780 | positive regulation of bone resorption | 2 | 12 | 6.36e-01 |
| GO:BP | GO:1900226 | negative regulation of NLRP3 inflammasome complex assembly | 2 | 6 | 6.36e-01 |
| GO:BP | GO:1903911 | positive regulation of receptor clustering | 1 | 6 | 6.36e-01 |
| GO:BP | GO:0033750 | ribosome localization | 3 | 15 | 6.36e-01 |
| GO:BP | GO:0000054 | ribosomal subunit export from nucleus | 3 | 15 | 6.36e-01 |
| GO:BP | GO:0098735 | positive regulation of the force of heart contraction | 1 | 4 | 6.36e-01 |
| GO:BP | GO:0042997 | negative regulation of Golgi to plasma membrane protein transport | 1 | 4 | 6.36e-01 |
| GO:BP | GO:0007095 | mitotic G2 DNA damage checkpoint signaling | 6 | 35 | 6.36e-01 |
| GO:BP | GO:0007621 | negative regulation of female receptivity | 1 | 1 | 6.37e-01 |
| GO:BP | GO:0070534 | protein K63-linked ubiquitination | 3 | 52 | 6.37e-01 |
| GO:BP | GO:0032527 | protein exit from endoplasmic reticulum | 7 | 43 | 6.37e-01 |
| GO:BP | GO:0098915 | membrane repolarization during ventricular cardiac muscle cell action potential | 1 | 10 | 6.37e-01 |
| GO:BP | GO:0010728 | regulation of hydrogen peroxide biosynthetic process | 1 | 5 | 6.37e-01 |
| GO:BP | GO:0048505 | regulation of timing of cell differentiation | 1 | 7 | 6.37e-01 |
| GO:BP | GO:0030326 | embryonic limb morphogenesis | 1 | 89 | 6.37e-01 |
| GO:BP | GO:0035113 | embryonic appendage morphogenesis | 1 | 89 | 6.37e-01 |
| GO:BP | GO:0007205 | protein kinase C-activating G protein-coupled receptor signaling pathway | 1 | 19 | 6.37e-01 |
| GO:BP | GO:0071042 | nuclear polyadenylation-dependent mRNA catabolic process | 1 | 4 | 6.38e-01 |
| GO:BP | GO:0071047 | polyadenylation-dependent mRNA catabolic process | 1 | 4 | 6.38e-01 |
| GO:BP | GO:2000172 | regulation of branching morphogenesis of a nerve | 1 | 3 | 6.38e-01 |
| GO:BP | GO:1903514 | release of sequestered calcium ion into cytosol by endoplasmic reticulum | 6 | 28 | 6.38e-01 |
| GO:BP | GO:0071359 | cellular response to dsRNA | 1 | 18 | 6.38e-01 |
| GO:BP | GO:0043377 | negative regulation of CD8-positive, alpha-beta T cell differentiation | 1 | 3 | 6.38e-01 |
| GO:BP | GO:0006835 | dicarboxylic acid transport | 2 | 62 | 6.39e-01 |
| GO:BP | GO:0071495 | cellular response to endogenous stimulus | 1 | 1107 | 6.39e-01 |
| GO:BP | GO:1902775 | mitochondrial large ribosomal subunit assembly | 1 | 4 | 6.39e-01 |
| GO:BP | GO:0090666 | scaRNA localization to Cajal body | 1 | 5 | 6.39e-01 |
| GO:BP | GO:0071622 | regulation of granulocyte chemotaxis | 1 | 27 | 6.39e-01 |
| GO:BP | GO:0006545 | glycine biosynthetic process | 1 | 4 | 6.39e-01 |
| GO:BP | GO:0017145 | stem cell division | 1 | 26 | 6.39e-01 |
| GO:BP | GO:0150105 | protein localization to cell-cell junction | 2 | 17 | 6.39e-01 |
| GO:BP | GO:0072675 | osteoclast fusion | 1 | 5 | 6.39e-01 |
| GO:BP | GO:0060715 | syncytiotrophoblast cell differentiation involved in labyrinthine layer development | 1 | 3 | 6.39e-01 |
| GO:BP | GO:0071482 | cellular response to light stimulus | 19 | 99 | 6.39e-01 |
| GO:BP | GO:0060117 | auditory receptor cell development | 5 | 14 | 6.40e-01 |
| GO:BP | GO:0000491 | small nucleolar ribonucleoprotein complex assembly | 1 | 12 | 6.40e-01 |
| GO:BP | GO:0003285 | septum secundum development | 1 | 3 | 6.40e-01 |
| GO:BP | GO:0043488 | regulation of mRNA stability | 27 | 147 | 6.40e-01 |
| GO:BP | GO:0009311 | oligosaccharide metabolic process | 3 | 43 | 6.40e-01 |
| GO:BP | GO:0048515 | spermatid differentiation | 1 | 111 | 6.41e-01 |
| GO:BP | GO:2000379 | positive regulation of reactive oxygen species metabolic process | 1 | 46 | 6.41e-01 |
| GO:BP | GO:1903573 | negative regulation of response to endoplasmic reticulum stress | 2 | 41 | 6.41e-01 |
| GO:BP | GO:0046530 | photoreceptor cell differentiation | 6 | 40 | 6.41e-01 |
| GO:BP | GO:0014897 | striated muscle hypertrophy | 12 | 73 | 6.41e-01 |
| GO:BP | GO:0009826 | unidimensional cell growth | 1 | 3 | 6.41e-01 |
| GO:BP | GO:0036465 | synaptic vesicle recycling | 11 | 73 | 6.41e-01 |
| GO:BP | GO:0035933 | glucocorticoid secretion | 1 | 7 | 6.41e-01 |
| GO:BP | GO:1902036 | regulation of hematopoietic stem cell differentiation | 1 | 15 | 6.41e-01 |
| GO:BP | GO:0070986 | left/right axis specification | 2 | 13 | 6.41e-01 |
| GO:BP | GO:0048699 | generation of neurons | 1 | 1119 | 6.41e-01 |
| GO:BP | GO:0016103 | diterpenoid catabolic process | 1 | 1 | 6.41e-01 |
| GO:BP | GO:0033693 | neurofilament bundle assembly | 1 | 3 | 6.41e-01 |
| GO:BP | GO:0099185 | postsynaptic intermediate filament cytoskeleton organization | 1 | 3 | 6.41e-01 |
| GO:BP | GO:0090036 | regulation of protein kinase C signaling | 3 | 14 | 6.41e-01 |
| GO:BP | GO:0140042 | lipid droplet formation | 2 | 12 | 6.41e-01 |
| GO:BP | GO:0045105 | intermediate filament polymerization or depolymerization | 1 | 2 | 6.41e-01 |
| GO:BP | GO:1902809 | regulation of skeletal muscle fiber differentiation | 1 | 4 | 6.41e-01 |
| GO:BP | GO:0034653 | retinoic acid catabolic process | 1 | 1 | 6.41e-01 |
| GO:BP | GO:0003158 | endothelium development | 2 | 104 | 6.41e-01 |
| GO:BP | GO:0034421 | post-translational protein acetylation | 1 | 3 | 6.42e-01 |
| GO:BP | GO:0060750 | epithelial cell proliferation involved in mammary gland duct elongation | 1 | 3 | 6.42e-01 |
| GO:BP | GO:0060686 | negative regulation of prostatic bud formation | 1 | 4 | 6.42e-01 |
| GO:BP | GO:0048852 | diencephalon morphogenesis | 1 | 2 | 6.42e-01 |
| GO:BP | GO:0060762 | regulation of branching involved in mammary gland duct morphogenesis | 1 | 4 | 6.42e-01 |
| GO:BP | GO:0090082 | positive regulation of heart induction by negative regulation of canonical Wnt signaling pathway | 1 | 4 | 6.42e-01 |
| GO:BP | GO:1901321 | positive regulation of heart induction | 1 | 4 | 6.42e-01 |
| GO:BP | GO:0032816 | positive regulation of natural killer cell activation | 2 | 16 | 6.42e-01 |
| GO:BP | GO:0009566 | fertilization | 1 | 93 | 6.42e-01 |
| GO:BP | GO:1904693 | midbrain morphogenesis | 1 | 3 | 6.42e-01 |
| GO:BP | GO:0060717 | chorion development | 2 | 8 | 6.42e-01 |
| GO:BP | GO:0031399 | regulation of protein modification process | 1 | 1173 | 6.42e-01 |
| GO:BP | GO:0010882 | regulation of cardiac muscle contraction by calcium ion signaling | 4 | 25 | 6.42e-01 |
| GO:BP | GO:0021884 | forebrain neuron development | 1 | 16 | 6.42e-01 |
| GO:BP | GO:0036344 | platelet morphogenesis | 2 | 19 | 6.42e-01 |
| GO:BP | GO:0021626 | central nervous system maturation | 1 | 5 | 6.43e-01 |
| GO:BP | GO:2001185 | regulation of CD8-positive, alpha-beta T cell activation | 1 | 13 | 6.43e-01 |
| GO:BP | GO:0002682 | regulation of immune system process | 1 | 877 | 6.43e-01 |
| GO:BP | GO:1902430 | negative regulation of amyloid-beta formation | 2 | 17 | 6.43e-01 |
| GO:BP | GO:1905710 | positive regulation of membrane permeability | 6 | 45 | 6.43e-01 |
| GO:BP | GO:1900363 | regulation of mRNA polyadenylation | 2 | 11 | 6.43e-01 |
| GO:BP | GO:0070099 | regulation of chemokine-mediated signaling pathway | 1 | 8 | 6.43e-01 |
| GO:BP | GO:0023056 | positive regulation of signaling | 2 | 1256 | 6.43e-01 |
| GO:BP | GO:0051875 | pigment granule localization | 4 | 22 | 6.43e-01 |
| GO:BP | GO:0016562 | protein import into peroxisome matrix, receptor recycling | 1 | 7 | 6.43e-01 |
| GO:BP | GO:0003221 | right ventricular cardiac muscle tissue morphogenesis | 1 | 3 | 6.43e-01 |
| GO:BP | GO:2001268 | negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway | 1 | 5 | 6.43e-01 |
| GO:BP | GO:0043200 | response to amino acid | 18 | 95 | 6.43e-01 |
| GO:BP | GO:1904589 | regulation of protein import | 1 | 3 | 6.43e-01 |
| GO:BP | GO:0072172 | mesonephric tubule formation | 1 | 6 | 6.43e-01 |
| GO:BP | GO:0048511 | rhythmic process | 10 | 237 | 6.43e-01 |
| GO:BP | GO:0030968 | endoplasmic reticulum unfolded protein response | 12 | 70 | 6.43e-01 |
| GO:BP | GO:2001054 | negative regulation of mesenchymal cell apoptotic process | 1 | 3 | 6.43e-01 |
| GO:BP | GO:0009651 | response to salt stress | 5 | 18 | 6.43e-01 |
| GO:BP | GO:0060421 | positive regulation of heart growth | 2 | 27 | 6.43e-01 |
| GO:BP | GO:0045472 | response to ether | 1 | 7 | 6.43e-01 |
| GO:BP | GO:0090075 | relaxation of muscle | 1 | 29 | 6.43e-01 |
| GO:BP | GO:0010763 | positive regulation of fibroblast migration | 3 | 15 | 6.44e-01 |
| GO:BP | GO:1901362 | organic cyclic compound biosynthetic process | 2 | 3237 | 6.44e-01 |
| GO:BP | GO:0021954 | central nervous system neuron development | 1 | 61 | 6.44e-01 |
| GO:BP | GO:0003208 | cardiac ventricle morphogenesis | 2 | 62 | 6.44e-01 |
| GO:BP | GO:0046847 | filopodium assembly | 5 | 56 | 6.44e-01 |
| GO:BP | GO:0070265 | necrotic cell death | 4 | 53 | 6.45e-01 |
| GO:BP | GO:0002065 | columnar/cuboidal epithelial cell differentiation | 7 | 80 | 6.45e-01 |
| GO:BP | GO:0061370 | testosterone biosynthetic process | 1 | 3 | 6.45e-01 |
| GO:BP | GO:1901576 | organic substance biosynthetic process | 3 | 4539 | 6.45e-01 |
| GO:BP | GO:0007143 | female meiotic nuclear division | 6 | 25 | 6.45e-01 |
| GO:BP | GO:0060317 | cardiac epithelial to mesenchymal transition | 1 | 28 | 6.45e-01 |
| GO:BP | GO:0051716 | cellular response to stimulus | 10 | 4953 | 6.45e-01 |
| GO:BP | GO:0060052 | neurofilament cytoskeleton organization | 2 | 9 | 6.45e-01 |
| GO:BP | GO:0080154 | regulation of fertilization | 1 | 7 | 6.45e-01 |
| GO:BP | GO:0045658 | regulation of neutrophil differentiation | 1 | 2 | 6.45e-01 |
| GO:BP | GO:0140352 | export from cell | 2 | 611 | 6.45e-01 |
| GO:BP | GO:0140285 | endosome fission | 1 | 3 | 6.45e-01 |
| GO:BP | GO:0050684 | regulation of mRNA processing | 1 | 127 | 6.45e-01 |
| GO:BP | GO:0007431 | salivary gland development | 1 | 26 | 6.45e-01 |
| GO:BP | GO:1900034 | regulation of cellular response to heat | 2 | 16 | 6.45e-01 |
| GO:BP | GO:0051481 | negative regulation of cytosolic calcium ion concentration | 2 | 9 | 6.45e-01 |
| GO:BP | GO:0000083 | regulation of transcription involved in G1/S transition of mitotic cell cycle | 2 | 20 | 6.45e-01 |
| GO:BP | GO:0010878 | cholesterol storage | 1 | 16 | 6.45e-01 |
| GO:BP | GO:0018243 | protein O-linked glycosylation via threonine | 1 | 7 | 6.45e-01 |
| GO:BP | GO:0018242 | protein O-linked glycosylation via serine | 1 | 7 | 6.45e-01 |
| GO:BP | GO:0014009 | glial cell proliferation | 1 | 40 | 6.45e-01 |
| GO:BP | GO:0043467 | regulation of generation of precursor metabolites and energy | 6 | 89 | 6.45e-01 |
| GO:BP | GO:1903542 | negative regulation of exosomal secretion | 1 | 4 | 6.45e-01 |
| GO:BP | GO:0002762 | negative regulation of myeloid leukocyte differentiation | 2 | 33 | 6.45e-01 |
| GO:BP | GO:0044093 | positive regulation of molecular function | 1 | 1149 | 6.45e-01 |
| GO:BP | GO:0050877 | nervous system process | 1 | 634 | 6.45e-01 |
| GO:BP | GO:0070676 | intralumenal vesicle formation | 1 | 4 | 6.45e-01 |
| GO:BP | GO:0006335 | DNA replication-dependent chromatin assembly | 1 | 6 | 6.46e-01 |
| GO:BP | GO:0072710 | response to hydroxyurea | 2 | 11 | 6.46e-01 |
| GO:BP | GO:0060155 | platelet dense granule organization | 1 | 23 | 6.46e-01 |
| GO:BP | GO:0010665 | regulation of cardiac muscle cell apoptotic process | 6 | 33 | 6.46e-01 |
| GO:BP | GO:0045738 | negative regulation of DNA repair | 2 | 32 | 6.46e-01 |
| GO:BP | GO:0035470 | positive regulation of vascular wound healing | 1 | 4 | 6.46e-01 |
| GO:BP | GO:0038159 | C-X-C chemokine receptor CXCR4 signaling pathway | 1 | 4 | 6.46e-01 |
| GO:BP | GO:1990441 | negative regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress | 1 | 4 | 6.46e-01 |
| GO:BP | GO:1903292 | protein localization to Golgi membrane | 1 | 4 | 6.47e-01 |
| GO:BP | GO:1904425 | negative regulation of GTP binding | 1 | 3 | 6.47e-01 |
| GO:BP | GO:0021548 | pons development | 2 | 7 | 6.47e-01 |
| GO:BP | GO:1990442 | intrinsic apoptotic signaling pathway in response to nitrosative stress | 1 | 3 | 6.47e-01 |
| GO:BP | GO:2000779 | regulation of double-strand break repair | 6 | 121 | 6.47e-01 |
| GO:BP | GO:0031342 | negative regulation of cell killing | 1 | 11 | 6.47e-01 |
| GO:BP | GO:0002710 | negative regulation of T cell mediated immunity | 1 | 8 | 6.47e-01 |
| GO:BP | GO:0034775 | glutathione transmembrane transport | 1 | 7 | 6.47e-01 |
| GO:BP | GO:0021605 | cranial nerve maturation | 1 | 1 | 6.48e-01 |
| GO:BP | GO:0150065 | regulation of deacetylase activity | 2 | 10 | 6.48e-01 |
| GO:BP | GO:0099590 | neurotransmitter receptor internalization | 2 | 19 | 6.48e-01 |
| GO:BP | GO:0038083 | peptidyl-tyrosine autophosphorylation | 2 | 18 | 6.48e-01 |
| GO:BP | GO:0044706 | multi-multicellular organism process | 1 | 135 | 6.48e-01 |
| GO:BP | GO:0009967 | positive regulation of signal transduction | 1 | 1133 | 6.48e-01 |
| GO:BP | GO:0055081 | monoatomic anion homeostasis | 2 | 14 | 6.48e-01 |
| GO:BP | GO:0050679 | positive regulation of epithelial cell proliferation | 7 | 155 | 6.48e-01 |
| GO:BP | GO:0031647 | regulation of protein stability | 5 | 290 | 6.48e-01 |
| GO:BP | GO:0001945 | lymph vessel development | 2 | 22 | 6.48e-01 |
| GO:BP | GO:0016080 | synaptic vesicle targeting | 1 | 3 | 6.48e-01 |
| GO:BP | GO:0010840 | regulation of circadian sleep/wake cycle, wakefulness | 1 | 1 | 6.48e-01 |
| GO:BP | GO:0042746 | circadian sleep/wake cycle, wakefulness | 1 | 1 | 6.48e-01 |
| GO:BP | GO:0016192 | vesicle-mediated transport | 6 | 1238 | 6.48e-01 |
| GO:BP | GO:0002939 | tRNA N1-guanine methylation | 1 | 3 | 6.48e-01 |
| GO:BP | GO:1904814 | regulation of protein localization to chromosome, telomeric region | 2 | 15 | 6.48e-01 |
| GO:BP | GO:1990379 | lipid transport across blood-brain barrier | 1 | 6 | 6.48e-01 |
| GO:BP | GO:1904231 | positive regulation of succinate dehydrogenase activity | 1 | 2 | 6.48e-01 |
| GO:BP | GO:0009629 | response to gravity | 1 | 5 | 6.48e-01 |
| GO:BP | GO:1904229 | regulation of succinate dehydrogenase activity | 1 | 2 | 6.48e-01 |
| GO:BP | GO:0045777 | positive regulation of blood pressure | 1 | 17 | 6.48e-01 |
| GO:BP | GO:1904232 | regulation of aconitate hydratase activity | 1 | 2 | 6.48e-01 |
| GO:BP | GO:1904234 | positive regulation of aconitate hydratase activity | 1 | 2 | 6.48e-01 |
| GO:BP | GO:0046033 | AMP metabolic process | 1 | 22 | 6.48e-01 |
| GO:BP | GO:0032228 | regulation of synaptic transmission, GABAergic | 1 | 23 | 6.48e-01 |
| GO:BP | GO:0006468 | protein phosphorylation | 1 | 1167 | 6.48e-01 |
| GO:BP | GO:0030225 | macrophage differentiation | 1 | 35 | 6.49e-01 |
| GO:BP | GO:1990074 | polyuridylation-dependent mRNA catabolic process | 1 | 3 | 6.49e-01 |
| GO:BP | GO:0010526 | retrotransposon silencing | 1 | 3 | 6.49e-01 |
| GO:BP | GO:0002673 | regulation of acute inflammatory response | 2 | 21 | 6.49e-01 |
| GO:BP | GO:0090038 | negative regulation of protein kinase C signaling | 1 | 4 | 6.49e-01 |
| GO:BP | GO:1900044 | regulation of protein K63-linked ubiquitination | 3 | 13 | 6.49e-01 |
| GO:BP | GO:0006112 | energy reserve metabolic process | 4 | 73 | 6.49e-01 |
| GO:BP | GO:1901098 | positive regulation of autophagosome maturation | 1 | 6 | 6.50e-01 |
| GO:BP | GO:1902037 | negative regulation of hematopoietic stem cell differentiation | 1 | 4 | 6.50e-01 |
| GO:BP | GO:0021953 | central nervous system neuron differentiation | 2 | 108 | 6.50e-01 |
| GO:BP | GO:0010157 | response to chlorate | 1 | 1 | 6.50e-01 |
| GO:BP | GO:0003306 | Wnt signaling pathway involved in heart development | 2 | 8 | 6.50e-01 |
| GO:BP | GO:0090179 | planar cell polarity pathway involved in neural tube closure | 2 | 12 | 6.50e-01 |
| GO:BP | GO:2000826 | regulation of heart morphogenesis | 2 | 10 | 6.50e-01 |
| GO:BP | GO:0070252 | actin-mediated cell contraction | 2 | 89 | 6.50e-01 |
| GO:BP | GO:0015837 | amine transport | 3 | 56 | 6.50e-01 |
| GO:BP | GO:0001701 | in utero embryonic development | 1 | 344 | 6.50e-01 |
| GO:BP | GO:0038027 | apolipoprotein A-I-mediated signaling pathway | 1 | 5 | 6.50e-01 |
| GO:BP | GO:0050748 | negative regulation of lipoprotein metabolic process | 1 | 4 | 6.50e-01 |
| GO:BP | GO:1901678 | iron coordination entity transport | 1 | 11 | 6.50e-01 |
| GO:BP | GO:1905598 | negative regulation of low-density lipoprotein receptor activity | 1 | 3 | 6.50e-01 |
| GO:BP | GO:0019915 | lipid storage | 4 | 66 | 6.50e-01 |
| GO:BP | GO:1990410 | adrenomedullin receptor signaling pathway | 1 | 3 | 6.50e-01 |
| GO:BP | GO:0002926 | tRNA wobble base 5-methoxycarbonylmethyl-2-thiouridinylation | 1 | 3 | 6.50e-01 |
| GO:BP | GO:2000191 | regulation of fatty acid transport | 1 | 19 | 6.51e-01 |
| GO:BP | GO:0032292 | peripheral nervous system axon ensheathment | 1 | 25 | 6.51e-01 |
| GO:BP | GO:0045601 | regulation of endothelial cell differentiation | 2 | 27 | 6.51e-01 |
| GO:BP | GO:1902953 | positive regulation of ER to Golgi vesicle-mediated transport | 1 | 4 | 6.51e-01 |
| GO:BP | GO:0086091 | regulation of heart rate by cardiac conduction | 2 | 36 | 6.51e-01 |
| GO:BP | GO:0034656 | nucleobase-containing small molecule catabolic process | 4 | 20 | 6.51e-01 |
| GO:BP | GO:0022011 | myelination in peripheral nervous system | 1 | 25 | 6.51e-01 |
| GO:BP | GO:0097485 | neuron projection guidance | 7 | 186 | 6.51e-01 |
| GO:BP | GO:0009058 | biosynthetic process | 3 | 4590 | 6.51e-01 |
| GO:BP | GO:1900246 | positive regulation of RIG-I signaling pathway | 2 | 7 | 6.51e-01 |
| GO:BP | GO:0034154 | toll-like receptor 7 signaling pathway | 1 | 4 | 6.51e-01 |
| GO:BP | GO:0045595 | regulation of cell differentiation | 1 | 1137 | 6.51e-01 |
| GO:BP | GO:0042753 | positive regulation of circadian rhythm | 1 | 10 | 6.51e-01 |
| GO:BP | GO:0036152 | phosphatidylethanolamine acyl-chain remodeling | 1 | 8 | 6.51e-01 |
| GO:BP | GO:0051754 | meiotic sister chromatid cohesion, centromeric | 1 | 4 | 6.51e-01 |
| GO:BP | GO:0009065 | glutamine family amino acid catabolic process | 1 | 20 | 6.51e-01 |
| GO:BP | GO:0062013 | positive regulation of small molecule metabolic process | 8 | 104 | 6.52e-01 |
| GO:BP | GO:0051926 | negative regulation of calcium ion transport | 2 | 45 | 6.52e-01 |
| GO:BP | GO:0048254 | snoRNA localization | 1 | 5 | 6.52e-01 |
| GO:BP | GO:0045116 | protein neddylation | 4 | 26 | 6.53e-01 |
| GO:BP | GO:0050708 | regulation of protein secretion | 6 | 185 | 6.53e-01 |
| GO:BP | GO:0055024 | regulation of cardiac muscle tissue development | 1 | 3 | 6.53e-01 |
| GO:BP | GO:0120187 | positive regulation of protein localization to chromatin | 1 | 3 | 6.53e-01 |
| GO:BP | GO:0050728 | negative regulation of inflammatory response | 12 | 87 | 6.53e-01 |
| GO:BP | GO:0006482 | protein demethylation | 3 | 27 | 6.53e-01 |
| GO:BP | GO:0008214 | protein dealkylation | 3 | 27 | 6.53e-01 |
| GO:BP | GO:0032379 | positive regulation of intracellular lipid transport | 1 | 4 | 6.54e-01 |
| GO:BP | GO:0099116 | tRNA 5’-end processing | 3 | 16 | 6.54e-01 |
| GO:BP | GO:1902747 | negative regulation of lens fiber cell differentiation | 1 | 5 | 6.54e-01 |
| GO:BP | GO:0044211 | CTP salvage | 1 | 3 | 6.55e-01 |
| GO:BP | GO:0009224 | CMP biosynthetic process | 1 | 3 | 6.55e-01 |
| GO:BP | GO:0051931 | regulation of sensory perception | 1 | 13 | 6.55e-01 |
| GO:BP | GO:0051930 | regulation of sensory perception of pain | 1 | 13 | 6.55e-01 |
| GO:BP | GO:0043306 | positive regulation of mast cell degranulation | 2 | 10 | 6.56e-01 |
| GO:BP | GO:0010712 | regulation of collagen metabolic process | 1 | 34 | 6.56e-01 |
| GO:BP | GO:0046425 | regulation of receptor signaling pathway via JAK-STAT | 2 | 52 | 6.56e-01 |
| GO:BP | GO:0002176 | male germ cell proliferation | 1 | 6 | 6.56e-01 |
| GO:BP | GO:0009313 | oligosaccharide catabolic process | 1 | 11 | 6.56e-01 |
| GO:BP | GO:0033008 | positive regulation of mast cell activation involved in immune response | 2 | 10 | 6.56e-01 |
| GO:BP | GO:1990182 | exosomal secretion | 3 | 18 | 6.56e-01 |
| GO:BP | GO:0010387 | COP9 signalosome assembly | 1 | 3 | 6.56e-01 |
| GO:BP | GO:1990542 | mitochondrial transmembrane transport | 1 | 39 | 6.56e-01 |
| GO:BP | GO:0048680 | positive regulation of axon regeneration | 1 | 8 | 6.56e-01 |
| GO:BP | GO:0090399 | replicative senescence | 1 | 13 | 6.56e-01 |
| GO:BP | GO:1990314 | cellular response to insulin-like growth factor stimulus | 1 | 8 | 6.56e-01 |
| GO:BP | GO:0042428 | serotonin metabolic process | 2 | 6 | 6.56e-01 |
| GO:BP | GO:0002208 | somatic diversification of immunoglobulins involved in immune response | 3 | 39 | 6.56e-01 |
| GO:BP | GO:0006924 | activation-induced cell death of T cells | 1 | 8 | 6.56e-01 |
| GO:BP | GO:0045190 | isotype switching | 3 | 39 | 6.56e-01 |
| GO:BP | GO:0120045 | stereocilium maintenance | 1 | 2 | 6.56e-01 |
| GO:BP | GO:0002204 | somatic recombination of immunoglobulin genes involved in immune response | 3 | 39 | 6.56e-01 |
| GO:BP | GO:0002024 | diet induced thermogenesis | 1 | 9 | 6.56e-01 |
| GO:BP | GO:0010827 | regulation of glucose transmembrane transport | 8 | 55 | 6.56e-01 |
| GO:BP | GO:0046325 | negative regulation of glucose import | 1 | 10 | 6.56e-01 |
| GO:BP | GO:0051697 | protein delipidation | 1 | 5 | 6.56e-01 |
| GO:BP | GO:0048871 | multicellular organismal-level homeostasis | 2 | 532 | 6.56e-01 |
| GO:BP | GO:0045834 | positive regulation of lipid metabolic process | 6 | 108 | 6.56e-01 |
| GO:BP | GO:0048730 | epidermis morphogenesis | 1 | 20 | 6.56e-01 |
| GO:BP | GO:0018401 | peptidyl-proline hydroxylation to 4-hydroxy-L-proline | 1 | 9 | 6.56e-01 |
| GO:BP | GO:0000467 | exonucleolytic trimming to generate mature 3’-end of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 2 | 9 | 6.56e-01 |
| GO:BP | GO:0000459 | exonucleolytic trimming involved in rRNA processing | 2 | 9 | 6.56e-01 |
| GO:BP | GO:0042921 | glucocorticoid receptor signaling pathway | 1 | 13 | 6.57e-01 |
| GO:BP | GO:0001568 | blood vessel development | 8 | 534 | 6.57e-01 |
| GO:BP | GO:0048041 | focal adhesion assembly | 1 | 81 | 6.57e-01 |
| GO:BP | GO:0071630 | nuclear protein quality control by the ubiquitin-proteasome system | 1 | 3 | 6.57e-01 |
| GO:BP | GO:0090313 | regulation of protein targeting to membrane | 3 | 27 | 6.57e-01 |
| GO:BP | GO:1903036 | positive regulation of response to wounding | 3 | 55 | 6.57e-01 |
| GO:BP | GO:0048318 | axial mesoderm development | 1 | 6 | 6.57e-01 |
| GO:BP | GO:0032415 | regulation of sodium:proton antiporter activity | 1 | 4 | 6.57e-01 |
| GO:BP | GO:1904251 | regulation of bile acid metabolic process | 2 | 9 | 6.57e-01 |
| GO:BP | GO:1900127 | positive regulation of hyaluronan biosynthetic process | 1 | 4 | 6.57e-01 |
| GO:BP | GO:0090090 | negative regulation of canonical Wnt signaling pathway | 1 | 114 | 6.57e-01 |
| GO:BP | GO:0051348 | negative regulation of transferase activity | 43 | 234 | 6.57e-01 |
| GO:BP | GO:0035640 | exploration behavior | 4 | 21 | 6.57e-01 |
| GO:BP | GO:0006287 | base-excision repair, gap-filling | 2 | 14 | 6.57e-01 |
| GO:BP | GO:2001259 | positive regulation of cation channel activity | 2 | 49 | 6.57e-01 |
| GO:BP | GO:0010631 | epithelial cell migration | 3 | 252 | 6.57e-01 |
| GO:BP | GO:0046851 | negative regulation of bone remodeling | 1 | 9 | 6.57e-01 |
| GO:BP | GO:1905146 | lysosomal protein catabolic process | 3 | 19 | 6.57e-01 |
| GO:BP | GO:0031947 | negative regulation of glucocorticoid biosynthetic process | 1 | 5 | 6.57e-01 |
| GO:BP | GO:1904953 | Wnt signaling pathway involved in midbrain dopaminergic neuron differentiation | 2 | 8 | 6.57e-01 |
| GO:BP | GO:0031102 | neuron projection regeneration | 1 | 47 | 6.57e-01 |
| GO:BP | GO:0051604 | protein maturation | 1 | 259 | 6.57e-01 |
| GO:BP | GO:0010165 | response to X-ray | 2 | 29 | 6.57e-01 |
| GO:BP | GO:1900120 | regulation of receptor binding | 1 | 17 | 6.57e-01 |
| GO:BP | GO:0048585 | negative regulation of response to stimulus | 1 | 1248 | 6.57e-01 |
| GO:BP | GO:0031944 | negative regulation of glucocorticoid metabolic process | 1 | 5 | 6.57e-01 |
| GO:BP | GO:0003331 | positive regulation of extracellular matrix constituent secretion | 1 | 4 | 6.57e-01 |
| GO:BP | GO:0009143 | nucleoside triphosphate catabolic process | 2 | 10 | 6.57e-01 |
| GO:BP | GO:0002175 | protein localization to paranode region of axon | 1 | 3 | 6.57e-01 |
| GO:BP | GO:0032757 | positive regulation of interleukin-8 production | 1 | 31 | 6.57e-01 |
| GO:BP | GO:1903650 | negative regulation of cytoplasmic transport | 1 | 3 | 6.57e-01 |
| GO:BP | GO:0046822 | regulation of nucleocytoplasmic transport | 6 | 97 | 6.57e-01 |
| GO:BP | GO:0032793 | positive regulation of CREB transcription factor activity | 1 | 15 | 6.57e-01 |
| GO:BP | GO:0009746 | response to hexose | 15 | 138 | 6.57e-01 |
| GO:BP | GO:0071476 | cellular hypotonic response | 1 | 8 | 6.57e-01 |
| GO:BP | GO:2000573 | positive regulation of DNA biosynthetic process | 1 | 67 | 6.57e-01 |
| GO:BP | GO:0061001 | regulation of dendritic spine morphogenesis | 7 | 39 | 6.58e-01 |
| GO:BP | GO:1900245 | positive regulation of MDA-5 signaling pathway | 1 | 2 | 6.59e-01 |
| GO:BP | GO:0071214 | cellular response to abiotic stimulus | 21 | 268 | 6.59e-01 |
| GO:BP | GO:0046469 | platelet activating factor metabolic process | 1 | 5 | 6.59e-01 |
| GO:BP | GO:0044068 | modulation by symbiont of host cellular process | 1 | 5 | 6.59e-01 |
| GO:BP | GO:0019054 | modulation by virus of host cellular process | 1 | 5 | 6.59e-01 |
| GO:BP | GO:0044003 | modulation by symbiont of host process | 1 | 5 | 6.59e-01 |
| GO:BP | GO:0019048 | modulation by virus of host process | 1 | 5 | 6.59e-01 |
| GO:BP | GO:0104004 | cellular response to environmental stimulus | 21 | 268 | 6.59e-01 |
| GO:BP | GO:0010893 | positive regulation of steroid biosynthetic process | 3 | 15 | 6.59e-01 |
| GO:BP | GO:0048598 | embryonic morphogenesis | 3 | 440 | 6.59e-01 |
| GO:BP | GO:0099163 | synaptic signaling by nitric oxide | 1 | 3 | 6.59e-01 |
| GO:BP | GO:0006541 | glutamine metabolic process | 1 | 24 | 6.59e-01 |
| GO:BP | GO:0031331 | positive regulation of cellular catabolic process | 16 | 277 | 6.59e-01 |
| GO:BP | GO:0038060 | nitric oxide-cGMP-mediated signaling pathway | 1 | 2 | 6.59e-01 |
| GO:BP | GO:0046898 | response to cycloheximide | 1 | 4 | 6.59e-01 |
| GO:BP | GO:0071839 | apoptotic process in bone marrow cell | 1 | 4 | 6.59e-01 |
| GO:BP | GO:0098722 | asymmetric stem cell division | 1 | 2 | 6.59e-01 |
| GO:BP | GO:0090154 | positive regulation of sphingolipid biosynthetic process | 1 | 5 | 6.59e-01 |
| GO:BP | GO:0072273 | metanephric nephron morphogenesis | 2 | 19 | 6.59e-01 |
| GO:BP | GO:2001032 | regulation of double-strand break repair via nonhomologous end joining | 1 | 25 | 6.59e-01 |
| GO:BP | GO:0042078 | germ-line stem cell division | 1 | 2 | 6.59e-01 |
| GO:BP | GO:0045830 | positive regulation of isotype switching | 1 | 19 | 6.59e-01 |
| GO:BP | GO:2000304 | positive regulation of ceramide biosynthetic process | 1 | 5 | 6.59e-01 |
| GO:BP | GO:0098728 | germline stem cell asymmetric division | 1 | 2 | 6.59e-01 |
| GO:BP | GO:0019538 | protein metabolic process | 1 | 4241 | 6.59e-01 |
| GO:BP | GO:0036314 | response to sterol | 3 | 19 | 6.59e-01 |
| GO:BP | GO:1990840 | response to lectin | 1 | 11 | 6.59e-01 |
| GO:BP | GO:0008340 | determination of adult lifespan | 3 | 16 | 6.59e-01 |
| GO:BP | GO:0043011 | myeloid dendritic cell differentiation | 1 | 10 | 6.59e-01 |
| GO:BP | GO:0042178 | xenobiotic catabolic process | 1 | 12 | 6.59e-01 |
| GO:BP | GO:1990858 | cellular response to lectin | 1 | 11 | 6.59e-01 |
| GO:BP | GO:0002223 | stimulatory C-type lectin receptor signaling pathway | 1 | 11 | 6.59e-01 |
| GO:BP | GO:0055129 | L-proline biosynthetic process | 1 | 5 | 6.59e-01 |
| GO:BP | GO:0008088 | axo-dendritic transport | 6 | 73 | 6.59e-01 |
| GO:BP | GO:0006561 | proline biosynthetic process | 1 | 5 | 6.59e-01 |
| GO:BP | GO:0009219 | pyrimidine deoxyribonucleotide metabolic process | 4 | 21 | 6.59e-01 |
| GO:BP | GO:0003401 | axis elongation | 2 | 24 | 6.59e-01 |
| GO:BP | GO:0000018 | regulation of DNA recombination | 2 | 101 | 6.59e-01 |
| GO:BP | GO:0060605 | tube lumen cavitation | 1 | 3 | 6.59e-01 |
| GO:BP | GO:0090132 | epithelium migration | 3 | 252 | 6.59e-01 |
| GO:BP | GO:0060662 | salivary gland cavitation | 1 | 3 | 6.59e-01 |
| GO:BP | GO:0032930 | positive regulation of superoxide anion generation | 1 | 10 | 6.59e-01 |
| GO:BP | GO:0021894 | cerebral cortex GABAergic interneuron development | 1 | 3 | 6.59e-01 |
| GO:BP | GO:0014896 | muscle hypertrophy | 12 | 74 | 6.59e-01 |
| GO:BP | GO:0001774 | microglial cell activation | 4 | 19 | 6.59e-01 |
| GO:BP | GO:0009791 | post-embryonic development | 1 | 74 | 6.59e-01 |
| GO:BP | GO:0035774 | positive regulation of insulin secretion involved in cellular response to glucose stimulus | 2 | 18 | 6.59e-01 |
| GO:BP | GO:0000966 | RNA 5’-end processing | 4 | 22 | 6.59e-01 |
| GO:BP | GO:1904526 | regulation of microtubule binding | 1 | 10 | 6.59e-01 |
| GO:BP | GO:0008090 | retrograde axonal transport | 2 | 19 | 6.59e-01 |
| GO:BP | GO:0071260 | cellular response to mechanical stimulus | 1 | 59 | 6.60e-01 |
| GO:BP | GO:0070314 | G1 to G0 transition | 2 | 15 | 6.60e-01 |
| GO:BP | GO:0010632 | regulation of epithelial cell migration | 4 | 195 | 6.60e-01 |
| GO:BP | GO:0038026 | reelin-mediated signaling pathway | 2 | 9 | 6.60e-01 |
| GO:BP | GO:0051988 | regulation of attachment of spindle microtubules to kinetochore | 1 | 18 | 6.61e-01 |
| GO:BP | GO:0046102 | inosine metabolic process | 1 | 4 | 6.61e-01 |
| GO:BP | GO:0006196 | AMP catabolic process | 1 | 3 | 6.61e-01 |
| GO:BP | GO:0140820 | cytosol to Golgi apparatus transport | 1 | 4 | 6.61e-01 |
| GO:BP | GO:0043518 | negative regulation of DNA damage response, signal transduction by p53 class mediator | 2 | 13 | 6.62e-01 |
| GO:BP | GO:0035771 | interleukin-4-mediated signaling pathway | 1 | 4 | 6.62e-01 |
| GO:BP | GO:0050821 | protein stabilization | 2 | 191 | 6.62e-01 |
| GO:BP | GO:0045618 | positive regulation of keratinocyte differentiation | 1 | 12 | 6.62e-01 |
| GO:BP | GO:0060947 | cardiac vascular smooth muscle cell differentiation | 1 | 8 | 6.62e-01 |
| GO:BP | GO:0072178 | nephric duct morphogenesis | 1 | 8 | 6.62e-01 |
| GO:BP | GO:0050779 | RNA destabilization | 16 | 92 | 6.62e-01 |
| GO:BP | GO:0045650 | negative regulation of macrophage differentiation | 1 | 5 | 6.62e-01 |
| GO:BP | GO:0036066 | protein O-linked fucosylation | 1 | 5 | 6.62e-01 |
| GO:BP | GO:0002328 | pro-B cell differentiation | 1 | 10 | 6.63e-01 |
| GO:BP | GO:0071318 | cellular response to ATP | 1 | 12 | 6.64e-01 |
| GO:BP | GO:0008535 | respiratory chain complex IV assembly | 5 | 29 | 6.64e-01 |
| GO:BP | GO:0046856 | phosphatidylinositol dephosphorylation | 2 | 29 | 6.64e-01 |
| GO:BP | GO:0045934 | negative regulation of nucleobase-containing compound metabolic process | 2 | 1209 | 6.64e-01 |
| GO:BP | GO:0019885 | antigen processing and presentation of endogenous peptide antigen via MHC class I | 1 | 12 | 6.64e-01 |
| GO:BP | GO:0022607 | cellular component assembly | 11 | 2466 | 6.64e-01 |
| GO:BP | GO:0065009 | regulation of molecular function | 3 | 1939 | 6.64e-01 |
| GO:BP | GO:1904358 | positive regulation of telomere maintenance via telomere lengthening | 4 | 33 | 6.64e-01 |
| GO:BP | GO:0048663 | neuron fate commitment | 1 | 29 | 6.64e-01 |
| GO:BP | GO:0071900 | regulation of protein serine/threonine kinase activity | 51 | 282 | 6.64e-01 |
| GO:BP | GO:1903901 | negative regulation of viral life cycle | 1 | 17 | 6.64e-01 |
| GO:BP | GO:0033619 | membrane protein proteolysis | 1 | 45 | 6.64e-01 |
| GO:BP | GO:0045723 | positive regulation of fatty acid biosynthetic process | 1 | 12 | 6.64e-01 |
| GO:BP | GO:0061523 | cilium disassembly | 1 | 4 | 6.64e-01 |
| GO:BP | GO:0019364 | pyridine nucleotide catabolic process | 1 | 4 | 6.64e-01 |
| GO:BP | GO:0045995 | regulation of embryonic development | 2 | 80 | 6.64e-01 |
| GO:BP | GO:0007186 | G protein-coupled receptor signaling pathway | 2 | 389 | 6.64e-01 |
| GO:BP | GO:0006163 | purine nucleotide metabolic process | 1 | 371 | 6.66e-01 |
| GO:BP | GO:0008333 | endosome to lysosome transport | 6 | 63 | 6.66e-01 |
| GO:BP | GO:0031943 | regulation of glucocorticoid metabolic process | 2 | 11 | 6.66e-01 |
| GO:BP | GO:0031111 | negative regulation of microtubule polymerization or depolymerization | 3 | 39 | 6.66e-01 |
| GO:BP | GO:2000047 | regulation of cell-cell adhesion mediated by cadherin | 3 | 16 | 6.66e-01 |
| GO:BP | GO:0032623 | interleukin-2 production | 3 | 31 | 6.66e-01 |
| GO:BP | GO:0042127 | regulation of cell population proliferation | 1 | 1147 | 6.66e-01 |
| GO:BP | GO:0032663 | regulation of interleukin-2 production | 3 | 31 | 6.66e-01 |
| GO:BP | GO:0048514 | blood vessel morphogenesis | 7 | 462 | 6.67e-01 |
| GO:BP | GO:0061082 | myeloid leukocyte cytokine production | 3 | 38 | 6.67e-01 |
| GO:BP | GO:0032785 | negative regulation of DNA-templated transcription, elongation | 2 | 20 | 6.67e-01 |
| GO:BP | GO:0016054 | organic acid catabolic process | 1 | 187 | 6.68e-01 |
| GO:BP | GO:2001267 | regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway | 2 | 13 | 6.68e-01 |
| GO:BP | GO:0046395 | carboxylic acid catabolic process | 1 | 187 | 6.68e-01 |
| GO:BP | GO:0043903 | regulation of biological process involved in symbiotic interaction | 2 | 40 | 6.68e-01 |
| GO:BP | GO:0070424 | regulation of nucleotide-binding oligomerization domain containing signaling pathway | 1 | 9 | 6.68e-01 |
| GO:BP | GO:0015801 | aromatic amino acid transport | 1 | 11 | 6.68e-01 |
| GO:BP | GO:0002733 | regulation of myeloid dendritic cell cytokine production | 1 | 6 | 6.68e-01 |
| GO:BP | GO:0002372 | myeloid dendritic cell cytokine production | 1 | 6 | 6.68e-01 |
| GO:BP | GO:1905063 | regulation of vascular associated smooth muscle cell differentiation | 2 | 14 | 6.68e-01 |
| GO:BP | GO:0002735 | positive regulation of myeloid dendritic cell cytokine production | 1 | 6 | 6.68e-01 |
| GO:BP | GO:1901071 | glucosamine-containing compound metabolic process | 4 | 19 | 6.69e-01 |
| GO:BP | GO:0007267 | cell-cell signaling | 1 | 1138 | 6.69e-01 |
| GO:BP | GO:0021602 | cranial nerve morphogenesis | 1 | 16 | 6.69e-01 |
| GO:BP | GO:0048522 | positive regulation of cellular process | 1 | 4099 | 6.69e-01 |
| GO:BP | GO:1990830 | cellular response to leukemia inhibitory factor | 15 | 84 | 6.69e-01 |
| GO:BP | GO:0006096 | glycolytic process | 7 | 70 | 6.69e-01 |
| GO:BP | GO:0008625 | extrinsic apoptotic signaling pathway via death domain receptors | 4 | 72 | 6.69e-01 |
| GO:BP | GO:0006925 | inflammatory cell apoptotic process | 1 | 15 | 6.69e-01 |
| GO:BP | GO:0009790 | embryo development | 5 | 875 | 6.69e-01 |
| GO:BP | GO:0048565 | digestive tract development | 8 | 92 | 6.69e-01 |
| GO:BP | GO:0015705 | iodide transport | 1 | 2 | 6.70e-01 |
| GO:BP | GO:0090130 | tissue migration | 3 | 256 | 6.70e-01 |
| GO:BP | GO:0022008 | neurogenesis | 1 | 1294 | 6.71e-01 |
| GO:BP | GO:2000179 | positive regulation of neural precursor cell proliferation | 4 | 34 | 6.71e-01 |
| GO:BP | GO:0016254 | preassembly of GPI anchor in ER membrane | 1 | 8 | 6.71e-01 |
| GO:BP | GO:0060055 | angiogenesis involved in wound healing | 4 | 25 | 6.71e-01 |
| GO:BP | GO:1905517 | macrophage migration | 1 | 34 | 6.71e-01 |
| GO:BP | GO:0033500 | carbohydrate homeostasis | 19 | 169 | 6.71e-01 |
| GO:BP | GO:0000028 | ribosomal small subunit assembly | 2 | 18 | 6.71e-01 |
| GO:BP | GO:0035634 | response to stilbenoid | 1 | 2 | 6.71e-01 |
| GO:BP | GO:0046548 | retinal rod cell development | 1 | 6 | 6.71e-01 |
| GO:BP | GO:0035965 | cardiolipin acyl-chain remodeling | 1 | 4 | 6.71e-01 |
| GO:BP | GO:1905155 | positive regulation of membrane invagination | 1 | 11 | 6.72e-01 |
| GO:BP | GO:0060100 | positive regulation of phagocytosis, engulfment | 1 | 11 | 6.72e-01 |
| GO:BP | GO:0043243 | positive regulation of protein-containing complex disassembly | 1 | 30 | 6.72e-01 |
| GO:BP | GO:0070102 | interleukin-6-mediated signaling pathway | 2 | 14 | 6.72e-01 |
| GO:BP | GO:1904035 | regulation of epithelial cell apoptotic process | 11 | 71 | 6.72e-01 |
| GO:BP | GO:0003301 | physiological cardiac muscle hypertrophy | 4 | 19 | 6.72e-01 |
| GO:BP | GO:0061049 | cell growth involved in cardiac muscle cell development | 4 | 19 | 6.72e-01 |
| GO:BP | GO:0003298 | physiological muscle hypertrophy | 4 | 19 | 6.72e-01 |
| GO:BP | GO:0014044 | Schwann cell development | 1 | 28 | 6.72e-01 |
| GO:BP | GO:0048806 | genitalia development | 8 | 28 | 6.72e-01 |
| GO:BP | GO:0038127 | ERBB signaling pathway | 10 | 107 | 6.72e-01 |
| GO:BP | GO:0043405 | regulation of MAP kinase activity | 6 | 141 | 6.72e-01 |
| GO:BP | GO:1902931 | negative regulation of alcohol biosynthetic process | 2 | 10 | 6.72e-01 |
| GO:BP | GO:0042168 | heme metabolic process | 1 | 40 | 6.72e-01 |
| GO:BP | GO:0031958 | corticosteroid receptor signaling pathway | 1 | 14 | 6.72e-01 |
| GO:BP | GO:0009719 | response to endogenous stimulus | 1 | 1278 | 6.72e-01 |
| GO:BP | GO:0032650 | regulation of interleukin-1 alpha production | 1 | 4 | 6.73e-01 |
| GO:BP | GO:0032610 | interleukin-1 alpha production | 1 | 4 | 6.73e-01 |
| GO:BP | GO:0071962 | mitotic sister chromatid cohesion, centromeric | 1 | 4 | 6.73e-01 |
| GO:BP | GO:0051341 | regulation of oxidoreductase activity | 1 | 68 | 6.73e-01 |
| GO:BP | GO:0072708 | response to sorbitol | 1 | 7 | 6.74e-01 |
| GO:BP | GO:1902531 | regulation of intracellular signal transduction | 1 | 1345 | 6.74e-01 |
| GO:BP | GO:0010664 | negative regulation of striated muscle cell apoptotic process | 3 | 24 | 6.74e-01 |
| GO:BP | GO:0045662 | negative regulation of myoblast differentiation | 2 | 19 | 6.74e-01 |
| GO:BP | GO:0048385 | regulation of retinoic acid receptor signaling pathway | 2 | 13 | 6.74e-01 |
| GO:BP | GO:0051898 | negative regulation of protein kinase B signaling | 1 | 36 | 6.74e-01 |
| GO:BP | GO:0090737 | telomere maintenance via telomere trimming | 2 | 13 | 6.74e-01 |
| GO:BP | GO:0090656 | t-circle formation | 2 | 13 | 6.74e-01 |
| GO:BP | GO:1904892 | regulation of receptor signaling pathway via STAT | 2 | 54 | 6.74e-01 |
| GO:BP | GO:0097435 | supramolecular fiber organization | 3 | 665 | 6.74e-01 |
| GO:BP | GO:0001325 | formation of extrachromosomal circular DNA | 2 | 13 | 6.74e-01 |
| GO:BP | GO:0001936 | regulation of endothelial cell proliferation | 2 | 102 | 6.75e-01 |
| GO:BP | GO:0051148 | negative regulation of muscle cell differentiation | 2 | 52 | 6.75e-01 |
| GO:BP | GO:1903296 | positive regulation of glutamate secretion, neurotransmission | 1 | 3 | 6.75e-01 |
| GO:BP | GO:1903576 | response to L-arginine | 1 | 3 | 6.75e-01 |
| GO:BP | GO:0090657 | telomeric loop disassembly | 1 | 9 | 6.75e-01 |
| GO:BP | GO:0050848 | regulation of calcium-mediated signaling | 6 | 52 | 6.76e-01 |
| GO:BP | GO:0140052 | cellular response to oxidised low-density lipoprotein particle stimulus | 1 | 7 | 6.76e-01 |
| GO:BP | GO:0060022 | hard palate development | 1 | 5 | 6.76e-01 |
| GO:BP | GO:0097012 | response to granulocyte macrophage colony-stimulating factor | 1 | 6 | 6.76e-01 |
| GO:BP | GO:0070673 | response to interleukin-18 | 1 | 5 | 6.76e-01 |
| GO:BP | GO:0018206 | peptidyl-methionine modification | 1 | 13 | 6.76e-01 |
| GO:BP | GO:0019346 | transsulfuration | 1 | 5 | 6.76e-01 |
| GO:BP | GO:0090092 | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 17 | 230 | 6.76e-01 |
| GO:BP | GO:0070813 | hydrogen sulfide metabolic process | 1 | 5 | 6.76e-01 |
| GO:BP | GO:0009092 | homoserine metabolic process | 1 | 5 | 6.76e-01 |
| GO:BP | GO:2001235 | positive regulation of apoptotic signaling pathway | 1 | 108 | 6.76e-01 |
| GO:BP | GO:0010918 | positive regulation of mitochondrial membrane potential | 1 | 9 | 6.76e-01 |
| GO:BP | GO:0010647 | positive regulation of cell communication | 1 | 1255 | 6.76e-01 |
| GO:BP | GO:0097011 | cellular response to granulocyte macrophage colony-stimulating factor stimulus | 1 | 6 | 6.76e-01 |
| GO:BP | GO:0072539 | T-helper 17 cell differentiation | 3 | 14 | 6.76e-01 |
| GO:BP | GO:0071496 | cellular response to external stimulus | 22 | 270 | 6.76e-01 |
| GO:BP | GO:0003016 | respiratory system process | 1 | 30 | 6.76e-01 |
| GO:BP | GO:0033673 | negative regulation of kinase activity | 36 | 197 | 6.76e-01 |
| GO:BP | GO:1903236 | regulation of leukocyte tethering or rolling | 1 | 6 | 6.76e-01 |
| GO:BP | GO:0006629 | lipid metabolic process | 1 | 994 | 6.76e-01 |
| GO:BP | GO:1900273 | positive regulation of long-term synaptic potentiation | 4 | 19 | 6.76e-01 |
| GO:BP | GO:2000310 | regulation of NMDA receptor activity | 4 | 19 | 6.77e-01 |
| GO:BP | GO:0097734 | extracellular exosome biogenesis | 3 | 18 | 6.77e-01 |
| GO:BP | GO:0048304 | positive regulation of isotype switching to IgG isotypes | 2 | 4 | 6.77e-01 |
| GO:BP | GO:0014068 | positive regulation of phosphatidylinositol 3-kinase signaling | 2 | 55 | 6.77e-01 |
| GO:BP | GO:0099173 | postsynapse organization | 1 | 155 | 6.77e-01 |
| GO:BP | GO:0060136 | embryonic process involved in female pregnancy | 1 | 6 | 6.77e-01 |
| GO:BP | GO:0036093 | germ cell proliferation | 1 | 7 | 6.77e-01 |
| GO:BP | GO:0002200 | somatic diversification of immune receptors | 4 | 62 | 6.78e-01 |
| GO:BP | GO:1903034 | regulation of response to wounding | 2 | 121 | 6.78e-01 |
| GO:BP | GO:0030193 | regulation of blood coagulation | 1 | 50 | 6.78e-01 |
| GO:BP | GO:0060314 | regulation of ryanodine-sensitive calcium-release channel activity | 1 | 23 | 6.78e-01 |
| GO:BP | GO:0070572 | positive regulation of neuron projection regeneration | 1 | 8 | 6.78e-01 |
| GO:BP | GO:2001016 | positive regulation of skeletal muscle cell differentiation | 1 | 5 | 6.79e-01 |
| GO:BP | GO:0042698 | ovulation cycle | 9 | 54 | 6.79e-01 |
| GO:BP | GO:0070346 | positive regulation of fat cell proliferation | 1 | 3 | 6.79e-01 |
| GO:BP | GO:0045191 | regulation of isotype switching | 3 | 27 | 6.79e-01 |
| GO:BP | GO:0006266 | DNA ligation | 3 | 16 | 6.80e-01 |
| GO:BP | GO:0010248 | establishment or maintenance of transmembrane electrochemical gradient | 2 | 7 | 6.80e-01 |
| GO:BP | GO:1901165 | positive regulation of trophoblast cell migration | 1 | 6 | 6.80e-01 |
| GO:BP | GO:0034380 | high-density lipoprotein particle assembly | 2 | 10 | 6.80e-01 |
| GO:BP | GO:0032964 | collagen biosynthetic process | 1 | 39 | 6.80e-01 |
| GO:BP | GO:0050775 | positive regulation of dendrite morphogenesis | 3 | 36 | 6.80e-01 |
| GO:BP | GO:2001140 | positive regulation of phospholipid transport | 1 | 11 | 6.80e-01 |
| GO:BP | GO:0045823 | positive regulation of heart contraction | 1 | 32 | 6.80e-01 |
| GO:BP | GO:0009123 | nucleoside monophosphate metabolic process | 2 | 64 | 6.81e-01 |
| GO:BP | GO:1990823 | response to leukemia inhibitory factor | 15 | 85 | 6.81e-01 |
| GO:BP | GO:0035108 | limb morphogenesis | 1 | 114 | 6.81e-01 |
| GO:BP | GO:0035107 | appendage morphogenesis | 1 | 114 | 6.81e-01 |
| GO:BP | GO:0007004 | telomere maintenance via telomerase | 7 | 63 | 6.81e-01 |
| GO:BP | GO:0060716 | labyrinthine layer blood vessel development | 2 | 16 | 6.81e-01 |
| GO:BP | GO:0002686 | negative regulation of leukocyte migration | 3 | 30 | 6.81e-01 |
| GO:BP | GO:1904152 | regulation of retrograde protein transport, ER to cytosol | 1 | 13 | 6.81e-01 |
| GO:BP | GO:0030889 | negative regulation of B cell proliferation | 1 | 9 | 6.81e-01 |
| GO:BP | GO:0010452 | histone H3-K36 methylation | 1 | 5 | 6.81e-01 |
| GO:BP | GO:0045794 | negative regulation of cell volume | 1 | 4 | 6.81e-01 |
| GO:BP | GO:0048701 | embryonic cranial skeleton morphogenesis | 4 | 31 | 6.81e-01 |
| GO:BP | GO:0051447 | negative regulation of meiotic cell cycle | 3 | 9 | 6.81e-01 |
| GO:BP | GO:0048708 | astrocyte differentiation | 1 | 58 | 6.81e-01 |
| GO:BP | GO:0007183 | SMAD protein complex assembly | 1 | 12 | 6.81e-01 |
| GO:BP | GO:2000371 | regulation of DNA topoisomerase (ATP-hydrolyzing) activity | 1 | 5 | 6.81e-01 |
| GO:BP | GO:2000373 | positive regulation of DNA topoisomerase (ATP-hydrolyzing) activity | 1 | 5 | 6.81e-01 |
| GO:BP | GO:0007044 | cell-substrate junction assembly | 1 | 91 | 6.81e-01 |
| GO:BP | GO:0051099 | positive regulation of binding | 5 | 150 | 6.81e-01 |
| GO:BP | GO:0006085 | acetyl-CoA biosynthetic process | 1 | 16 | 6.81e-01 |
| GO:BP | GO:0021799 | cerebral cortex radially oriented cell migration | 3 | 28 | 6.82e-01 |
| GO:BP | GO:0071025 | RNA surveillance | 3 | 16 | 6.82e-01 |
| GO:BP | GO:0016310 | phosphorylation | 1 | 1372 | 6.82e-01 |
| GO:BP | GO:0086100 | endothelin receptor signaling pathway | 2 | 9 | 6.82e-01 |
| GO:BP | GO:0048631 | regulation of skeletal muscle tissue growth | 1 | 7 | 6.82e-01 |
| GO:BP | GO:0050773 | regulation of dendrite development | 1 | 90 | 6.82e-01 |
| GO:BP | GO:1905456 | regulation of lymphoid progenitor cell differentiation | 1 | 10 | 6.82e-01 |
| GO:BP | GO:0090230 | regulation of centromere complex assembly | 1 | 4 | 6.82e-01 |
| GO:BP | GO:0000012 | single strand break repair | 1 | 10 | 6.82e-01 |
| GO:BP | GO:0042552 | myelination | 4 | 111 | 6.82e-01 |
| GO:BP | GO:0060398 | regulation of growth hormone receptor signaling pathway | 1 | 5 | 6.82e-01 |
| GO:BP | GO:0098900 | regulation of action potential | 1 | 44 | 6.83e-01 |
| GO:BP | GO:1901700 | response to oxygen-containing compound | 1 | 1223 | 6.84e-01 |
| GO:BP | GO:0050962 | detection of light stimulus involved in sensory perception | 1 | 9 | 6.84e-01 |
| GO:BP | GO:0010917 | negative regulation of mitochondrial membrane potential | 2 | 9 | 6.84e-01 |
| GO:BP | GO:0045837 | negative regulation of membrane potential | 2 | 9 | 6.84e-01 |
| GO:BP | GO:0050908 | detection of light stimulus involved in visual perception | 1 | 9 | 6.84e-01 |
| GO:BP | GO:0061743 | motor learning | 1 | 5 | 6.84e-01 |
| GO:BP | GO:0007000 | nucleolus organization | 1 | 17 | 6.85e-01 |
| GO:BP | GO:0051654 | establishment of mitochondrion localization | 3 | 30 | 6.85e-01 |
| GO:BP | GO:0086001 | cardiac muscle cell action potential | 3 | 68 | 6.85e-01 |
| GO:BP | GO:0030500 | regulation of bone mineralization | 2 | 53 | 6.85e-01 |
| GO:BP | GO:0033077 | T cell differentiation in thymus | 5 | 56 | 6.85e-01 |
| GO:BP | GO:0002063 | chondrocyte development | 3 | 24 | 6.85e-01 |
| GO:BP | GO:0140747 | regulation of ncRNA transcription | 4 | 23 | 6.85e-01 |
| GO:BP | GO:0030851 | granulocyte differentiation | 1 | 27 | 6.85e-01 |
| GO:BP | GO:0106119 | negative regulation of sterol biosynthetic process | 1 | 5 | 6.85e-01 |
| GO:BP | GO:0045541 | negative regulation of cholesterol biosynthetic process | 1 | 5 | 6.85e-01 |
| GO:BP | GO:1904220 | regulation of serine C-palmitoyltransferase activity | 1 | 3 | 6.85e-01 |
| GO:BP | GO:0016043 | cellular component organization | 8 | 5076 | 6.85e-01 |
| GO:BP | GO:0007215 | glutamate receptor signaling pathway | 4 | 29 | 6.85e-01 |
| GO:BP | GO:1904380 | endoplasmic reticulum mannose trimming | 2 | 14 | 6.85e-01 |
| GO:BP | GO:0090206 | negative regulation of cholesterol metabolic process | 1 | 5 | 6.85e-01 |
| GO:BP | GO:0006396 | RNA processing | 1 | 929 | 6.85e-01 |
| GO:BP | GO:0014812 | muscle cell migration | 7 | 76 | 6.85e-01 |
| GO:BP | GO:0002218 | activation of innate immune response | 10 | 142 | 6.85e-01 |
| GO:BP | GO:1900046 | regulation of hemostasis | 1 | 50 | 6.85e-01 |
| GO:BP | GO:0071637 | regulation of monocyte chemotactic protein-1 production | 1 | 7 | 6.85e-01 |
| GO:BP | GO:0071605 | monocyte chemotactic protein-1 production | 1 | 7 | 6.85e-01 |
| GO:BP | GO:0043406 | positive regulation of MAP kinase activity | 7 | 82 | 6.85e-01 |
| GO:BP | GO:0006405 | RNA export from nucleus | 7 | 78 | 6.85e-01 |
| GO:BP | GO:0035066 | positive regulation of histone acetylation | 4 | 25 | 6.85e-01 |
| GO:BP | GO:1903524 | positive regulation of blood circulation | 1 | 32 | 6.85e-01 |
| GO:BP | GO:0007288 | sperm axoneme assembly | 1 | 20 | 6.85e-01 |
| GO:BP | GO:0042713 | sperm ejaculation | 1 | 3 | 6.85e-01 |
| GO:BP | GO:0007411 | axon guidance | 1 | 185 | 6.86e-01 |
| GO:BP | GO:1902692 | regulation of neuroblast proliferation | 1 | 28 | 6.86e-01 |
| GO:BP | GO:0016973 | poly(A)+ mRNA export from nucleus | 1 | 15 | 6.86e-01 |
| GO:BP | GO:0007605 | sensory perception of sound | 2 | 98 | 6.86e-01 |
| GO:BP | GO:0051291 | protein heterooligomerization | 3 | 21 | 6.86e-01 |
| GO:BP | GO:0090066 | regulation of anatomical structure size | 1 | 395 | 6.86e-01 |
| GO:BP | GO:0060158 | phospholipase C-activating dopamine receptor signaling pathway | 1 | 4 | 6.86e-01 |
| GO:BP | GO:0042832 | defense response to protozoan | 1 | 10 | 6.86e-01 |
| GO:BP | GO:0051683 | establishment of Golgi localization | 1 | 8 | 6.86e-01 |
| GO:BP | GO:0097064 | ncRNA export from nucleus | 1 | 9 | 6.86e-01 |
| GO:BP | GO:0099563 | modification of synaptic structure | 2 | 24 | 6.86e-01 |
| GO:BP | GO:1902498 | regulation of protein autoubiquitination | 1 | 5 | 6.86e-01 |
| GO:BP | GO:1900182 | positive regulation of protein localization to nucleus | 5 | 75 | 6.86e-01 |
| GO:BP | GO:0018197 | peptidyl-aspartic acid modification | 1 | 5 | 6.86e-01 |
| GO:BP | GO:0030047 | actin modification | 1 | 5 | 6.86e-01 |
| GO:BP | GO:2000589 | regulation of metanephric mesenchymal cell migration | 1 | 3 | 6.86e-01 |
| GO:BP | GO:0045332 | phospholipid translocation | 1 | 33 | 6.86e-01 |
| GO:BP | GO:0019395 | fatty acid oxidation | 2 | 93 | 6.86e-01 |
| GO:BP | GO:0048015 | phosphatidylinositol-mediated signaling | 4 | 123 | 6.86e-01 |
| GO:BP | GO:0035789 | metanephric mesenchymal cell migration | 1 | 3 | 6.86e-01 |
| GO:BP | GO:0048259 | regulation of receptor-mediated endocytosis | 6 | 87 | 6.86e-01 |
| GO:BP | GO:0090140 | regulation of mitochondrial fission | 1 | 28 | 6.87e-01 |
| GO:BP | GO:0043542 | endothelial cell migration | 2 | 182 | 6.87e-01 |
| GO:BP | GO:0051028 | mRNA transport | 16 | 117 | 6.87e-01 |
| GO:BP | GO:0002381 | immunoglobulin production involved in immunoglobulin-mediated immune response | 3 | 41 | 6.87e-01 |
| GO:BP | GO:0042181 | ketone biosynthetic process | 5 | 37 | 6.87e-01 |
| GO:BP | GO:0001522 | pseudouridine synthesis | 1 | 18 | 6.87e-01 |
| GO:BP | GO:0090233 | negative regulation of spindle checkpoint | 1 | 3 | 6.87e-01 |
| GO:BP | GO:0048022 | negative regulation of melanin biosynthetic process | 1 | 4 | 6.87e-01 |
| GO:BP | GO:0090081 | regulation of heart induction by regulation of canonical Wnt signaling pathway | 1 | 4 | 6.87e-01 |
| GO:BP | GO:0060029 | convergent extension involved in organogenesis | 1 | 5 | 6.87e-01 |
| GO:BP | GO:0140499 | negative regulation of mitotic spindle assembly checkpoint signaling | 1 | 3 | 6.87e-01 |
| GO:BP | GO:1902426 | deactivation of mitotic spindle assembly checkpoint | 1 | 3 | 6.87e-01 |
| GO:BP | GO:0007512 | adult heart development | 1 | 9 | 6.87e-01 |
| GO:BP | GO:0007223 | Wnt signaling pathway, calcium modulating pathway | 1 | 5 | 6.87e-01 |
| GO:BP | GO:0097325 | melanocyte proliferation | 1 | 2 | 6.87e-01 |
| GO:BP | GO:0060744 | mammary gland branching involved in thelarche | 1 | 5 | 6.87e-01 |
| GO:BP | GO:0006111 | regulation of gluconeogenesis | 7 | 42 | 6.87e-01 |
| GO:BP | GO:0060751 | branch elongation involved in mammary gland duct branching | 1 | 4 | 6.87e-01 |
| GO:BP | GO:1900377 | negative regulation of secondary metabolite biosynthetic process | 1 | 4 | 6.87e-01 |
| GO:BP | GO:0042695 | thelarche | 1 | 5 | 6.87e-01 |
| GO:BP | GO:0006878 | intracellular copper ion homeostasis | 3 | 15 | 6.87e-01 |
| GO:BP | GO:0050790 | regulation of catalytic activity | 1 | 1380 | 6.87e-01 |
| GO:BP | GO:0010587 | miRNA catabolic process | 2 | 10 | 6.87e-01 |
| GO:BP | GO:0003300 | cardiac muscle hypertrophy | 13 | 72 | 6.87e-01 |
| GO:BP | GO:1990416 | cellular response to brain-derived neurotrophic factor stimulus | 1 | 8 | 6.88e-01 |
| GO:BP | GO:0035630 | bone mineralization involved in bone maturation | 2 | 6 | 6.88e-01 |
| GO:BP | GO:0044857 | plasma membrane raft organization | 1 | 9 | 6.88e-01 |
| GO:BP | GO:0061311 | cell surface receptor signaling pathway involved in heart development | 1 | 25 | 6.88e-01 |
| GO:BP | GO:0021537 | telencephalon development | 2 | 201 | 6.88e-01 |
| GO:BP | GO:0008366 | axon ensheathment | 4 | 113 | 6.88e-01 |
| GO:BP | GO:2000121 | regulation of removal of superoxide radicals | 1 | 6 | 6.88e-01 |
| GO:BP | GO:0007272 | ensheathment of neurons | 4 | 113 | 6.88e-01 |
| GO:BP | GO:0055021 | regulation of cardiac muscle tissue growth | 3 | 45 | 6.88e-01 |
| GO:BP | GO:0001944 | vasculature development | 8 | 559 | 6.88e-01 |
| GO:BP | GO:0031650 | regulation of heat generation | 2 | 7 | 6.89e-01 |
| GO:BP | GO:0032530 | regulation of microvillus organization | 2 | 10 | 6.89e-01 |
| GO:BP | GO:0060353 | regulation of cell adhesion molecule production | 1 | 6 | 6.89e-01 |
| GO:BP | GO:0097068 | response to thyroxine | 1 | 4 | 6.89e-01 |
| GO:BP | GO:0035377 | transepithelial water transport | 1 | 2 | 6.89e-01 |
| GO:BP | GO:0042417 | dopamine metabolic process | 1 | 23 | 6.90e-01 |
| GO:BP | GO:0008360 | regulation of cell shape | 5 | 126 | 6.90e-01 |
| GO:BP | GO:0002669 | positive regulation of T cell anergy | 1 | 2 | 6.90e-01 |
| GO:BP | GO:0002551 | mast cell chemotaxis | 1 | 9 | 6.90e-01 |
| GO:BP | GO:0002913 | positive regulation of lymphocyte anergy | 1 | 2 | 6.90e-01 |
| GO:BP | GO:0038095 | Fc-epsilon receptor signaling pathway | 1 | 17 | 6.90e-01 |
| GO:BP | GO:0061756 | leukocyte adhesion to vascular endothelial cell | 2 | 27 | 6.90e-01 |
| GO:BP | GO:2000316 | regulation of T-helper 17 type immune response | 3 | 16 | 6.90e-01 |
| GO:BP | GO:2000050 | regulation of non-canonical Wnt signaling pathway | 4 | 23 | 6.90e-01 |
| GO:BP | GO:0043616 | keratinocyte proliferation | 8 | 38 | 6.90e-01 |
| GO:BP | GO:1901097 | negative regulation of autophagosome maturation | 1 | 5 | 6.91e-01 |
| GO:BP | GO:0040014 | regulation of multicellular organism growth | 1 | 53 | 6.91e-01 |
| GO:BP | GO:0051955 | regulation of amino acid transport | 1 | 28 | 6.91e-01 |
| GO:BP | GO:0048496 | maintenance of animal organ identity | 1 | 4 | 6.91e-01 |
| GO:BP | GO:0009059 | macromolecule biosynthetic process | 2 | 3730 | 6.91e-01 |
| GO:BP | GO:0032105 | negative regulation of response to extracellular stimulus | 1 | 7 | 6.91e-01 |
| GO:BP | GO:0044827 | modulation by host of viral genome replication | 4 | 21 | 6.91e-01 |
| GO:BP | GO:2000249 | regulation of actin cytoskeleton reorganization | 2 | 32 | 6.91e-01 |
| GO:BP | GO:0032099 | negative regulation of appetite | 1 | 7 | 6.91e-01 |
| GO:BP | GO:0032108 | negative regulation of response to nutrient levels | 1 | 7 | 6.91e-01 |
| GO:BP | GO:0032096 | negative regulation of response to food | 1 | 7 | 6.91e-01 |
| GO:BP | GO:0014901 | satellite cell activation involved in skeletal muscle regeneration | 1 | 3 | 6.91e-01 |
| GO:BP | GO:0051972 | regulation of telomerase activity | 5 | 45 | 6.91e-01 |
| GO:BP | GO:0050794 | regulation of cellular process | 4 | 7552 | 6.91e-01 |
| GO:BP | GO:1903365 | regulation of fear response | 2 | 8 | 6.92e-01 |
| GO:BP | GO:1904781 | positive regulation of protein localization to centrosome | 1 | 7 | 6.92e-01 |
| GO:BP | GO:1903902 | positive regulation of viral life cycle | 2 | 19 | 6.92e-01 |
| GO:BP | GO:0031223 | auditory behavior | 1 | 6 | 6.92e-01 |
| GO:BP | GO:0000002 | mitochondrial genome maintenance | 5 | 29 | 6.92e-01 |
| GO:BP | GO:0051383 | kinetochore organization | 2 | 23 | 6.92e-01 |
| GO:BP | GO:0009117 | nucleotide metabolic process | 1 | 423 | 6.92e-01 |
| GO:BP | GO:0032230 | positive regulation of synaptic transmission, GABAergic | 3 | 10 | 6.92e-01 |
| GO:BP | GO:0022615 | protein to membrane docking | 1 | 5 | 6.92e-01 |
| GO:BP | GO:0050818 | regulation of coagulation | 1 | 55 | 6.92e-01 |
| GO:BP | GO:0060232 | delamination | 1 | 5 | 6.92e-01 |
| GO:BP | GO:1904978 | regulation of endosome organization | 1 | 5 | 6.92e-01 |
| GO:BP | GO:0071028 | nuclear mRNA surveillance | 2 | 10 | 6.92e-01 |
| GO:BP | GO:0070669 | response to interleukin-2 | 1 | 3 | 6.92e-01 |
| GO:BP | GO:0014910 | regulation of smooth muscle cell migration | 7 | 58 | 6.92e-01 |
| GO:BP | GO:0097623 | potassium ion export across plasma membrane | 1 | 10 | 6.92e-01 |
| GO:BP | GO:1900223 | positive regulation of amyloid-beta clearance | 1 | 5 | 6.93e-01 |
| GO:BP | GO:0043487 | regulation of RNA stability | 28 | 159 | 6.93e-01 |
| GO:BP | GO:0006635 | fatty acid beta-oxidation | 1 | 68 | 6.93e-01 |
| GO:BP | GO:0034142 | toll-like receptor 4 signaling pathway | 2 | 24 | 6.93e-01 |
| GO:BP | GO:0036493 | positive regulation of translation in response to endoplasmic reticulum stress | 1 | 5 | 6.93e-01 |
| GO:BP | GO:0031125 | rRNA 3’-end processing | 2 | 10 | 6.93e-01 |
| GO:BP | GO:1903912 | negative regulation of endoplasmic reticulum stress-induced eIF2 alpha phosphorylation | 1 | 5 | 6.93e-01 |
| GO:BP | GO:0033031 | positive regulation of neutrophil apoptotic process | 1 | 3 | 6.93e-01 |
| GO:BP | GO:0044458 | motile cilium assembly | 2 | 45 | 6.93e-01 |
| GO:BP | GO:0032770 | positive regulation of monooxygenase activity | 2 | 20 | 6.93e-01 |
| GO:BP | GO:0006573 | valine metabolic process | 1 | 7 | 6.93e-01 |
| GO:BP | GO:2001138 | regulation of phospholipid transport | 1 | 12 | 6.93e-01 |
| GO:BP | GO:0003352 | regulation of cilium movement | 3 | 17 | 6.93e-01 |
| GO:BP | GO:0015718 | monocarboxylic acid transport | 5 | 90 | 6.93e-01 |
| GO:BP | GO:0046666 | retinal cell programmed cell death | 1 | 3 | 6.93e-01 |
| GO:BP | GO:0061975 | articular cartilage development | 1 | 3 | 6.93e-01 |
| GO:BP | GO:0051767 | nitric-oxide synthase biosynthetic process | 1 | 13 | 6.93e-01 |
| GO:BP | GO:0051769 | regulation of nitric-oxide synthase biosynthetic process | 1 | 13 | 6.93e-01 |
| GO:BP | GO:0098771 | inorganic ion homeostasis | 1 | 351 | 6.93e-01 |
| GO:BP | GO:1902992 | negative regulation of amyloid precursor protein catabolic process | 2 | 20 | 6.93e-01 |
| GO:BP | GO:0010611 | regulation of cardiac muscle hypertrophy | 1 | 48 | 6.93e-01 |
| GO:BP | GO:0043651 | linoleic acid metabolic process | 1 | 12 | 6.93e-01 |
| GO:BP | GO:0035295 | tube development | 4 | 821 | 6.93e-01 |
| GO:BP | GO:0002269 | leukocyte activation involved in inflammatory response | 4 | 21 | 6.93e-01 |
| GO:BP | GO:0032928 | regulation of superoxide anion generation | 1 | 11 | 6.93e-01 |
| GO:BP | GO:1905382 | positive regulation of snRNA transcription by RNA polymerase II | 1 | 3 | 6.93e-01 |
| GO:BP | GO:0097500 | receptor localization to non-motile cilium | 1 | 4 | 6.93e-01 |
| GO:BP | GO:0033599 | regulation of mammary gland epithelial cell proliferation | 3 | 14 | 6.94e-01 |
| GO:BP | GO:0032413 | negative regulation of ion transmembrane transporter activity | 2 | 51 | 6.94e-01 |
| GO:BP | GO:0006379 | mRNA cleavage | 1 | 19 | 6.94e-01 |
| GO:BP | GO:0030162 | regulation of proteolysis | 7 | 535 | 6.94e-01 |
| GO:BP | GO:0043280 | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 14 | 96 | 6.94e-01 |
| GO:BP | GO:0001782 | B cell homeostasis | 5 | 24 | 6.94e-01 |
| GO:BP | GO:0150115 | cell-substrate junction organization | 1 | 98 | 6.94e-01 |
| GO:BP | GO:0044271 | cellular nitrogen compound biosynthetic process | 2 | 3750 | 6.94e-01 |
| GO:BP | GO:1902916 | positive regulation of protein polyubiquitination | 3 | 13 | 6.94e-01 |
| GO:BP | GO:0044346 | fibroblast apoptotic process | 4 | 23 | 6.95e-01 |
| GO:BP | GO:0048512 | circadian behavior | 1 | 30 | 6.95e-01 |
| GO:BP | GO:0060042 | retina morphogenesis in camera-type eye | 6 | 40 | 6.95e-01 |
| GO:BP | GO:0072678 | T cell migration | 1 | 38 | 6.95e-01 |
| GO:BP | GO:0032202 | telomere assembly | 1 | 4 | 6.95e-01 |
| GO:BP | GO:0042045 | epithelial fluid transport | 2 | 7 | 6.95e-01 |
| GO:BP | GO:0008315 | G2/MI transition of meiotic cell cycle | 1 | 5 | 6.96e-01 |
| GO:BP | GO:0090296 | regulation of mitochondrial DNA replication | 1 | 4 | 6.96e-01 |
| GO:BP | GO:0042711 | maternal behavior | 2 | 7 | 6.96e-01 |
| GO:BP | GO:0036305 | ameloblast differentiation | 1 | 5 | 6.96e-01 |
| GO:BP | GO:0001570 | vasculogenesis | 2 | 67 | 6.96e-01 |
| GO:BP | GO:0006753 | nucleoside phosphate metabolic process | 1 | 429 | 6.96e-01 |
| GO:BP | GO:0043484 | regulation of RNA splicing | 1 | 164 | 6.96e-01 |
| GO:BP | GO:0060746 | parental behavior | 2 | 7 | 6.96e-01 |
| GO:BP | GO:0060129 | thyroid-stimulating hormone-secreting cell differentiation | 1 | 4 | 6.96e-01 |
| GO:BP | GO:0060048 | cardiac muscle contraction | 5 | 123 | 6.96e-01 |
| GO:BP | GO:0035795 | negative regulation of mitochondrial membrane permeability | 3 | 17 | 6.96e-01 |
| GO:BP | GO:0090032 | negative regulation of steroid hormone biosynthetic process | 1 | 6 | 6.96e-01 |
| GO:BP | GO:0006971 | hypotonic response | 1 | 10 | 6.96e-01 |
| GO:BP | GO:0048017 | inositol lipid-mediated signaling | 4 | 126 | 6.96e-01 |
| GO:BP | GO:0034114 | regulation of heterotypic cell-cell adhesion | 2 | 13 | 6.97e-01 |
| GO:BP | GO:0038179 | neurotrophin signaling pathway | 3 | 35 | 6.97e-01 |
| GO:BP | GO:0016540 | protein autoprocessing | 1 | 16 | 6.97e-01 |
| GO:BP | GO:0017004 | cytochrome complex assembly | 6 | 38 | 6.97e-01 |
| GO:BP | GO:2001053 | regulation of mesenchymal cell apoptotic process | 1 | 5 | 6.97e-01 |
| GO:BP | GO:1903599 | positive regulation of autophagy of mitochondrion | 1 | 13 | 6.97e-01 |
| GO:BP | GO:0032252 | secretory granule localization | 1 | 9 | 6.97e-01 |
| GO:BP | GO:0018904 | ether metabolic process | 3 | 20 | 6.97e-01 |
| GO:BP | GO:0043547 | positive regulation of GTPase activity | 1 | 222 | 6.97e-01 |
| GO:BP | GO:0032811 | negative regulation of epinephrine secretion | 1 | 2 | 6.98e-01 |
| GO:BP | GO:0035624 | receptor transactivation | 1 | 3 | 6.98e-01 |
| GO:BP | GO:0010700 | negative regulation of norepinephrine secretion | 1 | 2 | 6.98e-01 |
| GO:BP | GO:0051937 | catecholamine transport | 2 | 38 | 6.98e-01 |
| GO:BP | GO:0034284 | response to monosaccharide | 15 | 142 | 6.98e-01 |
| GO:BP | GO:0043535 | regulation of blood vessel endothelial cell migration | 1 | 75 | 6.98e-01 |
| GO:BP | GO:0045117 | azole transmembrane transport | 1 | 9 | 6.98e-01 |
| GO:BP | GO:1904018 | positive regulation of vasculature development | 2 | 115 | 6.98e-01 |
| GO:BP | GO:0045766 | positive regulation of angiogenesis | 2 | 115 | 6.98e-01 |
| GO:BP | GO:0016255 | attachment of GPI anchor to protein | 1 | 6 | 6.98e-01 |
| GO:BP | GO:0034144 | negative regulation of toll-like receptor 4 signaling pathway | 2 | 6 | 6.99e-01 |
| GO:BP | GO:1900180 | regulation of protein localization to nucleus | 2 | 117 | 6.99e-01 |
| GO:BP | GO:0002092 | positive regulation of receptor internalization | 4 | 21 | 6.99e-01 |
| GO:BP | GO:1905153 | regulation of membrane invagination | 1 | 11 | 6.99e-01 |
| GO:BP | GO:0010662 | regulation of striated muscle cell apoptotic process | 6 | 36 | 6.99e-01 |
| GO:BP | GO:0060099 | regulation of phagocytosis, engulfment | 1 | 11 | 6.99e-01 |
| GO:BP | GO:0019229 | regulation of vasoconstriction | 1 | 38 | 6.99e-01 |
| GO:BP | GO:0014839 | myoblast migration involved in skeletal muscle regeneration | 1 | 3 | 6.99e-01 |
| GO:BP | GO:0046486 | glycerolipid metabolic process | 47 | 311 | 7.00e-01 |
| GO:BP | GO:0006071 | glycerol metabolic process | 1 | 12 | 7.00e-01 |
| GO:BP | GO:1905279 | regulation of retrograde transport, endosome to Golgi | 1 | 6 | 7.00e-01 |
| GO:BP | GO:0005984 | disaccharide metabolic process | 1 | 5 | 7.00e-01 |
| GO:BP | GO:0070601 | centromeric sister chromatid cohesion | 2 | 11 | 7.00e-01 |
| GO:BP | GO:0140013 | meiotic nuclear division | 30 | 120 | 7.00e-01 |
| GO:BP | GO:0046532 | regulation of photoreceptor cell differentiation | 1 | 4 | 7.00e-01 |
| GO:BP | GO:1900271 | regulation of long-term synaptic potentiation | 1 | 34 | 7.00e-01 |
| GO:BP | GO:0006637 | acyl-CoA metabolic process | 1 | 71 | 7.00e-01 |
| GO:BP | GO:0072173 | metanephric tubule morphogenesis | 1 | 6 | 7.00e-01 |
| GO:BP | GO:0035383 | thioester metabolic process | 1 | 71 | 7.00e-01 |
| GO:BP | GO:0090184 | positive regulation of kidney development | 1 | 9 | 7.00e-01 |
| GO:BP | GO:2000846 | regulation of corticosteroid hormone secretion | 1 | 9 | 7.00e-01 |
| GO:BP | GO:0061377 | mammary gland lobule development | 3 | 13 | 7.00e-01 |
| GO:BP | GO:0060749 | mammary gland alveolus development | 3 | 13 | 7.00e-01 |
| GO:BP | GO:1901658 | glycosyl compound catabolic process | 4 | 23 | 7.00e-01 |
| GO:BP | GO:0010922 | positive regulation of phosphatase activity | 4 | 26 | 7.00e-01 |
| GO:BP | GO:0001562 | response to protozoan | 1 | 11 | 7.00e-01 |
| GO:BP | GO:0010770 | positive regulation of cell morphogenesis involved in differentiation | 3 | 37 | 7.00e-01 |
| GO:BP | GO:0006778 | porphyrin-containing compound metabolic process | 1 | 44 | 7.00e-01 |
| GO:BP | GO:0045448 | mitotic cell cycle, embryonic | 1 | 4 | 7.00e-01 |
| GO:BP | GO:0009794 | regulation of mitotic cell cycle, embryonic | 1 | 4 | 7.00e-01 |
| GO:BP | GO:0061635 | regulation of protein complex stability | 2 | 11 | 7.00e-01 |
| GO:BP | GO:1903575 | cornified envelope assembly | 1 | 6 | 7.00e-01 |
| GO:BP | GO:0110104 | mRNA alternative polyadenylation | 1 | 5 | 7.00e-01 |
| GO:BP | GO:0048333 | mesodermal cell differentiation | 1 | 22 | 7.00e-01 |
| GO:BP | GO:0009172 | purine deoxyribonucleoside monophosphate catabolic process | 1 | 3 | 7.01e-01 |
| GO:BP | GO:0046121 | deoxyribonucleoside catabolic process | 1 | 4 | 7.01e-01 |
| GO:BP | GO:0030307 | positive regulation of cell growth | 27 | 135 | 7.01e-01 |
| GO:BP | GO:0046130 | purine ribonucleoside catabolic process | 1 | 5 | 7.01e-01 |
| GO:BP | GO:0036115 | fatty-acyl-CoA catabolic process | 1 | 6 | 7.01e-01 |
| GO:BP | GO:2000774 | positive regulation of cellular senescence | 2 | 9 | 7.01e-01 |
| GO:BP | GO:0050896 | response to stimulus | 4 | 5770 | 7.01e-01 |
| GO:BP | GO:1901355 | response to rapamycin | 1 | 3 | 7.01e-01 |
| GO:BP | GO:0010459 | negative regulation of heart rate | 2 | 7 | 7.01e-01 |
| GO:BP | GO:0042593 | glucose homeostasis | 14 | 168 | 7.01e-01 |
| GO:BP | GO:0032715 | negative regulation of interleukin-6 production | 2 | 24 | 7.01e-01 |
| GO:BP | GO:0034121 | regulation of toll-like receptor signaling pathway | 2 | 19 | 7.01e-01 |
| GO:BP | GO:0019509 | L-methionine salvage from methylthioadenosine | 1 | 5 | 7.01e-01 |
| GO:BP | GO:0045185 | maintenance of protein location | 14 | 83 | 7.01e-01 |
| GO:BP | GO:0034342 | response to type III interferon | 1 | 5 | 7.02e-01 |
| GO:BP | GO:1903842 | response to arsenite ion | 1 | 4 | 7.02e-01 |
| GO:BP | GO:1903843 | cellular response to arsenite ion | 1 | 4 | 7.02e-01 |
| GO:BP | GO:0034440 | lipid oxidation | 2 | 94 | 7.02e-01 |
| GO:BP | GO:0005976 | polysaccharide metabolic process | 4 | 80 | 7.02e-01 |
| GO:BP | GO:0030049 | muscle filament sliding | 1 | 10 | 7.02e-01 |
| GO:BP | GO:0046427 | positive regulation of receptor signaling pathway via JAK-STAT | 1 | 21 | 7.02e-01 |
| GO:BP | GO:0030178 | negative regulation of Wnt signaling pathway | 1 | 140 | 7.02e-01 |
| GO:BP | GO:0010288 | response to lead ion | 1 | 18 | 7.02e-01 |
| GO:BP | GO:0010960 | magnesium ion homeostasis | 1 | 9 | 7.02e-01 |
| GO:BP | GO:1900746 | regulation of vascular endothelial growth factor signaling pathway | 4 | 18 | 7.02e-01 |
| GO:BP | GO:0061484 | hematopoietic stem cell homeostasis | 2 | 20 | 7.02e-01 |
| GO:BP | GO:1904869 | regulation of protein localization to Cajal body | 2 | 11 | 7.02e-01 |
| GO:BP | GO:0051236 | establishment of RNA localization | 20 | 147 | 7.02e-01 |
| GO:BP | GO:1904871 | positive regulation of protein localization to Cajal body | 2 | 11 | 7.02e-01 |
| GO:BP | GO:0015866 | ADP transport | 1 | 6 | 7.02e-01 |
| GO:BP | GO:0033504 | floor plate development | 1 | 8 | 7.02e-01 |
| GO:BP | GO:0042167 | heme catabolic process | 1 | 6 | 7.02e-01 |
| GO:BP | GO:0046149 | pigment catabolic process | 1 | 6 | 7.02e-01 |
| GO:BP | GO:2000269 | regulation of fibroblast apoptotic process | 2 | 17 | 7.02e-01 |
| GO:BP | GO:1901836 | regulation of transcription of nucleolar large rRNA by RNA polymerase I | 2 | 15 | 7.03e-01 |
| GO:BP | GO:0090370 | negative regulation of cholesterol efflux | 1 | 3 | 7.03e-01 |
| GO:BP | GO:0048518 | positive regulation of biological process | 1 | 4579 | 7.03e-01 |
| GO:BP | GO:2000650 | negative regulation of sodium ion transmembrane transporter activity | 2 | 9 | 7.03e-01 |
| GO:BP | GO:0001920 | negative regulation of receptor recycling | 1 | 3 | 7.03e-01 |
| GO:BP | GO:2001013 | epithelial cell proliferation involved in renal tubule morphogenesis | 1 | 4 | 7.03e-01 |
| GO:BP | GO:0086046 | membrane depolarization during SA node cell action potential | 1 | 5 | 7.03e-01 |
| GO:BP | GO:2000108 | positive regulation of leukocyte apoptotic process | 4 | 18 | 7.03e-01 |
| GO:BP | GO:0003407 | neural retina development | 5 | 48 | 7.03e-01 |
| GO:BP | GO:0032024 | positive regulation of insulin secretion | 2 | 56 | 7.03e-01 |
| GO:BP | GO:0002526 | acute inflammatory response | 2 | 49 | 7.03e-01 |
| GO:BP | GO:0010838 | positive regulation of keratinocyte proliferation | 1 | 9 | 7.03e-01 |
| GO:BP | GO:0009156 | ribonucleoside monophosphate biosynthetic process | 1 | 30 | 7.03e-01 |
| GO:BP | GO:0003266 | regulation of secondary heart field cardioblast proliferation | 1 | 8 | 7.04e-01 |
| GO:BP | GO:0019933 | cAMP-mediated signaling | 4 | 35 | 7.04e-01 |
| GO:BP | GO:0009408 | response to heat | 1 | 84 | 7.04e-01 |
| GO:BP | GO:0042994 | cytoplasmic sequestering of transcription factor | 3 | 15 | 7.04e-01 |
| GO:BP | GO:0014743 | regulation of muscle hypertrophy | 1 | 49 | 7.04e-01 |
| GO:BP | GO:0008283 | cell population proliferation | 1 | 1378 | 7.05e-01 |
| GO:BP | GO:0061180 | mammary gland epithelium development | 1 | 57 | 7.05e-01 |
| GO:BP | GO:0014059 | regulation of dopamine secretion | 1 | 22 | 7.05e-01 |
| GO:BP | GO:1904997 | regulation of leukocyte adhesion to arterial endothelial cell | 1 | 3 | 7.05e-01 |
| GO:BP | GO:0034620 | cellular response to unfolded protein | 2 | 91 | 7.06e-01 |
| GO:BP | GO:0043647 | inositol phosphate metabolic process | 7 | 35 | 7.06e-01 |
| GO:BP | GO:0034104 | negative regulation of tissue remodeling | 1 | 13 | 7.06e-01 |
| GO:BP | GO:0051081 | nuclear membrane disassembly | 1 | 10 | 7.07e-01 |
| GO:BP | GO:0009129 | pyrimidine nucleoside monophosphate metabolic process | 2 | 18 | 7.07e-01 |
| GO:BP | GO:0001501 | skeletal system development | 2 | 377 | 7.07e-01 |
| GO:BP | GO:0060914 | heart formation | 1 | 29 | 7.08e-01 |
| GO:BP | GO:0021682 | nerve maturation | 1 | 2 | 7.08e-01 |
| GO:BP | GO:0006710 | androgen catabolic process | 1 | 3 | 7.08e-01 |
| GO:BP | GO:1905244 | regulation of modification of synaptic structure | 1 | 10 | 7.08e-01 |
| GO:BP | GO:0006694 | steroid biosynthetic process | 3 | 121 | 7.08e-01 |
| GO:BP | GO:2001169 | regulation of ATP biosynthetic process | 3 | 17 | 7.08e-01 |
| GO:BP | GO:0007405 | neuroblast proliferation | 5 | 51 | 7.08e-01 |
| GO:BP | GO:0003008 | system process | 3 | 1189 | 7.08e-01 |
| GO:BP | GO:0042747 | circadian sleep/wake cycle, REM sleep | 1 | 2 | 7.08e-01 |
| GO:BP | GO:0051281 | positive regulation of release of sequestered calcium ion into cytosol | 4 | 27 | 7.08e-01 |
| GO:BP | GO:0006536 | glutamate metabolic process | 1 | 25 | 7.08e-01 |
| GO:BP | GO:1901564 | organonitrogen compound metabolic process | 1 | 4955 | 7.08e-01 |
| GO:BP | GO:0034204 | lipid translocation | 1 | 38 | 7.09e-01 |
| GO:BP | GO:0014842 | regulation of skeletal muscle satellite cell proliferation | 2 | 8 | 7.09e-01 |
| GO:BP | GO:2000481 | positive regulation of cAMP-dependent protein kinase activity | 1 | 5 | 7.09e-01 |
| GO:BP | GO:0045061 | thymic T cell selection | 2 | 10 | 7.09e-01 |
| GO:BP | GO:0035272 | exocrine system development | 1 | 34 | 7.09e-01 |
| GO:BP | GO:0035307 | positive regulation of protein dephosphorylation | 1 | 36 | 7.09e-01 |
| GO:BP | GO:0002029 | desensitization of G protein-coupled receptor signaling pathway | 1 | 14 | 7.10e-01 |
| GO:BP | GO:0045740 | positive regulation of DNA replication | 6 | 35 | 7.10e-01 |
| GO:BP | GO:0006766 | vitamin metabolic process | 1 | 73 | 7.10e-01 |
| GO:BP | GO:0034109 | homotypic cell-cell adhesion | 1 | 70 | 7.10e-01 |
| GO:BP | GO:1903206 | negative regulation of hydrogen peroxide-induced cell death | 2 | 13 | 7.10e-01 |
| GO:BP | GO:1901032 | negative regulation of response to reactive oxygen species | 2 | 13 | 7.10e-01 |
| GO:BP | GO:0060439 | trachea morphogenesis | 1 | 7 | 7.11e-01 |
| GO:BP | GO:0046459 | short-chain fatty acid metabolic process | 1 | 10 | 7.12e-01 |
| GO:BP | GO:0010769 | regulation of cell morphogenesis involved in differentiation | 3 | 37 | 7.12e-01 |
| GO:BP | GO:0030516 | regulation of axon extension | 14 | 84 | 7.12e-01 |
| GO:BP | GO:0009957 | epidermal cell fate specification | 1 | 4 | 7.12e-01 |
| GO:BP | GO:0046642 | negative regulation of alpha-beta T cell proliferation | 3 | 9 | 7.12e-01 |
| GO:BP | GO:0010765 | positive regulation of sodium ion transport | 3 | 30 | 7.12e-01 |
| GO:BP | GO:0051573 | negative regulation of histone H3-K9 methylation | 1 | 5 | 7.13e-01 |
| GO:BP | GO:0003002 | regionalization | 1 | 273 | 7.13e-01 |
| GO:BP | GO:0050680 | negative regulation of epithelial cell proliferation | 7 | 111 | 7.13e-01 |
| GO:BP | GO:0071840 | cellular component organization or biogenesis | 8 | 5274 | 7.13e-01 |
| GO:BP | GO:0010255 | glucose mediated signaling pathway | 1 | 5 | 7.13e-01 |
| GO:BP | GO:0043032 | positive regulation of macrophage activation | 4 | 12 | 7.13e-01 |
| GO:BP | GO:0010182 | sugar mediated signaling pathway | 1 | 5 | 7.13e-01 |
| GO:BP | GO:0009757 | hexose mediated signaling | 1 | 5 | 7.13e-01 |
| GO:BP | GO:0071677 | positive regulation of mononuclear cell migration | 1 | 39 | 7.13e-01 |
| GO:BP | GO:0043534 | blood vessel endothelial cell migration | 7 | 97 | 7.13e-01 |
| GO:BP | GO:0006066 | alcohol metabolic process | 7 | 265 | 7.13e-01 |
| GO:BP | GO:0090325 | regulation of locomotion involved in locomotory behavior | 1 | 3 | 7.13e-01 |
| GO:BP | GO:1904036 | negative regulation of epithelial cell apoptotic process | 6 | 43 | 7.13e-01 |
| GO:BP | GO:0045591 | positive regulation of regulatory T cell differentiation | 1 | 14 | 7.13e-01 |
| GO:BP | GO:0071878 | negative regulation of adenylate cyclase-activating adrenergic receptor signaling pathway | 1 | 5 | 7.13e-01 |
| GO:BP | GO:0071385 | cellular response to glucocorticoid stimulus | 8 | 40 | 7.13e-01 |
| GO:BP | GO:0070431 | nucleotide-binding oligomerization domain containing 2 signaling pathway | 1 | 11 | 7.13e-01 |
| GO:BP | GO:0016240 | autophagosome membrane docking | 1 | 7 | 7.13e-01 |
| GO:BP | GO:0034383 | low-density lipoprotein particle clearance | 2 | 17 | 7.13e-01 |
| GO:BP | GO:0050919 | negative chemotaxis | 7 | 42 | 7.13e-01 |
| GO:BP | GO:0048519 | negative regulation of biological process | 8 | 4045 | 7.13e-01 |
| GO:BP | GO:0090394 | negative regulation of excitatory postsynaptic potential | 1 | 8 | 7.14e-01 |
| GO:BP | GO:0051342 | regulation of cyclic-nucleotide phosphodiesterase activity | 1 | 10 | 7.14e-01 |
| GO:BP | GO:2000765 | regulation of cytoplasmic translation | 5 | 27 | 7.14e-01 |
| GO:BP | GO:0045721 | negative regulation of gluconeogenesis | 1 | 12 | 7.14e-01 |
| GO:BP | GO:0042541 | hemoglobin biosynthetic process | 1 | 13 | 7.14e-01 |
| GO:BP | GO:0032328 | alanine transport | 1 | 14 | 7.15e-01 |
| GO:BP | GO:0051151 | negative regulation of smooth muscle cell differentiation | 2 | 14 | 7.15e-01 |
| GO:BP | GO:1901741 | positive regulation of myoblast fusion | 2 | 9 | 7.15e-01 |
| GO:BP | GO:0003309 | type B pancreatic cell differentiation | 2 | 22 | 7.15e-01 |
| GO:BP | GO:0003341 | cilium movement | 5 | 97 | 7.16e-01 |
| GO:BP | GO:1901978 | positive regulation of cell cycle checkpoint | 3 | 19 | 7.16e-01 |
| GO:BP | GO:0048026 | positive regulation of mRNA splicing, via spliceosome | 1 | 21 | 7.17e-01 |
| GO:BP | GO:0016447 | somatic recombination of immunoglobulin gene segments | 3 | 47 | 7.17e-01 |
| GO:BP | GO:0090407 | organophosphate biosynthetic process | 2 | 506 | 7.17e-01 |
| GO:BP | GO:0045590 | negative regulation of regulatory T cell differentiation | 1 | 3 | 7.17e-01 |
| GO:BP | GO:0016202 | regulation of striated muscle tissue development | 2 | 13 | 7.17e-01 |
| GO:BP | GO:2001223 | negative regulation of neuron migration | 1 | 8 | 7.17e-01 |
| GO:BP | GO:0010874 | regulation of cholesterol efflux | 6 | 31 | 7.18e-01 |
| GO:BP | GO:0019226 | transmission of nerve impulse | 1 | 40 | 7.18e-01 |
| GO:BP | GO:0001935 | endothelial cell proliferation | 2 | 116 | 7.18e-01 |
| GO:BP | GO:0140112 | extracellular vesicle biogenesis | 3 | 20 | 7.18e-01 |
| GO:BP | GO:0048640 | negative regulation of developmental growth | 17 | 95 | 7.18e-01 |
| GO:BP | GO:0051645 | Golgi localization | 2 | 14 | 7.18e-01 |
| GO:BP | GO:0031532 | actin cytoskeleton reorganization | 17 | 96 | 7.18e-01 |
| GO:BP | GO:0010659 | cardiac muscle cell apoptotic process | 6 | 36 | 7.18e-01 |
| GO:BP | GO:0035235 | ionotropic glutamate receptor signaling pathway | 2 | 14 | 7.18e-01 |
| GO:BP | GO:2000253 | positive regulation of feeding behavior | 1 | 4 | 7.18e-01 |
| GO:BP | GO:0046826 | negative regulation of protein export from nucleus | 1 | 6 | 7.18e-01 |
| GO:BP | GO:0030325 | adrenal gland development | 2 | 22 | 7.18e-01 |
| GO:BP | GO:0046148 | pigment biosynthetic process | 1 | 48 | 7.18e-01 |
| GO:BP | GO:0046513 | ceramide biosynthetic process | 6 | 53 | 7.18e-01 |
| GO:BP | GO:0032596 | protein transport into membrane raft | 1 | 4 | 7.18e-01 |
| GO:BP | GO:0043666 | regulation of phosphoprotein phosphatase activity | 1 | 47 | 7.18e-01 |
| GO:BP | GO:0060998 | regulation of dendritic spine development | 8 | 48 | 7.18e-01 |
| GO:BP | GO:0006474 | N-terminal protein amino acid acetylation | 1 | 15 | 7.18e-01 |
| GO:BP | GO:0006403 | RNA localization | 24 | 182 | 7.18e-01 |
| GO:BP | GO:0055080 | monoatomic cation homeostasis | 1 | 401 | 7.18e-01 |
| GO:BP | GO:0045616 | regulation of keratinocyte differentiation | 4 | 25 | 7.19e-01 |
| GO:BP | GO:0038146 | chemokine (C-X-C motif) ligand 12 signaling pathway | 1 | 6 | 7.19e-01 |
| GO:BP | GO:1904894 | positive regulation of receptor signaling pathway via STAT | 1 | 22 | 7.19e-01 |
| GO:BP | GO:0048200 | Golgi transport vesicle coating | 1 | 6 | 7.19e-01 |
| GO:BP | GO:0035964 | COPI-coated vesicle budding | 1 | 6 | 7.19e-01 |
| GO:BP | GO:0048205 | COPI coating of Golgi vesicle | 1 | 6 | 7.19e-01 |
| GO:BP | GO:0045829 | negative regulation of isotype switching | 1 | 4 | 7.19e-01 |
| GO:BP | GO:0030311 | poly-N-acetyllactosamine biosynthetic process | 1 | 5 | 7.19e-01 |
| GO:BP | GO:0060071 | Wnt signaling pathway, planar cell polarity pathway | 4 | 51 | 7.20e-01 |
| GO:BP | GO:0044794 | positive regulation by host of viral process | 3 | 20 | 7.20e-01 |
| GO:BP | GO:0071514 | genomic imprinting | 1 | 9 | 7.20e-01 |
| GO:BP | GO:0002842 | positive regulation of T cell mediated immune response to tumor cell | 1 | 3 | 7.20e-01 |
| GO:BP | GO:0044030 | regulation of DNA methylation | 3 | 16 | 7.20e-01 |
| GO:BP | GO:0010522 | regulation of calcium ion transport into cytosol | 3 | 10 | 7.21e-01 |
| GO:BP | GO:0007140 | male meiotic nuclear division | 4 | 27 | 7.21e-01 |
| GO:BP | GO:0019362 | pyridine nucleotide metabolic process | 3 | 66 | 7.21e-01 |
| GO:BP | GO:0046496 | nicotinamide nucleotide metabolic process | 3 | 66 | 7.21e-01 |
| GO:BP | GO:0048569 | post-embryonic animal organ development | 3 | 15 | 7.21e-01 |
| GO:BP | GO:0046189 | phenol-containing compound biosynthetic process | 1 | 28 | 7.21e-01 |
| GO:BP | GO:0032677 | regulation of interleukin-8 production | 1 | 43 | 7.21e-01 |
| GO:BP | GO:0001975 | response to amphetamine | 1 | 22 | 7.21e-01 |
| GO:BP | GO:0032637 | interleukin-8 production | 1 | 43 | 7.21e-01 |
| GO:BP | GO:0000455 | enzyme-directed rRNA pseudouridine synthesis | 1 | 6 | 7.21e-01 |
| GO:BP | GO:0006325 | chromatin organization | 8 | 551 | 7.21e-01 |
| GO:BP | GO:0002832 | negative regulation of response to biotic stimulus | 18 | 88 | 7.21e-01 |
| GO:BP | GO:0022401 | negative adaptation of signaling pathway | 1 | 15 | 7.21e-01 |
| GO:BP | GO:1902513 | regulation of organelle transport along microtubule | 1 | 9 | 7.21e-01 |
| GO:BP | GO:0090158 | endoplasmic reticulum membrane organization | 2 | 14 | 7.22e-01 |
| GO:BP | GO:0071455 | cellular response to hyperoxia | 1 | 5 | 7.22e-01 |
| GO:BP | GO:0031663 | lipopolysaccharide-mediated signaling pathway | 5 | 36 | 7.22e-01 |
| GO:BP | GO:0010171 | body morphogenesis | 3 | 45 | 7.22e-01 |
| GO:BP | GO:0019400 | alditol metabolic process | 1 | 14 | 7.22e-01 |
| GO:BP | GO:0043113 | receptor clustering | 7 | 45 | 7.22e-01 |
| GO:BP | GO:0001783 | B cell apoptotic process | 4 | 21 | 7.22e-01 |
| GO:BP | GO:2000637 | positive regulation of miRNA-mediated gene silencing | 2 | 15 | 7.22e-01 |
| GO:BP | GO:0031664 | regulation of lipopolysaccharide-mediated signaling pathway | 2 | 15 | 7.23e-01 |
| GO:BP | GO:0048011 | neurotrophin TRK receptor signaling pathway | 2 | 23 | 7.23e-01 |
| GO:BP | GO:0043385 | mycotoxin metabolic process | 1 | 2 | 7.23e-01 |
| GO:BP | GO:0050801 | monoatomic ion homeostasis | 1 | 408 | 7.23e-01 |
| GO:BP | GO:1901376 | organic heteropentacyclic compound metabolic process | 1 | 2 | 7.23e-01 |
| GO:BP | GO:0046222 | aflatoxin metabolic process | 1 | 2 | 7.23e-01 |
| GO:BP | GO:0048016 | inositol phosphate-mediated signaling | 4 | 45 | 7.23e-01 |
| GO:BP | GO:0043491 | protein kinase B signaling | 3 | 146 | 7.23e-01 |
| GO:BP | GO:1990009 | retinal cell apoptotic process | 1 | 5 | 7.23e-01 |
| GO:BP | GO:0002155 | regulation of thyroid hormone mediated signaling pathway | 1 | 5 | 7.23e-01 |
| GO:BP | GO:0021854 | hypothalamus development | 4 | 15 | 7.23e-01 |
| GO:BP | GO:0010891 | negative regulation of sequestering of triglyceride | 1 | 5 | 7.24e-01 |
| GO:BP | GO:0071902 | positive regulation of protein serine/threonine kinase activity | 11 | 135 | 7.24e-01 |
| GO:BP | GO:0042133 | neurotransmitter metabolic process | 2 | 18 | 7.24e-01 |
| GO:BP | GO:2000535 | regulation of entry of bacterium into host cell | 1 | 6 | 7.24e-01 |
| GO:BP | GO:0032402 | melanosome transport | 3 | 19 | 7.24e-01 |
| GO:BP | GO:0009744 | response to sucrose | 1 | 4 | 7.24e-01 |
| GO:BP | GO:0045910 | negative regulation of DNA recombination | 2 | 31 | 7.24e-01 |
| GO:BP | GO:0006551 | leucine metabolic process | 1 | 8 | 7.24e-01 |
| GO:BP | GO:0060039 | pericardium development | 3 | 17 | 7.24e-01 |
| GO:BP | GO:0044830 | modulation by host of viral RNA genome replication | 1 | 6 | 7.24e-01 |
| GO:BP | GO:0000245 | spliceosomal complex assembly | 2 | 73 | 7.24e-01 |
| GO:BP | GO:0034285 | response to disaccharide | 1 | 4 | 7.24e-01 |
| GO:BP | GO:0048520 | positive regulation of behavior | 2 | 13 | 7.24e-01 |
| GO:BP | GO:1903294 | regulation of glutamate secretion, neurotransmission | 1 | 4 | 7.24e-01 |
| GO:BP | GO:0043268 | positive regulation of potassium ion transport | 1 | 36 | 7.24e-01 |
| GO:BP | GO:0044085 | cellular component biogenesis | 11 | 2724 | 7.25e-01 |
| GO:BP | GO:0033865 | nucleoside bisphosphate metabolic process | 5 | 92 | 7.25e-01 |
| GO:BP | GO:0061326 | renal tubule development | 6 | 77 | 7.25e-01 |
| GO:BP | GO:0033875 | ribonucleoside bisphosphate metabolic process | 5 | 92 | 7.25e-01 |
| GO:BP | GO:0034032 | purine nucleoside bisphosphate metabolic process | 5 | 92 | 7.25e-01 |
| GO:BP | GO:1905671 | regulation of lysosome organization | 1 | 6 | 7.25e-01 |
| GO:BP | GO:0060348 | bone development | 1 | 170 | 7.25e-01 |
| GO:BP | GO:0002457 | T cell antigen processing and presentation | 1 | 4 | 7.25e-01 |
| GO:BP | GO:0072674 | multinuclear osteoclast differentiation | 1 | 6 | 7.25e-01 |
| GO:BP | GO:0022400 | regulation of rhodopsin mediated signaling pathway | 1 | 5 | 7.25e-01 |
| GO:BP | GO:0072126 | positive regulation of glomerular mesangial cell proliferation | 1 | 7 | 7.25e-01 |
| GO:BP | GO:0036037 | CD8-positive, alpha-beta T cell activation | 1 | 15 | 7.26e-01 |
| GO:BP | GO:0030514 | negative regulation of BMP signaling pathway | 3 | 45 | 7.26e-01 |
| GO:BP | GO:0010830 | regulation of myotube differentiation | 3 | 31 | 7.26e-01 |
| GO:BP | GO:0051952 | regulation of amine transport | 2 | 55 | 7.26e-01 |
| GO:BP | GO:0010595 | positive regulation of endothelial cell migration | 1 | 94 | 7.28e-01 |
| GO:BP | GO:0140058 | neuron projection arborization | 4 | 29 | 7.28e-01 |
| GO:BP | GO:0099003 | vesicle-mediated transport in synapse | 6 | 180 | 7.28e-01 |
| GO:BP | GO:0010829 | negative regulation of glucose transmembrane transport | 1 | 14 | 7.28e-01 |
| GO:BP | GO:0045663 | positive regulation of myoblast differentiation | 2 | 37 | 7.28e-01 |
| GO:BP | GO:0021543 | pallium development | 1 | 139 | 7.28e-01 |
| GO:BP | GO:0072176 | nephric duct development | 1 | 12 | 7.28e-01 |
| GO:BP | GO:0055093 | response to hyperoxia | 1 | 18 | 7.28e-01 |
| GO:BP | GO:0001947 | heart looping | 4 | 50 | 7.29e-01 |
| GO:BP | GO:0150011 | regulation of neuron projection arborization | 2 | 14 | 7.29e-01 |
| GO:BP | GO:0060685 | regulation of prostatic bud formation | 1 | 5 | 7.29e-01 |
| GO:BP | GO:0043455 | regulation of secondary metabolic process | 2 | 12 | 7.29e-01 |
| GO:BP | GO:0100012 | regulation of heart induction by canonical Wnt signaling pathway | 1 | 4 | 7.29e-01 |
| GO:BP | GO:0048021 | regulation of melanin biosynthetic process | 2 | 12 | 7.29e-01 |
| GO:BP | GO:1902474 | positive regulation of protein localization to synapse | 1 | 6 | 7.29e-01 |
| GO:BP | GO:0060028 | convergent extension involved in axis elongation | 1 | 6 | 7.29e-01 |
| GO:BP | GO:1900376 | regulation of secondary metabolite biosynthetic process | 2 | 12 | 7.29e-01 |
| GO:BP | GO:0038031 | non-canonical Wnt signaling pathway via JNK cascade | 1 | 4 | 7.29e-01 |
| GO:BP | GO:0021891 | olfactory bulb interneuron development | 1 | 5 | 7.29e-01 |
| GO:BP | GO:0034427 | nuclear-transcribed mRNA catabolic process, exonucleolytic, 3’-5’ | 2 | 11 | 7.29e-01 |
| GO:BP | GO:0090381 | regulation of heart induction | 1 | 4 | 7.29e-01 |
| GO:BP | GO:0097035 | regulation of membrane lipid distribution | 1 | 43 | 7.29e-01 |
| GO:BP | GO:0061028 | establishment of endothelial barrier | 2 | 38 | 7.29e-01 |
| GO:BP | GO:0001893 | maternal placenta development | 3 | 28 | 7.29e-01 |
| GO:BP | GO:0060333 | type II interferon-mediated signaling pathway | 1 | 21 | 7.30e-01 |
| GO:BP | GO:0070141 | response to UV-A | 1 | 11 | 7.30e-01 |
| GO:BP | GO:2000402 | negative regulation of lymphocyte migration | 1 | 10 | 7.30e-01 |
| GO:BP | GO:0046888 | negative regulation of hormone secretion | 3 | 46 | 7.30e-01 |
| GO:BP | GO:0006521 | regulation of cellular amino acid metabolic process | 1 | 7 | 7.30e-01 |
| GO:BP | GO:0098703 | calcium ion import across plasma membrane | 1 | 23 | 7.30e-01 |
| GO:BP | GO:0007638 | mechanosensory behavior | 1 | 8 | 7.30e-01 |
| GO:BP | GO:0001914 | regulation of T cell mediated cytotoxicity | 1 | 17 | 7.30e-01 |
| GO:BP | GO:0042446 | hormone biosynthetic process | 1 | 40 | 7.30e-01 |
| GO:BP | GO:0071354 | cellular response to interleukin-6 | 3 | 23 | 7.30e-01 |
| GO:BP | GO:0033628 | regulation of cell adhesion mediated by integrin | 1 | 36 | 7.30e-01 |
| GO:BP | GO:0015908 | fatty acid transport | 2 | 58 | 7.30e-01 |
| GO:BP | GO:0030397 | membrane disassembly | 1 | 11 | 7.30e-01 |
| GO:BP | GO:0070987 | error-free translesion synthesis | 1 | 5 | 7.30e-01 |
| GO:BP | GO:0006829 | zinc ion transport | 4 | 23 | 7.30e-01 |
| GO:BP | GO:1904874 | positive regulation of telomerase RNA localization to Cajal body | 2 | 15 | 7.30e-01 |
| GO:BP | GO:0003263 | cardioblast proliferation | 1 | 9 | 7.30e-01 |
| GO:BP | GO:0003264 | regulation of cardioblast proliferation | 1 | 9 | 7.30e-01 |
| GO:BP | GO:0072075 | metanephric mesenchyme development | 1 | 10 | 7.30e-01 |
| GO:BP | GO:1904386 | response to L-phenylalanine derivative | 1 | 5 | 7.30e-01 |
| GO:BP | GO:0032410 | negative regulation of transporter activity | 2 | 58 | 7.30e-01 |
| GO:BP | GO:0090312 | positive regulation of protein deacetylation | 2 | 28 | 7.30e-01 |
| GO:BP | GO:0050954 | sensory perception of mechanical stimulus | 2 | 112 | 7.30e-01 |
| GO:BP | GO:0070306 | lens fiber cell differentiation | 4 | 30 | 7.30e-01 |
| GO:BP | GO:0097152 | mesenchymal cell apoptotic process | 1 | 7 | 7.30e-01 |
| GO:BP | GO:0003206 | cardiac chamber morphogenesis | 6 | 109 | 7.31e-01 |
| GO:BP | GO:0007008 | outer mitochondrial membrane organization | 2 | 15 | 7.31e-01 |
| GO:BP | GO:0045040 | protein insertion into mitochondrial outer membrane | 2 | 15 | 7.31e-01 |
| GO:BP | GO:0002224 | toll-like receptor signaling pathway | 2 | 43 | 7.32e-01 |
| GO:BP | GO:0048742 | regulation of skeletal muscle fiber development | 1 | 8 | 7.32e-01 |
| GO:BP | GO:1903311 | regulation of mRNA metabolic process | 41 | 267 | 7.32e-01 |
| GO:BP | GO:2001137 | positive regulation of endocytic recycling | 1 | 7 | 7.32e-01 |
| GO:BP | GO:1990592 | protein K69-linked ufmylation | 1 | 5 | 7.32e-01 |
| GO:BP | GO:1900157 | regulation of bone mineralization involved in bone maturation | 1 | 4 | 7.32e-01 |
| GO:BP | GO:1903895 | negative regulation of IRE1-mediated unfolded protein response | 1 | 5 | 7.32e-01 |
| GO:BP | GO:2000064 | regulation of cortisol biosynthetic process | 1 | 7 | 7.32e-01 |
| GO:BP | GO:1902306 | negative regulation of sodium ion transmembrane transport | 2 | 10 | 7.32e-01 |
| GO:BP | GO:0035264 | multicellular organism growth | 9 | 123 | 7.32e-01 |
| GO:BP | GO:1903313 | positive regulation of mRNA metabolic process | 20 | 121 | 7.32e-01 |
| GO:BP | GO:0019886 | antigen processing and presentation of exogenous peptide antigen via MHC class II | 1 | 15 | 7.32e-01 |
| GO:BP | GO:1990564 | protein polyufmylation | 1 | 5 | 7.32e-01 |
| GO:BP | GO:0051894 | positive regulation of focal adhesion assembly | 3 | 24 | 7.32e-01 |
| GO:BP | GO:0060623 | regulation of chromosome condensation | 2 | 11 | 7.32e-01 |
| GO:BP | GO:0061000 | negative regulation of dendritic spine development | 2 | 10 | 7.33e-01 |
| GO:BP | GO:0060931 | sinoatrial node cell development | 1 | 4 | 7.33e-01 |
| GO:BP | GO:0006833 | water transport | 1 | 10 | 7.33e-01 |
| GO:BP | GO:0045445 | myoblast differentiation | 8 | 90 | 7.33e-01 |
| GO:BP | GO:0060416 | response to growth hormone | 4 | 25 | 7.33e-01 |
| GO:BP | GO:0055123 | digestive system development | 8 | 100 | 7.33e-01 |
| GO:BP | GO:0033032 | regulation of myeloid cell apoptotic process | 1 | 20 | 7.33e-01 |
| GO:BP | GO:0007188 | adenylate cyclase-modulating G protein-coupled receptor signaling pathway | 1 | 118 | 7.34e-01 |
| GO:BP | GO:1900378 | positive regulation of secondary metabolite biosynthetic process | 1 | 7 | 7.34e-01 |
| GO:BP | GO:1903298 | negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway | 1 | 6 | 7.34e-01 |
| GO:BP | GO:0033275 | actin-myosin filament sliding | 1 | 11 | 7.34e-01 |
| GO:BP | GO:0015848 | spermidine transport | 1 | 3 | 7.34e-01 |
| GO:BP | GO:0035022 | positive regulation of Rac protein signal transduction | 1 | 5 | 7.34e-01 |
| GO:BP | GO:1903898 | negative regulation of PERK-mediated unfolded protein response | 1 | 6 | 7.34e-01 |
| GO:BP | GO:0000768 | syncytium formation by plasma membrane fusion | 7 | 37 | 7.34e-01 |
| GO:BP | GO:0048023 | positive regulation of melanin biosynthetic process | 1 | 7 | 7.34e-01 |
| GO:BP | GO:1900747 | negative regulation of vascular endothelial growth factor signaling pathway | 2 | 7 | 7.34e-01 |
| GO:BP | GO:0030850 | prostate gland development | 2 | 35 | 7.34e-01 |
| GO:BP | GO:0050872 | white fat cell differentiation | 3 | 15 | 7.34e-01 |
| GO:BP | GO:0051152 | positive regulation of smooth muscle cell differentiation | 1 | 10 | 7.34e-01 |
| GO:BP | GO:1903297 | regulation of hypoxia-induced intrinsic apoptotic signaling pathway | 1 | 6 | 7.34e-01 |
| GO:BP | GO:0140253 | cell-cell fusion | 7 | 37 | 7.34e-01 |
| GO:BP | GO:0060402 | calcium ion transport into cytosol | 3 | 18 | 7.34e-01 |
| GO:BP | GO:0045940 | positive regulation of steroid metabolic process | 2 | 20 | 7.34e-01 |
| GO:BP | GO:0071230 | cellular response to amino acid stimulus | 11 | 65 | 7.34e-01 |
| GO:BP | GO:0046890 | regulation of lipid biosynthetic process | 19 | 134 | 7.34e-01 |
| GO:BP | GO:0043277 | apoptotic cell clearance | 8 | 35 | 7.34e-01 |
| GO:BP | GO:0060546 | negative regulation of necroptotic process | 1 | 16 | 7.34e-01 |
| GO:BP | GO:0023035 | CD40 signaling pathway | 1 | 11 | 7.34e-01 |
| GO:BP | GO:0061900 | glial cell activation | 4 | 23 | 7.35e-01 |
| GO:BP | GO:0006620 | post-translational protein targeting to endoplasmic reticulum membrane | 1 | 15 | 7.35e-01 |
| GO:BP | GO:0007191 | adenylate cyclase-activating dopamine receptor signaling pathway | 1 | 7 | 7.35e-01 |
| GO:BP | GO:0030643 | intracellular phosphate ion homeostasis | 1 | 5 | 7.35e-01 |
| GO:BP | GO:2000051 | negative regulation of non-canonical Wnt signaling pathway | 1 | 5 | 7.35e-01 |
| GO:BP | GO:0031126 | sno(s)RNA 3’-end processing | 1 | 12 | 7.35e-01 |
| GO:BP | GO:0009605 | response to external stimulus | 1 | 1719 | 7.35e-01 |
| GO:BP | GO:1903859 | regulation of dendrite extension | 4 | 17 | 7.35e-01 |
| GO:BP | GO:0060021 | roof of mouth development | 2 | 71 | 7.35e-01 |
| GO:BP | GO:0006665 | sphingolipid metabolic process | 5 | 131 | 7.35e-01 |
| GO:BP | GO:0017158 | regulation of calcium ion-dependent exocytosis | 1 | 29 | 7.35e-01 |
| GO:BP | GO:0007389 | pattern specification process | 1 | 306 | 7.35e-01 |
| GO:BP | GO:1903405 | protein localization to nuclear body | 2 | 12 | 7.35e-01 |
| GO:BP | GO:1904867 | protein localization to Cajal body | 2 | 12 | 7.35e-01 |
| GO:BP | GO:0021681 | cerebellar granular layer development | 1 | 11 | 7.35e-01 |
| GO:BP | GO:0032908 | regulation of transforming growth factor beta1 production | 1 | 10 | 7.35e-01 |
| GO:BP | GO:0010511 | regulation of phosphatidylinositol biosynthetic process | 1 | 2 | 7.35e-01 |
| GO:BP | GO:0072553 | terminal button organization | 1 | 5 | 7.35e-01 |
| GO:BP | GO:0035788 | cell migration involved in metanephros development | 1 | 4 | 7.35e-01 |
| GO:BP | GO:0048857 | neural nucleus development | 3 | 50 | 7.35e-01 |
| GO:BP | GO:0032534 | regulation of microvillus assembly | 1 | 6 | 7.35e-01 |
| GO:BP | GO:0031652 | positive regulation of heat generation | 1 | 4 | 7.35e-01 |
| GO:BP | GO:0051149 | positive regulation of muscle cell differentiation | 3 | 53 | 7.35e-01 |
| GO:BP | GO:0000466 | maturation of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 3 | 25 | 7.36e-01 |
| GO:BP | GO:0030335 | positive regulation of cell migration | 5 | 407 | 7.36e-01 |
| GO:BP | GO:0060405 | regulation of penile erection | 1 | 4 | 7.37e-01 |
| GO:BP | GO:0038061 | NIK/NF-kappaB signaling | 2 | 86 | 7.38e-01 |
| GO:BP | GO:0070198 | protein localization to chromosome, telomeric region | 3 | 30 | 7.38e-01 |
| GO:BP | GO:0019511 | peptidyl-proline hydroxylation | 1 | 14 | 7.38e-01 |
| GO:BP | GO:1902235 | regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway | 4 | 29 | 7.38e-01 |
| GO:BP | GO:1903909 | regulation of receptor clustering | 2 | 12 | 7.39e-01 |
| GO:BP | GO:0021800 | cerebral cortex tangential migration | 1 | 4 | 7.39e-01 |
| GO:BP | GO:0070341 | fat cell proliferation | 2 | 10 | 7.39e-01 |
| GO:BP | GO:0006760 | folic acid-containing compound metabolic process | 2 | 22 | 7.39e-01 |
| GO:BP | GO:0043462 | regulation of ATP-dependent activity | 2 | 63 | 7.39e-01 |
| GO:BP | GO:0021781 | glial cell fate commitment | 1 | 5 | 7.39e-01 |
| GO:BP | GO:0002312 | B cell activation involved in immune response | 4 | 57 | 7.39e-01 |
| GO:BP | GO:0150076 | neuroinflammatory response | 10 | 33 | 7.39e-01 |
| GO:BP | GO:0051881 | regulation of mitochondrial membrane potential | 1 | 60 | 7.39e-01 |
| GO:BP | GO:0090175 | regulation of establishment of planar polarity | 7 | 54 | 7.39e-01 |
| GO:BP | GO:0070295 | renal water absorption | 1 | 5 | 7.39e-01 |
| GO:BP | GO:0075509 | endocytosis involved in viral entry into host cell | 1 | 11 | 7.39e-01 |
| GO:BP | GO:0030185 | nitric oxide transport | 1 | 2 | 7.39e-01 |
| GO:BP | GO:0042632 | cholesterol homeostasis | 3 | 58 | 7.40e-01 |
| GO:BP | GO:0001773 | myeloid dendritic cell activation | 1 | 12 | 7.40e-01 |
| GO:BP | GO:0048534 | hematopoietic or lymphoid organ development | 1 | 70 | 7.40e-01 |
| GO:BP | GO:0006356 | regulation of transcription by RNA polymerase I | 5 | 45 | 7.40e-01 |
| GO:BP | GO:0097531 | mast cell migration | 1 | 12 | 7.40e-01 |
| GO:BP | GO:0035930 | corticosteroid hormone secretion | 1 | 12 | 7.40e-01 |
| GO:BP | GO:1903431 | positive regulation of cell maturation | 1 | 6 | 7.40e-01 |
| GO:BP | GO:0023058 | adaptation of signaling pathway | 1 | 16 | 7.40e-01 |
| GO:BP | GO:0010656 | negative regulation of muscle cell apoptotic process | 6 | 35 | 7.40e-01 |
| GO:BP | GO:0048584 | positive regulation of response to stimulus | 1 | 1555 | 7.40e-01 |
| GO:BP | GO:0035336 | long-chain fatty-acyl-CoA metabolic process | 1 | 19 | 7.40e-01 |
| GO:BP | GO:0050850 | positive regulation of calcium-mediated signaling | 1 | 22 | 7.41e-01 |
| GO:BP | GO:0098810 | neurotransmitter reuptake | 1 | 21 | 7.41e-01 |
| GO:BP | GO:0099149 | regulation of postsynaptic neurotransmitter receptor internalization | 1 | 11 | 7.41e-01 |
| GO:BP | GO:0046471 | phosphatidylglycerol metabolic process | 4 | 23 | 7.41e-01 |
| GO:BP | GO:0034370 | triglyceride-rich lipoprotein particle remodeling | 1 | 4 | 7.41e-01 |
| GO:BP | GO:0034372 | very-low-density lipoprotein particle remodeling | 1 | 4 | 7.41e-01 |
| GO:BP | GO:0032528 | microvillus organization | 3 | 19 | 7.42e-01 |
| GO:BP | GO:2000647 | negative regulation of stem cell proliferation | 2 | 18 | 7.42e-01 |
| GO:BP | GO:0070857 | regulation of bile acid biosynthetic process | 1 | 7 | 7.42e-01 |
| GO:BP | GO:0090461 | intracellular glutamate homeostasis | 1 | 4 | 7.42e-01 |
| GO:BP | GO:0070268 | cornification | 1 | 2 | 7.42e-01 |
| GO:BP | GO:0060420 | regulation of heart growth | 3 | 50 | 7.42e-01 |
| GO:BP | GO:0006787 | porphyrin-containing compound catabolic process | 1 | 7 | 7.42e-01 |
| GO:BP | GO:0033015 | tetrapyrrole catabolic process | 1 | 7 | 7.42e-01 |
| GO:BP | GO:0019755 | one-carbon compound transport | 1 | 23 | 7.42e-01 |
| GO:BP | GO:1903867 | extraembryonic membrane development | 2 | 11 | 7.42e-01 |
| GO:BP | GO:0098586 | cellular response to virus | 2 | 40 | 7.42e-01 |
| GO:BP | GO:0086042 | cardiac muscle cell-cardiac muscle cell adhesion | 1 | 7 | 7.42e-01 |
| GO:BP | GO:0050873 | brown fat cell differentiation | 1 | 41 | 7.43e-01 |
| GO:BP | GO:1905709 | negative regulation of membrane permeability | 3 | 19 | 7.43e-01 |
| GO:BP | GO:0045089 | positive regulation of innate immune response | 12 | 182 | 7.43e-01 |
| GO:BP | GO:0006703 | estrogen biosynthetic process | 1 | 6 | 7.43e-01 |
| GO:BP | GO:0033238 | regulation of amine metabolic process | 1 | 19 | 7.43e-01 |
| GO:BP | GO:0043951 | negative regulation of cAMP-mediated signaling | 1 | 10 | 7.43e-01 |
| GO:BP | GO:0006189 | ‘de novo’ IMP biosynthetic process | 1 | 6 | 7.43e-01 |
| GO:BP | GO:0022602 | ovulation cycle process | 1 | 37 | 7.43e-01 |
| GO:BP | GO:0055118 | negative regulation of cardiac muscle contraction | 1 | 4 | 7.44e-01 |
| GO:BP | GO:0051904 | pigment granule transport | 3 | 19 | 7.44e-01 |
| GO:BP | GO:0032401 | establishment of melanosome localization | 3 | 20 | 7.44e-01 |
| GO:BP | GO:0006880 | intracellular sequestering of iron ion | 1 | 3 | 7.44e-01 |
| GO:BP | GO:0046621 | negative regulation of organ growth | 5 | 27 | 7.44e-01 |
| GO:BP | GO:0007039 | protein catabolic process in the vacuole | 3 | 22 | 7.44e-01 |
| GO:BP | GO:0002262 | myeloid cell homeostasis | 2 | 140 | 7.44e-01 |
| GO:BP | GO:0009435 | NAD biosynthetic process | 1 | 17 | 7.44e-01 |
| GO:BP | GO:0090594 | inflammatory response to wounding | 1 | 12 | 7.44e-01 |
| GO:BP | GO:0060148 | positive regulation of post-transcriptional gene silencing | 2 | 16 | 7.44e-01 |
| GO:BP | GO:0043029 | T cell homeostasis | 4 | 27 | 7.44e-01 |
| GO:BP | GO:1900370 | positive regulation of post-transcriptional gene silencing by RNA | 2 | 16 | 7.44e-01 |
| GO:BP | GO:0099010 | modification of postsynaptic structure | 1 | 17 | 7.44e-01 |
| GO:BP | GO:0060761 | negative regulation of response to cytokine stimulus | 6 | 57 | 7.44e-01 |
| GO:BP | GO:0015936 | coenzyme A metabolic process | 2 | 18 | 7.44e-01 |
| GO:BP | GO:0071674 | mononuclear cell migration | 2 | 102 | 7.44e-01 |
| GO:BP | GO:0062014 | negative regulation of small molecule metabolic process | 4 | 71 | 7.44e-01 |
| GO:BP | GO:0051147 | regulation of muscle cell differentiation | 6 | 118 | 7.44e-01 |
| GO:BP | GO:0070296 | sarcoplasmic reticulum calcium ion transport | 6 | 31 | 7.44e-01 |
| GO:BP | GO:0002791 | regulation of peptide secretion | 4 | 134 | 7.44e-01 |
| GO:BP | GO:0055092 | sterol homeostasis | 3 | 59 | 7.44e-01 |
| GO:BP | GO:0009312 | oligosaccharide biosynthetic process | 2 | 15 | 7.44e-01 |
| GO:BP | GO:0048678 | response to axon injury | 1 | 64 | 7.44e-01 |
| GO:BP | GO:0023052 | signaling | 8 | 4141 | 7.44e-01 |
| GO:BP | GO:0030856 | regulation of epithelial cell differentiation | 1 | 101 | 7.44e-01 |
| GO:BP | GO:2001238 | positive regulation of extrinsic apoptotic signaling pathway | 3 | 40 | 7.44e-01 |
| GO:BP | GO:2000757 | negative regulation of peptidyl-lysine acetylation | 2 | 13 | 7.44e-01 |
| GO:BP | GO:0043923 | positive regulation by host of viral transcription | 3 | 18 | 7.45e-01 |
| GO:BP | GO:0050805 | negative regulation of synaptic transmission | 1 | 35 | 7.45e-01 |
| GO:BP | GO:0003338 | metanephros morphogenesis | 2 | 22 | 7.45e-01 |
| GO:BP | GO:0050657 | nucleic acid transport | 19 | 144 | 7.45e-01 |
| GO:BP | GO:0050658 | RNA transport | 19 | 144 | 7.45e-01 |
| GO:BP | GO:0071347 | cellular response to interleukin-1 | 3 | 64 | 7.46e-01 |
| GO:BP | GO:0060632 | regulation of microtubule-based movement | 4 | 31 | 7.46e-01 |
| GO:BP | GO:0043303 | mast cell degranulation | 3 | 30 | 7.46e-01 |
| GO:BP | GO:0033081 | regulation of T cell differentiation in thymus | 3 | 16 | 7.46e-01 |
| GO:BP | GO:0045165 | cell fate commitment | 4 | 155 | 7.46e-01 |
| GO:BP | GO:0072348 | sulfur compound transport | 1 | 39 | 7.46e-01 |
| GO:BP | GO:1901607 | alpha-amino acid biosynthetic process | 6 | 59 | 7.46e-01 |
| GO:BP | GO:0048741 | skeletal muscle fiber development | 1 | 30 | 7.46e-01 |
| GO:BP | GO:0031954 | positive regulation of protein autophosphorylation | 4 | 26 | 7.46e-01 |
| GO:BP | GO:0015844 | monoamine transport | 2 | 45 | 7.46e-01 |
| GO:BP | GO:0009416 | response to light stimulus | 27 | 246 | 7.46e-01 |
| GO:BP | GO:0019375 | galactolipid biosynthetic process | 1 | 4 | 7.46e-01 |
| GO:BP | GO:0072283 | metanephric renal vesicle morphogenesis | 1 | 11 | 7.46e-01 |
| GO:BP | GO:0090559 | regulation of membrane permeability | 6 | 64 | 7.46e-01 |
| GO:BP | GO:0006682 | galactosylceramide biosynthetic process | 1 | 4 | 7.46e-01 |
| GO:BP | GO:1901897 | regulation of relaxation of cardiac muscle | 1 | 5 | 7.46e-01 |
| GO:BP | GO:0051597 | response to methylmercury | 1 | 5 | 7.46e-01 |
| GO:BP | GO:0106049 | regulation of cellular response to osmotic stress | 1 | 10 | 7.46e-01 |
| GO:BP | GO:0044387 | negative regulation of protein kinase activity by regulation of protein phosphorylation | 1 | 7 | 7.46e-01 |
| GO:BP | GO:0010468 | regulation of gene expression | 2 | 3580 | 7.46e-01 |
| GO:BP | GO:0031323 | regulation of cellular metabolic process | 2 | 4174 | 7.47e-01 |
| GO:BP | GO:0035234 | ectopic germ cell programmed cell death | 2 | 11 | 7.47e-01 |
| GO:BP | GO:0051867 | general adaptation syndrome, behavioral process | 1 | 3 | 7.47e-01 |
| GO:BP | GO:0070175 | positive regulation of enamel mineralization | 1 | 2 | 7.48e-01 |
| GO:BP | GO:0097202 | activation of cysteine-type endopeptidase activity | 3 | 16 | 7.48e-01 |
| GO:BP | GO:0007166 | cell surface receptor signaling pathway | 2 | 1898 | 7.48e-01 |
| GO:BP | GO:0046677 | response to antibiotic | 2 | 43 | 7.48e-01 |
| GO:BP | GO:0070453 | regulation of heme biosynthetic process | 1 | 7 | 7.48e-01 |
| GO:BP | GO:0042551 | neuron maturation | 5 | 33 | 7.48e-01 |
| GO:BP | GO:0048710 | regulation of astrocyte differentiation | 1 | 21 | 7.48e-01 |
| GO:BP | GO:1901463 | regulation of tetrapyrrole biosynthetic process | 1 | 7 | 7.48e-01 |
| GO:BP | GO:0062099 | negative regulation of programmed necrotic cell death | 1 | 17 | 7.48e-01 |
| GO:BP | GO:0032725 | positive regulation of granulocyte macrophage colony-stimulating factor production | 1 | 5 | 7.48e-01 |
| GO:BP | GO:0031334 | positive regulation of protein-containing complex assembly | 2 | 161 | 7.48e-01 |
| GO:BP | GO:1902547 | regulation of cellular response to vascular endothelial growth factor stimulus | 4 | 20 | 7.48e-01 |
| GO:BP | GO:0071384 | cellular response to corticosteroid stimulus | 9 | 47 | 7.48e-01 |
| GO:BP | GO:0002483 | antigen processing and presentation of endogenous peptide antigen | 1 | 16 | 7.48e-01 |
| GO:BP | GO:0043536 | positive regulation of blood vessel endothelial cell migration | 3 | 47 | 7.49e-01 |
| GO:BP | GO:0090087 | regulation of peptide transport | 4 | 136 | 7.50e-01 |
| GO:BP | GO:0060088 | auditory receptor cell stereocilium organization | 3 | 9 | 7.51e-01 |
| GO:BP | GO:0048087 | positive regulation of developmental pigmentation | 1 | 7 | 7.51e-01 |
| GO:BP | GO:0070234 | positive regulation of T cell apoptotic process | 2 | 8 | 7.51e-01 |
| GO:BP | GO:0000266 | mitochondrial fission | 1 | 38 | 7.51e-01 |
| GO:BP | GO:0032535 | regulation of cellular component size | 28 | 305 | 7.52e-01 |
| GO:BP | GO:0031133 | regulation of axon diameter | 1 | 4 | 7.52e-01 |
| GO:BP | GO:0072524 | pyridine-containing compound metabolic process | 3 | 72 | 7.52e-01 |
| GO:BP | GO:2000562 | negative regulation of CD4-positive, alpha-beta T cell proliferation | 2 | 7 | 7.53e-01 |
| GO:BP | GO:0070536 | protein K63-linked deubiquitination | 1 | 33 | 7.53e-01 |
| GO:BP | GO:0032438 | melanosome organization | 1 | 36 | 7.53e-01 |
| GO:BP | GO:1904044 | response to aldosterone | 1 | 9 | 7.54e-01 |
| GO:BP | GO:0036508 | protein alpha-1,2-demannosylation | 2 | 17 | 7.54e-01 |
| GO:BP | GO:0072525 | pyridine-containing compound biosynthetic process | 4 | 22 | 7.54e-01 |
| GO:BP | GO:0036507 | protein demannosylation | 2 | 17 | 7.54e-01 |
| GO:BP | GO:0050852 | T cell receptor signaling pathway | 1 | 84 | 7.54e-01 |
| GO:BP | GO:0002714 | positive regulation of B cell mediated immunity | 1 | 26 | 7.54e-01 |
| GO:BP | GO:0002891 | positive regulation of immunoglobulin mediated immune response | 1 | 26 | 7.54e-01 |
| GO:BP | GO:1903071 | positive regulation of ER-associated ubiquitin-dependent protein catabolic process | 1 | 8 | 7.54e-01 |
| GO:BP | GO:0002573 | myeloid leukocyte differentiation | 6 | 151 | 7.54e-01 |
| GO:BP | GO:0034063 | stress granule assembly | 3 | 28 | 7.54e-01 |
| GO:BP | GO:0051932 | synaptic transmission, GABAergic | 1 | 36 | 7.55e-01 |
| GO:BP | GO:0045606 | positive regulation of epidermal cell differentiation | 1 | 16 | 7.55e-01 |
| GO:BP | GO:0060352 | cell adhesion molecule production | 1 | 9 | 7.56e-01 |
| GO:BP | GO:0090231 | regulation of spindle checkpoint | 2 | 19 | 7.56e-01 |
| GO:BP | GO:0071484 | cellular response to light intensity | 1 | 4 | 7.56e-01 |
| GO:BP | GO:0034508 | centromere complex assembly | 4 | 28 | 7.56e-01 |
| GO:BP | GO:1903504 | regulation of mitotic spindle checkpoint | 2 | 19 | 7.56e-01 |
| GO:BP | GO:2000625 | regulation of miRNA catabolic process | 1 | 5 | 7.56e-01 |
| GO:BP | GO:0090266 | regulation of mitotic cell cycle spindle assembly checkpoint | 2 | 19 | 7.56e-01 |
| GO:BP | GO:0000447 | endonucleolytic cleavage in ITS1 to separate SSU-rRNA from 5.8S rRNA and LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 1 | 10 | 7.56e-01 |
| GO:BP | GO:0043583 | ear development | 17 | 153 | 7.56e-01 |
| GO:BP | GO:0033572 | transferrin transport | 1 | 8 | 7.56e-01 |
| GO:BP | GO:0008594 | photoreceptor cell morphogenesis | 1 | 4 | 7.56e-01 |
| GO:BP | GO:0002637 | regulation of immunoglobulin production | 2 | 43 | 7.57e-01 |
| GO:BP | GO:0050795 | regulation of behavior | 5 | 39 | 7.57e-01 |
| GO:BP | GO:2000197 | regulation of ribonucleoprotein complex localization | 1 | 6 | 7.57e-01 |
| GO:BP | GO:0018095 | protein polyglutamylation | 1 | 9 | 7.57e-01 |
| GO:BP | GO:0045444 | fat cell differentiation | 28 | 187 | 7.57e-01 |
| GO:BP | GO:0097061 | dendritic spine organization | 11 | 67 | 7.57e-01 |
| GO:BP | GO:0034137 | positive regulation of toll-like receptor 2 signaling pathway | 1 | 5 | 7.58e-01 |
| GO:BP | GO:0007219 | Notch signaling pathway | 10 | 146 | 7.58e-01 |
| GO:BP | GO:0030035 | microspike assembly | 1 | 5 | 7.58e-01 |
| GO:BP | GO:0040038 | polar body extrusion after meiotic divisions | 1 | 5 | 7.58e-01 |
| GO:BP | GO:0030222 | eosinophil differentiation | 1 | 2 | 7.58e-01 |
| GO:BP | GO:1902653 | secondary alcohol biosynthetic process | 1 | 46 | 7.58e-01 |
| GO:BP | GO:0006695 | cholesterol biosynthetic process | 1 | 46 | 7.58e-01 |
| GO:BP | GO:0051014 | actin filament severing | 1 | 13 | 7.59e-01 |
| GO:BP | GO:0045199 | maintenance of epithelial cell apical/basal polarity | 1 | 10 | 7.59e-01 |
| GO:BP | GO:0032782 | bile acid secretion | 1 | 5 | 7.59e-01 |
| GO:BP | GO:0035090 | maintenance of apical/basal cell polarity | 1 | 10 | 7.59e-01 |
| GO:BP | GO:0016445 | somatic diversification of immunoglobulins | 3 | 53 | 7.59e-01 |
| GO:BP | GO:0002154 | thyroid hormone mediated signaling pathway | 1 | 6 | 7.60e-01 |
| GO:BP | GO:0048489 | synaptic vesicle transport | 1 | 36 | 7.60e-01 |
| GO:BP | GO:0048753 | pigment granule organization | 1 | 37 | 7.60e-01 |
| GO:BP | GO:0009743 | response to carbohydrate | 16 | 161 | 7.60e-01 |
| GO:BP | GO:0006750 | glutathione biosynthetic process | 2 | 13 | 7.60e-01 |
| GO:BP | GO:0002753 | cytosolic pattern recognition receptor signaling pathway | 4 | 68 | 7.60e-01 |
| GO:BP | GO:0008306 | associative learning | 8 | 65 | 7.60e-01 |
| GO:BP | GO:0061757 | leukocyte adhesion to arterial endothelial cell | 1 | 4 | 7.60e-01 |
| GO:BP | GO:0060180 | female mating behavior | 1 | 2 | 7.60e-01 |
| GO:BP | GO:0045924 | regulation of female receptivity | 1 | 2 | 7.60e-01 |
| GO:BP | GO:1904063 | negative regulation of cation transmembrane transport | 2 | 64 | 7.60e-01 |
| GO:BP | GO:0032430 | positive regulation of phospholipase A2 activity | 1 | 2 | 7.61e-01 |
| GO:BP | GO:0061548 | ganglion development | 1 | 12 | 7.61e-01 |
| GO:BP | GO:0051446 | positive regulation of meiotic cell cycle | 4 | 16 | 7.61e-01 |
| GO:BP | GO:0032516 | positive regulation of phosphoprotein phosphatase activity | 2 | 16 | 7.61e-01 |
| GO:BP | GO:0043485 | endosome to pigment granule transport | 1 | 9 | 7.61e-01 |
| GO:BP | GO:0035646 | endosome to melanosome transport | 1 | 9 | 7.61e-01 |
| GO:BP | GO:0048757 | pigment granule maturation | 1 | 9 | 7.61e-01 |
| GO:BP | GO:0060997 | dendritic spine morphogenesis | 8 | 50 | 7.61e-01 |
| GO:BP | GO:0045668 | negative regulation of osteoblast differentiation | 1 | 36 | 7.61e-01 |
| GO:BP | GO:0060627 | regulation of vesicle-mediated transport | 1 | 403 | 7.61e-01 |
| GO:BP | GO:0043628 | regulatory ncRNA 3’-end processing | 3 | 19 | 7.61e-01 |
| GO:BP | GO:0035483 | gastric emptying | 1 | 2 | 7.62e-01 |
| GO:BP | GO:0006451 | translational readthrough | 1 | 10 | 7.62e-01 |
| GO:BP | GO:0050881 | musculoskeletal movement | 4 | 41 | 7.62e-01 |
| GO:BP | GO:0002220 | innate immune response activating cell surface receptor signaling pathway | 3 | 37 | 7.62e-01 |
| GO:BP | GO:0001514 | selenocysteine incorporation | 1 | 10 | 7.62e-01 |
| GO:BP | GO:0016076 | snRNA catabolic process | 1 | 5 | 7.62e-01 |
| GO:BP | GO:0031952 | regulation of protein autophosphorylation | 6 | 39 | 7.62e-01 |
| GO:BP | GO:0009750 | response to fructose | 1 | 3 | 7.62e-01 |
| GO:BP | GO:1901606 | alpha-amino acid catabolic process | 2 | 63 | 7.62e-01 |
| GO:BP | GO:0060429 | epithelium development | 2 | 850 | 7.62e-01 |
| GO:BP | GO:0043648 | dicarboxylic acid metabolic process | 2 | 74 | 7.62e-01 |
| GO:BP | GO:0019230 | proprioception | 1 | 3 | 7.62e-01 |
| GO:BP | GO:0042310 | vasoconstriction | 1 | 51 | 7.62e-01 |
| GO:BP | GO:0044572 | [4Fe-4S] cluster assembly | 1 | 5 | 7.62e-01 |
| GO:BP | GO:0030522 | intracellular receptor signaling pathway | 12 | 227 | 7.62e-01 |
| GO:BP | GO:1903035 | negative regulation of response to wounding | 1 | 64 | 7.62e-01 |
| GO:BP | GO:0090051 | negative regulation of cell migration involved in sprouting angiogenesis | 1 | 12 | 7.62e-01 |
| GO:BP | GO:0061158 | 3’-UTR-mediated mRNA destabilization | 1 | 15 | 7.62e-01 |
| GO:BP | GO:0006560 | proline metabolic process | 1 | 7 | 7.63e-01 |
| GO:BP | GO:2001056 | positive regulation of cysteine-type endopeptidase activity | 15 | 107 | 7.63e-01 |
| GO:BP | GO:0006771 | riboflavin metabolic process | 1 | 3 | 7.63e-01 |
| GO:BP | GO:0050793 | regulation of developmental process | 1 | 1835 | 7.63e-01 |
| GO:BP | GO:0051171 | regulation of nitrogen compound metabolic process | 2 | 4292 | 7.63e-01 |
| GO:BP | GO:0035860 | glial cell-derived neurotrophic factor receptor signaling pathway | 1 | 6 | 7.63e-01 |
| GO:BP | GO:1904019 | epithelial cell apoptotic process | 13 | 98 | 7.63e-01 |
| GO:BP | GO:0019363 | pyridine nucleotide biosynthetic process | 1 | 19 | 7.63e-01 |
| GO:BP | GO:0035886 | vascular associated smooth muscle cell differentiation | 2 | 27 | 7.63e-01 |
| GO:BP | GO:0043304 | regulation of mast cell degranulation | 3 | 20 | 7.63e-01 |
| GO:BP | GO:0019359 | nicotinamide nucleotide biosynthetic process | 1 | 19 | 7.63e-01 |
| GO:BP | GO:0007127 | meiosis I | 20 | 77 | 7.63e-01 |
| GO:BP | GO:0002495 | antigen processing and presentation of peptide antigen via MHC class II | 1 | 17 | 7.63e-01 |
| GO:BP | GO:0002279 | mast cell activation involved in immune response | 3 | 31 | 7.63e-01 |
| GO:BP | GO:0048843 | negative regulation of axon extension involved in axon guidance | 4 | 26 | 7.63e-01 |
| GO:BP | GO:0021983 | pituitary gland development | 1 | 22 | 7.63e-01 |
| GO:BP | GO:0097306 | cellular response to alcohol | 8 | 70 | 7.63e-01 |
| GO:BP | GO:0032347 | regulation of aldosterone biosynthetic process | 1 | 8 | 7.63e-01 |
| GO:BP | GO:0032532 | regulation of microvillus length | 1 | 4 | 7.63e-01 |
| GO:BP | GO:0032344 | regulation of aldosterone metabolic process | 1 | 8 | 7.63e-01 |
| GO:BP | GO:0021979 | hypothalamus cell differentiation | 2 | 8 | 7.63e-01 |
| GO:BP | GO:0016126 | sterol biosynthetic process | 3 | 52 | 7.63e-01 |
| GO:BP | GO:0021892 | cerebral cortex GABAergic interneuron differentiation | 1 | 3 | 7.63e-01 |
| GO:BP | GO:2000726 | negative regulation of cardiac muscle cell differentiation | 1 | 8 | 7.63e-01 |
| GO:BP | GO:0051905 | establishment of pigment granule localization | 3 | 20 | 7.63e-01 |
| GO:BP | GO:0007158 | neuron cell-cell adhesion | 2 | 13 | 7.63e-01 |
| GO:BP | GO:0038030 | non-canonical Wnt signaling pathway via MAPK cascade | 1 | 5 | 7.63e-01 |
| GO:BP | GO:0014909 | smooth muscle cell migration | 7 | 65 | 7.63e-01 |
| GO:BP | GO:0030033 | microvillus assembly | 2 | 15 | 7.63e-01 |
| GO:BP | GO:1900020 | positive regulation of protein kinase C activity | 1 | 6 | 7.63e-01 |
| GO:BP | GO:0051246 | regulation of protein metabolic process | 1 | 1974 | 7.63e-01 |
| GO:BP | GO:0060638 | mesenchymal-epithelial cell signaling | 1 | 4 | 7.63e-01 |
| GO:BP | GO:0043087 | regulation of GTPase activity | 1 | 302 | 7.63e-01 |
| GO:BP | GO:1900019 | regulation of protein kinase C activity | 1 | 6 | 7.63e-01 |
| GO:BP | GO:0046543 | development of secondary female sexual characteristics | 1 | 7 | 7.63e-01 |
| GO:BP | GO:0007442 | hindgut morphogenesis | 1 | 4 | 7.63e-01 |
| GO:BP | GO:1901385 | regulation of voltage-gated calcium channel activity | 1 | 29 | 7.63e-01 |
| GO:BP | GO:0140895 | cell surface toll-like receptor signaling pathway | 2 | 27 | 7.63e-01 |
| GO:BP | GO:1904037 | positive regulation of epithelial cell apoptotic process | 4 | 26 | 7.63e-01 |
| GO:BP | GO:0010606 | positive regulation of cytoplasmic mRNA processing body assembly | 1 | 6 | 7.64e-01 |
| GO:BP | GO:0010524 | positive regulation of calcium ion transport into cytosol | 2 | 7 | 7.64e-01 |
| GO:BP | GO:2000147 | positive regulation of cell motility | 5 | 421 | 7.64e-01 |
| GO:BP | GO:0031345 | negative regulation of cell projection organization | 22 | 156 | 7.64e-01 |
| GO:BP | GO:0006584 | catecholamine metabolic process | 1 | 30 | 7.64e-01 |
| GO:BP | GO:2000352 | negative regulation of endothelial cell apoptotic process | 3 | 22 | 7.64e-01 |
| GO:BP | GO:0019082 | viral protein processing | 4 | 31 | 7.64e-01 |
| GO:BP | GO:0071621 | granulocyte chemotaxis | 2 | 53 | 7.64e-01 |
| GO:BP | GO:0022603 | regulation of anatomical structure morphogenesis | 9 | 691 | 7.64e-01 |
| GO:BP | GO:0034162 | toll-like receptor 9 signaling pathway | 1 | 12 | 7.64e-01 |
| GO:BP | GO:2000669 | negative regulation of dendritic cell apoptotic process | 1 | 5 | 7.64e-01 |
| GO:BP | GO:0070167 | regulation of biomineral tissue development | 2 | 67 | 7.64e-01 |
| GO:BP | GO:0009712 | catechol-containing compound metabolic process | 1 | 30 | 7.64e-01 |
| GO:BP | GO:0033085 | negative regulation of T cell differentiation in thymus | 1 | 5 | 7.64e-01 |
| GO:BP | GO:0042246 | tissue regeneration | 11 | 54 | 7.64e-01 |
| GO:BP | GO:0036324 | vascular endothelial growth factor receptor-2 signaling pathway | 1 | 4 | 7.64e-01 |
| GO:BP | GO:0007029 | endoplasmic reticulum organization | 13 | 83 | 7.64e-01 |
| GO:BP | GO:0006940 | regulation of smooth muscle contraction | 1 | 42 | 7.64e-01 |
| GO:BP | GO:0032060 | bleb assembly | 1 | 9 | 7.64e-01 |
| GO:BP | GO:0034105 | positive regulation of tissue remodeling | 1 | 4 | 7.64e-01 |
| GO:BP | GO:0061535 | glutamate secretion, neurotransmission | 1 | 5 | 7.65e-01 |
| GO:BP | GO:0030948 | negative regulation of vascular endothelial growth factor receptor signaling pathway | 2 | 11 | 7.65e-01 |
| GO:BP | GO:0051412 | response to corticosterone | 1 | 10 | 7.65e-01 |
| GO:BP | GO:0050885 | neuromuscular process controlling balance | 8 | 35 | 7.65e-01 |
| GO:BP | GO:0070373 | negative regulation of ERK1 and ERK2 cascade | 6 | 59 | 7.66e-01 |
| GO:BP | GO:0055070 | copper ion homeostasis | 3 | 18 | 7.66e-01 |
| GO:BP | GO:0097116 | gephyrin clustering involved in postsynaptic density assembly | 1 | 3 | 7.66e-01 |
| GO:BP | GO:0086103 | G protein-coupled receptor signaling pathway involved in heart process | 1 | 13 | 7.66e-01 |
| GO:BP | GO:0090183 | regulation of kidney development | 2 | 22 | 7.66e-01 |
| GO:BP | GO:0010658 | striated muscle cell apoptotic process | 6 | 39 | 7.67e-01 |
| GO:BP | GO:0070741 | response to interleukin-6 | 3 | 23 | 7.67e-01 |
| GO:BP | GO:0051101 | regulation of DNA binding | 3 | 104 | 7.67e-01 |
| GO:BP | GO:2000811 | negative regulation of anoikis | 2 | 17 | 7.67e-01 |
| GO:BP | GO:0008016 | regulation of heart contraction | 3 | 173 | 7.67e-01 |
| GO:BP | GO:0099527 | postsynapse to nucleus signaling pathway | 1 | 6 | 7.67e-01 |
| GO:BP | GO:1903426 | regulation of reactive oxygen species biosynthetic process | 4 | 29 | 7.67e-01 |
| GO:BP | GO:0001913 | T cell mediated cytotoxicity | 1 | 22 | 7.68e-01 |
| GO:BP | GO:0090322 | regulation of superoxide metabolic process | 1 | 19 | 7.68e-01 |
| GO:BP | GO:0006152 | purine nucleoside catabolic process | 1 | 6 | 7.68e-01 |
| GO:BP | GO:0002634 | regulation of germinal center formation | 1 | 6 | 7.68e-01 |
| GO:BP | GO:0021885 | forebrain cell migration | 6 | 46 | 7.68e-01 |
| GO:BP | GO:0065004 | protein-DNA complex assembly | 2 | 185 | 7.68e-01 |
| GO:BP | GO:0007399 | nervous system development | 1 | 1904 | 7.68e-01 |
| GO:BP | GO:0032776 | DNA methylation on cytosine | 1 | 4 | 7.69e-01 |
| GO:BP | GO:0015800 | acidic amino acid transport | 1 | 39 | 7.69e-01 |
| GO:BP | GO:0048839 | inner ear development | 14 | 132 | 7.69e-01 |
| GO:BP | GO:0050879 | multicellular organismal movement | 4 | 41 | 7.69e-01 |
| GO:BP | GO:0051480 | regulation of cytosolic calcium ion concentration | 1 | 40 | 7.69e-01 |
| GO:BP | GO:0032508 | DNA duplex unwinding | 11 | 74 | 7.69e-01 |
| GO:BP | GO:0048387 | negative regulation of retinoic acid receptor signaling pathway | 1 | 6 | 7.69e-01 |
| GO:BP | GO:0016115 | terpenoid catabolic process | 1 | 4 | 7.69e-01 |
| GO:BP | GO:0097479 | synaptic vesicle localization | 7 | 50 | 7.69e-01 |
| GO:BP | GO:0043415 | positive regulation of skeletal muscle tissue regeneration | 1 | 4 | 7.69e-01 |
| GO:BP | GO:0016226 | iron-sulfur cluster assembly | 2 | 29 | 7.69e-01 |
| GO:BP | GO:0031163 | metallo-sulfur cluster assembly | 2 | 29 | 7.69e-01 |
| GO:BP | GO:0002448 | mast cell mediated immunity | 3 | 33 | 7.69e-01 |
| GO:BP | GO:0002191 | cap-dependent translational initiation | 1 | 7 | 7.69e-01 |
| GO:BP | GO:0036492 | eiF2alpha phosphorylation in response to endoplasmic reticulum stress | 1 | 7 | 7.69e-01 |
| GO:BP | GO:0035065 | regulation of histone acetylation | 6 | 47 | 7.69e-01 |
| GO:BP | GO:1900028 | negative regulation of ruffle assembly | 1 | 4 | 7.70e-01 |
| GO:BP | GO:1990573 | potassium ion import across plasma membrane | 3 | 31 | 7.70e-01 |
| GO:BP | GO:0006687 | glycosphingolipid metabolic process | 5 | 48 | 7.70e-01 |
| GO:BP | GO:0035865 | cellular response to potassium ion | 1 | 9 | 7.71e-01 |
| GO:BP | GO:0043144 | sno(s)RNA processing | 1 | 13 | 7.71e-01 |
| GO:BP | GO:0021879 | forebrain neuron differentiation | 1 | 23 | 7.71e-01 |
| GO:BP | GO:0033574 | response to testosterone | 3 | 29 | 7.73e-01 |
| GO:BP | GO:0006353 | DNA-templated transcription termination | 1 | 22 | 7.73e-01 |
| GO:BP | GO:0060009 | Sertoli cell development | 1 | 10 | 7.73e-01 |
| GO:BP | GO:0034499 | late endosome to Golgi transport | 1 | 5 | 7.73e-01 |
| GO:BP | GO:0003143 | embryonic heart tube morphogenesis | 4 | 56 | 7.73e-01 |
| GO:BP | GO:0061371 | determination of heart left/right asymmetry | 4 | 52 | 7.73e-01 |
| GO:BP | GO:0060633 | negative regulation of transcription initiation by RNA polymerase II | 1 | 6 | 7.73e-01 |
| GO:BP | GO:0050994 | regulation of lipid catabolic process | 1 | 38 | 7.73e-01 |
| GO:BP | GO:0061087 | positive regulation of histone H3-K27 methylation | 1 | 4 | 7.73e-01 |
| GO:BP | GO:0033005 | positive regulation of mast cell activation | 2 | 13 | 7.73e-01 |
| GO:BP | GO:0035306 | positive regulation of dephosphorylation | 1 | 47 | 7.73e-01 |
| GO:BP | GO:2000377 | regulation of reactive oxygen species metabolic process | 5 | 108 | 7.73e-01 |
| GO:BP | GO:0006641 | triglyceride metabolic process | 3 | 68 | 7.73e-01 |
| GO:BP | GO:0006304 | DNA modification | 13 | 89 | 7.74e-01 |
| GO:BP | GO:0014904 | myotube cell development | 1 | 34 | 7.74e-01 |
| GO:BP | GO:0051150 | regulation of smooth muscle cell differentiation | 2 | 28 | 7.74e-01 |
| GO:BP | GO:1902969 | mitotic DNA replication | 1 | 14 | 7.74e-01 |
| GO:BP | GO:0071380 | cellular response to prostaglandin E stimulus | 1 | 14 | 7.74e-01 |
| GO:BP | GO:1904427 | positive regulation of calcium ion transmembrane transport | 2 | 60 | 7.74e-01 |
| GO:BP | GO:0031348 | negative regulation of defense response | 31 | 159 | 7.74e-01 |
| GO:BP | GO:0034080 | CENP-A containing chromatin assembly | 1 | 8 | 7.74e-01 |
| GO:BP | GO:0031055 | chromatin remodeling at centromere | 1 | 8 | 7.74e-01 |
| GO:BP | GO:0021960 | anterior commissure morphogenesis | 1 | 5 | 7.74e-01 |
| GO:BP | GO:0051962 | positive regulation of nervous system development | 7 | 221 | 7.74e-01 |
| GO:BP | GO:2000831 | regulation of steroid hormone secretion | 1 | 13 | 7.74e-01 |
| GO:BP | GO:0071569 | protein ufmylation | 1 | 6 | 7.74e-01 |
| GO:BP | GO:0021957 | corticospinal tract morphogenesis | 1 | 7 | 7.74e-01 |
| GO:BP | GO:0060562 | epithelial tube morphogenesis | 3 | 278 | 7.75e-01 |
| GO:BP | GO:0036376 | sodium ion export across plasma membrane | 2 | 12 | 7.75e-01 |
| GO:BP | GO:0060921 | sinoatrial node cell differentiation | 1 | 5 | 7.75e-01 |
| GO:BP | GO:0032536 | regulation of cell projection size | 2 | 8 | 7.75e-01 |
| GO:BP | GO:0009612 | response to mechanical stimulus | 2 | 158 | 7.75e-01 |
| GO:BP | GO:0015850 | organic hydroxy compound transport | 1 | 174 | 7.75e-01 |
| GO:BP | GO:0051154 | negative regulation of striated muscle cell differentiation | 4 | 31 | 7.75e-01 |
| GO:BP | GO:0014060 | regulation of epinephrine secretion | 1 | 2 | 7.75e-01 |
| GO:BP | GO:0080090 | regulation of primary metabolic process | 2 | 4417 | 7.75e-01 |
| GO:BP | GO:2001269 | positive regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway | 1 | 8 | 7.75e-01 |
| GO:BP | GO:0030509 | BMP signaling pathway | 3 | 123 | 7.75e-01 |
| GO:BP | GO:0048255 | mRNA stabilization | 1 | 50 | 7.75e-01 |
| GO:BP | GO:0048242 | epinephrine secretion | 1 | 2 | 7.75e-01 |
| GO:BP | GO:0043653 | mitochondrial fragmentation involved in apoptotic process | 1 | 9 | 7.75e-01 |
| GO:BP | GO:0032743 | positive regulation of interleukin-2 production | 1 | 20 | 7.75e-01 |
| GO:BP | GO:0002690 | positive regulation of leukocyte chemotaxis | 1 | 51 | 7.75e-01 |
| GO:BP | GO:0072567 | chemokine (C-X-C motif) ligand 2 production | 1 | 10 | 7.76e-01 |
| GO:BP | GO:0008285 | negative regulation of cell population proliferation | 1 | 513 | 7.76e-01 |
| GO:BP | GO:0000460 | maturation of 5.8S rRNA | 4 | 36 | 7.76e-01 |
| GO:BP | GO:2000341 | regulation of chemokine (C-X-C motif) ligand 2 production | 1 | 10 | 7.76e-01 |
| GO:BP | GO:0070050 | neuron cellular homeostasis | 1 | 46 | 7.77e-01 |
| GO:BP | GO:0032095 | regulation of response to food | 1 | 8 | 7.77e-01 |
| GO:BP | GO:0099504 | synaptic vesicle cycle | 5 | 163 | 7.77e-01 |
| GO:BP | GO:0051131 | chaperone-mediated protein complex assembly | 1 | 21 | 7.77e-01 |
| GO:BP | GO:0045987 | positive regulation of smooth muscle contraction | 3 | 17 | 7.78e-01 |
| GO:BP | GO:2000434 | regulation of protein neddylation | 2 | 19 | 7.79e-01 |
| GO:BP | GO:2000311 | regulation of AMPA receptor activity | 3 | 15 | 7.79e-01 |
| GO:BP | GO:0048143 | astrocyte activation | 3 | 12 | 7.79e-01 |
| GO:BP | GO:0035787 | cell migration involved in kidney development | 1 | 5 | 7.79e-01 |
| GO:BP | GO:0035902 | response to immobilization stress | 2 | 16 | 7.79e-01 |
| GO:BP | GO:0006949 | syncytium formation | 7 | 39 | 7.79e-01 |
| GO:BP | GO:0060684 | epithelial-mesenchymal cell signaling | 1 | 3 | 7.79e-01 |
| GO:BP | GO:0001776 | leukocyte homeostasis | 2 | 69 | 7.79e-01 |
| GO:BP | GO:0065003 | protein-containing complex assembly | 3 | 1335 | 7.79e-01 |
| GO:BP | GO:0060964 | regulation of miRNA-mediated gene silencing | 1 | 25 | 7.79e-01 |
| GO:BP | GO:0097293 | XMP biosynthetic process | 1 | 7 | 7.79e-01 |
| GO:BP | GO:0097292 | XMP metabolic process | 1 | 7 | 7.79e-01 |
| GO:BP | GO:0097294 | ‘de novo’ XMP biosynthetic process | 1 | 7 | 7.79e-01 |
| GO:BP | GO:0033028 | myeloid cell apoptotic process | 1 | 25 | 7.80e-01 |
| GO:BP | GO:0009756 | carbohydrate mediated signaling | 1 | 6 | 7.80e-01 |
| GO:BP | GO:0051973 | positive regulation of telomerase activity | 3 | 31 | 7.80e-01 |
| GO:BP | GO:0042592 | homeostatic process | 3 | 1159 | 7.80e-01 |
| GO:BP | GO:1901401 | regulation of tetrapyrrole metabolic process | 1 | 8 | 7.81e-01 |
| GO:BP | GO:0031623 | receptor internalization | 10 | 95 | 7.81e-01 |
| GO:BP | GO:0043102 | amino acid salvage | 1 | 5 | 7.81e-01 |
| GO:BP | GO:0071267 | L-methionine salvage | 1 | 5 | 7.81e-01 |
| GO:BP | GO:0071265 | L-methionine biosynthetic process | 1 | 5 | 7.81e-01 |
| GO:BP | GO:0033353 | S-adenosylmethionine cycle | 1 | 7 | 7.81e-01 |
| GO:BP | GO:0007276 | gamete generation | 3 | 461 | 7.82e-01 |
| GO:BP | GO:0035556 | intracellular signal transduction | 1 | 2065 | 7.82e-01 |
| GO:BP | GO:0051005 | negative regulation of lipoprotein lipase activity | 1 | 4 | 7.82e-01 |
| GO:BP | GO:0033059 | cellular pigmentation | 8 | 58 | 7.82e-01 |
| GO:BP | GO:0040017 | positive regulation of locomotion | 5 | 429 | 7.82e-01 |
| GO:BP | GO:0021535 | cell migration in hindbrain | 1 | 12 | 7.82e-01 |
| GO:BP | GO:0045653 | negative regulation of megakaryocyte differentiation | 2 | 17 | 7.82e-01 |
| GO:BP | GO:0009888 | tissue development | 3 | 1425 | 7.83e-01 |
| GO:BP | GO:0044314 | protein K27-linked ubiquitination | 1 | 8 | 7.83e-01 |
| GO:BP | GO:0014823 | response to activity | 9 | 46 | 7.83e-01 |
| GO:BP | GO:0043502 | regulation of muscle adaptation | 1 | 69 | 7.83e-01 |
| GO:BP | GO:0045744 | negative regulation of G protein-coupled receptor signaling pathway | 3 | 38 | 7.83e-01 |
| GO:BP | GO:0072236 | metanephric loop of Henle development | 1 | 3 | 7.83e-01 |
| GO:BP | GO:1901388 | regulation of transforming growth factor beta activation | 1 | 8 | 7.83e-01 |
| GO:BP | GO:0035635 | entry of bacterium into host cell | 1 | 8 | 7.83e-01 |
| GO:BP | GO:1904948 | midbrain dopaminergic neuron differentiation | 2 | 12 | 7.83e-01 |
| GO:BP | GO:0060462 | lung lobe development | 1 | 4 | 7.84e-01 |
| GO:BP | GO:0060463 | lung lobe morphogenesis | 1 | 4 | 7.84e-01 |
| GO:BP | GO:0032331 | negative regulation of chondrocyte differentiation | 1 | 18 | 7.84e-01 |
| GO:BP | GO:0061564 | axon development | 9 | 398 | 7.84e-01 |
| GO:BP | GO:0098907 | regulation of SA node cell action potential | 1 | 7 | 7.84e-01 |
| GO:BP | GO:0019374 | galactolipid metabolic process | 1 | 5 | 7.84e-01 |
| GO:BP | GO:0061308 | cardiac neural crest cell development involved in heart development | 1 | 15 | 7.84e-01 |
| GO:BP | GO:1900125 | regulation of hyaluronan biosynthetic process | 1 | 6 | 7.84e-01 |
| GO:BP | GO:0061307 | cardiac neural crest cell differentiation involved in heart development | 1 | 15 | 7.84e-01 |
| GO:BP | GO:0009653 | anatomical structure morphogenesis | 4 | 1974 | 7.84e-01 |
| GO:BP | GO:0006646 | phosphatidylethanolamine biosynthetic process | 1 | 8 | 7.84e-01 |
| GO:BP | GO:1901661 | quinone metabolic process | 4 | 32 | 7.84e-01 |
| GO:BP | GO:0099601 | regulation of neurotransmitter receptor activity | 4 | 40 | 7.84e-01 |
| GO:BP | GO:0006681 | galactosylceramide metabolic process | 1 | 5 | 7.84e-01 |
| GO:BP | GO:0010863 | positive regulation of phospholipase C activity | 1 | 18 | 7.84e-01 |
| GO:BP | GO:0014866 | skeletal myofibril assembly | 1 | 9 | 7.84e-01 |
| GO:BP | GO:1901724 | positive regulation of cell proliferation involved in kidney development | 1 | 8 | 7.84e-01 |
| GO:BP | GO:0051321 | meiotic cell cycle | 13 | 188 | 7.84e-01 |
| GO:BP | GO:1904116 | response to vasopressin | 1 | 5 | 7.85e-01 |
| GO:BP | GO:1904117 | cellular response to vasopressin | 1 | 5 | 7.85e-01 |
| GO:BP | GO:0033598 | mammary gland epithelial cell proliferation | 4 | 23 | 7.85e-01 |
| GO:BP | GO:0051897 | positive regulation of protein kinase B signaling | 1 | 79 | 7.85e-01 |
| GO:BP | GO:0001956 | positive regulation of neurotransmitter secretion | 2 | 12 | 7.85e-01 |
| GO:BP | GO:1901019 | regulation of calcium ion transmembrane transporter activity | 2 | 71 | 7.85e-01 |
| GO:BP | GO:0061061 | muscle structure development | 13 | 546 | 7.85e-01 |
| GO:BP | GO:0072074 | kidney mesenchyme development | 1 | 13 | 7.85e-01 |
| GO:BP | GO:2000629 | negative regulation of miRNA metabolic process | 3 | 20 | 7.85e-01 |
| GO:BP | GO:0060602 | branch elongation of an epithelium | 1 | 14 | 7.85e-01 |
| GO:BP | GO:0032377 | regulation of intracellular lipid transport | 1 | 7 | 7.86e-01 |
| GO:BP | GO:0030502 | negative regulation of bone mineralization | 1 | 10 | 7.86e-01 |
| GO:BP | GO:0007171 | activation of transmembrane receptor protein tyrosine kinase activity | 1 | 4 | 7.86e-01 |
| GO:BP | GO:0023051 | regulation of signaling | 5 | 2565 | 7.86e-01 |
| GO:BP | GO:0020027 | hemoglobin metabolic process | 1 | 16 | 7.86e-01 |
| GO:BP | GO:0001101 | response to acid chemical | 18 | 105 | 7.86e-01 |
| GO:BP | GO:0042532 | negative regulation of tyrosine phosphorylation of STAT protein | 1 | 12 | 7.86e-01 |
| GO:BP | GO:0006979 | response to oxidative stress | 2 | 352 | 7.86e-01 |
| GO:BP | GO:0060487 | lung epithelial cell differentiation | 3 | 18 | 7.86e-01 |
| GO:BP | GO:0060479 | lung cell differentiation | 3 | 18 | 7.86e-01 |
| GO:BP | GO:0021856 | hypothalamic tangential migration using cell-axon interactions | 1 | 6 | 7.86e-01 |
| GO:BP | GO:0021828 | gonadotrophin-releasing hormone neuronal migration to the hypothalamus | 1 | 6 | 7.86e-01 |
| GO:BP | GO:0000470 | maturation of LSU-rRNA | 3 | 28 | 7.86e-01 |
| GO:BP | GO:0048260 | positive regulation of receptor-mediated endocytosis | 2 | 42 | 7.86e-01 |
| GO:BP | GO:0045912 | negative regulation of carbohydrate metabolic process | 2 | 38 | 7.86e-01 |
| GO:BP | GO:0097577 | sequestering of iron ion | 1 | 3 | 7.86e-01 |
| GO:BP | GO:2000969 | positive regulation of AMPA receptor activity | 1 | 4 | 7.87e-01 |
| GO:BP | GO:0035265 | organ growth | 3 | 131 | 7.87e-01 |
| GO:BP | GO:0031065 | positive regulation of histone deacetylation | 3 | 22 | 7.87e-01 |
| GO:BP | GO:0010912 | positive regulation of isomerase activity | 1 | 5 | 7.87e-01 |
| GO:BP | GO:0010911 | regulation of isomerase activity | 1 | 5 | 7.87e-01 |
| GO:BP | GO:0002076 | osteoblast development | 2 | 12 | 7.87e-01 |
| GO:BP | GO:0031953 | negative regulation of protein autophosphorylation | 1 | 9 | 7.87e-01 |
| GO:BP | GO:0010752 | regulation of cGMP-mediated signaling | 2 | 8 | 7.88e-01 |
| GO:BP | GO:2000674 | regulation of type B pancreatic cell apoptotic process | 1 | 6 | 7.88e-01 |
| GO:BP | GO:0044805 | late nucleophagy | 1 | 7 | 7.89e-01 |
| GO:BP | GO:0032905 | transforming growth factor beta1 production | 1 | 11 | 7.89e-01 |
| GO:BP | GO:0098883 | synapse pruning | 1 | 8 | 7.89e-01 |
| GO:BP | GO:0050767 | regulation of neurogenesis | 24 | 301 | 7.89e-01 |
| GO:BP | GO:0034766 | negative regulation of monoatomic ion transmembrane transport | 2 | 70 | 7.89e-01 |
| GO:BP | GO:0002504 | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II | 1 | 19 | 7.89e-01 |
| GO:BP | GO:0033006 | regulation of mast cell activation involved in immune response | 3 | 21 | 7.90e-01 |
| GO:BP | GO:0043392 | negative regulation of DNA binding | 3 | 46 | 7.90e-01 |
| GO:BP | GO:0042116 | macrophage activation | 8 | 57 | 7.90e-01 |
| GO:BP | GO:0010605 | negative regulation of macromolecule metabolic process | 3 | 2135 | 7.91e-01 |
| GO:BP | GO:0006824 | cobalt ion transport | 1 | 5 | 7.91e-01 |
| GO:BP | GO:0048468 | cell development | 1 | 1963 | 7.91e-01 |
| GO:BP | GO:0042692 | muscle cell differentiation | 7 | 324 | 7.91e-01 |
| GO:BP | GO:0006796 | phosphate-containing compound metabolic process | 1 | 2139 | 7.91e-01 |
| GO:BP | GO:1901029 | negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway | 2 | 13 | 7.91e-01 |
| GO:BP | GO:1905198 | manchette assembly | 1 | 4 | 7.91e-01 |
| GO:BP | GO:1901077 | regulation of relaxation of muscle | 2 | 8 | 7.91e-01 |
| GO:BP | GO:0032201 | telomere maintenance via semi-conservative replication | 1 | 8 | 7.91e-01 |
| GO:BP | GO:0014857 | regulation of skeletal muscle cell proliferation | 2 | 10 | 7.91e-01 |
| GO:BP | GO:0035360 | positive regulation of peroxisome proliferator activated receptor signaling pathway | 1 | 7 | 7.91e-01 |
| GO:BP | GO:0051866 | general adaptation syndrome | 1 | 4 | 7.92e-01 |
| GO:BP | GO:0006284 | base-excision repair | 2 | 44 | 7.92e-01 |
| GO:BP | GO:0034219 | carbohydrate transmembrane transport | 17 | 92 | 7.92e-01 |
| GO:BP | GO:0021795 | cerebral cortex cell migration | 1 | 37 | 7.92e-01 |
| GO:BP | GO:2001186 | negative regulation of CD8-positive, alpha-beta T cell activation | 1 | 6 | 7.92e-01 |
| GO:BP | GO:0045446 | endothelial cell differentiation | 4 | 90 | 7.92e-01 |
| GO:BP | GO:1904851 | positive regulation of establishment of protein localization to telomere | 1 | 10 | 7.92e-01 |
| GO:BP | GO:0045542 | positive regulation of cholesterol biosynthetic process | 1 | 7 | 7.92e-01 |
| GO:BP | GO:0106120 | positive regulation of sterol biosynthetic process | 1 | 7 | 7.92e-01 |
| GO:BP | GO:0061668 | mitochondrial ribosome assembly | 1 | 8 | 7.92e-01 |
| GO:BP | GO:0032645 | regulation of granulocyte macrophage colony-stimulating factor production | 1 | 5 | 7.92e-01 |
| GO:BP | GO:0032604 | granulocyte macrophage colony-stimulating factor production | 1 | 5 | 7.92e-01 |
| GO:BP | GO:0046655 | folic acid metabolic process | 1 | 14 | 7.92e-01 |
| GO:BP | GO:1990173 | protein localization to nucleoplasm | 2 | 14 | 7.92e-01 |
| GO:BP | GO:0071166 | ribonucleoprotein complex localization | 1 | 7 | 7.92e-01 |
| GO:BP | GO:0006793 | phosphorus metabolic process | 1 | 2161 | 7.93e-01 |
| GO:BP | GO:0072526 | pyridine-containing compound catabolic process | 1 | 7 | 7.93e-01 |
| GO:BP | GO:0097094 | craniofacial suture morphogenesis | 1 | 15 | 7.94e-01 |
| GO:BP | GO:1900368 | regulation of post-transcriptional gene silencing by RNA | 1 | 27 | 7.94e-01 |
| GO:BP | GO:0140627 | ubiquitin-dependent protein catabolic process via the C-end degron rule pathway | 1 | 9 | 7.94e-01 |
| GO:BP | GO:0097484 | dendrite extension | 5 | 27 | 7.95e-01 |
| GO:BP | GO:2000178 | negative regulation of neural precursor cell proliferation | 1 | 21 | 7.95e-01 |
| GO:BP | GO:0150104 | transport across blood-brain barrier | 3 | 72 | 7.95e-01 |
| GO:BP | GO:0010232 | vascular transport | 3 | 72 | 7.95e-01 |
| GO:BP | GO:0045684 | positive regulation of epidermis development | 1 | 20 | 7.95e-01 |
| GO:BP | GO:0042440 | pigment metabolic process | 1 | 60 | 7.95e-01 |
| GO:BP | GO:1902603 | carnitine transmembrane transport | 1 | 4 | 7.96e-01 |
| GO:BP | GO:1903935 | response to sodium arsenite | 1 | 6 | 7.96e-01 |
| GO:BP | GO:0000019 | regulation of mitotic recombination | 1 | 5 | 7.96e-01 |
| GO:BP | GO:0001892 | embryonic placenta development | 1 | 71 | 7.96e-01 |
| GO:BP | GO:0032960 | regulation of inositol trisphosphate biosynthetic process | 1 | 4 | 7.96e-01 |
| GO:BP | GO:0000255 | allantoin metabolic process | 1 | 4 | 7.96e-01 |
| GO:BP | GO:0032713 | negative regulation of interleukin-4 production | 1 | 5 | 7.96e-01 |
| GO:BP | GO:0031272 | regulation of pseudopodium assembly | 1 | 11 | 7.96e-01 |
| GO:BP | GO:0036010 | protein localization to endosome | 3 | 26 | 7.96e-01 |
| GO:BP | GO:0070301 | cellular response to hydrogen peroxide | 8 | 73 | 7.96e-01 |
| GO:BP | GO:0038203 | TORC2 signaling | 2 | 12 | 7.96e-01 |
| GO:BP | GO:0002911 | regulation of lymphocyte anergy | 1 | 4 | 7.96e-01 |
| GO:BP | GO:1905331 | negative regulation of morphogenesis of an epithelium | 1 | 6 | 7.96e-01 |
| GO:BP | GO:0003096 | renal sodium ion transport | 1 | 10 | 7.96e-01 |
| GO:BP | GO:0048341 | paraxial mesoderm formation | 1 | 6 | 7.96e-01 |
| GO:BP | GO:0002870 | T cell anergy | 1 | 4 | 7.96e-01 |
| GO:BP | GO:0090277 | positive regulation of peptide hormone secretion | 2 | 69 | 7.96e-01 |
| GO:BP | GO:0090257 | regulation of muscle system process | 3 | 184 | 7.96e-01 |
| GO:BP | GO:0045627 | positive regulation of T-helper 1 cell differentiation | 1 | 3 | 7.96e-01 |
| GO:BP | GO:0048293 | regulation of isotype switching to IgE isotypes | 1 | 5 | 7.96e-01 |
| GO:BP | GO:0048289 | isotype switching to IgE isotypes | 1 | 5 | 7.96e-01 |
| GO:BP | GO:1905332 | positive regulation of morphogenesis of an epithelium | 2 | 28 | 7.96e-01 |
| GO:BP | GO:0002786 | regulation of antibacterial peptide production | 1 | 1 | 7.96e-01 |
| GO:BP | GO:0048537 | mucosa-associated lymphoid tissue development | 1 | 6 | 7.96e-01 |
| GO:BP | GO:0031274 | positive regulation of pseudopodium assembly | 1 | 11 | 7.96e-01 |
| GO:BP | GO:0050916 | sensory perception of sweet taste | 1 | 3 | 7.96e-01 |
| GO:BP | GO:1904528 | positive regulation of microtubule binding | 1 | 6 | 7.96e-01 |
| GO:BP | GO:0048541 | Peyer’s patch development | 1 | 6 | 7.96e-01 |
| GO:BP | GO:0033092 | positive regulation of immature T cell proliferation in thymus | 1 | 2 | 7.96e-01 |
| GO:BP | GO:0033091 | positive regulation of immature T cell proliferation | 1 | 2 | 7.96e-01 |
| GO:BP | GO:1902548 | negative regulation of cellular response to vascular endothelial growth factor stimulus | 2 | 9 | 7.96e-01 |
| GO:BP | GO:0098962 | regulation of postsynaptic neurotransmitter receptor activity | 3 | 12 | 7.96e-01 |
| GO:BP | GO:0044331 | cell-cell adhesion mediated by cadherin | 3 | 22 | 7.96e-01 |
| GO:BP | GO:1900004 | negative regulation of serine-type endopeptidase activity | 1 | 4 | 7.96e-01 |
| GO:BP | GO:1900026 | positive regulation of substrate adhesion-dependent cell spreading | 4 | 39 | 7.96e-01 |
| GO:BP | GO:0071824 | protein-DNA complex subunit organization | 2 | 204 | 7.96e-01 |
| GO:BP | GO:0071425 | hematopoietic stem cell proliferation | 5 | 29 | 7.96e-01 |
| GO:BP | GO:0047484 | regulation of response to osmotic stress | 1 | 12 | 7.96e-01 |
| GO:BP | GO:1902572 | negative regulation of serine-type peptidase activity | 1 | 4 | 7.96e-01 |
| GO:BP | GO:0003344 | pericardium morphogenesis | 1 | 7 | 7.96e-01 |
| GO:BP | GO:0070168 | negative regulation of biomineral tissue development | 2 | 19 | 7.96e-01 |
| GO:BP | GO:1903046 | meiotic cell cycle process | 31 | 135 | 7.96e-01 |
| GO:BP | GO:0097421 | liver regeneration | 3 | 23 | 7.96e-01 |
| GO:BP | GO:0048172 | regulation of short-term neuronal synaptic plasticity | 1 | 9 | 7.96e-01 |
| GO:BP | GO:0002249 | lymphocyte anergy | 1 | 4 | 7.96e-01 |
| GO:BP | GO:0007409 | axonogenesis | 8 | 359 | 7.96e-01 |
| GO:BP | GO:0061337 | cardiac conduction | 3 | 88 | 7.96e-01 |
| GO:BP | GO:1904872 | regulation of telomerase RNA localization to Cajal body | 2 | 18 | 7.96e-01 |
| GO:BP | GO:1900274 | regulation of phospholipase C activity | 1 | 20 | 7.96e-01 |
| GO:BP | GO:0002667 | regulation of T cell anergy | 1 | 4 | 7.96e-01 |
| GO:BP | GO:0048752 | semicircular canal morphogenesis | 1 | 5 | 7.96e-01 |
| GO:BP | GO:1904861 | excitatory synapse assembly | 5 | 26 | 7.96e-01 |
| GO:BP | GO:0032594 | protein transport within lipid bilayer | 1 | 6 | 7.96e-01 |
| GO:BP | GO:0051964 | negative regulation of synapse assembly | 1 | 6 | 7.96e-01 |
| GO:BP | GO:0051054 | positive regulation of DNA metabolic process | 2 | 265 | 7.96e-01 |
| GO:BP | GO:1904659 | glucose transmembrane transport | 10 | 81 | 7.96e-01 |
| GO:BP | GO:0032411 | positive regulation of transporter activity | 3 | 93 | 7.97e-01 |
| GO:BP | GO:0048712 | negative regulation of astrocyte differentiation | 1 | 9 | 7.97e-01 |
| GO:BP | GO:0060547 | negative regulation of necrotic cell death | 1 | 21 | 7.97e-01 |
| GO:BP | GO:0110096 | cellular response to aldehyde | 1 | 10 | 7.97e-01 |
| GO:BP | GO:0002026 | regulation of the force of heart contraction | 3 | 23 | 7.97e-01 |
| GO:BP | GO:0070318 | positive regulation of G0 to G1 transition | 1 | 5 | 7.97e-01 |
| GO:BP | GO:0051180 | vitamin transport | 4 | 28 | 7.98e-01 |
| GO:BP | GO:0045665 | negative regulation of neuron differentiation | 1 | 43 | 7.98e-01 |
| GO:BP | GO:0034502 | protein localization to chromosome | 7 | 110 | 7.98e-01 |
| GO:BP | GO:0071248 | cellular response to metal ion | 1 | 139 | 7.98e-01 |
| GO:BP | GO:0002093 | auditory receptor cell morphogenesis | 3 | 10 | 7.98e-01 |
| GO:BP | GO:0014719 | skeletal muscle satellite cell activation | 1 | 5 | 7.98e-01 |
| GO:BP | GO:0007200 | phospholipase C-activating G protein-coupled receptor signaling pathway | 1 | 40 | 7.98e-01 |
| GO:BP | GO:0001768 | establishment of T cell polarity | 2 | 10 | 7.98e-01 |
| GO:BP | GO:0060147 | regulation of post-transcriptional gene silencing | 1 | 28 | 7.99e-01 |
| GO:BP | GO:0032376 | positive regulation of cholesterol transport | 1 | 30 | 7.99e-01 |
| GO:BP | GO:0048266 | behavioral response to pain | 1 | 11 | 7.99e-01 |
| GO:BP | GO:0032373 | positive regulation of sterol transport | 1 | 30 | 7.99e-01 |
| GO:BP | GO:2000766 | negative regulation of cytoplasmic translation | 1 | 7 | 7.99e-01 |
| GO:BP | GO:0045923 | positive regulation of fatty acid metabolic process | 1 | 26 | 7.99e-01 |
| GO:BP | GO:0032094 | response to food | 2 | 22 | 7.99e-01 |
| GO:BP | GO:0009798 | axis specification | 5 | 63 | 7.99e-01 |
| GO:BP | GO:0071625 | vocalization behavior | 2 | 13 | 7.99e-01 |
| GO:BP | GO:0019882 | antigen processing and presentation | 4 | 69 | 7.99e-01 |
| GO:BP | GO:0090049 | regulation of cell migration involved in sprouting angiogenesis | 2 | 31 | 7.99e-01 |
| GO:BP | GO:0045008 | depyrimidination | 1 | 8 | 7.99e-01 |
| GO:BP | GO:0072111 | cell proliferation involved in kidney development | 2 | 17 | 7.99e-01 |
| GO:BP | GO:0043330 | response to exogenous dsRNA | 1 | 27 | 7.99e-01 |
| GO:BP | GO:0006704 | glucocorticoid biosynthetic process | 2 | 11 | 7.99e-01 |
| GO:BP | GO:0045589 | regulation of regulatory T cell differentiation | 1 | 21 | 8.00e-01 |
| GO:BP | GO:0002478 | antigen processing and presentation of exogenous peptide antigen | 1 | 24 | 8.00e-01 |
| GO:BP | GO:0008354 | germ cell migration | 1 | 6 | 8.00e-01 |
| GO:BP | GO:1904646 | cellular response to amyloid-beta | 2 | 29 | 8.00e-01 |
| GO:BP | GO:0060740 | prostate gland epithelium morphogenesis | 1 | 20 | 8.00e-01 |
| GO:BP | GO:0036491 | regulation of translation initiation in response to endoplasmic reticulum stress | 1 | 8 | 8.00e-01 |
| GO:BP | GO:0050796 | regulation of insulin secretion | 3 | 116 | 8.00e-01 |
| GO:BP | GO:0033029 | regulation of neutrophil apoptotic process | 1 | 5 | 8.00e-01 |
| GO:BP | GO:0043476 | pigment accumulation | 1 | 11 | 8.00e-01 |
| GO:BP | GO:0043482 | cellular pigment accumulation | 1 | 11 | 8.00e-01 |
| GO:BP | GO:1904936 | interneuron migration | 1 | 6 | 8.00e-01 |
| GO:BP | GO:0045347 | negative regulation of MHC class II biosynthetic process | 1 | 3 | 8.01e-01 |
| GO:BP | GO:0032768 | regulation of monooxygenase activity | 7 | 34 | 8.01e-01 |
| GO:BP | GO:0046661 | male sex differentiation | 3 | 114 | 8.01e-01 |
| GO:BP | GO:0090427 | activation of meiosis | 1 | 4 | 8.01e-01 |
| GO:BP | GO:1903537 | meiotic cell cycle process involved in oocyte maturation | 1 | 5 | 8.01e-01 |
| GO:BP | GO:0033198 | response to ATP | 1 | 24 | 8.01e-01 |
| GO:BP | GO:0010753 | positive regulation of cGMP-mediated signaling | 1 | 3 | 8.01e-01 |
| GO:BP | GO:0001649 | osteoblast differentiation | 4 | 179 | 8.01e-01 |
| GO:BP | GO:0008584 | male gonad development | 2 | 99 | 8.01e-01 |
| GO:BP | GO:0048165 | fused antrum stage | 1 | 2 | 8.01e-01 |
| GO:BP | GO:0034614 | cellular response to reactive oxygen species | 13 | 121 | 8.01e-01 |
| GO:BP | GO:1900016 | negative regulation of cytokine production involved in inflammatory response | 1 | 13 | 8.01e-01 |
| GO:BP | GO:0001941 | postsynaptic membrane organization | 4 | 29 | 8.01e-01 |
| GO:BP | GO:0016056 | rhodopsin mediated signaling pathway | 1 | 6 | 8.01e-01 |
| GO:BP | GO:0006040 | amino sugar metabolic process | 5 | 33 | 8.01e-01 |
| GO:BP | GO:1902883 | negative regulation of response to oxidative stress | 2 | 18 | 8.01e-01 |
| GO:BP | GO:0019184 | nonribosomal peptide biosynthetic process | 2 | 15 | 8.01e-01 |
| GO:BP | GO:0030279 | negative regulation of ossification | 2 | 25 | 8.01e-01 |
| GO:BP | GO:0097119 | postsynaptic density protein 95 clustering | 1 | 7 | 8.01e-01 |
| GO:BP | GO:0045933 | positive regulation of muscle contraction | 1 | 32 | 8.02e-01 |
| GO:BP | GO:0035282 | segmentation | 2 | 75 | 8.03e-01 |
| GO:BP | GO:0006644 | phospholipid metabolic process | 44 | 316 | 8.03e-01 |
| GO:BP | GO:0042726 | flavin-containing compound metabolic process | 1 | 4 | 8.03e-01 |
| GO:BP | GO:0000348 | mRNA branch site recognition | 1 | 1 | 8.03e-01 |
| GO:BP | GO:1902475 | L-alpha-amino acid transmembrane transport | 3 | 55 | 8.03e-01 |
| GO:BP | GO:0071773 | cellular response to BMP stimulus | 3 | 131 | 8.03e-01 |
| GO:BP | GO:0071772 | response to BMP | 3 | 131 | 8.03e-01 |
| GO:BP | GO:0050665 | hydrogen peroxide biosynthetic process | 1 | 11 | 8.03e-01 |
| GO:BP | GO:0002221 | pattern recognition receptor signaling pathway | 7 | 115 | 8.03e-01 |
| GO:BP | GO:0046546 | development of primary male sexual characteristics | 2 | 100 | 8.03e-01 |
| GO:BP | GO:0030517 | negative regulation of axon extension | 5 | 41 | 8.03e-01 |
| GO:BP | GO:0001960 | negative regulation of cytokine-mediated signaling pathway | 2 | 53 | 8.03e-01 |
| GO:BP | GO:0048562 | embryonic organ morphogenesis | 1 | 187 | 8.03e-01 |
| GO:BP | GO:0016075 | rRNA catabolic process | 3 | 19 | 8.03e-01 |
| GO:BP | GO:0070935 | 3’-UTR-mediated mRNA stabilization | 3 | 19 | 8.03e-01 |
| GO:BP | GO:0034088 | maintenance of mitotic sister chromatid cohesion | 1 | 12 | 8.03e-01 |
| GO:BP | GO:0034086 | maintenance of sister chromatid cohesion | 1 | 12 | 8.03e-01 |
| GO:BP | GO:1903069 | regulation of ER-associated ubiquitin-dependent protein catabolic process | 1 | 10 | 8.03e-01 |
| GO:BP | GO:1903578 | regulation of ATP metabolic process | 3 | 22 | 8.04e-01 |
| GO:BP | GO:0006591 | ornithine metabolic process | 1 | 6 | 8.04e-01 |
| GO:BP | GO:0043933 | protein-containing complex organization | 3 | 1496 | 8.04e-01 |
| GO:BP | GO:0034122 | negative regulation of toll-like receptor signaling pathway | 1 | 13 | 8.04e-01 |
| GO:BP | GO:0010032 | meiotic chromosome condensation | 1 | 6 | 8.04e-01 |
| GO:BP | GO:0060966 | regulation of gene silencing by RNA | 1 | 29 | 8.04e-01 |
| GO:BP | GO:0002732 | positive regulation of dendritic cell cytokine production | 1 | 8 | 8.04e-01 |
| GO:BP | GO:1900424 | regulation of defense response to bacterium | 1 | 12 | 8.04e-01 |
| GO:BP | GO:0032814 | regulation of natural killer cell activation | 2 | 20 | 8.04e-01 |
| GO:BP | GO:0097646 | calcitonin family receptor signaling pathway | 1 | 4 | 8.04e-01 |
| GO:BP | GO:0009264 | deoxyribonucleotide catabolic process | 3 | 22 | 8.04e-01 |
| GO:BP | GO:0046386 | deoxyribose phosphate catabolic process | 3 | 22 | 8.04e-01 |
| GO:BP | GO:1902042 | negative regulation of extrinsic apoptotic signaling pathway via death domain receptors | 3 | 24 | 8.04e-01 |
| GO:BP | GO:0002689 | negative regulation of leukocyte chemotaxis | 1 | 10 | 8.04e-01 |
| GO:BP | GO:0050433 | regulation of catecholamine secretion | 1 | 29 | 8.04e-01 |
| GO:BP | GO:0071577 | zinc ion transmembrane transport | 2 | 21 | 8.04e-01 |
| GO:BP | GO:0060351 | cartilage development involved in endochondral bone morphogenesis | 5 | 26 | 8.04e-01 |
| GO:BP | GO:0035434 | copper ion transmembrane transport | 1 | 6 | 8.04e-01 |
| GO:BP | GO:0030595 | leukocyte chemotaxis | 2 | 115 | 8.04e-01 |
| GO:BP | GO:0009110 | vitamin biosynthetic process | 3 | 14 | 8.04e-01 |
| GO:BP | GO:0042044 | fluid transport | 1 | 17 | 8.04e-01 |
| GO:BP | GO:0035372 | protein localization to microtubule | 1 | 18 | 8.04e-01 |
| GO:BP | GO:0060218 | hematopoietic stem cell differentiation | 1 | 30 | 8.05e-01 |
| GO:BP | GO:0070317 | negative regulation of G0 to G1 transition | 1 | 5 | 8.05e-01 |
| GO:BP | GO:0070059 | intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | 9 | 56 | 8.05e-01 |
| GO:BP | GO:0043553 | negative regulation of phosphatidylinositol 3-kinase activity | 1 | 4 | 8.05e-01 |
| GO:BP | GO:0043489 | RNA stabilization | 1 | 59 | 8.05e-01 |
| GO:BP | GO:0030855 | epithelial cell differentiation | 1 | 442 | 8.05e-01 |
| GO:BP | GO:0010634 | positive regulation of epithelial cell migration | 1 | 132 | 8.05e-01 |
| GO:BP | GO:0072124 | regulation of glomerular mesangial cell proliferation | 1 | 9 | 8.05e-01 |
| GO:BP | GO:0048634 | regulation of muscle organ development | 2 | 14 | 8.05e-01 |
| GO:BP | GO:0065008 | regulation of biological quality | 1 | 2102 | 8.05e-01 |
| GO:BP | GO:0034375 | high-density lipoprotein particle remodeling | 1 | 11 | 8.05e-01 |
| GO:BP | GO:0009066 | aspartate family amino acid metabolic process | 2 | 39 | 8.06e-01 |
| GO:BP | GO:1903204 | negative regulation of oxidative stress-induced neuron death | 1 | 19 | 8.06e-01 |
| GO:BP | GO:0002639 | positive regulation of immunoglobulin production | 1 | 30 | 8.06e-01 |
| GO:BP | GO:0002902 | regulation of B cell apoptotic process | 2 | 15 | 8.06e-01 |
| GO:BP | GO:2000143 | negative regulation of DNA-templated transcription initiation | 1 | 6 | 8.06e-01 |
| GO:BP | GO:0045664 | regulation of neuron differentiation | 1 | 137 | 8.06e-01 |
| GO:BP | GO:0051591 | response to cAMP | 4 | 66 | 8.06e-01 |
| GO:BP | GO:0031325 | positive regulation of cellular metabolic process | 1 | 2270 | 8.06e-01 |
| GO:BP | GO:0014874 | response to stimulus involved in regulation of muscle adaptation | 1 | 12 | 8.06e-01 |
| GO:BP | GO:0000098 | sulfur amino acid catabolic process | 1 | 7 | 8.06e-01 |
| GO:BP | GO:0035116 | embryonic hindlimb morphogenesis | 1 | 17 | 8.07e-01 |
| GO:BP | GO:0044206 | UMP salvage | 1 | 4 | 8.07e-01 |
| GO:BP | GO:0010138 | pyrimidine ribonucleotide salvage | 1 | 4 | 8.07e-01 |
| GO:BP | GO:0032262 | pyrimidine nucleotide salvage | 1 | 4 | 8.07e-01 |
| GO:BP | GO:0044208 | ‘de novo’ AMP biosynthetic process | 1 | 8 | 8.07e-01 |
| GO:BP | GO:0033120 | positive regulation of RNA splicing | 1 | 34 | 8.07e-01 |
| GO:BP | GO:0015931 | nucleobase-containing compound transport | 15 | 194 | 8.07e-01 |
| GO:BP | GO:0001756 | somitogenesis | 2 | 48 | 8.07e-01 |
| GO:BP | GO:0002752 | cell surface pattern recognition receptor signaling pathway | 2 | 27 | 8.07e-01 |
| GO:BP | GO:0061430 | bone trabecula morphogenesis | 1 | 12 | 8.07e-01 |
| GO:BP | GO:0060396 | growth hormone receptor signaling pathway | 2 | 18 | 8.08e-01 |
| GO:BP | GO:1902373 | negative regulation of mRNA catabolic process | 1 | 57 | 8.08e-01 |
| GO:BP | GO:0015833 | peptide transport | 10 | 179 | 8.08e-01 |
| GO:BP | GO:0002707 | negative regulation of lymphocyte mediated immunity | 1 | 24 | 8.08e-01 |
| GO:BP | GO:0150117 | positive regulation of cell-substrate junction organization | 3 | 29 | 8.08e-01 |
| GO:BP | GO:0032092 | positive regulation of protein binding | 2 | 78 | 8.08e-01 |
| GO:BP | GO:0071378 | cellular response to growth hormone stimulus | 2 | 18 | 8.08e-01 |
| GO:BP | GO:0072529 | pyrimidine-containing compound catabolic process | 4 | 29 | 8.08e-01 |
| GO:BP | GO:0071313 | cellular response to caffeine | 1 | 10 | 8.08e-01 |
| GO:BP | GO:0030838 | positive regulation of actin filament polymerization | 6 | 39 | 8.08e-01 |
| GO:BP | GO:1904383 | response to sodium phosphate | 1 | 5 | 8.08e-01 |
| GO:BP | GO:0043697 | cell dedifferentiation | 1 | 6 | 8.08e-01 |
| GO:BP | GO:0043696 | dedifferentiation | 1 | 6 | 8.08e-01 |
| GO:BP | GO:0000381 | regulation of alternative mRNA splicing, via spliceosome | 7 | 53 | 8.08e-01 |
| GO:BP | GO:0043627 | response to estrogen | 1 | 52 | 8.08e-01 |
| GO:BP | GO:0009966 | regulation of signal transduction | 1 | 2285 | 8.08e-01 |
| GO:BP | GO:0031998 | regulation of fatty acid beta-oxidation | 1 | 16 | 8.08e-01 |
| GO:BP | GO:0007141 | male meiosis I | 4 | 15 | 8.08e-01 |
| GO:BP | GO:0097050 | type B pancreatic cell apoptotic process | 1 | 7 | 8.08e-01 |
| GO:BP | GO:0048854 | brain morphogenesis | 4 | 28 | 8.09e-01 |
| GO:BP | GO:0003128 | heart field specification | 2 | 16 | 8.09e-01 |
| GO:BP | GO:0030206 | chondroitin sulfate biosynthetic process | 1 | 17 | 8.09e-01 |
| GO:BP | GO:0051896 | regulation of protein kinase B signaling | 2 | 123 | 8.09e-01 |
| GO:BP | GO:0048755 | branching morphogenesis of a nerve | 1 | 8 | 8.09e-01 |
| GO:BP | GO:0002833 | positive regulation of response to biotic stimulus | 12 | 192 | 8.09e-01 |
| GO:BP | GO:1901976 | regulation of cell cycle checkpoint | 4 | 45 | 8.09e-01 |
| GO:BP | GO:0071407 | cellular response to organic cyclic compound | 2 | 414 | 8.09e-01 |
| GO:BP | GO:0051239 | regulation of multicellular organismal process | 1 | 2035 | 8.10e-01 |
| GO:BP | GO:0070203 | regulation of establishment of protein localization to telomere | 1 | 11 | 8.10e-01 |
| GO:BP | GO:0060996 | dendritic spine development | 12 | 80 | 8.10e-01 |
| GO:BP | GO:0034651 | cortisol biosynthetic process | 1 | 8 | 8.10e-01 |
| GO:BP | GO:0071300 | cellular response to retinoic acid | 7 | 49 | 8.10e-01 |
| GO:BP | GO:1902914 | regulation of protein polyubiquitination | 4 | 23 | 8.10e-01 |
| GO:BP | GO:0072189 | ureter development | 1 | 10 | 8.10e-01 |
| GO:BP | GO:0014075 | response to amine | 1 | 34 | 8.10e-01 |
| GO:BP | GO:0008652 | amino acid biosynthetic process | 6 | 64 | 8.10e-01 |
| GO:BP | GO:0090685 | RNA localization to nucleus | 2 | 19 | 8.10e-01 |
| GO:BP | GO:1902645 | tertiary alcohol biosynthetic process | 1 | 8 | 8.10e-01 |
| GO:BP | GO:0031649 | heat generation | 2 | 11 | 8.10e-01 |
| GO:BP | GO:0090671 | telomerase RNA localization to Cajal body | 2 | 19 | 8.10e-01 |
| GO:BP | GO:0090670 | RNA localization to Cajal body | 2 | 19 | 8.10e-01 |
| GO:BP | GO:0046620 | regulation of organ growth | 4 | 71 | 8.10e-01 |
| GO:BP | GO:0006616 | SRP-dependent cotranslational protein targeting to membrane, translocation | 1 | 8 | 8.10e-01 |
| GO:BP | GO:0097187 | dentinogenesis | 1 | 4 | 8.10e-01 |
| GO:BP | GO:0090672 | telomerase RNA localization | 2 | 19 | 8.10e-01 |
| GO:BP | GO:0010668 | ectodermal cell differentiation | 1 | 5 | 8.10e-01 |
| GO:BP | GO:0046476 | glycosylceramide biosynthetic process | 1 | 6 | 8.10e-01 |
| GO:BP | GO:1903367 | positive regulation of fear response | 1 | 4 | 8.10e-01 |
| GO:BP | GO:0006576 | biogenic amine metabolic process | 2 | 57 | 8.10e-01 |
| GO:BP | GO:0032353 | negative regulation of hormone biosynthetic process | 1 | 8 | 8.10e-01 |
| GO:BP | GO:0071895 | odontoblast differentiation | 1 | 5 | 8.10e-01 |
| GO:BP | GO:0042177 | negative regulation of protein catabolic process | 1 | 100 | 8.11e-01 |
| GO:BP | GO:0016338 | calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules | 3 | 10 | 8.11e-01 |
| GO:BP | GO:0061982 | meiosis I cell cycle process | 20 | 81 | 8.11e-01 |
| GO:BP | GO:0051709 | regulation of killing of cells of another organism | 1 | 3 | 8.13e-01 |
| GO:BP | GO:0038093 | Fc receptor signaling pathway | 2 | 36 | 8.13e-01 |
| GO:BP | GO:2000177 | regulation of neural precursor cell proliferation | 5 | 64 | 8.13e-01 |
| GO:BP | GO:0035561 | regulation of chromatin binding | 3 | 20 | 8.13e-01 |
| GO:BP | GO:0007585 | respiratory gaseous exchange by respiratory system | 1 | 49 | 8.13e-01 |
| GO:BP | GO:0070423 | nucleotide-binding oligomerization domain containing signaling pathway | 1 | 18 | 8.13e-01 |
| GO:BP | GO:0071229 | cellular response to acid chemical | 11 | 71 | 8.14e-01 |
| GO:BP | GO:1903428 | positive regulation of reactive oxygen species biosynthetic process | 1 | 12 | 8.14e-01 |
| GO:BP | GO:0060512 | prostate gland morphogenesis | 1 | 21 | 8.15e-01 |
| GO:BP | GO:0051458 | corticotropin secretion | 1 | 4 | 8.15e-01 |
| GO:BP | GO:0010898 | positive regulation of triglyceride catabolic process | 1 | 4 | 8.15e-01 |
| GO:BP | GO:0006360 | transcription by RNA polymerase I | 6 | 62 | 8.15e-01 |
| GO:BP | GO:0034329 | cell junction assembly | 4 | 344 | 8.15e-01 |
| GO:BP | GO:0001764 | neuron migration | 3 | 133 | 8.15e-01 |
| GO:BP | GO:0009145 | purine nucleoside triphosphate biosynthetic process | 2 | 97 | 8.15e-01 |
| GO:BP | GO:0008156 | negative regulation of DNA replication | 3 | 19 | 8.15e-01 |
| GO:BP | GO:2000678 | negative regulation of transcription regulatory region DNA binding | 1 | 17 | 8.16e-01 |
| GO:BP | GO:0006412 | translation | 11 | 646 | 8.16e-01 |
| GO:BP | GO:2000425 | regulation of apoptotic cell clearance | 1 | 7 | 8.16e-01 |
| GO:BP | GO:0090181 | regulation of cholesterol metabolic process | 1 | 29 | 8.16e-01 |
| GO:BP | GO:0008543 | fibroblast growth factor receptor signaling pathway | 3 | 60 | 8.16e-01 |
| GO:BP | GO:0072676 | lymphocyte migration | 1 | 59 | 8.16e-01 |
| GO:BP | GO:0030321 | transepithelial chloride transport | 1 | 7 | 8.16e-01 |
| GO:BP | GO:0061041 | regulation of wound healing | 1 | 95 | 8.16e-01 |
| GO:BP | GO:0002823 | negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 1 | 26 | 8.16e-01 |
| GO:BP | GO:0021603 | cranial nerve formation | 1 | 4 | 8.16e-01 |
| GO:BP | GO:0071295 | cellular response to vitamin | 1 | 22 | 8.17e-01 |
| GO:BP | GO:0032925 | regulation of activin receptor signaling pathway | 1 | 20 | 8.17e-01 |
| GO:BP | GO:0045066 | regulatory T cell differentiation | 1 | 22 | 8.17e-01 |
| GO:BP | GO:0009892 | negative regulation of metabolic process | 3 | 2293 | 8.17e-01 |
| GO:BP | GO:0062111 | zinc ion import into organelle | 1 | 7 | 8.17e-01 |
| GO:BP | GO:0021924 | cell proliferation in external granule layer | 2 | 12 | 8.17e-01 |
| GO:BP | GO:0021930 | cerebellar granule cell precursor proliferation | 2 | 12 | 8.17e-01 |
| GO:BP | GO:0002433 | immune response-regulating cell surface receptor signaling pathway involved in phagocytosis | 1 | 19 | 8.17e-01 |
| GO:BP | GO:1901861 | regulation of muscle tissue development | 5 | 35 | 8.17e-01 |
| GO:BP | GO:0021534 | cell proliferation in hindbrain | 2 | 12 | 8.17e-01 |
| GO:BP | GO:0030073 | insulin secretion | 6 | 141 | 8.17e-01 |
| GO:BP | GO:0010842 | retina layer formation | 2 | 16 | 8.17e-01 |
| GO:BP | GO:0009169 | purine ribonucleoside monophosphate catabolic process | 1 | 7 | 8.17e-01 |
| GO:BP | GO:0038128 | ERBB2 signaling pathway | 2 | 14 | 8.17e-01 |
| GO:BP | GO:0009128 | purine nucleoside monophosphate catabolic process | 1 | 7 | 8.17e-01 |
| GO:BP | GO:0038096 | Fc-gamma receptor signaling pathway involved in phagocytosis | 1 | 19 | 8.17e-01 |
| GO:BP | GO:1902106 | negative regulation of leukocyte differentiation | 1 | 65 | 8.17e-01 |
| GO:BP | GO:0060713 | labyrinthine layer morphogenesis | 1 | 17 | 8.17e-01 |
| GO:BP | GO:0002698 | negative regulation of immune effector process | 2 | 59 | 8.17e-01 |
| GO:BP | GO:0045059 | positive thymic T cell selection | 1 | 6 | 8.17e-01 |
| GO:BP | GO:0030282 | bone mineralization | 1 | 82 | 8.17e-01 |
| GO:BP | GO:0062197 | cellular response to chemical stress | 24 | 293 | 8.17e-01 |
| GO:BP | GO:0055119 | relaxation of cardiac muscle | 2 | 17 | 8.17e-01 |
| GO:BP | GO:0021855 | hypothalamus cell migration | 1 | 6 | 8.17e-01 |
| GO:BP | GO:0043409 | negative regulation of MAPK cascade | 13 | 145 | 8.17e-01 |
| GO:BP | GO:2000001 | regulation of DNA damage checkpoint | 1 | 25 | 8.18e-01 |
| GO:BP | GO:0035929 | steroid hormone secretion | 1 | 18 | 8.18e-01 |
| GO:BP | GO:0045475 | locomotor rhythm | 1 | 13 | 8.18e-01 |
| GO:BP | GO:0001767 | establishment of lymphocyte polarity | 2 | 11 | 8.18e-01 |
| GO:BP | GO:0015867 | ATP transport | 1 | 9 | 8.18e-01 |
| GO:BP | GO:0060027 | convergent extension involved in gastrulation | 1 | 8 | 8.18e-01 |
| GO:BP | GO:0002244 | hematopoietic progenitor cell differentiation | 7 | 109 | 8.18e-01 |
| GO:BP | GO:0051173 | positive regulation of nitrogen compound metabolic process | 1 | 2412 | 8.18e-01 |
| GO:BP | GO:0019883 | antigen processing and presentation of endogenous antigen | 1 | 19 | 8.18e-01 |
| GO:BP | GO:1903861 | positive regulation of dendrite extension | 3 | 15 | 8.18e-01 |
| GO:BP | GO:0061043 | regulation of vascular wound healing | 1 | 9 | 8.19e-01 |
| GO:BP | GO:0040031 | snRNA modification | 1 | 7 | 8.19e-01 |
| GO:BP | GO:0002313 | mature B cell differentiation involved in immune response | 1 | 17 | 8.19e-01 |
| GO:BP | GO:0042304 | regulation of fatty acid biosynthetic process | 1 | 30 | 8.19e-01 |
| GO:BP | GO:0032735 | positive regulation of interleukin-12 production | 1 | 19 | 8.20e-01 |
| GO:BP | GO:0031295 | T cell costimulation | 2 | 22 | 8.20e-01 |
| GO:BP | GO:0017038 | protein import | 1 | 7 | 8.21e-01 |
| GO:BP | GO:0030900 | forebrain development | 2 | 281 | 8.21e-01 |
| GO:BP | GO:0007259 | receptor signaling pathway via JAK-STAT | 2 | 86 | 8.21e-01 |
| GO:BP | GO:0042790 | nucleolar large rRNA transcription by RNA polymerase I | 2 | 21 | 8.21e-01 |
| GO:BP | GO:0002666 | positive regulation of T cell tolerance induction | 1 | 4 | 8.21e-01 |
| GO:BP | GO:0007620 | copulation | 2 | 10 | 8.21e-01 |
| GO:BP | GO:0015879 | carnitine transport | 1 | 4 | 8.22e-01 |
| GO:BP | GO:0006935 | chemotaxis | 5 | 389 | 8.22e-01 |
| GO:BP | GO:0019217 | regulation of fatty acid metabolic process | 4 | 66 | 8.22e-01 |
| GO:BP | GO:0110025 | DNA strand resection involved in replication fork processing | 1 | 7 | 8.22e-01 |
| GO:BP | GO:0035563 | positive regulation of chromatin binding | 1 | 12 | 8.22e-01 |
| GO:BP | GO:0051093 | negative regulation of developmental process | 1 | 665 | 8.22e-01 |
| GO:BP | GO:0035735 | intraciliary transport involved in cilium assembly | 1 | 7 | 8.22e-01 |
| GO:BP | GO:1990806 | ligand-gated ion channel signaling pathway | 2 | 20 | 8.22e-01 |
| GO:BP | GO:0002281 | macrophage activation involved in immune response | 2 | 8 | 8.22e-01 |
| GO:BP | GO:0032367 | intracellular cholesterol transport | 3 | 28 | 8.22e-01 |
| GO:BP | GO:0051966 | regulation of synaptic transmission, glutamatergic | 1 | 46 | 8.22e-01 |
| GO:BP | GO:0035872 | nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway | 1 | 19 | 8.22e-01 |
| GO:BP | GO:0072091 | regulation of stem cell proliferation | 4 | 58 | 8.23e-01 |
| GO:BP | GO:0051261 | protein depolymerization | 14 | 105 | 8.23e-01 |
| GO:BP | GO:0008645 | hexose transmembrane transport | 10 | 84 | 8.23e-01 |
| GO:BP | GO:0070173 | regulation of enamel mineralization | 1 | 2 | 8.23e-01 |
| GO:BP | GO:0021545 | cranial nerve development | 1 | 31 | 8.23e-01 |
| GO:BP | GO:0042330 | taxis | 5 | 389 | 8.23e-01 |
| GO:BP | GO:0071396 | cellular response to lipid | 2 | 398 | 8.23e-01 |
| GO:BP | GO:0006283 | transcription-coupled nucleotide-excision repair | 1 | 10 | 8.24e-01 |
| GO:BP | GO:1900024 | regulation of substrate adhesion-dependent cell spreading | 7 | 54 | 8.24e-01 |
| GO:BP | GO:0007612 | learning | 10 | 115 | 8.24e-01 |
| GO:BP | GO:0050901 | leukocyte tethering or rolling | 1 | 16 | 8.24e-01 |
| GO:BP | GO:1903532 | positive regulation of secretion by cell | 5 | 199 | 8.24e-01 |
| GO:BP | GO:0032963 | collagen metabolic process | 5 | 74 | 8.24e-01 |
| GO:BP | GO:0035567 | non-canonical Wnt signaling pathway | 9 | 62 | 8.24e-01 |
| GO:BP | GO:0071216 | cellular response to biotic stimulus | 8 | 138 | 8.24e-01 |
| GO:BP | GO:0086005 | ventricular cardiac muscle cell action potential | 1 | 29 | 8.24e-01 |
| GO:BP | GO:0001503 | ossification | 7 | 313 | 8.24e-01 |
| GO:BP | GO:0007283 | spermatogenesis | 4 | 330 | 8.24e-01 |
| GO:BP | GO:0002377 | immunoglobulin production | 4 | 70 | 8.24e-01 |
| GO:BP | GO:0006937 | regulation of muscle contraction | 2 | 133 | 8.24e-01 |
| GO:BP | GO:0006930 | substrate-dependent cell migration, cell extension | 1 | 8 | 8.24e-01 |
| GO:BP | GO:0002840 | regulation of T cell mediated immune response to tumor cell | 1 | 5 | 8.24e-01 |
| GO:BP | GO:0001781 | neutrophil apoptotic process | 1 | 5 | 8.24e-01 |
| GO:BP | GO:1900038 | negative regulation of cellular response to hypoxia | 1 | 8 | 8.24e-01 |
| GO:BP | GO:1990144 | intrinsic apoptotic signaling pathway in response to hypoxia | 1 | 9 | 8.24e-01 |
| GO:BP | GO:0060290 | transdifferentiation | 1 | 2 | 8.24e-01 |
| GO:BP | GO:0042558 | pteridine-containing compound metabolic process | 2 | 28 | 8.25e-01 |
| GO:BP | GO:0071675 | regulation of mononuclear cell migration | 1 | 71 | 8.25e-01 |
| GO:BP | GO:0070542 | response to fatty acid | 2 | 43 | 8.25e-01 |
| GO:BP | GO:0090660 | cerebrospinal fluid circulation | 1 | 9 | 8.26e-01 |
| GO:BP | GO:1903707 | negative regulation of hemopoiesis | 1 | 69 | 8.26e-01 |
| GO:BP | GO:0070861 | regulation of protein exit from endoplasmic reticulum | 1 | 22 | 8.26e-01 |
| GO:BP | GO:0071880 | adenylate cyclase-activating adrenergic receptor signaling pathway | 3 | 19 | 8.26e-01 |
| GO:BP | GO:0010310 | regulation of hydrogen peroxide metabolic process | 1 | 14 | 8.26e-01 |
| GO:BP | GO:1901615 | organic hydroxy compound metabolic process | 9 | 376 | 8.26e-01 |
| GO:BP | GO:0006491 | N-glycan processing | 1 | 18 | 8.26e-01 |
| GO:BP | GO:0072110 | glomerular mesangial cell proliferation | 1 | 10 | 8.26e-01 |
| GO:BP | GO:2000347 | positive regulation of hepatocyte proliferation | 1 | 9 | 8.26e-01 |
| GO:BP | GO:0009063 | amino acid catabolic process | 2 | 78 | 8.26e-01 |
| GO:BP | GO:2000048 | negative regulation of cell-cell adhesion mediated by cadherin | 1 | 8 | 8.26e-01 |
| GO:BP | GO:0023041 | neuronal signal transduction | 1 | 6 | 8.26e-01 |
| GO:BP | GO:0036035 | osteoclast development | 1 | 10 | 8.26e-01 |
| GO:BP | GO:0006265 | DNA topological change | 1 | 10 | 8.26e-01 |
| GO:BP | GO:0060456 | positive regulation of digestive system process | 2 | 8 | 8.26e-01 |
| GO:BP | GO:0043331 | response to dsRNA | 1 | 33 | 8.27e-01 |
| GO:BP | GO:0006270 | DNA replication initiation | 2 | 35 | 8.27e-01 |
| GO:BP | GO:1901838 | positive regulation of transcription of nucleolar large rRNA by RNA polymerase I | 1 | 10 | 8.27e-01 |
| GO:BP | GO:0010603 | regulation of cytoplasmic mRNA processing body assembly | 1 | 7 | 8.28e-01 |
| GO:BP | GO:0070977 | bone maturation | 3 | 19 | 8.28e-01 |
| GO:BP | GO:0072210 | metanephric nephron development | 2 | 29 | 8.28e-01 |
| GO:BP | GO:0043567 | regulation of insulin-like growth factor receptor signaling pathway | 2 | 17 | 8.28e-01 |
| GO:BP | GO:0080134 | regulation of response to stress | 55 | 1075 | 8.28e-01 |
| GO:BP | GO:0032481 | positive regulation of type I interferon production | 2 | 45 | 8.28e-01 |
| GO:BP | GO:0050869 | negative regulation of B cell activation | 1 | 19 | 8.28e-01 |
| GO:BP | GO:0002027 | regulation of heart rate | 4 | 86 | 8.28e-01 |
| GO:BP | GO:1903205 | regulation of hydrogen peroxide-induced cell death | 2 | 20 | 8.29e-01 |
| GO:BP | GO:0006376 | mRNA splice site selection | 1 | 31 | 8.29e-01 |
| GO:BP | GO:0090102 | cochlea development | 3 | 35 | 8.29e-01 |
| GO:BP | GO:0030858 | positive regulation of epithelial cell differentiation | 2 | 37 | 8.29e-01 |
| GO:BP | GO:0070671 | response to interleukin-12 | 1 | 6 | 8.29e-01 |
| GO:BP | GO:0071224 | cellular response to peptidoglycan | 1 | 2 | 8.29e-01 |
| GO:BP | GO:0061037 | negative regulation of cartilage development | 1 | 23 | 8.29e-01 |
| GO:BP | GO:0046337 | phosphatidylethanolamine metabolic process | 2 | 19 | 8.29e-01 |
| GO:BP | GO:0071676 | negative regulation of mononuclear cell migration | 1 | 16 | 8.29e-01 |
| GO:BP | GO:0044058 | regulation of digestive system process | 1 | 22 | 8.29e-01 |
| GO:BP | GO:0000338 | protein deneddylation | 1 | 11 | 8.29e-01 |
| GO:BP | GO:0071379 | cellular response to prostaglandin stimulus | 1 | 16 | 8.29e-01 |
| GO:BP | GO:0071241 | cellular response to inorganic substance | 1 | 164 | 8.29e-01 |
| GO:BP | GO:0002643 | regulation of tolerance induction | 2 | 10 | 8.29e-01 |
| GO:BP | GO:0032392 | DNA geometric change | 11 | 80 | 8.29e-01 |
| GO:BP | GO:0036158 | outer dynein arm assembly | 1 | 11 | 8.29e-01 |
| GO:BP | GO:0070202 | regulation of establishment of protein localization to chromosome | 1 | 12 | 8.29e-01 |
| GO:BP | GO:0097530 | granulocyte migration | 2 | 67 | 8.29e-01 |
| GO:BP | GO:0044788 | modulation by host of viral process | 5 | 40 | 8.29e-01 |
| GO:BP | GO:0032731 | positive regulation of interleukin-1 beta production | 1 | 30 | 8.29e-01 |
| GO:BP | GO:0060428 | lung epithelium development | 2 | 30 | 8.29e-01 |
| GO:BP | GO:0042542 | response to hydrogen peroxide | 17 | 103 | 8.29e-01 |
| GO:BP | GO:0019098 | reproductive behavior | 6 | 26 | 8.29e-01 |
| GO:BP | GO:0046321 | positive regulation of fatty acid oxidation | 2 | 15 | 8.29e-01 |
| GO:BP | GO:0046475 | glycerophospholipid catabolic process | 2 | 21 | 8.29e-01 |
| GO:BP | GO:0002688 | regulation of leukocyte chemotaxis | 1 | 68 | 8.30e-01 |
| GO:BP | GO:0007625 | grooming behavior | 2 | 10 | 8.30e-01 |
| GO:BP | GO:0032354 | response to follicle-stimulating hormone | 2 | 13 | 8.30e-01 |
| GO:BP | GO:0034334 | adherens junction maintenance | 1 | 6 | 8.30e-01 |
| GO:BP | GO:0031053 | primary miRNA processing | 2 | 16 | 8.30e-01 |
| GO:BP | GO:0021756 | striatum development | 2 | 17 | 8.30e-01 |
| GO:BP | GO:0043045 | DNA methylation involved in embryo development | 1 | 7 | 8.30e-01 |
| GO:BP | GO:0005975 | carbohydrate metabolic process | 19 | 433 | 8.30e-01 |
| GO:BP | GO:0002679 | respiratory burst involved in defense response | 1 | 7 | 8.30e-01 |
| GO:BP | GO:0048609 | multicellular organismal reproductive process | 2 | 538 | 8.30e-01 |
| GO:BP | GO:0000052 | citrulline metabolic process | 1 | 7 | 8.30e-01 |
| GO:BP | GO:0043691 | reverse cholesterol transport | 1 | 11 | 8.30e-01 |
| GO:BP | GO:0007130 | synaptonemal complex assembly | 1 | 10 | 8.31e-01 |
| GO:BP | GO:0006206 | pyrimidine nucleobase metabolic process | 1 | 13 | 8.31e-01 |
| GO:BP | GO:0097696 | receptor signaling pathway via STAT | 2 | 88 | 8.31e-01 |
| GO:BP | GO:0008300 | isoprenoid catabolic process | 1 | 5 | 8.31e-01 |
| GO:BP | GO:0006730 | one-carbon metabolic process | 3 | 29 | 8.31e-01 |
| GO:BP | GO:2000027 | regulation of animal organ morphogenesis | 8 | 101 | 8.31e-01 |
| GO:BP | GO:0006776 | vitamin A metabolic process | 1 | 3 | 8.31e-01 |
| GO:BP | GO:0072575 | epithelial cell proliferation involved in liver morphogenesis | 2 | 18 | 8.31e-01 |
| GO:BP | GO:2000241 | regulation of reproductive process | 1 | 128 | 8.31e-01 |
| GO:BP | GO:0060047 | heart contraction | 3 | 205 | 8.31e-01 |
| GO:BP | GO:0072574 | hepatocyte proliferation | 2 | 18 | 8.31e-01 |
| GO:BP | GO:0060179 | male mating behavior | 1 | 5 | 8.31e-01 |
| GO:BP | GO:0001885 | endothelial cell development | 2 | 53 | 8.31e-01 |
| GO:BP | GO:0090400 | stress-induced premature senescence | 1 | 7 | 8.31e-01 |
| GO:BP | GO:0032342 | aldosterone biosynthetic process | 1 | 9 | 8.31e-01 |
| GO:BP | GO:0007340 | acrosome reaction | 1 | 20 | 8.31e-01 |
| GO:BP | GO:1900045 | negative regulation of protein K63-linked ubiquitination | 1 | 7 | 8.31e-01 |
| GO:BP | GO:0046640 | regulation of alpha-beta T cell proliferation | 6 | 23 | 8.32e-01 |
| GO:BP | GO:0071103 | DNA conformation change | 12 | 87 | 8.32e-01 |
| GO:BP | GO:0071321 | cellular response to cGMP | 1 | 7 | 8.33e-01 |
| GO:BP | GO:0035482 | gastric motility | 1 | 3 | 8.33e-01 |
| GO:BP | GO:2000822 | regulation of behavioral fear response | 1 | 7 | 8.33e-01 |
| GO:BP | GO:0060544 | regulation of necroptotic process | 1 | 23 | 8.33e-01 |
| GO:BP | GO:1903980 | positive regulation of microglial cell activation | 1 | 2 | 8.33e-01 |
| GO:BP | GO:0060711 | labyrinthine layer development | 2 | 35 | 8.33e-01 |
| GO:BP | GO:0031294 | lymphocyte costimulation | 2 | 23 | 8.33e-01 |
| GO:BP | GO:0071051 | polyadenylation-dependent snoRNA 3’-end processing | 1 | 7 | 8.33e-01 |
| GO:BP | GO:0034661 | ncRNA catabolic process | 6 | 41 | 8.33e-01 |
| GO:BP | GO:0055091 | phospholipid homeostasis | 1 | 12 | 8.33e-01 |
| GO:BP | GO:2000095 | regulation of Wnt signaling pathway, planar cell polarity pathway | 1 | 15 | 8.34e-01 |
| GO:BP | GO:0045576 | mast cell activation | 2 | 35 | 8.34e-01 |
| GO:BP | GO:0002820 | negative regulation of adaptive immune response | 1 | 27 | 8.34e-01 |
| GO:BP | GO:0097028 | dendritic cell differentiation | 1 | 23 | 8.34e-01 |
| GO:BP | GO:0045824 | negative regulation of innate immune response | 2 | 53 | 8.34e-01 |
| GO:BP | GO:0031118 | rRNA pseudouridine synthesis | 1 | 10 | 8.34e-01 |
| GO:BP | GO:0035162 | embryonic hemopoiesis | 1 | 19 | 8.34e-01 |
| GO:BP | GO:0060674 | placenta blood vessel development | 2 | 26 | 8.34e-01 |
| GO:BP | GO:0030513 | positive regulation of BMP signaling pathway | 1 | 34 | 8.34e-01 |
| GO:BP | GO:0060976 | coronary vasculature development | 3 | 44 | 8.34e-01 |
| GO:BP | GO:0033864 | positive regulation of NAD(P)H oxidase activity | 1 | 6 | 8.34e-01 |
| GO:BP | GO:0032098 | regulation of appetite | 1 | 8 | 8.34e-01 |
| GO:BP | GO:0010766 | negative regulation of sodium ion transport | 2 | 15 | 8.35e-01 |
| GO:BP | GO:1901621 | negative regulation of smoothened signaling pathway involved in dorsal/ventral neural tube patterning | 1 | 7 | 8.35e-01 |
| GO:BP | GO:0070830 | bicellular tight junction assembly | 1 | 43 | 8.35e-01 |
| GO:BP | GO:0014824 | artery smooth muscle contraction | 1 | 7 | 8.35e-01 |
| GO:BP | GO:0099558 | maintenance of synapse structure | 3 | 25 | 8.35e-01 |
| GO:BP | GO:1902966 | positive regulation of protein localization to early endosome | 1 | 9 | 8.35e-01 |
| GO:BP | GO:1902965 | regulation of protein localization to early endosome | 1 | 9 | 8.35e-01 |
| GO:BP | GO:0019637 | organophosphate metabolic process | 1 | 784 | 8.35e-01 |
| GO:BP | GO:0051561 | positive regulation of mitochondrial calcium ion concentration | 1 | 11 | 8.35e-01 |
| GO:BP | GO:0060982 | coronary artery morphogenesis | 1 | 8 | 8.35e-01 |
| GO:BP | GO:0007528 | neuromuscular junction development | 2 | 39 | 8.35e-01 |
| GO:BP | GO:0045348 | positive regulation of MHC class II biosynthetic process | 1 | 8 | 8.35e-01 |
| GO:BP | GO:0040037 | negative regulation of fibroblast growth factor receptor signaling pathway | 2 | 16 | 8.35e-01 |
| GO:BP | GO:0006357 | regulation of transcription by RNA polymerase II | 211 | 1914 | 8.35e-01 |
| GO:BP | GO:0033292 | T-tubule organization | 1 | 8 | 8.35e-01 |
| GO:BP | GO:0099612 | protein localization to axon | 1 | 6 | 8.35e-01 |
| GO:BP | GO:0033869 | nucleoside bisphosphate catabolic process | 1 | 11 | 8.36e-01 |
| GO:BP | GO:0034031 | ribonucleoside bisphosphate catabolic process | 1 | 11 | 8.36e-01 |
| GO:BP | GO:0034034 | purine nucleoside bisphosphate catabolic process | 1 | 11 | 8.36e-01 |
| GO:BP | GO:0033632 | regulation of cell-cell adhesion mediated by integrin | 1 | 6 | 8.36e-01 |
| GO:BP | GO:0046085 | adenosine metabolic process | 1 | 5 | 8.36e-01 |
| GO:BP | GO:0061053 | somite development | 5 | 63 | 8.37e-01 |
| GO:BP | GO:0001655 | urogenital system development | 2 | 49 | 8.37e-01 |
| GO:BP | GO:0016266 | O-glycan processing | 3 | 30 | 8.37e-01 |
| GO:BP | GO:0048245 | eosinophil chemotaxis | 1 | 5 | 8.37e-01 |
| GO:BP | GO:0015914 | phospholipid transport | 1 | 75 | 8.38e-01 |
| GO:BP | GO:0072538 | T-helper 17 type immune response | 3 | 24 | 8.38e-01 |
| GO:BP | GO:0048311 | mitochondrion distribution | 1 | 14 | 8.38e-01 |
| GO:BP | GO:0061003 | positive regulation of dendritic spine morphogenesis | 1 | 17 | 8.38e-01 |
| GO:BP | GO:0070555 | response to interleukin-1 | 3 | 83 | 8.38e-01 |
| GO:BP | GO:0070192 | chromosome organization involved in meiotic cell cycle | 4 | 35 | 8.38e-01 |
| GO:BP | GO:0048232 | male gamete generation | 4 | 343 | 8.38e-01 |
| GO:BP | GO:0031269 | pseudopodium assembly | 1 | 14 | 8.38e-01 |
| GO:BP | GO:0007614 | short-term memory | 1 | 9 | 8.38e-01 |
| GO:BP | GO:0043374 | CD8-positive, alpha-beta T cell differentiation | 2 | 8 | 8.38e-01 |
| GO:BP | GO:0048878 | chemical homeostasis | 1 | 676 | 8.38e-01 |
| GO:BP | GO:0014067 | negative regulation of phosphatidylinositol 3-kinase signaling | 1 | 12 | 8.38e-01 |
| GO:BP | GO:0006271 | DNA strand elongation involved in DNA replication | 2 | 15 | 8.38e-01 |
| GO:BP | GO:0051279 | regulation of release of sequestered calcium ion into cytosol | 11 | 60 | 8.39e-01 |
| GO:BP | GO:0060693 | regulation of branching involved in salivary gland morphogenesis | 1 | 6 | 8.40e-01 |
| GO:BP | GO:0006656 | phosphatidylcholine biosynthetic process | 2 | 25 | 8.40e-01 |
| GO:BP | GO:1905952 | regulation of lipid localization | 2 | 112 | 8.40e-01 |
| GO:BP | GO:0051960 | regulation of nervous system development | 28 | 357 | 8.40e-01 |
| GO:BP | GO:0032414 | positive regulation of ion transmembrane transporter activity | 2 | 85 | 8.41e-01 |
| GO:BP | GO:1903409 | reactive oxygen species biosynthetic process | 1 | 36 | 8.41e-01 |
| GO:BP | GO:0015749 | monosaccharide transmembrane transport | 10 | 85 | 8.41e-01 |
| GO:BP | GO:0010646 | regulation of cell communication | 1 | 2573 | 8.41e-01 |
| GO:BP | GO:1901984 | negative regulation of protein acetylation | 2 | 16 | 8.41e-01 |
| GO:BP | GO:1902369 | negative regulation of RNA catabolic process | 1 | 69 | 8.41e-01 |
| GO:BP | GO:0046950 | cellular ketone body metabolic process | 1 | 7 | 8.41e-01 |
| GO:BP | GO:0090050 | positive regulation of cell migration involved in sprouting angiogenesis | 1 | 18 | 8.41e-01 |
| GO:BP | GO:0060513 | prostatic bud formation | 1 | 8 | 8.41e-01 |
| GO:BP | GO:0035864 | response to potassium ion | 1 | 12 | 8.41e-01 |
| GO:BP | GO:0043302 | positive regulation of leukocyte degranulation | 2 | 15 | 8.42e-01 |
| GO:BP | GO:1900542 | regulation of purine nucleotide metabolic process | 6 | 40 | 8.42e-01 |
| GO:BP | GO:0006525 | arginine metabolic process | 1 | 13 | 8.42e-01 |
| GO:BP | GO:0030070 | insulin processing | 1 | 6 | 8.42e-01 |
| GO:BP | GO:0034983 | peptidyl-lysine deacetylation | 1 | 8 | 8.42e-01 |
| GO:BP | GO:0002474 | antigen processing and presentation of peptide antigen via MHC class I | 1 | 25 | 8.42e-01 |
| GO:BP | GO:0006941 | striated muscle contraction | 2 | 152 | 8.42e-01 |
| GO:BP | GO:0043500 | muscle adaptation | 1 | 90 | 8.43e-01 |
| GO:BP | GO:0046716 | muscle cell cellular homeostasis | 1 | 21 | 8.43e-01 |
| GO:BP | GO:0022029 | telencephalon cell migration | 5 | 44 | 8.43e-01 |
| GO:BP | GO:0046877 | regulation of saliva secretion | 1 | 3 | 8.43e-01 |
| GO:BP | GO:1900017 | positive regulation of cytokine production involved in inflammatory response | 1 | 15 | 8.43e-01 |
| GO:BP | GO:0051651 | maintenance of location in cell | 4 | 170 | 8.43e-01 |
| GO:BP | GO:0019884 | antigen processing and presentation of exogenous antigen | 1 | 28 | 8.43e-01 |
| GO:BP | GO:0045944 | positive regulation of transcription by RNA polymerase II | 41 | 937 | 8.43e-01 |
| GO:BP | GO:0060571 | morphogenesis of an epithelial fold | 1 | 16 | 8.43e-01 |
| GO:BP | GO:0070233 | negative regulation of T cell apoptotic process | 1 | 14 | 8.43e-01 |
| GO:BP | GO:0098698 | postsynaptic specialization assembly | 4 | 23 | 8.43e-01 |
| GO:BP | GO:0019058 | viral life cycle | 2 | 244 | 8.43e-01 |
| GO:BP | GO:0060255 | regulation of macromolecule metabolic process | 2 | 4617 | 8.43e-01 |
| GO:BP | GO:0002790 | peptide secretion | 4 | 170 | 8.43e-01 |
| GO:BP | GO:0036363 | transforming growth factor beta activation | 1 | 9 | 8.43e-01 |
| GO:BP | GO:0042554 | superoxide anion generation | 1 | 20 | 8.43e-01 |
| GO:BP | GO:0051665 | membrane raft localization | 1 | 4 | 8.43e-01 |
| GO:BP | GO:0106030 | neuron projection fasciculation | 2 | 18 | 8.43e-01 |
| GO:BP | GO:0007413 | axonal fasciculation | 2 | 18 | 8.43e-01 |
| GO:BP | GO:0034381 | plasma lipoprotein particle clearance | 1 | 25 | 8.43e-01 |
| GO:BP | GO:0043043 | peptide biosynthetic process | 11 | 666 | 8.43e-01 |
| GO:BP | GO:0014911 | positive regulation of smooth muscle cell migration | 3 | 30 | 8.43e-01 |
| GO:BP | GO:0042461 | photoreceptor cell development | 4 | 30 | 8.43e-01 |
| GO:BP | GO:0090287 | regulation of cellular response to growth factor stimulus | 1 | 265 | 8.43e-01 |
| GO:BP | GO:0035337 | fatty-acyl-CoA metabolic process | 1 | 31 | 8.43e-01 |
| GO:BP | GO:0021987 | cerebral cortex development | 2 | 101 | 8.43e-01 |
| GO:BP | GO:0035332 | positive regulation of hippo signaling | 1 | 6 | 8.43e-01 |
| GO:BP | GO:0006544 | glycine metabolic process | 1 | 10 | 8.43e-01 |
| GO:BP | GO:0043244 | regulation of protein-containing complex disassembly | 9 | 113 | 8.43e-01 |
| GO:BP | GO:0034599 | cellular response to oxidative stress | 1 | 240 | 8.43e-01 |
| GO:BP | GO:0072234 | metanephric nephron tubule development | 1 | 14 | 8.44e-01 |
| GO:BP | GO:0001505 | regulation of neurotransmitter levels | 5 | 149 | 8.44e-01 |
| GO:BP | GO:0044403 | biological process involved in symbiotic interaction | 1 | 223 | 8.44e-01 |
| GO:BP | GO:0072576 | liver morphogenesis | 2 | 19 | 8.44e-01 |
| GO:BP | GO:0009642 | response to light intensity | 2 | 11 | 8.44e-01 |
| GO:BP | GO:1901222 | regulation of NIK/NF-kappaB signaling | 2 | 65 | 8.44e-01 |
| GO:BP | GO:0061085 | regulation of histone H3-K27 methylation | 1 | 4 | 8.44e-01 |
| GO:BP | GO:0080144 | intracellular amino acid homeostasis | 1 | 7 | 8.44e-01 |
| GO:BP | GO:0051290 | protein heterotetramerization | 1 | 12 | 8.44e-01 |
| GO:BP | GO:0045143 | homologous chromosome segregation | 4 | 34 | 8.44e-01 |
| GO:BP | GO:0030252 | growth hormone secretion | 2 | 12 | 8.44e-01 |
| GO:BP | GO:0003334 | keratinocyte development | 1 | 8 | 8.45e-01 |
| GO:BP | GO:2000561 | regulation of CD4-positive, alpha-beta T cell proliferation | 3 | 12 | 8.45e-01 |
| GO:BP | GO:0035739 | CD4-positive, alpha-beta T cell proliferation | 3 | 12 | 8.45e-01 |
| GO:BP | GO:0032504 | multicellular organism reproduction | 2 | 556 | 8.45e-01 |
| GO:BP | GO:1901862 | negative regulation of muscle tissue development | 1 | 9 | 8.45e-01 |
| GO:BP | GO:0070493 | thrombin-activated receptor signaling pathway | 1 | 9 | 8.45e-01 |
| GO:BP | GO:0021886 | hypothalamus gonadotrophin-releasing hormone neuron differentiation | 1 | 7 | 8.45e-01 |
| GO:BP | GO:0002009 | morphogenesis of an epithelium | 4 | 418 | 8.45e-01 |
| GO:BP | GO:0021888 | hypothalamus gonadotrophin-releasing hormone neuron development | 1 | 7 | 8.45e-01 |
| GO:BP | GO:0098760 | response to interleukin-7 | 1 | 12 | 8.45e-01 |
| GO:BP | GO:0098761 | cellular response to interleukin-7 | 1 | 12 | 8.45e-01 |
| GO:BP | GO:0009306 | protein secretion | 6 | 262 | 8.45e-01 |
| GO:BP | GO:1902680 | positive regulation of RNA biosynthetic process | 140 | 1322 | 8.45e-01 |
| GO:BP | GO:0002260 | lymphocyte homeostasis | 3 | 45 | 8.45e-01 |
| GO:BP | GO:0033034 | positive regulation of myeloid cell apoptotic process | 1 | 6 | 8.45e-01 |
| GO:BP | GO:1901163 | regulation of trophoblast cell migration | 1 | 12 | 8.45e-01 |
| GO:BP | GO:0045988 | negative regulation of striated muscle contraction | 1 | 7 | 8.45e-01 |
| GO:BP | GO:0002712 | regulation of B cell mediated immunity | 1 | 39 | 8.45e-01 |
| GO:BP | GO:0002889 | regulation of immunoglobulin mediated immune response | 1 | 39 | 8.45e-01 |
| GO:BP | GO:0031061 | negative regulation of histone methylation | 1 | 9 | 8.45e-01 |
| GO:BP | GO:0050731 | positive regulation of peptidyl-tyrosine phosphorylation | 1 | 105 | 8.46e-01 |
| GO:BP | GO:0034698 | response to gonadotropin | 4 | 19 | 8.46e-01 |
| GO:BP | GO:0014074 | response to purine-containing compound | 6 | 108 | 8.46e-01 |
| GO:BP | GO:0071312 | cellular response to alkaloid | 3 | 29 | 8.46e-01 |
| GO:BP | GO:1903044 | protein localization to membrane raft | 1 | 8 | 8.46e-01 |
| GO:BP | GO:0035592 | establishment of protein localization to extracellular region | 6 | 262 | 8.46e-01 |
| GO:BP | GO:0097104 | postsynaptic membrane assembly | 1 | 8 | 8.47e-01 |
| GO:BP | GO:0010950 | positive regulation of endopeptidase activity | 16 | 126 | 8.47e-01 |
| GO:BP | GO:0032104 | regulation of response to extracellular stimulus | 2 | 19 | 8.47e-01 |
| GO:BP | GO:0032107 | regulation of response to nutrient levels | 2 | 19 | 8.47e-01 |
| GO:BP | GO:0097105 | presynaptic membrane assembly | 1 | 8 | 8.47e-01 |
| GO:BP | GO:0010831 | positive regulation of myotube differentiation | 1 | 10 | 8.47e-01 |
| GO:BP | GO:0042363 | fat-soluble vitamin catabolic process | 1 | 1 | 8.47e-01 |
| GO:BP | GO:0010604 | positive regulation of macromolecule metabolic process | 1 | 2646 | 8.47e-01 |
| GO:BP | GO:0002784 | regulation of antimicrobial peptide production | 1 | 1 | 8.47e-01 |
| GO:BP | GO:1902571 | regulation of serine-type peptidase activity | 1 | 4 | 8.47e-01 |
| GO:BP | GO:1903522 | regulation of blood circulation | 3 | 198 | 8.47e-01 |
| GO:BP | GO:0045833 | negative regulation of lipid metabolic process | 7 | 72 | 8.47e-01 |
| GO:BP | GO:0002778 | antibacterial peptide production | 1 | 1 | 8.47e-01 |
| GO:BP | GO:0046633 | alpha-beta T cell proliferation | 1 | 24 | 8.47e-01 |
| GO:BP | GO:1900003 | regulation of serine-type endopeptidase activity | 1 | 4 | 8.47e-01 |
| GO:BP | GO:0002424 | T cell mediated immune response to tumor cell | 1 | 6 | 8.47e-01 |
| GO:BP | GO:1905150 | regulation of voltage-gated sodium channel activity | 1 | 6 | 8.47e-01 |
| GO:BP | GO:0097107 | postsynaptic density assembly | 3 | 16 | 8.48e-01 |
| GO:BP | GO:0016079 | synaptic vesicle exocytosis | 2 | 74 | 8.48e-01 |
| GO:BP | GO:0032611 | interleukin-1 beta production | 6 | 48 | 8.48e-01 |
| GO:BP | GO:0032651 | regulation of interleukin-1 beta production | 6 | 48 | 8.48e-01 |
| GO:BP | GO:0052548 | regulation of endopeptidase activity | 1 | 232 | 8.48e-01 |
| GO:BP | GO:0032351 | negative regulation of hormone metabolic process | 1 | 10 | 8.49e-01 |
| GO:BP | GO:0006705 | mineralocorticoid biosynthetic process | 1 | 9 | 8.49e-01 |
| GO:BP | GO:0034650 | cortisol metabolic process | 1 | 9 | 8.49e-01 |
| GO:BP | GO:0003015 | heart process | 3 | 216 | 8.49e-01 |
| GO:BP | GO:0120192 | tight junction assembly | 1 | 47 | 8.49e-01 |
| GO:BP | GO:0007568 | aging | 12 | 115 | 8.49e-01 |
| GO:BP | GO:0002704 | negative regulation of leukocyte mediated immunity | 1 | 28 | 8.49e-01 |
| GO:BP | GO:0043376 | regulation of CD8-positive, alpha-beta T cell differentiation | 1 | 5 | 8.49e-01 |
| GO:BP | GO:0070172 | positive regulation of tooth mineralization | 1 | 2 | 8.49e-01 |
| GO:BP | GO:0106027 | neuron projection organization | 11 | 76 | 8.49e-01 |
| GO:BP | GO:0008643 | carbohydrate transport | 19 | 111 | 8.49e-01 |
| GO:BP | GO:0045056 | transcytosis | 1 | 17 | 8.49e-01 |
| GO:BP | GO:0031268 | pseudopodium organization | 1 | 14 | 8.49e-01 |
| GO:BP | GO:0045892 | negative regulation of DNA-templated transcription | 1 | 1015 | 8.50e-01 |
| GO:BP | GO:0046883 | regulation of hormone secretion | 4 | 168 | 8.50e-01 |
| GO:BP | GO:0048241 | epinephrine transport | 1 | 4 | 8.50e-01 |
| GO:BP | GO:0050771 | negative regulation of axonogenesis | 3 | 58 | 8.50e-01 |
| GO:BP | GO:0097048 | dendritic cell apoptotic process | 1 | 7 | 8.50e-01 |
| GO:BP | GO:2000668 | regulation of dendritic cell apoptotic process | 1 | 7 | 8.50e-01 |
| GO:BP | GO:2000272 | negative regulation of signaling receptor activity | 3 | 33 | 8.50e-01 |
| GO:BP | GO:0006140 | regulation of nucleotide metabolic process | 6 | 40 | 8.50e-01 |
| GO:BP | GO:2000107 | negative regulation of leukocyte apoptotic process | 1 | 33 | 8.50e-01 |
| GO:BP | GO:1903507 | negative regulation of nucleic acid-templated transcription | 1 | 1017 | 8.50e-01 |
| GO:BP | GO:1904424 | regulation of GTP binding | 2 | 16 | 8.50e-01 |
| GO:BP | GO:0003190 | atrioventricular valve formation | 1 | 8 | 8.50e-01 |
| GO:BP | GO:0061744 | motor behavior | 2 | 17 | 8.52e-01 |
| GO:BP | GO:0016070 | RNA metabolic process | 2 | 3600 | 8.52e-01 |
| GO:BP | GO:0009628 | response to abiotic stimulus | 1 | 868 | 8.52e-01 |
| GO:BP | GO:0014012 | peripheral nervous system axon regeneration | 1 | 6 | 8.52e-01 |
| GO:BP | GO:0120255 | olefinic compound biosynthetic process | 2 | 17 | 8.52e-01 |
| GO:BP | GO:0035050 | embryonic heart tube development | 4 | 69 | 8.52e-01 |
| GO:BP | GO:0070232 | regulation of T cell apoptotic process | 4 | 24 | 8.52e-01 |
| GO:BP | GO:0048513 | animal organ development | 4 | 2189 | 8.52e-01 |
| GO:BP | GO:0045110 | intermediate filament bundle assembly | 1 | 6 | 8.52e-01 |
| GO:BP | GO:0051602 | response to electrical stimulus | 6 | 26 | 8.52e-01 |
| GO:BP | GO:0009142 | nucleoside triphosphate biosynthetic process | 2 | 111 | 8.52e-01 |
| GO:BP | GO:0101023 | vascular endothelial cell proliferation | 1 | 21 | 8.52e-01 |
| GO:BP | GO:1905562 | regulation of vascular endothelial cell proliferation | 1 | 21 | 8.52e-01 |
| GO:BP | GO:0035754 | B cell chemotaxis | 1 | 5 | 8.52e-01 |
| GO:BP | GO:0060008 | Sertoli cell differentiation | 1 | 15 | 8.52e-01 |
| GO:BP | GO:1903508 | positive regulation of nucleic acid-templated transcription | 139 | 1315 | 8.52e-01 |
| GO:BP | GO:0045893 | positive regulation of DNA-templated transcription | 139 | 1315 | 8.52e-01 |
| GO:BP | GO:1902679 | negative regulation of RNA biosynthetic process | 1 | 1026 | 8.52e-01 |
| GO:BP | GO:0007320 | insemination | 1 | 5 | 8.53e-01 |
| GO:BP | GO:0070200 | establishment of protein localization to telomere | 2 | 16 | 8.53e-01 |
| GO:BP | GO:0048841 | regulation of axon extension involved in axon guidance | 4 | 31 | 8.53e-01 |
| GO:BP | GO:0009070 | serine family amino acid biosynthetic process | 1 | 16 | 8.53e-01 |
| GO:BP | GO:0051560 | mitochondrial calcium ion homeostasis | 3 | 23 | 8.53e-01 |
| GO:BP | GO:0033601 | positive regulation of mammary gland epithelial cell proliferation | 1 | 7 | 8.53e-01 |
| GO:BP | GO:0050789 | regulation of biological process | 4 | 8061 | 8.53e-01 |
| GO:BP | GO:0014820 | tonic smooth muscle contraction | 1 | 8 | 8.54e-01 |
| GO:BP | GO:0007351 | tripartite regional subdivision | 2 | 10 | 8.54e-01 |
| GO:BP | GO:0071875 | adrenergic receptor signaling pathway | 4 | 24 | 8.54e-01 |
| GO:BP | GO:1903077 | negative regulation of protein localization to plasma membrane | 2 | 21 | 8.54e-01 |
| GO:BP | GO:0008595 | anterior/posterior axis specification, embryo | 2 | 10 | 8.54e-01 |
| GO:BP | GO:0021553 | olfactory nerve development | 1 | 5 | 8.54e-01 |
| GO:BP | GO:0060872 | semicircular canal development | 1 | 7 | 8.54e-01 |
| GO:BP | GO:0030510 | regulation of BMP signaling pathway | 4 | 84 | 8.54e-01 |
| GO:BP | GO:0045773 | positive regulation of axon extension | 5 | 33 | 8.54e-01 |
| GO:BP | GO:0043281 | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 20 | 155 | 8.54e-01 |
| GO:BP | GO:1901654 | response to ketone | 10 | 147 | 8.54e-01 |
| GO:BP | GO:0097154 | GABAergic neuron differentiation | 1 | 5 | 8.54e-01 |
| GO:BP | GO:0050905 | neuromuscular process | 10 | 107 | 8.54e-01 |
| GO:BP | GO:0002758 | innate immune response-activating signaling pathway | 7 | 122 | 8.54e-01 |
| GO:BP | GO:0043416 | regulation of skeletal muscle tissue regeneration | 1 | 5 | 8.54e-01 |
| GO:BP | GO:0003006 | developmental process involved in reproduction | 2 | 598 | 8.55e-01 |
| GO:BP | GO:0070193 | synaptonemal complex organization | 1 | 13 | 8.55e-01 |
| GO:BP | GO:0043403 | skeletal muscle tissue regeneration | 5 | 31 | 8.55e-01 |
| GO:BP | GO:0062098 | regulation of programmed necrotic cell death | 1 | 26 | 8.56e-01 |
| GO:BP | GO:0071692 | protein localization to extracellular region | 6 | 266 | 8.56e-01 |
| GO:BP | GO:1905907 | negative regulation of amyloid fibril formation | 1 | 10 | 8.56e-01 |
| GO:BP | GO:0015807 | L-amino acid transport | 3 | 65 | 8.56e-01 |
| GO:BP | GO:0021940 | positive regulation of cerebellar granule cell precursor proliferation | 1 | 6 | 8.56e-01 |
| GO:BP | GO:0048002 | antigen processing and presentation of peptide antigen | 2 | 41 | 8.56e-01 |
| GO:BP | GO:0070327 | thyroid hormone transport | 1 | 7 | 8.56e-01 |
| GO:BP | GO:0006688 | glycosphingolipid biosynthetic process | 2 | 25 | 8.56e-01 |
| GO:BP | GO:0031018 | endocrine pancreas development | 2 | 32 | 8.56e-01 |
| GO:BP | GO:1902667 | regulation of axon guidance | 1 | 6 | 8.56e-01 |
| GO:BP | GO:0033206 | meiotic cytokinesis | 1 | 7 | 8.56e-01 |
| GO:BP | GO:0030854 | positive regulation of granulocyte differentiation | 1 | 5 | 8.56e-01 |
| GO:BP | GO:0071222 | cellular response to lipopolysaccharide | 5 | 110 | 8.56e-01 |
| GO:BP | GO:0030853 | negative regulation of granulocyte differentiation | 1 | 6 | 8.56e-01 |
| GO:BP | GO:2000136 | regulation of cell proliferation involved in heart morphogenesis | 1 | 17 | 8.56e-01 |
| GO:BP | GO:0061036 | positive regulation of cartilage development | 3 | 25 | 8.56e-01 |
| GO:BP | GO:0002523 | leukocyte migration involved in inflammatory response | 1 | 9 | 8.56e-01 |
| GO:BP | GO:0019372 | lipoxygenase pathway | 1 | 5 | 8.57e-01 |
| GO:BP | GO:0006825 | copper ion transport | 2 | 13 | 8.57e-01 |
| GO:BP | GO:0071415 | cellular response to purine-containing compound | 1 | 11 | 8.57e-01 |
| GO:BP | GO:0001675 | acrosome assembly | 3 | 16 | 8.57e-01 |
| GO:BP | GO:0019674 | NAD metabolic process | 1 | 33 | 8.57e-01 |
| GO:BP | GO:0048745 | smooth muscle tissue development | 3 | 19 | 8.58e-01 |
| GO:BP | GO:0071468 | cellular response to acidic pH | 1 | 10 | 8.59e-01 |
| GO:BP | GO:0061450 | trophoblast cell migration | 1 | 13 | 8.59e-01 |
| GO:BP | GO:0050808 | synapse organization | 2 | 365 | 8.59e-01 |
| GO:BP | GO:0045023 | G0 to G1 transition | 5 | 35 | 8.59e-01 |
| GO:BP | GO:0007494 | midgut development | 1 | 7 | 8.59e-01 |
| GO:BP | GO:0021889 | olfactory bulb interneuron differentiation | 1 | 7 | 8.59e-01 |
| GO:BP | GO:0051241 | negative regulation of multicellular organismal process | 1 | 748 | 8.59e-01 |
| GO:BP | GO:0060669 | embryonic placenta morphogenesis | 1 | 22 | 8.59e-01 |
| GO:BP | GO:0003139 | secondary heart field specification | 1 | 10 | 8.59e-01 |
| GO:BP | GO:1903748 | negative regulation of establishment of protein localization to mitochondrion | 1 | 5 | 8.59e-01 |
| GO:BP | GO:0051258 | protein polymerization | 11 | 241 | 8.59e-01 |
| GO:BP | GO:0048570 | notochord morphogenesis | 1 | 9 | 8.59e-01 |
| GO:BP | GO:0120193 | tight junction organization | 3 | 52 | 8.59e-01 |
| GO:BP | GO:0002335 | mature B cell differentiation | 1 | 21 | 8.59e-01 |
| GO:BP | GO:0090280 | positive regulation of calcium ion import | 1 | 11 | 8.59e-01 |
| GO:BP | GO:0034699 | response to luteinizing hormone | 1 | 7 | 8.59e-01 |
| GO:BP | GO:0050860 | negative regulation of T cell receptor signaling pathway | 3 | 17 | 8.59e-01 |
| GO:BP | GO:0050650 | chondroitin sulfate proteoglycan biosynthetic process | 1 | 20 | 8.59e-01 |
| GO:BP | GO:0048070 | regulation of developmental pigmentation | 1 | 11 | 8.59e-01 |
| GO:BP | GO:0120305 | regulation of pigmentation | 1 | 11 | 8.59e-01 |
| GO:BP | GO:0006702 | androgen biosynthetic process | 1 | 4 | 8.59e-01 |
| GO:BP | GO:0050807 | regulation of synapse organization | 1 | 184 | 8.60e-01 |
| GO:BP | GO:0072089 | stem cell proliferation | 5 | 84 | 8.60e-01 |
| GO:BP | GO:0010739 | positive regulation of protein kinase A signaling | 1 | 6 | 8.60e-01 |
| GO:BP | GO:0061052 | negative regulation of cell growth involved in cardiac muscle cell development | 1 | 10 | 8.61e-01 |
| GO:BP | GO:0043568 | positive regulation of insulin-like growth factor receptor signaling pathway | 1 | 8 | 8.61e-01 |
| GO:BP | GO:1902224 | ketone body metabolic process | 1 | 7 | 8.61e-01 |
| GO:BP | GO:0021772 | olfactory bulb development | 2 | 19 | 8.62e-01 |
| GO:BP | GO:0090276 | regulation of peptide hormone secretion | 3 | 132 | 8.62e-01 |
| GO:BP | GO:0051235 | maintenance of location | 6 | 260 | 8.62e-01 |
| GO:BP | GO:0046794 | transport of virus | 1 | 19 | 8.62e-01 |
| GO:BP | GO:0045835 | negative regulation of meiotic nuclear division | 1 | 5 | 8.62e-01 |
| GO:BP | GO:0032732 | positive regulation of interleukin-1 production | 1 | 35 | 8.62e-01 |
| GO:BP | GO:0015812 | gamma-aminobutyric acid transport | 1 | 11 | 8.62e-01 |
| GO:BP | GO:0002691 | regulation of cellular extravasation | 1 | 24 | 8.62e-01 |
| GO:BP | GO:0002232 | leukocyte chemotaxis involved in inflammatory response | 1 | 4 | 8.62e-01 |
| GO:BP | GO:0120033 | negative regulation of plasma membrane bounded cell projection assembly | 1 | 28 | 8.62e-01 |
| GO:BP | GO:1903059 | regulation of protein lipidation | 1 | 11 | 8.62e-01 |
| GO:BP | GO:1902259 | regulation of delayed rectifier potassium channel activity | 1 | 12 | 8.62e-01 |
| GO:BP | GO:0048645 | animal organ formation | 1 | 51 | 8.62e-01 |
| GO:BP | GO:0034695 | response to prostaglandin E | 1 | 17 | 8.62e-01 |
| GO:BP | GO:0016358 | dendrite development | 1 | 202 | 8.63e-01 |
| GO:BP | GO:0006970 | response to osmotic stress | 6 | 67 | 8.63e-01 |
| GO:BP | GO:0044344 | cellular response to fibroblast growth factor stimulus | 4 | 81 | 8.63e-01 |
| GO:BP | GO:1905821 | positive regulation of chromosome condensation | 1 | 8 | 8.63e-01 |
| GO:BP | GO:0006298 | mismatch repair | 3 | 29 | 8.63e-01 |
| GO:BP | GO:0034134 | toll-like receptor 2 signaling pathway | 2 | 11 | 8.63e-01 |
| GO:BP | GO:1904645 | response to amyloid-beta | 2 | 32 | 8.63e-01 |
| GO:BP | GO:0030808 | regulation of nucleotide biosynthetic process | 4 | 25 | 8.63e-01 |
| GO:BP | GO:1900181 | negative regulation of protein localization to nucleus | 4 | 28 | 8.63e-01 |
| GO:BP | GO:0061154 | endothelial tube morphogenesis | 2 | 14 | 8.63e-01 |
| GO:BP | GO:0003159 | morphogenesis of an endothelium | 2 | 14 | 8.63e-01 |
| GO:BP | GO:1900371 | regulation of purine nucleotide biosynthetic process | 4 | 25 | 8.63e-01 |
| GO:BP | GO:0051253 | negative regulation of RNA metabolic process | 6 | 1119 | 8.63e-01 |
| GO:BP | GO:0002021 | response to dietary excess | 1 | 22 | 8.63e-01 |
| GO:BP | GO:0021814 | cell motility involved in cerebral cortex radial glia guided migration | 1 | 7 | 8.63e-01 |
| GO:BP | GO:0002431 | Fc receptor mediated stimulatory signaling pathway | 1 | 24 | 8.63e-01 |
| GO:BP | GO:0032946 | positive regulation of mononuclear cell proliferation | 1 | 75 | 8.63e-01 |
| GO:BP | GO:0086012 | membrane depolarization during cardiac muscle cell action potential | 2 | 21 | 8.63e-01 |
| GO:BP | GO:0034356 | NAD biosynthesis via nicotinamide riboside salvage pathway | 1 | 8 | 8.64e-01 |
| GO:BP | GO:0051155 | positive regulation of striated muscle cell differentiation | 3 | 31 | 8.64e-01 |
| GO:BP | GO:0071711 | basement membrane organization | 1 | 33 | 8.64e-01 |
| GO:BP | GO:0010998 | regulation of translational initiation by eIF2 alpha phosphorylation | 1 | 11 | 8.64e-01 |
| GO:BP | GO:0036490 | regulation of translation in response to endoplasmic reticulum stress | 1 | 11 | 8.64e-01 |
| GO:BP | GO:0071168 | protein localization to chromatin | 7 | 48 | 8.64e-01 |
| GO:BP | GO:0099560 | synaptic membrane adhesion | 3 | 22 | 8.64e-01 |
| GO:BP | GO:0021978 | telencephalon regionalization | 1 | 4 | 8.64e-01 |
| GO:BP | GO:0032341 | aldosterone metabolic process | 1 | 10 | 8.64e-01 |
| GO:BP | GO:0070837 | dehydroascorbic acid transport | 1 | 6 | 8.64e-01 |
| GO:BP | GO:0002532 | production of molecular mediator involved in inflammatory response | 3 | 49 | 8.64e-01 |
| GO:BP | GO:1902416 | positive regulation of mRNA binding | 1 | 8 | 8.64e-01 |
| GO:BP | GO:0072239 | metanephric glomerulus vasculature development | 1 | 6 | 8.64e-01 |
| GO:BP | GO:0003097 | renal water transport | 1 | 6 | 8.64e-01 |
| GO:BP | GO:0009308 | amine metabolic process | 2 | 68 | 8.64e-01 |
| GO:BP | GO:0050803 | regulation of synapse structure or activity | 1 | 187 | 8.64e-01 |
| GO:BP | GO:0006534 | cysteine metabolic process | 1 | 11 | 8.65e-01 |
| GO:BP | GO:0010623 | programmed cell death involved in cell development | 2 | 13 | 8.65e-01 |
| GO:BP | GO:0032088 | negative regulation of NF-kappaB transcription factor activity | 2 | 66 | 8.65e-01 |
| GO:BP | GO:0030901 | midbrain development | 3 | 69 | 8.65e-01 |
| GO:BP | GO:0000122 | negative regulation of transcription by RNA polymerase II | 6 | 740 | 8.65e-01 |
| GO:BP | GO:0098976 | excitatory chemical synaptic transmission | 1 | 6 | 8.65e-01 |
| GO:BP | GO:0046035 | CMP metabolic process | 1 | 6 | 8.65e-01 |
| GO:BP | GO:0097090 | presynaptic membrane organization | 1 | 8 | 8.66e-01 |
| GO:BP | GO:0045161 | neuronal ion channel clustering | 1 | 8 | 8.66e-01 |
| GO:BP | GO:0002687 | positive regulation of leukocyte migration | 1 | 84 | 8.66e-01 |
| GO:BP | GO:0010557 | positive regulation of macromolecule biosynthetic process | 36 | 1507 | 8.66e-01 |
| GO:BP | GO:0060675 | ureteric bud morphogenesis | 3 | 49 | 8.67e-01 |
| GO:BP | GO:2000651 | positive regulation of sodium ion transmembrane transporter activity | 1 | 14 | 8.67e-01 |
| GO:BP | GO:0009893 | positive regulation of metabolic process | 1 | 2880 | 8.67e-01 |
| GO:BP | GO:0030100 | regulation of endocytosis | 12 | 211 | 8.67e-01 |
| GO:BP | GO:0030218 | erythrocyte differentiation | 1 | 107 | 8.67e-01 |
| GO:BP | GO:1902018 | negative regulation of cilium assembly | 1 | 15 | 8.67e-01 |
| GO:BP | GO:0032103 | positive regulation of response to external stimulus | 4 | 337 | 8.67e-01 |
| GO:BP | GO:0006869 | lipid transport | 1 | 272 | 8.67e-01 |
| GO:BP | GO:0061323 | cell proliferation involved in heart morphogenesis | 1 | 18 | 8.67e-01 |
| GO:BP | GO:0034763 | negative regulation of transmembrane transport | 2 | 96 | 8.67e-01 |
| GO:BP | GO:0007154 | cell communication | 7 | 4226 | 8.68e-01 |
| GO:BP | GO:0044828 | negative regulation by host of viral genome replication | 1 | 7 | 8.68e-01 |
| GO:BP | GO:0050709 | negative regulation of protein secretion | 2 | 44 | 8.68e-01 |
| GO:BP | GO:0031016 | pancreas development | 2 | 53 | 8.69e-01 |
| GO:BP | GO:0035067 | negative regulation of histone acetylation | 1 | 9 | 8.69e-01 |
| GO:BP | GO:0007189 | adenylate cyclase-activating G protein-coupled receptor signaling pathway | 1 | 78 | 8.69e-01 |
| GO:BP | GO:2001135 | regulation of endocytic recycling | 2 | 17 | 8.69e-01 |
| GO:BP | GO:0051260 | protein homooligomerization | 15 | 136 | 8.69e-01 |
| GO:BP | GO:0046887 | positive regulation of hormone secretion | 2 | 90 | 8.70e-01 |
| GO:BP | GO:0045836 | positive regulation of meiotic nuclear division | 2 | 9 | 8.70e-01 |
| GO:BP | GO:0038094 | Fc-gamma receptor signaling pathway | 1 | 20 | 8.70e-01 |
| GO:BP | GO:0060706 | cell differentiation involved in embryonic placenta development | 1 | 20 | 8.70e-01 |
| GO:BP | GO:0072170 | metanephric tubule development | 1 | 15 | 8.70e-01 |
| GO:BP | GO:0072243 | metanephric nephron epithelium development | 1 | 15 | 8.70e-01 |
| GO:BP | GO:2000114 | regulation of establishment of cell polarity | 3 | 22 | 8.71e-01 |
| GO:BP | GO:1902003 | regulation of amyloid-beta formation | 2 | 33 | 8.71e-01 |
| GO:BP | GO:0031328 | positive regulation of cellular biosynthetic process | 162 | 1564 | 8.71e-01 |
| GO:BP | GO:0035176 | social behavior | 3 | 34 | 8.71e-01 |
| GO:BP | GO:0055088 | lipid homeostasis | 4 | 115 | 8.71e-01 |
| GO:BP | GO:0043154 | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 4 | 59 | 8.71e-01 |
| GO:BP | GO:0009206 | purine ribonucleoside triphosphate biosynthetic process | 1 | 96 | 8.71e-01 |
| GO:BP | GO:0009069 | serine family amino acid metabolic process | 2 | 30 | 8.71e-01 |
| GO:BP | GO:0021695 | cerebellar cortex development | 1 | 44 | 8.72e-01 |
| GO:BP | GO:0031000 | response to caffeine | 1 | 13 | 8.72e-01 |
| GO:BP | GO:0048268 | clathrin coat assembly | 1 | 13 | 8.72e-01 |
| GO:BP | GO:0061820 | telomeric D-loop disassembly | 1 | 8 | 8.72e-01 |
| GO:BP | GO:0046549 | retinal cone cell development | 1 | 5 | 8.72e-01 |
| GO:BP | GO:0034330 | cell junction organization | 6 | 575 | 8.72e-01 |
| GO:BP | GO:0006188 | IMP biosynthetic process | 1 | 10 | 8.72e-01 |
| GO:BP | GO:0007253 | cytoplasmic sequestering of NF-kappaB | 1 | 7 | 8.72e-01 |
| GO:BP | GO:0072171 | mesonephric tubule morphogenesis | 3 | 50 | 8.72e-01 |
| GO:BP | GO:0007129 | homologous chromosome pairing at meiosis | 3 | 24 | 8.73e-01 |
| GO:BP | GO:0043271 | negative regulation of monoatomic ion transport | 2 | 90 | 8.73e-01 |
| GO:BP | GO:0055062 | phosphate ion homeostasis | 1 | 8 | 8.73e-01 |
| GO:BP | GO:0030011 | maintenance of cell polarity | 1 | 16 | 8.73e-01 |
| GO:BP | GO:0071071 | regulation of phospholipid biosynthetic process | 2 | 15 | 8.73e-01 |
| GO:BP | GO:0007520 | myoblast fusion | 4 | 30 | 8.73e-01 |
| GO:BP | GO:0048546 | digestive tract morphogenesis | 2 | 31 | 8.73e-01 |
| GO:BP | GO:0009584 | detection of visible light | 1 | 20 | 8.73e-01 |
| GO:BP | GO:0019222 | regulation of metabolic process | 2 | 5017 | 8.73e-01 |
| GO:BP | GO:0048639 | positive regulation of developmental growth | 3 | 124 | 8.73e-01 |
| GO:BP | GO:0019953 | sexual reproduction | 5 | 631 | 8.73e-01 |
| GO:BP | GO:0036474 | cell death in response to hydrogen peroxide | 2 | 23 | 8.73e-01 |
| GO:BP | GO:0070934 | CRD-mediated mRNA stabilization | 1 | 11 | 8.73e-01 |
| GO:BP | GO:0045954 | positive regulation of natural killer cell mediated cytotoxicity | 1 | 10 | 8.74e-01 |
| GO:BP | GO:0007603 | phototransduction, visible light | 1 | 9 | 8.74e-01 |
| GO:BP | GO:0051145 | smooth muscle cell differentiation | 3 | 54 | 8.74e-01 |
| GO:BP | GO:1901722 | regulation of cell proliferation involved in kidney development | 1 | 11 | 8.74e-01 |
| GO:BP | GO:0048667 | cell morphogenesis involved in neuron differentiation | 1 | 463 | 8.74e-01 |
| GO:BP | GO:0048799 | animal organ maturation | 3 | 20 | 8.74e-01 |
| GO:BP | GO:0051928 | positive regulation of calcium ion transport | 2 | 82 | 8.74e-01 |
| GO:BP | GO:0048617 | embryonic foregut morphogenesis | 1 | 6 | 8.74e-01 |
| GO:BP | GO:1903055 | positive regulation of extracellular matrix organization | 2 | 24 | 8.74e-01 |
| GO:BP | GO:0010894 | negative regulation of steroid biosynthetic process | 2 | 18 | 8.74e-01 |
| GO:BP | GO:0010269 | response to selenium ion | 1 | 8 | 8.74e-01 |
| GO:BP | GO:0097106 | postsynaptic density organization | 5 | 30 | 8.74e-01 |
| GO:BP | GO:0070782 | phosphatidylserine exposure on apoptotic cell surface | 1 | 3 | 8.74e-01 |
| GO:BP | GO:0090281 | negative regulation of calcium ion import | 1 | 6 | 8.74e-01 |
| GO:BP | GO:0006517 | protein deglycosylation | 2 | 25 | 8.75e-01 |
| GO:BP | GO:0043954 | cellular component maintenance | 7 | 59 | 8.75e-01 |
| GO:BP | GO:0010565 | regulation of cellular ketone metabolic process | 7 | 98 | 8.75e-01 |
| GO:BP | GO:0033700 | phospholipid efflux | 1 | 9 | 8.75e-01 |
| GO:BP | GO:0006527 | arginine catabolic process | 1 | 7 | 8.75e-01 |
| GO:BP | GO:0010738 | regulation of protein kinase A signaling | 2 | 13 | 8.75e-01 |
| GO:BP | GO:1902946 | protein localization to early endosome | 1 | 11 | 8.75e-01 |
| GO:BP | GO:0050856 | regulation of T cell receptor signaling pathway | 4 | 30 | 8.75e-01 |
| GO:BP | GO:0072677 | eosinophil migration | 1 | 7 | 8.75e-01 |
| GO:BP | GO:0048754 | branching morphogenesis of an epithelial tube | 1 | 121 | 8.75e-01 |
| GO:BP | GO:0042989 | sequestering of actin monomers | 1 | 9 | 8.75e-01 |
| GO:BP | GO:0071219 | cellular response to molecule of bacterial origin | 5 | 114 | 8.75e-01 |
| GO:BP | GO:0048731 | system development | 1 | 2901 | 8.75e-01 |
| GO:BP | GO:0009111 | vitamin catabolic process | 1 | 3 | 8.75e-01 |
| GO:BP | GO:0032959 | inositol trisphosphate biosynthetic process | 1 | 6 | 8.75e-01 |
| GO:BP | GO:0046942 | carboxylic acid transport | 4 | 216 | 8.75e-01 |
| GO:BP | GO:0002315 | marginal zone B cell differentiation | 1 | 6 | 8.75e-01 |
| GO:BP | GO:1905165 | regulation of lysosomal protein catabolic process | 1 | 11 | 8.75e-01 |
| GO:BP | GO:0002534 | cytokine production involved in inflammatory response | 2 | 33 | 8.75e-01 |
| GO:BP | GO:0046683 | response to organophosphorus | 5 | 96 | 8.75e-01 |
| GO:BP | GO:1900015 | regulation of cytokine production involved in inflammatory response | 2 | 33 | 8.75e-01 |
| GO:BP | GO:0051923 | sulfation | 1 | 13 | 8.75e-01 |
| GO:BP | GO:0060601 | lateral sprouting from an epithelium | 1 | 10 | 8.75e-01 |
| GO:BP | GO:1905809 | negative regulation of synapse organization | 1 | 8 | 8.75e-01 |
| GO:BP | GO:0000302 | response to reactive oxygen species | 12 | 160 | 8.75e-01 |
| GO:BP | GO:1904376 | negative regulation of protein localization to cell periphery | 2 | 23 | 8.75e-01 |
| GO:BP | GO:0031670 | cellular response to nutrient | 1 | 31 | 8.75e-01 |
| GO:BP | GO:0061549 | sympathetic ganglion development | 1 | 6 | 8.75e-01 |
| GO:BP | GO:0031282 | regulation of guanylate cyclase activity | 1 | 3 | 8.76e-01 |
| GO:BP | GO:0019233 | sensory perception of pain | 1 | 48 | 8.76e-01 |
| GO:BP | GO:0048583 | regulation of response to stimulus | 1 | 2890 | 8.76e-01 |
| GO:BP | GO:0071404 | cellular response to low-density lipoprotein particle stimulus | 1 | 19 | 8.76e-01 |
| GO:BP | GO:0030277 | maintenance of gastrointestinal epithelium | 2 | 8 | 8.76e-01 |
| GO:BP | GO:0031579 | membrane raft organization | 1 | 19 | 8.76e-01 |
| GO:BP | GO:0007213 | G protein-coupled acetylcholine receptor signaling pathway | 1 | 14 | 8.76e-01 |
| GO:BP | GO:0015849 | organic acid transport | 4 | 217 | 8.76e-01 |
| GO:BP | GO:1905954 | positive regulation of lipid localization | 2 | 75 | 8.76e-01 |
| GO:BP | GO:0021988 | olfactory lobe development | 2 | 21 | 8.77e-01 |
| GO:BP | GO:0010952 | positive regulation of peptidase activity | 1 | 135 | 8.77e-01 |
| GO:BP | GO:0071225 | cellular response to muramyl dipeptide | 1 | 7 | 8.77e-01 |
| GO:BP | GO:0002645 | positive regulation of tolerance induction | 1 | 6 | 8.78e-01 |
| GO:BP | GO:0035249 | synaptic transmission, glutamatergic | 1 | 64 | 8.78e-01 |
| GO:BP | GO:0043266 | regulation of potassium ion transport | 1 | 73 | 8.78e-01 |
| GO:BP | GO:0048638 | regulation of developmental growth | 15 | 258 | 8.78e-01 |
| GO:BP | GO:0060347 | heart trabecula formation | 1 | 13 | 8.78e-01 |
| GO:BP | GO:0042438 | melanin biosynthetic process | 2 | 17 | 8.78e-01 |
| GO:BP | GO:0035358 | regulation of peroxisome proliferator activated receptor signaling pathway | 1 | 11 | 8.79e-01 |
| GO:BP | GO:0008212 | mineralocorticoid metabolic process | 1 | 10 | 8.79e-01 |
| GO:BP | GO:0014829 | vascular associated smooth muscle contraction | 3 | 20 | 8.79e-01 |
| GO:BP | GO:0003207 | cardiac chamber formation | 1 | 14 | 8.79e-01 |
| GO:BP | GO:0070307 | lens fiber cell development | 1 | 11 | 8.79e-01 |
| GO:BP | GO:0002730 | regulation of dendritic cell cytokine production | 1 | 10 | 8.79e-01 |
| GO:BP | GO:1902476 | chloride transmembrane transport | 1 | 51 | 8.79e-01 |
| GO:BP | GO:0072102 | glomerulus morphogenesis | 1 | 7 | 8.79e-01 |
| GO:BP | GO:0034309 | primary alcohol biosynthetic process | 1 | 12 | 8.79e-01 |
| GO:BP | GO:0002371 | dendritic cell cytokine production | 1 | 10 | 8.79e-01 |
| GO:BP | GO:0070213 | protein auto-ADP-ribosylation | 1 | 11 | 8.79e-01 |
| GO:BP | GO:0051968 | positive regulation of synaptic transmission, glutamatergic | 4 | 20 | 8.80e-01 |
| GO:BP | GO:0009201 | ribonucleoside triphosphate biosynthetic process | 1 | 102 | 8.80e-01 |
| GO:BP | GO:0042060 | wound healing | 3 | 320 | 8.80e-01 |
| GO:BP | GO:0034101 | erythrocyte homeostasis | 1 | 114 | 8.80e-01 |
| GO:BP | GO:0003176 | aortic valve development | 1 | 37 | 8.80e-01 |
| GO:BP | GO:0006285 | base-excision repair, AP site formation | 1 | 12 | 8.80e-01 |
| GO:BP | GO:0050667 | homocysteine metabolic process | 1 | 11 | 8.81e-01 |
| GO:BP | GO:0034377 | plasma lipoprotein particle assembly | 2 | 19 | 8.81e-01 |
| GO:BP | GO:0003056 | regulation of vascular associated smooth muscle contraction | 1 | 8 | 8.81e-01 |
| GO:BP | GO:0050966 | detection of mechanical stimulus involved in sensory perception of pain | 1 | 8 | 8.81e-01 |
| GO:BP | GO:0035988 | chondrocyte proliferation | 3 | 18 | 8.81e-01 |
| GO:BP | GO:0001508 | action potential | 1 | 105 | 8.81e-01 |
| GO:BP | GO:0043299 | leukocyte degranulation | 2 | 41 | 8.81e-01 |
| GO:BP | GO:1902894 | negative regulation of miRNA transcription | 1 | 19 | 8.81e-01 |
| GO:BP | GO:0007274 | neuromuscular synaptic transmission | 3 | 14 | 8.82e-01 |
| GO:BP | GO:0045730 | respiratory burst | 2 | 21 | 8.82e-01 |
| GO:BP | GO:0106072 | negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway | 1 | 8 | 8.82e-01 |
| GO:BP | GO:0060385 | axonogenesis involved in innervation | 1 | 7 | 8.82e-01 |
| GO:BP | GO:0070305 | response to cGMP | 1 | 7 | 8.82e-01 |
| GO:BP | GO:0038063 | collagen-activated tyrosine kinase receptor signaling pathway | 1 | 10 | 8.83e-01 |
| GO:BP | GO:0030520 | intracellular estrogen receptor signaling pathway | 6 | 41 | 8.83e-01 |
| GO:BP | GO:0051703 | biological process involved in intraspecies interaction between organisms | 3 | 34 | 8.83e-01 |
| GO:BP | GO:0090304 | nucleic acid metabolic process | 2 | 4048 | 8.83e-01 |
| GO:BP | GO:2000648 | positive regulation of stem cell proliferation | 2 | 31 | 8.83e-01 |
| GO:BP | GO:0055094 | response to lipoprotein particle | 1 | 20 | 8.84e-01 |
| GO:BP | GO:0010558 | negative regulation of macromolecule biosynthetic process | 1 | 1214 | 8.84e-01 |
| GO:BP | GO:1901977 | negative regulation of cell cycle checkpoint | 1 | 8 | 8.84e-01 |
| GO:BP | GO:0009611 | response to wounding | 4 | 415 | 8.84e-01 |
| GO:BP | GO:0050851 | antigen receptor-mediated signaling pathway | 1 | 106 | 8.84e-01 |
| GO:BP | GO:0048675 | axon extension | 17 | 110 | 8.84e-01 |
| GO:BP | GO:1903351 | cellular response to dopamine | 7 | 47 | 8.84e-01 |
| GO:BP | GO:0002467 | germinal center formation | 1 | 10 | 8.84e-01 |
| GO:BP | GO:0009159 | deoxyribonucleoside monophosphate catabolic process | 1 | 8 | 8.84e-01 |
| GO:BP | GO:1900225 | regulation of NLRP3 inflammasome complex assembly | 3 | 23 | 8.84e-01 |
| GO:BP | GO:0021544 | subpallium development | 1 | 18 | 8.84e-01 |
| GO:BP | GO:1903715 | regulation of aerobic respiration | 1 | 28 | 8.84e-01 |
| GO:BP | GO:1903203 | regulation of oxidative stress-induced neuron death | 1 | 25 | 8.84e-01 |
| GO:BP | GO:0070665 | positive regulation of leukocyte proliferation | 1 | 83 | 8.85e-01 |
| GO:BP | GO:0055085 | transmembrane transport | 1 | 998 | 8.86e-01 |
| GO:BP | GO:0099068 | postsynapse assembly | 5 | 32 | 8.86e-01 |
| GO:BP | GO:0019369 | arachidonic acid metabolic process | 1 | 26 | 8.86e-01 |
| GO:BP | GO:0019725 | cellular homeostasis | 1 | 569 | 8.86e-01 |
| GO:BP | GO:0051590 | positive regulation of neurotransmitter transport | 2 | 16 | 8.87e-01 |
| GO:BP | GO:0030261 | chromosome condensation | 2 | 33 | 8.87e-01 |
| GO:BP | GO:0040019 | positive regulation of embryonic development | 1 | 17 | 8.87e-01 |
| GO:BP | GO:0021536 | diencephalon development | 1 | 41 | 8.87e-01 |
| GO:BP | GO:0035384 | thioester biosynthetic process | 1 | 38 | 8.87e-01 |
| GO:BP | GO:0071616 | acyl-CoA biosynthetic process | 1 | 38 | 8.87e-01 |
| GO:BP | GO:0001832 | blastocyst growth | 1 | 19 | 8.87e-01 |
| GO:BP | GO:1990000 | amyloid fibril formation | 1 | 35 | 8.88e-01 |
| GO:BP | GO:0042670 | retinal cone cell differentiation | 1 | 6 | 8.88e-01 |
| GO:BP | GO:0060326 | cell chemotaxis | 2 | 162 | 8.88e-01 |
| GO:BP | GO:0031128 | developmental induction | 3 | 26 | 8.88e-01 |
| GO:BP | GO:0021700 | developmental maturation | 2 | 211 | 8.88e-01 |
| GO:BP | GO:2000479 | regulation of cAMP-dependent protein kinase activity | 2 | 16 | 8.88e-01 |
| GO:BP | GO:0002775 | antimicrobial peptide production | 1 | 1 | 8.88e-01 |
| GO:BP | GO:0006171 | cAMP biosynthetic process | 1 | 8 | 8.88e-01 |
| GO:BP | GO:1905216 | positive regulation of RNA binding | 1 | 9 | 8.88e-01 |
| GO:BP | GO:0006939 | smooth muscle contraction | 1 | 75 | 8.88e-01 |
| GO:BP | GO:0071774 | response to fibroblast growth factor | 4 | 84 | 8.88e-01 |
| GO:BP | GO:1903265 | positive regulation of tumor necrosis factor-mediated signaling pathway | 1 | 9 | 8.88e-01 |
| GO:BP | GO:0015755 | fructose transmembrane transport | 1 | 5 | 8.88e-01 |
| GO:BP | GO:1905634 | regulation of protein localization to chromatin | 1 | 8 | 8.88e-01 |
| GO:BP | GO:0035331 | negative regulation of hippo signaling | 1 | 12 | 8.89e-01 |
| GO:BP | GO:0048643 | positive regulation of skeletal muscle tissue development | 1 | 14 | 8.89e-01 |
| GO:BP | GO:0010876 | lipid localization | 1 | 310 | 8.89e-01 |
| GO:BP | GO:0090205 | positive regulation of cholesterol metabolic process | 1 | 12 | 8.89e-01 |
| GO:BP | GO:0033003 | regulation of mast cell activation | 1 | 25 | 8.89e-01 |
| GO:BP | GO:0031214 | biomineral tissue development | 1 | 111 | 8.89e-01 |
| GO:BP | GO:0031327 | negative regulation of cellular biosynthetic process | 1 | 1239 | 8.89e-01 |
| GO:BP | GO:0048568 | embryonic organ development | 1 | 316 | 8.89e-01 |
| GO:BP | GO:2000243 | positive regulation of reproductive process | 8 | 54 | 8.89e-01 |
| GO:BP | GO:0070936 | protein K48-linked ubiquitination | 3 | 66 | 8.89e-01 |
| GO:BP | GO:2000810 | regulation of bicellular tight junction assembly | 1 | 15 | 8.89e-01 |
| GO:BP | GO:0051153 | regulation of striated muscle cell differentiation | 4 | 67 | 8.90e-01 |
| GO:BP | GO:0002831 | regulation of response to biotic stimulus | 21 | 293 | 8.90e-01 |
| GO:BP | GO:1903350 | response to dopamine | 7 | 48 | 8.90e-01 |
| GO:BP | GO:0032288 | myelin assembly | 2 | 19 | 8.90e-01 |
| GO:BP | GO:0042987 | amyloid precursor protein catabolic process | 3 | 53 | 8.90e-01 |
| GO:BP | GO:0009086 | methionine biosynthetic process | 1 | 10 | 8.90e-01 |
| GO:BP | GO:0006582 | melanin metabolic process | 2 | 18 | 8.91e-01 |
| GO:BP | GO:0001759 | organ induction | 2 | 17 | 8.91e-01 |
| GO:BP | GO:0090103 | cochlea morphogenesis | 2 | 15 | 8.91e-01 |
| GO:BP | GO:0060159 | regulation of dopamine receptor signaling pathway | 1 | 7 | 8.91e-01 |
| GO:BP | GO:0010613 | positive regulation of cardiac muscle hypertrophy | 3 | 22 | 8.91e-01 |
| GO:BP | GO:0014049 | positive regulation of glutamate secretion | 1 | 4 | 8.91e-01 |
| GO:BP | GO:0010039 | response to iron ion | 1 | 24 | 8.91e-01 |
| GO:BP | GO:0043652 | engulfment of apoptotic cell | 2 | 11 | 8.91e-01 |
| GO:BP | GO:0010224 | response to UV-B | 2 | 17 | 8.91e-01 |
| GO:BP | GO:0044060 | regulation of endocrine process | 1 | 24 | 8.92e-01 |
| GO:BP | GO:0002062 | chondrocyte differentiation | 5 | 90 | 8.92e-01 |
| GO:BP | GO:0002520 | immune system development | 1 | 144 | 8.92e-01 |
| GO:BP | GO:0010996 | response to auditory stimulus | 1 | 16 | 8.92e-01 |
| GO:BP | GO:0070562 | regulation of vitamin D receptor signaling pathway | 1 | 9 | 8.93e-01 |
| GO:BP | GO:1903232 | melanosome assembly | 1 | 19 | 8.93e-01 |
| GO:BP | GO:0032655 | regulation of interleukin-12 production | 1 | 29 | 8.93e-01 |
| GO:BP | GO:0032615 | interleukin-12 production | 1 | 29 | 8.93e-01 |
| GO:BP | GO:0051254 | positive regulation of RNA metabolic process | 147 | 1441 | 8.93e-01 |
| GO:BP | GO:0052547 | regulation of peptidase activity | 1 | 271 | 8.93e-01 |
| GO:BP | GO:0042474 | middle ear morphogenesis | 1 | 13 | 8.94e-01 |
| GO:BP | GO:0030593 | neutrophil chemotaxis | 1 | 39 | 8.94e-01 |
| GO:BP | GO:0046879 | hormone secretion | 5 | 210 | 8.94e-01 |
| GO:BP | GO:0035188 | hatching | 2 | 23 | 8.94e-01 |
| GO:BP | GO:0032355 | response to estradiol | 3 | 83 | 8.94e-01 |
| GO:BP | GO:0001835 | blastocyst hatching | 2 | 23 | 8.94e-01 |
| GO:BP | GO:0071684 | organism emergence from protective structure | 2 | 23 | 8.94e-01 |
| GO:BP | GO:0006338 | chromatin remodeling | 4 | 378 | 8.94e-01 |
| GO:BP | GO:0001974 | blood vessel remodeling | 5 | 32 | 8.94e-01 |
| GO:BP | GO:0002664 | regulation of T cell tolerance induction | 1 | 6 | 8.94e-01 |
| GO:BP | GO:0035821 | modulation of process of another organism | 1 | 5 | 8.94e-01 |
| GO:BP | GO:0032966 | negative regulation of collagen biosynthetic process | 1 | 7 | 8.94e-01 |
| GO:BP | GO:0030154 | cell differentiation | 1 | 2958 | 8.94e-01 |
| GO:BP | GO:0070344 | regulation of fat cell proliferation | 1 | 9 | 8.94e-01 |
| GO:BP | GO:1900544 | positive regulation of purine nucleotide metabolic process | 2 | 16 | 8.94e-01 |
| GO:BP | GO:0045981 | positive regulation of nucleotide metabolic process | 2 | 16 | 8.94e-01 |
| GO:BP | GO:0009064 | glutamine family amino acid metabolic process | 1 | 60 | 8.95e-01 |
| GO:BP | GO:0001910 | regulation of leukocyte mediated cytotoxicity | 1 | 30 | 8.95e-01 |
| GO:BP | GO:0007440 | foregut morphogenesis | 1 | 7 | 8.95e-01 |
| GO:BP | GO:0060688 | regulation of morphogenesis of a branching structure | 2 | 36 | 8.96e-01 |
| GO:BP | GO:0021794 | thalamus development | 1 | 6 | 8.96e-01 |
| GO:BP | GO:0009890 | negative regulation of biosynthetic process | 1 | 1280 | 8.96e-01 |
| GO:BP | GO:0045346 | regulation of MHC class II biosynthetic process | 1 | 11 | 8.96e-01 |
| GO:BP | GO:0071872 | cellular response to epinephrine stimulus | 1 | 10 | 8.96e-01 |
| GO:BP | GO:0042447 | hormone catabolic process | 1 | 7 | 8.96e-01 |
| GO:BP | GO:0048869 | cellular developmental process | 1 | 2984 | 8.96e-01 |
| GO:BP | GO:0062012 | regulation of small molecule metabolic process | 10 | 246 | 8.96e-01 |
| GO:BP | GO:0042359 | vitamin D metabolic process | 1 | 9 | 8.97e-01 |
| GO:BP | GO:0051965 | positive regulation of synapse assembly | 1 | 44 | 8.97e-01 |
| GO:BP | GO:0071277 | cellular response to calcium ion | 1 | 67 | 8.97e-01 |
| GO:BP | GO:0097164 | ammonium ion metabolic process | 2 | 14 | 8.97e-01 |
| GO:BP | GO:0000904 | cell morphogenesis involved in differentiation | 1 | 516 | 8.97e-01 |
| GO:BP | GO:1901018 | positive regulation of potassium ion transmembrane transporter activity | 3 | 20 | 8.97e-01 |
| GO:BP | GO:0032368 | regulation of lipid transport | 4 | 92 | 8.98e-01 |
| GO:BP | GO:0090630 | activation of GTPase activity | 16 | 99 | 8.98e-01 |
| GO:BP | GO:0051775 | response to redox state | 1 | 12 | 8.98e-01 |
| GO:BP | GO:0042574 | retinal metabolic process | 1 | 11 | 8.98e-01 |
| GO:BP | GO:0007165 | signal transduction | 6 | 3818 | 8.98e-01 |
| GO:BP | GO:0002903 | negative regulation of B cell apoptotic process | 1 | 11 | 8.98e-01 |
| GO:BP | GO:0009158 | ribonucleoside monophosphate catabolic process | 1 | 10 | 8.98e-01 |
| GO:BP | GO:0051353 | positive regulation of oxidoreductase activity | 2 | 43 | 8.98e-01 |
| GO:BP | GO:0045088 | regulation of innate immune response | 1 | 232 | 8.98e-01 |
| GO:BP | GO:0007617 | mating behavior | 3 | 21 | 8.98e-01 |
| GO:BP | GO:0042048 | olfactory behavior | 1 | 7 | 8.98e-01 |
| GO:BP | GO:0070391 | response to lipoteichoic acid | 1 | 6 | 8.99e-01 |
| GO:BP | GO:0048846 | axon extension involved in axon guidance | 4 | 35 | 8.99e-01 |
| GO:BP | GO:0045625 | regulation of T-helper 1 cell differentiation | 1 | 5 | 8.99e-01 |
| GO:BP | GO:1902284 | neuron projection extension involved in neuron projection guidance | 4 | 35 | 8.99e-01 |
| GO:BP | GO:2001257 | regulation of cation channel activity | 2 | 100 | 8.99e-01 |
| GO:BP | GO:0071223 | cellular response to lipoteichoic acid | 1 | 6 | 8.99e-01 |
| GO:BP | GO:0016051 | carbohydrate biosynthetic process | 6 | 155 | 8.99e-01 |
| GO:BP | GO:2000563 | positive regulation of CD4-positive, alpha-beta T cell proliferation | 1 | 5 | 8.99e-01 |
| GO:BP | GO:0033622 | integrin activation | 1 | 18 | 8.99e-01 |
| GO:BP | GO:0051238 | sequestering of metal ion | 1 | 17 | 8.99e-01 |
| GO:BP | GO:0072593 | reactive oxygen species metabolic process | 1 | 156 | 9.00e-01 |
| GO:BP | GO:0060707 | trophoblast giant cell differentiation | 1 | 10 | 9.00e-01 |
| GO:BP | GO:0061351 | neural precursor cell proliferation | 8 | 114 | 9.00e-01 |
| GO:BP | GO:0072109 | glomerular mesangium development | 1 | 13 | 9.00e-01 |
| GO:BP | GO:0072207 | metanephric epithelium development | 1 | 16 | 9.00e-01 |
| GO:BP | GO:0071372 | cellular response to follicle-stimulating hormone stimulus | 1 | 9 | 9.00e-01 |
| GO:BP | GO:0034135 | regulation of toll-like receptor 2 signaling pathway | 1 | 7 | 9.00e-01 |
| GO:BP | GO:0007601 | visual perception | 1 | 96 | 9.01e-01 |
| GO:BP | GO:0007212 | dopamine receptor signaling pathway | 2 | 27 | 9.01e-01 |
| GO:BP | GO:0030837 | negative regulation of actin filament polymerization | 6 | 57 | 9.01e-01 |
| GO:BP | GO:0001890 | placenta development | 1 | 117 | 9.01e-01 |
| GO:BP | GO:0021692 | cerebellar Purkinje cell layer morphogenesis | 1 | 16 | 9.01e-01 |
| GO:BP | GO:0060445 | branching involved in salivary gland morphogenesis | 2 | 17 | 9.01e-01 |
| GO:BP | GO:0009595 | detection of biotic stimulus | 1 | 20 | 9.01e-01 |
| GO:BP | GO:0002886 | regulation of myeloid leukocyte mediated immunity | 4 | 34 | 9.01e-01 |
| GO:BP | GO:0044550 | secondary metabolite biosynthetic process | 2 | 18 | 9.02e-01 |
| GO:BP | GO:0015838 | amino-acid betaine transport | 1 | 7 | 9.02e-01 |
| GO:BP | GO:0002274 | myeloid leukocyte activation | 6 | 123 | 9.02e-01 |
| GO:BP | GO:0048733 | sebaceous gland development | 1 | 6 | 9.02e-01 |
| GO:BP | GO:0033604 | negative regulation of catecholamine secretion | 1 | 6 | 9.02e-01 |
| GO:BP | GO:1902915 | negative regulation of protein polyubiquitination | 1 | 9 | 9.03e-01 |
| GO:BP | GO:0010896 | regulation of triglyceride catabolic process | 1 | 7 | 9.03e-01 |
| GO:BP | GO:0003333 | amino acid transmembrane transport | 3 | 71 | 9.03e-01 |
| GO:BP | GO:0072080 | nephron tubule development | 4 | 73 | 9.03e-01 |
| GO:BP | GO:0036475 | neuron death in response to oxidative stress | 1 | 28 | 9.03e-01 |
| GO:BP | GO:0070664 | negative regulation of leukocyte proliferation | 2 | 51 | 9.03e-01 |
| GO:BP | GO:0032374 | regulation of cholesterol transport | 1 | 45 | 9.03e-01 |
| GO:BP | GO:0032371 | regulation of sterol transport | 1 | 45 | 9.03e-01 |
| GO:BP | GO:0050953 | sensory perception of light stimulus | 1 | 97 | 9.03e-01 |
| GO:BP | GO:1901880 | negative regulation of protein depolymerization | 3 | 64 | 9.03e-01 |
| GO:BP | GO:0071402 | cellular response to lipoprotein particle stimulus | 1 | 23 | 9.03e-01 |
| GO:BP | GO:0006879 | intracellular iron ion homeostasis | 2 | 52 | 9.03e-01 |
| GO:BP | GO:0046676 | negative regulation of insulin secretion | 1 | 28 | 9.04e-01 |
| GO:BP | GO:0071363 | cellular response to growth factor stimulus | 43 | 551 | 9.04e-01 |
| GO:BP | GO:0007263 | nitric oxide mediated signal transduction | 3 | 20 | 9.04e-01 |
| GO:BP | GO:0014742 | positive regulation of muscle hypertrophy | 3 | 22 | 9.04e-01 |
| GO:BP | GO:0002759 | regulation of antimicrobial humoral response | 1 | 3 | 9.04e-01 |
| GO:BP | GO:0045577 | regulation of B cell differentiation | 1 | 20 | 9.04e-01 |
| GO:BP | GO:0018158 | protein oxidation | 1 | 12 | 9.04e-01 |
| GO:BP | GO:0046689 | response to mercury ion | 1 | 7 | 9.05e-01 |
| GO:BP | GO:0007271 | synaptic transmission, cholinergic | 1 | 15 | 9.05e-01 |
| GO:BP | GO:1901224 | positive regulation of NIK/NF-kappaB signaling | 1 | 40 | 9.05e-01 |
| GO:BP | GO:0006807 | nitrogen compound metabolic process | 2 | 7441 | 9.05e-01 |
| GO:BP | GO:0006000 | fructose metabolic process | 1 | 10 | 9.06e-01 |
| GO:BP | GO:0019748 | secondary metabolic process | 5 | 34 | 9.06e-01 |
| GO:BP | GO:0061101 | neuroendocrine cell differentiation | 1 | 9 | 9.06e-01 |
| GO:BP | GO:0007584 | response to nutrient | 1 | 109 | 9.06e-01 |
| GO:BP | GO:0045342 | MHC class II biosynthetic process | 1 | 12 | 9.06e-01 |
| GO:BP | GO:0042572 | retinol metabolic process | 1 | 24 | 9.06e-01 |
| GO:BP | GO:0018958 | phenol-containing compound metabolic process | 1 | 61 | 9.06e-01 |
| GO:BP | GO:0001840 | neural plate development | 1 | 7 | 9.06e-01 |
| GO:BP | GO:0072203 | cell proliferation involved in metanephros development | 1 | 8 | 9.06e-01 |
| GO:BP | GO:0050772 | positive regulation of axonogenesis | 10 | 72 | 9.06e-01 |
| GO:BP | GO:0006821 | chloride transport | 1 | 58 | 9.06e-01 |
| GO:BP | GO:0060837 | blood vessel endothelial cell differentiation | 1 | 10 | 9.06e-01 |
| GO:BP | GO:0045666 | positive regulation of neuron differentiation | 5 | 63 | 9.06e-01 |
| GO:BP | GO:0048853 | forebrain morphogenesis | 1 | 7 | 9.06e-01 |
| GO:BP | GO:0002717 | positive regulation of natural killer cell mediated immunity | 1 | 11 | 9.06e-01 |
| GO:BP | GO:0097006 | regulation of plasma lipoprotein particle levels | 3 | 45 | 9.06e-01 |
| GO:BP | GO:2000242 | negative regulation of reproductive process | 2 | 42 | 9.07e-01 |
| GO:BP | GO:0060041 | retina development in camera-type eye | 7 | 109 | 9.07e-01 |
| GO:BP | GO:0006836 | neurotransmitter transport | 4 | 138 | 9.07e-01 |
| GO:BP | GO:0060259 | regulation of feeding behavior | 1 | 9 | 9.07e-01 |
| GO:BP | GO:0090219 | negative regulation of lipid kinase activity | 1 | 8 | 9.07e-01 |
| GO:BP | GO:0140894 | endolysosomal toll-like receptor signaling pathway | 1 | 24 | 9.07e-01 |
| GO:BP | GO:0032375 | negative regulation of cholesterol transport | 1 | 5 | 9.07e-01 |
| GO:BP | GO:0032372 | negative regulation of sterol transport | 1 | 5 | 9.07e-01 |
| GO:BP | GO:0045939 | negative regulation of steroid metabolic process | 2 | 19 | 9.07e-01 |
| GO:BP | GO:0030213 | hyaluronan biosynthetic process | 1 | 10 | 9.07e-01 |
| GO:BP | GO:0021936 | regulation of cerebellar granule cell precursor proliferation | 1 | 8 | 9.07e-01 |
| GO:BP | GO:1905668 | positive regulation of protein localization to endosome | 1 | 13 | 9.07e-01 |
| GO:BP | GO:0009914 | hormone transport | 5 | 215 | 9.08e-01 |
| GO:BP | GO:0072078 | nephron tubule morphogenesis | 3 | 57 | 9.08e-01 |
| GO:BP | GO:0042430 | indole-containing compound metabolic process | 2 | 8 | 9.08e-01 |
| GO:BP | GO:1902307 | positive regulation of sodium ion transmembrane transport | 1 | 17 | 9.08e-01 |
| GO:BP | GO:1904350 | regulation of protein catabolic process in the vacuole | 1 | 13 | 9.08e-01 |
| GO:BP | GO:0044000 | movement in host | 9 | 138 | 9.08e-01 |
| GO:BP | GO:0002275 | myeloid cell activation involved in immune response | 7 | 48 | 9.09e-01 |
| GO:BP | GO:0015748 | organophosphate ester transport | 1 | 106 | 9.09e-01 |
| GO:BP | GO:0043300 | regulation of leukocyte degranulation | 1 | 27 | 9.09e-01 |
| GO:BP | GO:0006222 | UMP biosynthetic process | 1 | 8 | 9.09e-01 |
| GO:BP | GO:0099550 | trans-synaptic signaling, modulating synaptic transmission | 1 | 10 | 9.09e-01 |
| GO:BP | GO:0002040 | sprouting angiogenesis | 5 | 98 | 9.09e-01 |
| GO:BP | GO:0003228 | atrial cardiac muscle tissue development | 2 | 18 | 9.10e-01 |
| GO:BP | GO:0014902 | myotube differentiation | 2 | 88 | 9.10e-01 |
| GO:BP | GO:0050862 | positive regulation of T cell receptor signaling pathway | 1 | 11 | 9.10e-01 |
| GO:BP | GO:1901031 | regulation of response to reactive oxygen species | 2 | 28 | 9.10e-01 |
| GO:BP | GO:0043931 | ossification involved in bone maturation | 2 | 17 | 9.10e-01 |
| GO:BP | GO:0060216 | definitive hemopoiesis | 1 | 18 | 9.10e-01 |
| GO:BP | GO:0065007 | biological regulation | 4 | 8320 | 9.10e-01 |
| GO:BP | GO:0061138 | morphogenesis of a branching epithelium | 1 | 143 | 9.10e-01 |
| GO:BP | GO:0002685 | regulation of leukocyte migration | 2 | 131 | 9.10e-01 |
| GO:BP | GO:0018149 | peptide cross-linking | 1 | 14 | 9.11e-01 |
| GO:BP | GO:0010713 | negative regulation of collagen metabolic process | 1 | 8 | 9.11e-01 |
| GO:BP | GO:0006139 | nucleobase-containing compound metabolic process | 2 | 4455 | 9.11e-01 |
| GO:BP | GO:0065005 | protein-lipid complex assembly | 2 | 21 | 9.11e-01 |
| GO:BP | GO:0071493 | cellular response to UV-B | 1 | 11 | 9.11e-01 |
| GO:BP | GO:2000345 | regulation of hepatocyte proliferation | 1 | 13 | 9.11e-01 |
| GO:BP | GO:0030072 | peptide hormone secretion | 6 | 166 | 9.12e-01 |
| GO:BP | GO:1905906 | regulation of amyloid fibril formation | 1 | 14 | 9.12e-01 |
| GO:BP | GO:0050768 | negative regulation of neurogenesis | 6 | 113 | 9.12e-01 |
| GO:BP | GO:0007275 | multicellular organism development | 1 | 3386 | 9.12e-01 |
| GO:BP | GO:0001818 | negative regulation of cytokine production | 12 | 165 | 9.12e-01 |
| GO:BP | GO:1902236 | negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway | 2 | 17 | 9.12e-01 |
| GO:BP | GO:0043129 | surfactant homeostasis | 1 | 12 | 9.12e-01 |
| GO:BP | GO:0032729 | positive regulation of type II interferon production | 1 | 36 | 9.12e-01 |
| GO:BP | GO:0042415 | norepinephrine metabolic process | 1 | 7 | 9.12e-01 |
| GO:BP | GO:0048814 | regulation of dendrite morphogenesis | 3 | 58 | 9.12e-01 |
| GO:BP | GO:1902991 | regulation of amyloid precursor protein catabolic process | 2 | 39 | 9.12e-01 |
| GO:BP | GO:0031349 | positive regulation of defense response | 14 | 251 | 9.12e-01 |
| GO:BP | GO:0030878 | thyroid gland development | 2 | 17 | 9.12e-01 |
| GO:BP | GO:0085029 | extracellular matrix assembly | 1 | 41 | 9.14e-01 |
| GO:BP | GO:1900227 | positive regulation of NLRP3 inflammasome complex assembly | 1 | 16 | 9.14e-01 |
| GO:BP | GO:0006024 | glycosaminoglycan biosynthetic process | 3 | 60 | 9.14e-01 |
| GO:BP | GO:0045927 | positive regulation of growth | 36 | 199 | 9.14e-01 |
| GO:BP | GO:0034030 | ribonucleoside bisphosphate biosynthetic process | 2 | 49 | 9.14e-01 |
| GO:BP | GO:0034033 | purine nucleoside bisphosphate biosynthetic process | 2 | 49 | 9.14e-01 |
| GO:BP | GO:0048265 | response to pain | 1 | 17 | 9.14e-01 |
| GO:BP | GO:0033866 | nucleoside bisphosphate biosynthetic process | 2 | 49 | 9.14e-01 |
| GO:BP | GO:0090279 | regulation of calcium ion import | 3 | 24 | 9.14e-01 |
| GO:BP | GO:0034694 | response to prostaglandin | 1 | 21 | 9.14e-01 |
| GO:BP | GO:0061436 | establishment of skin barrier | 2 | 18 | 9.14e-01 |
| GO:BP | GO:0061042 | vascular wound healing | 2 | 17 | 9.14e-01 |
| GO:BP | GO:0050900 | leukocyte migration | 4 | 209 | 9.14e-01 |
| GO:BP | GO:0006734 | NADH metabolic process | 1 | 12 | 9.15e-01 |
| GO:BP | GO:0044546 | NLRP3 inflammasome complex assembly | 3 | 23 | 9.15e-01 |
| GO:BP | GO:0003163 | sinoatrial node development | 1 | 10 | 9.15e-01 |
| GO:BP | GO:0019216 | regulation of lipid metabolic process | 1 | 250 | 9.15e-01 |
| GO:BP | GO:0014061 | regulation of norepinephrine secretion | 1 | 5 | 9.16e-01 |
| GO:BP | GO:0048243 | norepinephrine secretion | 1 | 5 | 9.16e-01 |
| GO:BP | GO:0090330 | regulation of platelet aggregation | 1 | 21 | 9.16e-01 |
| GO:BP | GO:0008542 | visual learning | 2 | 37 | 9.16e-01 |
| GO:BP | GO:0002253 | activation of immune response | 2 | 272 | 9.16e-01 |
| GO:BP | GO:0072088 | nephron epithelium morphogenesis | 3 | 59 | 9.16e-01 |
| GO:BP | GO:1902047 | polyamine transmembrane transport | 1 | 10 | 9.16e-01 |
| GO:BP | GO:1901857 | positive regulation of cellular respiration | 1 | 11 | 9.16e-01 |
| GO:BP | GO:2001171 | positive regulation of ATP biosynthetic process | 1 | 10 | 9.16e-01 |
| GO:BP | GO:0007204 | positive regulation of cytosolic calcium ion concentration | 1 | 90 | 9.16e-01 |
| GO:BP | GO:0048872 | homeostasis of number of cells | 2 | 228 | 9.16e-01 |
| GO:BP | GO:0010566 | regulation of ketone biosynthetic process | 1 | 16 | 9.16e-01 |
| GO:BP | GO:0021984 | adenohypophysis development | 1 | 9 | 9.16e-01 |
| GO:BP | GO:0070863 | positive regulation of protein exit from endoplasmic reticulum | 1 | 10 | 9.16e-01 |
| GO:BP | GO:0061448 | connective tissue development | 13 | 208 | 9.16e-01 |
| GO:BP | GO:0009891 | positive regulation of biosynthetic process | 37 | 1604 | 9.17e-01 |
| GO:BP | GO:0040036 | regulation of fibroblast growth factor receptor signaling pathway | 3 | 25 | 9.18e-01 |
| GO:BP | GO:0098661 | inorganic anion transmembrane transport | 1 | 66 | 9.18e-01 |
| GO:BP | GO:2000480 | negative regulation of cAMP-dependent protein kinase activity | 1 | 10 | 9.18e-01 |
| GO:BP | GO:0031099 | regeneration | 1 | 142 | 9.18e-01 |
| GO:BP | GO:0090288 | negative regulation of cellular response to growth factor stimulus | 1 | 81 | 9.18e-01 |
| GO:BP | GO:1904064 | positive regulation of cation transmembrane transport | 2 | 99 | 9.18e-01 |
| GO:BP | GO:0010038 | response to metal ion | 1 | 264 | 9.18e-01 |
| GO:BP | GO:0002862 | negative regulation of inflammatory response to antigenic stimulus | 2 | 16 | 9.18e-01 |
| GO:BP | GO:0043170 | macromolecule metabolic process | 2 | 7069 | 9.18e-01 |
| GO:BP | GO:0070365 | hepatocyte differentiation | 1 | 12 | 9.18e-01 |
| GO:BP | GO:0002638 | negative regulation of immunoglobulin production | 1 | 5 | 9.18e-01 |
| GO:BP | GO:0140131 | positive regulation of lymphocyte chemotaxis | 2 | 10 | 9.18e-01 |
| GO:BP | GO:0032878 | regulation of establishment or maintenance of cell polarity | 3 | 26 | 9.18e-01 |
| GO:BP | GO:0046823 | negative regulation of nucleocytoplasmic transport | 2 | 21 | 9.18e-01 |
| GO:BP | GO:2000052 | positive regulation of non-canonical Wnt signaling pathway | 1 | 14 | 9.18e-01 |
| GO:BP | GO:0010820 | positive regulation of T cell chemotaxis | 1 | 7 | 9.18e-01 |
| GO:BP | GO:0016188 | synaptic vesicle maturation | 1 | 22 | 9.18e-01 |
| GO:BP | GO:0045429 | positive regulation of nitric oxide biosynthetic process | 2 | 26 | 9.18e-01 |
| GO:BP | GO:0032720 | negative regulation of tumor necrosis factor production | 1 | 32 | 9.18e-01 |
| GO:BP | GO:0009144 | purine nucleoside triphosphate metabolic process | 2 | 142 | 9.19e-01 |
| GO:BP | GO:0045686 | negative regulation of glial cell differentiation | 1 | 15 | 9.19e-01 |
| GO:BP | GO:0032429 | regulation of phospholipase A2 activity | 1 | 8 | 9.19e-01 |
| GO:BP | GO:0046483 | heterocycle metabolic process | 2 | 4570 | 9.19e-01 |
| GO:BP | GO:0007417 | central nervous system development | 7 | 792 | 9.19e-01 |
| GO:BP | GO:0001541 | ovarian follicle development | 4 | 41 | 9.19e-01 |
| GO:BP | GO:0045599 | negative regulation of fat cell differentiation | 2 | 43 | 9.19e-01 |
| GO:BP | GO:0032652 | regulation of interleukin-1 production | 2 | 56 | 9.19e-01 |
| GO:BP | GO:0032612 | interleukin-1 production | 2 | 56 | 9.19e-01 |
| GO:BP | GO:0072070 | loop of Henle development | 1 | 8 | 9.19e-01 |
| GO:BP | GO:0021562 | vestibulocochlear nerve development | 1 | 4 | 9.19e-01 |
| GO:BP | GO:0021670 | lateral ventricle development | 1 | 11 | 9.19e-01 |
| GO:BP | GO:0042180 | cellular ketone metabolic process | 12 | 158 | 9.19e-01 |
| GO:BP | GO:0002517 | T cell tolerance induction | 1 | 6 | 9.19e-01 |
| GO:BP | GO:0009954 | proximal/distal pattern formation | 2 | 15 | 9.19e-01 |
| GO:BP | GO:0007343 | egg activation | 1 | 4 | 9.19e-01 |
| GO:BP | GO:0001547 | antral ovarian follicle growth | 1 | 5 | 9.19e-01 |
| GO:BP | GO:1905666 | regulation of protein localization to endosome | 1 | 14 | 9.20e-01 |
| GO:BP | GO:1902514 | regulation of calcium ion transmembrane transport via high voltage-gated calcium channel | 1 | 12 | 9.20e-01 |
| GO:BP | GO:0097722 | sperm motility | 2 | 61 | 9.20e-01 |
| GO:BP | GO:1903670 | regulation of sprouting angiogenesis | 1 | 28 | 9.20e-01 |
| GO:BP | GO:0030317 | flagellated sperm motility | 2 | 61 | 9.20e-01 |
| GO:BP | GO:0036065 | fucosylation | 1 | 10 | 9.20e-01 |
| GO:BP | GO:0035330 | regulation of hippo signaling | 2 | 21 | 9.20e-01 |
| GO:BP | GO:0044571 | [2Fe-2S] cluster assembly | 1 | 11 | 9.20e-01 |
| GO:BP | GO:0043949 | regulation of cAMP-mediated signaling | 1 | 17 | 9.20e-01 |
| GO:BP | GO:0051259 | protein complex oligomerization | 19 | 185 | 9.20e-01 |
| GO:BP | GO:0002888 | positive regulation of myeloid leukocyte mediated immunity | 1 | 12 | 9.20e-01 |
| GO:BP | GO:0070316 | regulation of G0 to G1 transition | 4 | 34 | 9.20e-01 |
| GO:BP | GO:0050922 | negative regulation of chemotaxis | 3 | 44 | 9.20e-01 |
| GO:BP | GO:0033860 | regulation of NAD(P)H oxidase activity | 1 | 6 | 9.20e-01 |
| GO:BP | GO:0006725 | cellular aromatic compound metabolic process | 2 | 4596 | 9.20e-01 |
| GO:BP | GO:0042462 | eye photoreceptor cell development | 3 | 19 | 9.20e-01 |
| GO:BP | GO:0021591 | ventricular system development | 1 | 29 | 9.20e-01 |
| GO:BP | GO:2000300 | regulation of synaptic vesicle exocytosis | 4 | 35 | 9.20e-01 |
| GO:BP | GO:0051701 | biological process involved in interaction with host | 10 | 154 | 9.21e-01 |
| GO:BP | GO:0072205 | metanephric collecting duct development | 1 | 5 | 9.21e-01 |
| GO:BP | GO:0070229 | negative regulation of lymphocyte apoptotic process | 1 | 23 | 9.21e-01 |
| GO:BP | GO:0120178 | steroid hormone biosynthetic process | 4 | 29 | 9.22e-01 |
| GO:BP | GO:0006094 | gluconeogenesis | 2 | 67 | 9.22e-01 |
| GO:BP | GO:0061333 | renal tubule morphogenesis | 3 | 61 | 9.22e-01 |
| GO:BP | GO:0032496 | response to lipopolysaccharide | 7 | 178 | 9.22e-01 |
| GO:BP | GO:1900037 | regulation of cellular response to hypoxia | 1 | 13 | 9.22e-01 |
| GO:BP | GO:0099054 | presynapse assembly | 4 | 39 | 9.23e-01 |
| GO:BP | GO:0006813 | potassium ion transport | 2 | 147 | 9.23e-01 |
| GO:BP | GO:0001763 | morphogenesis of a branching structure | 1 | 154 | 9.23e-01 |
| GO:BP | GO:0034205 | amyloid-beta formation | 2 | 41 | 9.23e-01 |
| GO:BP | GO:0089718 | amino acid import across plasma membrane | 1 | 39 | 9.23e-01 |
| GO:BP | GO:0071371 | cellular response to gonadotropin stimulus | 2 | 13 | 9.23e-01 |
| GO:BP | GO:0022010 | central nervous system myelination | 1 | 12 | 9.23e-01 |
| GO:BP | GO:0070228 | regulation of lymphocyte apoptotic process | 5 | 37 | 9.23e-01 |
| GO:BP | GO:0032291 | axon ensheathment in central nervous system | 1 | 12 | 9.23e-01 |
| GO:BP | GO:1903556 | negative regulation of tumor necrosis factor superfamily cytokine production | 1 | 33 | 9.23e-01 |
| GO:BP | GO:0009583 | detection of light stimulus | 1 | 27 | 9.24e-01 |
| GO:BP | GO:2000106 | regulation of leukocyte apoptotic process | 8 | 57 | 9.24e-01 |
| GO:BP | GO:0007566 | embryo implantation | 1 | 39 | 9.24e-01 |
| GO:BP | GO:0021549 | cerebellum development | 5 | 78 | 9.24e-01 |
| GO:BP | GO:0018200 | peptidyl-glutamic acid modification | 1 | 17 | 9.24e-01 |
| GO:BP | GO:0099172 | presynapse organization | 5 | 42 | 9.24e-01 |
| GO:BP | GO:0070561 | vitamin D receptor signaling pathway | 1 | 10 | 9.25e-01 |
| GO:BP | GO:0009174 | pyrimidine ribonucleoside monophosphate biosynthetic process | 1 | 9 | 9.25e-01 |
| GO:BP | GO:0070166 | enamel mineralization | 2 | 11 | 9.25e-01 |
| GO:BP | GO:0007596 | blood coagulation | 1 | 150 | 9.26e-01 |
| GO:BP | GO:0070170 | regulation of tooth mineralization | 1 | 4 | 9.26e-01 |
| GO:BP | GO:0072028 | nephron morphogenesis | 3 | 62 | 9.26e-01 |
| GO:BP | GO:0008211 | glucocorticoid metabolic process | 2 | 18 | 9.26e-01 |
| GO:BP | GO:0010976 | positive regulation of neuron projection development | 14 | 131 | 9.26e-01 |
| GO:BP | GO:0035270 | endocrine system development | 6 | 86 | 9.26e-01 |
| GO:BP | GO:0098656 | monoatomic anion transmembrane transport | 1 | 71 | 9.26e-01 |
| GO:BP | GO:0106070 | regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway | 1 | 11 | 9.26e-01 |
| GO:BP | GO:0030324 | lung development | 17 | 146 | 9.26e-01 |
| GO:BP | GO:0097009 | energy homeostasis | 4 | 39 | 9.27e-01 |
| GO:BP | GO:0030204 | chondroitin sulfate metabolic process | 1 | 28 | 9.27e-01 |
| GO:BP | GO:0010939 | regulation of necrotic cell death | 1 | 38 | 9.27e-01 |
| GO:BP | GO:0051961 | negative regulation of nervous system development | 6 | 118 | 9.27e-01 |
| GO:BP | GO:0036444 | calcium import into the mitochondrion | 1 | 12 | 9.27e-01 |
| GO:BP | GO:1903580 | positive regulation of ATP metabolic process | 1 | 11 | 9.27e-01 |
| GO:BP | GO:0090278 | negative regulation of peptide hormone secretion | 1 | 30 | 9.27e-01 |
| GO:BP | GO:0019430 | removal of superoxide radicals | 1 | 17 | 9.27e-01 |
| GO:BP | GO:0050810 | regulation of steroid biosynthetic process | 3 | 51 | 9.27e-01 |
| GO:BP | GO:0031341 | regulation of cell killing | 1 | 36 | 9.27e-01 |
| GO:BP | GO:2000117 | negative regulation of cysteine-type endopeptidase activity | 4 | 64 | 9.27e-01 |
| GO:BP | GO:0034369 | plasma lipoprotein particle remodeling | 1 | 14 | 9.27e-01 |
| GO:BP | GO:0034368 | protein-lipid complex remodeling | 1 | 14 | 9.27e-01 |
| GO:BP | GO:0030198 | extracellular matrix organization | 3 | 233 | 9.27e-01 |
| GO:BP | GO:0006306 | DNA methylation | 5 | 46 | 9.27e-01 |
| GO:BP | GO:0060135 | maternal process involved in female pregnancy | 3 | 41 | 9.27e-01 |
| GO:BP | GO:2000116 | regulation of cysteine-type endopeptidase activity | 1 | 169 | 9.27e-01 |
| GO:BP | GO:0010819 | regulation of T cell chemotaxis | 1 | 7 | 9.27e-01 |
| GO:BP | GO:0043062 | extracellular structure organization | 3 | 234 | 9.27e-01 |
| GO:BP | GO:0060572 | morphogenesis of an epithelial bud | 1 | 11 | 9.27e-01 |
| GO:BP | GO:0006305 | DNA alkylation | 5 | 46 | 9.27e-01 |
| GO:BP | GO:0006023 | aminoglycan biosynthetic process | 3 | 63 | 9.27e-01 |
| GO:BP | GO:0060026 | convergent extension | 1 | 14 | 9.27e-01 |
| GO:BP | GO:0120254 | olefinic compound metabolic process | 3 | 84 | 9.27e-01 |
| GO:BP | GO:2000819 | regulation of nucleotide-excision repair | 2 | 27 | 9.27e-01 |
| GO:BP | GO:0099151 | regulation of postsynaptic density assembly | 1 | 9 | 9.27e-01 |
| GO:BP | GO:1903053 | regulation of extracellular matrix organization | 1 | 46 | 9.27e-01 |
| GO:BP | GO:0140353 | lipid export from cell | 1 | 28 | 9.27e-01 |
| GO:BP | GO:0045454 | cell redox homeostasis | 1 | 38 | 9.28e-01 |
| GO:BP | GO:0050817 | coagulation | 1 | 153 | 9.28e-01 |
| GO:BP | GO:0008406 | gonad development | 2 | 158 | 9.28e-01 |
| GO:BP | GO:1904407 | positive regulation of nitric oxide metabolic process | 2 | 27 | 9.28e-01 |
| GO:BP | GO:0007599 | hemostasis | 1 | 153 | 9.29e-01 |
| GO:BP | GO:0002829 | negative regulation of type 2 immune response | 1 | 7 | 9.29e-01 |
| GO:BP | GO:1904667 | negative regulation of ubiquitin protein ligase activity | 1 | 11 | 9.29e-01 |
| GO:BP | GO:2000767 | positive regulation of cytoplasmic translation | 1 | 13 | 9.29e-01 |
| GO:BP | GO:0061050 | regulation of cell growth involved in cardiac muscle cell development | 1 | 13 | 9.29e-01 |
| GO:BP | GO:0002836 | positive regulation of response to tumor cell | 1 | 7 | 9.29e-01 |
| GO:BP | GO:0002839 | positive regulation of immune response to tumor cell | 1 | 7 | 9.29e-01 |
| GO:BP | GO:0019319 | hexose biosynthetic process | 2 | 70 | 9.29e-01 |
| GO:BP | GO:0043046 | DNA methylation involved in gamete generation | 1 | 4 | 9.29e-01 |
| GO:BP | GO:0045229 | external encapsulating structure organization | 3 | 234 | 9.29e-01 |
| GO:BP | GO:0015868 | purine ribonucleotide transport | 1 | 19 | 9.29e-01 |
| GO:BP | GO:0009083 | branched-chain amino acid catabolic process | 1 | 21 | 9.29e-01 |
| GO:BP | GO:1990266 | neutrophil migration | 1 | 52 | 9.29e-01 |
| GO:BP | GO:0140632 | canonical inflammasome complex assembly | 3 | 23 | 9.29e-01 |
| GO:BP | GO:0002792 | negative regulation of peptide secretion | 1 | 31 | 9.30e-01 |
| GO:BP | GO:0030890 | positive regulation of B cell proliferation | 3 | 26 | 9.30e-01 |
| GO:BP | GO:0042886 | amide transport | 11 | 235 | 9.30e-01 |
| GO:BP | GO:0035924 | cellular response to vascular endothelial growth factor stimulus | 3 | 54 | 9.30e-01 |
| GO:BP | GO:0099084 | postsynaptic specialization organization | 5 | 36 | 9.30e-01 |
| GO:BP | GO:1901360 | organic cyclic compound metabolic process | 2 | 4747 | 9.31e-01 |
| GO:BP | GO:0010954 | positive regulation of protein processing | 1 | 18 | 9.31e-01 |
| GO:BP | GO:0090317 | negative regulation of intracellular protein transport | 1 | 37 | 9.31e-01 |
| GO:BP | GO:0008380 | RNA splicing | 7 | 419 | 9.32e-01 |
| GO:BP | GO:0032332 | positive regulation of chondrocyte differentiation | 1 | 13 | 9.32e-01 |
| GO:BP | GO:0098657 | import into cell | 10 | 166 | 9.32e-01 |
| GO:BP | GO:0046541 | saliva secretion | 1 | 4 | 9.32e-01 |
| GO:BP | GO:0048641 | regulation of skeletal muscle tissue development | 1 | 20 | 9.32e-01 |
| GO:BP | GO:0035542 | regulation of SNARE complex assembly | 1 | 13 | 9.32e-01 |
| GO:BP | GO:0046470 | phosphatidylcholine metabolic process | 3 | 53 | 9.32e-01 |
| GO:BP | GO:0032330 | regulation of chondrocyte differentiation | 1 | 37 | 9.32e-01 |
| GO:BP | GO:0031667 | response to nutrient levels | 30 | 353 | 9.32e-01 |
| GO:BP | GO:0006518 | peptide metabolic process | 11 | 771 | 9.32e-01 |
| GO:BP | GO:0051016 | barbed-end actin filament capping | 2 | 21 | 9.33e-01 |
| GO:BP | GO:0035112 | genitalia morphogenesis | 1 | 5 | 9.33e-01 |
| GO:BP | GO:0006801 | superoxide metabolic process | 1 | 42 | 9.33e-01 |
| GO:BP | GO:0045137 | development of primary sexual characteristics | 2 | 161 | 9.33e-01 |
| GO:BP | GO:0009991 | response to extracellular stimulus | 32 | 377 | 9.33e-01 |
| GO:BP | GO:0046697 | decidualization | 2 | 19 | 9.33e-01 |
| GO:BP | GO:0071871 | response to epinephrine | 1 | 12 | 9.33e-01 |
| GO:BP | GO:2000351 | regulation of endothelial cell apoptotic process | 3 | 35 | 9.33e-01 |
| GO:BP | GO:0009205 | purine ribonucleoside triphosphate metabolic process | 1 | 137 | 9.33e-01 |
| GO:BP | GO:2000773 | negative regulation of cellular senescence | 1 | 19 | 9.34e-01 |
| GO:BP | GO:0008203 | cholesterol metabolic process | 4 | 101 | 9.34e-01 |
| GO:BP | GO:0008202 | steroid metabolic process | 3 | 204 | 9.34e-01 |
| GO:BP | GO:1905476 | negative regulation of protein localization to membrane | 2 | 29 | 9.34e-01 |
| GO:BP | GO:0048706 | embryonic skeletal system development | 7 | 78 | 9.34e-01 |
| GO:BP | GO:1903725 | regulation of phospholipid metabolic process | 4 | 29 | 9.34e-01 |
| GO:BP | GO:0048148 | behavioral response to cocaine | 1 | 9 | 9.34e-01 |
| GO:BP | GO:1901841 | regulation of high voltage-gated calcium channel activity | 1 | 12 | 9.34e-01 |
| GO:BP | GO:0003156 | regulation of animal organ formation | 2 | 20 | 9.34e-01 |
| GO:BP | GO:0060541 | respiratory system development | 17 | 163 | 9.35e-01 |
| GO:BP | GO:0036075 | replacement ossification | 3 | 25 | 9.35e-01 |
| GO:BP | GO:1901142 | insulin metabolic process | 1 | 11 | 9.35e-01 |
| GO:BP | GO:0032924 | activin receptor signaling pathway | 1 | 34 | 9.35e-01 |
| GO:BP | GO:0098789 | pre-mRNA cleavage required for polyadenylation | 1 | 12 | 9.35e-01 |
| GO:BP | GO:0006865 | amino acid transport | 4 | 102 | 9.35e-01 |
| GO:BP | GO:0001958 | endochondral ossification | 3 | 25 | 9.35e-01 |
| GO:BP | GO:0050858 | negative regulation of antigen receptor-mediated signaling pathway | 3 | 20 | 9.35e-01 |
| GO:BP | GO:0006882 | intracellular zinc ion homeostasis | 1 | 28 | 9.35e-01 |
| GO:BP | GO:0006826 | iron ion transport | 1 | 40 | 9.35e-01 |
| GO:BP | GO:0048715 | negative regulation of oligodendrocyte differentiation | 1 | 8 | 9.35e-01 |
| GO:BP | GO:0016125 | sterol metabolic process | 5 | 111 | 9.35e-01 |
| GO:BP | GO:0032740 | positive regulation of interleukin-17 production | 1 | 12 | 9.36e-01 |
| GO:BP | GO:0032635 | interleukin-6 production | 3 | 86 | 9.36e-01 |
| GO:BP | GO:0032675 | regulation of interleukin-6 production | 3 | 86 | 9.36e-01 |
| GO:BP | GO:0043242 | negative regulation of protein-containing complex disassembly | 3 | 72 | 9.36e-01 |
| GO:BP | GO:0051055 | negative regulation of lipid biosynthetic process | 4 | 46 | 9.36e-01 |
| GO:BP | GO:0033993 | response to lipid | 2 | 592 | 9.36e-01 |
| GO:BP | GO:0097066 | response to thyroid hormone | 2 | 23 | 9.36e-01 |
| GO:BP | GO:0032370 | positive regulation of lipid transport | 2 | 58 | 9.36e-01 |
| GO:BP | GO:0043270 | positive regulation of monoatomic ion transport | 3 | 154 | 9.36e-01 |
| GO:BP | GO:0034605 | cellular response to heat | 1 | 51 | 9.36e-01 |
| GO:BP | GO:0009581 | detection of external stimulus | 1 | 67 | 9.36e-01 |
| GO:BP | GO:0001658 | branching involved in ureteric bud morphogenesis | 2 | 43 | 9.36e-01 |
| GO:BP | GO:0007586 | digestion | 2 | 60 | 9.36e-01 |
| GO:BP | GO:0007632 | visual behavior | 2 | 41 | 9.36e-01 |
| GO:BP | GO:0070633 | transepithelial transport | 3 | 24 | 9.36e-01 |
| GO:BP | GO:0034367 | protein-containing complex remodeling | 1 | 16 | 9.36e-01 |
| GO:BP | GO:0009125 | nucleoside monophosphate catabolic process | 1 | 13 | 9.36e-01 |
| GO:BP | GO:0097529 | myeloid leukocyte migration | 2 | 120 | 9.36e-01 |
| GO:BP | GO:0034764 | positive regulation of transmembrane transport | 3 | 158 | 9.37e-01 |
| GO:BP | GO:0046718 | viral entry into host cell | 2 | 107 | 9.37e-01 |
| GO:BP | GO:0034641 | cellular nitrogen compound metabolic process | 2 | 4946 | 9.37e-01 |
| GO:BP | GO:0030323 | respiratory tube development | 17 | 150 | 9.37e-01 |
| GO:BP | GO:0010737 | protein kinase A signaling | 3 | 23 | 9.38e-01 |
| GO:BP | GO:0070848 | response to growth factor | 48 | 572 | 9.38e-01 |
| GO:BP | GO:0000097 | sulfur amino acid biosynthetic process | 1 | 14 | 9.39e-01 |
| GO:BP | GO:0006555 | methionine metabolic process | 1 | 13 | 9.39e-01 |
| GO:BP | GO:0006658 | phosphatidylserine metabolic process | 2 | 21 | 9.39e-01 |
| GO:BP | GO:0032525 | somite rostral/caudal axis specification | 1 | 7 | 9.39e-01 |
| GO:BP | GO:0015846 | polyamine transport | 1 | 12 | 9.39e-01 |
| GO:BP | GO:0009582 | detection of abiotic stimulus | 1 | 68 | 9.40e-01 |
| GO:BP | GO:0009199 | ribonucleoside triphosphate metabolic process | 1 | 144 | 9.40e-01 |
| GO:BP | GO:0001662 | behavioral fear response | 3 | 29 | 9.40e-01 |
| GO:BP | GO:0034113 | heterotypic cell-cell adhesion | 4 | 37 | 9.40e-01 |
| GO:BP | GO:0015711 | organic anion transport | 4 | 264 | 9.40e-01 |
| GO:BP | GO:0043604 | amide biosynthetic process | 11 | 775 | 9.40e-01 |
| GO:BP | GO:0034333 | adherens junction assembly | 1 | 13 | 9.40e-01 |
| GO:BP | GO:0061577 | calcium ion transmembrane transport via high voltage-gated calcium channel | 1 | 14 | 9.40e-01 |
| GO:BP | GO:0014070 | response to organic cyclic compound | 2 | 640 | 9.40e-01 |
| GO:BP | GO:0071542 | dopaminergic neuron differentiation | 1 | 20 | 9.40e-01 |
| GO:BP | GO:0035136 | forelimb morphogenesis | 1 | 21 | 9.40e-01 |
| GO:BP | GO:0006677 | glycosylceramide metabolic process | 1 | 13 | 9.40e-01 |
| GO:BP | GO:0071467 | cellular response to pH | 1 | 16 | 9.40e-01 |
| GO:BP | GO:0009141 | nucleoside triphosphate metabolic process | 2 | 159 | 9.40e-01 |
| GO:BP | GO:0002429 | immune response-activating cell surface receptor signaling pathway | 1 | 151 | 9.41e-01 |
| GO:BP | GO:0019218 | regulation of steroid metabolic process | 4 | 69 | 9.41e-01 |
| GO:BP | GO:0006805 | xenobiotic metabolic process | 2 | 56 | 9.41e-01 |
| GO:BP | GO:0007269 | neurotransmitter secretion | 2 | 104 | 9.41e-01 |
| GO:BP | GO:0033084 | regulation of immature T cell proliferation in thymus | 1 | 6 | 9.41e-01 |
| GO:BP | GO:0033083 | regulation of immature T cell proliferation | 1 | 6 | 9.41e-01 |
| GO:BP | GO:0007350 | blastoderm segmentation | 2 | 17 | 9.41e-01 |
| GO:BP | GO:0019228 | neuronal action potential | 1 | 23 | 9.41e-01 |
| GO:BP | GO:1901889 | negative regulation of cell junction assembly | 2 | 24 | 9.41e-01 |
| GO:BP | GO:0099643 | signal release from synapse | 2 | 104 | 9.41e-01 |
| GO:BP | GO:0070527 | platelet aggregation | 6 | 52 | 9.41e-01 |
| GO:BP | GO:0009855 | determination of bilateral symmetry | 7 | 102 | 9.41e-01 |
| GO:BP | GO:0006397 | mRNA processing | 7 | 450 | 9.41e-01 |
| GO:BP | GO:0002237 | response to molecule of bacterial origin | 6 | 187 | 9.41e-01 |
| GO:BP | GO:0015804 | neutral amino acid transport | 1 | 43 | 9.41e-01 |
| GO:BP | GO:0071450 | cellular response to oxygen radical | 1 | 19 | 9.41e-01 |
| GO:BP | GO:1901566 | organonitrogen compound biosynthetic process | 3 | 1484 | 9.41e-01 |
| GO:BP | GO:0097067 | cellular response to thyroid hormone stimulus | 1 | 14 | 9.41e-01 |
| GO:BP | GO:0002028 | regulation of sodium ion transport | 5 | 72 | 9.41e-01 |
| GO:BP | GO:0038065 | collagen-activated signaling pathway | 1 | 13 | 9.41e-01 |
| GO:BP | GO:0071451 | cellular response to superoxide | 1 | 19 | 9.41e-01 |
| GO:BP | GO:0072520 | seminiferous tubule development | 1 | 13 | 9.41e-01 |
| GO:BP | GO:1903319 | positive regulation of protein maturation | 1 | 19 | 9.42e-01 |
| GO:BP | GO:0001937 | negative regulation of endothelial cell proliferation | 1 | 32 | 9.42e-01 |
| GO:BP | GO:0043320 | natural killer cell degranulation | 1 | 6 | 9.43e-01 |
| GO:BP | GO:0043312 | neutrophil degranulation | 1 | 5 | 9.43e-01 |
| GO:BP | GO:0006337 | nucleosome disassembly | 1 | 16 | 9.43e-01 |
| GO:BP | GO:0006349 | regulation of gene expression by genomic imprinting | 1 | 14 | 9.43e-01 |
| GO:BP | GO:0032642 | regulation of chemokine production | 3 | 46 | 9.43e-01 |
| GO:BP | GO:0023061 | signal release | 7 | 321 | 9.43e-01 |
| GO:BP | GO:0070972 | protein localization to endoplasmic reticulum | 1 | 78 | 9.43e-01 |
| GO:BP | GO:0030101 | natural killer cell activation | 3 | 42 | 9.43e-01 |
| GO:BP | GO:0002064 | epithelial cell development | 5 | 156 | 9.43e-01 |
| GO:BP | GO:0095500 | acetylcholine receptor signaling pathway | 1 | 18 | 9.43e-01 |
| GO:BP | GO:0033194 | response to hydroperoxide | 1 | 12 | 9.43e-01 |
| GO:BP | GO:0032602 | chemokine production | 3 | 46 | 9.43e-01 |
| GO:BP | GO:0043605 | amide catabolic process | 1 | 10 | 9.43e-01 |
| GO:BP | GO:0009948 | anterior/posterior axis specification | 1 | 32 | 9.43e-01 |
| GO:BP | GO:0016071 | mRNA metabolic process | 8 | 665 | 9.43e-01 |
| GO:BP | GO:0009799 | specification of symmetry | 7 | 103 | 9.43e-01 |
| GO:BP | GO:0006883 | intracellular sodium ion homeostasis | 1 | 13 | 9.44e-01 |
| GO:BP | GO:0098719 | sodium ion import across plasma membrane | 1 | 14 | 9.44e-01 |
| GO:BP | GO:0030888 | regulation of B cell proliferation | 1 | 35 | 9.45e-01 |
| GO:BP | GO:0002209 | behavioral defense response | 3 | 30 | 9.45e-01 |
| GO:BP | GO:0098787 | mRNA cleavage involved in mRNA processing | 1 | 13 | 9.45e-01 |
| GO:BP | GO:0052646 | alditol phosphate metabolic process | 1 | 10 | 9.45e-01 |
| GO:BP | GO:1905330 | regulation of morphogenesis of an epithelium | 2 | 47 | 9.45e-01 |
| GO:BP | GO:0044238 | primary metabolic process | 2 | 7806 | 9.45e-01 |
| GO:BP | GO:0150078 | positive regulation of neuroinflammatory response | 1 | 4 | 9.46e-01 |
| GO:BP | GO:0034767 | positive regulation of monoatomic ion transmembrane transport | 2 | 114 | 9.46e-01 |
| GO:BP | GO:0033146 | regulation of intracellular estrogen receptor signaling pathway | 3 | 28 | 9.46e-01 |
| GO:BP | GO:0002577 | regulation of antigen processing and presentation | 1 | 8 | 9.46e-01 |
| GO:BP | GO:0034110 | regulation of homotypic cell-cell adhesion | 1 | 26 | 9.46e-01 |
| GO:BP | GO:0044409 | entry into host | 2 | 113 | 9.46e-01 |
| GO:BP | GO:0042308 | negative regulation of protein import into nucleus | 1 | 13 | 9.46e-01 |
| GO:BP | GO:0050654 | chondroitin sulfate proteoglycan metabolic process | 1 | 31 | 9.47e-01 |
| GO:BP | GO:0071868 | cellular response to monoamine stimulus | 5 | 60 | 9.48e-01 |
| GO:BP | GO:0071870 | cellular response to catecholamine stimulus | 5 | 60 | 9.48e-01 |
| GO:BP | GO:0006700 | C21-steroid hormone biosynthetic process | 1 | 17 | 9.48e-01 |
| GO:BP | GO:0060907 | positive regulation of macrophage cytokine production | 2 | 18 | 9.48e-01 |
| GO:BP | GO:0099175 | regulation of postsynapse organization | 11 | 83 | 9.49e-01 |
| GO:BP | GO:0009223 | pyrimidine deoxyribonucleotide catabolic process | 1 | 15 | 9.49e-01 |
| GO:BP | GO:0048732 | gland development | 4 | 318 | 9.49e-01 |
| GO:BP | GO:0042596 | fear response | 4 | 32 | 9.49e-01 |
| GO:BP | GO:0002507 | tolerance induction | 2 | 15 | 9.50e-01 |
| GO:BP | GO:0021513 | spinal cord dorsal/ventral patterning | 1 | 7 | 9.50e-01 |
| GO:BP | GO:0046364 | monosaccharide biosynthetic process | 2 | 79 | 9.50e-01 |
| GO:BP | GO:0045935 | positive regulation of nucleobase-containing compound metabolic process | 158 | 1602 | 9.50e-01 |
| GO:BP | GO:0032944 | regulation of mononuclear cell proliferation | 1 | 129 | 9.50e-01 |
| GO:BP | GO:0000398 | mRNA splicing, via spliceosome | 6 | 289 | 9.50e-01 |
| GO:BP | GO:0000377 | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 6 | 289 | 9.50e-01 |
| GO:BP | GO:0060350 | endochondral bone morphogenesis | 1 | 47 | 9.50e-01 |
| GO:BP | GO:0007631 | feeding behavior | 4 | 52 | 9.50e-01 |
| GO:BP | GO:0042531 | positive regulation of tyrosine phosphorylation of STAT protein | 1 | 23 | 9.50e-01 |
| GO:BP | GO:0071257 | cellular response to electrical stimulus | 1 | 8 | 9.50e-01 |
| GO:BP | GO:0000375 | RNA splicing, via transesterification reactions | 6 | 293 | 9.50e-01 |
| GO:BP | GO:0106118 | regulation of sterol biosynthetic process | 1 | 16 | 9.50e-01 |
| GO:BP | GO:0002444 | myeloid leukocyte mediated immunity | 2 | 60 | 9.50e-01 |
| GO:BP | GO:0060986 | endocrine hormone secretion | 1 | 35 | 9.50e-01 |
| GO:BP | GO:1902652 | secondary alcohol metabolic process | 1 | 108 | 9.50e-01 |
| GO:BP | GO:0010467 | gene expression | 2 | 4587 | 9.50e-01 |
| GO:BP | GO:0045540 | regulation of cholesterol biosynthetic process | 1 | 16 | 9.50e-01 |
| GO:BP | GO:1905874 | regulation of postsynaptic density organization | 1 | 10 | 9.50e-01 |
| GO:BP | GO:0007379 | segment specification | 1 | 14 | 9.50e-01 |
| GO:BP | GO:0097475 | motor neuron migration | 1 | 10 | 9.50e-01 |
| GO:BP | GO:0042398 | cellular modified amino acid biosynthetic process | 1 | 26 | 9.50e-01 |
| GO:BP | GO:0044793 | negative regulation by host of viral process | 1 | 10 | 9.50e-01 |
| GO:BP | GO:0006820 | monoatomic anion transport | 1 | 83 | 9.50e-01 |
| GO:BP | GO:0034111 | negative regulation of homotypic cell-cell adhesion | 1 | 13 | 9.50e-01 |
| GO:BP | GO:0042448 | progesterone metabolic process | 1 | 13 | 9.51e-01 |
| GO:BP | GO:0071280 | cellular response to copper ion | 2 | 18 | 9.51e-01 |
| GO:BP | GO:0060123 | regulation of growth hormone secretion | 1 | 10 | 9.51e-01 |
| GO:BP | GO:0022037 | metencephalon development | 5 | 84 | 9.51e-01 |
| GO:BP | GO:1901879 | regulation of protein depolymerization | 3 | 78 | 9.51e-01 |
| GO:BP | GO:0033080 | immature T cell proliferation in thymus | 1 | 7 | 9.51e-01 |
| GO:BP | GO:0033079 | immature T cell proliferation | 1 | 7 | 9.51e-01 |
| GO:BP | GO:0002768 | immune response-regulating cell surface receptor signaling pathway | 1 | 162 | 9.51e-01 |
| GO:BP | GO:0032494 | response to peptidoglycan | 1 | 5 | 9.51e-01 |
| GO:BP | GO:0061081 | positive regulation of myeloid leukocyte cytokine production involved in immune response | 3 | 26 | 9.51e-01 |
| GO:BP | GO:0071474 | cellular hyperosmotic response | 1 | 13 | 9.51e-01 |
| GO:BP | GO:0099171 | presynaptic modulation of chemical synaptic transmission | 3 | 26 | 9.51e-01 |
| GO:BP | GO:0045058 | T cell selection | 2 | 22 | 9.51e-01 |
| GO:BP | GO:0097553 | calcium ion transmembrane import into cytosol | 2 | 115 | 9.52e-01 |
| GO:BP | GO:1905145 | cellular response to acetylcholine | 1 | 20 | 9.52e-01 |
| GO:BP | GO:0001656 | metanephros development | 3 | 64 | 9.52e-01 |
| GO:BP | GO:1904862 | inhibitory synapse assembly | 1 | 13 | 9.52e-01 |
| GO:BP | GO:0031665 | negative regulation of lipopolysaccharide-mediated signaling pathway | 1 | 7 | 9.52e-01 |
| GO:BP | GO:0051224 | negative regulation of protein transport | 3 | 91 | 9.52e-01 |
| GO:BP | GO:0034332 | adherens junction organization | 1 | 41 | 9.53e-01 |
| GO:BP | GO:0098659 | inorganic cation import across plasma membrane | 1 | 73 | 9.53e-01 |
| GO:BP | GO:0099587 | inorganic ion import across plasma membrane | 1 | 73 | 9.53e-01 |
| GO:BP | GO:0030007 | intracellular potassium ion homeostasis | 1 | 11 | 9.53e-01 |
| GO:BP | GO:1902644 | tertiary alcohol metabolic process | 1 | 17 | 9.53e-01 |
| GO:BP | GO:0051503 | adenine nucleotide transport | 1 | 23 | 9.53e-01 |
| GO:BP | GO:0070509 | calcium ion import | 4 | 37 | 9.53e-01 |
| GO:BP | GO:0002437 | inflammatory response to antigenic stimulus | 2 | 36 | 9.53e-01 |
| GO:BP | GO:0070293 | renal absorption | 1 | 24 | 9.53e-01 |
| GO:BP | GO:0046040 | IMP metabolic process | 1 | 15 | 9.53e-01 |
| GO:BP | GO:0038084 | vascular endothelial growth factor signaling pathway | 3 | 35 | 9.54e-01 |
| GO:BP | GO:0042098 | T cell proliferation | 3 | 120 | 9.54e-01 |
| GO:BP | GO:0010447 | response to acidic pH | 1 | 16 | 9.55e-01 |
| GO:BP | GO:1903169 | regulation of calcium ion transmembrane transport | 2 | 122 | 9.55e-01 |
| GO:BP | GO:0042953 | lipoprotein transport | 1 | 14 | 9.55e-01 |
| GO:BP | GO:0072577 | endothelial cell apoptotic process | 3 | 40 | 9.55e-01 |
| GO:BP | GO:0051289 | protein homotetramerization | 2 | 42 | 9.56e-01 |
| GO:BP | GO:0046688 | response to copper ion | 2 | 29 | 9.56e-01 |
| GO:BP | GO:0071867 | response to monoamine | 5 | 62 | 9.56e-01 |
| GO:BP | GO:0050435 | amyloid-beta metabolic process | 2 | 48 | 9.56e-01 |
| GO:BP | GO:0071869 | response to catecholamine | 5 | 62 | 9.56e-01 |
| GO:BP | GO:0046660 | female sex differentiation | 4 | 91 | 9.56e-01 |
| GO:BP | GO:0072009 | nephron epithelium development | 4 | 86 | 9.56e-01 |
| GO:BP | GO:0060977 | coronary vasculature morphogenesis | 1 | 17 | 9.56e-01 |
| GO:BP | GO:0009395 | phospholipid catabolic process | 2 | 37 | 9.56e-01 |
| GO:BP | GO:0007368 | determination of left/right symmetry | 12 | 97 | 9.56e-01 |
| GO:BP | GO:0002890 | negative regulation of immunoglobulin mediated immune response | 1 | 9 | 9.56e-01 |
| GO:BP | GO:0048856 | anatomical structure development | 1 | 4128 | 9.56e-01 |
| GO:BP | GO:0002713 | negative regulation of B cell mediated immunity | 1 | 9 | 9.56e-01 |
| GO:BP | GO:0032986 | protein-DNA complex disassembly | 1 | 18 | 9.57e-01 |
| GO:BP | GO:1903305 | regulation of regulated secretory pathway | 1 | 89 | 9.57e-01 |
| GO:BP | GO:0042269 | regulation of natural killer cell mediated cytotoxicity | 1 | 18 | 9.57e-01 |
| GO:BP | GO:1903020 | positive regulation of glycoprotein metabolic process | 1 | 17 | 9.58e-01 |
| GO:BP | GO:0051283 | negative regulation of sequestering of calcium ion | 14 | 83 | 9.58e-01 |
| GO:BP | GO:0043457 | regulation of cellular respiration | 1 | 42 | 9.58e-01 |
| GO:BP | GO:0044273 | sulfur compound catabolic process | 2 | 31 | 9.59e-01 |
| GO:BP | GO:0046049 | UMP metabolic process | 1 | 10 | 9.59e-01 |
| GO:BP | GO:0042976 | activation of Janus kinase activity | 1 | 7 | 9.60e-01 |
| GO:BP | GO:0099150 | regulation of postsynaptic specialization assembly | 1 | 12 | 9.60e-01 |
| GO:BP | GO:0070098 | chemokine-mediated signaling pathway | 3 | 28 | 9.60e-01 |
| GO:BP | GO:0000303 | response to superoxide | 1 | 21 | 9.60e-01 |
| GO:BP | GO:0008277 | regulation of G protein-coupled receptor signaling pathway | 7 | 94 | 9.60e-01 |
| GO:BP | GO:1904950 | negative regulation of establishment of protein localization | 3 | 95 | 9.60e-01 |
| GO:BP | GO:0071466 | cellular response to xenobiotic stimulus | 2 | 105 | 9.60e-01 |
| GO:BP | GO:0060192 | negative regulation of lipase activity | 1 | 13 | 9.60e-01 |
| GO:BP | GO:0035357 | peroxisome proliferator activated receptor signaling pathway | 1 | 19 | 9.60e-01 |
| GO:BP | GO:0042982 | amyloid precursor protein metabolic process | 3 | 69 | 9.60e-01 |
| GO:BP | GO:0000096 | sulfur amino acid metabolic process | 2 | 27 | 9.60e-01 |
| GO:BP | GO:0015670 | carbon dioxide transport | 1 | 2 | 9.61e-01 |
| GO:BP | GO:1901623 | regulation of lymphocyte chemotaxis | 2 | 13 | 9.61e-01 |
| GO:BP | GO:0006195 | purine nucleotide catabolic process | 4 | 48 | 9.62e-01 |
| GO:BP | GO:1901017 | negative regulation of potassium ion transmembrane transporter activity | 1 | 14 | 9.62e-01 |
| GO:BP | GO:0032271 | regulation of protein polymerization | 11 | 168 | 9.62e-01 |
| GO:BP | GO:1902041 | regulation of extrinsic apoptotic signaling pathway via death domain receptors | 3 | 40 | 9.62e-01 |
| GO:BP | GO:0006897 | endocytosis | 1 | 527 | 9.62e-01 |
| GO:BP | GO:0072160 | nephron tubule epithelial cell differentiation | 1 | 12 | 9.62e-01 |
| GO:BP | GO:0015865 | purine nucleotide transport | 1 | 23 | 9.63e-01 |
| GO:BP | GO:0070663 | regulation of leukocyte proliferation | 1 | 141 | 9.63e-01 |
| GO:BP | GO:0022414 | reproductive process | 2 | 927 | 9.63e-01 |
| GO:BP | GO:0007548 | sex differentiation | 3 | 191 | 9.63e-01 |
| GO:BP | GO:0035335 | peptidyl-tyrosine dephosphorylation | 1 | 26 | 9.63e-01 |
| GO:BP | GO:0032526 | response to retinoic acid | 2 | 85 | 9.63e-01 |
| GO:BP | GO:0044872 | lipoprotein localization | 1 | 15 | 9.64e-01 |
| GO:BP | GO:0051893 | regulation of focal adhesion assembly | 5 | 59 | 9.64e-01 |
| GO:BP | GO:0090109 | regulation of cell-substrate junction assembly | 5 | 59 | 9.64e-01 |
| GO:BP | GO:0045123 | cellular extravasation | 3 | 44 | 9.64e-01 |
| GO:BP | GO:0000003 | reproduction | 2 | 934 | 9.64e-01 |
| GO:BP | GO:0032755 | positive regulation of interleukin-6 production | 1 | 56 | 9.64e-01 |
| GO:BP | GO:1905144 | response to acetylcholine | 1 | 22 | 9.64e-01 |
| GO:BP | GO:0021511 | spinal cord patterning | 1 | 9 | 9.65e-01 |
| GO:BP | GO:0019370 | leukotriene biosynthetic process | 1 | 7 | 9.65e-01 |
| GO:BP | GO:0090659 | walking behavior | 3 | 25 | 9.65e-01 |
| GO:BP | GO:0002921 | negative regulation of humoral immune response | 1 | 10 | 9.65e-01 |
| GO:BP | GO:0072012 | glomerulus vasculature development | 2 | 22 | 9.65e-01 |
| GO:BP | GO:0021680 | cerebellar Purkinje cell layer development | 1 | 24 | 9.65e-01 |
| GO:BP | GO:2000649 | regulation of sodium ion transmembrane transporter activity | 2 | 44 | 9.65e-01 |
| GO:BP | GO:0051282 | regulation of sequestering of calcium ion | 14 | 85 | 9.65e-01 |
| GO:BP | GO:0010975 | regulation of neuron projection development | 1 | 372 | 9.65e-01 |
| GO:BP | GO:0031054 | pre-miRNA processing | 1 | 14 | 9.65e-01 |
| GO:BP | GO:0030902 | hindbrain development | 2 | 114 | 9.66e-01 |
| GO:BP | GO:0000305 | response to oxygen radical | 1 | 22 | 9.66e-01 |
| GO:BP | GO:0021871 | forebrain regionalization | 1 | 8 | 9.66e-01 |
| GO:BP | GO:0035338 | long-chain fatty-acyl-CoA biosynthetic process | 1 | 14 | 9.66e-01 |
| GO:BP | GO:0030903 | notochord development | 1 | 17 | 9.66e-01 |
| GO:BP | GO:0060343 | trabecula formation | 1 | 23 | 9.67e-01 |
| GO:BP | GO:0030810 | positive regulation of nucleotide biosynthetic process | 1 | 12 | 9.67e-01 |
| GO:BP | GO:1900373 | positive regulation of purine nucleotide biosynthetic process | 1 | 12 | 9.67e-01 |
| GO:BP | GO:0061644 | protein localization to CENP-A containing chromatin | 1 | 17 | 9.68e-01 |
| GO:BP | GO:0072073 | kidney epithelium development | 5 | 112 | 9.69e-01 |
| GO:BP | GO:1904889 | regulation of excitatory synapse assembly | 1 | 12 | 9.69e-01 |
| GO:BP | GO:0010919 | regulation of inositol phosphate biosynthetic process | 1 | 6 | 9.69e-01 |
| GO:BP | GO:0060993 | kidney morphogenesis | 3 | 73 | 9.69e-01 |
| GO:BP | GO:0001657 | ureteric bud development | 3 | 75 | 9.69e-01 |
| GO:BP | GO:0071526 | semaphorin-plexin signaling pathway | 1 | 44 | 9.69e-01 |
| GO:BP | GO:0072224 | metanephric glomerulus development | 1 | 10 | 9.69e-01 |
| GO:BP | GO:0050857 | positive regulation of antigen receptor-mediated signaling pathway | 1 | 16 | 9.69e-01 |
| GO:BP | GO:0006493 | protein O-linked glycosylation | 3 | 69 | 9.70e-01 |
| GO:BP | GO:0002715 | regulation of natural killer cell mediated immunity | 1 | 18 | 9.70e-01 |
| GO:BP | GO:0043603 | amide metabolic process | 17 | 993 | 9.70e-01 |
| GO:BP | GO:0042471 | ear morphogenesis | 6 | 73 | 9.70e-01 |
| GO:BP | GO:0032272 | negative regulation of protein polymerization | 6 | 71 | 9.70e-01 |
| GO:BP | GO:0008038 | neuron recognition | 3 | 39 | 9.70e-01 |
| GO:BP | GO:0048066 | developmental pigmentation | 2 | 36 | 9.70e-01 |
| GO:BP | GO:0061008 | hepaticobiliary system development | 14 | 112 | 9.70e-01 |
| GO:BP | GO:0070199 | establishment of protein localization to chromosome | 2 | 25 | 9.71e-01 |
| GO:BP | GO:0072163 | mesonephric epithelium development | 3 | 76 | 9.71e-01 |
| GO:BP | GO:0072164 | mesonephric tubule development | 3 | 76 | 9.71e-01 |
| GO:BP | GO:0042509 | regulation of tyrosine phosphorylation of STAT protein | 3 | 34 | 9.71e-01 |
| GO:BP | GO:0070734 | histone H3-K27 methylation | 1 | 9 | 9.71e-01 |
| GO:BP | GO:0001523 | retinoid metabolic process | 1 | 40 | 9.71e-01 |
| GO:BP | GO:0042220 | response to cocaine | 4 | 28 | 9.71e-01 |
| GO:BP | GO:0015698 | inorganic anion transport | 1 | 104 | 9.71e-01 |
| GO:BP | GO:0006022 | aminoglycan metabolic process | 2 | 93 | 9.71e-01 |
| GO:BP | GO:0060972 | left/right pattern formation | 12 | 101 | 9.71e-01 |
| GO:BP | GO:0003382 | epithelial cell morphogenesis | 1 | 24 | 9.71e-01 |
| GO:BP | GO:0030852 | regulation of granulocyte differentiation | 1 | 11 | 9.71e-01 |
| GO:BP | GO:0042445 | hormone metabolic process | 1 | 133 | 9.71e-01 |
| GO:BP | GO:0097186 | amelogenesis | 2 | 14 | 9.71e-01 |
| GO:BP | GO:0042102 | positive regulation of T cell proliferation | 1 | 47 | 9.72e-01 |
| GO:BP | GO:0002837 | regulation of immune response to tumor cell | 1 | 10 | 9.72e-01 |
| GO:BP | GO:0060252 | positive regulation of glial cell proliferation | 1 | 14 | 9.72e-01 |
| GO:BP | GO:0051262 | protein tetramerization | 4 | 64 | 9.72e-01 |
| GO:BP | GO:0000578 | embryonic axis specification | 4 | 26 | 9.72e-01 |
| GO:BP | GO:0060349 | bone morphogenesis | 3 | 74 | 9.72e-01 |
| GO:BP | GO:0090136 | epithelial cell-cell adhesion | 1 | 16 | 9.72e-01 |
| GO:BP | GO:0002407 | dendritic cell chemotaxis | 1 | 9 | 9.73e-01 |
| GO:BP | GO:0043551 | regulation of phosphatidylinositol 3-kinase activity | 4 | 30 | 9.73e-01 |
| GO:BP | GO:0030833 | regulation of actin filament polymerization | 16 | 110 | 9.73e-01 |
| GO:BP | GO:0061035 | regulation of cartilage development | 1 | 54 | 9.73e-01 |
| GO:BP | GO:0050727 | regulation of inflammatory response | 8 | 212 | 9.73e-01 |
| GO:BP | GO:0006909 | phagocytosis | 2 | 148 | 9.73e-01 |
| GO:BP | GO:1901890 | positive regulation of cell junction assembly | 1 | 82 | 9.73e-01 |
| GO:BP | GO:0032502 | developmental process | 1 | 4494 | 9.73e-01 |
| GO:BP | GO:0072044 | collecting duct development | 1 | 6 | 9.73e-01 |
| GO:BP | GO:0032387 | negative regulation of intracellular transport | 1 | 49 | 9.73e-01 |
| GO:BP | GO:0031281 | positive regulation of cyclase activity | 1 | 23 | 9.73e-01 |
| GO:BP | GO:0014002 | astrocyte development | 3 | 27 | 9.74e-01 |
| GO:BP | GO:0045921 | positive regulation of exocytosis | 6 | 62 | 9.74e-01 |
| GO:BP | GO:0098926 | postsynaptic signal transduction | 1 | 25 | 9.74e-01 |
| GO:BP | GO:0051592 | response to calcium ion | 1 | 113 | 9.74e-01 |
| GO:BP | GO:0003012 | muscle system process | 3 | 334 | 9.74e-01 |
| GO:BP | GO:0061318 | renal filtration cell differentiation | 1 | 17 | 9.74e-01 |
| GO:BP | GO:0072112 | podocyte differentiation | 1 | 17 | 9.74e-01 |
| GO:BP | GO:0019722 | calcium-mediated signaling | 2 | 122 | 9.74e-01 |
| GO:BP | GO:0051209 | release of sequestered calcium ion into cytosol | 1 | 82 | 9.74e-01 |
| GO:BP | GO:0032649 | regulation of type II interferon production | 1 | 52 | 9.74e-01 |
| GO:BP | GO:0006244 | pyrimidine nucleotide catabolic process | 1 | 19 | 9.74e-01 |
| GO:BP | GO:1903307 | positive regulation of regulated secretory pathway | 3 | 32 | 9.74e-01 |
| GO:BP | GO:0009067 | aspartate family amino acid biosynthetic process | 1 | 18 | 9.74e-01 |
| GO:BP | GO:0016101 | diterpenoid metabolic process | 1 | 43 | 9.74e-01 |
| GO:BP | GO:0034331 | cell junction maintenance | 3 | 40 | 9.74e-01 |
| GO:BP | GO:0048704 | embryonic skeletal system morphogenesis | 4 | 55 | 9.74e-01 |
| GO:BP | GO:0006775 | fat-soluble vitamin metabolic process | 2 | 20 | 9.75e-01 |
| GO:BP | GO:0032609 | type II interferon production | 1 | 53 | 9.75e-01 |
| GO:BP | GO:0008210 | estrogen metabolic process | 1 | 16 | 9.75e-01 |
| GO:BP | GO:0009173 | pyrimidine ribonucleoside monophosphate metabolic process | 1 | 12 | 9.75e-01 |
| GO:BP | GO:0061437 | renal system vasculature development | 2 | 24 | 9.75e-01 |
| GO:BP | GO:0061440 | kidney vasculature development | 2 | 24 | 9.75e-01 |
| GO:BP | GO:0007260 | tyrosine phosphorylation of STAT protein | 1 | 36 | 9.75e-01 |
| GO:BP | GO:0002088 | lens development in camera-type eye | 4 | 57 | 9.75e-01 |
| GO:BP | GO:0098739 | import across plasma membrane | 6 | 133 | 9.76e-01 |
| GO:BP | GO:0010035 | response to inorganic substance | 1 | 414 | 9.76e-01 |
| GO:BP | GO:0043278 | response to morphine | 1 | 16 | 9.76e-01 |
| GO:BP | GO:0022600 | digestive system process | 1 | 54 | 9.76e-01 |
| GO:BP | GO:0045217 | cell-cell junction maintenance | 1 | 13 | 9.76e-01 |
| GO:BP | GO:0001823 | mesonephros development | 3 | 77 | 9.76e-01 |
| GO:BP | GO:0086010 | membrane depolarization during action potential | 2 | 28 | 9.76e-01 |
| GO:BP | GO:0051208 | sequestering of calcium ion | 14 | 89 | 9.76e-01 |
| GO:BP | GO:0014072 | response to isoquinoline alkaloid | 1 | 16 | 9.76e-01 |
| GO:BP | GO:0010092 | specification of animal organ identity | 2 | 26 | 9.76e-01 |
| GO:BP | GO:0010812 | negative regulation of cell-substrate adhesion | 5 | 44 | 9.76e-01 |
| GO:BP | GO:0002834 | regulation of response to tumor cell | 1 | 11 | 9.76e-01 |
| GO:BP | GO:0050777 | negative regulation of immune response | 3 | 111 | 9.76e-01 |
| GO:BP | GO:0010460 | positive regulation of heart rate | 1 | 21 | 9.76e-01 |
| GO:BP | GO:0010629 | negative regulation of gene expression | 4 | 785 | 9.77e-01 |
| GO:BP | GO:0010721 | negative regulation of cell development | 1 | 191 | 9.77e-01 |
| GO:BP | GO:0050770 | regulation of axonogenesis | 6 | 139 | 9.77e-01 |
| GO:BP | GO:0048535 | lymph node development | 1 | 11 | 9.77e-01 |
| GO:BP | GO:1990868 | response to chemokine | 3 | 37 | 9.77e-01 |
| GO:BP | GO:1990869 | cellular response to chemokine | 3 | 37 | 9.77e-01 |
| GO:BP | GO:0035094 | response to nicotine | 1 | 28 | 9.77e-01 |
| GO:BP | GO:0002757 | immune response-activating signaling pathway | 1 | 230 | 9.77e-01 |
| GO:BP | GO:0072311 | glomerular epithelial cell differentiation | 1 | 17 | 9.77e-01 |
| GO:BP | GO:0050854 | regulation of antigen receptor-mediated signaling pathway | 4 | 40 | 9.77e-01 |
| GO:BP | GO:1902004 | positive regulation of amyloid-beta formation | 1 | 17 | 9.77e-01 |
| GO:BP | GO:0048608 | reproductive structure development | 2 | 212 | 9.77e-01 |
| GO:BP | GO:0007420 | brain development | 11 | 591 | 9.78e-01 |
| GO:BP | GO:0045596 | negative regulation of cell differentiation | 7 | 482 | 9.78e-01 |
| GO:BP | GO:0045428 | regulation of nitric oxide biosynthetic process | 2 | 38 | 9.78e-01 |
| GO:BP | GO:0045807 | positive regulation of endocytosis | 3 | 104 | 9.78e-01 |
| GO:BP | GO:0010544 | negative regulation of platelet activation | 1 | 17 | 9.78e-01 |
| GO:BP | GO:0030183 | B cell differentiation | 4 | 94 | 9.78e-01 |
| GO:BP | GO:0050672 | negative regulation of lymphocyte proliferation | 1 | 46 | 9.78e-01 |
| GO:BP | GO:0007626 | locomotory behavior | 2 | 138 | 9.78e-01 |
| GO:BP | GO:0031290 | retinal ganglion cell axon guidance | 1 | 13 | 9.78e-01 |
| GO:BP | GO:1902075 | cellular response to salt | 11 | 142 | 9.78e-01 |
| GO:BP | GO:1903510 | mucopolysaccharide metabolic process | 3 | 74 | 9.78e-01 |
| GO:BP | GO:0006851 | mitochondrial calcium ion transmembrane transport | 1 | 17 | 9.78e-01 |
| GO:BP | GO:0051546 | keratinocyte migration | 1 | 15 | 9.78e-01 |
| GO:BP | GO:1900006 | positive regulation of dendrite development | 1 | 14 | 9.78e-01 |
| GO:BP | GO:0061458 | reproductive system development | 2 | 215 | 9.78e-01 |
| GO:BP | GO:0032945 | negative regulation of mononuclear cell proliferation | 1 | 46 | 9.78e-01 |
| GO:BP | GO:0072523 | purine-containing compound catabolic process | 4 | 53 | 9.78e-01 |
| GO:BP | GO:0071827 | plasma lipoprotein particle organization | 1 | 27 | 9.78e-01 |
| GO:BP | GO:0042129 | regulation of T cell proliferation | 2 | 95 | 9.78e-01 |
| GO:BP | GO:0050766 | positive regulation of phagocytosis | 1 | 38 | 9.78e-01 |
| GO:BP | GO:0150116 | regulation of cell-substrate junction organization | 5 | 64 | 9.78e-01 |
| GO:BP | GO:0051963 | regulation of synapse assembly | 1 | 83 | 9.78e-01 |
| GO:BP | GO:0006862 | nucleotide transport | 1 | 28 | 9.78e-01 |
| GO:BP | GO:0032943 | mononuclear cell proliferation | 1 | 168 | 9.79e-01 |
| GO:BP | GO:0071800 | podosome assembly | 1 | 13 | 9.79e-01 |
| GO:BP | GO:0035269 | protein O-linked mannosylation | 1 | 16 | 9.79e-01 |
| GO:BP | GO:0051924 | regulation of calcium ion transport | 3 | 172 | 9.79e-01 |
| GO:BP | GO:1901380 | negative regulation of potassium ion transmembrane transport | 1 | 18 | 9.79e-01 |
| GO:BP | GO:0009154 | purine ribonucleotide catabolic process | 2 | 40 | 9.79e-01 |
| GO:BP | GO:0002827 | positive regulation of T-helper 1 type immune response | 1 | 5 | 9.79e-01 |
| GO:BP | GO:0015874 | norepinephrine transport | 1 | 9 | 9.79e-01 |
| GO:BP | GO:0016064 | immunoglobulin mediated immune response | 2 | 76 | 9.79e-01 |
| GO:BP | GO:0000041 | transition metal ion transport | 4 | 71 | 9.80e-01 |
| GO:BP | GO:0043368 | positive T cell selection | 1 | 16 | 9.80e-01 |
| GO:BP | GO:0014014 | negative regulation of gliogenesis | 1 | 26 | 9.80e-01 |
| GO:BP | GO:0006898 | receptor-mediated endocytosis | 4 | 196 | 9.80e-01 |
| GO:BP | GO:0003180 | aortic valve morphogenesis | 1 | 33 | 9.80e-01 |
| GO:BP | GO:0060973 | cell migration involved in heart development | 1 | 20 | 9.80e-01 |
| GO:BP | GO:0001912 | positive regulation of leukocyte mediated cytotoxicity | 1 | 20 | 9.81e-01 |
| GO:BP | GO:1902932 | positive regulation of alcohol biosynthetic process | 1 | 15 | 9.81e-01 |
| GO:BP | GO:0001889 | liver development | 13 | 110 | 9.81e-01 |
| GO:BP | GO:0050931 | pigment cell differentiation | 1 | 26 | 9.81e-01 |
| GO:BP | GO:1905606 | regulation of presynapse assembly | 1 | 25 | 9.81e-01 |
| GO:BP | GO:0099174 | regulation of presynapse organization | 1 | 25 | 9.81e-01 |
| GO:BP | GO:0019724 | B cell mediated immunity | 2 | 77 | 9.81e-01 |
| GO:BP | GO:0071391 | cellular response to estrogen stimulus | 1 | 15 | 9.81e-01 |
| GO:BP | GO:0031347 | regulation of defense response | 17 | 448 | 9.81e-01 |
| GO:BP | GO:0006936 | muscle contraction | 2 | 267 | 9.81e-01 |
| GO:BP | GO:0002764 | immune response-regulating signaling pathway | 1 | 242 | 9.81e-01 |
| GO:BP | GO:0032660 | regulation of interleukin-17 production | 1 | 20 | 9.82e-01 |
| GO:BP | GO:0032620 | interleukin-17 production | 1 | 20 | 9.82e-01 |
| GO:BP | GO:0050884 | neuromuscular process controlling posture | 1 | 12 | 9.82e-01 |
| GO:BP | GO:0045861 | negative regulation of proteolysis | 1 | 211 | 9.82e-01 |
| GO:BP | GO:0033273 | response to vitamin | 1 | 61 | 9.82e-01 |
| GO:BP | GO:0046545 | development of primary female sexual characteristics | 2 | 79 | 9.83e-01 |
| GO:BP | GO:0080164 | regulation of nitric oxide metabolic process | 2 | 40 | 9.83e-01 |
| GO:BP | GO:0042472 | inner ear morphogenesis | 4 | 59 | 9.83e-01 |
| GO:BP | GO:0010543 | regulation of platelet activation | 1 | 32 | 9.83e-01 |
| GO:BP | GO:0051384 | response to glucocorticoid | 6 | 93 | 9.83e-01 |
| GO:BP | GO:0006334 | nucleosome assembly | 1 | 80 | 9.83e-01 |
| GO:BP | GO:0006721 | terpenoid metabolic process | 1 | 50 | 9.84e-01 |
| GO:BP | GO:0071825 | protein-lipid complex subunit organization | 1 | 29 | 9.84e-01 |
| GO:BP | GO:1901016 | regulation of potassium ion transmembrane transporter activity | 5 | 45 | 9.85e-01 |
| GO:BP | GO:1901679 | nucleotide transmembrane transport | 1 | 18 | 9.85e-01 |
| GO:BP | GO:0060322 | head development | 2 | 633 | 9.85e-01 |
| GO:BP | GO:1902305 | regulation of sodium ion transmembrane transport | 2 | 51 | 9.85e-01 |
| GO:BP | GO:0045292 | mRNA cis splicing, via spliceosome | 4 | 26 | 9.85e-01 |
| GO:BP | GO:2000515 | negative regulation of CD4-positive, alpha-beta T cell activation | 2 | 21 | 9.85e-01 |
| GO:BP | GO:1905564 | positive regulation of vascular endothelial cell proliferation | 1 | 15 | 9.85e-01 |
| GO:BP | GO:0030041 | actin filament polymerization | 19 | 134 | 9.86e-01 |
| GO:BP | GO:0003351 | epithelial cilium movement involved in extracellular fluid movement | 1 | 29 | 9.86e-01 |
| GO:BP | GO:0042743 | hydrogen peroxide metabolic process | 1 | 29 | 9.86e-01 |
| GO:BP | GO:0050871 | positive regulation of B cell activation | 1 | 53 | 9.86e-01 |
| GO:BP | GO:0034505 | tooth mineralization | 2 | 17 | 9.87e-01 |
| GO:BP | GO:0008207 | C21-steroid hormone metabolic process | 2 | 28 | 9.87e-01 |
| GO:BP | GO:0007157 | heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules | 3 | 29 | 9.88e-01 |
| GO:BP | GO:0060425 | lung morphogenesis | 1 | 38 | 9.88e-01 |
| GO:BP | GO:0060563 | neuroepithelial cell differentiation | 2 | 22 | 9.88e-01 |
| GO:BP | GO:0032409 | regulation of transporter activity | 4 | 211 | 9.88e-01 |
| GO:BP | GO:0046777 | protein autophosphorylation | 9 | 188 | 9.88e-01 |
| GO:BP | GO:0021696 | cerebellar cortex morphogenesis | 1 | 30 | 9.88e-01 |
| GO:BP | GO:0030539 | male genitalia development | 1 | 13 | 9.88e-01 |
| GO:BP | GO:0006120 | mitochondrial electron transport, NADH to ubiquinone | 1 | 42 | 9.88e-01 |
| GO:BP | GO:0072010 | glomerular epithelium development | 1 | 18 | 9.88e-01 |
| GO:BP | GO:0002418 | immune response to tumor cell | 1 | 12 | 9.88e-01 |
| GO:BP | GO:1901381 | positive regulation of potassium ion transmembrane transport | 3 | 30 | 9.88e-01 |
| GO:BP | GO:0070661 | leukocyte proliferation | 1 | 188 | 9.88e-01 |
| GO:BP | GO:0043267 | negative regulation of potassium ion transport | 2 | 21 | 9.88e-01 |
| GO:BP | GO:0050729 | positive regulation of inflammatory response | 2 | 75 | 9.88e-01 |
| GO:BP | GO:0002861 | regulation of inflammatory response to antigenic stimulus | 2 | 24 | 9.88e-01 |
| GO:BP | GO:0036230 | granulocyte activation | 1 | 19 | 9.88e-01 |
| GO:BP | GO:0045581 | negative regulation of T cell differentiation | 4 | 27 | 9.88e-01 |
| GO:BP | GO:0031047 | RNA-mediated gene silencing | 1 | 103 | 9.88e-01 |
| GO:BP | GO:0009952 | anterior/posterior pattern specification | 4 | 127 | 9.88e-01 |
| GO:BP | GO:0007635 | chemosensory behavior | 1 | 10 | 9.88e-01 |
| GO:BP | GO:0032495 | response to muramyl dipeptide | 1 | 15 | 9.88e-01 |
| GO:BP | GO:0042100 | B cell proliferation | 6 | 45 | 9.88e-01 |
| GO:BP | GO:0010818 | T cell chemotaxis | 1 | 12 | 9.88e-01 |
| GO:BP | GO:0007194 | negative regulation of adenylate cyclase activity | 1 | 13 | 9.88e-01 |
| GO:BP | GO:0042573 | retinoic acid metabolic process | 1 | 12 | 9.89e-01 |
| GO:BP | GO:0031960 | response to corticosteroid | 7 | 109 | 9.90e-01 |
| GO:BP | GO:0034308 | primary alcohol metabolic process | 1 | 61 | 9.90e-01 |
| GO:BP | GO:0070613 | regulation of protein processing | 2 | 47 | 9.90e-01 |
| GO:BP | GO:0051938 | L-glutamate import | 2 | 25 | 9.91e-01 |
| GO:BP | GO:2000193 | positive regulation of fatty acid transport | 1 | 11 | 9.91e-01 |
| GO:BP | GO:0006706 | steroid catabolic process | 1 | 13 | 9.91e-01 |
| GO:BP | GO:0048813 | dendrite morphogenesis | 5 | 120 | 9.91e-01 |
| GO:BP | GO:0006817 | phosphate ion transport | 1 | 17 | 9.91e-01 |
| GO:BP | GO:0006929 | substrate-dependent cell migration | 1 | 24 | 9.91e-01 |
| GO:BP | GO:0030168 | platelet activation | 10 | 91 | 9.91e-01 |
| GO:BP | GO:0043552 | positive regulation of phosphatidylinositol 3-kinase activity | 2 | 21 | 9.91e-01 |
| GO:BP | GO:0042755 | eating behavior | 1 | 16 | 9.91e-01 |
| GO:BP | GO:0006858 | extracellular transport | 1 | 32 | 9.91e-01 |
| GO:BP | GO:0032101 | regulation of response to external stimulus | 5 | 662 | 9.91e-01 |
| GO:BP | GO:0036336 | dendritic cell migration | 1 | 15 | 9.91e-01 |
| GO:BP | GO:0015980 | energy derivation by oxidation of organic compounds | 7 | 288 | 9.91e-01 |
| GO:BP | GO:0009410 | response to xenobiotic stimulus | 10 | 279 | 9.91e-01 |
| GO:BP | GO:0002283 | neutrophil activation involved in immune response | 1 | 7 | 9.91e-01 |
| GO:BP | GO:0008064 | regulation of actin polymerization or depolymerization | 16 | 126 | 9.92e-01 |
| GO:BP | GO:0033108 | mitochondrial respiratory chain complex assembly | 6 | 94 | 9.92e-01 |
| GO:BP | GO:0023019 | signal transduction involved in regulation of gene expression | 1 | 14 | 9.92e-01 |
| GO:BP | GO:0008585 | female gonad development | 1 | 77 | 9.92e-01 |
| GO:BP | GO:0032722 | positive regulation of chemokine production | 1 | 32 | 9.92e-01 |
| GO:BP | GO:0022618 | ribonucleoprotein complex assembly | 1 | 203 | 9.92e-01 |
| GO:BP | GO:0071826 | ribonucleoprotein complex subunit organization | 1 | 211 | 9.92e-01 |
| GO:BP | GO:0031343 | positive regulation of cell killing | 1 | 23 | 9.92e-01 |
| GO:BP | GO:0002683 | negative regulation of immune system process | 3 | 289 | 9.92e-01 |
| GO:BP | GO:0071305 | cellular response to vitamin D | 1 | 14 | 9.93e-01 |
| GO:BP | GO:0042744 | hydrogen peroxide catabolic process | 1 | 12 | 9.93e-01 |
| GO:BP | GO:0032501 | multicellular organismal process | 1 | 4794 | 9.93e-01 |
| GO:BP | GO:0051693 | actin filament capping | 2 | 34 | 9.94e-01 |
| GO:BP | GO:0046717 | acid secretion | 1 | 25 | 9.94e-01 |
| GO:BP | GO:0048536 | spleen development | 2 | 28 | 9.94e-01 |
| GO:BP | GO:0050982 | detection of mechanical stimulus | 2 | 32 | 9.94e-01 |
| GO:BP | GO:0046636 | negative regulation of alpha-beta T cell activation | 3 | 25 | 9.94e-01 |
| GO:BP | GO:0007628 | adult walking behavior | 2 | 23 | 9.94e-01 |
| GO:BP | GO:0048485 | sympathetic nervous system development | 1 | 14 | 9.94e-01 |
| GO:BP | GO:2000401 | regulation of lymphocyte migration | 1 | 41 | 9.94e-01 |
| GO:BP | GO:0009261 | ribonucleotide catabolic process | 2 | 45 | 9.94e-01 |
| GO:BP | GO:0019433 | triglyceride catabolic process | 1 | 17 | 9.94e-01 |
| GO:BP | GO:0034728 | nucleosome organization | 1 | 98 | 9.94e-01 |
| GO:BP | GO:0051957 | positive regulation of amino acid transport | 1 | 16 | 9.94e-01 |
| GO:BP | GO:0008154 | actin polymerization or depolymerization | 22 | 160 | 9.94e-01 |
| GO:BP | GO:0045063 | T-helper 1 cell differentiation | 1 | 14 | 9.94e-01 |
| GO:BP | GO:0007602 | phototransduction | 1 | 17 | 9.94e-01 |
| GO:BP | GO:0031280 | negative regulation of cyclase activity | 1 | 13 | 9.94e-01 |
| GO:BP | GO:0009166 | nucleotide catabolic process | 5 | 69 | 9.94e-01 |
| GO:BP | GO:0009268 | response to pH | 1 | 26 | 9.95e-01 |
| GO:BP | GO:1902993 | positive regulation of amyloid precursor protein catabolic process | 1 | 22 | 9.95e-01 |
| GO:BP | GO:0046949 | fatty-acyl-CoA biosynthetic process | 1 | 20 | 9.95e-01 |
| GO:BP | GO:0043279 | response to alkaloid | 5 | 68 | 9.95e-01 |
| GO:BP | GO:0030832 | regulation of actin filament length | 16 | 127 | 9.95e-01 |
| GO:BP | GO:1903317 | regulation of protein maturation | 2 | 50 | 9.96e-01 |
| GO:BP | GO:0015669 | gas transport | 1 | 6 | 9.96e-01 |
| GO:BP | GO:0003091 | renal water homeostasis | 1 | 13 | 9.96e-01 |
| GO:BP | GO:0044237 | cellular metabolic process | 3 | 6996 | 9.96e-01 |
| GO:BP | GO:0050974 | detection of mechanical stimulus involved in sensory perception | 1 | 20 | 9.96e-01 |
| GO:BP | GO:0046058 | cAMP metabolic process | 1 | 19 | 9.96e-01 |
| GO:BP | GO:1902600 | proton transmembrane transport | 6 | 111 | 9.96e-01 |
| GO:BP | GO:0031100 | animal organ regeneration | 3 | 47 | 9.96e-01 |
| GO:BP | GO:0050671 | positive regulation of lymphocyte proliferation | 1 | 72 | 9.96e-01 |
| GO:BP | GO:1902930 | regulation of alcohol biosynthetic process | 2 | 33 | 9.97e-01 |
| GO:BP | GO:0032102 | negative regulation of response to external stimulus | 2 | 269 | 9.97e-01 |
| GO:BP | GO:0072006 | nephron development | 4 | 117 | 9.97e-01 |
| GO:BP | GO:0032412 | regulation of monoatomic ion transmembrane transporter activity | 2 | 190 | 9.97e-01 |
| GO:BP | GO:0010817 | regulation of hormone levels | 6 | 336 | 9.97e-01 |
| GO:BP | GO:0050886 | endocrine process | 1 | 57 | 9.97e-01 |
| GO:BP | GO:0006809 | nitric oxide biosynthetic process | 1 | 51 | 9.97e-01 |
| GO:BP | GO:0006614 | SRP-dependent cotranslational protein targeting to membrane | 1 | 30 | 9.97e-01 |
| GO:BP | GO:0035268 | protein mannosylation | 1 | 21 | 9.97e-01 |
| GO:BP | GO:0008344 | adult locomotory behavior | 2 | 60 | 9.98e-01 |
| GO:BP | GO:0021587 | cerebellum morphogenesis | 1 | 36 | 9.98e-01 |
| GO:BP | GO:0048240 | sperm capacitation | 1 | 7 | 9.98e-01 |
| GO:BP | GO:0050764 | regulation of phagocytosis | 5 | 57 | 9.98e-01 |
| GO:BP | GO:0006613 | cotranslational protein targeting to membrane | 1 | 35 | 9.98e-01 |
| GO:BP | GO:0001569 | branching involved in blood vessel morphogenesis | 2 | 29 | 9.99e-01 |
| GO:BP | GO:0051350 | negative regulation of lyase activity | 1 | 15 | 9.99e-01 |
| GO:BP | GO:0072001 | renal system development | 15 | 251 | 9.99e-01 |
| GO:BP | GO:0030042 | actin filament depolymerization | 3 | 50 | 9.99e-01 |
| GO:BP | GO:0030203 | glycosaminoglycan metabolic process | 3 | 87 | 9.99e-01 |
| GO:BP | GO:0048469 | cell maturation | 20 | 108 | 9.99e-01 |
| GO:BP | GO:0043550 | regulation of lipid kinase activity | 1 | 43 | 9.99e-01 |
| GO:BP | GO:0097502 | mannosylation | 2 | 32 | 9.99e-01 |
| GO:BP | GO:0022898 | regulation of transmembrane transporter activity | 2 | 199 | 9.99e-01 |
| GO:BP | GO:0030835 | negative regulation of actin filament depolymerization | 2 | 37 | 9.99e-01 |
| GO:BP | GO:0035024 | negative regulation of Rho protein signal transduction | 1 | 21 | 9.99e-01 |
| GO:BP | GO:0048247 | lymphocyte chemotaxis | 1 | 24 | 1.00e+00 |
| GO:BP | GO:0010608 | post-transcriptional regulation of gene expression | 1 | 468 | 1.00e+00 |
| GO:BP | GO:0007190 | activation of adenylate cyclase activity | 1 | 13 | 1.00e+00 |
| GO:BP | GO:1900047 | negative regulation of hemostasis | 1 | 34 | 1.00e+00 |
| GO:BP | GO:0002695 | negative regulation of leukocyte activation | 2 | 105 | 1.00e+00 |
| GO:BP | GO:0055082 | intracellular chemical homeostasis | 13 | 486 | 1.00e+00 |
| GO:BP | GO:0009060 | aerobic respiration | 2 | 168 | 1.00e+00 |
| GO:BP | GO:0000244 | spliceosomal tri-snRNP complex assembly | 1 | 20 | 1.00e+00 |
| GO:BP | GO:0048705 | skeletal system morphogenesis | 5 | 155 | 1.00e+00 |
| GO:BP | GO:0061005 | cell differentiation involved in kidney development | 3 | 42 | 1.00e+00 |
| GO:BP | GO:0030834 | regulation of actin filament depolymerization | 2 | 45 | 1.00e+00 |
| GO:BP | GO:0001822 | kidney development | 1 | 244 | 1.00e+00 |
| GO:BP | GO:0071805 | potassium ion transmembrane transport | 2 | 129 | 1.00e+00 |
| GO:BP | GO:0140448 | signaling receptor ligand precursor processing | 1 | 29 | 1.00e+00 |
| GO:BP | GO:0006691 | leukotriene metabolic process | 1 | 12 | 1.00e+00 |
| GO:BP | GO:0030857 | negative regulation of epithelial cell differentiation | 1 | 31 | 1.00e+00 |
| GO:BP | GO:1903038 | negative regulation of leukocyte cell-cell adhesion | 10 | 74 | 1.00e+00 |
| GO:BP | GO:0140962 | multicellular organismal-level chemical homeostasis | 1 | 34 | 1.00e+00 |
| GO:BP | GO:0006874 | intracellular calcium ion homeostasis | 1 | 200 | 1.00e+00 |
| GO:BP | GO:1903018 | regulation of glycoprotein metabolic process | 1 | 36 | 1.00e+00 |
| GO:BP | GO:0007565 | female pregnancy | 4 | 122 | 1.00e+00 |
| GO:BP | GO:0046209 | nitric oxide metabolic process | 1 | 55 | 1.00e+00 |
| GO:BP | GO:0042773 | ATP synthesis coupled electron transport | 1 | 82 | 1.00e+00 |
| GO:BP | GO:0006873 | intracellular monoatomic ion homeostasis | 2 | 362 | 1.00e+00 |
| GO:BP | GO:0050892 | intestinal absorption | 1 | 22 | 1.00e+00 |
| GO:BP | GO:0050891 | multicellular organismal-level water homeostasis | 1 | 16 | 1.00e+00 |
| GO:BP | GO:0050853 | B cell receptor signaling pathway | 4 | 32 | 1.00e+00 |
| GO:BP | GO:0010951 | negative regulation of endopeptidase activity | 3 | 102 | 1.00e+00 |
| GO:BP | GO:0010955 | negative regulation of protein processing | 1 | 19 | 1.00e+00 |
| GO:BP | GO:0050864 | regulation of B cell activation | 1 | 77 | 1.00e+00 |
| GO:BP | GO:0042130 | negative regulation of T cell proliferation | 5 | 38 | 1.00e+00 |
| GO:BP | GO:0006816 | calcium ion transport | 3 | 269 | 1.00e+00 |
| GO:BP | GO:0006814 | sodium ion transport | 1 | 160 | 1.00e+00 |
| GO:BP | GO:0050866 | negative regulation of cell activation | 2 | 124 | 1.00e+00 |
| GO:BP | GO:1902074 | response to salt | 1 | 271 | 1.00e+00 |
| GO:BP | GO:0002825 | regulation of T-helper 1 type immune response | 1 | 10 | 1.00e+00 |
| GO:BP | GO:0042119 | neutrophil activation | 2 | 16 | 1.00e+00 |
| GO:BP | GO:0042113 | B cell activation | 8 | 170 | 1.00e+00 |
| GO:BP | GO:0021575 | hindbrain morphogenesis | 1 | 38 | 1.00e+00 |
| GO:BP | GO:0050868 | negative regulation of T cell activation | 9 | 67 | 1.00e+00 |
| GO:BP | GO:0006812 | monoatomic cation transport | 1 | 669 | 1.00e+00 |
| GO:BP | GO:0002920 | regulation of humoral immune response | 1 | 18 | 1.00e+00 |
| GO:BP | GO:2000403 | positive regulation of lymphocyte migration | 2 | 24 | 1.00e+00 |
| GO:BP | GO:2000404 | regulation of T cell migration | 1 | 28 | 1.00e+00 |
| GO:BP | GO:0007339 | binding of sperm to zona pellucida | 1 | 20 | 1.00e+00 |
| GO:BP | GO:2000406 | positive regulation of T cell migration | 1 | 20 | 1.00e+00 |
| GO:BP | GO:0031279 | regulation of cyclase activity | 1 | 37 | 1.00e+00 |
| GO:BP | GO:1901888 | regulation of cell junction assembly | 1 | 168 | 1.00e+00 |
| GO:BP | GO:0010959 | regulation of metal ion transport | 4 | 275 | 1.00e+00 |
| GO:BP | GO:0043269 | regulation of monoatomic ion transport | 4 | 373 | 1.00e+00 |
| GO:BP | GO:1901570 | fatty acid derivative biosynthetic process | 1 | 33 | 1.00e+00 |
| GO:BP | GO:0050829 | defense response to Gram-negative bacterium | 1 | 20 | 1.00e+00 |
| GO:BP | GO:0035633 | maintenance of blood-brain barrier | 1 | 26 | 1.00e+00 |
| GO:BP | GO:0071706 | tumor necrosis factor superfamily cytokine production | 1 | 94 | 1.00e+00 |
| GO:BP | GO:0071704 | organic substance metabolic process | 1 | 8169 | 1.00e+00 |
| GO:BP | GO:0035725 | sodium ion transmembrane transport | 3 | 113 | 1.00e+00 |
| GO:BP | GO:0048821 | erythrocyte development | 1 | 30 | 1.00e+00 |
| GO:BP | GO:0035767 | endothelial cell chemotaxis | 1 | 23 | 1.00e+00 |
| GO:BP | GO:0042776 | proton motive force-driven mitochondrial ATP synthesis | 1 | 57 | 1.00e+00 |
| GO:BP | GO:0042775 | mitochondrial ATP synthesis coupled electron transport | 1 | 82 | 1.00e+00 |
| GO:BP | GO:0007416 | synapse assembly | 1 | 152 | 1.00e+00 |
| GO:BP | GO:0035850 | epithelial cell differentiation involved in kidney development | 2 | 35 | 1.00e+00 |
| GO:BP | GO:0006754 | ATP biosynthetic process | 3 | 87 | 1.00e+00 |
| GO:BP | GO:0050830 | defense response to Gram-positive bacterium | 1 | 33 | 1.00e+00 |
| GO:BP | GO:0050670 | regulation of lymphocyte proliferation | 3 | 126 | 1.00e+00 |
| GO:BP | GO:0019646 | aerobic electron transport chain | 1 | 74 | 1.00e+00 |
| GO:BP | GO:1901292 | nucleoside phosphate catabolic process | 5 | 74 | 1.00e+00 |
| GO:BP | GO:0060251 | regulation of glial cell proliferation | 1 | 26 | 1.00e+00 |
| GO:BP | GO:0001709 | cell fate determination | 1 | 25 | 1.00e+00 |
| GO:BP | GO:0031640 | killing of cells of another organism | 1 | 10 | 1.00e+00 |
| GO:BP | GO:0031638 | zymogen activation | 3 | 45 | 1.00e+00 |
| GO:BP | GO:1901379 | regulation of potassium ion transmembrane transport | 6 | 64 | 1.00e+00 |
| GO:BP | GO:0050913 | sensory perception of bitter taste | 1 | 4 | 1.00e+00 |
| GO:BP | GO:0050909 | sensory perception of taste | 1 | 13 | 1.00e+00 |
| GO:BP | GO:0050906 | detection of stimulus involved in sensory perception | 1 | 39 | 1.00e+00 |
| GO:BP | GO:0050819 | negative regulation of coagulation | 1 | 38 | 1.00e+00 |
| GO:BP | GO:0042742 | defense response to bacterium | 2 | 95 | 1.00e+00 |
| GO:BP | GO:1903318 | negative regulation of protein maturation | 1 | 19 | 1.00e+00 |
| GO:BP | GO:0032680 | regulation of tumor necrosis factor production | 1 | 91 | 1.00e+00 |
| GO:BP | GO:0017121 | plasma membrane phospholipid scrambling | 1 | 13 | 1.00e+00 |
| GO:BP | GO:0006968 | cellular defense response | 2 | 15 | 1.00e+00 |
| GO:BP | GO:0006959 | humoral immune response | 1 | 80 | 1.00e+00 |
| GO:BP | GO:0046639 | negative regulation of alpha-beta T cell differentiation | 1 | 17 | 1.00e+00 |
| GO:BP | GO:0046641 | positive regulation of alpha-beta T cell proliferation | 1 | 11 | 1.00e+00 |
| GO:BP | GO:0006953 | acute-phase response | 1 | 18 | 1.00e+00 |
| GO:BP | GO:0097305 | response to alcohol | 13 | 159 | 1.00e+00 |
| GO:BP | GO:0046651 | lymphocyte proliferation | 3 | 162 | 1.00e+00 |
| GO:BP | GO:0002043 | blood vessel endothelial cell proliferation involved in sprouting angiogenesis | 1 | 15 | 1.00e+00 |
| GO:BP | GO:1904062 | regulation of monoatomic cation transmembrane transport | 2 | 230 | 1.00e+00 |
| GO:BP | GO:0034220 | monoatomic ion transmembrane transport | 1 | 632 | 1.00e+00 |
| GO:BP | GO:0022904 | respiratory electron transport chain | 5 | 104 | 1.00e+00 |
| GO:BP | GO:0008037 | cell recognition | 1 | 87 | 1.00e+00 |
| GO:BP | GO:0022900 | electron transport chain | 6 | 142 | 1.00e+00 |
| GO:BP | GO:0002323 | natural killer cell activation involved in immune response | 1 | 6 | 1.00e+00 |
| GO:BP | GO:0030212 | hyaluronan metabolic process | 1 | 21 | 1.00e+00 |
| GO:BP | GO:0007608 | sensory perception of smell | 2 | 16 | 1.00e+00 |
| GO:BP | GO:0022613 | ribonucleoprotein complex biogenesis | 1 | 453 | 1.00e+00 |
| GO:BP | GO:0010257 | NADH dehydrogenase complex assembly | 1 | 55 | 1.00e+00 |
| GO:BP | GO:0000395 | mRNA 5’-splice site recognition | 1 | 8 | 1.00e+00 |
| GO:BP | GO:0032981 | mitochondrial respiratory chain complex I assembly | 1 | 55 | 1.00e+00 |
| GO:BP | GO:0007606 | sensory perception of chemical stimulus | 2 | 31 | 1.00e+00 |
| GO:BP | GO:0000387 | spliceosomal snRNP assembly | 1 | 45 | 1.00e+00 |
| GO:BP | GO:0046928 | regulation of neurotransmitter secretion | 4 | 57 | 1.00e+00 |
| GO:BP | GO:0010324 | membrane invagination | 2 | 49 | 1.00e+00 |
| GO:BP | GO:0045620 | negative regulation of lymphocyte differentiation | 4 | 33 | 1.00e+00 |
| GO:BP | GO:0009593 | detection of chemical stimulus | 1 | 27 | 1.00e+00 |
| GO:BP | GO:0009988 | cell-cell recognition | 1 | 32 | 1.00e+00 |
| GO:BP | GO:0030001 | metal ion transport | 1 | 562 | 1.00e+00 |
| GO:BP | GO:0009880 | embryonic pattern specification | 6 | 50 | 1.00e+00 |
| GO:BP | GO:0033555 | multicellular organismal response to stress | 2 | 57 | 1.00e+00 |
| GO:BP | GO:0046434 | organophosphate catabolic process | 8 | 113 | 1.00e+00 |
| GO:BP | GO:0046034 | ATP metabolic process | 2 | 116 | 1.00e+00 |
| GO:BP | GO:0015986 | proton motive force-driven ATP synthesis | 1 | 66 | 1.00e+00 |
| GO:BP | GO:0008209 | androgen metabolic process | 1 | 16 | 1.00e+00 |
| GO:BP | GO:0090218 | positive regulation of lipid kinase activity | 2 | 25 | 1.00e+00 |
| GO:BP | GO:0019835 | cytolysis | 1 | 6 | 1.00e+00 |
| GO:BP | GO:0045920 | negative regulation of exocytosis | 2 | 26 | 1.00e+00 |
| GO:BP | GO:0009620 | response to fungus | 1 | 22 | 1.00e+00 |
| GO:BP | GO:0006972 | hyperosmotic response | 1 | 19 | 1.00e+00 |
| GO:BP | GO:0009617 | response to bacterium | 1 | 321 | 1.00e+00 |
| GO:BP | GO:0051588 | regulation of neurotransmitter transport | 4 | 70 | 1.00e+00 |
| GO:BP | GO:0002251 | organ or tissue specific immune response | 1 | 13 | 1.00e+00 |
| GO:BP | GO:0030195 | negative regulation of blood coagulation | 1 | 34 | 1.00e+00 |
| GO:BP | GO:0008152 | metabolic process | 1 | 8518 | 1.00e+00 |
| GO:BP | GO:0061844 | antimicrobial humoral immune response mediated by antimicrobial peptide | 1 | 18 | 1.00e+00 |
| GO:BP | GO:0051349 | positive regulation of lyase activity | 2 | 23 | 1.00e+00 |
| GO:BP | GO:0009987 | cellular process | 1 | 11336 | 1.00e+00 |
| GO:BP | GO:0008150 | biological_process | 1 | 12070 | 1.00e+00 |
| GO:BP | GO:0045762 | positive regulation of adenylate cyclase activity | 1 | 19 | 1.00e+00 |
| GO:BP | GO:0045761 | regulation of adenylate cyclase activity | 2 | 32 | 1.00e+00 |
| GO:BP | GO:0006811 | monoatomic ion transport | 6 | 775 | 1.00e+00 |
| GO:BP | GO:0051339 | regulation of lyase activity | 4 | 39 | 1.00e+00 |
| GO:BP | GO:0030003 | intracellular monoatomic cation homeostasis | 2 | 357 | 1.00e+00 |
| GO:BP | GO:0002347 | response to tumor cell | 1 | 22 | 1.00e+00 |
| GO:BP | GO:0000365 | mRNA trans splicing, via spliceosome | 1 | 6 | 1.00e+00 |
| GO:BP | GO:0000353 | formation of quadruple SL/U4/U5/U6 snRNP | 1 | 6 | 1.00e+00 |
| GO:BP | GO:0001964 | startle response | 1 | 16 | 1.00e+00 |
| GO:BP | GO:0099024 | plasma membrane invagination | 1 | 42 | 1.00e+00 |
| GO:BP | GO:0016486 | peptide hormone processing | 1 | 27 | 1.00e+00 |
| GO:BP | GO:0034762 | regulation of transmembrane transport | 3 | 391 | 1.00e+00 |
| GO:BP | GO:1903557 | positive regulation of tumor necrosis factor superfamily cytokine production | 1 | 57 | 1.00e+00 |
| GO:BP | GO:1903555 | regulation of tumor necrosis factor superfamily cytokine production | 1 | 94 | 1.00e+00 |
| GO:BP | GO:0034765 | regulation of monoatomic ion transmembrane transport | 2 | 295 | 1.00e+00 |
| GO:BP | GO:0007600 | sensory perception | 3 | 269 | 1.00e+00 |
| GO:BP | GO:0051216 | cartilage development | 1 | 151 | 1.00e+00 |
| GO:BP | GO:0002548 | monocyte chemotaxis | 1 | 22 | 1.00e+00 |
| GO:BP | GO:0045047 | protein targeting to ER | 1 | 49 | 1.00e+00 |
| GO:BP | GO:0035036 | sperm-egg recognition | 1 | 22 | 1.00e+00 |
| GO:BP | GO:0006091 | generation of precursor metabolites and energy | 8 | 369 | 1.00e+00 |
| GO:BP | GO:0015697 | quaternary ammonium group transport | 1 | 17 | 1.00e+00 |
| GO:BP | GO:0033280 | response to vitamin D | 1 | 24 | 1.00e+00 |
| GO:BP | GO:0032640 | tumor necrosis factor production | 1 | 91 | 1.00e+00 |
| GO:BP | GO:2001057 | reactive nitrogen species metabolic process | 1 | 56 | 1.00e+00 |
| GO:BP | GO:0015695 | organic cation transport | 3 | 34 | 1.00e+00 |
| GO:BP | GO:0030534 | adult behavior | 3 | 92 | 1.00e+00 |
| GO:BP | GO:0030574 | collagen catabolic process | 1 | 26 | 1.00e+00 |
| GO:BP | GO:0044703 | multi-organism reproductive process | 4 | 131 | 1.00e+00 |
| GO:BP | GO:0035194 | ncRNA-mediated post-transcriptional gene silencing | 2 | 60 | 1.00e+00 |
| GO:BP | GO:0007187 | G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger | 1 | 18 | 1.00e+00 |
| GO:BP | GO:0055074 | calcium ion homeostasis | 1 | 214 | 1.00e+00 |
| GO:BP | GO:0035195 | miRNA-mediated gene silencing | 2 | 55 | 1.00e+00 |
| GO:BP | GO:0070588 | calcium ion transmembrane transport | 2 | 213 | 1.00e+00 |
| GO:BP | GO:0019730 | antimicrobial humoral response | 1 | 28 | 1.00e+00 |
| GO:BP | GO:0061045 | negative regulation of wound healing | 1 | 51 | 1.00e+00 |
| GO:BP | GO:0051954 | positive regulation of amine transport | 1 | 26 | 1.00e+00 |
| GO:BP | GO:0045103 | intermediate filament-based process | 4 | 40 | 1.00e+00 |
| GO:BP | GO:0098655 | monoatomic cation transmembrane transport | 2 | 540 | 1.00e+00 |
| GO:BP | GO:0098660 | inorganic ion transmembrane transport | 1 | 563 | 1.00e+00 |
| GO:BP | GO:0098662 | inorganic cation transmembrane transport | 2 | 517 | 1.00e+00 |
| GO:BP | GO:0045471 | response to ethanol | 4 | 73 | 1.00e+00 |
| GO:BP | GO:0022408 | negative regulation of cell-cell adhesion | 15 | 116 | 1.00e+00 |
| GO:BP | GO:0001953 | negative regulation of cell-matrix adhesion | 1 | 26 | 1.00e+00 |
| GO:BP | GO:0032892 | positive regulation of organic acid transport | 2 | 27 | 1.00e+00 |
| GO:BP | GO:0016339 | calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules | 1 | 28 | 1.00e+00 |
| GO:BP | GO:1903828 | negative regulation of protein localization | 5 | 160 | 1.00e+00 |
| GO:BP | GO:0045333 | cellular respiration | 2 | 211 | 1.00e+00 |
| GO:BP | GO:0051250 | negative regulation of lymphocyte activation | 1 | 90 | 1.00e+00 |
| GO:BP | GO:0032835 | glomerulus development | 4 | 54 | 1.00e+00 |
| GO:BP | GO:0045291 | mRNA trans splicing, SL addition | 1 | 6 | 1.00e+00 |
| GO:BP | GO:0016441 | post-transcriptional gene silencing | 3 | 65 | 1.00e+00 |
| GO:BP | GO:0006617 | SRP-dependent cotranslational protein targeting to membrane, signal sequence recognition | 1 | 17 | 1.00e+00 |
| GO:BP | GO:0072599 | establishment of protein localization to endoplasmic reticulum | 1 | 53 | 1.00e+00 |
| GO:BP | GO:0007156 | homophilic cell adhesion via plasma membrane adhesion molecules | 1 | 104 | 1.00e+00 |
| GO:BP | GO:0032760 | positive regulation of tumor necrosis factor production | 1 | 55 | 1.00e+00 |
| GO:BP | GO:0006119 | oxidative phosphorylation | 2 | 122 | 1.00e+00 |
| GO:BP | GO:0010466 | negative regulation of peptidase activity | 4 | 131 | 1.00e+00 |
| GO:BP | GO:0007162 | negative regulation of cell adhesion | 20 | 192 | 1.00e+00 |
| GO:BP | GO:0002446 | neutrophil mediated immunity | 1 | 17 | 1.00e+00 |
| GO:BP | GO:0019731 | antibacterial humoral response | 1 | 15 | 1.00e+00 |
| GO:BP | GO:0045109 | intermediate filament organization | 2 | 21 | 1.00e+00 |
| GO:BP | GO:0045104 | intermediate filament cytoskeleton organization | 4 | 39 | 1.00e+00 |
| GO:BP | GO:0006911 | phagocytosis, engulfment | 1 | 33 | 1.00e+00 |
| GO:BP | GO:0051606 | detection of stimulus | 1 | 110 | 1.00e+00 |
| KEGG | KEGG:04130 | SNARE interactions in vesicular transport | 7 | 32 | 5.51e-03 |
| KEGG | KEGG:04144 | Endocytosis | 36 | 232 | 2.32e-02 |
| KEGG | KEGG:05168 | Herpes simplex virus 1 infection | 66 | 415 | 2.32e-02 |
| KEGG | KEGG:05220 | Chronic myeloid leukemia | 12 | 75 | 8.11e-02 |
| KEGG | KEGG:00900 | Terpenoid backbone biosynthesis | 2 | 21 | 8.11e-02 |
| KEGG | KEGG:04120 | Ubiquitin mediated proteolysis | 21 | 134 | 8.11e-02 |
| KEGG | KEGG:05214 | Glioma | 20 | 67 | 8.11e-02 |
| KEGG | KEGG:05212 | Pancreatic cancer | 21 | 75 | 1.68e-01 |
| KEGG | KEGG:04115 | p53 signaling pathway | 8 | 65 | 1.68e-01 |
| KEGG | KEGG:03040 | Spliceosome | 4 | 132 | 2.25e-01 |
| KEGG | KEGG:03250 | Viral life cycle - HIV-1 | 14 | 56 | 2.34e-01 |
| KEGG | KEGG:01522 | Endocrine resistance | 15 | 85 | 2.34e-01 |
| KEGG | KEGG:04218 | Cellular senescence | 17 | 145 | 2.34e-01 |
| KEGG | KEGG:05210 | Colorectal cancer | 22 | 84 | 2.34e-01 |
| KEGG | KEGG:04141 | Protein processing in endoplasmic reticulum | 2 | 161 | 2.34e-01 |
| KEGG | KEGG:05216 | Thyroid cancer | 4 | 35 | 2.38e-01 |
| KEGG | KEGG:04930 | Type II diabetes mellitus | 1 | 35 | 2.38e-01 |
| KEGG | KEGG:05218 | Melanoma | 17 | 58 | 2.38e-01 |
| KEGG | KEGG:04070 | Phosphatidylinositol signaling system | 19 | 91 | 2.46e-01 |
| KEGG | KEGG:01250 | Biosynthesis of nucleotide sugars | 6 | 35 | 2.47e-01 |
| KEGG | KEGG:00750 | Vitamin B6 metabolism | 3 | 5 | 2.51e-01 |
| KEGG | KEGG:05012 | Parkinson disease | 1 | 226 | 2.83e-01 |
| KEGG | KEGG:05418 | Fluid shear stress and atherosclerosis | 1 | 114 | 2.87e-01 |
| KEGG | KEGG:04910 | Insulin signaling pathway | 1 | 121 | 2.87e-01 |
| KEGG | KEGG:05031 | Amphetamine addiction | 5 | 49 | 2.87e-01 |
| KEGG | KEGG:05022 | Pathways of neurodegeneration - multiple diseases | 1 | 385 | 2.87e-01 |
| KEGG | KEGG:04933 | AGE-RAGE signaling pathway in diabetic complications | 1 | 91 | 2.87e-01 |
| KEGG | KEGG:04931 | Insulin resistance | 1 | 95 | 2.87e-01 |
| KEGG | KEGG:04926 | Relaxin signaling pathway | 1 | 104 | 2.87e-01 |
| KEGG | KEGG:04666 | Fc gamma R-mediated phagocytosis | 3 | 75 | 2.87e-01 |
| KEGG | KEGG:04622 | RIG-I-like receptor signaling pathway | 6 | 49 | 2.87e-01 |
| KEGG | KEGG:04611 | Platelet activation | 1 | 89 | 2.87e-01 |
| KEGG | KEGG:05211 | Renal cell carcinoma | 8 | 65 | 2.87e-01 |
| KEGG | KEGG:04390 | Hippo signaling pathway | 1 | 134 | 2.87e-01 |
| KEGG | KEGG:04146 | Peroxisome | 3 | 68 | 2.87e-01 |
| KEGG | KEGG:05225 | Hepatocellular carcinoma | 30 | 145 | 2.87e-01 |
| KEGG | KEGG:04140 | Autophagy - animal | 23 | 133 | 2.87e-01 |
| KEGG | KEGG:04122 | Sulfur relay system | 3 | 8 | 2.87e-01 |
| KEGG | KEGG:04110 | Cell cycle | 13 | 151 | 2.87e-01 |
| KEGG | KEGG:04071 | Sphingolipid signaling pathway | 1 | 107 | 2.87e-01 |
| KEGG | KEGG:04068 | FoxO signaling pathway | 13 | 109 | 2.87e-01 |
| KEGG | KEGG:00290 | Valine, leucine and isoleucine biosynthesis | 2 | 3 | 2.87e-01 |
| KEGG | KEGG:00520 | Amino sugar and nucleotide sugar metabolism | 11 | 46 | 2.87e-01 |
| KEGG | KEGG:00562 | Inositol phosphate metabolism | 14 | 66 | 2.87e-01 |
| KEGG | KEGG:00590 | Arachidonic acid metabolism | 1 | 26 | 2.87e-01 |
| KEGG | KEGG:00920 | Sulfur metabolism | 2 | 10 | 2.87e-01 |
| KEGG | KEGG:00970 | Aminoacyl-tRNA biosynthesis | 3 | 44 | 2.87e-01 |
| KEGG | KEGG:01521 | EGFR tyrosine kinase inhibitor resistance | 16 | 74 | 2.87e-01 |
| KEGG | KEGG:03050 | Proteasome | 7 | 42 | 2.87e-01 |
| KEGG | KEGG:05161 | Hepatitis B | 8 | 136 | 2.87e-01 |
| KEGG | KEGG:05166 | Human T-cell leukemia virus 1 infection | 17 | 180 | 2.87e-01 |
| KEGG | KEGG:04370 | VEGF signaling pathway | 9 | 49 | 2.94e-01 |
| KEGG | KEGG:04530 | Tight junction | 1 | 137 | 2.94e-01 |
| KEGG | KEGG:04360 | Axon guidance | 1 | 162 | 3.08e-01 |
| KEGG | KEGG:04062 | Chemokine signaling pathway | 1 | 113 | 3.17e-01 |
| KEGG | KEGG:04015 | Rap1 signaling pathway | 1 | 164 | 3.31e-01 |
| KEGG | KEGG:00534 | Glycosaminoglycan biosynthesis - heparan sulfate / heparin | 1 | 20 | 3.31e-01 |
| KEGG | KEGG:05415 | Diabetic cardiomyopathy | 1 | 169 | 3.31e-01 |
| KEGG | KEGG:04210 | Apoptosis | 11 | 118 | 3.52e-01 |
| KEGG | KEGG:04012 | ErbB signaling pathway | 15 | 78 | 3.55e-01 |
| KEGG | KEGG:05213 | Endometrial cancer | 12 | 57 | 3.55e-01 |
| KEGG | KEGG:03018 | RNA degradation | 17 | 74 | 3.56e-01 |
| KEGG | KEGG:00052 | Galactose metabolism | 1 | 22 | 3.56e-01 |
| KEGG | KEGG:04145 | Phagosome | 2 | 99 | 3.60e-01 |
| KEGG | KEGG:04010 | MAPK signaling pathway | 22 | 240 | 3.69e-01 |
| KEGG | KEGG:01524 | Platinum drug resistance | 14 | 65 | 3.90e-01 |
| KEGG | KEGG:04137 | Mitophagy - animal | 1 | 70 | 3.90e-01 |
| KEGG | KEGG:05231 | Choline metabolism in cancer | 11 | 84 | 4.00e-01 |
| KEGG | KEGG:00524 | Neomycin, kanamycin and gentamicin biosynthesis | 1 | 4 | 4.00e-01 |
| KEGG | KEGG:00051 | Fructose and mannose metabolism | 3 | 27 | 4.02e-01 |
| KEGG | KEGG:03450 | Non-homologous end-joining | 4 | 12 | 4.02e-01 |
| KEGG | KEGG:05131 | Shigellosis | 24 | 210 | 4.02e-01 |
| KEGG | KEGG:05165 | Human papillomavirus infection | 1 | 272 | 4.09e-01 |
| KEGG | KEGG:05203 | Viral carcinogenesis | 12 | 172 | 4.34e-01 |
| KEGG | KEGG:03022 | Basal transcription factors | 4 | 40 | 4.34e-01 |
| KEGG | KEGG:03013 | Nucleocytoplasmic transport | 17 | 99 | 4.37e-01 |
| KEGG | KEGG:05030 | Cocaine addiction | 3 | 35 | 4.54e-01 |
| KEGG | KEGG:05160 | Hepatitis C | 9 | 115 | 4.54e-01 |
| KEGG | KEGG:03440 | Homologous recombination | 9 | 39 | 4.57e-01 |
| KEGG | KEGG:00630 | Glyoxylate and dicarboxylate metabolism | 4 | 25 | 4.65e-01 |
| KEGG | KEGG:05224 | Breast cancer | 15 | 117 | 4.65e-01 |
| KEGG | KEGG:04340 | Hedgehog signaling pathway | 7 | 49 | 4.65e-01 |
| KEGG | KEGG:00310 | Lysine degradation | 5 | 59 | 4.65e-01 |
| KEGG | KEGG:03015 | mRNA surveillance pathway | 6 | 86 | 4.69e-01 |
| KEGG | KEGG:00860 | Porphyrin metabolism | 2 | 22 | 4.69e-01 |
| KEGG | KEGG:05223 | Non-small cell lung cancer | 13 | 67 | 4.76e-01 |
| KEGG | KEGG:00600 | Sphingolipid metabolism | 7 | 44 | 4.76e-01 |
| KEGG | KEGG:00564 | Glycerophospholipid metabolism | 2 | 76 | 4.76e-01 |
| KEGG | KEGG:05135 | Yersinia infection | 14 | 112 | 4.76e-01 |
| KEGG | KEGG:05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 8 | 69 | 4.76e-01 |
| KEGG | KEGG:05217 | Basal cell carcinoma | 13 | 49 | 4.76e-01 |
| KEGG | KEGG:04977 | Vitamin digestion and absorption | 1 | 14 | 4.76e-01 |
| KEGG | KEGG:04270 | Vascular smooth muscle contraction | 1 | 94 | 4.76e-01 |
| KEGG | KEGG:03060 | Protein export | 2 | 23 | 4.76e-01 |
| KEGG | KEGG:04213 | Longevity regulating pathway - multiple species | 7 | 55 | 4.82e-01 |
| KEGG | KEGG:04211 | Longevity regulating pathway | 16 | 78 | 5.17e-01 |
| KEGG | KEGG:04520 | Adherens junction | 3 | 67 | 5.18e-01 |
| KEGG | KEGG:05222 | Small cell lung cancer | 7 | 87 | 5.18e-01 |
| KEGG | KEGG:04060 | Cytokine-cytokine receptor interaction | 1 | 98 | 5.18e-01 |
| KEGG | KEGG:00670 | One carbon pool by folate | 3 | 18 | 5.25e-01 |
| KEGG | KEGG:04022 | cGMP-PKG signaling pathway | 1 | 133 | 5.25e-01 |
| KEGG | KEGG:04136 | Autophagy - other | 7 | 31 | 5.25e-01 |
| KEGG | KEGG:04621 | NOD-like receptor signaling pathway | 1 | 117 | 5.55e-01 |
| KEGG | KEGG:04625 | C-type lectin receptor signaling pathway | 4 | 76 | 5.55e-01 |
| KEGG | KEGG:04720 | Long-term potentiation | 4 | 55 | 5.55e-01 |
| KEGG | KEGG:04392 | Hippo signaling pathway - multiple species | 6 | 25 | 5.55e-01 |
| KEGG | KEGG:05219 | Bladder cancer | 3 | 37 | 5.55e-01 |
| KEGG | KEGG:03264 | Virion - Flavivirus | 1 | 1 | 5.55e-01 |
| KEGG | KEGG:04215 | Apoptosis - multiple species | 5 | 30 | 5.55e-01 |
| KEGG | KEGG:05215 | Prostate cancer | 8 | 86 | 5.55e-01 |
| KEGG | KEGG:04330 | Notch signaling pathway | 1 | 51 | 5.55e-01 |
| KEGG | KEGG:05169 | Epstein-Barr virus infection | 10 | 153 | 5.55e-01 |
| KEGG | KEGG:05226 | Gastric cancer | 14 | 117 | 5.55e-01 |
| KEGG | KEGG:05100 | Bacterial invasion of epithelial cells | 1 | 74 | 5.55e-01 |
| KEGG | KEGG:01200 | Carbon metabolism | 7 | 98 | 5.78e-01 |
| KEGG | KEGG:05230 | Central carbon metabolism in cancer | 6 | 62 | 5.78e-01 |
| KEGG | KEGG:04710 | Circadian rhythm | 5 | 30 | 5.78e-01 |
| KEGG | KEGG:04660 | T cell receptor signaling pathway | 15 | 70 | 5.78e-01 |
| KEGG | KEGG:05132 | Salmonella infection | 24 | 214 | 6.03e-01 |
| KEGG | KEGG:05202 | Transcriptional misregulation in cancer | 19 | 128 | 6.03e-01 |
| KEGG | KEGG:04714 | Thermogenesis | 1 | 195 | 6.03e-01 |
| KEGG | KEGG:00240 | Pyrimidine metabolism | 6 | 46 | 6.03e-01 |
| KEGG | KEGG:04919 | Thyroid hormone signaling pathway | 10 | 112 | 6.05e-01 |
| KEGG | KEGG:00565 | Ether lipid metabolism | 8 | 28 | 6.09e-01 |
| KEGG | KEGG:04064 | NF-kappa B signaling pathway | 5 | 71 | 6.09e-01 |
| KEGG | KEGG:03420 | Nucleotide excision repair | 4 | 43 | 6.13e-01 |
| KEGG | KEGG:04975 | Fat digestion and absorption | 1 | 19 | 6.13e-01 |
| KEGG | KEGG:04728 | Dopaminergic synapse | 6 | 103 | 6.13e-01 |
| KEGG | KEGG:00100 | Steroid biosynthesis | 1 | 17 | 6.20e-01 |
| KEGG | KEGG:03460 | Fanconi anemia pathway | 9 | 48 | 6.20e-01 |
| KEGG | KEGG:05152 | Tuberculosis | 17 | 106 | 6.22e-01 |
| KEGG | KEGG:01232 | Nucleotide metabolism | 8 | 69 | 6.22e-01 |
| KEGG | KEGG:04668 | TNF signaling pathway | 13 | 87 | 6.22e-01 |
| KEGG | KEGG:04722 | Neurotrophin signaling pathway | 12 | 110 | 6.22e-01 |
| KEGG | KEGG:00563 | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 1 | 25 | 6.22e-01 |
| KEGG | KEGG:05034 | Alcoholism | 7 | 122 | 6.22e-01 |
| KEGG | KEGG:00513 | Various types of N-glycan biosynthesis | 1 | 36 | 6.22e-01 |
| KEGG | KEGG:04350 | TGF-beta signaling pathway | 3 | 84 | 6.23e-01 |
| KEGG | KEGG:00910 | Nitrogen metabolism | 1 | 10 | 6.28e-01 |
| KEGG | KEGG:00983 | Drug metabolism - other enzymes | 7 | 44 | 6.42e-01 |
| KEGG | KEGG:00020 | Citrate cycle (TCA cycle) | 2 | 28 | 6.42e-01 |
| KEGG | KEGG:04066 | HIF-1 signaling pathway | 8 | 89 | 6.42e-01 |
| KEGG | KEGG:01240 | Biosynthesis of cofactors | 18 | 115 | 6.48e-01 |
| KEGG | KEGG:02010 | ABC transporters | 1 | 29 | 6.52e-01 |
| KEGG | KEGG:03430 | Mismatch repair | 2 | 22 | 6.52e-01 |
| KEGG | KEGG:04721 | Synaptic vesicle cycle | 8 | 51 | 6.55e-01 |
| KEGG | KEGG:04929 | GnRH secretion | 5 | 53 | 6.55e-01 |
| KEGG | KEGG:05207 | Chemical carcinogenesis - receptor activation | 6 | 142 | 6.77e-01 |
| KEGG | KEGG:00000 | KEGG root term | 11 | 5558 | 6.97e-01 |
| KEGG | KEGG:00770 | Pantothenate and CoA biosynthesis | 3 | 15 | 6.97e-01 |
| KEGG | KEGG:00510 | N-Glycan biosynthesis | 1 | 48 | 6.97e-01 |
| KEGG | KEGG:00561 | Glycerolipid metabolism | 1 | 49 | 7.01e-01 |
| KEGG | KEGG:05167 | Kaposi sarcoma-associated herpesvirus infection | 11 | 145 | 7.05e-01 |
| KEGG | KEGG:04964 | Proximal tubule bicarbonate reclamation | 1 | 20 | 7.05e-01 |
| KEGG | KEGG:04934 | Cushing syndrome | 3 | 121 | 7.05e-01 |
| KEGG | KEGG:03267 | Virion - Adenovirus | 1 | 2 | 7.05e-01 |
| KEGG | KEGG:05142 | Chagas disease | 7 | 75 | 7.05e-01 |
| KEGG | KEGG:05323 | Rheumatoid arthritis | 6 | 43 | 7.05e-01 |
| KEGG | KEGG:00220 | Arginine biosynthesis | 1 | 16 | 7.05e-01 |
| KEGG | KEGG:04380 | Osteoclast differentiation | 4 | 87 | 7.05e-01 |
| KEGG | KEGG:05017 | Spinocerebellar ataxia | 2 | 124 | 7.05e-01 |
| KEGG | KEGG:04924 | Renin secretion | 2 | 50 | 7.06e-01 |
| KEGG | KEGG:05162 | Measles | 8 | 98 | 7.06e-01 |
| KEGG | KEGG:04620 | Toll-like receptor signaling pathway | 7 | 60 | 7.06e-01 |
| KEGG | KEGG:05410 | Hypertrophic cardiomyopathy | 2 | 73 | 7.06e-01 |
| KEGG | KEGG:04917 | Prolactin signaling pathway | 5 | 56 | 7.12e-01 |
| KEGG | KEGG:04662 | B cell receptor signaling pathway | 7 | 56 | 7.15e-01 |
| KEGG | KEGG:04962 | Vasopressin-regulated water reabsorption | 1 | 38 | 7.15e-01 |
| KEGG | KEGG:03260 | Virion - Human immunodeficiency virus | 1 | 1 | 7.15e-01 |
| KEGG | KEGG:05414 | Dilated cardiomyopathy | 2 | 78 | 7.31e-01 |
| KEGG | KEGG:05140 | Leishmaniasis | 5 | 42 | 7.31e-01 |
| KEGG | KEGG:05164 | Influenza A | 7 | 103 | 7.31e-01 |
| KEGG | KEGG:04072 | Phospholipase D signaling pathway | 24 | 110 | 7.37e-01 |
| KEGG | KEGG:03410 | Base excision repair | 6 | 33 | 7.42e-01 |
| KEGG | KEGG:00511 | Other glycan degradation | 1 | 16 | 7.45e-01 |
| KEGG | KEGG:05134 | Legionellosis | 1 | 39 | 7.59e-01 |
| KEGG | KEGG:05221 | Acute myeloid leukemia | 6 | 56 | 7.71e-01 |
| KEGG | KEGG:04920 | Adipocytokine signaling pathway | 4 | 51 | 7.74e-01 |
| KEGG | KEGG:05130 | Pathogenic Escherichia coli infection | 1 | 150 | 7.74e-01 |
| KEGG | KEGG:04966 | Collecting duct acid secretion | 2 | 19 | 7.75e-01 |
| KEGG | KEGG:00514 | Other types of O-glycan biosynthesis | 1 | 37 | 7.75e-01 |
| KEGG | KEGG:01100 | Metabolic pathways | 1 | 1146 | 7.87e-01 |
| KEGG | KEGG:04014 | Ras signaling pathway | 18 | 171 | 8.00e-01 |
| KEGG | KEGG:01210 | 2-Oxocarboxylic acid metabolism | 2 | 17 | 8.02e-01 |
| KEGG | KEGG:05144 | Malaria | 1 | 20 | 8.02e-01 |
| KEGG | KEGG:00250 | Alanine, aspartate and glutamate metabolism | 1 | 29 | 8.02e-01 |
| KEGG | KEGG:00500 | Starch and sucrose metabolism | 1 | 23 | 8.02e-01 |
| KEGG | KEGG:04927 | Cortisol synthesis and secretion | 1 | 48 | 8.02e-01 |
| KEGG | KEGG:04613 | Neutrophil extracellular trap formation | 1 | 110 | 8.02e-01 |
| KEGG | KEGG:04610 | Complement and coagulation cascades | 1 | 40 | 8.02e-01 |
| KEGG | KEGG:00480 | Glutathione metabolism | 2 | 44 | 8.02e-01 |
| KEGG | KEGG:04152 | AMPK signaling pathway | 2 | 103 | 8.02e-01 |
| KEGG | KEGG:03008 | Ribosome biogenesis in eukaryotes | 14 | 75 | 8.02e-01 |
| KEGG | KEGG:04623 | Cytosolic DNA-sensing pathway | 2 | 42 | 8.02e-01 |
| KEGG | KEGG:05170 | Human immunodeficiency virus 1 infection | 24 | 165 | 8.02e-01 |
| KEGG | KEGG:00030 | Pentose phosphate pathway | 1 | 24 | 8.02e-01 |
| KEGG | KEGG:01230 | Biosynthesis of amino acids | 7 | 60 | 8.02e-01 |
| KEGG | KEGG:04810 | Regulation of actin cytoskeleton | 1 | 179 | 8.02e-01 |
| KEGG | KEGG:04936 | Alcoholic liver disease | 6 | 97 | 8.02e-01 |
| KEGG | KEGG:04114 | Oocyte meiosis | 1 | 108 | 8.02e-01 |
| KEGG | KEGG:04217 | Necroptosis | 10 | 106 | 8.06e-01 |
| KEGG | KEGG:04921 | Oxytocin signaling pathway | 10 | 115 | 8.16e-01 |
| KEGG | KEGG:04657 | IL-17 signaling pathway | 6 | 56 | 8.19e-01 |
| KEGG | KEGG:04925 | Aldosterone synthesis and secretion | 3 | 77 | 8.22e-01 |
| KEGG | KEGG:00330 | Arginine and proline metabolism | 4 | 38 | 8.22e-01 |
| KEGG | KEGG:05417 | Lipid and atherosclerosis | 5 | 153 | 8.22e-01 |
| KEGG | KEGG:04923 | Regulation of lipolysis in adipocytes | 1 | 41 | 8.22e-01 |
| KEGG | KEGG:05204 | Chemical carcinogenesis - DNA adducts | 2 | 23 | 8.22e-01 |
| KEGG | KEGG:04550 | Signaling pathways regulating pluripotency of stem cells | 3 | 104 | 8.22e-01 |
| KEGG | KEGG:04061 | Viral protein interaction with cytokine and cytokine receptor | 1 | 20 | 8.22e-01 |
| KEGG | KEGG:05032 | Morphine addiction | 3 | 56 | 8.22e-01 |
| KEGG | KEGG:00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 1 | 13 | 8.22e-01 |
| KEGG | KEGG:03320 | PPAR signaling pathway | 2 | 50 | 8.22e-01 |
| KEGG | KEGG:00601 | Glycosphingolipid biosynthesis - lacto and neolacto series | 1 | 14 | 8.22e-01 |
| KEGG | KEGG:04978 | Mineral absorption | 1 | 42 | 8.22e-01 |
| KEGG | KEGG:05321 | Inflammatory bowel disease | 1 | 22 | 8.22e-01 |
| KEGG | KEGG:00603 | Glycosphingolipid biosynthesis - globo and isoglobo series | 1 | 9 | 8.22e-01 |
| KEGG | KEGG:04935 | Growth hormone synthesis, secretion and action | 9 | 98 | 8.22e-01 |
| KEGG | KEGG:04726 | Serotonergic synapse | 4 | 63 | 8.22e-01 |
| KEGG | KEGG:04973 | Carbohydrate digestion and absorption | 1 | 31 | 8.22e-01 |
| KEGG | KEGG:04922 | Glucagon signaling pathway | 2 | 84 | 8.22e-01 |
| KEGG | KEGG:04918 | Thyroid hormone synthesis | 1 | 55 | 8.22e-01 |
| KEGG | KEGG:05145 | Toxoplasmosis | 6 | 82 | 8.22e-01 |
| KEGG | KEGG:05163 | Human cytomegalovirus infection | 16 | 176 | 8.22e-01 |
| KEGG | KEGG:00232 | Caffeine metabolism | 1 | 1 | 8.22e-01 |
| KEGG | KEGG:04911 | Insulin secretion | 1 | 64 | 8.22e-01 |
| KEGG | KEGG:00982 | Drug metabolism - cytochrome P450 | 2 | 21 | 8.22e-01 |
| KEGG | KEGG:04150 | mTOR signaling pathway | 18 | 135 | 8.22e-01 |
| KEGG | KEGG:04914 | Progesterone-mediated oocyte maturation | 15 | 86 | 8.22e-01 |
| KEGG | KEGG:04151 | PI3K-Akt signaling pathway | 4 | 254 | 8.22e-01 |
| KEGG | KEGG:04664 | Fc epsilon RI signaling pathway | 5 | 46 | 8.22e-01 |
| KEGG | KEGG:00604 | Glycosphingolipid biosynthesis - ganglio series | 1 | 12 | 8.22e-01 |
| KEGG | KEGG:05412 | Arrhythmogenic right ventricular cardiomyopathy | 1 | 63 | 8.22e-01 |
| KEGG | KEGG:03020 | RNA polymerase | 1 | 34 | 8.22e-01 |
| KEGG | KEGG:04640 | Hematopoietic cell lineage | 1 | 31 | 8.22e-01 |
| KEGG | KEGG:04310 | Wnt signaling pathway | 3 | 138 | 8.22e-01 |
| KEGG | KEGG:05205 | Proteoglycans in cancer | 14 | 170 | 8.26e-01 |
| KEGG | KEGG:00010 | Glycolysis / Gluconeogenesis | 2 | 44 | 8.26e-01 |
| KEGG | KEGG:00980 | Metabolism of xenobiotics by cytochrome P450 | 2 | 26 | 8.27e-01 |
| KEGG | KEGG:00512 | Mucin type O-glycan biosynthesis | 2 | 22 | 8.42e-01 |
| KEGG | KEGG:00270 | Cysteine and methionine metabolism | 6 | 38 | 8.42e-01 |
| KEGG | KEGG:04916 | Melanogenesis | 2 | 77 | 8.42e-01 |
| KEGG | KEGG:01523 | Antifolate resistance | 2 | 24 | 8.42e-01 |
| KEGG | KEGG:05016 | Huntington disease | 3 | 256 | 8.42e-01 |
| KEGG | KEGG:03030 | DNA replication | 1 | 35 | 8.42e-01 |
| KEGG | KEGG:00760 | Nicotinate and nicotinamide metabolism | 1 | 28 | 8.42e-01 |
| KEGG | KEGG:04730 | Long-term depression | 3 | 42 | 8.53e-01 |
| KEGG | KEGG:04540 | Gap junction | 5 | 73 | 8.53e-01 |
| KEGG | KEGG:04915 | Estrogen signaling pathway | 7 | 97 | 8.61e-01 |
| KEGG | KEGG:00230 | Purine metabolism | 2 | 97 | 8.61e-01 |
| KEGG | KEGG:04928 | Parathyroid hormone synthesis, secretion and action | 1 | 82 | 8.61e-01 |
| KEGG | KEGG:05206 | MicroRNAs in cancer | 1 | 149 | 8.61e-01 |
| KEGG | KEGG:04961 | Endocrine and other factor-regulated calcium reabsorption | 4 | 41 | 8.61e-01 |
| KEGG | KEGG:00532 | Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 1 | 21 | 8.64e-01 |
| KEGG | KEGG:00790 | Folate biosynthesis | 1 | 18 | 8.79e-01 |
| KEGG | KEGG:04725 | Cholinergic synapse | 1 | 83 | 8.79e-01 |
| KEGG | KEGG:00260 | Glycine, serine and threonine metabolism | 2 | 31 | 8.86e-01 |
| KEGG | KEGG:05208 | Chemical carcinogenesis - reactive oxygen species | 4 | 186 | 8.86e-01 |
| KEGG | KEGG:00740 | Riboflavin metabolism | 1 | 6 | 8.90e-01 |
| KEGG | KEGG:05200 | Pathways in cancer | 26 | 409 | 8.97e-01 |
| KEGG | KEGG:00640 | Propanoate metabolism | 1 | 28 | 9.14e-01 |
| KEGG | KEGG:04658 | Th1 and Th2 cell differentiation | 4 | 53 | 9.14e-01 |
| KEGG | KEGG:05146 | Amoebiasis | 1 | 64 | 9.14e-01 |
| KEGG | KEGG:04932 | Non-alcoholic fatty liver disease | 6 | 131 | 9.14e-01 |
| KEGG | KEGG:05110 | Vibrio cholerae infection | 2 | 43 | 9.14e-01 |
| KEGG | KEGG:04650 | Natural killer cell mediated cytotoxicity | 2 | 63 | 9.14e-01 |
| KEGG | KEGG:04371 | Apelin signaling pathway | 10 | 106 | 9.14e-01 |
| KEGG | KEGG:00620 | Pyruvate metabolism | 1 | 33 | 9.14e-01 |
| KEGG | KEGG:04750 | Inflammatory mediator regulation of TRP channels | 2 | 72 | 9.17e-01 |
| KEGG | KEGG:05020 | Prion disease | 2 | 220 | 9.35e-01 |
| KEGG | KEGG:04630 | JAK-STAT signaling pathway | 1 | 88 | 9.37e-01 |
| KEGG | KEGG:04024 | cAMP signaling pathway | 2 | 151 | 9.37e-01 |
| KEGG | KEGG:03010 | Ribosome | 1 | 127 | 9.39e-01 |
| KEGG | KEGG:05133 | Pertussis | 3 | 45 | 9.42e-01 |
| KEGG | KEGG:04510 | Focal adhesion | 12 | 177 | 9.42e-01 |
| KEGG | KEGG:04261 | Adrenergic signaling in cardiomyocytes | 1 | 128 | 9.42e-01 |
| KEGG | KEGG:04960 | Aldosterone-regulated sodium reabsorption | 3 | 26 | 9.58e-01 |
| KEGG | KEGG:04659 | Th17 cell differentiation | 1 | 64 | 9.73e-01 |
| KEGG | KEGG:05010 | Alzheimer disease | 2 | 315 | 9.73e-01 |
| KEGG | KEGG:04913 | Ovarian steroidogenesis | 2 | 28 | 9.73e-01 |
| KEGG | KEGG:00280 | Valine, leucine and isoleucine degradation | 1 | 43 | 9.83e-01 |
| KEGG | KEGG:04142 | Lysosome | 5 | 118 | 9.83e-01 |
| KEGG | KEGG:04912 | GnRH signaling pathway | 1 | 76 | 9.83e-01 |
| KEGG | KEGG:04724 | Glutamatergic synapse | 1 | 74 | 9.84e-01 |
| KEGG | KEGG:04216 | Ferroptosis | 3 | 33 | 9.88e-01 |
| KEGG | KEGG:05340 | Primary immunodeficiency | 2 | 12 | 9.92e-01 |
| KEGG | KEGG:00061 | Fatty acid biosynthesis | 1 | 12 | 9.97e-01 |
| KEGG | KEGG:05120 | Epithelial cell signaling in Helicobacter pylori infection | 2 | 58 | 9.97e-01 |
| KEGG | KEGG:04080 | Neuroactive ligand-receptor interaction | 3 | 108 | 1.00e+00 |
| KEGG | KEGG:04612 | Antigen processing and presentation | 3 | 41 | 1.00e+00 |
| KEGG | KEGG:05014 | Amyotrophic lateral sclerosis | 2 | 303 | 1.00e+00 |
| KEGG | KEGG:00190 | Oxidative phosphorylation | 2 | 106 | 1.00e+00 |
| KEGG | KEGG:04972 | Pancreatic secretion | 1 | 58 | 1.00e+00 |
| KEGG | KEGG:04260 | Cardiac muscle contraction | 1 | 67 | 1.00e+00 |
| KEGG | KEGG:04976 | Bile secretion | 4 | 42 | 1.00e+00 |
| KEGG | KEGG:00140 | Steroid hormone biosynthesis | 1 | 19 | 1.00e+00 |
| KEGG | KEGG:00071 | Fatty acid degradation | 1 | 32 | 1.00e+00 |
| KEGG | KEGG:04512 | ECM-receptor interaction | 1 | 69 | 1.00e+00 |
| KEGG | KEGG:04514 | Cell adhesion molecules | 1 | 83 | 1.00e+00 |
| KEGG | KEGG:04974 | Protein digestion and absorption | 1 | 61 | 1.00e+00 |
| KEGG | KEGG:04979 | Cholesterol metabolism | 1 | 33 | 1.00e+00 |
| KEGG | KEGG:04971 | Gastric acid secretion | 3 | 52 | 1.00e+00 |
| KEGG | KEGG:05171 | Coronavirus disease - COVID-19 | 8 | 162 | 1.00e+00 |
| KEGG | KEGG:04670 | Leukocyte transendothelial migration | 2 | 79 | 1.00e+00 |
| KEGG | KEGG:04740 | Olfactory transduction | 1 | 25 | 1.00e+00 |
| KEGG | KEGG:04970 | Salivary secretion | 1 | 55 | 1.00e+00 |
| KEGG | KEGG:04723 | Retrograde endocannabinoid signaling | 2 | 99 | 1.00e+00 |
| KEGG | KEGG:01212 | Fatty acid metabolism | 1 | 50 | 1.00e+00 |
| KEGG | KEGG:05322 | Systemic lupus erythematosus | 5 | 61 | 1.00e+00 |
| KEGG | KEGG:04713 | Circadian entrainment | 3 | 69 | 1.00e+00 |
| KEGG | KEGG:04672 | Intestinal immune network for IgA production | 1 | 12 | 1.00e+00 |
| KEGG | KEGG:04744 | Phototransduction | 1 | 12 | 1.00e+00 |
| KEGG | KEGG:04727 | GABAergic synapse | 2 | 55 | 1.00e+00 |
| KEGG | KEGG:04950 | Maturity onset diabetes of the young | 1 | 4 | 1.00e+00 |
| KEGG | KEGG:05416 | Viral myocarditis | 2 | 40 | 1.00e+00 |
| KEGG | KEGG:00830 | Retinol metabolism | 2 | 16 | 1.00e+00 |
| KEGG | KEGG:04020 | Calcium signaling pathway | 1 | 157 | 1.00e+00 |
| KEGG | KEGG:00650 | Butanoate metabolism | 1 | 17 | 1.00e+00 |
EPI_var24_table %>%
filter(source=="KEGG") %>%
mutate_at(.vars = 6, .funs= scientific_format()) %>%
kable(.,caption = "KEGG EPI 24 hour enrichment terms of highly var genes using nominal p value") %>%
kable_paper("striped", full_width = FALSE) %>%
kable_styling(full_width = FALSE, position = "left",bootstrap_options = c("striped","hover")) %>%
scroll_box(width = "100%", height = "400px")| source | term_id | term_name | intersection_size | term_size | p_value |
|---|---|---|---|---|---|
| KEGG | KEGG:04130 | SNARE interactions in vesicular transport | 7 | 32 | 5.51e-03 |
| KEGG | KEGG:04144 | Endocytosis | 36 | 232 | 2.32e-02 |
| KEGG | KEGG:05168 | Herpes simplex virus 1 infection | 66 | 415 | 2.32e-02 |
| KEGG | KEGG:05220 | Chronic myeloid leukemia | 12 | 75 | 8.11e-02 |
| KEGG | KEGG:00900 | Terpenoid backbone biosynthesis | 2 | 21 | 8.11e-02 |
| KEGG | KEGG:04120 | Ubiquitin mediated proteolysis | 21 | 134 | 8.11e-02 |
| KEGG | KEGG:05214 | Glioma | 20 | 67 | 8.11e-02 |
| KEGG | KEGG:05212 | Pancreatic cancer | 21 | 75 | 1.68e-01 |
| KEGG | KEGG:04115 | p53 signaling pathway | 8 | 65 | 1.68e-01 |
| KEGG | KEGG:03040 | Spliceosome | 4 | 132 | 2.25e-01 |
| KEGG | KEGG:03250 | Viral life cycle - HIV-1 | 14 | 56 | 2.34e-01 |
| KEGG | KEGG:01522 | Endocrine resistance | 15 | 85 | 2.34e-01 |
| KEGG | KEGG:04218 | Cellular senescence | 17 | 145 | 2.34e-01 |
| KEGG | KEGG:05210 | Colorectal cancer | 22 | 84 | 2.34e-01 |
| KEGG | KEGG:04141 | Protein processing in endoplasmic reticulum | 2 | 161 | 2.34e-01 |
| KEGG | KEGG:05216 | Thyroid cancer | 4 | 35 | 2.38e-01 |
| KEGG | KEGG:04930 | Type II diabetes mellitus | 1 | 35 | 2.38e-01 |
| KEGG | KEGG:05218 | Melanoma | 17 | 58 | 2.38e-01 |
| KEGG | KEGG:04070 | Phosphatidylinositol signaling system | 19 | 91 | 2.46e-01 |
| KEGG | KEGG:01250 | Biosynthesis of nucleotide sugars | 6 | 35 | 2.47e-01 |
| KEGG | KEGG:00750 | Vitamin B6 metabolism | 3 | 5 | 2.51e-01 |
| KEGG | KEGG:05012 | Parkinson disease | 1 | 226 | 2.83e-01 |
| KEGG | KEGG:05418 | Fluid shear stress and atherosclerosis | 1 | 114 | 2.87e-01 |
| KEGG | KEGG:04910 | Insulin signaling pathway | 1 | 121 | 2.87e-01 |
| KEGG | KEGG:05031 | Amphetamine addiction | 5 | 49 | 2.87e-01 |
| KEGG | KEGG:05022 | Pathways of neurodegeneration - multiple diseases | 1 | 385 | 2.87e-01 |
| KEGG | KEGG:04933 | AGE-RAGE signaling pathway in diabetic complications | 1 | 91 | 2.87e-01 |
| KEGG | KEGG:04931 | Insulin resistance | 1 | 95 | 2.87e-01 |
| KEGG | KEGG:04926 | Relaxin signaling pathway | 1 | 104 | 2.87e-01 |
| KEGG | KEGG:04666 | Fc gamma R-mediated phagocytosis | 3 | 75 | 2.87e-01 |
| KEGG | KEGG:04622 | RIG-I-like receptor signaling pathway | 6 | 49 | 2.87e-01 |
| KEGG | KEGG:04611 | Platelet activation | 1 | 89 | 2.87e-01 |
| KEGG | KEGG:05211 | Renal cell carcinoma | 8 | 65 | 2.87e-01 |
| KEGG | KEGG:04390 | Hippo signaling pathway | 1 | 134 | 2.87e-01 |
| KEGG | KEGG:04146 | Peroxisome | 3 | 68 | 2.87e-01 |
| KEGG | KEGG:05225 | Hepatocellular carcinoma | 30 | 145 | 2.87e-01 |
| KEGG | KEGG:04140 | Autophagy - animal | 23 | 133 | 2.87e-01 |
| KEGG | KEGG:04122 | Sulfur relay system | 3 | 8 | 2.87e-01 |
| KEGG | KEGG:04110 | Cell cycle | 13 | 151 | 2.87e-01 |
| KEGG | KEGG:04071 | Sphingolipid signaling pathway | 1 | 107 | 2.87e-01 |
| KEGG | KEGG:04068 | FoxO signaling pathway | 13 | 109 | 2.87e-01 |
| KEGG | KEGG:00290 | Valine, leucine and isoleucine biosynthesis | 2 | 3 | 2.87e-01 |
| KEGG | KEGG:00520 | Amino sugar and nucleotide sugar metabolism | 11 | 46 | 2.87e-01 |
| KEGG | KEGG:00562 | Inositol phosphate metabolism | 14 | 66 | 2.87e-01 |
| KEGG | KEGG:00590 | Arachidonic acid metabolism | 1 | 26 | 2.87e-01 |
| KEGG | KEGG:00920 | Sulfur metabolism | 2 | 10 | 2.87e-01 |
| KEGG | KEGG:00970 | Aminoacyl-tRNA biosynthesis | 3 | 44 | 2.87e-01 |
| KEGG | KEGG:01521 | EGFR tyrosine kinase inhibitor resistance | 16 | 74 | 2.87e-01 |
| KEGG | KEGG:03050 | Proteasome | 7 | 42 | 2.87e-01 |
| KEGG | KEGG:05161 | Hepatitis B | 8 | 136 | 2.87e-01 |
| KEGG | KEGG:05166 | Human T-cell leukemia virus 1 infection | 17 | 180 | 2.87e-01 |
| KEGG | KEGG:04370 | VEGF signaling pathway | 9 | 49 | 2.94e-01 |
| KEGG | KEGG:04530 | Tight junction | 1 | 137 | 2.94e-01 |
| KEGG | KEGG:04360 | Axon guidance | 1 | 162 | 3.08e-01 |
| KEGG | KEGG:04062 | Chemokine signaling pathway | 1 | 113 | 3.17e-01 |
| KEGG | KEGG:04015 | Rap1 signaling pathway | 1 | 164 | 3.31e-01 |
| KEGG | KEGG:00534 | Glycosaminoglycan biosynthesis - heparan sulfate / heparin | 1 | 20 | 3.31e-01 |
| KEGG | KEGG:05415 | Diabetic cardiomyopathy | 1 | 169 | 3.31e-01 |
| KEGG | KEGG:04210 | Apoptosis | 11 | 118 | 3.52e-01 |
| KEGG | KEGG:04012 | ErbB signaling pathway | 15 | 78 | 3.55e-01 |
| KEGG | KEGG:05213 | Endometrial cancer | 12 | 57 | 3.55e-01 |
| KEGG | KEGG:03018 | RNA degradation | 17 | 74 | 3.56e-01 |
| KEGG | KEGG:00052 | Galactose metabolism | 1 | 22 | 3.56e-01 |
| KEGG | KEGG:04145 | Phagosome | 2 | 99 | 3.60e-01 |
| KEGG | KEGG:04010 | MAPK signaling pathway | 22 | 240 | 3.69e-01 |
| KEGG | KEGG:01524 | Platinum drug resistance | 14 | 65 | 3.90e-01 |
| KEGG | KEGG:04137 | Mitophagy - animal | 1 | 70 | 3.90e-01 |
| KEGG | KEGG:05231 | Choline metabolism in cancer | 11 | 84 | 4.00e-01 |
| KEGG | KEGG:00524 | Neomycin, kanamycin and gentamicin biosynthesis | 1 | 4 | 4.00e-01 |
| KEGG | KEGG:00051 | Fructose and mannose metabolism | 3 | 27 | 4.02e-01 |
| KEGG | KEGG:03450 | Non-homologous end-joining | 4 | 12 | 4.02e-01 |
| KEGG | KEGG:05131 | Shigellosis | 24 | 210 | 4.02e-01 |
| KEGG | KEGG:05165 | Human papillomavirus infection | 1 | 272 | 4.09e-01 |
| KEGG | KEGG:05203 | Viral carcinogenesis | 12 | 172 | 4.34e-01 |
| KEGG | KEGG:03022 | Basal transcription factors | 4 | 40 | 4.34e-01 |
| KEGG | KEGG:03013 | Nucleocytoplasmic transport | 17 | 99 | 4.37e-01 |
| KEGG | KEGG:05030 | Cocaine addiction | 3 | 35 | 4.54e-01 |
| KEGG | KEGG:05160 | Hepatitis C | 9 | 115 | 4.54e-01 |
| KEGG | KEGG:03440 | Homologous recombination | 9 | 39 | 4.57e-01 |
| KEGG | KEGG:00630 | Glyoxylate and dicarboxylate metabolism | 4 | 25 | 4.65e-01 |
| KEGG | KEGG:05224 | Breast cancer | 15 | 117 | 4.65e-01 |
| KEGG | KEGG:04340 | Hedgehog signaling pathway | 7 | 49 | 4.65e-01 |
| KEGG | KEGG:00310 | Lysine degradation | 5 | 59 | 4.65e-01 |
| KEGG | KEGG:03015 | mRNA surveillance pathway | 6 | 86 | 4.69e-01 |
| KEGG | KEGG:00860 | Porphyrin metabolism | 2 | 22 | 4.69e-01 |
| KEGG | KEGG:05223 | Non-small cell lung cancer | 13 | 67 | 4.76e-01 |
| KEGG | KEGG:00600 | Sphingolipid metabolism | 7 | 44 | 4.76e-01 |
| KEGG | KEGG:00564 | Glycerophospholipid metabolism | 2 | 76 | 4.76e-01 |
| KEGG | KEGG:05135 | Yersinia infection | 14 | 112 | 4.76e-01 |
| KEGG | KEGG:05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 8 | 69 | 4.76e-01 |
| KEGG | KEGG:05217 | Basal cell carcinoma | 13 | 49 | 4.76e-01 |
| KEGG | KEGG:04977 | Vitamin digestion and absorption | 1 | 14 | 4.76e-01 |
| KEGG | KEGG:04270 | Vascular smooth muscle contraction | 1 | 94 | 4.76e-01 |
| KEGG | KEGG:03060 | Protein export | 2 | 23 | 4.76e-01 |
| KEGG | KEGG:04213 | Longevity regulating pathway - multiple species | 7 | 55 | 4.82e-01 |
| KEGG | KEGG:04211 | Longevity regulating pathway | 16 | 78 | 5.17e-01 |
| KEGG | KEGG:04520 | Adherens junction | 3 | 67 | 5.18e-01 |
| KEGG | KEGG:05222 | Small cell lung cancer | 7 | 87 | 5.18e-01 |
| KEGG | KEGG:04060 | Cytokine-cytokine receptor interaction | 1 | 98 | 5.18e-01 |
| KEGG | KEGG:00670 | One carbon pool by folate | 3 | 18 | 5.25e-01 |
| KEGG | KEGG:04022 | cGMP-PKG signaling pathway | 1 | 133 | 5.25e-01 |
| KEGG | KEGG:04136 | Autophagy - other | 7 | 31 | 5.25e-01 |
| KEGG | KEGG:04621 | NOD-like receptor signaling pathway | 1 | 117 | 5.55e-01 |
| KEGG | KEGG:04625 | C-type lectin receptor signaling pathway | 4 | 76 | 5.55e-01 |
| KEGG | KEGG:04720 | Long-term potentiation | 4 | 55 | 5.55e-01 |
| KEGG | KEGG:04392 | Hippo signaling pathway - multiple species | 6 | 25 | 5.55e-01 |
| KEGG | KEGG:05219 | Bladder cancer | 3 | 37 | 5.55e-01 |
| KEGG | KEGG:03264 | Virion - Flavivirus | 1 | 1 | 5.55e-01 |
| KEGG | KEGG:04215 | Apoptosis - multiple species | 5 | 30 | 5.55e-01 |
| KEGG | KEGG:05215 | Prostate cancer | 8 | 86 | 5.55e-01 |
| KEGG | KEGG:04330 | Notch signaling pathway | 1 | 51 | 5.55e-01 |
| KEGG | KEGG:05169 | Epstein-Barr virus infection | 10 | 153 | 5.55e-01 |
| KEGG | KEGG:05226 | Gastric cancer | 14 | 117 | 5.55e-01 |
| KEGG | KEGG:05100 | Bacterial invasion of epithelial cells | 1 | 74 | 5.55e-01 |
| KEGG | KEGG:01200 | Carbon metabolism | 7 | 98 | 5.78e-01 |
| KEGG | KEGG:05230 | Central carbon metabolism in cancer | 6 | 62 | 5.78e-01 |
| KEGG | KEGG:04710 | Circadian rhythm | 5 | 30 | 5.78e-01 |
| KEGG | KEGG:04660 | T cell receptor signaling pathway | 15 | 70 | 5.78e-01 |
| KEGG | KEGG:05132 | Salmonella infection | 24 | 214 | 6.03e-01 |
| KEGG | KEGG:05202 | Transcriptional misregulation in cancer | 19 | 128 | 6.03e-01 |
| KEGG | KEGG:04714 | Thermogenesis | 1 | 195 | 6.03e-01 |
| KEGG | KEGG:00240 | Pyrimidine metabolism | 6 | 46 | 6.03e-01 |
| KEGG | KEGG:04919 | Thyroid hormone signaling pathway | 10 | 112 | 6.05e-01 |
| KEGG | KEGG:00565 | Ether lipid metabolism | 8 | 28 | 6.09e-01 |
| KEGG | KEGG:04064 | NF-kappa B signaling pathway | 5 | 71 | 6.09e-01 |
| KEGG | KEGG:03420 | Nucleotide excision repair | 4 | 43 | 6.13e-01 |
| KEGG | KEGG:04975 | Fat digestion and absorption | 1 | 19 | 6.13e-01 |
| KEGG | KEGG:04728 | Dopaminergic synapse | 6 | 103 | 6.13e-01 |
| KEGG | KEGG:00100 | Steroid biosynthesis | 1 | 17 | 6.20e-01 |
| KEGG | KEGG:03460 | Fanconi anemia pathway | 9 | 48 | 6.20e-01 |
| KEGG | KEGG:05152 | Tuberculosis | 17 | 106 | 6.22e-01 |
| KEGG | KEGG:01232 | Nucleotide metabolism | 8 | 69 | 6.22e-01 |
| KEGG | KEGG:04668 | TNF signaling pathway | 13 | 87 | 6.22e-01 |
| KEGG | KEGG:04722 | Neurotrophin signaling pathway | 12 | 110 | 6.22e-01 |
| KEGG | KEGG:00563 | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 1 | 25 | 6.22e-01 |
| KEGG | KEGG:05034 | Alcoholism | 7 | 122 | 6.22e-01 |
| KEGG | KEGG:00513 | Various types of N-glycan biosynthesis | 1 | 36 | 6.22e-01 |
| KEGG | KEGG:04350 | TGF-beta signaling pathway | 3 | 84 | 6.23e-01 |
| KEGG | KEGG:00910 | Nitrogen metabolism | 1 | 10 | 6.28e-01 |
| KEGG | KEGG:00983 | Drug metabolism - other enzymes | 7 | 44 | 6.42e-01 |
| KEGG | KEGG:00020 | Citrate cycle (TCA cycle) | 2 | 28 | 6.42e-01 |
| KEGG | KEGG:04066 | HIF-1 signaling pathway | 8 | 89 | 6.42e-01 |
| KEGG | KEGG:01240 | Biosynthesis of cofactors | 18 | 115 | 6.48e-01 |
| KEGG | KEGG:02010 | ABC transporters | 1 | 29 | 6.52e-01 |
| KEGG | KEGG:03430 | Mismatch repair | 2 | 22 | 6.52e-01 |
| KEGG | KEGG:04721 | Synaptic vesicle cycle | 8 | 51 | 6.55e-01 |
| KEGG | KEGG:04929 | GnRH secretion | 5 | 53 | 6.55e-01 |
| KEGG | KEGG:05207 | Chemical carcinogenesis - receptor activation | 6 | 142 | 6.77e-01 |
| KEGG | KEGG:00000 | KEGG root term | 11 | 5558 | 6.97e-01 |
| KEGG | KEGG:00770 | Pantothenate and CoA biosynthesis | 3 | 15 | 6.97e-01 |
| KEGG | KEGG:00510 | N-Glycan biosynthesis | 1 | 48 | 6.97e-01 |
| KEGG | KEGG:00561 | Glycerolipid metabolism | 1 | 49 | 7.01e-01 |
| KEGG | KEGG:05167 | Kaposi sarcoma-associated herpesvirus infection | 11 | 145 | 7.05e-01 |
| KEGG | KEGG:04964 | Proximal tubule bicarbonate reclamation | 1 | 20 | 7.05e-01 |
| KEGG | KEGG:04934 | Cushing syndrome | 3 | 121 | 7.05e-01 |
| KEGG | KEGG:03267 | Virion - Adenovirus | 1 | 2 | 7.05e-01 |
| KEGG | KEGG:05142 | Chagas disease | 7 | 75 | 7.05e-01 |
| KEGG | KEGG:05323 | Rheumatoid arthritis | 6 | 43 | 7.05e-01 |
| KEGG | KEGG:00220 | Arginine biosynthesis | 1 | 16 | 7.05e-01 |
| KEGG | KEGG:04380 | Osteoclast differentiation | 4 | 87 | 7.05e-01 |
| KEGG | KEGG:05017 | Spinocerebellar ataxia | 2 | 124 | 7.05e-01 |
| KEGG | KEGG:04924 | Renin secretion | 2 | 50 | 7.06e-01 |
| KEGG | KEGG:05162 | Measles | 8 | 98 | 7.06e-01 |
| KEGG | KEGG:04620 | Toll-like receptor signaling pathway | 7 | 60 | 7.06e-01 |
| KEGG | KEGG:05410 | Hypertrophic cardiomyopathy | 2 | 73 | 7.06e-01 |
| KEGG | KEGG:04917 | Prolactin signaling pathway | 5 | 56 | 7.12e-01 |
| KEGG | KEGG:04662 | B cell receptor signaling pathway | 7 | 56 | 7.15e-01 |
| KEGG | KEGG:04962 | Vasopressin-regulated water reabsorption | 1 | 38 | 7.15e-01 |
| KEGG | KEGG:03260 | Virion - Human immunodeficiency virus | 1 | 1 | 7.15e-01 |
| KEGG | KEGG:05414 | Dilated cardiomyopathy | 2 | 78 | 7.31e-01 |
| KEGG | KEGG:05140 | Leishmaniasis | 5 | 42 | 7.31e-01 |
| KEGG | KEGG:05164 | Influenza A | 7 | 103 | 7.31e-01 |
| KEGG | KEGG:04072 | Phospholipase D signaling pathway | 24 | 110 | 7.37e-01 |
| KEGG | KEGG:03410 | Base excision repair | 6 | 33 | 7.42e-01 |
| KEGG | KEGG:00511 | Other glycan degradation | 1 | 16 | 7.45e-01 |
| KEGG | KEGG:05134 | Legionellosis | 1 | 39 | 7.59e-01 |
| KEGG | KEGG:05221 | Acute myeloid leukemia | 6 | 56 | 7.71e-01 |
| KEGG | KEGG:04920 | Adipocytokine signaling pathway | 4 | 51 | 7.74e-01 |
| KEGG | KEGG:05130 | Pathogenic Escherichia coli infection | 1 | 150 | 7.74e-01 |
| KEGG | KEGG:04966 | Collecting duct acid secretion | 2 | 19 | 7.75e-01 |
| KEGG | KEGG:00514 | Other types of O-glycan biosynthesis | 1 | 37 | 7.75e-01 |
| KEGG | KEGG:01100 | Metabolic pathways | 1 | 1146 | 7.87e-01 |
| KEGG | KEGG:04014 | Ras signaling pathway | 18 | 171 | 8.00e-01 |
| KEGG | KEGG:01210 | 2-Oxocarboxylic acid metabolism | 2 | 17 | 8.02e-01 |
| KEGG | KEGG:05144 | Malaria | 1 | 20 | 8.02e-01 |
| KEGG | KEGG:00250 | Alanine, aspartate and glutamate metabolism | 1 | 29 | 8.02e-01 |
| KEGG | KEGG:00500 | Starch and sucrose metabolism | 1 | 23 | 8.02e-01 |
| KEGG | KEGG:04927 | Cortisol synthesis and secretion | 1 | 48 | 8.02e-01 |
| KEGG | KEGG:04613 | Neutrophil extracellular trap formation | 1 | 110 | 8.02e-01 |
| KEGG | KEGG:04610 | Complement and coagulation cascades | 1 | 40 | 8.02e-01 |
| KEGG | KEGG:00480 | Glutathione metabolism | 2 | 44 | 8.02e-01 |
| KEGG | KEGG:04152 | AMPK signaling pathway | 2 | 103 | 8.02e-01 |
| KEGG | KEGG:03008 | Ribosome biogenesis in eukaryotes | 14 | 75 | 8.02e-01 |
| KEGG | KEGG:04623 | Cytosolic DNA-sensing pathway | 2 | 42 | 8.02e-01 |
| KEGG | KEGG:05170 | Human immunodeficiency virus 1 infection | 24 | 165 | 8.02e-01 |
| KEGG | KEGG:00030 | Pentose phosphate pathway | 1 | 24 | 8.02e-01 |
| KEGG | KEGG:01230 | Biosynthesis of amino acids | 7 | 60 | 8.02e-01 |
| KEGG | KEGG:04810 | Regulation of actin cytoskeleton | 1 | 179 | 8.02e-01 |
| KEGG | KEGG:04936 | Alcoholic liver disease | 6 | 97 | 8.02e-01 |
| KEGG | KEGG:04114 | Oocyte meiosis | 1 | 108 | 8.02e-01 |
| KEGG | KEGG:04217 | Necroptosis | 10 | 106 | 8.06e-01 |
| KEGG | KEGG:04921 | Oxytocin signaling pathway | 10 | 115 | 8.16e-01 |
| KEGG | KEGG:04657 | IL-17 signaling pathway | 6 | 56 | 8.19e-01 |
| KEGG | KEGG:04925 | Aldosterone synthesis and secretion | 3 | 77 | 8.22e-01 |
| KEGG | KEGG:00330 | Arginine and proline metabolism | 4 | 38 | 8.22e-01 |
| KEGG | KEGG:05417 | Lipid and atherosclerosis | 5 | 153 | 8.22e-01 |
| KEGG | KEGG:04923 | Regulation of lipolysis in adipocytes | 1 | 41 | 8.22e-01 |
| KEGG | KEGG:05204 | Chemical carcinogenesis - DNA adducts | 2 | 23 | 8.22e-01 |
| KEGG | KEGG:04550 | Signaling pathways regulating pluripotency of stem cells | 3 | 104 | 8.22e-01 |
| KEGG | KEGG:04061 | Viral protein interaction with cytokine and cytokine receptor | 1 | 20 | 8.22e-01 |
| KEGG | KEGG:05032 | Morphine addiction | 3 | 56 | 8.22e-01 |
| KEGG | KEGG:00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 1 | 13 | 8.22e-01 |
| KEGG | KEGG:03320 | PPAR signaling pathway | 2 | 50 | 8.22e-01 |
| KEGG | KEGG:00601 | Glycosphingolipid biosynthesis - lacto and neolacto series | 1 | 14 | 8.22e-01 |
| KEGG | KEGG:04978 | Mineral absorption | 1 | 42 | 8.22e-01 |
| KEGG | KEGG:05321 | Inflammatory bowel disease | 1 | 22 | 8.22e-01 |
| KEGG | KEGG:00603 | Glycosphingolipid biosynthesis - globo and isoglobo series | 1 | 9 | 8.22e-01 |
| KEGG | KEGG:04935 | Growth hormone synthesis, secretion and action | 9 | 98 | 8.22e-01 |
| KEGG | KEGG:04726 | Serotonergic synapse | 4 | 63 | 8.22e-01 |
| KEGG | KEGG:04973 | Carbohydrate digestion and absorption | 1 | 31 | 8.22e-01 |
| KEGG | KEGG:04922 | Glucagon signaling pathway | 2 | 84 | 8.22e-01 |
| KEGG | KEGG:04918 | Thyroid hormone synthesis | 1 | 55 | 8.22e-01 |
| KEGG | KEGG:05145 | Toxoplasmosis | 6 | 82 | 8.22e-01 |
| KEGG | KEGG:05163 | Human cytomegalovirus infection | 16 | 176 | 8.22e-01 |
| KEGG | KEGG:00232 | Caffeine metabolism | 1 | 1 | 8.22e-01 |
| KEGG | KEGG:04911 | Insulin secretion | 1 | 64 | 8.22e-01 |
| KEGG | KEGG:00982 | Drug metabolism - cytochrome P450 | 2 | 21 | 8.22e-01 |
| KEGG | KEGG:04150 | mTOR signaling pathway | 18 | 135 | 8.22e-01 |
| KEGG | KEGG:04914 | Progesterone-mediated oocyte maturation | 15 | 86 | 8.22e-01 |
| KEGG | KEGG:04151 | PI3K-Akt signaling pathway | 4 | 254 | 8.22e-01 |
| KEGG | KEGG:04664 | Fc epsilon RI signaling pathway | 5 | 46 | 8.22e-01 |
| KEGG | KEGG:00604 | Glycosphingolipid biosynthesis - ganglio series | 1 | 12 | 8.22e-01 |
| KEGG | KEGG:05412 | Arrhythmogenic right ventricular cardiomyopathy | 1 | 63 | 8.22e-01 |
| KEGG | KEGG:03020 | RNA polymerase | 1 | 34 | 8.22e-01 |
| KEGG | KEGG:04640 | Hematopoietic cell lineage | 1 | 31 | 8.22e-01 |
| KEGG | KEGG:04310 | Wnt signaling pathway | 3 | 138 | 8.22e-01 |
| KEGG | KEGG:05205 | Proteoglycans in cancer | 14 | 170 | 8.26e-01 |
| KEGG | KEGG:00010 | Glycolysis / Gluconeogenesis | 2 | 44 | 8.26e-01 |
| KEGG | KEGG:00980 | Metabolism of xenobiotics by cytochrome P450 | 2 | 26 | 8.27e-01 |
| KEGG | KEGG:00512 | Mucin type O-glycan biosynthesis | 2 | 22 | 8.42e-01 |
| KEGG | KEGG:00270 | Cysteine and methionine metabolism | 6 | 38 | 8.42e-01 |
| KEGG | KEGG:04916 | Melanogenesis | 2 | 77 | 8.42e-01 |
| KEGG | KEGG:01523 | Antifolate resistance | 2 | 24 | 8.42e-01 |
| KEGG | KEGG:05016 | Huntington disease | 3 | 256 | 8.42e-01 |
| KEGG | KEGG:03030 | DNA replication | 1 | 35 | 8.42e-01 |
| KEGG | KEGG:00760 | Nicotinate and nicotinamide metabolism | 1 | 28 | 8.42e-01 |
| KEGG | KEGG:04730 | Long-term depression | 3 | 42 | 8.53e-01 |
| KEGG | KEGG:04540 | Gap junction | 5 | 73 | 8.53e-01 |
| KEGG | KEGG:04915 | Estrogen signaling pathway | 7 | 97 | 8.61e-01 |
| KEGG | KEGG:00230 | Purine metabolism | 2 | 97 | 8.61e-01 |
| KEGG | KEGG:04928 | Parathyroid hormone synthesis, secretion and action | 1 | 82 | 8.61e-01 |
| KEGG | KEGG:05206 | MicroRNAs in cancer | 1 | 149 | 8.61e-01 |
| KEGG | KEGG:04961 | Endocrine and other factor-regulated calcium reabsorption | 4 | 41 | 8.61e-01 |
| KEGG | KEGG:00532 | Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 1 | 21 | 8.64e-01 |
| KEGG | KEGG:00790 | Folate biosynthesis | 1 | 18 | 8.79e-01 |
| KEGG | KEGG:04725 | Cholinergic synapse | 1 | 83 | 8.79e-01 |
| KEGG | KEGG:00260 | Glycine, serine and threonine metabolism | 2 | 31 | 8.86e-01 |
| KEGG | KEGG:05208 | Chemical carcinogenesis - reactive oxygen species | 4 | 186 | 8.86e-01 |
| KEGG | KEGG:00740 | Riboflavin metabolism | 1 | 6 | 8.90e-01 |
| KEGG | KEGG:05200 | Pathways in cancer | 26 | 409 | 8.97e-01 |
| KEGG | KEGG:00640 | Propanoate metabolism | 1 | 28 | 9.14e-01 |
| KEGG | KEGG:04658 | Th1 and Th2 cell differentiation | 4 | 53 | 9.14e-01 |
| KEGG | KEGG:05146 | Amoebiasis | 1 | 64 | 9.14e-01 |
| KEGG | KEGG:04932 | Non-alcoholic fatty liver disease | 6 | 131 | 9.14e-01 |
| KEGG | KEGG:05110 | Vibrio cholerae infection | 2 | 43 | 9.14e-01 |
| KEGG | KEGG:04650 | Natural killer cell mediated cytotoxicity | 2 | 63 | 9.14e-01 |
| KEGG | KEGG:04371 | Apelin signaling pathway | 10 | 106 | 9.14e-01 |
| KEGG | KEGG:00620 | Pyruvate metabolism | 1 | 33 | 9.14e-01 |
| KEGG | KEGG:04750 | Inflammatory mediator regulation of TRP channels | 2 | 72 | 9.17e-01 |
| KEGG | KEGG:05020 | Prion disease | 2 | 220 | 9.35e-01 |
| KEGG | KEGG:04630 | JAK-STAT signaling pathway | 1 | 88 | 9.37e-01 |
| KEGG | KEGG:04024 | cAMP signaling pathway | 2 | 151 | 9.37e-01 |
| KEGG | KEGG:03010 | Ribosome | 1 | 127 | 9.39e-01 |
| KEGG | KEGG:05133 | Pertussis | 3 | 45 | 9.42e-01 |
| KEGG | KEGG:04510 | Focal adhesion | 12 | 177 | 9.42e-01 |
| KEGG | KEGG:04261 | Adrenergic signaling in cardiomyocytes | 1 | 128 | 9.42e-01 |
| KEGG | KEGG:04960 | Aldosterone-regulated sodium reabsorption | 3 | 26 | 9.58e-01 |
| KEGG | KEGG:04659 | Th17 cell differentiation | 1 | 64 | 9.73e-01 |
| KEGG | KEGG:05010 | Alzheimer disease | 2 | 315 | 9.73e-01 |
| KEGG | KEGG:04913 | Ovarian steroidogenesis | 2 | 28 | 9.73e-01 |
| KEGG | KEGG:00280 | Valine, leucine and isoleucine degradation | 1 | 43 | 9.83e-01 |
| KEGG | KEGG:04142 | Lysosome | 5 | 118 | 9.83e-01 |
| KEGG | KEGG:04912 | GnRH signaling pathway | 1 | 76 | 9.83e-01 |
| KEGG | KEGG:04724 | Glutamatergic synapse | 1 | 74 | 9.84e-01 |
| KEGG | KEGG:04216 | Ferroptosis | 3 | 33 | 9.88e-01 |
| KEGG | KEGG:05340 | Primary immunodeficiency | 2 | 12 | 9.92e-01 |
| KEGG | KEGG:00061 | Fatty acid biosynthesis | 1 | 12 | 9.97e-01 |
| KEGG | KEGG:05120 | Epithelial cell signaling in Helicobacter pylori infection | 2 | 58 | 9.97e-01 |
| KEGG | KEGG:04080 | Neuroactive ligand-receptor interaction | 3 | 108 | 1.00e+00 |
| KEGG | KEGG:04612 | Antigen processing and presentation | 3 | 41 | 1.00e+00 |
| KEGG | KEGG:05014 | Amyotrophic lateral sclerosis | 2 | 303 | 1.00e+00 |
| KEGG | KEGG:00190 | Oxidative phosphorylation | 2 | 106 | 1.00e+00 |
| KEGG | KEGG:04972 | Pancreatic secretion | 1 | 58 | 1.00e+00 |
| KEGG | KEGG:04260 | Cardiac muscle contraction | 1 | 67 | 1.00e+00 |
| KEGG | KEGG:04976 | Bile secretion | 4 | 42 | 1.00e+00 |
| KEGG | KEGG:00140 | Steroid hormone biosynthesis | 1 | 19 | 1.00e+00 |
| KEGG | KEGG:00071 | Fatty acid degradation | 1 | 32 | 1.00e+00 |
| KEGG | KEGG:04512 | ECM-receptor interaction | 1 | 69 | 1.00e+00 |
| KEGG | KEGG:04514 | Cell adhesion molecules | 1 | 83 | 1.00e+00 |
| KEGG | KEGG:04974 | Protein digestion and absorption | 1 | 61 | 1.00e+00 |
| KEGG | KEGG:04979 | Cholesterol metabolism | 1 | 33 | 1.00e+00 |
| KEGG | KEGG:04971 | Gastric acid secretion | 3 | 52 | 1.00e+00 |
| KEGG | KEGG:05171 | Coronavirus disease - COVID-19 | 8 | 162 | 1.00e+00 |
| KEGG | KEGG:04670 | Leukocyte transendothelial migration | 2 | 79 | 1.00e+00 |
| KEGG | KEGG:04740 | Olfactory transduction | 1 | 25 | 1.00e+00 |
| KEGG | KEGG:04970 | Salivary secretion | 1 | 55 | 1.00e+00 |
| KEGG | KEGG:04723 | Retrograde endocannabinoid signaling | 2 | 99 | 1.00e+00 |
| KEGG | KEGG:01212 | Fatty acid metabolism | 1 | 50 | 1.00e+00 |
| KEGG | KEGG:05322 | Systemic lupus erythematosus | 5 | 61 | 1.00e+00 |
| KEGG | KEGG:04713 | Circadian entrainment | 3 | 69 | 1.00e+00 |
| KEGG | KEGG:04672 | Intestinal immune network for IgA production | 1 | 12 | 1.00e+00 |
| KEGG | KEGG:04744 | Phototransduction | 1 | 12 | 1.00e+00 |
| KEGG | KEGG:04727 | GABAergic synapse | 2 | 55 | 1.00e+00 |
| KEGG | KEGG:04950 | Maturity onset diabetes of the young | 1 | 4 | 1.00e+00 |
| KEGG | KEGG:05416 | Viral myocarditis | 2 | 40 | 1.00e+00 |
| KEGG | KEGG:00830 | Retinol metabolism | 2 | 16 | 1.00e+00 |
| KEGG | KEGG:04020 | Calcium signaling pathway | 1 | 157 | 1.00e+00 |
| KEGG | KEGG:00650 | Butanoate metabolism | 1 | 17 | 1.00e+00 |
EPI 508 var genes (using q value <0.1)
Looking at variance in all treatment & time in the significantly variable EPI genes (n = 508)
EPIstore <- EPIstorelist24 %>%
dplyr::filter(EPIqvalues<0.1)
var508only <- mean_vardrug1 %>%
rownames_to_column(var = "entrezid") %>%
mutate(entrezid=as.integer(entrezid)) %>%
dplyr::filter(entrezid %in% EPIstore$ENTREZID) %>%
column_to_rownames("entrezid") %>%
dplyr::select(starts_with("var"))
var_corr <- cor(var508only)
ComplexHeatmap::Heatmap(var_corr)
var50824only <- var508only %>%
dplyr::select(starts_with("var")&contains(".24"))
var_24corr <- cor(var50824only)
ComplexHeatmap::Heatmap(var_24corr)
var_all <- mean_vardrug1 %>%
dplyr::select(starts_with("var"))
var_24all <- mean_vardrug1 %>%
dplyr::select(starts_with("var")&contains(".24"))
var_allcorr <- cor(var_all)
ComplexHeatmap::Heatmap(var_allcorr,col=col_fun)
var_24allcorr <- cor(var_24all)
ComplexHeatmap::Heatmap(var_24allcorr,col=col_fun)
DOXreQTLs <- readRDS("output/DOXreQTLs.RDS")
# storeEPI %>%
# filter (ENTREZID %in% DOXreQTLs$ENTREZID) %>%
# left_join(., backGL, by=c("ENTREZID"))
ggVennDiagram::ggVennDiagram(list(unique(EPIstore$ENTREZID),DOXreQTLs$ENTREZID),category.names = c("EPI var\nn = 508","DOXreQTLs\nn = 142"))
mean_vardrug1 <- read.csv("data/mean_vardrug1.csv", row.names = 1)
drug_frameepivar<- mean_vardrug1 %>%
rownames_to_column(var = "entrezid") %>%
dplyr::filter(entrezid %in% EPIstore$ENTREZID) %>%
pivot_longer(cols = mean.Da.3:var.Ve.24, names_to = "short", values_to = "values") %>%
separate(short, into=c("calc","treatment","time")) %>%
mutate(treatment= factor(treatment, levels = c("Do","Ep","Da","Mi","Tr","Ve"),labels = c("DOX","EPI","DNR","MTX","TRZ","VEH"))) %>%
mutate(time= factor(time, levels = c("3","24"), labels= c("3 hours","24 hours"))) %>%
group_by(treatment, time, calc) %>%
mutate(entrezid=as.integer(entrezid)) %>%
as.data.frame
drug_pal_fact <- c("#8B006D","#DF707E","#F1B72B", "#3386DD","#707031","#41B333")
drug_frameepivar %>%
filter(calc!="mean") %>%
ggplot(., aes(x= treatment, y=values, fill=treatment))+
geom_boxplot(outlier.shape=NA)+
geom_signif(comparisons =list(c("DOX","VEH"),
c("EPI","VEH"),
c("DNR","VEH"),
c("MTX","VEH"),
c("TRZ","VEH")),
test= "t.test",
tip_length = 0.01,
map_signif_level=FALSE,
textsize =4,
y_position=0.85,
step_increase = 0.1)+
facet_wrap(~time)+
ggtitle("Variance of 508 highly variable EPI genes")+
# coord_cartesian(ylim = c(0,1))+
# ylim(0,2)+
scale_fill_manual(values=drug_pal_fact)+
theme_bw()+
xlab(" ")+
ylab(expression("variance of log "[2]~" cpm "))+
theme(strip.background = element_rect(fill = "white",linetype=1, linewidth = 0.5),
plot.title = element_text(size=12,hjust = 0.5,face="bold"),
axis.title = element_text(size = 10, color = "black"),
axis.ticks = element_line(linewidth = 1.0),
panel.background = element_rect(colour = "black", size=1),
axis.text.x = element_blank(),
strip.text.x = element_text(margin = margin(2,0,2,0, "mm"),face = "bold"))
drug_frameepivar %>%
filter(calc!="var") %>%
ggplot(., aes(x= treatment, y=values,fill=treatment))+
geom_boxplot(outlier.shape=NA)+
geom_signif(comparisons =list(c("TRZ","VEH"),
c("MTX","VEH"),
c("DNR","VEH"),
c("EPI","VEH"),
c("DOX","VEH")),
test= "t.test",
tip_length = 0.01,
map_signif_level=FALSE,
textsize =4,
y_position=11,
step_increase = 0.05)+
facet_wrap(.~time)+
ggtitle("Means of the 508 highly variable EPI genes")+
ylim(0,15)+
scale_fill_manual(values=drug_pal_fact)+
theme_bw()+
xlab(" ")+
ylab(expression("counts log"[2]~"cpm "))+
theme(strip.background = element_rect(fill = "white",linetype=1, linewidth = 0.5),
plot.title = element_text(size=12,hjust = 0.5,face="bold"),
axis.title = element_text(size = 10, color = "black"),
axis.ticks = element_line(linewidth = 1.0),
panel.background = element_rect(colour = "black", size=1),
axis.text.x = element_blank(),
strip.text.x = element_text(margin = margin(2,0,2,0, "mm"),face = "bold"))
EPI var GO info
GO analysis across the 508 genes
#
# EPIvargostq <- gost(query = EPIstore$ENTREZID,
# organism = "hsapiens", significant = FALSE,
# ordered_query = TRUE,
# domain_scope = "custom",
# measure_underrepresentation = FALSE,
# evcodes = FALSE,
# user_threshold = 0.05,
# correction_method = c("fdr"),
# custom_bg =my_exp_genes$ENTREZID,
# sources=c("GO:BP","KEGG"))
# saveRDS(EPIvargostq,"data/DEG-GO/EPIvargostq.RDS")
EPIvargostq <- readRDS("data/DEG-GO/EPIvargostq.RDS")
# EPIvarq<- gostplot(EPIvargostq, capped = FALSE, interactive = TRUE)
# EPIvarq
EPI_table_var <- EPIvargostq$result %>%
dplyr::select(c(source, term_id, term_name,intersection_size, term_size, p_value))
EPI_table_var %>%
dplyr::filter(source=="GO:BP") %>%
dplyr::select(p_value,term_name,intersection_size) %>%
slice_min(., n=5 ,order_by=p_value) %>%
mutate(log_val = -log10(p_value)) %>%
ggplot(., aes(x = log_val, y =reorder(term_name,p_value),
col= intersection_size)) +
geom_point(aes(size = intersection_size)) +
geom_vline(xintercept = (-log10(0.05)))+
scale_y_discrete(labels = scales::label_wrap(30))+
guides(col="none",
size=guide_legend(title = "# of intersected \n terms"))+
ggtitle('EPI highly var genes GO:BP terms') +
xlab(expression(" -"~log[10]~("adj. p-value")))+
ylab("GO: BP term")+
theme_bw()+
theme(plot.title = element_text(size = rel(1.5), hjust = 0.5),
axis.title = element_text(size = 15, color = "black"),
axis.ticks = element_line(linewidth = 1.5),
axis.line = element_line(linewidth = 1.5),
axis.text = element_text(size = 10, color = "black", angle = 0),
strip.text.x = element_text(size = 15, color = "black", face = "bold"))
| Version | Author | Date |
|---|---|---|
| 3622a69 | reneeisnowhere | 2023-09-28 |
EPI_table_var %>%
dplyr::filter(source=="KEGG") %>%
dplyr::select(p_value,term_name,intersection_size) %>%
slice_min(., n=5 ,order_by=p_value) %>%
mutate(log_val = -log10(p_value)) %>%
ggplot(., aes(x = log_val, y =reorder(term_name,p_value),
col= intersection_size)) +
geom_point(aes(size = intersection_size)) +
geom_vline(xintercept = (-log10(0.05)))+
scale_y_discrete(labels = scales::label_wrap(30))+
guides(col="none",
size=guide_legend(title = "# of intersected \n terms"))+
ggtitle('EPI highly var genes KEGG terms') +
xlab(expression(" -"~log[10]~("adj. p-value")))+
ylab("KEGG term")+
theme_bw()+
theme(plot.title = element_text(size = rel(1.5), hjust = 0.5),
axis.title = element_text(size = 15, color = "black"),
axis.ticks = element_line(linewidth = 1.5),
axis.line = element_line(linewidth = 1.5),
axis.text = element_text(size = 10, color = "black", angle = 0),
strip.text.x = element_text(size = 15, color = "black", face = "bold"))
EPI_table_var %>%
mutate_at(.vars = 6, .funs= scientific_format()) %>%
kable(.,) %>%
kable(.,caption = "KEGG GO:BP var enrichment terms ") %>%
kable_paper("striped", full_width = FALSE) %>%
kable_styling(full_width = FALSE, position = "left",bootstrap_options = c("striped","hover")) %>%
scroll_box(width = "100%", height = "400px") | x |
|---|
| <table> <thead> <tr> <th style=“text-align:left;”> source </th> <th style=“text-align:left;”> term_id </th> <th style=“text-align:left;”> term_name </th> <th style=“text-align:right;”> intersection_size </th> <th style=“text-align:right;”> term_size </th> <th style=“text-align:left;”> p_value </th> </tr> </thead> <tbody> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046499 </td> <td style=“text-align:left;”> S-adenosylmethioninamine metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046498 </td> <td style=“text-align:left;”> S-adenosylhomocysteine metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 1.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002339 </td> <td style=“text-align:left;”> B cell selection </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 1.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006481 </td> <td style=“text-align:left;”> C-terminal protein methylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 1.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901645 </td> <td style=“text-align:left;”> regulation of synoviocyte proliferation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 1.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901647 </td> <td style=“text-align:left;”> positive regulation of synoviocyte proliferation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 1.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031848 </td> <td style=“text-align:left;”> protection from non-homologous end joining at telomere </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 1.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042770 </td> <td style=“text-align:left;”> signal transduction in response to DNA damage </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:right;”> 180 </td> <td style=“text-align:left;”> 1.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042659 </td> <td style=“text-align:left;”> regulation of cell fate specification </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 1.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002941 </td> <td style=“text-align:left;”> synoviocyte proliferation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 1.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036250 </td> <td style=“text-align:left;”> peroxisome transport along microtubule </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016236 </td> <td style=“text-align:left;”> macroautophagy </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:right;”> 308 </td> <td style=“text-align:left;”> 1.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048338 </td> <td style=“text-align:left;”> mesoderm structural organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902855 </td> <td style=“text-align:left;”> regulation of non-motile cilium assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902857 </td> <td style=“text-align:left;”> positive regulation of non-motile cilium assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048352 </td> <td style=“text-align:left;”> paraxial mesoderm structural organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050679 </td> <td style=“text-align:left;”> positive regulation of epithelial cell proliferation </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 152 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903301 </td> <td style=“text-align:left;”> positive regulation of hexokinase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002084 </td> <td style=“text-align:left;”> protein depalmitoylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903251 </td> <td style=“text-align:left;”> multi-ciliated epithelial cell differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042323 </td> <td style=“text-align:left;”> negative regulation of circadian sleep/wake cycle, non-REM sleep </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903047 </td> <td style=“text-align:left;”> mitotic cell cycle process </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:right;”> 689 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051640 </td> <td style=“text-align:left;”> organelle localization </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 521 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099123 </td> <td style=“text-align:left;”> somato-dendritic dopamine secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042278 </td> <td style=“text-align:left;”> purine nucleoside metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009119 </td> <td style=“text-align:left;”> ribonucleoside metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042267 </td> <td style=“text-align:left;”> natural killer cell mediated cytotoxicity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099547 </td> <td style=“text-align:left;”> regulation of translation at synapse, modulating synaptic transmission </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042137 </td> <td style=“text-align:left;”> sequestering of neurotransmitter </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048146 </td> <td style=“text-align:left;”> positive regulation of fibroblast proliferation </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002228 </td> <td style=“text-align:left;”> natural killer cell mediated immunity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099578 </td> <td style=“text-align:left;”> regulation of translation at postsynapse, modulating synaptic transmission </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030330 </td> <td style=“text-align:left;”> DNA damage response, signal transduction by p53 class mediator </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032784 </td> <td style=“text-align:left;”> regulation of DNA-templated transcription elongation </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:right;”> 99 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048264 </td> <td style=“text-align:left;”> determination of ventral identity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0110020 </td> <td style=“text-align:left;”> regulation of actomyosin structure organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 90 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060831 </td> <td style=“text-align:left;”> smoothened signaling pathway involved in dorsal/ventral neural tube patterning </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009648 </td> <td style=“text-align:left;”> photoperiodism </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048144 </td> <td style=“text-align:left;”> fibroblast proliferation </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 89 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0062232 </td> <td style=“text-align:left;”> prostanoid catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010332 </td> <td style=“text-align:left;”> response to gamma radiation </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 47 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097283 </td> <td style=“text-align:left;”> keratinocyte apoptotic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032922 </td> <td style=“text-align:left;”> circadian regulation of gene expression </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 63 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021915 </td> <td style=“text-align:left;”> neural tube development </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 143 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042754 </td> <td style=“text-align:left;”> negative regulation of circadian rhythm </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905285 </td> <td style=“text-align:left;”> fibrous ring of heart morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905344 </td> <td style=“text-align:left;”> prostaglandin catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061956 </td> <td style=“text-align:left;”> penetration of cumulus oophorus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061919 </td> <td style=“text-align:left;”> process utilizing autophagic mechanism </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:right;”> 516 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042733 </td> <td style=“text-align:left;”> embryonic digit morphogenesis </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021998 </td> <td style=“text-align:left;”> neural plate mediolateral regionalization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032900 </td> <td style=“text-align:left;”> negative regulation of neurotrophin production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903421 </td> <td style=“text-align:left;”> regulation of synaptic vesicle recycling </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905515 </td> <td style=“text-align:left;”> non-motile cilium assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032899 </td> <td style=“text-align:left;”> regulation of neurotrophin production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061572 </td> <td style=“text-align:left;”> actin filament bundle organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 138 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061343 </td> <td style=“text-align:left;”> cell adhesion involved in heart morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042543 </td> <td style=“text-align:left;”> protein N-linked glycosylation via arginine </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098727 </td> <td style=“text-align:left;”> maintenance of cell number </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 153 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061198 </td> <td style=“text-align:left;”> fungiform papilla formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061197 </td> <td style=“text-align:left;”> fungiform papilla morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098732 </td> <td style=“text-align:left;”> macromolecule deacylation </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 92 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098734 </td> <td style=“text-align:left;”> macromolecule depalmitoylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030038 </td> <td style=“text-align:left;”> contractile actin filament bundle assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 95 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009649 </td> <td style=“text-align:left;”> entrainment of circadian clock </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006906 </td> <td style=“text-align:left;”> vesicle fusion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 101 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048145 </td> <td style=“text-align:left;”> regulation of fibroblast proliferation </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 75 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002352 </td> <td style=“text-align:left;”> B cell negative selection </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006383 </td> <td style=“text-align:left;”> transcription by RNA polymerase III </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 61 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048372 </td> <td style=“text-align:left;”> lateral mesodermal cell fate commitment </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031570 </td> <td style=“text-align:left;”> DNA integrity checkpoint signaling </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 130 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060058 </td> <td style=“text-align:left;”> positive regulation of apoptotic process involved in mammary gland involution </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031627 </td> <td style=“text-align:left;”> telomeric loop formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060057 </td> <td style=“text-align:left;”> apoptotic process involved in mammary gland involution </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007346 </td> <td style=“text-align:left;”> regulation of mitotic cell cycle </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:right;”> 438 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007341 </td> <td style=“text-align:left;”> penetration of zona pellucida </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990849 </td> <td style=“text-align:left;”> vacuolar localization </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 61 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990755 </td> <td style=“text-align:left;”> mitotic spindle microtubule depolymerization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007032 </td> <td style=“text-align:left;”> endosome organization </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 93 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990683 </td> <td style=“text-align:left;”> DNA double-strand break attachment to nuclear envelope </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007033 </td> <td style=“text-align:left;”> vacuole organization </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:right;”> 200 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902339 </td> <td style=“text-align:left;”> positive regulation of apoptotic process involved in morphogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036293 </td> <td style=“text-align:left;”> response to decreased oxygen levels </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 248 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036258 </td> <td style=“text-align:left;”> multivesicular body assembly </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901988 </td> <td style=“text-align:left;”> negative regulation of cell cycle phase transition </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 234 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036257 </td> <td style=“text-align:left;”> multivesicular body organization </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032204 </td> <td style=“text-align:left;”> regulation of telomere maintenance </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 96 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902017 </td> <td style=“text-align:left;”> regulation of cilium assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 55 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032205 </td> <td style=“text-align:left;”> negative regulation of telomere maintenance </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032231 </td> <td style=“text-align:left;”> regulation of actin filament bundle assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 90 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902068 </td> <td style=“text-align:left;”> regulation of sphingolipid mediated signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055001 </td> <td style=“text-align:left;”> muscle cell development </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 166 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032242 </td> <td style=“text-align:left;”> regulation of nucleoside transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032244 </td> <td style=“text-align:left;”> positive regulation of nucleoside transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902117 </td> <td style=“text-align:left;”> positive regulation of organelle assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 75 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902172 </td> <td style=“text-align:left;”> regulation of keratinocyte apoptotic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902231 </td> <td style=“text-align:left;”> positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048597 </td> <td style=“text-align:left;”> post-embryonic camera-type eye morphogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031032 </td> <td style=“text-align:left;”> actomyosin structure organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 187 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0038166 </td> <td style=“text-align:left;”> angiotensin-activated signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901620 </td> <td style=“text-align:left;”> regulation of smoothened signaling pathway involved in dorsal/ventral neural tube patterning </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008635 </td> <td style=“text-align:left;”> activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome c </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006914 </td> <td style=“text-align:left;”> autophagy </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:right;”> 516 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010453 </td> <td style=“text-align:left;”> regulation of cell fate commitment </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000622 </td> <td style=“text-align:left;”> regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032418 </td> <td style=“text-align:left;”> lysosome localization </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 61 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902455 </td> <td style=“text-align:left;”> negative regulation of stem cell population maintenance </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048378 </td> <td style=“text-align:left;”> regulation of lateral mesodermal cell fate specification </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048382 </td> <td style=“text-align:left;”> mesendoderm development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900242 </td> <td style=“text-align:left;”> regulation of synaptic vesicle endocytosis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003274 </td> <td style=“text-align:left;”> endocardial cushion fusion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060260 </td> <td style=“text-align:left;”> regulation of transcription initiation by RNA polymerase II </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006996 </td> <td style=“text-align:left;”> organelle organization </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 2974 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002541 </td> <td style=“text-align:left;”> activation of plasma proteins involved in acute inflammatory response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002543 </td> <td style=“text-align:left;”> activation of blood coagulation via clotting cascade </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002552 </td> <td style=“text-align:left;”> serotonin secretion by mast cell </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048736 </td> <td style=“text-align:left;”> appendage development </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:right;”> 141 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035601 </td> <td style=“text-align:left;”> protein deacylation </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 91 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060173 </td> <td style=“text-align:left;”> limb development </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:right;”> 141 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002674 </td> <td style=“text-align:left;”> negative regulation of acute inflammatory response </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006998 </td> <td style=“text-align:left;”> nuclear envelope organization </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 54 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007623 </td> <td style=“text-align:left;”> circadian rhythm </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 160 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007010 </td> <td style=“text-align:left;”> cytoskeleton organization </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 1186 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060119 </td> <td style=“text-align:left;”> inner ear receptor cell development </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060113 </td> <td style=“text-align:left;”> inner ear receptor cell differentiation </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031468 </td> <td style=“text-align:left;”> nuclear membrane reassembly </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901523 </td> <td style=“text-align:left;”> icosanoid catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007017 </td> <td style=“text-align:left;”> microtubule-based process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 757 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007030 </td> <td style=“text-align:left;”> Golgi organization </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 133 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048377 </td> <td style=“text-align:left;”> lateral mesodermal cell fate specification </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042490 </td> <td style=“text-align:left;”> mechanoreceptor differentiation </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007097 </td> <td style=“text-align:left;”> nuclear migration </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090174 </td> <td style=“text-align:left;”> organelle membrane fusion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 103 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006352 </td> <td style=“text-align:left;”> DNA-templated transcription initiation </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:right;”> 131 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045786 </td> <td style=“text-align:left;”> negative regulation of cell cycle </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:right;”> 337 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016233 </td> <td style=“text-align:left;”> telomere capping </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000301 </td> <td style=“text-align:left;”> retrograde transport, vesicle recycling within Golgi </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051146 </td> <td style=“text-align:left;”> striated muscle cell differentiation </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 239 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016072 </td> <td style=“text-align:left;”> rRNA metabolic process </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:right;”> 252 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070897 </td> <td style=“text-align:left;”> transcription preinitiation complex assembly </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:right;”> 66 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043558 </td> <td style=“text-align:left;”> regulation of translational initiation in response to stress </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001666 </td> <td style=“text-align:left;”> response to hypoxia </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 235 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006625 </td> <td style=“text-align:left;”> protein targeting to peroxisome </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006354 </td> <td style=“text-align:left;”> DNA-templated transcription elongation </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:right;”> 126 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090201 </td> <td style=“text-align:left;”> negative regulation of release of cytochrome c from mitochondria </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006465 </td> <td style=“text-align:left;”> signal peptide processing </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034453 </td> <td style=“text-align:left;”> microtubule anchoring </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033133 </td> <td style=“text-align:left;”> positive regulation of glucokinase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090307 </td> <td style=“text-align:left;”> mitotic spindle assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010833 </td> <td style=“text-align:left;”> telomere maintenance via telomere lengthening </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 73 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019068 </td> <td style=“text-align:left;”> virion assembly </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072662 </td> <td style=“text-align:left;”> protein localization to peroxisome </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904747 </td> <td style=“text-align:left;”> positive regulation of apoptotic process involved in development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043574 </td> <td style=“text-align:left;”> peroxisomal transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006605 </td> <td style=“text-align:left;”> protein targeting </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 310 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016561 </td> <td style=“text-align:left;”> protein import into peroxisome matrix, translocation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016560 </td> <td style=“text-align:left;”> protein import into peroxisome matrix, docking </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016558 </td> <td style=“text-align:left;”> protein import into peroxisome matrix </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904412 </td> <td style=“text-align:left;”> regulation of cardiac ventricle development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043508 </td> <td style=“text-align:left;”> negative regulation of JUN kinase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034660 </td> <td style=“text-align:left;”> ncRNA metabolic process </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:right;”> 561 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000226 </td> <td style=“text-align:left;”> microtubule cytoskeleton organization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 549 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010948 </td> <td style=“text-align:left;”> negative regulation of cell cycle process </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:right;”> 271 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070933 </td> <td style=“text-align:left;”> histone H4 deacetylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072663 </td> <td style=“text-align:left;”> establishment of protein localization to peroxisome </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043967 </td> <td style=“text-align:left;”> histone H4 acetylation </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045724 </td> <td style=“text-align:left;”> positive regulation of cilium assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018410 </td> <td style=“text-align:left;”> C-terminal protein amino acid modification </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051053 </td> <td style=“text-align:left;”> negative regulation of DNA metabolic process </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 116 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000394 </td> <td style=“text-align:left;”> RNA splicing, via endonucleolytic cleavage and ligation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051017 </td> <td style=“text-align:left;”> actin filament bundle assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 136 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016311 </td> <td style=“text-align:left;”> dephosphorylation </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 278 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071763 </td> <td style=“text-align:left;”> nuclear membrane organization </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904414 </td> <td style=“text-align:left;”> positive regulation of cardiac ventricle development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046128 </td> <td style=“text-align:left;”> purine ribonucleoside metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006368 </td> <td style=“text-align:left;”> transcription elongation by RNA polymerase II </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:right;”> 110 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090402 </td> <td style=“text-align:left;”> oncogene-induced cell senescence </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000045 </td> <td style=“text-align:left;”> autophagosome assembly </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 100 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044773 </td> <td style=“text-align:left;”> mitotic DNA damage checkpoint signaling </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 80 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090398 </td> <td style=“text-align:left;”> cellular senescence </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 84 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019827 </td> <td style=“text-align:left;”> stem cell population maintenance </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 151 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000075 </td> <td style=“text-align:left;”> cell cycle checkpoint signaling </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 184 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070256 </td> <td style=“text-align:left;”> negative regulation of mucus secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032984 </td> <td style=“text-align:left;”> protein-containing complex disassembly </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:right;”> 220 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044774 </td> <td style=“text-align:left;”> mitotic DNA integrity checkpoint signaling </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 84 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043149 </td> <td style=“text-align:left;”> stress fiber assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 95 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043153 </td> <td style=“text-align:left;”> entrainment of circadian clock by photoperiod </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044772 </td> <td style=“text-align:left;”> mitotic cell cycle phase transition </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:right;”> 411 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006388 </td> <td style=“text-align:left;”> tRNA splicing, via endonucleolytic cleavage and ligation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000082 </td> <td style=“text-align:left;”> G1/S transition of mitotic cell cycle </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:right;”> 206 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000077 </td> <td style=“text-align:left;”> DNA damage checkpoint signaling </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:right;”> 121 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015919 </td> <td style=“text-align:left;”> peroxisomal membrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044770 </td> <td style=“text-align:left;”> cell cycle phase transition </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:right;”> 496 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051492 </td> <td style=“text-align:left;”> regulation of stress fiber assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 81 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034243 </td> <td style=“text-align:left;”> regulation of transcription elongation by RNA polymerase II </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:right;”> 85 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035019 </td> <td style=“text-align:left;”> somatic stem cell population maintenance </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044721 </td> <td style=“text-align:left;”> protein import into peroxisome matrix, substrate release </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033043 </td> <td style=“text-align:left;”> regulation of organelle organization </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 1001 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044843 </td> <td style=“text-align:left;”> cell cycle G1/S phase transition </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:right;”> 226 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015786 </td> <td style=“text-align:left;”> UDP-glucose transmembrane transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043247 </td> <td style=“text-align:left;”> telomere maintenance in response to DNA damage </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904357 </td> <td style=“text-align:left;”> negative regulation of telomere maintenance via telomere lengthening </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051225 </td> <td style=“text-align:left;”> spindle assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 119 </td> <td style=“text-align:left;”> 1.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0039702 </td> <td style=“text-align:left;”> viral budding via host ESCRT complex </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 1.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0110097 </td> <td style=“text-align:left;”> regulation of calcium import into the mitochondrion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 1.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061196 </td> <td style=“text-align:left;”> fungiform papilla development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 1.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031503 </td> <td style=“text-align:left;”> protein-containing complex localization </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 166 </td> <td style=“text-align:left;”> 1.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0040029 </td> <td style=“text-align:left;”> epigenetic regulation of gene expression </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 182 </td> <td style=“text-align:left;”> 1.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035732 </td> <td style=“text-align:left;”> nitric oxide storage </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060789 </td> <td style=“text-align:left;”> hair follicle placode formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 1.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007052 </td> <td style=“text-align:left;”> mitotic spindle organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 127 </td> <td style=“text-align:left;”> 1.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070932 </td> <td style=“text-align:left;”> histone H3 deacetylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 1.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032933 </td> <td style=“text-align:left;”> SREBP signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 1.57e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006890 </td> <td style=“text-align:left;”> retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 1.57e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045654 </td> <td style=“text-align:left;”> positive regulation of megakaryocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 1.57e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001736 </td> <td style=“text-align:left;”> establishment of planar polarity </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 1.57e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007164 </td> <td style=“text-align:left;”> establishment of tissue polarity </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 1.57e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031571 </td> <td style=“text-align:left;”> mitotic G1 DNA damage checkpoint signaling </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 1.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044819 </td> <td style=“text-align:left;”> mitotic G1/S transition checkpoint signaling </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 1.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006891 </td> <td style=“text-align:left;”> intra-Golgi vesicle-mediated transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 1.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007093 </td> <td style=“text-align:left;”> mitotic cell cycle checkpoint signaling </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:right;”> 137 </td> <td style=“text-align:left;”> 1.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071478 </td> <td style=“text-align:left;”> cellular response to radiation </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 150 </td> <td style=“text-align:left;”> 1.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071501 </td> <td style=“text-align:left;”> cellular response to sterol depletion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 1.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043968 </td> <td style=“text-align:left;”> histone H2A acetylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 1.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032968 </td> <td style=“text-align:left;”> positive regulation of transcription elongation by RNA polymerase II </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 1.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000142 </td> <td style=“text-align:left;”> regulation of DNA-templated transcription initiation </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 77 </td> <td style=“text-align:left;”> 1.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902459 </td> <td style=“text-align:left;”> positive regulation of stem cell population maintenance </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 1.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044743 </td> <td style=“text-align:left;”> protein transmembrane import into intracellular organelle </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 1.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016575 </td> <td style=“text-align:left;”> histone deacetylation </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 62 </td> <td style=“text-align:left;”> 1.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016050 </td> <td style=“text-align:left;”> vesicle organization </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:right;”> 317 </td> <td style=“text-align:left;”> 1.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0120034 </td> <td style=“text-align:left;”> positive regulation of plasma membrane bounded cell projection assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 92 </td> <td style=“text-align:left;”> 1.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009953 </td> <td style=“text-align:left;”> dorsal/ventral pattern formation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 1.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035720 </td> <td style=“text-align:left;”> intraciliary anterograde transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 1.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009116 </td> <td style=“text-align:left;”> nucleoside metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 1.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006367 </td> <td style=“text-align:left;”> transcription initiation at RNA polymerase II promoter </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 95 </td> <td style=“text-align:left;”> 1.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048284 </td> <td style=“text-align:left;”> organelle fusion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 133 </td> <td style=“text-align:left;”> 1.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045324 </td> <td style=“text-align:left;”> late endosome to vacuole transport </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 1.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070482 </td> <td style=“text-align:left;”> response to oxygen levels </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 271 </td> <td style=“text-align:left;”> 1.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031124 </td> <td style=“text-align:left;”> mRNA 3’-end processing </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 1.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901673 </td> <td style=“text-align:left;”> regulation of mitotic spindle assembly </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 1.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990116 </td> <td style=“text-align:left;”> ribosome-associated ubiquitin-dependent protein catabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 1.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007031 </td> <td style=“text-align:left;”> peroxisome organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 1.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902850 </td> <td style=“text-align:left;”> microtubule cytoskeleton organization involved in mitosis </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 157 </td> <td style=“text-align:left;”> 1.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904385 </td> <td style=“text-align:left;”> cellular response to angiotensin </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 1.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902262 </td> <td style=“text-align:left;”> apoptotic process involved in blood vessel morphogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 1.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006991 </td> <td style=“text-align:left;”> response to sterol depletion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 1.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050688 </td> <td style=“text-align:left;”> regulation of defense response to virus </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 1.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905037 </td> <td style=“text-align:left;”> autophagosome organization </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 107 </td> <td style=“text-align:left;”> 1.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010464 </td> <td style=“text-align:left;”> regulation of mesenchymal cell proliferation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 1.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031860 </td> <td style=“text-align:left;”> telomeric 3’ overhang formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 1.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043162 </td> <td style=“text-align:left;”> ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 1.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043555 </td> <td style=“text-align:left;”> regulation of translation in response to stress </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 1.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901987 </td> <td style=“text-align:left;”> regulation of cell cycle phase transition </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:right;”> 387 </td> <td style=“text-align:left;”> 1.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031167 </td> <td style=“text-align:left;”> rRNA methylation </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 1.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0101024 </td> <td style=“text-align:left;”> mitotic nuclear membrane organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 1.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007084 </td> <td style=“text-align:left;”> mitotic nuclear membrane reassembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 1.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097711 </td> <td style=“text-align:left;”> ciliary basal body-plasma membrane docking </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006378 </td> <td style=“text-align:left;”> mRNA polyadenylation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 1.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046755 </td> <td style=“text-align:left;”> viral budding </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 1.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0005980 </td> <td style=“text-align:left;”> glycogen catabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 1.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990776 </td> <td style=“text-align:left;”> response to angiotensin </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 1.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045814 </td> <td style=“text-align:left;”> negative regulation of gene expression, epigenetic </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 94 </td> <td style=“text-align:left;”> 1.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900453 </td> <td style=“text-align:left;”> negative regulation of long-term synaptic depression </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 1.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0110053 </td> <td style=“text-align:left;”> regulation of actin filament organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 224 </td> <td style=“text-align:left;”> 1.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000273 </td> <td style=“text-align:left;”> positive regulation of signaling receptor activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 1.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061024 </td> <td style=“text-align:left;”> membrane organization </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 665 </td> <td style=“text-align:left;”> 1.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006303 </td> <td style=“text-align:left;”> double-strand break repair via nonhomologous end joining </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 62 </td> <td style=“text-align:left;”> 1.78e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903894 </td> <td style=“text-align:left;”> regulation of IRE1-mediated unfolded protein response </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 1.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010569 </td> <td style=“text-align:left;”> regulation of double-strand break repair via homologous recombination </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 1.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905949 </td> <td style=“text-align:left;”> negative regulation of calcium ion import across plasma membrane </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 1.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140243 </td> <td style=“text-align:left;”> regulation of translation at synapse </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 1.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031338 </td> <td style=“text-align:left;”> regulation of vesicle fusion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 1.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140245 </td> <td style=“text-align:left;”> regulation of translation at postsynapse </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 1.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060271 </td> <td style=“text-align:left;”> cilium assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 296 </td> <td style=“text-align:left;”> 1.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045930 </td> <td style=“text-align:left;”> negative regulation of mitotic cell cycle </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:right;”> 209 </td> <td style=“text-align:left;”> 1.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043414 </td> <td style=“text-align:left;”> macromolecule methylation </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:right;”> 238 </td> <td style=“text-align:left;”> 1.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009251 </td> <td style=“text-align:left;”> glucan catabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 1.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001251 </td> <td style=“text-align:left;”> negative regulation of chromosome organization </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 89 </td> <td style=“text-align:left;”> 1.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061025 </td> <td style=“text-align:left;”> membrane fusion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 132 </td> <td style=“text-align:left;”> 1.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051102 </td> <td style=“text-align:left;”> DNA ligation involved in DNA recombination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070925 </td> <td style=“text-align:left;”> organelle assembly </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 828 </td> <td style=“text-align:left;”> 1.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0075713 </td> <td style=“text-align:left;”> establishment of integrated proviral latency </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030951 </td> <td style=“text-align:left;”> establishment or maintenance of microtubule cytoskeleton polarity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 1.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010641 </td> <td style=“text-align:left;”> positive regulation of platelet-derived growth factor receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 1.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021904 </td> <td style=“text-align:left;”> dorsal/ventral neural tube patterning </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 1.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000278 </td> <td style=“text-align:left;”> mitotic cell cycle </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:right;”> 815 </td> <td style=“text-align:left;”> 1.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014041 </td> <td style=“text-align:left;”> regulation of neuron maturation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 1.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008298 </td> <td style=“text-align:left;”> intracellular mRNA localization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 1.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042040 </td> <td style=“text-align:left;”> metal incorporation into metallo-molybdopterin complex </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016485 </td> <td style=“text-align:left;”> protein processing </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 185 </td> <td style=“text-align:left;”> 1.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043587 </td> <td style=“text-align:left;”> tongue morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 1.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018315 </td> <td style=“text-align:left;”> molybdenum incorporation into molybdenum-molybdopterin complex </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090199 </td> <td style=“text-align:left;”> regulation of release of cytochrome c from mitochondria </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 1.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006884 </td> <td style=“text-align:left;”> cell volume homeostasis </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 1.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0062025 </td> <td style=“text-align:left;”> regulation of SCF-dependent proteasomal ubiquitin-dependent protein catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003431 </td> <td style=“text-align:left;”> growth plate cartilage chondrocyte development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 1.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051647 </td> <td style=“text-align:left;”> nucleus localization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 1.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072579 </td> <td style=“text-align:left;”> glycine receptor clustering </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0062026 </td> <td style=“text-align:left;”> negative regulation of SCF-dependent proteasomal ubiquitin-dependent catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031550 </td> <td style=“text-align:left;”> positive regulation of brain-derived neurotrophic factor receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 1.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032509 </td> <td style=“text-align:left;”> endosome transport via multivesicular body sorting pathway </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 1.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001909 </td> <td style=“text-align:left;”> leukocyte mediated cytotoxicity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 1.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901657 </td> <td style=“text-align:left;”> glycosyl compound metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 63 </td> <td style=“text-align:left;”> 1.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016189 </td> <td style=“text-align:left;”> synaptic vesicle to endosome fusion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 1.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044782 </td> <td style=“text-align:left;”> cilium organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 317 </td> <td style=“text-align:left;”> 1.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035970 </td> <td style=“text-align:left;”> peptidyl-threonine dephosphorylation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 1.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0065002 </td> <td style=“text-align:left;”> intracellular protein transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 1.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009303 </td> <td style=“text-align:left;”> rRNA transcription </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 1.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051493 </td> <td style=“text-align:left;”> regulation of cytoskeleton organization </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:right;”> 429 </td> <td style=“text-align:left;”> 1.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032938 </td> <td style=“text-align:left;”> negative regulation of translation in response to oxidative stress </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090383 </td> <td style=“text-align:left;”> phagosome acidification </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 1.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022411 </td> <td style=“text-align:left;”> cellular component disassembly </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:right;”> 430 </td> <td style=“text-align:left;”> 1.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032915 </td> <td style=“text-align:left;”> positive regulation of transforming growth factor beta2 production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 1.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043556 </td> <td style=“text-align:left;”> regulation of translation in response to oxidative stress </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006997 </td> <td style=“text-align:left;”> nucleus organization </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 126 </td> <td style=“text-align:left;”> 1.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032898 </td> <td style=“text-align:left;”> neurotrophin production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 1.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901798 </td> <td style=“text-align:left;”> positive regulation of signal transduction by p53 class mediator </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 1.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048371 </td> <td style=“text-align:left;”> lateral mesodermal cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 1.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033554 </td> <td style=“text-align:left;”> cellular response to stress </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:right;”> 1662 </td> <td style=“text-align:left;”> 1.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001708 </td> <td style=“text-align:left;”> cell fate specification </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 55 </td> <td style=“text-align:left;”> 1.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060056 </td> <td style=“text-align:left;”> mammary gland involution </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 1.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904505 </td> <td style=“text-align:left;”> regulation of telomere maintenance in response to DNA damage </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 1.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042159 </td> <td style=“text-align:left;”> lipoprotein catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 1.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901569 </td> <td style=“text-align:left;”> fatty acid derivative catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 1.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000736 </td> <td style=“text-align:left;”> regulation of stem cell differentiation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 71 </td> <td style=“text-align:left;”> 1.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905768 </td> <td style=“text-align:left;”> negative regulation of double-stranded telomeric DNA binding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000272 </td> <td style=“text-align:left;”> polysaccharide catabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 1.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042321 </td> <td style=“text-align:left;”> negative regulation of circadian sleep/wake cycle, sleep </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 1.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905767 </td> <td style=“text-align:left;”> regulation of double-stranded telomeric DNA binding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036496 </td> <td style=“text-align:left;”> regulation of translational initiation by eIF2 alpha dephosphorylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 1.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045815 </td> <td style=“text-align:left;”> transcription initiation-coupled chromatin remodeling </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 1.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003203 </td> <td style=“text-align:left;”> endocardial cushion morphogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 1.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006364 </td> <td style=“text-align:left;”> rRNA processing </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:right;”> 215 </td> <td style=“text-align:left;”> 1.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051664 </td> <td style=“text-align:left;”> nuclear pore localization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 1.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051469 </td> <td style=“text-align:left;”> vesicle fusion with vacuole </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 1.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006446 </td> <td style=“text-align:left;”> regulation of translational initiation </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 72 </td> <td style=“text-align:left;”> 1.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032970 </td> <td style=“text-align:left;”> regulation of actin filament-based process </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 312 </td> <td style=“text-align:left;”> 1.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060402 </td> <td style=“text-align:left;”> calcium ion transport into cytosol </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 1.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090148 </td> <td style=“text-align:left;”> membrane fission </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 1.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002351 </td> <td style=“text-align:left;”> serotonin production involved in inflammatory response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 1.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060491 </td> <td style=“text-align:left;”> regulation of cell projection assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 165 </td> <td style=“text-align:left;”> 1.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000184 </td> <td style=“text-align:left;”> nuclear-transcribed mRNA catabolic process, nonsense-mediated decay </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 1.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0120032 </td> <td style=“text-align:left;”> regulation of plasma membrane bounded cell projection assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 163 </td> <td style=“text-align:left;”> 1.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0120009 </td> <td style=“text-align:left;”> intermembrane lipid transfer </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 1.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0080170 </td> <td style=“text-align:left;”> hydrogen peroxide transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042752 </td> <td style=“text-align:left;”> regulation of circadian rhythm </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 93 </td> <td style=“text-align:left;”> 1.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000070 </td> <td style=“text-align:left;”> mitotic sister chromatid segregation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 178 </td> <td style=“text-align:left;”> 1.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036297 </td> <td style=“text-align:left;”> interstrand cross-link repair </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 1.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045905 </td> <td style=“text-align:left;”> positive regulation of translational termination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 1.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901990 </td> <td style=“text-align:left;”> regulation of mitotic cell cycle phase transition </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:right;”> 305 </td> <td style=“text-align:left;”> 1.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061763 </td> <td style=“text-align:left;”> multivesicular body-lysosome fusion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 1.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015842 </td> <td style=“text-align:left;”> aminergic neurotransmitter loading into synaptic vesicle </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002442 </td> <td style=“text-align:left;”> serotonin secretion involved in inflammatory response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 1.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061912 </td> <td style=“text-align:left;”> selective autophagy </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 92 </td> <td style=“text-align:left;”> 1.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060340 </td> <td style=“text-align:left;”> positive regulation of type I interferon-mediated signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 1.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060788 </td> <td style=“text-align:left;”> ectodermal placode formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 1.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032956 </td> <td style=“text-align:left;”> regulation of actin cytoskeleton organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 271 </td> <td style=“text-align:left;”> 1.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021522 </td> <td style=“text-align:left;”> spinal cord motor neuron differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 1.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044087 </td> <td style=“text-align:left;”> regulation of cellular component biogenesis </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 802 </td> <td style=“text-align:left;”> 1.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032469 </td> <td style=“text-align:left;”> endoplasmic reticulum calcium ion homeostasis </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 1.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061029 </td> <td style=“text-align:left;”> eyelid development in camera-type eye </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 1.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000956 </td> <td style=“text-align:left;”> nuclear-transcribed mRNA catabolic process </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 122 </td> <td style=“text-align:left;”> 1.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007051 </td> <td style=“text-align:left;”> spindle organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 187 </td> <td style=“text-align:left;”> 1.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071697 </td> <td style=“text-align:left;”> ectodermal placode morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 1.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071806 </td> <td style=“text-align:left;”> protein transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 63 </td> <td style=“text-align:left;”> 1.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006392 </td> <td style=“text-align:left;”> transcription elongation by mitochondrial RNA polymerase </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045948 </td> <td style=“text-align:left;”> positive regulation of translational initiation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 1.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007507 </td> <td style=“text-align:left;”> heart development </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 512 </td> <td style=“text-align:left;”> 1.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050691 </td> <td style=“text-align:left;”> regulation of defense response to virus by host </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 1.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045214 </td> <td style=“text-align:left;”> sarcomere organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 1.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900864 </td> <td style=“text-align:left;”> mitochondrial RNA modification </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902115 </td> <td style=“text-align:left;”> regulation of organelle assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 189 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070900 </td> <td style=“text-align:left;”> mitochondrial tRNA modification </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006479 </td> <td style=“text-align:left;”> protein methylation </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 125 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008213 </td> <td style=“text-align:left;”> protein alkylation </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 125 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905168 </td> <td style=“text-align:left;”> positive regulation of double-strand break repair via homologous recombination </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008361 </td> <td style=“text-align:left;”> regulation of cell size </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 160 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904569 </td> <td style=“text-align:left;”> regulation of selenocysteine incorporation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097576 </td> <td style=“text-align:left;”> vacuole fusion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904570 </td> <td style=“text-align:left;”> negative regulation of selenocysteine incorporation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001252 </td> <td style=“text-align:left;”> positive regulation of chromosome organization </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 102 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904895 </td> <td style=“text-align:left;”> ESCRT complex assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010616 </td> <td style=“text-align:left;”> negative regulation of cardiac muscle adaptation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070727 </td> <td style=“text-align:left;”> cellular macromolecule localization </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 2137 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001843 </td> <td style=“text-align:left;”> neural tube closure </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 89 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904902 </td> <td style=“text-align:left;”> ESCRT III complex assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010463 </td> <td style=“text-align:left;”> mesenchymal cell proliferation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000819 </td> <td style=“text-align:left;”> sister chromatid segregation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 217 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072714 </td> <td style=“text-align:left;”> response to selenite ion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010639 </td> <td style=“text-align:left;”> negative regulation of organelle organization </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:right;”> 310 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905673 </td> <td style=“text-align:left;”> positive regulation of lysosome organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046329 </td> <td style=“text-align:left;”> negative regulation of JNK cascade </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072715 </td> <td style=“text-align:left;”> cellular response to selenite ion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043922 </td> <td style=“text-align:left;”> negative regulation by host of viral transcription </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001880 </td> <td style=“text-align:left;”> Mullerian duct regression </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060922 </td> <td style=“text-align:left;”> atrioventricular node cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098795 </td> <td style=“text-align:left;”> global gene silencing by mRNA cleavage </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003292 </td> <td style=“text-align:left;”> cardiac septum cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904572 </td> <td style=“text-align:left;”> negative regulation of mRNA binding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904573 </td> <td style=“text-align:left;”> regulation of selenocysteine insertion sequence binding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048370 </td> <td style=“text-align:left;”> lateral mesoderm formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904574 </td> <td style=“text-align:left;”> negative regulation of selenocysteine insertion sequence binding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048369 </td> <td style=“text-align:left;”> lateral mesoderm morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000279 </td> <td style=“text-align:left;”> negative regulation of DNA biosynthetic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003271 </td> <td style=“text-align:left;”> smoothened signaling pathway involved in regulation of secondary heart field cardioblast proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008104 </td> <td style=“text-align:left;”> protein localization </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 2128 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060211 </td> <td style=“text-align:left;”> regulation of nuclear-transcribed mRNA poly(A) tail shortening </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031548 </td> <td style=“text-align:left;”> regulation of brain-derived neurotrophic factor receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060766 </td> <td style=“text-align:left;”> negative regulation of androgen receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990611 </td> <td style=“text-align:left;”> regulation of cytoplasmic translational initiation in response to stress </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009304 </td> <td style=“text-align:left;”> tRNA transcription </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032049 </td> <td style=“text-align:left;”> cardiolipin biosynthetic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060928 </td> <td style=“text-align:left;”> atrioventricular node cell development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050678 </td> <td style=“text-align:left;”> regulation of epithelial cell proliferation </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 268 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990497 </td> <td style=“text-align:left;”> regulation of cytoplasmic translation in response to stress </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903243 </td> <td style=“text-align:left;”> negative regulation of cardiac muscle hypertrophy in response to stress </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045188 </td> <td style=“text-align:left;”> regulation of circadian sleep/wake cycle, non-REM sleep </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071696 </td> <td style=“text-align:left;”> ectodermal placode development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 1.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021532 </td> <td style=“text-align:left;”> neural tube patterning </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 2.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097352 </td> <td style=“text-align:left;”> autophagosome maturation </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 54 </td> <td style=“text-align:left;”> 2.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006575 </td> <td style=“text-align:left;”> cellular modified amino acid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 93 </td> <td style=“text-align:left;”> 2.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060606 </td> <td style=“text-align:left;”> tube closure </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 90 </td> <td style=“text-align:left;”> 2.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030490 </td> <td style=“text-align:left;”> maturation of SSU-rRNA </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 2.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010256 </td> <td style=“text-align:left;”> endomembrane system organization </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 497 </td> <td style=“text-align:left;”> 2.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006886 </td> <td style=“text-align:left;”> intracellular protein transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 803 </td> <td style=“text-align:left;”> 2.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033131 </td> <td style=“text-align:left;”> regulation of glucokinase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902903 </td> <td style=“text-align:left;”> regulation of supramolecular fiber organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 321 </td> <td style=“text-align:left;”> 2.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014050 </td> <td style=“text-align:left;”> negative regulation of glutamate secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072384 </td> <td style=“text-align:left;”> organelle transport along microtubule </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 83 </td> <td style=“text-align:left;”> 2.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072201 </td> <td style=“text-align:left;”> negative regulation of mesenchymal cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071483 </td> <td style=“text-align:left;”> cellular response to blue light </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045210 </td> <td style=“text-align:left;”> FasL biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006470 </td> <td style=“text-align:left;”> protein dephosphorylation </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 211 </td> <td style=“text-align:left;”> 2.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032241 </td> <td style=“text-align:left;”> positive regulation of nucleobase-containing compound transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042748 </td> <td style=“text-align:left;”> circadian sleep/wake cycle, non-REM sleep </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051615 </td> <td style=“text-align:left;”> histamine uptake </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098792 </td> <td style=“text-align:left;”> xenophagy </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 2.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009785 </td> <td style=“text-align:left;”> blue light signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0062033 </td> <td style=“text-align:left;”> positive regulation of mitotic sister chromatid segregation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032976 </td> <td style=“text-align:left;”> release of matrix enzymes from mitochondria </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030952 </td> <td style=“text-align:left;”> establishment or maintenance of cytoskeleton polarity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032229 </td> <td style=“text-align:left;”> negative regulation of synaptic transmission, GABAergic </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043124 </td> <td style=“text-align:left;”> negative regulation of canonical NF-kappaB signal transduction </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 2.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060338 </td> <td style=“text-align:left;”> regulation of type I interferon-mediated signaling pathway </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 2.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032786 </td> <td style=“text-align:left;”> positive regulation of DNA-templated transcription, elongation </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 2.10e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006384 </td> <td style=“text-align:left;”> transcription initiation at RNA polymerase III promoter </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.10e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007040 </td> <td style=“text-align:left;”> lysosome organization </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 91 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032091 </td> <td style=“text-align:left;”> negative regulation of protein binding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 77 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990739 </td> <td style=“text-align:left;”> granulosa cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900221 </td> <td style=“text-align:left;”> regulation of amyloid-beta clearance </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000056 </td> <td style=“text-align:left;”> ribosomal small subunit export from nucleus </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032511 </td> <td style=“text-align:left;”> late endosome to vacuole transport via multivesicular body sorting pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051771 </td> <td style=“text-align:left;”> negative regulation of nitric-oxide synthase biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000173 </td> <td style=“text-align:left;”> negative regulation of branching morphogenesis of a nerve </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0080171 </td> <td style=“text-align:left;”> lytic vacuole organization </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 91 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061015 </td> <td style=“text-align:left;”> snRNA import into nucleus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904197 </td> <td style=“text-align:left;”> positive regulation of granulosa cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904195 </td> <td style=“text-align:left;”> regulation of granulosa cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033484 </td> <td style=“text-align:left;”> intracellular nitric oxide homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001738 </td> <td style=“text-align:left;”> morphogenesis of a polarized epithelium </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 88 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904800 </td> <td style=“text-align:left;”> negative regulation of neuron remodeling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904799 </td> <td style=“text-align:left;”> regulation of neuron remodeling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140014 </td> <td style=“text-align:left;”> mitotic nuclear division </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 251 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051496 </td> <td style=“text-align:left;”> positive regulation of stress fiber assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035281 </td> <td style=“text-align:left;”> pre-miRNA export from nucleus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905671 </td> <td style=“text-align:left;”> regulation of lysosome organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090169 </td> <td style=“text-align:left;”> regulation of spindle assembly </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060122 </td> <td style=“text-align:left;”> inner ear receptor cell stereocilium organization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901068 </td> <td style=“text-align:left;”> guanosine-containing compound metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071824 </td> <td style=“text-align:left;”> protein-DNA complex organization </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:right;”> 711 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008617 </td> <td style=“text-align:left;”> guanosine metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010522 </td> <td style=“text-align:left;”> regulation of calcium ion transport into cytosol </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060020 </td> <td style=“text-align:left;”> Bergmann glial cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071985 </td> <td style=“text-align:left;”> multivesicular body sorting pathway </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 47 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048672 </td> <td style=“text-align:left;”> positive regulation of collateral sprouting </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003186 </td> <td style=“text-align:left;”> tricuspid valve morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003197 </td> <td style=“text-align:left;”> endocardial cushion development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042661 </td> <td style=“text-align:left;”> regulation of mesodermal cell fate specification </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002230 </td> <td style=“text-align:left;”> positive regulation of defense response to virus by host </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 2.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014745 </td> <td style=“text-align:left;”> negative regulation of muscle adaptation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010564 </td> <td style=“text-align:left;”> regulation of cell cycle process </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:right;”> 622 </td> <td style=“text-align:left;”> 2.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097240 </td> <td style=“text-align:left;”> chromosome attachment to the nuclear envelope </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014020 </td> <td style=“text-align:left;”> primary neural tube formation </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 93 </td> <td style=“text-align:left;”> 2.15e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021520 </td> <td style=“text-align:left;”> spinal cord motor neuron cell fate specification </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 2.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903299 </td> <td style=“text-align:left;”> regulation of hexokinase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031077 </td> <td style=“text-align:left;”> post-embryonic camera-type eye development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090312 </td> <td style=“text-align:left;”> positive regulation of protein deacetylation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 2.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042692 </td> <td style=“text-align:left;”> muscle cell differentiation </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 329 </td> <td style=“text-align:left;”> 2.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903896 </td> <td style=“text-align:left;”> positive regulation of IRE1-mediated unfolded protein response </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048050 </td> <td style=“text-align:left;”> post-embryonic eye morphogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006984 </td> <td style=“text-align:left;”> ER-nucleus signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 2.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097212 </td> <td style=“text-align:left;”> lysosomal membrane organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 2.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098813 </td> <td style=“text-align:left;”> nuclear chromosome segregation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 264 </td> <td style=“text-align:left;”> 2.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070783 </td> <td style=“text-align:left;”> growth of unicellular organism as a thread of attached cells </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070784 </td> <td style=“text-align:left;”> regulation of growth of unicellular organism as a thread of attached cells </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900461 </td> <td style=“text-align:left;”> positive regulation of pseudohyphal growth by positive regulation of transcription from RNA polymerase II promoter </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030447 </td> <td style=“text-align:left;”> filamentous growth </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044182 </td> <td style=“text-align:left;”> filamentous growth of a population of unicellular organisms </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000222 </td> <td style=“text-align:left;”> positive regulation of pseudohyphal growth </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000220 </td> <td style=“text-align:left;”> regulation of pseudohyphal growth </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006974 </td> <td style=“text-align:left;”> DNA damage response </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:right;”> 795 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097190 </td> <td style=“text-align:left;”> apoptotic signaling pathway </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 504 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007529 </td> <td style=“text-align:left;”> establishment of synaptic specificity at neuromuscular junction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003342 </td> <td style=“text-align:left;”> proepicardium development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003343 </td> <td style=“text-align:left;”> septum transversum development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043586 </td> <td style=“text-align:left;”> tongue development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0120031 </td> <td style=“text-align:left;”> plasma membrane bounded cell projection assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 463 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042249 </td> <td style=“text-align:left;”> establishment of planar polarity of embryonic epithelium </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061136 </td> <td style=“text-align:left;”> regulation of proteasomal protein catabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 179 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090033 </td> <td style=“text-align:left;”> positive regulation of filamentous growth </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070786 </td> <td style=“text-align:left;”> positive regulation of growth of unicellular organism as a thread of attached cells </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900430 </td> <td style=“text-align:left;”> positive regulation of filamentous growth of a population of unicellular organisms </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045652 </td> <td style=“text-align:left;”> regulation of megakaryocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007124 </td> <td style=“text-align:left;”> pseudohyphal growth </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060261 </td> <td style=“text-align:left;”> positive regulation of transcription initiation by RNA polymerase II </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 60 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006399 </td> <td style=“text-align:left;”> tRNA metabolic process </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:right;”> 189 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021527 </td> <td style=“text-align:left;”> spinal cord association neuron differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034470 </td> <td style=“text-align:left;”> ncRNA processing </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:right;”> 397 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990456 </td> <td style=“text-align:left;”> mitochondrion-endoplasmic reticulum membrane tethering </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010570 </td> <td style=“text-align:left;”> regulation of filamentous growth </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036120 </td> <td style=“text-align:left;”> cellular response to platelet-derived growth factor stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900428 </td> <td style=“text-align:left;”> regulation of filamentous growth of a population of unicellular organisms </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000042 </td> <td style=“text-align:left;”> negative regulation of double-strand break repair via homologous recombination </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002383 </td> <td style=“text-align:left;”> immune response in brain or nervous system </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030031 </td> <td style=“text-align:left;”> cell projection assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 473 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903242 </td> <td style=“text-align:left;”> regulation of cardiac muscle hypertrophy in response to stress </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009314 </td> <td style=“text-align:left;”> response to radiation </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:right;”> 339 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031346 </td> <td style=“text-align:left;”> positive regulation of cell projection organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 302 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045198 </td> <td style=“text-align:left;”> establishment of epithelial cell apical/basal polarity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071397 </td> <td style=“text-align:left;”> cellular response to cholesterol </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071214 </td> <td style=“text-align:left;”> cellular response to abiotic stimulus </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 260 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072132 </td> <td style=“text-align:left;”> mesenchyme morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033044 </td> <td style=“text-align:left;”> regulation of chromosome organization </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 235 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097281 </td> <td style=“text-align:left;”> immune complex formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007224 </td> <td style=“text-align:left;”> smoothened signaling pathway </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 123 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006977 </td> <td style=“text-align:left;”> DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000723 </td> <td style=“text-align:left;”> telomere maintenance </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 141 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060897 </td> <td style=“text-align:left;”> neural plate regionalization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0104004 </td> <td style=“text-align:left;”> cellular response to environmental stimulus </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 260 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003175 </td> <td style=“text-align:left;”> tricuspid valve development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044089 </td> <td style=“text-align:left;”> positive regulation of cellular component biogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 420 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045661 </td> <td style=“text-align:left;”> regulation of myoblast differentiation </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 60 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006413 </td> <td style=“text-align:left;”> translational initiation </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 113 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010638 </td> <td style=“text-align:left;”> positive regulation of organelle organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 433 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904668 </td> <td style=“text-align:left;”> positive regulation of ubiquitin protein ligase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006302 </td> <td style=“text-align:left;”> double-strand break repair </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:right;”> 277 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009411 </td> <td style=“text-align:left;”> response to UV </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:right;”> 141 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010612 </td> <td style=“text-align:left;”> regulation of cardiac muscle adaptation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006655 </td> <td style=“text-align:left;”> phosphatidylglycerol biosynthetic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901255 </td> <td style=“text-align:left;”> nucleotide-excision repair involved in interstrand cross-link repair </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904743 </td> <td style=“text-align:left;”> negative regulation of telomeric DNA binding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000779 </td> <td style=“text-align:left;”> regulation of double-strand break repair </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 123 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046461 </td> <td style=“text-align:left;”> neutral lipid catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021514 </td> <td style=“text-align:left;”> ventral spinal cord interneuron differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904748 </td> <td style=“text-align:left;”> regulation of apoptotic process involved in development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036498 </td> <td style=“text-align:left;”> IRE1-mediated unfolded protein response </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043201 </td> <td style=“text-align:left;”> response to leucine </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902337 </td> <td style=“text-align:left;”> regulation of apoptotic process involved in morphogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046464 </td> <td style=“text-align:left;”> acylglycerol catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032456 </td> <td style=“text-align:left;”> endocytic recycling </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 80 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000154 </td> <td style=“text-align:left;”> rRNA modification </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070255 </td> <td style=“text-align:left;”> regulation of mucus secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046761 </td> <td style=“text-align:left;”> viral budding from plasma membrane </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 2.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090241 </td> <td style=“text-align:left;”> negative regulation of histone H4 acetylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097712 </td> <td style=“text-align:left;”> vesicle targeting, trans-Golgi to periciliary membrane compartment </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904356 </td> <td style=“text-align:left;”> regulation of telomere maintenance via telomere lengthening </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 2.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904886 </td> <td style=“text-align:left;”> beta-catenin destruction complex disassembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007015 </td> <td style=“text-align:left;”> actin filament organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 372 </td> <td style=“text-align:left;”> 2.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099532 </td> <td style=“text-align:left;”> synaptic vesicle endosomal processing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036119 </td> <td style=“text-align:left;”> response to platelet-derived growth factor </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 2.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901796 </td> <td style=“text-align:left;”> regulation of signal transduction by p53 class mediator </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 102 </td> <td style=“text-align:left;”> 2.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901687 </td> <td style=“text-align:left;”> glutathione derivative biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901685 </td> <td style=“text-align:left;”> glutathione derivative metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001836 </td> <td style=“text-align:left;”> release of cytochrome c from mitochondria </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 2.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042254 </td> <td style=“text-align:left;”> ribosome biogenesis </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:right;”> 314 </td> <td style=“text-align:left;”> 2.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003430 </td> <td style=“text-align:left;”> growth plate cartilage chondrocyte growth </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051656 </td> <td style=“text-align:left;”> establishment of organelle localization </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 397 </td> <td style=“text-align:left;”> 2.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055015 </td> <td style=“text-align:left;”> ventricular cardiac muscle cell development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 2.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007076 </td> <td style=“text-align:left;”> mitotic chromosome condensation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 2.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044565 </td> <td style=“text-align:left;”> dendritic cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099003 </td> <td style=“text-align:left;”> vesicle-mediated transport in synapse </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 181 </td> <td style=“text-align:left;”> 2.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006476 </td> <td style=“text-align:left;”> protein deacetylation </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 81 </td> <td style=“text-align:left;”> 2.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072695 </td> <td style=“text-align:left;”> regulation of DNA recombination at telomere </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048239 </td> <td style=“text-align:left;”> negative regulation of DNA recombination at telomere </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003007 </td> <td style=“text-align:left;”> heart morphogenesis </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 217 </td> <td style=“text-align:left;”> 2.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000626 </td> <td style=“text-align:left;”> negative regulation of miRNA catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032233 </td> <td style=“text-align:left;”> positive regulation of actin filament bundle assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 2.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000206 </td> <td style=“text-align:left;”> regulation of ribosomal small subunit export from nucleus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000200 </td> <td style=“text-align:left;”> regulation of ribosomal subunit export from nucleus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000199 </td> <td style=“text-align:left;”> positive regulation of ribonucleoprotein complex localization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032703 </td> <td style=“text-align:left;”> negative regulation of interleukin-2 production </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 2.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000208 </td> <td style=“text-align:left;”> positive regulation of ribosomal small subunit export from nucleus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000202 </td> <td style=“text-align:left;”> positive regulation of ribosomal subunit export from nucleus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007049 </td> <td style=“text-align:left;”> cell cycle </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:right;”> 1515 </td> <td style=“text-align:left;”> 2.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051012 </td> <td style=“text-align:left;”> microtubule sliding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001845 </td> <td style=“text-align:left;”> phagolysosome assembly </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 2.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032471 </td> <td style=“text-align:left;”> negative regulation of endoplasmic reticulum calcium ion concentration </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031507 </td> <td style=“text-align:left;”> heterochromatin formation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 75 </td> <td style=“text-align:left;”> 2.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070898 </td> <td style=“text-align:left;”> RNA polymerase III preinitiation complex assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055008 </td> <td style=“text-align:left;”> cardiac muscle tissue morphogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 55 </td> <td style=“text-align:left;”> 2.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001841 </td> <td style=“text-align:left;”> neural tube formation </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 98 </td> <td style=“text-align:left;”> 2.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904058 </td> <td style=“text-align:left;”> positive regulation of sensory perception of pain </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036372 </td> <td style=“text-align:left;”> opsin transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140694 </td> <td style=“text-align:left;”> non-membrane-bounded organelle assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 364 </td> <td style=“text-align:left;”> 2.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051967 </td> <td style=“text-align:left;”> negative regulation of synaptic transmission, glutamatergic </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003093 </td> <td style=“text-align:left;”> regulation of glomerular filtration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015858 </td> <td style=“text-align:left;”> nucleoside transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031123 </td> <td style=“text-align:left;”> RNA 3’-end processing </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 92 </td> <td style=“text-align:left;”> 2.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090161 </td> <td style=“text-align:left;”> Golgi ribbon formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046753 </td> <td style=“text-align:left;”> non-lytic viral release </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 2.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001906 </td> <td style=“text-align:left;”> cell killing </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 77 </td> <td style=“text-align:left;”> 2.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905770 </td> <td style=“text-align:left;”> regulation of mesodermal cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016239 </td> <td style=“text-align:left;”> positive regulation of macroautophagy </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 2.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001510 </td> <td style=“text-align:left;”> RNA methylation </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 89 </td> <td style=“text-align:left;”> 2.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048714 </td> <td style=“text-align:left;”> positive regulation of oligodendrocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 2.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007059 </td> <td style=“text-align:left;”> chromosome segregation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 360 </td> <td style=“text-align:left;”> 2.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003433 </td> <td style=“text-align:left;”> chondrocyte development involved in endochondral bone morphogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010212 </td> <td style=“text-align:left;”> response to ionizing radiation </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 127 </td> <td style=“text-align:left;”> 2.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033036 </td> <td style=“text-align:left;”> macromolecule localization </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 2448 </td> <td style=“text-align:left;”> 2.30e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010508 </td> <td style=“text-align:left;”> positive regulation of autophagy </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 134 </td> <td style=“text-align:left;”> 2.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061890 </td> <td style=“text-align:left;”> positive regulation of astrocyte activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901605 </td> <td style=“text-align:left;”> alpha-amino acid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 151 </td> <td style=“text-align:left;”> 2.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051452 </td> <td style=“text-align:left;”> intracellular pH reduction </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 2.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140056 </td> <td style=“text-align:left;”> organelle localization by membrane tethering </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 2.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051726 </td> <td style=“text-align:left;”> regulation of cell cycle </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:right;”> 941 </td> <td style=“text-align:left;”> 2.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007220 </td> <td style=“text-align:left;”> Notch receptor processing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904888 </td> <td style=“text-align:left;”> cranial skeletal system development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 2.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048147 </td> <td style=“text-align:left;”> negative regulation of fibroblast proliferation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 2.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045910 </td> <td style=“text-align:left;”> negative regulation of DNA recombination </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 2.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008608 </td> <td style=“text-align:left;”> attachment of spindle microtubules to kinetochore </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 2.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002334 </td> <td style=“text-align:left;”> transitional two stage B cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0110012 </td> <td style=“text-align:left;”> protein localization to P-body </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032211 </td> <td style=“text-align:left;”> negative regulation of telomere maintenance via telomerase </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 2.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090481 </td> <td style=“text-align:left;”> pyrimidine nucleotide-sugar transmembrane transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 2.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034614 </td> <td style=“text-align:left;”> cellular response to reactive oxygen species </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 125 </td> <td style=“text-align:left;”> 2.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904613 </td> <td style=“text-align:left;”> cellular response to 2,3,7,8-tetrachlorodibenzodioxine </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035304 </td> <td style=“text-align:left;”> regulation of protein dephosphorylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 72 </td> <td style=“text-align:left;”> 2.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902229 </td> <td style=“text-align:left;”> regulation of intrinsic apoptotic signaling pathway in response to DNA damage </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 2.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000280 </td> <td style=“text-align:left;”> nuclear division </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 343 </td> <td style=“text-align:left;”> 2.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090646 </td> <td style=“text-align:left;”> mitochondrial tRNA processing </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 2.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060765 </td> <td style=“text-align:left;”> regulation of androgen receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 2.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014886 </td> <td style=“text-align:left;”> transition between slow and fast fiber </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006919 </td> <td style=“text-align:left;”> activation of cysteine-type endopeptidase activity involved in apoptotic process </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 63 </td> <td style=“text-align:left;”> 2.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903050 </td> <td style=“text-align:left;”> regulation of proteolysis involved in protein catabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 210 </td> <td style=“text-align:left;”> 2.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019043 </td> <td style=“text-align:left;”> establishment of viral latency </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032873 </td> <td style=“text-align:left;”> negative regulation of stress-activated MAPK cascade </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 2.39e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032510 </td> <td style=“text-align:left;”> endosome to lysosome transport via multivesicular body sorting pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048262 </td> <td style=“text-align:left;”> determination of dorsal/ventral asymmetry </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033631 </td> <td style=“text-align:left;”> cell-cell adhesion mediated by integrin </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098700 </td> <td style=“text-align:left;”> neurotransmitter loading into synaptic vesicle </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021517 </td> <td style=“text-align:left;”> ventral spinal cord development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905215 </td> <td style=“text-align:left;”> negative regulation of RNA binding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070828 </td> <td style=“text-align:left;”> heterochromatin organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 83 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051129 </td> <td style=“text-align:left;”> negative regulation of cellular component organization </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:right;”> 592 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015031 </td> <td style=“text-align:left;”> protein transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 1366 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0052647 </td> <td style=“text-align:left;”> pentitol phosphate metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0052648 </td> <td style=“text-align:left;”> ribitol phosphate metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000144 </td> <td style=“text-align:left;”> positive regulation of DNA-templated transcription initiation </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 66 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003162 </td> <td style=“text-align:left;”> atrioventricular node development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070303 </td> <td style=“text-align:left;”> negative regulation of stress-activated protein kinase signaling cascade </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 47 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060896 </td> <td style=“text-align:left;”> neural plate pattern specification </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003223 </td> <td style=“text-align:left;”> ventricular compact myocardium morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035912 </td> <td style=“text-align:left;”> dorsal aorta morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046444 </td> <td style=“text-align:left;”> FMN metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061842 </td> <td style=“text-align:left;”> microtubule organizing center localization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990786 </td> <td style=“text-align:left;”> cellular response to dsDNA </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051642 </td> <td style=“text-align:left;”> centrosome localization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071264 </td> <td style=“text-align:left;”> positive regulation of translational initiation in response to starvation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000671 </td> <td style=“text-align:left;”> regulation of motor neuron apoptotic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045204 </td> <td style=“text-align:left;”> MAPK export from nucleus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071262 </td> <td style=“text-align:left;”> regulation of translational initiation in response to starvation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061723 </td> <td style=“text-align:left;”> glycophagy </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008631 </td> <td style=“text-align:left;”> intrinsic apoptotic signaling pathway in response to oxidative stress </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009398 </td> <td style=“text-align:left;”> FMN biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990784 </td> <td style=“text-align:left;”> response to dsDNA </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042275 </td> <td style=“text-align:left;”> error-free postreplication DNA repair </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009231 </td> <td style=“text-align:left;”> riboflavin biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051100 </td> <td style=“text-align:left;”> negative regulation of binding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 133 </td> <td style=“text-align:left;”> 2.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097403 </td> <td style=“text-align:left;”> cellular response to raffinose </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901545 </td> <td style=“text-align:left;”> response to raffinose </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060068 </td> <td style=“text-align:left;”> vagina development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090520 </td> <td style=“text-align:left;”> sphingolipid mediated signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 2.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904582 </td> <td style=“text-align:left;”> positive regulation of intracellular mRNA localization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060887 </td> <td style=“text-align:left;”> limb epidermis development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006449 </td> <td style=“text-align:left;”> regulation of translational termination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 2.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048560 </td> <td style=“text-align:left;”> establishment of anatomical structure orientation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050000 </td> <td style=“text-align:left;”> chromosome localization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 101 </td> <td style=“text-align:left;”> 2.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048285 </td> <td style=“text-align:left;”> organelle fission </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 387 </td> <td style=“text-align:left;”> 2.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070384 </td> <td style=“text-align:left;”> Harderian gland development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901991 </td> <td style=“text-align:left;”> negative regulation of mitotic cell cycle phase transition </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:right;”> 165 </td> <td style=“text-align:left;”> 2.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000083 </td> <td style=“text-align:left;”> regulation of transcription involved in G1/S transition of mitotic cell cycle </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 2.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0062196 </td> <td style=“text-align:left;”> regulation of lysosome size </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000630 </td> <td style=“text-align:left;”> positive regulation of miRNA metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 2.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904637 </td> <td style=“text-align:left;”> cellular response to ionomycin </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051276 </td> <td style=“text-align:left;”> chromosome organization </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:right;”> 533 </td> <td style=“text-align:left;”> 2.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904636 </td> <td style=“text-align:left;”> response to ionomycin </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048488 </td> <td style=“text-align:left;”> synaptic vesicle endocytosis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 63 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990117 </td> <td style=“text-align:left;”> B cell receptor apoptotic signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000036 </td> <td style=“text-align:left;”> regulation of stem cell population maintenance </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 63 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015931 </td> <td style=“text-align:left;”> nucleobase-containing compound transport </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 193 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021515 </td> <td style=“text-align:left;”> cell differentiation in spinal cord </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051123 </td> <td style=“text-align:left;”> RNA polymerase II preinitiation complex assembly </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 54 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048208 </td> <td style=“text-align:left;”> COPII vesicle coating </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051128 </td> <td style=“text-align:left;”> regulation of cellular component organization </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 1981 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090435 </td> <td style=“text-align:left;”> protein localization to nuclear envelope </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032206 </td> <td style=“text-align:left;”> positive regulation of telomere maintenance </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060926 </td> <td style=“text-align:left;”> cardiac pacemaker cell development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015780 </td> <td style=“text-align:left;”> nucleotide-sugar transmembrane transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900272 </td> <td style=“text-align:left;”> negative regulation of long-term synaptic potentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021508 </td> <td style=“text-align:left;”> floor plate formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008589 </td> <td style=“text-align:left;”> regulation of smoothened signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 72 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001973 </td> <td style=“text-align:left;”> G protein-coupled adenosine receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000850 </td> <td style=“text-align:left;”> negative regulation of glucocorticoid secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035588 </td> <td style=“text-align:left;”> G protein-coupled purinergic receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003279 </td> <td style=“text-align:left;”> cardiac septum development </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 101 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031547 </td> <td style=“text-align:left;”> brain-derived neurotrophic factor receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010970 </td> <td style=“text-align:left;”> transport along microtubule </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 162 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022406 </td> <td style=“text-align:left;”> membrane docking </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 79 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016556 </td> <td style=“text-align:left;”> mRNA modification </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071044 </td> <td style=“text-align:left;”> histone mRNA catabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140238 </td> <td style=“text-align:left;”> presynaptic endocytosis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000673 </td> <td style=“text-align:left;”> positive regulation of motor neuron apoptotic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006670 </td> <td style=“text-align:left;”> sphingosine metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000045 </td> <td style=“text-align:left;”> regulation of G1/S transition of mitotic cell cycle </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 146 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051457 </td> <td style=“text-align:left;”> maintenance of protein location in nucleus </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905765 </td> <td style=“text-align:left;”> negative regulation of protection from non-homologous end joining at telomere </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905764 </td> <td style=“text-align:left;”> regulation of protection from non-homologous end joining at telomere </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043433 </td> <td style=“text-align:left;”> negative regulation of DNA-binding transcription factor activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 136 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001915 </td> <td style=“text-align:left;”> negative regulation of T cell mediated cytotoxicity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007004 </td> <td style=“text-align:left;”> telomere maintenance via telomerase </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 63 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002358 </td> <td style=“text-align:left;”> B cell homeostatic proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048207 </td> <td style=“text-align:left;”> vesicle targeting, rough ER to cis-Golgi </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032909 </td> <td style=“text-align:left;”> regulation of transforming growth factor beta2 production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032906 </td> <td style=“text-align:left;”> transforming growth factor beta2 production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006338 </td> <td style=“text-align:left;”> chromatin remodeling </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:right;”> 520 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000847 </td> <td style=“text-align:left;”> negative regulation of corticosteroid hormone secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006346 </td> <td style=“text-align:left;”> DNA methylation-dependent heterochromatin formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061819 </td> <td style=“text-align:left;”> telomeric DNA-containing double minutes formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030239 </td> <td style=“text-align:left;”> myofibril assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 66 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000832 </td> <td style=“text-align:left;”> negative regulation of steroid hormone secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090303 </td> <td style=“text-align:left;”> positive regulation of wound healing </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060415 </td> <td style=“text-align:left;”> muscle tissue morphogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 61 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009894 </td> <td style=“text-align:left;”> regulation of catabolic process </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:right;”> 883 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031529 </td> <td style=“text-align:left;”> ruffle organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045931 </td> <td style=“text-align:left;”> positive regulation of mitotic cell cycle </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 111 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016570 </td> <td style=“text-align:left;”> histone modification </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 271 </td> <td style=“text-align:left;”> 2.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090102 </td> <td style=“text-align:left;”> cochlea development </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 2.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045727 </td> <td style=“text-align:left;”> positive regulation of translation </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 126 </td> <td style=“text-align:left;”> 2.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035621 </td> <td style=“text-align:left;”> ER to Golgi ceramide transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060212 </td> <td style=“text-align:left;”> negative regulation of nuclear-transcribed mRNA poly(A) tail shortening </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050673 </td> <td style=“text-align:left;”> epithelial cell proliferation </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 318 </td> <td style=“text-align:left;”> 2.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032790 </td> <td style=“text-align:left;”> ribosome disassembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 2.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046039 </td> <td style=“text-align:left;”> GTP metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 2.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0005981 </td> <td style=“text-align:left;”> regulation of glycogen catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 2.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003281 </td> <td style=“text-align:left;”> ventricular septum development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 2.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055002 </td> <td style=“text-align:left;”> striated muscle cell development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 2.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071638 </td> <td style=“text-align:left;”> negative regulation of monocyte chemotactic protein-1 production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905281 </td> <td style=“text-align:left;”> positive regulation of retrograde transport, endosome to Golgi </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021516 </td> <td style=“text-align:left;”> dorsal spinal cord development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002526 </td> <td style=“text-align:left;”> acute inflammatory response </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 2.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045945 </td> <td style=“text-align:left;”> positive regulation of transcription by RNA polymerase III </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 2.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045184 </td> <td style=“text-align:left;”> establishment of protein localization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 1468 </td> <td style=“text-align:left;”> 2.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061952 </td> <td style=“text-align:left;”> midbody abscission </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002673 </td> <td style=“text-align:left;”> regulation of acute inflammatory response </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042073 </td> <td style=“text-align:left;”> intraciliary transport </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035089 </td> <td style=“text-align:left;”> establishment of apical/basal cell polarity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006278 </td> <td style=“text-align:left;”> RNA-templated DNA biosynthetic process </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055012 </td> <td style=“text-align:left;”> ventricular cardiac muscle cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060236 </td> <td style=“text-align:left;”> regulation of mitotic spindle organization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032460 </td> <td style=“text-align:left;”> negative regulation of protein oligomerization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035082 </td> <td style=“text-align:left;”> axoneme assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 54 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002087 </td> <td style=“text-align:left;”> regulation of respiratory gaseous exchange by nervous system process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097242 </td> <td style=“text-align:left;”> amyloid-beta clearance </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034486 </td> <td style=“text-align:left;”> vacuolar transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036444 </td> <td style=“text-align:left;”> calcium import into the mitochondrion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071479 </td> <td style=“text-align:left;”> cellular response to ionizing radiation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033144 </td> <td style=“text-align:left;”> negative regulation of intracellular steroid hormone receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904293 </td> <td style=“text-align:left;”> negative regulation of ERAD pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010248 </td> <td style=“text-align:left;”> establishment or maintenance of transmembrane electrochemical gradient </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002441 </td> <td style=“text-align:left;”> histamine secretion involved in inflammatory response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000302 </td> <td style=“text-align:left;”> response to reactive oxygen species </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 163 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060920 </td> <td style=“text-align:left;”> cardiac pacemaker cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048521 </td> <td style=“text-align:left;”> negative regulation of behavior </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046519 </td> <td style=“text-align:left;”> sphingoid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035137 </td> <td style=“text-align:left;”> hindlimb morphogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002553 </td> <td style=“text-align:left;”> histamine secretion by mast cell </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002349 </td> <td style=“text-align:left;”> histamine production involved in inflammatory response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022402 </td> <td style=“text-align:left;”> cell cycle process </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:right;”> 1078 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030219 </td> <td style=“text-align:left;”> megakaryocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090176 </td> <td style=“text-align:left;”> microtubule cytoskeleton organization involved in establishment of planar polarity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032463 </td> <td style=“text-align:left;”> negative regulation of protein homooligomerization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045741 </td> <td style=“text-align:left;”> positive regulation of epidermal growth factor-activated receptor activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035907 </td> <td style=“text-align:left;”> dorsal aorta development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003084 </td> <td style=“text-align:left;”> positive regulation of systemic arterial blood pressure </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061626 </td> <td style=“text-align:left;”> pharyngeal arch artery morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034141 </td> <td style=“text-align:left;”> positive regulation of toll-like receptor 3 signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006404 </td> <td style=“text-align:left;”> RNA import into nucleus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036315 </td> <td style=“text-align:left;”> cellular response to sterol </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018022 </td> <td style=“text-align:left;”> peptidyl-lysine methylation </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 83 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001820 </td> <td style=“text-align:left;”> serotonin secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 2.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002568 </td> <td style=“text-align:left;”> somatic diversification of T cell receptor genes </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002681 </td> <td style=“text-align:left;”> somatic recombination of T cell receptor gene segments </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905691 </td> <td style=“text-align:left;”> lipid droplet disassembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0106217 </td> <td style=“text-align:left;”> tRNA C3-cytosine methylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019042 </td> <td style=“text-align:left;”> viral latency </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904155 </td> <td style=“text-align:left;”> DN2 thymocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000724 </td> <td style=“text-align:left;”> double-strand break repair via homologous recombination </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 154 </td> <td style=“text-align:left;”> 2.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006520 </td> <td style=“text-align:left;”> amino acid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 222 </td> <td style=“text-align:left;”> 2.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001267 </td> <td style=“text-align:left;”> regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 2.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033153 </td> <td style=“text-align:left;”> T cell receptor V(D)J recombination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001233 </td> <td style=“text-align:left;”> regulation of apoptotic signaling pathway </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:right;”> 318 </td> <td style=“text-align:left;”> 2.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043393 </td> <td style=“text-align:left;”> regulation of protein binding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 173 </td> <td style=“text-align:left;”> 2.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000210 </td> <td style=“text-align:left;”> positive regulation of anoikis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033047 </td> <td style=“text-align:left;”> regulation of mitotic sister chromatid segregation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 2.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900122 </td> <td style=“text-align:left;”> positive regulation of receptor binding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046600 </td> <td style=“text-align:left;”> negative regulation of centriole replication </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071560 </td> <td style=“text-align:left;”> cellular response to transforming growth factor beta stimulus </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 222 </td> <td style=“text-align:left;”> 2.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051148 </td> <td style=“text-align:left;”> negative regulation of muscle cell differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 2.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046503 </td> <td style=“text-align:left;”> glycerolipid catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 2.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905665 </td> <td style=“text-align:left;”> positive regulation of calcium ion import across plasma membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001977 </td> <td style=“text-align:left;”> renal system process involved in regulation of blood volume </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009416 </td> <td style=“text-align:left;”> response to light stimulus </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:right;”> 241 </td> <td style=“text-align:left;”> 2.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030705 </td> <td style=“text-align:left;”> cytoskeleton-dependent intracellular transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 195 </td> <td style=“text-align:left;”> 2.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055013 </td> <td style=“text-align:left;”> cardiac muscle cell development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 2.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070254 </td> <td style=“text-align:left;”> mucus secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031987 </td> <td style=“text-align:left;”> locomotion involved in locomotory behavior </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 2.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904780 </td> <td style=“text-align:left;”> negative regulation of protein localization to centrosome </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048511 </td> <td style=“text-align:left;”> rhythmic process </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 233 </td> <td style=“text-align:left;”> 2.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099111 </td> <td style=“text-align:left;”> microtubule-based transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 192 </td> <td style=“text-align:left;”> 2.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099022 </td> <td style=“text-align:left;”> vesicle tethering </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 2.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901701 </td> <td style=“text-align:left;”> cellular response to oxygen-containing compound </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 891 </td> <td style=“text-align:left;”> 2.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006790 </td> <td style=“text-align:left;”> sulfur compound metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 246 </td> <td style=“text-align:left;”> 2.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009950 </td> <td style=“text-align:left;”> dorsal/ventral axis specification </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048644 </td> <td style=“text-align:left;”> muscle organ morphogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 2.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010994 </td> <td style=“text-align:left;”> free ubiquitin chain polymerization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072334 </td> <td style=“text-align:left;”> UDP-galactose transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071709 </td> <td style=“text-align:left;”> membrane assembly </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 54 </td> <td style=“text-align:left;”> 2.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032259 </td> <td style=“text-align:left;”> methylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 285 </td> <td style=“text-align:left;”> 2.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035891 </td> <td style=“text-align:left;”> exit from host cell </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 2.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043328 </td> <td style=“text-align:left;”> protein transport to vacuole involved in ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 2.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003418 </td> <td style=“text-align:left;”> growth plate cartilage chondrocyte differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048340 </td> <td style=“text-align:left;”> paraxial mesoderm morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019076 </td> <td style=“text-align:left;”> viral release from host cell </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 2.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904580 </td> <td style=“text-align:left;”> regulation of intracellular mRNA localization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900151 </td> <td style=“text-align:left;”> regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 2.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034260 </td> <td style=“text-align:left;”> negative regulation of GTPase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 2.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0120035 </td> <td style=“text-align:left;”> regulation of plasma membrane bounded cell projection organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 529 </td> <td style=“text-align:left;”> 2.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050893 </td> <td style=“text-align:left;”> sensory processing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001783 </td> <td style=“text-align:left;”> B cell apoptotic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 2.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036465 </td> <td style=“text-align:left;”> synaptic vesicle recycling </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 73 </td> <td style=“text-align:left;”> 2.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048199 </td> <td style=“text-align:left;”> vesicle targeting, to, from or within Golgi </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 2.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060561 </td> <td style=“text-align:left;”> apoptotic process involved in morphogenesis </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 2.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032775 </td> <td style=“text-align:left;”> DNA methylation on adenine </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018872 </td> <td style=“text-align:left;”> arsonoacetate metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031116 </td> <td style=“text-align:left;”> positive regulation of microtubule polymerization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 2.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032239 </td> <td style=“text-align:left;”> regulation of nucleobase-containing compound transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 2.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900452 </td> <td style=“text-align:left;”> regulation of long-term synaptic depression </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 2.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008045 </td> <td style=“text-align:left;”> motor neuron axon guidance </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 2.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032691 </td> <td style=“text-align:left;”> negative regulation of interleukin-1 beta production </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 2.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031344 </td> <td style=“text-align:left;”> regulation of cell projection organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 542 </td> <td style=“text-align:left;”> 2.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061162 </td> <td style=“text-align:left;”> establishment of monopolar cell polarity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 2.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051641 </td> <td style=“text-align:left;”> cellular localization </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 2822 </td> <td style=“text-align:left;”> 2.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099509 </td> <td style=“text-align:left;”> regulation of presynaptic cytosolic calcium ion concentration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010640 </td> <td style=“text-align:left;”> regulation of platelet-derived growth factor receptor signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 2.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045187 </td> <td style=“text-align:left;”> regulation of circadian sleep/wake cycle, sleep </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033344 </td> <td style=“text-align:left;”> cholesterol efflux </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 2.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014878 </td> <td style=“text-align:left;”> response to electrical stimulus involved in regulation of muscle adaptation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046907 </td> <td style=“text-align:left;”> intracellular transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 1440 </td> <td style=“text-align:left;”> 2.62e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000725 </td> <td style=“text-align:left;”> recombinational repair </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 158 </td> <td style=“text-align:left;”> 2.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002449 </td> <td style=“text-align:left;”> lymphocyte mediated immunity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 147 </td> <td style=“text-align:left;”> 2.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032957 </td> <td style=“text-align:left;”> inositol trisphosphate metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 2.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071559 </td> <td style=“text-align:left;”> response to transforming growth factor beta </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 227 </td> <td style=“text-align:left;”> 2.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015793 </td> <td style=“text-align:left;”> glycerol transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045687 </td> <td style=“text-align:left;”> positive regulation of glial cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 2.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009992 </td> <td style=“text-align:left;”> intracellular water homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032535 </td> <td style=“text-align:left;”> regulation of cellular component size </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:right;”> 306 </td> <td style=“text-align:left;”> 2.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902425 </td> <td style=“text-align:left;”> positive regulation of attachment of mitotic spindle microtubules to kinetochore </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902423 </td> <td style=“text-align:left;”> regulation of attachment of mitotic spindle microtubules to kinetochore </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031119 </td> <td style=“text-align:left;”> tRNA pseudouridine synthesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048563 </td> <td style=“text-align:left;”> post-embryonic animal organ morphogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033762 </td> <td style=“text-align:left;”> response to glucagon </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 2.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140718 </td> <td style=“text-align:left;”> facultative heterochromatin formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050802 </td> <td style=“text-align:left;”> circadian sleep/wake cycle, sleep </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0080135 </td> <td style=“text-align:left;”> regulation of cellular response to stress </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:right;”> 585 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090385 </td> <td style=“text-align:left;”> phagosome-lysosome fusion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007174 </td> <td style=“text-align:left;”> epidermal growth factor catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904979 </td> <td style=“text-align:left;”> negative regulation of endosome organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048661 </td> <td style=“text-align:left;”> positive regulation of smooth muscle cell proliferation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 60 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904742 </td> <td style=“text-align:left;”> regulation of telomeric DNA binding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044065 </td> <td style=“text-align:left;”> regulation of respiratory system process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006612 </td> <td style=“text-align:left;”> protein targeting to membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 120 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055089 </td> <td style=“text-align:left;”> fatty acid homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033505 </td> <td style=“text-align:left;”> floor plate morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044088 </td> <td style=“text-align:left;”> regulation of vacuole organization </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904506 </td> <td style=“text-align:left;”> negative regulation of telomere maintenance in response to DNA damage </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007501 </td> <td style=“text-align:left;”> mesodermal cell fate specification </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904161 </td> <td style=“text-align:left;”> DNA synthesis involved in UV-damage excision repair </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905365 </td> <td style=“text-align:left;”> regulation of intralumenal vesicle formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055006 </td> <td style=“text-align:left;”> cardiac cell development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 80 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000780 </td> <td style=“text-align:left;”> negative regulation of double-strand break repair </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030859 </td> <td style=“text-align:left;”> polarized epithelial cell differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070922 </td> <td style=“text-align:left;”> RISC complex assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060612 </td> <td style=“text-align:left;”> adipose tissue development </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051956 </td> <td style=“text-align:left;”> negative regulation of amino acid transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048713 </td> <td style=“text-align:left;”> regulation of oligodendrocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905366 </td> <td style=“text-align:left;”> negative regulation of intralumenal vesicle formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061339 </td> <td style=“text-align:left;”> establishment or maintenance of monopolar cell polarity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001961 </td> <td style=“text-align:left;”> positive regulation of cytokine-mediated signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003183 </td> <td style=“text-align:left;”> mitral valve morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070507 </td> <td style=“text-align:left;”> regulation of microtubule cytoskeleton organization </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 145 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018195 </td> <td style=“text-align:left;”> peptidyl-arginine modification </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090224 </td> <td style=“text-align:left;”> regulation of spindle organization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903036 </td> <td style=“text-align:left;”> positive regulation of response to wounding </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 55 </td> <td style=“text-align:left;”> 2.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001821 </td> <td style=“text-align:left;”> histamine secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031109 </td> <td style=“text-align:left;”> microtubule polymerization or depolymerization </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 119 </td> <td style=“text-align:left;”> 2.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031331 </td> <td style=“text-align:left;”> positive regulation of cellular catabolic process </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:right;”> 282 </td> <td style=“text-align:left;”> 2.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001702 </td> <td style=“text-align:left;”> gastrulation with mouth forming second </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 2.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007492 </td> <td style=“text-align:left;”> endoderm development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 65 </td> <td style=“text-align:left;”> 2.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905786 </td> <td style=“text-align:left;”> positive regulation of anaphase-promoting complex-dependent catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904612 </td> <td style=“text-align:left;”> response to 2,3,7,8-tetrachlorodibenzodioxine </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034139 </td> <td style=“text-align:left;”> regulation of toll-like receptor 3 signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030162 </td> <td style=“text-align:left;”> regulation of proteolysis </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 522 </td> <td style=“text-align:left;”> 2.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060819 </td> <td style=“text-align:left;”> inactivation of X chromosome by genomic imprinting </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032200 </td> <td style=“text-align:left;”> telomere organization </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 155 </td> <td style=“text-align:left;”> 2.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051121 </td> <td style=“text-align:left;”> hepoxilin metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000132 </td> <td style=“text-align:left;”> establishment of mitotic spindle orientation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 2.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051122 </td> <td style=“text-align:left;”> hepoxilin biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003415 </td> <td style=“text-align:left;”> chondrocyte hypertrophy </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048278 </td> <td style=“text-align:left;”> vesicle docking </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 54 </td> <td style=“text-align:left;”> 2.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905664 </td> <td style=“text-align:left;”> regulation of calcium ion import across plasma membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006043 </td> <td style=“text-align:left;”> glucosamine catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050658 </td> <td style=“text-align:left;”> RNA transport </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 141 </td> <td style=“text-align:left;”> 2.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050657 </td> <td style=“text-align:left;”> nucleic acid transport </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 141 </td> <td style=“text-align:left;”> 2.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034599 </td> <td style=“text-align:left;”> cellular response to oxidative stress </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 218 </td> <td style=“text-align:left;”> 2.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008217 </td> <td style=“text-align:left;”> regulation of blood pressure </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 114 </td> <td style=“text-align:left;”> 2.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010835 </td> <td style=“text-align:left;”> regulation of protein ADP-ribosylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140157 </td> <td style=“text-align:left;”> ammonium import across plasma membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903051 </td> <td style=“text-align:left;”> negative regulation of proteolysis involved in protein catabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 62 </td> <td style=“text-align:left;”> 2.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051103 </td> <td style=“text-align:left;”> DNA ligation involved in DNA repair </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 2.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006297 </td> <td style=“text-align:left;”> nucleotide-excision repair, DNA gap filling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 2.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901568 </td> <td style=“text-align:left;”> fatty acid derivative metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 2.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903929 </td> <td style=“text-align:left;”> primary palate development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051877 </td> <td style=“text-align:left;”> pigment granule aggregation in cell center </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001578 </td> <td style=“text-align:left;”> microtubule bundle formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 79 </td> <td style=“text-align:left;”> 2.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007023 </td> <td style=“text-align:left;”> post-chaperonin tubulin folding pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016197 </td> <td style=“text-align:left;”> endosomal transport </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:right;”> 234 </td> <td style=“text-align:left;”> 2.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003174 </td> <td style=“text-align:left;”> mitral valve development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 2.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032447 </td> <td style=“text-align:left;”> protein urmylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018205 </td> <td style=“text-align:left;”> peptidyl-lysine modification </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:right;”> 286 </td> <td style=“text-align:left;”> 2.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031400 </td> <td style=“text-align:left;”> negative regulation of protein modification process </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:right;”> 396 </td> <td style=“text-align:left;”> 2.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002143 </td> <td style=“text-align:left;”> tRNA wobble position uridine thiolation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099554 </td> <td style=“text-align:left;”> trans-synaptic signaling by soluble gas, modulating synaptic transmission </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099555 </td> <td style=“text-align:left;”> trans-synaptic signaling by nitric oxide, modulating synaptic transmission </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010747 </td> <td style=“text-align:left;”> positive regulation of long-chain fatty acid import across plasma membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030521 </td> <td style=“text-align:left;”> androgen receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 2.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051490 </td> <td style=“text-align:left;”> negative regulation of filopodium assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045738 </td> <td style=“text-align:left;”> negative regulation of DNA repair </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 2.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050927 </td> <td style=“text-align:left;”> positive regulation of positive chemotaxis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 2.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035113 </td> <td style=“text-align:left;”> embryonic appendage morphogenesis </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 89 </td> <td style=“text-align:left;”> 2.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034644 </td> <td style=“text-align:left;”> cellular response to UV </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 86 </td> <td style=“text-align:left;”> 2.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072359 </td> <td style=“text-align:left;”> circulatory system development </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 888 </td> <td style=“text-align:left;”> 2.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043622 </td> <td style=“text-align:left;”> cortical microtubule organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030326 </td> <td style=“text-align:left;”> embryonic limb morphogenesis </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 89 </td> <td style=“text-align:left;”> 2.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032364 </td> <td style=“text-align:left;”> intracellular oxygen homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006901 </td> <td style=“text-align:left;”> vesicle coating </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 2.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001235 </td> <td style=“text-align:left;”> positive regulation of apoptotic signaling pathway </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 113 </td> <td style=“text-align:left;”> 2.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030036 </td> <td style=“text-align:left;”> actin cytoskeleton organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 566 </td> <td style=“text-align:left;”> 2.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070723 </td> <td style=“text-align:left;”> response to cholesterol </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 2.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001838 </td> <td style=“text-align:left;”> embryonic epithelial tube formation </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 113 </td> <td style=“text-align:left;”> 2.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006427 </td> <td style=“text-align:left;”> histidyl-tRNA aminoacylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051036 </td> <td style=“text-align:left;”> regulation of endosome size </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 2.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904507 </td> <td style=“text-align:left;”> positive regulation of telomere maintenance in response to DNA damage </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 2.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051236 </td> <td style=“text-align:left;”> establishment of RNA localization </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 144 </td> <td style=“text-align:left;”> 2.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002904 </td> <td style=“text-align:left;”> positive regulation of B cell apoptotic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097112 </td> <td style=“text-align:left;”> gamma-aminobutyric acid receptor clustering </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902263 </td> <td style=“text-align:left;”> apoptotic process involved in embryonic digit morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006606 </td> <td style=“text-align:left;”> protein import into nucleus </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 146 </td> <td style=“text-align:left;”> 2.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050926 </td> <td style=“text-align:left;”> regulation of positive chemotaxis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 2.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050965 </td> <td style=“text-align:left;”> detection of temperature stimulus involved in sensory perception of pain </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034311 </td> <td style=“text-align:left;”> diol metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 2.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000479 </td> <td style=“text-align:left;”> endonucleolytic cleavage of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 2.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009637 </td> <td style=“text-align:left;”> response to blue light </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006808 </td> <td style=“text-align:left;”> regulation of nitrogen utilization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902774 </td> <td style=“text-align:left;”> late endosome to lysosome transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 2.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097296 </td> <td style=“text-align:left;”> activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000323 </td> <td style=“text-align:left;”> negative regulation of glucocorticoid receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902445 </td> <td style=“text-align:left;”> regulation of mitochondrial membrane permeability involved in programmed necrotic cell death </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902389 </td> <td style=“text-align:left;”> ceramide 1-phosphate transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060070 </td> <td style=“text-align:left;”> canonical Wnt signaling pathway </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 254 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014887 </td> <td style=“text-align:left;”> cardiac muscle adaptation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0080009 </td> <td style=“text-align:left;”> mRNA methylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051028 </td> <td style=“text-align:left;”> mRNA transport </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 115 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033750 </td> <td style=“text-align:left;”> ribosome localization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016925 </td> <td style=“text-align:left;”> protein sumoylation </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 60 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006289 </td> <td style=“text-align:left;”> nucleotide-excision repair </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 80 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032048 </td> <td style=“text-align:left;”> cardiolipin metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044091 </td> <td style=“text-align:left;”> membrane biogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 59 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035726 </td> <td style=“text-align:left;”> common myeloid progenitor cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043407 </td> <td style=“text-align:left;”> negative regulation of MAP kinase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014898 </td> <td style=“text-align:left;”> cardiac muscle hypertrophy in response to stress </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003150 </td> <td style=“text-align:left;”> muscular septum morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003299 </td> <td style=“text-align:left;”> muscle hypertrophy in response to stress </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003222 </td> <td style=“text-align:left;”> ventricular trabecula myocardium morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010587 </td> <td style=“text-align:left;”> miRNA catabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900048 </td> <td style=“text-align:left;”> positive regulation of hemostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031112 </td> <td style=“text-align:left;”> positive regulation of microtubule polymerization or depolymerization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008630 </td> <td style=“text-align:left;”> intrinsic apoptotic signaling pathway in response to DNA damage </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 93 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001933 </td> <td style=“text-align:left;”> negative regulation of protein phosphorylation </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:right;”> 265 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030194 </td> <td style=“text-align:left;”> positive regulation of blood coagulation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048193 </td> <td style=“text-align:left;”> Golgi vesicle transport </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:right;”> 280 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006415 </td> <td style=“text-align:left;”> translational termination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098696 </td> <td style=“text-align:left;”> regulation of neurotransmitter receptor localization to postsynaptic specialization membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000054 </td> <td style=“text-align:left;”> ribosomal subunit export from nucleus </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140374 </td> <td style=“text-align:left;”> antiviral innate immune response </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 2.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019083 </td> <td style=“text-align:left;”> viral transcription </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 2.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072331 </td> <td style=“text-align:left;”> signal transduction by p53 class mediator </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 163 </td> <td style=“text-align:left;”> 2.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071897 </td> <td style=“text-align:left;”> DNA biosynthetic process </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 174 </td> <td style=“text-align:left;”> 2.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901660 </td> <td style=“text-align:left;”> calcium ion export </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051610 </td> <td style=“text-align:left;”> serotonin uptake </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032057 </td> <td style=“text-align:left;”> negative regulation of translational initiation in response to stress </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 2.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901985 </td> <td style=“text-align:left;”> positive regulation of protein acetylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 2.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022410 </td> <td style=“text-align:left;”> circadian sleep/wake cycle process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 2.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042749 </td> <td style=“text-align:left;”> regulation of circadian sleep/wake cycle </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 2.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071482 </td> <td style=“text-align:left;”> cellular response to light stimulus </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 98 </td> <td style=“text-align:left;”> 2.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032055 </td> <td style=“text-align:left;”> negative regulation of translation in response to stress </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 2.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090114 </td> <td style=“text-align:left;”> COPII-coated vesicle budding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 2.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006597 </td> <td style=“text-align:left;”> spermine biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002332 </td> <td style=“text-align:left;”> transitional stage B cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051030 </td> <td style=“text-align:left;”> snRNA transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043687 </td> <td style=“text-align:left;”> post-translational protein modification </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:right;”> 1102 </td> <td style=“text-align:left;”> 2.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014043 </td> <td style=“text-align:left;”> negative regulation of neuron maturation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060534 </td> <td style=“text-align:left;”> trachea cartilage development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046070 </td> <td style=“text-align:left;”> dGTP metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0106381 </td> <td style=“text-align:left;”> purine deoxyribonucleotide salvage </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0106383 </td> <td style=“text-align:left;”> dAMP salvage </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006170 </td> <td style=“text-align:left;”> dAMP biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090235 </td> <td style=“text-align:left;”> regulation of metaphase plate congression </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 2.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031647 </td> <td style=“text-align:left;”> regulation of protein stability </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 293 </td> <td style=“text-align:left;”> 2.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042475 </td> <td style=“text-align:left;”> odontogenesis of dentin-containing tooth </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 55 </td> <td style=“text-align:left;”> 2.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009171 </td> <td style=“text-align:left;”> purine deoxyribonucleoside monophosphate biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048368 </td> <td style=“text-align:left;”> lateral mesoderm development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 2.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045639 </td> <td style=“text-align:left;”> positive regulation of myeloid cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 66 </td> <td style=“text-align:left;”> 2.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044778 </td> <td style=“text-align:left;”> meiotic DNA integrity checkpoint signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051170 </td> <td style=“text-align:left;”> import into nucleus </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 151 </td> <td style=“text-align:left;”> 2.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050820 </td> <td style=“text-align:left;”> positive regulation of coagulation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 2.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071705 </td> <td style=“text-align:left;”> nitrogen compound transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 1689 </td> <td style=“text-align:left;”> 2.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030091 </td> <td style=“text-align:left;”> protein repair </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006405 </td> <td style=“text-align:left;”> RNA export from nucleus </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 79 </td> <td style=“text-align:left;”> 2.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097049 </td> <td style=“text-align:left;”> motor neuron apoptotic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 2.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014048 </td> <td style=“text-align:left;”> regulation of glutamate secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035493 </td> <td style=“text-align:left;”> SNARE complex assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 2.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048384 </td> <td style=“text-align:left;”> retinoic acid receptor signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 2.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097680 </td> <td style=“text-align:left;”> double-strand break repair via classical nonhomologous end joining </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045736 </td> <td style=“text-align:left;”> negative regulation of cyclin-dependent protein serine/threonine kinase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 2.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009124 </td> <td style=“text-align:left;”> nucleoside monophosphate biosynthetic process </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 2.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905870 </td> <td style=“text-align:left;”> positive regulation of 3’-UTR-mediated mRNA stabilization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016055 </td> <td style=“text-align:left;”> Wnt signaling pathway </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:right;”> 379 </td> <td style=“text-align:left;”> 2.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070525 </td> <td style=“text-align:left;”> tRNA threonylcarbamoyladenosine metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 2.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000288 </td> <td style=“text-align:left;”> nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 2.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006851 </td> <td style=“text-align:left;”> mitochondrial calcium ion transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 2.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071076 </td> <td style=“text-align:left;”> RNA 3’ uridylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000628 </td> <td style=“text-align:left;”> regulation of miRNA metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 2.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036500 </td> <td style=“text-align:left;”> ATF6-mediated unfolded protein response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035303 </td> <td style=“text-align:left;”> regulation of dephosphorylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 102 </td> <td style=“text-align:left;”> 2.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043506 </td> <td style=“text-align:left;”> regulation of JUN kinase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 2.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001241 </td> <td style=“text-align:left;”> positive regulation of extrinsic apoptotic signaling pathway in absence of ligand </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 2.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900103 </td> <td style=“text-align:left;”> positive regulation of endoplasmic reticulum unfolded protein response </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 2.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051608 </td> <td style=“text-align:left;”> histamine transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 2.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010524 </td> <td style=“text-align:left;”> positive regulation of calcium ion transport into cytosol </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0062197 </td> <td style=“text-align:left;”> cellular response to chemical stress </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 269 </td> <td style=“text-align:left;”> 2.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905857 </td> <td style=“text-align:left;”> positive regulation of pentose-phosphate shunt </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0198738 </td> <td style=“text-align:left;”> cell-cell signaling by wnt </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:right;”> 380 </td> <td style=“text-align:left;”> 2.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000134 </td> <td style=“text-align:left;”> negative regulation of G1/S transition of mitotic cell cycle </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 2.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060760 </td> <td style=“text-align:left;”> positive regulation of response to cytokine stimulus </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 2.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010992 </td> <td style=“text-align:left;”> ubiquitin recycling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051571 </td> <td style=“text-align:left;”> positive regulation of histone H3-K4 methylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051987 </td> <td style=“text-align:left;”> positive regulation of attachment of spindle microtubules to kinetochore </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034227 </td> <td style=“text-align:left;”> tRNA thio-modification </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905258 </td> <td style=“text-align:left;”> regulation of nitrosative stress-induced intrinsic apoptotic signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032515 </td> <td style=“text-align:left;”> negative regulation of phosphoprotein phosphatase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010804 </td> <td style=“text-align:left;”> negative regulation of tumor necrosis factor-mediated signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905259 </td> <td style=“text-align:left;”> negative regulation of nitrosative stress-induced intrinsic apoptotic signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051930 </td> <td style=“text-align:left;”> regulation of sensory perception of pain </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071353 </td> <td style=“text-align:left;”> cellular response to interleukin-4 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043545 </td> <td style=“text-align:left;”> molybdopterin cofactor metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006777 </td> <td style=“text-align:left;”> Mo-molybdopterin cofactor biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043516 </td> <td style=“text-align:left;”> regulation of DNA damage response, signal transduction by p53 class mediator </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051931 </td> <td style=“text-align:left;”> regulation of sensory perception </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046836 </td> <td style=“text-align:left;”> glycolipid transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006970 </td> <td style=“text-align:left;”> response to osmotic stress </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032692 </td> <td style=“text-align:left;”> negative regulation of interleukin-1 production </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042745 </td> <td style=“text-align:left;”> circadian sleep/wake cycle </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019720 </td> <td style=“text-align:left;”> Mo-molybdopterin cofactor metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042727 </td> <td style=“text-align:left;”> flavin-containing compound biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051189 </td> <td style=“text-align:left;”> prosthetic group metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097191 </td> <td style=“text-align:left;”> extrinsic apoptotic signaling pathway </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 181 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0039534 </td> <td style=“text-align:left;”> negative regulation of MDA-5 signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010498 </td> <td style=“text-align:left;”> proteasomal protein catabolic process </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:right;”> 482 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032058 </td> <td style=“text-align:left;”> positive regulation of translational initiation in response to stress </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007020 </td> <td style=“text-align:left;”> microtubule nucleation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901387 </td> <td style=“text-align:left;”> positive regulation of voltage-gated calcium channel activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048665 </td> <td style=“text-align:left;”> neuron fate specification </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008053 </td> <td style=“text-align:left;”> mitochondrial fusion </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031065 </td> <td style=“text-align:left;”> positive regulation of histone deacetylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140469 </td> <td style=“text-align:left;”> GCN2-mediated signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016032 </td> <td style=“text-align:left;”> viral process </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:right;”> 347 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046604 </td> <td style=“text-align:left;”> positive regulation of mitotic centrosome separation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032324 </td> <td style=“text-align:left;”> molybdopterin cofactor biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001946 </td> <td style=“text-align:left;”> lymphangiogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000322 </td> <td style=“text-align:left;”> regulation of glucocorticoid receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019751 </td> <td style=“text-align:left;”> polyol metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 82 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904030 </td> <td style=“text-align:left;”> negative regulation of cyclin-dependent protein kinase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 2.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015791 </td> <td style=“text-align:left;”> polyol transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072014 </td> <td style=“text-align:left;”> proximal tubule development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 2.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048863 </td> <td style=“text-align:left;”> stem cell differentiation </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 196 </td> <td style=“text-align:left;”> 2.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036376 </td> <td style=“text-align:left;”> sodium ion export across plasma membrane </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 2.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902174 </td> <td style=“text-align:left;”> positive regulation of keratinocyte apoptotic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042157 </td> <td style=“text-align:left;”> lipoprotein metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 116 </td> <td style=“text-align:left;”> 2.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090387 </td> <td style=“text-align:left;”> phagolysosome assembly involved in apoptotic cell clearance </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050821 </td> <td style=“text-align:left;”> protein stabilization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 196 </td> <td style=“text-align:left;”> 2.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090386 </td> <td style=“text-align:left;”> phagosome maturation involved in apoptotic cell clearance </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098693 </td> <td style=“text-align:left;”> regulation of synaptic vesicle cycle </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030431 </td> <td style=“text-align:left;”> sleep </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000963 </td> <td style=“text-align:left;”> mitochondrial RNA processing </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900101 </td> <td style=“text-align:left;”> regulation of endoplasmic reticulum unfolded protein response </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071362 </td> <td style=“text-align:left;”> cellular response to ether </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034501 </td> <td style=“text-align:left;”> protein localization to kinetochore </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0038180 </td> <td style=“text-align:left;”> nerve growth factor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000583 </td> <td style=“text-align:left;”> regulation of platelet-derived growth factor receptor-alpha signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006432 </td> <td style=“text-align:left;”> phenylalanyl-tRNA aminoacylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903429 </td> <td style=“text-align:left;”> regulation of cell maturation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007517 </td> <td style=“text-align:left;”> muscle organ development </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 279 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098801 </td> <td style=“text-align:left;”> regulation of renal system process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050961 </td> <td style=“text-align:left;”> detection of temperature stimulus involved in sensory perception </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046328 </td> <td style=“text-align:left;”> regulation of JNK cascade </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 113 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048532 </td> <td style=“text-align:left;”> anatomical structure arrangement </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903083 </td> <td style=“text-align:left;”> protein localization to condensed chromosome </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902659 </td> <td style=“text-align:left;”> regulation of glucose mediated signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072521 </td> <td style=“text-align:left;”> purine-containing compound metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 387 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902661 </td> <td style=“text-align:left;”> positive regulation of glucose mediated signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901096 </td> <td style=“text-align:left;”> regulation of autophagosome maturation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003085 </td> <td style=“text-align:left;”> negative regulation of systemic arterial blood pressure </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034067 </td> <td style=“text-align:left;”> protein localization to Golgi apparatus </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060033 </td> <td style=“text-align:left;”> anatomical structure regression </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030029 </td> <td style=“text-align:left;”> actin filament-based process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 643 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001710 </td> <td style=“text-align:left;”> mesodermal cell fate commitment </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000642 </td> <td style=“text-align:left;”> negative regulation of early endosome to late endosome transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060712 </td> <td style=“text-align:left;”> spongiotrophoblast layer development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000055 </td> <td style=“text-align:left;”> ribosomal large subunit export from nucleus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036211 </td> <td style=“text-align:left;”> protein modification process </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:right;”> 2751 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090150 </td> <td style=“text-align:left;”> establishment of protein localization to membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 258 </td> <td style=“text-align:left;”> 2.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046785 </td> <td style=“text-align:left;”> microtubule polymerization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 84 </td> <td style=“text-align:left;”> 2.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000781 </td> <td style=“text-align:left;”> positive regulation of double-strand break repair </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 79 </td> <td style=“text-align:left;”> 2.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045911 </td> <td style=“text-align:left;”> positive regulation of DNA recombination </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 2.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060382 </td> <td style=“text-align:left;”> regulation of DNA strand elongation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 2.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043029 </td> <td style=“text-align:left;”> T cell homeostasis </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 2.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035434 </td> <td style=“text-align:left;”> copper ion transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 2.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010614 </td> <td style=“text-align:left;”> negative regulation of cardiac muscle hypertrophy </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 2.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010823 </td> <td style=“text-align:left;”> negative regulation of mitochondrion organization </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 2.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022616 </td> <td style=“text-align:left;”> DNA strand elongation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 2.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990481 </td> <td style=“text-align:left;”> mRNA pseudouridine synthesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 2.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030578 </td> <td style=“text-align:left;”> PML body organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 2.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099504 </td> <td style=“text-align:left;”> synaptic vesicle cycle </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 163 </td> <td style=“text-align:left;”> 2.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900029 </td> <td style=“text-align:left;”> positive regulation of ruffle assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 2.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099179 </td> <td style=“text-align:left;”> regulation of synaptic membrane adhesion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0047496 </td> <td style=“text-align:left;”> vesicle transport along microtubule </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 2.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032210 </td> <td style=“text-align:left;”> regulation of telomere maintenance via telomerase </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 2.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009451 </td> <td style=“text-align:left;”> RNA modification </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:right;”> 167 </td> <td style=“text-align:left;”> 2.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042256 </td> <td style=“text-align:left;”> cytosolic ribosome assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 2.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070198 </td> <td style=“text-align:left;”> protein localization to chromosome, telomeric region </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 2.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098876 </td> <td style=“text-align:left;”> vesicle-mediated transport to the plasma membrane </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 141 </td> <td style=“text-align:left;”> 2.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035781 </td> <td style=“text-align:left;”> CD86 biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 2.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042176 </td> <td style=“text-align:left;”> regulation of protein catabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 328 </td> <td style=“text-align:left;”> 2.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007019 </td> <td style=“text-align:left;”> microtubule depolymerization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 2.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051984 </td> <td style=“text-align:left;”> positive regulation of chromosome segregation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 2.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051310 </td> <td style=“text-align:left;”> metaphase chromosome alignment </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 87 </td> <td style=“text-align:left;”> 2.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060213 </td> <td style=“text-align:left;”> positive regulation of nuclear-transcribed mRNA poly(A) tail shortening </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 2.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070670 </td> <td style=“text-align:left;”> response to interleukin-4 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 2.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046606 </td> <td style=“text-align:left;”> negative regulation of centrosome cycle </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 2.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903427 </td> <td style=“text-align:left;”> negative regulation of reactive oxygen species biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 2.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010826 </td> <td style=“text-align:left;”> negative regulation of centrosome duplication </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 2.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007418 </td> <td style=“text-align:left;”> ventral midline development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 2.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051348 </td> <td style=“text-align:left;”> negative regulation of transferase activity </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 225 </td> <td style=“text-align:left;”> 2.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051254 </td> <td style=“text-align:left;”> positive regulation of RNA metabolic process </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:right;”> 1425 </td> <td style=“text-align:left;”> 2.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000289 </td> <td style=“text-align:left;”> nuclear-transcribed mRNA poly(A) tail shortening </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 2.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071901 </td> <td style=“text-align:left;”> negative regulation of protein serine/threonine kinase activity </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 96 </td> <td style=“text-align:left;”> 2.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014015 </td> <td style=“text-align:left;”> positive regulation of gliogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 2.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003071 </td> <td style=“text-align:left;”> renal system process involved in regulation of systemic arterial blood pressure </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 2.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0141067 </td> <td style=“text-align:left;”> intracellular nitrogen homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001777 </td> <td style=“text-align:left;”> T cell homeostatic proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:left;”> 2.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097435 </td> <td style=“text-align:left;”> supramolecular fiber organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 666 </td> <td style=“text-align:left;”> 2.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019740 </td> <td style=“text-align:left;”> nitrogen utilization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 2.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046839 </td> <td style=“text-align:left;”> phospholipid dephosphorylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 2.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901386 </td> <td style=“text-align:left;”> negative regulation of voltage-gated calcium channel activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 2.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007080 </td> <td style=“text-align:left;”> mitotic metaphase chromosome alignment </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 55 </td> <td style=“text-align:left;”> 2.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032891 </td> <td style=“text-align:left;”> negative regulation of organic acid transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 2.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0040001 </td> <td style=“text-align:left;”> establishment of mitotic spindle localization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 2.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033138 </td> <td style=“text-align:left;”> positive regulation of peptidyl-serine phosphorylation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 68 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048738 </td> <td style=“text-align:left;”> cardiac muscle tissue development </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 202 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043303 </td> <td style=“text-align:left;”> mast cell degranulation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061009 </td> <td style=“text-align:left;”> common bile duct development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034250 </td> <td style=“text-align:left;”> positive regulation of amide metabolic process </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 149 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070901 </td> <td style=“text-align:left;”> mitochondrial tRNA methylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071384 </td> <td style=“text-align:left;”> cellular response to corticosteroid stimulus </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048339 </td> <td style=“text-align:left;”> paraxial mesoderm development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051098 </td> <td style=“text-align:left;”> regulation of binding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 314 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060391 </td> <td style=“text-align:left;”> positive regulation of SMAD protein signal transduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021895 </td> <td style=“text-align:left;”> cerebral cortex neuron differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048490 </td> <td style=“text-align:left;”> anterograde synaptic vesicle transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060155 </td> <td style=“text-align:left;”> platelet dense granule organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046467 </td> <td style=“text-align:left;”> membrane lipid biosynthetic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 124 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016048 </td> <td style=“text-align:left;”> detection of temperature stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048670 </td> <td style=“text-align:left;”> regulation of collateral sprouting </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043576 </td> <td style=“text-align:left;”> regulation of respiratory gaseous exchange </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070291 </td> <td style=“text-align:left;”> N-acylethanolamine metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035774 </td> <td style=“text-align:left;”> positive regulation of insulin secretion involved in cellular response to glucose stimulus </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036314 </td> <td style=“text-align:left;”> response to sterol </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072175 </td> <td style=“text-align:left;”> epithelial tube formation </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 124 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904353 </td> <td style=“text-align:left;”> regulation of telomere capping </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010506 </td> <td style=“text-align:left;”> regulation of autophagy </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:right;”> 315 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006046 </td> <td style=“text-align:left;”> N-acetylglucosamine catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006041 </td> <td style=“text-align:left;”> glucosamine metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003215 </td> <td style=“text-align:left;”> cardiac right ventricle morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905868 </td> <td style=“text-align:left;”> regulation of 3’-UTR-mediated mRNA stabilization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007021 </td> <td style=“text-align:left;”> tubulin complex assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902065 </td> <td style=“text-align:left;”> response to L-glutamate </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904666 </td> <td style=“text-align:left;”> regulation of ubiquitin protein ligase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902807 </td> <td style=“text-align:left;”> negative regulation of cell cycle G1/S phase transition </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 68 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099514 </td> <td style=“text-align:left;”> synaptic vesicle cytoskeletal transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014741 </td> <td style=“text-align:left;”> negative regulation of muscle hypertrophy </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904628 </td> <td style=“text-align:left;”> cellular response to phorbol 13-acetate 12-myristate </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000018 </td> <td style=“text-align:left;”> regulation of DNA recombination </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 103 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010867 </td> <td style=“text-align:left;”> positive regulation of triglyceride biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099517 </td> <td style=“text-align:left;”> synaptic vesicle transport along microtubule </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006950 </td> <td style=“text-align:left;”> response to stress </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:right;”> 2763 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904627 </td> <td style=“text-align:left;”> response to phorbol 13-acetate 12-myristate </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010832 </td> <td style=“text-align:left;”> negative regulation of myotube differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033143 </td> <td style=“text-align:left;”> regulation of intracellular steroid hormone receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 61 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031086 </td> <td style=“text-align:left;”> nuclear-transcribed mRNA catabolic process, deadenylation-independent decay </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051294 </td> <td style=“text-align:left;”> establishment of spindle orientation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904415 </td> <td style=“text-align:left;”> regulation of xenophagy </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0017157 </td> <td style=“text-align:left;”> regulation of exocytosis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 139 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006499 </td> <td style=“text-align:left;”> N-terminal protein myristoylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043470 </td> <td style=“text-align:left;”> regulation of carbohydrate catabolic process </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051130 </td> <td style=“text-align:left;”> positive regulation of cellular component organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 905 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010800 </td> <td style=“text-align:left;”> positive regulation of peptidyl-threonine phosphorylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018377 </td> <td style=“text-align:left;”> protein myristoylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010803 </td> <td style=“text-align:left;”> regulation of tumor necrosis factor-mediated signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043517 </td> <td style=“text-align:left;”> positive regulation of DNA damage response, signal transduction by p53 class mediator </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904417 </td> <td style=“text-align:left;”> positive regulation of xenophagy </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010469 </td> <td style=“text-align:left;”> regulation of signaling receptor activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 97 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903860 </td> <td style=“text-align:left;”> negative regulation of dendrite extension </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902806 </td> <td style=“text-align:left;”> regulation of cell cycle G1/S phase transition </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 164 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060710 </td> <td style=“text-align:left;”> chorio-allantoic fusion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098781 </td> <td style=“text-align:left;”> ncRNA transcription </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 118 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009651 </td> <td style=“text-align:left;”> response to salt stress </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051649 </td> <td style=“text-align:left;”> establishment of localization in cell </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 1842 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001234 </td> <td style=“text-align:left;”> negative regulation of apoptotic signaling pathway </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 199 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002793 </td> <td style=“text-align:left;”> positive regulation of peptide secretion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 73 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009267 </td> <td style=“text-align:left;”> cellular response to starvation </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 148 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099543 </td> <td style=“text-align:left;”> trans-synaptic signaling by soluble gas </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099548 </td> <td style=“text-align:left;”> trans-synaptic signaling by nitric oxide </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044539 </td> <td style=“text-align:left;”> long-chain fatty acid import into cell </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045900 </td> <td style=“text-align:left;”> negative regulation of translational elongation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032462 </td> <td style=“text-align:left;”> regulation of protein homooligomerization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902410 </td> <td style=“text-align:left;”> mitotic cytokinetic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140214 </td> <td style=“text-align:left;”> positive regulation of long-chain fatty acid import into cell </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 3.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905271 </td> <td style=“text-align:left;”> regulation of proton-transporting ATP synthase activity, rotational mechanism </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905273 </td> <td style=“text-align:left;”> positive regulation of proton-transporting ATP synthase activity, rotational mechanism </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905706 </td> <td style=“text-align:left;”> regulation of mitochondrial ATP synthesis coupled proton transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000012 </td> <td style=“text-align:left;”> single strand break repair </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 3.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021540 </td> <td style=“text-align:left;”> corpus callosum morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 3.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032365 </td> <td style=“text-align:left;”> intracellular lipid transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 3.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051661 </td> <td style=“text-align:left;”> maintenance of centrosome location </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 3.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051569 </td> <td style=“text-align:left;”> regulation of histone H3-K4 methylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 3.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097494 </td> <td style=“text-align:left;”> regulation of vesicle size </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 3.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140650 </td> <td style=“text-align:left;”> radial glia-guided pyramidal neuron migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002443 </td> <td style=“text-align:left;”> leukocyte mediated immunity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 197 </td> <td style=“text-align:left;”> 3.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060339 </td> <td style=“text-align:left;”> negative regulation of type I interferon-mediated signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 3.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014047 </td> <td style=“text-align:left;”> glutamate secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 3.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034497 </td> <td style=“text-align:left;”> protein localization to phagophore assembly site </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 3.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016192 </td> <td style=“text-align:left;”> vesicle-mediated transport </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:right;”> 1233 </td> <td style=“text-align:left;”> 3.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002279 </td> <td style=“text-align:left;”> mast cell activation involved in immune response </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 3.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030334 </td> <td style=“text-align:left;”> regulation of cell migration </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 707 </td> <td style=“text-align:left;”> 3.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006979 </td> <td style=“text-align:left;”> response to oxidative stress </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 328 </td> <td style=“text-align:left;”> 3.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099072 </td> <td style=“text-align:left;”> regulation of postsynaptic membrane neurotransmitter receptor levels </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 72 </td> <td style=“text-align:left;”> 3.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0106058 </td> <td style=“text-align:left;”> positive regulation of calcineurin-mediated signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 3.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001782 </td> <td style=“text-align:left;”> B cell homeostasis </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 3.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051438 </td> <td style=“text-align:left;”> regulation of ubiquitin-protein transferase activity </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 52 </td> <td style=“text-align:left;”> 3.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070886 </td> <td style=“text-align:left;”> positive regulation of calcineurin-NFAT signaling cascade </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 3.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030111 </td> <td style=“text-align:left;”> regulation of Wnt signaling pathway </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 274 </td> <td style=“text-align:left;”> 3.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045685 </td> <td style=“text-align:left;”> regulation of glial cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 47 </td> <td style=“text-align:left;”> 3.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903008 </td> <td style=“text-align:left;”> organelle disassembly </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 141 </td> <td style=“text-align:left;”> 3.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071375 </td> <td style=“text-align:left;”> cellular response to peptide hormone stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 234 </td> <td style=“text-align:left;”> 3.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008637 </td> <td style=“text-align:left;”> apoptotic mitochondrial changes </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 90 </td> <td style=“text-align:left;”> 3.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033152 </td> <td style=“text-align:left;”> immunoglobulin V(D)J recombination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 3.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008033 </td> <td style=“text-align:left;”> tRNA processing </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 131 </td> <td style=“text-align:left;”> 3.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901700 </td> <td style=“text-align:left;”> response to oxygen-containing compound </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 1219 </td> <td style=“text-align:left;”> 3.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050996 </td> <td style=“text-align:left;”> positive regulation of lipid catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 3.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050995 </td> <td style=“text-align:left;”> negative regulation of lipid catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 3.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0062149 </td> <td style=“text-align:left;”> detection of stimulus involved in sensory perception of pain </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 3.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051983 </td> <td style=“text-align:left;”> regulation of chromosome segregation </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 121 </td> <td style=“text-align:left;”> 3.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905784 </td> <td style=“text-align:left;”> regulation of anaphase-promoting complex-dependent catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006420 </td> <td style=“text-align:left;”> arginyl-tRNA aminoacylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902905 </td> <td style=“text-align:left;”> positive regulation of supramolecular fiber organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 149 </td> <td style=“text-align:left;”> 3.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055086 </td> <td style=“text-align:left;”> nucleobase-containing small molecule metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 485 </td> <td style=“text-align:left;”> 3.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002448 </td> <td style=“text-align:left;”> mast cell mediated immunity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 3.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006359 </td> <td style=“text-align:left;”> regulation of transcription by RNA polymerase III </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 3.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002098 </td> <td style=“text-align:left;”> tRNA wobble uridine modification </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 3.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097485 </td> <td style=“text-align:left;”> neuron projection guidance </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 177 </td> <td style=“text-align:left;”> 3.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015914 </td> <td style=“text-align:left;”> phospholipid transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 73 </td> <td style=“text-align:left;”> 3.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007411 </td> <td style=“text-align:left;”> axon guidance </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 177 </td> <td style=“text-align:left;”> 3.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015886 </td> <td style=“text-align:left;”> heme transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 3.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035107 </td> <td style=“text-align:left;”> appendage morphogenesis </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 113 </td> <td style=“text-align:left;”> 3.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035108 </td> <td style=“text-align:left;”> limb morphogenesis </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 113 </td> <td style=“text-align:left;”> 3.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007398 </td> <td style=“text-align:left;”> ectoderm development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 3.10e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010001 </td> <td style=“text-align:left;”> glial cell differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 181 </td> <td style=“text-align:left;”> 3.10e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0080134 </td> <td style=“text-align:left;”> regulation of response to stress </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:right;”> 1074 </td> <td style=“text-align:left;”> 3.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0039692 </td> <td style=“text-align:left;”> single stranded viral RNA replication via double stranded DNA intermediate </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 3.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036303 </td> <td style=“text-align:left;”> lymph vessel morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 3.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031333 </td> <td style=“text-align:left;”> negative regulation of protein-containing complex assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 125 </td> <td style=“text-align:left;”> 3.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051489 </td> <td style=“text-align:left;”> regulation of filopodium assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 3.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010046 </td> <td style=“text-align:left;”> response to mycotoxin </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050951 </td> <td style=“text-align:left;”> sensory perception of temperature stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 3.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051953 </td> <td style=“text-align:left;”> negative regulation of amine transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 3.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003094 </td> <td style=“text-align:left;”> glomerular filtration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 3.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000277 </td> <td style=“text-align:left;”> positive regulation of oxidative phosphorylation uncoupler activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030512 </td> <td style=“text-align:left;”> negative regulation of transforming growth factor beta receptor signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 85 </td> <td style=“text-align:left;”> 3.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090382 </td> <td style=“text-align:left;”> phagosome maturation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 3.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055007 </td> <td style=“text-align:left;”> cardiac muscle cell differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 108 </td> <td style=“text-align:left;”> 3.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018126 </td> <td style=“text-align:left;”> protein hydroxylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 3.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042796 </td> <td style=“text-align:left;”> snRNA transcription by RNA polymerase III </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 3.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000479 </td> <td style=“text-align:left;”> regulation of cAMP-dependent protein kinase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 3.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009896 </td> <td style=“text-align:left;”> positive regulation of catabolic process </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:right;”> 465 </td> <td style=“text-align:left;”> 3.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010586 </td> <td style=“text-align:left;”> miRNA metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 85 </td> <td style=“text-align:left;”> 3.15e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035308 </td> <td style=“text-align:left;”> negative regulation of protein dephosphorylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 3.15e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007018 </td> <td style=“text-align:left;”> microtubule-based movement </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 300 </td> <td style=“text-align:left;”> 3.15e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051495 </td> <td style=“text-align:left;”> positive regulation of cytoskeleton organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 156 </td> <td style=“text-align:left;”> 3.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006639 </td> <td style=“text-align:left;”> acylglycerol metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 91 </td> <td style=“text-align:left;”> 3.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031329 </td> <td style=“text-align:left;”> regulation of cellular catabolic process </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:right;”> 562 </td> <td style=“text-align:left;”> 3.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034244 </td> <td style=“text-align:left;”> negative regulation of transcription elongation by RNA polymerase II </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 3.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002344 </td> <td style=“text-align:left;”> B cell affinity maturation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 3.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990959 </td> <td style=“text-align:left;”> eosinophil homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 3.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045647 </td> <td style=“text-align:left;”> negative regulation of erythrocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002343 </td> <td style=“text-align:left;”> peripheral B cell selection </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 3.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006638 </td> <td style=“text-align:left;”> neutral lipid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 92 </td> <td style=“text-align:left;”> 3.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008284 </td> <td style=“text-align:left;”> positive regulation of cell population proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 886 </td> <td style=“text-align:left;”> 3.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140499 </td> <td style=“text-align:left;”> negative regulation of mitotic spindle assembly checkpoint signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 3.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006995 </td> <td style=“text-align:left;”> cellular response to nitrogen starvation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 3.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001236 </td> <td style=“text-align:left;”> regulation of extrinsic apoptotic signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 124 </td> <td style=“text-align:left;”> 3.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001778 </td> <td style=“text-align:left;”> plasma membrane repair </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 3.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043412 </td> <td style=“text-align:left;”> macromolecule modification </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:right;”> 2948 </td> <td style=“text-align:left;”> 3.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902426 </td> <td style=“text-align:left;”> deactivation of mitotic spindle assembly checkpoint </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 3.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001921 </td> <td style=“text-align:left;”> positive regulation of receptor recycling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 3.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030301 </td> <td style=“text-align:left;”> cholesterol transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 81 </td> <td style=“text-align:left;”> 3.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001911 </td> <td style=“text-align:left;”> negative regulation of leukocyte mediated cytotoxicity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 3.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007176 </td> <td style=“text-align:left;”> regulation of epidermal growth factor-activated receptor activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 3.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006903 </td> <td style=“text-align:left;”> vesicle targeting </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 62 </td> <td style=“text-align:left;”> 3.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043923 </td> <td style=“text-align:left;”> positive regulation by host of viral transcription </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 3.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043562 </td> <td style=“text-align:left;”> cellular response to nitrogen levels </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 3.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018364 </td> <td style=“text-align:left;”> peptidyl-glutamine methylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014706 </td> <td style=“text-align:left;”> striated muscle tissue development </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 214 </td> <td style=“text-align:left;”> 3.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034138 </td> <td style=“text-align:left;”> toll-like receptor 3 signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 3.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051301 </td> <td style=“text-align:left;”> cell division </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:right;”> 569 </td> <td style=“text-align:left;”> 3.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016267 </td> <td style=“text-align:left;”> O-glycan processing, core 1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 3.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090233 </td> <td style=“text-align:left;”> negative regulation of spindle checkpoint </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 3.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051248 </td> <td style=“text-align:left;”> negative regulation of protein metabolic process </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:right;”> 799 </td> <td style=“text-align:left;”> 3.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090162 </td> <td style=“text-align:left;”> establishment of epithelial cell polarity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 3.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030311 </td> <td style=“text-align:left;”> poly-N-acetyllactosamine biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048167 </td> <td style=“text-align:left;”> regulation of synaptic plasticity </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 146 </td> <td style=“text-align:left;”> 3.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048633 </td> <td style=“text-align:left;”> positive regulation of skeletal muscle tissue growth </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 3.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051444 </td> <td style=“text-align:left;”> negative regulation of ubiquitin-protein transferase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 3.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060965 </td> <td style=“text-align:left;”> negative regulation of miRNA-mediated gene silencing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 3.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006506 </td> <td style=“text-align:left;”> GPI anchor biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 3.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014732 </td> <td style=“text-align:left;”> skeletal muscle atrophy </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000492 </td> <td style=“text-align:left;”> box C/D snoRNP assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 3.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045017 </td> <td style=“text-align:left;”> glycerolipid biosynthetic process </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:right;”> 217 </td> <td style=“text-align:left;”> 3.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097205 </td> <td style=“text-align:left;”> renal filtration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 3.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0120036 </td> <td style=“text-align:left;”> plasma membrane bounded cell projection organization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 1203 </td> <td style=“text-align:left;”> 3.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000849 </td> <td style=“text-align:left;”> regulation of glucocorticoid secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904153 </td> <td style=“text-align:left;”> negative regulation of retrograde protein transport, ER to cytosol </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 3.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902512 </td> <td style=“text-align:left;”> positive regulation of apoptotic DNA fragmentation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051090 </td> <td style=“text-align:left;”> regulation of DNA-binding transcription factor activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 333 </td> <td style=“text-align:left;”> 3.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006661 </td> <td style=“text-align:left;”> phosphatidylinositol biosynthetic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 119 </td> <td style=“text-align:left;”> 3.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071636 </td> <td style=“text-align:left;”> positive regulation of transforming growth factor beta production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 3.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035994 </td> <td style=“text-align:left;”> response to muscle stretch </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 3.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043616 </td> <td style=“text-align:left;”> keratinocyte proliferation </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 3.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097062 </td> <td style=“text-align:left;”> dendritic spine maintenance </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 3.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048538 </td> <td style=“text-align:left;”> thymus development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 3.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001959 </td> <td style=“text-align:left;”> regulation of cytokine-mediated signaling pathway </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 118 </td> <td style=“text-align:left;”> 3.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009644 </td> <td style=“text-align:left;”> response to high light intensity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 3.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0038026 </td> <td style=“text-align:left;”> reelin-mediated signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044090 </td> <td style=“text-align:left;”> positive regulation of vacuole organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 3.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048388 </td> <td style=“text-align:left;”> endosomal lumen acidification </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 3.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071456 </td> <td style=“text-align:left;”> cellular response to hypoxia </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 121 </td> <td style=“text-align:left;”> 3.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042326 </td> <td style=“text-align:left;”> negative regulation of phosphorylation </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:right;”> 290 </td> <td style=“text-align:left;”> 3.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015837 </td> <td style=“text-align:left;”> amine transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 59 </td> <td style=“text-align:left;”> 3.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070262 </td> <td style=“text-align:left;”> peptidyl-serine dephosphorylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 3.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051453 </td> <td style=“text-align:left;”> regulation of intracellular pH </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 66 </td> <td style=“text-align:left;”> 3.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006505 </td> <td style=“text-align:left;”> GPI anchor metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 3.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006837 </td> <td style=“text-align:left;”> serotonin transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 3.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022607 </td> <td style=“text-align:left;”> cellular component assembly </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 2459 </td> <td style=“text-align:left;”> 3.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043456 </td> <td style=“text-align:left;”> regulation of pentose-phosphate shunt </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 3.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032930 </td> <td style=“text-align:left;”> positive regulation of superoxide anion generation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035790 </td> <td style=“text-align:left;”> platelet-derived growth factor receptor-alpha signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 3.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051851 </td> <td style=“text-align:left;”> modulation by host of symbiont process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 71 </td> <td style=“text-align:left;”> 3.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060045 </td> <td style=“text-align:left;”> positive regulation of cardiac muscle cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 3.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045893 </td> <td style=“text-align:left;”> positive regulation of DNA-templated transcription </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:right;”> 1298 </td> <td style=“text-align:left;”> 3.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051169 </td> <td style=“text-align:left;”> nuclear transport </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:right;”> 294 </td> <td style=“text-align:left;”> 3.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060914 </td> <td style=“text-align:left;”> heart formation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 3.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904354 </td> <td style=“text-align:left;”> negative regulation of telomere capping </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 3.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002260 </td> <td style=“text-align:left;”> lymphocyte homeostasis </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 3.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014912 </td> <td style=“text-align:left;”> negative regulation of smooth muscle cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 3.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045332 </td> <td style=“text-align:left;”> phospholipid translocation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 3.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006913 </td> <td style=“text-align:left;”> nucleocytoplasmic transport </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:right;”> 294 </td> <td style=“text-align:left;”> 3.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018026 </td> <td style=“text-align:left;”> peptidyl-lysine monomethylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 3.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002091 </td> <td style=“text-align:left;”> negative regulation of receptor internalization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 3.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900369 </td> <td style=“text-align:left;”> negative regulation of post-transcriptional gene silencing by regulatory ncRNA </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 3.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060149 </td> <td style=“text-align:left;”> negative regulation of post-transcriptional gene silencing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 3.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060967 </td> <td style=“text-align:left;”> negative regulation of gene silencing by regulatory ncRNA </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 3.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051865 </td> <td style=“text-align:left;”> protein autoubiquitination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 76 </td> <td style=“text-align:left;”> 3.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098735 </td> <td style=“text-align:left;”> positive regulation of the force of heart contraction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070676 </td> <td style=“text-align:left;”> intralumenal vesicle formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903542 </td> <td style=“text-align:left;”> negative regulation of exosomal secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001268 </td> <td style=“text-align:left;”> negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035148 </td> <td style=“text-align:left;”> tube formation </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 133 </td> <td style=“text-align:left;”> 3.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990442 </td> <td style=“text-align:left;”> intrinsic apoptotic signaling pathway in response to nitrosative stress </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010923 </td> <td style=“text-align:left;”> negative regulation of phosphatase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 3.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016562 </td> <td style=“text-align:left;”> protein import into peroxisome matrix, receptor recycling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030030 </td> <td style=“text-align:left;”> cell projection organization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 1236 </td> <td style=“text-align:left;”> 3.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905232 </td> <td style=“text-align:left;”> cellular response to L-glutamate </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.30e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901653 </td> <td style=“text-align:left;”> cellular response to peptide </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 277 </td> <td style=“text-align:left;”> 3.30e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033059 </td> <td style=“text-align:left;”> cellular pigmentation </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 3.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097193 </td> <td style=“text-align:left;”> intrinsic apoptotic signaling pathway </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 271 </td> <td style=“text-align:left;”> 3.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090038 </td> <td style=“text-align:left;”> negative regulation of protein kinase C signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061013 </td> <td style=“text-align:left;”> regulation of mRNA catabolic process </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 163 </td> <td style=“text-align:left;”> 3.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009153 </td> <td style=“text-align:left;”> purine deoxyribonucleotide biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0120186 </td> <td style=“text-align:left;”> negative regulation of protein localization to chromatin </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902036 </td> <td style=“text-align:left;”> regulation of hematopoietic stem cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 3.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000959 </td> <td style=“text-align:left;”> mitochondrial RNA metabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 3.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006325 </td> <td style=“text-align:left;”> chromatin organization </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:right;”> 631 </td> <td style=“text-align:left;”> 3.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046122 </td> <td style=“text-align:left;”> purine deoxyribonucleoside metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009886 </td> <td style=“text-align:left;”> post-embryonic animal morphogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 3.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046854 </td> <td style=“text-align:left;”> phosphatidylinositol phosphate biosynthetic process </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 59 </td> <td style=“text-align:left;”> 3.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016191 </td> <td style=“text-align:left;”> synaptic vesicle uncoating </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 3.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016241 </td> <td style=“text-align:left;”> regulation of macroautophagy </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 149 </td> <td style=“text-align:left;”> 3.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090239 </td> <td style=“text-align:left;”> regulation of histone H4 acetylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003148 </td> <td style=“text-align:left;”> outflow tract septum morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 3.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031573 </td> <td style=“text-align:left;”> mitotic intra-S DNA damage checkpoint signaling </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 3.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015918 </td> <td style=“text-align:left;”> sterol transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 93 </td> <td style=“text-align:left;”> 3.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035590 </td> <td style=“text-align:left;”> purinergic nucleotide receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 3.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060292 </td> <td style=“text-align:left;”> long-term synaptic depression </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 3.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902680 </td> <td style=“text-align:left;”> positive regulation of RNA biosynthetic process </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:right;”> 1305 </td> <td style=“text-align:left;”> 3.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031342 </td> <td style=“text-align:left;”> negative regulation of cell killing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 3.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045777 </td> <td style=“text-align:left;”> positive regulation of blood pressure </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 3.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010927 </td> <td style=“text-align:left;”> cellular component assembly involved in morphogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 106 </td> <td style=“text-align:left;”> 3.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006369 </td> <td style=“text-align:left;”> termination of RNA polymerase II transcription </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 3.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030336 </td> <td style=“text-align:left;”> negative regulation of cell migration </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 224 </td> <td style=“text-align:left;”> 3.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060411 </td> <td style=“text-align:left;”> cardiac septum morphogenesis </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 67 </td> <td style=“text-align:left;”> 3.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006351 </td> <td style=“text-align:left;”> DNA-templated transcription </td> <td style=“text-align:right;”> 82 </td> <td style=“text-align:right;”> 2669 </td> <td style=“text-align:left;”> 3.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901098 </td> <td style=“text-align:left;”> positive regulation of autophagosome maturation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 3.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903650 </td> <td style=“text-align:left;”> negative regulation of cytoplasmic transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006266 </td> <td style=“text-align:left;”> DNA ligation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 3.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003231 </td> <td style=“text-align:left;”> cardiac ventricle development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 115 </td> <td style=“text-align:left;”> 3.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072595 </td> <td style=“text-align:left;”> maintenance of protein localization in organelle </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 3.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070862 </td> <td style=“text-align:left;”> negative regulation of protein exit from endoplasmic reticulum </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 3.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010649 </td> <td style=“text-align:left;”> regulation of cell communication by electrical coupling </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 3.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000145 </td> <td style=“text-align:left;”> regulation of cell motility </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 741 </td> <td style=“text-align:left;”> 3.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035878 </td> <td style=“text-align:left;”> nail development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 3.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902683 </td> <td style=“text-align:left;”> regulation of receptor localization to synapse </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 3.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0017148 </td> <td style=“text-align:left;”> negative regulation of translation </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 175 </td> <td style=“text-align:left;”> 3.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048169 </td> <td style=“text-align:left;”> regulation of long-term neuronal synaptic plasticity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 3.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021766 </td> <td style=“text-align:left;”> hippocampus development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 3.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001881 </td> <td style=“text-align:left;”> receptor recycling </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 3.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007088 </td> <td style=“text-align:left;”> regulation of mitotic nuclear division </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 99 </td> <td style=“text-align:left;”> 3.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007338 </td> <td style=“text-align:left;”> single fertilization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 3.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0086004 </td> <td style=“text-align:left;”> regulation of cardiac muscle cell contraction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 3.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060395 </td> <td style=“text-align:left;”> SMAD protein signal transduction </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 65 </td> <td style=“text-align:left;”> 3.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002053 </td> <td style=“text-align:left;”> positive regulation of mesenchymal cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 3.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003181 </td> <td style=“text-align:left;”> atrioventricular valve morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 3.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001942 </td> <td style=“text-align:left;”> hair follicle development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 68 </td> <td style=“text-align:left;”> 3.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140861 </td> <td style=“text-align:left;”> DNA repair-dependent chromatin remodeling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 3.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006406 </td> <td style=“text-align:left;”> mRNA export from nucleus </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 60 </td> <td style=“text-align:left;”> 3.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140354 </td> <td style=“text-align:left;”> lipid import into cell </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 3.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035092 </td> <td style=“text-align:left;”> sperm DNA condensation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0038060 </td> <td style=“text-align:left;”> nitric oxide-cGMP-mediated signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 3.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042753 </td> <td style=“text-align:left;”> positive regulation of circadian rhythm </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 3.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051303 </td> <td style=“text-align:left;”> establishment of chromosome localization </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 93 </td> <td style=“text-align:left;”> 3.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034201 </td> <td style=“text-align:left;”> response to oleic acid </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032436 </td> <td style=“text-align:left;”> positive regulation of proteasomal ubiquitin-dependent protein catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 86 </td> <td style=“text-align:left;”> 3.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099163 </td> <td style=“text-align:left;”> synaptic signaling by nitric oxide </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003413 </td> <td style=“text-align:left;”> chondrocyte differentiation involved in endochondral bone morphogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 3.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021953 </td> <td style=“text-align:left;”> central nervous system neuron differentiation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 112 </td> <td style=“text-align:left;”> 3.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042439 </td> <td style=“text-align:left;”> ethanolamine-containing compound metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043243 </td> <td style=“text-align:left;”> positive regulation of protein-containing complex disassembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 3.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045663 </td> <td style=“text-align:left;”> positive regulation of myoblast differentiation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 3.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046469 </td> <td style=“text-align:left;”> platelet activating factor metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030641 </td> <td style=“text-align:left;”> regulation of cellular pH </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 3.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016331 </td> <td style=“text-align:left;”> morphogenesis of embryonic epithelium </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 130 </td> <td style=“text-align:left;”> 3.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006281 </td> <td style=“text-align:left;”> DNA repair </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:right;”> 541 </td> <td style=“text-align:left;”> 3.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060537 </td> <td style=“text-align:left;”> muscle tissue development </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 347 </td> <td style=“text-align:left;”> 3.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036294 </td> <td style=“text-align:left;”> cellular response to decreased oxygen levels </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 131 </td> <td style=“text-align:left;”> 3.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022405 </td> <td style=“text-align:left;”> hair cycle process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 3.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022404 </td> <td style=“text-align:left;”> molting cycle process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 3.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060828 </td> <td style=“text-align:left;”> regulation of canonical Wnt signaling pathway </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 214 </td> <td style=“text-align:left;”> 3.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009127 </td> <td style=“text-align:left;”> purine nucleoside monophosphate biosynthetic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 3.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902473 </td> <td style=“text-align:left;”> regulation of protein localization to synapse </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 3.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032958 </td> <td style=“text-align:left;”> inositol phosphate biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 3.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044790 </td> <td style=“text-align:left;”> suppression of viral release by host </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 3.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030309 </td> <td style=“text-align:left;”> poly-N-acetyllactosamine metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002710 </td> <td style=“text-align:left;”> negative regulation of T cell mediated immunity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 3.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050994 </td> <td style=“text-align:left;”> regulation of lipid catabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 3.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901678 </td> <td style=“text-align:left;”> iron coordination entity transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 3.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030540 </td> <td style=“text-align:left;”> female genitalia development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098953 </td> <td style=“text-align:left;”> receptor diffusion trapping </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099628 </td> <td style=“text-align:left;”> neurotransmitter receptor diffusion trapping </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000491 </td> <td style=“text-align:left;”> small nucleolar ribonucleoprotein complex assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060999 </td> <td style=“text-align:left;”> positive regulation of dendritic spine development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098970 </td> <td style=“text-align:left;”> postsynaptic neurotransmitter receptor diffusion trapping </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900120 </td> <td style=“text-align:left;”> regulation of receptor binding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042476 </td> <td style=“text-align:left;”> odontogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 82 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051988 </td> <td style=“text-align:left;”> regulation of attachment of spindle microtubules to kinetochore </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060011 </td> <td style=“text-align:left;”> Sertoli cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007179 </td> <td style=“text-align:left;”> transforming growth factor beta receptor signaling pathway </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 177 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032228 </td> <td style=“text-align:left;”> regulation of synaptic transmission, GABAergic </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903626 </td> <td style=“text-align:left;”> positive regulation of DNA catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021894 </td> <td style=“text-align:left;”> cerebral cortex GABAergic interneuron development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001826 </td> <td style=“text-align:left;”> inner cell mass cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006308 </td> <td style=“text-align:left;”> DNA catabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036066 </td> <td style=“text-align:left;”> protein O-linked fucosylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001844 </td> <td style=“text-align:left;”> protein insertion into mitochondrial membrane involved in apoptotic signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035933 </td> <td style=“text-align:left;”> glucocorticoid secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000291 </td> <td style=“text-align:left;”> nuclear-transcribed mRNA catabolic process, exonucleolytic </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048588 </td> <td style=“text-align:left;”> developmental cell growth </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 194 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033363 </td> <td style=“text-align:left;”> secretory granule organization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050687 </td> <td style=“text-align:left;”> negative regulation of defense response to virus </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045657 </td> <td style=“text-align:left;”> positive regulation of monocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000076 </td> <td style=“text-align:left;”> DNA replication checkpoint signaling </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006978 </td> <td style=“text-align:left;”> DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014013 </td> <td style=“text-align:left;”> regulation of gliogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 66 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006900 </td> <td style=“text-align:left;”> vesicle budding from membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 77 </td> <td style=“text-align:left;”> 3.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097345 </td> <td style=“text-align:left;”> mitochondrial outer membrane permeabilization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 3.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003272 </td> <td style=“text-align:left;”> endocardial cushion formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 3.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055023 </td> <td style=“text-align:left;”> positive regulation of cardiac muscle tissue growth </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 3.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019080 </td> <td style=“text-align:left;”> viral gene expression </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 97 </td> <td style=“text-align:left;”> 3.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032928 </td> <td style=“text-align:left;”> regulation of superoxide anion generation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 3.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001244 </td> <td style=“text-align:left;”> positive regulation of intrinsic apoptotic signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 52 </td> <td style=“text-align:left;”> 3.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002097 </td> <td style=“text-align:left;”> tRNA wobble base modification </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 3.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007254 </td> <td style=“text-align:left;”> JNK cascade </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 137 </td> <td style=“text-align:left;”> 3.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0039533 </td> <td style=“text-align:left;”> regulation of MDA-5 signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045050 </td> <td style=“text-align:left;”> protein insertion into ER membrane by stop-transfer membrane-anchor sequence </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 3.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035634 </td> <td style=“text-align:left;”> response to stilbenoid </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 3.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061370 </td> <td style=“text-align:left;”> testosterone biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035264 </td> <td style=“text-align:left;”> multicellular organism growth </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 124 </td> <td style=“text-align:left;”> 3.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034204 </td> <td style=“text-align:left;”> lipid translocation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 3.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014888 </td> <td style=“text-align:left;”> striated muscle adaptation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 3.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070346 </td> <td style=“text-align:left;”> positive regulation of fat cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904688 </td> <td style=“text-align:left;”> regulation of cytoplasmic translational initiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001960 </td> <td style=“text-align:left;”> negative regulation of cytokine-mediated signaling pathway </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 52 </td> <td style=“text-align:left;”> 3.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033045 </td> <td style=“text-align:left;”> regulation of sister chromatid segregation </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 99 </td> <td style=“text-align:left;”> 3.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006403 </td> <td style=“text-align:left;”> RNA localization </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 177 </td> <td style=“text-align:left;”> 3.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072666 </td> <td style=“text-align:left;”> establishment of protein localization to vacuole </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 3.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031397 </td> <td style=“text-align:left;”> negative regulation of protein ubiquitination </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 76 </td> <td style=“text-align:left;”> 3.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050731 </td> <td style=“text-align:left;”> positive regulation of peptidyl-tyrosine phosphorylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 103 </td> <td style=“text-align:left;”> 3.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060022 </td> <td style=“text-align:left;”> hard palate development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003149 </td> <td style=“text-align:left;”> membranous septum morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 3.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048709 </td> <td style=“text-align:left;”> oligodendrocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 72 </td> <td style=“text-align:left;”> 3.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032785 </td> <td style=“text-align:left;”> negative regulation of DNA-templated transcription, elongation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 3.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042551 </td> <td style=“text-align:left;”> neuron maturation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098742 </td> <td style=“text-align:left;”> cell-cell adhesion via plasma-membrane adhesion molecules </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 165 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072657 </td> <td style=“text-align:left;”> protein localization to membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 530 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090311 </td> <td style=“text-align:left;”> regulation of protein deacetylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042771 </td> <td style=“text-align:left;”> intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043434 </td> <td style=“text-align:left;”> response to peptide hormone </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 315 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042327 </td> <td style=“text-align:left;”> positive regulation of phosphorylation </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 511 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072344 </td> <td style=“text-align:left;”> rescue of stalled ribosome </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060037 </td> <td style=“text-align:left;”> pharyngeal system development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045165 </td> <td style=“text-align:left;”> cell fate commitment </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 157 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901799 </td> <td style=“text-align:left;”> negative regulation of proteasomal protein catabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 47 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031113 </td> <td style=“text-align:left;”> regulation of microtubule polymerization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001945 </td> <td style=“text-align:left;”> lymph vessel development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003171 </td> <td style=“text-align:left;”> atrioventricular valve development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070328 </td> <td style=“text-align:left;”> triglyceride homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055090 </td> <td style=“text-align:left;”> acylglycerol homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048660 </td> <td style=“text-align:left;”> regulation of smooth muscle cell proliferation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 100 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042772 </td> <td style=“text-align:left;”> DNA damage response, signal transduction resulting in transcription </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010866 </td> <td style=“text-align:left;”> regulation of triglyceride biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006414 </td> <td style=“text-align:left;”> translational elongation </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 73 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072318 </td> <td style=“text-align:left;”> clathrin coat disassembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006417 </td> <td style=“text-align:left;”> regulation of translation </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:right;”> 373 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045576 </td> <td style=“text-align:left;”> mast cell activation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015748 </td> <td style=“text-align:left;”> organophosphate ester transport </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 106 </td> <td style=“text-align:left;”> 3.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008295 </td> <td style=“text-align:left;”> spermidine biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032608 </td> <td style=“text-align:left;”> interferon-beta production </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 3.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032648 </td> <td style=“text-align:left;”> regulation of interferon-beta production </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 3.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071389 </td> <td style=“text-align:left;”> cellular response to mineralocorticoid stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 3.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000172 </td> <td style=“text-align:left;”> regulation of branching morphogenesis of a nerve </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006895 </td> <td style=“text-align:left;”> Golgi to endosome transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 3.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006282 </td> <td style=“text-align:left;”> regulation of DNA repair </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 201 </td> <td style=“text-align:left;”> 3.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048008 </td> <td style=“text-align:left;”> platelet-derived growth factor receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 52 </td> <td style=“text-align:left;”> 3.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045821 </td> <td style=“text-align:left;”> positive regulation of glycolytic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 3.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140239 </td> <td style=“text-align:left;”> postsynaptic endocytosis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 3.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098884 </td> <td style=“text-align:left;”> postsynaptic neurotransmitter receptor internalization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 3.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044085 </td> <td style=“text-align:left;”> cellular component biogenesis </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 2722 </td> <td style=“text-align:left;”> 3.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008625 </td> <td style=“text-align:left;”> extrinsic apoptotic signaling pathway via death domain receptors </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 73 </td> <td style=“text-align:left;”> 3.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001243 </td> <td style=“text-align:left;”> negative regulation of intrinsic apoptotic signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 97 </td> <td style=“text-align:left;”> 3.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046474 </td> <td style=“text-align:left;”> glycerophospholipid biosynthetic process </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 188 </td> <td style=“text-align:left;”> 3.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045472 </td> <td style=“text-align:left;”> response to ether </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 3.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042921 </td> <td style=“text-align:left;”> glucocorticoid receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 3.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006469 </td> <td style=“text-align:left;”> negative regulation of protein kinase activity </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 173 </td> <td style=“text-align:left;”> 3.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0040012 </td> <td style=“text-align:left;”> regulation of locomotion </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 762 </td> <td style=“text-align:left;”> 3.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048569 </td> <td style=“text-align:left;”> post-embryonic animal organ development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 3.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045936 </td> <td style=“text-align:left;”> negative regulation of phosphate metabolic process </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:right;”> 334 </td> <td style=“text-align:left;”> 3.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032402 </td> <td style=“text-align:left;”> melanosome transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 3.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901097 </td> <td style=“text-align:left;”> negative regulation of autophagosome maturation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010971 </td> <td style=“text-align:left;”> positive regulation of G2/M transition of mitotic cell cycle </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 3.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045445 </td> <td style=“text-align:left;”> myoblast differentiation </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 90 </td> <td style=“text-align:left;”> 3.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901165 </td> <td style=“text-align:left;”> positive regulation of trophoblast cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 3.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048668 </td> <td style=“text-align:left;”> collateral sprouting </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 3.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051604 </td> <td style=“text-align:left;”> protein maturation </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 440 </td> <td style=“text-align:left;”> 3.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000679 </td> <td style=“text-align:left;”> positive regulation of transcription regulatory region DNA binding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 3.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010563 </td> <td style=“text-align:left;”> negative regulation of phosphorus metabolic process </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:right;”> 335 </td> <td style=“text-align:left;”> 3.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903115 </td> <td style=“text-align:left;”> regulation of actin filament-based movement </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 3.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032941 </td> <td style=“text-align:left;”> secretion by tissue </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 3.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022615 </td> <td style=“text-align:left;”> protein to membrane docking </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002320 </td> <td style=“text-align:left;”> lymphoid progenitor cell differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 3.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904978 </td> <td style=“text-align:left;”> regulation of endosome organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014891 </td> <td style=“text-align:left;”> striated muscle atrophy </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 3.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048631 </td> <td style=“text-align:left;”> regulation of skeletal muscle tissue growth </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003016 </td> <td style=“text-align:left;”> respiratory system process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 3.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048659 </td> <td style=“text-align:left;”> smooth muscle cell proliferation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 104 </td> <td style=“text-align:left;”> 3.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051252 </td> <td style=“text-align:left;”> regulation of RNA metabolic process </td> <td style=“text-align:right;”> 89 </td> <td style=“text-align:right;”> 2824 </td> <td style=“text-align:left;”> 3.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046488 </td> <td style=“text-align:left;”> phosphatidylinositol metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 137 </td> <td style=“text-align:left;”> 3.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032774 </td> <td style=“text-align:left;”> RNA biosynthetic process </td> <td style=“text-align:right;”> 82 </td> <td style=“text-align:right;”> 2699 </td> <td style=“text-align:left;”> 3.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051315 </td> <td style=“text-align:left;”> attachment of mitotic spindle microtubules to kinetochore </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 3.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090208 </td> <td style=“text-align:left;”> positive regulation of triglyceride metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 3.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031669 </td> <td style=“text-align:left;”> cellular response to nutrient levels </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 198 </td> <td style=“text-align:left;”> 3.57e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002328 </td> <td style=“text-align:left;”> pro-B cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 3.57e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071383 </td> <td style=“text-align:left;”> cellular response to steroid hormone stimulus </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 166 </td> <td style=“text-align:left;”> 3.57e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060759 </td> <td style=“text-align:left;”> regulation of response to cytokine stimulus </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 127 </td> <td style=“text-align:left;”> 3.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000146 </td> <td style=“text-align:left;”> negative regulation of cell motility </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 233 </td> <td style=“text-align:left;”> 3.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043161 </td> <td style=“text-align:left;”> proteasome-mediated ubiquitin-dependent protein catabolic process </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:right;”> 421 </td> <td style=“text-align:left;”> 3.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032663 </td> <td style=“text-align:left;”> regulation of interleukin-2 production </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 3.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032623 </td> <td style=“text-align:left;”> interleukin-2 production </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 3.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900180 </td> <td style=“text-align:left;”> regulation of protein localization to nucleus </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 124 </td> <td style=“text-align:left;”> 3.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007286 </td> <td style=“text-align:left;”> spermatid development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 108 </td> <td style=“text-align:left;”> 3.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009628 </td> <td style=“text-align:left;”> response to abiotic stimulus </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:right;”> 848 </td> <td style=“text-align:left;”> 3.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000060 </td> <td style=“text-align:left;”> positive regulation of ubiquitin-dependent protein catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 99 </td> <td style=“text-align:left;”> 3.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035305 </td> <td style=“text-align:left;”> negative regulation of dephosphorylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 3.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035624 </td> <td style=“text-align:left;”> receptor transactivation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042791 </td> <td style=“text-align:left;”> 5S class rRNA transcription by RNA polymerase III </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 3.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071702 </td> <td style=“text-align:left;”> organic substance transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 2133 </td> <td style=“text-align:left;”> 3.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010700 </td> <td style=“text-align:left;”> negative regulation of norepinephrine secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 3.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032811 </td> <td style=“text-align:left;”> negative regulation of epinephrine secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 3.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902415 </td> <td style=“text-align:left;”> regulation of mRNA binding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 3.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990416 </td> <td style=“text-align:left;”> cellular response to brain-derived neurotrophic factor stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 3.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902742 </td> <td style=“text-align:left;”> apoptotic process involved in development </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 3.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042832 </td> <td style=“text-align:left;”> defense response to protozoan </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 3.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051769 </td> <td style=“text-align:left;”> regulation of nitric-oxide synthase biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 3.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071605 </td> <td style=“text-align:left;”> monocyte chemotactic protein-1 production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071480 </td> <td style=“text-align:left;”> cellular response to gamma radiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 3.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051443 </td> <td style=“text-align:left;”> positive regulation of ubiquitin-protein transferase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 3.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051767 </td> <td style=“text-align:left;”> nitric-oxide synthase biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 3.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071637 </td> <td style=“text-align:left;”> regulation of monocyte chemotactic protein-1 production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043405 </td> <td style=“text-align:left;”> regulation of MAP kinase activity </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 141 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048598 </td> <td style=“text-align:left;”> embryonic morphogenesis </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 438 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033504 </td> <td style=“text-align:left;”> floor plate development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030261 </td> <td style=“text-align:left;”> chromosome condensation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061469 </td> <td style=“text-align:left;”> regulation of type B pancreatic cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035458 </td> <td style=“text-align:left;”> cellular response to interferon-beta </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098534 </td> <td style=“text-align:left;”> centriole assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045637 </td> <td style=“text-align:left;”> regulation of myeloid cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 139 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060795 </td> <td style=“text-align:left;”> cell fate commitment involved in formation of primary germ layer </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009566 </td> <td style=“text-align:left;”> fertilization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 93 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051904 </td> <td style=“text-align:left;”> pigment granule transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090066 </td> <td style=“text-align:left;”> regulation of anatomical structure size </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:right;”> 395 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045739 </td> <td style=“text-align:left;”> positive regulation of DNA repair </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 120 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099633 </td> <td style=“text-align:left;”> protein localization to postsynaptic specialization membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099645 </td> <td style=“text-align:left;”> neurotransmitter receptor localization to postsynaptic specialization membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043651 </td> <td style=“text-align:left;”> linoleic acid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035967 </td> <td style=“text-align:left;”> cellular response to topologically incorrect protein </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 103 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060761 </td> <td style=“text-align:left;”> negative regulation of response to cytokine stimulus </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904152 </td> <td style=“text-align:left;”> regulation of retrograde protein transport, ER to cytosol </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032757 </td> <td style=“text-align:left;”> positive regulation of interleukin-8 production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051783 </td> <td style=“text-align:left;”> regulation of nuclear division </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 115 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010611 </td> <td style=“text-align:left;”> regulation of cardiac muscle hypertrophy </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009650 </td> <td style=“text-align:left;”> UV protection </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061061 </td> <td style=“text-align:left;”> muscle structure development </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 552 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010288 </td> <td style=“text-align:left;”> response to lead ion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010837 </td> <td style=“text-align:left;”> regulation of keratinocyte proliferation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061041 </td> <td style=“text-align:left;”> regulation of wound healing </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 93 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019752 </td> <td style=“text-align:left;”> carboxylic acid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 684 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097035 </td> <td style=“text-align:left;”> regulation of membrane lipid distribution </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051168 </td> <td style=“text-align:left;”> nuclear export </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 149 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051660 </td> <td style=“text-align:left;”> establishment of centrosome localization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010839 </td> <td style=“text-align:left;”> negative regulation of keratinocyte proliferation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045879 </td> <td style=“text-align:left;”> negative regulation of smoothened signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051668 </td> <td style=“text-align:left;”> localization within membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 611 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051702 </td> <td style=“text-align:left;”> biological process involved in interaction with symbiont </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 81 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061384 </td> <td style=“text-align:left;”> heart trabecula morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036261 </td> <td style=“text-align:left;”> 7-methylguanosine cap hypermethylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021510 </td> <td style=“text-align:left;”> spinal cord development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 61 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043281 </td> <td style=“text-align:left;”> regulation of cysteine-type endopeptidase activity involved in apoptotic process </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 143 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090314 </td> <td style=“text-align:left;”> positive regulation of protein targeting to membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006418 </td> <td style=“text-align:left;”> tRNA aminoacylation for protein translation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030518 </td> <td style=“text-align:left;”> intracellular steroid hormone receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 96 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046666 </td> <td style=“text-align:left;”> retinal cell programmed cell death </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060485 </td> <td style=“text-align:left;”> mesenchyme development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 250 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001140 </td> <td style=“text-align:left;”> positive regulation of phospholipid transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071453 </td> <td style=“text-align:left;”> cellular response to oxygen levels </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 144 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032056 </td> <td style=“text-align:left;”> positive regulation of translation in response to stress </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051081 </td> <td style=“text-align:left;”> nuclear membrane disassembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902110 </td> <td style=“text-align:left;”> positive regulation of mitochondrial membrane permeability involved in apoptotic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031958 </td> <td style=“text-align:left;”> corticosteroid receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060421 </td> <td style=“text-align:left;”> positive regulation of heart growth </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071396 </td> <td style=“text-align:left;”> cellular response to lipid </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:right;”> 401 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060412 </td> <td style=“text-align:left;”> ventricular septum morphogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060390 </td> <td style=“text-align:left;”> regulation of SMAD protein signal transduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051955 </td> <td style=“text-align:left;”> regulation of amino acid transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901020 </td> <td style=“text-align:left;”> negative regulation of calcium ion transmembrane transporter activity </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048333 </td> <td style=“text-align:left;”> mesodermal cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044092 </td> <td style=“text-align:left;”> negative regulation of molecular function </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:right;”> 730 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904896 </td> <td style=“text-align:left;”> ESCRT complex disassembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904903 </td> <td style=“text-align:left;”> ESCRT III complex disassembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035025 </td> <td style=“text-align:left;”> positive regulation of Rho protein signal transduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000737 </td> <td style=“text-align:left;”> negative regulation of stem cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006310 </td> <td style=“text-align:left;”> DNA recombination </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:right;”> 261 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048512 </td> <td style=“text-align:left;”> circadian behavior </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901800 </td> <td style=“text-align:left;”> positive regulation of proteasomal protein catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 107 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042303 </td> <td style=“text-align:left;”> molting cycle </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 79 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044706 </td> <td style=“text-align:left;”> multi-multicellular organism process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 136 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905279 </td> <td style=“text-align:left;”> regulation of retrograde transport, endosome to Golgi </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009156 </td> <td style=“text-align:left;”> ribonucleoside monophosphate biosynthetic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016567 </td> <td style=“text-align:left;”> protein ubiquitination </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 684 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001938 </td> <td style=“text-align:left;”> positive regulation of endothelial cell proliferation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031440 </td> <td style=“text-align:left;”> regulation of mRNA 3’-end processing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048515 </td> <td style=“text-align:left;”> spermatid differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 114 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032401 </td> <td style=“text-align:left;”> establishment of melanosome localization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042633 </td> <td style=“text-align:left;”> hair cycle </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 79 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015937 </td> <td style=“text-align:left;”> coenzyme A biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034248 </td> <td style=“text-align:left;”> regulation of amide metabolic process </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:right;”> 426 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072319 </td> <td style=“text-align:left;”> vesicle uncoating </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 3.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035051 </td> <td style=“text-align:left;”> cardiocyte differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 134 </td> <td style=“text-align:left;”> 3.62e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071285 </td> <td style=“text-align:left;”> cellular response to lithium ion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 3.62e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900271 </td> <td style=“text-align:left;”> regulation of long-term synaptic potentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 3.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007622 </td> <td style=“text-align:left;”> rhythmic behavior </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 3.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035307 </td> <td style=“text-align:left;”> positive regulation of protein dephosphorylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 3.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006643 </td> <td style=“text-align:left;”> membrane lipid metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 171 </td> <td style=“text-align:left;”> 3.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021761 </td> <td style=“text-align:left;”> limbic system development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 89 </td> <td style=“text-align:left;”> 3.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003266 </td> <td style=“text-align:left;”> regulation of secondary heart field cardioblast proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 3.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000481 </td> <td style=“text-align:left;”> positive regulation of cAMP-dependent protein kinase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006885 </td> <td style=“text-align:left;”> regulation of pH </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 3.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001056 </td> <td style=“text-align:left;”> positive regulation of cysteine-type endopeptidase activity </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 103 </td> <td style=“text-align:left;”> 3.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030163 </td> <td style=“text-align:left;”> protein catabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 906 </td> <td style=“text-align:left;”> 3.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050714 </td> <td style=“text-align:left;”> positive regulation of protein secretion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 103 </td> <td style=“text-align:left;”> 3.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060337 </td> <td style=“text-align:left;”> type I interferon-mediated signaling pathway </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 54 </td> <td style=“text-align:left;”> 3.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035909 </td> <td style=“text-align:left;”> aorta morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 3.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043436 </td> <td style=“text-align:left;”> oxoacid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 699 </td> <td style=“text-align:left;”> 3.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043280 </td> <td style=“text-align:left;”> positive regulation of cysteine-type endopeptidase activity involved in apoptotic process </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 92 </td> <td style=“text-align:left;”> 3.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044093 </td> <td style=“text-align:left;”> positive regulation of molecular function </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:right;”> 1132 </td> <td style=“text-align:left;”> 3.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032459 </td> <td style=“text-align:left;”> regulation of protein oligomerization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901652 </td> <td style=“text-align:left;”> response to peptide </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 367 </td> <td style=“text-align:left;”> 3.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0005977 </td> <td style=“text-align:left;”> glycogen metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 3.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006082 </td> <td style=“text-align:left;”> organic acid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 703 </td> <td style=“text-align:left;”> 3.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061098 </td> <td style=“text-align:left;”> positive regulation of protein tyrosine kinase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 3.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006693 </td> <td style=“text-align:left;”> prostaglandin metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 3.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001955 </td> <td style=“text-align:left;”> blood vessel maturation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 3.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046599 </td> <td style=“text-align:left;”> regulation of centriole replication </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 3.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006498 </td> <td style=“text-align:left;”> N-terminal protein lipidation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034504 </td> <td style=“text-align:left;”> protein localization to nucleus </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 282 </td> <td style=“text-align:left;”> 3.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0040013 </td> <td style=“text-align:left;”> negative regulation of locomotion </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 262 </td> <td style=“text-align:left;”> 3.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008334 </td> <td style=“text-align:left;”> histone mRNA metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 3.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030522 </td> <td style=“text-align:left;”> intracellular receptor signaling pathway </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 256 </td> <td style=“text-align:left;”> 3.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901264 </td> <td style=“text-align:left;”> carbohydrate derivative transport </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 67 </td> <td style=“text-align:left;”> 3.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018394 </td> <td style=“text-align:left;”> peptidyl-lysine acetylation </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 126 </td> <td style=“text-align:left;”> 3.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030193 </td> <td style=“text-align:left;”> regulation of blood coagulation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 3.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008015 </td> <td style=“text-align:left;”> blood circulation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 372 </td> <td style=“text-align:left;”> 3.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048663 </td> <td style=“text-align:left;”> neuron fate commitment </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 3.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035627 </td> <td style=“text-align:left;”> ceramide transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 3.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070528 </td> <td style=“text-align:left;”> protein kinase C signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 3.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001975 </td> <td style=“text-align:left;”> response to amphetamine </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 3.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046053 </td> <td style=“text-align:left;”> dAMP metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009215 </td> <td style=“text-align:left;”> purine deoxyribonucleoside triphosphate metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014743 </td> <td style=“text-align:left;”> regulation of muscle hypertrophy </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 47 </td> <td style=“text-align:left;”> 3.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001522 </td> <td style=“text-align:left;”> pseudouridine synthesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 3.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043268 </td> <td style=“text-align:left;”> positive regulation of potassium ion transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 3.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001562 </td> <td style=“text-align:left;”> response to protozoan </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 3.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010628 </td> <td style=“text-align:left;”> positive regulation of gene expression </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:right;”> 795 </td> <td style=“text-align:left;”> 3.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050918 </td> <td style=“text-align:left;”> positive chemotaxis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 3.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033135 </td> <td style=“text-align:left;”> regulation of peptidyl-serine phosphorylation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 97 </td> <td style=“text-align:left;”> 3.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042311 </td> <td style=“text-align:left;”> vasodilation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 3.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032872 </td> <td style=“text-align:left;”> regulation of stress-activated MAPK cascade </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 153 </td> <td style=“text-align:left;”> 3.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072594 </td> <td style=“text-align:left;”> establishment of protein localization to organelle </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 418 </td> <td style=“text-align:left;”> 3.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051974 </td> <td style=“text-align:left;”> negative regulation of telomerase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 3.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902533 </td> <td style=“text-align:left;”> positive regulation of intracellular signal transduction </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 707 </td> <td style=“text-align:left;”> 3.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045591 </td> <td style=“text-align:left;”> positive regulation of regulatory T cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 3.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902570 </td> <td style=“text-align:left;”> protein localization to nucleolus </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 3.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071357 </td> <td style=“text-align:left;”> cellular response to type I interferon </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 55 </td> <td style=“text-align:left;”> 3.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051905 </td> <td style=“text-align:left;”> establishment of pigment granule localization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 3.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042063 </td> <td style=“text-align:left;”> gliogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 244 </td> <td style=“text-align:left;”> 3.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060560 </td> <td style=“text-align:left;”> developmental growth involved in morphogenesis </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 207 </td> <td style=“text-align:left;”> 3.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901875 </td> <td style=“text-align:left;”> positive regulation of post-translational protein modification </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 170 </td> <td style=“text-align:left;”> 3.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032480 </td> <td style=“text-align:left;”> negative regulation of type I interferon production </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 3.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000059 </td> <td style=“text-align:left;”> negative regulation of ubiquitin-dependent protein catabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 3.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006692 </td> <td style=“text-align:left;”> prostanoid metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 3.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070242 </td> <td style=“text-align:left;”> thymocyte apoptotic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 3.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001238 </td> <td style=“text-align:left;”> positive regulation of extrinsic apoptotic signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 3.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001138 </td> <td style=“text-align:left;”> regulation of phospholipid transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 3.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000275 </td> <td style=“text-align:left;”> regulation of oxidative phosphorylation uncoupler activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098773 </td> <td style=“text-align:left;”> skin epidermis development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 90 </td> <td style=“text-align:left;”> 3.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043415 </td> <td style=“text-align:left;”> positive regulation of skeletal muscle tissue regeneration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002457 </td> <td style=“text-align:left;”> T cell antigen processing and presentation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010824 </td> <td style=“text-align:left;”> regulation of centrosome duplication </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 3.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006887 </td> <td style=“text-align:left;”> exocytosis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 251 </td> <td style=“text-align:left;”> 3.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900046 </td> <td style=“text-align:left;”> regulation of hemostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 3.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902031 </td> <td style=“text-align:left;”> regulation of NADP metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 3.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051056 </td> <td style=“text-align:left;”> regulation of small GTPase mediated signal transduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 249 </td> <td style=“text-align:left;”> 3.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902751 </td> <td style=“text-align:left;”> positive regulation of cell cycle G2/M phase transition </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 3.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034205 </td> <td style=“text-align:left;”> amyloid-beta formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 3.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0039532 </td> <td style=“text-align:left;”> negative regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 3.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003417 </td> <td style=“text-align:left;”> growth plate cartilage development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 3.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006509 </td> <td style=“text-align:left;”> membrane protein ectodomain proteolysis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 3.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061888 </td> <td style=“text-align:left;”> regulation of astrocyte activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071218 </td> <td style=“text-align:left;”> cellular response to misfolded protein </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 3.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001237 </td> <td style=“text-align:left;”> negative regulation of extrinsic apoptotic signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 78 </td> <td style=“text-align:left;”> 3.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044042 </td> <td style=“text-align:left;”> glucan metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 65 </td> <td style=“text-align:left;”> 3.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048873 </td> <td style=“text-align:left;”> homeostasis of number of cells within a tissue </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 3.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003161 </td> <td style=“text-align:left;”> cardiac conduction system development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 3.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900027 </td> <td style=“text-align:left;”> regulation of ruffle assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 3.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032682 </td> <td style=“text-align:left;”> negative regulation of chemokine production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 3.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034315 </td> <td style=“text-align:left;”> regulation of Arp2/3 complex-mediated actin nucleation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 3.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990564 </td> <td style=“text-align:left;”> protein polyufmylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990592 </td> <td style=“text-align:left;”> protein K69-linked ufmylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903895 </td> <td style=“text-align:left;”> negative regulation of IRE1-mediated unfolded protein response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090090 </td> <td style=“text-align:left;”> negative regulation of canonical Wnt signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 114 </td> <td style=“text-align:left;”> 3.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045776 </td> <td style=“text-align:left;”> negative regulation of blood pressure </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 3.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030397 </td> <td style=“text-align:left;”> membrane disassembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 3.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070302 </td> <td style=“text-align:left;”> regulation of stress-activated protein kinase signaling cascade </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 157 </td> <td style=“text-align:left;”> 3.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0052548 </td> <td style=“text-align:left;”> regulation of endopeptidase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 220 </td> <td style=“text-align:left;”> 3.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000846 </td> <td style=“text-align:left;”> regulation of corticosteroid hormone secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 3.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061157 </td> <td style=“text-align:left;”> mRNA destabilization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 92 </td> <td style=“text-align:left;”> 3.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008215 </td> <td style=“text-align:left;”> spermine metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901983 </td> <td style=“text-align:left;”> regulation of protein acetylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 3.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904292 </td> <td style=“text-align:left;”> regulation of ERAD pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 3.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046847 </td> <td style=“text-align:left;”> filopodium assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 3.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0065004 </td> <td style=“text-align:left;”> protein-DNA complex assembly </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:right;”> 171 </td> <td style=“text-align:left;”> 3.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030970 </td> <td style=“text-align:left;”> retrograde protein transport, ER to cytosol </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 3.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903513 </td> <td style=“text-align:left;”> endoplasmic reticulum to cytosol transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 3.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070266 </td> <td style=“text-align:left;”> necroptotic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 3.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030488 </td> <td style=“text-align:left;”> tRNA methylation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 3.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043392 </td> <td style=“text-align:left;”> negative regulation of DNA binding </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 3.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902686 </td> <td style=“text-align:left;”> mitochondrial outer membrane permeabilization involved in programmed cell death </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 3.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060043 </td> <td style=“text-align:left;”> regulation of cardiac muscle cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 3.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032886 </td> <td style=“text-align:left;”> regulation of microtubule-based process </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 216 </td> <td style=“text-align:left;”> 3.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901135 </td> <td style=“text-align:left;”> carbohydrate derivative metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 841 </td> <td style=“text-align:left;”> 3.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900152 </td> <td style=“text-align:left;”> negative regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 3.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043547 </td> <td style=“text-align:left;”> positive regulation of GTPase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 211 </td> <td style=“text-align:left;”> 3.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050818 </td> <td style=“text-align:left;”> regulation of coagulation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 54 </td> <td style=“text-align:left;”> 3.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0017015 </td> <td style=“text-align:left;”> regulation of transforming growth factor beta receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 126 </td> <td style=“text-align:left;”> 3.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002686 </td> <td style=“text-align:left;”> negative regulation of leukocyte migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 3.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035067 </td> <td style=“text-align:left;”> negative regulation of histone acetylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 3.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003263 </td> <td style=“text-align:left;”> cardioblast proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 3.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003264 </td> <td style=“text-align:left;”> regulation of cardioblast proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 3.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033627 </td> <td style=“text-align:left;”> cell adhesion mediated by integrin </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 61 </td> <td style=“text-align:left;”> 3.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006623 </td> <td style=“text-align:left;”> protein targeting to vacuole </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 3.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034612 </td> <td style=“text-align:left;”> response to tumor necrosis factor </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 176 </td> <td style=“text-align:left;”> 3.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032400 </td> <td style=“text-align:left;”> melanosome localization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 3.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001137 </td> <td style=“text-align:left;”> positive regulation of endocytic recycling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904816 </td> <td style=“text-align:left;”> positive regulation of protein localization to chromosome, telomeric region </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 3.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902166 </td> <td style=“text-align:left;”> negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 3.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043666 </td> <td style=“text-align:left;”> regulation of phosphoprotein phosphatase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 3.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904707 </td> <td style=“text-align:left;”> positive regulation of vascular associated smooth muscle cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 3.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006189 </td> <td style=“text-align:left;”> ‘de novo’ IMP biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 3.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099590 </td> <td style=“text-align:left;”> neurotransmitter receptor internalization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 3.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043401 </td> <td style=“text-align:left;”> steroid hormone mediated signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 115 </td> <td style=“text-align:left;”> 3.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903844 </td> <td style=“text-align:left;”> regulation of cellular response to transforming growth factor beta stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 127 </td> <td style=“text-align:left;”> 3.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055118 </td> <td style=“text-align:left;”> negative regulation of cardiac muscle contraction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031062 </td> <td style=“text-align:left;”> positive regulation of histone methylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 3.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044242 </td> <td style=“text-align:left;”> cellular lipid catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 168 </td> <td style=“text-align:left;”> 3.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000209 </td> <td style=“text-align:left;”> regulation of anoikis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 3.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072488 </td> <td style=“text-align:left;”> ammonium transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 3.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010226 </td> <td style=“text-align:left;”> response to lithium ion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 3.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043039 </td> <td style=“text-align:left;”> tRNA aminoacylation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 3.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071472 </td> <td style=“text-align:left;”> cellular response to salt stress </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 3.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050850 </td> <td style=“text-align:left;”> positive regulation of calcium-mediated signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 3.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070884 </td> <td style=“text-align:left;”> regulation of calcineurin-NFAT signaling cascade </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 3.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048741 </td> <td style=“text-align:left;”> skeletal muscle fiber development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 3.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903052 </td> <td style=“text-align:left;”> positive regulation of proteolysis involved in protein catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 122 </td> <td style=“text-align:left;”> 3.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006703 </td> <td style=“text-align:left;”> estrogen biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 3.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044557 </td> <td style=“text-align:left;”> relaxation of smooth muscle </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901992 </td> <td style=“text-align:left;”> positive regulation of mitotic cell cycle phase transition </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 84 </td> <td style=“text-align:left;”> 3.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090101 </td> <td style=“text-align:left;”> negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 122 </td> <td style=“text-align:left;”> 3.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034249 </td> <td style=“text-align:left;”> negative regulation of amide metabolic process </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 196 </td> <td style=“text-align:left;”> 3.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048708 </td> <td style=“text-align:left;”> astrocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 3.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007613 </td> <td style=“text-align:left;”> memory </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 93 </td> <td style=“text-align:left;”> 3.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042059 </td> <td style=“text-align:left;”> negative regulation of epidermal growth factor receptor signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 3.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046888 </td> <td style=“text-align:left;”> negative regulation of hormone secretion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 3.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090394 </td> <td style=“text-align:left;”> negative regulation of excitatory postsynaptic potential </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 3.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000171 </td> <td style=“text-align:left;”> negative regulation of dendrite development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 3.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098810 </td> <td style=“text-align:left;”> neurotransmitter reuptake </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 3.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903430 </td> <td style=“text-align:left;”> negative regulation of cell maturation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032870 </td> <td style=“text-align:left;”> cellular response to hormone stimulus </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 449 </td> <td style=“text-align:left;”> 3.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043299 </td> <td style=“text-align:left;”> leukocyte degranulation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 3.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010746 </td> <td style=“text-align:left;”> regulation of long-chain fatty acid import across plasma membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903321 </td> <td style=“text-align:left;”> negative regulation of protein modification by small protein conjugation or removal </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 86 </td> <td style=“text-align:left;”> 3.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006611 </td> <td style=“text-align:left;”> protein export from nucleus </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 3.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0106056 </td> <td style=“text-align:left;”> regulation of calcineurin-mediated signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 3.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000729 </td> <td style=“text-align:left;”> DNA double-strand break processing </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 3.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0040011 </td> <td style=“text-align:left;”> locomotion </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 854 </td> <td style=“text-align:left;”> 3.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009157 </td> <td style=“text-align:left;”> deoxyribonucleoside monophosphate biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 3.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090313 </td> <td style=“text-align:left;”> regulation of protein targeting to membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 3.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901463 </td> <td style=“text-align:left;”> regulation of tetrapyrrole biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000625 </td> <td style=“text-align:left;”> regulation of miRNA catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007205 </td> <td style=“text-align:left;”> protein kinase C-activating G protein-coupled receptor signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 3.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060438 </td> <td style=“text-align:left;”> trachea development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 3.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051047 </td> <td style=“text-align:left;”> positive regulation of secretion </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 209 </td> <td style=“text-align:left;”> 3.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016573 </td> <td style=“text-align:left;”> histone acetylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 110 </td> <td style=“text-align:left;”> 3.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046339 </td> <td style=“text-align:left;”> diacylglycerol metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 3.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050779 </td> <td style=“text-align:left;”> RNA destabilization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 95 </td> <td style=“text-align:left;”> 3.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001919 </td> <td style=“text-align:left;”> regulation of receptor recycling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 3.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000197 </td> <td style=“text-align:left;”> regulation of ribonucleoprotein complex localization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 3.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061014 </td> <td style=“text-align:left;”> positive regulation of mRNA catabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 96 </td> <td style=“text-align:left;”> 3.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070453 </td> <td style=“text-align:left;”> regulation of heme biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905897 </td> <td style=“text-align:left;”> regulation of response to endoplasmic reticulum stress </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 76 </td> <td style=“text-align:left;”> 3.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032434 </td> <td style=“text-align:left;”> regulation of proteasomal ubiquitin-dependent protein catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 130 </td> <td style=“text-align:left;”> 3.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030071 </td> <td style=“text-align:left;”> regulation of mitotic metaphase/anaphase transition </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 87 </td> <td style=“text-align:left;”> 3.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042127 </td> <td style=“text-align:left;”> regulation of cell population proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1568 </td> <td style=“text-align:left;”> 3.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903441 </td> <td style=“text-align:left;”> protein localization to ciliary membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 3.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071549 </td> <td style=“text-align:left;”> cellular response to dexamethasone stimulus </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 3.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051293 </td> <td style=“text-align:left;”> establishment of spindle localization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 3.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045935 </td> <td style=“text-align:left;”> positive regulation of nucleobase-containing compound metabolic process </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:right;”> 1589 </td> <td style=“text-align:left;”> 3.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043038 </td> <td style=“text-align:left;”> amino acid activation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 3.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051875 </td> <td style=“text-align:left;”> pigment granule localization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 3.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014902 </td> <td style=“text-align:left;”> myotube differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 88 </td> <td style=“text-align:left;”> 3.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045089 </td> <td style=“text-align:left;”> positive regulation of innate immune response </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 207 </td> <td style=“text-align:left;”> 3.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034316 </td> <td style=“text-align:left;”> negative regulation of Arp2/3 complex-mediated actin nucleation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003013 </td> <td style=“text-align:left;”> circulatory system process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 445 </td> <td style=“text-align:left;”> 3.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006400 </td> <td style=“text-align:left;”> tRNA modification </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 93 </td> <td style=“text-align:left;”> 3.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007289 </td> <td style=“text-align:left;”> spermatid nucleus differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 3.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033864 </td> <td style=“text-align:left;”> positive regulation of NAD(P)H oxidase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 3.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006771 </td> <td style=“text-align:left;”> riboflavin metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902108 </td> <td style=“text-align:left;”> regulation of mitochondrial membrane permeability involved in apoptotic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 3.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032438 </td> <td style=“text-align:left;”> melanosome organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 3.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090322 </td> <td style=“text-align:left;”> regulation of superoxide metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 3.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035794 </td> <td style=“text-align:left;”> positive regulation of mitochondrial membrane permeability </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 3.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071634 </td> <td style=“text-align:left;”> regulation of transforming growth factor beta production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 3.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042594 </td> <td style=“text-align:left;”> response to starvation </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 176 </td> <td style=“text-align:left;”> 3.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003205 </td> <td style=“text-align:left;”> cardiac chamber development </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 150 </td> <td style=“text-align:left;”> 3.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048087 </td> <td style=“text-align:left;”> positive regulation of developmental pigmentation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045721 </td> <td style=“text-align:left;”> negative regulation of gluconeogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 3.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043647 </td> <td style=“text-align:left;”> inositol phosphate metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 3.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900153 </td> <td style=“text-align:left;”> positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 3.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000209 </td> <td style=“text-align:left;”> protein polyubiquitination </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 238 </td> <td style=“text-align:left;”> 3.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905634 </td> <td style=“text-align:left;”> regulation of protein localization to chromatin </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 3.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010155 </td> <td style=“text-align:left;”> regulation of proton transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 3.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030262 </td> <td style=“text-align:left;”> apoptotic nuclear changes </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 3.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010799 </td> <td style=“text-align:left;”> regulation of peptidyl-threonine phosphorylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 3.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901385 </td> <td style=“text-align:left;”> regulation of voltage-gated calcium channel activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 3.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035456 </td> <td style=“text-align:left;”> response to interferon-beta </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 3.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051788 </td> <td style=“text-align:left;”> response to misfolded protein </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 3.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097116 </td> <td style=“text-align:left;”> gephyrin clustering involved in postsynaptic density assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032728 </td> <td style=“text-align:left;”> positive regulation of interferon-beta production </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 3.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042797 </td> <td style=“text-align:left;”> tRNA transcription by RNA polymerase III </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 3.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048630 </td> <td style=“text-align:left;”> skeletal muscle tissue growth </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 3.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014889 </td> <td style=“text-align:left;”> muscle atrophy </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 3.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071385 </td> <td style=“text-align:left;”> cellular response to glucocorticoid stimulus </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 3.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010562 </td> <td style=“text-align:left;”> positive regulation of phosphorus metabolic process </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 559 </td> <td style=“text-align:left;”> 3.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045937 </td> <td style=“text-align:left;”> positive regulation of phosphate metabolic process </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 559 </td> <td style=“text-align:left;”> 3.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048489 </td> <td style=“text-align:left;”> synaptic vesicle transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 3.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048753 </td> <td style=“text-align:left;”> pigment granule organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 3.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140467 </td> <td style=“text-align:left;”> integrated stress response signaling </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 3.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000819 </td> <td style=“text-align:left;”> regulation of nucleotide-excision repair </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 3.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006825 </td> <td style=“text-align:left;”> copper ion transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 3.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034502 </td> <td style=“text-align:left;”> protein localization to chromosome </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 101 </td> <td style=“text-align:left;”> 3.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000722 </td> <td style=“text-align:left;”> telomere maintenance via recombination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 3.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033674 </td> <td style=“text-align:left;”> positive regulation of kinase activity </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 307 </td> <td style=“text-align:left;”> 3.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051383 </td> <td style=“text-align:left;”> kinetochore organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 3.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050435 </td> <td style=“text-align:left;”> amyloid-beta metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 3.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034499 </td> <td style=“text-align:left;”> late endosome to Golgi transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 3.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051603 </td> <td style=“text-align:left;”> proteolysis involved in protein catabolic process </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:right;”> 712 </td> <td style=“text-align:left;”> 3.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902165 </td> <td style=“text-align:left;”> regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 3.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061724 </td> <td style=“text-align:left;”> lipophagy </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042759 </td> <td style=“text-align:left;”> long-chain fatty acid biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 3.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072089 </td> <td style=“text-align:left;”> stem cell proliferation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 84 </td> <td style=“text-align:left;”> 3.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090257 </td> <td style=“text-align:left;”> regulation of muscle system process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 180 </td> <td style=“text-align:left;”> 3.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090179 </td> <td style=“text-align:left;”> planar cell polarity pathway involved in neural tube closure </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 3.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050805 </td> <td style=“text-align:left;”> negative regulation of synaptic transmission </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 3.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046530 </td> <td style=“text-align:left;”> photoreceptor cell differentiation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 3.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006110 </td> <td style=“text-align:left;”> regulation of glycolytic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 3.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031349 </td> <td style=“text-align:left;”> positive regulation of defense response </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 273 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050890 </td> <td style=“text-align:left;”> cognition </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 226 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034340 </td> <td style=“text-align:left;”> response to type I interferon </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 60 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032677 </td> <td style=“text-align:left;”> regulation of interleukin-8 production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051657 </td> <td style=“text-align:left;”> maintenance of organelle location </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032637 </td> <td style=“text-align:left;”> interleukin-8 production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043501 </td> <td style=“text-align:left;”> skeletal muscle adaptation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021983 </td> <td style=“text-align:left;”> pituitary gland development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006355 </td> <td style=“text-align:left;”> regulation of DNA-templated transcription </td> <td style=“text-align:right;”> 80 </td> <td style=“text-align:right;”> 2560 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099170 </td> <td style=“text-align:left;”> postsynaptic modulation of chemical synaptic transmission </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042795 </td> <td style=“text-align:left;”> snRNA transcription by RNA polymerase II </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006508 </td> <td style=“text-align:left;”> proteolysis </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 1310 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048757 </td> <td style=“text-align:left;”> pigment granule maturation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007519 </td> <td style=“text-align:left;”> skeletal muscle tissue development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 129 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035646 </td> <td style=“text-align:left;”> endosome to melanosome transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046622 </td> <td style=“text-align:left;”> positive regulation of organ growth </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905214 </td> <td style=“text-align:left;”> regulation of RNA binding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043485 </td> <td style=“text-align:left;”> endosome to pigment granule transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031063 </td> <td style=“text-align:left;”> regulation of histone deacetylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016049 </td> <td style=“text-align:left;”> cell growth </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:right;”> 416 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060633 </td> <td style=“text-align:left;”> negative regulation of transcription initiation by RNA polymerase II </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006893 </td> <td style=“text-align:left;”> Golgi to plasma membrane transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014904 </td> <td style=“text-align:left;”> myotube cell development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033673 </td> <td style=“text-align:left;”> negative regulation of kinase activity </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 191 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036353 </td> <td style=“text-align:left;”> histone H2A-K119 monoubiquitination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033173 </td> <td style=“text-align:left;”> calcineurin-NFAT signaling cascade </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050790 </td> <td style=“text-align:left;”> regulation of catalytic activity </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 1349 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032506 </td> <td style=“text-align:left;”> cytokinetic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045722 </td> <td style=“text-align:left;”> positive regulation of gluconeogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034472 </td> <td style=“text-align:left;”> snRNA 3’-end processing </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901021 </td> <td style=“text-align:left;”> positive regulation of calcium ion transmembrane transporter activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035930 </td> <td style=“text-align:left;”> corticosteroid hormone secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033151 </td> <td style=“text-align:left;”> V(D)J recombination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904814 </td> <td style=“text-align:left;”> regulation of protein localization to chromosome, telomeric region </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021892 </td> <td style=“text-align:left;”> cerebral cortex GABAergic interneuron differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071569 </td> <td style=“text-align:left;”> protein ufmylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 3.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018393 </td> <td style=“text-align:left;”> internal peptidyl-lysine acetylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 114 </td> <td style=“text-align:left;”> 4.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048242 </td> <td style=“text-align:left;”> epinephrine secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 4.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006515 </td> <td style=“text-align:left;”> protein quality control for misfolded or incompletely synthesized proteins </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 4.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014060 </td> <td style=“text-align:left;”> regulation of epinephrine secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 4.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071604 </td> <td style=“text-align:left;”> transforming growth factor beta production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 4.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003002 </td> <td style=“text-align:left;”> regionalization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 271 </td> <td style=“text-align:left;”> 4.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030501 </td> <td style=“text-align:left;”> positive regulation of bone mineralization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 4.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0038173 </td> <td style=“text-align:left;”> interleukin-17A-mediated signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 4.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071417 </td> <td style=“text-align:left;”> cellular response to organonitrogen compound </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 471 </td> <td style=“text-align:left;”> 4.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097120 </td> <td style=“text-align:left;”> receptor localization to synapse </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 4.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090200 </td> <td style=“text-align:left;”> positive regulation of release of cytochrome c from mitochondria </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 4.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019262 </td> <td style=“text-align:left;”> N-acetylneuraminate catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 4.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097292 </td> <td style=“text-align:left;”> XMP metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 4.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001258 </td> <td style=“text-align:left;”> negative regulation of cation channel activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 4.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0039530 </td> <td style=“text-align:left;”> MDA-5 signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 4.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097293 </td> <td style=“text-align:left;”> XMP biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 4.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051932 </td> <td style=“text-align:left;”> synaptic transmission, GABAergic </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 4.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097294 </td> <td style=“text-align:left;”> ‘de novo’ XMP biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 4.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034109 </td> <td style=“text-align:left;”> homotypic cell-cell adhesion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 4.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903169 </td> <td style=“text-align:left;”> regulation of calcium ion transmembrane transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 120 </td> <td style=“text-align:left;”> 4.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097484 </td> <td style=“text-align:left;”> dendrite extension </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 4.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060964 </td> <td style=“text-align:left;”> regulation of miRNA-mediated gene silencing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 4.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902099 </td> <td style=“text-align:left;”> regulation of metaphase/anaphase transition of cell cycle </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 88 </td> <td style=“text-align:left;”> 4.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042149 </td> <td style=“text-align:left;”> cellular response to glucose starvation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 4.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051497 </td> <td style=“text-align:left;”> negative regulation of stress fiber assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 4.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009200 </td> <td style=“text-align:left;”> deoxyribonucleoside triphosphate metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 4.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903426 </td> <td style=“text-align:left;”> regulation of reactive oxygen species biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 4.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032197 </td> <td style=“text-align:left;”> retrotransposition </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 4.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031953 </td> <td style=“text-align:left;”> negative regulation of protein autophosphorylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 4.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014046 </td> <td style=“text-align:left;”> dopamine secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 4.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032606 </td> <td style=“text-align:left;”> type I interferon production </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 87 </td> <td style=“text-align:left;”> 4.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032479 </td> <td style=“text-align:left;”> regulation of type I interferon production </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 87 </td> <td style=“text-align:left;”> 4.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097300 </td> <td style=“text-align:left;”> programmed necrotic cell death </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 4.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031023 </td> <td style=“text-align:left;”> microtubule organizing center organization </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 139 </td> <td style=“text-align:left;”> 4.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070887 </td> <td style=“text-align:left;”> cellular response to chemical stimulus </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 1857 </td> <td style=“text-align:left;”> 4.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035306 </td> <td style=“text-align:left;”> positive regulation of dephosphorylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 4.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045197 </td> <td style=“text-align:left;”> establishment or maintenance of epithelial cell apical/basal polarity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 4.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006475 </td> <td style=“text-align:left;”> internal protein amino acid acetylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 116 </td> <td style=“text-align:left;”> 4.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051246 </td> <td style=“text-align:left;”> regulation of protein metabolic process </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:right;”> 1895 </td> <td style=“text-align:left;”> 4.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042596 </td> <td style=“text-align:left;”> fear response </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 4.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046605 </td> <td style=“text-align:left;”> regulation of centrosome cycle </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 4.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006888 </td> <td style=“text-align:left;”> endoplasmic reticulum to Golgi vesicle-mediated transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 118 </td> <td style=“text-align:left;”> 4.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048261 </td> <td style=“text-align:left;”> negative regulation of receptor-mediated endocytosis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 4.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0039536 </td> <td style=“text-align:left;”> negative regulation of RIG-I signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 4.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010962 </td> <td style=“text-align:left;”> regulation of glucan biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 4.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0005979 </td> <td style=“text-align:left;”> regulation of glycogen biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 4.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006112 </td> <td style=“text-align:left;”> energy reserve metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 72 </td> <td style=“text-align:left;”> 4.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042274 </td> <td style=“text-align:left;”> ribosomal small subunit biogenesis </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 102 </td> <td style=“text-align:left;”> 4.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001914 </td> <td style=“text-align:left;”> regulation of T cell mediated cytotoxicity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 4.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071459 </td> <td style=“text-align:left;”> protein localization to chromosome, centromeric region </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 4.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010255 </td> <td style=“text-align:left;”> glucose mediated signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 4.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042987 </td> <td style=“text-align:left;”> amyloid precursor protein catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 4.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009757 </td> <td style=“text-align:left;”> hexose mediated signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 4.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010182 </td> <td style=“text-align:left;”> sugar mediated signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 4.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010863 </td> <td style=“text-align:left;”> positive regulation of phospholipase C activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 4.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001269 </td> <td style=“text-align:left;”> positive regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 4.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0039694 </td> <td style=“text-align:left;”> viral RNA genome replication </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 4.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006880 </td> <td style=“text-align:left;”> intracellular sequestering of iron ion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 4.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901401 </td> <td style=“text-align:left;”> regulation of tetrapyrrole metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 4.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045837 </td> <td style=“text-align:left;”> negative regulation of membrane potential </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 4.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035556 </td> <td style=“text-align:left;”> intracellular signal transduction </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:right;”> 2036 </td> <td style=“text-align:left;”> 4.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045136 </td> <td style=“text-align:left;”> development of secondary sexual characteristics </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 4.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043653 </td> <td style=“text-align:left;”> mitochondrial fragmentation involved in apoptotic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 4.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010917 </td> <td style=“text-align:left;”> negative regulation of mitochondrial membrane potential </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 4.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033211 </td> <td style=“text-align:left;”> adiponectin-activated signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 4.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030178 </td> <td style=“text-align:left;”> negative regulation of Wnt signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 140 </td> <td style=“text-align:left;”> 4.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000772 </td> <td style=“text-align:left;”> regulation of cellular senescence </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 4.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007091 </td> <td style=“text-align:left;”> metaphase/anaphase transition of mitotic cell cycle </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 91 </td> <td style=“text-align:left;”> 4.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051147 </td> <td style=“text-align:left;”> regulation of muscle cell differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 118 </td> <td style=“text-align:left;”> 4.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000278 </td> <td style=“text-align:left;”> regulation of DNA biosynthetic process </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 110 </td> <td style=“text-align:left;”> 4.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006921 </td> <td style=“text-align:left;”> cellular component disassembly involved in execution phase of apoptosis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 4.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090178 </td> <td style=“text-align:left;”> regulation of establishment of planar polarity involved in neural tube closure </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 4.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990090 </td> <td style=“text-align:left;”> cellular response to nerve growth factor stimulus </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 4.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000647 </td> <td style=“text-align:left;”> negative regulation of stem cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 4.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045862 </td> <td style=“text-align:left;”> positive regulation of proteolysis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 289 </td> <td style=“text-align:left;”> 4.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097720 </td> <td style=“text-align:left;”> calcineurin-mediated signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 4.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098703 </td> <td style=“text-align:left;”> calcium ion import across plasma membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 4.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006487 </td> <td style=“text-align:left;”> protein N-linked glycosylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 65 </td> <td style=“text-align:left;”> 4.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048701 </td> <td style=“text-align:left;”> embryonic cranial skeleton morphogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 4.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051480 </td> <td style=“text-align:left;”> regulation of cytosolic calcium ion concentration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 4.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030575 </td> <td style=“text-align:left;”> nuclear body organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 4.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002252 </td> <td style=“text-align:left;”> immune effector process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 325 </td> <td style=“text-align:left;”> 4.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031056 </td> <td style=“text-align:left;”> regulation of histone modification </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 76 </td> <td style=“text-align:left;”> 4.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901699 </td> <td style=“text-align:left;”> cellular response to nitrogen compound </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 502 </td> <td style=“text-align:left;”> 4.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061158 </td> <td style=“text-align:left;”> 3’-UTR-mediated mRNA destabilization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 4.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006353 </td> <td style=“text-align:left;”> DNA-templated transcription termination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 4.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035722 </td> <td style=“text-align:left;”> interleukin-12-mediated signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 4.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900244 </td> <td style=“text-align:left;”> positive regulation of synaptic vesicle endocytosis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 4.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043085 </td> <td style=“text-align:left;”> positive regulation of catalytic activity </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 815 </td> <td style=“text-align:left;”> 4.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990138 </td> <td style=“text-align:left;”> neuron projection extension </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 149 </td> <td style=“text-align:left;”> 4.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055010 </td> <td style=“text-align:left;”> ventricular cardiac muscle tissue morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 4.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032103 </td> <td style=“text-align:left;”> positive regulation of response to external stimulus </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 360 </td> <td style=“text-align:left;”> 4.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051154 </td> <td style=“text-align:left;”> negative regulation of striated muscle cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 4.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048534 </td> <td style=“text-align:left;”> hematopoietic or lymphoid organ development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 71 </td> <td style=“text-align:left;”> 4.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900368 </td> <td style=“text-align:left;”> regulation of post-transcriptional gene silencing by regulatory ncRNA </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 4.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006451 </td> <td style=“text-align:left;”> translational readthrough </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 4.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071166 </td> <td style=“text-align:left;”> ribonucleoprotein complex localization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 4.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901223 </td> <td style=“text-align:left;”> negative regulation of non-canonical NF-kappaB signal transduction </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 4.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001514 </td> <td style=“text-align:left;”> selenocysteine incorporation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 4.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901874 </td> <td style=“text-align:left;”> negative regulation of post-translational protein modification </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 98 </td> <td style=“text-align:left;”> 4.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033619 </td> <td style=“text-align:left;”> membrane protein proteolysis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 4.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071233 </td> <td style=“text-align:left;”> cellular response to leucine </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 4.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035966 </td> <td style=“text-align:left;”> response to topologically incorrect protein </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 148 </td> <td style=“text-align:left;”> 4.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905710 </td> <td style=“text-align:left;”> positive regulation of membrane permeability </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 4.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015800 </td> <td style=“text-align:left;”> acidic amino acid transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 4.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903170 </td> <td style=“text-align:left;”> negative regulation of calcium ion transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 4.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032446 </td> <td style=“text-align:left;”> protein modification by small protein conjugation </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 759 </td> <td style=“text-align:left;”> 4.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000629 </td> <td style=“text-align:left;”> negative regulation of miRNA metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 4.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015866 </td> <td style=“text-align:left;”> ADP transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 4.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035845 </td> <td style=“text-align:left;”> photoreceptor cell outer segment organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 4.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006644 </td> <td style=“text-align:left;”> phospholipid metabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 309 </td> <td style=“text-align:left;”> 4.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032011 </td> <td style=“text-align:left;”> ARF protein signal transduction </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 4.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032012 </td> <td style=“text-align:left;”> regulation of ARF protein signal transduction </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 4.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900274 </td> <td style=“text-align:left;”> regulation of phospholipase C activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 4.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031668 </td> <td style=“text-align:left;”> cellular response to extracellular stimulus </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 223 </td> <td style=“text-align:left;”> 4.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061383 </td> <td style=“text-align:left;”> trabecula morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 4.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070050 </td> <td style=“text-align:left;”> neuron cellular homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 4.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010595 </td> <td style=“text-align:left;”> positive regulation of endothelial cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 94 </td> <td style=“text-align:left;”> 4.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001141 </td> <td style=“text-align:left;”> regulation of RNA biosynthetic process </td> <td style=“text-align:right;”> 80 </td> <td style=“text-align:right;”> 2577 </td> <td style=“text-align:left;”> 4.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006833 </td> <td style=“text-align:left;”> water transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 4.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046602 </td> <td style=“text-align:left;”> regulation of mitotic centrosome separation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 4.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140894 </td> <td style=“text-align:left;”> endolysosomal toll-like receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 4.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051653 </td> <td style=“text-align:left;”> spindle localization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 4.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006650 </td> <td style=“text-align:left;”> glycerophospholipid metabolic process </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:right;”> 245 </td> <td style=“text-align:left;”> 4.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060147 </td> <td style=“text-align:left;”> regulation of post-transcriptional gene silencing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 4.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051179 </td> <td style=“text-align:left;”> localization </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 3983 </td> <td style=“text-align:left;”> 4.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060538 </td> <td style=“text-align:left;”> skeletal muscle organ development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 138 </td> <td style=“text-align:left;”> 4.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0040016 </td> <td style=“text-align:left;”> embryonic cleavage </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 4.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007389 </td> <td style=“text-align:left;”> pattern specification process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 304 </td> <td style=“text-align:left;”> 4.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099518 </td> <td style=“text-align:left;”> vesicle cytoskeletal trafficking </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 61 </td> <td style=“text-align:left;”> 4.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006672 </td> <td style=“text-align:left;”> ceramide metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 81 </td> <td style=“text-align:left;”> 4.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016310 </td> <td style=“text-align:left;”> phosphorylation </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:right;”> 1338 </td> <td style=“text-align:left;”> 4.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071500 </td> <td style=“text-align:left;”> cellular response to nitrosative stress </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 4.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050730 </td> <td style=“text-align:left;”> regulation of peptidyl-tyrosine phosphorylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 160 </td> <td style=“text-align:left;”> 4.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042726 </td> <td style=“text-align:left;”> flavin-containing compound metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 4.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000423 </td> <td style=“text-align:left;”> mitophagy </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 4.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060038 </td> <td style=“text-align:left;”> cardiac muscle cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 4.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051125 </td> <td style=“text-align:left;”> regulation of actin nucleation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 4.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043502 </td> <td style=“text-align:left;”> regulation of muscle adaptation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 68 </td> <td style=“text-align:left;”> 4.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002833 </td> <td style=“text-align:left;”> positive regulation of response to biotic stimulus </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 218 </td> <td style=“text-align:left;”> 4.15e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072578 </td> <td style=“text-align:left;”> neurotransmitter-gated ion channel clustering </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 4.15e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001242 </td> <td style=“text-align:left;”> regulation of intrinsic apoptotic signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 156 </td> <td style=“text-align:left;”> 4.15e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000378 </td> <td style=“text-align:left;”> negative regulation of reactive oxygen species metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 4.15e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046486 </td> <td style=“text-align:left;”> glycerolipid metabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 304 </td> <td style=“text-align:left;”> 4.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032232 </td> <td style=“text-align:left;”> negative regulation of actin filament bundle assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 4.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043087 </td> <td style=“text-align:left;”> regulation of GTPase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 288 </td> <td style=“text-align:left;”> 4.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010032 </td> <td style=“text-align:left;”> meiotic chromosome condensation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 4.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051491 </td> <td style=“text-align:left;”> positive regulation of filopodium assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 4.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002244 </td> <td style=“text-align:left;”> hematopoietic progenitor cell differentiation </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 108 </td> <td style=“text-align:left;”> 4.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903573 </td> <td style=“text-align:left;”> negative regulation of response to endoplasmic reticulum stress </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 4.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070059 </td> <td style=“text-align:left;”> intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 4.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904037 </td> <td style=“text-align:left;”> positive regulation of epithelial cell apoptotic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 4.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990542 </td> <td style=“text-align:left;”> mitochondrial transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 57 </td> <td style=“text-align:left;”> 4.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990089 </td> <td style=“text-align:left;”> response to nerve growth factor </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 4.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000058 </td> <td style=“text-align:left;”> regulation of ubiquitin-dependent protein catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 157 </td> <td style=“text-align:left;”> 4.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904936 </td> <td style=“text-align:left;”> interneuron migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 4.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021819 </td> <td style=“text-align:left;”> layer formation in cerebral cortex </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 4.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090177 </td> <td style=“text-align:left;”> establishment of planar polarity involved in neural tube closure </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 4.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060966 </td> <td style=“text-align:left;”> regulation of gene silencing by regulatory ncRNA </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 4.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032196 </td> <td style=“text-align:left;”> transposition </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 4.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046879 </td> <td style=“text-align:left;”> hormone secretion </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 212 </td> <td style=“text-align:left;”> 4.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009790 </td> <td style=“text-align:left;”> embryo development </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 859 </td> <td style=“text-align:left;”> 4.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001504 </td> <td style=“text-align:left;”> neurotransmitter uptake </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 4.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000143 </td> <td style=“text-align:left;”> negative regulation of DNA-templated transcription initiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 4.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030148 </td> <td style=“text-align:left;”> sphingolipid biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 87 </td> <td style=“text-align:left;”> 4.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000831 </td> <td style=“text-align:left;”> regulation of steroid hormone secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 4.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031929 </td> <td style=“text-align:left;”> TOR signaling </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 120 </td> <td style=“text-align:left;”> 4.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042981 </td> <td style=“text-align:left;”> regulation of apoptotic process </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:right;”> 1092 </td> <td style=“text-align:left;”> 4.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061726 </td> <td style=“text-align:left;”> mitochondrion disassembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 90 </td> <td style=“text-align:left;”> 4.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044208 </td> <td style=“text-align:left;”> ‘de novo’ AMP biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 4.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000422 </td> <td style=“text-align:left;”> autophagy of mitochondrion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 90 </td> <td style=“text-align:left;”> 4.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044784 </td> <td style=“text-align:left;”> metaphase/anaphase transition of cell cycle </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 92 </td> <td style=“text-align:left;”> 4.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006892 </td> <td style=“text-align:left;”> post-Golgi vesicle-mediated transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 101 </td> <td style=“text-align:left;”> 4.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903034 </td> <td style=“text-align:left;”> regulation of response to wounding </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 123 </td> <td style=“text-align:left;”> 4.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0038179 </td> <td style=“text-align:left;”> neurotrophin signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 4.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003300 </td> <td style=“text-align:left;”> cardiac muscle hypertrophy </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 72 </td> <td style=“text-align:left;”> 4.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006448 </td> <td style=“text-align:left;”> regulation of translational elongation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 4.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071173 </td> <td style=“text-align:left;”> spindle assembly checkpoint signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 4.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034389 </td> <td style=“text-align:left;”> lipid droplet organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 4.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071816 </td> <td style=“text-align:left;”> tail-anchored membrane protein insertion into ER membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 4.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045589 </td> <td style=“text-align:left;”> regulation of regulatory T cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 4.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007094 </td> <td style=“text-align:left;”> mitotic spindle assembly checkpoint signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 4.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071174 </td> <td style=“text-align:left;”> mitotic spindle checkpoint signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 4.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000712 </td> <td style=“text-align:left;”> resolution of meiotic recombination intermediates </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 4.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001188 </td> <td style=“text-align:left;”> RNA polymerase I preinitiation complex assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 4.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015074 </td> <td style=“text-align:left;”> DNA integration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 4.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009301 </td> <td style=“text-align:left;”> snRNA transcription </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 4.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097178 </td> <td style=“text-align:left;”> ruffle assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 4.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904427 </td> <td style=“text-align:left;”> positive regulation of calcium ion transmembrane transport </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 59 </td> <td style=“text-align:left;”> 4.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030010 </td> <td style=“text-align:left;”> establishment of cell polarity </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 135 </td> <td style=“text-align:left;”> 4.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098586 </td> <td style=“text-align:left;”> cellular response to virus </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 4.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090084 </td> <td style=“text-align:left;”> negative regulation of inclusion body assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 4.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006307 </td> <td style=“text-align:left;”> DNA dealkylation involved in DNA repair </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 4.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903367 </td> <td style=“text-align:left;”> positive regulation of fear response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 4.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031060 </td> <td style=“text-align:left;”> regulation of histone methylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 4.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060998 </td> <td style=“text-align:left;”> regulation of dendritic spine development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 52 </td> <td style=“text-align:left;”> 4.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071470 </td> <td style=“text-align:left;”> cellular response to osmotic stress </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 4.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043482 </td> <td style=“text-align:left;”> cellular pigment accumulation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 4.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055021 </td> <td style=“text-align:left;”> regulation of cardiac muscle tissue growth </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 4.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043476 </td> <td style=“text-align:left;”> pigment accumulation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 4.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902895 </td> <td style=“text-align:left;”> positive regulation of miRNA transcription </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 4.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043009 </td> <td style=“text-align:left;”> chordate embryonic development </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:right;”> 525 </td> <td style=“text-align:left;”> 4.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901185 </td> <td style=“text-align:left;”> negative regulation of ERBB signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 4.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031577 </td> <td style=“text-align:left;”> spindle checkpoint signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 4.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045655 </td> <td style=“text-align:left;”> regulation of monocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 4.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070383 </td> <td style=“text-align:left;”> DNA cytosine deamination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 4.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140212 </td> <td style=“text-align:left;”> regulation of long-chain fatty acid import into cell </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061245 </td> <td style=“text-align:left;”> establishment or maintenance of bipolar cell polarity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032331 </td> <td style=“text-align:left;”> negative regulation of chondrocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014075 </td> <td style=“text-align:left;”> response to amine </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043473 </td> <td style=“text-align:left;”> pigmentation </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 92 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034198 </td> <td style=“text-align:left;”> cellular response to amino acid starvation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 47 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007281 </td> <td style=“text-align:left;”> germ cell development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 194 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007369 </td> <td style=“text-align:left;”> gastrulation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 147 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035088 </td> <td style=“text-align:left;”> establishment or maintenance of apical/basal cell polarity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015936 </td> <td style=“text-align:left;”> coenzyme A metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009247 </td> <td style=“text-align:left;”> glycolipid biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 62 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990253 </td> <td style=“text-align:left;”> cellular response to leucine starvation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060218 </td> <td style=“text-align:left;”> hematopoietic stem cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007163 </td> <td style=“text-align:left;”> establishment or maintenance of cell polarity </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 197 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061387 </td> <td style=“text-align:left;”> regulation of extent of cell growth </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 96 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021543 </td> <td style=“text-align:left;”> pallium development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 146 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045778 </td> <td style=“text-align:left;”> positive regulation of ossification </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051494 </td> <td style=“text-align:left;”> negative regulation of cytoskeleton organization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 136 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097306 </td> <td style=“text-align:left;”> cellular response to alcohol </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 72 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045841 </td> <td style=“text-align:left;”> negative regulation of mitotic metaphase/anaphase transition </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002707 </td> <td style=“text-align:left;”> negative regulation of lymphocyte mediated immunity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033046 </td> <td style=“text-align:left;”> negative regulation of sister chromatid segregation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043276 </td> <td style=“text-align:left;”> anoikis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022038 </td> <td style=“text-align:left;”> corpus callosum development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0065009 </td> <td style=“text-align:left;”> regulation of molecular function </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:right;”> 1905 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033048 </td> <td style=“text-align:left;”> negative regulation of mitotic sister chromatid segregation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071313 </td> <td style=“text-align:left;”> cellular response to caffeine </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014897 </td> <td style=“text-align:left;”> striated muscle hypertrophy </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 73 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099566 </td> <td style=“text-align:left;”> regulation of postsynaptic cytosolic calcium ion concentration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000816 </td> <td style=“text-align:left;”> negative regulation of mitotic sister chromatid separation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006259 </td> <td style=“text-align:left;”> DNA metabolic process </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:right;”> 886 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001913 </td> <td style=“text-align:left;”> T cell mediated cytotoxicity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015850 </td> <td style=“text-align:left;”> organic hydroxy compound transport </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 181 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031623 </td> <td style=“text-align:left;”> receptor internalization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 98 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002275 </td> <td style=“text-align:left;”> myeloid cell activation involved in immune response </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 47 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009755 </td> <td style=“text-align:left;”> hormone-mediated signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 142 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030307 </td> <td style=“text-align:left;”> positive regulation of cell growth </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 132 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007229 </td> <td style=“text-align:left;”> integrin-mediated signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 87 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097577 </td> <td style=“text-align:left;”> sequestering of iron ion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000008 </td> <td style=“text-align:left;”> regulation of protein localization to cell surface </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008089 </td> <td style=“text-align:left;”> anterograde axonal transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034341 </td> <td style=“text-align:left;”> response to type II interferon </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 82 </td> <td style=“text-align:left;”> 4.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904779 </td> <td style=“text-align:left;”> regulation of protein localization to centrosome </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 4.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051220 </td> <td style=“text-align:left;”> cytoplasmic sequestering of protein </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 4.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033137 </td> <td style=“text-align:left;”> negative regulation of peptidyl-serine phosphorylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 4.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0086064 </td> <td style=“text-align:left;”> cell communication by electrical coupling involved in cardiac conduction </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 4.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033235 </td> <td style=“text-align:left;”> positive regulation of protein sumoylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 4.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009914 </td> <td style=“text-align:left;”> hormone transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 217 </td> <td style=“text-align:left;”> 4.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060627 </td> <td style=“text-align:left;”> regulation of vesicle-mediated transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 397 </td> <td style=“text-align:left;”> 4.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070169 </td> <td style=“text-align:left;”> positive regulation of biomineral tissue development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 4.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032868 </td> <td style=“text-align:left;”> response to insulin </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 210 </td> <td style=“text-align:left;”> 4.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051382 </td> <td style=“text-align:left;”> kinetochore assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 4.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014896 </td> <td style=“text-align:left;”> muscle hypertrophy </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 4.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902254 </td> <td style=“text-align:left;”> negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 4.30e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051338 </td> <td style=“text-align:left;”> regulation of transferase activity </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 664 </td> <td style=“text-align:left;”> 4.30e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060071 </td> <td style=“text-align:left;”> Wnt signaling pathway, planar cell polarity pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 4.30e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009170 </td> <td style=“text-align:left;”> purine deoxyribonucleoside monophosphate metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 4.30e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043549 </td> <td style=“text-align:left;”> regulation of kinase activity </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 548 </td> <td style=“text-align:left;”> 4.30e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016477 </td> <td style=“text-align:left;”> cell migration </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 1065 </td> <td style=“text-align:left;”> 4.30e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070873 </td> <td style=“text-align:left;”> regulation of glycogen metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 4.30e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051402 </td> <td style=“text-align:left;”> neuron apoptotic process </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 211 </td> <td style=“text-align:left;”> 4.30e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009120 </td> <td style=“text-align:left;”> deoxyribonucleoside metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 4.30e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032261 </td> <td style=“text-align:left;”> purine nucleotide salvage </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 4.30e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030865 </td> <td style=“text-align:left;”> cortical cytoskeleton organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 4.30e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072583 </td> <td style=“text-align:left;”> clathrin-dependent endocytosis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 4.30e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090092 </td> <td style=“text-align:left;”> regulation of transmembrane receptor protein serine/threonine kinase signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 211 </td> <td style=“text-align:left;”> 4.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002791 </td> <td style=“text-align:left;”> regulation of peptide secretion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 137 </td> <td style=“text-align:left;”> 4.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030968 </td> <td style=“text-align:left;”> endoplasmic reticulum unfolded protein response </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 4.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031122 </td> <td style=“text-align:left;”> cytoplasmic microtubule organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 4.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0086003 </td> <td style=“text-align:left;”> cardiac muscle cell contraction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 67 </td> <td style=“text-align:left;”> 4.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903539 </td> <td style=“text-align:left;”> protein localization to postsynaptic membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 4.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902510 </td> <td style=“text-align:left;”> regulation of apoptotic DNA fragmentation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 4.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002823 </td> <td style=“text-align:left;”> negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 4.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051222 </td> <td style=“text-align:left;”> positive regulation of protein transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 245 </td> <td style=“text-align:left;”> 4.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006402 </td> <td style=“text-align:left;”> mRNA catabolic process </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 220 </td> <td style=“text-align:left;”> 4.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007175 </td> <td style=“text-align:left;”> negative regulation of epidermal growth factor-activated receptor activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 4.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071392 </td> <td style=“text-align:left;”> cellular response to estradiol stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 4.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033002 </td> <td style=“text-align:left;”> muscle cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 153 </td> <td style=“text-align:left;”> 4.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902100 </td> <td style=“text-align:left;”> negative regulation of metaphase/anaphase transition of cell cycle </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 4.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051985 </td> <td style=“text-align:left;”> negative regulation of chromosome segregation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 4.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905819 </td> <td style=“text-align:left;”> negative regulation of chromosome separation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 4.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090087 </td> <td style=“text-align:left;”> regulation of peptide transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 139 </td> <td style=“text-align:left;”> 4.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032727 </td> <td style=“text-align:left;”> positive regulation of interferon-alpha production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 4.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061178 </td> <td style=“text-align:left;”> regulation of insulin secretion involved in cellular response to glucose stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 4.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003229 </td> <td style=“text-align:left;”> ventricular cardiac muscle tissue development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 4.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010830 </td> <td style=“text-align:left;”> regulation of myotube differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 4.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032885 </td> <td style=“text-align:left;”> regulation of polysaccharide biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 4.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0062237 </td> <td style=“text-align:left;”> protein localization to postsynapse </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 4.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051403 </td> <td style=“text-align:left;”> stress-activated MAPK cascade </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 188 </td> <td style=“text-align:left;”> 4.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036035 </td> <td style=“text-align:left;”> osteoclast development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 4.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098751 </td> <td style=“text-align:left;”> bone cell development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 4.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061003 </td> <td style=“text-align:left;”> positive regulation of dendritic spine morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 4.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0005976 </td> <td style=“text-align:left;”> polysaccharide metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 81 </td> <td style=“text-align:left;”> 4.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010921 </td> <td style=“text-align:left;”> regulation of phosphatase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 4.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0052547 </td> <td style=“text-align:left;”> regulation of peptidase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 265 </td> <td style=“text-align:left;”> 4.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032507 </td> <td style=“text-align:left;”> maintenance of protein location in cell </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 57 </td> <td style=“text-align:left;”> 4.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051897 </td> <td style=“text-align:left;”> positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 78 </td> <td style=“text-align:left;”> 4.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006511 </td> <td style=“text-align:left;”> ubiquitin-dependent protein catabolic process </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:right;”> 618 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046173 </td> <td style=“text-align:left;”> polyol biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 47 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901072 </td> <td style=“text-align:left;”> glucosamine-containing compound catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014874 </td> <td style=“text-align:left;”> response to stimulus involved in regulation of muscle adaptation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060740 </td> <td style=“text-align:left;”> prostate gland epithelium morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006048 </td> <td style=“text-align:left;”> UDP-N-acetylglucosamine biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071333 </td> <td style=“text-align:left;”> cellular response to glucose stimulus </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 95 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045066 </td> <td style=“text-align:left;”> regulatory T cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043416 </td> <td style=“text-align:left;”> regulation of skeletal muscle tissue regeneration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007178 </td> <td style=“text-align:left;”> transmembrane receptor protein serine/threonine kinase signaling pathway </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 298 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009756 </td> <td style=“text-align:left;”> carbohydrate mediated signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901838 </td> <td style=“text-align:left;”> positive regulation of transcription of nucleolar large rRNA by RNA polymerase I </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019432 </td> <td style=“text-align:left;”> triglyceride biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046471 </td> <td style=“text-align:left;”> phosphatidylglycerol metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072665 </td> <td style=“text-align:left;”> protein localization to vacuole </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 73 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009048 </td> <td style=“text-align:left;”> dosage compensation by inactivation of X chromosome </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071349 </td> <td style=“text-align:left;”> cellular response to interleukin-12 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032897 </td> <td style=“text-align:left;”> negative regulation of viral transcription </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050795 </td> <td style=“text-align:left;”> regulation of behavior </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007585 </td> <td style=“text-align:left;”> respiratory gaseous exchange by respiratory system </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055117 </td> <td style=“text-align:left;”> regulation of cardiac muscle contraction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032008 </td> <td style=“text-align:left;”> positive regulation of TOR signaling </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 47 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042088 </td> <td style=“text-align:left;”> T-helper 1 type immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051972 </td> <td style=“text-align:left;”> regulation of telomerase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903980 </td> <td style=“text-align:left;”> positive regulation of microglial cell activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:left;”> 4.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006779 </td> <td style=“text-align:left;”> porphyrin-containing compound biosynthetic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 4.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033014 </td> <td style=“text-align:left;”> tetrapyrrole biosynthetic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 4.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031399 </td> <td style=“text-align:left;”> regulation of protein modification process </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:right;”> 1096 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097479 </td> <td style=“text-align:left;”> synaptic vesicle localization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051126 </td> <td style=“text-align:left;”> negative regulation of actin nucleation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043045 </td> <td style=“text-align:left;”> post-fertilization epigenetic regulation of gene expression </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060420 </td> <td style=“text-align:left;”> regulation of heart growth </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045947 </td> <td style=“text-align:left;”> negative regulation of translational initiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 4.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903530 </td> <td style=“text-align:left;”> regulation of secretion by cell </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 382 </td> <td style=“text-align:left;”> 4.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030308 </td> <td style=“text-align:left;”> negative regulation of cell growth </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 161 </td> <td style=“text-align:left;”> 4.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071331 </td> <td style=“text-align:left;”> cellular response to hexose stimulus </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 96 </td> <td style=“text-align:left;”> 4.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901532 </td> <td style=“text-align:left;”> regulation of hematopoietic progenitor cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 4.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990928 </td> <td style=“text-align:left;”> response to amino acid starvation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 4.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000116 </td> <td style=“text-align:left;”> regulation of cysteine-type endopeptidase activity </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 159 </td> <td style=“text-align:left;”> 4.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008216 </td> <td style=“text-align:left;”> spermidine metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 4.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043524 </td> <td style=“text-align:left;”> negative regulation of neuron apoptotic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 124 </td> <td style=“text-align:left;”> 4.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043122 </td> <td style=“text-align:left;”> regulation of canonical NF-kappaB signal transduction </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 206 </td> <td style=“text-align:left;”> 4.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002447 </td> <td style=“text-align:left;”> eosinophil mediated immunity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 4.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048671 </td> <td style=“text-align:left;”> negative regulation of collateral sprouting </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 4.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032890 </td> <td style=“text-align:left;”> regulation of organic acid transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 4.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061097 </td> <td style=“text-align:left;”> regulation of protein tyrosine kinase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 61 </td> <td style=“text-align:left;”> 4.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048755 </td> <td style=“text-align:left;”> branching morphogenesis of a nerve </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 4.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0017183 </td> <td style=“text-align:left;”> protein histidyl modification to diphthamide </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 4.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016042 </td> <td style=“text-align:left;”> lipid catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 224 </td> <td style=“text-align:left;”> 4.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003416 </td> <td style=“text-align:left;”> endochondral bone growth </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 4.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035116 </td> <td style=“text-align:left;”> embryonic hindlimb morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 4.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051650 </td> <td style=“text-align:left;”> establishment of vesicle localization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 178 </td> <td style=“text-align:left;”> 4.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046579 </td> <td style=“text-align:left;”> positive regulation of Ras protein signal transduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 4.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048839 </td> <td style=“text-align:left;”> inner ear development </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 129 </td> <td style=“text-align:left;”> 4.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048729 </td> <td style=“text-align:left;”> tissue morphogenesis </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:right;”> 501 </td> <td style=“text-align:left;”> 4.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071496 </td> <td style=“text-align:left;”> cellular response to external stimulus </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 271 </td> <td style=“text-align:left;”> 4.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900454 </td> <td style=“text-align:left;”> positive regulation of long-term synaptic depression </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 4.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051351 </td> <td style=“text-align:left;”> positive regulation of ligase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 4.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000480 </td> <td style=“text-align:left;”> negative regulation of cAMP-dependent protein kinase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 4.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044342 </td> <td style=“text-align:left;”> type B pancreatic cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 4.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043067 </td> <td style=“text-align:left;”> regulation of programmed cell death </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:right;”> 1124 </td> <td style=“text-align:left;”> 4.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007264 </td> <td style=“text-align:left;”> small GTPase mediated signal transduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 413 </td> <td style=“text-align:left;”> 4.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043652 </td> <td style=“text-align:left;”> engulfment of apoptotic cell </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 4.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043304 </td> <td style=“text-align:left;”> regulation of mast cell degranulation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 4.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000001 </td> <td style=“text-align:left;”> regulation of DNA damage checkpoint </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 4.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071326 </td> <td style=“text-align:left;”> cellular response to monosaccharide stimulus </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 97 </td> <td style=“text-align:left;”> 4.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051101 </td> <td style=“text-align:left;”> regulation of DNA binding </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 102 </td> <td style=“text-align:left;”> 4.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000095 </td> <td style=“text-align:left;”> regulation of Wnt signaling pathway, planar cell polarity pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 4.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090207 </td> <td style=“text-align:left;”> regulation of triglyceride metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 4.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002820 </td> <td style=“text-align:left;”> negative regulation of adaptive immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 4.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045995 </td> <td style=“text-align:left;”> regulation of embryonic development </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 80 </td> <td style=“text-align:left;”> 4.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046902 </td> <td style=“text-align:left;”> regulation of mitochondrial membrane permeability </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 4.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009725 </td> <td style=“text-align:left;”> response to hormone </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 624 </td> <td style=“text-align:left;”> 4.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051085 </td> <td style=“text-align:left;”> chaperone cofactor-dependent protein refolding </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 4.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032880 </td> <td style=“text-align:left;”> regulation of protein localization </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 719 </td> <td style=“text-align:left;”> 4.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051665 </td> <td style=“text-align:left;”> membrane raft localization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 4.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042982 </td> <td style=“text-align:left;”> amyloid precursor protein metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 4.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060443 </td> <td style=“text-align:left;”> mammary gland morphogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 4.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051966 </td> <td style=“text-align:left;”> regulation of synaptic transmission, glutamatergic </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 4.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034314 </td> <td style=“text-align:left;”> Arp2/3 complex-mediated actin nucleation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 4.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007193 </td> <td style=“text-align:left;”> adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 4.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019219 </td> <td style=“text-align:left;”> regulation of nucleobase-containing compound metabolic process </td> <td style=“text-align:right;”> 92 </td> <td style=“text-align:right;”> 3059 </td> <td style=“text-align:left;”> 4.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903409 </td> <td style=“text-align:left;”> reactive oxygen species biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 4.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033313 </td> <td style=“text-align:left;”> meiotic cell cycle checkpoint signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 4.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048639 </td> <td style=“text-align:left;”> positive regulation of developmental growth </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 123 </td> <td style=“text-align:left;”> 4.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033120 </td> <td style=“text-align:left;”> positive regulation of RNA splicing </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 4.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031098 </td> <td style=“text-align:left;”> stress-activated protein kinase signaling cascade </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 194 </td> <td style=“text-align:left;”> 4.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060713 </td> <td style=“text-align:left;”> labyrinthine layer morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 4.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006622 </td> <td style=“text-align:left;”> protein targeting to lysosome </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 4.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003179 </td> <td style=“text-align:left;”> heart valve morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 4.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019233 </td> <td style=“text-align:left;”> sensory perception of pain </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 4.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045732 </td> <td style=“text-align:left;”> positive regulation of protein catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 189 </td> <td style=“text-align:left;”> 4.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055064 </td> <td style=“text-align:left;”> chloride ion homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 4.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904705 </td> <td style=“text-align:left;”> regulation of vascular associated smooth muscle cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 4.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035904 </td> <td style=“text-align:left;”> aorta development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 52 </td> <td style=“text-align:left;”> 4.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050772 </td> <td style=“text-align:left;”> positive regulation of axonogenesis </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 71 </td> <td style=“text-align:left;”> 4.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046596 </td> <td style=“text-align:left;”> regulation of viral entry into host cell </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 4.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007026 </td> <td style=“text-align:left;”> negative regulation of microtubule depolymerization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 4.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060512 </td> <td style=“text-align:left;”> prostate gland morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 4.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070085 </td> <td style=“text-align:left;”> glycosylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 197 </td> <td style=“text-align:left;”> 4.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045988 </td> <td style=“text-align:left;”> negative regulation of striated muscle contraction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 4.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001936 </td> <td style=“text-align:left;”> regulation of endothelial cell proliferation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 102 </td> <td style=“text-align:left;”> 4.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904951 </td> <td style=“text-align:left;”> positive regulation of establishment of protein localization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 261 </td> <td style=“text-align:left;”> 4.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042554 </td> <td style=“text-align:left;”> superoxide anion generation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 4.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015872 </td> <td style=“text-align:left;”> dopamine transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 4.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010959 </td> <td style=“text-align:left;”> regulation of metal ion transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 271 </td> <td style=“text-align:left;”> 4.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016180 </td> <td style=“text-align:left;”> snRNA processing </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 4.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090175 </td> <td style=“text-align:left;”> regulation of establishment of planar polarity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 54 </td> <td style=“text-align:left;”> 4.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016073 </td> <td style=“text-align:left;”> snRNA metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 54 </td> <td style=“text-align:left;”> 4.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007409 </td> <td style=“text-align:left;”> axonogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 350 </td> <td style=“text-align:left;”> 4.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042060 </td> <td style=“text-align:left;”> wound healing </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 304 </td> <td style=“text-align:left;”> 4.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035929 </td> <td style=“text-align:left;”> steroid hormone secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 4.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905150 </td> <td style=“text-align:left;”> regulation of voltage-gated sodium channel activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 4.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010950 </td> <td style=“text-align:left;”> positive regulation of endopeptidase activity </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 122 </td> <td style=“text-align:left;”> 4.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050885 </td> <td style=“text-align:left;”> neuromuscular process controlling balance </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 4.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008283 </td> <td style=“text-align:left;”> cell population proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2340 </td> <td style=“text-align:left;”> 4.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072332 </td> <td style=“text-align:left;”> intrinsic apoptotic signaling pathway by p53 class mediator </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 78 </td> <td style=“text-align:left;”> 4.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000766 </td> <td style=“text-align:left;”> negative regulation of cytoplasmic translation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019058 </td> <td style=“text-align:left;”> viral life cycle </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:right;”> 245 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007099 </td> <td style=“text-align:left;”> centriole replication </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032879 </td> <td style=“text-align:left;”> regulation of localization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 1570 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070671 </td> <td style=“text-align:left;”> response to interleukin-12 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902116 </td> <td style=“text-align:left;”> negative regulation of organelle assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044818 </td> <td style=“text-align:left;”> mitotic G2/M transition checkpoint </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098930 </td> <td style=“text-align:left;”> axonal transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 60 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032366 </td> <td style=“text-align:left;”> intracellular sterol transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903423 </td> <td style=“text-align:left;”> positive regulation of synaptic vesicle recycling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006361 </td> <td style=“text-align:left;”> transcription initiation at RNA polymerase I promoter </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000757 </td> <td style=“text-align:left;”> negative regulation of peptidyl-lysine acetylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045892 </td> <td style=“text-align:left;”> negative regulation of DNA-templated transcription </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:right;”> 1005 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034968 </td> <td style=“text-align:left;”> histone lysine methylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 66 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043086 </td> <td style=“text-align:left;”> negative regulation of catalytic activity </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:right;”> 456 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051291 </td> <td style=“text-align:left;”> protein heterooligomerization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045839 </td> <td style=“text-align:left;”> negative regulation of mitotic nuclear division </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000731 </td> <td style=“text-align:left;”> DNA synthesis involved in DNA repair </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009792 </td> <td style=“text-align:left;”> embryo development ending in birth or egg hatching </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:right;”> 542 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033365 </td> <td style=“text-align:left;”> protein localization to organelle </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 860 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0017156 </td> <td style=“text-align:left;”> calcium-ion regulated exocytosis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051926 </td> <td style=“text-align:left;”> negative regulation of calcium ion transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007549 </td> <td style=“text-align:left;”> dosage compensation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 4.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990874 </td> <td style=“text-align:left;”> vascular associated smooth muscle cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 4.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006109 </td> <td style=“text-align:left;”> regulation of carbohydrate metabolic process </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 147 </td> <td style=“text-align:left;”> 4.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903706 </td> <td style=“text-align:left;”> regulation of hemopoiesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 266 </td> <td style=“text-align:left;”> 4.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042044 </td> <td style=“text-align:left;”> fluid transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 4.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010518 </td> <td style=“text-align:left;”> positive regulation of phospholipase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 4.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019941 </td> <td style=“text-align:left;”> modification-dependent protein catabolic process </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:right;”> 628 </td> <td style=“text-align:left;”> 4.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009113 </td> <td style=“text-align:left;”> purine nucleobase biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 4.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032688 </td> <td style=“text-align:left;”> negative regulation of interferon-beta production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 4.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000677 </td> <td style=“text-align:left;”> regulation of transcription regulatory region DNA binding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 4.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043277 </td> <td style=“text-align:left;”> apoptotic cell clearance </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 4.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902523 </td> <td style=“text-align:left;”> positive regulation of protein K63-linked ubiquitination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 4.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033006 </td> <td style=“text-align:left;”> regulation of mast cell activation involved in immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 4.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070861 </td> <td style=“text-align:left;”> regulation of protein exit from endoplasmic reticulum </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 4.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990403 </td> <td style=“text-align:left;”> embryonic brain development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 4.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002704 </td> <td style=“text-align:left;”> negative regulation of leukocyte mediated immunity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 4.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051046 </td> <td style=“text-align:left;”> regulation of secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 413 </td> <td style=“text-align:left;”> 4.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010389 </td> <td style=“text-align:left;”> regulation of G2/M transition of mitotic cell cycle </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 94 </td> <td style=“text-align:left;”> 4.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051290 </td> <td style=“text-align:left;”> protein heterotetramerization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 4.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032092 </td> <td style=“text-align:left;”> positive regulation of protein binding </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 78 </td> <td style=“text-align:left;”> 4.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060444 </td> <td style=“text-align:left;”> branching involved in mammary gland duct morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 4.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903624 </td> <td style=“text-align:left;”> regulation of DNA catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 4.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070316 </td> <td style=“text-align:left;”> regulation of G0 to G1 transition </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 4.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000765 </td> <td style=“text-align:left;”> regulation of cytoplasmic translation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 4.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010880 </td> <td style=“text-align:left;”> regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 4.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903322 </td> <td style=“text-align:left;”> positive regulation of protein modification by small protein conjugation or removal </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 126 </td> <td style=“text-align:left;”> 4.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901163 </td> <td style=“text-align:left;”> regulation of trophoblast cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 4.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051172 </td> <td style=“text-align:left;”> negative regulation of nitrogen compound metabolic process </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:right;”> 1832 </td> <td style=“text-align:left;”> 4.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031110 </td> <td style=“text-align:left;”> regulation of microtubule polymerization or depolymerization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 81 </td> <td style=“text-align:left;”> 4.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903748 </td> <td style=“text-align:left;”> negative regulation of establishment of protein localization to mitochondrion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 4.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043500 </td> <td style=“text-align:left;”> muscle adaptation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 89 </td> <td style=“text-align:left;”> 4.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072711 </td> <td style=“text-align:left;”> cellular response to hydroxyurea </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 4.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140888 </td> <td style=“text-align:left;”> interferon-mediated signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 4.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050769 </td> <td style=“text-align:left;”> positive regulation of neurogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 190 </td> <td style=“text-align:left;”> 4.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061037 </td> <td style=“text-align:left;”> negative regulation of cartilage development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 4.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042364 </td> <td style=“text-align:left;”> water-soluble vitamin biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 4.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098868 </td> <td style=“text-align:left;”> bone growth </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 4.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901565 </td> <td style=“text-align:left;”> organonitrogen compound catabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 1151 </td> <td style=“text-align:left;”> 4.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006390 </td> <td style=“text-align:left;”> mitochondrial transcription </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 4.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032881 </td> <td style=“text-align:left;”> regulation of polysaccharide metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 4.62e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048168 </td> <td style=“text-align:left;”> regulation of neuronal synaptic plasticity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 4.62e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051347 </td> <td style=“text-align:left;”> positive regulation of transferase activity </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 390 </td> <td style=“text-align:left;”> 4.62e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015911 </td> <td style=“text-align:left;”> long-chain fatty acid import across plasma membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 4.62e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035773 </td> <td style=“text-align:left;”> insulin secretion involved in cellular response to glucose stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 4.62e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001259 </td> <td style=“text-align:left;”> positive regulation of cation channel activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 4.62e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030099 </td> <td style=“text-align:left;”> myeloid cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 305 </td> <td style=“text-align:left;”> 4.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010965 </td> <td style=“text-align:left;”> regulation of mitotic sister chromatid separation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 4.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905821 </td> <td style=“text-align:left;”> positive regulation of chromosome condensation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 4.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015867 </td> <td style=“text-align:left;”> ATP transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 4.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014910 </td> <td style=“text-align:left;”> regulation of smooth muscle cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 57 </td> <td style=“text-align:left;”> 4.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903651 </td> <td style=“text-align:left;”> positive regulation of cytoplasmic transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 4.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002444 </td> <td style=“text-align:left;”> myeloid leukocyte mediated immunity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 59 </td> <td style=“text-align:left;”> 4.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032369 </td> <td style=“text-align:left;”> negative regulation of lipid transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 4.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051648 </td> <td style=“text-align:left;”> vesicle localization </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 195 </td> <td style=“text-align:left;”> 4.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018108 </td> <td style=“text-align:left;”> peptidyl-tyrosine phosphorylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 195 </td> <td style=“text-align:left;”> 4.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019220 </td> <td style=“text-align:left;”> regulation of phosphate metabolic process </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 949 </td> <td style=“text-align:left;”> 4.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010906 </td> <td style=“text-align:left;”> regulation of glucose metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 85 </td> <td style=“text-align:left;”> 4.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045834 </td> <td style=“text-align:left;”> positive regulation of lipid metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 108 </td> <td style=“text-align:left;”> 4.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000234 </td> <td style=“text-align:left;”> positive regulation of rRNA processing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 4.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043270 </td> <td style=“text-align:left;”> positive regulation of monoatomic ion transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 151 </td> <td style=“text-align:left;”> 4.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009913 </td> <td style=“text-align:left;”> epidermal cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 116 </td> <td style=“text-align:left;”> 4.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051174 </td> <td style=“text-align:left;”> regulation of phosphorus metabolic process </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 950 </td> <td style=“text-align:left;”> 4.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901977 </td> <td style=“text-align:left;”> negative regulation of cell cycle checkpoint </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 4.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000377 </td> <td style=“text-align:left;”> regulation of reactive oxygen species metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 107 </td> <td style=“text-align:left;”> 4.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048066 </td> <td style=“text-align:left;”> developmental pigmentation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 4.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045669 </td> <td style=“text-align:left;”> positive regulation of osteoblast differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 4.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055081 </td> <td style=“text-align:left;”> monoatomic anion homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 4.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060021 </td> <td style=“text-align:left;”> roof of mouth development </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 71 </td> <td style=“text-align:left;”> 4.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051057 </td> <td style=“text-align:left;”> positive regulation of small GTPase mediated signal transduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 4.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045071 </td> <td style=“text-align:left;”> negative regulation of viral genome replication </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 4.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050432 </td> <td style=“text-align:left;”> catecholamine secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 4.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044281 </td> <td style=“text-align:left;”> small molecule metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1386 </td> <td style=“text-align:left;”> 4.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007589 </td> <td style=“text-align:left;”> body fluid secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 4.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018212 </td> <td style=“text-align:left;”> peptidyl-tyrosine modification </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 197 </td> <td style=“text-align:left;”> 4.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000136 </td> <td style=“text-align:left;”> regulation of cell proliferation involved in heart morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 4.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098974 </td> <td style=“text-align:left;”> postsynaptic actin cytoskeleton organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 4.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071322 </td> <td style=“text-align:left;”> cellular response to carbohydrate stimulus </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 106 </td> <td style=“text-align:left;”> 4.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043154 </td> <td style=“text-align:left;”> negative regulation of cysteine-type endopeptidase activity involved in apoptotic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 4.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042255 </td> <td style=“text-align:left;”> ribosome assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 61 </td> <td style=“text-align:left;”> 4.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035510 </td> <td style=“text-align:left;”> DNA dealkylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 4.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071415 </td> <td style=“text-align:left;”> cellular response to purine-containing compound </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 4.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006631 </td> <td style=“text-align:left;”> fatty acid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 276 </td> <td style=“text-align:left;”> 4.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071712 </td> <td style=“text-align:left;”> ER-associated misfolded protein catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 4.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048645 </td> <td style=“text-align:left;”> animal organ formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 4.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009057 </td> <td style=“text-align:left;”> macromolecule catabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 1215 </td> <td style=“text-align:left;”> 4.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000041 </td> <td style=“text-align:left;”> transition metal ion transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 73 </td> <td style=“text-align:left;”> 4.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902679 </td> <td style=“text-align:left;”> negative regulation of RNA biosynthetic process </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:right;”> 1014 </td> <td style=“text-align:left;”> 4.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060284 </td> <td style=“text-align:left;”> regulation of cell development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 593 </td> <td style=“text-align:left;”> 4.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048646 </td> <td style=“text-align:left;”> anatomical structure formation involved in morphogenesis </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 868 </td> <td style=“text-align:left;”> 4.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071514 </td> <td style=“text-align:left;”> genomic imprinting </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 4.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010634 </td> <td style=“text-align:left;”> positive regulation of epithelial cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 132 </td> <td style=“text-align:left;”> 4.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043255 </td> <td style=“text-align:left;”> regulation of carbohydrate biosynthetic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 79 </td> <td style=“text-align:left;”> 4.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046460 </td> <td style=“text-align:left;”> neutral lipid biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 4.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046463 </td> <td style=“text-align:left;”> acylglycerol biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 4.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900034 </td> <td style=“text-align:left;”> regulation of cellular response to heat </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 4.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043112 </td> <td style=“text-align:left;”> receptor metabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 67 </td> <td style=“text-align:left;”> 4.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0120305 </td> <td style=“text-align:left;”> regulation of pigmentation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 4.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048070 </td> <td style=“text-align:left;”> regulation of developmental pigmentation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 4.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001756 </td> <td style=“text-align:left;”> somitogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 4.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032607 </td> <td style=“text-align:left;”> interferon-alpha production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 4.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032647 </td> <td style=“text-align:left;”> regulation of interferon-alpha production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 4.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061450 </td> <td style=“text-align:left;”> trophoblast cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 4.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031347 </td> <td style=“text-align:left;”> regulation of defense response </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 477 </td> <td style=“text-align:left;”> 4.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048241 </td> <td style=“text-align:left;”> epinephrine transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 4.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051306 </td> <td style=“text-align:left;”> mitotic sister chromatid separation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 59 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009972 </td> <td style=“text-align:left;”> cytidine deamination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006188 </td> <td style=“text-align:left;”> IMP biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000758 </td> <td style=“text-align:left;”> positive regulation of peptidyl-lysine acetylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006216 </td> <td style=“text-align:left;”> cytidine catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016554 </td> <td style=“text-align:left;”> cytidine to uridine editing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002063 </td> <td style=“text-align:left;”> chondrocyte development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043388 </td> <td style=“text-align:left;”> positive regulation of DNA binding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009263 </td> <td style=“text-align:left;”> deoxyribonucleotide biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046349 </td> <td style=“text-align:left;”> amino sugar biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046385 </td> <td style=“text-align:left;”> deoxyribose phosphate biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046087 </td> <td style=“text-align:left;”> cytidine metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0052372 </td> <td style=“text-align:left;”> modulation by symbiont of entry into host </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009265 </td> <td style=“text-align:left;”> 2’-deoxyribonucleotide biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045161 </td> <td style=“text-align:left;”> neuronal ion channel clustering </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006497 </td> <td style=“text-align:left;”> protein lipidation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 89 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051247 </td> <td style=“text-align:left;”> positive regulation of protein metabolic process </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:right;”> 1067 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006304 </td> <td style=“text-align:left;”> DNA modification </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 86 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046485 </td> <td style=“text-align:left;”> ether lipid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001819 </td> <td style=“text-align:left;”> positive regulation of cytokine production </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 284 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006662 </td> <td style=“text-align:left;”> glycerol ether metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030517 </td> <td style=“text-align:left;”> negative regulation of axon extension </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045088 </td> <td style=“text-align:left;”> regulation of innate immune response </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 262 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902893 </td> <td style=“text-align:left;”> regulation of miRNA transcription </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031114 </td> <td style=“text-align:left;”> regulation of microtubule depolymerization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003208 </td> <td style=“text-align:left;”> cardiac ventricle morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 62 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032989 </td> <td style=“text-align:left;”> cellular component morphogenesis </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 627 </td> <td style=“text-align:left;”> 4.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032273 </td> <td style=“text-align:left;”> positive regulation of protein polymerization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 75 </td> <td style=“text-align:left;”> 4.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022412 </td> <td style=“text-align:left;”> cellular process involved in reproduction in multicellular organism </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 255 </td> <td style=“text-align:left;”> 4.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009250 </td> <td style=“text-align:left;”> glucan biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 4.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0005978 </td> <td style=“text-align:left;”> glycogen biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 4.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900095 </td> <td style=“text-align:left;”> regulation of dosage compensation by inactivation of X chromosome </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 4.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019079 </td> <td style=“text-align:left;”> viral genome replication </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 104 </td> <td style=“text-align:left;”> 4.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051784 </td> <td style=“text-align:left;”> negative regulation of nuclear division </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 4.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045023 </td> <td style=“text-align:left;”> G0 to G1 transition </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 4.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045597 </td> <td style=“text-align:left;”> positive regulation of cell differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 618 </td> <td style=“text-align:left;”> 4.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043632 </td> <td style=“text-align:left;”> modification-dependent macromolecule catabolic process </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:right;”> 638 </td> <td style=“text-align:left;”> 4.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032966 </td> <td style=“text-align:left;”> negative regulation of collagen biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 4.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071407 </td> <td style=“text-align:left;”> cellular response to organic cyclic compound </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 409 </td> <td style=“text-align:left;”> 4.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008654 </td> <td style=“text-align:left;”> phospholipid biosynthetic process </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:right;”> 233 </td> <td style=“text-align:left;”> 4.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001678 </td> <td style=“text-align:left;”> intracellular glucose homeostasis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 112 </td> <td style=“text-align:left;”> 4.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006835 </td> <td style=“text-align:left;”> dicarboxylic acid transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 61 </td> <td style=“text-align:left;”> 4.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021695 </td> <td style=“text-align:left;”> cerebellar cortex development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 4.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904355 </td> <td style=“text-align:left;”> positive regulation of telomere capping </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 4.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061614 </td> <td style=“text-align:left;”> miRNA transcription </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 59 </td> <td style=“text-align:left;”> 4.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072710 </td> <td style=“text-align:left;”> response to hydroxyurea </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 4.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070344 </td> <td style=“text-align:left;”> regulation of fat cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 4.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900182 </td> <td style=“text-align:left;”> positive regulation of protein localization to nucleus </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 81 </td> <td style=“text-align:left;”> 4.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061323 </td> <td style=“text-align:left;”> cell proliferation involved in heart morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 4.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048675 </td> <td style=“text-align:left;”> axon extension </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 108 </td> <td style=“text-align:left;”> 4.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061448 </td> <td style=“text-align:left;”> connective tissue development </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 212 </td> <td style=“text-align:left;”> 4.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051099 </td> <td style=“text-align:left;”> positive regulation of binding </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 149 </td> <td style=“text-align:left;”> 4.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046782 </td> <td style=“text-align:left;”> regulation of viral transcription </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 4.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033209 </td> <td style=“text-align:left;”> tumor necrosis factor-mediated signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 80 </td> <td style=“text-align:left;”> 4.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018107 </td> <td style=“text-align:left;”> peptidyl-threonine phosphorylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 96 </td> <td style=“text-align:left;”> 4.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060351 </td> <td style=“text-align:left;”> cartilage development involved in endochondral bone morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 4.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099550 </td> <td style=“text-align:left;”> trans-synaptic signaling, modulating synaptic transmission </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 4.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006942 </td> <td style=“text-align:left;”> regulation of striated muscle contraction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 84 </td> <td style=“text-align:left;”> 4.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006182 </td> <td style=“text-align:left;”> cGMP biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 4.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001239 </td> <td style=“text-align:left;”> regulation of extrinsic apoptotic signaling pathway in absence of ligand </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 4.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048844 </td> <td style=“text-align:left;”> artery morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 59 </td> <td style=“text-align:left;”> 4.78e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071398 </td> <td style=“text-align:left;”> cellular response to fatty acid </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 4.78e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051340 </td> <td style=“text-align:left;”> regulation of ligase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 4.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010243 </td> <td style=“text-align:left;”> response to organonitrogen compound </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 764 </td> <td style=“text-align:left;”> 4.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032413 </td> <td style=“text-align:left;”> negative regulation of ion transmembrane transporter activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 52 </td> <td style=“text-align:left;”> 4.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090559 </td> <td style=“text-align:left;”> regulation of membrane permeability </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 62 </td> <td style=“text-align:left;”> 4.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045944 </td> <td style=“text-align:left;”> positive regulation of transcription by RNA polymerase II </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:right;”> 918 </td> <td style=“text-align:left;”> 4.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051481 </td> <td style=“text-align:left;”> negative regulation of cytosolic calcium ion concentration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 4.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042158 </td> <td style=“text-align:left;”> lipoprotein biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 92 </td> <td style=“text-align:left;”> 4.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014909 </td> <td style=“text-align:left;”> smooth muscle cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 4.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055017 </td> <td style=“text-align:left;”> cardiac muscle tissue growth </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 63 </td> <td style=“text-align:left;”> 4.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014855 </td> <td style=“text-align:left;”> striated muscle cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 4.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008090 </td> <td style=“text-align:left;”> retrograde axonal transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 4.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001707 </td> <td style=“text-align:left;”> mesoderm formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 4.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090083 </td> <td style=“text-align:left;”> regulation of inclusion body assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 4.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010739 </td> <td style=“text-align:left;”> positive regulation of protein kinase A signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 4.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007626 </td> <td style=“text-align:left;”> locomotory behavior </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 139 </td> <td style=“text-align:left;”> 4.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071260 </td> <td style=“text-align:left;”> cellular response to mechanical stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 4.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035914 </td> <td style=“text-align:left;”> skeletal muscle cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 4.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902230 </td> <td style=“text-align:left;”> negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 4.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097400 </td> <td style=“text-align:left;”> interleukin-17-mediated signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 4.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033860 </td> <td style=“text-align:left;”> regulation of NAD(P)H oxidase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 4.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016322 </td> <td style=“text-align:left;”> neuron remodeling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 4.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048048 </td> <td style=“text-align:left;”> embryonic eye morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 4.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043065 </td> <td style=“text-align:left;”> positive regulation of apoptotic process </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 394 </td> <td style=“text-align:left;”> 4.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050921 </td> <td style=“text-align:left;”> positive regulation of chemotaxis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 86 </td> <td style=“text-align:left;”> 4.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010764 </td> <td style=“text-align:left;”> negative regulation of fibroblast migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 4.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003073 </td> <td style=“text-align:left;”> regulation of systemic arterial blood pressure </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 62 </td> <td style=“text-align:left;”> 4.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051952 </td> <td style=“text-align:left;”> regulation of amine transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 4.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003170 </td> <td style=“text-align:left;”> heart valve development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 66 </td> <td style=“text-align:left;”> 4.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001947 </td> <td style=“text-align:left;”> heart looping </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 4.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060669 </td> <td style=“text-align:left;”> embryonic placenta morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 4.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034454 </td> <td style=“text-align:left;”> microtubule anchoring at centrosome </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 4.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904262 </td> <td style=“text-align:left;”> negative regulation of TORC1 signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 4.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006665 </td> <td style=“text-align:left;”> sphingolipid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 129 </td> <td style=“text-align:left;”> 4.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902531 </td> <td style=“text-align:left;”> regulation of intracellular signal transduction </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:right;”> 1318 </td> <td style=“text-align:left;”> 4.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043101 </td> <td style=“text-align:left;”> purine-containing compound salvage </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 4.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0038202 </td> <td style=“text-align:left;”> TORC1 signaling </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 60 </td> <td style=“text-align:left;”> 4.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001776 </td> <td style=“text-align:left;”> leukocyte homeostasis </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 73 </td> <td style=“text-align:left;”> 4.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006810 </td> <td style=“text-align:left;”> transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 3294 </td> <td style=“text-align:left;”> 4.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051298 </td> <td style=“text-align:left;”> centrosome duplication </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 68 </td> <td style=“text-align:left;”> 4.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044458 </td> <td style=“text-align:left;”> motile cilium assembly </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 4.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006098 </td> <td style=“text-align:left;”> pentose-phosphate shunt </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 4.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060193 </td> <td style=“text-align:left;”> positive regulation of lipase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 4.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048332 </td> <td style=“text-align:left;”> mesoderm morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 55 </td> <td style=“text-align:left;”> 4.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0120033 </td> <td style=“text-align:left;”> negative regulation of plasma membrane bounded cell projection assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 4.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007100 </td> <td style=“text-align:left;”> mitotic centrosome separation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 4.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006312 </td> <td style=“text-align:left;”> mitotic recombination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 4.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006473 </td> <td style=“text-align:left;”> protein acetylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 155 </td> <td style=“text-align:left;”> 4.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045006 </td> <td style=“text-align:left;”> DNA deamination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 4.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006664 </td> <td style=“text-align:left;”> glycolipid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 89 </td> <td style=“text-align:left;”> 4.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033314 </td> <td style=“text-align:left;”> mitotic DNA replication checkpoint signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 4.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061512 </td> <td style=“text-align:left;”> protein localization to cilium </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 62 </td> <td style=“text-align:left;”> 4.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006054 </td> <td style=“text-align:left;”> N-acetylneuraminate metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 4.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051054 </td> <td style=“text-align:left;”> positive regulation of DNA metabolic process </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:right;”> 265 </td> <td style=“text-align:left;”> 4.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002068 </td> <td style=“text-align:left;”> glandular epithelial cell development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 4.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043984 </td> <td style=“text-align:left;”> histone H4-K16 acetylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 4.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070475 </td> <td style=“text-align:left;”> rRNA base methylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 4.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033077 </td> <td style=“text-align:left;”> T cell differentiation in thymus </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 57 </td> <td style=“text-align:left;”> 4.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061564 </td> <td style=“text-align:left;”> axon development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 388 </td> <td style=“text-align:left;”> 4.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016024 </td> <td style=“text-align:left;”> CDP-diacylglycerol biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 4.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046341 </td> <td style=“text-align:left;”> CDP-diacylglycerol metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 4.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072091 </td> <td style=“text-align:left;”> regulation of stem cell proliferation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 4.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903313 </td> <td style=“text-align:left;”> positive regulation of mRNA metabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 121 </td> <td style=“text-align:left;”> 4.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010517 </td> <td style=“text-align:left;”> regulation of phospholipase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 4.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008542 </td> <td style=“text-align:left;”> visual learning </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 4.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903509 </td> <td style=“text-align:left;”> liposaccharide metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 89 </td> <td style=“text-align:left;”> 4.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014032 </td> <td style=“text-align:left;”> neural crest cell development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 4.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0040019 </td> <td style=“text-align:left;”> positive regulation of embryonic development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 4.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043266 </td> <td style=“text-align:left;”> regulation of potassium ion transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 4.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021537 </td> <td style=“text-align:left;”> telencephalon development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 208 </td> <td style=“text-align:left;”> 4.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008333 </td> <td style=“text-align:left;”> endosome to lysosome transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 63 </td> <td style=“text-align:left;”> 4.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903649 </td> <td style=“text-align:left;”> regulation of cytoplasmic transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 4.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045010 </td> <td style=“text-align:left;”> actin nucleation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 4.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010594 </td> <td style=“text-align:left;”> regulation of endothelial cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 143 </td> <td style=“text-align:left;”> 4.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045927 </td> <td style=“text-align:left;”> positive regulation of growth </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 195 </td> <td style=“text-align:left;”> 4.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051345 </td> <td style=“text-align:left;”> positive regulation of hydrolase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 412 </td> <td style=“text-align:left;”> 4.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070914 </td> <td style=“text-align:left;”> UV-damage excision repair </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 4.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006869 </td> <td style=“text-align:left;”> lipid transport </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 271 </td> <td style=“text-align:left;”> 4.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051084 </td> <td style=“text-align:left;”> ‘de novo’ post-translational protein folding </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 4.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010165 </td> <td style=“text-align:left;”> response to X-ray </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 4.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051253 </td> <td style=“text-align:left;”> negative regulation of RNA metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1112 </td> <td style=“text-align:left;”> 4.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002790 </td> <td style=“text-align:left;”> peptide secretion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 173 </td> <td style=“text-align:left;”> 4.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018130 </td> <td style=“text-align:left;”> heterocycle biosynthetic process </td> <td style=“text-align:right;”> 88 </td> <td style=“text-align:right;”> 3115 </td> <td style=“text-align:left;”> 4.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070252 </td> <td style=“text-align:left;”> actin-mediated cell contraction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 90 </td> <td style=“text-align:left;”> 4.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905820 </td> <td style=“text-align:left;”> positive regulation of chromosome separation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 4.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060628 </td> <td style=“text-align:left;”> regulation of ER to Golgi vesicle-mediated transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 4.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030100 </td> <td style=“text-align:left;”> regulation of endocytosis </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 208 </td> <td style=“text-align:left;”> 4.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031000 </td> <td style=“text-align:left;”> response to caffeine </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 4.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032543 </td> <td style=“text-align:left;”> mitochondrial translation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 129 </td> <td style=“text-align:left;”> 4.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901698 </td> <td style=“text-align:left;”> response to nitrogen compound </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 810 </td> <td style=“text-align:left;”> 4.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031076 </td> <td style=“text-align:left;”> embryonic camera-type eye development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 4.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060079 </td> <td style=“text-align:left;”> excitatory postsynaptic potential </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 4.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070230 </td> <td style=“text-align:left;”> positive regulation of lymphocyte apoptotic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 4.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033599 </td> <td style=“text-align:left;”> regulation of mammary gland epithelial cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 4.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003151 </td> <td style=“text-align:left;”> outflow tract morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 67 </td> <td style=“text-align:left;”> 4.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010713 </td> <td style=“text-align:left;”> negative regulation of collagen metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 4.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043903 </td> <td style=“text-align:left;”> regulation of biological process involved in symbiotic interaction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 4.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010977 </td> <td style=“text-align:left;”> negative regulation of neuron projection development </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 117 </td> <td style=“text-align:left;”> 4.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002062 </td> <td style=“text-align:left;”> chondrocyte differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 89 </td> <td style=“text-align:left;”> 4.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050848 </td> <td style=“text-align:left;”> regulation of calcium-mediated signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 4.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090596 </td> <td style=“text-align:left;”> sensory organ morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 179 </td> <td style=“text-align:left;”> 4.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009404 </td> <td style=“text-align:left;”> toxin metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 4.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902902 </td> <td style=“text-align:left;”> negative regulation of autophagosome assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 4.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016571 </td> <td style=“text-align:left;”> histone methylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 81 </td> <td style=“text-align:left;”> 4.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008306 </td> <td style=“text-align:left;”> associative learning </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 65 </td> <td style=“text-align:left;”> 4.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090110 </td> <td style=“text-align:left;”> COPII-coated vesicle cargo loading </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 4.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030252 </td> <td style=“text-align:left;”> growth hormone secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 4.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051962 </td> <td style=“text-align:left;”> positive regulation of nervous system development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 222 </td> <td style=“text-align:left;”> 4.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042574 </td> <td style=“text-align:left;”> retinal metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 4.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051924 </td> <td style=“text-align:left;”> regulation of calcium ion transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 167 </td> <td style=“text-align:left;”> 4.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071356 </td> <td style=“text-align:left;”> cellular response to tumor necrosis factor </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 159 </td> <td style=“text-align:left;”> 4.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030500 </td> <td style=“text-align:left;”> regulation of bone mineralization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 54 </td> <td style=“text-align:left;”> 4.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097154 </td> <td style=“text-align:left;”> GABAergic neuron differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 4.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099188 </td> <td style=“text-align:left;”> postsynaptic cytoskeleton organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 4.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009151 </td> <td style=“text-align:left;”> purine deoxyribonucleotide metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 4.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001935 </td> <td style=“text-align:left;”> endothelial cell proliferation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 120 </td> <td style=“text-align:left;”> 4.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048643 </td> <td style=“text-align:left;”> positive regulation of skeletal muscle tissue development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 4.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035023 </td> <td style=“text-align:left;”> regulation of Rho protein signal transduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 65 </td> <td style=“text-align:left;”> 4.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901989 </td> <td style=“text-align:left;”> positive regulation of cell cycle phase transition </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 101 </td> <td style=“text-align:left;”> 4.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090075 </td> <td style=“text-align:left;”> relaxation of muscle </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 4.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002832 </td> <td style=“text-align:left;”> negative regulation of response to biotic stimulus </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 102 </td> <td style=“text-align:left;”> 4.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021536 </td> <td style=“text-align:left;”> diencephalon development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 4.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006111 </td> <td style=“text-align:left;”> regulation of gluconeogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 4.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902253 </td> <td style=“text-align:left;”> regulation of intrinsic apoptotic signaling pathway by p53 class mediator </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 4.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032410 </td> <td style=“text-align:left;”> negative regulation of transporter activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 59 </td> <td style=“text-align:left;”> 4.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060291 </td> <td style=“text-align:left;”> long-term synaptic potentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 66 </td> <td style=“text-align:left;”> 4.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046883 </td> <td style=“text-align:left;”> regulation of hormone secretion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 171 </td> <td style=“text-align:left;”> 4.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901797 </td> <td style=“text-align:left;”> negative regulation of signal transduction by p53 class mediator </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 4.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007249 </td> <td style=“text-align:left;”> canonical NF-kappaB signal transduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 232 </td> <td style=“text-align:left;”> 4.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070935 </td> <td style=“text-align:left;”> 3’-UTR-mediated mRNA stabilization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 4.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0062208 </td> <td style=“text-align:left;”> positive regulation of pattern recognition receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 4.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051299 </td> <td style=“text-align:left;”> centrosome separation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 4.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051385 </td> <td style=“text-align:left;”> response to mineralocorticoid </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 5.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051234 </td> <td style=“text-align:left;”> establishment of localization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 3453 </td> <td style=“text-align:left;”> 5.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045833 </td> <td style=“text-align:left;”> negative regulation of lipid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 5.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008088 </td> <td style=“text-align:left;”> axo-dendritic transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 72 </td> <td style=“text-align:left;”> 5.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060419 </td> <td style=“text-align:left;”> heart growth </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 5.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042325 </td> <td style=“text-align:left;”> regulation of phosphorylation </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 841 </td> <td style=“text-align:left;”> 5.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098976 </td> <td style=“text-align:left;”> excitatory chemical synaptic transmission </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 5.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051409 </td> <td style=“text-align:left;”> response to nitrosative stress </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 5.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903365 </td> <td style=“text-align:left;”> regulation of fear response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 5.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033604 </td> <td style=“text-align:left;”> negative regulation of catecholamine secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 5.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046133 </td> <td style=“text-align:left;”> pyrimidine ribonucleoside catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 5.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048243 </td> <td style=“text-align:left;”> norepinephrine secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 5.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046131 </td> <td style=“text-align:left;”> pyrimidine ribonucleoside metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 5.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014061 </td> <td style=“text-align:left;”> regulation of norepinephrine secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:left;”> 5.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045646 </td> <td style=“text-align:left;”> regulation of erythrocyte differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 5.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000756 </td> <td style=“text-align:left;”> regulation of peptidyl-lysine acetylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 5.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045766 </td> <td style=“text-align:left;”> positive regulation of angiogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 114 </td> <td style=“text-align:left;”> 5.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904018 </td> <td style=“text-align:left;”> positive regulation of vasculature development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 114 </td> <td style=“text-align:left;”> 5.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051965 </td> <td style=“text-align:left;”> positive regulation of synapse assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 5.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010557 </td> <td style=“text-align:left;”> positive regulation of macromolecule biosynthetic process </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:right;”> 1896 </td> <td style=“text-align:left;”> 5.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903232 </td> <td style=“text-align:left;”> melanosome assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 5.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046626 </td> <td style=“text-align:left;”> regulation of insulin receptor signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 52 </td> <td style=“text-align:left;”> 5.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051336 </td> <td style=“text-align:left;”> regulation of hydrolase activity </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 680 </td> <td style=“text-align:left;”> 5.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006167 </td> <td style=“text-align:left;”> AMP biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 5.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042461 </td> <td style=“text-align:left;”> photoreceptor cell development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 5.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045087 </td> <td style=“text-align:left;”> innate immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 514 </td> <td style=“text-align:left;”> 5.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060541 </td> <td style=“text-align:left;”> respiratory system development </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 161 </td> <td style=“text-align:left;”> 5.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035234 </td> <td style=“text-align:left;”> ectopic germ cell programmed cell death </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 5.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018210 </td> <td style=“text-align:left;”> peptidyl-threonine modification </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 103 </td> <td style=“text-align:left;”> 5.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048843 </td> <td style=“text-align:left;”> negative regulation of axon extension involved in axon guidance </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 5.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903320 </td> <td style=“text-align:left;”> regulation of protein modification by small protein conjugation or removal </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 232 </td> <td style=“text-align:left;”> 5.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045055 </td> <td style=“text-align:left;”> regulated exocytosis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 152 </td> <td style=“text-align:left;”> 5.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042359 </td> <td style=“text-align:left;”> vitamin D metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 5.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009798 </td> <td style=“text-align:left;”> axis specification </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 61 </td> <td style=“text-align:left;”> 5.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008286 </td> <td style=“text-align:left;”> insulin receptor signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 101 </td> <td style=“text-align:left;”> 5.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061635 </td> <td style=“text-align:left;”> regulation of protein complex stability </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 5.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905818 </td> <td style=“text-align:left;”> regulation of chromosome separation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 5.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032024 </td> <td style=“text-align:left;”> positive regulation of insulin secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 59 </td> <td style=“text-align:left;”> 5.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001662 </td> <td style=“text-align:left;”> behavioral fear response </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 5.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035249 </td> <td style=“text-align:left;”> synaptic transmission, glutamatergic </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 65 </td> <td style=“text-align:left;”> 5.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061484 </td> <td style=“text-align:left;”> hematopoietic stem cell homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 5.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042058 </td> <td style=“text-align:left;”> regulation of epidermal growth factor receptor signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 5.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060562 </td> <td style=“text-align:left;”> epithelial tube morphogenesis </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 276 </td> <td style=“text-align:left;”> 5.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009642 </td> <td style=“text-align:left;”> response to light intensity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 5.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006749 </td> <td style=“text-align:left;”> glutathione metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 5.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045934 </td> <td style=“text-align:left;”> negative regulation of nucleobase-containing compound metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1203 </td> <td style=“text-align:left;”> 5.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060315 </td> <td style=“text-align:left;”> negative regulation of ryanodine-sensitive calcium-release channel activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 5.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016043 </td> <td style=“text-align:left;”> cellular component organization </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 5106 </td> <td style=“text-align:left;”> 5.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099565 </td> <td style=“text-align:left;”> chemical synaptic transmission, postsynaptic </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 5.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051896 </td> <td style=“text-align:left;”> regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 123 </td> <td style=“text-align:left;”> 5.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014808 </td> <td style=“text-align:left;”> release of sequestered calcium ion into cytosol by sarcoplasmic reticulum </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 5.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018202 </td> <td style=“text-align:left;”> peptidyl-histidine modification </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 5.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070647 </td> <td style=“text-align:left;”> protein modification by small protein conjugation or removal </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 870 </td> <td style=“text-align:left;”> 5.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010459 </td> <td style=“text-align:left;”> negative regulation of heart rate </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 5.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010644 </td> <td style=“text-align:left;”> cell communication by electrical coupling </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 5.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050728 </td> <td style=“text-align:left;”> negative regulation of inflammatory response </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 95 </td> <td style=“text-align:left;”> 5.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043068 </td> <td style=“text-align:left;”> positive regulation of programmed cell death </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 403 </td> <td style=“text-align:left;”> 5.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000086 </td> <td style=“text-align:left;”> G2/M transition of mitotic cell cycle </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 130 </td> <td style=“text-align:left;”> 5.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043244 </td> <td style=“text-align:left;”> regulation of protein-containing complex disassembly </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 109 </td> <td style=“text-align:left;”> 5.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034654 </td> <td style=“text-align:left;”> nucleobase-containing compound biosynthetic process </td> <td style=“text-align:right;”> 86 </td> <td style=“text-align:right;”> 3054 </td> <td style=“text-align:left;”> 5.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010952 </td> <td style=“text-align:left;”> positive regulation of peptidase activity </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 135 </td> <td style=“text-align:left;”> 5.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048870 </td> <td style=“text-align:left;”> cell motility </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 1169 </td> <td style=“text-align:left;”> 5.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034620 </td> <td style=“text-align:left;”> cellular response to unfolded protein </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 83 </td> <td style=“text-align:left;”> 5.10e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001754 </td> <td style=“text-align:left;”> eye photoreceptor cell differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 5.10e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055085 </td> <td style=“text-align:left;”> transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1014 </td> <td style=“text-align:left;”> 5.10e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051937 </td> <td style=“text-align:left;”> catecholamine transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 5.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014842 </td> <td style=“text-align:left;”> regulation of skeletal muscle satellite cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 5.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000288 </td> <td style=“text-align:left;”> positive regulation of myoblast proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 5.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090287 </td> <td style=“text-align:left;”> regulation of cellular response to growth factor stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 261 </td> <td style=“text-align:left;”> 5.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033003 </td> <td style=“text-align:left;”> regulation of mast cell activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 5.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901836 </td> <td style=“text-align:left;”> regulation of transcription of nucleolar large rRNA by RNA polymerase I </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 5.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905898 </td> <td style=“text-align:left;”> positive regulation of response to endoplasmic reticulum stress </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 5.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070365 </td> <td style=“text-align:left;”> hepatocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 5.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070534 </td> <td style=“text-align:left;”> protein K63-linked ubiquitination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 62 </td> <td style=“text-align:left;”> 5.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048864 </td> <td style=“text-align:left;”> stem cell development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 75 </td> <td style=“text-align:left;”> 5.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051304 </td> <td style=“text-align:left;”> chromosome separation </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 75 </td> <td style=“text-align:left;”> 5.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015833 </td> <td style=“text-align:left;”> peptide transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 182 </td> <td style=“text-align:left;”> 5.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032940 </td> <td style=“text-align:left;”> secretion by cell </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 573 </td> <td style=“text-align:left;”> 5.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904063 </td> <td style=“text-align:left;”> negative regulation of cation transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 5.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043583 </td> <td style=“text-align:left;”> ear development </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 150 </td> <td style=“text-align:left;”> 5.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001675 </td> <td style=“text-align:left;”> acrosome assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 5.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061077 </td> <td style=“text-align:left;”> chaperone-mediated protein folding </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 63 </td> <td style=“text-align:left;”> 5.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060219 </td> <td style=“text-align:left;”> camera-type eye photoreceptor cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 5.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904263 </td> <td style=“text-align:left;”> positive regulation of TORC1 signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 5.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046620 </td> <td style=“text-align:left;”> regulation of organ growth </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 5.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014812 </td> <td style=“text-align:left;”> muscle cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 75 </td> <td style=“text-align:left;”> 5.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060341 </td> <td style=“text-align:left;”> regulation of cellular localization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 805 </td> <td style=“text-align:left;”> 5.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071900 </td> <td style=“text-align:left;”> regulation of protein serine/threonine kinase activity </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 274 </td> <td style=“text-align:left;”> 5.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060117 </td> <td style=“text-align:left;”> auditory receptor cell development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 5.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018904 </td> <td style=“text-align:left;”> ether metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 5.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048711 </td> <td style=“text-align:left;”> positive regulation of astrocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 5.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002209 </td> <td style=“text-align:left;”> behavioral defense response </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 5.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071548 </td> <td style=“text-align:left;”> response to dexamethasone </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 5.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051607 </td> <td style=“text-align:left;”> defense response to virus </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:right;”> 224 </td> <td style=“text-align:left;”> 5.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006740 </td> <td style=“text-align:left;”> NADPH regeneration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 5.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051261 </td> <td style=“text-align:left;”> protein depolymerization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 100 </td> <td style=“text-align:left;”> 5.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043981 </td> <td style=“text-align:left;”> histone H4-K5 acetylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 5.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043982 </td> <td style=“text-align:left;”> histone H4-K8 acetylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 5.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072393 </td> <td style=“text-align:left;”> microtubule anchoring at microtubule organizing center </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 5.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097061 </td> <td style=“text-align:left;”> dendritic spine organization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 66 </td> <td style=“text-align:left;”> 5.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009123 </td> <td style=“text-align:left;”> nucleoside monophosphate metabolic process </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 5.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043588 </td> <td style=“text-align:left;”> skin development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 179 </td> <td style=“text-align:left;”> 5.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061053 </td> <td style=“text-align:left;”> somite development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 62 </td> <td style=“text-align:left;”> 5.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070131 </td> <td style=“text-align:left;”> positive regulation of mitochondrial translation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 5.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055119 </td> <td style=“text-align:left;”> relaxation of cardiac muscle </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 5.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033630 </td> <td style=“text-align:left;”> positive regulation of cell adhesion mediated by integrin </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 5.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071222 </td> <td style=“text-align:left;”> cellular response to lipopolysaccharide </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 114 </td> <td style=“text-align:left;”> 5.15e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032527 </td> <td style=“text-align:left;”> protein exit from endoplasmic reticulum </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 5.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006897 </td> <td style=“text-align:left;”> endocytosis </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 527 </td> <td style=“text-align:left;”> 5.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044403 </td> <td style=“text-align:left;”> biological process involved in symbiotic interaction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 225 </td> <td style=“text-align:left;”> 5.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140546 </td> <td style=“text-align:left;”> defense response to symbiont </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:right;”> 224 </td> <td style=“text-align:left;”> 5.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903514 </td> <td style=“text-align:left;”> release of sequestered calcium ion into cytosol by endoplasmic reticulum </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 5.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900087 </td> <td style=“text-align:left;”> positive regulation of G1/S transition of mitotic cell cycle </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 5.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001910 </td> <td style=“text-align:left;”> regulation of leukocyte mediated cytotoxicity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 5.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031111 </td> <td style=“text-align:left;”> negative regulation of microtubule polymerization or depolymerization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 5.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071346 </td> <td style=“text-align:left;”> cellular response to type II interferon </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 68 </td> <td style=“text-align:left;”> 5.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043543 </td> <td style=“text-align:left;”> protein acylation </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 193 </td> <td style=“text-align:left;”> 5.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007186 </td> <td style=“text-align:left;”> G protein-coupled receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 386 </td> <td style=“text-align:left;”> 5.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902749 </td> <td style=“text-align:left;”> regulation of cell cycle G2/M phase transition </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 105 </td> <td style=“text-align:left;”> 5.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006047 </td> <td style=“text-align:left;”> UDP-N-acetylglucosamine metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 5.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006177 </td> <td style=“text-align:left;”> GMP biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 5.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034394 </td> <td style=“text-align:left;”> protein localization to cell surface </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 60 </td> <td style=“text-align:left;”> 5.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090103 </td> <td style=“text-align:left;”> cochlea morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 5.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032729 </td> <td style=“text-align:left;”> positive regulation of type II interferon production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 5.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043409 </td> <td style=“text-align:left;”> negative regulation of MAPK cascade </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 145 </td> <td style=“text-align:left;”> 5.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044060 </td> <td style=“text-align:left;”> regulation of endocrine process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 5.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048545 </td> <td style=“text-align:left;”> response to steroid hormone </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 238 </td> <td style=“text-align:left;”> 5.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090267 </td> <td style=“text-align:left;”> positive regulation of mitotic cell cycle spindle assembly checkpoint </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 5.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007632 </td> <td style=“text-align:left;”> visual behavior </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 5.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045664 </td> <td style=“text-align:left;”> regulation of neuron differentiation </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 137 </td> <td style=“text-align:left;”> 5.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030032 </td> <td style=“text-align:left;”> lamellipodium assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 59 </td> <td style=“text-align:left;”> 5.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090232 </td> <td style=“text-align:left;”> positive regulation of spindle checkpoint </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 5.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061371 </td> <td style=“text-align:left;”> determination of heart left/right asymmetry </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 52 </td> <td style=“text-align:left;”> 5.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007611 </td> <td style=“text-align:left;”> learning or memory </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 201 </td> <td style=“text-align:left;”> 5.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043173 </td> <td style=“text-align:left;”> nucleotide salvage </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 5.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003143 </td> <td style=“text-align:left;”> embryonic heart tube morphogenesis </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 5.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009967 </td> <td style=“text-align:left;”> positive regulation of signal transduction </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:right;”> 1116 </td> <td style=“text-align:left;”> 5.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140029 </td> <td style=“text-align:left;”> exocytic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 5.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007095 </td> <td style=“text-align:left;”> mitotic G2 DNA damage checkpoint signaling </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 5.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001135 </td> <td style=“text-align:left;”> regulation of endocytic recycling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 5.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060216 </td> <td style=“text-align:left;”> definitive hemopoiesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 5.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061311 </td> <td style=“text-align:left;”> cell surface receptor signaling pathway involved in heart development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 5.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006412 </td> <td style=“text-align:left;”> translation </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:right;”> 657 </td> <td style=“text-align:left;”> 5.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030516 </td> <td style=“text-align:left;”> regulation of axon extension </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 82 </td> <td style=“text-align:left;”> 5.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000027 </td> <td style=“text-align:left;”> ribosomal large subunit assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 5.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030258 </td> <td style=“text-align:left;”> lipid modification </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 157 </td> <td style=“text-align:left;”> 5.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900544 </td> <td style=“text-align:left;”> positive regulation of purine nucleotide metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 5.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045981 </td> <td style=“text-align:left;”> positive regulation of nucleotide metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 5.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001934 </td> <td style=“text-align:left;”> positive regulation of protein phosphorylation </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 465 </td> <td style=“text-align:left;”> 5.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000785 </td> <td style=“text-align:left;”> regulation of autophagosome assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 5.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045048 </td> <td style=“text-align:left;”> protein insertion into ER membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 5.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045577 </td> <td style=“text-align:left;”> regulation of B cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 5.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050708 </td> <td style=“text-align:left;”> regulation of protein secretion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 186 </td> <td style=“text-align:left;”> 5.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000117 </td> <td style=“text-align:left;”> negative regulation of cysteine-type endopeptidase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 5.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090100 </td> <td style=“text-align:left;”> positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 82 </td> <td style=“text-align:left;”> 5.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903543 </td> <td style=“text-align:left;”> positive regulation of exosomal secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 5.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006458 </td> <td style=“text-align:left;”> ‘de novo’ protein folding </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 5.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014733 </td> <td style=“text-align:left;”> regulation of skeletal muscle adaptation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 5.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903533 </td> <td style=“text-align:left;”> regulation of protein targeting </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 67 </td> <td style=“text-align:left;”> 5.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031952 </td> <td style=“text-align:left;”> regulation of protein autophosphorylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 5.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0120255 </td> <td style=“text-align:left;”> olefinic compound biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 5.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031348 </td> <td style=“text-align:left;”> negative regulation of defense response </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:right;”> 182 </td> <td style=“text-align:left;”> 5.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901844 </td> <td style=“text-align:left;”> regulation of cell communication by electrical coupling involved in cardiac conduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 5.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051238 </td> <td style=“text-align:left;”> sequestering of metal ion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 5.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006309 </td> <td style=“text-align:left;”> apoptotic DNA fragmentation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 5.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003206 </td> <td style=“text-align:left;”> cardiac chamber morphogenesis </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 110 </td> <td style=“text-align:left;”> 5.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002902 </td> <td style=“text-align:left;”> regulation of B cell apoptotic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 5.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002709 </td> <td style=“text-align:left;”> regulation of T cell mediated immunity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 5.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901019 </td> <td style=“text-align:left;”> regulation of calcium ion transmembrane transporter activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 5.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901030 </td> <td style=“text-align:left;”> positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 5.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010225 </td> <td style=“text-align:left;”> response to UV-C </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 5.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140747 </td> <td style=“text-align:left;”> regulation of ncRNA transcription </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 79 </td> <td style=“text-align:left;”> 5.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034508 </td> <td style=“text-align:left;”> centromere complex assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 5.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051052 </td> <td style=“text-align:left;”> regulation of DNA metabolic process </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 456 </td> <td style=“text-align:left;”> 5.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030335 </td> <td style=“text-align:left;”> positive regulation of cell migration </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 408 </td> <td style=“text-align:left;”> 5.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032651 </td> <td style=“text-align:left;”> regulation of interleukin-1 beta production </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 5.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035567 </td> <td style=“text-align:left;”> non-canonical Wnt signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 67 </td> <td style=“text-align:left;”> 5.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002090 </td> <td style=“text-align:left;”> regulation of receptor internalization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 5.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0062009 </td> <td style=“text-align:left;”> secondary palate development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 5.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032611 </td> <td style=“text-align:left;”> interleukin-1 beta production </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 5.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140352 </td> <td style=“text-align:left;”> export from cell </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 617 </td> <td style=“text-align:left;”> 5.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051173 </td> <td style=“text-align:left;”> positive regulation of nitrogen compound metabolic process </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:right;”> 2367 </td> <td style=“text-align:left;”> 5.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060603 </td> <td style=“text-align:left;”> mammary gland duct morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 5.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021801 </td> <td style=“text-align:left;”> cerebral cortex radial glia-guided migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 5.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046135 </td> <td style=“text-align:left;”> pyrimidine nucleoside catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 5.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022030 </td> <td style=“text-align:left;”> telencephalon glial cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 5.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045869 </td> <td style=“text-align:left;”> negative regulation of single stranded viral RNA replication via double stranded DNA intermediate </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 5.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006366 </td> <td style=“text-align:left;”> transcription by RNA polymerase II </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:right;”> 1852 </td> <td style=“text-align:left;”> 5.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035518 </td> <td style=“text-align:left;”> histone H2A monoubiquitination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 5.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048667 </td> <td style=“text-align:left;”> cell morphogenesis involved in neuron differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 451 </td> <td style=“text-align:left;”> 5.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901984 </td> <td style=“text-align:left;”> negative regulation of protein acetylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 5.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006222 </td> <td style=“text-align:left;”> UMP biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 5.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042221 </td> <td style=“text-align:left;”> response to chemical </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 2456 </td> <td style=“text-align:left;”> 5.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036503 </td> <td style=“text-align:left;”> ERAD pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 104 </td> <td style=“text-align:left;”> 5.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045747 </td> <td style=“text-align:left;”> positive regulation of Notch signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 5.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036065 </td> <td style=“text-align:left;”> fucosylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 5.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034766 </td> <td style=“text-align:left;”> negative regulation of monoatomic ion transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 5.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006986 </td> <td style=“text-align:left;”> response to unfolded protein </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 126 </td> <td style=“text-align:left;”> 5.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010907 </td> <td style=“text-align:left;”> positive regulation of glucose metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 5.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003014 </td> <td style=“text-align:left;”> renal system process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 76 </td> <td style=“text-align:left;”> 5.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031396 </td> <td style=“text-align:left;”> regulation of protein ubiquitination </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 194 </td> <td style=“text-align:left;”> 5.30e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009126 </td> <td style=“text-align:left;”> purine nucleoside monophosphate metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 5.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046348 </td> <td style=“text-align:left;”> amino sugar catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 5.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032720 </td> <td style=“text-align:left;”> negative regulation of tumor necrosis factor production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 5.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031641 </td> <td style=“text-align:left;”> regulation of myelination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 5.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035418 </td> <td style=“text-align:left;”> protein localization to synapse </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 68 </td> <td style=“text-align:left;”> 5.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043200 </td> <td style=“text-align:left;”> response to amino acid </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 94 </td> <td style=“text-align:left;”> 5.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901863 </td> <td style=“text-align:left;”> positive regulation of muscle tissue development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 5.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006596 </td> <td style=“text-align:left;”> polyamine biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 5.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014033 </td> <td style=“text-align:left;”> neural crest cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 79 </td> <td style=“text-align:left;”> 5.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071840 </td> <td style=“text-align:left;”> cellular component organization or biogenesis </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 5307 </td> <td style=“text-align:left;”> 5.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002520 </td> <td style=“text-align:left;”> immune system development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 144 </td> <td style=“text-align:left;”> 5.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006607 </td> <td style=“text-align:left;”> NLS-bearing protein import into nucleus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 5.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043300 </td> <td style=“text-align:left;”> regulation of leukocyte degranulation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 5.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010765 </td> <td style=“text-align:left;”> positive regulation of sodium ion transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 5.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002327 </td> <td style=“text-align:left;”> immature B cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 5.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007283 </td> <td style=“text-align:left;”> spermatogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 333 </td> <td style=“text-align:left;”> 5.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097192 </td> <td style=“text-align:left;”> extrinsic apoptotic signaling pathway in absence of ligand </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 52 </td> <td style=“text-align:left;”> 5.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051568 </td> <td style=“text-align:left;”> histone H3-K4 methylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 5.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050878 </td> <td style=“text-align:left;”> regulation of body fluid levels </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 237 </td> <td style=“text-align:left;”> 5.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031401 </td> <td style=“text-align:left;”> positive regulation of protein modification process </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:right;”> 664 </td> <td style=“text-align:left;”> 5.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901362 </td> <td style=“text-align:left;”> organic cyclic compound biosynthetic process </td> <td style=“text-align:right;”> 90 </td> <td style=“text-align:right;”> 3221 </td> <td style=“text-align:left;”> 5.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0038034 </td> <td style=“text-align:left;”> signal transduction in absence of ligand </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 52 </td> <td style=“text-align:left;”> 5.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071219 </td> <td style=“text-align:left;”> cellular response to molecule of bacterial origin </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 118 </td> <td style=“text-align:left;”> 5.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009611 </td> <td style=“text-align:left;”> response to wounding </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 394 </td> <td style=“text-align:left;”> 5.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043010 </td> <td style=“text-align:left;”> camera-type eye development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 237 </td> <td style=“text-align:left;”> 5.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019438 </td> <td style=“text-align:left;”> aromatic compound biosynthetic process </td> <td style=“text-align:right;”> 87 </td> <td style=“text-align:right;”> 3116 </td> <td style=“text-align:left;”> 5.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030224 </td> <td style=“text-align:left;”> monocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 5.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001825 </td> <td style=“text-align:left;”> blastocyst formation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 5.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070584 </td> <td style=“text-align:left;”> mitochondrion morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 5.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002009 </td> <td style=“text-align:left;”> morphogenesis of an epithelium </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:right;”> 415 </td> <td style=“text-align:left;”> 5.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070936 </td> <td style=“text-align:left;”> protein K48-linked ubiquitination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 77 </td> <td style=“text-align:left;”> 5.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903241 </td> <td style=“text-align:left;”> U2-type prespliceosome assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 5.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071359 </td> <td style=“text-align:left;”> cellular response to dsRNA </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 5.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140053 </td> <td style=“text-align:left;”> mitochondrial gene expression </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 161 </td> <td style=“text-align:left;”> 5.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099638 </td> <td style=“text-align:left;”> endosome to plasma membrane protein transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 5.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015844 </td> <td style=“text-align:left;”> monoamine transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 5.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002532 </td> <td style=“text-align:left;”> production of molecular mediator involved in inflammatory response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 52 </td> <td style=“text-align:left;”> 5.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010821 </td> <td style=“text-align:left;”> regulation of mitochondrion organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 133 </td> <td style=“text-align:left;”> 5.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000050 </td> <td style=“text-align:left;”> regulation of non-canonical Wnt signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 5.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031345 </td> <td style=“text-align:left;”> negative regulation of cell projection organization </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 154 </td> <td style=“text-align:left;”> 5.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007035 </td> <td style=“text-align:left;”> vacuolar acidification </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 5.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010972 </td> <td style=“text-align:left;”> negative regulation of G2/M transition of mitotic cell cycle </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 60 </td> <td style=“text-align:left;”> 5.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903556 </td> <td style=“text-align:left;”> negative regulation of tumor necrosis factor superfamily cytokine production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 5.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030048 </td> <td style=“text-align:left;”> actin filament-based movement </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 111 </td> <td style=“text-align:left;”> 5.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006687 </td> <td style=“text-align:left;”> glycosphingolipid metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 5.39e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060191 </td> <td style=“text-align:left;”> regulation of lipase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 5.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001558 </td> <td style=“text-align:left;”> regulation of cell growth </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:right;”> 352 </td> <td style=“text-align:left;”> 5.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098609 </td> <td style=“text-align:left;”> cell-cell adhesion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 599 </td> <td style=“text-align:left;”> 5.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048232 </td> <td style=“text-align:left;”> male gamete generation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 346 </td> <td style=“text-align:left;”> 5.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048641 </td> <td style=“text-align:left;”> regulation of skeletal muscle tissue development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 5.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060623 </td> <td style=“text-align:left;”> regulation of chromosome condensation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 5.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046834 </td> <td style=“text-align:left;”> lipid phosphorylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 5.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002720 </td> <td style=“text-align:left;”> positive regulation of cytokine production involved in immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 5.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000773 </td> <td style=“text-align:left;”> negative regulation of cellular senescence </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 5.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043491 </td> <td style=“text-align:left;”> phosphatidylinositol 3-kinase/protein kinase B signal transduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 144 </td> <td style=“text-align:left;”> 5.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010876 </td> <td style=“text-align:left;”> lipid localization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 309 </td> <td style=“text-align:left;”> 5.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000079 </td> <td style=“text-align:left;”> regulation of cyclin-dependent protein serine/threonine kinase activity </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 83 </td> <td style=“text-align:left;”> 5.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051280 </td> <td style=“text-align:left;”> negative regulation of release of sequestered calcium ion into cytosol </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 5.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901841 </td> <td style=“text-align:left;”> regulation of high voltage-gated calcium channel activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 5.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070341 </td> <td style=“text-align:left;”> fat cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 5.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021952 </td> <td style=“text-align:left;”> central nervous system projection neuron axonogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 5.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032481 </td> <td style=“text-align:left;”> positive regulation of type I interferon production </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 5.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000147 </td> <td style=“text-align:left;”> positive regulation of cell motility </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 421 </td> <td style=“text-align:left;”> 5.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021772 </td> <td style=“text-align:left;”> olfactory bulb development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 5.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045913 </td> <td style=“text-align:left;”> positive regulation of carbohydrate metabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 61 </td> <td style=“text-align:left;”> 5.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000271 </td> <td style=“text-align:left;”> polysaccharide biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 54 </td> <td style=“text-align:left;”> 5.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070167 </td> <td style=“text-align:left;”> regulation of biomineral tissue development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 68 </td> <td style=“text-align:left;”> 5.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046903 </td> <td style=“text-align:left;”> secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 647 </td> <td style=“text-align:left;”> 5.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009855 </td> <td style=“text-align:left;”> determination of bilateral symmetry </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 101 </td> <td style=“text-align:left;”> 5.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009799 </td> <td style=“text-align:left;”> specification of symmetry </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 101 </td> <td style=“text-align:left;”> 5.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009887 </td> <td style=“text-align:left;”> animal organ morphogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 725 </td> <td style=“text-align:left;”> 5.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042307 </td> <td style=“text-align:left;”> positive regulation of protein import into nucleus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 5.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098657 </td> <td style=“text-align:left;”> import into cell </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 664 </td> <td style=“text-align:left;”> 5.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009749 </td> <td style=“text-align:left;”> response to glucose </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 138 </td> <td style=“text-align:left;”> 5.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048841 </td> <td style=“text-align:left;”> regulation of axon extension involved in axon guidance </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 5.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007034 </td> <td style=“text-align:left;”> vacuolar transport </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 149 </td> <td style=“text-align:left;”> 5.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043542 </td> <td style=“text-align:left;”> endothelial cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 184 </td> <td style=“text-align:left;”> 5.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045806 </td> <td style=“text-align:left;”> negative regulation of endocytosis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 5.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060048 </td> <td style=“text-align:left;”> cardiac muscle contraction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 121 </td> <td style=“text-align:left;”> 5.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0086012 </td> <td style=“text-align:left;”> membrane depolarization during cardiac muscle cell action potential </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 5.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010881 </td> <td style=“text-align:left;”> regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 5.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0012501 </td> <td style=“text-align:left;”> programmed cell death </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:right;”> 1498 </td> <td style=“text-align:left;”> 5.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044419 </td> <td style=“text-align:left;”> biological process involved in interspecies interaction between organisms </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 985 </td> <td style=“text-align:left;”> 5.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009174 </td> <td style=“text-align:left;”> pyrimidine ribonucleoside monophosphate biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 5.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032435 </td> <td style=“text-align:left;”> negative regulation of proteasomal ubiquitin-dependent protein catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 5.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060840 </td> <td style=“text-align:left;”> artery development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 85 </td> <td style=“text-align:left;”> 5.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035282 </td> <td style=“text-align:left;”> segmentation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 5.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030324 </td> <td style=“text-align:left;”> lung development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 144 </td> <td style=“text-align:left;”> 5.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003407 </td> <td style=“text-align:left;”> neural retina development </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 47 </td> <td style=“text-align:left;”> 5.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031341 </td> <td style=“text-align:left;”> regulation of cell killing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 5.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007417 </td> <td style=“text-align:left;”> central nervous system development </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 750 </td> <td style=“text-align:left;”> 5.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000027 </td> <td style=“text-align:left;”> regulation of animal organ morphogenesis </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 102 </td> <td style=“text-align:left;”> 5.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904035 </td> <td style=“text-align:left;”> regulation of epithelial cell apoptotic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 5.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043523 </td> <td style=“text-align:left;”> regulation of neuron apoptotic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 172 </td> <td style=“text-align:left;”> 5.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031328 </td> <td style=“text-align:left;”> positive regulation of cellular biosynthetic process </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:right;”> 1958 </td> <td style=“text-align:left;”> 5.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070841 </td> <td style=“text-align:left;”> inclusion body assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 5.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032387 </td> <td style=“text-align:left;”> negative regulation of intracellular transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 5.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905953 </td> <td style=“text-align:left;”> negative regulation of lipid localization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 5.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903541 </td> <td style=“text-align:left;”> regulation of exosomal secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 5.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033233 </td> <td style=“text-align:left;”> regulation of protein sumoylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 5.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051782 </td> <td style=“text-align:left;”> negative regulation of cell division </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 5.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061326 </td> <td style=“text-align:left;”> renal tubule development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 78 </td> <td style=“text-align:left;”> 5.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045069 </td> <td style=“text-align:left;”> regulation of viral genome replication </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 5.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018216 </td> <td style=“text-align:left;”> peptidyl-arginine methylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 5.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031644 </td> <td style=“text-align:left;”> regulation of nervous system process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 87 </td> <td style=“text-align:left;”> 5.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0040017 </td> <td style=“text-align:left;”> positive regulation of locomotion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 429 </td> <td style=“text-align:left;”> 5.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043248 </td> <td style=“text-align:left;”> proteasome assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 5.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071495 </td> <td style=“text-align:left;”> cellular response to endogenous stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1097 </td> <td style=“text-align:left;”> 5.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006801 </td> <td style=“text-align:left;”> superoxide metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 5.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000379 </td> <td style=“text-align:left;”> positive regulation of reactive oxygen species metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 5.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008219 </td> <td style=“text-align:left;”> cell death </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:right;”> 1504 </td> <td style=“text-align:left;”> 5.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902750 </td> <td style=“text-align:left;”> negative regulation of cell cycle G2/M phase transition </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 62 </td> <td style=“text-align:left;”> 5.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0038095 </td> <td style=“text-align:left;”> Fc-epsilon receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 5.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071732 </td> <td style=“text-align:left;”> cellular response to nitric oxide </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 5.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010632 </td> <td style=“text-align:left;”> regulation of epithelial cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 195 </td> <td style=“text-align:left;”> 5.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045616 </td> <td style=“text-align:left;”> regulation of keratinocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 5.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009746 </td> <td style=“text-align:left;”> response to hexose </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 139 </td> <td style=“text-align:left;”> 5.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901184 </td> <td style=“text-align:left;”> regulation of ERBB signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 59 </td> <td style=“text-align:left;”> 5.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050767 </td> <td style=“text-align:left;”> regulation of neurogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 302 </td> <td style=“text-align:left;”> 5.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903532 </td> <td style=“text-align:left;”> positive regulation of secretion by cell </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 198 </td> <td style=“text-align:left;”> 5.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901873 </td> <td style=“text-align:left;”> regulation of post-translational protein modification </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:right;”> 302 </td> <td style=“text-align:left;”> 5.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030850 </td> <td style=“text-align:left;”> prostate gland development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 5.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021988 </td> <td style=“text-align:left;”> olfactory lobe development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 5.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098542 </td> <td style=“text-align:left;”> defense response to other organism </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 635 </td> <td style=“text-align:left;”> 5.57e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030323 </td> <td style=“text-align:left;”> respiratory tube development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 148 </td> <td style=“text-align:left;”> 5.57e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031325 </td> <td style=“text-align:left;”> positive regulation of cellular metabolic process </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:right;”> 2518 </td> <td style=“text-align:left;”> 5.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097091 </td> <td style=“text-align:left;”> synaptic vesicle clustering </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 5.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0017145 </td> <td style=“text-align:left;”> stem cell division </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 5.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0052646 </td> <td style=“text-align:left;”> alditol phosphate metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 5.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001701 </td> <td style=“text-align:left;”> in utero embryonic development </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:right;”> 338 </td> <td style=“text-align:left;”> 5.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901029 </td> <td style=“text-align:left;”> negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 5.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008544 </td> <td style=“text-align:left;”> epidermis development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 213 </td> <td style=“text-align:left;”> 5.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051258 </td> <td style=“text-align:left;”> protein polymerization </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 237 </td> <td style=“text-align:left;”> 5.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045185 </td> <td style=“text-align:left;”> maintenance of protein location </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 84 </td> <td style=“text-align:left;”> 5.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006883 </td> <td style=“text-align:left;”> intracellular sodium ion homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 5.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001941 </td> <td style=“text-align:left;”> postsynaptic membrane organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 5.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000232 </td> <td style=“text-align:left;”> regulation of rRNA processing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 5.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904029 </td> <td style=“text-align:left;”> regulation of cyclin-dependent protein kinase activity </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 87 </td> <td style=“text-align:left;”> 5.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006401 </td> <td style=“text-align:left;”> RNA catabolic process </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 263 </td> <td style=“text-align:left;”> 5.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901077 </td> <td style=“text-align:left;”> regulation of relaxation of muscle </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 5.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018193 </td> <td style=“text-align:left;”> peptidyl-amino acid modification </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 866 </td> <td style=“text-align:left;”> 5.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061099 </td> <td style=“text-align:left;”> negative regulation of protein tyrosine kinase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 5.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009581 </td> <td style=“text-align:left;”> detection of external stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 66 </td> <td style=“text-align:left;”> 5.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044248 </td> <td style=“text-align:left;”> cellular catabolic process </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:right;”> 1243 </td> <td style=“text-align:left;”> 5.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051153 </td> <td style=“text-align:left;”> regulation of striated muscle cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 66 </td> <td style=“text-align:left;”> 5.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031145 </td> <td style=“text-align:left;”> anaphase-promoting complex-dependent catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 5.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090277 </td> <td style=“text-align:left;”> positive regulation of peptide hormone secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 72 </td> <td style=“text-align:left;”> 5.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002066 </td> <td style=“text-align:left;”> columnar/cuboidal epithelial cell development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 5.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009791 </td> <td style=“text-align:left;”> post-embryonic development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 76 </td> <td style=“text-align:left;”> 5.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0150078 </td> <td style=“text-align:left;”> positive regulation of neuroinflammatory response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:left;”> 5.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060042 </td> <td style=“text-align:left;”> retina morphogenesis in camera-type eye </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 5.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901976 </td> <td style=“text-align:left;”> regulation of cell cycle checkpoint </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 5.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042177 </td> <td style=“text-align:left;”> negative regulation of protein catabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 100 </td> <td style=“text-align:left;”> 5.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071347 </td> <td style=“text-align:left;”> cellular response to interleukin-1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 5.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031398 </td> <td style=“text-align:left;”> positive regulation of protein ubiquitination </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 109 </td> <td style=“text-align:left;”> 5.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009891 </td> <td style=“text-align:left;”> positive regulation of biosynthetic process </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:right;”> 1972 </td> <td style=“text-align:left;”> 5.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032787 </td> <td style=“text-align:left;”> monocarboxylic acid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 434 </td> <td style=“text-align:left;”> 5.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032496 </td> <td style=“text-align:left;”> response to lipopolysaccharide </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 184 </td> <td style=“text-align:left;”> 5.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006337 </td> <td style=“text-align:left;”> nucleosome disassembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 5.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042308 </td> <td style=“text-align:left;”> negative regulation of protein import into nucleus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 5.62e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097746 </td> <td style=“text-align:left;”> blood vessel diameter maintenance </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 98 </td> <td style=“text-align:left;”> 5.62e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035296 </td> <td style=“text-align:left;”> regulation of tube diameter </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 98 </td> <td style=“text-align:left;”> 5.62e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002753 </td> <td style=“text-align:left;”> cytosolic pattern recognition receptor signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 99 </td> <td style=“text-align:left;”> 5.62e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990830 </td> <td style=“text-align:left;”> cellular response to leukemia inhibitory factor </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 86 </td> <td style=“text-align:left;”> 5.62e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055075 </td> <td style=“text-align:left;”> potassium ion homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 5.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043066 </td> <td style=“text-align:left;”> negative regulation of apoptotic process </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 662 </td> <td style=“text-align:left;”> 5.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071466 </td> <td style=“text-align:left;”> cellular response to xenobiotic stimulus </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 108 </td> <td style=“text-align:left;”> 5.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035150 </td> <td style=“text-align:left;”> regulation of tube size </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 98 </td> <td style=“text-align:left;”> 5.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009582 </td> <td style=“text-align:left;”> detection of abiotic stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 67 </td> <td style=“text-align:left;”> 5.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060078 </td> <td style=“text-align:left;”> regulation of postsynaptic membrane potential </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 85 </td> <td style=“text-align:left;”> 5.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048812 </td> <td style=“text-align:left;”> neuron projection morphogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 500 </td> <td style=“text-align:left;”> 5.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043043 </td> <td style=“text-align:left;”> peptide biosynthetic process </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:right;”> 677 </td> <td style=“text-align:left;”> 5.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090263 </td> <td style=“text-align:left;”> positive regulation of canonical Wnt signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 91 </td> <td style=“text-align:left;”> 5.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140353 </td> <td style=“text-align:left;”> lipid export from cell </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 5.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043113 </td> <td style=“text-align:left;”> receptor clustering </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 5.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000272 </td> <td style=“text-align:left;”> negative regulation of signaling receptor activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 5.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009893 </td> <td style=“text-align:left;”> positive regulation of metabolic process </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:right;”> 2846 </td> <td style=“text-align:left;”> 5.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032414 </td> <td style=“text-align:left;”> positive regulation of ion transmembrane transporter activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 83 </td> <td style=“text-align:left;”> 5.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001654 </td> <td style=“text-align:left;”> eye development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 273 </td> <td style=“text-align:left;”> 5.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001768 </td> <td style=“text-align:left;”> establishment of T cell polarity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 5.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000266 </td> <td style=“text-align:left;”> mitochondrial fission </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 5.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045091 </td> <td style=“text-align:left;”> regulation of single stranded viral RNA replication via double stranded DNA intermediate </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 5.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990823 </td> <td style=“text-align:left;”> response to leukemia inhibitory factor </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 87 </td> <td style=“text-align:left;”> 5.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0039531 </td> <td style=“text-align:left;”> regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 67 </td> <td style=“text-align:left;”> 5.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016553 </td> <td style=“text-align:left;”> base conversion or substitution editing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 5.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070373 </td> <td style=“text-align:left;”> negative regulation of ERK1 and ERK2 cascade </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 5.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051156 </td> <td style=“text-align:left;”> glucose 6-phosphate metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 5.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046068 </td> <td style=“text-align:left;”> cGMP metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 5.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0106027 </td> <td style=“text-align:left;”> neuron projection organization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 75 </td> <td style=“text-align:left;”> 5.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055088 </td> <td style=“text-align:left;”> lipid homeostasis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 116 </td> <td style=“text-align:left;”> 5.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090036 </td> <td style=“text-align:left;”> regulation of protein kinase C signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 5.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098869 </td> <td style=“text-align:left;”> cellular oxidant detoxification </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 5.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046330 </td> <td style=“text-align:left;”> positive regulation of JNK cascade </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 71 </td> <td style=“text-align:left;”> 5.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034284 </td> <td style=“text-align:left;”> response to monosaccharide </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 143 </td> <td style=“text-align:left;”> 5.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006865 </td> <td style=“text-align:left;”> amino acid transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 103 </td> <td style=“text-align:left;”> 5.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060324 </td> <td style=“text-align:left;”> face development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 5.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032330 </td> <td style=“text-align:left;”> regulation of chondrocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 5.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098719 </td> <td style=“text-align:left;”> sodium ion import across plasma membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 5.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0150063 </td> <td style=“text-align:left;”> visual system development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 274 </td> <td style=“text-align:left;”> 5.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045842 </td> <td style=“text-align:left;”> positive regulation of mitotic metaphase/anaphase transition </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 5.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006778 </td> <td style=“text-align:left;”> porphyrin-containing compound metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 5.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097421 </td> <td style=“text-align:left;”> liver regeneration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 5.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090317 </td> <td style=“text-align:left;”> negative regulation of intracellular protein transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 5.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050872 </td> <td style=“text-align:left;”> white fat cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 5.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002281 </td> <td style=“text-align:left;”> macrophage activation involved in immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 5.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902284 </td> <td style=“text-align:left;”> neuron projection extension involved in neuron projection guidance </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 5.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048846 </td> <td style=“text-align:left;”> axon extension involved in axon guidance </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 5.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001974 </td> <td style=“text-align:left;”> blood vessel remodeling </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 5.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050775 </td> <td style=“text-align:left;”> positive regulation of dendrite morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 5.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0120039 </td> <td style=“text-align:left;”> plasma membrane bounded cell projection morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 515 </td> <td style=“text-align:left;”> 5.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903531 </td> <td style=“text-align:left;”> negative regulation of secretion by cell </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 101 </td> <td style=“text-align:left;”> 5.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097581 </td> <td style=“text-align:left;”> lamellipodium organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 77 </td> <td style=“text-align:left;”> 5.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014074 </td> <td style=“text-align:left;”> response to purine-containing compound </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 108 </td> <td style=“text-align:left;”> 5.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006357 </td> <td style=“text-align:left;”> regulation of transcription by RNA polymerase II </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:right;”> 1764 </td> <td style=“text-align:left;”> 5.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048880 </td> <td style=“text-align:left;”> sensory system development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 276 </td> <td style=“text-align:left;”> 5.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000291 </td> <td style=“text-align:left;”> regulation of myoblast proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 5.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014857 </td> <td style=“text-align:left;”> regulation of skeletal muscle cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 5.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070296 </td> <td style=“text-align:left;”> sarcoplasmic reticulum calcium ion transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 5.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015868 </td> <td style=“text-align:left;”> purine ribonucleotide transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 5.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006044 </td> <td style=“text-align:left;”> N-acetylglucosamine metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 5.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048525 </td> <td style=“text-align:left;”> negative regulation of viral process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 65 </td> <td style=“text-align:left;”> 5.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048858 </td> <td style=“text-align:left;”> cell projection morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 519 </td> <td style=“text-align:left;”> 5.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030900 </td> <td style=“text-align:left;”> forebrain development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 290 </td> <td style=“text-align:left;”> 5.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046112 </td> <td style=“text-align:left;”> nucleobase biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 5.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046040 </td> <td style=“text-align:left;”> IMP metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 5.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903311 </td> <td style=“text-align:left;”> regulation of mRNA metabolic process </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 255 </td> <td style=“text-align:left;”> 5.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002831 </td> <td style=“text-align:left;”> regulation of response to biotic stimulus </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 322 </td> <td style=“text-align:left;”> 5.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045926 </td> <td style=“text-align:left;”> negative regulation of growth </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 204 </td> <td style=“text-align:left;”> 5.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035295 </td> <td style=“text-align:left;”> tube development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 822 </td> <td style=“text-align:left;”> 5.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009161 </td> <td style=“text-align:left;”> ribonucleoside monophosphate metabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 5.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051284 </td> <td style=“text-align:left;”> positive regulation of sequestering of calcium ion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 5.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071577 </td> <td style=“text-align:left;”> zinc ion transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 5.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050920 </td> <td style=“text-align:left;”> regulation of chemotaxis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 143 </td> <td style=“text-align:left;”> 5.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900542 </td> <td style=“text-align:left;”> regulation of purine nucleotide metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 5.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010604 </td> <td style=“text-align:left;”> positive regulation of macromolecule metabolic process </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:right;”> 2607 </td> <td style=“text-align:left;”> 5.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007596 </td> <td style=“text-align:left;”> blood coagulation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 150 </td> <td style=“text-align:left;”> 5.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050770 </td> <td style=“text-align:left;”> regulation of axonogenesis </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 139 </td> <td style=“text-align:left;”> 5.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048706 </td> <td style=“text-align:left;”> embryonic skeletal system development </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 77 </td> <td style=“text-align:left;”> 5.78e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001944 </td> <td style=“text-align:left;”> vasculature development </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 562 </td> <td style=“text-align:left;”> 5.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900102 </td> <td style=“text-align:left;”> negative regulation of endoplasmic reticulum unfolded protein response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 5.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0086010 </td> <td style=“text-align:left;”> membrane depolarization during action potential </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 5.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042454 </td> <td style=“text-align:left;”> ribonucleoside catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 5.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021513 </td> <td style=“text-align:left;”> spinal cord dorsal/ventral patterning </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 5.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900226 </td> <td style=“text-align:left;”> negative regulation of NLRP3 inflammasome complex assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 5.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032368 </td> <td style=“text-align:left;”> regulation of lipid transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 91 </td> <td style=“text-align:left;”> 5.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009966 </td> <td style=“text-align:left;”> regulation of signal transduction </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:right;”> 2271 </td> <td style=“text-align:left;”> 5.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045744 </td> <td style=“text-align:left;”> negative regulation of G protein-coupled receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 5.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902170 </td> <td style=“text-align:left;”> cellular response to reactive nitrogen species </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 5.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002886 </td> <td style=“text-align:left;”> regulation of myeloid leukocyte mediated immunity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 5.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0023035 </td> <td style=“text-align:left;”> CD40 signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 5.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006360 </td> <td style=“text-align:left;”> transcription by RNA polymerase I </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 5.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001767 </td> <td style=“text-align:left;”> establishment of lymphocyte polarity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 5.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097398 </td> <td style=“text-align:left;”> cellular response to interleukin-17 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 5.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002698 </td> <td style=“text-align:left;”> negative regulation of immune effector process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 59 </td> <td style=“text-align:left;”> 5.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904064 </td> <td style=“text-align:left;”> positive regulation of cation transmembrane transport </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 97 </td> <td style=“text-align:left;”> 5.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032990 </td> <td style=“text-align:left;”> cell part morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 539 </td> <td style=“text-align:left;”> 5.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043069 </td> <td style=“text-align:left;”> negative regulation of programmed cell death </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 685 </td> <td style=“text-align:left;”> 5.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044839 </td> <td style=“text-align:left;”> cell cycle G2/M phase transition </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 145 </td> <td style=“text-align:left;”> 5.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010738 </td> <td style=“text-align:left;”> regulation of protein kinase A signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 5.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050817 </td> <td style=“text-align:left;”> coagulation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 153 </td> <td style=“text-align:left;”> 5.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071364 </td> <td style=“text-align:left;”> cellular response to epidermal growth factor stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 5.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016266 </td> <td style=“text-align:left;”> O-glycan processing </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 5.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006878 </td> <td style=“text-align:left;”> intracellular copper ion homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 5.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0039535 </td> <td style=“text-align:left;”> regulation of RIG-I signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 5.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070542 </td> <td style=“text-align:left;”> response to fatty acid </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 5.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006140 </td> <td style=“text-align:left;”> regulation of nucleotide metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 5.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061180 </td> <td style=“text-align:left;”> mammary gland epithelium development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 5.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006829 </td> <td style=“text-align:left;”> zinc ion transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 5.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902101 </td> <td style=“text-align:left;”> positive regulation of metaphase/anaphase transition of cell cycle </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 5.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007599 </td> <td style=“text-align:left;”> hemostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 154 </td> <td style=“text-align:left;”> 5.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045063 </td> <td style=“text-align:left;”> T-helper 1 cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 5.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043488 </td> <td style=“text-align:left;”> regulation of mRNA stability </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 149 </td> <td style=“text-align:left;”> 5.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042790 </td> <td style=“text-align:left;”> nucleolar large rRNA transcription by RNA polymerase I </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 5.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009162 </td> <td style=“text-align:left;”> deoxyribonucleoside monophosphate metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 5.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043254 </td> <td style=“text-align:left;”> regulation of protein-containing complex assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 340 </td> <td style=“text-align:left;”> 5.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010770 </td> <td style=“text-align:left;”> positive regulation of cell morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 5.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010623 </td> <td style=“text-align:left;”> programmed cell death involved in cell development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 5.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032986 </td> <td style=“text-align:left;”> protein-DNA complex disassembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 5.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060576 </td> <td style=“text-align:left;”> intestinal epithelial cell development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 5.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060996 </td> <td style=“text-align:left;”> dendritic spine development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 83 </td> <td style=“text-align:left;”> 5.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099587 </td> <td style=“text-align:left;”> inorganic ion import across plasma membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 71 </td> <td style=“text-align:left;”> 5.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009226 </td> <td style=“text-align:left;”> nucleotide-sugar biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 5.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002456 </td> <td style=“text-align:left;”> T cell mediated immunity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 61 </td> <td style=“text-align:left;”> 5.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098659 </td> <td style=“text-align:left;”> inorganic cation import across plasma membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 71 </td> <td style=“text-align:left;”> 5.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071216 </td> <td style=“text-align:left;”> cellular response to biotic stimulus </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 141 </td> <td style=“text-align:left;”> 5.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030278 </td> <td style=“text-align:left;”> regulation of ossification </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 85 </td> <td style=“text-align:left;”> 5.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032652 </td> <td style=“text-align:left;”> regulation of interleukin-1 production </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 5.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032612 </td> <td style=“text-align:left;”> interleukin-1 production </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 5.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009168 </td> <td style=“text-align:left;”> purine ribonucleoside monophosphate biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 5.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010720 </td> <td style=“text-align:left;”> positive regulation of cell development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 318 </td> <td style=“text-align:left;”> 5.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010842 </td> <td style=“text-align:left;”> retina layer formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 5.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014841 </td> <td style=“text-align:left;”> skeletal muscle satellite cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 5.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046321 </td> <td style=“text-align:left;”> positive regulation of fatty acid oxidation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 5.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003012 </td> <td style=“text-align:left;”> muscle system process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 334 </td> <td style=“text-align:left;”> 5.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034661 </td> <td style=“text-align:left;”> ncRNA catabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 5.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903779 </td> <td style=“text-align:left;”> regulation of cardiac conduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 5.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904062 </td> <td style=“text-align:left;”> regulation of monoatomic cation transmembrane transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 232 </td> <td style=“text-align:left;”> 5.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014829 </td> <td style=“text-align:left;”> vascular associated smooth muscle contraction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 5.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006826 </td> <td style=“text-align:left;”> iron ion transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 5.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990182 </td> <td style=“text-align:left;”> exosomal secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 5.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000122 </td> <td style=“text-align:left;”> negative regulation of transcription by RNA polymerase II </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:right;”> 744 </td> <td style=“text-align:left;”> 5.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035640 </td> <td style=“text-align:left;”> exploration behavior </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 5.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905477 </td> <td style=“text-align:left;”> positive regulation of protein localization to membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 84 </td> <td style=“text-align:left;”> 5.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007006 </td> <td style=“text-align:left;”> mitochondrial membrane organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 112 </td> <td style=“text-align:left;”> 5.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002237 </td> <td style=“text-align:left;”> response to molecule of bacterial origin </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 193 </td> <td style=“text-align:left;”> 5.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009719 </td> <td style=“text-align:left;”> response to endogenous stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1260 </td> <td style=“text-align:left;”> 5.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042994 </td> <td style=“text-align:left;”> cytoplasmic sequestering of transcription factor </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 5.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030282 </td> <td style=“text-align:left;”> bone mineralization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 83 </td> <td style=“text-align:left;”> 5.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051281 </td> <td style=“text-align:left;”> positive regulation of release of sequestered calcium ion into cytosol </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 5.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006518 </td> <td style=“text-align:left;”> peptide metabolic process </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:right;”> 781 </td> <td style=“text-align:left;”> 5.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034763 </td> <td style=“text-align:left;”> negative regulation of transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 96 </td> <td style=“text-align:left;”> 5.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032411 </td> <td style=“text-align:left;”> positive regulation of transporter activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 93 </td> <td style=“text-align:left;”> 5.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043271 </td> <td style=“text-align:left;”> negative regulation of monoatomic ion transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 88 </td> <td style=“text-align:left;”> 5.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903020 </td> <td style=“text-align:left;”> positive regulation of glycoprotein metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 5.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045773 </td> <td style=“text-align:left;”> positive regulation of axon extension </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 5.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009056 </td> <td style=“text-align:left;”> catabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 2108 </td> <td style=“text-align:left;”> 5.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021799 </td> <td style=“text-align:left;”> cerebral cortex radially oriented cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 5.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050771 </td> <td style=“text-align:left;”> negative regulation of axonogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 59 </td> <td style=“text-align:left;”> 5.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0023056 </td> <td style=“text-align:left;”> positive regulation of signaling </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:right;”> 1252 </td> <td style=“text-align:left;”> 5.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006937 </td> <td style=“text-align:left;”> regulation of muscle contraction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 130 </td> <td style=“text-align:left;”> 5.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046165 </td> <td style=“text-align:left;”> alcohol biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 111 </td> <td style=“text-align:left;”> 5.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032104 </td> <td style=“text-align:left;”> regulation of response to extracellular stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 5.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007276 </td> <td style=“text-align:left;”> gamete generation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 465 </td> <td style=“text-align:left;”> 5.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021854 </td> <td style=“text-align:left;”> hypothalamus development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 5.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060041 </td> <td style=“text-align:left;”> retina development in camera-type eye </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 109 </td> <td style=“text-align:left;”> 5.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010669 </td> <td style=“text-align:left;”> epithelial structure maintenance </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 5.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009266 </td> <td style=“text-align:left;”> response to temperature stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 122 </td> <td style=“text-align:left;”> 5.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070979 </td> <td style=“text-align:left;”> protein K11-linked ubiquitination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 5.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032107 </td> <td style=“text-align:left;”> regulation of response to nutrient levels </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 5.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031146 </td> <td style=“text-align:left;”> SCF-dependent proteasomal ubiquitin-dependent protein catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 5.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051928 </td> <td style=“text-align:left;”> positive regulation of calcium ion transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 80 </td> <td style=“text-align:left;”> 5.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010390 </td> <td style=“text-align:left;”> histone monoubiquitination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 5.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006595 </td> <td style=“text-align:left;”> polyamine metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 5.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051091 </td> <td style=“text-align:left;”> positive regulation of DNA-binding transcription factor activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 199 </td> <td style=“text-align:left;”> 5.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051503 </td> <td style=“text-align:left;”> adenine nucleotide transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 5.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035338 </td> <td style=“text-align:left;”> long-chain fatty-acyl-CoA biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 5.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001169 </td> <td style=“text-align:left;”> regulation of ATP biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 5.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018023 </td> <td style=“text-align:left;”> peptidyl-lysine trimethylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 5.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006006 </td> <td style=“text-align:left;”> glucose metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 153 </td> <td style=“text-align:left;”> 5.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061644 </td> <td style=“text-align:left;”> protein localization to CENP-A containing chromatin </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:left;”> 5.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046475 </td> <td style=“text-align:left;”> glycerophospholipid catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 5.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048522 </td> <td style=“text-align:left;”> positive regulation of cellular process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4197 </td> <td style=“text-align:left;”> 5.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097396 </td> <td style=“text-align:left;”> response to interleukin-17 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 5.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0023061 </td> <td style=“text-align:left;”> signal release </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 329 </td> <td style=“text-align:left;”> 5.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045667 </td> <td style=“text-align:left;”> regulation of osteoblast differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 97 </td> <td style=“text-align:left;”> 5.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034976 </td> <td style=“text-align:left;”> response to endoplasmic reticulum stress </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 235 </td> <td style=“text-align:left;”> 5.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048854 </td> <td style=“text-align:left;”> brain morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 5.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010882 </td> <td style=“text-align:left;”> regulation of cardiac muscle contraction by calcium ion signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 5.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048638 </td> <td style=“text-align:left;”> regulation of developmental growth </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 254 </td> <td style=“text-align:left;”> 5.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002026 </td> <td style=“text-align:left;”> regulation of the force of heart contraction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 5.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016052 </td> <td style=“text-align:left;”> carbohydrate catabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 125 </td> <td style=“text-align:left;”> 5.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001704 </td> <td style=“text-align:left;”> formation of primary germ layer </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 97 </td> <td style=“text-align:left;”> 5.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032869 </td> <td style=“text-align:left;”> cellular response to insulin stimulus </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 167 </td> <td style=“text-align:left;”> 5.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006144 </td> <td style=“text-align:left;”> purine nucleobase metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 5.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060711 </td> <td style=“text-align:left;”> labyrinthine layer development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 5.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051960 </td> <td style=“text-align:left;”> regulation of nervous system development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 357 </td> <td style=“text-align:left;”> 5.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021675 </td> <td style=“text-align:left;”> nerve development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 63 </td> <td style=“text-align:left;”> 5.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046889 </td> <td style=“text-align:left;”> positive regulation of lipid biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 5.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099560 </td> <td style=“text-align:left;”> synaptic membrane adhesion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 5.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006066 </td> <td style=“text-align:left;”> alcohol metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 263 </td> <td style=“text-align:left;”> 5.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903859 </td> <td style=“text-align:left;”> regulation of dendrite extension </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 5.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009130 </td> <td style=“text-align:left;”> pyrimidine nucleoside monophosphate biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 5.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031960 </td> <td style=“text-align:left;”> response to corticosteroid </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 93 </td> <td style=“text-align:left;”> 5.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046049 </td> <td style=“text-align:left;”> UMP metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 5.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010629 </td> <td style=“text-align:left;”> negative regulation of gene expression </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:right;”> 823 </td> <td style=“text-align:left;”> 5.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001101 </td> <td style=“text-align:left;”> response to acid chemical </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 103 </td> <td style=“text-align:left;”> 5.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097734 </td> <td style=“text-align:left;”> extracellular exosome biogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 5.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051048 </td> <td style=“text-align:left;”> negative regulation of secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 111 </td> <td style=“text-align:left;”> 5.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033189 </td> <td style=“text-align:left;”> response to vitamin A </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 5.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099149 </td> <td style=“text-align:left;”> regulation of postsynaptic neurotransmitter receptor internalization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 5.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000462 </td> <td style=“text-align:left;”> maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 5.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048584 </td> <td style=“text-align:left;”> positive regulation of response to stimulus </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:right;”> 1557 </td> <td style=“text-align:left;”> 5.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035050 </td> <td style=“text-align:left;”> embryonic heart tube development </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 5.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033500 </td> <td style=“text-align:left;”> carbohydrate homeostasis </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 172 </td> <td style=“text-align:left;”> 5.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000108 </td> <td style=“text-align:left;”> positive regulation of leukocyte apoptotic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 5.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060986 </td> <td style=“text-align:left;”> endocrine hormone secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 5.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060350 </td> <td style=“text-align:left;”> endochondral bone morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 47 </td> <td style=“text-align:left;”> 5.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045912 </td> <td style=“text-align:left;”> negative regulation of carbohydrate metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 5.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033598 </td> <td style=“text-align:left;”> mammary gland epithelial cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 5.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007266 </td> <td style=“text-align:left;”> Rho protein signal transduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 107 </td> <td style=“text-align:left;”> 5.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007167 </td> <td style=“text-align:left;”> enzyme-linked receptor protein signaling pathway </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 741 </td> <td style=“text-align:left;”> 5.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035265 </td> <td style=“text-align:left;”> organ growth </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 128 </td> <td style=“text-align:left;”> 5.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903978 </td> <td style=“text-align:left;”> regulation of microglial cell activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 5.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007612 </td> <td style=“text-align:left;”> learning </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 114 </td> <td style=“text-align:left;”> 5.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902904 </td> <td style=“text-align:left;”> negative regulation of supramolecular fiber organization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 136 </td> <td style=“text-align:left;”> 5.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048806 </td> <td style=“text-align:left;”> genitalia development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 6.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021511 </td> <td style=“text-align:left;”> spinal cord patterning </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:left;”> 6.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070849 </td> <td style=“text-align:left;”> response to epidermal growth factor </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 6.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001817 </td> <td style=“text-align:left;”> regulation of cytokine production </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 476 </td> <td style=“text-align:left;”> 6.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008360 </td> <td style=“text-align:left;”> regulation of cell shape </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 115 </td> <td style=“text-align:left;”> 6.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902414 </td> <td style=“text-align:left;”> protein localization to cell junction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 94 </td> <td style=“text-align:left;”> 6.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060429 </td> <td style=“text-align:left;”> epithelium development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 849 </td> <td style=“text-align:left;”> 6.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003228 </td> <td style=“text-align:left;”> atrial cardiac muscle tissue development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 6.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050806 </td> <td style=“text-align:left;”> positive regulation of synaptic transmission </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 110 </td> <td style=“text-align:left;”> 6.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061709 </td> <td style=“text-align:left;”> reticulophagy </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 6.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006915 </td> <td style=“text-align:left;”> apoptotic process </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:right;”> 1452 </td> <td style=“text-align:left;”> 6.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902001 </td> <td style=“text-align:left;”> fatty acid transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 6.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010822 </td> <td style=“text-align:left;”> positive regulation of mitochondrion organization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 66 </td> <td style=“text-align:left;”> 6.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006952 </td> <td style=“text-align:left;”> defense response </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:right;”> 967 </td> <td style=“text-align:left;”> 6.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015865 </td> <td style=“text-align:left;”> purine nucleotide transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 6.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009743 </td> <td style=“text-align:left;”> response to carbohydrate </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 161 </td> <td style=“text-align:left;”> 6.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001816 </td> <td style=“text-align:left;”> cytokine production </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 480 </td> <td style=“text-align:left;”> 6.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048592 </td> <td style=“text-align:left;”> eye morphogenesis </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 114 </td> <td style=“text-align:left;”> 6.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021955 </td> <td style=“text-align:left;”> central nervous system neuron axonogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 6.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002218 </td> <td style=“text-align:left;”> activation of innate immune response </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 167 </td> <td style=“text-align:left;”> 6.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032088 </td> <td style=“text-align:left;”> negative regulation of NF-kappaB transcription factor activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 66 </td> <td style=“text-align:left;”> 6.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006699 </td> <td style=“text-align:left;”> bile acid biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 6.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032488 </td> <td style=“text-align:left;”> Cdc42 protein signal transduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 6.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071363 </td> <td style=“text-align:left;”> cellular response to growth factor stimulus </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 549 </td> <td style=“text-align:left;”> 6.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071526 </td> <td style=“text-align:left;”> semaphorin-plexin signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 6.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070129 </td> <td style=“text-align:left;”> regulation of mitochondrial translation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 6.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0141086 </td> <td style=“text-align:left;”> negative regulation of inflammasome-mediated signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 6.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903829 </td> <td style=“text-align:left;”> positive regulation of protein localization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 392 </td> <td style=“text-align:left;”> 6.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032230 </td> <td style=“text-align:left;”> positive regulation of synaptic transmission, GABAergic </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 6.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070588 </td> <td style=“text-align:left;”> calcium ion transmembrane transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 221 </td> <td style=“text-align:left;”> 6.10e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901978 </td> <td style=“text-align:left;”> positive regulation of cell cycle checkpoint </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 6.10e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032101 </td> <td style=“text-align:left;”> regulation of response to external stimulus </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 690 </td> <td style=“text-align:left;”> 6.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050792 </td> <td style=“text-align:left;”> regulation of viral process </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 124 </td> <td style=“text-align:left;”> 6.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007498 </td> <td style=“text-align:left;”> mesoderm development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 88 </td> <td style=“text-align:left;”> 6.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097202 </td> <td style=“text-align:left;”> activation of cysteine-type endopeptidase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 6.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035795 </td> <td style=“text-align:left;”> negative regulation of mitochondrial membrane permeability </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 6.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042886 </td> <td style=“text-align:left;”> amide transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 237 </td> <td style=“text-align:left;”> 6.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070555 </td> <td style=“text-align:left;”> response to interleukin-1 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 82 </td> <td style=“text-align:left;”> 6.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043406 </td> <td style=“text-align:left;”> positive regulation of MAP kinase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 82 </td> <td style=“text-align:left;”> 6.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902916 </td> <td style=“text-align:left;”> positive regulation of protein polyubiquitination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 6.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900044 </td> <td style=“text-align:left;”> regulation of protein K63-linked ubiquitination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 6.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043269 </td> <td style=“text-align:left;”> regulation of monoatomic ion transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 369 </td> <td style=“text-align:left;”> 6.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031053 </td> <td style=“text-align:left;”> primary miRNA processing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 6.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006468 </td> <td style=“text-align:left;”> protein phosphorylation </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:right;”> 1130 </td> <td style=“text-align:left;”> 6.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0040020 </td> <td style=“text-align:left;”> regulation of meiotic nuclear division </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 6.15e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033559 </td> <td style=“text-align:left;”> unsaturated fatty acid metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 67 </td> <td style=“text-align:left;”> 6.15e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001932 </td> <td style=“text-align:left;”> regulation of protein phosphorylation </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:right;”> 758 </td> <td style=“text-align:left;”> 6.15e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071230 </td> <td style=“text-align:left;”> cellular response to amino acid stimulus </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 66 </td> <td style=“text-align:left;”> 6.15e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042593 </td> <td style=“text-align:left;”> glucose homeostasis </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 171 </td> <td style=“text-align:left;”> 6.15e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051707 </td> <td style=“text-align:left;”> response to other organism </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 843 </td> <td style=“text-align:left;”> 6.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006096 </td> <td style=“text-align:left;”> glycolytic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 6.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046627 </td> <td style=“text-align:left;”> negative regulation of insulin receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 6.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071731 </td> <td style=“text-align:left;”> response to nitric oxide </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 6.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043207 </td> <td style=“text-align:left;”> response to external biotic stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 843 </td> <td style=“text-align:left;”> 6.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009190 </td> <td style=“text-align:left;”> cyclic nucleotide biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 6.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097094 </td> <td style=“text-align:left;”> craniofacial suture morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 6.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032649 </td> <td style=“text-align:left;”> regulation of type II interferon production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 52 </td> <td style=“text-align:left;”> 6.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000281 </td> <td style=“text-align:left;”> mitotic cytokinesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 83 </td> <td style=“text-align:left;”> 6.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2001257 </td> <td style=“text-align:left;”> regulation of cation channel activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 100 </td> <td style=“text-align:left;”> 6.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006941 </td> <td style=“text-align:left;”> striated muscle contraction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 153 </td> <td style=“text-align:left;”> 6.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043487 </td> <td style=“text-align:left;”> regulation of RNA stability </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 161 </td> <td style=“text-align:left;”> 6.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046887 </td> <td style=“text-align:left;”> positive regulation of hormone secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 93 </td> <td style=“text-align:left;”> 6.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045022 </td> <td style=“text-align:left;”> early endosome to late endosome transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 6.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901890 </td> <td style=“text-align:left;”> positive regulation of cell junction assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 82 </td> <td style=“text-align:left;”> 6.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032609 </td> <td style=“text-align:left;”> type II interferon production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 6.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045190 </td> <td style=“text-align:left;”> isotype switching </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 6.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002208 </td> <td style=“text-align:left;”> somatic diversification of immunoglobulins involved in immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 6.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002204 </td> <td style=“text-align:left;”> somatic recombination of immunoglobulin genes involved in immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 6.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010761 </td> <td style=“text-align:left;”> fibroblast migration </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 52 </td> <td style=“text-align:left;”> 6.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050919 </td> <td style=“text-align:left;”> negative chemotaxis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 6.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048535 </td> <td style=“text-align:left;”> lymph node development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 6.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002460 </td> <td style=“text-align:left;”> adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 172 </td> <td style=“text-align:left;”> 6.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006213 </td> <td style=“text-align:left;”> pyrimidine nucleoside metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 6.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061001 </td> <td style=“text-align:left;”> regulation of dendritic spine morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 6.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140112 </td> <td style=“text-align:left;”> extracellular vesicle biogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 6.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022612 </td> <td style=“text-align:left;”> gland morphogenesis </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 99 </td> <td style=“text-align:left;”> 6.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0040014 </td> <td style=“text-align:left;”> regulation of multicellular organism growth </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 52 </td> <td style=“text-align:left;”> 6.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010631 </td> <td style=“text-align:left;”> epithelial cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 253 </td> <td style=“text-align:left;”> 6.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001659 </td> <td style=“text-align:left;”> temperature homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 135 </td> <td style=“text-align:left;”> 6.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009607 </td> <td style=“text-align:left;”> response to biotic stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 871 </td> <td style=“text-align:left;”> 6.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006805 </td> <td style=“text-align:left;”> xenobiotic metabolic process </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 6.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900077 </td> <td style=“text-align:left;”> negative regulation of cellular response to insulin stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 6.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021954 </td> <td style=“text-align:left;”> central nervous system neuron development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 6.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048678 </td> <td style=“text-align:left;”> response to axon injury </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 61 </td> <td style=“text-align:left;”> 6.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055070 </td> <td style=“text-align:left;”> copper ion homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 6.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051205 </td> <td style=“text-align:left;”> protein insertion into membrane </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 6.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008210 </td> <td style=“text-align:left;”> estrogen metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 6.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001655 </td> <td style=“text-align:left;”> urogenital system development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 6.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002269 </td> <td style=“text-align:left;”> leukocyte activation involved in inflammatory response </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 6.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048518 </td> <td style=“text-align:left;”> positive regulation of biological process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4566 </td> <td style=“text-align:left;”> 6.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035270 </td> <td style=“text-align:left;”> endocrine system development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 86 </td> <td style=“text-align:left;”> 6.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901970 </td> <td style=“text-align:left;”> positive regulation of mitotic sister chromatid separation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 6.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090132 </td> <td style=“text-align:left;”> epithelium migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 253 </td> <td style=“text-align:left;”> 6.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050804 </td> <td style=“text-align:left;”> modulation of chemical synaptic transmission </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 343 </td> <td style=“text-align:left;”> 6.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009636 </td> <td style=“text-align:left;”> response to toxic substance </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 158 </td> <td style=“text-align:left;”> 6.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072593 </td> <td style=“text-align:left;”> reactive oxygen species metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 157 </td> <td style=“text-align:left;”> 6.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051546 </td> <td style=“text-align:left;”> keratinocyte migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 6.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021549 </td> <td style=“text-align:left;”> cerebellum development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 77 </td> <td style=“text-align:left;”> 6.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032212 </td> <td style=“text-align:left;”> positive regulation of telomere maintenance via telomerase </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 6.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033013 </td> <td style=“text-align:left;”> tetrapyrrole metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 6.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099177 </td> <td style=“text-align:left;”> regulation of trans-synaptic signaling </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 344 </td> <td style=“text-align:left;”> 6.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051973 </td> <td style=“text-align:left;”> positive regulation of telomerase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 6.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007528 </td> <td style=“text-align:left;”> neuromuscular junction development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 6.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048609 </td> <td style=“text-align:left;”> multicellular organismal reproductive process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 538 </td> <td style=“text-align:left;”> 6.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048589 </td> <td style=“text-align:left;”> developmental growth </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 522 </td> <td style=“text-align:left;”> 6.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098815 </td> <td style=“text-align:left;”> modulation of excitatory postsynaptic potential </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 6.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033993 </td> <td style=“text-align:left;”> response to lipid </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:right;”> 594 </td> <td style=“text-align:left;”> 6.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033522 </td> <td style=“text-align:left;”> histone H2A ubiquitination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 6.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048754 </td> <td style=“text-align:left;”> branching morphogenesis of an epithelial tube </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 121 </td> <td style=“text-align:left;”> 6.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0038066 </td> <td style=“text-align:left;”> p38MAPK cascade </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 6.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050684 </td> <td style=“text-align:left;”> regulation of mRNA processing </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 114 </td> <td style=“text-align:left;”> 6.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071320 </td> <td style=“text-align:left;”> cellular response to cAMP </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 6.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009615 </td> <td style=“text-align:left;”> response to virus </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:right;”> 295 </td> <td style=“text-align:left;”> 6.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033157 </td> <td style=“text-align:left;”> regulation of intracellular protein transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 198 </td> <td style=“text-align:left;”> 6.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051094 </td> <td style=“text-align:left;”> positive regulation of developmental process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 957 </td> <td style=“text-align:left;”> 6.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006486 </td> <td style=“text-align:left;”> protein glycosylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 185 </td> <td style=“text-align:left;”> 6.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043413 </td> <td style=“text-align:left;”> macromolecule glycosylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 185 </td> <td style=“text-align:left;”> 6.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009173 </td> <td style=“text-align:left;”> pyrimidine ribonucleoside monophosphate metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 6.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007616 </td> <td style=“text-align:left;”> long-term memory </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 6.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051171 </td> <td style=“text-align:left;”> regulation of nitrogen compound metabolic process </td> <td style=“text-align:right;”> 120 </td> <td style=“text-align:right;”> 4243 </td> <td style=“text-align:left;”> 6.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090130 </td> <td style=“text-align:left;”> tissue migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 257 </td> <td style=“text-align:left;”> 6.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902808 </td> <td style=“text-align:left;”> positive regulation of cell cycle G1/S phase transition </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 6.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015874 </td> <td style=“text-align:left;”> norepinephrine transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 6.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045765 </td> <td style=“text-align:left;”> regulation of angiogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 200 </td> <td style=“text-align:left;”> 6.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902532 </td> <td style=“text-align:left;”> negative regulation of intracellular signal transduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 445 </td> <td style=“text-align:left;”> 6.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042147 </td> <td style=“text-align:left;”> retrograde transport, endosome to Golgi </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 91 </td> <td style=“text-align:left;”> 6.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002718 </td> <td style=“text-align:left;”> regulation of cytokine production involved in immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 6.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002367 </td> <td style=“text-align:left;”> cytokine production involved in immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 6.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001568 </td> <td style=“text-align:left;”> blood vessel development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 537 </td> <td style=“text-align:left;”> 6.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099174 </td> <td style=“text-align:left;”> regulation of presynapse organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 6.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905606 </td> <td style=“text-align:left;”> regulation of presynapse assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 6.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022409 </td> <td style=“text-align:left;”> positive regulation of cell-cell adhesion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 188 </td> <td style=“text-align:left;”> 6.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000678 </td> <td style=“text-align:left;”> negative regulation of transcription regulatory region DNA binding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 6.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002262 </td> <td style=“text-align:left;”> myeloid cell homeostasis </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 142 </td> <td style=“text-align:left;”> 6.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061462 </td> <td style=“text-align:left;”> protein localization to lysosome </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 47 </td> <td style=“text-align:left;”> 6.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071300 </td> <td style=“text-align:left;”> cellular response to retinoic acid </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 6.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009164 </td> <td style=“text-align:left;”> nucleoside catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 6.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060252 </td> <td style=“text-align:left;”> positive regulation of glial cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 6.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000413 </td> <td style=“text-align:left;”> protein peptidyl-prolyl isomerization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 6.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051346 </td> <td style=“text-align:left;”> negative regulation of hydrolase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 206 </td> <td style=“text-align:left;”> 6.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901342 </td> <td style=“text-align:left;”> regulation of vasculature development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 202 </td> <td style=“text-align:left;”> 6.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901222 </td> <td style=“text-align:left;”> regulation of non-canonical NF-kappaB signal transduction </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 67 </td> <td style=“text-align:left;”> 6.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071310 </td> <td style=“text-align:left;”> cellular response to organic substance </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1390 </td> <td style=“text-align:left;”> 6.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031365 </td> <td style=“text-align:left;”> N-terminal protein amino acid modification </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 6.30e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990573 </td> <td style=“text-align:left;”> potassium ion import across plasma membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 6.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050768 </td> <td style=“text-align:left;”> negative regulation of neurogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 113 </td> <td style=“text-align:left;”> 6.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006641 </td> <td style=“text-align:left;”> triglyceride metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 67 </td> <td style=“text-align:left;”> 6.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001835 </td> <td style=“text-align:left;”> blastocyst hatching </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 6.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006633 </td> <td style=“text-align:left;”> fatty acid biosynthetic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 105 </td> <td style=“text-align:left;”> 6.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035188 </td> <td style=“text-align:left;”> hatching </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 6.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071684 </td> <td style=“text-align:left;”> organism emergence from protective structure </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 6.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051963 </td> <td style=“text-align:left;”> regulation of synapse assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 82 </td> <td style=“text-align:left;”> 6.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032874 </td> <td style=“text-align:left;”> positive regulation of stress-activated MAPK cascade </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 95 </td> <td style=“text-align:left;”> 6.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022008 </td> <td style=“text-align:left;”> neurogenesis </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 1297 </td> <td style=“text-align:left;”> 6.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014911 </td> <td style=“text-align:left;”> positive regulation of smooth muscle cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 6.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050778 </td> <td style=“text-align:left;”> positive regulation of immune response </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 401 </td> <td style=“text-align:left;”> 6.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070664 </td> <td style=“text-align:left;”> negative regulation of leukocyte proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 6.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903504 </td> <td style=“text-align:left;”> regulation of mitotic spindle checkpoint </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 6.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050727 </td> <td style=“text-align:left;”> regulation of inflammatory response </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 215 </td> <td style=“text-align:left;”> 6.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090266 </td> <td style=“text-align:left;”> regulation of mitotic cell cycle spindle assembly checkpoint </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 6.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090231 </td> <td style=“text-align:left;”> regulation of spindle checkpoint </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 6.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905709 </td> <td style=“text-align:left;”> negative regulation of membrane permeability </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 6.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036260 </td> <td style=“text-align:left;”> RNA capping </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 6.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007219 </td> <td style=“text-align:left;”> Notch signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 145 </td> <td style=“text-align:left;”> 6.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070848 </td> <td style=“text-align:left;”> response to growth factor </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 571 </td> <td style=“text-align:left;”> 6.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019538 </td> <td style=“text-align:left;”> protein metabolic process </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:right;”> 4202 </td> <td style=“text-align:left;”> 6.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042306 </td> <td style=“text-align:left;”> regulation of protein import into nucleus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 6.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030097 </td> <td style=“text-align:left;”> hemopoiesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 651 </td> <td style=“text-align:left;”> 6.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046890 </td> <td style=“text-align:left;”> regulation of lipid biosynthetic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 136 </td> <td style=“text-align:left;”> 6.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072001 </td> <td style=“text-align:left;”> renal system development </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:right;”> 253 </td> <td style=“text-align:left;”> 6.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070304 </td> <td style=“text-align:left;”> positive regulation of stress-activated protein kinase signaling cascade </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 97 </td> <td style=“text-align:left;”> 6.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032602 </td> <td style=“text-align:left;”> chemokine production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 47 </td> <td style=“text-align:left;”> 6.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032642 </td> <td style=“text-align:left;”> regulation of chemokine production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 47 </td> <td style=“text-align:left;”> 6.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032504 </td> <td style=“text-align:left;”> multicellular organism reproduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 558 </td> <td style=“text-align:left;”> 6.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990748 </td> <td style=“text-align:left;”> cellular detoxification </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 79 </td> <td style=“text-align:left;”> 6.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009306 </td> <td style=“text-align:left;”> protein secretion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 262 </td> <td style=“text-align:left;”> 6.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000193 </td> <td style=“text-align:left;”> positive regulation of fatty acid transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 6.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008285 </td> <td style=“text-align:left;”> negative regulation of cell population proliferation </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:right;”> 643 </td> <td style=“text-align:left;”> 6.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002381 </td> <td style=“text-align:left;”> immunoglobulin production involved in immunoglobulin-mediated immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 6.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035592 </td> <td style=“text-align:left;”> establishment of protein localization to extracellular region </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 262 </td> <td style=“text-align:left;”> 6.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006796 </td> <td style=“text-align:left;”> phosphate-containing compound metabolic process </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:right;”> 2096 </td> <td style=“text-align:left;”> 6.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061035 </td> <td style=“text-align:left;”> regulation of cartilage development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 6.39e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903432 </td> <td style=“text-align:left;”> regulation of TORC1 signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 6.39e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048015 </td> <td style=“text-align:left;”> phosphatidylinositol-mediated signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 6.39e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000641 </td> <td style=“text-align:left;”> regulation of early endosome to late endosome transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 6.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051223 </td> <td style=“text-align:left;”> regulation of protein transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 404 </td> <td style=“text-align:left;”> 6.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045822 </td> <td style=“text-align:left;”> negative regulation of heart contraction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 6.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031648 </td> <td style=“text-align:left;”> protein destabilization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 6.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009895 </td> <td style=“text-align:left;”> negative regulation of catabolic process </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 287 </td> <td style=“text-align:left;”> 6.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006690 </td> <td style=“text-align:left;”> icosanoid metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 60 </td> <td style=“text-align:left;”> 6.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019318 </td> <td style=“text-align:left;”> hexose metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 187 </td> <td style=“text-align:left;”> 6.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033866 </td> <td style=“text-align:left;”> nucleoside bisphosphate biosynthetic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 6.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034033 </td> <td style=“text-align:left;”> purine nucleoside bisphosphate biosynthetic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 6.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098927 </td> <td style=“text-align:left;”> vesicle-mediated transport between endosomal compartments </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 6.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043094 </td> <td style=“text-align:left;”> cellular metabolic compound salvage </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 6.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034030 </td> <td style=“text-align:left;”> ribonucleoside bisphosphate biosynthetic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 6.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046824 </td> <td style=“text-align:left;”> positive regulation of nucleocytoplasmic transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 6.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008016 </td> <td style=“text-align:left;”> regulation of heart contraction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 171 </td> <td style=“text-align:left;”> 6.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904358 </td> <td style=“text-align:left;”> positive regulation of telomere maintenance via telomere lengthening </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 6.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051961 </td> <td style=“text-align:left;”> negative regulation of nervous system development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 119 </td> <td style=“text-align:left;”> 6.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045730 </td> <td style=“text-align:left;”> respiratory burst </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 6.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010558 </td> <td style=“text-align:left;”> negative regulation of macromolecule biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1669 </td> <td style=“text-align:left;”> 6.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901575 </td> <td style=“text-align:left;”> organic substance catabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 1731 </td> <td style=“text-align:left;”> 6.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050773 </td> <td style=“text-align:left;”> regulation of dendrite development </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 83 </td> <td style=“text-align:left;”> 6.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900273 </td> <td style=“text-align:left;”> positive regulation of long-term synaptic potentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 6.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001818 </td> <td style=“text-align:left;”> negative regulation of cytokine production </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 171 </td> <td style=“text-align:left;”> 6.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905952 </td> <td style=“text-align:left;”> regulation of lipid localization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 110 </td> <td style=“text-align:left;”> 6.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002067 </td> <td style=“text-align:left;”> glandular epithelial cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 6.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071692 </td> <td style=“text-align:left;”> protein localization to extracellular region </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 266 </td> <td style=“text-align:left;”> 6.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050931 </td> <td style=“text-align:left;”> pigment cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 6.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071786 </td> <td style=“text-align:left;”> endoplasmic reticulum tubular network organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 6.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022037 </td> <td style=“text-align:left;”> metencephalon development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 83 </td> <td style=“text-align:left;”> 6.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016482 </td> <td style=“text-align:left;”> cytosolic transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 168 </td> <td style=“text-align:left;”> 6.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042491 </td> <td style=“text-align:left;”> inner ear auditory receptor cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 6.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048704 </td> <td style=“text-align:left;”> embryonic skeletal system morphogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 54 </td> <td style=“text-align:left;”> 6.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030520 </td> <td style=“text-align:left;”> intracellular estrogen receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 6.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003006 </td> <td style=“text-align:left;”> developmental process involved in reproduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 603 </td> <td style=“text-align:left;”> 6.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002092 </td> <td style=“text-align:left;”> positive regulation of receptor internalization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 6.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070306 </td> <td style=“text-align:left;”> lens fiber cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 6.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070227 </td> <td style=“text-align:left;”> lymphocyte apoptotic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 6.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904375 </td> <td style=“text-align:left;”> regulation of protein localization to cell periphery </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 116 </td> <td style=“text-align:left;”> 6.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045861 </td> <td style=“text-align:left;”> negative regulation of proteolysis </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 204 </td> <td style=“text-align:left;”> 6.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042178 </td> <td style=“text-align:left;”> xenobiotic catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 6.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006862 </td> <td style=“text-align:left;”> nucleotide transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 6.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010817 </td> <td style=“text-align:left;”> regulation of hormone levels </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 337 </td> <td style=“text-align:left;”> 6.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090141 </td> <td style=“text-align:left;”> positive regulation of mitochondrial fission </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 6.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903578 </td> <td style=“text-align:left;”> regulation of ATP metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 6.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901071 </td> <td style=“text-align:left;”> glucosamine-containing compound metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 6.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090316 </td> <td style=“text-align:left;”> positive regulation of intracellular protein transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 135 </td> <td style=“text-align:left;”> 6.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006954 </td> <td style=“text-align:left;”> inflammatory response </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 451 </td> <td style=“text-align:left;”> 6.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050852 </td> <td style=“text-align:left;”> T cell receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 86 </td> <td style=“text-align:left;”> 6.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002183 </td> <td style=“text-align:left;”> cytoplasmic translational initiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 6.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031327 </td> <td style=“text-align:left;”> negative regulation of cellular biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1708 </td> <td style=“text-align:left;”> 6.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046033 </td> <td style=“text-align:left;”> AMP metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 6.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0039529 </td> <td style=“text-align:left;”> RIG-I signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 6.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030217 </td> <td style=“text-align:left;”> T cell differentiation </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 189 </td> <td style=“text-align:left;”> 6.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0062125 </td> <td style=“text-align:left;”> regulation of mitochondrial gene expression </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 6.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048593 </td> <td style=“text-align:left;”> camera-type eye morphogenesis </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 92 </td> <td style=“text-align:left;”> 6.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0120178 </td> <td style=“text-align:left;”> steroid hormone biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 6.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046856 </td> <td style=“text-align:left;”> phosphatidylinositol dephosphorylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 6.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006898 </td> <td style=“text-align:left;”> receptor-mediated endocytosis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 195 </td> <td style=“text-align:left;”> 6.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016447 </td> <td style=“text-align:left;”> somatic recombination of immunoglobulin gene segments </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 6.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009890 </td> <td style=“text-align:left;”> negative regulation of biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1721 </td> <td style=“text-align:left;”> 6.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007368 </td> <td style=“text-align:left;”> determination of left/right symmetry </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 96 </td> <td style=“text-align:left;”> 6.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000026 </td> <td style=“text-align:left;”> regulation of multicellular organismal development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 997 </td> <td style=“text-align:left;”> 6.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006793 </td> <td style=“text-align:left;”> phosphorus metabolic process </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:right;”> 2118 </td> <td style=“text-align:left;”> 6.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045604 </td> <td style=“text-align:left;”> regulation of epidermal cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 6.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002763 </td> <td style=“text-align:left;”> positive regulation of myeloid leukocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 6.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045859 </td> <td style=“text-align:left;”> regulation of protein kinase activity </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:right;”> 473 </td> <td style=“text-align:left;”> 6.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903523 </td> <td style=“text-align:left;”> negative regulation of blood circulation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 6.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050776 </td> <td style=“text-align:left;”> regulation of immune response </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 514 </td> <td style=“text-align:left;”> 6.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901880 </td> <td style=“text-align:left;”> negative regulation of protein depolymerization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 60 </td> <td style=“text-align:left;”> 6.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045932 </td> <td style=“text-align:left;”> negative regulation of muscle contraction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 6.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030182 </td> <td style=“text-align:left;”> neuron differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 1058 </td> <td style=“text-align:left;”> 6.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051204 </td> <td style=“text-align:left;”> protein insertion into mitochondrial membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 6.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000243 </td> <td style=“text-align:left;”> positive regulation of reproductive process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 6.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007155 </td> <td style=“text-align:left;”> cell adhesion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 996 </td> <td style=“text-align:left;”> 6.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902236 </td> <td style=“text-align:left;”> negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 6.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051279 </td> <td style=“text-align:left;”> regulation of release of sequestered calcium ion into cytosol </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 60 </td> <td style=“text-align:left;”> 6.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097553 </td> <td style=“text-align:left;”> calcium ion transmembrane import into cytosol </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 125 </td> <td style=“text-align:left;”> 6.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010647 </td> <td style=“text-align:left;”> positive regulation of cell communication </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:right;”> 1249 </td> <td style=“text-align:left;”> 6.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042181 </td> <td style=“text-align:left;”> ketone biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 6.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030509 </td> <td style=“text-align:left;”> BMP signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 122 </td> <td style=“text-align:left;”> 6.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021795 </td> <td style=“text-align:left;”> cerebral cortex cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 6.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007610 </td> <td style=“text-align:left;”> behavior </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 439 </td> <td style=“text-align:left;”> 6.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071294 </td> <td style=“text-align:left;”> cellular response to zinc ion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 6.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071880 </td> <td style=“text-align:left;”> adenylate cyclase-activating adrenergic receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 6.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010526 </td> <td style=“text-align:left;”> retrotransposon silencing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 6.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071229 </td> <td style=“text-align:left;”> cellular response to acid chemical </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 72 </td> <td style=“text-align:left;”> 6.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048524 </td> <td style=“text-align:left;”> positive regulation of viral process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 55 </td> <td style=“text-align:left;”> 6.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035336 </td> <td style=“text-align:left;”> long-chain fatty-acyl-CoA metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 6.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002862 </td> <td style=“text-align:left;”> negative regulation of inflammatory response to antigenic stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 6.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031324 </td> <td style=“text-align:left;”> negative regulation of cellular metabolic process </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:right;”> 2069 </td> <td style=“text-align:left;”> 6.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902369 </td> <td style=“text-align:left;”> negative regulation of RNA catabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 71 </td> <td style=“text-align:left;”> 6.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001763 </td> <td style=“text-align:left;”> morphogenesis of a branching structure </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 155 </td> <td style=“text-align:left;”> 6.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007566 </td> <td style=“text-align:left;”> embryo implantation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 6.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048143 </td> <td style=“text-align:left;”> astrocyte activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 6.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048259 </td> <td style=“text-align:left;”> regulation of receptor-mediated endocytosis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 86 </td> <td style=“text-align:left;”> 6.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007265 </td> <td style=“text-align:left;”> Ras protein signal transduction </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 287 </td> <td style=“text-align:left;”> 6.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002702 </td> <td style=“text-align:left;”> positive regulation of production of molecular mediator of immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 78 </td> <td style=“text-align:left;”> 6.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035235 </td> <td style=“text-align:left;”> ionotropic glutamate receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 6.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050796 </td> <td style=“text-align:left;”> regulation of insulin secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 119 </td> <td style=“text-align:left;”> 6.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046823 </td> <td style=“text-align:left;”> negative regulation of nucleocytoplasmic transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 6.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032007 </td> <td style=“text-align:left;”> negative regulation of TOR signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 6.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900026 </td> <td style=“text-align:left;”> positive regulation of substrate adhesion-dependent cell spreading </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 6.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032355 </td> <td style=“text-align:left;”> response to estradiol </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 79 </td> <td style=“text-align:left;”> 6.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904019 </td> <td style=“text-align:left;”> epithelial cell apoptotic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 101 </td> <td style=“text-align:left;”> 6.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061640 </td> <td style=“text-align:left;”> cytoskeleton-dependent cytokinesis </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 106 </td> <td style=“text-align:left;”> 6.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009408 </td> <td style=“text-align:left;”> response to heat </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 6.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070201 </td> <td style=“text-align:left;”> regulation of establishment of protein localization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 428 </td> <td style=“text-align:left;”> 6.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035459 </td> <td style=“text-align:left;”> vesicle cargo loading </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 6.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003008 </td> <td style=“text-align:left;”> system process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1194 </td> <td style=“text-align:left;”> 6.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007423 </td> <td style=“text-align:left;”> sensory organ development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 395 </td> <td style=“text-align:left;”> 6.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042632 </td> <td style=“text-align:left;”> cholesterol homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 6.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003009 </td> <td style=“text-align:left;”> skeletal muscle contraction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 6.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000902 </td> <td style=“text-align:left;”> cell morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 740 </td> <td style=“text-align:left;”> 6.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033574 </td> <td style=“text-align:left;”> response to testosterone </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 6.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043123 </td> <td style=“text-align:left;”> positive regulation of canonical NF-kappaB signal transduction </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 154 </td> <td style=“text-align:left;”> 6.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043467 </td> <td style=“text-align:left;”> regulation of generation of precursor metabolites and energy </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 119 </td> <td style=“text-align:left;”> 6.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071168 </td> <td style=“text-align:left;”> protein localization to chromatin </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 6.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034656 </td> <td style=“text-align:left;”> nucleobase-containing small molecule catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 6.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019953 </td> <td style=“text-align:left;”> sexual reproduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 633 </td> <td style=“text-align:left;”> 6.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051051 </td> <td style=“text-align:left;”> negative regulation of transport </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 317 </td> <td style=“text-align:left;”> 6.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0023019 </td> <td style=“text-align:left;”> signal transduction involved in regulation of gene expression </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 6.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055092 </td> <td style=“text-align:left;”> sterol homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 59 </td> <td style=“text-align:left;”> 6.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097237 </td> <td style=“text-align:left;”> cellular response to toxic substance </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 85 </td> <td style=“text-align:left;”> 6.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045582 </td> <td style=“text-align:left;”> positive regulation of T cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 6.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034767 </td> <td style=“text-align:left;”> positive regulation of monoatomic ion transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 112 </td> <td style=“text-align:left;”> 6.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009892 </td> <td style=“text-align:left;”> negative regulation of metabolic process </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:right;”> 2297 </td> <td style=“text-align:left;”> 6.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903747 </td> <td style=“text-align:left;”> regulation of establishment of protein localization to mitochondrion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 6.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014823 </td> <td style=“text-align:left;”> response to activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 6.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0062207 </td> <td style=“text-align:left;”> regulation of pattern recognition receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 94 </td> <td style=“text-align:left;”> 6.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018105 </td> <td style=“text-align:left;”> peptidyl-serine phosphorylation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 242 </td> <td style=“text-align:left;”> 6.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050905 </td> <td style=“text-align:left;”> neuromuscular process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 110 </td> <td style=“text-align:left;”> 6.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072080 </td> <td style=“text-align:left;”> nephron tubule development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 6.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007041 </td> <td style=“text-align:left;”> lysosomal transport </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 115 </td> <td style=“text-align:left;”> 6.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016601 </td> <td style=“text-align:left;”> Rac protein signal transduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 6.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001676 </td> <td style=“text-align:left;”> long-chain fatty acid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 63 </td> <td style=“text-align:left;”> 6.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051131 </td> <td style=“text-align:left;”> chaperone-mediated protein complex assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 6.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046037 </td> <td style=“text-align:left;”> GMP metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 6.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0023057 </td> <td style=“text-align:left;”> negative regulation of signaling </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 1090 </td> <td style=“text-align:left;”> 6.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009110 </td> <td style=“text-align:left;”> vitamin biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 6.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901655 </td> <td style=“text-align:left;”> cellular response to ketone </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 82 </td> <td style=“text-align:left;”> 6.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071539 </td> <td style=“text-align:left;”> protein localization to centrosome </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 6.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016445 </td> <td style=“text-align:left;”> somatic diversification of immunoglobulins </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 6.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0005996 </td> <td style=“text-align:left;”> monosaccharide metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 212 </td> <td style=“text-align:left;”> 6.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006739 </td> <td style=“text-align:left;”> NADP metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 6.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007268 </td> <td style=“text-align:left;”> chemical synaptic transmission </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 490 </td> <td style=“text-align:left;”> 6.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098916 </td> <td style=“text-align:left;”> anterograde trans-synaptic signaling </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 490 </td> <td style=“text-align:left;”> 6.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045648 </td> <td style=“text-align:left;”> positive regulation of erythrocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 6.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031175 </td> <td style=“text-align:left;”> neuron projection development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 774 </td> <td style=“text-align:left;”> 6.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071773 </td> <td style=“text-align:left;”> cellular response to BMP stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 130 </td> <td style=“text-align:left;”> 6.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071772 </td> <td style=“text-align:left;”> response to BMP </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 130 </td> <td style=“text-align:left;”> 6.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060135 </td> <td style=“text-align:left;”> maternal process involved in female pregnancy </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 6.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002685 </td> <td style=“text-align:left;”> regulation of leukocyte migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 130 </td> <td style=“text-align:left;”> 6.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0040007 </td> <td style=“text-align:left;”> growth </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:right;”> 737 </td> <td style=“text-align:left;”> 6.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031214 </td> <td style=“text-align:left;”> biomineral tissue development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 112 </td> <td style=“text-align:left;”> 6.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071312 </td> <td style=“text-align:left;”> cellular response to alkaloid </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 6.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090151 </td> <td style=“text-align:left;”> establishment of protein localization to mitochondrial membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 6.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900016 </td> <td style=“text-align:left;”> negative regulation of cytokine production involved in inflammatory response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 14 </td> <td style=“text-align:left;”> 6.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001755 </td> <td style=“text-align:left;”> neural crest cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 6.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051602 </td> <td style=“text-align:left;”> response to electrical stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 6.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903900 </td> <td style=“text-align:left;”> regulation of viral life cycle </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 101 </td> <td style=“text-align:left;”> 6.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070371 </td> <td style=“text-align:left;”> ERK1 and ERK2 cascade </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 211 </td> <td style=“text-align:left;”> 6.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048699 </td> <td style=“text-align:left;”> generation of neurons </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 1120 </td> <td style=“text-align:left;”> 6.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048872 </td> <td style=“text-align:left;”> homeostasis of number of cells </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:right;”> 236 </td> <td style=“text-align:left;”> 6.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044255 </td> <td style=“text-align:left;”> cellular lipid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 736 </td> <td style=“text-align:left;”> 6.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046661 </td> <td style=“text-align:left;”> male sex differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 115 </td> <td style=“text-align:left;”> 6.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060972 </td> <td style=“text-align:left;”> left/right pattern formation </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 101 </td> <td style=“text-align:left;”> 6.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016338 </td> <td style=“text-align:left;”> calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:left;”> 6.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099537 </td> <td style=“text-align:left;”> trans-synaptic signaling </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 494 </td> <td style=“text-align:left;”> 6.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002706 </td> <td style=“text-align:left;”> regulation of lymphocyte mediated immunity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 90 </td> <td style=“text-align:left;”> 6.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140527 </td> <td style=“text-align:left;”> reciprocal homologous recombination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 6.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902894 </td> <td style=“text-align:left;”> negative regulation of miRNA transcription </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 6.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098754 </td> <td style=“text-align:left;”> detoxification </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 87 </td> <td style=“text-align:left;”> 6.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007131 </td> <td style=“text-align:left;”> reciprocal meiotic recombination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 6.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019725 </td> <td style=“text-align:left;”> cellular homeostasis </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 583 </td> <td style=“text-align:left;”> 6.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905508 </td> <td style=“text-align:left;”> protein localization to microtubule organizing center </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 6.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006955 </td> <td style=“text-align:left;”> immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 913 </td> <td style=“text-align:left;”> 6.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046949 </td> <td style=“text-align:left;”> fatty-acyl-CoA biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 6.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051450 </td> <td style=“text-align:left;”> myoblast proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 6.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046697 </td> <td style=“text-align:left;”> decidualization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 6.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044346 </td> <td style=“text-align:left;”> fibroblast apoptotic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 6.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045292 </td> <td style=“text-align:left;”> mRNA cis splicing, via spliceosome </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 6.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010605 </td> <td style=“text-align:left;”> negative regulation of macromolecule metabolic process </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:right;”> 2131 </td> <td style=“text-align:left;”> 6.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014856 </td> <td style=“text-align:left;”> skeletal muscle cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 6.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901861 </td> <td style=“text-align:left;”> regulation of muscle tissue development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 6.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042026 </td> <td style=“text-align:left;”> protein refolding </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 6.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043604 </td> <td style=“text-align:left;”> amide biosynthetic process </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:right;”> 785 </td> <td style=“text-align:left;”> 6.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045682 </td> <td style=“text-align:left;”> regulation of epidermis development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 6.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030183 </td> <td style=“text-align:left;”> B cell differentiation </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 91 </td> <td style=“text-align:left;”> 6.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043507 </td> <td style=“text-align:left;”> positive regulation of JUN kinase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 6.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008206 </td> <td style=“text-align:left;”> bile acid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 6.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060047 </td> <td style=“text-align:left;”> heart contraction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 202 </td> <td style=“text-align:left;”> 6.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097194 </td> <td style=“text-align:left;”> execution phase of apoptosis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 52 </td> <td style=“text-align:left;”> 6.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090497 </td> <td style=“text-align:left;”> mesenchymal cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 6.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006909 </td> <td style=“text-align:left;”> phagocytosis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 145 </td> <td style=“text-align:left;”> 6.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007188 </td> <td style=“text-align:left;”> adenylate cyclase-modulating G protein-coupled receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 113 </td> <td style=“text-align:left;”> 6.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008610 </td> <td style=“text-align:left;”> lipid biosynthetic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 563 </td> <td style=“text-align:left;”> 6.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002822 </td> <td style=“text-align:left;”> regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 104 </td> <td style=“text-align:left;”> 6.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051651 </td> <td style=“text-align:left;”> maintenance of location in cell </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 177 </td> <td style=“text-align:left;”> 6.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030903 </td> <td style=“text-align:left;”> notochord development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 6.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016444 </td> <td style=“text-align:left;”> somatic cell DNA recombination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 55 </td> <td style=“text-align:left;”> 6.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019722 </td> <td style=“text-align:left;”> calcium-mediated signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 118 </td> <td style=“text-align:left;”> 6.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002562 </td> <td style=“text-align:left;”> somatic diversification of immune receptors via germline recombination within a single locus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 55 </td> <td style=“text-align:left;”> 6.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046578 </td> <td style=“text-align:left;”> regulation of Ras protein signal transduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 156 </td> <td style=“text-align:left;”> 6.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044057 </td> <td style=“text-align:left;”> regulation of system process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 398 </td> <td style=“text-align:left;”> 6.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006783 </td> <td style=“text-align:left;”> heme biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 6.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043242 </td> <td style=“text-align:left;”> negative regulation of protein-containing complex disassembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 68 </td> <td style=“text-align:left;”> 6.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006813 </td> <td style=“text-align:left;”> potassium ion transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 146 </td> <td style=“text-align:left;”> 6.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070536 </td> <td style=“text-align:left;”> protein K63-linked deubiquitination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 6.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097107 </td> <td style=“text-align:left;”> postsynaptic density assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 6.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050922 </td> <td style=“text-align:left;”> negative regulation of chemotaxis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 6.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045860 </td> <td style=“text-align:left;”> positive regulation of protein kinase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 258 </td> <td style=“text-align:left;”> 6.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099173 </td> <td style=“text-align:left;”> postsynapse organization </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 160 </td> <td style=“text-align:left;”> 6.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045600 </td> <td style=“text-align:left;”> positive regulation of fat cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 6.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045662 </td> <td style=“text-align:left;”> negative regulation of myoblast differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 6.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050896 </td> <td style=“text-align:left;”> response to stimulus </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 5721 </td> <td style=“text-align:left;”> 6.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032781 </td> <td style=“text-align:left;”> positive regulation of ATP-dependent activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 6.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051235 </td> <td style=“text-align:left;”> maintenance of location </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 263 </td> <td style=“text-align:left;”> 6.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043954 </td> <td style=“text-align:left;”> cellular component maintenance </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 60 </td> <td style=“text-align:left;”> 6.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018209 </td> <td style=“text-align:left;”> peptidyl-serine modification </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 254 </td> <td style=“text-align:left;”> 6.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0023051 </td> <td style=“text-align:left;”> regulation of signaling </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 2560 </td> <td style=“text-align:left;”> 6.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019082 </td> <td style=“text-align:left;”> viral protein processing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 6.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060997 </td> <td style=“text-align:left;”> dendritic spine morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 6.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035315 </td> <td style=“text-align:left;”> hair cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 6.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0040008 </td> <td style=“text-align:left;”> regulation of growth </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:right;”> 493 </td> <td style=“text-align:left;”> 6.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010646 </td> <td style=“text-align:left;”> regulation of cell communication </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 2567 </td> <td style=“text-align:left;”> 6.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009129 </td> <td style=“text-align:left;”> pyrimidine nucleoside monophosphate metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 6.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070231 </td> <td style=“text-align:left;”> T cell apoptotic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 6.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050777 </td> <td style=“text-align:left;”> negative regulation of immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 118 </td> <td style=“text-align:left;”> 6.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045070 </td> <td style=“text-align:left;”> positive regulation of viral genome replication </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 6.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006260 </td> <td style=“text-align:left;”> DNA replication </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 256 </td> <td style=“text-align:left;”> 6.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009653 </td> <td style=“text-align:left;”> anatomical structure morphogenesis </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 1952 </td> <td style=“text-align:left;”> 6.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032148 </td> <td style=“text-align:left;”> activation of protein kinase B activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 6.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045742 </td> <td style=“text-align:left;”> positive regulation of epidermal growth factor receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 6.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044271 </td> <td style=“text-align:left;”> cellular nitrogen compound biosynthetic process </td> <td style=“text-align:right;”> 98 </td> <td style=“text-align:right;”> 3743 </td> <td style=“text-align:left;”> 6.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032271 </td> <td style=“text-align:left;”> regulation of protein polymerization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 164 </td> <td style=“text-align:left;”> 6.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0065003 </td> <td style=“text-align:left;”> protein-containing complex assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1320 </td> <td style=“text-align:left;”> 6.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007263 </td> <td style=“text-align:left;”> nitric oxide mediated signal transduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 6.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033555 </td> <td style=“text-align:left;”> multicellular organismal response to stress </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 6.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003015 </td> <td style=“text-align:left;”> heart process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 213 </td> <td style=“text-align:left;”> 6.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099536 </td> <td style=“text-align:left;”> synaptic signaling </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 512 </td> <td style=“text-align:left;”> 6.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045595 </td> <td style=“text-align:left;”> regulation of cell differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 1122 </td> <td style=“text-align:left;”> 6.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042462 </td> <td style=“text-align:left;”> eye photoreceptor cell development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 6.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006775 </td> <td style=“text-align:left;”> fat-soluble vitamin metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 6.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006094 </td> <td style=“text-align:left;”> gluconeogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 6.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006816 </td> <td style=“text-align:left;”> calcium ion transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 275 </td> <td style=“text-align:left;”> 6.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051049 </td> <td style=“text-align:left;”> regulation of transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1268 </td> <td style=“text-align:left;”> 6.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046718 </td> <td style=“text-align:left;”> viral entry into host cell </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 109 </td> <td style=“text-align:left;”> 6.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060976 </td> <td style=“text-align:left;”> coronary vasculature development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 6.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045621 </td> <td style=“text-align:left;”> positive regulation of lymphocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 86 </td> <td style=“text-align:left;”> 6.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002376 </td> <td style=“text-align:left;”> immune system process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 1482 </td> <td style=“text-align:left;”> 6.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901658 </td> <td style=“text-align:left;”> glycosyl compound catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 6.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903522 </td> <td style=“text-align:left;”> regulation of blood circulation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 197 </td> <td style=“text-align:left;”> 6.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001822 </td> <td style=“text-align:left;”> kidney development </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:right;”> 246 </td> <td style=“text-align:left;”> 6.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902600 </td> <td style=“text-align:left;”> proton transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 119 </td> <td style=“text-align:left;”> 6.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016574 </td> <td style=“text-align:left;”> histone ubiquitination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 7.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033617 </td> <td style=“text-align:left;”> mitochondrial cytochrome c oxidase assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 7.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051216 </td> <td style=“text-align:left;”> cartilage development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 149 </td> <td style=“text-align:left;”> 7.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098739 </td> <td style=“text-align:left;”> import across plasma membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 130 </td> <td style=“text-align:left;”> 7.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035065 </td> <td style=“text-align:left;”> regulation of histone acetylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 7.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016242 </td> <td style=“text-align:left;”> negative regulation of macroautophagy </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 7.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043032 </td> <td style=“text-align:left;”> positive regulation of macrophage activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:left;”> 7.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048568 </td> <td style=“text-align:left;”> embryonic organ development </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 314 </td> <td style=“text-align:left;”> 7.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050732 </td> <td style=“text-align:left;”> negative regulation of peptidyl-tyrosine phosphorylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 7.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060575 </td> <td style=“text-align:left;”> intestinal epithelial cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 7.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033628 </td> <td style=“text-align:left;”> regulation of cell adhesion mediated by integrin </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 7.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051092 </td> <td style=“text-align:left;”> positive regulation of NF-kappaB transcription factor activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 116 </td> <td style=“text-align:left;”> 7.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006298 </td> <td style=“text-align:left;”> mismatch repair </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 7.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090276 </td> <td style=“text-align:left;”> regulation of peptide hormone secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 135 </td> <td style=“text-align:left;”> 7.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002819 </td> <td style=“text-align:left;”> regulation of adaptive immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 113 </td> <td style=“text-align:left;”> 7.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140115 </td> <td style=“text-align:left;”> export across plasma membrane </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 7.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015909 </td> <td style=“text-align:left;”> long-chain fatty acid transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 7.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901879 </td> <td style=“text-align:left;”> regulation of protein depolymerization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 7.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006513 </td> <td style=“text-align:left;”> protein monoubiquitination </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 71 </td> <td style=“text-align:left;”> 7.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007005 </td> <td style=“text-align:left;”> mitochondrion organization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 500 </td> <td style=“text-align:left;”> 7.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007399 </td> <td style=“text-align:left;”> nervous system development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 1886 </td> <td style=“text-align:left;”> 7.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006839 </td> <td style=“text-align:left;”> mitochondrial transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 172 </td> <td style=“text-align:left;”> 7.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0080111 </td> <td style=“text-align:left;”> DNA demethylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 7.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006654 </td> <td style=“text-align:left;”> phosphatidic acid biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 7.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030177 </td> <td style=“text-align:left;”> positive regulation of Wnt signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 120 </td> <td style=“text-align:left;”> 7.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002200 </td> <td style=“text-align:left;”> somatic diversification of immune receptors </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 61 </td> <td style=“text-align:left;”> 7.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901028 </td> <td style=“text-align:left;”> regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 7.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048255 </td> <td style=“text-align:left;”> mRNA stabilization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 52 </td> <td style=“text-align:left;”> 7.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030073 </td> <td style=“text-align:left;”> insulin secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 144 </td> <td style=“text-align:left;”> 7.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048732 </td> <td style=“text-align:left;”> gland development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 319 </td> <td style=“text-align:left;”> 7.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035239 </td> <td style=“text-align:left;”> tube morphogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 663 </td> <td style=“text-align:left;”> 7.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006911 </td> <td style=“text-align:left;”> phagocytosis, engulfment </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 7.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001667 </td> <td style=“text-align:left;”> ameboidal-type cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 358 </td> <td style=“text-align:left;”> 7.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035825 </td> <td style=“text-align:left;”> homologous recombination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 7.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002437 </td> <td style=“text-align:left;”> inflammatory response to antigenic stimulus </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 7.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032006 </td> <td style=“text-align:left;”> regulation of TOR signaling </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 102 </td> <td style=“text-align:left;”> 7.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045943 </td> <td style=“text-align:left;”> positive regulation of transcription by RNA polymerase I </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 7.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042531 </td> <td style=“text-align:left;”> positive regulation of tyrosine phosphorylation of STAT protein </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 7.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009101 </td> <td style=“text-align:left;”> glycoprotein biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 251 </td> <td style=“text-align:left;”> 7.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008347 </td> <td style=“text-align:left;”> glial cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 7.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044409 </td> <td style=“text-align:left;”> entry into host </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 115 </td> <td style=“text-align:left;”> 7.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018230 </td> <td style=“text-align:left;”> peptidyl-L-cysteine S-palmitoylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 7.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018231 </td> <td style=“text-align:left;”> peptidyl-S-diacylglycerol-L-cysteine biosynthetic process from peptidyl-cysteine </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 7.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071875 </td> <td style=“text-align:left;”> adrenergic receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 7.10e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019319 </td> <td style=“text-align:left;”> hexose biosynthetic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 73 </td> <td style=“text-align:left;”> 7.10e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030855 </td> <td style=“text-align:left;”> epithelial cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 439 </td> <td style=“text-align:left;”> 7.10e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032370 </td> <td style=“text-align:left;”> positive regulation of lipid transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 57 </td> <td style=“text-align:left;”> 7.10e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048666 </td> <td style=“text-align:left;”> neuron development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 873 </td> <td style=“text-align:left;”> 7.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055082 </td> <td style=“text-align:left;”> intracellular chemical homeostasis </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 498 </td> <td style=“text-align:left;”> 7.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010976 </td> <td style=“text-align:left;”> positive regulation of neuron projection development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 134 </td> <td style=“text-align:left;”> 7.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019915 </td> <td style=“text-align:left;”> lipid storage </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 68 </td> <td style=“text-align:left;”> 7.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007098 </td> <td style=“text-align:left;”> centrosome cycle </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 127 </td> <td style=“text-align:left;”> 7.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061138 </td> <td style=“text-align:left;”> morphogenesis of a branching epithelium </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 143 </td> <td style=“text-align:left;”> 7.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009952 </td> <td style=“text-align:left;”> anterior/posterior pattern specification </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 125 </td> <td style=“text-align:left;”> 7.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034219 </td> <td style=“text-align:left;”> carbohydrate transmembrane transport </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 95 </td> <td style=“text-align:left;”> 7.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050729 </td> <td style=“text-align:left;”> positive regulation of inflammatory response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 72 </td> <td style=“text-align:left;”> 7.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901186 </td> <td style=“text-align:left;”> positive regulation of ERBB signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 7.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034765 </td> <td style=“text-align:left;”> regulation of monoatomic ion transmembrane transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 296 </td> <td style=“text-align:left;”> 7.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072009 </td> <td style=“text-align:left;”> nephron epithelium development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 87 </td> <td style=“text-align:left;”> 7.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003018 </td> <td style=“text-align:left;”> vascular process in circulatory system </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 198 </td> <td style=“text-align:left;”> 7.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009394 </td> <td style=“text-align:left;”> 2’-deoxyribonucleotide metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 7.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031646 </td> <td style=“text-align:left;”> positive regulation of nervous system process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 7.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009220 </td> <td style=“text-align:left;”> pyrimidine ribonucleotide biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 7.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0086065 </td> <td style=“text-align:left;”> cell communication involved in cardiac conduction </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 7.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034097 </td> <td style=“text-align:left;”> response to cytokine </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:right;”> 609 </td> <td style=“text-align:left;”> 7.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009410 </td> <td style=“text-align:left;”> response to xenobiotic stimulus </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 275 </td> <td style=“text-align:left;”> 7.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060314 </td> <td style=“text-align:left;”> regulation of ryanodine-sensitive calcium-release channel activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 7.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022604 </td> <td style=“text-align:left;”> regulation of cell morphogenesis </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 208 </td> <td style=“text-align:left;”> 7.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007420 </td> <td style=“text-align:left;”> brain development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 546 </td> <td style=“text-align:left;”> 7.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042098 </td> <td style=“text-align:left;”> T cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 120 </td> <td style=“text-align:left;”> 7.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008340 </td> <td style=“text-align:left;”> determination of adult lifespan </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 7.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071345 </td> <td style=“text-align:left;”> cellular response to cytokine stimulus </td> <td style=“text-align:right;”> 10 </td> <td style=“text-align:right;”> 544 </td> <td style=“text-align:left;”> 7.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048705 </td> <td style=“text-align:left;”> skeletal system morphogenesis </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 155 </td> <td style=“text-align:left;”> 7.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097305 </td> <td style=“text-align:left;”> response to alcohol </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 160 </td> <td style=“text-align:left;”> 7.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001505 </td> <td style=“text-align:left;”> regulation of neurotransmitter levels </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 132 </td> <td style=“text-align:left;”> 7.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048710 </td> <td style=“text-align:left;”> regulation of astrocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 7.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051716 </td> <td style=“text-align:left;”> cellular response to stimulus </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 4929 </td> <td style=“text-align:left;”> 7.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009395 </td> <td style=“text-align:left;”> phospholipid catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 7.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035176 </td> <td style=“text-align:left;”> social behavior </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 7.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009262 </td> <td style=“text-align:left;”> deoxyribonucleotide metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 7.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019692 </td> <td style=“text-align:left;”> deoxyribose phosphate metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 7.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022029 </td> <td style=“text-align:left;”> telencephalon cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 7.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050680 </td> <td style=“text-align:left;”> negative regulation of epithelial cell proliferation </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 107 </td> <td style=“text-align:left;”> 7.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010033 </td> <td style=“text-align:left;”> response to organic substance </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1942 </td> <td style=“text-align:left;”> 7.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000191 </td> <td style=“text-align:left;”> regulation of fatty acid transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 7.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0080090 </td> <td style=“text-align:left;”> regulation of primary metabolic process </td> <td style=“text-align:right;”> 121 </td> <td style=“text-align:right;”> 4371 </td> <td style=“text-align:left;”> 7.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031100 </td> <td style=“text-align:left;”> animal organ regeneration </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 47 </td> <td style=“text-align:left;”> 7.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099054 </td> <td style=“text-align:left;”> presynapse assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 7.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032508 </td> <td style=“text-align:left;”> DNA duplex unwinding </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 7.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050886 </td> <td style=“text-align:left;”> endocrine process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 7.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002250 </td> <td style=“text-align:left;”> adaptive immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 226 </td> <td style=“text-align:left;”> 7.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002697 </td> <td style=“text-align:left;”> regulation of immune effector process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 196 </td> <td style=“text-align:left;”> 7.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048814 </td> <td style=“text-align:left;”> regulation of dendrite morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 54 </td> <td style=“text-align:left;”> 7.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009144 </td> <td style=“text-align:left;”> purine nucleoside triphosphate metabolic process </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 142 </td> <td style=“text-align:left;”> 7.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046324 </td> <td style=“text-align:left;”> regulation of glucose import </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 7.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001824 </td> <td style=“text-align:left;”> blastocyst development </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 94 </td> <td style=“text-align:left;”> 7.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031069 </td> <td style=“text-align:left;”> hair follicle morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 7.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061008 </td> <td style=“text-align:left;”> hepaticobiliary system development </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 113 </td> <td style=“text-align:left;”> 7.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070372 </td> <td style=“text-align:left;”> regulation of ERK1 and ERK2 cascade </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 192 </td> <td style=“text-align:left;”> 7.30e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002274 </td> <td style=“text-align:left;”> myeloid leukocyte activation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 121 </td> <td style=“text-align:left;”> 7.30e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019934 </td> <td style=“text-align:left;”> cGMP-mediated signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 7.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051703 </td> <td style=“text-align:left;”> biological process involved in intraspecies interaction between organisms </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 7.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901617 </td> <td style=“text-align:left;”> organic hydroxy compound biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 174 </td> <td style=“text-align:left;”> 7.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015701 </td> <td style=“text-align:left;”> bicarbonate transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 7.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050881 </td> <td style=“text-align:left;”> musculoskeletal movement </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 7.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045665 </td> <td style=“text-align:left;”> negative regulation of neuron differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 7.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030902 </td> <td style=“text-align:left;”> hindbrain development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 114 </td> <td style=“text-align:left;”> 7.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0062012 </td> <td style=“text-align:left;”> regulation of small molecule metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 248 </td> <td style=“text-align:left;”> 7.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002683 </td> <td style=“text-align:left;”> negative regulation of immune system process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 304 </td> <td style=“text-align:left;”> 7.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905475 </td> <td style=“text-align:left;”> regulation of protein localization to membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 154 </td> <td style=“text-align:left;”> 7.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030808 </td> <td style=“text-align:left;”> regulation of nucleotide biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 7.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0120254 </td> <td style=“text-align:left;”> olefinic compound metabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 84 </td> <td style=“text-align:left;”> 7.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900371 </td> <td style=“text-align:left;”> regulation of purine nucleotide biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 7.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060349 </td> <td style=“text-align:left;”> bone morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 7.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901137 </td> <td style=“text-align:left;”> carbohydrate derivative biosynthetic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 544 </td> <td style=“text-align:left;”> 7.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009205 </td> <td style=“text-align:left;”> purine ribonucleoside triphosphate metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 135 </td> <td style=“text-align:left;”> 7.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002221 </td> <td style=“text-align:left;”> pattern recognition receptor signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 143 </td> <td style=“text-align:left;”> 7.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045920 </td> <td style=“text-align:left;”> negative regulation of exocytosis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 7.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010737 </td> <td style=“text-align:left;”> protein kinase A signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 7.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021885 </td> <td style=“text-align:left;”> forebrain cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 7.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001570 </td> <td style=“text-align:left;”> vasculogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 67 </td> <td style=“text-align:left;”> 7.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022407 </td> <td style=“text-align:left;”> regulation of cell-cell adhesion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 292 </td> <td style=“text-align:left;”> 7.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045785 </td> <td style=“text-align:left;”> positive regulation of cell adhesion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 319 </td> <td style=“text-align:left;”> 7.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009888 </td> <td style=“text-align:left;”> tissue development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1425 </td> <td style=“text-align:left;”> 7.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031667 </td> <td style=“text-align:left;”> response to nutrient levels </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 355 </td> <td style=“text-align:left;”> 7.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050851 </td> <td style=“text-align:left;”> antigen receptor-mediated signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 107 </td> <td style=“text-align:left;”> 7.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019216 </td> <td style=“text-align:left;”> regulation of lipid metabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 251 </td> <td style=“text-align:left;”> 7.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050879 </td> <td style=“text-align:left;”> multicellular organismal movement </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 7.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016051 </td> <td style=“text-align:left;”> carbohydrate biosynthetic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 160 </td> <td style=“text-align:left;”> 7.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060322 </td> <td style=“text-align:left;”> head development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 588 </td> <td style=“text-align:left;”> 7.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009612 </td> <td style=“text-align:left;”> response to mechanical stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 155 </td> <td style=“text-align:left;”> 7.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043603 </td> <td style=“text-align:left;”> amide metabolic process </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 1003 </td> <td style=“text-align:left;”> 7.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072529 </td> <td style=“text-align:left;”> pyrimidine-containing compound catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 7.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901224 </td> <td style=“text-align:left;”> positive regulation of non-canonical NF-kappaB signal transduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 7.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009112 </td> <td style=“text-align:left;”> nucleobase metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 7.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0065008 </td> <td style=“text-align:left;”> regulation of biological quality </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2085 </td> <td style=“text-align:left;”> 7.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051384 </td> <td style=“text-align:left;”> response to glucocorticoid </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 82 </td> <td style=“text-align:left;”> 7.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010951 </td> <td style=“text-align:left;”> negative regulation of endopeptidase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 93 </td> <td style=“text-align:left;”> 7.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046473 </td> <td style=“text-align:left;”> phosphatidic acid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 7.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048562 </td> <td style=“text-align:left;”> embryonic organ morphogenesis </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 186 </td> <td style=“text-align:left;”> 7.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055078 </td> <td style=“text-align:left;”> sodium ion homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 7.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002703 </td> <td style=“text-align:left;”> regulation of leukocyte mediated immunity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 124 </td> <td style=“text-align:left;”> 7.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071902 </td> <td style=“text-align:left;”> positive regulation of protein serine/threonine kinase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 132 </td> <td style=“text-align:left;”> 7.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072655 </td> <td style=“text-align:left;”> establishment of protein localization to mitochondrion </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 117 </td> <td style=“text-align:left;”> 7.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090630 </td> <td style=“text-align:left;”> activation of GTPase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 93 </td> <td style=“text-align:left;”> 7.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090140 </td> <td style=“text-align:left;”> regulation of mitochondrial fission </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 7.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030837 </td> <td style=“text-align:left;”> negative regulation of actin filament polymerization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 7.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006493 </td> <td style=“text-align:left;”> protein O-linked glycosylation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 75 </td> <td style=“text-align:left;”> 7.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018208 </td> <td style=“text-align:left;”> peptidyl-proline modification </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 7.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019226 </td> <td style=“text-align:left;”> transmission of nerve impulse </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 7.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034655 </td> <td style=“text-align:left;”> nucleobase-containing compound catabolic process </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 369 </td> <td style=“text-align:left;”> 7.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043489 </td> <td style=“text-align:left;”> RNA stabilization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 61 </td> <td style=“text-align:left;”> 7.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034764 </td> <td style=“text-align:left;”> positive regulation of transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 155 </td> <td style=“text-align:left;”> 7.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045824 </td> <td style=“text-align:left;”> negative regulation of innate immune response </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 61 </td> <td style=“text-align:left;”> 7.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045684 </td> <td style=“text-align:left;”> positive regulation of epidermis development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 7.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046364 </td> <td style=“text-align:left;”> monosaccharide biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 82 </td> <td style=“text-align:left;”> 7.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034446 </td> <td style=“text-align:left;”> substrate adhesion-dependent cell spreading </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 90 </td> <td style=“text-align:left;”> 7.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034308 </td> <td style=“text-align:left;”> primary alcohol metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 60 </td> <td style=“text-align:left;”> 7.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990806 </td> <td style=“text-align:left;”> ligand-gated ion channel signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 7.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099172 </td> <td style=“text-align:left;”> presynapse organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 7.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006139 </td> <td style=“text-align:left;”> nucleobase-containing compound metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 4423 </td> <td style=“text-align:left;”> 7.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006836 </td> <td style=“text-align:left;”> neurotransmitter transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 141 </td> <td style=“text-align:left;”> 7.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002312 </td> <td style=“text-align:left;”> B cell activation involved in immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 7.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032388 </td> <td style=“text-align:left;”> positive regulation of intracellular transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 174 </td> <td style=“text-align:left;”> 7.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001649 </td> <td style=“text-align:left;”> osteoblast differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 179 </td> <td style=“text-align:left;”> 7.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902373 </td> <td style=“text-align:left;”> negative regulation of mRNA catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 59 </td> <td style=“text-align:left;”> 7.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048583 </td> <td style=“text-align:left;”> regulation of response to stimulus </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:right;”> 2877 </td> <td style=“text-align:left;”> 7.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000038 </td> <td style=“text-align:left;”> very long-chain fatty acid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 7.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008535 </td> <td style=“text-align:left;”> respiratory chain complex IV assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 7.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044000 </td> <td style=“text-align:left;”> movement in host </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 140 </td> <td style=“text-align:left;”> 7.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048468 </td> <td style=“text-align:left;”> cell development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 1950 </td> <td style=“text-align:left;”> 7.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045787 </td> <td style=“text-align:left;”> positive regulation of cell cycle </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 272 </td> <td style=“text-align:left;”> 7.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903018 </td> <td style=“text-align:left;”> regulation of glycoprotein metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 7.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070661 </td> <td style=“text-align:left;”> leukocyte proliferation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 188 </td> <td style=“text-align:left;”> 7.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002700 </td> <td style=“text-align:left;”> regulation of production of molecular mediator of immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 108 </td> <td style=“text-align:left;”> 7.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032526 </td> <td style=“text-align:left;”> response to retinoic acid </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 81 </td> <td style=“text-align:left;”> 7.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006090 </td> <td style=“text-align:left;”> pyruvate metabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 97 </td> <td style=“text-align:left;”> 7.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051241 </td> <td style=“text-align:left;”> negative regulation of multicellular organismal process </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 744 </td> <td style=“text-align:left;”> 7.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009199 </td> <td style=“text-align:left;”> ribonucleoside triphosphate metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 142 </td> <td style=“text-align:left;”> 7.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070509 </td> <td style=“text-align:left;”> calcium ion import </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 7.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009225 </td> <td style=“text-align:left;”> nucleotide-sugar metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 7.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099024 </td> <td style=“text-align:left;”> plasma membrane invagination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 7.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043331 </td> <td style=“text-align:left;”> response to dsRNA </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 7.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032392 </td> <td style=“text-align:left;”> DNA geometric change </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 80 </td> <td style=“text-align:left;”> 7.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090407 </td> <td style=“text-align:left;”> organophosphate biosynthetic process </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:right;”> 507 </td> <td style=“text-align:left;”> 7.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002253 </td> <td style=“text-align:left;”> activation of immune response </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 297 </td> <td style=“text-align:left;”> 7.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0062013 </td> <td style=“text-align:left;”> positive regulation of small molecule metabolic process </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 107 </td> <td style=“text-align:left;”> 7.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042446 </td> <td style=“text-align:left;”> hormone biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 7.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000463 </td> <td style=“text-align:left;”> positive regulation of excitatory postsynaptic potential </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 7.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903708 </td> <td style=“text-align:left;”> positive regulation of hemopoiesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 118 </td> <td style=“text-align:left;”> 7.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902107 </td> <td style=“text-align:left;”> positive regulation of leukocyte differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 118 </td> <td style=“text-align:left;”> 7.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031334 </td> <td style=“text-align:left;”> positive regulation of protein-containing complex assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 161 </td> <td style=“text-align:left;”> 7.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0120162 </td> <td style=“text-align:left;”> positive regulation of cold-induced thermogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 72 </td> <td style=“text-align:left;”> 7.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042509 </td> <td style=“text-align:left;”> regulation of tyrosine phosphorylation of STAT protein </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 7.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072330 </td> <td style=“text-align:left;”> monocarboxylic acid biosynthetic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 146 </td> <td style=“text-align:left;”> 7.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006935 </td> <td style=“text-align:left;”> chemotaxis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 264 </td> <td style=“text-align:left;”> 7.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002682 </td> <td style=“text-align:left;”> regulation of immune system process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 910 </td> <td style=“text-align:left;”> 7.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006874 </td> <td style=“text-align:left;”> intracellular calcium ion homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 208 </td> <td style=“text-align:left;”> 7.57e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042330 </td> <td style=“text-align:left;”> taxis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 264 </td> <td style=“text-align:left;”> 7.57e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043525 </td> <td style=“text-align:left;”> positive regulation of neuron apoptotic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 7.57e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048585 </td> <td style=“text-align:left;”> negative regulation of response to stimulus </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:right;”> 1267 </td> <td style=“text-align:left;”> 7.57e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048730 </td> <td style=“text-align:left;”> epidermis morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 7.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903146 </td> <td style=“text-align:left;”> regulation of autophagy of mitochondrion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 7.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060348 </td> <td style=“text-align:left;”> bone development </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 157 </td> <td style=“text-align:left;”> 7.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046483 </td> <td style=“text-align:left;”> heterocycle metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 4537 </td> <td style=“text-align:left;”> 7.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030072 </td> <td style=“text-align:left;”> peptide hormone secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 169 </td> <td style=“text-align:left;”> 7.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043933 </td> <td style=“text-align:left;”> protein-containing complex organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1964 </td> <td style=“text-align:left;”> 7.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044272 </td> <td style=“text-align:left;”> sulfur compound biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 122 </td> <td style=“text-align:left;”> 7.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002366 </td> <td style=“text-align:left;”> leukocyte activation involved in immune response </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 158 </td> <td style=“text-align:left;”> 7.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900024 </td> <td style=“text-align:left;”> regulation of substrate adhesion-dependent cell spreading </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 54 </td> <td style=“text-align:left;”> 7.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042310 </td> <td style=“text-align:left;”> vasoconstriction </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 7.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901615 </td> <td style=“text-align:left;”> organic hydroxy compound metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 375 </td> <td style=“text-align:left;”> 7.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010648 </td> <td style=“text-align:left;”> negative regulation of cell communication </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 1088 </td> <td style=“text-align:left;”> 7.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0038093 </td> <td style=“text-align:left;”> Fc receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 7.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098698 </td> <td style=“text-align:left;”> postsynaptic specialization assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 7.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006629 </td> <td style=“text-align:left;”> lipid metabolic process </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 989 </td> <td style=“text-align:left;”> 7.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050794 </td> <td style=“text-align:left;”> regulation of cellular process </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 7632 </td> <td style=“text-align:left;”> 7.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002377 </td> <td style=“text-align:left;”> immunoglobulin production </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 7.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006725 </td> <td style=“text-align:left;”> cellular aromatic compound metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 4561 </td> <td style=“text-align:left;”> 7.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0062014 </td> <td style=“text-align:left;”> negative regulation of small molecule metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 75 </td> <td style=“text-align:left;”> 7.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0150077 </td> <td style=“text-align:left;”> regulation of neuroinflammatory response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 7.62e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051881 </td> <td style=“text-align:left;”> regulation of mitochondrial membrane potential </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 63 </td> <td style=“text-align:left;”> 7.62e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022414 </td> <td style=“text-align:left;”> reproductive process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 924 </td> <td style=“text-align:left;”> 7.62e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007165 </td> <td style=“text-align:left;”> signal transduction </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 3803 </td> <td style=“text-align:left;”> 7.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007173 </td> <td style=“text-align:left;”> epidermal growth factor receptor signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 89 </td> <td style=“text-align:left;”> 7.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051591 </td> <td style=“text-align:left;”> response to cAMP </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 7.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001892 </td> <td style=“text-align:left;”> embryonic placenta development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 7.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002758 </td> <td style=“text-align:left;”> innate immune response-activating signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 150 </td> <td style=“text-align:left;”> 7.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902914 </td> <td style=“text-align:left;”> regulation of protein polyubiquitination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 7.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000003 </td> <td style=“text-align:left;”> reproduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 933 </td> <td style=“text-align:left;”> 7.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042572 </td> <td style=“text-align:left;”> retinol metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 7.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045880 </td> <td style=“text-align:left;”> positive regulation of smoothened signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 7.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007260 </td> <td style=“text-align:left;”> tyrosine phosphorylation of STAT protein </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 7.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006261 </td> <td style=“text-align:left;”> DNA-templated DNA replication </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 150 </td> <td style=“text-align:left;”> 7.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048762 </td> <td style=“text-align:left;”> mesenchymal cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 205 </td> <td style=“text-align:left;”> 7.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042273 </td> <td style=“text-align:left;”> ribosomal large subunit biogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 7.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070374 </td> <td style=“text-align:left;”> positive regulation of ERK1 and ERK2 cascade </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 120 </td> <td style=“text-align:left;”> 7.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002263 </td> <td style=“text-align:left;”> cell activation involved in immune response </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 161 </td> <td style=“text-align:left;”> 7.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001893 </td> <td style=“text-align:left;”> maternal placenta development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 7.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009100 </td> <td style=“text-align:left;”> glycoprotein metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 315 </td> <td style=“text-align:left;”> 7.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0038061 </td> <td style=“text-align:left;”> non-canonical NF-kappaB signal transduction </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 94 </td> <td style=“text-align:left;”> 7.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032965 </td> <td style=“text-align:left;”> regulation of collagen biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 7.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007520 </td> <td style=“text-align:left;”> myoblast fusion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 7.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002699 </td> <td style=“text-align:left;”> positive regulation of immune effector process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 136 </td> <td style=“text-align:left;”> 7.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010507 </td> <td style=“text-align:left;”> negative regulation of autophagy </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 75 </td> <td style=“text-align:left;”> 7.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900076 </td> <td style=“text-align:left;”> regulation of cellular response to insulin stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 54 </td> <td style=“text-align:left;”> 7.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043408 </td> <td style=“text-align:left;”> regulation of MAPK cascade </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 473 </td> <td style=“text-align:left;”> 7.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009605 </td> <td style=“text-align:left;”> response to external stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 1635 </td> <td style=“text-align:left;”> 7.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099175 </td> <td style=“text-align:left;”> regulation of postsynapse organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 84 </td> <td style=“text-align:left;”> 7.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002861 </td> <td style=“text-align:left;”> regulation of inflammatory response to antigenic stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 7.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002065 </td> <td style=“text-align:left;”> columnar/cuboidal epithelial cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 80 </td> <td style=“text-align:left;”> 7.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905954 </td> <td style=“text-align:left;”> positive regulation of lipid localization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 7.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072073 </td> <td style=“text-align:left;”> kidney epithelium development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 113 </td> <td style=“text-align:left;”> 7.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045638 </td> <td style=“text-align:left;”> negative regulation of myeloid cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 7.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033146 </td> <td style=“text-align:left;”> regulation of intracellular estrogen receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 7.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903318 </td> <td style=“text-align:left;”> negative regulation of protein maturation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 7.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010955 </td> <td style=“text-align:left;”> negative regulation of protein processing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 7.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014070 </td> <td style=“text-align:left;”> response to organic cyclic compound </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 634 </td> <td style=“text-align:left;”> 7.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002251 </td> <td style=“text-align:left;”> organ or tissue specific immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 13 </td> <td style=“text-align:left;”> 7.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903305 </td> <td style=“text-align:left;”> regulation of regulated secretory pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 86 </td> <td style=“text-align:left;”> 7.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010762 </td> <td style=“text-align:left;”> regulation of fibroblast migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 7.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046320 </td> <td style=“text-align:left;”> regulation of fatty acid oxidation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 7.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090068 </td> <td style=“text-align:left;”> positive regulation of cell cycle process </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 206 </td> <td style=“text-align:left;”> 7.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070585 </td> <td style=“text-align:left;”> protein localization to mitochondrion </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 123 </td> <td style=“text-align:left;”> 7.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032680 </td> <td style=“text-align:left;”> regulation of tumor necrosis factor production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 91 </td> <td style=“text-align:left;”> 7.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032640 </td> <td style=“text-align:left;”> tumor necrosis factor production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 91 </td> <td style=“text-align:left;”> 7.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055074 </td> <td style=“text-align:left;”> calcium ion homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 221 </td> <td style=“text-align:left;”> 7.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008643 </td> <td style=“text-align:left;”> carbohydrate transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 114 </td> <td style=“text-align:left;”> 7.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048640 </td> <td style=“text-align:left;”> negative regulation of developmental growth </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 94 </td> <td style=“text-align:left;”> 7.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051701 </td> <td style=“text-align:left;”> biological process involved in interaction with host </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 153 </td> <td style=“text-align:left;”> 7.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001525 </td> <td style=“text-align:left;”> angiogenesis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 389 </td> <td style=“text-align:left;”> 7.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032412 </td> <td style=“text-align:left;”> regulation of monoatomic ion transmembrane transporter activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 189 </td> <td style=“text-align:left;”> 7.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051093 </td> <td style=“text-align:left;”> negative regulation of developmental process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 654 </td> <td style=“text-align:left;”> 7.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050830 </td> <td style=“text-align:left;”> defense response to Gram-positive bacterium </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 7.78e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060688 </td> <td style=“text-align:left;”> regulation of morphogenesis of a branching structure </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 7.78e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046822 </td> <td style=“text-align:left;”> regulation of nucleocytoplasmic transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 98 </td> <td style=“text-align:left;”> 7.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901360 </td> <td style=“text-align:left;”> organic cyclic compound metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 4713 </td> <td style=“text-align:left;”> 7.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006936 </td> <td style=“text-align:left;”> muscle contraction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 266 </td> <td style=“text-align:left;”> 7.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072006 </td> <td style=“text-align:left;”> nephron development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 118 </td> <td style=“text-align:left;”> 7.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001541 </td> <td style=“text-align:left;”> ovarian follicle development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 7.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009991 </td> <td style=“text-align:left;”> response to extracellular stimulus </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 379 </td> <td style=“text-align:left;”> 7.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010324 </td> <td style=“text-align:left;”> membrane invagination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 7.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035337 </td> <td style=“text-align:left;”> fatty-acyl-CoA metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 7.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007204 </td> <td style=“text-align:left;”> positive regulation of cytosolic calcium ion concentration </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 78 </td> <td style=“text-align:left;”> 7.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007169 </td> <td style=“text-align:left;”> transmembrane receptor protein tyrosine kinase signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 470 </td> <td style=“text-align:left;”> 7.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045580 </td> <td style=“text-align:left;”> regulation of T cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 110 </td> <td style=“text-align:left;”> 7.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007416 </td> <td style=“text-align:left;”> synapse assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 153 </td> <td style=“text-align:left;”> 7.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051445 </td> <td style=“text-align:left;”> regulation of meiotic cell cycle </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 7.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071706 </td> <td style=“text-align:left;”> tumor necrosis factor superfamily cytokine production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 94 </td> <td style=“text-align:left;”> 7.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903555 </td> <td style=“text-align:left;”> regulation of tumor necrosis factor superfamily cytokine production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 94 </td> <td style=“text-align:left;”> 7.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002028 </td> <td style=“text-align:left;”> regulation of sodium ion transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 71 </td> <td style=“text-align:left;”> 7.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006040 </td> <td style=“text-align:left;”> amino sugar metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 7.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009167 </td> <td style=“text-align:left;”> purine ribonucleoside monophosphate metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 7.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904950 </td> <td style=“text-align:left;”> negative regulation of establishment of protein localization </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 98 </td> <td style=“text-align:left;”> 7.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046942 </td> <td style=“text-align:left;”> carboxylic acid transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 213 </td> <td style=“text-align:left;”> 7.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034605 </td> <td style=“text-align:left;”> cellular response to heat </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 7.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015849 </td> <td style=“text-align:left;”> organic acid transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 214 </td> <td style=“text-align:left;”> 7.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0052652 </td> <td style=“text-align:left;”> cyclic purine nucleotide metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 7.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002757 </td> <td style=“text-align:left;”> immune response-activating signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 259 </td> <td style=“text-align:left;”> 7.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071103 </td> <td style=“text-align:left;”> DNA conformation change </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 87 </td> <td style=“text-align:left;”> 7.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051050 </td> <td style=“text-align:left;”> positive regulation of transport </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 665 </td> <td style=“text-align:left;”> 7.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007405 </td> <td style=“text-align:left;”> neuroblast proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 7.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006306 </td> <td style=“text-align:left;”> DNA methylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 7.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009141 </td> <td style=“text-align:left;”> nucleoside triphosphate metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 158 </td> <td style=“text-align:left;”> 7.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042168 </td> <td style=“text-align:left;”> heme metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 7.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000380 </td> <td style=“text-align:left;”> alternative mRNA splicing, via spliceosome </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 63 </td> <td style=“text-align:left;”> 7.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006305 </td> <td style=“text-align:left;”> DNA alkylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 7.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060251 </td> <td style=“text-align:left;”> regulation of glial cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 7.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022898 </td> <td style=“text-align:left;”> regulation of transmembrane transporter activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 200 </td> <td style=“text-align:left;”> 7.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006301 </td> <td style=“text-align:left;”> postreplication repair </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 7.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903214 </td> <td style=“text-align:left;”> regulation of protein targeting to mitochondrion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 7.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042401 </td> <td style=“text-align:left;”> biogenic amine biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 7.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902275 </td> <td style=“text-align:left;”> regulation of chromatin organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 7.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002440 </td> <td style=“text-align:left;”> production of molecular mediator of immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 134 </td> <td style=“text-align:left;”> 7.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904659 </td> <td style=“text-align:left;”> glucose transmembrane transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 84 </td> <td style=“text-align:left;”> 7.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015908 </td> <td style=“text-align:left;”> fatty acid transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 7.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006356 </td> <td style=“text-align:left;”> regulation of transcription by RNA polymerase I </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 47 </td> <td style=“text-align:left;”> 7.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034641 </td> <td style=“text-align:left;”> cellular nitrogen compound metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 4913 </td> <td style=“text-align:left;”> 7.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032272 </td> <td style=“text-align:left;”> negative regulation of protein polymerization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 7.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009187 </td> <td style=“text-align:left;”> cyclic nucleotide metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 7.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900181 </td> <td style=“text-align:left;”> negative regulation of protein localization to nucleus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 7.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902235 </td> <td style=“text-align:left;”> regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 7.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018345 </td> <td style=“text-align:left;”> protein palmitoylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 7.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901888 </td> <td style=“text-align:left;”> regulation of cell junction assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 166 </td> <td style=“text-align:left;”> 7.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045923 </td> <td style=“text-align:left;”> positive regulation of fatty acid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 7.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010721 </td> <td style=“text-align:left;”> negative regulation of cell development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 190 </td> <td style=“text-align:left;”> 7.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046323 </td> <td style=“text-align:left;”> glucose import </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 55 </td> <td style=“text-align:left;”> 7.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009309 </td> <td style=“text-align:left;”> amine biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 24 </td> <td style=“text-align:left;”> 7.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061515 </td> <td style=“text-align:left;”> myeloid cell development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 7.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048536 </td> <td style=“text-align:left;”> spleen development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 7.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070613 </td> <td style=“text-align:left;”> regulation of protein processing </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 7.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035329 </td> <td style=“text-align:left;”> hippo signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 7.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006221 </td> <td style=“text-align:left;”> pyrimidine nucleotide biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 7.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009218 </td> <td style=“text-align:left;”> pyrimidine ribonucleotide metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 7.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070228 </td> <td style=“text-align:left;”> regulation of lymphocyte apoptotic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 7.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043410 </td> <td style=“text-align:left;”> positive regulation of MAPK cascade </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 316 </td> <td style=“text-align:left;”> 7.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019932 </td> <td style=“text-align:left;”> second-messenger-mediated signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 182 </td> <td style=“text-align:left;”> 7.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010827 </td> <td style=“text-align:left;”> regulation of glucose transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 7.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904861 </td> <td style=“text-align:left;”> excitatory synapse assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 8.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008593 </td> <td style=“text-align:left;”> regulation of Notch signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 78 </td> <td style=“text-align:left;”> 8.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010712 </td> <td style=“text-align:left;”> regulation of collagen metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 8.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043403 </td> <td style=“text-align:left;”> skeletal muscle tissue regeneration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 8.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072698 </td> <td style=“text-align:left;”> protein localization to microtubule cytoskeleton </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 8.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007029 </td> <td style=“text-align:left;”> endoplasmic reticulum organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 91 </td> <td style=“text-align:left;”> 8.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008645 </td> <td style=“text-align:left;”> hexose transmembrane transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 87 </td> <td style=“text-align:left;”> 8.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006270 </td> <td style=“text-align:left;”> DNA replication initiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 8.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046513 </td> <td style=“text-align:left;”> ceramide biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 8.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032409 </td> <td style=“text-align:left;”> regulation of transporter activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 212 </td> <td style=“text-align:left;”> 8.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061351 </td> <td style=“text-align:left;”> neural precursor cell proliferation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 122 </td> <td style=“text-align:left;”> 8.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007275 </td> <td style=“text-align:left;”> multicellular organism development </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 3355 </td> <td style=“text-align:left;”> 8.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006953 </td> <td style=“text-align:left;”> acute-phase response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 8.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034762 </td> <td style=“text-align:left;”> regulation of transmembrane transport </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 392 </td> <td style=“text-align:left;”> 8.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008344 </td> <td style=“text-align:left;”> adult locomotory behavior </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 60 </td> <td style=“text-align:left;”> 8.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046777 </td> <td style=“text-align:left;”> protein autophosphorylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 183 </td> <td style=“text-align:left;”> 8.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001501 </td> <td style=“text-align:left;”> skeletal system development </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 361 </td> <td style=“text-align:left;”> 8.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901564 </td> <td style=“text-align:left;”> organonitrogen compound metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4919 </td> <td style=“text-align:left;”> 8.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044270 </td> <td style=“text-align:left;”> cellular nitrogen compound catabolic process </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 388 </td> <td style=“text-align:left;”> 8.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035633 </td> <td style=“text-align:left;”> maintenance of blood-brain barrier </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 8.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032386 </td> <td style=“text-align:left;”> regulation of intracellular transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 293 </td> <td style=“text-align:left;”> 8.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046700 </td> <td style=“text-align:left;”> heterocycle catabolic process </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 391 </td> <td style=“text-align:left;”> 8.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900225 </td> <td style=“text-align:left;”> regulation of NLRP3 inflammasome complex assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 8.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045619 </td> <td style=“text-align:left;”> regulation of lymphocyte differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 131 </td> <td style=“text-align:left;”> 8.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002764 </td> <td style=“text-align:left;”> immune response-regulating signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 270 </td> <td style=“text-align:left;”> 8.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014002 </td> <td style=“text-align:left;”> astrocyte development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 8.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0023052 </td> <td style=“text-align:left;”> signaling </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 4134 </td> <td style=“text-align:left;”> 8.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007548 </td> <td style=“text-align:left;”> sex differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 193 </td> <td style=“text-align:left;”> 8.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016525 </td> <td style=“text-align:left;”> negative regulation of angiogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 71 </td> <td style=“text-align:left;”> 8.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044344 </td> <td style=“text-align:left;”> cellular response to fibroblast growth factor stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 81 </td> <td style=“text-align:left;”> 8.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045666 </td> <td style=“text-align:left;”> positive regulation of neuron differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 63 </td> <td style=“text-align:left;”> 8.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043457 </td> <td style=“text-align:left;”> regulation of cellular respiration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 8.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051968 </td> <td style=“text-align:left;”> positive regulation of synaptic transmission, glutamatergic </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 8.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045444 </td> <td style=“text-align:left;”> fat cell differentiation </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 187 </td> <td style=“text-align:left;”> 8.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000181 </td> <td style=“text-align:left;”> negative regulation of blood vessel morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 72 </td> <td style=“text-align:left;”> 8.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015749 </td> <td style=“text-align:left;”> monosaccharide transmembrane transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 88 </td> <td style=“text-align:left;”> 8.15e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046651 </td> <td style=“text-align:left;”> lymphocyte proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 162 </td> <td style=“text-align:left;”> 8.15e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901343 </td> <td style=“text-align:left;”> negative regulation of vasculature development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 72 </td> <td style=“text-align:left;”> 8.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042092 </td> <td style=“text-align:left;”> type 2 immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 8.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045471 </td> <td style=“text-align:left;”> response to ethanol </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 72 </td> <td style=“text-align:left;”> 8.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021987 </td> <td style=“text-align:left;”> cerebral cortex development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 102 </td> <td style=“text-align:left;”> 8.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032892 </td> <td style=“text-align:left;”> positive regulation of organic acid transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 8.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071887 </td> <td style=“text-align:left;”> leukocyte apoptotic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 82 </td> <td style=“text-align:left;”> 8.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050900 </td> <td style=“text-align:left;”> leukocyte migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 207 </td> <td style=“text-align:left;”> 8.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009152 </td> <td style=“text-align:left;”> purine ribonucleotide biosynthetic process </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 178 </td> <td style=“text-align:left;”> 8.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903317 </td> <td style=“text-align:left;”> regulation of protein maturation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 8.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0017004 </td> <td style=“text-align:left;”> cytochrome complex assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 8.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032943 </td> <td style=“text-align:left;”> mononuclear cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 168 </td> <td style=“text-align:left;”> 8.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007154 </td> <td style=“text-align:left;”> cell communication </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 4210 </td> <td style=“text-align:left;”> 8.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000573 </td> <td style=“text-align:left;”> positive regulation of DNA biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 66 </td> <td style=“text-align:left;”> 8.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044380 </td> <td style=“text-align:left;”> protein localization to cytoskeleton </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 54 </td> <td style=“text-align:left;”> 8.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042552 </td> <td style=“text-align:left;”> myelination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 114 </td> <td style=“text-align:left;”> 8.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903312 </td> <td style=“text-align:left;”> negative regulation of mRNA metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 84 </td> <td style=“text-align:left;”> 8.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071616 </td> <td style=“text-align:left;”> acyl-CoA biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 8.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030001 </td> <td style=“text-align:left;”> metal ion transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 568 </td> <td style=“text-align:left;”> 8.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044546 </td> <td style=“text-align:left;”> NLRP3 inflammasome complex assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 8.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007166 </td> <td style=“text-align:left;”> cell surface receptor signaling pathway </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:right;”> 1889 </td> <td style=“text-align:left;”> 8.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035384 </td> <td style=“text-align:left;”> thioester biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 8.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009260 </td> <td style=“text-align:left;”> ribonucleotide biosynthetic process </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 191 </td> <td style=“text-align:left;”> 8.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1904031 </td> <td style=“text-align:left;”> positive regulation of cyclin-dependent protein kinase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 8.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050865 </td> <td style=“text-align:left;”> regulation of cell activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 378 </td> <td style=“text-align:left;”> 8.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042119 </td> <td style=“text-align:left;”> neutrophil activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 8.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000165 </td> <td style=“text-align:left;”> MAPK cascade </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 553 </td> <td style=“text-align:left;”> 8.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043462 </td> <td style=“text-align:left;”> regulation of ATP-dependent activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 63 </td> <td style=“text-align:left;”> 8.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019637 </td> <td style=“text-align:left;”> organophosphate metabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 776 </td> <td style=“text-align:left;”> 8.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007272 </td> <td style=“text-align:left;”> ensheathment of neurons </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 116 </td> <td style=“text-align:left;”> 8.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008277 </td> <td style=“text-align:left;”> regulation of G protein-coupled receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 93 </td> <td style=“text-align:left;”> 8.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008366 </td> <td style=“text-align:left;”> axon ensheathment </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 116 </td> <td style=“text-align:left;”> 8.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019362 </td> <td style=“text-align:left;”> pyridine nucleotide metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 8.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046496 </td> <td style=“text-align:left;”> nicotinamide nucleotide metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 8.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032964 </td> <td style=“text-align:left;”> collagen biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 8.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045596 </td> <td style=“text-align:left;”> negative regulation of cell differentiation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 471 </td> <td style=“text-align:left;”> 8.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035196 </td> <td style=“text-align:left;”> miRNA processing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 8.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048260 </td> <td style=“text-align:left;”> positive regulation of receptor-mediated endocytosis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 8.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000768 </td> <td style=“text-align:left;”> syncytium formation by plasma membrane fusion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 8.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050807 </td> <td style=“text-align:left;”> regulation of synapse organization </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 185 </td> <td style=“text-align:left;”> 8.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140253 </td> <td style=“text-align:left;”> cell-cell fusion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 8.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048878 </td> <td style=“text-align:left;”> chemical homeostasis </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:right;”> 689 </td> <td style=“text-align:left;”> 8.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043484 </td> <td style=“text-align:left;”> regulation of RNA splicing </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 163 </td> <td style=“text-align:left;”> 8.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051224 </td> <td style=“text-align:left;”> negative regulation of protein transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 94 </td> <td style=“text-align:left;”> 8.30e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0141085 </td> <td style=“text-align:left;”> regulation of inflammasome-mediated signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 8.30e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071774 </td> <td style=“text-align:left;”> response to fibroblast growth factor </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 85 </td> <td style=“text-align:left;”> 8.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034728 </td> <td style=“text-align:left;”> nucleosome organization </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 84 </td> <td style=“text-align:left;”> 8.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030225 </td> <td style=“text-align:left;”> macrophage differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 8.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019748 </td> <td style=“text-align:left;”> secondary metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 8.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0038127 </td> <td style=“text-align:left;”> ERBB signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 103 </td> <td style=“text-align:left;”> 8.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051321 </td> <td style=“text-align:left;”> meiotic cell cycle </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 183 </td> <td style=“text-align:left;”> 8.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071241 </td> <td style=“text-align:left;”> cellular response to inorganic substance </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 165 </td> <td style=“text-align:left;”> 8.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048514 </td> <td style=“text-align:left;”> blood vessel morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 461 </td> <td style=“text-align:left;”> 8.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050853 </td> <td style=“text-align:left;”> B cell receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 8.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009968 </td> <td style=“text-align:left;”> negative regulation of signal transduction </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 1017 </td> <td style=“text-align:left;”> 8.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030879 </td> <td style=“text-align:left;”> mammary gland development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 105 </td> <td style=“text-align:left;”> 8.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010608 </td> <td style=“text-align:left;”> post-transcriptional regulation of gene expression </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 475 </td> <td style=“text-align:left;”> 8.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048546 </td> <td style=“text-align:left;”> digestive tract morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 8.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006457 </td> <td style=“text-align:left;”> protein folding </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 188 </td> <td style=“text-align:left;”> 8.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006694 </td> <td style=“text-align:left;”> steroid biosynthetic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 124 </td> <td style=“text-align:left;”> 8.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019439 </td> <td style=“text-align:left;”> aromatic compound catabolic process </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 398 </td> <td style=“text-align:left;”> 8.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006164 </td> <td style=“text-align:left;”> purine nucleotide biosynthetic process </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 209 </td> <td style=“text-align:left;”> 8.36e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140632 </td> <td style=“text-align:left;”> canonical inflammasome complex assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 8.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006081 </td> <td style=“text-align:left;”> cellular aldehyde metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 52 </td> <td style=“text-align:left;”> 8.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021782 </td> <td style=“text-align:left;”> glial cell development </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 87 </td> <td style=“text-align:left;”> 8.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902476 </td> <td style=“text-align:left;”> chloride transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 8.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050803 </td> <td style=“text-align:left;”> regulation of synapse structure or activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 189 </td> <td style=“text-align:left;”> 8.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007157 </td> <td style=“text-align:left;”> heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 8.39e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901570 </td> <td style=“text-align:left;”> fatty acid derivative biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 8.39e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006811 </td> <td style=“text-align:left;”> monoatomic ion transport </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 788 </td> <td style=“text-align:left;”> 8.39e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030098 </td> <td style=“text-align:left;”> lymphocyte differentiation </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 262 </td> <td style=“text-align:left;”> 8.39e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006023 </td> <td style=“text-align:left;”> aminoglycan biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 61 </td> <td style=“text-align:left;”> 8.39e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032102 </td> <td style=“text-align:left;”> negative regulation of response to external stimulus </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:right;”> 291 </td> <td style=“text-align:left;”> 8.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021762 </td> <td style=“text-align:left;”> substantia nigra development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 8.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001774 </td> <td style=“text-align:left;”> microglial cell activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 8.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034220 </td> <td style=“text-align:left;”> monoatomic ion transmembrane transport </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 650 </td> <td style=“text-align:left;”> 8.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051260 </td> <td style=“text-align:left;”> protein homooligomerization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 138 </td> <td style=“text-align:left;”> 8.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072528 </td> <td style=“text-align:left;”> pyrimidine-containing compound biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 8.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002761 </td> <td style=“text-align:left;”> regulation of myeloid leukocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 76 </td> <td style=“text-align:left;”> 8.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046148 </td> <td style=“text-align:left;”> pigment biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 47 </td> <td style=“text-align:left;”> 8.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990778 </td> <td style=“text-align:left;”> protein localization to cell periphery </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 303 </td> <td style=“text-align:left;”> 8.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031330 </td> <td style=“text-align:left;”> negative regulation of cellular catabolic process </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 170 </td> <td style=“text-align:left;”> 8.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099068 </td> <td style=“text-align:left;”> postsynapse assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 8.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042391 </td> <td style=“text-align:left;”> regulation of membrane potential </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 295 </td> <td style=“text-align:left;”> 8.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097106 </td> <td style=“text-align:left;”> postsynaptic density organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 8.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006949 </td> <td style=“text-align:left;”> syncytium formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 8.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001658 </td> <td style=“text-align:left;”> branching involved in ureteric bud morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 8.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072524 </td> <td style=“text-align:left;”> pyridine-containing compound metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 8.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045840 </td> <td style=“text-align:left;”> positive regulation of mitotic nuclear division </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 8.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002429 </td> <td style=“text-align:left;”> immune response-activating cell surface receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 154 </td> <td style=“text-align:left;”> 8.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015711 </td> <td style=“text-align:left;”> organic anion transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 270 </td> <td style=“text-align:left;”> 8.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016064 </td> <td style=“text-align:left;”> immunoglobulin mediated immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 76 </td> <td style=“text-align:left;”> 8.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046390 </td> <td style=“text-align:left;”> ribose phosphate biosynthetic process </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 198 </td> <td style=“text-align:left;”> 8.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048771 </td> <td style=“text-align:left;”> tissue remodeling </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 115 </td> <td style=“text-align:left;”> 8.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031018 </td> <td style=“text-align:left;”> endocrine pancreas development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 8.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006812 </td> <td style=“text-align:left;”> monoatomic cation transport </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 677 </td> <td style=“text-align:left;”> 8.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000241 </td> <td style=“text-align:left;”> regulation of reproductive process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 126 </td> <td style=“text-align:left;”> 8.49e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030218 </td> <td style=“text-align:left;”> erythrocyte differentiation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 109 </td> <td style=“text-align:left;”> 8.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051209 </td> <td style=“text-align:left;”> release of sequestered calcium ion into cytosol </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 90 </td> <td style=“text-align:left;”> 8.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019724 </td> <td style=“text-align:left;”> B cell mediated immunity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 77 </td> <td style=“text-align:left;”> 8.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072538 </td> <td style=“text-align:left;”> T-helper 17 type immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 8.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007215 </td> <td style=“text-align:left;”> glutamate receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 8.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006939 </td> <td style=“text-align:left;”> smooth muscle contraction </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 71 </td> <td style=“text-align:left;”> 8.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019217 </td> <td style=“text-align:left;”> regulation of fatty acid metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 68 </td> <td style=“text-align:left;”> 8.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051283 </td> <td style=“text-align:left;”> negative regulation of sequestering of calcium ion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 91 </td> <td style=“text-align:left;”> 8.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001889 </td> <td style=“text-align:left;”> liver development </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 111 </td> <td style=“text-align:left;”> 8.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030316 </td> <td style=“text-align:left;”> osteoclast differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 65 </td> <td style=“text-align:left;”> 8.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903828 </td> <td style=“text-align:left;”> negative regulation of protein localization </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 171 </td> <td style=“text-align:left;”> 8.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0141084 </td> <td style=“text-align:left;”> inflammasome-mediated signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 8.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050433 </td> <td style=“text-align:left;”> regulation of catecholamine secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 8.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030003 </td> <td style=“text-align:left;”> intracellular monoatomic cation homeostasis </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 364 </td> <td style=“text-align:left;”> 8.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048513 </td> <td style=“text-align:left;”> animal organ development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 2156 </td> <td style=“text-align:left;”> 8.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072522 </td> <td style=“text-align:left;”> purine-containing compound biosynthetic process </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 218 </td> <td style=“text-align:left;”> 8.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006119 </td> <td style=“text-align:left;”> oxidative phosphorylation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 123 </td> <td style=“text-align:left;”> 8.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0120161 </td> <td style=“text-align:left;”> regulation of cold-induced thermogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 115 </td> <td style=“text-align:left;”> 8.56e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0106106 </td> <td style=“text-align:left;”> cold-induced thermogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 116 </td> <td style=“text-align:left;”> 8.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051282 </td> <td style=“text-align:left;”> regulation of sequestering of calcium ion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 93 </td> <td style=“text-align:left;”> 8.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034032 </td> <td style=“text-align:left;”> purine nucleoside bisphosphate metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 91 </td> <td style=“text-align:left;”> 8.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033875 </td> <td style=“text-align:left;”> ribonucleoside bisphosphate metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 91 </td> <td style=“text-align:left;”> 8.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048662 </td> <td style=“text-align:left;”> negative regulation of smooth muscle cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 8.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033865 </td> <td style=“text-align:left;”> nucleoside bisphosphate metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 91 </td> <td style=“text-align:left;”> 8.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014003 </td> <td style=“text-align:left;”> oligodendrocyte development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 8.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010468 </td> <td style=“text-align:left;”> regulation of gene expression </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3587 </td> <td style=“text-align:left;”> 8.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007595 </td> <td style=“text-align:left;”> lactation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 8.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006940 </td> <td style=“text-align:left;”> regulation of smooth muscle contraction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 8.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048523 </td> <td style=“text-align:left;”> negative regulation of cellular process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3773 </td> <td style=“text-align:left;”> 8.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050870 </td> <td style=“text-align:left;”> positive regulation of T cell activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 144 </td> <td style=“text-align:left;”> 8.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051899 </td> <td style=“text-align:left;”> membrane depolarization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 8.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050864 </td> <td style=“text-align:left;”> regulation of B cell activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 77 </td> <td style=“text-align:left;”> 8.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0086001 </td> <td style=“text-align:left;”> cardiac muscle cell action potential </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 68 </td> <td style=“text-align:left;”> 8.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002064 </td> <td style=“text-align:left;”> epithelial cell development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 156 </td> <td style=“text-align:left;”> 8.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0036230 </td> <td style=“text-align:left;”> granulocyte activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 8.60e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007009 </td> <td style=“text-align:left;”> plasma membrane organization </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 114 </td> <td style=“text-align:left;”> 8.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046683 </td> <td style=“text-align:left;”> response to organophosphorus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 94 </td> <td style=“text-align:left;”> 8.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045598 </td> <td style=“text-align:left;”> regulation of fat cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 101 </td> <td style=“text-align:left;”> 8.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030155 </td> <td style=“text-align:left;”> regulation of cell adhesion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 535 </td> <td style=“text-align:left;”> 8.62e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098662 </td> <td style=“text-align:left;”> inorganic cation transmembrane transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 537 </td> <td style=“text-align:left;”> 8.62e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006873 </td> <td style=“text-align:left;”> intracellular monoatomic ion homeostasis </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 369 </td> <td style=“text-align:left;”> 8.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070988 </td> <td style=“text-align:left;”> demethylation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 8.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010556 </td> <td style=“text-align:left;”> regulation of macromolecule biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3702 </td> <td style=“text-align:left;”> 8.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009617 </td> <td style=“text-align:left;”> response to bacterium </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 322 </td> <td style=“text-align:left;”> 8.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050789 </td> <td style=“text-align:left;”> regulation of biological process </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 8017 </td> <td style=“text-align:left;”> 8.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019755 </td> <td style=“text-align:left;”> one-carbon compound transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 8.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051208 </td> <td style=“text-align:left;”> sequestering of calcium ion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 97 </td> <td style=“text-align:left;”> 8.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015980 </td> <td style=“text-align:left;”> energy derivation by oxidation of organic compounds </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 288 </td> <td style=“text-align:left;”> 8.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002768 </td> <td style=“text-align:left;”> immune response-regulating cell surface receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 165 </td> <td style=“text-align:left;”> 8.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901566 </td> <td style=“text-align:left;”> organonitrogen compound biosynthetic process </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 1496 </td> <td style=“text-align:left;”> 8.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006576 </td> <td style=“text-align:left;”> biogenic amine metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 57 </td> <td style=“text-align:left;”> 8.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002088 </td> <td style=“text-align:left;”> lens development in camera-type eye </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 57 </td> <td style=“text-align:left;”> 8.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070972 </td> <td style=“text-align:left;”> protein localization to endoplasmic reticulum </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 79 </td> <td style=“text-align:left;”> 8.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060675 </td> <td style=“text-align:left;”> ureteric bud morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 8.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006275 </td> <td style=“text-align:left;”> regulation of DNA replication </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 116 </td> <td style=“text-align:left;”> 8.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010038 </td> <td style=“text-align:left;”> response to metal ion </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 261 </td> <td style=“text-align:left;”> 8.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042113 </td> <td style=“text-align:left;”> B cell activation </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 169 </td> <td style=“text-align:left;”> 8.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051259 </td> <td style=“text-align:left;”> protein complex oligomerization </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 190 </td> <td style=“text-align:left;”> 8.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006968 </td> <td style=“text-align:left;”> cellular defense response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 8.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061951 </td> <td style=“text-align:left;”> establishment of protein localization to plasma membrane </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 59 </td> <td style=“text-align:left;”> 8.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006821 </td> <td style=“text-align:left;”> chloride transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 57 </td> <td style=“text-align:left;”> 8.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901361 </td> <td style=“text-align:left;”> organic cyclic compound catabolic process </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 415 </td> <td style=“text-align:left;”> 8.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072171 </td> <td style=“text-align:left;”> mesonephric tubule morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 8.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031326 </td> <td style=“text-align:left;”> regulation of cellular biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3794 </td> <td style=“text-align:left;”> 8.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002684 </td> <td style=“text-align:left;”> positive regulation of immune system process </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 610 </td> <td style=“text-align:left;”> 8.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042093 </td> <td style=“text-align:left;”> T-helper cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 8.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061900 </td> <td style=“text-align:left;”> glial cell activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 8.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098655 </td> <td style=“text-align:left;”> monoatomic cation transmembrane transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 554 </td> <td style=“text-align:left;”> 8.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009889 </td> <td style=“text-align:left;”> regulation of biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3820 </td> <td style=“text-align:left;”> 8.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010043 </td> <td style=“text-align:left;”> response to zinc ion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 8.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000910 </td> <td style=“text-align:left;”> cytokinesis </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 164 </td> <td style=“text-align:left;”> 8.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034101 </td> <td style=“text-align:left;”> erythrocyte homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 116 </td> <td style=“text-align:left;”> 8.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099084 </td> <td style=“text-align:left;”> postsynaptic specialization organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 8.75e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042472 </td> <td style=“text-align:left;”> inner ear morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 59 </td> <td style=“text-align:left;”> 8.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001523 </td> <td style=“text-align:left;”> retinoid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 8.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903131 </td> <td style=“text-align:left;”> mononuclear cell differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 295 </td> <td style=“text-align:left;”> 8.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0005975 </td> <td style=“text-align:left;”> carbohydrate metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 439 </td> <td style=“text-align:left;”> 8.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071248 </td> <td style=“text-align:left;”> cellular response to metal ion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 142 </td> <td style=“text-align:left;”> 8.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050793 </td> <td style=“text-align:left;”> regulation of developmental process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 1813 </td> <td style=“text-align:left;”> 8.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051239 </td> <td style=“text-align:left;”> regulation of multicellular organismal process </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 2052 </td> <td style=“text-align:left;”> 8.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051262 </td> <td style=“text-align:left;”> protein tetramerization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 8.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007127 </td> <td style=“text-align:left;”> meiosis I </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 73 </td> <td style=“text-align:left;”> 8.78e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002294 </td> <td style=“text-align:left;”> CD4-positive, alpha-beta T cell differentiation involved in immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 8.78e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903039 </td> <td style=“text-align:left;”> positive regulation of leukocyte cell-cell adhesion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 157 </td> <td style=“text-align:left;”> 8.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048519 </td> <td style=“text-align:left;”> negative regulation of biological process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4026 </td> <td style=“text-align:left;”> 8.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072527 </td> <td style=“text-align:left;”> pyrimidine-containing compound metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 8.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002287 </td> <td style=“text-align:left;”> alpha-beta T cell activation involved in immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 8.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019229 </td> <td style=“text-align:left;”> regulation of vasoconstriction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 8.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002293 </td> <td style=“text-align:left;”> alpha-beta T cell differentiation involved in immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 8.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1990845 </td> <td style=“text-align:left;”> adaptive thermogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 127 </td> <td style=“text-align:left;”> 8.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050906 </td> <td style=“text-align:left;”> detection of stimulus involved in sensory perception </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 8.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045446 </td> <td style=“text-align:left;”> endothelial cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 90 </td> <td style=“text-align:left;”> 8.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016101 </td> <td style=“text-align:left;”> diterpenoid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 8.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0018198 </td> <td style=“text-align:left;”> peptidyl-cysteine modification </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 8.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098661 </td> <td style=“text-align:left;”> inorganic anion transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 8.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015695 </td> <td style=“text-align:left;”> organic cation transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 8.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061337 </td> <td style=“text-align:left;”> cardiac conduction </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 88 </td> <td style=“text-align:left;”> 8.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000649 </td> <td style=“text-align:left;”> regulation of sodium ion transmembrane transporter activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 8.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098771 </td> <td style=“text-align:left;”> inorganic ion homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 355 </td> <td style=“text-align:left;”> 8.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010466 </td> <td style=“text-align:left;”> negative regulation of peptidase activity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 123 </td> <td style=“text-align:left;”> 8.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061982 </td> <td style=“text-align:left;”> meiosis I cell cycle process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 77 </td> <td style=“text-align:left;”> 8.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002931 </td> <td style=“text-align:left;”> response to ischemia </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 8.89e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010035 </td> <td style=“text-align:left;”> response to inorganic substance </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 393 </td> <td style=“text-align:left;”> 8.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055080 </td> <td style=“text-align:left;”> monoatomic cation homeostasis </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 410 </td> <td style=“text-align:left;”> 8.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051240 </td> <td style=“text-align:left;”> positive regulation of multicellular organismal process </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 1103 </td> <td style=“text-align:left;”> 8.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016126 </td> <td style=“text-align:left;”> sterol biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 8.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045453 </td> <td style=“text-align:left;”> bone resorption </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 8.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048731 </td> <td style=“text-align:left;”> system development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 2886 </td> <td style=“text-align:left;”> 8.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0014009 </td> <td style=“text-align:left;”> glial cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 8.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002534 </td> <td style=“text-align:left;”> cytokine production involved in inflammatory response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 8.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019221 </td> <td style=“text-align:left;”> cytokine-mediated signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 280 </td> <td style=“text-align:left;”> 8.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1900015 </td> <td style=“text-align:left;”> regulation of cytokine production involved in inflammatory response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 8.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043030 </td> <td style=“text-align:left;”> regulation of macrophage activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 8.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042116 </td> <td style=“text-align:left;”> macrophage activation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 8.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:2000106 </td> <td style=“text-align:left;”> regulation of leukocyte apoptotic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 57 </td> <td style=“text-align:left;”> 8.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016125 </td> <td style=“text-align:left;”> sterol metabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 108 </td> <td style=“text-align:left;”> 8.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001890 </td> <td style=“text-align:left;”> placenta development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 116 </td> <td style=“text-align:left;”> 8.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030856 </td> <td style=“text-align:left;”> regulation of epithelial cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 100 </td> <td style=“text-align:left;”> 8.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070663 </td> <td style=“text-align:left;”> regulation of leukocyte proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 140 </td> <td style=“text-align:left;”> 8.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001503 </td> <td style=“text-align:left;”> ossification </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 317 </td> <td style=“text-align:left;”> 8.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046394 </td> <td style=“text-align:left;”> carboxylic acid biosynthetic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 223 </td> <td style=“text-align:left;”> 8.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007156 </td> <td style=“text-align:left;”> homophilic cell adhesion via plasma membrane adhesion molecules </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 102 </td> <td style=“text-align:left;”> 8.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050801 </td> <td style=“text-align:left;”> monoatomic ion homeostasis </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 416 </td> <td style=“text-align:left;”> 8.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072078 </td> <td style=“text-align:left;”> nephron tubule morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 8.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045047 </td> <td style=“text-align:left;”> protein targeting to ER </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 9.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016053 </td> <td style=“text-align:left;”> organic acid biosynthetic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 224 </td> <td style=“text-align:left;”> 9.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009150 </td> <td style=“text-align:left;”> purine ribonucleotide metabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 291 </td> <td style=“text-align:left;”> 9.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033108 </td> <td style=“text-align:left;”> mitochondrial respiratory chain complex assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 96 </td> <td style=“text-align:left;”> 9.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002573 </td> <td style=“text-align:left;”> myeloid leukocyte differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 154 </td> <td style=“text-align:left;”> 9.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002027 </td> <td style=“text-align:left;”> regulation of heart rate </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 85 </td> <td style=“text-align:left;”> 9.01e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044283 </td> <td style=“text-align:left;”> small molecule biosynthetic process </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 432 </td> <td style=“text-align:left;”> 9.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098660 </td> <td style=“text-align:left;”> inorganic ion transmembrane transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 582 </td> <td style=“text-align:left;”> 9.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042776 </td> <td style=“text-align:left;”> proton motive force-driven mitochondrial ATP synthesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 57 </td> <td style=“text-align:left;”> 9.02e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072599 </td> <td style=“text-align:left;”> establishment of protein localization to endoplasmic reticulum </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 54 </td> <td style=“text-align:left;”> 9.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009165 </td> <td style=“text-align:left;”> nucleotide biosynthetic process </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 241 </td> <td style=“text-align:left;”> 9.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002292 </td> <td style=“text-align:left;”> T cell differentiation involved in immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 9.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0140013 </td> <td style=“text-align:left;”> meiotic nuclear division </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 117 </td> <td style=“text-align:left;”> 9.03e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072088 </td> <td style=“text-align:left;”> nephron epithelium morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 60 </td> <td style=“text-align:left;”> 9.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901654 </td> <td style=“text-align:left;”> response to ketone </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 144 </td> <td style=“text-align:left;”> 9.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901293 </td> <td style=“text-align:left;”> nucleoside phosphate biosynthetic process </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 242 </td> <td style=“text-align:left;”> 9.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016358 </td> <td style=“text-align:left;”> dendrite development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 194 </td> <td style=“text-align:left;”> 9.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043279 </td> <td style=“text-align:left;”> response to alkaloid </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 68 </td> <td style=“text-align:left;”> 9.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031638 </td> <td style=“text-align:left;”> zymogen activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 9.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022603 </td> <td style=“text-align:left;”> regulation of anatomical structure morphogenesis </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 680 </td> <td style=“text-align:left;”> 9.08e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009308 </td> <td style=“text-align:left;”> amine metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 68 </td> <td style=“text-align:left;”> 9.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061333 </td> <td style=“text-align:left;”> renal tubule morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 62 </td> <td style=“text-align:left;”> 9.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072028 </td> <td style=“text-align:left;”> nephron morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 62 </td> <td style=“text-align:left;”> 9.09e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002637 </td> <td style=“text-align:left;”> regulation of immunoglobulin production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 9.10e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010633 </td> <td style=“text-align:left;”> negative regulation of epithelial cell migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 9.10e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006721 </td> <td style=“text-align:left;”> terpenoid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 9.10e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006766 </td> <td style=“text-align:left;”> vitamin metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 75 </td> <td style=“text-align:left;”> 9.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007584 </td> <td style=“text-align:left;”> response to nutrient </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 107 </td> <td style=“text-align:left;”> 9.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051785 </td> <td style=“text-align:left;”> positive regulation of nuclear division </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 9.12e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048469 </td> <td style=“text-align:left;”> cell maturation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 110 </td> <td style=“text-align:left;”> 9.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010257 </td> <td style=“text-align:left;”> NADH dehydrogenase complex assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 9.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032981 </td> <td style=“text-align:left;”> mitochondrial respiratory chain complex I assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 9.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048871 </td> <td style=“text-align:left;”> multicellular organismal-level homeostasis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 570 </td> <td style=“text-align:left;”> 9.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0098656 </td> <td style=“text-align:left;”> monoatomic anion transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 80 </td> <td style=“text-align:left;”> 9.13e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042471 </td> <td style=“text-align:left;”> ear morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 73 </td> <td style=“text-align:left;”> 9.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902105 </td> <td style=“text-align:left;”> regulation of leukocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 197 </td> <td style=“text-align:left;”> 9.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042110 </td> <td style=“text-align:left;”> T cell activation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 317 </td> <td style=“text-align:left;”> 9.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007267 </td> <td style=“text-align:left;”> cell-cell signaling </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 1150 </td> <td style=“text-align:left;”> 9.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030833 </td> <td style=“text-align:left;”> regulation of actin filament polymerization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 107 </td> <td style=“text-align:left;”> 9.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006220 </td> <td style=“text-align:left;”> pyrimidine nucleotide metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 47 </td> <td style=“text-align:left;”> 9.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009060 </td> <td style=“text-align:left;”> aerobic respiration </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 169 </td> <td style=“text-align:left;”> 9.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031323 </td> <td style=“text-align:left;”> regulation of cellular metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4563 </td> <td style=“text-align:left;”> 9.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048813 </td> <td style=“text-align:left;”> dendrite morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 117 </td> <td style=“text-align:left;”> 9.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001764 </td> <td style=“text-align:left;”> neuron migration </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 133 </td> <td style=“text-align:left;”> 9.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030433 </td> <td style=“text-align:left;”> ubiquitin-dependent ERAD pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 80 </td> <td style=“text-align:left;”> 9.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042440 </td> <td style=“text-align:left;”> pigment metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 60 </td> <td style=“text-align:left;”> 9.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009259 </td> <td style=“text-align:left;”> ribonucleotide metabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 308 </td> <td style=“text-align:left;”> 9.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003158 </td> <td style=“text-align:left;”> endothelium development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 105 </td> <td style=“text-align:left;”> 9.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008585 </td> <td style=“text-align:left;”> female gonad development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 77 </td> <td style=“text-align:left;”> 9.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060255 </td> <td style=“text-align:left;”> regulation of macromolecule metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4593 </td> <td style=“text-align:left;”> 9.19e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051251 </td> <td style=“text-align:left;”> positive regulation of lymphocyte activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 200 </td> <td style=“text-align:left;”> 9.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030154 </td> <td style=“text-align:left;”> cell differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 2942 </td> <td style=“text-align:left;”> 9.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042100 </td> <td style=“text-align:left;”> B cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 9.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048869 </td> <td style=“text-align:left;”> cellular developmental process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 2943 </td> <td style=“text-align:left;”> 9.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902305 </td> <td style=“text-align:left;”> regulation of sodium ion transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 9.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030168 </td> <td style=“text-align:left;”> platelet activation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 90 </td> <td style=“text-align:left;”> 9.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045921 </td> <td style=“text-align:left;”> positive regulation of exocytosis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 9.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051353 </td> <td style=“text-align:left;”> positive regulation of oxidoreductase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 9.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006767 </td> <td style=“text-align:left;”> water-soluble vitamin metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 9.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048856 </td> <td style=“text-align:left;”> anatomical structure development </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 4100 </td> <td style=“text-align:left;”> 9.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030216 </td> <td style=“text-align:left;”> keratinocyte differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 76 </td> <td style=“text-align:left;”> 9.22e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043367 </td> <td style=“text-align:left;”> CD4-positive, alpha-beta T cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 54 </td> <td style=“text-align:left;”> 9.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019693 </td> <td style=“text-align:left;”> ribose phosphate metabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 316 </td> <td style=“text-align:left;”> 9.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016070 </td> <td style=“text-align:left;”> RNA metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 3573 </td> <td style=“text-align:left;”> 9.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046545 </td> <td style=“text-align:left;”> development of primary female sexual characteristics </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 79 </td> <td style=“text-align:left;”> 9.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010811 </td> <td style=“text-align:left;”> positive regulation of cell-substrate adhesion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 99 </td> <td style=“text-align:left;”> 9.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048857 </td> <td style=“text-align:left;”> neural nucleus development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 52 </td> <td style=“text-align:left;”> 9.27e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009620 </td> <td style=“text-align:left;”> response to fungus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 9.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042775 </td> <td style=“text-align:left;”> mitochondrial ATP synthesis coupled electron transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 82 </td> <td style=“text-align:left;”> 9.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042773 </td> <td style=“text-align:left;”> ATP synthesis coupled electron transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 82 </td> <td style=“text-align:left;”> 9.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051606 </td> <td style=“text-align:left;”> detection of stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 109 </td> <td style=“text-align:left;”> 9.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030534 </td> <td style=“text-align:left;”> adult behavior </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 94 </td> <td style=“text-align:left;”> 9.28e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045333 </td> <td style=“text-align:left;”> cellular respiration </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 212 </td> <td style=“text-align:left;”> 9.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903046 </td> <td style=“text-align:left;”> meiotic cell cycle process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 132 </td> <td style=“text-align:left;”> 9.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046660 </td> <td style=“text-align:left;”> female sex differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 91 </td> <td style=“text-align:left;”> 9.30e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071695 </td> <td style=“text-align:left;”> anatomical structure maturation </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 157 </td> <td style=“text-align:left;”> 9.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015986 </td> <td style=“text-align:left;”> proton motive force-driven ATP synthesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 66 </td> <td style=“text-align:left;”> 9.31e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902075 </td> <td style=“text-align:left;”> cellular response to salt </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 144 </td> <td style=“text-align:left;”> 9.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006879 </td> <td style=“text-align:left;”> intracellular iron ion homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 57 </td> <td style=“text-align:left;”> 9.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007259 </td> <td style=“text-align:left;”> receptor signaling pathway via JAK-STAT </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 89 </td> <td style=“text-align:left;”> 9.37e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0065007 </td> <td style=“text-align:left;”> biological regulation </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 8282 </td> <td style=“text-align:left;”> 9.38e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042246 </td> <td style=“text-align:left;”> tissue regeneration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 54 </td> <td style=“text-align:left;”> 9.39e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008064 </td> <td style=“text-align:left;”> regulation of actin polymerization or depolymerization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 122 </td> <td style=“text-align:left;”> 9.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019222 </td> <td style=“text-align:left;”> regulation of metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4998 </td> <td style=“text-align:left;”> 9.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042130 </td> <td style=“text-align:left;”> negative regulation of T cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 9.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030199 </td> <td style=“text-align:left;”> collagen fibril organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 57 </td> <td style=“text-align:left;”> 9.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0150076 </td> <td style=“text-align:left;”> neuroinflammatory response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 36 </td> <td style=“text-align:left;”> 9.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015698 </td> <td style=“text-align:left;”> inorganic anion transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 87 </td> <td style=“text-align:left;”> 9.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001775 </td> <td style=“text-align:left;”> cell activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 655 </td> <td style=“text-align:left;”> 9.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903037 </td> <td style=“text-align:left;”> regulation of leukocyte cell-cell adhesion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 210 </td> <td style=“text-align:left;”> 9.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007565 </td> <td style=“text-align:left;”> female pregnancy </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 123 </td> <td style=“text-align:left;”> 9.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016079 </td> <td style=“text-align:left;”> synaptic vesicle exocytosis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 9.42e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001657 </td> <td style=“text-align:left;”> ureteric bud development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 75 </td> <td style=“text-align:left;”> 9.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016441 </td> <td style=“text-align:left;”> post-transcriptional gene silencing </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 9.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030832 </td> <td style=“text-align:left;”> regulation of actin filament length </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 123 </td> <td style=“text-align:left;”> 9.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006635 </td> <td style=“text-align:left;”> fatty acid beta-oxidation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 68 </td> <td style=“text-align:left;”> 9.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006820 </td> <td style=“text-align:left;”> monoatomic anion transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 92 </td> <td style=“text-align:left;”> 9.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060993 </td> <td style=“text-align:left;”> kidney morphogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 73 </td> <td style=“text-align:left;”> 9.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070192 </td> <td style=“text-align:left;”> chromosome organization involved in meiotic cell cycle </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 9.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002696 </td> <td style=“text-align:left;”> positive regulation of leukocyte activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 222 </td> <td style=“text-align:left;”> 9.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072164 </td> <td style=“text-align:left;”> mesonephric tubule development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 76 </td> <td style=“text-align:left;”> 9.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072163 </td> <td style=“text-align:left;”> mesonephric epithelium development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 76 </td> <td style=“text-align:left;”> 9.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097009 </td> <td style=“text-align:left;”> energy homeostasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 59 </td> <td style=“text-align:left;”> 9.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002521 </td> <td style=“text-align:left;”> leukocyte differentiation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 387 </td> <td style=“text-align:left;”> 9.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002285 </td> <td style=“text-align:left;”> lymphocyte activation involved in immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 116 </td> <td style=“text-align:left;”> 9.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050863 </td> <td style=“text-align:left;”> regulation of T cell activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 215 </td> <td style=“text-align:left;”> 9.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0090304 </td> <td style=“text-align:left;”> nucleic acid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4018 </td> <td style=“text-align:left;”> 9.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097696 </td> <td style=“text-align:left;”> receptor signaling pathway via STAT </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 92 </td> <td style=“text-align:left;”> 9.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0015718 </td> <td style=“text-align:left;”> monocarboxylic acid transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 91 </td> <td style=“text-align:left;”> 9.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006163 </td> <td style=“text-align:left;”> purine nucleotide metabolic process </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 368 </td> <td style=“text-align:left;”> 9.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0150104 </td> <td style=“text-align:left;”> transport across blood-brain barrier </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 72 </td> <td style=“text-align:left;”> 9.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046434 </td> <td style=“text-align:left;”> organophosphate catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 113 </td> <td style=“text-align:left;”> 9.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010232 </td> <td style=“text-align:left;”> vascular transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 72 </td> <td style=“text-align:left;”> 9.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016579 </td> <td style=“text-align:left;”> protein deubiquitination </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 127 </td> <td style=“text-align:left;”> 9.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019935 </td> <td style=“text-align:left;”> cyclic-nucleotide-mediated signaling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 52 </td> <td style=“text-align:left;”> 9.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070918 </td> <td style=“text-align:left;”> regulatory ncRNA processing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 9.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032501 </td> <td style=“text-align:left;”> multicellular organismal process </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 4807 </td> <td style=“text-align:left;”> 9.45e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046849 </td> <td style=“text-align:left;”> bone remodeling </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 60 </td> <td style=“text-align:left;”> 9.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032760 </td> <td style=“text-align:left;”> positive regulation of tumor necrosis factor production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 55 </td> <td style=“text-align:left;”> 9.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006022 </td> <td style=“text-align:left;”> aminoglycan metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 92 </td> <td style=“text-align:left;”> 9.47e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0021700 </td> <td style=“text-align:left;”> developmental maturation </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 213 </td> <td style=“text-align:left;”> 9.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031016 </td> <td style=“text-align:left;”> pancreas development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 52 </td> <td style=“text-align:left;”> 9.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001823 </td> <td style=“text-align:left;”> mesonephros development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 77 </td> <td style=“text-align:left;”> 9.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010565 </td> <td style=“text-align:left;”> regulation of cellular ketone metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 101 </td> <td style=“text-align:left;”> 9.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050867 </td> <td style=“text-align:left;”> positive regulation of cell activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 227 </td> <td style=“text-align:left;”> 9.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006814 </td> <td style=“text-align:left;”> sodium ion transport </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 158 </td> <td style=“text-align:left;”> 9.50e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001894 </td> <td style=“text-align:left;”> tissue homeostasis </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 179 </td> <td style=“text-align:left;”> 9.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060249 </td> <td style=“text-align:left;”> anatomical structure homeostasis </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 179 </td> <td style=“text-align:left;”> 9.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030041 </td> <td style=“text-align:left;”> actin filament polymerization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 132 </td> <td style=“text-align:left;”> 9.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008203 </td> <td style=“text-align:left;”> cholesterol metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 99 </td> <td style=“text-align:left;”> 9.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903557 </td> <td style=“text-align:left;”> positive regulation of tumor necrosis factor superfamily cytokine production </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 57 </td> <td style=“text-align:left;”> 9.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032502 </td> <td style=“text-align:left;”> developmental process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 4445 </td> <td style=“text-align:left;”> 9.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034329 </td> <td style=“text-align:left;”> cell junction assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 347 </td> <td style=“text-align:left;”> 9.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007159 </td> <td style=“text-align:left;”> leukocyte cell-cell adhesion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 233 </td> <td style=“text-align:left;”> 9.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010975 </td> <td style=“text-align:left;”> regulation of neuron projection development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 374 </td> <td style=“text-align:left;”> 9.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008202 </td> <td style=“text-align:left;”> steroid metabolic process </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 203 </td> <td style=“text-align:left;”> 9.55e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072659 </td> <td style=“text-align:left;”> protein localization to plasma membrane </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 252 </td> <td style=“text-align:left;”> 9.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031099 </td> <td style=“text-align:left;”> regeneration </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 142 </td> <td style=“text-align:left;”> 9.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022904 </td> <td style=“text-align:left;”> respiratory electron transport chain </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 104 </td> <td style=“text-align:left;”> 9.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006637 </td> <td style=“text-align:left;”> acyl-CoA metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 9.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035383 </td> <td style=“text-align:left;”> thioester metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 9.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050808 </td> <td style=“text-align:left;”> synapse organization </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 373 </td> <td style=“text-align:left;”> 9.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035710 </td> <td style=“text-align:left;”> CD4-positive, alpha-beta T cell activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 68 </td> <td style=“text-align:left;”> 9.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031047 </td> <td style=“text-align:left;”> regulatory ncRNA-mediated gene silencing </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 119 </td> <td style=“text-align:left;”> 9.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048565 </td> <td style=“text-align:left;”> digestive tract development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 92 </td> <td style=“text-align:left;”> 9.62e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050868 </td> <td style=“text-align:left;”> negative regulation of T cell activation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 67 </td> <td style=“text-align:left;”> 9.62e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002181 </td> <td style=“text-align:left;”> cytoplasmic translation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 150 </td> <td style=“text-align:left;”> 9.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006720 </td> <td style=“text-align:left;”> isoprenoid metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 83 </td> <td style=“text-align:left;”> 9.63e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002286 </td> <td style=“text-align:left;”> T cell activation involved in immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 59 </td> <td style=“text-align:left;”> 9.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0070646 </td> <td style=“text-align:left;”> protein modification by small protein removal </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 145 </td> <td style=“text-align:left;”> 9.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902652 </td> <td style=“text-align:left;”> secondary alcohol metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 106 </td> <td style=“text-align:left;”> 9.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0033273 </td> <td style=“text-align:left;”> response to vitamin </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 63 </td> <td style=“text-align:left;”> 9.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050672 </td> <td style=“text-align:left;”> negative regulation of lymphocyte proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 9.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046632 </td> <td style=“text-align:left;”> alpha-beta T cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 71 </td> <td style=“text-align:left;”> 9.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006626 </td> <td style=“text-align:left;”> protein targeting to mitochondrion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 100 </td> <td style=“text-align:left;”> 9.66e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032945 </td> <td style=“text-align:left;”> negative regulation of mononuclear cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 9.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006614 </td> <td style=“text-align:left;”> SRP-dependent cotranslational protein targeting to membrane </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 9.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045321 </td> <td style=“text-align:left;”> leukocyte activation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 556 </td> <td style=“text-align:left;”> 9.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044703 </td> <td style=“text-align:left;”> multi-organism reproductive process </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 132 </td> <td style=“text-align:left;”> 9.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035725 </td> <td style=“text-align:left;”> sodium ion transmembrane transport </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 112 </td> <td style=“text-align:left;”> 9.67e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048608 </td> <td style=“text-align:left;”> reproductive structure development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 214 </td> <td style=“text-align:left;”> 9.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008543 </td> <td style=“text-align:left;”> fibroblast growth factor receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 59 </td> <td style=“text-align:left;”> 9.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006091 </td> <td style=“text-align:left;”> generation of precursor metabolites and energy </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 423 </td> <td style=“text-align:left;”> 9.69e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006613 </td> <td style=“text-align:left;”> cotranslational protein targeting to membrane </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 9.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030901 </td> <td style=“text-align:left;”> midbrain development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 9.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0061458 </td> <td style=“text-align:left;”> reproductive system development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 217 </td> <td style=“text-align:left;”> 9.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006754 </td> <td style=“text-align:left;”> ATP biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 85 </td> <td style=“text-align:left;”> 9.70e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019882 </td> <td style=“text-align:left;”> antigen processing and presentation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 73 </td> <td style=“text-align:left;”> 9.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008154 </td> <td style=“text-align:left;”> actin polymerization or depolymerization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 157 </td> <td style=“text-align:left;”> 9.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032147 </td> <td style=“text-align:left;”> activation of protein kinase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 82 </td> <td style=“text-align:left;”> 9.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042742 </td> <td style=“text-align:left;”> defense response to bacterium </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 94 </td> <td style=“text-align:left;”> 9.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001508 </td> <td style=“text-align:left;”> action potential </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 106 </td> <td style=“text-align:left;”> 9.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901136 </td> <td style=“text-align:left;”> carbohydrate derivative catabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 137 </td> <td style=“text-align:left;”> 9.72e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006029 </td> <td style=“text-align:left;”> proteoglycan metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 77 </td> <td style=“text-align:left;”> 9.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071805 </td> <td style=“text-align:left;”> potassium ion transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 129 </td> <td style=“text-align:left;”> 9.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903038 </td> <td style=“text-align:left;”> negative regulation of leukocyte cell-cell adhesion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 9.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0055123 </td> <td style=“text-align:left;”> digestive system development </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 100 </td> <td style=“text-align:left;”> 9.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008584 </td> <td style=“text-align:left;”> male gonad development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 100 </td> <td style=“text-align:left;”> 9.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046546 </td> <td style=“text-align:left;”> development of primary male sexual characteristics </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 101 </td> <td style=“text-align:left;”> 9.74e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007601 </td> <td style=“text-align:left;”> visual perception </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 97 </td> <td style=“text-align:left;”> 9.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042542 </td> <td style=“text-align:left;”> response to hydrogen peroxide </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 85 </td> <td style=“text-align:left;”> 9.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050953 </td> <td style=“text-align:left;”> sensory perception of light stimulus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 98 </td> <td style=“text-align:left;”> 9.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032963 </td> <td style=“text-align:left;”> collagen metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 72 </td> <td style=“text-align:left;”> 9.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042445 </td> <td style=“text-align:left;”> hormone metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 132 </td> <td style=“text-align:left;”> 9.78e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045132 </td> <td style=“text-align:left;”> meiotic chromosome segregation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 9.78e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051249 </td> <td style=“text-align:left;”> regulation of lymphocyte activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 296 </td> <td style=“text-align:left;”> 9.79e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006334 </td> <td style=“text-align:left;”> nucleosome assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 66 </td> <td style=“text-align:left;”> 9.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032465 </td> <td style=“text-align:left;”> regulation of cytokinesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 77 </td> <td style=“text-align:left;”> 9.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046649 </td> <td style=“text-align:left;”> lymphocyte activation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 469 </td> <td style=“text-align:left;”> 9.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009206 </td> <td style=“text-align:left;”> purine ribonucleoside triphosphate biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 94 </td> <td style=“text-align:left;”> 9.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007600 </td> <td style=“text-align:left;”> sensory perception </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 259 </td> <td style=“text-align:left;”> 9.80e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009145 </td> <td style=“text-align:left;”> purine nucleoside triphosphate biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 95 </td> <td style=“text-align:left;”> 9.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009117 </td> <td style=“text-align:left;”> nucleotide metabolic process </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 421 </td> <td style=“text-align:left;”> 9.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009062 </td> <td style=“text-align:left;”> fatty acid catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 89 </td> <td style=“text-align:left;”> 9.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002694 </td> <td style=“text-align:left;”> regulation of leukocyte activation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 346 </td> <td style=“text-align:left;”> 9.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042180 </td> <td style=“text-align:left;”> cellular ketone metabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 161 </td> <td style=“text-align:left;”> 9.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000395 </td> <td style=“text-align:left;”> mRNA 5’-splice site recognition </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 9.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010467 </td> <td style=“text-align:left;”> gene expression </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 4733 </td> <td style=“text-align:left;”> 9.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0019395 </td> <td style=“text-align:left;”> fatty acid oxidation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 91 </td> <td style=“text-align:left;”> 9.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0048024 </td> <td style=“text-align:left;”> regulation of mRNA splicing, via spliceosome </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 92 </td> <td style=“text-align:left;”> 9.83e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051341 </td> <td style=“text-align:left;”> regulation of oxidoreductase activity </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 67 </td> <td style=“text-align:left;”> 9.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042592 </td> <td style=“text-align:left;”> homeostatic process </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:right;”> 1189 </td> <td style=“text-align:left;”> 9.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097529 </td> <td style=“text-align:left;”> myeloid leukocyte migration </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 118 </td> <td style=“text-align:left;”> 9.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045807 </td> <td style=“text-align:left;”> positive regulation of endocytosis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 104 </td> <td style=“text-align:left;”> 9.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006753 </td> <td style=“text-align:left;”> nucleoside phosphate metabolic process </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 427 </td> <td style=“text-align:left;”> 9.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007269 </td> <td style=“text-align:left;”> neurotransmitter secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 105 </td> <td style=“text-align:left;”> 9.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009201 </td> <td style=“text-align:left;”> ribonucleoside triphosphate biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 100 </td> <td style=“text-align:left;”> 9.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006807 </td> <td style=“text-align:left;”> nitrogen compound metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 7431 </td> <td style=“text-align:left;”> 9.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0099643 </td> <td style=“text-align:left;”> signal release from synapse </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 105 </td> <td style=“text-align:left;”> 9.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034440 </td> <td style=“text-align:left;”> lipid oxidation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 92 </td> <td style=“text-align:left;”> 9.87e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008380 </td> <td style=“text-align:left;”> RNA splicing </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 426 </td> <td style=“text-align:left;”> 9.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009142 </td> <td style=“text-align:left;”> nucleoside triphosphate biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 109 </td> <td style=“text-align:left;”> 9.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009059 </td> <td style=“text-align:left;”> macromolecule biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5148 </td> <td style=“text-align:left;”> 9.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0010810 </td> <td style=“text-align:left;”> regulation of cell-substrate adhesion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 171 </td> <td style=“text-align:left;”> 9.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051250 </td> <td style=“text-align:left;”> negative regulation of lymphocyte activation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 89 </td> <td style=“text-align:left;”> 9.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043170 </td> <td style=“text-align:left;”> macromolecule metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 7084 </td> <td style=“text-align:left;”> 9.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006376 </td> <td style=“text-align:left;”> mRNA splice site recognition </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 9.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022900 </td> <td style=“text-align:left;”> electron transport chain </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 142 </td> <td style=“text-align:left;”> 9.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035195 </td> <td style=“text-align:left;”> miRNA-mediated post-transcriptional gene silencing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 57 </td> <td style=“text-align:left;”> 9.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006397 </td> <td style=“text-align:left;”> mRNA processing </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 451 </td> <td style=“text-align:left;”> 9.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022613 </td> <td style=“text-align:left;”> ribonucleoprotein complex biogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 464 </td> <td style=“text-align:left;”> 9.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007189 </td> <td style=“text-align:left;”> adenylate cyclase-activating G protein-coupled receptor signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 71 </td> <td style=“text-align:left;”> 9.92e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0035194 </td> <td style=“text-align:left;”> regulatory ncRNA-mediated post-transcriptional gene silencing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 62 </td> <td style=“text-align:left;”> 9.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046034 </td> <td style=“text-align:left;”> ATP metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 115 </td> <td style=“text-align:left;”> 9.93e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046631 </td> <td style=“text-align:left;”> alpha-beta T cell activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 93 </td> <td style=“text-align:left;”> 9.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0072329 </td> <td style=“text-align:left;”> monocarboxylic acid catabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 105 </td> <td style=“text-align:left;”> 9.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1902074 </td> <td style=“text-align:left;”> response to salt </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 261 </td> <td style=“text-align:left;”> 9.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000245 </td> <td style=“text-align:left;”> spliceosomal complex assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 9.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006617 </td> <td style=“text-align:left;”> SRP-dependent cotranslational protein targeting to membrane, signal sequence recognition </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 17 </td> <td style=“text-align:left;”> 9.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044238 </td> <td style=“text-align:left;”> primary metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 7788 </td> <td style=“text-align:left;”> 9.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1905039 </td> <td style=“text-align:left;”> carboxylic acid transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 111 </td> <td style=“text-align:left;”> 9.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1903825 </td> <td style=“text-align:left;”> organic acid transmembrane transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 112 </td> <td style=“text-align:left;”> 9.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0034330 </td> <td style=“text-align:left;”> cell junction organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 586 </td> <td style=“text-align:left;”> 9.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0051302 </td> <td style=“text-align:left;”> regulation of cell division </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 140 </td> <td style=“text-align:left;”> 9.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044249 </td> <td style=“text-align:left;”> cellular biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5813 </td> <td style=“text-align:left;”> 9.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016071 </td> <td style=“text-align:left;”> mRNA metabolic process </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 671 </td> <td style=“text-align:left;”> 9.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050877 </td> <td style=“text-align:left;”> nervous system process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 628 </td> <td style=“text-align:left;”> 9.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:1901576 </td> <td style=“text-align:left;”> organic substance biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5875 </td> <td style=“text-align:left;”> 9.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022408 </td> <td style=“text-align:left;”> negative regulation of cell-cell adhesion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 115 </td> <td style=“text-align:left;”> 9.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009058 </td> <td style=“text-align:left;”> biosynthetic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 5912 </td> <td style=“text-align:left;”> 9.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007608 </td> <td style=“text-align:left;”> sensory perception of smell </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 9.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0002695 </td> <td style=“text-align:left;”> negative regulation of leukocyte activation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 103 </td> <td style=“text-align:left;”> 9.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008406 </td> <td style=“text-align:left;”> gonad development </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 160 </td> <td style=“text-align:left;”> 9.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045137 </td> <td style=“text-align:left;”> development of primary sexual characteristics </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 163 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044237 </td> <td style=“text-align:left;”> cellular metabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 7562 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045291 </td> <td style=“text-align:left;”> mRNA trans splicing, SL addition </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000244 </td> <td style=“text-align:left;”> spliceosomal tri-snRNP complex assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0044282 </td> <td style=“text-align:left;”> small molecule catabolic process </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 270 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0045229 </td> <td style=“text-align:left;”> external encapsulating structure organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 234 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007162 </td> <td style=“text-align:left;”> negative regulation of cell adhesion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 191 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000353 </td> <td style=“text-align:left;”> formation of quadruple SL/U4/U5/U6 snRNP </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0003341 </td> <td style=“text-align:left;”> cilium movement </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 97 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000375 </td> <td style=“text-align:left;”> RNA splicing, via transesterification reactions </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 292 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0022618 </td> <td style=“text-align:left;”> protein-RNA complex assembly </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 203 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0016054 </td> <td style=“text-align:left;”> organic acid catabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 187 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030198 </td> <td style=“text-align:left;”> extracellular matrix organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 233 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0030317 </td> <td style=“text-align:left;”> flagellated sperm motility </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 62 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071704 </td> <td style=“text-align:left;”> organic substance metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8176 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060294 </td> <td style=“text-align:left;”> cilium movement involved in cell motility </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0060285 </td> <td style=“text-align:left;”> cilium-dependent cell motility </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 72 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0071826 </td> <td style=“text-align:left;”> protein-RNA complex organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 211 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0031589 </td> <td style=“text-align:left;”> cell-substrate adhesion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 271 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006396 </td> <td style=“text-align:left;”> RNA processing </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 928 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0032944 </td> <td style=“text-align:left;”> regulation of mononuclear cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 128 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050866 </td> <td style=“text-align:left;”> negative regulation of cell activation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 121 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0097722 </td> <td style=“text-align:left;”> sperm motility </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 62 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0050670 </td> <td style=“text-align:left;”> regulation of lymphocyte proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 125 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0042129 </td> <td style=“text-align:left;”> regulation of T cell proliferation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 94 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0001539 </td> <td style=“text-align:left;”> cilium or flagellum-dependent cell motility </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 72 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0043062 </td> <td style=“text-align:left;”> extracellular structure organization </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 234 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0046395 </td> <td style=“text-align:left;”> carboxylic acid catabolic process </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 187 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008152 </td> <td style=“text-align:left;”> metabolic process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8522 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0008150 </td> <td style=“text-align:left;”> biological_process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12027 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0007606 </td> <td style=“text-align:left;”> sensory perception of chemical stimulus </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 29 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0006959 </td> <td style=“text-align:left;”> humoral immune response </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 79 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000398 </td> <td style=“text-align:left;”> mRNA splicing, via spliceosome </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 288 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000387 </td> <td style=“text-align:left;”> spliceosomal snRNP assembly </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 45 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000377 </td> <td style=“text-align:left;”> RNA splicing, via transesterification reactions with bulged adenosine as nucleophile </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 288 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0000365 </td> <td style=“text-align:left;”> mRNA trans splicing, via spliceosome </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> GO:BP </td> <td style=“text-align:left;”> GO:0009987 </td> <td style=“text-align:left;”> cellular process </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 11410 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05168 </td> <td style=“text-align:left;”> Herpes simplex virus 1 infection </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:right;”> 415 </td> <td style=“text-align:left;”> 1.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05031 </td> <td style=“text-align:left;”> Amphetamine addiction </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 1.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:03250 </td> <td style=“text-align:left;”> Viral life cycle - HIV-1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 1.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04218 </td> <td style=“text-align:left;”> Cellular senescence </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 145 </td> <td style=“text-align:left;”> 1.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:03015 </td> <td style=“text-align:left;”> mRNA surveillance pathway </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 86 </td> <td style=“text-align:left;”> 1.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04213 </td> <td style=“text-align:left;”> Longevity regulating pathway - multiple species </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 55 </td> <td style=“text-align:left;”> 1.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04144 </td> <td style=“text-align:left;”> Endocytosis </td> <td style=“text-align:right;”> 11 </td> <td style=“text-align:right;”> 232 </td> <td style=“text-align:left;”> 1.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00900 </td> <td style=“text-align:left;”> Terpenoid backbone biosynthesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 1.90e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05034 </td> <td style=“text-align:left;”> Alcoholism </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 112 </td> <td style=“text-align:left;”> 2.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00565 </td> <td style=“text-align:left;”> Ether lipid metabolism </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 2.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04720 </td> <td style=“text-align:left;”> Long-term potentiation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 55 </td> <td style=“text-align:left;”> 2.33e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04666 </td> <td style=“text-align:left;”> Fc gamma R-mediated phagocytosis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 75 </td> <td style=“text-align:left;”> 3.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04146 </td> <td style=“text-align:left;”> Peroxisome </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 68 </td> <td style=“text-align:left;”> 3.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00564 </td> <td style=“text-align:left;”> Glycerophospholipid metabolism </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 76 </td> <td style=“text-align:left;”> 3.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05212 </td> <td style=“text-align:left;”> Pancreatic cancer </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 75 </td> <td style=“text-align:left;”> 3.04e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:03060 </td> <td style=“text-align:left;”> Protein export </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 3.11e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04211 </td> <td style=“text-align:left;”> Longevity regulating pathway </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 78 </td> <td style=“text-align:left;”> 3.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04924 </td> <td style=“text-align:left;”> Renin secretion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 3.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05210 </td> <td style=“text-align:left;”> Colorectal cancer </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 84 </td> <td style=“text-align:left;”> 3.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05220 </td> <td style=“text-align:left;”> Chronic myeloid leukemia </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 75 </td> <td style=“text-align:left;”> 3.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:03013 </td> <td style=“text-align:left;”> Nucleocytoplasmic transport </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 99 </td> <td style=“text-align:left;”> 3.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05166 </td> <td style=“text-align:left;”> Human T-cell leukemia virus 1 infection </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 180 </td> <td style=“text-align:left;”> 3.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05030 </td> <td style=“text-align:left;”> Cocaine addiction </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 3.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04137 </td> <td style=“text-align:left;”> Mitophagy - animal </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 3.46e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04370 </td> <td style=“text-align:left;”> VEGF signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 3.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04710 </td> <td style=“text-align:left;”> Circadian rhythm </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 4.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05170 </td> <td style=“text-align:left;”> Human immunodeficiency virus 1 infection </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 165 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05215 </td> <td style=“text-align:left;”> Prostate cancer </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 86 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05214 </td> <td style=“text-align:left;”> Glioma </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 67 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04726 </td> <td style=“text-align:left;”> Serotonergic synapse </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 63 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05216 </td> <td style=“text-align:left;”> Thyroid cancer </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00562 </td> <td style=“text-align:left;”> Inositol phosphate metabolism </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 66 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00563 </td> <td style=“text-align:left;”> Glycosylphosphatidylinositol (GPI)-anchor biosynthesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05235 </td> <td style=“text-align:left;”> PD-L1 expression and PD-1 checkpoint pathway in cancer </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05231 </td> <td style=“text-align:left;”> Choline metabolism in cancer </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 84 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05225 </td> <td style=“text-align:left;”> Hepatocellular carcinoma </td> <td style=“text-align:right;”> 9 </td> <td style=“text-align:right;”> 145 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00310 </td> <td style=“text-align:left;”> Lysine degradation </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 59 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:03020 </td> <td style=“text-align:left;”> RNA polymerase </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 34 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05223 </td> <td style=“text-align:left;”> Non-small cell lung cancer </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 67 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05219 </td> <td style=“text-align:left;”> Bladder cancer </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00600 </td> <td style=“text-align:left;”> Sphingolipid metabolism </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00970 </td> <td style=“text-align:left;”> Aminoacyl-tRNA biosynthesis </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:01522 </td> <td style=“text-align:left;”> Endocrine resistance </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 85 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05218 </td> <td style=“text-align:left;”> Melanoma </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:03008 </td> <td style=“text-align:left;”> Ribosome biogenesis in eukaryotes </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 75 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05221 </td> <td style=“text-align:left;”> Acute myeloid leukemia </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:03420 </td> <td style=“text-align:left;”> Nucleotide excision repair </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 43 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05132 </td> <td style=“text-align:left;”> Salmonella infection </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 214 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05167 </td> <td style=“text-align:left;”> Kaposi sarcoma-associated herpesvirus infection </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 145 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04975 </td> <td style=“text-align:left;”> Fat digestion and absorption </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04210 </td> <td style=“text-align:left;”> Apoptosis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 118 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04215 </td> <td style=“text-align:left;”> Apoptosis - multiple species </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 30 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04933 </td> <td style=“text-align:left;”> AGE-RAGE signaling pathway in diabetic complications </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 91 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04330 </td> <td style=“text-align:left;”> Notch signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04921 </td> <td style=“text-align:left;”> Oxytocin signaling pathway </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 115 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04919 </td> <td style=“text-align:left;”> Thyroid hormone signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 112 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04625 </td> <td style=“text-align:left;”> C-type lectin receptor signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 76 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04650 </td> <td style=“text-align:left;”> Natural killer cell mediated cytotoxicity </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 63 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04660 </td> <td style=“text-align:left;”> T cell receptor signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 70 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04662 </td> <td style=“text-align:left;”> B cell receptor signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04664 </td> <td style=“text-align:left;”> Fc epsilon RI signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04910 </td> <td style=“text-align:left;”> Insulin signaling pathway </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 121 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04721 </td> <td style=“text-align:left;”> Synaptic vesicle cycle </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04728 </td> <td style=“text-align:left;”> Dopaminergic synapse </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 103 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04150 </td> <td style=“text-align:left;”> mTOR signaling pathway </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 135 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05169 </td> <td style=“text-align:left;”> Epstein-Barr virus infection </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 153 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05016 </td> <td style=“text-align:left;”> Huntington disease </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 256 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04140 </td> <td style=“text-align:left;”> Autophagy - animal </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 133 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05164 </td> <td style=“text-align:left;”> Influenza A </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 103 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05163 </td> <td style=“text-align:left;”> Human cytomegalovirus infection </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 176 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05161 </td> <td style=“text-align:left;”> Hepatitis B </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 136 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:03430 </td> <td style=“text-align:left;”> Mismatch repair </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:03450 </td> <td style=“text-align:left;”> Non-homologous end-joining </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04722 </td> <td style=“text-align:left;”> Neurotrophin signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 110 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04022 </td> <td style=“text-align:left;”> cGMP-PKG signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 133 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04068 </td> <td style=“text-align:left;”> FoxO signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 109 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04070 </td> <td style=“text-align:left;”> Phosphatidylinositol signaling system </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 91 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04071 </td> <td style=“text-align:left;”> Sphingolipid signaling pathway </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 107 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04110 </td> <td style=“text-align:left;”> Cell cycle </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 151 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04115 </td> <td style=“text-align:left;”> p53 signaling pathway </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 65 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04122 </td> <td style=“text-align:left;”> Sulfur relay system </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04130 </td> <td style=“text-align:left;”> SNARE interactions in vesicular transport </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04136 </td> <td style=“text-align:left;”> Autophagy - other </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 31 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04145 </td> <td style=“text-align:left;”> Phagosome </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 99 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00561 </td> <td style=“text-align:left;”> Glycerolipid metabolism </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05418 </td> <td style=“text-align:left;”> Fluid shear stress and atherosclerosis </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 114 </td> <td style=“text-align:left;”> 4.41e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04550 </td> <td style=“text-align:left;”> Signaling pathways regulating pluripotency of stem cells </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 104 </td> <td style=“text-align:left;”> 4.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04610 </td> <td style=“text-align:left;”> Complement and coagulation cascades </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 4.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:03040 </td> <td style=“text-align:left;”> Spliceosome </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 132 </td> <td style=“text-align:left;”> 4.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05224 </td> <td style=“text-align:left;”> Breast cancer </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 117 </td> <td style=“text-align:left;”> 4.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:01521 </td> <td style=“text-align:left;”> EGFR tyrosine kinase inhibitor resistance </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 4.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04072 </td> <td style=“text-align:left;”> Phospholipase D signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 110 </td> <td style=“text-align:left;”> 4.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04923 </td> <td style=“text-align:left;”> Regulation of lipolysis in adipocytes </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 4.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:03050 </td> <td style=“text-align:left;”> Proteasome </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 4.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05160 </td> <td style=“text-align:left;”> Hepatitis C </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 115 </td> <td style=“text-align:left;”> 4.65e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:03410 </td> <td style=“text-align:left;”> Base excision repair </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 4.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05412 </td> <td style=“text-align:left;”> Arrhythmogenic right ventricular cardiomyopathy </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 63 </td> <td style=“text-align:left;”> 4.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04024 </td> <td style=“text-align:left;”> cAMP signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 151 </td> <td style=“text-align:left;”> 4.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04360 </td> <td style=“text-align:left;”> Axon guidance </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 162 </td> <td style=“text-align:left;”> 4.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04012 </td> <td style=“text-align:left;”> ErbB signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 78 </td> <td style=“text-align:left;”> 4.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04613 </td> <td style=“text-align:left;”> Neutrophil extracellular trap formation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 100 </td> <td style=“text-align:left;”> 4.81e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05202 </td> <td style=“text-align:left;”> Transcriptional misregulation in cancer </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 128 </td> <td style=“text-align:left;”> 4.85e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05203 </td> <td style=“text-align:left;”> Viral carcinogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 162 </td> <td style=“text-align:left;”> 4.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:03030 </td> <td style=“text-align:left;”> DNA replication </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 4.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04350 </td> <td style=“text-align:left;”> TGF-beta signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 84 </td> <td style=“text-align:left;”> 4.94e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04114 </td> <td style=“text-align:left;”> Oocyte meiosis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 108 </td> <td style=“text-align:left;”> 4.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05410 </td> <td style=“text-align:left;”> Hypertrophic cardiomyopathy </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 73 </td> <td style=“text-align:left;”> 5.07e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04141 </td> <td style=“text-align:left;”> Protein processing in endoplasmic reticulum </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 161 </td> <td style=“text-align:left;”> 5.10e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05414 </td> <td style=“text-align:left;”> Dilated cardiomyopathy </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 78 </td> <td style=“text-align:left;”> 5.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00770 </td> <td style=“text-align:left;”> Pantothenate and CoA biosynthesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 15 </td> <td style=“text-align:left;”> 5.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04010 </td> <td style=“text-align:left;”> MAPK signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 240 </td> <td style=“text-align:left;”> 5.14e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04961 </td> <td style=“text-align:left;”> Endocrine and other factor-regulated calcium reabsorption </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 41 </td> <td style=“text-align:left;”> 5.15e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:03440 </td> <td style=“text-align:left;”> Homologous recombination </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 5.15e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04120 </td> <td style=“text-align:left;”> Ubiquitin mediated proteolysis </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 134 </td> <td style=“text-align:left;”> 5.15e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00740 </td> <td style=“text-align:left;”> Riboflavin metabolism </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:left;”> 5.24e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05032 </td> <td style=“text-align:left;”> Morphine addiction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 5.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05213 </td> <td style=“text-align:left;”> Endometrial cancer </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 57 </td> <td style=“text-align:left;”> 5.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04931 </td> <td style=“text-align:left;”> Insulin resistance </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 95 </td> <td style=“text-align:left;”> 5.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04730 </td> <td style=“text-align:left;”> Long-term depression </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 5.34e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00790 </td> <td style=“text-align:left;”> Folate biosynthesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 18 </td> <td style=“text-align:left;”> 5.40e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05222 </td> <td style=“text-align:left;”> Small cell lung cancer </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 87 </td> <td style=“text-align:left;”> 5.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04390 </td> <td style=“text-align:left;”> Hippo signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 134 </td> <td style=“text-align:left;”> 5.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04727 </td> <td style=“text-align:left;”> GABAergic synapse </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 55 </td> <td style=“text-align:left;”> 5.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04014 </td> <td style=“text-align:left;”> Ras signaling pathway </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 171 </td> <td style=“text-align:left;”> 5.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04917 </td> <td style=“text-align:left;”> Prolactin signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 5.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00983 </td> <td style=“text-align:left;”> Drug metabolism - other enzymes </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 5.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04922 </td> <td style=“text-align:left;”> Glucagon signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 84 </td> <td style=“text-align:left;”> 5.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05211 </td> <td style=“text-align:left;”> Renal cell carcinoma </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 65 </td> <td style=“text-align:left;”> 5.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05230 </td> <td style=“text-align:left;”> Central carbon metabolism in cancer </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 62 </td> <td style=“text-align:left;”> 5.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05217 </td> <td style=“text-align:left;”> Basal cell carcinoma </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 5.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05417 </td> <td style=“text-align:left;”> Lipid and atherosclerosis </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 153 </td> <td style=“text-align:left;”> 5.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04929 </td> <td style=“text-align:left;”> GnRH secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 5.53e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05206 </td> <td style=“text-align:left;”> MicroRNAs in cancer </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 149 </td> <td style=“text-align:left;”> 5.64e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04658 </td> <td style=“text-align:left;”> Th1 and Th2 cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 53 </td> <td style=“text-align:left;”> 5.68e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00480 </td> <td style=“text-align:left;”> Glutathione metabolism </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 44 </td> <td style=“text-align:left;”> 5.76e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04371 </td> <td style=“text-align:left;”> Apelin signaling pathway </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 106 </td> <td style=“text-align:left;”> 5.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:03010 </td> <td style=“text-align:left;”> Ribosome </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 127 </td> <td style=“text-align:left;”> 5.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05165 </td> <td style=“text-align:left;”> Human papillomavirus infection </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 272 </td> <td style=“text-align:left;”> 5.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04152 </td> <td style=“text-align:left;”> AMPK signaling pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 103 </td> <td style=“text-align:left;”> 5.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05226 </td> <td style=“text-align:left;”> Gastric cancer </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 117 </td> <td style=“text-align:left;”> 5.88e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04659 </td> <td style=“text-align:left;”> Th17 cell differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 6.17e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04540 </td> <td style=“text-align:left;”> Gap junction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 73 </td> <td style=“text-align:left;”> 6.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05162 </td> <td style=“text-align:left;”> Measles </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 98 </td> <td style=“text-align:left;”> 6.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05204 </td> <td style=“text-align:left;”> Chemical carcinogenesis - DNA adducts </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 23 </td> <td style=“text-align:left;”> 6.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00982 </td> <td style=“text-align:left;”> Drug metabolism - cytochrome P450 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 21 </td> <td style=“text-align:left;”> 6.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:03022 </td> <td style=“text-align:left;”> Basal transcription factors </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 6.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:01524 </td> <td style=“text-align:left;”> Platinum drug resistance </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 65 </td> <td style=“text-align:left;”> 6.20e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04912 </td> <td style=“text-align:left;”> GnRH signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 76 </td> <td style=“text-align:left;”> 6.21e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04724 </td> <td style=“text-align:left;”> Glutamatergic synapse </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 6.23e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00520 </td> <td style=“text-align:left;”> Amino sugar and nucleotide sugar metabolism </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 46 </td> <td style=“text-align:left;”> 6.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04623 </td> <td style=“text-align:left;”> Cytosolic DNA-sensing pathway </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 6.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00980 </td> <td style=“text-align:left;”> Metabolism of xenobiotics by cytochrome P450 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 26 </td> <td style=“text-align:left;”> 6.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04916 </td> <td style=“text-align:left;”> Melanogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 77 </td> <td style=“text-align:left;”> 6.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00061 </td> <td style=“text-align:left;”> Fatty acid biosynthesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 12 </td> <td style=“text-align:left;”> 6.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05205 </td> <td style=“text-align:left;”> Proteoglycans in cancer </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 170 </td> <td style=“text-align:left;”> 6.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04510 </td> <td style=“text-align:left;”> Focal adhesion </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 177 </td> <td style=“text-align:left;”> 6.32e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04380 </td> <td style=“text-align:left;”> Osteoclast differentiation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 87 </td> <td style=“text-align:left;”> 6.35e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04936 </td> <td style=“text-align:left;”> Alcoholic liver disease </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 97 </td> <td style=“text-align:left;”> 6.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04725 </td> <td style=“text-align:left;”> Cholinergic synapse </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 83 </td> <td style=“text-align:left;”> 6.71e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05135 </td> <td style=“text-align:left;”> Yersinia infection </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 112 </td> <td style=“text-align:left;”> 6.77e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04714 </td> <td style=“text-align:left;”> Thermogenesis </td> <td style=“text-align:right;”> 8 </td> <td style=“text-align:right;”> 195 </td> <td style=“text-align:left;”> 6.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04810 </td> <td style=“text-align:left;”> Regulation of actin cytoskeleton </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 179 </td> <td style=“text-align:left;”> 6.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04935 </td> <td style=“text-align:left;”> Growth hormone synthesis, secretion and action </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 98 </td> <td style=“text-align:left;”> 6.84e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:01240 </td> <td style=“text-align:left;”> Biosynthesis of cofactors </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 115 </td> <td style=“text-align:left;”> 6.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05200 </td> <td style=“text-align:left;”> Pathways in cancer </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 409 </td> <td style=“text-align:left;”> 6.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04622 </td> <td style=“text-align:left;”> RIG-I-like receptor signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 6.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04964 </td> <td style=“text-align:left;”> Proximal tubule bicarbonate reclamation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 20 </td> <td style=“text-align:left;”> 6.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04217 </td> <td style=“text-align:left;”> Necroptosis </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 106 </td> <td style=“text-align:left;”> 6.91e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04926 </td> <td style=“text-align:left;”> Relaxin signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 104 </td> <td style=“text-align:left;”> 6.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04750 </td> <td style=“text-align:left;”> Inflammatory mediator regulation of TRP channels </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 72 </td> <td style=“text-align:left;”> 6.97e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05131 </td> <td style=“text-align:left;”> Shigellosis </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 210 </td> <td style=“text-align:left;”> 6.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:03460 </td> <td style=“text-align:left;”> Fanconi anemia pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 48 </td> <td style=“text-align:left;”> 6.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04920 </td> <td style=“text-align:left;”> Adipocytokine signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 6.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04915 </td> <td style=“text-align:left;”> Estrogen signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 97 </td> <td style=“text-align:left;”> 6.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05022 </td> <td style=“text-align:left;”> Pathways of neurodegeneration - multiple diseases </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 385 </td> <td style=“text-align:left;”> 6.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04310 </td> <td style=“text-align:left;”> Wnt signaling pathway </td> <td style=“text-align:right;”> 6 </td> <td style=“text-align:right;”> 138 </td> <td style=“text-align:left;”> 6.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04621 </td> <td style=“text-align:left;”> NOD-like receptor signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 117 </td> <td style=“text-align:left;”> 6.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04630 </td> <td style=“text-align:left;”> JAK-STAT signaling pathway </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 88 </td> <td style=“text-align:left;”> 6.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04530 </td> <td style=“text-align:left;”> Tight junction </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 137 </td> <td style=“text-align:left;”> 6.98e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05152 </td> <td style=“text-align:left;”> Tuberculosis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 106 </td> <td style=“text-align:left;”> 7.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00051 </td> <td style=“text-align:left;”> Fructose and mannose metabolism </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 27 </td> <td style=“text-align:left;”> 7.16e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04913 </td> <td style=“text-align:left;”> Ovarian steroidogenesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 28 </td> <td style=“text-align:left;”> 7.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04392 </td> <td style=“text-align:left;”> Hippo signaling pathway - multiple species </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 7.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04620 </td> <td style=“text-align:left;”> Toll-like receptor signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 60 </td> <td style=“text-align:left;”> 7.29e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04611 </td> <td style=“text-align:left;”> Platelet activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 89 </td> <td style=“text-align:left;”> 7.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04657 </td> <td style=“text-align:left;”> IL-17 signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 56 </td> <td style=“text-align:left;”> 7.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:01250 </td> <td style=“text-align:left;”> Biosynthesis of nucleotide sugars </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 35 </td> <td style=“text-align:left;”> 7.48e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05010 </td> <td style=“text-align:left;”> Alzheimer disease </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 315 </td> <td style=“text-align:left;”> 7.52e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04340 </td> <td style=“text-align:left;”> Hedgehog signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 49 </td> <td style=“text-align:left;”> 7.58e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04270 </td> <td style=“text-align:left;”> Vascular smooth muscle contraction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 94 </td> <td style=“text-align:left;”> 7.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05017 </td> <td style=“text-align:left;”> Spinocerebellar ataxia </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 124 </td> <td style=“text-align:left;”> 7.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04151 </td> <td style=“text-align:left;”> PI3K-Akt signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 254 </td> <td style=“text-align:left;”> 7.59e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04914 </td> <td style=“text-align:left;”> Progesterone-mediated oocyte maturation </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 86 </td> <td style=“text-align:left;”> 7.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00140 </td> <td style=“text-align:left;”> Steroid hormone biosynthesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 19 </td> <td style=“text-align:left;”> 7.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05416 </td> <td style=“text-align:left;”> Viral myocarditis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 40 </td> <td style=“text-align:left;”> 7.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04062 </td> <td style=“text-align:left;”> Chemokine signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 113 </td> <td style=“text-align:left;”> 7.73e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04020 </td> <td style=“text-align:left;”> Calcium signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 157 </td> <td style=“text-align:left;”> 7.86e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00000 </td> <td style=“text-align:left;”> KEGG root term </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 5548 </td> <td style=“text-align:left;”> 7.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04261 </td> <td style=“text-align:left;”> Adrenergic signaling in cardiomyocytes </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 128 </td> <td style=“text-align:left;”> 7.95e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05207 </td> <td style=“text-align:left;”> Chemical carcinogenesis - receptor activation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 142 </td> <td style=“text-align:left;”> 7.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04015 </td> <td style=“text-align:left;”> Rap1 signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 164 </td> <td style=“text-align:left;”> 7.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:03018 </td> <td style=“text-align:left;”> RNA degradation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 7.96e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04080 </td> <td style=“text-align:left;”> Neuroactive ligand-receptor interaction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 108 </td> <td style=“text-align:left;”> 7.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00512 </td> <td style=“text-align:left;”> Mucin type O-glycan biosynthesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 7.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00071 </td> <td style=“text-align:left;”> Fatty acid degradation </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 32 </td> <td style=“text-align:left;”> 7.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00230 </td> <td style=“text-align:left;”> Purine metabolism </td> <td style=“text-align:right;”> 3 </td> <td style=“text-align:right;”> 97 </td> <td style=“text-align:left;”> 7.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:03320 </td> <td style=“text-align:left;”> PPAR signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 7.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04142 </td> <td style=“text-align:left;”> Lysosome </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 118 </td> <td style=“text-align:left;”> 7.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04216 </td> <td style=“text-align:left;”> Ferroptosis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 33 </td> <td style=“text-align:left;”> 7.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05208 </td> <td style=“text-align:left;”> Chemical carcinogenesis - reactive oxygen species </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 186 </td> <td style=“text-align:left;”> 7.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05012 </td> <td style=“text-align:left;”> Parkinson disease </td> <td style=“text-align:right;”> 5 </td> <td style=“text-align:right;”> 226 </td> <td style=“text-align:left;”> 7.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05014 </td> <td style=“text-align:left;”> Amyotrophic lateral sclerosis </td> <td style=“text-align:right;”> 7 </td> <td style=“text-align:right;”> 303 </td> <td style=“text-align:left;”> 7.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04520 </td> <td style=“text-align:left;”> Adherens junction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 67 </td> <td style=“text-align:left;”> 7.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05020 </td> <td style=“text-align:left;”> Prion disease </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 220 </td> <td style=“text-align:left;”> 7.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04934 </td> <td style=“text-align:left;”> Cushing syndrome </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 121 </td> <td style=“text-align:left;”> 7.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05134 </td> <td style=“text-align:left;”> Legionellosis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 39 </td> <td style=“text-align:left;”> 7.99e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04978 </td> <td style=“text-align:left;”> Mineral absorption </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 8.05e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04060 </td> <td style=“text-align:left;”> Cytokine-cytokine receptor interaction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 98 </td> <td style=“text-align:left;”> 8.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04668 </td> <td style=“text-align:left;”> TNF signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 87 </td> <td style=“text-align:left;”> 8.06e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00830 </td> <td style=“text-align:left;”> Retinol metabolism </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 16 </td> <td style=“text-align:left;”> 8.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05415 </td> <td style=“text-align:left;”> Diabetic cardiomyopathy </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 169 </td> <td style=“text-align:left;”> 8.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05321 </td> <td style=“text-align:left;”> Inflammatory bowel disease </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 22 </td> <td style=“text-align:left;”> 8.26e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00330 </td> <td style=“text-align:left;”> Arginine and proline metabolism </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 8.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00514 </td> <td style=“text-align:left;”> Other types of O-glycan biosynthesis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 37 </td> <td style=“text-align:left;”> 8.51e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:00270 </td> <td style=“text-align:left;”> Cysteine and methionine metabolism </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 38 </td> <td style=“text-align:left;”> 8.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04932 </td> <td style=“text-align:left;”> Non-alcoholic fatty liver disease </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 131 </td> <td style=“text-align:left;”> 8.54e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:01212 </td> <td style=“text-align:left;”> Fatty acid metabolism </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 50 </td> <td style=“text-align:left;”> 8.61e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04066 </td> <td style=“text-align:left;”> HIF-1 signaling pathway </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 89 </td> <td style=“text-align:left;”> 8.62e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04064 </td> <td style=“text-align:left;”> NF-kappa B signaling pathway </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 71 </td> <td style=“text-align:left;”> 8.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05100 </td> <td style=“text-align:left;”> Bacterial invasion of epithelial cells </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 74 </td> <td style=“text-align:left;”> 8.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:01232 </td> <td style=“text-align:left;”> Nucleotide metabolism </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 8.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04260 </td> <td style=“text-align:left;”> Cardiac muscle contraction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 67 </td> <td style=“text-align:left;”> 8.82e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:01100 </td> <td style=“text-align:left;”> Metabolic pathways </td> <td style=“text-align:right;”> 4 </td> <td style=“text-align:right;”> 1146 </td> <td style=“text-align:left;”> 9.00e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05171 </td> <td style=“text-align:left;”> Coronavirus disease - COVID-19 </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 162 </td> <td style=“text-align:left;”> 9.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04974 </td> <td style=“text-align:left;”> Protein digestion and absorption </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 61 </td> <td style=“text-align:left;”> 9.18e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05322 </td> <td style=“text-align:left;”> Systemic lupus erythematosus </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 51 </td> <td style=“text-align:left;”> 9.25e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05130 </td> <td style=“text-align:left;”> Pathogenic Escherichia coli infection </td> <td style=“text-align:right;”> 2 </td> <td style=“text-align:right;”> 150 </td> <td style=“text-align:left;”> 9.39e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04976 </td> <td style=“text-align:left;”> Bile secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 42 </td> <td style=“text-align:left;”> 9.39e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04970 </td> <td style=“text-align:left;”> Salivary secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 55 </td> <td style=“text-align:left;”> 9.39e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:05146 </td> <td style=“text-align:left;”> Amoebiasis </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 64 </td> <td style=“text-align:left;”> 9.43e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04713 </td> <td style=“text-align:left;”> Circadian entrainment </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 69 </td> <td style=“text-align:left;”> 9.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04972 </td> <td style=“text-align:left;”> Pancreatic secretion </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 58 </td> <td style=“text-align:left;”> 9.44e-01 </td> </tr> <tr> <td style=“text-align:left;”> KEGG </td> <td style=“text-align:left;”> KEGG:04740 </td> <td style=“text-align:left;”> Olfactory transduction </td> <td style=“text-align:right;”> 1 </td> <td style=“text-align:right;”> 25 </td> <td style=“text-align:left;”> 1.00e+00 </td> </tr> </tbody> </table> |
EPI_table_var %>%
filter(source=="KEGG") %>%
mutate_at(.vars = 6, .funs= scientific_format()) %>%
kable(.,caption = "KEGG EPI var enrichment terms of highly var genes") %>%
kable_paper("striped", full_width = FALSE) %>%
kable_styling(full_width = FALSE, position = "left",bootstrap_options = c("striped","hover")) %>%
scroll_box(width = "100%", height = "400px")| source | term_id | term_name | intersection_size | term_size | p_value |
|---|---|---|---|---|---|
| KEGG | KEGG:05168 | Herpes simplex virus 1 infection | 22 | 415 | 1.48e-01 |
| KEGG | KEGG:05031 | Amphetamine addiction | 4 | 49 | 1.48e-01 |
| KEGG | KEGG:03250 | Viral life cycle - HIV-1 | 6 | 56 | 1.90e-01 |
| KEGG | KEGG:04218 | Cellular senescence | 7 | 145 | 1.90e-01 |
| KEGG | KEGG:03015 | mRNA surveillance pathway | 6 | 86 | 1.90e-01 |
| KEGG | KEGG:04213 | Longevity regulating pathway - multiple species | 5 | 55 | 1.90e-01 |
| KEGG | KEGG:04144 | Endocytosis | 11 | 232 | 1.90e-01 |
| KEGG | KEGG:00900 | Terpenoid backbone biosynthesis | 1 | 21 | 1.90e-01 |
| KEGG | KEGG:05034 | Alcoholism | 5 | 112 | 2.16e-01 |
| KEGG | KEGG:00565 | Ether lipid metabolism | 4 | 28 | 2.16e-01 |
| KEGG | KEGG:04720 | Long-term potentiation | 3 | 55 | 2.33e-01 |
| KEGG | KEGG:04666 | Fc gamma R-mediated phagocytosis | 2 | 75 | 3.04e-01 |
| KEGG | KEGG:04146 | Peroxisome | 1 | 68 | 3.04e-01 |
| KEGG | KEGG:00564 | Glycerophospholipid metabolism | 2 | 76 | 3.04e-01 |
| KEGG | KEGG:05212 | Pancreatic cancer | 7 | 75 | 3.04e-01 |
| KEGG | KEGG:03060 | Protein export | 3 | 23 | 3.11e-01 |
| KEGG | KEGG:04211 | Longevity regulating pathway | 5 | 78 | 3.46e-01 |
| KEGG | KEGG:04924 | Renin secretion | 2 | 50 | 3.46e-01 |
| KEGG | KEGG:05210 | Colorectal cancer | 7 | 84 | 3.46e-01 |
| KEGG | KEGG:05220 | Chronic myeloid leukemia | 6 | 75 | 3.46e-01 |
| KEGG | KEGG:03013 | Nucleocytoplasmic transport | 6 | 99 | 3.46e-01 |
| KEGG | KEGG:05166 | Human T-cell leukemia virus 1 infection | 6 | 180 | 3.46e-01 |
| KEGG | KEGG:05030 | Cocaine addiction | 2 | 35 | 3.46e-01 |
| KEGG | KEGG:04137 | Mitophagy - animal | 4 | 70 | 3.46e-01 |
| KEGG | KEGG:04370 | VEGF signaling pathway | 2 | 49 | 3.51e-01 |
| KEGG | KEGG:04710 | Circadian rhythm | 2 | 30 | 4.35e-01 |
| KEGG | KEGG:05170 | Human immunodeficiency virus 1 infection | 8 | 165 | 4.41e-01 |
| KEGG | KEGG:05215 | Prostate cancer | 2 | 86 | 4.41e-01 |
| KEGG | KEGG:05214 | Glioma | 2 | 67 | 4.41e-01 |
| KEGG | KEGG:04726 | Serotonergic synapse | 2 | 63 | 4.41e-01 |
| KEGG | KEGG:05216 | Thyroid cancer | 3 | 35 | 4.41e-01 |
| KEGG | KEGG:00562 | Inositol phosphate metabolism | 4 | 66 | 4.41e-01 |
| KEGG | KEGG:00563 | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 1 | 25 | 4.41e-01 |
| KEGG | KEGG:05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2 | 69 | 4.41e-01 |
| KEGG | KEGG:05231 | Choline metabolism in cancer | 4 | 84 | 4.41e-01 |
| KEGG | KEGG:05225 | Hepatocellular carcinoma | 9 | 145 | 4.41e-01 |
| KEGG | KEGG:00310 | Lysine degradation | 2 | 59 | 4.41e-01 |
| KEGG | KEGG:03020 | RNA polymerase | 3 | 34 | 4.41e-01 |
| KEGG | KEGG:05223 | Non-small cell lung cancer | 2 | 67 | 4.41e-01 |
| KEGG | KEGG:05219 | Bladder cancer | 2 | 37 | 4.41e-01 |
| KEGG | KEGG:00600 | Sphingolipid metabolism | 1 | 44 | 4.41e-01 |
| KEGG | KEGG:00970 | Aminoacyl-tRNA biosynthesis | 3 | 44 | 4.41e-01 |
| KEGG | KEGG:01522 | Endocrine resistance | 4 | 85 | 4.41e-01 |
| KEGG | KEGG:05218 | Melanoma | 2 | 58 | 4.41e-01 |
| KEGG | KEGG:03008 | Ribosome biogenesis in eukaryotes | 4 | 75 | 4.41e-01 |
| KEGG | KEGG:05221 | Acute myeloid leukemia | 3 | 56 | 4.41e-01 |
| KEGG | KEGG:03420 | Nucleotide excision repair | 2 | 43 | 4.41e-01 |
| KEGG | KEGG:05132 | Salmonella infection | 1 | 214 | 4.41e-01 |
| KEGG | KEGG:05167 | Kaposi sarcoma-associated herpesvirus infection | 4 | 145 | 4.41e-01 |
| KEGG | KEGG:04975 | Fat digestion and absorption | 1 | 19 | 4.41e-01 |
| KEGG | KEGG:04210 | Apoptosis | 2 | 118 | 4.41e-01 |
| KEGG | KEGG:04215 | Apoptosis - multiple species | 3 | 30 | 4.41e-01 |
| KEGG | KEGG:04933 | AGE-RAGE signaling pathway in diabetic complications | 3 | 91 | 4.41e-01 |
| KEGG | KEGG:04330 | Notch signaling pathway | 1 | 51 | 4.41e-01 |
| KEGG | KEGG:04921 | Oxytocin signaling pathway | 4 | 115 | 4.41e-01 |
| KEGG | KEGG:04919 | Thyroid hormone signaling pathway | 3 | 112 | 4.41e-01 |
| KEGG | KEGG:04625 | C-type lectin receptor signaling pathway | 2 | 76 | 4.41e-01 |
| KEGG | KEGG:04650 | Natural killer cell mediated cytotoxicity | 2 | 63 | 4.41e-01 |
| KEGG | KEGG:04660 | T cell receptor signaling pathway | 3 | 70 | 4.41e-01 |
| KEGG | KEGG:04662 | B cell receptor signaling pathway | 2 | 56 | 4.41e-01 |
| KEGG | KEGG:04664 | Fc epsilon RI signaling pathway | 3 | 46 | 4.41e-01 |
| KEGG | KEGG:04910 | Insulin signaling pathway | 5 | 121 | 4.41e-01 |
| KEGG | KEGG:04721 | Synaptic vesicle cycle | 2 | 51 | 4.41e-01 |
| KEGG | KEGG:04728 | Dopaminergic synapse | 3 | 103 | 4.41e-01 |
| KEGG | KEGG:04150 | mTOR signaling pathway | 5 | 135 | 4.41e-01 |
| KEGG | KEGG:05169 | Epstein-Barr virus infection | 7 | 153 | 4.41e-01 |
| KEGG | KEGG:05016 | Huntington disease | 4 | 256 | 4.41e-01 |
| KEGG | KEGG:04140 | Autophagy - animal | 7 | 133 | 4.41e-01 |
| KEGG | KEGG:05164 | Influenza A | 6 | 103 | 4.41e-01 |
| KEGG | KEGG:05163 | Human cytomegalovirus infection | 7 | 176 | 4.41e-01 |
| KEGG | KEGG:05161 | Hepatitis B | 6 | 136 | 4.41e-01 |
| KEGG | KEGG:03430 | Mismatch repair | 1 | 22 | 4.41e-01 |
| KEGG | KEGG:03450 | Non-homologous end-joining | 1 | 12 | 4.41e-01 |
| KEGG | KEGG:04722 | Neurotrophin signaling pathway | 2 | 110 | 4.41e-01 |
| KEGG | KEGG:04022 | cGMP-PKG signaling pathway | 3 | 133 | 4.41e-01 |
| KEGG | KEGG:04068 | FoxO signaling pathway | 3 | 109 | 4.41e-01 |
| KEGG | KEGG:04070 | Phosphatidylinositol signaling system | 5 | 91 | 4.41e-01 |
| KEGG | KEGG:04071 | Sphingolipid signaling pathway | 5 | 107 | 4.41e-01 |
| KEGG | KEGG:04110 | Cell cycle | 5 | 151 | 4.41e-01 |
| KEGG | KEGG:04115 | p53 signaling pathway | 4 | 65 | 4.41e-01 |
| KEGG | KEGG:04122 | Sulfur relay system | 1 | 8 | 4.41e-01 |
| KEGG | KEGG:04130 | SNARE interactions in vesicular transport | 1 | 32 | 4.41e-01 |
| KEGG | KEGG:04136 | Autophagy - other | 2 | 31 | 4.41e-01 |
| KEGG | KEGG:04145 | Phagosome | 1 | 99 | 4.41e-01 |
| KEGG | KEGG:00561 | Glycerolipid metabolism | 1 | 49 | 4.41e-01 |
| KEGG | KEGG:05418 | Fluid shear stress and atherosclerosis | 5 | 114 | 4.41e-01 |
| KEGG | KEGG:04550 | Signaling pathways regulating pluripotency of stem cells | 2 | 104 | 4.59e-01 |
| KEGG | KEGG:04610 | Complement and coagulation cascades | 1 | 40 | 4.59e-01 |
| KEGG | KEGG:03040 | Spliceosome | 7 | 132 | 4.59e-01 |
| KEGG | KEGG:05224 | Breast cancer | 5 | 117 | 4.59e-01 |
| KEGG | KEGG:01521 | EGFR tyrosine kinase inhibitor resistance | 4 | 74 | 4.59e-01 |
| KEGG | KEGG:04072 | Phospholipase D signaling pathway | 2 | 110 | 4.59e-01 |
| KEGG | KEGG:04923 | Regulation of lipolysis in adipocytes | 1 | 41 | 4.59e-01 |
| KEGG | KEGG:03050 | Proteasome | 3 | 42 | 4.59e-01 |
| KEGG | KEGG:05160 | Hepatitis C | 3 | 115 | 4.65e-01 |
| KEGG | KEGG:03410 | Base excision repair | 1 | 33 | 4.81e-01 |
| KEGG | KEGG:05412 | Arrhythmogenic right ventricular cardiomyopathy | 1 | 63 | 4.81e-01 |
| KEGG | KEGG:04024 | cAMP signaling pathway | 3 | 151 | 4.81e-01 |
| KEGG | KEGG:04360 | Axon guidance | 5 | 162 | 4.81e-01 |
| KEGG | KEGG:04012 | ErbB signaling pathway | 3 | 78 | 4.81e-01 |
| KEGG | KEGG:04613 | Neutrophil extracellular trap formation | 1 | 100 | 4.81e-01 |
| KEGG | KEGG:05202 | Transcriptional misregulation in cancer | 1 | 128 | 4.85e-01 |
| KEGG | KEGG:05203 | Viral carcinogenesis | 1 | 162 | 4.94e-01 |
| KEGG | KEGG:03030 | DNA replication | 1 | 35 | 4.94e-01 |
| KEGG | KEGG:04350 | TGF-beta signaling pathway | 3 | 84 | 4.94e-01 |
| KEGG | KEGG:04114 | Oocyte meiosis | 2 | 108 | 4.98e-01 |
| KEGG | KEGG:05410 | Hypertrophic cardiomyopathy | 1 | 73 | 5.07e-01 |
| KEGG | KEGG:04141 | Protein processing in endoplasmic reticulum | 6 | 161 | 5.10e-01 |
| KEGG | KEGG:05414 | Dilated cardiomyopathy | 1 | 78 | 5.14e-01 |
| KEGG | KEGG:00770 | Pantothenate and CoA biosynthesis | 1 | 15 | 5.14e-01 |
| KEGG | KEGG:04010 | MAPK signaling pathway | 3 | 240 | 5.14e-01 |
| KEGG | KEGG:04961 | Endocrine and other factor-regulated calcium reabsorption | 1 | 41 | 5.15e-01 |
| KEGG | KEGG:03440 | Homologous recombination | 1 | 39 | 5.15e-01 |
| KEGG | KEGG:04120 | Ubiquitin mediated proteolysis | 4 | 134 | 5.15e-01 |
| KEGG | KEGG:00740 | Riboflavin metabolism | 1 | 6 | 5.24e-01 |
| KEGG | KEGG:05032 | Morphine addiction | 1 | 56 | 5.32e-01 |
| KEGG | KEGG:05213 | Endometrial cancer | 1 | 57 | 5.32e-01 |
| KEGG | KEGG:04931 | Insulin resistance | 3 | 95 | 5.34e-01 |
| KEGG | KEGG:04730 | Long-term depression | 1 | 42 | 5.34e-01 |
| KEGG | KEGG:00790 | Folate biosynthesis | 1 | 18 | 5.40e-01 |
| KEGG | KEGG:05222 | Small cell lung cancer | 3 | 87 | 5.51e-01 |
| KEGG | KEGG:04390 | Hippo signaling pathway | 2 | 134 | 5.53e-01 |
| KEGG | KEGG:04727 | GABAergic synapse | 2 | 55 | 5.53e-01 |
| KEGG | KEGG:04014 | Ras signaling pathway | 4 | 171 | 5.53e-01 |
| KEGG | KEGG:04917 | Prolactin signaling pathway | 1 | 56 | 5.53e-01 |
| KEGG | KEGG:00983 | Drug metabolism - other enzymes | 2 | 44 | 5.53e-01 |
| KEGG | KEGG:04922 | Glucagon signaling pathway | 2 | 84 | 5.53e-01 |
| KEGG | KEGG:05211 | Renal cell carcinoma | 1 | 65 | 5.53e-01 |
| KEGG | KEGG:05230 | Central carbon metabolism in cancer | 1 | 62 | 5.53e-01 |
| KEGG | KEGG:05217 | Basal cell carcinoma | 3 | 49 | 5.53e-01 |
| KEGG | KEGG:05417 | Lipid and atherosclerosis | 2 | 153 | 5.53e-01 |
| KEGG | KEGG:04929 | GnRH secretion | 1 | 53 | 5.53e-01 |
| KEGG | KEGG:05206 | MicroRNAs in cancer | 1 | 149 | 5.64e-01 |
| KEGG | KEGG:04658 | Th1 and Th2 cell differentiation | 1 | 53 | 5.68e-01 |
| KEGG | KEGG:00480 | Glutathione metabolism | 1 | 44 | 5.76e-01 |
| KEGG | KEGG:04371 | Apelin signaling pathway | 4 | 106 | 5.77e-01 |
| KEGG | KEGG:03010 | Ribosome | 1 | 127 | 5.77e-01 |
| KEGG | KEGG:05165 | Human papillomavirus infection | 1 | 272 | 5.77e-01 |
| KEGG | KEGG:04152 | AMPK signaling pathway | 3 | 103 | 5.88e-01 |
| KEGG | KEGG:05226 | Gastric cancer | 4 | 117 | 5.88e-01 |
| KEGG | KEGG:04659 | Th17 cell differentiation | 1 | 64 | 6.17e-01 |
| KEGG | KEGG:04540 | Gap junction | 1 | 73 | 6.20e-01 |
| KEGG | KEGG:05162 | Measles | 2 | 98 | 6.20e-01 |
| KEGG | KEGG:05204 | Chemical carcinogenesis - DNA adducts | 1 | 23 | 6.20e-01 |
| KEGG | KEGG:00982 | Drug metabolism - cytochrome P450 | 1 | 21 | 6.20e-01 |
| KEGG | KEGG:03022 | Basal transcription factors | 1 | 40 | 6.20e-01 |
| KEGG | KEGG:01524 | Platinum drug resistance | 3 | 65 | 6.20e-01 |
| KEGG | KEGG:04912 | GnRH signaling pathway | 1 | 76 | 6.21e-01 |
| KEGG | KEGG:04724 | Glutamatergic synapse | 1 | 74 | 6.23e-01 |
| KEGG | KEGG:00520 | Amino sugar and nucleotide sugar metabolism | 2 | 46 | 6.25e-01 |
| KEGG | KEGG:04623 | Cytosolic DNA-sensing pathway | 3 | 42 | 6.32e-01 |
| KEGG | KEGG:00980 | Metabolism of xenobiotics by cytochrome P450 | 1 | 26 | 6.32e-01 |
| KEGG | KEGG:04916 | Melanogenesis | 1 | 77 | 6.32e-01 |
| KEGG | KEGG:00061 | Fatty acid biosynthesis | 1 | 12 | 6.32e-01 |
| KEGG | KEGG:05205 | Proteoglycans in cancer | 2 | 170 | 6.32e-01 |
| KEGG | KEGG:04510 | Focal adhesion | 2 | 177 | 6.32e-01 |
| KEGG | KEGG:04380 | Osteoclast differentiation | 1 | 87 | 6.35e-01 |
| KEGG | KEGG:04936 | Alcoholic liver disease | 2 | 97 | 6.52e-01 |
| KEGG | KEGG:04725 | Cholinergic synapse | 1 | 83 | 6.71e-01 |
| KEGG | KEGG:05135 | Yersinia infection | 3 | 112 | 6.77e-01 |
| KEGG | KEGG:04714 | Thermogenesis | 8 | 195 | 6.84e-01 |
| KEGG | KEGG:04810 | Regulation of actin cytoskeleton | 2 | 179 | 6.84e-01 |
| KEGG | KEGG:04935 | Growth hormone synthesis, secretion and action | 1 | 98 | 6.84e-01 |
| KEGG | KEGG:01240 | Biosynthesis of cofactors | 4 | 115 | 6.86e-01 |
| KEGG | KEGG:05200 | Pathways in cancer | 1 | 409 | 6.91e-01 |
| KEGG | KEGG:04622 | RIG-I-like receptor signaling pathway | 2 | 49 | 6.91e-01 |
| KEGG | KEGG:04964 | Proximal tubule bicarbonate reclamation | 1 | 20 | 6.91e-01 |
| KEGG | KEGG:04217 | Necroptosis | 4 | 106 | 6.91e-01 |
| KEGG | KEGG:04926 | Relaxin signaling pathway | 1 | 104 | 6.95e-01 |
| KEGG | KEGG:04750 | Inflammatory mediator regulation of TRP channels | 1 | 72 | 6.97e-01 |
| KEGG | KEGG:05131 | Shigellosis | 6 | 210 | 6.98e-01 |
| KEGG | KEGG:03460 | Fanconi anemia pathway | 1 | 48 | 6.98e-01 |
| KEGG | KEGG:04920 | Adipocytokine signaling pathway | 1 | 51 | 6.98e-01 |
| KEGG | KEGG:04915 | Estrogen signaling pathway | 1 | 97 | 6.98e-01 |
| KEGG | KEGG:05022 | Pathways of neurodegeneration - multiple diseases | 3 | 385 | 6.98e-01 |
| KEGG | KEGG:04310 | Wnt signaling pathway | 6 | 138 | 6.98e-01 |
| KEGG | KEGG:04621 | NOD-like receptor signaling pathway | 2 | 117 | 6.98e-01 |
| KEGG | KEGG:04630 | JAK-STAT signaling pathway | 4 | 88 | 6.98e-01 |
| KEGG | KEGG:04530 | Tight junction | 2 | 137 | 6.98e-01 |
| KEGG | KEGG:05152 | Tuberculosis | 1 | 106 | 7.06e-01 |
| KEGG | KEGG:00051 | Fructose and mannose metabolism | 1 | 27 | 7.16e-01 |
| KEGG | KEGG:04913 | Ovarian steroidogenesis | 1 | 28 | 7.26e-01 |
| KEGG | KEGG:04392 | Hippo signaling pathway - multiple species | 1 | 25 | 7.29e-01 |
| KEGG | KEGG:04620 | Toll-like receptor signaling pathway | 2 | 60 | 7.29e-01 |
| KEGG | KEGG:04611 | Platelet activation | 1 | 89 | 7.48e-01 |
| KEGG | KEGG:04657 | IL-17 signaling pathway | 1 | 56 | 7.48e-01 |
| KEGG | KEGG:01250 | Biosynthesis of nucleotide sugars | 1 | 35 | 7.48e-01 |
| KEGG | KEGG:05010 | Alzheimer disease | 2 | 315 | 7.52e-01 |
| KEGG | KEGG:04340 | Hedgehog signaling pathway | 1 | 49 | 7.58e-01 |
| KEGG | KEGG:04270 | Vascular smooth muscle contraction | 1 | 94 | 7.59e-01 |
| KEGG | KEGG:05017 | Spinocerebellar ataxia | 1 | 124 | 7.59e-01 |
| KEGG | KEGG:04151 | PI3K-Akt signaling pathway | 2 | 254 | 7.59e-01 |
| KEGG | KEGG:04914 | Progesterone-mediated oocyte maturation | 3 | 86 | 7.73e-01 |
| KEGG | KEGG:00140 | Steroid hormone biosynthesis | 1 | 19 | 7.73e-01 |
| KEGG | KEGG:05416 | Viral myocarditis | 1 | 40 | 7.73e-01 |
| KEGG | KEGG:04062 | Chemokine signaling pathway | 1 | 113 | 7.73e-01 |
| KEGG | KEGG:04020 | Calcium signaling pathway | 1 | 157 | 7.86e-01 |
| KEGG | KEGG:00000 | KEGG root term | 2 | 5548 | 7.95e-01 |
| KEGG | KEGG:04261 | Adrenergic signaling in cardiomyocytes | 1 | 128 | 7.95e-01 |
| KEGG | KEGG:05207 | Chemical carcinogenesis - receptor activation | 1 | 142 | 7.96e-01 |
| KEGG | KEGG:04015 | Rap1 signaling pathway | 1 | 164 | 7.96e-01 |
| KEGG | KEGG:03018 | RNA degradation | 1 | 74 | 7.96e-01 |
| KEGG | KEGG:04080 | Neuroactive ligand-receptor interaction | 1 | 108 | 7.99e-01 |
| KEGG | KEGG:00512 | Mucin type O-glycan biosynthesis | 1 | 22 | 7.99e-01 |
| KEGG | KEGG:00071 | Fatty acid degradation | 1 | 32 | 7.99e-01 |
| KEGG | KEGG:00230 | Purine metabolism | 3 | 97 | 7.99e-01 |
| KEGG | KEGG:03320 | PPAR signaling pathway | 2 | 50 | 7.99e-01 |
| KEGG | KEGG:04142 | Lysosome | 2 | 118 | 7.99e-01 |
| KEGG | KEGG:04216 | Ferroptosis | 1 | 33 | 7.99e-01 |
| KEGG | KEGG:05208 | Chemical carcinogenesis - reactive oxygen species | 1 | 186 | 7.99e-01 |
| KEGG | KEGG:05012 | Parkinson disease | 5 | 226 | 7.99e-01 |
| KEGG | KEGG:05014 | Amyotrophic lateral sclerosis | 7 | 303 | 7.99e-01 |
| KEGG | KEGG:04520 | Adherens junction | 1 | 67 | 7.99e-01 |
| KEGG | KEGG:05020 | Prion disease | 1 | 220 | 7.99e-01 |
| KEGG | KEGG:04934 | Cushing syndrome | 2 | 121 | 7.99e-01 |
| KEGG | KEGG:05134 | Legionellosis | 1 | 39 | 7.99e-01 |
| KEGG | KEGG:04978 | Mineral absorption | 1 | 42 | 8.05e-01 |
| KEGG | KEGG:04060 | Cytokine-cytokine receptor interaction | 1 | 98 | 8.06e-01 |
| KEGG | KEGG:04668 | TNF signaling pathway | 2 | 87 | 8.06e-01 |
| KEGG | KEGG:00830 | Retinol metabolism | 1 | 16 | 8.26e-01 |
| KEGG | KEGG:05415 | Diabetic cardiomyopathy | 1 | 169 | 8.26e-01 |
| KEGG | KEGG:05321 | Inflammatory bowel disease | 1 | 22 | 8.26e-01 |
| KEGG | KEGG:00330 | Arginine and proline metabolism | 1 | 38 | 8.51e-01 |
| KEGG | KEGG:00514 | Other types of O-glycan biosynthesis | 1 | 37 | 8.51e-01 |
| KEGG | KEGG:00270 | Cysteine and methionine metabolism | 1 | 38 | 8.54e-01 |
| KEGG | KEGG:04932 | Non-alcoholic fatty liver disease | 1 | 131 | 8.54e-01 |
| KEGG | KEGG:01212 | Fatty acid metabolism | 1 | 50 | 8.61e-01 |
| KEGG | KEGG:04066 | HIF-1 signaling pathway | 2 | 89 | 8.62e-01 |
| KEGG | KEGG:04064 | NF-kappa B signaling pathway | 1 | 71 | 8.82e-01 |
| KEGG | KEGG:05100 | Bacterial invasion of epithelial cells | 1 | 74 | 8.82e-01 |
| KEGG | KEGG:01232 | Nucleotide metabolism | 1 | 69 | 8.82e-01 |
| KEGG | KEGG:04260 | Cardiac muscle contraction | 1 | 67 | 8.82e-01 |
| KEGG | KEGG:01100 | Metabolic pathways | 4 | 1146 | 9.00e-01 |
| KEGG | KEGG:05171 | Coronavirus disease - COVID-19 | 1 | 162 | 9.18e-01 |
| KEGG | KEGG:04974 | Protein digestion and absorption | 2 | 61 | 9.18e-01 |
| KEGG | KEGG:05322 | Systemic lupus erythematosus | 1 | 51 | 9.25e-01 |
| KEGG | KEGG:05130 | Pathogenic Escherichia coli infection | 2 | 150 | 9.39e-01 |
| KEGG | KEGG:04976 | Bile secretion | 1 | 42 | 9.39e-01 |
| KEGG | KEGG:04970 | Salivary secretion | 1 | 55 | 9.39e-01 |
| KEGG | KEGG:05146 | Amoebiasis | 1 | 64 | 9.43e-01 |
| KEGG | KEGG:04713 | Circadian entrainment | 1 | 69 | 9.44e-01 |
| KEGG | KEGG:04972 | Pancreatic secretion | 1 | 58 | 9.44e-01 |
| KEGG | KEGG:04740 | Olfactory transduction | 1 | 25 | 1.00e+00 |
we did not find significantly enriched GO:BP or KEGG pathways enrichment in the 508 highly variable EPI gene names
24 hour DNR highly variable genes
based on nominal pvalues <0.05
# DNR_var24gost <- gost(query = DNR_24_var$ENTREZID,
# organism = "hsapiens",
# significant = FALSE,
# ordered_query = TRUE,
# domain_scope = "custom",
# measure_underrepresentation = FALSE,
# evcodes = FALSE,
# numeric_ns="ENTREZGENE",
# user_threshold = 0.05,
# correction_method = "fdr",
# custom_bg = backGL$ENTREZID,
# sources=c("GO:BP","KEGG"))
#
# saveRDS(DNR_var24gost,"data/DEG-GO/var/DNR_var24gost.RDS")
DNR_var24gost <- readRDS("data/DEG-GO/var/DNR_var24gost.RDS")
DNR_var24p <- gostplot(DNR_var24gost, capped = FALSE, interactive = TRUE)
DNR_var24pDNR_var24_table <- DNR_var24gost$result %>%
dplyr::select(c(source, term_id, term_name,intersection_size, term_size, p_value))
DNR_var24_table %>%
dplyr::filter(source=="GO:BP") %>%
dplyr::select(p_value,term_name,intersection_size) %>%
slice_min(., n=3 ,order_by=p_value) %>%
mutate(log_val = -log10(p_value)) %>%
# slice_max(., n=10,order_by = p_value) %>%
ggplot(., aes(x = log_val, y =reorder(term_name,p_value), col= intersection_size)) +
geom_point(aes(size = intersection_size)) +
geom_vline(xintercept = (-log10(0.05)), col="red")+
scale_y_discrete(labels = label_wrap(30))+
guides(col="none", size=guide_legend(title = "# of intersected \n terms"))+
ggtitle('DNR24 hour top 10 GO:BP terms') +
xlab(expression(" -"~log[10]~("adj. p-value")))+
ylab("GO: BP term")+
theme_bw()+
theme(plot.title = element_text(size = rel(1.5), hjust = 0.5),
axis.title = element_text(size = 15, color = "black"),
axis.ticks = element_line(linewidth = 1.5),
axis.line = element_line(linewidth = 1.5),
axis.text = element_text(size = 10, color = "black", angle = 0),
strip.text.x = element_text(size = 15, color = "black", face = "bold")) 
DNR_var24_table %>%
mutate_at(.vars = 6, .funs= scientific_format()) %>%
kable(.,caption = "DNR 24 enrichment terms of highly var genes") %>%
kable_paper("striped", full_width = FALSE) %>%
kable_styling(full_width = FALSE, position = "left",bootstrap_options = c("striped","hover")) %>%
scroll_box(width = "100%", height = "400px")| source | term_id | term_name | intersection_size | term_size | p_value |
|---|---|---|---|---|---|
| GO:BP | GO:0021999 | neural plate anterior/posterior regionalization | 2 | 5 | 1.57e-01 |
| GO:BP | GO:0002089 | lens morphogenesis in camera-type eye | 2 | 18 | 1.57e-01 |
| GO:BP | GO:0001946 | lymphangiogenesis | 2 | 12 | 1.57e-01 |
| GO:BP | GO:0001945 | lymph vessel development | 2 | 22 | 1.57e-01 |
| GO:BP | GO:0021915 | neural tube development | 5 | 146 | 1.57e-01 |
| GO:BP | GO:0036303 | lymph vessel morphogenesis | 2 | 17 | 1.57e-01 |
| GO:BP | GO:0017015 | regulation of transforming growth factor beta receptor signaling pathway | 15 | 128 | 1.57e-01 |
| GO:BP | GO:1903844 | regulation of cellular response to transforming growth factor beta stimulus | 15 | 129 | 1.57e-01 |
| GO:BP | GO:0060897 | neural plate regionalization | 2 | 6 | 1.57e-01 |
| GO:BP | GO:0060576 | intestinal epithelial cell development | 6 | 11 | 1.57e-01 |
| GO:BP | GO:0043536 | positive regulation of blood vessel endothelial cell migration | 10 | 47 | 1.63e-01 |
| GO:BP | GO:0010595 | positive regulation of endothelial cell migration | 15 | 94 | 1.63e-01 |
| GO:BP | GO:0010634 | positive regulation of epithelial cell migration | 19 | 132 | 1.63e-01 |
| GO:BP | GO:0044539 | long-chain fatty acid import into cell | 6 | 14 | 1.70e-01 |
| GO:BP | GO:0046499 | S-adenosylmethioninamine metabolic process | 1 | 1 | 1.70e-01 |
| GO:BP | GO:0060896 | neural plate pattern specification | 2 | 8 | 1.70e-01 |
| GO:BP | GO:0036250 | peroxisome transport along microtubule | 1 | 1 | 1.70e-01 |
| GO:BP | GO:0043585 | nose morphogenesis | 1 | 3 | 1.70e-01 |
| GO:BP | GO:0015911 | long-chain fatty acid import across plasma membrane | 3 | 9 | 1.73e-01 |
| GO:BP | GO:0061956 | penetration of cumulus oophorus | 1 | 1 | 1.73e-01 |
| GO:BP | GO:0140354 | lipid import into cell | 6 | 15 | 1.73e-01 |
| GO:BP | GO:0043534 | blood vessel endothelial cell migration | 9 | 97 | 1.73e-01 |
| GO:BP | GO:0034959 | endothelin maturation | 1 | 1 | 1.73e-01 |
| GO:BP | GO:0043535 | regulation of blood vessel endothelial cell migration | 8 | 75 | 1.73e-01 |
| GO:BP | GO:0010626 | negative regulation of Schwann cell proliferation | 1 | 6 | 1.73e-01 |
| GO:BP | GO:0070875 | positive regulation of glycogen metabolic process | 5 | 13 | 1.73e-01 |
| GO:BP | GO:0046824 | positive regulation of nucleocytoplasmic transport | 6 | 51 | 1.73e-01 |
| GO:BP | GO:0030335 | positive regulation of cell migration | 52 | 407 | 1.73e-01 |
| GO:BP | GO:0030512 | negative regulation of transforming growth factor beta receptor signaling pathway | 11 | 86 | 1.73e-01 |
| GO:BP | GO:0060606 | tube closure | 9 | 91 | 1.73e-01 |
| GO:BP | GO:0010624 | regulation of Schwann cell proliferation | 1 | 7 | 1.73e-01 |
| GO:BP | GO:0045725 | positive regulation of glycogen biosynthetic process | 5 | 12 | 1.73e-01 |
| GO:BP | GO:0007164 | establishment of tissue polarity | 13 | 70 | 1.73e-01 |
| GO:BP | GO:1904328 | regulation of myofibroblast contraction | 1 | 1 | 1.73e-01 |
| GO:BP | GO:1902747 | negative regulation of lens fiber cell differentiation | 3 | 5 | 1.73e-01 |
| GO:BP | GO:1990764 | myofibroblast contraction | 1 | 2 | 1.73e-01 |
| GO:BP | GO:2000147 | positive regulation of cell motility | 54 | 421 | 1.73e-01 |
| GO:BP | GO:0044721 | protein import into peroxisome matrix, substrate release | 1 | 2 | 1.73e-01 |
| GO:BP | GO:0014010 | Schwann cell proliferation | 1 | 7 | 1.73e-01 |
| GO:BP | GO:0016561 | protein import into peroxisome matrix, translocation | 1 | 3 | 1.73e-01 |
| GO:BP | GO:0001736 | establishment of planar polarity | 13 | 70 | 1.73e-01 |
| GO:BP | GO:0010816 | calcitonin catabolic process | 1 | 1 | 1.73e-01 |
| GO:BP | GO:0060034 | notochord cell differentiation | 1 | 1 | 1.73e-01 |
| GO:BP | GO:0060035 | notochord cell development | 1 | 1 | 1.73e-01 |
| GO:BP | GO:0106230 | protein depropionylation | 2 | 2 | 1.73e-01 |
| GO:BP | GO:0006481 | C-terminal protein methylation | 1 | 2 | 1.73e-01 |
| GO:BP | GO:0001843 | neural tube closure | 9 | 90 | 1.73e-01 |
| GO:BP | GO:0046498 | S-adenosylhomocysteine metabolic process | 1 | 2 | 1.73e-01 |
| GO:BP | GO:1902743 | regulation of lamellipodium organization | 2 | 44 | 1.73e-01 |
| GO:BP | GO:0035924 | cellular response to vascular endothelial growth factor stimulus | 10 | 54 | 1.73e-01 |
| GO:BP | GO:0046015 | regulation of transcription by glucose | 2 | 6 | 1.73e-01 |
| GO:BP | GO:1900029 | positive regulation of ruffle assembly | 5 | 12 | 1.73e-01 |
| GO:BP | GO:0090125 | cell-cell adhesion involved in synapse maturation | 2 | 2 | 1.77e-01 |
| GO:BP | GO:1904716 | positive regulation of chaperone-mediated autophagy | 1 | 1 | 1.77e-01 |
| GO:BP | GO:1904875 | regulation of DNA ligase activity | 2 | 2 | 1.77e-01 |
| GO:BP | GO:1905696 | regulation of polysome binding | 2 | 2 | 1.77e-01 |
| GO:BP | GO:0006537 | glutamate biosynthetic process | 2 | 5 | 1.77e-01 |
| GO:BP | GO:0001738 | morphogenesis of a polarized epithelium | 15 | 88 | 1.77e-01 |
| GO:BP | GO:0005979 | regulation of glycogen biosynthetic process | 4 | 25 | 1.77e-01 |
| GO:BP | GO:0048646 | anatomical structure formation involved in morphogenesis | 20 | 870 | 1.77e-01 |
| GO:BP | GO:0001935 | endothelial cell proliferation | 6 | 116 | 1.77e-01 |
| GO:BP | GO:1901342 | regulation of vasculature development | 8 | 206 | 1.77e-01 |
| GO:BP | GO:0010641 | positive regulation of platelet-derived growth factor receptor signaling pathway | 3 | 4 | 1.77e-01 |
| GO:BP | GO:0010746 | regulation of long-chain fatty acid import across plasma membrane | 3 | 5 | 1.77e-01 |
| GO:BP | GO:0010748 | negative regulation of long-chain fatty acid import across plasma membrane | 2 | 4 | 1.77e-01 |
| GO:BP | GO:0010962 | regulation of glucan biosynthetic process | 4 | 25 | 1.77e-01 |
| GO:BP | GO:0045765 | regulation of angiogenesis | 8 | 203 | 1.77e-01 |
| GO:BP | GO:0014020 | primary neural tube formation | 9 | 94 | 1.77e-01 |
| GO:BP | GO:0014028 | notochord formation | 1 | 3 | 1.77e-01 |
| GO:BP | GO:0014878 | response to electrical stimulus involved in regulation of muscle adaptation | 2 | 2 | 1.77e-01 |
| GO:BP | GO:0140213 | negative regulation of long-chain fatty acid import into cell | 2 | 4 | 1.77e-01 |
| GO:BP | GO:0016560 | protein import into peroxisome matrix, docking | 1 | 3 | 1.77e-01 |
| GO:BP | GO:0110009 | formin-nucleated actin cable organization | 2 | 3 | 1.77e-01 |
| GO:BP | GO:0018107 | peptidyl-threonine phosphorylation | 11 | 97 | 1.77e-01 |
| GO:BP | GO:1904018 | positive regulation of vasculature development | 6 | 115 | 1.77e-01 |
| GO:BP | GO:0045766 | positive regulation of angiogenesis | 6 | 115 | 1.77e-01 |
| GO:BP | GO:0021501 | prechordal plate formation | 1 | 1 | 1.77e-01 |
| GO:BP | GO:0021541 | ammon gyrus development | 1 | 1 | 1.77e-01 |
| GO:BP | GO:0021547 | midbrain-hindbrain boundary initiation | 1 | 1 | 1.77e-01 |
| GO:BP | GO:0046705 | CDP biosynthetic process | 1 | 1 | 1.77e-01 |
| GO:BP | GO:0046704 | CDP metabolic process | 1 | 1 | 1.77e-01 |
| GO:BP | GO:1903301 | positive regulation of hexokinase activity | 2 | 5 | 1.77e-01 |
| GO:BP | GO:1901491 | negative regulation of lymphangiogenesis | 1 | 3 | 1.77e-01 |
| GO:BP | GO:0002066 | columnar/cuboidal epithelial cell development | 10 | 38 | 1.77e-01 |
| GO:BP | GO:0007529 | establishment of synaptic specificity at neuromuscular junction | 2 | 2 | 1.77e-01 |
| GO:BP | GO:0007265 | Ras protein signal transduction | 22 | 294 | 1.77e-01 |
| GO:BP | GO:0007264 | small GTPase mediated signal transduction | 51 | 421 | 1.77e-01 |
| GO:BP | GO:2000463 | positive regulation of excitatory postsynaptic potential | 7 | 28 | 1.77e-01 |
| GO:BP | GO:0043584 | nose development | 1 | 10 | 1.77e-01 |
| GO:BP | GO:0050893 | sensory processing | 2 | 4 | 1.77e-01 |
| GO:BP | GO:0097581 | lamellipodium organization | 2 | 78 | 1.77e-01 |
| GO:BP | GO:0002088 | lens development in camera-type eye | 2 | 57 | 1.77e-01 |
| GO:BP | GO:0036124 | histone H3-K9 trimethylation | 2 | 9 | 1.77e-01 |
| GO:BP | GO:0036293 | response to decreased oxygen levels | 15 | 249 | 1.77e-01 |
| GO:BP | GO:0048320 | axial mesoderm formation | 2 | 2 | 1.77e-01 |
| GO:BP | GO:0048319 | axial mesoderm morphogenesis | 1 | 3 | 1.77e-01 |
| GO:BP | GO:0070649 | formin-nucleated actin cable assembly | 2 | 3 | 1.77e-01 |
| GO:BP | GO:0070482 | response to oxygen levels | 16 | 272 | 1.77e-01 |
| GO:BP | GO:0061041 | regulation of wound healing | 7 | 95 | 1.77e-01 |
| GO:BP | GO:0035295 | tube development | 49 | 821 | 1.77e-01 |
| GO:BP | GO:0040017 | positive regulation of locomotion | 54 | 429 | 1.77e-01 |
| GO:BP | GO:0060838 | lymphatic endothelial cell fate commitment | 1 | 3 | 1.77e-01 |
| GO:BP | GO:0060253 | negative regulation of glial cell proliferation | 1 | 13 | 1.77e-01 |
| GO:BP | GO:0032926 | negative regulation of activin receptor signaling pathway | 1 | 9 | 1.77e-01 |
| GO:BP | GO:0002009 | morphogenesis of an epithelium | 4 | 418 | 1.82e-01 |
| GO:BP | GO:0001936 | regulation of endothelial cell proliferation | 9 | 102 | 1.82e-01 |
| GO:BP | GO:0010814 | substance P catabolic process | 1 | 3 | 1.82e-01 |
| GO:BP | GO:0042543 | protein N-linked glycosylation via arginine | 1 | 1 | 1.85e-01 |
| GO:BP | GO:0014044 | Schwann cell development | 1 | 28 | 1.85e-01 |
| GO:BP | GO:0060251 | regulation of glial cell proliferation | 1 | 26 | 1.85e-01 |
| GO:BP | GO:0070183 | mitochondrial tryptophanyl-tRNA aminoacylation | 1 | 1 | 1.85e-01 |
| GO:BP | GO:0014037 | Schwann cell differentiation | 1 | 34 | 1.85e-01 |
| GO:BP | GO:0048592 | eye morphogenesis | 2 | 113 | 1.85e-01 |
| GO:BP | GO:0035740 | CD8-positive, alpha-beta T cell proliferation | 2 | 7 | 1.85e-01 |
| GO:BP | GO:0048593 | camera-type eye morphogenesis | 2 | 91 | 1.85e-01 |
| GO:BP | GO:2001186 | negative regulation of CD8-positive, alpha-beta T cell activation | 3 | 6 | 1.85e-01 |
| GO:BP | GO:0048598 | embryonic morphogenesis | 4 | 440 | 1.85e-01 |
| GO:BP | GO:2001185 | regulation of CD8-positive, alpha-beta T cell activation | 5 | 13 | 1.85e-01 |
| GO:BP | GO:0061136 | regulation of proteasomal protein catabolic process | 21 | 183 | 1.85e-01 |
| GO:BP | GO:0010907 | positive regulation of glucose metabolic process | 7 | 36 | 1.85e-01 |
| GO:BP | GO:1900242 | regulation of synaptic vesicle endocytosis | 5 | 16 | 1.85e-01 |
| GO:BP | GO:0032925 | regulation of activin receptor signaling pathway | 1 | 20 | 1.85e-01 |
| GO:BP | GO:0022011 | myelination in peripheral nervous system | 1 | 25 | 1.85e-01 |
| GO:BP | GO:0021856 | hypothalamic tangential migration using cell-axon interactions | 3 | 6 | 1.85e-01 |
| GO:BP | GO:2000145 | regulation of cell motility | 44 | 742 | 1.85e-01 |
| GO:BP | GO:0021855 | hypothalamus cell migration | 3 | 6 | 1.85e-01 |
| GO:BP | GO:0021828 | gonadotrophin-releasing hormone neuronal migration to the hypothalamus | 3 | 6 | 1.85e-01 |
| GO:BP | GO:0021772 | olfactory bulb development | 1 | 19 | 1.85e-01 |
| GO:BP | GO:0098815 | modulation of excitatory postsynaptic potential | 8 | 40 | 1.85e-01 |
| GO:BP | GO:0035113 | embryonic appendage morphogenesis | 2 | 89 | 1.85e-01 |
| GO:BP | GO:0098971 | anterograde dendritic transport of neurotransmitter receptor complex | 1 | 5 | 1.85e-01 |
| GO:BP | GO:0098696 | regulation of neurotransmitter receptor localization to postsynaptic specialization membrane | 4 | 11 | 1.85e-01 |
| GO:BP | GO:0051347 | positive regulation of transferase activity | 51 | 400 | 1.85e-01 |
| GO:BP | GO:0060323 | head morphogenesis | 2 | 33 | 1.85e-01 |
| GO:BP | GO:0018410 | C-terminal protein amino acid modification | 1 | 10 | 1.85e-01 |
| GO:BP | GO:0018210 | peptidyl-threonine modification | 11 | 104 | 1.85e-01 |
| GO:BP | GO:0061870 | positive regulation of hepatic stellate cell migration | 2 | 2 | 1.85e-01 |
| GO:BP | GO:0061869 | regulation of hepatic stellate cell migration | 2 | 2 | 1.85e-01 |
| GO:BP | GO:0061868 | hepatic stellate cell migration | 2 | 2 | 1.85e-01 |
| GO:BP | GO:0035330 | regulation of hippo signaling | 6 | 21 | 1.85e-01 |
| GO:BP | GO:0021988 | olfactory lobe development | 1 | 21 | 1.85e-01 |
| GO:BP | GO:0016358 | dendrite development | 14 | 202 | 1.85e-01 |
| GO:BP | GO:0035332 | positive regulation of hippo signaling | 2 | 6 | 1.85e-01 |
| GO:BP | GO:0099625 | ventricular cardiac muscle cell membrane repolarization | 3 | 21 | 1.85e-01 |
| GO:BP | GO:0140212 | regulation of long-chain fatty acid import into cell | 3 | 7 | 1.85e-01 |
| GO:BP | GO:0060325 | face morphogenesis | 1 | 28 | 1.85e-01 |
| GO:BP | GO:0035970 | peptidyl-threonine dephosphorylation | 5 | 17 | 1.85e-01 |
| GO:BP | GO:0007422 | peripheral nervous system development | 3 | 67 | 1.85e-01 |
| GO:BP | GO:2000480 | negative regulation of cAMP-dependent protein kinase activity | 4 | 10 | 1.85e-01 |
| GO:BP | GO:0007289 | spermatid nucleus differentiation | 2 | 16 | 1.85e-01 |
| GO:BP | GO:0039695 | DNA-templated viral transcription | 1 | 1 | 1.85e-01 |
| GO:BP | GO:1903893 | positive regulation of ATF6-mediated unfolded protein response | 1 | 1 | 1.85e-01 |
| GO:BP | GO:1904238 | pericyte cell differentiation | 2 | 8 | 1.85e-01 |
| GO:BP | GO:0000054 | ribosomal subunit export from nucleus | 4 | 15 | 1.85e-01 |
| GO:BP | GO:0003100 | regulation of systemic arterial blood pressure by endothelin | 1 | 5 | 1.85e-01 |
| GO:BP | GO:0060575 | intestinal epithelial cell differentiation | 6 | 17 | 1.85e-01 |
| GO:BP | GO:0007423 | sensory organ development | 4 | 396 | 1.85e-01 |
| GO:BP | GO:1905651 | regulation of artery morphogenesis | 2 | 5 | 1.85e-01 |
| GO:BP | GO:0042149 | cellular response to glucose starvation | 2 | 51 | 1.85e-01 |
| GO:BP | GO:1905698 | positive regulation of polysome binding | 1 | 1 | 1.85e-01 |
| GO:BP | GO:0042176 | regulation of protein catabolic process | 38 | 331 | 1.85e-01 |
| GO:BP | GO:0006266 | DNA ligation | 4 | 16 | 1.85e-01 |
| GO:BP | GO:0006231 | dTMP biosynthetic process | 2 | 4 | 1.85e-01 |
| GO:BP | GO:0046578 | regulation of Ras protein signal transduction | 23 | 166 | 1.85e-01 |
| GO:BP | GO:0048741 | skeletal muscle fiber development | 3 | 30 | 1.85e-01 |
| GO:BP | GO:0003363 | lamellipodium assembly involved in ameboidal cell migration | 1 | 1 | 1.85e-01 |
| GO:BP | GO:0048729 | tissue morphogenesis | 54 | 504 | 1.85e-01 |
| GO:BP | GO:1905653 | positive regulation of artery morphogenesis | 2 | 5 | 1.85e-01 |
| GO:BP | GO:1903421 | regulation of synaptic vesicle recycling | 6 | 23 | 1.85e-01 |
| GO:BP | GO:1903348 | positive regulation of bicellular tight junction assembly | 1 | 5 | 1.85e-01 |
| GO:BP | GO:0060836 | lymphatic endothelial cell differentiation | 1 | 5 | 1.85e-01 |
| GO:BP | GO:0010660 | regulation of muscle cell apoptotic process | 5 | 56 | 1.85e-01 |
| GO:BP | GO:0097492 | sympathetic neuron axon guidance | 1 | 4 | 1.85e-01 |
| GO:BP | GO:0010632 | regulation of epithelial cell migration | 22 | 195 | 1.85e-01 |
| GO:BP | GO:0010631 | epithelial cell migration | 27 | 252 | 1.85e-01 |
| GO:BP | GO:0000294 | nuclear-transcribed mRNA catabolic process, RNase MRP-dependent | 1 | 2 | 1.85e-01 |
| GO:BP | GO:0010594 | regulation of endothelial cell migration | 17 | 143 | 1.85e-01 |
| GO:BP | GO:0051094 | positive regulation of developmental process | 21 | 957 | 1.85e-01 |
| GO:BP | GO:1901490 | regulation of lymphangiogenesis | 1 | 5 | 1.85e-01 |
| GO:BP | GO:0010508 | positive regulation of autophagy | 6 | 133 | 1.85e-01 |
| GO:BP | GO:2000777 | positive regulation of proteasomal ubiquitin-dependent protein catabolic process involved in cellular response to hypoxia | 1 | 2 | 1.85e-01 |
| GO:BP | GO:2000744 | positive regulation of anterior head development | 1 | 2 | 1.85e-01 |
| GO:BP | GO:2000742 | regulation of anterior head development | 1 | 2 | 1.85e-01 |
| GO:BP | GO:1902285 | semaphorin-plexin signaling pathway involved in neuron projection guidance | 4 | 16 | 1.85e-01 |
| GO:BP | GO:0036500 | ATF6-mediated unfolded protein response | 2 | 9 | 1.85e-01 |
| GO:BP | GO:0009177 | pyrimidine deoxyribonucleoside monophosphate biosynthetic process | 2 | 4 | 1.85e-01 |
| GO:BP | GO:0048318 | axial mesoderm development | 1 | 6 | 1.85e-01 |
| GO:BP | GO:1902746 | regulation of lens fiber cell differentiation | 3 | 8 | 1.85e-01 |
| GO:BP | GO:2000564 | regulation of CD8-positive, alpha-beta T cell proliferation | 2 | 7 | 1.85e-01 |
| GO:BP | GO:0038084 | vascular endothelial growth factor signaling pathway | 8 | 35 | 1.85e-01 |
| GO:BP | GO:1903034 | regulation of response to wounding | 7 | 121 | 1.85e-01 |
| GO:BP | GO:0060839 | endothelial cell fate commitment | 1 | 7 | 1.85e-01 |
| GO:BP | GO:0010813 | neuropeptide catabolic process | 1 | 4 | 1.85e-01 |
| GO:BP | GO:0002042 | cell migration involved in sprouting angiogenesis | 5 | 45 | 1.85e-01 |
| GO:BP | GO:1900244 | positive regulation of synaptic vesicle endocytosis | 3 | 4 | 1.85e-01 |
| GO:BP | GO:0043433 | negative regulation of DNA-binding transcription factor activity | 3 | 138 | 1.85e-01 |
| GO:BP | GO:0043247 | telomere maintenance in response to DNA damage | 6 | 29 | 1.85e-01 |
| GO:BP | GO:0090596 | sensory organ morphogenesis | 3 | 178 | 1.85e-01 |
| GO:BP | GO:0070309 | lens fiber cell morphogenesis | 1 | 5 | 1.85e-01 |
| GO:BP | GO:0072014 | proximal tubule development | 2 | 7 | 1.85e-01 |
| GO:BP | GO:0034352 | positive regulation of glial cell apoptotic process | 2 | 2 | 1.85e-01 |
| GO:BP | GO:0032292 | peripheral nervous system axon ensheathment | 1 | 25 | 1.85e-01 |
| GO:BP | GO:0001938 | positive regulation of endothelial cell proliferation | 12 | 74 | 1.85e-01 |
| GO:BP | GO:0090132 | epithelium migration | 27 | 252 | 1.85e-01 |
| GO:BP | GO:0032874 | positive regulation of stress-activated MAPK cascade | 10 | 96 | 1.85e-01 |
| GO:BP | GO:0080135 | regulation of cellular response to stress | 35 | 616 | 1.85e-01 |
| GO:BP | GO:0048147 | negative regulation of fibroblast proliferation | 1 | 31 | 1.85e-01 |
| GO:BP | GO:0043549 | regulation of kinase activity | 65 | 560 | 1.85e-01 |
| GO:BP | GO:0001841 | neural tube formation | 9 | 101 | 1.85e-01 |
| GO:BP | GO:0090091 | positive regulation of extracellular matrix disassembly | 1 | 6 | 1.85e-01 |
| GO:BP | GO:0033750 | ribosome localization | 4 | 15 | 1.85e-01 |
| GO:BP | GO:0033674 | positive regulation of kinase activity | 43 | 317 | 1.85e-01 |
| GO:BP | GO:0090050 | positive regulation of cell migration involved in sprouting angiogenesis | 3 | 18 | 1.85e-01 |
| GO:BP | GO:0070873 | regulation of glycogen metabolic process | 4 | 28 | 1.85e-01 |
| GO:BP | GO:0090130 | tissue migration | 28 | 256 | 1.85e-01 |
| GO:BP | GO:0030334 | regulation of cell migration | 42 | 706 | 1.85e-01 |
| GO:BP | GO:0033189 | response to vitamin A | 5 | 12 | 1.85e-01 |
| GO:BP | GO:0033025 | regulation of mast cell apoptotic process | 2 | 3 | 1.85e-01 |
| GO:BP | GO:0030326 | embryonic limb morphogenesis | 2 | 89 | 1.85e-01 |
| GO:BP | GO:0033024 | mast cell apoptotic process | 2 | 3 | 1.85e-01 |
| GO:BP | GO:0032885 | regulation of polysaccharide biosynthetic process | 4 | 31 | 1.85e-01 |
| GO:BP | GO:0048264 | determination of ventral identity | 1 | 1 | 1.85e-01 |
| GO:BP | GO:0032924 | activin receptor signaling pathway | 1 | 34 | 1.85e-01 |
| GO:BP | GO:0010815 | bradykinin catabolic process | 1 | 6 | 1.85e-01 |
| GO:BP | GO:0048488 | synaptic vesicle endocytosis | 11 | 63 | 1.85e-01 |
| GO:BP | GO:0007113 | endomitotic cell cycle | 1 | 3 | 1.85e-01 |
| GO:BP | GO:0048010 | vascular endothelial growth factor receptor signaling pathway | 8 | 48 | 1.85e-01 |
| GO:BP | GO:2000392 | regulation of lamellipodium morphogenesis | 1 | 10 | 1.85e-01 |
| GO:BP | GO:0001516 | prostaglandin biosynthetic process | 1 | 19 | 1.85e-01 |
| GO:BP | GO:0016558 | protein import into peroxisome matrix | 1 | 14 | 1.85e-01 |
| GO:BP | GO:0089700 | protein kinase D signaling | 2 | 4 | 1.85e-01 |
| GO:BP | GO:2000479 | regulation of cAMP-dependent protein kinase activity | 5 | 16 | 1.85e-01 |
| GO:BP | GO:0032436 | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 12 | 89 | 1.85e-01 |
| GO:BP | GO:0060766 | negative regulation of androgen receptor signaling pathway | 2 | 12 | 1.85e-01 |
| GO:BP | GO:0014014 | negative regulation of gliogenesis | 1 | 26 | 1.85e-01 |
| GO:BP | GO:0032434 | regulation of proteasomal ubiquitin-dependent protein catabolic process | 16 | 133 | 1.85e-01 |
| GO:BP | GO:0043009 | chordate embryonic development | 4 | 534 | 1.85e-01 |
| GO:BP | GO:0014904 | myotube cell development | 3 | 34 | 1.85e-01 |
| GO:BP | GO:1990755 | mitotic spindle microtubule depolymerization | 1 | 1 | 1.85e-01 |
| GO:BP | GO:1900075 | positive regulation of neuromuscular synaptic transmission | 2 | 2 | 1.85e-01 |
| GO:BP | GO:2001222 | regulation of neuron migration | 5 | 38 | 1.85e-01 |
| GO:BP | GO:0099542 | trans-synaptic signaling by endocannabinoid | 3 | 6 | 1.85e-01 |
| GO:BP | GO:1900073 | regulation of neuromuscular synaptic transmission | 2 | 2 | 1.85e-01 |
| GO:BP | GO:0002040 | sprouting angiogenesis | 8 | 98 | 1.85e-01 |
| GO:BP | GO:1905515 | non-motile cilium assembly | 9 | 58 | 1.85e-01 |
| GO:BP | GO:1905786 | positive regulation of anaphase-promoting complex-dependent catabolic process | 1 | 2 | 1.85e-01 |
| GO:BP | GO:0070304 | positive regulation of stress-activated protein kinase signaling cascade | 10 | 98 | 1.85e-01 |
| GO:BP | GO:0060541 | respiratory system development | 2 | 163 | 1.85e-01 |
| GO:BP | GO:0001764 | neuron migration | 21 | 133 | 1.85e-01 |
| GO:BP | GO:0099541 | trans-synaptic signaling by lipid | 3 | 6 | 1.85e-01 |
| GO:BP | GO:0046457 | prostanoid biosynthetic process | 1 | 19 | 1.85e-01 |
| GO:BP | GO:0060562 | epithelial tube morphogenesis | 3 | 278 | 1.85e-01 |
| GO:BP | GO:0002543 | activation of blood coagulation via clotting cascade | 1 | 2 | 1.85e-01 |
| GO:BP | GO:0097324 | melanocyte migration | 2 | 3 | 1.85e-01 |
| GO:BP | GO:1901731 | positive regulation of platelet aggregation | 1 | 7 | 1.86e-01 |
| GO:BP | GO:0033023 | mast cell homeostasis | 2 | 4 | 1.86e-01 |
| GO:BP | GO:0045668 | negative regulation of osteoblast differentiation | 1 | 36 | 1.86e-01 |
| GO:BP | GO:0009896 | positive regulation of catabolic process | 8 | 464 | 1.86e-01 |
| GO:BP | GO:0097091 | synaptic vesicle clustering | 4 | 16 | 1.87e-01 |
| GO:BP | GO:2000588 | positive regulation of platelet-derived growth factor receptor-beta signaling pathway | 2 | 3 | 1.87e-01 |
| GO:BP | GO:0009130 | pyrimidine nucleoside monophosphate biosynthetic process | 3 | 13 | 1.87e-01 |
| GO:BP | GO:2000785 | regulation of autophagosome assembly | 3 | 44 | 1.87e-01 |
| GO:BP | GO:0036342 | post-anal tail morphogenesis | 3 | 13 | 1.87e-01 |
| GO:BP | GO:2000192 | negative regulation of fatty acid transport | 2 | 7 | 1.87e-01 |
| GO:BP | GO:0055118 | negative regulation of cardiac muscle contraction | 1 | 4 | 1.87e-01 |
| GO:BP | GO:0000012 | single strand break repair | 3 | 10 | 1.87e-01 |
| GO:BP | GO:0038061 | NIK/NF-kappaB signaling | 9 | 86 | 1.87e-01 |
| GO:BP | GO:1990748 | cellular detoxification | 3 | 76 | 1.87e-01 |
| GO:BP | GO:0031848 | protection from non-homologous end joining at telomere | 3 | 10 | 1.87e-01 |
| GO:BP | GO:2000625 | regulation of miRNA catabolic process | 1 | 5 | 1.87e-01 |
| GO:BP | GO:0051045 | negative regulation of membrane protein ectodomain proteolysis | 3 | 7 | 1.87e-01 |
| GO:BP | GO:0001649 | osteoblast differentiation | 2 | 179 | 1.87e-01 |
| GO:BP | GO:0043501 | skeletal muscle adaptation | 2 | 19 | 1.87e-01 |
| GO:BP | GO:0009948 | anterior/posterior axis specification | 1 | 32 | 1.87e-01 |
| GO:BP | GO:0009792 | embryo development ending in birth or egg hatching | 4 | 551 | 1.87e-01 |
| GO:BP | GO:0009952 | anterior/posterior pattern specification | 4 | 127 | 1.87e-01 |
| GO:BP | GO:1902001 | fatty acid transmembrane transport | 3 | 15 | 1.87e-01 |
| GO:BP | GO:0060038 | cardiac muscle cell proliferation | 1 | 44 | 1.87e-01 |
| GO:BP | GO:2000655 | negative regulation of cellular response to testosterone stimulus | 1 | 1 | 1.87e-01 |
| GO:BP | GO:0001838 | embryonic epithelial tube formation | 3 | 116 | 1.87e-01 |
| GO:BP | GO:1901753 | leukotriene A4 biosynthetic process | 1 | 1 | 1.87e-01 |
| GO:BP | GO:0006225 | UDP biosynthetic process | 1 | 4 | 1.87e-01 |
| GO:BP | GO:0032071 | regulation of endodeoxyribonuclease activity | 2 | 7 | 1.87e-01 |
| GO:BP | GO:0010171 | body morphogenesis | 2 | 45 | 1.87e-01 |
| GO:BP | GO:2000637 | positive regulation of miRNA-mediated gene silencing | 2 | 15 | 1.87e-01 |
| GO:BP | GO:0038033 | positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway | 2 | 5 | 1.87e-01 |
| GO:BP | GO:2000627 | positive regulation of miRNA catabolic process | 1 | 4 | 1.87e-01 |
| GO:BP | GO:0043508 | negative regulation of JUN kinase activity | 2 | 13 | 1.87e-01 |
| GO:BP | GO:0009194 | pyrimidine ribonucleoside diphosphate biosynthetic process | 1 | 4 | 1.87e-01 |
| GO:BP | GO:0006436 | tryptophanyl-tRNA aminoacylation | 1 | 2 | 1.87e-01 |
| GO:BP | GO:0001654 | eye development | 3 | 272 | 1.87e-01 |
| GO:BP | GO:0032881 | regulation of polysaccharide metabolic process | 4 | 34 | 1.87e-01 |
| GO:BP | GO:1904257 | zinc ion import into Golgi lumen | 1 | 3 | 1.87e-01 |
| GO:BP | GO:0040038 | polar body extrusion after meiotic divisions | 2 | 5 | 1.87e-01 |
| GO:BP | GO:0046128 | purine ribonucleoside metabolic process | 1 | 16 | 1.87e-01 |
| GO:BP | GO:1904636 | response to ionomycin | 1 | 3 | 1.87e-01 |
| GO:BP | GO:1904637 | cellular response to ionomycin | 1 | 3 | 1.87e-01 |
| GO:BP | GO:0071559 | response to transforming growth factor beta | 18 | 227 | 1.87e-01 |
| GO:BP | GO:0046328 | regulation of JNK cascade | 17 | 114 | 1.87e-01 |
| GO:BP | GO:0046330 | positive regulation of JNK cascade | 13 | 72 | 1.87e-01 |
| GO:BP | GO:0042273 | ribosomal large subunit biogenesis | 3 | 73 | 1.87e-01 |
| GO:BP | GO:0006693 | prostaglandin metabolic process | 1 | 32 | 1.87e-01 |
| GO:BP | GO:0006692 | prostanoid metabolic process | 1 | 32 | 1.87e-01 |
| GO:BP | GO:1905026 | positive regulation of membrane repolarization during ventricular cardiac muscle cell action potential | 1 | 2 | 1.87e-01 |
| GO:BP | GO:1905033 | positive regulation of membrane repolarization during cardiac muscle cell action potential | 1 | 2 | 1.87e-01 |
| GO:BP | GO:0006636 | unsaturated fatty acid biosynthetic process | 1 | 34 | 1.87e-01 |
| GO:BP | GO:0006625 | protein targeting to peroxisome | 1 | 19 | 1.87e-01 |
| GO:BP | GO:0006541 | glutamine metabolic process | 3 | 24 | 1.87e-01 |
| GO:BP | GO:0055017 | cardiac muscle tissue growth | 1 | 65 | 1.87e-01 |
| GO:BP | GO:0006530 | asparagine catabolic process | 1 | 1 | 1.87e-01 |
| GO:BP | GO:0046456 | icosanoid biosynthetic process | 3 | 29 | 1.87e-01 |
| GO:BP | GO:0042137 | sequestering of neurotransmitter | 1 | 1 | 1.87e-01 |
| GO:BP | GO:0043388 | positive regulation of DNA binding | 1 | 44 | 1.87e-01 |
| GO:BP | GO:0007084 | mitotic nuclear membrane reassembly | 2 | 9 | 1.87e-01 |
| GO:BP | GO:0042278 | purine nucleoside metabolic process | 1 | 20 | 1.87e-01 |
| GO:BP | GO:1904016 | response to Thyroglobulin triiodothyronine | 1 | 4 | 1.87e-01 |
| GO:BP | GO:0009065 | glutamine family amino acid catabolic process | 3 | 20 | 1.87e-01 |
| GO:BP | GO:1903003 | positive regulation of protein deubiquitination | 1 | 6 | 1.87e-01 |
| GO:BP | GO:0072663 | establishment of protein localization to peroxisome | 1 | 19 | 1.87e-01 |
| GO:BP | GO:1903299 | regulation of hexokinase activity | 2 | 8 | 1.87e-01 |
| GO:BP | GO:0072662 | protein localization to peroxisome | 1 | 19 | 1.87e-01 |
| GO:BP | GO:0007599 | hemostasis | 6 | 153 | 1.87e-01 |
| GO:BP | GO:1905784 | regulation of anaphase-promoting complex-dependent catabolic process | 1 | 4 | 1.87e-01 |
| GO:BP | GO:0001666 | response to hypoxia | 13 | 237 | 1.87e-01 |
| GO:BP | GO:0072175 | epithelial tube formation | 3 | 127 | 1.87e-01 |
| GO:BP | GO:0007341 | penetration of zona pellucida | 1 | 4 | 1.87e-01 |
| GO:BP | GO:0072673 | lamellipodium morphogenesis | 1 | 17 | 1.87e-01 |
| GO:BP | GO:0050820 | positive regulation of coagulation | 2 | 23 | 1.87e-01 |
| GO:BP | GO:0038134 | ERBB2-EGFR signaling pathway | 3 | 6 | 1.87e-01 |
| GO:BP | GO:0042307 | positive regulation of protein import into nucleus | 4 | 32 | 1.87e-01 |
| GO:BP | GO:0007254 | JNK cascade | 20 | 138 | 1.87e-01 |
| GO:BP | GO:1903762 | positive regulation of voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization | 1 | 2 | 1.87e-01 |
| GO:BP | GO:0040012 | regulation of locomotion | 45 | 763 | 1.87e-01 |
| GO:BP | GO:0007179 | transforming growth factor beta receptor signaling pathway | 15 | 179 | 1.87e-01 |
| GO:BP | GO:0050817 | coagulation | 6 | 153 | 1.87e-01 |
| GO:BP | GO:0006303 | double-strand break repair via nonhomologous end joining | 8 | 61 | 1.87e-01 |
| GO:BP | GO:1903935 | response to sodium arsenite | 1 | 6 | 1.87e-01 |
| GO:BP | GO:1903936 | cellular response to sodium arsenite | 1 | 5 | 1.87e-01 |
| GO:BP | GO:0072148 | epithelial cell fate commitment | 1 | 9 | 1.87e-01 |
| GO:BP | GO:0007596 | blood coagulation | 6 | 150 | 1.87e-01 |
| GO:BP | GO:0030194 | positive regulation of blood coagulation | 2 | 21 | 1.87e-01 |
| GO:BP | GO:2001311 | lysobisphosphatidic acid metabolic process | 1 | 2 | 1.87e-01 |
| GO:BP | GO:0019321 | pentose metabolic process | 3 | 9 | 1.87e-01 |
| GO:BP | GO:0019086 | late viral transcription | 2 | 4 | 1.87e-01 |
| GO:BP | GO:0061872 | hepatic stellate cell contraction | 1 | 1 | 1.87e-01 |
| GO:BP | GO:0090331 | negative regulation of platelet aggregation | 2 | 11 | 1.87e-01 |
| GO:BP | GO:0101024 | mitotic nuclear membrane organization | 2 | 9 | 1.87e-01 |
| GO:BP | GO:0051295 | establishment of meiotic spindle localization | 2 | 4 | 1.87e-01 |
| GO:BP | GO:0090330 | regulation of platelet aggregation | 3 | 21 | 1.87e-01 |
| GO:BP | GO:0048011 | neurotrophin TRK receptor signaling pathway | 5 | 23 | 1.87e-01 |
| GO:BP | GO:0035331 | negative regulation of hippo signaling | 4 | 12 | 1.87e-01 |
| GO:BP | GO:0016242 | negative regulation of macroautophagy | 4 | 34 | 1.87e-01 |
| GO:BP | GO:0120158 | positive regulation of collagen catabolic process | 1 | 1 | 1.87e-01 |
| GO:BP | GO:0033326 | cerebrospinal fluid secretion | 1 | 3 | 1.87e-01 |
| GO:BP | GO:0051222 | positive regulation of protein transport | 13 | 242 | 1.87e-01 |
| GO:BP | GO:0045186 | zonula adherens assembly | 1 | 1 | 1.87e-01 |
| GO:BP | GO:0060148 | positive regulation of post-transcriptional gene silencing | 2 | 16 | 1.87e-01 |
| GO:BP | GO:0070555 | response to interleukin-1 | 3 | 83 | 1.87e-01 |
| GO:BP | GO:0140238 | presynaptic endocytosis | 11 | 65 | 1.87e-01 |
| GO:BP | GO:0015919 | peroxisomal membrane transport | 1 | 20 | 1.87e-01 |
| GO:BP | GO:0060324 | face development | 1 | 45 | 1.87e-01 |
| GO:BP | GO:0015789 | UDP-N-acetylgalactosamine transmembrane transport | 1 | 4 | 1.87e-01 |
| GO:BP | GO:0015787 | UDP-glucuronic acid transmembrane transport | 1 | 4 | 1.87e-01 |
| GO:BP | GO:0099123 | somato-dendritic dopamine secretion | 1 | 1 | 1.87e-01 |
| GO:BP | GO:0150063 | visual system development | 3 | 273 | 1.87e-01 |
| GO:BP | GO:0061873 | regulation of hepatic stellate cell contraction | 1 | 1 | 1.87e-01 |
| GO:BP | GO:0044773 | mitotic DNA damage checkpoint signaling | 12 | 81 | 1.87e-01 |
| GO:BP | GO:0044088 | regulation of vacuole organization | 3 | 50 | 1.87e-01 |
| GO:BP | GO:0022614 | membrane to membrane docking | 2 | 5 | 1.87e-01 |
| GO:BP | GO:0002064 | epithelial cell development | 17 | 156 | 1.87e-01 |
| GO:BP | GO:0097119 | postsynaptic density protein 95 clustering | 3 | 7 | 1.87e-01 |
| GO:BP | GO:0022030 | telencephalon glial cell migration | 2 | 22 | 1.87e-01 |
| GO:BP | GO:0034983 | peptidyl-lysine deacetylation | 2 | 8 | 1.87e-01 |
| GO:BP | GO:0021888 | hypothalamus gonadotrophin-releasing hormone neuron development | 3 | 7 | 1.87e-01 |
| GO:BP | GO:0021886 | hypothalamus gonadotrophin-releasing hormone neuron differentiation | 3 | 7 | 1.87e-01 |
| GO:BP | GO:0035019 | somatic stem cell population maintenance | 1 | 50 | 1.87e-01 |
| GO:BP | GO:0035107 | appendage morphogenesis | 2 | 114 | 1.87e-01 |
| GO:BP | GO:0043010 | camera-type eye development | 3 | 236 | 1.87e-01 |
| GO:BP | GO:0048535 | lymph node development | 1 | 11 | 1.87e-01 |
| GO:BP | GO:0021801 | cerebral cortex radial glia-guided migration | 2 | 22 | 1.87e-01 |
| GO:BP | GO:0098708 | glucose import across plasma membrane | 1 | 5 | 1.87e-01 |
| GO:BP | GO:0070307 | lens fiber cell development | 1 | 11 | 1.87e-01 |
| GO:BP | GO:0035108 | limb morphogenesis | 2 | 114 | 1.87e-01 |
| GO:BP | GO:0030514 | negative regulation of BMP signaling pathway | 1 | 45 | 1.87e-01 |
| GO:BP | GO:0000720 | pyrimidine dimer repair by nucleotide-excision repair | 2 | 4 | 1.87e-01 |
| GO:BP | GO:0098935 | dendritic transport | 1 | 13 | 1.87e-01 |
| GO:BP | GO:0098937 | anterograde dendritic transport | 1 | 9 | 1.87e-01 |
| GO:BP | GO:0021517 | ventral spinal cord development | 2 | 25 | 1.87e-01 |
| GO:BP | GO:0061874 | positive regulation of hepatic stellate cell contraction | 1 | 1 | 1.87e-01 |
| GO:BP | GO:0014855 | striated muscle cell proliferation | 1 | 57 | 1.87e-01 |
| GO:BP | GO:0060429 | epithelium development | 5 | 850 | 1.87e-01 |
| GO:BP | GO:0001921 | positive regulation of receptor recycling | 1 | 11 | 1.87e-01 |
| GO:BP | GO:0010715 | regulation of extracellular matrix disassembly | 1 | 11 | 1.87e-01 |
| GO:BP | GO:0034112 | positive regulation of homotypic cell-cell adhesion | 1 | 10 | 1.87e-01 |
| GO:BP | GO:0010970 | transport along microtubule | 2 | 162 | 1.87e-01 |
| GO:BP | GO:0002552 | serotonin secretion by mast cell | 1 | 1 | 1.87e-01 |
| GO:BP | GO:0010657 | muscle cell apoptotic process | 5 | 60 | 1.87e-01 |
| GO:BP | GO:0002540 | leukotriene production involved in inflammatory response | 2 | 2 | 1.87e-01 |
| GO:BP | GO:0010801 | negative regulation of peptidyl-threonine phosphorylation | 4 | 15 | 1.87e-01 |
| GO:BP | GO:0042447 | hormone catabolic process | 1 | 7 | 1.87e-01 |
| GO:BP | GO:0014009 | glial cell proliferation | 1 | 40 | 1.87e-01 |
| GO:BP | GO:0045598 | regulation of fat cell differentiation | 8 | 102 | 1.87e-01 |
| GO:BP | GO:0043574 | peroxisomal transport | 1 | 22 | 1.87e-01 |
| GO:BP | GO:0002541 | activation of plasma proteins involved in acute inflammatory response | 1 | 2 | 1.87e-01 |
| GO:BP | GO:0048146 | positive regulation of fibroblast proliferation | 8 | 45 | 1.87e-01 |
| GO:BP | GO:0060385 | axonogenesis involved in innervation | 1 | 7 | 1.87e-01 |
| GO:BP | GO:1900370 | positive regulation of post-transcriptional gene silencing by RNA | 2 | 16 | 1.87e-01 |
| GO:BP | GO:0033345 | asparagine catabolic process via L-aspartate | 1 | 1 | 1.87e-01 |
| GO:BP | GO:0051098 | regulation of binding | 2 | 317 | 1.87e-01 |
| GO:BP | GO:0010763 | positive regulation of fibroblast migration | 4 | 15 | 1.87e-01 |
| GO:BP | GO:0002538 | arachidonic acid metabolite production involved in inflammatory response | 2 | 2 | 1.87e-01 |
| GO:BP | GO:0048570 | notochord morphogenesis | 1 | 9 | 1.87e-01 |
| GO:BP | GO:1900048 | positive regulation of hemostasis | 2 | 21 | 1.87e-01 |
| GO:BP | GO:0045444 | fat cell differentiation | 12 | 187 | 1.87e-01 |
| GO:BP | GO:0014732 | skeletal muscle atrophy | 1 | 5 | 1.87e-01 |
| GO:BP | GO:1903423 | positive regulation of synaptic vesicle recycling | 3 | 6 | 1.88e-01 |
| GO:BP | GO:0001667 | ameboidal-type cell migration | 34 | 358 | 1.88e-01 |
| GO:BP | GO:0021816 | extension of a leading process involved in cell motility in cerebral cortex radial glia guided migration | 1 | 2 | 1.88e-01 |
| GO:BP | GO:0048104 | establishment of body hair or bristle planar orientation | 2 | 3 | 1.88e-01 |
| GO:BP | GO:0048105 | establishment of body hair planar orientation | 2 | 3 | 1.88e-01 |
| GO:BP | GO:0030705 | cytoskeleton-dependent intracellular transport | 2 | 194 | 1.88e-01 |
| GO:BP | GO:0048880 | sensory system development | 3 | 275 | 1.88e-01 |
| GO:BP | GO:0010640 | regulation of platelet-derived growth factor receptor signaling pathway | 5 | 19 | 1.88e-01 |
| GO:BP | GO:0014891 | striated muscle atrophy | 1 | 6 | 1.89e-01 |
| GO:BP | GO:0014031 | mesenchymal cell development | 1 | 6 | 1.89e-01 |
| GO:BP | GO:0034453 | microtubule anchoring | 1 | 25 | 1.89e-01 |
| GO:BP | GO:0033138 | positive regulation of peptidyl-serine phosphorylation | 7 | 70 | 1.91e-01 |
| GO:BP | GO:0055093 | response to hyperoxia | 1 | 18 | 1.91e-01 |
| GO:BP | GO:0045654 | positive regulation of megakaryocyte differentiation | 1 | 9 | 1.91e-01 |
| GO:BP | GO:0097112 | gamma-aminobutyric acid receptor clustering | 2 | 3 | 1.91e-01 |
| GO:BP | GO:0097237 | cellular response to toxic substance | 3 | 82 | 1.91e-01 |
| GO:BP | GO:0035148 | tube formation | 3 | 138 | 1.91e-01 |
| GO:BP | GO:0098704 | carbohydrate import across plasma membrane | 1 | 5 | 1.91e-01 |
| GO:BP | GO:0060419 | heart growth | 1 | 72 | 1.91e-01 |
| GO:BP | GO:1903050 | regulation of proteolysis involved in protein catabolic process | 25 | 214 | 1.91e-01 |
| GO:BP | GO:0090287 | regulation of cellular response to growth factor stimulus | 20 | 265 | 1.91e-01 |
| GO:BP | GO:0099111 | microtubule-based transport | 2 | 191 | 1.91e-01 |
| GO:BP | GO:0140271 | hexose import across plasma membrane | 1 | 5 | 1.91e-01 |
| GO:BP | GO:0090316 | positive regulation of intracellular protein transport | 8 | 133 | 1.91e-01 |
| GO:BP | GO:0016331 | morphogenesis of embryonic epithelium | 3 | 132 | 1.93e-01 |
| GO:BP | GO:0060395 | SMAD protein signal transduction | 1 | 65 | 1.95e-01 |
| GO:BP | GO:0048388 | endosomal lumen acidification | 2 | 13 | 1.95e-01 |
| GO:BP | GO:0051639 | actin filament network formation | 3 | 7 | 1.97e-01 |
| GO:BP | GO:0043542 | endothelial cell migration | 16 | 182 | 1.97e-01 |
| GO:BP | GO:0022603 | regulation of anatomical structure morphogenesis | 71 | 691 | 1.98e-01 |
| GO:BP | GO:2000810 | regulation of bicellular tight junction assembly | 1 | 15 | 1.98e-01 |
| GO:BP | GO:0036294 | cellular response to decreased oxygen levels | 8 | 131 | 1.98e-01 |
| GO:BP | GO:0009119 | ribonucleoside metabolic process | 1 | 23 | 1.98e-01 |
| GO:BP | GO:1900087 | positive regulation of G1/S transition of mitotic cell cycle | 7 | 42 | 1.98e-01 |
| GO:BP | GO:0048145 | regulation of fibroblast proliferation | 1 | 77 | 1.98e-01 |
| GO:BP | GO:0044774 | mitotic DNA integrity checkpoint signaling | 12 | 85 | 1.98e-01 |
| GO:BP | GO:0051567 | histone H3-K9 methylation | 2 | 18 | 1.98e-01 |
| GO:BP | GO:1901524 | regulation of mitophagy | 2 | 13 | 1.98e-01 |
| GO:BP | GO:0048736 | appendage development | 2 | 142 | 1.98e-01 |
| GO:BP | GO:0002043 | blood vessel endothelial cell proliferation involved in sprouting angiogenesis | 2 | 15 | 1.98e-01 |
| GO:BP | GO:0045600 | positive regulation of fat cell differentiation | 5 | 50 | 1.98e-01 |
| GO:BP | GO:1902287 | semaphorin-plexin signaling pathway involved in axon guidance | 1 | 14 | 1.98e-01 |
| GO:BP | GO:0060173 | limb development | 2 | 142 | 1.98e-01 |
| GO:BP | GO:0070668 | positive regulation of mast cell proliferation | 2 | 4 | 1.98e-01 |
| GO:BP | GO:0090179 | planar cell polarity pathway involved in neural tube closure | 3 | 12 | 1.99e-01 |
| GO:BP | GO:0060021 | roof of mouth development | 1 | 71 | 1.99e-01 |
| GO:BP | GO:0009250 | glucan biosynthetic process | 4 | 39 | 1.99e-01 |
| GO:BP | GO:0071479 | cellular response to ionizing radiation | 5 | 68 | 1.99e-01 |
| GO:BP | GO:0005978 | glycogen biosynthetic process | 4 | 39 | 1.99e-01 |
| GO:BP | GO:1902151 | regulation of response to DNA integrity checkpoint signaling | 1 | 1 | 1.99e-01 |
| GO:BP | GO:1902153 | regulation of response to DNA damage checkpoint signaling | 1 | 1 | 1.99e-01 |
| GO:BP | GO:1902145 | regulation of response to cell cycle checkpoint signaling | 1 | 1 | 1.99e-01 |
| GO:BP | GO:0035526 | retrograde transport, plasma membrane to Golgi | 1 | 2 | 2.00e-01 |
| GO:BP | GO:1902268 | negative regulation of polyamine transmembrane transport | 1 | 3 | 2.00e-01 |
| GO:BP | GO:0030903 | notochord development | 1 | 17 | 2.00e-01 |
| GO:BP | GO:1904951 | positive regulation of establishment of protein localization | 13 | 258 | 2.00e-01 |
| GO:BP | GO:0031269 | pseudopodium assembly | 2 | 14 | 2.00e-01 |
| GO:BP | GO:0034110 | regulation of homotypic cell-cell adhesion | 3 | 26 | 2.00e-01 |
| GO:BP | GO:0060534 | trachea cartilage development | 2 | 4 | 2.00e-01 |
| GO:BP | GO:0006207 | ‘de novo’ pyrimidine nucleobase biosynthetic process | 1 | 6 | 2.01e-01 |
| GO:BP | GO:1904999 | positive regulation of leukocyte adhesion to arterial endothelial cell | 1 | 1 | 2.01e-01 |
| GO:BP | GO:0042060 | wound healing | 10 | 320 | 2.01e-01 |
| GO:BP | GO:0099622 | cardiac muscle cell membrane repolarization | 3 | 31 | 2.01e-01 |
| GO:BP | GO:0099553 | trans-synaptic signaling by endocannabinoid, modulating synaptic transmission | 2 | 2 | 2.01e-01 |
| GO:BP | GO:0099552 | trans-synaptic signaling by lipid, modulating synaptic transmission | 2 | 2 | 2.01e-01 |
| GO:BP | GO:0044828 | negative regulation by host of viral genome replication | 1 | 7 | 2.01e-01 |
| GO:BP | GO:0060444 | branching involved in mammary gland duct morphogenesis | 1 | 20 | 2.01e-01 |
| GO:BP | GO:0071362 | cellular response to ether | 1 | 5 | 2.01e-01 |
| GO:BP | GO:0050890 | cognition | 22 | 227 | 2.01e-01 |
| GO:BP | GO:0032872 | regulation of stress-activated MAPK cascade | 12 | 154 | 2.01e-01 |
| GO:BP | GO:0072108 | positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis | 2 | 2 | 2.01e-01 |
| GO:BP | GO:0030193 | regulation of blood coagulation | 4 | 50 | 2.01e-01 |
| GO:BP | GO:0045932 | negative regulation of muscle contraction | 2 | 20 | 2.01e-01 |
| GO:BP | GO:0030382 | sperm mitochondrion organization | 1 | 3 | 2.01e-01 |
| GO:BP | GO:2000324 | positive regulation of glucocorticoid receptor signaling pathway | 1 | 1 | 2.01e-01 |
| GO:BP | GO:0031573 | mitotic intra-S DNA damage checkpoint signaling | 4 | 15 | 2.01e-01 |
| GO:BP | GO:0090178 | regulation of establishment of planar polarity involved in neural tube closure | 1 | 13 | 2.01e-01 |
| GO:BP | GO:0045988 | negative regulation of striated muscle contraction | 1 | 7 | 2.01e-01 |
| GO:BP | GO:0032682 | negative regulation of chemokine production | 1 | 12 | 2.01e-01 |
| GO:BP | GO:0050679 | positive regulation of epithelial cell proliferation | 10 | 155 | 2.01e-01 |
| GO:BP | GO:0038179 | neurotrophin signaling pathway | 6 | 35 | 2.01e-01 |
| GO:BP | GO:0046579 | positive regulation of Ras protein signal transduction | 9 | 45 | 2.01e-01 |
| GO:BP | GO:0014013 | regulation of gliogenesis | 1 | 68 | 2.01e-01 |
| GO:BP | GO:0000430 | regulation of transcription from RNA polymerase II promoter by glucose | 1 | 2 | 2.01e-01 |
| GO:BP | GO:0009798 | axis specification | 1 | 63 | 2.01e-01 |
| GO:BP | GO:1901751 | leukotriene A4 metabolic process | 1 | 2 | 2.01e-01 |
| GO:BP | GO:0016241 | regulation of macroautophagy | 10 | 151 | 2.01e-01 |
| GO:BP | GO:0000432 | positive regulation of transcription from RNA polymerase II promoter by glucose | 1 | 2 | 2.01e-01 |
| GO:BP | GO:0035444 | nickel cation transmembrane transport | 1 | 1 | 2.01e-01 |
| GO:BP | GO:0060349 | bone morphogenesis | 1 | 74 | 2.01e-01 |
| GO:BP | GO:0070252 | actin-mediated cell contraction | 5 | 89 | 2.01e-01 |
| GO:BP | GO:0015675 | nickel cation transport | 1 | 1 | 2.01e-01 |
| GO:BP | GO:0060574 | intestinal epithelial cell maturation | 2 | 3 | 2.01e-01 |
| GO:BP | GO:0015676 | vanadium ion transport | 1 | 1 | 2.01e-01 |
| GO:BP | GO:0015692 | lead ion transport | 1 | 1 | 2.01e-01 |
| GO:BP | GO:0140820 | cytosol to Golgi apparatus transport | 1 | 4 | 2.01e-01 |
| GO:BP | GO:0006282 | regulation of DNA repair | 18 | 198 | 2.01e-01 |
| GO:BP | GO:0009139 | pyrimidine nucleoside diphosphate biosynthetic process | 1 | 6 | 2.01e-01 |
| GO:BP | GO:0034111 | negative regulation of homotypic cell-cell adhesion | 2 | 13 | 2.01e-01 |
| GO:BP | GO:0010799 | regulation of peptidyl-threonine phosphorylation | 6 | 35 | 2.01e-01 |
| GO:BP | GO:0031393 | negative regulation of prostaglandin biosynthetic process | 1 | 2 | 2.01e-01 |
| GO:BP | GO:0033135 | regulation of peptidyl-serine phosphorylation | 8 | 100 | 2.01e-01 |
| GO:BP | GO:0046058 | cAMP metabolic process | 1 | 19 | 2.01e-01 |
| GO:BP | GO:0042595 | behavioral response to starvation | 1 | 1 | 2.01e-01 |
| GO:BP | GO:0071526 | semaphorin-plexin signaling pathway | 7 | 44 | 2.01e-01 |
| GO:BP | GO:0048144 | fibroblast proliferation | 1 | 92 | 2.01e-01 |
| GO:BP | GO:0006997 | nucleus organization | 3 | 126 | 2.01e-01 |
| GO:BP | GO:1905024 | regulation of membrane repolarization during ventricular cardiac muscle cell action potential | 1 | 2 | 2.01e-01 |
| GO:BP | GO:2000170 | positive regulation of peptidyl-cysteine S-nitrosylation | 1 | 3 | 2.01e-01 |
| GO:BP | GO:1901727 | positive regulation of histone deacetylase activity | 2 | 5 | 2.01e-01 |
| GO:BP | GO:0046822 | regulation of nucleocytoplasmic transport | 8 | 97 | 2.01e-01 |
| GO:BP | GO:0048568 | embryonic organ development | 3 | 316 | 2.01e-01 |
| GO:BP | GO:0045739 | positive regulation of DNA repair | 6 | 120 | 2.01e-01 |
| GO:BP | GO:1900046 | regulation of hemostasis | 4 | 50 | 2.01e-01 |
| GO:BP | GO:2000654 | regulation of cellular response to testosterone stimulus | 1 | 2 | 2.01e-01 |
| GO:BP | GO:0014889 | muscle atrophy | 1 | 9 | 2.01e-01 |
| GO:BP | GO:1903055 | positive regulation of extracellular matrix organization | 1 | 24 | 2.01e-01 |
| GO:BP | GO:0106004 | tRNA (guanine-N7)-methylation | 1 | 1 | 2.01e-01 |
| GO:BP | GO:0090288 | negative regulation of cellular response to growth factor stimulus | 1 | 81 | 2.01e-01 |
| GO:BP | GO:0031268 | pseudopodium organization | 2 | 14 | 2.01e-01 |
| GO:BP | GO:0030510 | regulation of BMP signaling pathway | 1 | 84 | 2.01e-01 |
| GO:BP | GO:0090166 | Golgi disassembly | 1 | 6 | 2.01e-01 |
| GO:BP | GO:0035358 | regulation of peroxisome proliferator activated receptor signaling pathway | 2 | 11 | 2.02e-01 |
| GO:BP | GO:1990569 | UDP-N-acetylglucosamine transmembrane transport | 1 | 6 | 2.02e-01 |
| GO:BP | GO:0061045 | negative regulation of wound healing | 4 | 51 | 2.02e-01 |
| GO:BP | GO:0050434 | positive regulation of viral transcription | 1 | 3 | 2.02e-01 |
| GO:BP | GO:0009221 | pyrimidine deoxyribonucleotide biosynthetic process | 2 | 7 | 2.02e-01 |
| GO:BP | GO:0061029 | eyelid development in camera-type eye | 1 | 12 | 2.02e-01 |
| GO:BP | GO:0009084 | glutamine family amino acid biosynthetic process | 3 | 16 | 2.02e-01 |
| GO:BP | GO:0060071 | Wnt signaling pathway, planar cell polarity pathway | 5 | 51 | 2.02e-01 |
| GO:BP | GO:0070837 | dehydroascorbic acid transport | 1 | 6 | 2.02e-01 |
| GO:BP | GO:2000565 | negative regulation of CD8-positive, alpha-beta T cell proliferation | 1 | 2 | 2.02e-01 |
| GO:BP | GO:0033026 | negative regulation of mast cell apoptotic process | 1 | 1 | 2.02e-01 |
| GO:BP | GO:0018916 | nitrobenzene metabolic process | 1 | 4 | 2.02e-01 |
| GO:BP | GO:1904973 | positive regulation of viral translation | 1 | 3 | 2.02e-01 |
| GO:BP | GO:1904971 | regulation of viral translation | 1 | 3 | 2.02e-01 |
| GO:BP | GO:0036296 | response to increased oxygen levels | 1 | 25 | 2.02e-01 |
| GO:BP | GO:0098915 | membrane repolarization during ventricular cardiac muscle cell action potential | 2 | 10 | 2.02e-01 |
| GO:BP | GO:0008065 | establishment of blood-nerve barrier | 1 | 3 | 2.02e-01 |
| GO:BP | GO:0046073 | dTMP metabolic process | 2 | 7 | 2.02e-01 |
| GO:BP | GO:0002074 | extraocular skeletal muscle development | 1 | 2 | 2.02e-01 |
| GO:BP | GO:0090177 | establishment of planar polarity involved in neural tube closure | 1 | 14 | 2.02e-01 |
| GO:BP | GO:0030865 | cortical cytoskeleton organization | 9 | 55 | 2.02e-01 |
| GO:BP | GO:0070302 | regulation of stress-activated protein kinase signaling cascade | 12 | 157 | 2.02e-01 |
| GO:BP | GO:0006970 | response to osmotic stress | 2 | 67 | 2.02e-01 |
| GO:BP | GO:0044743 | protein transmembrane import into intracellular organelle | 1 | 36 | 2.02e-01 |
| GO:BP | GO:2000773 | negative regulation of cellular senescence | 2 | 19 | 2.02e-01 |
| GO:BP | GO:0030046 | parallel actin filament bundle assembly | 2 | 5 | 2.02e-01 |
| GO:BP | GO:0036089 | cleavage furrow formation | 2 | 7 | 2.02e-01 |
| GO:BP | GO:1901214 | regulation of neuron death | 14 | 246 | 2.02e-01 |
| GO:BP | GO:0046048 | UDP metabolic process | 1 | 7 | 2.02e-01 |
| GO:BP | GO:0009193 | pyrimidine ribonucleoside diphosphate metabolic process | 1 | 7 | 2.02e-01 |
| GO:BP | GO:2000169 | regulation of peptidyl-cysteine S-nitrosylation | 2 | 9 | 2.02e-01 |
| GO:BP | GO:1900119 | positive regulation of execution phase of apoptosis | 1 | 7 | 2.04e-01 |
| GO:BP | GO:0007031 | peroxisome organization | 1 | 34 | 2.04e-01 |
| GO:BP | GO:0045591 | positive regulation of regulatory T cell differentiation | 3 | 14 | 2.04e-01 |
| GO:BP | GO:0018026 | peptidyl-lysine monomethylation | 2 | 11 | 2.04e-01 |
| GO:BP | GO:0051338 | regulation of transferase activity | 72 | 679 | 2.04e-01 |
| GO:BP | GO:1903116 | positive regulation of actin filament-based movement | 1 | 2 | 2.04e-01 |
| GO:BP | GO:0098754 | detoxification | 3 | 91 | 2.04e-01 |
| GO:BP | GO:0021815 | modulation of microtubule cytoskeleton involved in cerebral cortex radial glia guided migration | 2 | 5 | 2.04e-01 |
| GO:BP | GO:0097466 | ubiquitin-dependent glycoprotein ERAD pathway | 2 | 5 | 2.04e-01 |
| GO:BP | GO:0000027 | ribosomal large subunit assembly | 1 | 23 | 2.04e-01 |
| GO:BP | GO:0045820 | negative regulation of glycolytic process | 2 | 13 | 2.04e-01 |
| GO:BP | GO:0021782 | glial cell development | 1 | 84 | 2.04e-01 |
| GO:BP | GO:0045732 | positive regulation of protein catabolic process | 4 | 192 | 2.04e-01 |
| GO:BP | GO:0003180 | aortic valve morphogenesis | 5 | 33 | 2.04e-01 |
| GO:BP | GO:1901800 | positive regulation of proteasomal protein catabolic process | 13 | 111 | 2.04e-01 |
| GO:BP | GO:0035977 | protein deglycosylation involved in glycoprotein catabolic process | 2 | 5 | 2.04e-01 |
| GO:BP | GO:0043552 | positive regulation of phosphatidylinositol 3-kinase activity | 6 | 21 | 2.04e-01 |
| GO:BP | GO:0032989 | cellular component morphogenesis | 8 | 639 | 2.04e-01 |
| GO:BP | GO:1904382 | mannose trimming involved in glycoprotein ERAD pathway | 2 | 5 | 2.04e-01 |
| GO:BP | GO:0032388 | positive regulation of intracellular transport | 9 | 170 | 2.04e-01 |
| GO:BP | GO:0050818 | regulation of coagulation | 4 | 55 | 2.05e-01 |
| GO:BP | GO:0032070 | regulation of deoxyribonuclease activity | 2 | 9 | 2.05e-01 |
| GO:BP | GO:0048859 | formation of anatomical boundary | 1 | 3 | 2.05e-01 |
| GO:BP | GO:0030917 | midbrain-hindbrain boundary development | 1 | 3 | 2.05e-01 |
| GO:BP | GO:0097065 | anterior head development | 1 | 7 | 2.05e-01 |
| GO:BP | GO:0051490 | negative regulation of filopodium assembly | 2 | 6 | 2.05e-01 |
| GO:BP | GO:0051101 | regulation of DNA binding | 1 | 104 | 2.05e-01 |
| GO:BP | GO:0001100 | negative regulation of exit from mitosis | 1 | 1 | 2.05e-01 |
| GO:BP | GO:0036465 | synaptic vesicle recycling | 11 | 73 | 2.05e-01 |
| GO:BP | GO:0048632 | negative regulation of skeletal muscle tissue growth | 1 | 1 | 2.05e-01 |
| GO:BP | GO:0090101 | negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 11 | 124 | 2.05e-01 |
| GO:BP | GO:0072359 | circulatory system development | 4 | 884 | 2.05e-01 |
| GO:BP | GO:1904714 | regulation of chaperone-mediated autophagy | 1 | 8 | 2.05e-01 |
| GO:BP | GO:0070914 | UV-damage excision repair | 3 | 13 | 2.05e-01 |
| GO:BP | GO:0006003 | fructose 2,6-bisphosphate metabolic process | 2 | 4 | 2.06e-01 |
| GO:BP | GO:0033598 | mammary gland epithelial cell proliferation | 1 | 23 | 2.06e-01 |
| GO:BP | GO:0090049 | regulation of cell migration involved in sprouting angiogenesis | 3 | 31 | 2.06e-01 |
| GO:BP | GO:0014874 | response to stimulus involved in regulation of muscle adaptation | 1 | 12 | 2.06e-01 |
| GO:BP | GO:0038128 | ERBB2 signaling pathway | 4 | 14 | 2.06e-01 |
| GO:BP | GO:0070848 | response to growth factor | 37 | 572 | 2.07e-01 |
| GO:BP | GO:0007266 | Rho protein signal transduction | 12 | 114 | 2.07e-01 |
| GO:BP | GO:0045667 | regulation of osteoblast differentiation | 1 | 99 | 2.07e-01 |
| GO:BP | GO:0014902 | myotube differentiation | 1 | 88 | 2.07e-01 |
| GO:BP | GO:0042249 | establishment of planar polarity of embryonic epithelium | 1 | 15 | 2.08e-01 |
| GO:BP | GO:0007519 | skeletal muscle tissue development | 5 | 129 | 2.08e-01 |
| GO:BP | GO:0060999 | positive regulation of dendritic spine development | 3 | 33 | 2.08e-01 |
| GO:BP | GO:0051102 | DNA ligation involved in DNA recombination | 1 | 1 | 2.08e-01 |
| GO:BP | GO:0075713 | establishment of integrated proviral latency | 1 | 1 | 2.08e-01 |
| GO:BP | GO:1901097 | negative regulation of autophagosome maturation | 2 | 5 | 2.08e-01 |
| GO:BP | GO:0048668 | collateral sprouting | 2 | 25 | 2.10e-01 |
| GO:BP | GO:0019856 | pyrimidine nucleobase biosynthetic process | 1 | 8 | 2.10e-01 |
| GO:BP | GO:0015949 | nucleobase-containing small molecule interconversion | 1 | 8 | 2.10e-01 |
| GO:BP | GO:0000436 | carbon catabolite activation of transcription from RNA polymerase II promoter | 1 | 3 | 2.10e-01 |
| GO:BP | GO:0046016 | positive regulation of transcription by glucose | 1 | 3 | 2.10e-01 |
| GO:BP | GO:1903251 | multi-ciliated epithelial cell differentiation | 2 | 6 | 2.10e-01 |
| GO:BP | GO:0000429 | carbon catabolite regulation of transcription from RNA polymerase II promoter | 1 | 3 | 2.10e-01 |
| GO:BP | GO:0043650 | dicarboxylic acid biosynthetic process | 2 | 9 | 2.10e-01 |
| GO:BP | GO:0060119 | inner ear receptor cell development | 5 | 33 | 2.10e-01 |
| GO:BP | GO:0090175 | regulation of establishment of planar polarity | 2 | 54 | 2.10e-01 |
| GO:BP | GO:1901165 | positive regulation of trophoblast cell migration | 2 | 6 | 2.11e-01 |
| GO:BP | GO:0021799 | cerebral cortex radially oriented cell migration | 2 | 28 | 2.11e-01 |
| GO:BP | GO:0007611 | learning or memory | 19 | 202 | 2.11e-01 |
| GO:BP | GO:0048631 | regulation of skeletal muscle tissue growth | 2 | 7 | 2.11e-01 |
| GO:BP | GO:0031915 | positive regulation of synaptic plasticity | 1 | 6 | 2.12e-01 |
| GO:BP | GO:0090129 | positive regulation of synapse maturation | 1 | 8 | 2.12e-01 |
| GO:BP | GO:0035239 | tube morphogenesis | 48 | 663 | 2.13e-01 |
| GO:BP | GO:1905897 | regulation of response to endoplasmic reticulum stress | 4 | 76 | 2.13e-01 |
| GO:BP | GO:1902035 | positive regulation of hematopoietic stem cell proliferation | 2 | 7 | 2.13e-01 |
| GO:BP | GO:0034316 | negative regulation of Arp2/3 complex-mediated actin nucleation | 1 | 5 | 2.13e-01 |
| GO:BP | GO:0060765 | regulation of androgen receptor signaling pathway | 2 | 24 | 2.14e-01 |
| GO:BP | GO:0070458 | cellular detoxification of nitrogen compound | 1 | 5 | 2.14e-01 |
| GO:BP | GO:0043171 | peptide catabolic process | 1 | 16 | 2.14e-01 |
| GO:BP | GO:1903891 | regulation of ATF6-mediated unfolded protein response | 1 | 4 | 2.14e-01 |
| GO:BP | GO:1901334 | lactone metabolic process | 1 | 9 | 2.14e-01 |
| GO:BP | GO:1903760 | regulation of voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization | 1 | 4 | 2.14e-01 |
| GO:BP | GO:0030177 | positive regulation of Wnt signaling pathway | 1 | 120 | 2.14e-01 |
| GO:BP | GO:0090505 | epiboly involved in wound healing | 1 | 30 | 2.14e-01 |
| GO:BP | GO:0060709 | glycogen cell differentiation involved in embryonic placenta development | 1 | 1 | 2.14e-01 |
| GO:BP | GO:0097475 | motor neuron migration | 3 | 10 | 2.14e-01 |
| GO:BP | GO:0042552 | myelination | 1 | 111 | 2.14e-01 |
| GO:BP | GO:0097114 | NMDA glutamate receptor clustering | 2 | 5 | 2.14e-01 |
| GO:BP | GO:0044319 | wound healing, spreading of cells | 1 | 30 | 2.14e-01 |
| GO:BP | GO:2000320 | negative regulation of T-helper 17 cell differentiation | 1 | 6 | 2.14e-01 |
| GO:BP | GO:0001919 | regulation of receptor recycling | 1 | 19 | 2.14e-01 |
| GO:BP | GO:0051410 | detoxification of nitrogen compound | 1 | 5 | 2.14e-01 |
| GO:BP | GO:0010906 | regulation of glucose metabolic process | 6 | 86 | 2.14e-01 |
| GO:BP | GO:0035624 | receptor transactivation | 2 | 3 | 2.14e-01 |
| GO:BP | GO:1990983 | tRNA demethylation | 1 | 1 | 2.14e-01 |
| GO:BP | GO:0048382 | mesendoderm development | 1 | 5 | 2.14e-01 |
| GO:BP | GO:0051056 | regulation of small GTPase mediated signal transduction | 30 | 257 | 2.14e-01 |
| GO:BP | GO:0009116 | nucleoside metabolic process | 1 | 42 | 2.14e-01 |
| GO:BP | GO:2000058 | regulation of ubiquitin-dependent protein catabolic process | 19 | 160 | 2.14e-01 |
| GO:BP | GO:0120039 | plasma membrane bounded cell projection morphogenesis | 7 | 527 | 2.14e-01 |
| GO:BP | GO:1905031 | regulation of membrane repolarization during cardiac muscle cell action potential | 1 | 3 | 2.14e-01 |
| GO:BP | GO:0072579 | glycine receptor clustering | 1 | 1 | 2.14e-01 |
| GO:BP | GO:0001825 | blastocyst formation | 6 | 37 | 2.14e-01 |
| GO:BP | GO:0018315 | molybdenum incorporation into molybdenum-molybdopterin complex | 1 | 1 | 2.14e-01 |
| GO:BP | GO:0051340 | regulation of ligase activity | 3 | 11 | 2.14e-01 |
| GO:BP | GO:0042040 | metal incorporation into metallo-molybdopterin complex | 1 | 1 | 2.14e-01 |
| GO:BP | GO:0010332 | response to gamma radiation | 4 | 50 | 2.14e-01 |
| GO:BP | GO:0098869 | cellular oxidant detoxification | 1 | 65 | 2.14e-01 |
| GO:BP | GO:0010765 | positive regulation of sodium ion transport | 4 | 30 | 2.14e-01 |
| GO:BP | GO:0019417 | sulfur oxidation | 1 | 2 | 2.14e-01 |
| GO:BP | GO:0019852 | L-ascorbic acid metabolic process | 1 | 9 | 2.14e-01 |
| GO:BP | GO:0048858 | cell projection morphogenesis | 7 | 531 | 2.14e-01 |
| GO:BP | GO:0003281 | ventricular septum development | 2 | 69 | 2.14e-01 |
| GO:BP | GO:0061314 | Notch signaling involved in heart development | 1 | 9 | 2.14e-01 |
| GO:BP | GO:0090504 | epiboly | 1 | 31 | 2.14e-01 |
| GO:BP | GO:0009138 | pyrimidine nucleoside diphosphate metabolic process | 1 | 9 | 2.14e-01 |
| GO:BP | GO:0098795 | global gene silencing by mRNA cleavage | 1 | 4 | 2.14e-01 |
| GO:BP | GO:1904380 | endoplasmic reticulum mannose trimming | 3 | 14 | 2.14e-01 |
| GO:BP | GO:1904544 | positive regulation of free ubiquitin chain polymerization | 1 | 2 | 2.14e-01 |
| GO:BP | GO:0071900 | regulation of protein serine/threonine kinase activity | 34 | 282 | 2.14e-01 |
| GO:BP | GO:1904542 | regulation of free ubiquitin chain polymerization | 1 | 2 | 2.14e-01 |
| GO:BP | GO:0007258 | JUN phosphorylation | 1 | 2 | 2.14e-01 |
| GO:BP | GO:0050768 | negative regulation of neurogenesis | 1 | 113 | 2.14e-01 |
| GO:BP | GO:0060603 | mammary gland duct morphogenesis | 1 | 28 | 2.14e-01 |
| GO:BP | GO:0007399 | nervous system development | 12 | 1904 | 2.14e-01 |
| GO:BP | GO:0008366 | axon ensheathment | 1 | 113 | 2.14e-01 |
| GO:BP | GO:0010665 | regulation of cardiac muscle cell apoptotic process | 3 | 33 | 2.14e-01 |
| GO:BP | GO:0007272 | ensheathment of neurons | 1 | 113 | 2.14e-01 |
| GO:BP | GO:0072537 | fibroblast activation | 2 | 11 | 2.17e-01 |
| GO:BP | GO:0033206 | meiotic cytokinesis | 2 | 7 | 2.17e-01 |
| GO:BP | GO:0006605 | protein targeting | 2 | 307 | 2.17e-01 |
| GO:BP | GO:0061647 | histone H3-K9 modification | 2 | 23 | 2.17e-01 |
| GO:BP | GO:0007093 | mitotic cell cycle checkpoint signaling | 15 | 139 | 2.17e-01 |
| GO:BP | GO:0140059 | dendrite arborization | 2 | 9 | 2.17e-01 |
| GO:BP | GO:0036261 | 7-methylguanosine cap hypermethylation | 2 | 8 | 2.17e-01 |
| GO:BP | GO:0038026 | reelin-mediated signaling pathway | 1 | 9 | 2.17e-01 |
| GO:BP | GO:0042256 | cytosolic ribosome assembly | 2 | 5 | 2.17e-01 |
| GO:BP | GO:2000045 | regulation of G1/S transition of mitotic cell cycle | 15 | 149 | 2.19e-01 |
| GO:BP | GO:0031929 | TOR signaling | 4 | 115 | 2.19e-01 |
| GO:BP | GO:0051961 | negative regulation of nervous system development | 1 | 118 | 2.19e-01 |
| GO:BP | GO:2000317 | negative regulation of T-helper 17 type immune response | 1 | 7 | 2.20e-01 |
| GO:BP | GO:0010587 | miRNA catabolic process | 1 | 10 | 2.20e-01 |
| GO:BP | GO:0090085 | regulation of protein deubiquitination | 1 | 12 | 2.20e-01 |
| GO:BP | GO:0071456 | cellular response to hypoxia | 7 | 123 | 2.20e-01 |
| GO:BP | GO:0007411 | axon guidance | 2 | 185 | 2.20e-01 |
| GO:BP | GO:0072350 | tricarboxylic acid metabolic process | 2 | 13 | 2.20e-01 |
| GO:BP | GO:1902267 | regulation of polyamine transmembrane transport | 1 | 5 | 2.20e-01 |
| GO:BP | GO:0007613 | memory | 8 | 92 | 2.20e-01 |
| GO:BP | GO:0071453 | cellular response to oxygen levels | 8 | 144 | 2.20e-01 |
| GO:BP | GO:0097479 | synaptic vesicle localization | 8 | 50 | 2.20e-01 |
| GO:BP | GO:0043087 | regulation of GTPase activity | 15 | 302 | 2.20e-01 |
| GO:BP | GO:0097485 | neuron projection guidance | 2 | 186 | 2.20e-01 |
| GO:BP | GO:0090303 | positive regulation of wound healing | 3 | 45 | 2.20e-01 |
| GO:BP | GO:0048193 | Golgi vesicle transport | 30 | 285 | 2.20e-01 |
| GO:BP | GO:0060296 | regulation of cilium beat frequency involved in ciliary motility | 2 | 6 | 2.20e-01 |
| GO:BP | GO:0050691 | regulation of defense response to virus by host | 2 | 30 | 2.20e-01 |
| GO:BP | GO:0007398 | ectoderm development | 1 | 15 | 2.20e-01 |
| GO:BP | GO:1903115 | regulation of actin filament-based movement | 1 | 39 | 2.20e-01 |
| GO:BP | GO:0032486 | Rap protein signal transduction | 2 | 13 | 2.20e-01 |
| GO:BP | GO:0070459 | prolactin secretion | 1 | 4 | 2.20e-01 |
| GO:BP | GO:0030509 | BMP signaling pathway | 1 | 123 | 2.21e-01 |
| GO:BP | GO:0090630 | activation of GTPase activity | 4 | 99 | 2.21e-01 |
| GO:BP | GO:0051099 | positive regulation of binding | 4 | 150 | 2.21e-01 |
| GO:BP | GO:0006580 | ethanolamine metabolic process | 1 | 1 | 2.21e-01 |
| GO:BP | GO:0032091 | negative regulation of protein binding | 7 | 77 | 2.21e-01 |
| GO:BP | GO:1900113 | negative regulation of histone H3-K9 trimethylation | 1 | 3 | 2.21e-01 |
| GO:BP | GO:2000111 | positive regulation of macrophage apoptotic process | 1 | 2 | 2.21e-01 |
| GO:BP | GO:2000481 | positive regulation of cAMP-dependent protein kinase activity | 2 | 5 | 2.21e-01 |
| GO:BP | GO:0036260 | RNA capping | 3 | 20 | 2.21e-01 |
| GO:BP | GO:0009188 | ribonucleoside diphosphate biosynthetic process | 1 | 8 | 2.22e-01 |
| GO:BP | GO:0006222 | UMP biosynthetic process | 1 | 8 | 2.22e-01 |
| GO:BP | GO:0045990 | carbon catabolite regulation of transcription | 1 | 4 | 2.22e-01 |
| GO:BP | GO:0051090 | regulation of DNA-binding transcription factor activity | 4 | 335 | 2.22e-01 |
| GO:BP | GO:0065002 | intracellular protein transmembrane transport | 1 | 52 | 2.22e-01 |
| GO:BP | GO:0045991 | carbon catabolite activation of transcription | 1 | 4 | 2.22e-01 |
| GO:BP | GO:0035265 | organ growth | 1 | 131 | 2.22e-01 |
| GO:BP | GO:2000060 | positive regulation of ubiquitin-dependent protein catabolic process | 13 | 103 | 2.22e-01 |
| GO:BP | GO:0036496 | regulation of translational initiation by eIF2 alpha dephosphorylation | 1 | 2 | 2.22e-01 |
| GO:BP | GO:0060041 | retina development in camera-type eye | 1 | 109 | 2.22e-01 |
| GO:BP | GO:0030859 | polarized epithelial cell differentiation | 3 | 19 | 2.24e-01 |
| GO:BP | GO:0051105 | regulation of DNA ligation | 2 | 6 | 2.24e-01 |
| GO:BP | GO:0032793 | positive regulation of CREB transcription factor activity | 3 | 15 | 2.24e-01 |
| GO:BP | GO:0033559 | unsaturated fatty acid metabolic process | 1 | 66 | 2.24e-01 |
| GO:BP | GO:0045472 | response to ether | 1 | 7 | 2.24e-01 |
| GO:BP | GO:0044793 | negative regulation by host of viral process | 1 | 10 | 2.24e-01 |
| GO:BP | GO:0080170 | hydrogen peroxide transmembrane transport | 1 | 1 | 2.25e-01 |
| GO:BP | GO:0000956 | nuclear-transcribed mRNA catabolic process | 2 | 120 | 2.25e-01 |
| GO:BP | GO:0008286 | insulin receptor signaling pathway | 11 | 105 | 2.25e-01 |
| GO:BP | GO:0045859 | regulation of protein kinase activity | 53 | 479 | 2.25e-01 |
| GO:BP | GO:0032990 | cell part morphogenesis | 7 | 551 | 2.25e-01 |
| GO:BP | GO:0071773 | cellular response to BMP stimulus | 1 | 131 | 2.25e-01 |
| GO:BP | GO:0070306 | lens fiber cell differentiation | 1 | 30 | 2.25e-01 |
| GO:BP | GO:0071772 | response to BMP | 1 | 131 | 2.25e-01 |
| GO:BP | GO:0060538 | skeletal muscle organ development | 5 | 139 | 2.25e-01 |
| GO:BP | GO:0018027 | peptidyl-lysine dimethylation | 2 | 22 | 2.25e-01 |
| GO:BP | GO:0033133 | positive regulation of glucokinase activity | 1 | 4 | 2.26e-01 |
| GO:BP | GO:0045176 | apical protein localization | 3 | 13 | 2.28e-01 |
| GO:BP | GO:0043547 | positive regulation of GTPase activity | 7 | 222 | 2.28e-01 |
| GO:BP | GO:0061484 | hematopoietic stem cell homeostasis | 3 | 20 | 2.28e-01 |
| GO:BP | GO:0043687 | post-translational protein modification | 1 | 64 | 2.28e-01 |
| GO:BP | GO:0060384 | innervation | 1 | 22 | 2.28e-01 |
| GO:BP | GO:0042636 | negative regulation of hair cycle | 1 | 1 | 2.29e-01 |
| GO:BP | GO:0036037 | CD8-positive, alpha-beta T cell activation | 3 | 15 | 2.29e-01 |
| GO:BP | GO:1902261 | positive regulation of delayed rectifier potassium channel activity | 1 | 5 | 2.29e-01 |
| GO:BP | GO:0010750 | positive regulation of nitric oxide mediated signal transduction | 1 | 4 | 2.29e-01 |
| GO:BP | GO:0050878 | regulation of body fluid levels | 7 | 236 | 2.29e-01 |
| GO:BP | GO:0019827 | stem cell population maintenance | 1 | 149 | 2.29e-01 |
| GO:BP | GO:0009129 | pyrimidine nucleoside monophosphate metabolic process | 3 | 18 | 2.29e-01 |
| GO:BP | GO:1904481 | response to tetrahydrofolate | 1 | 1 | 2.29e-01 |
| GO:BP | GO:1904482 | cellular response to tetrahydrofolate | 1 | 1 | 2.29e-01 |
| GO:BP | GO:0010544 | negative regulation of platelet activation | 2 | 17 | 2.29e-01 |
| GO:BP | GO:0052652 | cyclic purine nucleotide metabolic process | 1 | 30 | 2.30e-01 |
| GO:BP | GO:0043470 | regulation of carbohydrate catabolic process | 8 | 47 | 2.30e-01 |
| GO:BP | GO:2000371 | regulation of DNA topoisomerase (ATP-hydrolyzing) activity | 1 | 5 | 2.30e-01 |
| GO:BP | GO:0045019 | negative regulation of nitric oxide biosynthetic process | 1 | 10 | 2.30e-01 |
| GO:BP | GO:0099550 | trans-synaptic signaling, modulating synaptic transmission | 3 | 10 | 2.30e-01 |
| GO:BP | GO:0014888 | striated muscle adaptation | 2 | 40 | 2.30e-01 |
| GO:BP | GO:1904406 | negative regulation of nitric oxide metabolic process | 1 | 10 | 2.30e-01 |
| GO:BP | GO:0006939 | smooth muscle contraction | 11 | 75 | 2.30e-01 |
| GO:BP | GO:0009174 | pyrimidine ribonucleoside monophosphate biosynthetic process | 1 | 9 | 2.30e-01 |
| GO:BP | GO:1903035 | negative regulation of response to wounding | 6 | 64 | 2.30e-01 |
| GO:BP | GO:0098727 | maintenance of cell number | 1 | 151 | 2.30e-01 |
| GO:BP | GO:0046833 | positive regulation of RNA export from nucleus | 1 | 5 | 2.30e-01 |
| GO:BP | GO:2000467 | positive regulation of glycogen (starch) synthase activity | 2 | 4 | 2.30e-01 |
| GO:BP | GO:2000373 | positive regulation of DNA topoisomerase (ATP-hydrolyzing) activity | 1 | 5 | 2.30e-01 |
| GO:BP | GO:0006690 | icosanoid metabolic process | 1 | 60 | 2.30e-01 |
| GO:BP | GO:0006392 | transcription elongation by mitochondrial RNA polymerase | 1 | 1 | 2.30e-01 |
| GO:BP | GO:0010662 | regulation of striated muscle cell apoptotic process | 3 | 36 | 2.30e-01 |
| GO:BP | GO:0035567 | non-canonical Wnt signaling pathway | 2 | 62 | 2.31e-01 |
| GO:BP | GO:0043085 | positive regulation of catalytic activity | 89 | 834 | 2.31e-01 |
| GO:BP | GO:0007169 | transmembrane receptor protein tyrosine kinase signaling pathway | 54 | 484 | 2.31e-01 |
| GO:BP | GO:0000082 | G1/S transition of mitotic cell cycle | 19 | 207 | 2.31e-01 |
| GO:BP | GO:0009187 | cyclic nucleotide metabolic process | 1 | 31 | 2.31e-01 |
| GO:BP | GO:0021903 | rostrocaudal neural tube patterning | 1 | 5 | 2.31e-01 |
| GO:BP | GO:0050678 | regulation of epithelial cell proliferation | 14 | 276 | 2.31e-01 |
| GO:BP | GO:1905364 | regulation of endosomal vesicle fusion | 1 | 1 | 2.31e-01 |
| GO:BP | GO:0002351 | serotonin production involved in inflammatory response | 1 | 2 | 2.31e-01 |
| GO:BP | GO:0072714 | response to selenite ion | 1 | 1 | 2.31e-01 |
| GO:BP | GO:0072715 | cellular response to selenite ion | 1 | 1 | 2.31e-01 |
| GO:BP | GO:1900027 | regulation of ruffle assembly | 5 | 23 | 2.31e-01 |
| GO:BP | GO:0030195 | negative regulation of blood coagulation | 3 | 34 | 2.31e-01 |
| GO:BP | GO:0000077 | DNA damage checkpoint signaling | 5 | 121 | 2.31e-01 |
| GO:BP | GO:0031331 | positive regulation of cellular catabolic process | 5 | 277 | 2.31e-01 |
| GO:BP | GO:0060706 | cell differentiation involved in embryonic placenta development | 4 | 20 | 2.31e-01 |
| GO:BP | GO:0007088 | regulation of mitotic nuclear division | 2 | 100 | 2.31e-01 |
| GO:BP | GO:0060037 | pharyngeal system development | 1 | 23 | 2.31e-01 |
| GO:BP | GO:0007076 | mitotic chromosome condensation | 4 | 19 | 2.31e-01 |
| GO:BP | GO:1903047 | mitotic cell cycle process | 48 | 694 | 2.31e-01 |
| GO:BP | GO:0051057 | positive regulation of small GTPase mediated signal transduction | 7 | 51 | 2.31e-01 |
| GO:BP | GO:0031503 | protein-containing complex localization | 20 | 168 | 2.31e-01 |
| GO:BP | GO:0021648 | vestibulocochlear nerve morphogenesis | 2 | 3 | 2.31e-01 |
| GO:BP | GO:0070054 | mRNA splicing, via endonucleolytic cleavage and ligation | 1 | 1 | 2.31e-01 |
| GO:BP | GO:0005996 | monosaccharide metabolic process | 11 | 209 | 2.31e-01 |
| GO:BP | GO:0038089 | positive regulation of cell migration by vascular endothelial growth factor signaling pathway | 2 | 8 | 2.31e-01 |
| GO:BP | GO:0090045 | positive regulation of deacetylase activity | 2 | 7 | 2.31e-01 |
| GO:BP | GO:0034446 | substrate adhesion-dependent cell spreading | 3 | 97 | 2.31e-01 |
| GO:BP | GO:0043491 | protein kinase B signaling | 3 | 146 | 2.31e-01 |
| GO:BP | GO:0036290 | protein trans-autophosphorylation | 1 | 1 | 2.31e-01 |
| GO:BP | GO:0051898 | negative regulation of protein kinase B signaling | 1 | 36 | 2.31e-01 |
| GO:BP | GO:0016236 | macroautophagy | 16 | 308 | 2.31e-01 |
| GO:BP | GO:0006476 | protein deacetylation | 9 | 106 | 2.31e-01 |
| GO:BP | GO:0032825 | positive regulation of natural killer cell differentiation | 2 | 7 | 2.31e-01 |
| GO:BP | GO:0045741 | positive regulation of epidermal growth factor-activated receptor activity | 3 | 8 | 2.31e-01 |
| GO:BP | GO:0050773 | regulation of dendrite development | 2 | 90 | 2.31e-01 |
| GO:BP | GO:0060010 | Sertoli cell fate commitment | 1 | 1 | 2.31e-01 |
| GO:BP | GO:0003176 | aortic valve development | 5 | 37 | 2.31e-01 |
| GO:BP | GO:0071901 | negative regulation of protein serine/threonine kinase activity | 13 | 101 | 2.31e-01 |
| GO:BP | GO:0010739 | positive regulation of protein kinase A signaling | 3 | 6 | 2.31e-01 |
| GO:BP | GO:0046521 | sphingoid catabolic process | 1 | 1 | 2.31e-01 |
| GO:BP | GO:0055001 | muscle cell development | 1 | 165 | 2.31e-01 |
| GO:BP | GO:1904574 | negative regulation of selenocysteine insertion sequence binding | 1 | 1 | 2.31e-01 |
| GO:BP | GO:1904573 | regulation of selenocysteine insertion sequence binding | 1 | 1 | 2.31e-01 |
| GO:BP | GO:0048384 | retinoic acid receptor signaling pathway | 4 | 26 | 2.31e-01 |
| GO:BP | GO:1904572 | negative regulation of mRNA binding | 1 | 1 | 2.31e-01 |
| GO:BP | GO:1902031 | regulation of NADP metabolic process | 2 | 8 | 2.31e-01 |
| GO:BP | GO:1904570 | negative regulation of selenocysteine incorporation | 1 | 1 | 2.31e-01 |
| GO:BP | GO:0003271 | smoothened signaling pathway involved in regulation of secondary heart field cardioblast proliferation | 1 | 1 | 2.31e-01 |
| GO:BP | GO:0071394 | cellular response to testosterone stimulus | 3 | 11 | 2.31e-01 |
| GO:BP | GO:0071806 | protein transmembrane transport | 1 | 62 | 2.31e-01 |
| GO:BP | GO:0043393 | regulation of protein binding | 15 | 172 | 2.31e-01 |
| GO:BP | GO:1990579 | peptidyl-serine trans-autophosphorylation | 1 | 1 | 2.31e-01 |
| GO:BP | GO:0035999 | tetrahydrofolate interconversion | 2 | 9 | 2.31e-01 |
| GO:BP | GO:0046940 | nucleoside monophosphate phosphorylation | 1 | 9 | 2.31e-01 |
| GO:BP | GO:0010659 | cardiac muscle cell apoptotic process | 3 | 36 | 2.31e-01 |
| GO:BP | GO:0051126 | negative regulation of actin nucleation | 1 | 6 | 2.31e-01 |
| GO:BP | GO:0002442 | serotonin secretion involved in inflammatory response | 1 | 2 | 2.31e-01 |
| GO:BP | GO:1904569 | regulation of selenocysteine incorporation | 1 | 1 | 2.31e-01 |
| GO:BP | GO:2001223 | negative regulation of neuron migration | 2 | 8 | 2.31e-01 |
| GO:BP | GO:0010591 | regulation of lamellipodium assembly | 1 | 33 | 2.31e-01 |
| GO:BP | GO:1900103 | positive regulation of endoplasmic reticulum unfolded protein response | 3 | 13 | 2.31e-01 |
| GO:BP | GO:0062111 | zinc ion import into organelle | 1 | 7 | 2.31e-01 |
| GO:BP | GO:0001503 | ossification | 2 | 313 | 2.31e-01 |
| GO:BP | GO:0032119 | sequestering of zinc ion | 1 | 5 | 2.31e-01 |
| GO:BP | GO:0008630 | intrinsic apoptotic signaling pathway in response to DNA damage | 5 | 94 | 2.31e-01 |
| GO:BP | GO:0010738 | regulation of protein kinase A signaling | 4 | 13 | 2.31e-01 |
| GO:BP | GO:0090103 | cochlea morphogenesis | 1 | 15 | 2.31e-01 |
| GO:BP | GO:0007072 | positive regulation of transcription involved in exit from mitosis | 1 | 1 | 2.31e-01 |
| GO:BP | GO:0060674 | placenta blood vessel development | 4 | 26 | 2.31e-01 |
| GO:BP | GO:0051452 | intracellular pH reduction | 4 | 45 | 2.31e-01 |
| GO:BP | GO:0032808 | lacrimal gland development | 1 | 5 | 2.31e-01 |
| GO:BP | GO:0071560 | cellular response to transforming growth factor beta stimulus | 16 | 222 | 2.31e-01 |
| GO:BP | GO:0006611 | protein export from nucleus | 6 | 55 | 2.31e-01 |
| GO:BP | GO:1901657 | glycosyl compound metabolic process | 1 | 62 | 2.31e-01 |
| GO:BP | GO:0001501 | skeletal system development | 3 | 377 | 2.31e-01 |
| GO:BP | GO:1904058 | positive regulation of sensory perception of pain | 2 | 3 | 2.31e-01 |
| GO:BP | GO:0086009 | membrane repolarization | 3 | 41 | 2.31e-01 |
| GO:BP | GO:1904997 | regulation of leukocyte adhesion to arterial endothelial cell | 1 | 3 | 2.32e-01 |
| GO:BP | GO:0048813 | dendrite morphogenesis | 8 | 120 | 2.32e-01 |
| GO:BP | GO:0006682 | galactosylceramide biosynthetic process | 1 | 4 | 2.32e-01 |
| GO:BP | GO:0019375 | galactolipid biosynthetic process | 1 | 4 | 2.32e-01 |
| GO:BP | GO:2001301 | lipoxin biosynthetic process | 1 | 2 | 2.32e-01 |
| GO:BP | GO:2000630 | positive regulation of miRNA metabolic process | 3 | 48 | 2.33e-01 |
| GO:BP | GO:1900138 | negative regulation of phospholipase A2 activity | 1 | 4 | 2.33e-01 |
| GO:BP | GO:0033002 | muscle cell proliferation | 1 | 157 | 2.33e-01 |
| GO:BP | GO:0043583 | ear development | 2 | 153 | 2.33e-01 |
| GO:BP | GO:0034260 | negative regulation of GTPase activity | 3 | 29 | 2.35e-01 |
| GO:BP | GO:1904668 | positive regulation of ubiquitin protein ligase activity | 1 | 13 | 2.35e-01 |
| GO:BP | GO:1900047 | negative regulation of hemostasis | 3 | 34 | 2.35e-01 |
| GO:BP | GO:0010656 | negative regulation of muscle cell apoptotic process | 3 | 35 | 2.35e-01 |
| GO:BP | GO:0120034 | positive regulation of plasma membrane bounded cell projection assembly | 12 | 94 | 2.35e-01 |
| GO:BP | GO:0060307 | regulation of ventricular cardiac muscle cell membrane repolarization | 2 | 16 | 2.35e-01 |
| GO:BP | GO:0045862 | positive regulation of proteolysis | 33 | 295 | 2.35e-01 |
| GO:BP | GO:0090128 | regulation of synapse maturation | 4 | 15 | 2.35e-01 |
| GO:BP | GO:0071474 | cellular hyperosmotic response | 1 | 13 | 2.35e-01 |
| GO:BP | GO:0021537 | telencephalon development | 3 | 201 | 2.35e-01 |
| GO:BP | GO:0034727 | piecemeal microautophagy of the nucleus | 1 | 9 | 2.35e-01 |
| GO:BP | GO:0010543 | regulation of platelet activation | 1 | 32 | 2.36e-01 |
| GO:BP | GO:0003062 | regulation of heart rate by chemical signal | 1 | 6 | 2.36e-01 |
| GO:BP | GO:0010714 | positive regulation of collagen metabolic process | 3 | 24 | 2.36e-01 |
| GO:BP | GO:1903670 | regulation of sprouting angiogenesis | 2 | 28 | 2.38e-01 |
| GO:BP | GO:0071245 | cellular response to carbon monoxide | 1 | 1 | 2.38e-01 |
| GO:BP | GO:0060443 | mammary gland morphogenesis | 1 | 39 | 2.38e-01 |
| GO:BP | GO:0061044 | negative regulation of vascular wound healing | 2 | 4 | 2.38e-01 |
| GO:BP | GO:0010718 | positive regulation of epithelial to mesenchymal transition | 1 | 48 | 2.38e-01 |
| GO:BP | GO:0050793 | regulation of developmental process | 14 | 1835 | 2.38e-01 |
| GO:BP | GO:0006642 | triglyceride mobilization | 1 | 3 | 2.38e-01 |
| GO:BP | GO:0000045 | autophagosome assembly | 4 | 103 | 2.38e-01 |
| GO:BP | GO:0045743 | positive regulation of fibroblast growth factor receptor signaling pathway | 2 | 6 | 2.40e-01 |
| GO:BP | GO:0097711 | ciliary basal body-plasma membrane docking | 1 | 2 | 2.40e-01 |
| GO:BP | GO:0032241 | positive regulation of nucleobase-containing compound transport | 1 | 6 | 2.40e-01 |
| GO:BP | GO:0000056 | ribosomal small subunit export from nucleus | 2 | 8 | 2.40e-01 |
| GO:BP | GO:0000055 | ribosomal large subunit export from nucleus | 2 | 8 | 2.40e-01 |
| GO:BP | GO:0061158 | 3’-UTR-mediated mRNA destabilization | 1 | 15 | 2.40e-01 |
| GO:BP | GO:1901837 | negative regulation of transcription of nucleolar large rRNA by RNA polymerase I | 1 | 4 | 2.40e-01 |
| GO:BP | GO:1900117 | regulation of execution phase of apoptosis | 1 | 13 | 2.40e-01 |
| GO:BP | GO:0033628 | regulation of cell adhesion mediated by integrin | 1 | 36 | 2.40e-01 |
| GO:BP | GO:0042306 | regulation of protein import into nucleus | 4 | 51 | 2.40e-01 |
| GO:BP | GO:1901160 | primary amino compound metabolic process | 3 | 8 | 2.40e-01 |
| GO:BP | GO:0046373 | L-arabinose metabolic process | 1 | 1 | 2.41e-01 |
| GO:BP | GO:0010710 | regulation of collagen catabolic process | 1 | 3 | 2.41e-01 |
| GO:BP | GO:0019566 | arabinose metabolic process | 1 | 1 | 2.41e-01 |
| GO:BP | GO:1905949 | negative regulation of calcium ion import across plasma membrane | 2 | 4 | 2.41e-01 |
| GO:BP | GO:2000234 | positive regulation of rRNA processing | 2 | 10 | 2.41e-01 |
| GO:BP | GO:0022411 | cellular component disassembly | 2 | 427 | 2.41e-01 |
| GO:BP | GO:0045597 | positive regulation of cell differentiation | 6 | 620 | 2.41e-01 |
| GO:BP | GO:0140569 | extraction of mislocalized protein from ER membrane | 1 | 1 | 2.41e-01 |
| GO:BP | GO:1903053 | regulation of extracellular matrix organization | 1 | 46 | 2.41e-01 |
| GO:BP | GO:0051345 | positive regulation of hydrolase activity | 20 | 422 | 2.41e-01 |
| GO:BP | GO:0048738 | cardiac muscle tissue development | 1 | 198 | 2.41e-01 |
| GO:BP | GO:0021795 | cerebral cortex cell migration | 2 | 37 | 2.42e-01 |
| GO:BP | GO:0010288 | response to lead ion | 2 | 18 | 2.42e-01 |
| GO:BP | GO:0019083 | viral transcription | 2 | 48 | 2.42e-01 |
| GO:BP | GO:0007389 | pattern specification process | 5 | 306 | 2.43e-01 |
| GO:BP | GO:0010506 | regulation of autophagy | 17 | 313 | 2.43e-01 |
| GO:BP | GO:0003198 | epithelial to mesenchymal transition involved in endocardial cushion formation | 1 | 14 | 2.43e-01 |
| GO:BP | GO:0007286 | spermatid development | 3 | 105 | 2.43e-01 |
| GO:BP | GO:0048013 | ephrin receptor signaling pathway | 1 | 41 | 2.43e-01 |
| GO:BP | GO:0051403 | stress-activated MAPK cascade | 23 | 190 | 2.43e-01 |
| GO:BP | GO:0045623 | negative regulation of T-helper cell differentiation | 1 | 11 | 2.43e-01 |
| GO:BP | GO:1903217 | negative regulation of protein processing involved in protein targeting to mitochondrion | 1 | 1 | 2.43e-01 |
| GO:BP | GO:1903216 | regulation of protein processing involved in protein targeting to mitochondrion | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0009157 | deoxyribonucleoside monophosphate biosynthetic process | 2 | 9 | 2.43e-01 |
| GO:BP | GO:1990849 | vacuolar localization | 6 | 62 | 2.43e-01 |
| GO:BP | GO:0021520 | spinal cord motor neuron cell fate specification | 1 | 5 | 2.43e-01 |
| GO:BP | GO:0042177 | negative regulation of protein catabolic process | 13 | 100 | 2.43e-01 |
| GO:BP | GO:0051225 | spindle assembly | 2 | 120 | 2.43e-01 |
| GO:BP | GO:1903461 | Okazaki fragment processing involved in mitotic DNA replication | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0009133 | nucleoside diphosphate biosynthetic process | 1 | 11 | 2.43e-01 |
| GO:BP | GO:0043031 | negative regulation of macrophage activation | 1 | 9 | 2.43e-01 |
| GO:BP | GO:0033144 | negative regulation of intracellular steroid hormone receptor signaling pathway | 2 | 31 | 2.43e-01 |
| GO:BP | GO:0032287 | peripheral nervous system myelin maintenance | 2 | 8 | 2.43e-01 |
| GO:BP | GO:0090218 | positive regulation of lipid kinase activity | 6 | 25 | 2.43e-01 |
| GO:BP | GO:0055107 | Golgi to secretory granule transport | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0071356 | cellular response to tumor necrosis factor | 5 | 155 | 2.43e-01 |
| GO:BP | GO:0071243 | cellular response to arsenic-containing substance | 1 | 18 | 2.43e-01 |
| GO:BP | GO:0046049 | UMP metabolic process | 1 | 10 | 2.43e-01 |
| GO:BP | GO:1904877 | positive regulation of DNA ligase activity | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0032418 | lysosome localization | 6 | 62 | 2.43e-01 |
| GO:BP | GO:0033037 | polysaccharide localization | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0060716 | labyrinthine layer blood vessel development | 4 | 16 | 2.43e-01 |
| GO:BP | GO:0031570 | DNA integrity checkpoint signaling | 5 | 129 | 2.43e-01 |
| GO:BP | GO:0060670 | branching involved in labyrinthine layer morphogenesis | 3 | 10 | 2.43e-01 |
| GO:BP | GO:0048705 | skeletal system morphogenesis | 1 | 155 | 2.43e-01 |
| GO:BP | GO:0010001 | glial cell differentiation | 1 | 170 | 2.43e-01 |
| GO:BP | GO:1904996 | positive regulation of leukocyte adhesion to vascular endothelial cell | 2 | 13 | 2.43e-01 |
| GO:BP | GO:0002011 | morphogenesis of an epithelial sheet | 1 | 52 | 2.43e-01 |
| GO:BP | GO:0006633 | fatty acid biosynthetic process | 1 | 104 | 2.43e-01 |
| GO:BP | GO:0001980 | regulation of systemic arterial blood pressure by ischemic conditions | 1 | 1 | 2.44e-01 |
| GO:BP | GO:1905898 | positive regulation of response to endoplasmic reticulum stress | 2 | 34 | 2.44e-01 |
| GO:BP | GO:0090481 | pyrimidine nucleotide-sugar transmembrane transport | 1 | 12 | 2.44e-01 |
| GO:BP | GO:1901725 | regulation of histone deacetylase activity | 2 | 8 | 2.44e-01 |
| GO:BP | GO:0035281 | pre-miRNA export from nucleus | 1 | 2 | 2.44e-01 |
| GO:BP | GO:0010658 | striated muscle cell apoptotic process | 3 | 39 | 2.44e-01 |
| GO:BP | GO:0016486 | peptide hormone processing | 1 | 27 | 2.44e-01 |
| GO:BP | GO:0014706 | striated muscle tissue development | 1 | 210 | 2.44e-01 |
| GO:BP | GO:0006681 | galactosylceramide metabolic process | 1 | 5 | 2.44e-01 |
| GO:BP | GO:0061015 | snRNA import into nucleus | 1 | 2 | 2.44e-01 |
| GO:BP | GO:0086002 | cardiac muscle cell action potential involved in contraction | 3 | 45 | 2.44e-01 |
| GO:BP | GO:0019374 | galactolipid metabolic process | 1 | 5 | 2.44e-01 |
| GO:BP | GO:0036123 | histone H3-K9 dimethylation | 1 | 3 | 2.44e-01 |
| GO:BP | GO:2000515 | negative regulation of CD4-positive, alpha-beta T cell activation | 2 | 21 | 2.44e-01 |
| GO:BP | GO:0060348 | bone development | 1 | 170 | 2.44e-01 |
| GO:BP | GO:1902570 | protein localization to nucleolus | 2 | 15 | 2.44e-01 |
| GO:BP | GO:0051169 | nuclear transport | 16 | 295 | 2.44e-01 |
| GO:BP | GO:0006913 | nucleocytoplasmic transport | 16 | 295 | 2.44e-01 |
| GO:BP | GO:0050819 | negative regulation of coagulation | 3 | 38 | 2.45e-01 |
| GO:BP | GO:0072001 | renal system development | 25 | 251 | 2.45e-01 |
| GO:BP | GO:0022617 | extracellular matrix disassembly | 1 | 36 | 2.45e-01 |
| GO:BP | GO:1900024 | regulation of substrate adhesion-dependent cell spreading | 1 | 54 | 2.45e-01 |
| GO:BP | GO:1903036 | positive regulation of response to wounding | 3 | 55 | 2.46e-01 |
| GO:BP | GO:0048313 | Golgi inheritance | 1 | 15 | 2.46e-01 |
| GO:BP | GO:0090272 | negative regulation of fibroblast growth factor production | 1 | 2 | 2.46e-01 |
| GO:BP | GO:0006486 | protein glycosylation | 4 | 187 | 2.46e-01 |
| GO:BP | GO:0061684 | chaperone-mediated autophagy | 1 | 16 | 2.46e-01 |
| GO:BP | GO:0006110 | regulation of glycolytic process | 7 | 40 | 2.46e-01 |
| GO:BP | GO:0097120 | receptor localization to synapse | 9 | 55 | 2.46e-01 |
| GO:BP | GO:0048308 | organelle inheritance | 1 | 15 | 2.46e-01 |
| GO:BP | GO:0006206 | pyrimidine nucleobase metabolic process | 1 | 13 | 2.46e-01 |
| GO:BP | GO:0045428 | regulation of nitric oxide biosynthetic process | 2 | 38 | 2.46e-01 |
| GO:BP | GO:0043413 | macromolecule glycosylation | 4 | 187 | 2.46e-01 |
| GO:BP | GO:0071902 | positive regulation of protein serine/threonine kinase activity | 14 | 135 | 2.47e-01 |
| GO:BP | GO:0036508 | protein alpha-1,2-demannosylation | 3 | 17 | 2.47e-01 |
| GO:BP | GO:0036507 | protein demannosylation | 3 | 17 | 2.47e-01 |
| GO:BP | GO:1905518 | regulation of presynaptic active zone assembly | 1 | 1 | 2.47e-01 |
| GO:BP | GO:0150036 | regulation of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission | 1 | 1 | 2.47e-01 |
| GO:BP | GO:1905520 | positive regulation of presynaptic active zone assembly | 1 | 1 | 2.47e-01 |
| GO:BP | GO:0090126 | protein-containing complex assembly involved in synapse maturation | 1 | 1 | 2.47e-01 |
| GO:BP | GO:0048630 | skeletal muscle tissue growth | 2 | 8 | 2.47e-01 |
| GO:BP | GO:0098903 | regulation of membrane repolarization during action potential | 1 | 6 | 2.47e-01 |
| GO:BP | GO:0007052 | mitotic spindle organization | 2 | 129 | 2.47e-01 |
| GO:BP | GO:0048515 | spermatid differentiation | 3 | 111 | 2.47e-01 |
| GO:BP | GO:0021527 | spinal cord association neuron differentiation | 1 | 3 | 2.47e-01 |
| GO:BP | GO:0048667 | cell morphogenesis involved in neuron differentiation | 6 | 463 | 2.47e-01 |
| GO:BP | GO:0010614 | negative regulation of cardiac muscle hypertrophy | 1 | 26 | 2.47e-01 |
| GO:BP | GO:0048534 | hematopoietic or lymphoid organ development | 2 | 70 | 2.48e-01 |
| GO:BP | GO:0044806 | G-quadruplex DNA unwinding | 1 | 7 | 2.48e-01 |
| GO:BP | GO:0071397 | cellular response to cholesterol | 1 | 11 | 2.48e-01 |
| GO:BP | GO:0021819 | layer formation in cerebral cortex | 1 | 12 | 2.48e-01 |
| GO:BP | GO:0061757 | leukocyte adhesion to arterial endothelial cell | 1 | 4 | 2.48e-01 |
| GO:BP | GO:0106014 | regulation of inflammatory response to wounding | 1 | 4 | 2.48e-01 |
| GO:BP | GO:1903608 | protein localization to cytoplasmic stress granule | 1 | 7 | 2.48e-01 |
| GO:BP | GO:0001990 | regulation of systemic arterial blood pressure by hormone | 1 | 22 | 2.48e-01 |
| GO:BP | GO:0097176 | epoxide metabolic process | 1 | 4 | 2.48e-01 |
| GO:BP | GO:0040011 | locomotion | 54 | 954 | 2.48e-01 |
| GO:BP | GO:1903847 | regulation of aorta morphogenesis | 1 | 2 | 2.48e-01 |
| GO:BP | GO:0032741 | positive regulation of interleukin-18 production | 1 | 1 | 2.48e-01 |
| GO:BP | GO:0061436 | establishment of skin barrier | 1 | 18 | 2.48e-01 |
| GO:BP | GO:0003184 | pulmonary valve morphogenesis | 1 | 19 | 2.48e-01 |
| GO:BP | GO:0097211 | cellular response to gonadotropin-releasing hormone | 2 | 3 | 2.48e-01 |
| GO:BP | GO:0097531 | mast cell migration | 3 | 12 | 2.48e-01 |
| GO:BP | GO:1903849 | positive regulation of aorta morphogenesis | 1 | 2 | 2.48e-01 |
| GO:BP | GO:0033320 | UDP-D-xylose biosynthetic process | 1 | 1 | 2.48e-01 |
| GO:BP | GO:0033319 | UDP-D-xylose metabolic process | 1 | 1 | 2.48e-01 |
| GO:BP | GO:0015780 | nucleotide-sugar transmembrane transport | 1 | 13 | 2.48e-01 |
| GO:BP | GO:0016477 | cell migration | 20 | 1081 | 2.48e-01 |
| GO:BP | GO:0021979 | hypothalamus cell differentiation | 3 | 8 | 2.48e-01 |
| GO:BP | GO:0016237 | lysosomal microautophagy | 1 | 11 | 2.48e-01 |
| GO:BP | GO:0006423 | cysteinyl-tRNA aminoacylation | 1 | 2 | 2.48e-01 |
| GO:BP | GO:0000226 | microtubule cytoskeleton organization | 5 | 552 | 2.48e-01 |
| GO:BP | GO:0140448 | signaling receptor ligand precursor processing | 1 | 29 | 2.48e-01 |
| GO:BP | GO:0015842 | aminergic neurotransmitter loading into synaptic vesicle | 1 | 1 | 2.48e-01 |
| GO:BP | GO:0031468 | nuclear membrane reassembly | 1 | 24 | 2.48e-01 |
| GO:BP | GO:1904031 | positive regulation of cyclin-dependent protein kinase activity | 6 | 26 | 2.48e-01 |
| GO:BP | GO:0006109 | regulation of carbohydrate metabolic process | 8 | 144 | 2.48e-01 |
| GO:BP | GO:0030048 | actin filament-based movement | 5 | 112 | 2.48e-01 |
| GO:BP | GO:0051615 | histamine uptake | 1 | 3 | 2.48e-01 |
| GO:BP | GO:0060964 | regulation of miRNA-mediated gene silencing | 2 | 25 | 2.48e-01 |
| GO:BP | GO:2001032 | regulation of double-strand break repair via nonhomologous end joining | 4 | 25 | 2.49e-01 |
| GO:BP | GO:0051918 | negative regulation of fibrinolysis | 3 | 8 | 2.49e-01 |
| GO:BP | GO:0009173 | pyrimidine ribonucleoside monophosphate metabolic process | 1 | 12 | 2.49e-01 |
| GO:BP | GO:1905037 | autophagosome organization | 4 | 110 | 2.49e-01 |
| GO:BP | GO:0021510 | spinal cord development | 2 | 59 | 2.49e-01 |
| GO:BP | GO:0072283 | metanephric renal vesicle morphogenesis | 3 | 11 | 2.49e-01 |
| GO:BP | GO:0018023 | peptidyl-lysine trimethylation | 2 | 33 | 2.49e-01 |
| GO:BP | GO:0070127 | tRNA aminoacylation for mitochondrial protein translation | 1 | 8 | 2.50e-01 |
| GO:BP | GO:1903322 | positive regulation of protein modification by small protein conjugation or removal | 2 | 126 | 2.50e-01 |
| GO:BP | GO:0042771 | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 3 | 43 | 2.50e-01 |
| GO:BP | GO:0046831 | regulation of RNA export from nucleus | 2 | 12 | 2.50e-01 |
| GO:BP | GO:0016072 | rRNA metabolic process | 6 | 258 | 2.50e-01 |
| GO:BP | GO:0072384 | organelle transport along microtubule | 1 | 84 | 2.50e-01 |
| GO:BP | GO:0046322 | negative regulation of fatty acid oxidation | 2 | 12 | 2.50e-01 |
| GO:BP | GO:0086013 | membrane repolarization during cardiac muscle cell action potential | 2 | 18 | 2.51e-01 |
| GO:BP | GO:0042998 | positive regulation of Golgi to plasma membrane protein transport | 1 | 5 | 2.51e-01 |
| GO:BP | GO:2000042 | negative regulation of double-strand break repair via homologous recombination | 2 | 16 | 2.51e-01 |
| GO:BP | GO:2000559 | regulation of CD24 production | 1 | 1 | 2.51e-01 |
| GO:BP | GO:0021987 | cerebral cortex development | 3 | 101 | 2.51e-01 |
| GO:BP | GO:0030162 | regulation of proteolysis | 59 | 535 | 2.51e-01 |
| GO:BP | GO:0071421 | manganese ion transmembrane transport | 2 | 7 | 2.51e-01 |
| GO:BP | GO:0071363 | cellular response to growth factor stimulus | 34 | 551 | 2.51e-01 |
| GO:BP | GO:1905630 | response to glyceraldehyde | 1 | 1 | 2.51e-01 |
| GO:BP | GO:0014741 | negative regulation of muscle hypertrophy | 1 | 27 | 2.51e-01 |
| GO:BP | GO:0043405 | regulation of MAP kinase activity | 13 | 141 | 2.51e-01 |
| GO:BP | GO:1901096 | regulation of autophagosome maturation | 3 | 16 | 2.51e-01 |
| GO:BP | GO:0006509 | membrane protein ectodomain proteolysis | 5 | 34 | 2.51e-01 |
| GO:BP | GO:0045652 | regulation of megakaryocyte differentiation | 1 | 33 | 2.51e-01 |
| GO:BP | GO:2000807 | regulation of synaptic vesicle clustering | 2 | 7 | 2.51e-01 |
| GO:BP | GO:0001881 | receptor recycling | 1 | 38 | 2.51e-01 |
| GO:BP | GO:0048280 | vesicle fusion with Golgi apparatus | 1 | 8 | 2.51e-01 |
| GO:BP | GO:0001837 | epithelial to mesenchymal transition | 2 | 138 | 2.51e-01 |
| GO:BP | GO:0080164 | regulation of nitric oxide metabolic process | 2 | 40 | 2.51e-01 |
| GO:BP | GO:0051097 | negative regulation of helicase activity | 1 | 5 | 2.51e-01 |
| GO:BP | GO:0045922 | negative regulation of fatty acid metabolic process | 3 | 25 | 2.51e-01 |
| GO:BP | GO:2000560 | positive regulation of CD24 production | 1 | 1 | 2.51e-01 |
| GO:BP | GO:0032984 | protein-containing complex disassembly | 9 | 222 | 2.51e-01 |
| GO:BP | GO:1900182 | positive regulation of protein localization to nucleus | 5 | 75 | 2.51e-01 |
| GO:BP | GO:0060672 | epithelial cell morphogenesis involved in placental branching | 1 | 2 | 2.51e-01 |
| GO:BP | GO:1903078 | positive regulation of protein localization to plasma membrane | 1 | 50 | 2.51e-01 |
| GO:BP | GO:0046326 | positive regulation of glucose import | 3 | 26 | 2.51e-01 |
| GO:BP | GO:0060671 | epithelial cell differentiation involved in embryonic placenta development | 1 | 2 | 2.51e-01 |
| GO:BP | GO:0035724 | CD24 biosynthetic process | 1 | 1 | 2.51e-01 |
| GO:BP | GO:0006828 | manganese ion transport | 2 | 7 | 2.51e-01 |
| GO:BP | GO:2000438 | negative regulation of monocyte extravasation | 1 | 1 | 2.51e-01 |
| GO:BP | GO:1905314 | semi-lunar valve development | 5 | 41 | 2.51e-01 |
| GO:BP | GO:0009790 | embryo development | 4 | 875 | 2.51e-01 |
| GO:BP | GO:0061444 | endocardial cushion cell development | 1 | 1 | 2.51e-01 |
| GO:BP | GO:0090092 | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 1 | 230 | 2.51e-01 |
| GO:BP | GO:1903052 | positive regulation of proteolysis involved in protein catabolic process | 2 | 127 | 2.51e-01 |
| GO:BP | GO:0021514 | ventral spinal cord interneuron differentiation | 1 | 5 | 2.51e-01 |
| GO:BP | GO:0046476 | glycosylceramide biosynthetic process | 1 | 6 | 2.51e-01 |
| GO:BP | GO:0048870 | cell motility | 22 | 1182 | 2.51e-01 |
| GO:BP | GO:0098703 | calcium ion import across plasma membrane | 2 | 23 | 2.51e-01 |
| GO:BP | GO:0010721 | negative regulation of cell development | 1 | 191 | 2.51e-01 |
| GO:BP | GO:2000319 | regulation of T-helper 17 cell differentiation | 1 | 10 | 2.51e-01 |
| GO:BP | GO:1905631 | cellular response to glyceraldehyde | 1 | 1 | 2.51e-01 |
| GO:BP | GO:1990390 | protein K33-linked ubiquitination | 1 | 2 | 2.51e-01 |
| GO:BP | GO:0060491 | regulation of cell projection assembly | 16 | 167 | 2.51e-01 |
| GO:BP | GO:0099072 | regulation of postsynaptic membrane neurotransmitter receptor levels | 11 | 70 | 2.51e-01 |
| GO:BP | GO:1902888 | protein localization to astral microtubule | 1 | 1 | 2.51e-01 |
| GO:BP | GO:0072521 | purine-containing compound metabolic process | 2 | 390 | 2.51e-01 |
| GO:BP | GO:0051783 | regulation of nuclear division | 2 | 116 | 2.51e-01 |
| GO:BP | GO:0042245 | RNA repair | 1 | 2 | 2.51e-01 |
| GO:BP | GO:0051146 | striated muscle cell differentiation | 1 | 233 | 2.51e-01 |
| GO:BP | GO:0050852 | T cell receptor signaling pathway | 2 | 84 | 2.51e-01 |
| GO:BP | GO:0045780 | positive regulation of bone resorption | 3 | 12 | 2.51e-01 |
| GO:BP | GO:0010529 | negative regulation of transposition | 1 | 14 | 2.51e-01 |
| GO:BP | GO:0010528 | regulation of transposition | 1 | 14 | 2.51e-01 |
| GO:BP | GO:0002101 | tRNA wobble cytosine modification | 1 | 2 | 2.51e-01 |
| GO:BP | GO:0051168 | nuclear export | 12 | 150 | 2.51e-01 |
| GO:BP | GO:1904024 | negative regulation of glucose catabolic process to lactate via pyruvate | 1 | 3 | 2.51e-01 |
| GO:BP | GO:0040036 | regulation of fibroblast growth factor receptor signaling pathway | 4 | 25 | 2.51e-01 |
| GO:BP | GO:0006596 | polyamine biosynthetic process | 3 | 13 | 2.51e-01 |
| GO:BP | GO:0044827 | modulation by host of viral genome replication | 1 | 21 | 2.52e-01 |
| GO:BP | GO:0043371 | negative regulation of CD4-positive, alpha-beta T cell differentiation | 1 | 14 | 2.52e-01 |
| GO:BP | GO:0000271 | polysaccharide biosynthetic process | 4 | 53 | 2.53e-01 |
| GO:BP | GO:0002069 | columnar/cuboidal epithelial cell maturation | 3 | 9 | 2.53e-01 |
| GO:BP | GO:0035357 | peroxisome proliferator activated receptor signaling pathway | 2 | 19 | 2.53e-01 |
| GO:BP | GO:0015012 | heparan sulfate proteoglycan biosynthetic process | 1 | 27 | 2.53e-01 |
| GO:BP | GO:0090398 | cellular senescence | 4 | 83 | 2.53e-01 |
| GO:BP | GO:1900006 | positive regulation of dendrite development | 1 | 14 | 2.53e-01 |
| GO:BP | GO:0042770 | signal transduction in response to DNA damage | 6 | 178 | 2.53e-01 |
| GO:BP | GO:0009950 | dorsal/ventral axis specification | 2 | 9 | 2.53e-01 |
| GO:BP | GO:0045834 | positive regulation of lipid metabolic process | 7 | 108 | 2.53e-01 |
| GO:BP | GO:0007420 | brain development | 12 | 591 | 2.54e-01 |
| GO:BP | GO:2000767 | positive regulation of cytoplasmic translation | 2 | 13 | 2.54e-01 |
| GO:BP | GO:0099623 | regulation of cardiac muscle cell membrane repolarization | 2 | 20 | 2.54e-01 |
| GO:BP | GO:0010911 | regulation of isomerase activity | 1 | 5 | 2.54e-01 |
| GO:BP | GO:0010912 | positive regulation of isomerase activity | 1 | 5 | 2.54e-01 |
| GO:BP | GO:0021761 | limbic system development | 13 | 81 | 2.54e-01 |
| GO:BP | GO:0001822 | kidney development | 24 | 244 | 2.54e-01 |
| GO:BP | GO:0035790 | platelet-derived growth factor receptor-alpha signaling pathway | 2 | 6 | 2.54e-01 |
| GO:BP | GO:1900368 | regulation of post-transcriptional gene silencing by RNA | 2 | 27 | 2.54e-01 |
| GO:BP | GO:0046320 | regulation of fatty acid oxidation | 3 | 31 | 2.54e-01 |
| GO:BP | GO:0019752 | carboxylic acid metabolic process | 2 | 681 | 2.55e-01 |
| GO:BP | GO:0042255 | ribosome assembly | 1 | 56 | 2.55e-01 |
| GO:BP | GO:0000075 | cell cycle checkpoint signaling | 6 | 183 | 2.55e-01 |
| GO:BP | GO:0046323 | glucose import | 6 | 53 | 2.55e-01 |
| GO:BP | GO:1904876 | negative regulation of DNA ligase activity | 1 | 1 | 2.55e-01 |
| GO:BP | GO:0002692 | negative regulation of cellular extravasation | 2 | 5 | 2.55e-01 |
| GO:BP | GO:0070527 | platelet aggregation | 1 | 52 | 2.55e-01 |
| GO:BP | GO:0051107 | negative regulation of DNA ligation | 1 | 1 | 2.55e-01 |
| GO:BP | GO:0046112 | nucleobase biosynthetic process | 1 | 18 | 2.55e-01 |
| GO:BP | GO:0090131 | mesenchyme migration | 1 | 4 | 2.55e-01 |
| GO:BP | GO:0072144 | glomerular mesangial cell development | 1 | 4 | 2.55e-01 |
| GO:BP | GO:0001893 | maternal placenta development | 5 | 28 | 2.55e-01 |
| GO:BP | GO:2000491 | positive regulation of hepatic stellate cell activation | 1 | 4 | 2.55e-01 |
| GO:BP | GO:0045822 | negative regulation of heart contraction | 1 | 17 | 2.55e-01 |
| GO:BP | GO:0003279 | cardiac septum development | 2 | 101 | 2.55e-01 |
| GO:BP | GO:0072578 | neurotransmitter-gated ion channel clustering | 3 | 12 | 2.56e-01 |
| GO:BP | GO:0007173 | epidermal growth factor receptor signaling pathway | 12 | 93 | 2.56e-01 |
| GO:BP | GO:0060489 | planar dichotomous subdivision of terminal units involved in lung branching morphogenesis | 1 | 1 | 2.57e-01 |
| GO:BP | GO:0060490 | lateral sprouting involved in lung morphogenesis | 1 | 1 | 2.57e-01 |
| GO:BP | GO:0006405 | RNA export from nucleus | 6 | 78 | 2.57e-01 |
| GO:BP | GO:0060488 | orthogonal dichotomous subdivision of terminal units involved in lung branching morphogenesis | 1 | 1 | 2.57e-01 |
| GO:BP | GO:1901607 | alpha-amino acid biosynthetic process | 5 | 59 | 2.57e-01 |
| GO:BP | GO:0070830 | bicellular tight junction assembly | 1 | 43 | 2.57e-01 |
| GO:BP | GO:0002532 | production of molecular mediator involved in inflammatory response | 3 | 49 | 2.58e-01 |
| GO:BP | GO:0061003 | positive regulation of dendritic spine morphogenesis | 1 | 17 | 2.59e-01 |
| GO:BP | GO:0007018 | microtubule-based movement | 2 | 300 | 2.59e-01 |
| GO:BP | GO:0006082 | organic acid metabolic process | 2 | 700 | 2.59e-01 |
| GO:BP | GO:0003430 | growth plate cartilage chondrocyte growth | 1 | 3 | 2.59e-01 |
| GO:BP | GO:0070997 | neuron death | 14 | 286 | 2.59e-01 |
| GO:BP | GO:0002383 | immune response in brain or nervous system | 1 | 1 | 2.59e-01 |
| GO:BP | GO:0021814 | cell motility involved in cerebral cortex radial glia guided migration | 2 | 7 | 2.59e-01 |
| GO:BP | GO:0035601 | protein deacylation | 9 | 116 | 2.59e-01 |
| GO:BP | GO:1904377 | positive regulation of protein localization to cell periphery | 1 | 57 | 2.59e-01 |
| GO:BP | GO:0017014 | protein nitrosylation | 2 | 11 | 2.59e-01 |
| GO:BP | GO:0071347 | cellular response to interleukin-1 | 2 | 64 | 2.59e-01 |
| GO:BP | GO:0031532 | actin cytoskeleton reorganization | 12 | 96 | 2.59e-01 |
| GO:BP | GO:0006977 | DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest | 1 | 18 | 2.59e-01 |
| GO:BP | GO:0003177 | pulmonary valve development | 1 | 22 | 2.59e-01 |
| GO:BP | GO:0043436 | oxoacid metabolic process | 2 | 696 | 2.59e-01 |
| GO:BP | GO:0060147 | regulation of post-transcriptional gene silencing | 2 | 28 | 2.59e-01 |
| GO:BP | GO:0018119 | peptidyl-cysteine S-nitrosylation | 2 | 11 | 2.59e-01 |
| GO:BP | GO:0097281 | immune complex formation | 1 | 1 | 2.59e-01 |
| GO:BP | GO:2001300 | lipoxin metabolic process | 1 | 3 | 2.59e-01 |
| GO:BP | GO:1903523 | negative regulation of blood circulation | 1 | 18 | 2.59e-01 |
| GO:BP | GO:0010884 | positive regulation of lipid storage | 1 | 18 | 2.59e-01 |
| GO:BP | GO:0016575 | histone deacetylation | 7 | 87 | 2.59e-01 |
| GO:BP | GO:0042063 | gliogenesis | 3 | 235 | 2.60e-01 |
| GO:BP | GO:0060996 | dendritic spine development | 3 | 80 | 2.60e-01 |
| GO:BP | GO:0048672 | positive regulation of collateral sprouting | 1 | 10 | 2.60e-01 |
| GO:BP | GO:1900016 | negative regulation of cytokine production involved in inflammatory response | 1 | 13 | 2.61e-01 |
| GO:BP | GO:0001707 | mesoderm formation | 1 | 53 | 2.61e-01 |
| GO:BP | GO:0010498 | proteasomal protein catabolic process | 45 | 486 | 2.61e-01 |
| GO:BP | GO:0045589 | regulation of regulatory T cell differentiation | 3 | 21 | 2.61e-01 |
| GO:BP | GO:0060966 | regulation of gene silencing by RNA | 2 | 29 | 2.61e-01 |
| GO:BP | GO:1900112 | regulation of histone H3-K9 trimethylation | 1 | 5 | 2.61e-01 |
| GO:BP | GO:0061180 | mammary gland epithelium development | 1 | 57 | 2.61e-01 |
| GO:BP | GO:2000698 | positive regulation of epithelial cell differentiation involved in kidney development | 2 | 5 | 2.61e-01 |
| GO:BP | GO:0072330 | monocarboxylic acid biosynthetic process | 1 | 145 | 2.61e-01 |
| GO:BP | GO:0010265 | SCF complex assembly | 1 | 2 | 2.61e-01 |
| GO:BP | GO:0003044 | regulation of systemic arterial blood pressure mediated by a chemical signal | 1 | 30 | 2.61e-01 |
| GO:BP | GO:0048789 | cytoskeletal matrix organization at active zone | 1 | 1 | 2.61e-01 |
| GO:BP | GO:0010212 | response to ionizing radiation | 5 | 130 | 2.61e-01 |
| GO:BP | GO:1902033 | regulation of hematopoietic stem cell proliferation | 2 | 12 | 2.61e-01 |
| GO:BP | GO:0010501 | RNA secondary structure unwinding | 1 | 8 | 2.61e-01 |
| GO:BP | GO:0006290 | pyrimidine dimer repair | 2 | 8 | 2.61e-01 |
| GO:BP | GO:0070922 | RISC complex assembly | 1 | 9 | 2.61e-01 |
| GO:BP | GO:0016260 | selenocysteine biosynthetic process | 1 | 2 | 2.61e-01 |
| GO:BP | GO:0048207 | vesicle targeting, rough ER to cis-Golgi | 1 | 24 | 2.61e-01 |
| GO:BP | GO:0051496 | positive regulation of stress fiber assembly | 4 | 47 | 2.61e-01 |
| GO:BP | GO:0048208 | COPII vesicle coating | 1 | 24 | 2.61e-01 |
| GO:BP | GO:1905610 | regulation of mRNA cap binding | 1 | 1 | 2.61e-01 |
| GO:BP | GO:0007498 | mesoderm development | 2 | 89 | 2.61e-01 |
| GO:BP | GO:0070932 | histone H3 deacetylation | 2 | 12 | 2.61e-01 |
| GO:BP | GO:1905612 | positive regulation of mRNA cap binding | 1 | 1 | 2.61e-01 |
| GO:BP | GO:0033169 | histone H3-K9 demethylation | 1 | 5 | 2.61e-01 |
| GO:BP | GO:0071359 | cellular response to dsRNA | 3 | 18 | 2.61e-01 |
| GO:BP | GO:0003339 | regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis | 2 | 4 | 2.61e-01 |
| GO:BP | GO:0031098 | stress-activated protein kinase signaling cascade | 23 | 196 | 2.61e-01 |
| GO:BP | GO:0007143 | female meiotic nuclear division | 4 | 25 | 2.61e-01 |
| GO:BP | GO:0034612 | response to tumor necrosis factor | 5 | 172 | 2.61e-01 |
| GO:BP | GO:0033028 | myeloid cell apoptotic process | 4 | 25 | 2.61e-01 |
| GO:BP | GO:0001887 | selenium compound metabolic process | 1 | 2 | 2.61e-01 |
| GO:BP | GO:0008360 | regulation of cell shape | 15 | 126 | 2.61e-01 |
| GO:BP | GO:0008347 | glial cell migration | 2 | 47 | 2.61e-01 |
| GO:BP | GO:0032196 | transposition | 1 | 17 | 2.61e-01 |
| GO:BP | GO:0120192 | tight junction assembly | 1 | 47 | 2.61e-01 |
| GO:BP | GO:0070085 | glycosylation | 4 | 202 | 2.61e-01 |
| GO:BP | GO:0009176 | pyrimidine deoxyribonucleoside monophosphate metabolic process | 2 | 9 | 2.61e-01 |
| GO:BP | GO:0006575 | cellular modified amino acid metabolic process | 1 | 96 | 2.61e-01 |
| GO:BP | GO:0097115 | neurexin clustering involved in presynaptic membrane assembly | 1 | 1 | 2.61e-01 |
| GO:BP | GO:1905535 | regulation of eukaryotic translation initiation factor 4F complex assembly | 1 | 1 | 2.61e-01 |
| GO:BP | GO:0006543 | glutamine catabolic process | 1 | 3 | 2.61e-01 |
| GO:BP | GO:0032273 | positive regulation of protein polymerization | 5 | 76 | 2.61e-01 |
| GO:BP | GO:1905537 | positive regulation of eukaryotic translation initiation factor 4F complex assembly | 1 | 1 | 2.61e-01 |
| GO:BP | GO:0051573 | negative regulation of histone H3-K9 methylation | 1 | 5 | 2.61e-01 |
| GO:BP | GO:0007296 | vitellogenesis | 1 | 4 | 2.61e-01 |
| GO:BP | GO:0016032 | viral process | 3 | 344 | 2.61e-01 |
| GO:BP | GO:0140243 | regulation of translation at synapse | 2 | 6 | 2.61e-01 |
| GO:BP | GO:0140245 | regulation of translation at postsynapse | 2 | 6 | 2.61e-01 |
| GO:BP | GO:0046697 | decidualization | 4 | 19 | 2.61e-01 |
| GO:BP | GO:1904886 | beta-catenin destruction complex disassembly | 1 | 4 | 2.61e-01 |
| GO:BP | GO:0097712 | vesicle targeting, trans-Golgi to periciliary membrane compartment | 1 | 1 | 2.61e-01 |
| GO:BP | GO:0046324 | regulation of glucose import | 5 | 41 | 2.61e-01 |
| GO:BP | GO:0030111 | regulation of Wnt signaling pathway | 1 | 273 | 2.61e-01 |
| GO:BP | GO:0036159 | inner dynein arm assembly | 1 | 8 | 2.61e-01 |
| GO:BP | GO:0016239 | positive regulation of macroautophagy | 3 | 70 | 2.61e-01 |
| GO:BP | GO:1904528 | positive regulation of microtubule binding | 2 | 6 | 2.61e-01 |
| GO:BP | GO:0044557 | relaxation of smooth muscle | 2 | 9 | 2.61e-01 |
| GO:BP | GO:0007417 | central nervous system development | 15 | 792 | 2.62e-01 |
| GO:BP | GO:1904587 | response to glycoprotein | 1 | 5 | 2.62e-01 |
| GO:BP | GO:0030032 | lamellipodium assembly | 1 | 61 | 2.62e-01 |
| GO:BP | GO:0003181 | atrioventricular valve morphogenesis | 1 | 25 | 2.62e-01 |
| GO:BP | GO:0003189 | aortic valve formation | 1 | 2 | 2.62e-01 |
| GO:BP | GO:0006782 | protoporphyrinogen IX biosynthetic process | 1 | 9 | 2.62e-01 |
| GO:BP | GO:0032689 | negative regulation of type II interferon production | 2 | 16 | 2.62e-01 |
| GO:BP | GO:0051648 | vesicle localization | 17 | 192 | 2.62e-01 |
| GO:BP | GO:0048332 | mesoderm morphogenesis | 1 | 55 | 2.62e-01 |
| GO:BP | GO:0030033 | microvillus assembly | 3 | 15 | 2.62e-01 |
| GO:BP | GO:0043297 | apical junction assembly | 1 | 51 | 2.62e-01 |
| GO:BP | GO:0097326 | melanocyte adhesion | 1 | 1 | 2.62e-01 |
| GO:BP | GO:0050790 | regulation of catalytic activity | 53 | 1380 | 2.62e-01 |
| GO:BP | GO:1990765 | colon smooth muscle contraction | 1 | 1 | 2.62e-01 |
| GO:BP | GO:0014828 | distal stomach smooth muscle contraction | 1 | 1 | 2.62e-01 |
| GO:BP | GO:0006903 | vesicle targeting | 7 | 61 | 2.62e-01 |
| GO:BP | GO:1904343 | positive regulation of colon smooth muscle contraction | 1 | 1 | 2.62e-01 |
| GO:BP | GO:1904341 | regulation of colon smooth muscle contraction | 1 | 1 | 2.62e-01 |
| GO:BP | GO:0120072 | positive regulation of pyloric antrum smooth muscle contraction | 1 | 1 | 2.62e-01 |
| GO:BP | GO:0120071 | regulation of pyloric antrum smooth muscle contraction | 1 | 1 | 2.62e-01 |
| GO:BP | GO:0120065 | pyloric antrum smooth muscle contraction | 1 | 1 | 2.62e-01 |
| GO:BP | GO:0120064 | stomach pylorus smooth muscle contraction | 1 | 1 | 2.62e-01 |
| GO:BP | GO:0120063 | stomach smooth muscle contraction | 1 | 1 | 2.62e-01 |
| GO:BP | GO:0048562 | embryonic organ morphogenesis | 2 | 187 | 2.62e-01 |
| GO:BP | GO:0060600 | dichotomous subdivision of an epithelial terminal unit | 2 | 8 | 2.62e-01 |
| GO:BP | GO:0036315 | cellular response to sterol | 1 | 14 | 2.62e-01 |
| GO:BP | GO:0021522 | spinal cord motor neuron differentiation | 2 | 18 | 2.63e-01 |
| GO:BP | GO:0007612 | learning | 11 | 115 | 2.63e-01 |
| GO:BP | GO:0038180 | nerve growth factor signaling pathway | 1 | 10 | 2.63e-01 |
| GO:BP | GO:0070070 | proton-transporting V-type ATPase complex assembly | 1 | 7 | 2.63e-01 |
| GO:BP | GO:0097345 | mitochondrial outer membrane permeabilization | 2 | 35 | 2.63e-01 |
| GO:BP | GO:0022407 | regulation of cell-cell adhesion | 16 | 295 | 2.64e-01 |
| GO:BP | GO:0140239 | postsynaptic endocytosis | 4 | 17 | 2.64e-01 |
| GO:BP | GO:0098884 | postsynaptic neurotransmitter receptor internalization | 4 | 17 | 2.64e-01 |
| GO:BP | GO:0051444 | negative regulation of ubiquitin-protein transferase activity | 1 | 21 | 2.64e-01 |
| GO:BP | GO:0033131 | regulation of glucokinase activity | 1 | 7 | 2.64e-01 |
| GO:BP | GO:0009064 | glutamine family amino acid metabolic process | 4 | 60 | 2.65e-01 |
| GO:BP | GO:0097022 | lymphocyte migration into lymph node | 1 | 2 | 2.66e-01 |
| GO:BP | GO:0006337 | nucleosome disassembly | 3 | 16 | 2.66e-01 |
| GO:BP | GO:0009267 | cellular response to starvation | 2 | 152 | 2.66e-01 |
| GO:BP | GO:0071896 | protein localization to adherens junction | 1 | 6 | 2.66e-01 |
| GO:BP | GO:0031065 | positive regulation of histone deacetylation | 3 | 22 | 2.66e-01 |
| GO:BP | GO:0046341 | CDP-diacylglycerol metabolic process | 3 | 13 | 2.66e-01 |
| GO:BP | GO:0120193 | tight junction organization | 1 | 52 | 2.66e-01 |
| GO:BP | GO:0046639 | negative regulation of alpha-beta T cell differentiation | 1 | 17 | 2.66e-01 |
| GO:BP | GO:0001570 | vasculogenesis | 2 | 67 | 2.66e-01 |
| GO:BP | GO:0007017 | microtubule-based process | 6 | 760 | 2.66e-01 |
| GO:BP | GO:0031954 | positive regulation of protein autophosphorylation | 4 | 26 | 2.66e-01 |
| GO:BP | GO:0010032 | meiotic chromosome condensation | 2 | 6 | 2.67e-01 |
| GO:BP | GO:0009636 | response to toxic substance | 1 | 158 | 2.67e-01 |
| GO:BP | GO:0150065 | regulation of deacetylase activity | 2 | 10 | 2.67e-01 |
| GO:BP | GO:0007517 | muscle organ development | 1 | 277 | 2.68e-01 |
| GO:BP | GO:0035845 | photoreceptor cell outer segment organization | 2 | 10 | 2.69e-01 |
| GO:BP | GO:0072143 | mesangial cell development | 1 | 5 | 2.69e-01 |
| GO:BP | GO:0019264 | glycine biosynthetic process from serine | 1 | 2 | 2.69e-01 |
| GO:BP | GO:0043588 | skin development | 2 | 175 | 2.69e-01 |
| GO:BP | GO:0072008 | glomerular mesangial cell differentiation | 1 | 4 | 2.69e-01 |
| GO:BP | GO:0035025 | positive regulation of Rho protein signal transduction | 5 | 22 | 2.70e-01 |
| GO:BP | GO:0022029 | telencephalon cell migration | 2 | 44 | 2.70e-01 |
| GO:BP | GO:2000626 | negative regulation of miRNA catabolic process | 1 | 1 | 2.70e-01 |
| GO:BP | GO:0032720 | negative regulation of tumor necrosis factor production | 5 | 32 | 2.70e-01 |
| GO:BP | GO:0010950 | positive regulation of endopeptidase activity | 7 | 126 | 2.70e-01 |
| GO:BP | GO:1900004 | negative regulation of serine-type endopeptidase activity | 1 | 4 | 2.70e-01 |
| GO:BP | GO:1902572 | negative regulation of serine-type peptidase activity | 1 | 4 | 2.70e-01 |
| GO:BP | GO:1901385 | regulation of voltage-gated calcium channel activity | 2 | 29 | 2.70e-01 |
| GO:BP | GO:1900134 | negative regulation of renin secretion into blood stream | 1 | 1 | 2.70e-01 |
| GO:BP | GO:0140235 | RNA polyadenylation at postsynapse | 1 | 1 | 2.70e-01 |
| GO:BP | GO:0036372 | opsin transport | 1 | 2 | 2.70e-01 |
| GO:BP | GO:0009894 | regulation of catabolic process | 10 | 875 | 2.70e-01 |
| GO:BP | GO:0140673 | transcription elongation-coupled chromatin remodeling | 1 | 2 | 2.70e-01 |
| GO:BP | GO:0045664 | regulation of neuron differentiation | 3 | 137 | 2.70e-01 |
| GO:BP | GO:1900745 | positive regulation of p38MAPK cascade | 1 | 22 | 2.70e-01 |
| GO:BP | GO:1901223 | negative regulation of NIK/NF-kappaB signaling | 1 | 21 | 2.70e-01 |
| GO:BP | GO:0039530 | MDA-5 signaling pathway | 2 | 8 | 2.70e-01 |
| GO:BP | GO:0060087 | relaxation of vascular associated smooth muscle | 1 | 7 | 2.71e-01 |
| GO:BP | GO:0002065 | columnar/cuboidal epithelial cell differentiation | 13 | 80 | 2.71e-01 |
| GO:BP | GO:0034486 | vacuolar transmembrane transport | 1 | 3 | 2.71e-01 |
| GO:BP | GO:0098732 | macromolecule deacylation | 9 | 119 | 2.71e-01 |
| GO:BP | GO:0021675 | nerve development | 2 | 57 | 2.71e-01 |
| GO:BP | GO:0051543 | regulation of elastin biosynthetic process | 1 | 1 | 2.71e-01 |
| GO:BP | GO:0051545 | negative regulation of elastin biosynthetic process | 1 | 1 | 2.71e-01 |
| GO:BP | GO:0060219 | camera-type eye photoreceptor cell differentiation | 3 | 18 | 2.71e-01 |
| GO:BP | GO:0001178 | regulation of transcriptional start site selection at RNA polymerase II promoter | 1 | 1 | 2.71e-01 |
| GO:BP | GO:2000772 | regulation of cellular senescence | 2 | 38 | 2.71e-01 |
| GO:BP | GO:0006356 | regulation of transcription by RNA polymerase I | 2 | 45 | 2.71e-01 |
| GO:BP | GO:1902850 | microtubule cytoskeleton organization involved in mitosis | 2 | 157 | 2.71e-01 |
| GO:BP | GO:0071279 | cellular response to cobalt ion | 1 | 4 | 2.71e-01 |
| GO:BP | GO:1904023 | regulation of glucose catabolic process to lactate via pyruvate | 1 | 4 | 2.71e-01 |
| GO:BP | GO:0097210 | response to gonadotropin-releasing hormone | 2 | 4 | 2.71e-01 |
| GO:BP | GO:0050673 | epithelial cell proliferation | 15 | 323 | 2.71e-01 |
| GO:BP | GO:0060074 | synapse maturation | 5 | 25 | 2.71e-01 |
| GO:BP | GO:0019659 | glucose catabolic process to lactate | 1 | 4 | 2.71e-01 |
| GO:BP | GO:0019660 | glycolytic fermentation | 1 | 4 | 2.71e-01 |
| GO:BP | GO:0010667 | negative regulation of cardiac muscle cell apoptotic process | 2 | 21 | 2.71e-01 |
| GO:BP | GO:0019661 | glucose catabolic process to lactate via pyruvate | 1 | 4 | 2.71e-01 |
| GO:BP | GO:0008285 | negative regulation of cell population proliferation | 20 | 513 | 2.71e-01 |
| GO:BP | GO:0030521 | androgen receptor signaling pathway | 2 | 39 | 2.71e-01 |
| GO:BP | GO:0035092 | sperm DNA condensation | 1 | 7 | 2.71e-01 |
| GO:BP | GO:0042254 | ribosome biogenesis | 19 | 301 | 2.71e-01 |
| GO:BP | GO:0003149 | membranous septum morphogenesis | 2 | 8 | 2.71e-01 |
| GO:BP | GO:0048008 | platelet-derived growth factor receptor signaling pathway | 7 | 52 | 2.71e-01 |
| GO:BP | GO:0140694 | non-membrane-bounded organelle assembly | 3 | 357 | 2.71e-01 |
| GO:BP | GO:1904749 | regulation of protein localization to nucleolus | 1 | 7 | 2.71e-01 |
| GO:BP | GO:1901003 | negative regulation of fermentation | 1 | 4 | 2.71e-01 |
| GO:BP | GO:0006790 | sulfur compound metabolic process | 3 | 248 | 2.71e-01 |
| GO:BP | GO:2000779 | regulation of double-strand break repair | 11 | 121 | 2.71e-01 |
| GO:BP | GO:0045913 | positive regulation of carbohydrate metabolic process | 8 | 60 | 2.71e-01 |
| GO:BP | GO:0098974 | postsynaptic actin cytoskeleton organization | 2 | 11 | 2.71e-01 |
| GO:BP | GO:0045860 | positive regulation of protein kinase activity | 32 | 260 | 2.71e-01 |
| GO:BP | GO:0006528 | asparagine metabolic process | 1 | 5 | 2.71e-01 |
| GO:BP | GO:0048227 | plasma membrane to endosome transport | 1 | 8 | 2.71e-01 |
| GO:BP | GO:0048812 | neuron projection morphogenesis | 6 | 512 | 2.71e-01 |
| GO:BP | GO:0043255 | regulation of carbohydrate biosynthetic process | 5 | 77 | 2.71e-01 |
| GO:BP | GO:0032691 | negative regulation of interleukin-1 beta production | 1 | 13 | 2.71e-01 |
| GO:BP | GO:0003171 | atrioventricular valve development | 1 | 27 | 2.72e-01 |
| GO:BP | GO:1902047 | polyamine transmembrane transport | 1 | 10 | 2.72e-01 |
| GO:BP | GO:0003272 | endocardial cushion formation | 1 | 24 | 2.72e-01 |
| GO:BP | GO:0046636 | negative regulation of alpha-beta T cell activation | 2 | 25 | 2.72e-01 |
| GO:BP | GO:0035356 | intracellular triglyceride homeostasis | 1 | 5 | 2.72e-01 |
| GO:BP | GO:0006809 | nitric oxide biosynthetic process | 2 | 51 | 2.72e-01 |
| GO:BP | GO:0030030 | cell projection organization | 4 | 1233 | 2.72e-01 |
| GO:BP | GO:0009220 | pyrimidine ribonucleotide biosynthetic process | 1 | 18 | 2.72e-01 |
| GO:BP | GO:0070662 | mast cell proliferation | 2 | 6 | 2.73e-01 |
| GO:BP | GO:0070666 | regulation of mast cell proliferation | 2 | 6 | 2.73e-01 |
| GO:BP | GO:0007178 | transmembrane receptor protein serine/threonine kinase signaling pathway | 1 | 303 | 2.73e-01 |
| GO:BP | GO:0060284 | regulation of cell development | 5 | 605 | 2.73e-01 |
| GO:BP | GO:0051492 | regulation of stress fiber assembly | 6 | 81 | 2.73e-01 |
| GO:BP | GO:0045595 | regulation of cell differentiation | 3 | 1137 | 2.73e-01 |
| GO:BP | GO:0001967 | suckling behavior | 1 | 10 | 2.73e-01 |
| GO:BP | GO:0050767 | regulation of neurogenesis | 1 | 301 | 2.73e-01 |
| GO:BP | GO:0033619 | membrane protein proteolysis | 6 | 45 | 2.73e-01 |
| GO:BP | GO:1900101 | regulation of endoplasmic reticulum unfolded protein response | 3 | 29 | 2.73e-01 |
| GO:BP | GO:0022008 | neurogenesis | 8 | 1294 | 2.73e-01 |
| GO:BP | GO:0042692 | muscle cell differentiation | 1 | 324 | 2.73e-01 |
| GO:BP | GO:0060998 | regulation of dendritic spine development | 3 | 48 | 2.73e-01 |
| GO:BP | GO:1901990 | regulation of mitotic cell cycle phase transition | 27 | 308 | 2.73e-01 |
| GO:BP | GO:0061919 | process utilizing autophagic mechanism | 24 | 513 | 2.73e-01 |
| GO:BP | GO:0046685 | response to arsenic-containing substance | 1 | 30 | 2.73e-01 |
| GO:BP | GO:1902808 | positive regulation of cell cycle G1/S phase transition | 7 | 52 | 2.73e-01 |
| GO:BP | GO:0043124 | negative regulation of I-kappaB kinase/NF-kappaB signaling | 2 | 36 | 2.73e-01 |
| GO:BP | GO:0071480 | cellular response to gamma radiation | 2 | 29 | 2.73e-01 |
| GO:BP | GO:0006914 | autophagy | 24 | 513 | 2.73e-01 |
| GO:BP | GO:1904692 | positive regulation of type B pancreatic cell proliferation | 1 | 2 | 2.73e-01 |
| GO:BP | GO:0031145 | anaphase-promoting complex-dependent catabolic process | 1 | 23 | 2.73e-01 |
| GO:BP | GO:0061890 | positive regulation of astrocyte activation | 1 | 1 | 2.73e-01 |
| GO:BP | GO:0099022 | vesicle tethering | 1 | 31 | 2.73e-01 |
| GO:BP | GO:0019043 | establishment of viral latency | 1 | 3 | 2.73e-01 |
| GO:BP | GO:0072539 | T-helper 17 cell differentiation | 1 | 14 | 2.73e-01 |
| GO:BP | GO:1904994 | regulation of leukocyte adhesion to vascular endothelial cell | 2 | 16 | 2.73e-01 |
| GO:BP | GO:0006354 | DNA-templated transcription elongation | 7 | 122 | 2.74e-01 |
| GO:BP | GO:0010749 | regulation of nitric oxide mediated signal transduction | 1 | 10 | 2.74e-01 |
| GO:BP | GO:0010717 | regulation of epithelial to mesenchymal transition | 1 | 86 | 2.74e-01 |
| GO:BP | GO:0034109 | homotypic cell-cell adhesion | 1 | 70 | 2.74e-01 |
| GO:BP | GO:1902110 | positive regulation of mitochondrial membrane permeability involved in apoptotic process | 2 | 38 | 2.74e-01 |
| GO:BP | GO:0002070 | epithelial cell maturation | 4 | 16 | 2.74e-01 |
| GO:BP | GO:0006972 | hyperosmotic response | 1 | 19 | 2.74e-01 |
| GO:BP | GO:0021885 | forebrain cell migration | 2 | 46 | 2.74e-01 |
| GO:BP | GO:0086011 | membrane repolarization during action potential | 2 | 22 | 2.74e-01 |
| GO:BP | GO:0045066 | regulatory T cell differentiation | 3 | 22 | 2.74e-01 |
| GO:BP | GO:0034242 | negative regulation of syncytium formation by plasma membrane fusion | 1 | 3 | 2.75e-01 |
| GO:BP | GO:0051495 | positive regulation of cytoskeleton organization | 8 | 165 | 2.75e-01 |
| GO:BP | GO:1900748 | positive regulation of vascular endothelial growth factor signaling pathway | 1 | 7 | 2.75e-01 |
| GO:BP | GO:0034474 | U2 snRNA 3’-end processing | 1 | 1 | 2.75e-01 |
| GO:BP | GO:0042733 | embryonic digit morphogenesis | 1 | 51 | 2.75e-01 |
| GO:BP | GO:0002068 | glandular epithelial cell development | 4 | 28 | 2.75e-01 |
| GO:BP | GO:0061709 | reticulophagy | 1 | 17 | 2.75e-01 |
| GO:BP | GO:1905215 | negative regulation of RNA binding | 1 | 2 | 2.75e-01 |
| GO:BP | GO:0045666 | positive regulation of neuron differentiation | 2 | 63 | 2.75e-01 |
| GO:BP | GO:0036048 | protein desuccinylation | 1 | 2 | 2.75e-01 |
| GO:BP | GO:0052646 | alditol phosphate metabolic process | 1 | 10 | 2.75e-01 |
| GO:BP | GO:0071313 | cellular response to caffeine | 2 | 10 | 2.75e-01 |
| GO:BP | GO:2000316 | regulation of T-helper 17 type immune response | 1 | 16 | 2.75e-01 |
| GO:BP | GO:0036049 | peptidyl-lysine desuccinylation | 1 | 2 | 2.75e-01 |
| GO:BP | GO:0003231 | cardiac ventricle development | 2 | 114 | 2.75e-01 |
| GO:BP | GO:0046501 | protoporphyrinogen IX metabolic process | 1 | 11 | 2.75e-01 |
| GO:BP | GO:0019229 | regulation of vasoconstriction | 1 | 38 | 2.75e-01 |
| GO:BP | GO:0032621 | interleukin-18 production | 1 | 1 | 2.75e-01 |
| GO:BP | GO:0006890 | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 4 | 52 | 2.75e-01 |
| GO:BP | GO:0070934 | CRD-mediated mRNA stabilization | 1 | 11 | 2.75e-01 |
| GO:BP | GO:0061698 | protein deglutarylation | 1 | 2 | 2.75e-01 |
| GO:BP | GO:0032661 | regulation of interleukin-18 production | 1 | 1 | 2.75e-01 |
| GO:BP | GO:1900143 | positive regulation of oligodendrocyte apoptotic process | 1 | 1 | 2.75e-01 |
| GO:BP | GO:0046605 | regulation of centrosome cycle | 6 | 51 | 2.75e-01 |
| GO:BP | GO:1904505 | regulation of telomere maintenance in response to DNA damage | 3 | 17 | 2.75e-01 |
| GO:BP | GO:0033627 | cell adhesion mediated by integrin | 1 | 63 | 2.75e-01 |
| GO:BP | GO:0043163 | cell envelope organization | 1 | 1 | 2.75e-01 |
| GO:BP | GO:0000904 | cell morphogenesis involved in differentiation | 6 | 516 | 2.76e-01 |
| GO:BP | GO:0051602 | response to electrical stimulus | 1 | 26 | 2.76e-01 |
| GO:BP | GO:1903556 | negative regulation of tumor necrosis factor superfamily cytokine production | 5 | 33 | 2.76e-01 |
| GO:BP | GO:0055086 | nucleobase-containing small molecule metabolic process | 2 | 487 | 2.76e-01 |
| GO:BP | GO:0001944 | vasculature development | 11 | 559 | 2.76e-01 |
| GO:BP | GO:0032239 | regulation of nucleobase-containing compound transport | 2 | 15 | 2.77e-01 |
| GO:BP | GO:0070723 | response to cholesterol | 1 | 16 | 2.77e-01 |
| GO:BP | GO:0090102 | cochlea development | 1 | 35 | 2.77e-01 |
| GO:BP | GO:0002232 | leukocyte chemotaxis involved in inflammatory response | 1 | 4 | 2.77e-01 |
| GO:BP | GO:0010837 | regulation of keratinocyte proliferation | 3 | 33 | 2.77e-01 |
| GO:BP | GO:0035490 | regulation of leukotriene production involved in inflammatory response | 1 | 1 | 2.77e-01 |
| GO:BP | GO:1990784 | response to dsDNA | 1 | 2 | 2.77e-01 |
| GO:BP | GO:1900224 | positive regulation of nodal signaling pathway involved in determination of lateral mesoderm left/right asymmetry | 1 | 1 | 2.77e-01 |
| GO:BP | GO:1900019 | regulation of protein kinase C activity | 2 | 6 | 2.77e-01 |
| GO:BP | GO:1900020 | positive regulation of protein kinase C activity | 2 | 6 | 2.77e-01 |
| GO:BP | GO:0110061 | regulation of angiotensin-activated signaling pathway | 1 | 2 | 2.77e-01 |
| GO:BP | GO:0035491 | positive regulation of leukotriene production involved in inflammatory response | 1 | 1 | 2.77e-01 |
| GO:BP | GO:1990786 | cellular response to dsDNA | 1 | 2 | 2.77e-01 |
| GO:BP | GO:0048262 | determination of dorsal/ventral asymmetry | 1 | 6 | 2.77e-01 |
| GO:BP | GO:0060537 | muscle tissue development | 1 | 343 | 2.77e-01 |
| GO:BP | GO:0010519 | negative regulation of phospholipase activity | 1 | 7 | 2.77e-01 |
| GO:BP | GO:0030900 | forebrain development | 1 | 281 | 2.77e-01 |
| GO:BP | GO:0070208 | protein heterotrimerization | 1 | 1 | 2.77e-01 |
| GO:BP | GO:0046849 | bone remodeling | 1 | 59 | 2.77e-01 |
| GO:BP | GO:1901331 | positive regulation of odontoblast differentiation | 1 | 1 | 2.77e-01 |
| GO:BP | GO:0048199 | vesicle targeting, to, from or within Golgi | 1 | 31 | 2.77e-01 |
| GO:BP | GO:0007352 | zygotic specification of dorsal/ventral axis | 1 | 2 | 2.77e-01 |
| GO:BP | GO:0007019 | microtubule depolymerization | 3 | 43 | 2.77e-01 |
| GO:BP | GO:0060113 | inner ear receptor cell differentiation | 5 | 47 | 2.77e-01 |
| GO:BP | GO:0005981 | regulation of glycogen catabolic process | 1 | 4 | 2.77e-01 |
| GO:BP | GO:0070384 | Harderian gland development | 1 | 4 | 2.77e-01 |
| GO:BP | GO:0042724 | thiamine-containing compound biosynthetic process | 1 | 1 | 2.78e-01 |
| GO:BP | GO:0070925 | organelle assembly | 8 | 817 | 2.78e-01 |
| GO:BP | GO:1902683 | regulation of receptor localization to synapse | 4 | 21 | 2.78e-01 |
| GO:BP | GO:0061311 | cell surface receptor signaling pathway involved in heart development | 1 | 25 | 2.78e-01 |
| GO:BP | GO:2000622 | regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 2 | 12 | 2.78e-01 |
| GO:BP | GO:1990440 | positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress | 1 | 11 | 2.78e-01 |
| GO:BP | GO:1902176 | negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway | 2 | 18 | 2.78e-01 |
| GO:BP | GO:1902473 | regulation of protein localization to synapse | 4 | 22 | 2.78e-01 |
| GO:BP | GO:0072007 | mesangial cell differentiation | 1 | 5 | 2.78e-01 |
| GO:BP | GO:0009229 | thiamine diphosphate biosynthetic process | 1 | 1 | 2.78e-01 |
| GO:BP | GO:0032006 | regulation of TOR signaling | 3 | 96 | 2.78e-01 |
| GO:BP | GO:0001525 | angiogenesis | 8 | 390 | 2.78e-01 |
| GO:BP | GO:0070262 | peptidyl-serine dephosphorylation | 3 | 14 | 2.78e-01 |
| GO:BP | GO:0010883 | regulation of lipid storage | 2 | 39 | 2.78e-01 |
| GO:BP | GO:0062014 | negative regulation of small molecule metabolic process | 5 | 71 | 2.78e-01 |
| GO:BP | GO:0021516 | dorsal spinal cord development | 1 | 7 | 2.78e-01 |
| GO:BP | GO:2000489 | regulation of hepatic stellate cell activation | 1 | 6 | 2.78e-01 |
| GO:BP | GO:0021766 | hippocampus development | 10 | 62 | 2.78e-01 |
| GO:BP | GO:0099533 | positive regulation of presynaptic cytosolic calcium concentration | 1 | 1 | 2.78e-01 |
| GO:BP | GO:0032602 | chemokine production | 1 | 46 | 2.78e-01 |
| GO:BP | GO:0032642 | regulation of chemokine production | 1 | 46 | 2.78e-01 |
| GO:BP | GO:0035552 | oxidative single-stranded DNA demethylation | 1 | 3 | 2.78e-01 |
| GO:BP | GO:1903426 | regulation of reactive oxygen species biosynthetic process | 2 | 29 | 2.80e-01 |
| GO:BP | GO:1902686 | mitochondrial outer membrane permeabilization involved in programmed cell death | 2 | 40 | 2.80e-01 |
| GO:BP | GO:0048560 | establishment of anatomical structure orientation | 1 | 2 | 2.80e-01 |
| GO:BP | GO:0060322 | head development | 12 | 633 | 2.80e-01 |
| GO:BP | GO:0002230 | positive regulation of defense response to virus by host | 1 | 23 | 2.80e-01 |
| GO:BP | GO:1901215 | negative regulation of neuron death | 9 | 167 | 2.80e-01 |
| GO:BP | GO:0072077 | renal vesicle morphogenesis | 3 | 14 | 2.80e-01 |
| GO:BP | GO:0007346 | regulation of mitotic cell cycle | 35 | 441 | 2.80e-01 |
| GO:BP | GO:0008088 | axo-dendritic transport | 1 | 73 | 2.80e-01 |
| GO:BP | GO:0010828 | positive regulation of glucose transmembrane transport | 3 | 31 | 2.81e-01 |
| GO:BP | GO:0042275 | error-free postreplication DNA repair | 1 | 1 | 2.81e-01 |
| GO:BP | GO:1903526 | negative regulation of membrane tubulation | 1 | 2 | 2.81e-01 |
| GO:BP | GO:1904179 | positive regulation of adipose tissue development | 1 | 6 | 2.81e-01 |
| GO:BP | GO:0140058 | neuron projection arborization | 4 | 29 | 2.81e-01 |
| GO:BP | GO:0000902 | cell morphogenesis | 3 | 761 | 2.81e-01 |
| GO:BP | GO:1990418 | response to insulin-like growth factor stimulus | 1 | 2 | 2.81e-01 |
| GO:BP | GO:0051574 | positive regulation of histone H3-K9 methylation | 1 | 5 | 2.81e-01 |
| GO:BP | GO:0034243 | regulation of transcription elongation by RNA polymerase II | 9 | 85 | 2.81e-01 |
| GO:BP | GO:0090400 | stress-induced premature senescence | 1 | 7 | 2.81e-01 |
| GO:BP | GO:0006364 | rRNA processing | 5 | 221 | 2.81e-01 |
| GO:BP | GO:0051043 | regulation of membrane protein ectodomain proteolysis | 4 | 18 | 2.81e-01 |
| GO:BP | GO:0048016 | inositol phosphate-mediated signaling | 3 | 45 | 2.81e-01 |
| GO:BP | GO:0042669 | regulation of inner ear auditory receptor cell fate specification | 1 | 1 | 2.81e-01 |
| GO:BP | GO:1904666 | regulation of ubiquitin protein ligase activity | 1 | 26 | 2.81e-01 |
| GO:BP | GO:0072092 | ureteric bud invasion | 1 | 3 | 2.81e-01 |
| GO:BP | GO:0002843 | regulation of tolerance induction to tumor cell | 1 | 1 | 2.81e-01 |
| GO:BP | GO:0002413 | tolerance induction to tumor cell | 1 | 1 | 2.81e-01 |
| GO:BP | GO:0033089 | positive regulation of T cell differentiation in thymus | 2 | 5 | 2.81e-01 |
| GO:BP | GO:0002845 | positive regulation of tolerance induction to tumor cell | 1 | 1 | 2.81e-01 |
| GO:BP | GO:1905404 | positive regulation of activated CD8-positive, alpha-beta T cell apoptotic process | 1 | 1 | 2.81e-01 |
| GO:BP | GO:0046653 | tetrahydrofolate metabolic process | 2 | 14 | 2.81e-01 |
| GO:BP | GO:0061485 | memory T cell proliferation | 1 | 1 | 2.81e-01 |
| GO:BP | GO:1900152 | negative regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 1 | 12 | 2.81e-01 |
| GO:BP | GO:0046329 | negative regulation of JNK cascade | 2 | 36 | 2.81e-01 |
| GO:BP | GO:0046209 | nitric oxide metabolic process | 2 | 55 | 2.81e-01 |
| GO:BP | GO:0003356 | regulation of cilium beat frequency | 2 | 10 | 2.82e-01 |
| GO:BP | GO:0015846 | polyamine transport | 1 | 12 | 2.82e-01 |
| GO:BP | GO:1901526 | positive regulation of mitophagy | 1 | 6 | 2.82e-01 |
| GO:BP | GO:0046381 | CMP-N-acetylneuraminate metabolic process | 1 | 1 | 2.82e-01 |
| GO:BP | GO:0030947 | regulation of vascular endothelial growth factor receptor signaling pathway | 4 | 27 | 2.82e-01 |
| GO:BP | GO:0006055 | CMP-N-acetylneuraminate biosynthetic process | 1 | 1 | 2.82e-01 |
| GO:BP | GO:0003002 | regionalization | 1 | 273 | 2.82e-01 |
| GO:BP | GO:0018105 | peptidyl-serine phosphorylation | 17 | 247 | 2.82e-01 |
| GO:BP | GO:0010737 | protein kinase A signaling | 5 | 23 | 2.83e-01 |
| GO:BP | GO:0023041 | neuronal signal transduction | 2 | 6 | 2.83e-01 |
| GO:BP | GO:0021854 | hypothalamus development | 4 | 15 | 2.83e-01 |
| GO:BP | GO:0043112 | receptor metabolic process | 1 | 62 | 2.83e-01 |
| GO:BP | GO:0060317 | cardiac epithelial to mesenchymal transition | 1 | 28 | 2.83e-01 |
| GO:BP | GO:0006536 | glutamate metabolic process | 3 | 25 | 2.83e-01 |
| GO:BP | GO:0007064 | mitotic sister chromatid cohesion | 1 | 30 | 2.83e-01 |
| GO:BP | GO:1902902 | negative regulation of autophagosome assembly | 1 | 14 | 2.83e-01 |
| GO:BP | GO:0008652 | amino acid biosynthetic process | 5 | 64 | 2.83e-01 |
| GO:BP | GO:0140568 | extraction of mislocalized protein from membrane | 1 | 2 | 2.83e-01 |
| GO:BP | GO:0043467 | regulation of generation of precursor metabolites and energy | 5 | 89 | 2.83e-01 |
| GO:BP | GO:0062002 | regulation of all-trans-retinyl-ester hydrolase, 11-cis retinol forming activity | 1 | 1 | 2.83e-01 |
| GO:BP | GO:0062003 | negative regulation of all-trans-retinyl-ester hydrolase, 11-cis retinol forming activity | 1 | 1 | 2.83e-01 |
| GO:BP | GO:0045742 | positive regulation of epidermal growth factor receptor signaling pathway | 5 | 26 | 2.83e-01 |
| GO:BP | GO:0044804 | autophagy of nucleus | 1 | 18 | 2.83e-01 |
| GO:BP | GO:0071763 | nuclear membrane organization | 1 | 42 | 2.83e-01 |
| GO:BP | GO:0045446 | endothelial cell differentiation | 1 | 90 | 2.83e-01 |
| GO:BP | GO:2000786 | positive regulation of autophagosome assembly | 1 | 19 | 2.83e-01 |
| GO:BP | GO:1901991 | negative regulation of mitotic cell cycle phase transition | 2 | 166 | 2.83e-01 |
| GO:BP | GO:2001057 | reactive nitrogen species metabolic process | 2 | 56 | 2.83e-01 |
| GO:BP | GO:0032986 | protein-DNA complex disassembly | 3 | 18 | 2.83e-01 |
| GO:BP | GO:1903589 | positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis | 1 | 4 | 2.83e-01 |
| GO:BP | GO:0120035 | regulation of plasma membrane bounded cell projection organization | 2 | 529 | 2.83e-01 |
| GO:BP | GO:1903241 | U2-type prespliceosome assembly | 3 | 24 | 2.84e-01 |
| GO:BP | GO:0019320 | hexose catabolic process | 3 | 32 | 2.84e-01 |
| GO:BP | GO:0071398 | cellular response to fatty acid | 1 | 25 | 2.84e-01 |
| GO:BP | GO:0021543 | pallium development | 17 | 139 | 2.84e-01 |
| GO:BP | GO:0008643 | carbohydrate transport | 2 | 111 | 2.84e-01 |
| GO:BP | GO:0032692 | negative regulation of interleukin-1 production | 1 | 15 | 2.84e-01 |
| GO:BP | GO:0030968 | endoplasmic reticulum unfolded protein response | 5 | 70 | 2.84e-01 |
| GO:BP | GO:0016055 | Wnt signaling pathway | 1 | 375 | 2.85e-01 |
| GO:BP | GO:0198738 | cell-cell signaling by wnt | 1 | 376 | 2.86e-01 |
| GO:BP | GO:0140014 | mitotic nuclear division | 17 | 251 | 2.86e-01 |
| GO:BP | GO:0031998 | regulation of fatty acid beta-oxidation | 2 | 16 | 2.86e-01 |
| GO:BP | GO:0046039 | GTP metabolic process | 3 | 21 | 2.86e-01 |
| GO:BP | GO:0051121 | hepoxilin metabolic process | 1 | 5 | 2.86e-01 |
| GO:BP | GO:0051122 | hepoxilin biosynthetic process | 1 | 5 | 2.86e-01 |
| GO:BP | GO:1903518 | positive regulation of single strand break repair | 1 | 2 | 2.86e-01 |
| GO:BP | GO:1990785 | response to water-immersion restraint stress | 1 | 1 | 2.86e-01 |
| GO:BP | GO:0042996 | regulation of Golgi to plasma membrane protein transport | 1 | 9 | 2.86e-01 |
| GO:BP | GO:0071577 | zinc ion transmembrane transport | 2 | 21 | 2.86e-01 |
| GO:BP | GO:0071887 | leukocyte apoptotic process | 8 | 81 | 2.86e-01 |
| GO:BP | GO:1902108 | regulation of mitochondrial membrane permeability involved in apoptotic process | 2 | 42 | 2.86e-01 |
| GO:BP | GO:0009611 | response to wounding | 9 | 415 | 2.86e-01 |
| GO:BP | GO:0006891 | intra-Golgi vesicle-mediated transport | 1 | 33 | 2.86e-01 |
| GO:BP | GO:1901841 | regulation of high voltage-gated calcium channel activity | 1 | 12 | 2.86e-01 |
| GO:BP | GO:1900746 | regulation of vascular endothelial growth factor signaling pathway | 2 | 18 | 2.86e-01 |
| GO:BP | GO:1900003 | regulation of serine-type endopeptidase activity | 1 | 4 | 2.86e-01 |
| GO:BP | GO:1902571 | regulation of serine-type peptidase activity | 1 | 4 | 2.86e-01 |
| GO:BP | GO:0006479 | protein methylation | 1 | 160 | 2.86e-01 |
| GO:BP | GO:0008213 | protein alkylation | 1 | 160 | 2.86e-01 |
| GO:BP | GO:0016525 | negative regulation of angiogenesis | 1 | 72 | 2.86e-01 |
| GO:BP | GO:0000423 | mitophagy | 3 | 37 | 2.86e-01 |
| GO:BP | GO:0043465 | regulation of fermentation | 1 | 5 | 2.86e-01 |
| GO:BP | GO:0006113 | fermentation | 1 | 5 | 2.86e-01 |
| GO:BP | GO:0033567 | DNA replication, Okazaki fragment processing | 1 | 2 | 2.86e-01 |
| GO:BP | GO:0010952 | positive regulation of peptidase activity | 7 | 135 | 2.86e-01 |
| GO:BP | GO:0002862 | negative regulation of inflammatory response to antigenic stimulus | 4 | 16 | 2.86e-01 |
| GO:BP | GO:2000628 | regulation of miRNA metabolic process | 3 | 67 | 2.86e-01 |
| GO:BP | GO:1904182 | regulation of pyruvate dehydrogenase activity | 1 | 4 | 2.86e-01 |
| GO:BP | GO:0043551 | regulation of phosphatidylinositol 3-kinase activity | 5 | 30 | 2.86e-01 |
| GO:BP | GO:0031344 | regulation of cell projection organization | 2 | 541 | 2.86e-01 |
| GO:BP | GO:0051960 | regulation of nervous system development | 1 | 357 | 2.86e-01 |
| GO:BP | GO:0006538 | glutamate catabolic process | 1 | 7 | 2.86e-01 |
| GO:BP | GO:0030316 | osteoclast differentiation | 1 | 66 | 2.86e-01 |
| GO:BP | GO:2000181 | negative regulation of blood vessel morphogenesis | 1 | 73 | 2.86e-01 |
| GO:BP | GO:0070682 | proteasome regulatory particle assembly | 1 | 3 | 2.87e-01 |
| GO:BP | GO:0021562 | vestibulocochlear nerve development | 2 | 4 | 2.87e-01 |
| GO:BP | GO:0010664 | negative regulation of striated muscle cell apoptotic process | 2 | 24 | 2.87e-01 |
| GO:BP | GO:0003376 | sphingosine-1-phosphate receptor signaling pathway | 2 | 10 | 2.87e-01 |
| GO:BP | GO:0000462 | maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 3 | 38 | 2.87e-01 |
| GO:BP | GO:1901343 | negative regulation of vasculature development | 1 | 73 | 2.87e-01 |
| GO:BP | GO:1905477 | positive regulation of protein localization to membrane | 1 | 84 | 2.87e-01 |
| GO:BP | GO:1903076 | regulation of protein localization to plasma membrane | 1 | 90 | 2.87e-01 |
| GO:BP | GO:0043377 | negative regulation of CD8-positive, alpha-beta T cell differentiation | 1 | 3 | 2.87e-01 |
| GO:BP | GO:0032823 | regulation of natural killer cell differentiation | 2 | 8 | 2.88e-01 |
| GO:BP | GO:0120032 | regulation of plasma membrane bounded cell projection assembly | 15 | 165 | 2.89e-01 |
| GO:BP | GO:0001941 | postsynaptic membrane organization | 5 | 29 | 2.89e-01 |
| GO:BP | GO:0006404 | RNA import into nucleus | 1 | 4 | 2.90e-01 |
| GO:BP | GO:0032007 | negative regulation of TOR signaling | 2 | 47 | 2.90e-01 |
| GO:BP | GO:0035794 | positive regulation of mitochondrial membrane permeability | 2 | 43 | 2.90e-01 |
| GO:BP | GO:1901890 | positive regulation of cell junction assembly | 1 | 82 | 2.91e-01 |
| GO:BP | GO:2000109 | regulation of macrophage apoptotic process | 1 | 6 | 2.91e-01 |
| GO:BP | GO:0051100 | negative regulation of binding | 1 | 135 | 2.91e-01 |
| GO:BP | GO:0150018 | basal dendrite development | 1 | 3 | 2.91e-01 |
| GO:BP | GO:0010611 | regulation of cardiac muscle hypertrophy | 1 | 48 | 2.91e-01 |
| GO:BP | GO:0150019 | basal dendrite morphogenesis | 1 | 3 | 2.91e-01 |
| GO:BP | GO:0150020 | basal dendrite arborization | 1 | 3 | 2.91e-01 |
| GO:BP | GO:1901836 | regulation of transcription of nucleolar large rRNA by RNA polymerase I | 2 | 15 | 2.91e-01 |
| GO:BP | GO:0006901 | vesicle coating | 1 | 36 | 2.91e-01 |
| GO:BP | GO:0001542 | ovulation from ovarian follicle | 1 | 8 | 2.91e-01 |
| GO:BP | GO:0006776 | vitamin A metabolic process | 2 | 3 | 2.91e-01 |
| GO:BP | GO:0035329 | hippo signaling | 6 | 41 | 2.91e-01 |
| GO:BP | GO:0030219 | megakaryocyte differentiation | 1 | 54 | 2.91e-01 |
| GO:BP | GO:0071140 | resolution of mitotic recombination intermediates | 1 | 2 | 2.91e-01 |
| GO:BP | GO:0060306 | regulation of membrane repolarization | 2 | 28 | 2.91e-01 |
| GO:BP | GO:0000183 | rDNA heterochromatin formation | 1 | 9 | 2.91e-01 |
| GO:BP | GO:0019217 | regulation of fatty acid metabolic process | 9 | 66 | 2.92e-01 |
| GO:BP | GO:0046394 | carboxylic acid biosynthetic process | 1 | 223 | 2.92e-01 |
| GO:BP | GO:0044090 | positive regulation of vacuole organization | 1 | 21 | 2.92e-01 |
| GO:BP | GO:0071888 | macrophage apoptotic process | 2 | 9 | 2.92e-01 |
| GO:BP | GO:1904029 | regulation of cyclin-dependent protein kinase activity | 11 | 88 | 2.92e-01 |
| GO:BP | GO:0062196 | regulation of lysosome size | 1 | 8 | 2.92e-01 |
| GO:BP | GO:0071894 | histone H2B conserved C-terminal lysine ubiquitination | 1 | 3 | 2.92e-01 |
| GO:BP | GO:0050775 | positive regulation of dendrite morphogenesis | 3 | 36 | 2.92e-01 |
| GO:BP | GO:0051055 | negative regulation of lipid biosynthetic process | 2 | 46 | 2.92e-01 |
| GO:BP | GO:0036314 | response to sterol | 1 | 19 | 2.92e-01 |
| GO:BP | GO:1902514 | regulation of calcium ion transmembrane transport via high voltage-gated calcium channel | 1 | 12 | 2.92e-01 |
| GO:BP | GO:0072087 | renal vesicle development | 3 | 15 | 2.92e-01 |
| GO:BP | GO:0016259 | selenocysteine metabolic process | 1 | 2 | 2.92e-01 |
| GO:BP | GO:0007409 | axonogenesis | 2 | 359 | 2.92e-01 |
| GO:BP | GO:0046385 | deoxyribose phosphate biosynthetic process | 2 | 14 | 2.92e-01 |
| GO:BP | GO:0042594 | response to starvation | 2 | 178 | 2.92e-01 |
| GO:BP | GO:0040020 | regulation of meiotic nuclear division | 1 | 19 | 2.92e-01 |
| GO:BP | GO:0032703 | negative regulation of interleukin-2 production | 2 | 10 | 2.92e-01 |
| GO:BP | GO:0009263 | deoxyribonucleotide biosynthetic process | 2 | 14 | 2.92e-01 |
| GO:BP | GO:0031571 | mitotic G1 DNA damage checkpoint signaling | 1 | 30 | 2.92e-01 |
| GO:BP | GO:0097499 | protein localization to non-motile cilium | 2 | 10 | 2.92e-01 |
| GO:BP | GO:0002534 | cytokine production involved in inflammatory response | 2 | 33 | 2.92e-01 |
| GO:BP | GO:1900015 | regulation of cytokine production involved in inflammatory response | 2 | 33 | 2.92e-01 |
| GO:BP | GO:0047496 | vesicle transport along microtubule | 3 | 41 | 2.92e-01 |
| GO:BP | GO:0009265 | 2’-deoxyribonucleotide biosynthetic process | 2 | 14 | 2.92e-01 |
| GO:BP | GO:0005977 | glycogen metabolic process | 4 | 64 | 2.92e-01 |
| GO:BP | GO:0016053 | organic acid biosynthetic process | 1 | 224 | 2.92e-01 |
| GO:BP | GO:0006919 | activation of cysteine-type endopeptidase activity involved in apoptotic process | 9 | 65 | 2.92e-01 |
| GO:BP | GO:0050873 | brown fat cell differentiation | 2 | 41 | 2.92e-01 |
| GO:BP | GO:0099188 | postsynaptic cytoskeleton organization | 3 | 14 | 2.92e-01 |
| GO:BP | GO:1905039 | carboxylic acid transmembrane transport | 2 | 118 | 2.92e-01 |
| GO:BP | GO:0097117 | guanylate kinase-associated protein clustering | 1 | 2 | 2.93e-01 |
| GO:BP | GO:1905608 | positive regulation of presynapse assembly | 1 | 2 | 2.93e-01 |
| GO:BP | GO:0010827 | regulation of glucose transmembrane transport | 6 | 55 | 2.93e-01 |
| GO:BP | GO:0045793 | positive regulation of cell size | 1 | 11 | 2.93e-01 |
| GO:BP | GO:0051000 | positive regulation of nitric-oxide synthase activity | 2 | 14 | 2.93e-01 |
| GO:BP | GO:0061098 | positive regulation of protein tyrosine kinase activity | 6 | 33 | 2.93e-01 |
| GO:BP | GO:0051387 | negative regulation of neurotrophin TRK receptor signaling pathway | 1 | 3 | 2.94e-01 |
| GO:BP | GO:1902806 | regulation of cell cycle G1/S phase transition | 15 | 169 | 2.94e-01 |
| GO:BP | GO:1903825 | organic acid transmembrane transport | 2 | 119 | 2.94e-01 |
| GO:BP | GO:0045197 | establishment or maintenance of epithelial cell apical/basal polarity | 4 | 47 | 2.94e-01 |
| GO:BP | GO:0050688 | regulation of defense response to virus | 2 | 63 | 2.94e-01 |
| GO:BP | GO:0044819 | mitotic G1/S transition checkpoint signaling | 1 | 30 | 2.95e-01 |
| GO:BP | GO:0009185 | ribonucleoside diphosphate metabolic process | 1 | 27 | 2.95e-01 |
| GO:BP | GO:2001035 | regulation of tongue muscle cell differentiation | 1 | 1 | 2.95e-01 |
| GO:BP | GO:0097193 | intrinsic apoptotic signaling pathway | 7 | 262 | 2.95e-01 |
| GO:BP | GO:0001915 | negative regulation of T cell mediated cytotoxicity | 1 | 3 | 2.95e-01 |
| GO:BP | GO:2001037 | positive regulation of tongue muscle cell differentiation | 1 | 1 | 2.95e-01 |
| GO:BP | GO:0034249 | negative regulation of amide metabolic process | 11 | 186 | 2.95e-01 |
| GO:BP | GO:0001953 | negative regulation of cell-matrix adhesion | 5 | 26 | 2.95e-01 |
| GO:BP | GO:0090204 | protein localization to nuclear pore | 1 | 3 | 2.95e-01 |
| GO:BP | GO:0006610 | ribosomal protein import into nucleus | 1 | 4 | 2.95e-01 |
| GO:BP | GO:0007051 | spindle organization | 2 | 188 | 2.95e-01 |
| GO:BP | GO:0044706 | multi-multicellular organism process | 2 | 135 | 2.95e-01 |
| GO:BP | GO:0006221 | pyrimidine nucleotide biosynthetic process | 3 | 28 | 2.95e-01 |
| GO:BP | GO:1904293 | negative regulation of ERAD pathway | 1 | 6 | 2.95e-01 |
| GO:BP | GO:0035981 | tongue muscle cell differentiation | 1 | 1 | 2.95e-01 |
| GO:BP | GO:0045198 | establishment of epithelial cell apical/basal polarity | 2 | 14 | 2.95e-01 |
| GO:BP | GO:0003032 | detection of oxygen | 1 | 5 | 2.95e-01 |
| GO:BP | GO:0015691 | cadmium ion transport | 1 | 5 | 2.95e-01 |
| GO:BP | GO:0070574 | cadmium ion transmembrane transport | 1 | 5 | 2.95e-01 |
| GO:BP | GO:0014743 | regulation of muscle hypertrophy | 1 | 49 | 2.95e-01 |
| GO:BP | GO:0030029 | actin filament-based process | 60 | 687 | 2.95e-01 |
| GO:BP | GO:0003431 | growth plate cartilage chondrocyte development | 1 | 5 | 2.95e-01 |
| GO:BP | GO:1901620 | regulation of smoothened signaling pathway involved in dorsal/ventral neural tube patterning | 2 | 12 | 2.95e-01 |
| GO:BP | GO:0019042 | viral latency | 1 | 4 | 2.95e-01 |
| GO:BP | GO:0090257 | regulation of muscle system process | 2 | 184 | 2.95e-01 |
| GO:BP | GO:1904155 | DN2 thymocyte differentiation | 1 | 1 | 2.95e-01 |
| GO:BP | GO:0044042 | glucan metabolic process | 4 | 64 | 2.95e-01 |
| GO:BP | GO:0048762 | mesenchymal cell differentiation | 18 | 204 | 2.97e-01 |
| GO:BP | GO:0098700 | neurotransmitter loading into synaptic vesicle | 1 | 1 | 2.97e-01 |
| GO:BP | GO:0021603 | cranial nerve formation | 2 | 4 | 2.97e-01 |
| GO:BP | GO:0043586 | tongue development | 3 | 15 | 2.97e-01 |
| GO:BP | GO:0008544 | epidermis development | 2 | 210 | 2.97e-01 |
| GO:BP | GO:0060032 | notochord regression | 1 | 1 | 2.97e-01 |
| GO:BP | GO:0006829 | zinc ion transport | 2 | 23 | 2.97e-01 |
| GO:BP | GO:0009888 | tissue development | 5 | 1425 | 2.98e-01 |
| GO:BP | GO:0042310 | vasoconstriction | 1 | 51 | 2.98e-01 |
| GO:BP | GO:0019085 | early viral transcription | 1 | 2 | 2.98e-01 |
| GO:BP | GO:0042490 | mechanoreceptor differentiation | 5 | 49 | 2.98e-01 |
| GO:BP | GO:0003158 | endothelium development | 1 | 104 | 2.98e-01 |
| GO:BP | GO:0051443 | positive regulation of ubiquitin-protein transferase activity | 1 | 31 | 2.98e-01 |
| GO:BP | GO:0022408 | negative regulation of cell-cell adhesion | 8 | 116 | 2.98e-01 |
| GO:BP | GO:0009218 | pyrimidine ribonucleotide metabolic process | 1 | 25 | 2.98e-01 |
| GO:BP | GO:0099149 | regulation of postsynaptic neurotransmitter receptor internalization | 3 | 11 | 2.98e-01 |
| GO:BP | GO:0032024 | positive regulation of insulin secretion | 4 | 56 | 2.98e-01 |
| GO:BP | GO:1901605 | alpha-amino acid metabolic process | 1 | 151 | 2.98e-01 |
| GO:BP | GO:0044772 | mitotic cell cycle phase transition | 36 | 418 | 2.98e-01 |
| GO:BP | GO:0071415 | cellular response to purine-containing compound | 1 | 11 | 2.98e-01 |
| GO:BP | GO:0090114 | COPII-coated vesicle budding | 1 | 40 | 2.98e-01 |
| GO:BP | GO:1903546 | protein localization to photoreceptor outer segment | 1 | 5 | 2.99e-01 |
| GO:BP | GO:0006941 | striated muscle contraction | 3 | 152 | 2.99e-01 |
| GO:BP | GO:1900180 | regulation of protein localization to nucleus | 6 | 117 | 3.00e-01 |
| GO:BP | GO:0045622 | regulation of T-helper cell differentiation | 1 | 20 | 3.00e-01 |
| GO:BP | GO:1900744 | regulation of p38MAPK cascade | 1 | 32 | 3.00e-01 |
| GO:BP | GO:0099173 | postsynapse organization | 17 | 155 | 3.00e-01 |
| GO:BP | GO:0006895 | Golgi to endosome transport | 3 | 17 | 3.00e-01 |
| GO:BP | GO:0035733 | hepatic stellate cell activation | 1 | 8 | 3.01e-01 |
| GO:BP | GO:1901503 | ether biosynthetic process | 2 | 11 | 3.01e-01 |
| GO:BP | GO:0044843 | cell cycle G1/S phase transition | 19 | 229 | 3.02e-01 |
| GO:BP | GO:0030099 | myeloid cell differentiation | 2 | 310 | 3.02e-01 |
| GO:BP | GO:0044093 | positive regulation of molecular function | 14 | 1149 | 3.02e-01 |
| GO:BP | GO:1902547 | regulation of cellular response to vascular endothelial growth factor stimulus | 2 | 20 | 3.02e-01 |
| GO:BP | GO:0006368 | transcription elongation by RNA polymerase II | 6 | 106 | 3.02e-01 |
| GO:BP | GO:1990700 | nucleolar chromatin organization | 1 | 10 | 3.02e-01 |
| GO:BP | GO:0031392 | regulation of prostaglandin biosynthetic process | 1 | 6 | 3.02e-01 |
| GO:BP | GO:0033034 | positive regulation of myeloid cell apoptotic process | 1 | 6 | 3.02e-01 |
| GO:BP | GO:2000586 | regulation of platelet-derived growth factor receptor-beta signaling pathway | 2 | 8 | 3.02e-01 |
| GO:BP | GO:0051917 | regulation of fibrinolysis | 2 | 10 | 3.02e-01 |
| GO:BP | GO:0045899 | positive regulation of RNA polymerase II transcription preinitiation complex assembly | 1 | 4 | 3.02e-01 |
| GO:BP | GO:0030168 | platelet activation | 1 | 91 | 3.02e-01 |
| GO:BP | GO:0043370 | regulation of CD4-positive, alpha-beta T cell differentiation | 6 | 27 | 3.02e-01 |
| GO:BP | GO:1905710 | positive regulation of membrane permeability | 2 | 45 | 3.02e-01 |
| GO:BP | GO:0006936 | muscle contraction | 6 | 267 | 3.02e-01 |
| GO:BP | GO:1901796 | regulation of signal transduction by p53 class mediator | 5 | 101 | 3.02e-01 |
| GO:BP | GO:0009628 | response to abiotic stimulus | 6 | 868 | 3.02e-01 |
| GO:BP | GO:1903033 | positive regulation of microtubule plus-end binding | 1 | 2 | 3.02e-01 |
| GO:BP | GO:1903031 | regulation of microtubule plus-end binding | 1 | 2 | 3.02e-01 |
| GO:BP | GO:1990646 | cellular response to prolactin | 1 | 2 | 3.02e-01 |
| GO:BP | GO:0019372 | lipoxygenase pathway | 1 | 5 | 3.02e-01 |
| GO:BP | GO:0032069 | regulation of nuclease activity | 2 | 17 | 3.02e-01 |
| GO:BP | GO:0003203 | endocardial cushion morphogenesis | 1 | 36 | 3.02e-01 |
| GO:BP | GO:1903375 | facioacoustic ganglion development | 1 | 2 | 3.02e-01 |
| GO:BP | GO:1905755 | protein localization to cytoplasmic microtubule | 1 | 2 | 3.02e-01 |
| GO:BP | GO:0042364 | water-soluble vitamin biosynthetic process | 2 | 8 | 3.02e-01 |
| GO:BP | GO:1901525 | negative regulation of mitophagy | 1 | 6 | 3.02e-01 |
| GO:BP | GO:0006677 | glycosylceramide metabolic process | 1 | 13 | 3.02e-01 |
| GO:BP | GO:0006402 | mRNA catabolic process | 2 | 216 | 3.02e-01 |
| GO:BP | GO:0002823 | negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 2 | 26 | 3.02e-01 |
| GO:BP | GO:0035050 | embryonic heart tube development | 1 | 69 | 3.02e-01 |
| GO:BP | GO:2000232 | regulation of rRNA processing | 2 | 16 | 3.02e-01 |
| GO:BP | GO:0032233 | positive regulation of actin filament bundle assembly | 4 | 54 | 3.02e-01 |
| GO:BP | GO:0036498 | IRE1-mediated unfolded protein response | 3 | 19 | 3.02e-01 |
| GO:BP | GO:0021649 | vestibulocochlear nerve structural organization | 1 | 2 | 3.02e-01 |
| GO:BP | GO:0000472 | endonucleolytic cleavage to generate mature 5’-end of SSU-rRNA from (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 1 | 5 | 3.02e-01 |
| GO:BP | GO:0034471 | ncRNA 5’-end processing | 1 | 5 | 3.02e-01 |
| GO:BP | GO:0060466 | activation of meiosis involved in egg activation | 1 | 2 | 3.02e-01 |
| GO:BP | GO:0000967 | rRNA 5’-end processing | 1 | 5 | 3.02e-01 |
| GO:BP | GO:0060412 | ventricular septum morphogenesis | 1 | 40 | 3.02e-01 |
| GO:BP | GO:0000278 | mitotic cell cycle | 53 | 827 | 3.02e-01 |
| GO:BP | GO:0061552 | ganglion morphogenesis | 1 | 2 | 3.02e-01 |
| GO:BP | GO:1903672 | positive regulation of sprouting angiogenesis | 2 | 14 | 3.02e-01 |
| GO:BP | GO:0061443 | endocardial cushion cell differentiation | 1 | 2 | 3.02e-01 |
| GO:BP | GO:0051640 | organelle localization | 38 | 503 | 3.02e-01 |
| GO:BP | GO:1901186 | positive regulation of ERBB signaling pathway | 5 | 28 | 3.02e-01 |
| GO:BP | GO:1902415 | regulation of mRNA binding | 2 | 10 | 3.02e-01 |
| GO:BP | GO:0090503 | RNA phosphodiester bond hydrolysis, exonucleolytic | 1 | 41 | 3.02e-01 |
| GO:BP | GO:1902626 | assembly of large subunit precursor of preribosome | 1 | 1 | 3.02e-01 |
| GO:BP | GO:0045636 | positive regulation of melanocyte differentiation | 1 | 4 | 3.02e-01 |
| GO:BP | GO:0030855 | epithelial cell differentiation | 2 | 442 | 3.02e-01 |
| GO:BP | GO:1903671 | negative regulation of sprouting angiogenesis | 1 | 11 | 3.02e-01 |
| GO:BP | GO:1903829 | positive regulation of protein localization | 15 | 386 | 3.02e-01 |
| GO:BP | GO:0009112 | nucleobase metabolic process | 3 | 27 | 3.02e-01 |
| GO:BP | GO:0051291 | protein heterooligomerization | 2 | 21 | 3.02e-01 |
| GO:BP | GO:2000256 | positive regulation of male germ cell proliferation | 1 | 2 | 3.02e-01 |
| GO:BP | GO:0006886 | intracellular protein transport | 2 | 803 | 3.02e-01 |
| GO:BP | GO:0001545 | primary ovarian follicle growth | 1 | 1 | 3.02e-01 |
| GO:BP | GO:0031000 | response to caffeine | 1 | 13 | 3.02e-01 |
| GO:BP | GO:0110020 | regulation of actomyosin structure organization | 6 | 90 | 3.02e-01 |
| GO:BP | GO:1904835 | dorsal root ganglion morphogenesis | 1 | 2 | 3.02e-01 |
| GO:BP | GO:0045737 | positive regulation of cyclin-dependent protein serine/threonine kinase activity | 4 | 23 | 3.02e-01 |
| GO:BP | GO:0046600 | negative regulation of centriole replication | 1 | 7 | 3.02e-01 |
| GO:BP | GO:0060134 | prepulse inhibition | 2 | 7 | 3.02e-01 |
| GO:BP | GO:0030490 | maturation of SSU-rRNA | 4 | 54 | 3.02e-01 |
| GO:BP | GO:0051336 | regulation of hydrolase activity | 29 | 701 | 3.02e-01 |
| GO:BP | GO:0001704 | formation of primary germ layer | 1 | 96 | 3.02e-01 |
| GO:BP | GO:0031175 | neuron projection development | 39 | 780 | 3.02e-01 |
| GO:BP | GO:0031161 | phosphatidylinositol catabolic process | 1 | 2 | 3.02e-01 |
| GO:BP | GO:0010770 | positive regulation of cell morphogenesis involved in differentiation | 3 | 37 | 3.02e-01 |
| GO:BP | GO:0016479 | negative regulation of transcription by RNA polymerase I | 1 | 10 | 3.02e-01 |
| GO:BP | GO:0050830 | defense response to Gram-positive bacterium | 1 | 33 | 3.02e-01 |
| GO:BP | GO:0010757 | negative regulation of plasminogen activation | 2 | 7 | 3.02e-01 |
| GO:BP | GO:0042659 | regulation of cell fate specification | 1 | 23 | 3.02e-01 |
| GO:BP | GO:0044089 | positive regulation of cellular component biogenesis | 22 | 420 | 3.02e-01 |
| GO:BP | GO:0009156 | ribonucleoside monophosphate biosynthetic process | 1 | 30 | 3.02e-01 |
| GO:BP | GO:0030166 | proteoglycan biosynthetic process | 1 | 51 | 3.02e-01 |
| GO:BP | GO:0061043 | regulation of vascular wound healing | 1 | 9 | 3.02e-01 |
| GO:BP | GO:0007158 | neuron cell-cell adhesion | 3 | 13 | 3.02e-01 |
| GO:BP | GO:0006595 | polyamine metabolic process | 3 | 16 | 3.02e-01 |
| GO:BP | GO:0071169 | establishment of protein localization to chromatin | 1 | 8 | 3.02e-01 |
| GO:BP | GO:1905938 | positive regulation of germ cell proliferation | 1 | 2 | 3.02e-01 |
| GO:BP | GO:0097105 | presynaptic membrane assembly | 2 | 8 | 3.02e-01 |
| GO:BP | GO:1902889 | protein localization to spindle microtubule | 1 | 2 | 3.02e-01 |
| GO:BP | GO:0097104 | postsynaptic membrane assembly | 2 | 8 | 3.02e-01 |
| GO:BP | GO:1902618 | cellular response to fluoride | 1 | 2 | 3.02e-01 |
| GO:BP | GO:0043456 | regulation of pentose-phosphate shunt | 1 | 6 | 3.02e-01 |
| GO:BP | GO:2000386 | positive regulation of ovarian follicle development | 1 | 2 | 3.02e-01 |
| GO:BP | GO:0032429 | regulation of phospholipase A2 activity | 1 | 8 | 3.02e-01 |
| GO:BP | GO:0086005 | ventricular cardiac muscle cell action potential | 2 | 29 | 3.02e-01 |
| GO:BP | GO:1902229 | regulation of intrinsic apoptotic signaling pathway in response to DNA damage | 2 | 37 | 3.02e-01 |
| GO:BP | GO:0002053 | positive regulation of mesenchymal cell proliferation | 2 | 18 | 3.02e-01 |
| GO:BP | GO:0061577 | calcium ion transmembrane transport via high voltage-gated calcium channel | 1 | 14 | 3.02e-01 |
| GO:BP | GO:0014846 | esophagus smooth muscle contraction | 1 | 2 | 3.02e-01 |
| GO:BP | GO:0030031 | cell projection assembly | 37 | 469 | 3.03e-01 |
| GO:BP | GO:0072538 | T-helper 17 type immune response | 1 | 24 | 3.03e-01 |
| GO:BP | GO:0022612 | gland morphogenesis | 1 | 98 | 3.04e-01 |
| GO:BP | GO:0035023 | regulation of Rho protein signal transduction | 7 | 71 | 3.04e-01 |
| GO:BP | GO:1903573 | negative regulation of response to endoplasmic reticulum stress | 3 | 41 | 3.04e-01 |
| GO:BP | GO:0048213 | Golgi vesicle prefusion complex stabilization | 1 | 2 | 3.04e-01 |
| GO:BP | GO:0032079 | positive regulation of endodeoxyribonuclease activity | 1 | 4 | 3.04e-01 |
| GO:BP | GO:0045931 | positive regulation of mitotic cell cycle | 10 | 113 | 3.04e-01 |
| GO:BP | GO:1902231 | positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage | 1 | 7 | 3.04e-01 |
| GO:BP | GO:0099566 | regulation of postsynaptic cytosolic calcium ion concentration | 2 | 6 | 3.05e-01 |
| GO:BP | GO:0032970 | regulation of actin filament-based process | 2 | 340 | 3.05e-01 |
| GO:BP | GO:2001224 | positive regulation of neuron migration | 2 | 19 | 3.05e-01 |
| GO:BP | GO:0031669 | cellular response to nutrient levels | 2 | 194 | 3.05e-01 |
| GO:BP | GO:0072093 | metanephric renal vesicle formation | 1 | 4 | 3.05e-01 |
| GO:BP | GO:0070781 | response to biotin | 1 | 1 | 3.05e-01 |
| GO:BP | GO:0071709 | membrane assembly | 1 | 53 | 3.05e-01 |
| GO:BP | GO:1901163 | regulation of trophoblast cell migration | 2 | 12 | 3.06e-01 |
| GO:BP | GO:0006779 | porphyrin-containing compound biosynthetic process | 3 | 33 | 3.06e-01 |
| GO:BP | GO:0033014 | tetrapyrrole biosynthetic process | 3 | 33 | 3.06e-01 |
| GO:BP | GO:0010712 | regulation of collagen metabolic process | 5 | 34 | 3.06e-01 |
| GO:BP | GO:2000465 | regulation of glycogen (starch) synthase activity | 2 | 8 | 3.06e-01 |
| GO:BP | GO:0002441 | histamine secretion involved in inflammatory response | 1 | 8 | 3.06e-01 |
| GO:BP | GO:0001820 | serotonin secretion | 1 | 5 | 3.06e-01 |
| GO:BP | GO:0060122 | inner ear receptor cell stereocilium organization | 3 | 23 | 3.06e-01 |
| GO:BP | GO:0002553 | histamine secretion by mast cell | 1 | 8 | 3.06e-01 |
| GO:BP | GO:0034661 | ncRNA catabolic process | 1 | 41 | 3.06e-01 |
| GO:BP | GO:0002349 | histamine production involved in inflammatory response | 1 | 8 | 3.06e-01 |
| GO:BP | GO:1902905 | positive regulation of supramolecular fiber organization | 7 | 151 | 3.06e-01 |
| GO:BP | GO:0044788 | modulation by host of viral process | 1 | 40 | 3.06e-01 |
| GO:BP | GO:0032922 | circadian regulation of gene expression | 3 | 63 | 3.06e-01 |
| GO:BP | GO:0009259 | ribonucleotide metabolic process | 3 | 311 | 3.06e-01 |
| GO:BP | GO:0061564 | axon development | 2 | 398 | 3.07e-01 |
| GO:BP | GO:0097352 | autophagosome maturation | 4 | 55 | 3.07e-01 |
| GO:BP | GO:0051152 | positive regulation of smooth muscle cell differentiation | 1 | 10 | 3.07e-01 |
| GO:BP | GO:0032891 | negative regulation of organic acid transport | 2 | 17 | 3.07e-01 |
| GO:BP | GO:1904375 | regulation of protein localization to cell periphery | 1 | 113 | 3.07e-01 |
| GO:BP | GO:0099578 | regulation of translation at postsynapse, modulating synaptic transmission | 1 | 3 | 3.07e-01 |
| GO:BP | GO:0070857 | regulation of bile acid biosynthetic process | 1 | 7 | 3.07e-01 |
| GO:BP | GO:0051352 | negative regulation of ligase activity | 1 | 2 | 3.07e-01 |
| GO:BP | GO:0044087 | regulation of cellular component biogenesis | 39 | 809 | 3.07e-01 |
| GO:BP | GO:0086003 | cardiac muscle cell contraction | 3 | 67 | 3.07e-01 |
| GO:BP | GO:0060313 | negative regulation of blood vessel remodeling | 1 | 2 | 3.07e-01 |
| GO:BP | GO:1902237 | positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway | 1 | 10 | 3.07e-01 |
| GO:BP | GO:0031061 | negative regulation of histone methylation | 1 | 9 | 3.07e-01 |
| GO:BP | GO:0032364 | intracellular oxygen homeostasis | 1 | 6 | 3.07e-01 |
| GO:BP | GO:1903522 | regulation of blood circulation | 2 | 198 | 3.07e-01 |
| GO:BP | GO:0099547 | regulation of translation at synapse, modulating synaptic transmission | 1 | 3 | 3.07e-01 |
| GO:BP | GO:0043314 | negative regulation of neutrophil degranulation | 1 | 1 | 3.07e-01 |
| GO:BP | GO:1905114 | cell surface receptor signaling pathway involved in cell-cell signaling | 1 | 448 | 3.07e-01 |
| GO:BP | GO:0009992 | intracellular water homeostasis | 1 | 3 | 3.07e-01 |
| GO:BP | GO:0033210 | leptin-mediated signaling pathway | 1 | 10 | 3.07e-01 |
| GO:BP | GO:0033157 | regulation of intracellular protein transport | 8 | 197 | 3.07e-01 |
| GO:BP | GO:0010769 | regulation of cell morphogenesis involved in differentiation | 3 | 37 | 3.07e-01 |
| GO:BP | GO:0007566 | embryo implantation | 6 | 39 | 3.07e-01 |
| GO:BP | GO:0050927 | positive regulation of positive chemotaxis | 1 | 20 | 3.07e-01 |
| GO:BP | GO:0048670 | regulation of collateral sprouting | 1 | 18 | 3.08e-01 |
| GO:BP | GO:0009440 | cyanate catabolic process | 1 | 2 | 3.08e-01 |
| GO:BP | GO:0009439 | cyanate metabolic process | 1 | 2 | 3.08e-01 |
| GO:BP | GO:0070831 | basement membrane assembly | 1 | 13 | 3.08e-01 |
| GO:BP | GO:0042058 | regulation of epidermal growth factor receptor signaling pathway | 8 | 60 | 3.08e-01 |
| GO:BP | GO:0043587 | tongue morphogenesis | 2 | 7 | 3.08e-01 |
| GO:BP | GO:0032458 | slow endocytic recycling | 1 | 2 | 3.08e-01 |
| GO:BP | GO:0042908 | xenobiotic transport | 1 | 30 | 3.08e-01 |
| GO:BP | GO:1903008 | organelle disassembly | 2 | 137 | 3.08e-01 |
| GO:BP | GO:0033143 | regulation of intracellular steroid hormone receptor signaling pathway | 3 | 61 | 3.08e-01 |
| GO:BP | GO:0034315 | regulation of Arp2/3 complex-mediated actin nucleation | 1 | 25 | 3.08e-01 |
| GO:BP | GO:0007507 | heart development | 1 | 506 | 3.08e-01 |
| GO:BP | GO:0090307 | mitotic spindle assembly | 2 | 70 | 3.08e-01 |
| GO:BP | GO:0060448 | dichotomous subdivision of terminal units involved in lung branching | 1 | 2 | 3.08e-01 |
| GO:BP | GO:0031022 | nuclear migration along microfilament | 1 | 2 | 3.08e-01 |
| GO:BP | GO:0050886 | endocrine process | 1 | 57 | 3.08e-01 |
| GO:BP | GO:0031668 | cellular response to extracellular stimulus | 6 | 219 | 3.08e-01 |
| GO:BP | GO:0090251 | protein localization involved in establishment of planar polarity | 1 | 2 | 3.08e-01 |
| GO:BP | GO:0006631 | fatty acid metabolic process | 1 | 276 | 3.08e-01 |
| GO:BP | GO:0051223 | regulation of protein transport | 15 | 404 | 3.09e-01 |
| GO:BP | GO:0019860 | uracil metabolic process | 1 | 2 | 3.09e-01 |
| GO:BP | GO:0001964 | startle response | 3 | 16 | 3.10e-01 |
| GO:BP | GO:0002819 | regulation of adaptive immune response | 4 | 106 | 3.10e-01 |
| GO:BP | GO:0035434 | copper ion transmembrane transport | 1 | 6 | 3.11e-01 |
| GO:BP | GO:0043414 | macromolecule methylation | 2 | 272 | 3.11e-01 |
| GO:BP | GO:0003331 | positive regulation of extracellular matrix constituent secretion | 1 | 4 | 3.11e-01 |
| GO:BP | GO:2000027 | regulation of animal organ morphogenesis | 2 | 101 | 3.11e-01 |
| GO:BP | GO:0009057 | macromolecule catabolic process | 12 | 1199 | 3.11e-01 |
| GO:BP | GO:0009266 | response to temperature stimulus | 2 | 133 | 3.11e-01 |
| GO:BP | GO:0009070 | serine family amino acid biosynthetic process | 2 | 16 | 3.11e-01 |
| GO:BP | GO:0000731 | DNA synthesis involved in DNA repair | 2 | 36 | 3.11e-01 |
| GO:BP | GO:0032869 | cellular response to insulin stimulus | 14 | 174 | 3.11e-01 |
| GO:BP | GO:1905821 | positive regulation of chromosome condensation | 2 | 8 | 3.11e-01 |
| GO:BP | GO:0045494 | photoreceptor cell maintenance | 1 | 27 | 3.11e-01 |
| GO:BP | GO:1905205 | positive regulation of connective tissue replacement | 1 | 3 | 3.11e-01 |
| GO:BP | GO:1900220 | semaphorin-plexin signaling pathway involved in bone trabecula morphogenesis | 1 | 2 | 3.11e-01 |
| GO:BP | GO:0003415 | chondrocyte hypertrophy | 1 | 6 | 3.11e-01 |
| GO:BP | GO:0046640 | regulation of alpha-beta T cell proliferation | 2 | 23 | 3.11e-01 |
| GO:BP | GO:0043506 | regulation of JUN kinase activity | 4 | 49 | 3.11e-01 |
| GO:BP | GO:1904161 | DNA synthesis involved in UV-damage excision repair | 1 | 2 | 3.11e-01 |
| GO:BP | GO:0006998 | nuclear envelope organization | 1 | 57 | 3.11e-01 |
| GO:BP | GO:0006783 | heme biosynthetic process | 2 | 30 | 3.11e-01 |
| GO:BP | GO:0050926 | regulation of positive chemotaxis | 1 | 20 | 3.12e-01 |
| GO:BP | GO:0019693 | ribose phosphate metabolic process | 3 | 319 | 3.12e-01 |
| GO:BP | GO:1905665 | positive regulation of calcium ion import across plasma membrane | 1 | 6 | 3.12e-01 |
| GO:BP | GO:0035338 | long-chain fatty-acyl-CoA biosynthetic process | 3 | 14 | 3.12e-01 |
| GO:BP | GO:0031987 | locomotion involved in locomotory behavior | 1 | 9 | 3.12e-01 |
| GO:BP | GO:0031456 | glycine betaine biosynthetic process | 1 | 2 | 3.12e-01 |
| GO:BP | GO:0031455 | glycine betaine metabolic process | 1 | 2 | 3.12e-01 |
| GO:BP | GO:0019285 | glycine betaine biosynthetic process from choline | 1 | 2 | 3.12e-01 |
| GO:BP | GO:0060711 | labyrinthine layer development | 6 | 35 | 3.12e-01 |
| GO:BP | GO:1904753 | negative regulation of vascular associated smooth muscle cell migration | 1 | 11 | 3.12e-01 |
| GO:BP | GO:0031109 | microtubule polymerization or depolymerization | 5 | 119 | 3.12e-01 |
| GO:BP | GO:0044091 | membrane biogenesis | 1 | 58 | 3.12e-01 |
| GO:BP | GO:0061884 | regulation of mini excitatory postsynaptic potential | 1 | 2 | 3.12e-01 |
| GO:BP | GO:0030879 | mammary gland development | 1 | 106 | 3.12e-01 |
| GO:BP | GO:0045944 | positive regulation of transcription by RNA polymerase II | 7 | 937 | 3.12e-01 |
| GO:BP | GO:0099645 | neurotransmitter receptor localization to postsynaptic specialization membrane | 2 | 19 | 3.12e-01 |
| GO:BP | GO:0051940 | regulation of catecholamine uptake involved in synaptic transmission | 2 | 6 | 3.12e-01 |
| GO:BP | GO:0099633 | protein localization to postsynaptic specialization membrane | 2 | 19 | 3.12e-01 |
| GO:BP | GO:0098816 | mini excitatory postsynaptic potential | 1 | 2 | 3.12e-01 |
| GO:BP | GO:0051584 | regulation of dopamine uptake involved in synaptic transmission | 2 | 6 | 3.12e-01 |
| GO:BP | GO:0072528 | pyrimidine-containing compound biosynthetic process | 1 | 33 | 3.12e-01 |
| GO:BP | GO:0061885 | positive regulation of mini excitatory postsynaptic potential | 1 | 2 | 3.12e-01 |
| GO:BP | GO:0061817 | endoplasmic reticulum-plasma membrane tethering | 1 | 5 | 3.12e-01 |
| GO:BP | GO:0010256 | endomembrane system organization | 8 | 496 | 3.12e-01 |
| GO:BP | GO:2001028 | positive regulation of endothelial cell chemotaxis | 2 | 13 | 3.12e-01 |
| GO:BP | GO:0002691 | regulation of cellular extravasation | 4 | 24 | 3.13e-01 |
| GO:BP | GO:0051351 | positive regulation of ligase activity | 2 | 9 | 3.13e-01 |
| GO:BP | GO:0035966 | response to topologically incorrect protein | 15 | 150 | 3.13e-01 |
| GO:BP | GO:0086001 | cardiac muscle cell action potential | 3 | 68 | 3.13e-01 |
| GO:BP | GO:2000026 | regulation of multicellular organismal development | 17 | 1014 | 3.13e-01 |
| GO:BP | GO:0099003 | vesicle-mediated transport in synapse | 20 | 180 | 3.13e-01 |
| GO:BP | GO:0000280 | nuclear division | 24 | 344 | 3.13e-01 |
| GO:BP | GO:0022409 | positive regulation of cell-cell adhesion | 13 | 189 | 3.13e-01 |
| GO:BP | GO:0007492 | endoderm development | 2 | 65 | 3.13e-01 |
| GO:BP | GO:0021628 | olfactory nerve formation | 1 | 2 | 3.13e-01 |
| GO:BP | GO:0045581 | negative regulation of T cell differentiation | 1 | 27 | 3.14e-01 |
| GO:BP | GO:0070071 | proton-transporting two-sector ATPase complex assembly | 1 | 15 | 3.14e-01 |
| GO:BP | GO:0033554 | cellular response to stress | 61 | 1681 | 3.14e-01 |
| GO:BP | GO:0051095 | regulation of helicase activity | 1 | 12 | 3.14e-01 |
| GO:BP | GO:2000774 | positive regulation of cellular senescence | 1 | 9 | 3.14e-01 |
| GO:BP | GO:0007033 | vacuole organization | 5 | 197 | 3.14e-01 |
| GO:BP | GO:0032715 | negative regulation of interleukin-6 production | 1 | 24 | 3.14e-01 |
| GO:BP | GO:0032231 | regulation of actin filament bundle assembly | 6 | 91 | 3.14e-01 |
| GO:BP | GO:0002681 | somatic recombination of T cell receptor gene segments | 1 | 4 | 3.14e-01 |
| GO:BP | GO:0018195 | peptidyl-arginine modification | 1 | 18 | 3.14e-01 |
| GO:BP | GO:0002183 | cytoplasmic translational initiation | 1 | 38 | 3.14e-01 |
| GO:BP | GO:1903202 | negative regulation of oxidative stress-induced cell death | 3 | 40 | 3.14e-01 |
| GO:BP | GO:1903146 | regulation of autophagy of mitochondrion | 2 | 37 | 3.14e-01 |
| GO:BP | GO:0006297 | nucleotide-excision repair, DNA gap filling | 1 | 5 | 3.14e-01 |
| GO:BP | GO:0030155 | regulation of cell adhesion | 2 | 539 | 3.14e-01 |
| GO:BP | GO:1904177 | regulation of adipose tissue development | 1 | 8 | 3.14e-01 |
| GO:BP | GO:0015876 | acetyl-CoA transport | 1 | 1 | 3.14e-01 |
| GO:BP | GO:0003073 | regulation of systemic arterial blood pressure | 1 | 62 | 3.14e-01 |
| GO:BP | GO:0010824 | regulation of centrosome duplication | 4 | 44 | 3.14e-01 |
| GO:BP | GO:0051103 | DNA ligation involved in DNA repair | 1 | 5 | 3.14e-01 |
| GO:BP | GO:0090312 | positive regulation of protein deacetylation | 3 | 28 | 3.14e-01 |
| GO:BP | GO:1903406 | regulation of P-type sodium:potassium-exchanging transporter activity | 1 | 2 | 3.14e-01 |
| GO:BP | GO:0008045 | motor neuron axon guidance | 1 | 25 | 3.14e-01 |
| GO:BP | GO:2001279 | regulation of unsaturated fatty acid biosynthetic process | 1 | 7 | 3.14e-01 |
| GO:BP | GO:0045621 | positive regulation of lymphocyte differentiation | 10 | 86 | 3.14e-01 |
| GO:BP | GO:1902856 | negative regulation of non-motile cilium assembly | 1 | 2 | 3.14e-01 |
| GO:BP | GO:0072205 | metanephric collecting duct development | 1 | 5 | 3.14e-01 |
| GO:BP | GO:0009132 | nucleoside diphosphate metabolic process | 1 | 32 | 3.14e-01 |
| GO:BP | GO:0002820 | negative regulation of adaptive immune response | 2 | 27 | 3.14e-01 |
| GO:BP | GO:0001675 | acrosome assembly | 1 | 16 | 3.14e-01 |
| GO:BP | GO:0072132 | mesenchyme morphogenesis | 2 | 50 | 3.14e-01 |
| GO:BP | GO:0002568 | somatic diversification of T cell receptor genes | 1 | 4 | 3.14e-01 |
| GO:BP | GO:0033153 | T cell receptor V(D)J recombination | 1 | 4 | 3.14e-01 |
| GO:BP | GO:0043407 | negative regulation of MAP kinase activity | 3 | 50 | 3.14e-01 |
| GO:BP | GO:0051238 | sequestering of metal ion | 1 | 17 | 3.14e-01 |
| GO:BP | GO:1903408 | positive regulation of P-type sodium:potassium-exchanging transporter activity | 1 | 2 | 3.14e-01 |
| GO:BP | GO:0070266 | necroptotic process | 2 | 32 | 3.14e-01 |
| GO:BP | GO:0009101 | glycoprotein biosynthetic process | 4 | 252 | 3.15e-01 |
| GO:BP | GO:0097090 | presynaptic membrane organization | 2 | 8 | 3.15e-01 |
| GO:BP | GO:0060438 | trachea development | 2 | 13 | 3.15e-01 |
| GO:BP | GO:1903147 | negative regulation of autophagy of mitochondrion | 1 | 7 | 3.15e-01 |
| GO:BP | GO:0061450 | trophoblast cell migration | 2 | 13 | 3.15e-01 |
| GO:BP | GO:1901387 | positive regulation of voltage-gated calcium channel activity | 3 | 13 | 3.15e-01 |
| GO:BP | GO:0006360 | transcription by RNA polymerase I | 2 | 62 | 3.16e-01 |
| GO:BP | GO:0042327 | positive regulation of phosphorylation | 25 | 547 | 3.16e-01 |
| GO:BP | GO:0061157 | mRNA destabilization | 2 | 89 | 3.16e-01 |
| GO:BP | GO:0042274 | ribosomal small subunit biogenesis | 5 | 79 | 3.16e-01 |
| GO:BP | GO:0019081 | viral translation | 1 | 18 | 3.16e-01 |
| GO:BP | GO:0007250 | activation of NF-kappaB-inducing kinase activity | 3 | 13 | 3.16e-01 |
| GO:BP | GO:0015937 | coenzyme A biosynthetic process | 1 | 11 | 3.16e-01 |
| GO:BP | GO:0090520 | sphingolipid mediated signaling pathway | 2 | 11 | 3.16e-01 |
| GO:BP | GO:2000144 | positive regulation of DNA-templated transcription initiation | 3 | 65 | 3.16e-01 |
| GO:BP | GO:0035088 | establishment or maintenance of apical/basal cell polarity | 4 | 50 | 3.16e-01 |
| GO:BP | GO:2001243 | negative regulation of intrinsic apoptotic signaling pathway | 3 | 89 | 3.16e-01 |
| GO:BP | GO:0061245 | establishment or maintenance of bipolar cell polarity | 4 | 50 | 3.16e-01 |
| GO:BP | GO:0030336 | negative regulation of cell migration | 11 | 227 | 3.16e-01 |
| GO:BP | GO:0010994 | free ubiquitin chain polymerization | 1 | 8 | 3.17e-01 |
| GO:BP | GO:1903039 | positive regulation of leukocyte cell-cell adhesion | 10 | 157 | 3.17e-01 |
| GO:BP | GO:0006940 | regulation of smooth muscle contraction | 6 | 42 | 3.17e-01 |
| GO:BP | GO:0036003 | positive regulation of transcription from RNA polymerase II promoter in response to stress | 1 | 18 | 3.17e-01 |
| GO:BP | GO:0003290 | atrial septum secundum morphogenesis | 1 | 2 | 3.17e-01 |
| GO:BP | GO:1905150 | regulation of voltage-gated sodium channel activity | 2 | 6 | 3.17e-01 |
| GO:BP | GO:0031397 | negative regulation of protein ubiquitination | 9 | 76 | 3.17e-01 |
| GO:BP | GO:0140467 | integrated stress response signaling | 2 | 35 | 3.18e-01 |
| GO:BP | GO:0018209 | peptidyl-serine modification | 17 | 259 | 3.18e-01 |
| GO:BP | GO:0060601 | lateral sprouting from an epithelium | 2 | 10 | 3.18e-01 |
| GO:BP | GO:0048589 | developmental growth | 1 | 522 | 3.18e-01 |
| GO:BP | GO:1901534 | positive regulation of hematopoietic progenitor cell differentiation | 1 | 6 | 3.18e-01 |
| GO:BP | GO:0045634 | regulation of melanocyte differentiation | 1 | 5 | 3.18e-01 |
| GO:BP | GO:0045582 | positive regulation of T cell differentiation | 6 | 74 | 3.18e-01 |
| GO:BP | GO:0003179 | heart valve morphogenesis | 5 | 55 | 3.18e-01 |
| GO:BP | GO:0051014 | actin filament severing | 1 | 13 | 3.18e-01 |
| GO:BP | GO:0032957 | inositol trisphosphate metabolic process | 2 | 10 | 3.18e-01 |
| GO:BP | GO:0042754 | negative regulation of circadian rhythm | 1 | 10 | 3.18e-01 |
| GO:BP | GO:0070373 | negative regulation of ERK1 and ERK2 cascade | 6 | 59 | 3.18e-01 |
| GO:BP | GO:0060612 | adipose tissue development | 2 | 41 | 3.18e-01 |
| GO:BP | GO:0006043 | glucosamine catabolic process | 1 | 2 | 3.19e-01 |
| GO:BP | GO:1903818 | positive regulation of voltage-gated potassium channel activity | 1 | 11 | 3.19e-01 |
| GO:BP | GO:0050868 | negative regulation of T cell activation | 3 | 67 | 3.19e-01 |
| GO:BP | GO:0006517 | protein deglycosylation | 3 | 25 | 3.19e-01 |
| GO:BP | GO:0003205 | cardiac chamber development | 2 | 149 | 3.19e-01 |
| GO:BP | GO:0007043 | cell-cell junction assembly | 1 | 105 | 3.19e-01 |
| GO:BP | GO:0044057 | regulation of system process | 3 | 405 | 3.19e-01 |
| GO:BP | GO:2000322 | regulation of glucocorticoid receptor signaling pathway | 1 | 7 | 3.19e-01 |
| GO:BP | GO:0015793 | glycerol transmembrane transport | 1 | 4 | 3.19e-01 |
| GO:BP | GO:0061061 | muscle structure development | 1 | 546 | 3.19e-01 |
| GO:BP | GO:0009314 | response to radiation | 10 | 352 | 3.19e-01 |
| GO:BP | GO:0051054 | positive regulation of DNA metabolic process | 20 | 265 | 3.19e-01 |
| GO:BP | GO:0001974 | blood vessel remodeling | 5 | 32 | 3.19e-01 |
| GO:BP | GO:1902116 | negative regulation of organelle assembly | 2 | 40 | 3.19e-01 |
| GO:BP | GO:0005975 | carbohydrate metabolic process | 14 | 433 | 3.20e-01 |
| GO:BP | GO:0033032 | regulation of myeloid cell apoptotic process | 2 | 20 | 3.20e-01 |
| GO:BP | GO:0055007 | cardiac muscle cell differentiation | 9 | 103 | 3.20e-01 |
| GO:BP | GO:0046365 | monosaccharide catabolic process | 3 | 38 | 3.20e-01 |
| GO:BP | GO:1903409 | reactive oxygen species biosynthetic process | 2 | 36 | 3.20e-01 |
| GO:BP | GO:0048565 | digestive tract development | 12 | 92 | 3.20e-01 |
| GO:BP | GO:0032873 | negative regulation of stress-activated MAPK cascade | 2 | 46 | 3.20e-01 |
| GO:BP | GO:0051180 | vitamin transport | 1 | 28 | 3.20e-01 |
| GO:BP | GO:1903358 | regulation of Golgi organization | 2 | 17 | 3.20e-01 |
| GO:BP | GO:0061819 | telomeric DNA-containing double minutes formation | 1 | 3 | 3.20e-01 |
| GO:BP | GO:0051877 | pigment granule aggregation in cell center | 1 | 2 | 3.20e-01 |
| GO:BP | GO:0006054 | N-acetylneuraminate metabolic process | 2 | 11 | 3.20e-01 |
| GO:BP | GO:0060831 | smoothened signaling pathway involved in dorsal/ventral neural tube patterning | 2 | 14 | 3.20e-01 |
| GO:BP | GO:0099170 | postsynaptic modulation of chemical synaptic transmission | 4 | 23 | 3.20e-01 |
| GO:BP | GO:0046633 | alpha-beta T cell proliferation | 2 | 24 | 3.20e-01 |
| GO:BP | GO:1903516 | regulation of single strand break repair | 1 | 3 | 3.20e-01 |
| GO:BP | GO:0007030 | Golgi organization | 3 | 137 | 3.20e-01 |
| GO:BP | GO:0033689 | negative regulation of osteoblast proliferation | 2 | 10 | 3.20e-01 |
| GO:BP | GO:0038066 | p38MAPK cascade | 1 | 43 | 3.20e-01 |
| GO:BP | GO:0042178 | xenobiotic catabolic process | 1 | 12 | 3.20e-01 |
| GO:BP | GO:0071470 | cellular response to osmotic stress | 1 | 42 | 3.20e-01 |
| GO:BP | GO:0048814 | regulation of dendrite morphogenesis | 4 | 58 | 3.20e-01 |
| GO:BP | GO:0071173 | spindle assembly checkpoint signaling | 1 | 44 | 3.20e-01 |
| GO:BP | GO:0071174 | mitotic spindle checkpoint signaling | 1 | 44 | 3.20e-01 |
| GO:BP | GO:1905764 | regulation of protection from non-homologous end joining at telomere | 1 | 3 | 3.20e-01 |
| GO:BP | GO:1905765 | negative regulation of protection from non-homologous end joining at telomere | 1 | 3 | 3.20e-01 |
| GO:BP | GO:0043401 | steroid hormone mediated signaling pathway | 3 | 112 | 3.20e-01 |
| GO:BP | GO:0045596 | negative regulation of cell differentiation | 1 | 482 | 3.20e-01 |
| GO:BP | GO:0006007 | glucose catabolic process | 2 | 22 | 3.20e-01 |
| GO:BP | GO:0046718 | viral entry into host cell | 1 | 107 | 3.20e-01 |
| GO:BP | GO:2000514 | regulation of CD4-positive, alpha-beta T cell activation | 5 | 39 | 3.20e-01 |
| GO:BP | GO:0007094 | mitotic spindle assembly checkpoint signaling | 1 | 44 | 3.20e-01 |
| GO:BP | GO:0045930 | negative regulation of mitotic cell cycle | 2 | 211 | 3.20e-01 |
| GO:BP | GO:0038166 | angiotensin-activated signaling pathway | 2 | 10 | 3.20e-01 |
| GO:BP | GO:0071360 | cellular response to exogenous dsRNA | 1 | 14 | 3.20e-01 |
| GO:BP | GO:0070303 | negative regulation of stress-activated protein kinase signaling cascade | 2 | 46 | 3.20e-01 |
| GO:BP | GO:0048203 | vesicle targeting, trans-Golgi to endosome | 1 | 2 | 3.20e-01 |
| GO:BP | GO:1903929 | primary palate development | 1 | 2 | 3.20e-01 |
| GO:BP | GO:0035774 | positive regulation of insulin secretion involved in cellular response to glucose stimulus | 4 | 18 | 3.20e-01 |
| GO:BP | GO:0030038 | contractile actin filament bundle assembly | 6 | 94 | 3.20e-01 |
| GO:BP | GO:0032868 | response to insulin | 17 | 215 | 3.20e-01 |
| GO:BP | GO:0099555 | trans-synaptic signaling by nitric oxide, modulating synaptic transmission | 1 | 2 | 3.20e-01 |
| GO:BP | GO:0099554 | trans-synaptic signaling by soluble gas, modulating synaptic transmission | 1 | 2 | 3.20e-01 |
| GO:BP | GO:0043149 | stress fiber assembly | 6 | 94 | 3.20e-01 |
| GO:BP | GO:0046902 | regulation of mitochondrial membrane permeability | 2 | 54 | 3.21e-01 |
| GO:BP | GO:0014068 | positive regulation of phosphatidylinositol 3-kinase signaling | 8 | 55 | 3.21e-01 |
| GO:BP | GO:1901492 | positive regulation of lymphangiogenesis | 1 | 2 | 3.21e-01 |
| GO:BP | GO:0043616 | keratinocyte proliferation | 3 | 38 | 3.21e-01 |
| GO:BP | GO:0006984 | ER-nucleus signaling pathway | 3 | 45 | 3.21e-01 |
| GO:BP | GO:0003197 | endocardial cushion development | 1 | 46 | 3.21e-01 |
| GO:BP | GO:0010747 | positive regulation of long-chain fatty acid import across plasma membrane | 1 | 1 | 3.21e-01 |
| GO:BP | GO:0006305 | DNA alkylation | 1 | 46 | 3.21e-01 |
| GO:BP | GO:0006306 | DNA methylation | 1 | 46 | 3.21e-01 |
| GO:BP | GO:0014003 | oligodendrocyte development | 1 | 27 | 3.21e-01 |
| GO:BP | GO:0010586 | miRNA metabolic process | 3 | 81 | 3.21e-01 |
| GO:BP | GO:0031577 | spindle checkpoint signaling | 1 | 45 | 3.21e-01 |
| GO:BP | GO:0072657 | protein localization to membrane | 2 | 523 | 3.21e-01 |
| GO:BP | GO:0035513 | oxidative RNA demethylation | 1 | 5 | 3.21e-01 |
| GO:BP | GO:0060441 | epithelial tube branching involved in lung morphogenesis | 2 | 20 | 3.21e-01 |
| GO:BP | GO:0061014 | positive regulation of mRNA catabolic process | 2 | 93 | 3.21e-01 |
| GO:BP | GO:0050779 | RNA destabilization | 2 | 92 | 3.21e-01 |
| GO:BP | GO:0043406 | positive regulation of MAP kinase activity | 8 | 82 | 3.22e-01 |
| GO:BP | GO:0071803 | positive regulation of podosome assembly | 2 | 6 | 3.22e-01 |
| GO:BP | GO:0071383 | cellular response to steroid hormone stimulus | 4 | 166 | 3.22e-01 |
| GO:BP | GO:0048754 | branching morphogenesis of an epithelial tube | 1 | 121 | 3.22e-01 |
| GO:BP | GO:0009124 | nucleoside monophosphate biosynthetic process | 1 | 37 | 3.22e-01 |
| GO:BP | GO:1902259 | regulation of delayed rectifier potassium channel activity | 1 | 12 | 3.22e-01 |
| GO:BP | GO:1902430 | negative regulation of amyloid-beta formation | 2 | 17 | 3.22e-01 |
| GO:BP | GO:0021784 | postganglionic parasympathetic fiber development | 1 | 2 | 3.22e-01 |
| GO:BP | GO:0043502 | regulation of muscle adaptation | 1 | 69 | 3.22e-01 |
| GO:BP | GO:0061642 | chemoattraction of axon | 1 | 2 | 3.22e-01 |
| GO:BP | GO:0034103 | regulation of tissue remodeling | 6 | 45 | 3.22e-01 |
| GO:BP | GO:2000047 | regulation of cell-cell adhesion mediated by cadherin | 2 | 16 | 3.22e-01 |
| GO:BP | GO:0032077 | positive regulation of deoxyribonuclease activity | 1 | 5 | 3.23e-01 |
| GO:BP | GO:0003417 | growth plate cartilage development | 2 | 15 | 3.23e-01 |
| GO:BP | GO:0001821 | histamine secretion | 1 | 9 | 3.23e-01 |
| GO:BP | GO:0003300 | cardiac muscle hypertrophy | 1 | 72 | 3.23e-01 |
| GO:BP | GO:1903846 | positive regulation of cellular response to transforming growth factor beta stimulus | 3 | 30 | 3.23e-01 |
| GO:BP | GO:0045841 | negative regulation of mitotic metaphase/anaphase transition | 1 | 46 | 3.23e-01 |
| GO:BP | GO:0036145 | dendritic cell homeostasis | 1 | 2 | 3.23e-01 |
| GO:BP | GO:0030309 | poly-N-acetyllactosamine metabolic process | 1 | 6 | 3.23e-01 |
| GO:BP | GO:0006824 | cobalt ion transport | 1 | 5 | 3.23e-01 |
| GO:BP | GO:0090176 | microtubule cytoskeleton organization involved in establishment of planar polarity | 1 | 3 | 3.23e-01 |
| GO:BP | GO:0051030 | snRNA transport | 1 | 6 | 3.23e-01 |
| GO:BP | GO:0044409 | entry into host | 1 | 113 | 3.23e-01 |
| GO:BP | GO:0070601 | centromeric sister chromatid cohesion | 2 | 11 | 3.23e-01 |
| GO:BP | GO:0072656 | maintenance of protein location in mitochondrion | 1 | 5 | 3.23e-01 |
| GO:BP | GO:0019896 | axonal transport of mitochondrion | 3 | 17 | 3.23e-01 |
| GO:BP | GO:0021532 | neural tube patterning | 1 | 31 | 3.23e-01 |
| GO:BP | GO:0030511 | positive regulation of transforming growth factor beta receptor signaling pathway | 3 | 30 | 3.23e-01 |
| GO:BP | GO:0097553 | calcium ion transmembrane import into cytosol | 8 | 115 | 3.23e-01 |
| GO:BP | GO:1901663 | quinone biosynthetic process | 1 | 17 | 3.24e-01 |
| GO:BP | GO:0006744 | ubiquinone biosynthetic process | 1 | 17 | 3.24e-01 |
| GO:BP | GO:1900034 | regulation of cellular response to heat | 2 | 16 | 3.24e-01 |
| GO:BP | GO:0001818 | negative regulation of cytokine production | 2 | 165 | 3.24e-01 |
| GO:BP | GO:0002071 | glandular epithelial cell maturation | 2 | 7 | 3.24e-01 |
| GO:BP | GO:0048468 | cell development | 16 | 1963 | 3.24e-01 |
| GO:BP | GO:0071403 | cellular response to high density lipoprotein particle stimulus | 1 | 3 | 3.24e-01 |
| GO:BP | GO:0050796 | regulation of insulin secretion | 6 | 116 | 3.24e-01 |
| GO:BP | GO:0033387 | putrescine biosynthetic process from ornithine | 1 | 3 | 3.24e-01 |
| GO:BP | GO:0099560 | synaptic membrane adhesion | 4 | 22 | 3.25e-01 |
| GO:BP | GO:0046782 | regulation of viral transcription | 1 | 19 | 3.25e-01 |
| GO:BP | GO:1902045 | negative regulation of Fas signaling pathway | 1 | 2 | 3.25e-01 |
| GO:BP | GO:0019080 | viral gene expression | 2 | 96 | 3.26e-01 |
| GO:BP | GO:0051542 | elastin biosynthetic process | 1 | 2 | 3.26e-01 |
| GO:BP | GO:1905664 | regulation of calcium ion import across plasma membrane | 1 | 8 | 3.26e-01 |
| GO:BP | GO:0043462 | regulation of ATP-dependent activity | 5 | 63 | 3.26e-01 |
| GO:BP | GO:1902115 | regulation of organelle assembly | 5 | 186 | 3.26e-01 |
| GO:BP | GO:0003018 | vascular process in circulatory system | 2 | 198 | 3.26e-01 |
| GO:BP | GO:0090270 | regulation of fibroblast growth factor production | 1 | 4 | 3.26e-01 |
| GO:BP | GO:0090269 | fibroblast growth factor production | 1 | 4 | 3.26e-01 |
| GO:BP | GO:0007026 | negative regulation of microtubule depolymerization | 2 | 27 | 3.26e-01 |
| GO:BP | GO:0048665 | neuron fate specification | 1 | 14 | 3.26e-01 |
| GO:BP | GO:0051084 | ‘de novo’ post-translational protein folding | 1 | 35 | 3.27e-01 |
| GO:BP | GO:0038127 | ERBB signaling pathway | 12 | 107 | 3.27e-01 |
| GO:BP | GO:1901660 | calcium ion export | 1 | 3 | 3.27e-01 |
| GO:BP | GO:0072396 | response to cell cycle checkpoint signaling | 1 | 8 | 3.28e-01 |
| GO:BP | GO:0002063 | chondrocyte development | 2 | 24 | 3.28e-01 |
| GO:BP | GO:0061001 | regulation of dendritic spine morphogenesis | 1 | 39 | 3.28e-01 |
| GO:BP | GO:0003150 | muscular septum morphogenesis | 1 | 4 | 3.28e-01 |
| GO:BP | GO:0001173 | DNA-templated transcriptional start site selection | 1 | 2 | 3.28e-01 |
| GO:BP | GO:2000780 | negative regulation of double-strand break repair | 2 | 30 | 3.28e-01 |
| GO:BP | GO:0033048 | negative regulation of mitotic sister chromatid segregation | 1 | 47 | 3.28e-01 |
| GO:BP | GO:0001174 | transcriptional start site selection at RNA polymerase II promoter | 1 | 2 | 3.28e-01 |
| GO:BP | GO:0033046 | negative regulation of sister chromatid segregation | 1 | 47 | 3.28e-01 |
| GO:BP | GO:0036265 | RNA (guanine-N7)-methylation | 1 | 6 | 3.28e-01 |
| GO:BP | GO:0046889 | positive regulation of lipid biosynthetic process | 4 | 63 | 3.28e-01 |
| GO:BP | GO:0051017 | actin filament bundle assembly | 8 | 138 | 3.28e-01 |
| GO:BP | GO:1902100 | negative regulation of metaphase/anaphase transition of cell cycle | 1 | 47 | 3.28e-01 |
| GO:BP | GO:0071407 | cellular response to organic cyclic compound | 8 | 414 | 3.28e-01 |
| GO:BP | GO:0045124 | regulation of bone resorption | 4 | 24 | 3.28e-01 |
| GO:BP | GO:0051896 | regulation of protein kinase B signaling | 1 | 123 | 3.28e-01 |
| GO:BP | GO:0014897 | striated muscle hypertrophy | 1 | 73 | 3.28e-01 |
| GO:BP | GO:2000816 | negative regulation of mitotic sister chromatid separation | 1 | 47 | 3.28e-01 |
| GO:BP | GO:0072423 | response to DNA damage checkpoint signaling | 1 | 8 | 3.28e-01 |
| GO:BP | GO:0072402 | response to DNA integrity checkpoint signaling | 1 | 8 | 3.28e-01 |
| GO:BP | GO:0097118 | neuroligin clustering involved in postsynaptic membrane assembly | 1 | 2 | 3.28e-01 |
| GO:BP | GO:1904862 | inhibitory synapse assembly | 1 | 13 | 3.28e-01 |
| GO:BP | GO:0045639 | positive regulation of myeloid cell differentiation | 1 | 67 | 3.28e-01 |
| GO:BP | GO:0055012 | ventricular cardiac muscle cell differentiation | 2 | 15 | 3.29e-01 |
| GO:BP | GO:0048285 | organelle fission | 27 | 388 | 3.29e-01 |
| GO:BP | GO:0034333 | adherens junction assembly | 1 | 13 | 3.29e-01 |
| GO:BP | GO:0006520 | amino acid metabolic process | 1 | 222 | 3.29e-01 |
| GO:BP | GO:0043030 | regulation of macrophage activation | 1 | 31 | 3.29e-01 |
| GO:BP | GO:0106057 | negative regulation of calcineurin-mediated signaling | 2 | 14 | 3.29e-01 |
| GO:BP | GO:0070885 | negative regulation of calcineurin-NFAT signaling cascade | 2 | 14 | 3.29e-01 |
| GO:BP | GO:0060437 | lung growth | 1 | 5 | 3.29e-01 |
| GO:BP | GO:0016926 | protein desumoylation | 2 | 9 | 3.29e-01 |
| GO:BP | GO:0046963 | 3’-phosphoadenosine 5’-phosphosulfate transport | 1 | 2 | 3.29e-01 |
| GO:BP | GO:1902558 | 5’-adenylyl sulfate transmembrane transport | 1 | 2 | 3.29e-01 |
| GO:BP | GO:1902559 | 3’-phospho-5’-adenylyl sulfate transmembrane transport | 1 | 2 | 3.29e-01 |
| GO:BP | GO:0045348 | positive regulation of MHC class II biosynthetic process | 1 | 8 | 3.29e-01 |
| GO:BP | GO:1904251 | regulation of bile acid metabolic process | 1 | 9 | 3.29e-01 |
| GO:BP | GO:0007062 | sister chromatid cohesion | 2 | 52 | 3.29e-01 |
| GO:BP | GO:0030324 | lung development | 1 | 146 | 3.29e-01 |
| GO:BP | GO:0010948 | negative regulation of cell cycle process | 7 | 273 | 3.29e-01 |
| GO:BP | GO:1902811 | positive regulation of skeletal muscle fiber differentiation | 1 | 2 | 3.30e-01 |
| GO:BP | GO:0035600 | tRNA methylthiolation | 1 | 2 | 3.30e-01 |
| GO:BP | GO:1990145 | maintenance of translational fidelity | 1 | 2 | 3.30e-01 |
| GO:BP | GO:0038063 | collagen-activated tyrosine kinase receptor signaling pathway | 2 | 10 | 3.30e-01 |
| GO:BP | GO:0042428 | serotonin metabolic process | 2 | 6 | 3.30e-01 |
| GO:BP | GO:0032386 | regulation of intracellular transport | 4 | 292 | 3.30e-01 |
| GO:BP | GO:0099590 | neurotransmitter receptor internalization | 4 | 19 | 3.30e-01 |
| GO:BP | GO:0014896 | muscle hypertrophy | 1 | 74 | 3.30e-01 |
| GO:BP | GO:0045620 | negative regulation of lymphocyte differentiation | 1 | 33 | 3.31e-01 |
| GO:BP | GO:2001259 | positive regulation of cation channel activity | 2 | 49 | 3.31e-01 |
| GO:BP | GO:0002469 | myeloid dendritic cell antigen processing and presentation | 1 | 1 | 3.31e-01 |
| GO:BP | GO:0042537 | benzene-containing compound metabolic process | 1 | 14 | 3.31e-01 |
| GO:BP | GO:0006401 | RNA catabolic process | 2 | 256 | 3.31e-01 |
| GO:BP | GO:0002028 | regulation of sodium ion transport | 9 | 72 | 3.31e-01 |
| GO:BP | GO:0055014 | atrial cardiac muscle cell development | 1 | 3 | 3.31e-01 |
| GO:BP | GO:0006014 | D-ribose metabolic process | 1 | 3 | 3.31e-01 |
| GO:BP | GO:0002491 | antigen processing and presentation of endogenous peptide antigen via MHC class II | 1 | 1 | 3.31e-01 |
| GO:BP | GO:0097709 | connective tissue replacement | 2 | 8 | 3.31e-01 |
| GO:BP | GO:0055011 | atrial cardiac muscle cell differentiation | 1 | 3 | 3.31e-01 |
| GO:BP | GO:0048771 | tissue remodeling | 1 | 114 | 3.31e-01 |
| GO:BP | GO:0043217 | myelin maintenance | 2 | 15 | 3.31e-01 |
| GO:BP | GO:0043280 | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 5 | 96 | 3.31e-01 |
| GO:BP | GO:1903320 | regulation of protein modification by small protein conjugation or removal | 2 | 232 | 3.31e-01 |
| GO:BP | GO:0002479 | antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent | 1 | 2 | 3.31e-01 |
| GO:BP | GO:0043281 | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 18 | 155 | 3.31e-01 |
| GO:BP | GO:0097680 | double-strand break repair via classical nonhomologous end joining | 1 | 6 | 3.31e-01 |
| GO:BP | GO:0055006 | cardiac cell development | 7 | 77 | 3.31e-01 |
| GO:BP | GO:0019317 | fucose catabolic process | 1 | 3 | 3.31e-01 |
| GO:BP | GO:0097021 | lymphocyte migration into lymphoid organs | 1 | 6 | 3.31e-01 |
| GO:BP | GO:1901187 | regulation of ephrin receptor signaling pathway | 1 | 2 | 3.31e-01 |
| GO:BP | GO:0021508 | floor plate formation | 1 | 3 | 3.31e-01 |
| GO:BP | GO:1903507 | negative regulation of nucleic acid-templated transcription | 2 | 1017 | 3.31e-01 |
| GO:BP | GO:0045892 | negative regulation of DNA-templated transcription | 2 | 1015 | 3.31e-01 |
| GO:BP | GO:0030323 | respiratory tube development | 1 | 150 | 3.31e-01 |
| GO:BP | GO:0021965 | spinal cord ventral commissure morphogenesis | 1 | 2 | 3.31e-01 |
| GO:BP | GO:0030216 | keratinocyte differentiation | 1 | 75 | 3.31e-01 |
| GO:BP | GO:0021775 | smoothened signaling pathway involved in ventral spinal cord interneuron specification | 1 | 3 | 3.31e-01 |
| GO:BP | GO:0045986 | negative regulation of smooth muscle contraction | 1 | 12 | 3.31e-01 |
| GO:BP | GO:0050942 | positive regulation of pigment cell differentiation | 1 | 5 | 3.31e-01 |
| GO:BP | GO:0007339 | binding of sperm to zona pellucida | 2 | 20 | 3.31e-01 |
| GO:BP | GO:0021776 | smoothened signaling pathway involved in spinal cord motor neuron cell fate specification | 1 | 3 | 3.31e-01 |
| GO:BP | GO:2000106 | regulation of leukocyte apoptotic process | 6 | 57 | 3.31e-01 |
| GO:BP | GO:0051985 | negative regulation of chromosome segregation | 1 | 48 | 3.31e-01 |
| GO:BP | GO:1905819 | negative regulation of chromosome separation | 1 | 48 | 3.31e-01 |
| GO:BP | GO:0070286 | axonemal dynein complex assembly | 1 | 20 | 3.31e-01 |
| GO:BP | GO:2000562 | negative regulation of CD4-positive, alpha-beta T cell proliferation | 1 | 7 | 3.31e-01 |
| GO:BP | GO:0042355 | L-fucose catabolic process | 1 | 3 | 3.31e-01 |
| GO:BP | GO:0017148 | negative regulation of translation | 14 | 165 | 3.33e-01 |
| GO:BP | GO:0002320 | lymphoid progenitor cell differentiation | 3 | 17 | 3.33e-01 |
| GO:BP | GO:0006597 | spermine biosynthetic process | 1 | 2 | 3.33e-01 |
| GO:BP | GO:0061912 | selective autophagy | 5 | 90 | 3.35e-01 |
| GO:BP | GO:0007281 | germ cell development | 3 | 187 | 3.35e-01 |
| GO:BP | GO:0061037 | negative regulation of cartilage development | 3 | 23 | 3.35e-01 |
| GO:BP | GO:1902679 | negative regulation of RNA biosynthetic process | 2 | 1026 | 3.35e-01 |
| GO:BP | GO:0014909 | smooth muscle cell migration | 8 | 65 | 3.35e-01 |
| GO:BP | GO:0034976 | response to endoplasmic reticulum stress | 6 | 234 | 3.35e-01 |
| GO:BP | GO:0009629 | response to gravity | 1 | 5 | 3.35e-01 |
| GO:BP | GO:1903895 | negative regulation of IRE1-mediated unfolded protein response | 1 | 5 | 3.35e-01 |
| GO:BP | GO:1900141 | regulation of oligodendrocyte apoptotic process | 1 | 2 | 3.35e-01 |
| GO:BP | GO:0006112 | energy reserve metabolic process | 4 | 73 | 3.36e-01 |
| GO:BP | GO:0051125 | regulation of actin nucleation | 1 | 31 | 3.36e-01 |
| GO:BP | GO:0007042 | lysosomal lumen acidification | 1 | 21 | 3.36e-01 |
| GO:BP | GO:0043410 | positive regulation of MAPK cascade | 35 | 317 | 3.36e-01 |
| GO:BP | GO:0033673 | negative regulation of kinase activity | 8 | 197 | 3.36e-01 |
| GO:BP | GO:0048769 | sarcomerogenesis | 1 | 3 | 3.36e-01 |
| GO:BP | GO:0071688 | striated muscle myosin thick filament assembly | 1 | 3 | 3.36e-01 |
| GO:BP | GO:0030241 | skeletal muscle myosin thick filament assembly | 1 | 3 | 3.36e-01 |
| GO:BP | GO:0097164 | ammonium ion metabolic process | 3 | 14 | 3.36e-01 |
| GO:BP | GO:0070291 | N-acylethanolamine metabolic process | 1 | 4 | 3.37e-01 |
| GO:BP | GO:0002520 | immune system development | 1 | 144 | 3.37e-01 |
| GO:BP | GO:0051963 | regulation of synapse assembly | 9 | 83 | 3.37e-01 |
| GO:BP | GO:0006743 | ubiquinone metabolic process | 1 | 19 | 3.37e-01 |
| GO:BP | GO:0046075 | dTTP metabolic process | 1 | 4 | 3.37e-01 |
| GO:BP | GO:0042326 | negative regulation of phosphorylation | 12 | 300 | 3.37e-01 |
| GO:BP | GO:0034341 | response to type II interferon | 7 | 83 | 3.37e-01 |
| GO:BP | GO:0051570 | regulation of histone H3-K9 methylation | 1 | 11 | 3.37e-01 |
| GO:BP | GO:0071676 | negative regulation of mononuclear cell migration | 3 | 16 | 3.37e-01 |
| GO:BP | GO:0006448 | regulation of translational elongation | 2 | 19 | 3.37e-01 |
| GO:BP | GO:0009212 | pyrimidine deoxyribonucleoside triphosphate biosynthetic process | 1 | 4 | 3.37e-01 |
| GO:BP | GO:0051036 | regulation of endosome size | 1 | 13 | 3.37e-01 |
| GO:BP | GO:0043518 | negative regulation of DNA damage response, signal transduction by p53 class mediator | 1 | 13 | 3.37e-01 |
| GO:BP | GO:0043161 | proteasome-mediated ubiquitin-dependent protein catabolic process | 35 | 427 | 3.37e-01 |
| GO:BP | GO:0050919 | negative chemotaxis | 4 | 42 | 3.37e-01 |
| GO:BP | GO:0033363 | secretory granule organization | 2 | 50 | 3.37e-01 |
| GO:BP | GO:2000757 | negative regulation of peptidyl-lysine acetylation | 1 | 13 | 3.37e-01 |
| GO:BP | GO:0006235 | dTTP biosynthetic process | 1 | 4 | 3.37e-01 |
| GO:BP | GO:0061572 | actin filament bundle organization | 8 | 140 | 3.37e-01 |
| GO:BP | GO:0006767 | water-soluble vitamin metabolic process | 1 | 49 | 3.37e-01 |
| GO:BP | GO:0035089 | establishment of apical/basal cell polarity | 2 | 18 | 3.37e-01 |
| GO:BP | GO:0032259 | methylation | 2 | 313 | 3.37e-01 |
| GO:BP | GO:0042982 | amyloid precursor protein metabolic process | 5 | 69 | 3.37e-01 |
| GO:BP | GO:0045010 | actin nucleation | 4 | 50 | 3.37e-01 |
| GO:BP | GO:0044778 | meiotic DNA integrity checkpoint signaling | 1 | 1 | 3.37e-01 |
| GO:BP | GO:0006627 | protein processing involved in protein targeting to mitochondrion | 1 | 6 | 3.37e-01 |
| GO:BP | GO:0014831 | gastro-intestinal system smooth muscle contraction | 2 | 5 | 3.37e-01 |
| GO:BP | GO:0000820 | regulation of glutamine family amino acid metabolic process | 1 | 5 | 3.37e-01 |
| GO:BP | GO:0097374 | sensory neuron axon guidance | 1 | 2 | 3.37e-01 |
| GO:BP | GO:0036486 | ventral trunk neural crest cell migration | 1 | 3 | 3.37e-01 |
| GO:BP | GO:0090594 | inflammatory response to wounding | 1 | 12 | 3.37e-01 |
| GO:BP | GO:1905475 | regulation of protein localization to membrane | 1 | 150 | 3.38e-01 |
| GO:BP | GO:0070542 | response to fatty acid | 1 | 43 | 3.38e-01 |
| GO:BP | GO:0014066 | regulation of phosphatidylinositol 3-kinase signaling | 10 | 78 | 3.38e-01 |
| GO:BP | GO:0006458 | ‘de novo’ protein folding | 1 | 39 | 3.38e-01 |
| GO:BP | GO:0060715 | syncytiotrophoblast cell differentiation involved in labyrinthine layer development | 1 | 3 | 3.38e-01 |
| GO:BP | GO:1905564 | positive regulation of vascular endothelial cell proliferation | 1 | 15 | 3.38e-01 |
| GO:BP | GO:1903038 | negative regulation of leukocyte cell-cell adhesion | 3 | 74 | 3.38e-01 |
| GO:BP | GO:1903347 | negative regulation of bicellular tight junction assembly | 1 | 3 | 3.38e-01 |
| GO:BP | GO:0043500 | muscle adaptation | 2 | 90 | 3.38e-01 |
| GO:BP | GO:0003383 | apical constriction | 1 | 4 | 3.38e-01 |
| GO:BP | GO:0060192 | negative regulation of lipase activity | 1 | 13 | 3.38e-01 |
| GO:BP | GO:0039534 | negative regulation of MDA-5 signaling pathway | 1 | 3 | 3.38e-01 |
| GO:BP | GO:0009226 | nucleotide-sugar biosynthetic process | 3 | 19 | 3.38e-01 |
| GO:BP | GO:0033047 | regulation of mitotic sister chromatid segregation | 1 | 52 | 3.38e-01 |
| GO:BP | GO:0007032 | endosome organization | 3 | 92 | 3.38e-01 |
| GO:BP | GO:0003433 | chondrocyte development involved in endochondral bone morphogenesis | 1 | 6 | 3.38e-01 |
| GO:BP | GO:0044281 | small molecule metabolic process | 3 | 1389 | 3.38e-01 |
| GO:BP | GO:0045738 | negative regulation of DNA repair | 2 | 32 | 3.38e-01 |
| GO:BP | GO:0000079 | regulation of cyclin-dependent protein serine/threonine kinase activity | 10 | 85 | 3.38e-01 |
| GO:BP | GO:0007044 | cell-substrate junction assembly | 7 | 91 | 3.38e-01 |
| GO:BP | GO:0070201 | regulation of establishment of protein localization | 15 | 428 | 3.38e-01 |
| GO:BP | GO:1902913 | positive regulation of neuroepithelial cell differentiation | 1 | 2 | 3.38e-01 |
| GO:BP | GO:2001034 | positive regulation of double-strand break repair via nonhomologous end joining | 1 | 12 | 3.38e-01 |
| GO:BP | GO:0014032 | neural crest cell development | 8 | 71 | 3.38e-01 |
| GO:BP | GO:0046947 | hydroxylysine biosynthetic process | 1 | 2 | 3.38e-01 |
| GO:BP | GO:0008306 | associative learning | 6 | 65 | 3.38e-01 |
| GO:BP | GO:2000098 | negative regulation of smooth muscle cell-matrix adhesion | 1 | 1 | 3.38e-01 |
| GO:BP | GO:0050866 | negative regulation of cell activation | 4 | 124 | 3.38e-01 |
| GO:BP | GO:0046946 | hydroxylysine metabolic process | 1 | 2 | 3.38e-01 |
| GO:BP | GO:2001241 | positive regulation of extrinsic apoptotic signaling pathway in absence of ligand | 1 | 10 | 3.38e-01 |
| GO:BP | GO:0006777 | Mo-molybdopterin cofactor biosynthetic process | 1 | 6 | 3.38e-01 |
| GO:BP | GO:0043545 | molybdopterin cofactor metabolic process | 1 | 6 | 3.38e-01 |
| GO:BP | GO:0014812 | muscle cell migration | 9 | 76 | 3.38e-01 |
| GO:BP | GO:0006029 | proteoglycan metabolic process | 1 | 77 | 3.38e-01 |
| GO:BP | GO:0008625 | extrinsic apoptotic signaling pathway via death domain receptors | 5 | 72 | 3.38e-01 |
| GO:BP | GO:0032324 | molybdopterin cofactor biosynthetic process | 1 | 6 | 3.38e-01 |
| GO:BP | GO:0032700 | negative regulation of interleukin-17 production | 1 | 9 | 3.38e-01 |
| GO:BP | GO:0019720 | Mo-molybdopterin cofactor metabolic process | 1 | 6 | 3.38e-01 |
| GO:BP | GO:0051189 | prosthetic group metabolic process | 1 | 6 | 3.38e-01 |
| GO:BP | GO:0110032 | positive regulation of G2/MI transition of meiotic cell cycle | 1 | 3 | 3.38e-01 |
| GO:BP | GO:0060135 | maternal process involved in female pregnancy | 6 | 41 | 3.38e-01 |
| GO:BP | GO:0031116 | positive regulation of microtubule polymerization | 2 | 31 | 3.38e-01 |
| GO:BP | GO:0021515 | cell differentiation in spinal cord | 2 | 24 | 3.38e-01 |
| GO:BP | GO:0099178 | regulation of retrograde trans-synaptic signaling by endocanabinoid | 1 | 3 | 3.38e-01 |
| GO:BP | GO:0046370 | fructose biosynthetic process | 1 | 2 | 3.39e-01 |
| GO:BP | GO:0010453 | regulation of cell fate commitment | 1 | 26 | 3.39e-01 |
| GO:BP | GO:0042357 | thiamine diphosphate metabolic process | 1 | 2 | 3.39e-01 |
| GO:BP | GO:0046825 | regulation of protein export from nucleus | 3 | 30 | 3.39e-01 |
| GO:BP | GO:0021591 | ventricular system development | 1 | 29 | 3.39e-01 |
| GO:BP | GO:0045839 | negative regulation of mitotic nuclear division | 1 | 54 | 3.39e-01 |
| GO:BP | GO:0045893 | positive regulation of DNA-templated transcription | 6 | 1315 | 3.39e-01 |
| GO:BP | GO:0006974 | DNA damage response | 39 | 785 | 3.39e-01 |
| GO:BP | GO:0006006 | glucose metabolic process | 7 | 151 | 3.39e-01 |
| GO:BP | GO:1903508 | positive regulation of nucleic acid-templated transcription | 6 | 1315 | 3.39e-01 |
| GO:BP | GO:0070584 | mitochondrion morphogenesis | 2 | 21 | 3.39e-01 |
| GO:BP | GO:0048731 | system development | 14 | 2901 | 3.39e-01 |
| GO:BP | GO:0022604 | regulation of cell morphogenesis | 21 | 220 | 3.39e-01 |
| GO:BP | GO:2000273 | positive regulation of signaling receptor activity | 5 | 33 | 3.39e-01 |
| GO:BP | GO:0044000 | movement in host | 1 | 138 | 3.39e-01 |
| GO:BP | GO:0090263 | positive regulation of canonical Wnt signaling pathway | 10 | 91 | 3.39e-01 |
| GO:BP | GO:0061138 | morphogenesis of a branching epithelium | 1 | 143 | 3.39e-01 |
| GO:BP | GO:1990637 | response to prolactin | 1 | 3 | 3.39e-01 |
| GO:BP | GO:0061343 | cell adhesion involved in heart morphogenesis | 1 | 6 | 3.39e-01 |
| GO:BP | GO:1901988 | negative regulation of cell cycle phase transition | 2 | 235 | 3.39e-01 |
| GO:BP | GO:0060411 | cardiac septum morphogenesis | 6 | 67 | 3.39e-01 |
| GO:BP | GO:0120163 | negative regulation of cold-induced thermogenesis | 1 | 40 | 3.39e-01 |
| GO:BP | GO:1900407 | regulation of cellular response to oxidative stress | 4 | 67 | 3.39e-01 |
| GO:BP | GO:0086098 | angiotensin-activated signaling pathway involved in heart process | 1 | 3 | 3.39e-01 |
| GO:BP | GO:1903997 | positive regulation of non-membrane spanning protein tyrosine kinase activity | 1 | 2 | 3.39e-01 |
| GO:BP | GO:0045814 | negative regulation of gene expression, epigenetic | 3 | 79 | 3.39e-01 |
| GO:BP | GO:0010507 | negative regulation of autophagy | 7 | 74 | 3.39e-01 |
| GO:BP | GO:0051656 | establishment of organelle localization | 29 | 378 | 3.39e-01 |
| GO:BP | GO:0051610 | serotonin uptake | 1 | 8 | 3.39e-01 |
| GO:BP | GO:1903729 | regulation of plasma membrane organization | 2 | 15 | 3.39e-01 |
| GO:BP | GO:1903587 | regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis | 1 | 9 | 3.39e-01 |
| GO:BP | GO:1903937 | response to acrylamide | 1 | 1 | 3.40e-01 |
| GO:BP | GO:0048666 | neuron development | 43 | 877 | 3.40e-01 |
| GO:BP | GO:1904715 | negative regulation of chaperone-mediated autophagy | 1 | 3 | 3.40e-01 |
| GO:BP | GO:0032649 | regulation of type II interferon production | 3 | 52 | 3.40e-01 |
| GO:BP | GO:0010955 | negative regulation of protein processing | 4 | 19 | 3.40e-01 |
| GO:BP | GO:1903318 | negative regulation of protein maturation | 4 | 19 | 3.40e-01 |
| GO:BP | GO:0051668 | localization within membrane | 2 | 605 | 3.40e-01 |
| GO:BP | GO:1902680 | positive regulation of RNA biosynthetic process | 6 | 1322 | 3.40e-01 |
| GO:BP | GO:0006768 | biotin metabolic process | 1 | 3 | 3.40e-01 |
| GO:BP | GO:0055089 | fatty acid homeostasis | 1 | 12 | 3.40e-01 |
| GO:BP | GO:0016050 | vesicle organization | 6 | 320 | 3.40e-01 |
| GO:BP | GO:0002551 | mast cell chemotaxis | 2 | 9 | 3.40e-01 |
| GO:BP | GO:0007369 | gastrulation | 1 | 146 | 3.40e-01 |
| GO:BP | GO:0042489 | negative regulation of odontogenesis of dentin-containing tooth | 1 | 1 | 3.40e-01 |
| GO:BP | GO:0032835 | glomerulus development | 2 | 54 | 3.40e-01 |
| GO:BP | GO:0006935 | chemotaxis | 2 | 389 | 3.40e-01 |
| GO:BP | GO:0097178 | ruffle assembly | 5 | 37 | 3.40e-01 |
| GO:BP | GO:0007416 | synapse assembly | 18 | 152 | 3.40e-01 |
| GO:BP | GO:0050851 | antigen receptor-mediated signaling pathway | 2 | 106 | 3.40e-01 |
| GO:BP | GO:1901799 | negative regulation of proteasomal protein catabolic process | 6 | 47 | 3.40e-01 |
| GO:BP | GO:0006888 | endoplasmic reticulum to Golgi vesicle-mediated transport | 2 | 119 | 3.40e-01 |
| GO:BP | GO:0042483 | negative regulation of odontogenesis | 1 | 1 | 3.40e-01 |
| GO:BP | GO:0034465 | response to carbon monoxide | 1 | 3 | 3.40e-01 |
| GO:BP | GO:0097300 | programmed necrotic cell death | 2 | 39 | 3.40e-01 |
| GO:BP | GO:0045717 | negative regulation of fatty acid biosynthetic process | 1 | 14 | 3.40e-01 |
| GO:BP | GO:1902166 | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 1 | 15 | 3.40e-01 |
| GO:BP | GO:0042667 | auditory receptor cell fate specification | 1 | 1 | 3.40e-01 |
| GO:BP | GO:0033194 | response to hydroperoxide | 2 | 12 | 3.40e-01 |
| GO:BP | GO:0042354 | L-fucose metabolic process | 1 | 4 | 3.40e-01 |
| GO:BP | GO:0061756 | leukocyte adhesion to vascular endothelial cell | 2 | 27 | 3.40e-01 |
| GO:BP | GO:0048514 | blood vessel morphogenesis | 8 | 462 | 3.40e-01 |
| GO:BP | GO:1901135 | carbohydrate derivative metabolic process | 9 | 843 | 3.40e-01 |
| GO:BP | GO:0042330 | taxis | 2 | 389 | 3.40e-01 |
| GO:BP | GO:0010810 | regulation of cell-substrate adhesion | 1 | 172 | 3.40e-01 |
| GO:BP | GO:0060712 | spongiotrophoblast layer development | 2 | 11 | 3.40e-01 |
| GO:BP | GO:0090141 | positive regulation of mitochondrial fission | 3 | 21 | 3.40e-01 |
| GO:BP | GO:2000116 | regulation of cysteine-type endopeptidase activity | 20 | 169 | 3.40e-01 |
| GO:BP | GO:0042472 | inner ear morphogenesis | 1 | 59 | 3.40e-01 |
| GO:BP | GO:0110111 | negative regulation of animal organ morphogenesis | 1 | 1 | 3.40e-01 |
| GO:BP | GO:0045898 | regulation of RNA polymerase II transcription preinitiation complex assembly | 1 | 7 | 3.40e-01 |
| GO:BP | GO:0031999 | negative regulation of fatty acid beta-oxidation | 1 | 5 | 3.40e-01 |
| GO:BP | GO:2000379 | positive regulation of reactive oxygen species metabolic process | 1 | 46 | 3.41e-01 |
| GO:BP | GO:0032609 | type II interferon production | 3 | 53 | 3.41e-01 |
| GO:BP | GO:0050807 | regulation of synapse organization | 2 | 184 | 3.41e-01 |
| GO:BP | GO:0006606 | protein import into nucleus | 7 | 147 | 3.41e-01 |
| GO:BP | GO:0035360 | positive regulation of peroxisome proliferator activated receptor signaling pathway | 1 | 7 | 3.41e-01 |
| GO:BP | GO:0000448 | cleavage in ITS2 between 5.8S rRNA and LSU-rRNA of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 1 | 2 | 3.41e-01 |
| GO:BP | GO:0002658 | regulation of peripheral tolerance induction | 1 | 1 | 3.41e-01 |
| GO:BP | GO:0030948 | negative regulation of vascular endothelial growth factor receptor signaling pathway | 2 | 11 | 3.41e-01 |
| GO:BP | GO:0002654 | positive regulation of tolerance induction dependent upon immune response | 1 | 1 | 3.41e-01 |
| GO:BP | GO:0002660 | positive regulation of peripheral tolerance induction | 1 | 1 | 3.41e-01 |
| GO:BP | GO:0032968 | positive regulation of transcription elongation by RNA polymerase II | 4 | 49 | 3.41e-01 |
| GO:BP | GO:0002034 | maintenance of blood vessel diameter homeostasis by renin-angiotensin | 1 | 3 | 3.41e-01 |
| GO:BP | GO:1905259 | negative regulation of nitrosative stress-induced intrinsic apoptotic signaling pathway | 1 | 2 | 3.41e-01 |
| GO:BP | GO:0003072 | renal control of peripheral vascular resistance involved in regulation of systemic arterial blood pressure | 1 | 3 | 3.41e-01 |
| GO:BP | GO:1905258 | regulation of nitrosative stress-induced intrinsic apoptotic signaling pathway | 1 | 2 | 3.41e-01 |
| GO:BP | GO:0051348 | negative regulation of transferase activity | 9 | 234 | 3.41e-01 |
| GO:BP | GO:0019058 | viral life cycle | 2 | 244 | 3.41e-01 |
| GO:BP | GO:0018022 | peptidyl-lysine methylation | 3 | 104 | 3.41e-01 |
| GO:BP | GO:0051093 | negative regulation of developmental process | 2 | 665 | 3.41e-01 |
| GO:BP | GO:1904526 | regulation of microtubule binding | 2 | 10 | 3.41e-01 |
| GO:BP | GO:0044283 | small molecule biosynthetic process | 1 | 425 | 3.41e-01 |
| GO:BP | GO:0046634 | regulation of alpha-beta T cell activation | 3 | 58 | 3.41e-01 |
| GO:BP | GO:0060449 | bud elongation involved in lung branching | 1 | 7 | 3.41e-01 |
| GO:BP | GO:0010464 | regulation of mesenchymal cell proliferation | 2 | 25 | 3.42e-01 |
| GO:BP | GO:0044403 | biological process involved in symbiotic interaction | 2 | 223 | 3.42e-01 |
| GO:BP | GO:0015909 | long-chain fatty acid transport | 4 | 38 | 3.42e-01 |
| GO:BP | GO:0036503 | ERAD pathway | 2 | 106 | 3.42e-01 |
| GO:BP | GO:0045580 | regulation of T cell differentiation | 13 | 110 | 3.43e-01 |
| GO:BP | GO:2000146 | negative regulation of cell motility | 11 | 236 | 3.43e-01 |
| GO:BP | GO:0003337 | mesenchymal to epithelial transition involved in metanephros morphogenesis | 2 | 8 | 3.43e-01 |
| GO:BP | GO:0000390 | spliceosomal complex disassembly | 1 | 3 | 3.43e-01 |
| GO:BP | GO:0006612 | protein targeting to membrane | 1 | 118 | 3.43e-01 |
| GO:BP | GO:0006220 | pyrimidine nucleotide metabolic process | 1 | 46 | 3.43e-01 |
| GO:BP | GO:0042730 | fibrinolysis | 1 | 15 | 3.43e-01 |
| GO:BP | GO:0006465 | signal peptide processing | 2 | 13 | 3.43e-01 |
| GO:BP | GO:0086016 | AV node cell action potential | 1 | 9 | 3.44e-01 |
| GO:BP | GO:0050932 | regulation of pigment cell differentiation | 1 | 6 | 3.44e-01 |
| GO:BP | GO:0086027 | AV node cell to bundle of His cell signaling | 1 | 9 | 3.44e-01 |
| GO:BP | GO:0032369 | negative regulation of lipid transport | 2 | 20 | 3.44e-01 |
| GO:BP | GO:0001579 | medium-chain fatty acid transport | 1 | 2 | 3.44e-01 |
| GO:BP | GO:1905214 | regulation of RNA binding | 2 | 13 | 3.44e-01 |
| GO:BP | GO:0033043 | regulation of organelle organization | 74 | 1028 | 3.44e-01 |
| GO:BP | GO:0042790 | nucleolar large rRNA transcription by RNA polymerase I | 2 | 21 | 3.44e-01 |
| GO:BP | GO:0006565 | L-serine catabolic process | 1 | 4 | 3.44e-01 |
| GO:BP | GO:1902175 | regulation of oxidative stress-induced intrinsic apoptotic signaling pathway | 2 | 25 | 3.44e-01 |
| GO:BP | GO:1903984 | positive regulation of TRAIL-activated apoptotic signaling pathway | 1 | 3 | 3.44e-01 |
| GO:BP | GO:0003013 | circulatory system process | 3 | 447 | 3.44e-01 |
| GO:BP | GO:0042093 | T-helper cell differentiation | 1 | 40 | 3.44e-01 |
| GO:BP | GO:0060155 | platelet dense granule organization | 3 | 23 | 3.44e-01 |
| GO:BP | GO:2000249 | regulation of actin cytoskeleton reorganization | 5 | 32 | 3.44e-01 |
| GO:BP | GO:0006470 | protein dephosphorylation | 6 | 214 | 3.44e-01 |
| GO:BP | GO:2000727 | positive regulation of cardiac muscle cell differentiation | 1 | 6 | 3.44e-01 |
| GO:BP | GO:0051453 | regulation of intracellular pH | 4 | 65 | 3.44e-01 |
| GO:BP | GO:0007163 | establishment or maintenance of cell polarity | 21 | 206 | 3.44e-01 |
| GO:BP | GO:0000480 | endonucleolytic cleavage in 5’-ETS of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 1 | 8 | 3.44e-01 |
| GO:BP | GO:0090292 | nuclear matrix anchoring at nuclear membrane | 1 | 3 | 3.45e-01 |
| GO:BP | GO:0043578 | nuclear matrix organization | 1 | 3 | 3.45e-01 |
| GO:BP | GO:2000583 | regulation of platelet-derived growth factor receptor-alpha signaling pathway | 1 | 4 | 3.45e-01 |
| GO:BP | GO:0030330 | DNA damage response, signal transduction by p53 class mediator | 2 | 69 | 3.45e-01 |
| GO:BP | GO:0021817 | nucleokinesis involved in cell motility in cerebral cortex radial glia guided migration | 1 | 3 | 3.45e-01 |
| GO:BP | GO:0010793 | regulation of mRNA export from nucleus | 1 | 5 | 3.45e-01 |
| GO:BP | GO:0090383 | phagosome acidification | 1 | 5 | 3.46e-01 |
| GO:BP | GO:0060485 | mesenchyme development | 2 | 249 | 3.46e-01 |
| GO:BP | GO:0050803 | regulation of synapse structure or activity | 2 | 187 | 3.46e-01 |
| GO:BP | GO:0019884 | antigen processing and presentation of exogenous antigen | 5 | 28 | 3.46e-01 |
| GO:BP | GO:2000378 | negative regulation of reactive oxygen species metabolic process | 2 | 34 | 3.46e-01 |
| GO:BP | GO:0030163 | protein catabolic process | 9 | 901 | 3.46e-01 |
| GO:BP | GO:0036510 | trimming of terminal mannose on C branch | 1 | 3 | 3.46e-01 |
| GO:BP | GO:0120031 | plasma membrane bounded cell projection assembly | 35 | 461 | 3.46e-01 |
| GO:BP | GO:0051298 | centrosome duplication | 5 | 68 | 3.46e-01 |
| GO:BP | GO:0051608 | histamine transport | 1 | 11 | 3.46e-01 |
| GO:BP | GO:0032727 | positive regulation of interferon-alpha production | 1 | 17 | 3.46e-01 |
| GO:BP | GO:1904154 | positive regulation of retrograde protein transport, ER to cytosol | 1 | 3 | 3.46e-01 |
| GO:BP | GO:0042130 | negative regulation of T cell proliferation | 2 | 38 | 3.46e-01 |
| GO:BP | GO:0051438 | regulation of ubiquitin-protein transferase activity | 1 | 55 | 3.46e-01 |
| GO:BP | GO:0010965 | regulation of mitotic sister chromatid separation | 1 | 58 | 3.46e-01 |
| GO:BP | GO:2000642 | negative regulation of early endosome to late endosome transport | 1 | 2 | 3.46e-01 |
| GO:BP | GO:0051650 | establishment of vesicle localization | 14 | 175 | 3.46e-01 |
| GO:BP | GO:0060713 | labyrinthine layer morphogenesis | 3 | 17 | 3.46e-01 |
| GO:BP | GO:0001763 | morphogenesis of a branching structure | 1 | 154 | 3.46e-01 |
| GO:BP | GO:0051253 | negative regulation of RNA metabolic process | 2 | 1119 | 3.46e-01 |
| GO:BP | GO:0031114 | regulation of microtubule depolymerization | 2 | 31 | 3.46e-01 |
| GO:BP | GO:0045722 | positive regulation of gluconeogenesis | 1 | 16 | 3.47e-01 |
| GO:BP | GO:0007000 | nucleolus organization | 1 | 17 | 3.47e-01 |
| GO:BP | GO:0010836 | negative regulation of protein ADP-ribosylation | 1 | 4 | 3.47e-01 |
| GO:BP | GO:1901184 | regulation of ERBB signaling pathway | 8 | 66 | 3.47e-01 |
| GO:BP | GO:1904506 | negative regulation of telomere maintenance in response to DNA damage | 1 | 3 | 3.47e-01 |
| GO:BP | GO:0060586 | multicellular organismal-level iron ion homeostasis | 1 | 7 | 3.47e-01 |
| GO:BP | GO:0002294 | CD4-positive, alpha-beta T cell differentiation involved in immune response | 1 | 40 | 3.47e-01 |
| GO:BP | GO:0034332 | adherens junction organization | 3 | 41 | 3.47e-01 |
| GO:BP | GO:0006406 | mRNA export from nucleus | 4 | 59 | 3.48e-01 |
| GO:BP | GO:0060591 | chondroblast differentiation | 1 | 3 | 3.48e-01 |
| GO:BP | GO:0040013 | negative regulation of locomotion | 12 | 265 | 3.48e-01 |
| GO:BP | GO:0009887 | animal organ morphogenesis | 3 | 742 | 3.48e-01 |
| GO:BP | GO:0035781 | CD86 biosynthetic process | 1 | 2 | 3.48e-01 |
| GO:BP | GO:0072044 | collecting duct development | 1 | 6 | 3.49e-01 |
| GO:BP | GO:0006273 | lagging strand elongation | 1 | 4 | 3.49e-01 |
| GO:BP | GO:0032528 | microvillus organization | 3 | 19 | 3.49e-01 |
| GO:BP | GO:0035296 | regulation of tube diameter | 1 | 99 | 3.49e-01 |
| GO:BP | GO:0045216 | cell-cell junction organization | 1 | 153 | 3.49e-01 |
| GO:BP | GO:0097746 | blood vessel diameter maintenance | 1 | 99 | 3.49e-01 |
| GO:BP | GO:0015791 | polyol transmembrane transport | 1 | 6 | 3.49e-01 |
| GO:BP | GO:0060079 | excitatory postsynaptic potential | 11 | 70 | 3.49e-01 |
| GO:BP | GO:0030388 | fructose 1,6-bisphosphate metabolic process | 1 | 6 | 3.49e-01 |
| GO:BP | GO:0032025 | response to cobalt ion | 1 | 10 | 3.49e-01 |
| GO:BP | GO:0002287 | alpha-beta T cell activation involved in immune response | 1 | 40 | 3.49e-01 |
| GO:BP | GO:0032515 | negative regulation of phosphoprotein phosphatase activity | 1 | 21 | 3.49e-01 |
| GO:BP | GO:0034314 | Arp2/3 complex-mediated actin nucleation | 1 | 40 | 3.49e-01 |
| GO:BP | GO:0046637 | regulation of alpha-beta T cell differentiation | 1 | 38 | 3.49e-01 |
| GO:BP | GO:0002293 | alpha-beta T cell differentiation involved in immune response | 1 | 40 | 3.49e-01 |
| GO:BP | GO:1902992 | negative regulation of amyloid precursor protein catabolic process | 2 | 20 | 3.49e-01 |
| GO:BP | GO:0060809 | mesodermal to mesenchymal transition involved in gastrulation | 1 | 2 | 3.49e-01 |
| GO:BP | GO:1902083 | negative regulation of peptidyl-cysteine S-nitrosylation | 1 | 6 | 3.49e-01 |
| GO:BP | GO:0097355 | protein localization to heterochromatin | 1 | 3 | 3.49e-01 |
| GO:BP | GO:0035150 | regulation of tube size | 1 | 99 | 3.49e-01 |
| GO:BP | GO:0012501 | programmed cell death | 65 | 1479 | 3.49e-01 |
| GO:BP | GO:0051643 | endoplasmic reticulum localization | 1 | 8 | 3.49e-01 |
| GO:BP | GO:0043331 | response to dsRNA | 4 | 33 | 3.49e-01 |
| GO:BP | GO:0031272 | regulation of pseudopodium assembly | 2 | 11 | 3.50e-01 |
| GO:BP | GO:0031274 | positive regulation of pseudopodium assembly | 2 | 11 | 3.50e-01 |
| GO:BP | GO:0003208 | cardiac ventricle morphogenesis | 1 | 62 | 3.50e-01 |
| GO:BP | GO:0051784 | negative regulation of nuclear division | 1 | 57 | 3.50e-01 |
| GO:BP | GO:0060048 | cardiac muscle contraction | 4 | 123 | 3.50e-01 |
| GO:BP | GO:0009719 | response to endogenous stimulus | 7 | 1278 | 3.50e-01 |
| GO:BP | GO:0051701 | biological process involved in interaction with host | 1 | 154 | 3.51e-01 |
| GO:BP | GO:0071346 | cellular response to type II interferon | 6 | 69 | 3.51e-01 |
| GO:BP | GO:0061162 | establishment of monopolar cell polarity | 2 | 20 | 3.51e-01 |
| GO:BP | GO:1900151 | regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 1 | 24 | 3.51e-01 |
| GO:BP | GO:0070269 | pyroptosis | 1 | 11 | 3.51e-01 |
| GO:BP | GO:0031329 | regulation of cellular catabolic process | 6 | 555 | 3.51e-01 |
| GO:BP | GO:0007167 | enzyme-linked receptor protein signaling pathway | 48 | 763 | 3.52e-01 |
| GO:BP | GO:0021627 | olfactory nerve morphogenesis | 1 | 3 | 3.52e-01 |
| GO:BP | GO:0072109 | glomerular mesangium development | 1 | 13 | 3.52e-01 |
| GO:BP | GO:0061009 | common bile duct development | 1 | 4 | 3.52e-01 |
| GO:BP | GO:0051386 | regulation of neurotrophin TRK receptor signaling pathway | 2 | 11 | 3.53e-01 |
| GO:BP | GO:0010992 | ubiquitin recycling | 1 | 12 | 3.53e-01 |
| GO:BP | GO:1903599 | positive regulation of autophagy of mitochondrion | 1 | 13 | 3.53e-01 |
| GO:BP | GO:0051306 | mitotic sister chromatid separation | 1 | 61 | 3.53e-01 |
| GO:BP | GO:0120033 | negative regulation of plasma membrane bounded cell projection assembly | 3 | 28 | 3.53e-01 |
| GO:BP | GO:0051445 | regulation of meiotic cell cycle | 1 | 45 | 3.53e-01 |
| GO:BP | GO:0032787 | monocarboxylic acid metabolic process | 1 | 433 | 3.53e-01 |
| GO:BP | GO:0031122 | cytoplasmic microtubule organization | 1 | 60 | 3.53e-01 |
| GO:BP | GO:0033504 | floor plate development | 2 | 8 | 3.53e-01 |
| GO:BP | GO:0046426 | negative regulation of receptor signaling pathway via JAK-STAT | 2 | 20 | 3.54e-01 |
| GO:BP | GO:0070884 | regulation of calcineurin-NFAT signaling cascade | 2 | 32 | 3.54e-01 |
| GO:BP | GO:1901888 | regulation of cell junction assembly | 1 | 168 | 3.54e-01 |
| GO:BP | GO:0019370 | leukotriene biosynthetic process | 1 | 7 | 3.54e-01 |
| GO:BP | GO:0019318 | hexose metabolic process | 8 | 185 | 3.54e-01 |
| GO:BP | GO:0002244 | hematopoietic progenitor cell differentiation | 2 | 109 | 3.54e-01 |
| GO:BP | GO:0050872 | white fat cell differentiation | 1 | 15 | 3.54e-01 |
| GO:BP | GO:0030036 | actin cytoskeleton organization | 52 | 612 | 3.54e-01 |
| GO:BP | GO:2000629 | negative regulation of miRNA metabolic process | 3 | 20 | 3.54e-01 |
| GO:BP | GO:0008283 | cell population proliferation | 3 | 1378 | 3.54e-01 |
| GO:BP | GO:0035914 | skeletal muscle cell differentiation | 1 | 52 | 3.54e-01 |
| GO:BP | GO:2000765 | regulation of cytoplasmic translation | 2 | 27 | 3.54e-01 |
| GO:BP | GO:2000142 | regulation of DNA-templated transcription initiation | 3 | 76 | 3.54e-01 |
| GO:BP | GO:0015916 | fatty-acyl-CoA transport | 1 | 2 | 3.54e-01 |
| GO:BP | GO:0072273 | metanephric nephron morphogenesis | 3 | 19 | 3.54e-01 |
| GO:BP | GO:1902165 | regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 1 | 17 | 3.54e-01 |
| GO:BP | GO:2000377 | regulation of reactive oxygen species metabolic process | 4 | 108 | 3.54e-01 |
| GO:BP | GO:0031334 | positive regulation of protein-containing complex assembly | 7 | 161 | 3.54e-01 |
| GO:BP | GO:0042987 | amyloid precursor protein catabolic process | 4 | 53 | 3.54e-01 |
| GO:BP | GO:1901337 | thioester transport | 1 | 2 | 3.54e-01 |
| GO:BP | GO:0001885 | endothelial cell development | 5 | 53 | 3.54e-01 |
| GO:BP | GO:0044320 | cellular response to leptin stimulus | 1 | 15 | 3.54e-01 |
| GO:BP | GO:0009409 | response to cold | 1 | 41 | 3.54e-01 |
| GO:BP | GO:0040007 | growth | 1 | 742 | 3.54e-01 |
| GO:BP | GO:0010826 | negative regulation of centrosome duplication | 1 | 12 | 3.54e-01 |
| GO:BP | GO:0046606 | negative regulation of centrosome cycle | 1 | 12 | 3.54e-01 |
| GO:BP | GO:0044770 | cell cycle phase transition | 3 | 504 | 3.54e-01 |
| GO:BP | GO:0030182 | neuron differentiation | 9 | 1061 | 3.54e-01 |
| GO:BP | GO:0045299 | otolith mineralization | 1 | 2 | 3.54e-01 |
| GO:BP | GO:0061028 | establishment of endothelial barrier | 4 | 38 | 3.54e-01 |
| GO:BP | GO:0010719 | negative regulation of epithelial to mesenchymal transition | 3 | 29 | 3.54e-01 |
| GO:BP | GO:2000302 | positive regulation of synaptic vesicle exocytosis | 1 | 3 | 3.55e-01 |
| GO:BP | GO:2001056 | positive regulation of cysteine-type endopeptidase activity | 13 | 107 | 3.55e-01 |
| GO:BP | GO:0051170 | import into nucleus | 7 | 152 | 3.55e-01 |
| GO:BP | GO:0010841 | positive regulation of circadian sleep/wake cycle, wakefulness | 1 | 1 | 3.55e-01 |
| GO:BP | GO:2000809 | positive regulation of synaptic vesicle clustering | 1 | 3 | 3.55e-01 |
| GO:BP | GO:0030857 | negative regulation of epithelial cell differentiation | 4 | 31 | 3.55e-01 |
| GO:BP | GO:0003341 | cilium movement | 3 | 97 | 3.55e-01 |
| GO:BP | GO:0097010 | eukaryotic translation initiation factor 4F complex assembly | 1 | 3 | 3.56e-01 |
| GO:BP | GO:0003170 | heart valve development | 1 | 65 | 3.56e-01 |
| GO:BP | GO:0060997 | dendritic spine morphogenesis | 1 | 50 | 3.56e-01 |
| GO:BP | GO:1900060 | negative regulation of ceramide biosynthetic process | 1 | 5 | 3.56e-01 |
| GO:BP | GO:2000648 | positive regulation of stem cell proliferation | 5 | 31 | 3.56e-01 |
| GO:BP | GO:0055117 | regulation of cardiac muscle contraction | 1 | 70 | 3.56e-01 |
| GO:BP | GO:0097194 | execution phase of apoptosis | 1 | 53 | 3.56e-01 |
| GO:BP | GO:0045429 | positive regulation of nitric oxide biosynthetic process | 3 | 26 | 3.56e-01 |
| GO:BP | GO:0045618 | positive regulation of keratinocyte differentiation | 1 | 12 | 3.56e-01 |
| GO:BP | GO:0018377 | protein myristoylation | 1 | 4 | 3.56e-01 |
| GO:BP | GO:0045900 | negative regulation of translational elongation | 1 | 5 | 3.56e-01 |
| GO:BP | GO:0006499 | N-terminal protein myristoylation | 1 | 4 | 3.56e-01 |
| GO:BP | GO:1903037 | regulation of leukocyte cell-cell adhesion | 12 | 211 | 3.56e-01 |
| GO:BP | GO:0034219 | carbohydrate transmembrane transport | 5 | 92 | 3.57e-01 |
| GO:BP | GO:0007263 | nitric oxide mediated signal transduction | 1 | 20 | 3.57e-01 |
| GO:BP | GO:0003285 | septum secundum development | 1 | 3 | 3.57e-01 |
| GO:BP | GO:0035589 | G protein-coupled purinergic nucleotide receptor signaling pathway | 2 | 4 | 3.58e-01 |
| GO:BP | GO:0090559 | regulation of membrane permeability | 2 | 64 | 3.58e-01 |
| GO:BP | GO:1904071 | presynaptic active zone assembly | 1 | 4 | 3.58e-01 |
| GO:BP | GO:0046642 | negative regulation of alpha-beta T cell proliferation | 1 | 9 | 3.58e-01 |
| GO:BP | GO:0000122 | negative regulation of transcription by RNA polymerase II | 1 | 740 | 3.58e-01 |
| GO:BP | GO:0006900 | vesicle budding from membrane | 1 | 76 | 3.58e-01 |
| GO:BP | GO:0098586 | cellular response to virus | 1 | 40 | 3.58e-01 |
| GO:BP | GO:0032784 | regulation of DNA-templated transcription elongation | 9 | 99 | 3.58e-01 |
| GO:BP | GO:0006937 | regulation of muscle contraction | 3 | 133 | 3.59e-01 |
| GO:BP | GO:0031333 | negative regulation of protein-containing complex assembly | 3 | 130 | 3.59e-01 |
| GO:BP | GO:0061726 | mitochondrion disassembly | 3 | 92 | 3.59e-01 |
| GO:BP | GO:0032770 | positive regulation of monooxygenase activity | 2 | 20 | 3.59e-01 |
| GO:BP | GO:0000422 | autophagy of mitochondrion | 3 | 92 | 3.59e-01 |
| GO:BP | GO:1903012 | positive regulation of bone development | 1 | 1 | 3.59e-01 |
| GO:BP | GO:0106056 | regulation of calcineurin-mediated signaling | 2 | 32 | 3.59e-01 |
| GO:BP | GO:0009161 | ribonucleoside monophosphate metabolic process | 1 | 50 | 3.59e-01 |
| GO:BP | GO:0048087 | positive regulation of developmental pigmentation | 1 | 7 | 3.59e-01 |
| GO:BP | GO:0032075 | positive regulation of nuclease activity | 1 | 7 | 3.59e-01 |
| GO:BP | GO:1903721 | positive regulation of I-kappaB phosphorylation | 1 | 5 | 3.59e-01 |
| GO:BP | GO:0006041 | glucosamine metabolic process | 1 | 3 | 3.60e-01 |
| GO:BP | GO:0009953 | dorsal/ventral pattern formation | 6 | 55 | 3.60e-01 |
| GO:BP | GO:0010562 | positive regulation of phosphorus metabolic process | 26 | 597 | 3.60e-01 |
| GO:BP | GO:0002573 | myeloid leukocyte differentiation | 1 | 151 | 3.60e-01 |
| GO:BP | GO:0031641 | regulation of myelination | 3 | 36 | 3.60e-01 |
| GO:BP | GO:0034350 | regulation of glial cell apoptotic process | 2 | 10 | 3.60e-01 |
| GO:BP | GO:1904349 | positive regulation of small intestine smooth muscle contraction | 1 | 1 | 3.60e-01 |
| GO:BP | GO:1904347 | regulation of small intestine smooth muscle contraction | 1 | 1 | 3.60e-01 |
| GO:BP | GO:0072276 | metanephric glomerulus vasculature morphogenesis | 1 | 2 | 3.60e-01 |
| GO:BP | GO:0045786 | negative regulation of cell cycle | 8 | 338 | 3.60e-01 |
| GO:BP | GO:0038086 | VEGF-activated platelet-derived growth factor receptor signaling pathway | 1 | 3 | 3.60e-01 |
| GO:BP | GO:0072275 | metanephric glomerulus morphogenesis | 1 | 2 | 3.60e-01 |
| GO:BP | GO:0038091 | positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway | 1 | 3 | 3.60e-01 |
| GO:BP | GO:0072277 | metanephric glomerular capillary formation | 1 | 2 | 3.60e-01 |
| GO:BP | GO:0045937 | positive regulation of phosphate metabolic process | 26 | 597 | 3.60e-01 |
| GO:BP | GO:1901987 | regulation of cell cycle phase transition | 29 | 391 | 3.60e-01 |
| GO:BP | GO:0016051 | carbohydrate biosynthetic process | 7 | 155 | 3.60e-01 |
| GO:BP | GO:0019284 | L-methionine salvage from S-adenosylmethionine | 1 | 3 | 3.60e-01 |
| GO:BP | GO:0061339 | establishment or maintenance of monopolar cell polarity | 2 | 20 | 3.60e-01 |
| GO:BP | GO:0061042 | vascular wound healing | 1 | 17 | 3.60e-01 |
| GO:BP | GO:0006353 | DNA-templated transcription termination | 1 | 22 | 3.61e-01 |
| GO:BP | GO:0006654 | phosphatidic acid biosynthetic process | 1 | 30 | 3.61e-01 |
| GO:BP | GO:0072593 | reactive oxygen species metabolic process | 6 | 156 | 3.61e-01 |
| GO:BP | GO:0019915 | lipid storage | 2 | 66 | 3.61e-01 |
| GO:BP | GO:0031112 | positive regulation of microtubule polymerization or depolymerization | 2 | 35 | 3.61e-01 |
| GO:BP | GO:0098773 | skin epidermis development | 1 | 87 | 3.61e-01 |
| GO:BP | GO:0042732 | D-xylose metabolic process | 1 | 2 | 3.61e-01 |
| GO:BP | GO:0071897 | DNA biosynthetic process | 10 | 175 | 3.61e-01 |
| GO:BP | GO:1901018 | positive regulation of potassium ion transmembrane transporter activity | 1 | 20 | 3.61e-01 |
| GO:BP | GO:0035509 | negative regulation of myosin-light-chain-phosphatase activity | 1 | 3 | 3.61e-01 |
| GO:BP | GO:0033212 | iron import into cell | 1 | 7 | 3.61e-01 |
| GO:BP | GO:0032648 | regulation of interferon-beta production | 4 | 43 | 3.61e-01 |
| GO:BP | GO:0033152 | immunoglobulin V(D)J recombination | 1 | 8 | 3.61e-01 |
| GO:BP | GO:0048538 | thymus development | 1 | 35 | 3.61e-01 |
| GO:BP | GO:0003382 | epithelial cell morphogenesis | 4 | 24 | 3.61e-01 |
| GO:BP | GO:0003418 | growth plate cartilage chondrocyte differentiation | 1 | 8 | 3.61e-01 |
| GO:BP | GO:0032608 | interferon-beta production | 4 | 43 | 3.61e-01 |
| GO:BP | GO:1905584 | outer hair cell apoptotic process | 1 | 2 | 3.61e-01 |
| GO:BP | GO:0045346 | regulation of MHC class II biosynthetic process | 1 | 11 | 3.61e-01 |
| GO:BP | GO:0006882 | intracellular zinc ion homeostasis | 1 | 28 | 3.61e-01 |
| GO:BP | GO:0050804 | modulation of chemical synaptic transmission | 36 | 341 | 3.61e-01 |
| GO:BP | GO:0060623 | regulation of chromosome condensation | 1 | 11 | 3.61e-01 |
| GO:BP | GO:0050808 | synapse organization | 5 | 365 | 3.61e-01 |
| GO:BP | GO:0042471 | ear morphogenesis | 1 | 73 | 3.61e-01 |
| GO:BP | GO:0036462 | TRAIL-activated apoptotic signaling pathway | 2 | 10 | 3.61e-01 |
| GO:BP | GO:1900175 | regulation of nodal signaling pathway involved in determination of lateral mesoderm left/right asymmetry | 1 | 2 | 3.62e-01 |
| GO:BP | GO:2000672 | negative regulation of motor neuron apoptotic process | 2 | 10 | 3.62e-01 |
| GO:BP | GO:0021587 | cerebellum morphogenesis | 5 | 36 | 3.62e-01 |
| GO:BP | GO:1900145 | regulation of nodal signaling pathway involved in determination of left/right asymmetry | 1 | 2 | 3.62e-01 |
| GO:BP | GO:0002292 | T cell differentiation involved in immune response | 1 | 42 | 3.62e-01 |
| GO:BP | GO:0010558 | negative regulation of macromolecule biosynthetic process | 2 | 1214 | 3.62e-01 |
| GO:BP | GO:0032967 | positive regulation of collagen biosynthetic process | 2 | 23 | 3.62e-01 |
| GO:BP | GO:1903238 | positive regulation of leukocyte tethering or rolling | 1 | 5 | 3.62e-01 |
| GO:BP | GO:0033505 | floor plate morphogenesis | 1 | 3 | 3.63e-01 |
| GO:BP | GO:0051385 | response to mineralocorticoid | 2 | 25 | 3.63e-01 |
| GO:BP | GO:0007565 | female pregnancy | 9 | 122 | 3.63e-01 |
| GO:BP | GO:0099543 | trans-synaptic signaling by soluble gas | 1 | 2 | 3.63e-01 |
| GO:BP | GO:0099548 | trans-synaptic signaling by nitric oxide | 1 | 2 | 3.63e-01 |
| GO:BP | GO:0032941 | secretion by tissue | 1 | 25 | 3.63e-01 |
| GO:BP | GO:1900747 | negative regulation of vascular endothelial growth factor signaling pathway | 2 | 7 | 3.63e-01 |
| GO:BP | GO:0008090 | retrograde axonal transport | 3 | 19 | 3.63e-01 |
| GO:BP | GO:0031346 | positive regulation of cell projection organization | 22 | 303 | 3.63e-01 |
| GO:BP | GO:0021650 | vestibulocochlear nerve formation | 1 | 1 | 3.63e-01 |
| GO:BP | GO:2000819 | regulation of nucleotide-excision repair | 3 | 27 | 3.63e-01 |
| GO:BP | GO:0071260 | cellular response to mechanical stimulus | 1 | 59 | 3.63e-01 |
| GO:BP | GO:1904861 | excitatory synapse assembly | 4 | 26 | 3.63e-01 |
| GO:BP | GO:0030641 | regulation of cellular pH | 4 | 70 | 3.63e-01 |
| GO:BP | GO:0034205 | amyloid-beta formation | 3 | 41 | 3.63e-01 |
| GO:BP | GO:0046530 | photoreceptor cell differentiation | 4 | 40 | 3.63e-01 |
| GO:BP | GO:0043649 | dicarboxylic acid catabolic process | 1 | 14 | 3.64e-01 |
| GO:BP | GO:0099177 | regulation of trans-synaptic signaling | 36 | 342 | 3.64e-01 |
| GO:BP | GO:0045934 | negative regulation of nucleobase-containing compound metabolic process | 2 | 1209 | 3.64e-01 |
| GO:BP | GO:0140214 | positive regulation of long-chain fatty acid import into cell | 1 | 2 | 3.64e-01 |
| GO:BP | GO:0010517 | regulation of phospholipase activity | 2 | 37 | 3.65e-01 |
| GO:BP | GO:0006469 | negative regulation of protein kinase activity | 7 | 179 | 3.65e-01 |
| GO:BP | GO:1905273 | positive regulation of proton-transporting ATP synthase activity, rotational mechanism | 1 | 3 | 3.66e-01 |
| GO:BP | GO:0046626 | regulation of insulin receptor signaling pathway | 5 | 53 | 3.66e-01 |
| GO:BP | GO:1900076 | regulation of cellular response to insulin stimulus | 5 | 56 | 3.66e-01 |
| GO:BP | GO:1905271 | regulation of proton-transporting ATP synthase activity, rotational mechanism | 1 | 3 | 3.66e-01 |
| GO:BP | GO:1905706 | regulation of mitochondrial ATP synthesis coupled proton transport | 1 | 3 | 3.66e-01 |
| GO:BP | GO:0034620 | cellular response to unfolded protein | 5 | 91 | 3.66e-01 |
| GO:BP | GO:0009408 | response to heat | 6 | 84 | 3.66e-01 |
| GO:BP | GO:0098901 | regulation of cardiac muscle cell action potential | 1 | 30 | 3.66e-01 |
| GO:BP | GO:2001260 | regulation of semaphorin-plexin signaling pathway | 1 | 3 | 3.66e-01 |
| GO:BP | GO:0003151 | outflow tract morphogenesis | 1 | 68 | 3.66e-01 |
| GO:BP | GO:0061643 | chemorepulsion of axon | 1 | 6 | 3.67e-01 |
| GO:BP | GO:0031034 | myosin filament assembly | 1 | 4 | 3.67e-01 |
| GO:BP | GO:0043651 | linoleic acid metabolic process | 1 | 12 | 3.67e-01 |
| GO:BP | GO:0086067 | AV node cell to bundle of His cell communication | 1 | 11 | 3.67e-01 |
| GO:BP | GO:0002523 | leukocyte migration involved in inflammatory response | 1 | 9 | 3.67e-01 |
| GO:BP | GO:1990090 | cellular response to nerve growth factor stimulus | 3 | 41 | 3.67e-01 |
| GO:BP | GO:1900133 | regulation of renin secretion into blood stream | 1 | 2 | 3.68e-01 |
| GO:BP | GO:1901386 | negative regulation of voltage-gated calcium channel activity | 1 | 13 | 3.68e-01 |
| GO:BP | GO:0043524 | negative regulation of neuron apoptotic process | 13 | 120 | 3.68e-01 |
| GO:BP | GO:2000370 | positive regulation of clathrin-dependent endocytosis | 1 | 5 | 3.68e-01 |
| GO:BP | GO:0010499 | proteasomal ubiquitin-independent protein catabolic process | 1 | 3 | 3.68e-01 |
| GO:BP | GO:1990603 | dark adaptation | 1 | 3 | 3.68e-01 |
| GO:BP | GO:0071485 | cellular response to absence of light | 1 | 3 | 3.68e-01 |
| GO:BP | GO:0009646 | response to absence of light | 1 | 3 | 3.68e-01 |
| GO:BP | GO:0048545 | response to steroid hormone | 2 | 245 | 3.68e-01 |
| GO:BP | GO:0051851 | modulation by host of symbiont process | 1 | 68 | 3.68e-01 |
| GO:BP | GO:0071496 | cellular response to external stimulus | 2 | 270 | 3.68e-01 |
| GO:BP | GO:0045936 | negative regulation of phosphate metabolic process | 13 | 344 | 3.68e-01 |
| GO:BP | GO:0045342 | MHC class II biosynthetic process | 1 | 12 | 3.68e-01 |
| GO:BP | GO:0015936 | coenzyme A metabolic process | 1 | 18 | 3.68e-01 |
| GO:BP | GO:1901984 | negative regulation of protein acetylation | 1 | 16 | 3.68e-01 |
| GO:BP | GO:0010944 | negative regulation of transcription by competitive promoter binding | 1 | 8 | 3.68e-01 |
| GO:BP | GO:0009725 | response to hormone | 4 | 642 | 3.68e-01 |
| GO:BP | GO:0005976 | polysaccharide metabolic process | 4 | 80 | 3.68e-01 |
| GO:BP | GO:0034660 | ncRNA metabolic process | 24 | 561 | 3.68e-01 |
| GO:BP | GO:2000197 | regulation of ribonucleoprotein complex localization | 1 | 6 | 3.68e-01 |
| GO:BP | GO:0097490 | sympathetic neuron projection extension | 1 | 4 | 3.68e-01 |
| GO:BP | GO:0031327 | negative regulation of cellular biosynthetic process | 2 | 1239 | 3.68e-01 |
| GO:BP | GO:0097491 | sympathetic neuron projection guidance | 1 | 4 | 3.68e-01 |
| GO:BP | GO:0014910 | regulation of smooth muscle cell migration | 7 | 58 | 3.68e-01 |
| GO:BP | GO:1901673 | regulation of mitotic spindle assembly | 1 | 23 | 3.68e-01 |
| GO:BP | GO:1901550 | regulation of endothelial cell development | 2 | 12 | 3.68e-01 |
| GO:BP | GO:0032640 | tumor necrosis factor production | 3 | 91 | 3.68e-01 |
| GO:BP | GO:1903140 | regulation of establishment of endothelial barrier | 2 | 12 | 3.68e-01 |
| GO:BP | GO:0032680 | regulation of tumor necrosis factor production | 3 | 91 | 3.68e-01 |
| GO:BP | GO:0061551 | trigeminal ganglion development | 1 | 3 | 3.68e-01 |
| GO:BP | GO:0032965 | regulation of collagen biosynthetic process | 4 | 30 | 3.69e-01 |
| GO:BP | GO:0051591 | response to cAMP | 3 | 66 | 3.69e-01 |
| GO:BP | GO:0052548 | regulation of endopeptidase activity | 10 | 232 | 3.69e-01 |
| GO:BP | GO:0032147 | activation of protein kinase activity | 8 | 82 | 3.69e-01 |
| GO:BP | GO:2000573 | positive regulation of DNA biosynthetic process | 7 | 67 | 3.69e-01 |
| GO:BP | GO:0060061 | Spemann organizer formation | 1 | 3 | 3.69e-01 |
| GO:BP | GO:0010563 | negative regulation of phosphorus metabolic process | 13 | 345 | 3.69e-01 |
| GO:BP | GO:0046627 | negative regulation of insulin receptor signaling pathway | 3 | 29 | 3.69e-01 |
| GO:BP | GO:0072332 | intrinsic apoptotic signaling pathway by p53 class mediator | 3 | 77 | 3.69e-01 |
| GO:BP | GO:2001237 | negative regulation of extrinsic apoptotic signaling pathway | 9 | 78 | 3.69e-01 |
| GO:BP | GO:0002051 | osteoblast fate commitment | 1 | 2 | 3.69e-01 |
| GO:BP | GO:0065009 | regulation of molecular function | 20 | 1939 | 3.70e-01 |
| GO:BP | GO:0007283 | spermatogenesis | 5 | 330 | 3.70e-01 |
| GO:BP | GO:0150115 | cell-substrate junction organization | 7 | 98 | 3.70e-01 |
| GO:BP | GO:2001242 | regulation of intrinsic apoptotic signaling pathway | 4 | 147 | 3.70e-01 |
| GO:BP | GO:0035751 | regulation of lysosomal lumen pH | 1 | 26 | 3.70e-01 |
| GO:BP | GO:0042593 | glucose homeostasis | 4 | 168 | 3.70e-01 |
| GO:BP | GO:0030011 | maintenance of cell polarity | 1 | 16 | 3.70e-01 |
| GO:BP | GO:0015886 | heme transport | 1 | 9 | 3.71e-01 |
| GO:BP | GO:0009913 | epidermal cell differentiation | 1 | 116 | 3.71e-01 |
| GO:BP | GO:1904407 | positive regulation of nitric oxide metabolic process | 3 | 27 | 3.71e-01 |
| GO:BP | GO:1903427 | negative regulation of reactive oxygen species biosynthetic process | 1 | 12 | 3.71e-01 |
| GO:BP | GO:0046676 | negative regulation of insulin secretion | 2 | 28 | 3.71e-01 |
| GO:BP | GO:1904659 | glucose transmembrane transport | 7 | 81 | 3.71e-01 |
| GO:BP | GO:0042796 | snRNA transcription by RNA polymerase III | 1 | 8 | 3.71e-01 |
| GO:BP | GO:0110030 | regulation of G2/MI transition of meiotic cell cycle | 1 | 3 | 3.71e-01 |
| GO:BP | GO:1901995 | positive regulation of meiotic cell cycle phase transition | 1 | 3 | 3.71e-01 |
| GO:BP | GO:0032693 | negative regulation of interleukin-10 production | 1 | 7 | 3.72e-01 |
| GO:BP | GO:0035385 | Roundabout signaling pathway | 1 | 5 | 3.72e-01 |
| GO:BP | GO:0031111 | negative regulation of microtubule polymerization or depolymerization | 5 | 39 | 3.72e-01 |
| GO:BP | GO:0090277 | positive regulation of peptide hormone secretion | 4 | 69 | 3.72e-01 |
| GO:BP | GO:0035722 | interleukin-12-mediated signaling pathway | 1 | 3 | 3.72e-01 |
| GO:BP | GO:0008610 | lipid biosynthetic process | 1 | 560 | 3.72e-01 |
| GO:BP | GO:0033500 | carbohydrate homeostasis | 4 | 169 | 3.72e-01 |
| GO:BP | GO:0061073 | ciliary body morphogenesis | 1 | 3 | 3.72e-01 |
| GO:BP | GO:0006526 | arginine biosynthetic process | 1 | 4 | 3.73e-01 |
| GO:BP | GO:0055123 | digestive system development | 12 | 100 | 3.73e-01 |
| GO:BP | GO:0001895 | retina homeostasis | 1 | 44 | 3.73e-01 |
| GO:BP | GO:0043516 | regulation of DNA damage response, signal transduction by p53 class mediator | 2 | 35 | 3.74e-01 |
| GO:BP | GO:0062197 | cellular response to chemical stress | 2 | 293 | 3.74e-01 |
| GO:BP | GO:0043154 | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 7 | 59 | 3.74e-01 |
| GO:BP | GO:0042439 | ethanolamine-containing compound metabolic process | 1 | 5 | 3.74e-01 |
| GO:BP | GO:0000447 | endonucleolytic cleavage in ITS1 to separate SSU-rRNA from 5.8S rRNA and LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 1 | 10 | 3.74e-01 |
| GO:BP | GO:1902532 | negative regulation of intracellular signal transduction | 7 | 438 | 3.74e-01 |
| GO:BP | GO:0048864 | stem cell development | 8 | 76 | 3.75e-01 |
| GO:BP | GO:0045943 | positive regulation of transcription by RNA polymerase I | 3 | 34 | 3.75e-01 |
| GO:BP | GO:0140747 | regulation of ncRNA transcription | 2 | 23 | 3.75e-01 |
| GO:BP | GO:0048701 | embryonic cranial skeleton morphogenesis | 3 | 31 | 3.75e-01 |
| GO:BP | GO:1903995 | regulation of non-membrane spanning protein tyrosine kinase activity | 1 | 3 | 3.75e-01 |
| GO:BP | GO:0032607 | interferon-alpha production | 1 | 19 | 3.75e-01 |
| GO:BP | GO:0032647 | regulation of interferon-alpha production | 1 | 19 | 3.75e-01 |
| GO:BP | GO:0051254 | positive regulation of RNA metabolic process | 6 | 1441 | 3.75e-01 |
| GO:BP | GO:0030728 | ovulation | 1 | 14 | 3.75e-01 |
| GO:BP | GO:1901483 | regulation of transcription factor catabolic process | 1 | 3 | 3.75e-01 |
| GO:BP | GO:0006986 | response to unfolded protein | 7 | 128 | 3.75e-01 |
| GO:BP | GO:1901485 | positive regulation of transcription factor catabolic process | 1 | 3 | 3.75e-01 |
| GO:BP | GO:1902882 | regulation of response to oxidative stress | 4 | 76 | 3.75e-01 |
| GO:BP | GO:0061833 | protein localization to tricellular tight junction | 1 | 2 | 3.75e-01 |
| GO:BP | GO:0071801 | regulation of podosome assembly | 2 | 8 | 3.76e-01 |
| GO:BP | GO:0046850 | regulation of bone remodeling | 4 | 30 | 3.76e-01 |
| GO:BP | GO:1905818 | regulation of chromosome separation | 1 | 71 | 3.76e-01 |
| GO:BP | GO:0048703 | embryonic viscerocranium morphogenesis | 1 | 8 | 3.76e-01 |
| GO:BP | GO:0006098 | pentose-phosphate shunt | 2 | 19 | 3.77e-01 |
| GO:BP | GO:0032728 | positive regulation of interferon-beta production | 3 | 29 | 3.77e-01 |
| GO:BP | GO:0045165 | cell fate commitment | 1 | 155 | 3.77e-01 |
| GO:BP | GO:0099504 | synaptic vesicle cycle | 17 | 163 | 3.77e-01 |
| GO:BP | GO:0048845 | venous blood vessel morphogenesis | 1 | 9 | 3.77e-01 |
| GO:BP | GO:1900273 | positive regulation of long-term synaptic potentiation | 3 | 19 | 3.77e-01 |
| GO:BP | GO:0006760 | folic acid-containing compound metabolic process | 2 | 22 | 3.77e-01 |
| GO:BP | GO:1903719 | regulation of I-kappaB phosphorylation | 1 | 6 | 3.77e-01 |
| GO:BP | GO:0021602 | cranial nerve morphogenesis | 3 | 16 | 3.77e-01 |
| GO:BP | GO:1902107 | positive regulation of leukocyte differentiation | 12 | 118 | 3.77e-01 |
| GO:BP | GO:0043648 | dicarboxylic acid metabolic process | 5 | 74 | 3.77e-01 |
| GO:BP | GO:0072210 | metanephric nephron development | 4 | 29 | 3.77e-01 |
| GO:BP | GO:1903708 | positive regulation of hemopoiesis | 12 | 118 | 3.77e-01 |
| GO:BP | GO:0051106 | positive regulation of DNA ligation | 1 | 5 | 3.77e-01 |
| GO:BP | GO:0090502 | RNA phosphodiester bond hydrolysis, endonucleolytic | 1 | 72 | 3.77e-01 |
| GO:BP | GO:1904507 | positive regulation of telomere maintenance in response to DNA damage | 2 | 14 | 3.77e-01 |
| GO:BP | GO:0048633 | positive regulation of skeletal muscle tissue growth | 1 | 6 | 3.77e-01 |
| GO:BP | GO:0048015 | phosphatidylinositol-mediated signaling | 14 | 123 | 3.77e-01 |
| GO:BP | GO:0051241 | negative regulation of multicellular organismal process | 1 | 748 | 3.77e-01 |
| GO:BP | GO:0032088 | negative regulation of NF-kappaB transcription factor activity | 1 | 66 | 3.77e-01 |
| GO:BP | GO:0009890 | negative regulation of biosynthetic process | 2 | 1280 | 3.77e-01 |
| GO:BP | GO:0097350 | neutrophil clearance | 1 | 5 | 3.77e-01 |
| GO:BP | GO:0071287 | cellular response to manganese ion | 1 | 8 | 3.77e-01 |
| GO:BP | GO:0006688 | glycosphingolipid biosynthetic process | 1 | 25 | 3.77e-01 |
| GO:BP | GO:0009219 | pyrimidine deoxyribonucleotide metabolic process | 2 | 21 | 3.77e-01 |
| GO:BP | GO:0006892 | post-Golgi vesicle-mediated transport | 4 | 103 | 3.77e-01 |
| GO:BP | GO:1905918 | regulation of CoA-transferase activity | 1 | 5 | 3.77e-01 |
| GO:BP | GO:1905920 | positive regulation of CoA-transferase activity | 1 | 5 | 3.77e-01 |
| GO:BP | GO:2000638 | regulation of SREBP signaling pathway | 1 | 7 | 3.77e-01 |
| GO:BP | GO:0070424 | regulation of nucleotide-binding oligomerization domain containing signaling pathway | 1 | 9 | 3.77e-01 |
| GO:BP | GO:0035278 | miRNA-mediated gene silencing by inhibition of translation | 2 | 15 | 3.77e-01 |
| GO:BP | GO:2001026 | regulation of endothelial cell chemotaxis | 2 | 16 | 3.77e-01 |
| GO:BP | GO:0046473 | phosphatidic acid metabolic process | 1 | 32 | 3.77e-01 |
| GO:BP | GO:0006607 | NLS-bearing protein import into nucleus | 2 | 18 | 3.77e-01 |
| GO:BP | GO:0072033 | renal vesicle formation | 1 | 8 | 3.77e-01 |
| GO:BP | GO:0030579 | ubiquitin-dependent SMAD protein catabolic process | 1 | 5 | 3.77e-01 |
| GO:BP | GO:0021796 | cerebral cortex regionalization | 1 | 2 | 3.77e-01 |
| GO:BP | GO:2000134 | negative regulation of G1/S transition of mitotic cell cycle | 1 | 64 | 3.77e-01 |
| GO:BP | GO:0031396 | regulation of protein ubiquitination | 18 | 191 | 3.78e-01 |
| GO:BP | GO:0071706 | tumor necrosis factor superfamily cytokine production | 3 | 94 | 3.78e-01 |
| GO:BP | GO:0010996 | response to auditory stimulus | 3 | 16 | 3.78e-01 |
| GO:BP | GO:1903313 | positive regulation of mRNA metabolic process | 2 | 121 | 3.78e-01 |
| GO:BP | GO:0098657 | import into cell | 8 | 166 | 3.78e-01 |
| GO:BP | GO:1903555 | regulation of tumor necrosis factor superfamily cytokine production | 3 | 94 | 3.78e-01 |
| GO:BP | GO:0021957 | corticospinal tract morphogenesis | 1 | 7 | 3.78e-01 |
| GO:BP | GO:0031063 | regulation of histone deacetylation | 3 | 36 | 3.78e-01 |
| GO:BP | GO:0051457 | maintenance of protein location in nucleus | 3 | 22 | 3.78e-01 |
| GO:BP | GO:0043367 | CD4-positive, alpha-beta T cell differentiation | 1 | 50 | 3.78e-01 |
| GO:BP | GO:0033209 | tumor necrosis factor-mediated signaling pathway | 6 | 76 | 3.78e-01 |
| GO:BP | GO:0002793 | positive regulation of peptide secretion | 4 | 70 | 3.79e-01 |
| GO:BP | GO:0045912 | negative regulation of carbohydrate metabolic process | 2 | 38 | 3.79e-01 |
| GO:BP | GO:0051240 | positive regulation of multicellular organismal process | 19 | 1101 | 3.80e-01 |
| GO:BP | GO:0048490 | anterograde synaptic vesicle transport | 1 | 16 | 3.80e-01 |
| GO:BP | GO:2000191 | regulation of fatty acid transport | 2 | 19 | 3.80e-01 |
| GO:BP | GO:0033173 | calcineurin-NFAT signaling cascade | 2 | 37 | 3.80e-01 |
| GO:BP | GO:0048041 | focal adhesion assembly | 6 | 81 | 3.80e-01 |
| GO:BP | GO:0007020 | microtubule nucleation | 2 | 39 | 3.80e-01 |
| GO:BP | GO:0043550 | regulation of lipid kinase activity | 5 | 43 | 3.80e-01 |
| GO:BP | GO:0101023 | vascular endothelial cell proliferation | 1 | 21 | 3.80e-01 |
| GO:BP | GO:0043330 | response to exogenous dsRNA | 2 | 27 | 3.80e-01 |
| GO:BP | GO:0044331 | cell-cell adhesion mediated by cadherin | 2 | 22 | 3.80e-01 |
| GO:BP | GO:0007035 | vacuolar acidification | 2 | 30 | 3.80e-01 |
| GO:BP | GO:0090155 | negative regulation of sphingolipid biosynthetic process | 1 | 6 | 3.80e-01 |
| GO:BP | GO:0099517 | synaptic vesicle transport along microtubule | 1 | 16 | 3.80e-01 |
| GO:BP | GO:0090234 | regulation of kinetochore assembly | 1 | 3 | 3.80e-01 |
| GO:BP | GO:1905562 | regulation of vascular endothelial cell proliferation | 1 | 21 | 3.80e-01 |
| GO:BP | GO:0099514 | synaptic vesicle cytoskeletal transport | 1 | 16 | 3.80e-01 |
| GO:BP | GO:0097494 | regulation of vesicle size | 1 | 19 | 3.80e-01 |
| GO:BP | GO:1990089 | response to nerve growth factor | 3 | 41 | 3.80e-01 |
| GO:BP | GO:0051931 | regulation of sensory perception | 4 | 13 | 3.80e-01 |
| GO:BP | GO:0051930 | regulation of sensory perception of pain | 4 | 13 | 3.80e-01 |
| GO:BP | GO:0060708 | spongiotrophoblast differentiation | 1 | 2 | 3.80e-01 |
| GO:BP | GO:0044321 | response to leptin | 1 | 19 | 3.80e-01 |
| GO:BP | GO:0007584 | response to nutrient | 14 | 109 | 3.80e-01 |
| GO:BP | GO:0010804 | negative regulation of tumor necrosis factor-mediated signaling pathway | 1 | 18 | 3.80e-01 |
| GO:BP | GO:0106058 | positive regulation of calcineurin-mediated signaling | 1 | 16 | 3.80e-01 |
| GO:BP | GO:0030072 | peptide hormone secretion | 4 | 166 | 3.80e-01 |
| GO:BP | GO:0070886 | positive regulation of calcineurin-NFAT signaling cascade | 1 | 16 | 3.80e-01 |
| GO:BP | GO:0032780 | negative regulation of ATP-dependent activity | 1 | 18 | 3.80e-01 |
| GO:BP | GO:0045663 | positive regulation of myoblast differentiation | 4 | 37 | 3.80e-01 |
| GO:BP | GO:1904684 | negative regulation of metalloendopeptidase activity | 1 | 4 | 3.81e-01 |
| GO:BP | GO:1903121 | regulation of TRAIL-activated apoptotic signaling pathway | 1 | 4 | 3.81e-01 |
| GO:BP | GO:0090649 | response to oxygen-glucose deprivation | 1 | 7 | 3.81e-01 |
| GO:BP | GO:0008542 | visual learning | 5 | 37 | 3.81e-01 |
| GO:BP | GO:0043523 | regulation of neuron apoptotic process | 7 | 167 | 3.81e-01 |
| GO:BP | GO:0042168 | heme metabolic process | 2 | 40 | 3.81e-01 |
| GO:BP | GO:0042401 | biogenic amine biosynthetic process | 1 | 24 | 3.81e-01 |
| GO:BP | GO:0048699 | generation of neurons | 6 | 1119 | 3.81e-01 |
| GO:BP | GO:0008104 | protein localization | 4 | 2129 | 3.81e-01 |
| GO:BP | GO:0048711 | positive regulation of astrocyte differentiation | 2 | 11 | 3.81e-01 |
| GO:BP | GO:0070814 | hydrogen sulfide biosynthetic process | 1 | 4 | 3.81e-01 |
| GO:BP | GO:0010762 | regulation of fibroblast migration | 3 | 37 | 3.81e-01 |
| GO:BP | GO:0098656 | monoatomic anion transmembrane transport | 3 | 71 | 3.81e-01 |
| GO:BP | GO:0007350 | blastoderm segmentation | 3 | 17 | 3.81e-01 |
| GO:BP | GO:0062176 | R-loop processing | 1 | 6 | 3.81e-01 |
| GO:BP | GO:0140861 | DNA repair-dependent chromatin remodeling | 1 | 6 | 3.81e-01 |
| GO:BP | GO:1901992 | positive regulation of mitotic cell cycle phase transition | 8 | 86 | 3.81e-01 |
| GO:BP | GO:0051250 | negative regulation of lymphocyte activation | 3 | 90 | 3.81e-01 |
| GO:BP | GO:1903894 | regulation of IRE1-mediated unfolded protein response | 2 | 14 | 3.81e-01 |
| GO:BP | GO:1904893 | negative regulation of receptor signaling pathway via STAT | 2 | 21 | 3.81e-01 |
| GO:BP | GO:0009117 | nucleotide metabolic process | 3 | 423 | 3.82e-01 |
| GO:BP | GO:0016267 | O-glycan processing, core 1 | 1 | 2 | 3.82e-01 |
| GO:BP | GO:0035336 | long-chain fatty-acyl-CoA metabolic process | 3 | 19 | 3.82e-01 |
| GO:BP | GO:2001244 | positive regulation of intrinsic apoptotic signaling pathway | 2 | 52 | 3.82e-01 |
| GO:BP | GO:0030497 | fatty acid elongation | 2 | 12 | 3.82e-01 |
| GO:BP | GO:0070727 | cellular macromolecule localization | 4 | 2138 | 3.82e-01 |
| GO:BP | GO:0042761 | very long-chain fatty acid biosynthetic process | 2 | 12 | 3.82e-01 |
| GO:BP | GO:0002943 | tRNA dihydrouridine synthesis | 1 | 4 | 3.82e-01 |
| GO:BP | GO:0001568 | blood vessel development | 34 | 534 | 3.82e-01 |
| GO:BP | GO:0010666 | positive regulation of cardiac muscle cell apoptotic process | 1 | 12 | 3.82e-01 |
| GO:BP | GO:0002208 | somatic diversification of immunoglobulins involved in immune response | 3 | 39 | 3.82e-01 |
| GO:BP | GO:0009446 | putrescine biosynthetic process | 1 | 4 | 3.82e-01 |
| GO:BP | GO:0071447 | cellular response to hydroperoxide | 1 | 7 | 3.82e-01 |
| GO:BP | GO:0045190 | isotype switching | 3 | 39 | 3.82e-01 |
| GO:BP | GO:0010663 | positive regulation of striated muscle cell apoptotic process | 1 | 12 | 3.82e-01 |
| GO:BP | GO:0002204 | somatic recombination of immunoglobulin genes involved in immune response | 3 | 39 | 3.82e-01 |
| GO:BP | GO:0048232 | male gamete generation | 5 | 343 | 3.82e-01 |
| GO:BP | GO:0007617 | mating behavior | 1 | 21 | 3.83e-01 |
| GO:BP | GO:0009211 | pyrimidine deoxyribonucleoside triphosphate metabolic process | 1 | 6 | 3.83e-01 |
| GO:BP | GO:0150104 | transport across blood-brain barrier | 1 | 72 | 3.83e-01 |
| GO:BP | GO:0008219 | cell death | 69 | 1596 | 3.83e-01 |
| GO:BP | GO:1990253 | cellular response to leucine starvation | 2 | 13 | 3.83e-01 |
| GO:BP | GO:0010232 | vascular transport | 1 | 72 | 3.83e-01 |
| GO:BP | GO:0150105 | protein localization to cell-cell junction | 1 | 17 | 3.83e-01 |
| GO:BP | GO:0099565 | chemical synaptic transmission, postsynaptic | 9 | 75 | 3.83e-01 |
| GO:BP | GO:0006516 | glycoprotein catabolic process | 1 | 29 | 3.83e-01 |
| GO:BP | GO:0006907 | pinocytosis | 2 | 18 | 3.83e-01 |
| GO:BP | GO:0035308 | negative regulation of protein dephosphorylation | 1 | 28 | 3.84e-01 |
| GO:BP | GO:1901203 | positive regulation of extracellular matrix assembly | 1 | 10 | 3.84e-01 |
| GO:BP | GO:0032781 | positive regulation of ATP-dependent activity | 3 | 40 | 3.84e-01 |
| GO:BP | GO:0003330 | regulation of extracellular matrix constituent secretion | 1 | 7 | 3.84e-01 |
| GO:BP | GO:0045910 | negative regulation of DNA recombination | 2 | 31 | 3.84e-01 |
| GO:BP | GO:2000048 | negative regulation of cell-cell adhesion mediated by cadherin | 1 | 8 | 3.84e-01 |
| GO:BP | GO:0051130 | positive regulation of cellular component organization | 2 | 906 | 3.84e-01 |
| GO:BP | GO:0009309 | amine biosynthetic process | 1 | 25 | 3.84e-01 |
| GO:BP | GO:0009100 | glycoprotein metabolic process | 4 | 316 | 3.84e-01 |
| GO:BP | GO:0070372 | regulation of ERK1 and ERK2 cascade | 22 | 191 | 3.84e-01 |
| GO:BP | GO:0051304 | chromosome separation | 1 | 76 | 3.84e-01 |
| GO:BP | GO:0006413 | translational initiation | 8 | 116 | 3.84e-01 |
| GO:BP | GO:1905203 | regulation of connective tissue replacement | 1 | 5 | 3.84e-01 |
| GO:BP | GO:0070076 | histone lysine demethylation | 1 | 20 | 3.84e-01 |
| GO:BP | GO:0098735 | positive regulation of the force of heart contraction | 1 | 4 | 3.84e-01 |
| GO:BP | GO:0048546 | digestive tract morphogenesis | 5 | 31 | 3.84e-01 |
| GO:BP | GO:0032651 | regulation of interleukin-1 beta production | 1 | 48 | 3.85e-01 |
| GO:BP | GO:0032611 | interleukin-1 beta production | 1 | 48 | 3.85e-01 |
| GO:BP | GO:0006942 | regulation of striated muscle contraction | 1 | 85 | 3.85e-01 |
| GO:BP | GO:1901329 | regulation of odontoblast differentiation | 1 | 2 | 3.85e-01 |
| GO:BP | GO:1902254 | negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 1 | 22 | 3.85e-01 |
| GO:BP | GO:0009162 | deoxyribonucleoside monophosphate metabolic process | 2 | 18 | 3.85e-01 |
| GO:BP | GO:0034390 | smooth muscle cell apoptotic process | 1 | 15 | 3.85e-01 |
| GO:BP | GO:0006304 | DNA modification | 1 | 89 | 3.85e-01 |
| GO:BP | GO:0034391 | regulation of smooth muscle cell apoptotic process | 1 | 15 | 3.85e-01 |
| GO:BP | GO:0048839 | inner ear development | 13 | 132 | 3.85e-01 |
| GO:BP | GO:0045785 | positive regulation of cell adhesion | 19 | 320 | 3.85e-01 |
| GO:BP | GO:0031581 | hemidesmosome assembly | 1 | 6 | 3.85e-01 |
| GO:BP | GO:0035036 | sperm-egg recognition | 2 | 22 | 3.85e-01 |
| GO:BP | GO:0040037 | negative regulation of fibroblast growth factor receptor signaling pathway | 2 | 16 | 3.85e-01 |
| GO:BP | GO:0007182 | common-partner SMAD protein phosphorylation | 1 | 6 | 3.85e-01 |
| GO:BP | GO:1900077 | negative regulation of cellular response to insulin stimulus | 3 | 31 | 3.85e-01 |
| GO:BP | GO:0090311 | regulation of protein deacetylation | 4 | 53 | 3.85e-01 |
| GO:BP | GO:0097116 | gephyrin clustering involved in postsynaptic density assembly | 1 | 3 | 3.85e-01 |
| GO:BP | GO:0042297 | vocal learning | 1 | 4 | 3.85e-01 |
| GO:BP | GO:0033564 | anterior/posterior axon guidance | 1 | 4 | 3.85e-01 |
| GO:BP | GO:0098596 | imitative learning | 1 | 4 | 3.85e-01 |
| GO:BP | GO:0042426 | choline catabolic process | 1 | 3 | 3.85e-01 |
| GO:BP | GO:0040010 | positive regulation of growth rate | 1 | 2 | 3.85e-01 |
| GO:BP | GO:0006545 | glycine biosynthetic process | 1 | 4 | 3.86e-01 |
| GO:BP | GO:0090150 | establishment of protein localization to membrane | 1 | 250 | 3.86e-01 |
| GO:BP | GO:0071549 | cellular response to dexamethasone stimulus | 3 | 24 | 3.86e-01 |
| GO:BP | GO:0071962 | mitotic sister chromatid cohesion, centromeric | 1 | 4 | 3.86e-01 |
| GO:BP | GO:0032534 | regulation of microvillus assembly | 1 | 6 | 3.86e-01 |
| GO:BP | GO:0007338 | single fertilization | 1 | 70 | 3.86e-01 |
| GO:BP | GO:0051028 | mRNA transport | 6 | 117 | 3.86e-01 |
| GO:BP | GO:0002478 | antigen processing and presentation of exogenous peptide antigen | 4 | 24 | 3.86e-01 |
| GO:BP | GO:0042921 | glucocorticoid receptor signaling pathway | 1 | 13 | 3.86e-01 |
| GO:BP | GO:0035137 | hindlimb morphogenesis | 2 | 20 | 3.86e-01 |
| GO:BP | GO:0008217 | regulation of blood pressure | 1 | 115 | 3.86e-01 |
| GO:BP | GO:0002790 | peptide secretion | 4 | 170 | 3.86e-01 |
| GO:BP | GO:1901336 | lactone biosynthetic process | 1 | 3 | 3.86e-01 |
| GO:BP | GO:0019853 | L-ascorbic acid biosynthetic process | 1 | 3 | 3.86e-01 |
| GO:BP | GO:0014074 | response to purine-containing compound | 4 | 108 | 3.86e-01 |
| GO:BP | GO:0050849 | negative regulation of calcium-mediated signaling | 2 | 15 | 3.86e-01 |
| GO:BP | GO:0055013 | cardiac muscle cell development | 6 | 71 | 3.87e-01 |
| GO:BP | GO:0032012 | regulation of ARF protein signal transduction | 3 | 18 | 3.87e-01 |
| GO:BP | GO:0042634 | regulation of hair cycle | 2 | 22 | 3.87e-01 |
| GO:BP | GO:0031914 | negative regulation of synaptic plasticity | 1 | 2 | 3.87e-01 |
| GO:BP | GO:0032011 | ARF protein signal transduction | 3 | 18 | 3.87e-01 |
| GO:BP | GO:0043376 | regulation of CD8-positive, alpha-beta T cell differentiation | 1 | 5 | 3.87e-01 |
| GO:BP | GO:0006753 | nucleoside phosphate metabolic process | 3 | 429 | 3.87e-01 |
| GO:BP | GO:0007028 | cytoplasm organization | 1 | 8 | 3.87e-01 |
| GO:BP | GO:0042325 | regulation of phosphorylation | 55 | 881 | 3.87e-01 |
| GO:BP | GO:0034653 | retinoic acid catabolic process | 1 | 1 | 3.87e-01 |
| GO:BP | GO:0003012 | muscle system process | 6 | 334 | 3.87e-01 |
| GO:BP | GO:0006307 | DNA dealkylation involved in DNA repair | 1 | 9 | 3.87e-01 |
| GO:BP | GO:0071166 | ribonucleoprotein complex localization | 1 | 7 | 3.87e-01 |
| GO:BP | GO:0016103 | diterpenoid catabolic process | 1 | 1 | 3.87e-01 |
| GO:BP | GO:1902809 | regulation of skeletal muscle fiber differentiation | 1 | 4 | 3.87e-01 |
| GO:BP | GO:0006418 | tRNA aminoacylation for protein translation | 1 | 40 | 3.87e-01 |
| GO:BP | GO:0033629 | negative regulation of cell adhesion mediated by integrin | 2 | 10 | 3.87e-01 |
| GO:BP | GO:0060666 | dichotomous subdivision of terminal units involved in salivary gland branching | 1 | 4 | 3.87e-01 |
| GO:BP | GO:0016052 | carbohydrate catabolic process | 4 | 120 | 3.88e-01 |
| GO:BP | GO:0035051 | cardiocyte differentiation | 10 | 129 | 3.88e-01 |
| GO:BP | GO:0008645 | hexose transmembrane transport | 7 | 84 | 3.88e-01 |
| GO:BP | GO:0015031 | protein transport | 3 | 1361 | 3.88e-01 |
| GO:BP | GO:0009068 | aspartate family amino acid catabolic process | 1 | 12 | 3.88e-01 |
| GO:BP | GO:0018904 | ether metabolic process | 1 | 20 | 3.88e-01 |
| GO:BP | GO:0099185 | postsynaptic intermediate filament cytoskeleton organization | 1 | 3 | 3.88e-01 |
| GO:BP | GO:0086012 | membrane depolarization during cardiac muscle cell action potential | 2 | 21 | 3.88e-01 |
| GO:BP | GO:0033693 | neurofilament bundle assembly | 1 | 3 | 3.88e-01 |
| GO:BP | GO:0045105 | intermediate filament polymerization or depolymerization | 1 | 2 | 3.88e-01 |
| GO:BP | GO:0032230 | positive regulation of synaptic transmission, GABAergic | 2 | 10 | 3.88e-01 |
| GO:BP | GO:0006915 | apoptotic process | 62 | 1443 | 3.88e-01 |
| GO:BP | GO:0010812 | negative regulation of cell-substrate adhesion | 6 | 44 | 3.89e-01 |
| GO:BP | GO:1901222 | regulation of NIK/NF-kappaB signaling | 1 | 65 | 3.89e-01 |
| GO:BP | GO:0060295 | regulation of cilium movement involved in cell motility | 2 | 12 | 3.89e-01 |
| GO:BP | GO:1902807 | negative regulation of cell cycle G1/S phase transition | 1 | 70 | 3.89e-01 |
| GO:BP | GO:1990869 | cellular response to chemokine | 1 | 37 | 3.89e-01 |
| GO:BP | GO:0021575 | hindbrain morphogenesis | 5 | 38 | 3.89e-01 |
| GO:BP | GO:0008589 | regulation of smoothened signaling pathway | 2 | 73 | 3.89e-01 |
| GO:BP | GO:2001268 | negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway | 1 | 5 | 3.89e-01 |
| GO:BP | GO:1990868 | response to chemokine | 1 | 37 | 3.89e-01 |
| GO:BP | GO:1902019 | regulation of cilium-dependent cell motility | 2 | 12 | 3.89e-01 |
| GO:BP | GO:0050672 | negative regulation of lymphocyte proliferation | 2 | 46 | 3.89e-01 |
| GO:BP | GO:0016577 | histone demethylation | 1 | 21 | 3.89e-01 |
| GO:BP | GO:0045599 | negative regulation of fat cell differentiation | 4 | 43 | 3.89e-01 |
| GO:BP | GO:0072331 | signal transduction by p53 class mediator | 6 | 161 | 3.89e-01 |
| GO:BP | GO:0051384 | response to glucocorticoid | 1 | 93 | 3.89e-01 |
| GO:BP | GO:1903525 | regulation of membrane tubulation | 1 | 5 | 3.89e-01 |
| GO:BP | GO:0021938 | smoothened signaling pathway involved in regulation of cerebellar granule cell precursor cell proliferation | 1 | 3 | 3.89e-01 |
| GO:BP | GO:0006837 | serotonin transport | 1 | 11 | 3.89e-01 |
| GO:BP | GO:1990787 | negative regulation of hh target transcription factor activity | 1 | 4 | 3.89e-01 |
| GO:BP | GO:0021954 | central nervous system neuron development | 8 | 61 | 3.89e-01 |
| GO:BP | GO:0009755 | hormone-mediated signaling pathway | 5 | 139 | 3.89e-01 |
| GO:BP | GO:0060907 | positive regulation of macrophage cytokine production | 1 | 18 | 3.89e-01 |
| GO:BP | GO:0051129 | negative regulation of cellular component organization | 28 | 604 | 3.89e-01 |
| GO:BP | GO:1904752 | regulation of vascular associated smooth muscle cell migration | 1 | 23 | 3.89e-01 |
| GO:BP | GO:0071351 | cellular response to interleukin-18 | 1 | 3 | 3.89e-01 |
| GO:BP | GO:0001911 | negative regulation of leukocyte mediated cytotoxicity | 1 | 11 | 3.89e-01 |
| GO:BP | GO:0046580 | negative regulation of Ras protein signal transduction | 3 | 47 | 3.89e-01 |
| GO:BP | GO:0045630 | positive regulation of T-helper 2 cell differentiation | 1 | 4 | 3.89e-01 |
| GO:BP | GO:0022406 | membrane docking | 5 | 84 | 3.89e-01 |
| GO:BP | GO:0072091 | regulation of stem cell proliferation | 3 | 58 | 3.89e-01 |
| GO:BP | GO:0120036 | plasma membrane bounded cell projection organization | 3 | 1201 | 3.89e-01 |
| GO:BP | GO:0002091 | negative regulation of receptor internalization | 1 | 14 | 3.89e-01 |
| GO:BP | GO:0006925 | inflammatory cell apoptotic process | 1 | 15 | 3.89e-01 |
| GO:BP | GO:0061326 | renal tubule development | 4 | 77 | 3.89e-01 |
| GO:BP | GO:0035655 | interleukin-18-mediated signaling pathway | 1 | 3 | 3.89e-01 |
| GO:BP | GO:0031509 | subtelomeric heterochromatin formation | 1 | 7 | 3.89e-01 |
| GO:BP | GO:0090335 | regulation of brown fat cell differentiation | 1 | 17 | 3.89e-01 |
| GO:BP | GO:0043618 | regulation of transcription from RNA polymerase II promoter in response to stress | 1 | 36 | 3.89e-01 |
| GO:BP | GO:0072659 | protein localization to plasma membrane | 1 | 249 | 3.89e-01 |
| GO:BP | GO:2000074 | regulation of type B pancreatic cell development | 1 | 8 | 3.89e-01 |
| GO:BP | GO:0009123 | nucleoside monophosphate metabolic process | 1 | 64 | 3.90e-01 |
| GO:BP | GO:0044272 | sulfur compound biosynthetic process | 1 | 122 | 3.90e-01 |
| GO:BP | GO:0035272 | exocrine system development | 1 | 34 | 3.90e-01 |
| GO:BP | GO:0010840 | regulation of circadian sleep/wake cycle, wakefulness | 1 | 1 | 3.90e-01 |
| GO:BP | GO:0060677 | ureteric bud elongation | 1 | 7 | 3.90e-01 |
| GO:BP | GO:0042746 | circadian sleep/wake cycle, wakefulness | 1 | 1 | 3.90e-01 |
| GO:BP | GO:0016080 | synaptic vesicle targeting | 1 | 3 | 3.90e-01 |
| GO:BP | GO:0030198 | extracellular matrix organization | 1 | 233 | 3.90e-01 |
| GO:BP | GO:0043062 | extracellular structure organization | 1 | 234 | 3.90e-01 |
| GO:BP | GO:0002652 | regulation of tolerance induction dependent upon immune response | 1 | 1 | 3.90e-01 |
| GO:BP | GO:0045833 | negative regulation of lipid metabolic process | 4 | 72 | 3.90e-01 |
| GO:BP | GO:1905397 | activated CD8-positive, alpha-beta T cell apoptotic process | 1 | 3 | 3.90e-01 |
| GO:BP | GO:0032945 | negative regulation of mononuclear cell proliferation | 2 | 46 | 3.90e-01 |
| GO:BP | GO:0009968 | negative regulation of signal transduction | 1 | 1006 | 3.90e-01 |
| GO:BP | GO:0016311 | dephosphorylation | 7 | 284 | 3.90e-01 |
| GO:BP | GO:1905402 | regulation of activated CD8-positive, alpha-beta T cell apoptotic process | 1 | 3 | 3.90e-01 |
| GO:BP | GO:0031345 | negative regulation of cell projection organization | 15 | 156 | 3.90e-01 |
| GO:BP | GO:0044092 | negative regulation of molecular function | 4 | 755 | 3.90e-01 |
| GO:BP | GO:0050999 | regulation of nitric-oxide synthase activity | 1 | 25 | 3.90e-01 |
| GO:BP | GO:0048017 | inositol lipid-mediated signaling | 14 | 126 | 3.90e-01 |
| GO:BP | GO:0097062 | dendritic spine maintenance | 2 | 15 | 3.90e-01 |
| GO:BP | GO:0072089 | stem cell proliferation | 5 | 84 | 3.90e-01 |
| GO:BP | GO:1990442 | intrinsic apoptotic signaling pathway in response to nitrosative stress | 1 | 3 | 3.90e-01 |
| GO:BP | GO:0045601 | regulation of endothelial cell differentiation | 3 | 27 | 3.90e-01 |
| GO:BP | GO:0097720 | calcineurin-mediated signaling | 2 | 38 | 3.90e-01 |
| GO:BP | GO:0046907 | intracellular transport | 3 | 1453 | 3.90e-01 |
| GO:BP | GO:0051583 | dopamine uptake involved in synaptic transmission | 2 | 8 | 3.90e-01 |
| GO:BP | GO:0071712 | ER-associated misfolded protein catabolic process | 2 | 12 | 3.90e-01 |
| GO:BP | GO:0051934 | catecholamine uptake involved in synaptic transmission | 2 | 8 | 3.90e-01 |
| GO:BP | GO:0045229 | external encapsulating structure organization | 1 | 234 | 3.90e-01 |
| GO:BP | GO:0060078 | regulation of postsynaptic membrane potential | 12 | 82 | 3.90e-01 |
| GO:BP | GO:0038034 | signal transduction in absence of ligand | 3 | 52 | 3.91e-01 |
| GO:BP | GO:0043558 | regulation of translational initiation in response to stress | 1 | 16 | 3.91e-01 |
| GO:BP | GO:0097192 | extrinsic apoptotic signaling pathway in absence of ligand | 3 | 52 | 3.91e-01 |
| GO:BP | GO:0098958 | retrograde axonal transport of mitochondrion | 1 | 2 | 3.91e-01 |
| GO:BP | GO:0005980 | glycogen catabolic process | 1 | 14 | 3.91e-01 |
| GO:BP | GO:1901098 | positive regulation of autophagosome maturation | 1 | 6 | 3.91e-01 |
| GO:BP | GO:1901606 | alpha-amino acid catabolic process | 3 | 63 | 3.91e-01 |
| GO:BP | GO:0009880 | embryonic pattern specification | 7 | 50 | 3.91e-01 |
| GO:BP | GO:0045669 | positive regulation of osteoblast differentiation | 1 | 54 | 3.91e-01 |
| GO:BP | GO:0048298 | positive regulation of isotype switching to IgA isotypes | 1 | 3 | 3.91e-01 |
| GO:BP | GO:1903321 | negative regulation of protein modification by small protein conjugation or removal | 9 | 86 | 3.91e-01 |
| GO:BP | GO:0000041 | transition metal ion transport | 3 | 71 | 3.92e-01 |
| GO:BP | GO:0035739 | CD4-positive, alpha-beta T cell proliferation | 1 | 12 | 3.92e-01 |
| GO:BP | GO:1904645 | response to amyloid-beta | 3 | 32 | 3.92e-01 |
| GO:BP | GO:0050966 | detection of mechanical stimulus involved in sensory perception of pain | 1 | 8 | 3.92e-01 |
| GO:BP | GO:0090276 | regulation of peptide hormone secretion | 6 | 132 | 3.92e-01 |
| GO:BP | GO:2000561 | regulation of CD4-positive, alpha-beta T cell proliferation | 1 | 12 | 3.92e-01 |
| GO:BP | GO:0031076 | embryonic camera-type eye development | 3 | 28 | 3.92e-01 |
| GO:BP | GO:0010557 | positive regulation of macromolecule biosynthetic process | 6 | 1507 | 3.92e-01 |
| GO:BP | GO:0045619 | regulation of lymphocyte differentiation | 11 | 132 | 3.92e-01 |
| GO:BP | GO:0031033 | myosin filament organization | 1 | 5 | 3.92e-01 |
| GO:BP | GO:0072080 | nephron tubule development | 1 | 73 | 3.92e-01 |
| GO:BP | GO:0046879 | hormone secretion | 5 | 210 | 3.92e-01 |
| GO:BP | GO:2000210 | positive regulation of anoikis | 1 | 6 | 3.93e-01 |
| GO:BP | GO:0051754 | meiotic sister chromatid cohesion, centromeric | 1 | 4 | 3.93e-01 |
| GO:BP | GO:0071218 | cellular response to misfolded protein | 3 | 23 | 3.93e-01 |
| GO:BP | GO:1990770 | small intestine smooth muscle contraction | 1 | 1 | 3.93e-01 |
| GO:BP | GO:0032765 | positive regulation of mast cell cytokine production | 1 | 3 | 3.93e-01 |
| GO:BP | GO:1904706 | negative regulation of vascular associated smooth muscle cell proliferation | 1 | 24 | 3.93e-01 |
| GO:BP | GO:2000811 | negative regulation of anoikis | 2 | 17 | 3.93e-01 |
| GO:BP | GO:0001937 | negative regulation of endothelial cell proliferation | 2 | 32 | 3.93e-01 |
| GO:BP | GO:0051894 | positive regulation of focal adhesion assembly | 2 | 24 | 3.93e-01 |
| GO:BP | GO:0006046 | N-acetylglucosamine catabolic process | 1 | 3 | 3.93e-01 |
| GO:BP | GO:0031958 | corticosteroid receptor signaling pathway | 1 | 14 | 3.93e-01 |
| GO:BP | GO:0060560 | developmental growth involved in morphogenesis | 8 | 204 | 3.93e-01 |
| GO:BP | GO:0038162 | erythropoietin-mediated signaling pathway | 1 | 2 | 3.93e-01 |
| GO:BP | GO:0002399 | MHC class II protein complex assembly | 2 | 4 | 3.93e-01 |
| GO:BP | GO:0038109 | Kit signaling pathway | 1 | 4 | 3.93e-01 |
| GO:BP | GO:0033687 | osteoblast proliferation | 3 | 27 | 3.93e-01 |
| GO:BP | GO:0048254 | snoRNA localization | 1 | 5 | 3.93e-01 |
| GO:BP | GO:0033145 | positive regulation of intracellular steroid hormone receptor signaling pathway | 1 | 10 | 3.93e-01 |
| GO:BP | GO:1903899 | positive regulation of PERK-mediated unfolded protein response | 1 | 3 | 3.93e-01 |
| GO:BP | GO:0031952 | regulation of protein autophosphorylation | 4 | 39 | 3.93e-01 |
| GO:BP | GO:0051412 | response to corticosterone | 1 | 10 | 3.93e-01 |
| GO:BP | GO:0021884 | forebrain neuron development | 3 | 16 | 3.93e-01 |
| GO:BP | GO:0002503 | peptide antigen assembly with MHC class II protein complex | 2 | 4 | 3.93e-01 |
| GO:BP | GO:0036215 | response to stem cell factor | 1 | 4 | 3.93e-01 |
| GO:BP | GO:0043276 | anoikis | 3 | 32 | 3.93e-01 |
| GO:BP | GO:0046628 | positive regulation of insulin receptor signaling pathway | 1 | 20 | 3.93e-01 |
| GO:BP | GO:0071312 | cellular response to alkaloid | 1 | 29 | 3.93e-01 |
| GO:BP | GO:0036216 | cellular response to stem cell factor stimulus | 1 | 4 | 3.93e-01 |
| GO:BP | GO:0061550 | cranial ganglion development | 1 | 4 | 3.94e-01 |
| GO:BP | GO:1904030 | negative regulation of cyclin-dependent protein kinase activity | 2 | 27 | 3.94e-01 |
| GO:BP | GO:0036484 | trunk neural crest cell migration | 1 | 4 | 3.94e-01 |
| GO:BP | GO:0035290 | trunk segmentation | 1 | 4 | 3.94e-01 |
| GO:BP | GO:0045736 | negative regulation of cyclin-dependent protein serine/threonine kinase activity | 2 | 27 | 3.94e-01 |
| GO:BP | GO:0097061 | dendritic spine organization | 1 | 67 | 3.94e-01 |
| GO:BP | GO:0000002 | mitochondrial genome maintenance | 1 | 29 | 3.94e-01 |
| GO:BP | GO:0097360 | chorionic trophoblast cell proliferation | 1 | 2 | 3.94e-01 |
| GO:BP | GO:0097190 | apoptotic signaling pathway | 13 | 494 | 3.94e-01 |
| GO:BP | GO:0000038 | very long-chain fatty acid metabolic process | 4 | 27 | 3.94e-01 |
| GO:BP | GO:0051965 | positive regulation of synapse assembly | 5 | 44 | 3.94e-01 |
| GO:BP | GO:0030071 | regulation of mitotic metaphase/anaphase transition | 1 | 88 | 3.94e-01 |
| GO:BP | GO:0036376 | sodium ion export across plasma membrane | 2 | 12 | 3.94e-01 |
| GO:BP | GO:0061298 | retina vasculature development in camera-type eye | 1 | 14 | 3.94e-01 |
| GO:BP | GO:0051489 | regulation of filopodium assembly | 5 | 44 | 3.94e-01 |
| GO:BP | GO:1901382 | regulation of chorionic trophoblast cell proliferation | 1 | 2 | 3.94e-01 |
| GO:BP | GO:0034378 | chylomicron assembly | 1 | 3 | 3.94e-01 |
| GO:BP | GO:0010923 | negative regulation of phosphatase activity | 1 | 30 | 3.94e-01 |
| GO:BP | GO:0070374 | positive regulation of ERK1 and ERK2 cascade | 16 | 121 | 3.94e-01 |
| GO:BP | GO:0072527 | pyrimidine-containing compound metabolic process | 1 | 67 | 3.94e-01 |
| GO:BP | GO:1903650 | negative regulation of cytoplasmic transport | 1 | 3 | 3.95e-01 |
| GO:BP | GO:0030261 | chromosome condensation | 2 | 33 | 3.95e-01 |
| GO:BP | GO:0003416 | endochondral bone growth | 2 | 23 | 3.95e-01 |
| GO:BP | GO:1902533 | positive regulation of intracellular signal transduction | 14 | 726 | 3.95e-01 |
| GO:BP | GO:0034104 | negative regulation of tissue remodeling | 3 | 13 | 3.95e-01 |
| GO:BP | GO:0050687 | negative regulation of defense response to virus | 3 | 30 | 3.95e-01 |
| GO:BP | GO:0061097 | regulation of protein tyrosine kinase activity | 1 | 65 | 3.95e-01 |
| GO:BP | GO:0010832 | negative regulation of myotube differentiation | 1 | 10 | 3.95e-01 |
| GO:BP | GO:0042116 | macrophage activation | 1 | 57 | 3.96e-01 |
| GO:BP | GO:0062009 | secondary palate development | 2 | 20 | 3.96e-01 |
| GO:BP | GO:0030073 | insulin secretion | 6 | 141 | 3.96e-01 |
| GO:BP | GO:2000251 | positive regulation of actin cytoskeleton reorganization | 1 | 14 | 3.96e-01 |
| GO:BP | GO:0071361 | cellular response to ethanol | 1 | 9 | 3.96e-01 |
| GO:BP | GO:0006885 | regulation of pH | 4 | 74 | 3.96e-01 |
| GO:BP | GO:0007275 | multicellular organism development | 15 | 3386 | 3.96e-01 |
| GO:BP | GO:0098953 | receptor diffusion trapping | 1 | 4 | 3.96e-01 |
| GO:BP | GO:0045196 | establishment or maintenance of neuroblast polarity | 1 | 3 | 3.96e-01 |
| GO:BP | GO:0071711 | basement membrane organization | 2 | 33 | 3.96e-01 |
| GO:BP | GO:0009653 | anatomical structure morphogenesis | 15 | 1974 | 3.96e-01 |
| GO:BP | GO:0098970 | postsynaptic neurotransmitter receptor diffusion trapping | 1 | 4 | 3.96e-01 |
| GO:BP | GO:0045200 | establishment of neuroblast polarity | 1 | 3 | 3.96e-01 |
| GO:BP | GO:0006004 | fucose metabolic process | 1 | 10 | 3.96e-01 |
| GO:BP | GO:0043039 | tRNA aminoacylation | 1 | 43 | 3.96e-01 |
| GO:BP | GO:0099628 | neurotransmitter receptor diffusion trapping | 1 | 4 | 3.96e-01 |
| GO:BP | GO:1903706 | regulation of hemopoiesis | 2 | 279 | 3.97e-01 |
| GO:BP | GO:2000437 | regulation of monocyte extravasation | 1 | 4 | 3.97e-01 |
| GO:BP | GO:0098921 | retrograde trans-synaptic signaling by endocannabinoid | 1 | 4 | 3.97e-01 |
| GO:BP | GO:0098920 | retrograde trans-synaptic signaling by lipid | 1 | 4 | 3.97e-01 |
| GO:BP | GO:1902106 | negative regulation of leukocyte differentiation | 1 | 65 | 3.97e-01 |
| GO:BP | GO:1902617 | response to fluoride | 1 | 4 | 3.97e-01 |
| GO:BP | GO:0099163 | synaptic signaling by nitric oxide | 1 | 3 | 3.97e-01 |
| GO:BP | GO:0038060 | nitric oxide-cGMP-mediated signaling pathway | 1 | 2 | 3.97e-01 |
| GO:BP | GO:0002085 | inhibition of neuroepithelial cell differentiation | 1 | 4 | 3.97e-01 |
| GO:BP | GO:0034067 | protein localization to Golgi apparatus | 2 | 27 | 3.97e-01 |
| GO:BP | GO:0000076 | DNA replication checkpoint signaling | 1 | 15 | 3.97e-01 |
| GO:BP | GO:0016310 | phosphorylation | 49 | 1372 | 3.97e-01 |
| GO:BP | GO:0006521 | regulation of cellular amino acid metabolic process | 1 | 7 | 3.97e-01 |
| GO:BP | GO:0090066 | regulation of anatomical structure size | 9 | 395 | 3.97e-01 |
| GO:BP | GO:0043312 | neutrophil degranulation | 2 | 5 | 3.97e-01 |
| GO:BP | GO:0070265 | necrotic cell death | 2 | 53 | 3.97e-01 |
| GO:BP | GO:1904738 | vascular associated smooth muscle cell migration | 1 | 25 | 3.97e-01 |
| GO:BP | GO:1901678 | iron coordination entity transport | 1 | 11 | 3.97e-01 |
| GO:BP | GO:0090278 | negative regulation of peptide hormone secretion | 2 | 30 | 3.97e-01 |
| GO:BP | GO:0050709 | negative regulation of protein secretion | 3 | 44 | 3.97e-01 |
| GO:BP | GO:0002791 | regulation of peptide secretion | 6 | 134 | 3.97e-01 |
| GO:BP | GO:0006346 | DNA methylation-dependent heterochromatin formation | 1 | 22 | 3.97e-01 |
| GO:BP | GO:0009251 | glucan catabolic process | 1 | 14 | 3.97e-01 |
| GO:BP | GO:1902548 | negative regulation of cellular response to vascular endothelial growth factor stimulus | 2 | 9 | 3.97e-01 |
| GO:BP | GO:0010875 | positive regulation of cholesterol efflux | 1 | 23 | 3.97e-01 |
| GO:BP | GO:0014912 | negative regulation of smooth muscle cell migration | 1 | 25 | 3.97e-01 |
| GO:BP | GO:0015749 | monosaccharide transmembrane transport | 7 | 85 | 3.97e-01 |
| GO:BP | GO:0099518 | vesicle cytoskeletal trafficking | 3 | 60 | 3.98e-01 |
| GO:BP | GO:0021894 | cerebral cortex GABAergic interneuron development | 1 | 3 | 3.98e-01 |
| GO:BP | GO:0006929 | substrate-dependent cell migration | 3 | 24 | 3.98e-01 |
| GO:BP | GO:0016024 | CDP-diacylglycerol biosynthetic process | 2 | 12 | 3.98e-01 |
| GO:BP | GO:0050657 | nucleic acid transport | 7 | 144 | 3.98e-01 |
| GO:BP | GO:0050658 | RNA transport | 7 | 144 | 3.98e-01 |
| GO:BP | GO:0007091 | metaphase/anaphase transition of mitotic cell cycle | 1 | 91 | 3.98e-01 |
| GO:BP | GO:1902099 | regulation of metaphase/anaphase transition of cell cycle | 1 | 89 | 3.98e-01 |
| GO:BP | GO:0051973 | positive regulation of telomerase activity | 1 | 31 | 3.98e-01 |
| GO:BP | GO:0060546 | negative regulation of necroptotic process | 1 | 16 | 3.98e-01 |
| GO:BP | GO:0048210 | Golgi vesicle fusion to target membrane | 1 | 4 | 3.98e-01 |
| GO:BP | GO:0060992 | response to fungicide | 1 | 4 | 3.98e-01 |
| GO:BP | GO:0038065 | collagen-activated signaling pathway | 2 | 13 | 3.98e-01 |
| GO:BP | GO:0043038 | amino acid activation | 1 | 44 | 3.98e-01 |
| GO:BP | GO:0072107 | positive regulation of ureteric bud formation | 1 | 2 | 3.99e-01 |
| GO:BP | GO:1905954 | positive regulation of lipid localization | 1 | 75 | 3.99e-01 |
| GO:BP | GO:0030217 | T cell differentiation | 19 | 185 | 3.99e-01 |
| GO:BP | GO:0051261 | protein depolymerization | 4 | 105 | 3.99e-01 |
| GO:BP | GO:0072106 | regulation of ureteric bud formation | 1 | 2 | 3.99e-01 |
| GO:BP | GO:0010533 | regulation of activation of Janus kinase activity | 1 | 3 | 3.99e-01 |
| GO:BP | GO:0016233 | telomere capping | 4 | 36 | 3.99e-01 |
| GO:BP | GO:0031670 | cellular response to nutrient | 1 | 31 | 3.99e-01 |
| GO:BP | GO:0032000 | positive regulation of fatty acid beta-oxidation | 1 | 9 | 3.99e-01 |
| GO:BP | GO:0071865 | regulation of apoptotic process in bone marrow cell | 1 | 3 | 3.99e-01 |
| GO:BP | GO:0045740 | positive regulation of DNA replication | 1 | 35 | 3.99e-01 |
| GO:BP | GO:0071866 | negative regulation of apoptotic process in bone marrow cell | 1 | 3 | 3.99e-01 |
| GO:BP | GO:0071396 | cellular response to lipid | 3 | 398 | 3.99e-01 |
| GO:BP | GO:0023057 | negative regulation of signaling | 1 | 1076 | 3.99e-01 |
| GO:BP | GO:0060382 | regulation of DNA strand elongation | 2 | 16 | 3.99e-01 |
| GO:BP | GO:0009225 | nucleotide-sugar metabolic process | 4 | 35 | 3.99e-01 |
| GO:BP | GO:0051301 | cell division | 3 | 570 | 3.99e-01 |
| GO:BP | GO:0006351 | DNA-templated transcription | 12 | 2683 | 3.99e-01 |
| GO:BP | GO:0010648 | negative regulation of cell communication | 1 | 1074 | 3.99e-01 |
| GO:BP | GO:0098693 | regulation of synaptic vesicle cycle | 2 | 13 | 3.99e-01 |
| GO:BP | GO:0042759 | long-chain fatty acid biosynthetic process | 1 | 14 | 3.99e-01 |
| GO:BP | GO:0097659 | nucleic acid-templated transcription | 12 | 2684 | 3.99e-01 |
| GO:BP | GO:0034655 | nucleobase-containing compound catabolic process | 2 | 358 | 3.99e-01 |
| GO:BP | GO:0002381 | immunoglobulin production involved in immunoglobulin-mediated immune response | 3 | 41 | 3.99e-01 |
| GO:BP | GO:0060425 | lung morphogenesis | 4 | 38 | 3.99e-01 |
| GO:BP | GO:0030901 | midbrain development | 2 | 69 | 3.99e-01 |
| GO:BP | GO:0003105 | negative regulation of glomerular filtration | 1 | 3 | 3.99e-01 |
| GO:BP | GO:0006893 | Golgi to plasma membrane transport | 4 | 60 | 3.99e-01 |
| GO:BP | GO:0016485 | protein processing | 4 | 183 | 4.00e-01 |
| GO:BP | GO:0035507 | regulation of myosin-light-chain-phosphatase activity | 1 | 5 | 4.00e-01 |
| GO:BP | GO:0090521 | podocyte cell migration | 1 | 7 | 4.00e-01 |
| GO:BP | GO:0010800 | positive regulation of peptidyl-threonine phosphorylation | 2 | 23 | 4.00e-01 |
| GO:BP | GO:0019098 | reproductive behavior | 1 | 26 | 4.00e-01 |
| GO:BP | GO:0051383 | kinetochore organization | 3 | 23 | 4.00e-01 |
| GO:BP | GO:0006924 | activation-induced cell death of T cells | 1 | 8 | 4.00e-01 |
| GO:BP | GO:0060326 | cell chemotaxis | 1 | 162 | 4.00e-01 |
| GO:BP | GO:0046949 | fatty-acyl-CoA biosynthetic process | 3 | 20 | 4.00e-01 |
| GO:BP | GO:1903707 | negative regulation of hemopoiesis | 1 | 69 | 4.01e-01 |
| GO:BP | GO:0039533 | regulation of MDA-5 signaling pathway | 1 | 5 | 4.01e-01 |
| GO:BP | GO:0071320 | cellular response to cAMP | 2 | 41 | 4.01e-01 |
| GO:BP | GO:1900164 | nodal signaling pathway involved in determination of lateral mesoderm left/right asymmetry | 1 | 3 | 4.01e-01 |
| GO:BP | GO:0032465 | regulation of cytokinesis | 1 | 79 | 4.01e-01 |
| GO:BP | GO:0090087 | regulation of peptide transport | 6 | 136 | 4.01e-01 |
| GO:BP | GO:0035634 | response to stilbenoid | 1 | 2 | 4.01e-01 |
| GO:BP | GO:0032652 | regulation of interleukin-1 production | 1 | 56 | 4.01e-01 |
| GO:BP | GO:0032612 | interleukin-1 production | 1 | 56 | 4.01e-01 |
| GO:BP | GO:1901019 | regulation of calcium ion transmembrane transporter activity | 2 | 71 | 4.01e-01 |
| GO:BP | GO:0048873 | homeostasis of number of cells within a tissue | 1 | 24 | 4.01e-01 |
| GO:BP | GO:0038107 | nodal signaling pathway involved in determination of left/right asymmetry | 1 | 3 | 4.01e-01 |
| GO:BP | GO:0006749 | glutathione metabolic process | 1 | 41 | 4.01e-01 |
| GO:BP | GO:0045050 | protein insertion into ER membrane by stop-transfer membrane-anchor sequence | 1 | 10 | 4.01e-01 |
| GO:BP | GO:0071139 | resolution of recombination intermediates | 1 | 6 | 4.01e-01 |
| GO:BP | GO:0006298 | mismatch repair | 3 | 29 | 4.01e-01 |
| GO:BP | GO:0044784 | metaphase/anaphase transition of cell cycle | 1 | 92 | 4.01e-01 |
| GO:BP | GO:0002792 | negative regulation of peptide secretion | 2 | 31 | 4.01e-01 |
| GO:BP | GO:0033993 | response to lipid | 4 | 592 | 4.01e-01 |
| GO:BP | GO:2001251 | negative regulation of chromosome organization | 1 | 90 | 4.01e-01 |
| GO:BP | GO:0000301 | retrograde transport, vesicle recycling within Golgi | 1 | 9 | 4.01e-01 |
| GO:BP | GO:1902903 | regulation of supramolecular fiber organization | 11 | 326 | 4.01e-01 |
| GO:BP | GO:0006884 | cell volume homeostasis | 2 | 24 | 4.01e-01 |
| GO:BP | GO:0051239 | regulation of multicellular organismal process | 6 | 2035 | 4.01e-01 |
| GO:BP | GO:0060760 | positive regulation of response to cytokine stimulus | 4 | 49 | 4.01e-01 |
| GO:BP | GO:0032786 | positive regulation of DNA-templated transcription, elongation | 4 | 58 | 4.01e-01 |
| GO:BP | GO:0001880 | Mullerian duct regression | 1 | 4 | 4.02e-01 |
| GO:BP | GO:1902044 | regulation of Fas signaling pathway | 1 | 4 | 4.02e-01 |
| GO:BP | GO:0001523 | retinoid metabolic process | 1 | 40 | 4.02e-01 |
| GO:BP | GO:0010822 | positive regulation of mitochondrion organization | 2 | 68 | 4.02e-01 |
| GO:BP | GO:0140331 | aminophospholipid translocation | 1 | 6 | 4.02e-01 |
| GO:BP | GO:0045184 | establishment of protein localization | 3 | 1462 | 4.03e-01 |
| GO:BP | GO:0010629 | negative regulation of gene expression | 5 | 785 | 4.03e-01 |
| GO:BP | GO:0031342 | negative regulation of cell killing | 1 | 11 | 4.03e-01 |
| GO:BP | GO:0048663 | neuron fate commitment | 1 | 29 | 4.03e-01 |
| GO:BP | GO:0002710 | negative regulation of T cell mediated immunity | 1 | 8 | 4.03e-01 |
| GO:BP | GO:0001826 | inner cell mass cell differentiation | 1 | 5 | 4.03e-01 |
| GO:BP | GO:0006302 | double-strand break repair | 18 | 271 | 4.03e-01 |
| GO:BP | GO:0032757 | positive regulation of interleukin-8 production | 1 | 31 | 4.03e-01 |
| GO:BP | GO:0036065 | fucosylation | 1 | 10 | 4.03e-01 |
| GO:BP | GO:0006778 | porphyrin-containing compound metabolic process | 3 | 44 | 4.03e-01 |
| GO:BP | GO:0070371 | ERK1 and ERK2 cascade | 1 | 211 | 4.03e-01 |
| GO:BP | GO:1902564 | negative regulation of neutrophil activation | 1 | 2 | 4.03e-01 |
| GO:BP | GO:0006740 | NADPH regeneration | 2 | 22 | 4.03e-01 |
| GO:BP | GO:1903236 | regulation of leukocyte tethering or rolling | 1 | 6 | 4.03e-01 |
| GO:BP | GO:0070141 | response to UV-A | 2 | 11 | 4.03e-01 |
| GO:BP | GO:0060669 | embryonic placenta morphogenesis | 3 | 22 | 4.04e-01 |
| GO:BP | GO:0060055 | angiogenesis involved in wound healing | 1 | 25 | 4.04e-01 |
| GO:BP | GO:0042098 | T cell proliferation | 4 | 120 | 4.04e-01 |
| GO:BP | GO:1903046 | meiotic cell cycle process | 12 | 135 | 4.04e-01 |
| GO:BP | GO:0031589 | cell-substrate adhesion | 1 | 281 | 4.04e-01 |
| GO:BP | GO:0030853 | negative regulation of granulocyte differentiation | 1 | 6 | 4.04e-01 |
| GO:BP | GO:1990403 | embryonic brain development | 2 | 13 | 4.04e-01 |
| GO:BP | GO:0060426 | lung vasculature development | 1 | 3 | 4.04e-01 |
| GO:BP | GO:0002822 | regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 3 | 97 | 4.04e-01 |
| GO:BP | GO:0045606 | positive regulation of epidermal cell differentiation | 1 | 16 | 4.04e-01 |
| GO:BP | GO:1905691 | lipid droplet disassembly | 1 | 7 | 4.04e-01 |
| GO:BP | GO:0009914 | hormone transport | 5 | 215 | 4.05e-01 |
| GO:BP | GO:0042127 | regulation of cell population proliferation | 25 | 1147 | 4.05e-01 |
| GO:BP | GO:0070664 | negative regulation of leukocyte proliferation | 2 | 51 | 4.05e-01 |
| GO:BP | GO:1901264 | carbohydrate derivative transport | 1 | 63 | 4.05e-01 |
| GO:BP | GO:0046813 | receptor-mediated virion attachment to host cell | 1 | 6 | 4.05e-01 |
| GO:BP | GO:0098597 | observational learning | 1 | 5 | 4.05e-01 |
| GO:BP | GO:0015833 | peptide transport | 4 | 179 | 4.05e-01 |
| GO:BP | GO:0060022 | hard palate development | 1 | 5 | 4.05e-01 |
| GO:BP | GO:0032675 | regulation of interleukin-6 production | 2 | 86 | 4.05e-01 |
| GO:BP | GO:0009092 | homoserine metabolic process | 1 | 5 | 4.05e-01 |
| GO:BP | GO:2000821 | regulation of grooming behavior | 1 | 3 | 4.05e-01 |
| GO:BP | GO:0070813 | hydrogen sulfide metabolic process | 1 | 5 | 4.05e-01 |
| GO:BP | GO:0030501 | positive regulation of bone mineralization | 3 | 34 | 4.05e-01 |
| GO:BP | GO:0071425 | hematopoietic stem cell proliferation | 2 | 29 | 4.05e-01 |
| GO:BP | GO:0034097 | response to cytokine | 5 | 607 | 4.05e-01 |
| GO:BP | GO:0019346 | transsulfuration | 1 | 5 | 4.05e-01 |
| GO:BP | GO:0032635 | interleukin-6 production | 2 | 86 | 4.05e-01 |
| GO:BP | GO:0062099 | negative regulation of programmed necrotic cell death | 1 | 17 | 4.05e-01 |
| GO:BP | GO:0006446 | regulation of translational initiation | 6 | 73 | 4.06e-01 |
| GO:BP | GO:0043620 | regulation of DNA-templated transcription in response to stress | 1 | 41 | 4.06e-01 |
| GO:BP | GO:0000959 | mitochondrial RNA metabolic process | 1 | 50 | 4.06e-01 |
| GO:BP | GO:0030473 | nuclear migration along microtubule | 1 | 5 | 4.06e-01 |
| GO:BP | GO:0031960 | response to corticosteroid | 1 | 109 | 4.06e-01 |
| GO:BP | GO:0043086 | negative regulation of catalytic activity | 17 | 478 | 4.07e-01 |
| GO:BP | GO:0045987 | positive regulation of smooth muscle contraction | 3 | 17 | 4.07e-01 |
| GO:BP | GO:0051236 | establishment of RNA localization | 7 | 147 | 4.07e-01 |
| GO:BP | GO:0018401 | peptidyl-proline hydroxylation to 4-hydroxy-L-proline | 1 | 9 | 4.07e-01 |
| GO:BP | GO:1900078 | positive regulation of cellular response to insulin stimulus | 1 | 23 | 4.07e-01 |
| GO:BP | GO:0016101 | diterpenoid metabolic process | 1 | 43 | 4.07e-01 |
| GO:BP | GO:0034982 | mitochondrial protein processing | 1 | 12 | 4.07e-01 |
| GO:BP | GO:0120009 | intermembrane lipid transfer | 3 | 43 | 4.07e-01 |
| GO:BP | GO:0002429 | immune response-activating cell surface receptor signaling pathway | 2 | 151 | 4.07e-01 |
| GO:BP | GO:0000266 | mitochondrial fission | 4 | 38 | 4.07e-01 |
| GO:BP | GO:0032774 | RNA biosynthetic process | 12 | 2714 | 4.07e-01 |
| GO:BP | GO:0051293 | establishment of spindle localization | 5 | 48 | 4.07e-01 |
| GO:BP | GO:0050918 | positive chemotaxis | 1 | 40 | 4.07e-01 |
| GO:BP | GO:2001016 | positive regulation of skeletal muscle cell differentiation | 1 | 5 | 4.08e-01 |
| GO:BP | GO:0090169 | regulation of spindle assembly | 1 | 32 | 4.08e-01 |
| GO:BP | GO:0032958 | inositol phosphate biosynthetic process | 1 | 19 | 4.08e-01 |
| GO:BP | GO:0035710 | CD4-positive, alpha-beta T cell activation | 1 | 64 | 4.08e-01 |
| GO:BP | GO:0060136 | embryonic process involved in female pregnancy | 1 | 6 | 4.08e-01 |
| GO:BP | GO:0001779 | natural killer cell differentiation | 2 | 18 | 4.08e-01 |
| GO:BP | GO:0052547 | regulation of peptidase activity | 14 | 271 | 4.08e-01 |
| GO:BP | GO:0006766 | vitamin metabolic process | 1 | 73 | 4.09e-01 |
| GO:BP | GO:0051939 | gamma-aminobutyric acid import | 1 | 3 | 4.09e-01 |
| GO:BP | GO:0006096 | glycolytic process | 8 | 70 | 4.09e-01 |
| GO:BP | GO:0106027 | neuron projection organization | 1 | 76 | 4.09e-01 |
| GO:BP | GO:0050435 | amyloid-beta metabolic process | 3 | 48 | 4.10e-01 |
| GO:BP | GO:0021696 | cerebellar cortex morphogenesis | 4 | 30 | 4.10e-01 |
| GO:BP | GO:0009052 | pentose-phosphate shunt, non-oxidative branch | 1 | 6 | 4.10e-01 |
| GO:BP | GO:0140013 | meiotic nuclear division | 11 | 120 | 4.10e-01 |
| GO:BP | GO:0002286 | T cell activation involved in immune response | 1 | 55 | 4.10e-01 |
| GO:BP | GO:0034968 | histone lysine methylation | 2 | 89 | 4.10e-01 |
| GO:BP | GO:0072178 | nephric duct morphogenesis | 1 | 8 | 4.10e-01 |
| GO:BP | GO:0031529 | ruffle organization | 3 | 45 | 4.10e-01 |
| GO:BP | GO:0014070 | response to organic cyclic compound | 4 | 640 | 4.10e-01 |
| GO:BP | GO:0070199 | establishment of protein localization to chromosome | 1 | 25 | 4.10e-01 |
| GO:BP | GO:0006000 | fructose metabolic process | 2 | 10 | 4.11e-01 |
| GO:BP | GO:0045779 | negative regulation of bone resorption | 1 | 7 | 4.11e-01 |
| GO:BP | GO:0046967 | cytosol to endoplasmic reticulum transport | 1 | 4 | 4.11e-01 |
| GO:BP | GO:0006289 | nucleotide-excision repair | 6 | 79 | 4.11e-01 |
| GO:BP | GO:0010863 | positive regulation of phospholipase C activity | 4 | 18 | 4.11e-01 |
| GO:BP | GO:0002328 | pro-B cell differentiation | 1 | 10 | 4.11e-01 |
| GO:BP | GO:0071495 | cellular response to endogenous stimulus | 1 | 1107 | 4.11e-01 |
| GO:BP | GO:0051702 | biological process involved in interaction with symbiont | 1 | 78 | 4.11e-01 |
| GO:BP | GO:0098780 | response to mitochondrial depolarisation | 1 | 21 | 4.11e-01 |
| GO:BP | GO:0014829 | vascular associated smooth muscle contraction | 1 | 20 | 4.11e-01 |
| GO:BP | GO:0014033 | neural crest cell differentiation | 8 | 80 | 4.11e-01 |
| GO:BP | GO:0031328 | positive regulation of cellular biosynthetic process | 6 | 1564 | 4.11e-01 |
| GO:BP | GO:0032197 | retrotransposition | 1 | 4 | 4.11e-01 |
| GO:BP | GO:0070346 | positive regulation of fat cell proliferation | 1 | 3 | 4.11e-01 |
| GO:BP | GO:0071389 | cellular response to mineralocorticoid stimulus | 1 | 9 | 4.12e-01 |
| GO:BP | GO:1903539 | protein localization to postsynaptic membrane | 2 | 38 | 4.12e-01 |
| GO:BP | GO:0006826 | iron ion transport | 2 | 40 | 4.12e-01 |
| GO:BP | GO:0021513 | spinal cord dorsal/ventral patterning | 2 | 7 | 4.12e-01 |
| GO:BP | GO:0007418 | ventral midline development | 1 | 4 | 4.13e-01 |
| GO:BP | GO:0001754 | eye photoreceptor cell differentiation | 3 | 30 | 4.13e-01 |
| GO:BP | GO:1901381 | positive regulation of potassium ion transmembrane transport | 1 | 30 | 4.13e-01 |
| GO:BP | GO:0021910 | smoothened signaling pathway involved in ventral spinal cord patterning | 1 | 5 | 4.13e-01 |
| GO:BP | GO:0002698 | negative regulation of immune effector process | 1 | 59 | 4.13e-01 |
| GO:BP | GO:0046632 | alpha-beta T cell differentiation | 1 | 67 | 4.13e-01 |
| GO:BP | GO:0043201 | response to leucine | 2 | 13 | 4.13e-01 |
| GO:BP | GO:0035307 | positive regulation of protein dephosphorylation | 2 | 36 | 4.13e-01 |
| GO:BP | GO:1990000 | amyloid fibril formation | 2 | 35 | 4.13e-01 |
| GO:BP | GO:0046500 | S-adenosylmethionine metabolic process | 2 | 13 | 4.13e-01 |
| GO:BP | GO:0044255 | cellular lipid metabolic process | 1 | 740 | 4.14e-01 |
| GO:BP | GO:0039532 | negative regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway | 2 | 17 | 4.14e-01 |
| GO:BP | GO:0045123 | cellular extravasation | 5 | 44 | 4.14e-01 |
| GO:BP | GO:0000272 | polysaccharide catabolic process | 1 | 14 | 4.14e-01 |
| GO:BP | GO:0032956 | regulation of actin cytoskeleton organization | 14 | 299 | 4.14e-01 |
| GO:BP | GO:0060339 | negative regulation of type I interferon-mediated signaling pathway | 2 | 15 | 4.14e-01 |
| GO:BP | GO:0090230 | regulation of centromere complex assembly | 1 | 4 | 4.14e-01 |
| GO:BP | GO:0031400 | negative regulation of protein modification process | 6 | 418 | 4.14e-01 |
| GO:BP | GO:0009566 | fertilization | 1 | 93 | 4.14e-01 |
| GO:BP | GO:0008295 | spermidine biosynthetic process | 1 | 3 | 4.14e-01 |
| GO:BP | GO:2001239 | regulation of extrinsic apoptotic signaling pathway in absence of ligand | 4 | 35 | 4.14e-01 |
| GO:BP | GO:0033045 | regulation of sister chromatid segregation | 1 | 99 | 4.14e-01 |
| GO:BP | GO:0050870 | positive regulation of T cell activation | 8 | 144 | 4.14e-01 |
| GO:BP | GO:0007176 | regulation of epidermal growth factor-activated receptor activity | 3 | 24 | 4.14e-01 |
| GO:BP | GO:0048496 | maintenance of animal organ identity | 1 | 4 | 4.14e-01 |
| GO:BP | GO:0140052 | cellular response to oxidised low-density lipoprotein particle stimulus | 1 | 7 | 4.14e-01 |
| GO:BP | GO:0097012 | response to granulocyte macrophage colony-stimulating factor | 1 | 6 | 4.14e-01 |
| GO:BP | GO:0070673 | response to interleukin-18 | 1 | 5 | 4.14e-01 |
| GO:BP | GO:0010918 | positive regulation of mitochondrial membrane potential | 1 | 9 | 4.14e-01 |
| GO:BP | GO:0030518 | intracellular steroid hormone receptor signaling pathway | 1 | 95 | 4.14e-01 |
| GO:BP | GO:0097011 | cellular response to granulocyte macrophage colony-stimulating factor stimulus | 1 | 6 | 4.14e-01 |
| GO:BP | GO:1990416 | cellular response to brain-derived neurotrophic factor stimulus | 1 | 8 | 4.15e-01 |
| GO:BP | GO:0071732 | cellular response to nitric oxide | 2 | 14 | 4.15e-01 |
| GO:BP | GO:0042304 | regulation of fatty acid biosynthetic process | 4 | 30 | 4.15e-01 |
| GO:BP | GO:0045637 | regulation of myeloid cell differentiation | 1 | 152 | 4.15e-01 |
| GO:BP | GO:1990778 | protein localization to cell periphery | 1 | 300 | 4.15e-01 |
| GO:BP | GO:0034614 | cellular response to reactive oxygen species | 11 | 121 | 4.15e-01 |
| GO:BP | GO:0007614 | short-term memory | 1 | 9 | 4.15e-01 |
| GO:BP | GO:0010463 | mesenchymal cell proliferation | 2 | 35 | 4.15e-01 |
| GO:BP | GO:0048169 | regulation of long-term neuronal synaptic plasticity | 1 | 20 | 4.15e-01 |
| GO:BP | GO:0097252 | oligodendrocyte apoptotic process | 1 | 4 | 4.15e-01 |
| GO:BP | GO:2001235 | positive regulation of apoptotic signaling pathway | 3 | 108 | 4.15e-01 |
| GO:BP | GO:0000302 | response to reactive oxygen species | 15 | 160 | 4.15e-01 |
| GO:BP | GO:0045830 | positive regulation of isotype switching | 1 | 19 | 4.15e-01 |
| GO:BP | GO:0042445 | hormone metabolic process | 1 | 133 | 4.15e-01 |
| GO:BP | GO:0001933 | negative regulation of protein phosphorylation | 10 | 277 | 4.15e-01 |
| GO:BP | GO:0022412 | cellular process involved in reproduction in multicellular organism | 3 | 252 | 4.15e-01 |
| GO:BP | GO:1904772 | response to tetrachloromethane | 1 | 4 | 4.16e-01 |
| GO:BP | GO:0009247 | glycolipid biosynthetic process | 2 | 61 | 4.16e-01 |
| GO:BP | GO:0099054 | presynapse assembly | 4 | 39 | 4.16e-01 |
| GO:BP | GO:0071230 | cellular response to amino acid stimulus | 7 | 65 | 4.16e-01 |
| GO:BP | GO:0035590 | purinergic nucleotide receptor signaling pathway | 3 | 16 | 4.16e-01 |
| GO:BP | GO:0030240 | skeletal muscle thin filament assembly | 1 | 6 | 4.16e-01 |
| GO:BP | GO:0006930 | substrate-dependent cell migration, cell extension | 1 | 8 | 4.16e-01 |
| GO:BP | GO:0048549 | positive regulation of pinocytosis | 1 | 7 | 4.16e-01 |
| GO:BP | GO:0007224 | smoothened signaling pathway | 10 | 124 | 4.16e-01 |
| GO:BP | GO:0006482 | protein demethylation | 1 | 27 | 4.16e-01 |
| GO:BP | GO:0008214 | protein dealkylation | 1 | 27 | 4.16e-01 |
| GO:BP | GO:0014041 | regulation of neuron maturation | 1 | 6 | 4.17e-01 |
| GO:BP | GO:0050882 | voluntary musculoskeletal movement | 1 | 7 | 4.17e-01 |
| GO:BP | GO:0072009 | nephron epithelium development | 1 | 86 | 4.17e-01 |
| GO:BP | GO:0062237 | protein localization to postsynapse | 2 | 39 | 4.17e-01 |
| GO:BP | GO:1990414 | replication-born double-strand break repair via sister chromatid exchange | 1 | 5 | 4.17e-01 |
| GO:BP | GO:0090314 | positive regulation of protein targeting to membrane | 2 | 22 | 4.17e-01 |
| GO:BP | GO:0002181 | cytoplasmic translation | 2 | 156 | 4.18e-01 |
| GO:BP | GO:0034244 | negative regulation of transcription elongation by RNA polymerase II | 2 | 17 | 4.18e-01 |
| GO:BP | GO:0051447 | negative regulation of meiotic cell cycle | 2 | 9 | 4.18e-01 |
| GO:BP | GO:0048709 | oligodendrocyte differentiation | 1 | 68 | 4.18e-01 |
| GO:BP | GO:0051150 | regulation of smooth muscle cell differentiation | 1 | 28 | 4.18e-01 |
| GO:BP | GO:0045935 | positive regulation of nucleobase-containing compound metabolic process | 4 | 1602 | 4.18e-01 |
| GO:BP | GO:0032570 | response to progesterone | 3 | 27 | 4.18e-01 |
| GO:BP | GO:0002861 | regulation of inflammatory response to antigenic stimulus | 4 | 24 | 4.19e-01 |
| GO:BP | GO:0051788 | response to misfolded protein | 3 | 25 | 4.19e-01 |
| GO:BP | GO:0033137 | negative regulation of peptidyl-serine phosphorylation | 1 | 26 | 4.19e-01 |
| GO:BP | GO:0032816 | positive regulation of natural killer cell activation | 2 | 16 | 4.19e-01 |
| GO:BP | GO:0009967 | positive regulation of signal transduction | 1 | 1133 | 4.19e-01 |
| GO:BP | GO:0098868 | bone growth | 2 | 24 | 4.19e-01 |
| GO:BP | GO:0097205 | renal filtration | 3 | 23 | 4.19e-01 |
| GO:BP | GO:0035640 | exploration behavior | 2 | 21 | 4.19e-01 |
| GO:BP | GO:1901166 | neural crest cell migration involved in autonomic nervous system development | 1 | 5 | 4.19e-01 |
| GO:BP | GO:0007632 | visual behavior | 5 | 41 | 4.19e-01 |
| GO:BP | GO:0009311 | oligosaccharide metabolic process | 2 | 43 | 4.20e-01 |
| GO:BP | GO:0010605 | negative regulation of macromolecule metabolic process | 4 | 2135 | 4.20e-01 |
| GO:BP | GO:0097320 | plasma membrane tubulation | 2 | 18 | 4.20e-01 |
| GO:BP | GO:0033523 | histone H2B ubiquitination | 1 | 10 | 4.20e-01 |
| GO:BP | GO:0006825 | copper ion transport | 1 | 13 | 4.20e-01 |
| GO:BP | GO:2000696 | regulation of epithelial cell differentiation involved in kidney development | 2 | 12 | 4.20e-01 |
| GO:BP | GO:0060718 | chorionic trophoblast cell differentiation | 1 | 5 | 4.20e-01 |
| GO:BP | GO:0036493 | positive regulation of translation in response to endoplasmic reticulum stress | 1 | 5 | 4.20e-01 |
| GO:BP | GO:0019079 | viral genome replication | 1 | 101 | 4.20e-01 |
| GO:BP | GO:0048661 | positive regulation of smooth muscle cell proliferation | 4 | 63 | 4.21e-01 |
| GO:BP | GO:1900223 | positive regulation of amyloid-beta clearance | 1 | 5 | 4.21e-01 |
| GO:BP | GO:0043248 | proteasome assembly | 1 | 13 | 4.21e-01 |
| GO:BP | GO:0003413 | chondrocyte differentiation involved in endochondral bone morphogenesis | 1 | 12 | 4.21e-01 |
| GO:BP | GO:0019886 | antigen processing and presentation of exogenous peptide antigen via MHC class II | 3 | 15 | 4.22e-01 |
| GO:BP | GO:0048296 | regulation of isotype switching to IgA isotypes | 1 | 4 | 4.22e-01 |
| GO:BP | GO:0015908 | fatty acid transport | 1 | 58 | 4.22e-01 |
| GO:BP | GO:0010452 | histone H3-K36 methylation | 1 | 5 | 4.22e-01 |
| GO:BP | GO:0003289 | atrial septum primum morphogenesis | 1 | 5 | 4.22e-01 |
| GO:BP | GO:1900107 | regulation of nodal signaling pathway | 1 | 3 | 4.22e-01 |
| GO:BP | GO:0003140 | determination of left/right asymmetry in lateral mesoderm | 1 | 4 | 4.22e-01 |
| GO:BP | GO:0002836 | positive regulation of response to tumor cell | 2 | 7 | 4.22e-01 |
| GO:BP | GO:2000097 | regulation of smooth muscle cell-matrix adhesion | 1 | 3 | 4.22e-01 |
| GO:BP | GO:0002839 | positive regulation of immune response to tumor cell | 2 | 7 | 4.22e-01 |
| GO:BP | GO:0042981 | regulation of apoptotic process | 51 | 1088 | 4.22e-01 |
| GO:BP | GO:0032927 | positive regulation of activin receptor signaling pathway | 1 | 7 | 4.22e-01 |
| GO:BP | GO:0003284 | septum primum development | 1 | 5 | 4.22e-01 |
| GO:BP | GO:0071350 | cellular response to interleukin-15 | 1 | 2 | 4.23e-01 |
| GO:BP | GO:0007159 | leukocyte cell-cell adhesion | 12 | 234 | 4.23e-01 |
| GO:BP | GO:0032811 | negative regulation of epinephrine secretion | 1 | 2 | 4.23e-01 |
| GO:BP | GO:0044270 | cellular nitrogen compound catabolic process | 2 | 378 | 4.23e-01 |
| GO:BP | GO:0035723 | interleukin-15-mediated signaling pathway | 1 | 2 | 4.23e-01 |
| GO:BP | GO:0046785 | microtubule polymerization | 3 | 84 | 4.23e-01 |
| GO:BP | GO:0120305 | regulation of pigmentation | 1 | 11 | 4.23e-01 |
| GO:BP | GO:1905209 | positive regulation of cardiocyte differentiation | 1 | 11 | 4.23e-01 |
| GO:BP | GO:0016447 | somatic recombination of immunoglobulin gene segments | 3 | 47 | 4.23e-01 |
| GO:BP | GO:1902230 | negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage | 1 | 29 | 4.23e-01 |
| GO:BP | GO:0098532 | histone H3-K27 trimethylation | 1 | 4 | 4.23e-01 |
| GO:BP | GO:0097306 | cellular response to alcohol | 1 | 70 | 4.23e-01 |
| GO:BP | GO:0046700 | heterocycle catabolic process | 2 | 381 | 4.23e-01 |
| GO:BP | GO:0072012 | glomerulus vasculature development | 1 | 22 | 4.23e-01 |
| GO:BP | GO:0009615 | response to virus | 8 | 275 | 4.23e-01 |
| GO:BP | GO:0120161 | regulation of cold-induced thermogenesis | 2 | 112 | 4.23e-01 |
| GO:BP | GO:0003206 | cardiac chamber morphogenesis | 1 | 109 | 4.23e-01 |
| GO:BP | GO:0032880 | regulation of protein localization | 10 | 710 | 4.23e-01 |
| GO:BP | GO:0085029 | extracellular matrix assembly | 2 | 41 | 4.23e-01 |
| GO:BP | GO:0006772 | thiamine metabolic process | 1 | 2 | 4.23e-01 |
| GO:BP | GO:2000781 | positive regulation of double-strand break repair | 6 | 79 | 4.23e-01 |
| GO:BP | GO:0050962 | detection of light stimulus involved in sensory perception | 1 | 9 | 4.23e-01 |
| GO:BP | GO:0071349 | cellular response to interleukin-12 | 1 | 5 | 4.23e-01 |
| GO:BP | GO:0048070 | regulation of developmental pigmentation | 1 | 11 | 4.23e-01 |
| GO:BP | GO:0090427 | activation of meiosis | 1 | 4 | 4.23e-01 |
| GO:BP | GO:2000108 | positive regulation of leukocyte apoptotic process | 1 | 18 | 4.23e-01 |
| GO:BP | GO:0031398 | positive regulation of protein ubiquitination | 10 | 108 | 4.23e-01 |
| GO:BP | GO:0008361 | regulation of cell size | 7 | 159 | 4.23e-01 |
| GO:BP | GO:0008315 | G2/MI transition of meiotic cell cycle | 1 | 5 | 4.23e-01 |
| GO:BP | GO:2001225 | regulation of chloride transport | 1 | 4 | 4.23e-01 |
| GO:BP | GO:0000819 | sister chromatid segregation | 6 | 217 | 4.23e-01 |
| GO:BP | GO:0010700 | negative regulation of norepinephrine secretion | 1 | 2 | 4.23e-01 |
| GO:BP | GO:0050908 | detection of light stimulus involved in visual perception | 1 | 9 | 4.23e-01 |
| GO:BP | GO:0044703 | multi-organism reproductive process | 9 | 131 | 4.23e-01 |
| GO:BP | GO:0035234 | ectopic germ cell programmed cell death | 2 | 11 | 4.23e-01 |
| GO:BP | GO:0009150 | purine ribonucleotide metabolic process | 1 | 295 | 4.23e-01 |
| GO:BP | GO:0006312 | mitotic recombination | 2 | 22 | 4.23e-01 |
| GO:BP | GO:0035791 | platelet-derived growth factor receptor-beta signaling pathway | 2 | 15 | 4.23e-01 |
| GO:BP | GO:0035304 | regulation of protein dephosphorylation | 3 | 75 | 4.23e-01 |
| GO:BP | GO:1903201 | regulation of oxidative stress-induced cell death | 3 | 56 | 4.23e-01 |
| GO:BP | GO:0006691 | leukotriene metabolic process | 1 | 12 | 4.23e-01 |
| GO:BP | GO:0010639 | negative regulation of organelle organization | 3 | 318 | 4.23e-01 |
| GO:BP | GO:0061909 | autophagosome-lysosome fusion | 1 | 8 | 4.23e-01 |
| GO:BP | GO:0106106 | cold-induced thermogenesis | 2 | 113 | 4.23e-01 |
| GO:BP | GO:0034654 | nucleobase-containing compound biosynthetic process | 13 | 3070 | 4.23e-01 |
| GO:BP | GO:0018108 | peptidyl-tyrosine phosphorylation | 1 | 256 | 4.24e-01 |
| GO:BP | GO:0009891 | positive regulation of biosynthetic process | 4 | 1604 | 4.24e-01 |
| GO:BP | GO:1904306 | positive regulation of gastro-intestinal system smooth muscle contraction | 1 | 1 | 4.24e-01 |
| GO:BP | GO:1904304 | regulation of gastro-intestinal system smooth muscle contraction | 1 | 1 | 4.24e-01 |
| GO:BP | GO:2001286 | regulation of caveolin-mediated endocytosis | 1 | 5 | 4.24e-01 |
| GO:BP | GO:0019509 | L-methionine salvage from methylthioadenosine | 1 | 5 | 4.24e-01 |
| GO:BP | GO:2000354 | regulation of ovarian follicle development | 1 | 5 | 4.24e-01 |
| GO:BP | GO:1900121 | negative regulation of receptor binding | 1 | 8 | 4.24e-01 |
| GO:BP | GO:0046148 | pigment biosynthetic process | 2 | 48 | 4.24e-01 |
| GO:BP | GO:0031325 | positive regulation of cellular metabolic process | 10 | 2270 | 4.24e-01 |
| GO:BP | GO:0051902 | negative regulation of mitochondrial depolarization | 1 | 5 | 4.24e-01 |
| GO:BP | GO:2000254 | regulation of male germ cell proliferation | 1 | 4 | 4.24e-01 |
| GO:BP | GO:0046827 | positive regulation of protein export from nucleus | 1 | 15 | 4.24e-01 |
| GO:BP | GO:0010941 | regulation of cell death | 53 | 1219 | 4.24e-01 |
| GO:BP | GO:1901661 | quinone metabolic process | 1 | 32 | 4.24e-01 |
| GO:BP | GO:0006721 | terpenoid metabolic process | 1 | 50 | 4.24e-01 |
| GO:BP | GO:0018212 | peptidyl-tyrosine modification | 1 | 258 | 4.24e-01 |
| GO:BP | GO:0070316 | regulation of G0 to G1 transition | 4 | 34 | 4.24e-01 |
| GO:BP | GO:0060341 | regulation of cellular localization | 11 | 798 | 4.25e-01 |
| GO:BP | GO:0018198 | peptidyl-cysteine modification | 1 | 41 | 4.25e-01 |
| GO:BP | GO:0046427 | positive regulation of receptor signaling pathway via JAK-STAT | 4 | 21 | 4.25e-01 |
| GO:BP | GO:0039535 | regulation of RIG-I signaling pathway | 2 | 17 | 4.25e-01 |
| GO:BP | GO:0006739 | NADP metabolic process | 3 | 40 | 4.25e-01 |
| GO:BP | GO:0045933 | positive regulation of muscle contraction | 4 | 32 | 4.25e-01 |
| GO:BP | GO:0048585 | negative regulation of response to stimulus | 1 | 1248 | 4.25e-01 |
| GO:BP | GO:0051058 | negative regulation of small GTPase mediated signal transduction | 3 | 53 | 4.25e-01 |
| GO:BP | GO:0035383 | thioester metabolic process | 1 | 71 | 4.25e-01 |
| GO:BP | GO:0031110 | regulation of microtubule polymerization or depolymerization | 3 | 82 | 4.25e-01 |
| GO:BP | GO:0006637 | acyl-CoA metabolic process | 1 | 71 | 4.25e-01 |
| GO:BP | GO:0001920 | negative regulation of receptor recycling | 1 | 3 | 4.25e-01 |
| GO:BP | GO:0090210 | regulation of establishment of blood-brain barrier | 1 | 3 | 4.25e-01 |
| GO:BP | GO:0043372 | positive regulation of CD4-positive, alpha-beta T cell differentiation | 2 | 16 | 4.25e-01 |
| GO:BP | GO:0003338 | metanephros morphogenesis | 3 | 22 | 4.25e-01 |
| GO:BP | GO:0030097 | hemopoiesis | 4 | 656 | 4.25e-01 |
| GO:BP | GO:0086100 | endothelin receptor signaling pathway | 1 | 9 | 4.25e-01 |
| GO:BP | GO:0060033 | anatomical structure regression | 2 | 11 | 4.25e-01 |
| GO:BP | GO:0034248 | regulation of amide metabolic process | 19 | 424 | 4.25e-01 |
| GO:BP | GO:0003266 | regulation of secondary heart field cardioblast proliferation | 1 | 8 | 4.26e-01 |
| GO:BP | GO:0090140 | regulation of mitochondrial fission | 2 | 28 | 4.26e-01 |
| GO:BP | GO:0060216 | definitive hemopoiesis | 2 | 18 | 4.26e-01 |
| GO:BP | GO:0033574 | response to testosterone | 4 | 29 | 4.26e-01 |
| GO:BP | GO:0031330 | negative regulation of cellular catabolic process | 13 | 165 | 4.26e-01 |
| GO:BP | GO:0061723 | glycophagy | 1 | 4 | 4.26e-01 |
| GO:BP | GO:0097191 | extrinsic apoptotic signaling pathway | 17 | 179 | 4.26e-01 |
| GO:BP | GO:0060191 | regulation of lipase activity | 2 | 52 | 4.26e-01 |
| GO:BP | GO:0046851 | negative regulation of bone remodeling | 1 | 9 | 4.26e-01 |
| GO:BP | GO:0002768 | immune response-regulating cell surface receptor signaling pathway | 2 | 162 | 4.26e-01 |
| GO:BP | GO:0051607 | defense response to virus | 3 | 202 | 4.26e-01 |
| GO:BP | GO:0035305 | negative regulation of dephosphorylation | 1 | 39 | 4.26e-01 |
| GO:BP | GO:0090162 | establishment of epithelial cell polarity | 2 | 29 | 4.26e-01 |
| GO:BP | GO:0006498 | N-terminal protein lipidation | 1 | 7 | 4.27e-01 |
| GO:BP | GO:0036289 | peptidyl-serine autophosphorylation | 1 | 8 | 4.27e-01 |
| GO:BP | GO:0036336 | dendritic cell migration | 1 | 15 | 4.27e-01 |
| GO:BP | GO:0099175 | regulation of postsynapse organization | 1 | 83 | 4.27e-01 |
| GO:BP | GO:0019068 | virion assembly | 1 | 35 | 4.28e-01 |
| GO:BP | GO:0140546 | defense response to symbiont | 3 | 202 | 4.28e-01 |
| GO:BP | GO:0051968 | positive regulation of synaptic transmission, glutamatergic | 3 | 20 | 4.28e-01 |
| GO:BP | GO:0001955 | blood vessel maturation | 1 | 6 | 4.29e-01 |
| GO:BP | GO:0045840 | positive regulation of mitotic nuclear division | 3 | 29 | 4.29e-01 |
| GO:BP | GO:1903905 | positive regulation of establishment of T cell polarity | 1 | 4 | 4.29e-01 |
| GO:BP | GO:0002465 | peripheral tolerance induction | 1 | 2 | 4.29e-01 |
| GO:BP | GO:0098739 | import across plasma membrane | 3 | 133 | 4.29e-01 |
| GO:BP | GO:1902460 | regulation of mesenchymal stem cell proliferation | 1 | 4 | 4.30e-01 |
| GO:BP | GO:0043488 | regulation of mRNA stability | 2 | 147 | 4.30e-01 |
| GO:BP | GO:0032252 | secretory granule localization | 1 | 9 | 4.30e-01 |
| GO:BP | GO:1902462 | positive regulation of mesenchymal stem cell proliferation | 1 | 4 | 4.30e-01 |
| GO:BP | GO:0002446 | neutrophil mediated immunity | 4 | 17 | 4.30e-01 |
| GO:BP | GO:0034201 | response to oleic acid | 1 | 5 | 4.30e-01 |
| GO:BP | GO:0010564 | regulation of cell cycle process | 3 | 626 | 4.30e-01 |
| GO:BP | GO:0019953 | sexual reproduction | 7 | 631 | 4.30e-01 |
| GO:BP | GO:0006820 | monoatomic anion transport | 3 | 83 | 4.31e-01 |
| GO:BP | GO:1902527 | positive regulation of protein monoubiquitination | 1 | 5 | 4.31e-01 |
| GO:BP | GO:0036324 | vascular endothelial growth factor receptor-2 signaling pathway | 1 | 4 | 4.31e-01 |
| GO:BP | GO:0045684 | positive regulation of epidermis development | 1 | 20 | 4.31e-01 |
| GO:BP | GO:0051603 | proteolysis involved in protein catabolic process | 25 | 706 | 4.31e-01 |
| GO:BP | GO:0042742 | defense response to bacterium | 1 | 95 | 4.31e-01 |
| GO:BP | GO:0060312 | regulation of blood vessel remodeling | 1 | 4 | 4.31e-01 |
| GO:BP | GO:0046847 | filopodium assembly | 6 | 56 | 4.31e-01 |
| GO:BP | GO:0042747 | circadian sleep/wake cycle, REM sleep | 1 | 2 | 4.31e-01 |
| GO:BP | GO:0060268 | negative regulation of respiratory burst | 1 | 4 | 4.31e-01 |
| GO:BP | GO:0007162 | negative regulation of cell adhesion | 4 | 192 | 4.31e-01 |
| GO:BP | GO:1900274 | regulation of phospholipase C activity | 4 | 20 | 4.31e-01 |
| GO:BP | GO:0006710 | androgen catabolic process | 1 | 3 | 4.31e-01 |
| GO:BP | GO:0060252 | positive regulation of glial cell proliferation | 2 | 14 | 4.31e-01 |
| GO:BP | GO:2000095 | regulation of Wnt signaling pathway, planar cell polarity pathway | 2 | 15 | 4.31e-01 |
| GO:BP | GO:0043507 | positive regulation of JUN kinase activity | 3 | 34 | 4.31e-01 |
| GO:BP | GO:0006089 | lactate metabolic process | 1 | 16 | 4.32e-01 |
| GO:BP | GO:0060070 | canonical Wnt signaling pathway | 11 | 251 | 4.32e-01 |
| GO:BP | GO:0048854 | brain morphogenesis | 1 | 28 | 4.32e-01 |
| GO:BP | GO:0032768 | regulation of monooxygenase activity | 1 | 34 | 4.32e-01 |
| GO:BP | GO:0061217 | regulation of mesonephros development | 1 | 2 | 4.32e-01 |
| GO:BP | GO:0051785 | positive regulation of nuclear division | 4 | 38 | 4.32e-01 |
| GO:BP | GO:0019439 | aromatic compound catabolic process | 2 | 387 | 4.33e-01 |
| GO:BP | GO:0071839 | apoptotic process in bone marrow cell | 1 | 4 | 4.33e-01 |
| GO:BP | GO:0090394 | negative regulation of excitatory postsynaptic potential | 1 | 8 | 4.33e-01 |
| GO:BP | GO:1902235 | regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway | 1 | 29 | 4.33e-01 |
| GO:BP | GO:2000671 | regulation of motor neuron apoptotic process | 2 | 12 | 4.33e-01 |
| GO:BP | GO:0061440 | kidney vasculature development | 1 | 24 | 4.33e-01 |
| GO:BP | GO:0061437 | renal system vasculature development | 1 | 24 | 4.33e-01 |
| GO:BP | GO:0009113 | purine nucleobase biosynthetic process | 1 | 10 | 4.33e-01 |
| GO:BP | GO:0035967 | cellular response to topologically incorrect protein | 10 | 111 | 4.33e-01 |
| GO:BP | GO:0042558 | pteridine-containing compound metabolic process | 2 | 28 | 4.33e-01 |
| GO:BP | GO:0002695 | negative regulation of leukocyte activation | 3 | 105 | 4.33e-01 |
| GO:BP | GO:1901655 | cellular response to ketone | 2 | 86 | 4.34e-01 |
| GO:BP | GO:0043001 | Golgi to plasma membrane protein transport | 1 | 37 | 4.34e-01 |
| GO:BP | GO:0042832 | defense response to protozoan | 1 | 10 | 4.35e-01 |
| GO:BP | GO:0060261 | positive regulation of transcription initiation by RNA polymerase II | 3 | 59 | 4.35e-01 |
| GO:BP | GO:0071285 | cellular response to lithium ion | 1 | 8 | 4.35e-01 |
| GO:BP | GO:0007267 | cell-cell signaling | 1 | 1138 | 4.36e-01 |
| GO:BP | GO:0048486 | parasympathetic nervous system development | 2 | 12 | 4.36e-01 |
| GO:BP | GO:0030154 | cell differentiation | 16 | 2958 | 4.37e-01 |
| GO:BP | GO:0043268 | positive regulation of potassium ion transport | 1 | 36 | 4.37e-01 |
| GO:BP | GO:0033273 | response to vitamin | 7 | 61 | 4.37e-01 |
| GO:BP | GO:0140253 | cell-cell fusion | 2 | 37 | 4.37e-01 |
| GO:BP | GO:0000768 | syncytium formation by plasma membrane fusion | 2 | 37 | 4.37e-01 |
| GO:BP | GO:0090385 | phagosome-lysosome fusion | 1 | 12 | 4.37e-01 |
| GO:BP | GO:0002437 | inflammatory response to antigenic stimulus | 6 | 36 | 4.37e-01 |
| GO:BP | GO:0007442 | hindgut morphogenesis | 1 | 4 | 4.38e-01 |
| GO:BP | GO:0090075 | relaxation of muscle | 1 | 29 | 4.38e-01 |
| GO:BP | GO:0021521 | ventral spinal cord interneuron specification | 1 | 3 | 4.38e-01 |
| GO:BP | GO:0055003 | cardiac myofibril assembly | 2 | 19 | 4.38e-01 |
| GO:BP | GO:0021937 | cerebellar Purkinje cell-granule cell precursor cell signaling involved in regulation of granule cell precursor cell proliferation | 1 | 4 | 4.38e-01 |
| GO:BP | GO:0014065 | phosphatidylinositol 3-kinase signaling | 11 | 100 | 4.38e-01 |
| GO:BP | GO:0060573 | cell fate specification involved in pattern specification | 1 | 3 | 4.38e-01 |
| GO:BP | GO:0019934 | cGMP-mediated signaling | 1 | 22 | 4.38e-01 |
| GO:BP | GO:0036337 | Fas signaling pathway | 1 | 5 | 4.38e-01 |
| GO:BP | GO:0150117 | positive regulation of cell-substrate junction organization | 2 | 29 | 4.38e-01 |
| GO:BP | GO:0003352 | regulation of cilium movement | 1 | 17 | 4.38e-01 |
| GO:BP | GO:2000253 | positive regulation of feeding behavior | 1 | 4 | 4.39e-01 |
| GO:BP | GO:0038135 | ERBB2-ERBB4 signaling pathway | 1 | 4 | 4.39e-01 |
| GO:BP | GO:2000669 | negative regulation of dendritic cell apoptotic process | 1 | 5 | 4.39e-01 |
| GO:BP | GO:0034440 | lipid oxidation | 4 | 94 | 4.39e-01 |
| GO:BP | GO:0032435 | negative regulation of proteasomal ubiquitin-dependent protein catabolic process | 4 | 35 | 4.39e-01 |
| GO:BP | GO:1902253 | regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 1 | 32 | 4.39e-01 |
| GO:BP | GO:1901797 | negative regulation of signal transduction by p53 class mediator | 1 | 32 | 4.39e-01 |
| GO:BP | GO:0061081 | positive regulation of myeloid leukocyte cytokine production involved in immune response | 1 | 26 | 4.39e-01 |
| GO:BP | GO:0035352 | NAD transmembrane transport | 1 | 3 | 4.39e-01 |
| GO:BP | GO:1901201 | regulation of extracellular matrix assembly | 1 | 14 | 4.39e-01 |
| GO:BP | GO:1904354 | negative regulation of telomere capping | 1 | 8 | 4.39e-01 |
| GO:BP | GO:0070278 | extracellular matrix constituent secretion | 1 | 12 | 4.39e-01 |
| GO:BP | GO:0010882 | regulation of cardiac muscle contraction by calcium ion signaling | 2 | 25 | 4.39e-01 |
| GO:BP | GO:0042542 | response to hydrogen peroxide | 7 | 103 | 4.41e-01 |
| GO:BP | GO:0010458 | exit from mitosis | 2 | 30 | 4.41e-01 |
| GO:BP | GO:0000463 | maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 2 | 15 | 4.41e-01 |
| GO:BP | GO:0060547 | negative regulation of necrotic cell death | 1 | 21 | 4.41e-01 |
| GO:BP | GO:0016191 | synaptic vesicle uncoating | 1 | 7 | 4.41e-01 |
| GO:BP | GO:0051388 | positive regulation of neurotrophin TRK receptor signaling pathway | 1 | 5 | 4.41e-01 |
| GO:BP | GO:1903593 | regulation of histamine secretion by mast cell | 1 | 4 | 4.41e-01 |
| GO:BP | GO:1903595 | positive regulation of histamine secretion by mast cell | 1 | 4 | 4.41e-01 |
| GO:BP | GO:0007059 | chromosome segregation | 2 | 369 | 4.41e-01 |
| GO:BP | GO:0023056 | positive regulation of signaling | 1 | 1256 | 4.41e-01 |
| GO:BP | GO:1905671 | regulation of lysosome organization | 1 | 6 | 4.41e-01 |
| GO:BP | GO:0043923 | positive regulation by host of viral transcription | 2 | 18 | 4.41e-01 |
| GO:BP | GO:0035082 | axoneme assembly | 1 | 52 | 4.41e-01 |
| GO:BP | GO:0046599 | regulation of centriole replication | 1 | 21 | 4.41e-01 |
| GO:BP | GO:0002457 | T cell antigen processing and presentation | 1 | 4 | 4.41e-01 |
| GO:BP | GO:0034643 | establishment of mitochondrion localization, microtubule-mediated | 3 | 26 | 4.41e-01 |
| GO:BP | GO:0047497 | mitochondrion transport along microtubule | 3 | 26 | 4.41e-01 |
| GO:BP | GO:0021697 | cerebellar cortex formation | 3 | 22 | 4.41e-01 |
| GO:BP | GO:0000070 | mitotic sister chromatid segregation | 5 | 179 | 4.41e-01 |
| GO:BP | GO:0035850 | epithelial cell differentiation involved in kidney development | 4 | 35 | 4.41e-01 |
| GO:BP | GO:0001768 | establishment of T cell polarity | 2 | 10 | 4.41e-01 |
| GO:BP | GO:0071514 | genomic imprinting | 1 | 9 | 4.41e-01 |
| GO:BP | GO:0010647 | positive regulation of cell communication | 1 | 1255 | 4.41e-01 |
| GO:BP | GO:2001236 | regulation of extrinsic apoptotic signaling pathway | 12 | 123 | 4.41e-01 |
| GO:BP | GO:0050863 | regulation of T cell activation | 11 | 216 | 4.41e-01 |
| GO:BP | GO:0008543 | fibroblast growth factor receptor signaling pathway | 5 | 60 | 4.41e-01 |
| GO:BP | GO:1904292 | regulation of ERAD pathway | 1 | 22 | 4.41e-01 |
| GO:BP | GO:0048617 | embryonic foregut morphogenesis | 1 | 6 | 4.41e-01 |
| GO:BP | GO:0019695 | choline metabolic process | 1 | 4 | 4.42e-01 |
| GO:BP | GO:0071593 | lymphocyte aggregation | 1 | 4 | 4.42e-01 |
| GO:BP | GO:0006578 | amino-acid betaine biosynthetic process | 1 | 5 | 4.42e-01 |
| GO:BP | GO:0046512 | sphingosine biosynthetic process | 2 | 13 | 4.42e-01 |
| GO:BP | GO:0046520 | sphingoid biosynthetic process | 2 | 13 | 4.42e-01 |
| GO:BP | GO:0006108 | malate metabolic process | 1 | 7 | 4.42e-01 |
| GO:BP | GO:0007528 | neuromuscular junction development | 1 | 39 | 4.42e-01 |
| GO:BP | GO:0007549 | dosage compensation | 1 | 29 | 4.42e-01 |
| GO:BP | GO:0051209 | release of sequestered calcium ion into cytosol | 4 | 82 | 4.42e-01 |
| GO:BP | GO:0048268 | clathrin coat assembly | 2 | 13 | 4.42e-01 |
| GO:BP | GO:0010838 | positive regulation of keratinocyte proliferation | 1 | 9 | 4.42e-01 |
| GO:BP | GO:0035995 | detection of muscle stretch | 1 | 7 | 4.42e-01 |
| GO:BP | GO:0007520 | myoblast fusion | 1 | 30 | 4.42e-01 |
| GO:BP | GO:0032482 | Rab protein signal transduction | 1 | 19 | 4.42e-01 |
| GO:BP | GO:0035767 | endothelial cell chemotaxis | 2 | 23 | 4.42e-01 |
| GO:BP | GO:1901565 | organonitrogen compound catabolic process | 10 | 1145 | 4.42e-01 |
| GO:BP | GO:0022402 | cell cycle process | 67 | 1086 | 4.42e-01 |
| GO:BP | GO:0021511 | spinal cord patterning | 2 | 9 | 4.42e-01 |
| GO:BP | GO:0035666 | TRIF-dependent toll-like receptor signaling pathway | 1 | 4 | 4.42e-01 |
| GO:BP | GO:0018130 | heterocycle biosynthetic process | 13 | 3132 | 4.42e-01 |
| GO:BP | GO:0048869 | cellular developmental process | 16 | 2984 | 4.42e-01 |
| GO:BP | GO:0033630 | positive regulation of cell adhesion mediated by integrin | 2 | 14 | 4.42e-01 |
| GO:BP | GO:0021904 | dorsal/ventral neural tube patterning | 2 | 21 | 4.42e-01 |
| GO:BP | GO:0015917 | aminophospholipid transport | 1 | 8 | 4.42e-01 |
| GO:BP | GO:0071816 | tail-anchored membrane protein insertion into ER membrane | 2 | 17 | 4.42e-01 |
| GO:BP | GO:0032331 | negative regulation of chondrocyte differentiation | 2 | 18 | 4.42e-01 |
| GO:BP | GO:0090527 | actin filament reorganization | 1 | 10 | 4.42e-01 |
| GO:BP | GO:0036369 | transcription factor catabolic process | 1 | 5 | 4.43e-01 |
| GO:BP | GO:0060351 | cartilage development involved in endochondral bone morphogenesis | 2 | 26 | 4.43e-01 |
| GO:BP | GO:1901216 | positive regulation of neuron death | 3 | 70 | 4.43e-01 |
| GO:BP | GO:0042532 | negative regulation of tyrosine phosphorylation of STAT protein | 1 | 12 | 4.43e-01 |
| GO:BP | GO:0046321 | positive regulation of fatty acid oxidation | 2 | 15 | 4.43e-01 |
| GO:BP | GO:0001892 | embryonic placenta development | 8 | 71 | 4.43e-01 |
| GO:BP | GO:0008631 | intrinsic apoptotic signaling pathway in response to oxidative stress | 2 | 41 | 4.43e-01 |
| GO:BP | GO:0031295 | T cell costimulation | 2 | 22 | 4.43e-01 |
| GO:BP | GO:0071478 | cellular response to radiation | 4 | 156 | 4.43e-01 |
| GO:BP | GO:1990791 | dorsal root ganglion development | 1 | 6 | 4.44e-01 |
| GO:BP | GO:0099587 | inorganic ion import across plasma membrane | 3 | 73 | 4.45e-01 |
| GO:BP | GO:0098659 | inorganic cation import across plasma membrane | 3 | 73 | 4.45e-01 |
| GO:BP | GO:1902117 | positive regulation of organelle assembly | 1 | 73 | 4.45e-01 |
| GO:BP | GO:0003264 | regulation of cardioblast proliferation | 1 | 9 | 4.45e-01 |
| GO:BP | GO:0043562 | cellular response to nitrogen levels | 1 | 9 | 4.45e-01 |
| GO:BP | GO:0006995 | cellular response to nitrogen starvation | 1 | 9 | 4.45e-01 |
| GO:BP | GO:0045879 | negative regulation of smoothened signaling pathway | 1 | 30 | 4.45e-01 |
| GO:BP | GO:0003263 | cardioblast proliferation | 1 | 9 | 4.45e-01 |
| GO:BP | GO:0019438 | aromatic compound biosynthetic process | 13 | 3133 | 4.45e-01 |
| GO:BP | GO:0010890 | positive regulation of sequestering of triglyceride | 1 | 7 | 4.45e-01 |
| GO:BP | GO:0000478 | endonucleolytic cleavage involved in rRNA processing | 1 | 17 | 4.45e-01 |
| GO:BP | GO:0000479 | endonucleolytic cleavage of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 1 | 17 | 4.45e-01 |
| GO:BP | GO:0051283 | negative regulation of sequestering of calcium ion | 4 | 83 | 4.45e-01 |
| GO:BP | GO:0042181 | ketone biosynthetic process | 1 | 37 | 4.45e-01 |
| GO:BP | GO:0072595 | maintenance of protein localization in organelle | 4 | 39 | 4.45e-01 |
| GO:BP | GO:1902170 | cellular response to reactive nitrogen species | 2 | 16 | 4.45e-01 |
| GO:BP | GO:0001706 | endoderm formation | 3 | 46 | 4.45e-01 |
| GO:BP | GO:0035987 | endodermal cell differentiation | 1 | 38 | 4.46e-01 |
| GO:BP | GO:0002291 | T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell | 1 | 3 | 4.46e-01 |
| GO:BP | GO:2000725 | regulation of cardiac muscle cell differentiation | 1 | 14 | 4.46e-01 |
| GO:BP | GO:0050865 | regulation of cell activation | 10 | 384 | 4.46e-01 |
| GO:BP | GO:0033036 | macromolecule localization | 4 | 2450 | 4.47e-01 |
| GO:BP | GO:0002842 | positive regulation of T cell mediated immune response to tumor cell | 1 | 3 | 4.47e-01 |
| GO:BP | GO:0001963 | synaptic transmission, dopaminergic | 3 | 16 | 4.47e-01 |
| GO:BP | GO:2000049 | positive regulation of cell-cell adhesion mediated by cadherin | 1 | 8 | 4.47e-01 |
| GO:BP | GO:0001562 | response to protozoan | 1 | 11 | 4.48e-01 |
| GO:BP | GO:0002903 | negative regulation of B cell apoptotic process | 1 | 11 | 4.48e-01 |
| GO:BP | GO:0009445 | putrescine metabolic process | 1 | 6 | 4.48e-01 |
| GO:BP | GO:1990845 | adaptive thermogenesis | 2 | 121 | 4.48e-01 |
| GO:BP | GO:0051091 | positive regulation of DNA-binding transcription factor activity | 10 | 199 | 4.48e-01 |
| GO:BP | GO:0051247 | positive regulation of protein metabolic process | 10 | 1123 | 4.48e-01 |
| GO:BP | GO:0060294 | cilium movement involved in cell motility | 2 | 69 | 4.49e-01 |
| GO:BP | GO:0033013 | tetrapyrrole metabolic process | 2 | 52 | 4.49e-01 |
| GO:BP | GO:0006699 | bile acid biosynthetic process | 1 | 25 | 4.49e-01 |
| GO:BP | GO:0010935 | regulation of macrophage cytokine production | 1 | 27 | 4.49e-01 |
| GO:BP | GO:0010934 | macrophage cytokine production | 1 | 27 | 4.49e-01 |
| GO:BP | GO:0061888 | regulation of astrocyte activation | 1 | 3 | 4.49e-01 |
| GO:BP | GO:0031644 | regulation of nervous system process | 11 | 90 | 4.49e-01 |
| GO:BP | GO:0034470 | ncRNA processing | 2 | 400 | 4.49e-01 |
| GO:BP | GO:0070671 | response to interleukin-12 | 1 | 6 | 4.49e-01 |
| GO:BP | GO:0051653 | spindle localization | 5 | 52 | 4.49e-01 |
| GO:BP | GO:1902531 | regulation of intracellular signal transduction | 18 | 1345 | 4.49e-01 |
| GO:BP | GO:0051983 | regulation of chromosome segregation | 1 | 121 | 4.49e-01 |
| GO:BP | GO:0061156 | pulmonary artery morphogenesis | 1 | 7 | 4.49e-01 |
| GO:BP | GO:0010042 | response to manganese ion | 1 | 15 | 4.49e-01 |
| GO:BP | GO:0031324 | negative regulation of cellular metabolic process | 2 | 1735 | 4.49e-01 |
| GO:BP | GO:0032637 | interleukin-8 production | 1 | 43 | 4.49e-01 |
| GO:BP | GO:0010569 | regulation of double-strand break repair via homologous recombination | 3 | 63 | 4.49e-01 |
| GO:BP | GO:0032414 | positive regulation of ion transmembrane transporter activity | 2 | 85 | 4.49e-01 |
| GO:BP | GO:0034349 | glial cell apoptotic process | 2 | 15 | 4.49e-01 |
| GO:BP | GO:0032677 | regulation of interleukin-8 production | 1 | 43 | 4.49e-01 |
| GO:BP | GO:0045023 | G0 to G1 transition | 4 | 35 | 4.49e-01 |
| GO:BP | GO:0072553 | terminal button organization | 1 | 5 | 4.49e-01 |
| GO:BP | GO:0060236 | regulation of mitotic spindle organization | 1 | 42 | 4.49e-01 |
| GO:BP | GO:0034198 | cellular response to amino acid starvation | 2 | 48 | 4.50e-01 |
| GO:BP | GO:0099172 | presynapse organization | 4 | 42 | 4.50e-01 |
| GO:BP | GO:0030540 | female genitalia development | 2 | 14 | 4.50e-01 |
| GO:BP | GO:0046942 | carboxylic acid transport | 2 | 216 | 4.50e-01 |
| GO:BP | GO:0008637 | apoptotic mitochondrial changes | 2 | 90 | 4.50e-01 |
| GO:BP | GO:0008215 | spermine metabolic process | 1 | 5 | 4.50e-01 |
| GO:BP | GO:0009892 | negative regulation of metabolic process | 4 | 2293 | 4.50e-01 |
| GO:BP | GO:2000825 | positive regulation of androgen receptor activity | 1 | 5 | 4.50e-01 |
| GO:BP | GO:1903506 | regulation of nucleic acid-templated transcription | 3 | 2576 | 4.50e-01 |
| GO:BP | GO:0048489 | synaptic vesicle transport | 4 | 36 | 4.50e-01 |
| GO:BP | GO:0006979 | response to oxidative stress | 2 | 352 | 4.50e-01 |
| GO:BP | GO:0032725 | positive regulation of granulocyte macrophage colony-stimulating factor production | 2 | 5 | 4.50e-01 |
| GO:BP | GO:0043029 | T cell homeostasis | 2 | 27 | 4.50e-01 |
| GO:BP | GO:1905953 | negative regulation of lipid localization | 2 | 32 | 4.50e-01 |
| GO:BP | GO:0006355 | regulation of DNA-templated transcription | 3 | 2574 | 4.50e-01 |
| GO:BP | GO:0035556 | intracellular signal transduction | 3 | 2065 | 4.50e-01 |
| GO:BP | GO:0022616 | DNA strand elongation | 3 | 35 | 4.50e-01 |
| GO:BP | GO:0060563 | neuroepithelial cell differentiation | 1 | 22 | 4.50e-01 |
| GO:BP | GO:0032456 | endocytic recycling | 1 | 80 | 4.50e-01 |
| GO:BP | GO:0048023 | positive regulation of melanin biosynthetic process | 1 | 7 | 4.50e-01 |
| GO:BP | GO:1900378 | positive regulation of secondary metabolite biosynthetic process | 1 | 7 | 4.50e-01 |
| GO:BP | GO:0071393 | cellular response to progesterone stimulus | 1 | 5 | 4.50e-01 |
| GO:BP | GO:1905936 | regulation of germ cell proliferation | 1 | 5 | 4.50e-01 |
| GO:BP | GO:2000394 | positive regulation of lamellipodium morphogenesis | 1 | 6 | 4.50e-01 |
| GO:BP | GO:1904180 | negative regulation of membrane depolarization | 1 | 6 | 4.50e-01 |
| GO:BP | GO:1901361 | organic cyclic compound catabolic process | 2 | 406 | 4.50e-01 |
| GO:BP | GO:0015849 | organic acid transport | 2 | 217 | 4.50e-01 |
| GO:BP | GO:0046488 | phosphatidylinositol metabolic process | 10 | 140 | 4.50e-01 |
| GO:BP | GO:0043487 | regulation of RNA stability | 2 | 159 | 4.50e-01 |
| GO:BP | GO:0043555 | regulation of translation in response to stress | 1 | 23 | 4.51e-01 |
| GO:BP | GO:0051282 | regulation of sequestering of calcium ion | 4 | 85 | 4.51e-01 |
| GO:BP | GO:1901652 | response to peptide | 26 | 377 | 4.51e-01 |
| GO:BP | GO:0048290 | isotype switching to IgA isotypes | 1 | 4 | 4.51e-01 |
| GO:BP | GO:0034770 | histone H4-K20 methylation | 1 | 6 | 4.51e-01 |
| GO:BP | GO:0000578 | embryonic axis specification | 4 | 26 | 4.51e-01 |
| GO:BP | GO:0021684 | cerebellar granular layer formation | 1 | 6 | 4.52e-01 |
| GO:BP | GO:0021707 | cerebellar granule cell differentiation | 1 | 6 | 4.52e-01 |
| GO:BP | GO:0098598 | learned vocalization behavior or vocal learning | 1 | 4 | 4.52e-01 |
| GO:BP | GO:0000209 | protein polyubiquitination | 8 | 226 | 4.52e-01 |
| GO:BP | GO:0050931 | pigment cell differentiation | 3 | 26 | 4.52e-01 |
| GO:BP | GO:0055090 | acylglycerol homeostasis | 1 | 17 | 4.52e-01 |
| GO:BP | GO:0010874 | regulation of cholesterol efflux | 1 | 31 | 4.52e-01 |
| GO:BP | GO:0045191 | regulation of isotype switching | 2 | 27 | 4.52e-01 |
| GO:BP | GO:0070328 | triglyceride homeostasis | 1 | 17 | 4.52e-01 |
| GO:BP | GO:1990830 | cellular response to leukemia inhibitory factor | 7 | 84 | 4.52e-01 |
| GO:BP | GO:0048681 | negative regulation of axon regeneration | 1 | 11 | 4.53e-01 |
| GO:BP | GO:0030866 | cortical actin cytoskeleton organization | 4 | 35 | 4.53e-01 |
| GO:BP | GO:2001141 | regulation of RNA biosynthetic process | 3 | 2593 | 4.53e-01 |
| GO:BP | GO:0033033 | negative regulation of myeloid cell apoptotic process | 1 | 10 | 4.53e-01 |
| GO:BP | GO:1904894 | positive regulation of receptor signaling pathway via STAT | 4 | 22 | 4.53e-01 |
| GO:BP | GO:0043627 | response to estrogen | 1 | 52 | 4.53e-01 |
| GO:BP | GO:0051798 | positive regulation of hair follicle development | 1 | 9 | 4.53e-01 |
| GO:BP | GO:0035306 | positive regulation of dephosphorylation | 4 | 47 | 4.53e-01 |
| GO:BP | GO:0008015 | blood circulation | 2 | 374 | 4.53e-01 |
| GO:BP | GO:0006949 | syncytium formation | 2 | 39 | 4.53e-01 |
| GO:BP | GO:0006281 | DNA repair | 32 | 534 | 4.53e-01 |
| GO:BP | GO:0050769 | positive regulation of neurogenesis | 2 | 189 | 4.53e-01 |
| GO:BP | GO:0072073 | kidney epithelium development | 1 | 112 | 4.53e-01 |
| GO:BP | GO:2000402 | negative regulation of lymphocyte migration | 1 | 10 | 4.53e-01 |
| GO:BP | GO:2000649 | regulation of sodium ion transmembrane transporter activity | 5 | 44 | 4.54e-01 |
| GO:BP | GO:0006248 | CMP catabolic process | 1 | 3 | 4.54e-01 |
| GO:BP | GO:1903371 | regulation of endoplasmic reticulum tubular network organization | 1 | 6 | 4.54e-01 |
| GO:BP | GO:0019262 | N-acetylneuraminate catabolic process | 1 | 6 | 4.54e-01 |
| GO:BP | GO:0070734 | histone H3-K27 methylation | 2 | 9 | 4.54e-01 |
| GO:BP | GO:0036018 | cellular response to erythropoietin | 1 | 4 | 4.54e-01 |
| GO:BP | GO:0072104 | glomerular capillary formation | 1 | 5 | 4.54e-01 |
| GO:BP | GO:0060374 | mast cell differentiation | 1 | 4 | 4.54e-01 |
| GO:BP | GO:0072575 | epithelial cell proliferation involved in liver morphogenesis | 2 | 18 | 4.54e-01 |
| GO:BP | GO:0098528 | skeletal muscle fiber differentiation | 1 | 5 | 4.54e-01 |
| GO:BP | GO:0072574 | hepatocyte proliferation | 2 | 18 | 4.54e-01 |
| GO:BP | GO:0048170 | positive regulation of long-term neuronal synaptic plasticity | 1 | 5 | 4.54e-01 |
| GO:BP | GO:0072103 | glomerulus vasculature morphogenesis | 1 | 5 | 4.54e-01 |
| GO:BP | GO:2000117 | negative regulation of cysteine-type endopeptidase activity | 7 | 64 | 4.54e-01 |
| GO:BP | GO:0098900 | regulation of action potential | 1 | 44 | 4.54e-01 |
| GO:BP | GO:0007010 | cytoskeleton organization | 5 | 1226 | 4.54e-01 |
| GO:BP | GO:0070268 | cornification | 1 | 2 | 4.54e-01 |
| GO:BP | GO:0034329 | cell junction assembly | 1 | 344 | 4.54e-01 |
| GO:BP | GO:1905065 | positive regulation of vascular associated smooth muscle cell differentiation | 1 | 6 | 4.54e-01 |
| GO:BP | GO:0050901 | leukocyte tethering or rolling | 2 | 16 | 4.54e-01 |
| GO:BP | GO:0048732 | gland development | 1 | 318 | 4.54e-01 |
| GO:BP | GO:0034330 | cell junction organization | 6 | 575 | 4.54e-01 |
| GO:BP | GO:0106074 | aminoacyl-tRNA metabolism involved in translational fidelity | 1 | 11 | 4.54e-01 |
| GO:BP | GO:0001757 | somite specification | 1 | 2 | 4.54e-01 |
| GO:BP | GO:0048669 | collateral sprouting in absence of injury | 1 | 4 | 4.54e-01 |
| GO:BP | GO:0006833 | water transport | 1 | 10 | 4.54e-01 |
| GO:BP | GO:0045628 | regulation of T-helper 2 cell differentiation | 1 | 7 | 4.54e-01 |
| GO:BP | GO:0009303 | rRNA transcription | 1 | 37 | 4.54e-01 |
| GO:BP | GO:0030201 | heparan sulfate proteoglycan metabolic process | 2 | 11 | 4.54e-01 |
| GO:BP | GO:0031294 | lymphocyte costimulation | 2 | 23 | 4.54e-01 |
| GO:BP | GO:0033077 | T cell differentiation in thymus | 5 | 56 | 4.55e-01 |
| GO:BP | GO:0002821 | positive regulation of adaptive immune response | 2 | 66 | 4.55e-01 |
| GO:BP | GO:0016445 | somatic diversification of immunoglobulins | 3 | 53 | 4.55e-01 |
| GO:BP | GO:0140719 | constitutive heterochromatin formation | 1 | 10 | 4.55e-01 |
| GO:BP | GO:0009069 | serine family amino acid metabolic process | 3 | 30 | 4.55e-01 |
| GO:BP | GO:0007351 | tripartite regional subdivision | 2 | 10 | 4.55e-01 |
| GO:BP | GO:0090201 | negative regulation of release of cytochrome c from mitochondria | 2 | 18 | 4.55e-01 |
| GO:BP | GO:0006622 | protein targeting to lysosome | 3 | 28 | 4.55e-01 |
| GO:BP | GO:0008595 | anterior/posterior axis specification, embryo | 2 | 10 | 4.55e-01 |
| GO:BP | GO:0000050 | urea cycle | 1 | 7 | 4.55e-01 |
| GO:BP | GO:0060841 | venous blood vessel development | 1 | 13 | 4.55e-01 |
| GO:BP | GO:0072176 | nephric duct development | 1 | 12 | 4.55e-01 |
| GO:BP | GO:0030206 | chondroitin sulfate biosynthetic process | 1 | 17 | 4.56e-01 |
| GO:BP | GO:0032376 | positive regulation of cholesterol transport | 1 | 30 | 4.56e-01 |
| GO:BP | GO:0032373 | positive regulation of sterol transport | 1 | 30 | 4.56e-01 |
| GO:BP | GO:0061013 | regulation of mRNA catabolic process | 2 | 161 | 4.56e-01 |
| GO:BP | GO:0008284 | positive regulation of cell population proliferation | 31 | 631 | 4.56e-01 |
| GO:BP | GO:0006880 | intracellular sequestering of iron ion | 1 | 3 | 4.56e-01 |
| GO:BP | GO:0010876 | lipid localization | 2 | 310 | 4.56e-01 |
| GO:BP | GO:0009063 | amino acid catabolic process | 3 | 78 | 4.56e-01 |
| GO:BP | GO:0016925 | protein sumoylation | 2 | 59 | 4.56e-01 |
| GO:BP | GO:0070613 | regulation of protein processing | 6 | 47 | 4.57e-01 |
| GO:BP | GO:0072594 | establishment of protein localization to organelle | 1 | 422 | 4.57e-01 |
| GO:BP | GO:0051493 | regulation of cytoskeleton organization | 14 | 459 | 4.57e-01 |
| GO:BP | GO:0032480 | negative regulation of type I interferon production | 3 | 23 | 4.57e-01 |
| GO:BP | GO:0060463 | lung lobe morphogenesis | 1 | 4 | 4.57e-01 |
| GO:BP | GO:0042147 | retrograde transport, endosome to Golgi | 8 | 88 | 4.57e-01 |
| GO:BP | GO:0001767 | establishment of lymphocyte polarity | 2 | 11 | 4.57e-01 |
| GO:BP | GO:0010835 | regulation of protein ADP-ribosylation | 1 | 9 | 4.57e-01 |
| GO:BP | GO:0060462 | lung lobe development | 1 | 4 | 4.57e-01 |
| GO:BP | GO:0007440 | foregut morphogenesis | 1 | 7 | 4.57e-01 |
| GO:BP | GO:0031667 | response to nutrient levels | 2 | 353 | 4.57e-01 |
| GO:BP | GO:1990823 | response to leukemia inhibitory factor | 7 | 85 | 4.57e-01 |
| GO:BP | GO:0002501 | peptide antigen assembly with MHC protein complex | 2 | 8 | 4.57e-01 |
| GO:BP | GO:2001033 | negative regulation of double-strand break repair via nonhomologous end joining | 1 | 7 | 4.57e-01 |
| GO:BP | GO:0072307 | regulation of metanephric nephron tubule epithelial cell differentiation | 1 | 5 | 4.57e-01 |
| GO:BP | GO:0072257 | metanephric nephron tubule epithelial cell differentiation | 1 | 5 | 4.57e-01 |
| GO:BP | GO:0072006 | nephron development | 10 | 117 | 4.57e-01 |
| GO:BP | GO:0006687 | glycosphingolipid metabolic process | 1 | 48 | 4.57e-01 |
| GO:BP | GO:0002396 | MHC protein complex assembly | 2 | 8 | 4.57e-01 |
| GO:BP | GO:0051972 | regulation of telomerase activity | 1 | 45 | 4.57e-01 |
| GO:BP | GO:0010165 | response to X-ray | 2 | 29 | 4.57e-01 |
| GO:BP | GO:0061525 | hindgut development | 1 | 5 | 4.58e-01 |
| GO:BP | GO:0001975 | response to amphetamine | 1 | 22 | 4.58e-01 |
| GO:BP | GO:0032271 | regulation of protein polymerization | 6 | 168 | 4.58e-01 |
| GO:BP | GO:0010649 | regulation of cell communication by electrical coupling | 2 | 17 | 4.58e-01 |
| GO:BP | GO:0032964 | collagen biosynthetic process | 4 | 39 | 4.58e-01 |
| GO:BP | GO:1904683 | regulation of metalloendopeptidase activity | 1 | 6 | 4.58e-01 |
| GO:BP | GO:1905049 | negative regulation of metallopeptidase activity | 1 | 7 | 4.58e-01 |
| GO:BP | GO:0043666 | regulation of phosphoprotein phosphatase activity | 1 | 47 | 4.58e-01 |
| GO:BP | GO:0006515 | protein quality control for misfolded or incompletely synthesized proteins | 3 | 28 | 4.58e-01 |
| GO:BP | GO:0045616 | regulation of keratinocyte differentiation | 1 | 25 | 4.58e-01 |
| GO:BP | GO:1903978 | regulation of microglial cell activation | 2 | 9 | 4.59e-01 |
| GO:BP | GO:0035372 | protein localization to microtubule | 2 | 18 | 4.59e-01 |
| GO:BP | GO:0043434 | response to peptide hormone | 2 | 321 | 4.59e-01 |
| GO:BP | GO:0051353 | positive regulation of oxidoreductase activity | 1 | 43 | 4.59e-01 |
| GO:BP | GO:0032785 | negative regulation of DNA-templated transcription, elongation | 2 | 20 | 4.59e-01 |
| GO:BP | GO:0035994 | response to muscle stretch | 2 | 26 | 4.59e-01 |
| GO:BP | GO:0017145 | stem cell division | 1 | 26 | 4.59e-01 |
| GO:BP | GO:0060754 | positive regulation of mast cell chemotaxis | 1 | 5 | 4.59e-01 |
| GO:BP | GO:0001755 | neural crest cell migration | 5 | 49 | 4.59e-01 |
| GO:BP | GO:0031113 | regulation of microtubule polymerization | 2 | 52 | 4.59e-01 |
| GO:BP | GO:1903020 | positive regulation of glycoprotein metabolic process | 2 | 17 | 4.59e-01 |
| GO:BP | GO:0043067 | regulation of programmed cell death | 51 | 1111 | 4.60e-01 |
| GO:BP | GO:0051491 | positive regulation of filopodium assembly | 3 | 25 | 4.60e-01 |
| GO:BP | GO:0140718 | facultative heterochromatin formation | 1 | 35 | 4.60e-01 |
| GO:BP | GO:0071705 | nitrogen compound transport | 2 | 1684 | 4.60e-01 |
| GO:BP | GO:0010638 | positive regulation of organelle organization | 12 | 439 | 4.60e-01 |
| GO:BP | GO:0090501 | RNA phosphodiester bond hydrolysis | 1 | 136 | 4.60e-01 |
| GO:BP | GO:1902525 | regulation of protein monoubiquitination | 1 | 6 | 4.60e-01 |
| GO:BP | GO:0051962 | positive regulation of nervous system development | 17 | 221 | 4.61e-01 |
| GO:BP | GO:0050680 | negative regulation of epithelial cell proliferation | 4 | 111 | 4.61e-01 |
| GO:BP | GO:0007155 | cell adhesion | 2 | 1012 | 4.61e-01 |
| GO:BP | GO:0072318 | clathrin coat disassembly | 1 | 8 | 4.61e-01 |
| GO:BP | GO:0009893 | positive regulation of metabolic process | 12 | 2880 | 4.62e-01 |
| GO:BP | GO:0031133 | regulation of axon diameter | 1 | 4 | 4.63e-01 |
| GO:BP | GO:0060828 | regulation of canonical Wnt signaling pathway | 9 | 213 | 4.63e-01 |
| GO:BP | GO:0000470 | maturation of LSU-rRNA | 3 | 28 | 4.63e-01 |
| GO:BP | GO:0033603 | positive regulation of dopamine secretion | 1 | 4 | 4.63e-01 |
| GO:BP | GO:0090224 | regulation of spindle organization | 1 | 45 | 4.63e-01 |
| GO:BP | GO:0009988 | cell-cell recognition | 2 | 32 | 4.63e-01 |
| GO:BP | GO:0099505 | regulation of presynaptic membrane potential | 2 | 14 | 4.63e-01 |
| GO:BP | GO:0002686 | negative regulation of leukocyte migration | 4 | 30 | 4.63e-01 |
| GO:BP | GO:0006163 | purine nucleotide metabolic process | 1 | 371 | 4.63e-01 |
| GO:BP | GO:0042918 | alkanesulfonate transport | 1 | 6 | 4.63e-01 |
| GO:BP | GO:0015734 | taurine transport | 1 | 6 | 4.63e-01 |
| GO:BP | GO:0006198 | cAMP catabolic process | 1 | 9 | 4.63e-01 |
| GO:BP | GO:0044351 | macropinocytosis | 1 | 8 | 4.63e-01 |
| GO:BP | GO:0034755 | iron ion transmembrane transport | 1 | 16 | 4.63e-01 |
| GO:BP | GO:0001999 | renal response to blood flow involved in circulatory renin-angiotensin regulation of systemic arterial blood pressure | 1 | 4 | 4.63e-01 |
| GO:BP | GO:1905952 | regulation of lipid localization | 1 | 112 | 4.63e-01 |
| GO:BP | GO:0001914 | regulation of T cell mediated cytotoxicity | 1 | 17 | 4.63e-01 |
| GO:BP | GO:0032623 | interleukin-2 production | 2 | 31 | 4.63e-01 |
| GO:BP | GO:0033572 | transferrin transport | 1 | 8 | 4.63e-01 |
| GO:BP | GO:1900026 | positive regulation of substrate adhesion-dependent cell spreading | 3 | 39 | 4.63e-01 |
| GO:BP | GO:0002248 | connective tissue replacement involved in inflammatory response wound healing | 1 | 4 | 4.63e-01 |
| GO:BP | GO:0051346 | negative regulation of hydrolase activity | 11 | 220 | 4.63e-01 |
| GO:BP | GO:1901020 | negative regulation of calcium ion transmembrane transporter activity | 1 | 27 | 4.63e-01 |
| GO:BP | GO:0002001 | renin secretion into blood stream | 1 | 4 | 4.63e-01 |
| GO:BP | GO:0006563 | L-serine metabolic process | 1 | 10 | 4.63e-01 |
| GO:BP | GO:0032663 | regulation of interleukin-2 production | 2 | 31 | 4.63e-01 |
| GO:BP | GO:0051208 | sequestering of calcium ion | 4 | 89 | 4.63e-01 |
| GO:BP | GO:0060740 | prostate gland epithelium morphogenesis | 2 | 20 | 4.63e-01 |
| GO:BP | GO:0071484 | cellular response to light intensity | 1 | 4 | 4.64e-01 |
| GO:BP | GO:0060231 | mesenchymal to epithelial transition | 2 | 12 | 4.64e-01 |
| GO:BP | GO:0021978 | telencephalon regionalization | 1 | 4 | 4.64e-01 |
| GO:BP | GO:0070571 | negative regulation of neuron projection regeneration | 1 | 12 | 4.64e-01 |
| GO:BP | GO:0071384 | cellular response to corticosteroid stimulus | 3 | 47 | 4.64e-01 |
| GO:BP | GO:0046887 | positive regulation of hormone secretion | 4 | 90 | 4.64e-01 |
| GO:BP | GO:0060120 | inner ear receptor cell fate commitment | 1 | 4 | 4.64e-01 |
| GO:BP | GO:0016579 | protein deubiquitination | 1 | 129 | 4.64e-01 |
| GO:BP | GO:1990928 | response to amino acid starvation | 2 | 51 | 4.64e-01 |
| GO:BP | GO:0009912 | auditory receptor cell fate commitment | 1 | 4 | 4.64e-01 |
| GO:BP | GO:0018095 | protein polyglutamylation | 1 | 9 | 4.64e-01 |
| GO:BP | GO:0051173 | positive regulation of nitrogen compound metabolic process | 10 | 2412 | 4.65e-01 |
| GO:BP | GO:0070588 | calcium ion transmembrane transport | 11 | 213 | 4.65e-01 |
| GO:BP | GO:0034058 | endosomal vesicle fusion | 1 | 10 | 4.65e-01 |
| GO:BP | GO:0072576 | liver morphogenesis | 2 | 19 | 4.66e-01 |
| GO:BP | GO:0007220 | Notch receptor processing | 1 | 9 | 4.66e-01 |
| GO:BP | GO:0021612 | facial nerve structural organization | 1 | 7 | 4.66e-01 |
| GO:BP | GO:0098876 | vesicle-mediated transport to the plasma membrane | 2 | 143 | 4.66e-01 |
| GO:BP | GO:0045995 | regulation of embryonic development | 6 | 80 | 4.66e-01 |
| GO:BP | GO:0006451 | translational readthrough | 1 | 10 | 4.66e-01 |
| GO:BP | GO:0001514 | selenocysteine incorporation | 1 | 10 | 4.66e-01 |
| GO:BP | GO:0050850 | positive regulation of calcium-mediated signaling | 2 | 22 | 4.66e-01 |
| GO:BP | GO:0031077 | post-embryonic camera-type eye development | 1 | 7 | 4.66e-01 |
| GO:BP | GO:0032008 | positive regulation of TOR signaling | 1 | 43 | 4.67e-01 |
| GO:BP | GO:0062012 | regulation of small molecule metabolic process | 21 | 246 | 4.67e-01 |
| GO:BP | GO:0071800 | podosome assembly | 2 | 13 | 4.67e-01 |
| GO:BP | GO:2000107 | negative regulation of leukocyte apoptotic process | 3 | 33 | 4.67e-01 |
| GO:BP | GO:0045453 | bone resorption | 3 | 40 | 4.67e-01 |
| GO:BP | GO:0060338 | regulation of type I interferon-mediated signaling pathway | 3 | 35 | 4.67e-01 |
| GO:BP | GO:0051402 | neuron apoptotic process | 7 | 200 | 4.68e-01 |
| GO:BP | GO:0002495 | antigen processing and presentation of peptide antigen via MHC class II | 3 | 17 | 4.68e-01 |
| GO:BP | GO:0062013 | positive regulation of small molecule metabolic process | 10 | 104 | 4.68e-01 |
| GO:BP | GO:0061469 | regulation of type B pancreatic cell proliferation | 1 | 14 | 4.68e-01 |
| GO:BP | GO:0034032 | purine nucleoside bisphosphate metabolic process | 1 | 92 | 4.68e-01 |
| GO:BP | GO:0033875 | ribonucleoside bisphosphate metabolic process | 1 | 92 | 4.68e-01 |
| GO:BP | GO:0019511 | peptidyl-proline hydroxylation | 1 | 14 | 4.68e-01 |
| GO:BP | GO:0033865 | nucleoside bisphosphate metabolic process | 1 | 92 | 4.68e-01 |
| GO:BP | GO:0034087 | establishment of mitotic sister chromatid cohesion | 1 | 7 | 4.68e-01 |
| GO:BP | GO:0035609 | C-terminal protein deglutamylation | 1 | 2 | 4.68e-01 |
| GO:BP | GO:0090313 | regulation of protein targeting to membrane | 2 | 27 | 4.69e-01 |
| GO:BP | GO:0070423 | nucleotide-binding oligomerization domain containing signaling pathway | 1 | 18 | 4.69e-01 |
| GO:BP | GO:0060544 | regulation of necroptotic process | 1 | 23 | 4.69e-01 |
| GO:BP | GO:2000353 | positive regulation of endothelial cell apoptotic process | 1 | 13 | 4.69e-01 |
| GO:BP | GO:1990806 | ligand-gated ion channel signaling pathway | 3 | 20 | 4.69e-01 |
| GO:BP | GO:0051156 | glucose 6-phosphate metabolic process | 2 | 25 | 4.69e-01 |
| GO:BP | GO:0098902 | regulation of membrane depolarization during action potential | 1 | 5 | 4.69e-01 |
| GO:BP | GO:0043485 | endosome to pigment granule transport | 1 | 9 | 4.69e-01 |
| GO:BP | GO:0048757 | pigment granule maturation | 1 | 9 | 4.69e-01 |
| GO:BP | GO:0021892 | cerebral cortex GABAergic interneuron differentiation | 1 | 3 | 4.69e-01 |
| GO:BP | GO:0009142 | nucleoside triphosphate biosynthetic process | 1 | 111 | 4.69e-01 |
| GO:BP | GO:0035646 | endosome to melanosome transport | 1 | 9 | 4.69e-01 |
| GO:BP | GO:0010927 | cellular component assembly involved in morphogenesis | 2 | 106 | 4.69e-01 |
| GO:BP | GO:1901099 | negative regulation of signal transduction in absence of ligand | 3 | 25 | 4.69e-01 |
| GO:BP | GO:0042795 | snRNA transcription by RNA polymerase II | 1 | 15 | 4.69e-01 |
| GO:BP | GO:2001240 | negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 3 | 25 | 4.69e-01 |
| GO:BP | GO:0070672 | response to interleukin-15 | 1 | 3 | 4.69e-01 |
| GO:BP | GO:0000086 | G2/M transition of mitotic cell cycle | 1 | 134 | 4.69e-01 |
| GO:BP | GO:0051593 | response to folic acid | 1 | 9 | 4.69e-01 |
| GO:BP | GO:1904116 | response to vasopressin | 1 | 5 | 4.69e-01 |
| GO:BP | GO:1904117 | cellular response to vasopressin | 1 | 5 | 4.69e-01 |
| GO:BP | GO:0050982 | detection of mechanical stimulus | 4 | 32 | 4.69e-01 |
| GO:BP | GO:0032620 | interleukin-17 production | 1 | 20 | 4.69e-01 |
| GO:BP | GO:0032660 | regulation of interleukin-17 production | 1 | 20 | 4.69e-01 |
| GO:BP | GO:0060285 | cilium-dependent cell motility | 2 | 74 | 4.69e-01 |
| GO:BP | GO:0035696 | monocyte extravasation | 1 | 5 | 4.69e-01 |
| GO:BP | GO:0001539 | cilium or flagellum-dependent cell motility | 2 | 74 | 4.69e-01 |
| GO:BP | GO:0007097 | nuclear migration | 2 | 23 | 4.69e-01 |
| GO:BP | GO:0048012 | hepatocyte growth factor receptor signaling pathway | 1 | 10 | 4.69e-01 |
| GO:BP | GO:0007207 | phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway | 1 | 6 | 4.69e-01 |
| GO:BP | GO:0051604 | protein maturation | 1 | 259 | 4.69e-01 |
| GO:BP | GO:0032754 | positive regulation of interleukin-5 production | 1 | 6 | 4.69e-01 |
| GO:BP | GO:0044381 | glucose import in response to insulin stimulus | 1 | 4 | 4.70e-01 |
| GO:BP | GO:0006629 | lipid metabolic process | 1 | 994 | 4.70e-01 |
| GO:BP | GO:1902916 | positive regulation of protein polyubiquitination | 2 | 13 | 4.70e-01 |
| GO:BP | GO:0035418 | protein localization to synapse | 7 | 68 | 4.70e-01 |
| GO:BP | GO:1901016 | regulation of potassium ion transmembrane transporter activity | 1 | 45 | 4.70e-01 |
| GO:BP | GO:0030850 | prostate gland development | 3 | 35 | 4.71e-01 |
| GO:BP | GO:0006508 | proteolysis | 6 | 1318 | 4.71e-01 |
| GO:BP | GO:0019626 | short-chain fatty acid catabolic process | 1 | 6 | 4.71e-01 |
| GO:BP | GO:1990709 | presynaptic active zone organization | 1 | 9 | 4.71e-01 |
| GO:BP | GO:0051446 | positive regulation of meiotic cell cycle | 2 | 16 | 4.71e-01 |
| GO:BP | GO:0060042 | retina morphogenesis in camera-type eye | 3 | 40 | 4.71e-01 |
| GO:BP | GO:0051172 | negative regulation of nitrogen compound metabolic process | 2 | 1849 | 4.71e-01 |
| GO:BP | GO:1903051 | negative regulation of proteolysis involved in protein catabolic process | 6 | 61 | 4.71e-01 |
| GO:BP | GO:0090027 | negative regulation of monocyte chemotaxis | 1 | 4 | 4.72e-01 |
| GO:BP | GO:0071229 | cellular response to acid chemical | 7 | 71 | 4.72e-01 |
| GO:BP | GO:0034763 | negative regulation of transmembrane transport | 4 | 96 | 4.72e-01 |
| GO:BP | GO:0032060 | bleb assembly | 1 | 9 | 4.72e-01 |
| GO:BP | GO:0034105 | positive regulation of tissue remodeling | 1 | 4 | 4.72e-01 |
| GO:BP | GO:0070301 | cellular response to hydrogen peroxide | 5 | 73 | 4.72e-01 |
| GO:BP | GO:0001890 | placenta development | 11 | 117 | 4.72e-01 |
| GO:BP | GO:0007172 | signal complex assembly | 1 | 7 | 4.73e-01 |
| GO:BP | GO:0048255 | mRNA stabilization | 1 | 50 | 4.73e-01 |
| GO:BP | GO:0002483 | antigen processing and presentation of endogenous peptide antigen | 2 | 16 | 4.73e-01 |
| GO:BP | GO:2000647 | negative regulation of stem cell proliferation | 1 | 18 | 4.73e-01 |
| GO:BP | GO:0071375 | cellular response to peptide hormone stimulus | 15 | 241 | 4.73e-01 |
| GO:BP | GO:0045778 | positive regulation of ossification | 3 | 40 | 4.73e-01 |
| GO:BP | GO:0051649 | establishment of localization in cell | 2 | 1836 | 4.73e-01 |
| GO:BP | GO:0010803 | regulation of tumor necrosis factor-mediated signaling pathway | 3 | 41 | 4.73e-01 |
| GO:BP | GO:0045880 | positive regulation of smoothened signaling pathway | 1 | 31 | 4.73e-01 |
| GO:BP | GO:0031062 | positive regulation of histone methylation | 1 | 36 | 4.73e-01 |
| GO:BP | GO:0007589 | body fluid secretion | 1 | 60 | 4.73e-01 |
| GO:BP | GO:0032411 | positive regulation of transporter activity | 2 | 93 | 4.73e-01 |
| GO:BP | GO:0033081 | regulation of T cell differentiation in thymus | 2 | 16 | 4.74e-01 |
| GO:BP | GO:0098810 | neurotransmitter reuptake | 1 | 21 | 4.74e-01 |
| GO:BP | GO:0048340 | paraxial mesoderm morphogenesis | 1 | 9 | 4.74e-01 |
| GO:BP | GO:0050772 | positive regulation of axonogenesis | 1 | 72 | 4.74e-01 |
| GO:BP | GO:0016115 | terpenoid catabolic process | 1 | 4 | 4.74e-01 |
| GO:BP | GO:0048387 | negative regulation of retinoic acid receptor signaling pathway | 1 | 6 | 4.74e-01 |
| GO:BP | GO:0032504 | multicellular organism reproduction | 6 | 556 | 4.75e-01 |
| GO:BP | GO:0061002 | negative regulation of dendritic spine morphogenesis | 1 | 6 | 4.75e-01 |
| GO:BP | GO:0045861 | negative regulation of proteolysis | 24 | 211 | 4.75e-01 |
| GO:BP | GO:0009991 | response to extracellular stimulus | 2 | 377 | 4.75e-01 |
| GO:BP | GO:0060068 | vagina development | 1 | 8 | 4.75e-01 |
| GO:BP | GO:0034499 | late endosome to Golgi transport | 1 | 5 | 4.75e-01 |
| GO:BP | GO:0046631 | alpha-beta T cell activation | 1 | 89 | 4.76e-01 |
| GO:BP | GO:0035872 | nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway | 1 | 19 | 4.76e-01 |
| GO:BP | GO:0002191 | cap-dependent translational initiation | 1 | 7 | 4.76e-01 |
| GO:BP | GO:0061087 | positive regulation of histone H3-K27 methylation | 1 | 4 | 4.76e-01 |
| GO:BP | GO:0043132 | NAD transport | 1 | 3 | 4.76e-01 |
| GO:BP | GO:2000209 | regulation of anoikis | 2 | 23 | 4.76e-01 |
| GO:BP | GO:0010604 | positive regulation of macromolecule metabolic process | 11 | 2646 | 4.76e-01 |
| GO:BP | GO:0032481 | positive regulation of type I interferon production | 1 | 45 | 4.76e-01 |
| GO:BP | GO:0061025 | membrane fusion | 2 | 137 | 4.76e-01 |
| GO:BP | GO:0045838 | positive regulation of membrane potential | 1 | 12 | 4.76e-01 |
| GO:BP | GO:0016444 | somatic cell DNA recombination | 3 | 55 | 4.76e-01 |
| GO:BP | GO:0002562 | somatic diversification of immune receptors via germline recombination within a single locus | 3 | 55 | 4.76e-01 |
| GO:BP | GO:1901698 | response to nitrogen compound | 8 | 830 | 4.76e-01 |
| GO:BP | GO:0071280 | cellular response to copper ion | 1 | 18 | 4.76e-01 |
| GO:BP | GO:0032933 | SREBP signaling pathway | 1 | 14 | 4.76e-01 |
| GO:BP | GO:0001659 | temperature homeostasis | 2 | 132 | 4.76e-01 |
| GO:BP | GO:1905906 | regulation of amyloid fibril formation | 1 | 14 | 4.77e-01 |
| GO:BP | GO:0046513 | ceramide biosynthetic process | 1 | 53 | 4.77e-01 |
| GO:BP | GO:0033151 | V(D)J recombination | 1 | 16 | 4.77e-01 |
| GO:BP | GO:0090497 | mesenchymal cell migration | 5 | 51 | 4.78e-01 |
| GO:BP | GO:0051127 | positive regulation of actin nucleation | 1 | 14 | 4.78e-01 |
| GO:BP | GO:0010755 | regulation of plasminogen activation | 2 | 16 | 4.78e-01 |
| GO:BP | GO:0022410 | circadian sleep/wake cycle process | 2 | 10 | 4.78e-01 |
| GO:BP | GO:0043408 | regulation of MAPK cascade | 43 | 475 | 4.78e-01 |
| GO:BP | GO:0043415 | positive regulation of skeletal muscle tissue regeneration | 1 | 4 | 4.78e-01 |
| GO:BP | GO:0051382 | kinetochore assembly | 2 | 18 | 4.78e-01 |
| GO:BP | GO:0019233 | sensory perception of pain | 8 | 48 | 4.78e-01 |
| GO:BP | GO:0010975 | regulation of neuron projection development | 3 | 372 | 4.78e-01 |
| GO:BP | GO:0007096 | regulation of exit from mitosis | 1 | 17 | 4.79e-01 |
| GO:BP | GO:0010661 | positive regulation of muscle cell apoptotic process | 1 | 20 | 4.79e-01 |
| GO:BP | GO:0048242 | epinephrine secretion | 1 | 2 | 4.79e-01 |
| GO:BP | GO:0014060 | regulation of epinephrine secretion | 1 | 2 | 4.79e-01 |
| GO:BP | GO:0098976 | excitatory chemical synaptic transmission | 1 | 6 | 4.79e-01 |
| GO:BP | GO:0051123 | RNA polymerase II preinitiation complex assembly | 3 | 54 | 4.79e-01 |
| GO:BP | GO:0044248 | cellular catabolic process | 10 | 1229 | 4.79e-01 |
| GO:BP | GO:1902003 | regulation of amyloid-beta formation | 2 | 33 | 4.79e-01 |
| GO:BP | GO:1901137 | carbohydrate derivative biosynthetic process | 5 | 544 | 4.79e-01 |
| GO:BP | GO:0008016 | regulation of heart contraction | 2 | 173 | 4.79e-01 |
| GO:BP | GO:1901362 | organic cyclic compound biosynthetic process | 13 | 3237 | 4.79e-01 |
| GO:BP | GO:0007006 | mitochondrial membrane organization | 2 | 114 | 4.79e-01 |
| GO:BP | GO:0032535 | regulation of cellular component size | 12 | 305 | 4.79e-01 |
| GO:BP | GO:0039536 | negative regulation of RIG-I signaling pathway | 1 | 7 | 4.79e-01 |
| GO:BP | GO:0010565 | regulation of cellular ketone metabolic process | 4 | 98 | 4.80e-01 |
| GO:BP | GO:0019062 | virion attachment to host cell | 1 | 9 | 4.80e-01 |
| GO:BP | GO:0048588 | developmental cell growth | 5 | 192 | 4.80e-01 |
| GO:BP | GO:0006720 | isoprenoid metabolic process | 1 | 85 | 4.80e-01 |
| GO:BP | GO:0043313 | regulation of neutrophil degranulation | 1 | 1 | 4.81e-01 |
| GO:BP | GO:0098781 | ncRNA transcription | 3 | 61 | 4.81e-01 |
| GO:BP | GO:1901532 | regulation of hematopoietic progenitor cell differentiation | 2 | 34 | 4.81e-01 |
| GO:BP | GO:0050714 | positive regulation of protein secretion | 4 | 100 | 4.81e-01 |
| GO:BP | GO:0070169 | positive regulation of biomineral tissue development | 3 | 39 | 4.81e-01 |
| GO:BP | GO:0043647 | inositol phosphate metabolic process | 1 | 35 | 4.81e-01 |
| GO:BP | GO:2000303 | regulation of ceramide biosynthetic process | 1 | 11 | 4.81e-01 |
| GO:BP | GO:0006417 | regulation of translation | 16 | 370 | 4.81e-01 |
| GO:BP | GO:0042976 | activation of Janus kinase activity | 1 | 7 | 4.81e-01 |
| GO:BP | GO:0032988 | ribonucleoprotein complex disassembly | 1 | 8 | 4.81e-01 |
| GO:BP | GO:0032762 | mast cell cytokine production | 1 | 6 | 4.82e-01 |
| GO:BP | GO:0032763 | regulation of mast cell cytokine production | 1 | 6 | 4.82e-01 |
| GO:BP | GO:0010821 | regulation of mitochondrion organization | 6 | 135 | 4.82e-01 |
| GO:BP | GO:0036017 | response to erythropoietin | 1 | 4 | 4.82e-01 |
| GO:BP | GO:2000310 | regulation of NMDA receptor activity | 2 | 19 | 4.82e-01 |
| GO:BP | GO:0048524 | positive regulation of viral process | 1 | 55 | 4.82e-01 |
| GO:BP | GO:0071265 | L-methionine biosynthetic process | 1 | 5 | 4.82e-01 |
| GO:BP | GO:0032092 | positive regulation of protein binding | 5 | 78 | 4.82e-01 |
| GO:BP | GO:0033353 | S-adenosylmethionine cycle | 1 | 7 | 4.82e-01 |
| GO:BP | GO:0090435 | protein localization to nuclear envelope | 1 | 14 | 4.82e-01 |
| GO:BP | GO:0043102 | amino acid salvage | 1 | 5 | 4.82e-01 |
| GO:BP | GO:0071267 | L-methionine salvage | 1 | 5 | 4.82e-01 |
| GO:BP | GO:1902414 | protein localization to cell junction | 9 | 93 | 4.82e-01 |
| GO:BP | GO:0007276 | gamete generation | 5 | 461 | 4.83e-01 |
| GO:BP | GO:0072319 | vesicle uncoating | 1 | 9 | 4.83e-01 |
| GO:BP | GO:0016571 | histone methylation | 2 | 117 | 4.83e-01 |
| GO:BP | GO:0032402 | melanosome transport | 2 | 19 | 4.83e-01 |
| GO:BP | GO:0060602 | branch elongation of an epithelium | 1 | 14 | 4.83e-01 |
| GO:BP | GO:0034196 | acylglycerol transport | 1 | 4 | 4.83e-01 |
| GO:BP | GO:0034197 | triglyceride transport | 1 | 4 | 4.83e-01 |
| GO:BP | GO:1902389 | ceramide 1-phosphate transport | 1 | 7 | 4.83e-01 |
| GO:BP | GO:0002158 | osteoclast proliferation | 1 | 7 | 4.84e-01 |
| GO:BP | GO:0060143 | positive regulation of syncytium formation by plasma membrane fusion | 1 | 12 | 4.84e-01 |
| GO:BP | GO:0043153 | entrainment of circadian clock by photoperiod | 1 | 27 | 4.84e-01 |
| GO:BP | GO:0014866 | skeletal myofibril assembly | 1 | 9 | 4.85e-01 |
| GO:BP | GO:0046467 | membrane lipid biosynthetic process | 7 | 124 | 4.85e-01 |
| GO:BP | GO:0006487 | protein N-linked glycosylation | 1 | 65 | 4.85e-01 |
| GO:BP | GO:0061718 | glucose catabolic process to pyruvate | 1 | 15 | 4.85e-01 |
| GO:BP | GO:0060512 | prostate gland morphogenesis | 2 | 21 | 4.85e-01 |
| GO:BP | GO:0021952 | central nervous system projection neuron axonogenesis | 2 | 23 | 4.85e-01 |
| GO:BP | GO:0061621 | canonical glycolysis | 1 | 15 | 4.85e-01 |
| GO:BP | GO:0006735 | NADH regeneration | 1 | 15 | 4.85e-01 |
| GO:BP | GO:0048513 | animal organ development | 5 | 2189 | 4.85e-01 |
| GO:BP | GO:2000243 | positive regulation of reproductive process | 5 | 54 | 4.85e-01 |
| GO:BP | GO:0070646 | protein modification by small protein removal | 1 | 147 | 4.85e-01 |
| GO:BP | GO:0051235 | maintenance of location | 9 | 260 | 4.86e-01 |
| GO:BP | GO:0046890 | regulation of lipid biosynthetic process | 5 | 134 | 4.86e-01 |
| GO:BP | GO:0010951 | negative regulation of endopeptidase activity | 11 | 102 | 4.86e-01 |
| GO:BP | GO:0071941 | nitrogen cycle metabolic process | 1 | 7 | 4.86e-01 |
| GO:BP | GO:0032438 | melanosome organization | 1 | 36 | 4.86e-01 |
| GO:BP | GO:0002891 | positive regulation of immunoglobulin mediated immune response | 1 | 26 | 4.86e-01 |
| GO:BP | GO:0019627 | urea metabolic process | 1 | 7 | 4.86e-01 |
| GO:BP | GO:0002714 | positive regulation of B cell mediated immunity | 1 | 26 | 4.86e-01 |
| GO:BP | GO:0009175 | pyrimidine ribonucleoside monophosphate catabolic process | 1 | 4 | 4.86e-01 |
| GO:BP | GO:0050777 | negative regulation of immune response | 1 | 111 | 4.86e-01 |
| GO:BP | GO:0048640 | negative regulation of developmental growth | 9 | 95 | 4.87e-01 |
| GO:BP | GO:0016197 | endosomal transport | 15 | 231 | 4.87e-01 |
| GO:BP | GO:1903779 | regulation of cardiac conduction | 2 | 23 | 4.87e-01 |
| GO:BP | GO:0044249 | cellular biosynthetic process | 4 | 4245 | 4.87e-01 |
| GO:BP | GO:0097009 | energy homeostasis | 1 | 39 | 4.87e-01 |
| GO:BP | GO:0015698 | inorganic anion transport | 3 | 104 | 4.87e-01 |
| GO:BP | GO:0048261 | negative regulation of receptor-mediated endocytosis | 1 | 25 | 4.87e-01 |
| GO:BP | GO:0001708 | cell fate specification | 1 | 56 | 4.88e-01 |
| GO:BP | GO:0051252 | regulation of RNA metabolic process | 3 | 2845 | 4.88e-01 |
| GO:BP | GO:0061549 | sympathetic ganglion development | 1 | 6 | 4.89e-01 |
| GO:BP | GO:1904385 | cellular response to angiotensin | 2 | 23 | 4.89e-01 |
| GO:BP | GO:0071731 | response to nitric oxide | 2 | 16 | 4.89e-01 |
| GO:BP | GO:0071380 | cellular response to prostaglandin E stimulus | 1 | 14 | 4.89e-01 |
| GO:BP | GO:0097168 | mesenchymal stem cell proliferation | 1 | 4 | 4.89e-01 |
| GO:BP | GO:0060717 | chorion development | 1 | 8 | 4.89e-01 |
| GO:BP | GO:0010761 | fibroblast migration | 3 | 52 | 4.89e-01 |
| GO:BP | GO:0035313 | wound healing, spreading of epidermal cells | 2 | 17 | 4.89e-01 |
| GO:BP | GO:0032606 | type I interferon production | 6 | 76 | 4.89e-01 |
| GO:BP | GO:0033211 | adiponectin-activated signaling pathway | 1 | 7 | 4.89e-01 |
| GO:BP | GO:0098792 | xenophagy | 1 | 12 | 4.89e-01 |
| GO:BP | GO:0060402 | calcium ion transport into cytosol | 2 | 18 | 4.89e-01 |
| GO:BP | GO:0032479 | regulation of type I interferon production | 6 | 76 | 4.89e-01 |
| GO:BP | GO:0046683 | response to organophosphorus | 3 | 96 | 4.89e-01 |
| GO:BP | GO:0002757 | immune response-activating signaling pathway | 2 | 230 | 4.89e-01 |
| GO:BP | GO:0006414 | translational elongation | 3 | 65 | 4.89e-01 |
| GO:BP | GO:0001578 | microtubule bundle formation | 1 | 79 | 4.89e-01 |
| GO:BP | GO:0060759 | regulation of response to cytokine stimulus | 9 | 126 | 4.90e-01 |
| GO:BP | GO:0071345 | cellular response to cytokine stimulus | 4 | 540 | 4.90e-01 |
| GO:BP | GO:0051044 | positive regulation of membrane protein ectodomain proteolysis | 1 | 11 | 4.90e-01 |
| GO:BP | GO:0001845 | phagolysosome assembly | 1 | 14 | 4.90e-01 |
| GO:BP | GO:0071548 | response to dexamethasone | 1 | 36 | 4.90e-01 |
| GO:BP | GO:0000132 | establishment of mitotic spindle orientation | 3 | 31 | 4.90e-01 |
| GO:BP | GO:0030522 | intracellular receptor signaling pathway | 6 | 227 | 4.90e-01 |
| GO:BP | GO:0071501 | cellular response to sterol depletion | 1 | 14 | 4.90e-01 |
| GO:BP | GO:0044839 | cell cycle G2/M phase transition | 1 | 149 | 4.90e-01 |
| GO:BP | GO:1901983 | regulation of protein acetylation | 2 | 69 | 4.90e-01 |
| GO:BP | GO:0039529 | RIG-I signaling pathway | 1 | 22 | 4.90e-01 |
| GO:BP | GO:0097577 | sequestering of iron ion | 1 | 3 | 4.90e-01 |
| GO:BP | GO:0010524 | positive regulation of calcium ion transport into cytosol | 1 | 7 | 4.90e-01 |
| GO:BP | GO:0062098 | regulation of programmed necrotic cell death | 1 | 26 | 4.90e-01 |
| GO:BP | GO:0014046 | dopamine secretion | 1 | 23 | 4.90e-01 |
| GO:BP | GO:0003007 | heart morphogenesis | 15 | 216 | 4.90e-01 |
| GO:BP | GO:0060260 | regulation of transcription initiation by RNA polymerase II | 3 | 69 | 4.90e-01 |
| GO:BP | GO:0048753 | pigment granule organization | 1 | 37 | 4.90e-01 |
| GO:BP | GO:0000288 | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 1 | 64 | 4.90e-01 |
| GO:BP | GO:2000641 | regulation of early endosome to late endosome transport | 2 | 17 | 4.90e-01 |
| GO:BP | GO:0051546 | keratinocyte migration | 2 | 15 | 4.90e-01 |
| GO:BP | GO:0014856 | skeletal muscle cell proliferation | 2 | 14 | 4.90e-01 |
| GO:BP | GO:0010823 | negative regulation of mitochondrion organization | 2 | 46 | 4.90e-01 |
| GO:BP | GO:0061302 | smooth muscle cell-matrix adhesion | 1 | 5 | 4.90e-01 |
| GO:BP | GO:0062149 | detection of stimulus involved in sensory perception of pain | 1 | 15 | 4.90e-01 |
| GO:BP | GO:0060676 | ureteric bud formation | 1 | 5 | 4.90e-01 |
| GO:BP | GO:0048584 | positive regulation of response to stimulus | 1 | 1555 | 4.91e-01 |
| GO:BP | GO:0007183 | SMAD protein complex assembly | 1 | 12 | 4.91e-01 |
| GO:BP | GO:0007219 | Notch signaling pathway | 1 | 146 | 4.91e-01 |
| GO:BP | GO:0042481 | regulation of odontogenesis | 2 | 10 | 4.91e-01 |
| GO:BP | GO:0021683 | cerebellar granular layer morphogenesis | 1 | 8 | 4.91e-01 |
| GO:BP | GO:0040009 | regulation of growth rate | 1 | 3 | 4.91e-01 |
| GO:BP | GO:1901993 | regulation of meiotic cell cycle phase transition | 1 | 5 | 4.91e-01 |
| GO:BP | GO:0015718 | monocarboxylic acid transport | 1 | 90 | 4.92e-01 |
| GO:BP | GO:0030574 | collagen catabolic process | 1 | 26 | 4.92e-01 |
| GO:BP | GO:0046655 | folic acid metabolic process | 1 | 14 | 4.92e-01 |
| GO:BP | GO:1901570 | fatty acid derivative biosynthetic process | 4 | 33 | 4.92e-01 |
| GO:BP | GO:0006730 | one-carbon metabolic process | 2 | 29 | 4.92e-01 |
| GO:BP | GO:1900262 | regulation of DNA-directed DNA polymerase activity | 1 | 13 | 4.92e-01 |
| GO:BP | GO:0006264 | mitochondrial DNA replication | 1 | 13 | 4.92e-01 |
| GO:BP | GO:0060271 | cilium assembly | 21 | 292 | 4.92e-01 |
| GO:BP | GO:0023019 | signal transduction involved in regulation of gene expression | 2 | 14 | 4.92e-01 |
| GO:BP | GO:1900264 | positive regulation of DNA-directed DNA polymerase activity | 1 | 13 | 4.92e-01 |
| GO:BP | GO:0030838 | positive regulation of actin filament polymerization | 2 | 39 | 4.92e-01 |
| GO:BP | GO:0045602 | negative regulation of endothelial cell differentiation | 1 | 7 | 4.92e-01 |
| GO:BP | GO:0062043 | positive regulation of cardiac epithelial to mesenchymal transition | 1 | 9 | 4.92e-01 |
| GO:BP | GO:0045214 | sarcomere organization | 1 | 43 | 4.92e-01 |
| GO:BP | GO:0071402 | cellular response to lipoprotein particle stimulus | 2 | 23 | 4.92e-01 |
| GO:BP | GO:0009312 | oligosaccharide biosynthetic process | 1 | 15 | 4.93e-01 |
| GO:BP | GO:0051654 | establishment of mitochondrion localization | 3 | 30 | 4.93e-01 |
| GO:BP | GO:0010936 | negative regulation of macrophage cytokine production | 1 | 7 | 4.93e-01 |
| GO:BP | GO:0007029 | endoplasmic reticulum organization | 3 | 83 | 4.93e-01 |
| GO:BP | GO:0042129 | regulation of T cell proliferation | 3 | 95 | 4.93e-01 |
| GO:BP | GO:0048485 | sympathetic nervous system development | 2 | 14 | 4.93e-01 |
| GO:BP | GO:0043374 | CD8-positive, alpha-beta T cell differentiation | 1 | 8 | 4.93e-01 |
| GO:BP | GO:0060334 | regulation of type II interferon-mediated signaling pathway | 1 | 12 | 4.93e-01 |
| GO:BP | GO:0060330 | regulation of response to type II interferon | 1 | 12 | 4.93e-01 |
| GO:BP | GO:0098534 | centriole assembly | 2 | 41 | 4.93e-01 |
| GO:BP | GO:0060632 | regulation of microtubule-based movement | 1 | 31 | 4.93e-01 |
| GO:BP | GO:0046826 | negative regulation of protein export from nucleus | 1 | 6 | 4.93e-01 |
| GO:BP | GO:0070989 | oxidative demethylation | 1 | 10 | 4.95e-01 |
| GO:BP | GO:1900102 | negative regulation of endoplasmic reticulum unfolded protein response | 1 | 16 | 4.95e-01 |
| GO:BP | GO:0021553 | olfactory nerve development | 1 | 5 | 4.95e-01 |
| GO:BP | GO:0040016 | embryonic cleavage | 1 | 7 | 4.95e-01 |
| GO:BP | GO:0050847 | progesterone receptor signaling pathway | 1 | 9 | 4.95e-01 |
| GO:BP | GO:0002176 | male germ cell proliferation | 1 | 6 | 4.95e-01 |
| GO:BP | GO:0035635 | entry of bacterium into host cell | 1 | 8 | 4.95e-01 |
| GO:BP | GO:0001913 | T cell mediated cytotoxicity | 1 | 22 | 4.95e-01 |
| GO:BP | GO:0006457 | protein folding | 2 | 192 | 4.95e-01 |
| GO:BP | GO:0090231 | regulation of spindle checkpoint | 2 | 19 | 4.95e-01 |
| GO:BP | GO:2000516 | positive regulation of CD4-positive, alpha-beta T cell activation | 2 | 20 | 4.95e-01 |
| GO:BP | GO:0042311 | vasodilation | 1 | 39 | 4.95e-01 |
| GO:BP | GO:0097421 | liver regeneration | 3 | 23 | 4.95e-01 |
| GO:BP | GO:0090266 | regulation of mitotic cell cycle spindle assembly checkpoint | 2 | 19 | 4.95e-01 |
| GO:BP | GO:0050881 | musculoskeletal movement | 3 | 41 | 4.95e-01 |
| GO:BP | GO:1903504 | regulation of mitotic spindle checkpoint | 2 | 19 | 4.95e-01 |
| GO:BP | GO:0030517 | negative regulation of axon extension | 4 | 41 | 4.96e-01 |
| GO:BP | GO:0090153 | regulation of sphingolipid biosynthetic process | 1 | 12 | 4.96e-01 |
| GO:BP | GO:1905038 | regulation of membrane lipid metabolic process | 1 | 12 | 4.96e-01 |
| GO:BP | GO:0031401 | positive regulation of protein modification process | 26 | 719 | 4.97e-01 |
| GO:BP | GO:0033617 | mitochondrial cytochrome c oxidase assembly | 2 | 25 | 4.97e-01 |
| GO:BP | GO:0001776 | leukocyte homeostasis | 5 | 69 | 4.97e-01 |
| GO:BP | GO:0032401 | establishment of melanosome localization | 2 | 20 | 4.97e-01 |
| GO:BP | GO:0055015 | ventricular cardiac muscle cell development | 1 | 10 | 4.97e-01 |
| GO:BP | GO:0051904 | pigment granule transport | 2 | 19 | 4.97e-01 |
| GO:BP | GO:0051865 | protein autoubiquitination | 3 | 75 | 4.97e-01 |
| GO:BP | GO:0110053 | regulation of actin filament organization | 10 | 228 | 4.97e-01 |
| GO:BP | GO:0006661 | phosphatidylinositol biosynthetic process | 8 | 119 | 4.97e-01 |
| GO:BP | GO:0071420 | cellular response to histamine | 1 | 4 | 4.97e-01 |
| GO:BP | GO:0051897 | positive regulation of protein kinase B signaling | 1 | 79 | 4.98e-01 |
| GO:BP | GO:1902855 | regulation of non-motile cilium assembly | 1 | 10 | 4.98e-01 |
| GO:BP | GO:0010839 | negative regulation of keratinocyte proliferation | 2 | 19 | 4.98e-01 |
| GO:BP | GO:0002831 | regulation of response to biotic stimulus | 2 | 293 | 4.99e-01 |
| GO:BP | GO:0000966 | RNA 5’-end processing | 1 | 22 | 4.99e-01 |
| GO:BP | GO:0010642 | negative regulation of platelet-derived growth factor receptor signaling pathway | 1 | 10 | 4.99e-01 |
| GO:BP | GO:0030148 | sphingolipid biosynthetic process | 5 | 88 | 4.99e-01 |
| GO:BP | GO:1902041 | regulation of extrinsic apoptotic signaling pathway via death domain receptors | 4 | 40 | 4.99e-01 |
| GO:BP | GO:0060644 | mammary gland epithelial cell differentiation | 1 | 14 | 4.99e-01 |
| GO:BP | GO:0002702 | positive regulation of production of molecular mediator of immune response | 2 | 77 | 4.99e-01 |
| GO:BP | GO:0043489 | RNA stabilization | 1 | 59 | 4.99e-01 |
| GO:BP | GO:0061448 | connective tissue development | 4 | 208 | 5.00e-01 |
| GO:BP | GO:0060513 | prostatic bud formation | 1 | 8 | 5.00e-01 |
| GO:BP | GO:2001258 | negative regulation of cation channel activity | 1 | 30 | 5.00e-01 |
| GO:BP | GO:1901021 | positive regulation of calcium ion transmembrane transporter activity | 1 | 39 | 5.00e-01 |
| GO:BP | GO:0021940 | positive regulation of cerebellar granule cell precursor proliferation | 1 | 6 | 5.00e-01 |
| GO:BP | GO:0036297 | interstrand cross-link repair | 1 | 37 | 5.01e-01 |
| GO:BP | GO:0010976 | positive regulation of neuron projection development | 1 | 131 | 5.01e-01 |
| GO:BP | GO:0099171 | presynaptic modulation of chemical synaptic transmission | 2 | 26 | 5.01e-01 |
| GO:BP | GO:0034498 | early endosome to Golgi transport | 1 | 9 | 5.01e-01 |
| GO:BP | GO:0051651 | maintenance of location in cell | 7 | 170 | 5.01e-01 |
| GO:BP | GO:1903317 | regulation of protein maturation | 6 | 50 | 5.01e-01 |
| GO:BP | GO:1903903 | regulation of establishment of T cell polarity | 1 | 6 | 5.02e-01 |
| GO:BP | GO:0050650 | chondroitin sulfate proteoglycan biosynthetic process | 1 | 20 | 5.02e-01 |
| GO:BP | GO:0032056 | positive regulation of translation in response to stress | 1 | 8 | 5.02e-01 |
| GO:BP | GO:1902416 | positive regulation of mRNA binding | 1 | 8 | 5.02e-01 |
| GO:BP | GO:0001934 | positive regulation of protein phosphorylation | 23 | 496 | 5.02e-01 |
| GO:BP | GO:0002461 | tolerance induction dependent upon immune response | 1 | 2 | 5.02e-01 |
| GO:BP | GO:0071786 | endoplasmic reticulum tubular network organization | 2 | 19 | 5.02e-01 |
| GO:BP | GO:0051984 | positive regulation of chromosome segregation | 1 | 27 | 5.02e-01 |
| GO:BP | GO:0032604 | granulocyte macrophage colony-stimulating factor production | 1 | 5 | 5.02e-01 |
| GO:BP | GO:1903753 | negative regulation of p38MAPK cascade | 1 | 5 | 5.02e-01 |
| GO:BP | GO:0032645 | regulation of granulocyte macrophage colony-stimulating factor production | 1 | 5 | 5.02e-01 |
| GO:BP | GO:0009301 | snRNA transcription | 1 | 18 | 5.02e-01 |
| GO:BP | GO:1902373 | negative regulation of mRNA catabolic process | 1 | 57 | 5.02e-01 |
| GO:BP | GO:0071500 | cellular response to nitrosative stress | 1 | 6 | 5.02e-01 |
| GO:BP | GO:0090494 | dopamine uptake | 2 | 10 | 5.02e-01 |
| GO:BP | GO:2000766 | negative regulation of cytoplasmic translation | 1 | 7 | 5.02e-01 |
| GO:BP | GO:1902075 | cellular response to salt | 1 | 142 | 5.03e-01 |
| GO:BP | GO:0006090 | pyruvate metabolic process | 7 | 93 | 5.03e-01 |
| GO:BP | GO:0090084 | negative regulation of inclusion body assembly | 1 | 10 | 5.03e-01 |
| GO:BP | GO:0090280 | positive regulation of calcium ion import | 1 | 11 | 5.03e-01 |
| GO:BP | GO:0098957 | anterograde axonal transport of mitochondrion | 1 | 5 | 5.03e-01 |
| GO:BP | GO:0035610 | protein side chain deglutamylation | 1 | 2 | 5.03e-01 |
| GO:BP | GO:0050879 | multicellular organismal movement | 3 | 41 | 5.04e-01 |
| GO:BP | GO:0061082 | myeloid leukocyte cytokine production | 1 | 38 | 5.04e-01 |
| GO:BP | GO:0008206 | bile acid metabolic process | 1 | 34 | 5.04e-01 |
| GO:BP | GO:0072520 | seminiferous tubule development | 1 | 13 | 5.04e-01 |
| GO:BP | GO:0043482 | cellular pigment accumulation | 1 | 11 | 5.05e-01 |
| GO:BP | GO:0043476 | pigment accumulation | 1 | 11 | 5.05e-01 |
| GO:BP | GO:0006591 | ornithine metabolic process | 1 | 6 | 5.06e-01 |
| GO:BP | GO:0051451 | myoblast migration | 1 | 11 | 5.06e-01 |
| GO:BP | GO:0003188 | heart valve formation | 1 | 16 | 5.06e-01 |
| GO:BP | GO:0048861 | leukemia inhibitory factor signaling pathway | 1 | 6 | 5.06e-01 |
| GO:BP | GO:0045835 | negative regulation of meiotic nuclear division | 1 | 5 | 5.06e-01 |
| GO:BP | GO:0032488 | Cdc42 protein signal transduction | 1 | 10 | 5.06e-01 |
| GO:BP | GO:0002090 | regulation of receptor internalization | 5 | 49 | 5.06e-01 |
| GO:BP | GO:0046854 | phosphatidylinositol phosphate biosynthetic process | 5 | 59 | 5.06e-01 |
| GO:BP | GO:0035162 | embryonic hemopoiesis | 1 | 19 | 5.07e-01 |
| GO:BP | GO:0002521 | leukocyte differentiation | 2 | 382 | 5.07e-01 |
| GO:BP | GO:1990379 | lipid transport across blood-brain barrier | 1 | 6 | 5.07e-01 |
| GO:BP | GO:0043069 | negative regulation of programmed cell death | 22 | 678 | 5.07e-01 |
| GO:BP | GO:0046888 | negative regulation of hormone secretion | 2 | 46 | 5.07e-01 |
| GO:BP | GO:0010977 | negative regulation of neuron projection development | 11 | 117 | 5.07e-01 |
| GO:BP | GO:0043066 | negative regulation of apoptotic process | 3 | 660 | 5.08e-01 |
| GO:BP | GO:0015711 | organic anion transport | 2 | 264 | 5.08e-01 |
| GO:BP | GO:0042745 | circadian sleep/wake cycle | 2 | 11 | 5.08e-01 |
| GO:BP | GO:0015931 | nucleobase-containing compound transport | 8 | 194 | 5.08e-01 |
| GO:BP | GO:0021762 | substantia nigra development | 1 | 41 | 5.08e-01 |
| GO:BP | GO:1903896 | positive regulation of IRE1-mediated unfolded protein response | 1 | 7 | 5.08e-01 |
| GO:BP | GO:0098787 | mRNA cleavage involved in mRNA processing | 1 | 13 | 5.08e-01 |
| GO:BP | GO:0000098 | sulfur amino acid catabolic process | 1 | 7 | 5.08e-01 |
| GO:BP | GO:0000394 | RNA splicing, via endonucleolytic cleavage and ligation | 1 | 14 | 5.08e-01 |
| GO:BP | GO:0032829 | regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation | 1 | 2 | 5.08e-01 |
| GO:BP | GO:0031648 | protein destabilization | 1 | 45 | 5.08e-01 |
| GO:BP | GO:2000739 | regulation of mesenchymal stem cell differentiation | 1 | 8 | 5.08e-01 |
| GO:BP | GO:0061438 | renal system vasculature morphogenesis | 1 | 7 | 5.08e-01 |
| GO:BP | GO:0032831 | positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation | 1 | 2 | 5.08e-01 |
| GO:BP | GO:0002764 | immune response-regulating signaling pathway | 2 | 242 | 5.08e-01 |
| GO:BP | GO:0002285 | lymphocyte activation involved in immune response | 1 | 111 | 5.08e-01 |
| GO:BP | GO:0061439 | kidney vasculature morphogenesis | 1 | 7 | 5.08e-01 |
| GO:BP | GO:0070507 | regulation of microtubule cytoskeleton organization | 4 | 146 | 5.08e-01 |
| GO:BP | GO:0043113 | receptor clustering | 5 | 45 | 5.08e-01 |
| GO:BP | GO:0043242 | negative regulation of protein-containing complex disassembly | 3 | 72 | 5.08e-01 |
| GO:BP | GO:1900227 | positive regulation of NLRP3 inflammasome complex assembly | 1 | 16 | 5.08e-01 |
| GO:BP | GO:0006111 | regulation of gluconeogenesis | 1 | 42 | 5.08e-01 |
| GO:BP | GO:0006511 | ubiquitin-dependent protein catabolic process | 49 | 615 | 5.08e-01 |
| GO:BP | GO:0014827 | intestine smooth muscle contraction | 1 | 3 | 5.08e-01 |
| GO:BP | GO:0061620 | glycolytic process through glucose-6-phosphate | 1 | 17 | 5.08e-01 |
| GO:BP | GO:0002902 | regulation of B cell apoptotic process | 1 | 15 | 5.09e-01 |
| GO:BP | GO:0021610 | facial nerve morphogenesis | 1 | 8 | 5.09e-01 |
| GO:BP | GO:0002526 | acute inflammatory response | 1 | 49 | 5.09e-01 |
| GO:BP | GO:0021561 | facial nerve development | 1 | 8 | 5.09e-01 |
| GO:BP | GO:1904646 | cellular response to amyloid-beta | 2 | 29 | 5.09e-01 |
| GO:BP | GO:0032530 | regulation of microvillus organization | 1 | 10 | 5.09e-01 |
| GO:BP | GO:0033198 | response to ATP | 2 | 24 | 5.10e-01 |
| GO:BP | GO:0071716 | leukotriene transport | 1 | 5 | 5.10e-01 |
| GO:BP | GO:0009648 | photoperiodism | 1 | 28 | 5.10e-01 |
| GO:BP | GO:0080134 | regulation of response to stress | 41 | 1075 | 5.10e-01 |
| GO:BP | GO:0048266 | behavioral response to pain | 1 | 11 | 5.11e-01 |
| GO:BP | GO:0034121 | regulation of toll-like receptor signaling pathway | 1 | 19 | 5.11e-01 |
| GO:BP | GO:0019368 | fatty acid elongation, unsaturated fatty acid | 1 | 6 | 5.11e-01 |
| GO:BP | GO:0034625 | fatty acid elongation, monounsaturated fatty acid | 1 | 6 | 5.11e-01 |
| GO:BP | GO:0034626 | fatty acid elongation, polyunsaturated fatty acid | 1 | 6 | 5.11e-01 |
| GO:BP | GO:0019367 | fatty acid elongation, saturated fatty acid | 1 | 6 | 5.11e-01 |
| GO:BP | GO:0001961 | positive regulation of cytokine-mediated signaling pathway | 3 | 44 | 5.11e-01 |
| GO:BP | GO:0010556 | regulation of macromolecule biosynthetic process | 3 | 3012 | 5.11e-01 |
| GO:BP | GO:1902004 | positive regulation of amyloid-beta formation | 1 | 17 | 5.11e-01 |
| GO:BP | GO:0097048 | dendritic cell apoptotic process | 1 | 7 | 5.11e-01 |
| GO:BP | GO:2000668 | regulation of dendritic cell apoptotic process | 1 | 7 | 5.11e-01 |
| GO:BP | GO:0048548 | regulation of pinocytosis | 1 | 11 | 5.11e-01 |
| GO:BP | GO:0031223 | auditory behavior | 1 | 6 | 5.11e-01 |
| GO:BP | GO:0035457 | cellular response to interferon-alpha | 1 | 7 | 5.11e-01 |
| GO:BP | GO:0042440 | pigment metabolic process | 1 | 60 | 5.11e-01 |
| GO:BP | GO:2001257 | regulation of cation channel activity | 2 | 100 | 5.11e-01 |
| GO:BP | GO:0051905 | establishment of pigment granule localization | 2 | 20 | 5.12e-01 |
| GO:BP | GO:0070317 | negative regulation of G0 to G1 transition | 1 | 5 | 5.12e-01 |
| GO:BP | GO:0043954 | cellular component maintenance | 5 | 59 | 5.12e-01 |
| GO:BP | GO:0048872 | homeostasis of number of cells | 18 | 228 | 5.12e-01 |
| GO:BP | GO:0030856 | regulation of epithelial cell differentiation | 8 | 101 | 5.12e-01 |
| GO:BP | GO:0036150 | phosphatidylserine acyl-chain remodeling | 1 | 7 | 5.12e-01 |
| GO:BP | GO:1904352 | positive regulation of protein catabolic process in the vacuole | 1 | 6 | 5.12e-01 |
| GO:BP | GO:0002837 | regulation of immune response to tumor cell | 2 | 10 | 5.12e-01 |
| GO:BP | GO:0032886 | regulation of microtubule-based process | 6 | 217 | 5.13e-01 |
| GO:BP | GO:2000171 | negative regulation of dendrite development | 1 | 7 | 5.13e-01 |
| GO:BP | GO:0071222 | cellular response to lipopolysaccharide | 1 | 110 | 5.13e-01 |
| GO:BP | GO:0051641 | cellular localization | 4 | 2810 | 5.13e-01 |
| GO:BP | GO:0000723 | telomere maintenance | 11 | 142 | 5.13e-01 |
| GO:BP | GO:0055059 | asymmetric neuroblast division | 1 | 6 | 5.13e-01 |
| GO:BP | GO:0043303 | mast cell degranulation | 2 | 30 | 5.13e-01 |
| GO:BP | GO:0044650 | adhesion of symbiont to host cell | 1 | 9 | 5.13e-01 |
| GO:BP | GO:0006896 | Golgi to vacuole transport | 1 | 19 | 5.14e-01 |
| GO:BP | GO:0006655 | phosphatidylglycerol biosynthetic process | 1 | 9 | 5.14e-01 |
| GO:BP | GO:0032736 | positive regulation of interleukin-13 production | 1 | 7 | 5.14e-01 |
| GO:BP | GO:0043308 | eosinophil degranulation | 1 | 4 | 5.14e-01 |
| GO:BP | GO:0098917 | retrograde trans-synaptic signaling | 1 | 7 | 5.14e-01 |
| GO:BP | GO:0002278 | eosinophil activation involved in immune response | 1 | 4 | 5.14e-01 |
| GO:BP | GO:0030318 | melanocyte differentiation | 1 | 16 | 5.14e-01 |
| GO:BP | GO:0002067 | glandular epithelial cell differentiation | 3 | 50 | 5.14e-01 |
| GO:BP | GO:0062042 | regulation of cardiac epithelial to mesenchymal transition | 1 | 10 | 5.14e-01 |
| GO:BP | GO:0001508 | action potential | 3 | 105 | 5.15e-01 |
| GO:BP | GO:0071481 | cellular response to X-ray | 1 | 10 | 5.15e-01 |
| GO:BP | GO:0042044 | fluid transport | 1 | 17 | 5.15e-01 |
| GO:BP | GO:0051149 | positive regulation of muscle cell differentiation | 2 | 53 | 5.15e-01 |
| GO:BP | GO:0002504 | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II | 3 | 19 | 5.15e-01 |
| GO:BP | GO:1903367 | positive regulation of fear response | 1 | 4 | 5.15e-01 |
| GO:BP | GO:0006991 | response to sterol depletion | 1 | 16 | 5.15e-01 |
| GO:BP | GO:0045039 | protein insertion into mitochondrial inner membrane | 1 | 13 | 5.15e-01 |
| GO:BP | GO:0060753 | regulation of mast cell chemotaxis | 1 | 7 | 5.15e-01 |
| GO:BP | GO:0000466 | maturation of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 1 | 25 | 5.16e-01 |
| GO:BP | GO:0009649 | entrainment of circadian clock | 1 | 31 | 5.16e-01 |
| GO:BP | GO:0048662 | negative regulation of smooth muscle cell proliferation | 1 | 42 | 5.16e-01 |
| GO:BP | GO:0002200 | somatic diversification of immune receptors | 3 | 62 | 5.16e-01 |
| GO:BP | GO:0022602 | ovulation cycle process | 1 | 37 | 5.16e-01 |
| GO:BP | GO:1905820 | positive regulation of chromosome separation | 1 | 28 | 5.16e-01 |
| GO:BP | GO:0002097 | tRNA wobble base modification | 1 | 19 | 5.17e-01 |
| GO:BP | GO:0032527 | protein exit from endoplasmic reticulum | 3 | 43 | 5.17e-01 |
| GO:BP | GO:0036093 | germ cell proliferation | 1 | 7 | 5.18e-01 |
| GO:BP | GO:1903170 | negative regulation of calcium ion transmembrane transport | 1 | 35 | 5.18e-01 |
| GO:BP | GO:0106035 | protein maturation by [4Fe-4S] cluster transfer | 1 | 7 | 5.18e-01 |
| GO:BP | GO:0006357 | regulation of transcription by RNA polymerase II | 1 | 1914 | 5.18e-01 |
| GO:BP | GO:2001044 | regulation of integrin-mediated signaling pathway | 1 | 20 | 5.18e-01 |
| GO:BP | GO:0030010 | establishment of cell polarity | 12 | 134 | 5.18e-01 |
| GO:BP | GO:0007095 | mitotic G2 DNA damage checkpoint signaling | 2 | 35 | 5.19e-01 |
| GO:BP | GO:0035860 | glial cell-derived neurotrophic factor receptor signaling pathway | 1 | 6 | 5.19e-01 |
| GO:BP | GO:0016339 | calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules | 3 | 28 | 5.20e-01 |
| GO:BP | GO:0009411 | response to UV | 2 | 141 | 5.20e-01 |
| GO:BP | GO:0006450 | regulation of translational fidelity | 1 | 16 | 5.20e-01 |
| GO:BP | GO:0051258 | protein polymerization | 21 | 241 | 5.20e-01 |
| GO:BP | GO:0036473 | cell death in response to oxidative stress | 3 | 75 | 5.20e-01 |
| GO:BP | GO:0061951 | establishment of protein localization to plasma membrane | 1 | 59 | 5.20e-01 |
| GO:BP | GO:0003407 | neural retina development | 5 | 48 | 5.21e-01 |
| GO:BP | GO:0061615 | glycolytic process through fructose-6-phosphate | 1 | 17 | 5.21e-01 |
| GO:BP | GO:0060581 | cell fate commitment involved in pattern specification | 1 | 3 | 5.21e-01 |
| GO:BP | GO:0060579 | ventral spinal cord interneuron fate commitment | 1 | 3 | 5.21e-01 |
| GO:BP | GO:0002246 | wound healing involved in inflammatory response | 1 | 6 | 5.22e-01 |
| GO:BP | GO:0048730 | epidermis morphogenesis | 3 | 20 | 5.22e-01 |
| GO:BP | GO:0061008 | hepaticobiliary system development | 11 | 112 | 5.22e-01 |
| GO:BP | GO:2000010 | positive regulation of protein localization to cell surface | 1 | 16 | 5.22e-01 |
| GO:BP | GO:0051580 | regulation of neurotransmitter uptake | 2 | 15 | 5.22e-01 |
| GO:BP | GO:1901653 | cellular response to peptide | 17 | 287 | 5.22e-01 |
| GO:BP | GO:0032506 | cytokinetic process | 2 | 39 | 5.22e-01 |
| GO:BP | GO:0007252 | I-kappaB phosphorylation | 1 | 14 | 5.22e-01 |
| GO:BP | GO:0051341 | regulation of oxidoreductase activity | 3 | 68 | 5.22e-01 |
| GO:BP | GO:0090493 | catecholamine uptake | 2 | 11 | 5.22e-01 |
| GO:BP | GO:0006906 | vesicle fusion | 5 | 104 | 5.23e-01 |
| GO:BP | GO:0009059 | macromolecule biosynthetic process | 14 | 3730 | 5.23e-01 |
| GO:BP | GO:0035116 | embryonic hindlimb morphogenesis | 1 | 17 | 5.23e-01 |
| GO:BP | GO:1901142 | insulin metabolic process | 1 | 11 | 5.23e-01 |
| GO:BP | GO:0032508 | DNA duplex unwinding | 1 | 74 | 5.23e-01 |
| GO:BP | GO:0071219 | cellular response to molecule of bacterial origin | 1 | 114 | 5.23e-01 |
| GO:BP | GO:0030539 | male genitalia development | 2 | 13 | 5.23e-01 |
| GO:BP | GO:2000311 | regulation of AMPA receptor activity | 2 | 15 | 5.24e-01 |
| GO:BP | GO:0071895 | odontoblast differentiation | 1 | 5 | 5.24e-01 |
| GO:BP | GO:0010623 | programmed cell death involved in cell development | 1 | 13 | 5.24e-01 |
| GO:BP | GO:0060142 | regulation of syncytium formation by plasma membrane fusion | 1 | 15 | 5.24e-01 |
| GO:BP | GO:0097187 | dentinogenesis | 1 | 4 | 5.24e-01 |
| GO:BP | GO:0006664 | glycolipid metabolic process | 2 | 88 | 5.24e-01 |
| GO:BP | GO:1903265 | positive regulation of tumor necrosis factor-mediated signaling pathway | 1 | 9 | 5.24e-01 |
| GO:BP | GO:1902894 | negative regulation of miRNA transcription | 2 | 19 | 5.24e-01 |
| GO:BP | GO:0035335 | peptidyl-tyrosine dephosphorylation | 1 | 26 | 5.24e-01 |
| GO:BP | GO:0045671 | negative regulation of osteoclast differentiation | 1 | 20 | 5.24e-01 |
| GO:BP | GO:0014821 | phasic smooth muscle contraction | 2 | 12 | 5.25e-01 |
| GO:BP | GO:0033119 | negative regulation of RNA splicing | 1 | 28 | 5.25e-01 |
| GO:BP | GO:0019369 | arachidonic acid metabolic process | 1 | 26 | 5.25e-01 |
| GO:BP | GO:1903513 | endoplasmic reticulum to cytosol transport | 2 | 28 | 5.25e-01 |
| GO:BP | GO:0090267 | positive regulation of mitotic cell cycle spindle assembly checkpoint | 1 | 12 | 5.25e-01 |
| GO:BP | GO:0090232 | positive regulation of spindle checkpoint | 1 | 12 | 5.25e-01 |
| GO:BP | GO:0030970 | retrograde protein transport, ER to cytosol | 2 | 28 | 5.25e-01 |
| GO:BP | GO:0046777 | protein autophosphorylation | 16 | 188 | 5.25e-01 |
| GO:BP | GO:0019219 | regulation of nucleobase-containing compound metabolic process | 3 | 3080 | 5.25e-01 |
| GO:BP | GO:0031326 | regulation of cellular biosynthetic process | 3 | 3080 | 5.26e-01 |
| GO:BP | GO:0046504 | glycerol ether biosynthetic process | 1 | 10 | 5.26e-01 |
| GO:BP | GO:0071475 | cellular hyperosmotic salinity response | 1 | 6 | 5.26e-01 |
| GO:BP | GO:0016574 | histone ubiquitination | 2 | 46 | 5.26e-01 |
| GO:BP | GO:0006855 | xenobiotic transmembrane transport | 1 | 11 | 5.26e-01 |
| GO:BP | GO:0007049 | cell cycle | 90 | 1529 | 5.26e-01 |
| GO:BP | GO:0051541 | elastin metabolic process | 1 | 5 | 5.26e-01 |
| GO:BP | GO:0042430 | indole-containing compound metabolic process | 2 | 8 | 5.26e-01 |
| GO:BP | GO:0001504 | neurotransmitter uptake | 1 | 29 | 5.26e-01 |
| GO:BP | GO:0097384 | cellular lipid biosynthetic process | 1 | 10 | 5.26e-01 |
| GO:BP | GO:0008611 | ether lipid biosynthetic process | 1 | 10 | 5.26e-01 |
| GO:BP | GO:0051503 | adenine nucleotide transport | 3 | 23 | 5.26e-01 |
| GO:BP | GO:0002279 | mast cell activation involved in immune response | 2 | 31 | 5.26e-01 |
| GO:BP | GO:0045787 | positive regulation of cell cycle | 16 | 274 | 5.26e-01 |
| GO:BP | GO:0042723 | thiamine-containing compound metabolic process | 1 | 4 | 5.26e-01 |
| GO:BP | GO:0046883 | regulation of hormone secretion | 6 | 168 | 5.26e-01 |
| GO:BP | GO:1903509 | liposaccharide metabolic process | 2 | 88 | 5.26e-01 |
| GO:BP | GO:0032400 | melanosome localization | 2 | 22 | 5.26e-01 |
| GO:BP | GO:0071276 | cellular response to cadmium ion | 3 | 24 | 5.27e-01 |
| GO:BP | GO:0009394 | 2’-deoxyribonucleotide metabolic process | 2 | 35 | 5.27e-01 |
| GO:BP | GO:1901989 | positive regulation of cell cycle phase transition | 7 | 103 | 5.27e-01 |
| GO:BP | GO:1905806 | regulation of synapse pruning | 1 | 5 | 5.27e-01 |
| GO:BP | GO:1905216 | positive regulation of RNA binding | 1 | 9 | 5.27e-01 |
| GO:BP | GO:0035519 | protein K29-linked ubiquitination | 1 | 6 | 5.27e-01 |
| GO:BP | GO:0051302 | regulation of cell division | 1 | 145 | 5.27e-01 |
| GO:BP | GO:0050848 | regulation of calcium-mediated signaling | 3 | 52 | 5.28e-01 |
| GO:BP | GO:0030852 | regulation of granulocyte differentiation | 1 | 11 | 5.29e-01 |
| GO:BP | GO:1903018 | regulation of glycoprotein metabolic process | 4 | 36 | 5.29e-01 |
| GO:BP | GO:0006366 | transcription by RNA polymerase II | 1 | 1995 | 5.29e-01 |
| GO:BP | GO:0032688 | negative regulation of interferon-beta production | 1 | 10 | 5.29e-01 |
| GO:BP | GO:0006518 | peptide metabolic process | 3 | 771 | 5.29e-01 |
| GO:BP | GO:0033344 | cholesterol efflux | 1 | 40 | 5.29e-01 |
| GO:BP | GO:0071168 | protein localization to chromatin | 1 | 48 | 5.29e-01 |
| GO:BP | GO:0030225 | macrophage differentiation | 1 | 35 | 5.29e-01 |
| GO:BP | GO:0072583 | clathrin-dependent endocytosis | 4 | 43 | 5.30e-01 |
| GO:BP | GO:0055085 | transmembrane transport | 10 | 998 | 5.30e-01 |
| GO:BP | GO:0051494 | negative regulation of cytoskeleton organization | 4 | 140 | 5.30e-01 |
| GO:BP | GO:0033688 | regulation of osteoblast proliferation | 2 | 23 | 5.30e-01 |
| GO:BP | GO:0061005 | cell differentiation involved in kidney development | 4 | 42 | 5.30e-01 |
| GO:BP | GO:0048167 | regulation of synaptic plasticity | 3 | 141 | 5.30e-01 |
| GO:BP | GO:1903543 | positive regulation of exosomal secretion | 1 | 13 | 5.30e-01 |
| GO:BP | GO:0000910 | cytokinesis | 1 | 164 | 5.30e-01 |
| GO:BP | GO:0095500 | acetylcholine receptor signaling pathway | 2 | 18 | 5.30e-01 |
| GO:BP | GO:0021604 | cranial nerve structural organization | 1 | 8 | 5.30e-01 |
| GO:BP | GO:0043065 | positive regulation of apoptotic process | 9 | 393 | 5.30e-01 |
| GO:BP | GO:1901576 | organic substance biosynthetic process | 4 | 4539 | 5.30e-01 |
| GO:BP | GO:0086010 | membrane depolarization during action potential | 2 | 28 | 5.30e-01 |
| GO:BP | GO:0106070 | regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway | 1 | 11 | 5.30e-01 |
| GO:BP | GO:0009214 | cyclic nucleotide catabolic process | 1 | 13 | 5.30e-01 |
| GO:BP | GO:0099151 | regulation of postsynaptic density assembly | 1 | 9 | 5.30e-01 |
| GO:BP | GO:0009067 | aspartate family amino acid biosynthetic process | 2 | 18 | 5.30e-01 |
| GO:BP | GO:1902991 | regulation of amyloid precursor protein catabolic process | 2 | 39 | 5.31e-01 |
| GO:BP | GO:0002834 | regulation of response to tumor cell | 2 | 11 | 5.31e-01 |
| GO:BP | GO:0051321 | meiotic cell cycle | 14 | 188 | 5.31e-01 |
| GO:BP | GO:1902523 | positive regulation of protein K63-linked ubiquitination | 1 | 5 | 5.31e-01 |
| GO:BP | GO:1904491 | protein localization to ciliary transition zone | 1 | 7 | 5.32e-01 |
| GO:BP | GO:0010811 | positive regulation of cell-substrate adhesion | 5 | 100 | 5.32e-01 |
| GO:BP | GO:0090174 | organelle membrane fusion | 5 | 106 | 5.32e-01 |
| GO:BP | GO:0002448 | mast cell mediated immunity | 2 | 33 | 5.32e-01 |
| GO:BP | GO:1903010 | regulation of bone development | 1 | 6 | 5.32e-01 |
| GO:BP | GO:0006403 | RNA localization | 7 | 182 | 5.33e-01 |
| GO:BP | GO:0000380 | alternative mRNA splicing, via spliceosome | 1 | 70 | 5.34e-01 |
| GO:BP | GO:0055088 | lipid homeostasis | 2 | 115 | 5.34e-01 |
| GO:BP | GO:0045923 | positive regulation of fatty acid metabolic process | 3 | 26 | 5.34e-01 |
| GO:BP | GO:0006048 | UDP-N-acetylglucosamine biosynthetic process | 1 | 9 | 5.34e-01 |
| GO:BP | GO:0034250 | positive regulation of amide metabolic process | 6 | 149 | 5.34e-01 |
| GO:BP | GO:1902624 | positive regulation of neutrophil migration | 1 | 21 | 5.34e-01 |
| GO:BP | GO:0060047 | heart contraction | 2 | 205 | 5.34e-01 |
| GO:BP | GO:0009071 | serine family amino acid catabolic process | 1 | 10 | 5.34e-01 |
| GO:BP | GO:0002283 | neutrophil activation involved in immune response | 2 | 7 | 5.34e-01 |
| GO:BP | GO:0072102 | glomerulus morphogenesis | 1 | 7 | 5.34e-01 |
| GO:BP | GO:0072239 | metanephric glomerulus vasculature development | 1 | 6 | 5.34e-01 |
| GO:BP | GO:0008300 | isoprenoid catabolic process | 1 | 5 | 5.34e-01 |
| GO:BP | GO:0008354 | germ cell migration | 1 | 6 | 5.34e-01 |
| GO:BP | GO:0035701 | hematopoietic stem cell migration | 1 | 6 | 5.34e-01 |
| GO:BP | GO:0009110 | vitamin biosynthetic process | 2 | 14 | 5.35e-01 |
| GO:BP | GO:0044771 | meiotic cell cycle phase transition | 1 | 7 | 5.35e-01 |
| GO:BP | GO:0061178 | regulation of insulin secretion involved in cellular response to glucose stimulus | 1 | 40 | 5.35e-01 |
| GO:BP | GO:0031023 | microtubule organizing center organization | 9 | 137 | 5.35e-01 |
| GO:BP | GO:0002707 | negative regulation of lymphocyte mediated immunity | 1 | 24 | 5.35e-01 |
| GO:BP | GO:0009262 | deoxyribonucleotide metabolic process | 2 | 36 | 5.35e-01 |
| GO:BP | GO:0019692 | deoxyribose phosphate metabolic process | 2 | 36 | 5.35e-01 |
| GO:BP | GO:0000184 | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 2 | 39 | 5.35e-01 |
| GO:BP | GO:0007343 | egg activation | 1 | 4 | 5.35e-01 |
| GO:BP | GO:1901889 | negative regulation of cell junction assembly | 2 | 24 | 5.35e-01 |
| GO:BP | GO:0010921 | regulation of phosphatase activity | 1 | 65 | 5.35e-01 |
| GO:BP | GO:1990776 | response to angiotensin | 2 | 24 | 5.35e-01 |
| GO:BP | GO:0099105 | ion channel modulating, G protein-coupled receptor signaling pathway | 1 | 7 | 5.35e-01 |
| GO:BP | GO:0048505 | regulation of timing of cell differentiation | 1 | 7 | 5.36e-01 |
| GO:BP | GO:1902369 | negative regulation of RNA catabolic process | 1 | 69 | 5.36e-01 |
| GO:BP | GO:0035720 | intraciliary anterograde transport | 1 | 17 | 5.36e-01 |
| GO:BP | GO:0019935 | cyclic-nucleotide-mediated signaling | 2 | 55 | 5.36e-01 |
| GO:BP | GO:0002639 | positive regulation of immunoglobulin production | 1 | 30 | 5.36e-01 |
| GO:BP | GO:0010954 | positive regulation of protein processing | 2 | 18 | 5.36e-01 |
| GO:BP | GO:0044271 | cellular nitrogen compound biosynthetic process | 14 | 3750 | 5.36e-01 |
| GO:BP | GO:0007274 | neuromuscular synaptic transmission | 2 | 14 | 5.36e-01 |
| GO:BP | GO:0050905 | neuromuscular process | 7 | 107 | 5.36e-01 |
| GO:BP | GO:0009612 | response to mechanical stimulus | 1 | 158 | 5.36e-01 |
| GO:BP | GO:0071385 | cellular response to glucocorticoid stimulus | 1 | 40 | 5.37e-01 |
| GO:BP | GO:0014850 | response to muscle activity | 2 | 17 | 5.37e-01 |
| GO:BP | GO:0031060 | regulation of histone methylation | 1 | 47 | 5.37e-01 |
| GO:BP | GO:0002840 | regulation of T cell mediated immune response to tumor cell | 1 | 5 | 5.37e-01 |
| GO:BP | GO:0035608 | protein deglutamylation | 1 | 2 | 5.37e-01 |
| GO:BP | GO:0050731 | positive regulation of peptidyl-tyrosine phosphorylation | 1 | 105 | 5.37e-01 |
| GO:BP | GO:0035729 | cellular response to hepatocyte growth factor stimulus | 1 | 13 | 5.37e-01 |
| GO:BP | GO:1902893 | regulation of miRNA transcription | 5 | 56 | 5.37e-01 |
| GO:BP | GO:1904064 | positive regulation of cation transmembrane transport | 2 | 99 | 5.38e-01 |
| GO:BP | GO:0048660 | regulation of smooth muscle cell proliferation | 5 | 106 | 5.38e-01 |
| GO:BP | GO:0042886 | amide transport | 4 | 235 | 5.38e-01 |
| GO:BP | GO:0048368 | lateral mesoderm development | 1 | 10 | 5.38e-01 |
| GO:BP | GO:0072584 | caveolin-mediated endocytosis | 1 | 9 | 5.38e-01 |
| GO:BP | GO:0019941 | modification-dependent protein catabolic process | 49 | 625 | 5.38e-01 |
| GO:BP | GO:0033625 | positive regulation of integrin activation | 1 | 6 | 5.38e-01 |
| GO:BP | GO:0006468 | protein phosphorylation | 70 | 1167 | 5.38e-01 |
| GO:BP | GO:1901575 | organic substance catabolic process | 6 | 1712 | 5.38e-01 |
| GO:BP | GO:0032392 | DNA geometric change | 1 | 80 | 5.38e-01 |
| GO:BP | GO:0008089 | anterograde axonal transport | 1 | 45 | 5.38e-01 |
| GO:BP | GO:0072202 | cell differentiation involved in metanephros development | 2 | 16 | 5.38e-01 |
| GO:BP | GO:1903980 | positive regulation of microglial cell activation | 1 | 2 | 5.38e-01 |
| GO:BP | GO:0009058 | biosynthetic process | 4 | 4590 | 5.39e-01 |
| GO:BP | GO:2000736 | regulation of stem cell differentiation | 5 | 71 | 5.39e-01 |
| GO:BP | GO:0001959 | regulation of cytokine-mediated signaling pathway | 8 | 117 | 5.39e-01 |
| GO:BP | GO:0002253 | activation of immune response | 2 | 272 | 5.39e-01 |
| GO:BP | GO:0097049 | motor neuron apoptotic process | 2 | 18 | 5.39e-01 |
| GO:BP | GO:0009889 | regulation of biosynthetic process | 3 | 3169 | 5.39e-01 |
| GO:BP | GO:0031146 | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process | 2 | 47 | 5.39e-01 |
| GO:BP | GO:0042760 | very long-chain fatty acid catabolic process | 1 | 5 | 5.39e-01 |
| GO:BP | GO:0032836 | glomerular basement membrane development | 1 | 9 | 5.39e-01 |
| GO:BP | GO:0006576 | biogenic amine metabolic process | 1 | 57 | 5.39e-01 |
| GO:BP | GO:0086019 | cell-cell signaling involved in cardiac conduction | 1 | 33 | 5.39e-01 |
| GO:BP | GO:0014075 | response to amine | 1 | 34 | 5.39e-01 |
| GO:BP | GO:2001267 | regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway | 1 | 13 | 5.39e-01 |
| GO:BP | GO:0034504 | protein localization to nucleus | 9 | 276 | 5.39e-01 |
| GO:BP | GO:2000241 | regulation of reproductive process | 1 | 128 | 5.39e-01 |
| GO:BP | GO:0051875 | pigment granule localization | 2 | 22 | 5.39e-01 |
| GO:BP | GO:0002274 | myeloid leukocyte activation | 1 | 123 | 5.40e-01 |
| GO:BP | GO:0003081 | regulation of systemic arterial blood pressure by renin-angiotensin | 2 | 15 | 5.41e-01 |
| GO:BP | GO:0009141 | nucleoside triphosphate metabolic process | 1 | 159 | 5.41e-01 |
| GO:BP | GO:0008216 | spermidine metabolic process | 1 | 7 | 5.41e-01 |
| GO:BP | GO:0009749 | response to glucose | 1 | 137 | 5.41e-01 |
| GO:BP | GO:0003071 | renal system process involved in regulation of systemic arterial blood pressure | 2 | 14 | 5.41e-01 |
| GO:BP | GO:0007623 | circadian rhythm | 4 | 165 | 5.41e-01 |
| GO:BP | GO:1902459 | positive regulation of stem cell population maintenance | 4 | 44 | 5.41e-01 |
| GO:BP | GO:0046834 | lipid phosphorylation | 1 | 16 | 5.41e-01 |
| GO:BP | GO:0042789 | mRNA transcription by RNA polymerase II | 2 | 45 | 5.42e-01 |
| GO:BP | GO:0071379 | cellular response to prostaglandin stimulus | 1 | 16 | 5.43e-01 |
| GO:BP | GO:0048874 | host-mediated regulation of intestinal microbiota composition | 1 | 2 | 5.43e-01 |
| GO:BP | GO:0032495 | response to muramyl dipeptide | 2 | 15 | 5.43e-01 |
| GO:BP | GO:0009895 | negative regulation of catabolic process | 24 | 280 | 5.44e-01 |
| GO:BP | GO:0001932 | regulation of protein phosphorylation | 69 | 796 | 5.44e-01 |
| GO:BP | GO:0007005 | mitochondrion organization | 7 | 500 | 5.44e-01 |
| GO:BP | GO:0033615 | mitochondrial proton-transporting ATP synthase complex assembly | 1 | 8 | 5.44e-01 |
| GO:BP | GO:0043461 | proton-transporting ATP synthase complex assembly | 1 | 8 | 5.44e-01 |
| GO:BP | GO:0010889 | regulation of sequestering of triglyceride | 1 | 12 | 5.44e-01 |
| GO:BP | GO:0043328 | protein transport to vacuole involved in ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway | 1 | 16 | 5.44e-01 |
| GO:BP | GO:0001678 | intracellular glucose homeostasis | 2 | 110 | 5.45e-01 |
| GO:BP | GO:1902305 | regulation of sodium ion transmembrane transport | 5 | 51 | 5.45e-01 |
| GO:BP | GO:0061387 | regulation of extent of cell growth | 1 | 97 | 5.45e-01 |
| GO:BP | GO:1905278 | positive regulation of epithelial tube formation | 1 | 7 | 5.45e-01 |
| GO:BP | GO:1905276 | regulation of epithelial tube formation | 1 | 7 | 5.45e-01 |
| GO:BP | GO:0051279 | regulation of release of sequestered calcium ion into cytosol | 6 | 60 | 5.45e-01 |
| GO:BP | GO:0043277 | apoptotic cell clearance | 4 | 35 | 5.45e-01 |
| GO:BP | GO:1901379 | regulation of potassium ion transmembrane transport | 1 | 64 | 5.45e-01 |
| GO:BP | GO:0010468 | regulation of gene expression | 5 | 3580 | 5.46e-01 |
| GO:BP | GO:0051647 | nucleus localization | 2 | 28 | 5.46e-01 |
| GO:BP | GO:1903975 | regulation of glial cell migration | 1 | 12 | 5.46e-01 |
| GO:BP | GO:1905207 | regulation of cardiocyte differentiation | 1 | 22 | 5.46e-01 |
| GO:BP | GO:0090305 | nucleic acid phosphodiester bond hydrolysis | 7 | 211 | 5.46e-01 |
| GO:BP | GO:0034728 | nucleosome organization | 3 | 98 | 5.46e-01 |
| GO:BP | GO:0007215 | glutamate receptor signaling pathway | 4 | 29 | 5.46e-01 |
| GO:BP | GO:0061085 | regulation of histone H3-K27 methylation | 1 | 4 | 5.46e-01 |
| GO:BP | GO:0006544 | glycine metabolic process | 1 | 10 | 5.46e-01 |
| GO:BP | GO:0010226 | response to lithium ion | 1 | 16 | 5.46e-01 |
| GO:BP | GO:0061614 | miRNA transcription | 5 | 57 | 5.46e-01 |
| GO:BP | GO:0000722 | telomere maintenance via recombination | 1 | 14 | 5.46e-01 |
| GO:BP | GO:2001234 | negative regulation of apoptotic signaling pathway | 16 | 194 | 5.46e-01 |
| GO:BP | GO:1904888 | cranial skeletal system development | 3 | 51 | 5.46e-01 |
| GO:BP | GO:0007015 | actin filament organization | 15 | 373 | 5.46e-01 |
| GO:BP | GO:0030433 | ubiquitin-dependent ERAD pathway | 1 | 83 | 5.46e-01 |
| GO:BP | GO:0046035 | CMP metabolic process | 1 | 6 | 5.47e-01 |
| GO:BP | GO:0009746 | response to hexose | 1 | 138 | 5.47e-01 |
| GO:BP | GO:0045048 | protein insertion into ER membrane | 2 | 23 | 5.47e-01 |
| GO:BP | GO:0016073 | snRNA metabolic process | 2 | 54 | 5.47e-01 |
| GO:BP | GO:0009056 | catabolic process | 16 | 2088 | 5.47e-01 |
| GO:BP | GO:0051665 | membrane raft localization | 1 | 4 | 5.47e-01 |
| GO:BP | GO:1900120 | regulation of receptor binding | 1 | 17 | 5.47e-01 |
| GO:BP | GO:0007166 | cell surface receptor signaling pathway | 1 | 1898 | 5.47e-01 |
| GO:BP | GO:0048844 | artery morphogenesis | 1 | 58 | 5.47e-01 |
| GO:BP | GO:0016567 | protein ubiquitination | 26 | 717 | 5.47e-01 |
| GO:BP | GO:0034599 | cellular response to oxidative stress | 3 | 240 | 5.47e-01 |
| GO:BP | GO:0030949 | positive regulation of vascular endothelial growth factor receptor signaling pathway | 1 | 13 | 5.47e-01 |
| GO:BP | GO:0071216 | cellular response to biotic stimulus | 1 | 138 | 5.47e-01 |
| GO:BP | GO:0007638 | mechanosensory behavior | 1 | 8 | 5.47e-01 |
| GO:BP | GO:0006287 | base-excision repair, gap-filling | 1 | 14 | 5.48e-01 |
| GO:BP | GO:0019220 | regulation of phosphate metabolic process | 57 | 993 | 5.48e-01 |
| GO:BP | GO:1902969 | mitotic DNA replication | 1 | 14 | 5.48e-01 |
| GO:BP | GO:0033313 | meiotic cell cycle checkpoint signaling | 1 | 6 | 5.48e-01 |
| GO:BP | GO:0002447 | eosinophil mediated immunity | 1 | 5 | 5.48e-01 |
| GO:BP | GO:0010257 | NADH dehydrogenase complex assembly | 2 | 55 | 5.48e-01 |
| GO:BP | GO:0032981 | mitochondrial respiratory chain complex I assembly | 2 | 55 | 5.48e-01 |
| GO:BP | GO:0045604 | regulation of epidermal cell differentiation | 1 | 39 | 5.48e-01 |
| GO:BP | GO:0042088 | T-helper 1 type immune response | 1 | 26 | 5.48e-01 |
| GO:BP | GO:0048840 | otolith development | 1 | 6 | 5.48e-01 |
| GO:BP | GO:0043409 | negative regulation of MAPK cascade | 4 | 145 | 5.48e-01 |
| GO:BP | GO:0043307 | eosinophil activation | 1 | 4 | 5.48e-01 |
| GO:BP | GO:1901566 | organonitrogen compound biosynthetic process | 11 | 1484 | 5.48e-01 |
| GO:BP | GO:0006670 | sphingosine metabolic process | 2 | 18 | 5.48e-01 |
| GO:BP | GO:0000469 | cleavage involved in rRNA processing | 1 | 29 | 5.48e-01 |
| GO:BP | GO:0048520 | positive regulation of behavior | 2 | 13 | 5.48e-01 |
| GO:BP | GO:0097688 | glutamate receptor clustering | 1 | 7 | 5.48e-01 |
| GO:BP | GO:0019932 | second-messenger-mediated signaling | 6 | 191 | 5.48e-01 |
| GO:BP | GO:0097113 | AMPA glutamate receptor clustering | 1 | 7 | 5.48e-01 |
| GO:BP | GO:0009954 | proximal/distal pattern formation | 2 | 15 | 5.48e-01 |
| GO:BP | GO:1902455 | negative regulation of stem cell population maintenance | 1 | 21 | 5.48e-01 |
| GO:BP | GO:1903867 | extraembryonic membrane development | 1 | 11 | 5.49e-01 |
| GO:BP | GO:0050994 | regulation of lipid catabolic process | 2 | 38 | 5.49e-01 |
| GO:BP | GO:0010039 | response to iron ion | 1 | 24 | 5.49e-01 |
| GO:BP | GO:0003015 | heart process | 2 | 216 | 5.49e-01 |
| GO:BP | GO:1903204 | negative regulation of oxidative stress-induced neuron death | 1 | 19 | 5.49e-01 |
| GO:BP | GO:0051174 | regulation of phosphorus metabolic process | 57 | 994 | 5.49e-01 |
| GO:BP | GO:0000028 | ribosomal small subunit assembly | 1 | 18 | 5.49e-01 |
| GO:BP | GO:1904705 | regulation of vascular associated smooth muscle cell proliferation | 1 | 53 | 5.49e-01 |
| GO:BP | GO:0051248 | negative regulation of protein metabolic process | 35 | 816 | 5.49e-01 |
| GO:BP | GO:0050974 | detection of mechanical stimulus involved in sensory perception | 1 | 20 | 5.49e-01 |
| GO:BP | GO:0043455 | regulation of secondary metabolic process | 1 | 12 | 5.49e-01 |
| GO:BP | GO:0098760 | response to interleukin-7 | 1 | 12 | 5.49e-01 |
| GO:BP | GO:0045661 | regulation of myoblast differentiation | 6 | 61 | 5.49e-01 |
| GO:BP | GO:1900376 | regulation of secondary metabolite biosynthetic process | 1 | 12 | 5.49e-01 |
| GO:BP | GO:0070897 | transcription preinitiation complex assembly | 2 | 67 | 5.49e-01 |
| GO:BP | GO:1902904 | negative regulation of supramolecular fiber organization | 1 | 140 | 5.49e-01 |
| GO:BP | GO:0009306 | protein secretion | 4 | 262 | 5.49e-01 |
| GO:BP | GO:0002756 | MyD88-independent toll-like receptor signaling pathway | 1 | 8 | 5.49e-01 |
| GO:BP | GO:0048021 | regulation of melanin biosynthetic process | 1 | 12 | 5.49e-01 |
| GO:BP | GO:0098761 | cellular response to interleukin-7 | 1 | 12 | 5.49e-01 |
| GO:BP | GO:0140056 | organelle localization by membrane tethering | 2 | 74 | 5.49e-01 |
| GO:BP | GO:0006390 | mitochondrial transcription | 1 | 18 | 5.49e-01 |
| GO:BP | GO:0010831 | positive regulation of myotube differentiation | 1 | 10 | 5.49e-01 |
| GO:BP | GO:0034389 | lipid droplet organization | 2 | 30 | 5.49e-01 |
| GO:BP | GO:0042363 | fat-soluble vitamin catabolic process | 1 | 1 | 5.49e-01 |
| GO:BP | GO:0051145 | smooth muscle cell differentiation | 1 | 54 | 5.49e-01 |
| GO:BP | GO:1903361 | protein localization to basolateral plasma membrane | 1 | 7 | 5.49e-01 |
| GO:BP | GO:0050708 | regulation of protein secretion | 6 | 185 | 5.49e-01 |
| GO:BP | GO:0046475 | glycerophospholipid catabolic process | 2 | 21 | 5.49e-01 |
| GO:BP | GO:0000083 | regulation of transcription involved in G1/S transition of mitotic cell cycle | 2 | 20 | 5.49e-01 |
| GO:BP | GO:1905145 | cellular response to acetylcholine | 2 | 20 | 5.49e-01 |
| GO:BP | GO:0060548 | negative regulation of cell death | 25 | 756 | 5.49e-01 |
| GO:BP | GO:0035592 | establishment of protein localization to extracellular region | 4 | 262 | 5.50e-01 |
| GO:BP | GO:0046173 | polyol biosynthetic process | 1 | 47 | 5.50e-01 |
| GO:BP | GO:0035909 | aorta morphogenesis | 2 | 26 | 5.50e-01 |
| GO:BP | GO:0050921 | positive regulation of chemotaxis | 1 | 85 | 5.51e-01 |
| GO:BP | GO:0010720 | positive regulation of cell development | 13 | 317 | 5.51e-01 |
| GO:BP | GO:0001976 | nervous system process involved in regulation of systemic arterial blood pressure | 1 | 9 | 5.52e-01 |
| GO:BP | GO:0015865 | purine nucleotide transport | 3 | 23 | 5.52e-01 |
| GO:BP | GO:0048659 | smooth muscle cell proliferation | 5 | 110 | 5.52e-01 |
| GO:BP | GO:0061309 | cardiac neural crest cell development involved in outflow tract morphogenesis | 1 | 12 | 5.52e-01 |
| GO:BP | GO:0043122 | regulation of I-kappaB kinase/NF-kappaB signaling | 1 | 203 | 5.52e-01 |
| GO:BP | GO:0032653 | regulation of interleukin-10 production | 1 | 24 | 5.52e-01 |
| GO:BP | GO:0051259 | protein complex oligomerization | 1 | 185 | 5.52e-01 |
| GO:BP | GO:0043068 | positive regulation of programmed cell death | 9 | 399 | 5.52e-01 |
| GO:BP | GO:1902284 | neuron projection extension involved in neuron projection guidance | 3 | 35 | 5.52e-01 |
| GO:BP | GO:0002830 | positive regulation of type 2 immune response | 1 | 7 | 5.52e-01 |
| GO:BP | GO:0040034 | regulation of development, heterochronic | 1 | 8 | 5.52e-01 |
| GO:BP | GO:2000344 | positive regulation of acrosome reaction | 1 | 6 | 5.52e-01 |
| GO:BP | GO:0045727 | positive regulation of translation | 5 | 126 | 5.52e-01 |
| GO:BP | GO:0048241 | epinephrine transport | 1 | 4 | 5.52e-01 |
| GO:BP | GO:0032613 | interleukin-10 production | 1 | 24 | 5.52e-01 |
| GO:BP | GO:0051797 | regulation of hair follicle development | 1 | 16 | 5.52e-01 |
| GO:BP | GO:0072015 | podocyte development | 1 | 9 | 5.52e-01 |
| GO:BP | GO:0072017 | distal tubule development | 1 | 6 | 5.52e-01 |
| GO:BP | GO:0045064 | T-helper 2 cell differentiation | 1 | 10 | 5.52e-01 |
| GO:BP | GO:0072070 | loop of Henle development | 1 | 8 | 5.52e-01 |
| GO:BP | GO:0045806 | negative regulation of endocytosis | 2 | 56 | 5.52e-01 |
| GO:BP | GO:0048846 | axon extension involved in axon guidance | 3 | 35 | 5.52e-01 |
| GO:BP | GO:0048523 | negative regulation of cellular process | 4 | 3625 | 5.52e-01 |
| GO:BP | GO:0033059 | cellular pigmentation | 4 | 58 | 5.52e-01 |
| GO:BP | GO:2000756 | regulation of peptidyl-lysine acetylation | 1 | 57 | 5.52e-01 |
| GO:BP | GO:0045747 | positive regulation of Notch signaling pathway | 3 | 37 | 5.52e-01 |
| GO:BP | GO:0034284 | response to monosaccharide | 1 | 142 | 5.53e-01 |
| GO:BP | GO:0030858 | positive regulation of epithelial cell differentiation | 1 | 37 | 5.53e-01 |
| GO:BP | GO:0002027 | regulation of heart rate | 2 | 86 | 5.53e-01 |
| GO:BP | GO:0043603 | amide metabolic process | 4 | 993 | 5.53e-01 |
| GO:BP | GO:1901072 | glucosamine-containing compound catabolic process | 1 | 5 | 5.53e-01 |
| GO:BP | GO:0035337 | fatty-acyl-CoA metabolic process | 3 | 31 | 5.53e-01 |
| GO:BP | GO:0002762 | negative regulation of myeloid leukocyte differentiation | 2 | 33 | 5.54e-01 |
| GO:BP | GO:0038083 | peptidyl-tyrosine autophosphorylation | 2 | 18 | 5.54e-01 |
| GO:BP | GO:0009966 | regulation of signal transduction | 1 | 2285 | 5.54e-01 |
| GO:BP | GO:1903541 | regulation of exosomal secretion | 1 | 15 | 5.54e-01 |
| GO:BP | GO:0021936 | regulation of cerebellar granule cell precursor proliferation | 1 | 8 | 5.54e-01 |
| GO:BP | GO:0002318 | myeloid progenitor cell differentiation | 1 | 7 | 5.54e-01 |
| GO:BP | GO:0010466 | negative regulation of peptidase activity | 7 | 131 | 5.54e-01 |
| GO:BP | GO:0002467 | germinal center formation | 1 | 10 | 5.54e-01 |
| GO:BP | GO:1990874 | vascular associated smooth muscle cell proliferation | 1 | 55 | 5.54e-01 |
| GO:BP | GO:0015872 | dopamine transport | 1 | 29 | 5.54e-01 |
| GO:BP | GO:0007099 | centriole replication | 1 | 38 | 5.55e-01 |
| GO:BP | GO:0031032 | actomyosin structure organization | 7 | 186 | 5.55e-01 |
| GO:BP | GO:0071103 | DNA conformation change | 1 | 87 | 5.55e-01 |
| GO:BP | GO:0034605 | cellular response to heat | 1 | 51 | 5.55e-01 |
| GO:BP | GO:0070059 | intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | 1 | 56 | 5.55e-01 |
| GO:BP | GO:0045724 | positive regulation of cilium assembly | 2 | 25 | 5.55e-01 |
| GO:BP | GO:0014012 | peripheral nervous system axon regeneration | 1 | 6 | 5.55e-01 |
| GO:BP | GO:0008535 | respiratory chain complex IV assembly | 2 | 29 | 5.55e-01 |
| GO:BP | GO:0035235 | ionotropic glutamate receptor signaling pathway | 2 | 14 | 5.55e-01 |
| GO:BP | GO:0072711 | cellular response to hydroxyurea | 1 | 10 | 5.55e-01 |
| GO:BP | GO:0045110 | intermediate filament bundle assembly | 1 | 6 | 5.55e-01 |
| GO:BP | GO:0040001 | establishment of mitotic spindle localization | 3 | 36 | 5.55e-01 |
| GO:BP | GO:0006399 | tRNA metabolic process | 5 | 186 | 5.55e-01 |
| GO:BP | GO:0051131 | chaperone-mediated protein complex assembly | 1 | 21 | 5.55e-01 |
| GO:BP | GO:0001817 | regulation of cytokine production | 1 | 447 | 5.55e-01 |
| GO:BP | GO:0048609 | multicellular organismal reproductive process | 4 | 538 | 5.55e-01 |
| GO:BP | GO:0044406 | adhesion of symbiont to host | 1 | 10 | 5.56e-01 |
| GO:BP | GO:0006805 | xenobiotic metabolic process | 1 | 56 | 5.56e-01 |
| GO:BP | GO:0097154 | GABAergic neuron differentiation | 1 | 5 | 5.56e-01 |
| GO:BP | GO:0070327 | thyroid hormone transport | 1 | 7 | 5.57e-01 |
| GO:BP | GO:0051050 | positive regulation of transport | 9 | 667 | 5.57e-01 |
| GO:BP | GO:0035728 | response to hepatocyte growth factor | 1 | 15 | 5.57e-01 |
| GO:BP | GO:0031365 | N-terminal protein amino acid modification | 2 | 28 | 5.57e-01 |
| GO:BP | GO:0015914 | phospholipid transport | 4 | 75 | 5.57e-01 |
| GO:BP | GO:0001816 | cytokine production | 1 | 451 | 5.57e-01 |
| GO:BP | GO:2000136 | regulation of cell proliferation involved in heart morphogenesis | 1 | 17 | 5.58e-01 |
| GO:BP | GO:0002031 | G protein-coupled receptor internalization | 1 | 10 | 5.58e-01 |
| GO:BP | GO:0071702 | organic substance transport | 2 | 2116 | 5.58e-01 |
| GO:BP | GO:0032446 | protein modification by small protein conjugation | 28 | 787 | 5.58e-01 |
| GO:BP | GO:0030325 | adrenal gland development | 2 | 22 | 5.58e-01 |
| GO:BP | GO:0010942 | positive regulation of cell death | 10 | 441 | 5.58e-01 |
| GO:BP | GO:0034085 | establishment of sister chromatid cohesion | 1 | 11 | 5.60e-01 |
| GO:BP | GO:0032374 | regulation of cholesterol transport | 1 | 45 | 5.60e-01 |
| GO:BP | GO:0032371 | regulation of sterol transport | 1 | 45 | 5.60e-01 |
| GO:BP | GO:0007631 | feeding behavior | 1 | 52 | 5.60e-01 |
| GO:BP | GO:0045056 | transcytosis | 2 | 17 | 5.60e-01 |
| GO:BP | GO:0071692 | protein localization to extracellular region | 4 | 266 | 5.60e-01 |
| GO:BP | GO:1902993 | positive regulation of amyloid precursor protein catabolic process | 1 | 22 | 5.60e-01 |
| GO:BP | GO:0043382 | positive regulation of memory T cell differentiation | 1 | 3 | 5.60e-01 |
| GO:BP | GO:0002424 | T cell mediated immune response to tumor cell | 1 | 6 | 5.60e-01 |
| GO:BP | GO:0042590 | antigen processing and presentation of exogenous peptide antigen via MHC class I | 1 | 7 | 5.61e-01 |
| GO:BP | GO:0050776 | regulation of immune response | 3 | 484 | 5.61e-01 |
| GO:BP | GO:0043270 | positive regulation of monoatomic ion transport | 7 | 154 | 5.61e-01 |
| GO:BP | GO:0046638 | positive regulation of alpha-beta T cell differentiation | 2 | 27 | 5.61e-01 |
| GO:BP | GO:1903319 | positive regulation of protein maturation | 2 | 19 | 5.61e-01 |
| GO:BP | GO:0033866 | nucleoside bisphosphate biosynthetic process | 1 | 49 | 5.61e-01 |
| GO:BP | GO:0010518 | positive regulation of phospholipase activity | 4 | 27 | 5.61e-01 |
| GO:BP | GO:0034030 | ribonucleoside bisphosphate biosynthetic process | 1 | 49 | 5.61e-01 |
| GO:BP | GO:0039531 | regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway | 3 | 40 | 5.61e-01 |
| GO:BP | GO:0034033 | purine nucleoside bisphosphate biosynthetic process | 1 | 49 | 5.61e-01 |
| GO:BP | GO:0043416 | regulation of skeletal muscle tissue regeneration | 1 | 5 | 5.61e-01 |
| GO:BP | GO:0006271 | DNA strand elongation involved in DNA replication | 1 | 15 | 5.61e-01 |
| GO:BP | GO:0001783 | B cell apoptotic process | 1 | 21 | 5.61e-01 |
| GO:BP | GO:0021681 | cerebellar granular layer development | 1 | 11 | 5.61e-01 |
| GO:BP | GO:1905874 | regulation of postsynaptic density organization | 1 | 10 | 5.61e-01 |
| GO:BP | GO:0051052 | regulation of DNA metabolic process | 17 | 452 | 5.62e-01 |
| GO:BP | GO:1903748 | negative regulation of establishment of protein localization to mitochondrion | 1 | 5 | 5.63e-01 |
| GO:BP | GO:1903312 | negative regulation of mRNA metabolic process | 1 | 81 | 5.63e-01 |
| GO:BP | GO:0048048 | embryonic eye morphogenesis | 2 | 25 | 5.63e-01 |
| GO:BP | GO:0043254 | regulation of protein-containing complex assembly | 10 | 348 | 5.63e-01 |
| GO:BP | GO:0051571 | positive regulation of histone H3-K4 methylation | 2 | 20 | 5.63e-01 |
| GO:BP | GO:0034312 | diol biosynthetic process | 2 | 20 | 5.63e-01 |
| GO:BP | GO:0007098 | centrosome cycle | 8 | 127 | 5.63e-01 |
| GO:BP | GO:0001960 | negative regulation of cytokine-mediated signaling pathway | 1 | 53 | 5.64e-01 |
| GO:BP | GO:0071391 | cellular response to estrogen stimulus | 1 | 15 | 5.64e-01 |
| GO:BP | GO:0031053 | primary miRNA processing | 1 | 16 | 5.64e-01 |
| GO:BP | GO:0010522 | regulation of calcium ion transport into cytosol | 1 | 10 | 5.64e-01 |
| GO:BP | GO:0002887 | negative regulation of myeloid leukocyte mediated immunity | 1 | 3 | 5.64e-01 |
| GO:BP | GO:0009066 | aspartate family amino acid metabolic process | 1 | 39 | 5.64e-01 |
| GO:BP | GO:1903902 | positive regulation of viral life cycle | 2 | 19 | 5.64e-01 |
| GO:BP | GO:0002697 | regulation of immune effector process | 4 | 190 | 5.64e-01 |
| GO:BP | GO:0006702 | androgen biosynthetic process | 1 | 4 | 5.64e-01 |
| GO:BP | GO:1905522 | negative regulation of macrophage migration | 1 | 6 | 5.64e-01 |
| GO:BP | GO:0051154 | negative regulation of striated muscle cell differentiation | 1 | 31 | 5.65e-01 |
| GO:BP | GO:0034405 | response to fluid shear stress | 2 | 31 | 5.66e-01 |
| GO:BP | GO:0072172 | mesonephric tubule formation | 1 | 6 | 5.66e-01 |
| GO:BP | GO:0046688 | response to copper ion | 1 | 29 | 5.66e-01 |
| GO:BP | GO:0000460 | maturation of 5.8S rRNA | 3 | 36 | 5.67e-01 |
| GO:BP | GO:0000165 | MAPK cascade | 1 | 556 | 5.67e-01 |
| GO:BP | GO:0032814 | regulation of natural killer cell activation | 2 | 20 | 5.67e-01 |
| GO:BP | GO:0051450 | myoblast proliferation | 2 | 17 | 5.67e-01 |
| GO:BP | GO:2000096 | positive regulation of Wnt signaling pathway, planar cell polarity pathway | 1 | 9 | 5.67e-01 |
| GO:BP | GO:0051294 | establishment of spindle orientation | 3 | 36 | 5.67e-01 |
| GO:BP | GO:0018193 | peptidyl-amino acid modification | 38 | 963 | 5.67e-01 |
| GO:BP | GO:0032148 | activation of protein kinase B activity | 2 | 23 | 5.67e-01 |
| GO:BP | GO:0006144 | purine nucleobase metabolic process | 1 | 15 | 5.67e-01 |
| GO:BP | GO:0006672 | ceramide metabolic process | 1 | 80 | 5.68e-01 |
| GO:BP | GO:0035303 | regulation of dephosphorylation | 3 | 105 | 5.68e-01 |
| GO:BP | GO:0032755 | positive regulation of interleukin-6 production | 1 | 56 | 5.68e-01 |
| GO:BP | GO:0003093 | regulation of glomerular filtration | 1 | 9 | 5.68e-01 |
| GO:BP | GO:0010817 | regulation of hormone levels | 1 | 336 | 5.69e-01 |
| GO:BP | GO:0006534 | cysteine metabolic process | 1 | 11 | 5.69e-01 |
| GO:BP | GO:0002312 | B cell activation involved in immune response | 3 | 57 | 5.69e-01 |
| GO:BP | GO:0003323 | type B pancreatic cell development | 1 | 19 | 5.70e-01 |
| GO:BP | GO:0033044 | regulation of chromosome organization | 16 | 236 | 5.70e-01 |
| GO:BP | GO:0007144 | female meiosis I | 1 | 9 | 5.70e-01 |
| GO:BP | GO:0036490 | regulation of translation in response to endoplasmic reticulum stress | 1 | 11 | 5.70e-01 |
| GO:BP | GO:0070647 | protein modification by small protein conjugation or removal | 3 | 898 | 5.71e-01 |
| GO:BP | GO:0031638 | zymogen activation | 1 | 45 | 5.71e-01 |
| GO:BP | GO:0140042 | lipid droplet formation | 1 | 12 | 5.71e-01 |
| GO:BP | GO:0032963 | collagen metabolic process | 7 | 74 | 5.71e-01 |
| GO:BP | GO:0010939 | regulation of necrotic cell death | 1 | 38 | 5.71e-01 |
| GO:BP | GO:0050996 | positive regulation of lipid catabolic process | 1 | 16 | 5.71e-01 |
| GO:BP | GO:0042073 | intraciliary transport | 3 | 46 | 5.71e-01 |
| GO:BP | GO:0035773 | insulin secretion involved in cellular response to glucose stimulus | 1 | 49 | 5.71e-01 |
| GO:BP | GO:2001252 | positive regulation of chromosome organization | 8 | 103 | 5.71e-01 |
| GO:BP | GO:0061323 | cell proliferation involved in heart morphogenesis | 1 | 18 | 5.71e-01 |
| GO:BP | GO:0044458 | motile cilium assembly | 4 | 45 | 5.71e-01 |
| GO:BP | GO:0010820 | positive regulation of T cell chemotaxis | 1 | 7 | 5.71e-01 |
| GO:BP | GO:0072310 | glomerular epithelial cell development | 1 | 9 | 5.71e-01 |
| GO:BP | GO:1902017 | regulation of cilium assembly | 4 | 57 | 5.71e-01 |
| GO:BP | GO:0009222 | pyrimidine ribonucleotide catabolic process | 1 | 7 | 5.71e-01 |
| GO:BP | GO:0009617 | response to bacterium | 1 | 321 | 5.71e-01 |
| GO:BP | GO:0043632 | modification-dependent macromolecule catabolic process | 49 | 637 | 5.71e-01 |
| GO:BP | GO:0009131 | pyrimidine nucleoside monophosphate catabolic process | 1 | 6 | 5.71e-01 |
| GO:BP | GO:0099558 | maintenance of synapse structure | 2 | 25 | 5.72e-01 |
| GO:BP | GO:0045682 | regulation of epidermis development | 1 | 45 | 5.72e-01 |
| GO:BP | GO:1902105 | regulation of leukocyte differentiation | 6 | 199 | 5.72e-01 |
| GO:BP | GO:1901880 | negative regulation of protein depolymerization | 2 | 64 | 5.72e-01 |
| GO:BP | GO:0098698 | postsynaptic specialization assembly | 2 | 23 | 5.72e-01 |
| GO:BP | GO:0033365 | protein localization to organelle | 1 | 859 | 5.72e-01 |
| GO:BP | GO:0001732 | formation of cytoplasmic translation initiation complex | 1 | 16 | 5.72e-01 |
| GO:BP | GO:2000651 | positive regulation of sodium ion transmembrane transporter activity | 1 | 14 | 5.73e-01 |
| GO:BP | GO:1902018 | negative regulation of cilium assembly | 1 | 15 | 5.73e-01 |
| GO:BP | GO:0038130 | ERBB4 signaling pathway | 1 | 6 | 5.73e-01 |
| GO:BP | GO:0086091 | regulation of heart rate by cardiac conduction | 1 | 36 | 5.73e-01 |
| GO:BP | GO:0070129 | regulation of mitochondrial translation | 1 | 26 | 5.74e-01 |
| GO:BP | GO:0051974 | negative regulation of telomerase activity | 1 | 11 | 5.75e-01 |
| GO:BP | GO:0046425 | regulation of receptor signaling pathway via JAK-STAT | 7 | 52 | 5.75e-01 |
| GO:BP | GO:0043279 | response to alkaloid | 1 | 68 | 5.75e-01 |
| GO:BP | GO:0046823 | negative regulation of nucleocytoplasmic transport | 2 | 21 | 5.75e-01 |
| GO:BP | GO:0071636 | positive regulation of transforming growth factor beta production | 1 | 16 | 5.76e-01 |
| GO:BP | GO:0019395 | fatty acid oxidation | 3 | 93 | 5.76e-01 |
| GO:BP | GO:0031623 | receptor internalization | 5 | 95 | 5.76e-01 |
| GO:BP | GO:0046651 | lymphocyte proliferation | 4 | 162 | 5.76e-01 |
| GO:BP | GO:0032760 | positive regulation of tumor necrosis factor production | 1 | 55 | 5.76e-01 |
| GO:BP | GO:0051481 | negative regulation of cytosolic calcium ion concentration | 1 | 9 | 5.76e-01 |
| GO:BP | GO:1900221 | regulation of amyloid-beta clearance | 1 | 13 | 5.76e-01 |
| GO:BP | GO:0098909 | regulation of cardiac muscle cell action potential involved in regulation of contraction | 1 | 8 | 5.76e-01 |
| GO:BP | GO:1903897 | regulation of PERK-mediated unfolded protein response | 1 | 10 | 5.76e-01 |
| GO:BP | GO:0061635 | regulation of protein complex stability | 1 | 11 | 5.77e-01 |
| GO:BP | GO:0048644 | muscle organ morphogenesis | 4 | 63 | 5.77e-01 |
| GO:BP | GO:0051147 | regulation of muscle cell differentiation | 6 | 118 | 5.77e-01 |
| GO:BP | GO:0006954 | inflammatory response | 1 | 429 | 5.77e-01 |
| GO:BP | GO:0046349 | amino sugar biosynthetic process | 1 | 11 | 5.77e-01 |
| GO:BP | GO:0050862 | positive regulation of T cell receptor signaling pathway | 1 | 11 | 5.77e-01 |
| GO:BP | GO:0071824 | protein-DNA complex subunit organization | 5 | 204 | 5.77e-01 |
| GO:BP | GO:0072710 | response to hydroxyurea | 1 | 11 | 5.77e-01 |
| GO:BP | GO:0060761 | negative regulation of response to cytokine stimulus | 1 | 57 | 5.77e-01 |
| GO:BP | GO:0072497 | mesenchymal stem cell differentiation | 1 | 11 | 5.77e-01 |
| GO:BP | GO:0021955 | central nervous system neuron axonogenesis | 2 | 31 | 5.77e-01 |
| GO:BP | GO:0002732 | positive regulation of dendritic cell cytokine production | 1 | 8 | 5.77e-01 |
| GO:BP | GO:0002889 | regulation of immunoglobulin mediated immune response | 1 | 39 | 5.77e-01 |
| GO:BP | GO:0036120 | cellular response to platelet-derived growth factor stimulus | 2 | 21 | 5.77e-01 |
| GO:BP | GO:0002712 | regulation of B cell mediated immunity | 1 | 39 | 5.77e-01 |
| GO:BP | GO:0006525 | arginine metabolic process | 1 | 13 | 5.77e-01 |
| GO:BP | GO:0061842 | microtubule organizing center localization | 2 | 31 | 5.77e-01 |
| GO:BP | GO:0051642 | centrosome localization | 2 | 31 | 5.77e-01 |
| GO:BP | GO:0002704 | negative regulation of leukocyte mediated immunity | 1 | 28 | 5.78e-01 |
| GO:BP | GO:0038092 | nodal signaling pathway | 1 | 8 | 5.78e-01 |
| GO:BP | GO:0043266 | regulation of potassium ion transport | 1 | 73 | 5.78e-01 |
| GO:BP | GO:0017156 | calcium-ion regulated exocytosis | 1 | 46 | 5.78e-01 |
| GO:BP | GO:0051926 | negative regulation of calcium ion transport | 1 | 45 | 5.78e-01 |
| GO:BP | GO:0017185 | peptidyl-lysine hydroxylation | 1 | 9 | 5.78e-01 |
| GO:BP | GO:0099150 | regulation of postsynaptic specialization assembly | 1 | 12 | 5.78e-01 |
| GO:BP | GO:0050995 | negative regulation of lipid catabolic process | 1 | 14 | 5.78e-01 |
| GO:BP | GO:0034695 | response to prostaglandin E | 1 | 17 | 5.78e-01 |
| GO:BP | GO:0090309 | positive regulation of DNA methylation-dependent heterochromatin formation | 1 | 12 | 5.79e-01 |
| GO:BP | GO:0016973 | poly(A)+ mRNA export from nucleus | 1 | 15 | 5.79e-01 |
| GO:BP | GO:0009308 | amine metabolic process | 1 | 68 | 5.79e-01 |
| GO:BP | GO:0003334 | keratinocyte development | 1 | 8 | 5.79e-01 |
| GO:BP | GO:0040029 | epigenetic regulation of gene expression | 3 | 153 | 5.79e-01 |
| GO:BP | GO:0016482 | cytosolic transport | 11 | 161 | 5.79e-01 |
| GO:BP | GO:0034379 | very-low-density lipoprotein particle assembly | 1 | 8 | 5.79e-01 |
| GO:BP | GO:0007196 | adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathway | 1 | 1 | 5.79e-01 |
| GO:BP | GO:0002418 | immune response to tumor cell | 2 | 12 | 5.79e-01 |
| GO:BP | GO:0097484 | dendrite extension | 1 | 27 | 5.79e-01 |
| GO:BP | GO:0030204 | chondroitin sulfate metabolic process | 1 | 28 | 5.79e-01 |
| GO:BP | GO:0090110 | COPII-coated vesicle cargo loading | 1 | 15 | 5.79e-01 |
| GO:BP | GO:0003401 | axis elongation | 1 | 24 | 5.79e-01 |
| GO:BP | GO:0046519 | sphingoid metabolic process | 2 | 19 | 5.79e-01 |
| GO:BP | GO:1904263 | positive regulation of TORC1 signaling | 1 | 24 | 5.79e-01 |
| GO:BP | GO:0022414 | reproductive process | 8 | 927 | 5.79e-01 |
| GO:BP | GO:0021953 | central nervous system neuron differentiation | 1 | 108 | 5.79e-01 |
| GO:BP | GO:0019883 | antigen processing and presentation of endogenous antigen | 2 | 19 | 5.79e-01 |
| GO:BP | GO:0044597 | daunorubicin metabolic process | 1 | 7 | 5.79e-01 |
| GO:BP | GO:0001894 | tissue homeostasis | 1 | 170 | 5.80e-01 |
| GO:BP | GO:0060249 | anatomical structure homeostasis | 1 | 170 | 5.80e-01 |
| GO:BP | GO:0035902 | response to immobilization stress | 2 | 16 | 5.80e-01 |
| GO:BP | GO:0007249 | I-kappaB kinase/NF-kappaB signaling | 1 | 227 | 5.80e-01 |
| GO:BP | GO:0061512 | protein localization to cilium | 3 | 61 | 5.80e-01 |
| GO:BP | GO:0035020 | regulation of Rac protein signal transduction | 2 | 21 | 5.80e-01 |
| GO:BP | GO:0050810 | regulation of steroid biosynthetic process | 1 | 51 | 5.80e-01 |
| GO:BP | GO:0050885 | neuromuscular process controlling balance | 3 | 35 | 5.81e-01 |
| GO:BP | GO:1901679 | nucleotide transmembrane transport | 2 | 18 | 5.81e-01 |
| GO:BP | GO:1905144 | response to acetylcholine | 2 | 22 | 5.81e-01 |
| GO:BP | GO:0042752 | regulation of circadian rhythm | 2 | 97 | 5.81e-01 |
| GO:BP | GO:0009743 | response to carbohydrate | 1 | 161 | 5.81e-01 |
| GO:BP | GO:0001701 | in utero embryonic development | 21 | 344 | 5.81e-01 |
| GO:BP | GO:0009111 | vitamin catabolic process | 1 | 3 | 5.81e-01 |
| GO:BP | GO:0032102 | negative regulation of response to external stimulus | 25 | 269 | 5.81e-01 |
| GO:BP | GO:0010172 | embryonic body morphogenesis | 1 | 11 | 5.81e-01 |
| GO:BP | GO:0009299 | mRNA transcription | 2 | 50 | 5.81e-01 |
| GO:BP | GO:0048066 | developmental pigmentation | 3 | 36 | 5.81e-01 |
| GO:BP | GO:0070585 | protein localization to mitochondrion | 9 | 123 | 5.82e-01 |
| GO:BP | GO:0019216 | regulation of lipid metabolic process | 8 | 250 | 5.83e-01 |
| GO:BP | GO:0030730 | sequestering of triglyceride | 1 | 13 | 5.83e-01 |
| GO:BP | GO:0044818 | mitotic G2/M transition checkpoint | 4 | 50 | 5.83e-01 |
| GO:BP | GO:0060052 | neurofilament cytoskeleton organization | 1 | 9 | 5.83e-01 |
| GO:BP | GO:0006182 | cGMP biosynthetic process | 1 | 6 | 5.83e-01 |
| GO:BP | GO:0097106 | postsynaptic density organization | 3 | 30 | 5.83e-01 |
| GO:BP | GO:0034472 | snRNA 3’-end processing | 1 | 21 | 5.83e-01 |
| GO:BP | GO:0003351 | epithelial cilium movement involved in extracellular fluid movement | 1 | 29 | 5.83e-01 |
| GO:BP | GO:1903557 | positive regulation of tumor necrosis factor superfamily cytokine production | 1 | 57 | 5.84e-01 |
| GO:BP | GO:0060571 | morphogenesis of an epithelial fold | 2 | 16 | 5.84e-01 |
| GO:BP | GO:0031100 | animal organ regeneration | 5 | 47 | 5.84e-01 |
| GO:BP | GO:0034767 | positive regulation of monoatomic ion transmembrane transport | 2 | 114 | 5.84e-01 |
| GO:BP | GO:0051092 | positive regulation of NF-kappaB transcription factor activity | 6 | 116 | 5.84e-01 |
| GO:BP | GO:0045657 | positive regulation of monocyte differentiation | 1 | 7 | 5.84e-01 |
| GO:BP | GO:0060347 | heart trabecula formation | 1 | 13 | 5.84e-01 |
| GO:BP | GO:0000003 | reproduction | 8 | 934 | 5.84e-01 |
| GO:BP | GO:0002693 | positive regulation of cellular extravasation | 1 | 13 | 5.84e-01 |
| GO:BP | GO:0050432 | catecholamine secretion | 1 | 31 | 5.84e-01 |
| GO:BP | GO:0009148 | pyrimidine nucleoside triphosphate biosynthetic process | 1 | 17 | 5.84e-01 |
| GO:BP | GO:0018126 | protein hydroxylation | 1 | 26 | 5.84e-01 |
| GO:BP | GO:0072182 | regulation of nephron tubule epithelial cell differentiation | 1 | 10 | 5.84e-01 |
| GO:BP | GO:0006379 | mRNA cleavage | 1 | 19 | 5.84e-01 |
| GO:BP | GO:0060707 | trophoblast giant cell differentiation | 1 | 10 | 5.84e-01 |
| GO:BP | GO:0002361 | CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation | 1 | 3 | 5.84e-01 |
| GO:BP | GO:0009260 | ribonucleotide biosynthetic process | 1 | 191 | 5.85e-01 |
| GO:BP | GO:0010819 | regulation of T cell chemotaxis | 1 | 7 | 5.85e-01 |
| GO:BP | GO:1904262 | negative regulation of TORC1 signaling | 2 | 24 | 5.85e-01 |
| GO:BP | GO:0042461 | photoreceptor cell development | 2 | 30 | 5.86e-01 |
| GO:BP | GO:0001510 | RNA methylation | 2 | 87 | 5.86e-01 |
| GO:BP | GO:0044342 | type B pancreatic cell proliferation | 1 | 26 | 5.86e-01 |
| GO:BP | GO:0010887 | negative regulation of cholesterol storage | 1 | 9 | 5.86e-01 |
| GO:BP | GO:0015868 | purine ribonucleotide transport | 2 | 19 | 5.86e-01 |
| GO:BP | GO:0030239 | myofibril assembly | 1 | 66 | 5.86e-01 |
| GO:BP | GO:0050667 | homocysteine metabolic process | 1 | 11 | 5.86e-01 |
| GO:BP | GO:0045624 | positive regulation of T-helper cell differentiation | 1 | 11 | 5.86e-01 |
| GO:BP | GO:0032943 | mononuclear cell proliferation | 4 | 168 | 5.86e-01 |
| GO:BP | GO:0032674 | regulation of interleukin-5 production | 1 | 8 | 5.86e-01 |
| GO:BP | GO:0032634 | interleukin-5 production | 1 | 8 | 5.86e-01 |
| GO:BP | GO:0090382 | phagosome maturation | 1 | 24 | 5.86e-01 |
| GO:BP | GO:1904353 | regulation of telomere capping | 2 | 23 | 5.87e-01 |
| GO:BP | GO:0051251 | positive regulation of lymphocyte activation | 10 | 199 | 5.87e-01 |
| GO:BP | GO:0002366 | leukocyte activation involved in immune response | 1 | 154 | 5.87e-01 |
| GO:BP | GO:0071679 | commissural neuron axon guidance | 1 | 11 | 5.87e-01 |
| GO:BP | GO:0030100 | regulation of endocytosis | 20 | 211 | 5.88e-01 |
| GO:BP | GO:0023051 | regulation of signaling | 1 | 2565 | 5.88e-01 |
| GO:BP | GO:0010573 | vascular endothelial growth factor production | 2 | 23 | 5.88e-01 |
| GO:BP | GO:0036109 | alpha-linolenic acid metabolic process | 1 | 9 | 5.88e-01 |
| GO:BP | GO:0080171 | lytic vacuole organization | 1 | 88 | 5.88e-01 |
| GO:BP | GO:0044782 | cilium organization | 21 | 313 | 5.88e-01 |
| GO:BP | GO:2000050 | regulation of non-canonical Wnt signaling pathway | 2 | 23 | 5.88e-01 |
| GO:BP | GO:0098609 | cell-cell adhesion | 1 | 609 | 5.88e-01 |
| GO:BP | GO:0007040 | lysosome organization | 1 | 88 | 5.88e-01 |
| GO:BP | GO:0010646 | regulation of cell communication | 1 | 2573 | 5.88e-01 |
| GO:BP | GO:0048857 | neural nucleus development | 1 | 50 | 5.88e-01 |
| GO:BP | GO:0031115 | negative regulation of microtubule polymerization | 1 | 13 | 5.89e-01 |
| GO:BP | GO:1901568 | fatty acid derivative metabolic process | 1 | 48 | 5.89e-01 |
| GO:BP | GO:0032543 | mitochondrial translation | 1 | 130 | 5.89e-01 |
| GO:BP | GO:0014911 | positive regulation of smooth muscle cell migration | 3 | 30 | 5.89e-01 |
| GO:BP | GO:0060039 | pericardium development | 1 | 17 | 5.89e-01 |
| GO:BP | GO:0006352 | DNA-templated transcription initiation | 3 | 130 | 5.89e-01 |
| GO:BP | GO:0048339 | paraxial mesoderm development | 1 | 15 | 5.89e-01 |
| GO:BP | GO:0045954 | positive regulation of natural killer cell mediated cytotoxicity | 1 | 10 | 5.89e-01 |
| GO:BP | GO:0055002 | striated muscle cell development | 1 | 67 | 5.89e-01 |
| GO:BP | GO:0048168 | regulation of neuronal synaptic plasticity | 1 | 42 | 5.89e-01 |
| GO:BP | GO:0030199 | collagen fibril organization | 1 | 56 | 5.89e-01 |
| GO:BP | GO:0071044 | histone mRNA catabolic process | 1 | 11 | 5.89e-01 |
| GO:BP | GO:1904152 | regulation of retrograde protein transport, ER to cytosol | 1 | 13 | 5.89e-01 |
| GO:BP | GO:0070863 | positive regulation of protein exit from endoplasmic reticulum | 1 | 10 | 5.89e-01 |
| GO:BP | GO:0002263 | cell activation involved in immune response | 1 | 157 | 5.90e-01 |
| GO:BP | GO:0044344 | cellular response to fibroblast growth factor stimulus | 5 | 81 | 5.90e-01 |
| GO:BP | GO:0090083 | regulation of inclusion body assembly | 1 | 16 | 5.90e-01 |
| GO:BP | GO:0070988 | demethylation | 1 | 52 | 5.90e-01 |
| GO:BP | GO:0070887 | cellular response to chemical stimulus | 10 | 1869 | 5.90e-01 |
| GO:BP | GO:0033238 | regulation of amine metabolic process | 1 | 19 | 5.90e-01 |
| GO:BP | GO:0034454 | microtubule anchoring at centrosome | 1 | 12 | 5.90e-01 |
| GO:BP | GO:0032200 | telomere organization | 12 | 166 | 5.91e-01 |
| GO:BP | GO:0120162 | positive regulation of cold-induced thermogenesis | 1 | 69 | 5.91e-01 |
| GO:BP | GO:0002706 | regulation of lymphocyte mediated immunity | 2 | 83 | 5.91e-01 |
| GO:BP | GO:0021871 | forebrain regionalization | 1 | 8 | 5.91e-01 |
| GO:BP | GO:0046390 | ribose phosphate biosynthetic process | 1 | 197 | 5.91e-01 |
| GO:BP | GO:0048806 | genitalia development | 3 | 28 | 5.91e-01 |
| GO:BP | GO:1990182 | exosomal secretion | 1 | 18 | 5.91e-01 |
| GO:BP | GO:0003094 | glomerular filtration | 2 | 21 | 5.92e-01 |
| GO:BP | GO:0009855 | determination of bilateral symmetry | 2 | 102 | 5.92e-01 |
| GO:BP | GO:0046660 | female sex differentiation | 7 | 91 | 5.92e-01 |
| GO:BP | GO:1904889 | regulation of excitatory synapse assembly | 1 | 12 | 5.92e-01 |
| GO:BP | GO:0021695 | cerebellar cortex development | 4 | 44 | 5.92e-01 |
| GO:BP | GO:0048821 | erythrocyte development | 1 | 30 | 5.92e-01 |
| GO:BP | GO:0001655 | urogenital system development | 4 | 49 | 5.93e-01 |
| GO:BP | GO:0048679 | regulation of axon regeneration | 1 | 23 | 5.93e-01 |
| GO:BP | GO:1903311 | regulation of mRNA metabolic process | 1 | 267 | 5.93e-01 |
| GO:BP | GO:0061430 | bone trabecula morphogenesis | 1 | 12 | 5.93e-01 |
| GO:BP | GO:0009584 | detection of visible light | 1 | 20 | 5.93e-01 |
| GO:BP | GO:2000059 | negative regulation of ubiquitin-dependent protein catabolic process | 4 | 47 | 5.93e-01 |
| GO:BP | GO:0030252 | growth hormone secretion | 1 | 12 | 5.93e-01 |
| GO:BP | GO:1901654 | response to ketone | 3 | 147 | 5.94e-01 |
| GO:BP | GO:0048511 | rhythmic process | 3 | 237 | 5.94e-01 |
| GO:BP | GO:0051177 | meiotic sister chromatid cohesion | 1 | 12 | 5.94e-01 |
| GO:BP | GO:0033762 | response to glucagon | 1 | 13 | 5.94e-01 |
| GO:BP | GO:0001889 | liver development | 10 | 110 | 5.94e-01 |
| GO:BP | GO:0048706 | embryonic skeletal system development | 7 | 78 | 5.94e-01 |
| GO:BP | GO:0048643 | positive regulation of skeletal muscle tissue development | 1 | 14 | 5.94e-01 |
| GO:BP | GO:0071404 | cellular response to low-density lipoprotein particle stimulus | 1 | 19 | 5.94e-01 |
| GO:BP | GO:0009799 | specification of symmetry | 2 | 103 | 5.94e-01 |
| GO:BP | GO:0045576 | mast cell activation | 2 | 35 | 5.94e-01 |
| GO:BP | GO:0030500 | regulation of bone mineralization | 1 | 53 | 5.94e-01 |
| GO:BP | GO:0098930 | axonal transport | 1 | 60 | 5.94e-01 |
| GO:BP | GO:1902895 | positive regulation of miRNA transcription | 1 | 42 | 5.95e-01 |
| GO:BP | GO:0015755 | fructose transmembrane transport | 1 | 5 | 5.95e-01 |
| GO:BP | GO:0032205 | negative regulation of telomere maintenance | 2 | 33 | 5.95e-01 |
| GO:BP | GO:0001553 | luteinization | 1 | 10 | 5.95e-01 |
| GO:BP | GO:0033327 | Leydig cell differentiation | 1 | 9 | 5.95e-01 |
| GO:BP | GO:0006260 | DNA replication | 12 | 255 | 5.95e-01 |
| GO:BP | GO:1904707 | positive regulation of vascular associated smooth muscle cell proliferation | 2 | 29 | 5.95e-01 |
| GO:BP | GO:0048385 | regulation of retinoic acid receptor signaling pathway | 1 | 13 | 5.96e-01 |
| GO:BP | GO:0042698 | ovulation cycle | 1 | 54 | 5.96e-01 |
| GO:BP | GO:0048103 | somatic stem cell division | 1 | 10 | 5.96e-01 |
| GO:BP | GO:0003009 | skeletal muscle contraction | 2 | 31 | 5.96e-01 |
| GO:BP | GO:0033314 | mitotic DNA replication checkpoint signaling | 1 | 9 | 5.96e-01 |
| GO:BP | GO:1903169 | regulation of calcium ion transmembrane transport | 3 | 122 | 5.96e-01 |
| GO:BP | GO:0032656 | regulation of interleukin-13 production | 1 | 10 | 5.96e-01 |
| GO:BP | GO:0032616 | interleukin-13 production | 1 | 10 | 5.96e-01 |
| GO:BP | GO:0009086 | methionine biosynthetic process | 1 | 10 | 5.96e-01 |
| GO:BP | GO:0060008 | Sertoli cell differentiation | 1 | 15 | 5.96e-01 |
| GO:BP | GO:0021533 | cell differentiation in hindbrain | 2 | 18 | 5.96e-01 |
| GO:BP | GO:1902622 | regulation of neutrophil migration | 1 | 28 | 5.97e-01 |
| GO:BP | GO:0043200 | response to amino acid | 8 | 95 | 5.97e-01 |
| GO:BP | GO:1904851 | positive regulation of establishment of protein localization to telomere | 1 | 10 | 5.97e-01 |
| GO:BP | GO:2000369 | regulation of clathrin-dependent endocytosis | 1 | 18 | 5.97e-01 |
| GO:BP | GO:0003006 | developmental process involved in reproduction | 2 | 598 | 5.97e-01 |
| GO:BP | GO:1990314 | cellular response to insulin-like growth factor stimulus | 1 | 8 | 5.97e-01 |
| GO:BP | GO:0001325 | formation of extrachromosomal circular DNA | 1 | 13 | 5.98e-01 |
| GO:BP | GO:0090737 | telomere maintenance via telomere trimming | 1 | 13 | 5.98e-01 |
| GO:BP | GO:0090656 | t-circle formation | 1 | 13 | 5.98e-01 |
| GO:BP | GO:0006858 | extracellular transport | 1 | 32 | 5.99e-01 |
| GO:BP | GO:0006040 | amino sugar metabolic process | 1 | 33 | 5.99e-01 |
| GO:BP | GO:0006968 | cellular defense response | 1 | 15 | 5.99e-01 |
| GO:BP | GO:0034698 | response to gonadotropin | 2 | 19 | 5.99e-01 |
| GO:BP | GO:0006506 | GPI anchor biosynthetic process | 2 | 30 | 5.99e-01 |
| GO:BP | GO:0046686 | response to cadmium ion | 4 | 41 | 5.99e-01 |
| GO:BP | GO:0050771 | negative regulation of axonogenesis | 5 | 58 | 5.99e-01 |
| GO:BP | GO:0043301 | negative regulation of leukocyte degranulation | 1 | 5 | 5.99e-01 |
| GO:BP | GO:1902563 | regulation of neutrophil activation | 1 | 3 | 5.99e-01 |
| GO:BP | GO:0002260 | lymphocyte homeostasis | 2 | 45 | 5.99e-01 |
| GO:BP | GO:0000018 | regulation of DNA recombination | 4 | 101 | 5.99e-01 |
| GO:BP | GO:0010830 | regulation of myotube differentiation | 1 | 31 | 6.00e-01 |
| GO:BP | GO:0001829 | trophectodermal cell differentiation | 1 | 15 | 6.00e-01 |
| GO:BP | GO:2001238 | positive regulation of extrinsic apoptotic signaling pathway | 1 | 40 | 6.00e-01 |
| GO:BP | GO:0086064 | cell communication by electrical coupling involved in cardiac conduction | 2 | 26 | 6.02e-01 |
| GO:BP | GO:0071300 | cellular response to retinoic acid | 3 | 49 | 6.02e-01 |
| GO:BP | GO:0031069 | hair follicle morphogenesis | 2 | 18 | 6.02e-01 |
| GO:BP | GO:0060572 | morphogenesis of an epithelial bud | 1 | 11 | 6.03e-01 |
| GO:BP | GO:0061154 | endothelial tube morphogenesis | 1 | 14 | 6.03e-01 |
| GO:BP | GO:0003159 | morphogenesis of an endothelium | 1 | 14 | 6.03e-01 |
| GO:BP | GO:0043537 | negative regulation of blood vessel endothelial cell migration | 1 | 25 | 6.03e-01 |
| GO:BP | GO:1902043 | positive regulation of extrinsic apoptotic signaling pathway via death domain receptors | 1 | 11 | 6.03e-01 |
| GO:BP | GO:0055094 | response to lipoprotein particle | 1 | 20 | 6.03e-01 |
| GO:BP | GO:0048519 | negative regulation of biological process | 5 | 4045 | 6.03e-01 |
| GO:BP | GO:0051155 | positive regulation of striated muscle cell differentiation | 2 | 31 | 6.03e-01 |
| GO:BP | GO:0097734 | extracellular exosome biogenesis | 1 | 18 | 6.03e-01 |
| GO:BP | GO:0051775 | response to redox state | 1 | 12 | 6.03e-01 |
| GO:BP | GO:1900225 | regulation of NLRP3 inflammasome complex assembly | 1 | 23 | 6.03e-01 |
| GO:BP | GO:0061308 | cardiac neural crest cell development involved in heart development | 1 | 15 | 6.03e-01 |
| GO:BP | GO:0061307 | cardiac neural crest cell differentiation involved in heart development | 1 | 15 | 6.03e-01 |
| GO:BP | GO:0044070 | regulation of monoatomic anion transport | 1 | 12 | 6.03e-01 |
| GO:BP | GO:0044598 | doxorubicin metabolic process | 1 | 8 | 6.03e-01 |
| GO:BP | GO:0030638 | polyketide metabolic process | 1 | 8 | 6.03e-01 |
| GO:BP | GO:0030647 | aminoglycoside antibiotic metabolic process | 1 | 7 | 6.03e-01 |
| GO:BP | GO:0031639 | plasminogen activation | 2 | 19 | 6.04e-01 |
| GO:BP | GO:0045911 | positive regulation of DNA recombination | 1 | 57 | 6.04e-01 |
| GO:BP | GO:0070979 | protein K11-linked ubiquitination | 1 | 29 | 6.04e-01 |
| GO:BP | GO:2000351 | regulation of endothelial cell apoptotic process | 2 | 35 | 6.04e-01 |
| GO:BP | GO:1903232 | melanosome assembly | 1 | 19 | 6.05e-01 |
| GO:BP | GO:0006284 | base-excision repair | 2 | 44 | 6.05e-01 |
| GO:BP | GO:0051153 | regulation of striated muscle cell differentiation | 2 | 67 | 6.05e-01 |
| GO:BP | GO:0038095 | Fc-epsilon receptor signaling pathway | 2 | 17 | 6.05e-01 |
| GO:BP | GO:1902745 | positive regulation of lamellipodium organization | 2 | 32 | 6.06e-01 |
| GO:BP | GO:0061462 | protein localization to lysosome | 4 | 46 | 6.06e-01 |
| GO:BP | GO:1903429 | regulation of cell maturation | 1 | 13 | 6.06e-01 |
| GO:BP | GO:0086103 | G protein-coupled receptor signaling pathway involved in heart process | 1 | 13 | 6.07e-01 |
| GO:BP | GO:0061000 | negative regulation of dendritic spine development | 1 | 10 | 6.07e-01 |
| GO:BP | GO:0002087 | regulation of respiratory gaseous exchange by nervous system process | 1 | 8 | 6.07e-01 |
| GO:BP | GO:0021794 | thalamus development | 1 | 6 | 6.07e-01 |
| GO:BP | GO:2001233 | regulation of apoptotic signaling pathway | 5 | 307 | 6.07e-01 |
| GO:BP | GO:0071872 | cellular response to epinephrine stimulus | 1 | 10 | 6.07e-01 |
| GO:BP | GO:0032042 | mitochondrial DNA metabolic process | 1 | 22 | 6.07e-01 |
| GO:BP | GO:0032413 | negative regulation of ion transmembrane transporter activity | 1 | 51 | 6.07e-01 |
| GO:BP | GO:0048002 | antigen processing and presentation of peptide antigen | 4 | 41 | 6.08e-01 |
| GO:BP | GO:0034331 | cell junction maintenance | 3 | 40 | 6.08e-01 |
| GO:BP | GO:0030432 | peristalsis | 1 | 6 | 6.08e-01 |
| GO:BP | GO:0009791 | post-embryonic development | 2 | 74 | 6.08e-01 |
| GO:BP | GO:0032966 | negative regulation of collagen biosynthetic process | 1 | 7 | 6.08e-01 |
| GO:BP | GO:0070344 | regulation of fat cell proliferation | 1 | 9 | 6.08e-01 |
| GO:BP | GO:0006261 | DNA-templated DNA replication | 7 | 148 | 6.09e-01 |
| GO:BP | GO:0036119 | response to platelet-derived growth factor | 2 | 23 | 6.09e-01 |
| GO:BP | GO:0002720 | positive regulation of cytokine production involved in immune response | 1 | 49 | 6.09e-01 |
| GO:BP | GO:0000096 | sulfur amino acid metabolic process | 2 | 27 | 6.09e-01 |
| GO:BP | GO:0050730 | regulation of peptidyl-tyrosine phosphorylation | 1 | 166 | 6.10e-01 |
| GO:BP | GO:0048843 | negative regulation of axon extension involved in axon guidance | 1 | 26 | 6.11e-01 |
| GO:BP | GO:0030242 | autophagy of peroxisome | 1 | 10 | 6.11e-01 |
| GO:BP | GO:0098926 | postsynaptic signal transduction | 2 | 25 | 6.11e-01 |
| GO:BP | GO:0104004 | cellular response to environmental stimulus | 5 | 268 | 6.11e-01 |
| GO:BP | GO:1900542 | regulation of purine nucleotide metabolic process | 2 | 40 | 6.11e-01 |
| GO:BP | GO:0071214 | cellular response to abiotic stimulus | 5 | 268 | 6.11e-01 |
| GO:BP | GO:0007157 | heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules | 3 | 29 | 6.11e-01 |
| GO:BP | GO:1902774 | late endosome to lysosome transport | 1 | 20 | 6.11e-01 |
| GO:BP | GO:0048856 | anatomical structure development | 8 | 4128 | 6.12e-01 |
| GO:BP | GO:0006505 | GPI anchor metabolic process | 2 | 31 | 6.12e-01 |
| GO:BP | GO:0071233 | cellular response to leucine | 1 | 10 | 6.12e-01 |
| GO:BP | GO:0045631 | regulation of mechanoreceptor differentiation | 1 | 8 | 6.12e-01 |
| GO:BP | GO:0045607 | regulation of inner ear auditory receptor cell differentiation | 1 | 8 | 6.12e-01 |
| GO:BP | GO:2000980 | regulation of inner ear receptor cell differentiation | 1 | 8 | 6.12e-01 |
| GO:BP | GO:0061035 | regulation of cartilage development | 4 | 54 | 6.13e-01 |
| GO:BP | GO:0050654 | chondroitin sulfate proteoglycan metabolic process | 1 | 31 | 6.13e-01 |
| GO:BP | GO:1901700 | response to oxygen-containing compound | 5 | 1223 | 6.13e-01 |
| GO:BP | GO:0033604 | negative regulation of catecholamine secretion | 1 | 6 | 6.13e-01 |
| GO:BP | GO:0050670 | regulation of lymphocyte proliferation | 5 | 126 | 6.13e-01 |
| GO:BP | GO:0097305 | response to alcohol | 1 | 159 | 6.13e-01 |
| GO:BP | GO:0021783 | preganglionic parasympathetic fiber development | 1 | 11 | 6.14e-01 |
| GO:BP | GO:0007156 | homophilic cell adhesion via plasma membrane adhesion molecules | 1 | 104 | 6.14e-01 |
| GO:BP | GO:0016226 | iron-sulfur cluster assembly | 1 | 29 | 6.15e-01 |
| GO:BP | GO:0031163 | metallo-sulfur cluster assembly | 1 | 29 | 6.15e-01 |
| GO:BP | GO:0062125 | regulation of mitochondrial gene expression | 1 | 31 | 6.15e-01 |
| GO:BP | GO:0032496 | response to lipopolysaccharide | 1 | 178 | 6.15e-01 |
| GO:BP | GO:0035024 | negative regulation of Rho protein signal transduction | 1 | 21 | 6.15e-01 |
| GO:BP | GO:0006665 | sphingolipid metabolic process | 6 | 131 | 6.15e-01 |
| GO:BP | GO:0007229 | integrin-mediated signaling pathway | 4 | 89 | 6.16e-01 |
| GO:BP | GO:0030042 | actin filament depolymerization | 1 | 50 | 6.16e-01 |
| GO:BP | GO:0051409 | response to nitrosative stress | 1 | 10 | 6.16e-01 |
| GO:BP | GO:0006635 | fatty acid beta-oxidation | 2 | 68 | 6.17e-01 |
| GO:BP | GO:0061640 | cytoskeleton-dependent cytokinesis | 4 | 104 | 6.17e-01 |
| GO:BP | GO:0051549 | positive regulation of keratinocyte migration | 1 | 11 | 6.17e-01 |
| GO:BP | GO:0010561 | negative regulation of glycoprotein biosynthetic process | 1 | 10 | 6.17e-01 |
| GO:BP | GO:1903365 | regulation of fear response | 1 | 8 | 6.17e-01 |
| GO:BP | GO:0002327 | immature B cell differentiation | 1 | 11 | 6.17e-01 |
| GO:BP | GO:0001910 | regulation of leukocyte mediated cytotoxicity | 3 | 30 | 6.17e-01 |
| GO:BP | GO:0042180 | cellular ketone metabolic process | 5 | 158 | 6.17e-01 |
| GO:BP | GO:1904892 | regulation of receptor signaling pathway via STAT | 7 | 54 | 6.18e-01 |
| GO:BP | GO:0034776 | response to histamine | 1 | 5 | 6.18e-01 |
| GO:BP | GO:0060333 | type II interferon-mediated signaling pathway | 1 | 21 | 6.18e-01 |
| GO:BP | GO:0051482 | positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway | 2 | 12 | 6.19e-01 |
| GO:BP | GO:0006140 | regulation of nucleotide metabolic process | 2 | 40 | 6.19e-01 |
| GO:BP | GO:0055119 | relaxation of cardiac muscle | 1 | 17 | 6.19e-01 |
| GO:BP | GO:0002637 | regulation of immunoglobulin production | 1 | 43 | 6.19e-01 |
| GO:BP | GO:0050770 | regulation of axonogenesis | 11 | 139 | 6.20e-01 |
| GO:BP | GO:1900025 | negative regulation of substrate adhesion-dependent cell spreading | 1 | 11 | 6.20e-01 |
| GO:BP | GO:0072160 | nephron tubule epithelial cell differentiation | 1 | 12 | 6.20e-01 |
| GO:BP | GO:1903025 | regulation of RNA polymerase II regulatory region sequence-specific DNA binding | 1 | 15 | 6.20e-01 |
| GO:BP | GO:0070167 | regulation of biomineral tissue development | 4 | 67 | 6.20e-01 |
| GO:BP | GO:0051726 | regulation of cell cycle | 3 | 956 | 6.20e-01 |
| GO:BP | GO:0060046 | regulation of acrosome reaction | 1 | 8 | 6.20e-01 |
| GO:BP | GO:0016180 | snRNA processing | 1 | 26 | 6.20e-01 |
| GO:BP | GO:0048566 | embryonic digestive tract development | 2 | 20 | 6.20e-01 |
| GO:BP | GO:0042398 | cellular modified amino acid biosynthetic process | 2 | 26 | 6.21e-01 |
| GO:BP | GO:0018205 | peptidyl-lysine modification | 7 | 336 | 6.21e-01 |
| GO:BP | GO:0042167 | heme catabolic process | 1 | 6 | 6.21e-01 |
| GO:BP | GO:0046149 | pigment catabolic process | 1 | 6 | 6.21e-01 |
| GO:BP | GO:0061101 | neuroendocrine cell differentiation | 1 | 9 | 6.21e-01 |
| GO:BP | GO:0032507 | maintenance of protein location in cell | 2 | 58 | 6.21e-01 |
| GO:BP | GO:0006334 | nucleosome assembly | 2 | 80 | 6.21e-01 |
| GO:BP | GO:0030488 | tRNA methylation | 1 | 42 | 6.21e-01 |
| GO:BP | GO:0070570 | regulation of neuron projection regeneration | 1 | 25 | 6.21e-01 |
| GO:BP | GO:1905048 | regulation of metallopeptidase activity | 1 | 14 | 6.21e-01 |
| GO:BP | GO:0023061 | signal release | 5 | 321 | 6.21e-01 |
| GO:BP | GO:0001824 | blastocyst development | 6 | 94 | 6.22e-01 |
| GO:BP | GO:0031507 | heterochromatin formation | 1 | 69 | 6.22e-01 |
| GO:BP | GO:0032729 | positive regulation of type II interferon production | 2 | 36 | 6.22e-01 |
| GO:BP | GO:1904869 | regulation of protein localization to Cajal body | 1 | 11 | 6.22e-01 |
| GO:BP | GO:0002700 | regulation of production of molecular mediator of immune response | 2 | 108 | 6.22e-01 |
| GO:BP | GO:0070203 | regulation of establishment of protein localization to telomere | 1 | 11 | 6.22e-01 |
| GO:BP | GO:0060259 | regulation of feeding behavior | 1 | 9 | 6.22e-01 |
| GO:BP | GO:1904871 | positive regulation of protein localization to Cajal body | 1 | 11 | 6.22e-01 |
| GO:BP | GO:1901985 | positive regulation of protein acetylation | 1 | 41 | 6.22e-01 |
| GO:BP | GO:0045730 | respiratory burst | 2 | 21 | 6.22e-01 |
| GO:BP | GO:0097435 | supramolecular fiber organization | 25 | 665 | 6.22e-01 |
| GO:BP | GO:0006325 | chromatin organization | 19 | 551 | 6.22e-01 |
| GO:BP | GO:0051128 | regulation of cellular component organization | 9 | 2011 | 6.22e-01 |
| GO:BP | GO:0032944 | regulation of mononuclear cell proliferation | 3 | 129 | 6.22e-01 |
| GO:BP | GO:1902307 | positive regulation of sodium ion transmembrane transport | 1 | 17 | 6.23e-01 |
| GO:BP | GO:1900017 | positive regulation of cytokine production involved in inflammatory response | 2 | 15 | 6.23e-01 |
| GO:BP | GO:0010459 | negative regulation of heart rate | 1 | 7 | 6.24e-01 |
| GO:BP | GO:0060315 | negative regulation of ryanodine-sensitive calcium-release channel activity | 1 | 10 | 6.24e-01 |
| GO:BP | GO:0006623 | protein targeting to vacuole | 3 | 42 | 6.24e-01 |
| GO:BP | GO:0090160 | Golgi to lysosome transport | 1 | 10 | 6.25e-01 |
| GO:BP | GO:0001656 | metanephros development | 6 | 64 | 6.25e-01 |
| GO:BP | GO:0010035 | response to inorganic substance | 29 | 414 | 6.25e-01 |
| GO:BP | GO:0043473 | pigmentation | 6 | 92 | 6.25e-01 |
| GO:BP | GO:0019221 | cytokine-mediated signaling pathway | 2 | 274 | 6.25e-01 |
| GO:BP | GO:0006094 | gluconeogenesis | 1 | 67 | 6.25e-01 |
| GO:BP | GO:2000114 | regulation of establishment of cell polarity | 2 | 22 | 6.25e-01 |
| GO:BP | GO:0090109 | regulation of cell-substrate junction assembly | 3 | 59 | 6.25e-01 |
| GO:BP | GO:0051893 | regulation of focal adhesion assembly | 3 | 59 | 6.25e-01 |
| GO:BP | GO:0021536 | diencephalon development | 5 | 41 | 6.25e-01 |
| GO:BP | GO:0043244 | regulation of protein-containing complex disassembly | 4 | 113 | 6.26e-01 |
| GO:BP | GO:0060840 | artery development | 1 | 83 | 6.26e-01 |
| GO:BP | GO:0006775 | fat-soluble vitamin metabolic process | 3 | 20 | 6.26e-01 |
| GO:BP | GO:0140112 | extracellular vesicle biogenesis | 1 | 20 | 6.27e-01 |
| GO:BP | GO:0034508 | centromere complex assembly | 2 | 28 | 6.28e-01 |
| GO:BP | GO:0044546 | NLRP3 inflammasome complex assembly | 1 | 23 | 6.28e-01 |
| GO:BP | GO:0019637 | organophosphate metabolic process | 3 | 784 | 6.28e-01 |
| GO:BP | GO:0033622 | integrin activation | 2 | 18 | 6.29e-01 |
| GO:BP | GO:0060350 | endochondral bone morphogenesis | 2 | 47 | 6.29e-01 |
| GO:BP | GO:0006862 | nucleotide transport | 3 | 28 | 6.30e-01 |
| GO:BP | GO:0061548 | ganglion development | 1 | 12 | 6.30e-01 |
| GO:BP | GO:0048532 | anatomical structure arrangement | 1 | 13 | 6.30e-01 |
| GO:BP | GO:0046474 | glycerophospholipid biosynthetic process | 2 | 189 | 6.30e-01 |
| GO:BP | GO:0002237 | response to molecule of bacterial origin | 1 | 187 | 6.30e-01 |
| GO:BP | GO:0042110 | T cell activation | 13 | 313 | 6.30e-01 |
| GO:BP | GO:1901978 | positive regulation of cell cycle checkpoint | 1 | 19 | 6.30e-01 |
| GO:BP | GO:0033605 | positive regulation of catecholamine secretion | 1 | 7 | 6.30e-01 |
| GO:BP | GO:0001952 | regulation of cell-matrix adhesion | 8 | 97 | 6.30e-01 |
| GO:BP | GO:0007271 | synaptic transmission, cholinergic | 1 | 15 | 6.30e-01 |
| GO:BP | GO:0043380 | regulation of memory T cell differentiation | 1 | 4 | 6.30e-01 |
| GO:BP | GO:0072393 | microtubule anchoring at microtubule organizing center | 1 | 14 | 6.30e-01 |
| GO:BP | GO:0006643 | membrane lipid metabolic process | 8 | 173 | 6.30e-01 |
| GO:BP | GO:0048639 | positive regulation of developmental growth | 1 | 124 | 6.30e-01 |
| GO:BP | GO:0060193 | positive regulation of lipase activity | 1 | 34 | 6.30e-01 |
| GO:BP | GO:0042415 | norepinephrine metabolic process | 1 | 7 | 6.30e-01 |
| GO:BP | GO:1900271 | regulation of long-term synaptic potentiation | 3 | 34 | 6.30e-01 |
| GO:BP | GO:0042596 | fear response | 3 | 32 | 6.30e-01 |
| GO:BP | GO:0035384 | thioester biosynthetic process | 3 | 38 | 6.31e-01 |
| GO:BP | GO:0014842 | regulation of skeletal muscle satellite cell proliferation | 1 | 8 | 6.31e-01 |
| GO:BP | GO:2000288 | positive regulation of myoblast proliferation | 1 | 9 | 6.31e-01 |
| GO:BP | GO:0010713 | negative regulation of collagen metabolic process | 1 | 8 | 6.31e-01 |
| GO:BP | GO:0071616 | acyl-CoA biosynthetic process | 3 | 38 | 6.31e-01 |
| GO:BP | GO:0070936 | protein K48-linked ubiquitination | 2 | 66 | 6.31e-01 |
| GO:BP | GO:0070493 | thrombin-activated receptor signaling pathway | 1 | 9 | 6.31e-01 |
| GO:BP | GO:0061024 | membrane organization | 2 | 671 | 6.31e-01 |
| GO:BP | GO:0001947 | heart looping | 1 | 50 | 6.31e-01 |
| GO:BP | GO:0099174 | regulation of presynapse organization | 2 | 25 | 6.31e-01 |
| GO:BP | GO:1905606 | regulation of presynapse assembly | 2 | 25 | 6.31e-01 |
| GO:BP | GO:0002717 | positive regulation of natural killer cell mediated immunity | 1 | 11 | 6.32e-01 |
| GO:BP | GO:0071774 | response to fibroblast growth factor | 5 | 84 | 6.32e-01 |
| GO:BP | GO:0048243 | norepinephrine secretion | 1 | 5 | 6.32e-01 |
| GO:BP | GO:0014061 | regulation of norepinephrine secretion | 1 | 5 | 6.32e-01 |
| GO:BP | GO:0050867 | positive regulation of cell activation | 11 | 229 | 6.32e-01 |
| GO:BP | GO:0002460 | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 4 | 161 | 6.32e-01 |
| GO:BP | GO:0120263 | positive regulation of heterochromatin organization | 1 | 15 | 6.32e-01 |
| GO:BP | GO:0021534 | cell proliferation in hindbrain | 1 | 12 | 6.32e-01 |
| GO:BP | GO:0031453 | positive regulation of heterochromatin formation | 1 | 15 | 6.32e-01 |
| GO:BP | GO:0002076 | osteoblast development | 1 | 12 | 6.32e-01 |
| GO:BP | GO:0021924 | cell proliferation in external granule layer | 1 | 12 | 6.32e-01 |
| GO:BP | GO:0021879 | forebrain neuron differentiation | 3 | 23 | 6.32e-01 |
| GO:BP | GO:0021930 | cerebellar granule cell precursor proliferation | 1 | 12 | 6.32e-01 |
| GO:BP | GO:0048284 | organelle fusion | 1 | 135 | 6.32e-01 |
| GO:BP | GO:0060340 | positive regulation of type I interferon-mediated signaling pathway | 1 | 17 | 6.33e-01 |
| GO:BP | GO:0032410 | negative regulation of transporter activity | 1 | 58 | 6.33e-01 |
| GO:BP | GO:0090025 | regulation of monocyte chemotaxis | 2 | 12 | 6.33e-01 |
| GO:BP | GO:0048259 | regulation of receptor-mediated endocytosis | 7 | 87 | 6.33e-01 |
| GO:BP | GO:0019319 | hexose biosynthetic process | 1 | 70 | 6.33e-01 |
| GO:BP | GO:0060856 | establishment of blood-brain barrier | 1 | 9 | 6.33e-01 |
| GO:BP | GO:0042632 | cholesterol homeostasis | 1 | 58 | 6.33e-01 |
| GO:BP | GO:0032370 | positive regulation of lipid transport | 1 | 58 | 6.33e-01 |
| GO:BP | GO:0006047 | UDP-N-acetylglucosamine metabolic process | 1 | 13 | 6.33e-01 |
| GO:BP | GO:0001954 | positive regulation of cell-matrix adhesion | 2 | 44 | 6.33e-01 |
| GO:BP | GO:0035090 | maintenance of apical/basal cell polarity | 1 | 10 | 6.33e-01 |
| GO:BP | GO:0045199 | maintenance of epithelial cell apical/basal polarity | 1 | 10 | 6.33e-01 |
| GO:BP | GO:0006275 | regulation of DNA replication | 1 | 116 | 6.33e-01 |
| GO:BP | GO:1903059 | regulation of protein lipidation | 1 | 11 | 6.34e-01 |
| GO:BP | GO:0045836 | positive regulation of meiotic nuclear division | 1 | 9 | 6.34e-01 |
| GO:BP | GO:0002029 | desensitization of G protein-coupled receptor signaling pathway | 1 | 14 | 6.34e-01 |
| GO:BP | GO:0098813 | nuclear chromosome segregation | 6 | 273 | 6.34e-01 |
| GO:BP | GO:0048583 | regulation of response to stimulus | 1 | 2890 | 6.34e-01 |
| GO:BP | GO:0080154 | regulation of fertilization | 1 | 7 | 6.34e-01 |
| GO:BP | GO:0031338 | regulation of vesicle fusion | 1 | 17 | 6.34e-01 |
| GO:BP | GO:1905063 | regulation of vascular associated smooth muscle cell differentiation | 1 | 14 | 6.34e-01 |
| GO:BP | GO:0071625 | vocalization behavior | 1 | 13 | 6.34e-01 |
| GO:BP | GO:0045651 | positive regulation of macrophage differentiation | 1 | 12 | 6.35e-01 |
| GO:BP | GO:1902914 | regulation of protein polyubiquitination | 1 | 23 | 6.35e-01 |
| GO:BP | GO:0032890 | regulation of organic acid transport | 2 | 49 | 6.35e-01 |
| GO:BP | GO:0010469 | regulation of signaling receptor activity | 10 | 107 | 6.35e-01 |
| GO:BP | GO:0003309 | type B pancreatic cell differentiation | 1 | 22 | 6.35e-01 |
| GO:BP | GO:0048710 | regulation of astrocyte differentiation | 2 | 21 | 6.35e-01 |
| GO:BP | GO:0055092 | sterol homeostasis | 1 | 59 | 6.35e-01 |
| GO:BP | GO:0038093 | Fc receptor signaling pathway | 4 | 36 | 6.35e-01 |
| GO:BP | GO:0071241 | cellular response to inorganic substance | 14 | 164 | 6.35e-01 |
| GO:BP | GO:0042487 | regulation of odontogenesis of dentin-containing tooth | 1 | 6 | 6.35e-01 |
| GO:BP | GO:1990573 | potassium ion import across plasma membrane | 1 | 31 | 6.36e-01 |
| GO:BP | GO:0030307 | positive regulation of cell growth | 1 | 135 | 6.36e-01 |
| GO:BP | GO:1903533 | regulation of protein targeting | 4 | 66 | 6.36e-01 |
| GO:BP | GO:0043517 | positive regulation of DNA damage response, signal transduction by p53 class mediator | 1 | 16 | 6.36e-01 |
| GO:BP | GO:0032272 | negative regulation of protein polymerization | 1 | 71 | 6.36e-01 |
| GO:BP | GO:0014015 | positive regulation of gliogenesis | 4 | 45 | 6.37e-01 |
| GO:BP | GO:0080111 | DNA demethylation | 1 | 23 | 6.37e-01 |
| GO:BP | GO:0043525 | positive regulation of neuron apoptotic process | 1 | 41 | 6.37e-01 |
| GO:BP | GO:1901863 | positive regulation of muscle tissue development | 1 | 18 | 6.37e-01 |
| GO:BP | GO:0051895 | negative regulation of focal adhesion assembly | 1 | 14 | 6.37e-01 |
| GO:BP | GO:0033623 | regulation of integrin activation | 1 | 11 | 6.37e-01 |
| GO:BP | GO:0150118 | negative regulation of cell-substrate junction organization | 1 | 14 | 6.37e-01 |
| GO:BP | GO:0036035 | osteoclast development | 1 | 10 | 6.37e-01 |
| GO:BP | GO:0046459 | short-chain fatty acid metabolic process | 1 | 10 | 6.38e-01 |
| GO:BP | GO:0043928 | exonucleolytic catabolism of deadenylated mRNA | 1 | 13 | 6.38e-01 |
| GO:BP | GO:0002709 | regulation of T cell mediated immunity | 1 | 39 | 6.38e-01 |
| GO:BP | GO:0007292 | female gamete generation | 7 | 103 | 6.38e-01 |
| GO:BP | GO:0048512 | circadian behavior | 3 | 30 | 6.38e-01 |
| GO:BP | GO:0001775 | cell activation | 1 | 655 | 6.38e-01 |
| GO:BP | GO:0070232 | regulation of T cell apoptotic process | 3 | 24 | 6.38e-01 |
| GO:BP | GO:0032753 | positive regulation of interleukin-4 production | 1 | 8 | 6.38e-01 |
| GO:BP | GO:0051937 | catecholamine transport | 1 | 38 | 6.38e-01 |
| GO:BP | GO:2000008 | regulation of protein localization to cell surface | 3 | 37 | 6.38e-01 |
| GO:BP | GO:0042501 | serine phosphorylation of STAT protein | 2 | 9 | 6.38e-01 |
| GO:BP | GO:1904427 | positive regulation of calcium ion transmembrane transport | 6 | 60 | 6.38e-01 |
| GO:BP | GO:2000345 | regulation of hepatocyte proliferation | 1 | 13 | 6.38e-01 |
| GO:BP | GO:0032228 | regulation of synaptic transmission, GABAergic | 2 | 23 | 6.38e-01 |
| GO:BP | GO:0006878 | intracellular copper ion homeostasis | 1 | 15 | 6.39e-01 |
| GO:BP | GO:0010559 | regulation of glycoprotein biosynthetic process | 3 | 32 | 6.39e-01 |
| GO:BP | GO:1903203 | regulation of oxidative stress-induced neuron death | 1 | 25 | 6.39e-01 |
| GO:BP | GO:1901879 | regulation of protein depolymerization | 2 | 78 | 6.40e-01 |
| GO:BP | GO:0140632 | canonical inflammasome complex assembly | 1 | 23 | 6.40e-01 |
| GO:BP | GO:0060415 | muscle tissue morphogenesis | 3 | 60 | 6.40e-01 |
| GO:BP | GO:0009147 | pyrimidine nucleoside triphosphate metabolic process | 1 | 22 | 6.40e-01 |
| GO:BP | GO:0072577 | endothelial cell apoptotic process | 2 | 40 | 6.40e-01 |
| GO:BP | GO:0070486 | leukocyte aggregation | 1 | 9 | 6.40e-01 |
| GO:BP | GO:0019722 | calcium-mediated signaling | 8 | 122 | 6.41e-01 |
| GO:BP | GO:0040015 | negative regulation of multicellular organism growth | 1 | 13 | 6.41e-01 |
| GO:BP | GO:0140053 | mitochondrial gene expression | 1 | 162 | 6.41e-01 |
| GO:BP | GO:0008585 | female gonad development | 2 | 77 | 6.41e-01 |
| GO:BP | GO:0010940 | positive regulation of necrotic cell death | 1 | 13 | 6.42e-01 |
| GO:BP | GO:1904867 | protein localization to Cajal body | 1 | 12 | 6.42e-01 |
| GO:BP | GO:0070202 | regulation of establishment of protein localization to chromosome | 1 | 12 | 6.42e-01 |
| GO:BP | GO:1903405 | protein localization to nuclear body | 1 | 12 | 6.42e-01 |
| GO:BP | GO:0001956 | positive regulation of neurotransmitter secretion | 1 | 12 | 6.42e-01 |
| GO:BP | GO:0034694 | response to prostaglandin | 1 | 21 | 6.42e-01 |
| GO:BP | GO:1905208 | negative regulation of cardiocyte differentiation | 1 | 11 | 6.42e-01 |
| GO:BP | GO:0048265 | response to pain | 1 | 17 | 6.42e-01 |
| GO:BP | GO:0070229 | negative regulation of lymphocyte apoptotic process | 1 | 23 | 6.43e-01 |
| GO:BP | GO:0070661 | leukocyte proliferation | 4 | 188 | 6.43e-01 |
| GO:BP | GO:0010880 | regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | 2 | 27 | 6.44e-01 |
| GO:BP | GO:0051224 | negative regulation of protein transport | 3 | 91 | 6.44e-01 |
| GO:BP | GO:0000338 | protein deneddylation | 1 | 11 | 6.44e-01 |
| GO:BP | GO:1901844 | regulation of cell communication by electrical coupling involved in cardiac conduction | 1 | 12 | 6.44e-01 |
| GO:BP | GO:0042059 | negative regulation of epidermal growth factor receptor signaling pathway | 2 | 26 | 6.44e-01 |
| GO:BP | GO:0045662 | negative regulation of myoblast differentiation | 2 | 19 | 6.44e-01 |
| GO:BP | GO:0022401 | negative adaptation of signaling pathway | 1 | 15 | 6.45e-01 |
| GO:BP | GO:0051932 | synaptic transmission, GABAergic | 3 | 36 | 6.45e-01 |
| GO:BP | GO:0043589 | skin morphogenesis | 1 | 10 | 6.45e-01 |
| GO:BP | GO:0050778 | positive regulation of immune response | 2 | 369 | 6.45e-01 |
| GO:BP | GO:0018149 | peptide cross-linking | 1 | 14 | 6.45e-01 |
| GO:BP | GO:1902042 | negative regulation of extrinsic apoptotic signaling pathway via death domain receptors | 2 | 24 | 6.46e-01 |
| GO:BP | GO:0072655 | establishment of protein localization to mitochondrion | 8 | 118 | 6.46e-01 |
| GO:BP | GO:0060413 | atrial septum morphogenesis | 1 | 15 | 6.46e-01 |
| GO:BP | GO:0021700 | developmental maturation | 1 | 211 | 6.46e-01 |
| GO:BP | GO:0001886 | endothelial cell morphogenesis | 1 | 10 | 6.46e-01 |
| GO:BP | GO:0034644 | cellular response to UV | 1 | 86 | 6.47e-01 |
| GO:BP | GO:0070828 | heterochromatin organization | 1 | 77 | 6.47e-01 |
| GO:BP | GO:0042509 | regulation of tyrosine phosphorylation of STAT protein | 4 | 34 | 6.47e-01 |
| GO:BP | GO:0018200 | peptidyl-glutamic acid modification | 1 | 17 | 6.47e-01 |
| GO:BP | GO:0043114 | regulation of vascular permeability | 3 | 35 | 6.47e-01 |
| GO:BP | GO:1905269 | positive regulation of chromatin organization | 1 | 15 | 6.47e-01 |
| GO:BP | GO:0045869 | negative regulation of single stranded viral RNA replication via double stranded DNA intermediate | 1 | 12 | 6.47e-01 |
| GO:BP | GO:0051966 | regulation of synaptic transmission, glutamatergic | 5 | 46 | 6.48e-01 |
| GO:BP | GO:0009165 | nucleotide biosynthetic process | 1 | 240 | 6.48e-01 |
| GO:BP | GO:0021545 | cranial nerve development | 3 | 31 | 6.48e-01 |
| GO:BP | GO:0043379 | memory T cell differentiation | 1 | 5 | 6.48e-01 |
| GO:BP | GO:0019885 | antigen processing and presentation of endogenous peptide antigen via MHC class I | 1 | 12 | 6.49e-01 |
| GO:BP | GO:0006400 | tRNA modification | 3 | 90 | 6.49e-01 |
| GO:BP | GO:0071472 | cellular response to salt stress | 1 | 11 | 6.49e-01 |
| GO:BP | GO:0048009 | insulin-like growth factor receptor signaling pathway | 3 | 42 | 6.49e-01 |
| GO:BP | GO:1902074 | response to salt | 1 | 271 | 6.49e-01 |
| GO:BP | GO:1904037 | positive regulation of epithelial cell apoptotic process | 1 | 26 | 6.49e-01 |
| GO:BP | GO:0001780 | neutrophil homeostasis | 1 | 16 | 6.49e-01 |
| GO:BP | GO:0045185 | maintenance of protein location | 6 | 83 | 6.49e-01 |
| GO:BP | GO:0035455 | response to interferon-alpha | 1 | 16 | 6.49e-01 |
| GO:BP | GO:0045471 | response to ethanol | 4 | 73 | 6.49e-01 |
| GO:BP | GO:0070341 | fat cell proliferation | 1 | 10 | 6.49e-01 |
| GO:BP | GO:0099084 | postsynaptic specialization organization | 3 | 36 | 6.50e-01 |
| GO:BP | GO:0046348 | amino sugar catabolic process | 1 | 9 | 6.50e-01 |
| GO:BP | GO:1901293 | nucleoside phosphate biosynthetic process | 1 | 241 | 6.50e-01 |
| GO:BP | GO:0017004 | cytochrome complex assembly | 2 | 38 | 6.51e-01 |
| GO:BP | GO:0038096 | Fc-gamma receptor signaling pathway involved in phagocytosis | 2 | 19 | 6.51e-01 |
| GO:BP | GO:0002433 | immune response-regulating cell surface receptor signaling pathway involved in phagocytosis | 2 | 19 | 6.51e-01 |
| GO:BP | GO:0070509 | calcium ion import | 2 | 37 | 6.51e-01 |
| GO:BP | GO:0002377 | immunoglobulin production | 3 | 70 | 6.51e-01 |
| GO:BP | GO:0048755 | branching morphogenesis of a nerve | 1 | 8 | 6.51e-01 |
| GO:BP | GO:0010390 | histone monoubiquitination | 1 | 31 | 6.51e-01 |
| GO:BP | GO:0009410 | response to xenobiotic stimulus | 2 | 279 | 6.51e-01 |
| GO:BP | GO:0031323 | regulation of cellular metabolic process | 4 | 4174 | 6.51e-01 |
| GO:BP | GO:0140131 | positive regulation of lymphocyte chemotaxis | 1 | 10 | 6.51e-01 |
| GO:BP | GO:2001014 | regulation of skeletal muscle cell differentiation | 1 | 16 | 6.51e-01 |
| GO:BP | GO:0048671 | negative regulation of collateral sprouting | 1 | 9 | 6.51e-01 |
| GO:BP | GO:0010842 | retina layer formation | 1 | 16 | 6.51e-01 |
| GO:BP | GO:0002682 | regulation of immune system process | 4 | 877 | 6.51e-01 |
| GO:BP | GO:0003143 | embryonic heart tube morphogenesis | 1 | 56 | 6.51e-01 |
| GO:BP | GO:0061371 | determination of heart left/right asymmetry | 1 | 52 | 6.51e-01 |
| GO:BP | GO:0032740 | positive regulation of interleukin-17 production | 2 | 12 | 6.51e-01 |
| GO:BP | GO:0019218 | regulation of steroid metabolic process | 1 | 69 | 6.51e-01 |
| GO:BP | GO:0070102 | interleukin-6-mediated signaling pathway | 1 | 14 | 6.51e-01 |
| GO:BP | GO:0045945 | positive regulation of transcription by RNA polymerase III | 1 | 19 | 6.51e-01 |
| GO:BP | GO:1904063 | negative regulation of cation transmembrane transport | 1 | 64 | 6.52e-01 |
| GO:BP | GO:0006412 | translation | 2 | 646 | 6.52e-01 |
| GO:BP | GO:0051547 | regulation of keratinocyte migration | 1 | 13 | 6.54e-01 |
| GO:BP | GO:1901699 | cellular response to nitrogen compound | 46 | 517 | 6.55e-01 |
| GO:BP | GO:0042119 | neutrophil activation | 3 | 16 | 6.56e-01 |
| GO:BP | GO:0046545 | development of primary female sexual characteristics | 2 | 79 | 6.57e-01 |
| GO:BP | GO:0010881 | regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion | 1 | 20 | 6.57e-01 |
| GO:BP | GO:0050920 | regulation of chemotaxis | 1 | 142 | 6.58e-01 |
| GO:BP | GO:0048641 | regulation of skeletal muscle tissue development | 1 | 20 | 6.58e-01 |
| GO:BP | GO:0070231 | T cell apoptotic process | 4 | 39 | 6.58e-01 |
| GO:BP | GO:0071364 | cellular response to epidermal growth factor stimulus | 3 | 41 | 6.58e-01 |
| GO:BP | GO:1903649 | regulation of cytoplasmic transport | 2 | 25 | 6.58e-01 |
| GO:BP | GO:0006367 | transcription initiation at RNA polymerase II promoter | 2 | 93 | 6.58e-01 |
| GO:BP | GO:0010243 | response to organonitrogen compound | 6 | 782 | 6.58e-01 |
| GO:BP | GO:0046364 | monosaccharide biosynthetic process | 1 | 79 | 6.58e-01 |
| GO:BP | GO:0050684 | regulation of mRNA processing | 1 | 127 | 6.58e-01 |
| GO:BP | GO:2000278 | regulation of DNA biosynthetic process | 1 | 111 | 6.59e-01 |
| GO:BP | GO:0070227 | lymphocyte apoptotic process | 2 | 56 | 6.59e-01 |
| GO:BP | GO:0044065 | regulation of respiratory system process | 1 | 11 | 6.60e-01 |
| GO:BP | GO:0043299 | leukocyte degranulation | 2 | 41 | 6.60e-01 |
| GO:BP | GO:0048841 | regulation of axon extension involved in axon guidance | 1 | 31 | 6.60e-01 |
| GO:BP | GO:0007622 | rhythmic behavior | 3 | 32 | 6.61e-01 |
| GO:BP | GO:0007625 | grooming behavior | 1 | 10 | 6.61e-01 |
| GO:BP | GO:0002645 | positive regulation of tolerance induction | 1 | 6 | 6.61e-01 |
| GO:BP | GO:1904950 | negative regulation of establishment of protein localization | 3 | 95 | 6.61e-01 |
| GO:BP | GO:0008608 | attachment of spindle microtubules to kinetochore | 2 | 42 | 6.61e-01 |
| GO:BP | GO:0050930 | induction of positive chemotaxis | 1 | 12 | 6.62e-01 |
| GO:BP | GO:0150116 | regulation of cell-substrate junction organization | 3 | 64 | 6.62e-01 |
| GO:BP | GO:0042438 | melanin biosynthetic process | 1 | 17 | 6.63e-01 |
| GO:BP | GO:0033015 | tetrapyrrole catabolic process | 1 | 7 | 6.63e-01 |
| GO:BP | GO:0006787 | porphyrin-containing compound catabolic process | 1 | 7 | 6.63e-01 |
| GO:BP | GO:0071466 | cellular response to xenobiotic stimulus | 1 | 105 | 6.63e-01 |
| GO:BP | GO:1903432 | regulation of TORC1 signaling | 3 | 48 | 6.63e-01 |
| GO:BP | GO:0014029 | neural crest formation | 1 | 13 | 6.63e-01 |
| GO:BP | GO:2000179 | positive regulation of neural precursor cell proliferation | 3 | 34 | 6.63e-01 |
| GO:BP | GO:0001541 | ovarian follicle development | 3 | 41 | 6.64e-01 |
| GO:BP | GO:0060749 | mammary gland alveolus development | 1 | 13 | 6.64e-01 |
| GO:BP | GO:0071871 | response to epinephrine | 1 | 12 | 6.64e-01 |
| GO:BP | GO:0006577 | amino-acid betaine metabolic process | 1 | 13 | 6.64e-01 |
| GO:BP | GO:0060263 | regulation of respiratory burst | 1 | 10 | 6.64e-01 |
| GO:BP | GO:0009583 | detection of light stimulus | 1 | 27 | 6.64e-01 |
| GO:BP | GO:0003215 | cardiac right ventricle morphogenesis | 1 | 17 | 6.64e-01 |
| GO:BP | GO:0061377 | mammary gland lobule development | 1 | 13 | 6.64e-01 |
| GO:BP | GO:1904816 | positive regulation of protein localization to chromosome, telomeric region | 1 | 13 | 6.64e-01 |
| GO:BP | GO:0036475 | neuron death in response to oxidative stress | 1 | 28 | 6.64e-01 |
| GO:BP | GO:0002931 | response to ischemia | 1 | 46 | 6.65e-01 |
| GO:BP | GO:0032467 | positive regulation of cytokinesis | 2 | 33 | 6.65e-01 |
| GO:BP | GO:0048484 | enteric nervous system development | 1 | 7 | 6.65e-01 |
| GO:BP | GO:0006662 | glycerol ether metabolic process | 1 | 16 | 6.65e-01 |
| GO:BP | GO:0046485 | ether lipid metabolic process | 1 | 16 | 6.65e-01 |
| GO:BP | GO:0010613 | positive regulation of cardiac muscle hypertrophy | 1 | 22 | 6.66e-01 |
| GO:BP | GO:0006474 | N-terminal protein amino acid acetylation | 1 | 15 | 6.66e-01 |
| GO:BP | GO:0051280 | negative regulation of release of sequestered calcium ion into cytosol | 1 | 11 | 6.66e-01 |
| GO:BP | GO:0086065 | cell communication involved in cardiac conduction | 1 | 58 | 6.67e-01 |
| GO:BP | GO:0000724 | double-strand break repair via homologous recombination | 3 | 149 | 6.68e-01 |
| GO:BP | GO:0001709 | cell fate determination | 2 | 25 | 6.68e-01 |
| GO:BP | GO:0051900 | regulation of mitochondrial depolarization | 1 | 15 | 6.68e-01 |
| GO:BP | GO:0032511 | late endosome to vacuole transport via multivesicular body sorting pathway | 1 | 27 | 6.68e-01 |
| GO:BP | GO:0001977 | renal system process involved in regulation of blood volume | 1 | 9 | 6.68e-01 |
| GO:BP | GO:0023058 | adaptation of signaling pathway | 1 | 16 | 6.68e-01 |
| GO:BP | GO:0043604 | amide biosynthetic process | 5 | 775 | 6.68e-01 |
| GO:BP | GO:0007435 | salivary gland morphogenesis | 2 | 25 | 6.68e-01 |
| GO:BP | GO:0050729 | positive regulation of inflammatory response | 1 | 75 | 6.68e-01 |
| GO:BP | GO:0031347 | regulation of defense response | 2 | 448 | 6.68e-01 |
| GO:BP | GO:0035521 | monoubiquitinated histone deubiquitination | 1 | 30 | 6.69e-01 |
| GO:BP | GO:0019882 | antigen processing and presentation | 6 | 69 | 6.69e-01 |
| GO:BP | GO:0048522 | positive regulation of cellular process | 4 | 4099 | 6.69e-01 |
| GO:BP | GO:0090715 | immunological memory formation process | 1 | 6 | 6.69e-01 |
| GO:BP | GO:0048704 | embryonic skeletal system morphogenesis | 3 | 55 | 6.69e-01 |
| GO:BP | GO:0002468 | dendritic cell antigen processing and presentation | 1 | 6 | 6.69e-01 |
| GO:BP | GO:0070663 | regulation of leukocyte proliferation | 3 | 141 | 6.69e-01 |
| GO:BP | GO:0035522 | monoubiquitinated histone H2A deubiquitination | 1 | 30 | 6.69e-01 |
| GO:BP | GO:0006839 | mitochondrial transport | 2 | 185 | 6.69e-01 |
| GO:BP | GO:0042221 | response to chemical | 14 | 2559 | 6.69e-01 |
| GO:BP | GO:0002730 | regulation of dendritic cell cytokine production | 1 | 10 | 6.69e-01 |
| GO:BP | GO:0002371 | dendritic cell cytokine production | 1 | 10 | 6.69e-01 |
| GO:BP | GO:0043043 | peptide biosynthetic process | 2 | 666 | 6.69e-01 |
| GO:BP | GO:0016322 | neuron remodeling | 1 | 11 | 6.69e-01 |
| GO:BP | GO:0002275 | myeloid cell activation involved in immune response | 5 | 48 | 6.69e-01 |
| GO:BP | GO:0000097 | sulfur amino acid biosynthetic process | 1 | 14 | 6.70e-01 |
| GO:BP | GO:0021895 | cerebral cortex neuron differentiation | 1 | 14 | 6.70e-01 |
| GO:BP | GO:0006555 | methionine metabolic process | 1 | 13 | 6.70e-01 |
| GO:BP | GO:0014841 | skeletal muscle satellite cell proliferation | 1 | 10 | 6.70e-01 |
| GO:BP | GO:0007260 | tyrosine phosphorylation of STAT protein | 4 | 36 | 6.70e-01 |
| GO:BP | GO:0032673 | regulation of interleukin-4 production | 2 | 14 | 6.70e-01 |
| GO:BP | GO:0032633 | interleukin-4 production | 2 | 14 | 6.70e-01 |
| GO:BP | GO:0042538 | hyperosmotic salinity response | 1 | 8 | 6.70e-01 |
| GO:BP | GO:0045653 | negative regulation of megakaryocyte differentiation | 1 | 17 | 6.70e-01 |
| GO:BP | GO:0032368 | regulation of lipid transport | 3 | 92 | 6.70e-01 |
| GO:BP | GO:0048569 | post-embryonic animal organ development | 1 | 15 | 6.71e-01 |
| GO:BP | GO:0046856 | phosphatidylinositol dephosphorylation | 2 | 29 | 6.71e-01 |
| GO:BP | GO:0035627 | ceramide transport | 1 | 15 | 6.71e-01 |
| GO:BP | GO:0034374 | low-density lipoprotein particle remodeling | 1 | 5 | 6.71e-01 |
| GO:BP | GO:0065004 | protein-DNA complex assembly | 4 | 185 | 6.71e-01 |
| GO:BP | GO:0045746 | negative regulation of Notch signaling pathway | 1 | 31 | 6.71e-01 |
| GO:BP | GO:0051249 | regulation of lymphocyte activation | 13 | 296 | 6.72e-01 |
| GO:BP | GO:0014047 | glutamate secretion | 1 | 14 | 6.72e-01 |
| GO:BP | GO:0006582 | melanin metabolic process | 1 | 18 | 6.72e-01 |
| GO:BP | GO:0031128 | developmental induction | 2 | 26 | 6.72e-01 |
| GO:BP | GO:1903019 | negative regulation of glycoprotein metabolic process | 1 | 12 | 6.72e-01 |
| GO:BP | GO:0035510 | DNA dealkylation | 1 | 28 | 6.73e-01 |
| GO:BP | GO:0019933 | cAMP-mediated signaling | 1 | 35 | 6.73e-01 |
| GO:BP | GO:0015812 | gamma-aminobutyric acid transport | 1 | 11 | 6.73e-01 |
| GO:BP | GO:2000352 | negative regulation of endothelial cell apoptotic process | 2 | 22 | 6.73e-01 |
| GO:BP | GO:0070841 | inclusion body assembly | 1 | 22 | 6.73e-01 |
| GO:BP | GO:0034764 | positive regulation of transmembrane transport | 5 | 158 | 6.73e-01 |
| GO:BP | GO:0072530 | purine-containing compound transmembrane transport | 2 | 20 | 6.73e-01 |
| GO:BP | GO:0006641 | triglyceride metabolic process | 1 | 68 | 6.74e-01 |
| GO:BP | GO:0015015 | heparan sulfate proteoglycan biosynthetic process, enzymatic modification | 1 | 9 | 6.75e-01 |
| GO:BP | GO:0032536 | regulation of cell projection size | 1 | 8 | 6.75e-01 |
| GO:BP | GO:0015844 | monoamine transport | 1 | 45 | 6.75e-01 |
| GO:BP | GO:0014742 | positive regulation of muscle hypertrophy | 1 | 22 | 6.75e-01 |
| GO:BP | GO:0034766 | negative regulation of monoatomic ion transmembrane transport | 1 | 70 | 6.76e-01 |
| GO:BP | GO:0050857 | positive regulation of antigen receptor-mediated signaling pathway | 1 | 16 | 6.76e-01 |
| GO:BP | GO:0031297 | replication fork processing | 2 | 42 | 6.76e-01 |
| GO:BP | GO:0032330 | regulation of chondrocyte differentiation | 1 | 37 | 6.76e-01 |
| GO:BP | GO:0043320 | natural killer cell degranulation | 1 | 6 | 6.76e-01 |
| GO:BP | GO:0046068 | cGMP metabolic process | 1 | 11 | 6.76e-01 |
| GO:BP | GO:0070228 | regulation of lymphocyte apoptotic process | 4 | 37 | 6.76e-01 |
| GO:BP | GO:0008154 | actin polymerization or depolymerization | 6 | 160 | 6.76e-01 |
| GO:BP | GO:0009416 | response to light stimulus | 4 | 246 | 6.77e-01 |
| GO:BP | GO:0098542 | defense response to other organism | 4 | 608 | 6.78e-01 |
| GO:BP | GO:0032870 | cellular response to hormone stimulus | 5 | 457 | 6.78e-01 |
| GO:BP | GO:0001833 | inner cell mass cell proliferation | 1 | 14 | 6.78e-01 |
| GO:BP | GO:0140029 | exocytic process | 1 | 69 | 6.78e-01 |
| GO:BP | GO:0000725 | recombinational repair | 3 | 153 | 6.78e-01 |
| GO:BP | GO:0014823 | response to activity | 4 | 46 | 6.78e-01 |
| GO:BP | GO:0016570 | histone modification | 14 | 433 | 6.78e-01 |
| GO:BP | GO:0048675 | axon extension | 5 | 110 | 6.78e-01 |
| GO:BP | GO:0042402 | cellular biogenic amine catabolic process | 1 | 13 | 6.78e-01 |
| GO:BP | GO:0032094 | response to food | 1 | 22 | 6.78e-01 |
| GO:BP | GO:0060416 | response to growth hormone | 1 | 25 | 6.78e-01 |
| GO:BP | GO:0035883 | enteroendocrine cell differentiation | 1 | 24 | 6.78e-01 |
| GO:BP | GO:0030098 | lymphocyte differentiation | 1 | 260 | 6.79e-01 |
| GO:BP | GO:0051560 | mitochondrial calcium ion homeostasis | 1 | 23 | 6.79e-01 |
| GO:BP | GO:0030003 | intracellular monoatomic cation homeostasis | 11 | 357 | 6.80e-01 |
| GO:BP | GO:0006259 | DNA metabolic process | 35 | 884 | 6.80e-01 |
| GO:BP | GO:0002683 | negative regulation of immune system process | 4 | 289 | 6.80e-01 |
| GO:BP | GO:0071498 | cellular response to fluid shear stress | 1 | 19 | 6.80e-01 |
| GO:BP | GO:0006883 | intracellular sodium ion homeostasis | 1 | 13 | 6.81e-01 |
| GO:BP | GO:0032878 | regulation of establishment or maintenance of cell polarity | 2 | 26 | 6.81e-01 |
| GO:BP | GO:0031341 | regulation of cell killing | 1 | 36 | 6.81e-01 |
| GO:BP | GO:0098719 | sodium ion import across plasma membrane | 1 | 14 | 6.81e-01 |
| GO:BP | GO:0046635 | positive regulation of alpha-beta T cell activation | 2 | 36 | 6.81e-01 |
| GO:BP | GO:0001676 | long-chain fatty acid metabolic process | 1 | 65 | 6.81e-01 |
| GO:BP | GO:0098916 | anterograde trans-synaptic signaling | 2 | 490 | 6.82e-01 |
| GO:BP | GO:0007268 | chemical synaptic transmission | 2 | 490 | 6.82e-01 |
| GO:BP | GO:1901224 | positive regulation of NIK/NF-kappaB signaling | 2 | 40 | 6.82e-01 |
| GO:BP | GO:0070192 | chromosome organization involved in meiotic cell cycle | 2 | 35 | 6.82e-01 |
| GO:BP | GO:0060049 | regulation of protein glycosylation | 1 | 10 | 6.82e-01 |
| GO:BP | GO:1901617 | organic hydroxy compound biosynthetic process | 2 | 172 | 6.82e-01 |
| GO:BP | GO:0009581 | detection of external stimulus | 2 | 67 | 6.83e-01 |
| GO:BP | GO:0002440 | production of molecular mediator of immune response | 2 | 135 | 6.83e-01 |
| GO:BP | GO:0044550 | secondary metabolite biosynthetic process | 1 | 18 | 6.83e-01 |
| GO:BP | GO:1990173 | protein localization to nucleoplasm | 1 | 14 | 6.83e-01 |
| GO:BP | GO:0001662 | behavioral fear response | 2 | 29 | 6.83e-01 |
| GO:BP | GO:1905332 | positive regulation of morphogenesis of an epithelium | 2 | 28 | 6.84e-01 |
| GO:BP | GO:0021702 | cerebellar Purkinje cell differentiation | 1 | 10 | 6.84e-01 |
| GO:BP | GO:0097107 | postsynaptic density assembly | 1 | 16 | 6.84e-01 |
| GO:BP | GO:0072224 | metanephric glomerulus development | 1 | 10 | 6.85e-01 |
| GO:BP | GO:0048557 | embryonic digestive tract morphogenesis | 1 | 8 | 6.85e-01 |
| GO:BP | GO:0055070 | copper ion homeostasis | 1 | 18 | 6.85e-01 |
| GO:BP | GO:0070168 | negative regulation of biomineral tissue development | 1 | 19 | 6.85e-01 |
| GO:BP | GO:0050910 | detection of mechanical stimulus involved in sensory perception of sound | 1 | 8 | 6.85e-01 |
| GO:BP | GO:1901077 | regulation of relaxation of muscle | 1 | 8 | 6.85e-01 |
| GO:BP | GO:0150077 | regulation of neuroinflammatory response | 2 | 13 | 6.85e-01 |
| GO:BP | GO:0099537 | trans-synaptic signaling | 2 | 495 | 6.85e-01 |
| GO:BP | GO:0010628 | positive regulation of gene expression | 10 | 783 | 6.86e-01 |
| GO:BP | GO:0046598 | positive regulation of viral entry into host cell | 1 | 11 | 6.87e-01 |
| GO:BP | GO:0075294 | positive regulation by symbiont of entry into host | 1 | 11 | 6.87e-01 |
| GO:BP | GO:2000009 | negative regulation of protein localization to cell surface | 1 | 12 | 6.87e-01 |
| GO:BP | GO:0019751 | polyol metabolic process | 1 | 82 | 6.87e-01 |
| GO:BP | GO:0070528 | protein kinase C signaling | 1 | 24 | 6.87e-01 |
| GO:BP | GO:0051569 | regulation of histone H3-K4 methylation | 2 | 26 | 6.87e-01 |
| GO:BP | GO:0032328 | alanine transport | 1 | 14 | 6.87e-01 |
| GO:BP | GO:0042953 | lipoprotein transport | 1 | 14 | 6.87e-01 |
| GO:BP | GO:0035136 | forelimb morphogenesis | 1 | 21 | 6.87e-01 |
| GO:BP | GO:0090279 | regulation of calcium ion import | 1 | 24 | 6.88e-01 |
| GO:BP | GO:0014857 | regulation of skeletal muscle cell proliferation | 1 | 10 | 6.88e-01 |
| GO:BP | GO:0150078 | positive regulation of neuroinflammatory response | 1 | 4 | 6.89e-01 |
| GO:BP | GO:0140962 | multicellular organismal-level chemical homeostasis | 1 | 34 | 6.89e-01 |
| GO:BP | GO:0007213 | G protein-coupled acetylcholine receptor signaling pathway | 1 | 14 | 6.90e-01 |
| GO:BP | GO:0051782 | negative regulation of cell division | 1 | 15 | 6.90e-01 |
| GO:BP | GO:0051716 | cellular response to stimulus | 2 | 4953 | 6.91e-01 |
| GO:BP | GO:0002696 | positive regulation of leukocyte activation | 10 | 222 | 6.91e-01 |
| GO:BP | GO:0042753 | positive regulation of circadian rhythm | 1 | 10 | 6.91e-01 |
| GO:BP | GO:0045017 | glycerolipid biosynthetic process | 2 | 218 | 6.91e-01 |
| GO:BP | GO:0009582 | detection of abiotic stimulus | 2 | 68 | 6.91e-01 |
| GO:BP | GO:0048148 | behavioral response to cocaine | 1 | 9 | 6.92e-01 |
| GO:BP | GO:0099068 | postsynapse assembly | 2 | 32 | 6.92e-01 |
| GO:BP | GO:0038203 | TORC2 signaling | 1 | 12 | 6.93e-01 |
| GO:BP | GO:0051315 | attachment of mitotic spindle microtubules to kinetochore | 1 | 21 | 6.93e-01 |
| GO:BP | GO:0030301 | cholesterol transport | 1 | 80 | 6.93e-01 |
| GO:BP | GO:0072348 | sulfur compound transport | 3 | 39 | 6.93e-01 |
| GO:BP | GO:0019362 | pyridine nucleotide metabolic process | 3 | 66 | 6.93e-01 |
| GO:BP | GO:0046496 | nicotinamide nucleotide metabolic process | 3 | 66 | 6.93e-01 |
| GO:BP | GO:0051148 | negative regulation of muscle cell differentiation | 1 | 52 | 6.93e-01 |
| GO:BP | GO:0007431 | salivary gland development | 2 | 26 | 6.93e-01 |
| GO:BP | GO:0006816 | calcium ion transport | 11 | 269 | 6.93e-01 |
| GO:BP | GO:0015748 | organophosphate ester transport | 8 | 106 | 6.93e-01 |
| GO:BP | GO:1990840 | response to lectin | 1 | 11 | 6.93e-01 |
| GO:BP | GO:0032211 | negative regulation of telomere maintenance via telomerase | 1 | 19 | 6.93e-01 |
| GO:BP | GO:0010669 | epithelial structure maintenance | 1 | 15 | 6.93e-01 |
| GO:BP | GO:0045091 | regulation of single stranded viral RNA replication via double stranded DNA intermediate | 1 | 15 | 6.93e-01 |
| GO:BP | GO:0002209 | behavioral defense response | 2 | 30 | 6.93e-01 |
| GO:BP | GO:0051882 | mitochondrial depolarization | 1 | 17 | 6.93e-01 |
| GO:BP | GO:0002223 | stimulatory C-type lectin receptor signaling pathway | 1 | 11 | 6.93e-01 |
| GO:BP | GO:0090308 | regulation of DNA methylation-dependent heterochromatin formation | 1 | 16 | 6.93e-01 |
| GO:BP | GO:1990858 | cellular response to lectin | 1 | 11 | 6.93e-01 |
| GO:BP | GO:0009310 | amine catabolic process | 1 | 14 | 6.93e-01 |
| GO:BP | GO:0032204 | regulation of telomere maintenance | 6 | 96 | 6.93e-01 |
| GO:BP | GO:0051276 | chromosome organization | 6 | 543 | 6.93e-01 |
| GO:BP | GO:2000052 | positive regulation of non-canonical Wnt signaling pathway | 1 | 14 | 6.93e-01 |
| GO:BP | GO:0001657 | ureteric bud development | 3 | 75 | 6.93e-01 |
| GO:BP | GO:0030890 | positive regulation of B cell proliferation | 1 | 26 | 6.93e-01 |
| GO:BP | GO:0045948 | positive regulation of translational initiation | 1 | 23 | 6.93e-01 |
| GO:BP | GO:0030041 | actin filament polymerization | 5 | 134 | 6.94e-01 |
| GO:BP | GO:1900095 | regulation of dosage compensation by inactivation of X chromosome | 1 | 13 | 6.94e-01 |
| GO:BP | GO:0050792 | regulation of viral process | 1 | 122 | 6.94e-01 |
| GO:BP | GO:0090068 | positive regulation of cell cycle process | 10 | 209 | 6.95e-01 |
| GO:BP | GO:0035176 | social behavior | 2 | 34 | 6.95e-01 |
| GO:BP | GO:1904350 | regulation of protein catabolic process in the vacuole | 1 | 13 | 6.95e-01 |
| GO:BP | GO:0034311 | diol metabolic process | 2 | 26 | 6.95e-01 |
| GO:BP | GO:0098751 | bone cell development | 2 | 26 | 6.95e-01 |
| GO:BP | GO:0014808 | release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | 2 | 28 | 6.95e-01 |
| GO:BP | GO:0006873 | intracellular monoatomic ion homeostasis | 11 | 362 | 6.96e-01 |
| GO:BP | GO:0030516 | regulation of axon extension | 3 | 84 | 6.96e-01 |
| GO:BP | GO:0042448 | progesterone metabolic process | 1 | 13 | 6.96e-01 |
| GO:BP | GO:0045088 | regulation of innate immune response | 2 | 232 | 6.96e-01 |
| GO:BP | GO:2001256 | regulation of store-operated calcium entry | 1 | 11 | 6.96e-01 |
| GO:BP | GO:0099515 | actin filament-based transport | 1 | 15 | 6.96e-01 |
| GO:BP | GO:0099536 | synaptic signaling | 2 | 511 | 6.96e-01 |
| GO:BP | GO:0002761 | regulation of myeloid leukocyte differentiation | 2 | 77 | 6.98e-01 |
| GO:BP | GO:0032103 | positive regulation of response to external stimulus | 3 | 337 | 6.98e-01 |
| GO:BP | GO:0036499 | PERK-mediated unfolded protein response | 1 | 17 | 6.98e-01 |
| GO:BP | GO:0009158 | ribonucleoside monophosphate catabolic process | 1 | 10 | 6.98e-01 |
| GO:BP | GO:0072163 | mesonephric epithelium development | 3 | 76 | 6.98e-01 |
| GO:BP | GO:0072164 | mesonephric tubule development | 3 | 76 | 6.98e-01 |
| GO:BP | GO:0001101 | response to acid chemical | 8 | 105 | 6.99e-01 |
| GO:BP | GO:0032206 | positive regulation of telomere maintenance | 4 | 64 | 6.99e-01 |
| GO:BP | GO:0097067 | cellular response to thyroid hormone stimulus | 1 | 14 | 7.00e-01 |
| GO:BP | GO:0045217 | cell-cell junction maintenance | 1 | 13 | 7.00e-01 |
| GO:BP | GO:0090136 | epithelial cell-cell adhesion | 1 | 16 | 7.00e-01 |
| GO:BP | GO:0002753 | cytosolic pattern recognition receptor signaling pathway | 4 | 68 | 7.00e-01 |
| GO:BP | GO:0001991 | regulation of systemic arterial blood pressure by circulatory renin-angiotensin | 1 | 10 | 7.00e-01 |
| GO:BP | GO:0002062 | chondrocyte differentiation | 2 | 90 | 7.00e-01 |
| GO:BP | GO:0002828 | regulation of type 2 immune response | 1 | 15 | 7.01e-01 |
| GO:BP | GO:0033108 | mitochondrial respiratory chain complex assembly | 5 | 94 | 7.01e-01 |
| GO:BP | GO:1904814 | regulation of protein localization to chromosome, telomeric region | 1 | 15 | 7.01e-01 |
| GO:BP | GO:0002456 | T cell mediated immunity | 1 | 53 | 7.01e-01 |
| GO:BP | GO:1904874 | positive regulation of telomerase RNA localization to Cajal body | 1 | 15 | 7.01e-01 |
| GO:BP | GO:0099601 | regulation of neurotransmitter receptor activity | 3 | 40 | 7.02e-01 |
| GO:BP | GO:0030278 | regulation of ossification | 1 | 84 | 7.02e-01 |
| GO:BP | GO:0061318 | renal filtration cell differentiation | 1 | 17 | 7.02e-01 |
| GO:BP | GO:0072112 | podocyte differentiation | 1 | 17 | 7.02e-01 |
| GO:BP | GO:0070849 | response to epidermal growth factor | 3 | 44 | 7.02e-01 |
| GO:BP | GO:0044872 | lipoprotein localization | 1 | 15 | 7.02e-01 |
| GO:BP | GO:0044282 | small molecule catabolic process | 8 | 271 | 7.03e-01 |
| GO:BP | GO:0045445 | myoblast differentiation | 6 | 90 | 7.03e-01 |
| GO:BP | GO:0006869 | lipid transport | 1 | 272 | 7.03e-01 |
| GO:BP | GO:0090100 | positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 4 | 100 | 7.03e-01 |
| GO:BP | GO:0051284 | positive regulation of sequestering of calcium ion | 1 | 13 | 7.03e-01 |
| GO:BP | GO:0002224 | toll-like receptor signaling pathway | 1 | 43 | 7.04e-01 |
| GO:BP | GO:0010972 | negative regulation of G2/M transition of mitotic cell cycle | 4 | 60 | 7.04e-01 |
| GO:BP | GO:0002281 | macrophage activation involved in immune response | 1 | 8 | 7.04e-01 |
| GO:BP | GO:0051085 | chaperone cofactor-dependent protein refolding | 2 | 30 | 7.04e-01 |
| GO:BP | GO:0046622 | positive regulation of organ growth | 1 | 33 | 7.04e-01 |
| GO:BP | GO:0032212 | positive regulation of telomere maintenance via telomerase | 2 | 31 | 7.05e-01 |
| GO:BP | GO:2000291 | regulation of myoblast proliferation | 1 | 11 | 7.05e-01 |
| GO:BP | GO:0031348 | negative regulation of defense response | 13 | 159 | 7.05e-01 |
| GO:BP | GO:1903077 | negative regulation of protein localization to plasma membrane | 1 | 21 | 7.05e-01 |
| GO:BP | GO:0098962 | regulation of postsynaptic neurotransmitter receptor activity | 1 | 12 | 7.05e-01 |
| GO:BP | GO:0050728 | negative regulation of inflammatory response | 8 | 87 | 7.06e-01 |
| GO:BP | GO:0033141 | positive regulation of peptidyl-serine phosphorylation of STAT protein | 1 | 3 | 7.06e-01 |
| GO:BP | GO:1903747 | regulation of establishment of protein localization to mitochondrion | 3 | 44 | 7.06e-01 |
| GO:BP | GO:0072234 | metanephric nephron tubule development | 1 | 14 | 7.06e-01 |
| GO:BP | GO:0007585 | respiratory gaseous exchange by respiratory system | 2 | 49 | 7.06e-01 |
| GO:BP | GO:0008654 | phospholipid biosynthetic process | 2 | 234 | 7.06e-01 |
| GO:BP | GO:0007626 | locomotory behavior | 2 | 138 | 7.06e-01 |
| GO:BP | GO:0030282 | bone mineralization | 1 | 82 | 7.06e-01 |
| GO:BP | GO:0039692 | single stranded viral RNA replication via double stranded DNA intermediate | 1 | 16 | 7.06e-01 |
| GO:BP | GO:0051205 | protein insertion into membrane | 4 | 62 | 7.06e-01 |
| GO:BP | GO:0007610 | behavior | 18 | 436 | 7.07e-01 |
| GO:BP | GO:0060255 | regulation of macromolecule metabolic process | 8 | 4617 | 7.07e-01 |
| GO:BP | GO:0007216 | G protein-coupled glutamate receptor signaling pathway | 1 | 5 | 7.07e-01 |
| GO:BP | GO:0048333 | mesodermal cell differentiation | 1 | 22 | 7.07e-01 |
| GO:BP | GO:0010644 | cell communication by electrical coupling | 2 | 31 | 7.07e-01 |
| GO:BP | GO:1903514 | release of sequestered calcium ion into cytosol by endoplasmic reticulum | 2 | 28 | 7.07e-01 |
| GO:BP | GO:0045670 | regulation of osteoclast differentiation | 1 | 38 | 7.07e-01 |
| GO:BP | GO:0030220 | platelet formation | 1 | 17 | 7.07e-01 |
| GO:BP | GO:0030149 | sphingolipid catabolic process | 2 | 26 | 7.07e-01 |
| GO:BP | GO:0032502 | developmental process | 30 | 4494 | 7.07e-01 |
| GO:BP | GO:0006626 | protein targeting to mitochondrion | 5 | 100 | 7.07e-01 |
| GO:BP | GO:1901623 | regulation of lymphocyte chemotaxis | 1 | 13 | 7.07e-01 |
| GO:BP | GO:0001942 | hair follicle development | 6 | 67 | 7.09e-01 |
| GO:BP | GO:0051703 | biological process involved in intraspecies interaction between organisms | 2 | 34 | 7.09e-01 |
| GO:BP | GO:0098883 | synapse pruning | 1 | 8 | 7.09e-01 |
| GO:BP | GO:1903131 | mononuclear cell differentiation | 1 | 294 | 7.10e-01 |
| GO:BP | GO:0016049 | cell growth | 4 | 418 | 7.10e-01 |
| GO:BP | GO:0032494 | response to peptidoglycan | 1 | 5 | 7.10e-01 |
| GO:BP | GO:0002703 | regulation of leukocyte mediated immunity | 2 | 118 | 7.10e-01 |
| GO:BP | GO:0002367 | cytokine production involved in immune response | 1 | 70 | 7.10e-01 |
| GO:BP | GO:0002718 | regulation of cytokine production involved in immune response | 1 | 70 | 7.10e-01 |
| GO:BP | GO:0048871 | multicellular organismal-level homeostasis | 2 | 532 | 7.10e-01 |
| GO:BP | GO:0048863 | stem cell differentiation | 12 | 197 | 7.11e-01 |
| GO:BP | GO:1903214 | regulation of protein targeting to mitochondrion | 2 | 39 | 7.11e-01 |
| GO:BP | GO:0032354 | response to follicle-stimulating hormone | 1 | 13 | 7.11e-01 |
| GO:BP | GO:0050802 | circadian sleep/wake cycle, sleep | 1 | 9 | 7.11e-01 |
| GO:BP | GO:0036258 | multivesicular body assembly | 1 | 32 | 7.11e-01 |
| GO:BP | GO:0007080 | mitotic metaphase plate congression | 3 | 55 | 7.11e-01 |
| GO:BP | GO:0010596 | negative regulation of endothelial cell migration | 1 | 40 | 7.12e-01 |
| GO:BP | GO:1901136 | carbohydrate derivative catabolic process | 1 | 137 | 7.12e-01 |
| GO:BP | GO:1901185 | negative regulation of ERBB signaling pathway | 2 | 30 | 7.12e-01 |
| GO:BP | GO:0002824 | positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 1 | 62 | 7.12e-01 |
| GO:BP | GO:0006044 | N-acetylglucosamine metabolic process | 1 | 16 | 7.13e-01 |
| GO:BP | GO:0010560 | positive regulation of glycoprotein biosynthetic process | 1 | 15 | 7.13e-01 |
| GO:BP | GO:0040019 | positive regulation of embryonic development | 1 | 17 | 7.13e-01 |
| GO:BP | GO:0010224 | response to UV-B | 1 | 17 | 7.13e-01 |
| GO:BP | GO:0002026 | regulation of the force of heart contraction | 1 | 23 | 7.13e-01 |
| GO:BP | GO:0036230 | granulocyte activation | 2 | 19 | 7.13e-01 |
| GO:BP | GO:0072311 | glomerular epithelial cell differentiation | 1 | 17 | 7.13e-01 |
| GO:BP | GO:0097150 | neuronal stem cell population maintenance | 1 | 21 | 7.13e-01 |
| GO:BP | GO:0043984 | histone H4-K16 acetylation | 1 | 14 | 7.14e-01 |
| GO:BP | GO:0034762 | regulation of transmembrane transport | 8 | 391 | 7.14e-01 |
| GO:BP | GO:0006139 | nucleobase-containing compound metabolic process | 6 | 4455 | 7.14e-01 |
| GO:BP | GO:0006383 | transcription by RNA polymerase III | 3 | 54 | 7.14e-01 |
| GO:BP | GO:1900044 | regulation of protein K63-linked ubiquitination | 1 | 13 | 7.14e-01 |
| GO:BP | GO:0010592 | positive regulation of lamellipodium assembly | 1 | 25 | 7.14e-01 |
| GO:BP | GO:0051246 | regulation of protein metabolic process | 133 | 1974 | 7.15e-01 |
| GO:BP | GO:0046486 | glycerolipid metabolic process | 3 | 311 | 7.15e-01 |
| GO:BP | GO:0055057 | neuroblast division | 1 | 12 | 7.15e-01 |
| GO:BP | GO:0042308 | negative regulation of protein import into nucleus | 1 | 13 | 7.15e-01 |
| GO:BP | GO:0051171 | regulation of nitrogen compound metabolic process | 3 | 4292 | 7.15e-01 |
| GO:BP | GO:0002763 | positive regulation of myeloid leukocyte differentiation | 1 | 34 | 7.15e-01 |
| GO:BP | GO:0035520 | monoubiquitinated protein deubiquitination | 1 | 36 | 7.16e-01 |
| GO:BP | GO:0060914 | heart formation | 1 | 29 | 7.16e-01 |
| GO:BP | GO:0008340 | determination of adult lifespan | 1 | 16 | 7.16e-01 |
| GO:BP | GO:0071248 | cellular response to metal ion | 4 | 139 | 7.17e-01 |
| GO:BP | GO:0071277 | cellular response to calcium ion | 4 | 67 | 7.17e-01 |
| GO:BP | GO:0001823 | mesonephros development | 3 | 77 | 7.17e-01 |
| GO:BP | GO:0034502 | protein localization to chromosome | 1 | 110 | 7.17e-01 |
| GO:BP | GO:0042749 | regulation of circadian sleep/wake cycle | 1 | 9 | 7.18e-01 |
| GO:BP | GO:0010818 | T cell chemotaxis | 1 | 12 | 7.18e-01 |
| GO:BP | GO:0090713 | immunological memory process | 1 | 7 | 7.18e-01 |
| GO:BP | GO:0032210 | regulation of telomere maintenance via telomerase | 3 | 49 | 7.18e-01 |
| GO:BP | GO:0001771 | immunological synapse formation | 1 | 7 | 7.18e-01 |
| GO:BP | GO:0016045 | detection of bacterium | 1 | 8 | 7.18e-01 |
| GO:BP | GO:2000300 | regulation of synaptic vesicle exocytosis | 2 | 35 | 7.18e-01 |
| GO:BP | GO:0065008 | regulation of biological quality | 25 | 2102 | 7.18e-01 |
| GO:BP | GO:0009451 | RNA modification | 5 | 162 | 7.18e-01 |
| GO:BP | GO:0046007 | negative regulation of activated T cell proliferation | 1 | 8 | 7.18e-01 |
| GO:BP | GO:0050954 | sensory perception of mechanical stimulus | 4 | 112 | 7.18e-01 |
| GO:BP | GO:0042531 | positive regulation of tyrosine phosphorylation of STAT protein | 3 | 23 | 7.18e-01 |
| GO:BP | GO:0006879 | intracellular iron ion homeostasis | 1 | 52 | 7.18e-01 |
| GO:BP | GO:2000401 | regulation of lymphocyte migration | 4 | 41 | 7.19e-01 |
| GO:BP | GO:0042269 | regulation of natural killer cell mediated cytotoxicity | 1 | 18 | 7.19e-01 |
| GO:BP | GO:1901522 | positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus | 1 | 16 | 7.19e-01 |
| GO:BP | GO:0036257 | multivesicular body organization | 1 | 33 | 7.19e-01 |
| GO:BP | GO:0042994 | cytoplasmic sequestering of transcription factor | 1 | 15 | 7.19e-01 |
| GO:BP | GO:0010885 | regulation of cholesterol storage | 1 | 14 | 7.20e-01 |
| GO:BP | GO:0021694 | cerebellar Purkinje cell layer formation | 1 | 12 | 7.21e-01 |
| GO:BP | GO:0046621 | negative regulation of organ growth | 2 | 27 | 7.21e-01 |
| GO:BP | GO:1902750 | negative regulation of cell cycle G2/M phase transition | 4 | 62 | 7.21e-01 |
| GO:BP | GO:0021872 | forebrain generation of neurons | 3 | 29 | 7.21e-01 |
| GO:BP | GO:0090399 | replicative senescence | 1 | 13 | 7.21e-01 |
| GO:BP | GO:0016054 | organic acid catabolic process | 5 | 187 | 7.22e-01 |
| GO:BP | GO:0046395 | carboxylic acid catabolic process | 5 | 187 | 7.22e-01 |
| GO:BP | GO:0002832 | negative regulation of response to biotic stimulus | 5 | 88 | 7.23e-01 |
| GO:BP | GO:0060445 | branching involved in salivary gland morphogenesis | 1 | 17 | 7.23e-01 |
| GO:BP | GO:0045475 | locomotor rhythm | 1 | 13 | 7.23e-01 |
| GO:BP | GO:0015918 | sterol transport | 1 | 92 | 7.23e-01 |
| GO:BP | GO:0060343 | trabecula formation | 1 | 23 | 7.24e-01 |
| GO:BP | GO:0048286 | lung alveolus development | 2 | 39 | 7.24e-01 |
| GO:BP | GO:0002444 | myeloid leukocyte mediated immunity | 7 | 60 | 7.25e-01 |
| GO:BP | GO:0015721 | bile acid and bile salt transport | 1 | 11 | 7.25e-01 |
| GO:BP | GO:1904355 | positive regulation of telomere capping | 1 | 14 | 7.25e-01 |
| GO:BP | GO:1904376 | negative regulation of protein localization to cell periphery | 1 | 23 | 7.25e-01 |
| GO:BP | GO:0007041 | lysosomal transport | 8 | 115 | 7.25e-01 |
| GO:BP | GO:0048260 | positive regulation of receptor-mediated endocytosis | 3 | 42 | 7.25e-01 |
| GO:BP | GO:0030258 | lipid modification | 4 | 162 | 7.25e-01 |
| GO:BP | GO:0034501 | protein localization to kinetochore | 1 | 18 | 7.26e-01 |
| GO:BP | GO:1903083 | protein localization to condensed chromosome | 1 | 18 | 7.26e-01 |
| GO:BP | GO:0008277 | regulation of G protein-coupled receptor signaling pathway | 4 | 94 | 7.26e-01 |
| GO:BP | GO:0072524 | pyridine-containing compound metabolic process | 3 | 72 | 7.26e-01 |
| GO:BP | GO:0090190 | positive regulation of branching involved in ureteric bud morphogenesis | 1 | 13 | 7.27e-01 |
| GO:BP | GO:0051646 | mitochondrion localization | 3 | 47 | 7.27e-01 |
| GO:BP | GO:0090199 | regulation of release of cytochrome c from mitochondria | 1 | 39 | 7.28e-01 |
| GO:BP | GO:0045773 | positive regulation of axon extension | 1 | 33 | 7.28e-01 |
| GO:BP | GO:1903531 | negative regulation of secretion by cell | 7 | 99 | 7.28e-01 |
| GO:BP | GO:0060065 | uterus development | 1 | 13 | 7.28e-01 |
| GO:BP | GO:0003148 | outflow tract septum morphogenesis | 1 | 23 | 7.29e-01 |
| GO:BP | GO:0010744 | positive regulation of macrophage derived foam cell differentiation | 1 | 8 | 7.29e-01 |
| GO:BP | GO:0007194 | negative regulation of adenylate cyclase activity | 1 | 13 | 7.29e-01 |
| GO:BP | GO:0003228 | atrial cardiac muscle tissue development | 1 | 18 | 7.29e-01 |
| GO:BP | GO:0002708 | positive regulation of lymphocyte mediated immunity | 1 | 58 | 7.29e-01 |
| GO:BP | GO:0009642 | response to light intensity | 1 | 11 | 7.29e-01 |
| GO:BP | GO:0031646 | positive regulation of nervous system process | 2 | 21 | 7.29e-01 |
| GO:BP | GO:0043243 | positive regulation of protein-containing complex disassembly | 1 | 30 | 7.29e-01 |
| GO:BP | GO:0045649 | regulation of macrophage differentiation | 1 | 17 | 7.30e-01 |
| GO:BP | GO:0007259 | receptor signaling pathway via JAK-STAT | 8 | 86 | 7.30e-01 |
| GO:BP | GO:2000406 | positive regulation of T cell migration | 2 | 20 | 7.30e-01 |
| GO:BP | GO:0045005 | DNA-templated DNA replication maintenance of fidelity | 2 | 48 | 7.30e-01 |
| GO:BP | GO:0022405 | hair cycle process | 6 | 69 | 7.30e-01 |
| GO:BP | GO:0036344 | platelet morphogenesis | 1 | 19 | 7.30e-01 |
| GO:BP | GO:0071634 | regulation of transforming growth factor beta production | 1 | 31 | 7.30e-01 |
| GO:BP | GO:0022404 | molting cycle process | 6 | 69 | 7.30e-01 |
| GO:BP | GO:0051590 | positive regulation of neurotransmitter transport | 1 | 16 | 7.30e-01 |
| GO:BP | GO:0061383 | trabecula morphogenesis | 2 | 43 | 7.31e-01 |
| GO:BP | GO:0010389 | regulation of G2/M transition of mitotic cell cycle | 6 | 92 | 7.31e-01 |
| GO:BP | GO:0006022 | aminoglycan metabolic process | 2 | 93 | 7.31e-01 |
| GO:BP | GO:0061644 | protein localization to CENP-A containing chromatin | 1 | 17 | 7.31e-01 |
| GO:BP | GO:1990138 | neuron projection extension | 10 | 148 | 7.31e-01 |
| GO:BP | GO:0071482 | cellular response to light stimulus | 1 | 99 | 7.31e-01 |
| GO:BP | GO:0008584 | male gonad development | 7 | 99 | 7.32e-01 |
| GO:BP | GO:0031663 | lipopolysaccharide-mediated signaling pathway | 2 | 36 | 7.32e-01 |
| GO:BP | GO:0090090 | negative regulation of canonical Wnt signaling pathway | 3 | 114 | 7.32e-01 |
| GO:BP | GO:1903307 | positive regulation of regulated secretory pathway | 3 | 32 | 7.32e-01 |
| GO:BP | GO:0007616 | long-term memory | 1 | 31 | 7.33e-01 |
| GO:BP | GO:0070200 | establishment of protein localization to telomere | 1 | 16 | 7.34e-01 |
| GO:BP | GO:0007160 | cell-matrix adhesion | 14 | 179 | 7.35e-01 |
| GO:BP | GO:0033008 | positive regulation of mast cell activation involved in immune response | 1 | 10 | 7.35e-01 |
| GO:BP | GO:0043306 | positive regulation of mast cell degranulation | 1 | 10 | 7.35e-01 |
| GO:BP | GO:0080090 | regulation of primary metabolic process | 3 | 4417 | 7.35e-01 |
| GO:BP | GO:0015837 | amine transport | 1 | 56 | 7.36e-01 |
| GO:BP | GO:0070234 | positive regulation of T cell apoptotic process | 1 | 8 | 7.36e-01 |
| GO:BP | GO:0006650 | glycerophospholipid metabolic process | 14 | 252 | 7.37e-01 |
| GO:BP | GO:0071417 | cellular response to organonitrogen compound | 26 | 485 | 7.37e-01 |
| GO:BP | GO:0018208 | peptidyl-proline modification | 1 | 43 | 7.37e-01 |
| GO:BP | GO:0046483 | heterocycle metabolic process | 6 | 4570 | 7.38e-01 |
| GO:BP | GO:0046546 | development of primary male sexual characteristics | 7 | 100 | 7.38e-01 |
| GO:BP | GO:0071675 | regulation of mononuclear cell migration | 7 | 71 | 7.38e-01 |
| GO:BP | GO:1904358 | positive regulation of telomere maintenance via telomere lengthening | 2 | 33 | 7.38e-01 |
| GO:BP | GO:0000291 | nuclear-transcribed mRNA catabolic process, exonucleolytic | 1 | 19 | 7.38e-01 |
| GO:BP | GO:0097202 | activation of cysteine-type endopeptidase activity | 1 | 16 | 7.39e-01 |
| GO:BP | GO:0006639 | acylglycerol metabolic process | 1 | 92 | 7.39e-01 |
| GO:BP | GO:0032412 | regulation of monoatomic ion transmembrane transporter activity | 2 | 190 | 7.40e-01 |
| GO:BP | GO:0035094 | response to nicotine | 1 | 28 | 7.41e-01 |
| GO:BP | GO:0002726 | positive regulation of T cell cytokine production | 1 | 14 | 7.41e-01 |
| GO:BP | GO:0048596 | embryonic camera-type eye morphogenesis | 1 | 18 | 7.41e-01 |
| GO:BP | GO:0051592 | response to calcium ion | 7 | 113 | 7.41e-01 |
| GO:BP | GO:0006638 | neutral lipid metabolic process | 1 | 93 | 7.41e-01 |
| GO:BP | GO:0072079 | nephron tubule formation | 1 | 12 | 7.41e-01 |
| GO:BP | GO:0007605 | sensory perception of sound | 8 | 98 | 7.41e-01 |
| GO:BP | GO:0045821 | positive regulation of glycolytic process | 1 | 15 | 7.41e-01 |
| GO:BP | GO:0021983 | pituitary gland development | 2 | 22 | 7.41e-01 |
| GO:BP | GO:0072170 | metanephric tubule development | 1 | 15 | 7.41e-01 |
| GO:BP | GO:0033139 | regulation of peptidyl-serine phosphorylation of STAT protein | 1 | 6 | 7.41e-01 |
| GO:BP | GO:0072243 | metanephric nephron epithelium development | 1 | 15 | 7.41e-01 |
| GO:BP | GO:0002699 | positive regulation of immune effector process | 2 | 130 | 7.41e-01 |
| GO:BP | GO:1904062 | regulation of monoatomic cation transmembrane transport | 4 | 230 | 7.41e-01 |
| GO:BP | GO:0051924 | regulation of calcium ion transport | 2 | 172 | 7.42e-01 |
| GO:BP | GO:0002715 | regulation of natural killer cell mediated immunity | 1 | 18 | 7.43e-01 |
| GO:BP | GO:0099509 | regulation of presynaptic cytosolic calcium ion concentration | 1 | 10 | 7.43e-01 |
| GO:BP | GO:0051770 | positive regulation of nitric-oxide synthase biosynthetic process | 1 | 10 | 7.43e-01 |
| GO:BP | GO:0045956 | positive regulation of calcium ion-dependent exocytosis | 1 | 11 | 7.43e-01 |
| GO:BP | GO:0002431 | Fc receptor mediated stimulatory signaling pathway | 2 | 24 | 7.43e-01 |
| GO:BP | GO:1903532 | positive regulation of secretion by cell | 5 | 199 | 7.43e-01 |
| GO:BP | GO:0043968 | histone H2A acetylation | 1 | 22 | 7.44e-01 |
| GO:BP | GO:0003014 | renal system process | 7 | 78 | 7.44e-01 |
| GO:BP | GO:0043412 | macromolecule modification | 9 | 3090 | 7.44e-01 |
| GO:BP | GO:0006725 | cellular aromatic compound metabolic process | 6 | 4596 | 7.44e-01 |
| GO:BP | GO:0051051 | negative regulation of transport | 9 | 318 | 7.45e-01 |
| GO:BP | GO:0045055 | regulated exocytosis | 2 | 155 | 7.45e-01 |
| GO:BP | GO:0009395 | phospholipid catabolic process | 2 | 37 | 7.45e-01 |
| GO:BP | GO:0030851 | granulocyte differentiation | 1 | 27 | 7.46e-01 |
| GO:BP | GO:2000318 | positive regulation of T-helper 17 type immune response | 1 | 7 | 7.46e-01 |
| GO:BP | GO:2000036 | regulation of stem cell population maintenance | 3 | 62 | 7.46e-01 |
| GO:BP | GO:0031047 | RNA-mediated gene silencing | 1 | 103 | 7.46e-01 |
| GO:BP | GO:0051899 | membrane depolarization | 3 | 60 | 7.46e-01 |
| GO:BP | GO:0072010 | glomerular epithelium development | 1 | 18 | 7.46e-01 |
| GO:BP | GO:0001909 | leukocyte mediated cytotoxicity | 1 | 54 | 7.47e-01 |
| GO:BP | GO:0006996 | organelle organization | 183 | 3000 | 7.47e-01 |
| GO:BP | GO:0048172 | regulation of short-term neuronal synaptic plasticity | 1 | 9 | 7.47e-01 |
| GO:BP | GO:0097428 | protein maturation by iron-sulfur cluster transfer | 1 | 17 | 7.47e-01 |
| GO:BP | GO:0046165 | alcohol biosynthetic process | 1 | 110 | 7.47e-01 |
| GO:BP | GO:0042100 | B cell proliferation | 2 | 45 | 7.47e-01 |
| GO:BP | GO:0051928 | positive regulation of calcium ion transport | 3 | 82 | 7.48e-01 |
| GO:BP | GO:0046466 | membrane lipid catabolic process | 1 | 30 | 7.48e-01 |
| GO:BP | GO:0034765 | regulation of monoatomic ion transmembrane transport | 6 | 295 | 7.48e-01 |
| GO:BP | GO:0009190 | cyclic nucleotide biosynthetic process | 1 | 14 | 7.49e-01 |
| GO:BP | GO:0098742 | cell-cell adhesion via plasma-membrane adhesion molecules | 1 | 168 | 7.49e-01 |
| GO:BP | GO:0045655 | regulation of monocyte differentiation | 1 | 13 | 7.49e-01 |
| GO:BP | GO:0010038 | response to metal ion | 7 | 264 | 7.49e-01 |
| GO:BP | GO:0051151 | negative regulation of smooth muscle cell differentiation | 1 | 14 | 7.49e-01 |
| GO:BP | GO:1904872 | regulation of telomerase RNA localization to Cajal body | 1 | 18 | 7.49e-01 |
| GO:BP | GO:0009062 | fatty acid catabolic process | 2 | 89 | 7.49e-01 |
| GO:BP | GO:0031018 | endocrine pancreas development | 1 | 32 | 7.49e-01 |
| GO:BP | GO:0043981 | histone H4-K5 acetylation | 1 | 16 | 7.49e-01 |
| GO:BP | GO:0043982 | histone H4-K8 acetylation | 1 | 16 | 7.49e-01 |
| GO:BP | GO:1902476 | chloride transmembrane transport | 1 | 51 | 7.49e-01 |
| GO:BP | GO:0032101 | regulation of response to external stimulus | 5 | 662 | 7.50e-01 |
| GO:BP | GO:0045324 | late endosome to vacuole transport | 1 | 36 | 7.50e-01 |
| GO:BP | GO:1903306 | negative regulation of regulated secretory pathway | 1 | 14 | 7.50e-01 |
| GO:BP | GO:0010878 | cholesterol storage | 1 | 16 | 7.50e-01 |
| GO:BP | GO:0060561 | apoptotic process involved in morphogenesis | 1 | 21 | 7.50e-01 |
| GO:BP | GO:0043271 | negative regulation of monoatomic ion transport | 1 | 90 | 7.50e-01 |
| GO:BP | GO:0071604 | transforming growth factor beta production | 1 | 32 | 7.50e-01 |
| GO:BP | GO:0045926 | negative regulation of growth | 2 | 206 | 7.50e-01 |
| GO:BP | GO:0034394 | protein localization to cell surface | 4 | 61 | 7.50e-01 |
| GO:BP | GO:0010922 | positive regulation of phosphatase activity | 1 | 26 | 7.50e-01 |
| GO:BP | GO:0055082 | intracellular chemical homeostasis | 14 | 486 | 7.51e-01 |
| GO:BP | GO:0038202 | TORC1 signaling | 3 | 58 | 7.52e-01 |
| GO:BP | GO:0060337 | type I interferon-mediated signaling pathway | 3 | 51 | 7.52e-01 |
| GO:BP | GO:0070206 | protein trimerization | 1 | 12 | 7.52e-01 |
| GO:BP | GO:0086004 | regulation of cardiac muscle cell contraction | 2 | 34 | 7.52e-01 |
| GO:BP | GO:0046835 | carbohydrate phosphorylation | 1 | 21 | 7.52e-01 |
| GO:BP | GO:2001169 | regulation of ATP biosynthetic process | 1 | 17 | 7.52e-01 |
| GO:BP | GO:0031280 | negative regulation of cyclase activity | 1 | 13 | 7.53e-01 |
| GO:BP | GO:0045927 | positive regulation of growth | 1 | 199 | 7.53e-01 |
| GO:BP | GO:0038094 | Fc-gamma receptor signaling pathway | 2 | 20 | 7.54e-01 |
| GO:BP | GO:0022898 | regulation of transmembrane transporter activity | 2 | 199 | 7.55e-01 |
| GO:BP | GO:0002689 | negative regulation of leukocyte chemotaxis | 1 | 10 | 7.55e-01 |
| GO:BP | GO:0033120 | positive regulation of RNA splicing | 1 | 34 | 7.55e-01 |
| GO:BP | GO:0070498 | interleukin-1-mediated signaling pathway | 1 | 20 | 7.56e-01 |
| GO:BP | GO:0051707 | response to other organism | 1 | 820 | 7.56e-01 |
| GO:BP | GO:0055008 | cardiac muscle tissue morphogenesis | 2 | 54 | 7.56e-01 |
| GO:BP | GO:2000737 | negative regulation of stem cell differentiation | 1 | 24 | 7.56e-01 |
| GO:BP | GO:0043207 | response to external biotic stimulus | 1 | 820 | 7.57e-01 |
| GO:BP | GO:0051204 | protein insertion into mitochondrial membrane | 1 | 34 | 7.57e-01 |
| GO:BP | GO:0043116 | negative regulation of vascular permeability | 1 | 16 | 7.57e-01 |
| GO:BP | GO:0006120 | mitochondrial electron transport, NADH to ubiquinone | 1 | 42 | 7.57e-01 |
| GO:BP | GO:0031103 | axon regeneration | 1 | 42 | 7.57e-01 |
| GO:BP | GO:0090036 | regulation of protein kinase C signaling | 1 | 14 | 7.57e-01 |
| GO:BP | GO:0002719 | negative regulation of cytokine production involved in immune response | 1 | 16 | 7.57e-01 |
| GO:BP | GO:0043162 | ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway | 1 | 35 | 7.57e-01 |
| GO:BP | GO:0035904 | aorta development | 1 | 50 | 7.57e-01 |
| GO:BP | GO:0140888 | interferon-mediated signaling pathway | 4 | 67 | 7.57e-01 |
| GO:BP | GO:0008207 | C21-steroid hormone metabolic process | 2 | 28 | 7.58e-01 |
| GO:BP | GO:0097242 | amyloid-beta clearance | 1 | 27 | 7.58e-01 |
| GO:BP | GO:0070861 | regulation of protein exit from endoplasmic reticulum | 1 | 22 | 7.58e-01 |
| GO:BP | GO:0042092 | type 2 immune response | 1 | 19 | 7.58e-01 |
| GO:BP | GO:0097696 | receptor signaling pathway via STAT | 8 | 88 | 7.58e-01 |
| GO:BP | GO:0046661 | male sex differentiation | 8 | 114 | 7.59e-01 |
| GO:BP | GO:0006338 | chromatin remodeling | 21 | 378 | 7.59e-01 |
| GO:BP | GO:0003283 | atrial septum development | 1 | 23 | 7.59e-01 |
| GO:BP | GO:0006658 | phosphatidylserine metabolic process | 1 | 21 | 7.61e-01 |
| GO:BP | GO:0009125 | nucleoside monophosphate catabolic process | 1 | 13 | 7.61e-01 |
| GO:BP | GO:0015874 | norepinephrine transport | 1 | 9 | 7.61e-01 |
| GO:BP | GO:0071805 | potassium ion transmembrane transport | 1 | 129 | 7.61e-01 |
| GO:BP | GO:0048518 | positive regulation of biological process | 4 | 4579 | 7.61e-01 |
| GO:BP | GO:0031056 | regulation of histone modification | 1 | 125 | 7.62e-01 |
| GO:BP | GO:0098543 | detection of other organism | 1 | 9 | 7.63e-01 |
| GO:BP | GO:0015850 | organic hydroxy compound transport | 3 | 174 | 7.63e-01 |
| GO:BP | GO:0006308 | DNA catabolic process | 1 | 19 | 7.63e-01 |
| GO:BP | GO:0009607 | response to biotic stimulus | 1 | 850 | 7.63e-01 |
| GO:BP | GO:0035458 | cellular response to interferon-beta | 1 | 15 | 7.63e-01 |
| GO:BP | GO:0050746 | regulation of lipoprotein metabolic process | 1 | 15 | 7.64e-01 |
| GO:BP | GO:0090672 | telomerase RNA localization | 1 | 19 | 7.64e-01 |
| GO:BP | GO:0090685 | RNA localization to nucleus | 1 | 19 | 7.64e-01 |
| GO:BP | GO:0090670 | RNA localization to Cajal body | 1 | 19 | 7.64e-01 |
| GO:BP | GO:0090671 | telomerase RNA localization to Cajal body | 1 | 19 | 7.64e-01 |
| GO:BP | GO:0051053 | negative regulation of DNA metabolic process | 2 | 112 | 7.64e-01 |
| GO:BP | GO:0071333 | cellular response to glucose stimulus | 1 | 93 | 7.64e-01 |
| GO:BP | GO:0071357 | cellular response to type I interferon | 3 | 52 | 7.64e-01 |
| GO:BP | GO:0010971 | positive regulation of G2/M transition of mitotic cell cycle | 1 | 27 | 7.64e-01 |
| GO:BP | GO:0035066 | positive regulation of histone acetylation | 1 | 25 | 7.64e-01 |
| GO:BP | GO:0007530 | sex determination | 1 | 12 | 7.64e-01 |
| GO:BP | GO:0007601 | visual perception | 1 | 96 | 7.64e-01 |
| GO:BP | GO:0035855 | megakaryocyte development | 1 | 16 | 7.64e-01 |
| GO:BP | GO:0051216 | cartilage development | 3 | 151 | 7.65e-01 |
| GO:BP | GO:0120261 | regulation of heterochromatin organization | 1 | 22 | 7.65e-01 |
| GO:BP | GO:0090189 | regulation of branching involved in ureteric bud morphogenesis | 1 | 14 | 7.65e-01 |
| GO:BP | GO:0031445 | regulation of heterochromatin formation | 1 | 22 | 7.65e-01 |
| GO:BP | GO:0036010 | protein localization to endosome | 1 | 26 | 7.65e-01 |
| GO:BP | GO:2000678 | negative regulation of transcription regulatory region DNA binding | 1 | 17 | 7.65e-01 |
| GO:BP | GO:0061049 | cell growth involved in cardiac muscle cell development | 1 | 19 | 7.66e-01 |
| GO:BP | GO:0019432 | triglyceride biosynthetic process | 2 | 31 | 7.66e-01 |
| GO:BP | GO:0003301 | physiological cardiac muscle hypertrophy | 1 | 19 | 7.66e-01 |
| GO:BP | GO:0003298 | physiological muscle hypertrophy | 1 | 19 | 7.66e-01 |
| GO:BP | GO:0006810 | transport | 2 | 3298 | 7.67e-01 |
| GO:BP | GO:0008593 | regulation of Notch signaling pathway | 4 | 78 | 7.67e-01 |
| GO:BP | GO:0071392 | cellular response to estradiol stimulus | 2 | 26 | 7.67e-01 |
| GO:BP | GO:0042303 | molting cycle | 7 | 78 | 7.67e-01 |
| GO:BP | GO:0071331 | cellular response to hexose stimulus | 1 | 94 | 7.67e-01 |
| GO:BP | GO:0050953 | sensory perception of light stimulus | 1 | 97 | 7.67e-01 |
| GO:BP | GO:0042633 | hair cycle | 7 | 78 | 7.67e-01 |
| GO:BP | GO:0007165 | signal transduction | 1 | 3818 | 7.70e-01 |
| GO:BP | GO:0043392 | negative regulation of DNA binding | 1 | 46 | 7.70e-01 |
| GO:BP | GO:2000272 | negative regulation of signaling receptor activity | 1 | 33 | 7.70e-01 |
| GO:BP | GO:0071459 | protein localization to chromosome, centromeric region | 2 | 42 | 7.71e-01 |
| GO:BP | GO:0010575 | positive regulation of vascular endothelial growth factor production | 1 | 18 | 7.71e-01 |
| GO:BP | GO:0070296 | sarcoplasmic reticulum calcium ion transport | 2 | 31 | 7.71e-01 |
| GO:BP | GO:0048645 | animal organ formation | 3 | 51 | 7.71e-01 |
| GO:BP | GO:0050795 | regulation of behavior | 3 | 39 | 7.71e-01 |
| GO:BP | GO:0071326 | cellular response to monosaccharide stimulus | 1 | 95 | 7.72e-01 |
| GO:BP | GO:0043931 | ossification involved in bone maturation | 1 | 17 | 7.73e-01 |
| GO:BP | GO:0001819 | positive regulation of cytokine production | 18 | 276 | 7.74e-01 |
| GO:BP | GO:1901798 | positive regulation of signal transduction by p53 class mediator | 1 | 28 | 7.74e-01 |
| GO:BP | GO:0002705 | positive regulation of leukocyte mediated immunity | 1 | 68 | 7.75e-01 |
| GO:BP | GO:0043652 | engulfment of apoptotic cell | 1 | 11 | 7.75e-01 |
| GO:BP | GO:0002347 | response to tumor cell | 2 | 22 | 7.75e-01 |
| GO:BP | GO:0001836 | release of cytochrome c from mitochondria | 1 | 47 | 7.75e-01 |
| GO:BP | GO:0051781 | positive regulation of cell division | 4 | 64 | 7.75e-01 |
| GO:BP | GO:0030513 | positive regulation of BMP signaling pathway | 1 | 34 | 7.75e-01 |
| GO:BP | GO:0051350 | negative regulation of lyase activity | 1 | 15 | 7.76e-01 |
| GO:BP | GO:1901360 | organic cyclic compound metabolic process | 6 | 4747 | 7.76e-01 |
| GO:BP | GO:0032743 | positive regulation of interleukin-2 production | 1 | 20 | 7.76e-01 |
| GO:BP | GO:0010888 | negative regulation of lipid storage | 1 | 16 | 7.78e-01 |
| GO:BP | GO:0120254 | olefinic compound metabolic process | 1 | 84 | 7.78e-01 |
| GO:BP | GO:0043576 | regulation of respiratory gaseous exchange | 1 | 15 | 7.78e-01 |
| GO:BP | GO:0032509 | endosome transport via multivesicular body sorting pathway | 1 | 41 | 7.78e-01 |
| GO:BP | GO:0045687 | positive regulation of glial cell differentiation | 2 | 28 | 7.78e-01 |
| GO:BP | GO:0001912 | positive regulation of leukocyte mediated cytotoxicity | 1 | 20 | 7.79e-01 |
| GO:BP | GO:0032409 | regulation of transporter activity | 2 | 211 | 7.79e-01 |
| GO:BP | GO:1904357 | negative regulation of telomere maintenance via telomere lengthening | 1 | 26 | 7.79e-01 |
| GO:BP | GO:0006024 | glycosaminoglycan biosynthetic process | 1 | 60 | 7.80e-01 |
| GO:BP | GO:0045723 | positive regulation of fatty acid biosynthetic process | 1 | 12 | 7.80e-01 |
| GO:BP | GO:0051260 | protein homooligomerization | 2 | 136 | 7.80e-01 |
| GO:BP | GO:0010633 | negative regulation of epithelial cell migration | 1 | 53 | 7.80e-01 |
| GO:BP | GO:0032026 | response to magnesium ion | 1 | 10 | 7.80e-01 |
| GO:BP | GO:0008334 | histone mRNA metabolic process | 1 | 21 | 7.81e-01 |
| GO:BP | GO:0002115 | store-operated calcium entry | 1 | 15 | 7.82e-01 |
| GO:BP | GO:0035459 | vesicle cargo loading | 1 | 27 | 7.83e-01 |
| GO:BP | GO:0002687 | positive regulation of leukocyte migration | 2 | 84 | 7.83e-01 |
| GO:BP | GO:0016578 | histone deubiquitination | 1 | 46 | 7.83e-01 |
| GO:BP | GO:0070230 | positive regulation of lymphocyte apoptotic process | 1 | 10 | 7.83e-01 |
| GO:BP | GO:0072207 | metanephric epithelium development | 1 | 16 | 7.83e-01 |
| GO:BP | GO:0006359 | regulation of transcription by RNA polymerase III | 1 | 30 | 7.83e-01 |
| GO:BP | GO:0007034 | vacuolar transport | 4 | 149 | 7.85e-01 |
| GO:BP | GO:0051234 | establishment of localization | 2 | 3433 | 7.85e-01 |
| GO:BP | GO:0051767 | nitric-oxide synthase biosynthetic process | 1 | 13 | 7.85e-01 |
| GO:BP | GO:0051769 | regulation of nitric-oxide synthase biosynthetic process | 1 | 13 | 7.85e-01 |
| GO:BP | GO:0044380 | protein localization to cytoskeleton | 3 | 55 | 7.85e-01 |
| GO:BP | GO:0050732 | negative regulation of peptidyl-tyrosine phosphorylation | 1 | 46 | 7.85e-01 |
| GO:BP | GO:0006497 | protein lipidation | 4 | 89 | 7.85e-01 |
| GO:BP | GO:0010033 | response to organic substance | 14 | 1957 | 7.85e-01 |
| GO:BP | GO:0036092 | phosphatidylinositol-3-phosphate biosynthetic process | 1 | 19 | 7.85e-01 |
| GO:BP | GO:0021692 | cerebellar Purkinje cell layer morphogenesis | 1 | 16 | 7.85e-01 |
| GO:BP | GO:0016137 | glycoside metabolic process | 1 | 16 | 7.85e-01 |
| GO:BP | GO:0044794 | positive regulation by host of viral process | 1 | 20 | 7.85e-01 |
| GO:BP | GO:0044419 | biological process involved in interspecies interaction between organisms | 1 | 963 | 7.86e-01 |
| GO:BP | GO:0006950 | response to stress | 52 | 2780 | 7.86e-01 |
| GO:BP | GO:0061458 | reproductive system development | 2 | 215 | 7.86e-01 |
| GO:BP | GO:0090151 | establishment of protein localization to mitochondrial membrane | 1 | 38 | 7.86e-01 |
| GO:BP | GO:0048483 | autonomic nervous system development | 2 | 28 | 7.86e-01 |
| GO:BP | GO:0006821 | chloride transport | 1 | 58 | 7.86e-01 |
| GO:BP | GO:1905476 | negative regulation of protein localization to membrane | 1 | 29 | 7.87e-01 |
| GO:BP | GO:0045638 | negative regulation of myeloid cell differentiation | 1 | 69 | 7.88e-01 |
| GO:BP | GO:1903955 | positive regulation of protein targeting to mitochondrion | 1 | 30 | 7.88e-01 |
| GO:BP | GO:0061384 | heart trabecula morphogenesis | 1 | 29 | 7.88e-01 |
| GO:BP | GO:0010447 | response to acidic pH | 1 | 16 | 7.88e-01 |
| GO:BP | GO:0010155 | regulation of proton transport | 1 | 18 | 7.89e-01 |
| GO:BP | GO:0050922 | negative regulation of chemotaxis | 3 | 44 | 7.89e-01 |
| GO:BP | GO:0003008 | system process | 4 | 1189 | 7.89e-01 |
| GO:BP | GO:0007186 | G protein-coupled receptor signaling pathway | 1 | 389 | 7.89e-01 |
| GO:BP | GO:0061515 | myeloid cell development | 1 | 57 | 7.89e-01 |
| GO:BP | GO:0045071 | negative regulation of viral genome replication | 2 | 37 | 7.89e-01 |
| GO:BP | GO:0007379 | segment specification | 1 | 14 | 7.91e-01 |
| GO:BP | GO:0048143 | astrocyte activation | 1 | 12 | 7.91e-01 |
| GO:BP | GO:0019222 | regulation of metabolic process | 5 | 5017 | 7.91e-01 |
| GO:BP | GO:0030878 | thyroid gland development | 1 | 17 | 7.91e-01 |
| GO:BP | GO:0022618 | ribonucleoprotein complex assembly | 1 | 203 | 7.91e-01 |
| GO:BP | GO:0016126 | sterol biosynthetic process | 1 | 52 | 7.91e-01 |
| GO:BP | GO:0032526 | response to retinoic acid | 6 | 85 | 7.91e-01 |
| GO:BP | GO:0036211 | protein modification process | 8 | 2901 | 7.91e-01 |
| GO:BP | GO:0060291 | long-term synaptic potentiation | 5 | 64 | 7.91e-01 |
| GO:BP | GO:1902751 | positive regulation of cell cycle G2/M phase transition | 1 | 30 | 7.91e-01 |
| GO:BP | GO:0061337 | cardiac conduction | 1 | 88 | 7.91e-01 |
| GO:BP | GO:0072666 | establishment of protein localization to vacuole | 3 | 55 | 7.91e-01 |
| GO:BP | GO:0001556 | oocyte maturation | 1 | 22 | 7.91e-01 |
| GO:BP | GO:0006813 | potassium ion transport | 1 | 147 | 7.92e-01 |
| GO:BP | GO:0071826 | ribonucleoprotein complex subunit organization | 1 | 211 | 7.92e-01 |
| GO:BP | GO:0007007 | inner mitochondrial membrane organization | 1 | 40 | 7.92e-01 |
| GO:BP | GO:0042573 | retinoic acid metabolic process | 1 | 12 | 7.92e-01 |
| GO:BP | GO:0031102 | neuron projection regeneration | 1 | 47 | 7.92e-01 |
| GO:BP | GO:1904356 | regulation of telomere maintenance via telomere lengthening | 3 | 56 | 7.93e-01 |
| GO:BP | GO:0031399 | regulation of protein modification process | 89 | 1173 | 7.93e-01 |
| GO:BP | GO:0030888 | regulation of B cell proliferation | 1 | 35 | 7.93e-01 |
| GO:BP | GO:0006023 | aminoglycan biosynthetic process | 1 | 63 | 7.94e-01 |
| GO:BP | GO:0022607 | cellular component assembly | 3 | 2466 | 7.94e-01 |
| GO:BP | GO:0071322 | cellular response to carbohydrate stimulus | 1 | 105 | 7.94e-01 |
| GO:BP | GO:0090026 | positive regulation of monocyte chemotaxis | 1 | 7 | 7.94e-01 |
| GO:BP | GO:0046931 | pore complex assembly | 1 | 19 | 7.94e-01 |
| GO:BP | GO:0002643 | regulation of tolerance induction | 1 | 10 | 7.96e-01 |
| GO:BP | GO:0031016 | pancreas development | 2 | 53 | 7.96e-01 |
| GO:BP | GO:0002694 | regulation of leukocyte activation | 6 | 348 | 7.96e-01 |
| GO:BP | GO:1901071 | glucosamine-containing compound metabolic process | 1 | 19 | 7.96e-01 |
| GO:BP | GO:0010959 | regulation of metal ion transport | 9 | 275 | 7.96e-01 |
| GO:BP | GO:0046514 | ceramide catabolic process | 1 | 16 | 7.96e-01 |
| GO:BP | GO:0034641 | cellular nitrogen compound metabolic process | 6 | 4946 | 7.96e-01 |
| GO:BP | GO:0006952 | defense response | 1 | 944 | 7.96e-01 |
| GO:BP | GO:0072676 | lymphocyte migration | 2 | 59 | 7.96e-01 |
| GO:BP | GO:2000193 | positive regulation of fatty acid transport | 1 | 11 | 7.96e-01 |
| GO:BP | GO:0023052 | signaling | 1 | 4141 | 7.96e-01 |
| GO:BP | GO:0006953 | acute-phase response | 1 | 18 | 7.96e-01 |
| GO:BP | GO:0035809 | regulation of urine volume | 1 | 14 | 7.97e-01 |
| GO:BP | GO:0006700 | C21-steroid hormone biosynthetic process | 1 | 17 | 7.97e-01 |
| GO:BP | GO:0001832 | blastocyst growth | 1 | 19 | 7.97e-01 |
| GO:BP | GO:0002684 | positive regulation of immune system process | 2 | 581 | 7.97e-01 |
| GO:BP | GO:0071674 | mononuclear cell migration | 2 | 102 | 7.97e-01 |
| GO:BP | GO:0006706 | steroid catabolic process | 1 | 13 | 7.98e-01 |
| GO:BP | GO:0033260 | nuclear DNA replication | 1 | 35 | 7.98e-01 |
| GO:BP | GO:0051281 | positive regulation of release of sequestered calcium ion into cytosol | 2 | 27 | 7.99e-01 |
| GO:BP | GO:0034340 | response to type I interferon | 3 | 57 | 7.99e-01 |
| GO:BP | GO:0010043 | response to zinc ion | 1 | 31 | 7.99e-01 |
| GO:BP | GO:0001759 | organ induction | 1 | 17 | 7.99e-01 |
| GO:BP | GO:0034377 | plasma lipoprotein particle assembly | 1 | 19 | 7.99e-01 |
| GO:BP | GO:0051480 | regulation of cytosolic calcium ion concentration | 3 | 40 | 7.99e-01 |
| GO:BP | GO:0006244 | pyrimidine nucleotide catabolic process | 1 | 19 | 7.99e-01 |
| GO:BP | GO:0051179 | localization | 4 | 3969 | 8.00e-01 |
| GO:BP | GO:0051047 | positive regulation of secretion | 5 | 215 | 8.00e-01 |
| GO:BP | GO:0033555 | multicellular organismal response to stress | 2 | 57 | 8.00e-01 |
| GO:BP | GO:0031214 | biomineral tissue development | 1 | 111 | 8.00e-01 |
| GO:BP | GO:0015980 | energy derivation by oxidation of organic compounds | 8 | 288 | 8.00e-01 |
| GO:BP | GO:0045143 | homologous chromosome segregation | 2 | 34 | 8.01e-01 |
| GO:BP | GO:0030833 | regulation of actin filament polymerization | 3 | 110 | 8.01e-01 |
| GO:BP | GO:0070977 | bone maturation | 1 | 19 | 8.01e-01 |
| GO:BP | GO:0048536 | spleen development | 1 | 28 | 8.01e-01 |
| GO:BP | GO:0042551 | neuron maturation | 2 | 33 | 8.01e-01 |
| GO:BP | GO:0065003 | protein-containing complex assembly | 2 | 1335 | 8.01e-01 |
| GO:BP | GO:0009081 | branched-chain amino acid metabolic process | 1 | 26 | 8.02e-01 |
| GO:BP | GO:0098661 | inorganic anion transmembrane transport | 1 | 66 | 8.02e-01 |
| GO:BP | GO:0007154 | cell communication | 1 | 4226 | 8.02e-01 |
| GO:BP | GO:0071539 | protein localization to centrosome | 1 | 31 | 8.02e-01 |
| GO:BP | GO:0001774 | microglial cell activation | 2 | 19 | 8.02e-01 |
| GO:BP | GO:0071880 | adenylate cyclase-activating adrenergic receptor signaling pathway | 1 | 19 | 8.02e-01 |
| GO:BP | GO:0045116 | protein neddylation | 1 | 26 | 8.02e-01 |
| GO:BP | GO:0051953 | negative regulation of amine transport | 1 | 15 | 8.02e-01 |
| GO:BP | GO:0000729 | DNA double-strand break processing | 1 | 18 | 8.02e-01 |
| GO:BP | GO:1901861 | regulation of muscle tissue development | 1 | 35 | 8.02e-01 |
| GO:BP | GO:0046839 | phospholipid dephosphorylation | 2 | 39 | 8.03e-01 |
| GO:BP | GO:0030308 | negative regulation of cell growth | 4 | 160 | 8.04e-01 |
| GO:BP | GO:0051048 | negative regulation of secretion | 3 | 111 | 8.04e-01 |
| GO:BP | GO:0007127 | meiosis I | 1 | 77 | 8.04e-01 |
| GO:BP | GO:0010574 | regulation of vascular endothelial growth factor production | 1 | 20 | 8.05e-01 |
| GO:BP | GO:0062207 | regulation of pattern recognition receptor signaling pathway | 1 | 68 | 8.05e-01 |
| GO:BP | GO:0045089 | positive regulation of innate immune response | 3 | 182 | 8.07e-01 |
| GO:BP | GO:0055080 | monoatomic cation homeostasis | 11 | 401 | 8.07e-01 |
| GO:BP | GO:0090148 | membrane fission | 1 | 44 | 8.07e-01 |
| GO:BP | GO:0035270 | endocrine system development | 6 | 86 | 8.07e-01 |
| GO:BP | GO:0050896 | response to stimulus | 2 | 5770 | 8.08e-01 |
| GO:BP | GO:1903578 | regulation of ATP metabolic process | 1 | 22 | 8.08e-01 |
| GO:BP | GO:1902644 | tertiary alcohol metabolic process | 1 | 17 | 8.08e-01 |
| GO:BP | GO:0002252 | immune effector process | 1 | 318 | 8.08e-01 |
| GO:BP | GO:1902749 | regulation of cell cycle G2/M phase transition | 6 | 103 | 8.08e-01 |
| GO:BP | GO:0070534 | protein K63-linked ubiquitination | 1 | 52 | 8.08e-01 |
| GO:BP | GO:0006513 | protein monoubiquitination | 4 | 80 | 8.08e-01 |
| GO:BP | GO:0008356 | asymmetric cell division | 1 | 14 | 8.09e-01 |
| GO:BP | GO:0042158 | lipoprotein biosynthetic process | 4 | 92 | 8.10e-01 |
| GO:BP | GO:0048638 | regulation of developmental growth | 1 | 258 | 8.11e-01 |
| GO:BP | GO:0045648 | positive regulation of erythrocyte differentiation | 1 | 27 | 8.11e-01 |
| GO:BP | GO:0045022 | early endosome to late endosome transport | 2 | 40 | 8.11e-01 |
| GO:BP | GO:2000403 | positive regulation of lymphocyte migration | 2 | 24 | 8.11e-01 |
| GO:BP | GO:0035196 | miRNA processing | 1 | 41 | 8.12e-01 |
| GO:BP | GO:0000281 | mitotic cytokinesis | 2 | 81 | 8.13e-01 |
| GO:BP | GO:1901976 | regulation of cell cycle checkpoint | 2 | 45 | 8.13e-01 |
| GO:BP | GO:1901998 | toxin transport | 2 | 37 | 8.13e-01 |
| GO:BP | GO:0035282 | segmentation | 4 | 75 | 8.13e-01 |
| GO:BP | GO:0045069 | regulation of viral genome replication | 3 | 64 | 8.13e-01 |
| GO:BP | GO:0018394 | peptidyl-lysine acetylation | 1 | 160 | 8.13e-01 |
| GO:BP | GO:0046885 | regulation of hormone biosynthetic process | 1 | 21 | 8.13e-01 |
| GO:BP | GO:2000758 | positive regulation of peptidyl-lysine acetylation | 1 | 31 | 8.13e-01 |
| GO:BP | GO:0009154 | purine ribonucleotide catabolic process | 1 | 40 | 8.14e-01 |
| GO:BP | GO:0050871 | positive regulation of B cell activation | 1 | 53 | 8.15e-01 |
| GO:BP | GO:0006694 | steroid biosynthetic process | 1 | 121 | 8.15e-01 |
| GO:BP | GO:0042476 | odontogenesis | 7 | 86 | 8.16e-01 |
| GO:BP | GO:0061982 | meiosis I cell cycle process | 1 | 81 | 8.17e-01 |
| GO:BP | GO:0031343 | positive regulation of cell killing | 1 | 23 | 8.17e-01 |
| GO:BP | GO:0008053 | mitochondrial fusion | 1 | 28 | 8.17e-01 |
| GO:BP | GO:1903749 | positive regulation of establishment of protein localization to mitochondrion | 1 | 33 | 8.19e-01 |
| GO:BP | GO:1905508 | protein localization to microtubule organizing center | 1 | 33 | 8.19e-01 |
| GO:BP | GO:0071985 | multivesicular body sorting pathway | 1 | 48 | 8.19e-01 |
| GO:BP | GO:0006874 | intracellular calcium ion homeostasis | 9 | 200 | 8.19e-01 |
| GO:BP | GO:0046503 | glycerolipid catabolic process | 2 | 42 | 8.20e-01 |
| GO:BP | GO:0071354 | cellular response to interleukin-6 | 1 | 23 | 8.20e-01 |
| GO:BP | GO:0003209 | cardiac atrium morphogenesis | 1 | 26 | 8.20e-01 |
| GO:BP | GO:0007368 | determination of left/right symmetry | 1 | 97 | 8.21e-01 |
| GO:BP | GO:0098581 | detection of external biotic stimulus | 1 | 11 | 8.21e-01 |
| GO:BP | GO:0051310 | metaphase plate congression | 3 | 69 | 8.21e-01 |
| GO:BP | GO:0016192 | vesicle-mediated transport | 1 | 1238 | 8.21e-01 |
| GO:BP | GO:0019082 | viral protein processing | 1 | 31 | 8.21e-01 |
| GO:BP | GO:0002250 | adaptive immune response | 1 | 218 | 8.21e-01 |
| GO:BP | GO:0002269 | leukocyte activation involved in inflammatory response | 1 | 21 | 8.21e-01 |
| GO:BP | GO:0007205 | protein kinase C-activating G protein-coupled receptor signaling pathway | 1 | 19 | 8.22e-01 |
| GO:BP | GO:0039694 | viral RNA genome replication | 1 | 27 | 8.22e-01 |
| GO:BP | GO:0016601 | Rac protein signal transduction | 1 | 42 | 8.22e-01 |
| GO:BP | GO:0006213 | pyrimidine nucleoside metabolic process | 1 | 16 | 8.22e-01 |
| GO:BP | GO:0120178 | steroid hormone biosynthetic process | 2 | 29 | 8.22e-01 |
| GO:BP | GO:0032387 | negative regulation of intracellular transport | 3 | 49 | 8.22e-01 |
| GO:BP | GO:0050801 | monoatomic ion homeostasis | 11 | 408 | 8.23e-01 |
| GO:BP | GO:0046471 | phosphatidylglycerol metabolic process | 1 | 23 | 8.23e-01 |
| GO:BP | GO:0033005 | positive regulation of mast cell activation | 1 | 13 | 8.23e-01 |
| GO:BP | GO:0050671 | positive regulation of lymphocyte proliferation | 2 | 72 | 8.23e-01 |
| GO:BP | GO:0016070 | RNA metabolic process | 1 | 3600 | 8.23e-01 |
| GO:BP | GO:0090317 | negative regulation of intracellular protein transport | 2 | 37 | 8.24e-01 |
| GO:BP | GO:0019725 | cellular homeostasis | 15 | 569 | 8.24e-01 |
| GO:BP | GO:0044085 | cellular component biogenesis | 3 | 2724 | 8.24e-01 |
| GO:BP | GO:0043933 | protein-containing complex organization | 2 | 1496 | 8.25e-01 |
| GO:BP | GO:0015800 | acidic amino acid transport | 2 | 39 | 8.25e-01 |
| GO:BP | GO:0035886 | vascular associated smooth muscle cell differentiation | 1 | 27 | 8.25e-01 |
| GO:BP | GO:0015701 | bicarbonate transport | 1 | 19 | 8.25e-01 |
| GO:BP | GO:0003254 | regulation of membrane depolarization | 2 | 37 | 8.25e-01 |
| GO:BP | GO:0008033 | tRNA processing | 3 | 128 | 8.25e-01 |
| GO:BP | GO:0090329 | regulation of DNA-templated DNA replication | 1 | 47 | 8.25e-01 |
| GO:BP | GO:0035249 | synaptic transmission, glutamatergic | 5 | 64 | 8.25e-01 |
| GO:BP | GO:0051220 | cytoplasmic sequestering of protein | 1 | 23 | 8.26e-01 |
| GO:BP | GO:0048678 | response to axon injury | 2 | 64 | 8.26e-01 |
| GO:BP | GO:0065005 | protein-lipid complex assembly | 1 | 21 | 8.27e-01 |
| GO:BP | GO:0006796 | phosphate-containing compound metabolic process | 6 | 2139 | 8.27e-01 |
| GO:BP | GO:2000242 | negative regulation of reproductive process | 3 | 42 | 8.27e-01 |
| GO:BP | GO:0002685 | regulation of leukocyte migration | 12 | 131 | 8.29e-01 |
| GO:BP | GO:0060972 | left/right pattern formation | 1 | 101 | 8.30e-01 |
| GO:BP | GO:0044786 | cell cycle DNA replication | 1 | 40 | 8.30e-01 |
| GO:BP | GO:0090407 | organophosphate biosynthetic process | 2 | 506 | 8.30e-01 |
| GO:BP | GO:0060675 | ureteric bud morphogenesis | 1 | 49 | 8.30e-01 |
| GO:BP | GO:0034220 | monoatomic ion transmembrane transport | 5 | 632 | 8.30e-01 |
| GO:BP | GO:0032946 | positive regulation of mononuclear cell proliferation | 2 | 75 | 8.30e-01 |
| GO:BP | GO:0003091 | renal water homeostasis | 1 | 13 | 8.31e-01 |
| GO:BP | GO:0022613 | ribonucleoprotein complex biogenesis | 1 | 453 | 8.31e-01 |
| GO:BP | GO:0021549 | cerebellum development | 3 | 78 | 8.31e-01 |
| GO:BP | GO:0002262 | myeloid cell homeostasis | 2 | 140 | 8.32e-01 |
| GO:BP | GO:0051881 | regulation of mitochondrial membrane potential | 1 | 60 | 8.32e-01 |
| GO:BP | GO:0045070 | positive regulation of viral genome replication | 1 | 28 | 8.32e-01 |
| GO:BP | GO:0050727 | regulation of inflammatory response | 2 | 212 | 8.32e-01 |
| GO:BP | GO:0042220 | response to cocaine | 1 | 28 | 8.32e-01 |
| GO:BP | GO:0030178 | negative regulation of Wnt signaling pathway | 3 | 140 | 8.33e-01 |
| GO:BP | GO:0072329 | monocarboxylic acid catabolic process | 2 | 105 | 8.33e-01 |
| GO:BP | GO:0006793 | phosphorus metabolic process | 6 | 2161 | 8.33e-01 |
| GO:BP | GO:0097066 | response to thyroid hormone | 1 | 23 | 8.33e-01 |
| GO:BP | GO:0002052 | positive regulation of neuroblast proliferation | 1 | 19 | 8.33e-01 |
| GO:BP | GO:0072171 | mesonephric tubule morphogenesis | 1 | 50 | 8.33e-01 |
| GO:BP | GO:0033146 | regulation of intracellular estrogen receptor signaling pathway | 1 | 28 | 8.34e-01 |
| GO:BP | GO:0043094 | cellular metabolic compound salvage | 1 | 25 | 8.34e-01 |
| GO:BP | GO:0048799 | animal organ maturation | 1 | 20 | 8.34e-01 |
| GO:BP | GO:0035456 | response to interferon-beta | 1 | 22 | 8.34e-01 |
| GO:BP | GO:0034368 | protein-lipid complex remodeling | 1 | 14 | 8.35e-01 |
| GO:BP | GO:0034369 | plasma lipoprotein particle remodeling | 1 | 14 | 8.35e-01 |
| GO:BP | GO:0030431 | sleep | 1 | 13 | 8.36e-01 |
| GO:BP | GO:0002376 | immune system process | 7 | 1447 | 8.37e-01 |
| GO:BP | GO:0032879 | regulation of localization | 1 | 1555 | 8.37e-01 |
| GO:BP | GO:0002701 | negative regulation of production of molecular mediator of immune response | 1 | 21 | 8.37e-01 |
| GO:BP | GO:0098927 | vesicle-mediated transport between endosomal compartments | 2 | 42 | 8.37e-01 |
| GO:BP | GO:0071310 | cellular response to organic substance | 10 | 1399 | 8.37e-01 |
| GO:BP | GO:0046189 | phenol-containing compound biosynthetic process | 1 | 28 | 8.37e-01 |
| GO:BP | GO:0046460 | neutral lipid biosynthetic process | 2 | 36 | 8.37e-01 |
| GO:BP | GO:0046463 | acylglycerol biosynthetic process | 2 | 36 | 8.37e-01 |
| GO:BP | GO:0042446 | hormone biosynthetic process | 3 | 40 | 8.37e-01 |
| GO:BP | GO:0072088 | nephron epithelium morphogenesis | 3 | 59 | 8.37e-01 |
| GO:BP | GO:0002369 | T cell cytokine production | 1 | 18 | 8.38e-01 |
| GO:BP | GO:0045807 | positive regulation of endocytosis | 8 | 104 | 8.38e-01 |
| GO:BP | GO:0002724 | regulation of T cell cytokine production | 1 | 18 | 8.38e-01 |
| GO:BP | GO:0007405 | neuroblast proliferation | 1 | 51 | 8.39e-01 |
| GO:BP | GO:0050856 | regulation of T cell receptor signaling pathway | 1 | 30 | 8.39e-01 |
| GO:BP | GO:0098655 | monoatomic cation transmembrane transport | 4 | 540 | 8.39e-01 |
| GO:BP | GO:0061351 | neural precursor cell proliferation | 3 | 114 | 8.40e-01 |
| GO:BP | GO:0061900 | glial cell activation | 1 | 23 | 8.40e-01 |
| GO:BP | GO:0070741 | response to interleukin-6 | 1 | 23 | 8.40e-01 |
| GO:BP | GO:0072698 | protein localization to microtubule cytoskeleton | 2 | 52 | 8.40e-01 |
| GO:BP | GO:0002833 | positive regulation of response to biotic stimulus | 3 | 192 | 8.40e-01 |
| GO:BP | GO:0043032 | positive regulation of macrophage activation | 1 | 12 | 8.41e-01 |
| GO:BP | GO:0072665 | protein localization to vacuole | 4 | 72 | 8.41e-01 |
| GO:BP | GO:0022038 | corpus callosum development | 1 | 20 | 8.42e-01 |
| GO:BP | GO:0042267 | natural killer cell mediated cytotoxicity | 1 | 34 | 8.42e-01 |
| GO:BP | GO:0097028 | dendritic cell differentiation | 1 | 23 | 8.42e-01 |
| GO:BP | GO:0035264 | multicellular organism growth | 3 | 123 | 8.42e-01 |
| GO:BP | GO:0051289 | protein homotetramerization | 1 | 42 | 8.42e-01 |
| GO:BP | GO:0007039 | protein catabolic process in the vacuole | 1 | 22 | 8.43e-01 |
| GO:BP | GO:0006310 | DNA recombination | 13 | 257 | 8.43e-01 |
| GO:BP | GO:0008209 | androgen metabolic process | 1 | 16 | 8.43e-01 |
| GO:BP | GO:0003156 | regulation of animal organ formation | 1 | 20 | 8.45e-01 |
| GO:BP | GO:0071875 | adrenergic receptor signaling pathway | 1 | 24 | 8.45e-01 |
| GO:BP | GO:0099637 | neurotransmitter receptor transport | 1 | 21 | 8.45e-01 |
| GO:BP | GO:0007004 | telomere maintenance via telomerase | 3 | 63 | 8.45e-01 |
| GO:BP | GO:0019538 | protein metabolic process | 6 | 4241 | 8.45e-01 |
| GO:BP | GO:0032501 | multicellular organismal process | 9 | 4794 | 8.45e-01 |
| GO:BP | GO:0009605 | response to external stimulus | 8 | 1719 | 8.46e-01 |
| GO:BP | GO:0001906 | cell killing | 1 | 69 | 8.47e-01 |
| GO:BP | GO:0050433 | regulation of catecholamine secretion | 2 | 29 | 8.47e-01 |
| GO:BP | GO:0044273 | sulfur compound catabolic process | 1 | 31 | 8.48e-01 |
| GO:BP | GO:0001916 | positive regulation of T cell mediated cytotoxicity | 1 | 13 | 8.48e-01 |
| GO:BP | GO:0007129 | homologous chromosome pairing at meiosis | 1 | 24 | 8.49e-01 |
| GO:BP | GO:0061760 | antifungal innate immune response | 1 | 7 | 8.50e-01 |
| GO:BP | GO:0008344 | adult locomotory behavior | 2 | 60 | 8.50e-01 |
| GO:BP | GO:0002218 | activation of innate immune response | 2 | 142 | 8.50e-01 |
| GO:BP | GO:0070233 | negative regulation of T cell apoptotic process | 1 | 14 | 8.51e-01 |
| GO:BP | GO:0090304 | nucleic acid metabolic process | 1 | 4048 | 8.51e-01 |
| GO:BP | GO:0034367 | protein-containing complex remodeling | 1 | 16 | 8.51e-01 |
| GO:BP | GO:0009261 | ribonucleotide catabolic process | 1 | 45 | 8.51e-01 |
| GO:BP | GO:0006278 | RNA-templated DNA biosynthetic process | 3 | 64 | 8.51e-01 |
| GO:BP | GO:0055010 | ventricular cardiac muscle tissue morphogenesis | 1 | 43 | 8.51e-01 |
| GO:BP | GO:0002228 | natural killer cell mediated immunity | 1 | 34 | 8.52e-01 |
| GO:BP | GO:0072028 | nephron morphogenesis | 3 | 62 | 8.53e-01 |
| GO:BP | GO:0061036 | positive regulation of cartilage development | 1 | 25 | 8.55e-01 |
| GO:BP | GO:1903510 | mucopolysaccharide metabolic process | 1 | 74 | 8.55e-01 |
| GO:BP | GO:0060314 | regulation of ryanodine-sensitive calcium-release channel activity | 1 | 23 | 8.56e-01 |
| GO:BP | GO:0045907 | positive regulation of vasoconstriction | 1 | 15 | 8.56e-01 |
| GO:BP | GO:0045332 | phospholipid translocation | 1 | 33 | 8.56e-01 |
| GO:BP | GO:0042491 | inner ear auditory receptor cell differentiation | 2 | 29 | 8.56e-01 |
| GO:BP | GO:0008064 | regulation of actin polymerization or depolymerization | 3 | 126 | 8.56e-01 |
| GO:BP | GO:0031424 | keratinization | 1 | 13 | 8.56e-01 |
| GO:BP | GO:0007340 | acrosome reaction | 1 | 20 | 8.56e-01 |
| GO:BP | GO:0046339 | diacylglycerol metabolic process | 1 | 23 | 8.56e-01 |
| GO:BP | GO:0043966 | histone H3 acetylation | 1 | 59 | 8.57e-01 |
| GO:BP | GO:1902742 | apoptotic process involved in development | 1 | 30 | 8.57e-01 |
| GO:BP | GO:0045920 | negative regulation of exocytosis | 1 | 26 | 8.57e-01 |
| GO:BP | GO:0002474 | antigen processing and presentation of peptide antigen via MHC class I | 1 | 25 | 8.57e-01 |
| GO:BP | GO:0050764 | regulation of phagocytosis | 3 | 57 | 8.58e-01 |
| GO:BP | GO:0046677 | response to antibiotic | 2 | 43 | 8.58e-01 |
| GO:BP | GO:2000404 | regulation of T cell migration | 2 | 28 | 8.58e-01 |
| GO:BP | GO:0010324 | membrane invagination | 3 | 49 | 8.59e-01 |
| GO:BP | GO:0006644 | phospholipid metabolic process | 2 | 316 | 8.59e-01 |
| GO:BP | GO:0006473 | protein acetylation | 2 | 190 | 8.59e-01 |
| GO:BP | GO:2000279 | negative regulation of DNA biosynthetic process | 1 | 34 | 8.59e-01 |
| GO:BP | GO:0046649 | lymphocyte activation | 1 | 465 | 8.60e-01 |
| GO:BP | GO:0072078 | nephron tubule morphogenesis | 1 | 57 | 8.60e-01 |
| GO:BP | GO:0071695 | anatomical structure maturation | 2 | 48 | 8.60e-01 |
| GO:BP | GO:0006195 | purine nucleotide catabolic process | 1 | 48 | 8.60e-01 |
| GO:BP | GO:0032801 | receptor catabolic process | 1 | 24 | 8.60e-01 |
| GO:BP | GO:0048477 | oogenesis | 3 | 64 | 8.61e-01 |
| GO:BP | GO:1990266 | neutrophil migration | 1 | 52 | 8.61e-01 |
| GO:BP | GO:0060292 | long-term synaptic depression | 1 | 21 | 8.61e-01 |
| GO:BP | GO:0002449 | lymphocyte mediated immunity | 2 | 142 | 8.61e-01 |
| GO:BP | GO:0002443 | leukocyte mediated immunity | 3 | 194 | 8.61e-01 |
| GO:BP | GO:0045921 | positive regulation of exocytosis | 4 | 62 | 8.62e-01 |
| GO:BP | GO:0030832 | regulation of actin filament length | 3 | 127 | 8.62e-01 |
| GO:BP | GO:0008333 | endosome to lysosome transport | 1 | 63 | 8.63e-01 |
| GO:BP | GO:0050766 | positive regulation of phagocytosis | 2 | 38 | 8.63e-01 |
| GO:BP | GO:2000677 | regulation of transcription regulatory region DNA binding | 2 | 43 | 8.66e-01 |
| GO:BP | GO:0042102 | positive regulation of T cell proliferation | 1 | 47 | 8.66e-01 |
| GO:BP | GO:0045744 | negative regulation of G protein-coupled receptor signaling pathway | 1 | 38 | 8.66e-01 |
| GO:BP | GO:0016071 | mRNA metabolic process | 1 | 665 | 8.67e-01 |
| GO:BP | GO:0055074 | calcium ion homeostasis | 5 | 214 | 8.68e-01 |
| GO:BP | GO:0070665 | positive regulation of leukocyte proliferation | 2 | 83 | 8.68e-01 |
| GO:BP | GO:0010743 | regulation of macrophage derived foam cell differentiation | 1 | 18 | 8.68e-01 |
| GO:BP | GO:0022037 | metencephalon development | 3 | 84 | 8.68e-01 |
| GO:BP | GO:0009651 | response to salt stress | 1 | 18 | 8.68e-01 |
| GO:BP | GO:0002711 | positive regulation of T cell mediated immunity | 2 | 29 | 8.69e-01 |
| GO:BP | GO:0150146 | cell junction disassembly | 1 | 20 | 8.70e-01 |
| GO:BP | GO:0042026 | protein refolding | 1 | 26 | 8.71e-01 |
| GO:BP | GO:0061333 | renal tubule morphogenesis | 1 | 61 | 8.72e-01 |
| GO:BP | GO:0008037 | cell recognition | 2 | 87 | 8.74e-01 |
| GO:BP | GO:0032735 | positive regulation of interleukin-12 production | 1 | 19 | 8.74e-01 |
| GO:BP | GO:0001782 | B cell homeostasis | 1 | 24 | 8.75e-01 |
| GO:BP | GO:0016064 | immunoglobulin mediated immune response | 1 | 76 | 8.76e-01 |
| GO:BP | GO:0030534 | adult behavior | 7 | 92 | 8.76e-01 |
| GO:BP | GO:0043302 | positive regulation of leukocyte degranulation | 1 | 15 | 8.76e-01 |
| GO:BP | GO:0090183 | regulation of kidney development | 1 | 22 | 8.76e-01 |
| GO:BP | GO:0045087 | innate immune response | 2 | 488 | 8.77e-01 |
| GO:BP | GO:0007009 | plasma membrane organization | 4 | 116 | 8.77e-01 |
| GO:BP | GO:0061077 | chaperone-mediated protein folding | 3 | 65 | 8.78e-01 |
| GO:BP | GO:0098801 | regulation of renal system process | 1 | 21 | 8.78e-01 |
| GO:BP | GO:0007202 | activation of phospholipase C activity | 1 | 10 | 8.79e-01 |
| GO:BP | GO:1903828 | negative regulation of protein localization | 3 | 160 | 8.79e-01 |
| GO:BP | GO:0019724 | B cell mediated immunity | 1 | 77 | 8.79e-01 |
| GO:BP | GO:0050864 | regulation of B cell activation | 1 | 77 | 8.79e-01 |
| GO:BP | GO:0042475 | odontogenesis of dentin-containing tooth | 4 | 55 | 8.79e-01 |
| GO:BP | GO:0003230 | cardiac atrium development | 1 | 34 | 8.80e-01 |
| GO:BP | GO:0043123 | positive regulation of I-kappaB kinase/NF-kappaB signaling | 8 | 153 | 8.80e-01 |
| GO:BP | GO:0030595 | leukocyte chemotaxis | 1 | 115 | 8.81e-01 |
| GO:BP | GO:0034204 | lipid translocation | 1 | 38 | 8.82e-01 |
| GO:BP | GO:0072523 | purine-containing compound catabolic process | 1 | 53 | 8.83e-01 |
| GO:BP | GO:0030837 | negative regulation of actin filament polymerization | 1 | 57 | 8.83e-01 |
| GO:BP | GO:1904035 | regulation of epithelial cell apoptotic process | 2 | 71 | 8.84e-01 |
| GO:BP | GO:0030101 | natural killer cell activation | 2 | 42 | 8.84e-01 |
| GO:BP | GO:0001558 | regulation of cell growth | 1 | 357 | 8.84e-01 |
| GO:BP | GO:0051303 | establishment of chromosome localization | 3 | 75 | 8.84e-01 |
| GO:BP | GO:0098662 | inorganic cation transmembrane transport | 3 | 517 | 8.85e-01 |
| GO:BP | GO:0050829 | defense response to Gram-negative bacterium | 1 | 20 | 8.85e-01 |
| GO:BP | GO:1901031 | regulation of response to reactive oxygen species | 1 | 28 | 8.86e-01 |
| GO:BP | GO:0000289 | nuclear-transcribed mRNA poly(A) tail shortening | 1 | 33 | 8.86e-01 |
| GO:BP | GO:0006898 | receptor-mediated endocytosis | 13 | 196 | 8.86e-01 |
| GO:BP | GO:1904036 | negative regulation of epithelial cell apoptotic process | 1 | 43 | 8.86e-01 |
| GO:BP | GO:0008406 | gonad development | 1 | 158 | 8.86e-01 |
| GO:BP | GO:0140115 | export across plasma membrane | 2 | 46 | 8.86e-01 |
| GO:BP | GO:1901701 | cellular response to oxygen-containing compound | 2 | 893 | 8.86e-01 |
| GO:BP | GO:0043269 | regulation of monoatomic ion transport | 2 | 373 | 8.86e-01 |
| GO:BP | GO:0070198 | protein localization to chromosome, telomeric region | 1 | 30 | 8.86e-01 |
| GO:BP | GO:0001756 | somitogenesis | 1 | 48 | 8.87e-01 |
| GO:BP | GO:1905168 | positive regulation of double-strand break repair via homologous recombination | 1 | 35 | 8.88e-01 |
| GO:BP | GO:0071677 | positive regulation of mononuclear cell migration | 3 | 39 | 8.89e-01 |
| GO:BP | GO:0021680 | cerebellar Purkinje cell layer development | 1 | 24 | 8.89e-01 |
| GO:BP | GO:0042133 | neurotransmitter metabolic process | 1 | 18 | 8.89e-01 |
| GO:BP | GO:0110110 | positive regulation of animal organ morphogenesis | 1 | 26 | 8.89e-01 |
| GO:BP | GO:0045824 | negative regulation of innate immune response | 2 | 53 | 8.89e-01 |
| GO:BP | GO:0048878 | chemical homeostasis | 6 | 676 | 8.89e-01 |
| GO:BP | GO:0046620 | regulation of organ growth | 1 | 71 | 8.89e-01 |
| GO:BP | GO:0042572 | retinol metabolic process | 2 | 24 | 8.90e-01 |
| GO:BP | GO:0006656 | phosphatidylcholine biosynthetic process | 1 | 25 | 8.90e-01 |
| GO:BP | GO:0045137 | development of primary sexual characteristics | 1 | 161 | 8.90e-01 |
| GO:BP | GO:1905330 | regulation of morphogenesis of an epithelium | 2 | 47 | 8.91e-01 |
| GO:BP | GO:0043300 | regulation of leukocyte degranulation | 2 | 27 | 8.92e-01 |
| GO:BP | GO:1905521 | regulation of macrophage migration | 1 | 24 | 8.92e-01 |
| GO:BP | GO:0048499 | synaptic vesicle membrane organization | 1 | 23 | 8.92e-01 |
| GO:BP | GO:0009268 | response to pH | 1 | 26 | 8.92e-01 |
| GO:BP | GO:2000177 | regulation of neural precursor cell proliferation | 3 | 64 | 8.93e-01 |
| GO:BP | GO:0003229 | ventricular cardiac muscle tissue development | 1 | 52 | 8.94e-01 |
| GO:BP | GO:0030808 | regulation of nucleotide biosynthetic process | 1 | 25 | 8.94e-01 |
| GO:BP | GO:1900371 | regulation of purine nucleotide biosynthetic process | 1 | 25 | 8.94e-01 |
| GO:BP | GO:0014059 | regulation of dopamine secretion | 1 | 22 | 8.94e-01 |
| GO:BP | GO:0003161 | cardiac conduction system development | 1 | 33 | 8.94e-01 |
| GO:BP | GO:0006836 | neurotransmitter transport | 1 | 138 | 8.94e-01 |
| GO:BP | GO:0034101 | erythrocyte homeostasis | 5 | 114 | 8.94e-01 |
| GO:BP | GO:0008210 | estrogen metabolic process | 1 | 16 | 8.95e-01 |
| GO:BP | GO:0019748 | secondary metabolic process | 1 | 34 | 8.95e-01 |
| GO:BP | GO:0043484 | regulation of RNA splicing | 4 | 164 | 8.95e-01 |
| GO:BP | GO:0009152 | purine ribonucleotide biosynthetic process | 1 | 179 | 8.96e-01 |
| GO:BP | GO:0030218 | erythrocyte differentiation | 1 | 107 | 8.96e-01 |
| GO:BP | GO:0050806 | positive regulation of synaptic transmission | 7 | 106 | 8.96e-01 |
| GO:BP | GO:0006887 | exocytosis | 2 | 256 | 8.96e-01 |
| GO:BP | GO:0002251 | organ or tissue specific immune response | 1 | 13 | 8.96e-01 |
| GO:BP | GO:0051588 | regulation of neurotransmitter transport | 4 | 70 | 8.97e-01 |
| GO:BP | GO:0022904 | respiratory electron transport chain | 2 | 104 | 8.97e-01 |
| GO:BP | GO:0042391 | regulation of membrane potential | 17 | 293 | 8.98e-01 |
| GO:BP | GO:0003016 | respiratory system process | 1 | 30 | 8.98e-01 |
| GO:BP | GO:0097035 | regulation of membrane lipid distribution | 1 | 43 | 8.98e-01 |
| GO:BP | GO:0007140 | male meiotic nuclear division | 1 | 27 | 8.99e-01 |
| GO:BP | GO:0010092 | specification of animal organ identity | 1 | 26 | 8.99e-01 |
| GO:BP | GO:0045646 | regulation of erythrocyte differentiation | 1 | 39 | 8.99e-01 |
| GO:BP | GO:0030203 | glycosaminoglycan metabolic process | 1 | 87 | 8.99e-01 |
| GO:BP | GO:0045321 | leukocyte activation | 8 | 554 | 9.00e-01 |
| GO:BP | GO:0098771 | inorganic ion homeostasis | 1 | 351 | 9.00e-01 |
| GO:BP | GO:0090077 | foam cell differentiation | 1 | 22 | 9.01e-01 |
| GO:BP | GO:0010742 | macrophage derived foam cell differentiation | 1 | 22 | 9.01e-01 |
| GO:BP | GO:0043543 | protein acylation | 1 | 228 | 9.01e-01 |
| GO:BP | GO:0019646 | aerobic electron transport chain | 1 | 74 | 9.02e-01 |
| GO:BP | GO:0010467 | gene expression | 9 | 4587 | 9.03e-01 |
| GO:BP | GO:1903530 | regulation of secretion by cell | 3 | 382 | 9.04e-01 |
| GO:BP | GO:0042776 | proton motive force-driven mitochondrial ATP synthesis | 2 | 57 | 9.04e-01 |
| GO:BP | GO:0055078 | sodium ion homeostasis | 1 | 26 | 9.04e-01 |
| GO:BP | GO:0050891 | multicellular organismal-level water homeostasis | 1 | 16 | 9.05e-01 |
| GO:BP | GO:0001505 | regulation of neurotransmitter levels | 1 | 149 | 9.06e-01 |
| GO:BP | GO:0030224 | monocyte differentiation | 1 | 26 | 9.06e-01 |
| GO:BP | GO:0033280 | response to vitamin D | 1 | 24 | 9.06e-01 |
| GO:BP | GO:0006897 | endocytosis | 1 | 527 | 9.06e-01 |
| GO:BP | GO:0097530 | granulocyte migration | 1 | 67 | 9.06e-01 |
| GO:BP | GO:0035065 | regulation of histone acetylation | 1 | 47 | 9.06e-01 |
| GO:BP | GO:1903351 | cellular response to dopamine | 2 | 47 | 9.06e-01 |
| GO:BP | GO:0044060 | regulation of endocrine process | 1 | 24 | 9.06e-01 |
| GO:BP | GO:0002507 | tolerance induction | 1 | 15 | 9.06e-01 |
| GO:BP | GO:0001569 | branching involved in blood vessel morphogenesis | 1 | 29 | 9.06e-01 |
| GO:BP | GO:0150076 | neuroinflammatory response | 1 | 33 | 9.07e-01 |
| GO:BP | GO:0030001 | metal ion transport | 10 | 562 | 9.07e-01 |
| GO:BP | GO:0035315 | hair cell differentiation | 2 | 34 | 9.08e-01 |
| GO:BP | GO:0010833 | telomere maintenance via telomere lengthening | 3 | 73 | 9.09e-01 |
| GO:BP | GO:1903350 | response to dopamine | 2 | 48 | 9.10e-01 |
| GO:BP | GO:0048278 | vesicle docking | 1 | 57 | 9.10e-01 |
| GO:BP | GO:0048608 | reproductive structure development | 12 | 212 | 9.11e-01 |
| GO:BP | GO:0050000 | chromosome localization | 3 | 82 | 9.11e-01 |
| GO:BP | GO:0009595 | detection of biotic stimulus | 1 | 20 | 9.11e-01 |
| GO:BP | GO:0010608 | post-transcriptional regulation of gene expression | 1 | 468 | 9.13e-01 |
| GO:BP | GO:0006955 | immune response | 4 | 882 | 9.14e-01 |
| GO:BP | GO:0046928 | regulation of neurotransmitter secretion | 2 | 57 | 9.15e-01 |
| GO:BP | GO:0070918 | regulatory ncRNA processing | 1 | 47 | 9.15e-01 |
| GO:BP | GO:0060993 | kidney morphogenesis | 1 | 73 | 9.15e-01 |
| GO:BP | GO:0007628 | adult walking behavior | 1 | 23 | 9.15e-01 |
| GO:BP | GO:1902275 | regulation of chromatin organization | 2 | 49 | 9.15e-01 |
| GO:BP | GO:0009048 | dosage compensation by inactivation of X chromosome | 1 | 27 | 9.17e-01 |
| GO:BP | GO:0099643 | signal release from synapse | 3 | 104 | 9.17e-01 |
| GO:BP | GO:0051262 | protein tetramerization | 3 | 64 | 9.17e-01 |
| GO:BP | GO:0007269 | neurotransmitter secretion | 3 | 104 | 9.17e-01 |
| GO:BP | GO:0050854 | regulation of antigen receptor-mediated signaling pathway | 1 | 40 | 9.19e-01 |
| GO:BP | GO:0042775 | mitochondrial ATP synthesis coupled electron transport | 1 | 82 | 9.19e-01 |
| GO:BP | GO:0042773 | ATP synthesis coupled electron transport | 1 | 82 | 9.19e-01 |
| GO:BP | GO:0043304 | regulation of mast cell degranulation | 1 | 20 | 9.19e-01 |
| GO:BP | GO:0009205 | purine ribonucleoside triphosphate metabolic process | 2 | 137 | 9.19e-01 |
| GO:BP | GO:1903900 | regulation of viral life cycle | 4 | 101 | 9.19e-01 |
| GO:BP | GO:0071868 | cellular response to monoamine stimulus | 3 | 60 | 9.19e-01 |
| GO:BP | GO:0071870 | cellular response to catecholamine stimulus | 3 | 60 | 9.19e-01 |
| GO:BP | GO:0007568 | aging | 3 | 115 | 9.21e-01 |
| GO:BP | GO:0032350 | regulation of hormone metabolic process | 1 | 30 | 9.21e-01 |
| GO:BP | GO:0006301 | postreplication repair | 1 | 34 | 9.21e-01 |
| GO:BP | GO:0098660 | inorganic ion transmembrane transport | 3 | 563 | 9.21e-01 |
| GO:BP | GO:0022900 | electron transport chain | 6 | 142 | 9.22e-01 |
| GO:BP | GO:0031123 | RNA 3’-end processing | 1 | 100 | 9.22e-01 |
| GO:BP | GO:0043457 | regulation of cellular respiration | 1 | 42 | 9.22e-01 |
| GO:BP | GO:0048469 | cell maturation | 5 | 108 | 9.23e-01 |
| GO:BP | GO:0048247 | lymphocyte chemotaxis | 1 | 24 | 9.23e-01 |
| GO:BP | GO:0051954 | positive regulation of amine transport | 1 | 26 | 9.24e-01 |
| GO:BP | GO:0034308 | primary alcohol metabolic process | 4 | 61 | 9.24e-01 |
| GO:BP | GO:0007548 | sex differentiation | 11 | 191 | 9.24e-01 |
| GO:BP | GO:0072529 | pyrimidine-containing compound catabolic process | 1 | 29 | 9.24e-01 |
| GO:BP | GO:0071827 | plasma lipoprotein particle organization | 1 | 27 | 9.25e-01 |
| GO:BP | GO:0090659 | walking behavior | 1 | 25 | 9.25e-01 |
| GO:BP | GO:0044242 | cellular lipid catabolic process | 4 | 170 | 9.26e-01 |
| GO:BP | GO:0009144 | purine nucleoside triphosphate metabolic process | 2 | 142 | 9.26e-01 |
| GO:BP | GO:1900181 | negative regulation of protein localization to nucleus | 1 | 28 | 9.26e-01 |
| GO:BP | GO:0016043 | cellular component organization | 5 | 5076 | 9.26e-01 |
| GO:BP | GO:0030520 | intracellular estrogen receptor signaling pathway | 1 | 41 | 9.27e-01 |
| GO:BP | GO:0032940 | secretion by cell | 5 | 569 | 9.27e-01 |
| GO:BP | GO:0032731 | positive regulation of interleukin-1 beta production | 2 | 30 | 9.27e-01 |
| GO:BP | GO:0071869 | response to catecholamine | 3 | 62 | 9.28e-01 |
| GO:BP | GO:0071867 | response to monoamine | 3 | 62 | 9.28e-01 |
| GO:BP | GO:0046903 | secretion | 6 | 645 | 9.28e-01 |
| GO:BP | GO:0009199 | ribonucleoside triphosphate metabolic process | 2 | 144 | 9.29e-01 |
| GO:BP | GO:0042592 | homeostatic process | 10 | 1159 | 9.29e-01 |
| GO:BP | GO:1902692 | regulation of neuroblast proliferation | 1 | 28 | 9.29e-01 |
| GO:BP | GO:0031349 | positive regulation of defense response | 1 | 251 | 9.29e-01 |
| GO:BP | GO:0033006 | regulation of mast cell activation involved in immune response | 1 | 21 | 9.29e-01 |
| GO:BP | GO:0006812 | monoatomic cation transport | 4 | 669 | 9.29e-01 |
| GO:BP | GO:0089718 | amino acid import across plasma membrane | 1 | 39 | 9.30e-01 |
| GO:BP | GO:0006811 | monoatomic ion transport | 5 | 775 | 9.30e-01 |
| GO:BP | GO:0043403 | skeletal muscle tissue regeneration | 1 | 31 | 9.30e-01 |
| GO:BP | GO:0014002 | astrocyte development | 1 | 27 | 9.30e-01 |
| GO:BP | GO:0035725 | sodium ion transmembrane transport | 1 | 113 | 9.31e-01 |
| GO:BP | GO:0006119 | oxidative phosphorylation | 2 | 122 | 9.32e-01 |
| GO:BP | GO:0006164 | purine nucleotide biosynthetic process | 1 | 209 | 9.33e-01 |
| GO:BP | GO:0061053 | somite development | 1 | 63 | 9.33e-01 |
| GO:BP | GO:0097529 | myeloid leukocyte migration | 2 | 120 | 9.33e-01 |
| GO:BP | GO:0051046 | regulation of secretion | 3 | 418 | 9.33e-01 |
| GO:BP | GO:0002323 | natural killer cell activation involved in immune response | 1 | 6 | 9.34e-01 |
| GO:BP | GO:0051049 | regulation of transport | 11 | 1267 | 9.34e-01 |
| GO:BP | GO:0045132 | meiotic chromosome segregation | 2 | 64 | 9.35e-01 |
| GO:BP | GO:0043967 | histone H4 acetylation | 2 | 57 | 9.35e-01 |
| GO:BP | GO:0071825 | protein-lipid complex subunit organization | 1 | 29 | 9.35e-01 |
| GO:BP | GO:0048599 | oocyte development | 1 | 38 | 9.35e-01 |
| GO:BP | GO:0050900 | leukocyte migration | 16 | 209 | 9.35e-01 |
| GO:BP | GO:0002221 | pattern recognition receptor signaling pathway | 1 | 115 | 9.36e-01 |
| GO:BP | GO:0009166 | nucleotide catabolic process | 1 | 69 | 9.36e-01 |
| GO:BP | GO:0006956 | complement activation | 1 | 23 | 9.36e-01 |
| GO:BP | GO:0006378 | mRNA polyadenylation | 1 | 39 | 9.36e-01 |
| GO:BP | GO:1902600 | proton transmembrane transport | 1 | 111 | 9.36e-01 |
| GO:BP | GO:0015986 | proton motive force-driven ATP synthesis | 2 | 66 | 9.37e-01 |
| GO:BP | GO:1904019 | epithelial cell apoptotic process | 1 | 98 | 9.37e-01 |
| GO:BP | GO:0002886 | regulation of myeloid leukocyte mediated immunity | 2 | 34 | 9.37e-01 |
| GO:BP | GO:0006959 | humoral immune response | 1 | 80 | 9.37e-01 |
| GO:BP | GO:0019228 | neuronal action potential | 1 | 23 | 9.37e-01 |
| GO:BP | GO:0072522 | purine-containing compound biosynthetic process | 1 | 218 | 9.37e-01 |
| GO:BP | GO:0071840 | cellular component organization or biogenesis | 5 | 5274 | 9.39e-01 |
| GO:BP | GO:0032722 | positive regulation of chemokine production | 1 | 32 | 9.40e-01 |
| GO:BP | GO:0042157 | lipoprotein metabolic process | 4 | 116 | 9.40e-01 |
| GO:BP | GO:0044237 | cellular metabolic process | 5 | 6996 | 9.41e-01 |
| GO:BP | GO:0099024 | plasma membrane invagination | 2 | 42 | 9.41e-01 |
| GO:BP | GO:0060627 | regulation of vesicle-mediated transport | 28 | 403 | 9.41e-01 |
| GO:BP | GO:0072678 | T cell migration | 1 | 38 | 9.42e-01 |
| GO:BP | GO:0032892 | positive regulation of organic acid transport | 1 | 27 | 9.42e-01 |
| GO:BP | GO:0043631 | RNA polyadenylation | 1 | 41 | 9.43e-01 |
| GO:BP | GO:0002548 | monocyte chemotaxis | 2 | 22 | 9.43e-01 |
| GO:BP | GO:0032615 | interleukin-12 production | 1 | 29 | 9.43e-01 |
| GO:BP | GO:0032655 | regulation of interleukin-12 production | 1 | 29 | 9.43e-01 |
| GO:BP | GO:0016266 | O-glycan processing | 1 | 30 | 9.43e-01 |
| GO:BP | GO:0040014 | regulation of multicellular organism growth | 2 | 53 | 9.43e-01 |
| GO:BP | GO:0031099 | regeneration | 8 | 142 | 9.44e-01 |
| GO:BP | GO:0048525 | negative regulation of viral process | 2 | 64 | 9.44e-01 |
| GO:BP | GO:0009994 | oocyte differentiation | 1 | 39 | 9.44e-01 |
| GO:BP | GO:0008202 | steroid metabolic process | 1 | 204 | 9.44e-01 |
| GO:BP | GO:1901564 | organonitrogen compound metabolic process | 6 | 4955 | 9.45e-01 |
| GO:BP | GO:0031647 | regulation of protein stability | 1 | 290 | 9.45e-01 |
| GO:BP | GO:0006091 | generation of precursor metabolites and energy | 6 | 369 | 9.46e-01 |
| GO:BP | GO:0017158 | regulation of calcium ion-dependent exocytosis | 1 | 29 | 9.46e-01 |
| GO:BP | GO:0045685 | regulation of glial cell differentiation | 2 | 47 | 9.46e-01 |
| GO:BP | GO:0040008 | regulation of growth | 3 | 501 | 9.48e-01 |
| GO:BP | GO:0045776 | negative regulation of blood pressure | 1 | 30 | 9.48e-01 |
| GO:BP | GO:0032733 | positive regulation of interleukin-10 production | 1 | 16 | 9.48e-01 |
| GO:BP | GO:1905517 | macrophage migration | 1 | 34 | 9.48e-01 |
| GO:BP | GO:0007595 | lactation | 1 | 32 | 9.48e-01 |
| GO:BP | GO:0007200 | phospholipase C-activating G protein-coupled receptor signaling pathway | 3 | 40 | 9.48e-01 |
| GO:BP | GO:0015804 | neutral amino acid transport | 1 | 43 | 9.49e-01 |
| GO:BP | GO:0002758 | innate immune response-activating signaling pathway | 1 | 122 | 9.49e-01 |
| GO:BP | GO:0140352 | export from cell | 5 | 611 | 9.49e-01 |
| GO:BP | GO:0002690 | positive regulation of leukocyte chemotaxis | 3 | 51 | 9.50e-01 |
| GO:BP | GO:0019755 | one-carbon compound transport | 1 | 23 | 9.51e-01 |
| GO:BP | GO:0045104 | intermediate filament cytoskeleton organization | 3 | 39 | 9.51e-01 |
| GO:BP | GO:0018958 | phenol-containing compound metabolic process | 3 | 61 | 9.51e-01 |
| GO:BP | GO:0060688 | regulation of morphogenesis of a branching structure | 1 | 36 | 9.52e-01 |
| GO:BP | GO:0046596 | regulation of viral entry into host cell | 1 | 32 | 9.52e-01 |
| GO:BP | GO:0045454 | cell redox homeostasis | 1 | 38 | 9.52e-01 |
| GO:BP | GO:0051568 | histone H3-K4 methylation | 2 | 57 | 9.53e-01 |
| GO:BP | GO:0016573 | histone acetylation | 4 | 143 | 9.53e-01 |
| GO:BP | GO:1901292 | nucleoside phosphate catabolic process | 1 | 74 | 9.53e-01 |
| GO:BP | GO:0045103 | intermediate filament-based process | 3 | 40 | 9.53e-01 |
| GO:BP | GO:0016079 | synaptic vesicle exocytosis | 3 | 74 | 9.53e-01 |
| GO:BP | GO:0046434 | organophosphate catabolic process | 3 | 113 | 9.53e-01 |
| GO:BP | GO:0045761 | regulation of adenylate cyclase activity | 1 | 32 | 9.54e-01 |
| GO:BP | GO:0006801 | superoxide metabolic process | 1 | 42 | 9.56e-01 |
| GO:BP | GO:0006814 | sodium ion transport | 3 | 160 | 9.57e-01 |
| GO:BP | GO:0046006 | regulation of activated T cell proliferation | 1 | 21 | 9.57e-01 |
| GO:BP | GO:0006396 | RNA processing | 1 | 929 | 9.58e-01 |
| GO:BP | GO:0006493 | protein O-linked glycosylation | 3 | 69 | 9.58e-01 |
| GO:BP | GO:1901615 | organic hydroxy compound metabolic process | 2 | 376 | 9.58e-01 |
| GO:BP | GO:0032732 | positive regulation of interleukin-1 production | 2 | 35 | 9.59e-01 |
| GO:BP | GO:0002688 | regulation of leukocyte chemotaxis | 4 | 68 | 9.59e-01 |
| GO:BP | GO:1903305 | regulation of regulated secretory pathway | 5 | 89 | 9.60e-01 |
| GO:BP | GO:0030902 | hindbrain development | 3 | 114 | 9.60e-01 |
| GO:BP | GO:0042113 | B cell activation | 4 | 170 | 9.61e-01 |
| GO:BP | GO:0006066 | alcohol metabolic process | 1 | 265 | 9.61e-01 |
| GO:BP | GO:0050805 | negative regulation of synaptic transmission | 1 | 35 | 9.62e-01 |
| GO:BP | GO:0018393 | internal peptidyl-lysine acetylation | 4 | 148 | 9.63e-01 |
| GO:BP | GO:1990542 | mitochondrial transmembrane transport | 1 | 39 | 9.64e-01 |
| GO:BP | GO:0006584 | catecholamine metabolic process | 1 | 30 | 9.64e-01 |
| GO:BP | GO:0009712 | catechol-containing compound metabolic process | 1 | 30 | 9.64e-01 |
| GO:BP | GO:0050821 | protein stabilization | 1 | 191 | 9.65e-01 |
| GO:BP | GO:0007193 | adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway | 2 | 37 | 9.65e-01 |
| GO:BP | GO:0006475 | internal protein amino acid acetylation | 4 | 150 | 9.66e-01 |
| GO:BP | GO:0006835 | dicarboxylic acid transport | 1 | 62 | 9.66e-01 |
| GO:BP | GO:0045665 | negative regulation of neuron differentiation | 1 | 43 | 9.66e-01 |
| GO:BP | GO:0015695 | organic cation transport | 1 | 34 | 9.66e-01 |
| GO:BP | GO:0033003 | regulation of mast cell activation | 1 | 25 | 9.67e-01 |
| GO:BP | GO:0048708 | astrocyte differentiation | 2 | 58 | 9.67e-01 |
| GO:BP | GO:0051952 | regulation of amine transport | 3 | 55 | 9.67e-01 |
| GO:BP | GO:0050798 | activated T cell proliferation | 1 | 25 | 9.67e-01 |
| GO:BP | GO:0052372 | modulation by symbiont of entry into host | 1 | 38 | 9.69e-01 |
| GO:BP | GO:0007189 | adenylate cyclase-activating G protein-coupled receptor signaling pathway | 2 | 78 | 9.70e-01 |
| GO:BP | GO:0002220 | innate immune response activating cell surface receptor signaling pathway | 1 | 37 | 9.70e-01 |
| GO:BP | GO:0017157 | regulation of exocytosis | 8 | 147 | 9.71e-01 |
| GO:BP | GO:0016125 | sterol metabolic process | 1 | 111 | 9.71e-01 |
| GO:BP | GO:0001658 | branching involved in ureteric bud morphogenesis | 1 | 43 | 9.73e-01 |
| GO:BP | GO:0031279 | regulation of cyclase activity | 1 | 37 | 9.75e-01 |
| GO:BP | GO:0016042 | lipid catabolic process | 4 | 225 | 9.75e-01 |
| GO:BP | GO:0035195 | miRNA-mediated gene silencing | 1 | 55 | 9.75e-01 |
| GO:BP | GO:0035194 | ncRNA-mediated post-transcriptional gene silencing | 1 | 60 | 9.77e-01 |
| GO:BP | GO:0032355 | response to estradiol | 1 | 83 | 9.77e-01 |
| GO:BP | GO:0050794 | regulation of cellular process | 1 | 7552 | 9.77e-01 |
| GO:BP | GO:0016441 | post-transcriptional gene silencing | 1 | 65 | 9.77e-01 |
| GO:BP | GO:0051339 | regulation of lyase activity | 1 | 39 | 9.79e-01 |
| GO:BP | GO:0009060 | aerobic respiration | 2 | 168 | 9.79e-01 |
| GO:BP | GO:0070098 | chemokine-mediated signaling pathway | 1 | 28 | 9.79e-01 |
| GO:BP | GO:0050853 | B cell receptor signaling pathway | 1 | 32 | 9.79e-01 |
| GO:BP | GO:0045333 | cellular respiration | 7 | 211 | 9.79e-01 |
| GO:BP | GO:0043903 | regulation of biological process involved in symbiotic interaction | 1 | 40 | 9.80e-01 |
| GO:BP | GO:0097006 | regulation of plasma lipoprotein particle levels | 1 | 45 | 9.82e-01 |
| GO:BP | GO:0031124 | mRNA 3’-end processing | 1 | 58 | 9.82e-01 |
| GO:BP | GO:0006909 | phagocytosis | 8 | 148 | 9.83e-01 |
| GO:BP | GO:0006754 | ATP biosynthetic process | 2 | 87 | 9.84e-01 |
| GO:BP | GO:1902653 | secondary alcohol biosynthetic process | 1 | 46 | 9.84e-01 |
| GO:BP | GO:0006695 | cholesterol biosynthetic process | 1 | 46 | 9.84e-01 |
| GO:BP | GO:0030183 | B cell differentiation | 2 | 94 | 9.84e-01 |
| GO:BP | GO:0071715 | icosanoid transport | 1 | 24 | 9.87e-01 |
| GO:BP | GO:0007204 | positive regulation of cytosolic calcium ion concentration | 5 | 90 | 9.88e-01 |
| GO:BP | GO:0050832 | defense response to fungus | 1 | 14 | 9.89e-01 |
| GO:BP | GO:0070050 | neuron cellular homeostasis | 1 | 46 | 9.89e-01 |
| GO:BP | GO:0009206 | purine ribonucleoside triphosphate biosynthetic process | 2 | 96 | 9.92e-01 |
| GO:BP | GO:0006614 | SRP-dependent cotranslational protein targeting to membrane | 3 | 30 | 9.92e-01 |
| GO:BP | GO:0009145 | purine nucleoside triphosphate biosynthetic process | 2 | 97 | 9.93e-01 |
| GO:BP | GO:0042246 | tissue regeneration | 1 | 54 | 9.93e-01 |
| GO:BP | GO:0006613 | cotranslational protein targeting to membrane | 3 | 35 | 9.94e-01 |
| GO:BP | GO:0000381 | regulation of alternative mRNA splicing, via spliceosome | 1 | 53 | 9.94e-01 |
| GO:BP | GO:0045109 | intermediate filament organization | 1 | 21 | 9.95e-01 |
| GO:BP | GO:0030593 | neutrophil chemotaxis | 1 | 39 | 9.95e-01 |
| GO:BP | GO:0044238 | primary metabolic process | 2 | 7806 | 9.95e-01 |
| GO:BP | GO:0009201 | ribonucleoside triphosphate biosynthetic process | 2 | 102 | 9.95e-01 |
| GO:BP | GO:0006807 | nitrogen compound metabolic process | 1 | 7441 | 9.95e-01 |
| GO:BP | GO:0006865 | amino acid transport | 2 | 102 | 9.96e-01 |
| GO:BP | GO:0003333 | amino acid transmembrane transport | 1 | 71 | 9.96e-01 |
| GO:BP | GO:0045047 | protein targeting to ER | 3 | 49 | 9.97e-01 |
| GO:BP | GO:0009620 | response to fungus | 1 | 22 | 9.97e-01 |
| GO:BP | GO:0050906 | detection of stimulus involved in sensory perception | 2 | 39 | 9.97e-01 |
| GO:BP | GO:0072599 | establishment of protein localization to endoplasmic reticulum | 3 | 53 | 9.97e-01 |
| GO:BP | GO:0043170 | macromolecule metabolic process | 1 | 7069 | 9.97e-01 |
| GO:BP | GO:0019226 | transmission of nerve impulse | 1 | 40 | 9.97e-01 |
| GO:BP | GO:0046470 | phosphatidylcholine metabolic process | 1 | 53 | 9.98e-01 |
| GO:BP | GO:0050789 | regulation of biological process | 1 | 8061 | 9.98e-01 |
| GO:BP | GO:0007600 | sensory perception | 1 | 269 | 1.00e+00 |
| GO:BP | GO:0046034 | ATP metabolic process | 2 | 116 | 1.00e+00 |
| GO:BP | GO:0007608 | sensory perception of smell | 4 | 16 | 1.00e+00 |
| GO:BP | GO:0007606 | sensory perception of chemical stimulus | 4 | 31 | 1.00e+00 |
| GO:BP | GO:0065007 | biological regulation | 1 | 8320 | 1.00e+00 |
| GO:BP | GO:0007188 | adenylate cyclase-modulating G protein-coupled receptor signaling pathway | 2 | 118 | 1.00e+00 |
| GO:BP | GO:0000365 | mRNA trans splicing, via spliceosome | 1 | 6 | 1.00e+00 |
| GO:BP | GO:0045291 | mRNA trans splicing, SL addition | 1 | 6 | 1.00e+00 |
| GO:BP | GO:0006911 | phagocytosis, engulfment | 2 | 33 | 1.00e+00 |
| GO:BP | GO:0006617 | SRP-dependent cotranslational protein targeting to membrane, signal sequence recognition | 1 | 17 | 1.00e+00 |
| GO:BP | GO:0006397 | mRNA processing | 1 | 450 | 1.00e+00 |
| GO:BP | GO:0050877 | nervous system process | 2 | 634 | 1.00e+00 |
| GO:BP | GO:0070972 | protein localization to endoplasmic reticulum | 3 | 78 | 1.00e+00 |
| GO:BP | GO:0008150 | biological_process | 1 | 12070 | 1.00e+00 |
| GO:BP | GO:0000353 | formation of quadruple SL/U4/U5/U6 snRNP | 1 | 6 | 1.00e+00 |
| GO:BP | GO:0008152 | metabolic process | 1 | 8518 | 1.00e+00 |
| GO:BP | GO:0071704 | organic substance metabolic process | 1 | 8169 | 1.00e+00 |
| GO:BP | GO:0000375 | RNA splicing, via transesterification reactions | 1 | 293 | 1.00e+00 |
| GO:BP | GO:0000377 | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 1 | 289 | 1.00e+00 |
| GO:BP | GO:0000387 | spliceosomal snRNP assembly | 1 | 45 | 1.00e+00 |
| GO:BP | GO:0000398 | mRNA splicing, via spliceosome | 1 | 289 | 1.00e+00 |
| GO:BP | GO:0030317 | flagellated sperm motility | 1 | 61 | 1.00e+00 |
| GO:BP | GO:0048024 | regulation of mRNA splicing, via spliceosome | 1 | 96 | 1.00e+00 |
| GO:BP | GO:0071621 | granulocyte chemotaxis | 1 | 53 | 1.00e+00 |
| GO:BP | GO:0000245 | spliceosomal complex assembly | 1 | 73 | 1.00e+00 |
| GO:BP | GO:0097722 | sperm motility | 1 | 61 | 1.00e+00 |
| GO:BP | GO:0009987 | cellular process | 1 | 11336 | 1.00e+00 |
| GO:BP | GO:0009593 | detection of chemical stimulus | 1 | 27 | 1.00e+00 |
| GO:BP | GO:1902652 | secondary alcohol metabolic process | 2 | 108 | 1.00e+00 |
| GO:BP | GO:0008380 | RNA splicing | 1 | 419 | 1.00e+00 |
| GO:BP | GO:0008203 | cholesterol metabolic process | 2 | 101 | 1.00e+00 |
| GO:BP | GO:0000244 | spliceosomal tri-snRNP complex assembly | 1 | 20 | 1.00e+00 |
| GO:BP | GO:0051606 | detection of stimulus | 3 | 110 | 1.00e+00 |
| KEGG | KEGG:04726 | Serotonergic synapse | 7 | 63 | 6.86e-02 |
| KEGG | KEGG:04720 | Long-term potentiation | 6 | 55 | 6.86e-02 |
| KEGG | KEGG:04922 | Glucagon signaling pathway | 9 | 84 | 6.86e-02 |
| KEGG | KEGG:04022 | cGMP-PKG signaling pathway | 9 | 133 | 6.86e-02 |
| KEGG | KEGG:05230 | Central carbon metabolism in cancer | 7 | 62 | 6.86e-02 |
| KEGG | KEGG:05010 | Alzheimer disease | 19 | 315 | 6.86e-02 |
| KEGG | KEGG:04218 | Cellular senescence | 8 | 145 | 7.89e-02 |
| KEGG | KEGG:04929 | GnRH secretion | 6 | 53 | 7.89e-02 |
| KEGG | KEGG:05017 | Spinocerebellar ataxia | 11 | 124 | 7.89e-02 |
| KEGG | KEGG:04935 | Growth hormone synthesis, secretion and action | 9 | 98 | 1.01e-01 |
| KEGG | KEGG:04015 | Rap1 signaling pathway | 24 | 164 | 1.11e-01 |
| KEGG | KEGG:05210 | Colorectal cancer | 9 | 84 | 1.11e-01 |
| KEGG | KEGG:04371 | Apelin signaling pathway | 13 | 106 | 1.11e-01 |
| KEGG | KEGG:04933 | AGE-RAGE signaling pathway in diabetic complications | 13 | 91 | 1.40e-01 |
| KEGG | KEGG:05222 | Small cell lung cancer | 8 | 87 | 1.42e-01 |
| KEGG | KEGG:04370 | VEGF signaling pathway | 6 | 49 | 1.42e-01 |
| KEGG | KEGG:04213 | Longevity regulating pathway - multiple species | 6 | 55 | 1.42e-01 |
| KEGG | KEGG:00900 | Terpenoid backbone biosynthesis | 1 | 21 | 1.43e-01 |
| KEGG | KEGG:05031 | Amphetamine addiction | 4 | 49 | 1.50e-01 |
| KEGG | KEGG:00590 | Arachidonic acid metabolism | 1 | 26 | 1.50e-01 |
| KEGG | KEGG:03050 | Proteasome | 4 | 42 | 1.50e-01 |
| KEGG | KEGG:05166 | Human T-cell leukemia virus 1 infection | 7 | 180 | 1.50e-01 |
| KEGG | KEGG:05211 | Renal cell carcinoma | 5 | 65 | 1.50e-01 |
| KEGG | KEGG:04730 | Long-term depression | 4 | 42 | 1.50e-01 |
| KEGG | KEGG:04071 | Sphingolipid signaling pathway | 9 | 107 | 1.50e-01 |
| KEGG | KEGG:05212 | Pancreatic cancer | 10 | 75 | 1.50e-01 |
| KEGG | KEGG:04270 | Vascular smooth muscle contraction | 6 | 94 | 1.50e-01 |
| KEGG | KEGG:04360 | Axon guidance | 12 | 162 | 1.50e-01 |
| KEGG | KEGG:04725 | Cholinergic synapse | 7 | 83 | 1.50e-01 |
| KEGG | KEGG:04728 | Dopaminergic synapse | 6 | 103 | 1.50e-01 |
| KEGG | KEGG:04072 | Phospholipase D signaling pathway | 16 | 110 | 1.52e-01 |
| KEGG | KEGG:04924 | Renin secretion | 4 | 50 | 1.58e-01 |
| KEGG | KEGG:04140 | Autophagy - animal | 9 | 133 | 1.58e-01 |
| KEGG | KEGG:04611 | Platelet activation | 7 | 89 | 1.58e-01 |
| KEGG | KEGG:04625 | C-type lectin receptor signaling pathway | 5 | 76 | 1.58e-01 |
| KEGG | KEGG:04010 | MAPK signaling pathway | 25 | 240 | 1.58e-01 |
| KEGG | KEGG:00250 | Alanine, aspartate and glutamate metabolism | 3 | 29 | 1.61e-01 |
| KEGG | KEGG:04919 | Thyroid hormone signaling pathway | 5 | 112 | 1.61e-01 |
| KEGG | KEGG:00220 | Arginine biosynthesis | 3 | 16 | 1.62e-01 |
| KEGG | KEGG:05034 | Alcoholism | 7 | 122 | 1.62e-01 |
| KEGG | KEGG:04613 | Neutrophil extracellular trap formation | 7 | 110 | 1.62e-01 |
| KEGG | KEGG:04510 | Focal adhesion | 21 | 177 | 1.62e-01 |
| KEGG | KEGG:04210 | Apoptosis | 9 | 118 | 1.73e-01 |
| KEGG | KEGG:04217 | Necroptosis | 6 | 106 | 1.75e-01 |
| KEGG | KEGG:05225 | Hepatocellular carcinoma | 14 | 145 | 1.75e-01 |
| KEGG | KEGG:04921 | Oxytocin signaling pathway | 6 | 115 | 1.75e-01 |
| KEGG | KEGG:04261 | Adrenergic signaling in cardiomyocytes | 6 | 128 | 1.75e-01 |
| KEGG | KEGG:04920 | Adipocytokine signaling pathway | 5 | 51 | 1.77e-01 |
| KEGG | KEGG:04350 | TGF-beta signaling pathway | 7 | 84 | 1.78e-01 |
| KEGG | KEGG:04961 | Endocrine and other factor-regulated calcium reabsorption | 6 | 41 | 1.80e-01 |
| KEGG | KEGG:00534 | Glycosaminoglycan biosynthesis - heparan sulfate / heparin | 1 | 20 | 1.85e-01 |
| KEGG | KEGG:04664 | Fc epsilon RI signaling pathway | 3 | 46 | 1.88e-01 |
| KEGG | KEGG:05213 | Endometrial cancer | 5 | 57 | 1.90e-01 |
| KEGG | KEGG:04540 | Gap junction | 9 | 73 | 1.90e-01 |
| KEGG | KEGG:04923 | Regulation of lipolysis in adipocytes | 4 | 41 | 1.95e-01 |
| KEGG | KEGG:00515 | Mannose type O-glycan biosynthesis | 2 | 19 | 1.95e-01 |
| KEGG | KEGG:04146 | Peroxisome | 1 | 68 | 1.97e-01 |
| KEGG | KEGG:05145 | Toxoplasmosis | 6 | 82 | 2.02e-01 |
| KEGG | KEGG:05012 | Parkinson disease | 9 | 226 | 2.02e-01 |
| KEGG | KEGG:00983 | Drug metabolism - other enzymes | 2 | 44 | 2.02e-01 |
| KEGG | KEGG:05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 6 | 69 | 2.02e-01 |
| KEGG | KEGG:01521 | EGFR tyrosine kinase inhibitor resistance | 8 | 74 | 2.02e-01 |
| KEGG | KEGG:05221 | Acute myeloid leukemia | 5 | 56 | 2.02e-01 |
| KEGG | KEGG:05200 | Pathways in cancer | 30 | 409 | 2.02e-01 |
| KEGG | KEGG:04211 | Longevity regulating pathway | 6 | 78 | 2.02e-01 |
| KEGG | KEGG:04926 | Relaxin signaling pathway | 13 | 104 | 2.05e-01 |
| KEGG | KEGG:04668 | TNF signaling pathway | 11 | 87 | 2.05e-01 |
| KEGG | KEGG:04068 | FoxO signaling pathway | 4 | 109 | 2.09e-01 |
| KEGG | KEGG:04912 | GnRH signaling pathway | 4 | 76 | 2.11e-01 |
| KEGG | KEGG:00601 | Glycosphingolipid biosynthesis - lacto and neolacto series | 2 | 14 | 2.11e-01 |
| KEGG | KEGG:04964 | Proximal tubule bicarbonate reclamation | 2 | 20 | 2.15e-01 |
| KEGG | KEGG:05223 | Non-small cell lung cancer | 6 | 67 | 2.15e-01 |
| KEGG | KEGG:04662 | B cell receptor signaling pathway | 3 | 56 | 2.16e-01 |
| KEGG | KEGG:04750 | Inflammatory mediator regulation of TRP channels | 4 | 72 | 2.30e-01 |
| KEGG | KEGG:05022 | Pathways of neurodegeneration - multiple diseases | 10 | 385 | 2.30e-01 |
| KEGG | KEGG:04012 | ErbB signaling pathway | 9 | 78 | 2.37e-01 |
| KEGG | KEGG:01250 | Biosynthesis of nucleotide sugars | 4 | 35 | 2.40e-01 |
| KEGG | KEGG:01524 | Platinum drug resistance | 4 | 65 | 2.66e-01 |
| KEGG | KEGG:04927 | Cortisol synthesis and secretion | 3 | 48 | 2.66e-01 |
| KEGG | KEGG:00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 1 | 13 | 2.71e-01 |
| KEGG | KEGG:04660 | T cell receptor signaling pathway | 5 | 70 | 2.74e-01 |
| KEGG | KEGG:04973 | Carbohydrate digestion and absorption | 3 | 31 | 2.77e-01 |
| KEGG | KEGG:04911 | Insulin secretion | 3 | 64 | 2.77e-01 |
| KEGG | KEGG:05163 | Human cytomegalovirus infection | 11 | 176 | 2.77e-01 |
| KEGG | KEGG:05224 | Breast cancer | 10 | 117 | 2.80e-01 |
| KEGG | KEGG:04931 | Insulin resistance | 5 | 95 | 2.85e-01 |
| KEGG | KEGG:04917 | Prolactin signaling pathway | 4 | 56 | 2.85e-01 |
| KEGG | KEGG:05168 | Herpes simplex virus 1 infection | 24 | 415 | 2.92e-01 |
| KEGG | KEGG:04330 | Notch signaling pathway | 5 | 51 | 2.94e-01 |
| KEGG | KEGG:05131 | Shigellosis | 22 | 210 | 2.94e-01 |
| KEGG | KEGG:04216 | Ferroptosis | 3 | 33 | 2.94e-01 |
| KEGG | KEGG:05226 | Gastric cancer | 8 | 117 | 2.94e-01 |
| KEGG | KEGG:00760 | Nicotinate and nicotinamide metabolism | 3 | 28 | 2.94e-01 |
| KEGG | KEGG:03060 | Protein export | 3 | 23 | 2.94e-01 |
| KEGG | KEGG:04930 | Type II diabetes mellitus | 3 | 35 | 2.96e-01 |
| KEGG | KEGG:04910 | Insulin signaling pathway | 7 | 121 | 2.96e-01 |
| KEGG | KEGG:00470 | D-Amino acid metabolism | 1 | 4 | 2.96e-01 |
| KEGG | KEGG:03013 | Nucleocytoplasmic transport | 6 | 99 | 3.06e-01 |
| KEGG | KEGG:05417 | Lipid and atherosclerosis | 5 | 153 | 3.06e-01 |
| KEGG | KEGG:04713 | Circadian entrainment | 3 | 69 | 3.06e-01 |
| KEGG | KEGG:05415 | Diabetic cardiomyopathy | 5 | 169 | 3.06e-01 |
| KEGG | KEGG:03410 | Base excision repair | 3 | 33 | 3.06e-01 |
| KEGG | KEGG:05020 | Prion disease | 8 | 220 | 3.06e-01 |
| KEGG | KEGG:01522 | Endocrine resistance | 9 | 85 | 3.06e-01 |
| KEGG | KEGG:04070 | Phosphatidylinositol signaling system | 8 | 91 | 3.06e-01 |
| KEGG | KEGG:04120 | Ubiquitin mediated proteolysis | 3 | 134 | 3.06e-01 |
| KEGG | KEGG:05217 | Basal cell carcinoma | 5 | 49 | 3.06e-01 |
| KEGG | KEGG:04724 | Glutamatergic synapse | 4 | 74 | 3.06e-01 |
| KEGG | KEGG:05170 | Human immunodeficiency virus 1 infection | 11 | 165 | 3.09e-01 |
| KEGG | KEGG:04915 | Estrogen signaling pathway | 9 | 97 | 3.17e-01 |
| KEGG | KEGG:04020 | Calcium signaling pathway | 17 | 157 | 3.21e-01 |
| KEGG | KEGG:05205 | Proteoglycans in cancer | 18 | 170 | 3.21e-01 |
| KEGG | KEGG:00670 | One carbon pool by folate | 2 | 18 | 3.29e-01 |
| KEGG | KEGG:04722 | Neurotrophin signaling pathway | 3 | 110 | 3.29e-01 |
| KEGG | KEGG:04114 | Oocyte meiosis | 4 | 108 | 3.29e-01 |
| KEGG | KEGG:00780 | Biotin metabolism | 1 | 3 | 3.31e-01 |
| KEGG | KEGG:00562 | Inositol phosphate metabolism | 7 | 66 | 3.37e-01 |
| KEGG | KEGG:04621 | NOD-like receptor signaling pathway | 5 | 117 | 3.39e-01 |
| KEGG | KEGG:04925 | Aldosterone synthesis and secretion | 4 | 77 | 3.42e-01 |
| KEGG | KEGG:04014 | Ras signaling pathway | 8 | 171 | 3.42e-01 |
| KEGG | KEGG:00240 | Pyrimidine metabolism | 1 | 46 | 3.48e-01 |
| KEGG | KEGG:00051 | Fructose and mannose metabolism | 4 | 27 | 3.49e-01 |
| KEGG | KEGG:04137 | Mitophagy - animal | 4 | 70 | 3.51e-01 |
| KEGG | KEGG:00910 | Nitrogen metabolism | 1 | 10 | 3.51e-01 |
| KEGG | KEGG:04130 | SNARE interactions in vesicular transport | 1 | 32 | 3.51e-01 |
| KEGG | KEGG:05214 | Glioma | 5 | 67 | 3.55e-01 |
| KEGG | KEGG:04810 | Regulation of actin cytoskeleton | 10 | 179 | 3.57e-01 |
| KEGG | KEGG:04970 | Salivary secretion | 3 | 55 | 3.57e-01 |
| KEGG | KEGG:04390 | Hippo signaling pathway | 14 | 134 | 3.65e-01 |
| KEGG | KEGG:03015 | mRNA surveillance pathway | 5 | 86 | 3.65e-01 |
| KEGG | KEGG:01240 | Biosynthesis of cofactors | 3 | 115 | 3.65e-01 |
| KEGG | KEGG:04310 | Wnt signaling pathway | 14 | 138 | 3.65e-01 |
| KEGG | KEGG:04151 | PI3K-Akt signaling pathway | 6 | 254 | 3.65e-01 |
| KEGG | KEGG:05016 | Huntington disease | 6 | 256 | 3.65e-01 |
| KEGG | KEGG:05164 | Influenza A | 9 | 103 | 3.76e-01 |
| KEGG | KEGG:05231 | Choline metabolism in cancer | 5 | 84 | 3.76e-01 |
| KEGG | KEGG:04380 | Osteoclast differentiation | 5 | 87 | 3.77e-01 |
| KEGG | KEGG:04066 | HIF-1 signaling pathway | 2 | 89 | 3.81e-01 |
| KEGG | KEGG:05207 | Chemical carcinogenesis - receptor activation | 4 | 142 | 3.81e-01 |
| KEGG | KEGG:04976 | Bile secretion | 1 | 42 | 3.81e-01 |
| KEGG | KEGG:05218 | Melanoma | 2 | 58 | 3.81e-01 |
| KEGG | KEGG:03250 | Viral life cycle - HIV-1 | 5 | 56 | 3.82e-01 |
| KEGG | KEGG:04666 | Fc gamma R-mediated phagocytosis | 5 | 75 | 3.82e-01 |
| KEGG | KEGG:05143 | African trypanosomiasis | 3 | 16 | 3.82e-01 |
| KEGG | KEGG:05152 | Tuberculosis | 3 | 106 | 3.82e-01 |
| KEGG | KEGG:00513 | Various types of N-glycan biosynthesis | 1 | 36 | 3.82e-01 |
| KEGG | KEGG:00970 | Aminoacyl-tRNA biosynthesis | 1 | 44 | 3.82e-01 |
| KEGG | KEGG:00770 | Pantothenate and CoA biosynthesis | 1 | 15 | 3.82e-01 |
| KEGG | KEGG:03450 | Non-homologous end-joining | 2 | 12 | 3.82e-01 |
| KEGG | KEGG:05220 | Chronic myeloid leukemia | 2 | 75 | 3.82e-01 |
| KEGG | KEGG:03430 | Mismatch repair | 2 | 22 | 3.82e-01 |
| KEGG | KEGG:05167 | Kaposi sarcoma-associated herpesvirus infection | 11 | 145 | 3.82e-01 |
| KEGG | KEGG:01232 | Nucleotide metabolism | 1 | 69 | 3.90e-01 |
| KEGG | KEGG:05208 | Chemical carcinogenesis - reactive oxygen species | 4 | 186 | 3.93e-01 |
| KEGG | KEGG:00860 | Porphyrin metabolism | 1 | 22 | 3.95e-01 |
| KEGG | KEGG:00520 | Amino sugar and nucleotide sugar metabolism | 5 | 46 | 3.99e-01 |
| KEGG | KEGG:05416 | Viral myocarditis | 5 | 40 | 4.04e-01 |
| KEGG | KEGG:00480 | Glutathione metabolism | 1 | 44 | 4.11e-01 |
| KEGG | KEGG:04064 | NF-kappa B signaling pathway | 5 | 71 | 4.15e-01 |
| KEGG | KEGG:04150 | mTOR signaling pathway | 3 | 135 | 4.15e-01 |
| KEGG | KEGG:00514 | Other types of O-glycan biosynthesis | 1 | 37 | 4.15e-01 |
| KEGG | KEGG:03008 | Ribosome biogenesis in eukaryotes | 8 | 75 | 4.15e-01 |
| KEGG | KEGG:00310 | Lysine degradation | 6 | 59 | 4.24e-01 |
| KEGG | KEGG:01523 | Antifolate resistance | 2 | 24 | 4.24e-01 |
| KEGG | KEGG:04916 | Melanogenesis | 6 | 77 | 4.24e-01 |
| KEGG | KEGG:05219 | Bladder cancer | 4 | 37 | 4.24e-01 |
| KEGG | KEGG:00510 | N-Glycan biosynthesis | 1 | 48 | 4.24e-01 |
| KEGG | KEGG:05134 | Legionellosis | 1 | 39 | 4.24e-01 |
| KEGG | KEGG:04141 | Protein processing in endoplasmic reticulum | 2 | 161 | 4.39e-01 |
| KEGG | KEGG:05418 | Fluid shear stress and atherosclerosis | 2 | 114 | 4.43e-01 |
| KEGG | KEGG:05204 | Chemical carcinogenesis - DNA adducts | 1 | 23 | 4.45e-01 |
| KEGG | KEGG:04024 | cAMP signaling pathway | 10 | 151 | 4.47e-01 |
| KEGG | KEGG:00982 | Drug metabolism - cytochrome P450 | 1 | 21 | 4.47e-01 |
| KEGG | KEGG:04152 | AMPK signaling pathway | 2 | 103 | 4.58e-01 |
| KEGG | KEGG:05014 | Amyotrophic lateral sclerosis | 6 | 303 | 4.62e-01 |
| KEGG | KEGG:04610 | Complement and coagulation cascades | 1 | 40 | 4.62e-01 |
| KEGG | KEGG:00980 | Metabolism of xenobiotics by cytochrome P450 | 1 | 26 | 4.63e-01 |
| KEGG | KEGG:05215 | Prostate cancer | 2 | 86 | 4.63e-01 |
| KEGG | KEGG:04062 | Chemokine signaling pathway | 10 | 113 | 4.63e-01 |
| KEGG | KEGG:04550 | Signaling pathways regulating pluripotency of stem cells | 6 | 104 | 4.67e-01 |
| KEGG | KEGG:05410 | Hypertrophic cardiomyopathy | 5 | 73 | 4.75e-01 |
| KEGG | KEGG:04727 | GABAergic synapse | 3 | 55 | 4.75e-01 |
| KEGG | KEGG:05142 | Chagas disease | 8 | 75 | 4.83e-01 |
| KEGG | KEGG:05322 | Systemic lupus erythematosus | 3 | 61 | 4.83e-01 |
| KEGG | KEGG:04658 | Th1 and Th2 cell differentiation | 7 | 53 | 4.95e-01 |
| KEGG | KEGG:03040 | Spliceosome | 6 | 132 | 4.95e-01 |
| KEGG | KEGG:04122 | Sulfur relay system | 1 | 8 | 4.95e-01 |
| KEGG | KEGG:04110 | Cell cycle | 1 | 151 | 4.95e-01 |
| KEGG | KEGG:04918 | Thyroid hormone synthesis | 2 | 55 | 4.95e-01 |
| KEGG | KEGG:05165 | Human papillomavirus infection | 12 | 272 | 4.95e-01 |
| KEGG | KEGG:01230 | Biosynthesis of amino acids | 4 | 60 | 4.95e-01 |
| KEGG | KEGG:00532 | Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 1 | 21 | 4.95e-01 |
| KEGG | KEGG:04971 | Gastric acid secretion | 2 | 52 | 4.97e-01 |
| KEGG | KEGG:01100 | Metabolic pathways | 1 | 1146 | 4.97e-01 |
| KEGG | KEGG:05414 | Dilated cardiomyopathy | 5 | 78 | 5.02e-01 |
| KEGG | KEGG:04936 | Alcoholic liver disease | 2 | 97 | 5.04e-01 |
| KEGG | KEGG:05146 | Amoebiasis | 2 | 64 | 5.04e-01 |
| KEGG | KEGG:00450 | Selenocompound metabolism | 1 | 14 | 5.04e-01 |
| KEGG | KEGG:00232 | Caffeine metabolism | 1 | 1 | 5.04e-01 |
| KEGG | KEGG:05135 | Yersinia infection | 6 | 112 | 5.04e-01 |
| KEGG | KEGG:03420 | Nucleotide excision repair | 3 | 43 | 5.04e-01 |
| KEGG | KEGG:05216 | Thyroid cancer | 2 | 35 | 5.04e-01 |
| KEGG | KEGG:04913 | Ovarian steroidogenesis | 1 | 28 | 5.04e-01 |
| KEGG | KEGG:05132 | Salmonella infection | 18 | 214 | 5.10e-01 |
| KEGG | KEGG:04215 | Apoptosis - multiple species | 1 | 30 | 5.31e-01 |
| KEGG | KEGG:03030 | DNA replication | 2 | 35 | 5.34e-01 |
| KEGG | KEGG:05412 | Arrhythmogenic right ventricular cardiomyopathy | 1 | 63 | 5.36e-01 |
| KEGG | KEGG:04979 | Cholesterol metabolism | 1 | 33 | 5.40e-01 |
| KEGG | KEGG:04650 | Natural killer cell mediated cytotoxicity | 2 | 63 | 5.41e-01 |
| KEGG | KEGG:00920 | Sulfur metabolism | 1 | 10 | 5.41e-01 |
| KEGG | KEGG:00563 | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 2 | 25 | 5.41e-01 |
| KEGG | KEGG:05203 | Viral carcinogenesis | 1 | 172 | 5.41e-01 |
| KEGG | KEGG:04723 | Retrograde endocannabinoid signaling | 3 | 99 | 5.44e-01 |
| KEGG | KEGG:05206 | MicroRNAs in cancer | 7 | 149 | 5.54e-01 |
| KEGG | KEGG:05030 | Cocaine addiction | 1 | 35 | 5.58e-01 |
| KEGG | KEGG:04260 | Cardiac muscle contraction | 1 | 67 | 5.63e-01 |
| KEGG | KEGG:04934 | Cushing syndrome | 3 | 121 | 5.63e-01 |
| KEGG | KEGG:05100 | Bacterial invasion of epithelial cells | 4 | 74 | 5.64e-01 |
| KEGG | KEGG:04710 | Circadian rhythm | 1 | 30 | 5.64e-01 |
| KEGG | KEGG:05120 | Epithelial cell signaling in Helicobacter pylori infection | 5 | 58 | 5.64e-01 |
| KEGG | KEGG:03440 | Homologous recombination | 1 | 39 | 5.64e-01 |
| KEGG | KEGG:05033 | Nicotine addiction | 2 | 12 | 5.69e-01 |
| KEGG | KEGG:00630 | Glyoxylate and dicarboxylate metabolism | 2 | 25 | 5.78e-01 |
| KEGG | KEGG:04512 | ECM-receptor interaction | 1 | 69 | 5.78e-01 |
| KEGG | KEGG:01210 | 2-Oxocarboxylic acid metabolism | 1 | 17 | 5.78e-01 |
| KEGG | KEGG:00790 | Folate biosynthesis | 1 | 18 | 5.82e-01 |
| KEGG | KEGG:03266 | Virion - Herpesvirus | 1 | 6 | 5.82e-01 |
| KEGG | KEGG:00620 | Pyruvate metabolism | 2 | 33 | 5.87e-01 |
| KEGG | KEGG:01200 | Carbon metabolism | 5 | 98 | 5.91e-01 |
| KEGG | KEGG:04972 | Pancreatic secretion | 2 | 58 | 5.99e-01 |
| KEGG | KEGG:04657 | IL-17 signaling pathway | 3 | 56 | 6.01e-01 |
| KEGG | KEGG:05310 | Asthma | 2 | 3 | 6.14e-01 |
| KEGG | KEGG:04659 | Th17 cell differentiation | 7 | 64 | 6.14e-01 |
| KEGG | KEGG:04928 | Parathyroid hormone synthesis, secretion and action | 2 | 82 | 6.14e-01 |
| KEGG | KEGG:01040 | Biosynthesis of unsaturated fatty acids | 2 | 24 | 6.14e-01 |
| KEGG | KEGG:00062 | Fatty acid elongation | 2 | 24 | 6.14e-01 |
| KEGG | KEGG:05321 | Inflammatory bowel disease | 4 | 22 | 6.14e-01 |
| KEGG | KEGG:04914 | Progesterone-mediated oocyte maturation | 6 | 86 | 6.19e-01 |
| KEGG | KEGG:04392 | Hippo signaling pathway - multiple species | 2 | 25 | 6.23e-01 |
| KEGG | KEGG:05160 | Hepatitis C | 2 | 115 | 6.27e-01 |
| KEGG | KEGG:04670 | Leukocyte transendothelial migration | 4 | 79 | 6.27e-01 |
| KEGG | KEGG:04144 | Endocytosis | 17 | 232 | 6.27e-01 |
| KEGG | KEGG:04145 | Phagosome | 1 | 99 | 6.30e-01 |
| KEGG | KEGG:04721 | Synaptic vesicle cycle | 3 | 51 | 6.36e-01 |
| KEGG | KEGG:00604 | Glycosphingolipid biosynthesis - ganglio series | 1 | 12 | 6.36e-01 |
| KEGG | KEGG:00600 | Sphingolipid metabolism | 2 | 44 | 6.36e-01 |
| KEGG | KEGG:05161 | Hepatitis B | 2 | 136 | 6.36e-01 |
| KEGG | KEGG:04620 | Toll-like receptor signaling pathway | 1 | 60 | 6.37e-01 |
| KEGG | KEGG:04978 | Mineral absorption | 3 | 42 | 6.37e-01 |
| KEGG | KEGG:04630 | JAK-STAT signaling pathway | 2 | 88 | 6.44e-01 |
| KEGG | KEGG:05169 | Epstein-Barr virus infection | 7 | 153 | 6.57e-01 |
| KEGG | KEGG:00270 | Cysteine and methionine metabolism | 3 | 38 | 6.65e-01 |
| KEGG | KEGG:04622 | RIG-I-like receptor signaling pathway | 3 | 49 | 6.65e-01 |
| KEGG | KEGG:00260 | Glycine, serine and threonine metabolism | 2 | 31 | 6.65e-01 |
| KEGG | KEGG:04612 | Antigen processing and presentation | 4 | 41 | 6.74e-01 |
| KEGG | KEGG:05202 | Transcriptional misregulation in cancer | 8 | 128 | 6.76e-01 |
| KEGG | KEGG:04142 | Lysosome | 3 | 118 | 6.82e-01 |
| KEGG | KEGG:05330 | Allograft rejection | 2 | 10 | 7.06e-01 |
| KEGG | KEGG:00061 | Fatty acid biosynthesis | 1 | 12 | 7.44e-01 |
| KEGG | KEGG:05162 | Measles | 1 | 98 | 7.44e-01 |
| KEGG | KEGG:00730 | Thiamine metabolism | 1 | 10 | 7.44e-01 |
| KEGG | KEGG:04614 | Renin-angiotensin system | 1 | 12 | 7.45e-01 |
| KEGG | KEGG:05332 | Graft-versus-host disease | 2 | 10 | 7.45e-01 |
| KEGG | KEGG:04742 | Taste transduction | 1 | 22 | 7.45e-01 |
| KEGG | KEGG:04640 | Hematopoietic cell lineage | 5 | 31 | 7.45e-01 |
| KEGG | KEGG:04340 | Hedgehog signaling pathway | 2 | 49 | 7.48e-01 |
| KEGG | KEGG:04514 | Cell adhesion molecules | 9 | 83 | 7.48e-01 |
| KEGG | KEGG:01212 | Fatty acid metabolism | 3 | 50 | 7.48e-01 |
| KEGG | KEGG:04932 | Non-alcoholic fatty liver disease | 4 | 131 | 7.48e-01 |
| KEGG | KEGG:04940 | Type I diabetes mellitus | 2 | 15 | 7.77e-01 |
| KEGG | KEGG:04115 | p53 signaling pathway | 4 | 65 | 7.77e-01 |
| KEGG | KEGG:00030 | Pentose phosphate pathway | 1 | 24 | 7.96e-01 |
| KEGG | KEGG:04714 | Thermogenesis | 2 | 195 | 7.99e-01 |
| KEGG | KEGG:04623 | Cytosolic DNA-sensing pathway | 4 | 42 | 7.99e-01 |
| KEGG | KEGG:03022 | Basal transcription factors | 1 | 40 | 8.01e-01 |
| KEGG | KEGG:05130 | Pathogenic Escherichia coli infection | 11 | 150 | 8.16e-01 |
| KEGG | KEGG:04672 | Intestinal immune network for IgA production | 2 | 12 | 8.16e-01 |
| KEGG | KEGG:04060 | Cytokine-cytokine receptor interaction | 1 | 98 | 8.16e-01 |
| KEGG | KEGG:04977 | Vitamin digestion and absorption | 1 | 14 | 8.16e-01 |
| KEGG | KEGG:02010 | ABC transporters | 2 | 29 | 8.27e-01 |
| KEGG | KEGG:00100 | Steroid biosynthesis | 1 | 17 | 8.47e-01 |
| KEGG | KEGG:00330 | Arginine and proline metabolism | 2 | 38 | 8.62e-01 |
| KEGG | KEGG:05320 | Autoimmune thyroid disease | 2 | 11 | 8.62e-01 |
| KEGG | KEGG:04975 | Fat digestion and absorption | 2 | 19 | 8.65e-01 |
| KEGG | KEGG:00010 | Glycolysis / Gluconeogenesis | 1 | 44 | 8.68e-01 |
| KEGG | KEGG:00640 | Propanoate metabolism | 1 | 28 | 8.71e-01 |
| KEGG | KEGG:05144 | Malaria | 1 | 20 | 8.75e-01 |
| KEGG | KEGG:04520 | Adherens junction | 3 | 67 | 8.79e-01 |
| KEGG | KEGG:00000 | KEGG root term | 3 | 5558 | 9.07e-01 |
| KEGG | KEGG:05150 | Staphylococcus aureus infection | 3 | 18 | 9.33e-01 |
| KEGG | KEGG:03460 | Fanconi anemia pathway | 1 | 48 | 9.33e-01 |
| KEGG | KEGG:00830 | Retinol metabolism | 2 | 16 | 9.33e-01 |
| KEGG | KEGG:00052 | Galactose metabolism | 1 | 22 | 9.33e-01 |
| KEGG | KEGG:03320 | PPAR signaling pathway | 3 | 50 | 9.33e-01 |
| KEGG | KEGG:00565 | Ether lipid metabolism | 1 | 28 | 9.33e-01 |
| KEGG | KEGG:04136 | Autophagy - other | 1 | 31 | 9.33e-01 |
| KEGG | KEGG:03020 | RNA polymerase | 1 | 34 | 9.33e-01 |
| KEGG | KEGG:05323 | Rheumatoid arthritis | 3 | 43 | 9.36e-01 |
| KEGG | KEGG:00512 | Mucin type O-glycan biosynthesis | 1 | 22 | 9.37e-01 |
| KEGG | KEGG:00040 | Pentose and glucuronate interconversions | 1 | 12 | 9.37e-01 |
| KEGG | KEGG:05340 | Primary immunodeficiency | 1 | 12 | 9.37e-01 |
| KEGG | KEGG:03010 | Ribosome | 4 | 127 | 9.37e-01 |
| KEGG | KEGG:00071 | Fatty acid degradation | 1 | 32 | 9.40e-01 |
| KEGG | KEGG:00280 | Valine, leucine and isoleucine degradation | 1 | 43 | 9.42e-01 |
| KEGG | KEGG:00561 | Glycerolipid metabolism | 2 | 49 | 9.42e-01 |
| KEGG | KEGG:00564 | Glycerophospholipid metabolism | 1 | 76 | 9.46e-01 |
| KEGG | KEGG:05140 | Leishmaniasis | 2 | 42 | 9.51e-01 |
| KEGG | KEGG:05133 | Pertussis | 2 | 45 | 9.57e-01 |
| KEGG | KEGG:04530 | Tight junction | 7 | 137 | 9.62e-01 |
| KEGG | KEGG:05032 | Morphine addiction | 1 | 56 | 9.68e-01 |
| KEGG | KEGG:04740 | Olfactory transduction | 1 | 25 | 9.83e-01 |
| KEGG | KEGG:05171 | Coronavirus disease - COVID-19 | 4 | 162 | 9.83e-01 |
| KEGG | KEGG:00140 | Steroid hormone biosynthesis | 1 | 19 | 9.83e-01 |
| KEGG | KEGG:04974 | Protein digestion and absorption | 1 | 61 | 9.92e-01 |
| KEGG | KEGG:00230 | Purine metabolism | 1 | 97 | 9.94e-01 |
| KEGG | KEGG:03018 | RNA degradation | 1 | 74 | 9.96e-01 |
| KEGG | KEGG:00190 | Oxidative phosphorylation | 1 | 106 | 9.99e-01 |
| KEGG | KEGG:04061 | Viral protein interaction with cytokine and cytokine receptor | 1 | 20 | 9.99e-01 |
| KEGG | KEGG:04080 | Neuroactive ligand-receptor interaction | 2 | 108 | 9.99e-01 |
DNR_var24_table %>%
filter(source=="KEGG") %>%
mutate_at(.vars = 6, .funs= scientific_format()) %>%
kable(.,caption = "KEGG DNR 24 hour enrichment terms of highly var genes") %>%
kable_paper("striped", full_width = FALSE) %>%
kable_styling(full_width = FALSE, position = "left",bootstrap_options = c("striped","hover")) %>%
scroll_box(width = "100%", height = "400px")| source | term_id | term_name | intersection_size | term_size | p_value |
|---|---|---|---|---|---|
| KEGG | KEGG:04726 | Serotonergic synapse | 7 | 63 | 6.86e-02 |
| KEGG | KEGG:04720 | Long-term potentiation | 6 | 55 | 6.86e-02 |
| KEGG | KEGG:04922 | Glucagon signaling pathway | 9 | 84 | 6.86e-02 |
| KEGG | KEGG:04022 | cGMP-PKG signaling pathway | 9 | 133 | 6.86e-02 |
| KEGG | KEGG:05230 | Central carbon metabolism in cancer | 7 | 62 | 6.86e-02 |
| KEGG | KEGG:05010 | Alzheimer disease | 19 | 315 | 6.86e-02 |
| KEGG | KEGG:04218 | Cellular senescence | 8 | 145 | 7.89e-02 |
| KEGG | KEGG:04929 | GnRH secretion | 6 | 53 | 7.89e-02 |
| KEGG | KEGG:05017 | Spinocerebellar ataxia | 11 | 124 | 7.89e-02 |
| KEGG | KEGG:04935 | Growth hormone synthesis, secretion and action | 9 | 98 | 1.01e-01 |
| KEGG | KEGG:04015 | Rap1 signaling pathway | 24 | 164 | 1.11e-01 |
| KEGG | KEGG:05210 | Colorectal cancer | 9 | 84 | 1.11e-01 |
| KEGG | KEGG:04371 | Apelin signaling pathway | 13 | 106 | 1.11e-01 |
| KEGG | KEGG:04933 | AGE-RAGE signaling pathway in diabetic complications | 13 | 91 | 1.40e-01 |
| KEGG | KEGG:05222 | Small cell lung cancer | 8 | 87 | 1.42e-01 |
| KEGG | KEGG:04370 | VEGF signaling pathway | 6 | 49 | 1.42e-01 |
| KEGG | KEGG:04213 | Longevity regulating pathway - multiple species | 6 | 55 | 1.42e-01 |
| KEGG | KEGG:00900 | Terpenoid backbone biosynthesis | 1 | 21 | 1.43e-01 |
| KEGG | KEGG:05031 | Amphetamine addiction | 4 | 49 | 1.50e-01 |
| KEGG | KEGG:00590 | Arachidonic acid metabolism | 1 | 26 | 1.50e-01 |
| KEGG | KEGG:03050 | Proteasome | 4 | 42 | 1.50e-01 |
| KEGG | KEGG:05166 | Human T-cell leukemia virus 1 infection | 7 | 180 | 1.50e-01 |
| KEGG | KEGG:05211 | Renal cell carcinoma | 5 | 65 | 1.50e-01 |
| KEGG | KEGG:04730 | Long-term depression | 4 | 42 | 1.50e-01 |
| KEGG | KEGG:04071 | Sphingolipid signaling pathway | 9 | 107 | 1.50e-01 |
| KEGG | KEGG:05212 | Pancreatic cancer | 10 | 75 | 1.50e-01 |
| KEGG | KEGG:04270 | Vascular smooth muscle contraction | 6 | 94 | 1.50e-01 |
| KEGG | KEGG:04360 | Axon guidance | 12 | 162 | 1.50e-01 |
| KEGG | KEGG:04725 | Cholinergic synapse | 7 | 83 | 1.50e-01 |
| KEGG | KEGG:04728 | Dopaminergic synapse | 6 | 103 | 1.50e-01 |
| KEGG | KEGG:04072 | Phospholipase D signaling pathway | 16 | 110 | 1.52e-01 |
| KEGG | KEGG:04924 | Renin secretion | 4 | 50 | 1.58e-01 |
| KEGG | KEGG:04140 | Autophagy - animal | 9 | 133 | 1.58e-01 |
| KEGG | KEGG:04611 | Platelet activation | 7 | 89 | 1.58e-01 |
| KEGG | KEGG:04625 | C-type lectin receptor signaling pathway | 5 | 76 | 1.58e-01 |
| KEGG | KEGG:04010 | MAPK signaling pathway | 25 | 240 | 1.58e-01 |
| KEGG | KEGG:00250 | Alanine, aspartate and glutamate metabolism | 3 | 29 | 1.61e-01 |
| KEGG | KEGG:04919 | Thyroid hormone signaling pathway | 5 | 112 | 1.61e-01 |
| KEGG | KEGG:00220 | Arginine biosynthesis | 3 | 16 | 1.62e-01 |
| KEGG | KEGG:05034 | Alcoholism | 7 | 122 | 1.62e-01 |
| KEGG | KEGG:04613 | Neutrophil extracellular trap formation | 7 | 110 | 1.62e-01 |
| KEGG | KEGG:04510 | Focal adhesion | 21 | 177 | 1.62e-01 |
| KEGG | KEGG:04210 | Apoptosis | 9 | 118 | 1.73e-01 |
| KEGG | KEGG:04217 | Necroptosis | 6 | 106 | 1.75e-01 |
| KEGG | KEGG:05225 | Hepatocellular carcinoma | 14 | 145 | 1.75e-01 |
| KEGG | KEGG:04921 | Oxytocin signaling pathway | 6 | 115 | 1.75e-01 |
| KEGG | KEGG:04261 | Adrenergic signaling in cardiomyocytes | 6 | 128 | 1.75e-01 |
| KEGG | KEGG:04920 | Adipocytokine signaling pathway | 5 | 51 | 1.77e-01 |
| KEGG | KEGG:04350 | TGF-beta signaling pathway | 7 | 84 | 1.78e-01 |
| KEGG | KEGG:04961 | Endocrine and other factor-regulated calcium reabsorption | 6 | 41 | 1.80e-01 |
| KEGG | KEGG:00534 | Glycosaminoglycan biosynthesis - heparan sulfate / heparin | 1 | 20 | 1.85e-01 |
| KEGG | KEGG:04664 | Fc epsilon RI signaling pathway | 3 | 46 | 1.88e-01 |
| KEGG | KEGG:05213 | Endometrial cancer | 5 | 57 | 1.90e-01 |
| KEGG | KEGG:04540 | Gap junction | 9 | 73 | 1.90e-01 |
| KEGG | KEGG:04923 | Regulation of lipolysis in adipocytes | 4 | 41 | 1.95e-01 |
| KEGG | KEGG:00515 | Mannose type O-glycan biosynthesis | 2 | 19 | 1.95e-01 |
| KEGG | KEGG:04146 | Peroxisome | 1 | 68 | 1.97e-01 |
| KEGG | KEGG:05145 | Toxoplasmosis | 6 | 82 | 2.02e-01 |
| KEGG | KEGG:05012 | Parkinson disease | 9 | 226 | 2.02e-01 |
| KEGG | KEGG:00983 | Drug metabolism - other enzymes | 2 | 44 | 2.02e-01 |
| KEGG | KEGG:05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 6 | 69 | 2.02e-01 |
| KEGG | KEGG:01521 | EGFR tyrosine kinase inhibitor resistance | 8 | 74 | 2.02e-01 |
| KEGG | KEGG:05221 | Acute myeloid leukemia | 5 | 56 | 2.02e-01 |
| KEGG | KEGG:05200 | Pathways in cancer | 30 | 409 | 2.02e-01 |
| KEGG | KEGG:04211 | Longevity regulating pathway | 6 | 78 | 2.02e-01 |
| KEGG | KEGG:04926 | Relaxin signaling pathway | 13 | 104 | 2.05e-01 |
| KEGG | KEGG:04668 | TNF signaling pathway | 11 | 87 | 2.05e-01 |
| KEGG | KEGG:04068 | FoxO signaling pathway | 4 | 109 | 2.09e-01 |
| KEGG | KEGG:04912 | GnRH signaling pathway | 4 | 76 | 2.11e-01 |
| KEGG | KEGG:00601 | Glycosphingolipid biosynthesis - lacto and neolacto series | 2 | 14 | 2.11e-01 |
| KEGG | KEGG:04964 | Proximal tubule bicarbonate reclamation | 2 | 20 | 2.15e-01 |
| KEGG | KEGG:05223 | Non-small cell lung cancer | 6 | 67 | 2.15e-01 |
| KEGG | KEGG:04662 | B cell receptor signaling pathway | 3 | 56 | 2.16e-01 |
| KEGG | KEGG:04750 | Inflammatory mediator regulation of TRP channels | 4 | 72 | 2.30e-01 |
| KEGG | KEGG:05022 | Pathways of neurodegeneration - multiple diseases | 10 | 385 | 2.30e-01 |
| KEGG | KEGG:04012 | ErbB signaling pathway | 9 | 78 | 2.37e-01 |
| KEGG | KEGG:01250 | Biosynthesis of nucleotide sugars | 4 | 35 | 2.40e-01 |
| KEGG | KEGG:01524 | Platinum drug resistance | 4 | 65 | 2.66e-01 |
| KEGG | KEGG:04927 | Cortisol synthesis and secretion | 3 | 48 | 2.66e-01 |
| KEGG | KEGG:00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 1 | 13 | 2.71e-01 |
| KEGG | KEGG:04660 | T cell receptor signaling pathway | 5 | 70 | 2.74e-01 |
| KEGG | KEGG:04973 | Carbohydrate digestion and absorption | 3 | 31 | 2.77e-01 |
| KEGG | KEGG:04911 | Insulin secretion | 3 | 64 | 2.77e-01 |
| KEGG | KEGG:05163 | Human cytomegalovirus infection | 11 | 176 | 2.77e-01 |
| KEGG | KEGG:05224 | Breast cancer | 10 | 117 | 2.80e-01 |
| KEGG | KEGG:04931 | Insulin resistance | 5 | 95 | 2.85e-01 |
| KEGG | KEGG:04917 | Prolactin signaling pathway | 4 | 56 | 2.85e-01 |
| KEGG | KEGG:05168 | Herpes simplex virus 1 infection | 24 | 415 | 2.92e-01 |
| KEGG | KEGG:04330 | Notch signaling pathway | 5 | 51 | 2.94e-01 |
| KEGG | KEGG:05131 | Shigellosis | 22 | 210 | 2.94e-01 |
| KEGG | KEGG:04216 | Ferroptosis | 3 | 33 | 2.94e-01 |
| KEGG | KEGG:05226 | Gastric cancer | 8 | 117 | 2.94e-01 |
| KEGG | KEGG:00760 | Nicotinate and nicotinamide metabolism | 3 | 28 | 2.94e-01 |
| KEGG | KEGG:03060 | Protein export | 3 | 23 | 2.94e-01 |
| KEGG | KEGG:04930 | Type II diabetes mellitus | 3 | 35 | 2.96e-01 |
| KEGG | KEGG:04910 | Insulin signaling pathway | 7 | 121 | 2.96e-01 |
| KEGG | KEGG:00470 | D-Amino acid metabolism | 1 | 4 | 2.96e-01 |
| KEGG | KEGG:03013 | Nucleocytoplasmic transport | 6 | 99 | 3.06e-01 |
| KEGG | KEGG:05417 | Lipid and atherosclerosis | 5 | 153 | 3.06e-01 |
| KEGG | KEGG:04713 | Circadian entrainment | 3 | 69 | 3.06e-01 |
| KEGG | KEGG:05415 | Diabetic cardiomyopathy | 5 | 169 | 3.06e-01 |
| KEGG | KEGG:03410 | Base excision repair | 3 | 33 | 3.06e-01 |
| KEGG | KEGG:05020 | Prion disease | 8 | 220 | 3.06e-01 |
| KEGG | KEGG:01522 | Endocrine resistance | 9 | 85 | 3.06e-01 |
| KEGG | KEGG:04070 | Phosphatidylinositol signaling system | 8 | 91 | 3.06e-01 |
| KEGG | KEGG:04120 | Ubiquitin mediated proteolysis | 3 | 134 | 3.06e-01 |
| KEGG | KEGG:05217 | Basal cell carcinoma | 5 | 49 | 3.06e-01 |
| KEGG | KEGG:04724 | Glutamatergic synapse | 4 | 74 | 3.06e-01 |
| KEGG | KEGG:05170 | Human immunodeficiency virus 1 infection | 11 | 165 | 3.09e-01 |
| KEGG | KEGG:04915 | Estrogen signaling pathway | 9 | 97 | 3.17e-01 |
| KEGG | KEGG:04020 | Calcium signaling pathway | 17 | 157 | 3.21e-01 |
| KEGG | KEGG:05205 | Proteoglycans in cancer | 18 | 170 | 3.21e-01 |
| KEGG | KEGG:00670 | One carbon pool by folate | 2 | 18 | 3.29e-01 |
| KEGG | KEGG:04722 | Neurotrophin signaling pathway | 3 | 110 | 3.29e-01 |
| KEGG | KEGG:04114 | Oocyte meiosis | 4 | 108 | 3.29e-01 |
| KEGG | KEGG:00780 | Biotin metabolism | 1 | 3 | 3.31e-01 |
| KEGG | KEGG:00562 | Inositol phosphate metabolism | 7 | 66 | 3.37e-01 |
| KEGG | KEGG:04621 | NOD-like receptor signaling pathway | 5 | 117 | 3.39e-01 |
| KEGG | KEGG:04925 | Aldosterone synthesis and secretion | 4 | 77 | 3.42e-01 |
| KEGG | KEGG:04014 | Ras signaling pathway | 8 | 171 | 3.42e-01 |
| KEGG | KEGG:00240 | Pyrimidine metabolism | 1 | 46 | 3.48e-01 |
| KEGG | KEGG:00051 | Fructose and mannose metabolism | 4 | 27 | 3.49e-01 |
| KEGG | KEGG:04137 | Mitophagy - animal | 4 | 70 | 3.51e-01 |
| KEGG | KEGG:00910 | Nitrogen metabolism | 1 | 10 | 3.51e-01 |
| KEGG | KEGG:04130 | SNARE interactions in vesicular transport | 1 | 32 | 3.51e-01 |
| KEGG | KEGG:05214 | Glioma | 5 | 67 | 3.55e-01 |
| KEGG | KEGG:04810 | Regulation of actin cytoskeleton | 10 | 179 | 3.57e-01 |
| KEGG | KEGG:04970 | Salivary secretion | 3 | 55 | 3.57e-01 |
| KEGG | KEGG:04390 | Hippo signaling pathway | 14 | 134 | 3.65e-01 |
| KEGG | KEGG:03015 | mRNA surveillance pathway | 5 | 86 | 3.65e-01 |
| KEGG | KEGG:01240 | Biosynthesis of cofactors | 3 | 115 | 3.65e-01 |
| KEGG | KEGG:04310 | Wnt signaling pathway | 14 | 138 | 3.65e-01 |
| KEGG | KEGG:04151 | PI3K-Akt signaling pathway | 6 | 254 | 3.65e-01 |
| KEGG | KEGG:05016 | Huntington disease | 6 | 256 | 3.65e-01 |
| KEGG | KEGG:05164 | Influenza A | 9 | 103 | 3.76e-01 |
| KEGG | KEGG:05231 | Choline metabolism in cancer | 5 | 84 | 3.76e-01 |
| KEGG | KEGG:04380 | Osteoclast differentiation | 5 | 87 | 3.77e-01 |
| KEGG | KEGG:04066 | HIF-1 signaling pathway | 2 | 89 | 3.81e-01 |
| KEGG | KEGG:05207 | Chemical carcinogenesis - receptor activation | 4 | 142 | 3.81e-01 |
| KEGG | KEGG:04976 | Bile secretion | 1 | 42 | 3.81e-01 |
| KEGG | KEGG:05218 | Melanoma | 2 | 58 | 3.81e-01 |
| KEGG | KEGG:03250 | Viral life cycle - HIV-1 | 5 | 56 | 3.82e-01 |
| KEGG | KEGG:04666 | Fc gamma R-mediated phagocytosis | 5 | 75 | 3.82e-01 |
| KEGG | KEGG:05143 | African trypanosomiasis | 3 | 16 | 3.82e-01 |
| KEGG | KEGG:05152 | Tuberculosis | 3 | 106 | 3.82e-01 |
| KEGG | KEGG:00513 | Various types of N-glycan biosynthesis | 1 | 36 | 3.82e-01 |
| KEGG | KEGG:00970 | Aminoacyl-tRNA biosynthesis | 1 | 44 | 3.82e-01 |
| KEGG | KEGG:00770 | Pantothenate and CoA biosynthesis | 1 | 15 | 3.82e-01 |
| KEGG | KEGG:03450 | Non-homologous end-joining | 2 | 12 | 3.82e-01 |
| KEGG | KEGG:05220 | Chronic myeloid leukemia | 2 | 75 | 3.82e-01 |
| KEGG | KEGG:03430 | Mismatch repair | 2 | 22 | 3.82e-01 |
| KEGG | KEGG:05167 | Kaposi sarcoma-associated herpesvirus infection | 11 | 145 | 3.82e-01 |
| KEGG | KEGG:01232 | Nucleotide metabolism | 1 | 69 | 3.90e-01 |
| KEGG | KEGG:05208 | Chemical carcinogenesis - reactive oxygen species | 4 | 186 | 3.93e-01 |
| KEGG | KEGG:00860 | Porphyrin metabolism | 1 | 22 | 3.95e-01 |
| KEGG | KEGG:00520 | Amino sugar and nucleotide sugar metabolism | 5 | 46 | 3.99e-01 |
| KEGG | KEGG:05416 | Viral myocarditis | 5 | 40 | 4.04e-01 |
| KEGG | KEGG:00480 | Glutathione metabolism | 1 | 44 | 4.11e-01 |
| KEGG | KEGG:04064 | NF-kappa B signaling pathway | 5 | 71 | 4.15e-01 |
| KEGG | KEGG:04150 | mTOR signaling pathway | 3 | 135 | 4.15e-01 |
| KEGG | KEGG:00514 | Other types of O-glycan biosynthesis | 1 | 37 | 4.15e-01 |
| KEGG | KEGG:03008 | Ribosome biogenesis in eukaryotes | 8 | 75 | 4.15e-01 |
| KEGG | KEGG:00310 | Lysine degradation | 6 | 59 | 4.24e-01 |
| KEGG | KEGG:01523 | Antifolate resistance | 2 | 24 | 4.24e-01 |
| KEGG | KEGG:04916 | Melanogenesis | 6 | 77 | 4.24e-01 |
| KEGG | KEGG:05219 | Bladder cancer | 4 | 37 | 4.24e-01 |
| KEGG | KEGG:00510 | N-Glycan biosynthesis | 1 | 48 | 4.24e-01 |
| KEGG | KEGG:05134 | Legionellosis | 1 | 39 | 4.24e-01 |
| KEGG | KEGG:04141 | Protein processing in endoplasmic reticulum | 2 | 161 | 4.39e-01 |
| KEGG | KEGG:05418 | Fluid shear stress and atherosclerosis | 2 | 114 | 4.43e-01 |
| KEGG | KEGG:05204 | Chemical carcinogenesis - DNA adducts | 1 | 23 | 4.45e-01 |
| KEGG | KEGG:04024 | cAMP signaling pathway | 10 | 151 | 4.47e-01 |
| KEGG | KEGG:00982 | Drug metabolism - cytochrome P450 | 1 | 21 | 4.47e-01 |
| KEGG | KEGG:04152 | AMPK signaling pathway | 2 | 103 | 4.58e-01 |
| KEGG | KEGG:05014 | Amyotrophic lateral sclerosis | 6 | 303 | 4.62e-01 |
| KEGG | KEGG:04610 | Complement and coagulation cascades | 1 | 40 | 4.62e-01 |
| KEGG | KEGG:00980 | Metabolism of xenobiotics by cytochrome P450 | 1 | 26 | 4.63e-01 |
| KEGG | KEGG:05215 | Prostate cancer | 2 | 86 | 4.63e-01 |
| KEGG | KEGG:04062 | Chemokine signaling pathway | 10 | 113 | 4.63e-01 |
| KEGG | KEGG:04550 | Signaling pathways regulating pluripotency of stem cells | 6 | 104 | 4.67e-01 |
| KEGG | KEGG:05410 | Hypertrophic cardiomyopathy | 5 | 73 | 4.75e-01 |
| KEGG | KEGG:04727 | GABAergic synapse | 3 | 55 | 4.75e-01 |
| KEGG | KEGG:05142 | Chagas disease | 8 | 75 | 4.83e-01 |
| KEGG | KEGG:05322 | Systemic lupus erythematosus | 3 | 61 | 4.83e-01 |
| KEGG | KEGG:04658 | Th1 and Th2 cell differentiation | 7 | 53 | 4.95e-01 |
| KEGG | KEGG:03040 | Spliceosome | 6 | 132 | 4.95e-01 |
| KEGG | KEGG:04122 | Sulfur relay system | 1 | 8 | 4.95e-01 |
| KEGG | KEGG:04110 | Cell cycle | 1 | 151 | 4.95e-01 |
| KEGG | KEGG:04918 | Thyroid hormone synthesis | 2 | 55 | 4.95e-01 |
| KEGG | KEGG:05165 | Human papillomavirus infection | 12 | 272 | 4.95e-01 |
| KEGG | KEGG:01230 | Biosynthesis of amino acids | 4 | 60 | 4.95e-01 |
| KEGG | KEGG:00532 | Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 1 | 21 | 4.95e-01 |
| KEGG | KEGG:04971 | Gastric acid secretion | 2 | 52 | 4.97e-01 |
| KEGG | KEGG:01100 | Metabolic pathways | 1 | 1146 | 4.97e-01 |
| KEGG | KEGG:05414 | Dilated cardiomyopathy | 5 | 78 | 5.02e-01 |
| KEGG | KEGG:04936 | Alcoholic liver disease | 2 | 97 | 5.04e-01 |
| KEGG | KEGG:05146 | Amoebiasis | 2 | 64 | 5.04e-01 |
| KEGG | KEGG:00450 | Selenocompound metabolism | 1 | 14 | 5.04e-01 |
| KEGG | KEGG:00232 | Caffeine metabolism | 1 | 1 | 5.04e-01 |
| KEGG | KEGG:05135 | Yersinia infection | 6 | 112 | 5.04e-01 |
| KEGG | KEGG:03420 | Nucleotide excision repair | 3 | 43 | 5.04e-01 |
| KEGG | KEGG:05216 | Thyroid cancer | 2 | 35 | 5.04e-01 |
| KEGG | KEGG:04913 | Ovarian steroidogenesis | 1 | 28 | 5.04e-01 |
| KEGG | KEGG:05132 | Salmonella infection | 18 | 214 | 5.10e-01 |
| KEGG | KEGG:04215 | Apoptosis - multiple species | 1 | 30 | 5.31e-01 |
| KEGG | KEGG:03030 | DNA replication | 2 | 35 | 5.34e-01 |
| KEGG | KEGG:05412 | Arrhythmogenic right ventricular cardiomyopathy | 1 | 63 | 5.36e-01 |
| KEGG | KEGG:04979 | Cholesterol metabolism | 1 | 33 | 5.40e-01 |
| KEGG | KEGG:04650 | Natural killer cell mediated cytotoxicity | 2 | 63 | 5.41e-01 |
| KEGG | KEGG:00920 | Sulfur metabolism | 1 | 10 | 5.41e-01 |
| KEGG | KEGG:00563 | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 2 | 25 | 5.41e-01 |
| KEGG | KEGG:05203 | Viral carcinogenesis | 1 | 172 | 5.41e-01 |
| KEGG | KEGG:04723 | Retrograde endocannabinoid signaling | 3 | 99 | 5.44e-01 |
| KEGG | KEGG:05206 | MicroRNAs in cancer | 7 | 149 | 5.54e-01 |
| KEGG | KEGG:05030 | Cocaine addiction | 1 | 35 | 5.58e-01 |
| KEGG | KEGG:04260 | Cardiac muscle contraction | 1 | 67 | 5.63e-01 |
| KEGG | KEGG:04934 | Cushing syndrome | 3 | 121 | 5.63e-01 |
| KEGG | KEGG:05100 | Bacterial invasion of epithelial cells | 4 | 74 | 5.64e-01 |
| KEGG | KEGG:04710 | Circadian rhythm | 1 | 30 | 5.64e-01 |
| KEGG | KEGG:05120 | Epithelial cell signaling in Helicobacter pylori infection | 5 | 58 | 5.64e-01 |
| KEGG | KEGG:03440 | Homologous recombination | 1 | 39 | 5.64e-01 |
| KEGG | KEGG:05033 | Nicotine addiction | 2 | 12 | 5.69e-01 |
| KEGG | KEGG:00630 | Glyoxylate and dicarboxylate metabolism | 2 | 25 | 5.78e-01 |
| KEGG | KEGG:04512 | ECM-receptor interaction | 1 | 69 | 5.78e-01 |
| KEGG | KEGG:01210 | 2-Oxocarboxylic acid metabolism | 1 | 17 | 5.78e-01 |
| KEGG | KEGG:00790 | Folate biosynthesis | 1 | 18 | 5.82e-01 |
| KEGG | KEGG:03266 | Virion - Herpesvirus | 1 | 6 | 5.82e-01 |
| KEGG | KEGG:00620 | Pyruvate metabolism | 2 | 33 | 5.87e-01 |
| KEGG | KEGG:01200 | Carbon metabolism | 5 | 98 | 5.91e-01 |
| KEGG | KEGG:04972 | Pancreatic secretion | 2 | 58 | 5.99e-01 |
| KEGG | KEGG:04657 | IL-17 signaling pathway | 3 | 56 | 6.01e-01 |
| KEGG | KEGG:05310 | Asthma | 2 | 3 | 6.14e-01 |
| KEGG | KEGG:04659 | Th17 cell differentiation | 7 | 64 | 6.14e-01 |
| KEGG | KEGG:04928 | Parathyroid hormone synthesis, secretion and action | 2 | 82 | 6.14e-01 |
| KEGG | KEGG:01040 | Biosynthesis of unsaturated fatty acids | 2 | 24 | 6.14e-01 |
| KEGG | KEGG:00062 | Fatty acid elongation | 2 | 24 | 6.14e-01 |
| KEGG | KEGG:05321 | Inflammatory bowel disease | 4 | 22 | 6.14e-01 |
| KEGG | KEGG:04914 | Progesterone-mediated oocyte maturation | 6 | 86 | 6.19e-01 |
| KEGG | KEGG:04392 | Hippo signaling pathway - multiple species | 2 | 25 | 6.23e-01 |
| KEGG | KEGG:05160 | Hepatitis C | 2 | 115 | 6.27e-01 |
| KEGG | KEGG:04670 | Leukocyte transendothelial migration | 4 | 79 | 6.27e-01 |
| KEGG | KEGG:04144 | Endocytosis | 17 | 232 | 6.27e-01 |
| KEGG | KEGG:04145 | Phagosome | 1 | 99 | 6.30e-01 |
| KEGG | KEGG:04721 | Synaptic vesicle cycle | 3 | 51 | 6.36e-01 |
| KEGG | KEGG:00604 | Glycosphingolipid biosynthesis - ganglio series | 1 | 12 | 6.36e-01 |
| KEGG | KEGG:00600 | Sphingolipid metabolism | 2 | 44 | 6.36e-01 |
| KEGG | KEGG:05161 | Hepatitis B | 2 | 136 | 6.36e-01 |
| KEGG | KEGG:04620 | Toll-like receptor signaling pathway | 1 | 60 | 6.37e-01 |
| KEGG | KEGG:04978 | Mineral absorption | 3 | 42 | 6.37e-01 |
| KEGG | KEGG:04630 | JAK-STAT signaling pathway | 2 | 88 | 6.44e-01 |
| KEGG | KEGG:05169 | Epstein-Barr virus infection | 7 | 153 | 6.57e-01 |
| KEGG | KEGG:00270 | Cysteine and methionine metabolism | 3 | 38 | 6.65e-01 |
| KEGG | KEGG:04622 | RIG-I-like receptor signaling pathway | 3 | 49 | 6.65e-01 |
| KEGG | KEGG:00260 | Glycine, serine and threonine metabolism | 2 | 31 | 6.65e-01 |
| KEGG | KEGG:04612 | Antigen processing and presentation | 4 | 41 | 6.74e-01 |
| KEGG | KEGG:05202 | Transcriptional misregulation in cancer | 8 | 128 | 6.76e-01 |
| KEGG | KEGG:04142 | Lysosome | 3 | 118 | 6.82e-01 |
| KEGG | KEGG:05330 | Allograft rejection | 2 | 10 | 7.06e-01 |
| KEGG | KEGG:00061 | Fatty acid biosynthesis | 1 | 12 | 7.44e-01 |
| KEGG | KEGG:05162 | Measles | 1 | 98 | 7.44e-01 |
| KEGG | KEGG:00730 | Thiamine metabolism | 1 | 10 | 7.44e-01 |
| KEGG | KEGG:04614 | Renin-angiotensin system | 1 | 12 | 7.45e-01 |
| KEGG | KEGG:05332 | Graft-versus-host disease | 2 | 10 | 7.45e-01 |
| KEGG | KEGG:04742 | Taste transduction | 1 | 22 | 7.45e-01 |
| KEGG | KEGG:04640 | Hematopoietic cell lineage | 5 | 31 | 7.45e-01 |
| KEGG | KEGG:04340 | Hedgehog signaling pathway | 2 | 49 | 7.48e-01 |
| KEGG | KEGG:04514 | Cell adhesion molecules | 9 | 83 | 7.48e-01 |
| KEGG | KEGG:01212 | Fatty acid metabolism | 3 | 50 | 7.48e-01 |
| KEGG | KEGG:04932 | Non-alcoholic fatty liver disease | 4 | 131 | 7.48e-01 |
| KEGG | KEGG:04940 | Type I diabetes mellitus | 2 | 15 | 7.77e-01 |
| KEGG | KEGG:04115 | p53 signaling pathway | 4 | 65 | 7.77e-01 |
| KEGG | KEGG:00030 | Pentose phosphate pathway | 1 | 24 | 7.96e-01 |
| KEGG | KEGG:04714 | Thermogenesis | 2 | 195 | 7.99e-01 |
| KEGG | KEGG:04623 | Cytosolic DNA-sensing pathway | 4 | 42 | 7.99e-01 |
| KEGG | KEGG:03022 | Basal transcription factors | 1 | 40 | 8.01e-01 |
| KEGG | KEGG:05130 | Pathogenic Escherichia coli infection | 11 | 150 | 8.16e-01 |
| KEGG | KEGG:04672 | Intestinal immune network for IgA production | 2 | 12 | 8.16e-01 |
| KEGG | KEGG:04060 | Cytokine-cytokine receptor interaction | 1 | 98 | 8.16e-01 |
| KEGG | KEGG:04977 | Vitamin digestion and absorption | 1 | 14 | 8.16e-01 |
| KEGG | KEGG:02010 | ABC transporters | 2 | 29 | 8.27e-01 |
| KEGG | KEGG:00100 | Steroid biosynthesis | 1 | 17 | 8.47e-01 |
| KEGG | KEGG:00330 | Arginine and proline metabolism | 2 | 38 | 8.62e-01 |
| KEGG | KEGG:05320 | Autoimmune thyroid disease | 2 | 11 | 8.62e-01 |
| KEGG | KEGG:04975 | Fat digestion and absorption | 2 | 19 | 8.65e-01 |
| KEGG | KEGG:00010 | Glycolysis / Gluconeogenesis | 1 | 44 | 8.68e-01 |
| KEGG | KEGG:00640 | Propanoate metabolism | 1 | 28 | 8.71e-01 |
| KEGG | KEGG:05144 | Malaria | 1 | 20 | 8.75e-01 |
| KEGG | KEGG:04520 | Adherens junction | 3 | 67 | 8.79e-01 |
| KEGG | KEGG:00000 | KEGG root term | 3 | 5558 | 9.07e-01 |
| KEGG | KEGG:05150 | Staphylococcus aureus infection | 3 | 18 | 9.33e-01 |
| KEGG | KEGG:03460 | Fanconi anemia pathway | 1 | 48 | 9.33e-01 |
| KEGG | KEGG:00830 | Retinol metabolism | 2 | 16 | 9.33e-01 |
| KEGG | KEGG:00052 | Galactose metabolism | 1 | 22 | 9.33e-01 |
| KEGG | KEGG:03320 | PPAR signaling pathway | 3 | 50 | 9.33e-01 |
| KEGG | KEGG:00565 | Ether lipid metabolism | 1 | 28 | 9.33e-01 |
| KEGG | KEGG:04136 | Autophagy - other | 1 | 31 | 9.33e-01 |
| KEGG | KEGG:03020 | RNA polymerase | 1 | 34 | 9.33e-01 |
| KEGG | KEGG:05323 | Rheumatoid arthritis | 3 | 43 | 9.36e-01 |
| KEGG | KEGG:00512 | Mucin type O-glycan biosynthesis | 1 | 22 | 9.37e-01 |
| KEGG | KEGG:00040 | Pentose and glucuronate interconversions | 1 | 12 | 9.37e-01 |
| KEGG | KEGG:05340 | Primary immunodeficiency | 1 | 12 | 9.37e-01 |
| KEGG | KEGG:03010 | Ribosome | 4 | 127 | 9.37e-01 |
| KEGG | KEGG:00071 | Fatty acid degradation | 1 | 32 | 9.40e-01 |
| KEGG | KEGG:00280 | Valine, leucine and isoleucine degradation | 1 | 43 | 9.42e-01 |
| KEGG | KEGG:00561 | Glycerolipid metabolism | 2 | 49 | 9.42e-01 |
| KEGG | KEGG:00564 | Glycerophospholipid metabolism | 1 | 76 | 9.46e-01 |
| KEGG | KEGG:05140 | Leishmaniasis | 2 | 42 | 9.51e-01 |
| KEGG | KEGG:05133 | Pertussis | 2 | 45 | 9.57e-01 |
| KEGG | KEGG:04530 | Tight junction | 7 | 137 | 9.62e-01 |
| KEGG | KEGG:05032 | Morphine addiction | 1 | 56 | 9.68e-01 |
| KEGG | KEGG:04740 | Olfactory transduction | 1 | 25 | 9.83e-01 |
| KEGG | KEGG:05171 | Coronavirus disease - COVID-19 | 4 | 162 | 9.83e-01 |
| KEGG | KEGG:00140 | Steroid hormone biosynthesis | 1 | 19 | 9.83e-01 |
| KEGG | KEGG:04974 | Protein digestion and absorption | 1 | 61 | 9.92e-01 |
| KEGG | KEGG:00230 | Purine metabolism | 1 | 97 | 9.94e-01 |
| KEGG | KEGG:03018 | RNA degradation | 1 | 74 | 9.96e-01 |
| KEGG | KEGG:00190 | Oxidative phosphorylation | 1 | 106 | 9.99e-01 |
| KEGG | KEGG:04061 | Viral protein interaction with cytokine and cytokine receptor | 1 | 20 | 9.99e-01 |
| KEGG | KEGG:04080 | Neuroactive ligand-receptor interaction | 2 | 108 | 9.99e-01 |
24 hour MTX highly variable genes
based on nominal pvalues <0.05
# MTX_var24gost <- gost(query = MTX_24_var$ENTREZID,
# organism = "hsapiens",
# significant = FALSE,
# ordered_query = TRUE,
# domain_scope = "custom",
# measure_underrepresentation = FALSE,
# evcodes = FALSE,
# numeric_ns="ENTREZGENE",
# user_threshold = 0.05,
# correction_method = "fdr",
# custom_bg = backGL$ENTREZID,
# sources=c("GO:BP","KEGG"))
#
# saveRDS(MTX_var24gost,"data/DEG-GO/var/MTX_var24gost.RDS")
MTX_var24gost <- readRDS("data/DEG-GO/var/MTX_var24gost.RDS")
MTX_var24p <- gostplot(MTX_var24gost, capped = FALSE, interactive = TRUE)
MTX_var24pMTX_var24_table <- MTX_var24gost$result %>%
dplyr::select(c(source, term_id, term_name,intersection_size, term_size, p_value))
MTX_var24_table %>%
dplyr::filter(source=="GO:BP") %>%
dplyr::select(p_value,term_name,intersection_size) %>%
slice_min(., n=10 ,order_by=p_value) %>%
mutate(log_val = -log10(p_value)) %>%
# slice_max(., n=10,order_by = p_value) %>%
ggplot(., aes(x = log_val, y =reorder(term_name,p_value), col= intersection_size)) +
geom_point(aes(size = intersection_size)) +
geom_vline(xintercept = (-log10(0.05)), col="red")+
scale_y_discrete(labels = label_wrap(30))+
guides(col="none", size=guide_legend(title = "# of intersected \n terms"))+
ggtitle('MTX24 hour top 10 GO:BP terms') +
xlab(expression(" -"~log[10]~("adj. p-value")))+
ylab("GO: BP term")+
theme_bw()+
theme(plot.title = element_text(size = rel(1.5), hjust = 0.5),
axis.title = element_text(size = 15, color = "black"),
axis.ticks = element_line(linewidth = 1.5),
axis.line = element_line(linewidth = 1.5),
axis.text = element_text(size = 10, color = "black", angle = 0),
strip.text.x = element_text(size = 15, color = "black", face = "bold")) 
MTX_var24_table %>%
mutate_at(.vars = 6, .funs= scientific_format()) %>%
kable(.,caption = "MTX 24 enrichment terms of highly var genes") %>%
kable_paper("striped", full_width = FALSE) %>%
kable_styling(full_width = FALSE, position = "left",bootstrap_options = c("striped","hover")) %>%
scroll_box(width = "100%", height = "400px")| source | term_id | term_name | intersection_size | term_size | p_value |
|---|---|---|---|---|---|
| GO:BP | GO:0010867 | positive regulation of triglyceride biosynthetic process | 5 | 14 | 4.46e-04 |
| GO:BP | GO:0010866 | regulation of triglyceride biosynthetic process | 5 | 19 | 1.65e-03 |
| GO:BP | GO:0090208 | positive regulation of triglyceride metabolic process | 5 | 18 | 2.34e-03 |
| GO:BP | GO:0046463 | acylglycerol biosynthetic process | 6 | 36 | 2.92e-03 |
| GO:BP | GO:0046460 | neutral lipid biosynthetic process | 6 | 36 | 2.92e-03 |
| GO:BP | GO:0019432 | triglyceride biosynthetic process | 5 | 31 | 1.56e-02 |
| GO:BP | GO:0090207 | regulation of triglyceride metabolic process | 5 | 29 | 1.73e-02 |
| GO:BP | GO:0045017 | glycerolipid biosynthetic process | 10 | 218 | 5.22e-02 |
| GO:BP | GO:0072384 | organelle transport along microtubule | 8 | 84 | 6.74e-02 |
| GO:BP | GO:0046499 | S-adenosylmethioninamine metabolic process | 1 | 1 | 7.98e-02 |
| GO:BP | GO:0019896 | axonal transport of mitochondrion | 4 | 17 | 7.98e-02 |
| GO:BP | GO:1902455 | negative regulation of stem cell population maintenance | 3 | 21 | 1.03e-01 |
| GO:BP | GO:0008090 | retrograde axonal transport | 4 | 19 | 1.07e-01 |
| GO:BP | GO:0046498 | S-adenosylhomocysteine metabolic process | 1 | 2 | 1.07e-01 |
| GO:BP | GO:0033762 | response to glucagon | 4 | 13 | 1.07e-01 |
| GO:BP | GO:0036250 | peroxisome transport along microtubule | 1 | 1 | 1.07e-01 |
| GO:BP | GO:0006481 | C-terminal protein methylation | 1 | 2 | 1.07e-01 |
| GO:BP | GO:0010972 | negative regulation of G2/M transition of mitotic cell cycle | 2 | 60 | 1.26e-01 |
| GO:BP | GO:1902750 | negative regulation of cell cycle G2/M phase transition | 2 | 62 | 1.28e-01 |
| GO:BP | GO:0046457 | prostanoid biosynthetic process | 2 | 19 | 1.31e-01 |
| GO:BP | GO:0001516 | prostaglandin biosynthetic process | 2 | 19 | 1.31e-01 |
| GO:BP | GO:0044721 | protein import into peroxisome matrix, substrate release | 1 | 2 | 1.31e-01 |
| GO:BP | GO:0010970 | transport along microtubule | 10 | 162 | 1.32e-01 |
| GO:BP | GO:0003058 | hormonal regulation of the force of heart contraction | 1 | 1 | 1.33e-01 |
| GO:BP | GO:0016561 | protein import into peroxisome matrix, translocation | 1 | 3 | 1.33e-01 |
| GO:BP | GO:0098930 | axonal transport | 6 | 60 | 1.33e-01 |
| GO:BP | GO:0046889 | positive regulation of lipid biosynthetic process | 5 | 63 | 1.33e-01 |
| GO:BP | GO:0006054 | N-acetylneuraminate metabolic process | 3 | 11 | 1.33e-01 |
| GO:BP | GO:0034643 | establishment of mitochondrion localization, microtubule-mediated | 4 | 26 | 1.33e-01 |
| GO:BP | GO:0030705 | cytoskeleton-dependent intracellular transport | 11 | 194 | 1.33e-01 |
| GO:BP | GO:0047497 | mitochondrion transport along microtubule | 4 | 26 | 1.33e-01 |
| GO:BP | GO:0006639 | acylglycerol metabolic process | 6 | 92 | 1.33e-01 |
| GO:BP | GO:0035520 | monoubiquitinated protein deubiquitination | 3 | 36 | 1.33e-01 |
| GO:BP | GO:0035521 | monoubiquitinated histone deubiquitination | 2 | 30 | 1.33e-01 |
| GO:BP | GO:0035522 | monoubiquitinated histone H2A deubiquitination | 2 | 30 | 1.33e-01 |
| GO:BP | GO:0006638 | neutral lipid metabolic process | 6 | 93 | 1.33e-01 |
| GO:BP | GO:0043508 | negative regulation of JUN kinase activity | 2 | 13 | 1.33e-01 |
| GO:BP | GO:0009932 | cell tip growth | 1 | 1 | 1.33e-01 |
| GO:BP | GO:0045663 | positive regulation of myoblast differentiation | 3 | 37 | 1.33e-01 |
| GO:BP | GO:0010389 | regulation of G2/M transition of mitotic cell cycle | 2 | 92 | 1.37e-01 |
| GO:BP | GO:0016560 | protein import into peroxisome matrix, docking | 1 | 3 | 1.37e-01 |
| GO:BP | GO:1901096 | regulation of autophagosome maturation | 3 | 16 | 1.37e-01 |
| GO:BP | GO:0016570 | histone modification | 9 | 433 | 1.53e-01 |
| GO:BP | GO:0008089 | anterograde axonal transport | 5 | 45 | 1.53e-01 |
| GO:BP | GO:1902749 | regulation of cell cycle G2/M phase transition | 2 | 103 | 1.53e-01 |
| GO:BP | GO:0006693 | prostaglandin metabolic process | 2 | 32 | 1.53e-01 |
| GO:BP | GO:0006636 | unsaturated fatty acid biosynthetic process | 2 | 34 | 1.53e-01 |
| GO:BP | GO:0006692 | prostanoid metabolic process | 2 | 32 | 1.53e-01 |
| GO:BP | GO:0051654 | establishment of mitochondrion localization | 4 | 30 | 1.54e-01 |
| GO:BP | GO:1902459 | positive regulation of stem cell population maintenance | 3 | 44 | 1.59e-01 |
| GO:BP | GO:0048318 | axial mesoderm development | 2 | 6 | 1.74e-01 |
| GO:BP | GO:0048264 | determination of ventral identity | 1 | 1 | 1.74e-01 |
| GO:BP | GO:0006641 | triglyceride metabolic process | 5 | 68 | 1.74e-01 |
| GO:BP | GO:0016578 | histone deubiquitination | 2 | 46 | 1.74e-01 |
| GO:BP | GO:0061888 | regulation of astrocyte activation | 2 | 3 | 1.74e-01 |
| GO:BP | GO:0008088 | axo-dendritic transport | 6 | 73 | 1.74e-01 |
| GO:BP | GO:0046456 | icosanoid biosynthetic process | 2 | 29 | 1.74e-01 |
| GO:BP | GO:1901800 | positive regulation of proteasomal protein catabolic process | 6 | 111 | 1.95e-01 |
| GO:BP | GO:0018410 | C-terminal protein amino acid modification | 1 | 10 | 1.95e-01 |
| GO:BP | GO:0006552 | leucine catabolic process | 2 | 6 | 1.95e-01 |
| GO:BP | GO:0042116 | macrophage activation | 5 | 57 | 1.95e-01 |
| GO:BP | GO:0000086 | G2/M transition of mitotic cell cycle | 2 | 134 | 1.95e-01 |
| GO:BP | GO:0072383 | plus-end-directed vesicle transport along microtubule | 2 | 6 | 1.96e-01 |
| GO:BP | GO:0090341 | negative regulation of secretion of lysosomal enzymes | 1 | 1 | 1.96e-01 |
| GO:BP | GO:0048512 | circadian behavior | 2 | 30 | 1.96e-01 |
| GO:BP | GO:1901098 | positive regulation of autophagosome maturation | 2 | 6 | 1.96e-01 |
| GO:BP | GO:0044839 | cell cycle G2/M phase transition | 2 | 149 | 2.06e-01 |
| GO:BP | GO:0046486 | glycerolipid metabolic process | 10 | 311 | 2.06e-01 |
| GO:BP | GO:0007622 | rhythmic behavior | 2 | 32 | 2.06e-01 |
| GO:BP | GO:0099111 | microtubule-based transport | 10 | 191 | 2.15e-01 |
| GO:BP | GO:0003099 | positive regulation of the force of heart contraction by chemical signal | 1 | 2 | 2.16e-01 |
| GO:BP | GO:0009826 | unidimensional cell growth | 1 | 3 | 2.16e-01 |
| GO:BP | GO:0030581 | symbiont intracellular protein transport in host | 1 | 2 | 2.21e-01 |
| GO:BP | GO:0045187 | regulation of circadian sleep/wake cycle, sleep | 1 | 7 | 2.21e-01 |
| GO:BP | GO:0042749 | regulation of circadian sleep/wake cycle | 1 | 9 | 2.21e-01 |
| GO:BP | GO:0061146 | Peyer’s patch morphogenesis | 1 | 3 | 2.21e-01 |
| GO:BP | GO:0010526 | retrotransposon silencing | 1 | 3 | 2.21e-01 |
| GO:BP | GO:0006551 | leucine metabolic process | 2 | 8 | 2.21e-01 |
| GO:BP | GO:0019060 | intracellular transport of viral protein in host cell | 1 | 2 | 2.21e-01 |
| GO:BP | GO:0008645 | hexose transmembrane transport | 7 | 84 | 2.21e-01 |
| GO:BP | GO:0050802 | circadian sleep/wake cycle, sleep | 1 | 9 | 2.21e-01 |
| GO:BP | GO:0061298 | retina vasculature development in camera-type eye | 2 | 14 | 2.21e-01 |
| GO:BP | GO:0014826 | vein smooth muscle contraction | 1 | 3 | 2.21e-01 |
| GO:BP | GO:0007623 | circadian rhythm | 6 | 165 | 2.21e-01 |
| GO:BP | GO:0042040 | metal incorporation into metallo-molybdopterin complex | 1 | 1 | 2.21e-01 |
| GO:BP | GO:0045661 | regulation of myoblast differentiation | 3 | 61 | 2.21e-01 |
| GO:BP | GO:0015749 | monosaccharide transmembrane transport | 7 | 85 | 2.21e-01 |
| GO:BP | GO:0072386 | plus-end-directed organelle transport along microtubule | 2 | 7 | 2.21e-01 |
| GO:BP | GO:0018315 | molybdenum incorporation into molybdenum-molybdopterin complex | 1 | 1 | 2.21e-01 |
| GO:BP | GO:1903146 | regulation of autophagy of mitochondrion | 3 | 37 | 2.21e-01 |
| GO:BP | GO:2000171 | negative regulation of dendrite development | 2 | 7 | 2.21e-01 |
| GO:BP | GO:0042278 | purine nucleoside metabolic process | 1 | 20 | 2.21e-01 |
| GO:BP | GO:0008542 | visual learning | 3 | 37 | 2.21e-01 |
| GO:BP | GO:1904659 | glucose transmembrane transport | 7 | 81 | 2.21e-01 |
| GO:BP | GO:0010586 | miRNA metabolic process | 4 | 81 | 2.21e-01 |
| GO:BP | GO:0032436 | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 5 | 89 | 2.21e-01 |
| GO:BP | GO:0016558 | protein import into peroxisome matrix | 1 | 14 | 2.21e-01 |
| GO:BP | GO:0047496 | vesicle transport along microtubule | 4 | 41 | 2.21e-01 |
| GO:BP | GO:0046128 | purine ribonucleoside metabolic process | 1 | 16 | 2.21e-01 |
| GO:BP | GO:0016260 | selenocysteine biosynthetic process | 1 | 2 | 2.21e-01 |
| GO:BP | GO:0042789 | mRNA transcription by RNA polymerase II | 3 | 45 | 2.21e-01 |
| GO:BP | GO:1901991 | negative regulation of mitotic cell cycle phase transition | 2 | 166 | 2.21e-01 |
| GO:BP | GO:2000250 | negative regulation of actin cytoskeleton reorganization | 1 | 1 | 2.21e-01 |
| GO:BP | GO:0060584 | regulation of prostaglandin-endoperoxide synthase activity | 1 | 2 | 2.21e-01 |
| GO:BP | GO:0060585 | positive regulation of prostaglandin-endoperoxide synthase activity | 1 | 2 | 2.21e-01 |
| GO:BP | GO:1990074 | polyuridylation-dependent mRNA catabolic process | 1 | 3 | 2.21e-01 |
| GO:BP | GO:0072579 | glycine receptor clustering | 1 | 1 | 2.21e-01 |
| GO:BP | GO:0022410 | circadian sleep/wake cycle process | 1 | 10 | 2.23e-01 |
| GO:BP | GO:0046329 | negative regulation of JNK cascade | 2 | 36 | 2.24e-01 |
| GO:BP | GO:1903052 | positive regulation of proteolysis involved in protein catabolic process | 6 | 127 | 2.24e-01 |
| GO:BP | GO:0007258 | JUN phosphorylation | 1 | 2 | 2.24e-01 |
| GO:BP | GO:0016575 | histone deacetylation | 4 | 87 | 2.24e-01 |
| GO:BP | GO:2000036 | regulation of stem cell population maintenance | 3 | 62 | 2.25e-01 |
| GO:BP | GO:0043405 | regulation of MAP kinase activity | 7 | 141 | 2.25e-01 |
| GO:BP | GO:0090182 | regulation of secretion of lysosomal enzymes | 1 | 2 | 2.25e-01 |
| GO:BP | GO:0009299 | mRNA transcription | 3 | 50 | 2.25e-01 |
| GO:BP | GO:0043506 | regulation of JUN kinase activity | 3 | 49 | 2.25e-01 |
| GO:BP | GO:0042745 | circadian sleep/wake cycle | 1 | 11 | 2.25e-01 |
| GO:BP | GO:0009119 | ribonucleoside metabolic process | 1 | 23 | 2.25e-01 |
| GO:BP | GO:1903507 | negative regulation of nucleic acid-templated transcription | 3 | 1017 | 2.25e-01 |
| GO:BP | GO:0071076 | RNA 3’ uridylation | 1 | 4 | 2.25e-01 |
| GO:BP | GO:0072662 | protein localization to peroxisome | 1 | 19 | 2.25e-01 |
| GO:BP | GO:0006625 | protein targeting to peroxisome | 1 | 19 | 2.25e-01 |
| GO:BP | GO:0033027 | positive regulation of mast cell apoptotic process | 1 | 1 | 2.25e-01 |
| GO:BP | GO:1904481 | response to tetrahydrofolate | 1 | 1 | 2.25e-01 |
| GO:BP | GO:1902895 | positive regulation of miRNA transcription | 3 | 42 | 2.25e-01 |
| GO:BP | GO:1904482 | cellular response to tetrahydrofolate | 1 | 1 | 2.25e-01 |
| GO:BP | GO:0003100 | regulation of systemic arterial blood pressure by endothelin | 1 | 5 | 2.25e-01 |
| GO:BP | GO:0032197 | retrotransposition | 1 | 4 | 2.25e-01 |
| GO:BP | GO:0006335 | DNA replication-dependent chromatin assembly | 1 | 6 | 2.25e-01 |
| GO:BP | GO:0016259 | selenocysteine metabolic process | 1 | 2 | 2.25e-01 |
| GO:BP | GO:0045930 | negative regulation of mitotic cell cycle | 2 | 211 | 2.25e-01 |
| GO:BP | GO:0045892 | negative regulation of DNA-templated transcription | 3 | 1015 | 2.25e-01 |
| GO:BP | GO:0061534 | gamma-aminobutyric acid secretion, neurotransmission | 1 | 1 | 2.25e-01 |
| GO:BP | GO:0007632 | visual behavior | 3 | 41 | 2.25e-01 |
| GO:BP | GO:0048712 | negative regulation of astrocyte differentiation | 2 | 9 | 2.25e-01 |
| GO:BP | GO:0072663 | establishment of protein localization to peroxisome | 1 | 19 | 2.25e-01 |
| GO:BP | GO:0003057 | regulation of the force of heart contraction by chemical signal | 1 | 5 | 2.25e-01 |
| GO:BP | GO:1902679 | negative regulation of RNA biosynthetic process | 3 | 1026 | 2.26e-01 |
| GO:BP | GO:0032922 | circadian regulation of gene expression | 2 | 63 | 2.26e-01 |
| GO:BP | GO:0030431 | sleep | 1 | 13 | 2.28e-01 |
| GO:BP | GO:0048016 | inositol phosphate-mediated signaling | 3 | 45 | 2.28e-01 |
| GO:BP | GO:0043153 | entrainment of circadian clock by photoperiod | 1 | 27 | 2.28e-01 |
| GO:BP | GO:0034463 | 90S preribosome assembly | 1 | 1 | 2.28e-01 |
| GO:BP | GO:0015919 | peroxisomal membrane transport | 1 | 20 | 2.28e-01 |
| GO:BP | GO:0099642 | retrograde axonal protein transport | 1 | 2 | 2.28e-01 |
| GO:BP | GO:0009070 | serine family amino acid biosynthetic process | 2 | 16 | 2.37e-01 |
| GO:BP | GO:1901988 | negative regulation of cell cycle phase transition | 2 | 235 | 2.37e-01 |
| GO:BP | GO:0006451 | translational readthrough | 1 | 10 | 2.37e-01 |
| GO:BP | GO:0044027 | negative regulation of gene expression via CpG island methylation | 1 | 1 | 2.37e-01 |
| GO:BP | GO:0046349 | amino sugar biosynthetic process | 2 | 11 | 2.37e-01 |
| GO:BP | GO:2000630 | positive regulation of miRNA metabolic process | 3 | 48 | 2.37e-01 |
| GO:BP | GO:0043574 | peroxisomal transport | 1 | 22 | 2.37e-01 |
| GO:BP | GO:0050821 | protein stabilization | 2 | 191 | 2.37e-01 |
| GO:BP | GO:0009649 | entrainment of circadian clock | 1 | 31 | 2.37e-01 |
| GO:BP | GO:0009648 | photoperiodism | 1 | 28 | 2.37e-01 |
| GO:BP | GO:1904226 | regulation of glycogen synthase activity, transferring glucose-1-phosphate | 1 | 1 | 2.37e-01 |
| GO:BP | GO:0034219 | carbohydrate transmembrane transport | 7 | 92 | 2.37e-01 |
| GO:BP | GO:0034453 | microtubule anchoring | 1 | 25 | 2.37e-01 |
| GO:BP | GO:0071879 | positive regulation of adenylate cyclase-activating adrenergic receptor signaling pathway | 1 | 1 | 2.37e-01 |
| GO:BP | GO:0001514 | selenocysteine incorporation | 1 | 10 | 2.37e-01 |
| GO:BP | GO:0055113 | epiboly involved in gastrulation with mouth forming second | 1 | 1 | 2.37e-01 |
| GO:BP | GO:1904227 | negative regulation of glycogen synthase activity, transferring glucose-1-phosphate | 1 | 1 | 2.37e-01 |
| GO:BP | GO:0033559 | unsaturated fatty acid metabolic process | 2 | 66 | 2.37e-01 |
| GO:BP | GO:0010904 | regulation of UDP-glucose catabolic process | 1 | 1 | 2.37e-01 |
| GO:BP | GO:0010905 | negative regulation of UDP-glucose catabolic process | 1 | 1 | 2.37e-01 |
| GO:BP | GO:0043407 | negative regulation of MAP kinase activity | 3 | 50 | 2.37e-01 |
| GO:BP | GO:0051253 | negative regulation of RNA metabolic process | 3 | 1119 | 2.37e-01 |
| GO:BP | GO:0042752 | regulation of circadian rhythm | 3 | 97 | 2.38e-01 |
| GO:BP | GO:0070303 | negative regulation of stress-activated protein kinase signaling cascade | 2 | 46 | 2.40e-01 |
| GO:BP | GO:0032873 | negative regulation of stress-activated MAPK cascade | 2 | 46 | 2.40e-01 |
| GO:BP | GO:0021556 | central nervous system formation | 1 | 1 | 2.43e-01 |
| GO:BP | GO:1904327 | protein localization to cytosolic proteasome complex | 1 | 2 | 2.43e-01 |
| GO:BP | GO:0048537 | mucosa-associated lymphoid tissue development | 1 | 6 | 2.43e-01 |
| GO:BP | GO:0048541 | Peyer’s patch development | 1 | 6 | 2.43e-01 |
| GO:BP | GO:0007529 | establishment of synaptic specificity at neuromuscular junction | 1 | 2 | 2.43e-01 |
| GO:BP | GO:1905168 | positive regulation of double-strand break repair via homologous recombination | 2 | 35 | 2.43e-01 |
| GO:BP | GO:0007411 | axon guidance | 7 | 185 | 2.43e-01 |
| GO:BP | GO:0045834 | positive regulation of lipid metabolic process | 5 | 108 | 2.43e-01 |
| GO:BP | GO:0022411 | cellular component disassembly | 14 | 427 | 2.43e-01 |
| GO:BP | GO:0097021 | lymphocyte migration into lymphoid organs | 1 | 6 | 2.43e-01 |
| GO:BP | GO:0051097 | negative regulation of helicase activity | 1 | 5 | 2.43e-01 |
| GO:BP | GO:0097370 | protein O-GlcNAcylation via threonine | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0098972 | anterograde dendritic transport of mitochondrion | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0045934 | negative regulation of nucleobase-containing compound metabolic process | 3 | 1209 | 2.43e-01 |
| GO:BP | GO:1903988 | iron ion export across plasma membrane | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0016191 | synaptic vesicle uncoating | 1 | 7 | 2.43e-01 |
| GO:BP | GO:0006476 | protein deacetylation | 3 | 106 | 2.43e-01 |
| GO:BP | GO:0009743 | response to carbohydrate | 7 | 161 | 2.43e-01 |
| GO:BP | GO:0030336 | negative regulation of cell migration | 7 | 227 | 2.43e-01 |
| GO:BP | GO:0046293 | formaldehyde biosynthetic process | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0046380 | N-acetylneuraminate biosynthetic process | 1 | 1 | 2.43e-01 |
| GO:BP | GO:1904379 | protein localization to cytosolic proteasome complex involved in ERAD pathway | 1 | 2 | 2.43e-01 |
| GO:BP | GO:0097485 | neuron projection guidance | 7 | 186 | 2.43e-01 |
| GO:BP | GO:0014824 | artery smooth muscle contraction | 1 | 7 | 2.43e-01 |
| GO:BP | GO:0006940 | regulation of smooth muscle contraction | 2 | 42 | 2.43e-01 |
| GO:BP | GO:0043031 | negative regulation of macrophage activation | 2 | 9 | 2.43e-01 |
| GO:BP | GO:0043277 | apoptotic cell clearance | 2 | 35 | 2.43e-01 |
| GO:BP | GO:0010558 | negative regulation of macromolecule biosynthetic process | 3 | 1214 | 2.43e-01 |
| GO:BP | GO:0048710 | regulation of astrocyte differentiation | 3 | 21 | 2.43e-01 |
| GO:BP | GO:0006349 | regulation of gene expression by genomic imprinting | 2 | 14 | 2.43e-01 |
| GO:BP | GO:0010587 | miRNA catabolic process | 2 | 10 | 2.43e-01 |
| GO:BP | GO:2000060 | positive regulation of ubiquitin-dependent protein catabolic process | 5 | 103 | 2.43e-01 |
| GO:BP | GO:0009116 | nucleoside metabolic process | 1 | 42 | 2.43e-01 |
| GO:BP | GO:0090188 | negative regulation of pancreatic juice secretion | 1 | 4 | 2.43e-01 |
| GO:BP | GO:0060345 | spleen trabecula formation | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0006690 | icosanoid metabolic process | 2 | 60 | 2.43e-01 |
| GO:BP | GO:0043030 | regulation of macrophage activation | 4 | 31 | 2.43e-01 |
| GO:BP | GO:0010948 | negative regulation of cell cycle process | 2 | 273 | 2.43e-01 |
| GO:BP | GO:0051646 | mitochondrion localization | 4 | 47 | 2.43e-01 |
| GO:BP | GO:0006289 | nucleotide-excision repair | 3 | 79 | 2.43e-01 |
| GO:BP | GO:0031327 | negative regulation of cellular biosynthetic process | 3 | 1239 | 2.43e-01 |
| GO:BP | GO:0002127 | tRNA wobble base cytosine methylation | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0017015 | regulation of transforming growth factor beta receptor signaling pathway | 4 | 128 | 2.45e-01 |
| GO:BP | GO:0072318 | clathrin coat disassembly | 1 | 8 | 2.45e-01 |
| GO:BP | GO:0061890 | positive regulation of astrocyte activation | 1 | 1 | 2.46e-01 |
| GO:BP | GO:0006633 | fatty acid biosynthetic process | 3 | 104 | 2.46e-01 |
| GO:BP | GO:0140235 | RNA polyadenylation at postsynapse | 1 | 1 | 2.46e-01 |
| GO:BP | GO:1901990 | regulation of mitotic cell cycle phase transition | 2 | 308 | 2.46e-01 |
| GO:BP | GO:0019752 | carboxylic acid metabolic process | 2 | 681 | 2.46e-01 |
| GO:BP | GO:0048017 | inositol lipid-mediated signaling | 5 | 126 | 2.46e-01 |
| GO:BP | GO:0048015 | phosphatidylinositol-mediated signaling | 5 | 123 | 2.46e-01 |
| GO:BP | GO:0098869 | cellular oxidant detoxification | 1 | 65 | 2.46e-01 |
| GO:BP | GO:0033344 | cholesterol efflux | 2 | 40 | 2.46e-01 |
| GO:BP | GO:1902893 | regulation of miRNA transcription | 3 | 56 | 2.46e-01 |
| GO:BP | GO:0019827 | stem cell population maintenance | 4 | 149 | 2.46e-01 |
| GO:BP | GO:0006605 | protein targeting | 2 | 307 | 2.46e-01 |
| GO:BP | GO:0019264 | glycine biosynthetic process from serine | 1 | 2 | 2.46e-01 |
| GO:BP | GO:1902961 | positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process | 1 | 7 | 2.46e-01 |
| GO:BP | GO:0098732 | macromolecule deacylation | 3 | 119 | 2.46e-01 |
| GO:BP | GO:0014820 | tonic smooth muscle contraction | 1 | 8 | 2.46e-01 |
| GO:BP | GO:2000626 | negative regulation of miRNA catabolic process | 1 | 1 | 2.46e-01 |
| GO:BP | GO:0150077 | regulation of neuroinflammatory response | 3 | 13 | 2.46e-01 |
| GO:BP | GO:0031123 | RNA 3’-end processing | 2 | 100 | 2.46e-01 |
| GO:BP | GO:0045732 | positive regulation of protein catabolic process | 7 | 192 | 2.46e-01 |
| GO:BP | GO:0048511 | rhythmic process | 7 | 237 | 2.46e-01 |
| GO:BP | GO:0061614 | miRNA transcription | 3 | 57 | 2.46e-01 |
| GO:BP | GO:0043436 | oxoacid metabolic process | 2 | 696 | 2.46e-01 |
| GO:BP | GO:0044743 | protein transmembrane import into intracellular organelle | 1 | 36 | 2.46e-01 |
| GO:BP | GO:0009890 | negative regulation of biosynthetic process | 3 | 1280 | 2.46e-01 |
| GO:BP | GO:0043687 | post-translational protein modification | 1 | 64 | 2.46e-01 |
| GO:BP | GO:0006082 | organic acid metabolic process | 2 | 700 | 2.46e-01 |
| GO:BP | GO:1903844 | regulation of cellular response to transforming growth factor beta stimulus | 4 | 129 | 2.46e-01 |
| GO:BP | GO:0007031 | peroxisome organization | 1 | 34 | 2.46e-01 |
| GO:BP | GO:0072319 | vesicle uncoating | 1 | 9 | 2.46e-01 |
| GO:BP | GO:0035601 | protein deacylation | 3 | 116 | 2.46e-01 |
| GO:BP | GO:0030512 | negative regulation of transforming growth factor beta receptor signaling pathway | 3 | 86 | 2.46e-01 |
| GO:BP | GO:0015871 | choline transport | 1 | 6 | 2.49e-01 |
| GO:BP | GO:0098727 | maintenance of cell number | 4 | 151 | 2.51e-01 |
| GO:BP | GO:0008610 | lipid biosynthetic process | 13 | 560 | 2.51e-01 |
| GO:BP | GO:0021502 | neural fold elevation formation | 1 | 3 | 2.51e-01 |
| GO:BP | GO:0070101 | positive regulation of chemokine-mediated signaling pathway | 1 | 2 | 2.51e-01 |
| GO:BP | GO:1990748 | cellular detoxification | 1 | 76 | 2.51e-01 |
| GO:BP | GO:0048550 | negative regulation of pinocytosis | 1 | 4 | 2.51e-01 |
| GO:BP | GO:1905247 | positive regulation of aspartic-type peptidase activity | 1 | 8 | 2.51e-01 |
| GO:BP | GO:0045445 | myoblast differentiation | 3 | 90 | 2.51e-01 |
| GO:BP | GO:1904792 | positive regulation of shelterin complex assembly | 1 | 1 | 2.55e-01 |
| GO:BP | GO:0050921 | positive regulation of chemotaxis | 2 | 85 | 2.55e-01 |
| GO:BP | GO:0006479 | protein methylation | 4 | 160 | 2.55e-01 |
| GO:BP | GO:0097237 | cellular response to toxic substance | 1 | 82 | 2.55e-01 |
| GO:BP | GO:1904914 | negative regulation of establishment of protein-containing complex localization to telomere | 1 | 1 | 2.55e-01 |
| GO:BP | GO:1904850 | negative regulation of establishment of protein localization to telomere | 1 | 1 | 2.55e-01 |
| GO:BP | GO:1904911 | negative regulation of establishment of RNA localization to telomere | 1 | 1 | 2.55e-01 |
| GO:BP | GO:1904913 | regulation of establishment of protein-containing complex localization to telomere | 1 | 1 | 2.55e-01 |
| GO:BP | GO:2000146 | negative regulation of cell motility | 7 | 236 | 2.55e-01 |
| GO:BP | GO:1904910 | regulation of establishment of RNA localization to telomere | 1 | 1 | 2.55e-01 |
| GO:BP | GO:0046890 | regulation of lipid biosynthetic process | 6 | 134 | 2.55e-01 |
| GO:BP | GO:0008213 | protein alkylation | 4 | 160 | 2.55e-01 |
| GO:BP | GO:0000027 | ribosomal large subunit assembly | 2 | 23 | 2.55e-01 |
| GO:BP | GO:0019082 | viral protein processing | 3 | 31 | 2.55e-01 |
| GO:BP | GO:1901657 | glycosyl compound metabolic process | 1 | 62 | 2.57e-01 |
| GO:BP | GO:0071000 | response to magnetism | 1 | 2 | 2.57e-01 |
| GO:BP | GO:0002319 | memory B cell differentiation | 1 | 1 | 2.57e-01 |
| GO:BP | GO:0009749 | response to glucose | 6 | 137 | 2.57e-01 |
| GO:BP | GO:0040012 | regulation of locomotion | 16 | 763 | 2.57e-01 |
| GO:BP | GO:0062003 | negative regulation of all-trans-retinyl-ester hydrolase, 11-cis retinol forming activity | 1 | 1 | 2.61e-01 |
| GO:BP | GO:0062002 | regulation of all-trans-retinyl-ester hydrolase, 11-cis retinol forming activity | 1 | 1 | 2.61e-01 |
| GO:BP | GO:0015697 | quaternary ammonium group transport | 2 | 17 | 2.64e-01 |
| GO:BP | GO:0007405 | neuroblast proliferation | 3 | 51 | 2.65e-01 |
| GO:BP | GO:2000077 | negative regulation of type B pancreatic cell development | 1 | 2 | 2.71e-01 |
| GO:BP | GO:0006258 | UDP-glucose catabolic process | 1 | 2 | 2.71e-01 |
| GO:BP | GO:0048320 | axial mesoderm formation | 1 | 2 | 2.71e-01 |
| GO:BP | GO:0098754 | detoxification | 1 | 91 | 2.75e-01 |
| GO:BP | GO:0065002 | intracellular protein transmembrane transport | 1 | 52 | 2.76e-01 |
| GO:BP | GO:0045786 | negative regulation of cell cycle | 2 | 338 | 2.76e-01 |
| GO:BP | GO:0009746 | response to hexose | 6 | 138 | 2.76e-01 |
| GO:BP | GO:0009408 | response to heat | 4 | 84 | 2.76e-01 |
| GO:BP | GO:1902959 | regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process | 1 | 10 | 2.77e-01 |
| GO:BP | GO:0007095 | mitotic G2 DNA damage checkpoint signaling | 1 | 35 | 2.77e-01 |
| GO:BP | GO:0035963 | cellular response to interleukin-13 | 1 | 1 | 2.77e-01 |
| GO:BP | GO:0015757 | galactose transmembrane transport | 1 | 4 | 2.77e-01 |
| GO:BP | GO:0033025 | regulation of mast cell apoptotic process | 1 | 3 | 2.77e-01 |
| GO:BP | GO:0090186 | regulation of pancreatic juice secretion | 1 | 6 | 2.77e-01 |
| GO:BP | GO:0031647 | regulation of protein stability | 2 | 290 | 2.77e-01 |
| GO:BP | GO:1900148 | negative regulation of Schwann cell migration | 1 | 3 | 2.77e-01 |
| GO:BP | GO:0090204 | protein localization to nuclear pore | 1 | 3 | 2.77e-01 |
| GO:BP | GO:0007167 | enzyme-linked receptor protein signaling pathway | 18 | 763 | 2.77e-01 |
| GO:BP | GO:0033024 | mast cell apoptotic process | 1 | 3 | 2.77e-01 |
| GO:BP | GO:0016053 | organic acid biosynthetic process | 4 | 224 | 2.77e-01 |
| GO:BP | GO:0031054 | pre-miRNA processing | 1 | 14 | 2.77e-01 |
| GO:BP | GO:0045944 | positive regulation of transcription by RNA polymerase II | 26 | 937 | 2.77e-01 |
| GO:BP | GO:0030947 | regulation of vascular endothelial growth factor receptor signaling pathway | 2 | 27 | 2.77e-01 |
| GO:BP | GO:0046394 | carboxylic acid biosynthetic process | 4 | 223 | 2.77e-01 |
| GO:BP | GO:0034605 | cellular response to heat | 3 | 51 | 2.77e-01 |
| GO:BP | GO:0034395 | regulation of transcription from RNA polymerase II promoter in response to iron | 1 | 2 | 2.77e-01 |
| GO:BP | GO:0097368 | establishment of Sertoli cell barrier | 1 | 3 | 2.77e-01 |
| GO:BP | GO:0046719 | regulation by virus of viral protein levels in host cell | 1 | 8 | 2.77e-01 |
| GO:BP | GO:0033299 | secretion of lysosomal enzymes | 1 | 7 | 2.77e-01 |
| GO:BP | GO:0021896 | forebrain astrocyte differentiation | 1 | 2 | 2.77e-01 |
| GO:BP | GO:0032984 | protein-containing complex disassembly | 8 | 222 | 2.77e-01 |
| GO:BP | GO:0021897 | forebrain astrocyte development | 1 | 2 | 2.77e-01 |
| GO:BP | GO:1902993 | positive regulation of amyloid precursor protein catabolic process | 2 | 22 | 2.77e-01 |
| GO:BP | GO:2000628 | regulation of miRNA metabolic process | 3 | 67 | 2.77e-01 |
| GO:BP | GO:0031460 | glycine betaine transport | 1 | 2 | 2.77e-01 |
| GO:BP | GO:0050930 | induction of positive chemotaxis | 1 | 12 | 2.77e-01 |
| GO:BP | GO:0120163 | negative regulation of cold-induced thermogenesis | 3 | 40 | 2.77e-01 |
| GO:BP | GO:0060749 | mammary gland alveolus development | 2 | 13 | 2.77e-01 |
| GO:BP | GO:0150078 | positive regulation of neuroinflammatory response | 2 | 4 | 2.77e-01 |
| GO:BP | GO:0099518 | vesicle cytoskeletal trafficking | 4 | 60 | 2.77e-01 |
| GO:BP | GO:0061377 | mammary gland lobule development | 2 | 13 | 2.77e-01 |
| GO:BP | GO:0061030 | epithelial cell differentiation involved in mammary gland alveolus development | 1 | 2 | 2.77e-01 |
| GO:BP | GO:0050795 | regulation of behavior | 1 | 39 | 2.77e-01 |
| GO:BP | GO:0140861 | DNA repair-dependent chromatin remodeling | 1 | 6 | 2.77e-01 |
| GO:BP | GO:0001922 | B-1 B cell homeostasis | 1 | 4 | 2.77e-01 |
| GO:BP | GO:0098708 | glucose import across plasma membrane | 1 | 5 | 2.77e-01 |
| GO:BP | GO:0098939 | dendritic transport of mitochondrion | 1 | 2 | 2.77e-01 |
| GO:BP | GO:0006703 | estrogen biosynthetic process | 1 | 6 | 2.78e-01 |
| GO:BP | GO:0048262 | determination of dorsal/ventral asymmetry | 1 | 6 | 2.78e-01 |
| GO:BP | GO:0014878 | response to electrical stimulus involved in regulation of muscle adaptation | 1 | 2 | 2.78e-01 |
| GO:BP | GO:0034284 | response to monosaccharide | 6 | 142 | 2.78e-01 |
| GO:BP | GO:0090287 | regulation of cellular response to growth factor stimulus | 7 | 265 | 2.78e-01 |
| GO:BP | GO:0045686 | negative regulation of glial cell differentiation | 2 | 15 | 2.78e-01 |
| GO:BP | GO:0071806 | protein transmembrane transport | 1 | 62 | 2.78e-01 |
| GO:BP | GO:0071732 | cellular response to nitric oxide | 2 | 14 | 2.78e-01 |
| GO:BP | GO:1901073 | glucosamine-containing compound biosynthetic process | 1 | 2 | 2.78e-01 |
| GO:BP | GO:1903546 | protein localization to photoreceptor outer segment | 1 | 5 | 2.78e-01 |
| GO:BP | GO:1902396 | protein localization to bicellular tight junction | 1 | 3 | 2.78e-01 |
| GO:BP | GO:0006045 | N-acetylglucosamine biosynthetic process | 1 | 2 | 2.78e-01 |
| GO:BP | GO:0008643 | carbohydrate transport | 7 | 111 | 2.78e-01 |
| GO:BP | GO:0006651 | diacylglycerol biosynthetic process | 1 | 7 | 2.79e-01 |
| GO:BP | GO:0043985 | histone H4-R3 methylation | 1 | 6 | 2.79e-01 |
| GO:BP | GO:1905245 | regulation of aspartic-type peptidase activity | 1 | 11 | 2.79e-01 |
| GO:BP | GO:0090312 | positive regulation of protein deacetylation | 2 | 28 | 2.79e-01 |
| GO:BP | GO:0010226 | response to lithium ion | 2 | 16 | 2.80e-01 |
| GO:BP | GO:0034244 | negative regulation of transcription elongation by RNA polymerase II | 2 | 17 | 2.80e-01 |
| GO:BP | GO:0014002 | astrocyte development | 3 | 27 | 2.81e-01 |
| GO:BP | GO:0035879 | plasma membrane lactate transport | 1 | 3 | 2.81e-01 |
| GO:BP | GO:0002337 | B-1a B cell differentiation | 1 | 2 | 2.81e-01 |
| GO:BP | GO:0140271 | hexose import across plasma membrane | 1 | 5 | 2.81e-01 |
| GO:BP | GO:0045870 | positive regulation of single stranded viral RNA replication via double stranded DNA intermediate | 1 | 2 | 2.81e-01 |
| GO:BP | GO:0042867 | pyruvate catabolic process | 1 | 2 | 2.81e-01 |
| GO:BP | GO:1901987 | regulation of cell cycle phase transition | 2 | 391 | 2.81e-01 |
| GO:BP | GO:0098704 | carbohydrate import across plasma membrane | 1 | 5 | 2.81e-01 |
| GO:BP | GO:0007616 | long-term memory | 3 | 31 | 2.82e-01 |
| GO:BP | GO:1905691 | lipid droplet disassembly | 1 | 7 | 2.82e-01 |
| GO:BP | GO:0062033 | positive regulation of mitotic sister chromatid segregation | 1 | 6 | 2.82e-01 |
| GO:BP | GO:0048319 | axial mesoderm morphogenesis | 1 | 3 | 2.82e-01 |
| GO:BP | GO:0006021 | inositol biosynthetic process | 1 | 3 | 2.82e-01 |
| GO:BP | GO:0007197 | adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway | 1 | 3 | 2.82e-01 |
| GO:BP | GO:0002101 | tRNA wobble cytosine modification | 1 | 2 | 2.82e-01 |
| GO:BP | GO:0032091 | negative regulation of protein binding | 2 | 77 | 2.82e-01 |
| GO:BP | GO:0071312 | cellular response to alkaloid | 3 | 29 | 2.82e-01 |
| GO:BP | GO:0060331 | negative regulation of response to type II interferon | 1 | 6 | 2.82e-01 |
| GO:BP | GO:0060336 | negative regulation of type II interferon-mediated signaling pathway | 1 | 6 | 2.82e-01 |
| GO:BP | GO:2000210 | positive regulation of anoikis | 1 | 6 | 2.83e-01 |
| GO:BP | GO:0033045 | regulation of sister chromatid segregation | 3 | 99 | 2.83e-01 |
| GO:BP | GO:0097411 | hypoxia-inducible factor-1alpha signaling pathway | 1 | 4 | 2.83e-01 |
| GO:BP | GO:0006575 | cellular modified amino acid metabolic process | 1 | 96 | 2.83e-01 |
| GO:BP | GO:0061889 | negative regulation of astrocyte activation | 1 | 2 | 2.83e-01 |
| GO:BP | GO:0061771 | response to caloric restriction | 1 | 3 | 2.83e-01 |
| GO:BP | GO:0032434 | regulation of proteasomal ubiquitin-dependent protein catabolic process | 5 | 133 | 2.83e-01 |
| GO:BP | GO:0034773 | histone H4-K20 trimethylation | 1 | 5 | 2.83e-01 |
| GO:BP | GO:0060574 | intestinal epithelial cell maturation | 1 | 3 | 2.83e-01 |
| GO:BP | GO:0046600 | negative regulation of centriole replication | 1 | 7 | 2.83e-01 |
| GO:BP | GO:0061419 | positive regulation of transcription from RNA polymerase II promoter in response to hypoxia | 1 | 5 | 2.83e-01 |
| GO:BP | GO:0044772 | mitotic cell cycle phase transition | 2 | 418 | 2.83e-01 |
| GO:BP | GO:0048844 | artery morphogenesis | 3 | 58 | 2.83e-01 |
| GO:BP | GO:0006043 | glucosamine catabolic process | 1 | 2 | 2.83e-01 |
| GO:BP | GO:0097112 | gamma-aminobutyric acid receptor clustering | 1 | 3 | 2.83e-01 |
| GO:BP | GO:0046627 | negative regulation of insulin receptor signaling pathway | 3 | 29 | 2.83e-01 |
| GO:BP | GO:0010899 | regulation of phosphatidylcholine catabolic process | 1 | 3 | 2.83e-01 |
| GO:BP | GO:1903377 | negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway | 1 | 5 | 2.83e-01 |
| GO:BP | GO:0046470 | phosphatidylcholine metabolic process | 2 | 53 | 2.83e-01 |
| GO:BP | GO:0006044 | N-acetylglucosamine metabolic process | 2 | 16 | 2.84e-01 |
| GO:BP | GO:2000564 | regulation of CD8-positive, alpha-beta T cell proliferation | 1 | 7 | 2.85e-01 |
| GO:BP | GO:0035740 | CD8-positive, alpha-beta T cell proliferation | 1 | 7 | 2.85e-01 |
| GO:BP | GO:0008306 | associative learning | 3 | 65 | 2.85e-01 |
| GO:BP | GO:1902425 | positive regulation of attachment of mitotic spindle microtubules to kinetochore | 1 | 8 | 2.85e-01 |
| GO:BP | GO:1902423 | regulation of attachment of mitotic spindle microtubules to kinetochore | 1 | 8 | 2.85e-01 |
| GO:BP | GO:0035021 | negative regulation of Rac protein signal transduction | 1 | 4 | 2.85e-01 |
| GO:BP | GO:0002026 | regulation of the force of heart contraction | 2 | 23 | 2.85e-01 |
| GO:BP | GO:0035962 | response to interleukin-13 | 1 | 1 | 2.85e-01 |
| GO:BP | GO:0033023 | mast cell homeostasis | 1 | 4 | 2.85e-01 |
| GO:BP | GO:0009177 | pyrimidine deoxyribonucleoside monophosphate biosynthetic process | 1 | 4 | 2.85e-01 |
| GO:BP | GO:0099555 | trans-synaptic signaling by nitric oxide, modulating synaptic transmission | 1 | 2 | 2.85e-01 |
| GO:BP | GO:0016579 | protein deubiquitination | 2 | 129 | 2.85e-01 |
| GO:BP | GO:0044818 | mitotic G2/M transition checkpoint | 1 | 50 | 2.85e-01 |
| GO:BP | GO:2000466 | negative regulation of glycogen (starch) synthase activity | 1 | 3 | 2.85e-01 |
| GO:BP | GO:0042659 | regulation of cell fate specification | 1 | 23 | 2.85e-01 |
| GO:BP | GO:0097155 | fasciculation of sensory neuron axon | 1 | 3 | 2.85e-01 |
| GO:BP | GO:0010800 | positive regulation of peptidyl-threonine phosphorylation | 2 | 23 | 2.85e-01 |
| GO:BP | GO:1900077 | negative regulation of cellular response to insulin stimulus | 3 | 31 | 2.85e-01 |
| GO:BP | GO:0032663 | regulation of interleukin-2 production | 3 | 31 | 2.85e-01 |
| GO:BP | GO:0045475 | locomotor rhythm | 1 | 13 | 2.85e-01 |
| GO:BP | GO:0099554 | trans-synaptic signaling by soluble gas, modulating synaptic transmission | 1 | 2 | 2.85e-01 |
| GO:BP | GO:0002316 | follicular B cell differentiation | 1 | 1 | 2.85e-01 |
| GO:BP | GO:0048593 | camera-type eye morphogenesis | 4 | 91 | 2.85e-01 |
| GO:BP | GO:0036135 | Schwann cell migration | 1 | 4 | 2.85e-01 |
| GO:BP | GO:0014829 | vascular associated smooth muscle contraction | 2 | 20 | 2.85e-01 |
| GO:BP | GO:0099173 | postsynapse organization | 8 | 155 | 2.85e-01 |
| GO:BP | GO:0040013 | negative regulation of locomotion | 7 | 265 | 2.85e-01 |
| GO:BP | GO:1902170 | cellular response to reactive nitrogen species | 2 | 16 | 2.85e-01 |
| GO:BP | GO:0032623 | interleukin-2 production | 3 | 31 | 2.85e-01 |
| GO:BP | GO:0043414 | macromolecule methylation | 5 | 272 | 2.85e-01 |
| GO:BP | GO:1900147 | regulation of Schwann cell migration | 1 | 4 | 2.85e-01 |
| GO:BP | GO:0070667 | negative regulation of mast cell proliferation | 1 | 2 | 2.85e-01 |
| GO:BP | GO:0009227 | nucleotide-sugar catabolic process | 1 | 3 | 2.85e-01 |
| GO:BP | GO:0051006 | positive regulation of lipoprotein lipase activity | 1 | 4 | 2.85e-01 |
| GO:BP | GO:1905605 | positive regulation of blood-brain barrier permeability | 1 | 4 | 2.85e-01 |
| GO:BP | GO:0061136 | regulation of proteasomal protein catabolic process | 6 | 183 | 2.85e-01 |
| GO:BP | GO:0006231 | dTMP biosynthetic process | 1 | 4 | 2.85e-01 |
| GO:BP | GO:0046323 | glucose import | 3 | 53 | 2.87e-01 |
| GO:BP | GO:0046165 | alcohol biosynthetic process | 4 | 110 | 2.87e-01 |
| GO:BP | GO:0010460 | positive regulation of heart rate | 1 | 21 | 2.87e-01 |
| GO:BP | GO:0006777 | Mo-molybdopterin cofactor biosynthetic process | 1 | 6 | 2.87e-01 |
| GO:BP | GO:0009896 | positive regulation of catabolic process | 10 | 464 | 2.87e-01 |
| GO:BP | GO:0030091 | protein repair | 1 | 7 | 2.87e-01 |
| GO:BP | GO:0006730 | one-carbon metabolic process | 2 | 29 | 2.87e-01 |
| GO:BP | GO:0065004 | protein-DNA complex assembly | 2 | 185 | 2.87e-01 |
| GO:BP | GO:0043244 | regulation of protein-containing complex disassembly | 5 | 113 | 2.87e-01 |
| GO:BP | GO:0030334 | regulation of cell migration | 14 | 706 | 2.87e-01 |
| GO:BP | GO:0040011 | locomotion | 14 | 954 | 2.87e-01 |
| GO:BP | GO:0014821 | phasic smooth muscle contraction | 1 | 12 | 2.87e-01 |
| GO:BP | GO:0009636 | response to toxic substance | 1 | 158 | 2.87e-01 |
| GO:BP | GO:0051095 | regulation of helicase activity | 1 | 12 | 2.87e-01 |
| GO:BP | GO:1905839 | negative regulation of telomeric D-loop disassembly | 1 | 2 | 2.87e-01 |
| GO:BP | GO:0035994 | response to muscle stretch | 2 | 26 | 2.87e-01 |
| GO:BP | GO:0002335 | mature B cell differentiation | 3 | 21 | 2.87e-01 |
| GO:BP | GO:0051797 | regulation of hair follicle development | 1 | 16 | 2.87e-01 |
| GO:BP | GO:0051189 | prosthetic group metabolic process | 1 | 6 | 2.87e-01 |
| GO:BP | GO:0032214 | negative regulation of telomere maintenance via semi-conservative replication | 1 | 2 | 2.87e-01 |
| GO:BP | GO:0010835 | regulation of protein ADP-ribosylation | 1 | 9 | 2.87e-01 |
| GO:BP | GO:0032213 | regulation of telomere maintenance via semi-conservative replication | 1 | 2 | 2.87e-01 |
| GO:BP | GO:0001936 | regulation of endothelial cell proliferation | 4 | 102 | 2.87e-01 |
| GO:BP | GO:2000736 | regulation of stem cell differentiation | 2 | 71 | 2.87e-01 |
| GO:BP | GO:1904790 | regulation of shelterin complex assembly | 1 | 2 | 2.87e-01 |
| GO:BP | GO:1903937 | response to acrylamide | 1 | 1 | 2.87e-01 |
| GO:BP | GO:0031324 | negative regulation of cellular metabolic process | 3 | 1735 | 2.87e-01 |
| GO:BP | GO:2000369 | regulation of clathrin-dependent endocytosis | 1 | 18 | 2.87e-01 |
| GO:BP | GO:0002248 | connective tissue replacement involved in inflammatory response wound healing | 1 | 4 | 2.87e-01 |
| GO:BP | GO:0072330 | monocarboxylic acid biosynthetic process | 1 | 145 | 2.87e-01 |
| GO:BP | GO:0034770 | histone H4-K20 methylation | 1 | 6 | 2.87e-01 |
| GO:BP | GO:1904815 | negative regulation of protein localization to chromosome, telomeric region | 1 | 2 | 2.87e-01 |
| GO:BP | GO:0010887 | negative regulation of cholesterol storage | 1 | 9 | 2.87e-01 |
| GO:BP | GO:1903614 | negative regulation of protein tyrosine phosphatase activity | 1 | 3 | 2.87e-01 |
| GO:BP | GO:1903978 | regulation of microglial cell activation | 2 | 9 | 2.87e-01 |
| GO:BP | GO:0019720 | Mo-molybdopterin cofactor metabolic process | 1 | 6 | 2.87e-01 |
| GO:BP | GO:0070837 | dehydroascorbic acid transport | 1 | 6 | 2.87e-01 |
| GO:BP | GO:1905838 | regulation of telomeric D-loop disassembly | 1 | 2 | 2.87e-01 |
| GO:BP | GO:0071573 | shelterin complex assembly | 1 | 2 | 2.87e-01 |
| GO:BP | GO:1901660 | calcium ion export | 1 | 3 | 2.87e-01 |
| GO:BP | GO:0071900 | regulation of protein serine/threonine kinase activity | 10 | 282 | 2.87e-01 |
| GO:BP | GO:1905777 | regulation of exonuclease activity | 1 | 2 | 2.87e-01 |
| GO:BP | GO:1904534 | negative regulation of telomeric loop disassembly | 1 | 2 | 2.87e-01 |
| GO:BP | GO:0043545 | molybdopterin cofactor metabolic process | 1 | 6 | 2.87e-01 |
| GO:BP | GO:0003208 | cardiac ventricle morphogenesis | 3 | 62 | 2.87e-01 |
| GO:BP | GO:0071901 | negative regulation of protein serine/threonine kinase activity | 4 | 101 | 2.87e-01 |
| GO:BP | GO:0061365 | positive regulation of triglyceride lipase activity | 1 | 4 | 2.87e-01 |
| GO:BP | GO:0007346 | regulation of mitotic cell cycle | 2 | 441 | 2.87e-01 |
| GO:BP | GO:0021551 | central nervous system morphogenesis | 1 | 2 | 2.87e-01 |
| GO:BP | GO:0045671 | negative regulation of osteoclast differentiation | 2 | 20 | 2.87e-01 |
| GO:BP | GO:0032324 | molybdopterin cofactor biosynthetic process | 1 | 6 | 2.87e-01 |
| GO:BP | GO:0032785 | negative regulation of DNA-templated transcription, elongation | 2 | 20 | 2.87e-01 |
| GO:BP | GO:1905778 | negative regulation of exonuclease activity | 1 | 2 | 2.87e-01 |
| GO:BP | GO:0001937 | negative regulation of endothelial cell proliferation | 3 | 32 | 2.89e-01 |
| GO:BP | GO:0032570 | response to progesterone | 2 | 27 | 2.89e-01 |
| GO:BP | GO:1905403 | negative regulation of activated CD8-positive, alpha-beta T cell apoptotic process | 1 | 2 | 2.91e-01 |
| GO:BP | GO:0043161 | proteasome-mediated ubiquitin-dependent protein catabolic process | 9 | 427 | 2.91e-01 |
| GO:BP | GO:0070646 | protein modification by small protein removal | 2 | 147 | 2.91e-01 |
| GO:BP | GO:0071896 | protein localization to adherens junction | 1 | 6 | 2.91e-01 |
| GO:BP | GO:0050927 | positive regulation of positive chemotaxis | 1 | 20 | 2.91e-01 |
| GO:BP | GO:0006939 | smooth muscle contraction | 2 | 75 | 2.92e-01 |
| GO:BP | GO:0006623 | protein targeting to vacuole | 3 | 42 | 2.92e-01 |
| GO:BP | GO:1905704 | positive regulation of inhibitory synapse assembly | 1 | 2 | 2.92e-01 |
| GO:BP | GO:1900220 | semaphorin-plexin signaling pathway involved in bone trabecula morphogenesis | 1 | 2 | 2.92e-01 |
| GO:BP | GO:1905167 | positive regulation of lysosomal protein catabolic process | 1 | 4 | 2.92e-01 |
| GO:BP | GO:0034969 | histone arginine methylation | 1 | 8 | 2.93e-01 |
| GO:BP | GO:0001579 | medium-chain fatty acid transport | 1 | 2 | 2.93e-01 |
| GO:BP | GO:0050926 | regulation of positive chemotaxis | 1 | 20 | 2.97e-01 |
| GO:BP | GO:0099641 | anterograde axonal protein transport | 1 | 9 | 2.97e-01 |
| GO:BP | GO:0001842 | neural fold formation | 1 | 5 | 2.98e-01 |
| GO:BP | GO:0006565 | L-serine catabolic process | 1 | 4 | 2.98e-01 |
| GO:BP | GO:0150076 | neuroinflammatory response | 4 | 33 | 2.98e-01 |
| GO:BP | GO:0043619 | regulation of transcription from RNA polymerase II promoter in response to oxidative stress | 1 | 7 | 2.98e-01 |
| GO:BP | GO:0032364 | intracellular oxygen homeostasis | 1 | 6 | 2.98e-01 |
| GO:BP | GO:0071322 | cellular response to carbohydrate stimulus | 4 | 105 | 2.98e-01 |
| GO:BP | GO:0045911 | positive regulation of DNA recombination | 2 | 57 | 2.98e-01 |
| GO:BP | GO:0021764 | amygdala development | 1 | 3 | 2.98e-01 |
| GO:BP | GO:0007289 | spermatid nucleus differentiation | 2 | 16 | 2.98e-01 |
| GO:BP | GO:0034145 | positive regulation of toll-like receptor 4 signaling pathway | 1 | 7 | 3.00e-01 |
| GO:BP | GO:0071824 | protein-DNA complex subunit organization | 2 | 204 | 3.00e-01 |
| GO:BP | GO:0060982 | coronary artery morphogenesis | 1 | 8 | 3.00e-01 |
| GO:BP | GO:0045987 | positive regulation of smooth muscle contraction | 1 | 17 | 3.00e-01 |
| GO:BP | GO:0048548 | regulation of pinocytosis | 1 | 11 | 3.00e-01 |
| GO:BP | GO:0050920 | regulation of chemotaxis | 2 | 142 | 3.00e-01 |
| GO:BP | GO:0106071 | positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway | 1 | 3 | 3.00e-01 |
| GO:BP | GO:0071731 | response to nitric oxide | 2 | 16 | 3.00e-01 |
| GO:BP | GO:0044539 | long-chain fatty acid import into cell | 2 | 14 | 3.00e-01 |
| GO:BP | GO:0006040 | amino sugar metabolic process | 3 | 33 | 3.00e-01 |
| GO:BP | GO:0002946 | tRNA C5-cytosine methylation | 1 | 3 | 3.00e-01 |
| GO:BP | GO:0009069 | serine family amino acid metabolic process | 2 | 30 | 3.00e-01 |
| GO:BP | GO:0001938 | positive regulation of endothelial cell proliferation | 3 | 74 | 3.00e-01 |
| GO:BP | GO:0003301 | physiological cardiac muscle hypertrophy | 2 | 19 | 3.01e-01 |
| GO:BP | GO:0044770 | cell cycle phase transition | 2 | 504 | 3.01e-01 |
| GO:BP | GO:0003298 | physiological muscle hypertrophy | 2 | 19 | 3.01e-01 |
| GO:BP | GO:0080135 | regulation of cellular response to stress | 9 | 616 | 3.01e-01 |
| GO:BP | GO:0010569 | regulation of double-strand break repair via homologous recombination | 2 | 63 | 3.01e-01 |
| GO:BP | GO:0009416 | response to light stimulus | 6 | 246 | 3.01e-01 |
| GO:BP | GO:0051172 | negative regulation of nitrogen compound metabolic process | 3 | 1849 | 3.01e-01 |
| GO:BP | GO:0072709 | cellular response to sorbitol | 1 | 5 | 3.01e-01 |
| GO:BP | GO:0045765 | regulation of angiogenesis | 6 | 203 | 3.01e-01 |
| GO:BP | GO:0010529 | negative regulation of transposition | 1 | 14 | 3.01e-01 |
| GO:BP | GO:0051353 | positive regulation of oxidoreductase activity | 2 | 43 | 3.01e-01 |
| GO:BP | GO:2001234 | negative regulation of apoptotic signaling pathway | 5 | 194 | 3.01e-01 |
| GO:BP | GO:0061049 | cell growth involved in cardiac muscle cell development | 2 | 19 | 3.01e-01 |
| GO:BP | GO:0010528 | regulation of transposition | 1 | 14 | 3.01e-01 |
| GO:BP | GO:0071398 | cellular response to fatty acid | 2 | 25 | 3.01e-01 |
| GO:BP | GO:0009083 | branched-chain amino acid catabolic process | 2 | 21 | 3.01e-01 |
| GO:BP | GO:0090181 | regulation of cholesterol metabolic process | 2 | 29 | 3.01e-01 |
| GO:BP | GO:0010508 | positive regulation of autophagy | 5 | 133 | 3.01e-01 |
| GO:BP | GO:0051987 | positive regulation of attachment of spindle microtubules to kinetochore | 1 | 11 | 3.01e-01 |
| GO:BP | GO:0006041 | glucosamine metabolic process | 1 | 3 | 3.01e-01 |
| GO:BP | GO:0006768 | biotin metabolic process | 1 | 3 | 3.01e-01 |
| GO:BP | GO:0044283 | small molecule biosynthetic process | 5 | 425 | 3.01e-01 |
| GO:BP | GO:0099640 | axo-dendritic protein transport | 1 | 10 | 3.01e-01 |
| GO:BP | GO:0034334 | adherens junction maintenance | 1 | 6 | 3.03e-01 |
| GO:BP | GO:0099548 | trans-synaptic signaling by nitric oxide | 1 | 2 | 3.03e-01 |
| GO:BP | GO:0043113 | receptor clustering | 2 | 45 | 3.03e-01 |
| GO:BP | GO:0002246 | wound healing involved in inflammatory response | 1 | 6 | 3.03e-01 |
| GO:BP | GO:0030157 | pancreatic juice secretion | 1 | 11 | 3.03e-01 |
| GO:BP | GO:0006767 | water-soluble vitamin metabolic process | 3 | 49 | 3.03e-01 |
| GO:BP | GO:0090101 | negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 4 | 124 | 3.03e-01 |
| GO:BP | GO:1905706 | regulation of mitochondrial ATP synthesis coupled proton transport | 1 | 3 | 3.03e-01 |
| GO:BP | GO:1901342 | regulation of vasculature development | 6 | 206 | 3.03e-01 |
| GO:BP | GO:1905271 | regulation of proton-transporting ATP synthase activity, rotational mechanism | 1 | 3 | 3.03e-01 |
| GO:BP | GO:0099543 | trans-synaptic signaling by soluble gas | 1 | 2 | 3.03e-01 |
| GO:BP | GO:1905273 | positive regulation of proton-transporting ATP synthase activity, rotational mechanism | 1 | 3 | 3.03e-01 |
| GO:BP | GO:0006886 | intracellular protein transport | 3 | 803 | 3.03e-01 |
| GO:BP | GO:0019852 | L-ascorbic acid metabolic process | 1 | 9 | 3.03e-01 |
| GO:BP | GO:1901334 | lactone metabolic process | 1 | 9 | 3.03e-01 |
| GO:BP | GO:0010745 | negative regulation of macrophage derived foam cell differentiation | 1 | 10 | 3.03e-01 |
| GO:BP | GO:0051541 | elastin metabolic process | 1 | 5 | 3.03e-01 |
| GO:BP | GO:0071485 | cellular response to absence of light | 1 | 3 | 3.04e-01 |
| GO:BP | GO:1990603 | dark adaptation | 1 | 3 | 3.04e-01 |
| GO:BP | GO:0007290 | spermatid nucleus elongation | 1 | 1 | 3.04e-01 |
| GO:BP | GO:0032237 | activation of store-operated calcium channel activity | 1 | 5 | 3.04e-01 |
| GO:BP | GO:0097499 | protein localization to non-motile cilium | 1 | 10 | 3.04e-01 |
| GO:BP | GO:0007017 | microtubule-based process | 11 | 760 | 3.04e-01 |
| GO:BP | GO:0009646 | response to absence of light | 1 | 3 | 3.04e-01 |
| GO:BP | GO:0046292 | formaldehyde metabolic process | 1 | 3 | 3.04e-01 |
| GO:BP | GO:0009052 | pentose-phosphate shunt, non-oxidative branch | 1 | 6 | 3.05e-01 |
| GO:BP | GO:0060047 | heart contraction | 6 | 205 | 3.07e-01 |
| GO:BP | GO:0032793 | positive regulation of CREB transcription factor activity | 2 | 15 | 3.08e-01 |
| GO:BP | GO:0046929 | negative regulation of neurotransmitter secretion | 1 | 6 | 3.08e-01 |
| GO:BP | GO:0048143 | astrocyte activation | 2 | 12 | 3.08e-01 |
| GO:BP | GO:0003062 | regulation of heart rate by chemical signal | 1 | 6 | 3.08e-01 |
| GO:BP | GO:0034472 | snRNA 3’-end processing | 1 | 21 | 3.08e-01 |
| GO:BP | GO:1905383 | protein localization to presynapse | 1 | 11 | 3.08e-01 |
| GO:BP | GO:0070084 | protein initiator methionine removal | 1 | 4 | 3.08e-01 |
| GO:BP | GO:0046710 | GDP metabolic process | 1 | 10 | 3.08e-01 |
| GO:BP | GO:1903976 | negative regulation of glial cell migration | 1 | 5 | 3.08e-01 |
| GO:BP | GO:0098597 | observational learning | 1 | 5 | 3.08e-01 |
| GO:BP | GO:0001920 | negative regulation of receptor recycling | 1 | 3 | 3.08e-01 |
| GO:BP | GO:0000422 | autophagy of mitochondrion | 4 | 92 | 3.08e-01 |
| GO:BP | GO:0033047 | regulation of mitotic sister chromatid segregation | 2 | 52 | 3.08e-01 |
| GO:BP | GO:0061726 | mitochondrion disassembly | 4 | 92 | 3.08e-01 |
| GO:BP | GO:0036151 | phosphatidylcholine acyl-chain remodeling | 1 | 12 | 3.08e-01 |
| GO:BP | GO:0061535 | glutamate secretion, neurotransmission | 1 | 5 | 3.08e-01 |
| GO:BP | GO:1901605 | alpha-amino acid metabolic process | 1 | 151 | 3.09e-01 |
| GO:BP | GO:0042634 | regulation of hair cycle | 1 | 22 | 3.10e-01 |
| GO:BP | GO:0035845 | photoreceptor cell outer segment organization | 1 | 10 | 3.10e-01 |
| GO:BP | GO:0046606 | negative regulation of centrosome cycle | 1 | 12 | 3.10e-01 |
| GO:BP | GO:0007179 | transforming growth factor beta receptor signaling pathway | 4 | 179 | 3.10e-01 |
| GO:BP | GO:0048278 | vesicle docking | 1 | 57 | 3.10e-01 |
| GO:BP | GO:0001556 | oocyte maturation | 1 | 22 | 3.10e-01 |
| GO:BP | GO:1990049 | retrograde neuronal dense core vesicle transport | 1 | 4 | 3.10e-01 |
| GO:BP | GO:2000271 | positive regulation of fibroblast apoptotic process | 1 | 9 | 3.10e-01 |
| GO:BP | GO:0010826 | negative regulation of centrosome duplication | 1 | 12 | 3.10e-01 |
| GO:BP | GO:0032196 | transposition | 1 | 17 | 3.10e-01 |
| GO:BP | GO:0010453 | regulation of cell fate commitment | 1 | 26 | 3.10e-01 |
| GO:BP | GO:0051983 | regulation of chromosome segregation | 3 | 121 | 3.10e-01 |
| GO:BP | GO:1903376 | regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway | 1 | 8 | 3.10e-01 |
| GO:BP | GO:1902692 | regulation of neuroblast proliferation | 2 | 28 | 3.10e-01 |
| GO:BP | GO:0002071 | glandular epithelial cell maturation | 1 | 7 | 3.10e-01 |
| GO:BP | GO:0036480 | neuron intrinsic apoptotic signaling pathway in response to oxidative stress | 1 | 8 | 3.10e-01 |
| GO:BP | GO:2000467 | positive regulation of glycogen (starch) synthase activity | 1 | 4 | 3.10e-01 |
| GO:BP | GO:1905603 | regulation of blood-brain barrier permeability | 1 | 6 | 3.10e-01 |
| GO:BP | GO:0034661 | ncRNA catabolic process | 3 | 41 | 3.10e-01 |
| GO:BP | GO:0140354 | lipid import into cell | 2 | 15 | 3.10e-01 |
| GO:BP | GO:0061072 | iris morphogenesis | 1 | 5 | 3.10e-01 |
| GO:BP | GO:0048633 | positive regulation of skeletal muscle tissue growth | 1 | 6 | 3.10e-01 |
| GO:BP | GO:0032906 | transforming growth factor beta2 production | 1 | 9 | 3.10e-01 |
| GO:BP | GO:0016601 | Rac protein signal transduction | 2 | 42 | 3.10e-01 |
| GO:BP | GO:0090235 | regulation of metaphase plate congression | 1 | 13 | 3.10e-01 |
| GO:BP | GO:0032909 | regulation of transforming growth factor beta2 production | 1 | 9 | 3.10e-01 |
| GO:BP | GO:0016180 | snRNA processing | 1 | 26 | 3.10e-01 |
| GO:BP | GO:0045603 | positive regulation of endothelial cell differentiation | 1 | 8 | 3.10e-01 |
| GO:BP | GO:0032259 | methylation | 5 | 313 | 3.10e-01 |
| GO:BP | GO:2000145 | regulation of cell motility | 14 | 742 | 3.10e-01 |
| GO:BP | GO:1903524 | positive regulation of blood circulation | 1 | 32 | 3.10e-01 |
| GO:BP | GO:0044773 | mitotic DNA damage checkpoint signaling | 1 | 81 | 3.10e-01 |
| GO:BP | GO:0007409 | axonogenesis | 4 | 359 | 3.10e-01 |
| GO:BP | GO:1901071 | glucosamine-containing compound metabolic process | 2 | 19 | 3.10e-01 |
| GO:BP | GO:0001990 | regulation of systemic arterial blood pressure by hormone | 1 | 22 | 3.10e-01 |
| GO:BP | GO:0099185 | postsynaptic intermediate filament cytoskeleton organization | 1 | 3 | 3.10e-01 |
| GO:BP | GO:0097694 | establishment of RNA localization to telomere | 1 | 3 | 3.10e-01 |
| GO:BP | GO:0030301 | cholesterol transport | 2 | 80 | 3.10e-01 |
| GO:BP | GO:0010039 | response to iron ion | 2 | 24 | 3.10e-01 |
| GO:BP | GO:0097695 | establishment of protein-containing complex localization to telomere | 1 | 3 | 3.10e-01 |
| GO:BP | GO:0006656 | phosphatidylcholine biosynthetic process | 1 | 25 | 3.10e-01 |
| GO:BP | GO:0071331 | cellular response to hexose stimulus | 3 | 94 | 3.10e-01 |
| GO:BP | GO:0044774 | mitotic DNA integrity checkpoint signaling | 1 | 85 | 3.10e-01 |
| GO:BP | GO:0000289 | nuclear-transcribed mRNA poly(A) tail shortening | 1 | 33 | 3.10e-01 |
| GO:BP | GO:0007018 | microtubule-based movement | 6 | 300 | 3.10e-01 |
| GO:BP | GO:0060971 | embryonic heart tube left/right pattern formation | 1 | 5 | 3.10e-01 |
| GO:BP | GO:0001878 | response to yeast | 1 | 3 | 3.10e-01 |
| GO:BP | GO:0009891 | positive regulation of biosynthetic process | 38 | 1604 | 3.10e-01 |
| GO:BP | GO:0060330 | regulation of response to type II interferon | 1 | 12 | 3.10e-01 |
| GO:BP | GO:0002068 | glandular epithelial cell development | 2 | 28 | 3.10e-01 |
| GO:BP | GO:0071333 | cellular response to glucose stimulus | 3 | 93 | 3.10e-01 |
| GO:BP | GO:0006848 | pyruvate transport | 1 | 5 | 3.10e-01 |
| GO:BP | GO:1901475 | pyruvate transmembrane transport | 1 | 5 | 3.10e-01 |
| GO:BP | GO:0015822 | ornithine transport | 1 | 5 | 3.10e-01 |
| GO:BP | GO:0007178 | transmembrane receptor protein serine/threonine kinase signaling pathway | 8 | 303 | 3.10e-01 |
| GO:BP | GO:0097352 | autophagosome maturation | 3 | 55 | 3.10e-01 |
| GO:BP | GO:0044281 | small molecule metabolic process | 2 | 1389 | 3.10e-01 |
| GO:BP | GO:1903721 | positive regulation of I-kappaB phosphorylation | 1 | 5 | 3.10e-01 |
| GO:BP | GO:0016973 | poly(A)+ mRNA export from nucleus | 1 | 15 | 3.10e-01 |
| GO:BP | GO:0071360 | cellular response to exogenous dsRNA | 1 | 14 | 3.10e-01 |
| GO:BP | GO:1901341 | positive regulation of store-operated calcium channel activity | 1 | 6 | 3.10e-01 |
| GO:BP | GO:0032747 | positive regulation of interleukin-23 production | 1 | 3 | 3.10e-01 |
| GO:BP | GO:0033693 | neurofilament bundle assembly | 1 | 3 | 3.10e-01 |
| GO:BP | GO:0001825 | blastocyst formation | 2 | 37 | 3.10e-01 |
| GO:BP | GO:0060334 | regulation of type II interferon-mediated signaling pathway | 1 | 12 | 3.10e-01 |
| GO:BP | GO:0001935 | endothelial cell proliferation | 4 | 116 | 3.10e-01 |
| GO:BP | GO:1903008 | organelle disassembly | 4 | 137 | 3.10e-01 |
| GO:BP | GO:1904533 | regulation of telomeric loop disassembly | 1 | 2 | 3.10e-01 |
| GO:BP | GO:0015914 | phospholipid transport | 4 | 75 | 3.10e-01 |
| GO:BP | GO:0030183 | B cell differentiation | 5 | 94 | 3.10e-01 |
| GO:BP | GO:0045823 | positive regulation of heart contraction | 1 | 32 | 3.10e-01 |
| GO:BP | GO:0008333 | endosome to lysosome transport | 4 | 63 | 3.10e-01 |
| GO:BP | GO:0045105 | intermediate filament polymerization or depolymerization | 1 | 2 | 3.10e-01 |
| GO:BP | GO:0006659 | phosphatidylserine biosynthetic process | 1 | 4 | 3.11e-01 |
| GO:BP | GO:0098735 | positive regulation of the force of heart contraction | 1 | 4 | 3.11e-01 |
| GO:BP | GO:0046886 | positive regulation of hormone biosynthetic process | 1 | 9 | 3.11e-01 |
| GO:BP | GO:0042446 | hormone biosynthetic process | 2 | 40 | 3.11e-01 |
| GO:BP | GO:0070244 | negative regulation of thymocyte apoptotic process | 1 | 6 | 3.11e-01 |
| GO:BP | GO:0009221 | pyrimidine deoxyribonucleotide biosynthetic process | 1 | 7 | 3.11e-01 |
| GO:BP | GO:0098885 | modification of postsynaptic actin cytoskeleton | 1 | 10 | 3.11e-01 |
| GO:BP | GO:0016311 | dephosphorylation | 11 | 284 | 3.11e-01 |
| GO:BP | GO:0009190 | cyclic nucleotide biosynthetic process | 2 | 14 | 3.11e-01 |
| GO:BP | GO:0032743 | positive regulation of interleukin-2 production | 2 | 20 | 3.11e-01 |
| GO:BP | GO:1905397 | activated CD8-positive, alpha-beta T cell apoptotic process | 1 | 3 | 3.11e-01 |
| GO:BP | GO:2001054 | negative regulation of mesenchymal cell apoptotic process | 1 | 3 | 3.11e-01 |
| GO:BP | GO:0010693 | negative regulation of alkaline phosphatase activity | 1 | 2 | 3.11e-01 |
| GO:BP | GO:2001268 | negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway | 1 | 5 | 3.11e-01 |
| GO:BP | GO:0036124 | histone H3-K9 trimethylation | 1 | 9 | 3.11e-01 |
| GO:BP | GO:0003015 | heart process | 6 | 216 | 3.11e-01 |
| GO:BP | GO:0046073 | dTMP metabolic process | 1 | 7 | 3.11e-01 |
| GO:BP | GO:0090118 | receptor-mediated endocytosis involved in cholesterol transport | 1 | 5 | 3.11e-01 |
| GO:BP | GO:0035865 | cellular response to potassium ion | 1 | 9 | 3.11e-01 |
| GO:BP | GO:0070099 | regulation of chemokine-mediated signaling pathway | 1 | 8 | 3.11e-01 |
| GO:BP | GO:1904352 | positive regulation of protein catabolic process in the vacuole | 1 | 6 | 3.11e-01 |
| GO:BP | GO:0034199 | activation of protein kinase A activity | 1 | 3 | 3.11e-01 |
| GO:BP | GO:2000781 | positive regulation of double-strand break repair | 2 | 79 | 3.11e-01 |
| GO:BP | GO:0006545 | glycine biosynthetic process | 1 | 4 | 3.11e-01 |
| GO:BP | GO:0071326 | cellular response to monosaccharide stimulus | 3 | 95 | 3.11e-01 |
| GO:BP | GO:1905402 | regulation of activated CD8-positive, alpha-beta T cell apoptotic process | 1 | 3 | 3.11e-01 |
| GO:BP | GO:0048246 | macrophage chemotaxis | 1 | 21 | 3.12e-01 |
| GO:BP | GO:0006046 | N-acetylglucosamine catabolic process | 1 | 3 | 3.12e-01 |
| GO:BP | GO:0098953 | receptor diffusion trapping | 1 | 4 | 3.12e-01 |
| GO:BP | GO:0006650 | glycerophospholipid metabolic process | 8 | 252 | 3.12e-01 |
| GO:BP | GO:0099628 | neurotransmitter receptor diffusion trapping | 1 | 4 | 3.12e-01 |
| GO:BP | GO:0098970 | postsynaptic neurotransmitter receptor diffusion trapping | 1 | 4 | 3.12e-01 |
| GO:BP | GO:0099175 | regulation of postsynapse organization | 4 | 83 | 3.12e-01 |
| GO:BP | GO:0060457 | negative regulation of digestive system process | 1 | 7 | 3.12e-01 |
| GO:BP | GO:0010885 | regulation of cholesterol storage | 1 | 14 | 3.12e-01 |
| GO:BP | GO:0051348 | negative regulation of transferase activity | 9 | 234 | 3.12e-01 |
| GO:BP | GO:0010883 | regulation of lipid storage | 2 | 39 | 3.13e-01 |
| GO:BP | GO:0006368 | transcription elongation by RNA polymerase II | 1 | 106 | 3.13e-01 |
| GO:BP | GO:0060024 | rhythmic synaptic transmission | 1 | 3 | 3.13e-01 |
| GO:BP | GO:2000273 | positive regulation of signaling receptor activity | 3 | 33 | 3.13e-01 |
| GO:BP | GO:0014732 | skeletal muscle atrophy | 1 | 5 | 3.13e-01 |
| GO:BP | GO:0099163 | synaptic signaling by nitric oxide | 1 | 3 | 3.14e-01 |
| GO:BP | GO:0043652 | engulfment of apoptotic cell | 1 | 11 | 3.14e-01 |
| GO:BP | GO:0038060 | nitric oxide-cGMP-mediated signaling pathway | 1 | 2 | 3.14e-01 |
| GO:BP | GO:0001944 | vasculature development | 13 | 559 | 3.16e-01 |
| GO:BP | GO:0072708 | response to sorbitol | 1 | 7 | 3.16e-01 |
| GO:BP | GO:0010827 | regulation of glucose transmembrane transport | 3 | 55 | 3.16e-01 |
| GO:BP | GO:0032780 | negative regulation of ATP-dependent activity | 1 | 18 | 3.17e-01 |
| GO:BP | GO:0000819 | sister chromatid segregation | 4 | 217 | 3.17e-01 |
| GO:BP | GO:0014014 | negative regulation of gliogenesis | 2 | 26 | 3.17e-01 |
| GO:BP | GO:0097120 | receptor localization to synapse | 2 | 55 | 3.17e-01 |
| GO:BP | GO:0006011 | UDP-glucose metabolic process | 1 | 6 | 3.18e-01 |
| GO:BP | GO:0060261 | positive regulation of transcription initiation by RNA polymerase II | 1 | 59 | 3.18e-01 |
| GO:BP | GO:0051004 | regulation of lipoprotein lipase activity | 1 | 11 | 3.18e-01 |
| GO:BP | GO:0043966 | histone H3 acetylation | 1 | 59 | 3.18e-01 |
| GO:BP | GO:1903719 | regulation of I-kappaB phosphorylation | 1 | 6 | 3.18e-01 |
| GO:BP | GO:0035873 | lactate transmembrane transport | 1 | 5 | 3.18e-01 |
| GO:BP | GO:0015727 | lactate transport | 1 | 5 | 3.18e-01 |
| GO:BP | GO:0097009 | energy homeostasis | 1 | 39 | 3.18e-01 |
| GO:BP | GO:0006414 | translational elongation | 1 | 65 | 3.18e-01 |
| GO:BP | GO:2000058 | regulation of ubiquitin-dependent protein catabolic process | 5 | 160 | 3.18e-01 |
| GO:BP | GO:0006631 | fatty acid metabolic process | 1 | 276 | 3.18e-01 |
| GO:BP | GO:0051100 | negative regulation of binding | 1 | 135 | 3.18e-01 |
| GO:BP | GO:0097709 | connective tissue replacement | 1 | 8 | 3.18e-01 |
| GO:BP | GO:2001185 | regulation of CD8-positive, alpha-beta T cell activation | 1 | 13 | 3.18e-01 |
| GO:BP | GO:0061418 | regulation of transcription from RNA polymerase II promoter in response to hypoxia | 1 | 11 | 3.18e-01 |
| GO:BP | GO:1990048 | anterograde neuronal dense core vesicle transport | 1 | 4 | 3.18e-01 |
| GO:BP | GO:0038007 | netrin-activated signaling pathway | 1 | 8 | 3.19e-01 |
| GO:BP | GO:0045542 | positive regulation of cholesterol biosynthetic process | 1 | 7 | 3.20e-01 |
| GO:BP | GO:0106120 | positive regulation of sterol biosynthetic process | 1 | 7 | 3.20e-01 |
| GO:BP | GO:1990266 | neutrophil migration | 2 | 52 | 3.21e-01 |
| GO:BP | GO:0140056 | organelle localization by membrane tethering | 1 | 74 | 3.21e-01 |
| GO:BP | GO:1902680 | positive regulation of RNA biosynthetic process | 32 | 1322 | 3.23e-01 |
| GO:BP | GO:0032456 | endocytic recycling | 1 | 80 | 3.23e-01 |
| GO:BP | GO:0010626 | negative regulation of Schwann cell proliferation | 1 | 6 | 3.23e-01 |
| GO:BP | GO:0070662 | mast cell proliferation | 1 | 6 | 3.23e-01 |
| GO:BP | GO:0048592 | eye morphogenesis | 4 | 113 | 3.23e-01 |
| GO:BP | GO:0070666 | regulation of mast cell proliferation | 1 | 6 | 3.23e-01 |
| GO:BP | GO:0045933 | positive regulation of muscle contraction | 1 | 32 | 3.24e-01 |
| GO:BP | GO:0071218 | cellular response to misfolded protein | 2 | 23 | 3.25e-01 |
| GO:BP | GO:1903050 | regulation of proteolysis involved in protein catabolic process | 6 | 214 | 3.25e-01 |
| GO:BP | GO:0099118 | microtubule-based protein transport | 1 | 14 | 3.25e-01 |
| GO:BP | GO:0090503 | RNA phosphodiester bond hydrolysis, exonucleolytic | 1 | 41 | 3.25e-01 |
| GO:BP | GO:0001826 | inner cell mass cell differentiation | 1 | 5 | 3.25e-01 |
| GO:BP | GO:0006695 | cholesterol biosynthetic process | 3 | 46 | 3.25e-01 |
| GO:BP | GO:0098840 | protein transport along microtubule | 1 | 14 | 3.25e-01 |
| GO:BP | GO:0001923 | B-1 B cell differentiation | 1 | 3 | 3.25e-01 |
| GO:BP | GO:1902653 | secondary alcohol biosynthetic process | 3 | 46 | 3.25e-01 |
| GO:BP | GO:0010878 | cholesterol storage | 1 | 16 | 3.25e-01 |
| GO:BP | GO:0071359 | cellular response to dsRNA | 1 | 18 | 3.25e-01 |
| GO:BP | GO:0016525 | negative regulation of angiogenesis | 3 | 72 | 3.25e-01 |
| GO:BP | GO:0045070 | positive regulation of viral genome replication | 2 | 28 | 3.25e-01 |
| GO:BP | GO:0009314 | response to radiation | 7 | 352 | 3.25e-01 |
| GO:BP | GO:0015918 | sterol transport | 2 | 92 | 3.25e-01 |
| GO:BP | GO:0051254 | positive regulation of RNA metabolic process | 34 | 1441 | 3.25e-01 |
| GO:BP | GO:0006003 | fructose 2,6-bisphosphate metabolic process | 1 | 4 | 3.25e-01 |
| GO:BP | GO:1902036 | regulation of hematopoietic stem cell differentiation | 1 | 15 | 3.25e-01 |
| GO:BP | GO:0008209 | androgen metabolic process | 1 | 16 | 3.25e-01 |
| GO:BP | GO:0007182 | common-partner SMAD protein phosphorylation | 1 | 6 | 3.25e-01 |
| GO:BP | GO:0031122 | cytoplasmic microtubule organization | 2 | 60 | 3.25e-01 |
| GO:BP | GO:0060696 | regulation of phospholipid catabolic process | 1 | 5 | 3.26e-01 |
| GO:BP | GO:0009081 | branched-chain amino acid metabolic process | 2 | 26 | 3.26e-01 |
| GO:BP | GO:0043433 | negative regulation of DNA-binding transcription factor activity | 1 | 138 | 3.26e-01 |
| GO:BP | GO:2000181 | negative regulation of blood vessel morphogenesis | 3 | 73 | 3.26e-01 |
| GO:BP | GO:0048286 | lung alveolus development | 1 | 39 | 3.26e-01 |
| GO:BP | GO:0048631 | regulation of skeletal muscle tissue growth | 1 | 7 | 3.26e-01 |
| GO:BP | GO:2000144 | positive regulation of DNA-templated transcription initiation | 1 | 65 | 3.26e-01 |
| GO:BP | GO:0032959 | inositol trisphosphate biosynthetic process | 1 | 6 | 3.26e-01 |
| GO:BP | GO:0035721 | intraciliary retrograde transport | 1 | 14 | 3.26e-01 |
| GO:BP | GO:0046474 | glycerophospholipid biosynthetic process | 6 | 189 | 3.26e-01 |
| GO:BP | GO:0071907 | determination of digestive tract left/right asymmetry | 1 | 5 | 3.26e-01 |
| GO:BP | GO:1901339 | regulation of store-operated calcium channel activity | 1 | 8 | 3.26e-01 |
| GO:BP | GO:0048010 | vascular endothelial growth factor receptor signaling pathway | 2 | 48 | 3.26e-01 |
| GO:BP | GO:0060840 | artery development | 3 | 83 | 3.26e-01 |
| GO:BP | GO:0051443 | positive regulation of ubiquitin-protein transferase activity | 2 | 31 | 3.26e-01 |
| GO:BP | GO:0038026 | reelin-mediated signaling pathway | 1 | 9 | 3.26e-01 |
| GO:BP | GO:0090557 | establishment of endothelial intestinal barrier | 1 | 10 | 3.26e-01 |
| GO:BP | GO:0045723 | positive regulation of fatty acid biosynthetic process | 1 | 12 | 3.26e-01 |
| GO:BP | GO:0045719 | negative regulation of glycogen biosynthetic process | 1 | 7 | 3.26e-01 |
| GO:BP | GO:0051224 | negative regulation of protein transport | 3 | 91 | 3.26e-01 |
| GO:BP | GO:0051123 | RNA polymerase II preinitiation complex assembly | 1 | 54 | 3.26e-01 |
| GO:BP | GO:0046328 | regulation of JNK cascade | 3 | 114 | 3.26e-01 |
| GO:BP | GO:0036015 | response to interleukin-3 | 1 | 6 | 3.26e-01 |
| GO:BP | GO:0045806 | negative regulation of endocytosis | 3 | 56 | 3.26e-01 |
| GO:BP | GO:0035999 | tetrahydrofolate interconversion | 1 | 9 | 3.26e-01 |
| GO:BP | GO:0007213 | G protein-coupled acetylcholine receptor signaling pathway | 1 | 14 | 3.26e-01 |
| GO:BP | GO:0033169 | histone H3-K9 demethylation | 1 | 5 | 3.26e-01 |
| GO:BP | GO:0022406 | membrane docking | 1 | 84 | 3.26e-01 |
| GO:BP | GO:0051090 | regulation of DNA-binding transcription factor activity | 2 | 335 | 3.26e-01 |
| GO:BP | GO:1902991 | regulation of amyloid precursor protein catabolic process | 2 | 39 | 3.26e-01 |
| GO:BP | GO:0036016 | cellular response to interleukin-3 | 1 | 6 | 3.26e-01 |
| GO:BP | GO:0060260 | regulation of transcription initiation by RNA polymerase II | 1 | 69 | 3.26e-01 |
| GO:BP | GO:0051589 | negative regulation of neurotransmitter transport | 1 | 8 | 3.26e-01 |
| GO:BP | GO:0010799 | regulation of peptidyl-threonine phosphorylation | 2 | 35 | 3.26e-01 |
| GO:BP | GO:0140374 | antiviral innate immune response | 1 | 17 | 3.26e-01 |
| GO:BP | GO:0010624 | regulation of Schwann cell proliferation | 1 | 7 | 3.26e-01 |
| GO:BP | GO:0035092 | sperm DNA condensation | 1 | 7 | 3.26e-01 |
| GO:BP | GO:0042753 | positive regulation of circadian rhythm | 1 | 10 | 3.26e-01 |
| GO:BP | GO:0006282 | regulation of DNA repair | 3 | 198 | 3.26e-01 |
| GO:BP | GO:2000371 | regulation of DNA topoisomerase (ATP-hydrolyzing) activity | 1 | 5 | 3.26e-01 |
| GO:BP | GO:0006354 | DNA-templated transcription elongation | 1 | 122 | 3.26e-01 |
| GO:BP | GO:2000373 | positive regulation of DNA topoisomerase (ATP-hydrolyzing) activity | 1 | 5 | 3.26e-01 |
| GO:BP | GO:0061564 | axon development | 4 | 398 | 3.26e-01 |
| GO:BP | GO:1903613 | regulation of protein tyrosine phosphatase activity | 1 | 4 | 3.26e-01 |
| GO:BP | GO:1903214 | regulation of protein targeting to mitochondrion | 2 | 39 | 3.26e-01 |
| GO:BP | GO:0051256 | mitotic spindle midzone assembly | 1 | 9 | 3.26e-01 |
| GO:BP | GO:0048842 | positive regulation of axon extension involved in axon guidance | 1 | 6 | 3.26e-01 |
| GO:BP | GO:0010888 | negative regulation of lipid storage | 1 | 16 | 3.26e-01 |
| GO:BP | GO:1901097 | negative regulation of autophagosome maturation | 1 | 5 | 3.26e-01 |
| GO:BP | GO:0051640 | organelle localization | 2 | 503 | 3.26e-01 |
| GO:BP | GO:0010564 | regulation of cell cycle process | 2 | 626 | 3.26e-01 |
| GO:BP | GO:2000049 | positive regulation of cell-cell adhesion mediated by cadherin | 1 | 8 | 3.26e-01 |
| GO:BP | GO:0014010 | Schwann cell proliferation | 1 | 7 | 3.26e-01 |
| GO:BP | GO:0006520 | amino acid metabolic process | 1 | 222 | 3.26e-01 |
| GO:BP | GO:0003044 | regulation of systemic arterial blood pressure mediated by a chemical signal | 1 | 30 | 3.26e-01 |
| GO:BP | GO:0035196 | miRNA processing | 1 | 41 | 3.26e-01 |
| GO:BP | GO:1901343 | negative regulation of vasculature development | 3 | 73 | 3.26e-01 |
| GO:BP | GO:0018216 | peptidyl-arginine methylation | 1 | 15 | 3.27e-01 |
| GO:BP | GO:0098957 | anterograde axonal transport of mitochondrion | 1 | 5 | 3.27e-01 |
| GO:BP | GO:0031167 | rRNA methylation | 2 | 24 | 3.27e-01 |
| GO:BP | GO:0046339 | diacylglycerol metabolic process | 1 | 23 | 3.29e-01 |
| GO:BP | GO:0002069 | columnar/cuboidal epithelial cell maturation | 1 | 9 | 3.29e-01 |
| GO:BP | GO:1903599 | positive regulation of autophagy of mitochondrion | 1 | 13 | 3.29e-01 |
| GO:BP | GO:2001053 | regulation of mesenchymal cell apoptotic process | 1 | 5 | 3.29e-01 |
| GO:BP | GO:0097211 | cellular response to gonadotropin-releasing hormone | 1 | 3 | 3.29e-01 |
| GO:BP | GO:1904950 | negative regulation of establishment of protein localization | 5 | 95 | 3.29e-01 |
| GO:BP | GO:0051988 | regulation of attachment of spindle microtubules to kinetochore | 1 | 18 | 3.29e-01 |
| GO:BP | GO:0006978 | DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator | 1 | 18 | 3.29e-01 |
| GO:BP | GO:0001678 | intracellular glucose homeostasis | 3 | 110 | 3.30e-01 |
| GO:BP | GO:0071317 | cellular response to isoquinoline alkaloid | 1 | 2 | 3.30e-01 |
| GO:BP | GO:0071315 | cellular response to morphine | 1 | 2 | 3.30e-01 |
| GO:BP | GO:0006790 | sulfur compound metabolic process | 1 | 248 | 3.30e-01 |
| GO:BP | GO:0030316 | osteoclast differentiation | 3 | 66 | 3.30e-01 |
| GO:BP | GO:0009950 | dorsal/ventral axis specification | 1 | 9 | 3.30e-01 |
| GO:BP | GO:0010557 | positive regulation of macromolecule biosynthetic process | 35 | 1507 | 3.31e-01 |
| GO:BP | GO:0043462 | regulation of ATP-dependent activity | 3 | 63 | 3.31e-01 |
| GO:BP | GO:0032667 | regulation of interleukin-23 production | 1 | 6 | 3.31e-01 |
| GO:BP | GO:0032627 | interleukin-23 production | 1 | 6 | 3.31e-01 |
| GO:BP | GO:0010989 | negative regulation of low-density lipoprotein particle clearance | 1 | 4 | 3.31e-01 |
| GO:BP | GO:0006907 | pinocytosis | 1 | 18 | 3.31e-01 |
| GO:BP | GO:1905702 | regulation of inhibitory synapse assembly | 1 | 3 | 3.31e-01 |
| GO:BP | GO:0014891 | striated muscle atrophy | 1 | 6 | 3.31e-01 |
| GO:BP | GO:0051788 | response to misfolded protein | 2 | 25 | 3.31e-01 |
| GO:BP | GO:1903047 | mitotic cell cycle process | 2 | 694 | 3.31e-01 |
| GO:BP | GO:1904058 | positive regulation of sensory perception of pain | 1 | 3 | 3.31e-01 |
| GO:BP | GO:0150094 | amyloid-beta clearance by cellular catabolic process | 1 | 7 | 3.31e-01 |
| GO:BP | GO:0015820 | leucine transport | 1 | 10 | 3.31e-01 |
| GO:BP | GO:0002274 | myeloid leukocyte activation | 5 | 123 | 3.31e-01 |
| GO:BP | GO:1903979 | negative regulation of microglial cell activation | 1 | 5 | 3.31e-01 |
| GO:BP | GO:0016239 | positive regulation of macroautophagy | 3 | 70 | 3.31e-01 |
| GO:BP | GO:0001955 | blood vessel maturation | 1 | 6 | 3.33e-01 |
| GO:BP | GO:0050962 | detection of light stimulus involved in sensory perception | 1 | 9 | 3.33e-01 |
| GO:BP | GO:0050908 | detection of light stimulus involved in visual perception | 1 | 9 | 3.33e-01 |
| GO:BP | GO:0043393 | regulation of protein binding | 1 | 172 | 3.34e-01 |
| GO:BP | GO:0000022 | mitotic spindle elongation | 1 | 10 | 3.35e-01 |
| GO:BP | GO:0042772 | DNA damage response, signal transduction resulting in transcription | 1 | 19 | 3.35e-01 |
| GO:BP | GO:0070233 | negative regulation of T cell apoptotic process | 2 | 14 | 3.36e-01 |
| GO:BP | GO:0035864 | response to potassium ion | 1 | 12 | 3.36e-01 |
| GO:BP | GO:0000077 | DNA damage checkpoint signaling | 1 | 121 | 3.36e-01 |
| GO:BP | GO:0042541 | hemoglobin biosynthetic process | 1 | 13 | 3.36e-01 |
| GO:BP | GO:0002322 | B cell proliferation involved in immune response | 1 | 3 | 3.36e-01 |
| GO:BP | GO:1903595 | positive regulation of histamine secretion by mast cell | 1 | 4 | 3.36e-01 |
| GO:BP | GO:0019751 | polyol metabolic process | 3 | 82 | 3.36e-01 |
| GO:BP | GO:0002762 | negative regulation of myeloid leukocyte differentiation | 2 | 33 | 3.36e-01 |
| GO:BP | GO:2000142 | regulation of DNA-templated transcription initiation | 1 | 76 | 3.36e-01 |
| GO:BP | GO:0050890 | cognition | 6 | 227 | 3.36e-01 |
| GO:BP | GO:0090311 | regulation of protein deacetylation | 2 | 53 | 3.36e-01 |
| GO:BP | GO:0010498 | proteasomal protein catabolic process | 9 | 486 | 3.36e-01 |
| GO:BP | GO:1903593 | regulation of histamine secretion by mast cell | 1 | 4 | 3.36e-01 |
| GO:BP | GO:0009113 | purine nucleobase biosynthetic process | 1 | 10 | 3.36e-01 |
| GO:BP | GO:0009157 | deoxyribonucleoside monophosphate biosynthetic process | 1 | 9 | 3.36e-01 |
| GO:BP | GO:0030949 | positive regulation of vascular endothelial growth factor receptor signaling pathway | 1 | 13 | 3.36e-01 |
| GO:BP | GO:0021987 | cerebral cortex development | 5 | 101 | 3.36e-01 |
| GO:BP | GO:0033034 | positive regulation of myeloid cell apoptotic process | 1 | 6 | 3.37e-01 |
| GO:BP | GO:2001241 | positive regulation of extrinsic apoptotic signaling pathway in absence of ligand | 1 | 10 | 3.37e-01 |
| GO:BP | GO:0006895 | Golgi to endosome transport | 1 | 17 | 3.37e-01 |
| GO:BP | GO:0015695 | organic cation transport | 2 | 34 | 3.38e-01 |
| GO:BP | GO:0032228 | regulation of synaptic transmission, GABAergic | 2 | 23 | 3.38e-01 |
| GO:BP | GO:0060297 | regulation of sarcomere organization | 1 | 7 | 3.38e-01 |
| GO:BP | GO:0060977 | coronary vasculature morphogenesis | 1 | 17 | 3.38e-01 |
| GO:BP | GO:0002312 | B cell activation involved in immune response | 4 | 57 | 3.38e-01 |
| GO:BP | GO:0070874 | negative regulation of glycogen metabolic process | 1 | 7 | 3.38e-01 |
| GO:BP | GO:0071514 | genomic imprinting | 1 | 9 | 3.38e-01 |
| GO:BP | GO:0001659 | temperature homeostasis | 5 | 132 | 3.38e-01 |
| GO:BP | GO:0006612 | protein targeting to membrane | 1 | 118 | 3.38e-01 |
| GO:BP | GO:0051315 | attachment of mitotic spindle microtubules to kinetochore | 1 | 21 | 3.39e-01 |
| GO:BP | GO:0072583 | clathrin-dependent endocytosis | 1 | 43 | 3.39e-01 |
| GO:BP | GO:0043243 | positive regulation of protein-containing complex disassembly | 2 | 30 | 3.39e-01 |
| GO:BP | GO:0051291 | protein heterooligomerization | 2 | 21 | 3.39e-01 |
| GO:BP | GO:0010663 | positive regulation of striated muscle cell apoptotic process | 1 | 12 | 3.39e-01 |
| GO:BP | GO:0010666 | positive regulation of cardiac muscle cell apoptotic process | 1 | 12 | 3.39e-01 |
| GO:BP | GO:0006937 | regulation of muscle contraction | 2 | 133 | 3.39e-01 |
| GO:BP | GO:0034143 | regulation of toll-like receptor 4 signaling pathway | 1 | 15 | 3.39e-01 |
| GO:BP | GO:0006020 | inositol metabolic process | 1 | 8 | 3.39e-01 |
| GO:BP | GO:0010876 | lipid localization | 8 | 310 | 3.40e-01 |
| GO:BP | GO:0000045 | autophagosome assembly | 1 | 103 | 3.40e-01 |
| GO:BP | GO:0031328 | positive regulation of cellular biosynthetic process | 36 | 1564 | 3.40e-01 |
| GO:BP | GO:0050863 | regulation of T cell activation | 4 | 216 | 3.40e-01 |
| GO:BP | GO:0031570 | DNA integrity checkpoint signaling | 1 | 129 | 3.40e-01 |
| GO:BP | GO:0070897 | transcription preinitiation complex assembly | 1 | 67 | 3.40e-01 |
| GO:BP | GO:0016126 | sterol biosynthetic process | 2 | 52 | 3.40e-01 |
| GO:BP | GO:1902042 | negative regulation of extrinsic apoptotic signaling pathway via death domain receptors | 1 | 24 | 3.40e-01 |
| GO:BP | GO:1904018 | positive regulation of vasculature development | 3 | 115 | 3.40e-01 |
| GO:BP | GO:1905517 | macrophage migration | 1 | 34 | 3.40e-01 |
| GO:BP | GO:0045766 | positive regulation of angiogenesis | 3 | 115 | 3.40e-01 |
| GO:BP | GO:0060009 | Sertoli cell development | 1 | 10 | 3.40e-01 |
| GO:BP | GO:0002732 | positive regulation of dendritic cell cytokine production | 1 | 8 | 3.40e-01 |
| GO:BP | GO:0097152 | mesenchymal cell apoptotic process | 1 | 7 | 3.40e-01 |
| GO:BP | GO:0043553 | negative regulation of phosphatidylinositol 3-kinase activity | 1 | 4 | 3.40e-01 |
| GO:BP | GO:0019229 | regulation of vasoconstriction | 1 | 38 | 3.40e-01 |
| GO:BP | GO:0010592 | positive regulation of lamellipodium assembly | 1 | 25 | 3.40e-01 |
| GO:BP | GO:0070243 | regulation of thymocyte apoptotic process | 1 | 11 | 3.40e-01 |
| GO:BP | GO:0032352 | positive regulation of hormone metabolic process | 1 | 11 | 3.40e-01 |
| GO:BP | GO:2001233 | regulation of apoptotic signaling pathway | 6 | 307 | 3.40e-01 |
| GO:BP | GO:0120009 | intermembrane lipid transfer | 2 | 43 | 3.40e-01 |
| GO:BP | GO:0090461 | intracellular glutamate homeostasis | 1 | 4 | 3.40e-01 |
| GO:BP | GO:0060576 | intestinal epithelial cell development | 1 | 11 | 3.40e-01 |
| GO:BP | GO:0051494 | negative regulation of cytoskeleton organization | 3 | 140 | 3.40e-01 |
| GO:BP | GO:0048742 | regulation of skeletal muscle fiber development | 1 | 8 | 3.40e-01 |
| GO:BP | GO:0043968 | histone H2A acetylation | 1 | 22 | 3.40e-01 |
| GO:BP | GO:0018195 | peptidyl-arginine modification | 1 | 18 | 3.40e-01 |
| GO:BP | GO:0006337 | nucleosome disassembly | 1 | 16 | 3.40e-01 |
| GO:BP | GO:0051693 | actin filament capping | 2 | 34 | 3.42e-01 |
| GO:BP | GO:0008210 | estrogen metabolic process | 1 | 16 | 3.42e-01 |
| GO:BP | GO:0019262 | N-acetylneuraminate catabolic process | 1 | 6 | 3.42e-01 |
| GO:BP | GO:0001568 | blood vessel development | 12 | 534 | 3.45e-01 |
| GO:BP | GO:0060976 | coronary vasculature development | 2 | 44 | 3.46e-01 |
| GO:BP | GO:0071373 | cellular response to luteinizing hormone stimulus | 1 | 5 | 3.46e-01 |
| GO:BP | GO:0048013 | ephrin receptor signaling pathway | 2 | 41 | 3.47e-01 |
| GO:BP | GO:0007406 | negative regulation of neuroblast proliferation | 1 | 9 | 3.47e-01 |
| GO:BP | GO:0097210 | response to gonadotropin-releasing hormone | 1 | 4 | 3.47e-01 |
| GO:BP | GO:0007163 | establishment or maintenance of cell polarity | 3 | 206 | 3.47e-01 |
| GO:BP | GO:0007093 | mitotic cell cycle checkpoint signaling | 1 | 139 | 3.48e-01 |
| GO:BP | GO:0010875 | positive regulation of cholesterol efflux | 1 | 23 | 3.49e-01 |
| GO:BP | GO:1905037 | autophagosome organization | 1 | 110 | 3.50e-01 |
| GO:BP | GO:1903747 | regulation of establishment of protein localization to mitochondrion | 2 | 44 | 3.50e-01 |
| GO:BP | GO:0006351 | DNA-templated transcription | 4 | 2683 | 3.51e-01 |
| GO:BP | GO:0090594 | inflammatory response to wounding | 1 | 12 | 3.51e-01 |
| GO:BP | GO:0038134 | ERBB2-EGFR signaling pathway | 1 | 6 | 3.51e-01 |
| GO:BP | GO:0097530 | granulocyte migration | 2 | 67 | 3.51e-01 |
| GO:BP | GO:0051255 | spindle midzone assembly | 1 | 12 | 3.51e-01 |
| GO:BP | GO:0051231 | spindle elongation | 1 | 12 | 3.51e-01 |
| GO:BP | GO:0015838 | amino-acid betaine transport | 1 | 7 | 3.51e-01 |
| GO:BP | GO:0072666 | establishment of protein localization to vacuole | 3 | 55 | 3.51e-01 |
| GO:BP | GO:0097659 | nucleic acid-templated transcription | 4 | 2684 | 3.51e-01 |
| GO:BP | GO:1905897 | regulation of response to endoplasmic reticulum stress | 2 | 76 | 3.51e-01 |
| GO:BP | GO:0031133 | regulation of axon diameter | 1 | 4 | 3.51e-01 |
| GO:BP | GO:0002262 | myeloid cell homeostasis | 4 | 140 | 3.51e-01 |
| GO:BP | GO:0009135 | purine nucleoside diphosphate metabolic process | 1 | 17 | 3.51e-01 |
| GO:BP | GO:2000625 | regulation of miRNA catabolic process | 1 | 5 | 3.51e-01 |
| GO:BP | GO:0045893 | positive regulation of DNA-templated transcription | 31 | 1315 | 3.51e-01 |
| GO:BP | GO:2000465 | regulation of glycogen (starch) synthase activity | 1 | 8 | 3.51e-01 |
| GO:BP | GO:0009179 | purine ribonucleoside diphosphate metabolic process | 1 | 17 | 3.51e-01 |
| GO:BP | GO:0071484 | cellular response to light intensity | 1 | 4 | 3.51e-01 |
| GO:BP | GO:0050859 | negative regulation of B cell receptor signaling pathway | 1 | 3 | 3.51e-01 |
| GO:BP | GO:0007589 | body fluid secretion | 2 | 60 | 3.51e-01 |
| GO:BP | GO:2000074 | regulation of type B pancreatic cell development | 1 | 8 | 3.51e-01 |
| GO:BP | GO:0036037 | CD8-positive, alpha-beta T cell activation | 1 | 15 | 3.51e-01 |
| GO:BP | GO:1903508 | positive regulation of nucleic acid-templated transcription | 31 | 1315 | 3.51e-01 |
| GO:BP | GO:0048630 | skeletal muscle tissue growth | 1 | 8 | 3.51e-01 |
| GO:BP | GO:0045471 | response to ethanol | 3 | 73 | 3.51e-01 |
| GO:BP | GO:0042255 | ribosome assembly | 2 | 56 | 3.53e-01 |
| GO:BP | GO:0006906 | vesicle fusion | 1 | 104 | 3.53e-01 |
| GO:BP | GO:0045591 | positive regulation of regulatory T cell differentiation | 1 | 14 | 3.53e-01 |
| GO:BP | GO:0006515 | protein quality control for misfolded or incompletely synthesized proteins | 2 | 28 | 3.53e-01 |
| GO:BP | GO:1900027 | regulation of ruffle assembly | 1 | 23 | 3.54e-01 |
| GO:BP | GO:0032774 | RNA biosynthetic process | 4 | 2714 | 3.55e-01 |
| GO:BP | GO:0071034 | CUT catabolic process | 1 | 5 | 3.55e-01 |
| GO:BP | GO:0048599 | oocyte development | 1 | 38 | 3.55e-01 |
| GO:BP | GO:0032986 | protein-DNA complex disassembly | 1 | 18 | 3.55e-01 |
| GO:BP | GO:2000269 | regulation of fibroblast apoptotic process | 1 | 17 | 3.55e-01 |
| GO:BP | GO:0071043 | CUT metabolic process | 1 | 5 | 3.55e-01 |
| GO:BP | GO:0046599 | regulation of centriole replication | 1 | 21 | 3.55e-01 |
| GO:BP | GO:0055017 | cardiac muscle tissue growth | 3 | 65 | 3.55e-01 |
| GO:BP | GO:0090174 | organelle membrane fusion | 1 | 106 | 3.55e-01 |
| GO:BP | GO:0070508 | cholesterol import | 1 | 6 | 3.55e-01 |
| GO:BP | GO:0009225 | nucleotide-sugar metabolic process | 2 | 35 | 3.55e-01 |
| GO:BP | GO:0006563 | L-serine metabolic process | 1 | 10 | 3.55e-01 |
| GO:BP | GO:0050918 | positive chemotaxis | 1 | 40 | 3.55e-01 |
| GO:BP | GO:0150172 | regulation of phosphatidylcholine metabolic process | 1 | 10 | 3.55e-01 |
| GO:BP | GO:0016477 | cell migration | 5 | 1081 | 3.55e-01 |
| GO:BP | GO:0009176 | pyrimidine deoxyribonucleoside monophosphate metabolic process | 1 | 9 | 3.55e-01 |
| GO:BP | GO:1904753 | negative regulation of vascular associated smooth muscle cell migration | 1 | 11 | 3.55e-01 |
| GO:BP | GO:0030948 | negative regulation of vascular endothelial growth factor receptor signaling pathway | 1 | 11 | 3.55e-01 |
| GO:BP | GO:0014051 | gamma-aminobutyric acid secretion | 1 | 8 | 3.55e-01 |
| GO:BP | GO:0060333 | type II interferon-mediated signaling pathway | 1 | 21 | 3.55e-01 |
| GO:BP | GO:0002066 | columnar/cuboidal epithelial cell development | 2 | 38 | 3.55e-01 |
| GO:BP | GO:0044381 | glucose import in response to insulin stimulus | 1 | 4 | 3.55e-01 |
| GO:BP | GO:1904294 | positive regulation of ERAD pathway | 1 | 16 | 3.55e-01 |
| GO:BP | GO:0042304 | regulation of fatty acid biosynthetic process | 2 | 30 | 3.56e-01 |
| GO:BP | GO:0050709 | negative regulation of protein secretion | 2 | 44 | 3.56e-01 |
| GO:BP | GO:0008045 | motor neuron axon guidance | 1 | 25 | 3.56e-01 |
| GO:BP | GO:0010822 | positive regulation of mitochondrion organization | 3 | 68 | 3.56e-01 |
| GO:BP | GO:0042832 | defense response to protozoan | 1 | 10 | 3.56e-01 |
| GO:BP | GO:0099170 | postsynaptic modulation of chemical synaptic transmission | 2 | 23 | 3.56e-01 |
| GO:BP | GO:0043485 | endosome to pigment granule transport | 1 | 9 | 3.56e-01 |
| GO:BP | GO:0055013 | cardiac muscle cell development | 3 | 71 | 3.56e-01 |
| GO:BP | GO:0032787 | monocarboxylic acid metabolic process | 1 | 433 | 3.56e-01 |
| GO:BP | GO:0048757 | pigment granule maturation | 1 | 9 | 3.56e-01 |
| GO:BP | GO:0035646 | endosome to melanosome transport | 1 | 9 | 3.56e-01 |
| GO:BP | GO:0045582 | positive regulation of T cell differentiation | 2 | 74 | 3.56e-01 |
| GO:BP | GO:0072578 | neurotransmitter-gated ion channel clustering | 1 | 12 | 3.57e-01 |
| GO:BP | GO:0071560 | cellular response to transforming growth factor beta stimulus | 4 | 222 | 3.57e-01 |
| GO:BP | GO:0050870 | positive regulation of T cell activation | 3 | 144 | 3.57e-01 |
| GO:BP | GO:0009395 | phospholipid catabolic process | 2 | 37 | 3.57e-01 |
| GO:BP | GO:0043473 | pigmentation | 3 | 92 | 3.57e-01 |
| GO:BP | GO:0006537 | glutamate biosynthetic process | 1 | 5 | 3.58e-01 |
| GO:BP | GO:0016073 | snRNA metabolic process | 1 | 54 | 3.58e-01 |
| GO:BP | GO:0032957 | inositol trisphosphate metabolic process | 1 | 10 | 3.58e-01 |
| GO:BP | GO:0032007 | negative regulation of TOR signaling | 2 | 47 | 3.58e-01 |
| GO:BP | GO:0120178 | steroid hormone biosynthetic process | 1 | 29 | 3.58e-01 |
| GO:BP | GO:0032369 | negative regulation of lipid transport | 1 | 20 | 3.58e-01 |
| GO:BP | GO:0044249 | cellular biosynthetic process | 4 | 4245 | 3.58e-01 |
| GO:BP | GO:0032411 | positive regulation of transporter activity | 5 | 93 | 3.58e-01 |
| GO:BP | GO:0043353 | enucleate erythrocyte differentiation | 1 | 9 | 3.59e-01 |
| GO:BP | GO:0062013 | positive regulation of small molecule metabolic process | 3 | 104 | 3.60e-01 |
| GO:BP | GO:0009994 | oocyte differentiation | 1 | 39 | 3.60e-01 |
| GO:BP | GO:0016049 | cell growth | 5 | 418 | 3.60e-01 |
| GO:BP | GO:0030835 | negative regulation of actin filament depolymerization | 2 | 37 | 3.60e-01 |
| GO:BP | GO:0098664 | G protein-coupled serotonin receptor signaling pathway | 1 | 8 | 3.60e-01 |
| GO:BP | GO:0033673 | negative regulation of kinase activity | 6 | 197 | 3.60e-01 |
| GO:BP | GO:0014889 | muscle atrophy | 1 | 9 | 3.60e-01 |
| GO:BP | GO:1901522 | positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus | 1 | 16 | 3.60e-01 |
| GO:BP | GO:0060644 | mammary gland epithelial cell differentiation | 1 | 14 | 3.60e-01 |
| GO:BP | GO:0031503 | protein-containing complex localization | 3 | 168 | 3.60e-01 |
| GO:BP | GO:0090205 | positive regulation of cholesterol metabolic process | 1 | 12 | 3.62e-01 |
| GO:BP | GO:0032926 | negative regulation of activin receptor signaling pathway | 1 | 9 | 3.63e-01 |
| GO:BP | GO:0019217 | regulation of fatty acid metabolic process | 3 | 66 | 3.64e-01 |
| GO:BP | GO:0099010 | modification of postsynaptic structure | 1 | 17 | 3.64e-01 |
| GO:BP | GO:0071281 | cellular response to iron ion | 1 | 6 | 3.64e-01 |
| GO:BP | GO:0006470 | protein dephosphorylation | 8 | 214 | 3.64e-01 |
| GO:BP | GO:1902176 | negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway | 1 | 18 | 3.64e-01 |
| GO:BP | GO:0043117 | positive regulation of vascular permeability | 1 | 14 | 3.64e-01 |
| GO:BP | GO:0006089 | lactate metabolic process | 1 | 16 | 3.64e-01 |
| GO:BP | GO:0090435 | protein localization to nuclear envelope | 1 | 14 | 3.64e-01 |
| GO:BP | GO:0010985 | negative regulation of lipoprotein particle clearance | 1 | 6 | 3.64e-01 |
| GO:BP | GO:0009266 | response to temperature stimulus | 4 | 133 | 3.64e-01 |
| GO:BP | GO:0071559 | response to transforming growth factor beta | 4 | 227 | 3.64e-01 |
| GO:BP | GO:0032049 | cardiolipin biosynthetic process | 1 | 7 | 3.64e-01 |
| GO:BP | GO:1902745 | positive regulation of lamellipodium organization | 1 | 32 | 3.64e-01 |
| GO:BP | GO:0036003 | positive regulation of transcription from RNA polymerase II promoter in response to stress | 1 | 18 | 3.64e-01 |
| GO:BP | GO:0001562 | response to protozoan | 1 | 11 | 3.64e-01 |
| GO:BP | GO:0045217 | cell-cell junction maintenance | 1 | 13 | 3.64e-01 |
| GO:BP | GO:1905165 | regulation of lysosomal protein catabolic process | 1 | 11 | 3.64e-01 |
| GO:BP | GO:0019216 | regulation of lipid metabolic process | 6 | 250 | 3.64e-01 |
| GO:BP | GO:1905155 | positive regulation of membrane invagination | 1 | 11 | 3.64e-01 |
| GO:BP | GO:0010743 | regulation of macrophage derived foam cell differentiation | 1 | 18 | 3.64e-01 |
| GO:BP | GO:0051480 | regulation of cytosolic calcium ion concentration | 3 | 40 | 3.64e-01 |
| GO:BP | GO:0060586 | multicellular organismal-level iron ion homeostasis | 1 | 7 | 3.64e-01 |
| GO:BP | GO:0032703 | negative regulation of interleukin-2 production | 1 | 10 | 3.64e-01 |
| GO:BP | GO:0000278 | mitotic cell cycle | 2 | 827 | 3.64e-01 |
| GO:BP | GO:0007034 | vacuolar transport | 6 | 149 | 3.64e-01 |
| GO:BP | GO:0098792 | xenophagy | 1 | 12 | 3.64e-01 |
| GO:BP | GO:0006338 | chromatin remodeling | 6 | 378 | 3.64e-01 |
| GO:BP | GO:0002027 | regulation of heart rate | 3 | 86 | 3.64e-01 |
| GO:BP | GO:2000209 | regulation of anoikis | 1 | 23 | 3.64e-01 |
| GO:BP | GO:0080182 | histone H3-K4 trimethylation | 1 | 16 | 3.64e-01 |
| GO:BP | GO:0043525 | positive regulation of neuron apoptotic process | 2 | 41 | 3.64e-01 |
| GO:BP | GO:1900122 | positive regulation of receptor binding | 1 | 7 | 3.64e-01 |
| GO:BP | GO:0140245 | regulation of translation at postsynapse | 1 | 6 | 3.64e-01 |
| GO:BP | GO:1901985 | positive regulation of protein acetylation | 2 | 41 | 3.64e-01 |
| GO:BP | GO:0030502 | negative regulation of bone mineralization | 1 | 10 | 3.64e-01 |
| GO:BP | GO:0060219 | camera-type eye photoreceptor cell differentiation | 1 | 18 | 3.64e-01 |
| GO:BP | GO:0095500 | acetylcholine receptor signaling pathway | 1 | 18 | 3.64e-01 |
| GO:BP | GO:0034384 | high-density lipoprotein particle clearance | 1 | 7 | 3.64e-01 |
| GO:BP | GO:0140243 | regulation of translation at synapse | 1 | 6 | 3.64e-01 |
| GO:BP | GO:0020027 | hemoglobin metabolic process | 1 | 16 | 3.64e-01 |
| GO:BP | GO:0060100 | positive regulation of phagocytosis, engulfment | 1 | 11 | 3.64e-01 |
| GO:BP | GO:1990743 | protein sialylation | 1 | 5 | 3.64e-01 |
| GO:BP | GO:0035774 | positive regulation of insulin secretion involved in cellular response to glucose stimulus | 2 | 18 | 3.64e-01 |
| GO:BP | GO:0034470 | ncRNA processing | 3 | 400 | 3.64e-01 |
| GO:BP | GO:0000288 | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 1 | 64 | 3.64e-01 |
| GO:BP | GO:0007041 | lysosomal transport | 5 | 115 | 3.64e-01 |
| GO:BP | GO:2001243 | negative regulation of intrinsic apoptotic signaling pathway | 2 | 89 | 3.64e-01 |
| GO:BP | GO:0072359 | circulatory system development | 17 | 884 | 3.64e-01 |
| GO:BP | GO:0099519 | dense core granule cytoskeletal transport | 1 | 7 | 3.64e-01 |
| GO:BP | GO:0046655 | folic acid metabolic process | 1 | 14 | 3.64e-01 |
| GO:BP | GO:0046653 | tetrahydrofolate metabolic process | 1 | 14 | 3.64e-01 |
| GO:BP | GO:1901950 | dense core granule transport | 1 | 7 | 3.64e-01 |
| GO:BP | GO:0061052 | negative regulation of cell growth involved in cardiac muscle cell development | 1 | 10 | 3.64e-01 |
| GO:BP | GO:0044557 | relaxation of smooth muscle | 1 | 9 | 3.64e-01 |
| GO:BP | GO:1903935 | response to sodium arsenite | 1 | 6 | 3.64e-01 |
| GO:BP | GO:0051984 | positive regulation of chromosome segregation | 1 | 27 | 3.64e-01 |
| GO:BP | GO:0032933 | SREBP signaling pathway | 1 | 14 | 3.64e-01 |
| GO:BP | GO:0045069 | regulation of viral genome replication | 3 | 64 | 3.64e-01 |
| GO:BP | GO:0046324 | regulation of glucose import | 2 | 41 | 3.64e-01 |
| GO:BP | GO:0098937 | anterograde dendritic transport | 1 | 9 | 3.64e-01 |
| GO:BP | GO:1903313 | positive regulation of mRNA metabolic process | 2 | 121 | 3.64e-01 |
| GO:BP | GO:0010911 | regulation of isomerase activity | 1 | 5 | 3.64e-01 |
| GO:BP | GO:0090092 | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 5 | 230 | 3.64e-01 |
| GO:BP | GO:0071385 | cellular response to glucocorticoid stimulus | 2 | 40 | 3.64e-01 |
| GO:BP | GO:1905145 | cellular response to acetylcholine | 1 | 20 | 3.64e-01 |
| GO:BP | GO:0043409 | negative regulation of MAPK cascade | 2 | 145 | 3.64e-01 |
| GO:BP | GO:0014910 | regulation of smooth muscle cell migration | 2 | 58 | 3.64e-01 |
| GO:BP | GO:0010706 | ganglioside biosynthetic process via lactosylceramide | 1 | 5 | 3.64e-01 |
| GO:BP | GO:0010182 | sugar mediated signaling pathway | 1 | 5 | 3.64e-01 |
| GO:BP | GO:0010255 | glucose mediated signaling pathway | 1 | 5 | 3.64e-01 |
| GO:BP | GO:0048853 | forebrain morphogenesis | 1 | 7 | 3.64e-01 |
| GO:BP | GO:0048715 | negative regulation of oligodendrocyte differentiation | 1 | 8 | 3.64e-01 |
| GO:BP | GO:0006367 | transcription initiation at RNA polymerase II promoter | 1 | 93 | 3.64e-01 |
| GO:BP | GO:0048667 | cell morphogenesis involved in neuron differentiation | 4 | 463 | 3.64e-01 |
| GO:BP | GO:0010605 | negative regulation of macromolecule metabolic process | 3 | 2135 | 3.64e-01 |
| GO:BP | GO:1901607 | alpha-amino acid biosynthetic process | 2 | 59 | 3.64e-01 |
| GO:BP | GO:1900454 | positive regulation of long-term synaptic depression | 1 | 3 | 3.64e-01 |
| GO:BP | GO:0032253 | dense core granule localization | 1 | 7 | 3.64e-01 |
| GO:BP | GO:1900363 | regulation of mRNA polyadenylation | 1 | 11 | 3.64e-01 |
| GO:BP | GO:0043470 | regulation of carbohydrate catabolic process | 2 | 47 | 3.64e-01 |
| GO:BP | GO:0006469 | negative regulation of protein kinase activity | 5 | 179 | 3.64e-01 |
| GO:BP | GO:0070918 | regulatory ncRNA processing | 1 | 47 | 3.64e-01 |
| GO:BP | GO:0009757 | hexose mediated signaling | 1 | 5 | 3.64e-01 |
| GO:BP | GO:0010912 | positive regulation of isomerase activity | 1 | 5 | 3.64e-01 |
| GO:BP | GO:0051341 | regulation of oxidoreductase activity | 2 | 68 | 3.64e-01 |
| GO:BP | GO:0030488 | tRNA methylation | 1 | 42 | 3.64e-01 |
| GO:BP | GO:0042310 | vasoconstriction | 1 | 51 | 3.64e-01 |
| GO:BP | GO:0048026 | positive regulation of mRNA splicing, via spliceosome | 1 | 21 | 3.64e-01 |
| GO:BP | GO:1905907 | negative regulation of amyloid fibril formation | 1 | 10 | 3.64e-01 |
| GO:BP | GO:0010591 | regulation of lamellipodium assembly | 1 | 33 | 3.64e-01 |
| GO:BP | GO:0018023 | peptidyl-lysine trimethylation | 2 | 33 | 3.64e-01 |
| GO:BP | GO:0046173 | polyol biosynthetic process | 2 | 47 | 3.64e-01 |
| GO:BP | GO:0046037 | GMP metabolic process | 1 | 23 | 3.64e-01 |
| GO:BP | GO:0071314 | cellular response to cocaine | 1 | 7 | 3.64e-01 |
| GO:BP | GO:0090257 | regulation of muscle system process | 5 | 184 | 3.64e-01 |
| GO:BP | GO:1901606 | alpha-amino acid catabolic process | 4 | 63 | 3.64e-01 |
| GO:BP | GO:1903204 | negative regulation of oxidative stress-induced neuron death | 1 | 19 | 3.64e-01 |
| GO:BP | GO:0010563 | negative regulation of phosphorus metabolic process | 9 | 345 | 3.64e-01 |
| GO:BP | GO:0055006 | cardiac cell development | 3 | 77 | 3.64e-01 |
| GO:BP | GO:0051403 | stress-activated MAPK cascade | 5 | 190 | 3.64e-01 |
| GO:BP | GO:0034699 | response to luteinizing hormone | 1 | 7 | 3.64e-01 |
| GO:BP | GO:0042770 | signal transduction in response to DNA damage | 1 | 178 | 3.64e-01 |
| GO:BP | GO:0021522 | spinal cord motor neuron differentiation | 1 | 18 | 3.64e-01 |
| GO:BP | GO:0007254 | JNK cascade | 2 | 138 | 3.64e-01 |
| GO:BP | GO:0071392 | cellular response to estradiol stimulus | 2 | 26 | 3.64e-01 |
| GO:BP | GO:1903083 | protein localization to condensed chromosome | 1 | 18 | 3.64e-01 |
| GO:BP | GO:0034501 | protein localization to kinetochore | 1 | 18 | 3.64e-01 |
| GO:BP | GO:0045821 | positive regulation of glycolytic process | 1 | 15 | 3.64e-01 |
| GO:BP | GO:0099509 | regulation of presynaptic cytosolic calcium ion concentration | 1 | 10 | 3.64e-01 |
| GO:BP | GO:0007613 | memory | 3 | 92 | 3.64e-01 |
| GO:BP | GO:0007210 | serotonin receptor signaling pathway | 1 | 8 | 3.64e-01 |
| GO:BP | GO:0000075 | cell cycle checkpoint signaling | 1 | 183 | 3.64e-01 |
| GO:BP | GO:0007369 | gastrulation | 1 | 146 | 3.64e-01 |
| GO:BP | GO:0021543 | pallium development | 6 | 139 | 3.64e-01 |
| GO:BP | GO:0007204 | positive regulation of cytosolic calcium ion concentration | 2 | 90 | 3.64e-01 |
| GO:BP | GO:0021537 | telencephalon development | 8 | 201 | 3.64e-01 |
| GO:BP | GO:0042987 | amyloid precursor protein catabolic process | 2 | 53 | 3.64e-01 |
| GO:BP | GO:0043116 | negative regulation of vascular permeability | 1 | 16 | 3.64e-01 |
| GO:BP | GO:0002278 | eosinophil activation involved in immune response | 1 | 4 | 3.64e-01 |
| GO:BP | GO:0034097 | response to cytokine | 15 | 607 | 3.64e-01 |
| GO:BP | GO:1903531 | negative regulation of secretion by cell | 3 | 99 | 3.64e-01 |
| GO:BP | GO:0090596 | sensory organ morphogenesis | 5 | 178 | 3.64e-01 |
| GO:BP | GO:0043308 | eosinophil degranulation | 1 | 4 | 3.64e-01 |
| GO:BP | GO:0071501 | cellular response to sterol depletion | 1 | 14 | 3.64e-01 |
| GO:BP | GO:0006869 | lipid transport | 7 | 272 | 3.64e-01 |
| GO:BP | GO:0014874 | response to stimulus involved in regulation of muscle adaptation | 1 | 12 | 3.64e-01 |
| GO:BP | GO:1903826 | L-arginine transmembrane transport | 1 | 12 | 3.64e-01 |
| GO:BP | GO:0048284 | organelle fusion | 1 | 135 | 3.64e-01 |
| GO:BP | GO:0010506 | regulation of autophagy | 8 | 313 | 3.64e-01 |
| GO:BP | GO:0009265 | 2’-deoxyribonucleotide biosynthetic process | 1 | 14 | 3.64e-01 |
| GO:BP | GO:0043476 | pigment accumulation | 1 | 11 | 3.64e-01 |
| GO:BP | GO:0015803 | branched-chain amino acid transport | 1 | 14 | 3.64e-01 |
| GO:BP | GO:0007422 | peripheral nervous system development | 1 | 67 | 3.64e-01 |
| GO:BP | GO:0043482 | cellular pigment accumulation | 1 | 11 | 3.64e-01 |
| GO:BP | GO:0072521 | purine-containing compound metabolic process | 1 | 390 | 3.64e-01 |
| GO:BP | GO:0050900 | leukocyte migration | 2 | 209 | 3.64e-01 |
| GO:BP | GO:0090084 | negative regulation of inclusion body assembly | 1 | 10 | 3.64e-01 |
| GO:BP | GO:1990379 | lipid transport across blood-brain barrier | 1 | 6 | 3.64e-01 |
| GO:BP | GO:0098876 | vesicle-mediated transport to the plasma membrane | 1 | 143 | 3.64e-01 |
| GO:BP | GO:0048523 | negative regulation of cellular process | 5 | 3625 | 3.64e-01 |
| GO:BP | GO:0030071 | regulation of mitotic metaphase/anaphase transition | 2 | 88 | 3.64e-01 |
| GO:BP | GO:0009263 | deoxyribonucleotide biosynthetic process | 1 | 14 | 3.64e-01 |
| GO:BP | GO:0006355 | regulation of DNA-templated transcription | 3 | 2574 | 3.64e-01 |
| GO:BP | GO:0070242 | thymocyte apoptotic process | 1 | 17 | 3.64e-01 |
| GO:BP | GO:0009130 | pyrimidine nucleoside monophosphate biosynthetic process | 1 | 13 | 3.64e-01 |
| GO:BP | GO:1903506 | regulation of nucleic acid-templated transcription | 3 | 2576 | 3.64e-01 |
| GO:BP | GO:0002220 | innate immune response activating cell surface receptor signaling pathway | 2 | 37 | 3.64e-01 |
| GO:BP | GO:0051000 | positive regulation of nitric-oxide synthase activity | 1 | 14 | 3.64e-01 |
| GO:BP | GO:1902904 | negative regulation of supramolecular fiber organization | 4 | 140 | 3.64e-01 |
| GO:BP | GO:2000434 | regulation of protein neddylation | 1 | 19 | 3.64e-01 |
| GO:BP | GO:0090150 | establishment of protein localization to membrane | 1 | 250 | 3.64e-01 |
| GO:BP | GO:0046385 | deoxyribose phosphate biosynthetic process | 1 | 14 | 3.64e-01 |
| GO:BP | GO:0032308 | positive regulation of prostaglandin secretion | 1 | 6 | 3.65e-01 |
| GO:BP | GO:0045685 | regulation of glial cell differentiation | 3 | 47 | 3.66e-01 |
| GO:BP | GO:0048820 | hair follicle maturation | 1 | 15 | 3.66e-01 |
| GO:BP | GO:0019722 | calcium-mediated signaling | 2 | 122 | 3.66e-01 |
| GO:BP | GO:0042308 | negative regulation of protein import into nucleus | 1 | 13 | 3.66e-01 |
| GO:BP | GO:2001141 | regulation of RNA biosynthetic process | 3 | 2593 | 3.66e-01 |
| GO:BP | GO:0099566 | regulation of postsynaptic cytosolic calcium ion concentration | 1 | 6 | 3.66e-01 |
| GO:BP | GO:0045739 | positive regulation of DNA repair | 2 | 120 | 3.66e-01 |
| GO:BP | GO:0071313 | cellular response to caffeine | 1 | 10 | 3.66e-01 |
| GO:BP | GO:1905144 | response to acetylcholine | 1 | 22 | 3.66e-01 |
| GO:BP | GO:0045621 | positive regulation of lymphocyte differentiation | 2 | 86 | 3.66e-01 |
| GO:BP | GO:0000018 | regulation of DNA recombination | 2 | 101 | 3.66e-01 |
| GO:BP | GO:0060042 | retina morphogenesis in camera-type eye | 2 | 40 | 3.67e-01 |
| GO:BP | GO:0060099 | regulation of phagocytosis, engulfment | 1 | 11 | 3.67e-01 |
| GO:BP | GO:1905153 | regulation of membrane invagination | 1 | 11 | 3.67e-01 |
| GO:BP | GO:0002730 | regulation of dendritic cell cytokine production | 1 | 10 | 3.67e-01 |
| GO:BP | GO:0002371 | dendritic cell cytokine production | 1 | 10 | 3.67e-01 |
| GO:BP | GO:0002313 | mature B cell differentiation involved in immune response | 2 | 17 | 3.67e-01 |
| GO:BP | GO:1903039 | positive regulation of leukocyte cell-cell adhesion | 3 | 157 | 3.67e-01 |
| GO:BP | GO:0051567 | histone H3-K9 methylation | 1 | 18 | 3.67e-01 |
| GO:BP | GO:0060008 | Sertoli cell differentiation | 1 | 15 | 3.67e-01 |
| GO:BP | GO:0007611 | learning or memory | 5 | 202 | 3.69e-01 |
| GO:BP | GO:0090077 | foam cell differentiation | 1 | 22 | 3.69e-01 |
| GO:BP | GO:0010742 | macrophage derived foam cell differentiation | 1 | 22 | 3.69e-01 |
| GO:BP | GO:1904350 | regulation of protein catabolic process in the vacuole | 1 | 13 | 3.69e-01 |
| GO:BP | GO:0060419 | heart growth | 3 | 72 | 3.69e-01 |
| GO:BP | GO:0044346 | fibroblast apoptotic process | 1 | 23 | 3.69e-01 |
| GO:BP | GO:0034341 | response to type II interferon | 3 | 83 | 3.69e-01 |
| GO:BP | GO:0070782 | phosphatidylserine exposure on apoptotic cell surface | 1 | 3 | 3.69e-01 |
| GO:BP | GO:0006661 | phosphatidylinositol biosynthetic process | 3 | 119 | 3.69e-01 |
| GO:BP | GO:2000779 | regulation of double-strand break repair | 2 | 121 | 3.70e-01 |
| GO:BP | GO:0016573 | histone acetylation | 2 | 143 | 3.70e-01 |
| GO:BP | GO:2000810 | regulation of bicellular tight junction assembly | 1 | 15 | 3.71e-01 |
| GO:BP | GO:0070542 | response to fatty acid | 2 | 43 | 3.71e-01 |
| GO:BP | GO:1902099 | regulation of metaphase/anaphase transition of cell cycle | 2 | 89 | 3.71e-01 |
| GO:BP | GO:2000819 | regulation of nucleotide-excision repair | 1 | 27 | 3.71e-01 |
| GO:BP | GO:0007091 | metaphase/anaphase transition of mitotic cell cycle | 2 | 91 | 3.71e-01 |
| GO:BP | GO:0043201 | response to leucine | 1 | 13 | 3.71e-01 |
| GO:BP | GO:0120161 | regulation of cold-induced thermogenesis | 4 | 112 | 3.71e-01 |
| GO:BP | GO:0032781 | positive regulation of ATP-dependent activity | 2 | 40 | 3.72e-01 |
| GO:BP | GO:0006913 | nucleocytoplasmic transport | 5 | 295 | 3.72e-01 |
| GO:BP | GO:0051169 | nuclear transport | 5 | 295 | 3.72e-01 |
| GO:BP | GO:1901576 | organic substance biosynthetic process | 4 | 4539 | 3.72e-01 |
| GO:BP | GO:0010874 | regulation of cholesterol efflux | 1 | 31 | 3.72e-01 |
| GO:BP | GO:0055090 | acylglycerol homeostasis | 1 | 17 | 3.72e-01 |
| GO:BP | GO:0070328 | triglyceride homeostasis | 1 | 17 | 3.72e-01 |
| GO:BP | GO:0032306 | regulation of prostaglandin secretion | 1 | 7 | 3.73e-01 |
| GO:BP | GO:0031098 | stress-activated protein kinase signaling cascade | 5 | 196 | 3.73e-01 |
| GO:BP | GO:0106106 | cold-induced thermogenesis | 4 | 113 | 3.73e-01 |
| GO:BP | GO:0000070 | mitotic sister chromatid segregation | 3 | 179 | 3.73e-01 |
| GO:BP | GO:0034389 | lipid droplet organization | 1 | 30 | 3.73e-01 |
| GO:BP | GO:0048488 | synaptic vesicle endocytosis | 1 | 63 | 3.73e-01 |
| GO:BP | GO:0060253 | negative regulation of glial cell proliferation | 1 | 13 | 3.73e-01 |
| GO:BP | GO:0032074 | negative regulation of nuclease activity | 1 | 6 | 3.73e-01 |
| GO:BP | GO:0050886 | endocrine process | 1 | 57 | 3.73e-01 |
| GO:BP | GO:0009892 | negative regulation of metabolic process | 3 | 2293 | 3.73e-01 |
| GO:BP | GO:0048514 | blood vessel morphogenesis | 9 | 462 | 3.73e-01 |
| GO:BP | GO:1903980 | positive regulation of microglial cell activation | 1 | 2 | 3.73e-01 |
| GO:BP | GO:0009058 | biosynthetic process | 4 | 4590 | 3.73e-01 |
| GO:BP | GO:0044784 | metaphase/anaphase transition of cell cycle | 2 | 92 | 3.73e-01 |
| GO:BP | GO:0008652 | amino acid biosynthetic process | 2 | 64 | 3.73e-01 |
| GO:BP | GO:0009071 | serine family amino acid catabolic process | 1 | 10 | 3.73e-01 |
| GO:BP | GO:0002070 | epithelial cell maturation | 1 | 16 | 3.73e-01 |
| GO:BP | GO:0003007 | heart morphogenesis | 5 | 216 | 3.73e-01 |
| GO:BP | GO:0006935 | chemotaxis | 4 | 389 | 3.73e-01 |
| GO:BP | GO:0006991 | response to sterol depletion | 1 | 16 | 3.73e-01 |
| GO:BP | GO:0046325 | negative regulation of glucose import | 1 | 10 | 3.73e-01 |
| GO:BP | GO:0032438 | melanosome organization | 2 | 36 | 3.73e-01 |
| GO:BP | GO:0150105 | protein localization to cell-cell junction | 1 | 17 | 3.73e-01 |
| GO:BP | GO:0002690 | positive regulation of leukocyte chemotaxis | 1 | 51 | 3.73e-01 |
| GO:BP | GO:0071029 | nuclear ncRNA surveillance | 1 | 7 | 3.73e-01 |
| GO:BP | GO:0006941 | striated muscle contraction | 4 | 152 | 3.73e-01 |
| GO:BP | GO:0032688 | negative regulation of interferon-beta production | 1 | 10 | 3.73e-01 |
| GO:BP | GO:0071035 | nuclear polyadenylation-dependent rRNA catabolic process | 1 | 7 | 3.73e-01 |
| GO:BP | GO:0098926 | postsynaptic signal transduction | 1 | 25 | 3.73e-01 |
| GO:BP | GO:0002218 | activation of innate immune response | 4 | 142 | 3.73e-01 |
| GO:BP | GO:0046928 | regulation of neurotransmitter secretion | 2 | 57 | 3.73e-01 |
| GO:BP | GO:0001776 | leukocyte homeostasis | 3 | 69 | 3.73e-01 |
| GO:BP | GO:1990314 | cellular response to insulin-like growth factor stimulus | 1 | 8 | 3.73e-01 |
| GO:BP | GO:0071046 | nuclear polyadenylation-dependent ncRNA catabolic process | 1 | 7 | 3.73e-01 |
| GO:BP | GO:0106354 | tRNA surveillance | 1 | 7 | 3.73e-01 |
| GO:BP | GO:0035162 | embryonic hemopoiesis | 1 | 19 | 3.73e-01 |
| GO:BP | GO:0006655 | phosphatidylglycerol biosynthetic process | 1 | 9 | 3.73e-01 |
| GO:BP | GO:0032872 | regulation of stress-activated MAPK cascade | 2 | 154 | 3.73e-01 |
| GO:BP | GO:0071051 | polyadenylation-dependent snoRNA 3’-end processing | 1 | 7 | 3.73e-01 |
| GO:BP | GO:0120032 | regulation of plasma membrane bounded cell projection assembly | 2 | 165 | 3.73e-01 |
| GO:BP | GO:1904292 | regulation of ERAD pathway | 1 | 22 | 3.73e-01 |
| GO:BP | GO:1901030 | positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway | 1 | 12 | 3.73e-01 |
| GO:BP | GO:0055001 | muscle cell development | 5 | 165 | 3.73e-01 |
| GO:BP | GO:0009123 | nucleoside monophosphate metabolic process | 2 | 64 | 3.73e-01 |
| GO:BP | GO:0009185 | ribonucleoside diphosphate metabolic process | 1 | 27 | 3.73e-01 |
| GO:BP | GO:0140238 | presynaptic endocytosis | 1 | 65 | 3.73e-01 |
| GO:BP | GO:0071038 | nuclear polyadenylation-dependent tRNA catabolic process | 1 | 7 | 3.73e-01 |
| GO:BP | GO:0043242 | negative regulation of protein-containing complex disassembly | 3 | 72 | 3.73e-01 |
| GO:BP | GO:0006265 | DNA topological change | 1 | 10 | 3.73e-01 |
| GO:BP | GO:0048753 | pigment granule organization | 2 | 37 | 3.73e-01 |
| GO:BP | GO:0018393 | internal peptidyl-lysine acetylation | 2 | 148 | 3.73e-01 |
| GO:BP | GO:0061351 | neural precursor cell proliferation | 3 | 114 | 3.73e-01 |
| GO:BP | GO:0045923 | positive regulation of fatty acid metabolic process | 1 | 26 | 3.73e-01 |
| GO:BP | GO:0051091 | positive regulation of DNA-binding transcription factor activity | 5 | 199 | 3.73e-01 |
| GO:BP | GO:0018243 | protein O-linked glycosylation via threonine | 1 | 7 | 3.73e-01 |
| GO:BP | GO:0071241 | cellular response to inorganic substance | 6 | 164 | 3.73e-01 |
| GO:BP | GO:0018210 | peptidyl-threonine modification | 4 | 104 | 3.73e-01 |
| GO:BP | GO:2000047 | regulation of cell-cell adhesion mediated by cadherin | 1 | 16 | 3.73e-01 |
| GO:BP | GO:0032373 | positive regulation of sterol transport | 1 | 30 | 3.73e-01 |
| GO:BP | GO:0043001 | Golgi to plasma membrane protein transport | 2 | 37 | 3.73e-01 |
| GO:BP | GO:0007612 | learning | 3 | 115 | 3.73e-01 |
| GO:BP | GO:0032376 | positive regulation of cholesterol transport | 1 | 30 | 3.73e-01 |
| GO:BP | GO:0006048 | UDP-N-acetylglucosamine biosynthetic process | 1 | 9 | 3.73e-01 |
| GO:BP | GO:0010038 | response to metal ion | 8 | 264 | 3.73e-01 |
| GO:BP | GO:0042303 | molting cycle | 3 | 78 | 3.73e-01 |
| GO:BP | GO:0042760 | very long-chain fatty acid catabolic process | 1 | 5 | 3.73e-01 |
| GO:BP | GO:0150079 | negative regulation of neuroinflammatory response | 1 | 6 | 3.73e-01 |
| GO:BP | GO:0042633 | hair cycle | 3 | 78 | 3.73e-01 |
| GO:BP | GO:0042330 | taxis | 4 | 389 | 3.73e-01 |
| GO:BP | GO:1903672 | positive regulation of sprouting angiogenesis | 1 | 14 | 3.73e-01 |
| GO:BP | GO:0014909 | smooth muscle cell migration | 2 | 65 | 3.73e-01 |
| GO:BP | GO:0060491 | regulation of cell projection assembly | 2 | 167 | 3.73e-01 |
| GO:BP | GO:0043542 | endothelial cell migration | 4 | 182 | 3.73e-01 |
| GO:BP | GO:0045589 | regulation of regulatory T cell differentiation | 1 | 21 | 3.73e-01 |
| GO:BP | GO:0036342 | post-anal tail morphogenesis | 1 | 13 | 3.73e-01 |
| GO:BP | GO:0080144 | intracellular amino acid homeostasis | 1 | 7 | 3.73e-01 |
| GO:BP | GO:1990822 | basic amino acid transmembrane transport | 1 | 14 | 3.73e-01 |
| GO:BP | GO:0030834 | regulation of actin filament depolymerization | 2 | 45 | 3.74e-01 |
| GO:BP | GO:0009953 | dorsal/ventral pattern formation | 2 | 55 | 3.74e-01 |
| GO:BP | GO:0071347 | cellular response to interleukin-1 | 2 | 64 | 3.74e-01 |
| GO:BP | GO:0034654 | nucleobase-containing compound biosynthetic process | 4 | 3070 | 3.74e-01 |
| GO:BP | GO:0000154 | rRNA modification | 2 | 35 | 3.74e-01 |
| GO:BP | GO:1903428 | positive regulation of reactive oxygen species biosynthetic process | 1 | 12 | 3.74e-01 |
| GO:BP | GO:2001267 | regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway | 1 | 13 | 3.74e-01 |
| GO:BP | GO:0006475 | internal protein amino acid acetylation | 2 | 150 | 3.74e-01 |
| GO:BP | GO:0003073 | regulation of systemic arterial blood pressure | 1 | 62 | 3.74e-01 |
| GO:BP | GO:0043330 | response to exogenous dsRNA | 1 | 27 | 3.74e-01 |
| GO:BP | GO:0034142 | toll-like receptor 4 signaling pathway | 1 | 24 | 3.74e-01 |
| GO:BP | GO:0022409 | positive regulation of cell-cell adhesion | 4 | 189 | 3.74e-01 |
| GO:BP | GO:0045935 | positive regulation of nucleobase-containing compound metabolic process | 35 | 1602 | 3.74e-01 |
| GO:BP | GO:0070302 | regulation of stress-activated protein kinase signaling cascade | 2 | 157 | 3.75e-01 |
| GO:BP | GO:0030500 | regulation of bone mineralization | 3 | 53 | 3.75e-01 |
| GO:BP | GO:1902041 | regulation of extrinsic apoptotic signaling pathway via death domain receptors | 1 | 40 | 3.75e-01 |
| GO:BP | GO:0010631 | epithelial cell migration | 5 | 252 | 3.75e-01 |
| GO:BP | GO:0043307 | eosinophil activation | 1 | 4 | 3.75e-01 |
| GO:BP | GO:0002447 | eosinophil mediated immunity | 1 | 5 | 3.75e-01 |
| GO:BP | GO:0061001 | regulation of dendritic spine morphogenesis | 2 | 39 | 3.75e-01 |
| GO:BP | GO:0000132 | establishment of mitotic spindle orientation | 1 | 31 | 3.75e-01 |
| GO:BP | GO:0046885 | regulation of hormone biosynthetic process | 1 | 21 | 3.75e-01 |
| GO:BP | GO:0032941 | secretion by tissue | 1 | 25 | 3.75e-01 |
| GO:BP | GO:0014850 | response to muscle activity | 1 | 17 | 3.75e-01 |
| GO:BP | GO:1905150 | regulation of voltage-gated sodium channel activity | 1 | 6 | 3.75e-01 |
| GO:BP | GO:0097242 | amyloid-beta clearance | 2 | 27 | 3.75e-01 |
| GO:BP | GO:0048841 | regulation of axon extension involved in axon guidance | 2 | 31 | 3.75e-01 |
| GO:BP | GO:0071695 | anatomical structure maturation | 3 | 48 | 3.75e-01 |
| GO:BP | GO:0060218 | hematopoietic stem cell differentiation | 1 | 30 | 3.75e-01 |
| GO:BP | GO:0060571 | morphogenesis of an epithelial fold | 1 | 16 | 3.75e-01 |
| GO:BP | GO:0060575 | intestinal epithelial cell differentiation | 1 | 17 | 3.75e-01 |
| GO:BP | GO:1900017 | positive regulation of cytokine production involved in inflammatory response | 1 | 15 | 3.75e-01 |
| GO:BP | GO:0008286 | insulin receptor signaling pathway | 3 | 105 | 3.75e-01 |
| GO:BP | GO:0097178 | ruffle assembly | 1 | 37 | 3.75e-01 |
| GO:BP | GO:0045670 | regulation of osteoclast differentiation | 2 | 38 | 3.75e-01 |
| GO:BP | GO:0046716 | muscle cell cellular homeostasis | 1 | 21 | 3.75e-01 |
| GO:BP | GO:0006884 | cell volume homeostasis | 1 | 24 | 3.75e-01 |
| GO:BP | GO:0034728 | nucleosome organization | 2 | 98 | 3.75e-01 |
| GO:BP | GO:0055086 | nucleobase-containing small molecule metabolic process | 1 | 487 | 3.75e-01 |
| GO:BP | GO:0043406 | positive regulation of MAP kinase activity | 3 | 82 | 3.76e-01 |
| GO:BP | GO:0019915 | lipid storage | 2 | 66 | 3.76e-01 |
| GO:BP | GO:0018130 | heterocycle biosynthetic process | 4 | 3132 | 3.76e-01 |
| GO:BP | GO:0034660 | ncRNA metabolic process | 4 | 561 | 3.76e-01 |
| GO:BP | GO:0071396 | cellular response to lipid | 10 | 398 | 3.76e-01 |
| GO:BP | GO:0045110 | intermediate filament bundle assembly | 1 | 6 | 3.76e-01 |
| GO:BP | GO:0034638 | phosphatidylcholine catabolic process | 1 | 9 | 3.76e-01 |
| GO:BP | GO:0061025 | membrane fusion | 1 | 137 | 3.76e-01 |
| GO:BP | GO:2001236 | regulation of extrinsic apoptotic signaling pathway | 3 | 123 | 3.76e-01 |
| GO:BP | GO:0003206 | cardiac chamber morphogenesis | 3 | 109 | 3.76e-01 |
| GO:BP | GO:0010988 | regulation of low-density lipoprotein particle clearance | 1 | 8 | 3.76e-01 |
| GO:BP | GO:1900076 | regulation of cellular response to insulin stimulus | 3 | 56 | 3.76e-01 |
| GO:BP | GO:0048812 | neuron projection morphogenesis | 4 | 512 | 3.76e-01 |
| GO:BP | GO:0048534 | hematopoietic or lymphoid organ development | 1 | 70 | 3.76e-01 |
| GO:BP | GO:0051098 | regulation of binding | 1 | 317 | 3.76e-01 |
| GO:BP | GO:0090219 | negative regulation of lipid kinase activity | 1 | 8 | 3.76e-01 |
| GO:BP | GO:0046112 | nucleobase biosynthetic process | 1 | 18 | 3.76e-01 |
| GO:BP | GO:0042273 | ribosomal large subunit biogenesis | 2 | 73 | 3.76e-01 |
| GO:BP | GO:0071285 | cellular response to lithium ion | 1 | 8 | 3.76e-01 |
| GO:BP | GO:0006066 | alcohol metabolic process | 6 | 265 | 3.76e-01 |
| GO:BP | GO:0014012 | peripheral nervous system axon regeneration | 1 | 6 | 3.76e-01 |
| GO:BP | GO:0106070 | regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway | 1 | 11 | 3.76e-01 |
| GO:BP | GO:0021782 | glial cell development | 4 | 84 | 3.76e-01 |
| GO:BP | GO:0030218 | erythrocyte differentiation | 3 | 107 | 3.76e-01 |
| GO:BP | GO:0046330 | positive regulation of JNK cascade | 2 | 72 | 3.76e-01 |
| GO:BP | GO:1903975 | regulation of glial cell migration | 1 | 12 | 3.76e-01 |
| GO:BP | GO:0006544 | glycine metabolic process | 1 | 10 | 3.76e-01 |
| GO:BP | GO:1901072 | glucosamine-containing compound catabolic process | 1 | 5 | 3.76e-01 |
| GO:BP | GO:0090132 | epithelium migration | 5 | 252 | 3.76e-01 |
| GO:BP | GO:0046626 | regulation of insulin receptor signaling pathway | 3 | 53 | 3.76e-01 |
| GO:BP | GO:0015812 | gamma-aminobutyric acid transport | 1 | 11 | 3.76e-01 |
| GO:BP | GO:0001708 | cell fate specification | 1 | 56 | 3.76e-01 |
| GO:BP | GO:0035329 | hippo signaling | 1 | 41 | 3.76e-01 |
| GO:BP | GO:0038083 | peptidyl-tyrosine autophosphorylation | 1 | 18 | 3.76e-01 |
| GO:BP | GO:0043276 | anoikis | 1 | 32 | 3.76e-01 |
| GO:BP | GO:0030593 | neutrophil chemotaxis | 1 | 39 | 3.76e-01 |
| GO:BP | GO:0045741 | positive regulation of epidermal growth factor-activated receptor activity | 1 | 8 | 3.77e-01 |
| GO:BP | GO:0006098 | pentose-phosphate shunt | 1 | 19 | 3.77e-01 |
| GO:BP | GO:0019438 | aromatic compound biosynthetic process | 4 | 3133 | 3.77e-01 |
| GO:BP | GO:1902622 | regulation of neutrophil migration | 1 | 28 | 3.77e-01 |
| GO:BP | GO:0006417 | regulation of translation | 2 | 370 | 3.77e-01 |
| GO:BP | GO:0032252 | secretory granule localization | 1 | 9 | 3.77e-01 |
| GO:BP | GO:0048870 | cell motility | 5 | 1182 | 3.78e-01 |
| GO:BP | GO:0071384 | cellular response to corticosteroid stimulus | 2 | 47 | 3.78e-01 |
| GO:BP | GO:0036465 | synaptic vesicle recycling | 1 | 73 | 3.78e-01 |
| GO:BP | GO:0045066 | regulatory T cell differentiation | 1 | 22 | 3.78e-01 |
| GO:BP | GO:0032496 | response to lipopolysaccharide | 5 | 178 | 3.78e-01 |
| GO:BP | GO:0008654 | phospholipid biosynthetic process | 6 | 234 | 3.78e-01 |
| GO:BP | GO:0048872 | homeostasis of number of cells | 6 | 228 | 3.79e-01 |
| GO:BP | GO:0008203 | cholesterol metabolic process | 3 | 101 | 3.79e-01 |
| GO:BP | GO:0106118 | regulation of sterol biosynthetic process | 1 | 16 | 3.79e-01 |
| GO:BP | GO:0043632 | modification-dependent macromolecule catabolic process | 8 | 637 | 3.79e-01 |
| GO:BP | GO:0008625 | extrinsic apoptotic signaling pathway via death domain receptors | 2 | 72 | 3.79e-01 |
| GO:BP | GO:0050685 | positive regulation of mRNA processing | 1 | 30 | 3.79e-01 |
| GO:BP | GO:0099563 | modification of synaptic structure | 1 | 24 | 3.79e-01 |
| GO:BP | GO:0003231 | cardiac ventricle development | 3 | 114 | 3.79e-01 |
| GO:BP | GO:0045540 | regulation of cholesterol biosynthetic process | 1 | 16 | 3.79e-01 |
| GO:BP | GO:0009756 | carbohydrate mediated signaling | 1 | 6 | 3.79e-01 |
| GO:BP | GO:0015031 | protein transport | 2 | 1361 | 3.79e-01 |
| GO:BP | GO:0051252 | regulation of RNA metabolic process | 3 | 2845 | 3.79e-01 |
| GO:BP | GO:0031929 | TOR signaling | 3 | 115 | 3.79e-01 |
| GO:BP | GO:0000226 | microtubule cytoskeleton organization | 7 | 552 | 3.79e-01 |
| GO:BP | GO:1903573 | negative regulation of response to endoplasmic reticulum stress | 1 | 41 | 3.79e-01 |
| GO:BP | GO:0043634 | polyadenylation-dependent ncRNA catabolic process | 1 | 8 | 3.79e-01 |
| GO:BP | GO:0051351 | positive regulation of ligase activity | 1 | 9 | 3.79e-01 |
| GO:BP | GO:0034475 | U4 snRNA 3’-end processing | 1 | 8 | 3.79e-01 |
| GO:BP | GO:0006334 | nucleosome assembly | 1 | 80 | 3.79e-01 |
| GO:BP | GO:0045599 | negative regulation of fat cell differentiation | 2 | 43 | 3.79e-01 |
| GO:BP | GO:0044058 | regulation of digestive system process | 1 | 22 | 3.79e-01 |
| GO:BP | GO:0046640 | regulation of alpha-beta T cell proliferation | 1 | 23 | 3.79e-01 |
| GO:BP | GO:0045071 | negative regulation of viral genome replication | 1 | 37 | 3.79e-01 |
| GO:BP | GO:0090130 | tissue migration | 5 | 256 | 3.79e-01 |
| GO:BP | GO:0071456 | cellular response to hypoxia | 4 | 123 | 3.79e-01 |
| GO:BP | GO:0060368 | regulation of Fc receptor mediated stimulatory signaling pathway | 1 | 10 | 3.79e-01 |
| GO:BP | GO:1900227 | positive regulation of NLRP3 inflammasome complex assembly | 1 | 16 | 3.79e-01 |
| GO:BP | GO:0042159 | lipoprotein catabolic process | 1 | 14 | 3.79e-01 |
| GO:BP | GO:0061157 | mRNA destabilization | 1 | 89 | 3.79e-01 |
| GO:BP | GO:1905906 | regulation of amyloid fibril formation | 1 | 14 | 3.79e-01 |
| GO:BP | GO:0007252 | I-kappaB phosphorylation | 1 | 14 | 3.79e-01 |
| GO:BP | GO:1902743 | regulation of lamellipodium organization | 1 | 44 | 3.79e-01 |
| GO:BP | GO:0002281 | macrophage activation involved in immune response | 1 | 8 | 3.79e-01 |
| GO:BP | GO:0045862 | positive regulation of proteolysis | 7 | 295 | 3.79e-01 |
| GO:BP | GO:1902075 | cellular response to salt | 4 | 142 | 3.79e-01 |
| GO:BP | GO:0018394 | peptidyl-lysine acetylation | 2 | 160 | 3.79e-01 |
| GO:BP | GO:0003214 | cardiac left ventricle morphogenesis | 1 | 12 | 3.79e-01 |
| GO:BP | GO:0060998 | regulation of dendritic spine development | 2 | 48 | 3.79e-01 |
| GO:BP | GO:0000904 | cell morphogenesis involved in differentiation | 4 | 516 | 3.79e-01 |
| GO:BP | GO:0046907 | intracellular transport | 2 | 1453 | 3.79e-01 |
| GO:BP | GO:0006352 | DNA-templated transcription initiation | 1 | 130 | 3.79e-01 |
| GO:BP | GO:0051726 | regulation of cell cycle | 13 | 956 | 3.79e-01 |
| GO:BP | GO:1903078 | positive regulation of protein localization to plasma membrane | 2 | 50 | 3.79e-01 |
| GO:BP | GO:0010632 | regulation of epithelial cell migration | 4 | 195 | 3.80e-01 |
| GO:BP | GO:0051770 | positive regulation of nitric-oxide synthase biosynthetic process | 1 | 10 | 3.80e-01 |
| GO:BP | GO:0071415 | cellular response to purine-containing compound | 1 | 11 | 3.80e-01 |
| GO:BP | GO:0021684 | cerebellar granular layer formation | 1 | 6 | 3.81e-01 |
| GO:BP | GO:1901532 | regulation of hematopoietic progenitor cell differentiation | 1 | 34 | 3.81e-01 |
| GO:BP | GO:0042982 | amyloid precursor protein metabolic process | 1 | 69 | 3.81e-01 |
| GO:BP | GO:0042129 | regulation of T cell proliferation | 2 | 95 | 3.81e-01 |
| GO:BP | GO:0002064 | epithelial cell development | 3 | 156 | 3.81e-01 |
| GO:BP | GO:1905953 | negative regulation of lipid localization | 1 | 32 | 3.81e-01 |
| GO:BP | GO:0021707 | cerebellar granule cell differentiation | 1 | 6 | 3.81e-01 |
| GO:BP | GO:0062208 | positive regulation of pattern recognition receptor signaling pathway | 1 | 27 | 3.81e-01 |
| GO:BP | GO:0030900 | forebrain development | 11 | 281 | 3.81e-01 |
| GO:BP | GO:0015748 | organophosphate ester transport | 4 | 106 | 3.81e-01 |
| GO:BP | GO:1902414 | protein localization to cell junction | 2 | 93 | 3.81e-01 |
| GO:BP | GO:2000969 | positive regulation of AMPA receptor activity | 1 | 4 | 3.81e-01 |
| GO:BP | GO:0010575 | positive regulation of vascular endothelial growth factor production | 1 | 18 | 3.81e-01 |
| GO:BP | GO:0045116 | protein neddylation | 1 | 26 | 3.81e-01 |
| GO:BP | GO:0061014 | positive regulation of mRNA catabolic process | 1 | 93 | 3.81e-01 |
| GO:BP | GO:0015802 | basic amino acid transport | 1 | 17 | 3.81e-01 |
| GO:BP | GO:0060996 | dendritic spine development | 3 | 80 | 3.81e-01 |
| GO:BP | GO:0043331 | response to dsRNA | 1 | 33 | 3.81e-01 |
| GO:BP | GO:0006538 | glutamate catabolic process | 1 | 7 | 3.81e-01 |
| GO:BP | GO:0006144 | purine nucleobase metabolic process | 1 | 15 | 3.81e-01 |
| GO:BP | GO:0098935 | dendritic transport | 1 | 13 | 3.81e-01 |
| GO:BP | GO:0006281 | DNA repair | 6 | 534 | 3.81e-01 |
| GO:BP | GO:0021915 | neural tube development | 3 | 146 | 3.81e-01 |
| GO:BP | GO:0000028 | ribosomal small subunit assembly | 1 | 18 | 3.81e-01 |
| GO:BP | GO:0070168 | negative regulation of biomineral tissue development | 1 | 19 | 3.81e-01 |
| GO:BP | GO:0051668 | localization within membrane | 2 | 605 | 3.81e-01 |
| GO:BP | GO:0006406 | mRNA export from nucleus | 1 | 59 | 3.81e-01 |
| GO:BP | GO:0050779 | RNA destabilization | 1 | 92 | 3.81e-01 |
| GO:BP | GO:0048588 | developmental cell growth | 7 | 192 | 3.81e-01 |
| GO:BP | GO:0120039 | plasma membrane bounded cell projection morphogenesis | 4 | 527 | 3.81e-01 |
| GO:BP | GO:1900222 | negative regulation of amyloid-beta clearance | 1 | 7 | 3.81e-01 |
| GO:BP | GO:0010661 | positive regulation of muscle cell apoptotic process | 1 | 20 | 3.81e-01 |
| GO:BP | GO:0030042 | actin filament depolymerization | 2 | 50 | 3.81e-01 |
| GO:BP | GO:0048858 | cell projection morphogenesis | 4 | 531 | 3.81e-01 |
| GO:BP | GO:0007250 | activation of NF-kappaB-inducing kinase activity | 1 | 13 | 3.81e-01 |
| GO:BP | GO:0043549 | regulation of kinase activity | 14 | 560 | 3.81e-01 |
| GO:BP | GO:0051048 | negative regulation of secretion | 3 | 111 | 3.81e-01 |
| GO:BP | GO:0006366 | transcription by RNA polymerase II | 3 | 1995 | 3.82e-01 |
| GO:BP | GO:0001942 | hair follicle development | 1 | 67 | 3.82e-01 |
| GO:BP | GO:0044255 | cellular lipid metabolic process | 1 | 740 | 3.82e-01 |
| GO:BP | GO:1990858 | cellular response to lectin | 1 | 11 | 3.83e-01 |
| GO:BP | GO:0002223 | stimulatory C-type lectin receptor signaling pathway | 1 | 11 | 3.83e-01 |
| GO:BP | GO:1990840 | response to lectin | 1 | 11 | 3.83e-01 |
| GO:BP | GO:0046633 | alpha-beta T cell proliferation | 1 | 24 | 3.83e-01 |
| GO:BP | GO:0070498 | interleukin-1-mediated signaling pathway | 1 | 20 | 3.83e-01 |
| GO:BP | GO:0048708 | astrocyte differentiation | 3 | 58 | 3.83e-01 |
| GO:BP | GO:0098813 | nuclear chromosome segregation | 4 | 273 | 3.84e-01 |
| GO:BP | GO:0070229 | negative regulation of lymphocyte apoptotic process | 2 | 23 | 3.84e-01 |
| GO:BP | GO:0045446 | endothelial cell differentiation | 2 | 90 | 3.84e-01 |
| GO:BP | GO:0002052 | positive regulation of neuroblast proliferation | 1 | 19 | 3.84e-01 |
| GO:BP | GO:0051481 | negative regulation of cytosolic calcium ion concentration | 1 | 9 | 3.84e-01 |
| GO:BP | GO:0051656 | establishment of organelle localization | 12 | 378 | 3.84e-01 |
| GO:BP | GO:0042074 | cell migration involved in gastrulation | 1 | 10 | 3.84e-01 |
| GO:BP | GO:1990845 | adaptive thermogenesis | 4 | 121 | 3.84e-01 |
| GO:BP | GO:0060052 | neurofilament cytoskeleton organization | 1 | 9 | 3.84e-01 |
| GO:BP | GO:0038034 | signal transduction in absence of ligand | 2 | 52 | 3.84e-01 |
| GO:BP | GO:0051261 | protein depolymerization | 3 | 105 | 3.84e-01 |
| GO:BP | GO:0006182 | cGMP biosynthetic process | 1 | 6 | 3.84e-01 |
| GO:BP | GO:0018206 | peptidyl-methionine modification | 1 | 13 | 3.84e-01 |
| GO:BP | GO:0061647 | histone H3-K9 modification | 1 | 23 | 3.84e-01 |
| GO:BP | GO:0040001 | establishment of mitotic spindle localization | 1 | 36 | 3.84e-01 |
| GO:BP | GO:0060537 | muscle tissue development | 7 | 343 | 3.84e-01 |
| GO:BP | GO:0061820 | telomeric D-loop disassembly | 1 | 8 | 3.84e-01 |
| GO:BP | GO:0030501 | positive regulation of bone mineralization | 2 | 34 | 3.84e-01 |
| GO:BP | GO:1901362 | organic cyclic compound biosynthetic process | 4 | 3237 | 3.84e-01 |
| GO:BP | GO:0010893 | positive regulation of steroid biosynthetic process | 1 | 15 | 3.84e-01 |
| GO:BP | GO:0097192 | extrinsic apoptotic signaling pathway in absence of ligand | 2 | 52 | 3.84e-01 |
| GO:BP | GO:0031000 | response to caffeine | 1 | 13 | 3.84e-01 |
| GO:BP | GO:0022405 | hair cycle process | 1 | 69 | 3.84e-01 |
| GO:BP | GO:0006071 | glycerol metabolic process | 1 | 12 | 3.84e-01 |
| GO:BP | GO:0022404 | molting cycle process | 1 | 69 | 3.84e-01 |
| GO:BP | GO:0007169 | transmembrane receptor protein tyrosine kinase signaling pathway | 10 | 484 | 3.84e-01 |
| GO:BP | GO:1900034 | regulation of cellular response to heat | 1 | 16 | 3.84e-01 |
| GO:BP | GO:0061050 | regulation of cell growth involved in cardiac muscle cell development | 1 | 13 | 3.84e-01 |
| GO:BP | GO:0006378 | mRNA polyadenylation | 2 | 39 | 3.84e-01 |
| GO:BP | GO:1902175 | regulation of oxidative stress-induced intrinsic apoptotic signaling pathway | 1 | 25 | 3.84e-01 |
| GO:BP | GO:0032201 | telomere maintenance via semi-conservative replication | 1 | 8 | 3.84e-01 |
| GO:BP | GO:0032310 | prostaglandin secretion | 1 | 8 | 3.84e-01 |
| GO:BP | GO:0009267 | cellular response to starvation | 3 | 152 | 3.84e-01 |
| GO:BP | GO:0051092 | positive regulation of NF-kappaB transcription factor activity | 3 | 116 | 3.84e-01 |
| GO:BP | GO:0034101 | erythrocyte homeostasis | 3 | 114 | 3.85e-01 |
| GO:BP | GO:0033120 | positive regulation of RNA splicing | 1 | 34 | 3.86e-01 |
| GO:BP | GO:0070316 | regulation of G0 to G1 transition | 1 | 34 | 3.86e-01 |
| GO:BP | GO:0045184 | establishment of protein localization | 2 | 1462 | 3.86e-01 |
| GO:BP | GO:0031915 | positive regulation of synaptic plasticity | 1 | 6 | 3.86e-01 |
| GO:BP | GO:0051294 | establishment of spindle orientation | 1 | 36 | 3.86e-01 |
| GO:BP | GO:0042176 | regulation of protein catabolic process | 7 | 331 | 3.86e-01 |
| GO:BP | GO:0000467 | exonucleolytic trimming to generate mature 3’-end of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 1 | 9 | 3.87e-01 |
| GO:BP | GO:0006644 | phospholipid metabolic process | 8 | 316 | 3.87e-01 |
| GO:BP | GO:0048661 | positive regulation of smooth muscle cell proliferation | 2 | 63 | 3.87e-01 |
| GO:BP | GO:0007033 | vacuole organization | 1 | 197 | 3.87e-01 |
| GO:BP | GO:0043535 | regulation of blood vessel endothelial cell migration | 2 | 75 | 3.87e-01 |
| GO:BP | GO:0071044 | histone mRNA catabolic process | 1 | 11 | 3.87e-01 |
| GO:BP | GO:0000459 | exonucleolytic trimming involved in rRNA processing | 1 | 9 | 3.87e-01 |
| GO:BP | GO:0048863 | stem cell differentiation | 3 | 197 | 3.87e-01 |
| GO:BP | GO:0009132 | nucleoside diphosphate metabolic process | 1 | 32 | 3.87e-01 |
| GO:BP | GO:0072665 | protein localization to vacuole | 3 | 72 | 3.87e-01 |
| GO:BP | GO:0140895 | cell surface toll-like receptor signaling pathway | 1 | 27 | 3.87e-01 |
| GO:BP | GO:0002685 | regulation of leukocyte migration | 2 | 131 | 3.87e-01 |
| GO:BP | GO:0043633 | polyadenylation-dependent RNA catabolic process | 1 | 9 | 3.87e-01 |
| GO:BP | GO:0006974 | DNA damage response | 8 | 785 | 3.87e-01 |
| GO:BP | GO:0048477 | oogenesis | 1 | 64 | 3.87e-01 |
| GO:BP | GO:0015807 | L-amino acid transport | 2 | 65 | 3.87e-01 |
| GO:BP | GO:0010556 | regulation of macromolecule biosynthetic process | 3 | 3012 | 3.87e-01 |
| GO:BP | GO:0016024 | CDP-diacylglycerol biosynthetic process | 1 | 12 | 3.87e-01 |
| GO:BP | GO:0006740 | NADPH regeneration | 1 | 22 | 3.87e-01 |
| GO:BP | GO:0001503 | ossification | 7 | 313 | 3.88e-01 |
| GO:BP | GO:1902284 | neuron projection extension involved in neuron projection guidance | 2 | 35 | 3.88e-01 |
| GO:BP | GO:0097484 | dendrite extension | 1 | 27 | 3.88e-01 |
| GO:BP | GO:0048846 | axon extension involved in axon guidance | 2 | 35 | 3.88e-01 |
| GO:BP | GO:0010923 | negative regulation of phosphatase activity | 2 | 30 | 3.88e-01 |
| GO:BP | GO:0010692 | regulation of alkaline phosphatase activity | 1 | 8 | 3.88e-01 |
| GO:BP | GO:0008608 | attachment of spindle microtubules to kinetochore | 1 | 42 | 3.88e-01 |
| GO:BP | GO:0070475 | rRNA base methylation | 1 | 8 | 3.89e-01 |
| GO:BP | GO:0002688 | regulation of leukocyte chemotaxis | 1 | 68 | 3.89e-01 |
| GO:BP | GO:0000731 | DNA synthesis involved in DNA repair | 1 | 36 | 3.89e-01 |
| GO:BP | GO:0051338 | regulation of transferase activity | 16 | 679 | 3.89e-01 |
| GO:BP | GO:0001941 | postsynaptic membrane organization | 2 | 29 | 3.89e-01 |
| GO:BP | GO:0032990 | cell part morphogenesis | 4 | 551 | 3.89e-01 |
| GO:BP | GO:0042474 | middle ear morphogenesis | 1 | 13 | 3.89e-01 |
| GO:BP | GO:0007099 | centriole replication | 1 | 38 | 3.90e-01 |
| GO:BP | GO:0006936 | muscle contraction | 6 | 267 | 3.90e-01 |
| GO:BP | GO:0090083 | regulation of inclusion body assembly | 1 | 16 | 3.91e-01 |
| GO:BP | GO:0021517 | ventral spinal cord development | 1 | 25 | 3.91e-01 |
| GO:BP | GO:0048485 | sympathetic nervous system development | 1 | 14 | 3.91e-01 |
| GO:BP | GO:0043631 | RNA polyadenylation | 2 | 41 | 3.91e-01 |
| GO:BP | GO:0045023 | G0 to G1 transition | 1 | 35 | 3.91e-01 |
| GO:BP | GO:0002237 | response to molecule of bacterial origin | 5 | 187 | 3.91e-01 |
| GO:BP | GO:0035020 | regulation of Rac protein signal transduction | 1 | 21 | 3.91e-01 |
| GO:BP | GO:0036376 | sodium ion export across plasma membrane | 1 | 12 | 3.91e-01 |
| GO:BP | GO:0010763 | positive regulation of fibroblast migration | 1 | 15 | 3.91e-01 |
| GO:BP | GO:0048675 | axon extension | 1 | 110 | 3.91e-01 |
| GO:BP | GO:2000647 | negative regulation of stem cell proliferation | 1 | 18 | 3.91e-01 |
| GO:BP | GO:0006930 | substrate-dependent cell migration, cell extension | 1 | 8 | 3.91e-01 |
| GO:BP | GO:1903715 | regulation of aerobic respiration | 1 | 28 | 3.91e-01 |
| GO:BP | GO:0060999 | positive regulation of dendritic spine development | 1 | 33 | 3.91e-01 |
| GO:BP | GO:0032770 | positive regulation of monooxygenase activity | 1 | 20 | 3.91e-01 |
| GO:BP | GO:0044331 | cell-cell adhesion mediated by cadherin | 1 | 22 | 3.91e-01 |
| GO:BP | GO:1903203 | regulation of oxidative stress-induced neuron death | 1 | 25 | 3.91e-01 |
| GO:BP | GO:1902652 | secondary alcohol metabolic process | 3 | 108 | 3.91e-01 |
| GO:BP | GO:0072676 | lymphocyte migration | 1 | 59 | 3.91e-01 |
| GO:BP | GO:0045648 | positive regulation of erythrocyte differentiation | 1 | 27 | 3.91e-01 |
| GO:BP | GO:0048643 | positive regulation of skeletal muscle tissue development | 1 | 14 | 3.91e-01 |
| GO:BP | GO:0009129 | pyrimidine nucleoside monophosphate metabolic process | 1 | 18 | 3.91e-01 |
| GO:BP | GO:0051497 | negative regulation of stress fiber assembly | 1 | 23 | 3.91e-01 |
| GO:BP | GO:0014812 | muscle cell migration | 2 | 76 | 3.91e-01 |
| GO:BP | GO:0007519 | skeletal muscle tissue development | 3 | 129 | 3.91e-01 |
| GO:BP | GO:0036294 | cellular response to decreased oxygen levels | 4 | 131 | 3.91e-01 |
| GO:BP | GO:0031529 | ruffle organization | 1 | 45 | 3.92e-01 |
| GO:BP | GO:0002694 | regulation of leukocyte activation | 5 | 348 | 3.92e-01 |
| GO:BP | GO:0002553 | histamine secretion by mast cell | 1 | 8 | 3.92e-01 |
| GO:BP | GO:0007605 | sensory perception of sound | 3 | 98 | 3.92e-01 |
| GO:BP | GO:0002349 | histamine production involved in inflammatory response | 1 | 8 | 3.92e-01 |
| GO:BP | GO:0021762 | substantia nigra development | 2 | 41 | 3.92e-01 |
| GO:BP | GO:0002441 | histamine secretion involved in inflammatory response | 1 | 8 | 3.92e-01 |
| GO:BP | GO:0001774 | microglial cell activation | 2 | 19 | 3.92e-01 |
| GO:BP | GO:0052652 | cyclic purine nucleotide metabolic process | 2 | 30 | 3.92e-01 |
| GO:BP | GO:0048524 | positive regulation of viral process | 1 | 55 | 3.92e-01 |
| GO:BP | GO:0061371 | determination of heart left/right asymmetry | 2 | 52 | 3.92e-01 |
| GO:BP | GO:0019400 | alditol metabolic process | 1 | 14 | 3.92e-01 |
| GO:BP | GO:0045601 | regulation of endothelial cell differentiation | 1 | 27 | 3.92e-01 |
| GO:BP | GO:0003143 | embryonic heart tube morphogenesis | 2 | 56 | 3.92e-01 |
| GO:BP | GO:0051767 | nitric-oxide synthase biosynthetic process | 1 | 13 | 3.92e-01 |
| GO:BP | GO:0051769 | regulation of nitric-oxide synthase biosynthetic process | 1 | 13 | 3.92e-01 |
| GO:BP | GO:0032305 | positive regulation of icosanoid secretion | 1 | 8 | 3.92e-01 |
| GO:BP | GO:0045859 | regulation of protein kinase activity | 13 | 479 | 3.93e-01 |
| GO:BP | GO:0051340 | regulation of ligase activity | 1 | 11 | 3.93e-01 |
| GO:BP | GO:0071621 | granulocyte chemotaxis | 1 | 53 | 3.93e-01 |
| GO:BP | GO:0046605 | regulation of centrosome cycle | 2 | 51 | 3.93e-01 |
| GO:BP | GO:1902116 | negative regulation of organelle assembly | 1 | 40 | 3.93e-01 |
| GO:BP | GO:0019219 | regulation of nucleobase-containing compound metabolic process | 3 | 3080 | 3.93e-01 |
| GO:BP | GO:0010574 | regulation of vascular endothelial growth factor production | 1 | 20 | 3.93e-01 |
| GO:BP | GO:0032370 | positive regulation of lipid transport | 2 | 58 | 3.93e-01 |
| GO:BP | GO:2000106 | regulation of leukocyte apoptotic process | 2 | 57 | 3.93e-01 |
| GO:BP | GO:1905146 | lysosomal protein catabolic process | 1 | 19 | 3.93e-01 |
| GO:BP | GO:0046341 | CDP-diacylglycerol metabolic process | 1 | 13 | 3.93e-01 |
| GO:BP | GO:0035640 | exploration behavior | 1 | 21 | 3.93e-01 |
| GO:BP | GO:0030299 | intestinal cholesterol absorption | 1 | 8 | 3.93e-01 |
| GO:BP | GO:2000177 | regulation of neural precursor cell proliferation | 2 | 64 | 3.93e-01 |
| GO:BP | GO:1901617 | organic hydroxy compound biosynthetic process | 4 | 172 | 3.93e-01 |
| GO:BP | GO:0043484 | regulation of RNA splicing | 1 | 164 | 3.93e-01 |
| GO:BP | GO:0003407 | neural retina development | 2 | 48 | 3.93e-01 |
| GO:BP | GO:0045141 | meiotic telomere clustering | 1 | 5 | 3.93e-01 |
| GO:BP | GO:0031326 | regulation of cellular biosynthetic process | 3 | 3080 | 3.93e-01 |
| GO:BP | GO:0015711 | organic anion transport | 6 | 264 | 3.93e-01 |
| GO:BP | GO:0061760 | antifungal innate immune response | 1 | 7 | 3.94e-01 |
| GO:BP | GO:0038095 | Fc-epsilon receptor signaling pathway | 1 | 17 | 3.94e-01 |
| GO:BP | GO:0010829 | negative regulation of glucose transmembrane transport | 1 | 14 | 3.94e-01 |
| GO:BP | GO:0060907 | positive regulation of macrophage cytokine production | 1 | 18 | 3.94e-01 |
| GO:BP | GO:0046184 | aldehyde biosynthetic process | 1 | 14 | 3.94e-01 |
| GO:BP | GO:0048871 | multicellular organismal-level homeostasis | 12 | 532 | 3.94e-01 |
| GO:BP | GO:0046823 | negative regulation of nucleocytoplasmic transport | 1 | 21 | 3.95e-01 |
| GO:BP | GO:0048169 | regulation of long-term neuronal synaptic plasticity | 1 | 20 | 3.95e-01 |
| GO:BP | GO:0005977 | glycogen metabolic process | 2 | 64 | 3.95e-01 |
| GO:BP | GO:0006357 | regulation of transcription by RNA polymerase II | 2 | 1914 | 3.95e-01 |
| GO:BP | GO:0009167 | purine ribonucleoside monophosphate metabolic process | 1 | 37 | 3.95e-01 |
| GO:BP | GO:0006171 | cAMP biosynthetic process | 1 | 8 | 3.95e-01 |
| GO:BP | GO:0071108 | protein K48-linked deubiquitination | 1 | 24 | 3.95e-01 |
| GO:BP | GO:0071377 | cellular response to glucagon stimulus | 1 | 4 | 3.95e-01 |
| GO:BP | GO:0034058 | endosomal vesicle fusion | 1 | 10 | 3.95e-01 |
| GO:BP | GO:0030837 | negative regulation of actin filament polymerization | 2 | 57 | 3.95e-01 |
| GO:BP | GO:0009187 | cyclic nucleotide metabolic process | 2 | 31 | 3.95e-01 |
| GO:BP | GO:0010649 | regulation of cell communication by electrical coupling | 1 | 17 | 3.95e-01 |
| GO:BP | GO:0009584 | detection of visible light | 1 | 20 | 3.95e-01 |
| GO:BP | GO:0060081 | membrane hyperpolarization | 1 | 7 | 3.95e-01 |
| GO:BP | GO:0051438 | regulation of ubiquitin-protein transferase activity | 2 | 55 | 3.95e-01 |
| GO:BP | GO:0006879 | intracellular iron ion homeostasis | 2 | 52 | 3.95e-01 |
| GO:BP | GO:0051588 | regulation of neurotransmitter transport | 2 | 70 | 3.95e-01 |
| GO:BP | GO:1903232 | melanosome assembly | 1 | 19 | 3.95e-01 |
| GO:BP | GO:0051932 | synaptic transmission, GABAergic | 2 | 36 | 3.95e-01 |
| GO:BP | GO:0034248 | regulation of amide metabolic process | 2 | 424 | 3.95e-01 |
| GO:BP | GO:0001782 | B cell homeostasis | 1 | 24 | 3.95e-01 |
| GO:BP | GO:0006000 | fructose metabolic process | 1 | 10 | 3.95e-01 |
| GO:BP | GO:0010821 | regulation of mitochondrion organization | 4 | 135 | 3.95e-01 |
| GO:BP | GO:0097529 | myeloid leukocyte migration | 2 | 120 | 3.95e-01 |
| GO:BP | GO:0032467 | positive regulation of cytokinesis | 2 | 33 | 3.95e-01 |
| GO:BP | GO:1903706 | regulation of hemopoiesis | 6 | 279 | 3.95e-01 |
| GO:BP | GO:0003012 | muscle system process | 7 | 334 | 3.97e-01 |
| GO:BP | GO:0044042 | glucan metabolic process | 2 | 64 | 3.97e-01 |
| GO:BP | GO:0031125 | rRNA 3’-end processing | 1 | 10 | 3.97e-01 |
| GO:BP | GO:0016571 | histone methylation | 2 | 117 | 3.98e-01 |
| GO:BP | GO:0016197 | endosomal transport | 1 | 231 | 3.98e-01 |
| GO:BP | GO:1904377 | positive regulation of protein localization to cell periphery | 2 | 57 | 3.98e-01 |
| GO:BP | GO:0098534 | centriole assembly | 1 | 41 | 3.98e-01 |
| GO:BP | GO:0043434 | response to peptide hormone | 11 | 321 | 3.98e-01 |
| GO:BP | GO:0050807 | regulation of synapse organization | 7 | 184 | 3.98e-01 |
| GO:BP | GO:0006760 | folic acid-containing compound metabolic process | 1 | 22 | 3.98e-01 |
| GO:BP | GO:0009219 | pyrimidine deoxyribonucleotide metabolic process | 1 | 21 | 3.98e-01 |
| GO:BP | GO:0031290 | retinal ganglion cell axon guidance | 1 | 13 | 3.99e-01 |
| GO:BP | GO:0016125 | sterol metabolic process | 3 | 111 | 3.99e-01 |
| GO:BP | GO:0001754 | eye photoreceptor cell differentiation | 1 | 30 | 4.00e-01 |
| GO:BP | GO:0002067 | glandular epithelial cell differentiation | 2 | 50 | 4.00e-01 |
| GO:BP | GO:0022402 | cell cycle process | 2 | 1086 | 4.00e-01 |
| GO:BP | GO:0072657 | protein localization to membrane | 1 | 523 | 4.00e-01 |
| GO:BP | GO:1902004 | positive regulation of amyloid-beta formation | 1 | 17 | 4.00e-01 |
| GO:BP | GO:2000178 | negative regulation of neural precursor cell proliferation | 1 | 21 | 4.00e-01 |
| GO:BP | GO:0046488 | phosphatidylinositol metabolic process | 3 | 140 | 4.00e-01 |
| GO:BP | GO:0099550 | trans-synaptic signaling, modulating synaptic transmission | 1 | 10 | 4.00e-01 |
| GO:BP | GO:0032835 | glomerulus development | 1 | 54 | 4.00e-01 |
| GO:BP | GO:0002752 | cell surface pattern recognition receptor signaling pathway | 1 | 27 | 4.00e-01 |
| GO:BP | GO:0016236 | macroautophagy | 8 | 308 | 4.00e-01 |
| GO:BP | GO:0036475 | neuron death in response to oxidative stress | 1 | 28 | 4.00e-01 |
| GO:BP | GO:0048745 | smooth muscle tissue development | 1 | 19 | 4.00e-01 |
| GO:BP | GO:0001667 | ameboidal-type cell migration | 7 | 358 | 4.00e-01 |
| GO:BP | GO:0010824 | regulation of centrosome duplication | 1 | 44 | 4.00e-01 |
| GO:BP | GO:0032232 | negative regulation of actin filament bundle assembly | 1 | 26 | 4.01e-01 |
| GO:BP | GO:0061484 | hematopoietic stem cell homeostasis | 1 | 20 | 4.01e-01 |
| GO:BP | GO:0000724 | double-strand break repair via homologous recombination | 2 | 149 | 4.01e-01 |
| GO:BP | GO:0021515 | cell differentiation in spinal cord | 1 | 24 | 4.01e-01 |
| GO:BP | GO:0097094 | craniofacial suture morphogenesis | 1 | 15 | 4.01e-01 |
| GO:BP | GO:0048259 | regulation of receptor-mediated endocytosis | 1 | 87 | 4.01e-01 |
| GO:BP | GO:0009855 | determination of bilateral symmetry | 3 | 102 | 4.02e-01 |
| GO:BP | GO:1902932 | positive regulation of alcohol biosynthetic process | 1 | 15 | 4.02e-01 |
| GO:BP | GO:0097746 | blood vessel diameter maintenance | 1 | 99 | 4.02e-01 |
| GO:BP | GO:0021683 | cerebellar granular layer morphogenesis | 1 | 8 | 4.02e-01 |
| GO:BP | GO:0031065 | positive regulation of histone deacetylation | 1 | 22 | 4.02e-01 |
| GO:BP | GO:0042461 | photoreceptor cell development | 1 | 30 | 4.02e-01 |
| GO:BP | GO:0032303 | regulation of icosanoid secretion | 1 | 9 | 4.02e-01 |
| GO:BP | GO:0035296 | regulation of tube diameter | 1 | 99 | 4.02e-01 |
| GO:BP | GO:0009126 | purine nucleoside monophosphate metabolic process | 1 | 39 | 4.02e-01 |
| GO:BP | GO:0009889 | regulation of biosynthetic process | 3 | 3169 | 4.02e-01 |
| GO:BP | GO:0097104 | postsynaptic membrane assembly | 1 | 8 | 4.02e-01 |
| GO:BP | GO:0097105 | presynaptic membrane assembly | 1 | 8 | 4.02e-01 |
| GO:BP | GO:0030865 | cortical cytoskeleton organization | 1 | 55 | 4.02e-01 |
| GO:BP | GO:0009162 | deoxyribonucleoside monophosphate metabolic process | 1 | 18 | 4.03e-01 |
| GO:BP | GO:0009799 | specification of symmetry | 3 | 103 | 4.03e-01 |
| GO:BP | GO:0060048 | cardiac muscle contraction | 3 | 123 | 4.03e-01 |
| GO:BP | GO:0009063 | amino acid catabolic process | 4 | 78 | 4.03e-01 |
| GO:BP | GO:0035150 | regulation of tube size | 1 | 99 | 4.03e-01 |
| GO:BP | GO:0016241 | regulation of macroautophagy | 4 | 151 | 4.03e-01 |
| GO:BP | GO:0003215 | cardiac right ventricle morphogenesis | 1 | 17 | 4.03e-01 |
| GO:BP | GO:0045717 | negative regulation of fatty acid biosynthetic process | 1 | 14 | 4.03e-01 |
| GO:BP | GO:0055119 | relaxation of cardiac muscle | 1 | 17 | 4.03e-01 |
| GO:BP | GO:2000672 | negative regulation of motor neuron apoptotic process | 1 | 10 | 4.03e-01 |
| GO:BP | GO:0002269 | leukocyte activation involved in inflammatory response | 2 | 21 | 4.03e-01 |
| GO:BP | GO:0008016 | regulation of heart contraction | 4 | 173 | 4.03e-01 |
| GO:BP | GO:0014047 | glutamate secretion | 1 | 14 | 4.04e-01 |
| GO:BP | GO:0070203 | regulation of establishment of protein localization to telomere | 1 | 11 | 4.04e-01 |
| GO:BP | GO:0060041 | retina development in camera-type eye | 3 | 109 | 4.04e-01 |
| GO:BP | GO:0010984 | regulation of lipoprotein particle clearance | 1 | 12 | 4.04e-01 |
| GO:BP | GO:0034397 | telomere localization | 1 | 5 | 4.04e-01 |
| GO:BP | GO:1904752 | regulation of vascular associated smooth muscle cell migration | 1 | 23 | 4.04e-01 |
| GO:BP | GO:0090657 | telomeric loop disassembly | 1 | 9 | 4.04e-01 |
| GO:BP | GO:0090220 | chromosome localization to nuclear envelope involved in homologous chromosome segregation | 1 | 5 | 4.04e-01 |
| GO:BP | GO:0006047 | UDP-N-acetylglucosamine metabolic process | 1 | 13 | 4.04e-01 |
| GO:BP | GO:1903533 | regulation of protein targeting | 2 | 66 | 4.04e-01 |
| GO:BP | GO:0070555 | response to interleukin-1 | 2 | 83 | 4.04e-01 |
| GO:BP | GO:0000725 | recombinational repair | 2 | 153 | 4.04e-01 |
| GO:BP | GO:0060216 | definitive hemopoiesis | 1 | 18 | 4.04e-01 |
| GO:BP | GO:0006890 | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 1 | 52 | 4.04e-01 |
| GO:BP | GO:0043501 | skeletal muscle adaptation | 1 | 19 | 4.04e-01 |
| GO:BP | GO:0140115 | export across plasma membrane | 2 | 46 | 4.04e-01 |
| GO:BP | GO:0007610 | behavior | 1 | 436 | 4.04e-01 |
| GO:BP | GO:0038128 | ERBB2 signaling pathway | 1 | 14 | 4.04e-01 |
| GO:BP | GO:0003158 | endothelium development | 4 | 104 | 4.05e-01 |
| GO:BP | GO:0031398 | positive regulation of protein ubiquitination | 3 | 108 | 4.05e-01 |
| GO:BP | GO:0010573 | vascular endothelial growth factor production | 1 | 23 | 4.06e-01 |
| GO:BP | GO:0097191 | extrinsic apoptotic signaling pathway | 4 | 179 | 4.06e-01 |
| GO:BP | GO:0042098 | T cell proliferation | 2 | 120 | 4.06e-01 |
| GO:BP | GO:0070232 | regulation of T cell apoptotic process | 2 | 24 | 4.06e-01 |
| GO:BP | GO:0038003 | G protein-coupled opioid receptor signaling pathway | 1 | 5 | 4.06e-01 |
| GO:BP | GO:0050772 | positive regulation of axonogenesis | 3 | 72 | 4.06e-01 |
| GO:BP | GO:0045940 | positive regulation of steroid metabolic process | 1 | 20 | 4.06e-01 |
| GO:BP | GO:0006766 | vitamin metabolic process | 3 | 73 | 4.06e-01 |
| GO:BP | GO:0000956 | nuclear-transcribed mRNA catabolic process | 1 | 120 | 4.07e-01 |
| GO:BP | GO:0048311 | mitochondrion distribution | 1 | 14 | 4.07e-01 |
| GO:BP | GO:0010594 | regulation of endothelial cell migration | 3 | 143 | 4.07e-01 |
| GO:BP | GO:0043502 | regulation of muscle adaptation | 2 | 69 | 4.07e-01 |
| GO:BP | GO:0002092 | positive regulation of receptor internalization | 1 | 21 | 4.07e-01 |
| GO:BP | GO:0010035 | response to inorganic substance | 11 | 414 | 4.07e-01 |
| GO:BP | GO:0021510 | spinal cord development | 2 | 59 | 4.07e-01 |
| GO:BP | GO:0002687 | positive regulation of leukocyte migration | 1 | 84 | 4.08e-01 |
| GO:BP | GO:0006473 | protein acetylation | 1 | 190 | 4.09e-01 |
| GO:BP | GO:0034427 | nuclear-transcribed mRNA catabolic process, exonucleolytic, 3’-5’ | 1 | 11 | 4.09e-01 |
| GO:BP | GO:0050803 | regulation of synapse structure or activity | 7 | 187 | 4.10e-01 |
| GO:BP | GO:0030032 | lamellipodium assembly | 1 | 61 | 4.10e-01 |
| GO:BP | GO:0043618 | regulation of transcription from RNA polymerase II promoter in response to stress | 1 | 36 | 4.10e-01 |
| GO:BP | GO:0001525 | angiogenesis | 7 | 390 | 4.10e-01 |
| GO:BP | GO:0007187 | G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger | 1 | 18 | 4.10e-01 |
| GO:BP | GO:0060538 | skeletal muscle organ development | 3 | 139 | 4.10e-01 |
| GO:BP | GO:0050999 | regulation of nitric-oxide synthase activity | 1 | 25 | 4.10e-01 |
| GO:BP | GO:0023057 | negative regulation of signaling | 17 | 1076 | 4.10e-01 |
| GO:BP | GO:0032048 | cardiolipin metabolic process | 1 | 13 | 4.10e-01 |
| GO:BP | GO:0048711 | positive regulation of astrocyte differentiation | 1 | 11 | 4.10e-01 |
| GO:BP | GO:0048672 | positive regulation of collateral sprouting | 1 | 10 | 4.10e-01 |
| GO:BP | GO:0001919 | regulation of receptor recycling | 1 | 19 | 4.10e-01 |
| GO:BP | GO:0044241 | lipid digestion | 1 | 10 | 4.10e-01 |
| GO:BP | GO:0045580 | regulation of T cell differentiation | 2 | 110 | 4.10e-01 |
| GO:BP | GO:1901863 | positive regulation of muscle tissue development | 1 | 18 | 4.10e-01 |
| GO:BP | GO:0042149 | cellular response to glucose starvation | 1 | 51 | 4.10e-01 |
| GO:BP | GO:0006405 | RNA export from nucleus | 1 | 78 | 4.11e-01 |
| GO:BP | GO:0001510 | RNA methylation | 3 | 87 | 4.13e-01 |
| GO:BP | GO:0048568 | embryonic organ development | 7 | 316 | 4.13e-01 |
| GO:BP | GO:0006626 | protein targeting to mitochondrion | 3 | 100 | 4.13e-01 |
| GO:BP | GO:0032103 | positive regulation of response to external stimulus | 2 | 337 | 4.14e-01 |
| GO:BP | GO:0062012 | regulation of small molecule metabolic process | 7 | 246 | 4.14e-01 |
| GO:BP | GO:2000193 | positive regulation of fatty acid transport | 1 | 11 | 4.14e-01 |
| GO:BP | GO:0071985 | multivesicular body sorting pathway | 2 | 48 | 4.14e-01 |
| GO:BP | GO:0015850 | organic hydroxy compound transport | 1 | 174 | 4.14e-01 |
| GO:BP | GO:2001237 | negative regulation of extrinsic apoptotic signaling pathway | 2 | 78 | 4.14e-01 |
| GO:BP | GO:1902107 | positive regulation of leukocyte differentiation | 2 | 118 | 4.14e-01 |
| GO:BP | GO:0046348 | amino sugar catabolic process | 1 | 9 | 4.14e-01 |
| GO:BP | GO:0098773 | skin epidermis development | 1 | 87 | 4.14e-01 |
| GO:BP | GO:0098880 | maintenance of postsynaptic specialization structure | 1 | 9 | 4.14e-01 |
| GO:BP | GO:0033500 | carbohydrate homeostasis | 3 | 169 | 4.14e-01 |
| GO:BP | GO:0030279 | negative regulation of ossification | 1 | 25 | 4.14e-01 |
| GO:BP | GO:0042593 | glucose homeostasis | 3 | 168 | 4.14e-01 |
| GO:BP | GO:0007413 | axonal fasciculation | 1 | 18 | 4.14e-01 |
| GO:BP | GO:0097090 | presynaptic membrane organization | 1 | 8 | 4.14e-01 |
| GO:BP | GO:0032092 | positive regulation of protein binding | 3 | 78 | 4.14e-01 |
| GO:BP | GO:1903708 | positive regulation of hemopoiesis | 2 | 118 | 4.14e-01 |
| GO:BP | GO:0071357 | cellular response to type I interferon | 1 | 52 | 4.14e-01 |
| GO:BP | GO:0106030 | neuron projection fasciculation | 1 | 18 | 4.14e-01 |
| GO:BP | GO:0051156 | glucose 6-phosphate metabolic process | 1 | 25 | 4.14e-01 |
| GO:BP | GO:0046942 | carboxylic acid transport | 5 | 216 | 4.14e-01 |
| GO:BP | GO:0070423 | nucleotide-binding oligomerization domain containing signaling pathway | 1 | 18 | 4.14e-01 |
| GO:BP | GO:0014912 | negative regulation of smooth muscle cell migration | 1 | 25 | 4.15e-01 |
| GO:BP | GO:1904738 | vascular associated smooth muscle cell migration | 1 | 25 | 4.15e-01 |
| GO:BP | GO:0051180 | vitamin transport | 1 | 28 | 4.15e-01 |
| GO:BP | GO:0070536 | protein K63-linked deubiquitination | 1 | 33 | 4.15e-01 |
| GO:BP | GO:1903846 | positive regulation of cellular response to transforming growth factor beta stimulus | 1 | 30 | 4.15e-01 |
| GO:BP | GO:0048821 | erythrocyte development | 1 | 30 | 4.15e-01 |
| GO:BP | GO:0030511 | positive regulation of transforming growth factor beta receptor signaling pathway | 1 | 30 | 4.15e-01 |
| GO:BP | GO:0015849 | organic acid transport | 5 | 217 | 4.15e-01 |
| GO:BP | GO:0040017 | positive regulation of locomotion | 2 | 429 | 4.16e-01 |
| GO:BP | GO:0007039 | protein catabolic process in the vacuole | 1 | 22 | 4.16e-01 |
| GO:BP | GO:0098856 | intestinal lipid absorption | 1 | 10 | 4.16e-01 |
| GO:BP | GO:0035633 | maintenance of blood-brain barrier | 1 | 26 | 4.16e-01 |
| GO:BP | GO:0070202 | regulation of establishment of protein localization to chromosome | 1 | 12 | 4.16e-01 |
| GO:BP | GO:0032374 | regulation of cholesterol transport | 1 | 45 | 4.16e-01 |
| GO:BP | GO:0009410 | response to xenobiotic stimulus | 7 | 279 | 4.16e-01 |
| GO:BP | GO:0042632 | cholesterol homeostasis | 2 | 58 | 4.16e-01 |
| GO:BP | GO:0032371 | regulation of sterol transport | 1 | 45 | 4.16e-01 |
| GO:BP | GO:0045936 | negative regulation of phosphate metabolic process | 8 | 344 | 4.16e-01 |
| GO:BP | GO:0035542 | regulation of SNARE complex assembly | 1 | 13 | 4.16e-01 |
| GO:BP | GO:0001821 | histamine secretion | 1 | 9 | 4.16e-01 |
| GO:BP | GO:0010639 | negative regulation of organelle organization | 4 | 318 | 4.16e-01 |
| GO:BP | GO:0071634 | regulation of transforming growth factor beta production | 1 | 31 | 4.16e-01 |
| GO:BP | GO:0010665 | regulation of cardiac muscle cell apoptotic process | 1 | 33 | 4.18e-01 |
| GO:BP | GO:0042326 | negative regulation of phosphorylation | 9 | 300 | 4.18e-01 |
| GO:BP | GO:0018108 | peptidyl-tyrosine phosphorylation | 5 | 256 | 4.18e-01 |
| GO:BP | GO:0032958 | inositol phosphate biosynthetic process | 1 | 19 | 4.18e-01 |
| GO:BP | GO:0031440 | regulation of mRNA 3’-end processing | 1 | 22 | 4.18e-01 |
| GO:BP | GO:0051781 | positive regulation of cell division | 3 | 64 | 4.18e-01 |
| GO:BP | GO:0035872 | nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway | 1 | 19 | 4.18e-01 |
| GO:BP | GO:0055092 | sterol homeostasis | 2 | 59 | 4.19e-01 |
| GO:BP | GO:2000480 | negative regulation of cAMP-dependent protein kinase activity | 1 | 10 | 4.19e-01 |
| GO:BP | GO:1905898 | positive regulation of response to endoplasmic reticulum stress | 1 | 34 | 4.19e-01 |
| GO:BP | GO:0050790 | regulation of catalytic activity | 9 | 1380 | 4.19e-01 |
| GO:BP | GO:0045778 | positive regulation of ossification | 2 | 40 | 4.19e-01 |
| GO:BP | GO:0060997 | dendritic spine morphogenesis | 2 | 50 | 4.19e-01 |
| GO:BP | GO:0015718 | monocarboxylic acid transport | 3 | 90 | 4.19e-01 |
| GO:BP | GO:0051153 | regulation of striated muscle cell differentiation | 2 | 67 | 4.19e-01 |
| GO:BP | GO:0030325 | adrenal gland development | 1 | 22 | 4.20e-01 |
| GO:BP | GO:0032350 | regulation of hormone metabolic process | 1 | 30 | 4.20e-01 |
| GO:BP | GO:0018212 | peptidyl-tyrosine modification | 5 | 258 | 4.20e-01 |
| GO:BP | GO:0050688 | regulation of defense response to virus | 1 | 63 | 4.20e-01 |
| GO:BP | GO:0051293 | establishment of spindle localization | 1 | 48 | 4.20e-01 |
| GO:BP | GO:0060038 | cardiac muscle cell proliferation | 1 | 44 | 4.20e-01 |
| GO:BP | GO:0090398 | cellular senescence | 2 | 83 | 4.20e-01 |
| GO:BP | GO:0051093 | negative regulation of developmental process | 12 | 665 | 4.20e-01 |
| GO:BP | GO:0007080 | mitotic metaphase plate congression | 1 | 55 | 4.20e-01 |
| GO:BP | GO:0061900 | glial cell activation | 2 | 23 | 4.21e-01 |
| GO:BP | GO:0048641 | regulation of skeletal muscle tissue development | 1 | 20 | 4.21e-01 |
| GO:BP | GO:0051241 | negative regulation of multicellular organismal process | 14 | 748 | 4.21e-01 |
| GO:BP | GO:0050679 | positive regulation of epithelial cell proliferation | 4 | 155 | 4.21e-01 |
| GO:BP | GO:0031126 | sno(s)RNA 3’-end processing | 1 | 12 | 4.21e-01 |
| GO:BP | GO:1900271 | regulation of long-term synaptic potentiation | 2 | 34 | 4.21e-01 |
| GO:BP | GO:0032465 | regulation of cytokinesis | 3 | 79 | 4.21e-01 |
| GO:BP | GO:0006629 | lipid metabolic process | 1 | 994 | 4.21e-01 |
| GO:BP | GO:0002221 | pattern recognition receptor signaling pathway | 3 | 115 | 4.22e-01 |
| GO:BP | GO:0045945 | positive regulation of transcription by RNA polymerase III | 1 | 19 | 4.22e-01 |
| GO:BP | GO:0050865 | regulation of cell activation | 5 | 384 | 4.23e-01 |
| GO:BP | GO:0050708 | regulation of protein secretion | 4 | 185 | 4.23e-01 |
| GO:BP | GO:0021700 | developmental maturation | 5 | 211 | 4.23e-01 |
| GO:BP | GO:0071248 | cellular response to metal ion | 4 | 139 | 4.24e-01 |
| GO:BP | GO:0060193 | positive regulation of lipase activity | 1 | 34 | 4.24e-01 |
| GO:BP | GO:0071705 | nitrogen compound transport | 2 | 1684 | 4.24e-01 |
| GO:BP | GO:0045197 | establishment or maintenance of epithelial cell apical/basal polarity | 1 | 47 | 4.24e-01 |
| GO:BP | GO:0070169 | positive regulation of biomineral tissue development | 2 | 39 | 4.24e-01 |
| GO:BP | GO:0034340 | response to type I interferon | 1 | 57 | 4.24e-01 |
| GO:BP | GO:0022011 | myelination in peripheral nervous system | 1 | 25 | 4.24e-01 |
| GO:BP | GO:0071453 | cellular response to oxygen levels | 4 | 144 | 4.24e-01 |
| GO:BP | GO:0031331 | positive regulation of cellular catabolic process | 5 | 277 | 4.24e-01 |
| GO:BP | GO:0032292 | peripheral nervous system axon ensheathment | 1 | 25 | 4.24e-01 |
| GO:BP | GO:1903670 | regulation of sprouting angiogenesis | 1 | 28 | 4.24e-01 |
| GO:BP | GO:0055022 | negative regulation of cardiac muscle tissue growth | 1 | 19 | 4.24e-01 |
| GO:BP | GO:0006979 | response to oxidative stress | 4 | 352 | 4.24e-01 |
| GO:BP | GO:0032874 | positive regulation of stress-activated MAPK cascade | 2 | 96 | 4.24e-01 |
| GO:BP | GO:0032925 | regulation of activin receptor signaling pathway | 1 | 20 | 4.24e-01 |
| GO:BP | GO:1903351 | cellular response to dopamine | 2 | 47 | 4.24e-01 |
| GO:BP | GO:0043967 | histone H4 acetylation | 1 | 57 | 4.24e-01 |
| GO:BP | GO:0048738 | cardiac muscle tissue development | 5 | 198 | 4.24e-01 |
| GO:BP | GO:0001959 | regulation of cytokine-mediated signaling pathway | 2 | 117 | 4.24e-01 |
| GO:BP | GO:0046849 | bone remodeling | 2 | 59 | 4.24e-01 |
| GO:BP | GO:0010881 | regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion | 1 | 20 | 4.24e-01 |
| GO:BP | GO:0002682 | regulation of immune system process | 9 | 877 | 4.24e-01 |
| GO:BP | GO:0061117 | negative regulation of heart growth | 1 | 19 | 4.24e-01 |
| GO:BP | GO:0010565 | regulation of cellular ketone metabolic process | 3 | 98 | 4.24e-01 |
| GO:BP | GO:0002260 | lymphocyte homeostasis | 2 | 45 | 4.24e-01 |
| GO:BP | GO:1901880 | negative regulation of protein depolymerization | 2 | 64 | 4.24e-01 |
| GO:BP | GO:0086012 | membrane depolarization during cardiac muscle cell action potential | 1 | 21 | 4.24e-01 |
| GO:BP | GO:0006793 | phosphorus metabolic process | 46 | 2161 | 4.25e-01 |
| GO:BP | GO:0060155 | platelet dense granule organization | 1 | 23 | 4.25e-01 |
| GO:BP | GO:1903828 | negative regulation of protein localization | 3 | 160 | 4.25e-01 |
| GO:BP | GO:0045638 | negative regulation of myeloid cell differentiation | 2 | 69 | 4.25e-01 |
| GO:BP | GO:0055007 | cardiac muscle cell differentiation | 3 | 103 | 4.25e-01 |
| GO:BP | GO:0032536 | regulation of cell projection size | 1 | 8 | 4.25e-01 |
| GO:BP | GO:0071549 | cellular response to dexamethasone stimulus | 1 | 24 | 4.25e-01 |
| GO:BP | GO:0000712 | resolution of meiotic recombination intermediates | 1 | 13 | 4.26e-01 |
| GO:BP | GO:0010842 | retina layer formation | 1 | 16 | 4.26e-01 |
| GO:BP | GO:0031333 | negative regulation of protein-containing complex assembly | 2 | 130 | 4.26e-01 |
| GO:BP | GO:0071604 | transforming growth factor beta production | 1 | 32 | 4.26e-01 |
| GO:BP | GO:0051974 | negative regulation of telomerase activity | 1 | 11 | 4.26e-01 |
| GO:BP | GO:1990138 | neuron projection extension | 2 | 148 | 4.26e-01 |
| GO:BP | GO:0007595 | lactation | 1 | 32 | 4.26e-01 |
| GO:BP | GO:1900225 | regulation of NLRP3 inflammasome complex assembly | 1 | 23 | 4.26e-01 |
| GO:BP | GO:0048771 | tissue remodeling | 3 | 114 | 4.26e-01 |
| GO:BP | GO:0070167 | regulation of biomineral tissue development | 3 | 67 | 4.26e-01 |
| GO:BP | GO:0042073 | intraciliary transport | 1 | 46 | 4.26e-01 |
| GO:BP | GO:0046068 | cGMP metabolic process | 1 | 11 | 4.26e-01 |
| GO:BP | GO:0033044 | regulation of chromosome organization | 3 | 236 | 4.26e-01 |
| GO:BP | GO:0050954 | sensory perception of mechanical stimulus | 3 | 112 | 4.26e-01 |
| GO:BP | GO:1903350 | response to dopamine | 2 | 48 | 4.26e-01 |
| GO:BP | GO:0043320 | natural killer cell degranulation | 1 | 6 | 4.26e-01 |
| GO:BP | GO:0043312 | neutrophil degranulation | 1 | 5 | 4.26e-01 |
| GO:BP | GO:0070304 | positive regulation of stress-activated protein kinase signaling cascade | 2 | 98 | 4.28e-01 |
| GO:BP | GO:0010662 | regulation of striated muscle cell apoptotic process | 1 | 36 | 4.29e-01 |
| GO:BP | GO:0009059 | macromolecule biosynthetic process | 4 | 3730 | 4.29e-01 |
| GO:BP | GO:0035050 | embryonic heart tube development | 2 | 69 | 4.29e-01 |
| GO:BP | GO:0043620 | regulation of DNA-templated transcription in response to stress | 1 | 41 | 4.31e-01 |
| GO:BP | GO:0006112 | energy reserve metabolic process | 2 | 73 | 4.31e-01 |
| GO:BP | GO:0035902 | response to immobilization stress | 1 | 16 | 4.31e-01 |
| GO:BP | GO:0070841 | inclusion body assembly | 1 | 22 | 4.31e-01 |
| GO:BP | GO:0014013 | regulation of gliogenesis | 3 | 68 | 4.31e-01 |
| GO:BP | GO:0071222 | cellular response to lipopolysaccharide | 3 | 110 | 4.31e-01 |
| GO:BP | GO:0071542 | dopaminergic neuron differentiation | 1 | 20 | 4.31e-01 |
| GO:BP | GO:1903037 | regulation of leukocyte cell-cell adhesion | 3 | 211 | 4.31e-01 |
| GO:BP | GO:0001889 | liver development | 3 | 110 | 4.31e-01 |
| GO:BP | GO:0019932 | second-messenger-mediated signaling | 2 | 191 | 4.32e-01 |
| GO:BP | GO:0006400 | tRNA modification | 1 | 90 | 4.32e-01 |
| GO:BP | GO:0032526 | response to retinoic acid | 2 | 85 | 4.33e-01 |
| GO:BP | GO:0045006 | DNA deamination | 1 | 9 | 4.33e-01 |
| GO:BP | GO:0051653 | spindle localization | 1 | 52 | 4.33e-01 |
| GO:BP | GO:0033003 | regulation of mast cell activation | 2 | 25 | 4.33e-01 |
| GO:BP | GO:0043928 | exonucleolytic catabolism of deadenylated mRNA | 1 | 13 | 4.33e-01 |
| GO:BP | GO:0061512 | protein localization to cilium | 1 | 61 | 4.33e-01 |
| GO:BP | GO:0009583 | detection of light stimulus | 1 | 27 | 4.33e-01 |
| GO:BP | GO:0016054 | organic acid catabolic process | 7 | 187 | 4.33e-01 |
| GO:BP | GO:0046395 | carboxylic acid catabolic process | 7 | 187 | 4.33e-01 |
| GO:BP | GO:0042558 | pteridine-containing compound metabolic process | 1 | 28 | 4.33e-01 |
| GO:BP | GO:0071353 | cellular response to interleukin-4 | 1 | 21 | 4.33e-01 |
| GO:BP | GO:0042110 | T cell activation | 4 | 313 | 4.33e-01 |
| GO:BP | GO:0070486 | leukocyte aggregation | 1 | 9 | 4.33e-01 |
| GO:BP | GO:0010659 | cardiac muscle cell apoptotic process | 1 | 36 | 4.33e-01 |
| GO:BP | GO:0050670 | regulation of lymphocyte proliferation | 2 | 126 | 4.33e-01 |
| GO:BP | GO:0061430 | bone trabecula morphogenesis | 1 | 12 | 4.33e-01 |
| GO:BP | GO:0090501 | RNA phosphodiester bond hydrolysis | 1 | 136 | 4.34e-01 |
| GO:BP | GO:0071375 | cellular response to peptide hormone stimulus | 8 | 241 | 4.34e-01 |
| GO:BP | GO:0051649 | establishment of localization in cell | 2 | 1836 | 4.34e-01 |
| GO:BP | GO:0001701 | in utero embryonic development | 5 | 344 | 4.34e-01 |
| GO:BP | GO:2000108 | positive regulation of leukocyte apoptotic process | 1 | 18 | 4.34e-01 |
| GO:BP | GO:0034755 | iron ion transmembrane transport | 1 | 16 | 4.34e-01 |
| GO:BP | GO:0019218 | regulation of steroid metabolic process | 2 | 69 | 4.34e-01 |
| GO:BP | GO:0043543 | protein acylation | 1 | 228 | 4.34e-01 |
| GO:BP | GO:0046530 | photoreceptor cell differentiation | 1 | 40 | 4.34e-01 |
| GO:BP | GO:0044271 | cellular nitrogen compound biosynthetic process | 4 | 3750 | 4.35e-01 |
| GO:BP | GO:0003018 | vascular process in circulatory system | 3 | 198 | 4.35e-01 |
| GO:BP | GO:0045091 | regulation of single stranded viral RNA replication via double stranded DNA intermediate | 1 | 15 | 4.35e-01 |
| GO:BP | GO:0006383 | transcription by RNA polymerase III | 2 | 54 | 4.36e-01 |
| GO:BP | GO:1901135 | carbohydrate derivative metabolic process | 1 | 843 | 4.36e-01 |
| GO:BP | GO:0001960 | negative regulation of cytokine-mediated signaling pathway | 1 | 53 | 4.37e-01 |
| GO:BP | GO:0035088 | establishment or maintenance of apical/basal cell polarity | 1 | 50 | 4.37e-01 |
| GO:BP | GO:0032944 | regulation of mononuclear cell proliferation | 2 | 129 | 4.37e-01 |
| GO:BP | GO:0098719 | sodium ion import across plasma membrane | 1 | 14 | 4.37e-01 |
| GO:BP | GO:0048525 | negative regulation of viral process | 1 | 64 | 4.37e-01 |
| GO:BP | GO:0010596 | negative regulation of endothelial cell migration | 2 | 40 | 4.37e-01 |
| GO:BP | GO:0035305 | negative regulation of dephosphorylation | 2 | 39 | 4.37e-01 |
| GO:BP | GO:0061245 | establishment or maintenance of bipolar cell polarity | 1 | 50 | 4.37e-01 |
| GO:BP | GO:0030099 | myeloid cell differentiation | 6 | 310 | 4.37e-01 |
| GO:BP | GO:0003323 | type B pancreatic cell development | 1 | 19 | 4.37e-01 |
| GO:BP | GO:0045824 | negative regulation of innate immune response | 1 | 53 | 4.37e-01 |
| GO:BP | GO:0061383 | trabecula morphogenesis | 2 | 43 | 4.37e-01 |
| GO:BP | GO:2000378 | negative regulation of reactive oxygen species metabolic process | 1 | 34 | 4.37e-01 |
| GO:BP | GO:0006883 | intracellular sodium ion homeostasis | 1 | 13 | 4.37e-01 |
| GO:BP | GO:0008631 | intrinsic apoptotic signaling pathway in response to oxidative stress | 1 | 41 | 4.37e-01 |
| GO:BP | GO:0045646 | regulation of erythrocyte differentiation | 1 | 39 | 4.37e-01 |
| GO:BP | GO:0032989 | cellular component morphogenesis | 4 | 639 | 4.37e-01 |
| GO:BP | GO:0002087 | regulation of respiratory gaseous exchange by nervous system process | 1 | 8 | 4.37e-01 |
| GO:BP | GO:0061008 | hepaticobiliary system development | 3 | 112 | 4.37e-01 |
| GO:BP | GO:0030007 | intracellular potassium ion homeostasis | 1 | 11 | 4.37e-01 |
| GO:BP | GO:0042594 | response to starvation | 3 | 178 | 4.37e-01 |
| GO:BP | GO:0031325 | positive regulation of cellular metabolic process | 1 | 2270 | 4.37e-01 |
| GO:BP | GO:1901983 | regulation of protein acetylation | 2 | 69 | 4.37e-01 |
| GO:BP | GO:1903530 | regulation of secretion by cell | 7 | 382 | 4.37e-01 |
| GO:BP | GO:0015732 | prostaglandin transport | 1 | 10 | 4.38e-01 |
| GO:BP | GO:0033032 | regulation of myeloid cell apoptotic process | 1 | 20 | 4.38e-01 |
| GO:BP | GO:0014044 | Schwann cell development | 1 | 28 | 4.38e-01 |
| GO:BP | GO:0006511 | ubiquitin-dependent protein catabolic process | 7 | 615 | 4.40e-01 |
| GO:BP | GO:0080134 | regulation of response to stress | 17 | 1075 | 4.40e-01 |
| GO:BP | GO:1902074 | response to salt | 6 | 271 | 4.40e-01 |
| GO:BP | GO:0034383 | low-density lipoprotein particle clearance | 1 | 17 | 4.40e-01 |
| GO:BP | GO:1900452 | regulation of long-term synaptic depression | 1 | 10 | 4.41e-01 |
| GO:BP | GO:0032272 | negative regulation of protein polymerization | 2 | 71 | 4.41e-01 |
| GO:BP | GO:0097581 | lamellipodium organization | 1 | 78 | 4.41e-01 |
| GO:BP | GO:0061081 | positive regulation of myeloid leukocyte cytokine production involved in immune response | 1 | 26 | 4.41e-01 |
| GO:BP | GO:1904322 | cellular response to forskolin | 1 | 11 | 4.41e-01 |
| GO:BP | GO:0044546 | NLRP3 inflammasome complex assembly | 1 | 23 | 4.41e-01 |
| GO:BP | GO:1904321 | response to forskolin | 1 | 11 | 4.41e-01 |
| GO:BP | GO:0060759 | regulation of response to cytokine stimulus | 2 | 126 | 4.41e-01 |
| GO:BP | GO:0030324 | lung development | 1 | 146 | 4.41e-01 |
| GO:BP | GO:0043534 | blood vessel endothelial cell migration | 2 | 97 | 4.41e-01 |
| GO:BP | GO:0045948 | positive regulation of translational initiation | 1 | 23 | 4.41e-01 |
| GO:BP | GO:0090715 | immunological memory formation process | 1 | 6 | 4.41e-01 |
| GO:BP | GO:1901216 | positive regulation of neuron death | 2 | 70 | 4.42e-01 |
| GO:BP | GO:0007193 | adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway | 1 | 37 | 4.42e-01 |
| GO:BP | GO:0060712 | spongiotrophoblast layer development | 1 | 11 | 4.42e-01 |
| GO:BP | GO:0006221 | pyrimidine nucleotide biosynthetic process | 1 | 28 | 4.42e-01 |
| GO:BP | GO:0072594 | establishment of protein localization to organelle | 1 | 422 | 4.43e-01 |
| GO:BP | GO:0006892 | post-Golgi vesicle-mediated transport | 3 | 103 | 4.43e-01 |
| GO:BP | GO:0044320 | cellular response to leptin stimulus | 1 | 15 | 4.43e-01 |
| GO:BP | GO:0007292 | female gamete generation | 1 | 103 | 4.43e-01 |
| GO:BP | GO:0039692 | single stranded viral RNA replication via double stranded DNA intermediate | 1 | 16 | 4.43e-01 |
| GO:BP | GO:0016078 | tRNA catabolic process | 1 | 14 | 4.43e-01 |
| GO:BP | GO:0070076 | histone lysine demethylation | 1 | 20 | 4.43e-01 |
| GO:BP | GO:0071027 | nuclear RNA surveillance | 1 | 14 | 4.43e-01 |
| GO:BP | GO:0043144 | sno(s)RNA processing | 1 | 13 | 4.43e-01 |
| GO:BP | GO:0051129 | negative regulation of cellular component organization | 13 | 604 | 4.43e-01 |
| GO:BP | GO:1903202 | negative regulation of oxidative stress-induced cell death | 1 | 40 | 4.44e-01 |
| GO:BP | GO:0009161 | ribonucleoside monophosphate metabolic process | 1 | 50 | 4.44e-01 |
| GO:BP | GO:0071219 | cellular response to molecule of bacterial origin | 3 | 114 | 4.44e-01 |
| GO:BP | GO:1905954 | positive regulation of lipid localization | 2 | 75 | 4.44e-01 |
| GO:BP | GO:0034497 | protein localization to phagophore assembly site | 1 | 17 | 4.44e-01 |
| GO:BP | GO:0010658 | striated muscle cell apoptotic process | 1 | 39 | 4.44e-01 |
| GO:BP | GO:0008217 | regulation of blood pressure | 1 | 115 | 4.44e-01 |
| GO:BP | GO:0030323 | respiratory tube development | 1 | 150 | 4.44e-01 |
| GO:BP | GO:0045089 | positive regulation of innate immune response | 4 | 182 | 4.45e-01 |
| GO:BP | GO:0071404 | cellular response to low-density lipoprotein particle stimulus | 1 | 19 | 4.45e-01 |
| GO:BP | GO:0071363 | cellular response to growth factor stimulus | 9 | 551 | 4.45e-01 |
| GO:BP | GO:0051568 | histone H3-K4 methylation | 2 | 57 | 4.45e-01 |
| GO:BP | GO:0060761 | negative regulation of response to cytokine stimulus | 1 | 57 | 4.45e-01 |
| GO:BP | GO:0048741 | skeletal muscle fiber development | 1 | 30 | 4.47e-01 |
| GO:BP | GO:0072575 | epithelial cell proliferation involved in liver morphogenesis | 1 | 18 | 4.47e-01 |
| GO:BP | GO:0070670 | response to interleukin-4 | 1 | 22 | 4.47e-01 |
| GO:BP | GO:0009112 | nucleobase metabolic process | 1 | 27 | 4.47e-01 |
| GO:BP | GO:0072574 | hepatocyte proliferation | 1 | 18 | 4.47e-01 |
| GO:BP | GO:0043488 | regulation of mRNA stability | 1 | 147 | 4.47e-01 |
| GO:BP | GO:0051173 | positive regulation of nitrogen compound metabolic process | 1 | 2412 | 4.47e-01 |
| GO:BP | GO:0002097 | tRNA wobble base modification | 1 | 19 | 4.48e-01 |
| GO:BP | GO:0006110 | regulation of glycolytic process | 1 | 40 | 4.48e-01 |
| GO:BP | GO:0019079 | viral genome replication | 3 | 101 | 4.48e-01 |
| GO:BP | GO:0001325 | formation of extrachromosomal circular DNA | 1 | 13 | 4.48e-01 |
| GO:BP | GO:0051249 | regulation of lymphocyte activation | 4 | 296 | 4.48e-01 |
| GO:BP | GO:0021681 | cerebellar granular layer development | 1 | 11 | 4.48e-01 |
| GO:BP | GO:0045745 | positive regulation of G protein-coupled receptor signaling pathway | 1 | 13 | 4.48e-01 |
| GO:BP | GO:0140632 | canonical inflammasome complex assembly | 1 | 23 | 4.48e-01 |
| GO:BP | GO:0001702 | gastrulation with mouth forming second | 1 | 21 | 4.48e-01 |
| GO:BP | GO:0015936 | coenzyme A metabolic process | 1 | 18 | 4.48e-01 |
| GO:BP | GO:1900120 | regulation of receptor binding | 1 | 17 | 4.48e-01 |
| GO:BP | GO:0016577 | histone demethylation | 1 | 21 | 4.48e-01 |
| GO:BP | GO:0001824 | blastocyst development | 2 | 94 | 4.48e-01 |
| GO:BP | GO:0061919 | process utilizing autophagic mechanism | 12 | 513 | 4.48e-01 |
| GO:BP | GO:0033002 | muscle cell proliferation | 3 | 157 | 4.48e-01 |
| GO:BP | GO:0051028 | mRNA transport | 2 | 117 | 4.48e-01 |
| GO:BP | GO:0060395 | SMAD protein signal transduction | 2 | 65 | 4.48e-01 |
| GO:BP | GO:0019941 | modification-dependent protein catabolic process | 7 | 625 | 4.48e-01 |
| GO:BP | GO:1903779 | regulation of cardiac conduction | 1 | 23 | 4.48e-01 |
| GO:BP | GO:0048519 | negative regulation of biological process | 4 | 4045 | 4.48e-01 |
| GO:BP | GO:0006914 | autophagy | 12 | 513 | 4.48e-01 |
| GO:BP | GO:1904814 | regulation of protein localization to chromosome, telomeric region | 1 | 15 | 4.48e-01 |
| GO:BP | GO:2000671 | regulation of motor neuron apoptotic process | 1 | 12 | 4.48e-01 |
| GO:BP | GO:0010830 | regulation of myotube differentiation | 1 | 31 | 4.48e-01 |
| GO:BP | GO:0032147 | activation of protein kinase activity | 2 | 82 | 4.48e-01 |
| GO:BP | GO:0071459 | protein localization to chromosome, centromeric region | 1 | 42 | 4.48e-01 |
| GO:BP | GO:0010934 | macrophage cytokine production | 1 | 27 | 4.48e-01 |
| GO:BP | GO:0010935 | regulation of macrophage cytokine production | 1 | 27 | 4.48e-01 |
| GO:BP | GO:0045619 | regulation of lymphocyte differentiation | 2 | 132 | 4.48e-01 |
| GO:BP | GO:0009226 | nucleotide-sugar biosynthetic process | 1 | 19 | 4.48e-01 |
| GO:BP | GO:0090656 | t-circle formation | 1 | 13 | 4.48e-01 |
| GO:BP | GO:0090737 | telomere maintenance via telomere trimming | 1 | 13 | 4.48e-01 |
| GO:BP | GO:0034331 | cell junction maintenance | 2 | 40 | 4.48e-01 |
| GO:BP | GO:0006796 | phosphate-containing compound metabolic process | 45 | 2139 | 4.48e-01 |
| GO:BP | GO:0043328 | protein transport to vacuole involved in ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway | 1 | 16 | 4.48e-01 |
| GO:BP | GO:2000249 | regulation of actin cytoskeleton reorganization | 1 | 32 | 4.48e-01 |
| GO:BP | GO:0050855 | regulation of B cell receptor signaling pathway | 1 | 11 | 4.48e-01 |
| GO:BP | GO:0043457 | regulation of cellular respiration | 1 | 42 | 4.48e-01 |
| GO:BP | GO:0055094 | response to lipoprotein particle | 1 | 20 | 4.48e-01 |
| GO:BP | GO:0043650 | dicarboxylic acid biosynthetic process | 1 | 9 | 4.48e-01 |
| GO:BP | GO:0002521 | leukocyte differentiation | 8 | 382 | 4.48e-01 |
| GO:BP | GO:0051608 | histamine transport | 1 | 11 | 4.49e-01 |
| GO:BP | GO:0002758 | innate immune response-activating signaling pathway | 3 | 122 | 4.50e-01 |
| GO:BP | GO:1903322 | positive regulation of protein modification by small protein conjugation or removal | 3 | 126 | 4.50e-01 |
| GO:BP | GO:0018279 | protein N-linked glycosylation via asparagine | 1 | 23 | 4.50e-01 |
| GO:BP | GO:2001242 | regulation of intrinsic apoptotic signaling pathway | 2 | 147 | 4.50e-01 |
| GO:BP | GO:0060251 | regulation of glial cell proliferation | 1 | 26 | 4.51e-01 |
| GO:BP | GO:0048147 | negative regulation of fibroblast proliferation | 1 | 31 | 4.51e-01 |
| GO:BP | GO:0072576 | liver morphogenesis | 1 | 19 | 4.52e-01 |
| GO:BP | GO:0090068 | positive regulation of cell cycle process | 6 | 209 | 4.52e-01 |
| GO:BP | GO:0032768 | regulation of monooxygenase activity | 1 | 34 | 4.53e-01 |
| GO:BP | GO:0048546 | digestive tract morphogenesis | 1 | 31 | 4.53e-01 |
| GO:BP | GO:0016050 | vesicle organization | 1 | 320 | 4.53e-01 |
| GO:BP | GO:0090288 | negative regulation of cellular response to growth factor stimulus | 2 | 81 | 4.53e-01 |
| GO:BP | GO:0071345 | cellular response to cytokine stimulus | 12 | 540 | 4.54e-01 |
| GO:BP | GO:0003205 | cardiac chamber development | 3 | 149 | 4.54e-01 |
| GO:BP | GO:0010614 | negative regulation of cardiac muscle hypertrophy | 1 | 26 | 4.54e-01 |
| GO:BP | GO:0005979 | regulation of glycogen biosynthetic process | 1 | 25 | 4.54e-01 |
| GO:BP | GO:0010962 | regulation of glucan biosynthetic process | 1 | 25 | 4.54e-01 |
| GO:BP | GO:1901028 | regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway | 1 | 25 | 4.54e-01 |
| GO:BP | GO:0051310 | metaphase plate congression | 1 | 69 | 4.54e-01 |
| GO:BP | GO:0043507 | positive regulation of JUN kinase activity | 1 | 34 | 4.55e-01 |
| GO:BP | GO:0032869 | cellular response to insulin stimulus | 4 | 174 | 4.55e-01 |
| GO:BP | GO:0010882 | regulation of cardiac muscle contraction by calcium ion signaling | 1 | 25 | 4.55e-01 |
| GO:BP | GO:0086064 | cell communication by electrical coupling involved in cardiac conduction | 1 | 26 | 4.55e-01 |
| GO:BP | GO:0061951 | establishment of protein localization to plasma membrane | 2 | 59 | 4.55e-01 |
| GO:BP | GO:0048666 | neuron development | 6 | 877 | 4.55e-01 |
| GO:BP | GO:0007568 | aging | 3 | 115 | 4.56e-01 |
| GO:BP | GO:0071887 | leukocyte apoptotic process | 2 | 81 | 4.56e-01 |
| GO:BP | GO:0014706 | striated muscle tissue development | 5 | 210 | 4.56e-01 |
| GO:BP | GO:0045762 | positive regulation of adenylate cyclase activity | 1 | 19 | 4.57e-01 |
| GO:BP | GO:0001953 | negative regulation of cell-matrix adhesion | 1 | 26 | 4.57e-01 |
| GO:BP | GO:0002244 | hematopoietic progenitor cell differentiation | 4 | 109 | 4.57e-01 |
| GO:BP | GO:1903241 | U2-type prespliceosome assembly | 1 | 24 | 4.57e-01 |
| GO:BP | GO:1900181 | negative regulation of protein localization to nucleus | 1 | 28 | 4.57e-01 |
| GO:BP | GO:0017148 | negative regulation of translation | 1 | 165 | 4.57e-01 |
| GO:BP | GO:0099188 | postsynaptic cytoskeleton organization | 1 | 14 | 4.57e-01 |
| GO:BP | GO:0007528 | neuromuscular junction development | 1 | 39 | 4.58e-01 |
| GO:BP | GO:0000281 | mitotic cytokinesis | 2 | 81 | 4.58e-01 |
| GO:BP | GO:0006911 | phagocytosis, engulfment | 2 | 33 | 4.58e-01 |
| GO:BP | GO:0005976 | polysaccharide metabolic process | 2 | 80 | 4.58e-01 |
| GO:BP | GO:2000191 | regulation of fatty acid transport | 1 | 19 | 4.58e-01 |
| GO:BP | GO:0009642 | response to light intensity | 1 | 11 | 4.58e-01 |
| GO:BP | GO:0043487 | regulation of RNA stability | 1 | 159 | 4.58e-01 |
| GO:BP | GO:0018107 | peptidyl-threonine phosphorylation | 3 | 97 | 4.58e-01 |
| GO:BP | GO:1901654 | response to ketone | 3 | 147 | 4.58e-01 |
| GO:BP | GO:0071371 | cellular response to gonadotropin stimulus | 1 | 13 | 4.59e-01 |
| GO:BP | GO:0071674 | mononuclear cell migration | 1 | 102 | 4.59e-01 |
| GO:BP | GO:2000300 | regulation of synaptic vesicle exocytosis | 1 | 35 | 4.59e-01 |
| GO:BP | GO:0002520 | immune system development | 1 | 144 | 4.59e-01 |
| GO:BP | GO:0043536 | positive regulation of blood vessel endothelial cell migration | 1 | 47 | 4.60e-01 |
| GO:BP | GO:0006893 | Golgi to plasma membrane transport | 2 | 60 | 4.60e-01 |
| GO:BP | GO:0040007 | growth | 7 | 742 | 4.60e-01 |
| GO:BP | GO:0071174 | mitotic spindle checkpoint signaling | 1 | 44 | 4.61e-01 |
| GO:BP | GO:0007094 | mitotic spindle assembly checkpoint signaling | 1 | 44 | 4.61e-01 |
| GO:BP | GO:0071173 | spindle assembly checkpoint signaling | 1 | 44 | 4.61e-01 |
| GO:BP | GO:0060541 | respiratory system development | 1 | 163 | 4.61e-01 |
| GO:BP | GO:0060326 | cell chemotaxis | 2 | 162 | 4.61e-01 |
| GO:BP | GO:0032367 | intracellular cholesterol transport | 1 | 28 | 4.61e-01 |
| GO:BP | GO:1902106 | negative regulation of leukocyte differentiation | 2 | 65 | 4.61e-01 |
| GO:BP | GO:1904707 | positive regulation of vascular associated smooth muscle cell proliferation | 1 | 29 | 4.61e-01 |
| GO:BP | GO:0030100 | regulation of endocytosis | 2 | 211 | 4.61e-01 |
| GO:BP | GO:0051938 | L-glutamate import | 1 | 25 | 4.61e-01 |
| GO:BP | GO:0061178 | regulation of insulin secretion involved in cellular response to glucose stimulus | 2 | 40 | 4.62e-01 |
| GO:BP | GO:0051251 | positive regulation of lymphocyte activation | 3 | 199 | 4.62e-01 |
| GO:BP | GO:0061013 | regulation of mRNA catabolic process | 1 | 161 | 4.62e-01 |
| GO:BP | GO:0070663 | regulation of leukocyte proliferation | 2 | 141 | 4.62e-01 |
| GO:BP | GO:0033008 | positive regulation of mast cell activation involved in immune response | 1 | 10 | 4.62e-01 |
| GO:BP | GO:0018146 | keratan sulfate biosynthetic process | 1 | 13 | 4.62e-01 |
| GO:BP | GO:0043306 | positive regulation of mast cell degranulation | 1 | 10 | 4.62e-01 |
| GO:BP | GO:0051591 | response to cAMP | 2 | 66 | 4.62e-01 |
| GO:BP | GO:0051571 | positive regulation of histone H3-K4 methylation | 1 | 20 | 4.63e-01 |
| GO:BP | GO:0009968 | negative regulation of signal transduction | 15 | 1006 | 4.63e-01 |
| GO:BP | GO:2001259 | positive regulation of cation channel activity | 2 | 49 | 4.63e-01 |
| GO:BP | GO:0030330 | DNA damage response, signal transduction by p53 class mediator | 1 | 69 | 4.63e-01 |
| GO:BP | GO:0043114 | regulation of vascular permeability | 1 | 35 | 4.64e-01 |
| GO:BP | GO:0006090 | pyruvate metabolic process | 2 | 93 | 4.64e-01 |
| GO:BP | GO:0072528 | pyrimidine-containing compound biosynthetic process | 1 | 33 | 4.64e-01 |
| GO:BP | GO:0031577 | spindle checkpoint signaling | 1 | 45 | 4.64e-01 |
| GO:BP | GO:0014904 | myotube cell development | 1 | 34 | 4.64e-01 |
| GO:BP | GO:0030858 | positive regulation of epithelial cell differentiation | 1 | 37 | 4.64e-01 |
| GO:BP | GO:0051085 | chaperone cofactor-dependent protein refolding | 1 | 30 | 4.64e-01 |
| GO:BP | GO:0043279 | response to alkaloid | 3 | 68 | 4.64e-01 |
| GO:BP | GO:0033059 | cellular pigmentation | 2 | 58 | 4.64e-01 |
| GO:BP | GO:0032515 | negative regulation of phosphoprotein phosphatase activity | 1 | 21 | 4.64e-01 |
| GO:BP | GO:0060191 | regulation of lipase activity | 1 | 52 | 4.64e-01 |
| GO:BP | GO:0007159 | leukocyte cell-cell adhesion | 3 | 234 | 4.64e-01 |
| GO:BP | GO:0050765 | negative regulation of phagocytosis | 1 | 15 | 4.64e-01 |
| GO:BP | GO:0051298 | centrosome duplication | 1 | 68 | 4.64e-01 |
| GO:BP | GO:0015908 | fatty acid transport | 2 | 58 | 4.64e-01 |
| GO:BP | GO:0071025 | RNA surveillance | 1 | 16 | 4.64e-01 |
| GO:BP | GO:0010288 | response to lead ion | 1 | 18 | 4.64e-01 |
| GO:BP | GO:0006779 | porphyrin-containing compound biosynthetic process | 1 | 33 | 4.64e-01 |
| GO:BP | GO:0071402 | cellular response to lipoprotein particle stimulus | 1 | 23 | 4.64e-01 |
| GO:BP | GO:0070884 | regulation of calcineurin-NFAT signaling cascade | 1 | 32 | 4.64e-01 |
| GO:BP | GO:0014037 | Schwann cell differentiation | 1 | 34 | 4.64e-01 |
| GO:BP | GO:0014741 | negative regulation of muscle hypertrophy | 1 | 27 | 4.64e-01 |
| GO:BP | GO:0034656 | nucleobase-containing small molecule catabolic process | 1 | 20 | 4.64e-01 |
| GO:BP | GO:0072655 | establishment of protein localization to mitochondrion | 3 | 118 | 4.64e-01 |
| GO:BP | GO:0071870 | cellular response to catecholamine stimulus | 2 | 60 | 4.64e-01 |
| GO:BP | GO:0071868 | cellular response to monoamine stimulus | 2 | 60 | 4.64e-01 |
| GO:BP | GO:0033014 | tetrapyrrole biosynthetic process | 1 | 33 | 4.64e-01 |
| GO:BP | GO:0140014 | mitotic nuclear division | 3 | 251 | 4.64e-01 |
| GO:BP | GO:0006360 | transcription by RNA polymerase I | 2 | 62 | 4.64e-01 |
| GO:BP | GO:0000122 | negative regulation of transcription by RNA polymerase II | 1 | 740 | 4.64e-01 |
| GO:BP | GO:0050850 | positive regulation of calcium-mediated signaling | 1 | 22 | 4.64e-01 |
| GO:BP | GO:0032094 | response to food | 1 | 22 | 4.65e-01 |
| GO:BP | GO:0061028 | establishment of endothelial barrier | 1 | 38 | 4.65e-01 |
| GO:BP | GO:0031669 | cellular response to nutrient levels | 3 | 194 | 4.66e-01 |
| GO:BP | GO:0051412 | response to corticosterone | 1 | 10 | 4.66e-01 |
| GO:BP | GO:0007173 | epidermal growth factor receptor signaling pathway | 1 | 93 | 4.66e-01 |
| GO:BP | GO:0045841 | negative regulation of mitotic metaphase/anaphase transition | 1 | 46 | 4.66e-01 |
| GO:BP | GO:0060343 | trabecula formation | 1 | 23 | 4.66e-01 |
| GO:BP | GO:2000107 | negative regulation of leukocyte apoptotic process | 2 | 33 | 4.66e-01 |
| GO:BP | GO:0022600 | digestive system process | 2 | 54 | 4.66e-01 |
| GO:BP | GO:1904029 | regulation of cyclin-dependent protein kinase activity | 3 | 88 | 4.66e-01 |
| GO:BP | GO:0006909 | phagocytosis | 6 | 148 | 4.67e-01 |
| GO:BP | GO:0070200 | establishment of protein localization to telomere | 1 | 16 | 4.67e-01 |
| GO:BP | GO:0043010 | camera-type eye development | 7 | 236 | 4.68e-01 |
| GO:BP | GO:0014855 | striated muscle cell proliferation | 1 | 57 | 4.68e-01 |
| GO:BP | GO:0014911 | positive regulation of smooth muscle cell migration | 1 | 30 | 4.68e-01 |
| GO:BP | GO:0010604 | positive regulation of macromolecule metabolic process | 1 | 2646 | 4.68e-01 |
| GO:BP | GO:0016358 | dendrite development | 5 | 202 | 4.68e-01 |
| GO:BP | GO:0048469 | cell maturation | 1 | 108 | 4.68e-01 |
| GO:BP | GO:0032733 | positive regulation of interleukin-10 production | 1 | 16 | 4.69e-01 |
| GO:BP | GO:0048854 | brain morphogenesis | 1 | 28 | 4.69e-01 |
| GO:BP | GO:0106056 | regulation of calcineurin-mediated signaling | 1 | 32 | 4.69e-01 |
| GO:BP | GO:1900221 | regulation of amyloid-beta clearance | 1 | 13 | 4.69e-01 |
| GO:BP | GO:0018022 | peptidyl-lysine methylation | 3 | 104 | 4.69e-01 |
| GO:BP | GO:1901701 | cellular response to oxygen-containing compound | 13 | 893 | 4.69e-01 |
| GO:BP | GO:0033028 | myeloid cell apoptotic process | 1 | 25 | 4.69e-01 |
| GO:BP | GO:0007158 | neuron cell-cell adhesion | 1 | 13 | 4.69e-01 |
| GO:BP | GO:0071346 | cellular response to type II interferon | 2 | 69 | 4.69e-01 |
| GO:BP | GO:2001169 | regulation of ATP biosynthetic process | 1 | 17 | 4.69e-01 |
| GO:BP | GO:0044065 | regulation of respiratory system process | 1 | 11 | 4.69e-01 |
| GO:BP | GO:0007200 | phospholipase C-activating G protein-coupled receptor signaling pathway | 1 | 40 | 4.69e-01 |
| GO:BP | GO:1903955 | positive regulation of protein targeting to mitochondrion | 1 | 30 | 4.69e-01 |
| GO:BP | GO:0046475 | glycerophospholipid catabolic process | 1 | 21 | 4.69e-01 |
| GO:BP | GO:0046676 | negative regulation of insulin secretion | 1 | 28 | 4.69e-01 |
| GO:BP | GO:0060080 | inhibitory postsynaptic potential | 1 | 8 | 4.69e-01 |
| GO:BP | GO:1903707 | negative regulation of hemopoiesis | 2 | 69 | 4.69e-01 |
| GO:BP | GO:0008104 | protein localization | 2 | 2129 | 4.69e-01 |
| GO:BP | GO:0043467 | regulation of generation of precursor metabolites and energy | 2 | 89 | 4.69e-01 |
| GO:BP | GO:0090713 | immunological memory process | 1 | 7 | 4.69e-01 |
| GO:BP | GO:2000179 | positive regulation of neural precursor cell proliferation | 1 | 34 | 4.69e-01 |
| GO:BP | GO:0120034 | positive regulation of plasma membrane bounded cell projection assembly | 1 | 94 | 4.69e-01 |
| GO:BP | GO:0010648 | negative regulation of cell communication | 16 | 1074 | 4.69e-01 |
| GO:BP | GO:0001574 | ganglioside biosynthetic process | 1 | 14 | 4.69e-01 |
| GO:BP | GO:0031124 | mRNA 3’-end processing | 2 | 58 | 4.70e-01 |
| GO:BP | GO:0070727 | cellular macromolecule localization | 2 | 2138 | 4.70e-01 |
| GO:BP | GO:1901879 | regulation of protein depolymerization | 2 | 78 | 4.71e-01 |
| GO:BP | GO:0033046 | negative regulation of sister chromatid segregation | 1 | 47 | 4.71e-01 |
| GO:BP | GO:0033048 | negative regulation of mitotic sister chromatid segregation | 1 | 47 | 4.71e-01 |
| GO:BP | GO:0046835 | carbohydrate phosphorylation | 1 | 21 | 4.71e-01 |
| GO:BP | GO:0034332 | adherens junction organization | 1 | 41 | 4.71e-01 |
| GO:BP | GO:1905818 | regulation of chromosome separation | 2 | 71 | 4.71e-01 |
| GO:BP | GO:1901615 | organic hydroxy compound metabolic process | 7 | 376 | 4.71e-01 |
| GO:BP | GO:2000816 | negative regulation of mitotic sister chromatid separation | 1 | 47 | 4.71e-01 |
| GO:BP | GO:1902100 | negative regulation of metaphase/anaphase transition of cell cycle | 1 | 47 | 4.71e-01 |
| GO:BP | GO:0010880 | regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | 1 | 27 | 4.71e-01 |
| GO:BP | GO:0070848 | response to growth factor | 9 | 572 | 4.71e-01 |
| GO:BP | GO:0071869 | response to catecholamine | 2 | 62 | 4.71e-01 |
| GO:BP | GO:0071867 | response to monoamine | 2 | 62 | 4.71e-01 |
| GO:BP | GO:0097194 | execution phase of apoptosis | 2 | 53 | 4.71e-01 |
| GO:BP | GO:1903426 | regulation of reactive oxygen species biosynthetic process | 1 | 29 | 4.71e-01 |
| GO:BP | GO:0016074 | sno(s)RNA metabolic process | 1 | 16 | 4.71e-01 |
| GO:BP | GO:0036120 | cellular response to platelet-derived growth factor stimulus | 1 | 21 | 4.71e-01 |
| GO:BP | GO:0007096 | regulation of exit from mitosis | 1 | 17 | 4.71e-01 |
| GO:BP | GO:0044321 | response to leptin | 1 | 19 | 4.71e-01 |
| GO:BP | GO:0021772 | olfactory bulb development | 1 | 19 | 4.71e-01 |
| GO:BP | GO:0031063 | regulation of histone deacetylation | 1 | 36 | 4.72e-01 |
| GO:BP | GO:0099024 | plasma membrane invagination | 2 | 42 | 4.74e-01 |
| GO:BP | GO:0019080 | viral gene expression | 3 | 96 | 4.74e-01 |
| GO:BP | GO:0032366 | intracellular sterol transport | 1 | 30 | 4.74e-01 |
| GO:BP | GO:0071875 | adrenergic receptor signaling pathway | 1 | 24 | 4.74e-01 |
| GO:BP | GO:0046621 | negative regulation of organ growth | 1 | 27 | 4.74e-01 |
| GO:BP | GO:0002833 | positive regulation of response to biotic stimulus | 4 | 192 | 4.75e-01 |
| GO:BP | GO:0034249 | negative regulation of amide metabolic process | 1 | 186 | 4.75e-01 |
| GO:BP | GO:0001933 | negative regulation of protein phosphorylation | 2 | 277 | 4.75e-01 |
| GO:BP | GO:0001961 | positive regulation of cytokine-mediated signaling pathway | 1 | 44 | 4.76e-01 |
| GO:BP | GO:1900015 | regulation of cytokine production involved in inflammatory response | 1 | 33 | 4.76e-01 |
| GO:BP | GO:0002534 | cytokine production involved in inflammatory response | 1 | 33 | 4.76e-01 |
| GO:BP | GO:0032735 | positive regulation of interleukin-12 production | 1 | 19 | 4.76e-01 |
| GO:BP | GO:0007059 | chromosome segregation | 4 | 369 | 4.76e-01 |
| GO:BP | GO:0002831 | regulation of response to biotic stimulus | 3 | 293 | 4.76e-01 |
| GO:BP | GO:1903076 | regulation of protein localization to plasma membrane | 1 | 90 | 4.76e-01 |
| GO:BP | GO:1905477 | positive regulation of protein localization to membrane | 1 | 84 | 4.76e-01 |
| GO:BP | GO:0043009 | chordate embryonic development | 7 | 534 | 4.76e-01 |
| GO:BP | GO:0051303 | establishment of chromosome localization | 1 | 75 | 4.78e-01 |
| GO:BP | GO:0043500 | muscle adaptation | 2 | 90 | 4.78e-01 |
| GO:BP | GO:0030595 | leukocyte chemotaxis | 1 | 115 | 4.78e-01 |
| GO:BP | GO:0045321 | leukocyte activation | 6 | 554 | 4.78e-01 |
| GO:BP | GO:0035304 | regulation of protein dephosphorylation | 2 | 75 | 4.79e-01 |
| GO:BP | GO:0099149 | regulation of postsynaptic neurotransmitter receptor internalization | 1 | 11 | 4.79e-01 |
| GO:BP | GO:0044458 | motile cilium assembly | 1 | 45 | 4.79e-01 |
| GO:BP | GO:0045198 | establishment of epithelial cell apical/basal polarity | 1 | 14 | 4.79e-01 |
| GO:BP | GO:0038061 | NIK/NF-kappaB signaling | 3 | 86 | 4.79e-01 |
| GO:BP | GO:1905819 | negative regulation of chromosome separation | 1 | 48 | 4.79e-01 |
| GO:BP | GO:0001755 | neural crest cell migration | 1 | 49 | 4.79e-01 |
| GO:BP | GO:0009394 | 2’-deoxyribonucleotide metabolic process | 1 | 35 | 4.79e-01 |
| GO:BP | GO:0051985 | negative regulation of chromosome segregation | 1 | 48 | 4.79e-01 |
| GO:BP | GO:0051246 | regulation of protein metabolic process | 24 | 1974 | 4.80e-01 |
| GO:BP | GO:0048857 | neural nucleus development | 2 | 50 | 4.80e-01 |
| GO:BP | GO:0042339 | keratan sulfate metabolic process | 1 | 15 | 4.80e-01 |
| GO:BP | GO:0060560 | developmental growth involved in morphogenesis | 1 | 204 | 4.80e-01 |
| GO:BP | GO:0003309 | type B pancreatic cell differentiation | 1 | 22 | 4.80e-01 |
| GO:BP | GO:0001662 | behavioral fear response | 1 | 29 | 4.81e-01 |
| GO:BP | GO:0070585 | protein localization to mitochondrion | 3 | 123 | 4.82e-01 |
| GO:BP | GO:0007176 | regulation of epidermal growth factor-activated receptor activity | 1 | 24 | 4.82e-01 |
| GO:BP | GO:0006739 | NADP metabolic process | 1 | 40 | 4.84e-01 |
| GO:BP | GO:0071216 | cellular response to biotic stimulus | 3 | 138 | 4.84e-01 |
| GO:BP | GO:1903522 | regulation of blood circulation | 4 | 198 | 4.85e-01 |
| GO:BP | GO:0060402 | calcium ion transport into cytosol | 1 | 18 | 4.85e-01 |
| GO:BP | GO:0009262 | deoxyribonucleotide metabolic process | 1 | 36 | 4.85e-01 |
| GO:BP | GO:0021988 | olfactory lobe development | 1 | 21 | 4.85e-01 |
| GO:BP | GO:0009124 | nucleoside monophosphate biosynthetic process | 1 | 37 | 4.85e-01 |
| GO:BP | GO:0019692 | deoxyribose phosphate metabolic process | 1 | 36 | 4.85e-01 |
| GO:BP | GO:0062014 | negative regulation of small molecule metabolic process | 3 | 71 | 4.85e-01 |
| GO:BP | GO:0010737 | protein kinase A signaling | 1 | 23 | 4.86e-01 |
| GO:BP | GO:0040029 | epigenetic regulation of gene expression | 3 | 153 | 4.86e-01 |
| GO:BP | GO:0006658 | phosphatidylserine metabolic process | 1 | 21 | 4.86e-01 |
| GO:BP | GO:0002209 | behavioral defense response | 1 | 30 | 4.86e-01 |
| GO:BP | GO:0006482 | protein demethylation | 1 | 27 | 4.86e-01 |
| GO:BP | GO:0008214 | protein dealkylation | 1 | 27 | 4.86e-01 |
| GO:BP | GO:0043647 | inositol phosphate metabolic process | 1 | 35 | 4.86e-01 |
| GO:BP | GO:0033173 | calcineurin-NFAT signaling cascade | 1 | 37 | 4.86e-01 |
| GO:BP | GO:0070231 | T cell apoptotic process | 1 | 39 | 4.86e-01 |
| GO:BP | GO:2000377 | regulation of reactive oxygen species metabolic process | 2 | 108 | 4.86e-01 |
| GO:BP | GO:0009893 | positive regulation of metabolic process | 1 | 2880 | 4.86e-01 |
| GO:BP | GO:0090497 | mesenchymal cell migration | 1 | 51 | 4.86e-01 |
| GO:BP | GO:0007265 | Ras protein signal transduction | 2 | 294 | 4.86e-01 |
| GO:BP | GO:0070873 | regulation of glycogen metabolic process | 1 | 28 | 4.87e-01 |
| GO:BP | GO:0032480 | negative regulation of type I interferon production | 1 | 23 | 4.87e-01 |
| GO:BP | GO:1902850 | microtubule cytoskeleton organization involved in mitosis | 2 | 157 | 4.88e-01 |
| GO:BP | GO:0032006 | regulation of TOR signaling | 2 | 96 | 4.88e-01 |
| GO:BP | GO:0035307 | positive regulation of protein dephosphorylation | 1 | 36 | 4.89e-01 |
| GO:BP | GO:0035066 | positive regulation of histone acetylation | 1 | 25 | 4.89e-01 |
| GO:BP | GO:0051650 | establishment of vesicle localization | 5 | 175 | 4.89e-01 |
| GO:BP | GO:0032418 | lysosome localization | 1 | 62 | 4.89e-01 |
| GO:BP | GO:0006260 | DNA replication | 1 | 255 | 4.89e-01 |
| GO:BP | GO:1990849 | vacuolar localization | 1 | 62 | 4.89e-01 |
| GO:BP | GO:1903900 | regulation of viral life cycle | 3 | 101 | 4.89e-01 |
| GO:BP | GO:0051084 | ‘de novo’ post-translational protein folding | 1 | 35 | 4.89e-01 |
| GO:BP | GO:0045165 | cell fate commitment | 1 | 155 | 4.89e-01 |
| GO:BP | GO:0010721 | negative regulation of cell development | 4 | 191 | 4.89e-01 |
| GO:BP | GO:0033138 | positive regulation of peptidyl-serine phosphorylation | 2 | 70 | 4.89e-01 |
| GO:BP | GO:0030278 | regulation of ossification | 3 | 84 | 4.89e-01 |
| GO:BP | GO:2000629 | negative regulation of miRNA metabolic process | 1 | 20 | 4.89e-01 |
| GO:BP | GO:0050931 | pigment cell differentiation | 1 | 26 | 4.89e-01 |
| GO:BP | GO:0006325 | chromatin organization | 6 | 551 | 4.89e-01 |
| GO:BP | GO:0090317 | negative regulation of intracellular protein transport | 1 | 37 | 4.89e-01 |
| GO:BP | GO:0008334 | histone mRNA metabolic process | 1 | 21 | 4.89e-01 |
| GO:BP | GO:0031365 | N-terminal protein amino acid modification | 1 | 28 | 4.89e-01 |
| GO:BP | GO:1901021 | positive regulation of calcium ion transmembrane transporter activity | 1 | 39 | 4.89e-01 |
| GO:BP | GO:0008033 | tRNA processing | 1 | 128 | 4.89e-01 |
| GO:BP | GO:0036119 | response to platelet-derived growth factor | 1 | 23 | 4.89e-01 |
| GO:BP | GO:0045124 | regulation of bone resorption | 1 | 24 | 4.89e-01 |
| GO:BP | GO:0031281 | positive regulation of cyclase activity | 1 | 23 | 4.89e-01 |
| GO:BP | GO:0048713 | regulation of oligodendrocyte differentiation | 1 | 25 | 4.89e-01 |
| GO:BP | GO:0140888 | interferon-mediated signaling pathway | 1 | 67 | 4.89e-01 |
| GO:BP | GO:0070129 | regulation of mitochondrial translation | 1 | 26 | 4.89e-01 |
| GO:BP | GO:0035418 | protein localization to synapse | 1 | 68 | 4.89e-01 |
| GO:BP | GO:1903725 | regulation of phospholipid metabolic process | 1 | 29 | 4.89e-01 |
| GO:BP | GO:0010324 | membrane invagination | 2 | 49 | 4.89e-01 |
| GO:BP | GO:0016310 | phosphorylation | 22 | 1372 | 4.89e-01 |
| GO:BP | GO:0051345 | positive regulation of hydrolase activity | 3 | 422 | 4.89e-01 |
| GO:BP | GO:0062207 | regulation of pattern recognition receptor signaling pathway | 1 | 68 | 4.89e-01 |
| GO:BP | GO:0060390 | regulation of SMAD protein signal transduction | 1 | 27 | 4.90e-01 |
| GO:BP | GO:1903749 | positive regulation of establishment of protein localization to mitochondrion | 1 | 33 | 4.91e-01 |
| GO:BP | GO:0070228 | regulation of lymphocyte apoptotic process | 1 | 37 | 4.91e-01 |
| GO:BP | GO:0032885 | regulation of polysaccharide biosynthetic process | 1 | 31 | 4.91e-01 |
| GO:BP | GO:0043649 | dicarboxylic acid catabolic process | 1 | 14 | 4.91e-01 |
| GO:BP | GO:0038127 | ERBB signaling pathway | 1 | 107 | 4.91e-01 |
| GO:BP | GO:0000291 | nuclear-transcribed mRNA catabolic process, exonucleolytic | 1 | 19 | 4.91e-01 |
| GO:BP | GO:0045879 | negative regulation of smoothened signaling pathway | 1 | 30 | 4.91e-01 |
| GO:BP | GO:0043628 | regulatory ncRNA 3’-end processing | 1 | 19 | 4.91e-01 |
| GO:BP | GO:0007049 | cell cycle | 2 | 1529 | 4.91e-01 |
| GO:BP | GO:0050000 | chromosome localization | 1 | 82 | 4.91e-01 |
| GO:BP | GO:0010950 | positive regulation of endopeptidase activity | 1 | 126 | 4.91e-01 |
| GO:BP | GO:0017121 | plasma membrane phospholipid scrambling | 1 | 13 | 4.91e-01 |
| GO:BP | GO:0099504 | synaptic vesicle cycle | 1 | 163 | 4.91e-01 |
| GO:BP | GO:0045839 | negative regulation of mitotic nuclear division | 1 | 54 | 4.92e-01 |
| GO:BP | GO:0045637 | regulation of myeloid cell differentiation | 3 | 152 | 4.92e-01 |
| GO:BP | GO:0010155 | regulation of proton transport | 1 | 18 | 4.92e-01 |
| GO:BP | GO:0032088 | negative regulation of NF-kappaB transcription factor activity | 1 | 66 | 4.92e-01 |
| GO:BP | GO:0007269 | neurotransmitter secretion | 2 | 104 | 4.92e-01 |
| GO:BP | GO:0007507 | heart development | 8 | 506 | 4.92e-01 |
| GO:BP | GO:0099643 | signal release from synapse | 2 | 104 | 4.92e-01 |
| GO:BP | GO:1904862 | inhibitory synapse assembly | 1 | 13 | 4.92e-01 |
| GO:BP | GO:0090278 | negative regulation of peptide hormone secretion | 1 | 30 | 4.92e-01 |
| GO:BP | GO:0033574 | response to testosterone | 1 | 29 | 4.92e-01 |
| GO:BP | GO:0051349 | positive regulation of lyase activity | 1 | 23 | 4.92e-01 |
| GO:BP | GO:0044057 | regulation of system process | 3 | 405 | 4.92e-01 |
| GO:BP | GO:0035773 | insulin secretion involved in cellular response to glucose stimulus | 1 | 49 | 4.92e-01 |
| GO:BP | GO:0006984 | ER-nucleus signaling pathway | 1 | 45 | 4.92e-01 |
| GO:BP | GO:0090128 | regulation of synapse maturation | 1 | 15 | 4.92e-01 |
| GO:BP | GO:0002761 | regulation of myeloid leukocyte differentiation | 2 | 77 | 4.93e-01 |
| GO:BP | GO:0051304 | chromosome separation | 2 | 76 | 4.93e-01 |
| GO:BP | GO:0009628 | response to abiotic stimulus | 1 | 868 | 4.93e-01 |
| GO:BP | GO:0033198 | response to ATP | 1 | 24 | 4.93e-01 |
| GO:BP | GO:0030262 | apoptotic nuclear changes | 1 | 20 | 4.93e-01 |
| GO:BP | GO:0014808 | release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | 1 | 28 | 4.93e-01 |
| GO:BP | GO:0030282 | bone mineralization | 3 | 82 | 4.93e-01 |
| GO:BP | GO:0051046 | regulation of secretion | 7 | 418 | 4.93e-01 |
| GO:BP | GO:0065009 | regulation of molecular function | 11 | 1939 | 4.94e-01 |
| GO:BP | GO:0051154 | negative regulation of striated muscle cell differentiation | 1 | 31 | 4.94e-01 |
| GO:BP | GO:1902003 | regulation of amyloid-beta formation | 1 | 33 | 4.94e-01 |
| GO:BP | GO:0007214 | gamma-aminobutyric acid signaling pathway | 1 | 12 | 4.95e-01 |
| GO:BP | GO:0071709 | membrane assembly | 2 | 53 | 4.95e-01 |
| GO:BP | GO:0032479 | regulation of type I interferon production | 2 | 76 | 4.95e-01 |
| GO:BP | GO:0019221 | cytokine-mediated signaling pathway | 4 | 274 | 4.95e-01 |
| GO:BP | GO:0030098 | lymphocyte differentiation | 7 | 260 | 4.95e-01 |
| GO:BP | GO:0090630 | activation of GTPase activity | 2 | 99 | 4.95e-01 |
| GO:BP | GO:0097720 | calcineurin-mediated signaling | 1 | 38 | 4.95e-01 |
| GO:BP | GO:0032606 | type I interferon production | 2 | 76 | 4.95e-01 |
| GO:BP | GO:0006139 | nucleobase-containing compound metabolic process | 6 | 4455 | 4.95e-01 |
| GO:BP | GO:0060760 | positive regulation of response to cytokine stimulus | 1 | 49 | 4.95e-01 |
| GO:BP | GO:0010634 | positive regulation of epithelial cell migration | 2 | 132 | 4.95e-01 |
| GO:BP | GO:0009792 | embryo development ending in birth or egg hatching | 7 | 551 | 4.95e-01 |
| GO:BP | GO:2001239 | regulation of extrinsic apoptotic signaling pathway in absence of ligand | 1 | 35 | 4.95e-01 |
| GO:BP | GO:0008283 | cell population proliferation | 4 | 1378 | 4.95e-01 |
| GO:BP | GO:0002792 | negative regulation of peptide secretion | 1 | 31 | 4.95e-01 |
| GO:BP | GO:0071548 | response to dexamethasone | 1 | 36 | 4.95e-01 |
| GO:BP | GO:0003009 | skeletal muscle contraction | 1 | 31 | 4.95e-01 |
| GO:BP | GO:0072337 | modified amino acid transport | 1 | 35 | 4.96e-01 |
| GO:BP | GO:0030097 | hemopoiesis | 11 | 656 | 4.96e-01 |
| GO:BP | GO:0008015 | blood circulation | 7 | 374 | 4.96e-01 |
| GO:BP | GO:2000479 | regulation of cAMP-dependent protein kinase activity | 1 | 16 | 4.96e-01 |
| GO:BP | GO:0046634 | regulation of alpha-beta T cell activation | 1 | 58 | 4.96e-01 |
| GO:BP | GO:0003013 | circulatory system process | 8 | 447 | 4.96e-01 |
| GO:BP | GO:0042398 | cellular modified amino acid biosynthetic process | 1 | 26 | 4.96e-01 |
| GO:BP | GO:1900242 | regulation of synaptic vesicle endocytosis | 1 | 16 | 4.96e-01 |
| GO:BP | GO:0018205 | peptidyl-lysine modification | 7 | 336 | 4.96e-01 |
| GO:BP | GO:0006359 | regulation of transcription by RNA polymerase III | 1 | 30 | 4.96e-01 |
| GO:BP | GO:1903514 | release of sequestered calcium ion into cytosol by endoplasmic reticulum | 1 | 28 | 4.96e-01 |
| GO:BP | GO:0061082 | myeloid leukocyte cytokine production | 1 | 38 | 4.96e-01 |
| GO:BP | GO:0001947 | heart looping | 1 | 50 | 4.96e-01 |
| GO:BP | GO:0043086 | negative regulation of catalytic activity | 14 | 478 | 4.96e-01 |
| GO:BP | GO:0034250 | positive regulation of amide metabolic process | 4 | 149 | 4.96e-01 |
| GO:BP | GO:0031329 | regulation of cellular catabolic process | 12 | 555 | 4.96e-01 |
| GO:BP | GO:0043489 | RNA stabilization | 2 | 59 | 4.96e-01 |
| GO:BP | GO:0046651 | lymphocyte proliferation | 2 | 162 | 4.96e-01 |
| GO:BP | GO:0010644 | cell communication by electrical coupling | 1 | 31 | 4.96e-01 |
| GO:BP | GO:0031146 | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process | 1 | 47 | 4.96e-01 |
| GO:BP | GO:0071625 | vocalization behavior | 1 | 13 | 4.96e-01 |
| GO:BP | GO:0050773 | regulation of dendrite development | 3 | 90 | 4.98e-01 |
| GO:BP | GO:0110020 | regulation of actomyosin structure organization | 2 | 90 | 4.98e-01 |
| GO:BP | GO:0002696 | positive regulation of leukocyte activation | 3 | 222 | 4.98e-01 |
| GO:BP | GO:0046717 | acid secretion | 1 | 25 | 4.98e-01 |
| GO:BP | GO:1902930 | regulation of alcohol biosynthetic process | 1 | 33 | 4.98e-01 |
| GO:BP | GO:0002283 | neutrophil activation involved in immune response | 1 | 7 | 4.98e-01 |
| GO:BP | GO:0051602 | response to electrical stimulus | 1 | 26 | 4.99e-01 |
| GO:BP | GO:0090504 | epiboly | 1 | 31 | 4.99e-01 |
| GO:BP | GO:0010952 | positive regulation of peptidase activity | 1 | 135 | 4.99e-01 |
| GO:BP | GO:0050729 | positive regulation of inflammatory response | 4 | 75 | 5.00e-01 |
| GO:BP | GO:0031056 | regulation of histone modification | 3 | 125 | 5.00e-01 |
| GO:BP | GO:0097049 | motor neuron apoptotic process | 1 | 18 | 5.00e-01 |
| GO:BP | GO:0097061 | dendritic spine organization | 2 | 67 | 5.00e-01 |
| GO:BP | GO:0003300 | cardiac muscle hypertrophy | 2 | 72 | 5.00e-01 |
| GO:BP | GO:0071702 | organic substance transport | 2 | 2116 | 5.00e-01 |
| GO:BP | GO:0014065 | phosphatidylinositol 3-kinase signaling | 2 | 100 | 5.00e-01 |
| GO:BP | GO:0060284 | regulation of cell development | 10 | 605 | 5.00e-01 |
| GO:BP | GO:1990000 | amyloid fibril formation | 1 | 35 | 5.00e-01 |
| GO:BP | GO:0034381 | plasma lipoprotein particle clearance | 1 | 25 | 5.00e-01 |
| GO:BP | GO:0007498 | mesoderm development | 2 | 89 | 5.01e-01 |
| GO:BP | GO:0090075 | relaxation of muscle | 1 | 29 | 5.01e-01 |
| GO:BP | GO:0045787 | positive regulation of cell cycle | 4 | 274 | 5.01e-01 |
| GO:BP | GO:0010232 | vascular transport | 1 | 72 | 5.01e-01 |
| GO:BP | GO:0086010 | membrane depolarization during action potential | 1 | 28 | 5.01e-01 |
| GO:BP | GO:1990830 | cellular response to leukemia inhibitory factor | 2 | 84 | 5.01e-01 |
| GO:BP | GO:0050657 | nucleic acid transport | 1 | 144 | 5.01e-01 |
| GO:BP | GO:0010633 | negative regulation of epithelial cell migration | 2 | 53 | 5.01e-01 |
| GO:BP | GO:0048598 | embryonic morphogenesis | 1 | 440 | 5.01e-01 |
| GO:BP | GO:0050658 | RNA transport | 1 | 144 | 5.01e-01 |
| GO:BP | GO:0150104 | transport across blood-brain barrier | 1 | 72 | 5.01e-01 |
| GO:BP | GO:0032211 | negative regulation of telomere maintenance via telomerase | 1 | 19 | 5.01e-01 |
| GO:BP | GO:0048483 | autonomic nervous system development | 1 | 28 | 5.01e-01 |
| GO:BP | GO:0006865 | amino acid transport | 2 | 102 | 5.01e-01 |
| GO:BP | GO:0032368 | regulation of lipid transport | 2 | 92 | 5.02e-01 |
| GO:BP | GO:0006694 | steroid biosynthetic process | 1 | 121 | 5.02e-01 |
| GO:BP | GO:0014888 | striated muscle adaptation | 1 | 40 | 5.02e-01 |
| GO:BP | GO:0042596 | fear response | 1 | 32 | 5.02e-01 |
| GO:BP | GO:0035493 | SNARE complex assembly | 1 | 22 | 5.02e-01 |
| GO:BP | GO:0031076 | embryonic camera-type eye development | 1 | 28 | 5.02e-01 |
| GO:BP | GO:0032943 | mononuclear cell proliferation | 2 | 168 | 5.02e-01 |
| GO:BP | GO:1902774 | late endosome to lysosome transport | 1 | 20 | 5.02e-01 |
| GO:BP | GO:0090305 | nucleic acid phosphodiester bond hydrolysis | 1 | 211 | 5.02e-01 |
| GO:BP | GO:0006468 | protein phosphorylation | 19 | 1167 | 5.02e-01 |
| GO:BP | GO:0006458 | ‘de novo’ protein folding | 1 | 39 | 5.02e-01 |
| GO:BP | GO:0006921 | cellular component disassembly involved in execution phase of apoptosis | 1 | 22 | 5.02e-01 |
| GO:BP | GO:0042102 | positive regulation of T cell proliferation | 1 | 47 | 5.02e-01 |
| GO:BP | GO:0045773 | positive regulation of axon extension | 1 | 33 | 5.02e-01 |
| GO:BP | GO:1903578 | regulation of ATP metabolic process | 1 | 22 | 5.03e-01 |
| GO:BP | GO:1990823 | response to leukemia inhibitory factor | 2 | 85 | 5.03e-01 |
| GO:BP | GO:0008277 | regulation of G protein-coupled receptor signaling pathway | 1 | 94 | 5.03e-01 |
| GO:BP | GO:0010965 | regulation of mitotic sister chromatid separation | 1 | 58 | 5.03e-01 |
| GO:BP | GO:0097503 | sialylation | 1 | 18 | 5.03e-01 |
| GO:BP | GO:0051236 | establishment of RNA localization | 1 | 147 | 5.03e-01 |
| GO:BP | GO:0006402 | mRNA catabolic process | 1 | 216 | 5.03e-01 |
| GO:BP | GO:0002686 | negative regulation of leukocyte migration | 1 | 30 | 5.05e-01 |
| GO:BP | GO:0035883 | enteroendocrine cell differentiation | 1 | 24 | 5.05e-01 |
| GO:BP | GO:0032722 | positive regulation of chemokine production | 1 | 32 | 5.05e-01 |
| GO:BP | GO:0002684 | positive regulation of immune system process | 6 | 581 | 5.05e-01 |
| GO:BP | GO:0035249 | synaptic transmission, glutamatergic | 3 | 64 | 5.05e-01 |
| GO:BP | GO:0016075 | rRNA catabolic process | 1 | 19 | 5.05e-01 |
| GO:BP | GO:1901861 | regulation of muscle tissue development | 1 | 35 | 5.05e-01 |
| GO:BP | GO:0035308 | negative regulation of protein dephosphorylation | 1 | 28 | 5.05e-01 |
| GO:BP | GO:1902105 | regulation of leukocyte differentiation | 4 | 199 | 5.05e-01 |
| GO:BP | GO:0061061 | muscle structure development | 9 | 546 | 5.05e-01 |
| GO:BP | GO:0043408 | regulation of MAPK cascade | 7 | 475 | 5.05e-01 |
| GO:BP | GO:0051168 | nuclear export | 1 | 150 | 5.05e-01 |
| GO:BP | GO:0044093 | positive regulation of molecular function | 17 | 1149 | 5.05e-01 |
| GO:BP | GO:0007212 | dopamine receptor signaling pathway | 1 | 27 | 5.05e-01 |
| GO:BP | GO:0044092 | negative regulation of molecular function | 1 | 755 | 5.05e-01 |
| GO:BP | GO:0097345 | mitochondrial outer membrane permeabilization | 1 | 35 | 5.05e-01 |
| GO:BP | GO:0009084 | glutamine family amino acid biosynthetic process | 1 | 16 | 5.05e-01 |
| GO:BP | GO:0031668 | cellular response to extracellular stimulus | 3 | 219 | 5.06e-01 |
| GO:BP | GO:0048660 | regulation of smooth muscle cell proliferation | 2 | 106 | 5.06e-01 |
| GO:BP | GO:0099003 | vesicle-mediated transport in synapse | 1 | 180 | 5.07e-01 |
| GO:BP | GO:0030163 | protein catabolic process | 12 | 901 | 5.07e-01 |
| GO:BP | GO:0048670 | regulation of collateral sprouting | 1 | 18 | 5.07e-01 |
| GO:BP | GO:0006412 | translation | 2 | 646 | 5.07e-01 |
| GO:BP | GO:0014823 | response to activity | 1 | 46 | 5.08e-01 |
| GO:BP | GO:2001238 | positive regulation of extrinsic apoptotic signaling pathway | 1 | 40 | 5.08e-01 |
| GO:BP | GO:1903201 | regulation of oxidative stress-induced cell death | 1 | 56 | 5.08e-01 |
| GO:BP | GO:0050892 | intestinal absorption | 1 | 22 | 5.08e-01 |
| GO:BP | GO:0018193 | peptidyl-amino acid modification | 12 | 963 | 5.08e-01 |
| GO:BP | GO:0032069 | regulation of nuclease activity | 1 | 17 | 5.08e-01 |
| GO:BP | GO:0014897 | striated muscle hypertrophy | 2 | 73 | 5.10e-01 |
| GO:BP | GO:0022407 | regulation of cell-cell adhesion | 4 | 295 | 5.10e-01 |
| GO:BP | GO:0051784 | negative regulation of nuclear division | 1 | 57 | 5.10e-01 |
| GO:BP | GO:0031323 | regulation of cellular metabolic process | 3 | 4174 | 5.11e-01 |
| GO:BP | GO:0010468 | regulation of gene expression | 3 | 3580 | 5.11e-01 |
| GO:BP | GO:0050867 | positive regulation of cell activation | 3 | 229 | 5.11e-01 |
| GO:BP | GO:0045785 | positive regulation of cell adhesion | 4 | 320 | 5.11e-01 |
| GO:BP | GO:0070482 | response to oxygen levels | 6 | 272 | 5.11e-01 |
| GO:BP | GO:0061180 | mammary gland epithelium development | 1 | 57 | 5.11e-01 |
| GO:BP | GO:0046483 | heterocycle metabolic process | 6 | 4570 | 5.12e-01 |
| GO:BP | GO:0039694 | viral RNA genome replication | 1 | 27 | 5.12e-01 |
| GO:BP | GO:0048545 | response to steroid hormone | 5 | 245 | 5.12e-01 |
| GO:BP | GO:0035051 | cardiocyte differentiation | 3 | 129 | 5.13e-01 |
| GO:BP | GO:0046850 | regulation of bone remodeling | 1 | 30 | 5.13e-01 |
| GO:BP | GO:0021761 | limbic system development | 3 | 81 | 5.13e-01 |
| GO:BP | GO:0000902 | cell morphogenesis | 3 | 761 | 5.13e-01 |
| GO:BP | GO:0140467 | integrated stress response signaling | 1 | 35 | 5.13e-01 |
| GO:BP | GO:0140353 | lipid export from cell | 1 | 28 | 5.13e-01 |
| GO:BP | GO:1904375 | regulation of protein localization to cell periphery | 1 | 113 | 5.13e-01 |
| GO:BP | GO:0001881 | receptor recycling | 1 | 38 | 5.13e-01 |
| GO:BP | GO:0051306 | mitotic sister chromatid separation | 1 | 61 | 5.13e-01 |
| GO:BP | GO:0042127 | regulation of cell population proliferation | 12 | 1147 | 5.13e-01 |
| GO:BP | GO:0016032 | viral process | 7 | 344 | 5.14e-01 |
| GO:BP | GO:0048260 | positive regulation of receptor-mediated endocytosis | 1 | 42 | 5.14e-01 |
| GO:BP | GO:0002832 | negative regulation of response to biotic stimulus | 1 | 88 | 5.14e-01 |
| GO:BP | GO:0051569 | regulation of histone H3-K4 methylation | 1 | 26 | 5.14e-01 |
| GO:BP | GO:1905820 | positive regulation of chromosome separation | 1 | 28 | 5.14e-01 |
| GO:BP | GO:0039702 | viral budding via host ESCRT complex | 1 | 22 | 5.15e-01 |
| GO:BP | GO:0045742 | positive regulation of epidermal growth factor receptor signaling pathway | 1 | 26 | 5.16e-01 |
| GO:BP | GO:0007263 | nitric oxide mediated signal transduction | 1 | 20 | 5.16e-01 |
| GO:BP | GO:0048659 | smooth muscle cell proliferation | 2 | 110 | 5.16e-01 |
| GO:BP | GO:0002090 | regulation of receptor internalization | 2 | 49 | 5.16e-01 |
| GO:BP | GO:0098703 | calcium ion import across plasma membrane | 1 | 23 | 5.17e-01 |
| GO:BP | GO:2000758 | positive regulation of peptidyl-lysine acetylation | 1 | 31 | 5.17e-01 |
| GO:BP | GO:0062125 | regulation of mitochondrial gene expression | 1 | 31 | 5.17e-01 |
| GO:BP | GO:0014896 | muscle hypertrophy | 2 | 74 | 5.17e-01 |
| GO:BP | GO:0007626 | locomotory behavior | 1 | 138 | 5.17e-01 |
| GO:BP | GO:0045943 | positive regulation of transcription by RNA polymerase I | 1 | 34 | 5.17e-01 |
| GO:BP | GO:0010660 | regulation of muscle cell apoptotic process | 1 | 56 | 5.17e-01 |
| GO:BP | GO:0070830 | bicellular tight junction assembly | 1 | 43 | 5.17e-01 |
| GO:BP | GO:0006874 | intracellular calcium ion homeostasis | 1 | 200 | 5.17e-01 |
| GO:BP | GO:0033005 | positive regulation of mast cell activation | 1 | 13 | 5.17e-01 |
| GO:BP | GO:1903409 | reactive oxygen species biosynthetic process | 1 | 36 | 5.17e-01 |
| GO:BP | GO:0044091 | membrane biogenesis | 2 | 58 | 5.17e-01 |
| GO:BP | GO:0031175 | neuron projection development | 3 | 780 | 5.17e-01 |
| GO:BP | GO:0032892 | positive regulation of organic acid transport | 1 | 27 | 5.17e-01 |
| GO:BP | GO:0002065 | columnar/cuboidal epithelial cell differentiation | 2 | 80 | 5.17e-01 |
| GO:BP | GO:0001885 | endothelial cell development | 1 | 53 | 5.17e-01 |
| GO:BP | GO:0032881 | regulation of polysaccharide metabolic process | 1 | 34 | 5.17e-01 |
| GO:BP | GO:0006725 | cellular aromatic compound metabolic process | 6 | 4596 | 5.17e-01 |
| GO:BP | GO:0046580 | negative regulation of Ras protein signal transduction | 1 | 47 | 5.17e-01 |
| GO:BP | GO:0034243 | regulation of transcription elongation by RNA polymerase II | 2 | 85 | 5.17e-01 |
| GO:BP | GO:1901652 | response to peptide | 11 | 377 | 5.18e-01 |
| GO:BP | GO:0042274 | ribosomal small subunit biogenesis | 2 | 79 | 5.19e-01 |
| GO:BP | GO:0030030 | cell projection organization | 6 | 1233 | 5.19e-01 |
| GO:BP | GO:0035239 | tube morphogenesis | 11 | 663 | 5.19e-01 |
| GO:BP | GO:0033036 | macromolecule localization | 2 | 2450 | 5.19e-01 |
| GO:BP | GO:0070050 | neuron cellular homeostasis | 1 | 46 | 5.20e-01 |
| GO:BP | GO:0002573 | myeloid leukocyte differentiation | 3 | 151 | 5.20e-01 |
| GO:BP | GO:0043043 | peptide biosynthetic process | 2 | 666 | 5.20e-01 |
| GO:BP | GO:1902110 | positive regulation of mitochondrial membrane permeability involved in apoptotic process | 1 | 38 | 5.21e-01 |
| GO:BP | GO:0097305 | response to alcohol | 3 | 159 | 5.21e-01 |
| GO:BP | GO:0032309 | icosanoid secretion | 1 | 18 | 5.22e-01 |
| GO:BP | GO:0036211 | protein modification process | 33 | 2901 | 5.22e-01 |
| GO:BP | GO:0051965 | positive regulation of synapse assembly | 2 | 44 | 5.22e-01 |
| GO:BP | GO:0022038 | corpus callosum development | 1 | 20 | 5.22e-01 |
| GO:BP | GO:0010762 | regulation of fibroblast migration | 1 | 37 | 5.22e-01 |
| GO:BP | GO:0006220 | pyrimidine nucleotide metabolic process | 1 | 46 | 5.22e-01 |
| GO:BP | GO:0045913 | positive regulation of carbohydrate metabolic process | 1 | 60 | 5.22e-01 |
| GO:BP | GO:0051603 | proteolysis involved in protein catabolic process | 7 | 706 | 5.22e-01 |
| GO:BP | GO:0035089 | establishment of apical/basal cell polarity | 1 | 18 | 5.22e-01 |
| GO:BP | GO:0045664 | regulation of neuron differentiation | 1 | 137 | 5.23e-01 |
| GO:BP | GO:0071300 | cellular response to retinoic acid | 1 | 49 | 5.23e-01 |
| GO:BP | GO:0001558 | regulation of cell growth | 3 | 357 | 5.23e-01 |
| GO:BP | GO:0050858 | negative regulation of antigen receptor-mediated signaling pathway | 1 | 20 | 5.23e-01 |
| GO:BP | GO:0014009 | glial cell proliferation | 1 | 40 | 5.24e-01 |
| GO:BP | GO:0043032 | positive regulation of macrophage activation | 1 | 12 | 5.25e-01 |
| GO:BP | GO:0051247 | positive regulation of protein metabolic process | 14 | 1123 | 5.25e-01 |
| GO:BP | GO:0008284 | positive regulation of cell population proliferation | 5 | 631 | 5.25e-01 |
| GO:BP | GO:0098586 | cellular response to virus | 1 | 40 | 5.25e-01 |
| GO:BP | GO:0072006 | nephron development | 1 | 117 | 5.25e-01 |
| GO:BP | GO:0007266 | Rho protein signal transduction | 1 | 114 | 5.25e-01 |
| GO:BP | GO:0038093 | Fc receptor signaling pathway | 1 | 36 | 5.25e-01 |
| GO:BP | GO:2001252 | positive regulation of chromosome organization | 1 | 103 | 5.26e-01 |
| GO:BP | GO:1901186 | positive regulation of ERBB signaling pathway | 1 | 28 | 5.27e-01 |
| GO:BP | GO:0008156 | negative regulation of DNA replication | 1 | 19 | 5.27e-01 |
| GO:BP | GO:0032924 | activin receptor signaling pathway | 1 | 34 | 5.27e-01 |
| GO:BP | GO:0048536 | spleen development | 1 | 28 | 5.27e-01 |
| GO:BP | GO:0034698 | response to gonadotropin | 1 | 19 | 5.27e-01 |
| GO:BP | GO:0051171 | regulation of nitrogen compound metabolic process | 3 | 4292 | 5.27e-01 |
| GO:BP | GO:0070296 | sarcoplasmic reticulum calcium ion transport | 1 | 31 | 5.28e-01 |
| GO:BP | GO:0050680 | negative regulation of epithelial cell proliferation | 2 | 111 | 5.28e-01 |
| GO:BP | GO:0051099 | positive regulation of binding | 4 | 150 | 5.31e-01 |
| GO:BP | GO:0006611 | protein export from nucleus | 1 | 55 | 5.31e-01 |
| GO:BP | GO:0022602 | ovulation cycle process | 1 | 37 | 5.32e-01 |
| GO:BP | GO:1900273 | positive regulation of long-term synaptic potentiation | 1 | 19 | 5.32e-01 |
| GO:BP | GO:0046058 | cAMP metabolic process | 1 | 19 | 5.32e-01 |
| GO:BP | GO:0015804 | neutral amino acid transport | 1 | 43 | 5.32e-01 |
| GO:BP | GO:0045922 | negative regulation of fatty acid metabolic process | 1 | 25 | 5.32e-01 |
| GO:BP | GO:0009250 | glucan biosynthetic process | 1 | 39 | 5.32e-01 |
| GO:BP | GO:0003151 | outflow tract morphogenesis | 1 | 68 | 5.32e-01 |
| GO:BP | GO:0034205 | amyloid-beta formation | 1 | 41 | 5.32e-01 |
| GO:BP | GO:0005978 | glycogen biosynthetic process | 1 | 39 | 5.32e-01 |
| GO:BP | GO:1902686 | mitochondrial outer membrane permeabilization involved in programmed cell death | 1 | 40 | 5.32e-01 |
| GO:BP | GO:0006259 | DNA metabolic process | 2 | 884 | 5.32e-01 |
| GO:BP | GO:0044843 | cell cycle G1/S phase transition | 3 | 229 | 5.32e-01 |
| GO:BP | GO:0007281 | germ cell development | 2 | 187 | 5.32e-01 |
| GO:BP | GO:0050792 | regulation of viral process | 1 | 122 | 5.33e-01 |
| GO:BP | GO:0010657 | muscle cell apoptotic process | 1 | 60 | 5.33e-01 |
| GO:BP | GO:0071902 | positive regulation of protein serine/threonine kinase activity | 3 | 135 | 5.33e-01 |
| GO:BP | GO:1902808 | positive regulation of cell cycle G1/S phase transition | 1 | 52 | 5.34e-01 |
| GO:BP | GO:0050832 | defense response to fungus | 1 | 14 | 5.34e-01 |
| GO:BP | GO:0120192 | tight junction assembly | 1 | 47 | 5.34e-01 |
| GO:BP | GO:0055074 | calcium ion homeostasis | 1 | 214 | 5.34e-01 |
| GO:BP | GO:0006898 | receptor-mediated endocytosis | 1 | 196 | 5.34e-01 |
| GO:BP | GO:0071383 | cellular response to steroid hormone stimulus | 4 | 166 | 5.34e-01 |
| GO:BP | GO:0051648 | vesicle localization | 5 | 192 | 5.34e-01 |
| GO:BP | GO:0038066 | p38MAPK cascade | 1 | 43 | 5.35e-01 |
| GO:BP | GO:0045088 | regulation of innate immune response | 4 | 232 | 5.35e-01 |
| GO:BP | GO:0033622 | integrin activation | 1 | 18 | 5.35e-01 |
| GO:BP | GO:0097190 | apoptotic signaling pathway | 6 | 494 | 5.35e-01 |
| GO:BP | GO:0006778 | porphyrin-containing compound metabolic process | 1 | 44 | 5.35e-01 |
| GO:BP | GO:0046471 | phosphatidylglycerol metabolic process | 1 | 23 | 5.35e-01 |
| GO:BP | GO:2000114 | regulation of establishment of cell polarity | 1 | 22 | 5.35e-01 |
| GO:BP | GO:0035456 | response to interferon-beta | 1 | 22 | 5.35e-01 |
| GO:BP | GO:0048145 | regulation of fibroblast proliferation | 2 | 77 | 5.35e-01 |
| GO:BP | GO:0031349 | positive regulation of defense response | 5 | 251 | 5.35e-01 |
| GO:BP | GO:0051146 | striated muscle cell differentiation | 5 | 233 | 5.35e-01 |
| GO:BP | GO:0043523 | regulation of neuron apoptotic process | 3 | 167 | 5.35e-01 |
| GO:BP | GO:0048168 | regulation of neuronal synaptic plasticity | 1 | 42 | 5.36e-01 |
| GO:BP | GO:0035306 | positive regulation of dephosphorylation | 1 | 47 | 5.36e-01 |
| GO:BP | GO:0015909 | long-chain fatty acid transport | 2 | 38 | 5.36e-01 |
| GO:BP | GO:0070661 | leukocyte proliferation | 2 | 188 | 5.36e-01 |
| GO:BP | GO:0032613 | interleukin-10 production | 1 | 24 | 5.36e-01 |
| GO:BP | GO:0043069 | negative regulation of programmed cell death | 9 | 678 | 5.36e-01 |
| GO:BP | GO:0032653 | regulation of interleukin-10 production | 1 | 24 | 5.36e-01 |
| GO:BP | GO:0032365 | intracellular lipid transport | 1 | 42 | 5.36e-01 |
| GO:BP | GO:1903320 | regulation of protein modification by small protein conjugation or removal | 4 | 232 | 5.36e-01 |
| GO:BP | GO:0023061 | signal release | 5 | 321 | 5.36e-01 |
| GO:BP | GO:0106027 | neuron projection organization | 2 | 76 | 5.36e-01 |
| GO:BP | GO:0050714 | positive regulation of protein secretion | 2 | 100 | 5.36e-01 |
| GO:BP | GO:1903311 | regulation of mRNA metabolic process | 2 | 267 | 5.37e-01 |
| GO:BP | GO:0002285 | lymphocyte activation involved in immune response | 5 | 111 | 5.37e-01 |
| GO:BP | GO:0070887 | cellular response to chemical stimulus | 1 | 1869 | 5.37e-01 |
| GO:BP | GO:0006622 | protein targeting to lysosome | 1 | 28 | 5.37e-01 |
| GO:BP | GO:0002532 | production of molecular mediator involved in inflammatory response | 1 | 49 | 5.37e-01 |
| GO:BP | GO:0043954 | cellular component maintenance | 1 | 59 | 5.37e-01 |
| GO:BP | GO:0009451 | RNA modification | 1 | 162 | 5.37e-01 |
| GO:BP | GO:0061515 | myeloid cell development | 1 | 57 | 5.37e-01 |
| GO:BP | GO:0033365 | protein localization to organelle | 1 | 859 | 5.37e-01 |
| GO:BP | GO:1900407 | regulation of cellular response to oxidative stress | 1 | 67 | 5.37e-01 |
| GO:BP | GO:0042254 | ribosome biogenesis | 7 | 301 | 5.38e-01 |
| GO:BP | GO:0045761 | regulation of adenylate cyclase activity | 1 | 32 | 5.38e-01 |
| GO:BP | GO:0030182 | neuron differentiation | 10 | 1061 | 5.38e-01 |
| GO:BP | GO:0032511 | late endosome to vacuole transport via multivesicular body sorting pathway | 1 | 27 | 5.39e-01 |
| GO:BP | GO:0061640 | cytoskeleton-dependent cytokinesis | 2 | 104 | 5.39e-01 |
| GO:BP | GO:0014032 | neural crest cell development | 1 | 71 | 5.40e-01 |
| GO:BP | GO:0030859 | polarized epithelial cell differentiation | 1 | 19 | 5.40e-01 |
| GO:BP | GO:0043297 | apical junction assembly | 1 | 51 | 5.40e-01 |
| GO:BP | GO:0098884 | postsynaptic neurotransmitter receptor internalization | 1 | 17 | 5.40e-01 |
| GO:BP | GO:0061162 | establishment of monopolar cell polarity | 1 | 20 | 5.40e-01 |
| GO:BP | GO:0007088 | regulation of mitotic nuclear division | 2 | 100 | 5.40e-01 |
| GO:BP | GO:0140239 | postsynaptic endocytosis | 1 | 17 | 5.40e-01 |
| GO:BP | GO:1902108 | regulation of mitochondrial membrane permeability involved in apoptotic process | 1 | 42 | 5.40e-01 |
| GO:BP | GO:0030901 | midbrain development | 1 | 69 | 5.40e-01 |
| GO:BP | GO:0002431 | Fc receptor mediated stimulatory signaling pathway | 1 | 24 | 5.40e-01 |
| GO:BP | GO:0051289 | protein homotetramerization | 1 | 42 | 5.40e-01 |
| GO:BP | GO:0021533 | cell differentiation in hindbrain | 1 | 18 | 5.40e-01 |
| GO:BP | GO:0007586 | digestion | 2 | 60 | 5.41e-01 |
| GO:BP | GO:0000466 | maturation of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 1 | 25 | 5.41e-01 |
| GO:BP | GO:0006401 | RNA catabolic process | 1 | 256 | 5.41e-01 |
| GO:BP | GO:0018105 | peptidyl-serine phosphorylation | 4 | 247 | 5.41e-01 |
| GO:BP | GO:0043410 | positive regulation of MAPK cascade | 5 | 317 | 5.41e-01 |
| GO:BP | GO:0050796 | regulation of insulin secretion | 2 | 116 | 5.41e-01 |
| GO:BP | GO:0008347 | glial cell migration | 1 | 47 | 5.41e-01 |
| GO:BP | GO:0032615 | interleukin-12 production | 1 | 29 | 5.41e-01 |
| GO:BP | GO:0032655 | regulation of interleukin-12 production | 1 | 29 | 5.41e-01 |
| GO:BP | GO:0051058 | negative regulation of small GTPase mediated signal transduction | 1 | 53 | 5.41e-01 |
| GO:BP | GO:0019220 | regulation of phosphate metabolic process | 21 | 993 | 5.42e-01 |
| GO:BP | GO:0048024 | regulation of mRNA splicing, via spliceosome | 1 | 96 | 5.42e-01 |
| GO:BP | GO:0051963 | regulation of synapse assembly | 3 | 83 | 5.42e-01 |
| GO:BP | GO:0032024 | positive regulation of insulin secretion | 1 | 56 | 5.42e-01 |
| GO:BP | GO:0080090 | regulation of primary metabolic process | 3 | 4417 | 5.42e-01 |
| GO:BP | GO:0051174 | regulation of phosphorus metabolic process | 21 | 994 | 5.43e-01 |
| GO:BP | GO:0071407 | cellular response to organic cyclic compound | 3 | 414 | 5.43e-01 |
| GO:BP | GO:0006403 | RNA localization | 1 | 182 | 5.43e-01 |
| GO:BP | GO:0035794 | positive regulation of mitochondrial membrane permeability | 1 | 43 | 5.43e-01 |
| GO:BP | GO:0006606 | protein import into nucleus | 2 | 147 | 5.43e-01 |
| GO:BP | GO:0032355 | response to estradiol | 1 | 83 | 5.44e-01 |
| GO:BP | GO:0048066 | developmental pigmentation | 1 | 36 | 5.44e-01 |
| GO:BP | GO:0050881 | musculoskeletal movement | 1 | 41 | 5.44e-01 |
| GO:BP | GO:0008360 | regulation of cell shape | 1 | 126 | 5.44e-01 |
| GO:BP | GO:0032387 | negative regulation of intracellular transport | 1 | 49 | 5.44e-01 |
| GO:BP | GO:0032481 | positive regulation of type I interferon production | 1 | 45 | 5.44e-01 |
| GO:BP | GO:0010812 | negative regulation of cell-substrate adhesion | 1 | 44 | 5.44e-01 |
| GO:BP | GO:0070227 | lymphocyte apoptotic process | 1 | 56 | 5.44e-01 |
| GO:BP | GO:0031663 | lipopolysaccharide-mediated signaling pathway | 1 | 36 | 5.44e-01 |
| GO:BP | GO:0031330 | negative regulation of cellular catabolic process | 4 | 165 | 5.44e-01 |
| GO:BP | GO:1901360 | organic cyclic compound metabolic process | 6 | 4747 | 5.45e-01 |
| GO:BP | GO:0051302 | regulation of cell division | 4 | 145 | 5.45e-01 |
| GO:BP | GO:0046755 | viral budding | 1 | 26 | 5.45e-01 |
| GO:BP | GO:0032414 | positive regulation of ion transmembrane transporter activity | 3 | 85 | 5.45e-01 |
| GO:BP | GO:0048193 | Golgi vesicle transport | 7 | 285 | 5.47e-01 |
| GO:BP | GO:0006096 | glycolytic process | 1 | 70 | 5.47e-01 |
| GO:BP | GO:1901653 | cellular response to peptide | 8 | 287 | 5.48e-01 |
| GO:BP | GO:0002931 | response to ischemia | 1 | 46 | 5.48e-01 |
| GO:BP | GO:0061912 | selective autophagy | 2 | 90 | 5.48e-01 |
| GO:BP | GO:0050879 | multicellular organismal movement | 1 | 41 | 5.48e-01 |
| GO:BP | GO:0019637 | organophosphate metabolic process | 16 | 784 | 5.48e-01 |
| GO:BP | GO:0120193 | tight junction organization | 1 | 52 | 5.48e-01 |
| GO:BP | GO:0006302 | double-strand break repair | 2 | 271 | 5.48e-01 |
| GO:BP | GO:0043065 | positive regulation of apoptotic process | 6 | 393 | 5.48e-01 |
| GO:BP | GO:0061339 | establishment or maintenance of monopolar cell polarity | 1 | 20 | 5.48e-01 |
| GO:BP | GO:0042306 | regulation of protein import into nucleus | 1 | 51 | 5.48e-01 |
| GO:BP | GO:1902369 | negative regulation of RNA catabolic process | 2 | 69 | 5.48e-01 |
| GO:BP | GO:0030217 | T cell differentiation | 2 | 185 | 5.49e-01 |
| GO:BP | GO:0043576 | regulation of respiratory gaseous exchange | 1 | 15 | 5.49e-01 |
| GO:BP | GO:0001666 | response to hypoxia | 5 | 237 | 5.50e-01 |
| GO:BP | GO:0035295 | tube development | 12 | 821 | 5.50e-01 |
| GO:BP | GO:0019725 | cellular homeostasis | 7 | 569 | 5.50e-01 |
| GO:BP | GO:0090307 | mitotic spindle assembly | 1 | 70 | 5.50e-01 |
| GO:BP | GO:0000910 | cytokinesis | 4 | 164 | 5.50e-01 |
| GO:BP | GO:0032956 | regulation of actin cytoskeleton organization | 3 | 299 | 5.50e-01 |
| GO:BP | GO:0043931 | ossification involved in bone maturation | 1 | 17 | 5.50e-01 |
| GO:BP | GO:0016242 | negative regulation of macroautophagy | 1 | 34 | 5.51e-01 |
| GO:BP | GO:0001707 | mesoderm formation | 1 | 53 | 5.51e-01 |
| GO:BP | GO:0043067 | regulation of programmed cell death | 14 | 1111 | 5.52e-01 |
| GO:BP | GO:0015800 | acidic amino acid transport | 1 | 39 | 5.52e-01 |
| GO:BP | GO:0006487 | protein N-linked glycosylation | 2 | 65 | 5.52e-01 |
| GO:BP | GO:0048207 | vesicle targeting, rough ER to cis-Golgi | 1 | 24 | 5.52e-01 |
| GO:BP | GO:0048208 | COPII vesicle coating | 1 | 24 | 5.52e-01 |
| GO:BP | GO:0090407 | organophosphate biosynthetic process | 10 | 506 | 5.52e-01 |
| GO:BP | GO:0051054 | positive regulation of DNA metabolic process | 2 | 265 | 5.52e-01 |
| GO:BP | GO:0030162 | regulation of proteolysis | 7 | 535 | 5.53e-01 |
| GO:BP | GO:0050678 | regulation of epithelial cell proliferation | 5 | 276 | 5.53e-01 |
| GO:BP | GO:0051170 | import into nucleus | 2 | 152 | 5.53e-01 |
| GO:BP | GO:0042445 | hormone metabolic process | 2 | 133 | 5.53e-01 |
| GO:BP | GO:0001654 | eye development | 7 | 272 | 5.54e-01 |
| GO:BP | GO:0090090 | negative regulation of canonical Wnt signaling pathway | 2 | 114 | 5.54e-01 |
| GO:BP | GO:0048565 | digestive tract development | 2 | 92 | 5.54e-01 |
| GO:BP | GO:0008038 | neuron recognition | 1 | 39 | 5.54e-01 |
| GO:BP | GO:0048864 | stem cell development | 1 | 76 | 5.54e-01 |
| GO:BP | GO:0001573 | ganglioside metabolic process | 1 | 22 | 5.54e-01 |
| GO:BP | GO:0030335 | positive regulation of cell migration | 7 | 407 | 5.54e-01 |
| GO:BP | GO:0048468 | cell development | 29 | 1963 | 5.54e-01 |
| GO:BP | GO:0006821 | chloride transport | 1 | 58 | 5.55e-01 |
| GO:BP | GO:1904705 | regulation of vascular associated smooth muscle cell proliferation | 1 | 53 | 5.55e-01 |
| GO:BP | GO:0045840 | positive regulation of mitotic nuclear division | 1 | 29 | 5.55e-01 |
| GO:BP | GO:0061098 | positive regulation of protein tyrosine kinase activity | 1 | 33 | 5.55e-01 |
| GO:BP | GO:0050764 | regulation of phagocytosis | 2 | 57 | 5.55e-01 |
| GO:BP | GO:0070098 | chemokine-mediated signaling pathway | 1 | 28 | 5.56e-01 |
| GO:BP | GO:0007368 | determination of left/right symmetry | 2 | 97 | 5.56e-01 |
| GO:BP | GO:0045214 | sarcomere organization | 1 | 43 | 5.56e-01 |
| GO:BP | GO:0001775 | cell activation | 6 | 655 | 5.56e-01 |
| GO:BP | GO:0033157 | regulation of intracellular protein transport | 3 | 197 | 5.56e-01 |
| GO:BP | GO:0051147 | regulation of muscle cell differentiation | 2 | 118 | 5.56e-01 |
| GO:BP | GO:1903421 | regulation of synaptic vesicle recycling | 1 | 23 | 5.56e-01 |
| GO:BP | GO:0001892 | embryonic placenta development | 1 | 71 | 5.56e-01 |
| GO:BP | GO:0045830 | positive regulation of isotype switching | 1 | 19 | 5.56e-01 |
| GO:BP | GO:0046434 | organophosphate catabolic process | 2 | 113 | 5.56e-01 |
| GO:BP | GO:0048332 | mesoderm morphogenesis | 1 | 55 | 5.56e-01 |
| GO:BP | GO:2000311 | regulation of AMPA receptor activity | 1 | 15 | 5.56e-01 |
| GO:BP | GO:0070199 | establishment of protein localization to chromosome | 1 | 25 | 5.56e-01 |
| GO:BP | GO:0051209 | release of sequestered calcium ion into cytosol | 2 | 82 | 5.56e-01 |
| GO:BP | GO:2000379 | positive regulation of reactive oxygen species metabolic process | 1 | 46 | 5.57e-01 |
| GO:BP | GO:0051223 | regulation of protein transport | 6 | 404 | 5.57e-01 |
| GO:BP | GO:0009306 | protein secretion | 4 | 262 | 5.57e-01 |
| GO:BP | GO:0030199 | collagen fibril organization | 1 | 56 | 5.57e-01 |
| GO:BP | GO:0009581 | detection of external stimulus | 1 | 67 | 5.57e-01 |
| GO:BP | GO:1902882 | regulation of response to oxidative stress | 1 | 76 | 5.58e-01 |
| GO:BP | GO:0036473 | cell death in response to oxidative stress | 1 | 75 | 5.58e-01 |
| GO:BP | GO:0009065 | glutamine family amino acid catabolic process | 1 | 20 | 5.58e-01 |
| GO:BP | GO:0035592 | establishment of protein localization to extracellular region | 4 | 262 | 5.58e-01 |
| GO:BP | GO:0051094 | positive regulation of developmental process | 9 | 957 | 5.58e-01 |
| GO:BP | GO:0009894 | regulation of catabolic process | 11 | 875 | 5.58e-01 |
| GO:BP | GO:0045576 | mast cell activation | 2 | 35 | 5.58e-01 |
| GO:BP | GO:0050728 | negative regulation of inflammatory response | 1 | 87 | 5.58e-01 |
| GO:BP | GO:0150063 | visual system development | 5 | 273 | 5.58e-01 |
| GO:BP | GO:0043302 | positive regulation of leukocyte degranulation | 1 | 15 | 5.58e-01 |
| GO:BP | GO:0016070 | RNA metabolic process | 5 | 3600 | 5.58e-01 |
| GO:BP | GO:0051283 | negative regulation of sequestering of calcium ion | 2 | 83 | 5.58e-01 |
| GO:BP | GO:0031018 | endocrine pancreas development | 1 | 32 | 5.59e-01 |
| GO:BP | GO:1905710 | positive regulation of membrane permeability | 1 | 45 | 5.59e-01 |
| GO:BP | GO:1905952 | regulation of lipid localization | 2 | 112 | 5.59e-01 |
| GO:BP | GO:0006399 | tRNA metabolic process | 1 | 186 | 5.59e-01 |
| GO:BP | GO:0014072 | response to isoquinoline alkaloid | 1 | 16 | 5.59e-01 |
| GO:BP | GO:0045926 | negative regulation of growth | 2 | 206 | 5.59e-01 |
| GO:BP | GO:0035459 | vesicle cargo loading | 1 | 27 | 5.59e-01 |
| GO:BP | GO:0043278 | response to morphine | 1 | 16 | 5.59e-01 |
| GO:BP | GO:0019934 | cGMP-mediated signaling | 1 | 22 | 5.59e-01 |
| GO:BP | GO:0050768 | negative regulation of neurogenesis | 2 | 113 | 5.59e-01 |
| GO:BP | GO:0032101 | regulation of response to external stimulus | 5 | 662 | 5.59e-01 |
| GO:BP | GO:1990874 | vascular associated smooth muscle cell proliferation | 1 | 55 | 5.59e-01 |
| GO:BP | GO:0009582 | detection of abiotic stimulus | 1 | 68 | 5.61e-01 |
| GO:BP | GO:0032878 | regulation of establishment or maintenance of cell polarity | 1 | 26 | 5.61e-01 |
| GO:BP | GO:0033554 | cellular response to stress | 14 | 1681 | 5.62e-01 |
| GO:BP | GO:0021895 | cerebral cortex neuron differentiation | 1 | 14 | 5.63e-01 |
| GO:BP | GO:0021697 | cerebellar cortex formation | 1 | 22 | 5.63e-01 |
| GO:BP | GO:0033013 | tetrapyrrole metabolic process | 1 | 52 | 5.63e-01 |
| GO:BP | GO:0042267 | natural killer cell mediated cytotoxicity | 2 | 34 | 5.63e-01 |
| GO:BP | GO:1905039 | carboxylic acid transmembrane transport | 2 | 118 | 5.63e-01 |
| GO:BP | GO:0006929 | substrate-dependent cell migration | 1 | 24 | 5.63e-01 |
| GO:BP | GO:0045912 | negative regulation of carbohydrate metabolic process | 1 | 38 | 5.63e-01 |
| GO:BP | GO:0050435 | amyloid-beta metabolic process | 1 | 48 | 5.63e-01 |
| GO:BP | GO:0043588 | skin development | 1 | 175 | 5.63e-01 |
| GO:BP | GO:1904357 | negative regulation of telomere maintenance via telomere lengthening | 1 | 26 | 5.63e-01 |
| GO:BP | GO:0034641 | cellular nitrogen compound metabolic process | 6 | 4946 | 5.63e-01 |
| GO:BP | GO:0051282 | regulation of sequestering of calcium ion | 2 | 85 | 5.63e-01 |
| GO:BP | GO:0051052 | regulation of DNA metabolic process | 1 | 452 | 5.63e-01 |
| GO:BP | GO:0032602 | chemokine production | 1 | 46 | 5.63e-01 |
| GO:BP | GO:0032642 | regulation of chemokine production | 1 | 46 | 5.63e-01 |
| GO:BP | GO:0050684 | regulation of mRNA processing | 2 | 127 | 5.63e-01 |
| GO:BP | GO:0048668 | collateral sprouting | 1 | 25 | 5.64e-01 |
| GO:BP | GO:0050808 | synapse organization | 10 | 365 | 5.64e-01 |
| GO:BP | GO:0035265 | organ growth | 3 | 131 | 5.64e-01 |
| GO:BP | GO:0048843 | negative regulation of axon extension involved in axon guidance | 1 | 26 | 5.64e-01 |
| GO:BP | GO:0043068 | positive regulation of programmed cell death | 6 | 399 | 5.64e-01 |
| GO:BP | GO:1903825 | organic acid transmembrane transport | 2 | 119 | 5.64e-01 |
| GO:BP | GO:0051641 | cellular localization | 2 | 2810 | 5.64e-01 |
| GO:BP | GO:0002224 | toll-like receptor signaling pathway | 1 | 43 | 5.64e-01 |
| GO:BP | GO:0009620 | response to fungus | 1 | 22 | 5.64e-01 |
| GO:BP | GO:0046888 | negative regulation of hormone secretion | 1 | 46 | 5.64e-01 |
| GO:BP | GO:0007010 | cytoskeleton organization | 11 | 1226 | 5.65e-01 |
| GO:BP | GO:0060972 | left/right pattern formation | 2 | 101 | 5.65e-01 |
| GO:BP | GO:0140694 | non-membrane-bounded organelle assembly | 4 | 357 | 5.65e-01 |
| GO:BP | GO:0045453 | bone resorption | 1 | 40 | 5.65e-01 |
| GO:BP | GO:0030307 | positive regulation of cell growth | 1 | 135 | 5.65e-01 |
| GO:BP | GO:0032868 | response to insulin | 4 | 215 | 5.65e-01 |
| GO:BP | GO:1903131 | mononuclear cell differentiation | 7 | 294 | 5.65e-01 |
| GO:BP | GO:0033135 | regulation of peptidyl-serine phosphorylation | 2 | 100 | 5.65e-01 |
| GO:BP | GO:0015931 | nucleobase-containing compound transport | 1 | 194 | 5.65e-01 |
| GO:BP | GO:0048880 | sensory system development | 5 | 275 | 5.65e-01 |
| GO:BP | GO:0030521 | androgen receptor signaling pathway | 1 | 39 | 5.65e-01 |
| GO:BP | GO:0071692 | protein localization to extracellular region | 4 | 266 | 5.65e-01 |
| GO:BP | GO:0018209 | peptidyl-serine modification | 4 | 259 | 5.65e-01 |
| GO:BP | GO:0070509 | calcium ion import | 1 | 37 | 5.65e-01 |
| GO:BP | GO:0099072 | regulation of postsynaptic membrane neurotransmitter receptor levels | 1 | 70 | 5.65e-01 |
| GO:BP | GO:0006518 | peptide metabolic process | 2 | 771 | 5.66e-01 |
| GO:BP | GO:0046683 | response to organophosphorus | 2 | 96 | 5.66e-01 |
| GO:BP | GO:0051384 | response to glucocorticoid | 2 | 93 | 5.66e-01 |
| GO:BP | GO:0030514 | negative regulation of BMP signaling pathway | 1 | 45 | 5.66e-01 |
| GO:BP | GO:0035270 | endocrine system development | 2 | 86 | 5.66e-01 |
| GO:BP | GO:0033993 | response to lipid | 10 | 592 | 5.66e-01 |
| GO:BP | GO:0010458 | exit from mitosis | 1 | 30 | 5.66e-01 |
| GO:BP | GO:0050671 | positive regulation of lymphocyte proliferation | 1 | 72 | 5.66e-01 |
| GO:BP | GO:0045104 | intermediate filament cytoskeleton organization | 1 | 39 | 5.66e-01 |
| GO:BP | GO:0014033 | neural crest cell differentiation | 1 | 80 | 5.66e-01 |
| GO:BP | GO:0031667 | response to nutrient levels | 6 | 353 | 5.66e-01 |
| GO:BP | GO:2000352 | negative regulation of endothelial cell apoptotic process | 1 | 22 | 5.66e-01 |
| GO:BP | GO:0046685 | response to arsenic-containing substance | 1 | 30 | 5.66e-01 |
| GO:BP | GO:0006809 | nitric oxide biosynthetic process | 1 | 51 | 5.66e-01 |
| GO:BP | GO:0043085 | positive regulation of catalytic activity | 12 | 834 | 5.67e-01 |
| GO:BP | GO:0000423 | mitophagy | 1 | 37 | 5.68e-01 |
| GO:BP | GO:0055088 | lipid homeostasis | 1 | 115 | 5.68e-01 |
| GO:BP | GO:0000469 | cleavage involved in rRNA processing | 1 | 29 | 5.68e-01 |
| GO:BP | GO:0050766 | positive regulation of phagocytosis | 1 | 38 | 5.68e-01 |
| GO:BP | GO:0048522 | positive regulation of cellular process | 1 | 4099 | 5.68e-01 |
| GO:BP | GO:0070979 | protein K11-linked ubiquitination | 1 | 29 | 5.68e-01 |
| GO:BP | GO:0032784 | regulation of DNA-templated transcription elongation | 2 | 99 | 5.68e-01 |
| GO:BP | GO:0045103 | intermediate filament-based process | 1 | 40 | 5.68e-01 |
| GO:BP | GO:0043412 | macromolecule modification | 34 | 3090 | 5.68e-01 |
| GO:BP | GO:0055082 | intracellular chemical homeostasis | 6 | 486 | 5.68e-01 |
| GO:BP | GO:0010611 | regulation of cardiac muscle hypertrophy | 1 | 48 | 5.68e-01 |
| GO:BP | GO:0055021 | regulation of cardiac muscle tissue growth | 1 | 45 | 5.68e-01 |
| GO:BP | GO:0050810 | regulation of steroid biosynthetic process | 1 | 51 | 5.68e-01 |
| GO:BP | GO:0045595 | regulation of cell differentiation | 17 | 1137 | 5.68e-01 |
| GO:BP | GO:0070977 | bone maturation | 1 | 19 | 5.69e-01 |
| GO:BP | GO:0036258 | multivesicular body assembly | 1 | 32 | 5.69e-01 |
| GO:BP | GO:0051493 | regulation of cytoskeleton organization | 4 | 459 | 5.69e-01 |
| GO:BP | GO:0031646 | positive regulation of nervous system process | 1 | 21 | 5.69e-01 |
| GO:BP | GO:0032946 | positive regulation of mononuclear cell proliferation | 1 | 75 | 5.69e-01 |
| GO:BP | GO:0031279 | regulation of cyclase activity | 1 | 37 | 5.69e-01 |
| GO:BP | GO:0045727 | positive regulation of translation | 3 | 126 | 5.69e-01 |
| GO:BP | GO:0030808 | regulation of nucleotide biosynthetic process | 1 | 25 | 5.69e-01 |
| GO:BP | GO:1900371 | regulation of purine nucleotide biosynthetic process | 1 | 25 | 5.69e-01 |
| GO:BP | GO:0006356 | regulation of transcription by RNA polymerase I | 1 | 45 | 5.69e-01 |
| GO:BP | GO:0045833 | negative regulation of lipid metabolic process | 2 | 72 | 5.69e-01 |
| GO:BP | GO:0051931 | regulation of sensory perception | 1 | 13 | 5.69e-01 |
| GO:BP | GO:0051930 | regulation of sensory perception of pain | 1 | 13 | 5.69e-01 |
| GO:BP | GO:0036293 | response to decreased oxygen levels | 5 | 249 | 5.69e-01 |
| GO:BP | GO:0051961 | negative regulation of nervous system development | 2 | 118 | 5.69e-01 |
| GO:BP | GO:0051208 | sequestering of calcium ion | 2 | 89 | 5.69e-01 |
| GO:BP | GO:1902806 | regulation of cell cycle G1/S phase transition | 2 | 169 | 5.69e-01 |
| GO:BP | GO:0006310 | DNA recombination | 2 | 257 | 5.69e-01 |
| GO:BP | GO:0043604 | amide biosynthetic process | 2 | 775 | 5.69e-01 |
| GO:BP | GO:0010212 | response to ionizing radiation | 1 | 130 | 5.69e-01 |
| GO:BP | GO:0046578 | regulation of Ras protein signal transduction | 1 | 166 | 5.70e-01 |
| GO:BP | GO:0001756 | somitogenesis | 1 | 48 | 5.70e-01 |
| GO:BP | GO:1990868 | response to chemokine | 1 | 37 | 5.70e-01 |
| GO:BP | GO:1990869 | cellular response to chemokine | 1 | 37 | 5.70e-01 |
| GO:BP | GO:0031399 | regulation of protein modification process | 19 | 1173 | 5.70e-01 |
| GO:BP | GO:0002228 | natural killer cell mediated immunity | 2 | 34 | 5.72e-01 |
| GO:BP | GO:0000470 | maturation of LSU-rRNA | 1 | 28 | 5.72e-01 |
| GO:BP | GO:0002028 | regulation of sodium ion transport | 2 | 72 | 5.72e-01 |
| GO:BP | GO:0010720 | positive regulation of cell development | 3 | 317 | 5.72e-01 |
| GO:BP | GO:1901699 | cellular response to nitrogen compound | 11 | 517 | 5.73e-01 |
| GO:BP | GO:0014020 | primary neural tube formation | 1 | 94 | 5.73e-01 |
| GO:BP | GO:0007098 | centrosome cycle | 1 | 127 | 5.73e-01 |
| GO:BP | GO:0045639 | positive regulation of myeloid cell differentiation | 1 | 67 | 5.73e-01 |
| GO:BP | GO:0070198 | protein localization to chromosome, telomeric region | 1 | 30 | 5.73e-01 |
| GO:BP | GO:0034968 | histone lysine methylation | 2 | 89 | 5.73e-01 |
| GO:BP | GO:0006364 | rRNA processing | 5 | 221 | 5.74e-01 |
| GO:BP | GO:1905475 | regulation of protein localization to membrane | 1 | 150 | 5.74e-01 |
| GO:BP | GO:0036257 | multivesicular body organization | 1 | 33 | 5.75e-01 |
| GO:BP | GO:1902903 | regulation of supramolecular fiber organization | 5 | 326 | 5.75e-01 |
| GO:BP | GO:0048678 | response to axon injury | 2 | 64 | 5.75e-01 |
| GO:BP | GO:0051492 | regulation of stress fiber assembly | 1 | 81 | 5.75e-01 |
| GO:BP | GO:0050769 | positive regulation of neurogenesis | 5 | 189 | 5.75e-01 |
| GO:BP | GO:0043388 | positive regulation of DNA binding | 1 | 44 | 5.75e-01 |
| GO:BP | GO:0048699 | generation of neurons | 10 | 1119 | 5.75e-01 |
| GO:BP | GO:0071715 | icosanoid transport | 1 | 24 | 5.77e-01 |
| GO:BP | GO:0046856 | phosphatidylinositol dephosphorylation | 1 | 29 | 5.77e-01 |
| GO:BP | GO:0055123 | digestive system development | 2 | 100 | 5.77e-01 |
| GO:BP | GO:0003229 | ventricular cardiac muscle tissue development | 1 | 52 | 5.78e-01 |
| GO:BP | GO:0051248 | negative regulation of protein metabolic process | 4 | 816 | 5.78e-01 |
| GO:BP | GO:0030522 | intracellular receptor signaling pathway | 4 | 227 | 5.78e-01 |
| GO:BP | GO:0006997 | nucleus organization | 1 | 126 | 5.78e-01 |
| GO:BP | GO:0051339 | regulation of lyase activity | 1 | 39 | 5.78e-01 |
| GO:BP | GO:0040008 | regulation of growth | 7 | 501 | 5.78e-01 |
| GO:BP | GO:0046631 | alpha-beta T cell activation | 1 | 89 | 5.79e-01 |
| GO:BP | GO:0051701 | biological process involved in interaction with host | 1 | 154 | 5.79e-01 |
| GO:BP | GO:0014743 | regulation of muscle hypertrophy | 1 | 49 | 5.79e-01 |
| GO:BP | GO:0044237 | cellular metabolic process | 5 | 6996 | 5.79e-01 |
| GO:BP | GO:0003002 | regionalization | 5 | 273 | 5.79e-01 |
| GO:BP | GO:1904894 | positive regulation of receptor signaling pathway via STAT | 1 | 22 | 5.79e-01 |
| GO:BP | GO:0006513 | protein monoubiquitination | 2 | 80 | 5.79e-01 |
| GO:BP | GO:1902475 | L-alpha-amino acid transmembrane transport | 1 | 55 | 5.80e-01 |
| GO:BP | GO:0032963 | collagen metabolic process | 1 | 74 | 5.80e-01 |
| GO:BP | GO:0044282 | small molecule catabolic process | 8 | 271 | 5.80e-01 |
| GO:BP | GO:0016925 | protein sumoylation | 1 | 59 | 5.80e-01 |
| GO:BP | GO:0072331 | signal transduction by p53 class mediator | 2 | 161 | 5.81e-01 |
| GO:BP | GO:2000147 | positive regulation of cell motility | 7 | 421 | 5.82e-01 |
| GO:BP | GO:0099558 | maintenance of synapse structure | 1 | 25 | 5.82e-01 |
| GO:BP | GO:0035303 | regulation of dephosphorylation | 3 | 105 | 5.82e-01 |
| GO:BP | GO:2001257 | regulation of cation channel activity | 3 | 100 | 5.82e-01 |
| GO:BP | GO:0070201 | regulation of establishment of protein localization | 6 | 428 | 5.83e-01 |
| GO:BP | GO:0046902 | regulation of mitochondrial membrane permeability | 1 | 54 | 5.83e-01 |
| GO:BP | GO:0046209 | nitric oxide metabolic process | 1 | 55 | 5.83e-01 |
| GO:BP | GO:0034504 | protein localization to nucleus | 3 | 276 | 5.85e-01 |
| GO:BP | GO:0060292 | long-term synaptic depression | 1 | 21 | 5.86e-01 |
| GO:BP | GO:0010595 | positive regulation of endothelial cell migration | 1 | 94 | 5.86e-01 |
| GO:BP | GO:0010761 | fibroblast migration | 1 | 52 | 5.86e-01 |
| GO:BP | GO:0055075 | potassium ion homeostasis | 1 | 22 | 5.86e-01 |
| GO:BP | GO:2001057 | reactive nitrogen species metabolic process | 1 | 56 | 5.88e-01 |
| GO:BP | GO:0031062 | positive regulation of histone methylation | 1 | 36 | 5.88e-01 |
| GO:BP | GO:0051966 | regulation of synaptic transmission, glutamatergic | 2 | 46 | 5.88e-01 |
| GO:BP | GO:0048144 | fibroblast proliferation | 2 | 92 | 5.88e-01 |
| GO:BP | GO:0009612 | response to mechanical stimulus | 3 | 158 | 5.88e-01 |
| GO:BP | GO:0060828 | regulation of canonical Wnt signaling pathway | 3 | 213 | 5.89e-01 |
| GO:BP | GO:0034103 | regulation of tissue remodeling | 1 | 45 | 5.90e-01 |
| GO:BP | GO:0050994 | regulation of lipid catabolic process | 1 | 38 | 5.90e-01 |
| GO:BP | GO:0035966 | response to topologically incorrect protein | 2 | 150 | 5.90e-01 |
| GO:BP | GO:0002720 | positive regulation of cytokine production involved in immune response | 1 | 49 | 5.90e-01 |
| GO:BP | GO:0002011 | morphogenesis of an epithelial sheet | 1 | 52 | 5.91e-01 |
| GO:BP | GO:0051260 | protein homooligomerization | 2 | 136 | 5.91e-01 |
| GO:BP | GO:0046854 | phosphatidylinositol phosphate biosynthetic process | 1 | 59 | 5.91e-01 |
| GO:BP | GO:0050804 | modulation of chemical synaptic transmission | 10 | 341 | 5.91e-01 |
| GO:BP | GO:0071320 | cellular response to cAMP | 1 | 41 | 5.91e-01 |
| GO:BP | GO:0099590 | neurotransmitter receptor internalization | 1 | 19 | 5.91e-01 |
| GO:BP | GO:0001822 | kidney development | 3 | 244 | 5.91e-01 |
| GO:BP | GO:0000165 | MAPK cascade | 3 | 556 | 5.91e-01 |
| GO:BP | GO:0030879 | mammary gland development | 2 | 106 | 5.91e-01 |
| GO:BP | GO:2000463 | positive regulation of excitatory postsynaptic potential | 1 | 28 | 5.92e-01 |
| GO:BP | GO:0051962 | positive regulation of nervous system development | 6 | 221 | 5.92e-01 |
| GO:BP | GO:0099177 | regulation of trans-synaptic signaling | 10 | 342 | 5.92e-01 |
| GO:BP | GO:0051148 | negative regulation of muscle cell differentiation | 1 | 52 | 5.92e-01 |
| GO:BP | GO:0001841 | neural tube formation | 1 | 101 | 5.93e-01 |
| GO:BP | GO:0030010 | establishment of cell polarity | 1 | 134 | 5.94e-01 |
| GO:BP | GO:0021766 | hippocampus development | 2 | 62 | 5.94e-01 |
| GO:BP | GO:0034976 | response to endoplasmic reticulum stress | 2 | 234 | 5.94e-01 |
| GO:BP | GO:0032970 | regulation of actin filament-based process | 3 | 340 | 5.94e-01 |
| GO:BP | GO:0030833 | regulation of actin filament polymerization | 2 | 110 | 5.95e-01 |
| GO:BP | GO:0060074 | synapse maturation | 1 | 25 | 5.95e-01 |
| GO:BP | GO:0090276 | regulation of peptide hormone secretion | 2 | 132 | 5.95e-01 |
| GO:BP | GO:0090277 | positive regulation of peptide hormone secretion | 1 | 69 | 5.95e-01 |
| GO:BP | GO:0033363 | secretory granule organization | 1 | 50 | 5.95e-01 |
| GO:BP | GO:0055078 | sodium ion homeostasis | 1 | 26 | 5.95e-01 |
| GO:BP | GO:0070665 | positive regulation of leukocyte proliferation | 1 | 83 | 5.96e-01 |
| GO:BP | GO:0031023 | microtubule organizing center organization | 1 | 137 | 5.96e-01 |
| GO:BP | GO:0060420 | regulation of heart growth | 1 | 50 | 5.97e-01 |
| GO:BP | GO:0050727 | regulation of inflammatory response | 4 | 212 | 5.97e-01 |
| GO:BP | GO:2001251 | negative regulation of chromosome organization | 1 | 90 | 5.98e-01 |
| GO:BP | GO:0032648 | regulation of interferon-beta production | 1 | 43 | 5.98e-01 |
| GO:BP | GO:0035065 | regulation of histone acetylation | 1 | 47 | 5.98e-01 |
| GO:BP | GO:0032608 | interferon-beta production | 1 | 43 | 5.98e-01 |
| GO:BP | GO:0046496 | nicotinamide nucleotide metabolic process | 1 | 66 | 5.98e-01 |
| GO:BP | GO:0019362 | pyridine nucleotide metabolic process | 1 | 66 | 5.98e-01 |
| GO:BP | GO:0031400 | negative regulation of protein modification process | 2 | 418 | 5.98e-01 |
| GO:BP | GO:0007264 | small GTPase mediated signal transduction | 2 | 421 | 5.98e-01 |
| GO:BP | GO:0030073 | insulin secretion | 2 | 141 | 5.98e-01 |
| GO:BP | GO:0043154 | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 1 | 59 | 5.98e-01 |
| GO:BP | GO:0050848 | regulation of calcium-mediated signaling | 1 | 52 | 5.99e-01 |
| GO:BP | GO:0002793 | positive regulation of peptide secretion | 1 | 70 | 5.99e-01 |
| GO:BP | GO:0051347 | positive regulation of transferase activity | 7 | 400 | 5.99e-01 |
| GO:BP | GO:0048799 | animal organ maturation | 1 | 20 | 5.99e-01 |
| GO:BP | GO:0055085 | transmembrane transport | 1 | 998 | 5.99e-01 |
| GO:BP | GO:0051128 | regulation of cellular component organization | 16 | 2011 | 5.99e-01 |
| GO:BP | GO:0033043 | regulation of organelle organization | 14 | 1028 | 5.99e-01 |
| GO:BP | GO:0002791 | regulation of peptide secretion | 2 | 134 | 6.00e-01 |
| GO:BP | GO:0000271 | polysaccharide biosynthetic process | 1 | 53 | 6.00e-01 |
| GO:BP | GO:0048199 | vesicle targeting, to, from or within Golgi | 1 | 31 | 6.01e-01 |
| GO:BP | GO:0071496 | cellular response to external stimulus | 3 | 270 | 6.01e-01 |
| GO:BP | GO:0006688 | glycosphingolipid biosynthetic process | 1 | 25 | 6.01e-01 |
| GO:BP | GO:0051402 | neuron apoptotic process | 3 | 200 | 6.02e-01 |
| GO:BP | GO:0016052 | carbohydrate catabolic process | 2 | 120 | 6.02e-01 |
| GO:BP | GO:0043304 | regulation of mast cell degranulation | 1 | 20 | 6.02e-01 |
| GO:BP | GO:0042113 | B cell activation | 7 | 170 | 6.03e-01 |
| GO:BP | GO:0043551 | regulation of phosphatidylinositol 3-kinase activity | 1 | 30 | 6.03e-01 |
| GO:BP | GO:0045324 | late endosome to vacuole transport | 1 | 36 | 6.03e-01 |
| GO:BP | GO:0019068 | virion assembly | 1 | 35 | 6.03e-01 |
| GO:BP | GO:0010921 | regulation of phosphatase activity | 2 | 65 | 6.03e-01 |
| GO:BP | GO:0006836 | neurotransmitter transport | 2 | 138 | 6.03e-01 |
| GO:BP | GO:0022008 | neurogenesis | 7 | 1294 | 6.03e-01 |
| GO:BP | GO:0090087 | regulation of peptide transport | 2 | 136 | 6.03e-01 |
| GO:BP | GO:0046503 | glycerolipid catabolic process | 1 | 42 | 6.03e-01 |
| GO:BP | GO:0050777 | negative regulation of immune response | 1 | 111 | 6.04e-01 |
| GO:BP | GO:0014074 | response to purine-containing compound | 2 | 108 | 6.04e-01 |
| GO:BP | GO:0042698 | ovulation cycle | 1 | 54 | 6.04e-01 |
| GO:BP | GO:0000079 | regulation of cyclin-dependent protein serine/threonine kinase activity | 2 | 85 | 6.05e-01 |
| GO:BP | GO:0090066 | regulation of anatomical structure size | 6 | 395 | 6.06e-01 |
| GO:BP | GO:0031396 | regulation of protein ubiquitination | 3 | 191 | 6.06e-01 |
| GO:BP | GO:0016079 | synaptic vesicle exocytosis | 1 | 74 | 6.06e-01 |
| GO:BP | GO:0072001 | renal system development | 3 | 251 | 6.06e-01 |
| GO:BP | GO:0009991 | response to extracellular stimulus | 6 | 377 | 6.06e-01 |
| GO:BP | GO:0042981 | regulation of apoptotic process | 13 | 1088 | 6.06e-01 |
| GO:BP | GO:0048518 | positive regulation of biological process | 1 | 4579 | 6.08e-01 |
| GO:BP | GO:0032231 | regulation of actin filament bundle assembly | 1 | 91 | 6.09e-01 |
| GO:BP | GO:0008544 | epidermis development | 1 | 210 | 6.09e-01 |
| GO:BP | GO:1903532 | positive regulation of secretion by cell | 3 | 199 | 6.10e-01 |
| GO:BP | GO:0014070 | response to organic cyclic compound | 4 | 640 | 6.10e-01 |
| GO:BP | GO:0030509 | BMP signaling pathway | 2 | 123 | 6.10e-01 |
| GO:BP | GO:0043162 | ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway | 1 | 35 | 6.10e-01 |
| GO:BP | GO:0051783 | regulation of nuclear division | 2 | 116 | 6.10e-01 |
| GO:BP | GO:0043112 | receptor metabolic process | 1 | 62 | 6.12e-01 |
| GO:BP | GO:0009798 | axis specification | 1 | 63 | 6.12e-01 |
| GO:BP | GO:0072527 | pyrimidine-containing compound metabolic process | 1 | 67 | 6.12e-01 |
| GO:BP | GO:0032409 | regulation of transporter activity | 6 | 211 | 6.13e-01 |
| GO:BP | GO:0086065 | cell communication involved in cardiac conduction | 1 | 58 | 6.13e-01 |
| GO:BP | GO:0043547 | positive regulation of GTPase activity | 3 | 222 | 6.14e-01 |
| GO:BP | GO:0043149 | stress fiber assembly | 1 | 94 | 6.14e-01 |
| GO:BP | GO:0045927 | positive regulation of growth | 3 | 199 | 6.14e-01 |
| GO:BP | GO:0006826 | iron ion transport | 1 | 40 | 6.14e-01 |
| GO:BP | GO:0030038 | contractile actin filament bundle assembly | 1 | 94 | 6.14e-01 |
| GO:BP | GO:0043066 | negative regulation of apoptotic process | 8 | 660 | 6.14e-01 |
| GO:BP | GO:0090162 | establishment of epithelial cell polarity | 1 | 29 | 6.14e-01 |
| GO:BP | GO:0045598 | regulation of fat cell differentiation | 2 | 102 | 6.15e-01 |
| GO:BP | GO:0048639 | positive regulation of developmental growth | 2 | 124 | 6.15e-01 |
| GO:BP | GO:0010977 | negative regulation of neuron projection development | 3 | 117 | 6.16e-01 |
| GO:BP | GO:0042180 | cellular ketone metabolic process | 3 | 158 | 6.16e-01 |
| GO:BP | GO:0036503 | ERAD pathway | 1 | 106 | 6.16e-01 |
| GO:BP | GO:0072524 | pyridine-containing compound metabolic process | 1 | 72 | 6.17e-01 |
| GO:BP | GO:0071277 | cellular response to calcium ion | 2 | 67 | 6.17e-01 |
| GO:BP | GO:0002695 | negative regulation of leukocyte activation | 1 | 105 | 6.17e-01 |
| GO:BP | GO:0006536 | glutamate metabolic process | 1 | 25 | 6.17e-01 |
| GO:BP | GO:0002062 | chondrocyte differentiation | 1 | 90 | 6.17e-01 |
| GO:BP | GO:0000038 | very long-chain fatty acid metabolic process | 1 | 27 | 6.18e-01 |
| GO:BP | GO:0140962 | multicellular organismal-level chemical homeostasis | 1 | 34 | 6.18e-01 |
| GO:BP | GO:0043666 | regulation of phosphoprotein phosphatase activity | 1 | 47 | 6.18e-01 |
| GO:BP | GO:0009755 | hormone-mediated signaling pathway | 1 | 139 | 6.18e-01 |
| GO:BP | GO:0033006 | regulation of mast cell activation involved in immune response | 1 | 21 | 6.18e-01 |
| GO:BP | GO:0060548 | negative regulation of cell death | 9 | 756 | 6.18e-01 |
| GO:BP | GO:0032205 | negative regulation of telomere maintenance | 1 | 33 | 6.18e-01 |
| GO:BP | GO:0051259 | protein complex oligomerization | 5 | 185 | 6.18e-01 |
| GO:BP | GO:0006820 | monoatomic anion transport | 1 | 83 | 6.18e-01 |
| GO:BP | GO:0097006 | regulation of plasma lipoprotein particle levels | 1 | 45 | 6.19e-01 |
| GO:BP | GO:0034655 | nucleobase-containing compound catabolic process | 1 | 358 | 6.19e-01 |
| GO:BP | GO:0061077 | chaperone-mediated protein folding | 1 | 65 | 6.19e-01 |
| GO:BP | GO:0009790 | embryo development | 10 | 875 | 6.20e-01 |
| GO:BP | GO:0051055 | negative regulation of lipid biosynthetic process | 1 | 46 | 6.20e-01 |
| GO:BP | GO:0034612 | response to tumor necrosis factor | 3 | 172 | 6.20e-01 |
| GO:BP | GO:0001818 | negative regulation of cytokine production | 2 | 165 | 6.22e-01 |
| GO:BP | GO:0051785 | positive regulation of nuclear division | 1 | 38 | 6.22e-01 |
| GO:BP | GO:0021953 | central nervous system neuron differentiation | 1 | 108 | 6.22e-01 |
| GO:BP | GO:0006261 | DNA-templated DNA replication | 1 | 148 | 6.22e-01 |
| GO:BP | GO:0032890 | regulation of organic acid transport | 1 | 49 | 6.22e-01 |
| GO:BP | GO:0051235 | maintenance of location | 3 | 260 | 6.22e-01 |
| GO:BP | GO:0006493 | protein O-linked glycosylation | 2 | 69 | 6.22e-01 |
| GO:BP | GO:0051385 | response to mineralocorticoid | 1 | 25 | 6.22e-01 |
| GO:BP | GO:0042220 | response to cocaine | 1 | 28 | 6.22e-01 |
| GO:BP | GO:0051968 | positive regulation of synaptic transmission, glutamatergic | 1 | 20 | 6.22e-01 |
| GO:BP | GO:0006953 | acute-phase response | 1 | 18 | 6.22e-01 |
| GO:BP | GO:0090304 | nucleic acid metabolic process | 5 | 4048 | 6.22e-01 |
| GO:BP | GO:0031960 | response to corticosteroid | 2 | 109 | 6.23e-01 |
| GO:BP | GO:0045687 | positive regulation of glial cell differentiation | 1 | 28 | 6.23e-01 |
| GO:BP | GO:1904031 | positive regulation of cyclin-dependent protein kinase activity | 1 | 26 | 6.23e-01 |
| GO:BP | GO:0000209 | protein polyubiquitination | 2 | 226 | 6.23e-01 |
| GO:BP | GO:0033260 | nuclear DNA replication | 1 | 35 | 6.23e-01 |
| GO:BP | GO:0031401 | positive regulation of protein modification process | 12 | 719 | 6.23e-01 |
| GO:BP | GO:0009719 | response to endogenous stimulus | 21 | 1278 | 6.23e-01 |
| GO:BP | GO:0001505 | regulation of neurotransmitter levels | 2 | 149 | 6.23e-01 |
| GO:BP | GO:0097193 | intrinsic apoptotic signaling pathway | 2 | 262 | 6.24e-01 |
| GO:BP | GO:0002323 | natural killer cell activation involved in immune response | 1 | 6 | 6.24e-01 |
| GO:BP | GO:0048813 | dendrite morphogenesis | 3 | 120 | 6.24e-01 |
| GO:BP | GO:1902532 | negative regulation of intracellular signal transduction | 2 | 438 | 6.24e-01 |
| GO:BP | GO:0045191 | regulation of isotype switching | 1 | 27 | 6.25e-01 |
| GO:BP | GO:0000460 | maturation of 5.8S rRNA | 1 | 36 | 6.25e-01 |
| GO:BP | GO:0006446 | regulation of translational initiation | 1 | 73 | 6.25e-01 |
| GO:BP | GO:0007283 | spermatogenesis | 4 | 330 | 6.25e-01 |
| GO:BP | GO:0052548 | regulation of endopeptidase activity | 1 | 232 | 6.25e-01 |
| GO:BP | GO:0048589 | developmental growth | 7 | 522 | 6.25e-01 |
| GO:BP | GO:0030178 | negative regulation of Wnt signaling pathway | 2 | 140 | 6.28e-01 |
| GO:BP | GO:0061024 | membrane organization | 1 | 671 | 6.28e-01 |
| GO:BP | GO:0072091 | regulation of stem cell proliferation | 1 | 58 | 6.29e-01 |
| GO:BP | GO:0032509 | endosome transport via multivesicular body sorting pathway | 1 | 41 | 6.29e-01 |
| GO:BP | GO:0098657 | import into cell | 3 | 166 | 6.29e-01 |
| GO:BP | GO:0042325 | regulation of phosphorylation | 17 | 881 | 6.29e-01 |
| GO:BP | GO:0006897 | endocytosis | 3 | 527 | 6.30e-01 |
| GO:BP | GO:0048709 | oligodendrocyte differentiation | 2 | 68 | 6.31e-01 |
| GO:BP | GO:0061053 | somite development | 1 | 63 | 6.32e-01 |
| GO:BP | GO:0010810 | regulation of cell-substrate adhesion | 2 | 172 | 6.32e-01 |
| GO:BP | GO:0072593 | reactive oxygen species metabolic process | 2 | 156 | 6.32e-01 |
| GO:BP | GO:0120036 | plasma membrane bounded cell projection organization | 5 | 1201 | 6.32e-01 |
| GO:BP | GO:0008202 | steroid metabolic process | 1 | 204 | 6.32e-01 |
| GO:BP | GO:0110053 | regulation of actin filament organization | 2 | 228 | 6.33e-01 |
| GO:BP | GO:0010608 | post-transcriptional regulation of gene expression | 2 | 468 | 6.33e-01 |
| GO:BP | GO:0030003 | intracellular monoatomic cation homeostasis | 1 | 357 | 6.33e-01 |
| GO:BP | GO:0035967 | cellular response to topologically incorrect protein | 1 | 111 | 6.33e-01 |
| GO:BP | GO:0060255 | regulation of macromolecule metabolic process | 1 | 4617 | 6.33e-01 |
| GO:BP | GO:1904427 | positive regulation of calcium ion transmembrane transport | 1 | 60 | 6.33e-01 |
| GO:BP | GO:0046887 | positive regulation of hormone secretion | 3 | 90 | 6.33e-01 |
| GO:BP | GO:0007032 | endosome organization | 2 | 92 | 6.33e-01 |
| GO:BP | GO:0031532 | actin cytoskeleton reorganization | 1 | 96 | 6.34e-01 |
| GO:BP | GO:0090559 | regulation of membrane permeability | 1 | 64 | 6.34e-01 |
| GO:BP | GO:0007276 | gamete generation | 5 | 461 | 6.34e-01 |
| GO:BP | GO:0051262 | protein tetramerization | 1 | 64 | 6.34e-01 |
| GO:BP | GO:0022412 | cellular process involved in reproduction in multicellular organism | 2 | 252 | 6.34e-01 |
| GO:BP | GO:0071772 | response to BMP | 2 | 131 | 6.34e-01 |
| GO:BP | GO:0021696 | cerebellar cortex morphogenesis | 1 | 30 | 6.34e-01 |
| GO:BP | GO:0031347 | regulation of defense response | 7 | 448 | 6.34e-01 |
| GO:BP | GO:0071773 | cellular response to BMP stimulus | 2 | 131 | 6.34e-01 |
| GO:BP | GO:0051960 | regulation of nervous system development | 9 | 357 | 6.34e-01 |
| GO:BP | GO:0007584 | response to nutrient | 2 | 109 | 6.34e-01 |
| GO:BP | GO:0046649 | lymphocyte activation | 4 | 465 | 6.35e-01 |
| GO:BP | GO:0006873 | intracellular monoatomic ion homeostasis | 1 | 362 | 6.36e-01 |
| GO:BP | GO:0016233 | telomere capping | 1 | 36 | 6.36e-01 |
| GO:BP | GO:2000279 | negative regulation of DNA biosynthetic process | 1 | 34 | 6.36e-01 |
| GO:BP | GO:0045332 | phospholipid translocation | 1 | 33 | 6.36e-01 |
| GO:BP | GO:2000117 | negative regulation of cysteine-type endopeptidase activity | 1 | 64 | 6.36e-01 |
| GO:BP | GO:0030155 | regulation of cell adhesion | 5 | 539 | 6.38e-01 |
| GO:BP | GO:0045454 | cell redox homeostasis | 1 | 38 | 6.38e-01 |
| GO:BP | GO:0050878 | regulation of body fluid levels | 3 | 236 | 6.38e-01 |
| GO:BP | GO:0001838 | embryonic epithelial tube formation | 1 | 116 | 6.38e-01 |
| GO:BP | GO:0002446 | neutrophil mediated immunity | 1 | 17 | 6.38e-01 |
| GO:BP | GO:0031214 | biomineral tissue development | 3 | 111 | 6.41e-01 |
| GO:BP | GO:1901019 | regulation of calcium ion transmembrane transporter activity | 1 | 71 | 6.41e-01 |
| GO:BP | GO:0098771 | inorganic ion homeostasis | 1 | 351 | 6.42e-01 |
| GO:BP | GO:0044270 | cellular nitrogen compound catabolic process | 1 | 378 | 6.42e-01 |
| GO:BP | GO:2000756 | regulation of peptidyl-lysine acetylation | 1 | 57 | 6.42e-01 |
| GO:BP | GO:0033674 | positive regulation of kinase activity | 4 | 317 | 6.42e-01 |
| GO:BP | GO:0046700 | heterocycle catabolic process | 1 | 381 | 6.42e-01 |
| GO:BP | GO:0008064 | regulation of actin polymerization or depolymerization | 2 | 126 | 6.42e-01 |
| GO:BP | GO:0050853 | B cell receptor signaling pathway | 2 | 32 | 6.42e-01 |
| GO:BP | GO:0050767 | regulation of neurogenesis | 4 | 301 | 6.42e-01 |
| GO:BP | GO:0032755 | positive regulation of interleukin-6 production | 1 | 56 | 6.42e-01 |
| GO:BP | GO:2000045 | regulation of G1/S transition of mitotic cell cycle | 1 | 149 | 6.42e-01 |
| GO:BP | GO:0042221 | response to chemical | 1 | 2559 | 6.42e-01 |
| GO:BP | GO:0001656 | metanephros development | 1 | 64 | 6.42e-01 |
| GO:BP | GO:0048232 | male gamete generation | 4 | 343 | 6.42e-01 |
| GO:BP | GO:1904888 | cranial skeletal system development | 1 | 51 | 6.42e-01 |
| GO:BP | GO:0007389 | pattern specification process | 5 | 306 | 6.42e-01 |
| GO:BP | GO:0050866 | negative regulation of cell activation | 1 | 124 | 6.42e-01 |
| GO:BP | GO:0090102 | cochlea development | 1 | 35 | 6.42e-01 |
| GO:BP | GO:0043648 | dicarboxylic acid metabolic process | 1 | 74 | 6.42e-01 |
| GO:BP | GO:0006901 | vesicle coating | 1 | 36 | 6.42e-01 |
| GO:BP | GO:0070647 | protein modification by small protein conjugation or removal | 2 | 898 | 6.43e-01 |
| GO:BP | GO:0007015 | actin filament organization | 3 | 373 | 6.44e-01 |
| GO:BP | GO:0006835 | dicarboxylic acid transport | 1 | 62 | 6.45e-01 |
| GO:BP | GO:0014003 | oligodendrocyte development | 1 | 27 | 6.45e-01 |
| GO:BP | GO:0034502 | protein localization to chromosome | 1 | 110 | 6.46e-01 |
| GO:BP | GO:0070925 | organelle assembly | 1 | 817 | 6.46e-01 |
| GO:BP | GO:0010942 | positive regulation of cell death | 6 | 441 | 6.46e-01 |
| GO:BP | GO:0042886 | amide transport | 3 | 235 | 6.47e-01 |
| GO:BP | GO:0032729 | positive regulation of type II interferon production | 1 | 36 | 6.47e-01 |
| GO:BP | GO:0030856 | regulation of epithelial cell differentiation | 1 | 101 | 6.47e-01 |
| GO:BP | GO:0000280 | nuclear division | 3 | 344 | 6.48e-01 |
| GO:BP | GO:0007131 | reciprocal meiotic recombination | 1 | 36 | 6.48e-01 |
| GO:BP | GO:0140527 | reciprocal homologous recombination | 1 | 36 | 6.48e-01 |
| GO:BP | GO:0120031 | plasma membrane bounded cell projection assembly | 2 | 461 | 6.49e-01 |
| GO:BP | GO:0030832 | regulation of actin filament length | 2 | 127 | 6.49e-01 |
| GO:BP | GO:0060078 | regulation of postsynaptic membrane potential | 3 | 82 | 6.51e-01 |
| GO:BP | GO:0070664 | negative regulation of leukocyte proliferation | 1 | 51 | 6.51e-01 |
| GO:BP | GO:0036297 | interstrand cross-link repair | 1 | 37 | 6.51e-01 |
| GO:BP | GO:0003333 | amino acid transmembrane transport | 1 | 71 | 6.51e-01 |
| GO:BP | GO:0032760 | positive regulation of tumor necrosis factor production | 1 | 55 | 6.51e-01 |
| GO:BP | GO:0002275 | myeloid cell activation involved in immune response | 1 | 48 | 6.51e-01 |
| GO:BP | GO:0033555 | multicellular organismal response to stress | 1 | 57 | 6.51e-01 |
| GO:BP | GO:0002714 | positive regulation of B cell mediated immunity | 1 | 26 | 6.51e-01 |
| GO:BP | GO:0007423 | sensory organ development | 9 | 396 | 6.51e-01 |
| GO:BP | GO:0002891 | positive regulation of immunoglobulin mediated immune response | 1 | 26 | 6.51e-01 |
| GO:BP | GO:0019439 | aromatic compound catabolic process | 1 | 387 | 6.51e-01 |
| GO:BP | GO:0048146 | positive regulation of fibroblast proliferation | 1 | 45 | 6.51e-01 |
| GO:BP | GO:0010469 | regulation of signaling receptor activity | 2 | 107 | 6.52e-01 |
| GO:BP | GO:0060627 | regulation of vesicle-mediated transport | 2 | 403 | 6.53e-01 |
| GO:BP | GO:0006109 | regulation of carbohydrate metabolic process | 2 | 144 | 6.53e-01 |
| GO:BP | GO:1900542 | regulation of purine nucleotide metabolic process | 1 | 40 | 6.53e-01 |
| GO:BP | GO:0007601 | visual perception | 1 | 96 | 6.53e-01 |
| GO:BP | GO:0070059 | intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | 1 | 56 | 6.53e-01 |
| GO:BP | GO:0006508 | proteolysis | 14 | 1318 | 6.53e-01 |
| GO:BP | GO:0030516 | regulation of axon extension | 2 | 84 | 6.53e-01 |
| GO:BP | GO:0007286 | spermatid development | 1 | 105 | 6.53e-01 |
| GO:BP | GO:0097106 | postsynaptic density organization | 1 | 30 | 6.53e-01 |
| GO:BP | GO:0051047 | positive regulation of secretion | 3 | 215 | 6.54e-01 |
| GO:BP | GO:0051056 | regulation of small GTPase mediated signal transduction | 3 | 257 | 6.54e-01 |
| GO:BP | GO:0002040 | sprouting angiogenesis | 1 | 98 | 6.54e-01 |
| GO:BP | GO:0005975 | carbohydrate metabolic process | 8 | 433 | 6.54e-01 |
| GO:BP | GO:0044786 | cell cycle DNA replication | 1 | 40 | 6.54e-01 |
| GO:BP | GO:0030239 | myofibril assembly | 1 | 66 | 6.54e-01 |
| GO:BP | GO:0048585 | negative regulation of response to stimulus | 16 | 1248 | 6.54e-01 |
| GO:BP | GO:0045444 | fat cell differentiation | 4 | 187 | 6.54e-01 |
| GO:BP | GO:0015698 | inorganic anion transport | 1 | 104 | 6.55e-01 |
| GO:BP | GO:0050953 | sensory perception of light stimulus | 1 | 97 | 6.55e-01 |
| GO:BP | GO:0030031 | cell projection assembly | 2 | 469 | 6.55e-01 |
| GO:BP | GO:0045132 | meiotic chromosome segregation | 2 | 64 | 6.56e-01 |
| GO:BP | GO:0030168 | platelet activation | 2 | 91 | 6.56e-01 |
| GO:BP | GO:0090148 | membrane fission | 1 | 44 | 6.57e-01 |
| GO:BP | GO:0044087 | regulation of cellular component biogenesis | 6 | 809 | 6.57e-01 |
| GO:BP | GO:0010941 | regulation of cell death | 14 | 1219 | 6.57e-01 |
| GO:BP | GO:0006140 | regulation of nucleotide metabolic process | 1 | 40 | 6.57e-01 |
| GO:BP | GO:0050673 | epithelial cell proliferation | 5 | 323 | 6.57e-01 |
| GO:BP | GO:0055002 | striated muscle cell development | 1 | 67 | 6.58e-01 |
| GO:BP | GO:0016266 | O-glycan processing | 1 | 30 | 6.60e-01 |
| GO:BP | GO:0019222 | regulation of metabolic process | 1 | 5017 | 6.60e-01 |
| GO:BP | GO:0090100 | positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 1 | 100 | 6.60e-01 |
| GO:BP | GO:0006081 | cellular aldehyde metabolic process | 1 | 52 | 6.60e-01 |
| GO:BP | GO:1903557 | positive regulation of tumor necrosis factor superfamily cytokine production | 1 | 57 | 6.60e-01 |
| GO:BP | GO:0090114 | COPII-coated vesicle budding | 1 | 40 | 6.61e-01 |
| GO:BP | GO:0003016 | respiratory system process | 1 | 30 | 6.61e-01 |
| GO:BP | GO:0099068 | postsynapse assembly | 1 | 32 | 6.61e-01 |
| GO:BP | GO:0008361 | regulation of cell size | 1 | 159 | 6.61e-01 |
| GO:BP | GO:0006839 | mitochondrial transport | 3 | 185 | 6.61e-01 |
| GO:BP | GO:0016482 | cytosolic transport | 1 | 161 | 6.61e-01 |
| GO:BP | GO:0046839 | phospholipid dephosphorylation | 1 | 39 | 6.61e-01 |
| GO:BP | GO:0001817 | regulation of cytokine production | 8 | 447 | 6.61e-01 |
| GO:BP | GO:0007517 | muscle organ development | 3 | 277 | 6.61e-01 |
| GO:BP | GO:0042058 | regulation of epidermal growth factor receptor signaling pathway | 1 | 60 | 6.61e-01 |
| GO:BP | GO:0048515 | spermatid differentiation | 1 | 111 | 6.61e-01 |
| GO:BP | GO:0072175 | epithelial tube formation | 1 | 127 | 6.61e-01 |
| GO:BP | GO:0010001 | glial cell differentiation | 4 | 170 | 6.61e-01 |
| GO:BP | GO:0031060 | regulation of histone methylation | 1 | 47 | 6.62e-01 |
| GO:BP | GO:0042592 | homeostatic process | 19 | 1159 | 6.62e-01 |
| GO:BP | GO:0034204 | lipid translocation | 1 | 38 | 6.62e-01 |
| GO:BP | GO:0086001 | cardiac muscle cell action potential | 1 | 68 | 6.63e-01 |
| GO:BP | GO:0008584 | male gonad development | 1 | 99 | 6.63e-01 |
| GO:BP | GO:0061462 | protein localization to lysosome | 1 | 46 | 6.63e-01 |
| GO:BP | GO:0051051 | negative regulation of transport | 6 | 318 | 6.64e-01 |
| GO:BP | GO:0046546 | development of primary male sexual characteristics | 1 | 100 | 6.65e-01 |
| GO:BP | GO:0008380 | RNA splicing | 2 | 419 | 6.65e-01 |
| GO:BP | GO:0022604 | regulation of cell morphogenesis | 1 | 220 | 6.65e-01 |
| GO:BP | GO:0071310 | cellular response to organic substance | 17 | 1399 | 6.66e-01 |
| GO:BP | GO:0031641 | regulation of myelination | 1 | 36 | 6.66e-01 |
| GO:BP | GO:0030041 | actin filament polymerization | 2 | 134 | 6.66e-01 |
| GO:BP | GO:1901361 | organic cyclic compound catabolic process | 1 | 406 | 6.66e-01 |
| GO:BP | GO:0055080 | monoatomic cation homeostasis | 1 | 401 | 6.66e-01 |
| GO:BP | GO:0001816 | cytokine production | 8 | 451 | 6.68e-01 |
| GO:BP | GO:0007188 | adenylate cyclase-modulating G protein-coupled receptor signaling pathway | 1 | 118 | 6.68e-01 |
| GO:BP | GO:0002753 | cytosolic pattern recognition receptor signaling pathway | 1 | 68 | 6.68e-01 |
| GO:BP | GO:0042119 | neutrophil activation | 1 | 16 | 6.70e-01 |
| GO:BP | GO:0060291 | long-term synaptic potentiation | 1 | 64 | 6.70e-01 |
| GO:BP | GO:0006954 | inflammatory response | 6 | 429 | 6.70e-01 |
| GO:BP | GO:0014902 | myotube differentiation | 1 | 88 | 6.70e-01 |
| GO:BP | GO:0043550 | regulation of lipid kinase activity | 1 | 43 | 6.70e-01 |
| GO:BP | GO:0055117 | regulation of cardiac muscle contraction | 1 | 70 | 6.70e-01 |
| GO:BP | GO:0050854 | regulation of antigen receptor-mediated signaling pathway | 1 | 40 | 6.70e-01 |
| GO:BP | GO:0031348 | negative regulation of defense response | 1 | 159 | 6.71e-01 |
| GO:BP | GO:0030072 | peptide hormone secretion | 2 | 166 | 6.71e-01 |
| GO:BP | GO:0045860 | positive regulation of protein kinase activity | 4 | 260 | 6.71e-01 |
| GO:BP | GO:0007268 | chemical synaptic transmission | 14 | 490 | 6.71e-01 |
| GO:BP | GO:0098916 | anterograde trans-synaptic signaling | 14 | 490 | 6.71e-01 |
| GO:BP | GO:0030490 | maturation of SSU-rRNA | 1 | 54 | 6.71e-01 |
| GO:BP | GO:0050770 | regulation of axonogenesis | 3 | 139 | 6.71e-01 |
| GO:BP | GO:0050801 | monoatomic ion homeostasis | 1 | 408 | 6.71e-01 |
| GO:BP | GO:0098542 | defense response to other organism | 5 | 608 | 6.71e-01 |
| GO:BP | GO:0071897 | DNA biosynthetic process | 1 | 175 | 6.71e-01 |
| GO:BP | GO:0000082 | G1/S transition of mitotic cell cycle | 2 | 207 | 6.71e-01 |
| GO:BP | GO:0051607 | defense response to virus | 1 | 202 | 6.71e-01 |
| GO:BP | GO:0140546 | defense response to symbiont | 1 | 202 | 6.72e-01 |
| GO:BP | GO:0051239 | regulation of multicellular organismal process | 33 | 2035 | 6.72e-01 |
| GO:BP | GO:0070988 | demethylation | 1 | 52 | 6.73e-01 |
| GO:BP | GO:0016072 | rRNA metabolic process | 5 | 258 | 6.73e-01 |
| GO:BP | GO:0051225 | spindle assembly | 1 | 120 | 6.74e-01 |
| GO:BP | GO:0001704 | formation of primary germ layer | 1 | 96 | 6.74e-01 |
| GO:BP | GO:0090263 | positive regulation of canonical Wnt signaling pathway | 1 | 91 | 6.74e-01 |
| GO:BP | GO:0071495 | cellular response to endogenous stimulus | 16 | 1107 | 6.74e-01 |
| GO:BP | GO:0097435 | supramolecular fiber organization | 9 | 665 | 6.74e-01 |
| GO:BP | GO:0043603 | amide metabolic process | 2 | 993 | 6.74e-01 |
| GO:BP | GO:0001649 | osteoblast differentiation | 2 | 179 | 6.74e-01 |
| GO:BP | GO:0031016 | pancreas development | 1 | 53 | 6.74e-01 |
| GO:BP | GO:0030308 | negative regulation of cell growth | 2 | 160 | 6.74e-01 |
| GO:BP | GO:0071526 | semaphorin-plexin signaling pathway | 1 | 44 | 6.74e-01 |
| GO:BP | GO:0035825 | homologous recombination | 1 | 43 | 6.74e-01 |
| GO:BP | GO:0051276 | chromosome organization | 4 | 543 | 6.75e-01 |
| GO:BP | GO:0045087 | innate immune response | 4 | 488 | 6.76e-01 |
| GO:BP | GO:0021587 | cerebellum morphogenesis | 1 | 36 | 6.76e-01 |
| GO:BP | GO:0032535 | regulation of cellular component size | 4 | 305 | 6.76e-01 |
| GO:BP | GO:1902115 | regulation of organelle assembly | 1 | 186 | 6.78e-01 |
| GO:BP | GO:0002790 | peptide secretion | 2 | 170 | 6.78e-01 |
| GO:BP | GO:0060070 | canonical Wnt signaling pathway | 3 | 251 | 6.78e-01 |
| GO:BP | GO:0001890 | placenta development | 1 | 117 | 6.78e-01 |
| GO:BP | GO:0043524 | negative regulation of neuron apoptotic process | 1 | 120 | 6.80e-01 |
| GO:BP | GO:0019058 | viral life cycle | 1 | 244 | 6.81e-01 |
| GO:BP | GO:2000351 | regulation of endothelial cell apoptotic process | 1 | 35 | 6.81e-01 |
| GO:BP | GO:0050793 | regulation of developmental process | 16 | 1835 | 6.81e-01 |
| GO:BP | GO:0099537 | trans-synaptic signaling | 14 | 495 | 6.81e-01 |
| GO:BP | GO:0052547 | regulation of peptidase activity | 1 | 271 | 6.82e-01 |
| GO:BP | GO:0044403 | biological process involved in symbiotic interaction | 1 | 223 | 6.82e-01 |
| GO:BP | GO:0098739 | import across plasma membrane | 1 | 133 | 6.83e-01 |
| GO:BP | GO:1901989 | positive regulation of cell cycle phase transition | 1 | 103 | 6.83e-01 |
| GO:BP | GO:0098815 | modulation of excitatory postsynaptic potential | 1 | 40 | 6.83e-01 |
| GO:BP | GO:0009887 | animal organ morphogenesis | 12 | 742 | 6.83e-01 |
| GO:BP | GO:0007052 | mitotic spindle organization | 1 | 129 | 6.83e-01 |
| GO:BP | GO:0008285 | negative regulation of cell population proliferation | 1 | 513 | 6.83e-01 |
| GO:BP | GO:0032940 | secretion by cell | 7 | 569 | 6.83e-01 |
| GO:BP | GO:0097035 | regulation of membrane lipid distribution | 1 | 43 | 6.83e-01 |
| GO:BP | GO:0035148 | tube formation | 1 | 138 | 6.83e-01 |
| GO:BP | GO:1901888 | regulation of cell junction assembly | 4 | 168 | 6.83e-01 |
| GO:BP | GO:1903305 | regulation of regulated secretory pathway | 1 | 89 | 6.83e-01 |
| GO:BP | GO:1903829 | positive regulation of protein localization | 5 | 386 | 6.83e-01 |
| GO:BP | GO:0031103 | axon regeneration | 1 | 42 | 6.84e-01 |
| GO:BP | GO:1901184 | regulation of ERBB signaling pathway | 1 | 66 | 6.84e-01 |
| GO:BP | GO:0016331 | morphogenesis of embryonic epithelium | 1 | 132 | 6.84e-01 |
| GO:BP | GO:0048562 | embryonic organ morphogenesis | 3 | 187 | 6.84e-01 |
| GO:BP | GO:0006810 | transport | 2 | 3298 | 6.84e-01 |
| GO:BP | GO:0010975 | regulation of neuron projection development | 8 | 372 | 6.84e-01 |
| GO:BP | GO:0046822 | regulation of nucleocytoplasmic transport | 1 | 97 | 6.85e-01 |
| GO:BP | GO:0046883 | regulation of hormone secretion | 2 | 168 | 6.85e-01 |
| GO:BP | GO:0016192 | vesicle-mediated transport | 6 | 1238 | 6.85e-01 |
| GO:BP | GO:0050919 | negative chemotaxis | 1 | 42 | 6.85e-01 |
| GO:BP | GO:0030517 | negative regulation of axon extension | 1 | 41 | 6.85e-01 |
| GO:BP | GO:0002718 | regulation of cytokine production involved in immune response | 1 | 70 | 6.85e-01 |
| GO:BP | GO:0002367 | cytokine production involved in immune response | 1 | 70 | 6.85e-01 |
| GO:BP | GO:0097553 | calcium ion transmembrane import into cytosol | 2 | 115 | 6.85e-01 |
| GO:BP | GO:0006306 | DNA methylation | 1 | 46 | 6.86e-01 |
| GO:BP | GO:0006305 | DNA alkylation | 1 | 46 | 6.86e-01 |
| GO:BP | GO:0099084 | postsynaptic specialization organization | 1 | 36 | 6.87e-01 |
| GO:BP | GO:0072659 | protein localization to plasma membrane | 1 | 249 | 6.87e-01 |
| GO:BP | GO:0008589 | regulation of smoothened signaling pathway | 1 | 73 | 6.87e-01 |
| GO:BP | GO:0120035 | regulation of plasma membrane bounded cell projection organization | 2 | 529 | 6.88e-01 |
| GO:BP | GO:0051899 | membrane depolarization | 1 | 60 | 6.88e-01 |
| GO:BP | GO:0046620 | regulation of organ growth | 1 | 71 | 6.88e-01 |
| GO:BP | GO:0009605 | response to external stimulus | 28 | 1719 | 6.89e-01 |
| GO:BP | GO:0035282 | segmentation | 1 | 75 | 6.89e-01 |
| GO:BP | GO:0050731 | positive regulation of peptidyl-tyrosine phosphorylation | 2 | 105 | 6.89e-01 |
| GO:BP | GO:0001837 | epithelial to mesenchymal transition | 1 | 138 | 6.90e-01 |
| GO:BP | GO:0061097 | regulation of protein tyrosine kinase activity | 1 | 65 | 6.90e-01 |
| GO:BP | GO:0001819 | positive regulation of cytokine production | 5 | 276 | 6.90e-01 |
| GO:BP | GO:2000649 | regulation of sodium ion transmembrane transporter activity | 1 | 44 | 6.90e-01 |
| GO:BP | GO:0051972 | regulation of telomerase activity | 1 | 45 | 6.90e-01 |
| GO:BP | GO:0045668 | negative regulation of osteoblast differentiation | 1 | 36 | 6.90e-01 |
| GO:BP | GO:0048646 | anatomical structure formation involved in morphogenesis | 13 | 870 | 6.90e-01 |
| GO:BP | GO:0051240 | positive regulation of multicellular organismal process | 10 | 1101 | 6.90e-01 |
| GO:BP | GO:0033209 | tumor necrosis factor-mediated signaling pathway | 1 | 76 | 6.90e-01 |
| GO:BP | GO:1903169 | regulation of calcium ion transmembrane transport | 2 | 122 | 6.91e-01 |
| GO:BP | GO:0021575 | hindbrain morphogenesis | 1 | 38 | 6.92e-01 |
| GO:BP | GO:1901655 | cellular response to ketone | 2 | 86 | 6.93e-01 |
| GO:BP | GO:0050873 | brown fat cell differentiation | 1 | 41 | 6.93e-01 |
| GO:BP | GO:0048285 | organelle fission | 3 | 388 | 6.94e-01 |
| GO:BP | GO:0051279 | regulation of release of sequestered calcium ion into cytosol | 1 | 60 | 6.94e-01 |
| GO:BP | GO:1901796 | regulation of signal transduction by p53 class mediator | 1 | 101 | 6.94e-01 |
| GO:BP | GO:0097696 | receptor signaling pathway via STAT | 2 | 88 | 6.95e-01 |
| GO:BP | GO:0051222 | positive regulation of protein transport | 3 | 242 | 6.96e-01 |
| GO:BP | GO:0048513 | animal organ development | 5 | 2189 | 6.96e-01 |
| GO:BP | GO:0031344 | regulation of cell projection organization | 2 | 541 | 6.96e-01 |
| GO:BP | GO:1901700 | response to oxygen-containing compound | 16 | 1223 | 6.96e-01 |
| GO:BP | GO:0071417 | cellular response to organonitrogen compound | 9 | 485 | 6.96e-01 |
| GO:BP | GO:0010638 | positive regulation of organelle organization | 7 | 439 | 6.98e-01 |
| GO:BP | GO:0048729 | tissue morphogenesis | 1 | 504 | 6.99e-01 |
| GO:BP | GO:0007043 | cell-cell junction assembly | 1 | 105 | 6.99e-01 |
| GO:BP | GO:0098609 | cell-cell adhesion | 4 | 609 | 6.99e-01 |
| GO:BP | GO:0048640 | negative regulation of developmental growth | 2 | 95 | 7.00e-01 |
| GO:BP | GO:0051234 | establishment of localization | 2 | 3433 | 7.01e-01 |
| GO:BP | GO:0046718 | viral entry into host cell | 2 | 107 | 7.01e-01 |
| GO:BP | GO:0046661 | male sex differentiation | 1 | 114 | 7.02e-01 |
| GO:BP | GO:1901890 | positive regulation of cell junction assembly | 2 | 82 | 7.02e-01 |
| GO:BP | GO:0012501 | programmed cell death | 16 | 1479 | 7.03e-01 |
| GO:BP | GO:0009895 | negative regulation of catabolic process | 6 | 280 | 7.03e-01 |
| GO:BP | GO:0072089 | stem cell proliferation | 1 | 84 | 7.03e-01 |
| GO:BP | GO:1901565 | organonitrogen compound catabolic process | 13 | 1145 | 7.03e-01 |
| GO:BP | GO:0015833 | peptide transport | 2 | 179 | 7.03e-01 |
| GO:BP | GO:0036230 | granulocyte activation | 1 | 19 | 7.03e-01 |
| GO:BP | GO:0045292 | mRNA cis splicing, via spliceosome | 1 | 26 | 7.03e-01 |
| GO:BP | GO:0043254 | regulation of protein-containing complex assembly | 3 | 348 | 7.03e-01 |
| GO:BP | GO:0035556 | intracellular signal transduction | 28 | 2065 | 7.04e-01 |
| GO:BP | GO:0072577 | endothelial cell apoptotic process | 1 | 40 | 7.05e-01 |
| GO:BP | GO:0031623 | receptor internalization | 1 | 95 | 7.06e-01 |
| GO:BP | GO:0045814 | negative regulation of gene expression, epigenetic | 1 | 79 | 7.07e-01 |
| GO:BP | GO:0061387 | regulation of extent of cell growth | 2 | 97 | 7.08e-01 |
| GO:BP | GO:0001952 | regulation of cell-matrix adhesion | 1 | 97 | 7.09e-01 |
| GO:BP | GO:0010976 | positive regulation of neuron projection development | 1 | 131 | 7.09e-01 |
| GO:BP | GO:0048704 | embryonic skeletal system morphogenesis | 1 | 55 | 7.09e-01 |
| GO:BP | GO:1903307 | positive regulation of regulated secretory pathway | 1 | 32 | 7.09e-01 |
| GO:BP | GO:0099536 | synaptic signaling | 6 | 511 | 7.09e-01 |
| GO:BP | GO:0000302 | response to reactive oxygen species | 2 | 160 | 7.10e-01 |
| GO:BP | GO:0032271 | regulation of protein polymerization | 3 | 168 | 7.11e-01 |
| GO:BP | GO:0002639 | positive regulation of immunoglobulin production | 1 | 30 | 7.11e-01 |
| GO:BP | GO:0048878 | chemical homeostasis | 7 | 676 | 7.11e-01 |
| GO:BP | GO:0030510 | regulation of BMP signaling pathway | 1 | 84 | 7.11e-01 |
| GO:BP | GO:0099054 | presynapse assembly | 1 | 39 | 7.11e-01 |
| GO:BP | GO:0016042 | lipid catabolic process | 1 | 225 | 7.12e-01 |
| GO:BP | GO:0009791 | post-embryonic development | 1 | 74 | 7.12e-01 |
| GO:BP | GO:0032210 | regulation of telomere maintenance via telomerase | 1 | 49 | 7.12e-01 |
| GO:BP | GO:0043255 | regulation of carbohydrate biosynthetic process | 1 | 77 | 7.12e-01 |
| GO:BP | GO:0060249 | anatomical structure homeostasis | 2 | 170 | 7.13e-01 |
| GO:BP | GO:0001894 | tissue homeostasis | 2 | 170 | 7.13e-01 |
| GO:BP | GO:0001932 | regulation of protein phosphorylation | 11 | 796 | 7.13e-01 |
| GO:BP | GO:0060322 | head development | 14 | 633 | 7.13e-01 |
| GO:BP | GO:1901214 | regulation of neuron death | 3 | 246 | 7.14e-01 |
| GO:BP | GO:0043300 | regulation of leukocyte degranulation | 1 | 27 | 7.14e-01 |
| GO:BP | GO:0031100 | animal organ regeneration | 1 | 47 | 7.14e-01 |
| GO:BP | GO:0009057 | macromolecule catabolic process | 13 | 1199 | 7.14e-01 |
| GO:BP | GO:0048609 | multicellular organismal reproductive process | 7 | 538 | 7.14e-01 |
| GO:BP | GO:0051017 | actin filament bundle assembly | 1 | 138 | 7.14e-01 |
| GO:BP | GO:0045190 | isotype switching | 1 | 39 | 7.14e-01 |
| GO:BP | GO:0022603 | regulation of anatomical structure morphogenesis | 5 | 691 | 7.14e-01 |
| GO:BP | GO:0050806 | positive regulation of synaptic transmission | 3 | 106 | 7.14e-01 |
| GO:BP | GO:0007420 | brain development | 1 | 591 | 7.14e-01 |
| GO:BP | GO:0002208 | somatic diversification of immunoglobulins involved in immune response | 1 | 39 | 7.14e-01 |
| GO:BP | GO:0002204 | somatic recombination of immunoglobulin genes involved in immune response | 1 | 39 | 7.14e-01 |
| GO:BP | GO:1901799 | negative regulation of proteasomal protein catabolic process | 1 | 47 | 7.14e-01 |
| GO:BP | GO:0048638 | regulation of developmental growth | 3 | 258 | 7.14e-01 |
| GO:BP | GO:0042692 | muscle cell differentiation | 4 | 324 | 7.15e-01 |
| GO:BP | GO:0051928 | positive regulation of calcium ion transport | 1 | 82 | 7.15e-01 |
| GO:BP | GO:0030111 | regulation of Wnt signaling pathway | 3 | 273 | 7.15e-01 |
| GO:BP | GO:0031346 | positive regulation of cell projection organization | 1 | 303 | 7.15e-01 |
| GO:BP | GO:0048255 | mRNA stabilization | 1 | 50 | 7.16e-01 |
| GO:BP | GO:0050732 | negative regulation of peptidyl-tyrosine phosphorylation | 1 | 46 | 7.16e-01 |
| GO:BP | GO:0002702 | positive regulation of production of molecular mediator of immune response | 1 | 77 | 7.17e-01 |
| GO:BP | GO:0042177 | negative regulation of protein catabolic process | 2 | 100 | 7.17e-01 |
| GO:BP | GO:0050885 | neuromuscular process controlling balance | 1 | 35 | 7.17e-01 |
| GO:BP | GO:0002683 | negative regulation of immune system process | 4 | 289 | 7.17e-01 |
| GO:BP | GO:0044409 | entry into host | 2 | 113 | 7.17e-01 |
| GO:BP | GO:0044242 | cellular lipid catabolic process | 2 | 170 | 7.17e-01 |
| GO:BP | GO:0031102 | neuron projection regeneration | 1 | 47 | 7.17e-01 |
| GO:BP | GO:0030326 | embryonic limb morphogenesis | 2 | 89 | 7.17e-01 |
| GO:BP | GO:0065008 | regulation of biological quality | 1 | 2102 | 7.17e-01 |
| GO:BP | GO:0035113 | embryonic appendage morphogenesis | 2 | 89 | 7.17e-01 |
| GO:BP | GO:0061572 | actin filament bundle organization | 1 | 140 | 7.18e-01 |
| GO:BP | GO:0045931 | positive regulation of mitotic cell cycle | 1 | 113 | 7.18e-01 |
| GO:BP | GO:0042776 | proton motive force-driven mitochondrial ATP synthesis | 1 | 57 | 7.19e-01 |
| GO:BP | GO:1904951 | positive regulation of establishment of protein localization | 3 | 258 | 7.19e-01 |
| GO:BP | GO:0032870 | cellular response to hormone stimulus | 8 | 457 | 7.19e-01 |
| GO:BP | GO:1901566 | organonitrogen compound biosynthetic process | 3 | 1484 | 7.19e-01 |
| GO:BP | GO:0051336 | regulation of hydrolase activity | 3 | 701 | 7.22e-01 |
| GO:BP | GO:1904036 | negative regulation of epithelial cell apoptotic process | 1 | 43 | 7.22e-01 |
| GO:BP | GO:0006304 | DNA modification | 2 | 89 | 7.23e-01 |
| GO:BP | GO:0016071 | mRNA metabolic process | 2 | 665 | 7.23e-01 |
| GO:BP | GO:0010906 | regulation of glucose metabolic process | 1 | 86 | 7.24e-01 |
| GO:BP | GO:0050805 | negative regulation of synaptic transmission | 1 | 35 | 7.25e-01 |
| GO:BP | GO:0050852 | T cell receptor signaling pathway | 1 | 84 | 7.25e-01 |
| GO:BP | GO:0002705 | positive regulation of leukocyte mediated immunity | 1 | 68 | 7.25e-01 |
| GO:BP | GO:0001501 | skeletal system development | 5 | 377 | 7.25e-01 |
| GO:BP | GO:0043200 | response to amino acid | 1 | 95 | 7.25e-01 |
| GO:BP | GO:2001235 | positive regulation of apoptotic signaling pathway | 1 | 108 | 7.25e-01 |
| GO:BP | GO:0006942 | regulation of striated muscle contraction | 1 | 85 | 7.26e-01 |
| GO:BP | GO:0008154 | actin polymerization or depolymerization | 2 | 160 | 7.26e-01 |
| GO:BP | GO:2000026 | regulation of multicellular organismal development | 14 | 1014 | 7.28e-01 |
| GO:BP | GO:0030855 | epithelial cell differentiation | 4 | 442 | 7.28e-01 |
| GO:BP | GO:0021695 | cerebellar cortex development | 1 | 44 | 7.29e-01 |
| GO:BP | GO:0060349 | bone morphogenesis | 1 | 74 | 7.29e-01 |
| GO:BP | GO:0061337 | cardiac conduction | 1 | 88 | 7.29e-01 |
| GO:BP | GO:0035176 | social behavior | 1 | 34 | 7.30e-01 |
| GO:BP | GO:0015980 | energy derivation by oxidation of organic compounds | 3 | 288 | 7.30e-01 |
| GO:BP | GO:0032386 | regulation of intracellular transport | 3 | 292 | 7.30e-01 |
| GO:BP | GO:0099172 | presynapse organization | 1 | 42 | 7.30e-01 |
| GO:BP | GO:0014015 | positive regulation of gliogenesis | 1 | 45 | 7.30e-01 |
| GO:BP | GO:0002253 | activation of immune response | 2 | 272 | 7.30e-01 |
| GO:BP | GO:0006091 | generation of precursor metabolites and energy | 4 | 369 | 7.32e-01 |
| GO:BP | GO:0005996 | monosaccharide metabolic process | 3 | 209 | 7.32e-01 |
| GO:BP | GO:0032886 | regulation of microtubule-based process | 1 | 217 | 7.32e-01 |
| GO:BP | GO:1902305 | regulation of sodium ion transmembrane transport | 1 | 51 | 7.32e-01 |
| GO:BP | GO:0016055 | Wnt signaling pathway | 4 | 375 | 7.33e-01 |
| GO:BP | GO:0002381 | immunoglobulin production involved in immunoglobulin-mediated immune response | 1 | 41 | 7.34e-01 |
| GO:BP | GO:0008637 | apoptotic mitochondrial changes | 1 | 90 | 7.35e-01 |
| GO:BP | GO:0009615 | response to virus | 2 | 275 | 7.35e-01 |
| GO:BP | GO:0198738 | cell-cell signaling by wnt | 4 | 376 | 7.35e-01 |
| GO:BP | GO:0030036 | actin cytoskeleton organization | 4 | 612 | 7.35e-01 |
| GO:BP | GO:0002376 | immune system process | 11 | 1447 | 7.35e-01 |
| GO:BP | GO:0034767 | positive regulation of monoatomic ion transmembrane transport | 3 | 114 | 7.37e-01 |
| GO:BP | GO:0042733 | embryonic digit morphogenesis | 1 | 51 | 7.38e-01 |
| GO:BP | GO:0001541 | ovarian follicle development | 1 | 41 | 7.38e-01 |
| GO:BP | GO:0007267 | cell-cell signaling | 13 | 1138 | 7.38e-01 |
| GO:BP | GO:0140352 | export from cell | 7 | 611 | 7.39e-01 |
| GO:BP | GO:1904064 | positive regulation of cation transmembrane transport | 2 | 99 | 7.39e-01 |
| GO:BP | GO:0051703 | biological process involved in intraspecies interaction between organisms | 1 | 34 | 7.41e-01 |
| GO:BP | GO:0031032 | actomyosin structure organization | 2 | 186 | 7.41e-01 |
| GO:BP | GO:1990778 | protein localization to cell periphery | 1 | 300 | 7.41e-01 |
| GO:BP | GO:0031047 | RNA-mediated gene silencing | 1 | 103 | 7.41e-01 |
| GO:BP | GO:0045861 | negative regulation of proteolysis | 1 | 211 | 7.41e-01 |
| GO:BP | GO:0006413 | translational initiation | 1 | 116 | 7.41e-01 |
| GO:BP | GO:0045669 | positive regulation of osteoblast differentiation | 1 | 54 | 7.41e-01 |
| GO:BP | GO:0045596 | negative regulation of cell differentiation | 6 | 482 | 7.42e-01 |
| GO:BP | GO:0006915 | apoptotic process | 15 | 1443 | 7.43e-01 |
| GO:BP | GO:0009060 | aerobic respiration | 1 | 168 | 7.43e-01 |
| GO:BP | GO:0034330 | cell junction organization | 4 | 575 | 7.43e-01 |
| GO:BP | GO:0043303 | mast cell degranulation | 1 | 30 | 7.43e-01 |
| GO:BP | GO:0042471 | ear morphogenesis | 1 | 73 | 7.44e-01 |
| GO:BP | GO:0000398 | mRNA splicing, via spliceosome | 1 | 289 | 7.44e-01 |
| GO:BP | GO:0000377 | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 1 | 289 | 7.44e-01 |
| GO:BP | GO:0000375 | RNA splicing, via transesterification reactions | 1 | 293 | 7.45e-01 |
| GO:BP | GO:1901698 | response to nitrogen compound | 15 | 830 | 7.45e-01 |
| GO:BP | GO:0120162 | positive regulation of cold-induced thermogenesis | 1 | 69 | 7.45e-01 |
| GO:BP | GO:0043087 | regulation of GTPase activity | 3 | 302 | 7.45e-01 |
| GO:BP | GO:0010467 | gene expression | 1 | 4587 | 7.45e-01 |
| GO:BP | GO:0006275 | regulation of DNA replication | 2 | 116 | 7.45e-01 |
| GO:BP | GO:1900180 | regulation of protein localization to nucleus | 1 | 117 | 7.45e-01 |
| GO:BP | GO:0051707 | response to other organism | 12 | 820 | 7.45e-01 |
| GO:BP | GO:0043207 | response to external biotic stimulus | 12 | 820 | 7.47e-01 |
| GO:BP | GO:0006687 | glycosphingolipid metabolic process | 1 | 48 | 7.49e-01 |
| GO:BP | GO:0042060 | wound healing | 3 | 320 | 7.51e-01 |
| GO:BP | GO:0032504 | multicellular organism reproduction | 7 | 556 | 7.53e-01 |
| GO:BP | GO:0000041 | transition metal ion transport | 1 | 71 | 7.53e-01 |
| GO:BP | GO:1904356 | regulation of telomere maintenance via telomere lengthening | 1 | 56 | 7.53e-01 |
| GO:BP | GO:0016447 | somatic recombination of immunoglobulin gene segments | 1 | 47 | 7.53e-01 |
| GO:BP | GO:0030177 | positive regulation of Wnt signaling pathway | 1 | 120 | 7.53e-01 |
| GO:BP | GO:0002279 | mast cell activation involved in immune response | 1 | 31 | 7.53e-01 |
| GO:BP | GO:0007009 | plasma membrane organization | 2 | 116 | 7.54e-01 |
| GO:BP | GO:0051592 | response to calcium ion | 1 | 113 | 7.54e-01 |
| GO:BP | GO:0002366 | leukocyte activation involved in immune response | 5 | 154 | 7.54e-01 |
| GO:BP | GO:0048705 | skeletal system morphogenesis | 2 | 155 | 7.54e-01 |
| GO:BP | GO:0042552 | myelination | 1 | 111 | 7.54e-01 |
| GO:BP | GO:0045667 | regulation of osteoblast differentiation | 2 | 99 | 7.57e-01 |
| GO:BP | GO:0031345 | negative regulation of cell projection organization | 3 | 156 | 7.57e-01 |
| GO:BP | GO:0015986 | proton motive force-driven ATP synthesis | 1 | 66 | 7.57e-01 |
| GO:BP | GO:0032675 | regulation of interleukin-6 production | 1 | 86 | 7.57e-01 |
| GO:BP | GO:0032635 | interleukin-6 production | 1 | 86 | 7.57e-01 |
| GO:BP | GO:1902373 | negative regulation of mRNA catabolic process | 1 | 57 | 7.57e-01 |
| GO:BP | GO:0002448 | mast cell mediated immunity | 1 | 33 | 7.57e-01 |
| GO:BP | GO:0007272 | ensheathment of neurons | 1 | 113 | 7.57e-01 |
| GO:BP | GO:0008366 | axon ensheathment | 1 | 113 | 7.57e-01 |
| GO:BP | GO:0007127 | meiosis I | 2 | 77 | 7.58e-01 |
| GO:BP | GO:0060079 | excitatory postsynaptic potential | 2 | 70 | 7.59e-01 |
| GO:BP | GO:0060348 | bone development | 2 | 170 | 7.59e-01 |
| GO:BP | GO:0001101 | response to acid chemical | 1 | 105 | 7.59e-01 |
| GO:BP | GO:0050922 | negative regulation of chemotaxis | 1 | 44 | 7.59e-01 |
| GO:BP | GO:0032649 | regulation of type II interferon production | 1 | 52 | 7.60e-01 |
| GO:BP | GO:0002889 | regulation of immunoglobulin mediated immune response | 1 | 39 | 7.60e-01 |
| GO:BP | GO:0051179 | localization | 2 | 3969 | 7.60e-01 |
| GO:BP | GO:0045807 | positive regulation of endocytosis | 1 | 104 | 7.60e-01 |
| GO:BP | GO:0002712 | regulation of B cell mediated immunity | 1 | 39 | 7.60e-01 |
| GO:BP | GO:0070192 | chromosome organization involved in meiotic cell cycle | 1 | 35 | 7.60e-01 |
| GO:BP | GO:0031334 | positive regulation of protein-containing complex assembly | 3 | 161 | 7.60e-01 |
| GO:BP | GO:0072329 | monocarboxylic acid catabolic process | 1 | 105 | 7.60e-01 |
| GO:BP | GO:0051216 | cartilage development | 1 | 151 | 7.60e-01 |
| GO:BP | GO:0002886 | regulation of myeloid leukocyte mediated immunity | 1 | 34 | 7.61e-01 |
| GO:BP | GO:0032609 | type II interferon production | 1 | 53 | 7.61e-01 |
| GO:BP | GO:0002263 | cell activation involved in immune response | 5 | 157 | 7.61e-01 |
| GO:BP | GO:0045597 | positive regulation of cell differentiation | 4 | 620 | 7.62e-01 |
| GO:BP | GO:0007006 | mitochondrial membrane organization | 1 | 114 | 7.63e-01 |
| GO:BP | GO:0046879 | hormone secretion | 2 | 210 | 7.63e-01 |
| GO:BP | GO:0045143 | homologous chromosome segregation | 1 | 34 | 7.64e-01 |
| GO:BP | GO:0002429 | immune response-activating cell surface receptor signaling pathway | 4 | 151 | 7.64e-01 |
| GO:BP | GO:1901136 | carbohydrate derivative catabolic process | 2 | 137 | 7.65e-01 |
| GO:BP | GO:0009611 | response to wounding | 4 | 415 | 7.65e-01 |
| GO:BP | GO:0002088 | lens development in camera-type eye | 1 | 57 | 7.65e-01 |
| GO:BP | GO:0051101 | regulation of DNA binding | 1 | 104 | 7.65e-01 |
| GO:BP | GO:0044248 | cellular catabolic process | 1 | 1229 | 7.66e-01 |
| GO:BP | GO:0010817 | regulation of hormone levels | 1 | 336 | 7.67e-01 |
| GO:BP | GO:0071103 | DNA conformation change | 1 | 87 | 7.69e-01 |
| GO:BP | GO:1901215 | negative regulation of neuron death | 1 | 167 | 7.70e-01 |
| GO:BP | GO:0010507 | negative regulation of autophagy | 1 | 74 | 7.71e-01 |
| GO:BP | GO:0009607 | response to biotic stimulus | 12 | 850 | 7.71e-01 |
| GO:BP | GO:0009725 | response to hormone | 11 | 642 | 7.72e-01 |
| GO:BP | GO:0010951 | negative regulation of endopeptidase activity | 1 | 102 | 7.73e-01 |
| GO:BP | GO:0006903 | vesicle targeting | 1 | 61 | 7.74e-01 |
| GO:BP | GO:0032680 | regulation of tumor necrosis factor production | 1 | 91 | 7.74e-01 |
| GO:BP | GO:0032640 | tumor necrosis factor production | 1 | 91 | 7.74e-01 |
| GO:BP | GO:0006397 | mRNA processing | 1 | 450 | 7.74e-01 |
| GO:BP | GO:0061982 | meiosis I cell cycle process | 2 | 81 | 7.75e-01 |
| GO:BP | GO:0051651 | maintenance of location in cell | 2 | 170 | 7.75e-01 |
| GO:BP | GO:0003006 | developmental process involved in reproduction | 5 | 598 | 7.75e-01 |
| GO:BP | GO:0001909 | leukocyte mediated cytotoxicity | 2 | 54 | 7.76e-01 |
| GO:BP | GO:1904892 | regulation of receptor signaling pathway via STAT | 1 | 54 | 7.76e-01 |
| GO:BP | GO:0070997 | neuron death | 3 | 286 | 7.77e-01 |
| GO:BP | GO:0009914 | hormone transport | 2 | 215 | 7.77e-01 |
| GO:BP | GO:0016445 | somatic diversification of immunoglobulins | 1 | 53 | 7.77e-01 |
| GO:BP | GO:0046513 | ceramide biosynthetic process | 1 | 53 | 7.78e-01 |
| GO:BP | GO:0045109 | intermediate filament organization | 1 | 21 | 7.78e-01 |
| GO:BP | GO:0044000 | movement in host | 2 | 138 | 7.80e-01 |
| GO:BP | GO:0050771 | negative regulation of axonogenesis | 1 | 58 | 7.80e-01 |
| GO:BP | GO:0099601 | regulation of neurotransmitter receptor activity | 1 | 40 | 7.80e-01 |
| GO:BP | GO:0099565 | chemical synaptic transmission, postsynaptic | 2 | 75 | 7.80e-01 |
| GO:BP | GO:0032206 | positive regulation of telomere maintenance | 1 | 64 | 7.80e-01 |
| GO:BP | GO:0007399 | nervous system development | 14 | 1904 | 7.82e-01 |
| GO:BP | GO:0071706 | tumor necrosis factor superfamily cytokine production | 1 | 94 | 7.82e-01 |
| GO:BP | GO:1903555 | regulation of tumor necrosis factor superfamily cytokine production | 1 | 94 | 7.82e-01 |
| GO:BP | GO:0019935 | cyclic-nucleotide-mediated signaling | 1 | 55 | 7.84e-01 |
| GO:BP | GO:0045216 | cell-cell junction organization | 1 | 153 | 7.84e-01 |
| GO:BP | GO:0007004 | telomere maintenance via telomerase | 1 | 63 | 7.84e-01 |
| GO:BP | GO:0019538 | protein metabolic process | 44 | 4241 | 7.84e-01 |
| GO:BP | GO:0008406 | gonad development | 1 | 158 | 7.85e-01 |
| GO:BP | GO:0048732 | gland development | 4 | 318 | 7.85e-01 |
| GO:BP | GO:0034763 | negative regulation of transmembrane transport | 1 | 96 | 7.86e-01 |
| GO:BP | GO:0017156 | calcium-ion regulated exocytosis | 1 | 46 | 7.87e-01 |
| GO:BP | GO:1903051 | negative regulation of proteolysis involved in protein catabolic process | 1 | 61 | 7.87e-01 |
| GO:BP | GO:0010562 | positive regulation of phosphorus metabolic process | 8 | 597 | 7.87e-01 |
| GO:BP | GO:0048814 | regulation of dendrite morphogenesis | 1 | 58 | 7.87e-01 |
| GO:BP | GO:0007051 | spindle organization | 1 | 188 | 7.87e-01 |
| GO:BP | GO:0045937 | positive regulation of phosphate metabolic process | 8 | 597 | 7.87e-01 |
| GO:BP | GO:0006278 | RNA-templated DNA biosynthetic process | 1 | 64 | 7.87e-01 |
| GO:BP | GO:0002768 | immune response-regulating cell surface receptor signaling pathway | 1 | 162 | 7.88e-01 |
| GO:BP | GO:0032880 | regulation of protein localization | 8 | 710 | 7.88e-01 |
| GO:BP | GO:0044238 | primary metabolic process | 5 | 7806 | 7.88e-01 |
| GO:BP | GO:0099587 | inorganic ion import across plasma membrane | 1 | 73 | 7.89e-01 |
| GO:BP | GO:0098659 | inorganic cation import across plasma membrane | 1 | 73 | 7.89e-01 |
| GO:BP | GO:0045137 | development of primary sexual characteristics | 1 | 161 | 7.90e-01 |
| GO:BP | GO:0017157 | regulation of exocytosis | 1 | 147 | 7.91e-01 |
| GO:BP | GO:0048706 | embryonic skeletal system development | 1 | 78 | 7.91e-01 |
| GO:BP | GO:0042157 | lipoprotein metabolic process | 1 | 116 | 7.92e-01 |
| GO:BP | GO:0002562 | somatic diversification of immune receptors via germline recombination within a single locus | 1 | 55 | 7.92e-01 |
| GO:BP | GO:0010243 | response to organonitrogen compound | 11 | 782 | 7.92e-01 |
| GO:BP | GO:0016444 | somatic cell DNA recombination | 1 | 55 | 7.92e-01 |
| GO:BP | GO:0072522 | purine-containing compound biosynthetic process | 4 | 218 | 7.92e-01 |
| GO:BP | GO:0006986 | response to unfolded protein | 1 | 128 | 7.92e-01 |
| GO:BP | GO:0006024 | glycosaminoglycan biosynthetic process | 1 | 60 | 7.92e-01 |
| GO:BP | GO:0030518 | intracellular steroid hormone receptor signaling pathway | 1 | 95 | 7.93e-01 |
| GO:BP | GO:0006888 | endoplasmic reticulum to Golgi vesicle-mediated transport | 2 | 119 | 7.95e-01 |
| GO:BP | GO:0046903 | secretion | 7 | 645 | 7.95e-01 |
| GO:BP | GO:0042542 | response to hydrogen peroxide | 1 | 103 | 7.95e-01 |
| GO:BP | GO:0050905 | neuromuscular process | 1 | 107 | 7.95e-01 |
| GO:BP | GO:0009247 | glycolipid biosynthetic process | 1 | 61 | 7.96e-01 |
| GO:BP | GO:0051346 | negative regulation of hydrolase activity | 5 | 220 | 7.96e-01 |
| GO:BP | GO:0035108 | limb morphogenesis | 2 | 114 | 7.97e-01 |
| GO:BP | GO:0035107 | appendage morphogenesis | 2 | 114 | 7.97e-01 |
| GO:BP | GO:0030029 | actin filament-based process | 4 | 687 | 7.97e-01 |
| GO:BP | GO:0008219 | cell death | 16 | 1596 | 7.99e-01 |
| GO:BP | GO:0007416 | synapse assembly | 3 | 152 | 7.99e-01 |
| GO:BP | GO:0032412 | regulation of monoatomic ion transmembrane transporter activity | 4 | 190 | 7.99e-01 |
| GO:BP | GO:0042100 | B cell proliferation | 1 | 45 | 7.99e-01 |
| GO:BP | GO:0007417 | central nervous system development | 10 | 792 | 7.99e-01 |
| GO:BP | GO:0048762 | mesenchymal cell differentiation | 1 | 204 | 7.99e-01 |
| GO:BP | GO:0051258 | protein polymerization | 4 | 241 | 7.99e-01 |
| GO:BP | GO:0002181 | cytoplasmic translation | 1 | 156 | 8.00e-01 |
| GO:BP | GO:0045333 | cellular respiration | 1 | 211 | 8.00e-01 |
| GO:BP | GO:0032102 | negative regulation of response to external stimulus | 1 | 269 | 8.02e-01 |
| GO:BP | GO:0002637 | regulation of immunoglobulin production | 1 | 43 | 8.08e-01 |
| GO:BP | GO:0006023 | aminoglycan biosynthetic process | 1 | 63 | 8.08e-01 |
| GO:BP | GO:0065003 | protein-containing complex assembly | 1 | 1335 | 8.08e-01 |
| GO:BP | GO:0042327 | positive regulation of phosphorylation | 7 | 547 | 8.09e-01 |
| GO:BP | GO:0006952 | defense response | 6 | 944 | 8.10e-01 |
| GO:BP | GO:0022612 | gland morphogenesis | 1 | 98 | 8.10e-01 |
| GO:BP | GO:0002757 | immune response-activating signaling pathway | 3 | 230 | 8.10e-01 |
| GO:BP | GO:0002700 | regulation of production of molecular mediator of immune response | 1 | 108 | 8.11e-01 |
| GO:BP | GO:0010927 | cellular component assembly involved in morphogenesis | 1 | 106 | 8.11e-01 |
| GO:BP | GO:0009152 | purine ribonucleotide biosynthetic process | 3 | 179 | 8.11e-01 |
| GO:BP | GO:0060429 | epithelium development | 8 | 850 | 8.15e-01 |
| GO:BP | GO:0044089 | positive regulation of cellular component biogenesis | 1 | 420 | 8.16e-01 |
| GO:BP | GO:0050730 | regulation of peptidyl-tyrosine phosphorylation | 2 | 166 | 8.18e-01 |
| GO:BP | GO:0046777 | protein autophosphorylation | 1 | 188 | 8.19e-01 |
| GO:BP | GO:0002200 | somatic diversification of immune receptors | 1 | 62 | 8.19e-01 |
| GO:BP | GO:0009653 | anatomical structure morphogenesis | 3 | 1974 | 8.21e-01 |
| GO:BP | GO:0032273 | positive regulation of protein polymerization | 1 | 76 | 8.21e-01 |
| GO:BP | GO:0007224 | smoothened signaling pathway | 2 | 124 | 8.23e-01 |
| GO:BP | GO:0022898 | regulation of transmembrane transporter activity | 4 | 199 | 8.23e-01 |
| GO:BP | GO:1901222 | regulation of NIK/NF-kappaB signaling | 1 | 65 | 8.23e-01 |
| GO:BP | GO:0043122 | regulation of I-kappaB kinase/NF-kappaB signaling | 2 | 203 | 8.23e-01 |
| GO:BP | GO:0007219 | Notch signaling pathway | 1 | 146 | 8.23e-01 |
| GO:BP | GO:0007585 | respiratory gaseous exchange by respiratory system | 1 | 49 | 8.23e-01 |
| GO:BP | GO:0019953 | sexual reproduction | 5 | 631 | 8.23e-01 |
| GO:BP | GO:0043933 | protein-containing complex organization | 1 | 1496 | 8.27e-01 |
| GO:BP | GO:0009617 | response to bacterium | 5 | 321 | 8.27e-01 |
| GO:BP | GO:0014068 | positive regulation of phosphatidylinositol 3-kinase signaling | 1 | 55 | 8.29e-01 |
| GO:BP | GO:0007189 | adenylate cyclase-activating G protein-coupled receptor signaling pathway | 2 | 78 | 8.30e-01 |
| GO:BP | GO:0010833 | telomere maintenance via telomere lengthening | 1 | 73 | 8.31e-01 |
| GO:BP | GO:0006900 | vesicle budding from membrane | 1 | 76 | 8.31e-01 |
| GO:BP | GO:0009117 | nucleotide metabolic process | 3 | 423 | 8.31e-01 |
| GO:BP | GO:0051924 | regulation of calcium ion transport | 2 | 172 | 8.33e-01 |
| GO:BP | GO:0042063 | gliogenesis | 4 | 235 | 8.33e-01 |
| GO:BP | GO:0007156 | homophilic cell adhesion via plasma membrane adhesion molecules | 1 | 104 | 8.34e-01 |
| GO:BP | GO:0043413 | macromolecule glycosylation | 3 | 187 | 8.34e-01 |
| GO:BP | GO:0006486 | protein glycosylation | 3 | 187 | 8.34e-01 |
| GO:BP | GO:0045055 | regulated exocytosis | 1 | 155 | 8.34e-01 |
| GO:BP | GO:1903312 | negative regulation of mRNA metabolic process | 1 | 81 | 8.35e-01 |
| GO:BP | GO:0031589 | cell-substrate adhesion | 2 | 281 | 8.35e-01 |
| GO:BP | GO:0019233 | sensory perception of pain | 1 | 48 | 8.35e-01 |
| GO:BP | GO:0031644 | regulation of nervous system process | 2 | 90 | 8.36e-01 |
| GO:BP | GO:0034614 | cellular response to reactive oxygen species | 1 | 121 | 8.36e-01 |
| GO:BP | GO:0034599 | cellular response to oxidative stress | 1 | 240 | 8.39e-01 |
| GO:BP | GO:0002764 | immune response-regulating signaling pathway | 3 | 242 | 8.39e-01 |
| GO:BP | GO:0043401 | steroid hormone mediated signaling pathway | 1 | 112 | 8.39e-01 |
| GO:BP | GO:0090316 | positive regulation of intracellular protein transport | 1 | 133 | 8.40e-01 |
| GO:BP | GO:0006996 | organelle organization | 1 | 3000 | 8.40e-01 |
| GO:BP | GO:0001508 | action potential | 1 | 105 | 8.40e-01 |
| GO:BP | GO:0006754 | ATP biosynthetic process | 1 | 87 | 8.40e-01 |
| GO:BP | GO:0006753 | nucleoside phosphate metabolic process | 3 | 429 | 8.40e-01 |
| GO:BP | GO:0061448 | connective tissue development | 1 | 208 | 8.40e-01 |
| GO:BP | GO:0009165 | nucleotide biosynthetic process | 4 | 240 | 8.40e-01 |
| GO:BP | GO:0009260 | ribonucleotide biosynthetic process | 3 | 191 | 8.40e-01 |
| GO:BP | GO:0001934 | positive regulation of protein phosphorylation | 6 | 496 | 8.41e-01 |
| GO:BP | GO:0009064 | glutamine family amino acid metabolic process | 1 | 60 | 8.41e-01 |
| GO:BP | GO:0007005 | mitochondrion organization | 6 | 500 | 8.42e-01 |
| GO:BP | GO:0009150 | purine ribonucleotide metabolic process | 5 | 295 | 8.42e-01 |
| GO:BP | GO:0007548 | sex differentiation | 1 | 191 | 8.43e-01 |
| GO:BP | GO:0035264 | multicellular organism growth | 1 | 123 | 8.43e-01 |
| GO:BP | GO:0000245 | spliceosomal complex assembly | 1 | 73 | 8.44e-01 |
| GO:BP | GO:0002526 | acute inflammatory response | 1 | 49 | 8.45e-01 |
| GO:BP | GO:1901293 | nucleoside phosphate biosynthetic process | 4 | 241 | 8.45e-01 |
| GO:BP | GO:0044419 | biological process involved in interspecies interaction between organisms | 12 | 963 | 8.45e-01 |
| GO:BP | GO:0050778 | positive regulation of immune response | 2 | 369 | 8.45e-01 |
| GO:BP | GO:0019318 | hexose metabolic process | 2 | 185 | 8.45e-01 |
| GO:BP | GO:0006814 | sodium ion transport | 3 | 160 | 8.47e-01 |
| GO:BP | GO:0048584 | positive regulation of response to stimulus | 8 | 1555 | 8.47e-01 |
| GO:BP | GO:0043281 | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 1 | 155 | 8.48e-01 |
| GO:BP | GO:0043491 | protein kinase B signaling | 1 | 146 | 8.48e-01 |
| GO:BP | GO:0051716 | cellular response to stimulus | 1 | 4953 | 8.49e-01 |
| GO:BP | GO:0009888 | tissue development | 14 | 1425 | 8.49e-01 |
| GO:BP | GO:0007166 | cell surface receptor signaling pathway | 25 | 1898 | 8.49e-01 |
| GO:BP | GO:0043299 | leukocyte degranulation | 1 | 41 | 8.51e-01 |
| GO:BP | GO:0045921 | positive regulation of exocytosis | 1 | 62 | 8.51e-01 |
| GO:BP | GO:0009411 | response to UV | 1 | 141 | 8.52e-01 |
| GO:BP | GO:0002440 | production of molecular mediator of immune response | 1 | 135 | 8.52e-01 |
| GO:BP | GO:0048167 | regulation of synaptic plasticity | 1 | 141 | 8.52e-01 |
| GO:BP | GO:0046390 | ribose phosphate biosynthetic process | 3 | 197 | 8.52e-01 |
| GO:BP | GO:0006396 | RNA processing | 4 | 929 | 8.52e-01 |
| GO:BP | GO:0035725 | sodium ion transmembrane transport | 2 | 113 | 8.52e-01 |
| GO:BP | GO:0010628 | positive regulation of gene expression | 10 | 783 | 8.54e-01 |
| GO:BP | GO:0007155 | cell adhesion | 5 | 1012 | 8.56e-01 |
| GO:BP | GO:0009259 | ribonucleotide metabolic process | 1 | 311 | 8.56e-01 |
| GO:BP | GO:0140029 | exocytic process | 1 | 69 | 8.56e-01 |
| GO:BP | GO:0007596 | blood coagulation | 2 | 150 | 8.57e-01 |
| GO:BP | GO:0035023 | regulation of Rho protein signal transduction | 1 | 71 | 8.58e-01 |
| GO:BP | GO:0048608 | reproductive structure development | 1 | 212 | 8.58e-01 |
| GO:BP | GO:1904062 | regulation of monoatomic cation transmembrane transport | 4 | 230 | 8.62e-01 |
| GO:BP | GO:0061458 | reproductive system development | 1 | 215 | 8.62e-01 |
| GO:BP | GO:0019693 | ribose phosphate metabolic process | 1 | 319 | 8.62e-01 |
| GO:BP | GO:0050794 | regulation of cellular process | 1 | 7552 | 8.63e-01 |
| GO:BP | GO:0009206 | purine ribonucleoside triphosphate biosynthetic process | 1 | 96 | 8.64e-01 |
| GO:BP | GO:0010033 | response to organic substance | 27 | 1957 | 8.64e-01 |
| GO:BP | GO:0050817 | coagulation | 2 | 153 | 8.64e-01 |
| GO:BP | GO:0060485 | mesenchyme development | 1 | 249 | 8.64e-01 |
| GO:BP | GO:0007249 | I-kappaB kinase/NF-kappaB signaling | 2 | 227 | 8.65e-01 |
| GO:BP | GO:0007599 | hemostasis | 2 | 153 | 8.65e-01 |
| GO:BP | GO:0006163 | purine nucleotide metabolic process | 5 | 371 | 8.65e-01 |
| GO:BP | GO:0009145 | purine nucleoside triphosphate biosynthetic process | 1 | 97 | 8.65e-01 |
| GO:BP | GO:0070085 | glycosylation | 3 | 202 | 8.65e-01 |
| GO:BP | GO:0043270 | positive regulation of monoatomic ion transport | 3 | 154 | 8.67e-01 |
| GO:BP | GO:1905114 | cell surface receptor signaling pathway involved in cell-cell signaling | 4 | 448 | 8.67e-01 |
| GO:BP | GO:0034764 | positive regulation of transmembrane transport | 3 | 158 | 8.68e-01 |
| GO:BP | GO:0002703 | regulation of leukocyte mediated immunity | 1 | 118 | 8.69e-01 |
| GO:BP | GO:0032543 | mitochondrial translation | 1 | 130 | 8.69e-01 |
| GO:BP | GO:1903510 | mucopolysaccharide metabolic process | 1 | 74 | 8.70e-01 |
| GO:BP | GO:0097306 | cellular response to alcohol | 1 | 70 | 8.71e-01 |
| GO:BP | GO:0010466 | negative regulation of peptidase activity | 1 | 131 | 8.71e-01 |
| GO:BP | GO:0060341 | regulation of cellular localization | 8 | 798 | 8.71e-01 |
| GO:BP | GO:0006950 | response to stress | 29 | 2780 | 8.72e-01 |
| GO:BP | GO:0050851 | antigen receptor-mediated signaling pathway | 2 | 106 | 8.72e-01 |
| GO:BP | GO:0009952 | anterior/posterior pattern specification | 1 | 127 | 8.72e-01 |
| GO:BP | GO:1904035 | regulation of epithelial cell apoptotic process | 1 | 71 | 8.73e-01 |
| GO:BP | GO:0050906 | detection of stimulus involved in sensory perception | 1 | 39 | 8.73e-01 |
| GO:BP | GO:1902533 | positive regulation of intracellular signal transduction | 2 | 726 | 8.74e-01 |
| GO:BP | GO:0048736 | appendage development | 2 | 142 | 8.74e-01 |
| GO:BP | GO:0060173 | limb development | 2 | 142 | 8.74e-01 |
| GO:BP | GO:0009201 | ribonucleoside triphosphate biosynthetic process | 1 | 102 | 8.74e-01 |
| GO:BP | GO:0033875 | ribonucleoside bisphosphate metabolic process | 1 | 92 | 8.75e-01 |
| GO:BP | GO:0034032 | purine nucleoside bisphosphate metabolic process | 1 | 92 | 8.75e-01 |
| GO:BP | GO:0033865 | nucleoside bisphosphate metabolic process | 1 | 92 | 8.75e-01 |
| GO:BP | GO:0034762 | regulation of transmembrane transport | 5 | 391 | 8.79e-01 |
| GO:BP | GO:2000116 | regulation of cysteine-type endopeptidase activity | 1 | 169 | 8.80e-01 |
| GO:BP | GO:1901575 | organic substance catabolic process | 15 | 1712 | 8.80e-01 |
| GO:BP | GO:0001906 | cell killing | 1 | 69 | 8.80e-01 |
| GO:BP | GO:0006006 | glucose metabolic process | 1 | 151 | 8.80e-01 |
| GO:BP | GO:0001738 | morphogenesis of a polarized epithelium | 1 | 88 | 8.80e-01 |
| GO:BP | GO:0060271 | cilium assembly | 1 | 292 | 8.80e-01 |
| GO:BP | GO:0043583 | ear development | 2 | 153 | 8.80e-01 |
| GO:BP | GO:1901137 | carbohydrate derivative biosynthetic process | 9 | 544 | 8.81e-01 |
| GO:BP | GO:0032204 | regulation of telomere maintenance | 1 | 96 | 8.82e-01 |
| GO:BP | GO:0007160 | cell-matrix adhesion | 1 | 179 | 8.82e-01 |
| GO:BP | GO:0062197 | cellular response to chemical stress | 1 | 293 | 8.83e-01 |
| GO:BP | GO:0060562 | epithelial tube morphogenesis | 1 | 278 | 8.83e-01 |
| GO:BP | GO:0031099 | regeneration | 2 | 142 | 8.84e-01 |
| GO:BP | GO:0002699 | positive regulation of immune effector process | 1 | 130 | 8.85e-01 |
| GO:BP | GO:0048583 | regulation of response to stimulus | 13 | 2890 | 8.85e-01 |
| GO:BP | GO:0030101 | natural killer cell activation | 1 | 42 | 8.85e-01 |
| GO:BP | GO:0071482 | cellular response to light stimulus | 1 | 99 | 8.85e-01 |
| GO:BP | GO:0006664 | glycolipid metabolic process | 1 | 88 | 8.86e-01 |
| GO:BP | GO:0006672 | ceramide metabolic process | 1 | 80 | 8.86e-01 |
| GO:BP | GO:0032446 | protein modification by small protein conjugation | 4 | 787 | 8.87e-01 |
| GO:BP | GO:0140013 | meiotic nuclear division | 2 | 120 | 8.88e-01 |
| GO:BP | GO:0022607 | cellular component assembly | 4 | 2466 | 8.88e-01 |
| GO:BP | GO:0008585 | female gonad development | 1 | 77 | 8.88e-01 |
| GO:BP | GO:1903509 | liposaccharide metabolic process | 1 | 88 | 8.88e-01 |
| GO:BP | GO:0071356 | cellular response to tumor necrosis factor | 1 | 155 | 8.88e-01 |
| GO:BP | GO:1901564 | organonitrogen compound metabolic process | 1 | 4955 | 8.88e-01 |
| GO:BP | GO:0002377 | immunoglobulin production | 1 | 70 | 8.88e-01 |
| GO:BP | GO:0007259 | receptor signaling pathway via JAK-STAT | 1 | 86 | 8.90e-01 |
| GO:BP | GO:0006164 | purine nucleotide biosynthetic process | 3 | 209 | 8.91e-01 |
| GO:BP | GO:0009142 | nucleoside triphosphate biosynthetic process | 1 | 111 | 8.92e-01 |
| GO:BP | GO:0032388 | positive regulation of intracellular transport | 1 | 170 | 8.94e-01 |
| GO:BP | GO:0002824 | positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 1 | 62 | 8.95e-01 |
| GO:BP | GO:0044782 | cilium organization | 1 | 313 | 8.96e-01 |
| GO:BP | GO:0046545 | development of primary female sexual characteristics | 1 | 79 | 8.96e-01 |
| GO:BP | GO:0051130 | positive regulation of cellular component organization | 9 | 906 | 8.96e-01 |
| GO:BP | GO:0009062 | fatty acid catabolic process | 1 | 89 | 8.97e-01 |
| GO:BP | GO:0030148 | sphingolipid biosynthetic process | 1 | 88 | 8.98e-01 |
| GO:BP | GO:0016051 | carbohydrate biosynthetic process | 1 | 155 | 8.99e-01 |
| GO:BP | GO:0021549 | cerebellum development | 1 | 78 | 9.00e-01 |
| GO:BP | GO:0009056 | catabolic process | 18 | 2088 | 9.00e-01 |
| GO:BP | GO:0014066 | regulation of phosphatidylinositol 3-kinase signaling | 1 | 78 | 9.00e-01 |
| GO:BP | GO:0046034 | ATP metabolic process | 1 | 116 | 9.03e-01 |
| GO:BP | GO:0003008 | system process | 15 | 1189 | 9.04e-01 |
| GO:BP | GO:0043123 | positive regulation of I-kappaB kinase/NF-kappaB signaling | 1 | 153 | 9.05e-01 |
| GO:BP | GO:0001676 | long-chain fatty acid metabolic process | 1 | 65 | 9.05e-01 |
| GO:BP | GO:0030154 | cell differentiation | 5 | 2958 | 9.05e-01 |
| GO:BP | GO:0006457 | protein folding | 1 | 192 | 9.05e-01 |
| GO:BP | GO:0002821 | positive regulation of adaptive immune response | 1 | 66 | 9.06e-01 |
| GO:BP | GO:0002708 | positive regulation of lymphocyte mediated immunity | 1 | 58 | 9.08e-01 |
| GO:BP | GO:0048869 | cellular developmental process | 5 | 2984 | 9.08e-01 |
| GO:BP | GO:0030203 | glycosaminoglycan metabolic process | 1 | 87 | 9.11e-01 |
| GO:BP | GO:0006119 | oxidative phosphorylation | 1 | 122 | 9.11e-01 |
| GO:BP | GO:0070588 | calcium ion transmembrane transport | 2 | 213 | 9.11e-01 |
| GO:BP | GO:0006617 | SRP-dependent cotranslational protein targeting to membrane, signal sequence recognition | 1 | 17 | 9.13e-01 |
| GO:BP | GO:0050776 | regulation of immune response | 2 | 484 | 9.14e-01 |
| GO:BP | GO:0140053 | mitochondrial gene expression | 1 | 162 | 9.14e-01 |
| GO:BP | GO:0009100 | glycoprotein metabolic process | 1 | 316 | 9.14e-01 |
| GO:BP | GO:0044085 | cellular component biogenesis | 4 | 2724 | 9.14e-01 |
| GO:BP | GO:1903046 | meiotic cell cycle process | 2 | 135 | 9.14e-01 |
| GO:BP | GO:0002444 | myeloid leukocyte mediated immunity | 1 | 60 | 9.14e-01 |
| GO:BP | GO:0050896 | response to stimulus | 1 | 5770 | 9.17e-01 |
| GO:BP | GO:0009967 | positive regulation of signal transduction | 13 | 1133 | 9.17e-01 |
| GO:BP | GO:2000278 | regulation of DNA biosynthetic process | 1 | 111 | 9.17e-01 |
| GO:BP | GO:0022037 | metencephalon development | 1 | 84 | 9.18e-01 |
| GO:BP | GO:0050877 | nervous system process | 11 | 634 | 9.19e-01 |
| GO:BP | GO:2001056 | positive regulation of cysteine-type endopeptidase activity | 1 | 107 | 9.19e-01 |
| GO:BP | GO:0007162 | negative regulation of cell adhesion | 1 | 192 | 9.20e-01 |
| GO:BP | GO:0051050 | positive regulation of transport | 6 | 667 | 9.20e-01 |
| GO:BP | GO:0006807 | nitrogen compound metabolic process | 1 | 7441 | 9.20e-01 |
| GO:BP | GO:0051606 | detection of stimulus | 1 | 110 | 9.20e-01 |
| GO:BP | GO:0046660 | female sex differentiation | 1 | 91 | 9.21e-01 |
| GO:BP | GO:0051301 | cell division | 8 | 570 | 9.22e-01 |
| GO:BP | GO:0001764 | neuron migration | 1 | 133 | 9.22e-01 |
| GO:BP | GO:0006614 | SRP-dependent cotranslational protein targeting to membrane | 1 | 30 | 9.22e-01 |
| GO:BP | GO:1904019 | epithelial cell apoptotic process | 1 | 98 | 9.23e-01 |
| GO:BP | GO:0006887 | exocytosis | 1 | 256 | 9.25e-01 |
| GO:BP | GO:0006022 | aminoglycan metabolic process | 1 | 93 | 9.27e-01 |
| GO:BP | GO:0006613 | cotranslational protein targeting to membrane | 1 | 35 | 9.27e-01 |
| GO:BP | GO:1902600 | proton transmembrane transport | 1 | 111 | 9.27e-01 |
| GO:BP | GO:0008037 | cell recognition | 1 | 87 | 9.29e-01 |
| GO:BP | GO:0043170 | macromolecule metabolic process | 1 | 7069 | 9.30e-01 |
| GO:BP | GO:0009205 | purine ribonucleoside triphosphate metabolic process | 1 | 137 | 9.34e-01 |
| GO:BP | GO:0042391 | regulation of membrane potential | 5 | 293 | 9.34e-01 |
| GO:BP | GO:0048731 | system development | 40 | 2901 | 9.35e-01 |
| GO:BP | GO:0016567 | protein ubiquitination | 3 | 717 | 9.36e-01 |
| GO:BP | GO:0045047 | protein targeting to ER | 1 | 49 | 9.37e-01 |
| GO:BP | GO:0009101 | glycoprotein biosynthetic process | 2 | 252 | 9.38e-01 |
| GO:BP | GO:0050789 | regulation of biological process | 1 | 8061 | 9.38e-01 |
| GO:BP | GO:0072599 | establishment of protein localization to endoplasmic reticulum | 1 | 53 | 9.38e-01 |
| GO:BP | GO:0022414 | reproductive process | 1 | 927 | 9.38e-01 |
| GO:BP | GO:0051053 | negative regulation of DNA metabolic process | 1 | 112 | 9.38e-01 |
| GO:BP | GO:0000003 | reproduction | 1 | 934 | 9.38e-01 |
| GO:BP | GO:0009144 | purine nucleoside triphosphate metabolic process | 1 | 142 | 9.38e-01 |
| GO:BP | GO:0007275 | multicellular organism development | 23 | 3386 | 9.38e-01 |
| GO:BP | GO:0009199 | ribonucleoside triphosphate metabolic process | 1 | 144 | 9.39e-01 |
| GO:BP | GO:0098742 | cell-cell adhesion via plasma-membrane adhesion molecules | 1 | 168 | 9.39e-01 |
| GO:BP | GO:0030198 | extracellular matrix organization | 1 | 233 | 9.40e-01 |
| GO:BP | GO:0043062 | extracellular structure organization | 1 | 234 | 9.40e-01 |
| GO:BP | GO:0007186 | G protein-coupled receptor signaling pathway | 2 | 389 | 9.41e-01 |
| GO:BP | GO:0045229 | external encapsulating structure organization | 1 | 234 | 9.41e-01 |
| GO:BP | GO:1902531 | regulation of intracellular signal transduction | 3 | 1345 | 9.42e-01 |
| GO:BP | GO:0010629 | negative regulation of gene expression | 1 | 785 | 9.42e-01 |
| GO:BP | GO:0034329 | cell junction assembly | 5 | 344 | 9.42e-01 |
| GO:BP | GO:0010959 | regulation of metal ion transport | 2 | 275 | 9.50e-01 |
| GO:BP | GO:0046467 | membrane lipid biosynthetic process | 1 | 124 | 9.51e-01 |
| GO:BP | GO:0002443 | leukocyte mediated immunity | 2 | 194 | 9.54e-01 |
| GO:BP | GO:0009141 | nucleoside triphosphate metabolic process | 1 | 159 | 9.54e-01 |
| GO:BP | GO:0044272 | sulfur compound biosynthetic process | 1 | 122 | 9.54e-01 |
| GO:BP | GO:0070972 | protein localization to endoplasmic reticulum | 1 | 78 | 9.54e-01 |
| GO:BP | GO:0002697 | regulation of immune effector process | 1 | 190 | 9.54e-01 |
| GO:BP | GO:0023056 | positive regulation of signaling | 3 | 1256 | 9.55e-01 |
| GO:BP | GO:0010647 | positive regulation of cell communication | 3 | 1255 | 9.55e-01 |
| GO:BP | GO:0030534 | adult behavior | 1 | 92 | 9.56e-01 |
| GO:BP | GO:0000723 | telomere maintenance | 1 | 142 | 9.57e-01 |
| GO:BP | GO:0071478 | cellular response to radiation | 1 | 156 | 9.57e-01 |
| GO:BP | GO:0034765 | regulation of monoatomic ion transmembrane transport | 5 | 295 | 9.57e-01 |
| GO:BP | GO:0050871 | positive regulation of B cell activation | 1 | 53 | 9.60e-01 |
| GO:BP | GO:0048839 | inner ear development | 1 | 132 | 9.60e-01 |
| GO:BP | GO:0002009 | morphogenesis of an epithelium | 1 | 418 | 9.60e-01 |
| GO:BP | GO:0065007 | biological regulation | 1 | 8320 | 9.62e-01 |
| GO:BP | GO:0006665 | sphingolipid metabolic process | 1 | 131 | 9.62e-01 |
| GO:BP | GO:0006816 | calcium ion transport | 2 | 269 | 9.63e-01 |
| GO:BP | GO:0009966 | regulation of signal transduction | 6 | 2285 | 9.65e-01 |
| GO:BP | GO:0030902 | hindbrain development | 1 | 114 | 9.66e-01 |
| GO:BP | GO:0051049 | regulation of transport | 10 | 1267 | 9.66e-01 |
| GO:BP | GO:0002706 | regulation of lymphocyte mediated immunity | 1 | 83 | 9.70e-01 |
| GO:BP | GO:0007600 | sensory perception | 3 | 269 | 9.72e-01 |
| GO:BP | GO:0002822 | regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 1 | 97 | 9.72e-01 |
| GO:BP | GO:0006955 | immune response | 4 | 882 | 9.72e-01 |
| GO:BP | GO:0051321 | meiotic cell cycle | 2 | 188 | 9.73e-01 |
| GO:BP | GO:0048856 | anatomical structure development | 6 | 4128 | 9.73e-01 |
| GO:BP | GO:0032501 | multicellular organismal process | 1 | 4794 | 9.76e-01 |
| GO:BP | GO:0032879 | regulation of localization | 12 | 1555 | 9.76e-01 |
| GO:BP | GO:0032200 | telomere organization | 1 | 166 | 9.76e-01 |
| GO:BP | GO:0002449 | lymphocyte mediated immunity | 3 | 142 | 9.76e-01 |
| GO:BP | GO:0002819 | regulation of adaptive immune response | 1 | 106 | 9.80e-01 |
| GO:BP | GO:0030258 | lipid modification | 1 | 162 | 9.82e-01 |
| GO:BP | GO:0016064 | immunoglobulin mediated immune response | 1 | 76 | 9.85e-01 |
| GO:BP | GO:0050864 | regulation of B cell activation | 1 | 77 | 9.86e-01 |
| GO:BP | GO:0019724 | B cell mediated immunity | 1 | 77 | 9.86e-01 |
| GO:BP | GO:0006643 | membrane lipid metabolic process | 1 | 173 | 9.87e-01 |
| GO:BP | GO:0023051 | regulation of signaling | 6 | 2565 | 9.91e-01 |
| GO:BP | GO:0010646 | regulation of cell communication | 6 | 2573 | 9.91e-01 |
| GO:BP | GO:0010256 | endomembrane system organization | 5 | 496 | 9.91e-01 |
| GO:BP | GO:0032502 | developmental process | 6 | 4494 | 9.93e-01 |
| GO:BP | GO:0043269 | regulation of monoatomic ion transport | 2 | 373 | 9.95e-01 |
| GO:BP | GO:0007165 | signal transduction | 13 | 3818 | 9.96e-01 |
| GO:BP | GO:0016043 | cellular component organization | 1 | 5076 | 9.96e-01 |
| GO:BP | GO:0071840 | cellular component organization or biogenesis | 1 | 5274 | 9.98e-01 |
| GO:BP | GO:0002252 | immune effector process | 2 | 318 | 9.98e-01 |
| GO:BP | GO:0104004 | cellular response to environmental stimulus | 1 | 268 | 1.00e+00 |
| GO:BP | GO:0071214 | cellular response to abiotic stimulus | 1 | 268 | 1.00e+00 |
| GO:BP | GO:0023052 | signaling | 1 | 4141 | 1.00e+00 |
| GO:BP | GO:0000387 | spliceosomal snRNP assembly | 1 | 45 | 1.00e+00 |
| GO:BP | GO:0006811 | monoatomic ion transport | 1 | 775 | 1.00e+00 |
| GO:BP | GO:0071826 | ribonucleoprotein complex subunit organization | 2 | 211 | 1.00e+00 |
| GO:BP | GO:0098655 | monoatomic cation transmembrane transport | 3 | 540 | 1.00e+00 |
| GO:BP | GO:0071704 | organic substance metabolic process | 1 | 8169 | 1.00e+00 |
| GO:BP | GO:0006812 | monoatomic cation transport | 3 | 669 | 1.00e+00 |
| GO:BP | GO:0098660 | inorganic ion transmembrane transport | 3 | 563 | 1.00e+00 |
| GO:BP | GO:0098662 | inorganic cation transmembrane transport | 3 | 517 | 1.00e+00 |
| GO:BP | GO:0035195 | miRNA-mediated gene silencing | 1 | 55 | 1.00e+00 |
| GO:BP | GO:0008150 | biological_process | 1 | 12070 | 1.00e+00 |
| GO:BP | GO:0008152 | metabolic process | 1 | 8518 | 1.00e+00 |
| GO:BP | GO:0009987 | cellular process | 1 | 11336 | 1.00e+00 |
| GO:BP | GO:0016441 | post-transcriptional gene silencing | 1 | 65 | 1.00e+00 |
| GO:BP | GO:0022613 | ribonucleoprotein complex biogenesis | 2 | 453 | 1.00e+00 |
| GO:BP | GO:0022618 | ribonucleoprotein complex assembly | 2 | 203 | 1.00e+00 |
| GO:BP | GO:0030001 | metal ion transport | 3 | 562 | 1.00e+00 |
| GO:BP | GO:0034220 | monoatomic ion transmembrane transport | 3 | 632 | 1.00e+00 |
| GO:BP | GO:0002250 | adaptive immune response | 1 | 218 | 1.00e+00 |
| GO:BP | GO:0035194 | ncRNA-mediated post-transcriptional gene silencing | 1 | 60 | 1.00e+00 |
| GO:BP | GO:0007154 | cell communication | 1 | 4226 | 1.00e+00 |
| GO:BP | GO:0002460 | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 1 | 161 | 1.00e+00 |
| KEGG | KEGG:04713 | Circadian entrainment | 1 | 69 | 5.24e-01 |
| KEGG | KEGG:05132 | Salmonella infection | 5 | 214 | 5.24e-01 |
| KEGG | KEGG:05131 | Shigellosis | 6 | 210 | 5.24e-01 |
| KEGG | KEGG:04913 | Ovarian steroidogenesis | 3 | 28 | 5.24e-01 |
| KEGG | KEGG:00900 | Terpenoid backbone biosynthesis | 1 | 21 | 5.24e-01 |
| KEGG | KEGG:04919 | Thyroid hormone signaling pathway | 3 | 112 | 5.24e-01 |
| KEGG | KEGG:03022 | Basal transcription factors | 1 | 40 | 5.24e-01 |
| KEGG | KEGG:04931 | Insulin resistance | 4 | 95 | 5.24e-01 |
| KEGG | KEGG:04070 | Phosphatidylinositol signaling system | 3 | 91 | 5.24e-01 |
| KEGG | KEGG:05017 | Spinocerebellar ataxia | 3 | 124 | 5.24e-01 |
| KEGG | KEGG:05210 | Colorectal cancer | 3 | 84 | 5.24e-01 |
| KEGG | KEGG:00750 | Vitamin B6 metabolism | 1 | 5 | 5.24e-01 |
| KEGG | KEGG:01521 | EGFR tyrosine kinase inhibitor resistance | 4 | 74 | 5.24e-01 |
| KEGG | KEGG:05110 | Vibrio cholerae infection | 2 | 43 | 5.24e-01 |
| KEGG | KEGG:04710 | Circadian rhythm | 1 | 30 | 5.24e-01 |
| KEGG | KEGG:00910 | Nitrogen metabolism | 1 | 10 | 5.24e-01 |
| KEGG | KEGG:04014 | Ras signaling pathway | 7 | 171 | 5.24e-01 |
| KEGG | KEGG:05225 | Hepatocellular carcinoma | 5 | 145 | 5.24e-01 |
| KEGG | KEGG:00590 | Arachidonic acid metabolism | 1 | 26 | 5.24e-01 |
| KEGG | KEGG:00100 | Steroid biosynthesis | 1 | 17 | 5.24e-01 |
| KEGG | KEGG:04146 | Peroxisome | 1 | 68 | 5.24e-01 |
| KEGG | KEGG:04012 | ErbB signaling pathway | 3 | 78 | 5.24e-01 |
| KEGG | KEGG:00450 | Selenocompound metabolism | 1 | 14 | 5.24e-01 |
| KEGG | KEGG:05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 3 | 69 | 5.24e-01 |
| KEGG | KEGG:04010 | MAPK signaling pathway | 8 | 240 | 5.24e-01 |
| KEGG | KEGG:04066 | HIF-1 signaling pathway | 3 | 89 | 5.24e-01 |
| KEGG | KEGG:05231 | Choline metabolism in cancer | 3 | 84 | 5.24e-01 |
| KEGG | KEGG:00562 | Inositol phosphate metabolism | 3 | 66 | 5.24e-01 |
| KEGG | KEGG:05160 | Hepatitis C | 2 | 115 | 5.69e-01 |
| KEGG | KEGG:04152 | AMPK signaling pathway | 4 | 103 | 5.69e-01 |
| KEGG | KEGG:03430 | Mismatch repair | 1 | 22 | 5.69e-01 |
| KEGG | KEGG:05205 | Proteoglycans in cancer | 4 | 170 | 5.69e-01 |
| KEGG | KEGG:05120 | Epithelial cell signaling in Helicobacter pylori infection | 2 | 58 | 5.69e-01 |
| KEGG | KEGG:04392 | Hippo signaling pathway - multiple species | 1 | 25 | 5.69e-01 |
| KEGG | KEGG:04390 | Hippo signaling pathway | 3 | 134 | 5.69e-01 |
| KEGG | KEGG:03040 | Spliceosome | 1 | 132 | 5.69e-01 |
| KEGG | KEGG:04924 | Renin secretion | 1 | 50 | 5.69e-01 |
| KEGG | KEGG:04910 | Insulin signaling pathway | 3 | 121 | 5.80e-01 |
| KEGG | KEGG:04145 | Phagosome | 1 | 99 | 5.83e-01 |
| KEGG | KEGG:04664 | Fc epsilon RI signaling pathway | 2 | 46 | 5.83e-01 |
| KEGG | KEGG:04137 | Mitophagy - animal | 2 | 70 | 5.86e-01 |
| KEGG | KEGG:04015 | Rap1 signaling pathway | 2 | 164 | 5.86e-01 |
| KEGG | KEGG:04270 | Vascular smooth muscle contraction | 1 | 94 | 5.95e-01 |
| KEGG | KEGG:00790 | Folate biosynthesis | 1 | 18 | 5.95e-01 |
| KEGG | KEGG:01100 | Metabolic pathways | 1 | 1146 | 5.95e-01 |
| KEGG | KEGG:01523 | Antifolate resistance | 1 | 24 | 5.95e-01 |
| KEGG | KEGG:03030 | DNA replication | 1 | 35 | 5.95e-01 |
| KEGG | KEGG:04933 | AGE-RAGE signaling pathway in diabetic complications | 2 | 91 | 5.95e-01 |
| KEGG | KEGG:05100 | Bacterial invasion of epithelial cells | 1 | 74 | 5.95e-01 |
| KEGG | KEGG:04932 | Non-alcoholic fatty liver disease | 3 | 131 | 5.95e-01 |
| KEGG | KEGG:04750 | Inflammatory mediator regulation of TRP channels | 2 | 72 | 5.95e-01 |
| KEGG | KEGG:04727 | GABAergic synapse | 3 | 55 | 5.95e-01 |
| KEGG | KEGG:04722 | Neurotrophin signaling pathway | 2 | 110 | 5.95e-01 |
| KEGG | KEGG:03050 | Proteasome | 2 | 42 | 5.95e-01 |
| KEGG | KEGG:04962 | Vasopressin-regulated water reabsorption | 1 | 38 | 5.95e-01 |
| KEGG | KEGG:00670 | One carbon pool by folate | 1 | 18 | 5.95e-01 |
| KEGG | KEGG:00604 | Glycosphingolipid biosynthesis - ganglio series | 1 | 12 | 5.95e-01 |
| KEGG | KEGG:03320 | PPAR signaling pathway | 1 | 50 | 5.95e-01 |
| KEGG | KEGG:05219 | Bladder cancer | 1 | 37 | 5.95e-01 |
| KEGG | KEGG:05214 | Glioma | 2 | 67 | 5.95e-01 |
| KEGG | KEGG:05212 | Pancreatic cancer | 2 | 75 | 5.95e-01 |
| KEGG | KEGG:05211 | Renal cell carcinoma | 2 | 65 | 5.95e-01 |
| KEGG | KEGG:00140 | Steroid hormone biosynthesis | 1 | 19 | 5.95e-01 |
| KEGG | KEGG:00280 | Valine, leucine and isoleucine degradation | 2 | 43 | 5.95e-01 |
| KEGG | KEGG:00630 | Glyoxylate and dicarboxylate metabolism | 1 | 25 | 5.95e-01 |
| KEGG | KEGG:00520 | Amino sugar and nucleotide sugar metabolism | 2 | 46 | 5.95e-01 |
| KEGG | KEGG:05223 | Non-small cell lung cancer | 2 | 67 | 5.95e-01 |
| KEGG | KEGG:05206 | MicroRNAs in cancer | 5 | 149 | 5.95e-01 |
| KEGG | KEGG:05170 | Human immunodeficiency virus 1 infection | 4 | 165 | 5.95e-01 |
| KEGG | KEGG:05167 | Kaposi sarcoma-associated herpesvirus infection | 3 | 145 | 5.95e-01 |
| KEGG | KEGG:04218 | Cellular senescence | 1 | 145 | 5.95e-01 |
| KEGG | KEGG:05230 | Central carbon metabolism in cancer | 2 | 62 | 5.95e-01 |
| KEGG | KEGG:00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 1 | 13 | 5.95e-01 |
| KEGG | KEGG:03410 | Base excision repair | 1 | 33 | 5.95e-01 |
| KEGG | KEGG:04978 | Mineral absorption | 2 | 42 | 5.95e-01 |
| KEGG | KEGG:03420 | Nucleotide excision repair | 1 | 43 | 5.95e-01 |
| KEGG | KEGG:04024 | cAMP signaling pathway | 2 | 151 | 5.95e-01 |
| KEGG | KEGG:03440 | Homologous recombination | 1 | 39 | 5.95e-01 |
| KEGG | KEGG:04064 | NF-kappa B signaling pathway | 2 | 71 | 5.95e-01 |
| KEGG | KEGG:04520 | Adherens junction | 2 | 67 | 5.95e-01 |
| KEGG | KEGG:04540 | Gap junction | 3 | 73 | 5.95e-01 |
| KEGG | KEGG:04360 | Axon guidance | 4 | 162 | 5.95e-01 |
| KEGG | KEGG:04666 | Fc gamma R-mediated phagocytosis | 2 | 75 | 5.95e-01 |
| KEGG | KEGG:00603 | Glycosphingolipid biosynthesis - globo and isoglobo series | 1 | 9 | 6.21e-01 |
| KEGG | KEGG:04668 | TNF signaling pathway | 2 | 87 | 6.21e-01 |
| KEGG | KEGG:04020 | Calcium signaling pathway | 4 | 157 | 6.23e-01 |
| KEGG | KEGG:01240 | Biosynthesis of cofactors | 3 | 115 | 6.23e-01 |
| KEGG | KEGG:05221 | Acute myeloid leukemia | 2 | 56 | 6.23e-01 |
| KEGG | KEGG:00260 | Glycine, serine and threonine metabolism | 1 | 31 | 6.39e-01 |
| KEGG | KEGG:04935 | Growth hormone synthesis, secretion and action | 2 | 98 | 6.39e-01 |
| KEGG | KEGG:05145 | Toxoplasmosis | 2 | 82 | 6.44e-01 |
| KEGG | KEGG:04530 | Tight junction | 2 | 137 | 6.53e-01 |
| KEGG | KEGG:04380 | Osteoclast differentiation | 2 | 87 | 6.55e-01 |
| KEGG | KEGG:04725 | Cholinergic synapse | 1 | 83 | 6.92e-01 |
| KEGG | KEGG:05226 | Gastric cancer | 2 | 117 | 6.92e-01 |
| KEGG | KEGG:05224 | Breast cancer | 2 | 117 | 6.92e-01 |
| KEGG | KEGG:04080 | Neuroactive ligand-receptor interaction | 2 | 108 | 6.92e-01 |
| KEGG | KEGG:04140 | Autophagy - animal | 3 | 133 | 6.92e-01 |
| KEGG | KEGG:05217 | Basal cell carcinoma | 1 | 49 | 6.92e-01 |
| KEGG | KEGG:00051 | Fructose and mannose metabolism | 1 | 27 | 6.92e-01 |
| KEGG | KEGG:03018 | RNA degradation | 1 | 74 | 6.92e-01 |
| KEGG | KEGG:05213 | Endometrial cancer | 1 | 57 | 6.92e-01 |
| KEGG | KEGG:04927 | Cortisol synthesis and secretion | 2 | 48 | 6.92e-01 |
| KEGG | KEGG:04213 | Longevity regulating pathway - multiple species | 2 | 55 | 6.92e-01 |
| KEGG | KEGG:04936 | Alcoholic liver disease | 2 | 97 | 6.92e-01 |
| KEGG | KEGG:04964 | Proximal tubule bicarbonate reclamation | 1 | 20 | 6.92e-01 |
| KEGG | KEGG:05022 | Pathways of neurodegeneration - multiple diseases | 5 | 385 | 6.92e-01 |
| KEGG | KEGG:00220 | Arginine biosynthesis | 1 | 16 | 6.92e-01 |
| KEGG | KEGG:04144 | Endocytosis | 1 | 232 | 6.92e-01 |
| KEGG | KEGG:05135 | Yersinia infection | 2 | 112 | 6.92e-01 |
| KEGG | KEGG:04370 | VEGF signaling pathway | 1 | 49 | 6.92e-01 |
| KEGG | KEGG:00000 | KEGG root term | 4 | 5558 | 6.92e-01 |
| KEGG | KEGG:04974 | Protein digestion and absorption | 2 | 61 | 6.92e-01 |
| KEGG | KEGG:05418 | Fluid shear stress and atherosclerosis | 2 | 114 | 6.92e-01 |
| KEGG | KEGG:01250 | Biosynthesis of nucleotide sugars | 1 | 35 | 6.93e-01 |
| KEGG | KEGG:04216 | Ferroptosis | 1 | 33 | 7.11e-01 |
| KEGG | KEGG:04979 | Cholesterol metabolism | 1 | 33 | 7.11e-01 |
| KEGG | KEGG:04611 | Platelet activation | 3 | 89 | 7.12e-01 |
| KEGG | KEGG:04934 | Cushing syndrome | 2 | 121 | 7.33e-01 |
| KEGG | KEGG:04340 | Hedgehog signaling pathway | 1 | 49 | 7.33e-01 |
| KEGG | KEGG:04659 | Th17 cell differentiation | 1 | 64 | 7.33e-01 |
| KEGG | KEGG:00510 | N-Glycan biosynthesis | 1 | 48 | 7.33e-01 |
| KEGG | KEGG:05012 | Parkinson disease | 2 | 226 | 7.33e-01 |
| KEGG | KEGG:03020 | RNA polymerase | 1 | 34 | 7.33e-01 |
| KEGG | KEGG:05020 | Prion disease | 2 | 220 | 7.33e-01 |
| KEGG | KEGG:04350 | TGF-beta signaling pathway | 2 | 84 | 7.33e-01 |
| KEGG | KEGG:04961 | Endocrine and other factor-regulated calcium reabsorption | 1 | 41 | 7.33e-01 |
| KEGG | KEGG:04371 | Apelin signaling pathway | 2 | 106 | 7.33e-01 |
| KEGG | KEGG:05200 | Pathways in cancer | 7 | 409 | 7.33e-01 |
| KEGG | KEGG:01230 | Biosynthesis of amino acids | 1 | 60 | 7.33e-01 |
| KEGG | KEGG:04512 | ECM-receptor interaction | 1 | 69 | 7.33e-01 |
| KEGG | KEGG:05161 | Hepatitis B | 3 | 136 | 7.33e-01 |
| KEGG | KEGG:04211 | Longevity regulating pathway | 2 | 78 | 7.39e-01 |
| KEGG | KEGG:00512 | Mucin type O-glycan biosynthesis | 1 | 22 | 7.39e-01 |
| KEGG | KEGG:00514 | Other types of O-glycan biosynthesis | 1 | 37 | 7.39e-01 |
| KEGG | KEGG:05016 | Huntington disease | 2 | 256 | 7.39e-01 |
| KEGG | KEGG:04970 | Salivary secretion | 2 | 55 | 7.39e-01 |
| KEGG | KEGG:04141 | Protein processing in endoplasmic reticulum | 2 | 161 | 7.39e-01 |
| KEGG | KEGG:05164 | Influenza A | 2 | 103 | 7.39e-01 |
| KEGG | KEGG:04130 | SNARE interactions in vesicular transport | 1 | 32 | 7.39e-01 |
| KEGG | KEGG:05010 | Alzheimer disease | 3 | 315 | 7.39e-01 |
| KEGG | KEGG:04976 | Bile secretion | 2 | 42 | 7.39e-01 |
| KEGG | KEGG:04662 | B cell receptor signaling pathway | 1 | 56 | 7.39e-01 |
| KEGG | KEGG:04975 | Fat digestion and absorption | 1 | 19 | 7.40e-01 |
| KEGG | KEGG:05163 | Human cytomegalovirus infection | 2 | 176 | 7.40e-01 |
| KEGG | KEGG:05171 | Coronavirus disease - COVID-19 | 2 | 162 | 7.40e-01 |
| KEGG | KEGG:04022 | cGMP-PKG signaling pathway | 3 | 133 | 7.40e-01 |
| KEGG | KEGG:04972 | Pancreatic secretion | 1 | 58 | 7.40e-01 |
| KEGG | KEGG:04912 | GnRH signaling pathway | 2 | 76 | 7.40e-01 |
| KEGG | KEGG:04670 | Leukocyte transendothelial migration | 1 | 79 | 7.40e-01 |
| KEGG | KEGG:04151 | PI3K-Akt signaling pathway | 1 | 254 | 7.40e-01 |
| KEGG | KEGG:05202 | Transcriptional misregulation in cancer | 3 | 128 | 7.40e-01 |
| KEGG | KEGG:05014 | Amyotrophic lateral sclerosis | 2 | 303 | 7.40e-01 |
| KEGG | KEGG:04625 | C-type lectin receptor signaling pathway | 1 | 76 | 7.40e-01 |
| KEGG | KEGG:04261 | Adrenergic signaling in cardiomyocytes | 2 | 128 | 7.40e-01 |
| KEGG | KEGG:05414 | Dilated cardiomyopathy | 2 | 78 | 7.40e-01 |
| KEGG | KEGG:03250 | Viral life cycle - HIV-1 | 1 | 56 | 7.40e-01 |
| KEGG | KEGG:04730 | Long-term depression | 1 | 42 | 7.40e-01 |
| KEGG | KEGG:04914 | Progesterone-mediated oocyte maturation | 2 | 86 | 7.40e-01 |
| KEGG | KEGG:01522 | Endocrine resistance | 2 | 85 | 7.40e-01 |
| KEGG | KEGG:05169 | Epstein-Barr virus infection | 2 | 153 | 7.40e-01 |
| KEGG | KEGG:04810 | Regulation of actin cytoskeleton | 1 | 179 | 7.40e-01 |
| KEGG | KEGG:04925 | Aldosterone synthesis and secretion | 2 | 77 | 7.40e-01 |
| KEGG | KEGG:05412 | Arrhythmogenic right ventricular cardiomyopathy | 1 | 63 | 7.40e-01 |
| KEGG | KEGG:05165 | Human papillomavirus infection | 3 | 272 | 7.40e-01 |
| KEGG | KEGG:04062 | Chemokine signaling pathway | 2 | 113 | 7.40e-01 |
| KEGG | KEGG:04620 | Toll-like receptor signaling pathway | 1 | 60 | 7.40e-01 |
| KEGG | KEGG:05166 | Human T-cell leukemia virus 1 infection | 1 | 180 | 7.40e-01 |
| KEGG | KEGG:04922 | Glucagon signaling pathway | 1 | 84 | 7.40e-01 |
| KEGG | KEGG:00250 | Alanine, aspartate and glutamate metabolism | 1 | 29 | 7.40e-01 |
| KEGG | KEGG:05321 | Inflammatory bowel disease | 1 | 22 | 7.40e-01 |
| KEGG | KEGG:04120 | Ubiquitin mediated proteolysis | 1 | 134 | 7.40e-01 |
| KEGG | KEGG:05417 | Lipid and atherosclerosis | 2 | 153 | 7.46e-01 |
| KEGG | KEGG:01200 | Carbon metabolism | 1 | 98 | 7.46e-01 |
| KEGG | KEGG:05203 | Viral carcinogenesis | 3 | 172 | 7.46e-01 |
| KEGG | KEGG:04650 | Natural killer cell mediated cytotoxicity | 1 | 63 | 7.47e-01 |
| KEGG | KEGG:03013 | Nucleocytoplasmic transport | 1 | 99 | 7.47e-01 |
| KEGG | KEGG:01524 | Platinum drug resistance | 1 | 65 | 7.47e-01 |
| KEGG | KEGG:04260 | Cardiac muscle contraction | 1 | 67 | 7.48e-01 |
| KEGG | KEGG:04550 | Signaling pathways regulating pluripotency of stem cells | 1 | 104 | 7.50e-01 |
| KEGG | KEGG:05410 | Hypertrophic cardiomyopathy | 1 | 73 | 7.52e-01 |
| KEGG | KEGG:03460 | Fanconi anemia pathway | 1 | 48 | 7.52e-01 |
| KEGG | KEGG:05215 | Prostate cancer | 1 | 86 | 7.76e-01 |
| KEGG | KEGG:04923 | Regulation of lipolysis in adipocytes | 1 | 41 | 7.76e-01 |
| KEGG | KEGG:04110 | Cell cycle | 2 | 151 | 7.76e-01 |
| KEGG | KEGG:04658 | Th1 and Th2 cell differentiation | 1 | 53 | 7.76e-01 |
| KEGG | KEGG:00230 | Purine metabolism | 2 | 97 | 7.80e-01 |
| KEGG | KEGG:04072 | Phospholipase D signaling pathway | 1 | 110 | 7.81e-01 |
| KEGG | KEGG:04310 | Wnt signaling pathway | 1 | 138 | 7.89e-01 |
| KEGG | KEGG:04623 | Cytosolic DNA-sensing pathway | 1 | 42 | 7.99e-01 |
| KEGG | KEGG:05208 | Chemical carcinogenesis - reactive oxygen species | 1 | 186 | 8.04e-01 |
| KEGG | KEGG:05130 | Pathogenic Escherichia coli infection | 1 | 150 | 8.04e-01 |
| KEGG | KEGG:04720 | Long-term potentiation | 1 | 55 | 8.04e-01 |
| KEGG | KEGG:04915 | Estrogen signaling pathway | 2 | 97 | 8.04e-01 |
| KEGG | KEGG:04150 | mTOR signaling pathway | 1 | 135 | 8.10e-01 |
| KEGG | KEGG:04142 | Lysosome | 1 | 118 | 8.10e-01 |
| KEGG | KEGG:04728 | Dopaminergic synapse | 1 | 103 | 8.10e-01 |
| KEGG | KEGG:04714 | Thermogenesis | 2 | 195 | 8.10e-01 |
| KEGG | KEGG:03010 | Ribosome | 1 | 127 | 8.10e-01 |
| KEGG | KEGG:04918 | Thyroid hormone synthesis | 1 | 55 | 8.16e-01 |
| KEGG | KEGG:04514 | Cell adhesion molecules | 1 | 83 | 8.16e-01 |
| KEGG | KEGG:04971 | Gastric acid secretion | 1 | 52 | 8.16e-01 |
| KEGG | KEGG:04613 | Neutrophil extracellular trap formation | 1 | 110 | 8.18e-01 |
| KEGG | KEGG:05168 | Herpes simplex virus 1 infection | 4 | 415 | 8.23e-01 |
| KEGG | KEGG:04921 | Oxytocin signaling pathway | 2 | 115 | 8.23e-01 |
| KEGG | KEGG:04742 | Taste transduction | 1 | 22 | 8.41e-01 |
| KEGG | KEGG:04911 | Insulin secretion | 1 | 64 | 8.41e-01 |
| KEGG | KEGG:05032 | Morphine addiction | 1 | 56 | 8.49e-01 |
| KEGG | KEGG:04217 | Necroptosis | 2 | 106 | 8.55e-01 |
| KEGG | KEGG:05152 | Tuberculosis | 1 | 106 | 8.61e-01 |
| KEGG | KEGG:05207 | Chemical carcinogenesis - receptor activation | 1 | 142 | 8.61e-01 |
| KEGG | KEGG:04916 | Melanogenesis | 1 | 77 | 8.74e-01 |
| KEGG | KEGG:04928 | Parathyroid hormone synthesis, secretion and action | 1 | 82 | 8.82e-01 |
| KEGG | KEGG:04630 | JAK-STAT signaling pathway | 1 | 88 | 8.83e-01 |
| KEGG | KEGG:05322 | Systemic lupus erythematosus | 1 | 61 | 8.90e-01 |
| KEGG | KEGG:04724 | Glutamatergic synapse | 1 | 74 | 8.92e-01 |
| KEGG | KEGG:04114 | Oocyte meiosis | 1 | 108 | 9.15e-01 |
| KEGG | KEGG:04926 | Relaxin signaling pathway | 1 | 104 | 9.15e-01 |
| KEGG | KEGG:04723 | Retrograde endocannabinoid signaling | 1 | 99 | 9.40e-01 |
| KEGG | KEGG:05034 | Alcoholism | 1 | 122 | 9.47e-01 |
| KEGG | KEGG:04740 | Olfactory transduction | 1 | 25 | 9.90e-01 |
MTX_var24_table %>%
filter(source=="KEGG") %>%
mutate_at(.vars = 6, .funs= scientific_format()) %>%
kable(.,caption = "KEGG MTX 24 hour enrichment terms of highly var genes") %>%
kable_paper("striped", full_width = FALSE) %>%
kable_styling(full_width = FALSE, position = "left",bootstrap_options = c("striped","hover")) %>%
scroll_box(width = "100%", height = "400px")| source | term_id | term_name | intersection_size | term_size | p_value |
|---|---|---|---|---|---|
| KEGG | KEGG:04713 | Circadian entrainment | 1 | 69 | 5.24e-01 |
| KEGG | KEGG:05132 | Salmonella infection | 5 | 214 | 5.24e-01 |
| KEGG | KEGG:05131 | Shigellosis | 6 | 210 | 5.24e-01 |
| KEGG | KEGG:04913 | Ovarian steroidogenesis | 3 | 28 | 5.24e-01 |
| KEGG | KEGG:00900 | Terpenoid backbone biosynthesis | 1 | 21 | 5.24e-01 |
| KEGG | KEGG:04919 | Thyroid hormone signaling pathway | 3 | 112 | 5.24e-01 |
| KEGG | KEGG:03022 | Basal transcription factors | 1 | 40 | 5.24e-01 |
| KEGG | KEGG:04931 | Insulin resistance | 4 | 95 | 5.24e-01 |
| KEGG | KEGG:04070 | Phosphatidylinositol signaling system | 3 | 91 | 5.24e-01 |
| KEGG | KEGG:05017 | Spinocerebellar ataxia | 3 | 124 | 5.24e-01 |
| KEGG | KEGG:05210 | Colorectal cancer | 3 | 84 | 5.24e-01 |
| KEGG | KEGG:00750 | Vitamin B6 metabolism | 1 | 5 | 5.24e-01 |
| KEGG | KEGG:01521 | EGFR tyrosine kinase inhibitor resistance | 4 | 74 | 5.24e-01 |
| KEGG | KEGG:05110 | Vibrio cholerae infection | 2 | 43 | 5.24e-01 |
| KEGG | KEGG:04710 | Circadian rhythm | 1 | 30 | 5.24e-01 |
| KEGG | KEGG:00910 | Nitrogen metabolism | 1 | 10 | 5.24e-01 |
| KEGG | KEGG:04014 | Ras signaling pathway | 7 | 171 | 5.24e-01 |
| KEGG | KEGG:05225 | Hepatocellular carcinoma | 5 | 145 | 5.24e-01 |
| KEGG | KEGG:00590 | Arachidonic acid metabolism | 1 | 26 | 5.24e-01 |
| KEGG | KEGG:00100 | Steroid biosynthesis | 1 | 17 | 5.24e-01 |
| KEGG | KEGG:04146 | Peroxisome | 1 | 68 | 5.24e-01 |
| KEGG | KEGG:04012 | ErbB signaling pathway | 3 | 78 | 5.24e-01 |
| KEGG | KEGG:00450 | Selenocompound metabolism | 1 | 14 | 5.24e-01 |
| KEGG | KEGG:05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 3 | 69 | 5.24e-01 |
| KEGG | KEGG:04010 | MAPK signaling pathway | 8 | 240 | 5.24e-01 |
| KEGG | KEGG:04066 | HIF-1 signaling pathway | 3 | 89 | 5.24e-01 |
| KEGG | KEGG:05231 | Choline metabolism in cancer | 3 | 84 | 5.24e-01 |
| KEGG | KEGG:00562 | Inositol phosphate metabolism | 3 | 66 | 5.24e-01 |
| KEGG | KEGG:05160 | Hepatitis C | 2 | 115 | 5.69e-01 |
| KEGG | KEGG:04152 | AMPK signaling pathway | 4 | 103 | 5.69e-01 |
| KEGG | KEGG:03430 | Mismatch repair | 1 | 22 | 5.69e-01 |
| KEGG | KEGG:05205 | Proteoglycans in cancer | 4 | 170 | 5.69e-01 |
| KEGG | KEGG:05120 | Epithelial cell signaling in Helicobacter pylori infection | 2 | 58 | 5.69e-01 |
| KEGG | KEGG:04392 | Hippo signaling pathway - multiple species | 1 | 25 | 5.69e-01 |
| KEGG | KEGG:04390 | Hippo signaling pathway | 3 | 134 | 5.69e-01 |
| KEGG | KEGG:03040 | Spliceosome | 1 | 132 | 5.69e-01 |
| KEGG | KEGG:04924 | Renin secretion | 1 | 50 | 5.69e-01 |
| KEGG | KEGG:04910 | Insulin signaling pathway | 3 | 121 | 5.80e-01 |
| KEGG | KEGG:04145 | Phagosome | 1 | 99 | 5.83e-01 |
| KEGG | KEGG:04664 | Fc epsilon RI signaling pathway | 2 | 46 | 5.83e-01 |
| KEGG | KEGG:04137 | Mitophagy - animal | 2 | 70 | 5.86e-01 |
| KEGG | KEGG:04015 | Rap1 signaling pathway | 2 | 164 | 5.86e-01 |
| KEGG | KEGG:04270 | Vascular smooth muscle contraction | 1 | 94 | 5.95e-01 |
| KEGG | KEGG:00790 | Folate biosynthesis | 1 | 18 | 5.95e-01 |
| KEGG | KEGG:01100 | Metabolic pathways | 1 | 1146 | 5.95e-01 |
| KEGG | KEGG:01523 | Antifolate resistance | 1 | 24 | 5.95e-01 |
| KEGG | KEGG:03030 | DNA replication | 1 | 35 | 5.95e-01 |
| KEGG | KEGG:04933 | AGE-RAGE signaling pathway in diabetic complications | 2 | 91 | 5.95e-01 |
| KEGG | KEGG:05100 | Bacterial invasion of epithelial cells | 1 | 74 | 5.95e-01 |
| KEGG | KEGG:04932 | Non-alcoholic fatty liver disease | 3 | 131 | 5.95e-01 |
| KEGG | KEGG:04750 | Inflammatory mediator regulation of TRP channels | 2 | 72 | 5.95e-01 |
| KEGG | KEGG:04727 | GABAergic synapse | 3 | 55 | 5.95e-01 |
| KEGG | KEGG:04722 | Neurotrophin signaling pathway | 2 | 110 | 5.95e-01 |
| KEGG | KEGG:03050 | Proteasome | 2 | 42 | 5.95e-01 |
| KEGG | KEGG:04962 | Vasopressin-regulated water reabsorption | 1 | 38 | 5.95e-01 |
| KEGG | KEGG:00670 | One carbon pool by folate | 1 | 18 | 5.95e-01 |
| KEGG | KEGG:00604 | Glycosphingolipid biosynthesis - ganglio series | 1 | 12 | 5.95e-01 |
| KEGG | KEGG:03320 | PPAR signaling pathway | 1 | 50 | 5.95e-01 |
| KEGG | KEGG:05219 | Bladder cancer | 1 | 37 | 5.95e-01 |
| KEGG | KEGG:05214 | Glioma | 2 | 67 | 5.95e-01 |
| KEGG | KEGG:05212 | Pancreatic cancer | 2 | 75 | 5.95e-01 |
| KEGG | KEGG:05211 | Renal cell carcinoma | 2 | 65 | 5.95e-01 |
| KEGG | KEGG:00140 | Steroid hormone biosynthesis | 1 | 19 | 5.95e-01 |
| KEGG | KEGG:00280 | Valine, leucine and isoleucine degradation | 2 | 43 | 5.95e-01 |
| KEGG | KEGG:00630 | Glyoxylate and dicarboxylate metabolism | 1 | 25 | 5.95e-01 |
| KEGG | KEGG:00520 | Amino sugar and nucleotide sugar metabolism | 2 | 46 | 5.95e-01 |
| KEGG | KEGG:05223 | Non-small cell lung cancer | 2 | 67 | 5.95e-01 |
| KEGG | KEGG:05206 | MicroRNAs in cancer | 5 | 149 | 5.95e-01 |
| KEGG | KEGG:05170 | Human immunodeficiency virus 1 infection | 4 | 165 | 5.95e-01 |
| KEGG | KEGG:05167 | Kaposi sarcoma-associated herpesvirus infection | 3 | 145 | 5.95e-01 |
| KEGG | KEGG:04218 | Cellular senescence | 1 | 145 | 5.95e-01 |
| KEGG | KEGG:05230 | Central carbon metabolism in cancer | 2 | 62 | 5.95e-01 |
| KEGG | KEGG:00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 1 | 13 | 5.95e-01 |
| KEGG | KEGG:03410 | Base excision repair | 1 | 33 | 5.95e-01 |
| KEGG | KEGG:04978 | Mineral absorption | 2 | 42 | 5.95e-01 |
| KEGG | KEGG:03420 | Nucleotide excision repair | 1 | 43 | 5.95e-01 |
| KEGG | KEGG:04024 | cAMP signaling pathway | 2 | 151 | 5.95e-01 |
| KEGG | KEGG:03440 | Homologous recombination | 1 | 39 | 5.95e-01 |
| KEGG | KEGG:04064 | NF-kappa B signaling pathway | 2 | 71 | 5.95e-01 |
| KEGG | KEGG:04520 | Adherens junction | 2 | 67 | 5.95e-01 |
| KEGG | KEGG:04540 | Gap junction | 3 | 73 | 5.95e-01 |
| KEGG | KEGG:04360 | Axon guidance | 4 | 162 | 5.95e-01 |
| KEGG | KEGG:04666 | Fc gamma R-mediated phagocytosis | 2 | 75 | 5.95e-01 |
| KEGG | KEGG:00603 | Glycosphingolipid biosynthesis - globo and isoglobo series | 1 | 9 | 6.21e-01 |
| KEGG | KEGG:04668 | TNF signaling pathway | 2 | 87 | 6.21e-01 |
| KEGG | KEGG:04020 | Calcium signaling pathway | 4 | 157 | 6.23e-01 |
| KEGG | KEGG:01240 | Biosynthesis of cofactors | 3 | 115 | 6.23e-01 |
| KEGG | KEGG:05221 | Acute myeloid leukemia | 2 | 56 | 6.23e-01 |
| KEGG | KEGG:00260 | Glycine, serine and threonine metabolism | 1 | 31 | 6.39e-01 |
| KEGG | KEGG:04935 | Growth hormone synthesis, secretion and action | 2 | 98 | 6.39e-01 |
| KEGG | KEGG:05145 | Toxoplasmosis | 2 | 82 | 6.44e-01 |
| KEGG | KEGG:04530 | Tight junction | 2 | 137 | 6.53e-01 |
| KEGG | KEGG:04380 | Osteoclast differentiation | 2 | 87 | 6.55e-01 |
| KEGG | KEGG:04725 | Cholinergic synapse | 1 | 83 | 6.92e-01 |
| KEGG | KEGG:05226 | Gastric cancer | 2 | 117 | 6.92e-01 |
| KEGG | KEGG:05224 | Breast cancer | 2 | 117 | 6.92e-01 |
| KEGG | KEGG:04080 | Neuroactive ligand-receptor interaction | 2 | 108 | 6.92e-01 |
| KEGG | KEGG:04140 | Autophagy - animal | 3 | 133 | 6.92e-01 |
| KEGG | KEGG:05217 | Basal cell carcinoma | 1 | 49 | 6.92e-01 |
| KEGG | KEGG:00051 | Fructose and mannose metabolism | 1 | 27 | 6.92e-01 |
| KEGG | KEGG:03018 | RNA degradation | 1 | 74 | 6.92e-01 |
| KEGG | KEGG:05213 | Endometrial cancer | 1 | 57 | 6.92e-01 |
| KEGG | KEGG:04927 | Cortisol synthesis and secretion | 2 | 48 | 6.92e-01 |
| KEGG | KEGG:04213 | Longevity regulating pathway - multiple species | 2 | 55 | 6.92e-01 |
| KEGG | KEGG:04936 | Alcoholic liver disease | 2 | 97 | 6.92e-01 |
| KEGG | KEGG:04964 | Proximal tubule bicarbonate reclamation | 1 | 20 | 6.92e-01 |
| KEGG | KEGG:05022 | Pathways of neurodegeneration - multiple diseases | 5 | 385 | 6.92e-01 |
| KEGG | KEGG:00220 | Arginine biosynthesis | 1 | 16 | 6.92e-01 |
| KEGG | KEGG:04144 | Endocytosis | 1 | 232 | 6.92e-01 |
| KEGG | KEGG:05135 | Yersinia infection | 2 | 112 | 6.92e-01 |
| KEGG | KEGG:04370 | VEGF signaling pathway | 1 | 49 | 6.92e-01 |
| KEGG | KEGG:00000 | KEGG root term | 4 | 5558 | 6.92e-01 |
| KEGG | KEGG:04974 | Protein digestion and absorption | 2 | 61 | 6.92e-01 |
| KEGG | KEGG:05418 | Fluid shear stress and atherosclerosis | 2 | 114 | 6.92e-01 |
| KEGG | KEGG:01250 | Biosynthesis of nucleotide sugars | 1 | 35 | 6.93e-01 |
| KEGG | KEGG:04216 | Ferroptosis | 1 | 33 | 7.11e-01 |
| KEGG | KEGG:04979 | Cholesterol metabolism | 1 | 33 | 7.11e-01 |
| KEGG | KEGG:04611 | Platelet activation | 3 | 89 | 7.12e-01 |
| KEGG | KEGG:04934 | Cushing syndrome | 2 | 121 | 7.33e-01 |
| KEGG | KEGG:04340 | Hedgehog signaling pathway | 1 | 49 | 7.33e-01 |
| KEGG | KEGG:04659 | Th17 cell differentiation | 1 | 64 | 7.33e-01 |
| KEGG | KEGG:00510 | N-Glycan biosynthesis | 1 | 48 | 7.33e-01 |
| KEGG | KEGG:05012 | Parkinson disease | 2 | 226 | 7.33e-01 |
| KEGG | KEGG:03020 | RNA polymerase | 1 | 34 | 7.33e-01 |
| KEGG | KEGG:05020 | Prion disease | 2 | 220 | 7.33e-01 |
| KEGG | KEGG:04350 | TGF-beta signaling pathway | 2 | 84 | 7.33e-01 |
| KEGG | KEGG:04961 | Endocrine and other factor-regulated calcium reabsorption | 1 | 41 | 7.33e-01 |
| KEGG | KEGG:04371 | Apelin signaling pathway | 2 | 106 | 7.33e-01 |
| KEGG | KEGG:05200 | Pathways in cancer | 7 | 409 | 7.33e-01 |
| KEGG | KEGG:01230 | Biosynthesis of amino acids | 1 | 60 | 7.33e-01 |
| KEGG | KEGG:04512 | ECM-receptor interaction | 1 | 69 | 7.33e-01 |
| KEGG | KEGG:05161 | Hepatitis B | 3 | 136 | 7.33e-01 |
| KEGG | KEGG:04211 | Longevity regulating pathway | 2 | 78 | 7.39e-01 |
| KEGG | KEGG:00512 | Mucin type O-glycan biosynthesis | 1 | 22 | 7.39e-01 |
| KEGG | KEGG:00514 | Other types of O-glycan biosynthesis | 1 | 37 | 7.39e-01 |
| KEGG | KEGG:05016 | Huntington disease | 2 | 256 | 7.39e-01 |
| KEGG | KEGG:04970 | Salivary secretion | 2 | 55 | 7.39e-01 |
| KEGG | KEGG:04141 | Protein processing in endoplasmic reticulum | 2 | 161 | 7.39e-01 |
| KEGG | KEGG:05164 | Influenza A | 2 | 103 | 7.39e-01 |
| KEGG | KEGG:04130 | SNARE interactions in vesicular transport | 1 | 32 | 7.39e-01 |
| KEGG | KEGG:05010 | Alzheimer disease | 3 | 315 | 7.39e-01 |
| KEGG | KEGG:04976 | Bile secretion | 2 | 42 | 7.39e-01 |
| KEGG | KEGG:04662 | B cell receptor signaling pathway | 1 | 56 | 7.39e-01 |
| KEGG | KEGG:04975 | Fat digestion and absorption | 1 | 19 | 7.40e-01 |
| KEGG | KEGG:05163 | Human cytomegalovirus infection | 2 | 176 | 7.40e-01 |
| KEGG | KEGG:05171 | Coronavirus disease - COVID-19 | 2 | 162 | 7.40e-01 |
| KEGG | KEGG:04022 | cGMP-PKG signaling pathway | 3 | 133 | 7.40e-01 |
| KEGG | KEGG:04972 | Pancreatic secretion | 1 | 58 | 7.40e-01 |
| KEGG | KEGG:04912 | GnRH signaling pathway | 2 | 76 | 7.40e-01 |
| KEGG | KEGG:04670 | Leukocyte transendothelial migration | 1 | 79 | 7.40e-01 |
| KEGG | KEGG:04151 | PI3K-Akt signaling pathway | 1 | 254 | 7.40e-01 |
| KEGG | KEGG:05202 | Transcriptional misregulation in cancer | 3 | 128 | 7.40e-01 |
| KEGG | KEGG:05014 | Amyotrophic lateral sclerosis | 2 | 303 | 7.40e-01 |
| KEGG | KEGG:04625 | C-type lectin receptor signaling pathway | 1 | 76 | 7.40e-01 |
| KEGG | KEGG:04261 | Adrenergic signaling in cardiomyocytes | 2 | 128 | 7.40e-01 |
| KEGG | KEGG:05414 | Dilated cardiomyopathy | 2 | 78 | 7.40e-01 |
| KEGG | KEGG:03250 | Viral life cycle - HIV-1 | 1 | 56 | 7.40e-01 |
| KEGG | KEGG:04730 | Long-term depression | 1 | 42 | 7.40e-01 |
| KEGG | KEGG:04914 | Progesterone-mediated oocyte maturation | 2 | 86 | 7.40e-01 |
| KEGG | KEGG:01522 | Endocrine resistance | 2 | 85 | 7.40e-01 |
| KEGG | KEGG:05169 | Epstein-Barr virus infection | 2 | 153 | 7.40e-01 |
| KEGG | KEGG:04810 | Regulation of actin cytoskeleton | 1 | 179 | 7.40e-01 |
| KEGG | KEGG:04925 | Aldosterone synthesis and secretion | 2 | 77 | 7.40e-01 |
| KEGG | KEGG:05412 | Arrhythmogenic right ventricular cardiomyopathy | 1 | 63 | 7.40e-01 |
| KEGG | KEGG:05165 | Human papillomavirus infection | 3 | 272 | 7.40e-01 |
| KEGG | KEGG:04062 | Chemokine signaling pathway | 2 | 113 | 7.40e-01 |
| KEGG | KEGG:04620 | Toll-like receptor signaling pathway | 1 | 60 | 7.40e-01 |
| KEGG | KEGG:05166 | Human T-cell leukemia virus 1 infection | 1 | 180 | 7.40e-01 |
| KEGG | KEGG:04922 | Glucagon signaling pathway | 1 | 84 | 7.40e-01 |
| KEGG | KEGG:00250 | Alanine, aspartate and glutamate metabolism | 1 | 29 | 7.40e-01 |
| KEGG | KEGG:05321 | Inflammatory bowel disease | 1 | 22 | 7.40e-01 |
| KEGG | KEGG:04120 | Ubiquitin mediated proteolysis | 1 | 134 | 7.40e-01 |
| KEGG | KEGG:05417 | Lipid and atherosclerosis | 2 | 153 | 7.46e-01 |
| KEGG | KEGG:01200 | Carbon metabolism | 1 | 98 | 7.46e-01 |
| KEGG | KEGG:05203 | Viral carcinogenesis | 3 | 172 | 7.46e-01 |
| KEGG | KEGG:04650 | Natural killer cell mediated cytotoxicity | 1 | 63 | 7.47e-01 |
| KEGG | KEGG:03013 | Nucleocytoplasmic transport | 1 | 99 | 7.47e-01 |
| KEGG | KEGG:01524 | Platinum drug resistance | 1 | 65 | 7.47e-01 |
| KEGG | KEGG:04260 | Cardiac muscle contraction | 1 | 67 | 7.48e-01 |
| KEGG | KEGG:04550 | Signaling pathways regulating pluripotency of stem cells | 1 | 104 | 7.50e-01 |
| KEGG | KEGG:05410 | Hypertrophic cardiomyopathy | 1 | 73 | 7.52e-01 |
| KEGG | KEGG:03460 | Fanconi anemia pathway | 1 | 48 | 7.52e-01 |
| KEGG | KEGG:05215 | Prostate cancer | 1 | 86 | 7.76e-01 |
| KEGG | KEGG:04923 | Regulation of lipolysis in adipocytes | 1 | 41 | 7.76e-01 |
| KEGG | KEGG:04110 | Cell cycle | 2 | 151 | 7.76e-01 |
| KEGG | KEGG:04658 | Th1 and Th2 cell differentiation | 1 | 53 | 7.76e-01 |
| KEGG | KEGG:00230 | Purine metabolism | 2 | 97 | 7.80e-01 |
| KEGG | KEGG:04072 | Phospholipase D signaling pathway | 1 | 110 | 7.81e-01 |
| KEGG | KEGG:04310 | Wnt signaling pathway | 1 | 138 | 7.89e-01 |
| KEGG | KEGG:04623 | Cytosolic DNA-sensing pathway | 1 | 42 | 7.99e-01 |
| KEGG | KEGG:05208 | Chemical carcinogenesis - reactive oxygen species | 1 | 186 | 8.04e-01 |
| KEGG | KEGG:05130 | Pathogenic Escherichia coli infection | 1 | 150 | 8.04e-01 |
| KEGG | KEGG:04720 | Long-term potentiation | 1 | 55 | 8.04e-01 |
| KEGG | KEGG:04915 | Estrogen signaling pathway | 2 | 97 | 8.04e-01 |
| KEGG | KEGG:04150 | mTOR signaling pathway | 1 | 135 | 8.10e-01 |
| KEGG | KEGG:04142 | Lysosome | 1 | 118 | 8.10e-01 |
| KEGG | KEGG:04728 | Dopaminergic synapse | 1 | 103 | 8.10e-01 |
| KEGG | KEGG:04714 | Thermogenesis | 2 | 195 | 8.10e-01 |
| KEGG | KEGG:03010 | Ribosome | 1 | 127 | 8.10e-01 |
| KEGG | KEGG:04918 | Thyroid hormone synthesis | 1 | 55 | 8.16e-01 |
| KEGG | KEGG:04514 | Cell adhesion molecules | 1 | 83 | 8.16e-01 |
| KEGG | KEGG:04971 | Gastric acid secretion | 1 | 52 | 8.16e-01 |
| KEGG | KEGG:04613 | Neutrophil extracellular trap formation | 1 | 110 | 8.18e-01 |
| KEGG | KEGG:05168 | Herpes simplex virus 1 infection | 4 | 415 | 8.23e-01 |
| KEGG | KEGG:04921 | Oxytocin signaling pathway | 2 | 115 | 8.23e-01 |
| KEGG | KEGG:04742 | Taste transduction | 1 | 22 | 8.41e-01 |
| KEGG | KEGG:04911 | Insulin secretion | 1 | 64 | 8.41e-01 |
| KEGG | KEGG:05032 | Morphine addiction | 1 | 56 | 8.49e-01 |
| KEGG | KEGG:04217 | Necroptosis | 2 | 106 | 8.55e-01 |
| KEGG | KEGG:05152 | Tuberculosis | 1 | 106 | 8.61e-01 |
| KEGG | KEGG:05207 | Chemical carcinogenesis - receptor activation | 1 | 142 | 8.61e-01 |
| KEGG | KEGG:04916 | Melanogenesis | 1 | 77 | 8.74e-01 |
| KEGG | KEGG:04928 | Parathyroid hormone synthesis, secretion and action | 1 | 82 | 8.82e-01 |
| KEGG | KEGG:04630 | JAK-STAT signaling pathway | 1 | 88 | 8.83e-01 |
| KEGG | KEGG:05322 | Systemic lupus erythematosus | 1 | 61 | 8.90e-01 |
| KEGG | KEGG:04724 | Glutamatergic synapse | 1 | 74 | 8.92e-01 |
| KEGG | KEGG:04114 | Oocyte meiosis | 1 | 108 | 9.15e-01 |
| KEGG | KEGG:04926 | Relaxin signaling pathway | 1 | 104 | 9.15e-01 |
| KEGG | KEGG:04723 | Retrograde endocannabinoid signaling | 1 | 99 | 9.40e-01 |
| KEGG | KEGG:05034 | Alcoholism | 1 | 122 | 9.47e-01 |
| KEGG | KEGG:04740 | Olfactory transduction | 1 | 25 | 9.90e-01 |
24 hour TRZ highly variable genes
based on nominal pvalues <0.05
# TRZ_var24gost <- gost(query = TRZ_24_var$ENTREZID,
# organism = "hsapiens",
# significant = FALSE,
# ordered_query = TRUE,
# domain_scope = "custom",
# measure_underrepresentation = FALSE,
# evcodes = FALSE,
# numeric_ns="ENTREZGENE",
# user_threshold = 0.05,
# correction_method = "fdr",
# custom_bg = backGL$ENTREZID,
# sources=c("GO:BP","KEGG"))
#
# saveRDS(TRZ_var24gost,"data/DEG-GO/var/TRZ_var24gost.RDS")
TRZ_var24gost <- readRDS("data/DEG-GO/var/TRZ_var24gost.RDS")
TRZ_var24p <- gostplot(TRZ_var24gost, capped = FALSE, interactive = TRUE)
TRZ_var24pTRZ_var24_table <- TRZ_var24gost$result %>%
dplyr::select(c(source, term_id, term_name,intersection_size, term_size, p_value))
TRZ_var24_table %>%
dplyr::filter(source=="GO:BP") %>%
dplyr::select(p_value,term_name,intersection_size) %>%
slice_min(., n=10 ,order_by=p_value) %>%
mutate(log_val = -log10(p_value)) %>%
# slice_max(., n=10,order_by = p_value) %>%
ggplot(., aes(x = log_val, y =reorder(term_name,p_value), col= intersection_size)) +
geom_point(aes(size = intersection_size)) +
geom_vline(xintercept = (-log10(0.05)), col="red")+
scale_y_discrete(labels = label_wrap(30))+
guides(col="none", size=guide_legend(title = "# of intersected \n terms"))+
ggtitle('TRZ24 hour top 10 GO:BP terms') +
xlab(expression(" -"~log[10]~("adj. p-value")))+
ylab("GO: BP term")+
theme_bw()+
theme(plot.title = element_text(size = rel(1.5), hjust = 0.5),
axis.title = element_text(size = 15, color = "black"),
axis.ticks = element_line(linewidth = 1.5),
axis.line = element_line(linewidth = 1.5),
axis.text = element_text(size = 10, color = "black", angle = 0),
strip.text.x = element_text(size = 15, color = "black", face = "bold")) 
TRZ_var24_table %>%
mutate_at(.vars = 6, .funs= scientific_format()) %>%
kable(.,caption = "TRZ 24 enrichment terms of highly var genes") %>%
kable_paper("striped", full_width = FALSE) %>%
kable_styling(full_width = FALSE, position = "left",bootstrap_options = c("striped","hover")) %>%
scroll_box(width = "100%", height = "400px")| source | term_id | term_name | intersection_size | term_size | p_value |
|---|---|---|---|---|---|
| GO:BP | GO:0090132 | epithelium migration | 3 | 252 | 7.90e-02 |
| GO:BP | GO:0090130 | tissue migration | 3 | 256 | 7.90e-02 |
| GO:BP | GO:0043542 | endothelial cell migration | 3 | 182 | 7.90e-02 |
| GO:BP | GO:0010631 | epithelial cell migration | 3 | 252 | 7.90e-02 |
| GO:BP | GO:0018195 | peptidyl-arginine modification | 2 | 18 | 7.90e-02 |
| GO:BP | GO:0016050 | vesicle organization | 13 | 320 | 9.81e-02 |
| GO:BP | GO:0001667 | ameboidal-type cell migration | 3 | 358 | 1.25e-01 |
| GO:BP | GO:0043534 | blood vessel endothelial cell migration | 2 | 97 | 1.27e-01 |
| GO:BP | GO:0086055 | Purkinje myocyte to ventricular cardiac muscle cell communication by electrical coupling | 1 | 1 | 1.27e-01 |
| GO:BP | GO:0010645 | regulation of cell communication by chemical coupling | 1 | 1 | 1.27e-01 |
| GO:BP | GO:0098906 | regulation of Purkinje myocyte action potential | 1 | 1 | 1.27e-01 |
| GO:BP | GO:0086044 | atrial cardiac muscle cell to AV node cell communication by electrical coupling | 1 | 1 | 1.27e-01 |
| GO:BP | GO:0006890 | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 3 | 52 | 1.27e-01 |
| GO:BP | GO:0007032 | endosome organization | 4 | 92 | 1.27e-01 |
| GO:BP | GO:1990029 | vasomotion | 1 | 1 | 1.27e-01 |
| GO:BP | GO:1902068 | regulation of sphingolipid mediated signaling pathway | 1 | 1 | 1.27e-01 |
| GO:BP | GO:0010652 | positive regulation of cell communication by chemical coupling | 1 | 1 | 1.27e-01 |
| GO:BP | GO:0098815 | modulation of excitatory postsynaptic potential | 4 | 40 | 1.31e-01 |
| GO:BP | GO:1904058 | positive regulation of sensory perception of pain | 2 | 3 | 1.31e-01 |
| GO:BP | GO:0042543 | protein N-linked glycosylation via arginine | 1 | 1 | 1.31e-01 |
| GO:BP | GO:0051452 | intracellular pH reduction | 3 | 45 | 1.33e-01 |
| GO:BP | GO:0086054 | bundle of His cell to Purkinje myocyte communication by electrical coupling | 1 | 2 | 1.33e-01 |
| GO:BP | GO:0098905 | regulation of bundle of His cell action potential | 1 | 2 | 1.33e-01 |
| GO:BP | GO:0090394 | negative regulation of excitatory postsynaptic potential | 2 | 8 | 1.33e-01 |
| GO:BP | GO:0003193 | pulmonary valve formation | 1 | 2 | 1.33e-01 |
| GO:BP | GO:0086021 | SA node cell to atrial cardiac muscle cell communication by electrical coupling | 1 | 2 | 1.33e-01 |
| GO:BP | GO:0010594 | regulation of endothelial cell migration | 2 | 143 | 1.33e-01 |
| GO:BP | GO:0001568 | blood vessel development | 4 | 534 | 1.33e-01 |
| GO:BP | GO:0002066 | columnar/cuboidal epithelial cell development | 4 | 38 | 1.33e-01 |
| GO:BP | GO:0001944 | vasculature development | 4 | 559 | 1.33e-01 |
| GO:BP | GO:0048388 | endosomal lumen acidification | 2 | 13 | 1.33e-01 |
| GO:BP | GO:0033140 | negative regulation of peptidyl-serine phosphorylation of STAT protein | 1 | 3 | 1.33e-01 |
| GO:BP | GO:0010643 | cell communication by chemical coupling | 1 | 2 | 1.33e-01 |
| GO:BP | GO:0060528 | secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development | 1 | 2 | 1.52e-01 |
| GO:BP | GO:0009221 | pyrimidine deoxyribonucleotide biosynthetic process | 2 | 7 | 1.53e-01 |
| GO:BP | GO:0006392 | transcription elongation by mitochondrial RNA polymerase | 1 | 1 | 1.57e-01 |
| GO:BP | GO:1903779 | regulation of cardiac conduction | 2 | 23 | 1.57e-01 |
| GO:BP | GO:0051045 | negative regulation of membrane protein ectodomain proteolysis | 1 | 7 | 1.57e-01 |
| GO:BP | GO:0006644 | phospholipid metabolic process | 2 | 316 | 1.57e-01 |
| GO:BP | GO:0036092 | phosphatidylinositol-3-phosphate biosynthetic process | 1 | 19 | 1.57e-01 |
| GO:BP | GO:1904572 | negative regulation of mRNA binding | 1 | 1 | 1.57e-01 |
| GO:BP | GO:1905513 | negative regulation of short-term synaptic potentiation | 1 | 1 | 1.57e-01 |
| GO:BP | GO:1904338 | regulation of dopaminergic neuron differentiation | 2 | 7 | 1.57e-01 |
| GO:BP | GO:1904570 | negative regulation of selenocysteine incorporation | 1 | 1 | 1.57e-01 |
| GO:BP | GO:1904574 | negative regulation of selenocysteine insertion sequence binding | 1 | 1 | 1.57e-01 |
| GO:BP | GO:0009130 | pyrimidine nucleoside monophosphate biosynthetic process | 2 | 13 | 1.57e-01 |
| GO:BP | GO:1990966 | ATP generation from poly-ADP-D-ribose | 1 | 4 | 1.57e-01 |
| GO:BP | GO:0090520 | sphingolipid mediated signaling pathway | 1 | 11 | 1.57e-01 |
| GO:BP | GO:0033631 | cell-cell adhesion mediated by integrin | 1 | 12 | 1.57e-01 |
| GO:BP | GO:0034969 | histone arginine methylation | 1 | 8 | 1.57e-01 |
| GO:BP | GO:0051100 | negative regulation of binding | 6 | 135 | 1.57e-01 |
| GO:BP | GO:0007035 | vacuolar acidification | 3 | 30 | 1.57e-01 |
| GO:BP | GO:0098910 | regulation of atrial cardiac muscle cell action potential | 1 | 4 | 1.57e-01 |
| GO:BP | GO:1904481 | response to tetrahydrofolate | 1 | 1 | 1.57e-01 |
| GO:BP | GO:1904482 | cellular response to tetrahydrofolate | 1 | 1 | 1.57e-01 |
| GO:BP | GO:0060373 | regulation of ventricular cardiac muscle cell membrane depolarization | 1 | 6 | 1.57e-01 |
| GO:BP | GO:0098904 | regulation of AV node cell action potential | 1 | 3 | 1.57e-01 |
| GO:BP | GO:2000811 | negative regulation of anoikis | 1 | 17 | 1.57e-01 |
| GO:BP | GO:0035137 | hindlimb morphogenesis | 3 | 20 | 1.57e-01 |
| GO:BP | GO:0006014 | D-ribose metabolic process | 1 | 3 | 1.57e-01 |
| GO:BP | GO:0007308 | oocyte construction | 1 | 3 | 1.57e-01 |
| GO:BP | GO:0007309 | oocyte axis specification | 1 | 3 | 1.57e-01 |
| GO:BP | GO:1904573 | regulation of selenocysteine insertion sequence binding | 1 | 1 | 1.57e-01 |
| GO:BP | GO:0006221 | pyrimidine nucleotide biosynthetic process | 3 | 28 | 1.57e-01 |
| GO:BP | GO:0006884 | cell volume homeostasis | 2 | 24 | 1.57e-01 |
| GO:BP | GO:1905512 | regulation of short-term synaptic potentiation | 1 | 1 | 1.57e-01 |
| GO:BP | GO:0033363 | secretory granule organization | 4 | 50 | 1.57e-01 |
| GO:BP | GO:1990089 | response to nerve growth factor | 3 | 41 | 1.57e-01 |
| GO:BP | GO:1990090 | cellular response to nerve growth factor stimulus | 3 | 41 | 1.57e-01 |
| GO:BP | GO:0060770 | negative regulation of epithelial cell proliferation involved in prostate gland development | 1 | 6 | 1.57e-01 |
| GO:BP | GO:0030334 | regulation of cell migration | 4 | 706 | 1.57e-01 |
| GO:BP | GO:0003105 | negative regulation of glomerular filtration | 1 | 3 | 1.57e-01 |
| GO:BP | GO:0002880 | regulation of chronic inflammatory response to non-antigenic stimulus | 1 | 1 | 1.57e-01 |
| GO:BP | GO:0072359 | circulatory system development | 3 | 884 | 1.57e-01 |
| GO:BP | GO:0019323 | pentose catabolic process | 1 | 2 | 1.57e-01 |
| GO:BP | GO:0040012 | regulation of locomotion | 4 | 763 | 1.57e-01 |
| GO:BP | GO:1902866 | regulation of retina development in camera-type eye | 1 | 1 | 1.57e-01 |
| GO:BP | GO:0002545 | chronic inflammatory response to non-antigenic stimulus | 1 | 1 | 1.57e-01 |
| GO:BP | GO:0086017 | Purkinje myocyte action potential | 1 | 4 | 1.57e-01 |
| GO:BP | GO:0002882 | positive regulation of chronic inflammatory response to non-antigenic stimulus | 1 | 1 | 1.57e-01 |
| GO:BP | GO:0043985 | histone H4-R3 methylation | 1 | 6 | 1.57e-01 |
| GO:BP | GO:0080170 | hydrogen peroxide transmembrane transport | 1 | 1 | 1.57e-01 |
| GO:BP | GO:2000209 | regulation of anoikis | 1 | 23 | 1.57e-01 |
| GO:BP | GO:0051453 | regulation of intracellular pH | 3 | 65 | 1.57e-01 |
| GO:BP | GO:0072715 | cellular response to selenite ion | 1 | 1 | 1.57e-01 |
| GO:BP | GO:0060020 | Bergmann glial cell differentiation | 1 | 9 | 1.57e-01 |
| GO:BP | GO:1904569 | regulation of selenocysteine incorporation | 1 | 1 | 1.57e-01 |
| GO:BP | GO:0010632 | regulation of epithelial cell migration | 2 | 195 | 1.57e-01 |
| GO:BP | GO:0072714 | response to selenite ion | 1 | 1 | 1.57e-01 |
| GO:BP | GO:0019303 | D-ribose catabolic process | 1 | 2 | 1.57e-01 |
| GO:BP | GO:0043276 | anoikis | 1 | 32 | 1.57e-01 |
| GO:BP | GO:2000145 | regulation of cell motility | 4 | 742 | 1.57e-01 |
| GO:BP | GO:0016477 | cell migration | 5 | 1081 | 1.57e-01 |
| GO:BP | GO:0001932 | regulation of protein phosphorylation | 3 | 796 | 1.57e-01 |
| GO:BP | GO:0086028 | bundle of His cell to Purkinje myocyte signaling | 1 | 6 | 1.57e-01 |
| GO:BP | GO:0001933 | negative regulation of protein phosphorylation | 2 | 277 | 1.57e-01 |
| GO:BP | GO:0086029 | Purkinje myocyte to ventricular cardiac muscle cell signaling | 1 | 6 | 1.57e-01 |
| GO:BP | GO:0086053 | AV node cell to bundle of His cell communication by electrical coupling | 1 | 3 | 1.57e-01 |
| GO:BP | GO:0086043 | bundle of His cell action potential | 1 | 6 | 1.57e-01 |
| GO:BP | GO:0086068 | Purkinje myocyte to ventricular cardiac muscle cell communication | 1 | 6 | 1.57e-01 |
| GO:BP | GO:0031987 | locomotion involved in locomotory behavior | 2 | 9 | 1.58e-01 |
| GO:BP | GO:0071245 | cellular response to carbon monoxide | 1 | 1 | 1.58e-01 |
| GO:BP | GO:0072528 | pyrimidine-containing compound biosynthetic process | 3 | 33 | 1.58e-01 |
| GO:BP | GO:0001525 | angiogenesis | 3 | 390 | 1.58e-01 |
| GO:BP | GO:0010256 | endomembrane system organization | 11 | 496 | 1.58e-01 |
| GO:BP | GO:0042325 | regulation of phosphorylation | 3 | 881 | 1.58e-01 |
| GO:BP | GO:0060371 | regulation of atrial cardiac muscle cell membrane depolarization | 1 | 7 | 1.58e-01 |
| GO:BP | GO:0060525 | prostate glandular acinus development | 1 | 5 | 1.58e-01 |
| GO:BP | GO:0060768 | regulation of epithelial cell proliferation involved in prostate gland development | 1 | 9 | 1.58e-01 |
| GO:BP | GO:0030641 | regulation of cellular pH | 3 | 70 | 1.60e-01 |
| GO:BP | GO:0006670 | sphingosine metabolic process | 1 | 18 | 1.60e-01 |
| GO:BP | GO:0045936 | negative regulation of phosphate metabolic process | 3 | 344 | 1.60e-01 |
| GO:BP | GO:0010563 | negative regulation of phosphorus metabolic process | 3 | 345 | 1.60e-01 |
| GO:BP | GO:0060767 | epithelial cell proliferation involved in prostate gland development | 1 | 10 | 1.61e-01 |
| GO:BP | GO:0150101 | regulation of microtubule anchoring at centrosome | 1 | 1 | 1.61e-01 |
| GO:BP | GO:0019220 | regulation of phosphate metabolic process | 3 | 993 | 1.61e-01 |
| GO:BP | GO:1903676 | positive regulation of cap-dependent translational initiation | 1 | 1 | 1.61e-01 |
| GO:BP | GO:0060742 | epithelial cell differentiation involved in prostate gland development | 1 | 8 | 1.61e-01 |
| GO:BP | GO:0002065 | columnar/cuboidal epithelial cell differentiation | 5 | 80 | 1.61e-01 |
| GO:BP | GO:0150037 | regulation of calcium-dependent activation of synaptic vesicle fusion | 1 | 2 | 1.61e-01 |
| GO:BP | GO:0033139 | regulation of peptidyl-serine phosphorylation of STAT protein | 1 | 6 | 1.61e-01 |
| GO:BP | GO:0046519 | sphingoid metabolic process | 1 | 19 | 1.61e-01 |
| GO:BP | GO:0048870 | cell motility | 5 | 1182 | 1.61e-01 |
| GO:BP | GO:0099565 | chemical synaptic transmission, postsynaptic | 5 | 75 | 1.61e-01 |
| GO:BP | GO:0006892 | post-Golgi vesicle-mediated transport | 4 | 103 | 1.61e-01 |
| GO:BP | GO:0110099 | negative regulation of calcium import into the mitochondrion | 1 | 1 | 1.61e-01 |
| GO:BP | GO:0002042 | cell migration involved in sprouting angiogenesis | 1 | 45 | 1.61e-01 |
| GO:BP | GO:0006885 | regulation of pH | 3 | 74 | 1.61e-01 |
| GO:BP | GO:0042326 | negative regulation of phosphorylation | 2 | 300 | 1.61e-01 |
| GO:BP | GO:0043550 | regulation of lipid kinase activity | 1 | 43 | 1.61e-01 |
| GO:BP | GO:1903350 | response to dopamine | 4 | 48 | 1.61e-01 |
| GO:BP | GO:1902888 | protein localization to astral microtubule | 1 | 1 | 1.61e-01 |
| GO:BP | GO:0040011 | locomotion | 4 | 954 | 1.61e-01 |
| GO:BP | GO:0060155 | platelet dense granule organization | 2 | 23 | 1.61e-01 |
| GO:BP | GO:0086027 | AV node cell to bundle of His cell signaling | 1 | 9 | 1.61e-01 |
| GO:BP | GO:0048681 | negative regulation of axon regeneration | 1 | 11 | 1.61e-01 |
| GO:BP | GO:1903351 | cellular response to dopamine | 4 | 47 | 1.61e-01 |
| GO:BP | GO:0048193 | Golgi vesicle transport | 9 | 285 | 1.61e-01 |
| GO:BP | GO:0009191 | ribonucleoside diphosphate catabolic process | 1 | 7 | 1.61e-01 |
| GO:BP | GO:0009263 | deoxyribonucleotide biosynthetic process | 2 | 14 | 1.61e-01 |
| GO:BP | GO:0009265 | 2’-deoxyribonucleotide biosynthetic process | 2 | 14 | 1.61e-01 |
| GO:BP | GO:0003174 | mitral valve development | 1 | 12 | 1.61e-01 |
| GO:BP | GO:0030335 | positive regulation of cell migration | 2 | 407 | 1.61e-01 |
| GO:BP | GO:0003093 | regulation of glomerular filtration | 1 | 9 | 1.61e-01 |
| GO:BP | GO:0090066 | regulation of anatomical structure size | 10 | 395 | 1.61e-01 |
| GO:BP | GO:0086067 | AV node cell to bundle of His cell communication | 1 | 11 | 1.61e-01 |
| GO:BP | GO:0097581 | lamellipodium organization | 4 | 78 | 1.61e-01 |
| GO:BP | GO:0046385 | deoxyribose phosphate biosynthetic process | 2 | 14 | 1.61e-01 |
| GO:BP | GO:0031651 | negative regulation of heat generation | 1 | 1 | 1.61e-01 |
| GO:BP | GO:0060079 | excitatory postsynaptic potential | 5 | 70 | 1.61e-01 |
| GO:BP | GO:0042177 | negative regulation of protein catabolic process | 3 | 100 | 1.61e-01 |
| GO:BP | GO:0035544 | negative regulation of SNARE complex assembly | 1 | 2 | 1.61e-01 |
| GO:BP | GO:1905091 | positive regulation of parkin-mediated stimulation of mitophagy in response to mitochondrial depolarization | 1 | 1 | 1.61e-01 |
| GO:BP | GO:0035542 | regulation of SNARE complex assembly | 2 | 13 | 1.61e-01 |
| GO:BP | GO:0043551 | regulation of phosphatidylinositol 3-kinase activity | 1 | 30 | 1.61e-01 |
| GO:BP | GO:0086016 | AV node cell action potential | 1 | 9 | 1.61e-01 |
| GO:BP | GO:1903674 | regulation of cap-dependent translational initiation | 1 | 1 | 1.61e-01 |
| GO:BP | GO:0001702 | gastrulation with mouth forming second | 1 | 21 | 1.61e-01 |
| GO:BP | GO:0051174 | regulation of phosphorus metabolic process | 3 | 994 | 1.61e-01 |
| GO:BP | GO:0048026 | positive regulation of mRNA splicing, via spliceosome | 2 | 21 | 1.61e-01 |
| GO:BP | GO:0032535 | regulation of cellular component size | 8 | 305 | 1.61e-01 |
| GO:BP | GO:0061890 | positive regulation of astrocyte activation | 1 | 1 | 1.61e-01 |
| GO:BP | GO:0060576 | intestinal epithelial cell development | 2 | 11 | 1.61e-01 |
| GO:BP | GO:0051560 | mitochondrial calcium ion homeostasis | 2 | 23 | 1.61e-01 |
| GO:BP | GO:0070571 | negative regulation of neuron projection regeneration | 1 | 12 | 1.61e-01 |
| GO:BP | GO:0019264 | glycine biosynthetic process from serine | 1 | 2 | 1.61e-01 |
| GO:BP | GO:0033512 | L-lysine catabolic process to acetyl-CoA via saccharopine | 1 | 3 | 1.61e-01 |
| GO:BP | GO:0034311 | diol metabolic process | 1 | 26 | 1.61e-01 |
| GO:BP | GO:0048514 | blood vessel morphogenesis | 3 | 462 | 1.61e-01 |
| GO:BP | GO:0072092 | ureteric bud invasion | 1 | 3 | 1.61e-01 |
| GO:BP | GO:0031400 | negative regulation of protein modification process | 3 | 418 | 1.61e-01 |
| GO:BP | GO:2000147 | positive regulation of cell motility | 2 | 421 | 1.61e-01 |
| GO:BP | GO:0071477 | cellular hypotonic salinity response | 1 | 2 | 1.61e-01 |
| GO:BP | GO:0062196 | regulation of lysosome size | 1 | 8 | 1.61e-01 |
| GO:BP | GO:0046854 | phosphatidylinositol phosphate biosynthetic process | 1 | 59 | 1.61e-01 |
| GO:BP | GO:0099170 | postsynaptic modulation of chemical synaptic transmission | 2 | 23 | 1.61e-01 |
| GO:BP | GO:0042539 | hypotonic salinity response | 1 | 2 | 1.61e-01 |
| GO:BP | GO:0006303 | double-strand break repair via nonhomologous end joining | 2 | 61 | 1.61e-01 |
| GO:BP | GO:0032273 | positive regulation of protein polymerization | 4 | 76 | 1.61e-01 |
| GO:BP | GO:0009129 | pyrimidine nucleoside monophosphate metabolic process | 2 | 18 | 1.61e-01 |
| GO:BP | GO:0018216 | peptidyl-arginine methylation | 1 | 15 | 1.62e-01 |
| GO:BP | GO:0042501 | serine phosphorylation of STAT protein | 1 | 9 | 1.62e-01 |
| GO:BP | GO:1900745 | positive regulation of p38MAPK cascade | 1 | 22 | 1.62e-01 |
| GO:BP | GO:1905215 | negative regulation of RNA binding | 1 | 2 | 1.62e-01 |
| GO:BP | GO:0086070 | SA node cell to atrial cardiac muscle cell communication | 1 | 14 | 1.62e-01 |
| GO:BP | GO:0040017 | positive regulation of locomotion | 2 | 429 | 1.62e-01 |
| GO:BP | GO:0051451 | myoblast migration | 1 | 11 | 1.64e-01 |
| GO:BP | GO:0033137 | negative regulation of peptidyl-serine phosphorylation | 1 | 26 | 1.65e-01 |
| GO:BP | GO:0006851 | mitochondrial calcium ion transmembrane transport | 2 | 17 | 1.65e-01 |
| GO:BP | GO:0001977 | renal system process involved in regulation of blood volume | 1 | 9 | 1.67e-01 |
| GO:BP | GO:1904293 | negative regulation of ERAD pathway | 1 | 6 | 1.67e-01 |
| GO:BP | GO:1903526 | negative regulation of membrane tubulation | 1 | 2 | 1.67e-01 |
| GO:BP | GO:0086069 | bundle of His cell to Purkinje myocyte communication | 1 | 14 | 1.67e-01 |
| GO:BP | GO:0031399 | regulation of protein modification process | 3 | 1173 | 1.68e-01 |
| GO:BP | GO:0048646 | anatomical structure formation involved in morphogenesis | 4 | 870 | 1.68e-01 |
| GO:BP | GO:0033008 | positive regulation of mast cell activation involved in immune response | 2 | 10 | 1.70e-01 |
| GO:BP | GO:0043306 | positive regulation of mast cell degranulation | 2 | 10 | 1.70e-01 |
| GO:BP | GO:0003188 | heart valve formation | 1 | 16 | 1.74e-01 |
| GO:BP | GO:0018335 | protein succinylation | 1 | 4 | 1.74e-01 |
| GO:BP | GO:0106077 | histone succinylation | 1 | 4 | 1.74e-01 |
| GO:BP | GO:0046440 | L-lysine metabolic process | 1 | 4 | 1.74e-01 |
| GO:BP | GO:0019477 | L-lysine catabolic process | 1 | 4 | 1.74e-01 |
| GO:BP | GO:0019474 | L-lysine catabolic process to acetyl-CoA | 1 | 4 | 1.74e-01 |
| GO:BP | GO:1905755 | protein localization to cytoplasmic microtubule | 1 | 2 | 1.74e-01 |
| GO:BP | GO:0051248 | negative regulation of protein metabolic process | 4 | 816 | 1.74e-01 |
| GO:BP | GO:0046839 | phospholipid dephosphorylation | 1 | 39 | 1.74e-01 |
| GO:BP | GO:0032364 | intracellular oxygen homeostasis | 1 | 6 | 1.74e-01 |
| GO:BP | GO:0031848 | protection from non-homologous end joining at telomere | 1 | 10 | 1.74e-01 |
| GO:BP | GO:1903033 | positive regulation of microtubule plus-end binding | 1 | 2 | 1.74e-01 |
| GO:BP | GO:0016264 | gap junction assembly | 1 | 14 | 1.74e-01 |
| GO:BP | GO:1905719 | protein localization to perinuclear region of cytoplasm | 1 | 8 | 1.74e-01 |
| GO:BP | GO:1902889 | protein localization to spindle microtubule | 1 | 2 | 1.74e-01 |
| GO:BP | GO:1903031 | regulation of microtubule plus-end binding | 1 | 2 | 1.74e-01 |
| GO:BP | GO:0010649 | regulation of cell communication by electrical coupling | 1 | 17 | 1.74e-01 |
| GO:BP | GO:0072093 | metanephric renal vesicle formation | 1 | 4 | 1.74e-01 |
| GO:BP | GO:0072014 | proximal tubule development | 1 | 7 | 1.74e-01 |
| GO:BP | GO:0086066 | atrial cardiac muscle cell to AV node cell communication | 1 | 17 | 1.74e-01 |
| GO:BP | GO:0043537 | negative regulation of blood vessel endothelial cell migration | 1 | 25 | 1.74e-01 |
| GO:BP | GO:2000010 | positive regulation of protein localization to cell surface | 1 | 16 | 1.74e-01 |
| GO:BP | GO:0086014 | atrial cardiac muscle cell action potential | 1 | 17 | 1.74e-01 |
| GO:BP | GO:0019321 | pentose metabolic process | 1 | 9 | 1.74e-01 |
| GO:BP | GO:0086026 | atrial cardiac muscle cell to AV node cell signaling | 1 | 17 | 1.74e-01 |
| GO:BP | GO:0009992 | intracellular water homeostasis | 1 | 3 | 1.74e-01 |
| GO:BP | GO:0140157 | ammonium import across plasma membrane | 1 | 3 | 1.74e-01 |
| GO:BP | GO:0006468 | protein phosphorylation | 3 | 1167 | 1.74e-01 |
| GO:BP | GO:2000845 | positive regulation of testosterone secretion | 1 | 2 | 1.75e-01 |
| GO:BP | GO:0099576 | regulation of protein catabolic process at postsynapse, modulating synaptic transmission | 1 | 4 | 1.75e-01 |
| GO:BP | GO:0099547 | regulation of translation at synapse, modulating synaptic transmission | 1 | 3 | 1.75e-01 |
| GO:BP | GO:1905424 | regulation of Wnt-mediated midbrain dopaminergic neuron differentiation | 1 | 2 | 1.75e-01 |
| GO:BP | GO:0009134 | nucleoside diphosphate catabolic process | 1 | 9 | 1.75e-01 |
| GO:BP | GO:0072673 | lamellipodium morphogenesis | 1 | 17 | 1.75e-01 |
| GO:BP | GO:0071901 | negative regulation of protein serine/threonine kinase activity | 3 | 101 | 1.75e-01 |
| GO:BP | GO:1905426 | positive regulation of Wnt-mediated midbrain dopaminergic neuron differentiation | 1 | 2 | 1.75e-01 |
| GO:BP | GO:0051036 | regulation of endosome size | 1 | 13 | 1.75e-01 |
| GO:BP | GO:0015793 | glycerol transmembrane transport | 1 | 4 | 1.75e-01 |
| GO:BP | GO:0060078 | regulation of postsynaptic membrane potential | 5 | 82 | 1.75e-01 |
| GO:BP | GO:0009148 | pyrimidine nucleoside triphosphate biosynthetic process | 2 | 17 | 1.75e-01 |
| GO:BP | GO:0050685 | positive regulation of mRNA processing | 2 | 30 | 1.75e-01 |
| GO:BP | GO:1905240 | negative regulation of canonical Wnt signaling pathway involved in osteoblast differentiation | 1 | 1 | 1.75e-01 |
| GO:BP | GO:2000740 | negative regulation of mesenchymal stem cell differentiation | 1 | 2 | 1.75e-01 |
| GO:BP | GO:1900744 | regulation of p38MAPK cascade | 1 | 32 | 1.75e-01 |
| GO:BP | GO:2000843 | regulation of testosterone secretion | 1 | 2 | 1.75e-01 |
| GO:BP | GO:0006220 | pyrimidine nucleotide metabolic process | 3 | 46 | 1.75e-01 |
| GO:BP | GO:0099578 | regulation of translation at postsynapse, modulating synaptic transmission | 1 | 3 | 1.75e-01 |
| GO:BP | GO:1905239 | regulation of canonical Wnt signaling pathway involved in osteoblast differentiation | 1 | 1 | 1.75e-01 |
| GO:BP | GO:0043097 | pyrimidine nucleoside salvage | 1 | 2 | 1.75e-01 |
| GO:BP | GO:0071868 | cellular response to monoamine stimulus | 4 | 60 | 1.75e-01 |
| GO:BP | GO:0003184 | pulmonary valve morphogenesis | 1 | 19 | 1.75e-01 |
| GO:BP | GO:1901984 | negative regulation of protein acetylation | 2 | 16 | 1.75e-01 |
| GO:BP | GO:0008361 | regulation of cell size | 5 | 159 | 1.75e-01 |
| GO:BP | GO:0071870 | cellular response to catecholamine stimulus | 4 | 60 | 1.75e-01 |
| GO:BP | GO:0001934 | positive regulation of protein phosphorylation | 2 | 496 | 1.75e-01 |
| GO:BP | GO:0060307 | regulation of ventricular cardiac muscle cell membrane repolarization | 1 | 16 | 1.75e-01 |
| GO:BP | GO:0035936 | testosterone secretion | 1 | 2 | 1.75e-01 |
| GO:BP | GO:0042770 | signal transduction in response to DNA damage | 2 | 178 | 1.75e-01 |
| GO:BP | GO:2000077 | negative regulation of type B pancreatic cell development | 1 | 2 | 1.75e-01 |
| GO:BP | GO:0031644 | regulation of nervous system process | 5 | 90 | 1.75e-01 |
| GO:BP | GO:0071109 | superior temporal gyrus development | 1 | 2 | 1.75e-01 |
| GO:BP | GO:0018009 | N-terminal peptidyl-L-cysteine N-palmitoylation | 1 | 2 | 1.78e-01 |
| GO:BP | GO:0010640 | regulation of platelet-derived growth factor receptor signaling pathway | 1 | 19 | 1.78e-01 |
| GO:BP | GO:0051043 | regulation of membrane protein ectodomain proteolysis | 1 | 18 | 1.78e-01 |
| GO:BP | GO:1903408 | positive regulation of P-type sodium:potassium-exchanging transporter activity | 1 | 2 | 1.78e-01 |
| GO:BP | GO:1902856 | negative regulation of non-motile cilium assembly | 1 | 2 | 1.78e-01 |
| GO:BP | GO:1903406 | regulation of P-type sodium:potassium-exchanging transporter activity | 1 | 2 | 1.78e-01 |
| GO:BP | GO:0006043 | glucosamine catabolic process | 1 | 2 | 1.78e-01 |
| GO:BP | GO:0008610 | lipid biosynthetic process | 2 | 560 | 1.78e-01 |
| GO:BP | GO:0071869 | response to catecholamine | 4 | 62 | 1.78e-01 |
| GO:BP | GO:0071867 | response to monoamine | 4 | 62 | 1.78e-01 |
| GO:BP | GO:0097742 | de novo centriole assembly | 1 | 4 | 1.80e-01 |
| GO:BP | GO:1905908 | positive regulation of amyloid fibril formation | 1 | 5 | 1.80e-01 |
| GO:BP | GO:0016310 | phosphorylation | 3 | 1372 | 1.80e-01 |
| GO:BP | GO:0009177 | pyrimidine deoxyribonucleoside monophosphate biosynthetic process | 1 | 4 | 1.80e-01 |
| GO:BP | GO:0098659 | inorganic cation import across plasma membrane | 3 | 73 | 1.80e-01 |
| GO:BP | GO:0098535 | de novo centriole assembly involved in multi-ciliated epithelial cell differentiation | 1 | 4 | 1.80e-01 |
| GO:BP | GO:0002040 | sprouting angiogenesis | 1 | 98 | 1.80e-01 |
| GO:BP | GO:0032515 | negative regulation of phosphoprotein phosphatase activity | 2 | 21 | 1.80e-01 |
| GO:BP | GO:1902558 | 5’-adenylyl sulfate transmembrane transport | 1 | 2 | 1.80e-01 |
| GO:BP | GO:0003177 | pulmonary valve development | 1 | 22 | 1.80e-01 |
| GO:BP | GO:0043461 | proton-transporting ATP synthase complex assembly | 1 | 8 | 1.80e-01 |
| GO:BP | GO:1904351 | negative regulation of protein catabolic process in the vacuole | 1 | 5 | 1.80e-01 |
| GO:BP | GO:0042327 | positive regulation of phosphorylation | 2 | 547 | 1.80e-01 |
| GO:BP | GO:1902559 | 3’-phospho-5’-adenylyl sulfate transmembrane transport | 1 | 2 | 1.80e-01 |
| GO:BP | GO:1905089 | regulation of parkin-mediated stimulation of mitophagy in response to mitochondrial depolarization | 1 | 2 | 1.80e-01 |
| GO:BP | GO:1905166 | negative regulation of lysosomal protein catabolic process | 1 | 5 | 1.80e-01 |
| GO:BP | GO:0070570 | regulation of neuron projection regeneration | 1 | 25 | 1.80e-01 |
| GO:BP | GO:0006542 | glutamine biosynthetic process | 1 | 2 | 1.80e-01 |
| GO:BP | GO:0048679 | regulation of axon regeneration | 1 | 23 | 1.80e-01 |
| GO:BP | GO:0018193 | peptidyl-amino acid modification | 4 | 963 | 1.80e-01 |
| GO:BP | GO:0046963 | 3’-phosphoadenosine 5’-phosphosulfate transport | 1 | 2 | 1.80e-01 |
| GO:BP | GO:0002678 | positive regulation of chronic inflammatory response | 1 | 1 | 1.80e-01 |
| GO:BP | GO:0099587 | inorganic ion import across plasma membrane | 3 | 73 | 1.80e-01 |
| GO:BP | GO:0008286 | insulin receptor signaling pathway | 1 | 105 | 1.80e-01 |
| GO:BP | GO:0086064 | cell communication by electrical coupling involved in cardiac conduction | 1 | 26 | 1.80e-01 |
| GO:BP | GO:0110097 | regulation of calcium import into the mitochondrion | 1 | 2 | 1.80e-01 |
| GO:BP | GO:0099623 | regulation of cardiac muscle cell membrane repolarization | 1 | 20 | 1.80e-01 |
| GO:BP | GO:0031339 | negative regulation of vesicle fusion | 1 | 3 | 1.80e-01 |
| GO:BP | GO:1902437 | positive regulation of male mating behavior | 1 | 2 | 1.80e-01 |
| GO:BP | GO:0099625 | ventricular cardiac muscle cell membrane repolarization | 1 | 21 | 1.80e-01 |
| GO:BP | GO:0033615 | mitochondrial proton-transporting ATP synthase complex assembly | 1 | 8 | 1.80e-01 |
| GO:BP | GO:0010596 | negative regulation of endothelial cell migration | 1 | 40 | 1.80e-01 |
| GO:BP | GO:1902435 | regulation of male mating behavior | 1 | 2 | 1.80e-01 |
| GO:BP | GO:1990926 | short-term synaptic potentiation | 1 | 4 | 1.80e-01 |
| GO:BP | GO:0003283 | atrial septum development | 1 | 23 | 1.80e-01 |
| GO:BP | GO:0033120 | positive regulation of RNA splicing | 2 | 34 | 1.80e-01 |
| GO:BP | GO:0033082 | regulation of extrathymic T cell differentiation | 1 | 1 | 1.80e-01 |
| GO:BP | GO:0006231 | dTMP biosynthetic process | 1 | 4 | 1.80e-01 |
| GO:BP | GO:1901739 | regulation of myoblast fusion | 1 | 12 | 1.80e-01 |
| GO:BP | GO:0090327 | negative regulation of locomotion involved in locomotory behavior | 1 | 1 | 1.80e-01 |
| GO:BP | GO:0003071 | renal system process involved in regulation of systemic arterial blood pressure | 1 | 14 | 1.80e-01 |
| GO:BP | GO:0060384 | innervation | 1 | 22 | 1.80e-01 |
| GO:BP | GO:0038066 | p38MAPK cascade | 1 | 43 | 1.83e-01 |
| GO:BP | GO:0051093 | negative regulation of developmental process | 3 | 665 | 1.83e-01 |
| GO:BP | GO:0006661 | phosphatidylinositol biosynthetic process | 1 | 119 | 1.83e-01 |
| GO:BP | GO:0048489 | synaptic vesicle transport | 2 | 36 | 1.87e-01 |
| GO:BP | GO:0015791 | polyol transmembrane transport | 1 | 6 | 1.87e-01 |
| GO:BP | GO:2000737 | negative regulation of stem cell differentiation | 2 | 24 | 1.88e-01 |
| GO:BP | GO:0032438 | melanosome organization | 2 | 36 | 1.88e-01 |
| GO:BP | GO:0003171 | atrioventricular valve development | 1 | 27 | 1.88e-01 |
| GO:BP | GO:0044211 | CTP salvage | 1 | 3 | 1.88e-01 |
| GO:BP | GO:0002067 | glandular epithelial cell differentiation | 3 | 50 | 1.88e-01 |
| GO:BP | GO:0098901 | regulation of cardiac muscle cell action potential | 1 | 30 | 1.90e-01 |
| GO:BP | GO:0036515 | serotonergic neuron axon guidance | 1 | 2 | 1.90e-01 |
| GO:BP | GO:0010562 | positive regulation of phosphorus metabolic process | 2 | 597 | 1.90e-01 |
| GO:BP | GO:0048490 | anterograde synaptic vesicle transport | 1 | 16 | 1.90e-01 |
| GO:BP | GO:0035493 | SNARE complex assembly | 2 | 22 | 1.90e-01 |
| GO:BP | GO:0048250 | iron import into the mitochondrion | 1 | 2 | 1.90e-01 |
| GO:BP | GO:1904958 | positive regulation of midbrain dopaminergic neuron differentiation | 1 | 3 | 1.90e-01 |
| GO:BP | GO:0030032 | lamellipodium assembly | 3 | 61 | 1.90e-01 |
| GO:BP | GO:0097494 | regulation of vesicle size | 1 | 19 | 1.90e-01 |
| GO:BP | GO:0009147 | pyrimidine nucleoside triphosphate metabolic process | 2 | 22 | 1.90e-01 |
| GO:BP | GO:0034465 | response to carbon monoxide | 1 | 3 | 1.90e-01 |
| GO:BP | GO:0035239 | tube morphogenesis | 3 | 663 | 1.90e-01 |
| GO:BP | GO:0009219 | pyrimidine deoxyribonucleotide metabolic process | 2 | 21 | 1.90e-01 |
| GO:BP | GO:0006354 | DNA-templated transcription elongation | 4 | 122 | 1.90e-01 |
| GO:BP | GO:0045976 | negative regulation of mitotic cell cycle, embryonic | 1 | 2 | 1.90e-01 |
| GO:BP | GO:0099514 | synaptic vesicle cytoskeletal transport | 1 | 16 | 1.90e-01 |
| GO:BP | GO:0003094 | glomerular filtration | 1 | 21 | 1.90e-01 |
| GO:BP | GO:0048753 | pigment granule organization | 2 | 37 | 1.90e-01 |
| GO:BP | GO:0099517 | synaptic vesicle transport along microtubule | 1 | 16 | 1.90e-01 |
| GO:BP | GO:0033005 | positive regulation of mast cell activation | 2 | 13 | 1.90e-01 |
| GO:BP | GO:0045937 | positive regulation of phosphate metabolic process | 2 | 597 | 1.90e-01 |
| GO:BP | GO:0042311 | vasodilation | 2 | 39 | 1.90e-01 |
| GO:BP | GO:0006554 | lysine catabolic process | 1 | 6 | 1.90e-01 |
| GO:BP | GO:1990573 | potassium ion import across plasma membrane | 2 | 31 | 1.90e-01 |
| GO:BP | GO:0045907 | positive regulation of vasoconstriction | 1 | 15 | 1.92e-01 |
| GO:BP | GO:0097205 | renal filtration | 1 | 23 | 1.92e-01 |
| GO:BP | GO:1904339 | negative regulation of dopaminergic neuron differentiation | 1 | 1 | 1.92e-01 |
| GO:BP | GO:2000466 | negative regulation of glycogen (starch) synthase activity | 1 | 3 | 1.92e-01 |
| GO:BP | GO:0030183 | B cell differentiation | 1 | 94 | 1.93e-01 |
| GO:BP | GO:0006565 | L-serine catabolic process | 1 | 4 | 1.93e-01 |
| GO:BP | GO:0060142 | regulation of syncytium formation by plasma membrane fusion | 1 | 15 | 1.93e-01 |
| GO:BP | GO:1903679 | positive regulation of cap-independent translational initiation | 1 | 3 | 1.93e-01 |
| GO:BP | GO:1903677 | regulation of cap-independent translational initiation | 1 | 3 | 1.93e-01 |
| GO:BP | GO:0019082 | viral protein processing | 2 | 31 | 1.94e-01 |
| GO:BP | GO:0006500 | N-terminal protein palmitoylation | 1 | 3 | 1.94e-01 |
| GO:BP | GO:0046488 | phosphatidylinositol metabolic process | 1 | 140 | 1.94e-01 |
| GO:BP | GO:1902116 | negative regulation of organelle assembly | 2 | 40 | 1.96e-01 |
| GO:BP | GO:0006553 | lysine metabolic process | 1 | 7 | 1.96e-01 |
| GO:BP | GO:1905706 | regulation of mitochondrial ATP synthesis coupled proton transport | 1 | 3 | 1.96e-01 |
| GO:BP | GO:1901634 | positive regulation of synaptic vesicle membrane organization | 1 | 4 | 1.96e-01 |
| GO:BP | GO:0060306 | regulation of membrane repolarization | 1 | 28 | 1.96e-01 |
| GO:BP | GO:0098801 | regulation of renal system process | 1 | 21 | 1.96e-01 |
| GO:BP | GO:0071539 | protein localization to centrosome | 2 | 31 | 1.96e-01 |
| GO:BP | GO:0010644 | cell communication by electrical coupling | 1 | 31 | 1.96e-01 |
| GO:BP | GO:0006041 | glucosamine metabolic process | 1 | 3 | 1.96e-01 |
| GO:BP | GO:1905273 | positive regulation of proton-transporting ATP synthase activity, rotational mechanism | 1 | 3 | 1.96e-01 |
| GO:BP | GO:0086004 | regulation of cardiac muscle cell contraction | 1 | 34 | 1.96e-01 |
| GO:BP | GO:0060575 | intestinal epithelial cell differentiation | 2 | 17 | 1.96e-01 |
| GO:BP | GO:0031632 | positive regulation of synaptic vesicle fusion to presynaptic active zone membrane | 1 | 4 | 1.96e-01 |
| GO:BP | GO:1905271 | regulation of proton-transporting ATP synthase activity, rotational mechanism | 1 | 3 | 1.96e-01 |
| GO:BP | GO:2000379 | positive regulation of reactive oxygen species metabolic process | 1 | 46 | 1.96e-01 |
| GO:BP | GO:0010633 | negative regulation of epithelial cell migration | 1 | 53 | 1.96e-01 |
| GO:BP | GO:0048708 | astrocyte differentiation | 1 | 58 | 1.96e-01 |
| GO:BP | GO:0099502 | calcium-dependent activation of synaptic vesicle fusion | 1 | 4 | 1.96e-01 |
| GO:BP | GO:0006435 | threonyl-tRNA aminoacylation | 1 | 3 | 1.96e-01 |
| GO:BP | GO:0035116 | embryonic hindlimb morphogenesis | 2 | 17 | 1.96e-01 |
| GO:BP | GO:0045900 | negative regulation of translational elongation | 1 | 5 | 1.97e-01 |
| GO:BP | GO:0043549 | regulation of kinase activity | 2 | 560 | 1.97e-01 |
| GO:BP | GO:0086019 | cell-cell signaling involved in cardiac conduction | 1 | 33 | 1.97e-01 |
| GO:BP | GO:0072033 | renal vesicle formation | 1 | 8 | 1.98e-01 |
| GO:BP | GO:2001055 | positive regulation of mesenchymal cell apoptotic process | 1 | 2 | 1.98e-01 |
| GO:BP | GO:0071300 | cellular response to retinoic acid | 3 | 49 | 1.98e-01 |
| GO:BP | GO:0003161 | cardiac conduction system development | 1 | 33 | 1.98e-01 |
| GO:BP | GO:0099622 | cardiac muscle cell membrane repolarization | 1 | 31 | 1.98e-01 |
| GO:BP | GO:0016241 | regulation of macroautophagy | 5 | 151 | 1.98e-01 |
| GO:BP | GO:0033627 | cell adhesion mediated by integrin | 1 | 63 | 1.98e-01 |
| GO:BP | GO:0051795 | positive regulation of timing of catagen | 1 | 3 | 1.98e-01 |
| GO:BP | GO:0061591 | calcium activated galactosylceramide scrambling | 1 | 2 | 1.98e-01 |
| GO:BP | GO:0061589 | calcium activated phosphatidylserine scrambling | 1 | 3 | 1.98e-01 |
| GO:BP | GO:0032483 | regulation of Rab protein signal transduction | 1 | 7 | 1.99e-01 |
| GO:BP | GO:0050680 | negative regulation of epithelial cell proliferation | 2 | 111 | 2.00e-01 |
| GO:BP | GO:0001675 | acrosome assembly | 2 | 16 | 2.00e-01 |
| GO:BP | GO:0046134 | pyrimidine nucleoside biosynthetic process | 1 | 4 | 2.00e-01 |
| GO:BP | GO:0003416 | endochondral bone growth | 2 | 23 | 2.00e-01 |
| GO:BP | GO:0031284 | positive regulation of guanylate cyclase activity | 1 | 2 | 2.00e-01 |
| GO:BP | GO:2000370 | positive regulation of clathrin-dependent endocytosis | 1 | 5 | 2.00e-01 |
| GO:BP | GO:0010753 | positive regulation of cGMP-mediated signaling | 1 | 3 | 2.00e-01 |
| GO:BP | GO:0003230 | cardiac atrium development | 1 | 34 | 2.00e-01 |
| GO:BP | GO:0071260 | cellular response to mechanical stimulus | 1 | 59 | 2.00e-01 |
| GO:BP | GO:0071479 | cellular response to ionizing radiation | 1 | 68 | 2.00e-01 |
| GO:BP | GO:1905508 | protein localization to microtubule organizing center | 2 | 33 | 2.01e-01 |
| GO:BP | GO:1990654 | sebum secreting cell proliferation | 1 | 2 | 2.01e-01 |
| GO:BP | GO:0035308 | negative regulation of protein dephosphorylation | 2 | 28 | 2.01e-01 |
| GO:BP | GO:0033078 | extrathymic T cell differentiation | 1 | 1 | 2.01e-01 |
| GO:BP | GO:0031401 | positive regulation of protein modification process | 2 | 719 | 2.01e-01 |
| GO:BP | GO:2000008 | regulation of protein localization to cell surface | 1 | 37 | 2.01e-01 |
| GO:BP | GO:0061198 | fungiform papilla formation | 1 | 3 | 2.02e-01 |
| GO:BP | GO:1904029 | regulation of cyclin-dependent protein kinase activity | 4 | 88 | 2.03e-01 |
| GO:BP | GO:0060628 | regulation of ER to Golgi vesicle-mediated transport | 1 | 9 | 2.03e-01 |
| GO:BP | GO:0034109 | homotypic cell-cell adhesion | 1 | 70 | 2.03e-01 |
| GO:BP | GO:0019637 | organophosphate metabolic process | 2 | 784 | 2.03e-01 |
| GO:BP | GO:0030850 | prostate gland development | 1 | 35 | 2.03e-01 |
| GO:BP | GO:0007289 | spermatid nucleus differentiation | 2 | 16 | 2.03e-01 |
| GO:BP | GO:0060677 | ureteric bud elongation | 1 | 7 | 2.03e-01 |
| GO:BP | GO:0043491 | protein kinase B signaling | 1 | 146 | 2.03e-01 |
| GO:BP | GO:0006509 | membrane protein ectodomain proteolysis | 1 | 34 | 2.03e-01 |
| GO:BP | GO:0016267 | O-glycan processing, core 1 | 1 | 2 | 2.03e-01 |
| GO:BP | GO:1903115 | regulation of actin filament-based movement | 1 | 39 | 2.04e-01 |
| GO:BP | GO:0090649 | response to oxygen-glucose deprivation | 1 | 7 | 2.08e-01 |
| GO:BP | GO:0006104 | succinyl-CoA metabolic process | 1 | 9 | 2.08e-01 |
| GO:BP | GO:0003170 | heart valve development | 3 | 65 | 2.08e-01 |
| GO:BP | GO:0043535 | regulation of blood vessel endothelial cell migration | 1 | 75 | 2.08e-01 |
| GO:BP | GO:0031333 | negative regulation of protein-containing complex assembly | 4 | 130 | 2.08e-01 |
| GO:BP | GO:0002943 | tRNA dihydrouridine synthesis | 1 | 4 | 2.08e-01 |
| GO:BP | GO:1903525 | regulation of membrane tubulation | 1 | 5 | 2.08e-01 |
| GO:BP | GO:0044255 | cellular lipid metabolic process | 2 | 740 | 2.08e-01 |
| GO:BP | GO:0009895 | negative regulation of catabolic process | 4 | 280 | 2.08e-01 |
| GO:BP | GO:0036514 | dopaminergic neuron axon guidance | 1 | 3 | 2.08e-01 |
| GO:BP | GO:0002190 | cap-independent translational initiation | 1 | 4 | 2.08e-01 |
| GO:BP | GO:1904693 | midbrain morphogenesis | 1 | 3 | 2.08e-01 |
| GO:BP | GO:0051289 | protein homotetramerization | 2 | 42 | 2.08e-01 |
| GO:BP | GO:0010595 | positive regulation of endothelial cell migration | 1 | 94 | 2.08e-01 |
| GO:BP | GO:0031103 | axon regeneration | 1 | 42 | 2.08e-01 |
| GO:BP | GO:0050678 | regulation of epithelial cell proliferation | 3 | 276 | 2.08e-01 |
| GO:BP | GO:0019751 | polyol metabolic process | 1 | 82 | 2.08e-01 |
| GO:BP | GO:0006545 | glycine biosynthetic process | 1 | 4 | 2.08e-01 |
| GO:BP | GO:0061590 | calcium activated phosphatidylcholine scrambling | 1 | 3 | 2.08e-01 |
| GO:BP | GO:0030148 | sphingolipid biosynthetic process | 1 | 88 | 2.08e-01 |
| GO:BP | GO:0006942 | regulation of striated muscle contraction | 2 | 85 | 2.08e-01 |
| GO:BP | GO:0016579 | protein deubiquitination | 4 | 129 | 2.08e-01 |
| GO:BP | GO:0099171 | presynaptic modulation of chemical synaptic transmission | 2 | 26 | 2.08e-01 |
| GO:BP | GO:1903251 | multi-ciliated epithelial cell differentiation | 1 | 6 | 2.08e-01 |
| GO:BP | GO:0034982 | mitochondrial protein processing | 1 | 12 | 2.08e-01 |
| GO:BP | GO:1904938 | planar cell polarity pathway involved in axon guidance | 1 | 3 | 2.08e-01 |
| GO:BP | GO:1904886 | beta-catenin destruction complex disassembly | 1 | 4 | 2.08e-01 |
| GO:BP | GO:0003254 | regulation of membrane depolarization | 1 | 37 | 2.08e-01 |
| GO:BP | GO:0032869 | cellular response to insulin stimulus | 1 | 174 | 2.08e-01 |
| GO:BP | GO:0061337 | cardiac conduction | 2 | 88 | 2.08e-01 |
| GO:BP | GO:1990441 | negative regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress | 1 | 4 | 2.08e-01 |
| GO:BP | GO:0060087 | relaxation of vascular associated smooth muscle | 1 | 7 | 2.08e-01 |
| GO:BP | GO:2001222 | regulation of neuron migration | 1 | 38 | 2.08e-01 |
| GO:BP | GO:0098868 | bone growth | 2 | 24 | 2.08e-01 |
| GO:BP | GO:0046474 | glycerophospholipid biosynthetic process | 1 | 189 | 2.08e-01 |
| GO:BP | GO:0006672 | ceramide metabolic process | 1 | 80 | 2.08e-01 |
| GO:BP | GO:0006046 | N-acetylglucosamine catabolic process | 1 | 3 | 2.08e-01 |
| GO:BP | GO:0046073 | dTMP metabolic process | 1 | 7 | 2.08e-01 |
| GO:BP | GO:0002068 | glandular epithelial cell development | 2 | 28 | 2.09e-01 |
| GO:BP | GO:0043302 | positive regulation of leukocyte degranulation | 2 | 15 | 2.09e-01 |
| GO:BP | GO:0071476 | cellular hypotonic response | 1 | 8 | 2.09e-01 |
| GO:BP | GO:0009185 | ribonucleoside diphosphate metabolic process | 1 | 27 | 2.15e-01 |
| GO:BP | GO:0046330 | positive regulation of JNK cascade | 1 | 72 | 2.16e-01 |
| GO:BP | GO:0007229 | integrin-mediated signaling pathway | 1 | 89 | 2.16e-01 |
| GO:BP | GO:0006012 | galactose metabolic process | 1 | 9 | 2.16e-01 |
| GO:BP | GO:0048599 | oocyte development | 1 | 38 | 2.16e-01 |
| GO:BP | GO:0051794 | regulation of timing of catagen | 1 | 4 | 2.16e-01 |
| GO:BP | GO:1905314 | semi-lunar valve development | 1 | 41 | 2.16e-01 |
| GO:BP | GO:0060364 | frontal suture morphogenesis | 1 | 4 | 2.16e-01 |
| GO:BP | GO:0042637 | catagen | 1 | 4 | 2.16e-01 |
| GO:BP | GO:0035880 | embryonic nail plate morphogenesis | 1 | 4 | 2.16e-01 |
| GO:BP | GO:0010923 | negative regulation of phosphatase activity | 2 | 30 | 2.16e-01 |
| GO:BP | GO:1901098 | positive regulation of autophagosome maturation | 1 | 6 | 2.16e-01 |
| GO:BP | GO:0035634 | response to stilbenoid | 1 | 2 | 2.16e-01 |
| GO:BP | GO:0009141 | nucleoside triphosphate metabolic process | 5 | 159 | 2.16e-01 |
| GO:BP | GO:0009124 | nucleoside monophosphate biosynthetic process | 2 | 37 | 2.16e-01 |
| GO:BP | GO:0086009 | membrane repolarization | 1 | 41 | 2.16e-01 |
| GO:BP | GO:1904340 | positive regulation of dopaminergic neuron differentiation | 1 | 3 | 2.16e-01 |
| GO:BP | GO:0051338 | regulation of transferase activity | 2 | 679 | 2.16e-01 |
| GO:BP | GO:1904956 | regulation of midbrain dopaminergic neuron differentiation | 1 | 5 | 2.16e-01 |
| GO:BP | GO:0031334 | positive regulation of protein-containing complex assembly | 5 | 161 | 2.16e-01 |
| GO:BP | GO:0140245 | regulation of translation at postsynapse | 1 | 6 | 2.17e-01 |
| GO:BP | GO:0140243 | regulation of translation at synapse | 1 | 6 | 2.17e-01 |
| GO:BP | GO:0097345 | mitochondrial outer membrane permeabilization | 2 | 35 | 2.17e-01 |
| GO:BP | GO:0032486 | Rap protein signal transduction | 1 | 13 | 2.17e-01 |
| GO:BP | GO:0097479 | synaptic vesicle localization | 2 | 50 | 2.19e-01 |
| GO:BP | GO:0086002 | cardiac muscle cell action potential involved in contraction | 1 | 45 | 2.19e-01 |
| GO:BP | GO:0070507 | regulation of microtubule cytoskeleton organization | 4 | 146 | 2.19e-01 |
| GO:BP | GO:0031102 | neuron projection regeneration | 1 | 47 | 2.20e-01 |
| GO:BP | GO:0009994 | oocyte differentiation | 1 | 39 | 2.20e-01 |
| GO:BP | GO:0045017 | glycerolipid biosynthetic process | 1 | 218 | 2.20e-01 |
| GO:BP | GO:0046425 | regulation of receptor signaling pathway via JAK-STAT | 1 | 52 | 2.21e-01 |
| GO:BP | GO:0060040 | retinal bipolar neuron differentiation | 1 | 2 | 2.21e-01 |
| GO:BP | GO:0045776 | negative regulation of blood pressure | 1 | 30 | 2.21e-01 |
| GO:BP | GO:0016525 | negative regulation of angiogenesis | 1 | 72 | 2.21e-01 |
| GO:BP | GO:0046075 | dTTP metabolic process | 1 | 4 | 2.21e-01 |
| GO:BP | GO:2000736 | regulation of stem cell differentiation | 3 | 71 | 2.21e-01 |
| GO:BP | GO:0006235 | dTTP biosynthetic process | 1 | 4 | 2.21e-01 |
| GO:BP | GO:0009212 | pyrimidine deoxyribonucleoside triphosphate biosynthetic process | 1 | 4 | 2.21e-01 |
| GO:BP | GO:0044339 | canonical Wnt signaling pathway involved in osteoblast differentiation | 1 | 4 | 2.21e-01 |
| GO:BP | GO:0033619 | membrane protein proteolysis | 1 | 45 | 2.21e-01 |
| GO:BP | GO:2000181 | negative regulation of blood vessel morphogenesis | 1 | 73 | 2.21e-01 |
| GO:BP | GO:0048008 | platelet-derived growth factor receptor signaling pathway | 1 | 52 | 2.21e-01 |
| GO:BP | GO:0008654 | phospholipid biosynthetic process | 1 | 234 | 2.21e-01 |
| GO:BP | GO:0030516 | regulation of axon extension | 3 | 84 | 2.21e-01 |
| GO:BP | GO:1900371 | regulation of purine nucleotide biosynthetic process | 2 | 25 | 2.21e-01 |
| GO:BP | GO:1903912 | negative regulation of endoplasmic reticulum stress-induced eIF2 alpha phosphorylation | 1 | 5 | 2.21e-01 |
| GO:BP | GO:1901343 | negative regulation of vasculature development | 1 | 73 | 2.21e-01 |
| GO:BP | GO:0030808 | regulation of nucleotide biosynthetic process | 2 | 25 | 2.21e-01 |
| GO:BP | GO:1904690 | positive regulation of cytoplasmic translational initiation | 1 | 5 | 2.21e-01 |
| GO:BP | GO:0036493 | positive regulation of translation in response to endoplasmic reticulum stress | 1 | 5 | 2.21e-01 |
| GO:BP | GO:0001655 | urogenital system development | 1 | 49 | 2.22e-01 |
| GO:BP | GO:0060560 | developmental growth involved in morphogenesis | 5 | 204 | 2.22e-01 |
| GO:BP | GO:0009142 | nucleoside triphosphate biosynthetic process | 4 | 111 | 2.22e-01 |
| GO:BP | GO:0061588 | calcium activated phospholipid scrambling | 1 | 4 | 2.22e-01 |
| GO:BP | GO:0006971 | hypotonic response | 1 | 10 | 2.22e-01 |
| GO:BP | GO:1905165 | regulation of lysosomal protein catabolic process | 1 | 11 | 2.22e-01 |
| GO:BP | GO:0071472 | cellular response to salt stress | 1 | 11 | 2.22e-01 |
| GO:BP | GO:1904892 | regulation of receptor signaling pathway via STAT | 1 | 54 | 2.22e-01 |
| GO:BP | GO:0070071 | proton-transporting two-sector ATPase complex assembly | 1 | 15 | 2.22e-01 |
| GO:BP | GO:0043247 | telomere maintenance in response to DNA damage | 1 | 29 | 2.22e-01 |
| GO:BP | GO:0032868 | response to insulin | 1 | 215 | 2.22e-01 |
| GO:BP | GO:0035295 | tube development | 3 | 821 | 2.22e-01 |
| GO:BP | GO:1904528 | positive regulation of microtubule binding | 1 | 6 | 2.22e-01 |
| GO:BP | GO:0007520 | myoblast fusion | 1 | 30 | 2.23e-01 |
| GO:BP | GO:1904292 | regulation of ERAD pathway | 1 | 22 | 2.23e-01 |
| GO:BP | GO:0044206 | UMP salvage | 1 | 4 | 2.24e-01 |
| GO:BP | GO:1990416 | cellular response to brain-derived neurotrophic factor stimulus | 1 | 8 | 2.24e-01 |
| GO:BP | GO:0000079 | regulation of cyclin-dependent protein serine/threonine kinase activity | 1 | 85 | 2.24e-01 |
| GO:BP | GO:0032262 | pyrimidine nucleotide salvage | 1 | 4 | 2.24e-01 |
| GO:BP | GO:0006895 | Golgi to endosome transport | 1 | 17 | 2.24e-01 |
| GO:BP | GO:0010138 | pyrimidine ribonucleotide salvage | 1 | 4 | 2.24e-01 |
| GO:BP | GO:0072080 | nephron tubule development | 2 | 73 | 2.25e-01 |
| GO:BP | GO:1902110 | positive regulation of mitochondrial membrane permeability involved in apoptotic process | 2 | 38 | 2.26e-01 |
| GO:BP | GO:0035999 | tetrahydrofolate interconversion | 1 | 9 | 2.26e-01 |
| GO:BP | GO:0098900 | regulation of action potential | 1 | 44 | 2.26e-01 |
| GO:BP | GO:0006937 | regulation of muscle contraction | 3 | 133 | 2.27e-01 |
| GO:BP | GO:0016311 | dephosphorylation | 2 | 284 | 2.27e-01 |
| GO:BP | GO:0009794 | regulation of mitotic cell cycle, embryonic | 1 | 4 | 2.28e-01 |
| GO:BP | GO:0045448 | mitotic cell cycle, embryonic | 1 | 4 | 2.28e-01 |
| GO:BP | GO:0051241 | negative regulation of multicellular organismal process | 3 | 748 | 2.28e-01 |
| GO:BP | GO:0072488 | ammonium transmembrane transport | 1 | 6 | 2.28e-01 |
| GO:BP | GO:0009132 | nucleoside diphosphate metabolic process | 1 | 32 | 2.28e-01 |
| GO:BP | GO:2000242 | negative regulation of reproductive process | 1 | 42 | 2.28e-01 |
| GO:BP | GO:1902902 | negative regulation of autophagosome assembly | 1 | 14 | 2.28e-01 |
| GO:BP | GO:1903593 | regulation of histamine secretion by mast cell | 1 | 4 | 2.28e-01 |
| GO:BP | GO:0010666 | positive regulation of cardiac muscle cell apoptotic process | 1 | 12 | 2.28e-01 |
| GO:BP | GO:1903595 | positive regulation of histamine secretion by mast cell | 1 | 4 | 2.28e-01 |
| GO:BP | GO:0048818 | positive regulation of hair follicle maturation | 1 | 5 | 2.28e-01 |
| GO:BP | GO:0090325 | regulation of locomotion involved in locomotory behavior | 1 | 3 | 2.28e-01 |
| GO:BP | GO:0003179 | heart valve morphogenesis | 1 | 55 | 2.28e-01 |
| GO:BP | GO:0010663 | positive regulation of striated muscle cell apoptotic process | 1 | 12 | 2.28e-01 |
| GO:BP | GO:0006813 | potassium ion transport | 4 | 147 | 2.28e-01 |
| GO:BP | GO:0070646 | protein modification by small protein removal | 4 | 147 | 2.28e-01 |
| GO:BP | GO:0001955 | blood vessel maturation | 1 | 6 | 2.28e-01 |
| GO:BP | GO:0071542 | dopaminergic neuron differentiation | 2 | 20 | 2.28e-01 |
| GO:BP | GO:0071878 | negative regulation of adenylate cyclase-activating adrenergic receptor signaling pathway | 1 | 5 | 2.28e-01 |
| GO:BP | GO:0048731 | system development | 6 | 2901 | 2.28e-01 |
| GO:BP | GO:0010634 | positive regulation of epithelial cell migration | 1 | 132 | 2.28e-01 |
| GO:BP | GO:0086065 | cell communication involved in cardiac conduction | 1 | 58 | 2.28e-01 |
| GO:BP | GO:0006833 | water transport | 1 | 10 | 2.28e-01 |
| GO:BP | GO:0046467 | membrane lipid biosynthetic process | 1 | 124 | 2.28e-01 |
| GO:BP | GO:0061326 | renal tubule development | 2 | 77 | 2.29e-01 |
| GO:BP | GO:0030033 | microvillus assembly | 1 | 15 | 2.29e-01 |
| GO:BP | GO:0031111 | negative regulation of microtubule polymerization or depolymerization | 2 | 39 | 2.29e-01 |
| GO:BP | GO:1903898 | negative regulation of PERK-mediated unfolded protein response | 1 | 6 | 2.29e-01 |
| GO:BP | GO:0014819 | regulation of skeletal muscle contraction | 1 | 14 | 2.29e-01 |
| GO:BP | GO:0050804 | modulation of chemical synaptic transmission | 6 | 341 | 2.29e-01 |
| GO:BP | GO:0019229 | regulation of vasoconstriction | 1 | 38 | 2.29e-01 |
| GO:BP | GO:0071375 | cellular response to peptide hormone stimulus | 1 | 241 | 2.29e-01 |
| GO:BP | GO:0030217 | T cell differentiation | 1 | 185 | 2.29e-01 |
| GO:BP | GO:0072527 | pyrimidine-containing compound metabolic process | 3 | 67 | 2.29e-01 |
| GO:BP | GO:0009157 | deoxyribonucleoside monophosphate biosynthetic process | 1 | 9 | 2.29e-01 |
| GO:BP | GO:0009113 | purine nucleobase biosynthetic process | 1 | 10 | 2.29e-01 |
| GO:BP | GO:1902686 | mitochondrial outer membrane permeabilization involved in programmed cell death | 2 | 40 | 2.29e-01 |
| GO:BP | GO:0031340 | positive regulation of vesicle fusion | 1 | 9 | 2.29e-01 |
| GO:BP | GO:0006906 | vesicle fusion | 4 | 104 | 2.29e-01 |
| GO:BP | GO:0002676 | regulation of chronic inflammatory response | 1 | 2 | 2.29e-01 |
| GO:BP | GO:0051246 | regulation of protein metabolic process | 3 | 1974 | 2.29e-01 |
| GO:BP | GO:0006650 | glycerophospholipid metabolic process | 1 | 252 | 2.29e-01 |
| GO:BP | GO:0008333 | endosome to lysosome transport | 3 | 63 | 2.29e-01 |
| GO:BP | GO:0032874 | positive regulation of stress-activated MAPK cascade | 1 | 96 | 2.29e-01 |
| GO:BP | GO:1904688 | regulation of cytoplasmic translational initiation | 1 | 6 | 2.29e-01 |
| GO:BP | GO:0044557 | relaxation of smooth muscle | 1 | 9 | 2.29e-01 |
| GO:BP | GO:0031282 | regulation of guanylate cyclase activity | 1 | 3 | 2.29e-01 |
| GO:BP | GO:0035305 | negative regulation of dephosphorylation | 1 | 39 | 2.29e-01 |
| GO:BP | GO:0061888 | regulation of astrocyte activation | 1 | 3 | 2.29e-01 |
| GO:BP | GO:1905962 | glutamatergic neuron differentiation | 1 | 2 | 2.29e-01 |
| GO:BP | GO:0099177 | regulation of trans-synaptic signaling | 6 | 342 | 2.29e-01 |
| GO:BP | GO:0034394 | protein localization to cell surface | 1 | 61 | 2.29e-01 |
| GO:BP | GO:1904350 | regulation of protein catabolic process in the vacuole | 1 | 13 | 2.29e-01 |
| GO:BP | GO:1903573 | negative regulation of response to endoplasmic reticulum stress | 2 | 41 | 2.29e-01 |
| GO:BP | GO:0007020 | microtubule nucleation | 1 | 39 | 2.29e-01 |
| GO:BP | GO:0061197 | fungiform papilla morphogenesis | 1 | 4 | 2.29e-01 |
| GO:BP | GO:0070304 | positive regulation of stress-activated protein kinase signaling cascade | 1 | 98 | 2.31e-01 |
| GO:BP | GO:0006406 | mRNA export from nucleus | 2 | 59 | 2.31e-01 |
| GO:BP | GO:0008655 | pyrimidine-containing compound salvage | 1 | 5 | 2.32e-01 |
| GO:BP | GO:0043304 | regulation of mast cell degranulation | 2 | 20 | 2.33e-01 |
| GO:BP | GO:1990138 | neuron projection extension | 4 | 148 | 2.33e-01 |
| GO:BP | GO:0072283 | metanephric renal vesicle morphogenesis | 1 | 11 | 2.33e-01 |
| GO:BP | GO:0006457 | protein folding | 1 | 192 | 2.33e-01 |
| GO:BP | GO:0019262 | N-acetylneuraminate catabolic process | 1 | 6 | 2.33e-01 |
| GO:BP | GO:0006665 | sphingolipid metabolic process | 1 | 131 | 2.33e-01 |
| GO:BP | GO:0090174 | organelle membrane fusion | 4 | 106 | 2.33e-01 |
| GO:BP | GO:0050673 | epithelial cell proliferation | 3 | 323 | 2.34e-01 |
| GO:BP | GO:0051931 | regulation of sensory perception | 2 | 13 | 2.34e-01 |
| GO:BP | GO:0006281 | DNA repair | 4 | 534 | 2.34e-01 |
| GO:BP | GO:0035136 | forelimb morphogenesis | 2 | 21 | 2.34e-01 |
| GO:BP | GO:1902108 | regulation of mitochondrial membrane permeability involved in apoptotic process | 2 | 42 | 2.34e-01 |
| GO:BP | GO:0031646 | positive regulation of nervous system process | 2 | 21 | 2.34e-01 |
| GO:BP | GO:0051930 | regulation of sensory perception of pain | 2 | 13 | 2.34e-01 |
| GO:BP | GO:0016233 | telomere capping | 1 | 36 | 2.35e-01 |
| GO:BP | GO:0021522 | spinal cord motor neuron differentiation | 1 | 18 | 2.36e-01 |
| GO:BP | GO:1901632 | regulation of synaptic vesicle membrane organization | 1 | 8 | 2.36e-01 |
| GO:BP | GO:0031630 | regulation of synaptic vesicle fusion to presynaptic active zone membrane | 1 | 8 | 2.36e-01 |
| GO:BP | GO:0018345 | protein palmitoylation | 2 | 30 | 2.36e-01 |
| GO:BP | GO:0007098 | centrosome cycle | 1 | 127 | 2.36e-01 |
| GO:BP | GO:0000768 | syncytium formation by plasma membrane fusion | 1 | 37 | 2.36e-01 |
| GO:BP | GO:0036297 | interstrand cross-link repair | 1 | 37 | 2.36e-01 |
| GO:BP | GO:0009653 | anatomical structure morphogenesis | 5 | 1974 | 2.36e-01 |
| GO:BP | GO:0006103 | 2-oxoglutarate metabolic process | 1 | 16 | 2.36e-01 |
| GO:BP | GO:0006984 | ER-nucleus signaling pathway | 2 | 45 | 2.36e-01 |
| GO:BP | GO:0009068 | aspartate family amino acid catabolic process | 1 | 12 | 2.36e-01 |
| GO:BP | GO:0140253 | cell-cell fusion | 1 | 37 | 2.36e-01 |
| GO:BP | GO:1902905 | positive regulation of supramolecular fiber organization | 4 | 151 | 2.36e-01 |
| GO:BP | GO:0035794 | positive regulation of mitochondrial membrane permeability | 2 | 43 | 2.36e-01 |
| GO:BP | GO:1902415 | regulation of mRNA binding | 1 | 10 | 2.36e-01 |
| GO:BP | GO:0061795 | Golgi lumen acidification | 1 | 13 | 2.37e-01 |
| GO:BP | GO:0055117 | regulation of cardiac muscle contraction | 1 | 70 | 2.37e-01 |
| GO:BP | GO:0007270 | neuron-neuron synaptic transmission | 1 | 5 | 2.37e-01 |
| GO:BP | GO:0048757 | pigment granule maturation | 1 | 9 | 2.37e-01 |
| GO:BP | GO:0046365 | monosaccharide catabolic process | 1 | 38 | 2.37e-01 |
| GO:BP | GO:0006451 | translational readthrough | 1 | 10 | 2.37e-01 |
| GO:BP | GO:0061387 | regulation of extent of cell growth | 3 | 97 | 2.37e-01 |
| GO:BP | GO:0051136 | regulation of NK T cell differentiation | 1 | 4 | 2.37e-01 |
| GO:BP | GO:0045719 | negative regulation of glycogen biosynthetic process | 1 | 7 | 2.37e-01 |
| GO:BP | GO:0046328 | regulation of JNK cascade | 1 | 114 | 2.37e-01 |
| GO:BP | GO:2000377 | regulation of reactive oxygen species metabolic process | 1 | 108 | 2.37e-01 |
| GO:BP | GO:0033135 | regulation of peptidyl-serine phosphorylation | 1 | 100 | 2.37e-01 |
| GO:BP | GO:1901653 | cellular response to peptide | 1 | 287 | 2.37e-01 |
| GO:BP | GO:0006974 | DNA damage response | 5 | 785 | 2.37e-01 |
| GO:BP | GO:0035108 | limb morphogenesis | 4 | 114 | 2.37e-01 |
| GO:BP | GO:0061734 | parkin-mediated stimulation of mitophagy in response to mitochondrial depolarization | 1 | 6 | 2.37e-01 |
| GO:BP | GO:1904781 | positive regulation of protein localization to centrosome | 1 | 7 | 2.37e-01 |
| GO:BP | GO:0033572 | transferrin transport | 1 | 8 | 2.37e-01 |
| GO:BP | GO:0042113 | B cell activation | 1 | 170 | 2.37e-01 |
| GO:BP | GO:0006563 | L-serine metabolic process | 1 | 10 | 2.37e-01 |
| GO:BP | GO:0006949 | syncytium formation | 1 | 39 | 2.37e-01 |
| GO:BP | GO:0050731 | positive regulation of peptidyl-tyrosine phosphorylation | 1 | 105 | 2.37e-01 |
| GO:BP | GO:0033006 | regulation of mast cell activation involved in immune response | 2 | 21 | 2.37e-01 |
| GO:BP | GO:0060789 | hair follicle placode formation | 1 | 5 | 2.37e-01 |
| GO:BP | GO:0032792 | negative regulation of CREB transcription factor activity | 1 | 4 | 2.37e-01 |
| GO:BP | GO:0007041 | lysosomal transport | 4 | 115 | 2.37e-01 |
| GO:BP | GO:0033059 | cellular pigmentation | 2 | 58 | 2.37e-01 |
| GO:BP | GO:0061196 | fungiform papilla development | 1 | 5 | 2.37e-01 |
| GO:BP | GO:0035107 | appendage morphogenesis | 4 | 114 | 2.37e-01 |
| GO:BP | GO:0048844 | artery morphogenesis | 1 | 58 | 2.37e-01 |
| GO:BP | GO:0006498 | N-terminal protein lipidation | 1 | 7 | 2.37e-01 |
| GO:BP | GO:0051127 | positive regulation of actin nucleation | 1 | 14 | 2.37e-01 |
| GO:BP | GO:0007369 | gastrulation | 1 | 146 | 2.37e-01 |
| GO:BP | GO:0036492 | eiF2alpha phosphorylation in response to endoplasmic reticulum stress | 1 | 7 | 2.37e-01 |
| GO:BP | GO:0002191 | cap-dependent translational initiation | 1 | 7 | 2.37e-01 |
| GO:BP | GO:0035646 | endosome to melanosome transport | 1 | 9 | 2.37e-01 |
| GO:BP | GO:0032091 | negative regulation of protein binding | 3 | 77 | 2.37e-01 |
| GO:BP | GO:0065009 | regulation of molecular function | 3 | 1939 | 2.37e-01 |
| GO:BP | GO:0009176 | pyrimidine deoxyribonucleoside monophosphate metabolic process | 1 | 9 | 2.37e-01 |
| GO:BP | GO:0001514 | selenocysteine incorporation | 1 | 10 | 2.37e-01 |
| GO:BP | GO:0043485 | endosome to pigment granule transport | 1 | 9 | 2.37e-01 |
| GO:BP | GO:0048678 | response to axon injury | 1 | 64 | 2.37e-01 |
| GO:BP | GO:1903566 | positive regulation of protein localization to cilium | 1 | 7 | 2.37e-01 |
| GO:BP | GO:0045022 | early endosome to late endosome transport | 1 | 40 | 2.37e-01 |
| GO:BP | GO:0044351 | macropinocytosis | 1 | 8 | 2.37e-01 |
| GO:BP | GO:0060633 | negative regulation of transcription initiation by RNA polymerase II | 1 | 6 | 2.37e-01 |
| GO:BP | GO:0097116 | gephyrin clustering involved in postsynaptic density assembly | 1 | 3 | 2.37e-01 |
| GO:BP | GO:0045347 | negative regulation of MHC class II biosynthetic process | 1 | 3 | 2.37e-01 |
| GO:BP | GO:1901526 | positive regulation of mitophagy | 1 | 6 | 2.37e-01 |
| GO:BP | GO:0090427 | activation of meiosis | 1 | 4 | 2.37e-01 |
| GO:BP | GO:0043666 | regulation of phosphoprotein phosphatase activity | 1 | 47 | 2.37e-01 |
| GO:BP | GO:0086001 | cardiac muscle cell action potential | 1 | 68 | 2.37e-01 |
| GO:BP | GO:0009611 | response to wounding | 2 | 415 | 2.37e-01 |
| GO:BP | GO:0036015 | response to interleukin-3 | 1 | 6 | 2.37e-01 |
| GO:BP | GO:0003281 | ventricular septum development | 1 | 69 | 2.37e-01 |
| GO:BP | GO:0036150 | phosphatidylserine acyl-chain remodeling | 1 | 7 | 2.37e-01 |
| GO:BP | GO:0086003 | cardiac muscle cell contraction | 1 | 67 | 2.37e-01 |
| GO:BP | GO:0010212 | response to ionizing radiation | 1 | 130 | 2.37e-01 |
| GO:BP | GO:0036016 | cellular response to interleukin-3 | 1 | 6 | 2.37e-01 |
| GO:BP | GO:0031023 | microtubule organizing center organization | 1 | 137 | 2.37e-01 |
| GO:BP | GO:0047496 | vesicle transport along microtubule | 1 | 41 | 2.37e-01 |
| GO:BP | GO:0006955 | immune response | 2 | 882 | 2.37e-01 |
| GO:BP | GO:0009798 | axis specification | 1 | 63 | 2.37e-01 |
| GO:BP | GO:0009211 | pyrimidine deoxyribonucleoside triphosphate metabolic process | 1 | 6 | 2.37e-01 |
| GO:BP | GO:1905906 | regulation of amyloid fibril formation | 1 | 14 | 2.39e-01 |
| GO:BP | GO:0007033 | vacuole organization | 3 | 197 | 2.40e-01 |
| GO:BP | GO:0021675 | nerve development | 1 | 57 | 2.40e-01 |
| GO:BP | GO:0072009 | nephron epithelium development | 2 | 86 | 2.40e-01 |
| GO:BP | GO:0006629 | lipid metabolic process | 2 | 994 | 2.40e-01 |
| GO:BP | GO:0072077 | renal vesicle morphogenesis | 1 | 14 | 2.40e-01 |
| GO:BP | GO:0003151 | outflow tract morphogenesis | 1 | 68 | 2.40e-01 |
| GO:BP | GO:0008089 | anterograde axonal transport | 1 | 45 | 2.41e-01 |
| GO:BP | GO:0009199 | ribonucleoside triphosphate metabolic process | 4 | 144 | 2.41e-01 |
| GO:BP | GO:0035588 | G protein-coupled purinergic receptor signaling pathway | 1 | 8 | 2.41e-01 |
| GO:BP | GO:1903035 | negative regulation of response to wounding | 1 | 64 | 2.41e-01 |
| GO:BP | GO:0010752 | regulation of cGMP-mediated signaling | 1 | 8 | 2.41e-01 |
| GO:BP | GO:0046486 | glycerolipid metabolic process | 1 | 311 | 2.41e-01 |
| GO:BP | GO:0001973 | G protein-coupled adenosine receptor signaling pathway | 1 | 8 | 2.41e-01 |
| GO:BP | GO:0042310 | vasoconstriction | 1 | 51 | 2.42e-01 |
| GO:BP | GO:1905710 | positive regulation of membrane permeability | 2 | 45 | 2.42e-01 |
| GO:BP | GO:0006352 | DNA-templated transcription initiation | 4 | 130 | 2.43e-01 |
| GO:BP | GO:0043605 | amide catabolic process | 1 | 10 | 2.43e-01 |
| GO:BP | GO:0030258 | lipid modification | 1 | 162 | 2.43e-01 |
| GO:BP | GO:0032330 | regulation of chondrocyte differentiation | 2 | 37 | 2.43e-01 |
| GO:BP | GO:0051899 | membrane depolarization | 1 | 60 | 2.43e-01 |
| GO:BP | GO:0051247 | positive regulation of protein metabolic process | 2 | 1123 | 2.43e-01 |
| GO:BP | GO:0042044 | fluid transport | 1 | 17 | 2.43e-01 |
| GO:BP | GO:0098927 | vesicle-mediated transport between endosomal compartments | 1 | 42 | 2.43e-01 |
| GO:BP | GO:0060613 | fat pad development | 1 | 6 | 2.43e-01 |
| GO:BP | GO:0002064 | epithelial cell development | 5 | 156 | 2.44e-01 |
| GO:BP | GO:0070874 | negative regulation of glycogen metabolic process | 1 | 7 | 2.44e-01 |
| GO:BP | GO:2000739 | regulation of mesenchymal stem cell differentiation | 1 | 8 | 2.44e-01 |
| GO:BP | GO:0030512 | negative regulation of transforming growth factor beta receptor signaling pathway | 3 | 86 | 2.44e-01 |
| GO:BP | GO:0009394 | 2’-deoxyribonucleotide metabolic process | 2 | 35 | 2.44e-01 |
| GO:BP | GO:0007172 | signal complex assembly | 1 | 7 | 2.44e-01 |
| GO:BP | GO:0032056 | positive regulation of translation in response to stress | 1 | 8 | 2.44e-01 |
| GO:BP | GO:0007259 | receptor signaling pathway via JAK-STAT | 1 | 86 | 2.44e-01 |
| GO:BP | GO:0051098 | regulation of binding | 7 | 317 | 2.44e-01 |
| GO:BP | GO:0006643 | membrane lipid metabolic process | 1 | 173 | 2.44e-01 |
| GO:BP | GO:0072087 | renal vesicle development | 1 | 15 | 2.44e-01 |
| GO:BP | GO:0006796 | phosphate-containing compound metabolic process | 3 | 2139 | 2.44e-01 |
| GO:BP | GO:0043174 | nucleoside salvage | 1 | 9 | 2.44e-01 |
| GO:BP | GO:0048477 | oogenesis | 1 | 64 | 2.44e-01 |
| GO:BP | GO:0036491 | regulation of translation initiation in response to endoplasmic reticulum stress | 1 | 8 | 2.44e-01 |
| GO:BP | GO:0061312 | BMP signaling pathway involved in heart development | 1 | 7 | 2.44e-01 |
| GO:BP | GO:0050821 | protein stabilization | 1 | 191 | 2.44e-01 |
| GO:BP | GO:0032418 | lysosome localization | 2 | 62 | 2.44e-01 |
| GO:BP | GO:1990849 | vacuolar localization | 2 | 62 | 2.44e-01 |
| GO:BP | GO:0046985 | positive regulation of hemoglobin biosynthetic process | 1 | 6 | 2.46e-01 |
| GO:BP | GO:0006793 | phosphorus metabolic process | 3 | 2161 | 2.46e-01 |
| GO:BP | GO:0097696 | receptor signaling pathway via STAT | 1 | 88 | 2.46e-01 |
| GO:BP | GO:0030098 | lymphocyte differentiation | 1 | 260 | 2.46e-01 |
| GO:BP | GO:0045687 | positive regulation of glial cell differentiation | 2 | 28 | 2.46e-01 |
| GO:BP | GO:0043434 | response to peptide hormone | 1 | 321 | 2.46e-01 |
| GO:BP | GO:2000143 | negative regulation of DNA-templated transcription initiation | 1 | 6 | 2.47e-01 |
| GO:BP | GO:0007254 | JNK cascade | 1 | 138 | 2.47e-01 |
| GO:BP | GO:0080171 | lytic vacuole organization | 2 | 88 | 2.47e-01 |
| GO:BP | GO:0046653 | tetrahydrofolate metabolic process | 1 | 14 | 2.47e-01 |
| GO:BP | GO:0019692 | deoxyribose phosphate metabolic process | 2 | 36 | 2.47e-01 |
| GO:BP | GO:0009262 | deoxyribonucleotide metabolic process | 2 | 36 | 2.47e-01 |
| GO:BP | GO:0046655 | folic acid metabolic process | 1 | 14 | 2.47e-01 |
| GO:BP | GO:0007040 | lysosome organization | 2 | 88 | 2.47e-01 |
| GO:BP | GO:0098792 | xenophagy | 1 | 12 | 2.47e-01 |
| GO:BP | GO:0007169 | transmembrane receptor protein tyrosine kinase signaling pathway | 2 | 484 | 2.47e-01 |
| GO:BP | GO:0042176 | regulation of protein catabolic process | 6 | 331 | 2.47e-01 |
| GO:BP | GO:0072698 | protein localization to microtubule cytoskeleton | 2 | 52 | 2.47e-01 |
| GO:BP | GO:0006368 | transcription elongation by RNA polymerase II | 3 | 106 | 2.47e-01 |
| GO:BP | GO:0016482 | cytosolic transport | 2 | 161 | 2.47e-01 |
| GO:BP | GO:0060179 | male mating behavior | 1 | 5 | 2.47e-01 |
| GO:BP | GO:0070933 | histone H4 deacetylation | 1 | 7 | 2.47e-01 |
| GO:BP | GO:0048024 | regulation of mRNA splicing, via spliceosome | 1 | 96 | 2.47e-01 |
| GO:BP | GO:0055064 | chloride ion homeostasis | 1 | 13 | 2.47e-01 |
| GO:BP | GO:0043308 | eosinophil degranulation | 1 | 4 | 2.47e-01 |
| GO:BP | GO:1902855 | regulation of non-motile cilium assembly | 1 | 10 | 2.47e-01 |
| GO:BP | GO:0006487 | protein N-linked glycosylation | 1 | 65 | 2.47e-01 |
| GO:BP | GO:0030838 | positive regulation of actin filament polymerization | 2 | 39 | 2.47e-01 |
| GO:BP | GO:0002278 | eosinophil activation involved in immune response | 1 | 4 | 2.47e-01 |
| GO:BP | GO:0061136 | regulation of proteasomal protein catabolic process | 4 | 183 | 2.48e-01 |
| GO:BP | GO:0032528 | microvillus organization | 1 | 19 | 2.49e-01 |
| GO:BP | GO:1903367 | positive regulation of fear response | 1 | 4 | 2.49e-01 |
| GO:BP | GO:0051260 | protein homooligomerization | 3 | 136 | 2.49e-01 |
| GO:BP | GO:1905214 | regulation of RNA binding | 1 | 13 | 2.49e-01 |
| GO:BP | GO:0006469 | negative regulation of protein kinase activity | 3 | 179 | 2.49e-01 |
| GO:BP | GO:0006486 | protein glycosylation | 2 | 187 | 2.49e-01 |
| GO:BP | GO:1904526 | regulation of microtubule binding | 1 | 10 | 2.49e-01 |
| GO:BP | GO:0043413 | macromolecule glycosylation | 2 | 187 | 2.49e-01 |
| GO:BP | GO:0051607 | defense response to virus | 1 | 202 | 2.50e-01 |
| GO:BP | GO:0043476 | pigment accumulation | 1 | 11 | 2.50e-01 |
| GO:BP | GO:0036152 | phosphatidylethanolamine acyl-chain remodeling | 1 | 8 | 2.50e-01 |
| GO:BP | GO:0043482 | cellular pigment accumulation | 1 | 11 | 2.50e-01 |
| GO:BP | GO:0045986 | negative regulation of smooth muscle contraction | 1 | 12 | 2.50e-01 |
| GO:BP | GO:0006222 | UMP biosynthetic process | 1 | 8 | 2.50e-01 |
| GO:BP | GO:0140546 | defense response to symbiont | 1 | 202 | 2.50e-01 |
| GO:BP | GO:0046902 | regulation of mitochondrial membrane permeability | 1 | 54 | 2.50e-01 |
| GO:BP | GO:1905146 | lysosomal protein catabolic process | 1 | 19 | 2.50e-01 |
| GO:BP | GO:0098739 | import across plasma membrane | 3 | 133 | 2.50e-01 |
| GO:BP | GO:2000465 | regulation of glycogen (starch) synthase activity | 1 | 8 | 2.50e-01 |
| GO:BP | GO:2000074 | regulation of type B pancreatic cell development | 1 | 8 | 2.50e-01 |
| GO:BP | GO:0009165 | nucleotide biosynthetic process | 6 | 240 | 2.51e-01 |
| GO:BP | GO:0000731 | DNA synthesis involved in DNA repair | 1 | 36 | 2.51e-01 |
| GO:BP | GO:0010001 | glial cell differentiation | 1 | 170 | 2.52e-01 |
| GO:BP | GO:0071478 | cellular response to radiation | 1 | 156 | 2.53e-01 |
| GO:BP | GO:0051262 | protein tetramerization | 2 | 64 | 2.53e-01 |
| GO:BP | GO:0014812 | muscle cell migration | 1 | 76 | 2.53e-01 |
| GO:BP | GO:0007166 | cell surface receptor signaling pathway | 3 | 1898 | 2.53e-01 |
| GO:BP | GO:0001954 | positive regulation of cell-matrix adhesion | 2 | 44 | 2.53e-01 |
| GO:BP | GO:0006930 | substrate-dependent cell migration, cell extension | 1 | 8 | 2.53e-01 |
| GO:BP | GO:0032872 | regulation of stress-activated MAPK cascade | 1 | 154 | 2.53e-01 |
| GO:BP | GO:0071481 | cellular response to X-ray | 1 | 10 | 2.53e-01 |
| GO:BP | GO:0070302 | regulation of stress-activated protein kinase signaling cascade | 1 | 157 | 2.56e-01 |
| GO:BP | GO:0055081 | monoatomic anion homeostasis | 1 | 14 | 2.56e-01 |
| GO:BP | GO:1901606 | alpha-amino acid catabolic process | 2 | 63 | 2.56e-01 |
| GO:BP | GO:1904031 | positive regulation of cyclin-dependent protein kinase activity | 2 | 26 | 2.56e-01 |
| GO:BP | GO:1903131 | mononuclear cell differentiation | 1 | 294 | 2.56e-01 |
| GO:BP | GO:0006048 | UDP-N-acetylglucosamine biosynthetic process | 1 | 9 | 2.56e-01 |
| GO:BP | GO:0045964 | positive regulation of dopamine metabolic process | 1 | 6 | 2.56e-01 |
| GO:BP | GO:0010639 | negative regulation of organelle organization | 6 | 318 | 2.56e-01 |
| GO:BP | GO:0043648 | dicarboxylic acid metabolic process | 2 | 74 | 2.56e-01 |
| GO:BP | GO:0006623 | protein targeting to vacuole | 2 | 42 | 2.56e-01 |
| GO:BP | GO:1903980 | positive regulation of microglial cell activation | 1 | 2 | 2.56e-01 |
| GO:BP | GO:1901293 | nucleoside phosphate biosynthetic process | 6 | 241 | 2.56e-01 |
| GO:BP | GO:1900542 | regulation of purine nucleotide metabolic process | 2 | 40 | 2.56e-01 |
| GO:BP | GO:0017148 | negative regulation of translation | 3 | 165 | 2.56e-01 |
| GO:BP | GO:2000622 | regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 1 | 12 | 2.56e-01 |
| GO:BP | GO:0045915 | positive regulation of catecholamine metabolic process | 1 | 6 | 2.56e-01 |
| GO:BP | GO:0003073 | regulation of systemic arterial blood pressure | 1 | 62 | 2.57e-01 |
| GO:BP | GO:0070252 | actin-mediated cell contraction | 1 | 89 | 2.57e-01 |
| GO:BP | GO:0060840 | artery development | 1 | 83 | 2.57e-01 |
| GO:BP | GO:1900271 | regulation of long-term synaptic potentiation | 2 | 34 | 2.58e-01 |
| GO:BP | GO:0042596 | fear response | 2 | 32 | 2.58e-01 |
| GO:BP | GO:0021517 | ventral spinal cord development | 1 | 25 | 2.58e-01 |
| GO:BP | GO:0050730 | regulation of peptidyl-tyrosine phosphorylation | 1 | 166 | 2.58e-01 |
| GO:BP | GO:0043484 | regulation of RNA splicing | 3 | 164 | 2.59e-01 |
| GO:BP | GO:0042220 | response to cocaine | 2 | 28 | 2.59e-01 |
| GO:BP | GO:0010811 | positive regulation of cell-substrate adhesion | 3 | 100 | 2.59e-01 |
| GO:BP | GO:0044380 | protein localization to cytoskeleton | 2 | 55 | 2.59e-01 |
| GO:BP | GO:0006140 | regulation of nucleotide metabolic process | 2 | 40 | 2.59e-01 |
| GO:BP | GO:0032275 | luteinizing hormone secretion | 1 | 6 | 2.59e-01 |
| GO:BP | GO:0009174 | pyrimidine ribonucleoside monophosphate biosynthetic process | 1 | 9 | 2.59e-01 |
| GO:BP | GO:0050884 | neuromuscular process controlling posture | 1 | 12 | 2.59e-01 |
| GO:BP | GO:0008016 | regulation of heart contraction | 3 | 173 | 2.60e-01 |
| GO:BP | GO:1901652 | response to peptide | 1 | 377 | 2.60e-01 |
| GO:BP | GO:0031325 | positive regulation of cellular metabolic process | 3 | 2270 | 2.61e-01 |
| GO:BP | GO:0048675 | axon extension | 3 | 110 | 2.61e-01 |
| GO:BP | GO:0098930 | axonal transport | 1 | 60 | 2.61e-01 |
| GO:BP | GO:1904779 | regulation of protein localization to centrosome | 1 | 10 | 2.61e-01 |
| GO:BP | GO:0099111 | microtubule-based transport | 2 | 191 | 2.61e-01 |
| GO:BP | GO:0002447 | eosinophil mediated immunity | 1 | 5 | 2.61e-01 |
| GO:BP | GO:0043307 | eosinophil activation | 1 | 4 | 2.61e-01 |
| GO:BP | GO:0038083 | peptidyl-tyrosine autophosphorylation | 1 | 18 | 2.63e-01 |
| GO:BP | GO:0080135 | regulation of cellular response to stress | 2 | 616 | 2.63e-01 |
| GO:BP | GO:0070085 | glycosylation | 2 | 202 | 2.63e-01 |
| GO:BP | GO:1903313 | positive regulation of mRNA metabolic process | 1 | 121 | 2.63e-01 |
| GO:BP | GO:0097201 | negative regulation of transcription from RNA polymerase II promoter in response to stress | 1 | 10 | 2.63e-01 |
| GO:BP | GO:0035332 | positive regulation of hippo signaling | 1 | 6 | 2.63e-01 |
| GO:BP | GO:0031954 | positive regulation of protein autophosphorylation | 1 | 26 | 2.63e-01 |
| GO:BP | GO:0003279 | cardiac septum development | 1 | 101 | 2.64e-01 |
| GO:BP | GO:0009071 | serine family amino acid catabolic process | 1 | 10 | 2.64e-01 |
| GO:BP | GO:0030901 | midbrain development | 3 | 69 | 2.64e-01 |
| GO:BP | GO:1905114 | cell surface receptor signaling pathway involved in cell-cell signaling | 8 | 448 | 2.64e-01 |
| GO:BP | GO:0060363 | cranial suture morphogenesis | 1 | 8 | 2.64e-01 |
| GO:BP | GO:0048819 | regulation of hair follicle maturation | 1 | 9 | 2.64e-01 |
| GO:BP | GO:0044848 | biological phase | 1 | 9 | 2.64e-01 |
| GO:BP | GO:0045617 | negative regulation of keratinocyte differentiation | 1 | 3 | 2.64e-01 |
| GO:BP | GO:0051091 | positive regulation of DNA-binding transcription factor activity | 1 | 199 | 2.64e-01 |
| GO:BP | GO:0006936 | muscle contraction | 4 | 267 | 2.64e-01 |
| GO:BP | GO:0044851 | hair cycle phase | 1 | 9 | 2.64e-01 |
| GO:BP | GO:0006405 | RNA export from nucleus | 2 | 78 | 2.65e-01 |
| GO:BP | GO:0010942 | positive regulation of cell death | 9 | 441 | 2.66e-01 |
| GO:BP | GO:1901072 | glucosamine-containing compound catabolic process | 1 | 5 | 2.66e-01 |
| GO:BP | GO:1905515 | non-motile cilium assembly | 2 | 58 | 2.66e-01 |
| GO:BP | GO:0016571 | histone methylation | 1 | 117 | 2.66e-01 |
| GO:BP | GO:0060291 | long-term synaptic potentiation | 3 | 64 | 2.66e-01 |
| GO:BP | GO:0009612 | response to mechanical stimulus | 1 | 158 | 2.66e-01 |
| GO:BP | GO:0072273 | metanephric nephron morphogenesis | 1 | 19 | 2.66e-01 |
| GO:BP | GO:0051382 | kinetochore assembly | 1 | 18 | 2.66e-01 |
| GO:BP | GO:0010921 | regulation of phosphatase activity | 1 | 65 | 2.67e-01 |
| GO:BP | GO:0006893 | Golgi to plasma membrane transport | 2 | 60 | 2.67e-01 |
| GO:BP | GO:0042110 | T cell activation | 1 | 313 | 2.68e-01 |
| GO:BP | GO:0045744 | negative regulation of G protein-coupled receptor signaling pathway | 2 | 38 | 2.69e-01 |
| GO:BP | GO:0048149 | behavioral response to ethanol | 1 | 5 | 2.69e-01 |
| GO:BP | GO:0046984 | regulation of hemoglobin biosynthetic process | 1 | 8 | 2.69e-01 |
| GO:BP | GO:0046835 | carbohydrate phosphorylation | 1 | 21 | 2.69e-01 |
| GO:BP | GO:0050684 | regulation of mRNA processing | 1 | 127 | 2.69e-01 |
| GO:BP | GO:1901096 | regulation of autophagosome maturation | 1 | 16 | 2.69e-01 |
| GO:BP | GO:0090559 | regulation of membrane permeability | 1 | 64 | 2.69e-01 |
| GO:BP | GO:0007039 | protein catabolic process in the vacuole | 1 | 22 | 2.69e-01 |
| GO:BP | GO:0099518 | vesicle cytoskeletal trafficking | 1 | 60 | 2.69e-01 |
| GO:BP | GO:1903564 | regulation of protein localization to cilium | 1 | 11 | 2.69e-01 |
| GO:BP | GO:0051351 | positive regulation of ligase activity | 1 | 9 | 2.69e-01 |
| GO:BP | GO:0001886 | endothelial cell morphogenesis | 1 | 10 | 2.69e-01 |
| GO:BP | GO:0032482 | Rab protein signal transduction | 1 | 19 | 2.69e-01 |
| GO:BP | GO:0031109 | microtubule polymerization or depolymerization | 3 | 119 | 2.69e-01 |
| GO:BP | GO:0007042 | lysosomal lumen acidification | 1 | 21 | 2.69e-01 |
| GO:BP | GO:0021515 | cell differentiation in spinal cord | 1 | 24 | 2.69e-01 |
| GO:BP | GO:0072521 | purine-containing compound metabolic process | 5 | 390 | 2.69e-01 |
| GO:BP | GO:0006544 | glycine metabolic process | 1 | 10 | 2.69e-01 |
| GO:BP | GO:1905150 | regulation of voltage-gated sodium channel activity | 1 | 6 | 2.69e-01 |
| GO:BP | GO:0072497 | mesenchymal stem cell differentiation | 1 | 11 | 2.69e-01 |
| GO:BP | GO:0001942 | hair follicle development | 3 | 67 | 2.69e-01 |
| GO:BP | GO:0051894 | positive regulation of focal adhesion assembly | 1 | 24 | 2.69e-01 |
| GO:BP | GO:0072593 | reactive oxygen species metabolic process | 1 | 156 | 2.69e-01 |
| GO:BP | GO:0046112 | nucleobase biosynthetic process | 1 | 18 | 2.69e-01 |
| GO:BP | GO:0030177 | positive regulation of Wnt signaling pathway | 3 | 120 | 2.69e-01 |
| GO:BP | GO:0010661 | positive regulation of muscle cell apoptotic process | 1 | 20 | 2.69e-01 |
| GO:BP | GO:0033673 | negative regulation of kinase activity | 1 | 197 | 2.69e-01 |
| GO:BP | GO:0033278 | cell proliferation in midbrain | 1 | 4 | 2.69e-01 |
| GO:BP | GO:0043065 | positive regulation of apoptotic process | 8 | 393 | 2.69e-01 |
| GO:BP | GO:0010998 | regulation of translational initiation by eIF2 alpha phosphorylation | 1 | 11 | 2.70e-01 |
| GO:BP | GO:1904953 | Wnt signaling pathway involved in midbrain dopaminergic neuron differentiation | 1 | 8 | 2.70e-01 |
| GO:BP | GO:1903897 | regulation of PERK-mediated unfolded protein response | 1 | 10 | 2.70e-01 |
| GO:BP | GO:1902237 | positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway | 1 | 10 | 2.70e-01 |
| GO:BP | GO:0036490 | regulation of translation in response to endoplasmic reticulum stress | 1 | 11 | 2.70e-01 |
| GO:BP | GO:0045599 | negative regulation of fat cell differentiation | 2 | 43 | 2.70e-01 |
| GO:BP | GO:0006390 | mitochondrial transcription | 1 | 18 | 2.70e-01 |
| GO:BP | GO:0043392 | negative regulation of DNA binding | 2 | 46 | 2.71e-01 |
| GO:BP | GO:0044057 | regulation of system process | 6 | 405 | 2.71e-01 |
| GO:BP | GO:0036151 | phosphatidylcholine acyl-chain remodeling | 1 | 12 | 2.71e-01 |
| GO:BP | GO:0002031 | G protein-coupled receptor internalization | 1 | 10 | 2.72e-01 |
| GO:BP | GO:0072073 | kidney epithelium development | 2 | 112 | 2.72e-01 |
| GO:BP | GO:0055080 | monoatomic cation homeostasis | 5 | 401 | 2.72e-01 |
| GO:BP | GO:0051403 | stress-activated MAPK cascade | 1 | 190 | 2.72e-01 |
| GO:BP | GO:0035304 | regulation of protein dephosphorylation | 1 | 75 | 2.72e-01 |
| GO:BP | GO:0097484 | dendrite extension | 1 | 27 | 2.72e-01 |
| GO:BP | GO:0009201 | ribonucleoside triphosphate biosynthetic process | 3 | 102 | 2.72e-01 |
| GO:BP | GO:0006367 | transcription initiation at RNA polymerase II promoter | 3 | 93 | 2.72e-01 |
| GO:BP | GO:0098779 | positive regulation of mitophagy in response to mitochondrial depolarization | 1 | 10 | 2.72e-01 |
| GO:BP | GO:0009070 | serine family amino acid biosynthetic process | 1 | 16 | 2.72e-01 |
| GO:BP | GO:0043244 | regulation of protein-containing complex disassembly | 3 | 113 | 2.72e-01 |
| GO:BP | GO:0060346 | bone trabecula formation | 1 | 9 | 2.72e-01 |
| GO:BP | GO:0060070 | canonical Wnt signaling pathway | 1 | 251 | 2.74e-01 |
| GO:BP | GO:0003351 | epithelial cilium movement involved in extracellular fluid movement | 1 | 29 | 2.74e-01 |
| GO:BP | GO:0022404 | molting cycle process | 3 | 69 | 2.74e-01 |
| GO:BP | GO:0007339 | binding of sperm to zona pellucida | 1 | 20 | 2.74e-01 |
| GO:BP | GO:0046349 | amino sugar biosynthetic process | 1 | 11 | 2.74e-01 |
| GO:BP | GO:0006054 | N-acetylneuraminate metabolic process | 1 | 11 | 2.74e-01 |
| GO:BP | GO:0022405 | hair cycle process | 3 | 69 | 2.74e-01 |
| GO:BP | GO:0009615 | response to virus | 1 | 275 | 2.74e-01 |
| GO:BP | GO:0060999 | positive regulation of dendritic spine development | 1 | 33 | 2.74e-01 |
| GO:BP | GO:0033327 | Leydig cell differentiation | 1 | 9 | 2.74e-01 |
| GO:BP | GO:0010638 | positive regulation of organelle organization | 8 | 439 | 2.74e-01 |
| GO:BP | GO:0007275 | multicellular organism development | 6 | 3386 | 2.74e-01 |
| GO:BP | GO:0031098 | stress-activated protein kinase signaling cascade | 1 | 196 | 2.75e-01 |
| GO:BP | GO:1900373 | positive regulation of purine nucleotide biosynthetic process | 1 | 12 | 2.75e-01 |
| GO:BP | GO:0032870 | cellular response to hormone stimulus | 1 | 457 | 2.75e-01 |
| GO:BP | GO:0030810 | positive regulation of nucleotide biosynthetic process | 1 | 12 | 2.75e-01 |
| GO:BP | GO:0033003 | regulation of mast cell activation | 2 | 25 | 2.75e-01 |
| GO:BP | GO:0002544 | chronic inflammatory response | 1 | 6 | 2.75e-01 |
| GO:BP | GO:0090407 | organophosphate biosynthetic process | 1 | 506 | 2.75e-01 |
| GO:BP | GO:0002521 | leukocyte differentiation | 1 | 382 | 2.75e-01 |
| GO:BP | GO:1903358 | regulation of Golgi organization | 1 | 17 | 2.75e-01 |
| GO:BP | GO:1902018 | negative regulation of cilium assembly | 1 | 15 | 2.75e-01 |
| GO:BP | GO:0072006 | nephron development | 2 | 117 | 2.75e-01 |
| GO:BP | GO:2000651 | positive regulation of sodium ion transmembrane transporter activity | 1 | 14 | 2.75e-01 |
| GO:BP | GO:0008088 | axo-dendritic transport | 1 | 73 | 2.75e-01 |
| GO:BP | GO:0006983 | ER overload response | 1 | 12 | 2.75e-01 |
| GO:BP | GO:0071732 | cellular response to nitric oxide | 1 | 14 | 2.75e-01 |
| GO:BP | GO:0006144 | purine nucleobase metabolic process | 1 | 15 | 2.75e-01 |
| GO:BP | GO:0009651 | response to salt stress | 1 | 18 | 2.75e-01 |
| GO:BP | GO:0002062 | chondrocyte differentiation | 3 | 90 | 2.75e-01 |
| GO:BP | GO:0034454 | microtubule anchoring at centrosome | 1 | 12 | 2.75e-01 |
| GO:BP | GO:0003231 | cardiac ventricle development | 1 | 114 | 2.76e-01 |
| GO:BP | GO:1901799 | negative regulation of proteasomal protein catabolic process | 1 | 47 | 2.77e-01 |
| GO:BP | GO:0031115 | negative regulation of microtubule polymerization | 1 | 13 | 2.77e-01 |
| GO:BP | GO:0001865 | NK T cell differentiation | 1 | 7 | 2.77e-01 |
| GO:BP | GO:0010977 | negative regulation of neuron projection development | 1 | 117 | 2.77e-01 |
| GO:BP | GO:0033240 | positive regulation of amine metabolic process | 1 | 7 | 2.77e-01 |
| GO:BP | GO:0050801 | monoatomic ion homeostasis | 5 | 408 | 2.77e-01 |
| GO:BP | GO:0022409 | positive regulation of cell-cell adhesion | 1 | 189 | 2.77e-01 |
| GO:BP | GO:0043587 | tongue morphogenesis | 1 | 7 | 2.77e-01 |
| GO:BP | GO:0003014 | renal system process | 1 | 78 | 2.77e-01 |
| GO:BP | GO:0042063 | gliogenesis | 1 | 235 | 2.78e-01 |
| GO:BP | GO:1902017 | regulation of cilium assembly | 2 | 57 | 2.78e-01 |
| GO:BP | GO:0106072 | negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway | 1 | 8 | 2.78e-01 |
| GO:BP | GO:0016973 | poly(A)+ mRNA export from nucleus | 1 | 15 | 2.78e-01 |
| GO:BP | GO:0090257 | regulation of muscle system process | 3 | 184 | 2.78e-01 |
| GO:BP | GO:0030048 | actin filament-based movement | 1 | 112 | 2.78e-01 |
| GO:BP | GO:0061549 | sympathetic ganglion development | 1 | 6 | 2.78e-01 |
| GO:BP | GO:0031647 | regulation of protein stability | 1 | 290 | 2.78e-01 |
| GO:BP | GO:1900118 | negative regulation of execution phase of apoptosis | 1 | 6 | 2.78e-01 |
| GO:BP | GO:0043068 | positive regulation of programmed cell death | 8 | 399 | 2.78e-01 |
| GO:BP | GO:0032526 | response to retinoic acid | 3 | 85 | 2.78e-01 |
| GO:BP | GO:0046049 | UMP metabolic process | 1 | 10 | 2.78e-01 |
| GO:BP | GO:1901292 | nucleoside phosphate catabolic process | 1 | 74 | 2.78e-01 |
| GO:BP | GO:0006241 | CTP biosynthetic process | 1 | 12 | 2.78e-01 |
| GO:BP | GO:0006858 | extracellular transport | 1 | 32 | 2.78e-01 |
| GO:BP | GO:0006465 | signal peptide processing | 1 | 13 | 2.78e-01 |
| GO:BP | GO:0048284 | organelle fusion | 4 | 135 | 2.78e-01 |
| GO:BP | GO:0007292 | female gamete generation | 1 | 103 | 2.78e-01 |
| GO:BP | GO:0003158 | endothelium development | 1 | 104 | 2.78e-01 |
| GO:BP | GO:0030111 | regulation of Wnt signaling pathway | 1 | 273 | 2.78e-01 |
| GO:BP | GO:0042981 | regulation of apoptotic process | 2 | 1088 | 2.78e-01 |
| GO:BP | GO:0034249 | negative regulation of amide metabolic process | 3 | 186 | 2.79e-01 |
| GO:BP | GO:0035878 | nail development | 1 | 8 | 2.79e-01 |
| GO:BP | GO:0002098 | tRNA wobble uridine modification | 1 | 16 | 2.79e-01 |
| GO:BP | GO:0008625 | extrinsic apoptotic signaling pathway via death domain receptors | 1 | 72 | 2.79e-01 |
| GO:BP | GO:0002553 | histamine secretion by mast cell | 1 | 8 | 2.81e-01 |
| GO:BP | GO:1903050 | regulation of proteolysis involved in protein catabolic process | 5 | 214 | 2.81e-01 |
| GO:BP | GO:0002441 | histamine secretion involved in inflammatory response | 1 | 8 | 2.81e-01 |
| GO:BP | GO:0008284 | positive regulation of cell population proliferation | 4 | 631 | 2.81e-01 |
| GO:BP | GO:0002349 | histamine production involved in inflammatory response | 1 | 8 | 2.81e-01 |
| GO:BP | GO:0060998 | regulation of dendritic spine development | 2 | 48 | 2.82e-01 |
| GO:BP | GO:1901030 | positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway | 1 | 12 | 2.82e-01 |
| GO:BP | GO:0018198 | peptidyl-cysteine modification | 2 | 41 | 2.82e-01 |
| GO:BP | GO:0071417 | cellular response to organonitrogen compound | 1 | 485 | 2.82e-01 |
| GO:BP | GO:0006084 | acetyl-CoA metabolic process | 1 | 28 | 2.82e-01 |
| GO:BP | GO:0006479 | protein methylation | 4 | 160 | 2.82e-01 |
| GO:BP | GO:0008213 | protein alkylation | 4 | 160 | 2.82e-01 |
| GO:BP | GO:0043067 | regulation of programmed cell death | 2 | 1111 | 2.82e-01 |
| GO:BP | GO:0006941 | striated muscle contraction | 2 | 152 | 2.82e-01 |
| GO:BP | GO:0051340 | regulation of ligase activity | 1 | 11 | 2.82e-01 |
| GO:BP | GO:0031338 | regulation of vesicle fusion | 1 | 17 | 2.82e-01 |
| GO:BP | GO:0016242 | negative regulation of macroautophagy | 1 | 34 | 2.82e-01 |
| GO:BP | GO:0150117 | positive regulation of cell-substrate junction organization | 1 | 29 | 2.82e-01 |
| GO:BP | GO:0031629 | synaptic vesicle fusion to presynaptic active zone membrane | 1 | 19 | 2.82e-01 |
| GO:BP | GO:0051348 | negative regulation of transferase activity | 1 | 234 | 2.82e-01 |
| GO:BP | GO:0071549 | cellular response to dexamethasone stimulus | 1 | 24 | 2.82e-01 |
| GO:BP | GO:0060048 | cardiac muscle contraction | 1 | 123 | 2.82e-01 |
| GO:BP | GO:0006099 | tricarboxylic acid cycle | 1 | 30 | 2.85e-01 |
| GO:BP | GO:0034404 | nucleobase-containing small molecule biosynthetic process | 1 | 15 | 2.85e-01 |
| GO:BP | GO:0009209 | pyrimidine ribonucleoside triphosphate biosynthetic process | 1 | 13 | 2.85e-01 |
| GO:BP | GO:0048814 | regulation of dendrite morphogenesis | 2 | 58 | 2.85e-01 |
| GO:BP | GO:0009117 | nucleotide metabolic process | 5 | 423 | 2.85e-01 |
| GO:BP | GO:0051383 | kinetochore organization | 1 | 23 | 2.85e-01 |
| GO:BP | GO:0009163 | nucleoside biosynthetic process | 1 | 15 | 2.85e-01 |
| GO:BP | GO:0006448 | regulation of translational elongation | 1 | 19 | 2.85e-01 |
| GO:BP | GO:0014902 | myotube differentiation | 1 | 88 | 2.85e-01 |
| GO:BP | GO:1902170 | cellular response to reactive nitrogen species | 1 | 16 | 2.85e-01 |
| GO:BP | GO:0048588 | developmental cell growth | 4 | 192 | 2.85e-01 |
| GO:BP | GO:0046785 | microtubule polymerization | 1 | 84 | 2.85e-01 |
| GO:BP | GO:2000369 | regulation of clathrin-dependent endocytosis | 1 | 18 | 2.85e-01 |
| GO:BP | GO:1903729 | regulation of plasma membrane organization | 1 | 15 | 2.85e-01 |
| GO:BP | GO:0003338 | metanephros morphogenesis | 1 | 22 | 2.85e-01 |
| GO:BP | GO:0061035 | regulation of cartilage development | 2 | 54 | 2.85e-01 |
| GO:BP | GO:0031650 | regulation of heat generation | 1 | 7 | 2.86e-01 |
| GO:BP | GO:0048521 | negative regulation of behavior | 1 | 5 | 2.86e-01 |
| GO:BP | GO:0009063 | amino acid catabolic process | 2 | 78 | 2.86e-01 |
| GO:BP | GO:0036444 | calcium import into the mitochondrion | 1 | 12 | 2.86e-01 |
| GO:BP | GO:0072384 | organelle transport along microtubule | 1 | 84 | 2.86e-01 |
| GO:BP | GO:0048736 | appendage development | 4 | 142 | 2.86e-01 |
| GO:BP | GO:0099500 | vesicle fusion to plasma membrane | 1 | 19 | 2.86e-01 |
| GO:BP | GO:1903365 | regulation of fear response | 1 | 8 | 2.86e-01 |
| GO:BP | GO:2000649 | regulation of sodium ion transmembrane transporter activity | 2 | 44 | 2.86e-01 |
| GO:BP | GO:0097746 | blood vessel diameter maintenance | 1 | 99 | 2.86e-01 |
| GO:BP | GO:0060173 | limb development | 4 | 142 | 2.86e-01 |
| GO:BP | GO:0035296 | regulation of tube diameter | 1 | 99 | 2.86e-01 |
| GO:BP | GO:0033554 | cellular response to stress | 10 | 1681 | 2.86e-01 |
| GO:BP | GO:1903307 | positive regulation of regulated secretory pathway | 2 | 32 | 2.86e-01 |
| GO:BP | GO:0006400 | tRNA modification | 2 | 90 | 2.86e-01 |
| GO:BP | GO:1901699 | cellular response to nitrogen compound | 1 | 517 | 2.86e-01 |
| GO:BP | GO:0051798 | positive regulation of hair follicle development | 1 | 9 | 2.86e-01 |
| GO:BP | GO:0072393 | microtubule anchoring at microtubule organizing center | 1 | 14 | 2.86e-01 |
| GO:BP | GO:0030336 | negative regulation of cell migration | 1 | 227 | 2.86e-01 |
| GO:BP | GO:0001508 | action potential | 1 | 105 | 2.86e-01 |
| GO:BP | GO:0045765 | regulation of angiogenesis | 1 | 203 | 2.86e-01 |
| GO:BP | GO:0036293 | response to decreased oxygen levels | 3 | 249 | 2.86e-01 |
| GO:BP | GO:0032648 | regulation of interferon-beta production | 2 | 43 | 2.86e-01 |
| GO:BP | GO:2000052 | positive regulation of non-canonical Wnt signaling pathway | 1 | 14 | 2.86e-01 |
| GO:BP | GO:0009123 | nucleoside monophosphate metabolic process | 2 | 64 | 2.86e-01 |
| GO:BP | GO:0032608 | interferon-beta production | 2 | 43 | 2.86e-01 |
| GO:BP | GO:1903034 | regulation of response to wounding | 1 | 121 | 2.86e-01 |
| GO:BP | GO:0035150 | regulation of tube size | 1 | 99 | 2.86e-01 |
| GO:BP | GO:1903232 | melanosome assembly | 1 | 19 | 2.86e-01 |
| GO:BP | GO:1901342 | regulation of vasculature development | 1 | 206 | 2.86e-01 |
| GO:BP | GO:0007268 | chemical synaptic transmission | 7 | 490 | 2.86e-01 |
| GO:BP | GO:0098916 | anterograde trans-synaptic signaling | 7 | 490 | 2.86e-01 |
| GO:BP | GO:0043300 | regulation of leukocyte degranulation | 2 | 27 | 2.87e-01 |
| GO:BP | GO:0036211 | protein modification process | 6 | 2901 | 2.87e-01 |
| GO:BP | GO:0006753 | nucleoside phosphate metabolic process | 5 | 429 | 2.87e-01 |
| GO:BP | GO:0031323 | regulation of cellular metabolic process | 6 | 4174 | 2.87e-01 |
| GO:BP | GO:0045981 | positive regulation of nucleotide metabolic process | 1 | 16 | 2.87e-01 |
| GO:BP | GO:0046036 | CTP metabolic process | 1 | 14 | 2.87e-01 |
| GO:BP | GO:0009173 | pyrimidine ribonucleoside monophosphate metabolic process | 1 | 12 | 2.87e-01 |
| GO:BP | GO:0002376 | immune system process | 2 | 1447 | 2.87e-01 |
| GO:BP | GO:0045932 | negative regulation of muscle contraction | 1 | 20 | 2.87e-01 |
| GO:BP | GO:0097320 | plasma membrane tubulation | 1 | 18 | 2.87e-01 |
| GO:BP | GO:0034058 | endosomal vesicle fusion | 1 | 10 | 2.87e-01 |
| GO:BP | GO:0007605 | sensory perception of sound | 1 | 98 | 2.87e-01 |
| GO:BP | GO:0055012 | ventricular cardiac muscle cell differentiation | 1 | 15 | 2.87e-01 |
| GO:BP | GO:1900544 | positive regulation of purine nucleotide metabolic process | 1 | 16 | 2.87e-01 |
| GO:BP | GO:0018108 | peptidyl-tyrosine phosphorylation | 1 | 256 | 2.89e-01 |
| GO:BP | GO:0007043 | cell-cell junction assembly | 1 | 105 | 2.89e-01 |
| GO:BP | GO:0006066 | alcohol metabolic process | 1 | 265 | 2.90e-01 |
| GO:BP | GO:0018212 | peptidyl-tyrosine modification | 1 | 258 | 2.90e-01 |
| GO:BP | GO:0006760 | folic acid-containing compound metabolic process | 1 | 22 | 2.90e-01 |
| GO:BP | GO:0060047 | heart contraction | 3 | 205 | 2.90e-01 |
| GO:BP | GO:0071108 | protein K48-linked deubiquitination | 1 | 24 | 2.90e-01 |
| GO:BP | GO:0098703 | calcium ion import across plasma membrane | 1 | 23 | 2.90e-01 |
| GO:BP | GO:0099537 | trans-synaptic signaling | 7 | 495 | 2.91e-01 |
| GO:BP | GO:2000146 | negative regulation of cell motility | 1 | 236 | 2.91e-01 |
| GO:BP | GO:0070932 | histone H3 deacetylation | 1 | 12 | 2.93e-01 |
| GO:BP | GO:0006047 | UDP-N-acetylglucosamine metabolic process | 1 | 13 | 2.93e-01 |
| GO:BP | GO:0061430 | bone trabecula morphogenesis | 1 | 12 | 2.93e-01 |
| GO:BP | GO:0106057 | negative regulation of calcineurin-mediated signaling | 1 | 14 | 2.93e-01 |
| GO:BP | GO:0048469 | cell maturation | 1 | 108 | 2.93e-01 |
| GO:BP | GO:0016358 | dendrite development | 5 | 202 | 2.93e-01 |
| GO:BP | GO:0002097 | tRNA wobble base modification | 1 | 19 | 2.93e-01 |
| GO:BP | GO:0046034 | ATP metabolic process | 2 | 116 | 2.93e-01 |
| GO:BP | GO:2000480 | negative regulation of cAMP-dependent protein kinase activity | 1 | 10 | 2.93e-01 |
| GO:BP | GO:1902307 | positive regulation of sodium ion transmembrane transport | 1 | 17 | 2.93e-01 |
| GO:BP | GO:2001053 | regulation of mesenchymal cell apoptotic process | 1 | 5 | 2.93e-01 |
| GO:BP | GO:1903599 | positive regulation of autophagy of mitochondrion | 1 | 13 | 2.93e-01 |
| GO:BP | GO:0070885 | negative regulation of calcineurin-NFAT signaling cascade | 1 | 14 | 2.93e-01 |
| GO:BP | GO:1901524 | regulation of mitophagy | 1 | 13 | 2.93e-01 |
| GO:BP | GO:0007034 | vacuolar transport | 4 | 149 | 2.93e-01 |
| GO:BP | GO:0035751 | regulation of lysosomal lumen pH | 1 | 26 | 2.94e-01 |
| GO:BP | GO:0018105 | peptidyl-serine phosphorylation | 1 | 247 | 2.94e-01 |
| GO:BP | GO:0055075 | potassium ion homeostasis | 1 | 22 | 2.94e-01 |
| GO:BP | GO:0009162 | deoxyribonucleoside monophosphate metabolic process | 1 | 18 | 2.94e-01 |
| GO:BP | GO:0035113 | embryonic appendage morphogenesis | 3 | 89 | 2.94e-01 |
| GO:BP | GO:0030326 | embryonic limb morphogenesis | 3 | 89 | 2.94e-01 |
| GO:BP | GO:0060216 | definitive hemopoiesis | 1 | 18 | 2.94e-01 |
| GO:BP | GO:0031330 | negative regulation of cellular catabolic process | 2 | 165 | 2.95e-01 |
| GO:BP | GO:0071679 | commissural neuron axon guidance | 1 | 11 | 2.95e-01 |
| GO:BP | GO:0043393 | regulation of protein binding | 4 | 172 | 2.96e-01 |
| GO:BP | GO:0035036 | sperm-egg recognition | 1 | 22 | 2.96e-01 |
| GO:BP | GO:0070262 | peptidyl-serine dephosphorylation | 1 | 14 | 2.96e-01 |
| GO:BP | GO:0050806 | positive regulation of synaptic transmission | 4 | 106 | 2.96e-01 |
| GO:BP | GO:0098656 | monoatomic anion transmembrane transport | 3 | 71 | 2.96e-01 |
| GO:BP | GO:0048711 | positive regulation of astrocyte differentiation | 1 | 11 | 2.96e-01 |
| GO:BP | GO:0001764 | neuron migration | 1 | 133 | 2.97e-01 |
| GO:BP | GO:0010665 | regulation of cardiac muscle cell apoptotic process | 1 | 33 | 2.97e-01 |
| GO:BP | GO:0071805 | potassium ion transmembrane transport | 3 | 129 | 2.98e-01 |
| GO:BP | GO:0042733 | embryonic digit morphogenesis | 2 | 51 | 2.98e-01 |
| GO:BP | GO:0009101 | glycoprotein biosynthetic process | 2 | 252 | 2.98e-01 |
| GO:BP | GO:0035020 | regulation of Rac protein signal transduction | 1 | 21 | 2.98e-01 |
| GO:BP | GO:0071731 | response to nitric oxide | 1 | 16 | 2.98e-01 |
| GO:BP | GO:0006907 | pinocytosis | 1 | 18 | 2.98e-01 |
| GO:BP | GO:0002029 | desensitization of G protein-coupled receptor signaling pathway | 1 | 14 | 2.98e-01 |
| GO:BP | GO:0098657 | import into cell | 3 | 166 | 2.99e-01 |
| GO:BP | GO:1901998 | toxin transport | 1 | 37 | 2.99e-01 |
| GO:BP | GO:0032271 | regulation of protein polymerization | 4 | 168 | 3.00e-01 |
| GO:BP | GO:0043173 | nucleotide salvage | 1 | 15 | 3.00e-01 |
| GO:BP | GO:0045861 | negative regulation of proteolysis | 2 | 211 | 3.00e-01 |
| GO:BP | GO:0032823 | regulation of natural killer cell differentiation | 1 | 8 | 3.00e-01 |
| GO:BP | GO:0001821 | histamine secretion | 1 | 9 | 3.00e-01 |
| GO:BP | GO:0061000 | negative regulation of dendritic spine development | 1 | 10 | 3.00e-01 |
| GO:BP | GO:0010941 | regulation of cell death | 2 | 1219 | 3.00e-01 |
| GO:BP | GO:0071496 | cellular response to external stimulus | 1 | 270 | 3.00e-01 |
| GO:BP | GO:0071697 | ectodermal placode morphogenesis | 1 | 10 | 3.00e-01 |
| GO:BP | GO:1904925 | positive regulation of autophagy of mitochondrion in response to mitochondrial depolarization | 1 | 14 | 3.00e-01 |
| GO:BP | GO:0000077 | DNA damage checkpoint signaling | 1 | 121 | 3.00e-01 |
| GO:BP | GO:0048499 | synaptic vesicle membrane organization | 1 | 23 | 3.00e-01 |
| GO:BP | GO:2000241 | regulation of reproductive process | 1 | 128 | 3.00e-01 |
| GO:BP | GO:0031952 | regulation of protein autophosphorylation | 1 | 39 | 3.00e-01 |
| GO:BP | GO:0046348 | amino sugar catabolic process | 1 | 9 | 3.00e-01 |
| GO:BP | GO:0060788 | ectodermal placode formation | 1 | 10 | 3.00e-01 |
| GO:BP | GO:0048025 | negative regulation of mRNA splicing, via spliceosome | 1 | 23 | 3.00e-01 |
| GO:BP | GO:0009208 | pyrimidine ribonucleoside triphosphate metabolic process | 1 | 16 | 3.00e-01 |
| GO:BP | GO:1903051 | negative regulation of proteolysis involved in protein catabolic process | 1 | 61 | 3.00e-01 |
| GO:BP | GO:0060707 | trophoblast giant cell differentiation | 1 | 10 | 3.00e-01 |
| GO:BP | GO:0018209 | peptidyl-serine modification | 1 | 259 | 3.00e-01 |
| GO:BP | GO:1904948 | midbrain dopaminergic neuron differentiation | 1 | 12 | 3.00e-01 |
| GO:BP | GO:0106070 | regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway | 1 | 11 | 3.00e-01 |
| GO:BP | GO:0045605 | negative regulation of epidermal cell differentiation | 1 | 6 | 3.00e-01 |
| GO:BP | GO:0045683 | negative regulation of epidermis development | 1 | 6 | 3.00e-01 |
| GO:BP | GO:0034508 | centromere complex assembly | 1 | 28 | 3.00e-01 |
| GO:BP | GO:1903522 | regulation of blood circulation | 3 | 198 | 3.00e-01 |
| GO:BP | GO:0003205 | cardiac chamber development | 1 | 149 | 3.00e-01 |
| GO:BP | GO:0043558 | regulation of translational initiation in response to stress | 1 | 16 | 3.00e-01 |
| GO:BP | GO:1900102 | negative regulation of endoplasmic reticulum unfolded protein response | 1 | 16 | 3.00e-01 |
| GO:BP | GO:0050954 | sensory perception of mechanical stimulus | 1 | 112 | 3.00e-01 |
| GO:BP | GO:0003015 | heart process | 3 | 216 | 3.00e-01 |
| GO:BP | GO:0031929 | TOR signaling | 1 | 115 | 3.00e-01 |
| GO:BP | GO:0042416 | dopamine biosynthetic process | 1 | 8 | 3.00e-01 |
| GO:BP | GO:0008637 | apoptotic mitochondrial changes | 1 | 90 | 3.00e-01 |
| GO:BP | GO:0008360 | regulation of cell shape | 1 | 126 | 3.00e-01 |
| GO:BP | GO:0006826 | iron ion transport | 2 | 40 | 3.00e-01 |
| GO:BP | GO:0022401 | negative adaptation of signaling pathway | 1 | 15 | 3.00e-01 |
| GO:BP | GO:0051171 | regulation of nitrogen compound metabolic process | 6 | 4292 | 3.01e-01 |
| GO:BP | GO:0040013 | negative regulation of locomotion | 1 | 265 | 3.01e-01 |
| GO:BP | GO:0031345 | negative regulation of cell projection organization | 1 | 156 | 3.01e-01 |
| GO:BP | GO:0031099 | regeneration | 1 | 142 | 3.01e-01 |
| GO:BP | GO:0099536 | synaptic signaling | 7 | 511 | 3.01e-01 |
| GO:BP | GO:0104004 | cellular response to environmental stimulus | 1 | 268 | 3.01e-01 |
| GO:BP | GO:0034605 | cellular response to heat | 2 | 51 | 3.01e-01 |
| GO:BP | GO:0071214 | cellular response to abiotic stimulus | 1 | 268 | 3.01e-01 |
| GO:BP | GO:0051259 | protein complex oligomerization | 3 | 185 | 3.01e-01 |
| GO:BP | GO:0051258 | protein polymerization | 5 | 241 | 3.01e-01 |
| GO:BP | GO:0006355 | regulation of DNA-templated transcription | 4 | 2574 | 3.01e-01 |
| GO:BP | GO:0035303 | regulation of dephosphorylation | 1 | 105 | 3.01e-01 |
| GO:BP | GO:1903506 | regulation of nucleic acid-templated transcription | 4 | 2576 | 3.01e-01 |
| GO:BP | GO:0035372 | protein localization to microtubule | 1 | 18 | 3.01e-01 |
| GO:BP | GO:0032274 | gonadotropin secretion | 1 | 10 | 3.02e-01 |
| GO:BP | GO:0010575 | positive regulation of vascular endothelial growth factor production | 1 | 18 | 3.02e-01 |
| GO:BP | GO:0046649 | lymphocyte activation | 1 | 465 | 3.03e-01 |
| GO:BP | GO:0071695 | anatomical structure maturation | 2 | 48 | 3.03e-01 |
| GO:BP | GO:0010662 | regulation of striated muscle cell apoptotic process | 1 | 36 | 3.03e-01 |
| GO:BP | GO:2000785 | regulation of autophagosome assembly | 1 | 44 | 3.04e-01 |
| GO:BP | GO:0072666 | establishment of protein localization to vacuole | 2 | 55 | 3.04e-01 |
| GO:BP | GO:0070536 | protein K63-linked deubiquitination | 1 | 33 | 3.04e-01 |
| GO:BP | GO:0016236 | macroautophagy | 6 | 308 | 3.04e-01 |
| GO:BP | GO:0042060 | wound healing | 1 | 320 | 3.04e-01 |
| GO:BP | GO:0051125 | regulation of actin nucleation | 1 | 31 | 3.04e-01 |
| GO:BP | GO:0071696 | ectodermal placode development | 1 | 11 | 3.04e-01 |
| GO:BP | GO:0051090 | regulation of DNA-binding transcription factor activity | 1 | 335 | 3.04e-01 |
| GO:BP | GO:1901659 | glycosyl compound biosynthetic process | 1 | 19 | 3.04e-01 |
| GO:BP | GO:1904923 | regulation of autophagy of mitochondrion in response to mitochondrial depolarization | 1 | 15 | 3.04e-01 |
| GO:BP | GO:0031570 | DNA integrity checkpoint signaling | 1 | 129 | 3.04e-01 |
| GO:BP | GO:0043086 | negative regulation of catalytic activity | 2 | 478 | 3.04e-01 |
| GO:BP | GO:0043254 | regulation of protein-containing complex assembly | 7 | 348 | 3.04e-01 |
| GO:BP | GO:0070482 | response to oxygen levels | 3 | 272 | 3.04e-01 |
| GO:BP | GO:2001141 | regulation of RNA biosynthetic process | 4 | 2593 | 3.04e-01 |
| GO:BP | GO:0072210 | metanephric nephron development | 1 | 29 | 3.04e-01 |
| GO:BP | GO:0009725 | response to hormone | 1 | 642 | 3.04e-01 |
| GO:BP | GO:0097152 | mesenchymal cell apoptotic process | 1 | 7 | 3.04e-01 |
| GO:BP | GO:0007190 | activation of adenylate cyclase activity | 1 | 13 | 3.04e-01 |
| GO:BP | GO:0045653 | negative regulation of megakaryocyte differentiation | 1 | 17 | 3.04e-01 |
| GO:BP | GO:0007265 | Ras protein signal transduction | 4 | 294 | 3.04e-01 |
| GO:BP | GO:0043320 | natural killer cell degranulation | 1 | 6 | 3.04e-01 |
| GO:BP | GO:0043312 | neutrophil degranulation | 1 | 5 | 3.04e-01 |
| GO:BP | GO:0061029 | eyelid development in camera-type eye | 1 | 12 | 3.04e-01 |
| GO:BP | GO:0050686 | negative regulation of mRNA processing | 1 | 25 | 3.04e-01 |
| GO:BP | GO:1900034 | regulation of cellular response to heat | 1 | 16 | 3.04e-01 |
| GO:BP | GO:0055086 | nucleobase-containing small molecule metabolic process | 9 | 487 | 3.04e-01 |
| GO:BP | GO:0010659 | cardiac muscle cell apoptotic process | 1 | 36 | 3.04e-01 |
| GO:BP | GO:0048820 | hair follicle maturation | 1 | 15 | 3.04e-01 |
| GO:BP | GO:0046827 | positive regulation of protein export from nucleus | 1 | 15 | 3.04e-01 |
| GO:BP | GO:0003009 | skeletal muscle contraction | 1 | 31 | 3.04e-01 |
| GO:BP | GO:0050793 | regulation of developmental process | 4 | 1835 | 3.04e-01 |
| GO:BP | GO:0043473 | pigmentation | 1 | 92 | 3.04e-01 |
| GO:BP | GO:0043303 | mast cell degranulation | 2 | 30 | 3.05e-01 |
| GO:BP | GO:0016055 | Wnt signaling pathway | 1 | 375 | 3.05e-01 |
| GO:BP | GO:1901880 | negative regulation of protein depolymerization | 2 | 64 | 3.05e-01 |
| GO:BP | GO:0060339 | negative regulation of type I interferon-mediated signaling pathway | 1 | 15 | 3.05e-01 |
| GO:BP | GO:0043066 | negative regulation of apoptotic process | 1 | 660 | 3.05e-01 |
| GO:BP | GO:0098693 | regulation of synaptic vesicle cycle | 1 | 13 | 3.05e-01 |
| GO:BP | GO:1904030 | negative regulation of cyclin-dependent protein kinase activity | 1 | 27 | 3.06e-01 |
| GO:BP | GO:0045736 | negative regulation of cyclin-dependent protein serine/threonine kinase activity | 1 | 27 | 3.06e-01 |
| GO:BP | GO:0198738 | cell-cell signaling by wnt | 1 | 376 | 3.06e-01 |
| GO:BP | GO:0007611 | learning or memory | 5 | 202 | 3.06e-01 |
| GO:BP | GO:0071900 | regulation of protein serine/threonine kinase activity | 1 | 282 | 3.07e-01 |
| GO:BP | GO:1902004 | positive regulation of amyloid-beta formation | 1 | 17 | 3.07e-01 |
| GO:BP | GO:0150078 | positive regulation of neuroinflammatory response | 1 | 4 | 3.07e-01 |
| GO:BP | GO:0023058 | adaptation of signaling pathway | 1 | 16 | 3.07e-01 |
| GO:BP | GO:0014015 | positive regulation of gliogenesis | 2 | 45 | 3.08e-01 |
| GO:BP | GO:0043069 | negative regulation of programmed cell death | 1 | 678 | 3.09e-01 |
| GO:BP | GO:0007006 | mitochondrial membrane organization | 1 | 114 | 3.13e-01 |
| GO:BP | GO:1902305 | regulation of sodium ion transmembrane transport | 2 | 51 | 3.13e-01 |
| GO:BP | GO:0043412 | macromolecule modification | 6 | 3090 | 3.15e-01 |
| GO:BP | GO:0036499 | PERK-mediated unfolded protein response | 1 | 17 | 3.15e-01 |
| GO:BP | GO:0051315 | attachment of mitotic spindle microtubules to kinetochore | 1 | 21 | 3.15e-01 |
| GO:BP | GO:0010975 | regulation of neuron projection development | 7 | 372 | 3.15e-01 |
| GO:BP | GO:2000757 | negative regulation of peptidyl-lysine acetylation | 1 | 13 | 3.16e-01 |
| GO:BP | GO:0031000 | response to caffeine | 1 | 13 | 3.16e-01 |
| GO:BP | GO:0009066 | aspartate family amino acid metabolic process | 1 | 39 | 3.16e-01 |
| GO:BP | GO:0010658 | striated muscle cell apoptotic process | 1 | 39 | 3.16e-01 |
| GO:BP | GO:0002279 | mast cell activation involved in immune response | 2 | 31 | 3.16e-01 |
| GO:BP | GO:0022407 | regulation of cell-cell adhesion | 1 | 295 | 3.16e-01 |
| GO:BP | GO:0045785 | positive regulation of cell adhesion | 1 | 320 | 3.17e-01 |
| GO:BP | GO:0008217 | regulation of blood pressure | 1 | 115 | 3.17e-01 |
| GO:BP | GO:0034244 | negative regulation of transcription elongation by RNA polymerase II | 1 | 17 | 3.17e-01 |
| GO:BP | GO:0097659 | nucleic acid-templated transcription | 4 | 2684 | 3.17e-01 |
| GO:BP | GO:0006351 | DNA-templated transcription | 4 | 2683 | 3.17e-01 |
| GO:BP | GO:0030097 | hemopoiesis | 1 | 656 | 3.17e-01 |
| GO:BP | GO:0042558 | pteridine-containing compound metabolic process | 1 | 28 | 3.18e-01 |
| GO:BP | GO:0043543 | protein acylation | 5 | 228 | 3.18e-01 |
| GO:BP | GO:1990000 | amyloid fibril formation | 1 | 35 | 3.18e-01 |
| GO:BP | GO:0042633 | hair cycle | 3 | 78 | 3.18e-01 |
| GO:BP | GO:0032984 | protein-containing complex disassembly | 4 | 222 | 3.18e-01 |
| GO:BP | GO:0042303 | molting cycle | 3 | 78 | 3.18e-01 |
| GO:BP | GO:0007167 | enzyme-linked receptor protein signaling pathway | 2 | 763 | 3.19e-01 |
| GO:BP | GO:0051168 | nuclear export | 3 | 150 | 3.19e-01 |
| GO:BP | GO:0030011 | maintenance of cell polarity | 1 | 16 | 3.19e-01 |
| GO:BP | GO:0007099 | centriole replication | 1 | 38 | 3.19e-01 |
| GO:BP | GO:0080090 | regulation of primary metabolic process | 6 | 4417 | 3.19e-01 |
| GO:BP | GO:0010574 | regulation of vascular endothelial growth factor production | 1 | 20 | 3.19e-01 |
| GO:BP | GO:0072522 | purine-containing compound biosynthetic process | 3 | 218 | 3.19e-01 |
| GO:BP | GO:1904888 | cranial skeletal system development | 2 | 51 | 3.19e-01 |
| GO:BP | GO:0003417 | growth plate cartilage development | 1 | 15 | 3.19e-01 |
| GO:BP | GO:0044088 | regulation of vacuole organization | 1 | 50 | 3.19e-01 |
| GO:BP | GO:0002448 | mast cell mediated immunity | 2 | 33 | 3.19e-01 |
| GO:BP | GO:0032272 | negative regulation of protein polymerization | 2 | 71 | 3.19e-01 |
| GO:BP | GO:1905897 | regulation of response to endoplasmic reticulum stress | 2 | 76 | 3.19e-01 |
| GO:BP | GO:0007610 | behavior | 10 | 436 | 3.20e-01 |
| GO:BP | GO:0042541 | hemoglobin biosynthetic process | 1 | 13 | 3.21e-01 |
| GO:BP | GO:0031649 | heat generation | 1 | 11 | 3.21e-01 |
| GO:BP | GO:0032774 | RNA biosynthetic process | 4 | 2714 | 3.21e-01 |
| GO:BP | GO:0010508 | positive regulation of autophagy | 3 | 133 | 3.21e-01 |
| GO:BP | GO:0033119 | negative regulation of RNA splicing | 1 | 28 | 3.21e-01 |
| GO:BP | GO:0050790 | regulation of catalytic activity | 2 | 1380 | 3.21e-01 |
| GO:BP | GO:0097475 | motor neuron migration | 1 | 10 | 3.21e-01 |
| GO:BP | GO:1901607 | alpha-amino acid biosynthetic process | 2 | 59 | 3.21e-01 |
| GO:BP | GO:0008285 | negative regulation of cell population proliferation | 3 | 513 | 3.22e-01 |
| GO:BP | GO:0015986 | proton motive force-driven ATP synthesis | 2 | 66 | 3.22e-01 |
| GO:BP | GO:0010822 | positive regulation of mitochondrion organization | 2 | 68 | 3.23e-01 |
| GO:BP | GO:0003198 | epithelial to mesenchymal transition involved in endocardial cushion formation | 1 | 14 | 3.23e-01 |
| GO:BP | GO:0045836 | positive regulation of meiotic nuclear division | 1 | 9 | 3.23e-01 |
| GO:BP | GO:0016239 | positive regulation of macroautophagy | 2 | 70 | 3.23e-01 |
| GO:BP | GO:0060260 | regulation of transcription initiation by RNA polymerase II | 2 | 69 | 3.23e-01 |
| GO:BP | GO:0048167 | regulation of synaptic plasticity | 4 | 141 | 3.23e-01 |
| GO:BP | GO:0002886 | regulation of myeloid leukocyte mediated immunity | 2 | 34 | 3.23e-01 |
| GO:BP | GO:0061919 | process utilizing autophagic mechanism | 9 | 513 | 3.23e-01 |
| GO:BP | GO:0006914 | autophagy | 9 | 513 | 3.23e-01 |
| GO:BP | GO:0003012 | muscle system process | 4 | 334 | 3.23e-01 |
| GO:BP | GO:0009205 | purine ribonucleoside triphosphate metabolic process | 2 | 137 | 3.23e-01 |
| GO:BP | GO:0009893 | positive regulation of metabolic process | 3 | 2880 | 3.24e-01 |
| GO:BP | GO:0045216 | cell-cell junction organization | 1 | 153 | 3.24e-01 |
| GO:BP | GO:0031346 | positive regulation of cell projection organization | 5 | 303 | 3.24e-01 |
| GO:BP | GO:0050849 | negative regulation of calcium-mediated signaling | 1 | 15 | 3.25e-01 |
| GO:BP | GO:0001960 | negative regulation of cytokine-mediated signaling pathway | 2 | 53 | 3.25e-01 |
| GO:BP | GO:0051028 | mRNA transport | 2 | 117 | 3.25e-01 |
| GO:BP | GO:0051608 | histamine transport | 1 | 11 | 3.25e-01 |
| GO:BP | GO:0060548 | negative regulation of cell death | 1 | 756 | 3.25e-01 |
| GO:BP | GO:0000226 | microtubule cytoskeleton organization | 8 | 552 | 3.25e-01 |
| GO:BP | GO:0021756 | striatum development | 1 | 17 | 3.25e-01 |
| GO:BP | GO:0051494 | negative regulation of cytoskeleton organization | 3 | 140 | 3.25e-01 |
| GO:BP | GO:0009226 | nucleotide-sugar biosynthetic process | 1 | 19 | 3.25e-01 |
| GO:BP | GO:0006044 | N-acetylglucosamine metabolic process | 1 | 16 | 3.25e-01 |
| GO:BP | GO:0045321 | leukocyte activation | 1 | 554 | 3.25e-01 |
| GO:BP | GO:0006658 | phosphatidylserine metabolic process | 1 | 21 | 3.25e-01 |
| GO:BP | GO:0035640 | exploration behavior | 1 | 21 | 3.25e-01 |
| GO:BP | GO:0048565 | digestive tract development | 3 | 92 | 3.25e-01 |
| GO:BP | GO:0035590 | purinergic nucleotide receptor signaling pathway | 1 | 16 | 3.26e-01 |
| GO:BP | GO:0032922 | circadian regulation of gene expression | 2 | 63 | 3.26e-01 |
| GO:BP | GO:0055082 | intracellular chemical homeostasis | 5 | 486 | 3.26e-01 |
| GO:BP | GO:0031324 | negative regulation of cellular metabolic process | 4 | 1735 | 3.27e-01 |
| GO:BP | GO:1901018 | positive regulation of potassium ion transmembrane transporter activity | 1 | 20 | 3.27e-01 |
| GO:BP | GO:0019886 | antigen processing and presentation of exogenous peptide antigen via MHC class II | 1 | 15 | 3.27e-01 |
| GO:BP | GO:1902476 | chloride transmembrane transport | 2 | 51 | 3.27e-01 |
| GO:BP | GO:0009220 | pyrimidine ribonucleotide biosynthetic process | 1 | 18 | 3.27e-01 |
| GO:BP | GO:0034250 | positive regulation of amide metabolic process | 3 | 149 | 3.27e-01 |
| GO:BP | GO:0017015 | regulation of transforming growth factor beta receptor signaling pathway | 3 | 128 | 3.27e-01 |
| GO:BP | GO:0048147 | negative regulation of fibroblast proliferation | 1 | 31 | 3.27e-01 |
| GO:BP | GO:0010628 | positive regulation of gene expression | 2 | 783 | 3.27e-01 |
| GO:BP | GO:0009112 | nucleobase metabolic process | 1 | 27 | 3.27e-01 |
| GO:BP | GO:1902904 | negative regulation of supramolecular fiber organization | 3 | 140 | 3.27e-01 |
| GO:BP | GO:0032886 | regulation of microtubule-based process | 4 | 217 | 3.27e-01 |
| GO:BP | GO:0050905 | neuromuscular process | 2 | 107 | 3.27e-01 |
| GO:BP | GO:0048856 | anatomical structure development | 7 | 4128 | 3.28e-01 |
| GO:BP | GO:0006915 | apoptotic process | 2 | 1443 | 3.28e-01 |
| GO:BP | GO:0071548 | response to dexamethasone | 1 | 36 | 3.28e-01 |
| GO:BP | GO:0030003 | intracellular monoatomic cation homeostasis | 4 | 357 | 3.28e-01 |
| GO:BP | GO:0002076 | osteoblast development | 1 | 12 | 3.28e-01 |
| GO:BP | GO:0007017 | microtubule-based process | 11 | 760 | 3.28e-01 |
| GO:BP | GO:0098534 | centriole assembly | 1 | 41 | 3.28e-01 |
| GO:BP | GO:0009144 | purine nucleoside triphosphate metabolic process | 2 | 142 | 3.28e-01 |
| GO:BP | GO:0019934 | cGMP-mediated signaling | 1 | 22 | 3.28e-01 |
| GO:BP | GO:0090075 | relaxation of muscle | 1 | 29 | 3.28e-01 |
| GO:BP | GO:0032092 | positive regulation of protein binding | 2 | 78 | 3.29e-01 |
| GO:BP | GO:2000647 | negative regulation of stem cell proliferation | 1 | 18 | 3.29e-01 |
| GO:BP | GO:0046434 | organophosphate catabolic process | 1 | 113 | 3.31e-01 |
| GO:BP | GO:0021510 | spinal cord development | 1 | 59 | 3.31e-01 |
| GO:BP | GO:0061644 | protein localization to CENP-A containing chromatin | 1 | 17 | 3.31e-01 |
| GO:BP | GO:0010243 | response to organonitrogen compound | 1 | 782 | 3.31e-01 |
| GO:BP | GO:0071470 | cellular response to osmotic stress | 1 | 42 | 3.31e-01 |
| GO:BP | GO:0009988 | cell-cell recognition | 1 | 32 | 3.31e-01 |
| GO:BP | GO:0015914 | phospholipid transport | 2 | 75 | 3.32e-01 |
| GO:BP | GO:1903978 | regulation of microglial cell activation | 1 | 9 | 3.32e-01 |
| GO:BP | GO:0010592 | positive regulation of lamellipodium assembly | 1 | 25 | 3.32e-01 |
| GO:BP | GO:0010573 | vascular endothelial growth factor production | 1 | 23 | 3.33e-01 |
| GO:BP | GO:0015748 | organophosphate ester transport | 3 | 106 | 3.33e-01 |
| GO:BP | GO:0061025 | membrane fusion | 4 | 137 | 3.33e-01 |
| GO:BP | GO:0006213 | pyrimidine nucleoside metabolic process | 1 | 16 | 3.33e-01 |
| GO:BP | GO:0045762 | positive regulation of adenylate cyclase activity | 1 | 19 | 3.33e-01 |
| GO:BP | GO:0001938 | positive regulation of endothelial cell proliferation | 1 | 74 | 3.33e-01 |
| GO:BP | GO:1901888 | regulation of cell junction assembly | 2 | 168 | 3.33e-01 |
| GO:BP | GO:1903844 | regulation of cellular response to transforming growth factor beta stimulus | 3 | 129 | 3.33e-01 |
| GO:BP | GO:0048738 | cardiac muscle tissue development | 1 | 198 | 3.33e-01 |
| GO:BP | GO:0043242 | negative regulation of protein-containing complex disassembly | 2 | 72 | 3.33e-01 |
| GO:BP | GO:0048705 | skeletal system morphogenesis | 4 | 155 | 3.33e-01 |
| GO:BP | GO:0032785 | negative regulation of DNA-templated transcription, elongation | 1 | 20 | 3.36e-01 |
| GO:BP | GO:0006873 | intracellular monoatomic ion homeostasis | 4 | 362 | 3.36e-01 |
| GO:BP | GO:0051571 | positive regulation of histone H3-K4 methylation | 1 | 20 | 3.36e-01 |
| GO:BP | GO:0012501 | programmed cell death | 2 | 1479 | 3.36e-01 |
| GO:BP | GO:0098773 | skin epidermis development | 3 | 87 | 3.36e-01 |
| GO:BP | GO:0050881 | musculoskeletal movement | 1 | 41 | 3.36e-01 |
| GO:BP | GO:0007612 | learning | 3 | 115 | 3.36e-01 |
| GO:BP | GO:0060761 | negative regulation of response to cytokine stimulus | 2 | 57 | 3.36e-01 |
| GO:BP | GO:2000678 | negative regulation of transcription regulatory region DNA binding | 1 | 17 | 3.36e-01 |
| GO:BP | GO:0097094 | craniofacial suture morphogenesis | 1 | 15 | 3.36e-01 |
| GO:BP | GO:0031110 | regulation of microtubule polymerization or depolymerization | 2 | 82 | 3.36e-01 |
| GO:BP | GO:0051252 | regulation of RNA metabolic process | 4 | 2845 | 3.36e-01 |
| GO:BP | GO:0022603 | regulation of anatomical structure morphogenesis | 2 | 691 | 3.38e-01 |
| GO:BP | GO:0009314 | response to radiation | 1 | 352 | 3.38e-01 |
| GO:BP | GO:1901615 | organic hydroxy compound metabolic process | 1 | 376 | 3.38e-01 |
| GO:BP | GO:0017121 | plasma membrane phospholipid scrambling | 1 | 13 | 3.38e-01 |
| GO:BP | GO:0006950 | response to stress | 3 | 2780 | 3.38e-01 |
| GO:BP | GO:0045685 | regulation of glial cell differentiation | 2 | 47 | 3.38e-01 |
| GO:BP | GO:0050795 | regulation of behavior | 2 | 39 | 3.38e-01 |
| GO:BP | GO:0050879 | multicellular organismal movement | 1 | 41 | 3.38e-01 |
| GO:BP | GO:0006302 | double-strand break repair | 2 | 271 | 3.38e-01 |
| GO:BP | GO:1902993 | positive regulation of amyloid precursor protein catabolic process | 1 | 22 | 3.39e-01 |
| GO:BP | GO:0090101 | negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 3 | 124 | 3.41e-01 |
| GO:BP | GO:0010506 | regulation of autophagy | 6 | 313 | 3.41e-01 |
| GO:BP | GO:0032230 | positive regulation of synaptic transmission, GABAergic | 1 | 10 | 3.42e-01 |
| GO:BP | GO:1901698 | response to nitrogen compound | 1 | 830 | 3.43e-01 |
| GO:BP | GO:0010165 | response to X-ray | 1 | 29 | 3.43e-01 |
| GO:BP | GO:1901983 | regulation of protein acetylation | 2 | 69 | 3.43e-01 |
| GO:BP | GO:0016052 | carbohydrate catabolic process | 1 | 120 | 3.43e-01 |
| GO:BP | GO:0006820 | monoatomic anion transport | 3 | 83 | 3.43e-01 |
| GO:BP | GO:1901032 | negative regulation of response to reactive oxygen species | 1 | 13 | 3.45e-01 |
| GO:BP | GO:0009100 | glycoprotein metabolic process | 2 | 316 | 3.45e-01 |
| GO:BP | GO:0051797 | regulation of hair follicle development | 1 | 16 | 3.45e-01 |
| GO:BP | GO:0014706 | striated muscle tissue development | 1 | 210 | 3.45e-01 |
| GO:BP | GO:2001169 | regulation of ATP biosynthetic process | 1 | 17 | 3.45e-01 |
| GO:BP | GO:1903206 | negative regulation of hydrogen peroxide-induced cell death | 1 | 13 | 3.45e-01 |
| GO:BP | GO:0035567 | non-canonical Wnt signaling pathway | 2 | 62 | 3.45e-01 |
| GO:BP | GO:0006730 | one-carbon metabolic process | 1 | 29 | 3.45e-01 |
| GO:BP | GO:0032436 | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 2 | 89 | 3.45e-01 |
| GO:BP | GO:0001775 | cell activation | 1 | 655 | 3.45e-01 |
| GO:BP | GO:0051239 | regulation of multicellular organismal process | 4 | 2035 | 3.45e-01 |
| GO:BP | GO:0034243 | regulation of transcription elongation by RNA polymerase II | 2 | 85 | 3.45e-01 |
| GO:BP | GO:0030855 | epithelial cell differentiation | 10 | 442 | 3.47e-01 |
| GO:BP | GO:0008652 | amino acid biosynthetic process | 2 | 64 | 3.47e-01 |
| GO:BP | GO:0034248 | regulation of amide metabolic process | 6 | 424 | 3.47e-01 |
| GO:BP | GO:0045346 | regulation of MHC class II biosynthetic process | 1 | 11 | 3.47e-01 |
| GO:BP | GO:1900117 | regulation of execution phase of apoptosis | 1 | 13 | 3.47e-01 |
| GO:BP | GO:0043243 | positive regulation of protein-containing complex disassembly | 1 | 30 | 3.47e-01 |
| GO:BP | GO:0043410 | positive regulation of MAPK cascade | 1 | 317 | 3.47e-01 |
| GO:BP | GO:0002495 | antigen processing and presentation of peptide antigen via MHC class II | 1 | 17 | 3.47e-01 |
| GO:BP | GO:0006163 | purine nucleotide metabolic process | 4 | 371 | 3.47e-01 |
| GO:BP | GO:2000142 | regulation of DNA-templated transcription initiation | 2 | 76 | 3.47e-01 |
| GO:BP | GO:0001657 | ureteric bud development | 2 | 75 | 3.47e-01 |
| GO:BP | GO:0061548 | ganglion development | 1 | 12 | 3.47e-01 |
| GO:BP | GO:1903311 | regulation of mRNA metabolic process | 1 | 267 | 3.49e-01 |
| GO:BP | GO:0048608 | reproductive structure development | 1 | 212 | 3.50e-01 |
| GO:BP | GO:0032331 | negative regulation of chondrocyte differentiation | 1 | 18 | 3.50e-01 |
| GO:BP | GO:0072164 | mesonephric tubule development | 2 | 76 | 3.50e-01 |
| GO:BP | GO:0072163 | mesonephric epithelium development | 2 | 76 | 3.50e-01 |
| GO:BP | GO:1903830 | magnesium ion transmembrane transport | 1 | 16 | 3.50e-01 |
| GO:BP | GO:0098780 | response to mitochondrial depolarisation | 1 | 21 | 3.52e-01 |
| GO:BP | GO:0009084 | glutamine family amino acid biosynthetic process | 1 | 16 | 3.52e-01 |
| GO:BP | GO:0061458 | reproductive system development | 1 | 215 | 3.52e-01 |
| GO:BP | GO:1901879 | regulation of protein depolymerization | 2 | 78 | 3.52e-01 |
| GO:BP | GO:0010765 | positive regulation of sodium ion transport | 1 | 30 | 3.53e-01 |
| GO:BP | GO:2000050 | regulation of non-canonical Wnt signaling pathway | 1 | 23 | 3.53e-01 |
| GO:BP | GO:0048598 | embryonic morphogenesis | 1 | 440 | 3.53e-01 |
| GO:BP | GO:0000075 | cell cycle checkpoint signaling | 1 | 183 | 3.53e-01 |
| GO:BP | GO:0035313 | wound healing, spreading of epidermal cells | 1 | 17 | 3.53e-01 |
| GO:BP | GO:0048523 | negative regulation of cellular process | 5 | 3625 | 3.55e-01 |
| GO:BP | GO:0043555 | regulation of translation in response to stress | 1 | 23 | 3.55e-01 |
| GO:BP | GO:0055123 | digestive system development | 3 | 100 | 3.56e-01 |
| GO:BP | GO:0051131 | chaperone-mediated protein complex assembly | 1 | 21 | 3.56e-01 |
| GO:BP | GO:0090263 | positive regulation of canonical Wnt signaling pathway | 2 | 91 | 3.56e-01 |
| GO:BP | GO:0043586 | tongue development | 1 | 15 | 3.56e-01 |
| GO:BP | GO:0045342 | MHC class II biosynthetic process | 1 | 12 | 3.56e-01 |
| GO:BP | GO:0007096 | regulation of exit from mitosis | 1 | 17 | 3.57e-01 |
| GO:BP | GO:0034329 | cell junction assembly | 3 | 344 | 3.57e-01 |
| GO:BP | GO:0043414 | macromolecule methylation | 1 | 272 | 3.57e-01 |
| GO:BP | GO:0009069 | serine family amino acid metabolic process | 1 | 30 | 3.57e-01 |
| GO:BP | GO:0120033 | negative regulation of plasma membrane bounded cell projection assembly | 1 | 28 | 3.58e-01 |
| GO:BP | GO:0003323 | type B pancreatic cell development | 1 | 19 | 3.59e-01 |
| GO:BP | GO:2000479 | regulation of cAMP-dependent protein kinase activity | 1 | 16 | 3.59e-01 |
| GO:BP | GO:0003007 | heart morphogenesis | 1 | 216 | 3.61e-01 |
| GO:BP | GO:0015693 | magnesium ion transport | 1 | 17 | 3.63e-01 |
| GO:BP | GO:0008219 | cell death | 2 | 1596 | 3.63e-01 |
| GO:BP | GO:0070166 | enamel mineralization | 1 | 11 | 3.63e-01 |
| GO:BP | GO:0021700 | developmental maturation | 1 | 211 | 3.64e-01 |
| GO:BP | GO:0001823 | mesonephros development | 2 | 77 | 3.64e-01 |
| GO:BP | GO:0007281 | germ cell development | 1 | 187 | 3.64e-01 |
| GO:BP | GO:0010556 | regulation of macromolecule biosynthetic process | 4 | 3012 | 3.64e-01 |
| GO:BP | GO:1901679 | nucleotide transmembrane transport | 1 | 18 | 3.64e-01 |
| GO:BP | GO:0006357 | regulation of transcription by RNA polymerase II | 3 | 1914 | 3.64e-01 |
| GO:BP | GO:0003018 | vascular process in circulatory system | 1 | 198 | 3.64e-01 |
| GO:BP | GO:0021544 | subpallium development | 1 | 18 | 3.65e-01 |
| GO:BP | GO:0051172 | negative regulation of nitrogen compound metabolic process | 4 | 1849 | 3.65e-01 |
| GO:BP | GO:0010468 | regulation of gene expression | 5 | 3580 | 3.66e-01 |
| GO:BP | GO:0055093 | response to hyperoxia | 1 | 18 | 3.66e-01 |
| GO:BP | GO:0071385 | cellular response to glucocorticoid stimulus | 1 | 40 | 3.66e-01 |
| GO:BP | GO:1901701 | cellular response to oxygen-containing compound | 1 | 893 | 3.66e-01 |
| GO:BP | GO:0009150 | purine ribonucleotide metabolic process | 3 | 295 | 3.66e-01 |
| GO:BP | GO:0006821 | chloride transport | 2 | 58 | 3.66e-01 |
| GO:BP | GO:0019080 | viral gene expression | 2 | 96 | 3.66e-01 |
| GO:BP | GO:0048143 | astrocyte activation | 1 | 12 | 3.67e-01 |
| GO:BP | GO:0006417 | regulation of translation | 4 | 370 | 3.67e-01 |
| GO:BP | GO:0010970 | transport along microtubule | 1 | 162 | 3.68e-01 |
| GO:BP | GO:0031281 | positive regulation of cyclase activity | 1 | 23 | 3.68e-01 |
| GO:BP | GO:0000723 | telomere maintenance | 1 | 142 | 3.68e-01 |
| GO:BP | GO:0045010 | actin nucleation | 1 | 50 | 3.68e-01 |
| GO:BP | GO:0020027 | hemoglobin metabolic process | 1 | 16 | 3.68e-01 |
| GO:BP | GO:0045576 | mast cell activation | 2 | 35 | 3.68e-01 |
| GO:BP | GO:0002504 | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II | 1 | 19 | 3.68e-01 |
| GO:BP | GO:0010155 | regulation of proton transport | 1 | 18 | 3.68e-01 |
| GO:BP | GO:0006575 | cellular modified amino acid metabolic process | 2 | 96 | 3.68e-01 |
| GO:BP | GO:0044249 | cellular biosynthetic process | 5 | 4245 | 3.69e-01 |
| GO:BP | GO:0008033 | tRNA processing | 2 | 128 | 3.69e-01 |
| GO:BP | GO:0046777 | protein autophosphorylation | 2 | 188 | 3.69e-01 |
| GO:BP | GO:0023019 | signal transduction involved in regulation of gene expression | 1 | 14 | 3.70e-01 |
| GO:BP | GO:0060444 | branching involved in mammary gland duct morphogenesis | 1 | 20 | 3.70e-01 |
| GO:BP | GO:0050931 | pigment cell differentiation | 1 | 26 | 3.71e-01 |
| GO:BP | GO:0036503 | ERAD pathway | 1 | 106 | 3.71e-01 |
| GO:BP | GO:1902903 | regulation of supramolecular fiber organization | 5 | 326 | 3.71e-01 |
| GO:BP | GO:0043094 | cellular metabolic compound salvage | 1 | 25 | 3.72e-01 |
| GO:BP | GO:0051349 | positive regulation of lyase activity | 1 | 23 | 3.72e-01 |
| GO:BP | GO:0050688 | regulation of defense response to virus | 2 | 63 | 3.73e-01 |
| GO:BP | GO:0048666 | neuron development | 6 | 877 | 3.73e-01 |
| GO:BP | GO:0090109 | regulation of cell-substrate junction assembly | 1 | 59 | 3.73e-01 |
| GO:BP | GO:0034453 | microtubule anchoring | 1 | 25 | 3.73e-01 |
| GO:BP | GO:0051893 | regulation of focal adhesion assembly | 1 | 59 | 3.73e-01 |
| GO:BP | GO:1902745 | positive regulation of lamellipodium organization | 1 | 32 | 3.73e-01 |
| GO:BP | GO:0042053 | regulation of dopamine metabolic process | 1 | 11 | 3.74e-01 |
| GO:BP | GO:0042069 | regulation of catecholamine metabolic process | 1 | 11 | 3.74e-01 |
| GO:BP | GO:0002283 | neutrophil activation involved in immune response | 1 | 7 | 3.75e-01 |
| GO:BP | GO:0048522 | positive regulation of cellular process | 6 | 4099 | 3.75e-01 |
| GO:BP | GO:0042127 | regulation of cell population proliferation | 5 | 1147 | 3.76e-01 |
| GO:BP | GO:0072665 | protein localization to vacuole | 2 | 72 | 3.77e-01 |
| GO:BP | GO:0006929 | substrate-dependent cell migration | 1 | 24 | 3.77e-01 |
| GO:BP | GO:0050890 | cognition | 5 | 227 | 3.77e-01 |
| GO:BP | GO:0001822 | kidney development | 5 | 244 | 3.77e-01 |
| GO:BP | GO:1901071 | glucosamine-containing compound metabolic process | 1 | 19 | 3.77e-01 |
| GO:BP | GO:0034654 | nucleobase-containing compound biosynthetic process | 4 | 3070 | 3.77e-01 |
| GO:BP | GO:0022604 | regulation of cell morphogenesis | 1 | 220 | 3.78e-01 |
| GO:BP | GO:0019219 | regulation of nucleobase-containing compound metabolic process | 4 | 3080 | 3.78e-01 |
| GO:BP | GO:0002478 | antigen processing and presentation of exogenous peptide antigen | 1 | 24 | 3.78e-01 |
| GO:BP | GO:0036342 | post-anal tail morphogenesis | 1 | 13 | 3.78e-01 |
| GO:BP | GO:0031326 | regulation of cellular biosynthetic process | 4 | 3080 | 3.78e-01 |
| GO:BP | GO:0061912 | selective autophagy | 2 | 90 | 3.79e-01 |
| GO:BP | GO:0005979 | regulation of glycogen biosynthetic process | 1 | 25 | 3.80e-01 |
| GO:BP | GO:1901028 | regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway | 1 | 25 | 3.80e-01 |
| GO:BP | GO:0031116 | positive regulation of microtubule polymerization | 1 | 31 | 3.80e-01 |
| GO:BP | GO:0010962 | regulation of glucan biosynthetic process | 1 | 25 | 3.80e-01 |
| GO:BP | GO:0045724 | positive regulation of cilium assembly | 1 | 25 | 3.80e-01 |
| GO:BP | GO:0001837 | epithelial to mesenchymal transition | 3 | 138 | 3.80e-01 |
| GO:BP | GO:1901137 | carbohydrate derivative biosynthetic process | 9 | 544 | 3.81e-01 |
| GO:BP | GO:0050773 | regulation of dendrite development | 2 | 90 | 3.81e-01 |
| GO:BP | GO:0042391 | regulation of membrane potential | 4 | 293 | 3.81e-01 |
| GO:BP | GO:0035330 | regulation of hippo signaling | 1 | 21 | 3.83e-01 |
| GO:BP | GO:0009713 | catechol-containing compound biosynthetic process | 1 | 11 | 3.83e-01 |
| GO:BP | GO:1903578 | regulation of ATP metabolic process | 1 | 22 | 3.83e-01 |
| GO:BP | GO:0006366 | transcription by RNA polymerase II | 3 | 1995 | 3.83e-01 |
| GO:BP | GO:0042423 | catecholamine biosynthetic process | 1 | 11 | 3.83e-01 |
| GO:BP | GO:0051495 | positive regulation of cytoskeleton organization | 3 | 165 | 3.84e-01 |
| GO:BP | GO:0009218 | pyrimidine ribonucleotide metabolic process | 1 | 25 | 3.84e-01 |
| GO:BP | GO:0003148 | outflow tract septum morphogenesis | 1 | 23 | 3.87e-01 |
| GO:BP | GO:0034755 | iron ion transmembrane transport | 1 | 16 | 3.87e-01 |
| GO:BP | GO:0045664 | regulation of neuron differentiation | 3 | 137 | 3.87e-01 |
| GO:BP | GO:0098661 | inorganic anion transmembrane transport | 2 | 66 | 3.87e-01 |
| GO:BP | GO:1902042 | negative regulation of extrinsic apoptotic signaling pathway via death domain receptors | 1 | 24 | 3.87e-01 |
| GO:BP | GO:0045429 | positive regulation of nitric oxide biosynthetic process | 1 | 26 | 3.88e-01 |
| GO:BP | GO:0010660 | regulation of muscle cell apoptotic process | 1 | 56 | 3.88e-01 |
| GO:BP | GO:0032259 | methylation | 1 | 313 | 3.88e-01 |
| GO:BP | GO:0009259 | ribonucleotide metabolic process | 3 | 311 | 3.88e-01 |
| GO:BP | GO:0060675 | ureteric bud morphogenesis | 1 | 49 | 3.88e-01 |
| GO:BP | GO:0150116 | regulation of cell-substrate junction organization | 1 | 64 | 3.88e-01 |
| GO:BP | GO:0018130 | heterocycle biosynthetic process | 4 | 3132 | 3.88e-01 |
| GO:BP | GO:0010804 | negative regulation of tumor necrosis factor-mediated signaling pathway | 1 | 18 | 3.89e-01 |
| GO:BP | GO:0048863 | stem cell differentiation | 4 | 197 | 3.90e-01 |
| GO:BP | GO:0061037 | negative regulation of cartilage development | 1 | 23 | 3.90e-01 |
| GO:BP | GO:0051016 | barbed-end actin filament capping | 1 | 21 | 3.90e-01 |
| GO:BP | GO:0000184 | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 1 | 39 | 3.90e-01 |
| GO:BP | GO:0010043 | response to zinc ion | 1 | 31 | 3.90e-01 |
| GO:BP | GO:0072171 | mesonephric tubule morphogenesis | 1 | 50 | 3.90e-01 |
| GO:BP | GO:0050657 | nucleic acid transport | 2 | 144 | 3.90e-01 |
| GO:BP | GO:0019438 | aromatic compound biosynthetic process | 4 | 3133 | 3.90e-01 |
| GO:BP | GO:0050658 | RNA transport | 2 | 144 | 3.90e-01 |
| GO:BP | GO:2000765 | regulation of cytoplasmic translation | 1 | 27 | 3.90e-01 |
| GO:BP | GO:1902774 | late endosome to lysosome transport | 1 | 20 | 3.90e-01 |
| GO:BP | GO:0045087 | innate immune response | 1 | 488 | 3.91e-01 |
| GO:BP | GO:0071495 | cellular response to endogenous stimulus | 1 | 1107 | 3.91e-01 |
| GO:BP | GO:2000243 | positive regulation of reproductive process | 2 | 54 | 3.91e-01 |
| GO:BP | GO:1902883 | negative regulation of response to oxidative stress | 1 | 18 | 3.92e-01 |
| GO:BP | GO:0010591 | regulation of lamellipodium assembly | 1 | 33 | 3.92e-01 |
| GO:BP | GO:0051650 | establishment of vesicle localization | 1 | 175 | 3.92e-01 |
| GO:BP | GO:0051146 | striated muscle cell differentiation | 1 | 233 | 3.92e-01 |
| GO:BP | GO:0001666 | response to hypoxia | 2 | 237 | 3.92e-01 |
| GO:BP | GO:0051446 | positive regulation of meiotic cell cycle | 1 | 16 | 3.92e-01 |
| GO:BP | GO:1900273 | positive regulation of long-term synaptic potentiation | 1 | 19 | 3.92e-01 |
| GO:BP | GO:0060343 | trabecula formation | 1 | 23 | 3.92e-01 |
| GO:BP | GO:0051569 | regulation of histone H3-K4 methylation | 1 | 26 | 3.93e-01 |
| GO:BP | GO:0009889 | regulation of biosynthetic process | 4 | 3169 | 3.94e-01 |
| GO:BP | GO:0072001 | renal system development | 5 | 251 | 3.94e-01 |
| GO:BP | GO:0048701 | embryonic cranial skeleton morphogenesis | 1 | 31 | 3.94e-01 |
| GO:BP | GO:0045859 | regulation of protein kinase activity | 1 | 479 | 3.94e-01 |
| GO:BP | GO:0060996 | dendritic spine development | 1 | 80 | 3.94e-01 |
| GO:BP | GO:0009156 | ribonucleoside monophosphate biosynthetic process | 1 | 30 | 3.94e-01 |
| GO:BP | GO:0051236 | establishment of RNA localization | 2 | 147 | 3.95e-01 |
| GO:BP | GO:0048384 | retinoic acid receptor signaling pathway | 1 | 26 | 3.95e-01 |
| GO:BP | GO:0048485 | sympathetic nervous system development | 1 | 14 | 3.95e-01 |
| GO:BP | GO:0001779 | natural killer cell differentiation | 1 | 18 | 3.95e-01 |
| GO:BP | GO:1904407 | positive regulation of nitric oxide metabolic process | 1 | 27 | 3.95e-01 |
| GO:BP | GO:0071880 | adenylate cyclase-activating adrenergic receptor signaling pathway | 1 | 19 | 3.95e-01 |
| GO:BP | GO:0030155 | regulation of cell adhesion | 1 | 539 | 3.95e-01 |
| GO:BP | GO:0019693 | ribose phosphate metabolic process | 3 | 319 | 3.95e-01 |
| GO:BP | GO:0071384 | cellular response to corticosteroid stimulus | 1 | 47 | 3.95e-01 |
| GO:BP | GO:0032784 | regulation of DNA-templated transcription elongation | 2 | 99 | 3.96e-01 |
| GO:BP | GO:0031365 | N-terminal protein amino acid modification | 1 | 28 | 3.96e-01 |
| GO:BP | GO:1902455 | negative regulation of stem cell population maintenance | 1 | 21 | 3.96e-01 |
| GO:BP | GO:0120034 | positive regulation of plasma membrane bounded cell projection assembly | 2 | 94 | 3.96e-01 |
| GO:BP | GO:2000060 | positive regulation of ubiquitin-dependent protein catabolic process | 2 | 103 | 3.96e-01 |
| GO:BP | GO:0007026 | negative regulation of microtubule depolymerization | 1 | 27 | 3.96e-01 |
| GO:BP | GO:0051129 | negative regulation of cellular component organization | 8 | 604 | 3.96e-01 |
| GO:BP | GO:0001936 | regulation of endothelial cell proliferation | 1 | 102 | 3.97e-01 |
| GO:BP | GO:0003382 | epithelial cell morphogenesis | 1 | 24 | 3.97e-01 |
| GO:BP | GO:0051130 | positive regulation of cellular component organization | 13 | 906 | 3.97e-01 |
| GO:BP | GO:0034219 | carbohydrate transmembrane transport | 1 | 92 | 3.97e-01 |
| GO:BP | GO:0006839 | mitochondrial transport | 1 | 185 | 3.97e-01 |
| GO:BP | GO:0007030 | Golgi organization | 2 | 137 | 3.97e-01 |
| GO:BP | GO:1901381 | positive regulation of potassium ion transmembrane transport | 1 | 30 | 3.98e-01 |
| GO:BP | GO:0032200 | telomere organization | 1 | 166 | 3.98e-01 |
| GO:BP | GO:0032781 | positive regulation of ATP-dependent activity | 1 | 40 | 3.98e-01 |
| GO:BP | GO:1900026 | positive regulation of substrate adhesion-dependent cell spreading | 1 | 39 | 3.98e-01 |
| GO:BP | GO:0019725 | cellular homeostasis | 5 | 569 | 3.98e-01 |
| GO:BP | GO:0022008 | neurogenesis | 8 | 1294 | 3.98e-01 |
| GO:BP | GO:0015868 | purine ribonucleotide transport | 1 | 19 | 3.98e-01 |
| GO:BP | GO:0000132 | establishment of mitotic spindle orientation | 1 | 31 | 3.98e-01 |
| GO:BP | GO:0048566 | embryonic digestive tract development | 1 | 20 | 3.98e-01 |
| GO:BP | GO:0010657 | muscle cell apoptotic process | 1 | 60 | 3.98e-01 |
| GO:BP | GO:0031112 | positive regulation of microtubule polymerization or depolymerization | 1 | 35 | 3.98e-01 |
| GO:BP | GO:0030488 | tRNA methylation | 1 | 42 | 3.98e-01 |
| GO:BP | GO:1902115 | regulation of organelle assembly | 3 | 186 | 3.98e-01 |
| GO:BP | GO:0045948 | positive regulation of translational initiation | 1 | 23 | 3.99e-01 |
| GO:BP | GO:1900101 | regulation of endoplasmic reticulum unfolded protein response | 1 | 29 | 3.99e-01 |
| GO:BP | GO:0061726 | mitochondrion disassembly | 2 | 92 | 4.00e-01 |
| GO:BP | GO:0034330 | cell junction organization | 4 | 575 | 4.00e-01 |
| GO:BP | GO:0000422 | autophagy of mitochondrion | 2 | 92 | 4.00e-01 |
| GO:BP | GO:0000959 | mitochondrial RNA metabolic process | 1 | 50 | 4.00e-01 |
| GO:BP | GO:0048714 | positive regulation of oligodendrocyte differentiation | 1 | 13 | 4.00e-01 |
| GO:BP | GO:0032967 | positive regulation of collagen biosynthetic process | 1 | 23 | 4.00e-01 |
| GO:BP | GO:0002028 | regulation of sodium ion transport | 2 | 72 | 4.00e-01 |
| GO:BP | GO:0050729 | positive regulation of inflammatory response | 3 | 75 | 4.00e-01 |
| GO:BP | GO:0006470 | protein dephosphorylation | 1 | 214 | 4.00e-01 |
| GO:BP | GO:0042659 | regulation of cell fate specification | 1 | 23 | 4.00e-01 |
| GO:BP | GO:0043032 | positive regulation of macrophage activation | 1 | 12 | 4.00e-01 |
| GO:BP | GO:0042475 | odontogenesis of dentin-containing tooth | 2 | 55 | 4.00e-01 |
| GO:BP | GO:0015698 | inorganic anion transport | 3 | 104 | 4.00e-01 |
| GO:BP | GO:0016601 | Rac protein signal transduction | 1 | 42 | 4.00e-01 |
| GO:BP | GO:0071218 | cellular response to misfolded protein | 1 | 23 | 4.00e-01 |
| GO:BP | GO:0030705 | cytoskeleton-dependent intracellular transport | 1 | 194 | 4.00e-01 |
| GO:BP | GO:0033555 | multicellular organismal response to stress | 2 | 57 | 4.02e-01 |
| GO:BP | GO:0097186 | amelogenesis | 1 | 14 | 4.02e-01 |
| GO:BP | GO:0003272 | endocardial cushion formation | 1 | 24 | 4.02e-01 |
| GO:BP | GO:0006541 | glutamine metabolic process | 1 | 24 | 4.03e-01 |
| GO:BP | GO:1903205 | regulation of hydrogen peroxide-induced cell death | 1 | 20 | 4.04e-01 |
| GO:BP | GO:1901988 | negative regulation of cell cycle phase transition | 1 | 235 | 4.04e-01 |
| GO:BP | GO:0097107 | postsynaptic density assembly | 1 | 16 | 4.04e-01 |
| GO:BP | GO:0010507 | negative regulation of autophagy | 1 | 74 | 4.04e-01 |
| GO:BP | GO:0008015 | blood circulation | 4 | 374 | 4.04e-01 |
| GO:BP | GO:0072530 | purine-containing compound transmembrane transport | 1 | 20 | 4.04e-01 |
| GO:BP | GO:0006754 | ATP biosynthetic process | 2 | 87 | 4.05e-01 |
| GO:BP | GO:0002227 | innate immune response in mucosa | 1 | 8 | 4.05e-01 |
| GO:BP | GO:1901362 | organic cyclic compound biosynthetic process | 4 | 3237 | 4.05e-01 |
| GO:BP | GO:0051648 | vesicle localization | 1 | 192 | 4.05e-01 |
| GO:BP | GO:0060706 | cell differentiation involved in embryonic placenta development | 1 | 20 | 4.05e-01 |
| GO:BP | GO:0051298 | centrosome duplication | 1 | 68 | 4.05e-01 |
| GO:BP | GO:0003309 | type B pancreatic cell differentiation | 1 | 22 | 4.05e-01 |
| GO:BP | GO:0072078 | nephron tubule morphogenesis | 1 | 57 | 4.05e-01 |
| GO:BP | GO:0046825 | regulation of protein export from nucleus | 1 | 30 | 4.05e-01 |
| GO:BP | GO:0043408 | regulation of MAPK cascade | 1 | 475 | 4.05e-01 |
| GO:BP | GO:0010714 | positive regulation of collagen metabolic process | 1 | 24 | 4.08e-01 |
| GO:BP | GO:0032502 | developmental process | 7 | 4494 | 4.08e-01 |
| GO:BP | GO:0060351 | cartilage development involved in endochondral bone morphogenesis | 1 | 26 | 4.08e-01 |
| GO:BP | GO:0048048 | embryonic eye morphogenesis | 1 | 25 | 4.08e-01 |
| GO:BP | GO:0006622 | protein targeting to lysosome | 1 | 28 | 4.08e-01 |
| GO:BP | GO:0042634 | regulation of hair cycle | 1 | 22 | 4.08e-01 |
| GO:BP | GO:0009060 | aerobic respiration | 3 | 168 | 4.08e-01 |
| GO:BP | GO:0045652 | regulation of megakaryocyte differentiation | 1 | 33 | 4.08e-01 |
| GO:BP | GO:0072583 | clathrin-dependent endocytosis | 1 | 43 | 4.08e-01 |
| GO:BP | GO:0060429 | epithelium development | 2 | 850 | 4.09e-01 |
| GO:BP | GO:1902003 | regulation of amyloid-beta formation | 1 | 33 | 4.09e-01 |
| GO:BP | GO:1902235 | regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway | 1 | 29 | 4.09e-01 |
| GO:BP | GO:0007018 | microtubule-based movement | 2 | 300 | 4.09e-01 |
| GO:BP | GO:0070301 | cellular response to hydrogen peroxide | 2 | 73 | 4.09e-01 |
| GO:BP | GO:0010646 | regulation of cell communication | 4 | 2573 | 4.09e-01 |
| GO:BP | GO:1901576 | organic substance biosynthetic process | 4 | 4539 | 4.10e-01 |
| GO:BP | GO:0072088 | nephron epithelium morphogenesis | 1 | 59 | 4.10e-01 |
| GO:BP | GO:0051173 | positive regulation of nitrogen compound metabolic process | 2 | 2412 | 4.10e-01 |
| GO:BP | GO:0010810 | regulation of cell-substrate adhesion | 3 | 172 | 4.10e-01 |
| GO:BP | GO:0018230 | peptidyl-L-cysteine S-palmitoylation | 1 | 21 | 4.10e-01 |
| GO:BP | GO:0099072 | regulation of postsynaptic membrane neurotransmitter receptor levels | 1 | 70 | 4.10e-01 |
| GO:BP | GO:0018231 | peptidyl-S-diacylglycerol-L-cysteine biosynthetic process from peptidyl-cysteine | 1 | 21 | 4.10e-01 |
| GO:BP | GO:0006259 | DNA metabolic process | 4 | 884 | 4.10e-01 |
| GO:BP | GO:0070873 | regulation of glycogen metabolic process | 1 | 28 | 4.10e-01 |
| GO:BP | GO:0005996 | monosaccharide metabolic process | 2 | 209 | 4.11e-01 |
| GO:BP | GO:0019884 | antigen processing and presentation of exogenous antigen | 1 | 28 | 4.11e-01 |
| GO:BP | GO:1901800 | positive regulation of proteasomal protein catabolic process | 2 | 111 | 4.11e-01 |
| GO:BP | GO:0060349 | bone morphogenesis | 2 | 74 | 4.11e-01 |
| GO:BP | GO:0019538 | protein metabolic process | 7 | 4241 | 4.11e-01 |
| GO:BP | GO:0048520 | positive regulation of behavior | 1 | 13 | 4.13e-01 |
| GO:BP | GO:0036296 | response to increased oxygen levels | 1 | 25 | 4.13e-01 |
| GO:BP | GO:0045761 | regulation of adenylate cyclase activity | 1 | 32 | 4.14e-01 |
| GO:BP | GO:0048519 | negative regulation of biological process | 6 | 4045 | 4.14e-01 |
| GO:BP | GO:0042752 | regulation of circadian rhythm | 2 | 97 | 4.14e-01 |
| GO:BP | GO:0061333 | renal tubule morphogenesis | 1 | 61 | 4.14e-01 |
| GO:BP | GO:0120035 | regulation of plasma membrane bounded cell projection organization | 7 | 529 | 4.14e-01 |
| GO:BP | GO:0043299 | leukocyte degranulation | 2 | 41 | 4.14e-01 |
| GO:BP | GO:0045921 | positive regulation of exocytosis | 2 | 62 | 4.14e-01 |
| GO:BP | GO:0048732 | gland development | 1 | 318 | 4.14e-01 |
| GO:BP | GO:0097191 | extrinsic apoptotic signaling pathway | 1 | 179 | 4.14e-01 |
| GO:BP | GO:0006359 | regulation of transcription by RNA polymerase III | 1 | 30 | 4.14e-01 |
| GO:BP | GO:0022412 | cellular process involved in reproduction in multicellular organism | 1 | 252 | 4.14e-01 |
| GO:BP | GO:0051788 | response to misfolded protein | 1 | 25 | 4.14e-01 |
| GO:BP | GO:0006767 | water-soluble vitamin metabolic process | 1 | 49 | 4.14e-01 |
| GO:BP | GO:0072028 | nephron morphogenesis | 1 | 62 | 4.14e-01 |
| GO:BP | GO:0061448 | connective tissue development | 4 | 208 | 4.14e-01 |
| GO:BP | GO:0050769 | positive regulation of neurogenesis | 4 | 189 | 4.14e-01 |
| GO:BP | GO:0043279 | response to alkaloid | 2 | 68 | 4.14e-01 |
| GO:BP | GO:0032102 | negative regulation of response to external stimulus | 1 | 269 | 4.14e-01 |
| GO:BP | GO:0031329 | regulation of cellular catabolic process | 5 | 555 | 4.14e-01 |
| GO:BP | GO:0001952 | regulation of cell-matrix adhesion | 2 | 97 | 4.14e-01 |
| GO:BP | GO:0032885 | regulation of polysaccharide biosynthetic process | 1 | 31 | 4.14e-01 |
| GO:BP | GO:0031114 | regulation of microtubule depolymerization | 1 | 31 | 4.14e-01 |
| GO:BP | GO:1902600 | proton transmembrane transport | 3 | 111 | 4.15e-01 |
| GO:BP | GO:0009894 | regulation of catabolic process | 10 | 875 | 4.15e-01 |
| GO:BP | GO:0001935 | endothelial cell proliferation | 1 | 116 | 4.15e-01 |
| GO:BP | GO:0009719 | response to endogenous stimulus | 1 | 1278 | 4.15e-01 |
| GO:BP | GO:0009058 | biosynthetic process | 4 | 4590 | 4.15e-01 |
| GO:BP | GO:0120009 | intermembrane lipid transfer | 1 | 43 | 4.16e-01 |
| GO:BP | GO:0048710 | regulation of astrocyte differentiation | 1 | 21 | 4.16e-01 |
| GO:BP | GO:0050878 | regulation of body fluid levels | 1 | 236 | 4.17e-01 |
| GO:BP | GO:0006399 | tRNA metabolic process | 3 | 186 | 4.17e-01 |
| GO:BP | GO:0046627 | negative regulation of insulin receptor signaling pathway | 1 | 29 | 4.17e-01 |
| GO:BP | GO:0061311 | cell surface receptor signaling pathway involved in heart development | 1 | 25 | 4.18e-01 |
| GO:BP | GO:0019068 | virion assembly | 1 | 35 | 4.20e-01 |
| GO:BP | GO:0031175 | neuron projection development | 5 | 780 | 4.20e-01 |
| GO:BP | GO:1900181 | negative regulation of protein localization to nucleus | 1 | 28 | 4.20e-01 |
| GO:BP | GO:0006261 | DNA-templated DNA replication | 1 | 148 | 4.21e-01 |
| GO:BP | GO:0140029 | exocytic process | 2 | 69 | 4.21e-01 |
| GO:BP | GO:0048066 | developmental pigmentation | 1 | 36 | 4.22e-01 |
| GO:BP | GO:0043268 | positive regulation of potassium ion transport | 1 | 36 | 4.22e-01 |
| GO:BP | GO:0071875 | adrenergic receptor signaling pathway | 1 | 24 | 4.22e-01 |
| GO:BP | GO:0006940 | regulation of smooth muscle contraction | 1 | 42 | 4.22e-01 |
| GO:BP | GO:0048041 | focal adhesion assembly | 1 | 81 | 4.22e-01 |
| GO:BP | GO:0045773 | positive regulation of axon extension | 1 | 33 | 4.23e-01 |
| GO:BP | GO:0080134 | regulation of response to stress | 2 | 1075 | 4.24e-01 |
| GO:BP | GO:0040001 | establishment of mitotic spindle localization | 1 | 36 | 4.25e-01 |
| GO:BP | GO:0048709 | oligodendrocyte differentiation | 2 | 68 | 4.25e-01 |
| GO:BP | GO:0008643 | carbohydrate transport | 1 | 111 | 4.25e-01 |
| GO:BP | GO:1901700 | response to oxygen-containing compound | 1 | 1223 | 4.25e-01 |
| GO:BP | GO:0034505 | tooth mineralization | 1 | 17 | 4.25e-01 |
| GO:BP | GO:0035115 | embryonic forelimb morphogenesis | 1 | 17 | 4.25e-01 |
| GO:BP | GO:0044092 | negative regulation of molecular function | 2 | 755 | 4.26e-01 |
| GO:BP | GO:0051503 | adenine nucleotide transport | 1 | 23 | 4.28e-01 |
| GO:BP | GO:0014013 | regulation of gliogenesis | 2 | 68 | 4.29e-01 |
| GO:BP | GO:0006637 | acyl-CoA metabolic process | 1 | 71 | 4.29e-01 |
| GO:BP | GO:0098542 | defense response to other organism | 1 | 608 | 4.29e-01 |
| GO:BP | GO:0035383 | thioester metabolic process | 1 | 71 | 4.29e-01 |
| GO:BP | GO:0043001 | Golgi to plasma membrane protein transport | 1 | 37 | 4.29e-01 |
| GO:BP | GO:0007389 | pattern specification process | 1 | 306 | 4.29e-01 |
| GO:BP | GO:0031344 | regulation of cell projection organization | 7 | 541 | 4.29e-01 |
| GO:BP | GO:0098609 | cell-cell adhesion | 1 | 609 | 4.29e-01 |
| GO:BP | GO:0051294 | establishment of spindle orientation | 1 | 36 | 4.29e-01 |
| GO:BP | GO:0043618 | regulation of transcription from RNA polymerase II promoter in response to stress | 1 | 36 | 4.29e-01 |
| GO:BP | GO:1900077 | negative regulation of cellular response to insulin stimulus | 1 | 31 | 4.29e-01 |
| GO:BP | GO:1905898 | positive regulation of response to endoplasmic reticulum stress | 1 | 34 | 4.29e-01 |
| GO:BP | GO:0006970 | response to osmotic stress | 1 | 67 | 4.29e-01 |
| GO:BP | GO:0030154 | cell differentiation | 5 | 2958 | 4.29e-01 |
| GO:BP | GO:0021953 | central nervous system neuron differentiation | 1 | 108 | 4.30e-01 |
| GO:BP | GO:0032414 | positive regulation of ion transmembrane transporter activity | 2 | 85 | 4.30e-01 |
| GO:BP | GO:0002063 | chondrocyte development | 1 | 24 | 4.30e-01 |
| GO:BP | GO:0009225 | nucleotide-sugar metabolic process | 1 | 35 | 4.30e-01 |
| GO:BP | GO:0060603 | mammary gland duct morphogenesis | 1 | 28 | 4.30e-01 |
| GO:BP | GO:0000165 | MAPK cascade | 1 | 556 | 4.30e-01 |
| GO:BP | GO:0010948 | negative regulation of cell cycle process | 1 | 273 | 4.30e-01 |
| GO:BP | GO:1904646 | cellular response to amyloid-beta | 1 | 29 | 4.30e-01 |
| GO:BP | GO:0035725 | sodium ion transmembrane transport | 2 | 113 | 4.30e-01 |
| GO:BP | GO:0016570 | histone modification | 1 | 433 | 4.30e-01 |
| GO:BP | GO:1901605 | alpha-amino acid metabolic process | 2 | 151 | 4.30e-01 |
| GO:BP | GO:0040020 | regulation of meiotic nuclear division | 1 | 19 | 4.30e-01 |
| GO:BP | GO:0036474 | cell death in response to hydrogen peroxide | 1 | 23 | 4.30e-01 |
| GO:BP | GO:0060317 | cardiac epithelial to mesenchymal transition | 1 | 28 | 4.30e-01 |
| GO:BP | GO:0060338 | regulation of type I interferon-mediated signaling pathway | 1 | 35 | 4.30e-01 |
| GO:BP | GO:0016197 | endosomal transport | 1 | 231 | 4.30e-01 |
| GO:BP | GO:0051261 | protein depolymerization | 2 | 105 | 4.31e-01 |
| GO:BP | GO:0035556 | intracellular signal transduction | 2 | 2065 | 4.31e-01 |
| GO:BP | GO:1902743 | regulation of lamellipodium organization | 1 | 44 | 4.31e-01 |
| GO:BP | GO:0048869 | cellular developmental process | 5 | 2984 | 4.31e-01 |
| GO:BP | GO:0048260 | positive regulation of receptor-mediated endocytosis | 1 | 42 | 4.31e-01 |
| GO:BP | GO:0008608 | attachment of spindle microtubules to kinetochore | 1 | 42 | 4.31e-01 |
| GO:BP | GO:0051493 | regulation of cytoskeleton organization | 6 | 459 | 4.31e-01 |
| GO:BP | GO:0044282 | small molecule catabolic process | 3 | 271 | 4.32e-01 |
| GO:BP | GO:0060255 | regulation of macromolecule metabolic process | 6 | 4617 | 4.32e-01 |
| GO:BP | GO:0009206 | purine ribonucleoside triphosphate biosynthetic process | 2 | 96 | 4.32e-01 |
| GO:BP | GO:0032479 | regulation of type I interferon production | 2 | 76 | 4.32e-01 |
| GO:BP | GO:0032606 | type I interferon production | 2 | 76 | 4.32e-01 |
| GO:BP | GO:2000463 | positive regulation of excitatory postsynaptic potential | 1 | 28 | 4.32e-01 |
| GO:BP | GO:0007212 | dopamine receptor signaling pathway | 1 | 27 | 4.34e-01 |
| GO:BP | GO:0035883 | enteroendocrine cell differentiation | 1 | 24 | 4.34e-01 |
| GO:BP | GO:0006515 | protein quality control for misfolded or incompletely synthesized proteins | 1 | 28 | 4.34e-01 |
| GO:BP | GO:0034470 | ncRNA processing | 4 | 400 | 4.34e-01 |
| GO:BP | GO:0032480 | negative regulation of type I interferon production | 1 | 23 | 4.34e-01 |
| GO:BP | GO:0097352 | autophagosome maturation | 1 | 55 | 4.35e-01 |
| GO:BP | GO:0009145 | purine nucleoside triphosphate biosynthetic process | 2 | 97 | 4.35e-01 |
| GO:BP | GO:0090092 | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 4 | 230 | 4.35e-01 |
| GO:BP | GO:1902991 | regulation of amyloid precursor protein catabolic process | 1 | 39 | 4.35e-01 |
| GO:BP | GO:0001656 | metanephros development | 1 | 64 | 4.35e-01 |
| GO:BP | GO:0001975 | response to amphetamine | 1 | 22 | 4.36e-01 |
| GO:BP | GO:0019233 | sensory perception of pain | 2 | 48 | 4.37e-01 |
| GO:BP | GO:0015865 | purine nucleotide transport | 1 | 23 | 4.37e-01 |
| GO:BP | GO:0032970 | regulation of actin filament-based process | 1 | 340 | 4.37e-01 |
| GO:BP | GO:0051443 | positive regulation of ubiquitin-protein transferase activity | 1 | 31 | 4.38e-01 |
| GO:BP | GO:0060537 | muscle tissue development | 1 | 343 | 4.38e-01 |
| GO:BP | GO:0070884 | regulation of calcineurin-NFAT signaling cascade | 1 | 32 | 4.40e-01 |
| GO:BP | GO:0018107 | peptidyl-threonine phosphorylation | 2 | 97 | 4.41e-01 |
| GO:BP | GO:0002052 | positive regulation of neuroblast proliferation | 1 | 19 | 4.41e-01 |
| GO:BP | GO:0150077 | regulation of neuroinflammatory response | 1 | 13 | 4.41e-01 |
| GO:BP | GO:0045428 | regulation of nitric oxide biosynthetic process | 1 | 38 | 4.43e-01 |
| GO:BP | GO:0120036 | plasma membrane bounded cell projection organization | 3 | 1201 | 4.43e-01 |
| GO:BP | GO:0007044 | cell-substrate junction assembly | 1 | 91 | 4.44e-01 |
| GO:BP | GO:0000398 | mRNA splicing, via spliceosome | 2 | 289 | 4.44e-01 |
| GO:BP | GO:0000377 | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 2 | 289 | 4.44e-01 |
| GO:BP | GO:0002183 | cytoplasmic translational initiation | 1 | 38 | 4.45e-01 |
| GO:BP | GO:2000058 | regulation of ubiquitin-dependent protein catabolic process | 3 | 160 | 4.45e-01 |
| GO:BP | GO:2001235 | positive regulation of apoptotic signaling pathway | 2 | 108 | 4.45e-01 |
| GO:BP | GO:0000375 | RNA splicing, via transesterification reactions | 2 | 293 | 4.45e-01 |
| GO:BP | GO:0032881 | regulation of polysaccharide metabolic process | 1 | 34 | 4.45e-01 |
| GO:BP | GO:0034205 | amyloid-beta formation | 1 | 41 | 4.45e-01 |
| GO:BP | GO:0106056 | regulation of calcineurin-mediated signaling | 1 | 32 | 4.45e-01 |
| GO:BP | GO:0048468 | cell development | 3 | 1963 | 4.45e-01 |
| GO:BP | GO:0042692 | muscle cell differentiation | 1 | 324 | 4.45e-01 |
| GO:BP | GO:0031279 | regulation of cyclase activity | 1 | 37 | 4.46e-01 |
| GO:BP | GO:0000045 | autophagosome assembly | 1 | 103 | 4.46e-01 |
| GO:BP | GO:0000041 | transition metal ion transport | 2 | 71 | 4.46e-01 |
| GO:BP | GO:0009451 | RNA modification | 2 | 162 | 4.47e-01 |
| GO:BP | GO:0001825 | blastocyst formation | 1 | 37 | 4.48e-01 |
| GO:BP | GO:0051346 | negative regulation of hydrolase activity | 1 | 220 | 4.48e-01 |
| GO:BP | GO:0010458 | exit from mitosis | 1 | 30 | 4.48e-01 |
| GO:BP | GO:0090505 | epiboly involved in wound healing | 1 | 30 | 4.48e-01 |
| GO:BP | GO:0090305 | nucleic acid phosphodiester bond hydrolysis | 1 | 211 | 4.48e-01 |
| GO:BP | GO:0044319 | wound healing, spreading of cells | 1 | 30 | 4.48e-01 |
| GO:BP | GO:1903829 | positive regulation of protein localization | 1 | 386 | 4.48e-01 |
| GO:BP | GO:0032722 | positive regulation of chemokine production | 1 | 32 | 4.48e-01 |
| GO:BP | GO:0071310 | cellular response to organic substance | 1 | 1399 | 4.49e-01 |
| GO:BP | GO:0140467 | integrated stress response signaling | 1 | 35 | 4.49e-01 |
| GO:BP | GO:0051963 | regulation of synapse assembly | 1 | 83 | 4.49e-01 |
| GO:BP | GO:0031532 | actin cytoskeleton reorganization | 1 | 96 | 4.49e-01 |
| GO:BP | GO:0048512 | circadian behavior | 1 | 30 | 4.49e-01 |
| GO:BP | GO:0000281 | mitotic cytokinesis | 1 | 81 | 4.49e-01 |
| GO:BP | GO:0016192 | vesicle-mediated transport | 4 | 1238 | 4.49e-01 |
| GO:BP | GO:0018022 | peptidyl-lysine methylation | 2 | 104 | 4.49e-01 |
| GO:BP | GO:0070979 | protein K11-linked ubiquitination | 1 | 29 | 4.49e-01 |
| GO:BP | GO:0098662 | inorganic cation transmembrane transport | 11 | 517 | 4.50e-01 |
| GO:BP | GO:0006403 | RNA localization | 2 | 182 | 4.50e-01 |
| GO:BP | GO:1903146 | regulation of autophagy of mitochondrion | 1 | 37 | 4.51e-01 |
| GO:BP | GO:0000423 | mitophagy | 1 | 37 | 4.51e-01 |
| GO:BP | GO:0060993 | kidney morphogenesis | 1 | 73 | 4.51e-01 |
| GO:BP | GO:0098698 | postsynaptic specialization assembly | 1 | 23 | 4.51e-01 |
| GO:BP | GO:0010604 | positive regulation of macromolecule metabolic process | 2 | 2646 | 4.52e-01 |
| GO:BP | GO:0001893 | maternal placenta development | 1 | 28 | 4.53e-01 |
| GO:BP | GO:0042755 | eating behavior | 1 | 16 | 4.53e-01 |
| GO:BP | GO:0080164 | regulation of nitric oxide metabolic process | 1 | 40 | 4.53e-01 |
| GO:BP | GO:0090504 | epiboly | 1 | 31 | 4.53e-01 |
| GO:BP | GO:0018023 | peptidyl-lysine trimethylation | 1 | 33 | 4.53e-01 |
| GO:BP | GO:0030030 | cell projection organization | 3 | 1233 | 4.53e-01 |
| GO:BP | GO:0051339 | regulation of lyase activity | 1 | 39 | 4.53e-01 |
| GO:BP | GO:0009408 | response to heat | 2 | 84 | 4.53e-01 |
| GO:BP | GO:0006497 | protein lipidation | 2 | 89 | 4.55e-01 |
| GO:BP | GO:0051216 | cartilage development | 3 | 151 | 4.56e-01 |
| GO:BP | GO:1900024 | regulation of substrate adhesion-dependent cell spreading | 1 | 54 | 4.57e-01 |
| GO:BP | GO:1901031 | regulation of response to reactive oxygen species | 1 | 28 | 4.57e-01 |
| GO:BP | GO:0007417 | central nervous system development | 1 | 792 | 4.57e-01 |
| GO:BP | GO:0120039 | plasma membrane bounded cell projection morphogenesis | 3 | 527 | 4.57e-01 |
| GO:BP | GO:0031062 | positive regulation of histone methylation | 1 | 36 | 4.57e-01 |
| GO:BP | GO:0150115 | cell-substrate junction organization | 1 | 98 | 4.57e-01 |
| GO:BP | GO:0043620 | regulation of DNA-templated transcription in response to stress | 1 | 41 | 4.59e-01 |
| GO:BP | GO:0007622 | rhythmic behavior | 1 | 32 | 4.59e-01 |
| GO:BP | GO:0045616 | regulation of keratinocyte differentiation | 1 | 25 | 4.59e-01 |
| GO:BP | GO:1905037 | autophagosome organization | 1 | 110 | 4.59e-01 |
| GO:BP | GO:0009250 | glucan biosynthetic process | 1 | 39 | 4.59e-01 |
| GO:BP | GO:0005978 | glycogen biosynthetic process | 1 | 39 | 4.59e-01 |
| GO:BP | GO:0045055 | regulated exocytosis | 2 | 155 | 4.60e-01 |
| GO:BP | GO:0098660 | inorganic ion transmembrane transport | 12 | 563 | 4.60e-01 |
| GO:BP | GO:1903052 | positive regulation of proteolysis involved in protein catabolic process | 2 | 127 | 4.60e-01 |
| GO:BP | GO:0032411 | positive regulation of transporter activity | 2 | 93 | 4.60e-01 |
| GO:BP | GO:0000381 | regulation of alternative mRNA splicing, via spliceosome | 1 | 53 | 4.61e-01 |
| GO:BP | GO:0048858 | cell projection morphogenesis | 3 | 531 | 4.61e-01 |
| GO:BP | GO:0071897 | DNA biosynthetic process | 1 | 175 | 4.61e-01 |
| GO:BP | GO:0006040 | amino sugar metabolic process | 1 | 33 | 4.61e-01 |
| GO:BP | GO:0009605 | response to external stimulus | 2 | 1719 | 4.62e-01 |
| GO:BP | GO:0061564 | axon development | 1 | 398 | 4.63e-01 |
| GO:BP | GO:0046578 | regulation of Ras protein signal transduction | 2 | 166 | 4.63e-01 |
| GO:BP | GO:0030101 | natural killer cell activation | 2 | 42 | 4.63e-01 |
| GO:BP | GO:0048002 | antigen processing and presentation of peptide antigen | 1 | 41 | 4.63e-01 |
| GO:BP | GO:0051693 | actin filament capping | 1 | 34 | 4.63e-01 |
| GO:BP | GO:1901016 | regulation of potassium ion transmembrane transporter activity | 1 | 45 | 4.63e-01 |
| GO:BP | GO:0032728 | positive regulation of interferon-beta production | 1 | 29 | 4.64e-01 |
| GO:BP | GO:0033173 | calcineurin-NFAT signaling cascade | 1 | 37 | 4.64e-01 |
| GO:BP | GO:0030513 | positive regulation of BMP signaling pathway | 1 | 34 | 4.64e-01 |
| GO:BP | GO:0006414 | translational elongation | 1 | 65 | 4.64e-01 |
| GO:BP | GO:1901890 | positive regulation of cell junction assembly | 1 | 82 | 4.65e-01 |
| GO:BP | GO:0045332 | phospholipid translocation | 1 | 33 | 4.66e-01 |
| GO:BP | GO:0051726 | regulation of cell cycle | 2 | 956 | 4.66e-01 |
| GO:BP | GO:0032965 | regulation of collagen biosynthetic process | 1 | 30 | 4.67e-01 |
| GO:BP | GO:0032434 | regulation of proteasomal ubiquitin-dependent protein catabolic process | 2 | 133 | 4.68e-01 |
| GO:BP | GO:0009790 | embryo development | 1 | 875 | 4.68e-01 |
| GO:BP | GO:0006520 | amino acid metabolic process | 4 | 222 | 4.68e-01 |
| GO:BP | GO:0001662 | behavioral fear response | 1 | 29 | 4.68e-01 |
| GO:BP | GO:0002385 | mucosal immune response | 1 | 11 | 4.68e-01 |
| GO:BP | GO:0007264 | small GTPase mediated signal transduction | 4 | 421 | 4.68e-01 |
| GO:BP | GO:0060828 | regulation of canonical Wnt signaling pathway | 3 | 213 | 4.68e-01 |
| GO:BP | GO:0030521 | androgen receptor signaling pathway | 1 | 39 | 4.70e-01 |
| GO:BP | GO:0033238 | regulation of amine metabolic process | 1 | 19 | 4.70e-01 |
| GO:BP | GO:0071392 | cellular response to estradiol stimulus | 1 | 26 | 4.70e-01 |
| GO:BP | GO:0018210 | peptidyl-threonine modification | 2 | 104 | 4.70e-01 |
| GO:BP | GO:0008283 | cell population proliferation | 5 | 1378 | 4.72e-01 |
| GO:BP | GO:0048518 | positive regulation of biological process | 6 | 4579 | 4.72e-01 |
| GO:BP | GO:0006862 | nucleotide transport | 1 | 28 | 4.72e-01 |
| GO:BP | GO:0008380 | RNA splicing | 2 | 419 | 4.72e-01 |
| GO:BP | GO:0007338 | single fertilization | 1 | 70 | 4.72e-01 |
| GO:BP | GO:0048813 | dendrite morphogenesis | 2 | 120 | 4.73e-01 |
| GO:BP | GO:0002275 | myeloid cell activation involved in immune response | 2 | 48 | 4.73e-01 |
| GO:BP | GO:0009059 | macromolecule biosynthetic process | 4 | 3730 | 4.73e-01 |
| GO:BP | GO:0045727 | positive regulation of translation | 2 | 126 | 4.73e-01 |
| GO:BP | GO:0045494 | photoreceptor cell maintenance | 1 | 27 | 4.73e-01 |
| GO:BP | GO:0007617 | mating behavior | 1 | 21 | 4.73e-01 |
| GO:BP | GO:0140353 | lipid export from cell | 1 | 28 | 4.73e-01 |
| GO:BP | GO:0042158 | lipoprotein biosynthetic process | 2 | 92 | 4.73e-01 |
| GO:BP | GO:0002209 | behavioral defense response | 1 | 30 | 4.73e-01 |
| GO:BP | GO:0030833 | regulation of actin filament polymerization | 2 | 110 | 4.73e-01 |
| GO:BP | GO:0071407 | cellular response to organic cyclic compound | 7 | 414 | 4.73e-01 |
| GO:BP | GO:1904645 | response to amyloid-beta | 1 | 32 | 4.73e-01 |
| GO:BP | GO:0032990 | cell part morphogenesis | 3 | 551 | 4.73e-01 |
| GO:BP | GO:0099504 | synaptic vesicle cycle | 2 | 163 | 4.73e-01 |
| GO:BP | GO:0050679 | positive regulation of epithelial cell proliferation | 1 | 155 | 4.73e-01 |
| GO:BP | GO:0003203 | endocardial cushion morphogenesis | 1 | 36 | 4.74e-01 |
| GO:BP | GO:0009966 | regulation of signal transduction | 2 | 2285 | 4.75e-01 |
| GO:BP | GO:0048278 | vesicle docking | 1 | 57 | 4.75e-01 |
| GO:BP | GO:0006418 | tRNA aminoacylation for protein translation | 1 | 40 | 4.75e-01 |
| GO:BP | GO:0007179 | transforming growth factor beta receptor signaling pathway | 3 | 179 | 4.76e-01 |
| GO:BP | GO:0007613 | memory | 1 | 92 | 4.76e-01 |
| GO:BP | GO:0034032 | purine nucleoside bisphosphate metabolic process | 1 | 92 | 4.76e-01 |
| GO:BP | GO:0000122 | negative regulation of transcription by RNA polymerase II | 1 | 740 | 4.76e-01 |
| GO:BP | GO:1904861 | excitatory synapse assembly | 1 | 26 | 4.76e-01 |
| GO:BP | GO:0043603 | amide metabolic process | 1 | 993 | 4.76e-01 |
| GO:BP | GO:0033865 | nucleoside bisphosphate metabolic process | 1 | 92 | 4.76e-01 |
| GO:BP | GO:0000902 | cell morphogenesis | 4 | 761 | 4.76e-01 |
| GO:BP | GO:1902041 | regulation of extrinsic apoptotic signaling pathway via death domain receptors | 1 | 40 | 4.76e-01 |
| GO:BP | GO:1901135 | carbohydrate derivative metabolic process | 3 | 843 | 4.76e-01 |
| GO:BP | GO:0031113 | regulation of microtubule polymerization | 1 | 52 | 4.76e-01 |
| GO:BP | GO:0098876 | vesicle-mediated transport to the plasma membrane | 2 | 143 | 4.76e-01 |
| GO:BP | GO:0097720 | calcineurin-mediated signaling | 1 | 38 | 4.76e-01 |
| GO:BP | GO:0033875 | ribonucleoside bisphosphate metabolic process | 1 | 92 | 4.76e-01 |
| GO:BP | GO:0051707 | response to other organism | 1 | 820 | 4.77e-01 |
| GO:BP | GO:0043207 | response to external biotic stimulus | 1 | 820 | 4.77e-01 |
| GO:BP | GO:0009260 | ribonucleotide biosynthetic process | 3 | 191 | 4.78e-01 |
| GO:BP | GO:0050435 | amyloid-beta metabolic process | 1 | 48 | 4.78e-01 |
| GO:BP | GO:0015980 | energy derivation by oxidation of organic compounds | 4 | 288 | 4.78e-01 |
| GO:BP | GO:0014002 | astrocyte development | 1 | 27 | 4.78e-01 |
| GO:BP | GO:0003013 | circulatory system process | 4 | 447 | 4.78e-01 |
| GO:BP | GO:0006397 | mRNA processing | 2 | 450 | 4.79e-01 |
| GO:BP | GO:0044271 | cellular nitrogen compound biosynthetic process | 4 | 3750 | 4.80e-01 |
| GO:BP | GO:0045786 | negative regulation of cell cycle | 1 | 338 | 4.80e-01 |
| GO:BP | GO:0030835 | negative regulation of actin filament depolymerization | 1 | 37 | 4.80e-01 |
| GO:BP | GO:0044089 | positive regulation of cellular component biogenesis | 6 | 420 | 4.80e-01 |
| GO:BP | GO:0010453 | regulation of cell fate commitment | 1 | 26 | 4.82e-01 |
| GO:BP | GO:0051101 | regulation of DNA binding | 2 | 104 | 4.82e-01 |
| GO:BP | GO:0022411 | cellular component disassembly | 6 | 427 | 4.82e-01 |
| GO:BP | GO:0007009 | plasma membrane organization | 2 | 116 | 4.82e-01 |
| GO:BP | GO:0009607 | response to biotic stimulus | 1 | 850 | 4.83e-01 |
| GO:BP | GO:1902533 | positive regulation of intracellular signal transduction | 1 | 726 | 4.83e-01 |
| GO:BP | GO:0120031 | plasma membrane bounded cell projection assembly | 6 | 461 | 4.84e-01 |
| GO:BP | GO:0098655 | monoatomic cation transmembrane transport | 11 | 540 | 4.84e-01 |
| GO:BP | GO:0042462 | eye photoreceptor cell development | 1 | 19 | 4.87e-01 |
| GO:BP | GO:0042073 | intraciliary transport | 1 | 46 | 4.87e-01 |
| GO:BP | GO:0002323 | natural killer cell activation involved in immune response | 1 | 6 | 4.87e-01 |
| GO:BP | GO:0002251 | organ or tissue specific immune response | 1 | 13 | 4.88e-01 |
| GO:BP | GO:0034204 | lipid translocation | 1 | 38 | 4.88e-01 |
| GO:BP | GO:0007019 | microtubule depolymerization | 1 | 43 | 4.88e-01 |
| GO:BP | GO:0071459 | protein localization to chromosome, centromeric region | 1 | 42 | 4.88e-01 |
| GO:BP | GO:0006888 | endoplasmic reticulum to Golgi vesicle-mediated transport | 1 | 119 | 4.90e-01 |
| GO:BP | GO:0007080 | mitotic metaphase plate congression | 1 | 55 | 4.90e-01 |
| GO:BP | GO:0051293 | establishment of spindle localization | 1 | 48 | 4.90e-01 |
| GO:BP | GO:0032228 | regulation of synaptic transmission, GABAergic | 1 | 23 | 4.91e-01 |
| GO:BP | GO:0009116 | nucleoside metabolic process | 1 | 42 | 4.91e-01 |
| GO:BP | GO:0031018 | endocrine pancreas development | 1 | 32 | 4.91e-01 |
| GO:BP | GO:0015931 | nucleobase-containing compound transport | 2 | 194 | 4.91e-01 |
| GO:BP | GO:0035329 | hippo signaling | 1 | 41 | 4.91e-01 |
| GO:BP | GO:0050766 | positive regulation of phagocytosis | 1 | 38 | 4.92e-01 |
| GO:BP | GO:0006809 | nitric oxide biosynthetic process | 1 | 51 | 4.92e-01 |
| GO:BP | GO:0043462 | regulation of ATP-dependent activity | 1 | 63 | 4.92e-01 |
| GO:BP | GO:0032814 | regulation of natural killer cell activation | 1 | 20 | 4.92e-01 |
| GO:BP | GO:0045333 | cellular respiration | 2 | 211 | 4.92e-01 |
| GO:BP | GO:0046390 | ribose phosphate biosynthetic process | 3 | 197 | 4.93e-01 |
| GO:BP | GO:2000378 | negative regulation of reactive oxygen species metabolic process | 1 | 34 | 4.93e-01 |
| GO:BP | GO:0007623 | circadian rhythm | 3 | 165 | 4.93e-01 |
| GO:BP | GO:0042401 | biogenic amine biosynthetic process | 1 | 24 | 4.93e-01 |
| GO:BP | GO:0010712 | regulation of collagen metabolic process | 1 | 34 | 4.94e-01 |
| GO:BP | GO:0060627 | regulation of vesicle-mediated transport | 4 | 403 | 4.94e-01 |
| GO:BP | GO:0043039 | tRNA aminoacylation | 1 | 43 | 4.94e-01 |
| GO:BP | GO:0045912 | negative regulation of carbohydrate metabolic process | 1 | 38 | 4.94e-01 |
| GO:BP | GO:0048488 | synaptic vesicle endocytosis | 1 | 63 | 4.94e-01 |
| GO:BP | GO:0019935 | cyclic-nucleotide-mediated signaling | 1 | 55 | 4.94e-01 |
| GO:BP | GO:0010927 | cellular component assembly involved in morphogenesis | 2 | 106 | 4.94e-01 |
| GO:BP | GO:0042987 | amyloid precursor protein catabolic process | 1 | 53 | 4.95e-01 |
| GO:BP | GO:0048145 | regulation of fibroblast proliferation | 1 | 77 | 4.95e-01 |
| GO:BP | GO:0034976 | response to endoplasmic reticulum stress | 3 | 234 | 4.95e-01 |
| GO:BP | GO:0006364 | rRNA processing | 2 | 221 | 4.95e-01 |
| GO:BP | GO:0046395 | carboxylic acid catabolic process | 2 | 187 | 4.95e-01 |
| GO:BP | GO:0045598 | regulation of fat cell differentiation | 2 | 102 | 4.95e-01 |
| GO:BP | GO:1901655 | cellular response to ketone | 1 | 86 | 4.95e-01 |
| GO:BP | GO:0016054 | organic acid catabolic process | 2 | 187 | 4.95e-01 |
| GO:BP | GO:0010498 | proteasomal protein catabolic process | 7 | 486 | 4.95e-01 |
| GO:BP | GO:0030031 | cell projection assembly | 6 | 469 | 4.97e-01 |
| GO:BP | GO:0045737 | positive regulation of cyclin-dependent protein serine/threonine kinase activity | 1 | 23 | 4.97e-01 |
| GO:BP | GO:0009309 | amine biosynthetic process | 1 | 25 | 4.98e-01 |
| GO:BP | GO:0048013 | ephrin receptor signaling pathway | 1 | 41 | 4.99e-01 |
| GO:BP | GO:0002446 | neutrophil mediated immunity | 1 | 17 | 4.99e-01 |
| GO:BP | GO:0043038 | amino acid activation | 1 | 44 | 4.99e-01 |
| GO:BP | GO:0016079 | synaptic vesicle exocytosis | 1 | 74 | 4.99e-01 |
| GO:BP | GO:0010976 | positive regulation of neuron projection development | 2 | 131 | 4.99e-01 |
| GO:BP | GO:0120163 | negative regulation of cold-induced thermogenesis | 1 | 40 | 5.00e-01 |
| GO:BP | GO:0140238 | presynaptic endocytosis | 1 | 65 | 5.00e-01 |
| GO:BP | GO:0008277 | regulation of G protein-coupled receptor signaling pathway | 2 | 94 | 5.01e-01 |
| GO:BP | GO:0030010 | establishment of cell polarity | 2 | 134 | 5.02e-01 |
| GO:BP | GO:0044419 | biological process involved in interspecies interaction between organisms | 1 | 963 | 5.03e-01 |
| GO:BP | GO:0071456 | cellular response to hypoxia | 1 | 123 | 5.03e-01 |
| GO:BP | GO:0002244 | hematopoietic progenitor cell differentiation | 1 | 109 | 5.03e-01 |
| GO:BP | GO:0019222 | regulation of metabolic process | 6 | 5017 | 5.03e-01 |
| GO:BP | GO:0048854 | brain morphogenesis | 1 | 28 | 5.03e-01 |
| GO:BP | GO:0048713 | regulation of oligodendrocyte differentiation | 1 | 25 | 5.04e-01 |
| GO:BP | GO:0032968 | positive regulation of transcription elongation by RNA polymerase II | 1 | 49 | 5.05e-01 |
| GO:BP | GO:0001774 | microglial cell activation | 1 | 19 | 5.05e-01 |
| GO:BP | GO:0021762 | substantia nigra development | 1 | 41 | 5.05e-01 |
| GO:BP | GO:0009161 | ribonucleoside monophosphate metabolic process | 1 | 50 | 5.06e-01 |
| GO:BP | GO:0065008 | regulation of biological quality | 18 | 2102 | 5.06e-01 |
| GO:BP | GO:0016266 | O-glycan processing | 1 | 30 | 5.06e-01 |
| GO:BP | GO:0097035 | regulation of membrane lipid distribution | 1 | 43 | 5.07e-01 |
| GO:BP | GO:0050770 | regulation of axonogenesis | 2 | 139 | 5.07e-01 |
| GO:BP | GO:0030182 | neuron differentiation | 6 | 1061 | 5.07e-01 |
| GO:BP | GO:1901987 | regulation of cell cycle phase transition | 1 | 391 | 5.07e-01 |
| GO:BP | GO:0006164 | purine nucleotide biosynthetic process | 2 | 209 | 5.07e-01 |
| GO:BP | GO:0060986 | endocrine hormone secretion | 1 | 35 | 5.07e-01 |
| GO:BP | GO:0051653 | spindle localization | 1 | 52 | 5.08e-01 |
| GO:BP | GO:0060443 | mammary gland morphogenesis | 1 | 39 | 5.09e-01 |
| GO:BP | GO:0046209 | nitric oxide metabolic process | 1 | 55 | 5.09e-01 |
| GO:BP | GO:0019098 | reproductive behavior | 1 | 26 | 5.09e-01 |
| GO:BP | GO:0050691 | regulation of defense response to virus by host | 1 | 30 | 5.09e-01 |
| GO:BP | GO:0042552 | myelination | 1 | 111 | 5.09e-01 |
| GO:BP | GO:0090287 | regulation of cellular response to growth factor stimulus | 4 | 265 | 5.09e-01 |
| GO:BP | GO:0061383 | trabecula morphogenesis | 1 | 43 | 5.09e-01 |
| GO:BP | GO:0003341 | cilium movement | 1 | 97 | 5.09e-01 |
| GO:BP | GO:0042417 | dopamine metabolic process | 1 | 23 | 5.09e-01 |
| GO:BP | GO:0099003 | vesicle-mediated transport in synapse | 2 | 180 | 5.11e-01 |
| GO:BP | GO:0006952 | defense response | 1 | 944 | 5.11e-01 |
| GO:BP | GO:0008366 | axon ensheathment | 1 | 113 | 5.11e-01 |
| GO:BP | GO:0006119 | oxidative phosphorylation | 2 | 122 | 5.11e-01 |
| GO:BP | GO:0032642 | regulation of chemokine production | 1 | 46 | 5.11e-01 |
| GO:BP | GO:0051656 | establishment of organelle localization | 4 | 378 | 5.11e-01 |
| GO:BP | GO:0007272 | ensheathment of neurons | 1 | 113 | 5.11e-01 |
| GO:BP | GO:0032602 | chemokine production | 1 | 46 | 5.11e-01 |
| GO:BP | GO:0061640 | cytoskeleton-dependent cytokinesis | 1 | 104 | 5.11e-01 |
| GO:BP | GO:0022402 | cell cycle process | 2 | 1086 | 5.11e-01 |
| GO:BP | GO:2001057 | reactive nitrogen species metabolic process | 1 | 56 | 5.11e-01 |
| GO:BP | GO:0051640 | organelle localization | 5 | 503 | 5.12e-01 |
| GO:BP | GO:0002444 | myeloid leukocyte mediated immunity | 2 | 60 | 5.12e-01 |
| GO:BP | GO:0030857 | negative regulation of epithelial cell differentiation | 1 | 31 | 5.13e-01 |
| GO:BP | GO:0097106 | postsynaptic density organization | 1 | 30 | 5.13e-01 |
| GO:BP | GO:2000273 | positive regulation of signaling receptor activity | 1 | 33 | 5.13e-01 |
| GO:BP | GO:0051962 | positive regulation of nervous system development | 4 | 221 | 5.14e-01 |
| GO:BP | GO:0048016 | inositol phosphate-mediated signaling | 1 | 45 | 5.14e-01 |
| GO:BP | GO:0036294 | cellular response to decreased oxygen levels | 1 | 131 | 5.14e-01 |
| GO:BP | GO:0051603 | proteolysis involved in protein catabolic process | 10 | 706 | 5.15e-01 |
| GO:BP | GO:0009628 | response to abiotic stimulus | 1 | 868 | 5.15e-01 |
| GO:BP | GO:1903170 | negative regulation of calcium ion transmembrane transport | 1 | 35 | 5.15e-01 |
| GO:BP | GO:0000380 | alternative mRNA splicing, via spliceosome | 1 | 70 | 5.17e-01 |
| GO:BP | GO:0048589 | developmental growth | 7 | 522 | 5.17e-01 |
| GO:BP | GO:1904036 | negative regulation of epithelial cell apoptotic process | 1 | 43 | 5.18e-01 |
| GO:BP | GO:0070887 | cellular response to chemical stimulus | 1 | 1869 | 5.18e-01 |
| GO:BP | GO:0060612 | adipose tissue development | 1 | 41 | 5.18e-01 |
| GO:BP | GO:0008064 | regulation of actin polymerization or depolymerization | 2 | 126 | 5.18e-01 |
| GO:BP | GO:0099068 | postsynapse assembly | 1 | 32 | 5.18e-01 |
| GO:BP | GO:0010605 | negative regulation of macromolecule metabolic process | 2 | 2135 | 5.18e-01 |
| GO:BP | GO:0007507 | heart development | 1 | 506 | 5.18e-01 |
| GO:BP | GO:0007267 | cell-cell signaling | 2 | 1138 | 5.18e-01 |
| GO:BP | GO:0030834 | regulation of actin filament depolymerization | 1 | 45 | 5.18e-01 |
| GO:BP | GO:0002269 | leukocyte activation involved in inflammatory response | 1 | 21 | 5.18e-01 |
| GO:BP | GO:0090596 | sensory organ morphogenesis | 4 | 178 | 5.18e-01 |
| GO:BP | GO:1902459 | positive regulation of stem cell population maintenance | 1 | 44 | 5.18e-01 |
| GO:BP | GO:0060350 | endochondral bone morphogenesis | 1 | 47 | 5.18e-01 |
| GO:BP | GO:0032964 | collagen biosynthetic process | 1 | 39 | 5.18e-01 |
| GO:BP | GO:0032755 | positive regulation of interleukin-6 production | 1 | 56 | 5.19e-01 |
| GO:BP | GO:0009566 | fertilization | 1 | 93 | 5.19e-01 |
| GO:BP | GO:0032467 | positive regulation of cytokinesis | 1 | 33 | 5.19e-01 |
| GO:BP | GO:0033043 | regulation of organelle organization | 12 | 1028 | 5.19e-01 |
| GO:BP | GO:0008306 | associative learning | 1 | 65 | 5.19e-01 |
| GO:BP | GO:0060976 | coronary vasculature development | 1 | 44 | 5.20e-01 |
| GO:BP | GO:0035967 | cellular response to topologically incorrect protein | 2 | 111 | 5.20e-01 |
| GO:BP | GO:0030219 | megakaryocyte differentiation | 1 | 54 | 5.20e-01 |
| GO:BP | GO:0071241 | cellular response to inorganic substance | 2 | 164 | 5.22e-01 |
| GO:BP | GO:0061462 | protein localization to lysosome | 1 | 46 | 5.22e-01 |
| GO:BP | GO:0042542 | response to hydrogen peroxide | 2 | 103 | 5.22e-01 |
| GO:BP | GO:0014075 | response to amine | 1 | 34 | 5.22e-01 |
| GO:BP | GO:0031060 | regulation of histone methylation | 1 | 47 | 5.22e-01 |
| GO:BP | GO:0071333 | cellular response to glucose stimulus | 1 | 93 | 5.23e-01 |
| GO:BP | GO:0030832 | regulation of actin filament length | 2 | 127 | 5.23e-01 |
| GO:BP | GO:0061951 | establishment of protein localization to plasma membrane | 1 | 59 | 5.24e-01 |
| GO:BP | GO:0048878 | chemical homeostasis | 5 | 676 | 5.24e-01 |
| GO:BP | GO:0007005 | mitochondrion organization | 2 | 500 | 5.24e-01 |
| GO:BP | GO:0036465 | synaptic vesicle recycling | 1 | 73 | 5.24e-01 |
| GO:BP | GO:0016071 | mRNA metabolic process | 2 | 665 | 5.25e-01 |
| GO:BP | GO:2000677 | regulation of transcription regulatory region DNA binding | 1 | 43 | 5.25e-01 |
| GO:BP | GO:0003197 | endocardial cushion development | 1 | 46 | 5.25e-01 |
| GO:BP | GO:0023051 | regulation of signaling | 2 | 2565 | 5.25e-01 |
| GO:BP | GO:0006611 | protein export from nucleus | 1 | 55 | 5.25e-01 |
| GO:BP | GO:0071331 | cellular response to hexose stimulus | 1 | 94 | 5.25e-01 |
| GO:BP | GO:0042476 | odontogenesis | 2 | 86 | 5.25e-01 |
| GO:BP | GO:0010033 | response to organic substance | 1 | 1957 | 5.25e-01 |
| GO:BP | GO:0042119 | neutrophil activation | 1 | 16 | 5.25e-01 |
| GO:BP | GO:1904064 | positive regulation of cation transmembrane transport | 2 | 99 | 5.25e-01 |
| GO:BP | GO:0030178 | negative regulation of Wnt signaling pathway | 2 | 140 | 5.26e-01 |
| GO:BP | GO:0044782 | cilium organization | 5 | 313 | 5.26e-01 |
| GO:BP | GO:0035094 | response to nicotine | 1 | 28 | 5.26e-01 |
| GO:BP | GO:0140056 | organelle localization by membrane tethering | 1 | 74 | 5.27e-01 |
| GO:BP | GO:0010647 | positive regulation of cell communication | 2 | 1255 | 5.28e-01 |
| GO:BP | GO:0034655 | nucleobase-containing compound catabolic process | 1 | 358 | 5.28e-01 |
| GO:BP | GO:0046824 | positive regulation of nucleocytoplasmic transport | 1 | 51 | 5.28e-01 |
| GO:BP | GO:0071326 | cellular response to monosaccharide stimulus | 1 | 95 | 5.28e-01 |
| GO:BP | GO:0031640 | killing of cells of another organism | 1 | 10 | 5.28e-01 |
| GO:BP | GO:2001244 | positive regulation of intrinsic apoptotic signaling pathway | 1 | 52 | 5.29e-01 |
| GO:BP | GO:0001885 | endothelial cell development | 1 | 53 | 5.29e-01 |
| GO:BP | GO:1903008 | organelle disassembly | 2 | 137 | 5.30e-01 |
| GO:BP | GO:0030162 | regulation of proteolysis | 2 | 535 | 5.30e-01 |
| GO:BP | GO:0007276 | gamete generation | 1 | 461 | 5.31e-01 |
| GO:BP | GO:0044093 | positive regulation of molecular function | 1 | 1149 | 5.31e-01 |
| GO:BP | GO:0031146 | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process | 1 | 47 | 5.31e-01 |
| GO:BP | GO:1990830 | cellular response to leukemia inhibitory factor | 1 | 84 | 5.31e-01 |
| GO:BP | GO:0000271 | polysaccharide biosynthetic process | 1 | 53 | 5.32e-01 |
| GO:BP | GO:0007155 | cell adhesion | 1 | 1012 | 5.33e-01 |
| GO:BP | GO:0048144 | fibroblast proliferation | 1 | 92 | 5.33e-01 |
| GO:BP | GO:0010803 | regulation of tumor necrosis factor-mediated signaling pathway | 1 | 41 | 5.33e-01 |
| GO:BP | GO:0051602 | response to electrical stimulus | 1 | 26 | 5.34e-01 |
| GO:BP | GO:1902692 | regulation of neuroblast proliferation | 1 | 28 | 5.34e-01 |
| GO:BP | GO:1990823 | response to leukemia inhibitory factor | 1 | 85 | 5.34e-01 |
| GO:BP | GO:0010821 | regulation of mitochondrion organization | 2 | 135 | 5.34e-01 |
| GO:BP | GO:0061900 | glial cell activation | 1 | 23 | 5.35e-01 |
| GO:BP | GO:0046470 | phosphatidylcholine metabolic process | 1 | 53 | 5.37e-01 |
| GO:BP | GO:0006383 | transcription by RNA polymerase III | 1 | 54 | 5.37e-01 |
| GO:BP | GO:0006260 | DNA replication | 1 | 255 | 5.37e-01 |
| GO:BP | GO:0071453 | cellular response to oxygen levels | 1 | 144 | 5.37e-01 |
| GO:BP | GO:0065004 | protein-DNA complex assembly | 3 | 185 | 5.37e-01 |
| GO:BP | GO:0030042 | actin filament depolymerization | 1 | 50 | 5.37e-01 |
| GO:BP | GO:0071168 | protein localization to chromatin | 1 | 48 | 5.38e-01 |
| GO:BP | GO:0032989 | cellular component morphogenesis | 3 | 639 | 5.38e-01 |
| GO:BP | GO:0046189 | phenol-containing compound biosynthetic process | 1 | 28 | 5.40e-01 |
| GO:BP | GO:1903202 | negative regulation of oxidative stress-induced cell death | 1 | 40 | 5.40e-01 |
| GO:BP | GO:0051310 | metaphase plate congression | 1 | 69 | 5.40e-01 |
| GO:BP | GO:0048704 | embryonic skeletal system morphogenesis | 1 | 55 | 5.40e-01 |
| GO:BP | GO:0030041 | actin filament polymerization | 2 | 134 | 5.40e-01 |
| GO:BP | GO:1901379 | regulation of potassium ion transmembrane transport | 1 | 64 | 5.40e-01 |
| GO:BP | GO:0072348 | sulfur compound transport | 1 | 39 | 5.40e-01 |
| GO:BP | GO:0014065 | phosphatidylinositol 3-kinase signaling | 1 | 100 | 5.41e-01 |
| GO:BP | GO:0070059 | intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress | 1 | 56 | 5.41e-01 |
| GO:BP | GO:0048699 | generation of neurons | 6 | 1119 | 5.42e-01 |
| GO:BP | GO:0009892 | negative regulation of metabolic process | 2 | 2293 | 5.43e-01 |
| GO:BP | GO:0016070 | RNA metabolic process | 5 | 3600 | 5.45e-01 |
| GO:BP | GO:0099084 | postsynaptic specialization organization | 1 | 36 | 5.45e-01 |
| GO:BP | GO:0032786 | positive regulation of DNA-templated transcription, elongation | 1 | 58 | 5.46e-01 |
| GO:BP | GO:0051099 | positive regulation of binding | 2 | 150 | 5.47e-01 |
| GO:BP | GO:0006939 | smooth muscle contraction | 1 | 75 | 5.47e-01 |
| GO:BP | GO:0006814 | sodium ion transport | 2 | 160 | 5.47e-01 |
| GO:BP | GO:0007165 | signal transduction | 3 | 3818 | 5.47e-01 |
| GO:BP | GO:0007189 | adenylate cyclase-activating G protein-coupled receptor signaling pathway | 2 | 78 | 5.47e-01 |
| GO:BP | GO:0001959 | regulation of cytokine-mediated signaling pathway | 2 | 117 | 5.48e-01 |
| GO:BP | GO:0006766 | vitamin metabolic process | 1 | 73 | 5.49e-01 |
| GO:BP | GO:0045892 | negative regulation of DNA-templated transcription | 1 | 1015 | 5.50e-01 |
| GO:BP | GO:1903507 | negative regulation of nucleic acid-templated transcription | 1 | 1017 | 5.50e-01 |
| GO:BP | GO:0008037 | cell recognition | 1 | 87 | 5.50e-01 |
| GO:BP | GO:0071322 | cellular response to carbohydrate stimulus | 1 | 105 | 5.50e-01 |
| GO:BP | GO:0010718 | positive regulation of epithelial to mesenchymal transition | 1 | 48 | 5.51e-01 |
| GO:BP | GO:1903312 | negative regulation of mRNA metabolic process | 1 | 81 | 5.51e-01 |
| GO:BP | GO:0048483 | autonomic nervous system development | 1 | 28 | 5.51e-01 |
| GO:BP | GO:0044270 | cellular nitrogen compound catabolic process | 1 | 378 | 5.52e-01 |
| GO:BP | GO:0048762 | mesenchymal cell differentiation | 3 | 204 | 5.52e-01 |
| GO:BP | GO:0072132 | mesenchyme morphogenesis | 1 | 50 | 5.53e-01 |
| GO:BP | GO:0016072 | rRNA metabolic process | 2 | 258 | 5.53e-01 |
| GO:BP | GO:1902679 | negative regulation of RNA biosynthetic process | 1 | 1026 | 5.53e-01 |
| GO:BP | GO:0046700 | heterocycle catabolic process | 1 | 381 | 5.53e-01 |
| GO:BP | GO:0001754 | eye photoreceptor cell differentiation | 1 | 30 | 5.53e-01 |
| GO:BP | GO:0007049 | cell cycle | 3 | 1529 | 5.54e-01 |
| GO:BP | GO:0060261 | positive regulation of transcription initiation by RNA polymerase II | 1 | 59 | 5.54e-01 |
| GO:BP | GO:0051384 | response to glucocorticoid | 1 | 93 | 5.54e-01 |
| GO:BP | GO:0001510 | RNA methylation | 1 | 87 | 5.54e-01 |
| GO:BP | GO:0015850 | organic hydroxy compound transport | 1 | 174 | 5.55e-01 |
| GO:BP | GO:0002011 | morphogenesis of an epithelial sheet | 1 | 52 | 5.56e-01 |
| GO:BP | GO:0045604 | regulation of epidermal cell differentiation | 1 | 39 | 5.56e-01 |
| GO:BP | GO:0042147 | retrograde transport, endosome to Golgi | 1 | 88 | 5.56e-01 |
| GO:BP | GO:0022406 | membrane docking | 1 | 84 | 5.56e-01 |
| GO:BP | GO:0042982 | amyloid precursor protein metabolic process | 1 | 69 | 5.56e-01 |
| GO:BP | GO:0001678 | intracellular glucose homeostasis | 1 | 110 | 5.56e-01 |
| GO:BP | GO:0045824 | negative regulation of innate immune response | 1 | 53 | 5.57e-01 |
| GO:BP | GO:0050808 | synapse organization | 2 | 365 | 5.57e-01 |
| GO:BP | GO:0042461 | photoreceptor cell development | 1 | 30 | 5.57e-01 |
| GO:BP | GO:0051568 | histone H3-K4 methylation | 1 | 57 | 5.58e-01 |
| GO:BP | GO:0043030 | regulation of macrophage activation | 1 | 31 | 5.58e-01 |
| GO:BP | GO:0006997 | nucleus organization | 2 | 126 | 5.59e-01 |
| GO:BP | GO:0036230 | granulocyte activation | 1 | 19 | 5.59e-01 |
| GO:BP | GO:0038034 | signal transduction in absence of ligand | 1 | 52 | 5.59e-01 |
| GO:BP | GO:0097192 | extrinsic apoptotic signaling pathway in absence of ligand | 1 | 52 | 5.59e-01 |
| GO:BP | GO:0051438 | regulation of ubiquitin-protein transferase activity | 1 | 55 | 5.60e-01 |
| GO:BP | GO:0046626 | regulation of insulin receptor signaling pathway | 1 | 53 | 5.60e-01 |
| GO:BP | GO:1900076 | regulation of cellular response to insulin stimulus | 1 | 56 | 5.60e-01 |
| GO:BP | GO:0030837 | negative regulation of actin filament polymerization | 1 | 57 | 5.60e-01 |
| GO:BP | GO:0043547 | positive regulation of GTPase activity | 3 | 222 | 5.60e-01 |
| GO:BP | GO:0019439 | aromatic compound catabolic process | 1 | 387 | 5.62e-01 |
| GO:BP | GO:0071466 | cellular response to xenobiotic stimulus | 1 | 105 | 5.63e-01 |
| GO:BP | GO:0061512 | protein localization to cilium | 1 | 61 | 5.63e-01 |
| GO:BP | GO:0060337 | type I interferon-mediated signaling pathway | 1 | 51 | 5.64e-01 |
| GO:BP | GO:0006338 | chromatin remodeling | 1 | 378 | 5.64e-01 |
| GO:BP | GO:0051785 | positive regulation of nuclear division | 1 | 38 | 5.65e-01 |
| GO:BP | GO:0097553 | calcium ion transmembrane import into cytosol | 1 | 115 | 5.65e-01 |
| GO:BP | GO:1901564 | organonitrogen compound metabolic process | 8 | 4955 | 5.65e-01 |
| GO:BP | GO:0032481 | positive regulation of type I interferon production | 1 | 45 | 5.67e-01 |
| GO:BP | GO:2000026 | regulation of multicellular organismal development | 1 | 1014 | 5.67e-01 |
| GO:BP | GO:0044770 | cell cycle phase transition | 1 | 504 | 5.68e-01 |
| GO:BP | GO:0048609 | multicellular organismal reproductive process | 1 | 538 | 5.69e-01 |
| GO:BP | GO:0061061 | muscle structure development | 1 | 546 | 5.70e-01 |
| GO:BP | GO:0043588 | skin development | 4 | 175 | 5.71e-01 |
| GO:BP | GO:0050764 | regulation of phagocytosis | 1 | 57 | 5.71e-01 |
| GO:BP | GO:0071357 | cellular response to type I interferon | 1 | 52 | 5.72e-01 |
| GO:BP | GO:0035904 | aorta development | 1 | 50 | 5.72e-01 |
| GO:BP | GO:0035265 | organ growth | 2 | 131 | 5.72e-01 |
| GO:BP | GO:0007010 | cytoskeleton organization | 6 | 1226 | 5.73e-01 |
| GO:BP | GO:1901657 | glycosyl compound metabolic process | 1 | 62 | 5.73e-01 |
| GO:BP | GO:0034220 | monoatomic ion transmembrane transport | 12 | 632 | 5.75e-01 |
| GO:BP | GO:0051253 | negative regulation of RNA metabolic process | 1 | 1119 | 5.76e-01 |
| GO:BP | GO:1903305 | regulation of regulated secretory pathway | 2 | 89 | 5.76e-01 |
| GO:BP | GO:0060135 | maternal process involved in female pregnancy | 1 | 41 | 5.77e-01 |
| GO:BP | GO:0060759 | regulation of response to cytokine stimulus | 2 | 126 | 5.77e-01 |
| GO:BP | GO:1901566 | organonitrogen compound biosynthetic process | 1 | 1484 | 5.77e-01 |
| GO:BP | GO:2001259 | positive regulation of cation channel activity | 1 | 49 | 5.77e-01 |
| GO:BP | GO:0060071 | Wnt signaling pathway, planar cell polarity pathway | 1 | 51 | 5.77e-01 |
| GO:BP | GO:0005977 | glycogen metabolic process | 1 | 64 | 5.79e-01 |
| GO:BP | GO:0007416 | synapse assembly | 1 | 152 | 5.79e-01 |
| GO:BP | GO:0051445 | regulation of meiotic cell cycle | 1 | 45 | 5.79e-01 |
| GO:BP | GO:0009755 | hormone-mediated signaling pathway | 2 | 139 | 5.79e-01 |
| GO:BP | GO:0045665 | negative regulation of neuron differentiation | 1 | 43 | 5.79e-01 |
| GO:BP | GO:2000144 | positive regulation of DNA-templated transcription initiation | 1 | 65 | 5.79e-01 |
| GO:BP | GO:2001257 | regulation of cation channel activity | 2 | 100 | 5.79e-01 |
| GO:BP | GO:0034614 | cellular response to reactive oxygen species | 2 | 121 | 5.79e-01 |
| GO:BP | GO:1901361 | organic cyclic compound catabolic process | 1 | 406 | 5.80e-01 |
| GO:BP | GO:0071824 | protein-DNA complex subunit organization | 3 | 204 | 5.80e-01 |
| GO:BP | GO:0051303 | establishment of chromosome localization | 1 | 75 | 5.80e-01 |
| GO:BP | GO:0045862 | positive regulation of proteolysis | 4 | 295 | 5.81e-01 |
| GO:BP | GO:0042776 | proton motive force-driven mitochondrial ATP synthesis | 1 | 57 | 5.81e-01 |
| GO:BP | GO:0043266 | regulation of potassium ion transport | 1 | 73 | 5.81e-01 |
| GO:BP | GO:0032504 | multicellular organism reproduction | 1 | 556 | 5.82e-01 |
| GO:BP | GO:0044042 | glucan metabolic process | 1 | 64 | 5.82e-01 |
| GO:BP | GO:0034767 | positive regulation of monoatomic ion transmembrane transport | 2 | 114 | 5.82e-01 |
| GO:BP | GO:0019731 | antibacterial humoral response | 1 | 15 | 5.82e-01 |
| GO:BP | GO:0051926 | negative regulation of calcium ion transport | 1 | 45 | 5.84e-01 |
| GO:BP | GO:0051123 | RNA polymerase II preinitiation complex assembly | 1 | 54 | 5.87e-01 |
| GO:BP | GO:0019882 | antigen processing and presentation | 1 | 69 | 5.87e-01 |
| GO:BP | GO:0045682 | regulation of epidermis development | 1 | 45 | 5.87e-01 |
| GO:BP | GO:0071560 | cellular response to transforming growth factor beta stimulus | 3 | 222 | 5.88e-01 |
| GO:BP | GO:2000756 | regulation of peptidyl-lysine acetylation | 1 | 57 | 5.88e-01 |
| GO:BP | GO:0044281 | small molecule metabolic process | 1 | 1389 | 5.89e-01 |
| GO:BP | GO:0099643 | signal release from synapse | 1 | 104 | 5.89e-01 |
| GO:BP | GO:0007269 | neurotransmitter secretion | 1 | 104 | 5.89e-01 |
| GO:BP | GO:0090630 | activation of GTPase activity | 1 | 99 | 5.89e-01 |
| GO:BP | GO:0050772 | positive regulation of axonogenesis | 1 | 72 | 5.90e-01 |
| GO:BP | GO:0009888 | tissue development | 2 | 1425 | 5.90e-01 |
| GO:BP | GO:0016485 | protein processing | 1 | 183 | 5.91e-01 |
| GO:BP | GO:0006584 | catecholamine metabolic process | 1 | 30 | 5.91e-01 |
| GO:BP | GO:0042157 | lipoprotein metabolic process | 2 | 116 | 5.91e-01 |
| GO:BP | GO:0009712 | catechol-containing compound metabolic process | 1 | 30 | 5.91e-01 |
| GO:BP | GO:0120032 | regulation of plasma membrane bounded cell projection assembly | 2 | 165 | 5.91e-01 |
| GO:BP | GO:2000179 | positive regulation of neural precursor cell proliferation | 1 | 34 | 5.91e-01 |
| GO:BP | GO:0034340 | response to type I interferon | 1 | 57 | 5.91e-01 |
| GO:BP | GO:0032880 | regulation of protein localization | 1 | 710 | 5.91e-01 |
| GO:BP | GO:1904062 | regulation of monoatomic cation transmembrane transport | 4 | 230 | 5.91e-01 |
| GO:BP | GO:0003006 | developmental process involved in reproduction | 1 | 598 | 5.91e-01 |
| GO:BP | GO:0048638 | regulation of developmental growth | 3 | 258 | 5.92e-01 |
| GO:BP | GO:0048015 | phosphatidylinositol-mediated signaling | 1 | 123 | 5.92e-01 |
| GO:BP | GO:0009967 | positive regulation of signal transduction | 1 | 1133 | 5.92e-01 |
| GO:BP | GO:0010558 | negative regulation of macromolecule biosynthetic process | 1 | 1214 | 5.94e-01 |
| GO:BP | GO:0045669 | positive regulation of osteoblast differentiation | 1 | 54 | 5.94e-01 |
| GO:BP | GO:0030968 | endoplasmic reticulum unfolded protein response | 1 | 70 | 5.94e-01 |
| GO:BP | GO:0060491 | regulation of cell projection assembly | 2 | 167 | 5.94e-01 |
| GO:BP | GO:0031960 | response to corticosteroid | 1 | 109 | 5.95e-01 |
| GO:BP | GO:0034446 | substrate adhesion-dependent cell spreading | 1 | 97 | 5.95e-01 |
| GO:BP | GO:0048259 | regulation of receptor-mediated endocytosis | 1 | 87 | 5.95e-01 |
| GO:BP | GO:0051301 | cell division | 5 | 570 | 5.95e-01 |
| GO:BP | GO:0090175 | regulation of establishment of planar polarity | 1 | 54 | 5.95e-01 |
| GO:BP | GO:0046887 | positive regulation of hormone secretion | 2 | 90 | 5.95e-01 |
| GO:BP | GO:0045934 | negative regulation of nucleobase-containing compound metabolic process | 1 | 1209 | 5.95e-01 |
| GO:BP | GO:0048857 | neural nucleus development | 1 | 50 | 5.96e-01 |
| GO:BP | GO:0060042 | retina morphogenesis in camera-type eye | 1 | 40 | 5.96e-01 |
| GO:BP | GO:0060041 | retina development in camera-type eye | 2 | 109 | 5.97e-01 |
| GO:BP | GO:0070925 | organelle assembly | 8 | 817 | 5.97e-01 |
| GO:BP | GO:0023052 | signaling | 3 | 4141 | 5.97e-01 |
| GO:BP | GO:0048017 | inositol lipid-mediated signaling | 1 | 126 | 5.97e-01 |
| GO:BP | GO:0016925 | protein sumoylation | 1 | 59 | 5.97e-01 |
| GO:BP | GO:0071559 | response to transforming growth factor beta | 3 | 227 | 5.97e-01 |
| GO:BP | GO:0042531 | positive regulation of tyrosine phosphorylation of STAT protein | 1 | 23 | 5.98e-01 |
| GO:BP | GO:0071363 | cellular response to growth factor stimulus | 7 | 551 | 5.98e-01 |
| GO:BP | GO:0010467 | gene expression | 6 | 4587 | 5.99e-01 |
| GO:BP | GO:0030029 | actin filament-based process | 1 | 687 | 5.99e-01 |
| GO:BP | GO:0048583 | regulation of response to stimulus | 2 | 2890 | 5.99e-01 |
| GO:BP | GO:0050000 | chromosome localization | 1 | 82 | 5.99e-01 |
| GO:BP | GO:0031327 | negative regulation of cellular biosynthetic process | 1 | 1239 | 5.99e-01 |
| GO:BP | GO:0060411 | cardiac septum morphogenesis | 1 | 67 | 6.00e-01 |
| GO:BP | GO:1902117 | positive regulation of organelle assembly | 1 | 73 | 6.01e-01 |
| GO:BP | GO:0050896 | response to stimulus | 4 | 5770 | 6.01e-01 |
| GO:BP | GO:0006511 | ubiquitin-dependent protein catabolic process | 8 | 615 | 6.04e-01 |
| GO:BP | GO:0048592 | eye morphogenesis | 2 | 113 | 6.04e-01 |
| GO:BP | GO:0050848 | regulation of calcium-mediated signaling | 1 | 52 | 6.05e-01 |
| GO:BP | GO:0051932 | synaptic transmission, GABAergic | 1 | 36 | 6.05e-01 |
| GO:BP | GO:0008154 | actin polymerization or depolymerization | 2 | 160 | 6.06e-01 |
| GO:BP | GO:0006913 | nucleocytoplasmic transport | 3 | 295 | 6.07e-01 |
| GO:BP | GO:0051169 | nuclear transport | 3 | 295 | 6.07e-01 |
| GO:BP | GO:0007188 | adenylate cyclase-modulating G protein-coupled receptor signaling pathway | 3 | 118 | 6.08e-01 |
| GO:BP | GO:0061180 | mammary gland epithelium development | 1 | 57 | 6.09e-01 |
| GO:BP | GO:0007154 | cell communication | 3 | 4226 | 6.10e-01 |
| GO:BP | GO:0005975 | carbohydrate metabolic process | 1 | 433 | 6.10e-01 |
| GO:BP | GO:0009890 | negative regulation of biosynthetic process | 1 | 1280 | 6.10e-01 |
| GO:BP | GO:0006812 | monoatomic cation transport | 12 | 669 | 6.11e-01 |
| GO:BP | GO:0072091 | regulation of stem cell proliferation | 1 | 58 | 6.12e-01 |
| GO:BP | GO:0150076 | neuroinflammatory response | 1 | 33 | 6.12e-01 |
| GO:BP | GO:0045638 | negative regulation of myeloid cell differentiation | 1 | 69 | 6.12e-01 |
| GO:BP | GO:0071383 | cellular response to steroid hormone stimulus | 2 | 166 | 6.12e-01 |
| GO:BP | GO:0018205 | peptidyl-lysine modification | 4 | 336 | 6.12e-01 |
| GO:BP | GO:0031016 | pancreas development | 1 | 53 | 6.12e-01 |
| GO:BP | GO:0019953 | sexual reproduction | 1 | 631 | 6.12e-01 |
| GO:BP | GO:0007178 | transmembrane receptor protein serine/threonine kinase signaling pathway | 4 | 303 | 6.14e-01 |
| GO:BP | GO:0006996 | organelle organization | 16 | 3000 | 6.14e-01 |
| GO:BP | GO:0006446 | regulation of translational initiation | 1 | 73 | 6.14e-01 |
| GO:BP | GO:0062013 | positive regulation of small molecule metabolic process | 1 | 104 | 6.14e-01 |
| GO:BP | GO:0042254 | ribosome biogenesis | 2 | 301 | 6.15e-01 |
| GO:BP | GO:0009749 | response to glucose | 1 | 137 | 6.15e-01 |
| GO:BP | GO:0006612 | protein targeting to membrane | 1 | 118 | 6.16e-01 |
| GO:BP | GO:0032370 | positive regulation of lipid transport | 1 | 58 | 6.16e-01 |
| GO:BP | GO:0001895 | retina homeostasis | 1 | 44 | 6.16e-01 |
| GO:BP | GO:0019941 | modification-dependent protein catabolic process | 8 | 625 | 6.17e-01 |
| GO:BP | GO:0045666 | positive regulation of neuron differentiation | 1 | 63 | 6.18e-01 |
| GO:BP | GO:0000956 | nuclear-transcribed mRNA catabolic process | 1 | 120 | 6.19e-01 |
| GO:BP | GO:0140694 | non-membrane-bounded organelle assembly | 3 | 357 | 6.19e-01 |
| GO:BP | GO:0046530 | photoreceptor cell differentiation | 1 | 40 | 6.21e-01 |
| GO:BP | GO:0006887 | exocytosis | 2 | 256 | 6.21e-01 |
| GO:BP | GO:0090304 | nucleic acid metabolic process | 5 | 4048 | 6.21e-01 |
| GO:BP | GO:0070936 | protein K48-linked ubiquitination | 1 | 66 | 6.21e-01 |
| GO:BP | GO:0006112 | energy reserve metabolic process | 1 | 73 | 6.21e-01 |
| GO:BP | GO:0021766 | hippocampus development | 1 | 62 | 6.21e-01 |
| GO:BP | GO:0009746 | response to hexose | 1 | 138 | 6.22e-01 |
| GO:BP | GO:0044087 | regulation of cellular component biogenesis | 8 | 809 | 6.22e-01 |
| GO:BP | GO:0045732 | positive regulation of protein catabolic process | 2 | 192 | 6.22e-01 |
| GO:BP | GO:0048706 | embryonic skeletal system development | 1 | 78 | 6.22e-01 |
| GO:BP | GO:0060341 | regulation of cellular localization | 1 | 798 | 6.22e-01 |
| GO:BP | GO:2000036 | regulation of stem cell population maintenance | 1 | 62 | 6.22e-01 |
| GO:BP | GO:0007600 | sensory perception | 1 | 269 | 6.22e-01 |
| GO:BP | GO:0002274 | myeloid leukocyte activation | 3 | 123 | 6.23e-01 |
| GO:BP | GO:0046637 | regulation of alpha-beta T cell differentiation | 1 | 38 | 6.24e-01 |
| GO:BP | GO:0050807 | regulation of synapse organization | 1 | 184 | 6.24e-01 |
| GO:BP | GO:0009636 | response to toxic substance | 1 | 158 | 6.24e-01 |
| GO:BP | GO:1902531 | regulation of intracellular signal transduction | 1 | 1345 | 6.24e-01 |
| GO:BP | GO:0006518 | peptide metabolic process | 8 | 771 | 6.24e-01 |
| GO:BP | GO:0032732 | positive regulation of interleukin-1 production | 1 | 35 | 6.26e-01 |
| GO:BP | GO:0030001 | metal ion transport | 1 | 562 | 6.26e-01 |
| GO:BP | GO:0034660 | ncRNA metabolic process | 4 | 561 | 6.26e-01 |
| GO:BP | GO:0043433 | negative regulation of DNA-binding transcription factor activity | 2 | 138 | 6.26e-01 |
| GO:BP | GO:0023056 | positive regulation of signaling | 1 | 1256 | 6.27e-01 |
| GO:BP | GO:0031623 | receptor internalization | 1 | 95 | 6.30e-01 |
| GO:BP | GO:0106027 | neuron projection organization | 1 | 76 | 6.31e-01 |
| GO:BP | GO:0050803 | regulation of synapse structure or activity | 1 | 187 | 6.32e-01 |
| GO:BP | GO:0043632 | modification-dependent macromolecule catabolic process | 8 | 637 | 6.33e-01 |
| GO:BP | GO:0000910 | cytokinesis | 1 | 164 | 6.33e-01 |
| GO:BP | GO:0034284 | response to monosaccharide | 1 | 142 | 6.33e-01 |
| GO:BP | GO:0071396 | cellular response to lipid | 6 | 398 | 6.33e-01 |
| GO:BP | GO:0050886 | endocrine process | 1 | 57 | 6.34e-01 |
| GO:BP | GO:1901216 | positive regulation of neuron death | 1 | 70 | 6.34e-01 |
| GO:BP | GO:0032675 | regulation of interleukin-6 production | 1 | 86 | 6.34e-01 |
| GO:BP | GO:0051056 | regulation of small GTPase mediated signal transduction | 2 | 257 | 6.34e-01 |
| GO:BP | GO:0070897 | transcription preinitiation complex assembly | 1 | 67 | 6.34e-01 |
| GO:BP | GO:0032635 | interleukin-6 production | 1 | 86 | 6.34e-01 |
| GO:BP | GO:0070848 | response to growth factor | 7 | 572 | 6.35e-01 |
| GO:BP | GO:0044248 | cellular catabolic process | 2 | 1229 | 6.40e-01 |
| GO:BP | GO:0010564 | regulation of cell cycle process | 1 | 626 | 6.40e-01 |
| GO:BP | GO:0032101 | regulation of response to external stimulus | 1 | 662 | 6.40e-01 |
| GO:BP | GO:0035966 | response to topologically incorrect protein | 2 | 150 | 6.41e-01 |
| GO:BP | GO:0030163 | protein catabolic process | 1 | 901 | 6.41e-01 |
| GO:BP | GO:0060271 | cilium assembly | 4 | 292 | 6.41e-01 |
| GO:BP | GO:0097190 | apoptotic signaling pathway | 1 | 494 | 6.43e-01 |
| GO:BP | GO:0032412 | regulation of monoatomic ion transmembrane transporter activity | 3 | 190 | 6.43e-01 |
| GO:BP | GO:0042221 | response to chemical | 1 | 2559 | 6.43e-01 |
| GO:BP | GO:0140888 | interferon-mediated signaling pathway | 1 | 67 | 6.45e-01 |
| GO:BP | GO:1901264 | carbohydrate derivative transport | 1 | 63 | 6.45e-01 |
| GO:BP | GO:0017156 | calcium-ion regulated exocytosis | 1 | 46 | 6.46e-01 |
| GO:BP | GO:0042509 | regulation of tyrosine phosphorylation of STAT protein | 1 | 34 | 6.47e-01 |
| GO:BP | GO:0034341 | response to type II interferon | 1 | 83 | 6.47e-01 |
| GO:BP | GO:0003008 | system process | 2 | 1189 | 6.49e-01 |
| GO:BP | GO:0014070 | response to organic cyclic compound | 9 | 640 | 6.52e-01 |
| GO:BP | GO:0006091 | generation of precursor metabolites and energy | 4 | 369 | 6.52e-01 |
| GO:BP | GO:1903201 | regulation of oxidative stress-induced cell death | 1 | 56 | 6.52e-01 |
| GO:BP | GO:0007399 | nervous system development | 2 | 1904 | 6.53e-01 |
| GO:BP | GO:0009266 | response to temperature stimulus | 2 | 133 | 6.54e-01 |
| GO:BP | GO:0043255 | regulation of carbohydrate biosynthetic process | 1 | 77 | 6.55e-01 |
| GO:BP | GO:0005976 | polysaccharide metabolic process | 1 | 80 | 6.55e-01 |
| GO:BP | GO:0006874 | intracellular calcium ion homeostasis | 2 | 200 | 6.55e-01 |
| GO:BP | GO:0009064 | glutamine family amino acid metabolic process | 1 | 60 | 6.56e-01 |
| GO:BP | GO:0034765 | regulation of monoatomic ion transmembrane transport | 5 | 295 | 6.57e-01 |
| GO:BP | GO:0031331 | positive regulation of cellular catabolic process | 3 | 277 | 6.58e-01 |
| GO:BP | GO:2001237 | negative regulation of extrinsic apoptotic signaling pathway | 1 | 78 | 6.58e-01 |
| GO:BP | GO:0001654 | eye development | 4 | 272 | 6.58e-01 |
| GO:BP | GO:0001701 | in utero embryonic development | 4 | 344 | 6.59e-01 |
| GO:BP | GO:0061844 | antimicrobial humoral immune response mediated by antimicrobial peptide | 1 | 18 | 6.59e-01 |
| GO:BP | GO:0007260 | tyrosine phosphorylation of STAT protein | 1 | 36 | 6.59e-01 |
| GO:BP | GO:0003300 | cardiac muscle hypertrophy | 1 | 72 | 6.59e-01 |
| GO:BP | GO:0000387 | spliceosomal snRNP assembly | 1 | 45 | 6.59e-01 |
| GO:BP | GO:0098771 | inorganic ion homeostasis | 2 | 351 | 6.59e-01 |
| GO:BP | GO:0061024 | membrane organization | 7 | 671 | 6.61e-01 |
| GO:BP | GO:0031589 | cell-substrate adhesion | 3 | 281 | 6.62e-01 |
| GO:BP | GO:0001501 | skeletal system development | 5 | 377 | 6.64e-01 |
| GO:BP | GO:0003407 | neural retina development | 1 | 48 | 6.64e-01 |
| GO:BP | GO:1901654 | response to ketone | 1 | 147 | 6.64e-01 |
| GO:BP | GO:0150063 | visual system development | 4 | 273 | 6.64e-01 |
| GO:BP | GO:0006325 | chromatin organization | 1 | 551 | 6.64e-01 |
| GO:BP | GO:0007160 | cell-matrix adhesion | 1 | 179 | 6.66e-01 |
| GO:BP | GO:0043161 | proteasome-mediated ubiquitin-dependent protein catabolic process | 5 | 427 | 6.66e-01 |
| GO:BP | GO:0022898 | regulation of transmembrane transporter activity | 3 | 199 | 6.66e-01 |
| GO:BP | GO:0007405 | neuroblast proliferation | 1 | 51 | 6.66e-01 |
| GO:BP | GO:0034620 | cellular response to unfolded protein | 1 | 91 | 6.66e-01 |
| GO:BP | GO:0016049 | cell growth | 4 | 418 | 6.67e-01 |
| GO:BP | GO:0000086 | G2/M transition of mitotic cell cycle | 1 | 134 | 6.69e-01 |
| GO:BP | GO:0043467 | regulation of generation of precursor metabolites and energy | 1 | 89 | 6.69e-01 |
| GO:BP | GO:0014897 | striated muscle hypertrophy | 1 | 73 | 6.70e-01 |
| GO:BP | GO:0045446 | endothelial cell differentiation | 1 | 90 | 6.70e-01 |
| GO:BP | GO:0009743 | response to carbohydrate | 1 | 161 | 6.70e-01 |
| GO:BP | GO:1904035 | regulation of epithelial cell apoptotic process | 1 | 71 | 6.72e-01 |
| GO:BP | GO:1904063 | negative regulation of cation transmembrane transport | 1 | 64 | 6.72e-01 |
| GO:BP | GO:0042267 | natural killer cell mediated cytotoxicity | 1 | 34 | 6.72e-01 |
| GO:BP | GO:0140053 | mitochondrial gene expression | 1 | 162 | 6.72e-01 |
| GO:BP | GO:0048812 | neuron projection morphogenesis | 2 | 512 | 6.72e-01 |
| GO:BP | GO:0048880 | sensory system development | 4 | 275 | 6.74e-01 |
| GO:BP | GO:0009152 | purine ribonucleotide biosynthetic process | 2 | 179 | 6.74e-01 |
| GO:BP | GO:0001736 | establishment of planar polarity | 1 | 70 | 6.74e-01 |
| GO:BP | GO:0032501 | multicellular organismal process | 6 | 4794 | 6.74e-01 |
| GO:BP | GO:0007164 | establishment of tissue polarity | 1 | 70 | 6.74e-01 |
| GO:BP | GO:0006605 | protein targeting | 6 | 307 | 6.75e-01 |
| GO:BP | GO:2001233 | regulation of apoptotic signaling pathway | 3 | 307 | 6.75e-01 |
| GO:BP | GO:0014896 | muscle hypertrophy | 1 | 74 | 6.76e-01 |
| GO:BP | GO:0051604 | protein maturation | 1 | 259 | 6.77e-01 |
| GO:BP | GO:0072659 | protein localization to plasma membrane | 1 | 249 | 6.77e-01 |
| GO:BP | GO:0097194 | execution phase of apoptosis | 1 | 53 | 6.78e-01 |
| GO:BP | GO:0051276 | chromosome organization | 1 | 543 | 6.78e-01 |
| GO:BP | GO:0055007 | cardiac muscle cell differentiation | 1 | 103 | 6.79e-01 |
| GO:BP | GO:0007193 | adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway | 1 | 37 | 6.79e-01 |
| GO:BP | GO:0007163 | establishment or maintenance of cell polarity | 2 | 206 | 6.79e-01 |
| GO:BP | GO:0019318 | hexose metabolic process | 1 | 185 | 6.79e-01 |
| GO:BP | GO:0042102 | positive regulation of T cell proliferation | 1 | 47 | 6.79e-01 |
| GO:BP | GO:0001824 | blastocyst development | 1 | 94 | 6.82e-01 |
| GO:BP | GO:0042273 | ribosomal large subunit biogenesis | 1 | 73 | 6.82e-01 |
| GO:BP | GO:0060485 | mesenchyme development | 3 | 249 | 6.82e-01 |
| GO:BP | GO:1905954 | positive regulation of lipid localization | 1 | 75 | 6.82e-01 |
| GO:BP | GO:0009887 | animal organ morphogenesis | 1 | 742 | 6.82e-01 |
| GO:BP | GO:0048511 | rhythmic process | 3 | 237 | 6.82e-01 |
| GO:BP | GO:0042593 | glucose homeostasis | 1 | 168 | 6.82e-01 |
| GO:BP | GO:0002228 | natural killer cell mediated immunity | 1 | 34 | 6.83e-01 |
| GO:BP | GO:0033500 | carbohydrate homeostasis | 1 | 169 | 6.83e-01 |
| GO:BP | GO:0001763 | morphogenesis of a branching structure | 2 | 154 | 6.88e-01 |
| GO:BP | GO:0055074 | calcium ion homeostasis | 2 | 214 | 6.88e-01 |
| GO:BP | GO:0007286 | spermatid development | 2 | 105 | 6.88e-01 |
| GO:BP | GO:0050829 | defense response to Gram-negative bacterium | 1 | 20 | 6.88e-01 |
| GO:BP | GO:0034968 | histone lysine methylation | 1 | 89 | 6.88e-01 |
| GO:BP | GO:0001892 | embryonic placenta development | 1 | 71 | 6.91e-01 |
| GO:BP | GO:0001578 | microtubule bundle formation | 1 | 79 | 6.91e-01 |
| GO:BP | GO:0006836 | neurotransmitter transport | 1 | 138 | 6.91e-01 |
| GO:BP | GO:0006412 | translation | 4 | 646 | 6.91e-01 |
| GO:BP | GO:0045807 | positive regulation of endocytosis | 1 | 104 | 6.91e-01 |
| GO:BP | GO:0097435 | supramolecular fiber organization | 3 | 665 | 6.92e-01 |
| GO:BP | GO:0050767 | regulation of neurogenesis | 4 | 301 | 6.92e-01 |
| GO:BP | GO:0002832 | negative regulation of response to biotic stimulus | 1 | 88 | 6.92e-01 |
| GO:BP | GO:0051649 | establishment of localization in cell | 20 | 1836 | 6.92e-01 |
| GO:BP | GO:0046822 | regulation of nucleocytoplasmic transport | 1 | 97 | 6.93e-01 |
| GO:BP | GO:1900407 | regulation of cellular response to oxidative stress | 1 | 67 | 6.93e-01 |
| GO:BP | GO:0000904 | cell morphogenesis involved in differentiation | 5 | 516 | 6.93e-01 |
| GO:BP | GO:0006139 | nucleobase-containing compound metabolic process | 5 | 4455 | 6.93e-01 |
| GO:BP | GO:0034766 | negative regulation of monoatomic ion transmembrane transport | 1 | 70 | 6.96e-01 |
| GO:BP | GO:0006513 | protein monoubiquitination | 1 | 80 | 6.99e-01 |
| GO:BP | GO:0072089 | stem cell proliferation | 1 | 84 | 6.99e-01 |
| GO:BP | GO:0044839 | cell cycle G2/M phase transition | 1 | 149 | 6.99e-01 |
| GO:BP | GO:0070828 | heterochromatin organization | 1 | 77 | 6.99e-01 |
| GO:BP | GO:0032409 | regulation of transporter activity | 3 | 211 | 6.99e-01 |
| GO:BP | GO:0042274 | ribosomal small subunit biogenesis | 1 | 79 | 7.01e-01 |
| GO:BP | GO:0045047 | protein targeting to ER | 2 | 49 | 7.01e-01 |
| GO:BP | GO:0006473 | protein acetylation | 2 | 190 | 7.02e-01 |
| GO:BP | GO:0035418 | protein localization to synapse | 1 | 68 | 7.03e-01 |
| GO:BP | GO:0051225 | spindle assembly | 1 | 120 | 7.03e-01 |
| GO:BP | GO:0009791 | post-embryonic development | 1 | 74 | 7.03e-01 |
| GO:BP | GO:0030518 | intracellular steroid hormone receptor signaling pathway | 1 | 95 | 7.03e-01 |
| GO:BP | GO:0048515 | spermatid differentiation | 2 | 111 | 7.03e-01 |
| GO:BP | GO:0007631 | feeding behavior | 1 | 52 | 7.04e-01 |
| GO:BP | GO:0006493 | protein O-linked glycosylation | 1 | 69 | 7.04e-01 |
| GO:BP | GO:0043270 | positive regulation of monoatomic ion transport | 2 | 154 | 7.04e-01 |
| GO:BP | GO:0050727 | regulation of inflammatory response | 4 | 212 | 7.05e-01 |
| GO:BP | GO:0021761 | limbic system development | 1 | 81 | 7.06e-01 |
| GO:BP | GO:0034764 | positive regulation of transmembrane transport | 2 | 158 | 7.06e-01 |
| GO:BP | GO:0001505 | regulation of neurotransmitter levels | 1 | 149 | 7.07e-01 |
| GO:BP | GO:0072599 | establishment of protein localization to endoplasmic reticulum | 2 | 53 | 7.07e-01 |
| GO:BP | GO:0010035 | response to inorganic substance | 3 | 414 | 7.10e-01 |
| GO:BP | GO:0002532 | production of molecular mediator involved in inflammatory response | 1 | 49 | 7.10e-01 |
| GO:BP | GO:0110053 | regulation of actin filament organization | 1 | 228 | 7.10e-01 |
| GO:BP | GO:0015718 | monocarboxylic acid transport | 1 | 90 | 7.12e-01 |
| GO:BP | GO:0051716 | cellular response to stimulus | 3 | 4953 | 7.13e-01 |
| GO:BP | GO:0000302 | response to reactive oxygen species | 2 | 160 | 7.14e-01 |
| GO:BP | GO:0048584 | positive regulation of response to stimulus | 1 | 1555 | 7.14e-01 |
| GO:BP | GO:0043087 | regulation of GTPase activity | 3 | 302 | 7.14e-01 |
| GO:BP | GO:0001649 | osteoblast differentiation | 2 | 179 | 7.14e-01 |
| GO:BP | GO:0016575 | histone deacetylation | 1 | 87 | 7.14e-01 |
| GO:BP | GO:0017157 | regulation of exocytosis | 1 | 147 | 7.14e-01 |
| GO:BP | GO:0046907 | intracellular transport | 10 | 1453 | 7.15e-01 |
| GO:BP | GO:0090150 | establishment of protein localization to membrane | 1 | 250 | 7.15e-01 |
| GO:BP | GO:0043043 | peptide biosynthetic process | 4 | 666 | 7.16e-01 |
| GO:BP | GO:0046483 | heterocycle metabolic process | 5 | 4570 | 7.17e-01 |
| GO:BP | GO:0010717 | regulation of epithelial to mesenchymal transition | 1 | 86 | 7.17e-01 |
| GO:BP | GO:0051781 | positive regulation of cell division | 1 | 64 | 7.17e-01 |
| GO:BP | GO:0030510 | regulation of BMP signaling pathway | 1 | 84 | 7.19e-01 |
| GO:BP | GO:0009416 | response to light stimulus | 2 | 246 | 7.20e-01 |
| GO:BP | GO:0033209 | tumor necrosis factor-mediated signaling pathway | 1 | 76 | 7.21e-01 |
| GO:BP | GO:0032465 | regulation of cytokinesis | 1 | 79 | 7.21e-01 |
| GO:BP | GO:0022414 | reproductive process | 1 | 927 | 7.24e-01 |
| GO:BP | GO:0036473 | cell death in response to oxidative stress | 1 | 75 | 7.25e-01 |
| GO:BP | GO:1902882 | regulation of response to oxidative stress | 1 | 76 | 7.25e-01 |
| GO:BP | GO:0006725 | cellular aromatic compound metabolic process | 5 | 4596 | 7.25e-01 |
| GO:BP | GO:0000003 | reproduction | 1 | 934 | 7.26e-01 |
| GO:BP | GO:0055085 | transmembrane transport | 16 | 998 | 7.26e-01 |
| GO:BP | GO:0001906 | cell killing | 2 | 69 | 7.27e-01 |
| GO:BP | GO:0032760 | positive regulation of tumor necrosis factor production | 1 | 55 | 7.27e-01 |
| GO:BP | GO:0061013 | regulation of mRNA catabolic process | 1 | 161 | 7.27e-01 |
| GO:BP | GO:0051336 | regulation of hydrolase activity | 1 | 701 | 7.27e-01 |
| GO:BP | GO:1903508 | positive regulation of nucleic acid-templated transcription | 2 | 1315 | 7.28e-01 |
| GO:BP | GO:0051128 | regulation of cellular component organization | 2 | 2011 | 7.28e-01 |
| GO:BP | GO:0045893 | positive regulation of DNA-templated transcription | 2 | 1315 | 7.28e-01 |
| GO:BP | GO:0009411 | response to UV | 1 | 141 | 7.28e-01 |
| GO:BP | GO:0006811 | monoatomic ion transport | 13 | 775 | 7.28e-01 |
| GO:BP | GO:1901565 | organonitrogen compound catabolic process | 1 | 1145 | 7.28e-01 |
| GO:BP | GO:0042116 | macrophage activation | 1 | 57 | 7.28e-01 |
| GO:BP | GO:1902680 | positive regulation of RNA biosynthetic process | 2 | 1322 | 7.29e-01 |
| GO:BP | GO:0060348 | bone development | 2 | 170 | 7.30e-01 |
| GO:BP | GO:0045444 | fat cell differentiation | 2 | 187 | 7.30e-01 |
| GO:BP | GO:0009057 | macromolecule catabolic process | 1 | 1199 | 7.30e-01 |
| GO:BP | GO:0021537 | telencephalon development | 2 | 201 | 7.30e-01 |
| GO:BP | GO:0032386 | regulation of intracellular transport | 1 | 292 | 7.31e-01 |
| GO:BP | GO:0032963 | collagen metabolic process | 1 | 74 | 7.31e-01 |
| GO:BP | GO:0048562 | embryonic organ morphogenesis | 3 | 187 | 7.33e-01 |
| GO:BP | GO:0006790 | sulfur compound metabolic process | 1 | 248 | 7.33e-01 |
| GO:BP | GO:1903532 | positive regulation of secretion by cell | 3 | 199 | 7.33e-01 |
| GO:BP | GO:0006396 | RNA processing | 2 | 929 | 7.36e-01 |
| GO:BP | GO:1990778 | protein localization to cell periphery | 1 | 300 | 7.36e-01 |
| GO:BP | GO:2000177 | regulation of neural precursor cell proliferation | 1 | 64 | 7.36e-01 |
| GO:BP | GO:0021987 | cerebral cortex development | 1 | 101 | 7.36e-01 |
| GO:BP | GO:1903557 | positive regulation of tumor necrosis factor superfamily cytokine production | 1 | 57 | 7.36e-01 |
| GO:BP | GO:0016032 | viral process | 3 | 344 | 7.38e-01 |
| GO:BP | GO:0001843 | neural tube closure | 1 | 90 | 7.39e-01 |
| GO:BP | GO:0006090 | pyruvate metabolic process | 1 | 93 | 7.40e-01 |
| GO:BP | GO:0022618 | ribonucleoprotein complex assembly | 1 | 203 | 7.43e-01 |
| GO:BP | GO:0060606 | tube closure | 1 | 91 | 7.43e-01 |
| GO:BP | GO:0006869 | lipid transport | 3 | 272 | 7.43e-01 |
| GO:BP | GO:0071826 | ribonucleoprotein complex subunit organization | 1 | 211 | 7.44e-01 |
| GO:BP | GO:1904019 | epithelial cell apoptotic process | 1 | 98 | 7.45e-01 |
| GO:BP | GO:0070588 | calcium ion transmembrane transport | 1 | 213 | 7.46e-01 |
| GO:BP | GO:0006413 | translational initiation | 1 | 116 | 7.48e-01 |
| GO:BP | GO:0006576 | biogenic amine metabolic process | 1 | 57 | 7.49e-01 |
| GO:BP | GO:0001738 | morphogenesis of a polarized epithelium | 1 | 88 | 7.49e-01 |
| GO:BP | GO:0032368 | regulation of lipid transport | 1 | 92 | 7.49e-01 |
| GO:BP | GO:0002831 | regulation of response to biotic stimulus | 4 | 293 | 7.50e-01 |
| GO:BP | GO:0007626 | locomotory behavior | 2 | 138 | 7.50e-01 |
| GO:BP | GO:0001558 | regulation of cell growth | 3 | 357 | 7.50e-01 |
| GO:BP | GO:0043010 | camera-type eye development | 3 | 236 | 7.50e-01 |
| GO:BP | GO:0097722 | sperm motility | 1 | 61 | 7.50e-01 |
| GO:BP | GO:0043401 | steroid hormone mediated signaling pathway | 1 | 112 | 7.50e-01 |
| GO:BP | GO:0030317 | flagellated sperm motility | 1 | 61 | 7.50e-01 |
| GO:BP | GO:0070972 | protein localization to endoplasmic reticulum | 2 | 78 | 7.52e-01 |
| GO:BP | GO:0090090 | negative regulation of canonical Wnt signaling pathway | 1 | 114 | 7.52e-01 |
| GO:BP | GO:0090100 | positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 1 | 100 | 7.52e-01 |
| GO:BP | GO:0035051 | cardiocyte differentiation | 1 | 129 | 7.55e-01 |
| GO:BP | GO:0034612 | response to tumor necrosis factor | 2 | 172 | 7.55e-01 |
| GO:BP | GO:1901360 | organic cyclic compound metabolic process | 5 | 4747 | 7.56e-01 |
| GO:BP | GO:0032652 | regulation of interleukin-1 production | 1 | 56 | 7.56e-01 |
| GO:BP | GO:0032612 | interleukin-1 production | 1 | 56 | 7.56e-01 |
| GO:BP | GO:0046634 | regulation of alpha-beta T cell activation | 1 | 58 | 7.56e-01 |
| GO:BP | GO:0031398 | positive regulation of protein ubiquitination | 1 | 108 | 7.57e-01 |
| GO:BP | GO:0034502 | protein localization to chromosome | 1 | 110 | 7.57e-01 |
| GO:BP | GO:0014020 | primary neural tube formation | 1 | 94 | 7.57e-01 |
| GO:BP | GO:0050877 | nervous system process | 1 | 634 | 7.57e-01 |
| GO:BP | GO:0021782 | glial cell development | 1 | 84 | 7.59e-01 |
| GO:BP | GO:1900180 | regulation of protein localization to nucleus | 1 | 117 | 7.60e-01 |
| GO:BP | GO:0002703 | regulation of leukocyte mediated immunity | 1 | 118 | 7.61e-01 |
| GO:BP | GO:0000245 | spliceosomal complex assembly | 2 | 73 | 7.61e-01 |
| GO:BP | GO:0045184 | establishment of protein localization | 5 | 1462 | 7.61e-01 |
| GO:BP | GO:0006986 | response to unfolded protein | 1 | 128 | 7.61e-01 |
| GO:BP | GO:0051254 | positive regulation of RNA metabolic process | 2 | 1441 | 7.62e-01 |
| GO:BP | GO:0071705 | nitrogen compound transport | 12 | 1684 | 7.62e-01 |
| GO:BP | GO:0032355 | response to estradiol | 1 | 83 | 7.64e-01 |
| GO:BP | GO:0030522 | intracellular receptor signaling pathway | 2 | 227 | 7.64e-01 |
| GO:BP | GO:0050830 | defense response to Gram-positive bacterium | 1 | 33 | 7.64e-01 |
| GO:BP | GO:0048667 | cell morphogenesis involved in neuron differentiation | 4 | 463 | 7.65e-01 |
| GO:BP | GO:0001708 | cell fate specification | 1 | 56 | 7.65e-01 |
| GO:BP | GO:0001819 | positive regulation of cytokine production | 4 | 276 | 7.65e-01 |
| GO:BP | GO:0003206 | cardiac chamber morphogenesis | 1 | 109 | 7.65e-01 |
| GO:BP | GO:0035270 | endocrine system development | 1 | 86 | 7.65e-01 |
| GO:BP | GO:0008584 | male gonad development | 1 | 99 | 7.65e-01 |
| GO:BP | GO:0006476 | protein deacetylation | 1 | 106 | 7.67e-01 |
| GO:BP | GO:0060562 | epithelial tube morphogenesis | 1 | 278 | 7.67e-01 |
| GO:BP | GO:0046546 | development of primary male sexual characteristics | 1 | 100 | 7.67e-01 |
| GO:BP | GO:0006334 | nucleosome assembly | 1 | 80 | 7.67e-01 |
| GO:BP | GO:0033036 | macromolecule localization | 23 | 2450 | 7.68e-01 |
| GO:BP | GO:0009913 | epidermal cell differentiation | 2 | 116 | 7.68e-01 |
| GO:BP | GO:0035264 | multicellular organism growth | 1 | 123 | 7.72e-01 |
| GO:BP | GO:0045667 | regulation of osteoblast differentiation | 1 | 99 | 7.72e-01 |
| GO:BP | GO:0034763 | negative regulation of transmembrane transport | 1 | 96 | 7.72e-01 |
| GO:BP | GO:0072657 | protein localization to membrane | 2 | 523 | 7.72e-01 |
| GO:BP | GO:0046632 | alpha-beta T cell differentiation | 1 | 67 | 7.72e-01 |
| GO:BP | GO:0022612 | gland morphogenesis | 1 | 98 | 7.72e-01 |
| GO:BP | GO:0010720 | positive regulation of cell development | 4 | 317 | 7.72e-01 |
| GO:BP | GO:0062197 | cellular response to chemical stress | 1 | 293 | 7.72e-01 |
| GO:BP | GO:0060294 | cilium movement involved in cell motility | 1 | 69 | 7.72e-01 |
| GO:BP | GO:0031056 | regulation of histone modification | 1 | 125 | 7.73e-01 |
| GO:BP | GO:0048585 | negative regulation of response to stimulus | 1 | 1248 | 7.73e-01 |
| GO:BP | GO:0050671 | positive regulation of lymphocyte proliferation | 1 | 72 | 7.73e-01 |
| GO:BP | GO:1902850 | microtubule cytoskeleton organization involved in mitosis | 1 | 157 | 7.73e-01 |
| GO:BP | GO:0009896 | positive regulation of catabolic process | 4 | 464 | 7.74e-01 |
| GO:BP | GO:0034641 | cellular nitrogen compound metabolic process | 5 | 4946 | 7.74e-01 |
| GO:BP | GO:0043271 | negative regulation of monoatomic ion transport | 1 | 90 | 7.75e-01 |
| GO:BP | GO:0019730 | antimicrobial humoral response | 1 | 28 | 7.75e-01 |
| GO:BP | GO:0007218 | neuropeptide signaling pathway | 1 | 36 | 7.75e-01 |
| GO:BP | GO:0042472 | inner ear morphogenesis | 1 | 59 | 7.76e-01 |
| GO:BP | GO:0001841 | neural tube formation | 1 | 101 | 7.76e-01 |
| GO:BP | GO:0045787 | positive regulation of cell cycle | 3 | 274 | 7.76e-01 |
| GO:BP | GO:0009991 | response to extracellular stimulus | 2 | 377 | 7.77e-01 |
| GO:BP | GO:0032946 | positive regulation of mononuclear cell proliferation | 1 | 75 | 7.78e-01 |
| GO:BP | GO:0007409 | axonogenesis | 3 | 359 | 7.79e-01 |
| GO:BP | GO:0010557 | positive regulation of macromolecule biosynthetic process | 2 | 1507 | 7.79e-01 |
| GO:BP | GO:0008104 | protein localization | 7 | 2129 | 7.79e-01 |
| GO:BP | GO:0002699 | positive regulation of immune effector process | 1 | 130 | 7.79e-01 |
| GO:BP | GO:0051047 | positive regulation of secretion | 3 | 215 | 7.79e-01 |
| GO:BP | GO:0031347 | regulation of defense response | 7 | 448 | 7.79e-01 |
| GO:BP | GO:0043009 | chordate embryonic development | 4 | 534 | 7.81e-01 |
| GO:BP | GO:0030036 | actin cytoskeleton organization | 2 | 612 | 7.82e-01 |
| GO:BP | GO:0031349 | positive regulation of defense response | 4 | 251 | 7.82e-01 |
| GO:BP | GO:0018958 | phenol-containing compound metabolic process | 1 | 61 | 7.82e-01 |
| GO:BP | GO:0070727 | cellular macromolecule localization | 7 | 2138 | 7.82e-01 |
| GO:BP | GO:0022613 | ribonucleoprotein complex biogenesis | 1 | 453 | 7.83e-01 |
| GO:BP | GO:2001236 | regulation of extrinsic apoptotic signaling pathway | 1 | 123 | 7.83e-01 |
| GO:BP | GO:0070647 | protein modification by small protein conjugation or removal | 10 | 898 | 7.83e-01 |
| GO:BP | GO:0019932 | second-messenger-mediated signaling | 2 | 191 | 7.84e-01 |
| GO:BP | GO:1902414 | protein localization to cell junction | 1 | 93 | 7.86e-01 |
| GO:BP | GO:0048639 | positive regulation of developmental growth | 1 | 124 | 7.86e-01 |
| GO:BP | GO:0032956 | regulation of actin cytoskeleton organization | 1 | 299 | 7.86e-01 |
| GO:BP | GO:0090316 | positive regulation of intracellular protein transport | 1 | 133 | 7.87e-01 |
| GO:BP | GO:0031668 | cellular response to extracellular stimulus | 1 | 219 | 7.88e-01 |
| GO:BP | GO:0035601 | protein deacylation | 1 | 116 | 7.90e-01 |
| GO:BP | GO:0045471 | response to ethanol | 1 | 73 | 7.90e-01 |
| GO:BP | GO:1903322 | positive regulation of protein modification by small protein conjugation or removal | 1 | 126 | 7.94e-01 |
| GO:BP | GO:0006376 | mRNA splice site selection | 1 | 31 | 7.94e-01 |
| GO:BP | GO:0001539 | cilium or flagellum-dependent cell motility | 1 | 74 | 7.94e-01 |
| GO:BP | GO:0010876 | lipid localization | 3 | 310 | 7.94e-01 |
| GO:BP | GO:0009410 | response to xenobiotic stimulus | 1 | 279 | 7.94e-01 |
| GO:BP | GO:0060285 | cilium-dependent cell motility | 1 | 74 | 7.94e-01 |
| GO:BP | GO:0048513 | animal organ development | 2 | 2189 | 7.94e-01 |
| GO:BP | GO:0030879 | mammary gland development | 1 | 106 | 7.94e-01 |
| GO:BP | GO:0030307 | positive regulation of cell growth | 1 | 135 | 7.95e-01 |
| GO:BP | GO:0030100 | regulation of endocytosis | 2 | 211 | 7.95e-01 |
| GO:BP | GO:0048593 | camera-type eye morphogenesis | 1 | 91 | 7.95e-01 |
| GO:BP | GO:0031328 | positive regulation of cellular biosynthetic process | 2 | 1564 | 7.95e-01 |
| GO:BP | GO:0009308 | amine metabolic process | 1 | 68 | 7.95e-01 |
| GO:BP | GO:0015031 | protein transport | 9 | 1361 | 7.95e-01 |
| GO:BP | GO:0048545 | response to steroid hormone | 1 | 245 | 7.96e-01 |
| GO:BP | GO:1905952 | regulation of lipid localization | 1 | 112 | 7.96e-01 |
| GO:BP | GO:1901575 | organic substance catabolic process | 2 | 1712 | 7.96e-01 |
| GO:BP | GO:0051017 | actin filament bundle assembly | 1 | 138 | 7.96e-01 |
| GO:BP | GO:0098732 | macromolecule deacylation | 1 | 119 | 7.96e-01 |
| GO:BP | GO:0009792 | embryo development ending in birth or egg hatching | 4 | 551 | 7.97e-01 |
| GO:BP | GO:0002181 | cytoplasmic translation | 1 | 156 | 7.97e-01 |
| GO:BP | GO:0006508 | proteolysis | 1 | 1318 | 7.98e-01 |
| GO:BP | GO:0006402 | mRNA catabolic process | 1 | 216 | 7.98e-01 |
| GO:BP | GO:0045935 | positive regulation of nucleobase-containing compound metabolic process | 2 | 1602 | 8.00e-01 |
| GO:BP | GO:0061572 | actin filament bundle organization | 1 | 140 | 8.01e-01 |
| GO:BP | GO:0045596 | negative regulation of cell differentiation | 5 | 482 | 8.02e-01 |
| GO:BP | GO:0006617 | SRP-dependent cotranslational protein targeting to membrane, signal sequence recognition | 1 | 17 | 8.03e-01 |
| GO:BP | GO:0000070 | mitotic sister chromatid segregation | 1 | 179 | 8.03e-01 |
| GO:BP | GO:0046661 | male sex differentiation | 1 | 114 | 8.03e-01 |
| GO:BP | GO:0120161 | regulation of cold-induced thermogenesis | 1 | 112 | 8.03e-01 |
| GO:BP | GO:0051960 | regulation of nervous system development | 4 | 357 | 8.03e-01 |
| GO:BP | GO:0002696 | positive regulation of leukocyte activation | 4 | 222 | 8.04e-01 |
| GO:BP | GO:0048568 | embryonic organ development | 4 | 316 | 8.04e-01 |
| GO:BP | GO:0090068 | positive regulation of cell cycle process | 2 | 209 | 8.04e-01 |
| GO:BP | GO:0034728 | nucleosome organization | 1 | 98 | 8.04e-01 |
| GO:BP | GO:0106106 | cold-induced thermogenesis | 1 | 113 | 8.04e-01 |
| GO:BP | GO:0051783 | regulation of nuclear division | 1 | 116 | 8.05e-01 |
| GO:BP | GO:0070665 | positive regulation of leukocyte proliferation | 1 | 83 | 8.05e-01 |
| GO:BP | GO:0009891 | positive regulation of biosynthetic process | 2 | 1604 | 8.05e-01 |
| GO:BP | GO:2001056 | positive regulation of cysteine-type endopeptidase activity | 1 | 107 | 8.06e-01 |
| GO:BP | GO:0040007 | growth | 7 | 742 | 8.06e-01 |
| GO:BP | GO:0043604 | amide biosynthetic process | 4 | 775 | 8.08e-01 |
| GO:BP | GO:0006816 | calcium ion transport | 1 | 269 | 8.08e-01 |
| GO:BP | GO:0051668 | localization within membrane | 2 | 605 | 8.10e-01 |
| GO:BP | GO:0007283 | spermatogenesis | 1 | 330 | 8.10e-01 |
| GO:BP | GO:0050777 | negative regulation of immune response | 1 | 111 | 8.10e-01 |
| GO:BP | GO:0034762 | regulation of transmembrane transport | 5 | 391 | 8.10e-01 |
| GO:BP | GO:0051240 | positive regulation of multicellular organismal process | 1 | 1101 | 8.12e-01 |
| GO:BP | GO:2001242 | regulation of intrinsic apoptotic signaling pathway | 1 | 147 | 8.12e-01 |
| GO:BP | GO:0043269 | regulation of monoatomic ion transport | 5 | 373 | 8.12e-01 |
| GO:BP | GO:0006954 | inflammatory response | 1 | 429 | 8.12e-01 |
| GO:BP | GO:0006886 | intracellular protein transport | 8 | 803 | 8.13e-01 |
| GO:BP | GO:0006614 | SRP-dependent cotranslational protein targeting to membrane | 1 | 30 | 8.16e-01 |
| GO:BP | GO:0007051 | spindle organization | 1 | 188 | 8.17e-01 |
| GO:BP | GO:0030856 | regulation of epithelial cell differentiation | 1 | 101 | 8.18e-01 |
| GO:BP | GO:0048232 | male gamete generation | 1 | 343 | 8.19e-01 |
| GO:BP | GO:0002366 | leukocyte activation involved in immune response | 1 | 154 | 8.21e-01 |
| GO:BP | GO:0042471 | ear morphogenesis | 1 | 73 | 8.22e-01 |
| GO:BP | GO:0000209 | protein polyubiquitination | 2 | 226 | 8.23e-01 |
| GO:BP | GO:0050867 | positive regulation of cell activation | 4 | 229 | 8.23e-01 |
| GO:BP | GO:0045165 | cell fate commitment | 2 | 155 | 8.23e-01 |
| GO:BP | GO:0001838 | embryonic epithelial tube formation | 1 | 116 | 8.23e-01 |
| GO:BP | GO:0006613 | cotranslational protein targeting to membrane | 1 | 35 | 8.23e-01 |
| GO:BP | GO:0002263 | cell activation involved in immune response | 1 | 157 | 8.24e-01 |
| GO:BP | GO:0006109 | regulation of carbohydrate metabolic process | 1 | 144 | 8.24e-01 |
| GO:BP | GO:0048754 | branching morphogenesis of an epithelial tube | 1 | 121 | 8.24e-01 |
| GO:BP | GO:0014074 | response to purine-containing compound | 1 | 108 | 8.24e-01 |
| GO:BP | GO:2000027 | regulation of animal organ morphogenesis | 1 | 101 | 8.24e-01 |
| GO:BP | GO:1901136 | carbohydrate derivative catabolic process | 1 | 137 | 8.25e-01 |
| GO:BP | GO:0030534 | adult behavior | 1 | 92 | 8.25e-01 |
| GO:BP | GO:0006898 | receptor-mediated endocytosis | 1 | 196 | 8.26e-01 |
| GO:BP | GO:1990845 | adaptive thermogenesis | 1 | 121 | 8.26e-01 |
| GO:BP | GO:0001909 | leukocyte mediated cytotoxicity | 1 | 54 | 8.27e-01 |
| GO:BP | GO:0062012 | regulation of small molecule metabolic process | 2 | 246 | 8.27e-01 |
| GO:BP | GO:0030509 | BMP signaling pathway | 1 | 123 | 8.29e-01 |
| GO:BP | GO:0006911 | phagocytosis, engulfment | 1 | 33 | 8.29e-01 |
| GO:BP | GO:0051345 | positive regulation of hydrolase activity | 4 | 422 | 8.30e-01 |
| GO:BP | GO:0042129 | regulation of T cell proliferation | 1 | 95 | 8.30e-01 |
| GO:BP | GO:0001890 | placenta development | 1 | 117 | 8.32e-01 |
| GO:BP | GO:0021543 | pallium development | 1 | 139 | 8.32e-01 |
| GO:BP | GO:0007423 | sensory organ development | 5 | 396 | 8.37e-01 |
| GO:BP | GO:0140014 | mitotic nuclear division | 2 | 251 | 8.38e-01 |
| GO:BP | GO:0045637 | regulation of myeloid cell differentiation | 1 | 152 | 8.39e-01 |
| GO:BP | GO:0046883 | regulation of hormone secretion | 2 | 168 | 8.40e-01 |
| GO:BP | GO:0007015 | actin filament organization | 1 | 373 | 8.43e-01 |
| GO:BP | GO:0051223 | regulation of protein transport | 1 | 404 | 8.46e-01 |
| GO:BP | GO:0008544 | epidermis development | 3 | 210 | 8.46e-01 |
| GO:BP | GO:0007059 | chromosome segregation | 2 | 369 | 8.47e-01 |
| GO:BP | GO:0046394 | carboxylic acid biosynthetic process | 1 | 223 | 8.47e-01 |
| GO:BP | GO:0033674 | positive regulation of kinase activity | 1 | 317 | 8.47e-01 |
| GO:BP | GO:0071772 | response to BMP | 1 | 131 | 8.48e-01 |
| GO:BP | GO:0032879 | regulation of localization | 1 | 1555 | 8.48e-01 |
| GO:BP | GO:0099024 | plasma membrane invagination | 1 | 42 | 8.48e-01 |
| GO:BP | GO:0006401 | RNA catabolic process | 1 | 256 | 8.48e-01 |
| GO:BP | GO:0071773 | cellular response to BMP stimulus | 1 | 131 | 8.48e-01 |
| GO:BP | GO:0010950 | positive regulation of endopeptidase activity | 1 | 126 | 8.48e-01 |
| GO:BP | GO:0072175 | epithelial tube formation | 1 | 127 | 8.48e-01 |
| GO:BP | GO:0016053 | organic acid biosynthetic process | 1 | 224 | 8.48e-01 |
| GO:BP | GO:0032388 | positive regulation of intracellular transport | 1 | 170 | 8.49e-01 |
| GO:BP | GO:0051641 | cellular localization | 18 | 2810 | 8.49e-01 |
| GO:BP | GO:0030216 | keratinocyte differentiation | 1 | 75 | 8.49e-01 |
| GO:BP | GO:0032640 | tumor necrosis factor production | 1 | 91 | 8.50e-01 |
| GO:BP | GO:0032680 | regulation of tumor necrosis factor production | 1 | 91 | 8.50e-01 |
| GO:BP | GO:0031214 | biomineral tissue development | 1 | 111 | 8.50e-01 |
| GO:BP | GO:0034599 | cellular response to oxidative stress | 2 | 240 | 8.50e-01 |
| GO:BP | GO:0010469 | regulation of signaling receptor activity | 1 | 107 | 8.50e-01 |
| GO:BP | GO:1903828 | negative regulation of protein localization | 1 | 160 | 8.50e-01 |
| GO:BP | GO:0060284 | regulation of cell development | 7 | 605 | 8.50e-01 |
| GO:BP | GO:0007601 | visual perception | 1 | 96 | 8.51e-01 |
| GO:BP | GO:0000819 | sister chromatid segregation | 1 | 217 | 8.51e-01 |
| GO:BP | GO:0001659 | temperature homeostasis | 1 | 132 | 8.52e-01 |
| GO:BP | GO:0051347 | positive regulation of transferase activity | 4 | 400 | 8.53e-01 |
| GO:BP | GO:0051050 | positive regulation of transport | 6 | 667 | 8.53e-01 |
| GO:BP | GO:0016051 | carbohydrate biosynthetic process | 1 | 155 | 8.53e-01 |
| GO:BP | GO:0070201 | regulation of establishment of protein localization | 1 | 428 | 8.54e-01 |
| GO:BP | GO:0050953 | sensory perception of light stimulus | 1 | 97 | 8.54e-01 |
| GO:BP | GO:0010959 | regulation of metal ion transport | 3 | 275 | 8.54e-01 |
| GO:BP | GO:0031503 | protein-containing complex localization | 1 | 168 | 8.55e-01 |
| GO:BP | GO:1903555 | regulation of tumor necrosis factor superfamily cytokine production | 1 | 94 | 8.56e-01 |
| GO:BP | GO:0071706 | tumor necrosis factor superfamily cytokine production | 1 | 94 | 8.56e-01 |
| GO:BP | GO:0010324 | membrane invagination | 1 | 49 | 8.57e-01 |
| GO:BP | GO:0019722 | calcium-mediated signaling | 1 | 122 | 8.58e-01 |
| GO:BP | GO:0043085 | positive regulation of catalytic activity | 8 | 834 | 8.59e-01 |
| GO:BP | GO:0010952 | positive regulation of peptidase activity | 1 | 135 | 8.59e-01 |
| GO:BP | GO:0045597 | positive regulation of cell differentiation | 7 | 620 | 8.60e-01 |
| GO:BP | GO:0010038 | response to metal ion | 1 | 264 | 8.60e-01 |
| GO:BP | GO:0051234 | establishment of localization | 25 | 3433 | 8.61e-01 |
| GO:BP | GO:0018394 | peptidyl-lysine acetylation | 1 | 160 | 8.63e-01 |
| GO:BP | GO:1903169 | regulation of calcium ion transmembrane transport | 1 | 122 | 8.63e-01 |
| GO:BP | GO:0046631 | alpha-beta T cell activation | 1 | 89 | 8.66e-01 |
| GO:BP | GO:0042592 | homeostatic process | 5 | 1159 | 8.66e-01 |
| GO:BP | GO:0035148 | tube formation | 1 | 138 | 8.67e-01 |
| GO:BP | GO:0009056 | catabolic process | 2 | 2088 | 8.67e-01 |
| GO:BP | GO:0006810 | transport | 24 | 3298 | 8.67e-01 |
| GO:BP | GO:0016331 | morphogenesis of embryonic epithelium | 1 | 132 | 8.67e-01 |
| GO:BP | GO:1901215 | negative regulation of neuron death | 1 | 167 | 8.67e-01 |
| GO:BP | GO:0042098 | T cell proliferation | 1 | 120 | 8.67e-01 |
| GO:BP | GO:0061138 | morphogenesis of a branching epithelium | 1 | 143 | 8.67e-01 |
| GO:BP | GO:0061351 | neural precursor cell proliferation | 1 | 114 | 8.67e-01 |
| GO:BP | GO:0019827 | stem cell population maintenance | 1 | 149 | 8.67e-01 |
| GO:BP | GO:0045595 | regulation of cell differentiation | 12 | 1137 | 8.70e-01 |
| GO:BP | GO:0045580 | regulation of T cell differentiation | 1 | 110 | 8.70e-01 |
| GO:BP | GO:0000280 | nuclear division | 3 | 344 | 8.70e-01 |
| GO:BP | GO:0140013 | meiotic nuclear division | 1 | 120 | 8.72e-01 |
| GO:BP | GO:0030900 | forebrain development | 2 | 281 | 8.72e-01 |
| GO:BP | GO:0098727 | maintenance of cell number | 1 | 151 | 8.73e-01 |
| GO:BP | GO:0006979 | response to oxidative stress | 3 | 352 | 8.73e-01 |
| GO:BP | GO:0002697 | regulation of immune effector process | 1 | 190 | 8.73e-01 |
| GO:BP | GO:0031348 | negative regulation of defense response | 1 | 159 | 8.75e-01 |
| GO:BP | GO:0006909 | phagocytosis | 1 | 148 | 8.75e-01 |
| GO:BP | GO:0002009 | morphogenesis of an epithelium | 1 | 418 | 8.75e-01 |
| GO:BP | GO:0009267 | cellular response to starvation | 1 | 152 | 8.75e-01 |
| GO:BP | GO:0007565 | female pregnancy | 1 | 122 | 8.75e-01 |
| GO:BP | GO:0045088 | regulation of innate immune response | 2 | 232 | 8.77e-01 |
| GO:BP | GO:0008406 | gonad development | 1 | 158 | 8.77e-01 |
| GO:BP | GO:0033157 | regulation of intracellular protein transport | 1 | 197 | 8.79e-01 |
| GO:BP | GO:0071702 | organic substance transport | 23 | 2116 | 8.79e-01 |
| GO:BP | GO:2001234 | negative regulation of apoptotic signaling pathway | 1 | 194 | 8.81e-01 |
| GO:BP | GO:0021915 | neural tube development | 1 | 146 | 8.83e-01 |
| GO:BP | GO:0045137 | development of primary sexual characteristics | 1 | 161 | 8.83e-01 |
| GO:BP | GO:0010608 | post-transcriptional regulation of gene expression | 4 | 468 | 8.85e-01 |
| GO:BP | GO:0034097 | response to cytokine | 5 | 607 | 8.88e-01 |
| GO:BP | GO:0046942 | carboxylic acid transport | 1 | 216 | 8.88e-01 |
| GO:BP | GO:0015849 | organic acid transport | 1 | 217 | 8.88e-01 |
| GO:BP | GO:0031667 | response to nutrient levels | 1 | 353 | 8.90e-01 |
| GO:BP | GO:0009968 | negative regulation of signal transduction | 9 | 1006 | 8.91e-01 |
| GO:BP | GO:0051051 | negative regulation of transport | 1 | 318 | 8.91e-01 |
| GO:BP | GO:0031396 | regulation of protein ubiquitination | 1 | 191 | 8.91e-01 |
| GO:BP | GO:0001817 | regulation of cytokine production | 5 | 447 | 8.92e-01 |
| GO:BP | GO:1903046 | meiotic cell cycle process | 1 | 135 | 8.93e-01 |
| GO:BP | GO:0044237 | cellular metabolic process | 7 | 6996 | 8.93e-01 |
| GO:BP | GO:0045944 | positive regulation of transcription by RNA polymerase II | 9 | 937 | 8.93e-01 |
| GO:BP | GO:0050670 | regulation of lymphocyte proliferation | 1 | 126 | 8.93e-01 |
| GO:BP | GO:0051302 | regulation of cell division | 1 | 145 | 8.95e-01 |
| GO:BP | GO:0051179 | localization | 3 | 3969 | 8.95e-01 |
| GO:BP | GO:0001816 | cytokine production | 5 | 451 | 8.95e-01 |
| GO:BP | GO:0033993 | response to lipid | 2 | 592 | 8.95e-01 |
| GO:BP | GO:0032944 | regulation of mononuclear cell proliferation | 1 | 129 | 8.96e-01 |
| GO:BP | GO:0071216 | cellular response to biotic stimulus | 1 | 138 | 8.96e-01 |
| GO:BP | GO:0045927 | positive regulation of growth | 1 | 199 | 8.98e-01 |
| GO:BP | GO:0002694 | regulation of leukocyte activation | 5 | 348 | 8.99e-01 |
| GO:BP | GO:0050870 | positive regulation of T cell activation | 1 | 144 | 8.99e-01 |
| GO:BP | GO:0044703 | multi-organism reproductive process | 1 | 131 | 8.99e-01 |
| GO:BP | GO:0046879 | hormone secretion | 2 | 210 | 9.01e-01 |
| GO:BP | GO:0071902 | positive regulation of protein serine/threonine kinase activity | 1 | 135 | 9.04e-01 |
| GO:BP | GO:0045619 | regulation of lymphocyte differentiation | 1 | 132 | 9.06e-01 |
| GO:BP | GO:0040008 | regulation of growth | 3 | 501 | 9.07e-01 |
| GO:BP | GO:0050863 | regulation of T cell activation | 2 | 216 | 9.07e-01 |
| GO:BP | GO:0009952 | anterior/posterior pattern specification | 1 | 127 | 9.07e-01 |
| GO:BP | GO:0042742 | defense response to bacterium | 2 | 95 | 9.07e-01 |
| GO:BP | GO:0048285 | organelle fission | 3 | 388 | 9.07e-01 |
| GO:BP | GO:0071356 | cellular response to tumor necrosis factor | 1 | 155 | 9.09e-01 |
| GO:BP | GO:0044706 | multi-multicellular organism process | 1 | 135 | 9.09e-01 |
| GO:BP | GO:0023061 | signal release | 1 | 321 | 9.09e-01 |
| GO:BP | GO:0009914 | hormone transport | 2 | 215 | 9.11e-01 |
| GO:BP | GO:0032103 | positive regulation of response to external stimulus | 4 | 337 | 9.11e-01 |
| GO:BP | GO:0000278 | mitotic cell cycle | 4 | 827 | 9.11e-01 |
| GO:BP | GO:0050794 | regulation of cellular process | 8 | 7552 | 9.13e-01 |
| GO:BP | GO:0099173 | postsynapse organization | 1 | 155 | 9.14e-01 |
| GO:BP | GO:0019752 | carboxylic acid metabolic process | 6 | 681 | 9.15e-01 |
| GO:BP | GO:0048729 | tissue morphogenesis | 1 | 504 | 9.15e-01 |
| GO:BP | GO:0070663 | regulation of leukocyte proliferation | 1 | 141 | 9.15e-01 |
| GO:BP | GO:0002443 | leukocyte mediated immunity | 1 | 194 | 9.15e-01 |
| GO:BP | GO:1902074 | response to salt | 2 | 271 | 9.16e-01 |
| GO:BP | GO:1903039 | positive regulation of leukocyte cell-cell adhesion | 1 | 157 | 9.16e-01 |
| GO:BP | GO:0042594 | response to starvation | 1 | 178 | 9.16e-01 |
| GO:BP | GO:2000116 | regulation of cysteine-type endopeptidase activity | 1 | 169 | 9.17e-01 |
| GO:BP | GO:0010721 | negative regulation of cell development | 1 | 191 | 9.18e-01 |
| GO:BP | GO:0001503 | ossification | 2 | 313 | 9.20e-01 |
| GO:BP | GO:0045860 | positive regulation of protein kinase activity | 2 | 260 | 9.20e-01 |
| GO:BP | GO:0007548 | sex differentiation | 1 | 191 | 9.22e-01 |
| GO:BP | GO:0098813 | nuclear chromosome segregation | 1 | 273 | 9.22e-01 |
| GO:BP | GO:0048839 | inner ear development | 1 | 132 | 9.22e-01 |
| GO:BP | GO:0065003 | protein-containing complex assembly | 1 | 1335 | 9.22e-01 |
| GO:BP | GO:0043436 | oxoacid metabolic process | 6 | 696 | 9.23e-01 |
| GO:BP | GO:0060249 | anatomical structure homeostasis | 1 | 170 | 9.23e-01 |
| GO:BP | GO:0001894 | tissue homeostasis | 1 | 170 | 9.23e-01 |
| GO:BP | GO:0015711 | organic anion transport | 1 | 264 | 9.23e-01 |
| GO:BP | GO:1903320 | regulation of protein modification by small protein conjugation or removal | 1 | 232 | 9.24e-01 |
| GO:BP | GO:1903047 | mitotic cell cycle process | 3 | 694 | 9.25e-01 |
| GO:BP | GO:0006082 | organic acid metabolic process | 6 | 700 | 9.25e-01 |
| GO:BP | GO:0032940 | secretion by cell | 2 | 569 | 9.26e-01 |
| GO:BP | GO:0016043 | cellular component organization | 5 | 5076 | 9.29e-01 |
| GO:BP | GO:0030198 | extracellular matrix organization | 1 | 233 | 9.29e-01 |
| GO:BP | GO:0002285 | lymphocyte activation involved in immune response | 1 | 111 | 9.29e-01 |
| GO:BP | GO:0050865 | regulation of cell activation | 5 | 384 | 9.29e-01 |
| GO:BP | GO:0043062 | extracellular structure organization | 1 | 234 | 9.29e-01 |
| GO:BP | GO:0031669 | cellular response to nutrient levels | 1 | 194 | 9.30e-01 |
| GO:BP | GO:1903706 | regulation of hemopoiesis | 2 | 279 | 9.30e-01 |
| GO:BP | GO:0045229 | external encapsulating structure organization | 1 | 234 | 9.30e-01 |
| GO:BP | GO:0044283 | small molecule biosynthetic process | 3 | 425 | 9.31e-01 |
| GO:BP | GO:0023057 | negative regulation of signaling | 9 | 1076 | 9.31e-01 |
| GO:BP | GO:0010648 | negative regulation of cell communication | 9 | 1074 | 9.31e-01 |
| GO:BP | GO:0043933 | protein-containing complex organization | 1 | 1496 | 9.31e-01 |
| GO:BP | GO:0072594 | establishment of protein localization to organelle | 4 | 422 | 9.31e-01 |
| GO:BP | GO:0051924 | regulation of calcium ion transport | 1 | 172 | 9.32e-01 |
| GO:BP | GO:0022607 | cellular component assembly | 2 | 2466 | 9.33e-01 |
| GO:BP | GO:0019058 | viral life cycle | 1 | 244 | 9.33e-01 |
| GO:BP | GO:0097193 | intrinsic apoptotic signaling pathway | 1 | 262 | 9.33e-01 |
| GO:BP | GO:0034504 | protein localization to nucleus | 1 | 276 | 9.36e-01 |
| GO:BP | GO:0046651 | lymphocyte proliferation | 1 | 162 | 9.36e-01 |
| GO:BP | GO:0097305 | response to alcohol | 1 | 159 | 9.36e-01 |
| GO:BP | GO:0051222 | positive regulation of protein transport | 1 | 242 | 9.36e-01 |
| GO:BP | GO:0045930 | negative regulation of mitotic cell cycle | 1 | 211 | 9.40e-01 |
| GO:BP | GO:0032943 | mononuclear cell proliferation | 1 | 168 | 9.40e-01 |
| GO:BP | GO:0071840 | cellular component organization or biogenesis | 5 | 5274 | 9.40e-01 |
| GO:BP | GO:0140352 | export from cell | 2 | 611 | 9.41e-01 |
| GO:BP | GO:0043583 | ear development | 1 | 153 | 9.41e-01 |
| GO:BP | GO:1901617 | organic hydroxy compound biosynthetic process | 1 | 172 | 9.41e-01 |
| GO:BP | GO:1901214 | regulation of neuron death | 1 | 246 | 9.41e-01 |
| GO:BP | GO:0044772 | mitotic cell cycle phase transition | 1 | 418 | 9.42e-01 |
| GO:BP | GO:1904951 | positive regulation of establishment of protein localization | 1 | 258 | 9.44e-01 |
| GO:BP | GO:0051321 | meiotic cell cycle | 1 | 188 | 9.44e-01 |
| GO:BP | GO:0045089 | positive regulation of innate immune response | 1 | 182 | 9.45e-01 |
| GO:BP | GO:0044085 | cellular component biogenesis | 2 | 2724 | 9.47e-01 |
| GO:BP | GO:0032446 | protein modification by small protein conjugation | 6 | 787 | 9.47e-01 |
| GO:BP | GO:1903530 | regulation of secretion by cell | 1 | 382 | 9.48e-01 |
| GO:BP | GO:0007420 | brain development | 5 | 591 | 9.50e-01 |
| GO:BP | GO:0007411 | axon guidance | 1 | 185 | 9.50e-01 |
| GO:BP | GO:0097485 | neuron projection guidance | 1 | 186 | 9.51e-01 |
| GO:BP | GO:0019221 | cytokine-mediated signaling pathway | 2 | 274 | 9.52e-01 |
| GO:BP | GO:0070661 | leukocyte proliferation | 1 | 188 | 9.55e-01 |
| GO:BP | GO:0001818 | negative regulation of cytokine production | 1 | 165 | 9.55e-01 |
| GO:BP | GO:0046903 | secretion | 2 | 645 | 9.56e-01 |
| GO:BP | GO:0002833 | positive regulation of response to biotic stimulus | 1 | 192 | 9.57e-01 |
| GO:BP | GO:0006807 | nitrogen compound metabolic process | 7 | 7441 | 9.58e-01 |
| GO:BP | GO:0009617 | response to bacterium | 4 | 321 | 9.60e-01 |
| GO:BP | GO:0071345 | cellular response to cytokine stimulus | 4 | 540 | 9.60e-01 |
| GO:BP | GO:0070997 | neuron death | 1 | 286 | 9.60e-01 |
| GO:BP | GO:1903037 | regulation of leukocyte cell-cell adhesion | 1 | 211 | 9.60e-01 |
| GO:BP | GO:0051046 | regulation of secretion | 1 | 418 | 9.61e-01 |
| GO:BP | GO:0016567 | protein ubiquitination | 5 | 717 | 9.61e-01 |
| GO:BP | GO:0006959 | humoral immune response | 1 | 80 | 9.62e-01 |
| GO:BP | GO:0030099 | myeloid cell differentiation | 1 | 310 | 9.62e-01 |
| GO:BP | GO:0033365 | protein localization to organelle | 7 | 859 | 9.63e-01 |
| GO:BP | GO:0052548 | regulation of endopeptidase activity | 1 | 232 | 9.64e-01 |
| GO:BP | GO:1902105 | regulation of leukocyte differentiation | 1 | 199 | 9.64e-01 |
| GO:BP | GO:0060322 | head development | 5 | 633 | 9.64e-01 |
| GO:BP | GO:0051049 | regulation of transport | 10 | 1267 | 9.70e-01 |
| GO:BP | GO:0043170 | macromolecule metabolic process | 7 | 7069 | 9.70e-01 |
| GO:BP | GO:0051251 | positive regulation of lymphocyte activation | 1 | 199 | 9.70e-01 |
| GO:BP | GO:0007159 | leukocyte cell-cell adhesion | 1 | 234 | 9.71e-01 |
| GO:BP | GO:0032496 | response to lipopolysaccharide | 1 | 178 | 9.71e-01 |
| GO:BP | GO:0002252 | immune effector process | 1 | 318 | 9.73e-01 |
| GO:BP | GO:0002237 | response to molecule of bacterial origin | 1 | 187 | 9.76e-01 |
| GO:BP | GO:0002683 | negative regulation of immune system process | 1 | 289 | 9.76e-01 |
| GO:BP | GO:1901990 | regulation of mitotic cell cycle phase transition | 1 | 308 | 9.76e-01 |
| GO:BP | GO:0050778 | positive regulation of immune response | 1 | 369 | 9.78e-01 |
| GO:BP | GO:0051094 | positive regulation of developmental process | 1 | 957 | 9.78e-01 |
| GO:BP | GO:0006897 | endocytosis | 3 | 527 | 9.79e-01 |
| GO:BP | GO:0007346 | regulation of mitotic cell cycle | 2 | 441 | 9.79e-01 |
| GO:BP | GO:0051249 | regulation of lymphocyte activation | 2 | 296 | 9.81e-01 |
| GO:BP | GO:0052547 | regulation of peptidase activity | 1 | 271 | 9.85e-01 |
| GO:BP | GO:0002449 | lymphocyte mediated immunity | 1 | 142 | 9.88e-01 |
| GO:BP | GO:0003002 | regionalization | 1 | 273 | 9.88e-01 |
| GO:BP | GO:1902532 | negative regulation of intracellular signal transduction | 1 | 438 | 9.90e-01 |
| GO:BP | GO:0010817 | regulation of hormone levels | 2 | 336 | 9.91e-01 |
| GO:BP | GO:0044238 | primary metabolic process | 7 | 7806 | 9.91e-01 |
| GO:BP | GO:0050776 | regulation of immune response | 1 | 484 | 9.93e-01 |
| GO:BP | GO:0010629 | negative regulation of gene expression | 8 | 785 | 9.94e-01 |
| GO:BP | GO:0002684 | positive regulation of immune system process | 4 | 581 | 9.95e-01 |
| GO:BP | GO:0002682 | regulation of immune system process | 7 | 877 | 9.96e-01 |
| GO:BP | GO:0050789 | regulation of biological process | 8 | 8061 | 9.96e-01 |
| GO:BP | GO:0048871 | multicellular organismal-level homeostasis | 2 | 532 | 9.96e-01 |
| GO:BP | GO:0007186 | G protein-coupled receptor signaling pathway | 2 | 389 | 9.98e-01 |
| GO:BP | GO:0008152 | metabolic process | 1 | 8518 | 1.00e+00 |
| GO:BP | GO:0065007 | biological regulation | 1 | 8320 | 1.00e+00 |
| GO:BP | GO:0000244 | spliceosomal tri-snRNP complex assembly | 1 | 20 | 1.00e+00 |
| GO:BP | GO:0006935 | chemotaxis | 1 | 389 | 1.00e+00 |
| GO:BP | GO:0000365 | mRNA trans splicing, via spliceosome | 1 | 6 | 1.00e+00 |
| GO:BP | GO:0045291 | mRNA trans splicing, SL addition | 1 | 6 | 1.00e+00 |
| GO:BP | GO:0032787 | monocarboxylic acid metabolic process | 1 | 433 | 1.00e+00 |
| GO:BP | GO:0002250 | adaptive immune response | 1 | 218 | 1.00e+00 |
| GO:BP | GO:0008150 | biological_process | 1 | 12070 | 1.00e+00 |
| GO:BP | GO:0042330 | taxis | 1 | 389 | 1.00e+00 |
| GO:BP | GO:0009987 | cellular process | 1 | 11336 | 1.00e+00 |
| GO:BP | GO:0000353 | formation of quadruple SL/U4/U5/U6 snRNP | 1 | 6 | 1.00e+00 |
| GO:BP | GO:0071704 | organic substance metabolic process | 1 | 8169 | 1.00e+00 |
| KEGG | KEGG:05231 | Choline metabolism in cancer | 2 | 84 | 7.73e-03 |
| KEGG | KEGG:05212 | Pancreatic cancer | 2 | 75 | 7.73e-03 |
| KEGG | KEGG:05220 | Chronic myeloid leukemia | 2 | 75 | 7.73e-03 |
| KEGG | KEGG:05218 | Melanoma | 2 | 58 | 7.73e-03 |
| KEGG | KEGG:05213 | Endometrial cancer | 2 | 57 | 7.73e-03 |
| KEGG | KEGG:05214 | Glioma | 2 | 67 | 7.73e-03 |
| KEGG | KEGG:05223 | Non-small cell lung cancer | 2 | 67 | 7.73e-03 |
| KEGG | KEGG:04666 | Fc gamma R-mediated phagocytosis | 2 | 75 | 7.73e-03 |
| KEGG | KEGG:05210 | Colorectal cancer | 2 | 84 | 8.78e-03 |
| KEGG | KEGG:05222 | Small cell lung cancer | 2 | 87 | 9.04e-03 |
| KEGG | KEGG:04072 | Phospholipase D signaling pathway | 2 | 110 | 1.26e-02 |
| KEGG | KEGG:04210 | Apoptosis | 2 | 118 | 1.49e-02 |
| KEGG | KEGG:04068 | FoxO signaling pathway | 2 | 109 | 1.49e-02 |
| KEGG | KEGG:05224 | Breast cancer | 2 | 117 | 1.55e-02 |
| KEGG | KEGG:05226 | Gastric cancer | 2 | 117 | 1.55e-02 |
| KEGG | KEGG:04218 | Cellular senescence | 2 | 145 | 1.62e-02 |
| KEGG | KEGG:05225 | Hepatocellular carcinoma | 2 | 145 | 1.72e-02 |
| KEGG | KEGG:05169 | Epstein-Barr virus infection | 2 | 153 | 2.30e-02 |
| KEGG | KEGG:05215 | Prostate cancer | 1 | 86 | 5.44e-02 |
| KEGG | KEGG:04620 | Toll-like receptor signaling pathway | 1 | 60 | 5.44e-02 |
| KEGG | KEGG:04211 | Longevity regulating pathway | 1 | 78 | 5.44e-02 |
| KEGG | KEGG:04625 | C-type lectin receptor signaling pathway | 1 | 76 | 5.44e-02 |
| KEGG | KEGG:04066 | HIF-1 signaling pathway | 1 | 89 | 5.44e-02 |
| KEGG | KEGG:05200 | Pathways in cancer | 2 | 409 | 5.44e-02 |
| KEGG | KEGG:04650 | Natural killer cell mediated cytotoxicity | 1 | 63 | 5.44e-02 |
| KEGG | KEGG:01521 | EGFR tyrosine kinase inhibitor resistance | 1 | 74 | 5.44e-02 |
| KEGG | KEGG:05142 | Chagas disease | 1 | 75 | 5.44e-02 |
| KEGG | KEGG:01522 | Endocrine resistance | 1 | 85 | 5.44e-02 |
| KEGG | KEGG:04380 | Osteoclast differentiation | 1 | 87 | 5.44e-02 |
| KEGG | KEGG:01524 | Platinum drug resistance | 1 | 65 | 5.44e-02 |
| KEGG | KEGG:05146 | Amoebiasis | 1 | 64 | 5.44e-02 |
| KEGG | KEGG:04370 | VEGF signaling pathway | 1 | 49 | 5.44e-02 |
| KEGG | KEGG:04213 | Longevity regulating pathway - multiple species | 1 | 55 | 5.44e-02 |
| KEGG | KEGG:05216 | Thyroid cancer | 1 | 35 | 5.44e-02 |
| KEGG | KEGG:05221 | Acute myeloid leukemia | 1 | 56 | 5.44e-02 |
| KEGG | KEGG:04611 | Platelet activation | 1 | 89 | 5.44e-02 |
| KEGG | KEGG:00600 | Sphingolipid metabolism | 1 | 44 | 5.44e-02 |
| KEGG | KEGG:05230 | Central carbon metabolism in cancer | 1 | 62 | 5.44e-02 |
| KEGG | KEGG:00565 | Ether lipid metabolism | 1 | 28 | 5.44e-02 |
| KEGG | KEGG:05100 | Bacterial invasion of epithelial cells | 1 | 74 | 5.44e-02 |
| KEGG | KEGG:04070 | Phosphatidylinositol signaling system | 1 | 91 | 5.44e-02 |
| KEGG | KEGG:04071 | Sphingolipid signaling pathway | 1 | 107 | 5.44e-02 |
| KEGG | KEGG:04975 | Fat digestion and absorption | 1 | 19 | 5.44e-02 |
| KEGG | KEGG:04973 | Carbohydrate digestion and absorption | 1 | 31 | 5.44e-02 |
| KEGG | KEGG:04960 | Aldosterone-regulated sodium reabsorption | 1 | 26 | 5.44e-02 |
| KEGG | KEGG:04935 | Growth hormone synthesis, secretion and action | 1 | 98 | 5.44e-02 |
| KEGG | KEGG:04933 | AGE-RAGE signaling pathway in diabetic complications | 1 | 91 | 5.44e-02 |
| KEGG | KEGG:05211 | Renal cell carcinoma | 1 | 65 | 5.44e-02 |
| KEGG | KEGG:04931 | Insulin resistance | 1 | 95 | 5.44e-02 |
| KEGG | KEGG:04930 | Type II diabetes mellitus | 1 | 35 | 5.44e-02 |
| KEGG | KEGG:04929 | GnRH secretion | 1 | 53 | 5.44e-02 |
| KEGG | KEGG:04660 | T cell receptor signaling pathway | 1 | 70 | 5.44e-02 |
| KEGG | KEGG:04923 | Regulation of lipolysis in adipocytes | 1 | 41 | 5.44e-02 |
| KEGG | KEGG:04917 | Prolactin signaling pathway | 1 | 56 | 5.44e-02 |
| KEGG | KEGG:04914 | Progesterone-mediated oocyte maturation | 1 | 86 | 5.44e-02 |
| KEGG | KEGG:05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1 | 69 | 5.44e-02 |
| KEGG | KEGG:04012 | ErbB signaling pathway | 1 | 78 | 5.44e-02 |
| KEGG | KEGG:04152 | AMPK signaling pathway | 1 | 103 | 5.44e-02 |
| KEGG | KEGG:04750 | Inflammatory mediator regulation of TRP channels | 1 | 72 | 5.44e-02 |
| KEGG | KEGG:04725 | Cholinergic synapse | 1 | 83 | 5.44e-02 |
| KEGG | KEGG:04722 | Neurotrophin signaling pathway | 1 | 110 | 5.44e-02 |
| KEGG | KEGG:04670 | Leukocyte transendothelial migration | 1 | 79 | 5.44e-02 |
| KEGG | KEGG:04668 | TNF signaling pathway | 1 | 87 | 5.44e-02 |
| KEGG | KEGG:04664 | Fc epsilon RI signaling pathway | 1 | 46 | 5.44e-02 |
| KEGG | KEGG:00561 | Glycerolipid metabolism | 1 | 49 | 5.44e-02 |
| KEGG | KEGG:04662 | B cell receptor signaling pathway | 1 | 56 | 5.44e-02 |
| KEGG | KEGG:04919 | Thyroid hormone signaling pathway | 1 | 112 | 5.44e-02 |
| KEGG | KEGG:04360 | Axon guidance | 2 | 162 | 5.44e-02 |
| KEGG | KEGG:04140 | Autophagy - animal | 1 | 133 | 5.49e-02 |
| KEGG | KEGG:05418 | Fluid shear stress and atherosclerosis | 1 | 114 | 5.49e-02 |
| KEGG | KEGG:04915 | Estrogen signaling pathway | 1 | 97 | 5.49e-02 |
| KEGG | KEGG:05162 | Measles | 1 | 98 | 5.49e-02 |
| KEGG | KEGG:04550 | Signaling pathways regulating pluripotency of stem cells | 1 | 104 | 5.49e-02 |
| KEGG | KEGG:05017 | Spinocerebellar ataxia | 1 | 124 | 5.49e-02 |
| KEGG | KEGG:04926 | Relaxin signaling pathway | 1 | 104 | 5.49e-02 |
| KEGG | KEGG:04910 | Insulin signaling pathway | 1 | 121 | 5.49e-02 |
| KEGG | KEGG:05135 | Yersinia infection | 1 | 112 | 5.49e-02 |
| KEGG | KEGG:04932 | Non-alcoholic fatty liver disease | 1 | 131 | 5.73e-02 |
| KEGG | KEGG:05217 | Basal cell carcinoma | 1 | 49 | 5.73e-02 |
| KEGG | KEGG:05160 | Hepatitis C | 1 | 115 | 5.73e-02 |
| KEGG | KEGG:04150 | mTOR signaling pathway | 1 | 135 | 5.73e-02 |
| KEGG | KEGG:05161 | Hepatitis B | 1 | 136 | 5.80e-02 |
| KEGG | KEGG:05164 | Influenza A | 1 | 103 | 5.91e-02 |
| KEGG | KEGG:04630 | JAK-STAT signaling pathway | 1 | 88 | 5.91e-02 |
| KEGG | KEGG:04115 | p53 signaling pathway | 1 | 65 | 6.32e-02 |
| KEGG | KEGG:04613 | Neutrophil extracellular trap formation | 1 | 110 | 6.42e-02 |
| KEGG | KEGG:05208 | Chemical carcinogenesis - reactive oxygen species | 1 | 186 | 6.45e-02 |
| KEGG | KEGG:05415 | Diabetic cardiomyopathy | 1 | 169 | 6.45e-02 |
| KEGG | KEGG:05207 | Chemical carcinogenesis - receptor activation | 1 | 142 | 6.45e-02 |
| KEGG | KEGG:04024 | cAMP signaling pathway | 1 | 151 | 6.45e-02 |
| KEGG | KEGG:04062 | Chemokine signaling pathway | 1 | 113 | 6.45e-02 |
| KEGG | KEGG:04966 | Collecting duct acid secretion | 2 | 19 | 6.45e-02 |
| KEGG | KEGG:05166 | Human T-cell leukemia virus 1 infection | 1 | 180 | 6.45e-02 |
| KEGG | KEGG:04510 | Focal adhesion | 1 | 177 | 6.45e-02 |
| KEGG | KEGG:05167 | Kaposi sarcoma-associated herpesvirus infection | 1 | 145 | 6.45e-02 |
| KEGG | KEGG:00564 | Glycerophospholipid metabolism | 1 | 76 | 6.45e-02 |
| KEGG | KEGG:05417 | Lipid and atherosclerosis | 1 | 153 | 6.45e-02 |
| KEGG | KEGG:05205 | Proteoglycans in cancer | 1 | 170 | 6.45e-02 |
| KEGG | KEGG:05203 | Viral carcinogenesis | 1 | 172 | 6.45e-02 |
| KEGG | KEGG:05163 | Human cytomegalovirus infection | 1 | 176 | 6.45e-02 |
| KEGG | KEGG:05170 | Human immunodeficiency virus 1 infection | 1 | 165 | 6.45e-02 |
| KEGG | KEGG:04015 | Rap1 signaling pathway | 1 | 164 | 6.45e-02 |
| KEGG | KEGG:04961 | Endocrine and other factor-regulated calcium reabsorption | 2 | 41 | 6.49e-02 |
| KEGG | KEGG:04810 | Regulation of actin cytoskeleton | 1 | 179 | 6.49e-02 |
| KEGG | KEGG:05171 | Coronavirus disease - COVID-19 | 1 | 162 | 6.49e-02 |
| KEGG | KEGG:04014 | Ras signaling pathway | 1 | 171 | 6.51e-02 |
| KEGG | KEGG:05131 | Shigellosis | 1 | 210 | 6.77e-02 |
| KEGG | KEGG:04064 | NF-kappa B signaling pathway | 1 | 71 | 6.92e-02 |
| KEGG | KEGG:03430 | Mismatch repair | 1 | 22 | 7.09e-02 |
| KEGG | KEGG:04142 | Lysosome | 3 | 118 | 7.16e-02 |
| KEGG | KEGG:05020 | Prion disease | 1 | 220 | 7.21e-02 |
| KEGG | KEGG:05206 | MicroRNAs in cancer | 1 | 149 | 8.14e-02 |
| KEGG | KEGG:04721 | Synaptic vesicle cycle | 3 | 51 | 8.54e-02 |
| KEGG | KEGG:05165 | Human papillomavirus infection | 1 | 272 | 8.54e-02 |
| KEGG | KEGG:04137 | Mitophagy - animal | 2 | 70 | 8.86e-02 |
| KEGG | KEGG:04151 | PI3K-Akt signaling pathway | 1 | 254 | 8.93e-02 |
| KEGG | KEGG:03410 | Base excision repair | 1 | 33 | 9.40e-02 |
| KEGG | KEGG:05010 | Alzheimer disease | 1 | 315 | 9.49e-02 |
| KEGG | KEGG:04110 | Cell cycle | 1 | 151 | 9.59e-02 |
| KEGG | KEGG:00520 | Amino sugar and nucleotide sugar metabolism | 2 | 46 | 9.97e-02 |
| KEGG | KEGG:03030 | DNA replication | 1 | 35 | 9.97e-02 |
| KEGG | KEGG:03022 | Basal transcription factors | 2 | 40 | 1.04e-01 |
| KEGG | KEGG:03440 | Homologous recombination | 1 | 39 | 1.10e-01 |
| KEGG | KEGG:04340 | Hedgehog signaling pathway | 2 | 49 | 1.11e-01 |
| KEGG | KEGG:05202 | Transcriptional misregulation in cancer | 1 | 128 | 1.11e-01 |
| KEGG | KEGG:05168 | Herpes simplex virus 1 infection | 1 | 415 | 1.17e-01 |
| KEGG | KEGG:03420 | Nucleotide excision repair | 1 | 43 | 1.17e-01 |
| KEGG | KEGG:00020 | Citrate cycle (TCA cycle) | 1 | 28 | 1.37e-01 |
| KEGG | KEGG:03015 | mRNA surveillance pathway | 2 | 86 | 1.39e-01 |
| KEGG | KEGG:00670 | One carbon pool by folate | 1 | 18 | 1.39e-01 |
| KEGG | KEGG:05110 | Vibrio cholerae infection | 2 | 43 | 1.48e-01 |
| KEGG | KEGG:01200 | Carbon metabolism | 2 | 98 | 1.52e-01 |
| KEGG | KEGG:04010 | MAPK signaling pathway | 1 | 240 | 1.57e-01 |
| KEGG | KEGG:03013 | Nucleocytoplasmic transport | 2 | 99 | 1.61e-01 |
| KEGG | KEGG:00380 | Tryptophan metabolism | 1 | 23 | 1.75e-01 |
| KEGG | KEGG:01250 | Biosynthesis of nucleotide sugars | 1 | 35 | 1.83e-01 |
| KEGG | KEGG:00230 | Purine metabolism | 1 | 97 | 1.90e-01 |
| KEGG | KEGG:00630 | Glyoxylate and dicarboxylate metabolism | 1 | 25 | 1.90e-01 |
| KEGG | KEGG:01523 | Antifolate resistance | 1 | 24 | 1.90e-01 |
| KEGG | KEGG:03060 | Protein export | 1 | 23 | 2.28e-01 |
| KEGG | KEGG:04978 | Mineral absorption | 1 | 42 | 2.30e-01 |
| KEGG | KEGG:05132 | Salmonella infection | 3 | 214 | 2.30e-01 |
| KEGG | KEGG:04974 | Protein digestion and absorption | 2 | 61 | 2.30e-01 |
| KEGG | KEGG:05120 | Epithelial cell signaling in Helicobacter pylori infection | 2 | 58 | 2.31e-01 |
| KEGG | KEGG:00260 | Glycine, serine and threonine metabolism | 1 | 31 | 2.31e-01 |
| KEGG | KEGG:00310 | Lysine degradation | 1 | 59 | 2.40e-01 |
| KEGG | KEGG:04392 | Hippo signaling pathway - multiple species | 1 | 25 | 2.58e-01 |
| KEGG | KEGG:05412 | Arrhythmogenic right ventricular cardiomyopathy | 1 | 63 | 2.78e-01 |
| KEGG | KEGG:04710 | Circadian rhythm | 1 | 30 | 2.93e-01 |
| KEGG | KEGG:04934 | Cushing syndrome | 3 | 121 | 2.98e-01 |
| KEGG | KEGG:04260 | Cardiac muscle contraction | 1 | 67 | 3.04e-01 |
| KEGG | KEGG:05410 | Hypertrophic cardiomyopathy | 1 | 73 | 3.08e-01 |
| KEGG | KEGG:05323 | Rheumatoid arthritis | 2 | 43 | 3.08e-01 |
| KEGG | KEGG:04390 | Hippo signaling pathway | 3 | 134 | 3.08e-01 |
| KEGG | KEGG:05414 | Dilated cardiomyopathy | 1 | 78 | 3.19e-01 |
| KEGG | KEGG:03040 | Spliceosome | 2 | 132 | 3.23e-01 |
| KEGG | KEGG:05034 | Alcoholism | 3 | 122 | 3.26e-01 |
| KEGG | KEGG:03020 | RNA polymerase | 1 | 34 | 3.26e-01 |
| KEGG | KEGG:04310 | Wnt signaling pathway | 3 | 138 | 3.42e-01 |
| KEGG | KEGG:01230 | Biosynthesis of amino acids | 1 | 60 | 3.66e-01 |
| KEGG | KEGG:04916 | Melanogenesis | 2 | 77 | 3.66e-01 |
| KEGG | KEGG:00512 | Mucin type O-glycan biosynthesis | 1 | 22 | 3.69e-01 |
| KEGG | KEGG:04020 | Calcium signaling pathway | 2 | 157 | 3.69e-01 |
| KEGG | KEGG:04130 | SNARE interactions in vesicular transport | 1 | 32 | 3.76e-01 |
| KEGG | KEGG:00970 | Aminoacyl-tRNA biosynthesis | 1 | 44 | 3.83e-01 |
| KEGG | KEGG:00240 | Pyrimidine metabolism | 1 | 46 | 4.01e-01 |
| KEGG | KEGG:04371 | Apelin signaling pathway | 1 | 106 | 4.06e-01 |
| KEGG | KEGG:04144 | Endocytosis | 3 | 232 | 4.33e-01 |
| KEGG | KEGG:04979 | Cholesterol metabolism | 1 | 33 | 4.33e-01 |
| KEGG | KEGG:00514 | Other types of O-glycan biosynthesis | 1 | 37 | 4.35e-01 |
| KEGG | KEGG:04261 | Adrenergic signaling in cardiomyocytes | 1 | 128 | 4.35e-01 |
| KEGG | KEGG:01100 | Metabolic pathways | 1 | 1146 | 4.47e-01 |
| KEGG | KEGG:03250 | Viral life cycle - HIV-1 | 1 | 56 | 4.54e-01 |
| KEGG | KEGG:04022 | cGMP-PKG signaling pathway | 1 | 133 | 4.54e-01 |
| KEGG | KEGG:00190 | Oxidative phosphorylation | 2 | 106 | 4.73e-01 |
| KEGG | KEGG:00983 | Drug metabolism - other enzymes | 1 | 44 | 4.82e-01 |
| KEGG | KEGG:04330 | Notch signaling pathway | 1 | 51 | 4.83e-01 |
| KEGG | KEGG:04145 | Phagosome | 1 | 99 | 5.02e-01 |
| KEGG | KEGG:01232 | Nucleotide metabolism | 1 | 69 | 5.02e-01 |
| KEGG | KEGG:04270 | Vascular smooth muscle contraction | 1 | 94 | 5.16e-01 |
| KEGG | KEGG:04623 | Cytosolic DNA-sensing pathway | 1 | 42 | 5.29e-01 |
| KEGG | KEGG:05031 | Amphetamine addiction | 1 | 49 | 5.33e-01 |
| KEGG | KEGG:05152 | Tuberculosis | 1 | 106 | 5.54e-01 |
| KEGG | KEGG:04657 | IL-17 signaling pathway | 1 | 56 | 5.54e-01 |
| KEGG | KEGG:01240 | Biosynthesis of cofactors | 1 | 115 | 5.58e-01 |
| KEGG | KEGG:04921 | Oxytocin signaling pathway | 1 | 115 | 5.63e-01 |
| KEGG | KEGG:05016 | Huntington disease | 3 | 256 | 6.03e-01 |
| KEGG | KEGG:05022 | Pathways of neurodegeneration - multiple diseases | 5 | 385 | 6.07e-01 |
| KEGG | KEGG:04350 | TGF-beta signaling pathway | 1 | 84 | 6.07e-01 |
| KEGG | KEGG:04728 | Dopaminergic synapse | 1 | 103 | 6.80e-01 |
| KEGG | KEGG:04936 | Alcoholic liver disease | 1 | 97 | 7.04e-01 |
| KEGG | KEGG:00000 | KEGG root term | 3 | 5558 | 7.19e-01 |
| KEGG | KEGG:05322 | Systemic lupus erythematosus | 1 | 61 | 7.24e-01 |
| KEGG | KEGG:04740 | Olfactory transduction | 1 | 25 | 7.52e-01 |
| KEGG | KEGG:04114 | Oocyte meiosis | 1 | 108 | 7.57e-01 |
| KEGG | KEGG:04217 | Necroptosis | 1 | 106 | 7.78e-01 |
| KEGG | KEGG:05012 | Parkinson disease | 2 | 226 | 7.86e-01 |
| KEGG | KEGG:04120 | Ubiquitin mediated proteolysis | 1 | 134 | 7.95e-01 |
| KEGG | KEGG:05130 | Pathogenic Escherichia coli infection | 1 | 150 | 7.99e-01 |
| KEGG | KEGG:04621 | NOD-like receptor signaling pathway | 1 | 117 | 8.09e-01 |
| KEGG | KEGG:04080 | Neuroactive ligand-receptor interaction | 1 | 108 | 8.21e-01 |
| KEGG | KEGG:05014 | Amyotrophic lateral sclerosis | 1 | 303 | 9.60e-01 |
TRZ_var24_table %>%
filter(source=="KEGG") %>%
mutate_at(.vars = 6, .funs= scientific_format()) %>%
kable(.,caption = "KEGG TRZ 24 hour enrichment terms of highly var genes") %>%
kable_paper("striped", full_width = FALSE) %>%
kable_styling(full_width = FALSE, position = "left",bootstrap_options = c("striped","hover")) %>%
scroll_box(width = "100%", height = "400px")| source | term_id | term_name | intersection_size | term_size | p_value |
|---|---|---|---|---|---|
| KEGG | KEGG:05231 | Choline metabolism in cancer | 2 | 84 | 7.73e-03 |
| KEGG | KEGG:05212 | Pancreatic cancer | 2 | 75 | 7.73e-03 |
| KEGG | KEGG:05220 | Chronic myeloid leukemia | 2 | 75 | 7.73e-03 |
| KEGG | KEGG:05218 | Melanoma | 2 | 58 | 7.73e-03 |
| KEGG | KEGG:05213 | Endometrial cancer | 2 | 57 | 7.73e-03 |
| KEGG | KEGG:05214 | Glioma | 2 | 67 | 7.73e-03 |
| KEGG | KEGG:05223 | Non-small cell lung cancer | 2 | 67 | 7.73e-03 |
| KEGG | KEGG:04666 | Fc gamma R-mediated phagocytosis | 2 | 75 | 7.73e-03 |
| KEGG | KEGG:05210 | Colorectal cancer | 2 | 84 | 8.78e-03 |
| KEGG | KEGG:05222 | Small cell lung cancer | 2 | 87 | 9.04e-03 |
| KEGG | KEGG:04072 | Phospholipase D signaling pathway | 2 | 110 | 1.26e-02 |
| KEGG | KEGG:04210 | Apoptosis | 2 | 118 | 1.49e-02 |
| KEGG | KEGG:04068 | FoxO signaling pathway | 2 | 109 | 1.49e-02 |
| KEGG | KEGG:05224 | Breast cancer | 2 | 117 | 1.55e-02 |
| KEGG | KEGG:05226 | Gastric cancer | 2 | 117 | 1.55e-02 |
| KEGG | KEGG:04218 | Cellular senescence | 2 | 145 | 1.62e-02 |
| KEGG | KEGG:05225 | Hepatocellular carcinoma | 2 | 145 | 1.72e-02 |
| KEGG | KEGG:05169 | Epstein-Barr virus infection | 2 | 153 | 2.30e-02 |
| KEGG | KEGG:05215 | Prostate cancer | 1 | 86 | 5.44e-02 |
| KEGG | KEGG:04620 | Toll-like receptor signaling pathway | 1 | 60 | 5.44e-02 |
| KEGG | KEGG:04211 | Longevity regulating pathway | 1 | 78 | 5.44e-02 |
| KEGG | KEGG:04625 | C-type lectin receptor signaling pathway | 1 | 76 | 5.44e-02 |
| KEGG | KEGG:04066 | HIF-1 signaling pathway | 1 | 89 | 5.44e-02 |
| KEGG | KEGG:05200 | Pathways in cancer | 2 | 409 | 5.44e-02 |
| KEGG | KEGG:04650 | Natural killer cell mediated cytotoxicity | 1 | 63 | 5.44e-02 |
| KEGG | KEGG:01521 | EGFR tyrosine kinase inhibitor resistance | 1 | 74 | 5.44e-02 |
| KEGG | KEGG:05142 | Chagas disease | 1 | 75 | 5.44e-02 |
| KEGG | KEGG:01522 | Endocrine resistance | 1 | 85 | 5.44e-02 |
| KEGG | KEGG:04380 | Osteoclast differentiation | 1 | 87 | 5.44e-02 |
| KEGG | KEGG:01524 | Platinum drug resistance | 1 | 65 | 5.44e-02 |
| KEGG | KEGG:05146 | Amoebiasis | 1 | 64 | 5.44e-02 |
| KEGG | KEGG:04370 | VEGF signaling pathway | 1 | 49 | 5.44e-02 |
| KEGG | KEGG:04213 | Longevity regulating pathway - multiple species | 1 | 55 | 5.44e-02 |
| KEGG | KEGG:05216 | Thyroid cancer | 1 | 35 | 5.44e-02 |
| KEGG | KEGG:05221 | Acute myeloid leukemia | 1 | 56 | 5.44e-02 |
| KEGG | KEGG:04611 | Platelet activation | 1 | 89 | 5.44e-02 |
| KEGG | KEGG:00600 | Sphingolipid metabolism | 1 | 44 | 5.44e-02 |
| KEGG | KEGG:05230 | Central carbon metabolism in cancer | 1 | 62 | 5.44e-02 |
| KEGG | KEGG:00565 | Ether lipid metabolism | 1 | 28 | 5.44e-02 |
| KEGG | KEGG:05100 | Bacterial invasion of epithelial cells | 1 | 74 | 5.44e-02 |
| KEGG | KEGG:04070 | Phosphatidylinositol signaling system | 1 | 91 | 5.44e-02 |
| KEGG | KEGG:04071 | Sphingolipid signaling pathway | 1 | 107 | 5.44e-02 |
| KEGG | KEGG:04975 | Fat digestion and absorption | 1 | 19 | 5.44e-02 |
| KEGG | KEGG:04973 | Carbohydrate digestion and absorption | 1 | 31 | 5.44e-02 |
| KEGG | KEGG:04960 | Aldosterone-regulated sodium reabsorption | 1 | 26 | 5.44e-02 |
| KEGG | KEGG:04935 | Growth hormone synthesis, secretion and action | 1 | 98 | 5.44e-02 |
| KEGG | KEGG:04933 | AGE-RAGE signaling pathway in diabetic complications | 1 | 91 | 5.44e-02 |
| KEGG | KEGG:05211 | Renal cell carcinoma | 1 | 65 | 5.44e-02 |
| KEGG | KEGG:04931 | Insulin resistance | 1 | 95 | 5.44e-02 |
| KEGG | KEGG:04930 | Type II diabetes mellitus | 1 | 35 | 5.44e-02 |
| KEGG | KEGG:04929 | GnRH secretion | 1 | 53 | 5.44e-02 |
| KEGG | KEGG:04660 | T cell receptor signaling pathway | 1 | 70 | 5.44e-02 |
| KEGG | KEGG:04923 | Regulation of lipolysis in adipocytes | 1 | 41 | 5.44e-02 |
| KEGG | KEGG:04917 | Prolactin signaling pathway | 1 | 56 | 5.44e-02 |
| KEGG | KEGG:04914 | Progesterone-mediated oocyte maturation | 1 | 86 | 5.44e-02 |
| KEGG | KEGG:05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1 | 69 | 5.44e-02 |
| KEGG | KEGG:04012 | ErbB signaling pathway | 1 | 78 | 5.44e-02 |
| KEGG | KEGG:04152 | AMPK signaling pathway | 1 | 103 | 5.44e-02 |
| KEGG | KEGG:04750 | Inflammatory mediator regulation of TRP channels | 1 | 72 | 5.44e-02 |
| KEGG | KEGG:04725 | Cholinergic synapse | 1 | 83 | 5.44e-02 |
| KEGG | KEGG:04722 | Neurotrophin signaling pathway | 1 | 110 | 5.44e-02 |
| KEGG | KEGG:04670 | Leukocyte transendothelial migration | 1 | 79 | 5.44e-02 |
| KEGG | KEGG:04668 | TNF signaling pathway | 1 | 87 | 5.44e-02 |
| KEGG | KEGG:04664 | Fc epsilon RI signaling pathway | 1 | 46 | 5.44e-02 |
| KEGG | KEGG:00561 | Glycerolipid metabolism | 1 | 49 | 5.44e-02 |
| KEGG | KEGG:04662 | B cell receptor signaling pathway | 1 | 56 | 5.44e-02 |
| KEGG | KEGG:04919 | Thyroid hormone signaling pathway | 1 | 112 | 5.44e-02 |
| KEGG | KEGG:04360 | Axon guidance | 2 | 162 | 5.44e-02 |
| KEGG | KEGG:04140 | Autophagy - animal | 1 | 133 | 5.49e-02 |
| KEGG | KEGG:05418 | Fluid shear stress and atherosclerosis | 1 | 114 | 5.49e-02 |
| KEGG | KEGG:04915 | Estrogen signaling pathway | 1 | 97 | 5.49e-02 |
| KEGG | KEGG:05162 | Measles | 1 | 98 | 5.49e-02 |
| KEGG | KEGG:04550 | Signaling pathways regulating pluripotency of stem cells | 1 | 104 | 5.49e-02 |
| KEGG | KEGG:05017 | Spinocerebellar ataxia | 1 | 124 | 5.49e-02 |
| KEGG | KEGG:04926 | Relaxin signaling pathway | 1 | 104 | 5.49e-02 |
| KEGG | KEGG:04910 | Insulin signaling pathway | 1 | 121 | 5.49e-02 |
| KEGG | KEGG:05135 | Yersinia infection | 1 | 112 | 5.49e-02 |
| KEGG | KEGG:04932 | Non-alcoholic fatty liver disease | 1 | 131 | 5.73e-02 |
| KEGG | KEGG:05217 | Basal cell carcinoma | 1 | 49 | 5.73e-02 |
| KEGG | KEGG:05160 | Hepatitis C | 1 | 115 | 5.73e-02 |
| KEGG | KEGG:04150 | mTOR signaling pathway | 1 | 135 | 5.73e-02 |
| KEGG | KEGG:05161 | Hepatitis B | 1 | 136 | 5.80e-02 |
| KEGG | KEGG:05164 | Influenza A | 1 | 103 | 5.91e-02 |
| KEGG | KEGG:04630 | JAK-STAT signaling pathway | 1 | 88 | 5.91e-02 |
| KEGG | KEGG:04115 | p53 signaling pathway | 1 | 65 | 6.32e-02 |
| KEGG | KEGG:04613 | Neutrophil extracellular trap formation | 1 | 110 | 6.42e-02 |
| KEGG | KEGG:05208 | Chemical carcinogenesis - reactive oxygen species | 1 | 186 | 6.45e-02 |
| KEGG | KEGG:05415 | Diabetic cardiomyopathy | 1 | 169 | 6.45e-02 |
| KEGG | KEGG:05207 | Chemical carcinogenesis - receptor activation | 1 | 142 | 6.45e-02 |
| KEGG | KEGG:04024 | cAMP signaling pathway | 1 | 151 | 6.45e-02 |
| KEGG | KEGG:04062 | Chemokine signaling pathway | 1 | 113 | 6.45e-02 |
| KEGG | KEGG:04966 | Collecting duct acid secretion | 2 | 19 | 6.45e-02 |
| KEGG | KEGG:05166 | Human T-cell leukemia virus 1 infection | 1 | 180 | 6.45e-02 |
| KEGG | KEGG:04510 | Focal adhesion | 1 | 177 | 6.45e-02 |
| KEGG | KEGG:05167 | Kaposi sarcoma-associated herpesvirus infection | 1 | 145 | 6.45e-02 |
| KEGG | KEGG:00564 | Glycerophospholipid metabolism | 1 | 76 | 6.45e-02 |
| KEGG | KEGG:05417 | Lipid and atherosclerosis | 1 | 153 | 6.45e-02 |
| KEGG | KEGG:05205 | Proteoglycans in cancer | 1 | 170 | 6.45e-02 |
| KEGG | KEGG:05203 | Viral carcinogenesis | 1 | 172 | 6.45e-02 |
| KEGG | KEGG:05163 | Human cytomegalovirus infection | 1 | 176 | 6.45e-02 |
| KEGG | KEGG:05170 | Human immunodeficiency virus 1 infection | 1 | 165 | 6.45e-02 |
| KEGG | KEGG:04015 | Rap1 signaling pathway | 1 | 164 | 6.45e-02 |
| KEGG | KEGG:04961 | Endocrine and other factor-regulated calcium reabsorption | 2 | 41 | 6.49e-02 |
| KEGG | KEGG:04810 | Regulation of actin cytoskeleton | 1 | 179 | 6.49e-02 |
| KEGG | KEGG:05171 | Coronavirus disease - COVID-19 | 1 | 162 | 6.49e-02 |
| KEGG | KEGG:04014 | Ras signaling pathway | 1 | 171 | 6.51e-02 |
| KEGG | KEGG:05131 | Shigellosis | 1 | 210 | 6.77e-02 |
| KEGG | KEGG:04064 | NF-kappa B signaling pathway | 1 | 71 | 6.92e-02 |
| KEGG | KEGG:03430 | Mismatch repair | 1 | 22 | 7.09e-02 |
| KEGG | KEGG:04142 | Lysosome | 3 | 118 | 7.16e-02 |
| KEGG | KEGG:05020 | Prion disease | 1 | 220 | 7.21e-02 |
| KEGG | KEGG:05206 | MicroRNAs in cancer | 1 | 149 | 8.14e-02 |
| KEGG | KEGG:04721 | Synaptic vesicle cycle | 3 | 51 | 8.54e-02 |
| KEGG | KEGG:05165 | Human papillomavirus infection | 1 | 272 | 8.54e-02 |
| KEGG | KEGG:04137 | Mitophagy - animal | 2 | 70 | 8.86e-02 |
| KEGG | KEGG:04151 | PI3K-Akt signaling pathway | 1 | 254 | 8.93e-02 |
| KEGG | KEGG:03410 | Base excision repair | 1 | 33 | 9.40e-02 |
| KEGG | KEGG:05010 | Alzheimer disease | 1 | 315 | 9.49e-02 |
| KEGG | KEGG:04110 | Cell cycle | 1 | 151 | 9.59e-02 |
| KEGG | KEGG:00520 | Amino sugar and nucleotide sugar metabolism | 2 | 46 | 9.97e-02 |
| KEGG | KEGG:03030 | DNA replication | 1 | 35 | 9.97e-02 |
| KEGG | KEGG:03022 | Basal transcription factors | 2 | 40 | 1.04e-01 |
| KEGG | KEGG:03440 | Homologous recombination | 1 | 39 | 1.10e-01 |
| KEGG | KEGG:04340 | Hedgehog signaling pathway | 2 | 49 | 1.11e-01 |
| KEGG | KEGG:05202 | Transcriptional misregulation in cancer | 1 | 128 | 1.11e-01 |
| KEGG | KEGG:05168 | Herpes simplex virus 1 infection | 1 | 415 | 1.17e-01 |
| KEGG | KEGG:03420 | Nucleotide excision repair | 1 | 43 | 1.17e-01 |
| KEGG | KEGG:00020 | Citrate cycle (TCA cycle) | 1 | 28 | 1.37e-01 |
| KEGG | KEGG:03015 | mRNA surveillance pathway | 2 | 86 | 1.39e-01 |
| KEGG | KEGG:00670 | One carbon pool by folate | 1 | 18 | 1.39e-01 |
| KEGG | KEGG:05110 | Vibrio cholerae infection | 2 | 43 | 1.48e-01 |
| KEGG | KEGG:01200 | Carbon metabolism | 2 | 98 | 1.52e-01 |
| KEGG | KEGG:04010 | MAPK signaling pathway | 1 | 240 | 1.57e-01 |
| KEGG | KEGG:03013 | Nucleocytoplasmic transport | 2 | 99 | 1.61e-01 |
| KEGG | KEGG:00380 | Tryptophan metabolism | 1 | 23 | 1.75e-01 |
| KEGG | KEGG:01250 | Biosynthesis of nucleotide sugars | 1 | 35 | 1.83e-01 |
| KEGG | KEGG:00230 | Purine metabolism | 1 | 97 | 1.90e-01 |
| KEGG | KEGG:00630 | Glyoxylate and dicarboxylate metabolism | 1 | 25 | 1.90e-01 |
| KEGG | KEGG:01523 | Antifolate resistance | 1 | 24 | 1.90e-01 |
| KEGG | KEGG:03060 | Protein export | 1 | 23 | 2.28e-01 |
| KEGG | KEGG:04978 | Mineral absorption | 1 | 42 | 2.30e-01 |
| KEGG | KEGG:05132 | Salmonella infection | 3 | 214 | 2.30e-01 |
| KEGG | KEGG:04974 | Protein digestion and absorption | 2 | 61 | 2.30e-01 |
| KEGG | KEGG:05120 | Epithelial cell signaling in Helicobacter pylori infection | 2 | 58 | 2.31e-01 |
| KEGG | KEGG:00260 | Glycine, serine and threonine metabolism | 1 | 31 | 2.31e-01 |
| KEGG | KEGG:00310 | Lysine degradation | 1 | 59 | 2.40e-01 |
| KEGG | KEGG:04392 | Hippo signaling pathway - multiple species | 1 | 25 | 2.58e-01 |
| KEGG | KEGG:05412 | Arrhythmogenic right ventricular cardiomyopathy | 1 | 63 | 2.78e-01 |
| KEGG | KEGG:04710 | Circadian rhythm | 1 | 30 | 2.93e-01 |
| KEGG | KEGG:04934 | Cushing syndrome | 3 | 121 | 2.98e-01 |
| KEGG | KEGG:04260 | Cardiac muscle contraction | 1 | 67 | 3.04e-01 |
| KEGG | KEGG:05410 | Hypertrophic cardiomyopathy | 1 | 73 | 3.08e-01 |
| KEGG | KEGG:05323 | Rheumatoid arthritis | 2 | 43 | 3.08e-01 |
| KEGG | KEGG:04390 | Hippo signaling pathway | 3 | 134 | 3.08e-01 |
| KEGG | KEGG:05414 | Dilated cardiomyopathy | 1 | 78 | 3.19e-01 |
| KEGG | KEGG:03040 | Spliceosome | 2 | 132 | 3.23e-01 |
| KEGG | KEGG:05034 | Alcoholism | 3 | 122 | 3.26e-01 |
| KEGG | KEGG:03020 | RNA polymerase | 1 | 34 | 3.26e-01 |
| KEGG | KEGG:04310 | Wnt signaling pathway | 3 | 138 | 3.42e-01 |
| KEGG | KEGG:01230 | Biosynthesis of amino acids | 1 | 60 | 3.66e-01 |
| KEGG | KEGG:04916 | Melanogenesis | 2 | 77 | 3.66e-01 |
| KEGG | KEGG:00512 | Mucin type O-glycan biosynthesis | 1 | 22 | 3.69e-01 |
| KEGG | KEGG:04020 | Calcium signaling pathway | 2 | 157 | 3.69e-01 |
| KEGG | KEGG:04130 | SNARE interactions in vesicular transport | 1 | 32 | 3.76e-01 |
| KEGG | KEGG:00970 | Aminoacyl-tRNA biosynthesis | 1 | 44 | 3.83e-01 |
| KEGG | KEGG:00240 | Pyrimidine metabolism | 1 | 46 | 4.01e-01 |
| KEGG | KEGG:04371 | Apelin signaling pathway | 1 | 106 | 4.06e-01 |
| KEGG | KEGG:04144 | Endocytosis | 3 | 232 | 4.33e-01 |
| KEGG | KEGG:04979 | Cholesterol metabolism | 1 | 33 | 4.33e-01 |
| KEGG | KEGG:00514 | Other types of O-glycan biosynthesis | 1 | 37 | 4.35e-01 |
| KEGG | KEGG:04261 | Adrenergic signaling in cardiomyocytes | 1 | 128 | 4.35e-01 |
| KEGG | KEGG:01100 | Metabolic pathways | 1 | 1146 | 4.47e-01 |
| KEGG | KEGG:03250 | Viral life cycle - HIV-1 | 1 | 56 | 4.54e-01 |
| KEGG | KEGG:04022 | cGMP-PKG signaling pathway | 1 | 133 | 4.54e-01 |
| KEGG | KEGG:00190 | Oxidative phosphorylation | 2 | 106 | 4.73e-01 |
| KEGG | KEGG:00983 | Drug metabolism - other enzymes | 1 | 44 | 4.82e-01 |
| KEGG | KEGG:04330 | Notch signaling pathway | 1 | 51 | 4.83e-01 |
| KEGG | KEGG:04145 | Phagosome | 1 | 99 | 5.02e-01 |
| KEGG | KEGG:01232 | Nucleotide metabolism | 1 | 69 | 5.02e-01 |
| KEGG | KEGG:04270 | Vascular smooth muscle contraction | 1 | 94 | 5.16e-01 |
| KEGG | KEGG:04623 | Cytosolic DNA-sensing pathway | 1 | 42 | 5.29e-01 |
| KEGG | KEGG:05031 | Amphetamine addiction | 1 | 49 | 5.33e-01 |
| KEGG | KEGG:05152 | Tuberculosis | 1 | 106 | 5.54e-01 |
| KEGG | KEGG:04657 | IL-17 signaling pathway | 1 | 56 | 5.54e-01 |
| KEGG | KEGG:01240 | Biosynthesis of cofactors | 1 | 115 | 5.58e-01 |
| KEGG | KEGG:04921 | Oxytocin signaling pathway | 1 | 115 | 5.63e-01 |
| KEGG | KEGG:05016 | Huntington disease | 3 | 256 | 6.03e-01 |
| KEGG | KEGG:05022 | Pathways of neurodegeneration - multiple diseases | 5 | 385 | 6.07e-01 |
| KEGG | KEGG:04350 | TGF-beta signaling pathway | 1 | 84 | 6.07e-01 |
| KEGG | KEGG:04728 | Dopaminergic synapse | 1 | 103 | 6.80e-01 |
| KEGG | KEGG:04936 | Alcoholic liver disease | 1 | 97 | 7.04e-01 |
| KEGG | KEGG:00000 | KEGG root term | 3 | 5558 | 7.19e-01 |
| KEGG | KEGG:05322 | Systemic lupus erythematosus | 1 | 61 | 7.24e-01 |
| KEGG | KEGG:04740 | Olfactory transduction | 1 | 25 | 7.52e-01 |
| KEGG | KEGG:04114 | Oocyte meiosis | 1 | 108 | 7.57e-01 |
| KEGG | KEGG:04217 | Necroptosis | 1 | 106 | 7.78e-01 |
| KEGG | KEGG:05012 | Parkinson disease | 2 | 226 | 7.86e-01 |
| KEGG | KEGG:04120 | Ubiquitin mediated proteolysis | 1 | 134 | 7.95e-01 |
| KEGG | KEGG:05130 | Pathogenic Escherichia coli infection | 1 | 150 | 7.99e-01 |
| KEGG | KEGG:04621 | NOD-like receptor signaling pathway | 1 | 117 | 8.09e-01 |
| KEGG | KEGG:04080 | Neuroactive ligand-receptor interaction | 1 | 108 | 8.21e-01 |
| KEGG | KEGG:05014 | Amyotrophic lateral sclerosis | 1 | 303 | 9.60e-01 |
24 hour AC shared highly variable genes
based on nominal pvalues <0.05
venn24part <- VennDiagram::get.venn.partitions(geneset_24)
AC_share <- venn24part$..values..[[25]]
# AC_share_var24gost <- gost(query = AC_share,
# organism = "hsapiens",
# significant = FALSE,
# ordered_query = TRUE,
# domain_scope = "custom",
# measure_underrepresentation = FALSE,
# evcodes = FALSE,
# numeric_ns="ENTREZGENE",
# user_threshold = 0.05,
# correction_method = "fdr",
# custom_bg = backGL$ENTREZID,
# sources=c("GO:BP","KEGG"))
#
# saveRDS(AC_share_var24gost,"data/DEG-GO/var/AC_share_var24gost.RDS")
AC_share_var24gost <- readRDS("data/DEG-GO/var/AC_share_var24gost.RDS")
AC_share_var24p <- gostplot(AC_share_var24gost, capped = FALSE, interactive = TRUE)
AC_share_var24pAC_share_var24_table <- AC_share_var24gost$result %>%
dplyr::select(c(source, term_id, term_name,intersection_size, term_size, p_value))
AC_share_var24_table %>%
dplyr::filter(source=="GO:BP") %>%
dplyr::select(p_value,term_name,intersection_size) %>%
slice_min(., n=10 ,order_by=p_value) %>%
mutate(log_val = -log10(p_value)) %>%
# slice_max(., n=10,order_by = p_value) %>%
ggplot(., aes(x = log_val, y =reorder(term_name,p_value), col= intersection_size)) +
geom_point(aes(size = intersection_size)) +
geom_vline(xintercept = (-log10(0.05)), col="red")+
scale_y_discrete(labels = label_wrap(30))+
guides(col="none", size=guide_legend(title = "# of intersected \n terms"))+
ggtitle('AC_share24 hour top 10 GO:BP terms') +
xlab(expression(" -"~log[10]~("adj. p-value")))+
ylab("GO: BP term")+
theme_bw()+
theme(plot.title = element_text(size = rel(1.5), hjust = 0.5),
axis.title = element_text(size = 15, color = "black"),
axis.ticks = element_line(linewidth = 1.5),
axis.line = element_line(linewidth = 1.5),
axis.text = element_text(size = 10, color = "black", angle = 0),
strip.text.x = element_text(size = 15, color = "black", face = "bold")) 
AC_share_var24_table %>%
mutate_at(.vars = 6, .funs= scientific_format()) %>%
kable(.,caption = "AC_share 24 enrichment terms of highly var genes") %>%
kable_paper("striped", full_width = FALSE) %>%
kable_styling(full_width = FALSE, position = "left",bootstrap_options = c("striped","hover")) %>%
scroll_box(width = "100%", height = "400px")| source | term_id | term_name | intersection_size | term_size | p_value |
|---|---|---|---|---|---|
| GO:BP | GO:0043587 | tongue morphogenesis | 2 | 7 | 2.28e-01 |
| GO:BP | GO:0035281 | pre-miRNA export from nucleus | 1 | 2 | 2.28e-01 |
| GO:BP | GO:1902683 | regulation of receptor localization to synapse | 3 | 21 | 2.28e-01 |
| GO:BP | GO:0007286 | spermatid development | 2 | 105 | 2.28e-01 |
| GO:BP | GO:0007084 | mitotic nuclear membrane reassembly | 1 | 9 | 2.28e-01 |
| GO:BP | GO:1902473 | regulation of protein localization to synapse | 3 | 22 | 2.28e-01 |
| GO:BP | GO:0007224 | smoothened signaling pathway | 7 | 124 | 2.28e-01 |
| GO:BP | GO:0006997 | nucleus organization | 2 | 126 | 2.28e-01 |
| GO:BP | GO:0007164 | establishment of tissue polarity | 6 | 70 | 2.28e-01 |
| GO:BP | GO:0007341 | penetration of zona pellucida | 1 | 4 | 2.28e-01 |
| GO:BP | GO:0006888 | endoplasmic reticulum to Golgi vesicle-mediated transport | 2 | 119 | 2.28e-01 |
| GO:BP | GO:0043149 | stress fiber assembly | 4 | 94 | 2.28e-01 |
| GO:BP | GO:1903423 | positive regulation of synaptic vesicle recycling | 2 | 6 | 2.28e-01 |
| GO:BP | GO:0002351 | serotonin production involved in inflammatory response | 1 | 2 | 2.28e-01 |
| GO:BP | GO:0002442 | serotonin secretion involved in inflammatory response | 1 | 2 | 2.28e-01 |
| GO:BP | GO:0002541 | activation of plasma proteins involved in acute inflammatory response | 1 | 2 | 2.28e-01 |
| GO:BP | GO:0002543 | activation of blood coagulation via clotting cascade | 1 | 2 | 2.28e-01 |
| GO:BP | GO:0002552 | serotonin secretion by mast cell | 1 | 1 | 2.28e-01 |
| GO:BP | GO:0042176 | regulation of protein catabolic process | 13 | 331 | 2.28e-01 |
| GO:BP | GO:0042137 | sequestering of neurotransmitter | 1 | 1 | 2.28e-01 |
| GO:BP | GO:1900244 | positive regulation of synaptic vesicle endocytosis | 2 | 4 | 2.28e-01 |
| GO:BP | GO:0043217 | myelin maintenance | 2 | 15 | 2.28e-01 |
| GO:BP | GO:0043247 | telomere maintenance in response to DNA damage | 3 | 29 | 2.28e-01 |
| GO:BP | GO:2000807 | regulation of synaptic vesicle clustering | 2 | 7 | 2.28e-01 |
| GO:BP | GO:0003271 | smoothened signaling pathway involved in regulation of secondary heart field cardioblast proliferation | 1 | 1 | 2.28e-01 |
| GO:BP | GO:0003376 | sphingosine-1-phosphate receptor signaling pathway | 2 | 10 | 2.28e-01 |
| GO:BP | GO:0005979 | regulation of glycogen biosynthetic process | 2 | 25 | 2.28e-01 |
| GO:BP | GO:1990755 | mitotic spindle microtubule depolymerization | 1 | 1 | 2.28e-01 |
| GO:BP | GO:1905515 | non-motile cilium assembly | 6 | 58 | 2.28e-01 |
| GO:BP | GO:1905364 | regulation of endosomal vesicle fusion | 1 | 1 | 2.28e-01 |
| GO:BP | GO:0006580 | ethanolamine metabolic process | 1 | 1 | 2.28e-01 |
| GO:BP | GO:0036465 | synaptic vesicle recycling | 5 | 73 | 2.28e-01 |
| GO:BP | GO:0006790 | sulfur compound metabolic process | 2 | 248 | 2.28e-01 |
| GO:BP | GO:0036123 | histone H3-K9 dimethylation | 1 | 3 | 2.28e-01 |
| GO:BP | GO:1903421 | regulation of synaptic vesicle recycling | 3 | 23 | 2.28e-01 |
| GO:BP | GO:1900242 | regulation of synaptic vesicle endocytosis | 3 | 16 | 2.28e-01 |
| GO:BP | GO:0101024 | mitotic nuclear membrane organization | 1 | 9 | 2.28e-01 |
| GO:BP | GO:1900027 | regulation of ruffle assembly | 3 | 23 | 2.28e-01 |
| GO:BP | GO:0030031 | cell projection assembly | 15 | 469 | 2.28e-01 |
| GO:BP | GO:0046521 | sphingoid catabolic process | 1 | 1 | 2.28e-01 |
| GO:BP | GO:0021915 | neural tube development | 7 | 146 | 2.28e-01 |
| GO:BP | GO:0060119 | inner ear receptor cell development | 3 | 33 | 2.28e-01 |
| GO:BP | GO:0021527 | spinal cord association neuron differentiation | 1 | 3 | 2.28e-01 |
| GO:BP | GO:0021520 | spinal cord motor neuron cell fate specification | 1 | 5 | 2.28e-01 |
| GO:BP | GO:0021514 | ventral spinal cord interneuron differentiation | 1 | 5 | 2.28e-01 |
| GO:BP | GO:0060606 | tube closure | 6 | 91 | 2.28e-01 |
| GO:BP | GO:0060709 | glycogen cell differentiation involved in embryonic placenta development | 1 | 1 | 2.28e-01 |
| GO:BP | GO:0060716 | labyrinthine layer blood vessel development | 2 | 16 | 2.28e-01 |
| GO:BP | GO:0018107 | peptidyl-threonine phosphorylation | 4 | 97 | 2.28e-01 |
| GO:BP | GO:0018027 | peptidyl-lysine dimethylation | 2 | 22 | 2.28e-01 |
| GO:BP | GO:0018026 | peptidyl-lysine monomethylation | 2 | 11 | 2.28e-01 |
| GO:BP | GO:0061015 | snRNA import into nucleus | 1 | 2 | 2.28e-01 |
| GO:BP | GO:0046039 | GTP metabolic process | 2 | 21 | 2.28e-01 |
| GO:BP | GO:0030038 | contractile actin filament bundle assembly | 4 | 94 | 2.28e-01 |
| GO:BP | GO:0051615 | histamine uptake | 1 | 3 | 2.28e-01 |
| GO:BP | GO:0051493 | regulation of cytoskeleton organization | 10 | 459 | 2.28e-01 |
| GO:BP | GO:0051492 | regulation of stress fiber assembly | 4 | 81 | 2.28e-01 |
| GO:BP | GO:0032436 | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 5 | 89 | 2.28e-01 |
| GO:BP | GO:0048280 | vesicle fusion with Golgi apparatus | 1 | 8 | 2.28e-01 |
| GO:BP | GO:0048208 | COPII vesicle coating | 1 | 24 | 2.28e-01 |
| GO:BP | GO:0048207 | vesicle targeting, rough ER to cis-Golgi | 1 | 24 | 2.28e-01 |
| GO:BP | GO:0032287 | peripheral nervous system myelin maintenance | 2 | 8 | 2.28e-01 |
| GO:BP | GO:0048384 | retinoic acid receptor signaling pathway | 3 | 26 | 2.28e-01 |
| GO:BP | GO:0032231 | regulation of actin filament bundle assembly | 4 | 91 | 2.28e-01 |
| GO:BP | GO:0016242 | negative regulation of macroautophagy | 3 | 34 | 2.28e-01 |
| GO:BP | GO:0048488 | synaptic vesicle endocytosis | 5 | 63 | 2.28e-01 |
| GO:BP | GO:0048193 | Golgi vesicle transport | 3 | 285 | 2.28e-01 |
| GO:BP | GO:0031532 | actin cytoskeleton reorganization | 6 | 96 | 2.28e-01 |
| GO:BP | GO:0031503 | protein-containing complex localization | 10 | 168 | 2.28e-01 |
| GO:BP | GO:0031468 | nuclear membrane reassembly | 1 | 24 | 2.28e-01 |
| GO:BP | GO:0048146 | positive regulation of fibroblast proliferation | 3 | 45 | 2.28e-01 |
| GO:BP | GO:0051102 | DNA ligation involved in DNA recombination | 1 | 1 | 2.28e-01 |
| GO:BP | GO:0030219 | megakaryocyte differentiation | 1 | 54 | 2.28e-01 |
| GO:BP | GO:0048515 | spermatid differentiation | 2 | 111 | 2.28e-01 |
| GO:BP | GO:1900029 | positive regulation of ruffle assembly | 3 | 12 | 2.28e-01 |
| GO:BP | GO:0061956 | penetration of cumulus oophorus | 1 | 1 | 2.28e-01 |
| GO:BP | GO:0033189 | response to vitamin A | 3 | 12 | 2.28e-01 |
| GO:BP | GO:0009266 | response to temperature stimulus | 2 | 133 | 2.28e-01 |
| GO:BP | GO:0098884 | postsynaptic neurotransmitter receptor internalization | 3 | 17 | 2.28e-01 |
| GO:BP | GO:0099003 | vesicle-mediated transport in synapse | 9 | 180 | 2.28e-01 |
| GO:BP | GO:0099072 | regulation of postsynaptic membrane neurotransmitter receptor levels | 7 | 70 | 2.28e-01 |
| GO:BP | GO:0099123 | somato-dendritic dopamine secretion | 1 | 1 | 2.28e-01 |
| GO:BP | GO:0099633 | protein localization to postsynaptic specialization membrane | 3 | 19 | 2.28e-01 |
| GO:BP | GO:0099645 | neurotransmitter receptor localization to postsynaptic specialization membrane | 3 | 19 | 2.28e-01 |
| GO:BP | GO:0106057 | negative regulation of calcineurin-mediated signaling | 2 | 14 | 2.28e-01 |
| GO:BP | GO:0110020 | regulation of actomyosin structure organization | 4 | 90 | 2.28e-01 |
| GO:BP | GO:0120031 | plasma membrane bounded cell projection assembly | 14 | 461 | 2.28e-01 |
| GO:BP | GO:0044774 | mitotic DNA integrity checkpoint signaling | 5 | 85 | 2.28e-01 |
| GO:BP | GO:0044773 | mitotic DNA damage checkpoint signaling | 5 | 81 | 2.28e-01 |
| GO:BP | GO:0140212 | regulation of long-chain fatty acid import into cell | 2 | 7 | 2.28e-01 |
| GO:BP | GO:0140238 | presynaptic endocytosis | 5 | 65 | 2.28e-01 |
| GO:BP | GO:0140239 | postsynaptic endocytosis | 3 | 17 | 2.28e-01 |
| GO:BP | GO:0098696 | regulation of neurotransmitter receptor localization to postsynaptic specialization membrane | 3 | 11 | 2.28e-01 |
| GO:BP | GO:0097711 | ciliary basal body-plasma membrane docking | 1 | 2 | 2.28e-01 |
| GO:BP | GO:0097120 | receptor localization to synapse | 5 | 55 | 2.28e-01 |
| GO:BP | GO:0090520 | sphingolipid mediated signaling pathway | 2 | 11 | 2.28e-01 |
| GO:BP | GO:0015911 | long-chain fatty acid import across plasma membrane | 2 | 9 | 2.28e-01 |
| GO:BP | GO:0015842 | aminergic neurotransmitter loading into synaptic vesicle | 1 | 1 | 2.28e-01 |
| GO:BP | GO:0015012 | heparan sulfate proteoglycan biosynthetic process | 1 | 27 | 2.28e-01 |
| GO:BP | GO:0070875 | positive regulation of glycogen metabolic process | 2 | 13 | 2.28e-01 |
| GO:BP | GO:0070885 | negative regulation of calcineurin-NFAT signaling cascade | 2 | 14 | 2.28e-01 |
| GO:BP | GO:0014020 | primary neural tube formation | 6 | 94 | 2.28e-01 |
| GO:BP | GO:0010962 | regulation of glucan biosynthetic process | 2 | 25 | 2.28e-01 |
| GO:BP | GO:0016050 | vesicle organization | 3 | 320 | 2.28e-01 |
| GO:BP | GO:0071479 | cellular response to ionizing radiation | 5 | 68 | 2.28e-01 |
| GO:BP | GO:0075713 | establishment of integrated proviral latency | 1 | 1 | 2.28e-01 |
| GO:BP | GO:0045725 | positive regulation of glycogen biosynthetic process | 2 | 12 | 2.28e-01 |
| GO:BP | GO:0045654 | positive regulation of megakaryocyte differentiation | 1 | 9 | 2.28e-01 |
| GO:BP | GO:0010641 | positive regulation of platelet-derived growth factor receptor signaling pathway | 1 | 4 | 2.28e-01 |
| GO:BP | GO:0045652 | regulation of megakaryocyte differentiation | 1 | 33 | 2.28e-01 |
| GO:BP | GO:0045639 | positive regulation of myeloid cell differentiation | 1 | 67 | 2.28e-01 |
| GO:BP | GO:0090303 | positive regulation of wound healing | 2 | 45 | 2.28e-01 |
| GO:BP | GO:0010746 | regulation of long-chain fatty acid import across plasma membrane | 2 | 5 | 2.28e-01 |
| GO:BP | GO:0099590 | neurotransmitter receptor internalization | 3 | 19 | 2.28e-01 |
| GO:BP | GO:0032434 | regulation of proteasomal ubiquitin-dependent protein catabolic process | 7 | 133 | 2.28e-01 |
| GO:BP | GO:0001838 | embryonic epithelial tube formation | 6 | 116 | 2.28e-01 |
| GO:BP | GO:0001841 | neural tube formation | 6 | 101 | 2.28e-01 |
| GO:BP | GO:0001843 | neural tube closure | 6 | 90 | 2.28e-01 |
| GO:BP | GO:0002066 | columnar/cuboidal epithelial cell development | 3 | 38 | 2.28e-01 |
| GO:BP | GO:0001736 | establishment of planar polarity | 6 | 70 | 2.28e-01 |
| GO:BP | GO:0001738 | morphogenesis of a polarized epithelium | 6 | 88 | 2.28e-01 |
| GO:BP | GO:0006537 | glutamate biosynthetic process | 1 | 5 | 2.29e-01 |
| GO:BP | GO:1903847 | regulation of aorta morphogenesis | 1 | 2 | 2.34e-01 |
| GO:BP | GO:1903849 | positive regulation of aorta morphogenesis | 1 | 2 | 2.34e-01 |
| GO:BP | GO:2000249 | regulation of actin cytoskeleton reorganization | 2 | 32 | 2.36e-01 |
| GO:BP | GO:0051495 | positive regulation of cytoskeleton organization | 4 | 165 | 2.36e-01 |
| GO:BP | GO:1903047 | mitotic cell cycle process | 19 | 694 | 2.40e-01 |
| GO:BP | GO:0006596 | polyamine biosynthetic process | 2 | 13 | 2.43e-01 |
| GO:BP | GO:1905651 | regulation of artery morphogenesis | 1 | 5 | 2.43e-01 |
| GO:BP | GO:1905653 | positive regulation of artery morphogenesis | 1 | 5 | 2.43e-01 |
| GO:BP | GO:0090176 | microtubule cytoskeleton organization involved in establishment of planar polarity | 1 | 3 | 2.43e-01 |
| GO:BP | GO:0038061 | NIK/NF-kappaB signaling | 4 | 86 | 2.43e-01 |
| GO:BP | GO:1904507 | positive regulation of telomere maintenance in response to DNA damage | 2 | 14 | 2.43e-01 |
| GO:BP | GO:0006458 | ‘de novo’ protein folding | 1 | 39 | 2.43e-01 |
| GO:BP | GO:0006611 | protein export from nucleus | 2 | 55 | 2.43e-01 |
| GO:BP | GO:0034486 | vacuolar transmembrane transport | 1 | 3 | 2.43e-01 |
| GO:BP | GO:0097178 | ruffle assembly | 3 | 37 | 2.43e-01 |
| GO:BP | GO:0010453 | regulation of cell fate commitment | 1 | 26 | 2.43e-01 |
| GO:BP | GO:0010332 | response to gamma radiation | 3 | 50 | 2.43e-01 |
| GO:BP | GO:1905205 | positive regulation of connective tissue replacement | 1 | 3 | 2.43e-01 |
| GO:BP | GO:0010212 | response to ionizing radiation | 3 | 130 | 2.43e-01 |
| GO:BP | GO:0090316 | positive regulation of intracellular protein transport | 3 | 133 | 2.43e-01 |
| GO:BP | GO:0045190 | isotype switching | 2 | 39 | 2.43e-01 |
| GO:BP | GO:0010638 | positive regulation of organelle organization | 6 | 439 | 2.43e-01 |
| GO:BP | GO:0097281 | immune complex formation | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0006538 | glutamate catabolic process | 1 | 7 | 2.43e-01 |
| GO:BP | GO:0097091 | synaptic vesicle clustering | 2 | 16 | 2.43e-01 |
| GO:BP | GO:0045637 | regulation of myeloid cell differentiation | 1 | 152 | 2.43e-01 |
| GO:BP | GO:0006595 | polyamine metabolic process | 2 | 16 | 2.43e-01 |
| GO:BP | GO:0097115 | neurexin clustering involved in presynaptic membrane assembly | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0090125 | cell-cell adhesion involved in synapse maturation | 1 | 2 | 2.43e-01 |
| GO:BP | GO:0042490 | mechanoreceptor differentiation | 3 | 49 | 2.43e-01 |
| GO:BP | GO:0070384 | Harderian gland development | 1 | 4 | 2.43e-01 |
| GO:BP | GO:0070873 | regulation of glycogen metabolic process | 2 | 28 | 2.43e-01 |
| GO:BP | GO:0070884 | regulation of calcineurin-NFAT signaling cascade | 3 | 32 | 2.43e-01 |
| GO:BP | GO:0070925 | organelle assembly | 19 | 817 | 2.43e-01 |
| GO:BP | GO:0033387 | putrescine biosynthetic process from ornithine | 1 | 3 | 2.43e-01 |
| GO:BP | GO:0006297 | nucleotide-excision repair, DNA gap filling | 1 | 5 | 2.43e-01 |
| GO:BP | GO:0014003 | oligodendrocyte development | 1 | 27 | 2.43e-01 |
| GO:BP | GO:0034242 | negative regulation of syncytium formation by plasma membrane fusion | 1 | 3 | 2.43e-01 |
| GO:BP | GO:0071709 | membrane assembly | 1 | 53 | 2.43e-01 |
| GO:BP | GO:0010907 | positive regulation of glucose metabolic process | 2 | 36 | 2.43e-01 |
| GO:BP | GO:0007042 | lysosomal lumen acidification | 1 | 21 | 2.43e-01 |
| GO:BP | GO:2000060 | positive regulation of ubiquitin-dependent protein catabolic process | 5 | 103 | 2.43e-01 |
| GO:BP | GO:2000058 | regulation of ubiquitin-dependent protein catabolic process | 7 | 160 | 2.43e-01 |
| GO:BP | GO:0072175 | epithelial tube formation | 6 | 127 | 2.43e-01 |
| GO:BP | GO:0072350 | tricarboxylic acid metabolic process | 1 | 13 | 2.43e-01 |
| GO:BP | GO:0034260 | negative regulation of GTPase activity | 2 | 29 | 2.43e-01 |
| GO:BP | GO:0090114 | COPII-coated vesicle budding | 1 | 40 | 2.43e-01 |
| GO:BP | GO:0009566 | fertilization | 1 | 93 | 2.43e-01 |
| GO:BP | GO:0001659 | temperature homeostasis | 2 | 132 | 2.43e-01 |
| GO:BP | GO:0072656 | maintenance of protein location in mitochondrion | 1 | 5 | 2.43e-01 |
| GO:BP | GO:1990403 | embryonic brain development | 2 | 13 | 2.43e-01 |
| GO:BP | GO:1990418 | response to insulin-like growth factor stimulus | 1 | 2 | 2.43e-01 |
| GO:BP | GO:0010640 | regulation of platelet-derived growth factor receptor signaling pathway | 1 | 19 | 2.43e-01 |
| GO:BP | GO:0072595 | maintenance of protein localization in organelle | 2 | 39 | 2.43e-01 |
| GO:BP | GO:0042659 | regulation of cell fate specification | 1 | 23 | 2.43e-01 |
| GO:BP | GO:0010747 | positive regulation of long-chain fatty acid import across plasma membrane | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0010748 | negative regulation of long-chain fatty acid import across plasma membrane | 1 | 4 | 2.43e-01 |
| GO:BP | GO:0010765 | positive regulation of sodium ion transport | 2 | 30 | 2.43e-01 |
| GO:BP | GO:1990845 | adaptive thermogenesis | 2 | 121 | 2.43e-01 |
| GO:BP | GO:1990849 | vacuolar localization | 3 | 62 | 2.43e-01 |
| GO:BP | GO:0006404 | RNA import into nucleus | 1 | 4 | 2.43e-01 |
| GO:BP | GO:1904505 | regulation of telomere maintenance in response to DNA damage | 2 | 17 | 2.43e-01 |
| GO:BP | GO:0009250 | glucan biosynthetic process | 2 | 39 | 2.43e-01 |
| GO:BP | GO:0009439 | cyanate metabolic process | 1 | 2 | 2.43e-01 |
| GO:BP | GO:0006900 | vesicle budding from membrane | 1 | 76 | 2.43e-01 |
| GO:BP | GO:0006901 | vesicle coating | 1 | 36 | 2.43e-01 |
| GO:BP | GO:0006903 | vesicle targeting | 1 | 61 | 2.43e-01 |
| GO:BP | GO:0044706 | multi-multicellular organism process | 1 | 135 | 2.43e-01 |
| GO:BP | GO:0044539 | long-chain fatty acid import into cell | 2 | 14 | 2.43e-01 |
| GO:BP | GO:0006913 | nucleocytoplasmic transport | 5 | 295 | 2.43e-01 |
| GO:BP | GO:0007507 | heart development | 15 | 506 | 2.43e-01 |
| GO:BP | GO:0044272 | sulfur compound biosynthetic process | 1 | 122 | 2.43e-01 |
| GO:BP | GO:0044091 | membrane biogenesis | 1 | 58 | 2.43e-01 |
| GO:BP | GO:0044088 | regulation of vacuole organization | 3 | 50 | 2.43e-01 |
| GO:BP | GO:0044087 | regulation of cellular component biogenesis | 13 | 809 | 2.43e-01 |
| GO:BP | GO:0007338 | single fertilization | 1 | 70 | 2.43e-01 |
| GO:BP | GO:1902902 | negative regulation of autophagosome assembly | 2 | 14 | 2.43e-01 |
| GO:BP | GO:1901160 | primary amino compound metabolic process | 2 | 8 | 2.43e-01 |
| GO:BP | GO:1902850 | microtubule cytoskeleton organization involved in mitosis | 2 | 157 | 2.43e-01 |
| GO:BP | GO:0007289 | spermatid nucleus differentiation | 1 | 16 | 2.43e-01 |
| GO:BP | GO:0007281 | germ cell development | 2 | 187 | 2.43e-01 |
| GO:BP | GO:0007265 | Ras protein signal transduction | 7 | 294 | 2.43e-01 |
| GO:BP | GO:0007264 | small GTPase mediated signal transduction | 9 | 421 | 2.43e-01 |
| GO:BP | GO:0043650 | dicarboxylic acid biosynthetic process | 1 | 9 | 2.43e-01 |
| GO:BP | GO:0006996 | organelle organization | 35 | 3000 | 2.43e-01 |
| GO:BP | GO:1901796 | regulation of signal transduction by p53 class mediator | 3 | 101 | 2.43e-01 |
| GO:BP | GO:0006998 | nuclear envelope organization | 1 | 57 | 2.43e-01 |
| GO:BP | GO:1901800 | positive regulation of proteasomal protein catabolic process | 5 | 111 | 2.43e-01 |
| GO:BP | GO:0001893 | maternal placenta development | 3 | 28 | 2.43e-01 |
| GO:BP | GO:0043586 | tongue development | 2 | 15 | 2.43e-01 |
| GO:BP | GO:1902001 | fatty acid transmembrane transport | 2 | 15 | 2.43e-01 |
| GO:BP | GO:1902231 | positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage | 1 | 7 | 2.43e-01 |
| GO:BP | GO:0007052 | mitotic spindle organization | 2 | 129 | 2.43e-01 |
| GO:BP | GO:1903036 | positive regulation of response to wounding | 2 | 55 | 2.43e-01 |
| GO:BP | GO:0006891 | intra-Golgi vesicle-mediated transport | 1 | 33 | 2.43e-01 |
| GO:BP | GO:1903050 | regulation of proteolysis involved in protein catabolic process | 1 | 214 | 2.43e-01 |
| GO:BP | GO:1900048 | positive regulation of hemostasis | 1 | 21 | 2.43e-01 |
| GO:BP | GO:0098700 | neurotransmitter loading into synaptic vesicle | 1 | 1 | 2.43e-01 |
| GO:BP | GO:1904161 | DNA synthesis involved in UV-damage excision repair | 1 | 2 | 2.43e-01 |
| GO:BP | GO:1904155 | DN2 thymocyte differentiation | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0009409 | response to cold | 1 | 41 | 2.43e-01 |
| GO:BP | GO:0070071 | proton-transporting two-sector ATPase complex assembly | 1 | 15 | 2.43e-01 |
| GO:BP | GO:1903929 | primary palate development | 1 | 2 | 2.43e-01 |
| GO:BP | GO:0099022 | vesicle tethering | 1 | 31 | 2.43e-01 |
| GO:BP | GO:0044782 | cilium organization | 10 | 313 | 2.43e-01 |
| GO:BP | GO:0099149 | regulation of postsynaptic neurotransmitter receptor internalization | 2 | 11 | 2.43e-01 |
| GO:BP | GO:0035092 | sperm DNA condensation | 1 | 7 | 2.43e-01 |
| GO:BP | GO:0099504 | synaptic vesicle cycle | 7 | 163 | 2.43e-01 |
| GO:BP | GO:0032418 | lysosome localization | 3 | 62 | 2.43e-01 |
| GO:BP | GO:0106056 | regulation of calcineurin-mediated signaling | 3 | 32 | 2.43e-01 |
| GO:BP | GO:0006782 | protoporphyrinogen IX biosynthetic process | 1 | 9 | 2.43e-01 |
| GO:BP | GO:0009440 | cyanate catabolic process | 1 | 2 | 2.43e-01 |
| GO:BP | GO:0106106 | cold-induced thermogenesis | 2 | 113 | 2.43e-01 |
| GO:BP | GO:0036124 | histone H3-K9 trimethylation | 1 | 9 | 2.43e-01 |
| GO:BP | GO:0001820 | serotonin secretion | 1 | 5 | 2.43e-01 |
| GO:BP | GO:0120161 | regulation of cold-induced thermogenesis | 2 | 112 | 2.43e-01 |
| GO:BP | GO:0120163 | negative regulation of cold-induced thermogenesis | 1 | 40 | 2.43e-01 |
| GO:BP | GO:0035148 | tube formation | 6 | 138 | 2.43e-01 |
| GO:BP | GO:0140014 | mitotic nuclear division | 4 | 251 | 2.43e-01 |
| GO:BP | GO:0035981 | tongue muscle cell differentiation | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0001821 | histamine secretion | 1 | 9 | 2.43e-01 |
| GO:BP | GO:0035970 | peptidyl-threonine dephosphorylation | 2 | 17 | 2.43e-01 |
| GO:BP | GO:0140213 | negative regulation of long-chain fatty acid import into cell | 1 | 4 | 2.43e-01 |
| GO:BP | GO:0042669 | regulation of inner ear auditory receptor cell fate specification | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0140354 | lipid import into cell | 2 | 15 | 2.43e-01 |
| GO:BP | GO:0140694 | non-membrane-bounded organelle assembly | 3 | 357 | 2.43e-01 |
| GO:BP | GO:0008045 | motor neuron axon guidance | 1 | 25 | 2.43e-01 |
| GO:BP | GO:0110061 | regulation of angiotensin-activated signaling pathway | 1 | 2 | 2.43e-01 |
| GO:BP | GO:0070070 | proton-transporting V-type ATPase complex assembly | 1 | 7 | 2.43e-01 |
| GO:BP | GO:0071763 | nuclear membrane organization | 1 | 42 | 2.43e-01 |
| GO:BP | GO:0033153 | T cell receptor V(D)J recombination | 1 | 4 | 2.43e-01 |
| GO:BP | GO:0021522 | spinal cord motor neuron differentiation | 1 | 18 | 2.43e-01 |
| GO:BP | GO:0030865 | cortical cytoskeleton organization | 4 | 55 | 2.43e-01 |
| GO:BP | GO:0042754 | negative regulation of circadian rhythm | 1 | 10 | 2.43e-01 |
| GO:BP | GO:0051103 | DNA ligation involved in DNA repair | 1 | 5 | 2.43e-01 |
| GO:BP | GO:0051084 | ‘de novo’ post-translational protein folding | 1 | 35 | 2.43e-01 |
| GO:BP | GO:0021516 | dorsal spinal cord development | 1 | 7 | 2.43e-01 |
| GO:BP | GO:0051030 | snRNA transport | 1 | 6 | 2.43e-01 |
| GO:BP | GO:0050927 | positive regulation of positive chemotaxis | 1 | 20 | 2.43e-01 |
| GO:BP | GO:0050926 | regulation of positive chemotaxis | 1 | 20 | 2.43e-01 |
| GO:BP | GO:0031294 | lymphocyte costimulation | 2 | 23 | 2.43e-01 |
| GO:BP | GO:0031295 | T cell costimulation | 2 | 22 | 2.43e-01 |
| GO:BP | GO:0032970 | regulation of actin filament-based process | 7 | 340 | 2.43e-01 |
| GO:BP | GO:0002681 | somatic recombination of T cell receptor gene segments | 1 | 4 | 2.43e-01 |
| GO:BP | GO:0050893 | sensory processing | 1 | 4 | 2.43e-01 |
| GO:BP | GO:0002183 | cytoplasmic translational initiation | 1 | 38 | 2.43e-01 |
| GO:BP | GO:0060271 | cilium assembly | 10 | 292 | 2.43e-01 |
| GO:BP | GO:0002568 | somatic diversification of T cell receptor genes | 1 | 4 | 2.43e-01 |
| GO:BP | GO:0019860 | uracil metabolic process | 1 | 2 | 2.43e-01 |
| GO:BP | GO:0060296 | regulation of cilium beat frequency involved in ciliary motility | 1 | 6 | 2.43e-01 |
| GO:BP | GO:0051169 | nuclear transport | 5 | 295 | 2.43e-01 |
| GO:BP | GO:0060122 | inner ear receptor cell stereocilium organization | 2 | 23 | 2.43e-01 |
| GO:BP | GO:0046381 | CMP-N-acetylneuraminate metabolic process | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0060113 | inner ear receptor cell differentiation | 3 | 47 | 2.43e-01 |
| GO:BP | GO:2001035 | regulation of tongue muscle cell differentiation | 1 | 1 | 2.43e-01 |
| GO:BP | GO:2001034 | positive regulation of double-strand break repair via nonhomologous end joining | 1 | 12 | 2.43e-01 |
| GO:BP | GO:0051496 | positive regulation of stress fiber assembly | 2 | 47 | 2.43e-01 |
| GO:BP | GO:0030166 | proteoglycan biosynthetic process | 1 | 51 | 2.43e-01 |
| GO:BP | GO:0032881 | regulation of polysaccharide metabolic process | 2 | 34 | 2.43e-01 |
| GO:BP | GO:0030194 | positive regulation of blood coagulation | 1 | 21 | 2.43e-01 |
| GO:BP | GO:0002064 | epithelial cell development | 5 | 156 | 2.43e-01 |
| GO:BP | GO:0051490 | negative regulation of filopodium assembly | 1 | 6 | 2.43e-01 |
| GO:BP | GO:0051452 | intracellular pH reduction | 2 | 45 | 2.43e-01 |
| GO:BP | GO:0060382 | regulation of DNA strand elongation | 2 | 16 | 2.43e-01 |
| GO:BP | GO:0022412 | cellular process involved in reproduction in multicellular organism | 2 | 252 | 2.43e-01 |
| GO:BP | GO:0030309 | poly-N-acetyllactosamine metabolic process | 1 | 6 | 2.43e-01 |
| GO:BP | GO:0046824 | positive regulation of nucleocytoplasmic transport | 2 | 51 | 2.43e-01 |
| GO:BP | GO:0051301 | cell division | 16 | 570 | 2.43e-01 |
| GO:BP | GO:0002068 | glandular epithelial cell development | 2 | 28 | 2.43e-01 |
| GO:BP | GO:0046501 | protoporphyrinogen IX metabolic process | 1 | 11 | 2.43e-01 |
| GO:BP | GO:0022011 | myelination in peripheral nervous system | 2 | 25 | 2.43e-01 |
| GO:BP | GO:0051225 | spindle assembly | 2 | 120 | 2.43e-01 |
| GO:BP | GO:0046500 | S-adenosylmethionine metabolic process | 2 | 13 | 2.43e-01 |
| GO:BP | GO:0032956 | regulation of actin cytoskeleton organization | 7 | 299 | 2.43e-01 |
| GO:BP | GO:0032885 | regulation of polysaccharide biosynthetic process | 2 | 31 | 2.43e-01 |
| GO:BP | GO:0051877 | pigment granule aggregation in cell center | 1 | 2 | 2.43e-01 |
| GO:BP | GO:0033043 | regulation of organelle organization | 27 | 1028 | 2.43e-01 |
| GO:BP | GO:0060534 | trachea cartilage development | 1 | 4 | 2.43e-01 |
| GO:BP | GO:0006029 | proteoglycan metabolic process | 1 | 77 | 2.43e-01 |
| GO:BP | GO:0003356 | regulation of cilium beat frequency | 1 | 10 | 2.43e-01 |
| GO:BP | GO:0061024 | membrane organization | 4 | 671 | 2.43e-01 |
| GO:BP | GO:0006055 | CMP-N-acetylneuraminate biosynthetic process | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0002441 | histamine secretion involved in inflammatory response | 1 | 8 | 2.43e-01 |
| GO:BP | GO:0032077 | positive regulation of deoxyribonuclease activity | 1 | 5 | 2.43e-01 |
| GO:BP | GO:0061025 | membrane fusion | 2 | 137 | 2.43e-01 |
| GO:BP | GO:0032079 | positive regulation of endodeoxyribonuclease activity | 1 | 4 | 2.43e-01 |
| GO:BP | GO:0061136 | regulation of proteasomal protein catabolic process | 8 | 183 | 2.43e-01 |
| GO:BP | GO:0048560 | establishment of anatomical structure orientation | 1 | 2 | 2.43e-01 |
| GO:BP | GO:0002383 | immune response in brain or nervous system | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0048388 | endosomal lumen acidification | 1 | 13 | 2.43e-01 |
| GO:BP | GO:0016331 | morphogenesis of embryonic epithelium | 6 | 132 | 2.43e-01 |
| GO:BP | GO:0032233 | positive regulation of actin filament bundle assembly | 2 | 54 | 2.43e-01 |
| GO:BP | GO:0002349 | histamine production involved in inflammatory response | 1 | 8 | 2.43e-01 |
| GO:BP | GO:0032292 | peripheral nervous system axon ensheathment | 2 | 25 | 2.43e-01 |
| GO:BP | GO:0048199 | vesicle targeting, to, from or within Golgi | 1 | 31 | 2.43e-01 |
| GO:BP | GO:0018022 | peptidyl-lysine methylation | 3 | 104 | 2.43e-01 |
| GO:BP | GO:0048665 | neuron fate specification | 1 | 14 | 2.43e-01 |
| GO:BP | GO:0000076 | DNA replication checkpoint signaling | 2 | 15 | 2.43e-01 |
| GO:BP | GO:0018210 | peptidyl-threonine modification | 4 | 104 | 2.43e-01 |
| GO:BP | GO:0050849 | negative regulation of calcium-mediated signaling | 2 | 15 | 2.43e-01 |
| GO:BP | GO:0002553 | histamine secretion by mast cell | 1 | 8 | 2.43e-01 |
| GO:BP | GO:0050820 | positive regulation of coagulation | 1 | 23 | 2.43e-01 |
| GO:BP | GO:0003415 | chondrocyte hypertrophy | 1 | 6 | 2.43e-01 |
| GO:BP | GO:0002204 | somatic recombination of immunoglobulin genes involved in immune response | 2 | 39 | 2.43e-01 |
| GO:BP | GO:0060674 | placenta blood vessel development | 2 | 26 | 2.43e-01 |
| GO:BP | GO:0048789 | cytoskeletal matrix organization at active zone | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0003430 | growth plate cartilage chondrocyte growth | 1 | 3 | 2.43e-01 |
| GO:BP | GO:0003431 | growth plate cartilage chondrocyte development | 1 | 5 | 2.43e-01 |
| GO:BP | GO:0019043 | establishment of viral latency | 1 | 3 | 2.43e-01 |
| GO:BP | GO:0019042 | viral latency | 1 | 4 | 2.43e-01 |
| GO:BP | GO:0048145 | regulation of fibroblast proliferation | 3 | 77 | 2.43e-01 |
| GO:BP | GO:0031573 | mitotic intra-S DNA damage checkpoint signaling | 2 | 15 | 2.43e-01 |
| GO:BP | GO:0031641 | regulation of myelination | 2 | 36 | 2.43e-01 |
| GO:BP | GO:0005978 | glycogen biosynthetic process | 2 | 39 | 2.43e-01 |
| GO:BP | GO:0002208 | somatic diversification of immunoglobulins involved in immune response | 2 | 39 | 2.43e-01 |
| GO:BP | GO:2001037 | positive regulation of tongue muscle cell differentiation | 1 | 1 | 2.43e-01 |
| GO:BP | GO:0033173 | calcineurin-NFAT signaling cascade | 3 | 37 | 2.43e-01 |
| GO:BP | GO:0007033 | vacuole organization | 2 | 197 | 2.43e-01 |
| GO:BP | GO:0031529 | ruffle organization | 3 | 45 | 2.44e-01 |
| GO:BP | GO:0002320 | lymphoid progenitor cell differentiation | 2 | 17 | 2.44e-01 |
| GO:BP | GO:1902045 | negative regulation of Fas signaling pathway | 1 | 2 | 2.44e-01 |
| GO:BP | GO:0002381 | immunoglobulin production involved in immunoglobulin-mediated immune response | 2 | 41 | 2.44e-01 |
| GO:BP | GO:0051017 | actin filament bundle assembly | 4 | 138 | 2.44e-01 |
| GO:BP | GO:1902811 | positive regulation of skeletal muscle fiber differentiation | 1 | 2 | 2.44e-01 |
| GO:BP | GO:0051610 | serotonin uptake | 1 | 8 | 2.44e-01 |
| GO:BP | GO:0014044 | Schwann cell development | 2 | 28 | 2.44e-01 |
| GO:BP | GO:0006470 | protein dephosphorylation | 8 | 214 | 2.44e-01 |
| GO:BP | GO:0003150 | muscular septum morphogenesis | 1 | 4 | 2.45e-01 |
| GO:BP | GO:0097352 | autophagosome maturation | 3 | 55 | 2.45e-01 |
| GO:BP | GO:0036500 | ATF6-mediated unfolded protein response | 1 | 9 | 2.45e-01 |
| GO:BP | GO:0055014 | atrial cardiac muscle cell development | 1 | 3 | 2.46e-01 |
| GO:BP | GO:0055011 | atrial cardiac muscle cell differentiation | 1 | 3 | 2.46e-01 |
| GO:BP | GO:0097680 | double-strand break repair via classical nonhomologous end joining | 1 | 6 | 2.47e-01 |
| GO:BP | GO:0006597 | spermine biosynthetic process | 1 | 2 | 2.50e-01 |
| GO:BP | GO:0007088 | regulation of mitotic nuclear division | 1 | 100 | 2.50e-01 |
| GO:BP | GO:0051168 | nuclear export | 3 | 150 | 2.50e-01 |
| GO:BP | GO:0061572 | actin filament bundle organization | 4 | 140 | 2.50e-01 |
| GO:BP | GO:0003433 | chondrocyte development involved in endochondral bone morphogenesis | 1 | 6 | 2.51e-01 |
| GO:BP | GO:0070291 | N-acylethanolamine metabolic process | 1 | 4 | 2.51e-01 |
| GO:BP | GO:0006231 | dTMP biosynthetic process | 1 | 4 | 2.53e-01 |
| GO:BP | GO:0010256 | endomembrane system organization | 3 | 496 | 2.53e-01 |
| GO:BP | GO:0021517 | ventral spinal cord development | 1 | 25 | 2.53e-01 |
| GO:BP | GO:0009177 | pyrimidine deoxyribonucleoside monophosphate biosynthetic process | 1 | 4 | 2.53e-01 |
| GO:BP | GO:0046075 | dTTP metabolic process | 1 | 4 | 2.53e-01 |
| GO:BP | GO:0051608 | histamine transport | 1 | 11 | 2.53e-01 |
| GO:BP | GO:0007163 | establishment or maintenance of cell polarity | 8 | 206 | 2.53e-01 |
| GO:BP | GO:0006235 | dTTP biosynthetic process | 1 | 4 | 2.53e-01 |
| GO:BP | GO:0044778 | meiotic DNA integrity checkpoint signaling | 1 | 1 | 2.53e-01 |
| GO:BP | GO:0009212 | pyrimidine deoxyribonucleoside triphosphate biosynthetic process | 1 | 4 | 2.53e-01 |
| GO:BP | GO:0003383 | apical constriction | 1 | 4 | 2.54e-01 |
| GO:BP | GO:1903347 | negative regulation of bicellular tight junction assembly | 1 | 3 | 2.54e-01 |
| GO:BP | GO:0002042 | cell migration involved in sprouting angiogenesis | 2 | 45 | 2.54e-01 |
| GO:BP | GO:0051129 | negative regulation of cellular component organization | 10 | 604 | 2.56e-01 |
| GO:BP | GO:1905259 | negative regulation of nitrosative stress-induced intrinsic apoptotic signaling pathway | 1 | 2 | 2.56e-01 |
| GO:BP | GO:0042667 | auditory receptor cell fate specification | 1 | 1 | 2.56e-01 |
| GO:BP | GO:0016447 | somatic recombination of immunoglobulin gene segments | 2 | 47 | 2.56e-01 |
| GO:BP | GO:0030100 | regulation of endocytosis | 9 | 211 | 2.56e-01 |
| GO:BP | GO:1905258 | regulation of nitrosative stress-induced intrinsic apoptotic signaling pathway | 1 | 2 | 2.56e-01 |
| GO:BP | GO:0110032 | positive regulation of G2/MI transition of meiotic cell cycle | 1 | 3 | 2.56e-01 |
| GO:BP | GO:0097720 | calcineurin-mediated signaling | 3 | 38 | 2.56e-01 |
| GO:BP | GO:0031999 | negative regulation of fatty acid beta-oxidation | 1 | 5 | 2.56e-01 |
| GO:BP | GO:0048538 | thymus development | 1 | 35 | 2.56e-01 |
| GO:BP | GO:0036261 | 7-methylguanosine cap hypermethylation | 1 | 8 | 2.56e-01 |
| GO:BP | GO:0007051 | spindle organization | 2 | 188 | 2.56e-01 |
| GO:BP | GO:0002090 | regulation of receptor internalization | 2 | 49 | 2.57e-01 |
| GO:BP | GO:0043649 | dicarboxylic acid catabolic process | 1 | 14 | 2.57e-01 |
| GO:BP | GO:0000077 | DNA damage checkpoint signaling | 5 | 121 | 2.57e-01 |
| GO:BP | GO:2000727 | positive regulation of cardiac muscle cell differentiation | 1 | 6 | 2.57e-01 |
| GO:BP | GO:0051146 | striated muscle cell differentiation | 7 | 233 | 2.58e-01 |
| GO:BP | GO:2000642 | negative regulation of early endosome to late endosome transport | 1 | 2 | 2.58e-01 |
| GO:BP | GO:0010839 | negative regulation of keratinocyte proliferation | 2 | 19 | 2.58e-01 |
| GO:BP | GO:0035781 | CD86 biosynthetic process | 1 | 2 | 2.59e-01 |
| GO:BP | GO:0090383 | phagosome acidification | 1 | 5 | 2.59e-01 |
| GO:BP | GO:0006499 | N-terminal protein myristoylation | 1 | 4 | 2.59e-01 |
| GO:BP | GO:0006303 | double-strand break repair via nonhomologous end joining | 2 | 61 | 2.59e-01 |
| GO:BP | GO:0051567 | histone H3-K9 methylation | 1 | 18 | 2.59e-01 |
| GO:BP | GO:1903539 | protein localization to postsynaptic membrane | 3 | 38 | 2.59e-01 |
| GO:BP | GO:0061041 | regulation of wound healing | 2 | 95 | 2.59e-01 |
| GO:BP | GO:0021515 | cell differentiation in spinal cord | 1 | 24 | 2.59e-01 |
| GO:BP | GO:0043414 | macromolecule methylation | 4 | 272 | 2.59e-01 |
| GO:BP | GO:0035751 | regulation of lysosomal lumen pH | 1 | 26 | 2.59e-01 |
| GO:BP | GO:0035418 | protein localization to synapse | 4 | 68 | 2.59e-01 |
| GO:BP | GO:0097355 | protein localization to heterochromatin | 1 | 3 | 2.59e-01 |
| GO:BP | GO:0009084 | glutamine family amino acid biosynthetic process | 1 | 16 | 2.59e-01 |
| GO:BP | GO:0043303 | mast cell degranulation | 2 | 30 | 2.59e-01 |
| GO:BP | GO:0000056 | ribosomal small subunit export from nucleus | 1 | 8 | 2.59e-01 |
| GO:BP | GO:1902459 | positive regulation of stem cell population maintenance | 3 | 44 | 2.59e-01 |
| GO:BP | GO:0000055 | ribosomal large subunit export from nucleus | 1 | 8 | 2.59e-01 |
| GO:BP | GO:2000809 | positive regulation of synaptic vesicle clustering | 1 | 3 | 2.59e-01 |
| GO:BP | GO:0061009 | common bile duct development | 1 | 4 | 2.59e-01 |
| GO:BP | GO:0010841 | positive regulation of circadian sleep/wake cycle, wakefulness | 1 | 1 | 2.59e-01 |
| GO:BP | GO:0051489 | regulation of filopodium assembly | 3 | 44 | 2.59e-01 |
| GO:BP | GO:0042256 | cytosolic ribosome assembly | 1 | 5 | 2.59e-01 |
| GO:BP | GO:0021510 | spinal cord development | 4 | 59 | 2.59e-01 |
| GO:BP | GO:0006479 | protein methylation | 3 | 160 | 2.59e-01 |
| GO:BP | GO:0003279 | cardiac septum development | 3 | 101 | 2.59e-01 |
| GO:BP | GO:0008213 | protein alkylation | 3 | 160 | 2.59e-01 |
| GO:BP | GO:2000302 | positive regulation of synaptic vesicle exocytosis | 1 | 3 | 2.59e-01 |
| GO:BP | GO:1900073 | regulation of neuromuscular synaptic transmission | 1 | 2 | 2.59e-01 |
| GO:BP | GO:0051222 | positive regulation of protein transport | 4 | 242 | 2.59e-01 |
| GO:BP | GO:0051783 | regulation of nuclear division | 1 | 116 | 2.59e-01 |
| GO:BP | GO:0090141 | positive regulation of mitochondrial fission | 2 | 21 | 2.59e-01 |
| GO:BP | GO:0030099 | myeloid cell differentiation | 1 | 310 | 2.59e-01 |
| GO:BP | GO:1903427 | negative regulation of reactive oxygen species biosynthetic process | 1 | 12 | 2.59e-01 |
| GO:BP | GO:1902115 | regulation of organelle assembly | 2 | 186 | 2.59e-01 |
| GO:BP | GO:0018377 | protein myristoylation | 1 | 4 | 2.59e-01 |
| GO:BP | GO:0060809 | mesodermal to mesenchymal transition involved in gastrulation | 1 | 2 | 2.59e-01 |
| GO:BP | GO:2000042 | negative regulation of double-strand break repair via homologous recombination | 1 | 16 | 2.59e-01 |
| GO:BP | GO:1900075 | positive regulation of neuromuscular synaptic transmission | 1 | 2 | 2.59e-01 |
| GO:BP | GO:1903706 | regulation of hemopoiesis | 1 | 279 | 2.59e-01 |
| GO:BP | GO:0022614 | membrane to membrane docking | 1 | 5 | 2.60e-01 |
| GO:BP | GO:0062237 | protein localization to postsynapse | 3 | 39 | 2.60e-01 |
| GO:BP | GO:0032075 | positive regulation of nuclease activity | 1 | 7 | 2.60e-01 |
| GO:BP | GO:0043616 | keratinocyte proliferation | 3 | 38 | 2.60e-01 |
| GO:BP | GO:0035509 | negative regulation of myosin-light-chain-phosphatase activity | 1 | 3 | 2.60e-01 |
| GO:BP | GO:1901673 | regulation of mitotic spindle assembly | 1 | 23 | 2.60e-01 |
| GO:BP | GO:0016445 | somatic diversification of immunoglobulins | 2 | 53 | 2.60e-01 |
| GO:BP | GO:0014037 | Schwann cell differentiation | 2 | 34 | 2.60e-01 |
| GO:BP | GO:0048144 | fibroblast proliferation | 3 | 92 | 2.60e-01 |
| GO:BP | GO:0019284 | L-methionine salvage from S-adenosylmethionine | 1 | 3 | 2.60e-01 |
| GO:BP | GO:0060574 | intestinal epithelial cell maturation | 1 | 3 | 2.60e-01 |
| GO:BP | GO:1900060 | negative regulation of ceramide biosynthetic process | 1 | 5 | 2.60e-01 |
| GO:BP | GO:0033152 | immunoglobulin V(D)J recombination | 1 | 8 | 2.60e-01 |
| GO:BP | GO:0050852 | T cell receptor signaling pathway | 2 | 84 | 2.60e-01 |
| GO:BP | GO:0002279 | mast cell activation involved in immune response | 2 | 31 | 2.60e-01 |
| GO:BP | GO:0006783 | heme biosynthetic process | 1 | 30 | 2.60e-01 |
| GO:BP | GO:0003418 | growth plate cartilage chondrocyte differentiation | 1 | 8 | 2.60e-01 |
| GO:BP | GO:0006054 | N-acetylneuraminate metabolic process | 1 | 11 | 2.60e-01 |
| GO:BP | GO:0002448 | mast cell mediated immunity | 2 | 33 | 2.60e-01 |
| GO:BP | GO:0043413 | macromolecule glycosylation | 1 | 187 | 2.60e-01 |
| GO:BP | GO:0006890 | retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum | 2 | 52 | 2.60e-01 |
| GO:BP | GO:0006486 | protein glycosylation | 1 | 187 | 2.60e-01 |
| GO:BP | GO:1903721 | positive regulation of I-kappaB phosphorylation | 1 | 5 | 2.60e-01 |
| GO:BP | GO:0006110 | regulation of glycolytic process | 3 | 40 | 2.60e-01 |
| GO:BP | GO:0071480 | cellular response to gamma radiation | 2 | 29 | 2.60e-01 |
| GO:BP | GO:0031397 | negative regulation of protein ubiquitination | 4 | 76 | 2.61e-01 |
| GO:BP | GO:0140467 | integrated stress response signaling | 2 | 35 | 2.61e-01 |
| GO:BP | GO:2001252 | positive regulation of chromosome organization | 4 | 103 | 2.61e-01 |
| GO:BP | GO:2000192 | negative regulation of fatty acid transport | 1 | 7 | 2.63e-01 |
| GO:BP | GO:0007411 | axon guidance | 4 | 185 | 2.63e-01 |
| GO:BP | GO:0002562 | somatic diversification of immune receptors via germline recombination within a single locus | 2 | 55 | 2.63e-01 |
| GO:BP | GO:0007283 | spermatogenesis | 2 | 330 | 2.63e-01 |
| GO:BP | GO:0140214 | positive regulation of long-chain fatty acid import into cell | 1 | 2 | 2.63e-01 |
| GO:BP | GO:0048845 | venous blood vessel morphogenesis | 1 | 9 | 2.63e-01 |
| GO:BP | GO:0031570 | DNA integrity checkpoint signaling | 5 | 129 | 2.63e-01 |
| GO:BP | GO:0006837 | serotonin transport | 1 | 11 | 2.63e-01 |
| GO:BP | GO:1902905 | positive regulation of supramolecular fiber organization | 3 | 151 | 2.63e-01 |
| GO:BP | GO:0008286 | insulin receptor signaling pathway | 3 | 105 | 2.63e-01 |
| GO:BP | GO:0002051 | osteoblast fate commitment | 1 | 2 | 2.63e-01 |
| GO:BP | GO:0006260 | DNA replication | 7 | 255 | 2.63e-01 |
| GO:BP | GO:0015886 | heme transport | 1 | 9 | 2.63e-01 |
| GO:BP | GO:0042439 | ethanolamine-containing compound metabolic process | 1 | 5 | 2.63e-01 |
| GO:BP | GO:0070085 | glycosylation | 1 | 202 | 2.63e-01 |
| GO:BP | GO:0016073 | snRNA metabolic process | 2 | 54 | 2.63e-01 |
| GO:BP | GO:0110030 | regulation of G2/MI transition of meiotic cell cycle | 1 | 3 | 2.63e-01 |
| GO:BP | GO:0000271 | polysaccharide biosynthetic process | 2 | 53 | 2.63e-01 |
| GO:BP | GO:0006779 | porphyrin-containing compound biosynthetic process | 1 | 33 | 2.63e-01 |
| GO:BP | GO:0016236 | macroautophagy | 2 | 308 | 2.63e-01 |
| GO:BP | GO:1903719 | regulation of I-kappaB phosphorylation | 1 | 6 | 2.63e-01 |
| GO:BP | GO:0016444 | somatic cell DNA recombination | 2 | 55 | 2.63e-01 |
| GO:BP | GO:1904951 | positive regulation of establishment of protein localization | 4 | 258 | 2.63e-01 |
| GO:BP | GO:0033014 | tetrapyrrole biosynthetic process | 1 | 33 | 2.63e-01 |
| GO:BP | GO:0040012 | regulation of locomotion | 13 | 763 | 2.63e-01 |
| GO:BP | GO:0042796 | snRNA transcription by RNA polymerase III | 1 | 8 | 2.63e-01 |
| GO:BP | GO:0048709 | oligodendrocyte differentiation | 1 | 68 | 2.63e-01 |
| GO:BP | GO:1903052 | positive regulation of proteolysis involved in protein catabolic process | 5 | 127 | 2.63e-01 |
| GO:BP | GO:1901995 | positive regulation of meiotic cell cycle phase transition | 1 | 3 | 2.63e-01 |
| GO:BP | GO:0007035 | vacuolar acidification | 1 | 30 | 2.63e-01 |
| GO:BP | GO:0007015 | actin filament organization | 7 | 373 | 2.63e-01 |
| GO:BP | GO:0032071 | regulation of endodeoxyribonuclease activity | 1 | 7 | 2.63e-01 |
| GO:BP | GO:0001667 | ameboidal-type cell migration | 7 | 358 | 2.63e-01 |
| GO:BP | GO:0000070 | mitotic sister chromatid segregation | 3 | 179 | 2.63e-01 |
| GO:BP | GO:0042770 | signal transduction in response to DNA damage | 3 | 178 | 2.63e-01 |
| GO:BP | GO:0032480 | negative regulation of type I interferon production | 2 | 23 | 2.63e-01 |
| GO:BP | GO:0048008 | platelet-derived growth factor receptor signaling pathway | 1 | 52 | 2.63e-01 |
| GO:BP | GO:0048285 | organelle fission | 5 | 388 | 2.63e-01 |
| GO:BP | GO:0090234 | regulation of kinetochore assembly | 1 | 3 | 2.63e-01 |
| GO:BP | GO:0048232 | male gamete generation | 2 | 343 | 2.63e-01 |
| GO:BP | GO:0097485 | neuron projection guidance | 4 | 186 | 2.63e-01 |
| GO:BP | GO:1902116 | negative regulation of organelle assembly | 1 | 40 | 2.63e-01 |
| GO:BP | GO:0060295 | regulation of cilium movement involved in cell motility | 1 | 12 | 2.65e-01 |
| GO:BP | GO:0009446 | putrescine biosynthetic process | 1 | 4 | 2.65e-01 |
| GO:BP | GO:0009211 | pyrimidine deoxyribonucleoside triphosphate metabolic process | 1 | 6 | 2.65e-01 |
| GO:BP | GO:0032388 | positive regulation of intracellular transport | 3 | 170 | 2.65e-01 |
| GO:BP | GO:0030335 | positive regulation of cell migration | 8 | 407 | 2.65e-01 |
| GO:BP | GO:0009408 | response to heat | 1 | 84 | 2.65e-01 |
| GO:BP | GO:0046579 | positive regulation of Ras protein signal transduction | 2 | 45 | 2.65e-01 |
| GO:BP | GO:0060135 | maternal process involved in female pregnancy | 3 | 41 | 2.65e-01 |
| GO:BP | GO:0002091 | negative regulation of receptor internalization | 1 | 14 | 2.65e-01 |
| GO:BP | GO:0006576 | biogenic amine metabolic process | 4 | 57 | 2.65e-01 |
| GO:BP | GO:0070814 | hydrogen sulfide biosynthetic process | 1 | 4 | 2.65e-01 |
| GO:BP | GO:0048663 | neuron fate commitment | 1 | 29 | 2.65e-01 |
| GO:BP | GO:1902019 | regulation of cilium-dependent cell motility | 1 | 12 | 2.65e-01 |
| GO:BP | GO:0030036 | actin cytoskeleton organization | 10 | 612 | 2.65e-01 |
| GO:BP | GO:0032825 | positive regulation of natural killer cell differentiation | 1 | 7 | 2.65e-01 |
| GO:BP | GO:0061647 | histone H3-K9 modification | 1 | 23 | 2.65e-01 |
| GO:BP | GO:0090155 | negative regulation of sphingolipid biosynthetic process | 1 | 6 | 2.65e-01 |
| GO:BP | GO:0016103 | diterpenoid catabolic process | 1 | 1 | 2.65e-01 |
| GO:BP | GO:0046697 | decidualization | 2 | 19 | 2.65e-01 |
| GO:BP | GO:0034653 | retinoic acid catabolic process | 1 | 1 | 2.65e-01 |
| GO:BP | GO:2000785 | regulation of autophagosome assembly | 1 | 44 | 2.65e-01 |
| GO:BP | GO:1902809 | regulation of skeletal muscle fiber differentiation | 1 | 4 | 2.65e-01 |
| GO:BP | GO:0032486 | Rap protein signal transduction | 1 | 13 | 2.65e-01 |
| GO:BP | GO:0032011 | ARF protein signal transduction | 2 | 18 | 2.65e-01 |
| GO:BP | GO:0010498 | proteasomal protein catabolic process | 1 | 486 | 2.65e-01 |
| GO:BP | GO:0060562 | epithelial tube morphogenesis | 9 | 278 | 2.65e-01 |
| GO:BP | GO:0032012 | regulation of ARF protein signal transduction | 2 | 18 | 2.65e-01 |
| GO:BP | GO:0030010 | establishment of cell polarity | 4 | 134 | 2.66e-01 |
| GO:BP | GO:1905203 | regulation of connective tissue replacement | 1 | 5 | 2.66e-01 |
| GO:BP | GO:0035383 | thioester metabolic process | 1 | 71 | 2.67e-01 |
| GO:BP | GO:0009065 | glutamine family amino acid catabolic process | 1 | 20 | 2.67e-01 |
| GO:BP | GO:0016241 | regulation of macroautophagy | 3 | 151 | 2.67e-01 |
| GO:BP | GO:0006637 | acyl-CoA metabolic process | 1 | 71 | 2.67e-01 |
| GO:BP | GO:2000622 | regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 1 | 12 | 2.68e-01 |
| GO:BP | GO:0032757 | positive regulation of interleukin-8 production | 1 | 31 | 2.68e-01 |
| GO:BP | GO:1903251 | multi-ciliated epithelial cell differentiation | 1 | 6 | 2.68e-01 |
| GO:BP | GO:1990442 | intrinsic apoptotic signaling pathway in response to nitrosative stress | 1 | 3 | 2.68e-01 |
| GO:BP | GO:2000251 | positive regulation of actin cytoskeleton reorganization | 1 | 14 | 2.68e-01 |
| GO:BP | GO:2000074 | regulation of type B pancreatic cell development | 1 | 8 | 2.68e-01 |
| GO:BP | GO:0035655 | interleukin-18-mediated signaling pathway | 1 | 3 | 2.68e-01 |
| GO:BP | GO:0003281 | ventricular septum development | 1 | 69 | 2.68e-01 |
| GO:BP | GO:0044458 | motile cilium assembly | 3 | 45 | 2.68e-01 |
| GO:BP | GO:0071351 | cellular response to interleukin-18 | 1 | 3 | 2.68e-01 |
| GO:BP | GO:0010977 | negative regulation of neuron projection development | 5 | 117 | 2.68e-01 |
| GO:BP | GO:0050918 | positive chemotaxis | 1 | 40 | 2.68e-01 |
| GO:BP | GO:0032984 | protein-containing complex disassembly | 2 | 222 | 2.68e-01 |
| GO:BP | GO:0045446 | endothelial cell differentiation | 3 | 90 | 2.68e-01 |
| GO:BP | GO:0021782 | glial cell development | 1 | 84 | 2.68e-01 |
| GO:BP | GO:0010840 | regulation of circadian sleep/wake cycle, wakefulness | 1 | 1 | 2.68e-01 |
| GO:BP | GO:0006541 | glutamine metabolic process | 1 | 24 | 2.68e-01 |
| GO:BP | GO:0042746 | circadian sleep/wake cycle, wakefulness | 1 | 1 | 2.68e-01 |
| GO:BP | GO:0016080 | synaptic vesicle targeting | 1 | 3 | 2.68e-01 |
| GO:BP | GO:0110053 | regulation of actin filament organization | 5 | 228 | 2.69e-01 |
| GO:BP | GO:0048016 | inositol phosphate-mediated signaling | 3 | 45 | 2.70e-01 |
| GO:BP | GO:0002200 | somatic diversification of immune receptors | 2 | 62 | 2.70e-01 |
| GO:BP | GO:0035295 | tube development | 13 | 821 | 2.70e-01 |
| GO:BP | GO:1903650 | negative regulation of cytoplasmic transport | 1 | 3 | 2.70e-01 |
| GO:BP | GO:0031345 | negative regulation of cell projection organization | 6 | 156 | 2.70e-01 |
| GO:BP | GO:0051754 | meiotic sister chromatid cohesion, centromeric | 1 | 4 | 2.70e-01 |
| GO:BP | GO:0072001 | renal system development | 8 | 251 | 2.72e-01 |
| GO:BP | GO:0060711 | labyrinthine layer development | 2 | 35 | 2.72e-01 |
| GO:BP | GO:1902747 | negative regulation of lens fiber cell differentiation | 1 | 5 | 2.72e-01 |
| GO:BP | GO:1901678 | iron coordination entity transport | 1 | 11 | 2.72e-01 |
| GO:BP | GO:2001032 | regulation of double-strand break repair via nonhomologous end joining | 1 | 25 | 2.73e-01 |
| GO:BP | GO:0045830 | positive regulation of isotype switching | 1 | 19 | 2.73e-01 |
| GO:BP | GO:0035239 | tube morphogenesis | 11 | 663 | 2.73e-01 |
| GO:BP | GO:0048254 | snoRNA localization | 1 | 5 | 2.73e-01 |
| GO:BP | GO:0002520 | immune system development | 2 | 144 | 2.73e-01 |
| GO:BP | GO:0000278 | mitotic cell cycle | 16 | 827 | 2.73e-01 |
| GO:BP | GO:0007093 | mitotic cell cycle checkpoint signaling | 5 | 139 | 2.73e-01 |
| GO:BP | GO:0090169 | regulation of spindle assembly | 1 | 32 | 2.73e-01 |
| GO:BP | GO:0009101 | glycoprotein biosynthetic process | 1 | 252 | 2.73e-01 |
| GO:BP | GO:0061028 | establishment of endothelial barrier | 2 | 38 | 2.73e-01 |
| GO:BP | GO:0060071 | Wnt signaling pathway, planar cell polarity pathway | 2 | 51 | 2.73e-01 |
| GO:BP | GO:0050687 | negative regulation of defense response to virus | 2 | 30 | 2.73e-01 |
| GO:BP | GO:0007346 | regulation of mitotic cell cycle | 10 | 441 | 2.73e-01 |
| GO:BP | GO:0006405 | RNA export from nucleus | 2 | 78 | 2.73e-01 |
| GO:BP | GO:0030193 | regulation of blood coagulation | 1 | 50 | 2.73e-01 |
| GO:BP | GO:1903034 | regulation of response to wounding | 2 | 121 | 2.73e-01 |
| GO:BP | GO:0006606 | protein import into nucleus | 3 | 147 | 2.73e-01 |
| GO:BP | GO:0060491 | regulation of cell projection assembly | 6 | 167 | 2.74e-01 |
| GO:BP | GO:0046073 | dTMP metabolic process | 1 | 7 | 2.74e-01 |
| GO:BP | GO:0000301 | retrograde transport, vesicle recycling within Golgi | 1 | 9 | 2.74e-01 |
| GO:BP | GO:0021894 | cerebral cortex GABAergic interneuron development | 1 | 3 | 2.74e-01 |
| GO:BP | GO:0005977 | glycogen metabolic process | 2 | 64 | 2.74e-01 |
| GO:BP | GO:0060136 | embryonic process involved in female pregnancy | 1 | 6 | 2.74e-01 |
| GO:BP | GO:0045050 | protein insertion into ER membrane by stop-transfer membrane-anchor sequence | 1 | 10 | 2.74e-01 |
| GO:BP | GO:0016311 | dephosphorylation | 8 | 284 | 2.74e-01 |
| GO:BP | GO:0098869 | cellular oxidant detoxification | 1 | 65 | 2.74e-01 |
| GO:BP | GO:0009221 | pyrimidine deoxyribonucleotide biosynthetic process | 1 | 7 | 2.74e-01 |
| GO:BP | GO:0019346 | transsulfuration | 1 | 5 | 2.74e-01 |
| GO:BP | GO:0002009 | morphogenesis of an epithelium | 13 | 418 | 2.74e-01 |
| GO:BP | GO:0048169 | regulation of long-term neuronal synaptic plasticity | 1 | 20 | 2.74e-01 |
| GO:BP | GO:0003149 | membranous septum morphogenesis | 1 | 8 | 2.74e-01 |
| GO:BP | GO:0072178 | nephric duct morphogenesis | 1 | 8 | 2.74e-01 |
| GO:BP | GO:0090521 | podocyte cell migration | 1 | 7 | 2.74e-01 |
| GO:BP | GO:0051155 | positive regulation of striated muscle cell differentiation | 2 | 31 | 2.74e-01 |
| GO:BP | GO:0006906 | vesicle fusion | 3 | 104 | 2.74e-01 |
| GO:BP | GO:0051057 | positive regulation of small GTPase mediated signal transduction | 2 | 51 | 2.74e-01 |
| GO:BP | GO:0071389 | cellular response to mineralocorticoid stimulus | 1 | 9 | 2.74e-01 |
| GO:BP | GO:0051170 | import into nucleus | 3 | 152 | 2.74e-01 |
| GO:BP | GO:0050818 | regulation of coagulation | 1 | 55 | 2.74e-01 |
| GO:BP | GO:0071478 | cellular response to radiation | 3 | 156 | 2.74e-01 |
| GO:BP | GO:0006924 | activation-induced cell death of T cells | 1 | 8 | 2.74e-01 |
| GO:BP | GO:0032070 | regulation of deoxyribonuclease activity | 1 | 9 | 2.74e-01 |
| GO:BP | GO:0001880 | Mullerian duct regression | 1 | 4 | 2.74e-01 |
| GO:BP | GO:0043470 | regulation of carbohydrate catabolic process | 3 | 47 | 2.74e-01 |
| GO:BP | GO:0071897 | DNA biosynthetic process | 4 | 175 | 2.74e-01 |
| GO:BP | GO:0035507 | regulation of myosin-light-chain-phosphatase activity | 1 | 5 | 2.74e-01 |
| GO:BP | GO:0060022 | hard palate development | 1 | 5 | 2.74e-01 |
| GO:BP | GO:1900046 | regulation of hemostasis | 1 | 50 | 2.74e-01 |
| GO:BP | GO:2001016 | positive regulation of skeletal muscle cell differentiation | 1 | 5 | 2.74e-01 |
| GO:BP | GO:0009092 | homoserine metabolic process | 1 | 5 | 2.74e-01 |
| GO:BP | GO:0042168 | heme metabolic process | 1 | 40 | 2.74e-01 |
| GO:BP | GO:0140058 | neuron projection arborization | 2 | 29 | 2.74e-01 |
| GO:BP | GO:0070813 | hydrogen sulfide metabolic process | 1 | 5 | 2.74e-01 |
| GO:BP | GO:0045576 | mast cell activation | 2 | 35 | 2.74e-01 |
| GO:BP | GO:0006413 | translational initiation | 1 | 116 | 2.74e-01 |
| GO:BP | GO:0120032 | regulation of plasma membrane bounded cell projection assembly | 6 | 165 | 2.74e-01 |
| GO:BP | GO:0010569 | regulation of double-strand break repair via homologous recombination | 3 | 63 | 2.74e-01 |
| GO:BP | GO:1902044 | regulation of Fas signaling pathway | 1 | 4 | 2.74e-01 |
| GO:BP | GO:0032197 | retrotransposition | 1 | 4 | 2.74e-01 |
| GO:BP | GO:0097012 | response to granulocyte macrophage colony-stimulating factor | 1 | 6 | 2.75e-01 |
| GO:BP | GO:0010918 | positive regulation of mitochondrial membrane potential | 1 | 9 | 2.75e-01 |
| GO:BP | GO:0090174 | organelle membrane fusion | 3 | 106 | 2.75e-01 |
| GO:BP | GO:0090175 | regulation of establishment of planar polarity | 2 | 54 | 2.75e-01 |
| GO:BP | GO:0070346 | positive regulation of fat cell proliferation | 1 | 3 | 2.75e-01 |
| GO:BP | GO:0090230 | regulation of centromere complex assembly | 1 | 4 | 2.75e-01 |
| GO:BP | GO:0045913 | positive regulation of carbohydrate metabolic process | 2 | 60 | 2.75e-01 |
| GO:BP | GO:0097011 | cellular response to granulocyte macrophage colony-stimulating factor stimulus | 1 | 6 | 2.75e-01 |
| GO:BP | GO:0045879 | negative regulation of smoothened signaling pathway | 1 | 30 | 2.75e-01 |
| GO:BP | GO:2000147 | positive regulation of cell motility | 8 | 421 | 2.75e-01 |
| GO:BP | GO:0070673 | response to interleukin-18 | 1 | 5 | 2.75e-01 |
| GO:BP | GO:0090140 | regulation of mitochondrial fission | 1 | 28 | 2.75e-01 |
| GO:BP | GO:1901097 | negative regulation of autophagosome maturation | 1 | 5 | 2.75e-01 |
| GO:BP | GO:0002067 | glandular epithelial cell differentiation | 2 | 50 | 2.75e-01 |
| GO:BP | GO:0043009 | chordate embryonic development | 9 | 534 | 2.75e-01 |
| GO:BP | GO:0002065 | columnar/cuboidal epithelial cell differentiation | 3 | 80 | 2.75e-01 |
| GO:BP | GO:0008630 | intrinsic apoptotic signaling pathway in response to DNA damage | 2 | 94 | 2.75e-01 |
| GO:BP | GO:0031032 | actomyosin structure organization | 4 | 186 | 2.75e-01 |
| GO:BP | GO:0008295 | spermidine biosynthetic process | 1 | 3 | 2.75e-01 |
| GO:BP | GO:0044042 | glucan metabolic process | 2 | 64 | 2.75e-01 |
| GO:BP | GO:1902903 | regulation of supramolecular fiber organization | 6 | 326 | 2.75e-01 |
| GO:BP | GO:0000082 | G1/S transition of mitotic cell cycle | 1 | 207 | 2.75e-01 |
| GO:BP | GO:1901165 | positive regulation of trophoblast cell migration | 1 | 6 | 2.75e-01 |
| GO:BP | GO:0140052 | cellular response to oxidised low-density lipoprotein particle stimulus | 1 | 7 | 2.75e-01 |
| GO:BP | GO:0035025 | positive regulation of Rho protein signal transduction | 1 | 22 | 2.75e-01 |
| GO:BP | GO:0032259 | methylation | 4 | 313 | 2.75e-01 |
| GO:BP | GO:0003413 | chondrocyte differentiation involved in endochondral bone morphogenesis | 1 | 12 | 2.75e-01 |
| GO:BP | GO:0002328 | pro-B cell differentiation | 1 | 10 | 2.75e-01 |
| GO:BP | GO:0000096 | sulfur amino acid metabolic process | 2 | 27 | 2.75e-01 |
| GO:BP | GO:0048496 | maintenance of animal organ identity | 1 | 4 | 2.75e-01 |
| GO:BP | GO:0048843 | negative regulation of axon extension involved in axon guidance | 2 | 26 | 2.75e-01 |
| GO:BP | GO:0097114 | NMDA glutamate receptor clustering | 1 | 5 | 2.75e-01 |
| GO:BP | GO:0033865 | nucleoside bisphosphate metabolic process | 1 | 92 | 2.75e-01 |
| GO:BP | GO:0033875 | ribonucleoside bisphosphate metabolic process | 1 | 92 | 2.75e-01 |
| GO:BP | GO:0000012 | single strand break repair | 1 | 10 | 2.75e-01 |
| GO:BP | GO:0051276 | chromosome organization | 6 | 543 | 2.75e-01 |
| GO:BP | GO:0034032 | purine nucleoside bisphosphate metabolic process | 1 | 92 | 2.75e-01 |
| GO:BP | GO:0002312 | B cell activation involved in immune response | 2 | 57 | 2.75e-01 |
| GO:BP | GO:0032729 | positive regulation of type II interferon production | 2 | 36 | 2.75e-01 |
| GO:BP | GO:0051128 | regulation of cellular component organization | 26 | 2011 | 2.75e-01 |
| GO:BP | GO:1900223 | positive regulation of amyloid-beta clearance | 1 | 5 | 2.75e-01 |
| GO:BP | GO:0007030 | Golgi organization | 3 | 137 | 2.75e-01 |
| GO:BP | GO:0051045 | negative regulation of membrane protein ectodomain proteolysis | 1 | 7 | 2.75e-01 |
| GO:BP | GO:0006536 | glutamate metabolic process | 1 | 25 | 2.75e-01 |
| GO:BP | GO:0006919 | activation of cysteine-type endopeptidase activity involved in apoptotic process | 1 | 65 | 2.75e-01 |
| GO:BP | GO:1905209 | positive regulation of cardiocyte differentiation | 1 | 11 | 2.75e-01 |
| GO:BP | GO:1902455 | negative regulation of stem cell population maintenance | 2 | 21 | 2.75e-01 |
| GO:BP | GO:0072331 | signal transduction by p53 class mediator | 3 | 161 | 2.75e-01 |
| GO:BP | GO:0014041 | regulation of neuron maturation | 1 | 6 | 2.75e-01 |
| GO:BP | GO:0018023 | peptidyl-lysine trimethylation | 1 | 33 | 2.75e-01 |
| GO:BP | GO:0046827 | positive regulation of protein export from nucleus | 1 | 15 | 2.75e-01 |
| GO:BP | GO:0060074 | synapse maturation | 2 | 25 | 2.75e-01 |
| GO:BP | GO:1903321 | negative regulation of protein modification by small protein conjugation or removal | 4 | 86 | 2.75e-01 |
| GO:BP | GO:0033089 | positive regulation of T cell differentiation in thymus | 1 | 5 | 2.75e-01 |
| GO:BP | GO:0032874 | positive regulation of stress-activated MAPK cascade | 3 | 96 | 2.75e-01 |
| GO:BP | GO:0042832 | defense response to protozoan | 1 | 10 | 2.75e-01 |
| GO:BP | GO:0003352 | regulation of cilium movement | 1 | 17 | 2.75e-01 |
| GO:BP | GO:0009790 | embryo development | 22 | 875 | 2.75e-01 |
| GO:BP | GO:0030162 | regulation of proteolysis | 1 | 535 | 2.75e-01 |
| GO:BP | GO:0003205 | cardiac chamber development | 4 | 149 | 2.75e-01 |
| GO:BP | GO:2000780 | negative regulation of double-strand break repair | 1 | 30 | 2.75e-01 |
| GO:BP | GO:0032811 | negative regulation of epinephrine secretion | 1 | 2 | 2.75e-01 |
| GO:BP | GO:0035624 | receptor transactivation | 1 | 3 | 2.75e-01 |
| GO:BP | GO:0010700 | negative regulation of norepinephrine secretion | 1 | 2 | 2.75e-01 |
| GO:BP | GO:0032677 | regulation of interleukin-8 production | 1 | 43 | 2.76e-01 |
| GO:BP | GO:0032637 | interleukin-8 production | 1 | 43 | 2.76e-01 |
| GO:BP | GO:0032507 | maintenance of protein location in cell | 2 | 58 | 2.76e-01 |
| GO:BP | GO:0006498 | N-terminal protein lipidation | 1 | 7 | 2.76e-01 |
| GO:BP | GO:0006778 | porphyrin-containing compound metabolic process | 1 | 44 | 2.76e-01 |
| GO:BP | GO:1990748 | cellular detoxification | 1 | 76 | 2.76e-01 |
| GO:BP | GO:2000145 | regulation of cell motility | 12 | 742 | 2.76e-01 |
| GO:BP | GO:0030326 | embryonic limb morphogenesis | 4 | 89 | 2.76e-01 |
| GO:BP | GO:0003266 | regulation of secondary heart field cardioblast proliferation | 1 | 8 | 2.76e-01 |
| GO:BP | GO:0051453 | regulation of intracellular pH | 2 | 65 | 2.76e-01 |
| GO:BP | GO:0019509 | L-methionine salvage from methylthioadenosine | 1 | 5 | 2.76e-01 |
| GO:BP | GO:0070304 | positive regulation of stress-activated protein kinase signaling cascade | 3 | 98 | 2.76e-01 |
| GO:BP | GO:0051650 | establishment of vesicle localization | 1 | 175 | 2.76e-01 |
| GO:BP | GO:0097193 | intrinsic apoptotic signaling pathway | 4 | 262 | 2.76e-01 |
| GO:BP | GO:0008315 | G2/MI transition of meiotic cell cycle | 1 | 5 | 2.76e-01 |
| GO:BP | GO:0044843 | cell cycle G1/S phase transition | 1 | 229 | 2.76e-01 |
| GO:BP | GO:0035113 | embryonic appendage morphogenesis | 4 | 89 | 2.76e-01 |
| GO:BP | GO:0048534 | hematopoietic or lymphoid organ development | 1 | 70 | 2.76e-01 |
| GO:BP | GO:0006892 | post-Golgi vesicle-mediated transport | 2 | 103 | 2.76e-01 |
| GO:BP | GO:0086100 | endothelin receptor signaling pathway | 1 | 9 | 2.77e-01 |
| GO:BP | GO:2000481 | positive regulation of cAMP-dependent protein kinase activity | 1 | 5 | 2.78e-01 |
| GO:BP | GO:0009100 | glycoprotein metabolic process | 1 | 316 | 2.78e-01 |
| GO:BP | GO:0033157 | regulation of intracellular protein transport | 3 | 197 | 2.78e-01 |
| GO:BP | GO:0043524 | negative regulation of neuron apoptotic process | 5 | 120 | 2.78e-01 |
| GO:BP | GO:0045738 | negative regulation of DNA repair | 1 | 32 | 2.79e-01 |
| GO:BP | GO:0007276 | gamete generation | 2 | 461 | 2.79e-01 |
| GO:BP | GO:0032252 | secretory granule localization | 1 | 9 | 2.79e-01 |
| GO:BP | GO:0002181 | cytoplasmic translation | 1 | 156 | 2.79e-01 |
| GO:BP | GO:0001562 | response to protozoan | 1 | 11 | 2.79e-01 |
| GO:BP | GO:0060236 | regulation of mitotic spindle organization | 1 | 42 | 2.79e-01 |
| GO:BP | GO:0032482 | Rab protein signal transduction | 1 | 19 | 2.79e-01 |
| GO:BP | GO:0040017 | positive regulation of locomotion | 8 | 429 | 2.79e-01 |
| GO:BP | GO:0000280 | nuclear division | 8 | 344 | 2.79e-01 |
| GO:BP | GO:0034201 | response to oleic acid | 1 | 5 | 2.79e-01 |
| GO:BP | GO:0000819 | sister chromatid segregation | 3 | 217 | 2.79e-01 |
| GO:BP | GO:0071285 | cellular response to lithium ion | 1 | 8 | 2.79e-01 |
| GO:BP | GO:0048468 | cell development | 4 | 1963 | 2.80e-01 |
| GO:BP | GO:0002366 | leukocyte activation involved in immune response | 4 | 154 | 2.80e-01 |
| GO:BP | GO:0002457 | T cell antigen processing and presentation | 1 | 4 | 2.80e-01 |
| GO:BP | GO:1905671 | regulation of lysosome organization | 1 | 6 | 2.80e-01 |
| GO:BP | GO:0051603 | proteolysis involved in protein catabolic process | 1 | 706 | 2.80e-01 |
| GO:BP | GO:0046148 | pigment biosynthetic process | 1 | 48 | 2.80e-01 |
| GO:BP | GO:0000054 | ribosomal subunit export from nucleus | 1 | 15 | 2.80e-01 |
| GO:BP | GO:0001975 | response to amphetamine | 1 | 22 | 2.80e-01 |
| GO:BP | GO:0033750 | ribosome localization | 1 | 15 | 2.80e-01 |
| GO:BP | GO:0007049 | cell cycle | 24 | 1529 | 2.80e-01 |
| GO:BP | GO:0090385 | phagosome-lysosome fusion | 1 | 12 | 2.80e-01 |
| GO:BP | GO:0036337 | Fas signaling pathway | 1 | 5 | 2.80e-01 |
| GO:BP | GO:0016191 | synaptic vesicle uncoating | 1 | 7 | 2.80e-01 |
| GO:BP | GO:0097237 | cellular response to toxic substance | 1 | 82 | 2.80e-01 |
| GO:BP | GO:0035999 | tetrahydrofolate interconversion | 1 | 9 | 2.81e-01 |
| GO:BP | GO:0090314 | positive regulation of protein targeting to membrane | 1 | 22 | 2.81e-01 |
| GO:BP | GO:0009792 | embryo development ending in birth or egg hatching | 9 | 551 | 2.82e-01 |
| GO:BP | GO:0120034 | positive regulation of plasma membrane bounded cell projection assembly | 4 | 94 | 2.83e-01 |
| GO:BP | GO:0002263 | cell activation involved in immune response | 4 | 157 | 2.83e-01 |
| GO:BP | GO:0042330 | taxis | 2 | 389 | 2.83e-01 |
| GO:BP | GO:1902570 | protein localization to nucleolus | 1 | 15 | 2.83e-01 |
| GO:BP | GO:0051491 | positive regulation of filopodium assembly | 2 | 25 | 2.83e-01 |
| GO:BP | GO:0008215 | spermine metabolic process | 1 | 5 | 2.83e-01 |
| GO:BP | GO:0030641 | regulation of cellular pH | 2 | 70 | 2.83e-01 |
| GO:BP | GO:2000191 | regulation of fatty acid transport | 2 | 19 | 2.83e-01 |
| GO:BP | GO:0090527 | actin filament reorganization | 1 | 10 | 2.83e-01 |
| GO:BP | GO:0030163 | protein catabolic process | 4 | 901 | 2.83e-01 |
| GO:BP | GO:0010507 | negative regulation of autophagy | 3 | 74 | 2.83e-01 |
| GO:BP | GO:0035774 | positive regulation of insulin secretion involved in cellular response to glucose stimulus | 2 | 18 | 2.83e-01 |
| GO:BP | GO:1900378 | positive regulation of secondary metabolite biosynthetic process | 1 | 7 | 2.83e-01 |
| GO:BP | GO:0006935 | chemotaxis | 2 | 389 | 2.83e-01 |
| GO:BP | GO:0048023 | positive regulation of melanin biosynthetic process | 1 | 7 | 2.83e-01 |
| GO:BP | GO:0090224 | regulation of spindle organization | 1 | 45 | 2.83e-01 |
| GO:BP | GO:0001938 | positive regulation of endothelial cell proliferation | 1 | 74 | 2.83e-01 |
| GO:BP | GO:0051648 | vesicle localization | 1 | 192 | 2.83e-01 |
| GO:BP | GO:0060438 | trachea development | 1 | 13 | 2.83e-01 |
| GO:BP | GO:0006661 | phosphatidylinositol biosynthetic process | 4 | 119 | 2.83e-01 |
| GO:BP | GO:2000725 | regulation of cardiac muscle cell differentiation | 1 | 14 | 2.83e-01 |
| GO:BP | GO:0060284 | regulation of cell development | 1 | 605 | 2.83e-01 |
| GO:BP | GO:0009445 | putrescine metabolic process | 1 | 6 | 2.83e-01 |
| GO:BP | GO:0003263 | cardioblast proliferation | 1 | 9 | 2.83e-01 |
| GO:BP | GO:0003158 | endothelium development | 3 | 104 | 2.83e-01 |
| GO:BP | GO:0003264 | regulation of cardioblast proliferation | 1 | 9 | 2.83e-01 |
| GO:BP | GO:0045732 | positive regulation of protein catabolic process | 6 | 192 | 2.83e-01 |
| GO:BP | GO:0022616 | DNA strand elongation | 2 | 35 | 2.83e-01 |
| GO:BP | GO:0032823 | regulation of natural killer cell differentiation | 1 | 8 | 2.83e-01 |
| GO:BP | GO:0007019 | microtubule depolymerization | 1 | 43 | 2.83e-01 |
| GO:BP | GO:0045191 | regulation of isotype switching | 1 | 27 | 2.83e-01 |
| GO:BP | GO:0045597 | positive regulation of cell differentiation | 1 | 620 | 2.83e-01 |
| GO:BP | GO:1901215 | negative regulation of neuron death | 4 | 167 | 2.84e-01 |
| GO:BP | GO:0006995 | cellular response to nitrogen starvation | 1 | 9 | 2.84e-01 |
| GO:BP | GO:0072553 | terminal button organization | 1 | 5 | 2.84e-01 |
| GO:BP | GO:0043562 | cellular response to nitrogen levels | 1 | 9 | 2.84e-01 |
| GO:BP | GO:0098528 | skeletal muscle fiber differentiation | 1 | 5 | 2.84e-01 |
| GO:BP | GO:0033013 | tetrapyrrole metabolic process | 1 | 52 | 2.84e-01 |
| GO:BP | GO:0070268 | cornification | 1 | 2 | 2.84e-01 |
| GO:BP | GO:0003417 | growth plate cartilage development | 1 | 15 | 2.85e-01 |
| GO:BP | GO:0043299 | leukocyte degranulation | 2 | 41 | 2.86e-01 |
| GO:BP | GO:2000402 | negative regulation of lymphocyte migration | 1 | 10 | 2.86e-01 |
| GO:BP | GO:0070141 | response to UV-A | 1 | 11 | 2.86e-01 |
| GO:BP | GO:0060712 | spongiotrophoblast layer development | 1 | 11 | 2.86e-01 |
| GO:BP | GO:0060841 | venous blood vessel development | 1 | 13 | 2.86e-01 |
| GO:BP | GO:0006112 | energy reserve metabolic process | 2 | 73 | 2.86e-01 |
| GO:BP | GO:0098810 | neurotransmitter reuptake | 1 | 21 | 2.86e-01 |
| GO:BP | GO:0072176 | nephric duct development | 1 | 12 | 2.86e-01 |
| GO:BP | GO:0106074 | aminoacyl-tRNA metabolism involved in translational fidelity | 1 | 11 | 2.86e-01 |
| GO:BP | GO:0045682 | regulation of epidermis development | 3 | 45 | 2.87e-01 |
| GO:BP | GO:0006880 | intracellular sequestering of iron ion | 1 | 3 | 2.87e-01 |
| GO:BP | GO:0055118 | negative regulation of cardiac muscle contraction | 1 | 4 | 2.87e-01 |
| GO:BP | GO:1901565 | organonitrogen compound catabolic process | 5 | 1145 | 2.87e-01 |
| GO:BP | GO:0045214 | sarcomere organization | 1 | 43 | 2.87e-01 |
| GO:BP | GO:1902746 | regulation of lens fiber cell differentiation | 1 | 8 | 2.87e-01 |
| GO:BP | GO:0048609 | multicellular organismal reproductive process | 1 | 538 | 2.87e-01 |
| GO:BP | GO:0001708 | cell fate specification | 1 | 56 | 2.87e-01 |
| GO:BP | GO:0009157 | deoxyribonucleoside monophosphate biosynthetic process | 1 | 9 | 2.87e-01 |
| GO:BP | GO:0006266 | DNA ligation | 1 | 16 | 2.87e-01 |
| GO:BP | GO:0035924 | cellular response to vascular endothelial growth factor stimulus | 2 | 54 | 2.88e-01 |
| GO:BP | GO:0002714 | positive regulation of B cell mediated immunity | 1 | 26 | 2.89e-01 |
| GO:BP | GO:0002891 | positive regulation of immunoglobulin mediated immune response | 1 | 26 | 2.89e-01 |
| GO:BP | GO:0046822 | regulation of nucleocytoplasmic transport | 2 | 97 | 2.89e-01 |
| GO:BP | GO:0022402 | cell cycle process | 20 | 1086 | 2.89e-01 |
| GO:BP | GO:0046847 | filopodium assembly | 3 | 56 | 2.89e-01 |
| GO:BP | GO:1905949 | negative regulation of calcium ion import across plasma membrane | 1 | 4 | 2.89e-01 |
| GO:BP | GO:0010631 | epithelial cell migration | 5 | 252 | 2.89e-01 |
| GO:BP | GO:1900182 | positive regulation of protein localization to nucleus | 2 | 75 | 2.90e-01 |
| GO:BP | GO:0072318 | clathrin coat disassembly | 1 | 8 | 2.90e-01 |
| GO:BP | GO:0055007 | cardiac muscle cell differentiation | 3 | 103 | 2.90e-01 |
| GO:BP | GO:0098754 | detoxification | 1 | 91 | 2.90e-01 |
| GO:BP | GO:0032467 | positive regulation of cytokinesis | 2 | 33 | 2.90e-01 |
| GO:BP | GO:0009912 | auditory receptor cell fate commitment | 1 | 4 | 2.90e-01 |
| GO:BP | GO:0000266 | mitochondrial fission | 1 | 38 | 2.90e-01 |
| GO:BP | GO:0060120 | inner ear receptor cell fate commitment | 1 | 4 | 2.90e-01 |
| GO:BP | GO:0033077 | T cell differentiation in thymus | 2 | 56 | 2.91e-01 |
| GO:BP | GO:0060173 | limb development | 5 | 142 | 2.91e-01 |
| GO:BP | GO:0048736 | appendage development | 5 | 142 | 2.91e-01 |
| GO:BP | GO:0009308 | amine metabolic process | 4 | 68 | 2.91e-01 |
| GO:BP | GO:0007076 | mitotic chromosome condensation | 1 | 19 | 2.91e-01 |
| GO:BP | GO:2000672 | negative regulation of motor neuron apoptotic process | 1 | 10 | 2.91e-01 |
| GO:BP | GO:0030029 | actin filament-based process | 10 | 687 | 2.91e-01 |
| GO:BP | GO:0003006 | developmental process involved in reproduction | 1 | 598 | 2.91e-01 |
| GO:BP | GO:0046578 | regulation of Ras protein signal transduction | 6 | 166 | 2.91e-01 |
| GO:BP | GO:0051897 | positive regulation of protein kinase B signaling | 1 | 79 | 2.91e-01 |
| GO:BP | GO:0043523 | regulation of neuron apoptotic process | 6 | 167 | 2.91e-01 |
| GO:BP | GO:0048387 | negative regulation of retinoic acid receptor signaling pathway | 1 | 6 | 2.91e-01 |
| GO:BP | GO:0080171 | lytic vacuole organization | 2 | 88 | 2.91e-01 |
| GO:BP | GO:0009749 | response to glucose | 1 | 137 | 2.91e-01 |
| GO:BP | GO:0090132 | epithelium migration | 5 | 252 | 2.91e-01 |
| GO:BP | GO:0007040 | lysosome organization | 2 | 88 | 2.91e-01 |
| GO:BP | GO:0061002 | negative regulation of dendritic spine morphogenesis | 1 | 6 | 2.91e-01 |
| GO:BP | GO:0046322 | negative regulation of fatty acid oxidation | 1 | 12 | 2.91e-01 |
| GO:BP | GO:0060411 | cardiac septum morphogenesis | 2 | 67 | 2.91e-01 |
| GO:BP | GO:0090130 | tissue migration | 5 | 256 | 2.91e-01 |
| GO:BP | GO:0090162 | establishment of epithelial cell polarity | 2 | 29 | 2.91e-01 |
| GO:BP | GO:0036260 | RNA capping | 1 | 20 | 2.91e-01 |
| GO:BP | GO:0090179 | planar cell polarity pathway involved in neural tube closure | 1 | 12 | 2.91e-01 |
| GO:BP | GO:0046341 | CDP-diacylglycerol metabolic process | 1 | 13 | 2.91e-01 |
| GO:BP | GO:0097709 | connective tissue replacement | 1 | 8 | 2.91e-01 |
| GO:BP | GO:0003231 | cardiac ventricle development | 1 | 114 | 2.91e-01 |
| GO:BP | GO:0033151 | V(D)J recombination | 1 | 16 | 2.91e-01 |
| GO:BP | GO:0060143 | positive regulation of syncytium formation by plasma membrane fusion | 1 | 12 | 2.91e-01 |
| GO:BP | GO:0009636 | response to toxic substance | 2 | 158 | 2.91e-01 |
| GO:BP | GO:0021762 | substantia nigra development | 1 | 41 | 2.91e-01 |
| GO:BP | GO:0016115 | terpenoid catabolic process | 1 | 4 | 2.91e-01 |
| GO:BP | GO:0009746 | response to hexose | 1 | 138 | 2.91e-01 |
| GO:BP | GO:0061087 | positive regulation of histone H3-K27 methylation | 1 | 4 | 2.91e-01 |
| GO:BP | GO:0021892 | cerebral cortex GABAergic interneuron differentiation | 1 | 3 | 2.91e-01 |
| GO:BP | GO:0030097 | hemopoiesis | 1 | 656 | 2.91e-01 |
| GO:BP | GO:0051593 | response to folic acid | 1 | 9 | 2.91e-01 |
| GO:BP | GO:0002377 | immunoglobulin production | 2 | 70 | 2.91e-01 |
| GO:BP | GO:1901214 | regulation of neuron death | 4 | 246 | 2.91e-01 |
| GO:BP | GO:0042795 | snRNA transcription by RNA polymerase II | 1 | 15 | 2.91e-01 |
| GO:BP | GO:0014046 | dopamine secretion | 1 | 23 | 2.91e-01 |
| GO:BP | GO:0032060 | bleb assembly | 1 | 9 | 2.91e-01 |
| GO:BP | GO:0043415 | positive regulation of skeletal muscle tissue regeneration | 1 | 4 | 2.91e-01 |
| GO:BP | GO:0044770 | cell cycle phase transition | 12 | 504 | 2.91e-01 |
| GO:BP | GO:0071705 | nitrogen compound transport | 16 | 1684 | 2.91e-01 |
| GO:BP | GO:0034058 | endosomal vesicle fusion | 1 | 10 | 2.91e-01 |
| GO:BP | GO:0006310 | DNA recombination | 8 | 257 | 2.91e-01 |
| GO:BP | GO:1901135 | carbohydrate derivative metabolic process | 2 | 843 | 2.91e-01 |
| GO:BP | GO:0043542 | endothelial cell migration | 4 | 182 | 2.91e-01 |
| GO:BP | GO:0048012 | hepatocyte growth factor receptor signaling pathway | 1 | 10 | 2.91e-01 |
| GO:BP | GO:2000647 | negative regulation of stem cell proliferation | 1 | 18 | 2.91e-01 |
| GO:BP | GO:1901620 | regulation of smoothened signaling pathway involved in dorsal/ventral neural tube patterning | 1 | 12 | 2.91e-01 |
| GO:BP | GO:0090313 | regulation of protein targeting to membrane | 1 | 27 | 2.91e-01 |
| GO:BP | GO:0045838 | positive regulation of membrane potential | 1 | 12 | 2.91e-01 |
| GO:BP | GO:0032725 | positive regulation of granulocyte macrophage colony-stimulating factor production | 1 | 5 | 2.91e-01 |
| GO:BP | GO:0006885 | regulation of pH | 2 | 74 | 2.91e-01 |
| GO:BP | GO:0034105 | positive regulation of tissue remodeling | 1 | 4 | 2.91e-01 |
| GO:BP | GO:0045910 | negative regulation of DNA recombination | 1 | 31 | 2.91e-01 |
| GO:BP | GO:0032504 | multicellular organism reproduction | 1 | 556 | 2.91e-01 |
| GO:BP | GO:0071902 | positive regulation of protein serine/threonine kinase activity | 3 | 135 | 2.91e-01 |
| GO:BP | GO:0034499 | late endosome to Golgi transport | 1 | 5 | 2.91e-01 |
| GO:BP | GO:0009894 | regulation of catabolic process | 1 | 875 | 2.91e-01 |
| GO:BP | GO:0035567 | non-canonical Wnt signaling pathway | 2 | 62 | 2.91e-01 |
| GO:BP | GO:0031623 | receptor internalization | 3 | 95 | 2.91e-01 |
| GO:BP | GO:0030334 | regulation of cell migration | 11 | 706 | 2.91e-01 |
| GO:BP | GO:0060632 | regulation of microtubule-based movement | 1 | 31 | 2.91e-01 |
| GO:BP | GO:0010763 | positive regulation of fibroblast migration | 1 | 15 | 2.91e-01 |
| GO:BP | GO:0034284 | response to monosaccharide | 1 | 142 | 2.92e-01 |
| GO:BP | GO:0048261 | negative regulation of receptor-mediated endocytosis | 1 | 25 | 2.92e-01 |
| GO:BP | GO:0050679 | positive regulation of epithelial cell proliferation | 2 | 155 | 2.92e-01 |
| GO:BP | GO:0045184 | establishment of protein localization | 14 | 1462 | 2.93e-01 |
| GO:BP | GO:0039536 | negative regulation of RIG-I signaling pathway | 1 | 7 | 2.95e-01 |
| GO:BP | GO:0002158 | osteoclast proliferation | 1 | 7 | 2.95e-01 |
| GO:BP | GO:0002526 | acute inflammatory response | 1 | 49 | 2.95e-01 |
| GO:BP | GO:0048242 | epinephrine secretion | 1 | 2 | 2.95e-01 |
| GO:BP | GO:0014060 | regulation of epinephrine secretion | 1 | 2 | 2.95e-01 |
| GO:BP | GO:0072319 | vesicle uncoating | 1 | 9 | 2.95e-01 |
| GO:BP | GO:0048841 | regulation of axon extension involved in axon guidance | 2 | 31 | 2.96e-01 |
| GO:BP | GO:1903829 | positive regulation of protein localization | 5 | 386 | 2.96e-01 |
| GO:BP | GO:1903426 | regulation of reactive oxygen species biosynthetic process | 1 | 29 | 2.98e-01 |
| GO:BP | GO:0022603 | regulation of anatomical structure morphogenesis | 11 | 691 | 2.98e-01 |
| GO:BP | GO:0033353 | S-adenosylmethionine cycle | 1 | 7 | 2.98e-01 |
| GO:BP | GO:2000303 | regulation of ceramide biosynthetic process | 1 | 11 | 2.98e-01 |
| GO:BP | GO:0045198 | establishment of epithelial cell apical/basal polarity | 1 | 14 | 2.98e-01 |
| GO:BP | GO:0071267 | L-methionine salvage | 1 | 5 | 2.98e-01 |
| GO:BP | GO:0071265 | L-methionine biosynthetic process | 1 | 5 | 2.98e-01 |
| GO:BP | GO:0043102 | amino acid salvage | 1 | 5 | 2.98e-01 |
| GO:BP | GO:0001885 | endothelial cell development | 2 | 53 | 2.98e-01 |
| GO:BP | GO:0019953 | sexual reproduction | 1 | 631 | 2.98e-01 |
| GO:BP | GO:0021856 | hypothalamic tangential migration using cell-axon interactions | 1 | 6 | 2.98e-01 |
| GO:BP | GO:0097577 | sequestering of iron ion | 1 | 3 | 2.98e-01 |
| GO:BP | GO:0071380 | cellular response to prostaglandin E stimulus | 1 | 14 | 2.98e-01 |
| GO:BP | GO:0007059 | chromosome segregation | 4 | 369 | 2.98e-01 |
| GO:BP | GO:0005976 | polysaccharide metabolic process | 2 | 80 | 2.98e-01 |
| GO:BP | GO:0043255 | regulation of carbohydrate biosynthetic process | 2 | 77 | 2.98e-01 |
| GO:BP | GO:0021828 | gonadotrophin-releasing hormone neuronal migration to the hypothalamus | 1 | 6 | 2.98e-01 |
| GO:BP | GO:0090178 | regulation of establishment of planar polarity involved in neural tube closure | 1 | 13 | 2.98e-01 |
| GO:BP | GO:0048259 | regulation of receptor-mediated endocytosis | 2 | 87 | 3.00e-01 |
| GO:BP | GO:0009176 | pyrimidine deoxyribonucleoside monophosphate metabolic process | 1 | 9 | 3.00e-01 |
| GO:BP | GO:0001501 | skeletal system development | 1 | 377 | 3.00e-01 |
| GO:BP | GO:0001845 | phagolysosome assembly | 1 | 14 | 3.00e-01 |
| GO:BP | GO:0046320 | regulation of fatty acid oxidation | 2 | 31 | 3.00e-01 |
| GO:BP | GO:0032331 | negative regulation of chondrocyte differentiation | 1 | 18 | 3.00e-01 |
| GO:BP | GO:0043280 | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 1 | 96 | 3.01e-01 |
| GO:BP | GO:1902414 | protein localization to cell junction | 4 | 93 | 3.02e-01 |
| GO:BP | GO:0033211 | adiponectin-activated signaling pathway | 1 | 7 | 3.03e-01 |
| GO:BP | GO:1900262 | regulation of DNA-directed DNA polymerase activity | 1 | 13 | 3.04e-01 |
| GO:BP | GO:1900264 | positive regulation of DNA-directed DNA polymerase activity | 1 | 13 | 3.04e-01 |
| GO:BP | GO:0006264 | mitochondrial DNA replication | 1 | 13 | 3.04e-01 |
| GO:BP | GO:0046330 | positive regulation of JNK cascade | 2 | 72 | 3.04e-01 |
| GO:BP | GO:0042440 | pigment metabolic process | 1 | 60 | 3.04e-01 |
| GO:BP | GO:0072359 | circulatory system development | 21 | 884 | 3.04e-01 |
| GO:BP | GO:0055015 | ventricular cardiac muscle cell development | 1 | 10 | 3.04e-01 |
| GO:BP | GO:0010863 | positive regulation of phospholipase C activity | 1 | 18 | 3.05e-01 |
| GO:BP | GO:0002028 | regulation of sodium ion transport | 2 | 72 | 3.05e-01 |
| GO:BP | GO:0045995 | regulation of embryonic development | 3 | 80 | 3.05e-01 |
| GO:BP | GO:0002275 | myeloid cell activation involved in immune response | 3 | 48 | 3.05e-01 |
| GO:BP | GO:1901993 | regulation of meiotic cell cycle phase transition | 1 | 5 | 3.05e-01 |
| GO:BP | GO:0071500 | cellular response to nitrosative stress | 1 | 6 | 3.05e-01 |
| GO:BP | GO:0040016 | embryonic cleavage | 1 | 7 | 3.05e-01 |
| GO:BP | GO:2000766 | negative regulation of cytoplasmic translation | 1 | 7 | 3.05e-01 |
| GO:BP | GO:0090153 | regulation of sphingolipid biosynthetic process | 1 | 12 | 3.05e-01 |
| GO:BP | GO:0009301 | snRNA transcription | 1 | 18 | 3.05e-01 |
| GO:BP | GO:0008589 | regulation of smoothened signaling pathway | 3 | 73 | 3.05e-01 |
| GO:BP | GO:0032479 | regulation of type I interferon production | 3 | 76 | 3.05e-01 |
| GO:BP | GO:1903241 | U2-type prespliceosome assembly | 1 | 24 | 3.05e-01 |
| GO:BP | GO:0032606 | type I interferon production | 3 | 76 | 3.05e-01 |
| GO:BP | GO:0060644 | mammary gland epithelial cell differentiation | 1 | 14 | 3.05e-01 |
| GO:BP | GO:0003007 | heart morphogenesis | 6 | 216 | 3.05e-01 |
| GO:BP | GO:0043467 | regulation of generation of precursor metabolites and energy | 3 | 89 | 3.05e-01 |
| GO:BP | GO:0006591 | ornithine metabolic process | 1 | 6 | 3.05e-01 |
| GO:BP | GO:0009743 | response to carbohydrate | 1 | 161 | 3.05e-01 |
| GO:BP | GO:0010001 | glial cell differentiation | 1 | 170 | 3.05e-01 |
| GO:BP | GO:0097119 | postsynaptic density protein 95 clustering | 1 | 7 | 3.05e-01 |
| GO:BP | GO:0015031 | protein transport | 13 | 1361 | 3.05e-01 |
| GO:BP | GO:0071816 | tail-anchored membrane protein insertion into ER membrane | 1 | 17 | 3.05e-01 |
| GO:BP | GO:2000378 | negative regulation of reactive oxygen species metabolic process | 1 | 34 | 3.05e-01 |
| GO:BP | GO:1905038 | regulation of membrane lipid metabolic process | 1 | 12 | 3.05e-01 |
| GO:BP | GO:0001504 | neurotransmitter uptake | 1 | 29 | 3.05e-01 |
| GO:BP | GO:0090177 | establishment of planar polarity involved in neural tube closure | 1 | 14 | 3.05e-01 |
| GO:BP | GO:0002639 | positive regulation of immunoglobulin production | 1 | 30 | 3.06e-01 |
| GO:BP | GO:0098974 | postsynaptic actin cytoskeleton organization | 1 | 11 | 3.06e-01 |
| GO:BP | GO:0042177 | negative regulation of protein catabolic process | 4 | 100 | 3.06e-01 |
| GO:BP | GO:0009628 | response to abiotic stimulus | 2 | 868 | 3.06e-01 |
| GO:BP | GO:0032604 | granulocyte macrophage colony-stimulating factor production | 1 | 5 | 3.07e-01 |
| GO:BP | GO:0032645 | regulation of granulocyte macrophage colony-stimulating factor production | 1 | 5 | 3.07e-01 |
| GO:BP | GO:0002069 | columnar/cuboidal epithelial cell maturation | 1 | 9 | 3.07e-01 |
| GO:BP | GO:0044772 | mitotic cell cycle phase transition | 10 | 418 | 3.08e-01 |
| GO:BP | GO:0010906 | regulation of glucose metabolic process | 2 | 86 | 3.08e-01 |
| GO:BP | GO:0000098 | sulfur amino acid catabolic process | 1 | 7 | 3.08e-01 |
| GO:BP | GO:0031333 | negative regulation of protein-containing complex assembly | 1 | 130 | 3.08e-01 |
| GO:BP | GO:1900274 | regulation of phospholipase C activity | 1 | 20 | 3.08e-01 |
| GO:BP | GO:0060740 | prostate gland epithelium morphogenesis | 1 | 20 | 3.08e-01 |
| GO:BP | GO:0060831 | smoothened signaling pathway involved in dorsal/ventral neural tube patterning | 1 | 14 | 3.08e-01 |
| GO:BP | GO:0051451 | myoblast migration | 1 | 11 | 3.08e-01 |
| GO:BP | GO:0038166 | angiotensin-activated signaling pathway | 1 | 10 | 3.08e-01 |
| GO:BP | GO:0042401 | biogenic amine biosynthetic process | 2 | 24 | 3.09e-01 |
| GO:BP | GO:0048284 | organelle fusion | 3 | 135 | 3.09e-01 |
| GO:BP | GO:1902176 | negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway | 1 | 18 | 3.09e-01 |
| GO:BP | GO:0048266 | behavioral response to pain | 1 | 11 | 3.09e-01 |
| GO:BP | GO:0007584 | response to nutrient | 5 | 109 | 3.10e-01 |
| GO:BP | GO:0014075 | response to amine | 1 | 34 | 3.11e-01 |
| GO:BP | GO:0060142 | regulation of syncytium formation by plasma membrane fusion | 1 | 15 | 3.11e-01 |
| GO:BP | GO:0003206 | cardiac chamber morphogenesis | 3 | 109 | 3.11e-01 |
| GO:BP | GO:2000036 | regulation of stem cell population maintenance | 3 | 62 | 3.11e-01 |
| GO:BP | GO:0017015 | regulation of transforming growth factor beta receptor signaling pathway | 3 | 128 | 3.11e-01 |
| GO:BP | GO:0001822 | kidney development | 7 | 244 | 3.12e-01 |
| GO:BP | GO:0035116 | embryonic hindlimb morphogenesis | 1 | 17 | 3.13e-01 |
| GO:BP | GO:0001936 | regulation of endothelial cell proliferation | 1 | 102 | 3.13e-01 |
| GO:BP | GO:0006261 | DNA-templated DNA replication | 3 | 148 | 3.13e-01 |
| GO:BP | GO:0050851 | antigen receptor-mediated signaling pathway | 1 | 106 | 3.15e-01 |
| GO:BP | GO:1905477 | positive regulation of protein localization to membrane | 2 | 84 | 3.15e-01 |
| GO:BP | GO:0021855 | hypothalamus cell migration | 1 | 6 | 3.16e-01 |
| GO:BP | GO:0006450 | regulation of translational fidelity | 1 | 16 | 3.16e-01 |
| GO:BP | GO:0016032 | viral process | 1 | 344 | 3.16e-01 |
| GO:BP | GO:0009309 | amine biosynthetic process | 2 | 25 | 3.16e-01 |
| GO:BP | GO:0001825 | blastocyst formation | 2 | 37 | 3.16e-01 |
| GO:BP | GO:0045930 | negative regulation of mitotic cell cycle | 6 | 211 | 3.16e-01 |
| GO:BP | GO:0050921 | positive regulation of chemotaxis | 1 | 85 | 3.16e-01 |
| GO:BP | GO:0003416 | endochondral bone growth | 1 | 23 | 3.16e-01 |
| GO:BP | GO:0046653 | tetrahydrofolate metabolic process | 1 | 14 | 3.16e-01 |
| GO:BP | GO:0080135 | regulation of cellular response to stress | 7 | 616 | 3.16e-01 |
| GO:BP | GO:0007062 | sister chromatid cohesion | 2 | 52 | 3.16e-01 |
| GO:BP | GO:0007252 | I-kappaB phosphorylation | 1 | 14 | 3.16e-01 |
| GO:BP | GO:0031998 | regulation of fatty acid beta-oxidation | 1 | 16 | 3.16e-01 |
| GO:BP | GO:2001056 | positive regulation of cysteine-type endopeptidase activity | 1 | 107 | 3.16e-01 |
| GO:BP | GO:0060512 | prostate gland morphogenesis | 1 | 21 | 3.16e-01 |
| GO:BP | GO:0043603 | amide metabolic process | 2 | 993 | 3.16e-01 |
| GO:BP | GO:2000010 | positive regulation of protein localization to cell surface | 1 | 16 | 3.16e-01 |
| GO:BP | GO:0072089 | stem cell proliferation | 2 | 84 | 3.16e-01 |
| GO:BP | GO:0000075 | cell cycle checkpoint signaling | 2 | 183 | 3.18e-01 |
| GO:BP | GO:1902284 | neuron projection extension involved in neuron projection guidance | 2 | 35 | 3.18e-01 |
| GO:BP | GO:0048846 | axon extension involved in axon guidance | 2 | 35 | 3.18e-01 |
| GO:BP | GO:1903844 | regulation of cellular response to transforming growth factor beta stimulus | 3 | 129 | 3.18e-01 |
| GO:BP | GO:0032688 | negative regulation of interferon-beta production | 1 | 10 | 3.18e-01 |
| GO:BP | GO:0000045 | autophagosome assembly | 1 | 103 | 3.18e-01 |
| GO:BP | GO:0060021 | roof of mouth development | 3 | 71 | 3.19e-01 |
| GO:BP | GO:0023041 | neuronal signal transduction | 1 | 6 | 3.21e-01 |
| GO:BP | GO:0008300 | isoprenoid catabolic process | 1 | 5 | 3.23e-01 |
| GO:BP | GO:1904018 | positive regulation of vasculature development | 2 | 115 | 3.23e-01 |
| GO:BP | GO:1901020 | negative regulation of calcium ion transmembrane transporter activity | 2 | 27 | 3.23e-01 |
| GO:BP | GO:0042088 | T-helper 1 type immune response | 1 | 26 | 3.23e-01 |
| GO:BP | GO:0051000 | positive regulation of nitric-oxide synthase activity | 1 | 14 | 3.23e-01 |
| GO:BP | GO:0031396 | regulation of protein ubiquitination | 6 | 191 | 3.23e-01 |
| GO:BP | GO:0034103 | regulation of tissue remodeling | 2 | 45 | 3.23e-01 |
| GO:BP | GO:0018105 | peptidyl-serine phosphorylation | 5 | 247 | 3.23e-01 |
| GO:BP | GO:0045766 | positive regulation of angiogenesis | 2 | 115 | 3.23e-01 |
| GO:BP | GO:0046512 | sphingosine biosynthetic process | 1 | 13 | 3.23e-01 |
| GO:BP | GO:0046520 | sphingoid biosynthetic process | 1 | 13 | 3.23e-01 |
| GO:BP | GO:0042249 | establishment of planar polarity of embryonic epithelium | 1 | 15 | 3.23e-01 |
| GO:BP | GO:0090201 | negative regulation of release of cytochrome c from mitochondria | 1 | 18 | 3.23e-01 |
| GO:BP | GO:1901137 | carbohydrate derivative biosynthetic process | 1 | 544 | 3.23e-01 |
| GO:BP | GO:0015872 | dopamine transport | 1 | 29 | 3.23e-01 |
| GO:BP | GO:0033138 | positive regulation of peptidyl-serine phosphorylation | 2 | 70 | 3.23e-01 |
| GO:BP | GO:0090307 | mitotic spindle assembly | 1 | 70 | 3.23e-01 |
| GO:BP | GO:0042552 | myelination | 3 | 111 | 3.23e-01 |
| GO:BP | GO:0006289 | nucleotide-excision repair | 3 | 79 | 3.23e-01 |
| GO:BP | GO:0030239 | myofibril assembly | 1 | 66 | 3.23e-01 |
| GO:BP | GO:0000423 | mitophagy | 2 | 37 | 3.23e-01 |
| GO:BP | GO:0008366 | axon ensheathment | 3 | 113 | 3.23e-01 |
| GO:BP | GO:0007272 | ensheathment of neurons | 3 | 113 | 3.23e-01 |
| GO:BP | GO:0045988 | negative regulation of striated muscle contraction | 1 | 7 | 3.23e-01 |
| GO:BP | GO:0031109 | microtubule polymerization or depolymerization | 2 | 119 | 3.23e-01 |
| GO:BP | GO:0070997 | neuron death | 4 | 286 | 3.23e-01 |
| GO:BP | GO:2000026 | regulation of multicellular organismal development | 1 | 1014 | 3.23e-01 |
| GO:BP | GO:0098760 | response to interleukin-7 | 1 | 12 | 3.23e-01 |
| GO:BP | GO:0043455 | regulation of secondary metabolic process | 1 | 12 | 3.23e-01 |
| GO:BP | GO:1903409 | reactive oxygen species biosynthetic process | 1 | 36 | 3.23e-01 |
| GO:BP | GO:0009263 | deoxyribonucleotide biosynthetic process | 1 | 14 | 3.23e-01 |
| GO:BP | GO:0071379 | cellular response to prostaglandin stimulus | 1 | 16 | 3.23e-01 |
| GO:BP | GO:2000095 | regulation of Wnt signaling pathway, planar cell polarity pathway | 1 | 15 | 3.23e-01 |
| GO:BP | GO:0061085 | regulation of histone H3-K27 methylation | 1 | 4 | 3.23e-01 |
| GO:BP | GO:0051149 | positive regulation of muscle cell differentiation | 2 | 53 | 3.23e-01 |
| GO:BP | GO:0051094 | positive regulation of developmental process | 1 | 957 | 3.23e-01 |
| GO:BP | GO:0097104 | postsynaptic membrane assembly | 1 | 8 | 3.23e-01 |
| GO:BP | GO:0044771 | meiotic cell cycle phase transition | 1 | 7 | 3.23e-01 |
| GO:BP | GO:1904491 | protein localization to ciliary transition zone | 1 | 7 | 3.23e-01 |
| GO:BP | GO:0001935 | endothelial cell proliferation | 1 | 116 | 3.23e-01 |
| GO:BP | GO:0097105 | presynaptic membrane assembly | 1 | 8 | 3.23e-01 |
| GO:BP | GO:0002712 | regulation of B cell mediated immunity | 1 | 39 | 3.23e-01 |
| GO:BP | GO:0071346 | cellular response to type II interferon | 2 | 69 | 3.23e-01 |
| GO:BP | GO:0021888 | hypothalamus gonadotrophin-releasing hormone neuron development | 1 | 7 | 3.23e-01 |
| GO:BP | GO:0046834 | lipid phosphorylation | 1 | 16 | 3.23e-01 |
| GO:BP | GO:0010837 | regulation of keratinocyte proliferation | 2 | 33 | 3.23e-01 |
| GO:BP | GO:0097113 | AMPA glutamate receptor clustering | 1 | 7 | 3.23e-01 |
| GO:BP | GO:0010831 | positive regulation of myotube differentiation | 1 | 10 | 3.23e-01 |
| GO:BP | GO:0034504 | protein localization to nucleus | 4 | 276 | 3.23e-01 |
| GO:BP | GO:0097688 | glutamate receptor clustering | 1 | 7 | 3.23e-01 |
| GO:BP | GO:0046825 | regulation of protein export from nucleus | 1 | 30 | 3.23e-01 |
| GO:BP | GO:0032069 | regulation of nuclease activity | 1 | 17 | 3.23e-01 |
| GO:BP | GO:0008216 | spermidine metabolic process | 1 | 7 | 3.23e-01 |
| GO:BP | GO:0098868 | bone growth | 1 | 24 | 3.23e-01 |
| GO:BP | GO:0099054 | presynapse assembly | 2 | 39 | 3.23e-01 |
| GO:BP | GO:0002063 | chondrocyte development | 1 | 24 | 3.23e-01 |
| GO:BP | GO:0035108 | limb morphogenesis | 4 | 114 | 3.23e-01 |
| GO:BP | GO:0055002 | striated muscle cell development | 1 | 67 | 3.23e-01 |
| GO:BP | GO:0060576 | intestinal epithelial cell development | 1 | 11 | 3.23e-01 |
| GO:BP | GO:0060612 | adipose tissue development | 1 | 41 | 3.23e-01 |
| GO:BP | GO:0006914 | autophagy | 2 | 513 | 3.23e-01 |
| GO:BP | GO:0006206 | pyrimidine nucleobase metabolic process | 1 | 13 | 3.23e-01 |
| GO:BP | GO:0048021 | regulation of melanin biosynthetic process | 1 | 12 | 3.23e-01 |
| GO:BP | GO:0050848 | regulation of calcium-mediated signaling | 3 | 52 | 3.23e-01 |
| GO:BP | GO:0099188 | postsynaptic cytoskeleton organization | 1 | 14 | 3.23e-01 |
| GO:BP | GO:0098761 | cellular response to interleukin-7 | 1 | 12 | 3.23e-01 |
| GO:BP | GO:0060070 | canonical Wnt signaling pathway | 5 | 251 | 3.23e-01 |
| GO:BP | GO:0021886 | hypothalamus gonadotrophin-releasing hormone neuron differentiation | 1 | 7 | 3.23e-01 |
| GO:BP | GO:1905207 | regulation of cardiocyte differentiation | 1 | 22 | 3.23e-01 |
| GO:BP | GO:1902229 | regulation of intrinsic apoptotic signaling pathway in response to DNA damage | 1 | 37 | 3.23e-01 |
| GO:BP | GO:0035107 | appendage morphogenesis | 4 | 114 | 3.23e-01 |
| GO:BP | GO:0021953 | central nervous system neuron differentiation | 1 | 108 | 3.23e-01 |
| GO:BP | GO:1905037 | autophagosome organization | 1 | 110 | 3.23e-01 |
| GO:BP | GO:0046385 | deoxyribose phosphate biosynthetic process | 1 | 14 | 3.23e-01 |
| GO:BP | GO:0009130 | pyrimidine nucleoside monophosphate biosynthetic process | 1 | 13 | 3.23e-01 |
| GO:BP | GO:0035089 | establishment of apical/basal cell polarity | 1 | 18 | 3.23e-01 |
| GO:BP | GO:0061919 | process utilizing autophagic mechanism | 2 | 513 | 3.23e-01 |
| GO:BP | GO:0006259 | DNA metabolic process | 11 | 884 | 3.23e-01 |
| GO:BP | GO:2000671 | regulation of motor neuron apoptotic process | 1 | 12 | 3.23e-01 |
| GO:BP | GO:0071676 | negative regulation of mononuclear cell migration | 1 | 16 | 3.23e-01 |
| GO:BP | GO:0061037 | negative regulation of cartilage development | 1 | 23 | 3.23e-01 |
| GO:BP | GO:1900376 | regulation of secondary metabolite biosynthetic process | 1 | 12 | 3.23e-01 |
| GO:BP | GO:0002889 | regulation of immunoglobulin mediated immune response | 1 | 39 | 3.23e-01 |
| GO:BP | GO:0009265 | 2’-deoxyribonucleotide biosynthetic process | 1 | 14 | 3.23e-01 |
| GO:BP | GO:0016192 | vesicle-mediated transport | 11 | 1238 | 3.23e-01 |
| GO:BP | GO:0070601 | centromeric sister chromatid cohesion | 1 | 11 | 3.23e-01 |
| GO:BP | GO:0010226 | response to lithium ion | 1 | 16 | 3.23e-01 |
| GO:BP | GO:0002682 | regulation of immune system process | 2 | 877 | 3.23e-01 |
| GO:BP | GO:0070507 | regulation of microtubule cytoskeleton organization | 3 | 146 | 3.23e-01 |
| GO:BP | GO:0042363 | fat-soluble vitamin catabolic process | 1 | 1 | 3.23e-01 |
| GO:BP | GO:0045185 | maintenance of protein location | 2 | 83 | 3.23e-01 |
| GO:BP | GO:0035729 | cellular response to hepatocyte growth factor stimulus | 1 | 13 | 3.23e-01 |
| GO:BP | GO:0048857 | neural nucleus development | 1 | 50 | 3.23e-01 |
| GO:BP | GO:0051665 | membrane raft localization | 1 | 4 | 3.23e-01 |
| GO:BP | GO:0033313 | meiotic cell cycle checkpoint signaling | 1 | 6 | 3.23e-01 |
| GO:BP | GO:0009057 | macromolecule catabolic process | 1 | 1199 | 3.23e-01 |
| GO:BP | GO:0010564 | regulation of cell cycle process | 12 | 626 | 3.23e-01 |
| GO:BP | GO:0006776 | vitamin A metabolic process | 1 | 3 | 3.23e-01 |
| GO:BP | GO:0007032 | endosome organization | 1 | 92 | 3.23e-01 |
| GO:BP | GO:1901163 | regulation of trophoblast cell migration | 1 | 12 | 3.23e-01 |
| GO:BP | GO:0032891 | negative regulation of organic acid transport | 1 | 17 | 3.25e-01 |
| GO:BP | GO:0046488 | phosphatidylinositol metabolic process | 4 | 140 | 3.25e-01 |
| GO:BP | GO:0051896 | regulation of protein kinase B signaling | 1 | 123 | 3.25e-01 |
| GO:BP | GO:0043534 | blood vessel endothelial cell migration | 2 | 97 | 3.25e-01 |
| GO:BP | GO:0050920 | regulation of chemotaxis | 3 | 142 | 3.26e-01 |
| GO:BP | GO:0050678 | regulation of epithelial cell proliferation | 4 | 276 | 3.26e-01 |
| GO:BP | GO:0010950 | positive regulation of endopeptidase activity | 1 | 126 | 3.26e-01 |
| GO:BP | GO:0032024 | positive regulation of insulin secretion | 3 | 56 | 3.26e-01 |
| GO:BP | GO:0072711 | cellular response to hydroxyurea | 1 | 10 | 3.26e-01 |
| GO:BP | GO:0033273 | response to vitamin | 3 | 61 | 3.26e-01 |
| GO:BP | GO:1901987 | regulation of cell cycle phase transition | 8 | 391 | 3.26e-01 |
| GO:BP | GO:0062013 | positive regulation of small molecule metabolic process | 4 | 104 | 3.26e-01 |
| GO:BP | GO:0048241 | epinephrine transport | 1 | 4 | 3.27e-01 |
| GO:BP | GO:0061162 | establishment of monopolar cell polarity | 1 | 20 | 3.28e-01 |
| GO:BP | GO:0030859 | polarized epithelial cell differentiation | 1 | 19 | 3.28e-01 |
| GO:BP | GO:0050432 | catecholamine secretion | 1 | 31 | 3.28e-01 |
| GO:BP | GO:0002444 | myeloid leukocyte mediated immunity | 2 | 60 | 3.28e-01 |
| GO:BP | GO:0042692 | muscle cell differentiation | 6 | 324 | 3.29e-01 |
| GO:BP | GO:1903748 | negative regulation of establishment of protein localization to mitochondrion | 1 | 5 | 3.29e-01 |
| GO:BP | GO:0045931 | positive regulation of mitotic cell cycle | 3 | 113 | 3.30e-01 |
| GO:BP | GO:0006457 | protein folding | 1 | 192 | 3.30e-01 |
| GO:BP | GO:0071300 | cellular response to retinoic acid | 2 | 49 | 3.30e-01 |
| GO:BP | GO:0032435 | negative regulation of proteasomal ubiquitin-dependent protein catabolic process | 2 | 35 | 3.30e-01 |
| GO:BP | GO:0043416 | regulation of skeletal muscle tissue regeneration | 1 | 5 | 3.30e-01 |
| GO:BP | GO:0019217 | regulation of fatty acid metabolic process | 3 | 66 | 3.30e-01 |
| GO:BP | GO:0045780 | positive regulation of bone resorption | 1 | 12 | 3.30e-01 |
| GO:BP | GO:1901607 | alpha-amino acid biosynthetic process | 1 | 59 | 3.31e-01 |
| GO:BP | GO:0097154 | GABAergic neuron differentiation | 1 | 5 | 3.31e-01 |
| GO:BP | GO:2000136 | regulation of cell proliferation involved in heart morphogenesis | 1 | 17 | 3.31e-01 |
| GO:BP | GO:0060351 | cartilage development involved in endochondral bone morphogenesis | 1 | 26 | 3.32e-01 |
| GO:BP | GO:0048048 | embryonic eye morphogenesis | 1 | 25 | 3.32e-01 |
| GO:BP | GO:0035137 | hindlimb morphogenesis | 1 | 20 | 3.32e-01 |
| GO:BP | GO:0035728 | response to hepatocyte growth factor | 1 | 15 | 3.32e-01 |
| GO:BP | GO:0090263 | positive regulation of canonical Wnt signaling pathway | 1 | 91 | 3.32e-01 |
| GO:BP | GO:0000910 | cytokinesis | 4 | 164 | 3.32e-01 |
| GO:BP | GO:0002708 | positive regulation of lymphocyte mediated immunity | 2 | 58 | 3.32e-01 |
| GO:BP | GO:0043406 | positive regulation of MAP kinase activity | 2 | 82 | 3.32e-01 |
| GO:BP | GO:0061450 | trophoblast cell migration | 1 | 13 | 3.32e-01 |
| GO:BP | GO:0010739 | positive regulation of protein kinase A signaling | 1 | 6 | 3.32e-01 |
| GO:BP | GO:1901550 | regulation of endothelial cell development | 1 | 12 | 3.33e-01 |
| GO:BP | GO:0071712 | ER-associated misfolded protein catabolic process | 1 | 12 | 3.33e-01 |
| GO:BP | GO:0010518 | positive regulation of phospholipase activity | 1 | 27 | 3.33e-01 |
| GO:BP | GO:1903140 | regulation of establishment of endothelial barrier | 1 | 12 | 3.33e-01 |
| GO:BP | GO:0010952 | positive regulation of peptidase activity | 1 | 135 | 3.33e-01 |
| GO:BP | GO:0061339 | establishment or maintenance of monopolar cell polarity | 1 | 20 | 3.33e-01 |
| GO:BP | GO:0022414 | reproductive process | 1 | 927 | 3.34e-01 |
| GO:BP | GO:0042063 | gliogenesis | 1 | 235 | 3.35e-01 |
| GO:BP | GO:0000003 | reproduction | 1 | 934 | 3.35e-01 |
| GO:BP | GO:0070585 | protein localization to mitochondrion | 4 | 123 | 3.35e-01 |
| GO:BP | GO:0071241 | cellular response to inorganic substance | 5 | 164 | 3.35e-01 |
| GO:BP | GO:0006534 | cysteine metabolic process | 1 | 11 | 3.36e-01 |
| GO:BP | GO:0097435 | supramolecular fiber organization | 9 | 665 | 3.36e-01 |
| GO:BP | GO:0003323 | type B pancreatic cell development | 1 | 19 | 3.36e-01 |
| GO:BP | GO:0097090 | presynaptic membrane organization | 1 | 8 | 3.36e-01 |
| GO:BP | GO:0018209 | peptidyl-serine modification | 5 | 259 | 3.36e-01 |
| GO:BP | GO:0043087 | regulation of GTPase activity | 4 | 302 | 3.36e-01 |
| GO:BP | GO:0045911 | positive regulation of DNA recombination | 1 | 57 | 3.36e-01 |
| GO:BP | GO:1903978 | regulation of microglial cell activation | 1 | 9 | 3.37e-01 |
| GO:BP | GO:1905953 | negative regulation of lipid localization | 2 | 32 | 3.38e-01 |
| GO:BP | GO:0045048 | protein insertion into ER membrane | 1 | 23 | 3.38e-01 |
| GO:BP | GO:0061635 | regulation of protein complex stability | 1 | 11 | 3.38e-01 |
| GO:BP | GO:0072710 | response to hydroxyurea | 1 | 11 | 3.38e-01 |
| GO:BP | GO:0048168 | regulation of neuronal synaptic plasticity | 1 | 42 | 3.38e-01 |
| GO:BP | GO:0032649 | regulation of type II interferon production | 2 | 52 | 3.38e-01 |
| GO:BP | GO:0050863 | regulation of T cell activation | 7 | 216 | 3.38e-01 |
| GO:BP | GO:0061323 | cell proliferation involved in heart morphogenesis | 1 | 18 | 3.38e-01 |
| GO:BP | GO:0045595 | regulation of cell differentiation | 1 | 1137 | 3.39e-01 |
| GO:BP | GO:0031076 | embryonic camera-type eye development | 1 | 28 | 3.39e-01 |
| GO:BP | GO:0048268 | clathrin coat assembly | 1 | 13 | 3.39e-01 |
| GO:BP | GO:0120162 | positive regulation of cold-induced thermogenesis | 1 | 69 | 3.39e-01 |
| GO:BP | GO:0007144 | female meiosis I | 1 | 9 | 3.39e-01 |
| GO:BP | GO:0001779 | natural killer cell differentiation | 1 | 18 | 3.39e-01 |
| GO:BP | GO:2000630 | positive regulation of miRNA metabolic process | 1 | 48 | 3.39e-01 |
| GO:BP | GO:0001768 | establishment of T cell polarity | 1 | 10 | 3.39e-01 |
| GO:BP | GO:0032609 | type II interferon production | 2 | 53 | 3.39e-01 |
| GO:BP | GO:0120033 | negative regulation of plasma membrane bounded cell projection assembly | 1 | 28 | 3.39e-01 |
| GO:BP | GO:0009111 | vitamin catabolic process | 1 | 3 | 3.39e-01 |
| GO:BP | GO:0034472 | snRNA 3’-end processing | 1 | 21 | 3.39e-01 |
| GO:BP | GO:0090309 | positive regulation of DNA methylation-dependent heterochromatin formation | 1 | 12 | 3.39e-01 |
| GO:BP | GO:0099172 | presynapse organization | 2 | 42 | 3.40e-01 |
| GO:BP | GO:1900221 | regulation of amyloid-beta clearance | 1 | 13 | 3.40e-01 |
| GO:BP | GO:0050995 | negative regulation of lipid catabolic process | 1 | 14 | 3.40e-01 |
| GO:BP | GO:0007275 | multicellular organism development | 2 | 3386 | 3.40e-01 |
| GO:BP | GO:0034695 | response to prostaglandin E | 1 | 17 | 3.40e-01 |
| GO:BP | GO:1902430 | negative regulation of amyloid-beta formation | 1 | 17 | 3.40e-01 |
| GO:BP | GO:0051239 | regulation of multicellular organismal process | 4 | 2035 | 3.41e-01 |
| GO:BP | GO:0036294 | cellular response to decreased oxygen levels | 4 | 131 | 3.42e-01 |
| GO:BP | GO:0046879 | hormone secretion | 2 | 210 | 3.43e-01 |
| GO:BP | GO:0006775 | fat-soluble vitamin metabolic process | 2 | 20 | 3.43e-01 |
| GO:BP | GO:0040011 | locomotion | 14 | 954 | 3.43e-01 |
| GO:BP | GO:0055012 | ventricular cardiac muscle cell differentiation | 1 | 15 | 3.43e-01 |
| GO:BP | GO:0002637 | regulation of immunoglobulin production | 1 | 43 | 3.43e-01 |
| GO:BP | GO:0010887 | negative regulation of cholesterol storage | 1 | 9 | 3.43e-01 |
| GO:BP | GO:0060347 | heart trabecula formation | 1 | 13 | 3.43e-01 |
| GO:BP | GO:0044242 | cellular lipid catabolic process | 4 | 170 | 3.44e-01 |
| GO:BP | GO:0048015 | phosphatidylinositol-mediated signaling | 5 | 123 | 3.44e-01 |
| GO:BP | GO:0002040 | sprouting angiogenesis | 2 | 98 | 3.44e-01 |
| GO:BP | GO:0000463 | maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 1 | 15 | 3.44e-01 |
| GO:BP | GO:0032816 | positive regulation of natural killer cell activation | 1 | 16 | 3.44e-01 |
| GO:BP | GO:0097479 | synaptic vesicle localization | 2 | 50 | 3.44e-01 |
| GO:BP | GO:0008652 | amino acid biosynthetic process | 1 | 64 | 3.44e-01 |
| GO:BP | GO:0051345 | positive regulation of hydrolase activity | 7 | 422 | 3.44e-01 |
| GO:BP | GO:0002832 | negative regulation of response to biotic stimulus | 3 | 88 | 3.44e-01 |
| GO:BP | GO:0006984 | ER-nucleus signaling pathway | 1 | 45 | 3.44e-01 |
| GO:BP | GO:0050870 | positive regulation of T cell activation | 3 | 144 | 3.45e-01 |
| GO:BP | GO:0016926 | protein desumoylation | 1 | 9 | 3.45e-01 |
| GO:BP | GO:0060706 | cell differentiation involved in embryonic placenta development | 1 | 20 | 3.45e-01 |
| GO:BP | GO:0035051 | cardiocyte differentiation | 2 | 129 | 3.45e-01 |
| GO:BP | GO:0043491 | protein kinase B signaling | 1 | 146 | 3.45e-01 |
| GO:BP | GO:0050667 | homocysteine metabolic process | 1 | 11 | 3.45e-01 |
| GO:BP | GO:0090382 | phagosome maturation | 1 | 24 | 3.45e-01 |
| GO:BP | GO:1901385 | regulation of voltage-gated calcium channel activity | 2 | 29 | 3.45e-01 |
| GO:BP | GO:0001945 | lymph vessel development | 1 | 22 | 3.45e-01 |
| GO:BP | GO:0006040 | amino sugar metabolic process | 1 | 33 | 3.45e-01 |
| GO:BP | GO:0051457 | maintenance of protein location in nucleus | 1 | 22 | 3.45e-01 |
| GO:BP | GO:0009148 | pyrimidine nucleoside triphosphate biosynthetic process | 1 | 17 | 3.45e-01 |
| GO:BP | GO:0016049 | cell growth | 6 | 418 | 3.45e-01 |
| GO:BP | GO:0071526 | semaphorin-plexin signaling pathway | 2 | 44 | 3.45e-01 |
| GO:BP | GO:0002429 | immune response-activating cell surface receptor signaling pathway | 1 | 151 | 3.46e-01 |
| GO:BP | GO:0032869 | cellular response to insulin stimulus | 3 | 174 | 3.46e-01 |
| GO:BP | GO:0009064 | glutamine family amino acid metabolic process | 1 | 60 | 3.46e-01 |
| GO:BP | GO:0070914 | UV-damage excision repair | 1 | 13 | 3.46e-01 |
| GO:BP | GO:0031116 | positive regulation of microtubule polymerization | 1 | 31 | 3.47e-01 |
| GO:BP | GO:0048385 | regulation of retinoic acid receptor signaling pathway | 1 | 13 | 3.47e-01 |
| GO:BP | GO:0001767 | establishment of lymphocyte polarity | 1 | 11 | 3.47e-01 |
| GO:BP | GO:0042428 | serotonin metabolic process | 1 | 6 | 3.47e-01 |
| GO:BP | GO:0010822 | positive regulation of mitochondrion organization | 1 | 68 | 3.47e-01 |
| GO:BP | GO:0010595 | positive regulation of endothelial cell migration | 2 | 94 | 3.47e-01 |
| GO:BP | GO:0000184 | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 1 | 39 | 3.48e-01 |
| GO:BP | GO:0045954 | positive regulation of natural killer cell mediated cytotoxicity | 1 | 10 | 3.48e-01 |
| GO:BP | GO:0051656 | establishment of organelle localization | 1 | 378 | 3.49e-01 |
| GO:BP | GO:0006939 | smooth muscle contraction | 3 | 75 | 3.49e-01 |
| GO:BP | GO:0051177 | meiotic sister chromatid cohesion | 1 | 12 | 3.49e-01 |
| GO:BP | GO:0032870 | cellular response to hormone stimulus | 7 | 457 | 3.49e-01 |
| GO:BP | GO:0033314 | mitotic DNA replication checkpoint signaling | 1 | 9 | 3.49e-01 |
| GO:BP | GO:0009914 | hormone transport | 2 | 215 | 3.49e-01 |
| GO:BP | GO:0009059 | macromolecule biosynthetic process | 2 | 3730 | 3.49e-01 |
| GO:BP | GO:0071404 | cellular response to low-density lipoprotein particle stimulus | 1 | 19 | 3.49e-01 |
| GO:BP | GO:0005996 | monosaccharide metabolic process | 3 | 209 | 3.49e-01 |
| GO:BP | GO:0045893 | positive regulation of DNA-templated transcription | 1 | 1315 | 3.49e-01 |
| GO:BP | GO:1903508 | positive regulation of nucleic acid-templated transcription | 1 | 1315 | 3.49e-01 |
| GO:BP | GO:0043281 | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 1 | 155 | 3.50e-01 |
| GO:BP | GO:1902680 | positive regulation of RNA biosynthetic process | 1 | 1322 | 3.50e-01 |
| GO:BP | GO:0098813 | nuclear chromosome segregation | 3 | 273 | 3.50e-01 |
| GO:BP | GO:0050657 | nucleic acid transport | 2 | 144 | 3.50e-01 |
| GO:BP | GO:0050658 | RNA transport | 2 | 144 | 3.50e-01 |
| GO:BP | GO:0035023 | regulation of Rho protein signal transduction | 1 | 71 | 3.50e-01 |
| GO:BP | GO:0070584 | mitochondrion morphogenesis | 1 | 21 | 3.50e-01 |
| GO:BP | GO:0001829 | trophectodermal cell differentiation | 1 | 15 | 3.50e-01 |
| GO:BP | GO:0010165 | response to X-ray | 1 | 29 | 3.51e-01 |
| GO:BP | GO:0007422 | peripheral nervous system development | 2 | 67 | 3.51e-01 |
| GO:BP | GO:0035909 | aorta morphogenesis | 1 | 26 | 3.52e-01 |
| GO:BP | GO:0051775 | response to redox state | 1 | 12 | 3.52e-01 |
| GO:BP | GO:1902175 | regulation of oxidative stress-induced intrinsic apoptotic signaling pathway | 1 | 25 | 3.52e-01 |
| GO:BP | GO:0051402 | neuron apoptotic process | 6 | 200 | 3.52e-01 |
| GO:BP | GO:2000810 | regulation of bicellular tight junction assembly | 1 | 15 | 3.52e-01 |
| GO:BP | GO:2000980 | regulation of inner ear receptor cell differentiation | 1 | 8 | 3.52e-01 |
| GO:BP | GO:0055094 | response to lipoprotein particle | 1 | 20 | 3.52e-01 |
| GO:BP | GO:2001258 | negative regulation of cation channel activity | 2 | 30 | 3.52e-01 |
| GO:BP | GO:0070344 | regulation of fat cell proliferation | 1 | 9 | 3.52e-01 |
| GO:BP | GO:0032966 | negative regulation of collagen biosynthetic process | 1 | 7 | 3.52e-01 |
| GO:BP | GO:0060219 | camera-type eye photoreceptor cell differentiation | 1 | 18 | 3.52e-01 |
| GO:BP | GO:0006109 | regulation of carbohydrate metabolic process | 5 | 144 | 3.52e-01 |
| GO:BP | GO:0006670 | sphingosine metabolic process | 1 | 18 | 3.52e-01 |
| GO:BP | GO:1904375 | regulation of protein localization to cell periphery | 4 | 113 | 3.52e-01 |
| GO:BP | GO:0033081 | regulation of T cell differentiation in thymus | 1 | 16 | 3.52e-01 |
| GO:BP | GO:0051932 | synaptic transmission, GABAergic | 2 | 36 | 3.52e-01 |
| GO:BP | GO:0002768 | immune response-regulating cell surface receptor signaling pathway | 1 | 162 | 3.52e-01 |
| GO:BP | GO:0045607 | regulation of inner ear auditory receptor cell differentiation | 1 | 8 | 3.52e-01 |
| GO:BP | GO:0014065 | phosphatidylinositol 3-kinase signaling | 4 | 100 | 3.52e-01 |
| GO:BP | GO:0032369 | negative regulation of lipid transport | 1 | 20 | 3.52e-01 |
| GO:BP | GO:0048646 | anatomical structure formation involved in morphogenesis | 12 | 870 | 3.52e-01 |
| GO:BP | GO:0045631 | regulation of mechanoreceptor differentiation | 1 | 8 | 3.52e-01 |
| GO:BP | GO:0010517 | regulation of phospholipase activity | 1 | 37 | 3.52e-01 |
| GO:BP | GO:0009086 | methionine biosynthetic process | 1 | 10 | 3.52e-01 |
| GO:BP | GO:0034453 | microtubule anchoring | 1 | 25 | 3.52e-01 |
| GO:BP | GO:0090128 | regulation of synapse maturation | 1 | 15 | 3.52e-01 |
| GO:BP | GO:0034341 | response to type II interferon | 2 | 83 | 3.52e-01 |
| GO:BP | GO:0048017 | inositol lipid-mediated signaling | 5 | 126 | 3.52e-01 |
| GO:BP | GO:0050919 | negative chemotaxis | 2 | 42 | 3.52e-01 |
| GO:BP | GO:0007417 | central nervous system development | 2 | 792 | 3.52e-01 |
| GO:BP | GO:0007389 | pattern specification process | 9 | 306 | 3.52e-01 |
| GO:BP | GO:0006508 | proteolysis | 1 | 1318 | 3.52e-01 |
| GO:BP | GO:1901566 | organonitrogen compound biosynthetic process | 2 | 1484 | 3.52e-01 |
| GO:BP | GO:0007173 | epidermal growth factor receptor signaling pathway | 2 | 93 | 3.52e-01 |
| GO:BP | GO:0030517 | negative regulation of axon extension | 2 | 41 | 3.52e-01 |
| GO:BP | GO:0051236 | establishment of RNA localization | 2 | 147 | 3.52e-01 |
| GO:BP | GO:0002087 | regulation of respiratory gaseous exchange by nervous system process | 1 | 8 | 3.52e-01 |
| GO:BP | GO:0051937 | catecholamine transport | 1 | 38 | 3.52e-01 |
| GO:BP | GO:0051409 | response to nitrosative stress | 1 | 10 | 3.52e-01 |
| GO:BP | GO:0061000 | negative regulation of dendritic spine development | 1 | 10 | 3.52e-01 |
| GO:BP | GO:1901985 | positive regulation of protein acetylation | 1 | 41 | 3.53e-01 |
| GO:BP | GO:1903429 | regulation of cell maturation | 1 | 13 | 3.53e-01 |
| GO:BP | GO:0032042 | mitochondrial DNA metabolic process | 1 | 22 | 3.53e-01 |
| GO:BP | GO:0016180 | snRNA processing | 1 | 26 | 3.53e-01 |
| GO:BP | GO:0051223 | regulation of protein transport | 4 | 404 | 3.53e-01 |
| GO:BP | GO:0060193 | positive regulation of lipase activity | 1 | 34 | 3.53e-01 |
| GO:BP | GO:0051251 | positive regulation of lymphocyte activation | 4 | 199 | 3.53e-01 |
| GO:BP | GO:1901988 | negative regulation of cell cycle phase transition | 6 | 235 | 3.55e-01 |
| GO:BP | GO:0006096 | glycolytic process | 3 | 70 | 3.55e-01 |
| GO:BP | GO:0097049 | motor neuron apoptotic process | 1 | 18 | 3.55e-01 |
| GO:BP | GO:0048738 | cardiac muscle tissue development | 5 | 198 | 3.55e-01 |
| GO:BP | GO:0001892 | embryonic placenta development | 2 | 71 | 3.55e-01 |
| GO:BP | GO:0051865 | protein autoubiquitination | 1 | 75 | 3.55e-01 |
| GO:BP | GO:0022406 | membrane docking | 2 | 84 | 3.55e-01 |
| GO:BP | GO:0055013 | cardiac muscle cell development | 2 | 71 | 3.55e-01 |
| GO:BP | GO:0048011 | neurotrophin TRK receptor signaling pathway | 1 | 23 | 3.55e-01 |
| GO:BP | GO:1902992 | negative regulation of amyloid precursor protein catabolic process | 1 | 20 | 3.55e-01 |
| GO:BP | GO:0051385 | response to mineralocorticoid | 1 | 25 | 3.55e-01 |
| GO:BP | GO:0045580 | regulation of T cell differentiation | 4 | 110 | 3.55e-01 |
| GO:BP | GO:2000781 | positive regulation of double-strand break repair | 1 | 79 | 3.55e-01 |
| GO:BP | GO:0033604 | negative regulation of catecholamine secretion | 1 | 6 | 3.56e-01 |
| GO:BP | GO:0061013 | regulation of mRNA catabolic process | 3 | 161 | 3.56e-01 |
| GO:BP | GO:0051254 | positive regulation of RNA metabolic process | 1 | 1441 | 3.56e-01 |
| GO:BP | GO:0055001 | muscle cell development | 2 | 165 | 3.56e-01 |
| GO:BP | GO:0032872 | regulation of stress-activated MAPK cascade | 3 | 154 | 3.56e-01 |
| GO:BP | GO:0034968 | histone lysine methylation | 1 | 89 | 3.57e-01 |
| GO:BP | GO:0032386 | regulation of intracellular transport | 3 | 292 | 3.57e-01 |
| GO:BP | GO:0009755 | hormone-mediated signaling pathway | 2 | 139 | 3.57e-01 |
| GO:BP | GO:0000226 | microtubule cytoskeleton organization | 1 | 552 | 3.57e-01 |
| GO:BP | GO:0034312 | diol biosynthetic process | 1 | 20 | 3.57e-01 |
| GO:BP | GO:0045765 | regulation of angiogenesis | 4 | 203 | 3.57e-01 |
| GO:BP | GO:0006886 | intracellular protein transport | 9 | 803 | 3.58e-01 |
| GO:BP | GO:0032770 | positive regulation of monooxygenase activity | 1 | 20 | 3.58e-01 |
| GO:BP | GO:0031112 | positive regulation of microtubule polymerization or depolymerization | 1 | 35 | 3.58e-01 |
| GO:BP | GO:0033630 | positive regulation of cell adhesion mediated by integrin | 1 | 14 | 3.59e-01 |
| GO:BP | GO:0045937 | positive regulation of phosphate metabolic process | 9 | 597 | 3.60e-01 |
| GO:BP | GO:0071559 | response to transforming growth factor beta | 4 | 227 | 3.60e-01 |
| GO:BP | GO:0022411 | cellular component disassembly | 2 | 427 | 3.60e-01 |
| GO:BP | GO:0051640 | organelle localization | 6 | 503 | 3.60e-01 |
| GO:BP | GO:0010459 | negative regulation of heart rate | 1 | 7 | 3.60e-01 |
| GO:BP | GO:0010562 | positive regulation of phosphorus metabolic process | 9 | 597 | 3.60e-01 |
| GO:BP | GO:0043516 | regulation of DNA damage response, signal transduction by p53 class mediator | 1 | 35 | 3.60e-01 |
| GO:BP | GO:2000319 | regulation of T-helper 17 cell differentiation | 1 | 10 | 3.60e-01 |
| GO:BP | GO:0060315 | negative regulation of ryanodine-sensitive calcium-release channel activity | 1 | 10 | 3.60e-01 |
| GO:BP | GO:0009129 | pyrimidine nucleoside monophosphate metabolic process | 1 | 18 | 3.60e-01 |
| GO:BP | GO:0032091 | negative regulation of protein binding | 2 | 77 | 3.60e-01 |
| GO:BP | GO:0030901 | midbrain development | 1 | 69 | 3.60e-01 |
| GO:BP | GO:0030855 | epithelial cell differentiation | 9 | 442 | 3.60e-01 |
| GO:BP | GO:1905665 | positive regulation of calcium ion import across plasma membrane | 1 | 6 | 3.60e-01 |
| GO:BP | GO:0043161 | proteasome-mediated ubiquitin-dependent protein catabolic process | 10 | 427 | 3.60e-01 |
| GO:BP | GO:0044089 | positive regulation of cellular component biogenesis | 6 | 420 | 3.60e-01 |
| GO:BP | GO:0070302 | regulation of stress-activated protein kinase signaling cascade | 3 | 157 | 3.60e-01 |
| GO:BP | GO:0048729 | tissue morphogenesis | 13 | 504 | 3.60e-01 |
| GO:BP | GO:0014842 | regulation of skeletal muscle satellite cell proliferation | 1 | 8 | 3.60e-01 |
| GO:BP | GO:0009141 | nucleoside triphosphate metabolic process | 3 | 159 | 3.60e-01 |
| GO:BP | GO:1901606 | alpha-amino acid catabolic process | 1 | 63 | 3.60e-01 |
| GO:BP | GO:0010713 | negative regulation of collagen metabolic process | 1 | 8 | 3.60e-01 |
| GO:BP | GO:0007596 | blood coagulation | 1 | 150 | 3.60e-01 |
| GO:BP | GO:2000288 | positive regulation of myoblast proliferation | 1 | 9 | 3.60e-01 |
| GO:BP | GO:0043648 | dicarboxylic acid metabolic process | 1 | 74 | 3.60e-01 |
| GO:BP | GO:0048856 | anatomical structure development | 6 | 4128 | 3.60e-01 |
| GO:BP | GO:0042307 | positive regulation of protein import into nucleus | 1 | 32 | 3.61e-01 |
| GO:BP | GO:0071402 | cellular response to lipoprotein particle stimulus | 1 | 23 | 3.61e-01 |
| GO:BP | GO:0120263 | positive regulation of heterochromatin organization | 1 | 15 | 3.61e-01 |
| GO:BP | GO:1901342 | regulation of vasculature development | 4 | 206 | 3.61e-01 |
| GO:BP | GO:0031453 | positive regulation of heterochromatin formation | 1 | 15 | 3.61e-01 |
| GO:BP | GO:0010557 | positive regulation of macromolecule biosynthetic process | 1 | 1507 | 3.61e-01 |
| GO:BP | GO:0046519 | sphingoid metabolic process | 1 | 19 | 3.62e-01 |
| GO:BP | GO:0042149 | cellular response to glucose starvation | 2 | 51 | 3.62e-01 |
| GO:BP | GO:0048839 | inner ear development | 3 | 132 | 3.63e-01 |
| GO:BP | GO:2000116 | regulation of cysteine-type endopeptidase activity | 1 | 169 | 3.63e-01 |
| GO:BP | GO:1900180 | regulation of protein localization to nucleus | 2 | 117 | 3.63e-01 |
| GO:BP | GO:0002705 | positive regulation of leukocyte mediated immunity | 2 | 68 | 3.64e-01 |
| GO:BP | GO:0050817 | coagulation | 1 | 153 | 3.64e-01 |
| GO:BP | GO:0045860 | positive regulation of protein kinase activity | 7 | 260 | 3.64e-01 |
| GO:BP | GO:0008306 | associative learning | 2 | 65 | 3.64e-01 |
| GO:BP | GO:0090103 | cochlea morphogenesis | 1 | 15 | 3.64e-01 |
| GO:BP | GO:0042415 | norepinephrine metabolic process | 1 | 7 | 3.64e-01 |
| GO:BP | GO:0007599 | hemostasis | 1 | 153 | 3.64e-01 |
| GO:BP | GO:0071168 | protein localization to chromatin | 2 | 48 | 3.64e-01 |
| GO:BP | GO:0014061 | regulation of norepinephrine secretion | 1 | 5 | 3.64e-01 |
| GO:BP | GO:0048243 | norepinephrine secretion | 1 | 5 | 3.64e-01 |
| GO:BP | GO:0002532 | production of molecular mediator involved in inflammatory response | 1 | 49 | 3.64e-01 |
| GO:BP | GO:0030177 | positive regulation of Wnt signaling pathway | 1 | 120 | 3.64e-01 |
| GO:BP | GO:0003309 | type B pancreatic cell differentiation | 1 | 22 | 3.65e-01 |
| GO:BP | GO:0002717 | positive regulation of natural killer cell mediated immunity | 1 | 11 | 3.65e-01 |
| GO:BP | GO:1903039 | positive regulation of leukocyte cell-cell adhesion | 3 | 157 | 3.66e-01 |
| GO:BP | GO:0043434 | response to peptide hormone | 1 | 321 | 3.66e-01 |
| GO:BP | GO:2001244 | positive regulation of intrinsic apoptotic signaling pathway | 1 | 52 | 3.66e-01 |
| GO:BP | GO:0042771 | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 1 | 43 | 3.66e-01 |
| GO:BP | GO:0010389 | regulation of G2/M transition of mitotic cell cycle | 3 | 92 | 3.66e-01 |
| GO:BP | GO:0033135 | regulation of peptidyl-serine phosphorylation | 2 | 100 | 3.66e-01 |
| GO:BP | GO:0021904 | dorsal/ventral neural tube patterning | 1 | 21 | 3.68e-01 |
| GO:BP | GO:0021772 | olfactory bulb development | 1 | 19 | 3.68e-01 |
| GO:BP | GO:0044818 | mitotic G2/M transition checkpoint | 2 | 50 | 3.68e-01 |
| GO:BP | GO:0031328 | positive regulation of cellular biosynthetic process | 1 | 1564 | 3.68e-01 |
| GO:BP | GO:0006940 | regulation of smooth muscle contraction | 2 | 42 | 3.68e-01 |
| GO:BP | GO:0031338 | regulation of vesicle fusion | 1 | 17 | 3.68e-01 |
| GO:BP | GO:0007020 | microtubule nucleation | 1 | 39 | 3.68e-01 |
| GO:BP | GO:0034067 | protein localization to Golgi apparatus | 1 | 27 | 3.68e-01 |
| GO:BP | GO:0051153 | regulation of striated muscle cell differentiation | 2 | 67 | 3.68e-01 |
| GO:BP | GO:0009411 | response to UV | 4 | 141 | 3.69e-01 |
| GO:BP | GO:0002070 | epithelial cell maturation | 1 | 16 | 3.69e-01 |
| GO:BP | GO:2000050 | regulation of non-canonical Wnt signaling pathway | 1 | 23 | 3.69e-01 |
| GO:BP | GO:0042327 | positive regulation of phosphorylation | 8 | 547 | 3.69e-01 |
| GO:BP | GO:0006760 | folic acid-containing compound metabolic process | 1 | 22 | 3.69e-01 |
| GO:BP | GO:0009219 | pyrimidine deoxyribonucleotide metabolic process | 1 | 21 | 3.69e-01 |
| GO:BP | GO:0009150 | purine ribonucleotide metabolic process | 1 | 295 | 3.69e-01 |
| GO:BP | GO:1903533 | regulation of protein targeting | 1 | 66 | 3.69e-01 |
| GO:BP | GO:1903170 | negative regulation of calcium ion transmembrane transport | 2 | 35 | 3.69e-01 |
| GO:BP | GO:2001014 | regulation of skeletal muscle cell differentiation | 1 | 16 | 3.69e-01 |
| GO:BP | GO:0043547 | positive regulation of GTPase activity | 4 | 222 | 3.69e-01 |
| GO:BP | GO:1901844 | regulation of cell communication by electrical coupling involved in cardiac conduction | 1 | 12 | 3.69e-01 |
| GO:BP | GO:0007565 | female pregnancy | 3 | 122 | 3.69e-01 |
| GO:BP | GO:0009147 | pyrimidine nucleoside triphosphate metabolic process | 1 | 22 | 3.69e-01 |
| GO:BP | GO:0007566 | embryo implantation | 2 | 39 | 3.69e-01 |
| GO:BP | GO:0140029 | exocytic process | 1 | 69 | 3.69e-01 |
| GO:BP | GO:0001956 | positive regulation of neurotransmitter secretion | 1 | 12 | 3.69e-01 |
| GO:BP | GO:1905269 | positive regulation of chromatin organization | 1 | 15 | 3.69e-01 |
| GO:BP | GO:0048265 | response to pain | 1 | 17 | 3.69e-01 |
| GO:BP | GO:0016485 | protein processing | 1 | 183 | 3.69e-01 |
| GO:BP | GO:0051261 | protein depolymerization | 1 | 105 | 3.69e-01 |
| GO:BP | GO:0031330 | negative regulation of cellular catabolic process | 4 | 165 | 3.69e-01 |
| GO:BP | GO:0055006 | cardiac cell development | 2 | 77 | 3.69e-01 |
| GO:BP | GO:0046328 | regulation of JNK cascade | 2 | 114 | 3.69e-01 |
| GO:BP | GO:0062009 | secondary palate development | 1 | 20 | 3.69e-01 |
| GO:BP | GO:0070201 | regulation of establishment of protein localization | 4 | 428 | 3.69e-01 |
| GO:BP | GO:0070341 | fat cell proliferation | 1 | 10 | 3.69e-01 |
| GO:BP | GO:0015844 | monoamine transport | 1 | 45 | 3.69e-01 |
| GO:BP | GO:0045935 | positive regulation of nucleobase-containing compound metabolic process | 1 | 1602 | 3.69e-01 |
| GO:BP | GO:0030850 | prostate gland development | 1 | 35 | 3.69e-01 |
| GO:BP | GO:0045869 | negative regulation of single stranded viral RNA replication via double stranded DNA intermediate | 1 | 12 | 3.69e-01 |
| GO:BP | GO:0045833 | negative regulation of lipid metabolic process | 2 | 72 | 3.69e-01 |
| GO:BP | GO:0048514 | blood vessel morphogenesis | 7 | 462 | 3.69e-01 |
| GO:BP | GO:0034405 | response to fluid shear stress | 1 | 31 | 3.69e-01 |
| GO:BP | GO:0045664 | regulation of neuron differentiation | 5 | 137 | 3.69e-01 |
| GO:BP | GO:0051043 | regulation of membrane protein ectodomain proteolysis | 1 | 18 | 3.69e-01 |
| GO:BP | GO:0009891 | positive regulation of biosynthetic process | 1 | 1604 | 3.69e-01 |
| GO:BP | GO:0034694 | response to prostaglandin | 1 | 21 | 3.69e-01 |
| GO:BP | GO:0097194 | execution phase of apoptosis | 2 | 53 | 3.69e-01 |
| GO:BP | GO:0009725 | response to hormone | 9 | 642 | 3.69e-01 |
| GO:BP | GO:0071453 | cellular response to oxygen levels | 4 | 144 | 3.70e-01 |
| GO:BP | GO:0042752 | regulation of circadian rhythm | 1 | 97 | 3.71e-01 |
| GO:BP | GO:0045165 | cell fate commitment | 1 | 155 | 3.72e-01 |
| GO:BP | GO:0030261 | chromosome condensation | 1 | 33 | 3.72e-01 |
| GO:BP | GO:0021988 | olfactory lobe development | 1 | 21 | 3.74e-01 |
| GO:BP | GO:0043277 | apoptotic cell clearance | 2 | 35 | 3.74e-01 |
| GO:BP | GO:0042254 | ribosome biogenesis | 5 | 301 | 3.74e-01 |
| GO:BP | GO:0009311 | oligosaccharide metabolic process | 1 | 43 | 3.74e-01 |
| GO:BP | GO:0033674 | positive regulation of kinase activity | 8 | 317 | 3.74e-01 |
| GO:BP | GO:0009162 | deoxyribonucleoside monophosphate metabolic process | 1 | 18 | 3.75e-01 |
| GO:BP | GO:0016055 | Wnt signaling pathway | 6 | 375 | 3.75e-01 |
| GO:BP | GO:0060575 | intestinal epithelial cell differentiation | 1 | 17 | 3.75e-01 |
| GO:BP | GO:2000628 | regulation of miRNA metabolic process | 1 | 67 | 3.75e-01 |
| GO:BP | GO:0120035 | regulation of plasma membrane bounded cell projection organization | 12 | 529 | 3.75e-01 |
| GO:BP | GO:2001240 | negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 1 | 25 | 3.75e-01 |
| GO:BP | GO:1901575 | organic substance catabolic process | 1 | 1712 | 3.75e-01 |
| GO:BP | GO:0046326 | positive regulation of glucose import | 1 | 26 | 3.75e-01 |
| GO:BP | GO:0071276 | cellular response to cadmium ion | 1 | 24 | 3.75e-01 |
| GO:BP | GO:0043276 | anoikis | 1 | 32 | 3.75e-01 |
| GO:BP | GO:0045922 | negative regulation of fatty acid metabolic process | 1 | 25 | 3.75e-01 |
| GO:BP | GO:1901099 | negative regulation of signal transduction in absence of ligand | 1 | 25 | 3.75e-01 |
| GO:BP | GO:0034394 | protein localization to cell surface | 2 | 61 | 3.75e-01 |
| GO:BP | GO:0043401 | steroid hormone mediated signaling pathway | 1 | 112 | 3.76e-01 |
| GO:BP | GO:0001525 | angiogenesis | 6 | 390 | 3.76e-01 |
| GO:BP | GO:0198738 | cell-cell signaling by wnt | 6 | 376 | 3.76e-01 |
| GO:BP | GO:0032230 | positive regulation of synaptic transmission, GABAergic | 1 | 10 | 3.76e-01 |
| GO:BP | GO:0019538 | protein metabolic process | 2 | 4241 | 3.76e-01 |
| GO:BP | GO:0019933 | cAMP-mediated signaling | 1 | 35 | 3.76e-01 |
| GO:BP | GO:0071320 | cellular response to cAMP | 1 | 41 | 3.76e-01 |
| GO:BP | GO:0007158 | neuron cell-cell adhesion | 1 | 13 | 3.76e-01 |
| GO:BP | GO:0030512 | negative regulation of transforming growth factor beta receptor signaling pathway | 2 | 86 | 3.76e-01 |
| GO:BP | GO:0009259 | ribonucleotide metabolic process | 1 | 311 | 3.76e-01 |
| GO:BP | GO:0071396 | cellular response to lipid | 5 | 398 | 3.76e-01 |
| GO:BP | GO:0044065 | regulation of respiratory system process | 1 | 11 | 3.76e-01 |
| GO:BP | GO:0042438 | melanin biosynthetic process | 1 | 17 | 3.76e-01 |
| GO:BP | GO:0042733 | embryonic digit morphogenesis | 2 | 51 | 3.76e-01 |
| GO:BP | GO:0046475 | glycerophospholipid catabolic process | 1 | 21 | 3.76e-01 |
| GO:BP | GO:1901990 | regulation of mitotic cell cycle phase transition | 6 | 308 | 3.76e-01 |
| GO:BP | GO:0045806 | negative regulation of endocytosis | 1 | 56 | 3.76e-01 |
| GO:BP | GO:0060324 | face development | 1 | 45 | 3.76e-01 |
| GO:BP | GO:0021979 | hypothalamus cell differentiation | 1 | 8 | 3.76e-01 |
| GO:BP | GO:0002757 | immune response-activating signaling pathway | 1 | 230 | 3.76e-01 |
| GO:BP | GO:0045862 | positive regulation of proteolysis | 8 | 295 | 3.77e-01 |
| GO:BP | GO:0090277 | positive regulation of peptide hormone secretion | 1 | 69 | 3.77e-01 |
| GO:BP | GO:0051280 | negative regulation of release of sequestered calcium ion into cytosol | 1 | 11 | 3.77e-01 |
| GO:BP | GO:1901841 | regulation of high voltage-gated calcium channel activity | 1 | 12 | 3.77e-01 |
| GO:BP | GO:0050999 | regulation of nitric-oxide synthase activity | 1 | 25 | 3.77e-01 |
| GO:BP | GO:0010821 | regulation of mitochondrion organization | 2 | 135 | 3.77e-01 |
| GO:BP | GO:0000018 | regulation of DNA recombination | 2 | 101 | 3.78e-01 |
| GO:BP | GO:0019693 | ribose phosphate metabolic process | 1 | 319 | 3.78e-01 |
| GO:BP | GO:0014841 | skeletal muscle satellite cell proliferation | 1 | 10 | 3.78e-01 |
| GO:BP | GO:0001558 | regulation of cell growth | 5 | 357 | 3.78e-01 |
| GO:BP | GO:1901096 | regulation of autophagosome maturation | 1 | 16 | 3.78e-01 |
| GO:BP | GO:0006631 | fatty acid metabolic process | 1 | 276 | 3.78e-01 |
| GO:BP | GO:0035264 | multicellular organism growth | 2 | 123 | 3.78e-01 |
| GO:BP | GO:0044249 | cellular biosynthetic process | 2 | 4245 | 3.79e-01 |
| GO:BP | GO:0043393 | regulation of protein binding | 3 | 172 | 3.79e-01 |
| GO:BP | GO:0032330 | regulation of chondrocyte differentiation | 1 | 37 | 3.79e-01 |
| GO:BP | GO:0051894 | positive regulation of focal adhesion assembly | 1 | 24 | 3.79e-01 |
| GO:BP | GO:0002793 | positive regulation of peptide secretion | 1 | 70 | 3.79e-01 |
| GO:BP | GO:0009791 | post-embryonic development | 1 | 74 | 3.79e-01 |
| GO:BP | GO:1905664 | regulation of calcium ion import across plasma membrane | 1 | 8 | 3.79e-01 |
| GO:BP | GO:0032515 | negative regulation of phosphoprotein phosphatase activity | 1 | 21 | 3.79e-01 |
| GO:BP | GO:2000114 | regulation of establishment of cell polarity | 1 | 22 | 3.79e-01 |
| GO:BP | GO:0010613 | positive regulation of cardiac muscle hypertrophy | 1 | 22 | 3.79e-01 |
| GO:BP | GO:0043085 | positive regulation of catalytic activity | 2 | 834 | 3.79e-01 |
| GO:BP | GO:0071375 | cellular response to peptide hormone stimulus | 4 | 241 | 3.79e-01 |
| GO:BP | GO:0014047 | glutamate secretion | 1 | 14 | 3.79e-01 |
| GO:BP | GO:0034249 | negative regulation of amide metabolic process | 3 | 186 | 3.79e-01 |
| GO:BP | GO:0032740 | positive regulation of interleukin-17 production | 1 | 12 | 3.79e-01 |
| GO:BP | GO:0006582 | melanin metabolic process | 1 | 18 | 3.79e-01 |
| GO:BP | GO:0061178 | regulation of insulin secretion involved in cellular response to glucose stimulus | 2 | 40 | 3.79e-01 |
| GO:BP | GO:0014706 | striated muscle tissue development | 5 | 210 | 3.79e-01 |
| GO:BP | GO:0006826 | iron ion transport | 1 | 40 | 3.79e-01 |
| GO:BP | GO:0038127 | ERBB signaling pathway | 2 | 107 | 3.79e-01 |
| GO:BP | GO:2000779 | regulation of double-strand break repair | 2 | 121 | 3.79e-01 |
| GO:BP | GO:0021895 | cerebral cortex neuron differentiation | 1 | 14 | 3.79e-01 |
| GO:BP | GO:0002824 | positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 1 | 62 | 3.79e-01 |
| GO:BP | GO:0050673 | epithelial cell proliferation | 4 | 323 | 3.79e-01 |
| GO:BP | GO:0007423 | sensory organ development | 10 | 396 | 3.79e-01 |
| GO:BP | GO:0001701 | in utero embryonic development | 5 | 344 | 3.79e-01 |
| GO:BP | GO:0000723 | telomere maintenance | 4 | 142 | 3.79e-01 |
| GO:BP | GO:0009247 | glycolipid biosynthetic process | 1 | 61 | 3.79e-01 |
| GO:BP | GO:0045746 | negative regulation of Notch signaling pathway | 1 | 31 | 3.79e-01 |
| GO:BP | GO:0018205 | peptidyl-lysine modification | 3 | 336 | 3.79e-01 |
| GO:BP | GO:0036376 | sodium ion export across plasma membrane | 1 | 12 | 3.79e-01 |
| GO:BP | GO:0000097 | sulfur amino acid biosynthetic process | 1 | 14 | 3.81e-01 |
| GO:BP | GO:0006555 | methionine metabolic process | 1 | 13 | 3.81e-01 |
| GO:BP | GO:0006275 | regulation of DNA replication | 3 | 116 | 3.81e-01 |
| GO:BP | GO:0072578 | neurotransmitter-gated ion channel clustering | 1 | 12 | 3.83e-01 |
| GO:BP | GO:0006974 | DNA damage response | 6 | 785 | 3.83e-01 |
| GO:BP | GO:0060416 | response to growth hormone | 1 | 25 | 3.83e-01 |
| GO:BP | GO:0009063 | amino acid catabolic process | 1 | 78 | 3.83e-01 |
| GO:BP | GO:0010762 | regulation of fibroblast migration | 1 | 37 | 3.83e-01 |
| GO:BP | GO:0035883 | enteroendocrine cell differentiation | 1 | 24 | 3.83e-01 |
| GO:BP | GO:0032094 | response to food | 1 | 22 | 3.83e-01 |
| GO:BP | GO:0002764 | immune response-regulating signaling pathway | 1 | 242 | 3.83e-01 |
| GO:BP | GO:1990778 | protein localization to cell periphery | 5 | 300 | 3.83e-01 |
| GO:BP | GO:1904385 | cellular response to angiotensin | 1 | 23 | 3.83e-01 |
| GO:BP | GO:0014742 | positive regulation of muscle hypertrophy | 1 | 22 | 3.83e-01 |
| GO:BP | GO:0010800 | positive regulation of peptidyl-threonine phosphorylation | 1 | 23 | 3.84e-01 |
| GO:BP | GO:0044550 | secondary metabolite biosynthetic process | 1 | 18 | 3.84e-01 |
| GO:BP | GO:1900745 | positive regulation of p38MAPK cascade | 1 | 22 | 3.84e-01 |
| GO:BP | GO:0060191 | regulation of lipase activity | 1 | 52 | 3.84e-01 |
| GO:BP | GO:0034614 | cellular response to reactive oxygen species | 3 | 121 | 3.86e-01 |
| GO:BP | GO:0009314 | response to radiation | 4 | 352 | 3.86e-01 |
| GO:BP | GO:1901652 | response to peptide | 1 | 377 | 3.86e-01 |
| GO:BP | GO:0045739 | positive regulation of DNA repair | 3 | 120 | 3.87e-01 |
| GO:BP | GO:1901799 | negative regulation of proteasomal protein catabolic process | 2 | 47 | 3.87e-01 |
| GO:BP | GO:0014857 | regulation of skeletal muscle cell proliferation | 1 | 10 | 3.87e-01 |
| GO:BP | GO:1901077 | regulation of relaxation of muscle | 1 | 8 | 3.87e-01 |
| GO:BP | GO:0060339 | negative regulation of type I interferon-mediated signaling pathway | 1 | 15 | 3.88e-01 |
| GO:BP | GO:0031344 | regulation of cell projection organization | 12 | 541 | 3.88e-01 |
| GO:BP | GO:0045737 | positive regulation of cyclin-dependent protein serine/threonine kinase activity | 1 | 23 | 3.88e-01 |
| GO:BP | GO:0071248 | cellular response to metal ion | 3 | 139 | 3.88e-01 |
| GO:BP | GO:0002437 | inflammatory response to antigenic stimulus | 2 | 36 | 3.88e-01 |
| GO:BP | GO:0010927 | cellular component assembly involved in morphogenesis | 1 | 106 | 3.88e-01 |
| GO:BP | GO:0016571 | histone methylation | 1 | 117 | 3.88e-01 |
| GO:BP | GO:1903320 | regulation of protein modification by small protein conjugation or removal | 6 | 232 | 3.88e-01 |
| GO:BP | GO:0051726 | regulation of cell cycle | 5 | 956 | 3.89e-01 |
| GO:BP | GO:0002821 | positive regulation of adaptive immune response | 1 | 66 | 3.89e-01 |
| GO:BP | GO:0032501 | multicellular organismal process | 7 | 4794 | 3.89e-01 |
| GO:BP | GO:1900095 | regulation of dosage compensation by inactivation of X chromosome | 1 | 13 | 3.89e-01 |
| GO:BP | GO:0070168 | negative regulation of biomineral tissue development | 1 | 19 | 3.90e-01 |
| GO:BP | GO:0090308 | regulation of DNA methylation-dependent heterochromatin formation | 1 | 16 | 3.91e-01 |
| GO:BP | GO:2000479 | regulation of cAMP-dependent protein kinase activity | 1 | 16 | 3.91e-01 |
| GO:BP | GO:0045091 | regulation of single stranded viral RNA replication via double stranded DNA intermediate | 1 | 15 | 3.91e-01 |
| GO:BP | GO:0000002 | mitochondrial genome maintenance | 1 | 29 | 3.91e-01 |
| GO:BP | GO:0002696 | positive regulation of leukocyte activation | 4 | 222 | 3.91e-01 |
| GO:BP | GO:0045429 | positive regulation of nitric oxide biosynthetic process | 1 | 26 | 3.92e-01 |
| GO:BP | GO:0006403 | RNA localization | 2 | 182 | 3.92e-01 |
| GO:BP | GO:0002460 | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 2 | 161 | 3.92e-01 |
| GO:BP | GO:0042753 | positive regulation of circadian rhythm | 1 | 10 | 3.92e-01 |
| GO:BP | GO:0071456 | cellular response to hypoxia | 1 | 123 | 3.92e-01 |
| GO:BP | GO:0046907 | intracellular transport | 13 | 1453 | 3.92e-01 |
| GO:BP | GO:0071214 | cellular response to abiotic stimulus | 3 | 268 | 3.92e-01 |
| GO:BP | GO:0039532 | negative regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway | 1 | 17 | 3.92e-01 |
| GO:BP | GO:0032206 | positive regulation of telomere maintenance | 2 | 64 | 3.92e-01 |
| GO:BP | GO:2000059 | negative regulation of ubiquitin-dependent protein catabolic process | 2 | 47 | 3.92e-01 |
| GO:BP | GO:0104004 | cellular response to environmental stimulus | 3 | 268 | 3.92e-01 |
| GO:BP | GO:0061311 | cell surface receptor signaling pathway involved in heart development | 1 | 25 | 3.94e-01 |
| GO:BP | GO:0010669 | epithelial structure maintenance | 1 | 15 | 3.94e-01 |
| GO:BP | GO:0045017 | glycerolipid biosynthetic process | 5 | 218 | 3.94e-01 |
| GO:BP | GO:0060294 | cilium movement involved in cell motility | 1 | 69 | 3.94e-01 |
| GO:BP | GO:0000768 | syncytium formation by plasma membrane fusion | 1 | 37 | 3.94e-01 |
| GO:BP | GO:0140253 | cell-cell fusion | 1 | 37 | 3.94e-01 |
| GO:BP | GO:0021513 | spinal cord dorsal/ventral patterning | 1 | 7 | 3.94e-01 |
| GO:BP | GO:0051782 | negative regulation of cell division | 1 | 15 | 3.94e-01 |
| GO:BP | GO:0045197 | establishment or maintenance of epithelial cell apical/basal polarity | 2 | 47 | 3.95e-01 |
| GO:BP | GO:2000008 | regulation of protein localization to cell surface | 1 | 37 | 3.96e-01 |
| GO:BP | GO:0045987 | positive regulation of smooth muscle contraction | 1 | 17 | 3.96e-01 |
| GO:BP | GO:0006325 | chromatin organization | 5 | 551 | 3.96e-01 |
| GO:BP | GO:0050793 | regulation of developmental process | 1 | 1835 | 3.96e-01 |
| GO:BP | GO:0002281 | macrophage activation involved in immune response | 1 | 8 | 3.97e-01 |
| GO:BP | GO:0006406 | mRNA export from nucleus | 1 | 59 | 3.97e-01 |
| GO:BP | GO:0051246 | regulation of protein metabolic process | 1 | 1974 | 3.97e-01 |
| GO:BP | GO:0060350 | endochondral bone morphogenesis | 1 | 47 | 3.97e-01 |
| GO:BP | GO:0019827 | stem cell population maintenance | 2 | 149 | 3.97e-01 |
| GO:BP | GO:0002285 | lymphocyte activation involved in immune response | 3 | 111 | 3.97e-01 |
| GO:BP | GO:0010586 | miRNA metabolic process | 1 | 81 | 3.97e-01 |
| GO:BP | GO:2000291 | regulation of myoblast proliferation | 1 | 11 | 3.98e-01 |
| GO:BP | GO:0051284 | positive regulation of sequestering of calcium ion | 1 | 13 | 3.98e-01 |
| GO:BP | GO:0002253 | activation of immune response | 1 | 272 | 3.98e-01 |
| GO:BP | GO:0035265 | organ growth | 2 | 131 | 3.98e-01 |
| GO:BP | GO:0061008 | hepaticobiliary system development | 3 | 112 | 3.98e-01 |
| GO:BP | GO:0014066 | regulation of phosphatidylinositol 3-kinase signaling | 3 | 78 | 3.98e-01 |
| GO:BP | GO:0010738 | regulation of protein kinase A signaling | 1 | 13 | 3.98e-01 |
| GO:BP | GO:0002443 | leukocyte mediated immunity | 4 | 194 | 3.98e-01 |
| GO:BP | GO:0015837 | amine transport | 1 | 56 | 3.98e-01 |
| GO:BP | GO:0071364 | cellular response to epidermal growth factor stimulus | 1 | 41 | 3.98e-01 |
| GO:BP | GO:0046622 | positive regulation of organ growth | 1 | 33 | 3.98e-01 |
| GO:BP | GO:1902749 | regulation of cell cycle G2/M phase transition | 3 | 103 | 3.98e-01 |
| GO:BP | GO:0039692 | single stranded viral RNA replication via double stranded DNA intermediate | 1 | 16 | 3.98e-01 |
| GO:BP | GO:0010828 | positive regulation of glucose transmembrane transport | 1 | 31 | 3.98e-01 |
| GO:BP | GO:1904407 | positive regulation of nitric oxide metabolic process | 1 | 27 | 3.98e-01 |
| GO:BP | GO:1904031 | positive regulation of cyclin-dependent protein kinase activity | 1 | 26 | 3.98e-01 |
| GO:BP | GO:0039535 | regulation of RIG-I signaling pathway | 1 | 17 | 3.99e-01 |
| GO:BP | GO:0060033 | anatomical structure regression | 1 | 11 | 3.99e-01 |
| GO:BP | GO:0015908 | fatty acid transport | 3 | 58 | 3.99e-01 |
| GO:BP | GO:0032814 | regulation of natural killer cell activation | 1 | 20 | 3.99e-01 |
| GO:BP | GO:1901576 | organic substance biosynthetic process | 2 | 4539 | 3.99e-01 |
| GO:BP | GO:0043583 | ear development | 3 | 153 | 3.99e-01 |
| GO:BP | GO:0034311 | diol metabolic process | 1 | 26 | 3.99e-01 |
| GO:BP | GO:0007010 | cytoskeleton organization | 15 | 1226 | 3.99e-01 |
| GO:BP | GO:0032878 | regulation of establishment or maintenance of cell polarity | 1 | 26 | 3.99e-01 |
| GO:BP | GO:0048592 | eye morphogenesis | 2 | 113 | 3.99e-01 |
| GO:BP | GO:0048598 | embryonic morphogenesis | 10 | 440 | 3.99e-01 |
| GO:BP | GO:0043984 | histone H4-K16 acetylation | 1 | 14 | 3.99e-01 |
| GO:BP | GO:0001755 | neural crest cell migration | 2 | 49 | 4.00e-01 |
| GO:BP | GO:1905114 | cell surface receptor signaling pathway involved in cell-cell signaling | 7 | 448 | 4.00e-01 |
| GO:BP | GO:0051347 | positive regulation of transferase activity | 9 | 400 | 4.01e-01 |
| GO:BP | GO:0044703 | multi-organism reproductive process | 3 | 131 | 4.02e-01 |
| GO:BP | GO:0006163 | purine nucleotide metabolic process | 1 | 371 | 4.02e-01 |
| GO:BP | GO:0098727 | maintenance of cell number | 2 | 151 | 4.02e-01 |
| GO:BP | GO:0007179 | transforming growth factor beta receptor signaling pathway | 5 | 179 | 4.02e-01 |
| GO:BP | GO:1900087 | positive regulation of G1/S transition of mitotic cell cycle | 1 | 42 | 4.02e-01 |
| GO:BP | GO:0090398 | cellular senescence | 1 | 83 | 4.03e-01 |
| GO:BP | GO:1901222 | regulation of NIK/NF-kappaB signaling | 2 | 65 | 4.03e-01 |
| GO:BP | GO:0097421 | liver regeneration | 1 | 23 | 4.03e-01 |
| GO:BP | GO:0008340 | determination of adult lifespan | 1 | 16 | 4.03e-01 |
| GO:BP | GO:0042558 | pteridine-containing compound metabolic process | 1 | 28 | 4.03e-01 |
| GO:BP | GO:0009056 | catabolic process | 1 | 2088 | 4.03e-01 |
| GO:BP | GO:0050688 | regulation of defense response to virus | 2 | 63 | 4.03e-01 |
| GO:BP | GO:0010948 | negative regulation of cell cycle process | 2 | 273 | 4.03e-01 |
| GO:BP | GO:0006949 | syncytium formation | 1 | 39 | 4.03e-01 |
| GO:BP | GO:0043508 | negative regulation of JUN kinase activity | 1 | 13 | 4.03e-01 |
| GO:BP | GO:0009058 | biosynthetic process | 2 | 4590 | 4.04e-01 |
| GO:BP | GO:1901889 | negative regulation of cell junction assembly | 1 | 24 | 4.04e-01 |
| GO:BP | GO:0030149 | sphingolipid catabolic process | 1 | 26 | 4.04e-01 |
| GO:BP | GO:0034332 | adherens junction organization | 1 | 41 | 4.04e-01 |
| GO:BP | GO:0150117 | positive regulation of cell-substrate junction organization | 1 | 29 | 4.04e-01 |
| GO:BP | GO:0050867 | positive regulation of cell activation | 4 | 229 | 4.04e-01 |
| GO:BP | GO:1990776 | response to angiotensin | 1 | 24 | 4.04e-01 |
| GO:BP | GO:0072539 | T-helper 17 cell differentiation | 1 | 14 | 4.04e-01 |
| GO:BP | GO:0030968 | endoplasmic reticulum unfolded protein response | 1 | 70 | 4.05e-01 |
| GO:BP | GO:0007017 | microtubule-based process | 1 | 760 | 4.05e-01 |
| GO:BP | GO:0008631 | intrinsic apoptotic signaling pathway in response to oxidative stress | 1 | 41 | 4.05e-01 |
| GO:BP | GO:0015909 | long-chain fatty acid transport | 2 | 38 | 4.05e-01 |
| GO:BP | GO:0007266 | Rho protein signal transduction | 1 | 114 | 4.05e-01 |
| GO:BP | GO:0010885 | regulation of cholesterol storage | 1 | 14 | 4.05e-01 |
| GO:BP | GO:0046321 | positive regulation of fatty acid oxidation | 1 | 15 | 4.05e-01 |
| GO:BP | GO:0051346 | negative regulation of hydrolase activity | 4 | 220 | 4.05e-01 |
| GO:BP | GO:0060285 | cilium-dependent cell motility | 1 | 74 | 4.05e-01 |
| GO:BP | GO:2001242 | regulation of intrinsic apoptotic signaling pathway | 2 | 147 | 4.05e-01 |
| GO:BP | GO:1902275 | regulation of chromatin organization | 2 | 49 | 4.05e-01 |
| GO:BP | GO:0001539 | cilium or flagellum-dependent cell motility | 1 | 74 | 4.05e-01 |
| GO:BP | GO:0048873 | homeostasis of number of cells within a tissue | 1 | 24 | 4.05e-01 |
| GO:BP | GO:0052548 | regulation of endopeptidase activity | 1 | 232 | 4.05e-01 |
| GO:BP | GO:0071383 | cellular response to steroid hormone stimulus | 2 | 166 | 4.05e-01 |
| GO:BP | GO:0042994 | cytoplasmic sequestering of transcription factor | 1 | 15 | 4.05e-01 |
| GO:BP | GO:0043923 | positive regulation by host of viral transcription | 1 | 18 | 4.05e-01 |
| GO:BP | GO:0060914 | heart formation | 1 | 29 | 4.05e-01 |
| GO:BP | GO:0048013 | ephrin receptor signaling pathway | 1 | 41 | 4.06e-01 |
| GO:BP | GO:0000462 | maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 1 | 38 | 4.06e-01 |
| GO:BP | GO:0042749 | regulation of circadian sleep/wake cycle | 1 | 9 | 4.06e-01 |
| GO:BP | GO:0006511 | ubiquitin-dependent protein catabolic process | 12 | 615 | 4.06e-01 |
| GO:BP | GO:1901522 | positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus | 1 | 16 | 4.06e-01 |
| GO:BP | GO:0060343 | trabecula formation | 1 | 23 | 4.07e-01 |
| GO:BP | GO:0090497 | mesenchymal cell migration | 2 | 51 | 4.07e-01 |
| GO:BP | GO:2001239 | regulation of extrinsic apoptotic signaling pathway in absence of ligand | 1 | 35 | 4.07e-01 |
| GO:BP | GO:0043029 | T cell homeostasis | 1 | 27 | 4.07e-01 |
| GO:BP | GO:1990090 | cellular response to nerve growth factor stimulus | 1 | 41 | 4.07e-01 |
| GO:BP | GO:0006897 | endocytosis | 15 | 527 | 4.07e-01 |
| GO:BP | GO:0047496 | vesicle transport along microtubule | 1 | 41 | 4.08e-01 |
| GO:BP | GO:2000316 | regulation of T-helper 17 type immune response | 1 | 16 | 4.08e-01 |
| GO:BP | GO:0002376 | immune system process | 1 | 1447 | 4.08e-01 |
| GO:BP | GO:0000724 | double-strand break repair via homologous recombination | 4 | 149 | 4.08e-01 |
| GO:BP | GO:0001934 | positive regulation of protein phosphorylation | 7 | 496 | 4.08e-01 |
| GO:BP | GO:0042269 | regulation of natural killer cell mediated cytotoxicity | 1 | 18 | 4.08e-01 |
| GO:BP | GO:0038179 | neurotrophin signaling pathway | 1 | 35 | 4.08e-01 |
| GO:BP | GO:0001655 | urogenital system development | 1 | 49 | 4.08e-01 |
| GO:BP | GO:0003228 | atrial cardiac muscle tissue development | 1 | 18 | 4.08e-01 |
| GO:BP | GO:0006893 | Golgi to plasma membrane transport | 1 | 60 | 4.08e-01 |
| GO:BP | GO:0070734 | histone H3-K27 methylation | 1 | 9 | 4.08e-01 |
| GO:BP | GO:0021511 | spinal cord patterning | 1 | 9 | 4.08e-01 |
| GO:BP | GO:0045604 | regulation of epidermal cell differentiation | 2 | 39 | 4.09e-01 |
| GO:BP | GO:0072521 | purine-containing compound metabolic process | 1 | 390 | 4.09e-01 |
| GO:BP | GO:0002702 | positive regulation of production of molecular mediator of immune response | 1 | 77 | 4.09e-01 |
| GO:BP | GO:0050778 | positive regulation of immune response | 3 | 369 | 4.09e-01 |
| GO:BP | GO:0009205 | purine ribonucleoside triphosphate metabolic process | 2 | 137 | 4.09e-01 |
| GO:BP | GO:0061644 | protein localization to CENP-A containing chromatin | 1 | 17 | 4.09e-01 |
| GO:BP | GO:0008595 | anterior/posterior axis specification, embryo | 1 | 10 | 4.09e-01 |
| GO:BP | GO:0032502 | developmental process | 14 | 4494 | 4.09e-01 |
| GO:BP | GO:0071218 | cellular response to misfolded protein | 1 | 23 | 4.09e-01 |
| GO:BP | GO:0070849 | response to epidermal growth factor | 1 | 44 | 4.09e-01 |
| GO:BP | GO:0090199 | regulation of release of cytochrome c from mitochondria | 1 | 39 | 4.09e-01 |
| GO:BP | GO:0007351 | tripartite regional subdivision | 1 | 10 | 4.09e-01 |
| GO:BP | GO:1903202 | negative regulation of oxidative stress-induced cell death | 1 | 40 | 4.09e-01 |
| GO:BP | GO:0006221 | pyrimidine nucleotide biosynthetic process | 1 | 28 | 4.10e-01 |
| GO:BP | GO:0046887 | positive regulation of hormone secretion | 1 | 90 | 4.10e-01 |
| GO:BP | GO:0051604 | protein maturation | 1 | 259 | 4.10e-01 |
| GO:BP | GO:0031113 | regulation of microtubule polymerization | 1 | 52 | 4.10e-01 |
| GO:BP | GO:0045619 | regulation of lymphocyte differentiation | 4 | 132 | 4.10e-01 |
| GO:BP | GO:1901223 | negative regulation of NIK/NF-kappaB signaling | 1 | 21 | 4.10e-01 |
| GO:BP | GO:0035338 | long-chain fatty-acyl-CoA biosynthetic process | 1 | 14 | 4.10e-01 |
| GO:BP | GO:0050922 | negative regulation of chemotaxis | 2 | 44 | 4.10e-01 |
| GO:BP | GO:0150077 | regulation of neuroinflammatory response | 1 | 13 | 4.11e-01 |
| GO:BP | GO:2000027 | regulation of animal organ morphogenesis | 2 | 101 | 4.11e-01 |
| GO:BP | GO:0050901 | leukocyte tethering or rolling | 1 | 16 | 4.12e-01 |
| GO:BP | GO:0022410 | circadian sleep/wake cycle process | 1 | 10 | 4.12e-01 |
| GO:BP | GO:0022409 | positive regulation of cell-cell adhesion | 3 | 189 | 4.12e-01 |
| GO:BP | GO:0007409 | axonogenesis | 4 | 359 | 4.12e-01 |
| GO:BP | GO:0051590 | positive regulation of neurotransmitter transport | 1 | 16 | 4.12e-01 |
| GO:BP | GO:1990089 | response to nerve growth factor | 1 | 41 | 4.12e-01 |
| GO:BP | GO:0048009 | insulin-like growth factor receptor signaling pathway | 1 | 42 | 4.12e-01 |
| GO:BP | GO:0051960 | regulation of nervous system development | 4 | 357 | 4.13e-01 |
| GO:BP | GO:0010972 | negative regulation of G2/M transition of mitotic cell cycle | 2 | 60 | 4.13e-01 |
| GO:BP | GO:1903846 | positive regulation of cellular response to transforming growth factor beta stimulus | 1 | 30 | 4.13e-01 |
| GO:BP | GO:0010649 | regulation of cell communication by electrical coupling | 1 | 17 | 4.13e-01 |
| GO:BP | GO:0030511 | positive regulation of transforming growth factor beta receptor signaling pathway | 1 | 30 | 4.13e-01 |
| GO:BP | GO:2000243 | positive regulation of reproductive process | 2 | 54 | 4.13e-01 |
| GO:BP | GO:0043113 | receptor clustering | 2 | 45 | 4.14e-01 |
| GO:BP | GO:0061245 | establishment or maintenance of bipolar cell polarity | 2 | 50 | 4.14e-01 |
| GO:BP | GO:0009112 | nucleobase metabolic process | 1 | 27 | 4.14e-01 |
| GO:BP | GO:0035088 | establishment or maintenance of apical/basal cell polarity | 2 | 50 | 4.14e-01 |
| GO:BP | GO:0060349 | bone morphogenesis | 2 | 74 | 4.14e-01 |
| GO:BP | GO:0045600 | positive regulation of fat cell differentiation | 2 | 50 | 4.14e-01 |
| GO:BP | GO:0006282 | regulation of DNA repair | 4 | 198 | 4.14e-01 |
| GO:BP | GO:0042306 | regulation of protein import into nucleus | 1 | 51 | 4.15e-01 |
| GO:BP | GO:0032868 | response to insulin | 3 | 215 | 4.15e-01 |
| GO:BP | GO:0007368 | determination of left/right symmetry | 3 | 97 | 4.16e-01 |
| GO:BP | GO:0050714 | positive regulation of protein secretion | 1 | 100 | 4.16e-01 |
| GO:BP | GO:0003382 | epithelial cell morphogenesis | 1 | 24 | 4.16e-01 |
| GO:BP | GO:0033687 | osteoblast proliferation | 1 | 27 | 4.16e-01 |
| GO:BP | GO:0019941 | modification-dependent protein catabolic process | 12 | 625 | 4.16e-01 |
| GO:BP | GO:0002706 | regulation of lymphocyte mediated immunity | 2 | 83 | 4.16e-01 |
| GO:BP | GO:0002686 | negative regulation of leukocyte migration | 1 | 30 | 4.16e-01 |
| GO:BP | GO:0000725 | recombinational repair | 4 | 153 | 4.16e-01 |
| GO:BP | GO:0090596 | sensory organ morphogenesis | 4 | 178 | 4.16e-01 |
| GO:BP | GO:0035308 | negative regulation of protein dephosphorylation | 1 | 28 | 4.16e-01 |
| GO:BP | GO:0009144 | purine nucleoside triphosphate metabolic process | 2 | 142 | 4.16e-01 |
| GO:BP | GO:0009117 | nucleotide metabolic process | 1 | 423 | 4.17e-01 |
| GO:BP | GO:0007254 | JNK cascade | 2 | 138 | 4.17e-01 |
| GO:BP | GO:0051403 | stress-activated MAPK cascade | 3 | 190 | 4.17e-01 |
| GO:BP | GO:0043981 | histone H4-K5 acetylation | 1 | 16 | 4.17e-01 |
| GO:BP | GO:0043982 | histone H4-K8 acetylation | 1 | 16 | 4.17e-01 |
| GO:BP | GO:0060429 | epithelium development | 13 | 850 | 4.19e-01 |
| GO:BP | GO:0051053 | negative regulation of DNA metabolic process | 1 | 112 | 4.19e-01 |
| GO:BP | GO:0032768 | regulation of monooxygenase activity | 1 | 34 | 4.19e-01 |
| GO:BP | GO:0010878 | cholesterol storage | 1 | 16 | 4.19e-01 |
| GO:BP | GO:1901983 | regulation of protein acetylation | 1 | 69 | 4.19e-01 |
| GO:BP | GO:0002715 | regulation of natural killer cell mediated immunity | 1 | 18 | 4.19e-01 |
| GO:BP | GO:0033365 | protein localization to organelle | 9 | 859 | 4.19e-01 |
| GO:BP | GO:1901992 | positive regulation of mitotic cell cycle phase transition | 2 | 86 | 4.19e-01 |
| GO:BP | GO:0043968 | histone H2A acetylation | 1 | 22 | 4.19e-01 |
| GO:BP | GO:1905475 | regulation of protein localization to membrane | 2 | 150 | 4.19e-01 |
| GO:BP | GO:0006753 | nucleoside phosphate metabolic process | 1 | 429 | 4.19e-01 |
| GO:BP | GO:0009199 | ribonucleoside triphosphate metabolic process | 2 | 144 | 4.19e-01 |
| GO:BP | GO:0035773 | insulin secretion involved in cellular response to glucose stimulus | 2 | 49 | 4.19e-01 |
| GO:BP | GO:0046474 | glycerophospholipid biosynthetic process | 4 | 189 | 4.19e-01 |
| GO:BP | GO:0009067 | aspartate family amino acid biosynthetic process | 1 | 18 | 4.19e-01 |
| GO:BP | GO:0010634 | positive regulation of epithelial cell migration | 2 | 132 | 4.19e-01 |
| GO:BP | GO:0015931 | nucleobase-containing compound transport | 2 | 194 | 4.19e-01 |
| GO:BP | GO:0045821 | positive regulation of glycolytic process | 1 | 15 | 4.19e-01 |
| GO:BP | GO:0016064 | immunoglobulin mediated immune response | 2 | 76 | 4.19e-01 |
| GO:BP | GO:0061035 | regulation of cartilage development | 1 | 54 | 4.19e-01 |
| GO:BP | GO:1902750 | negative regulation of cell cycle G2/M phase transition | 2 | 62 | 4.20e-01 |
| GO:BP | GO:0031365 | N-terminal protein amino acid modification | 1 | 28 | 4.20e-01 |
| GO:BP | GO:0010811 | positive regulation of cell-substrate adhesion | 2 | 100 | 4.21e-01 |
| GO:BP | GO:0002274 | myeloid leukocyte activation | 3 | 123 | 4.21e-01 |
| GO:BP | GO:0031018 | endocrine pancreas development | 1 | 32 | 4.21e-01 |
| GO:BP | GO:0006302 | double-strand break repair | 6 | 271 | 4.21e-01 |
| GO:BP | GO:0051788 | response to misfolded protein | 1 | 25 | 4.22e-01 |
| GO:BP | GO:0051382 | kinetochore assembly | 1 | 18 | 4.22e-01 |
| GO:BP | GO:0050878 | regulation of body fluid levels | 1 | 236 | 4.22e-01 |
| GO:BP | GO:0031325 | positive regulation of cellular metabolic process | 1 | 2270 | 4.23e-01 |
| GO:BP | GO:0048167 | regulation of synaptic plasticity | 3 | 141 | 4.24e-01 |
| GO:BP | GO:0072659 | protein localization to plasma membrane | 4 | 249 | 4.24e-01 |
| GO:BP | GO:0019724 | B cell mediated immunity | 2 | 77 | 4.24e-01 |
| GO:BP | GO:0051446 | positive regulation of meiotic cell cycle | 1 | 16 | 4.24e-01 |
| GO:BP | GO:0051781 | positive regulation of cell division | 2 | 64 | 4.24e-01 |
| GO:BP | GO:0033617 | mitochondrial cytochrome c oxidase assembly | 1 | 25 | 4.24e-01 |
| GO:BP | GO:0090630 | activation of GTPase activity | 2 | 99 | 4.24e-01 |
| GO:BP | GO:0035904 | aorta development | 1 | 50 | 4.24e-01 |
| GO:BP | GO:0043536 | positive regulation of blood vessel endothelial cell migration | 1 | 47 | 4.24e-01 |
| GO:BP | GO:1902003 | regulation of amyloid-beta formation | 1 | 33 | 4.24e-01 |
| GO:BP | GO:0045601 | regulation of endothelial cell differentiation | 1 | 27 | 4.24e-01 |
| GO:BP | GO:0046466 | membrane lipid catabolic process | 1 | 30 | 4.24e-01 |
| GO:BP | GO:1901387 | positive regulation of voltage-gated calcium channel activity | 1 | 13 | 4.24e-01 |
| GO:BP | GO:0010922 | positive regulation of phosphatase activity | 1 | 26 | 4.24e-01 |
| GO:BP | GO:0000470 | maturation of LSU-rRNA | 1 | 28 | 4.24e-01 |
| GO:BP | GO:0071384 | cellular response to corticosteroid stimulus | 1 | 47 | 4.24e-01 |
| GO:BP | GO:0045069 | regulation of viral genome replication | 2 | 64 | 4.25e-01 |
| GO:BP | GO:1901605 | alpha-amino acid metabolic process | 4 | 151 | 4.25e-01 |
| GO:BP | GO:0042745 | circadian sleep/wake cycle | 1 | 11 | 4.25e-01 |
| GO:BP | GO:0046395 | carboxylic acid catabolic process | 5 | 187 | 4.25e-01 |
| GO:BP | GO:0043967 | histone H4 acetylation | 2 | 57 | 4.25e-01 |
| GO:BP | GO:0009895 | negative regulation of catabolic process | 4 | 280 | 4.25e-01 |
| GO:BP | GO:0016054 | organic acid catabolic process | 5 | 187 | 4.25e-01 |
| GO:BP | GO:2000310 | regulation of NMDA receptor activity | 1 | 19 | 4.25e-01 |
| GO:BP | GO:0010506 | regulation of autophagy | 4 | 313 | 4.25e-01 |
| GO:BP | GO:2000641 | regulation of early endosome to late endosome transport | 1 | 17 | 4.25e-01 |
| GO:BP | GO:0043254 | regulation of protein-containing complex assembly | 1 | 348 | 4.25e-01 |
| GO:BP | GO:0006006 | glucose metabolic process | 2 | 151 | 4.25e-01 |
| GO:BP | GO:0006308 | DNA catabolic process | 1 | 19 | 4.26e-01 |
| GO:BP | GO:0035458 | cellular response to interferon-beta | 1 | 15 | 4.26e-01 |
| GO:BP | GO:0032465 | regulation of cytokinesis | 2 | 79 | 4.26e-01 |
| GO:BP | GO:0010823 | negative regulation of mitochondrion organization | 1 | 46 | 4.26e-01 |
| GO:BP | GO:1901564 | organonitrogen compound metabolic process | 2 | 4955 | 4.26e-01 |
| GO:BP | GO:1901991 | negative regulation of mitotic cell cycle phase transition | 4 | 166 | 4.26e-01 |
| GO:BP | GO:0014856 | skeletal muscle cell proliferation | 1 | 14 | 4.26e-01 |
| GO:BP | GO:0051546 | keratinocyte migration | 1 | 15 | 4.26e-01 |
| GO:BP | GO:0090068 | positive regulation of cell cycle process | 4 | 209 | 4.27e-01 |
| GO:BP | GO:0033044 | regulation of chromosome organization | 5 | 236 | 4.27e-01 |
| GO:BP | GO:0003407 | neural retina development | 2 | 48 | 4.27e-01 |
| GO:BP | GO:0060412 | ventricular septum morphogenesis | 1 | 40 | 4.27e-01 |
| GO:BP | GO:0060972 | left/right pattern formation | 3 | 101 | 4.27e-01 |
| GO:BP | GO:0031098 | stress-activated protein kinase signaling cascade | 3 | 196 | 4.27e-01 |
| GO:BP | GO:0006383 | transcription by RNA polymerase III | 1 | 54 | 4.27e-01 |
| GO:BP | GO:0001837 | epithelial to mesenchymal transition | 3 | 138 | 4.27e-01 |
| GO:BP | GO:0120261 | regulation of heterochromatin organization | 1 | 22 | 4.27e-01 |
| GO:BP | GO:0031445 | regulation of heterochromatin formation | 1 | 22 | 4.27e-01 |
| GO:BP | GO:0000209 | protein polyubiquitination | 5 | 226 | 4.27e-01 |
| GO:BP | GO:0050890 | cognition | 3 | 227 | 4.27e-01 |
| GO:BP | GO:0010565 | regulation of cellular ketone metabolic process | 3 | 98 | 4.27e-01 |
| GO:BP | GO:0043632 | modification-dependent macromolecule catabolic process | 12 | 637 | 4.27e-01 |
| GO:BP | GO:0097242 | amyloid-beta clearance | 1 | 27 | 4.27e-01 |
| GO:BP | GO:0045730 | respiratory burst | 1 | 21 | 4.27e-01 |
| GO:BP | GO:0032402 | melanosome transport | 1 | 19 | 4.27e-01 |
| GO:BP | GO:0031122 | cytoplasmic microtubule organization | 1 | 60 | 4.27e-01 |
| GO:BP | GO:0030154 | cell differentiation | 4 | 2958 | 4.27e-01 |
| GO:BP | GO:0050771 | negative regulation of axonogenesis | 2 | 58 | 4.27e-01 |
| GO:BP | GO:0015874 | norepinephrine transport | 1 | 9 | 4.27e-01 |
| GO:BP | GO:0046683 | response to organophosphorus | 2 | 96 | 4.27e-01 |
| GO:BP | GO:0010761 | fibroblast migration | 1 | 52 | 4.27e-01 |
| GO:BP | GO:2000678 | negative regulation of transcription regulatory region DNA binding | 1 | 17 | 4.27e-01 |
| GO:BP | GO:0001754 | eye photoreceptor cell differentiation | 1 | 30 | 4.28e-01 |
| GO:BP | GO:0043405 | regulation of MAP kinase activity | 2 | 141 | 4.29e-01 |
| GO:BP | GO:0006730 | one-carbon metabolic process | 1 | 29 | 4.29e-01 |
| GO:BP | GO:0099171 | presynaptic modulation of chemical synaptic transmission | 1 | 26 | 4.29e-01 |
| GO:BP | GO:0072528 | pyrimidine-containing compound biosynthetic process | 1 | 33 | 4.29e-01 |
| GO:BP | GO:0071786 | endoplasmic reticulum tubular network organization | 1 | 19 | 4.29e-01 |
| GO:BP | GO:0051173 | positive regulation of nitrogen compound metabolic process | 1 | 2412 | 4.29e-01 |
| GO:BP | GO:0048762 | mesenchymal cell differentiation | 5 | 204 | 4.29e-01 |
| GO:BP | GO:0051926 | negative regulation of calcium ion transport | 2 | 45 | 4.29e-01 |
| GO:BP | GO:0048869 | cellular developmental process | 4 | 2984 | 4.30e-01 |
| GO:BP | GO:1901386 | negative regulation of voltage-gated calcium channel activity | 1 | 13 | 4.30e-01 |
| GO:BP | GO:0023061 | signal release | 2 | 321 | 4.30e-01 |
| GO:BP | GO:0021532 | neural tube patterning | 1 | 31 | 4.30e-01 |
| GO:BP | GO:0006664 | glycolipid metabolic process | 1 | 88 | 4.30e-01 |
| GO:BP | GO:0046324 | regulation of glucose import | 1 | 41 | 4.30e-01 |
| GO:BP | GO:0010923 | negative regulation of phosphatase activity | 1 | 30 | 4.30e-01 |
| GO:BP | GO:0010719 | negative regulation of epithelial to mesenchymal transition | 1 | 29 | 4.30e-01 |
| GO:BP | GO:0060537 | muscle tissue development | 7 | 343 | 4.30e-01 |
| GO:BP | GO:0045616 | regulation of keratinocyte differentiation | 1 | 25 | 4.30e-01 |
| GO:BP | GO:0003180 | aortic valve morphogenesis | 1 | 33 | 4.30e-01 |
| GO:BP | GO:0043652 | engulfment of apoptotic cell | 1 | 11 | 4.30e-01 |
| GO:BP | GO:0061436 | establishment of skin barrier | 1 | 18 | 4.30e-01 |
| GO:BP | GO:0046467 | membrane lipid biosynthetic process | 3 | 124 | 4.31e-01 |
| GO:BP | GO:0003341 | cilium movement | 1 | 97 | 4.31e-01 |
| GO:BP | GO:0048732 | gland development | 1 | 318 | 4.32e-01 |
| GO:BP | GO:0048568 | embryonic organ development | 5 | 316 | 4.32e-01 |
| GO:BP | GO:0045814 | negative regulation of gene expression, epigenetic | 1 | 79 | 4.32e-01 |
| GO:BP | GO:0045124 | regulation of bone resorption | 1 | 24 | 4.32e-01 |
| GO:BP | GO:1903509 | liposaccharide metabolic process | 1 | 88 | 4.32e-01 |
| GO:BP | GO:0006346 | DNA methylation-dependent heterochromatin formation | 1 | 22 | 4.32e-01 |
| GO:BP | GO:0010888 | negative regulation of lipid storage | 1 | 16 | 4.32e-01 |
| GO:BP | GO:0010971 | positive regulation of G2/M transition of mitotic cell cycle | 1 | 27 | 4.32e-01 |
| GO:BP | GO:0045785 | positive regulation of cell adhesion | 5 | 320 | 4.32e-01 |
| GO:BP | GO:0032570 | response to progesterone | 1 | 27 | 4.32e-01 |
| GO:BP | GO:0008654 | phospholipid biosynthetic process | 5 | 234 | 4.32e-01 |
| GO:BP | GO:0001836 | release of cytochrome c from mitochondria | 1 | 47 | 4.32e-01 |
| GO:BP | GO:0032660 | regulation of interleukin-17 production | 1 | 20 | 4.32e-01 |
| GO:BP | GO:0051904 | pigment granule transport | 1 | 19 | 4.32e-01 |
| GO:BP | GO:0032401 | establishment of melanosome localization | 1 | 20 | 4.32e-01 |
| GO:BP | GO:0032620 | interleukin-17 production | 1 | 20 | 4.32e-01 |
| GO:BP | GO:0006402 | mRNA catabolic process | 3 | 216 | 4.33e-01 |
| GO:BP | GO:0050871 | positive regulation of B cell activation | 1 | 53 | 4.34e-01 |
| GO:BP | GO:0030217 | T cell differentiation | 5 | 185 | 4.34e-01 |
| GO:BP | GO:0007095 | mitotic G2 DNA damage checkpoint signaling | 1 | 35 | 4.34e-01 |
| GO:BP | GO:0032880 | regulation of protein localization | 6 | 710 | 4.34e-01 |
| GO:BP | GO:0009855 | determination of bilateral symmetry | 3 | 102 | 4.34e-01 |
| GO:BP | GO:0006090 | pyruvate metabolic process | 3 | 93 | 4.34e-01 |
| GO:BP | GO:0009226 | nucleotide-sugar biosynthetic process | 1 | 19 | 4.34e-01 |
| GO:BP | GO:0050865 | regulation of cell activation | 8 | 384 | 4.34e-01 |
| GO:BP | GO:0061448 | connective tissue development | 2 | 208 | 4.34e-01 |
| GO:BP | GO:0006805 | xenobiotic metabolic process | 3 | 56 | 4.34e-01 |
| GO:BP | GO:0045428 | regulation of nitric oxide biosynthetic process | 1 | 38 | 4.34e-01 |
| GO:BP | GO:0043576 | regulation of respiratory gaseous exchange | 1 | 15 | 4.34e-01 |
| GO:BP | GO:0055086 | nucleobase-containing small molecule metabolic process | 1 | 487 | 4.34e-01 |
| GO:BP | GO:0040013 | negative regulation of locomotion | 7 | 265 | 4.34e-01 |
| GO:BP | GO:0061484 | hematopoietic stem cell homeostasis | 1 | 20 | 4.34e-01 |
| GO:BP | GO:0001568 | blood vessel development | 7 | 534 | 4.34e-01 |
| GO:BP | GO:0052547 | regulation of peptidase activity | 1 | 271 | 4.34e-01 |
| GO:BP | GO:0032526 | response to retinoic acid | 2 | 85 | 4.34e-01 |
| GO:BP | GO:0050796 | regulation of insulin secretion | 1 | 116 | 4.35e-01 |
| GO:BP | GO:0039529 | RIG-I signaling pathway | 1 | 22 | 4.35e-01 |
| GO:BP | GO:2000377 | regulation of reactive oxygen species metabolic process | 1 | 108 | 4.35e-01 |
| GO:BP | GO:0072329 | monocarboxylic acid catabolic process | 3 | 105 | 4.35e-01 |
| GO:BP | GO:1903513 | endoplasmic reticulum to cytosol transport | 1 | 28 | 4.35e-01 |
| GO:BP | GO:0006515 | protein quality control for misfolded or incompletely synthesized proteins | 1 | 28 | 4.35e-01 |
| GO:BP | GO:0030970 | retrograde protein transport, ER to cytosol | 1 | 28 | 4.35e-01 |
| GO:BP | GO:0002440 | production of molecular mediator of immune response | 2 | 135 | 4.35e-01 |
| GO:BP | GO:0042147 | retrograde transport, endosome to Golgi | 1 | 88 | 4.35e-01 |
| GO:BP | GO:1900744 | regulation of p38MAPK cascade | 1 | 32 | 4.35e-01 |
| GO:BP | GO:0009799 | specification of symmetry | 3 | 103 | 4.35e-01 |
| GO:BP | GO:0019935 | cyclic-nucleotide-mediated signaling | 1 | 55 | 4.35e-01 |
| GO:BP | GO:0001912 | positive regulation of leukocyte mediated cytotoxicity | 1 | 20 | 4.36e-01 |
| GO:BP | GO:0060828 | regulation of canonical Wnt signaling pathway | 1 | 213 | 4.36e-01 |
| GO:BP | GO:0097164 | ammonium ion metabolic process | 1 | 14 | 4.36e-01 |
| GO:BP | GO:0034620 | cellular response to unfolded protein | 1 | 91 | 4.37e-01 |
| GO:BP | GO:0051054 | positive regulation of DNA metabolic process | 5 | 265 | 4.37e-01 |
| GO:BP | GO:0042060 | wound healing | 2 | 320 | 4.38e-01 |
| GO:BP | GO:1902894 | negative regulation of miRNA transcription | 1 | 19 | 4.39e-01 |
| GO:BP | GO:0061384 | heart trabecula morphogenesis | 1 | 29 | 4.39e-01 |
| GO:BP | GO:0051905 | establishment of pigment granule localization | 1 | 20 | 4.39e-01 |
| GO:BP | GO:0031145 | anaphase-promoting complex-dependent catabolic process | 1 | 23 | 4.39e-01 |
| GO:BP | GO:0042573 | retinoic acid metabolic process | 1 | 12 | 4.40e-01 |
| GO:BP | GO:0006412 | translation | 1 | 646 | 4.40e-01 |
| GO:BP | GO:0046686 | response to cadmium ion | 1 | 41 | 4.41e-01 |
| GO:BP | GO:0032787 | monocarboxylic acid metabolic process | 1 | 433 | 4.41e-01 |
| GO:BP | GO:0032890 | regulation of organic acid transport | 2 | 49 | 4.41e-01 |
| GO:BP | GO:0051353 | positive regulation of oxidoreductase activity | 1 | 43 | 4.41e-01 |
| GO:BP | GO:0008361 | regulation of cell size | 2 | 159 | 4.41e-01 |
| GO:BP | GO:0016126 | sterol biosynthetic process | 1 | 52 | 4.41e-01 |
| GO:BP | GO:0048871 | multicellular organismal-level homeostasis | 2 | 532 | 4.41e-01 |
| GO:BP | GO:1902808 | positive regulation of cell cycle G1/S phase transition | 1 | 52 | 4.41e-01 |
| GO:BP | GO:2000311 | regulation of AMPA receptor activity | 1 | 15 | 4.42e-01 |
| GO:BP | GO:0030866 | cortical actin cytoskeleton organization | 1 | 35 | 4.42e-01 |
| GO:BP | GO:1901617 | organic hydroxy compound biosynthetic process | 3 | 172 | 4.42e-01 |
| GO:BP | GO:0072332 | intrinsic apoptotic signaling pathway by p53 class mediator | 1 | 77 | 4.42e-01 |
| GO:BP | GO:0009880 | embryonic pattern specification | 2 | 50 | 4.43e-01 |
| GO:BP | GO:0070306 | lens fiber cell differentiation | 1 | 30 | 4.43e-01 |
| GO:BP | GO:0035019 | somatic stem cell population maintenance | 1 | 50 | 4.43e-01 |
| GO:BP | GO:0003002 | regionalization | 7 | 273 | 4.44e-01 |
| GO:BP | GO:0045661 | regulation of myoblast differentiation | 2 | 61 | 4.44e-01 |
| GO:BP | GO:0006635 | fatty acid beta-oxidation | 2 | 68 | 4.44e-01 |
| GO:BP | GO:0080164 | regulation of nitric oxide metabolic process | 1 | 40 | 4.44e-01 |
| GO:BP | GO:0009394 | 2’-deoxyribonucleotide metabolic process | 1 | 35 | 4.44e-01 |
| GO:BP | GO:0010799 | regulation of peptidyl-threonine phosphorylation | 1 | 35 | 4.45e-01 |
| GO:BP | GO:0051591 | response to cAMP | 1 | 66 | 4.45e-01 |
| GO:BP | GO:0009954 | proximal/distal pattern formation | 1 | 15 | 4.45e-01 |
| GO:BP | GO:0016051 | carbohydrate biosynthetic process | 2 | 155 | 4.45e-01 |
| GO:BP | GO:0072091 | regulation of stem cell proliferation | 1 | 58 | 4.45e-01 |
| GO:BP | GO:0006355 | regulation of DNA-templated transcription | 1 | 2574 | 4.45e-01 |
| GO:BP | GO:0070231 | T cell apoptotic process | 1 | 39 | 4.45e-01 |
| GO:BP | GO:0032200 | telomere organization | 4 | 166 | 4.45e-01 |
| GO:BP | GO:0042113 | B cell activation | 3 | 170 | 4.45e-01 |
| GO:BP | GO:0042430 | indole-containing compound metabolic process | 1 | 8 | 4.45e-01 |
| GO:BP | GO:0030522 | intracellular receptor signaling pathway | 6 | 227 | 4.45e-01 |
| GO:BP | GO:1903506 | regulation of nucleic acid-templated transcription | 1 | 2576 | 4.45e-01 |
| GO:BP | GO:0032400 | melanosome localization | 1 | 22 | 4.45e-01 |
| GO:BP | GO:0072655 | establishment of protein localization to mitochondrion | 3 | 118 | 4.45e-01 |
| GO:BP | GO:1902991 | regulation of amyloid precursor protein catabolic process | 1 | 39 | 4.45e-01 |
| GO:BP | GO:1901653 | cellular response to peptide | 4 | 287 | 4.45e-01 |
| GO:BP | GO:0140056 | organelle localization by membrane tethering | 1 | 74 | 4.45e-01 |
| GO:BP | GO:0019692 | deoxyribose phosphate metabolic process | 1 | 36 | 4.45e-01 |
| GO:BP | GO:0001556 | oocyte maturation | 1 | 22 | 4.45e-01 |
| GO:BP | GO:0010594 | regulation of endothelial cell migration | 2 | 143 | 4.45e-01 |
| GO:BP | GO:2001141 | regulation of RNA biosynthetic process | 1 | 2593 | 4.45e-01 |
| GO:BP | GO:1902751 | positive regulation of cell cycle G2/M phase transition | 1 | 30 | 4.45e-01 |
| GO:BP | GO:0070886 | positive regulation of calcineurin-NFAT signaling cascade | 1 | 16 | 4.45e-01 |
| GO:BP | GO:0045622 | regulation of T-helper cell differentiation | 1 | 20 | 4.45e-01 |
| GO:BP | GO:0048731 | system development | 4 | 2901 | 4.45e-01 |
| GO:BP | GO:0002449 | lymphocyte mediated immunity | 3 | 142 | 4.45e-01 |
| GO:BP | GO:0120036 | plasma membrane bounded cell projection organization | 21 | 1201 | 4.45e-01 |
| GO:BP | GO:0042110 | T cell activation | 8 | 313 | 4.45e-01 |
| GO:BP | GO:2000629 | negative regulation of miRNA metabolic process | 1 | 20 | 4.45e-01 |
| GO:BP | GO:0106058 | positive regulation of calcineurin-mediated signaling | 1 | 16 | 4.45e-01 |
| GO:BP | GO:0046890 | regulation of lipid biosynthetic process | 3 | 134 | 4.45e-01 |
| GO:BP | GO:0009262 | deoxyribonucleotide metabolic process | 1 | 36 | 4.45e-01 |
| GO:BP | GO:0009124 | nucleoside monophosphate biosynthetic process | 1 | 37 | 4.45e-01 |
| GO:BP | GO:0043043 | peptide biosynthetic process | 1 | 666 | 4.45e-01 |
| GO:BP | GO:1903078 | positive regulation of protein localization to plasma membrane | 1 | 50 | 4.45e-01 |
| GO:BP | GO:0007274 | neuromuscular synaptic transmission | 1 | 14 | 4.45e-01 |
| GO:BP | GO:0030308 | negative regulation of cell growth | 2 | 160 | 4.45e-01 |
| GO:BP | GO:0030330 | DNA damage response, signal transduction by p53 class mediator | 1 | 69 | 4.45e-01 |
| GO:BP | GO:0009395 | phospholipid catabolic process | 1 | 37 | 4.45e-01 |
| GO:BP | GO:0042255 | ribosome assembly | 1 | 56 | 4.46e-01 |
| GO:BP | GO:0071277 | cellular response to calcium ion | 2 | 67 | 4.46e-01 |
| GO:BP | GO:0060627 | regulation of vesicle-mediated transport | 10 | 403 | 4.46e-01 |
| GO:BP | GO:0034763 | negative regulation of transmembrane transport | 3 | 96 | 4.46e-01 |
| GO:BP | GO:0019722 | calcium-mediated signaling | 3 | 122 | 4.46e-01 |
| GO:BP | GO:0006887 | exocytosis | 3 | 256 | 4.46e-01 |
| GO:BP | GO:0048844 | artery morphogenesis | 1 | 58 | 4.46e-01 |
| GO:BP | GO:0098781 | ncRNA transcription | 1 | 61 | 4.46e-01 |
| GO:BP | GO:0061564 | axon development | 4 | 398 | 4.46e-01 |
| GO:BP | GO:0003176 | aortic valve development | 1 | 37 | 4.46e-01 |
| GO:BP | GO:0008535 | respiratory chain complex IV assembly | 1 | 29 | 4.46e-01 |
| GO:BP | GO:0071900 | regulation of protein serine/threonine kinase activity | 7 | 282 | 4.46e-01 |
| GO:BP | GO:1900026 | positive regulation of substrate adhesion-dependent cell spreading | 1 | 39 | 4.46e-01 |
| GO:BP | GO:0035336 | long-chain fatty-acyl-CoA metabolic process | 1 | 19 | 4.46e-01 |
| GO:BP | GO:2000193 | positive regulation of fatty acid transport | 1 | 11 | 4.46e-01 |
| GO:BP | GO:0002822 | regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 1 | 97 | 4.46e-01 |
| GO:BP | GO:0042178 | xenobiotic catabolic process | 1 | 12 | 4.46e-01 |
| GO:BP | GO:0010604 | positive regulation of macromolecule metabolic process | 1 | 2646 | 4.48e-01 |
| GO:BP | GO:0007623 | circadian rhythm | 1 | 165 | 4.48e-01 |
| GO:BP | GO:0045116 | protein neddylation | 1 | 26 | 4.48e-01 |
| GO:BP | GO:0050994 | regulation of lipid catabolic process | 1 | 38 | 4.48e-01 |
| GO:BP | GO:1903051 | negative regulation of proteolysis involved in protein catabolic process | 2 | 61 | 4.48e-01 |
| GO:BP | GO:0031663 | lipopolysaccharide-mediated signaling pathway | 1 | 36 | 4.48e-01 |
| GO:BP | GO:0050680 | negative regulation of epithelial cell proliferation | 3 | 111 | 4.48e-01 |
| GO:BP | GO:0045840 | positive regulation of mitotic nuclear division | 1 | 29 | 4.48e-01 |
| GO:BP | GO:0009798 | axis specification | 2 | 63 | 4.48e-01 |
| GO:BP | GO:0030258 | lipid modification | 4 | 162 | 4.48e-01 |
| GO:BP | GO:0051953 | negative regulation of amine transport | 1 | 15 | 4.49e-01 |
| GO:BP | GO:0071880 | adenylate cyclase-activating adrenergic receptor signaling pathway | 1 | 19 | 4.49e-01 |
| GO:BP | GO:0006650 | glycerophospholipid metabolic process | 5 | 252 | 4.49e-01 |
| GO:BP | GO:0051875 | pigment granule localization | 1 | 22 | 4.49e-01 |
| GO:BP | GO:0016477 | cell migration | 2 | 1081 | 4.49e-01 |
| GO:BP | GO:0034205 | amyloid-beta formation | 1 | 41 | 4.50e-01 |
| GO:BP | GO:0006509 | membrane protein ectodomain proteolysis | 1 | 34 | 4.50e-01 |
| GO:BP | GO:0006351 | DNA-templated transcription | 1 | 2683 | 4.50e-01 |
| GO:BP | GO:0097659 | nucleic acid-templated transcription | 1 | 2684 | 4.50e-01 |
| GO:BP | GO:0048520 | positive regulation of behavior | 1 | 13 | 4.51e-01 |
| GO:BP | GO:0032886 | regulation of microtubule-based process | 3 | 217 | 4.51e-01 |
| GO:BP | GO:0060042 | retina morphogenesis in camera-type eye | 1 | 40 | 4.51e-01 |
| GO:BP | GO:0022008 | neurogenesis | 2 | 1294 | 4.52e-01 |
| GO:BP | GO:0007249 | I-kappaB kinase/NF-kappaB signaling | 4 | 227 | 4.52e-01 |
| GO:BP | GO:0016570 | histone modification | 2 | 433 | 4.52e-01 |
| GO:BP | GO:0001774 | microglial cell activation | 1 | 19 | 4.52e-01 |
| GO:BP | GO:2000819 | regulation of nucleotide-excision repair | 1 | 27 | 4.52e-01 |
| GO:BP | GO:0046850 | regulation of bone remodeling | 1 | 30 | 4.52e-01 |
| GO:BP | GO:0032774 | RNA biosynthetic process | 1 | 2714 | 4.53e-01 |
| GO:BP | GO:0044093 | positive regulation of molecular function | 2 | 1149 | 4.53e-01 |
| GO:BP | GO:1903037 | regulation of leukocyte cell-cell adhesion | 3 | 211 | 4.53e-01 |
| GO:BP | GO:0051091 | positive regulation of DNA-binding transcription factor activity | 3 | 199 | 4.53e-01 |
| GO:BP | GO:0035235 | ionotropic glutamate receptor signaling pathway | 1 | 14 | 4.53e-01 |
| GO:BP | GO:0030490 | maturation of SSU-rRNA | 1 | 54 | 4.53e-01 |
| GO:BP | GO:0051383 | kinetochore organization | 1 | 23 | 4.53e-01 |
| GO:BP | GO:0042551 | neuron maturation | 1 | 33 | 4.55e-01 |
| GO:BP | GO:0051571 | positive regulation of histone H3-K4 methylation | 1 | 20 | 4.55e-01 |
| GO:BP | GO:0006281 | DNA repair | 10 | 534 | 4.55e-01 |
| GO:BP | GO:0045822 | negative regulation of heart contraction | 1 | 17 | 4.55e-01 |
| GO:BP | GO:0071222 | cellular response to lipopolysaccharide | 2 | 110 | 4.55e-01 |
| GO:BP | GO:1902533 | positive regulation of intracellular signal transduction | 4 | 726 | 4.55e-01 |
| GO:BP | GO:0032196 | transposition | 1 | 17 | 4.55e-01 |
| GO:BP | GO:0072538 | T-helper 17 type immune response | 1 | 24 | 4.56e-01 |
| GO:BP | GO:0000041 | transition metal ion transport | 1 | 71 | 4.56e-01 |
| GO:BP | GO:0097746 | blood vessel diameter maintenance | 3 | 99 | 4.57e-01 |
| GO:BP | GO:0035296 | regulation of tube diameter | 3 | 99 | 4.57e-01 |
| GO:BP | GO:0045933 | positive regulation of muscle contraction | 1 | 32 | 4.57e-01 |
| GO:BP | GO:2000045 | regulation of G1/S transition of mitotic cell cycle | 3 | 149 | 4.57e-01 |
| GO:BP | GO:0051450 | myoblast proliferation | 1 | 17 | 4.58e-01 |
| GO:BP | GO:0007350 | blastoderm segmentation | 1 | 17 | 4.58e-01 |
| GO:BP | GO:0039694 | viral RNA genome replication | 1 | 27 | 4.58e-01 |
| GO:BP | GO:0031667 | response to nutrient levels | 8 | 353 | 4.58e-01 |
| GO:BP | GO:0032989 | cellular component morphogenesis | 8 | 639 | 4.58e-01 |
| GO:BP | GO:0001944 | vasculature development | 7 | 559 | 4.58e-01 |
| GO:BP | GO:0001894 | tissue homeostasis | 3 | 170 | 4.58e-01 |
| GO:BP | GO:0060249 | anatomical structure homeostasis | 3 | 170 | 4.58e-01 |
| GO:BP | GO:0002700 | regulation of production of molecular mediator of immune response | 1 | 108 | 4.58e-01 |
| GO:BP | GO:0045786 | negative regulation of cell cycle | 2 | 338 | 4.58e-01 |
| GO:BP | GO:0001819 | positive regulation of cytokine production | 2 | 276 | 4.59e-01 |
| GO:BP | GO:0090102 | cochlea development | 1 | 35 | 4.59e-01 |
| GO:BP | GO:0048010 | vascular endothelial growth factor receptor signaling pathway | 1 | 48 | 4.59e-01 |
| GO:BP | GO:0035150 | regulation of tube size | 3 | 99 | 4.59e-01 |
| GO:BP | GO:0140013 | meiotic nuclear division | 3 | 120 | 4.59e-01 |
| GO:BP | GO:0046856 | phosphatidylinositol dephosphorylation | 1 | 29 | 4.59e-01 |
| GO:BP | GO:0031343 | positive regulation of cell killing | 1 | 23 | 4.59e-01 |
| GO:BP | GO:0019932 | second-messenger-mediated signaling | 4 | 191 | 4.59e-01 |
| GO:BP | GO:0032413 | negative regulation of ion transmembrane transporter activity | 2 | 51 | 4.60e-01 |
| GO:BP | GO:0046949 | fatty-acyl-CoA biosynthetic process | 1 | 20 | 4.61e-01 |
| GO:BP | GO:0006022 | aminoglycan metabolic process | 1 | 93 | 4.61e-01 |
| GO:BP | GO:0031571 | mitotic G1 DNA damage checkpoint signaling | 1 | 30 | 4.61e-01 |
| GO:BP | GO:0007143 | female meiotic nuclear division | 1 | 25 | 4.61e-01 |
| GO:BP | GO:1905314 | semi-lunar valve development | 1 | 41 | 4.61e-01 |
| GO:BP | GO:1903523 | negative regulation of blood circulation | 1 | 18 | 4.61e-01 |
| GO:BP | GO:0032148 | activation of protein kinase B activity | 1 | 23 | 4.61e-01 |
| GO:BP | GO:0042221 | response to chemical | 4 | 2559 | 4.61e-01 |
| GO:BP | GO:0002819 | regulation of adaptive immune response | 1 | 106 | 4.61e-01 |
| GO:BP | GO:0061756 | leukocyte adhesion to vascular endothelial cell | 1 | 27 | 4.61e-01 |
| GO:BP | GO:0045932 | negative regulation of muscle contraction | 1 | 20 | 4.61e-01 |
| GO:BP | GO:2000401 | regulation of lymphocyte migration | 1 | 41 | 4.61e-01 |
| GO:BP | GO:0001510 | RNA methylation | 1 | 87 | 4.61e-01 |
| GO:BP | GO:0090276 | regulation of peptide hormone secretion | 1 | 132 | 4.61e-01 |
| GO:BP | GO:0051252 | regulation of RNA metabolic process | 1 | 2845 | 4.61e-01 |
| GO:BP | GO:0019221 | cytokine-mediated signaling pathway | 1 | 274 | 4.61e-01 |
| GO:BP | GO:0051220 | cytoplasmic sequestering of protein | 1 | 23 | 4.61e-01 |
| GO:BP | GO:0050982 | detection of mechanical stimulus | 1 | 32 | 4.61e-01 |
| GO:BP | GO:0010817 | regulation of hormone levels | 2 | 336 | 4.61e-01 |
| GO:BP | GO:0048469 | cell maturation | 3 | 108 | 4.62e-01 |
| GO:BP | GO:0035020 | regulation of Rac protein signal transduction | 1 | 21 | 4.62e-01 |
| GO:BP | GO:0098698 | postsynaptic specialization assembly | 1 | 23 | 4.62e-01 |
| GO:BP | GO:0099560 | synaptic membrane adhesion | 1 | 22 | 4.62e-01 |
| GO:BP | GO:0010639 | negative regulation of organelle organization | 1 | 318 | 4.62e-01 |
| GO:BP | GO:0099558 | maintenance of synapse structure | 1 | 25 | 4.62e-01 |
| GO:BP | GO:0051649 | establishment of localization in cell | 14 | 1836 | 4.62e-01 |
| GO:BP | GO:0030073 | insulin secretion | 1 | 141 | 4.62e-01 |
| GO:BP | GO:0002269 | leukocyte activation involved in inflammatory response | 1 | 21 | 4.62e-01 |
| GO:BP | GO:0045662 | negative regulation of myoblast differentiation | 1 | 19 | 4.63e-01 |
| GO:BP | GO:0002791 | regulation of peptide secretion | 1 | 134 | 4.63e-01 |
| GO:BP | GO:0097192 | extrinsic apoptotic signaling pathway in absence of ligand | 1 | 52 | 4.63e-01 |
| GO:BP | GO:1904377 | positive regulation of protein localization to cell periphery | 1 | 57 | 4.63e-01 |
| GO:BP | GO:0038034 | signal transduction in absence of ligand | 1 | 52 | 4.63e-01 |
| GO:BP | GO:0090329 | regulation of DNA-templated DNA replication | 1 | 47 | 4.63e-01 |
| GO:BP | GO:0070374 | positive regulation of ERK1 and ERK2 cascade | 2 | 121 | 4.64e-01 |
| GO:BP | GO:0015701 | bicarbonate transport | 1 | 19 | 4.64e-01 |
| GO:BP | GO:0009893 | positive regulation of metabolic process | 1 | 2880 | 4.64e-01 |
| GO:BP | GO:0090087 | regulation of peptide transport | 1 | 136 | 4.64e-01 |
| GO:BP | GO:0044819 | mitotic G1/S transition checkpoint signaling | 1 | 30 | 4.64e-01 |
| GO:BP | GO:0035967 | cellular response to topologically incorrect protein | 1 | 111 | 4.64e-01 |
| GO:BP | GO:0035456 | response to interferon-beta | 1 | 22 | 4.64e-01 |
| GO:BP | GO:0070848 | response to growth factor | 7 | 572 | 4.64e-01 |
| GO:BP | GO:0021766 | hippocampus development | 1 | 62 | 4.64e-01 |
| GO:BP | GO:0035556 | intracellular signal transduction | 11 | 2065 | 4.64e-01 |
| GO:BP | GO:0033628 | regulation of cell adhesion mediated by integrin | 1 | 36 | 4.64e-01 |
| GO:BP | GO:0035305 | negative regulation of dephosphorylation | 1 | 39 | 4.64e-01 |
| GO:BP | GO:0046530 | photoreceptor cell differentiation | 1 | 40 | 4.65e-01 |
| GO:BP | GO:0032990 | cell part morphogenesis | 7 | 551 | 4.65e-01 |
| GO:BP | GO:0045070 | positive regulation of viral genome replication | 1 | 28 | 4.65e-01 |
| GO:BP | GO:0051881 | regulation of mitochondrial membrane potential | 1 | 60 | 4.65e-01 |
| GO:BP | GO:0071219 | cellular response to molecule of bacterial origin | 2 | 114 | 4.65e-01 |
| GO:BP | GO:0006414 | translational elongation | 1 | 65 | 4.65e-01 |
| GO:BP | GO:0021884 | forebrain neuron development | 1 | 16 | 4.68e-01 |
| GO:BP | GO:1990830 | cellular response to leukemia inhibitory factor | 1 | 84 | 4.68e-01 |
| GO:BP | GO:2000463 | positive regulation of excitatory postsynaptic potential | 1 | 28 | 4.68e-01 |
| GO:BP | GO:0051249 | regulation of lymphocyte activation | 8 | 296 | 4.68e-01 |
| GO:BP | GO:0021700 | developmental maturation | 5 | 211 | 4.68e-01 |
| GO:BP | GO:0046323 | glucose import | 1 | 53 | 4.68e-01 |
| GO:BP | GO:1903201 | regulation of oxidative stress-induced cell death | 1 | 56 | 4.68e-01 |
| GO:BP | GO:0061061 | muscle structure development | 11 | 546 | 4.68e-01 |
| GO:BP | GO:0046189 | phenol-containing compound biosynthetic process | 1 | 28 | 4.68e-01 |
| GO:BP | GO:0006518 | peptide metabolic process | 1 | 771 | 4.69e-01 |
| GO:BP | GO:0042116 | macrophage activation | 2 | 57 | 4.69e-01 |
| GO:BP | GO:0032092 | positive regulation of protein binding | 1 | 78 | 4.69e-01 |
| GO:BP | GO:1990823 | response to leukemia inhibitory factor | 1 | 85 | 4.69e-01 |
| GO:BP | GO:0030030 | cell projection organization | 13 | 1233 | 4.69e-01 |
| GO:BP | GO:0014912 | negative regulation of smooth muscle cell migration | 1 | 25 | 4.70e-01 |
| GO:BP | GO:0010556 | regulation of macromolecule biosynthetic process | 1 | 3012 | 4.70e-01 |
| GO:BP | GO:0006298 | mismatch repair | 1 | 29 | 4.70e-01 |
| GO:BP | GO:0006898 | receptor-mediated endocytosis | 2 | 196 | 4.70e-01 |
| GO:BP | GO:0099518 | vesicle cytoskeletal trafficking | 1 | 60 | 4.71e-01 |
| GO:BP | GO:0006809 | nitric oxide biosynthetic process | 1 | 51 | 4.71e-01 |
| GO:BP | GO:0043094 | cellular metabolic compound salvage | 1 | 25 | 4.71e-01 |
| GO:BP | GO:0051205 | protein insertion into membrane | 1 | 62 | 4.71e-01 |
| GO:BP | GO:0014068 | positive regulation of phosphatidylinositol 3-kinase signaling | 2 | 55 | 4.71e-01 |
| GO:BP | GO:0061180 | mammary gland epithelium development | 1 | 57 | 4.71e-01 |
| GO:BP | GO:0006497 | protein lipidation | 2 | 89 | 4.71e-01 |
| GO:BP | GO:2001235 | positive regulation of apoptotic signaling pathway | 1 | 108 | 4.71e-01 |
| GO:BP | GO:0034243 | regulation of transcription elongation by RNA polymerase II | 1 | 85 | 4.71e-01 |
| GO:BP | GO:0050776 | regulation of immune response | 1 | 484 | 4.71e-01 |
| GO:BP | GO:0043604 | amide biosynthetic process | 1 | 775 | 4.71e-01 |
| GO:BP | GO:0010830 | regulation of myotube differentiation | 1 | 31 | 4.71e-01 |
| GO:BP | GO:0043543 | protein acylation | 4 | 228 | 4.71e-01 |
| GO:BP | GO:0002260 | lymphocyte homeostasis | 1 | 45 | 4.74e-01 |
| GO:BP | GO:0010827 | regulation of glucose transmembrane transport | 1 | 55 | 4.74e-01 |
| GO:BP | GO:0050864 | regulation of B cell activation | 1 | 77 | 4.74e-01 |
| GO:BP | GO:0007626 | locomotory behavior | 2 | 138 | 4.74e-01 |
| GO:BP | GO:0009953 | dorsal/ventral pattern formation | 2 | 55 | 4.75e-01 |
| GO:BP | GO:0001523 | retinoid metabolic process | 2 | 40 | 4.75e-01 |
| GO:BP | GO:0021854 | hypothalamus development | 1 | 15 | 4.75e-01 |
| GO:BP | GO:0090101 | negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 2 | 124 | 4.76e-01 |
| GO:BP | GO:0051238 | sequestering of metal ion | 1 | 17 | 4.76e-01 |
| GO:BP | GO:0019219 | regulation of nucleobase-containing compound metabolic process | 1 | 3080 | 4.76e-01 |
| GO:BP | GO:0048667 | cell morphogenesis involved in neuron differentiation | 1 | 463 | 4.76e-01 |
| GO:BP | GO:0086064 | cell communication by electrical coupling involved in cardiac conduction | 1 | 26 | 4.76e-01 |
| GO:BP | GO:0046503 | glycerolipid catabolic process | 1 | 42 | 4.76e-01 |
| GO:BP | GO:0019318 | hexose metabolic process | 2 | 185 | 4.76e-01 |
| GO:BP | GO:0034660 | ncRNA metabolic process | 5 | 561 | 4.76e-01 |
| GO:BP | GO:0042267 | natural killer cell mediated cytotoxicity | 1 | 34 | 4.76e-01 |
| GO:BP | GO:0038066 | p38MAPK cascade | 1 | 43 | 4.76e-01 |
| GO:BP | GO:0034654 | nucleobase-containing compound biosynthetic process | 1 | 3070 | 4.76e-01 |
| GO:BP | GO:0001890 | placenta development | 2 | 117 | 4.76e-01 |
| GO:BP | GO:0010803 | regulation of tumor necrosis factor-mediated signaling pathway | 1 | 41 | 4.76e-01 |
| GO:BP | GO:1901989 | positive regulation of cell cycle phase transition | 2 | 103 | 4.76e-01 |
| GO:BP | GO:0061900 | glial cell activation | 1 | 23 | 4.76e-01 |
| GO:BP | GO:0000086 | G2/M transition of mitotic cell cycle | 3 | 134 | 4.76e-01 |
| GO:BP | GO:0031326 | regulation of cellular biosynthetic process | 1 | 3080 | 4.76e-01 |
| GO:BP | GO:0001649 | osteoblast differentiation | 4 | 179 | 4.76e-01 |
| GO:BP | GO:0002694 | regulation of leukocyte activation | 9 | 348 | 4.76e-01 |
| GO:BP | GO:0006506 | GPI anchor biosynthetic process | 1 | 30 | 4.76e-01 |
| GO:BP | GO:0014812 | muscle cell migration | 2 | 76 | 4.77e-01 |
| GO:BP | GO:0044273 | sulfur compound catabolic process | 1 | 31 | 4.78e-01 |
| GO:BP | GO:0071875 | adrenergic receptor signaling pathway | 1 | 24 | 4.78e-01 |
| GO:BP | GO:0007159 | leukocyte cell-cell adhesion | 4 | 234 | 4.79e-01 |
| GO:BP | GO:0046777 | protein autophosphorylation | 2 | 188 | 4.79e-01 |
| GO:BP | GO:2000765 | regulation of cytoplasmic translation | 1 | 27 | 4.79e-01 |
| GO:BP | GO:0072583 | clathrin-dependent endocytosis | 1 | 43 | 4.79e-01 |
| GO:BP | GO:0050435 | amyloid-beta metabolic process | 1 | 48 | 4.79e-01 |
| GO:BP | GO:0018130 | heterocycle biosynthetic process | 1 | 3132 | 4.79e-01 |
| GO:BP | GO:0019438 | aromatic compound biosynthetic process | 1 | 3133 | 4.80e-01 |
| GO:BP | GO:0030111 | regulation of Wnt signaling pathway | 1 | 273 | 4.81e-01 |
| GO:BP | GO:0046785 | microtubule polymerization | 1 | 84 | 4.81e-01 |
| GO:BP | GO:0099175 | regulation of postsynapse organization | 2 | 83 | 4.81e-01 |
| GO:BP | GO:0008284 | positive regulation of cell population proliferation | 6 | 631 | 4.81e-01 |
| GO:BP | GO:0061640 | cytoskeleton-dependent cytokinesis | 2 | 104 | 4.81e-01 |
| GO:BP | GO:0031069 | hair follicle morphogenesis | 1 | 18 | 4.81e-01 |
| GO:BP | GO:0007169 | transmembrane receptor protein tyrosine kinase signaling pathway | 5 | 484 | 4.81e-01 |
| GO:BP | GO:0051100 | negative regulation of binding | 2 | 135 | 4.81e-01 |
| GO:BP | GO:0031329 | regulation of cellular catabolic process | 3 | 555 | 4.81e-01 |
| GO:BP | GO:0009889 | regulation of biosynthetic process | 1 | 3169 | 4.82e-01 |
| GO:BP | GO:0051056 | regulation of small GTPase mediated signal transduction | 6 | 257 | 4.82e-01 |
| GO:BP | GO:0014032 | neural crest cell development | 2 | 71 | 4.82e-01 |
| GO:BP | GO:0030307 | positive regulation of cell growth | 2 | 135 | 4.83e-01 |
| GO:BP | GO:0060314 | regulation of ryanodine-sensitive calcium-release channel activity | 1 | 23 | 4.83e-01 |
| GO:BP | GO:0051055 | negative regulation of lipid biosynthetic process | 1 | 46 | 4.83e-01 |
| GO:BP | GO:0042531 | positive regulation of tyrosine phosphorylation of STAT protein | 1 | 23 | 4.83e-01 |
| GO:BP | GO:0051235 | maintenance of location | 3 | 260 | 4.83e-01 |
| GO:BP | GO:0031110 | regulation of microtubule polymerization or depolymerization | 1 | 82 | 4.83e-01 |
| GO:BP | GO:0016125 | sterol metabolic process | 3 | 111 | 4.83e-01 |
| GO:BP | GO:0030857 | negative regulation of epithelial cell differentiation | 1 | 31 | 4.83e-01 |
| GO:BP | GO:0043154 | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 1 | 59 | 4.83e-01 |
| GO:BP | GO:0023056 | positive regulation of signaling | 4 | 1256 | 4.83e-01 |
| GO:BP | GO:0006505 | GPI anchor metabolic process | 1 | 31 | 4.83e-01 |
| GO:BP | GO:0010647 | positive regulation of cell communication | 4 | 1255 | 4.83e-01 |
| GO:BP | GO:0071560 | cellular response to transforming growth factor beta stimulus | 3 | 222 | 4.83e-01 |
| GO:BP | GO:0006220 | pyrimidine nucleotide metabolic process | 1 | 46 | 4.83e-01 |
| GO:BP | GO:0010737 | protein kinase A signaling | 1 | 23 | 4.83e-01 |
| GO:BP | GO:0002228 | natural killer cell mediated immunity | 1 | 34 | 4.83e-01 |
| GO:BP | GO:0001709 | cell fate determination | 1 | 25 | 4.83e-01 |
| GO:BP | GO:0016101 | diterpenoid metabolic process | 2 | 43 | 4.83e-01 |
| GO:BP | GO:0040007 | growth | 8 | 742 | 4.83e-01 |
| GO:BP | GO:1904861 | excitatory synapse assembly | 1 | 26 | 4.83e-01 |
| GO:BP | GO:0060544 | regulation of necroptotic process | 1 | 23 | 4.83e-01 |
| GO:BP | GO:0000302 | response to reactive oxygen species | 3 | 160 | 4.83e-01 |
| GO:BP | GO:0051147 | regulation of muscle cell differentiation | 2 | 118 | 4.84e-01 |
| GO:BP | GO:0046209 | nitric oxide metabolic process | 1 | 55 | 4.85e-01 |
| GO:BP | GO:1903046 | meiotic cell cycle process | 4 | 135 | 4.85e-01 |
| GO:BP | GO:0033554 | cellular response to stress | 16 | 1681 | 4.85e-01 |
| GO:BP | GO:0010611 | regulation of cardiac muscle hypertrophy | 1 | 48 | 4.85e-01 |
| GO:BP | GO:0042158 | lipoprotein biosynthetic process | 2 | 92 | 4.85e-01 |
| GO:BP | GO:0008610 | lipid biosynthetic process | 11 | 560 | 4.85e-01 |
| GO:BP | GO:0034508 | centromere complex assembly | 1 | 28 | 4.85e-01 |
| GO:BP | GO:0045444 | fat cell differentiation | 2 | 187 | 4.85e-01 |
| GO:BP | GO:0048870 | cell motility | 2 | 1182 | 4.86e-01 |
| GO:BP | GO:1901362 | organic cyclic compound biosynthetic process | 1 | 3237 | 4.87e-01 |
| GO:BP | GO:2001057 | reactive nitrogen species metabolic process | 1 | 56 | 4.88e-01 |
| GO:BP | GO:0032273 | positive regulation of protein polymerization | 1 | 76 | 4.89e-01 |
| GO:BP | GO:0032410 | negative regulation of transporter activity | 2 | 58 | 4.89e-01 |
| GO:BP | GO:0050885 | neuromuscular process controlling balance | 1 | 35 | 4.89e-01 |
| GO:BP | GO:0031960 | response to corticosteroid | 2 | 109 | 4.89e-01 |
| GO:BP | GO:0032103 | positive regulation of response to external stimulus | 1 | 337 | 4.90e-01 |
| GO:BP | GO:0051968 | positive regulation of synaptic transmission, glutamatergic | 1 | 20 | 4.90e-01 |
| GO:BP | GO:1901216 | positive regulation of neuron death | 1 | 70 | 4.90e-01 |
| GO:BP | GO:0042026 | protein refolding | 1 | 26 | 4.91e-01 |
| GO:BP | GO:0030856 | regulation of epithelial cell differentiation | 2 | 101 | 4.91e-01 |
| GO:BP | GO:0016042 | lipid catabolic process | 4 | 225 | 4.91e-01 |
| GO:BP | GO:0045055 | regulated exocytosis | 2 | 155 | 4.91e-01 |
| GO:BP | GO:0017004 | cytochrome complex assembly | 1 | 38 | 4.91e-01 |
| GO:BP | GO:0032204 | regulation of telomere maintenance | 2 | 96 | 4.91e-01 |
| GO:BP | GO:0006836 | neurotransmitter transport | 1 | 138 | 4.93e-01 |
| GO:BP | GO:0043370 | regulation of CD4-positive, alpha-beta T cell differentiation | 1 | 27 | 4.93e-01 |
| GO:BP | GO:0097190 | apoptotic signaling pathway | 4 | 494 | 4.93e-01 |
| GO:BP | GO:0006986 | response to unfolded protein | 1 | 128 | 4.93e-01 |
| GO:BP | GO:0000956 | nuclear-transcribed mRNA catabolic process | 1 | 120 | 4.93e-01 |
| GO:BP | GO:0009611 | response to wounding | 1 | 415 | 4.93e-01 |
| GO:BP | GO:0042987 | amyloid precursor protein catabolic process | 1 | 53 | 4.93e-01 |
| GO:BP | GO:0001954 | positive regulation of cell-matrix adhesion | 1 | 44 | 4.93e-01 |
| GO:BP | GO:0021954 | central nervous system neuron development | 2 | 61 | 4.93e-01 |
| GO:BP | GO:0002703 | regulation of leukocyte mediated immunity | 2 | 118 | 4.93e-01 |
| GO:BP | GO:0043030 | regulation of macrophage activation | 1 | 31 | 4.94e-01 |
| GO:BP | GO:0043124 | negative regulation of I-kappaB kinase/NF-kappaB signaling | 1 | 36 | 4.94e-01 |
| GO:BP | GO:0051028 | mRNA transport | 1 | 117 | 4.94e-01 |
| GO:BP | GO:0043488 | regulation of mRNA stability | 2 | 147 | 4.94e-01 |
| GO:BP | GO:0048588 | developmental cell growth | 2 | 192 | 4.94e-01 |
| GO:BP | GO:0048812 | neuron projection morphogenesis | 1 | 512 | 4.94e-01 |
| GO:BP | GO:0051641 | cellular localization | 20 | 2810 | 4.95e-01 |
| GO:BP | GO:1901890 | positive regulation of cell junction assembly | 2 | 82 | 4.95e-01 |
| GO:BP | GO:1900407 | regulation of cellular response to oxidative stress | 1 | 67 | 4.96e-01 |
| GO:BP | GO:0032228 | regulation of synaptic transmission, GABAergic | 1 | 23 | 4.96e-01 |
| GO:BP | GO:0060999 | positive regulation of dendritic spine development | 1 | 33 | 4.96e-01 |
| GO:BP | GO:0010880 | regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | 1 | 27 | 4.97e-01 |
| GO:BP | GO:0014743 | regulation of muscle hypertrophy | 1 | 49 | 4.97e-01 |
| GO:BP | GO:0002062 | chondrocyte differentiation | 1 | 90 | 4.97e-01 |
| GO:BP | GO:0060341 | regulation of cellular localization | 6 | 798 | 4.97e-01 |
| GO:BP | GO:0009991 | response to extracellular stimulus | 8 | 377 | 4.98e-01 |
| GO:BP | GO:0051240 | positive regulation of multicellular organismal process | 10 | 1101 | 4.98e-01 |
| GO:BP | GO:0000904 | cell morphogenesis involved in differentiation | 1 | 516 | 4.99e-01 |
| GO:BP | GO:0030216 | keratinocyte differentiation | 3 | 75 | 5.00e-01 |
| GO:BP | GO:0001654 | eye development | 6 | 272 | 5.00e-01 |
| GO:BP | GO:0030072 | peptide hormone secretion | 1 | 166 | 5.00e-01 |
| GO:BP | GO:1903649 | regulation of cytoplasmic transport | 1 | 25 | 5.00e-01 |
| GO:BP | GO:0006401 | RNA catabolic process | 3 | 256 | 5.00e-01 |
| GO:BP | GO:0140718 | facultative heterochromatin formation | 1 | 35 | 5.00e-01 |
| GO:BP | GO:0120039 | plasma membrane bounded cell projection morphogenesis | 1 | 527 | 5.00e-01 |
| GO:BP | GO:0033619 | membrane protein proteolysis | 1 | 45 | 5.01e-01 |
| GO:BP | GO:0048771 | tissue remodeling | 2 | 114 | 5.01e-01 |
| GO:BP | GO:0043666 | regulation of phosphoprotein phosphatase activity | 1 | 47 | 5.01e-01 |
| GO:BP | GO:0031016 | pancreas development | 1 | 53 | 5.01e-01 |
| GO:BP | GO:0001666 | response to hypoxia | 1 | 237 | 5.02e-01 |
| GO:BP | GO:0048858 | cell projection morphogenesis | 1 | 531 | 5.02e-01 |
| GO:BP | GO:0071216 | cellular response to biotic stimulus | 2 | 138 | 5.02e-01 |
| GO:BP | GO:0001941 | postsynaptic membrane organization | 1 | 29 | 5.02e-01 |
| GO:BP | GO:0010243 | response to organonitrogen compound | 1 | 782 | 5.02e-01 |
| GO:BP | GO:0045453 | bone resorption | 1 | 40 | 5.03e-01 |
| GO:BP | GO:0070227 | lymphocyte apoptotic process | 1 | 56 | 5.03e-01 |
| GO:BP | GO:0002790 | peptide secretion | 1 | 170 | 5.03e-01 |
| GO:BP | GO:0070316 | regulation of G0 to G1 transition | 1 | 34 | 5.03e-01 |
| GO:BP | GO:0046889 | positive regulation of lipid biosynthetic process | 1 | 63 | 5.03e-01 |
| GO:BP | GO:0061383 | trabecula morphogenesis | 1 | 43 | 5.03e-01 |
| GO:BP | GO:0045684 | positive regulation of epidermis development | 1 | 20 | 5.03e-01 |
| GO:BP | GO:0048661 | positive regulation of smooth muscle cell proliferation | 1 | 63 | 5.03e-01 |
| GO:BP | GO:0001505 | regulation of neurotransmitter levels | 1 | 149 | 5.03e-01 |
| GO:BP | GO:0002684 | positive regulation of immune system process | 1 | 581 | 5.03e-01 |
| GO:BP | GO:0009069 | serine family amino acid metabolic process | 1 | 30 | 5.04e-01 |
| GO:BP | GO:0046486 | glycerolipid metabolic process | 6 | 311 | 5.04e-01 |
| GO:BP | GO:0098657 | import into cell | 2 | 166 | 5.04e-01 |
| GO:BP | GO:0051785 | positive regulation of nuclear division | 1 | 38 | 5.04e-01 |
| GO:BP | GO:0032784 | regulation of DNA-templated transcription elongation | 1 | 99 | 5.04e-01 |
| GO:BP | GO:0001910 | regulation of leukocyte mediated cytotoxicity | 1 | 30 | 5.04e-01 |
| GO:BP | GO:0007612 | learning | 2 | 115 | 5.04e-01 |
| GO:BP | GO:0048864 | stem cell development | 2 | 76 | 5.04e-01 |
| GO:BP | GO:0008104 | protein localization | 15 | 2129 | 5.04e-01 |
| GO:BP | GO:0048730 | epidermis morphogenesis | 1 | 20 | 5.04e-01 |
| GO:BP | GO:0150063 | visual system development | 6 | 273 | 5.05e-01 |
| GO:BP | GO:1900024 | regulation of substrate adhesion-dependent cell spreading | 1 | 54 | 5.07e-01 |
| GO:BP | GO:0000731 | DNA synthesis involved in DNA repair | 1 | 36 | 5.07e-01 |
| GO:BP | GO:0060338 | regulation of type I interferon-mediated signaling pathway | 1 | 35 | 5.07e-01 |
| GO:BP | GO:0090092 | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 3 | 230 | 5.08e-01 |
| GO:BP | GO:0046883 | regulation of hormone secretion | 1 | 168 | 5.08e-01 |
| GO:BP | GO:0003179 | heart valve morphogenesis | 1 | 55 | 5.08e-01 |
| GO:BP | GO:0062098 | regulation of programmed necrotic cell death | 1 | 26 | 5.08e-01 |
| GO:BP | GO:0048584 | positive regulation of response to stimulus | 5 | 1555 | 5.08e-01 |
| GO:BP | GO:0051130 | positive regulation of cellular component organization | 6 | 906 | 5.10e-01 |
| GO:BP | GO:0000038 | very long-chain fatty acid metabolic process | 1 | 27 | 5.10e-01 |
| GO:BP | GO:0051336 | regulation of hydrolase activity | 6 | 701 | 5.10e-01 |
| GO:BP | GO:0070727 | cellular macromolecule localization | 15 | 2138 | 5.10e-01 |
| GO:BP | GO:0034097 | response to cytokine | 8 | 607 | 5.10e-01 |
| GO:BP | GO:0001775 | cell activation | 7 | 655 | 5.10e-01 |
| GO:BP | GO:0060840 | artery development | 1 | 83 | 5.10e-01 |
| GO:BP | GO:0062012 | regulation of small molecule metabolic process | 6 | 246 | 5.10e-01 |
| GO:BP | GO:0051090 | regulation of DNA-binding transcription factor activity | 4 | 335 | 5.10e-01 |
| GO:BP | GO:0099173 | postsynapse organization | 3 | 155 | 5.10e-01 |
| GO:BP | GO:1990806 | ligand-gated ion channel signaling pathway | 1 | 20 | 5.10e-01 |
| GO:BP | GO:0030837 | negative regulation of actin filament polymerization | 1 | 57 | 5.10e-01 |
| GO:BP | GO:0022612 | gland morphogenesis | 1 | 98 | 5.10e-01 |
| GO:BP | GO:0036293 | response to decreased oxygen levels | 1 | 249 | 5.10e-01 |
| GO:BP | GO:0046173 | polyol biosynthetic process | 1 | 47 | 5.11e-01 |
| GO:BP | GO:1905952 | regulation of lipid localization | 3 | 112 | 5.13e-01 |
| GO:BP | GO:0006364 | rRNA processing | 3 | 221 | 5.13e-01 |
| GO:BP | GO:0043535 | regulation of blood vessel endothelial cell migration | 1 | 75 | 5.13e-01 |
| GO:BP | GO:0046620 | regulation of organ growth | 1 | 71 | 5.13e-01 |
| GO:BP | GO:0050770 | regulation of axonogenesis | 2 | 139 | 5.14e-01 |
| GO:BP | GO:0042592 | homeostatic process | 3 | 1159 | 5.14e-01 |
| GO:BP | GO:0045023 | G0 to G1 transition | 1 | 35 | 5.14e-01 |
| GO:BP | GO:1905168 | positive regulation of double-strand break repair via homologous recombination | 1 | 35 | 5.14e-01 |
| GO:BP | GO:0010955 | negative regulation of protein processing | 1 | 19 | 5.14e-01 |
| GO:BP | GO:1903318 | negative regulation of protein maturation | 1 | 19 | 5.14e-01 |
| GO:BP | GO:0050790 | regulation of catalytic activity | 2 | 1380 | 5.14e-01 |
| GO:BP | GO:0060560 | developmental growth involved in morphogenesis | 2 | 204 | 5.15e-01 |
| GO:BP | GO:0048880 | sensory system development | 6 | 275 | 5.15e-01 |
| GO:BP | GO:0060322 | head development | 7 | 633 | 5.15e-01 |
| GO:BP | GO:0050684 | regulation of mRNA processing | 1 | 127 | 5.15e-01 |
| GO:BP | GO:0051569 | regulation of histone H3-K4 methylation | 1 | 26 | 5.15e-01 |
| GO:BP | GO:2000117 | negative regulation of cysteine-type endopeptidase activity | 1 | 64 | 5.15e-01 |
| GO:BP | GO:0050708 | regulation of protein secretion | 1 | 185 | 5.15e-01 |
| GO:BP | GO:0048545 | response to steroid hormone | 1 | 245 | 5.15e-01 |
| GO:BP | GO:1904063 | negative regulation of cation transmembrane transport | 2 | 64 | 5.16e-01 |
| GO:BP | GO:0002699 | positive regulation of immune effector process | 1 | 130 | 5.16e-01 |
| GO:BP | GO:0019748 | secondary metabolic process | 1 | 34 | 5.16e-01 |
| GO:BP | GO:0019752 | carboxylic acid metabolic process | 1 | 681 | 5.16e-01 |
| GO:BP | GO:0035306 | positive regulation of dephosphorylation | 1 | 47 | 5.16e-01 |
| GO:BP | GO:0008360 | regulation of cell shape | 3 | 126 | 5.16e-01 |
| GO:BP | GO:0015833 | peptide transport | 1 | 179 | 5.16e-01 |
| GO:BP | GO:0036473 | cell death in response to oxidative stress | 1 | 75 | 5.16e-01 |
| GO:BP | GO:1901698 | response to nitrogen compound | 1 | 830 | 5.16e-01 |
| GO:BP | GO:0043549 | regulation of kinase activity | 1 | 560 | 5.16e-01 |
| GO:BP | GO:0097106 | postsynaptic density organization | 1 | 30 | 5.16e-01 |
| GO:BP | GO:1902806 | regulation of cell cycle G1/S phase transition | 3 | 169 | 5.16e-01 |
| GO:BP | GO:0048511 | rhythmic process | 1 | 237 | 5.16e-01 |
| GO:BP | GO:0002251 | organ or tissue specific immune response | 1 | 13 | 5.16e-01 |
| GO:BP | GO:0042509 | regulation of tyrosine phosphorylation of STAT protein | 1 | 34 | 5.16e-01 |
| GO:BP | GO:1903311 | regulation of mRNA metabolic process | 3 | 267 | 5.16e-01 |
| GO:BP | GO:0017148 | negative regulation of translation | 2 | 165 | 5.16e-01 |
| GO:BP | GO:0006612 | protein targeting to membrane | 2 | 118 | 5.16e-01 |
| GO:BP | GO:1902882 | regulation of response to oxidative stress | 1 | 76 | 5.16e-01 |
| GO:BP | GO:0072593 | reactive oxygen species metabolic process | 1 | 156 | 5.16e-01 |
| GO:BP | GO:0007140 | male meiotic nuclear division | 1 | 27 | 5.16e-01 |
| GO:BP | GO:0006368 | transcription elongation by RNA polymerase II | 1 | 106 | 5.16e-01 |
| GO:BP | GO:0060415 | muscle tissue morphogenesis | 1 | 60 | 5.17e-01 |
| GO:BP | GO:0003161 | cardiac conduction system development | 1 | 33 | 5.17e-01 |
| GO:BP | GO:0031175 | neuron projection development | 9 | 780 | 5.17e-01 |
| GO:BP | GO:0072384 | organelle transport along microtubule | 1 | 84 | 5.17e-01 |
| GO:BP | GO:0043487 | regulation of RNA stability | 2 | 159 | 5.17e-01 |
| GO:BP | GO:0033555 | multicellular organismal response to stress | 1 | 57 | 5.18e-01 |
| GO:BP | GO:0044839 | cell cycle G2/M phase transition | 3 | 149 | 5.19e-01 |
| GO:BP | GO:1901224 | positive regulation of NIK/NF-kappaB signaling | 1 | 40 | 5.19e-01 |
| GO:BP | GO:0048645 | animal organ formation | 1 | 51 | 5.19e-01 |
| GO:BP | GO:0044271 | cellular nitrogen compound biosynthetic process | 1 | 3750 | 5.19e-01 |
| GO:BP | GO:0051893 | regulation of focal adhesion assembly | 1 | 59 | 5.19e-01 |
| GO:BP | GO:0090109 | regulation of cell-substrate junction assembly | 1 | 59 | 5.19e-01 |
| GO:BP | GO:0007029 | endoplasmic reticulum organization | 2 | 83 | 5.19e-01 |
| GO:BP | GO:0043436 | oxoacid metabolic process | 1 | 696 | 5.19e-01 |
| GO:BP | GO:0021761 | limbic system development | 1 | 81 | 5.19e-01 |
| GO:BP | GO:0032271 | regulation of protein polymerization | 2 | 168 | 5.19e-01 |
| GO:BP | GO:0007127 | meiosis I | 2 | 77 | 5.20e-01 |
| GO:BP | GO:0071345 | cellular response to cytokine stimulus | 5 | 540 | 5.20e-01 |
| GO:BP | GO:0006082 | organic acid metabolic process | 1 | 700 | 5.20e-01 |
| GO:BP | GO:0043010 | camera-type eye development | 5 | 236 | 5.20e-01 |
| GO:BP | GO:0015800 | acidic amino acid transport | 1 | 39 | 5.20e-01 |
| GO:BP | GO:0007611 | learning or memory | 3 | 202 | 5.20e-01 |
| GO:BP | GO:0006721 | terpenoid metabolic process | 2 | 50 | 5.20e-01 |
| GO:BP | GO:0003016 | respiratory system process | 1 | 30 | 5.20e-01 |
| GO:BP | GO:0099068 | postsynapse assembly | 1 | 32 | 5.20e-01 |
| GO:BP | GO:0014808 | release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | 1 | 28 | 5.21e-01 |
| GO:BP | GO:0035966 | response to topologically incorrect protein | 1 | 150 | 5.21e-01 |
| GO:BP | GO:0008344 | adult locomotory behavior | 1 | 60 | 5.21e-01 |
| GO:BP | GO:0045926 | negative regulation of growth | 2 | 206 | 5.21e-01 |
| GO:BP | GO:0019637 | organophosphate metabolic process | 1 | 784 | 5.22e-01 |
| GO:BP | GO:0010975 | regulation of neuron projection development | 6 | 372 | 5.22e-01 |
| GO:BP | GO:0045582 | positive regulation of T cell differentiation | 2 | 74 | 5.22e-01 |
| GO:BP | GO:0000578 | embryonic axis specification | 1 | 26 | 5.22e-01 |
| GO:BP | GO:0046839 | phospholipid dephosphorylation | 1 | 39 | 5.22e-01 |
| GO:BP | GO:0071702 | organic substance transport | 16 | 2116 | 5.23e-01 |
| GO:BP | GO:0007260 | tyrosine phosphorylation of STAT protein | 1 | 36 | 5.23e-01 |
| GO:BP | GO:0032608 | interferon-beta production | 1 | 43 | 5.23e-01 |
| GO:BP | GO:0032648 | regulation of interferon-beta production | 1 | 43 | 5.23e-01 |
| GO:BP | GO:0019432 | triglyceride biosynthetic process | 1 | 31 | 5.23e-01 |
| GO:BP | GO:0008593 | regulation of Notch signaling pathway | 1 | 78 | 5.24e-01 |
| GO:BP | GO:0046513 | ceramide biosynthetic process | 1 | 53 | 5.24e-01 |
| GO:BP | GO:0072657 | protein localization to membrane | 5 | 523 | 5.24e-01 |
| GO:BP | GO:0009267 | cellular response to starvation | 3 | 152 | 5.25e-01 |
| GO:BP | GO:0045880 | positive regulation of smoothened signaling pathway | 1 | 31 | 5.25e-01 |
| GO:BP | GO:0001569 | branching involved in blood vessel morphogenesis | 1 | 29 | 5.27e-01 |
| GO:BP | GO:0032527 | protein exit from endoplasmic reticulum | 1 | 43 | 5.27e-01 |
| GO:BP | GO:0014033 | neural crest cell differentiation | 2 | 80 | 5.27e-01 |
| GO:BP | GO:0051247 | positive regulation of protein metabolic process | 2 | 1123 | 5.27e-01 |
| GO:BP | GO:0071310 | cellular response to organic substance | 11 | 1399 | 5.27e-01 |
| GO:BP | GO:0001824 | blastocyst development | 2 | 94 | 5.27e-01 |
| GO:BP | GO:0086004 | regulation of cardiac muscle cell contraction | 1 | 34 | 5.27e-01 |
| GO:BP | GO:0044255 | cellular lipid metabolic process | 1 | 740 | 5.27e-01 |
| GO:BP | GO:0010644 | cell communication by electrical coupling | 1 | 31 | 5.27e-01 |
| GO:BP | GO:0070482 | response to oxygen levels | 1 | 272 | 5.27e-01 |
| GO:BP | GO:0031348 | negative regulation of defense response | 4 | 159 | 5.27e-01 |
| GO:BP | GO:0015980 | energy derivation by oxidation of organic compounds | 3 | 288 | 5.27e-01 |
| GO:BP | GO:0042274 | ribosomal small subunit biogenesis | 1 | 79 | 5.27e-01 |
| GO:BP | GO:0021537 | telencephalon development | 2 | 201 | 5.27e-01 |
| GO:BP | GO:1904427 | positive regulation of calcium ion transmembrane transport | 2 | 60 | 5.27e-01 |
| GO:BP | GO:0006473 | protein acetylation | 4 | 190 | 5.27e-01 |
| GO:BP | GO:1903514 | release of sequestered calcium ion into cytosol by endoplasmic reticulum | 1 | 28 | 5.27e-01 |
| GO:BP | GO:0070830 | bicellular tight junction assembly | 1 | 43 | 5.27e-01 |
| GO:BP | GO:0031100 | animal organ regeneration | 1 | 47 | 5.29e-01 |
| GO:BP | GO:0014074 | response to purine-containing compound | 1 | 108 | 5.29e-01 |
| GO:BP | GO:0045494 | photoreceptor cell maintenance | 1 | 27 | 5.29e-01 |
| GO:BP | GO:0051651 | maintenance of location in cell | 2 | 170 | 5.30e-01 |
| GO:BP | GO:0002250 | adaptive immune response | 4 | 218 | 5.30e-01 |
| GO:BP | GO:0097306 | cellular response to alcohol | 1 | 70 | 5.30e-01 |
| GO:BP | GO:2001237 | negative regulation of extrinsic apoptotic signaling pathway | 1 | 78 | 5.30e-01 |
| GO:BP | GO:0032965 | regulation of collagen biosynthetic process | 1 | 30 | 5.30e-01 |
| GO:BP | GO:0030516 | regulation of axon extension | 2 | 84 | 5.31e-01 |
| GO:BP | GO:0009896 | positive regulation of catabolic process | 1 | 464 | 5.32e-01 |
| GO:BP | GO:1902075 | cellular response to salt | 3 | 142 | 5.32e-01 |
| GO:BP | GO:0051341 | regulation of oxidoreductase activity | 1 | 68 | 5.34e-01 |
| GO:BP | GO:0009048 | dosage compensation by inactivation of X chromosome | 1 | 27 | 5.34e-01 |
| GO:BP | GO:0043270 | positive regulation of monoatomic ion transport | 2 | 154 | 5.34e-01 |
| GO:BP | GO:0006644 | phospholipid metabolic process | 6 | 316 | 5.34e-01 |
| GO:BP | GO:0090075 | relaxation of muscle | 1 | 29 | 5.34e-01 |
| GO:BP | GO:0150076 | neuroinflammatory response | 1 | 33 | 5.34e-01 |
| GO:BP | GO:0019079 | viral genome replication | 2 | 101 | 5.34e-01 |
| GO:BP | GO:0061982 | meiosis I cell cycle process | 2 | 81 | 5.34e-01 |
| GO:BP | GO:0035337 | fatty-acyl-CoA metabolic process | 1 | 31 | 5.34e-01 |
| GO:BP | GO:0010632 | regulation of epithelial cell migration | 2 | 195 | 5.34e-01 |
| GO:BP | GO:0150116 | regulation of cell-substrate junction organization | 1 | 64 | 5.34e-01 |
| GO:BP | GO:1903532 | positive regulation of secretion by cell | 1 | 199 | 5.34e-01 |
| GO:BP | GO:0007009 | plasma membrane organization | 2 | 116 | 5.34e-01 |
| GO:BP | GO:2001243 | negative regulation of intrinsic apoptotic signaling pathway | 1 | 89 | 5.34e-01 |
| GO:BP | GO:0071407 | cellular response to organic cyclic compound | 3 | 414 | 5.34e-01 |
| GO:BP | GO:0062014 | negative regulation of small molecule metabolic process | 1 | 71 | 5.34e-01 |
| GO:BP | GO:0045321 | leukocyte activation | 6 | 554 | 5.34e-01 |
| GO:BP | GO:0061001 | regulation of dendritic spine morphogenesis | 1 | 39 | 5.35e-01 |
| GO:BP | GO:0008285 | negative regulation of cell population proliferation | 4 | 513 | 5.35e-01 |
| GO:BP | GO:2000300 | regulation of synaptic vesicle exocytosis | 1 | 35 | 5.35e-01 |
| GO:BP | GO:0016339 | calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules | 1 | 28 | 5.35e-01 |
| GO:BP | GO:0009615 | response to virus | 5 | 275 | 5.36e-01 |
| GO:BP | GO:0048644 | muscle organ morphogenesis | 1 | 63 | 5.36e-01 |
| GO:BP | GO:0045923 | positive regulation of fatty acid metabolic process | 1 | 26 | 5.36e-01 |
| GO:BP | GO:0051302 | regulation of cell division | 3 | 145 | 5.36e-01 |
| GO:BP | GO:0030101 | natural killer cell activation | 1 | 42 | 5.37e-01 |
| GO:BP | GO:0002252 | immune effector process | 2 | 318 | 5.37e-01 |
| GO:BP | GO:0061326 | renal tubule development | 1 | 77 | 5.37e-01 |
| GO:BP | GO:0001953 | negative regulation of cell-matrix adhesion | 1 | 26 | 5.37e-01 |
| GO:BP | GO:0031123 | RNA 3’-end processing | 1 | 100 | 5.37e-01 |
| GO:BP | GO:2000573 | positive regulation of DNA biosynthetic process | 1 | 67 | 5.37e-01 |
| GO:BP | GO:1901019 | regulation of calcium ion transmembrane transporter activity | 2 | 71 | 5.37e-01 |
| GO:BP | GO:0009967 | positive regulation of signal transduction | 5 | 1133 | 5.37e-01 |
| GO:BP | GO:0006520 | amino acid metabolic process | 1 | 222 | 5.38e-01 |
| GO:BP | GO:0045742 | positive regulation of epidermal growth factor receptor signaling pathway | 1 | 26 | 5.39e-01 |
| GO:BP | GO:0098815 | modulation of excitatory postsynaptic potential | 1 | 40 | 5.40e-01 |
| GO:BP | GO:0048512 | circadian behavior | 1 | 30 | 5.40e-01 |
| GO:BP | GO:0034766 | negative regulation of monoatomic ion transmembrane transport | 2 | 70 | 5.42e-01 |
| GO:BP | GO:0031341 | regulation of cell killing | 1 | 36 | 5.42e-01 |
| GO:BP | GO:0003151 | outflow tract morphogenesis | 1 | 68 | 5.42e-01 |
| GO:BP | GO:0045663 | positive regulation of myoblast differentiation | 1 | 37 | 5.42e-01 |
| GO:BP | GO:0090257 | regulation of muscle system process | 4 | 184 | 5.42e-01 |
| GO:BP | GO:0042093 | T-helper cell differentiation | 1 | 40 | 5.42e-01 |
| GO:BP | GO:0060485 | mesenchyme development | 4 | 249 | 5.42e-01 |
| GO:BP | GO:0006338 | chromatin remodeling | 2 | 378 | 5.42e-01 |
| GO:BP | GO:0048666 | neuron development | 10 | 877 | 5.42e-01 |
| GO:BP | GO:0043457 | regulation of cellular respiration | 1 | 42 | 5.42e-01 |
| GO:BP | GO:0060079 | excitatory postsynaptic potential | 2 | 70 | 5.42e-01 |
| GO:BP | GO:0015718 | monocarboxylic acid transport | 3 | 90 | 5.42e-01 |
| GO:BP | GO:0070252 | actin-mediated cell contraction | 2 | 89 | 5.43e-01 |
| GO:BP | GO:0032760 | positive regulation of tumor necrosis factor production | 1 | 55 | 5.43e-01 |
| GO:BP | GO:0120192 | tight junction assembly | 1 | 47 | 5.43e-01 |
| GO:BP | GO:0070372 | regulation of ERK1 and ERK2 cascade | 3 | 191 | 5.43e-01 |
| GO:BP | GO:0018958 | phenol-containing compound metabolic process | 2 | 61 | 5.43e-01 |
| GO:BP | GO:0009062 | fatty acid catabolic process | 2 | 89 | 5.43e-01 |
| GO:BP | GO:0001817 | regulation of cytokine production | 1 | 447 | 5.45e-01 |
| GO:BP | GO:0099084 | postsynaptic specialization organization | 1 | 36 | 5.45e-01 |
| GO:BP | GO:0061912 | selective autophagy | 2 | 90 | 5.45e-01 |
| GO:BP | GO:0000122 | negative regulation of transcription by RNA polymerase II | 2 | 740 | 5.45e-01 |
| GO:BP | GO:0016482 | cytosolic transport | 1 | 161 | 5.45e-01 |
| GO:BP | GO:1903076 | regulation of protein localization to plasma membrane | 1 | 90 | 5.45e-01 |
| GO:BP | GO:0000079 | regulation of cyclin-dependent protein serine/threonine kinase activity | 2 | 85 | 5.45e-01 |
| GO:BP | GO:0007549 | dosage compensation | 1 | 29 | 5.46e-01 |
| GO:BP | GO:0042982 | amyloid precursor protein metabolic process | 1 | 69 | 5.46e-01 |
| GO:BP | GO:0003170 | heart valve development | 1 | 65 | 5.46e-01 |
| GO:BP | GO:0006937 | regulation of muscle contraction | 3 | 133 | 5.46e-01 |
| GO:BP | GO:0006354 | DNA-templated transcription elongation | 1 | 122 | 5.46e-01 |
| GO:BP | GO:0001816 | cytokine production | 1 | 451 | 5.46e-01 |
| GO:BP | GO:0001776 | leukocyte homeostasis | 1 | 69 | 5.47e-01 |
| GO:BP | GO:0002294 | CD4-positive, alpha-beta T cell differentiation involved in immune response | 1 | 40 | 5.47e-01 |
| GO:BP | GO:0008637 | apoptotic mitochondrial changes | 1 | 90 | 5.47e-01 |
| GO:BP | GO:0070887 | cellular response to chemical stimulus | 13 | 1869 | 5.48e-01 |
| GO:BP | GO:0051241 | negative regulation of multicellular organismal process | 1 | 748 | 5.48e-01 |
| GO:BP | GO:0030336 | negative regulation of cell migration | 2 | 227 | 5.48e-01 |
| GO:BP | GO:0009225 | nucleotide-sugar metabolic process | 1 | 35 | 5.50e-01 |
| GO:BP | GO:0071363 | cellular response to growth factor stimulus | 6 | 551 | 5.50e-01 |
| GO:BP | GO:0045123 | cellular extravasation | 1 | 44 | 5.50e-01 |
| GO:BP | GO:0007622 | rhythmic behavior | 1 | 32 | 5.50e-01 |
| GO:BP | GO:0006766 | vitamin metabolic process | 2 | 73 | 5.50e-01 |
| GO:BP | GO:0032272 | negative regulation of protein polymerization | 1 | 71 | 5.50e-01 |
| GO:BP | GO:0045944 | positive regulation of transcription by RNA polymerase II | 5 | 937 | 5.50e-01 |
| GO:BP | GO:0002287 | alpha-beta T cell activation involved in immune response | 1 | 40 | 5.50e-01 |
| GO:BP | GO:2000273 | positive regulation of signaling receptor activity | 1 | 33 | 5.50e-01 |
| GO:BP | GO:0046637 | regulation of alpha-beta T cell differentiation | 1 | 38 | 5.50e-01 |
| GO:BP | GO:0002293 | alpha-beta T cell differentiation involved in immune response | 1 | 40 | 5.50e-01 |
| GO:BP | GO:0010468 | regulation of gene expression | 1 | 3580 | 5.50e-01 |
| GO:BP | GO:1901186 | positive regulation of ERBB signaling pathway | 1 | 28 | 5.50e-01 |
| GO:BP | GO:0031323 | regulation of cellular metabolic process | 1 | 4174 | 5.50e-01 |
| GO:BP | GO:0009888 | tissue development | 31 | 1425 | 5.50e-01 |
| GO:BP | GO:0016525 | negative regulation of angiogenesis | 2 | 72 | 5.50e-01 |
| GO:BP | GO:0045861 | negative regulation of proteolysis | 3 | 211 | 5.51e-01 |
| GO:BP | GO:0043297 | apical junction assembly | 1 | 51 | 5.51e-01 |
| GO:BP | GO:0046649 | lymphocyte activation | 5 | 465 | 5.51e-01 |
| GO:BP | GO:0032535 | regulation of cellular component size | 3 | 305 | 5.51e-01 |
| GO:BP | GO:0042100 | B cell proliferation | 1 | 45 | 5.51e-01 |
| GO:BP | GO:1903557 | positive regulation of tumor necrosis factor superfamily cytokine production | 1 | 57 | 5.51e-01 |
| GO:BP | GO:0000422 | autophagy of mitochondrion | 2 | 92 | 5.51e-01 |
| GO:BP | GO:0061726 | mitochondrion disassembly | 2 | 92 | 5.51e-01 |
| GO:BP | GO:1904659 | glucose transmembrane transport | 2 | 81 | 5.51e-01 |
| GO:BP | GO:0051338 | regulation of transferase activity | 1 | 679 | 5.51e-01 |
| GO:BP | GO:0043403 | skeletal muscle tissue regeneration | 1 | 31 | 5.51e-01 |
| GO:BP | GO:0002027 | regulation of heart rate | 2 | 86 | 5.51e-01 |
| GO:BP | GO:0034764 | positive regulation of transmembrane transport | 4 | 158 | 5.53e-01 |
| GO:BP | GO:0006814 | sodium ion transport | 2 | 160 | 5.53e-01 |
| GO:BP | GO:0098703 | calcium ion import across plasma membrane | 1 | 23 | 5.53e-01 |
| GO:BP | GO:2000181 | negative regulation of blood vessel morphogenesis | 2 | 73 | 5.53e-01 |
| GO:BP | GO:1904029 | regulation of cyclin-dependent protein kinase activity | 2 | 88 | 5.53e-01 |
| GO:BP | GO:0051047 | positive regulation of secretion | 1 | 215 | 5.53e-01 |
| GO:BP | GO:0046394 | carboxylic acid biosynthetic process | 1 | 223 | 5.54e-01 |
| GO:BP | GO:0051050 | positive regulation of transport | 6 | 667 | 5.55e-01 |
| GO:BP | GO:0006643 | membrane lipid metabolic process | 1 | 173 | 5.56e-01 |
| GO:BP | GO:0039531 | regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway | 1 | 40 | 5.56e-01 |
| GO:BP | GO:0048522 | positive regulation of cellular process | 1 | 4099 | 5.56e-01 |
| GO:BP | GO:0031324 | negative regulation of cellular metabolic process | 5 | 1735 | 5.56e-01 |
| GO:BP | GO:0040029 | epigenetic regulation of gene expression | 1 | 153 | 5.56e-01 |
| GO:BP | GO:0002244 | hematopoietic progenitor cell differentiation | 2 | 109 | 5.56e-01 |
| GO:BP | GO:0031647 | regulation of protein stability | 4 | 290 | 5.56e-01 |
| GO:BP | GO:1901655 | cellular response to ketone | 1 | 86 | 5.56e-01 |
| GO:BP | GO:0016053 | organic acid biosynthetic process | 1 | 224 | 5.56e-01 |
| GO:BP | GO:0046427 | positive regulation of receptor signaling pathway via JAK-STAT | 1 | 21 | 5.56e-01 |
| GO:BP | GO:1903307 | positive regulation of regulated secretory pathway | 1 | 32 | 5.56e-01 |
| GO:BP | GO:0040008 | regulation of growth | 5 | 501 | 5.56e-01 |
| GO:BP | GO:0019395 | fatty acid oxidation | 2 | 93 | 5.56e-01 |
| GO:BP | GO:0045445 | myoblast differentiation | 2 | 90 | 5.56e-01 |
| GO:BP | GO:0010712 | regulation of collagen metabolic process | 1 | 34 | 5.56e-01 |
| GO:BP | GO:0034331 | cell junction maintenance | 1 | 40 | 5.56e-01 |
| GO:BP | GO:1901343 | negative regulation of vasculature development | 2 | 73 | 5.56e-01 |
| GO:BP | GO:0034248 | regulation of amide metabolic process | 4 | 424 | 5.56e-01 |
| GO:BP | GO:0016052 | carbohydrate catabolic process | 3 | 120 | 5.56e-01 |
| GO:BP | GO:0009719 | response to endogenous stimulus | 14 | 1278 | 5.57e-01 |
| GO:BP | GO:0071459 | protein localization to chromosome, centromeric region | 1 | 42 | 5.57e-01 |
| GO:BP | GO:0050808 | synapse organization | 4 | 365 | 5.57e-01 |
| GO:BP | GO:0051171 | regulation of nitrogen compound metabolic process | 1 | 4292 | 5.57e-01 |
| GO:BP | GO:0045859 | regulation of protein kinase activity | 10 | 479 | 5.58e-01 |
| GO:BP | GO:0098876 | vesicle-mediated transport to the plasma membrane | 1 | 143 | 5.58e-01 |
| GO:BP | GO:0045216 | cell-cell junction organization | 2 | 153 | 5.58e-01 |
| GO:BP | GO:0046329 | negative regulation of JNK cascade | 1 | 36 | 5.58e-01 |
| GO:BP | GO:0022407 | regulation of cell-cell adhesion | 3 | 295 | 5.58e-01 |
| GO:BP | GO:0015850 | organic hydroxy compound transport | 1 | 174 | 5.58e-01 |
| GO:BP | GO:0120193 | tight junction organization | 1 | 52 | 5.58e-01 |
| GO:BP | GO:0099565 | chemical synaptic transmission, postsynaptic | 2 | 75 | 5.58e-01 |
| GO:BP | GO:0009066 | aspartate family amino acid metabolic process | 1 | 39 | 5.58e-01 |
| GO:BP | GO:0009123 | nucleoside monophosphate metabolic process | 1 | 64 | 5.58e-01 |
| GO:BP | GO:1903115 | regulation of actin filament-based movement | 1 | 39 | 5.59e-01 |
| GO:BP | GO:0070296 | sarcoplasmic reticulum calcium ion transport | 1 | 31 | 5.59e-01 |
| GO:BP | GO:0140352 | export from cell | 13 | 611 | 5.59e-01 |
| GO:BP | GO:0045787 | positive regulation of cell cycle | 4 | 274 | 5.60e-01 |
| GO:BP | GO:0045621 | positive regulation of lymphocyte differentiation | 2 | 86 | 5.61e-01 |
| GO:BP | GO:0006954 | inflammatory response | 1 | 429 | 5.61e-01 |
| GO:BP | GO:0008645 | hexose transmembrane transport | 1 | 84 | 5.61e-01 |
| GO:BP | GO:0051216 | cartilage development | 2 | 151 | 5.61e-01 |
| GO:BP | GO:0043502 | regulation of muscle adaptation | 1 | 69 | 5.61e-01 |
| GO:BP | GO:0046460 | neutral lipid biosynthetic process | 1 | 36 | 5.62e-01 |
| GO:BP | GO:0022607 | cellular component assembly | 2 | 2466 | 5.62e-01 |
| GO:BP | GO:0046849 | bone remodeling | 1 | 59 | 5.62e-01 |
| GO:BP | GO:0070373 | negative regulation of ERK1 and ERK2 cascade | 1 | 59 | 5.62e-01 |
| GO:BP | GO:0071495 | cellular response to endogenous stimulus | 12 | 1107 | 5.62e-01 |
| GO:BP | GO:0046463 | acylglycerol biosynthetic process | 1 | 36 | 5.62e-01 |
| GO:BP | GO:0090287 | regulation of cellular response to growth factor stimulus | 3 | 265 | 5.62e-01 |
| GO:BP | GO:2000514 | regulation of CD4-positive, alpha-beta T cell activation | 1 | 39 | 5.62e-01 |
| GO:BP | GO:0071901 | negative regulation of protein serine/threonine kinase activity | 1 | 101 | 5.62e-01 |
| GO:BP | GO:0042073 | intraciliary transport | 1 | 46 | 5.62e-01 |
| GO:BP | GO:0050850 | positive regulation of calcium-mediated signaling | 1 | 22 | 5.63e-01 |
| GO:BP | GO:1901654 | response to ketone | 2 | 147 | 5.63e-01 |
| GO:BP | GO:0046854 | phosphatidylinositol phosphate biosynthetic process | 1 | 59 | 5.63e-01 |
| GO:BP | GO:0001889 | liver development | 2 | 110 | 5.63e-01 |
| GO:BP | GO:0003300 | cardiac muscle hypertrophy | 1 | 72 | 5.63e-01 |
| GO:BP | GO:0048589 | developmental growth | 4 | 522 | 5.63e-01 |
| GO:BP | GO:0070167 | regulation of biomineral tissue development | 2 | 67 | 5.63e-01 |
| GO:BP | GO:2000146 | negative regulation of cell motility | 2 | 236 | 5.63e-01 |
| GO:BP | GO:0080090 | regulation of primary metabolic process | 1 | 4417 | 5.66e-01 |
| GO:BP | GO:0048640 | negative regulation of developmental growth | 1 | 95 | 5.66e-01 |
| GO:BP | GO:0007610 | behavior | 4 | 436 | 5.66e-01 |
| GO:BP | GO:0015749 | monosaccharide transmembrane transport | 1 | 85 | 5.66e-01 |
| GO:BP | GO:0043410 | positive regulation of MAPK cascade | 4 | 317 | 5.66e-01 |
| GO:BP | GO:0035384 | thioester biosynthetic process | 1 | 38 | 5.66e-01 |
| GO:BP | GO:0090150 | establishment of protein localization to membrane | 3 | 250 | 5.66e-01 |
| GO:BP | GO:0048599 | oocyte development | 1 | 38 | 5.66e-01 |
| GO:BP | GO:0071616 | acyl-CoA biosynthetic process | 1 | 38 | 5.66e-01 |
| GO:BP | GO:0031398 | positive regulation of protein ubiquitination | 2 | 108 | 5.66e-01 |
| GO:BP | GO:0042325 | regulation of phosphorylation | 9 | 881 | 5.67e-01 |
| GO:BP | GO:0045071 | negative regulation of viral genome replication | 1 | 37 | 5.67e-01 |
| GO:BP | GO:0034502 | protein localization to chromosome | 2 | 110 | 5.67e-01 |
| GO:BP | GO:0003018 | vascular process in circulatory system | 4 | 198 | 5.67e-01 |
| GO:BP | GO:0044248 | cellular catabolic process | 2 | 1229 | 5.67e-01 |
| GO:BP | GO:0034440 | lipid oxidation | 1 | 94 | 5.67e-01 |
| GO:BP | GO:0051298 | centrosome duplication | 1 | 68 | 5.67e-01 |
| GO:BP | GO:0007018 | microtubule-based movement | 1 | 300 | 5.68e-01 |
| GO:BP | GO:1903900 | regulation of viral life cycle | 2 | 101 | 5.69e-01 |
| GO:BP | GO:1904894 | positive regulation of receptor signaling pathway via STAT | 1 | 22 | 5.69e-01 |
| GO:BP | GO:0032940 | secretion by cell | 12 | 569 | 5.69e-01 |
| GO:BP | GO:0072527 | pyrimidine-containing compound metabolic process | 1 | 67 | 5.69e-01 |
| GO:BP | GO:0061387 | regulation of extent of cell growth | 1 | 97 | 5.69e-01 |
| GO:BP | GO:0016567 | protein ubiquitination | 2 | 717 | 5.69e-01 |
| GO:BP | GO:0002292 | T cell differentiation involved in immune response | 1 | 42 | 5.70e-01 |
| GO:BP | GO:0034308 | primary alcohol metabolic process | 1 | 61 | 5.71e-01 |
| GO:BP | GO:1901701 | cellular response to oxygen-containing compound | 10 | 893 | 5.72e-01 |
| GO:BP | GO:0014897 | striated muscle hypertrophy | 1 | 73 | 5.72e-01 |
| GO:BP | GO:0030003 | intracellular monoatomic cation homeostasis | 1 | 357 | 5.73e-01 |
| GO:BP | GO:0070266 | necroptotic process | 1 | 32 | 5.75e-01 |
| GO:BP | GO:0072676 | lymphocyte migration | 1 | 59 | 5.75e-01 |
| GO:BP | GO:0010810 | regulation of cell-substrate adhesion | 2 | 172 | 5.75e-01 |
| GO:BP | GO:0070371 | ERK1 and ERK2 cascade | 3 | 211 | 5.76e-01 |
| GO:BP | GO:0042886 | amide transport | 1 | 235 | 5.76e-01 |
| GO:BP | GO:0098773 | skin epidermis development | 2 | 87 | 5.76e-01 |
| GO:BP | GO:0048546 | digestive tract morphogenesis | 1 | 31 | 5.76e-01 |
| GO:BP | GO:0051281 | positive regulation of release of sequestered calcium ion into cytosol | 1 | 27 | 5.76e-01 |
| GO:BP | GO:0016072 | rRNA metabolic process | 3 | 258 | 5.76e-01 |
| GO:BP | GO:0071887 | leukocyte apoptotic process | 1 | 81 | 5.76e-01 |
| GO:BP | GO:0070301 | cellular response to hydrogen peroxide | 1 | 73 | 5.76e-01 |
| GO:BP | GO:0071675 | regulation of mononuclear cell migration | 1 | 71 | 5.76e-01 |
| GO:BP | GO:0032892 | positive regulation of organic acid transport | 1 | 27 | 5.77e-01 |
| GO:BP | GO:0006873 | intracellular monoatomic ion homeostasis | 1 | 362 | 5.78e-01 |
| GO:BP | GO:1902532 | negative regulation of intracellular signal transduction | 5 | 438 | 5.78e-01 |
| GO:BP | GO:0014896 | muscle hypertrophy | 1 | 74 | 5.78e-01 |
| GO:BP | GO:0010921 | regulation of phosphatase activity | 1 | 65 | 5.78e-01 |
| GO:BP | GO:0045143 | homologous chromosome segregation | 1 | 34 | 5.78e-01 |
| GO:BP | GO:0071356 | cellular response to tumor necrosis factor | 2 | 155 | 5.78e-01 |
| GO:BP | GO:0051052 | regulation of DNA metabolic process | 4 | 452 | 5.78e-01 |
| GO:BP | GO:0007157 | heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules | 1 | 29 | 5.78e-01 |
| GO:BP | GO:0045022 | early endosome to late endosome transport | 1 | 40 | 5.79e-01 |
| GO:BP | GO:0033993 | response to lipid | 5 | 592 | 5.79e-01 |
| GO:BP | GO:0001570 | vasculogenesis | 1 | 67 | 5.80e-01 |
| GO:BP | GO:0000902 | cell morphogenesis | 1 | 761 | 5.80e-01 |
| GO:BP | GO:0035914 | skeletal muscle cell differentiation | 1 | 52 | 5.80e-01 |
| GO:BP | GO:0009913 | epidermal cell differentiation | 4 | 116 | 5.80e-01 |
| GO:BP | GO:0048041 | focal adhesion assembly | 1 | 81 | 5.81e-01 |
| GO:BP | GO:1901998 | toxin transport | 1 | 37 | 5.81e-01 |
| GO:BP | GO:0009306 | protein secretion | 1 | 262 | 5.81e-01 |
| GO:BP | GO:0032964 | collagen biosynthetic process | 1 | 39 | 5.81e-01 |
| GO:BP | GO:0035592 | establishment of protein localization to extracellular region | 1 | 262 | 5.81e-01 |
| GO:BP | GO:0090066 | regulation of anatomical structure size | 8 | 395 | 5.81e-01 |
| GO:BP | GO:0009994 | oocyte differentiation | 1 | 39 | 5.81e-01 |
| GO:BP | GO:0003015 | heart process | 4 | 216 | 5.81e-01 |
| GO:BP | GO:1901570 | fatty acid derivative biosynthetic process | 1 | 33 | 5.81e-01 |
| GO:BP | GO:0099643 | signal release from synapse | 2 | 104 | 5.81e-01 |
| GO:BP | GO:0007269 | neurotransmitter secretion | 2 | 104 | 5.81e-01 |
| GO:BP | GO:0010942 | positive regulation of cell death | 3 | 441 | 5.81e-01 |
| GO:BP | GO:0060998 | regulation of dendritic spine development | 1 | 48 | 5.82e-01 |
| GO:BP | GO:0001959 | regulation of cytokine-mediated signaling pathway | 2 | 117 | 5.83e-01 |
| GO:BP | GO:0033627 | cell adhesion mediated by integrin | 1 | 63 | 5.83e-01 |
| GO:BP | GO:0032102 | negative regulation of response to external stimulus | 6 | 269 | 5.84e-01 |
| GO:BP | GO:0021879 | forebrain neuron differentiation | 1 | 23 | 5.86e-01 |
| GO:BP | GO:0010939 | regulation of necrotic cell death | 1 | 38 | 5.86e-01 |
| GO:BP | GO:0051445 | regulation of meiotic cell cycle | 1 | 45 | 5.86e-01 |
| GO:BP | GO:0071692 | protein localization to extracellular region | 1 | 266 | 5.87e-01 |
| GO:BP | GO:0051668 | localization within membrane | 5 | 605 | 5.87e-01 |
| GO:BP | GO:0010628 | positive regulation of gene expression | 3 | 783 | 5.87e-01 |
| GO:BP | GO:0007399 | nervous system development | 2 | 1904 | 5.87e-01 |
| GO:BP | GO:0044085 | cellular component biogenesis | 2 | 2724 | 5.88e-01 |
| GO:BP | GO:1902105 | regulation of leukocyte differentiation | 4 | 199 | 5.88e-01 |
| GO:BP | GO:0009948 | anterior/posterior axis specification | 1 | 32 | 5.89e-01 |
| GO:BP | GO:0036211 | protein modification process | 1 | 2901 | 5.89e-01 |
| GO:BP | GO:0000281 | mitotic cytokinesis | 1 | 81 | 5.90e-01 |
| GO:BP | GO:0019755 | one-carbon compound transport | 1 | 23 | 5.90e-01 |
| GO:BP | GO:0042157 | lipoprotein metabolic process | 2 | 116 | 5.90e-01 |
| GO:BP | GO:0034219 | carbohydrate transmembrane transport | 1 | 92 | 5.90e-01 |
| GO:BP | GO:0044282 | small molecule catabolic process | 1 | 271 | 5.91e-01 |
| GO:BP | GO:0042311 | vasodilation | 1 | 39 | 5.92e-01 |
| GO:BP | GO:0048593 | camera-type eye morphogenesis | 1 | 91 | 5.93e-01 |
| GO:BP | GO:0031929 | TOR signaling | 1 | 115 | 5.93e-01 |
| GO:BP | GO:0031062 | positive regulation of histone methylation | 1 | 36 | 5.93e-01 |
| GO:BP | GO:0072073 | kidney epithelium development | 1 | 112 | 5.94e-01 |
| GO:BP | GO:0005975 | carbohydrate metabolic process | 9 | 433 | 5.94e-01 |
| GO:BP | GO:0048565 | digestive tract development | 2 | 92 | 5.94e-01 |
| GO:BP | GO:0018193 | peptidyl-amino acid modification | 10 | 963 | 5.94e-01 |
| GO:BP | GO:0048518 | positive regulation of biological process | 1 | 4579 | 5.94e-01 |
| GO:BP | GO:0007167 | enzyme-linked receptor protein signaling pathway | 8 | 763 | 5.94e-01 |
| GO:BP | GO:0001909 | leukocyte mediated cytotoxicity | 1 | 54 | 5.97e-01 |
| GO:BP | GO:0007005 | mitochondrion organization | 4 | 500 | 5.97e-01 |
| GO:BP | GO:0060997 | dendritic spine morphogenesis | 1 | 50 | 5.97e-01 |
| GO:BP | GO:1901021 | positive regulation of calcium ion transmembrane transporter activity | 1 | 39 | 5.98e-01 |
| GO:BP | GO:0010883 | regulation of lipid storage | 1 | 39 | 5.98e-01 |
| GO:BP | GO:0032446 | protein modification by small protein conjugation | 14 | 787 | 5.98e-01 |
| GO:BP | GO:0030098 | lymphocyte differentiation | 4 | 260 | 5.98e-01 |
| GO:BP | GO:0098927 | vesicle-mediated transport between endosomal compartments | 1 | 42 | 5.98e-01 |
| GO:BP | GO:0002697 | regulation of immune effector process | 1 | 190 | 5.98e-01 |
| GO:BP | GO:0035304 | regulation of protein dephosphorylation | 1 | 75 | 5.98e-01 |
| GO:BP | GO:0032611 | interleukin-1 beta production | 1 | 48 | 5.98e-01 |
| GO:BP | GO:0032651 | regulation of interleukin-1 beta production | 1 | 48 | 5.98e-01 |
| GO:BP | GO:0031401 | positive regulation of protein modification process | 6 | 719 | 5.98e-01 |
| GO:BP | GO:0046718 | viral entry into host cell | 1 | 107 | 5.98e-01 |
| GO:BP | GO:0051098 | regulation of binding | 3 | 317 | 5.98e-01 |
| GO:BP | GO:0050433 | regulation of catecholamine secretion | 1 | 29 | 5.98e-01 |
| GO:BP | GO:0007613 | memory | 1 | 92 | 5.99e-01 |
| GO:BP | GO:0019083 | viral transcription | 1 | 48 | 5.99e-01 |
| GO:BP | GO:0042273 | ribosomal large subunit biogenesis | 1 | 73 | 5.99e-01 |
| GO:BP | GO:0032496 | response to lipopolysaccharide | 2 | 178 | 5.99e-01 |
| GO:BP | GO:0045598 | regulation of fat cell differentiation | 1 | 102 | 5.99e-01 |
| GO:BP | GO:0050807 | regulation of synapse organization | 4 | 184 | 6.00e-01 |
| GO:BP | GO:0043367 | CD4-positive, alpha-beta T cell differentiation | 1 | 50 | 6.00e-01 |
| GO:BP | GO:0009451 | RNA modification | 1 | 162 | 6.00e-01 |
| GO:BP | GO:0007215 | glutamate receptor signaling pathway | 1 | 29 | 6.00e-01 |
| GO:BP | GO:0060078 | regulation of postsynaptic membrane potential | 2 | 82 | 6.01e-01 |
| GO:BP | GO:0048675 | axon extension | 1 | 110 | 6.01e-01 |
| GO:BP | GO:0007268 | chemical synaptic transmission | 2 | 490 | 6.06e-01 |
| GO:BP | GO:0098916 | anterograde trans-synaptic signaling | 2 | 490 | 6.06e-01 |
| GO:BP | GO:0032368 | regulation of lipid transport | 1 | 92 | 6.07e-01 |
| GO:BP | GO:0006629 | lipid metabolic process | 1 | 994 | 6.07e-01 |
| GO:BP | GO:0071466 | cellular response to xenobiotic stimulus | 3 | 105 | 6.07e-01 |
| GO:BP | GO:0061157 | mRNA destabilization | 1 | 89 | 6.07e-01 |
| GO:BP | GO:0043412 | macromolecule modification | 1 | 3090 | 6.09e-01 |
| GO:BP | GO:1903038 | negative regulation of leukocyte cell-cell adhesion | 1 | 74 | 6.09e-01 |
| GO:BP | GO:0061098 | positive regulation of protein tyrosine kinase activity | 1 | 33 | 6.09e-01 |
| GO:BP | GO:0071417 | cellular response to organonitrogen compound | 5 | 485 | 6.09e-01 |
| GO:BP | GO:0055080 | monoatomic cation homeostasis | 1 | 401 | 6.10e-01 |
| GO:BP | GO:0001952 | regulation of cell-matrix adhesion | 2 | 97 | 6.10e-01 |
| GO:BP | GO:0099537 | trans-synaptic signaling | 2 | 495 | 6.10e-01 |
| GO:BP | GO:0007044 | cell-substrate junction assembly | 1 | 91 | 6.10e-01 |
| GO:BP | GO:0030521 | androgen receptor signaling pathway | 1 | 39 | 6.10e-01 |
| GO:BP | GO:0030879 | mammary gland development | 1 | 106 | 6.10e-01 |
| GO:BP | GO:0016601 | Rac protein signal transduction | 1 | 42 | 6.11e-01 |
| GO:BP | GO:0044409 | entry into host | 1 | 113 | 6.11e-01 |
| GO:BP | GO:0002088 | lens development in camera-type eye | 1 | 57 | 6.12e-01 |
| GO:BP | GO:0032640 | tumor necrosis factor production | 2 | 91 | 6.13e-01 |
| GO:BP | GO:0060759 | regulation of response to cytokine stimulus | 2 | 126 | 6.13e-01 |
| GO:BP | GO:0048638 | regulation of developmental growth | 2 | 258 | 6.13e-01 |
| GO:BP | GO:0032680 | regulation of tumor necrosis factor production | 2 | 91 | 6.13e-01 |
| GO:BP | GO:0051592 | response to calcium ion | 2 | 113 | 6.13e-01 |
| GO:BP | GO:0090305 | nucleic acid phosphodiester bond hydrolysis | 1 | 211 | 6.13e-01 |
| GO:BP | GO:0017157 | regulation of exocytosis | 3 | 147 | 6.13e-01 |
| GO:BP | GO:0006936 | muscle contraction | 5 | 267 | 6.13e-01 |
| GO:BP | GO:0042594 | response to starvation | 3 | 178 | 6.13e-01 |
| GO:BP | GO:0044270 | cellular nitrogen compound catabolic process | 5 | 378 | 6.13e-01 |
| GO:BP | GO:0010038 | response to metal ion | 3 | 264 | 6.13e-01 |
| GO:BP | GO:0042472 | inner ear morphogenesis | 1 | 59 | 6.13e-01 |
| GO:BP | GO:0042491 | inner ear auditory receptor cell differentiation | 1 | 29 | 6.13e-01 |
| GO:BP | GO:0050801 | monoatomic ion homeostasis | 1 | 408 | 6.13e-01 |
| GO:BP | GO:0050764 | regulation of phagocytosis | 1 | 57 | 6.14e-01 |
| GO:BP | GO:0033036 | macromolecule localization | 16 | 2450 | 6.14e-01 |
| GO:BP | GO:0006835 | dicarboxylic acid transport | 1 | 62 | 6.14e-01 |
| GO:BP | GO:0050803 | regulation of synapse structure or activity | 4 | 187 | 6.14e-01 |
| GO:BP | GO:0048660 | regulation of smooth muscle cell proliferation | 1 | 106 | 6.14e-01 |
| GO:BP | GO:0048524 | positive regulation of viral process | 1 | 55 | 6.14e-01 |
| GO:BP | GO:0034612 | response to tumor necrosis factor | 2 | 172 | 6.14e-01 |
| GO:BP | GO:0035270 | endocrine system development | 1 | 86 | 6.15e-01 |
| GO:BP | GO:0006584 | catecholamine metabolic process | 1 | 30 | 6.15e-01 |
| GO:BP | GO:0097300 | programmed necrotic cell death | 1 | 39 | 6.15e-01 |
| GO:BP | GO:0050779 | RNA destabilization | 1 | 92 | 6.15e-01 |
| GO:BP | GO:0009712 | catechol-containing compound metabolic process | 1 | 30 | 6.15e-01 |
| GO:BP | GO:0007267 | cell-cell signaling | 4 | 1138 | 6.15e-01 |
| GO:BP | GO:0031424 | keratinization | 1 | 13 | 6.15e-01 |
| GO:BP | GO:0048662 | negative regulation of smooth muscle cell proliferation | 1 | 42 | 6.15e-01 |
| GO:BP | GO:0051099 | positive regulation of binding | 1 | 150 | 6.15e-01 |
| GO:BP | GO:0061014 | positive regulation of mRNA catabolic process | 1 | 93 | 6.15e-01 |
| GO:BP | GO:0043933 | protein-containing complex organization | 5 | 1496 | 6.16e-01 |
| GO:BP | GO:0007229 | integrin-mediated signaling pathway | 1 | 89 | 6.16e-01 |
| GO:BP | GO:0007156 | homophilic cell adhesion via plasma membrane adhesion molecules | 1 | 104 | 6.17e-01 |
| GO:BP | GO:0019229 | regulation of vasoconstriction | 1 | 38 | 6.17e-01 |
| GO:BP | GO:0032873 | negative regulation of stress-activated MAPK cascade | 1 | 46 | 6.17e-01 |
| GO:BP | GO:0045934 | negative regulation of nucleobase-containing compound metabolic process | 3 | 1209 | 6.17e-01 |
| GO:BP | GO:0060255 | regulation of macromolecule metabolic process | 1 | 4617 | 6.17e-01 |
| GO:BP | GO:0099536 | synaptic signaling | 2 | 511 | 6.17e-01 |
| GO:BP | GO:0033866 | nucleoside bisphosphate biosynthetic process | 1 | 49 | 6.17e-01 |
| GO:BP | GO:0043392 | negative regulation of DNA binding | 1 | 46 | 6.17e-01 |
| GO:BP | GO:0015695 | organic cation transport | 1 | 34 | 6.17e-01 |
| GO:BP | GO:0034033 | purine nucleoside bisphosphate biosynthetic process | 1 | 49 | 6.17e-01 |
| GO:BP | GO:0070303 | negative regulation of stress-activated protein kinase signaling cascade | 1 | 46 | 6.17e-01 |
| GO:BP | GO:0034030 | ribonucleoside bisphosphate biosynthetic process | 1 | 49 | 6.17e-01 |
| GO:BP | GO:0034314 | Arp2/3 complex-mediated actin nucleation | 1 | 40 | 6.17e-01 |
| GO:BP | GO:1903747 | regulation of establishment of protein localization to mitochondrion | 1 | 44 | 6.17e-01 |
| GO:BP | GO:0010633 | negative regulation of epithelial cell migration | 1 | 53 | 6.17e-01 |
| GO:BP | GO:1901615 | organic hydroxy compound metabolic process | 5 | 376 | 6.18e-01 |
| GO:BP | GO:0033209 | tumor necrosis factor-mediated signaling pathway | 1 | 76 | 6.18e-01 |
| GO:BP | GO:0051965 | positive regulation of synapse assembly | 1 | 44 | 6.19e-01 |
| GO:BP | GO:0043065 | positive regulation of apoptotic process | 2 | 393 | 6.19e-01 |
| GO:BP | GO:0002237 | response to molecule of bacterial origin | 2 | 187 | 6.19e-01 |
| GO:BP | GO:0048659 | smooth muscle cell proliferation | 1 | 110 | 6.19e-01 |
| GO:BP | GO:1903322 | positive regulation of protein modification by small protein conjugation or removal | 2 | 126 | 6.20e-01 |
| GO:BP | GO:0048872 | homeostasis of number of cells | 4 | 228 | 6.20e-01 |
| GO:BP | GO:0006796 | phosphate-containing compound metabolic process | 2 | 2139 | 6.20e-01 |
| GO:BP | GO:1903555 | regulation of tumor necrosis factor superfamily cytokine production | 2 | 94 | 6.20e-01 |
| GO:BP | GO:0071706 | tumor necrosis factor superfamily cytokine production | 2 | 94 | 6.20e-01 |
| GO:BP | GO:0006672 | ceramide metabolic process | 1 | 80 | 6.20e-01 |
| GO:BP | GO:1901700 | response to oxygen-containing compound | 1 | 1223 | 6.20e-01 |
| GO:BP | GO:0002931 | response to ischemia | 1 | 46 | 6.21e-01 |
| GO:BP | GO:2000677 | regulation of transcription regulatory region DNA binding | 1 | 43 | 6.21e-01 |
| GO:BP | GO:0051963 | regulation of synapse assembly | 2 | 83 | 6.22e-01 |
| GO:BP | GO:0050792 | regulation of viral process | 2 | 122 | 6.22e-01 |
| GO:BP | GO:0032101 | regulation of response to external stimulus | 1 | 662 | 6.22e-01 |
| GO:BP | GO:0099601 | regulation of neurotransmitter receptor activity | 1 | 40 | 6.22e-01 |
| GO:BP | GO:0006417 | regulation of translation | 4 | 370 | 6.22e-01 |
| GO:BP | GO:0051321 | meiotic cell cycle | 3 | 188 | 6.22e-01 |
| GO:BP | GO:0060541 | respiratory system development | 1 | 163 | 6.22e-01 |
| GO:BP | GO:0006793 | phosphorus metabolic process | 2 | 2161 | 6.23e-01 |
| GO:BP | GO:0055123 | digestive system development | 2 | 100 | 6.23e-01 |
| GO:BP | GO:0150115 | cell-substrate junction organization | 1 | 98 | 6.23e-01 |
| GO:BP | GO:0016070 | RNA metabolic process | 1 | 3600 | 6.25e-01 |
| GO:BP | GO:0021543 | pallium development | 1 | 139 | 6.25e-01 |
| GO:BP | GO:0098739 | import across plasma membrane | 3 | 133 | 6.26e-01 |
| GO:BP | GO:0042180 | cellular ketone metabolic process | 3 | 158 | 6.28e-01 |
| GO:BP | GO:0043500 | muscle adaptation | 1 | 90 | 6.30e-01 |
| GO:BP | GO:0045834 | positive regulation of lipid metabolic process | 1 | 108 | 6.31e-01 |
| GO:BP | GO:0021872 | forebrain generation of neurons | 1 | 29 | 6.31e-01 |
| GO:BP | GO:0030900 | forebrain development | 3 | 281 | 6.31e-01 |
| GO:BP | GO:0043068 | positive regulation of programmed cell death | 2 | 399 | 6.31e-01 |
| GO:BP | GO:0016197 | endosomal transport | 1 | 231 | 6.31e-01 |
| GO:BP | GO:0034976 | response to endoplasmic reticulum stress | 1 | 234 | 6.31e-01 |
| GO:BP | GO:0030278 | regulation of ossification | 2 | 84 | 6.32e-01 |
| GO:BP | GO:0010951 | negative regulation of endopeptidase activity | 1 | 102 | 6.32e-01 |
| GO:BP | GO:0008643 | carbohydrate transport | 1 | 111 | 6.32e-01 |
| GO:BP | GO:0097305 | response to alcohol | 2 | 159 | 6.32e-01 |
| GO:BP | GO:0045927 | positive regulation of growth | 2 | 199 | 6.32e-01 |
| GO:BP | GO:0030048 | actin filament-based movement | 2 | 112 | 6.33e-01 |
| GO:BP | GO:0010717 | regulation of epithelial to mesenchymal transition | 1 | 86 | 6.33e-01 |
| GO:BP | GO:0006720 | isoprenoid metabolic process | 2 | 85 | 6.33e-01 |
| GO:BP | GO:0019751 | polyol metabolic process | 1 | 82 | 6.33e-01 |
| GO:BP | GO:2001236 | regulation of extrinsic apoptotic signaling pathway | 1 | 123 | 6.33e-01 |
| GO:BP | GO:0006950 | response to stress | 3 | 2780 | 6.35e-01 |
| GO:BP | GO:0006111 | regulation of gluconeogenesis | 1 | 42 | 6.35e-01 |
| GO:BP | GO:0030316 | osteoclast differentiation | 1 | 66 | 6.35e-01 |
| GO:BP | GO:0030148 | sphingolipid biosynthetic process | 1 | 88 | 6.36e-01 |
| GO:BP | GO:0033059 | cellular pigmentation | 1 | 58 | 6.36e-01 |
| GO:BP | GO:0006446 | regulation of translational initiation | 1 | 73 | 6.36e-01 |
| GO:BP | GO:0001960 | negative regulation of cytokine-mediated signaling pathway | 1 | 53 | 6.37e-01 |
| GO:BP | GO:0045824 | negative regulation of innate immune response | 1 | 53 | 6.37e-01 |
| GO:BP | GO:0009952 | anterior/posterior pattern specification | 1 | 127 | 6.37e-01 |
| GO:BP | GO:2001233 | regulation of apoptotic signaling pathway | 2 | 307 | 6.38e-01 |
| GO:BP | GO:0032612 | interleukin-1 production | 1 | 56 | 6.38e-01 |
| GO:BP | GO:0032652 | regulation of interleukin-1 production | 1 | 56 | 6.38e-01 |
| GO:BP | GO:0070542 | response to fatty acid | 1 | 43 | 6.38e-01 |
| GO:BP | GO:0050768 | negative regulation of neurogenesis | 1 | 113 | 6.38e-01 |
| GO:BP | GO:0045892 | negative regulation of DNA-templated transcription | 6 | 1015 | 6.38e-01 |
| GO:BP | GO:0034446 | substrate adhesion-dependent cell spreading | 1 | 97 | 6.38e-01 |
| GO:BP | GO:0043687 | post-translational protein modification | 1 | 64 | 6.38e-01 |
| GO:BP | GO:0051258 | protein polymerization | 2 | 241 | 6.39e-01 |
| GO:BP | GO:0030534 | adult behavior | 2 | 92 | 6.39e-01 |
| GO:BP | GO:1903507 | negative regulation of nucleic acid-templated transcription | 6 | 1017 | 6.39e-01 |
| GO:BP | GO:0007519 | skeletal muscle tissue development | 2 | 129 | 6.39e-01 |
| GO:BP | GO:2000134 | negative regulation of G1/S transition of mitotic cell cycle | 1 | 64 | 6.39e-01 |
| GO:BP | GO:0065009 | regulation of molecular function | 2 | 1939 | 6.40e-01 |
| GO:BP | GO:0034599 | cellular response to oxidative stress | 3 | 240 | 6.40e-01 |
| GO:BP | GO:0031346 | positive regulation of cell projection organization | 1 | 303 | 6.40e-01 |
| GO:BP | GO:0043271 | negative regulation of monoatomic ion transport | 2 | 90 | 6.42e-01 |
| GO:BP | GO:0140115 | export across plasma membrane | 1 | 46 | 6.43e-01 |
| GO:BP | GO:0031669 | cellular response to nutrient levels | 2 | 194 | 6.43e-01 |
| GO:BP | GO:0080134 | regulation of response to stress | 4 | 1075 | 6.43e-01 |
| GO:BP | GO:0060337 | type I interferon-mediated signaling pathway | 1 | 51 | 6.43e-01 |
| GO:BP | GO:0006955 | immune response | 1 | 882 | 6.43e-01 |
| GO:BP | GO:0001947 | heart looping | 1 | 50 | 6.43e-01 |
| GO:BP | GO:1901699 | cellular response to nitrogen compound | 5 | 517 | 6.44e-01 |
| GO:BP | GO:1905039 | carboxylic acid transmembrane transport | 1 | 118 | 6.44e-01 |
| GO:BP | GO:0009887 | animal organ morphogenesis | 7 | 742 | 6.44e-01 |
| GO:BP | GO:0019222 | regulation of metabolic process | 1 | 5017 | 6.45e-01 |
| GO:BP | GO:0051928 | positive regulation of calcium ion transport | 2 | 82 | 6.45e-01 |
| GO:BP | GO:1902017 | regulation of cilium assembly | 1 | 57 | 6.45e-01 |
| GO:BP | GO:0046434 | organophosphate catabolic process | 1 | 113 | 6.45e-01 |
| GO:BP | GO:1903825 | organic acid transmembrane transport | 1 | 119 | 6.46e-01 |
| GO:BP | GO:0048639 | positive regulation of developmental growth | 1 | 124 | 6.46e-01 |
| GO:BP | GO:0007178 | transmembrane receptor protein serine/threonine kinase signaling pathway | 3 | 303 | 6.46e-01 |
| GO:BP | GO:0048705 | skeletal system morphogenesis | 1 | 155 | 6.46e-01 |
| GO:BP | GO:0060041 | retina development in camera-type eye | 2 | 109 | 6.46e-01 |
| GO:BP | GO:1902679 | negative regulation of RNA biosynthetic process | 6 | 1026 | 6.47e-01 |
| GO:BP | GO:0044000 | movement in host | 1 | 138 | 6.48e-01 |
| GO:BP | GO:0051961 | negative regulation of nervous system development | 1 | 118 | 6.48e-01 |
| GO:BP | GO:0010469 | regulation of signaling receptor activity | 2 | 107 | 6.50e-01 |
| GO:BP | GO:0060761 | negative regulation of response to cytokine stimulus | 1 | 57 | 6.50e-01 |
| GO:BP | GO:0071357 | cellular response to type I interferon | 1 | 52 | 6.50e-01 |
| GO:BP | GO:0060348 | bone development | 1 | 170 | 6.50e-01 |
| GO:BP | GO:0061512 | protein localization to cilium | 1 | 61 | 6.50e-01 |
| GO:BP | GO:0055082 | intracellular chemical homeostasis | 1 | 486 | 6.50e-01 |
| GO:BP | GO:0022904 | respiratory electron transport chain | 1 | 104 | 6.51e-01 |
| GO:BP | GO:0032508 | DNA duplex unwinding | 1 | 74 | 6.54e-01 |
| GO:BP | GO:0050853 | B cell receptor signaling pathway | 1 | 32 | 6.54e-01 |
| GO:BP | GO:1904950 | negative regulation of establishment of protein localization | 2 | 95 | 6.54e-01 |
| GO:BP | GO:0060048 | cardiac muscle contraction | 2 | 123 | 6.54e-01 |
| GO:BP | GO:0035315 | hair cell differentiation | 1 | 34 | 6.56e-01 |
| GO:BP | GO:0046903 | secretion | 2 | 645 | 6.56e-01 |
| GO:BP | GO:0090304 | nucleic acid metabolic process | 1 | 4048 | 6.56e-01 |
| GO:BP | GO:0042471 | ear morphogenesis | 1 | 73 | 6.57e-01 |
| GO:BP | GO:0046634 | regulation of alpha-beta T cell activation | 1 | 58 | 6.57e-01 |
| GO:BP | GO:0008154 | actin polymerization or depolymerization | 3 | 160 | 6.57e-01 |
| GO:BP | GO:0071333 | cellular response to glucose stimulus | 2 | 93 | 6.57e-01 |
| GO:BP | GO:0043954 | cellular component maintenance | 1 | 59 | 6.57e-01 |
| GO:BP | GO:0006694 | steroid biosynthetic process | 1 | 121 | 6.57e-01 |
| GO:BP | GO:0007568 | aging | 2 | 115 | 6.57e-01 |
| GO:BP | GO:2000278 | regulation of DNA biosynthetic process | 1 | 111 | 6.57e-01 |
| GO:BP | GO:0010812 | negative regulation of cell-substrate adhesion | 1 | 44 | 6.57e-01 |
| GO:BP | GO:0034655 | nucleobase-containing compound catabolic process | 3 | 358 | 6.57e-01 |
| GO:BP | GO:0086065 | cell communication involved in cardiac conduction | 1 | 58 | 6.59e-01 |
| GO:BP | GO:0006091 | generation of precursor metabolites and energy | 3 | 369 | 6.60e-01 |
| GO:BP | GO:0001503 | ossification | 6 | 313 | 6.60e-01 |
| GO:BP | GO:0050795 | regulation of behavior | 1 | 39 | 6.60e-01 |
| GO:BP | GO:0051174 | regulation of phosphorus metabolic process | 1 | 994 | 6.61e-01 |
| GO:BP | GO:0043407 | negative regulation of MAP kinase activity | 1 | 50 | 6.61e-01 |
| GO:BP | GO:0009653 | anatomical structure morphogenesis | 2 | 1974 | 6.61e-01 |
| GO:BP | GO:1903131 | mononuclear cell differentiation | 4 | 294 | 6.61e-01 |
| GO:BP | GO:0019220 | regulation of phosphate metabolic process | 1 | 993 | 6.61e-01 |
| GO:BP | GO:0042542 | response to hydrogen peroxide | 1 | 103 | 6.62e-01 |
| GO:BP | GO:0071331 | cellular response to hexose stimulus | 2 | 94 | 6.62e-01 |
| GO:BP | GO:0045669 | positive regulation of osteoblast differentiation | 1 | 54 | 6.63e-01 |
| GO:BP | GO:0070647 | protein modification by small protein conjugation or removal | 2 | 898 | 6.63e-01 |
| GO:BP | GO:0031334 | positive regulation of protein-containing complex assembly | 1 | 161 | 6.63e-01 |
| GO:BP | GO:0007585 | respiratory gaseous exchange by respiratory system | 1 | 49 | 6.64e-01 |
| GO:BP | GO:0003013 | circulatory system process | 8 | 447 | 6.65e-01 |
| GO:BP | GO:0007259 | receptor signaling pathway via JAK-STAT | 2 | 86 | 6.65e-01 |
| GO:BP | GO:0048706 | embryonic skeletal system development | 1 | 78 | 6.65e-01 |
| GO:BP | GO:0048562 | embryonic organ morphogenesis | 2 | 187 | 6.66e-01 |
| GO:BP | GO:0035710 | CD4-positive, alpha-beta T cell activation | 1 | 64 | 6.66e-01 |
| GO:BP | GO:0003143 | embryonic heart tube morphogenesis | 1 | 56 | 6.67e-01 |
| GO:BP | GO:0061371 | determination of heart left/right asymmetry | 1 | 52 | 6.67e-01 |
| GO:BP | GO:1902807 | negative regulation of cell cycle G1/S phase transition | 1 | 70 | 6.67e-01 |
| GO:BP | GO:0046928 | regulation of neurotransmitter secretion | 1 | 57 | 6.67e-01 |
| GO:BP | GO:0010970 | transport along microtubule | 1 | 162 | 6.67e-01 |
| GO:BP | GO:1903008 | organelle disassembly | 1 | 137 | 6.68e-01 |
| GO:BP | GO:0071326 | cellular response to monosaccharide stimulus | 2 | 95 | 6.68e-01 |
| GO:BP | GO:0002286 | T cell activation involved in immune response | 1 | 55 | 6.68e-01 |
| GO:BP | GO:0043408 | regulation of MAPK cascade | 5 | 475 | 6.68e-01 |
| GO:BP | GO:0031060 | regulation of histone methylation | 1 | 47 | 6.69e-01 |
| GO:BP | GO:0060538 | skeletal muscle organ development | 2 | 139 | 6.69e-01 |
| GO:BP | GO:0010035 | response to inorganic substance | 4 | 414 | 6.69e-01 |
| GO:BP | GO:0001932 | regulation of protein phosphorylation | 6 | 796 | 6.69e-01 |
| GO:BP | GO:0014910 | regulation of smooth muscle cell migration | 1 | 58 | 6.69e-01 |
| GO:BP | GO:0001895 | retina homeostasis | 1 | 44 | 6.69e-01 |
| GO:BP | GO:0031507 | heterochromatin formation | 1 | 69 | 6.69e-01 |
| GO:BP | GO:0007416 | synapse assembly | 1 | 152 | 6.69e-01 |
| GO:BP | GO:0043506 | regulation of JUN kinase activity | 1 | 49 | 6.69e-01 |
| GO:BP | GO:0034340 | response to type I interferon | 1 | 57 | 6.69e-01 |
| GO:BP | GO:0090100 | positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 1 | 100 | 6.70e-01 |
| GO:BP | GO:0030433 | ubiquitin-dependent ERAD pathway | 1 | 83 | 6.70e-01 |
| GO:BP | GO:0010033 | response to organic substance | 12 | 1957 | 6.71e-01 |
| GO:BP | GO:0050767 | regulation of neurogenesis | 2 | 301 | 6.71e-01 |
| GO:BP | GO:0046632 | alpha-beta T cell differentiation | 1 | 67 | 6.72e-01 |
| GO:BP | GO:0032392 | DNA geometric change | 1 | 80 | 6.72e-01 |
| GO:BP | GO:0009581 | detection of external stimulus | 1 | 67 | 6.73e-01 |
| GO:BP | GO:0051966 | regulation of synaptic transmission, glutamatergic | 1 | 46 | 6.73e-01 |
| GO:BP | GO:1902531 | regulation of intracellular signal transduction | 25 | 1345 | 6.73e-01 |
| GO:BP | GO:1902893 | regulation of miRNA transcription | 1 | 56 | 6.73e-01 |
| GO:BP | GO:0006575 | cellular modified amino acid metabolic process | 1 | 96 | 6.73e-01 |
| GO:BP | GO:0016925 | protein sumoylation | 1 | 59 | 6.73e-01 |
| GO:BP | GO:0006879 | intracellular iron ion homeostasis | 1 | 52 | 6.75e-01 |
| GO:BP | GO:0097061 | dendritic spine organization | 1 | 67 | 6.77e-01 |
| GO:BP | GO:0030182 | neuron differentiation | 1 | 1061 | 6.77e-01 |
| GO:BP | GO:0006605 | protein targeting | 2 | 307 | 6.77e-01 |
| GO:BP | GO:0061614 | miRNA transcription | 1 | 57 | 6.77e-01 |
| GO:BP | GO:0014855 | striated muscle cell proliferation | 1 | 57 | 6.77e-01 |
| GO:BP | GO:0045471 | response to ethanol | 1 | 73 | 6.78e-01 |
| GO:BP | GO:0097696 | receptor signaling pathway via STAT | 2 | 88 | 6.78e-01 |
| GO:BP | GO:0009582 | detection of abiotic stimulus | 1 | 68 | 6.78e-01 |
| GO:BP | GO:0030833 | regulation of actin filament polymerization | 1 | 110 | 6.78e-01 |
| GO:BP | GO:0044281 | small molecule metabolic process | 1 | 1389 | 6.78e-01 |
| GO:BP | GO:0007219 | Notch signaling pathway | 1 | 146 | 6.79e-01 |
| GO:BP | GO:2001257 | regulation of cation channel activity | 2 | 100 | 6.79e-01 |
| GO:BP | GO:0009890 | negative regulation of biosynthetic process | 6 | 1280 | 6.79e-01 |
| GO:BP | GO:0051701 | biological process involved in interaction with host | 1 | 154 | 6.79e-01 |
| GO:BP | GO:0032387 | negative regulation of intracellular transport | 1 | 49 | 6.80e-01 |
| GO:BP | GO:2000736 | regulation of stem cell differentiation | 1 | 71 | 6.80e-01 |
| GO:BP | GO:2000241 | regulation of reproductive process | 2 | 128 | 6.80e-01 |
| GO:BP | GO:0045010 | actin nucleation | 1 | 50 | 6.82e-01 |
| GO:BP | GO:0006139 | nucleobase-containing compound metabolic process | 1 | 4455 | 6.82e-01 |
| GO:BP | GO:0051253 | negative regulation of RNA metabolic process | 1 | 1119 | 6.82e-01 |
| GO:BP | GO:0034470 | ncRNA processing | 4 | 400 | 6.82e-01 |
| GO:BP | GO:0006399 | tRNA metabolic process | 1 | 186 | 6.85e-01 |
| GO:BP | GO:0014823 | response to activity | 1 | 46 | 6.85e-01 |
| GO:BP | GO:0051607 | defense response to virus | 3 | 202 | 6.86e-01 |
| GO:BP | GO:1903708 | positive regulation of hemopoiesis | 1 | 118 | 6.86e-01 |
| GO:BP | GO:0070265 | necrotic cell death | 1 | 53 | 6.86e-01 |
| GO:BP | GO:1902107 | positive regulation of leukocyte differentiation | 1 | 118 | 6.86e-01 |
| GO:BP | GO:1990138 | neuron projection extension | 1 | 148 | 6.86e-01 |
| GO:BP | GO:0042310 | vasoconstriction | 1 | 51 | 6.87e-01 |
| GO:BP | GO:0019725 | cellular homeostasis | 1 | 569 | 6.87e-01 |
| GO:BP | GO:0045132 | meiotic chromosome segregation | 1 | 64 | 6.87e-01 |
| GO:BP | GO:0140546 | defense response to symbiont | 3 | 202 | 6.87e-01 |
| GO:BP | GO:0043086 | negative regulation of catalytic activity | 3 | 478 | 6.88e-01 |
| GO:BP | GO:0007166 | cell surface receptor signaling pathway | 2 | 1898 | 6.88e-01 |
| GO:BP | GO:0035303 | regulation of dephosphorylation | 1 | 105 | 6.89e-01 |
| GO:BP | GO:1903313 | positive regulation of mRNA metabolic process | 1 | 121 | 6.89e-01 |
| GO:BP | GO:0022408 | negative regulation of cell-cell adhesion | 1 | 116 | 6.89e-01 |
| GO:BP | GO:0045921 | positive regulation of exocytosis | 1 | 62 | 6.89e-01 |
| GO:BP | GO:0009605 | response to external stimulus | 2 | 1719 | 6.90e-01 |
| GO:BP | GO:0009142 | nucleoside triphosphate biosynthetic process | 1 | 111 | 6.90e-01 |
| GO:BP | GO:1901568 | fatty acid derivative metabolic process | 1 | 48 | 6.90e-01 |
| GO:BP | GO:0043242 | negative regulation of protein-containing complex disassembly | 1 | 72 | 6.90e-01 |
| GO:BP | GO:0031668 | cellular response to extracellular stimulus | 2 | 219 | 6.90e-01 |
| GO:BP | GO:0048699 | generation of neurons | 1 | 1119 | 6.90e-01 |
| GO:BP | GO:0046483 | heterocycle metabolic process | 1 | 4570 | 6.90e-01 |
| GO:BP | GO:2001259 | positive regulation of cation channel activity | 1 | 49 | 6.91e-01 |
| GO:BP | GO:0046165 | alcohol biosynthetic process | 1 | 110 | 6.91e-01 |
| GO:BP | GO:1903530 | regulation of secretion by cell | 1 | 382 | 6.92e-01 |
| GO:BP | GO:0034644 | cellular response to UV | 1 | 86 | 6.92e-01 |
| GO:BP | GO:0006725 | cellular aromatic compound metabolic process | 1 | 4596 | 6.93e-01 |
| GO:BP | GO:0065003 | protein-containing complex assembly | 2 | 1335 | 6.94e-01 |
| GO:BP | GO:0001906 | cell killing | 1 | 69 | 6.94e-01 |
| GO:BP | GO:0042246 | tissue regeneration | 1 | 54 | 6.95e-01 |
| GO:BP | GO:0071103 | DNA conformation change | 1 | 87 | 6.95e-01 |
| GO:BP | GO:0014909 | smooth muscle cell migration | 1 | 65 | 6.95e-01 |
| GO:BP | GO:0048525 | negative regulation of viral process | 1 | 64 | 6.97e-01 |
| GO:BP | GO:0070828 | heterochromatin organization | 1 | 77 | 6.97e-01 |
| GO:BP | GO:0044283 | small molecule biosynthetic process | 1 | 425 | 6.98e-01 |
| GO:BP | GO:0002753 | cytosolic pattern recognition receptor signaling pathway | 1 | 68 | 6.99e-01 |
| GO:BP | GO:0042058 | regulation of epidermal growth factor receptor signaling pathway | 1 | 60 | 6.99e-01 |
| GO:BP | GO:0071322 | cellular response to carbohydrate stimulus | 2 | 105 | 7.00e-01 |
| GO:BP | GO:1901888 | regulation of cell junction assembly | 3 | 168 | 7.00e-01 |
| GO:BP | GO:0008277 | regulation of G protein-coupled receptor signaling pathway | 1 | 94 | 7.01e-01 |
| GO:BP | GO:0006909 | phagocytosis | 3 | 148 | 7.02e-01 |
| GO:BP | GO:0010558 | negative regulation of macromolecule biosynthetic process | 1 | 1214 | 7.03e-01 |
| GO:BP | GO:0071674 | mononuclear cell migration | 1 | 102 | 7.04e-01 |
| GO:BP | GO:0046700 | heterocycle catabolic process | 3 | 381 | 7.04e-01 |
| GO:BP | GO:0051051 | negative regulation of transport | 2 | 318 | 7.04e-01 |
| GO:BP | GO:0033108 | mitochondrial respiratory chain complex assembly | 1 | 94 | 7.05e-01 |
| GO:BP | GO:0070613 | regulation of protein processing | 1 | 47 | 7.07e-01 |
| GO:BP | GO:0086003 | cardiac muscle cell contraction | 1 | 67 | 7.08e-01 |
| GO:BP | GO:1901360 | organic cyclic compound metabolic process | 1 | 4747 | 7.09e-01 |
| GO:BP | GO:0051568 | histone H3-K4 methylation | 1 | 57 | 7.09e-01 |
| GO:BP | GO:0018108 | peptidyl-tyrosine phosphorylation | 2 | 256 | 7.09e-01 |
| GO:BP | GO:0051384 | response to glucocorticoid | 1 | 93 | 7.09e-01 |
| GO:BP | GO:0048754 | branching morphogenesis of an epithelial tube | 2 | 121 | 7.09e-01 |
| GO:BP | GO:0106027 | neuron projection organization | 1 | 76 | 7.09e-01 |
| GO:BP | GO:0033002 | muscle cell proliferation | 1 | 157 | 7.09e-01 |
| GO:BP | GO:1904064 | positive regulation of cation transmembrane transport | 2 | 99 | 7.10e-01 |
| GO:BP | GO:0031327 | negative regulation of cellular biosynthetic process | 1 | 1239 | 7.10e-01 |
| GO:BP | GO:0065008 | regulation of biological quality | 6 | 2102 | 7.10e-01 |
| GO:BP | GO:0001678 | intracellular glucose homeostasis | 2 | 110 | 7.10e-01 |
| GO:BP | GO:0018212 | peptidyl-tyrosine modification | 2 | 258 | 7.10e-01 |
| GO:BP | GO:0006469 | negative regulation of protein kinase activity | 1 | 179 | 7.10e-01 |
| GO:BP | GO:0030155 | regulation of cell adhesion | 5 | 539 | 7.11e-01 |
| GO:BP | GO:0045807 | positive regulation of endocytosis | 2 | 104 | 7.11e-01 |
| GO:BP | GO:0010232 | vascular transport | 1 | 72 | 7.11e-01 |
| GO:BP | GO:0072594 | establishment of protein localization to organelle | 3 | 422 | 7.11e-01 |
| GO:BP | GO:0019216 | regulation of lipid metabolic process | 4 | 250 | 7.11e-01 |
| GO:BP | GO:0150104 | transport across blood-brain barrier | 1 | 72 | 7.11e-01 |
| GO:BP | GO:0008544 | epidermis development | 5 | 210 | 7.12e-01 |
| GO:BP | GO:0008064 | regulation of actin polymerization or depolymerization | 1 | 126 | 7.12e-01 |
| GO:BP | GO:0050821 | protein stabilization | 2 | 191 | 7.12e-01 |
| GO:BP | GO:0010720 | positive regulation of cell development | 2 | 317 | 7.12e-01 |
| GO:BP | GO:0030071 | regulation of mitotic metaphase/anaphase transition | 1 | 88 | 7.12e-01 |
| GO:BP | GO:0007420 | brain development | 5 | 591 | 7.12e-01 |
| GO:BP | GO:0035050 | embryonic heart tube development | 1 | 69 | 7.13e-01 |
| GO:BP | GO:0050769 | positive regulation of neurogenesis | 1 | 189 | 7.13e-01 |
| GO:BP | GO:0051851 | modulation by host of symbiont process | 1 | 68 | 7.13e-01 |
| GO:BP | GO:0048477 | oogenesis | 1 | 64 | 7.14e-01 |
| GO:BP | GO:0046626 | regulation of insulin receptor signaling pathway | 1 | 53 | 7.15e-01 |
| GO:BP | GO:0062207 | regulation of pattern recognition receptor signaling pathway | 1 | 68 | 7.15e-01 |
| GO:BP | GO:0006468 | protein phosphorylation | 10 | 1167 | 7.15e-01 |
| GO:BP | GO:0034641 | cellular nitrogen compound metabolic process | 1 | 4946 | 7.15e-01 |
| GO:BP | GO:0015711 | organic anion transport | 5 | 264 | 7.15e-01 |
| GO:BP | GO:0009416 | response to light stimulus | 4 | 246 | 7.15e-01 |
| GO:BP | GO:0060996 | dendritic spine development | 1 | 80 | 7.15e-01 |
| GO:BP | GO:0060047 | heart contraction | 3 | 205 | 7.15e-01 |
| GO:BP | GO:0071230 | cellular response to amino acid stimulus | 1 | 65 | 7.15e-01 |
| GO:BP | GO:0030832 | regulation of actin filament length | 1 | 127 | 7.15e-01 |
| GO:BP | GO:0010508 | positive regulation of autophagy | 1 | 133 | 7.16e-01 |
| GO:BP | GO:0048608 | reproductive structure development | 1 | 212 | 7.18e-01 |
| GO:BP | GO:0051046 | regulation of secretion | 1 | 418 | 7.19e-01 |
| GO:BP | GO:0051588 | regulation of neurotransmitter transport | 1 | 70 | 7.19e-01 |
| GO:BP | GO:0051494 | negative regulation of cytoskeleton organization | 1 | 140 | 7.19e-01 |
| GO:BP | GO:0019058 | viral life cycle | 3 | 244 | 7.19e-01 |
| GO:BP | GO:0009892 | negative regulation of metabolic process | 3 | 2293 | 7.19e-01 |
| GO:BP | GO:0055117 | regulation of cardiac muscle contraction | 1 | 70 | 7.19e-01 |
| GO:BP | GO:0019439 | aromatic compound catabolic process | 3 | 387 | 7.19e-01 |
| GO:BP | GO:1902099 | regulation of metaphase/anaphase transition of cell cycle | 1 | 89 | 7.19e-01 |
| GO:BP | GO:0050731 | positive regulation of peptidyl-tyrosine phosphorylation | 1 | 105 | 7.19e-01 |
| GO:BP | GO:0140888 | interferon-mediated signaling pathway | 1 | 67 | 7.19e-01 |
| GO:BP | GO:0007091 | metaphase/anaphase transition of mitotic cell cycle | 1 | 91 | 7.19e-01 |
| GO:BP | GO:0030705 | cytoskeleton-dependent intracellular transport | 1 | 194 | 7.19e-01 |
| GO:BP | GO:0045666 | positive regulation of neuron differentiation | 1 | 63 | 7.19e-01 |
| GO:BP | GO:0048863 | stem cell differentiation | 3 | 197 | 7.19e-01 |
| GO:BP | GO:0061458 | reproductive system development | 1 | 215 | 7.20e-01 |
| GO:BP | GO:0006366 | transcription by RNA polymerase II | 12 | 1995 | 7.20e-01 |
| GO:BP | GO:0007043 | cell-cell junction assembly | 1 | 105 | 7.20e-01 |
| GO:BP | GO:0032370 | positive regulation of lipid transport | 1 | 58 | 7.20e-01 |
| GO:BP | GO:1902904 | negative regulation of supramolecular fiber organization | 1 | 140 | 7.20e-01 |
| GO:BP | GO:1901184 | regulation of ERBB signaling pathway | 1 | 66 | 7.21e-01 |
| GO:BP | GO:0099111 | microtubule-based transport | 1 | 191 | 7.21e-01 |
| GO:BP | GO:0060395 | SMAD protein signal transduction | 1 | 65 | 7.22e-01 |
| GO:BP | GO:1903317 | regulation of protein maturation | 1 | 50 | 7.22e-01 |
| GO:BP | GO:0014902 | myotube differentiation | 1 | 88 | 7.22e-01 |
| GO:BP | GO:0032922 | circadian regulation of gene expression | 1 | 63 | 7.23e-01 |
| GO:BP | GO:0019915 | lipid storage | 1 | 66 | 7.23e-01 |
| GO:BP | GO:0021536 | diencephalon development | 1 | 41 | 7.23e-01 |
| GO:BP | GO:0042098 | T cell proliferation | 1 | 120 | 7.23e-01 |
| GO:BP | GO:0042593 | glucose homeostasis | 3 | 168 | 7.23e-01 |
| GO:BP | GO:0051092 | positive regulation of NF-kappaB transcription factor activity | 1 | 116 | 7.23e-01 |
| GO:BP | GO:0006865 | amino acid transport | 1 | 102 | 7.23e-01 |
| GO:BP | GO:0050804 | modulation of chemical synaptic transmission | 1 | 341 | 7.24e-01 |
| GO:BP | GO:0099177 | regulation of trans-synaptic signaling | 1 | 342 | 7.24e-01 |
| GO:BP | GO:0007098 | centrosome cycle | 1 | 127 | 7.24e-01 |
| GO:BP | GO:0090407 | organophosphate biosynthetic process | 7 | 506 | 7.24e-01 |
| GO:BP | GO:0016079 | synaptic vesicle exocytosis | 1 | 74 | 7.24e-01 |
| GO:BP | GO:0033500 | carbohydrate homeostasis | 3 | 169 | 7.24e-01 |
| GO:BP | GO:0016310 | phosphorylation | 6 | 1372 | 7.25e-01 |
| GO:BP | GO:0044784 | metaphase/anaphase transition of cell cycle | 1 | 92 | 7.25e-01 |
| GO:BP | GO:0030041 | actin filament polymerization | 1 | 134 | 7.25e-01 |
| GO:BP | GO:0035082 | axoneme assembly | 1 | 52 | 7.27e-01 |
| GO:BP | GO:0010466 | negative regulation of peptidase activity | 1 | 131 | 7.28e-01 |
| GO:BP | GO:0097191 | extrinsic apoptotic signaling pathway | 1 | 179 | 7.30e-01 |
| GO:BP | GO:0019882 | antigen processing and presentation | 1 | 69 | 7.30e-01 |
| GO:BP | GO:0010467 | gene expression | 1 | 4587 | 7.30e-01 |
| GO:BP | GO:0046942 | carboxylic acid transport | 4 | 216 | 7.30e-01 |
| GO:BP | GO:0062197 | cellular response to chemical stress | 2 | 293 | 7.32e-01 |
| GO:BP | GO:0015849 | organic acid transport | 4 | 217 | 7.32e-01 |
| GO:BP | GO:0036503 | ERAD pathway | 1 | 106 | 7.32e-01 |
| GO:BP | GO:0002456 | T cell mediated immunity | 1 | 53 | 7.32e-01 |
| GO:BP | GO:0050905 | neuromuscular process | 1 | 107 | 7.33e-01 |
| GO:BP | GO:0002685 | regulation of leukocyte migration | 1 | 131 | 7.33e-01 |
| GO:BP | GO:0016573 | histone acetylation | 2 | 143 | 7.33e-01 |
| GO:BP | GO:0051952 | regulation of amine transport | 1 | 55 | 7.34e-01 |
| GO:BP | GO:0010959 | regulation of metal ion transport | 2 | 275 | 7.34e-01 |
| GO:BP | GO:0033673 | negative regulation of kinase activity | 1 | 197 | 7.34e-01 |
| GO:BP | GO:1903522 | regulation of blood circulation | 3 | 198 | 7.34e-01 |
| GO:BP | GO:0006665 | sphingolipid metabolic process | 1 | 131 | 7.34e-01 |
| GO:BP | GO:2001234 | negative regulation of apoptotic signaling pathway | 1 | 194 | 7.37e-01 |
| GO:BP | GO:0001942 | hair follicle development | 1 | 67 | 7.38e-01 |
| GO:BP | GO:0071229 | cellular response to acid chemical | 1 | 71 | 7.39e-01 |
| GO:BP | GO:0051707 | response to other organism | 7 | 820 | 7.40e-01 |
| GO:BP | GO:0043122 | regulation of I-kappaB kinase/NF-kappaB signaling | 2 | 203 | 7.41e-01 |
| GO:BP | GO:0043207 | response to external biotic stimulus | 7 | 820 | 7.42e-01 |
| GO:BP | GO:0002831 | regulation of response to biotic stimulus | 4 | 293 | 7.45e-01 |
| GO:BP | GO:0023051 | regulation of signaling | 5 | 2565 | 7.45e-01 |
| GO:BP | GO:0051279 | regulation of release of sequestered calcium ion into cytosol | 1 | 60 | 7.46e-01 |
| GO:BP | GO:0048878 | chemical homeostasis | 1 | 676 | 7.46e-01 |
| GO:BP | GO:0022900 | electron transport chain | 1 | 142 | 7.46e-01 |
| GO:BP | GO:0010646 | regulation of cell communication | 5 | 2573 | 7.47e-01 |
| GO:BP | GO:0035249 | synaptic transmission, glutamatergic | 1 | 64 | 7.47e-01 |
| GO:BP | GO:0035282 | segmentation | 1 | 75 | 7.47e-01 |
| GO:BP | GO:0022405 | hair cycle process | 1 | 69 | 7.47e-01 |
| GO:BP | GO:0022404 | molting cycle process | 1 | 69 | 7.47e-01 |
| GO:BP | GO:0030500 | regulation of bone mineralization | 1 | 53 | 7.47e-01 |
| GO:BP | GO:0033045 | regulation of sister chromatid segregation | 1 | 99 | 7.49e-01 |
| GO:BP | GO:1901361 | organic cyclic compound catabolic process | 3 | 406 | 7.49e-01 |
| GO:BP | GO:0010941 | regulation of cell death | 7 | 1219 | 7.49e-01 |
| GO:BP | GO:0046425 | regulation of receptor signaling pathway via JAK-STAT | 1 | 52 | 7.49e-01 |
| GO:BP | GO:0003012 | muscle system process | 5 | 334 | 7.49e-01 |
| GO:BP | GO:0098742 | cell-cell adhesion via plasma-membrane adhesion molecules | 1 | 168 | 7.50e-01 |
| GO:BP | GO:0031023 | microtubule organizing center organization | 1 | 137 | 7.50e-01 |
| GO:BP | GO:0051234 | establishment of localization | 23 | 3433 | 7.50e-01 |
| GO:BP | GO:0070646 | protein modification by small protein removal | 2 | 147 | 7.52e-01 |
| GO:BP | GO:0018393 | internal peptidyl-lysine acetylation | 2 | 148 | 7.52e-01 |
| GO:BP | GO:0051093 | negative regulation of developmental process | 9 | 665 | 7.55e-01 |
| GO:BP | GO:0000165 | MAPK cascade | 5 | 556 | 7.55e-01 |
| GO:BP | GO:0042127 | regulation of cell population proliferation | 1 | 1147 | 7.55e-01 |
| GO:BP | GO:0043409 | negative regulation of MAPK cascade | 2 | 145 | 7.55e-01 |
| GO:BP | GO:0042391 | regulation of membrane potential | 5 | 293 | 7.57e-01 |
| GO:BP | GO:0098609 | cell-cell adhesion | 4 | 609 | 7.57e-01 |
| GO:BP | GO:0006475 | internal protein amino acid acetylation | 2 | 150 | 7.57e-01 |
| GO:BP | GO:0006941 | striated muscle contraction | 2 | 152 | 7.57e-01 |
| GO:BP | GO:0061097 | regulation of protein tyrosine kinase activity | 1 | 65 | 7.57e-01 |
| GO:BP | GO:0006304 | DNA modification | 1 | 89 | 7.57e-01 |
| GO:BP | GO:0008015 | blood circulation | 6 | 374 | 7.57e-01 |
| GO:BP | GO:0031099 | regeneration | 2 | 142 | 7.57e-01 |
| GO:BP | GO:0009607 | response to biotic stimulus | 7 | 850 | 7.60e-01 |
| GO:BP | GO:0042326 | negative regulation of phosphorylation | 2 | 300 | 7.60e-01 |
| GO:BP | GO:0014070 | response to organic cyclic compound | 1 | 640 | 7.60e-01 |
| GO:BP | GO:0031214 | biomineral tissue development | 1 | 111 | 7.60e-01 |
| GO:BP | GO:0061138 | morphogenesis of a branching epithelium | 1 | 143 | 7.60e-01 |
| GO:BP | GO:0022604 | regulation of cell morphogenesis | 3 | 220 | 7.60e-01 |
| GO:BP | GO:0007517 | muscle organ development | 4 | 277 | 7.60e-01 |
| GO:BP | GO:0034767 | positive regulation of monoatomic ion transmembrane transport | 2 | 114 | 7.60e-01 |
| GO:BP | GO:0032147 | activation of protein kinase activity | 1 | 82 | 7.61e-01 |
| GO:BP | GO:0001657 | ureteric bud development | 1 | 75 | 7.62e-01 |
| GO:BP | GO:0051962 | positive regulation of nervous system development | 1 | 221 | 7.62e-01 |
| GO:BP | GO:0006641 | triglyceride metabolic process | 1 | 68 | 7.62e-01 |
| GO:BP | GO:0019080 | viral gene expression | 1 | 96 | 7.63e-01 |
| GO:BP | GO:0032412 | regulation of monoatomic ion transmembrane transporter activity | 3 | 190 | 7.63e-01 |
| GO:BP | GO:0045333 | cellular respiration | 2 | 211 | 7.63e-01 |
| GO:BP | GO:0006810 | transport | 22 | 3298 | 7.63e-01 |
| GO:BP | GO:1904892 | regulation of receptor signaling pathway via STAT | 1 | 54 | 7.64e-01 |
| GO:BP | GO:0072164 | mesonephric tubule development | 1 | 76 | 7.64e-01 |
| GO:BP | GO:0072163 | mesonephric epithelium development | 1 | 76 | 7.64e-01 |
| GO:BP | GO:0043066 | negative regulation of apoptotic process | 11 | 660 | 7.66e-01 |
| GO:BP | GO:0043588 | skin development | 3 | 175 | 7.67e-01 |
| GO:BP | GO:0032456 | endocytic recycling | 1 | 80 | 7.67e-01 |
| GO:BP | GO:0044237 | cellular metabolic process | 2 | 6996 | 7.67e-01 |
| GO:BP | GO:0009966 | regulation of signal transduction | 4 | 2285 | 7.67e-01 |
| GO:BP | GO:0070661 | leukocyte proliferation | 2 | 188 | 7.67e-01 |
| GO:BP | GO:0048583 | regulation of response to stimulus | 6 | 2890 | 7.68e-01 |
| GO:BP | GO:0006094 | gluconeogenesis | 1 | 67 | 7.68e-01 |
| GO:BP | GO:0045088 | regulation of innate immune response | 3 | 232 | 7.71e-01 |
| GO:BP | GO:0046631 | alpha-beta T cell activation | 1 | 89 | 7.71e-01 |
| GO:BP | GO:0006066 | alcohol metabolic process | 2 | 265 | 7.71e-01 |
| GO:BP | GO:0097553 | calcium ion transmembrane import into cytosol | 2 | 115 | 7.73e-01 |
| GO:BP | GO:0000245 | spliceosomal complex assembly | 1 | 73 | 7.75e-01 |
| GO:BP | GO:0001823 | mesonephros development | 1 | 77 | 7.76e-01 |
| GO:BP | GO:0006357 | regulation of transcription by RNA polymerase II | 3 | 1914 | 7.76e-01 |
| GO:BP | GO:0031589 | cell-substrate adhesion | 2 | 281 | 7.77e-01 |
| GO:BP | GO:0071482 | cellular response to light stimulus | 1 | 99 | 7.77e-01 |
| GO:BP | GO:0008219 | cell death | 9 | 1596 | 7.77e-01 |
| GO:BP | GO:0006952 | defense response | 1 | 944 | 7.77e-01 |
| GO:BP | GO:0019319 | hexose biosynthetic process | 1 | 70 | 7.78e-01 |
| GO:BP | GO:0071496 | cellular response to external stimulus | 2 | 270 | 7.78e-01 |
| GO:BP | GO:0006942 | regulation of striated muscle contraction | 1 | 85 | 7.78e-01 |
| GO:BP | GO:1903169 | regulation of calcium ion transmembrane transport | 2 | 122 | 7.78e-01 |
| GO:BP | GO:0018394 | peptidyl-lysine acetylation | 2 | 160 | 7.78e-01 |
| GO:BP | GO:0009612 | response to mechanical stimulus | 1 | 158 | 7.78e-01 |
| GO:BP | GO:0043484 | regulation of RNA splicing | 2 | 164 | 7.78e-01 |
| GO:BP | GO:1905954 | positive regulation of lipid localization | 1 | 75 | 7.80e-01 |
| GO:BP | GO:0061337 | cardiac conduction | 1 | 88 | 7.80e-01 |
| GO:BP | GO:0001763 | morphogenesis of a branching structure | 1 | 154 | 7.80e-01 |
| GO:BP | GO:0032963 | collagen metabolic process | 1 | 74 | 7.80e-01 |
| GO:BP | GO:0051348 | negative regulation of transferase activity | 1 | 234 | 7.80e-01 |
| GO:BP | GO:0022898 | regulation of transmembrane transporter activity | 3 | 199 | 7.82e-01 |
| GO:BP | GO:0043473 | pigmentation | 1 | 92 | 7.83e-01 |
| GO:BP | GO:0001676 | long-chain fatty acid metabolic process | 1 | 65 | 7.85e-01 |
| GO:BP | GO:0044403 | biological process involved in symbiotic interaction | 1 | 223 | 7.88e-01 |
| GO:BP | GO:0043069 | negative regulation of programmed cell death | 11 | 678 | 7.88e-01 |
| GO:BP | GO:0006493 | protein O-linked glycosylation | 1 | 69 | 7.91e-01 |
| GO:BP | GO:0002521 | leukocyte differentiation | 4 | 382 | 7.94e-01 |
| GO:BP | GO:0008202 | steroid metabolic process | 2 | 204 | 7.94e-01 |
| GO:BP | GO:0048523 | negative regulation of cellular process | 19 | 3625 | 7.95e-01 |
| GO:BP | GO:0043244 | regulation of protein-containing complex disassembly | 1 | 113 | 7.96e-01 |
| GO:BP | GO:0007608 | sensory perception of smell | 2 | 16 | 7.97e-01 |
| GO:BP | GO:0007162 | negative regulation of cell adhesion | 1 | 192 | 7.98e-01 |
| GO:BP | GO:0042303 | molting cycle | 1 | 78 | 8.04e-01 |
| GO:BP | GO:0042633 | hair cycle | 1 | 78 | 8.04e-01 |
| GO:BP | GO:0010721 | negative regulation of cell development | 1 | 191 | 8.06e-01 |
| GO:BP | GO:0008283 | cell population proliferation | 1 | 1378 | 8.06e-01 |
| GO:BP | GO:0034330 | cell junction organization | 4 | 575 | 8.06e-01 |
| GO:BP | GO:0051049 | regulation of transport | 7 | 1267 | 8.06e-01 |
| GO:BP | GO:0001578 | microtubule bundle formation | 1 | 79 | 8.07e-01 |
| GO:BP | GO:0046364 | monosaccharide biosynthetic process | 1 | 79 | 8.07e-01 |
| GO:BP | GO:0050730 | regulation of peptidyl-tyrosine phosphorylation | 1 | 166 | 8.08e-01 |
| GO:BP | GO:0051983 | regulation of chromosome segregation | 1 | 121 | 8.08e-01 |
| GO:BP | GO:1902074 | response to salt | 2 | 271 | 8.08e-01 |
| GO:BP | GO:0050900 | leukocyte migration | 2 | 209 | 8.08e-01 |
| GO:BP | GO:0051702 | biological process involved in interaction with symbiont | 1 | 78 | 8.10e-01 |
| GO:BP | GO:0001818 | negative regulation of cytokine production | 2 | 165 | 8.12e-01 |
| GO:BP | GO:1903305 | regulation of regulated secretory pathway | 1 | 89 | 8.12e-01 |
| GO:BP | GO:0032409 | regulation of transporter activity | 3 | 211 | 8.13e-01 |
| GO:BP | GO:0008016 | regulation of heart contraction | 2 | 173 | 8.15e-01 |
| GO:BP | GO:0045089 | positive regulation of innate immune response | 1 | 182 | 8.15e-01 |
| GO:BP | GO:0044057 | regulation of system process | 5 | 405 | 8.18e-01 |
| GO:BP | GO:0048585 | negative regulation of response to stimulus | 2 | 1248 | 8.20e-01 |
| GO:BP | GO:0045936 | negative regulation of phosphate metabolic process | 2 | 344 | 8.20e-01 |
| GO:BP | GO:0044419 | biological process involved in interspecies interaction between organisms | 7 | 963 | 8.20e-01 |
| GO:BP | GO:0010563 | negative regulation of phosphorus metabolic process | 2 | 345 | 8.21e-01 |
| GO:BP | GO:0006979 | response to oxidative stress | 2 | 352 | 8.25e-01 |
| GO:BP | GO:0030168 | platelet activation | 1 | 91 | 8.25e-01 |
| GO:BP | GO:0030001 | metal ion transport | 4 | 562 | 8.25e-01 |
| GO:BP | GO:0016043 | cellular component organization | 13 | 5076 | 8.26e-01 |
| GO:BP | GO:0098656 | monoatomic anion transmembrane transport | 1 | 71 | 8.26e-01 |
| GO:BP | GO:0046651 | lymphocyte proliferation | 1 | 162 | 8.26e-01 |
| GO:BP | GO:0051172 | negative regulation of nitrogen compound metabolic process | 1 | 1849 | 8.26e-01 |
| GO:BP | GO:0007165 | signal transduction | 8 | 3818 | 8.28e-01 |
| GO:BP | GO:0043200 | response to amino acid | 1 | 95 | 8.28e-01 |
| GO:BP | GO:0045667 | regulation of osteoblast differentiation | 1 | 99 | 8.30e-01 |
| GO:BP | GO:0001933 | negative regulation of protein phosphorylation | 1 | 277 | 8.31e-01 |
| GO:BP | GO:0031399 | regulation of protein modification process | 19 | 1173 | 8.31e-01 |
| GO:BP | GO:0006639 | acylglycerol metabolic process | 1 | 92 | 8.31e-01 |
| GO:BP | GO:0032943 | mononuclear cell proliferation | 1 | 168 | 8.31e-01 |
| GO:BP | GO:0007292 | female gamete generation | 1 | 103 | 8.32e-01 |
| GO:BP | GO:0006638 | neutral lipid metabolic process | 1 | 93 | 8.33e-01 |
| GO:BP | GO:0030218 | erythrocyte differentiation | 1 | 107 | 8.34e-01 |
| GO:BP | GO:0048813 | dendrite morphogenesis | 1 | 120 | 8.34e-01 |
| GO:BP | GO:0023052 | signaling | 13 | 4141 | 8.36e-01 |
| GO:BP | GO:0002833 | positive regulation of response to biotic stimulus | 1 | 192 | 8.36e-01 |
| GO:BP | GO:1903828 | negative regulation of protein localization | 2 | 160 | 8.37e-01 |
| GO:BP | GO:0032414 | positive regulation of ion transmembrane transporter activity | 1 | 85 | 8.39e-01 |
| GO:BP | GO:0006807 | nitrogen compound metabolic process | 2 | 7441 | 8.39e-01 |
| GO:BP | GO:0002573 | myeloid leukocyte differentiation | 1 | 151 | 8.41e-01 |
| GO:BP | GO:0042981 | regulation of apoptotic process | 8 | 1088 | 8.42e-01 |
| GO:BP | GO:1903531 | negative regulation of secretion by cell | 1 | 99 | 8.45e-01 |
| GO:BP | GO:0051101 | regulation of DNA binding | 1 | 104 | 8.46e-01 |
| GO:BP | GO:0031644 | regulation of nervous system process | 1 | 90 | 8.47e-01 |
| GO:BP | GO:0007160 | cell-matrix adhesion | 1 | 179 | 8.48e-01 |
| GO:BP | GO:0099587 | inorganic ion import across plasma membrane | 1 | 73 | 8.48e-01 |
| GO:BP | GO:0098659 | inorganic cation import across plasma membrane | 1 | 73 | 8.48e-01 |
| GO:BP | GO:0030518 | intracellular steroid hormone receptor signaling pathway | 1 | 95 | 8.48e-01 |
| GO:BP | GO:0032879 | regulation of localization | 8 | 1555 | 8.49e-01 |
| GO:BP | GO:0010976 | positive regulation of neuron projection development | 1 | 131 | 8.50e-01 |
| GO:BP | GO:0045596 | negative regulation of cell differentiation | 7 | 482 | 8.50e-01 |
| GO:BP | GO:0034101 | erythrocyte homeostasis | 1 | 114 | 8.51e-01 |
| GO:BP | GO:0034329 | cell junction assembly | 2 | 344 | 8.52e-01 |
| GO:BP | GO:0050794 | regulation of cellular process | 1 | 7552 | 8.52e-01 |
| GO:BP | GO:0016579 | protein deubiquitination | 1 | 129 | 8.53e-01 |
| GO:BP | GO:0032543 | mitochondrial translation | 1 | 130 | 8.54e-01 |
| GO:BP | GO:0009968 | negative regulation of signal transduction | 10 | 1006 | 8.56e-01 |
| GO:BP | GO:0007154 | cell communication | 13 | 4226 | 8.56e-01 |
| GO:BP | GO:0043067 | regulation of programmed cell death | 8 | 1111 | 8.57e-01 |
| GO:BP | GO:0043170 | macromolecule metabolic process | 2 | 7069 | 8.58e-01 |
| GO:BP | GO:0051209 | release of sequestered calcium ion into cytosol | 1 | 82 | 8.58e-01 |
| GO:BP | GO:0051716 | cellular response to stimulus | 10 | 4953 | 8.58e-01 |
| GO:BP | GO:0034728 | nucleosome organization | 1 | 98 | 8.58e-01 |
| GO:BP | GO:0043123 | positive regulation of I-kappaB kinase/NF-kappaB signaling | 1 | 153 | 8.58e-01 |
| GO:BP | GO:0001101 | response to acid chemical | 1 | 105 | 8.58e-01 |
| GO:BP | GO:0071840 | cellular component organization or biogenesis | 13 | 5274 | 8.59e-01 |
| GO:BP | GO:0051283 | negative regulation of sequestering of calcium ion | 1 | 83 | 8.59e-01 |
| GO:BP | GO:0007606 | sensory perception of chemical stimulus | 2 | 31 | 8.59e-01 |
| GO:BP | GO:0008203 | cholesterol metabolic process | 1 | 101 | 8.60e-01 |
| GO:BP | GO:0032411 | positive regulation of transporter activity | 1 | 93 | 8.60e-01 |
| GO:BP | GO:0007189 | adenylate cyclase-activating G protein-coupled receptor signaling pathway | 1 | 78 | 8.61e-01 |
| GO:BP | GO:0051282 | regulation of sequestering of calcium ion | 1 | 85 | 8.62e-01 |
| GO:BP | GO:0030282 | bone mineralization | 1 | 82 | 8.63e-01 |
| GO:BP | GO:0048513 | animal organ development | 32 | 2189 | 8.63e-01 |
| GO:BP | GO:0050868 | negative regulation of T cell activation | 1 | 67 | 8.64e-01 |
| GO:BP | GO:0060548 | negative regulation of cell death | 5 | 756 | 8.64e-01 |
| GO:BP | GO:0051224 | negative regulation of protein transport | 1 | 91 | 8.64e-01 |
| GO:BP | GO:0006911 | phagocytosis, engulfment | 1 | 33 | 8.65e-01 |
| GO:BP | GO:0006915 | apoptotic process | 7 | 1443 | 8.65e-01 |
| GO:BP | GO:0006820 | monoatomic anion transport | 1 | 83 | 8.67e-01 |
| GO:BP | GO:0051208 | sequestering of calcium ion | 1 | 89 | 8.69e-01 |
| GO:BP | GO:0002221 | pattern recognition receptor signaling pathway | 1 | 115 | 8.70e-01 |
| GO:BP | GO:0050806 | positive regulation of synaptic transmission | 1 | 106 | 8.73e-01 |
| GO:BP | GO:0031400 | negative regulation of protein modification process | 5 | 418 | 8.73e-01 |
| GO:BP | GO:0060326 | cell chemotaxis | 1 | 162 | 8.74e-01 |
| GO:BP | GO:0009410 | response to xenobiotic stimulus | 4 | 279 | 8.74e-01 |
| GO:BP | GO:0051179 | localization | 24 | 3969 | 8.75e-01 |
| GO:BP | GO:1902652 | secondary alcohol metabolic process | 1 | 108 | 8.77e-01 |
| GO:BP | GO:0050777 | negative regulation of immune response | 1 | 111 | 8.77e-01 |
| GO:BP | GO:0043269 | regulation of monoatomic ion transport | 2 | 373 | 8.77e-01 |
| GO:BP | GO:0051048 | negative regulation of secretion | 1 | 111 | 8.79e-01 |
| GO:BP | GO:0050728 | negative regulation of inflammatory response | 1 | 87 | 8.79e-01 |
| GO:BP | GO:0002683 | negative regulation of immune system process | 3 | 289 | 8.79e-01 |
| GO:BP | GO:0099024 | plasma membrane invagination | 1 | 42 | 8.81e-01 |
| GO:BP | GO:0070588 | calcium ion transmembrane transport | 3 | 213 | 8.82e-01 |
| GO:BP | GO:0050727 | regulation of inflammatory response | 3 | 212 | 8.82e-01 |
| GO:BP | GO:0050896 | response to stimulus | 5 | 5770 | 8.82e-01 |
| GO:BP | GO:0012501 | programmed cell death | 7 | 1479 | 8.82e-01 |
| GO:BP | GO:0030509 | BMP signaling pathway | 1 | 123 | 8.84e-01 |
| GO:BP | GO:0030317 | flagellated sperm motility | 1 | 61 | 8.85e-01 |
| GO:BP | GO:0097722 | sperm motility | 1 | 61 | 8.85e-01 |
| GO:BP | GO:0001508 | action potential | 1 | 105 | 8.85e-01 |
| GO:BP | GO:0031347 | regulation of defense response | 5 | 448 | 8.86e-01 |
| GO:BP | GO:0007369 | gastrulation | 1 | 146 | 8.86e-01 |
| GO:BP | GO:0071824 | protein-DNA complex subunit organization | 2 | 204 | 8.88e-01 |
| GO:BP | GO:0010629 | negative regulation of gene expression | 4 | 785 | 8.89e-01 |
| GO:BP | GO:0044092 | negative regulation of molecular function | 3 | 755 | 8.89e-01 |
| GO:BP | GO:0002758 | innate immune response-activating signaling pathway | 1 | 122 | 8.90e-01 |
| GO:BP | GO:0010324 | membrane invagination | 1 | 49 | 8.91e-01 |
| GO:BP | GO:0042445 | hormone metabolic process | 1 | 133 | 8.91e-01 |
| GO:BP | GO:0035725 | sodium ion transmembrane transport | 1 | 113 | 8.93e-01 |
| GO:BP | GO:0098542 | defense response to other organism | 4 | 608 | 8.94e-01 |
| GO:BP | GO:0009165 | nucleotide biosynthetic process | 1 | 240 | 8.97e-01 |
| GO:BP | GO:0046661 | male sex differentiation | 1 | 114 | 8.97e-01 |
| GO:BP | GO:0071772 | response to BMP | 1 | 131 | 8.98e-01 |
| GO:BP | GO:0045087 | innate immune response | 3 | 488 | 8.98e-01 |
| GO:BP | GO:0044238 | primary metabolic process | 2 | 7806 | 8.98e-01 |
| GO:BP | GO:0071773 | cellular response to BMP stimulus | 1 | 131 | 8.98e-01 |
| GO:BP | GO:0023057 | negative regulation of signaling | 1 | 1076 | 8.98e-01 |
| GO:BP | GO:0010648 | negative regulation of cell communication | 1 | 1074 | 8.98e-01 |
| GO:BP | GO:1901293 | nucleoside phosphate biosynthetic process | 1 | 241 | 8.98e-01 |
| GO:BP | GO:0002262 | myeloid cell homeostasis | 1 | 140 | 8.98e-01 |
| GO:BP | GO:0006869 | lipid transport | 1 | 272 | 8.98e-01 |
| GO:BP | GO:0140053 | mitochondrial gene expression | 1 | 162 | 8.99e-01 |
| GO:BP | GO:0015698 | inorganic anion transport | 1 | 104 | 8.99e-01 |
| GO:BP | GO:0031056 | regulation of histone modification | 1 | 125 | 8.99e-01 |
| GO:BP | GO:0031331 | positive regulation of cellular catabolic process | 2 | 277 | 8.99e-01 |
| GO:BP | GO:0048519 | negative regulation of biological process | 19 | 4045 | 8.99e-01 |
| GO:BP | GO:0006812 | monoatomic cation transport | 4 | 669 | 8.99e-01 |
| GO:BP | GO:0031349 | positive regulation of defense response | 1 | 251 | 9.00e-01 |
| GO:BP | GO:0051924 | regulation of calcium ion transport | 2 | 172 | 9.01e-01 |
| GO:BP | GO:0010605 | negative regulation of macromolecule metabolic process | 1 | 2135 | 9.12e-01 |
| GO:BP | GO:0009617 | response to bacterium | 2 | 321 | 9.13e-01 |
| GO:BP | GO:0002218 | activation of innate immune response | 1 | 142 | 9.13e-01 |
| GO:BP | GO:0007186 | G protein-coupled receptor signaling pathway | 6 | 389 | 9.14e-01 |
| GO:BP | GO:0051250 | negative regulation of lymphocyte activation | 1 | 90 | 9.16e-01 |
| GO:BP | GO:0010876 | lipid localization | 1 | 310 | 9.21e-01 |
| GO:BP | GO:0035195 | miRNA-mediated gene silencing | 1 | 55 | 9.22e-01 |
| GO:BP | GO:0035194 | ncRNA-mediated post-transcriptional gene silencing | 1 | 60 | 9.24e-01 |
| GO:BP | GO:0043433 | negative regulation of DNA-binding transcription factor activity | 1 | 138 | 9.25e-01 |
| GO:BP | GO:0016441 | post-transcriptional gene silencing | 1 | 65 | 9.26e-01 |
| GO:BP | GO:0001764 | neuron migration | 1 | 133 | 9.26e-01 |
| GO:BP | GO:0034762 | regulation of transmembrane transport | 5 | 391 | 9.29e-01 |
| GO:BP | GO:0007155 | cell adhesion | 7 | 1012 | 9.30e-01 |
| GO:BP | GO:0050789 | regulation of biological process | 1 | 8061 | 9.32e-01 |
| GO:BP | GO:0007601 | visual perception | 1 | 96 | 9.39e-01 |
| GO:BP | GO:0050953 | sensory perception of light stimulus | 1 | 97 | 9.41e-01 |
| GO:BP | GO:0006816 | calcium ion transport | 1 | 269 | 9.41e-01 |
| GO:BP | GO:0009152 | purine ribonucleotide biosynthetic process | 1 | 179 | 9.41e-01 |
| GO:BP | GO:0031047 | RNA-mediated gene silencing | 1 | 103 | 9.42e-01 |
| GO:BP | GO:0016358 | dendrite development | 1 | 202 | 9.44e-01 |
| GO:BP | GO:0002695 | negative regulation of leukocyte activation | 1 | 105 | 9.49e-01 |
| GO:BP | GO:0051248 | negative regulation of protein metabolic process | 4 | 816 | 9.49e-01 |
| GO:BP | GO:0007188 | adenylate cyclase-modulating G protein-coupled receptor signaling pathway | 1 | 118 | 9.50e-01 |
| GO:BP | GO:0009260 | ribonucleotide biosynthetic process | 1 | 191 | 9.51e-01 |
| GO:BP | GO:0006396 | RNA processing | 1 | 929 | 9.53e-01 |
| GO:BP | GO:0010608 | post-transcriptional regulation of gene expression | 4 | 468 | 9.55e-01 |
| GO:BP | GO:0046390 | ribose phosphate biosynthetic process | 1 | 197 | 9.55e-01 |
| GO:BP | GO:1904062 | regulation of monoatomic cation transmembrane transport | 2 | 230 | 9.56e-01 |
| GO:BP | GO:0065007 | biological regulation | 1 | 8320 | 9.58e-01 |
| GO:BP | GO:0006811 | monoatomic ion transport | 4 | 775 | 9.59e-01 |
| GO:BP | GO:0050866 | negative regulation of cell activation | 1 | 124 | 9.63e-01 |
| GO:BP | GO:0050877 | nervous system process | 6 | 634 | 9.63e-01 |
| GO:BP | GO:0055085 | transmembrane transport | 1 | 998 | 9.66e-01 |
| GO:BP | GO:0006164 | purine nucleotide biosynthetic process | 1 | 209 | 9.69e-01 |
| GO:BP | GO:0065004 | protein-DNA complex assembly | 1 | 185 | 9.69e-01 |
| GO:BP | GO:0072522 | purine-containing compound biosynthetic process | 1 | 218 | 9.72e-01 |
| GO:BP | GO:0007548 | sex differentiation | 1 | 191 | 9.79e-01 |
| GO:BP | GO:0051606 | detection of stimulus | 1 | 110 | 9.88e-01 |
| GO:BP | GO:0006874 | intracellular calcium ion homeostasis | 1 | 200 | 9.91e-01 |
| GO:BP | GO:0007600 | sensory perception | 2 | 269 | 9.94e-01 |
| GO:BP | GO:0034765 | regulation of monoatomic ion transmembrane transport | 2 | 295 | 9.95e-01 |
| GO:BP | GO:0000375 | RNA splicing, via transesterification reactions | 2 | 293 | 9.95e-01 |
| GO:BP | GO:0000377 | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 2 | 289 | 9.95e-01 |
| GO:BP | GO:0000398 | mRNA splicing, via spliceosome | 2 | 289 | 9.95e-01 |
| GO:BP | GO:0055074 | calcium ion homeostasis | 1 | 214 | 9.95e-01 |
| GO:BP | GO:0000387 | spliceosomal snRNP assembly | 1 | 45 | 9.95e-01 |
| GO:BP | GO:0098662 | inorganic cation transmembrane transport | 1 | 517 | 9.98e-01 |
| GO:BP | GO:0003008 | system process | 8 | 1189 | 9.98e-01 |
| GO:BP | GO:0008380 | RNA splicing | 2 | 419 | 9.98e-01 |
| GO:BP | GO:0098655 | monoatomic cation transmembrane transport | 1 | 540 | 9.98e-01 |
| GO:BP | GO:0006397 | mRNA processing | 2 | 450 | 9.98e-01 |
| GO:BP | GO:0022613 | ribonucleoprotein complex biogenesis | 2 | 453 | 9.99e-01 |
| GO:BP | GO:0098660 | inorganic ion transmembrane transport | 1 | 563 | 9.99e-01 |
| GO:BP | GO:0022618 | ribonucleoprotein complex assembly | 1 | 203 | 1.00e+00 |
| GO:BP | GO:0071826 | ribonucleoprotein complex subunit organization | 1 | 211 | 1.00e+00 |
| GO:BP | GO:0016071 | mRNA metabolic process | 2 | 665 | 1.00e+00 |
| GO:BP | GO:0034220 | monoatomic ion transmembrane transport | 1 | 632 | 1.00e+00 |
| GO:BP | GO:0098771 | inorganic ion homeostasis | 1 | 351 | 1.00e+00 |
| GO:BP | GO:0008152 | metabolic process | 1 | 8518 | 1.00e+00 |
| GO:BP | GO:0008150 | biological_process | 1 | 12070 | 1.00e+00 |
| GO:BP | GO:0009987 | cellular process | 1 | 11336 | 1.00e+00 |
| GO:BP | GO:0000244 | spliceosomal tri-snRNP complex assembly | 1 | 20 | 1.00e+00 |
| GO:BP | GO:0071704 | organic substance metabolic process | 1 | 8169 | 1.00e+00 |
| KEGG | KEGG:04360 | Axon guidance | 6 | 162 | 1.10e-01 |
| KEGG | KEGG:04071 | Sphingolipid signaling pathway | 5 | 107 | 1.10e-01 |
| KEGG | KEGG:04370 | VEGF signaling pathway | 4 | 49 | 1.10e-01 |
| KEGG | KEGG:00534 | Glycosaminoglycan biosynthesis - heparan sulfate / heparin | 1 | 20 | 1.68e-01 |
| KEGG | KEGG:04726 | Serotonergic synapse | 3 | 63 | 1.68e-01 |
| KEGG | KEGG:05135 | Yersinia infection | 4 | 112 | 1.68e-01 |
| KEGG | KEGG:04015 | Rap1 signaling pathway | 5 | 164 | 1.68e-01 |
| KEGG | KEGG:04810 | Regulation of actin cytoskeleton | 6 | 179 | 1.68e-01 |
| KEGG | KEGG:04664 | Fc epsilon RI signaling pathway | 3 | 46 | 1.68e-01 |
| KEGG | KEGG:04935 | Growth hormone synthesis, secretion and action | 4 | 98 | 1.68e-01 |
| KEGG | KEGG:04933 | AGE-RAGE signaling pathway in diabetic complications | 3 | 91 | 1.68e-01 |
| KEGG | KEGG:04660 | T cell receptor signaling pathway | 3 | 70 | 1.68e-01 |
| KEGG | KEGG:04371 | Apelin signaling pathway | 4 | 106 | 1.68e-01 |
| KEGG | KEGG:01250 | Biosynthesis of nucleotide sugars | 3 | 35 | 1.68e-01 |
| KEGG | KEGG:03450 | Non-homologous end-joining | 2 | 12 | 1.68e-01 |
| KEGG | KEGG:05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 3 | 69 | 1.68e-01 |
| KEGG | KEGG:04072 | Phospholipase D signaling pathway | 6 | 110 | 1.68e-01 |
| KEGG | KEGG:04510 | Focal adhesion | 5 | 177 | 1.68e-01 |
| KEGG | KEGG:04062 | Chemokine signaling pathway | 5 | 113 | 1.68e-01 |
| KEGG | KEGG:04662 | B cell receptor signaling pathway | 3 | 56 | 1.81e-01 |
| KEGG | KEGG:04720 | Long-term potentiation | 2 | 55 | 1.81e-01 |
| KEGG | KEGG:05163 | Human cytomegalovirus infection | 5 | 176 | 1.81e-01 |
| KEGG | KEGG:05210 | Colorectal cancer | 3 | 84 | 1.85e-01 |
| KEGG | KEGG:00310 | Lysine degradation | 2 | 59 | 2.01e-01 |
| KEGG | KEGG:00910 | Nitrogen metabolism | 1 | 10 | 2.06e-01 |
| KEGG | KEGG:04964 | Proximal tubule bicarbonate reclamation | 2 | 20 | 2.06e-01 |
| KEGG | KEGG:00270 | Cysteine and methionine metabolism | 3 | 38 | 2.06e-01 |
| KEGG | KEGG:05231 | Choline metabolism in cancer | 3 | 84 | 2.06e-01 |
| KEGG | KEGG:04130 | SNARE interactions in vesicular transport | 1 | 32 | 2.06e-01 |
| KEGG | KEGG:00520 | Amino sugar and nucleotide sugar metabolism | 3 | 46 | 2.15e-01 |
| KEGG | KEGG:05213 | Endometrial cancer | 2 | 57 | 2.15e-01 |
| KEGG | KEGG:00220 | Arginine biosynthesis | 1 | 16 | 2.19e-01 |
| KEGG | KEGG:04213 | Longevity regulating pathway - multiple species | 2 | 55 | 2.19e-01 |
| KEGG | KEGG:04917 | Prolactin signaling pathway | 2 | 56 | 2.19e-01 |
| KEGG | KEGG:05211 | Renal cell carcinoma | 2 | 65 | 2.19e-01 |
| KEGG | KEGG:00860 | Porphyrin metabolism | 1 | 22 | 2.19e-01 |
| KEGG | KEGG:04218 | Cellular senescence | 3 | 145 | 2.19e-01 |
| KEGG | KEGG:05230 | Central carbon metabolism in cancer | 2 | 62 | 2.19e-01 |
| KEGG | KEGG:05223 | Non-small cell lung cancer | 2 | 67 | 2.19e-01 |
| KEGG | KEGG:04929 | GnRH secretion | 2 | 53 | 2.19e-01 |
| KEGG | KEGG:05218 | Melanoma | 2 | 58 | 2.19e-01 |
| KEGG | KEGG:04670 | Leukocyte transendothelial migration | 3 | 79 | 2.19e-01 |
| KEGG | KEGG:03008 | Ribosome biogenesis in eukaryotes | 4 | 75 | 2.19e-01 |
| KEGG | KEGG:05221 | Acute myeloid leukemia | 2 | 56 | 2.19e-01 |
| KEGG | KEGG:05134 | Legionellosis | 1 | 39 | 2.21e-01 |
| KEGG | KEGG:05214 | Glioma | 2 | 67 | 2.21e-01 |
| KEGG | KEGG:05220 | Chronic myeloid leukemia | 2 | 75 | 2.21e-01 |
| KEGG | KEGG:04610 | Complement and coagulation cascades | 1 | 40 | 2.21e-01 |
| KEGG | KEGG:04611 | Platelet activation | 3 | 89 | 2.21e-01 |
| KEGG | KEGG:05205 | Proteoglycans in cancer | 4 | 170 | 2.21e-01 |
| KEGG | KEGG:01521 | EGFR tyrosine kinase inhibitor resistance | 2 | 74 | 2.21e-01 |
| KEGG | KEGG:04140 | Autophagy - animal | 3 | 133 | 2.21e-01 |
| KEGG | KEGG:05131 | Shigellosis | 7 | 210 | 2.23e-01 |
| KEGG | KEGG:04012 | ErbB signaling pathway | 2 | 78 | 2.23e-01 |
| KEGG | KEGG:05226 | Gastric cancer | 3 | 117 | 2.23e-01 |
| KEGG | KEGG:04010 | MAPK signaling pathway | 6 | 240 | 2.23e-01 |
| KEGG | KEGG:03013 | Nucleocytoplasmic transport | 2 | 99 | 2.23e-01 |
| KEGG | KEGG:04550 | Signaling pathways regulating pluripotency of stem cells | 3 | 104 | 2.23e-01 |
| KEGG | KEGG:05224 | Breast cancer | 3 | 117 | 2.23e-01 |
| KEGG | KEGG:00250 | Alanine, aspartate and glutamate metabolism | 1 | 29 | 2.23e-01 |
| KEGG | KEGG:05034 | Alcoholism | 2 | 122 | 2.23e-01 |
| KEGG | KEGG:04024 | cAMP signaling pathway | 4 | 151 | 2.23e-01 |
| KEGG | KEGG:04211 | Longevity regulating pathway | 2 | 78 | 2.23e-01 |
| KEGG | KEGG:04137 | Mitophagy - animal | 2 | 70 | 2.23e-01 |
| KEGG | KEGG:04014 | Ras signaling pathway | 4 | 171 | 2.24e-01 |
| KEGG | KEGG:00232 | Caffeine metabolism | 1 | 1 | 2.24e-01 |
| KEGG | KEGG:04122 | Sulfur relay system | 1 | 8 | 2.24e-01 |
| KEGG | KEGG:05212 | Pancreatic cancer | 3 | 75 | 2.24e-01 |
| KEGG | KEGG:05215 | Prostate cancer | 2 | 86 | 2.24e-01 |
| KEGG | KEGG:05216 | Thyroid cancer | 1 | 35 | 2.24e-01 |
| KEGG | KEGG:04144 | Endocytosis | 7 | 232 | 2.24e-01 |
| KEGG | KEGG:04150 | mTOR signaling pathway | 3 | 135 | 2.24e-01 |
| KEGG | KEGG:01522 | Endocrine resistance | 2 | 85 | 2.24e-01 |
| KEGG | KEGG:04668 | TNF signaling pathway | 3 | 87 | 2.29e-01 |
| KEGG | KEGG:04216 | Ferroptosis | 2 | 33 | 2.29e-01 |
| KEGG | KEGG:04380 | Osteoclast differentiation | 3 | 87 | 2.29e-01 |
| KEGG | KEGG:05225 | Hepatocellular carcinoma | 3 | 145 | 2.29e-01 |
| KEGG | KEGG:05166 | Human T-cell leukemia virus 1 infection | 3 | 180 | 2.29e-01 |
| KEGG | KEGG:05219 | Bladder cancer | 1 | 37 | 2.29e-01 |
| KEGG | KEGG:04625 | C-type lectin receptor signaling pathway | 2 | 76 | 2.29e-01 |
| KEGG | KEGG:05030 | Cocaine addiction | 1 | 35 | 2.29e-01 |
| KEGG | KEGG:00920 | Sulfur metabolism | 1 | 10 | 2.40e-01 |
| KEGG | KEGG:05100 | Bacterial invasion of epithelial cells | 3 | 74 | 2.46e-01 |
| KEGG | KEGG:03040 | Spliceosome | 2 | 132 | 2.48e-01 |
| KEGG | KEGG:04725 | Cholinergic synapse | 2 | 83 | 2.48e-01 |
| KEGG | KEGG:04722 | Neurotrophin signaling pathway | 2 | 110 | 2.60e-01 |
| KEGG | KEGG:05167 | Kaposi sarcoma-associated herpesvirus infection | 3 | 145 | 2.60e-01 |
| KEGG | KEGG:04919 | Thyroid hormone signaling pathway | 2 | 112 | 2.68e-01 |
| KEGG | KEGG:04922 | Glucagon signaling pathway | 2 | 84 | 2.70e-01 |
| KEGG | KEGG:05031 | Amphetamine addiction | 1 | 49 | 2.70e-01 |
| KEGG | KEGG:04068 | FoxO signaling pathway | 2 | 109 | 2.70e-01 |
| KEGG | KEGG:04728 | Dopaminergic synapse | 2 | 103 | 2.70e-01 |
| KEGG | KEGG:04210 | Apoptosis | 3 | 118 | 2.70e-01 |
| KEGG | KEGG:00670 | One carbon pool by folate | 1 | 18 | 2.70e-01 |
| KEGG | KEGG:04914 | Progesterone-mediated oocyte maturation | 3 | 86 | 2.70e-01 |
| KEGG | KEGG:04145 | Phagosome | 1 | 99 | 2.70e-01 |
| KEGG | KEGG:04730 | Long-term depression | 1 | 42 | 2.70e-01 |
| KEGG | KEGG:00330 | Arginine and proline metabolism | 2 | 38 | 2.70e-01 |
| KEGG | KEGG:04721 | Synaptic vesicle cycle | 2 | 51 | 2.70e-01 |
| KEGG | KEGG:04926 | Relaxin signaling pathway | 2 | 104 | 2.70e-01 |
| KEGG | KEGG:04916 | Melanogenesis | 2 | 77 | 2.70e-01 |
| KEGG | KEGG:04666 | Fc gamma R-mediated phagocytosis | 2 | 75 | 2.75e-01 |
| KEGG | KEGG:04910 | Insulin signaling pathway | 2 | 121 | 2.78e-01 |
| KEGG | KEGG:04915 | Estrogen signaling pathway | 2 | 97 | 2.78e-01 |
| KEGG | KEGG:01240 | Biosynthesis of cofactors | 1 | 115 | 2.89e-01 |
| KEGG | KEGG:05200 | Pathways in cancer | 6 | 409 | 3.12e-01 |
| KEGG | KEGG:00562 | Inositol phosphate metabolism | 2 | 66 | 3.17e-01 |
| KEGG | KEGG:01200 | Carbon metabolism | 1 | 98 | 3.17e-01 |
| KEGG | KEGG:04261 | Adrenergic signaling in cardiomyocytes | 2 | 128 | 3.17e-01 |
| KEGG | KEGG:04540 | Gap junction | 1 | 73 | 3.17e-01 |
| KEGG | KEGG:05170 | Human immunodeficiency virus 1 infection | 5 | 165 | 3.17e-01 |
| KEGG | KEGG:05168 | Herpes simplex virus 1 infection | 1 | 415 | 3.17e-01 |
| KEGG | KEGG:05160 | Hepatitis C | 2 | 115 | 3.17e-01 |
| KEGG | KEGG:05161 | Hepatitis B | 3 | 136 | 3.25e-01 |
| KEGG | KEGG:04912 | GnRH signaling pathway | 1 | 76 | 3.25e-01 |
| KEGG | KEGG:04120 | Ubiquitin mediated proteolysis | 1 | 134 | 3.31e-01 |
| KEGG | KEGG:01523 | Antifolate resistance | 1 | 24 | 3.31e-01 |
| KEGG | KEGG:04630 | JAK-STAT signaling pathway | 2 | 88 | 3.31e-01 |
| KEGG | KEGG:04022 | cGMP-PKG signaling pathway | 4 | 133 | 3.37e-01 |
| KEGG | KEGG:00061 | Fatty acid biosynthesis | 1 | 12 | 3.37e-01 |
| KEGG | KEGG:04973 | Carbohydrate digestion and absorption | 1 | 31 | 3.37e-01 |
| KEGG | KEGG:04920 | Adipocytokine signaling pathway | 2 | 51 | 3.37e-01 |
| KEGG | KEGG:04650 | Natural killer cell mediated cytotoxicity | 2 | 63 | 3.45e-01 |
| KEGG | KEGG:04310 | Wnt signaling pathway | 4 | 138 | 3.46e-01 |
| KEGG | KEGG:05152 | Tuberculosis | 3 | 106 | 3.47e-01 |
| KEGG | KEGG:01100 | Metabolic pathways | 1 | 1146 | 3.47e-01 |
| KEGG | KEGG:03250 | Viral life cycle - HIV-1 | 1 | 56 | 3.47e-01 |
| KEGG | KEGG:04217 | Necroptosis | 1 | 106 | 3.69e-01 |
| KEGG | KEGG:05418 | Fluid shear stress and atherosclerosis | 2 | 114 | 3.85e-01 |
| KEGG | KEGG:04923 | Regulation of lipolysis in adipocytes | 1 | 41 | 3.87e-01 |
| KEGG | KEGG:03320 | PPAR signaling pathway | 2 | 50 | 3.88e-01 |
| KEGG | KEGG:03015 | mRNA surveillance pathway | 1 | 86 | 3.94e-01 |
| KEGG | KEGG:04070 | Phosphatidylinositol signaling system | 2 | 91 | 3.94e-01 |
| KEGG | KEGG:00563 | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 1 | 25 | 3.94e-01 |
| KEGG | KEGG:00051 | Fructose and mannose metabolism | 1 | 27 | 4.06e-01 |
| KEGG | KEGG:05207 | Chemical carcinogenesis - receptor activation | 2 | 142 | 4.08e-01 |
| KEGG | KEGG:05417 | Lipid and atherosclerosis | 2 | 153 | 4.13e-01 |
| KEGG | KEGG:04921 | Oxytocin signaling pathway | 1 | 115 | 4.23e-01 |
| KEGG | KEGG:05132 | Salmonella infection | 5 | 214 | 4.25e-01 |
| KEGG | KEGG:05208 | Chemical carcinogenesis - reactive oxygen species | 2 | 186 | 4.25e-01 |
| KEGG | KEGG:01524 | Platinum drug resistance | 1 | 65 | 4.30e-01 |
| KEGG | KEGG:00600 | Sphingolipid metabolism | 1 | 44 | 4.38e-01 |
| KEGG | KEGG:05416 | Viral myocarditis | 1 | 40 | 4.59e-01 |
| KEGG | KEGG:00240 | Pyrimidine metabolism | 1 | 46 | 4.68e-01 |
| KEGG | KEGG:05217 | Basal cell carcinoma | 1 | 49 | 4.68e-01 |
| KEGG | KEGG:04350 | TGF-beta signaling pathway | 2 | 84 | 4.68e-01 |
| KEGG | KEGG:04961 | Endocrine and other factor-regulated calcium reabsorption | 1 | 41 | 4.72e-01 |
| KEGG | KEGG:05165 | Human papillomavirus infection | 3 | 272 | 4.79e-01 |
| KEGG | KEGG:05203 | Viral carcinogenesis | 1 | 172 | 4.86e-01 |
| KEGG | KEGG:05222 | Small cell lung cancer | 1 | 87 | 4.94e-01 |
| KEGG | KEGG:00480 | Glutathione metabolism | 1 | 44 | 4.95e-01 |
| KEGG | KEGG:05142 | Chagas disease | 1 | 75 | 5.21e-01 |
| KEGG | KEGG:04520 | Adherens junction | 1 | 67 | 5.21e-01 |
| KEGG | KEGG:04620 | Toll-like receptor signaling pathway | 1 | 60 | 5.22e-01 |
| KEGG | KEGG:04714 | Thermogenesis | 1 | 195 | 5.25e-01 |
| KEGG | KEGG:05012 | Parkinson disease | 1 | 226 | 5.28e-01 |
| KEGG | KEGG:00071 | Fatty acid degradation | 1 | 32 | 5.28e-01 |
| KEGG | KEGG:05145 | Toxoplasmosis | 1 | 82 | 5.28e-01 |
| KEGG | KEGG:04931 | Insulin resistance | 1 | 95 | 5.28e-01 |
| KEGG | KEGG:04066 | HIF-1 signaling pathway | 1 | 89 | 5.28e-01 |
| KEGG | KEGG:00564 | Glycerophospholipid metabolism | 1 | 76 | 5.38e-01 |
| KEGG | KEGG:05010 | Alzheimer disease | 3 | 315 | 5.48e-01 |
| KEGG | KEGG:00830 | Retinol metabolism | 1 | 16 | 5.48e-01 |
| KEGG | KEGG:01232 | Nucleotide metabolism | 1 | 69 | 5.56e-01 |
| KEGG | KEGG:04152 | AMPK signaling pathway | 1 | 103 | 5.56e-01 |
| KEGG | KEGG:04530 | Tight junction | 3 | 137 | 5.63e-01 |
| KEGG | KEGG:04622 | RIG-I-like receptor signaling pathway | 1 | 49 | 5.91e-01 |
| KEGG | KEGG:01212 | Fatty acid metabolism | 1 | 50 | 5.97e-01 |
| KEGG | KEGG:05017 | Spinocerebellar ataxia | 1 | 124 | 5.97e-01 |
| KEGG | KEGG:04936 | Alcoholic liver disease | 1 | 97 | 5.97e-01 |
| KEGG | KEGG:05162 | Measles | 1 | 98 | 5.97e-01 |
| KEGG | KEGG:05206 | MicroRNAs in cancer | 1 | 149 | 5.97e-01 |
| KEGG | KEGG:00514 | Other types of O-glycan biosynthesis | 1 | 37 | 6.03e-01 |
| KEGG | KEGG:04151 | PI3K-Akt signaling pathway | 2 | 254 | 6.03e-01 |
| KEGG | KEGG:04932 | Non-alcoholic fatty liver disease | 1 | 131 | 6.20e-01 |
| KEGG | KEGG:04623 | Cytosolic DNA-sensing pathway | 1 | 42 | 6.22e-01 |
| KEGG | KEGG:04114 | Oocyte meiosis | 2 | 108 | 6.23e-01 |
| KEGG | KEGG:05130 | Pathogenic Escherichia coli infection | 3 | 150 | 6.24e-01 |
| KEGG | KEGG:05164 | Influenza A | 1 | 103 | 6.42e-01 |
| KEGG | KEGG:05022 | Pathways of neurodegeneration - multiple diseases | 3 | 385 | 6.60e-01 |
| KEGG | KEGG:04613 | Neutrophil extracellular trap formation | 1 | 110 | 6.80e-01 |
| KEGG | KEGG:05204 | Chemical carcinogenesis - DNA adducts | 1 | 23 | 6.84e-01 |
| KEGG | KEGG:04270 | Vascular smooth muscle contraction | 1 | 94 | 6.87e-01 |
| KEGG | KEGG:05169 | Epstein-Barr virus infection | 1 | 153 | 6.88e-01 |
| KEGG | KEGG:04924 | Renin secretion | 1 | 50 | 6.88e-01 |
| KEGG | KEGG:04146 | Peroxisome | 1 | 68 | 6.88e-01 |
| KEGG | KEGG:04934 | Cushing syndrome | 1 | 121 | 6.88e-01 |
| KEGG | KEGG:05415 | Diabetic cardiomyopathy | 1 | 169 | 6.88e-01 |
| KEGG | KEGG:04390 | Hippo signaling pathway | 1 | 134 | 6.89e-01 |
| KEGG | KEGG:04976 | Bile secretion | 1 | 42 | 6.98e-01 |
| KEGG | KEGG:04621 | NOD-like receptor signaling pathway | 1 | 117 | 7.18e-01 |
| KEGG | KEGG:00983 | Drug metabolism - other enzymes | 1 | 44 | 7.18e-01 |
| KEGG | KEGG:04972 | Pancreatic secretion | 1 | 58 | 7.36e-01 |
| KEGG | KEGG:04141 | Protein processing in endoplasmic reticulum | 2 | 161 | 7.36e-01 |
| KEGG | KEGG:04658 | Th1 and Th2 cell differentiation | 1 | 53 | 7.54e-01 |
| KEGG | KEGG:04659 | Th17 cell differentiation | 1 | 64 | 8.11e-01 |
| KEGG | KEGG:04110 | Cell cycle | 1 | 151 | 8.18e-01 |
| KEGG | KEGG:04724 | Glutamatergic synapse | 1 | 74 | 8.32e-01 |
| KEGG | KEGG:05322 | Systemic lupus erythematosus | 1 | 61 | 8.33e-01 |
| KEGG | KEGG:04020 | Calcium signaling pathway | 1 | 157 | 8.33e-01 |
| KEGG | KEGG:04514 | Cell adhesion molecules | 1 | 83 | 8.39e-01 |
| KEGG | KEGG:00000 | KEGG root term | 1 | 5558 | 8.61e-01 |
| KEGG | KEGG:03010 | Ribosome | 1 | 127 | 8.78e-01 |
| KEGG | KEGG:05014 | Amyotrophic lateral sclerosis | 1 | 303 | 9.02e-01 |
| KEGG | KEGG:05016 | Huntington disease | 1 | 256 | 9.16e-01 |
| KEGG | KEGG:05020 | Prion disease | 1 | 220 | 9.83e-01 |
| KEGG | KEGG:04080 | Neuroactive ligand-receptor interaction | 1 | 108 | 9.85e-01 |
AC_share_var24_table %>%
filter(source=="KEGG") %>%
mutate_at(.vars = 6, .funs= scientific_format()) %>%
kable(.,caption = "KEGG AC_share 24 hour enrichment terms of highly var genes") %>%
kable_paper("striped", full_width = FALSE) %>%
kable_styling(full_width = FALSE, position = "left",bootstrap_options = c("striped","hover")) %>%
scroll_box(width = "100%", height = "400px")| source | term_id | term_name | intersection_size | term_size | p_value |
|---|---|---|---|---|---|
| KEGG | KEGG:04360 | Axon guidance | 6 | 162 | 1.10e-01 |
| KEGG | KEGG:04071 | Sphingolipid signaling pathway | 5 | 107 | 1.10e-01 |
| KEGG | KEGG:04370 | VEGF signaling pathway | 4 | 49 | 1.10e-01 |
| KEGG | KEGG:00534 | Glycosaminoglycan biosynthesis - heparan sulfate / heparin | 1 | 20 | 1.68e-01 |
| KEGG | KEGG:04726 | Serotonergic synapse | 3 | 63 | 1.68e-01 |
| KEGG | KEGG:05135 | Yersinia infection | 4 | 112 | 1.68e-01 |
| KEGG | KEGG:04015 | Rap1 signaling pathway | 5 | 164 | 1.68e-01 |
| KEGG | KEGG:04810 | Regulation of actin cytoskeleton | 6 | 179 | 1.68e-01 |
| KEGG | KEGG:04664 | Fc epsilon RI signaling pathway | 3 | 46 | 1.68e-01 |
| KEGG | KEGG:04935 | Growth hormone synthesis, secretion and action | 4 | 98 | 1.68e-01 |
| KEGG | KEGG:04933 | AGE-RAGE signaling pathway in diabetic complications | 3 | 91 | 1.68e-01 |
| KEGG | KEGG:04660 | T cell receptor signaling pathway | 3 | 70 | 1.68e-01 |
| KEGG | KEGG:04371 | Apelin signaling pathway | 4 | 106 | 1.68e-01 |
| KEGG | KEGG:01250 | Biosynthesis of nucleotide sugars | 3 | 35 | 1.68e-01 |
| KEGG | KEGG:03450 | Non-homologous end-joining | 2 | 12 | 1.68e-01 |
| KEGG | KEGG:05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 3 | 69 | 1.68e-01 |
| KEGG | KEGG:04072 | Phospholipase D signaling pathway | 6 | 110 | 1.68e-01 |
| KEGG | KEGG:04510 | Focal adhesion | 5 | 177 | 1.68e-01 |
| KEGG | KEGG:04062 | Chemokine signaling pathway | 5 | 113 | 1.68e-01 |
| KEGG | KEGG:04662 | B cell receptor signaling pathway | 3 | 56 | 1.81e-01 |
| KEGG | KEGG:04720 | Long-term potentiation | 2 | 55 | 1.81e-01 |
| KEGG | KEGG:05163 | Human cytomegalovirus infection | 5 | 176 | 1.81e-01 |
| KEGG | KEGG:05210 | Colorectal cancer | 3 | 84 | 1.85e-01 |
| KEGG | KEGG:00310 | Lysine degradation | 2 | 59 | 2.01e-01 |
| KEGG | KEGG:00910 | Nitrogen metabolism | 1 | 10 | 2.06e-01 |
| KEGG | KEGG:04964 | Proximal tubule bicarbonate reclamation | 2 | 20 | 2.06e-01 |
| KEGG | KEGG:00270 | Cysteine and methionine metabolism | 3 | 38 | 2.06e-01 |
| KEGG | KEGG:05231 | Choline metabolism in cancer | 3 | 84 | 2.06e-01 |
| KEGG | KEGG:04130 | SNARE interactions in vesicular transport | 1 | 32 | 2.06e-01 |
| KEGG | KEGG:00520 | Amino sugar and nucleotide sugar metabolism | 3 | 46 | 2.15e-01 |
| KEGG | KEGG:05213 | Endometrial cancer | 2 | 57 | 2.15e-01 |
| KEGG | KEGG:00220 | Arginine biosynthesis | 1 | 16 | 2.19e-01 |
| KEGG | KEGG:04213 | Longevity regulating pathway - multiple species | 2 | 55 | 2.19e-01 |
| KEGG | KEGG:04917 | Prolactin signaling pathway | 2 | 56 | 2.19e-01 |
| KEGG | KEGG:05211 | Renal cell carcinoma | 2 | 65 | 2.19e-01 |
| KEGG | KEGG:00860 | Porphyrin metabolism | 1 | 22 | 2.19e-01 |
| KEGG | KEGG:04218 | Cellular senescence | 3 | 145 | 2.19e-01 |
| KEGG | KEGG:05230 | Central carbon metabolism in cancer | 2 | 62 | 2.19e-01 |
| KEGG | KEGG:05223 | Non-small cell lung cancer | 2 | 67 | 2.19e-01 |
| KEGG | KEGG:04929 | GnRH secretion | 2 | 53 | 2.19e-01 |
| KEGG | KEGG:05218 | Melanoma | 2 | 58 | 2.19e-01 |
| KEGG | KEGG:04670 | Leukocyte transendothelial migration | 3 | 79 | 2.19e-01 |
| KEGG | KEGG:03008 | Ribosome biogenesis in eukaryotes | 4 | 75 | 2.19e-01 |
| KEGG | KEGG:05221 | Acute myeloid leukemia | 2 | 56 | 2.19e-01 |
| KEGG | KEGG:05134 | Legionellosis | 1 | 39 | 2.21e-01 |
| KEGG | KEGG:05214 | Glioma | 2 | 67 | 2.21e-01 |
| KEGG | KEGG:05220 | Chronic myeloid leukemia | 2 | 75 | 2.21e-01 |
| KEGG | KEGG:04610 | Complement and coagulation cascades | 1 | 40 | 2.21e-01 |
| KEGG | KEGG:04611 | Platelet activation | 3 | 89 | 2.21e-01 |
| KEGG | KEGG:05205 | Proteoglycans in cancer | 4 | 170 | 2.21e-01 |
| KEGG | KEGG:01521 | EGFR tyrosine kinase inhibitor resistance | 2 | 74 | 2.21e-01 |
| KEGG | KEGG:04140 | Autophagy - animal | 3 | 133 | 2.21e-01 |
| KEGG | KEGG:05131 | Shigellosis | 7 | 210 | 2.23e-01 |
| KEGG | KEGG:04012 | ErbB signaling pathway | 2 | 78 | 2.23e-01 |
| KEGG | KEGG:05226 | Gastric cancer | 3 | 117 | 2.23e-01 |
| KEGG | KEGG:04010 | MAPK signaling pathway | 6 | 240 | 2.23e-01 |
| KEGG | KEGG:03013 | Nucleocytoplasmic transport | 2 | 99 | 2.23e-01 |
| KEGG | KEGG:04550 | Signaling pathways regulating pluripotency of stem cells | 3 | 104 | 2.23e-01 |
| KEGG | KEGG:05224 | Breast cancer | 3 | 117 | 2.23e-01 |
| KEGG | KEGG:00250 | Alanine, aspartate and glutamate metabolism | 1 | 29 | 2.23e-01 |
| KEGG | KEGG:05034 | Alcoholism | 2 | 122 | 2.23e-01 |
| KEGG | KEGG:04024 | cAMP signaling pathway | 4 | 151 | 2.23e-01 |
| KEGG | KEGG:04211 | Longevity regulating pathway | 2 | 78 | 2.23e-01 |
| KEGG | KEGG:04137 | Mitophagy - animal | 2 | 70 | 2.23e-01 |
| KEGG | KEGG:04014 | Ras signaling pathway | 4 | 171 | 2.24e-01 |
| KEGG | KEGG:00232 | Caffeine metabolism | 1 | 1 | 2.24e-01 |
| KEGG | KEGG:04122 | Sulfur relay system | 1 | 8 | 2.24e-01 |
| KEGG | KEGG:05212 | Pancreatic cancer | 3 | 75 | 2.24e-01 |
| KEGG | KEGG:05215 | Prostate cancer | 2 | 86 | 2.24e-01 |
| KEGG | KEGG:05216 | Thyroid cancer | 1 | 35 | 2.24e-01 |
| KEGG | KEGG:04144 | Endocytosis | 7 | 232 | 2.24e-01 |
| KEGG | KEGG:04150 | mTOR signaling pathway | 3 | 135 | 2.24e-01 |
| KEGG | KEGG:01522 | Endocrine resistance | 2 | 85 | 2.24e-01 |
| KEGG | KEGG:04668 | TNF signaling pathway | 3 | 87 | 2.29e-01 |
| KEGG | KEGG:04216 | Ferroptosis | 2 | 33 | 2.29e-01 |
| KEGG | KEGG:04380 | Osteoclast differentiation | 3 | 87 | 2.29e-01 |
| KEGG | KEGG:05225 | Hepatocellular carcinoma | 3 | 145 | 2.29e-01 |
| KEGG | KEGG:05166 | Human T-cell leukemia virus 1 infection | 3 | 180 | 2.29e-01 |
| KEGG | KEGG:05219 | Bladder cancer | 1 | 37 | 2.29e-01 |
| KEGG | KEGG:04625 | C-type lectin receptor signaling pathway | 2 | 76 | 2.29e-01 |
| KEGG | KEGG:05030 | Cocaine addiction | 1 | 35 | 2.29e-01 |
| KEGG | KEGG:00920 | Sulfur metabolism | 1 | 10 | 2.40e-01 |
| KEGG | KEGG:05100 | Bacterial invasion of epithelial cells | 3 | 74 | 2.46e-01 |
| KEGG | KEGG:03040 | Spliceosome | 2 | 132 | 2.48e-01 |
| KEGG | KEGG:04725 | Cholinergic synapse | 2 | 83 | 2.48e-01 |
| KEGG | KEGG:04722 | Neurotrophin signaling pathway | 2 | 110 | 2.60e-01 |
| KEGG | KEGG:05167 | Kaposi sarcoma-associated herpesvirus infection | 3 | 145 | 2.60e-01 |
| KEGG | KEGG:04919 | Thyroid hormone signaling pathway | 2 | 112 | 2.68e-01 |
| KEGG | KEGG:04922 | Glucagon signaling pathway | 2 | 84 | 2.70e-01 |
| KEGG | KEGG:05031 | Amphetamine addiction | 1 | 49 | 2.70e-01 |
| KEGG | KEGG:04068 | FoxO signaling pathway | 2 | 109 | 2.70e-01 |
| KEGG | KEGG:04728 | Dopaminergic synapse | 2 | 103 | 2.70e-01 |
| KEGG | KEGG:04210 | Apoptosis | 3 | 118 | 2.70e-01 |
| KEGG | KEGG:00670 | One carbon pool by folate | 1 | 18 | 2.70e-01 |
| KEGG | KEGG:04914 | Progesterone-mediated oocyte maturation | 3 | 86 | 2.70e-01 |
| KEGG | KEGG:04145 | Phagosome | 1 | 99 | 2.70e-01 |
| KEGG | KEGG:04730 | Long-term depression | 1 | 42 | 2.70e-01 |
| KEGG | KEGG:00330 | Arginine and proline metabolism | 2 | 38 | 2.70e-01 |
| KEGG | KEGG:04721 | Synaptic vesicle cycle | 2 | 51 | 2.70e-01 |
| KEGG | KEGG:04926 | Relaxin signaling pathway | 2 | 104 | 2.70e-01 |
| KEGG | KEGG:04916 | Melanogenesis | 2 | 77 | 2.70e-01 |
| KEGG | KEGG:04666 | Fc gamma R-mediated phagocytosis | 2 | 75 | 2.75e-01 |
| KEGG | KEGG:04910 | Insulin signaling pathway | 2 | 121 | 2.78e-01 |
| KEGG | KEGG:04915 | Estrogen signaling pathway | 2 | 97 | 2.78e-01 |
| KEGG | KEGG:01240 | Biosynthesis of cofactors | 1 | 115 | 2.89e-01 |
| KEGG | KEGG:05200 | Pathways in cancer | 6 | 409 | 3.12e-01 |
| KEGG | KEGG:00562 | Inositol phosphate metabolism | 2 | 66 | 3.17e-01 |
| KEGG | KEGG:01200 | Carbon metabolism | 1 | 98 | 3.17e-01 |
| KEGG | KEGG:04261 | Adrenergic signaling in cardiomyocytes | 2 | 128 | 3.17e-01 |
| KEGG | KEGG:04540 | Gap junction | 1 | 73 | 3.17e-01 |
| KEGG | KEGG:05170 | Human immunodeficiency virus 1 infection | 5 | 165 | 3.17e-01 |
| KEGG | KEGG:05168 | Herpes simplex virus 1 infection | 1 | 415 | 3.17e-01 |
| KEGG | KEGG:05160 | Hepatitis C | 2 | 115 | 3.17e-01 |
| KEGG | KEGG:05161 | Hepatitis B | 3 | 136 | 3.25e-01 |
| KEGG | KEGG:04912 | GnRH signaling pathway | 1 | 76 | 3.25e-01 |
| KEGG | KEGG:04120 | Ubiquitin mediated proteolysis | 1 | 134 | 3.31e-01 |
| KEGG | KEGG:01523 | Antifolate resistance | 1 | 24 | 3.31e-01 |
| KEGG | KEGG:04630 | JAK-STAT signaling pathway | 2 | 88 | 3.31e-01 |
| KEGG | KEGG:04022 | cGMP-PKG signaling pathway | 4 | 133 | 3.37e-01 |
| KEGG | KEGG:00061 | Fatty acid biosynthesis | 1 | 12 | 3.37e-01 |
| KEGG | KEGG:04973 | Carbohydrate digestion and absorption | 1 | 31 | 3.37e-01 |
| KEGG | KEGG:04920 | Adipocytokine signaling pathway | 2 | 51 | 3.37e-01 |
| KEGG | KEGG:04650 | Natural killer cell mediated cytotoxicity | 2 | 63 | 3.45e-01 |
| KEGG | KEGG:04310 | Wnt signaling pathway | 4 | 138 | 3.46e-01 |
| KEGG | KEGG:05152 | Tuberculosis | 3 | 106 | 3.47e-01 |
| KEGG | KEGG:01100 | Metabolic pathways | 1 | 1146 | 3.47e-01 |
| KEGG | KEGG:03250 | Viral life cycle - HIV-1 | 1 | 56 | 3.47e-01 |
| KEGG | KEGG:04217 | Necroptosis | 1 | 106 | 3.69e-01 |
| KEGG | KEGG:05418 | Fluid shear stress and atherosclerosis | 2 | 114 | 3.85e-01 |
| KEGG | KEGG:04923 | Regulation of lipolysis in adipocytes | 1 | 41 | 3.87e-01 |
| KEGG | KEGG:03320 | PPAR signaling pathway | 2 | 50 | 3.88e-01 |
| KEGG | KEGG:03015 | mRNA surveillance pathway | 1 | 86 | 3.94e-01 |
| KEGG | KEGG:04070 | Phosphatidylinositol signaling system | 2 | 91 | 3.94e-01 |
| KEGG | KEGG:00563 | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 1 | 25 | 3.94e-01 |
| KEGG | KEGG:00051 | Fructose and mannose metabolism | 1 | 27 | 4.06e-01 |
| KEGG | KEGG:05207 | Chemical carcinogenesis - receptor activation | 2 | 142 | 4.08e-01 |
| KEGG | KEGG:05417 | Lipid and atherosclerosis | 2 | 153 | 4.13e-01 |
| KEGG | KEGG:04921 | Oxytocin signaling pathway | 1 | 115 | 4.23e-01 |
| KEGG | KEGG:05132 | Salmonella infection | 5 | 214 | 4.25e-01 |
| KEGG | KEGG:05208 | Chemical carcinogenesis - reactive oxygen species | 2 | 186 | 4.25e-01 |
| KEGG | KEGG:01524 | Platinum drug resistance | 1 | 65 | 4.30e-01 |
| KEGG | KEGG:00600 | Sphingolipid metabolism | 1 | 44 | 4.38e-01 |
| KEGG | KEGG:05416 | Viral myocarditis | 1 | 40 | 4.59e-01 |
| KEGG | KEGG:00240 | Pyrimidine metabolism | 1 | 46 | 4.68e-01 |
| KEGG | KEGG:05217 | Basal cell carcinoma | 1 | 49 | 4.68e-01 |
| KEGG | KEGG:04350 | TGF-beta signaling pathway | 2 | 84 | 4.68e-01 |
| KEGG | KEGG:04961 | Endocrine and other factor-regulated calcium reabsorption | 1 | 41 | 4.72e-01 |
| KEGG | KEGG:05165 | Human papillomavirus infection | 3 | 272 | 4.79e-01 |
| KEGG | KEGG:05203 | Viral carcinogenesis | 1 | 172 | 4.86e-01 |
| KEGG | KEGG:05222 | Small cell lung cancer | 1 | 87 | 4.94e-01 |
| KEGG | KEGG:00480 | Glutathione metabolism | 1 | 44 | 4.95e-01 |
| KEGG | KEGG:05142 | Chagas disease | 1 | 75 | 5.21e-01 |
| KEGG | KEGG:04520 | Adherens junction | 1 | 67 | 5.21e-01 |
| KEGG | KEGG:04620 | Toll-like receptor signaling pathway | 1 | 60 | 5.22e-01 |
| KEGG | KEGG:04714 | Thermogenesis | 1 | 195 | 5.25e-01 |
| KEGG | KEGG:05012 | Parkinson disease | 1 | 226 | 5.28e-01 |
| KEGG | KEGG:00071 | Fatty acid degradation | 1 | 32 | 5.28e-01 |
| KEGG | KEGG:05145 | Toxoplasmosis | 1 | 82 | 5.28e-01 |
| KEGG | KEGG:04931 | Insulin resistance | 1 | 95 | 5.28e-01 |
| KEGG | KEGG:04066 | HIF-1 signaling pathway | 1 | 89 | 5.28e-01 |
| KEGG | KEGG:00564 | Glycerophospholipid metabolism | 1 | 76 | 5.38e-01 |
| KEGG | KEGG:05010 | Alzheimer disease | 3 | 315 | 5.48e-01 |
| KEGG | KEGG:00830 | Retinol metabolism | 1 | 16 | 5.48e-01 |
| KEGG | KEGG:01232 | Nucleotide metabolism | 1 | 69 | 5.56e-01 |
| KEGG | KEGG:04152 | AMPK signaling pathway | 1 | 103 | 5.56e-01 |
| KEGG | KEGG:04530 | Tight junction | 3 | 137 | 5.63e-01 |
| KEGG | KEGG:04622 | RIG-I-like receptor signaling pathway | 1 | 49 | 5.91e-01 |
| KEGG | KEGG:01212 | Fatty acid metabolism | 1 | 50 | 5.97e-01 |
| KEGG | KEGG:05017 | Spinocerebellar ataxia | 1 | 124 | 5.97e-01 |
| KEGG | KEGG:04936 | Alcoholic liver disease | 1 | 97 | 5.97e-01 |
| KEGG | KEGG:05162 | Measles | 1 | 98 | 5.97e-01 |
| KEGG | KEGG:05206 | MicroRNAs in cancer | 1 | 149 | 5.97e-01 |
| KEGG | KEGG:00514 | Other types of O-glycan biosynthesis | 1 | 37 | 6.03e-01 |
| KEGG | KEGG:04151 | PI3K-Akt signaling pathway | 2 | 254 | 6.03e-01 |
| KEGG | KEGG:04932 | Non-alcoholic fatty liver disease | 1 | 131 | 6.20e-01 |
| KEGG | KEGG:04623 | Cytosolic DNA-sensing pathway | 1 | 42 | 6.22e-01 |
| KEGG | KEGG:04114 | Oocyte meiosis | 2 | 108 | 6.23e-01 |
| KEGG | KEGG:05130 | Pathogenic Escherichia coli infection | 3 | 150 | 6.24e-01 |
| KEGG | KEGG:05164 | Influenza A | 1 | 103 | 6.42e-01 |
| KEGG | KEGG:05022 | Pathways of neurodegeneration - multiple diseases | 3 | 385 | 6.60e-01 |
| KEGG | KEGG:04613 | Neutrophil extracellular trap formation | 1 | 110 | 6.80e-01 |
| KEGG | KEGG:05204 | Chemical carcinogenesis - DNA adducts | 1 | 23 | 6.84e-01 |
| KEGG | KEGG:04270 | Vascular smooth muscle contraction | 1 | 94 | 6.87e-01 |
| KEGG | KEGG:05169 | Epstein-Barr virus infection | 1 | 153 | 6.88e-01 |
| KEGG | KEGG:04924 | Renin secretion | 1 | 50 | 6.88e-01 |
| KEGG | KEGG:04146 | Peroxisome | 1 | 68 | 6.88e-01 |
| KEGG | KEGG:04934 | Cushing syndrome | 1 | 121 | 6.88e-01 |
| KEGG | KEGG:05415 | Diabetic cardiomyopathy | 1 | 169 | 6.88e-01 |
| KEGG | KEGG:04390 | Hippo signaling pathway | 1 | 134 | 6.89e-01 |
| KEGG | KEGG:04976 | Bile secretion | 1 | 42 | 6.98e-01 |
| KEGG | KEGG:04621 | NOD-like receptor signaling pathway | 1 | 117 | 7.18e-01 |
| KEGG | KEGG:00983 | Drug metabolism - other enzymes | 1 | 44 | 7.18e-01 |
| KEGG | KEGG:04972 | Pancreatic secretion | 1 | 58 | 7.36e-01 |
| KEGG | KEGG:04141 | Protein processing in endoplasmic reticulum | 2 | 161 | 7.36e-01 |
| KEGG | KEGG:04658 | Th1 and Th2 cell differentiation | 1 | 53 | 7.54e-01 |
| KEGG | KEGG:04659 | Th17 cell differentiation | 1 | 64 | 8.11e-01 |
| KEGG | KEGG:04110 | Cell cycle | 1 | 151 | 8.18e-01 |
| KEGG | KEGG:04724 | Glutamatergic synapse | 1 | 74 | 8.32e-01 |
| KEGG | KEGG:05322 | Systemic lupus erythematosus | 1 | 61 | 8.33e-01 |
| KEGG | KEGG:04020 | Calcium signaling pathway | 1 | 157 | 8.33e-01 |
| KEGG | KEGG:04514 | Cell adhesion molecules | 1 | 83 | 8.39e-01 |
| KEGG | KEGG:00000 | KEGG root term | 1 | 5558 | 8.61e-01 |
| KEGG | KEGG:03010 | Ribosome | 1 | 127 | 8.78e-01 |
| KEGG | KEGG:05014 | Amyotrophic lateral sclerosis | 1 | 303 | 9.02e-01 |
| KEGG | KEGG:05016 | Huntington disease | 1 | 256 | 9.16e-01 |
| KEGG | KEGG:05020 | Prion disease | 1 | 220 | 9.83e-01 |
| KEGG | KEGG:04080 | Neuroactive ligand-receptor interaction | 1 | 108 | 9.85e-01 |
24 hour TOP2i shared highly variable genes
based on nominal pvalues <0.05
TOP2i <- venn24part$..values..[[17]]
# TOP2i_var24gost <- gost(query = TOP2i,
# organism = "hsapiens",
# significant = FALSE,
# ordered_query = TRUE,
# domain_scope = "custom",
# measure_underrepresentation = FALSE,
# evcodes = FALSE,
# numeric_ns="ENTREZGENE",
# user_threshold = 0.05,
# correction_method = "fdr",
# custom_bg = backGL$ENTREZID,
# sources=c("GO:BP","KEGG"))
#
# saveRDS(TOP2i_var24gost,"data/DEG-GO/var/TOP2i_var24gost.RDS")
TOP2i_var24gost <- readRDS("data/DEG-GO/var/TOP2i_var24gost.RDS")
TOP2i_var24p <- gostplot(TOP2i_var24gost, capped = FALSE, interactive = TRUE)
TOP2i_var24pTOP2i_var24_table <- TOP2i_var24gost$result %>%
dplyr::select(c(source, term_id, term_name,intersection_size, term_size, p_value))
TOP2i_var24_table %>%
dplyr::filter(source=="GO:BP") %>%
dplyr::select(p_value,term_name,intersection_size) %>%
slice_min(., n=10 ,order_by=p_value) %>%
mutate(log_val = -log10(p_value)) %>%
# slice_max(., n=10,order_by = p_value) %>%
ggplot(., aes(x = log_val, y =reorder(term_name,p_value), col= intersection_size)) +
geom_point(aes(size = intersection_size)) +
geom_vline(xintercept = (-log10(0.05)), col="red")+
scale_y_discrete(labels = label_wrap(30))+
guides(col="none", size=guide_legend(title = "# of intersected \n terms"))+
ggtitle('TOP2i 24 hour top 10 GO:BP terms') +
xlab(expression(" -"~log[10]~("adj. p-value")))+
ylab("GO: BP term")+
theme_bw()+
theme(plot.title = element_text(size = rel(1.5), hjust = 0.5),
axis.title = element_text(size = 15, color = "black"),
axis.ticks = element_line(linewidth = 1.5),
axis.line = element_line(linewidth = 1.5),
axis.text = element_text(size = 10, color = "black", angle = 0),
strip.text.x = element_text(size = 15, color = "black", face = "bold")) 
TOP2i_var24_table %>%
mutate_at(.vars = 6, .funs= scientific_format()) %>%
kable(.,caption = "TOP2i 24 enrichment terms of highly var genes") %>%
kable_paper("striped", full_width = FALSE) %>%
kable_styling(full_width = FALSE, position = "left",bootstrap_options = c("striped","hover")) %>%
scroll_box(width = "100%", height = "400px")| source | term_id | term_name | intersection_size | term_size | p_value |
|---|---|---|---|---|---|
| GO:BP | GO:0043506 | regulation of JUN kinase activity | 3 | 49 | 1.45e-02 |
| GO:BP | GO:0043508 | negative regulation of JUN kinase activity | 2 | 13 | 1.75e-02 |
| GO:BP | GO:0046329 | negative regulation of JNK cascade | 2 | 36 | 3.04e-02 |
| GO:BP | GO:0044721 | protein import into peroxisome matrix, substrate release | 1 | 2 | 3.04e-02 |
| GO:BP | GO:0006481 | C-terminal protein methylation | 1 | 2 | 3.04e-02 |
| GO:BP | GO:0046328 | regulation of JNK cascade | 3 | 114 | 3.04e-02 |
| GO:BP | GO:0046498 | S-adenosylhomocysteine metabolic process | 1 | 2 | 3.04e-02 |
| GO:BP | GO:0032873 | negative regulation of stress-activated MAPK cascade | 2 | 46 | 3.04e-02 |
| GO:BP | GO:0046499 | S-adenosylmethioninamine metabolic process | 1 | 1 | 3.04e-02 |
| GO:BP | GO:0007254 | JNK cascade | 3 | 138 | 3.04e-02 |
| GO:BP | GO:0032872 | regulation of stress-activated MAPK cascade | 3 | 154 | 3.04e-02 |
| GO:BP | GO:0070303 | negative regulation of stress-activated protein kinase signaling cascade | 2 | 46 | 3.04e-02 |
| GO:BP | GO:0043405 | regulation of MAP kinase activity | 3 | 141 | 3.04e-02 |
| GO:BP | GO:0036250 | peroxisome transport along microtubule | 1 | 1 | 3.04e-02 |
| GO:BP | GO:0070302 | regulation of stress-activated protein kinase signaling cascade | 3 | 157 | 3.04e-02 |
| GO:BP | GO:0048264 | determination of ventral identity | 1 | 1 | 3.04e-02 |
| GO:BP | GO:0043407 | negative regulation of MAP kinase activity | 2 | 50 | 3.19e-02 |
| GO:BP | GO:0071901 | negative regulation of protein serine/threonine kinase activity | 3 | 101 | 3.68e-02 |
| GO:BP | GO:0072579 | glycine receptor clustering | 1 | 1 | 3.68e-02 |
| GO:BP | GO:0042040 | metal incorporation into metallo-molybdopterin complex | 1 | 1 | 3.68e-02 |
| GO:BP | GO:0016561 | protein import into peroxisome matrix, translocation | 1 | 3 | 3.68e-02 |
| GO:BP | GO:0018315 | molybdenum incorporation into molybdenum-molybdopterin complex | 1 | 1 | 3.68e-02 |
| GO:BP | GO:0051403 | stress-activated MAPK cascade | 3 | 190 | 3.73e-02 |
| GO:BP | GO:0031098 | stress-activated protein kinase signaling cascade | 3 | 196 | 3.89e-02 |
| GO:BP | GO:0016560 | protein import into peroxisome matrix, docking | 1 | 3 | 3.89e-02 |
| GO:BP | GO:0007258 | JUN phosphorylation | 1 | 2 | 4.98e-02 |
| GO:BP | GO:0007529 | establishment of synaptic specificity at neuromuscular junction | 1 | 2 | 6.00e-02 |
| GO:BP | GO:0140235 | RNA polyadenylation at postsynapse | 1 | 1 | 6.79e-02 |
| GO:BP | GO:0071900 | regulation of protein serine/threonine kinase activity | 4 | 282 | 6.79e-02 |
| GO:BP | GO:2000626 | negative regulation of miRNA catabolic process | 1 | 1 | 6.79e-02 |
| GO:BP | GO:2001234 | negative regulation of apoptotic signaling pathway | 3 | 194 | 6.79e-02 |
| GO:BP | GO:0018410 | C-terminal protein amino acid modification | 1 | 10 | 7.08e-02 |
| GO:BP | GO:0046457 | prostanoid biosynthetic process | 1 | 19 | 7.14e-02 |
| GO:BP | GO:0001516 | prostaglandin biosynthetic process | 1 | 19 | 7.14e-02 |
| GO:BP | GO:0009953 | dorsal/ventral pattern formation | 2 | 55 | 7.48e-02 |
| GO:BP | GO:0048320 | axial mesoderm formation | 1 | 2 | 7.48e-02 |
| GO:BP | GO:0046330 | positive regulation of JNK cascade | 2 | 72 | 7.66e-02 |
| GO:BP | GO:0090204 | protein localization to nuclear pore | 1 | 3 | 7.66e-02 |
| GO:BP | GO:0032324 | molybdopterin cofactor biosynthetic process | 1 | 6 | 7.87e-02 |
| GO:BP | GO:0072662 | protein localization to peroxisome | 1 | 19 | 7.87e-02 |
| GO:BP | GO:0072663 | establishment of protein localization to peroxisome | 1 | 19 | 7.87e-02 |
| GO:BP | GO:0014878 | response to electrical stimulus involved in regulation of muscle adaptation | 1 | 2 | 7.87e-02 |
| GO:BP | GO:0046456 | icosanoid biosynthetic process | 1 | 29 | 7.87e-02 |
| GO:BP | GO:0033673 | negative regulation of kinase activity | 3 | 197 | 7.87e-02 |
| GO:BP | GO:0006692 | prostanoid metabolic process | 1 | 32 | 7.87e-02 |
| GO:BP | GO:0006693 | prostaglandin metabolic process | 1 | 32 | 7.87e-02 |
| GO:BP | GO:1901660 | calcium ion export | 1 | 3 | 7.87e-02 |
| GO:BP | GO:0016558 | protein import into peroxisome matrix | 1 | 14 | 7.87e-02 |
| GO:BP | GO:0019720 | Mo-molybdopterin cofactor metabolic process | 1 | 6 | 7.87e-02 |
| GO:BP | GO:0006469 | negative regulation of protein kinase activity | 3 | 179 | 7.87e-02 |
| GO:BP | GO:0006777 | Mo-molybdopterin cofactor biosynthetic process | 1 | 6 | 7.87e-02 |
| GO:BP | GO:0097112 | gamma-aminobutyric acid receptor clustering | 1 | 3 | 7.87e-02 |
| GO:BP | GO:0046128 | purine ribonucleoside metabolic process | 1 | 16 | 7.87e-02 |
| GO:BP | GO:0006636 | unsaturated fatty acid biosynthetic process | 1 | 34 | 7.87e-02 |
| GO:BP | GO:0043409 | negative regulation of MAPK cascade | 2 | 145 | 7.87e-02 |
| GO:BP | GO:0006625 | protein targeting to peroxisome | 1 | 19 | 7.87e-02 |
| GO:BP | GO:0032874 | positive regulation of stress-activated MAPK cascade | 2 | 96 | 7.87e-02 |
| GO:BP | GO:0042278 | purine nucleoside metabolic process | 1 | 20 | 7.87e-02 |
| GO:BP | GO:0048262 | determination of dorsal/ventral asymmetry | 1 | 6 | 7.87e-02 |
| GO:BP | GO:0043545 | molybdopterin cofactor metabolic process | 1 | 6 | 7.87e-02 |
| GO:BP | GO:0051189 | prosthetic group metabolic process | 1 | 6 | 7.87e-02 |
| GO:BP | GO:0070304 | positive regulation of stress-activated protein kinase signaling cascade | 2 | 98 | 7.87e-02 |
| GO:BP | GO:0099555 | trans-synaptic signaling by nitric oxide, modulating synaptic transmission | 1 | 2 | 7.87e-02 |
| GO:BP | GO:0099554 | trans-synaptic signaling by soluble gas, modulating synaptic transmission | 1 | 2 | 7.87e-02 |
| GO:BP | GO:0048319 | axial mesoderm morphogenesis | 1 | 3 | 7.87e-02 |
| GO:BP | GO:0006082 | organic acid metabolic process | 2 | 700 | 7.98e-02 |
| GO:BP | GO:0006605 | protein targeting | 2 | 307 | 7.98e-02 |
| GO:BP | GO:0043436 | oxoacid metabolic process | 2 | 696 | 7.98e-02 |
| GO:BP | GO:0035740 | CD8-positive, alpha-beta T cell proliferation | 1 | 7 | 7.98e-02 |
| GO:BP | GO:0015919 | peroxisomal membrane transport | 1 | 20 | 7.98e-02 |
| GO:BP | GO:0009119 | ribonucleoside metabolic process | 1 | 23 | 7.98e-02 |
| GO:BP | GO:2000564 | regulation of CD8-positive, alpha-beta T cell proliferation | 1 | 7 | 7.98e-02 |
| GO:BP | GO:0019752 | carboxylic acid metabolic process | 2 | 681 | 7.98e-02 |
| GO:BP | GO:0099543 | trans-synaptic signaling by soluble gas | 1 | 2 | 7.98e-02 |
| GO:BP | GO:0043574 | peroxisomal transport | 1 | 22 | 7.98e-02 |
| GO:BP | GO:0099548 | trans-synaptic signaling by nitric oxide | 1 | 2 | 7.98e-02 |
| GO:BP | GO:0071485 | cellular response to absence of light | 1 | 3 | 7.98e-02 |
| GO:BP | GO:0009646 | response to absence of light | 1 | 3 | 7.98e-02 |
| GO:BP | GO:1990603 | dark adaptation | 1 | 3 | 7.98e-02 |
| GO:BP | GO:0034453 | microtubule anchoring | 1 | 25 | 8.18e-02 |
| GO:BP | GO:0051348 | negative regulation of transferase activity | 3 | 234 | 8.64e-02 |
| GO:BP | GO:0099163 | synaptic signaling by nitric oxide | 1 | 3 | 8.64e-02 |
| GO:BP | GO:0098970 | postsynaptic neurotransmitter receptor diffusion trapping | 1 | 4 | 8.64e-02 |
| GO:BP | GO:0030900 | forebrain development | 4 | 281 | 8.64e-02 |
| GO:BP | GO:0048318 | axial mesoderm development | 1 | 6 | 8.64e-02 |
| GO:BP | GO:0099628 | neurotransmitter receptor diffusion trapping | 1 | 4 | 8.64e-02 |
| GO:BP | GO:0003002 | regionalization | 3 | 273 | 8.64e-02 |
| GO:BP | GO:2001233 | regulation of apoptotic signaling pathway | 3 | 307 | 8.64e-02 |
| GO:BP | GO:2001268 | negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway | 1 | 5 | 8.64e-02 |
| GO:BP | GO:0098869 | cellular oxidant detoxification | 1 | 65 | 8.64e-02 |
| GO:BP | GO:0048633 | positive regulation of skeletal muscle tissue growth | 1 | 6 | 8.64e-02 |
| GO:BP | GO:0098735 | positive regulation of the force of heart contraction | 1 | 4 | 8.64e-02 |
| GO:BP | GO:0098953 | receptor diffusion trapping | 1 | 4 | 8.64e-02 |
| GO:BP | GO:0038060 | nitric oxide-cGMP-mediated signaling pathway | 1 | 2 | 8.64e-02 |
| GO:BP | GO:0014732 | skeletal muscle atrophy | 1 | 5 | 8.83e-02 |
| GO:BP | GO:0001826 | inner cell mass cell differentiation | 1 | 5 | 8.83e-02 |
| GO:BP | GO:0055013 | cardiac muscle cell development | 2 | 71 | 8.93e-02 |
| GO:BP | GO:0009116 | nucleoside metabolic process | 1 | 42 | 9.03e-02 |
| GO:BP | GO:1990748 | cellular detoxification | 1 | 76 | 9.03e-02 |
| GO:BP | GO:0044743 | protein transmembrane import into intracellular organelle | 1 | 36 | 9.03e-02 |
| GO:BP | GO:0033559 | unsaturated fatty acid metabolic process | 1 | 66 | 9.03e-02 |
| GO:BP | GO:0009408 | response to heat | 2 | 84 | 9.03e-02 |
| GO:BP | GO:0007031 | peroxisome organization | 1 | 34 | 9.17e-02 |
| GO:BP | GO:0097237 | cellular response to toxic substance | 1 | 82 | 9.19e-02 |
| GO:BP | GO:0009968 | negative regulation of signal transduction | 5 | 1006 | 9.19e-02 |
| GO:BP | GO:0009950 | dorsal/ventral axis specification | 1 | 9 | 9.19e-02 |
| GO:BP | GO:0048631 | regulation of skeletal muscle tissue growth | 1 | 7 | 9.19e-02 |
| GO:BP | GO:0006690 | icosanoid metabolic process | 1 | 60 | 9.19e-02 |
| GO:BP | GO:0055006 | cardiac cell development | 2 | 77 | 9.20e-02 |
| GO:BP | GO:0071514 | genomic imprinting | 1 | 9 | 9.54e-02 |
| GO:BP | GO:0007389 | pattern specification process | 3 | 306 | 9.54e-02 |
| GO:BP | GO:0080135 | regulation of cellular response to stress | 4 | 616 | 9.54e-02 |
| GO:BP | GO:0014891 | striated muscle atrophy | 1 | 6 | 9.63e-02 |
| GO:BP | GO:0098754 | detoxification | 1 | 91 | 9.66e-02 |
| GO:BP | GO:0043687 | post-translational protein modification | 1 | 64 | 9.83e-02 |
| GO:BP | GO:0045859 | regulation of protein kinase activity | 4 | 479 | 1.05e-01 |
| GO:BP | GO:2001185 | regulation of CD8-positive, alpha-beta T cell activation | 1 | 13 | 1.05e-01 |
| GO:BP | GO:0071484 | cellular response to light intensity | 1 | 4 | 1.05e-01 |
| GO:BP | GO:0001933 | negative regulation of protein phosphorylation | 3 | 277 | 1.05e-01 |
| GO:BP | GO:2000625 | regulation of miRNA catabolic process | 1 | 5 | 1.05e-01 |
| GO:BP | GO:0006633 | fatty acid biosynthetic process | 1 | 104 | 1.05e-01 |
| GO:BP | GO:0072578 | neurotransmitter-gated ion channel clustering | 1 | 12 | 1.07e-01 |
| GO:BP | GO:0044092 | negative regulation of molecular function | 4 | 755 | 1.07e-01 |
| GO:BP | GO:0065002 | intracellular protein transmembrane transport | 1 | 52 | 1.07e-01 |
| GO:BP | GO:0051248 | negative regulation of protein metabolic process | 4 | 816 | 1.07e-01 |
| GO:BP | GO:0090435 | protein localization to nuclear envelope | 1 | 14 | 1.07e-01 |
| GO:BP | GO:1901657 | glycosyl compound metabolic process | 1 | 62 | 1.07e-01 |
| GO:BP | GO:0048630 | skeletal muscle tissue growth | 1 | 8 | 1.07e-01 |
| GO:BP | GO:0010648 | negative regulation of cell communication | 5 | 1074 | 1.07e-01 |
| GO:BP | GO:0023057 | negative regulation of signaling | 5 | 1076 | 1.07e-01 |
| GO:BP | GO:0014889 | muscle atrophy | 1 | 9 | 1.09e-01 |
| GO:BP | GO:0043086 | negative regulation of catalytic activity | 4 | 478 | 1.09e-01 |
| GO:BP | GO:0140245 | regulation of translation at postsynapse | 1 | 6 | 1.09e-01 |
| GO:BP | GO:0140243 | regulation of translation at synapse | 1 | 6 | 1.09e-01 |
| GO:BP | GO:0042326 | negative regulation of phosphorylation | 3 | 300 | 1.15e-01 |
| GO:BP | GO:0034244 | negative regulation of transcription elongation by RNA polymerase II | 1 | 17 | 1.16e-01 |
| GO:BP | GO:0071806 | protein transmembrane transport | 1 | 62 | 1.16e-01 |
| GO:BP | GO:0044557 | relaxation of smooth muscle | 1 | 9 | 1.17e-01 |
| GO:BP | GO:0043408 | regulation of MAPK cascade | 3 | 475 | 1.17e-01 |
| GO:BP | GO:0021537 | telencephalon development | 3 | 201 | 1.17e-01 |
| GO:BP | GO:0090084 | negative regulation of inclusion body assembly | 1 | 10 | 1.17e-01 |
| GO:BP | GO:0014874 | response to stimulus involved in regulation of muscle adaptation | 1 | 12 | 1.19e-01 |
| GO:BP | GO:0036037 | CD8-positive, alpha-beta T cell activation | 1 | 15 | 1.21e-01 |
| GO:BP | GO:0072330 | monocarboxylic acid biosynthetic process | 1 | 145 | 1.21e-01 |
| GO:BP | GO:0043201 | response to leucine | 1 | 13 | 1.21e-01 |
| GO:BP | GO:0036342 | post-anal tail morphogenesis | 1 | 13 | 1.21e-01 |
| GO:BP | GO:0055007 | cardiac muscle cell differentiation | 2 | 103 | 1.21e-01 |
| GO:BP | GO:0071313 | cellular response to caffeine | 1 | 10 | 1.21e-01 |
| GO:BP | GO:0099566 | regulation of postsynaptic cytosolic calcium ion concentration | 1 | 6 | 1.21e-01 |
| GO:BP | GO:2001267 | regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway | 1 | 13 | 1.21e-01 |
| GO:BP | GO:0032785 | negative regulation of DNA-templated transcription, elongation | 1 | 20 | 1.23e-01 |
| GO:BP | GO:0009636 | response to toxic substance | 1 | 158 | 1.25e-01 |
| GO:BP | GO:0043549 | regulation of kinase activity | 3 | 560 | 1.29e-01 |
| GO:BP | GO:0006575 | cellular modified amino acid metabolic process | 1 | 96 | 1.32e-01 |
| GO:BP | GO:0044539 | long-chain fatty acid import into cell | 1 | 14 | 1.32e-01 |
| GO:BP | GO:0044281 | small molecule metabolic process | 2 | 1389 | 1.32e-01 |
| GO:BP | GO:0006886 | intracellular protein transport | 2 | 803 | 1.32e-01 |
| GO:BP | GO:0072384 | organelle transport along microtubule | 1 | 84 | 1.36e-01 |
| GO:BP | GO:0060322 | head development | 5 | 633 | 1.39e-01 |
| GO:BP | GO:0006182 | cGMP biosynthetic process | 1 | 6 | 1.39e-01 |
| GO:BP | GO:0140354 | lipid import into cell | 1 | 15 | 1.39e-01 |
| GO:BP | GO:0032091 | negative regulation of protein binding | 1 | 77 | 1.39e-01 |
| GO:BP | GO:1900034 | regulation of cellular response to heat | 1 | 16 | 1.39e-01 |
| GO:BP | GO:0045936 | negative regulation of phosphate metabolic process | 3 | 344 | 1.39e-01 |
| GO:BP | GO:0071044 | histone mRNA catabolic process | 1 | 11 | 1.39e-01 |
| GO:BP | GO:0010563 | negative regulation of phosphorus metabolic process | 3 | 345 | 1.39e-01 |
| GO:BP | GO:0071415 | cellular response to purine-containing compound | 1 | 11 | 1.39e-01 |
| GO:BP | GO:0000165 | MAPK cascade | 3 | 556 | 1.40e-01 |
| GO:BP | GO:0060828 | regulation of canonical Wnt signaling pathway | 2 | 213 | 1.40e-01 |
| GO:BP | GO:0007584 | response to nutrient | 2 | 109 | 1.40e-01 |
| GO:BP | GO:0090083 | regulation of inclusion body assembly | 1 | 16 | 1.40e-01 |
| GO:BP | GO:0033762 | response to glucagon | 1 | 13 | 1.40e-01 |
| GO:BP | GO:0048643 | positive regulation of skeletal muscle tissue development | 1 | 14 | 1.40e-01 |
| GO:BP | GO:0051481 | negative regulation of cytosolic calcium ion concentration | 1 | 9 | 1.40e-01 |
| GO:BP | GO:0031000 | response to caffeine | 1 | 13 | 1.40e-01 |
| GO:BP | GO:0000027 | ribosomal large subunit assembly | 1 | 23 | 1.40e-01 |
| GO:BP | GO:0010800 | positive regulation of peptidyl-threonine phosphorylation | 1 | 23 | 1.40e-01 |
| GO:BP | GO:0010587 | miRNA catabolic process | 1 | 10 | 1.40e-01 |
| GO:BP | GO:0061484 | hematopoietic stem cell homeostasis | 1 | 20 | 1.40e-01 |
| GO:BP | GO:0009266 | response to temperature stimulus | 2 | 133 | 1.40e-01 |
| GO:BP | GO:0010763 | positive regulation of fibroblast migration | 1 | 15 | 1.41e-01 |
| GO:BP | GO:0036376 | sodium ion export across plasma membrane | 1 | 12 | 1.41e-01 |
| GO:BP | GO:0099550 | trans-synaptic signaling, modulating synaptic transmission | 1 | 10 | 1.42e-01 |
| GO:BP | GO:0046394 | carboxylic acid biosynthetic process | 1 | 223 | 1.42e-01 |
| GO:BP | GO:0016053 | organic acid biosynthetic process | 1 | 224 | 1.43e-01 |
| GO:BP | GO:0010649 | regulation of cell communication by electrical coupling | 1 | 17 | 1.46e-01 |
| GO:BP | GO:0030511 | positive regulation of transforming growth factor beta receptor signaling pathway | 1 | 30 | 1.49e-01 |
| GO:BP | GO:1903846 | positive regulation of cellular response to transforming growth factor beta stimulus | 1 | 30 | 1.49e-01 |
| GO:BP | GO:0048585 | negative regulation of response to stimulus | 5 | 1248 | 1.49e-01 |
| GO:BP | GO:0043501 | skeletal muscle adaptation | 1 | 19 | 1.50e-01 |
| GO:BP | GO:0055119 | relaxation of cardiac muscle | 1 | 17 | 1.50e-01 |
| GO:BP | GO:0097190 | apoptotic signaling pathway | 3 | 494 | 1.50e-01 |
| GO:BP | GO:0035051 | cardiocyte differentiation | 2 | 129 | 1.51e-01 |
| GO:BP | GO:0006479 | protein methylation | 1 | 160 | 1.51e-01 |
| GO:BP | GO:0046640 | regulation of alpha-beta T cell proliferation | 1 | 23 | 1.51e-01 |
| GO:BP | GO:0008213 | protein alkylation | 1 | 160 | 1.51e-01 |
| GO:BP | GO:0001941 | postsynaptic membrane organization | 1 | 29 | 1.51e-01 |
| GO:BP | GO:1901863 | positive regulation of muscle tissue development | 1 | 18 | 1.51e-01 |
| GO:BP | GO:0006941 | striated muscle contraction | 2 | 152 | 1.54e-01 |
| GO:BP | GO:0051443 | positive regulation of ubiquitin-protein transferase activity | 1 | 31 | 1.54e-01 |
| GO:BP | GO:0046633 | alpha-beta T cell proliferation | 1 | 24 | 1.55e-01 |
| GO:BP | GO:0051338 | regulation of transferase activity | 3 | 679 | 1.55e-01 |
| GO:BP | GO:0046068 | cGMP metabolic process | 1 | 11 | 1.57e-01 |
| GO:BP | GO:0006631 | fatty acid metabolic process | 1 | 276 | 1.58e-01 |
| GO:BP | GO:0048641 | regulation of skeletal muscle tissue development | 1 | 20 | 1.58e-01 |
| GO:BP | GO:0010881 | regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion | 1 | 20 | 1.59e-01 |
| GO:BP | GO:0086012 | membrane depolarization during cardiac muscle cell action potential | 1 | 21 | 1.59e-01 |
| GO:BP | GO:0031400 | negative regulation of protein modification process | 2 | 418 | 1.59e-01 |
| GO:BP | GO:0071732 | cellular response to nitric oxide | 1 | 14 | 1.59e-01 |
| GO:BP | GO:0007018 | microtubule-based movement | 2 | 300 | 1.59e-01 |
| GO:BP | GO:0071549 | cellular response to dexamethasone stimulus | 1 | 24 | 1.59e-01 |
| GO:BP | GO:0070841 | inclusion body assembly | 1 | 22 | 1.59e-01 |
| GO:BP | GO:1901605 | alpha-amino acid metabolic process | 1 | 151 | 1.59e-01 |
| GO:BP | GO:0035902 | response to immobilization stress | 1 | 16 | 1.64e-01 |
| GO:BP | GO:0060070 | canonical Wnt signaling pathway | 2 | 251 | 1.66e-01 |
| GO:BP | GO:0043507 | positive regulation of JUN kinase activity | 1 | 34 | 1.67e-01 |
| GO:BP | GO:0018105 | peptidyl-serine phosphorylation | 3 | 247 | 1.67e-01 |
| GO:BP | GO:0098719 | sodium ion import across plasma membrane | 1 | 14 | 1.67e-01 |
| GO:BP | GO:0006883 | intracellular sodium ion homeostasis | 1 | 13 | 1.67e-01 |
| GO:BP | GO:0006913 | nucleocytoplasmic transport | 2 | 295 | 1.67e-01 |
| GO:BP | GO:0009749 | response to glucose | 2 | 137 | 1.67e-01 |
| GO:BP | GO:0051169 | nuclear transport | 2 | 295 | 1.67e-01 |
| GO:BP | GO:0045948 | positive regulation of translational initiation | 1 | 23 | 1.67e-01 |
| GO:BP | GO:0009746 | response to hexose | 2 | 138 | 1.68e-01 |
| GO:BP | GO:0060537 | muscle tissue development | 3 | 343 | 1.68e-01 |
| GO:BP | GO:1902532 | negative regulation of intracellular signal transduction | 2 | 438 | 1.68e-01 |
| GO:BP | GO:1902170 | cellular response to reactive nitrogen species | 1 | 16 | 1.68e-01 |
| GO:BP | GO:0010799 | regulation of peptidyl-threonine phosphorylation | 1 | 35 | 1.68e-01 |
| GO:BP | GO:0051100 | negative regulation of binding | 1 | 135 | 1.69e-01 |
| GO:BP | GO:0007017 | microtubule-based process | 3 | 760 | 1.70e-01 |
| GO:BP | GO:0010882 | regulation of cardiac muscle contraction by calcium ion signaling | 1 | 25 | 1.70e-01 |
| GO:BP | GO:0014829 | vascular associated smooth muscle contraction | 1 | 20 | 1.70e-01 |
| GO:BP | GO:0003012 | muscle system process | 3 | 334 | 1.70e-01 |
| GO:BP | GO:0002026 | regulation of the force of heart contraction | 1 | 23 | 1.70e-01 |
| GO:BP | GO:0033014 | tetrapyrrole biosynthetic process | 1 | 33 | 1.70e-01 |
| GO:BP | GO:0086064 | cell communication by electrical coupling involved in cardiac conduction | 1 | 26 | 1.70e-01 |
| GO:BP | GO:0035994 | response to muscle stretch | 1 | 26 | 1.70e-01 |
| GO:BP | GO:0010970 | transport along microtubule | 1 | 162 | 1.70e-01 |
| GO:BP | GO:0046627 | negative regulation of insulin receptor signaling pathway | 1 | 29 | 1.70e-01 |
| GO:BP | GO:0006779 | porphyrin-containing compound biosynthetic process | 1 | 33 | 1.70e-01 |
| GO:BP | GO:0007528 | neuromuscular junction development | 1 | 39 | 1.70e-01 |
| GO:BP | GO:0030111 | regulation of Wnt signaling pathway | 2 | 273 | 1.70e-01 |
| GO:BP | GO:0009190 | cyclic nucleotide biosynthetic process | 1 | 14 | 1.70e-01 |
| GO:BP | GO:0009642 | response to light intensity | 1 | 11 | 1.70e-01 |
| GO:BP | GO:0034284 | response to monosaccharide | 2 | 142 | 1.70e-01 |
| GO:BP | GO:1903779 | regulation of cardiac conduction | 1 | 23 | 1.70e-01 |
| GO:BP | GO:0051085 | chaperone cofactor-dependent protein refolding | 1 | 30 | 1.70e-01 |
| GO:BP | GO:0043433 | negative regulation of DNA-binding transcription factor activity | 1 | 138 | 1.70e-01 |
| GO:BP | GO:0003298 | physiological muscle hypertrophy | 1 | 19 | 1.72e-01 |
| GO:BP | GO:0007616 | long-term memory | 1 | 31 | 1.72e-01 |
| GO:BP | GO:0021772 | olfactory bulb development | 1 | 19 | 1.72e-01 |
| GO:BP | GO:0061049 | cell growth involved in cardiac muscle cell development | 1 | 19 | 1.72e-01 |
| GO:BP | GO:0071731 | response to nitric oxide | 1 | 16 | 1.72e-01 |
| GO:BP | GO:1900077 | negative regulation of cellular response to insulin stimulus | 1 | 31 | 1.72e-01 |
| GO:BP | GO:0003301 | physiological cardiac muscle hypertrophy | 1 | 19 | 1.72e-01 |
| GO:BP | GO:0014911 | positive regulation of smooth muscle cell migration | 1 | 30 | 1.72e-01 |
| GO:BP | GO:0018209 | peptidyl-serine modification | 3 | 259 | 1.72e-01 |
| GO:BP | GO:0009612 | response to mechanical stimulus | 2 | 158 | 1.73e-01 |
| GO:BP | GO:0043113 | receptor clustering | 1 | 45 | 1.77e-01 |
| GO:BP | GO:0010880 | regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | 1 | 27 | 1.77e-01 |
| GO:BP | GO:0021988 | olfactory lobe development | 1 | 21 | 1.77e-01 |
| GO:BP | GO:0045599 | negative regulation of fat cell differentiation | 1 | 43 | 1.78e-01 |
| GO:BP | GO:2000629 | negative regulation of miRNA metabolic process | 1 | 20 | 1.78e-01 |
| GO:BP | GO:0055001 | muscle cell development | 2 | 165 | 1.78e-01 |
| GO:BP | GO:0044283 | small molecule biosynthetic process | 1 | 425 | 1.78e-01 |
| GO:BP | GO:0001662 | behavioral fear response | 1 | 29 | 1.78e-01 |
| GO:BP | GO:0008334 | histone mRNA metabolic process | 1 | 21 | 1.78e-01 |
| GO:BP | GO:0001825 | blastocyst formation | 1 | 37 | 1.78e-01 |
| GO:BP | GO:0006520 | amino acid metabolic process | 1 | 222 | 1.78e-01 |
| GO:BP | GO:0051084 | ‘de novo’ post-translational protein folding | 1 | 35 | 1.79e-01 |
| GO:BP | GO:0002209 | behavioral defense response | 1 | 30 | 1.79e-01 |
| GO:BP | GO:0043393 | regulation of protein binding | 1 | 172 | 1.79e-01 |
| GO:BP | GO:0099173 | postsynapse organization | 2 | 155 | 1.79e-01 |
| GO:BP | GO:0060402 | calcium ion transport into cytosol | 1 | 18 | 1.79e-01 |
| GO:BP | GO:0030705 | cytoskeleton-dependent intracellular transport | 1 | 194 | 1.81e-01 |
| GO:BP | GO:0032787 | monocarboxylic acid metabolic process | 1 | 433 | 1.82e-01 |
| GO:BP | GO:0051172 | negative regulation of nitrogen compound metabolic process | 7 | 1849 | 1.82e-01 |
| GO:BP | GO:0090257 | regulation of muscle system process | 2 | 184 | 1.82e-01 |
| GO:BP | GO:0043414 | macromolecule methylation | 1 | 272 | 1.82e-01 |
| GO:BP | GO:0099111 | microtubule-based transport | 1 | 191 | 1.82e-01 |
| GO:BP | GO:0009743 | response to carbohydrate | 2 | 161 | 1.82e-01 |
| GO:BP | GO:0033574 | response to testosterone | 1 | 29 | 1.82e-01 |
| GO:BP | GO:0006790 | sulfur compound metabolic process | 1 | 248 | 1.82e-01 |
| GO:BP | GO:0003009 | skeletal muscle contraction | 1 | 31 | 1.82e-01 |
| GO:BP | GO:0014808 | release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | 1 | 28 | 1.82e-01 |
| GO:BP | GO:0033198 | response to ATP | 1 | 24 | 1.82e-01 |
| GO:BP | GO:0071548 | response to dexamethasone | 1 | 36 | 1.82e-01 |
| GO:BP | GO:0015031 | protein transport | 2 | 1361 | 1.83e-01 |
| GO:BP | GO:0006458 | ‘de novo’ protein folding | 1 | 39 | 1.83e-01 |
| GO:BP | GO:0001932 | regulation of protein phosphorylation | 3 | 796 | 1.83e-01 |
| GO:BP | GO:1903514 | release of sequestered calcium ion into cytosol by endoplasmic reticulum | 1 | 28 | 1.83e-01 |
| GO:BP | GO:0014888 | striated muscle adaptation | 1 | 40 | 1.83e-01 |
| GO:BP | GO:0042596 | fear response | 1 | 32 | 1.83e-01 |
| GO:BP | GO:0097120 | receptor localization to synapse | 1 | 55 | 1.83e-01 |
| GO:BP | GO:0031122 | cytoplasmic microtubule organization | 1 | 60 | 1.83e-01 |
| GO:BP | GO:0051438 | regulation of ubiquitin-protein transferase activity | 1 | 55 | 1.83e-01 |
| GO:BP | GO:0046907 | intracellular transport | 2 | 1453 | 1.83e-01 |
| GO:BP | GO:0051602 | response to electrical stimulus | 1 | 26 | 1.83e-01 |
| GO:BP | GO:0010644 | cell communication by electrical coupling | 1 | 31 | 1.83e-01 |
| GO:BP | GO:0086010 | membrane depolarization during action potential | 1 | 28 | 1.83e-01 |
| GO:BP | GO:0007263 | nitric oxide mediated signal transduction | 1 | 20 | 1.83e-01 |
| GO:BP | GO:0090075 | relaxation of muscle | 1 | 29 | 1.83e-01 |
| GO:BP | GO:1901861 | regulation of muscle tissue development | 1 | 35 | 1.84e-01 |
| GO:BP | GO:0006612 | protein targeting to membrane | 1 | 118 | 1.85e-01 |
| GO:BP | GO:0071312 | cellular response to alkaloid | 1 | 29 | 1.85e-01 |
| GO:BP | GO:0098657 | import into cell | 2 | 166 | 1.85e-01 |
| GO:BP | GO:0006611 | protein export from nucleus | 1 | 55 | 1.85e-01 |
| GO:BP | GO:0032984 | protein-containing complex disassembly | 1 | 222 | 1.90e-01 |
| GO:BP | GO:0032259 | methylation | 1 | 313 | 1.90e-01 |
| GO:BP | GO:0098703 | calcium ion import across plasma membrane | 1 | 23 | 1.90e-01 |
| GO:BP | GO:0008610 | lipid biosynthetic process | 1 | 560 | 1.90e-01 |
| GO:BP | GO:0099170 | postsynaptic modulation of chemical synaptic transmission | 1 | 23 | 1.90e-01 |
| GO:BP | GO:0045184 | establishment of protein localization | 2 | 1462 | 1.90e-01 |
| GO:BP | GO:0032781 | positive regulation of ATP-dependent activity | 1 | 40 | 1.90e-01 |
| GO:BP | GO:0051640 | organelle localization | 2 | 503 | 1.90e-01 |
| GO:BP | GO:0042255 | ribosome assembly | 1 | 56 | 1.92e-01 |
| GO:BP | GO:0006778 | porphyrin-containing compound metabolic process | 1 | 44 | 1.92e-01 |
| GO:BP | GO:0010762 | regulation of fibroblast migration | 1 | 37 | 1.93e-01 |
| GO:BP | GO:0043410 | positive regulation of MAPK cascade | 2 | 317 | 1.93e-01 |
| GO:BP | GO:1990849 | vacuolar localization | 1 | 62 | 1.94e-01 |
| GO:BP | GO:0061061 | muscle structure development | 4 | 546 | 1.94e-01 |
| GO:BP | GO:0001701 | in utero embryonic development | 2 | 344 | 1.94e-01 |
| GO:BP | GO:0032418 | lysosome localization | 1 | 62 | 1.94e-01 |
| GO:BP | GO:2001243 | negative regulation of intrinsic apoptotic signaling pathway | 1 | 89 | 1.94e-01 |
| GO:BP | GO:0001707 | mesoderm formation | 1 | 53 | 1.94e-01 |
| GO:BP | GO:0070296 | sarcoplasmic reticulum calcium ion transport | 1 | 31 | 1.94e-01 |
| GO:BP | GO:0048738 | cardiac muscle tissue development | 2 | 198 | 1.97e-01 |
| GO:BP | GO:0048332 | mesoderm morphogenesis | 1 | 55 | 1.97e-01 |
| GO:BP | GO:0071385 | cellular response to glucocorticoid stimulus | 1 | 40 | 1.97e-01 |
| GO:BP | GO:0046324 | regulation of glucose import | 1 | 41 | 1.97e-01 |
| GO:BP | GO:0048013 | ephrin receptor signaling pathway | 1 | 41 | 1.98e-01 |
| GO:BP | GO:0050881 | musculoskeletal movement | 1 | 41 | 2.03e-01 |
| GO:BP | GO:0030501 | positive regulation of bone mineralization | 1 | 34 | 2.03e-01 |
| GO:BP | GO:0019934 | cGMP-mediated signaling | 1 | 22 | 2.05e-01 |
| GO:BP | GO:0050879 | multicellular organismal movement | 1 | 41 | 2.05e-01 |
| GO:BP | GO:0009855 | determination of bilateral symmetry | 1 | 102 | 2.05e-01 |
| GO:BP | GO:0009628 | response to abiotic stimulus | 5 | 868 | 2.05e-01 |
| GO:BP | GO:0007420 | brain development | 4 | 591 | 2.05e-01 |
| GO:BP | GO:0009799 | specification of symmetry | 1 | 103 | 2.05e-01 |
| GO:BP | GO:0033013 | tetrapyrrole metabolic process | 1 | 52 | 2.06e-01 |
| GO:BP | GO:0042325 | regulation of phosphorylation | 3 | 881 | 2.06e-01 |
| GO:BP | GO:0001756 | somitogenesis | 1 | 48 | 2.06e-01 |
| GO:BP | GO:0046634 | regulation of alpha-beta T cell activation | 1 | 58 | 2.07e-01 |
| GO:BP | GO:0031333 | negative regulation of protein-containing complex assembly | 1 | 130 | 2.09e-01 |
| GO:BP | GO:0050804 | modulation of chemical synaptic transmission | 3 | 341 | 2.09e-01 |
| GO:BP | GO:0014706 | striated muscle tissue development | 2 | 210 | 2.09e-01 |
| GO:BP | GO:0099177 | regulation of trans-synaptic signaling | 3 | 342 | 2.09e-01 |
| GO:BP | GO:0099072 | regulation of postsynaptic membrane neurotransmitter receptor levels | 1 | 70 | 2.10e-01 |
| GO:BP | GO:0016055 | Wnt signaling pathway | 2 | 375 | 2.11e-01 |
| GO:BP | GO:0198738 | cell-cell signaling by wnt | 2 | 376 | 2.13e-01 |
| GO:BP | GO:0034243 | regulation of transcription elongation by RNA polymerase II | 1 | 85 | 2.14e-01 |
| GO:BP | GO:0071384 | cellular response to corticosteroid stimulus | 1 | 47 | 2.15e-01 |
| GO:BP | GO:0042273 | ribosomal large subunit biogenesis | 1 | 73 | 2.15e-01 |
| GO:BP | GO:0006468 | protein phosphorylation | 5 | 1167 | 2.15e-01 |
| GO:BP | GO:0065009 | regulation of molecular function | 7 | 1939 | 2.15e-01 |
| GO:BP | GO:0043066 | negative regulation of apoptotic process | 3 | 660 | 2.15e-01 |
| GO:BP | GO:0070509 | calcium ion import | 1 | 37 | 2.15e-01 |
| GO:BP | GO:0052652 | cyclic purine nucleotide metabolic process | 1 | 30 | 2.18e-01 |
| GO:BP | GO:0090150 | establishment of protein localization to membrane | 1 | 250 | 2.18e-01 |
| GO:BP | GO:0043154 | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 1 | 59 | 2.18e-01 |
| GO:BP | GO:0014910 | regulation of smooth muscle cell migration | 1 | 58 | 2.18e-01 |
| GO:BP | GO:1900076 | regulation of cellular response to insulin stimulus | 1 | 56 | 2.19e-01 |
| GO:BP | GO:0015909 | long-chain fatty acid transport | 1 | 38 | 2.19e-01 |
| GO:BP | GO:0046626 | regulation of insulin receptor signaling pathway | 1 | 53 | 2.19e-01 |
| GO:BP | GO:0072521 | purine-containing compound metabolic process | 1 | 390 | 2.19e-01 |
| GO:BP | GO:0009187 | cyclic nucleotide metabolic process | 1 | 31 | 2.19e-01 |
| GO:BP | GO:0043069 | negative regulation of programmed cell death | 3 | 678 | 2.20e-01 |
| GO:BP | GO:0032436 | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 1 | 89 | 2.20e-01 |
| GO:BP | GO:0045778 | positive regulation of ossification | 1 | 40 | 2.20e-01 |
| GO:BP | GO:0044255 | cellular lipid metabolic process | 1 | 740 | 2.21e-01 |
| GO:BP | GO:0061001 | regulation of dendritic spine morphogenesis | 1 | 39 | 2.22e-01 |
| GO:BP | GO:0046323 | glucose import | 1 | 53 | 2.22e-01 |
| GO:BP | GO:0034605 | cellular response to heat | 1 | 51 | 2.22e-01 |
| GO:BP | GO:0009798 | axis specification | 1 | 63 | 2.22e-01 |
| GO:BP | GO:0070169 | positive regulation of biomineral tissue development | 1 | 39 | 2.22e-01 |
| GO:BP | GO:0071705 | nitrogen compound transport | 2 | 1684 | 2.22e-01 |
| GO:BP | GO:0010761 | fibroblast migration | 1 | 52 | 2.24e-01 |
| GO:BP | GO:0010827 | regulation of glucose transmembrane transport | 1 | 55 | 2.26e-01 |
| GO:BP | GO:0071320 | cellular response to cAMP | 1 | 41 | 2.26e-01 |
| GO:BP | GO:0014909 | smooth muscle cell migration | 1 | 65 | 2.28e-01 |
| GO:BP | GO:0051098 | regulation of binding | 1 | 317 | 2.29e-01 |
| GO:BP | GO:0055078 | sodium ion homeostasis | 1 | 26 | 2.29e-01 |
| GO:BP | GO:0032784 | regulation of DNA-templated transcription elongation | 1 | 99 | 2.31e-01 |
| GO:BP | GO:0061053 | somite development | 1 | 63 | 2.32e-01 |
| GO:BP | GO:0051649 | establishment of localization in cell | 2 | 1836 | 2.33e-01 |
| GO:BP | GO:0034661 | ncRNA catabolic process | 1 | 41 | 2.35e-01 |
| GO:BP | GO:2000117 | negative regulation of cysteine-type endopeptidase activity | 1 | 64 | 2.35e-01 |
| GO:BP | GO:0010035 | response to inorganic substance | 3 | 414 | 2.35e-01 |
| GO:BP | GO:0061077 | chaperone-mediated protein folding | 1 | 65 | 2.37e-01 |
| GO:BP | GO:0043502 | regulation of muscle adaptation | 1 | 69 | 2.37e-01 |
| GO:BP | GO:0032147 | activation of protein kinase activity | 1 | 82 | 2.37e-01 |
| GO:BP | GO:0033138 | positive regulation of peptidyl-serine phosphorylation | 1 | 70 | 2.37e-01 |
| GO:BP | GO:0086065 | cell communication involved in cardiac conduction | 1 | 58 | 2.37e-01 |
| GO:BP | GO:0006378 | mRNA polyadenylation | 1 | 39 | 2.37e-01 |
| GO:BP | GO:0006368 | transcription elongation by RNA polymerase II | 1 | 106 | 2.37e-01 |
| GO:BP | GO:0051174 | regulation of phosphorus metabolic process | 3 | 994 | 2.37e-01 |
| GO:BP | GO:0019220 | regulation of phosphate metabolic process | 3 | 993 | 2.37e-01 |
| GO:BP | GO:0018107 | peptidyl-threonine phosphorylation | 1 | 97 | 2.38e-01 |
| GO:BP | GO:0051146 | striated muscle cell differentiation | 2 | 233 | 2.38e-01 |
| GO:BP | GO:0050790 | regulation of catalytic activity | 4 | 1380 | 2.38e-01 |
| GO:BP | GO:0051480 | regulation of cytosolic calcium ion concentration | 1 | 40 | 2.38e-01 |
| GO:BP | GO:2000060 | positive regulation of ubiquitin-dependent protein catabolic process | 1 | 103 | 2.38e-01 |
| GO:BP | GO:0006446 | regulation of translational initiation | 1 | 73 | 2.38e-01 |
| GO:BP | GO:0043631 | RNA polyadenylation | 1 | 41 | 2.38e-01 |
| GO:BP | GO:0055086 | nucleobase-containing small molecule metabolic process | 1 | 487 | 2.38e-01 |
| GO:BP | GO:0031324 | negative regulation of cellular metabolic process | 4 | 1735 | 2.38e-01 |
| GO:BP | GO:0043462 | regulation of ATP-dependent activity | 1 | 63 | 2.38e-01 |
| GO:BP | GO:0006936 | muscle contraction | 2 | 267 | 2.39e-01 |
| GO:BP | GO:0043406 | positive regulation of MAP kinase activity | 1 | 82 | 2.40e-01 |
| GO:BP | GO:0048661 | positive regulation of smooth muscle cell proliferation | 1 | 63 | 2.41e-01 |
| GO:BP | GO:0090100 | positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 1 | 100 | 2.45e-01 |
| GO:BP | GO:0014812 | muscle cell migration | 1 | 76 | 2.45e-01 |
| GO:BP | GO:1901800 | positive regulation of proteasomal protein catabolic process | 1 | 111 | 2.46e-01 |
| GO:BP | GO:0018210 | peptidyl-threonine modification | 1 | 104 | 2.49e-01 |
| GO:BP | GO:0051090 | regulation of DNA-binding transcription factor activity | 1 | 335 | 2.49e-01 |
| GO:BP | GO:0060548 | negative regulation of cell death | 3 | 756 | 2.49e-01 |
| GO:BP | GO:0031398 | positive regulation of protein ubiquitination | 1 | 108 | 2.49e-01 |
| GO:BP | GO:0140115 | export across plasma membrane | 1 | 46 | 2.49e-01 |
| GO:BP | GO:0000226 | microtubule cytoskeleton organization | 2 | 552 | 2.50e-01 |
| GO:BP | GO:0051656 | establishment of organelle localization | 1 | 378 | 2.50e-01 |
| GO:BP | GO:0090263 | positive regulation of canonical Wnt signaling pathway | 1 | 91 | 2.50e-01 |
| GO:BP | GO:2001242 | regulation of intrinsic apoptotic signaling pathway | 1 | 147 | 2.50e-01 |
| GO:BP | GO:0007267 | cell-cell signaling | 6 | 1138 | 2.51e-01 |
| GO:BP | GO:0001704 | formation of primary germ layer | 1 | 96 | 2.51e-01 |
| GO:BP | GO:0033555 | multicellular organismal response to stress | 1 | 57 | 2.51e-01 |
| GO:BP | GO:0080134 | regulation of response to stress | 4 | 1075 | 2.51e-01 |
| GO:BP | GO:0060997 | dendritic spine morphogenesis | 1 | 50 | 2.52e-01 |
| GO:BP | GO:0006354 | DNA-templated transcription elongation | 1 | 122 | 2.52e-01 |
| GO:BP | GO:0046631 | alpha-beta T cell activation | 1 | 89 | 2.54e-01 |
| GO:BP | GO:0046849 | bone remodeling | 1 | 59 | 2.60e-01 |
| GO:BP | GO:0035282 | segmentation | 1 | 75 | 2.60e-01 |
| GO:BP | GO:0007346 | regulation of mitotic cell cycle | 2 | 441 | 2.60e-01 |
| GO:BP | GO:0042129 | regulation of T cell proliferation | 1 | 95 | 2.60e-01 |
| GO:BP | GO:2001237 | negative regulation of extrinsic apoptotic signaling pathway | 1 | 78 | 2.61e-01 |
| GO:BP | GO:0006629 | lipid metabolic process | 1 | 994 | 2.61e-01 |
| GO:BP | GO:0008104 | protein localization | 2 | 2129 | 2.61e-01 |
| GO:BP | GO:0045598 | regulation of fat cell differentiation | 1 | 102 | 2.61e-01 |
| GO:BP | GO:0007498 | mesoderm development | 1 | 89 | 2.61e-01 |
| GO:BP | GO:0086001 | cardiac muscle cell action potential | 1 | 68 | 2.61e-01 |
| GO:BP | GO:1905114 | cell surface receptor signaling pathway involved in cell-cell signaling | 2 | 448 | 2.61e-01 |
| GO:BP | GO:0090090 | negative regulation of canonical Wnt signaling pathway | 1 | 114 | 2.61e-01 |
| GO:BP | GO:0070727 | cellular macromolecule localization | 2 | 2138 | 2.62e-01 |
| GO:BP | GO:0055117 | regulation of cardiac muscle contraction | 1 | 70 | 2.63e-01 |
| GO:BP | GO:0022411 | cellular component disassembly | 1 | 427 | 2.63e-01 |
| GO:BP | GO:0007167 | enzyme-linked receptor protein signaling pathway | 3 | 763 | 2.63e-01 |
| GO:BP | GO:1903052 | positive regulation of proteolysis involved in protein catabolic process | 1 | 127 | 2.64e-01 |
| GO:BP | GO:0001824 | blastocyst development | 1 | 94 | 2.64e-01 |
| GO:BP | GO:0017015 | regulation of transforming growth factor beta receptor signaling pathway | 1 | 128 | 2.65e-01 |
| GO:BP | GO:1903322 | positive regulation of protein modification by small protein conjugation or removal | 1 | 126 | 2.65e-01 |
| GO:BP | GO:0051028 | mRNA transport | 1 | 117 | 2.65e-01 |
| GO:BP | GO:0032434 | regulation of proteasomal ubiquitin-dependent protein catabolic process | 1 | 133 | 2.66e-01 |
| GO:BP | GO:0033135 | regulation of peptidyl-serine phosphorylation | 1 | 100 | 2.66e-01 |
| GO:BP | GO:0043500 | muscle adaptation | 1 | 90 | 2.66e-01 |
| GO:BP | GO:1903844 | regulation of cellular response to transforming growth factor beta stimulus | 1 | 129 | 2.66e-01 |
| GO:BP | GO:0030500 | regulation of bone mineralization | 1 | 53 | 2.66e-01 |
| GO:BP | GO:0031399 | regulation of protein modification process | 3 | 1173 | 2.70e-01 |
| GO:BP | GO:0016310 | phosphorylation | 5 | 1372 | 2.70e-01 |
| GO:BP | GO:0019932 | second-messenger-mediated signaling | 2 | 191 | 2.71e-01 |
| GO:BP | GO:0042310 | vasoconstriction | 1 | 51 | 2.71e-01 |
| GO:BP | GO:0051899 | membrane depolarization | 1 | 60 | 2.73e-01 |
| GO:BP | GO:1904659 | glucose transmembrane transport | 1 | 81 | 2.74e-01 |
| GO:BP | GO:0030316 | osteoclast differentiation | 1 | 66 | 2.75e-01 |
| GO:BP | GO:1901655 | cellular response to ketone | 1 | 86 | 2.75e-01 |
| GO:BP | GO:0072594 | establishment of protein localization to organelle | 2 | 422 | 2.76e-01 |
| GO:BP | GO:0051279 | regulation of release of sequestered calcium ion into cytosol | 1 | 60 | 2.76e-01 |
| GO:BP | GO:0072657 | protein localization to membrane | 1 | 523 | 2.76e-01 |
| GO:BP | GO:0002028 | regulation of sodium ion transport | 1 | 72 | 2.78e-01 |
| GO:BP | GO:0008645 | hexose transmembrane transport | 1 | 84 | 2.79e-01 |
| GO:BP | GO:0042098 | T cell proliferation | 1 | 120 | 2.79e-01 |
| GO:BP | GO:0070482 | response to oxygen levels | 2 | 272 | 2.82e-01 |
| GO:BP | GO:0015749 | monosaccharide transmembrane transport | 1 | 85 | 2.84e-01 |
| GO:BP | GO:0031124 | mRNA 3’-end processing | 1 | 58 | 2.85e-01 |
| GO:BP | GO:0015908 | fatty acid transport | 1 | 58 | 2.85e-01 |
| GO:BP | GO:0055017 | cardiac muscle tissue growth | 1 | 65 | 2.89e-01 |
| GO:BP | GO:0051246 | regulation of protein metabolic process | 5 | 1974 | 2.89e-01 |
| GO:BP | GO:0051591 | response to cAMP | 1 | 66 | 2.89e-01 |
| GO:BP | GO:0071702 | organic substance transport | 2 | 2116 | 2.89e-01 |
| GO:BP | GO:0045931 | positive regulation of mitotic cell cycle | 1 | 113 | 2.89e-01 |
| GO:BP | GO:0007605 | sensory perception of sound | 1 | 98 | 2.89e-01 |
| GO:BP | GO:0043489 | RNA stabilization | 1 | 59 | 2.91e-01 |
| GO:BP | GO:0030177 | positive regulation of Wnt signaling pathway | 1 | 120 | 2.91e-01 |
| GO:BP | GO:0071346 | cellular response to type II interferon | 1 | 69 | 2.91e-01 |
| GO:BP | GO:0007613 | memory | 1 | 92 | 2.92e-01 |
| GO:BP | GO:0043200 | response to amino acid | 1 | 95 | 2.92e-01 |
| GO:BP | GO:0030178 | negative regulation of Wnt signaling pathway | 1 | 140 | 2.92e-01 |
| GO:BP | GO:0051668 | localization within membrane | 1 | 605 | 2.94e-01 |
| GO:BP | GO:0050670 | regulation of lymphocyte proliferation | 1 | 126 | 2.95e-01 |
| GO:BP | GO:0031503 | protein-containing complex localization | 1 | 168 | 2.95e-01 |
| GO:BP | GO:0050657 | nucleic acid transport | 1 | 144 | 2.95e-01 |
| GO:BP | GO:0045471 | response to ethanol | 1 | 73 | 2.95e-01 |
| GO:BP | GO:0050658 | RNA transport | 1 | 144 | 2.95e-01 |
| GO:BP | GO:0008286 | insulin receptor signaling pathway | 1 | 105 | 2.95e-01 |
| GO:BP | GO:0031929 | TOR signaling | 1 | 115 | 2.95e-01 |
| GO:BP | GO:0061337 | cardiac conduction | 1 | 88 | 2.95e-01 |
| GO:BP | GO:0009410 | response to xenobiotic stimulus | 2 | 279 | 2.95e-01 |
| GO:BP | GO:2000058 | regulation of ubiquitin-dependent protein catabolic process | 1 | 160 | 2.95e-01 |
| GO:BP | GO:0097061 | dendritic spine organization | 1 | 67 | 2.95e-01 |
| GO:BP | GO:0006942 | regulation of striated muscle contraction | 1 | 85 | 2.95e-01 |
| GO:BP | GO:0043009 | chordate embryonic development | 2 | 534 | 2.95e-01 |
| GO:BP | GO:0034219 | carbohydrate transmembrane transport | 1 | 92 | 2.95e-01 |
| GO:BP | GO:0003300 | cardiac muscle hypertrophy | 1 | 72 | 2.95e-01 |
| GO:BP | GO:0032944 | regulation of mononuclear cell proliferation | 1 | 129 | 2.95e-01 |
| GO:BP | GO:0043279 | response to alkaloid | 1 | 68 | 2.95e-01 |
| GO:BP | GO:0006413 | translational initiation | 1 | 116 | 2.95e-01 |
| GO:BP | GO:0010951 | negative regulation of endopeptidase activity | 1 | 102 | 2.97e-01 |
| GO:BP | GO:0051236 | establishment of RNA localization | 1 | 147 | 2.97e-01 |
| GO:BP | GO:1901699 | cellular response to nitrogen compound | 3 | 517 | 2.97e-01 |
| GO:BP | GO:0014897 | striated muscle hypertrophy | 1 | 73 | 2.97e-01 |
| GO:BP | GO:0051168 | nuclear export | 1 | 150 | 2.97e-01 |
| GO:BP | GO:0070167 | regulation of biomineral tissue development | 1 | 67 | 2.97e-01 |
| GO:BP | GO:0006606 | protein import into nucleus | 1 | 147 | 2.97e-01 |
| GO:BP | GO:0060419 | heart growth | 1 | 72 | 2.97e-01 |
| GO:BP | GO:0014896 | muscle hypertrophy | 1 | 74 | 3.00e-01 |
| GO:BP | GO:0033036 | macromolecule localization | 2 | 2450 | 3.00e-01 |
| GO:BP | GO:2000628 | regulation of miRNA metabolic process | 1 | 67 | 3.01e-01 |
| GO:BP | GO:0036211 | protein modification process | 5 | 2901 | 3.01e-01 |
| GO:BP | GO:0051170 | import into nucleus | 1 | 152 | 3.01e-01 |
| GO:BP | GO:0002027 | regulation of heart rate | 1 | 86 | 3.01e-01 |
| GO:BP | GO:0007507 | heart development | 3 | 506 | 3.01e-01 |
| GO:BP | GO:0009792 | embryo development ending in birth or egg hatching | 2 | 551 | 3.01e-01 |
| GO:BP | GO:0050954 | sensory perception of mechanical stimulus | 1 | 112 | 3.01e-01 |
| GO:BP | GO:0040029 | epigenetic regulation of gene expression | 1 | 153 | 3.01e-01 |
| GO:BP | GO:0001101 | response to acid chemical | 1 | 105 | 3.03e-01 |
| GO:BP | GO:0030162 | regulation of proteolysis | 2 | 535 | 3.04e-01 |
| GO:BP | GO:0007369 | gastrulation | 1 | 146 | 3.04e-01 |
| GO:BP | GO:0045727 | positive regulation of translation | 1 | 126 | 3.04e-01 |
| GO:BP | GO:0048660 | regulation of smooth muscle cell proliferation | 1 | 106 | 3.04e-01 |
| GO:BP | GO:0071902 | positive regulation of protein serine/threonine kinase activity | 1 | 135 | 3.05e-01 |
| GO:BP | GO:0061136 | regulation of proteasomal protein catabolic process | 1 | 183 | 3.05e-01 |
| GO:BP | GO:0042692 | muscle cell differentiation | 2 | 324 | 3.05e-01 |
| GO:BP | GO:0106027 | neuron projection organization | 1 | 76 | 3.05e-01 |
| GO:BP | GO:0006915 | apoptotic process | 4 | 1443 | 3.05e-01 |
| GO:BP | GO:0051384 | response to glucocorticoid | 1 | 93 | 3.05e-01 |
| GO:BP | GO:0033554 | cellular response to stress | 5 | 1681 | 3.05e-01 |
| GO:BP | GO:0034341 | response to type II interferon | 1 | 83 | 3.05e-01 |
| GO:BP | GO:0070663 | regulation of leukocyte proliferation | 1 | 141 | 3.05e-01 |
| GO:BP | GO:0019935 | cyclic-nucleotide-mediated signaling | 1 | 55 | 3.05e-01 |
| GO:BP | GO:1902369 | negative regulation of RNA catabolic process | 1 | 69 | 3.05e-01 |
| GO:BP | GO:1901135 | carbohydrate derivative metabolic process | 1 | 843 | 3.05e-01 |
| GO:BP | GO:0048659 | smooth muscle cell proliferation | 1 | 110 | 3.05e-01 |
| GO:BP | GO:0006939 | smooth muscle contraction | 1 | 75 | 3.05e-01 |
| GO:BP | GO:0043434 | response to peptide hormone | 2 | 321 | 3.06e-01 |
| GO:BP | GO:1901698 | response to nitrogen compound | 4 | 830 | 3.07e-01 |
| GO:BP | GO:0007417 | central nervous system development | 4 | 792 | 3.07e-01 |
| GO:BP | GO:0060996 | dendritic spine development | 1 | 80 | 3.07e-01 |
| GO:BP | GO:0021766 | hippocampus development | 1 | 62 | 3.10e-01 |
| GO:BP | GO:0007179 | transforming growth factor beta receptor signaling pathway | 1 | 179 | 3.11e-01 |
| GO:BP | GO:1902531 | regulation of intracellular signal transduction | 3 | 1345 | 3.12e-01 |
| GO:BP | GO:0008643 | carbohydrate transport | 1 | 111 | 3.13e-01 |
| GO:BP | GO:2001236 | regulation of extrinsic apoptotic signaling pathway | 1 | 123 | 3.15e-01 |
| GO:BP | GO:0031667 | response to nutrient levels | 2 | 353 | 3.17e-01 |
| GO:BP | GO:0031396 | regulation of protein ubiquitination | 1 | 191 | 3.17e-01 |
| GO:BP | GO:0006986 | response to unfolded protein | 1 | 128 | 3.17e-01 |
| GO:BP | GO:0012501 | programmed cell death | 4 | 1479 | 3.18e-01 |
| GO:BP | GO:0045732 | positive regulation of protein catabolic process | 1 | 192 | 3.18e-01 |
| GO:BP | GO:0007219 | Notch signaling pathway | 1 | 146 | 3.20e-01 |
| GO:BP | GO:0030278 | regulation of ossification | 1 | 84 | 3.20e-01 |
| GO:BP | GO:0098659 | inorganic cation import across plasma membrane | 1 | 73 | 3.20e-01 |
| GO:BP | GO:0099587 | inorganic ion import across plasma membrane | 1 | 73 | 3.20e-01 |
| GO:BP | GO:0097193 | intrinsic apoptotic signaling pathway | 1 | 262 | 3.21e-01 |
| GO:BP | GO:0050905 | neuromuscular process | 1 | 107 | 3.21e-01 |
| GO:BP | GO:0006403 | RNA localization | 1 | 182 | 3.21e-01 |
| GO:BP | GO:0048639 | positive regulation of developmental growth | 1 | 124 | 3.22e-01 |
| GO:BP | GO:0030282 | bone mineralization | 1 | 82 | 3.22e-01 |
| GO:BP | GO:0099175 | regulation of postsynapse organization | 1 | 83 | 3.22e-01 |
| GO:BP | GO:0042542 | response to hydrogen peroxide | 1 | 103 | 3.23e-01 |
| GO:BP | GO:0010586 | miRNA metabolic process | 1 | 81 | 3.24e-01 |
| GO:BP | GO:0046651 | lymphocyte proliferation | 1 | 162 | 3.24e-01 |
| GO:BP | GO:0006796 | phosphate-containing compound metabolic process | 4 | 2139 | 3.26e-01 |
| GO:BP | GO:0007169 | transmembrane receptor protein tyrosine kinase signaling pathway | 2 | 484 | 3.26e-01 |
| GO:BP | GO:0031960 | response to corticosteroid | 1 | 109 | 3.26e-01 |
| GO:BP | GO:0034250 | positive regulation of amide metabolic process | 1 | 149 | 3.27e-01 |
| GO:BP | GO:0051209 | release of sequestered calcium ion into cytosol | 1 | 82 | 3.27e-01 |
| GO:BP | GO:0007268 | chemical synaptic transmission | 3 | 490 | 3.27e-01 |
| GO:BP | GO:0098916 | anterograde trans-synaptic signaling | 3 | 490 | 3.27e-01 |
| GO:BP | GO:0071363 | cellular response to growth factor stimulus | 2 | 551 | 3.27e-01 |
| GO:BP | GO:0032943 | mononuclear cell proliferation | 1 | 168 | 3.27e-01 |
| GO:BP | GO:0007519 | skeletal muscle tissue development | 1 | 129 | 3.27e-01 |
| GO:BP | GO:0043254 | regulation of protein-containing complex assembly | 1 | 348 | 3.27e-01 |
| GO:BP | GO:0006793 | phosphorus metabolic process | 4 | 2161 | 3.27e-01 |
| GO:BP | GO:0051283 | negative regulation of sequestering of calcium ion | 1 | 83 | 3.27e-01 |
| GO:BP | GO:0043412 | macromolecule modification | 5 | 3090 | 3.28e-01 |
| GO:BP | GO:1903050 | regulation of proteolysis involved in protein catabolic process | 1 | 214 | 3.28e-01 |
| GO:BP | GO:0009991 | response to extracellular stimulus | 2 | 377 | 3.29e-01 |
| GO:BP | GO:0099537 | trans-synaptic signaling | 3 | 495 | 3.29e-01 |
| GO:BP | GO:0051282 | regulation of sequestering of calcium ion | 1 | 85 | 3.29e-01 |
| GO:BP | GO:0045444 | fat cell differentiation | 1 | 187 | 3.29e-01 |
| GO:BP | GO:0009967 | positive regulation of signal transduction | 3 | 1133 | 3.29e-01 |
| GO:BP | GO:0007568 | aging | 1 | 115 | 3.29e-01 |
| GO:BP | GO:0051641 | cellular localization | 2 | 2810 | 3.29e-01 |
| GO:BP | GO:0043281 | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 1 | 155 | 3.30e-01 |
| GO:BP | GO:0046683 | response to organophosphorus | 1 | 96 | 3.30e-01 |
| GO:BP | GO:0048015 | phosphatidylinositol-mediated signaling | 1 | 123 | 3.30e-01 |
| GO:BP | GO:0015718 | monocarboxylic acid transport | 1 | 90 | 3.33e-01 |
| GO:BP | GO:0051208 | sequestering of calcium ion | 1 | 89 | 3.33e-01 |
| GO:BP | GO:0051179 | localization | 7 | 3969 | 3.34e-01 |
| GO:BP | GO:0048017 | inositol lipid-mediated signaling | 1 | 126 | 3.34e-01 |
| GO:BP | GO:0015931 | nucleobase-containing compound transport | 1 | 194 | 3.34e-01 |
| GO:BP | GO:0060048 | cardiac muscle contraction | 1 | 123 | 3.34e-01 |
| GO:BP | GO:0030335 | positive regulation of cell migration | 2 | 407 | 3.34e-01 |
| GO:BP | GO:0060538 | skeletal muscle organ development | 1 | 139 | 3.34e-01 |
| GO:BP | GO:0035966 | response to topologically incorrect protein | 1 | 150 | 3.34e-01 |
| GO:BP | GO:0048771 | tissue remodeling | 1 | 114 | 3.34e-01 |
| GO:BP | GO:0070848 | response to growth factor | 2 | 572 | 3.34e-01 |
| GO:BP | GO:0000209 | protein polyubiquitination | 1 | 226 | 3.36e-01 |
| GO:BP | GO:0051963 | regulation of synapse assembly | 1 | 83 | 3.36e-01 |
| GO:BP | GO:0099536 | synaptic signaling | 3 | 511 | 3.37e-01 |
| GO:BP | GO:0006417 | regulation of translation | 2 | 370 | 3.37e-01 |
| GO:BP | GO:0070661 | leukocyte proliferation | 1 | 188 | 3.38e-01 |
| GO:BP | GO:0071456 | cellular response to hypoxia | 1 | 123 | 3.38e-01 |
| GO:BP | GO:1903320 | regulation of protein modification by small protein conjugation or removal | 1 | 232 | 3.38e-01 |
| GO:BP | GO:0034614 | cellular response to reactive oxygen species | 1 | 121 | 3.41e-01 |
| GO:BP | GO:0035296 | regulation of tube diameter | 1 | 99 | 3.41e-01 |
| GO:BP | GO:0097746 | blood vessel diameter maintenance | 1 | 99 | 3.41e-01 |
| GO:BP | GO:1902533 | positive regulation of intracellular signal transduction | 2 | 726 | 3.41e-01 |
| GO:BP | GO:0001508 | action potential | 1 | 105 | 3.42e-01 |
| GO:BP | GO:0035150 | regulation of tube size | 1 | 99 | 3.42e-01 |
| GO:BP | GO:0071560 | cellular response to transforming growth factor beta stimulus | 1 | 222 | 3.42e-01 |
| GO:BP | GO:0018130 | heterocycle biosynthetic process | 8 | 3132 | 3.42e-01 |
| GO:BP | GO:0009952 | anterior/posterior pattern specification | 1 | 127 | 3.45e-01 |
| GO:BP | GO:0043491 | protein kinase B signaling | 1 | 146 | 3.45e-01 |
| GO:BP | GO:0071559 | response to transforming growth factor beta | 1 | 227 | 3.45e-01 |
| GO:BP | GO:0010466 | negative regulation of peptidase activity | 1 | 131 | 3.45e-01 |
| GO:BP | GO:0014074 | response to purine-containing compound | 1 | 108 | 3.45e-01 |
| GO:BP | GO:0010605 | negative regulation of macromolecule metabolic process | 5 | 2135 | 3.45e-01 |
| GO:BP | GO:1901652 | response to peptide | 2 | 377 | 3.46e-01 |
| GO:BP | GO:0036294 | cellular response to decreased oxygen levels | 1 | 131 | 3.46e-01 |
| GO:BP | GO:2000147 | positive regulation of cell motility | 2 | 421 | 3.46e-01 |
| GO:BP | GO:0008219 | cell death | 4 | 1596 | 3.47e-01 |
| GO:BP | GO:0050863 | regulation of T cell activation | 1 | 216 | 3.48e-01 |
| GO:BP | GO:0045930 | negative regulation of mitotic cell cycle | 1 | 211 | 3.48e-01 |
| GO:BP | GO:0021761 | limbic system development | 1 | 81 | 3.48e-01 |
| GO:BP | GO:0070887 | cellular response to chemical stimulus | 1 | 1869 | 3.48e-01 |
| GO:BP | GO:2000116 | regulation of cysteine-type endopeptidase activity | 1 | 169 | 3.49e-01 |
| GO:BP | GO:0090092 | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 1 | 230 | 3.49e-01 |
| GO:BP | GO:0044249 | cellular biosynthetic process | 10 | 4245 | 3.49e-01 |
| GO:BP | GO:0048705 | skeletal system morphogenesis | 1 | 155 | 3.49e-01 |
| GO:BP | GO:0050808 | synapse organization | 2 | 365 | 3.51e-01 |
| GO:BP | GO:0033002 | muscle cell proliferation | 1 | 157 | 3.51e-01 |
| GO:BP | GO:0040017 | positive regulation of locomotion | 2 | 429 | 3.54e-01 |
| GO:BP | GO:0044057 | regulation of system process | 2 | 405 | 3.54e-01 |
| GO:BP | GO:0032869 | cellular response to insulin stimulus | 1 | 174 | 3.57e-01 |
| GO:BP | GO:0071407 | cellular response to organic cyclic compound | 2 | 414 | 3.57e-01 |
| GO:BP | GO:0031123 | RNA 3’-end processing | 1 | 100 | 3.57e-01 |
| GO:BP | GO:1901654 | response to ketone | 1 | 147 | 3.59e-01 |
| GO:BP | GO:0071383 | cellular response to steroid hormone stimulus | 1 | 166 | 3.60e-01 |
| GO:BP | GO:0042981 | regulation of apoptotic process | 3 | 1088 | 3.62e-01 |
| GO:BP | GO:0071453 | cellular response to oxygen levels | 1 | 144 | 3.66e-01 |
| GO:BP | GO:0034762 | regulation of transmembrane transport | 2 | 391 | 3.66e-01 |
| GO:BP | GO:0071482 | cellular response to light stimulus | 1 | 99 | 3.67e-01 |
| GO:BP | GO:0000956 | nuclear-transcribed mRNA catabolic process | 1 | 120 | 3.69e-01 |
| GO:BP | GO:0006937 | regulation of muscle contraction | 1 | 133 | 3.72e-01 |
| GO:BP | GO:0097191 | extrinsic apoptotic signaling pathway | 1 | 179 | 3.73e-01 |
| GO:BP | GO:0043067 | regulation of programmed cell death | 3 | 1111 | 3.74e-01 |
| GO:BP | GO:0009966 | regulation of signal transduction | 5 | 2285 | 3.74e-01 |
| GO:BP | GO:0045892 | negative regulation of DNA-templated transcription | 3 | 1015 | 3.76e-01 |
| GO:BP | GO:0006334 | nucleosome assembly | 1 | 80 | 3.76e-01 |
| GO:BP | GO:1901362 | organic cyclic compound biosynthetic process | 8 | 3237 | 3.76e-01 |
| GO:BP | GO:1903507 | negative regulation of nucleic acid-templated transcription | 3 | 1017 | 3.76e-01 |
| GO:BP | GO:0000082 | G1/S transition of mitotic cell cycle | 1 | 207 | 3.76e-01 |
| GO:BP | GO:0048813 | dendrite morphogenesis | 1 | 120 | 3.76e-01 |
| GO:BP | GO:0031214 | biomineral tissue development | 1 | 111 | 3.77e-01 |
| GO:BP | GO:0023056 | positive regulation of signaling | 3 | 1256 | 3.77e-01 |
| GO:BP | GO:0010647 | positive regulation of cell communication | 3 | 1255 | 3.77e-01 |
| GO:BP | GO:0090287 | regulation of cellular response to growth factor stimulus | 1 | 265 | 3.77e-01 |
| GO:BP | GO:0034248 | regulation of amide metabolic process | 2 | 424 | 3.78e-01 |
| GO:BP | GO:0051129 | negative regulation of cellular component organization | 2 | 604 | 3.78e-01 |
| GO:BP | GO:1902679 | negative regulation of RNA biosynthetic process | 3 | 1026 | 3.78e-01 |
| GO:BP | GO:0035725 | sodium ion transmembrane transport | 1 | 113 | 3.81e-01 |
| GO:BP | GO:0002573 | myeloid leukocyte differentiation | 1 | 151 | 3.85e-01 |
| GO:BP | GO:0002244 | hematopoietic progenitor cell differentiation | 1 | 109 | 3.87e-01 |
| GO:BP | GO:0033365 | protein localization to organelle | 1 | 859 | 3.87e-01 |
| GO:BP | GO:0009892 | negative regulation of metabolic process | 5 | 2293 | 3.87e-01 |
| GO:BP | GO:0097553 | calcium ion transmembrane import into cytosol | 1 | 115 | 3.88e-01 |
| GO:BP | GO:0007259 | receptor signaling pathway via JAK-STAT | 1 | 86 | 3.88e-01 |
| GO:BP | GO:0034612 | response to tumor necrosis factor | 1 | 172 | 3.91e-01 |
| GO:BP | GO:0010038 | response to metal ion | 1 | 264 | 3.91e-01 |
| GO:BP | GO:1903169 | regulation of calcium ion transmembrane transport | 1 | 122 | 3.91e-01 |
| GO:BP | GO:0006457 | protein folding | 1 | 192 | 3.93e-01 |
| GO:BP | GO:0044087 | regulation of cellular component biogenesis | 3 | 809 | 3.93e-01 |
| GO:BP | GO:0034504 | protein localization to nucleus | 1 | 276 | 3.93e-01 |
| GO:BP | GO:0010243 | response to organonitrogen compound | 3 | 782 | 3.93e-01 |
| GO:BP | GO:0008015 | blood circulation | 2 | 374 | 3.93e-01 |
| GO:BP | GO:0097696 | receptor signaling pathway via STAT | 1 | 88 | 3.95e-01 |
| GO:BP | GO:0097305 | response to alcohol | 1 | 159 | 3.96e-01 |
| GO:BP | GO:0000302 | response to reactive oxygen species | 1 | 160 | 4.01e-01 |
| GO:BP | GO:0044843 | cell cycle G1/S phase transition | 1 | 229 | 4.02e-01 |
| GO:BP | GO:1901566 | organonitrogen compound biosynthetic process | 5 | 1484 | 4.02e-01 |
| GO:BP | GO:0045927 | positive regulation of growth | 1 | 199 | 4.02e-01 |
| GO:BP | GO:0035265 | organ growth | 1 | 131 | 4.03e-01 |
| GO:BP | GO:0098739 | import across plasma membrane | 1 | 133 | 4.04e-01 |
| GO:BP | GO:0071417 | cellular response to organonitrogen compound | 2 | 485 | 4.04e-01 |
| GO:BP | GO:0045862 | positive regulation of proteolysis | 1 | 295 | 4.04e-01 |
| GO:BP | GO:0048872 | homeostasis of number of cells | 1 | 228 | 4.04e-01 |
| GO:BP | GO:0007411 | axon guidance | 1 | 185 | 4.05e-01 |
| GO:BP | GO:0001667 | ameboidal-type cell migration | 2 | 358 | 4.05e-01 |
| GO:BP | GO:0034728 | nucleosome organization | 1 | 98 | 4.05e-01 |
| GO:BP | GO:0097485 | neuron projection guidance | 1 | 186 | 4.05e-01 |
| GO:BP | GO:0007204 | positive regulation of cytosolic calcium ion concentration | 1 | 90 | 4.06e-01 |
| GO:BP | GO:0045860 | positive regulation of protein kinase activity | 1 | 260 | 4.06e-01 |
| GO:BP | GO:0032868 | response to insulin | 1 | 215 | 4.08e-01 |
| GO:BP | GO:0006338 | chromatin remodeling | 2 | 378 | 4.08e-01 |
| GO:BP | GO:0042176 | regulation of protein catabolic process | 1 | 331 | 4.08e-01 |
| GO:BP | GO:0042254 | ribosome biogenesis | 1 | 301 | 4.08e-01 |
| GO:BP | GO:0001822 | kidney development | 1 | 244 | 4.09e-01 |
| GO:BP | GO:0008016 | regulation of heart contraction | 1 | 173 | 4.10e-01 |
| GO:BP | GO:0045861 | negative regulation of proteolysis | 1 | 211 | 4.13e-01 |
| GO:BP | GO:0007611 | learning or memory | 1 | 202 | 4.13e-01 |
| GO:BP | GO:0019722 | calcium-mediated signaling | 1 | 122 | 4.13e-01 |
| GO:BP | GO:0007178 | transmembrane receptor protein serine/threonine kinase signaling pathway | 1 | 303 | 4.14e-01 |
| GO:BP | GO:0051253 | negative regulation of RNA metabolic process | 3 | 1119 | 4.14e-01 |
| GO:BP | GO:0072001 | renal system development | 1 | 251 | 4.16e-01 |
| GO:BP | GO:0052548 | regulation of endopeptidase activity | 1 | 232 | 4.17e-01 |
| GO:BP | GO:0010941 | regulation of cell death | 3 | 1219 | 4.17e-01 |
| GO:BP | GO:0000278 | mitotic cell cycle | 2 | 827 | 4.17e-01 |
| GO:BP | GO:0060041 | retina development in camera-type eye | 1 | 109 | 4.18e-01 |
| GO:BP | GO:0051346 | negative regulation of hydrolase activity | 1 | 220 | 4.20e-01 |
| GO:BP | GO:0009888 | tissue development | 5 | 1425 | 4.22e-01 |
| GO:BP | GO:1901576 | organic substance biosynthetic process | 10 | 4539 | 4.26e-01 |
| GO:BP | GO:0042110 | T cell activation | 1 | 313 | 4.27e-01 |
| GO:BP | GO:0051171 | regulation of nitrogen compound metabolic process | 11 | 4292 | 4.27e-01 |
| GO:BP | GO:0048667 | cell morphogenesis involved in neuron differentiation | 2 | 463 | 4.27e-01 |
| GO:BP | GO:0006810 | transport | 2 | 3298 | 4.36e-01 |
| GO:BP | GO:0051651 | maintenance of location in cell | 1 | 170 | 4.40e-01 |
| GO:BP | GO:0051249 | regulation of lymphocyte activation | 1 | 296 | 4.41e-01 |
| GO:BP | GO:0071375 | cellular response to peptide hormone stimulus | 1 | 241 | 4.42e-01 |
| GO:BP | GO:0043487 | regulation of RNA stability | 1 | 159 | 4.46e-01 |
| GO:BP | GO:0009058 | biosynthetic process | 10 | 4590 | 4.46e-01 |
| GO:BP | GO:0010556 | regulation of macromolecule biosynthetic process | 8 | 3012 | 4.47e-01 |
| GO:BP | GO:0007010 | cytoskeleton organization | 1 | 1226 | 4.49e-01 |
| GO:BP | GO:0050890 | cognition | 1 | 227 | 4.51e-01 |
| GO:BP | GO:0048638 | regulation of developmental growth | 1 | 258 | 4.51e-01 |
| GO:BP | GO:0060047 | heart contraction | 1 | 205 | 4.51e-01 |
| GO:BP | GO:0051234 | establishment of localization | 2 | 3433 | 4.51e-01 |
| GO:BP | GO:0003013 | circulatory system process | 2 | 447 | 4.51e-01 |
| GO:BP | GO:0021543 | pallium development | 1 | 139 | 4.51e-01 |
| GO:BP | GO:0007416 | synapse assembly | 1 | 152 | 4.51e-01 |
| GO:BP | GO:0009790 | embryo development | 2 | 875 | 4.51e-01 |
| GO:BP | GO:0009719 | response to endogenous stimulus | 4 | 1278 | 4.51e-01 |
| GO:BP | GO:0042221 | response to chemical | 1 | 2559 | 4.51e-01 |
| GO:BP | GO:0033674 | positive regulation of kinase activity | 1 | 317 | 4.51e-01 |
| GO:BP | GO:0010558 | negative regulation of macromolecule biosynthetic process | 1 | 1214 | 4.51e-01 |
| GO:BP | GO:0045934 | negative regulation of nucleobase-containing compound metabolic process | 1 | 1209 | 4.53e-01 |
| GO:BP | GO:0055085 | transmembrane transport | 1 | 998 | 4.53e-01 |
| GO:BP | GO:0071478 | cellular response to radiation | 1 | 156 | 4.55e-01 |
| GO:BP | GO:0007281 | germ cell development | 1 | 187 | 4.55e-01 |
| GO:BP | GO:0090407 | organophosphate biosynthetic process | 2 | 506 | 4.56e-01 |
| GO:BP | GO:0006814 | sodium ion transport | 1 | 160 | 4.56e-01 |
| GO:BP | GO:0032496 | response to lipopolysaccharide | 1 | 178 | 4.56e-01 |
| GO:BP | GO:0031327 | negative regulation of cellular biosynthetic process | 1 | 1239 | 4.56e-01 |
| GO:BP | GO:0048646 | anatomical structure formation involved in morphogenesis | 2 | 870 | 4.56e-01 |
| GO:BP | GO:0044271 | cellular nitrogen compound biosynthetic process | 11 | 3750 | 4.56e-01 |
| GO:BP | GO:0043161 | proteasome-mediated ubiquitin-dependent protein catabolic process | 1 | 427 | 4.57e-01 |
| GO:BP | GO:0045786 | negative regulation of cell cycle | 1 | 338 | 4.57e-01 |
| GO:BP | GO:1903522 | regulation of blood circulation | 1 | 198 | 4.57e-01 |
| GO:BP | GO:0140694 | non-membrane-bounded organelle assembly | 1 | 357 | 4.57e-01 |
| GO:BP | GO:0003015 | heart process | 1 | 216 | 4.57e-01 |
| GO:BP | GO:0048545 | response to steroid hormone | 1 | 245 | 4.58e-01 |
| GO:BP | GO:0023051 | regulation of signaling | 5 | 2565 | 4.58e-01 |
| GO:BP | GO:0006355 | regulation of DNA-templated transcription | 7 | 2574 | 4.58e-01 |
| GO:BP | GO:1901888 | regulation of cell junction assembly | 1 | 168 | 4.58e-01 |
| GO:BP | GO:1903506 | regulation of nucleic acid-templated transcription | 7 | 2576 | 4.58e-01 |
| GO:BP | GO:0031330 | negative regulation of cellular catabolic process | 1 | 165 | 4.58e-01 |
| GO:BP | GO:0048812 | neuron projection morphogenesis | 2 | 512 | 4.59e-01 |
| GO:BP | GO:0009890 | negative regulation of biosynthetic process | 1 | 1280 | 4.59e-01 |
| GO:BP | GO:0010646 | regulation of cell communication | 5 | 2573 | 4.59e-01 |
| GO:BP | GO:0031326 | regulation of cellular biosynthetic process | 8 | 3080 | 4.62e-01 |
| GO:BP | GO:0045787 | positive regulation of cell cycle | 1 | 274 | 4.62e-01 |
| GO:BP | GO:0052547 | regulation of peptidase activity | 1 | 271 | 4.62e-01 |
| GO:BP | GO:0040011 | locomotion | 3 | 954 | 4.62e-01 |
| GO:BP | GO:0048589 | developmental growth | 2 | 522 | 4.62e-01 |
| GO:BP | GO:0002237 | response to molecule of bacterial origin | 1 | 187 | 4.62e-01 |
| GO:BP | GO:2001141 | regulation of RNA biosynthetic process | 7 | 2593 | 4.62e-01 |
| GO:BP | GO:0003018 | vascular process in circulatory system | 1 | 198 | 4.62e-01 |
| GO:BP | GO:0007517 | muscle organ development | 1 | 277 | 4.62e-01 |
| GO:BP | GO:0080090 | regulation of primary metabolic process | 11 | 4417 | 4.62e-01 |
| GO:BP | GO:0051924 | regulation of calcium ion transport | 1 | 172 | 4.63e-01 |
| GO:BP | GO:0000904 | cell morphogenesis involved in differentiation | 2 | 516 | 4.64e-01 |
| GO:BP | GO:0015849 | organic acid transport | 1 | 217 | 4.64e-01 |
| GO:BP | GO:0046942 | carboxylic acid transport | 1 | 216 | 4.64e-01 |
| GO:BP | GO:0002694 | regulation of leukocyte activation | 1 | 348 | 4.64e-01 |
| GO:BP | GO:0120039 | plasma membrane bounded cell projection morphogenesis | 2 | 527 | 4.65e-01 |
| GO:BP | GO:0009152 | purine ribonucleotide biosynthetic process | 1 | 179 | 4.69e-01 |
| GO:BP | GO:0048858 | cell projection morphogenesis | 2 | 531 | 4.69e-01 |
| GO:BP | GO:0048588 | developmental cell growth | 1 | 192 | 4.70e-01 |
| GO:BP | GO:0035556 | intracellular signal transduction | 4 | 2065 | 4.74e-01 |
| GO:BP | GO:0034599 | cellular response to oxidative stress | 1 | 240 | 4.74e-01 |
| GO:BP | GO:1901653 | cellular response to peptide | 1 | 287 | 4.74e-01 |
| GO:BP | GO:0019438 | aromatic compound biosynthetic process | 9 | 3133 | 4.77e-01 |
| GO:BP | GO:0001666 | response to hypoxia | 1 | 237 | 4.82e-01 |
| GO:BP | GO:0032990 | cell part morphogenesis | 2 | 551 | 4.82e-01 |
| GO:BP | GO:0050807 | regulation of synapse organization | 1 | 184 | 4.84e-01 |
| GO:BP | GO:0009896 | positive regulation of catabolic process | 1 | 464 | 4.87e-01 |
| GO:BP | GO:0071241 | cellular response to inorganic substance | 1 | 164 | 4.87e-01 |
| GO:BP | GO:0016358 | dendrite development | 1 | 202 | 4.87e-01 |
| GO:BP | GO:0009260 | ribonucleotide biosynthetic process | 1 | 191 | 4.87e-01 |
| GO:BP | GO:0050865 | regulation of cell activation | 1 | 384 | 4.87e-01 |
| GO:BP | GO:0010498 | proteasomal protein catabolic process | 1 | 486 | 4.87e-01 |
| GO:BP | GO:0050803 | regulation of synapse structure or activity | 1 | 187 | 4.89e-01 |
| GO:BP | GO:0006351 | DNA-templated transcription | 7 | 2683 | 4.89e-01 |
| GO:BP | GO:0097659 | nucleic acid-templated transcription | 7 | 2684 | 4.89e-01 |
| GO:BP | GO:0051347 | positive regulation of transferase activity | 1 | 400 | 4.89e-01 |
| GO:BP | GO:0009889 | regulation of biosynthetic process | 8 | 3169 | 4.89e-01 |
| GO:BP | GO:0051726 | regulation of cell cycle | 2 | 956 | 4.90e-01 |
| GO:BP | GO:0046390 | ribose phosphate biosynthetic process | 1 | 197 | 4.91e-01 |
| GO:BP | GO:0036293 | response to decreased oxygen levels | 1 | 249 | 4.91e-01 |
| GO:BP | GO:0006874 | intracellular calcium ion homeostasis | 1 | 200 | 4.94e-01 |
| GO:BP | GO:0032774 | RNA biosynthetic process | 7 | 2714 | 5.00e-01 |
| GO:BP | GO:0071495 | cellular response to endogenous stimulus | 3 | 1107 | 5.02e-01 |
| GO:BP | GO:0006402 | mRNA catabolic process | 1 | 216 | 5.09e-01 |
| GO:BP | GO:0048584 | positive regulation of response to stimulus | 3 | 1555 | 5.12e-01 |
| GO:BP | GO:0034330 | cell junction organization | 2 | 575 | 5.13e-01 |
| GO:BP | GO:0048523 | negative regulation of cellular process | 7 | 3625 | 5.15e-01 |
| GO:BP | GO:0015711 | organic anion transport | 1 | 264 | 5.17e-01 |
| GO:BP | GO:0048513 | animal organ development | 8 | 2189 | 5.18e-01 |
| GO:BP | GO:0065003 | protein-containing complex assembly | 4 | 1335 | 5.18e-01 |
| GO:BP | GO:0055074 | calcium ion homeostasis | 1 | 214 | 5.18e-01 |
| GO:BP | GO:0048583 | regulation of response to stimulus | 6 | 2890 | 5.19e-01 |
| GO:BP | GO:0006869 | lipid transport | 1 | 272 | 5.19e-01 |
| GO:BP | GO:0031323 | regulation of cellular metabolic process | 10 | 4174 | 5.23e-01 |
| GO:BP | GO:1904062 | regulation of monoatomic cation transmembrane transport | 1 | 230 | 5.23e-01 |
| GO:BP | GO:0006164 | purine nucleotide biosynthetic process | 1 | 209 | 5.23e-01 |
| GO:BP | GO:0071345 | cellular response to cytokine stimulus | 2 | 540 | 5.23e-01 |
| GO:BP | GO:0019538 | protein metabolic process | 7 | 4241 | 5.25e-01 |
| GO:BP | GO:0018193 | peptidyl-amino acid modification | 2 | 963 | 5.25e-01 |
| GO:BP | GO:0030099 | myeloid cell differentiation | 1 | 310 | 5.25e-01 |
| GO:BP | GO:0022412 | cellular process involved in reproduction in multicellular organism | 1 | 252 | 5.26e-01 |
| GO:BP | GO:0062197 | cellular response to chemical stress | 1 | 293 | 5.26e-01 |
| GO:BP | GO:0048598 | embryonic morphogenesis | 1 | 440 | 5.30e-01 |
| GO:BP | GO:0030334 | regulation of cell migration | 2 | 706 | 5.30e-01 |
| GO:BP | GO:0051235 | maintenance of location | 1 | 260 | 5.30e-01 |
| GO:BP | GO:0072522 | purine-containing compound biosynthetic process | 1 | 218 | 5.30e-01 |
| GO:BP | GO:0044772 | mitotic cell cycle phase transition | 1 | 418 | 5.30e-01 |
| GO:BP | GO:0070588 | calcium ion transmembrane transport | 1 | 213 | 5.30e-01 |
| GO:BP | GO:0046649 | lymphocyte activation | 1 | 465 | 5.30e-01 |
| GO:BP | GO:0065004 | protein-DNA complex assembly | 1 | 185 | 5.31e-01 |
| GO:BP | GO:0014070 | response to organic cyclic compound | 2 | 640 | 5.32e-01 |
| GO:BP | GO:0048729 | tissue morphogenesis | 1 | 504 | 5.38e-01 |
| GO:BP | GO:0051252 | regulation of RNA metabolic process | 7 | 2845 | 5.42e-01 |
| GO:BP | GO:0006325 | chromatin organization | 2 | 551 | 5.42e-01 |
| GO:BP | GO:0032989 | cellular component morphogenesis | 2 | 639 | 5.42e-01 |
| GO:BP | GO:0003008 | system process | 5 | 1189 | 5.42e-01 |
| GO:BP | GO:0001501 | skeletal system development | 1 | 377 | 5.43e-01 |
| GO:BP | GO:1901564 | organonitrogen compound metabolic process | 8 | 4955 | 5.45e-01 |
| GO:BP | GO:0010876 | lipid localization | 1 | 310 | 5.45e-01 |
| GO:BP | GO:0009725 | response to hormone | 2 | 642 | 5.45e-01 |
| GO:BP | GO:0006412 | translation | 2 | 646 | 5.47e-01 |
| GO:BP | GO:0007409 | axonogenesis | 1 | 359 | 5.50e-01 |
| GO:BP | GO:1901700 | response to oxygen-containing compound | 4 | 1223 | 5.51e-01 |
| GO:BP | GO:1901701 | cellular response to oxygen-containing compound | 3 | 893 | 5.52e-01 |
| GO:BP | GO:0071824 | protein-DNA complex subunit organization | 1 | 204 | 5.54e-01 |
| GO:BP | GO:0009165 | nucleotide biosynthetic process | 1 | 240 | 5.54e-01 |
| GO:BP | GO:0043933 | protein-containing complex organization | 4 | 1496 | 5.55e-01 |
| GO:BP | GO:0045596 | negative regulation of cell differentiation | 1 | 482 | 5.55e-01 |
| GO:BP | GO:2000145 | regulation of cell motility | 2 | 742 | 5.56e-01 |
| GO:BP | GO:0006401 | RNA catabolic process | 1 | 256 | 5.56e-01 |
| GO:BP | GO:1901293 | nucleoside phosphate biosynthetic process | 1 | 241 | 5.56e-01 |
| GO:BP | GO:1902074 | response to salt | 1 | 271 | 5.59e-01 |
| GO:BP | GO:0006511 | ubiquitin-dependent protein catabolic process | 1 | 615 | 5.62e-01 |
| GO:BP | GO:0048468 | cell development | 6 | 1963 | 5.62e-01 |
| GO:BP | GO:0043043 | peptide biosynthetic process | 2 | 666 | 5.63e-01 |
| GO:BP | GO:0006366 | transcription by RNA polymerase II | 5 | 1995 | 5.65e-01 |
| GO:BP | GO:0034097 | response to cytokine | 2 | 607 | 5.65e-01 |
| GO:BP | GO:0019941 | modification-dependent protein catabolic process | 1 | 625 | 5.65e-01 |
| GO:BP | GO:0001934 | positive regulation of protein phosphorylation | 1 | 496 | 5.68e-01 |
| GO:BP | GO:0043632 | modification-dependent macromolecule catabolic process | 1 | 637 | 5.71e-01 |
| GO:BP | GO:0007166 | cell surface receptor signaling pathway | 4 | 1898 | 5.74e-01 |
| GO:BP | GO:0040012 | regulation of locomotion | 2 | 763 | 5.77e-01 |
| GO:BP | GO:0010959 | regulation of metal ion transport | 1 | 275 | 5.77e-01 |
| GO:BP | GO:0072359 | circulatory system development | 3 | 884 | 5.77e-01 |
| GO:BP | GO:0061564 | axon development | 1 | 398 | 5.78e-01 |
| GO:BP | GO:0045321 | leukocyte activation | 1 | 554 | 5.82e-01 |
| GO:BP | GO:0001503 | ossification | 1 | 313 | 5.83e-01 |
| GO:BP | GO:0044770 | cell cycle phase transition | 1 | 504 | 5.89e-01 |
| GO:BP | GO:0009416 | response to light stimulus | 1 | 246 | 5.89e-01 |
| GO:BP | GO:0006979 | response to oxidative stress | 1 | 352 | 5.91e-01 |
| GO:BP | GO:0042391 | regulation of membrane potential | 1 | 293 | 5.96e-01 |
| GO:BP | GO:0009611 | response to wounding | 1 | 415 | 5.98e-01 |
| GO:BP | GO:0009895 | negative regulation of catabolic process | 1 | 280 | 5.98e-01 |
| GO:BP | GO:0042327 | positive regulation of phosphorylation | 1 | 547 | 5.99e-01 |
| GO:BP | GO:0034654 | nucleobase-containing compound biosynthetic process | 8 | 3070 | 6.01e-01 |
| GO:BP | GO:0006816 | calcium ion transport | 1 | 269 | 6.02e-01 |
| GO:BP | GO:0071214 | cellular response to abiotic stimulus | 1 | 268 | 6.03e-01 |
| GO:BP | GO:0104004 | cellular response to environmental stimulus | 1 | 268 | 6.03e-01 |
| GO:BP | GO:0030036 | actin cytoskeleton organization | 2 | 612 | 6.03e-01 |
| GO:BP | GO:0051247 | positive regulation of protein metabolic process | 2 | 1123 | 6.04e-01 |
| GO:BP | GO:0006950 | response to stress | 7 | 2780 | 6.05e-01 |
| GO:BP | GO:0051603 | proteolysis involved in protein catabolic process | 1 | 706 | 6.06e-01 |
| GO:BP | GO:0071396 | cellular response to lipid | 1 | 398 | 6.11e-01 |
| GO:BP | GO:0043010 | camera-type eye development | 1 | 236 | 6.11e-01 |
| GO:BP | GO:0032870 | cellular response to hormone stimulus | 1 | 457 | 6.11e-01 |
| GO:BP | GO:0061024 | membrane organization | 1 | 671 | 6.11e-01 |
| GO:BP | GO:0097435 | supramolecular fiber organization | 1 | 665 | 6.11e-01 |
| GO:BP | GO:0009150 | purine ribonucleotide metabolic process | 1 | 295 | 6.13e-01 |
| GO:BP | GO:0040007 | growth | 2 | 742 | 6.14e-01 |
| GO:BP | GO:0016567 | protein ubiquitination | 1 | 717 | 6.14e-01 |
| GO:BP | GO:0019219 | regulation of nucleobase-containing compound metabolic process | 7 | 3080 | 6.15e-01 |
| GO:BP | GO:0010631 | epithelial cell migration | 1 | 252 | 6.15e-01 |
| GO:BP | GO:0034765 | regulation of monoatomic ion transmembrane transport | 1 | 295 | 6.16e-01 |
| GO:BP | GO:0090132 | epithelium migration | 1 | 252 | 6.18e-01 |
| GO:BP | GO:0001775 | cell activation | 1 | 655 | 6.21e-01 |
| GO:BP | GO:0040008 | regulation of growth | 1 | 501 | 6.21e-01 |
| GO:BP | GO:0010562 | positive regulation of phosphorus metabolic process | 1 | 597 | 6.24e-01 |
| GO:BP | GO:0045937 | positive regulation of phosphate metabolic process | 1 | 597 | 6.24e-01 |
| GO:BP | GO:0090130 | tissue migration | 1 | 256 | 6.24e-01 |
| GO:BP | GO:0050877 | nervous system process | 2 | 634 | 6.24e-01 |
| GO:BP | GO:0009259 | ribonucleotide metabolic process | 1 | 311 | 6.27e-01 |
| GO:BP | GO:0030182 | neuron differentiation | 3 | 1061 | 6.28e-01 |
| GO:BP | GO:0002521 | leukocyte differentiation | 1 | 382 | 6.29e-01 |
| GO:BP | GO:0006518 | peptide metabolic process | 2 | 771 | 6.29e-01 |
| GO:BP | GO:0007610 | behavior | 1 | 436 | 6.29e-01 |
| GO:BP | GO:0042127 | regulation of cell population proliferation | 3 | 1147 | 6.31e-01 |
| GO:BP | GO:0006508 | proteolysis | 2 | 1318 | 6.31e-01 |
| GO:BP | GO:0000902 | cell morphogenesis | 2 | 761 | 6.31e-01 |
| GO:BP | GO:0019693 | ribose phosphate metabolic process | 1 | 319 | 6.31e-01 |
| GO:BP | GO:0048871 | multicellular organismal-level homeostasis | 1 | 532 | 6.35e-01 |
| GO:BP | GO:0043604 | amide biosynthetic process | 2 | 775 | 6.35e-01 |
| GO:BP | GO:0019637 | organophosphate metabolic process | 1 | 784 | 6.35e-01 |
| GO:BP | GO:0031175 | neuron projection development | 2 | 780 | 6.35e-01 |
| GO:BP | GO:0032446 | protein modification by small protein conjugation | 1 | 787 | 6.36e-01 |
| GO:BP | GO:0006935 | chemotaxis | 1 | 389 | 6.37e-01 |
| GO:BP | GO:0042330 | taxis | 1 | 389 | 6.37e-01 |
| GO:BP | GO:0090066 | regulation of anatomical structure size | 1 | 395 | 6.38e-01 |
| GO:BP | GO:0030030 | cell projection organization | 3 | 1233 | 6.39e-01 |
| GO:BP | GO:0009059 | macromolecule biosynthetic process | 7 | 3730 | 6.39e-01 |
| GO:BP | GO:0030003 | intracellular monoatomic cation homeostasis | 1 | 357 | 6.40e-01 |
| GO:BP | GO:0051093 | negative regulation of developmental process | 1 | 665 | 6.41e-01 |
| GO:BP | GO:0001654 | eye development | 1 | 272 | 6.45e-01 |
| GO:BP | GO:0006873 | intracellular monoatomic ion homeostasis | 1 | 362 | 6.45e-01 |
| GO:BP | GO:0030029 | actin filament-based process | 2 | 687 | 6.46e-01 |
| GO:BP | GO:0030097 | hemopoiesis | 2 | 656 | 6.47e-01 |
| GO:BP | GO:0150063 | visual system development | 1 | 273 | 6.47e-01 |
| GO:BP | GO:0019221 | cytokine-mediated signaling pathway | 1 | 274 | 6.47e-01 |
| GO:BP | GO:0034329 | cell junction assembly | 1 | 344 | 6.48e-01 |
| GO:BP | GO:0010975 | regulation of neuron projection development | 1 | 372 | 6.48e-01 |
| GO:BP | GO:0048880 | sensory system development | 1 | 275 | 6.48e-01 |
| GO:BP | GO:0007399 | nervous system development | 5 | 1904 | 6.48e-01 |
| GO:BP | GO:0051716 | cellular response to stimulus | 1 | 4953 | 6.48e-01 |
| GO:BP | GO:0098771 | inorganic ion homeostasis | 1 | 351 | 6.48e-01 |
| GO:BP | GO:0048699 | generation of neurons | 3 | 1119 | 6.48e-01 |
| GO:BP | GO:0034655 | nucleobase-containing compound catabolic process | 1 | 358 | 6.51e-01 |
| GO:BP | GO:0031401 | positive regulation of protein modification process | 1 | 719 | 6.51e-01 |
| GO:BP | GO:0010468 | regulation of gene expression | 9 | 3580 | 6.55e-01 |
| GO:BP | GO:0007600 | sensory perception | 1 | 269 | 6.55e-01 |
| GO:BP | GO:0009894 | regulation of catabolic process | 1 | 875 | 6.63e-01 |
| GO:BP | GO:1903047 | mitotic cell cycle process | 1 | 694 | 6.76e-01 |
| GO:BP | GO:0044093 | positive regulation of molecular function | 2 | 1149 | 6.77e-01 |
| GO:BP | GO:0030163 | protein catabolic process | 1 | 901 | 6.78e-01 |
| GO:BP | GO:0006163 | purine nucleotide metabolic process | 1 | 371 | 6.78e-01 |
| GO:BP | GO:0007276 | gamete generation | 1 | 461 | 6.79e-01 |
| GO:BP | GO:0043269 | regulation of monoatomic ion transport | 1 | 373 | 6.79e-01 |
| GO:BP | GO:0044270 | cellular nitrogen compound catabolic process | 1 | 378 | 6.79e-01 |
| GO:BP | GO:0060255 | regulation of macromolecule metabolic process | 11 | 4617 | 6.79e-01 |
| GO:BP | GO:0055080 | monoatomic cation homeostasis | 1 | 401 | 6.79e-01 |
| GO:BP | GO:0070647 | protein modification by small protein conjugation or removal | 1 | 898 | 6.79e-01 |
| GO:BP | GO:0051094 | positive regulation of developmental process | 2 | 957 | 6.79e-01 |
| GO:BP | GO:0009617 | response to bacterium | 1 | 321 | 6.79e-01 |
| GO:BP | GO:0009314 | response to radiation | 1 | 352 | 6.79e-01 |
| GO:BP | GO:0046700 | heterocycle catabolic process | 1 | 381 | 6.79e-01 |
| GO:BP | GO:0016049 | cell growth | 1 | 418 | 6.83e-01 |
| GO:BP | GO:0050801 | monoatomic ion homeostasis | 1 | 408 | 6.83e-01 |
| GO:BP | GO:0044237 | cellular metabolic process | 3 | 6996 | 6.89e-01 |
| GO:BP | GO:0006996 | organelle organization | 1 | 3000 | 6.90e-01 |
| GO:BP | GO:0019439 | aromatic compound catabolic process | 1 | 387 | 6.91e-01 |
| GO:BP | GO:0002682 | regulation of immune system process | 1 | 877 | 6.93e-01 |
| GO:BP | GO:0009057 | macromolecule catabolic process | 3 | 1199 | 6.93e-01 |
| GO:BP | GO:0043085 | positive regulation of catalytic activity | 1 | 834 | 6.95e-01 |
| GO:BP | GO:0048666 | neuron development | 2 | 877 | 6.95e-01 |
| GO:BP | GO:0070925 | organelle assembly | 1 | 817 | 6.99e-01 |
| GO:BP | GO:0007049 | cell cycle | 2 | 1529 | 7.00e-01 |
| GO:BP | GO:0051336 | regulation of hydrolase activity | 1 | 701 | 7.00e-01 |
| GO:BP | GO:0010608 | post-transcriptional regulation of gene expression | 2 | 468 | 7.00e-01 |
| GO:BP | GO:0006357 | regulation of transcription by RNA polymerase II | 4 | 1914 | 7.00e-01 |
| GO:BP | GO:0010557 | positive regulation of macromolecule biosynthetic process | 3 | 1507 | 7.09e-01 |
| GO:BP | GO:1901361 | organic cyclic compound catabolic process | 1 | 406 | 7.09e-01 |
| GO:BP | GO:0009117 | nucleotide metabolic process | 1 | 423 | 7.09e-01 |
| GO:BP | GO:0006139 | nucleobase-containing compound metabolic process | 2 | 4455 | 7.17e-01 |
| GO:BP | GO:0006753 | nucleoside phosphate metabolic process | 1 | 429 | 7.17e-01 |
| GO:BP | GO:0048609 | multicellular organismal reproductive process | 1 | 538 | 7.23e-01 |
| GO:BP | GO:0009653 | anatomical structure morphogenesis | 3 | 1974 | 7.25e-01 |
| GO:BP | GO:0008283 | cell population proliferation | 3 | 1378 | 7.25e-01 |
| GO:BP | GO:0016192 | vesicle-mediated transport | 1 | 1238 | 7.25e-01 |
| GO:BP | GO:0033993 | response to lipid | 1 | 592 | 7.26e-01 |
| GO:BP | GO:0022008 | neurogenesis | 3 | 1294 | 7.27e-01 |
| GO:BP | GO:0055082 | intracellular chemical homeostasis | 1 | 486 | 7.30e-01 |
| GO:BP | GO:0071310 | cellular response to organic substance | 3 | 1399 | 7.30e-01 |
| GO:BP | GO:0046483 | heterocycle metabolic process | 2 | 4570 | 7.30e-01 |
| GO:BP | GO:0031328 | positive regulation of cellular biosynthetic process | 3 | 1564 | 7.31e-01 |
| GO:BP | GO:0009887 | animal organ morphogenesis | 1 | 742 | 7.32e-01 |
| GO:BP | GO:0006725 | cellular aromatic compound metabolic process | 2 | 4596 | 7.34e-01 |
| GO:BP | GO:0032504 | multicellular organism reproduction | 1 | 556 | 7.35e-01 |
| GO:BP | GO:0050793 | regulation of developmental process | 4 | 1835 | 7.35e-01 |
| GO:BP | GO:0008284 | positive regulation of cell population proliferation | 1 | 631 | 7.37e-01 |
| GO:BP | GO:0016477 | cell migration | 2 | 1081 | 7.38e-01 |
| GO:BP | GO:0050896 | response to stimulus | 1 | 5770 | 7.38e-01 |
| GO:BP | GO:0022607 | cellular component assembly | 2 | 2466 | 7.38e-01 |
| GO:BP | GO:0048519 | negative regulation of biological process | 7 | 4045 | 7.40e-01 |
| GO:BP | GO:0003006 | developmental process involved in reproduction | 1 | 598 | 7.44e-01 |
| GO:BP | GO:0009891 | positive regulation of biosynthetic process | 3 | 1604 | 7.45e-01 |
| GO:BP | GO:0043603 | amide metabolic process | 2 | 993 | 7.48e-01 |
| GO:BP | GO:0045087 | innate immune response | 1 | 488 | 7.48e-01 |
| GO:BP | GO:1901360 | organic cyclic compound metabolic process | 2 | 4747 | 7.53e-01 |
| GO:BP | GO:0120035 | regulation of plasma membrane bounded cell projection organization | 1 | 529 | 7.54e-01 |
| GO:BP | GO:0007423 | sensory organ development | 1 | 396 | 7.58e-01 |
| GO:BP | GO:1901565 | organonitrogen compound catabolic process | 1 | 1145 | 7.59e-01 |
| GO:BP | GO:0031344 | regulation of cell projection organization | 1 | 541 | 7.60e-01 |
| GO:BP | GO:0010033 | response to organic substance | 4 | 1957 | 7.60e-01 |
| GO:BP | GO:0051128 | regulation of cellular component organization | 1 | 2011 | 7.63e-01 |
| GO:BP | GO:0019953 | sexual reproduction | 1 | 631 | 7.66e-01 |
| GO:BP | GO:0034641 | cellular nitrogen compound metabolic process | 2 | 4946 | 7.66e-01 |
| GO:BP | GO:0019725 | cellular homeostasis | 1 | 569 | 7.66e-01 |
| GO:BP | GO:0044085 | cellular component biogenesis | 2 | 2724 | 7.66e-01 |
| GO:BP | GO:0060429 | epithelium development | 1 | 850 | 7.70e-01 |
| GO:BP | GO:0034660 | ncRNA metabolic process | 1 | 561 | 7.71e-01 |
| GO:BP | GO:1901137 | carbohydrate derivative biosynthetic process | 1 | 544 | 7.73e-01 |
| GO:BP | GO:0007275 | multicellular organism development | 8 | 3386 | 7.74e-01 |
| GO:BP | GO:0000122 | negative regulation of transcription by RNA polymerase II | 1 | 740 | 7.74e-01 |
| GO:BP | GO:0098662 | inorganic cation transmembrane transport | 1 | 517 | 7.74e-01 |
| GO:BP | GO:0031329 | regulation of cellular catabolic process | 1 | 555 | 7.74e-01 |
| GO:BP | GO:0019222 | regulation of metabolic process | 10 | 5017 | 7.80e-01 |
| GO:BP | GO:0042592 | homeostatic process | 2 | 1159 | 7.81e-01 |
| GO:BP | GO:0098655 | monoatomic cation transmembrane transport | 1 | 540 | 7.85e-01 |
| GO:BP | GO:0048870 | cell motility | 2 | 1182 | 7.91e-01 |
| GO:BP | GO:0045595 | regulation of cell differentiation | 1 | 1137 | 7.94e-01 |
| GO:BP | GO:0010629 | negative regulation of gene expression | 1 | 785 | 7.94e-01 |
| GO:BP | GO:0010628 | positive regulation of gene expression | 1 | 783 | 7.94e-01 |
| GO:BP | GO:0140352 | export from cell | 1 | 611 | 7.94e-01 |
| GO:BP | GO:0030001 | metal ion transport | 1 | 562 | 7.98e-01 |
| GO:BP | GO:0051049 | regulation of transport | 2 | 1267 | 8.07e-01 |
| GO:BP | GO:0098660 | inorganic ion transmembrane transport | 1 | 563 | 8.07e-01 |
| GO:BP | GO:0098542 | defense response to other organism | 1 | 608 | 8.14e-01 |
| GO:BP | GO:0030154 | cell differentiation | 7 | 2958 | 8.18e-01 |
| GO:BP | GO:0022402 | cell cycle process | 1 | 1086 | 8.21e-01 |
| GO:BP | GO:0045893 | positive regulation of DNA-templated transcription | 1 | 1315 | 8.21e-01 |
| GO:BP | GO:1903508 | positive regulation of nucleic acid-templated transcription | 1 | 1315 | 8.21e-01 |
| GO:BP | GO:0048869 | cellular developmental process | 7 | 2984 | 8.21e-01 |
| GO:BP | GO:0120036 | plasma membrane bounded cell projection organization | 2 | 1201 | 8.21e-01 |
| GO:BP | GO:1902680 | positive regulation of RNA biosynthetic process | 1 | 1322 | 8.22e-01 |
| GO:BP | GO:0048878 | chemical homeostasis | 1 | 676 | 8.31e-01 |
| GO:BP | GO:0007165 | signal transduction | 6 | 3818 | 8.35e-01 |
| GO:BP | GO:0034220 | monoatomic ion transmembrane transport | 1 | 632 | 8.39e-01 |
| GO:BP | GO:0022603 | regulation of anatomical structure morphogenesis | 1 | 691 | 8.44e-01 |
| GO:BP | GO:0051254 | positive regulation of RNA metabolic process | 1 | 1441 | 8.45e-01 |
| GO:BP | GO:0006812 | monoatomic cation transport | 1 | 669 | 8.48e-01 |
| GO:BP | GO:0022618 | ribonucleoprotein complex assembly | 1 | 203 | 8.50e-01 |
| GO:BP | GO:0071826 | ribonucleoprotein complex subunit organization | 1 | 211 | 8.51e-01 |
| GO:BP | GO:0006952 | defense response | 2 | 944 | 8.56e-01 |
| GO:BP | GO:0048731 | system development | 6 | 2901 | 8.60e-01 |
| GO:BP | GO:0048856 | anatomical structure development | 6 | 4128 | 8.60e-01 |
| GO:BP | GO:0044238 | primary metabolic process | 3 | 7806 | 8.62e-01 |
| GO:BP | GO:0098609 | cell-cell adhesion | 1 | 609 | 8.63e-01 |
| GO:BP | GO:0002376 | immune system process | 1 | 1447 | 8.69e-01 |
| GO:BP | GO:0022414 | reproductive process | 1 | 927 | 8.69e-01 |
| GO:BP | GO:0009605 | response to external stimulus | 3 | 1719 | 8.69e-01 |
| GO:BP | GO:0000003 | reproduction | 1 | 934 | 8.69e-01 |
| GO:BP | GO:0045935 | positive regulation of nucleobase-containing compound metabolic process | 1 | 1602 | 8.69e-01 |
| GO:BP | GO:0032879 | regulation of localization | 2 | 1555 | 8.76e-01 |
| GO:BP | GO:0043207 | response to external biotic stimulus | 1 | 820 | 8.77e-01 |
| GO:BP | GO:0051707 | response to other organism | 1 | 820 | 8.77e-01 |
| GO:BP | GO:1901575 | organic substance catabolic process | 1 | 1712 | 8.82e-01 |
| GO:BP | GO:0065008 | regulation of biological quality | 4 | 2102 | 8.82e-01 |
| GO:BP | GO:0009607 | response to biotic stimulus | 1 | 850 | 8.82e-01 |
| GO:BP | GO:0022613 | ribonucleoprotein complex biogenesis | 1 | 453 | 8.84e-01 |
| GO:BP | GO:0051239 | regulation of multicellular organismal process | 3 | 2035 | 8.84e-01 |
| GO:BP | GO:0023052 | signaling | 6 | 4141 | 8.87e-01 |
| GO:BP | GO:0006811 | monoatomic ion transport | 1 | 775 | 8.88e-01 |
| GO:BP | GO:0007154 | cell communication | 6 | 4226 | 8.99e-01 |
| GO:BP | GO:0031325 | positive regulation of cellular metabolic process | 2 | 2270 | 8.99e-01 |
| GO:BP | GO:0044419 | biological process involved in interspecies interaction between organisms | 1 | 963 | 8.99e-01 |
| GO:BP | GO:0045944 | positive regulation of transcription by RNA polymerase II | 1 | 937 | 9.07e-01 |
| GO:BP | GO:0016070 | RNA metabolic process | 1 | 3600 | 9.09e-01 |
| GO:BP | GO:2000026 | regulation of multicellular organismal development | 1 | 1014 | 9.11e-01 |
| GO:BP | GO:0051173 | positive regulation of nitrogen compound metabolic process | 2 | 2412 | 9.15e-01 |
| GO:BP | GO:0016043 | cellular component organization | 5 | 5076 | 9.20e-01 |
| GO:BP | GO:0032502 | developmental process | 6 | 4494 | 9.20e-01 |
| GO:BP | GO:0006955 | immune response | 1 | 882 | 9.22e-01 |
| GO:BP | GO:0009056 | catabolic process | 1 | 2088 | 9.23e-01 |
| GO:BP | GO:0090304 | nucleic acid metabolic process | 1 | 4048 | 9.30e-01 |
| GO:BP | GO:0071840 | cellular component organization or biogenesis | 3 | 5274 | 9.35e-01 |
| GO:BP | GO:0048522 | positive regulation of cellular process | 4 | 4099 | 9.42e-01 |
| GO:BP | GO:0010604 | positive regulation of macromolecule metabolic process | 2 | 2646 | 9.47e-01 |
| GO:BP | GO:0051240 | positive regulation of multicellular organismal process | 1 | 1101 | 9.47e-01 |
| GO:BP | GO:0032501 | multicellular organismal process | 7 | 4794 | 9.53e-01 |
| GO:BP | GO:0007155 | cell adhesion | 1 | 1012 | 9.57e-01 |
| GO:BP | GO:0044248 | cellular catabolic process | 1 | 1229 | 9.66e-01 |
| GO:BP | GO:0009893 | positive regulation of metabolic process | 2 | 2880 | 9.66e-01 |
| GO:BP | GO:0010467 | gene expression | 1 | 4587 | 9.74e-01 |
| GO:BP | GO:0048518 | positive regulation of biological process | 4 | 4579 | 9.79e-01 |
| GO:BP | GO:0006807 | nitrogen compound metabolic process | 2 | 7441 | 9.79e-01 |
| GO:BP | GO:0043170 | macromolecule metabolic process | 2 | 7069 | 9.85e-01 |
| GO:BP | GO:0006397 | mRNA processing | 1 | 450 | 9.89e-01 |
| GO:BP | GO:0016071 | mRNA metabolic process | 1 | 665 | 9.96e-01 |
| GO:BP | GO:0006396 | RNA processing | 1 | 929 | 1.00e+00 |
| GO:BP | GO:0009987 | cellular process | 1 | 11336 | 1.00e+00 |
| GO:BP | GO:0050794 | regulation of cellular process | 1 | 7552 | 1.00e+00 |
| GO:BP | GO:0065007 | biological regulation | 1 | 8320 | 1.00e+00 |
| GO:BP | GO:0008150 | biological_process | 1 | 12070 | 1.00e+00 |
| GO:BP | GO:0008152 | metabolic process | 1 | 8518 | 1.00e+00 |
| GO:BP | GO:0050789 | regulation of biological process | 1 | 8061 | 1.00e+00 |
| GO:BP | GO:0071704 | organic substance metabolic process | 1 | 8169 | 1.00e+00 |
| KEGG | KEGG:00590 | Arachidonic acid metabolism | 1 | 26 | 1.33e-01 |
| KEGG | KEGG:05210 | Colorectal cancer | 2 | 84 | 1.33e-01 |
| KEGG | KEGG:00900 | Terpenoid backbone biosynthesis | 1 | 21 | 1.33e-01 |
| KEGG | KEGG:00790 | Folate biosynthesis | 1 | 18 | 1.88e-01 |
| KEGG | KEGG:05226 | Gastric cancer | 2 | 117 | 1.88e-01 |
| KEGG | KEGG:05225 | Hepatocellular carcinoma | 2 | 145 | 1.88e-01 |
| KEGG | KEGG:05224 | Breast cancer | 2 | 117 | 1.88e-01 |
| KEGG | KEGG:04371 | Apelin signaling pathway | 2 | 106 | 1.88e-01 |
| KEGG | KEGG:04146 | Peroxisome | 1 | 68 | 1.88e-01 |
| KEGG | KEGG:01100 | Metabolic pathways | 1 | 1146 | 2.43e-01 |
| KEGG | KEGG:04727 | GABAergic synapse | 1 | 55 | 2.43e-01 |
| KEGG | KEGG:01240 | Biosynthesis of cofactors | 1 | 115 | 2.43e-01 |
| KEGG | KEGG:04730 | Long-term depression | 1 | 42 | 2.43e-01 |
| KEGG | KEGG:01522 | Endocrine resistance | 1 | 85 | 2.43e-01 |
| KEGG | KEGG:05412 | Arrhythmogenic right ventricular cardiomyopathy | 1 | 63 | 2.43e-01 |
| KEGG | KEGG:04550 | Signaling pathways regulating pluripotency of stem cells | 1 | 104 | 2.43e-01 |
| KEGG | KEGG:04390 | Hippo signaling pathway | 1 | 134 | 2.43e-01 |
| KEGG | KEGG:04350 | TGF-beta signaling pathway | 1 | 84 | 2.43e-01 |
| KEGG | KEGG:04310 | Wnt signaling pathway | 1 | 138 | 2.43e-01 |
| KEGG | KEGG:04260 | Cardiac muscle contraction | 1 | 67 | 2.43e-01 |
| KEGG | KEGG:01521 | EGFR tyrosine kinase inhibitor resistance | 1 | 74 | 2.43e-01 |
| KEGG | KEGG:04213 | Longevity regulating pathway - multiple species | 1 | 55 | 2.43e-01 |
| KEGG | KEGG:04152 | AMPK signaling pathway | 1 | 103 | 2.43e-01 |
| KEGG | KEGG:04666 | Fc gamma R-mediated phagocytosis | 1 | 75 | 2.43e-01 |
| KEGG | KEGG:04151 | PI3K-Akt signaling pathway | 3 | 254 | 2.43e-01 |
| KEGG | KEGG:04066 | HIF-1 signaling pathway | 1 | 89 | 2.43e-01 |
| KEGG | KEGG:04012 | ErbB signaling pathway | 1 | 78 | 2.43e-01 |
| KEGG | KEGG:04010 | MAPK signaling pathway | 2 | 240 | 2.43e-01 |
| KEGG | KEGG:04211 | Longevity regulating pathway | 1 | 78 | 2.43e-01 |
| KEGG | KEGG:04022 | cGMP-PKG signaling pathway | 2 | 133 | 2.43e-01 |
| KEGG | KEGG:05414 | Dilated cardiomyopathy | 1 | 78 | 2.43e-01 |
| KEGG | KEGG:05212 | Pancreatic cancer | 1 | 75 | 2.43e-01 |
| KEGG | KEGG:04961 | Endocrine and other factor-regulated calcium reabsorption | 1 | 41 | 2.43e-01 |
| KEGG | KEGG:04931 | Insulin resistance | 1 | 95 | 2.43e-01 |
| KEGG | KEGG:05200 | Pathways in cancer | 3 | 409 | 2.43e-01 |
| KEGG | KEGG:04978 | Mineral absorption | 1 | 42 | 2.43e-01 |
| KEGG | KEGG:04924 | Renin secretion | 1 | 50 | 2.43e-01 |
| KEGG | KEGG:05010 | Alzheimer disease | 2 | 315 | 2.43e-01 |
| KEGG | KEGG:04934 | Cushing syndrome | 1 | 121 | 2.43e-01 |
| KEGG | KEGG:05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1 | 69 | 2.43e-01 |
| KEGG | KEGG:05231 | Choline metabolism in cancer | 1 | 84 | 2.43e-01 |
| KEGG | KEGG:05022 | Pathways of neurodegeneration - multiple diseases | 2 | 385 | 2.43e-01 |
| KEGG | KEGG:05165 | Human papillomavirus infection | 2 | 272 | 2.43e-01 |
| KEGG | KEGG:05221 | Acute myeloid leukemia | 1 | 56 | 2.43e-01 |
| KEGG | KEGG:05217 | Basal cell carcinoma | 1 | 49 | 2.43e-01 |
| KEGG | KEGG:05213 | Endometrial cancer | 1 | 57 | 2.43e-01 |
| KEGG | KEGG:05410 | Hypertrophic cardiomyopathy | 1 | 73 | 2.43e-01 |
| KEGG | KEGG:05321 | Inflammatory bowel disease | 1 | 22 | 2.43e-01 |
| KEGG | KEGG:04658 | Th1 and Th2 cell differentiation | 1 | 53 | 2.45e-01 |
| KEGG | KEGG:04910 | Insulin signaling pathway | 1 | 121 | 2.47e-01 |
| KEGG | KEGG:04974 | Protein digestion and absorption | 1 | 61 | 2.47e-01 |
| KEGG | KEGG:04140 | Autophagy - animal | 1 | 133 | 2.48e-01 |
| KEGG | KEGG:04970 | Salivary secretion | 1 | 55 | 2.48e-01 |
| KEGG | KEGG:04540 | Gap junction | 1 | 73 | 2.48e-01 |
| KEGG | KEGG:05132 | Salmonella infection | 1 | 214 | 2.48e-01 |
| KEGG | KEGG:05020 | Prion disease | 1 | 220 | 2.51e-01 |
| KEGG | KEGG:04713 | Circadian entrainment | 1 | 69 | 2.51e-01 |
| KEGG | KEGG:04150 | mTOR signaling pathway | 1 | 135 | 2.51e-01 |
| KEGG | KEGG:05012 | Parkinson disease | 1 | 226 | 2.51e-01 |
| KEGG | KEGG:04261 | Adrenergic signaling in cardiomyocytes | 1 | 128 | 2.65e-01 |
| KEGG | KEGG:04141 | Protein processing in endoplasmic reticulum | 1 | 161 | 2.65e-01 |
| KEGG | KEGG:05205 | Proteoglycans in cancer | 1 | 170 | 2.65e-01 |
| KEGG | KEGG:05207 | Chemical carcinogenesis - receptor activation | 1 | 142 | 2.65e-01 |
| KEGG | KEGG:00230 | Purine metabolism | 1 | 97 | 2.65e-01 |
| KEGG | KEGG:04611 | Platelet activation | 1 | 89 | 2.65e-01 |
| KEGG | KEGG:04270 | Vascular smooth muscle contraction | 1 | 94 | 2.65e-01 |
| KEGG | KEGG:05163 | Human cytomegalovirus infection | 1 | 176 | 2.65e-01 |
| KEGG | KEGG:00000 | KEGG root term | 3 | 5558 | 2.65e-01 |
| KEGG | KEGG:05016 | Huntington disease | 1 | 256 | 2.65e-01 |
| KEGG | KEGG:04015 | Rap1 signaling pathway | 1 | 164 | 2.65e-01 |
| KEGG | KEGG:05164 | Influenza A | 1 | 103 | 2.65e-01 |
| KEGG | KEGG:04360 | Axon guidance | 1 | 162 | 2.65e-01 |
| KEGG | KEGG:05014 | Amyotrophic lateral sclerosis | 1 | 303 | 2.65e-01 |
| KEGG | KEGG:05170 | Human immunodeficiency virus 1 infection | 1 | 165 | 2.65e-01 |
| KEGG | KEGG:04714 | Thermogenesis | 1 | 195 | 2.67e-01 |
| KEGG | KEGG:05161 | Hepatitis B | 1 | 136 | 2.67e-01 |
| KEGG | KEGG:05131 | Shigellosis | 1 | 210 | 2.67e-01 |
| KEGG | KEGG:04217 | Necroptosis | 1 | 106 | 2.67e-01 |
| KEGG | KEGG:04630 | JAK-STAT signaling pathway | 1 | 88 | 2.67e-01 |
| KEGG | KEGG:05322 | Systemic lupus erythematosus | 1 | 61 | 2.67e-01 |
| KEGG | KEGG:04014 | Ras signaling pathway | 1 | 171 | 2.67e-01 |
| KEGG | KEGG:04921 | Oxytocin signaling pathway | 1 | 115 | 2.69e-01 |
| KEGG | KEGG:04020 | Calcium signaling pathway | 1 | 157 | 3.21e-01 |
| KEGG | KEGG:05206 | MicroRNAs in cancer | 1 | 149 | 3.27e-01 |
| KEGG | KEGG:05034 | Alcoholism | 1 | 122 | 3.33e-01 |
| KEGG | KEGG:04613 | Neutrophil extracellular trap formation | 1 | 110 | 3.33e-01 |
| KEGG | KEGG:05203 | Viral carcinogenesis | 1 | 172 | 3.48e-01 |
| KEGG | KEGG:04740 | Olfactory transduction | 1 | 25 | 4.78e-01 |
| KEGG | KEGG:05168 | Herpes simplex virus 1 infection | 1 | 415 | 4.95e-01 |
TOP2i_var24_table %>%
filter(source=="KEGG") %>%
mutate_at(.vars = 6, .funs= scientific_format()) %>%
kable(.,caption = "KEGG TOP2i 24 hour enrichment terms of highly var genes") %>%
kable_paper("striped", full_width = FALSE) %>%
kable_styling(full_width = FALSE, position = "left",bootstrap_options = c("striped","hover")) %>%
scroll_box(width = "100%", height = "400px")| source | term_id | term_name | intersection_size | term_size | p_value |
|---|---|---|---|---|---|
| KEGG | KEGG:00590 | Arachidonic acid metabolism | 1 | 26 | 1.33e-01 |
| KEGG | KEGG:05210 | Colorectal cancer | 2 | 84 | 1.33e-01 |
| KEGG | KEGG:00900 | Terpenoid backbone biosynthesis | 1 | 21 | 1.33e-01 |
| KEGG | KEGG:00790 | Folate biosynthesis | 1 | 18 | 1.88e-01 |
| KEGG | KEGG:05226 | Gastric cancer | 2 | 117 | 1.88e-01 |
| KEGG | KEGG:05225 | Hepatocellular carcinoma | 2 | 145 | 1.88e-01 |
| KEGG | KEGG:05224 | Breast cancer | 2 | 117 | 1.88e-01 |
| KEGG | KEGG:04371 | Apelin signaling pathway | 2 | 106 | 1.88e-01 |
| KEGG | KEGG:04146 | Peroxisome | 1 | 68 | 1.88e-01 |
| KEGG | KEGG:01100 | Metabolic pathways | 1 | 1146 | 2.43e-01 |
| KEGG | KEGG:04727 | GABAergic synapse | 1 | 55 | 2.43e-01 |
| KEGG | KEGG:01240 | Biosynthesis of cofactors | 1 | 115 | 2.43e-01 |
| KEGG | KEGG:04730 | Long-term depression | 1 | 42 | 2.43e-01 |
| KEGG | KEGG:01522 | Endocrine resistance | 1 | 85 | 2.43e-01 |
| KEGG | KEGG:05412 | Arrhythmogenic right ventricular cardiomyopathy | 1 | 63 | 2.43e-01 |
| KEGG | KEGG:04550 | Signaling pathways regulating pluripotency of stem cells | 1 | 104 | 2.43e-01 |
| KEGG | KEGG:04390 | Hippo signaling pathway | 1 | 134 | 2.43e-01 |
| KEGG | KEGG:04350 | TGF-beta signaling pathway | 1 | 84 | 2.43e-01 |
| KEGG | KEGG:04310 | Wnt signaling pathway | 1 | 138 | 2.43e-01 |
| KEGG | KEGG:04260 | Cardiac muscle contraction | 1 | 67 | 2.43e-01 |
| KEGG | KEGG:01521 | EGFR tyrosine kinase inhibitor resistance | 1 | 74 | 2.43e-01 |
| KEGG | KEGG:04213 | Longevity regulating pathway - multiple species | 1 | 55 | 2.43e-01 |
| KEGG | KEGG:04152 | AMPK signaling pathway | 1 | 103 | 2.43e-01 |
| KEGG | KEGG:04666 | Fc gamma R-mediated phagocytosis | 1 | 75 | 2.43e-01 |
| KEGG | KEGG:04151 | PI3K-Akt signaling pathway | 3 | 254 | 2.43e-01 |
| KEGG | KEGG:04066 | HIF-1 signaling pathway | 1 | 89 | 2.43e-01 |
| KEGG | KEGG:04012 | ErbB signaling pathway | 1 | 78 | 2.43e-01 |
| KEGG | KEGG:04010 | MAPK signaling pathway | 2 | 240 | 2.43e-01 |
| KEGG | KEGG:04211 | Longevity regulating pathway | 1 | 78 | 2.43e-01 |
| KEGG | KEGG:04022 | cGMP-PKG signaling pathway | 2 | 133 | 2.43e-01 |
| KEGG | KEGG:05414 | Dilated cardiomyopathy | 1 | 78 | 2.43e-01 |
| KEGG | KEGG:05212 | Pancreatic cancer | 1 | 75 | 2.43e-01 |
| KEGG | KEGG:04961 | Endocrine and other factor-regulated calcium reabsorption | 1 | 41 | 2.43e-01 |
| KEGG | KEGG:04931 | Insulin resistance | 1 | 95 | 2.43e-01 |
| KEGG | KEGG:05200 | Pathways in cancer | 3 | 409 | 2.43e-01 |
| KEGG | KEGG:04978 | Mineral absorption | 1 | 42 | 2.43e-01 |
| KEGG | KEGG:04924 | Renin secretion | 1 | 50 | 2.43e-01 |
| KEGG | KEGG:05010 | Alzheimer disease | 2 | 315 | 2.43e-01 |
| KEGG | KEGG:04934 | Cushing syndrome | 1 | 121 | 2.43e-01 |
| KEGG | KEGG:05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1 | 69 | 2.43e-01 |
| KEGG | KEGG:05231 | Choline metabolism in cancer | 1 | 84 | 2.43e-01 |
| KEGG | KEGG:05022 | Pathways of neurodegeneration - multiple diseases | 2 | 385 | 2.43e-01 |
| KEGG | KEGG:05165 | Human papillomavirus infection | 2 | 272 | 2.43e-01 |
| KEGG | KEGG:05221 | Acute myeloid leukemia | 1 | 56 | 2.43e-01 |
| KEGG | KEGG:05217 | Basal cell carcinoma | 1 | 49 | 2.43e-01 |
| KEGG | KEGG:05213 | Endometrial cancer | 1 | 57 | 2.43e-01 |
| KEGG | KEGG:05410 | Hypertrophic cardiomyopathy | 1 | 73 | 2.43e-01 |
| KEGG | KEGG:05321 | Inflammatory bowel disease | 1 | 22 | 2.43e-01 |
| KEGG | KEGG:04658 | Th1 and Th2 cell differentiation | 1 | 53 | 2.45e-01 |
| KEGG | KEGG:04910 | Insulin signaling pathway | 1 | 121 | 2.47e-01 |
| KEGG | KEGG:04974 | Protein digestion and absorption | 1 | 61 | 2.47e-01 |
| KEGG | KEGG:04140 | Autophagy - animal | 1 | 133 | 2.48e-01 |
| KEGG | KEGG:04970 | Salivary secretion | 1 | 55 | 2.48e-01 |
| KEGG | KEGG:04540 | Gap junction | 1 | 73 | 2.48e-01 |
| KEGG | KEGG:05132 | Salmonella infection | 1 | 214 | 2.48e-01 |
| KEGG | KEGG:05020 | Prion disease | 1 | 220 | 2.51e-01 |
| KEGG | KEGG:04713 | Circadian entrainment | 1 | 69 | 2.51e-01 |
| KEGG | KEGG:04150 | mTOR signaling pathway | 1 | 135 | 2.51e-01 |
| KEGG | KEGG:05012 | Parkinson disease | 1 | 226 | 2.51e-01 |
| KEGG | KEGG:04261 | Adrenergic signaling in cardiomyocytes | 1 | 128 | 2.65e-01 |
| KEGG | KEGG:04141 | Protein processing in endoplasmic reticulum | 1 | 161 | 2.65e-01 |
| KEGG | KEGG:05205 | Proteoglycans in cancer | 1 | 170 | 2.65e-01 |
| KEGG | KEGG:05207 | Chemical carcinogenesis - receptor activation | 1 | 142 | 2.65e-01 |
| KEGG | KEGG:00230 | Purine metabolism | 1 | 97 | 2.65e-01 |
| KEGG | KEGG:04611 | Platelet activation | 1 | 89 | 2.65e-01 |
| KEGG | KEGG:04270 | Vascular smooth muscle contraction | 1 | 94 | 2.65e-01 |
| KEGG | KEGG:05163 | Human cytomegalovirus infection | 1 | 176 | 2.65e-01 |
| KEGG | KEGG:00000 | KEGG root term | 3 | 5558 | 2.65e-01 |
| KEGG | KEGG:05016 | Huntington disease | 1 | 256 | 2.65e-01 |
| KEGG | KEGG:04015 | Rap1 signaling pathway | 1 | 164 | 2.65e-01 |
| KEGG | KEGG:05164 | Influenza A | 1 | 103 | 2.65e-01 |
| KEGG | KEGG:04360 | Axon guidance | 1 | 162 | 2.65e-01 |
| KEGG | KEGG:05014 | Amyotrophic lateral sclerosis | 1 | 303 | 2.65e-01 |
| KEGG | KEGG:05170 | Human immunodeficiency virus 1 infection | 1 | 165 | 2.65e-01 |
| KEGG | KEGG:04714 | Thermogenesis | 1 | 195 | 2.67e-01 |
| KEGG | KEGG:05161 | Hepatitis B | 1 | 136 | 2.67e-01 |
| KEGG | KEGG:05131 | Shigellosis | 1 | 210 | 2.67e-01 |
| KEGG | KEGG:04217 | Necroptosis | 1 | 106 | 2.67e-01 |
| KEGG | KEGG:04630 | JAK-STAT signaling pathway | 1 | 88 | 2.67e-01 |
| KEGG | KEGG:05322 | Systemic lupus erythematosus | 1 | 61 | 2.67e-01 |
| KEGG | KEGG:04014 | Ras signaling pathway | 1 | 171 | 2.67e-01 |
| KEGG | KEGG:04921 | Oxytocin signaling pathway | 1 | 115 | 2.69e-01 |
| KEGG | KEGG:04020 | Calcium signaling pathway | 1 | 157 | 3.21e-01 |
| KEGG | KEGG:05206 | MicroRNAs in cancer | 1 | 149 | 3.27e-01 |
| KEGG | KEGG:05034 | Alcoholism | 1 | 122 | 3.33e-01 |
| KEGG | KEGG:04613 | Neutrophil extracellular trap formation | 1 | 110 | 3.33e-01 |
| KEGG | KEGG:05203 | Viral carcinogenesis | 1 | 172 | 3.48e-01 |
| KEGG | KEGG:04740 | Olfactory transduction | 1 | 25 | 4.78e-01 |
| KEGG | KEGG:05168 | Herpes simplex virus 1 infection | 1 | 415 | 4.95e-01 |
histogram of var
mean_vardrug1 <- read.csv("data/mean_vardrug1.csv", row.names = 1)
drug_frame <- mean_vardrug1 %>%
rownames_to_column(var = "entrezid") %>%
pivot_longer(cols = mean.Da.3:var.Ve.24,
names_to = "short",
values_to = "values") %>%
separate(short, into = c("calc", "treatment", "time")) %>%
mutate(treatment = factor(
treatment,
levels = c("Do", "Ep", "Da", "Mi", "Tr", "Ve"),
labels = c("DOX", "EPI", "DNR", "MTX", "TRZ", "VEH")
)) %>%
mutate(time = factor(
time,
levels = c("3", "24"),
labels = c("3 hours", "24 hours")
)) %>%
group_by(treatment, time, calc) %>%
as.data.frame
drug_frame %>%
dplyr::filter(calc=="var", time=="24 hours", treatment == "DOX"|treatment=="VEH")%>%
# group_by(treatment) %>%
# wilcox.test(., x=values, alternative="two.sided")
# arrange(.`,values, decending= TRUE)
# ggplot(., aes(x=treatment, y=values))+
# geom_boxplot(aes(fill=treatment))+
# ylim(0,1)
mutate(value=log2(values)) %>%
ggplot(., aes(x=value))+
geom_histogram(position = "identity", bins= 4000, aes(fill=treatment, alpha = 0.3))#+
# geom_density(aes(fill=treatment))+
# drug_frame %>%
# dplyr::filter(calc=="var", time=="24 hours", treatment == "DOX"|treatment=="VEH")%>%
# ggplot(., aes(x=value))+
# geom_histogram(position = "identity", bins= 4000, aes(fill=treatment, alpha = 0.3))#+
# # geom_density(aes(fill=treatment))+
# xlim(NA, 3)
sessionInfo()R version 4.3.1 (2023-06-16 ucrt)
Platform: x86_64-w64-mingw32/x64 (64-bit)
Running under: Windows 10 x64 (build 19045)
Matrix products: default
locale:
[1] LC_COLLATE=English_United States.utf8
[2] LC_CTYPE=English_United States.utf8
[3] LC_MONETARY=English_United States.utf8
[4] LC_NUMERIC=C
[5] LC_TIME=English_United States.utf8
time zone: America/Chicago
tzcode source: internal
attached base packages:
[1] grid stats graphics grDevices utils datasets methods
[8] base
other attached packages:
[1] ComplexHeatmap_2.16.0 data.table_1.14.8 qvalue_2.32.0
[4] kableExtra_1.3.4 scales_1.3.0 gridtext_0.1.5
[7] ggVennDiagram_1.5.0 paletteer_1.6.0 gprofiler2_0.2.2
[10] ggsignif_0.6.4 ggpubr_0.6.0 lubridate_1.9.3
[13] forcats_1.0.0 stringr_1.5.0 dplyr_1.1.3
[16] purrr_1.0.2 readr_2.1.4 tidyr_1.3.0
[19] tibble_3.2.1 ggplot2_3.4.4 tidyverse_2.0.0
[22] workflowr_1.7.1
loaded via a namespace (and not attached):
[1] RColorBrewer_1.1-3 rstudioapi_0.15.0 jsonlite_1.8.7
[4] shape_1.4.6 magrittr_2.0.3 magick_2.8.1
[7] farver_2.1.1 rmarkdown_2.25 GlobalOptions_0.1.2
[10] fs_1.6.3 vctrs_0.6.4 rstatix_0.7.2
[13] webshot_0.5.5 htmltools_0.5.7 lambda.r_1.2.4
[16] broom_1.0.5 sass_0.4.7 bslib_0.6.1
[19] htmlwidgets_1.6.4 plyr_1.8.9 futile.options_1.0.1
[22] plotly_4.10.4 cachem_1.0.8 whisker_0.4.1
[25] mime_0.12 lifecycle_1.0.4 iterators_1.0.14
[28] pkgconfig_2.0.3 R6_2.5.1 fastmap_1.1.1
[31] shiny_1.8.0 clue_0.3-65 digest_0.6.33
[34] colorspace_2.1-0 rematch2_2.1.2 S4Vectors_0.38.2
[37] ps_1.7.5 rprojroot_2.0.4 prismatic_1.1.1
[40] crosstalk_1.2.1 labeling_0.4.3 fansi_1.0.5
[43] timechange_0.2.0 httr_1.4.7 abind_1.4-5
[46] compiler_4.3.1 bit64_4.0.5 withr_3.0.0
[49] doParallel_1.0.17 backports_1.4.1 carData_3.0-5
[52] highr_0.10 rjson_0.2.21 tools_4.3.1
[55] httpuv_1.6.12 glue_1.6.2 VennDiagram_1.7.3
[58] callr_3.7.3 promises_1.2.1 getPass_0.2-2
[61] cluster_2.1.4 reshape2_1.4.4 generics_0.1.3
[64] gtable_0.3.4 tzdb_0.4.0 hms_1.1.3
[67] xml2_1.3.5 car_3.1-2 utf8_1.2.4
[70] BiocGenerics_0.46.0 foreach_1.5.2 pillar_1.9.0
[73] vroom_1.6.5 later_1.3.1 circlize_0.4.15
[76] splines_4.3.1 bit_4.0.5 tidyselect_1.2.0
[79] knitr_1.45 git2r_0.32.0 IRanges_2.34.1
[82] svglite_2.1.2 stats4_4.3.1 futile.logger_1.4.3
[85] xfun_0.41 matrixStats_1.1.0 stringi_1.7.12
[88] lazyeval_0.2.2 yaml_2.3.7 evaluate_0.23
[91] codetools_0.2-19 cli_3.6.1 xtable_1.8-4
[94] systemfonts_1.0.5 munsell_0.5.0 processx_3.8.2
[97] jquerylib_0.1.4 Rcpp_1.0.11 png_0.1-8
[100] parallel_4.3.1 ellipsis_0.3.2 viridisLite_0.4.2
[103] crayon_1.5.2 GetoptLong_1.0.5 rlang_1.1.2
[106] formatR_1.14 rvest_1.0.3